,split_0,split_1,split_2,split_tokens,split_anchor_span,split_anchor_indices,within_anchor_index,split_anchor_type,ID,Type,Index,ann_section,ann_source,order_cluster
0,Comparison of budesonide Turbuhaler with budesonide aqua in the treatment of,seasonal allergic rhinitis .,,"['Comparison', 'of', 'budesonide', 'Turbuhaler', 'with', 'budesonide', 'aqua', 'in', 'the', 'treatment', 'of', 'seasonal', 'allergic', 'rhinitis', '.']","(11, 15)","(76, 104)",-1,ss_p,10070173,Title,0,test,gold,3585.0
1,Comparison of,budesonide Turbuhaler,with budesonide aqua in the treatment of seasonal allergic rhinitis .,"['Comparison', 'of', 'budesonide', 'Turbuhaler', 'with', 'budesonide', 'aqua', 'in', 'the', 'treatment', 'of', 'seasonal', 'allergic', 'rhinitis', '.']","(2, 4)","(13, 34)",-1,ss_i,10070173,Title,0,test,gold,5231.0
2,Comparison of budesonide Turbuhaler with,budesonide aqua,in the treatment of seasonal allergic rhinitis .,"['Comparison', 'of', 'budesonide', 'Turbuhaler', 'with', 'budesonide', 'aqua', 'in', 'the', 'treatment', 'of', 'seasonal', 'allergic', 'rhinitis', '.']","(5, 7)","(40, 55)",-1,ss_i,10070173,Title,0,test,gold,5221.0
3,Comparison of budesonide Turbuhaler with budesonide aqua in the treatment of,seasonal allergic rhinitis .,,"['Comparison', 'of', 'budesonide', 'Turbuhaler', 'with', 'budesonide', 'aqua', 'in', 'the', 'treatment', 'of', 'seasonal', 'allergic', 'rhinitis', '.']","(11, 15)","(76, 104)",-1,hl_p,10070173,Title,0,test,gold,3586.0
4,Comparison of,budesonide Turbuhaler,with budesonide aqua in the treatment of seasonal allergic rhinitis .,"['Comparison', 'of', 'budesonide', 'Turbuhaler', 'with', 'budesonide', 'aqua', 'in', 'the', 'treatment', 'of', 'seasonal', 'allergic', 'rhinitis', '.']","(2, 4)","(13, 34)",-1,hl_i,10070173,Title,0,test,gold,5232.0
5,Comparison of budesonide Turbuhaler with,budesonide aqua,in the treatment of seasonal allergic rhinitis .,"['Comparison', 'of', 'budesonide', 'Turbuhaler', 'with', 'budesonide', 'aqua', 'in', 'the', 'treatment', 'of', 'seasonal', 'allergic', 'rhinitis', '.']","(5, 7)","(40, 55)",-1,hl_i,10070173,Title,0,test,gold,5222.0
6,Rhinocort Study Group .,,,"['Rhinocort', 'Study', 'Group', '.']",,,,,10070173,Abstract,0,test,gold,
7,OBJECTIVE To compare the effect of budesonide Turbuhaler 400 microg/day with budesonide aqua 256 microg/day in the treatment of,seasonal allergic rhinitis ( SAR ) .,,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'budesonide', 'Turbuhaler', '400', 'microg/day', 'with', 'budesonide', 'aqua', '256', 'microg/day', 'in', 'the', 'treatment', 'of', 'seasonal', 'allergic', 'rhinitis', '(', 'SAR', ')', '.']","(19, 26)","(127, 163)",-1,ss_p,10070173,Abstract,1,test,gold,3584.0
8,OBJECTIVE To compare the effect of,budesonide Turbuhaler,400 microg/day with budesonide aqua 256 microg/day in the treatment of seasonal allergic rhinitis ( SAR ) .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'budesonide', 'Turbuhaler', '400', 'microg/day', 'with', 'budesonide', 'aqua', '256', 'microg/day', 'in', 'the', 'treatment', 'of', 'seasonal', 'allergic', 'rhinitis', '(', 'SAR', ')', '.']","(6, 8)","(34, 55)",-1,ss_i,10070173,Abstract,1,test,gold,5230.0
9,OBJECTIVE To compare the effect of budesonide Turbuhaler 400 microg/day with,budesonide aqua,256 microg/day in the treatment of seasonal allergic rhinitis ( SAR ) .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'budesonide', 'Turbuhaler', '400', 'microg/day', 'with', 'budesonide', 'aqua', '256', 'microg/day', 'in', 'the', 'treatment', 'of', 'seasonal', 'allergic', 'rhinitis', '(', 'SAR', ')', '.']","(11, 13)","(76, 91)",-1,ss_i,10070173,Abstract,1,test,gold,5220.0
10,OBJECTIVE To compare the effect of,budesonide Turbuhaler,400 microg/day with budesonide aqua 256 microg/day in the treatment of seasonal allergic rhinitis ( SAR ) .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'budesonide', 'Turbuhaler', '400', 'microg/day', 'with', 'budesonide', 'aqua', '256', 'microg/day', 'in', 'the', 'treatment', 'of', 'seasonal', 'allergic', 'rhinitis', '(', 'SAR', ')', '.']","(6, 8)","(34, 55)",-1,hl_i,10070173,Abstract,1,test,gold,5229.0
11,OBJECTIVE To compare the effect of budesonide Turbuhaler 400 microg/day with,budesonide aqua,256 microg/day in the treatment of seasonal allergic rhinitis ( SAR ) .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'budesonide', 'Turbuhaler', '400', 'microg/day', 'with', 'budesonide', 'aqua', '256', 'microg/day', 'in', 'the', 'treatment', 'of', 'seasonal', 'allergic', 'rhinitis', '(', 'SAR', ')', '.']","(11, 13)","(76, 91)",-1,hl_i,10070173,Abstract,1,test,gold,5219.0
12,Secondarily to ascertain,patients ' preferences for the two nasal devices,and to assess quality of life .,"['Secondarily', 'to', 'ascertain', 'patients', ""'"", 'preferences', 'for', 'the', 'two', 'nasal', 'devices', 'and', 'to', 'assess', 'quality', 'of', 'life', '.']","(3, 11)","(24, 72)",-1,ss_o,10070173,Abstract,2,test,gold,3879.0
13,Secondarily to ascertain patients ' preferences for the two nasal devices and to assess,quality of life .,,"['Secondarily', 'to', 'ascertain', 'patients', ""'"", 'preferences', 'for', 'the', 'two', 'nasal', 'devices', 'and', 'to', 'assess', 'quality', 'of', 'life', '.']","(14, 18)","(87, 104)",-1,ss_o,10070173,Abstract,2,test,gold,1889.0
14,Secondarily to ascertain,patients ' preferences,for the two nasal devices and to assess quality of life .,"['Secondarily', 'to', 'ascertain', 'patients', ""'"", 'preferences', 'for', 'the', 'two', 'nasal', 'devices', 'and', 'to', 'assess', 'quality', 'of', 'life', '.']","(3, 6)","(24, 46)",-1,hl_o,10070173,Abstract,2,test,gold,3853.0
15,Secondarily to ascertain patients ' preferences for the two nasal devices and to assess,quality of life .,,"['Secondarily', 'to', 'ascertain', 'patients', ""'"", 'preferences', 'for', 'the', 'two', 'nasal', 'devices', 'and', 'to', 'assess', 'quality', 'of', 'life', '.']","(14, 18)","(87, 104)",-1,hl_o,10070173,Abstract,2,test,gold,1890.0
16,"DESIGN Randomized , multicentre , double-blind , double- dummy , parallel groups study .",,,"['DESIGN', 'Randomized', ',', 'multicentre', ',', 'double-blind', ',', 'double-', 'dummy', ',', 'parallel', 'groups', 'study', '.']",,,,,10070173,Abstract,3,test,gold,
17,SETTING Private practices and hospital clinics in,"Ontario , Quebec and Manitoba .",,"['SETTING', 'Private', 'practices', 'and', 'hospital', 'clinics', 'in', 'Ontario', ',', 'Quebec', 'and', 'Manitoba', '.']","(7, 13)","(49, 80)",-1,ss_p,10070173,Abstract,4,test,gold,1451.0
18,POPULATION,"Two hundred and eighty-four out-patients with SAR , who were symptomatic during the ragweed season , volunteered for enrolment ( 243 randomized ) .",,"['POPULATION', 'Two', 'hundred', 'and', 'eighty-four', 'out-patients', 'with', 'SAR', ',', 'who', 'were', 'symptomatic', 'during', 'the', 'ragweed', 'season', ',', 'volunteered', 'for', 'enrolment', '(', '243', 'randomized', ')', '.']","(1, 25)","(10, 157)",-1,ss_p,10070173,Abstract,5,test,gold,5848.0
19,POPULATION,Two hundred and eighty-four out-patients,"with SAR , who were symptomatic during the ragweed season , volunteered for enrolment ( 243 randomized ) .","['POPULATION', 'Two', 'hundred', 'and', 'eighty-four', 'out-patients', 'with', 'SAR', ',', 'who', 'were', 'symptomatic', 'during', 'the', 'ragweed', 'season', ',', 'volunteered', 'for', 'enrolment', '(', '243', 'randomized', ')', '.']","(1, 6)","(10, 50)",-1,hl_p,10070173,Abstract,5,test,gold,2063.0
20,POPULATION Two hundred and eighty-four out-patients with,SAR,", who were symptomatic during the ragweed season , volunteered for enrolment ( 243 randomized ) .","['POPULATION', 'Two', 'hundred', 'and', 'eighty-four', 'out-patients', 'with', 'SAR', ',', 'who', 'were', 'symptomatic', 'during', 'the', 'ragweed', 'season', ',', 'volunteered', 'for', 'enrolment', '(', '243', 'randomized', ')', '.']","(7, 8)","(56, 59)",-1,hl_p,10070173,Abstract,5,test,gold,1112.0
21,"POPULATION Two hundred and eighty-four out-patients with SAR , who were",symptomatic during the ragweed season,", volunteered for enrolment ( 243 randomized ) .","['POPULATION', 'Two', 'hundred', 'and', 'eighty-four', 'out-patients', 'with', 'SAR', ',', 'who', 'were', 'symptomatic', 'during', 'the', 'ragweed', 'season', ',', 'volunteered', 'for', 'enrolment', '(', '243', 'randomized', ')', '.']","(11, 16)","(71, 108)",-1,hl_p,10070173,Abstract,5,test,gold,3356.0
22,"POPULATION Two hundred and eighty-four out-patients with SAR , who were symptomatic during the ragweed season , volunteered for enrolment (",243,randomized ) .,"['POPULATION', 'Two', 'hundred', 'and', 'eighty-four', 'out-patients', 'with', 'SAR', ',', 'who', 'were', 'symptomatic', 'during', 'the', 'ragweed', 'season', ',', 'volunteered', 'for', 'enrolment', '(', '243', 'randomized', ')', '.']","(21, 22)","(139, 142)",-1,hl_p,10070173,Abstract,5,test,gold,
23,RESULTS,Mean daily nasal symptom scores,were significantly reduced with treatment .,"['RESULTS', 'Mean', 'daily', 'nasal', 'symptom', 'scores', 'were', 'significantly', 'reduced', 'with', 'treatment', '.']","(1, 6)","(7, 38)",-1,ss_o,10070173,Abstract,6,test,gold,3354.0
24,RESULTS,Mean daily nasal symptom scores,were significantly reduced with treatment .,"['RESULTS', 'Mean', 'daily', 'nasal', 'symptom', 'scores', 'were', 'significantly', 'reduced', 'with', 'treatment', '.']","(1, 6)","(7, 38)",-1,hl_o,10070173,Abstract,6,test,gold,3355.0
25,There were no statistically significant changes from baseline for,eye symptoms .,,"['There', 'were', 'no', 'statistically', 'significant', 'changes', 'from', 'baseline', 'for', 'eye', 'symptoms', '.']","(9, 12)","(65, 79)",-1,ss_o,10070173,Abstract,7,test,gold,3266.0
26,There were no statistically significant changes from baseline for,eye symptoms .,,"['There', 'were', 'no', 'statistically', 'significant', 'changes', 'from', 'baseline', 'for', 'eye', 'symptoms', '.']","(9, 12)","(65, 79)",-1,hl_o,10070173,Abstract,7,test,gold,3267.0
27,Most patients ( more than 80 % ) achieved substantial control of their symptoms with,budesonide .,,"['Most', 'patients', '(', 'more', 'than', '80', '%', ')', 'achieved', 'substantial', 'control', 'of', 'their', 'symptoms', 'with', 'budesonide', '.']","(15, 17)","(84, 96)",-1,ss_i,10070173,Abstract,8,test,gold,5225.0
28,Most patients ( more than 80 % ) achieved substantial control of their symptoms with,budesonide .,,"['Most', 'patients', '(', 'more', 'than', '80', '%', ')', 'achieved', 'substantial', 'control', 'of', 'their', 'symptoms', 'with', 'budesonide', '.']","(15, 17)","(84, 96)",-1,hl_i,10070173,Abstract,8,test,gold,5226.0
29,The most common,nasal and non-nasal adverse events,for both groups were epistaxis and headache .,"['The', 'most', 'common', 'nasal', 'and', 'non-nasal', 'adverse', 'events', 'for', 'both', 'groups', 'were', 'epistaxis', 'and', 'headache', '.']","(3, 8)","(15, 49)",-1,ss_o,10070173,Abstract,9,test,gold,3052.0
30,The most common nasal and non-nasal adverse events for both groups were,epistaxis,and headache .,"['The', 'most', 'common', 'nasal', 'and', 'non-nasal', 'adverse', 'events', 'for', 'both', 'groups', 'were', 'epistaxis', 'and', 'headache', '.']","(12, 13)","(71, 80)",-1,ss_o,10070173,Abstract,9,test,gold,61.0
31,The most common nasal and non-nasal adverse events for both groups were epistaxis and,headache .,,"['The', 'most', 'common', 'nasal', 'and', 'non-nasal', 'adverse', 'events', 'for', 'both', 'groups', 'were', 'epistaxis', 'and', 'headache', '.']","(14, 16)","(85, 95)",-1,ss_o,10070173,Abstract,9,test,gold,2697.0
32,The most common,nasal and non-nasal adverse events,for both groups were epistaxis and headache .,"['The', 'most', 'common', 'nasal', 'and', 'non-nasal', 'adverse', 'events', 'for', 'both', 'groups', 'were', 'epistaxis', 'and', 'headache', '.']","(3, 8)","(15, 49)",-1,hl_o,10070173,Abstract,9,test,gold,3053.0
33,The most common nasal and non-nasal adverse events for both groups were,epistaxis,and headache .,"['The', 'most', 'common', 'nasal', 'and', 'non-nasal', 'adverse', 'events', 'for', 'both', 'groups', 'were', 'epistaxis', 'and', 'headache', '.']","(12, 13)","(71, 80)",-1,hl_o,10070173,Abstract,9,test,gold,62.0
34,The most common nasal and non-nasal adverse events for both groups were epistaxis and,headache .,,"['The', 'most', 'common', 'nasal', 'and', 'non-nasal', 'adverse', 'events', 'for', 'both', 'groups', 'were', 'epistaxis', 'and', 'headache', '.']","(14, 16)","(85, 95)",-1,hl_o,10070173,Abstract,9,test,gold,2698.0
35,,Turbuhaler,"was easier to use and more convenient to carry , had less of an unpleasant taste , and caused less nasal irritation than the aqua spray .","['Turbuhaler', 'was', 'easier', 'to', 'use', 'and', 'more', 'convenient', 'to', 'carry', ',', 'had', 'less', 'of', 'an', 'unpleasant', 'taste', ',', 'and', 'caused', 'less', 'nasal', 'irritation', 'than', 'the', 'aqua', 'spray', '.']","(0, 1)","(0, 10)",-1,ss_i,10070173,Abstract,10,test,gold,1050.0
36,"Turbuhaler was easier to use and more convenient to carry , had less of an",unpleasant taste,", and caused less nasal irritation than the aqua spray .","['Turbuhaler', 'was', 'easier', 'to', 'use', 'and', 'more', 'convenient', 'to', 'carry', ',', 'had', 'less', 'of', 'an', 'unpleasant', 'taste', ',', 'and', 'caused', 'less', 'nasal', 'irritation', 'than', 'the', 'aqua', 'spray', '.']","(15, 17)","(74, 90)",-1,ss_o,10070173,Abstract,10,test,gold,2671.0
37,"Turbuhaler was easier to use and more convenient to carry , had less of an unpleasant taste , and caused less",nasal irritation,than the aqua spray .,"['Turbuhaler', 'was', 'easier', 'to', 'use', 'and', 'more', 'convenient', 'to', 'carry', ',', 'had', 'less', 'of', 'an', 'unpleasant', 'taste', ',', 'and', 'caused', 'less', 'nasal', 'irritation', 'than', 'the', 'aqua', 'spray', '.']","(21, 23)","(109, 125)",-1,ss_o,10070173,Abstract,10,test,gold,3127.0
38,,Turbuhaler,"was easier to use and more convenient to carry , had less of an unpleasant taste , and caused less nasal irritation than the aqua spray .","['Turbuhaler', 'was', 'easier', 'to', 'use', 'and', 'more', 'convenient', 'to', 'carry', ',', 'had', 'less', 'of', 'an', 'unpleasant', 'taste', ',', 'and', 'caused', 'less', 'nasal', 'irritation', 'than', 'the', 'aqua', 'spray', '.']","(0, 1)","(0, 10)",-1,hl_i,10070173,Abstract,10,test,gold,1051.0
39,"Turbuhaler was easier to use and more convenient to carry , had less of an unpleasant taste , and caused less",nasal irritation,than the aqua spray .,"['Turbuhaler', 'was', 'easier', 'to', 'use', 'and', 'more', 'convenient', 'to', 'carry', ',', 'had', 'less', 'of', 'an', 'unpleasant', 'taste', ',', 'and', 'caused', 'less', 'nasal', 'irritation', 'than', 'the', 'aqua', 'spray', '.']","(21, 23)","(109, 125)",-1,hl_o,10070173,Abstract,10,test,gold,3128.0
40,More than twice as many patients preferred,Turbuhaler,to the aqua spray ( 69 % versus 31 % ) .,"['More', 'than', 'twice', 'as', 'many', 'patients', 'preferred', 'Turbuhaler', 'to', 'the', 'aqua', 'spray', '(', '69', '%', 'versus', '31', '%', ')', '.']","(7, 8)","(42, 52)",-1,ss_i,10070173,Abstract,11,test,gold,1049.0
41,More than twice as many patients preferred Turbuhaler to the,aqua spray,( 69 % versus 31 % ) .,"['More', 'than', 'twice', 'as', 'many', 'patients', 'preferred', 'Turbuhaler', 'to', 'the', 'aqua', 'spray', '(', '69', '%', 'versus', '31', '%', ')', '.']","(10, 12)","(60, 70)",-1,ss_i,10070173,Abstract,11,test,gold,278.0
42,More than twice as many patients preferred,Turbuhaler,to the aqua spray ( 69 % versus 31 % ) .,"['More', 'than', 'twice', 'as', 'many', 'patients', 'preferred', 'Turbuhaler', 'to', 'the', 'aqua', 'spray', '(', '69', '%', 'versus', '31', '%', ')', '.']","(7, 8)","(42, 52)",-1,hl_i,10070173,Abstract,11,test,gold,1048.0
43,More than twice as many patients preferred Turbuhaler to the,aqua spray,( 69 % versus 31 % ) .,"['More', 'than', 'twice', 'as', 'many', 'patients', 'preferred', 'Turbuhaler', 'to', 'the', 'aqua', 'spray', '(', '69', '%', 'versus', '31', '%', ')', '.']","(10, 12)","(60, 70)",-1,hl_i,10070173,Abstract,11,test,gold,279.0
44,Improvement in,quality of life,from baseline to clinic visits was statistically significant in both groups .,"['Improvement', 'in', 'quality', 'of', 'life', 'from', 'baseline', 'to', 'clinic', 'visits', 'was', 'statistically', 'significant', 'in', 'both', 'groups', '.']","(2, 5)","(14, 29)",-1,ss_o,10070173,Abstract,12,test,gold,1888.0
45,Improvement in,quality of life,from baseline to clinic visits was statistically significant in both groups .,"['Improvement', 'in', 'quality', 'of', 'life', 'from', 'baseline', 'to', 'clinic', 'visits', 'was', 'statistically', 'significant', 'in', 'both', 'groups', '.']","(2, 5)","(14, 29)",-1,hl_o,10070173,Abstract,12,test,gold,1887.0
46,CONCLUSION Once daily use of 256 mg of budesonide aqua and 400 mg of budesonide Turbuhaler are equally safe and efficacious in the treatment of,SAR .,,"['CONCLUSION', 'Once', 'daily', 'use', 'of', '256', 'mg', 'of', 'budesonide', 'aqua', 'and', '400', 'mg', 'of', 'budesonide', 'Turbuhaler', 'are', 'equally', 'safe', 'and', 'efficacious', 'in', 'the', 'treatment', 'of', 'SAR', '.']","(25, 27)","(143, 148)",-1,ss_p,10070173,Abstract,13,test,gold,1113.0
47,CONCLUSION Once daily use of 256 mg of,budesonide aqua,and 400 mg of budesonide Turbuhaler are equally safe and efficacious in the treatment of SAR .,"['CONCLUSION', 'Once', 'daily', 'use', 'of', '256', 'mg', 'of', 'budesonide', 'aqua', 'and', '400', 'mg', 'of', 'budesonide', 'Turbuhaler', 'are', 'equally', 'safe', 'and', 'efficacious', 'in', 'the', 'treatment', 'of', 'SAR', '.']","(8, 10)","(38, 53)",-1,ss_i,10070173,Abstract,13,test,gold,5218.0
48,CONCLUSION Once daily use of 256 mg of budesonide aqua and 400 mg of,budesonide Turbuhaler,are equally safe and efficacious in the treatment of SAR .,"['CONCLUSION', 'Once', 'daily', 'use', 'of', '256', 'mg', 'of', 'budesonide', 'aqua', 'and', '400', 'mg', 'of', 'budesonide', 'Turbuhaler', 'are', 'equally', 'safe', 'and', 'efficacious', 'in', 'the', 'treatment', 'of', 'SAR', '.']","(14, 16)","(68, 89)",-1,ss_i,10070173,Abstract,13,test,gold,5228.0
49,CONCLUSION Once daily use of 256 mg of budesonide aqua and 400 mg of budesonide Turbuhaler are equally,safe,and efficacious in the treatment of SAR .,"['CONCLUSION', 'Once', 'daily', 'use', 'of', '256', 'mg', 'of', 'budesonide', 'aqua', 'and', '400', 'mg', 'of', 'budesonide', 'Turbuhaler', 'are', 'equally', 'safe', 'and', 'efficacious', 'in', 'the', 'treatment', 'of', 'SAR', '.']","(18, 19)","(102, 106)",-1,ss_o,10070173,Abstract,13,test,gold,889.0
50,CONCLUSION Once daily use of 256 mg of budesonide aqua and 400 mg of budesonide Turbuhaler are equally safe and,efficacious,in the treatment of SAR .,"['CONCLUSION', 'Once', 'daily', 'use', 'of', '256', 'mg', 'of', 'budesonide', 'aqua', 'and', '400', 'mg', 'of', 'budesonide', 'Turbuhaler', 'are', 'equally', 'safe', 'and', 'efficacious', 'in', 'the', 'treatment', 'of', 'SAR', '.']","(20, 21)","(111, 122)",-1,ss_o,10070173,Abstract,13,test,gold,871.0
51,CONCLUSION Once daily use of 256 mg of budesonide aqua and 400 mg of budesonide Turbuhaler are equally safe and efficacious in the treatment of,SAR .,,"['CONCLUSION', 'Once', 'daily', 'use', 'of', '256', 'mg', 'of', 'budesonide', 'aqua', 'and', '400', 'mg', 'of', 'budesonide', 'Turbuhaler', 'are', 'equally', 'safe', 'and', 'efficacious', 'in', 'the', 'treatment', 'of', 'SAR', '.']","(25, 27)","(143, 148)",-1,hl_p,10070173,Abstract,13,test,gold,1111.0
52,CONCLUSION Once daily use of 256 mg of,budesonide aqua,and 400 mg of budesonide Turbuhaler are equally safe and efficacious in the treatment of SAR .,"['CONCLUSION', 'Once', 'daily', 'use', 'of', '256', 'mg', 'of', 'budesonide', 'aqua', 'and', '400', 'mg', 'of', 'budesonide', 'Turbuhaler', 'are', 'equally', 'safe', 'and', 'efficacious', 'in', 'the', 'treatment', 'of', 'SAR', '.']","(8, 10)","(38, 53)",-1,hl_i,10070173,Abstract,13,test,gold,5217.0
53,CONCLUSION Once daily use of 256 mg of budesonide aqua and 400 mg of,budesonide Turbuhaler,are equally safe and efficacious in the treatment of SAR .,"['CONCLUSION', 'Once', 'daily', 'use', 'of', '256', 'mg', 'of', 'budesonide', 'aqua', 'and', '400', 'mg', 'of', 'budesonide', 'Turbuhaler', 'are', 'equally', 'safe', 'and', 'efficacious', 'in', 'the', 'treatment', 'of', 'SAR', '.']","(14, 16)","(68, 89)",-1,hl_i,10070173,Abstract,13,test,gold,5227.0
54,CONCLUSION Once daily use of 256 mg of budesonide aqua and 400 mg of budesonide Turbuhaler are equally,safe,and efficacious in the treatment of SAR .,"['CONCLUSION', 'Once', 'daily', 'use', 'of', '256', 'mg', 'of', 'budesonide', 'aqua', 'and', '400', 'mg', 'of', 'budesonide', 'Turbuhaler', 'are', 'equally', 'safe', 'and', 'efficacious', 'in', 'the', 'treatment', 'of', 'SAR', '.']","(18, 19)","(102, 106)",-1,hl_o,10070173,Abstract,13,test,gold,890.0
55,CONCLUSION Once daily use of 256 mg of budesonide aqua and 400 mg of budesonide Turbuhaler are equally safe and,efficacious,in the treatment of SAR .,"['CONCLUSION', 'Once', 'daily', 'use', 'of', '256', 'mg', 'of', 'budesonide', 'aqua', 'and', '400', 'mg', 'of', 'budesonide', 'Turbuhaler', 'are', 'equally', 'safe', 'and', 'efficacious', 'in', 'the', 'treatment', 'of', 'SAR', '.']","(20, 21)","(111, 122)",-1,hl_o,10070173,Abstract,13,test,gold,872.0
56,Patients preferred the,budesonide powder,formulation delivered via Turbuhaler two to one over the aqua formulation .,"['Patients', 'preferred', 'the', 'budesonide', 'powder', 'formulation', 'delivered', 'via', 'Turbuhaler', 'two', 'to', 'one', 'over', 'the', 'aqua', 'formulation', '.']","(3, 5)","(22, 39)",-1,ss_i,10070173,Abstract,14,test,gold,5223.0
57,Patients preferred the budesonide powder formulation delivered via,Turbuhaler,two to one over the aqua formulation .,"['Patients', 'preferred', 'the', 'budesonide', 'powder', 'formulation', 'delivered', 'via', 'Turbuhaler', 'two', 'to', 'one', 'over', 'the', 'aqua', 'formulation', '.']","(8, 9)","(66, 76)",-1,ss_i,10070173,Abstract,14,test,gold,1047.0
58,Patients preferred the budesonide powder formulation delivered via Turbuhaler two to one over the,aqua,formulation .,"['Patients', 'preferred', 'the', 'budesonide', 'powder', 'formulation', 'delivered', 'via', 'Turbuhaler', 'two', 'to', 'one', 'over', 'the', 'aqua', 'formulation', '.']","(14, 15)","(97, 101)",-1,ss_i,10070173,Abstract,14,test,gold,280.0
59,Patients preferred the,budesonide powder,formulation delivered via Turbuhaler two to one over the aqua formulation .,"['Patients', 'preferred', 'the', 'budesonide', 'powder', 'formulation', 'delivered', 'via', 'Turbuhaler', 'two', 'to', 'one', 'over', 'the', 'aqua', 'formulation', '.']","(3, 5)","(22, 39)",-1,hl_i,10070173,Abstract,14,test,gold,5224.0
60,Patients preferred the budesonide powder formulation delivered via,Turbuhaler,two to one over the aqua formulation .,"['Patients', 'preferred', 'the', 'budesonide', 'powder', 'formulation', 'delivered', 'via', 'Turbuhaler', 'two', 'to', 'one', 'over', 'the', 'aqua', 'formulation', '.']","(8, 9)","(66, 76)",-1,hl_i,10070173,Abstract,14,test,gold,1046.0
61,Patients preferred the budesonide powder formulation delivered via Turbuhaler two to one over the,aqua,formulation .,"['Patients', 'preferred', 'the', 'budesonide', 'powder', 'formulation', 'delivered', 'via', 'Turbuhaler', 'two', 'to', 'one', 'over', 'the', 'aqua', 'formulation', '.']","(14, 15)","(97, 101)",-1,hl_i,10070173,Abstract,14,test,gold,281.0
62,Anti-emetic efficacy of prophylactic granisetron compared with perphenazine for the prevention of post-operative vomiting in,children .,,"['Anti-emetic', 'efficacy', 'of', 'prophylactic', 'granisetron', 'compared', 'with', 'perphenazine', 'for', 'the', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', '.']","(15, 17)","(124, 134)",-1,ss_p,10390665,Title,0,test,gold,2150.0
63,Anti-emetic efficacy of prophylactic,granisetron,compared with perphenazine for the prevention of post-operative vomiting in children .,"['Anti-emetic', 'efficacy', 'of', 'prophylactic', 'granisetron', 'compared', 'with', 'perphenazine', 'for', 'the', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', '.']","(4, 5)","(36, 47)",-1,ss_i,10390665,Title,0,test,gold,5435.0
64,Anti-emetic efficacy of prophylactic granisetron compared with,perphenazine,for the prevention of post-operative vomiting in children .,"['Anti-emetic', 'efficacy', 'of', 'prophylactic', 'granisetron', 'compared', 'with', 'perphenazine', 'for', 'the', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', '.']","(7, 8)","(62, 74)",-1,ss_i,10390665,Title,0,test,gold,5627.0
65,,Anti-emetic efficacy,of prophylactic granisetron compared with perphenazine for the prevention of post-operative vomiting in children .,"['Anti-emetic', 'efficacy', 'of', 'prophylactic', 'granisetron', 'compared', 'with', 'perphenazine', 'for', 'the', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', '.']","(0, 2)","(0, 20)",-1,ss_o,10390665,Title,0,test,gold,4848.0
66,Anti-emetic efficacy of prophylactic granisetron compared with perphenazine for the,prevention,of post-operative vomiting in children .,"['Anti-emetic', 'efficacy', 'of', 'prophylactic', 'granisetron', 'compared', 'with', 'perphenazine', 'for', 'the', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', '.']","(10, 11)","(83, 93)",-1,ss_o,10390665,Title,0,test,gold,4038.0
67,Anti-emetic efficacy of prophylactic granisetron compared with perphenazine for the prevention of post-operative vomiting in,children .,,"['Anti-emetic', 'efficacy', 'of', 'prophylactic', 'granisetron', 'compared', 'with', 'perphenazine', 'for', 'the', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', '.']","(15, 17)","(124, 134)",-1,hl_p,10390665,Title,0,test,gold,2151.0
68,Anti-emetic efficacy of prophylactic,granisetron,compared with perphenazine for the prevention of post-operative vomiting in children .,"['Anti-emetic', 'efficacy', 'of', 'prophylactic', 'granisetron', 'compared', 'with', 'perphenazine', 'for', 'the', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', '.']","(4, 5)","(36, 47)",-1,hl_i,10390665,Title,0,test,gold,5436.0
69,Anti-emetic efficacy of prophylactic granisetron compared with,perphenazine,for the prevention of post-operative vomiting in children .,"['Anti-emetic', 'efficacy', 'of', 'prophylactic', 'granisetron', 'compared', 'with', 'perphenazine', 'for', 'the', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', '.']","(7, 8)","(62, 74)",-1,hl_i,10390665,Title,0,test,gold,5628.0
70,,Anti-emetic efficacy,of prophylactic granisetron compared with perphenazine for the prevention of post-operative vomiting in children .,"['Anti-emetic', 'efficacy', 'of', 'prophylactic', 'granisetron', 'compared', 'with', 'perphenazine', 'for', 'the', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', '.']","(0, 2)","(0, 20)",-1,hl_o,10390665,Title,0,test,gold,4849.0
71,Anti-emetic efficacy of prophylactic granisetron compared with perphenazine for the,prevention,of post-operative vomiting in children .,"['Anti-emetic', 'efficacy', 'of', 'prophylactic', 'granisetron', 'compared', 'with', 'perphenazine', 'for', 'the', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', '.']","(10, 11)","(83, 93)",-1,hl_o,10390665,Title,0,test,gold,4039.0
72,We have compared the efficacy of granisetron with perphenazine in the prevention of vomiting after,tonsillectomy with or without adenoidectomy in children .,,"['We', 'have', 'compared', 'the', 'efficacy', 'of', 'granisetron', 'with', 'perphenazine', 'in', 'the', 'prevention', 'of', 'vomiting', 'after', 'tonsillectomy', 'with', 'or', 'without', 'adenoidectomy', 'in', 'children', '.']","(15, 23)","(98, 155)",-1,ss_p,10390665,Abstract,0,test,gold,3716.0
73,We have compared the efficacy of,granisetron,with perphenazine in the prevention of vomiting after tonsillectomy with or without adenoidectomy in children .,"['We', 'have', 'compared', 'the', 'efficacy', 'of', 'granisetron', 'with', 'perphenazine', 'in', 'the', 'prevention', 'of', 'vomiting', 'after', 'tonsillectomy', 'with', 'or', 'without', 'adenoidectomy', 'in', 'children', '.']","(6, 7)","(32, 43)",-1,ss_i,10390665,Abstract,0,test,gold,5434.0
74,We have compared the efficacy of granisetron with,perphenazine,in the prevention of vomiting after tonsillectomy with or without adenoidectomy in children .,"['We', 'have', 'compared', 'the', 'efficacy', 'of', 'granisetron', 'with', 'perphenazine', 'in', 'the', 'prevention', 'of', 'vomiting', 'after', 'tonsillectomy', 'with', 'or', 'without', 'adenoidectomy', 'in', 'children', '.']","(8, 9)","(49, 61)",-1,ss_i,10390665,Abstract,0,test,gold,5626.0
75,We have compared the,efficacy,of granisetron with perphenazine in the prevention of vomiting after tonsillectomy with or without adenoidectomy in children .,"['We', 'have', 'compared', 'the', 'efficacy', 'of', 'granisetron', 'with', 'perphenazine', 'in', 'the', 'prevention', 'of', 'vomiting', 'after', 'tonsillectomy', 'with', 'or', 'without', 'adenoidectomy', 'in', 'children', '.']","(4, 5)","(20, 28)",-1,ss_o,10390665,Abstract,0,test,gold,4847.0
76,We have compared the efficacy of granisetron with perphenazine in the prevention of vomiting after,tonsillectomy with or without adenoidectomy,in children .,"['We', 'have', 'compared', 'the', 'efficacy', 'of', 'granisetron', 'with', 'perphenazine', 'in', 'the', 'prevention', 'of', 'vomiting', 'after', 'tonsillectomy', 'with', 'or', 'without', 'adenoidectomy', 'in', 'children', '.']","(15, 20)","(98, 141)",-1,hl_p,10390665,Abstract,0,test,gold,3717.0
77,We have compared the efficacy of granisetron with perphenazine in the prevention of vomiting after tonsillectomy with or without adenoidectomy in,children,.,"['We', 'have', 'compared', 'the', 'efficacy', 'of', 'granisetron', 'with', 'perphenazine', 'in', 'the', 'prevention', 'of', 'vomiting', 'after', 'tonsillectomy', 'with', 'or', 'without', 'adenoidectomy', 'in', 'children', '.']","(21, 22)","(145, 153)",-1,hl_p,10390665,Abstract,0,test,gold,2149.0
78,We have compared the efficacy of,granisetron,with perphenazine in the prevention of vomiting after tonsillectomy with or without adenoidectomy in children .,"['We', 'have', 'compared', 'the', 'efficacy', 'of', 'granisetron', 'with', 'perphenazine', 'in', 'the', 'prevention', 'of', 'vomiting', 'after', 'tonsillectomy', 'with', 'or', 'without', 'adenoidectomy', 'in', 'children', '.']","(6, 7)","(32, 43)",-1,hl_i,10390665,Abstract,0,test,gold,5433.0
79,We have compared the efficacy of granisetron with,perphenazine,in the prevention of vomiting after tonsillectomy with or without adenoidectomy in children .,"['We', 'have', 'compared', 'the', 'efficacy', 'of', 'granisetron', 'with', 'perphenazine', 'in', 'the', 'prevention', 'of', 'vomiting', 'after', 'tonsillectomy', 'with', 'or', 'without', 'adenoidectomy', 'in', 'children', '.']","(8, 9)","(49, 61)",-1,hl_i,10390665,Abstract,0,test,gold,5625.0
80,We have compared the,efficacy,of granisetron with perphenazine in the prevention of vomiting after tonsillectomy with or without adenoidectomy in children .,"['We', 'have', 'compared', 'the', 'efficacy', 'of', 'granisetron', 'with', 'perphenazine', 'in', 'the', 'prevention', 'of', 'vomiting', 'after', 'tonsillectomy', 'with', 'or', 'without', 'adenoidectomy', 'in', 'children', '.']","(4, 5)","(20, 28)",-1,hl_o,10390665,Abstract,0,test,gold,4846.0
81,"In a prospective , randomized , double-blind study ,","90 paediatric patients , ASA I , aged 4-10 years",", received granisetron 40 mg kg-1 or perphenazine 70 mg kg-1 ( n = 45 each ) intravenously immediately after an inhalation induction of anaesthesia .","['In', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', 'study', ',', '90', 'paediatric', 'patients', ',', 'ASA', 'I', ',', 'aged', '4-10', 'years', ',', 'received', 'granisetron', '40', 'mg', 'kg-1', 'or', 'perphenazine', '70', 'mg', 'kg-1', '(', 'n', '=', '45', 'each', ')', 'intravenously', 'immediately', 'after', 'an', 'inhalation', 'induction', 'of', 'anaesthesia', '.']","(9, 19)","(52, 100)",-1,ss_p,10390665,Abstract,1,test,gold,2039.0
82,"In a prospective , randomized , double-blind study , 90 paediatric patients , ASA I , aged 4-10 years , received",granisetron,40 mg kg-1 or perphenazine 70 mg kg-1 ( n = 45 each ) intravenously immediately after an inhalation induction of anaesthesia .,"['In', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', 'study', ',', '90', 'paediatric', 'patients', ',', 'ASA', 'I', ',', 'aged', '4-10', 'years', ',', 'received', 'granisetron', '40', 'mg', 'kg-1', 'or', 'perphenazine', '70', 'mg', 'kg-1', '(', 'n', '=', '45', 'each', ')', 'intravenously', 'immediately', 'after', 'an', 'inhalation', 'induction', 'of', 'anaesthesia', '.']","(21, 22)","(112, 123)",-1,ss_i,10390665,Abstract,1,test,gold,5432.0
83,"In a prospective , randomized , double-blind study , 90 paediatric patients , ASA I , aged 4-10 years , received granisetron 40 mg kg-1 or",perphenazine,70 mg kg-1 ( n = 45 each ) intravenously immediately after an inhalation induction of anaesthesia .,"['In', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', 'study', ',', '90', 'paediatric', 'patients', ',', 'ASA', 'I', ',', 'aged', '4-10', 'years', ',', 'received', 'granisetron', '40', 'mg', 'kg-1', 'or', 'perphenazine', '70', 'mg', 'kg-1', '(', 'n', '=', '45', 'each', ')', 'intravenously', 'immediately', 'after', 'an', 'inhalation', 'induction', 'of', 'anaesthesia', '.']","(26, 27)","(138, 150)",-1,ss_i,10390665,Abstract,1,test,gold,5624.0
84,"In a prospective , randomized , double-blind study ,",90 paediatric patients,", ASA I , aged 4-10 years , received granisetron 40 mg kg-1 or perphenazine 70 mg kg-1 ( n = 45 each ) intravenously immediately after an inhalation induction of anaesthesia .","['In', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', 'study', ',', '90', 'paediatric', 'patients', ',', 'ASA', 'I', ',', 'aged', '4-10', 'years', ',', 'received', 'granisetron', '40', 'mg', 'kg-1', 'or', 'perphenazine', '70', 'mg', 'kg-1', '(', 'n', '=', '45', 'each', ')', 'intravenously', 'immediately', 'after', 'an', 'inhalation', 'induction', 'of', 'anaesthesia', '.']","(9, 12)","(52, 74)",-1,hl_p,10390665,Abstract,1,test,gold,3755.0
85,"In a prospective , randomized , double-blind study , 90 paediatric patients ,",ASA I,", aged 4-10 years , received granisetron 40 mg kg-1 or perphenazine 70 mg kg-1 ( n = 45 each ) intravenously immediately after an inhalation induction of anaesthesia .","['In', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', 'study', ',', '90', 'paediatric', 'patients', ',', 'ASA', 'I', ',', 'aged', '4-10', 'years', ',', 'received', 'granisetron', '40', 'mg', 'kg-1', 'or', 'perphenazine', '70', 'mg', 'kg-1', '(', 'n', '=', '45', 'each', ')', 'intravenously', 'immediately', 'after', 'an', 'inhalation', 'induction', 'of', 'anaesthesia', '.']","(13, 15)","(77, 82)",-1,hl_p,10390665,Abstract,1,test,gold,1084.0
86,"In a prospective , randomized , double-blind study , 90 paediatric patients , ASA I ,",aged 4-10 years,", received granisetron 40 mg kg-1 or perphenazine 70 mg kg-1 ( n = 45 each ) intravenously immediately after an inhalation induction of anaesthesia .","['In', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', 'study', ',', '90', 'paediatric', 'patients', ',', 'ASA', 'I', ',', 'aged', '4-10', 'years', ',', 'received', 'granisetron', '40', 'mg', 'kg-1', 'or', 'perphenazine', '70', 'mg', 'kg-1', '(', 'n', '=', '45', 'each', ')', 'intravenously', 'immediately', 'after', 'an', 'inhalation', 'induction', 'of', 'anaesthesia', '.']","(16, 19)","(85, 100)",-1,hl_p,10390665,Abstract,1,test,gold,2028.0
87,"In a prospective , randomized , double-blind study , 90 paediatric patients , ASA I , aged 4-10 years , received",granisetron,40 mg kg-1 or perphenazine 70 mg kg-1 ( n = 45 each ) intravenously immediately after an inhalation induction of anaesthesia .,"['In', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', 'study', ',', '90', 'paediatric', 'patients', ',', 'ASA', 'I', ',', 'aged', '4-10', 'years', ',', 'received', 'granisetron', '40', 'mg', 'kg-1', 'or', 'perphenazine', '70', 'mg', 'kg-1', '(', 'n', '=', '45', 'each', ')', 'intravenously', 'immediately', 'after', 'an', 'inhalation', 'induction', 'of', 'anaesthesia', '.']","(21, 22)","(112, 123)",-1,hl_i,10390665,Abstract,1,test,gold,5431.0
88,"In a prospective , randomized , double-blind study , 90 paediatric patients , ASA I , aged 4-10 years , received granisetron 40 mg kg-1 or",perphenazine,70 mg kg-1 ( n = 45 each ) intravenously immediately after an inhalation induction of anaesthesia .,"['In', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', 'study', ',', '90', 'paediatric', 'patients', ',', 'ASA', 'I', ',', 'aged', '4-10', 'years', ',', 'received', 'granisetron', '40', 'mg', 'kg-1', 'or', 'perphenazine', '70', 'mg', 'kg-1', '(', 'n', '=', '45', 'each', ')', 'intravenously', 'immediately', 'after', 'an', 'inhalation', 'induction', 'of', 'anaesthesia', '.']","(26, 27)","(138, 150)",-1,hl_i,10390665,Abstract,1,test,gold,5623.0
89,A standard general anaesthetic technique was employed throughout .,,,"['A', 'standard', 'general', 'anaesthetic', 'technique', 'was', 'employed', 'throughout', '.']",,,,,10390665,Abstract,2,test,gold,
90,"A complete response , defined as no emesis with no need for another rescue antiemetic , during the first 3 h ( 0-3 h ) after anesthesia was 87 % with",granisetron,and 78 % with perphenazine ( P = 0.204 ) .,"['A', 'complete', 'response', ',', 'defined', 'as', 'no', 'emesis', 'with', 'no', 'need', 'for', 'another', 'rescue', 'antiemetic', ',', 'during', 'the', 'first', '3', 'h', '(', '0-3', 'h', ')', 'after', 'anesthesia', 'was', '87', '%', 'with', 'granisetron', 'and', '78', '%', 'with', 'perphenazine', '(', 'P', '=', '0.204', ')', '.']","(31, 32)","(149, 160)",-1,ss_i,10390665,Abstract,3,test,gold,5430.0
91,"A complete response , defined as no emesis with no need for another rescue antiemetic , during the first 3 h ( 0-3 h ) after anesthesia was 87 % with granisetron and 78 % with",perphenazine,( P = 0.204 ) .,"['A', 'complete', 'response', ',', 'defined', 'as', 'no', 'emesis', 'with', 'no', 'need', 'for', 'another', 'rescue', 'antiemetic', ',', 'during', 'the', 'first', '3', 'h', '(', '0-3', 'h', ')', 'after', 'anesthesia', 'was', '87', '%', 'with', 'granisetron', 'and', '78', '%', 'with', 'perphenazine', '(', 'P', '=', '0.204', ')', '.']","(36, 37)","(175, 187)",-1,ss_i,10390665,Abstract,3,test,gold,5622.0
92,A,"complete response , defined as no emesis with no need for another rescue antiemetic",", during the first 3 h ( 0-3 h ) after anesthesia was 87 % with granisetron and 78 % with perphenazine ( P = 0.204 ) .","['A', 'complete', 'response', ',', 'defined', 'as', 'no', 'emesis', 'with', 'no', 'need', 'for', 'another', 'rescue', 'antiemetic', ',', 'during', 'the', 'first', '3', 'h', '(', '0-3', 'h', ')', 'after', 'anesthesia', 'was', '87', '%', 'with', 'granisetron', 'and', '78', '%', 'with', 'perphenazine', '(', 'P', '=', '0.204', ')', '.']","(1, 15)","(1, 84)",-1,ss_o,10390665,Abstract,3,test,gold,5893.0
93,"A complete response , defined as no emesis with no need for another rescue antiemetic , during the first 3 h ( 0-3 h ) after anesthesia was 87 % with",granisetron,and 78 % with perphenazine ( P = 0.204 ) .,"['A', 'complete', 'response', ',', 'defined', 'as', 'no', 'emesis', 'with', 'no', 'need', 'for', 'another', 'rescue', 'antiemetic', ',', 'during', 'the', 'first', '3', 'h', '(', '0-3', 'h', ')', 'after', 'anesthesia', 'was', '87', '%', 'with', 'granisetron', 'and', '78', '%', 'with', 'perphenazine', '(', 'P', '=', '0.204', ')', '.']","(31, 32)","(149, 160)",-1,hl_i,10390665,Abstract,3,test,gold,5429.0
94,"A complete response , defined as no emesis with no need for another rescue antiemetic , during the first 3 h ( 0-3 h ) after anesthesia was 87 % with granisetron and 78 % with",perphenazine,( P = 0.204 ) .,"['A', 'complete', 'response', ',', 'defined', 'as', 'no', 'emesis', 'with', 'no', 'need', 'for', 'another', 'rescue', 'antiemetic', ',', 'during', 'the', 'first', '3', 'h', '(', '0-3', 'h', ')', 'after', 'anesthesia', 'was', '87', '%', 'with', 'granisetron', 'and', '78', '%', 'with', 'perphenazine', '(', 'P', '=', '0.204', ')', '.']","(36, 37)","(175, 187)",-1,hl_i,10390665,Abstract,3,test,gold,5621.0
95,A,"complete response , defined as no emesis with no need for another rescue antiemetic",", during the first 3 h ( 0-3 h ) after anesthesia was 87 % with granisetron and 78 % with perphenazine ( P = 0.204 ) .","['A', 'complete', 'response', ',', 'defined', 'as', 'no', 'emesis', 'with', 'no', 'need', 'for', 'another', 'rescue', 'antiemetic', ',', 'during', 'the', 'first', '3', 'h', '(', '0-3', 'h', ')', 'after', 'anesthesia', 'was', '87', '%', 'with', 'granisetron', 'and', '78', '%', 'with', 'perphenazine', '(', 'P', '=', '0.204', ')', '.']","(1, 15)","(1, 84)",-1,hl_o,10390665,Abstract,3,test,gold,5894.0
96,The,corresponding incidence,during the next 21 h ( 3-24 h ) after anaesthesia was 87 % and 62 % ( P = 0.007 ) .,"['The', 'corresponding', 'incidence', 'during', 'the', 'next', '21', 'h', '(', '3-24', 'h', ')', 'after', 'anaesthesia', 'was', '87', '%', 'and', '62', '%', '(', 'P', '=', '0.007', ')', '.']","(1, 3)","(3, 26)",-1,ss_o,10390665,Abstract,4,test,gold,3352.0
97,The,corresponding incidence,during the next 21 h ( 3-24 h ) after anaesthesia was 87 % and 62 % ( P = 0.007 ) .,"['The', 'corresponding', 'incidence', 'during', 'the', 'next', '21', 'h', '(', '3-24', 'h', ')', 'after', 'anaesthesia', 'was', '87', '%', 'and', '62', '%', '(', 'P', '=', '0.007', ')', '.']","(1, 3)","(3, 26)",-1,hl_o,10390665,Abstract,4,test,gold,3353.0
98,No clinically serious,adverse events,were observed in any of the groups .,"['No', 'clinically', 'serious', 'adverse', 'events', 'were', 'observed', 'in', 'any', 'of', 'the', 'groups', '.']","(3, 5)","(21, 35)",-1,ss_o,10390665,Abstract,5,test,gold,3072.0
99,No clinically serious,adverse events,were observed in any of the groups .,"['No', 'clinically', 'serious', 'adverse', 'events', 'were', 'observed', 'in', 'any', 'of', 'the', 'groups', '.']","(3, 5)","(21, 35)",-1,hl_o,10390665,Abstract,5,test,gold,3073.0
100,We conclude that granisetron is a better anti-emetic than perphenazine for the long-term prevention of post-operative vomiting in,children undergoing general anaesthesia for tonsillectomy .,,"['We', 'conclude', 'that', 'granisetron', 'is', 'a', 'better', 'anti-emetic', 'than', 'perphenazine', 'for', 'the', 'long-term', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', 'undergoing', 'general', 'anaesthesia', 'for', 'tonsillectomy', '.']","(18, 25)","(129, 188)",-1,ss_p,10390665,Abstract,6,test,gold,3714.0
101,We conclude that,granisetron,is a better anti-emetic than perphenazine for the long-term prevention of post-operative vomiting in children undergoing general anaesthesia for tonsillectomy .,"['We', 'conclude', 'that', 'granisetron', 'is', 'a', 'better', 'anti-emetic', 'than', 'perphenazine', 'for', 'the', 'long-term', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', 'undergoing', 'general', 'anaesthesia', 'for', 'tonsillectomy', '.']","(3, 4)","(16, 27)",-1,ss_i,10390665,Abstract,6,test,gold,5428.0
102,We conclude that granisetron is a better anti-emetic than,perphenazine,for the long-term prevention of post-operative vomiting in children undergoing general anaesthesia for tonsillectomy .,"['We', 'conclude', 'that', 'granisetron', 'is', 'a', 'better', 'anti-emetic', 'than', 'perphenazine', 'for', 'the', 'long-term', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', 'undergoing', 'general', 'anaesthesia', 'for', 'tonsillectomy', '.']","(9, 10)","(57, 69)",-1,ss_i,10390665,Abstract,6,test,gold,5620.0
103,We conclude that granisetron is a better anti-emetic than perphenazine for the,long-term prevention of post-operative vomiting,in children undergoing general anaesthesia for tonsillectomy .,"['We', 'conclude', 'that', 'granisetron', 'is', 'a', 'better', 'anti-emetic', 'than', 'perphenazine', 'for', 'the', 'long-term', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', 'undergoing', 'general', 'anaesthesia', 'for', 'tonsillectomy', '.']","(12, 17)","(78, 125)",-1,ss_o,10390665,Abstract,6,test,gold,2688.0
104,We conclude that granisetron is a better anti-emetic than perphenazine for the long-term prevention of post-operative vomiting in,children undergoing general anaesthesia for tonsillectomy,.,"['We', 'conclude', 'that', 'granisetron', 'is', 'a', 'better', 'anti-emetic', 'than', 'perphenazine', 'for', 'the', 'long-term', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', 'undergoing', 'general', 'anaesthesia', 'for', 'tonsillectomy', '.']","(18, 24)","(129, 186)",-1,hl_p,10390665,Abstract,6,test,gold,3715.0
105,We conclude that,granisetron,is a better anti-emetic than perphenazine for the long-term prevention of post-operative vomiting in children undergoing general anaesthesia for tonsillectomy .,"['We', 'conclude', 'that', 'granisetron', 'is', 'a', 'better', 'anti-emetic', 'than', 'perphenazine', 'for', 'the', 'long-term', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', 'undergoing', 'general', 'anaesthesia', 'for', 'tonsillectomy', '.']","(3, 4)","(16, 27)",-1,hl_i,10390665,Abstract,6,test,gold,5427.0
106,We conclude that granisetron is a better anti-emetic than,perphenazine,for the long-term prevention of post-operative vomiting in children undergoing general anaesthesia for tonsillectomy .,"['We', 'conclude', 'that', 'granisetron', 'is', 'a', 'better', 'anti-emetic', 'than', 'perphenazine', 'for', 'the', 'long-term', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', 'undergoing', 'general', 'anaesthesia', 'for', 'tonsillectomy', '.']","(9, 10)","(57, 69)",-1,hl_i,10390665,Abstract,6,test,gold,5619.0
107,We conclude that granisetron is a better anti-emetic than perphenazine for the,long-term prevention,of post-operative vomiting in children undergoing general anaesthesia for tonsillectomy .,"['We', 'conclude', 'that', 'granisetron', 'is', 'a', 'better', 'anti-emetic', 'than', 'perphenazine', 'for', 'the', 'long-term', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', 'undergoing', 'general', 'anaesthesia', 'for', 'tonsillectomy', '.']","(12, 14)","(78, 98)",-1,hl_o,10390665,Abstract,6,test,gold,4037.0
108,We conclude that granisetron is a better anti-emetic than perphenazine for the long-term prevention of,post-operative vomiting,in children undergoing general anaesthesia for tonsillectomy .,"['We', 'conclude', 'that', 'granisetron', 'is', 'a', 'better', 'anti-emetic', 'than', 'perphenazine', 'for', 'the', 'long-term', 'prevention', 'of', 'post-operative', 'vomiting', 'in', 'children', 'undergoing', 'general', 'anaesthesia', 'for', 'tonsillectomy', '.']","(15, 17)","(102, 125)",-1,hl_o,10390665,Abstract,6,test,gold,2690.0
109,The role of somatostatin ( octreotide ) in the regulation of melatonin secretion in,healthy volunteers and in patients with primary hypothyroidism .,,"['The', 'role', 'of', 'somatostatin', '(', 'octreotide', ')', 'in', 'the', 'regulation', 'of', 'melatonin', 'secretion', 'in', 'healthy', 'volunteers', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', '.']","(14, 23)","(83, 147)",-1,ss_p,10475150,Title,0,test,gold,6987.0
110,The role of,somatostatin ( octreotide ),in the regulation of melatonin secretion in healthy volunteers and in patients with primary hypothyroidism .,"['The', 'role', 'of', 'somatostatin', '(', 'octreotide', ')', 'in', 'the', 'regulation', 'of', 'melatonin', 'secretion', 'in', 'healthy', 'volunteers', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', '.']","(3, 7)","(11, 38)",-1,ss_i,10475150,Title,0,test,gold,5771.0
111,The role of somatostatin ( octreotide ) in the,regulation of melatonin secretion,in healthy volunteers and in patients with primary hypothyroidism .,"['The', 'role', 'of', 'somatostatin', '(', 'octreotide', ')', 'in', 'the', 'regulation', 'of', 'melatonin', 'secretion', 'in', 'healthy', 'volunteers', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', '.']","(9, 13)","(46, 79)",-1,ss_o,10475150,Title,0,test,gold,6599.0
112,The role of somatostatin ( octreotide ) in the regulation of melatonin secretion in,healthy volunteers and in patients with primary hypothyroidism .,,"['The', 'role', 'of', 'somatostatin', '(', 'octreotide', ')', 'in', 'the', 'regulation', 'of', 'melatonin', 'secretion', 'in', 'healthy', 'volunteers', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', '.']","(14, 23)","(83, 147)",-1,hl_p,10475150,Title,0,test,gold,6988.0
113,The role of,somatostatin ( octreotide ),in the regulation of melatonin secretion in healthy volunteers and in patients with primary hypothyroidism .,"['The', 'role', 'of', 'somatostatin', '(', 'octreotide', ')', 'in', 'the', 'regulation', 'of', 'melatonin', 'secretion', 'in', 'healthy', 'volunteers', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', '.']","(3, 7)","(11, 38)",-1,hl_i,10475150,Title,0,test,gold,5772.0
114,The role of somatostatin ( octreotide ) in the regulation of,melatonin secretion,in healthy volunteers and in patients with primary hypothyroidism .,"['The', 'role', 'of', 'somatostatin', '(', 'octreotide', ')', 'in', 'the', 'regulation', 'of', 'melatonin', 'secretion', 'in', 'healthy', 'volunteers', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', '.']","(11, 13)","(60, 79)",-1,hl_o,10475150,Title,0,test,gold,6596.0
115,,Somatostatin,"has been found in the pineal gland of several animal species , which suggests that it may be involved in the regulation of melatonin secretion .","['Somatostatin', 'has', 'been', 'found', 'in', 'the', 'pineal', 'gland', 'of', 'several', 'animal', 'species', ',', 'which', 'suggests', 'that', 'it', 'may', 'be', 'involved', 'in', 'the', 'regulation', 'of', 'melatonin', 'secretion', '.']","(0, 1)","(0, 12)",-1,ss_i,10475150,Abstract,0,test,gold,1053.0
116,"Somatostatin has been found in the pineal gland of several animal species , which suggests that it may be involved in the",regulation of melatonin secretion .,,"['Somatostatin', 'has', 'been', 'found', 'in', 'the', 'pineal', 'gland', 'of', 'several', 'animal', 'species', ',', 'which', 'suggests', 'that', 'it', 'may', 'be', 'involved', 'in', 'the', 'regulation', 'of', 'melatonin', 'secretion', '.']","(22, 27)","(121, 156)",-1,ss_o,10475150,Abstract,0,test,gold,6600.0
117,,Somatostatin,"has been found in the pineal gland of several animal species , which suggests that it may be involved in the regulation of melatonin secretion .","['Somatostatin', 'has', 'been', 'found', 'in', 'the', 'pineal', 'gland', 'of', 'several', 'animal', 'species', ',', 'which', 'suggests', 'that', 'it', 'may', 'be', 'involved', 'in', 'the', 'regulation', 'of', 'melatonin', 'secretion', '.']","(0, 1)","(0, 12)",-1,hl_i,10475150,Abstract,0,test,gold,1054.0
118,"Somatostatin has been found in the pineal gland of several animal species , which suggests that it may be involved in the regulation of",melatonin secretion .,,"['Somatostatin', 'has', 'been', 'found', 'in', 'the', 'pineal', 'gland', 'of', 'several', 'animal', 'species', ',', 'which', 'suggests', 'that', 'it', 'may', 'be', 'involved', 'in', 'the', 'regulation', 'of', 'melatonin', 'secretion', '.']","(24, 27)","(135, 156)",-1,hl_o,10475150,Abstract,0,test,gold,6597.0
119,Whether,somatostatin,has regulatory influence on melatonin secretion in man has never been unequivocally shown .,"['Whether', 'somatostatin', 'has', 'regulatory', 'influence', 'on', 'melatonin', 'secretion', 'in', 'man', 'has', 'never', 'been', 'unequivocally', 'shown', '.']","(1, 2)","(7, 19)",-1,ss_i,10475150,Abstract,1,test,gold,113.0
120,Whether somatostatin has,regulatory influence on melatonin secretion,in man has never been unequivocally shown .,"['Whether', 'somatostatin', 'has', 'regulatory', 'influence', 'on', 'melatonin', 'secretion', 'in', 'man', 'has', 'never', 'been', 'unequivocally', 'shown', '.']","(3, 8)","(24, 67)",-1,ss_o,10475150,Abstract,1,test,gold,6592.0
121,Whether,somatostatin,has regulatory influence on melatonin secretion in man has never been unequivocally shown .,"['Whether', 'somatostatin', 'has', 'regulatory', 'influence', 'on', 'melatonin', 'secretion', 'in', 'man', 'has', 'never', 'been', 'unequivocally', 'shown', '.']","(1, 2)","(7, 19)",-1,hl_i,10475150,Abstract,1,test,gold,114.0
122,Whether somatostatin has regulatory influence on,melatonin secretion,in man has never been unequivocally shown .,"['Whether', 'somatostatin', 'has', 'regulatory', 'influence', 'on', 'melatonin', 'secretion', 'in', 'man', 'has', 'never', 'been', 'unequivocally', 'shown', '.']","(6, 8)","(48, 67)",-1,hl_o,10475150,Abstract,1,test,gold,6595.0
123,We studied the nocturnal melatonin secretion in,"8 healthy volunteers , and 6 women with untreated primary hypothyroidism",", a disease state that is associated with increased nocturnal secretion of melatonin .","['We', 'studied', 'the', 'nocturnal', 'melatonin', 'secretion', 'in', '8', 'healthy', 'volunteers', ',', 'and', '6', 'women', 'with', 'untreated', 'primary', 'hypothyroidism', ',', 'a', 'disease', 'state', 'that', 'is', 'associated', 'with', 'increased', 'nocturnal', 'secretion', 'of', 'melatonin', '.']","(7, 18)","(47, 119)",-1,ss_p,10475150,Abstract,2,test,gold,6984.0
124,We studied the,nocturnal melatonin secretion,"in 8 healthy volunteers , and 6 women with untreated primary hypothyroidism , a disease state that is associated with increased nocturnal secretion of melatonin .","['We', 'studied', 'the', 'nocturnal', 'melatonin', 'secretion', 'in', '8', 'healthy', 'volunteers', ',', 'and', '6', 'women', 'with', 'untreated', 'primary', 'hypothyroidism', ',', 'a', 'disease', 'state', 'that', 'is', 'associated', 'with', 'increased', 'nocturnal', 'secretion', 'of', 'melatonin', '.']","(3, 6)","(14, 43)",-1,ss_o,10475150,Abstract,2,test,gold,6590.0
125,We studied the nocturnal melatonin secretion in,8 healthy volunteers,", and 6 women with untreated primary hypothyroidism , a disease state that is associated with increased nocturnal secretion of melatonin .","['We', 'studied', 'the', 'nocturnal', 'melatonin', 'secretion', 'in', '8', 'healthy', 'volunteers', ',', 'and', '6', 'women', 'with', 'untreated', 'primary', 'hypothyroidism', ',', 'a', 'disease', 'state', 'that', 'is', 'associated', 'with', 'increased', 'nocturnal', 'secretion', 'of', 'melatonin', '.']","(7, 10)","(47, 67)",-1,hl_p,10475150,Abstract,2,test,gold,2257.0
126,"We studied the nocturnal melatonin secretion in 8 healthy volunteers , and",6 women,"with untreated primary hypothyroidism , a disease state that is associated with increased nocturnal secretion of melatonin .","['We', 'studied', 'the', 'nocturnal', 'melatonin', 'secretion', 'in', '8', 'healthy', 'volunteers', ',', 'and', '6', 'women', 'with', 'untreated', 'primary', 'hypothyroidism', ',', 'a', 'disease', 'state', 'that', 'is', 'associated', 'with', 'increased', 'nocturnal', 'secretion', 'of', 'melatonin', '.']","(12, 14)","(74, 81)",-1,hl_p,10475150,Abstract,2,test,gold,2236.0
127,"We studied the nocturnal melatonin secretion in 8 healthy volunteers , and 6 women with",untreated primary hypothyroidism,", a disease state that is associated with increased nocturnal secretion of melatonin .","['We', 'studied', 'the', 'nocturnal', 'melatonin', 'secretion', 'in', '8', 'healthy', 'volunteers', ',', 'and', '6', 'women', 'with', 'untreated', 'primary', 'hypothyroidism', ',', 'a', 'disease', 'state', 'that', 'is', 'associated', 'with', 'increased', 'nocturnal', 'secretion', 'of', 'melatonin', '.']","(15, 18)","(87, 119)",-1,hl_p,10475150,Abstract,2,test,gold,3558.0
128,We studied the,nocturnal melatonin secretion,"in 8 healthy volunteers , and 6 women with untreated primary hypothyroidism , a disease state that is associated with increased nocturnal secretion of melatonin .","['We', 'studied', 'the', 'nocturnal', 'melatonin', 'secretion', 'in', '8', 'healthy', 'volunteers', ',', 'and', '6', 'women', 'with', 'untreated', 'primary', 'hypothyroidism', ',', 'a', 'disease', 'state', 'that', 'is', 'associated', 'with', 'increased', 'nocturnal', 'secretion', 'of', 'melatonin', '.']","(3, 6)","(14, 43)",-1,hl_o,10475150,Abstract,2,test,gold,6591.0
129,The participants were given subcutaneous injections at 18:00 h and 23:00 h of either,saline,or octreotide ( Sandostatin ; each injection 50 microg ) .,"['The', 'participants', 'were', 'given', 'subcutaneous', 'injections', 'at', '18:00', 'h', 'and', '23:00', 'h', 'of', 'either', 'saline', 'or', 'octreotide', '(', 'Sandostatin', ';', 'each', 'injection', '50', 'microg', ')', '.']","(14, 15)","(84, 90)",-1,ss_i,10475150,Abstract,3,test,gold,4924.0
130,The participants were given subcutaneous injections at 18:00 h and 23:00 h of either saline or,octreotide ( Sandostatin ;,each injection 50 microg ) .,"['The', 'participants', 'were', 'given', 'subcutaneous', 'injections', 'at', '18:00', 'h', 'and', '23:00', 'h', 'of', 'either', 'saline', 'or', 'octreotide', '(', 'Sandostatin', ';', 'each', 'injection', '50', 'microg', ')', '.']","(16, 20)","(94, 120)",-1,ss_i,10475150,Abstract,3,test,gold,5773.0
131,The participants were given subcutaneous injections at 18:00 h and 23:00 h of either,saline,or octreotide ( Sandostatin ; each injection 50 microg ) .,"['The', 'participants', 'were', 'given', 'subcutaneous', 'injections', 'at', '18:00', 'h', 'and', '23:00', 'h', 'of', 'either', 'saline', 'or', 'octreotide', '(', 'Sandostatin', ';', 'each', 'injection', '50', 'microg', ')', '.']","(14, 15)","(84, 90)",-1,hl_i,10475150,Abstract,3,test,gold,4925.0
132,The participants were given subcutaneous injections at 18:00 h and 23:00 h of either saline or,octreotide ( Sandostatin ;,each injection 50 microg ) .,"['The', 'participants', 'were', 'given', 'subcutaneous', 'injections', 'at', '18:00', 'h', 'and', '23:00', 'h', 'of', 'either', 'saline', 'or', 'octreotide', '(', 'Sandostatin', ';', 'each', 'injection', '50', 'microg', ')', '.']","(16, 20)","(94, 120)",-1,hl_i,10475150,Abstract,3,test,gold,5774.0
133,During the nights when the,healthy volunteers,"were given octreotide , melatonin secretion was similar to that recorded during administration of saline .","['During', 'the', 'nights', 'when', 'the', 'healthy', 'volunteers', 'were', 'given', 'octreotide', ',', 'melatonin', 'secretion', 'was', 'similar', 'to', 'that', 'recorded', 'during', 'administration', 'of', 'saline', '.']","(5, 7)","(26, 44)",-1,ss_p,10475150,Abstract,4,test,gold,2258.0
134,During the nights when the healthy volunteers were given,octreotide,", melatonin secretion was similar to that recorded during administration of saline .","['During', 'the', 'nights', 'when', 'the', 'healthy', 'volunteers', 'were', 'given', 'octreotide', ',', 'melatonin', 'secretion', 'was', 'similar', 'to', 'that', 'recorded', 'during', 'administration', 'of', 'saline', '.']","(9, 10)","(56, 66)",-1,ss_i,10475150,Abstract,4,test,gold,5789.0
135,"During the nights when the healthy volunteers were given octreotide , melatonin secretion was similar to that recorded during administration of",saline .,,"['During', 'the', 'nights', 'when', 'the', 'healthy', 'volunteers', 'were', 'given', 'octreotide', ',', 'melatonin', 'secretion', 'was', 'similar', 'to', 'that', 'recorded', 'during', 'administration', 'of', 'saline', '.']","(21, 23)","(143, 151)",-1,ss_i,10475150,Abstract,4,test,gold,4923.0
136,"During the nights when the healthy volunteers were given octreotide ,",melatonin secretion,was similar to that recorded during administration of saline .,"['During', 'the', 'nights', 'when', 'the', 'healthy', 'volunteers', 'were', 'given', 'octreotide', ',', 'melatonin', 'secretion', 'was', 'similar', 'to', 'that', 'recorded', 'during', 'administration', 'of', 'saline', '.']","(11, 13)","(69, 88)",-1,ss_o,10475150,Abstract,4,test,gold,6594.0
137,During the nights when the,healthy volunteers,"were given octreotide , melatonin secretion was similar to that recorded during administration of saline .","['During', 'the', 'nights', 'when', 'the', 'healthy', 'volunteers', 'were', 'given', 'octreotide', ',', 'melatonin', 'secretion', 'was', 'similar', 'to', 'that', 'recorded', 'during', 'administration', 'of', 'saline', '.']","(5, 7)","(26, 44)",-1,hl_p,10475150,Abstract,4,test,gold,2259.0
138,During the nights when the healthy volunteers were given,octreotide,", melatonin secretion was similar to that recorded during administration of saline .","['During', 'the', 'nights', 'when', 'the', 'healthy', 'volunteers', 'were', 'given', 'octreotide', ',', 'melatonin', 'secretion', 'was', 'similar', 'to', 'that', 'recorded', 'during', 'administration', 'of', 'saline', '.']","(9, 10)","(56, 66)",-1,hl_i,10475150,Abstract,4,test,gold,5790.0
139,"During the nights when the healthy volunteers were given octreotide , melatonin secretion was similar to that recorded during administration of",saline .,,"['During', 'the', 'nights', 'when', 'the', 'healthy', 'volunteers', 'were', 'given', 'octreotide', ',', 'melatonin', 'secretion', 'was', 'similar', 'to', 'that', 'recorded', 'during', 'administration', 'of', 'saline', '.']","(21, 23)","(143, 151)",-1,hl_i,10475150,Abstract,4,test,gold,4922.0
140,"During the nights when the healthy volunteers were given octreotide ,",melatonin secretion,was similar to that recorded during administration of saline .,"['During', 'the', 'nights', 'when', 'the', 'healthy', 'volunteers', 'were', 'given', 'octreotide', ',', 'melatonin', 'secretion', 'was', 'similar', 'to', 'that', 'recorded', 'during', 'administration', 'of', 'saline', '.']","(11, 13)","(69, 88)",-1,hl_o,10475150,Abstract,4,test,gold,6593.0
141,Also the,urinary excretion of melatonin,was of similar magnitude at these two occasions .,"['Also', 'the', 'urinary', 'excretion', 'of', 'melatonin', 'was', 'of', 'similar', 'magnitude', 'at', 'these', 'two', 'occasions', '.']","(2, 6)","(8, 38)",-1,ss_o,10475150,Abstract,5,test,gold,6586.0
142,Also the,urinary excretion of melatonin,was of similar magnitude at these two occasions .,"['Also', 'the', 'urinary', 'excretion', 'of', 'melatonin', 'was', 'of', 'similar', 'magnitude', 'at', 'these', 'two', 'occasions', '.']","(2, 6)","(8, 38)",-1,hl_o,10475150,Abstract,5,test,gold,6587.0
143,"By contrast , the GH secretion was significantly lower the nights the",healthy controls,were given octreotide ( GH AUC 22.6+/-5.4 mU/l x h during octreotide and 126.6+/-21.9 mU/l x h during saline ; p < 0.01 ) .,"['By', 'contrast', ',', 'the', 'GH', 'secretion', 'was', 'significantly', 'lower', 'the', 'nights', 'the', 'healthy', 'controls', 'were', 'given', 'octreotide', '(', 'GH', 'AUC', '22.6+/-5.4', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '126.6+/-21.9', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.01', ')', '.']","(12, 14)","(69, 85)",-1,ss_p,10475150,Abstract,6,test,gold,906.0
144,"By contrast , the GH secretion was significantly lower the nights the healthy controls were given",octreotide,( GH AUC 22.6+/-5.4 mU/l x h during octreotide and 126.6+/-21.9 mU/l x h during saline ; p < 0.01 ) .,"['By', 'contrast', ',', 'the', 'GH', 'secretion', 'was', 'significantly', 'lower', 'the', 'nights', 'the', 'healthy', 'controls', 'were', 'given', 'octreotide', '(', 'GH', 'AUC', '22.6+/-5.4', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '126.6+/-21.9', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.01', ')', '.']","(16, 17)","(97, 107)",-1,ss_i,10475150,Abstract,6,test,gold,5788.0
145,"By contrast , the GH secretion was significantly lower the nights the healthy controls were given octreotide ( GH AUC 22.6+/-5.4 mU/l x h during",octreotide,and 126.6+/-21.9 mU/l x h during saline ; p < 0.01 ) .,"['By', 'contrast', ',', 'the', 'GH', 'secretion', 'was', 'significantly', 'lower', 'the', 'nights', 'the', 'healthy', 'controls', 'were', 'given', 'octreotide', '(', 'GH', 'AUC', '22.6+/-5.4', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '126.6+/-21.9', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.01', ')', '.']","(25, 26)","(144, 154)",-1,ss_i,10475150,Abstract,6,test,gold,5787.0
146,"By contrast , the GH secretion was significantly lower the nights the healthy controls were given octreotide ( GH AUC 22.6+/-5.4 mU/l x h during octreotide and 126.6+/-21.9 mU/l x h during",saline ;,p < 0.01 ) .,"['By', 'contrast', ',', 'the', 'GH', 'secretion', 'was', 'significantly', 'lower', 'the', 'nights', 'the', 'healthy', 'controls', 'were', 'given', 'octreotide', '(', 'GH', 'AUC', '22.6+/-5.4', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '126.6+/-21.9', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.01', ')', '.']","(32, 34)","(188, 196)",-1,ss_i,10475150,Abstract,6,test,gold,4921.0
147,"By contrast , the",GH secretion,was significantly lower the nights the healthy controls were given octreotide ( GH AUC 22.6+/-5.4 mU/l x h during octreotide and 126.6+/-21.9 mU/l x h during saline ; p < 0.01 ) .,"['By', 'contrast', ',', 'the', 'GH', 'secretion', 'was', 'significantly', 'lower', 'the', 'nights', 'the', 'healthy', 'controls', 'were', 'given', 'octreotide', '(', 'GH', 'AUC', '22.6+/-5.4', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '126.6+/-21.9', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.01', ')', '.']","(4, 6)","(17, 29)",-1,ss_o,10475150,Abstract,6,test,gold,3177.0
148,"By contrast , the GH secretion was significantly lower the nights the healthy controls were given",octreotide,( GH AUC 22.6+/-5.4 mU/l x h during octreotide and 126.6+/-21.9 mU/l x h during saline ; p < 0.01 ) .,"['By', 'contrast', ',', 'the', 'GH', 'secretion', 'was', 'significantly', 'lower', 'the', 'nights', 'the', 'healthy', 'controls', 'were', 'given', 'octreotide', '(', 'GH', 'AUC', '22.6+/-5.4', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '126.6+/-21.9', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.01', ')', '.']","(16, 17)","(97, 107)",-1,hl_i,10475150,Abstract,6,test,gold,5786.0
149,"By contrast , the GH secretion was significantly lower the nights the healthy controls were given octreotide ( GH AUC 22.6+/-5.4 mU/l x h during",octreotide,and 126.6+/-21.9 mU/l x h during saline ; p < 0.01 ) .,"['By', 'contrast', ',', 'the', 'GH', 'secretion', 'was', 'significantly', 'lower', 'the', 'nights', 'the', 'healthy', 'controls', 'were', 'given', 'octreotide', '(', 'GH', 'AUC', '22.6+/-5.4', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '126.6+/-21.9', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.01', ')', '.']","(25, 26)","(144, 154)",-1,hl_i,10475150,Abstract,6,test,gold,5785.0
150,"By contrast , the GH secretion was significantly lower the nights the healthy controls were given octreotide ( GH AUC 22.6+/-5.4 mU/l x h during octreotide and 126.6+/-21.9 mU/l x h during",saline ;,p < 0.01 ) .,"['By', 'contrast', ',', 'the', 'GH', 'secretion', 'was', 'significantly', 'lower', 'the', 'nights', 'the', 'healthy', 'controls', 'were', 'given', 'octreotide', '(', 'GH', 'AUC', '22.6+/-5.4', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '126.6+/-21.9', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.01', ')', '.']","(32, 34)","(188, 196)",-1,hl_i,10475150,Abstract,6,test,gold,4920.0
151,"By contrast , the",GH secretion,was significantly lower the nights the healthy controls were given octreotide ( GH AUC 22.6+/-5.4 mU/l x h during octreotide and 126.6+/-21.9 mU/l x h during saline ; p < 0.01 ) .,"['By', 'contrast', ',', 'the', 'GH', 'secretion', 'was', 'significantly', 'lower', 'the', 'nights', 'the', 'healthy', 'controls', 'were', 'given', 'octreotide', '(', 'GH', 'AUC', '22.6+/-5.4', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '126.6+/-21.9', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.01', ')', '.']","(4, 6)","(17, 29)",-1,hl_o,10475150,Abstract,6,test,gold,3178.0
152,,The patients with hypothyroidism,also showed similar nocturnal melatonin secretion during octreotide and saline .,"['The', 'patients', 'with', 'hypothyroidism', 'also', 'showed', 'similar', 'nocturnal', 'melatonin', 'secretion', 'during', 'octreotide', 'and', 'saline', '.']","(0, 4)","(0, 32)",-1,ss_p,10475150,Abstract,7,test,gold,3788.0
153,The patients with hypothyroidism also showed similar nocturnal melatonin secretion during,octreotide,and saline .,"['The', 'patients', 'with', 'hypothyroidism', 'also', 'showed', 'similar', 'nocturnal', 'melatonin', 'secretion', 'during', 'octreotide', 'and', 'saline', '.']","(11, 12)","(89, 99)",-1,ss_i,10475150,Abstract,7,test,gold,5784.0
154,The patients with hypothyroidism also showed similar nocturnal melatonin secretion during octreotide and,saline .,,"['The', 'patients', 'with', 'hypothyroidism', 'also', 'showed', 'similar', 'nocturnal', 'melatonin', 'secretion', 'during', 'octreotide', 'and', 'saline', '.']","(13, 15)","(104, 112)",-1,ss_i,10475150,Abstract,7,test,gold,4919.0
155,The patients with hypothyroidism also showed similar,nocturnal melatonin secretion,during octreotide and saline .,"['The', 'patients', 'with', 'hypothyroidism', 'also', 'showed', 'similar', 'nocturnal', 'melatonin', 'secretion', 'during', 'octreotide', 'and', 'saline', '.']","(7, 10)","(52, 81)",-1,ss_o,10475150,Abstract,7,test,gold,6589.0
156,The,patients with hypothyroidism,also showed similar nocturnal melatonin secretion during octreotide and saline .,"['The', 'patients', 'with', 'hypothyroidism', 'also', 'showed', 'similar', 'nocturnal', 'melatonin', 'secretion', 'during', 'octreotide', 'and', 'saline', '.']","(1, 4)","(3, 31)",-1,hl_p,10475150,Abstract,7,test,gold,3789.0
157,The patients with hypothyroidism also showed similar nocturnal melatonin secretion during,octreotide,and saline .,"['The', 'patients', 'with', 'hypothyroidism', 'also', 'showed', 'similar', 'nocturnal', 'melatonin', 'secretion', 'during', 'octreotide', 'and', 'saline', '.']","(11, 12)","(89, 99)",-1,hl_i,10475150,Abstract,7,test,gold,5783.0
158,The patients with hypothyroidism also showed similar nocturnal melatonin secretion during octreotide and,saline .,,"['The', 'patients', 'with', 'hypothyroidism', 'also', 'showed', 'similar', 'nocturnal', 'melatonin', 'secretion', 'during', 'octreotide', 'and', 'saline', '.']","(13, 15)","(104, 112)",-1,hl_i,10475150,Abstract,7,test,gold,4918.0
159,The patients with hypothyroidism also showed similar,nocturnal melatonin secretion,during octreotide and saline .,"['The', 'patients', 'with', 'hypothyroidism', 'also', 'showed', 'similar', 'nocturnal', 'melatonin', 'secretion', 'during', 'octreotide', 'and', 'saline', '.']","(7, 10)","(52, 81)",-1,hl_o,10475150,Abstract,7,test,gold,6588.0
160,,Urinary excretion of melatonin,"also remained unchanged , as did GH secretion .","['Urinary', 'excretion', 'of', 'melatonin', 'also', 'remained', 'unchanged', ',', 'as', 'did', 'GH', 'secretion', '.']","(0, 4)","(0, 30)",-1,ss_o,10475150,Abstract,8,test,gold,6584.0
161,,Urinary excretion of melatonin,"also remained unchanged , as did GH secretion .","['Urinary', 'excretion', 'of', 'melatonin', 'also', 'remained', 'unchanged', ',', 'as', 'did', 'GH', 'secretion', '.']","(0, 4)","(0, 30)",-1,hl_o,10475150,Abstract,8,test,gold,6585.0
162,"The total nocturnal secretion of TSH was , however , significantly reduced by",octreotide,"( TSH AUC 562+/-136 mU/l x h during octreotide and 851+/-185 mU/l x h during saline ; p < 0.05 ) , thus suggesting that 100 microg of octreotide should be sufficient to inhibit also the pinealocytes if their function were regulated by somatostatin .","['The', 'total', 'nocturnal', 'secretion', 'of', 'TSH', 'was', ',', 'however', ',', 'significantly', 'reduced', 'by', 'octreotide', '(', 'TSH', 'AUC', '562+/-136', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '851+/-185', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.05', ')', ',', 'thus', 'suggesting', 'that', '100', 'microg', 'of', 'octreotide', 'should', 'be', 'sufficient', 'to', 'inhibit', 'also', 'the', 'pinealocytes', 'if', 'their', 'function', 'were', 'regulated', 'by', 'somatostatin', '.']","(13, 14)","(77, 87)",-1,ss_i,10475150,Abstract,9,test,gold,5782.0
163,"The total nocturnal secretion of TSH was , however , significantly reduced by octreotide ( TSH AUC 562+/-136 mU/l x h during",octreotide,"and 851+/-185 mU/l x h during saline ; p < 0.05 ) , thus suggesting that 100 microg of octreotide should be sufficient to inhibit also the pinealocytes if their function were regulated by somatostatin .","['The', 'total', 'nocturnal', 'secretion', 'of', 'TSH', 'was', ',', 'however', ',', 'significantly', 'reduced', 'by', 'octreotide', '(', 'TSH', 'AUC', '562+/-136', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '851+/-185', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.05', ')', ',', 'thus', 'suggesting', 'that', '100', 'microg', 'of', 'octreotide', 'should', 'be', 'sufficient', 'to', 'inhibit', 'also', 'the', 'pinealocytes', 'if', 'their', 'function', 'were', 'regulated', 'by', 'somatostatin', '.']","(22, 23)","(124, 134)",-1,ss_i,10475150,Abstract,9,test,gold,5781.0
164,"The total nocturnal secretion of TSH was , however , significantly reduced by octreotide ( TSH AUC 562+/-136 mU/l x h during octreotide and 851+/-185 mU/l x h during",saline ;,"p < 0.05 ) , thus suggesting that 100 microg of octreotide should be sufficient to inhibit also the pinealocytes if their function were regulated by somatostatin .","['The', 'total', 'nocturnal', 'secretion', 'of', 'TSH', 'was', ',', 'however', ',', 'significantly', 'reduced', 'by', 'octreotide', '(', 'TSH', 'AUC', '562+/-136', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '851+/-185', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.05', ')', ',', 'thus', 'suggesting', 'that', '100', 'microg', 'of', 'octreotide', 'should', 'be', 'sufficient', 'to', 'inhibit', 'also', 'the', 'pinealocytes', 'if', 'their', 'function', 'were', 'regulated', 'by', 'somatostatin', '.']","(29, 31)","(165, 173)",-1,ss_i,10475150,Abstract,9,test,gold,4917.0
165,"The total nocturnal secretion of TSH was , however , significantly reduced by octreotide ( TSH AUC 562+/-136 mU/l x h during octreotide and 851+/-185 mU/l x h during saline ; p < 0.05 ) , thus suggesting that 100 microg of",octreotide,should be sufficient to inhibit also the pinealocytes if their function were regulated by somatostatin .,"['The', 'total', 'nocturnal', 'secretion', 'of', 'TSH', 'was', ',', 'however', ',', 'significantly', 'reduced', 'by', 'octreotide', '(', 'TSH', 'AUC', '562+/-136', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '851+/-185', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.05', ')', ',', 'thus', 'suggesting', 'that', '100', 'microg', 'of', 'octreotide', 'should', 'be', 'sufficient', 'to', 'inhibit', 'also', 'the', 'pinealocytes', 'if', 'their', 'function', 'were', 'regulated', 'by', 'somatostatin', '.']","(42, 43)","(222, 232)",-1,ss_i,10475150,Abstract,9,test,gold,5780.0
166,"The total nocturnal secretion of TSH was , however , significantly reduced by octreotide ( TSH AUC 562+/-136 mU/l x h during octreotide and 851+/-185 mU/l x h during saline ; p < 0.05 ) , thus suggesting that 100 microg of octreotide should be sufficient to inhibit also the pinealocytes if their function were regulated by",somatostatin .,,"['The', 'total', 'nocturnal', 'secretion', 'of', 'TSH', 'was', ',', 'however', ',', 'significantly', 'reduced', 'by', 'octreotide', '(', 'TSH', 'AUC', '562+/-136', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '851+/-185', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.05', ')', ',', 'thus', 'suggesting', 'that', '100', 'microg', 'of', 'octreotide', 'should', 'be', 'sufficient', 'to', 'inhibit', 'also', 'the', 'pinealocytes', 'if', 'their', 'function', 'were', 'regulated', 'by', 'somatostatin', '.']","(57, 59)","(323, 337)",-1,ss_i,10475150,Abstract,9,test,gold,112.0
167,The,total nocturnal secretion of TSH,"was , however , significantly reduced by octreotide ( TSH AUC 562+/-136 mU/l x h during octreotide and 851+/-185 mU/l x h during saline ; p < 0.05 ) , thus suggesting that 100 microg of octreotide should be sufficient to inhibit also the pinealocytes if their function were regulated by somatostatin .","['The', 'total', 'nocturnal', 'secretion', 'of', 'TSH', 'was', ',', 'however', ',', 'significantly', 'reduced', 'by', 'octreotide', '(', 'TSH', 'AUC', '562+/-136', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '851+/-185', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.05', ')', ',', 'thus', 'suggesting', 'that', '100', 'microg', 'of', 'octreotide', 'should', 'be', 'sufficient', 'to', 'inhibit', 'also', 'the', 'pinealocytes', 'if', 'their', 'function', 'were', 'regulated', 'by', 'somatostatin', '.']","(1, 6)","(3, 35)",-1,ss_o,10475150,Abstract,9,test,gold,6601.0
168,"The total nocturnal secretion of TSH was , however , significantly reduced by",octreotide,"( TSH AUC 562+/-136 mU/l x h during octreotide and 851+/-185 mU/l x h during saline ; p < 0.05 ) , thus suggesting that 100 microg of octreotide should be sufficient to inhibit also the pinealocytes if their function were regulated by somatostatin .","['The', 'total', 'nocturnal', 'secretion', 'of', 'TSH', 'was', ',', 'however', ',', 'significantly', 'reduced', 'by', 'octreotide', '(', 'TSH', 'AUC', '562+/-136', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '851+/-185', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.05', ')', ',', 'thus', 'suggesting', 'that', '100', 'microg', 'of', 'octreotide', 'should', 'be', 'sufficient', 'to', 'inhibit', 'also', 'the', 'pinealocytes', 'if', 'their', 'function', 'were', 'regulated', 'by', 'somatostatin', '.']","(13, 14)","(77, 87)",-1,hl_i,10475150,Abstract,9,test,gold,5779.0
169,"The total nocturnal secretion of TSH was , however , significantly reduced by octreotide ( TSH AUC 562+/-136 mU/l x h during",octreotide,"and 851+/-185 mU/l x h during saline ; p < 0.05 ) , thus suggesting that 100 microg of octreotide should be sufficient to inhibit also the pinealocytes if their function were regulated by somatostatin .","['The', 'total', 'nocturnal', 'secretion', 'of', 'TSH', 'was', ',', 'however', ',', 'significantly', 'reduced', 'by', 'octreotide', '(', 'TSH', 'AUC', '562+/-136', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '851+/-185', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.05', ')', ',', 'thus', 'suggesting', 'that', '100', 'microg', 'of', 'octreotide', 'should', 'be', 'sufficient', 'to', 'inhibit', 'also', 'the', 'pinealocytes', 'if', 'their', 'function', 'were', 'regulated', 'by', 'somatostatin', '.']","(22, 23)","(124, 134)",-1,hl_i,10475150,Abstract,9,test,gold,5778.0
170,"The total nocturnal secretion of TSH was , however , significantly reduced by octreotide ( TSH AUC 562+/-136 mU/l x h during octreotide and 851+/-185 mU/l x h during",saline ;,"p < 0.05 ) , thus suggesting that 100 microg of octreotide should be sufficient to inhibit also the pinealocytes if their function were regulated by somatostatin .","['The', 'total', 'nocturnal', 'secretion', 'of', 'TSH', 'was', ',', 'however', ',', 'significantly', 'reduced', 'by', 'octreotide', '(', 'TSH', 'AUC', '562+/-136', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '851+/-185', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.05', ')', ',', 'thus', 'suggesting', 'that', '100', 'microg', 'of', 'octreotide', 'should', 'be', 'sufficient', 'to', 'inhibit', 'also', 'the', 'pinealocytes', 'if', 'their', 'function', 'were', 'regulated', 'by', 'somatostatin', '.']","(29, 31)","(165, 173)",-1,hl_i,10475150,Abstract,9,test,gold,4916.0
171,"The total nocturnal secretion of TSH was , however , significantly reduced by octreotide ( TSH AUC 562+/-136 mU/l x h during octreotide and 851+/-185 mU/l x h during saline ; p < 0.05 ) , thus suggesting that 100 microg of",octreotide,should be sufficient to inhibit also the pinealocytes if their function were regulated by somatostatin .,"['The', 'total', 'nocturnal', 'secretion', 'of', 'TSH', 'was', ',', 'however', ',', 'significantly', 'reduced', 'by', 'octreotide', '(', 'TSH', 'AUC', '562+/-136', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '851+/-185', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.05', ')', ',', 'thus', 'suggesting', 'that', '100', 'microg', 'of', 'octreotide', 'should', 'be', 'sufficient', 'to', 'inhibit', 'also', 'the', 'pinealocytes', 'if', 'their', 'function', 'were', 'regulated', 'by', 'somatostatin', '.']","(42, 43)","(222, 232)",-1,hl_i,10475150,Abstract,9,test,gold,5777.0
172,"The total nocturnal secretion of TSH was , however , significantly reduced by octreotide ( TSH AUC 562+/-136 mU/l x h during octreotide and 851+/-185 mU/l x h during saline ; p < 0.05 ) , thus suggesting that 100 microg of octreotide should be sufficient to inhibit also the pinealocytes if their function were regulated by",somatostatin .,,"['The', 'total', 'nocturnal', 'secretion', 'of', 'TSH', 'was', ',', 'however', ',', 'significantly', 'reduced', 'by', 'octreotide', '(', 'TSH', 'AUC', '562+/-136', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '851+/-185', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.05', ')', ',', 'thus', 'suggesting', 'that', '100', 'microg', 'of', 'octreotide', 'should', 'be', 'sufficient', 'to', 'inhibit', 'also', 'the', 'pinealocytes', 'if', 'their', 'function', 'were', 'regulated', 'by', 'somatostatin', '.']","(57, 59)","(323, 337)",-1,hl_i,10475150,Abstract,9,test,gold,111.0
173,The,total nocturnal secretion of TSH,"was , however , significantly reduced by octreotide ( TSH AUC 562+/-136 mU/l x h during octreotide and 851+/-185 mU/l x h during saline ; p < 0.05 ) , thus suggesting that 100 microg of octreotide should be sufficient to inhibit also the pinealocytes if their function were regulated by somatostatin .","['The', 'total', 'nocturnal', 'secretion', 'of', 'TSH', 'was', ',', 'however', ',', 'significantly', 'reduced', 'by', 'octreotide', '(', 'TSH', 'AUC', '562+/-136', 'mU/l', 'x', 'h', 'during', 'octreotide', 'and', '851+/-185', 'mU/l', 'x', 'h', 'during', 'saline', ';', 'p', '<', '0.05', ')', ',', 'thus', 'suggesting', 'that', '100', 'microg', 'of', 'octreotide', 'should', 'be', 'sufficient', 'to', 'inhibit', 'also', 'the', 'pinealocytes', 'if', 'their', 'function', 'were', 'regulated', 'by', 'somatostatin', '.']","(1, 6)","(3, 35)",-1,hl_o,10475150,Abstract,9,test,gold,6602.0
174,Since exogenous somatostatin -- in the form of octreotide -- fails to influence nocturnal secretion and urinary excretion of melatonin in,normal subjects and in patients with primary hypothyroidism,", it is reasonable to assume that endogenous somatostatin may not be an important regulator of melatonin secretion in man .","['Since', 'exogenous', 'somatostatin', '--', 'in', 'the', 'form', 'of', 'octreotide', '--', 'fails', 'to', 'influence', 'nocturnal', 'secretion', 'and', 'urinary', 'excretion', 'of', 'melatonin', 'in', 'normal', 'subjects', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', ',', 'it', 'is', 'reasonable', 'to', 'assume', 'that', 'endogenous', 'somatostatin', 'may', 'not', 'be', 'an', 'important', 'regulator', 'of', 'melatonin', 'secretion', 'in', 'man', '.']","(21, 29)","(137, 196)",-1,ss_p,10475150,Abstract,10,test,gold,6985.0
175,Since exogenous,somatostatin -- in,"the form of octreotide -- fails to influence nocturnal secretion and urinary excretion of melatonin in normal subjects and in patients with primary hypothyroidism , it is reasonable to assume that endogenous somatostatin may not be an important regulator of melatonin secretion in man .","['Since', 'exogenous', 'somatostatin', '--', 'in', 'the', 'form', 'of', 'octreotide', '--', 'fails', 'to', 'influence', 'nocturnal', 'secretion', 'and', 'urinary', 'excretion', 'of', 'melatonin', 'in', 'normal', 'subjects', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', ',', 'it', 'is', 'reasonable', 'to', 'assume', 'that', 'endogenous', 'somatostatin', 'may', 'not', 'be', 'an', 'important', 'regulator', 'of', 'melatonin', 'secretion', 'in', 'man', '.']","(2, 5)","(15, 33)",-1,ss_i,10475150,Abstract,10,test,gold,107.0
176,Since exogenous somatostatin -- in the form of,octreotide -- fails,"to influence nocturnal secretion and urinary excretion of melatonin in normal subjects and in patients with primary hypothyroidism , it is reasonable to assume that endogenous somatostatin may not be an important regulator of melatonin secretion in man .","['Since', 'exogenous', 'somatostatin', '--', 'in', 'the', 'form', 'of', 'octreotide', '--', 'fails', 'to', 'influence', 'nocturnal', 'secretion', 'and', 'urinary', 'excretion', 'of', 'melatonin', 'in', 'normal', 'subjects', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', ',', 'it', 'is', 'reasonable', 'to', 'assume', 'that', 'endogenous', 'somatostatin', 'may', 'not', 'be', 'an', 'important', 'regulator', 'of', 'melatonin', 'secretion', 'in', 'man', '.']","(8, 11)","(46, 65)",-1,ss_i,10475150,Abstract,10,test,gold,5775.0
177,"Since exogenous somatostatin -- in the form of octreotide -- fails to influence nocturnal secretion and urinary excretion of melatonin in normal subjects and in patients with primary hypothyroidism , it is reasonable to assume that endogenous",somatostatin,may not be an important regulator of melatonin secretion in man .,"['Since', 'exogenous', 'somatostatin', '--', 'in', 'the', 'form', 'of', 'octreotide', '--', 'fails', 'to', 'influence', 'nocturnal', 'secretion', 'and', 'urinary', 'excretion', 'of', 'melatonin', 'in', 'normal', 'subjects', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', ',', 'it', 'is', 'reasonable', 'to', 'assume', 'that', 'endogenous', 'somatostatin', 'may', 'not', 'be', 'an', 'important', 'regulator', 'of', 'melatonin', 'secretion', 'in', 'man', '.']","(37, 38)","(242, 254)",-1,ss_i,10475150,Abstract,10,test,gold,110.0
178,Since exogenous somatostatin -- in the form of octreotide -- fails to influence,nocturnal secretion and urinary excretion of melatonin,"in normal subjects and in patients with primary hypothyroidism , it is reasonable to assume that endogenous somatostatin may not be an important regulator of melatonin secretion in man .","['Since', 'exogenous', 'somatostatin', '--', 'in', 'the', 'form', 'of', 'octreotide', '--', 'fails', 'to', 'influence', 'nocturnal', 'secretion', 'and', 'urinary', 'excretion', 'of', 'melatonin', 'in', 'normal', 'subjects', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', ',', 'it', 'is', 'reasonable', 'to', 'assume', 'that', 'endogenous', 'somatostatin', 'may', 'not', 'be', 'an', 'important', 'regulator', 'of', 'melatonin', 'secretion', 'in', 'man', '.']","(13, 20)","(79, 133)",-1,ss_o,10475150,Abstract,10,test,gold,6582.0
179,"Since exogenous somatostatin -- in the form of octreotide -- fails to influence nocturnal secretion and urinary excretion of melatonin in normal subjects and in patients with primary hypothyroidism , it is reasonable to assume that endogenous somatostatin may not be an important",regulator of melatonin secretion,in man .,"['Since', 'exogenous', 'somatostatin', '--', 'in', 'the', 'form', 'of', 'octreotide', '--', 'fails', 'to', 'influence', 'nocturnal', 'secretion', 'and', 'urinary', 'excretion', 'of', 'melatonin', 'in', 'normal', 'subjects', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', ',', 'it', 'is', 'reasonable', 'to', 'assume', 'that', 'endogenous', 'somatostatin', 'may', 'not', 'be', 'an', 'important', 'regulator', 'of', 'melatonin', 'secretion', 'in', 'man', '.']","(43, 47)","(279, 311)",-1,ss_o,10475150,Abstract,10,test,gold,6598.0
180,Since exogenous somatostatin -- in the form of octreotide -- fails to influence nocturnal secretion and urinary excretion of melatonin in,normal subjects and in patients with primary hypothyroidism,", it is reasonable to assume that endogenous somatostatin may not be an important regulator of melatonin secretion in man .","['Since', 'exogenous', 'somatostatin', '--', 'in', 'the', 'form', 'of', 'octreotide', '--', 'fails', 'to', 'influence', 'nocturnal', 'secretion', 'and', 'urinary', 'excretion', 'of', 'melatonin', 'in', 'normal', 'subjects', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', ',', 'it', 'is', 'reasonable', 'to', 'assume', 'that', 'endogenous', 'somatostatin', 'may', 'not', 'be', 'an', 'important', 'regulator', 'of', 'melatonin', 'secretion', 'in', 'man', '.']","(21, 29)","(137, 196)",-1,hl_p,10475150,Abstract,10,test,gold,6986.0
181,Since exogenous,somatostatin,"-- in the form of octreotide -- fails to influence nocturnal secretion and urinary excretion of melatonin in normal subjects and in patients with primary hypothyroidism , it is reasonable to assume that endogenous somatostatin may not be an important regulator of melatonin secretion in man .","['Since', 'exogenous', 'somatostatin', '--', 'in', 'the', 'form', 'of', 'octreotide', '--', 'fails', 'to', 'influence', 'nocturnal', 'secretion', 'and', 'urinary', 'excretion', 'of', 'melatonin', 'in', 'normal', 'subjects', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', ',', 'it', 'is', 'reasonable', 'to', 'assume', 'that', 'endogenous', 'somatostatin', 'may', 'not', 'be', 'an', 'important', 'regulator', 'of', 'melatonin', 'secretion', 'in', 'man', '.']","(2, 3)","(15, 27)",-1,hl_i,10475150,Abstract,10,test,gold,109.0
182,Since exogenous somatostatin -- in the form of,octreotide,"-- fails to influence nocturnal secretion and urinary excretion of melatonin in normal subjects and in patients with primary hypothyroidism , it is reasonable to assume that endogenous somatostatin may not be an important regulator of melatonin secretion in man .","['Since', 'exogenous', 'somatostatin', '--', 'in', 'the', 'form', 'of', 'octreotide', '--', 'fails', 'to', 'influence', 'nocturnal', 'secretion', 'and', 'urinary', 'excretion', 'of', 'melatonin', 'in', 'normal', 'subjects', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', ',', 'it', 'is', 'reasonable', 'to', 'assume', 'that', 'endogenous', 'somatostatin', 'may', 'not', 'be', 'an', 'important', 'regulator', 'of', 'melatonin', 'secretion', 'in', 'man', '.']","(8, 9)","(46, 56)",-1,hl_i,10475150,Abstract,10,test,gold,5776.0
183,"Since exogenous somatostatin -- in the form of octreotide -- fails to influence nocturnal secretion and urinary excretion of melatonin in normal subjects and in patients with primary hypothyroidism , it is reasonable to assume that endogenous",somatostatin,may not be an important regulator of melatonin secretion in man .,"['Since', 'exogenous', 'somatostatin', '--', 'in', 'the', 'form', 'of', 'octreotide', '--', 'fails', 'to', 'influence', 'nocturnal', 'secretion', 'and', 'urinary', 'excretion', 'of', 'melatonin', 'in', 'normal', 'subjects', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', ',', 'it', 'is', 'reasonable', 'to', 'assume', 'that', 'endogenous', 'somatostatin', 'may', 'not', 'be', 'an', 'important', 'regulator', 'of', 'melatonin', 'secretion', 'in', 'man', '.']","(37, 38)","(242, 254)",-1,hl_i,10475150,Abstract,10,test,gold,108.0
184,Since exogenous somatostatin -- in the form of octreotide -- fails to influence,nocturnal secretion and urinary excretion of melatonin,"in normal subjects and in patients with primary hypothyroidism , it is reasonable to assume that endogenous somatostatin may not be an important regulator of melatonin secretion in man .","['Since', 'exogenous', 'somatostatin', '--', 'in', 'the', 'form', 'of', 'octreotide', '--', 'fails', 'to', 'influence', 'nocturnal', 'secretion', 'and', 'urinary', 'excretion', 'of', 'melatonin', 'in', 'normal', 'subjects', 'and', 'in', 'patients', 'with', 'primary', 'hypothyroidism', ',', 'it', 'is', 'reasonable', 'to', 'assume', 'that', 'endogenous', 'somatostatin', 'may', 'not', 'be', 'an', 'important', 'regulator', 'of', 'melatonin', 'secretion', 'in', 'man', '.']","(13, 20)","(79, 133)",-1,hl_o,10475150,Abstract,10,test,gold,6583.0
185,Effects of soy intake on sex hormone metabolism in,premenopausal women .,,"['Effects', 'of', 'soy', 'intake', 'on', 'sex', 'hormone', 'metabolism', 'in', 'premenopausal', 'women', '.']","(9, 12)","(50, 71)",-1,ss_p,10578479,Title,0,test,gold,2247.0
186,Effects of,soy,intake on sex hormone metabolism in premenopausal women .,"['Effects', 'of', 'soy', 'intake', 'on', 'sex', 'hormone', 'metabolism', 'in', 'premenopausal', 'women', '.']","(2, 3)","(10, 13)",-1,ss_i,10578479,Title,0,test,gold,1517.0
187,Effects of soy intake on,sex hormone metabolism,in premenopausal women .,"['Effects', 'of', 'soy', 'intake', 'on', 'sex', 'hormone', 'metabolism', 'in', 'premenopausal', 'women', '.']","(5, 8)","(24, 46)",-1,ss_o,10578479,Title,0,test,gold,6616.0
188,Effects of soy intake on sex hormone metabolism in,premenopausal women .,,"['Effects', 'of', 'soy', 'intake', 'on', 'sex', 'hormone', 'metabolism', 'in', 'premenopausal', 'women', '.']","(9, 12)","(50, 71)",-1,hl_p,10578479,Title,0,test,gold,2248.0
189,Effects of,soy,intake on sex hormone metabolism in premenopausal women .,"['Effects', 'of', 'soy', 'intake', 'on', 'sex', 'hormone', 'metabolism', 'in', 'premenopausal', 'women', '.']","(2, 3)","(10, 13)",-1,hl_i,10578479,Title,0,test,gold,1518.0
190,Effects of soy intake on,sex hormone metabolism,in premenopausal women .,"['Effects', 'of', 'soy', 'intake', 'on', 'sex', 'hormone', 'metabolism', 'in', 'premenopausal', 'women', '.']","(5, 8)","(24, 46)",-1,hl_o,10578479,Title,0,test,gold,6617.0
191,Studies suggest that phytoestrogens in,soy,products may impart hormonal effects that protect women against breast cancer .,"['Studies', 'suggest', 'that', 'phytoestrogens', 'in', 'soy', 'products', 'may', 'impart', 'hormonal', 'effects', 'that', 'protect', 'women', 'against', 'breast', 'cancer', '.']","(5, 6)","(38, 41)",-1,ss_i,10578479,Abstract,0,test,gold,1516.0
192,Studies suggest that phytoestrogens in soy products may impart,hormonal effects,that protect women against breast cancer .,"['Studies', 'suggest', 'that', 'phytoestrogens', 'in', 'soy', 'products', 'may', 'impart', 'hormonal', 'effects', 'that', 'protect', 'women', 'against', 'breast', 'cancer', '.']","(9, 11)","(62, 78)",-1,ss_o,10578479,Abstract,0,test,gold,2464.0
193,Studies suggest that phytoestrogens in,soy,products may impart hormonal effects that protect women against breast cancer .,"['Studies', 'suggest', 'that', 'phytoestrogens', 'in', 'soy', 'products', 'may', 'impart', 'hormonal', 'effects', 'that', 'protect', 'women', 'against', 'breast', 'cancer', '.']","(5, 6)","(38, 41)",-1,hl_i,10578479,Abstract,0,test,gold,1515.0
194,Limited research suggests that intake of,soy,"products high in isoflavonoid phytoestrogens affects sex hormone metabolism , but it is unknown whether phytoestrogens in soy have any effect on menstrual function or serum sex hormones in women on common hormone therapies , such as oral contraceptives ( OC ) .","['Limited', 'research', 'suggests', 'that', 'intake', 'of', 'soy', 'products', 'high', 'in', 'isoflavonoid', 'phytoestrogens', 'affects', 'sex', 'hormone', 'metabolism', ',', 'but', 'it', 'is', 'unknown', 'whether', 'phytoestrogens', 'in', 'soy', 'have', 'any', 'effect', 'on', 'menstrual', 'function', 'or', 'serum', 'sex', 'hormones', 'in', 'women', 'on', 'common', 'hormone', 'therapies', ',', 'such', 'as', 'oral', 'contraceptives', '(', 'OC', ')', '.']","(6, 7)","(40, 43)",-1,ss_i,10578479,Abstract,1,test,gold,1514.0
195,"Limited research suggests that intake of soy products high in isoflavonoid phytoestrogens affects sex hormone metabolism , but it is unknown whether phytoestrogens in",soy,"have any effect on menstrual function or serum sex hormones in women on common hormone therapies , such as oral contraceptives ( OC ) .","['Limited', 'research', 'suggests', 'that', 'intake', 'of', 'soy', 'products', 'high', 'in', 'isoflavonoid', 'phytoestrogens', 'affects', 'sex', 'hormone', 'metabolism', ',', 'but', 'it', 'is', 'unknown', 'whether', 'phytoestrogens', 'in', 'soy', 'have', 'any', 'effect', 'on', 'menstrual', 'function', 'or', 'serum', 'sex', 'hormones', 'in', 'women', 'on', 'common', 'hormone', 'therapies', ',', 'such', 'as', 'oral', 'contraceptives', '(', 'OC', ')', '.']","(24, 25)","(166, 169)",-1,ss_i,10578479,Abstract,1,test,gold,1513.0
196,Limited research suggests that intake of soy products high in isoflavonoid phytoestrogens affects,sex hormone metabolism,", but it is unknown whether phytoestrogens in soy have any effect on menstrual function or serum sex hormones in women on common hormone therapies , such as oral contraceptives ( OC ) .","['Limited', 'research', 'suggests', 'that', 'intake', 'of', 'soy', 'products', 'high', 'in', 'isoflavonoid', 'phytoestrogens', 'affects', 'sex', 'hormone', 'metabolism', ',', 'but', 'it', 'is', 'unknown', 'whether', 'phytoestrogens', 'in', 'soy', 'have', 'any', 'effect', 'on', 'menstrual', 'function', 'or', 'serum', 'sex', 'hormones', 'in', 'women', 'on', 'common', 'hormone', 'therapies', ',', 'such', 'as', 'oral', 'contraceptives', '(', 'OC', ')', '.']","(13, 16)","(97, 119)",-1,ss_o,10578479,Abstract,1,test,gold,6615.0
197,"Limited research suggests that intake of soy products high in isoflavonoid phytoestrogens affects sex hormone metabolism , but it is unknown whether phytoestrogens in soy have any effect on",menstrual function or serum sex hormones,"in women on common hormone therapies , such as oral contraceptives ( OC ) .","['Limited', 'research', 'suggests', 'that', 'intake', 'of', 'soy', 'products', 'high', 'in', 'isoflavonoid', 'phytoestrogens', 'affects', 'sex', 'hormone', 'metabolism', ',', 'but', 'it', 'is', 'unknown', 'whether', 'phytoestrogens', 'in', 'soy', 'have', 'any', 'effect', 'on', 'menstrual', 'function', 'or', 'serum', 'sex', 'hormones', 'in', 'women', 'on', 'common', 'hormone', 'therapies', ',', 'such', 'as', 'oral', 'contraceptives', '(', 'OC', ')', '.']","(29, 35)","(189, 229)",-1,ss_o,10578479,Abstract,1,test,gold,6613.0
198,Limited research suggests that intake of,soy,"products high in isoflavonoid phytoestrogens affects sex hormone metabolism , but it is unknown whether phytoestrogens in soy have any effect on menstrual function or serum sex hormones in women on common hormone therapies , such as oral contraceptives ( OC ) .","['Limited', 'research', 'suggests', 'that', 'intake', 'of', 'soy', 'products', 'high', 'in', 'isoflavonoid', 'phytoestrogens', 'affects', 'sex', 'hormone', 'metabolism', ',', 'but', 'it', 'is', 'unknown', 'whether', 'phytoestrogens', 'in', 'soy', 'have', 'any', 'effect', 'on', 'menstrual', 'function', 'or', 'serum', 'sex', 'hormones', 'in', 'women', 'on', 'common', 'hormone', 'therapies', ',', 'such', 'as', 'oral', 'contraceptives', '(', 'OC', ')', '.']","(6, 7)","(40, 43)",-1,hl_i,10578479,Abstract,1,test,gold,1512.0
199,Limited research suggests that intake of soy products high in isoflavonoid phytoestrogens affects,sex hormone metabolism,", but it is unknown whether phytoestrogens in soy have any effect on menstrual function or serum sex hormones in women on common hormone therapies , such as oral contraceptives ( OC ) .","['Limited', 'research', 'suggests', 'that', 'intake', 'of', 'soy', 'products', 'high', 'in', 'isoflavonoid', 'phytoestrogens', 'affects', 'sex', 'hormone', 'metabolism', ',', 'but', 'it', 'is', 'unknown', 'whether', 'phytoestrogens', 'in', 'soy', 'have', 'any', 'effect', 'on', 'menstrual', 'function', 'or', 'serum', 'sex', 'hormones', 'in', 'women', 'on', 'common', 'hormone', 'therapies', ',', 'such', 'as', 'oral', 'contraceptives', '(', 'OC', ')', '.']","(13, 16)","(97, 119)",-1,hl_o,10578479,Abstract,1,test,gold,6614.0
200,We studied the effects of soy in,"36 premenopausal women , 20 of whom used OC .",,"['We', 'studied', 'the', 'effects', 'of', 'soy', 'in', '36', 'premenopausal', 'women', ',', '20', 'of', 'whom', 'used', 'OC', '.']","(7, 17)","(32, 77)",-1,ss_p,10578479,Abstract,2,test,gold,2249.0
201,We studied the effects of,soy,"in 36 premenopausal women , 20 of whom used OC .","['We', 'studied', 'the', 'effects', 'of', 'soy', 'in', '36', 'premenopausal', 'women', ',', '20', 'of', 'whom', 'used', 'OC', '.']","(5, 6)","(25, 28)",-1,ss_i,10578479,Abstract,2,test,gold,1511.0
202,We studied the effects of soy in,36 premenopausal women,", 20 of whom used OC .","['We', 'studied', 'the', 'effects', 'of', 'soy', 'in', '36', 'premenopausal', 'women', ',', '20', 'of', 'whom', 'used', 'OC', '.']","(7, 10)","(32, 54)",-1,hl_p,10578479,Abstract,2,test,gold,2246.0
203,"We studied the effects of soy in 36 premenopausal women ,",20,of whom used OC .,"['We', 'studied', 'the', 'effects', 'of', 'soy', 'in', '36', 'premenopausal', 'women', ',', '20', 'of', 'whom', 'used', 'OC', '.']","(11, 12)","(57, 59)",-1,hl_p,10578479,Abstract,2,test,gold,
204,"We studied the effects of soy in 36 premenopausal women , 20 of whom",used OC,.,"['We', 'studied', 'the', 'effects', 'of', 'soy', 'in', '36', 'premenopausal', 'women', ',', '20', 'of', 'whom', 'used', 'OC', '.']","(14, 16)","(68, 75)",-1,hl_p,10578479,Abstract,2,test,gold,642.0
205,We studied the effects of,soy,"in 36 premenopausal women , 20 of whom used OC .","['We', 'studied', 'the', 'effects', 'of', 'soy', 'in', '36', 'premenopausal', 'women', ',', '20', 'of', 'whom', 'used', 'OC', '.']","(5, 6)","(25, 28)",-1,hl_i,10578479,Abstract,2,test,gold,1510.0
206,Subjects consumed their,normal diet,for two menstrual cycles and added a soy beverage containing 20 g of protein and 38 mg of total isoflavones to their usual diet for another two menstrual cycles .,"['Subjects', 'consumed', 'their', 'normal', 'diet', 'for', 'two', 'menstrual', 'cycles', 'and', 'added', 'a', 'soy', 'beverage', 'containing', '20', 'g', 'of', 'protein', 'and', '38', 'mg', 'of', 'total', 'isoflavones', 'to', 'their', 'usual', 'diet', 'for', 'another', 'two', 'menstrual', 'cycles', '.']","(3, 5)","(23, 34)",-1,ss_i,10578479,Abstract,3,test,gold,1527.0
207,Subjects consumed their normal diet for two menstrual cycles and added a,soy beverage,containing 20 g of protein and 38 mg of total isoflavones to their usual diet for another two menstrual cycles .,"['Subjects', 'consumed', 'their', 'normal', 'diet', 'for', 'two', 'menstrual', 'cycles', 'and', 'added', 'a', 'soy', 'beverage', 'containing', '20', 'g', 'of', 'protein', 'and', '38', 'mg', 'of', 'total', 'isoflavones', 'to', 'their', 'usual', 'diet', 'for', 'another', 'two', 'menstrual', 'cycles', '.']","(12, 14)","(72, 84)",-1,ss_i,10578479,Abstract,3,test,gold,1519.0
208,Subjects consumed their normal diet for two menstrual cycles and added a,soy beverage,containing 20 g of protein and 38 mg of total isoflavones to their usual diet for another two menstrual cycles .,"['Subjects', 'consumed', 'their', 'normal', 'diet', 'for', 'two', 'menstrual', 'cycles', 'and', 'added', 'a', 'soy', 'beverage', 'containing', '20', 'g', 'of', 'protein', 'and', '38', 'mg', 'of', 'total', 'isoflavones', 'to', 'their', 'usual', 'diet', 'for', 'another', 'two', 'menstrual', 'cycles', '.']","(12, 14)","(72, 84)",-1,hl_i,10578479,Abstract,3,test,gold,1520.0
209,"No significant differences were observed in serum estrone , estradiol , sex hormone-binding globulin , dehydroepiandrosterone sulfate , prolactin , or progesterone concentrations with",soy,feeding in the non-OC or the OC group .,"['No', 'significant', 'differences', 'were', 'observed', 'in', 'serum', 'estrone', ',', 'estradiol', ',', 'sex', 'hormone-binding', 'globulin', ',', 'dehydroepiandrosterone', 'sulfate', ',', 'prolactin', ',', 'or', 'progesterone', 'concentrations', 'with', 'soy', 'feeding', 'in', 'the', 'non-OC', 'or', 'the', 'OC', 'group', '.']","(24, 25)","(183, 186)",-1,ss_i,10578479,Abstract,4,test,gold,1509.0
210,No significant differences were observed in,"serum estrone , estradiol , sex hormone-binding globulin , dehydroepiandrosterone sulfate , prolactin , or progesterone concentrations",with soy feeding in the non-OC or the OC group .,"['No', 'significant', 'differences', 'were', 'observed', 'in', 'serum', 'estrone', ',', 'estradiol', ',', 'sex', 'hormone-binding', 'globulin', ',', 'dehydroepiandrosterone', 'sulfate', ',', 'prolactin', ',', 'or', 'progesterone', 'concentrations', 'with', 'soy', 'feeding', 'in', 'the', 'non-OC', 'or', 'the', 'OC', 'group', '.']","(6, 23)","(43, 177)",-1,ss_o,10578479,Abstract,4,test,gold,5815.0
211,"No significant differences were observed in serum estrone , estradiol , sex hormone-binding globulin , dehydroepiandrosterone sulfate , prolactin , or progesterone concentrations with",soy,feeding in the non-OC or the OC group .,"['No', 'significant', 'differences', 'were', 'observed', 'in', 'serum', 'estrone', ',', 'estradiol', ',', 'sex', 'hormone-binding', 'globulin', ',', 'dehydroepiandrosterone', 'sulfate', ',', 'prolactin', ',', 'or', 'progesterone', 'concentrations', 'with', 'soy', 'feeding', 'in', 'the', 'non-OC', 'or', 'the', 'OC', 'group', '.']","(24, 25)","(183, 186)",-1,hl_i,10578479,Abstract,4,test,gold,1508.0
212,No significant differences were observed in,"serum estrone , estradiol , sex hormone-binding globulin , dehydroepiandrosterone sulfate , prolactin , or progesterone concentrations",with soy feeding in the non-OC or the OC group .,"['No', 'significant', 'differences', 'were', 'observed', 'in', 'serum', 'estrone', ',', 'estradiol', ',', 'sex', 'hormone-binding', 'globulin', ',', 'dehydroepiandrosterone', 'sulfate', ',', 'prolactin', ',', 'or', 'progesterone', 'concentrations', 'with', 'soy', 'feeding', 'in', 'the', 'non-OC', 'or', 'the', 'OC', 'group', '.']","(6, 23)","(43, 177)",-1,hl_o,10578479,Abstract,4,test,gold,5816.0
213,No changes in,menstrual cycle length or the urinary estrogen metabolite ratio of 2-hydroxyestrone to 16 alpha-hydroxyestrone,were seen with soy feeding in the non-OC or the OC group .,"['No', 'changes', 'in', 'menstrual', 'cycle', 'length', 'or', 'the', 'urinary', 'estrogen', 'metabolite', 'ratio', 'of', '2-hydroxyestrone', 'to', '16', 'alpha-hydroxyestrone', 'were', 'seen', 'with', 'soy', 'feeding', 'in', 'the', 'non-OC', 'or', 'the', 'OC', 'group', '.']","(3, 17)","(13, 123)",-1,ss_o,10578479,Abstract,5,test,gold,6509.0
214,No changes in,menstrual cycle length or the urinary estrogen metabolite ratio of 2-hydroxyestrone to 16 alpha-hydroxyestrone,were seen with soy feeding in the non-OC or the OC group .,"['No', 'changes', 'in', 'menstrual', 'cycle', 'length', 'or', 'the', 'urinary', 'estrogen', 'metabolite', 'ratio', 'of', '2-hydroxyestrone', 'to', '16', 'alpha-hydroxyestrone', 'were', 'seen', 'with', 'soy', 'feeding', 'in', 'the', 'non-OC', 'or', 'the', 'OC', 'group', '.']","(3, 17)","(13, 123)",-1,hl_o,10578479,Abstract,5,test,gold,6510.0
215,Levels of,urinary estrogen metabolites,were significantly different between the non-OC and the OC group .,"['Levels', 'of', 'urinary', 'estrogen', 'metabolites', 'were', 'significantly', 'different', 'between', 'the', 'non-OC', 'and', 'the', 'OC', 'group', '.']","(2, 5)","(9, 37)",-1,ss_o,10578479,Abstract,6,test,gold,6622.0
216,Levels of,urinary estrogen metabolites,were significantly different between the non-OC and the OC group .,"['Levels', 'of', 'urinary', 'estrogen', 'metabolites', 'were', 'significantly', 'different', 'between', 'the', 'non-OC', 'and', 'the', 'OC', 'group', '.']","(2, 5)","(9, 37)",-1,hl_o,10578479,Abstract,6,test,gold,6623.0
217,"Thus soy consumption had no significant effect on the menstrual cycle , serum sex hormones , or urinary estrogen metabolite ratio in",premenopausal OC or non-OC users .,,"['Thus', 'soy', 'consumption', 'had', 'no', 'significant', 'effect', 'on', 'the', 'menstrual', 'cycle', ',', 'serum', 'sex', 'hormones', ',', 'or', 'urinary', 'estrogen', 'metabolite', 'ratio', 'in', 'premenopausal', 'OC', 'or', 'non-OC', 'users', '.']","(22, 28)","(132, 166)",-1,ss_p,10578479,Abstract,7,test,gold,2250.0
218,Thus,soy,"consumption had no significant effect on the menstrual cycle , serum sex hormones , or urinary estrogen metabolite ratio in premenopausal OC or non-OC users .","['Thus', 'soy', 'consumption', 'had', 'no', 'significant', 'effect', 'on', 'the', 'menstrual', 'cycle', ',', 'serum', 'sex', 'hormones', ',', 'or', 'urinary', 'estrogen', 'metabolite', 'ratio', 'in', 'premenopausal', 'OC', 'or', 'non-OC', 'users', '.']","(1, 2)","(4, 7)",-1,ss_i,10578479,Abstract,7,test,gold,1507.0
219,Thus soy consumption had no significant effect on the,"menstrual cycle , serum sex hormones , or urinary estrogen metabolite ratio",in premenopausal OC or non-OC users .,"['Thus', 'soy', 'consumption', 'had', 'no', 'significant', 'effect', 'on', 'the', 'menstrual', 'cycle', ',', 'serum', 'sex', 'hormones', ',', 'or', 'urinary', 'estrogen', 'metabolite', 'ratio', 'in', 'premenopausal', 'OC', 'or', 'non-OC', 'users', '.']","(9, 21)","(53, 128)",-1,ss_o,10578479,Abstract,7,test,gold,6511.0
220,"Thus soy consumption had no significant effect on the menstrual cycle , serum sex hormones , or urinary estrogen metabolite ratio in",premenopausal OC,or non-OC users .,"['Thus', 'soy', 'consumption', 'had', 'no', 'significant', 'effect', 'on', 'the', 'menstrual', 'cycle', ',', 'serum', 'sex', 'hormones', ',', 'or', 'urinary', 'estrogen', 'metabolite', 'ratio', 'in', 'premenopausal', 'OC', 'or', 'non-OC', 'users', '.']","(22, 24)","(132, 148)",-1,hl_p,10578479,Abstract,7,test,gold,2251.0
221,"Thus soy consumption had no significant effect on the menstrual cycle , serum sex hormones , or urinary estrogen metabolite ratio in premenopausal OC or",non-OC users .,,"['Thus', 'soy', 'consumption', 'had', 'no', 'significant', 'effect', 'on', 'the', 'menstrual', 'cycle', ',', 'serum', 'sex', 'hormones', ',', 'or', 'urinary', 'estrogen', 'metabolite', 'ratio', 'in', 'premenopausal', 'OC', 'or', 'non-OC', 'users', '.']","(25, 28)","(152, 166)",-1,hl_p,10578479,Abstract,7,test,gold,1266.0
222,Thus,soy,"consumption had no significant effect on the menstrual cycle , serum sex hormones , or urinary estrogen metabolite ratio in premenopausal OC or non-OC users .","['Thus', 'soy', 'consumption', 'had', 'no', 'significant', 'effect', 'on', 'the', 'menstrual', 'cycle', ',', 'serum', 'sex', 'hormones', ',', 'or', 'urinary', 'estrogen', 'metabolite', 'ratio', 'in', 'premenopausal', 'OC', 'or', 'non-OC', 'users', '.']","(1, 2)","(4, 7)",-1,hl_i,10578479,Abstract,7,test,gold,1506.0
223,Thus soy consumption had no significant effect on the,"menstrual cycle , serum sex hormones , or urinary estrogen metabolite ratio",in premenopausal OC or non-OC users .,"['Thus', 'soy', 'consumption', 'had', 'no', 'significant', 'effect', 'on', 'the', 'menstrual', 'cycle', ',', 'serum', 'sex', 'hormones', ',', 'or', 'urinary', 'estrogen', 'metabolite', 'ratio', 'in', 'premenopausal', 'OC', 'or', 'non-OC', 'users', '.']","(9, 21)","(53, 128)",-1,hl_o,10578479,Abstract,7,test,gold,6512.0
224,Clinical effects of root instrumentation using conventional steel or non-tooth substance removing plastic curettes during,supportive periodontal therapy ( SPT ) .,,"['Clinical', 'effects', 'of', 'root', 'instrumentation', 'using', 'conventional', 'steel', 'or', 'non-tooth', 'substance', 'removing', 'plastic', 'curettes', 'during', 'supportive', 'periodontal', 'therapy', '(', 'SPT', ')', '.']","(15, 22)","(121, 161)",-1,ss_p,10589810,Title,0,test,gold,4086.0
225,Clinical effects of root instrumentation using,conventional steel,or non-tooth substance removing plastic curettes during supportive periodontal therapy ( SPT ) .,"['Clinical', 'effects', 'of', 'root', 'instrumentation', 'using', 'conventional', 'steel', 'or', 'non-tooth', 'substance', 'removing', 'plastic', 'curettes', 'during', 'supportive', 'periodontal', 'therapy', '(', 'SPT', ')', '.']","(6, 8)","(46, 64)",-1,ss_i,10589810,Title,0,test,gold,1787.0
226,Clinical effects of root instrumentation using conventional steel or,non-tooth substance removing plastic curettes,during supportive periodontal therapy ( SPT ) .,"['Clinical', 'effects', 'of', 'root', 'instrumentation', 'using', 'conventional', 'steel', 'or', 'non-tooth', 'substance', 'removing', 'plastic', 'curettes', 'during', 'supportive', 'periodontal', 'therapy', '(', 'SPT', ')', '.']","(9, 14)","(68, 113)",-1,ss_i,10589810,Title,0,test,gold,1793.0
227,,Clinical effects,of root instrumentation using conventional steel or non-tooth substance removing plastic curettes during supportive periodontal therapy ( SPT ) .,"['Clinical', 'effects', 'of', 'root', 'instrumentation', 'using', 'conventional', 'steel', 'or', 'non-tooth', 'substance', 'removing', 'plastic', 'curettes', 'during', 'supportive', 'periodontal', 'therapy', '(', 'SPT', ')', '.']","(0, 2)","(0, 16)",-1,ss_o,10589810,Title,0,test,gold,2354.0
228,,Clinical effects,of root instrumentation using conventional steel or non-tooth substance removing plastic curettes during supportive periodontal therapy ( SPT ) .,"['Clinical', 'effects', 'of', 'root', 'instrumentation', 'using', 'conventional', 'steel', 'or', 'non-tooth', 'substance', 'removing', 'plastic', 'curettes', 'during', 'supportive', 'periodontal', 'therapy', '(', 'SPT', ')', '.']","(0, 2)","(0, 16)",-1,hl_o,10589810,Title,0,test,gold,2355.0
229,"Although root instrumentation has been accepted as the most important cause-related treatment of periodontal diseases , repeated scaling and root planing may over time result in substantive loss of tooth substance and increased sensitivity of the teeth .",,,"['Although', 'root', 'instrumentation', 'has', 'been', 'accepted', 'as', 'the', 'most', 'important', 'cause-related', 'treatment', 'of', 'periodontal', 'diseases', ',', 'repeated', 'scaling', 'and', 'root', 'planing', 'may', 'over', 'time', 'result', 'in', 'substantive', 'loss', 'of', 'tooth', 'substance', 'and', 'increased', 'sensitivity', 'of', 'the', 'teeth', '.']",,,,,10589810,Abstract,0,test,gold,
230,"In an effort to minimize these side effects of therapy ,",non-root substance removing curettes,have been developed .,"['In', 'an', 'effort', 'to', 'minimize', 'these', 'side', 'effects', 'of', 'therapy', ',', 'non-root', 'substance', 'removing', 'curettes', 'have', 'been', 'developed', '.']","(11, 15)","(56, 92)",-1,ss_i,10589810,Abstract,1,test,gold,1795.0
231,"However , the clinical effects of such",plastic curettes,with regard to the control of the periodontal infection has not yet been established .,"['However', ',', 'the', 'clinical', 'effects', 'of', 'such', 'plastic', 'curettes', 'with', 'regard', 'to', 'the', 'control', 'of', 'the', 'periodontal', 'infection', 'has', 'not', 'yet', 'been', 'established', '.']","(7, 9)","(38, 54)",-1,ss_i,10589810,Abstract,2,test,gold,285.0
232,"However , the",clinical effects,of such plastic curettes with regard to the control of the periodontal infection has not yet been established .,"['However', ',', 'the', 'clinical', 'effects', 'of', 'such', 'plastic', 'curettes', 'with', 'regard', 'to', 'the', 'control', 'of', 'the', 'periodontal', 'infection', 'has', 'not', 'yet', 'been', 'established', '.']","(3, 5)","(13, 29)",-1,ss_o,10589810,Abstract,2,test,gold,2352.0
233,"However , the",clinical effects,of such plastic curettes with regard to the control of the periodontal infection has not yet been established .,"['However', ',', 'the', 'clinical', 'effects', 'of', 'such', 'plastic', 'curettes', 'with', 'regard', 'to', 'the', 'control', 'of', 'the', 'periodontal', 'infection', 'has', 'not', 'yet', 'been', 'established', '.']","(3, 5)","(13, 29)",-1,hl_o,10589810,Abstract,2,test,gold,2353.0
234,"The aims of this study were , therefore , to compare the effects of root instrumentation using plastic curettes ( Universal Perio Soft Scaler , Hawe-Neos Dental , Bioggio , TI , Switzerland ) versus conventional steel curettes on the periodontal conditions",during supportive periodontal therapy .,,"['The', 'aims', 'of', 'this', 'study', 'were', ',', 'therefore', ',', 'to', 'compare', 'the', 'effects', 'of', 'root', 'instrumentation', 'using', 'plastic', 'curettes', '(', 'Universal', 'Perio', 'Soft', 'Scaler', ',', 'Hawe-Neos', 'Dental', ',', 'Bioggio', ',', 'TI', ',', 'Switzerland', ')', 'versus', 'conventional', 'steel', 'curettes', 'on', 'the', 'periodontal', 'conditions', 'during', 'supportive', 'periodontal', 'therapy', '.']","(42, 47)","(256, 295)",-1,ss_p,10589810,Abstract,3,test,gold,4087.0
235,"The aims of this study were , therefore , to compare the effects of root instrumentation using",plastic curettes,"( Universal Perio Soft Scaler , Hawe-Neos Dental , Bioggio , TI , Switzerland ) versus conventional steel curettes on the periodontal conditions during supportive periodontal therapy .","['The', 'aims', 'of', 'this', 'study', 'were', ',', 'therefore', ',', 'to', 'compare', 'the', 'effects', 'of', 'root', 'instrumentation', 'using', 'plastic', 'curettes', '(', 'Universal', 'Perio', 'Soft', 'Scaler', ',', 'Hawe-Neos', 'Dental', ',', 'Bioggio', ',', 'TI', ',', 'Switzerland', ')', 'versus', 'conventional', 'steel', 'curettes', 'on', 'the', 'periodontal', 'conditions', 'during', 'supportive', 'periodontal', 'therapy', '.']","(17, 19)","(94, 110)",-1,ss_i,10589810,Abstract,3,test,gold,286.0
236,"The aims of this study were , therefore , to compare the effects of root instrumentation using plastic curettes ( Universal Perio Soft Scaler , Hawe-Neos Dental , Bioggio , TI , Switzerland ) versus",conventional steel curettes,on the periodontal conditions during supportive periodontal therapy .,"['The', 'aims', 'of', 'this', 'study', 'were', ',', 'therefore', ',', 'to', 'compare', 'the', 'effects', 'of', 'root', 'instrumentation', 'using', 'plastic', 'curettes', '(', 'Universal', 'Perio', 'Soft', 'Scaler', ',', 'Hawe-Neos', 'Dental', ',', 'Bioggio', ',', 'TI', ',', 'Switzerland', ')', 'versus', 'conventional', 'steel', 'curettes', 'on', 'the', 'periodontal', 'conditions', 'during', 'supportive', 'periodontal', 'therapy', '.']","(35, 38)","(198, 225)",-1,ss_i,10589810,Abstract,3,test,gold,1788.0
237,"The aims of this study were , therefore , to compare the",effects,"of root instrumentation using plastic curettes ( Universal Perio Soft Scaler , Hawe-Neos Dental , Bioggio , TI , Switzerland ) versus conventional steel curettes on the periodontal conditions during supportive periodontal therapy .","['The', 'aims', 'of', 'this', 'study', 'were', ',', 'therefore', ',', 'to', 'compare', 'the', 'effects', 'of', 'root', 'instrumentation', 'using', 'plastic', 'curettes', '(', 'Universal', 'Perio', 'Soft', 'Scaler', ',', 'Hawe-Neos', 'Dental', ',', 'Bioggio', ',', 'TI', ',', 'Switzerland', ')', 'versus', 'conventional', 'steel', 'curettes', 'on', 'the', 'periodontal', 'conditions', 'during', 'supportive', 'periodontal', 'therapy', '.']","(12, 13)","(56, 63)",-1,ss_o,10589810,Abstract,3,test,gold,2384.0
238,"The aims of this study were , therefore , to compare the effects of root instrumentation using",plastic curettes,"( Universal Perio Soft Scaler , Hawe-Neos Dental , Bioggio , TI , Switzerland ) versus conventional steel curettes on the periodontal conditions during supportive periodontal therapy .","['The', 'aims', 'of', 'this', 'study', 'were', ',', 'therefore', ',', 'to', 'compare', 'the', 'effects', 'of', 'root', 'instrumentation', 'using', 'plastic', 'curettes', '(', 'Universal', 'Perio', 'Soft', 'Scaler', ',', 'Hawe-Neos', 'Dental', ',', 'Bioggio', ',', 'TI', ',', 'Switzerland', ')', 'versus', 'conventional', 'steel', 'curettes', 'on', 'the', 'periodontal', 'conditions', 'during', 'supportive', 'periodontal', 'therapy', '.']","(17, 19)","(94, 110)",-1,hl_i,10589810,Abstract,3,test,gold,284.0
239,"The aims of this study were , therefore , to compare the effects of root instrumentation using plastic curettes ( Universal Perio Soft Scaler , Hawe-Neos Dental , Bioggio , TI , Switzerland ) versus",conventional steel curettes,on the periodontal conditions during supportive periodontal therapy .,"['The', 'aims', 'of', 'this', 'study', 'were', ',', 'therefore', ',', 'to', 'compare', 'the', 'effects', 'of', 'root', 'instrumentation', 'using', 'plastic', 'curettes', '(', 'Universal', 'Perio', 'Soft', 'Scaler', ',', 'Hawe-Neos', 'Dental', ',', 'Bioggio', ',', 'TI', ',', 'Switzerland', ')', 'versus', 'conventional', 'steel', 'curettes', 'on', 'the', 'periodontal', 'conditions', 'during', 'supportive', 'periodontal', 'therapy', '.']","(35, 38)","(198, 225)",-1,hl_i,10589810,Abstract,3,test,gold,1786.0
240,,40 subjects,"participated in this parallel , randomized , double blind , prospective longitudinal clinical study following active peridontal therapy .","['40', 'subjects', 'participated', 'in', 'this', 'parallel', ',', 'randomized', ',', 'double', 'blind', ',', 'prospective', 'longitudinal', 'clinical', 'study', 'following', 'active', 'peridontal', 'therapy', '.']","(0, 2)","(0, 11)",-1,ss_p,10589810,Abstract,4,test,gold,2077.0
241,,40 subjects,"participated in this parallel , randomized , double blind , prospective longitudinal clinical study following active peridontal therapy .","['40', 'subjects', 'participated', 'in', 'this', 'parallel', ',', 'randomized', ',', 'double', 'blind', ',', 'prospective', 'longitudinal', 'clinical', 'study', 'following', 'active', 'peridontal', 'therapy', '.']","(0, 2)","(0, 11)",-1,hl_p,10589810,Abstract,4,test,gold,2078.0
242,20 subjects served as a control group and were treated with,conventional steel curettes,during a supportive periodontal care visit ( SPT ) .,"['20', 'subjects', 'served', 'as', 'a', 'control', 'group', 'and', 'were', 'treated', 'with', 'conventional', 'steel', 'curettes', 'during', 'a', 'supportive', 'periodontal', 'care', 'visit', '(', 'SPT', ')', '.']","(11, 14)","(59, 86)",-1,ss_i,10589810,Abstract,5,test,gold,1785.0
243,,20,subjects served as a control group and were treated with conventional steel curettes during a supportive periodontal care visit ( SPT ) .,"['20', 'subjects', 'served', 'as', 'a', 'control', 'group', 'and', 'were', 'treated', 'with', 'conventional', 'steel', 'curettes', 'during', 'a', 'supportive', 'periodontal', 'care', 'visit', '(', 'SPT', ')', '.']","(0, 1)","(0, 2)",-1,hl_p,10589810,Abstract,5,test,gold,
244,20 subjects served as a control group and were treated with,conventional steel curettes,during a supportive periodontal care visit ( SPT ) .,"['20', 'subjects', 'served', 'as', 'a', 'control', 'group', 'and', 'were', 'treated', 'with', 'conventional', 'steel', 'curettes', 'during', 'a', 'supportive', 'periodontal', 'care', 'visit', '(', 'SPT', ')', '.']","(11, 14)","(59, 86)",-1,hl_i,10589810,Abstract,5,test,gold,1784.0
245,"The other 20 subjects , the experimental group , were treated using",plastic curettes,during a similar SPT visit .,"['The', 'other', '20', 'subjects', ',', 'the', 'experimental', 'group', ',', 'were', 'treated', 'using', 'plastic', 'curettes', 'during', 'a', 'similar', 'SPT', 'visit', '.']","(12, 14)","(67, 83)",-1,ss_i,10589810,Abstract,6,test,gold,283.0
246,The other,20,"subjects , the experimental group , were treated using plastic curettes during a similar SPT visit .","['The', 'other', '20', 'subjects', ',', 'the', 'experimental', 'group', ',', 'were', 'treated', 'using', 'plastic', 'curettes', 'during', 'a', 'similar', 'SPT', 'visit', '.']","(2, 3)","(9, 11)",-1,hl_p,10589810,Abstract,6,test,gold,
247,"The other 20 subjects , the experimental group , were treated using",plastic curettes,during a similar SPT visit .,"['The', 'other', '20', 'subjects', ',', 'the', 'experimental', 'group', ',', 'were', 'treated', 'using', 'plastic', 'curettes', 'during', 'a', 'similar', 'SPT', 'visit', '.']","(12, 14)","(67, 83)",-1,hl_i,10589810,Abstract,6,test,gold,282.0
248,"Clinical parameters , such as",bleeding on probing ( BOP ) and probing pocket depth ( PPD ),", were assessed at baseline and 3-6 months later at the next regular SPT visit .","['Clinical', 'parameters', ',', 'such', 'as', 'bleeding', 'on', 'probing', '(', 'BOP', ')', 'and', 'probing', 'pocket', 'depth', '(', 'PPD', ')', ',', 'were', 'assessed', 'at', 'baseline', 'and', '3-6', 'months', 'later', 'at', 'the', 'next', 'regular', 'SPT', 'visit', '.']","(5, 18)","(29, 89)",-1,ss_o,10589810,Abstract,7,test,gold,6372.0
249,"Clinical parameters , such as",bleeding on probing ( BOP ) and probing pocket depth ( PPD ),", were assessed at baseline and 3-6 months later at the next regular SPT visit .","['Clinical', 'parameters', ',', 'such', 'as', 'bleeding', 'on', 'probing', '(', 'BOP', ')', 'and', 'probing', 'pocket', 'depth', '(', 'PPD', ')', ',', 'were', 'assessed', 'at', 'baseline', 'and', '3-6', 'months', 'later', 'at', 'the', 'next', 'regular', 'SPT', 'visit', '.']","(5, 18)","(29, 89)",-1,hl_o,10589810,Abstract,7,test,gold,6373.0
250,"In addition , the",BOP percentage,was determined 10 days following baseline .,"['In', 'addition', ',', 'the', 'BOP', 'percentage', 'was', 'determined', '10', 'days', 'following', 'baseline', '.']","(4, 6)","(17, 31)",-1,ss_o,10589810,Abstract,8,test,gold,1464.0
251,"In addition , the",BOP percentage,was determined 10 days following baseline .,"['In', 'addition', ',', 'the', 'BOP', 'percentage', 'was', 'determined', '10', 'days', 'following', 'baseline', '.']","(4, 6)","(17, 31)",-1,hl_o,10589810,Abstract,8,test,gold,1465.0
252,The results showed that there were no statistically significant differences between the 2 treatment modalities regarding,BOP and PPD,at any observation time .,"['The', 'results', 'showed', 'that', 'there', 'were', 'no', 'statistically', 'significant', 'differences', 'between', 'the', '2', 'treatment', 'modalities', 'regarding', 'BOP', 'and', 'PPD', 'at', 'any', 'observation', 'time', '.']","(16, 19)","(120, 131)",-1,ss_o,10589810,Abstract,9,test,gold,1470.0
253,The results showed that there were no statistically significant differences between the 2 treatment modalities regarding,BOP and PPD,at any observation time .,"['The', 'results', 'showed', 'that', 'there', 'were', 'no', 'statistically', 'significant', 'differences', 'between', 'the', '2', 'treatment', 'modalities', 'regarding', 'BOP', 'and', 'PPD', 'at', 'any', 'observation', 'time', '.']","(16, 19)","(120, 131)",-1,hl_o,10589810,Abstract,9,test,gold,1471.0
254,Both treatments were effective in reducing the,BOP percentage,"which ranged from 17-42 % at baseline by about 40 % after 10 days ( mean BOP baseline : 26 % , mean BOP after 10 days : 16 % ) .","['Both', 'treatments', 'were', 'effective', 'in', 'reducing', 'the', 'BOP', 'percentage', 'which', 'ranged', 'from', '17-42', '%', 'at', 'baseline', 'by', 'about', '40', '%', 'after', '10', 'days', '(', 'mean', 'BOP', 'baseline', ':', '26', '%', ',', 'mean', 'BOP', 'after', '10', 'days', ':', '16', '%', ')', '.']","(7, 9)","(46, 60)",-1,ss_o,10589810,Abstract,10,test,gold,1463.0
255,Both treatments were effective in reducing the BOP percentage which ranged from 17-42 % at baseline by about 40 % after 10 days ( mean,BOP,"baseline : 26 % , mean BOP after 10 days : 16 % ) .","['Both', 'treatments', 'were', 'effective', 'in', 'reducing', 'the', 'BOP', 'percentage', 'which', 'ranged', 'from', '17-42', '%', 'at', 'baseline', 'by', 'about', '40', '%', 'after', '10', 'days', '(', 'mean', 'BOP', 'baseline', ':', '26', '%', ',', 'mean', 'BOP', 'after', '10', 'days', ':', '16', '%', ')', '.']","(25, 26)","(134, 137)",-1,ss_o,10589810,Abstract,10,test,gold,1468.0
256,"Both treatments were effective in reducing the BOP percentage which ranged from 17-42 % at baseline by about 40 % after 10 days ( mean BOP baseline : 26 % , mean",BOP,after 10 days : 16 % ) .,"['Both', 'treatments', 'were', 'effective', 'in', 'reducing', 'the', 'BOP', 'percentage', 'which', 'ranged', 'from', '17-42', '%', 'at', 'baseline', 'by', 'about', '40', '%', 'after', '10', 'days', '(', 'mean', 'BOP', 'baseline', ':', '26', '%', ',', 'mean', 'BOP', 'after', '10', 'days', ':', '16', '%', ')', '.']","(32, 33)","(161, 164)",-1,ss_o,10589810,Abstract,10,test,gold,1469.0
257,Both treatments were effective in reducing the,BOP percentage,"which ranged from 17-42 % at baseline by about 40 % after 10 days ( mean BOP baseline : 26 % , mean BOP after 10 days : 16 % ) .","['Both', 'treatments', 'were', 'effective', 'in', 'reducing', 'the', 'BOP', 'percentage', 'which', 'ranged', 'from', '17-42', '%', 'at', 'baseline', 'by', 'about', '40', '%', 'after', '10', 'days', '(', 'mean', 'BOP', 'baseline', ':', '26', '%', ',', 'mean', 'BOP', 'after', '10', 'days', ':', '16', '%', ')', '.']","(7, 9)","(46, 60)",-1,hl_o,10589810,Abstract,10,test,gold,1462.0
258,Both treatments were effective in reducing the BOP percentage which ranged from 17-42 % at baseline by about 40 % after 10 days ( mean,BOP,"baseline : 26 % , mean BOP after 10 days : 16 % ) .","['Both', 'treatments', 'were', 'effective', 'in', 'reducing', 'the', 'BOP', 'percentage', 'which', 'ranged', 'from', '17-42', '%', 'at', 'baseline', 'by', 'about', '40', '%', 'after', '10', 'days', '(', 'mean', 'BOP', 'baseline', ':', '26', '%', ',', 'mean', 'BOP', 'after', '10', 'days', ':', '16', '%', ')', '.']","(25, 26)","(134, 137)",-1,hl_o,10589810,Abstract,10,test,gold,1467.0
259,"Both treatments were effective in reducing the BOP percentage which ranged from 17-42 % at baseline by about 40 % after 10 days ( mean BOP baseline : 26 % , mean",BOP,after 10 days : 16 % ) .,"['Both', 'treatments', 'were', 'effective', 'in', 'reducing', 'the', 'BOP', 'percentage', 'which', 'ranged', 'from', '17-42', '%', 'at', 'baseline', 'by', 'about', '40', '%', 'after', '10', 'days', '(', 'mean', 'BOP', 'baseline', ':', '26', '%', ',', 'mean', 'BOP', 'after', '10', 'days', ':', '16', '%', ')', '.']","(32, 33)","(161, 164)",-1,hl_o,10589810,Abstract,10,test,gold,1466.0
260,This clinical study suggests that,non-root substance removing curettes,"may be valuable instruments for periodontally treated patients during maintenance care , thus minimizing trauma on the hard structures of the teeth .","['This', 'clinical', 'study', 'suggests', 'that', 'non-root', 'substance', 'removing', 'curettes', 'may', 'be', 'valuable', 'instruments', 'for', 'periodontally', 'treated', 'patients', 'during', 'maintenance', 'care', ',', 'thus', 'minimizing', 'trauma', 'on', 'the', 'hard', 'structures', 'of', 'the', 'teeth', '.']","(5, 9)","(33, 69)",-1,ss_i,10589810,Abstract,11,test,gold,1796.0
261,This clinical study suggests that,non-root substance removing curettes,"may be valuable instruments for periodontally treated patients during maintenance care , thus minimizing trauma on the hard structures of the teeth .","['This', 'clinical', 'study', 'suggests', 'that', 'non-root', 'substance', 'removing', 'curettes', 'may', 'be', 'valuable', 'instruments', 'for', 'periodontally', 'treated', 'patients', 'during', 'maintenance', 'care', ',', 'thus', 'minimizing', 'trauma', 'on', 'the', 'hard', 'structures', 'of', 'the', 'teeth', '.']","(5, 9)","(33, 69)",-1,hl_i,10589810,Abstract,11,test,gold,1794.0
262,[ Improving wound healing,after nose surgery,by combined administration of xylometazoline and dexpanthenol ] .,"['[', 'Improving', 'wound', 'healing', 'after', 'nose', 'surgery', 'by', 'combined', 'administration', 'of', 'xylometazoline', 'and', 'dexpanthenol', ']', '.']","(4, 7)","(25, 43)",-1,ss_p,10763172,Title,0,test,gold,3659.0
263,[ Improving wound healing after nose surgery by combined administration of,xylometazoline,and dexpanthenol ] .,"['[', 'Improving', 'wound', 'healing', 'after', 'nose', 'surgery', 'by', 'combined', 'administration', 'of', 'xylometazoline', 'and', 'dexpanthenol', ']', '.']","(11, 12)","(74, 88)",-1,ss_i,10763172,Title,0,test,gold,
264,[ Improving wound healing after nose surgery by combined administration of xylometazoline and,dexpanthenol ],.,"['[', 'Improving', 'wound', 'healing', 'after', 'nose', 'surgery', 'by', 'combined', 'administration', 'of', 'xylometazoline', 'and', 'dexpanthenol', ']', '.']","(13, 15)","(93, 107)",-1,ss_i,10763172,Title,0,test,gold,
265,,[ Improving wound healing,after nose surgery by combined administration of xylometazoline and dexpanthenol ] .,"['[', 'Improving', 'wound', 'healing', 'after', 'nose', 'surgery', 'by', 'combined', 'administration', 'of', 'xylometazoline', 'and', 'dexpanthenol', ']', '.']","(0, 4)","(0, 25)",-1,ss_o,10763172,Title,0,test,gold,939.0
266,[ Improving wound healing,after nose surgery,by combined administration of xylometazoline and dexpanthenol ] .,"['[', 'Improving', 'wound', 'healing', 'after', 'nose', 'surgery', 'by', 'combined', 'administration', 'of', 'xylometazoline', 'and', 'dexpanthenol', ']', '.']","(4, 7)","(25, 43)",-1,hl_p,10763172,Title,0,test,gold,3660.0
267,[ Improving wound healing after nose surgery by combined administration of,xylometazoline,and dexpanthenol ] .,"['[', 'Improving', 'wound', 'healing', 'after', 'nose', 'surgery', 'by', 'combined', 'administration', 'of', 'xylometazoline', 'and', 'dexpanthenol', ']', '.']","(11, 12)","(74, 88)",-1,hl_i,10763172,Title,0,test,gold,
268,[ Improving wound healing after nose surgery by combined administration of xylometazoline and,dexpanthenol ],.,"['[', 'Improving', 'wound', 'healing', 'after', 'nose', 'surgery', 'by', 'combined', 'administration', 'of', 'xylometazoline', 'and', 'dexpanthenol', ']', '.']","(13, 15)","(93, 107)",-1,hl_i,10763172,Title,0,test,gold,
269,[ Improving,wound healing,after nose surgery by combined administration of xylometazoline and dexpanthenol ] .,"['[', 'Improving', 'wound', 'healing', 'after', 'nose', 'surgery', 'by', 'combined', 'administration', 'of', 'xylometazoline', 'and', 'dexpanthenol', ']', '.']","(2, 4)","(11, 24)",-1,hl_o,10763172,Title,0,test,gold,940.0
270,BACKGROUND The aim of this study was the examination of efficacy and tolerability of an application-form of the new combination of,Xylometazoline,with Dexpanthenol ( Nasic ) versus Xylometazoline alone .,"['BACKGROUND', 'The', 'aim', 'of', 'this', 'study', 'was', 'the', 'examination', 'of', 'efficacy', 'and', 'tolerability', 'of', 'an', 'application-form', 'of', 'the', 'new', 'combination', 'of', 'Xylometazoline', 'with', 'Dexpanthenol', '(', 'Nasic', ')', 'versus', 'Xylometazoline', 'alone', '.']","(21, 22)","(130, 144)",-1,ss_i,10763172,Abstract,0,test,gold,
271,BACKGROUND The aim of this study was the examination of efficacy and tolerability of an application-form of the new combination of Xylometazoline with,Dexpanthenol ( Nasic ),versus Xylometazoline alone .,"['BACKGROUND', 'The', 'aim', 'of', 'this', 'study', 'was', 'the', 'examination', 'of', 'efficacy', 'and', 'tolerability', 'of', 'an', 'application-form', 'of', 'the', 'new', 'combination', 'of', 'Xylometazoline', 'with', 'Dexpanthenol', '(', 'Nasic', ')', 'versus', 'Xylometazoline', 'alone', '.']","(23, 27)","(150, 172)",-1,ss_i,10763172,Abstract,0,test,gold,
272,BACKGROUND The aim of this study was the examination of efficacy and tolerability of an application-form of the new combination of Xylometazoline with Dexpanthenol ( Nasic ) versus,Xylometazoline alone .,,"['BACKGROUND', 'The', 'aim', 'of', 'this', 'study', 'was', 'the', 'examination', 'of', 'efficacy', 'and', 'tolerability', 'of', 'an', 'application-form', 'of', 'the', 'new', 'combination', 'of', 'Xylometazoline', 'with', 'Dexpanthenol', '(', 'Nasic', ')', 'versus', 'Xylometazoline', 'alone', '.']","(28, 31)","(180, 202)",-1,ss_i,10763172,Abstract,0,test,gold,1220.0
273,BACKGROUND The aim of this study was the examination of,efficacy,and tolerability of an application-form of the new combination of Xylometazoline with Dexpanthenol ( Nasic ) versus Xylometazoline alone .,"['BACKGROUND', 'The', 'aim', 'of', 'this', 'study', 'was', 'the', 'examination', 'of', 'efficacy', 'and', 'tolerability', 'of', 'an', 'application-form', 'of', 'the', 'new', 'combination', 'of', 'Xylometazoline', 'with', 'Dexpanthenol', '(', 'Nasic', ')', 'versus', 'Xylometazoline', 'alone', '.']","(10, 11)","(55, 63)",-1,ss_o,10763172,Abstract,0,test,gold,4845.0
274,BACKGROUND The aim of this study was the examination of efficacy and,tolerability,of an application-form of the new combination of Xylometazoline with Dexpanthenol ( Nasic ) versus Xylometazoline alone .,"['BACKGROUND', 'The', 'aim', 'of', 'this', 'study', 'was', 'the', 'examination', 'of', 'efficacy', 'and', 'tolerability', 'of', 'an', 'application-form', 'of', 'the', 'new', 'combination', 'of', 'Xylometazoline', 'with', 'Dexpanthenol', '(', 'Nasic', ')', 'versus', 'Xylometazoline', 'alone', '.']","(12, 13)","(68, 80)",-1,ss_o,10763172,Abstract,0,test,gold,4874.0
275,BACKGROUND The aim of this study was the examination of efficacy and tolerability of an application-form of the new combination of,Xylometazoline,with Dexpanthenol ( Nasic ) versus Xylometazoline alone .,"['BACKGROUND', 'The', 'aim', 'of', 'this', 'study', 'was', 'the', 'examination', 'of', 'efficacy', 'and', 'tolerability', 'of', 'an', 'application-form', 'of', 'the', 'new', 'combination', 'of', 'Xylometazoline', 'with', 'Dexpanthenol', '(', 'Nasic', ')', 'versus', 'Xylometazoline', 'alone', '.']","(21, 22)","(130, 144)",-1,hl_i,10763172,Abstract,0,test,gold,
276,BACKGROUND The aim of this study was the examination of efficacy and tolerability of an application-form of the new combination of Xylometazoline with,Dexpanthenol ( Nasic ),versus Xylometazoline alone .,"['BACKGROUND', 'The', 'aim', 'of', 'this', 'study', 'was', 'the', 'examination', 'of', 'efficacy', 'and', 'tolerability', 'of', 'an', 'application-form', 'of', 'the', 'new', 'combination', 'of', 'Xylometazoline', 'with', 'Dexpanthenol', '(', 'Nasic', ')', 'versus', 'Xylometazoline', 'alone', '.']","(23, 27)","(150, 172)",-1,hl_i,10763172,Abstract,0,test,gold,
277,BACKGROUND The aim of this study was the examination of efficacy and tolerability of an application-form of the new combination of Xylometazoline with Dexpanthenol ( Nasic ) versus,Xylometazoline,alone .,"['BACKGROUND', 'The', 'aim', 'of', 'this', 'study', 'was', 'the', 'examination', 'of', 'efficacy', 'and', 'tolerability', 'of', 'an', 'application-form', 'of', 'the', 'new', 'combination', 'of', 'Xylometazoline', 'with', 'Dexpanthenol', '(', 'Nasic', ')', 'versus', 'Xylometazoline', 'alone', '.']","(28, 29)","(180, 194)",-1,hl_i,10763172,Abstract,0,test,gold,
278,BACKGROUND The aim of this study was the examination of,efficacy,and tolerability of an application-form of the new combination of Xylometazoline with Dexpanthenol ( Nasic ) versus Xylometazoline alone .,"['BACKGROUND', 'The', 'aim', 'of', 'this', 'study', 'was', 'the', 'examination', 'of', 'efficacy', 'and', 'tolerability', 'of', 'an', 'application-form', 'of', 'the', 'new', 'combination', 'of', 'Xylometazoline', 'with', 'Dexpanthenol', '(', 'Nasic', ')', 'versus', 'Xylometazoline', 'alone', '.']","(10, 11)","(55, 63)",-1,hl_o,10763172,Abstract,0,test,gold,4844.0
279,BACKGROUND The aim of this study was the examination of efficacy and,tolerability,of an application-form of the new combination of Xylometazoline with Dexpanthenol ( Nasic ) versus Xylometazoline alone .,"['BACKGROUND', 'The', 'aim', 'of', 'this', 'study', 'was', 'the', 'examination', 'of', 'efficacy', 'and', 'tolerability', 'of', 'an', 'application-form', 'of', 'the', 'new', 'combination', 'of', 'Xylometazoline', 'with', 'Dexpanthenol', '(', 'Nasic', ')', 'versus', 'Xylometazoline', 'alone', '.']","(12, 13)","(68, 80)",-1,hl_o,10763172,Abstract,0,test,gold,4875.0
280,PATIENTS AND METHODS Randomized verum controlled parallel-group-comparison of two weeks treatment of a nasal-spray .,,,"['PATIENTS', 'AND', 'METHODS', 'Randomized', 'verum', 'controlled', 'parallel-group-comparison', 'of', 'two', 'weeks', 'treatment', 'of', 'a', 'nasal-spray', '.']",,,,,10763172,Abstract,1,test,gold,
281,,61 inpatients with the diagnosis Rhinitis following nasal operation,were included in this study and 30 patients were treated with verum and placebo each .,"['61', 'inpatients', 'with', 'the', 'diagnosis', 'Rhinitis', 'following', 'nasal', 'operation', 'were', 'included', 'in', 'this', 'study', 'and', '30', 'patients', 'were', 'treated', 'with', 'verum', 'and', 'placebo', 'each', '.']","(0, 9)","(0, 67)",-1,ss_p,10763172,Abstract,2,test,gold,7017.0
282,61 inpatients with the diagnosis Rhinitis following nasal operation were included in this study and 30 patients were treated with,verum,and placebo each .,"['61', 'inpatients', 'with', 'the', 'diagnosis', 'Rhinitis', 'following', 'nasal', 'operation', 'were', 'included', 'in', 'this', 'study', 'and', '30', 'patients', 'were', 'treated', 'with', 'verum', 'and', 'placebo', 'each', '.']","(20, 21)","(129, 134)",-1,ss_i,10763172,Abstract,2,test,gold,149.0
283,61 inpatients with the diagnosis Rhinitis following nasal operation were included in this study and 30 patients were treated with verum and,placebo,each .,"['61', 'inpatients', 'with', 'the', 'diagnosis', 'Rhinitis', 'following', 'nasal', 'operation', 'were', 'included', 'in', 'this', 'study', 'and', '30', 'patients', 'were', 'treated', 'with', 'verum', 'and', 'placebo', 'each', '.']","(22, 23)","(139, 146)",-1,ss_i,10763172,Abstract,2,test,gold,4422.0
284,,61 inpatients with the diagnosis Rhinitis following nasal operation,were included in this study and 30 patients were treated with verum and placebo each .,"['61', 'inpatients', 'with', 'the', 'diagnosis', 'Rhinitis', 'following', 'nasal', 'operation', 'were', 'included', 'in', 'this', 'study', 'and', '30', 'patients', 'were', 'treated', 'with', 'verum', 'and', 'placebo', 'each', '.']","(0, 9)","(0, 67)",-1,hl_p,10763172,Abstract,2,test,gold,7018.0
285,61 inpatients with the diagnosis Rhinitis following nasal operation were included in this study and 30 patients were treated with,verum,and placebo each .,"['61', 'inpatients', 'with', 'the', 'diagnosis', 'Rhinitis', 'following', 'nasal', 'operation', 'were', 'included', 'in', 'this', 'study', 'and', '30', 'patients', 'were', 'treated', 'with', 'verum', 'and', 'placebo', 'each', '.']","(20, 21)","(129, 134)",-1,hl_i,10763172,Abstract,2,test,gold,150.0
286,61 inpatients with the diagnosis Rhinitis following nasal operation were included in this study and 30 patients were treated with verum and,placebo,each .,"['61', 'inpatients', 'with', 'the', 'diagnosis', 'Rhinitis', 'following', 'nasal', 'operation', 'were', 'included', 'in', 'this', 'study', 'and', '30', 'patients', 'were', 'treated', 'with', 'verum', 'and', 'placebo', 'each', '.']","(22, 23)","(139, 146)",-1,hl_i,10763172,Abstract,2,test,gold,4423.0
287,The assessment of,nasal-breathing-resistance according to scores was defined as target-parameter .,,"['The', 'assessment', 'of', 'nasal-breathing-resistance', 'according', 'to', 'scores', 'was', 'defined', 'as', 'target-parameter', '.']","(3, 12)","(17, 97)",-1,ss_o,10763172,Abstract,3,test,gold,1430.0
288,The assessment of,nasal-breathing-resistance according to scores,was defined as target-parameter .,"['The', 'assessment', 'of', 'nasal-breathing-resistance', 'according', 'to', 'scores', 'was', 'defined', 'as', 'target-parameter', '.']","(3, 7)","(17, 63)",-1,hl_o,10763172,Abstract,3,test,gold,1431.0
289,Confirmatory statistical analysis was carried out according to Wilcoxon-Mann-Whitney-U two-sided at alpha < or = 0.05 .,,,"['Confirmatory', 'statistical', 'analysis', 'was', 'carried', 'out', 'according', 'to', 'Wilcoxon-Mann-Whitney-U', 'two-sided', 'at', 'alpha', '<', 'or', '=', '0.05', '.']",,,,,10763172,Abstract,4,test,gold,
290,MAIN OUTCOME MEASURE The superiority of the combination of,Xylometazoline-Dexpanthenol,nasal-spray versus Xylometazoline nasal spray could be proven for the target-parameter as clinically relevant and statistically significant .,"['MAIN', 'OUTCOME', 'MEASURE', 'The', 'superiority', 'of', 'the', 'combination', 'of', 'Xylometazoline-Dexpanthenol', 'nasal-spray', 'versus', 'Xylometazoline', 'nasal', 'spray', 'could', 'be', 'proven', 'for', 'the', 'target-parameter', 'as', 'clinically', 'relevant', 'and', 'statistically', 'significant', '.']","(9, 10)","(58, 85)",-1,ss_i,10763172,Abstract,5,test,gold,
291,MAIN OUTCOME MEASURE The superiority of the combination of Xylometazoline-Dexpanthenol nasal-spray versus,Xylometazoline,nasal spray could be proven for the target-parameter as clinically relevant and statistically significant .,"['MAIN', 'OUTCOME', 'MEASURE', 'The', 'superiority', 'of', 'the', 'combination', 'of', 'Xylometazoline-Dexpanthenol', 'nasal-spray', 'versus', 'Xylometazoline', 'nasal', 'spray', 'could', 'be', 'proven', 'for', 'the', 'target-parameter', 'as', 'clinically', 'relevant', 'and', 'statistically', 'significant', '.']","(12, 13)","(105, 119)",-1,ss_i,10763172,Abstract,5,test,gold,
292,MAIN OUTCOME MEASURE The,superiority,of the combination of Xylometazoline-Dexpanthenol nasal-spray versus Xylometazoline nasal spray could be proven for the target-parameter as clinically relevant and statistically significant .,"['MAIN', 'OUTCOME', 'MEASURE', 'The', 'superiority', 'of', 'the', 'combination', 'of', 'Xylometazoline-Dexpanthenol', 'nasal-spray', 'versus', 'Xylometazoline', 'nasal', 'spray', 'could', 'be', 'proven', 'for', 'the', 'target-parameter', 'as', 'clinically', 'relevant', 'and', 'statistically', 'significant', '.']","(4, 5)","(24, 35)",-1,ss_o,10763172,Abstract,5,test,gold,1200.0
293,MAIN OUTCOME MEASURE The superiority of the combination of Xylometazoline-Dexpanthenol nasal-spray versus Xylometazoline nasal spray could be proven for the,target-parameter,as clinically relevant and statistically significant .,"['MAIN', 'OUTCOME', 'MEASURE', 'The', 'superiority', 'of', 'the', 'combination', 'of', 'Xylometazoline-Dexpanthenol', 'nasal-spray', 'versus', 'Xylometazoline', 'nasal', 'spray', 'could', 'be', 'proven', 'for', 'the', 'target-parameter', 'as', 'clinically', 'relevant', 'and', 'statistically', 'significant', '.']","(20, 21)","(156, 172)",-1,ss_o,10763172,Abstract,5,test,gold,
294,MAIN OUTCOME MEASURE The superiority of the combination of,Xylometazoline-Dexpanthenol,nasal-spray versus Xylometazoline nasal spray could be proven for the target-parameter as clinically relevant and statistically significant .,"['MAIN', 'OUTCOME', 'MEASURE', 'The', 'superiority', 'of', 'the', 'combination', 'of', 'Xylometazoline-Dexpanthenol', 'nasal-spray', 'versus', 'Xylometazoline', 'nasal', 'spray', 'could', 'be', 'proven', 'for', 'the', 'target-parameter', 'as', 'clinically', 'relevant', 'and', 'statistically', 'significant', '.']","(9, 10)","(58, 85)",-1,hl_i,10763172,Abstract,5,test,gold,
295,MAIN OUTCOME MEASURE The superiority of the combination of Xylometazoline-Dexpanthenol nasal-spray versus,Xylometazoline,nasal spray could be proven for the target-parameter as clinically relevant and statistically significant .,"['MAIN', 'OUTCOME', 'MEASURE', 'The', 'superiority', 'of', 'the', 'combination', 'of', 'Xylometazoline-Dexpanthenol', 'nasal-spray', 'versus', 'Xylometazoline', 'nasal', 'spray', 'could', 'be', 'proven', 'for', 'the', 'target-parameter', 'as', 'clinically', 'relevant', 'and', 'statistically', 'significant', '.']","(12, 13)","(105, 119)",-1,hl_i,10763172,Abstract,5,test,gold,
296,The clinically proven,efficacy,is emphasized by good tolerability of both treatments .,"['The', 'clinically', 'proven', 'efficacy', 'is', 'emphasized', 'by', 'good', 'tolerability', 'of', 'both', 'treatments', '.']","(3, 4)","(21, 29)",-1,ss_o,10763172,Abstract,6,test,gold,4843.0
297,The clinically proven efficacy is emphasized by good,tolerability,of both treatments .,"['The', 'clinically', 'proven', 'efficacy', 'is', 'emphasized', 'by', 'good', 'tolerability', 'of', 'both', 'treatments', '.']","(8, 9)","(52, 64)",-1,ss_o,10763172,Abstract,6,test,gold,4873.0
298,The clinically proven,efficacy,is emphasized by good tolerability of both treatments .,"['The', 'clinically', 'proven', 'efficacy', 'is', 'emphasized', 'by', 'good', 'tolerability', 'of', 'both', 'treatments', '.']","(3, 4)","(21, 29)",-1,hl_o,10763172,Abstract,6,test,gold,4842.0
299,The clinically proven efficacy is emphasized by good,tolerability,of both treatments .,"['The', 'clinically', 'proven', 'efficacy', 'is', 'emphasized', 'by', 'good', 'tolerability', 'of', 'both', 'treatments', '.']","(8, 9)","(52, 64)",-1,hl_o,10763172,Abstract,6,test,gold,4872.0
300,Due to easy handling of the nasal-spray a good,compliance,was confirmed .,"['Due', 'to', 'easy', 'handling', 'of', 'the', 'nasal-spray', 'a', 'good', 'compliance', 'was', 'confirmed', '.']","(9, 10)","(46, 56)",-1,ss_o,10763172,Abstract,7,test,gold,1391.0
301,Due to easy handling of the nasal-spray a good,compliance,was confirmed .,"['Due', 'to', 'easy', 'handling', 'of', 'the', 'nasal-spray', 'a', 'good', 'compliance', 'was', 'confirmed', '.']","(9, 10)","(46, 56)",-1,hl_o,10763172,Abstract,7,test,gold,1392.0
302,CONCLUSION Distinct improvement of symptoms in,patients following nasal operations,underlines the efficacy of both medications .,"['CONCLUSION', 'Distinct', 'improvement', 'of', 'symptoms', 'in', 'patients', 'following', 'nasal', 'operations', 'underlines', 'the', 'efficacy', 'of', 'both', 'medications', '.']","(6, 10)","(46, 81)",-1,ss_p,10763172,Abstract,8,test,gold,3131.0
303,CONCLUSION Distinct,improvement,of symptoms in patients following nasal operations underlines the efficacy of both medications .,"['CONCLUSION', 'Distinct', 'improvement', 'of', 'symptoms', 'in', 'patients', 'following', 'nasal', 'operations', 'underlines', 'the', 'efficacy', 'of', 'both', 'medications', '.']","(2, 3)","(19, 30)",-1,ss_o,10763172,Abstract,8,test,gold,975.0
304,CONCLUSION Distinct improvement of symptoms in patients following nasal operations underlines the,efficacy,of both medications .,"['CONCLUSION', 'Distinct', 'improvement', 'of', 'symptoms', 'in', 'patients', 'following', 'nasal', 'operations', 'underlines', 'the', 'efficacy', 'of', 'both', 'medications', '.']","(12, 13)","(97, 105)",-1,ss_o,10763172,Abstract,8,test,gold,4841.0
305,CONCLUSION Distinct improvement of symptoms in,patients following nasal operations,underlines the efficacy of both medications .,"['CONCLUSION', 'Distinct', 'improvement', 'of', 'symptoms', 'in', 'patients', 'following', 'nasal', 'operations', 'underlines', 'the', 'efficacy', 'of', 'both', 'medications', '.']","(6, 10)","(46, 81)",-1,hl_p,10763172,Abstract,8,test,gold,3132.0
306,CONCLUSION Distinct,improvement,of symptoms in patients following nasal operations underlines the efficacy of both medications .,"['CONCLUSION', 'Distinct', 'improvement', 'of', 'symptoms', 'in', 'patients', 'following', 'nasal', 'operations', 'underlines', 'the', 'efficacy', 'of', 'both', 'medications', '.']","(2, 3)","(19, 30)",-1,hl_o,10763172,Abstract,8,test,gold,976.0
307,CONCLUSION Distinct improvement of symptoms in patients following nasal operations underlines the,efficacy,of both medications .,"['CONCLUSION', 'Distinct', 'improvement', 'of', 'symptoms', 'in', 'patients', 'following', 'nasal', 'operations', 'underlines', 'the', 'efficacy', 'of', 'both', 'medications', '.']","(12, 13)","(97, 105)",-1,hl_o,10763172,Abstract,8,test,gold,4840.0
308,With respect to the,tolerability,therapy with the combination is more beneficial in comparison to the alternative therapy .,"['With', 'respect', 'to', 'the', 'tolerability', 'therapy', 'with', 'the', 'combination', 'is', 'more', 'beneficial', 'in', 'comparison', 'to', 'the', 'alternative', 'therapy', '.']","(4, 5)","(19, 31)",-1,ss_o,10763172,Abstract,9,test,gold,4871.0
309,With respect to the,tolerability,therapy with the combination is more beneficial in comparison to the alternative therapy .,"['With', 'respect', 'to', 'the', 'tolerability', 'therapy', 'with', 'the', 'combination', 'is', 'more', 'beneficial', 'in', 'comparison', 'to', 'the', 'alternative', 'therapy', '.']","(4, 5)","(19, 31)",-1,hl_o,10763172,Abstract,9,test,gold,4870.0
310,The result of this controlled clinical study confirms that the combination Xylometazoline-Dexpanthenol is an enlargement and improvement of effective medicinal treatment of,rhinitis following nasal operation,in comparison to therapy with Xylometazoline alone .,"['The', 'result', 'of', 'this', 'controlled', 'clinical', 'study', 'confirms', 'that', 'the', 'combination', 'Xylometazoline-Dexpanthenol', 'is', 'an', 'enlargement', 'and', 'improvement', 'of', 'effective', 'medicinal', 'treatment', 'of', 'rhinitis', 'following', 'nasal', 'operation', 'in', 'comparison', 'to', 'therapy', 'with', 'Xylometazoline', 'alone', '.']","(22, 26)","(172, 206)",-1,ss_p,10763172,Abstract,10,test,gold,3129.0
311,The result of this controlled clinical study confirms that the combination,Xylometazoline-Dexpanthenol,is an enlargement and improvement of effective medicinal treatment of rhinitis following nasal operation in comparison to therapy with Xylometazoline alone .,"['The', 'result', 'of', 'this', 'controlled', 'clinical', 'study', 'confirms', 'that', 'the', 'combination', 'Xylometazoline-Dexpanthenol', 'is', 'an', 'enlargement', 'and', 'improvement', 'of', 'effective', 'medicinal', 'treatment', 'of', 'rhinitis', 'following', 'nasal', 'operation', 'in', 'comparison', 'to', 'therapy', 'with', 'Xylometazoline', 'alone', '.']","(11, 12)","(74, 101)",-1,ss_i,10763172,Abstract,10,test,gold,
312,The result of this controlled clinical study confirms that the combination Xylometazoline-Dexpanthenol is an enlargement and improvement of effective medicinal treatment of rhinitis following nasal operation in comparison to therapy with,Xylometazoline,alone .,"['The', 'result', 'of', 'this', 'controlled', 'clinical', 'study', 'confirms', 'that', 'the', 'combination', 'Xylometazoline-Dexpanthenol', 'is', 'an', 'enlargement', 'and', 'improvement', 'of', 'effective', 'medicinal', 'treatment', 'of', 'rhinitis', 'following', 'nasal', 'operation', 'in', 'comparison', 'to', 'therapy', 'with', 'Xylometazoline', 'alone', '.']","(31, 32)","(237, 251)",-1,ss_i,10763172,Abstract,10,test,gold,
313,The result of this controlled clinical study confirms that the combination Xylometazoline-Dexpanthenol is an enlargement and improvement of effective medicinal treatment of,rhinitis following nasal operation,in comparison to therapy with Xylometazoline alone .,"['The', 'result', 'of', 'this', 'controlled', 'clinical', 'study', 'confirms', 'that', 'the', 'combination', 'Xylometazoline-Dexpanthenol', 'is', 'an', 'enlargement', 'and', 'improvement', 'of', 'effective', 'medicinal', 'treatment', 'of', 'rhinitis', 'following', 'nasal', 'operation', 'in', 'comparison', 'to', 'therapy', 'with', 'Xylometazoline', 'alone', '.']","(22, 26)","(172, 206)",-1,hl_p,10763172,Abstract,10,test,gold,3130.0
314,The result of this controlled clinical study confirms that the combination,Xylometazoline-Dexpanthenol,is an enlargement and improvement of effective medicinal treatment of rhinitis following nasal operation in comparison to therapy with Xylometazoline alone .,"['The', 'result', 'of', 'this', 'controlled', 'clinical', 'study', 'confirms', 'that', 'the', 'combination', 'Xylometazoline-Dexpanthenol', 'is', 'an', 'enlargement', 'and', 'improvement', 'of', 'effective', 'medicinal', 'treatment', 'of', 'rhinitis', 'following', 'nasal', 'operation', 'in', 'comparison', 'to', 'therapy', 'with', 'Xylometazoline', 'alone', '.']","(11, 12)","(74, 101)",-1,hl_i,10763172,Abstract,10,test,gold,
315,The result of this controlled clinical study confirms that the combination Xylometazoline-Dexpanthenol is an enlargement and improvement of effective medicinal treatment of rhinitis following nasal operation in comparison to therapy with,Xylometazoline,alone .,"['The', 'result', 'of', 'this', 'controlled', 'clinical', 'study', 'confirms', 'that', 'the', 'combination', 'Xylometazoline-Dexpanthenol', 'is', 'an', 'enlargement', 'and', 'improvement', 'of', 'effective', 'medicinal', 'treatment', 'of', 'rhinitis', 'following', 'nasal', 'operation', 'in', 'comparison', 'to', 'therapy', 'with', 'Xylometazoline', 'alone', '.']","(31, 32)","(237, 251)",-1,hl_i,10763172,Abstract,10,test,gold,
316,Intrathecal morphine suppresses NK cell activity following,abdominal surgery .,,"['Intrathecal', 'morphine', 'suppresses', 'NK', 'cell', 'activity', 'following', 'abdominal', 'surgery', '.']","(7, 10)","(58, 77)",-1,ss_p,10764172,Title,0,test,gold,3664.0
317,Intrathecal,morphine,suppresses NK cell activity following abdominal surgery .,"['Intrathecal', 'morphine', 'suppresses', 'NK', 'cell', 'activity', 'following', 'abdominal', 'surgery', '.']","(1, 2)","(11, 19)",-1,ss_i,10764172,Title,0,test,gold,5110.0
318,Intrathecal morphine suppresses,NK cell activity,following abdominal surgery .,"['Intrathecal', 'morphine', 'suppresses', 'NK', 'cell', 'activity', 'following', 'abdominal', 'surgery', '.']","(3, 6)","(31, 47)",-1,ss_o,10764172,Title,0,test,gold,4551.0
319,Intrathecal,morphine,suppresses NK cell activity following abdominal surgery .,"['Intrathecal', 'morphine', 'suppresses', 'NK', 'cell', 'activity', 'following', 'abdominal', 'surgery', '.']","(1, 2)","(11, 19)",-1,hl_i,10764172,Title,0,test,gold,5111.0
320,Intrathecal morphine suppresses,NK cell activity,following abdominal surgery .,"['Intrathecal', 'morphine', 'suppresses', 'NK', 'cell', 'activity', 'following', 'abdominal', 'surgery', '.']","(3, 6)","(31, 47)",-1,hl_o,10764172,Title,0,test,gold,4552.0
321,PURPOSE The effects of morphine on natural killer ( NK ) cell activity were investigated in,patients who underwent hysterectomy .,,"['PURPOSE', 'The', 'effects', 'of', 'morphine', 'on', 'natural', 'killer', '(', 'NK', ')', 'cell', 'activity', 'were', 'investigated', 'in', 'patients', 'who', 'underwent', 'hysterectomy', '.']","(16, 21)","(91, 128)",-1,ss_p,10764172,Abstract,0,test,gold,3617.0
322,PURPOSE The effects of,morphine,on natural killer ( NK ) cell activity were investigated in patients who underwent hysterectomy .,"['PURPOSE', 'The', 'effects', 'of', 'morphine', 'on', 'natural', 'killer', '(', 'NK', ')', 'cell', 'activity', 'were', 'investigated', 'in', 'patients', 'who', 'underwent', 'hysterectomy', '.']","(4, 5)","(22, 30)",-1,ss_i,10764172,Abstract,0,test,gold,5109.0
323,PURPOSE The effects of morphine on,natural killer ( NK ) cell activity,were investigated in patients who underwent hysterectomy .,"['PURPOSE', 'The', 'effects', 'of', 'morphine', 'on', 'natural', 'killer', '(', 'NK', ')', 'cell', 'activity', 'were', 'investigated', 'in', 'patients', 'who', 'underwent', 'hysterectomy', '.']","(6, 13)","(34, 69)",-1,ss_o,10764172,Abstract,0,test,gold,4546.0
324,PURPOSE The effects of morphine on natural killer ( NK ) cell activity were investigated in patients who,underwent hysterectomy,.,"['PURPOSE', 'The', 'effects', 'of', 'morphine', 'on', 'natural', 'killer', '(', 'NK', ')', 'cell', 'activity', 'were', 'investigated', 'in', 'patients', 'who', 'underwent', 'hysterectomy', '.']","(18, 20)","(104, 126)",-1,hl_p,10764172,Abstract,0,test,gold,3618.0
325,PURPOSE The effects of,morphine,on natural killer ( NK ) cell activity were investigated in patients who underwent hysterectomy .,"['PURPOSE', 'The', 'effects', 'of', 'morphine', 'on', 'natural', 'killer', '(', 'NK', ')', 'cell', 'activity', 'were', 'investigated', 'in', 'patients', 'who', 'underwent', 'hysterectomy', '.']","(4, 5)","(22, 30)",-1,hl_i,10764172,Abstract,0,test,gold,5108.0
326,PURPOSE The effects of morphine on,natural killer ( NK ) cell activity,were investigated in patients who underwent hysterectomy .,"['PURPOSE', 'The', 'effects', 'of', 'morphine', 'on', 'natural', 'killer', '(', 'NK', ')', 'cell', 'activity', 'were', 'investigated', 'in', 'patients', 'who', 'underwent', 'hysterectomy', '.']","(6, 13)","(34, 69)",-1,hl_o,10764172,Abstract,0,test,gold,4547.0
327,METHODS,Forty patients were divided into four groups of ten .,,"['METHODS', 'Forty', 'patients', 'were', 'divided', 'into', 'four', 'groups', 'of', 'ten', '.']","(1, 11)","(7, 60)",-1,ss_p,10764172,Abstract,1,test,gold,5846.0
328,METHODS,Forty patients were divided into four groups of ten .,,"['METHODS', 'Forty', 'patients', 'were', 'divided', 'into', 'four', 'groups', 'of', 'ten', '.']","(1, 11)","(7, 60)",-1,hl_p,10764172,Abstract,1,test,gold,5847.0
329,The groups received intrathecal 0.5 mg,morphine,"( Group IT0.5 ) , intrathecal 0.1 mg morphine ( Group IT0.1 ) or 10 mg morphine i.v .","['The', 'groups', 'received', 'intrathecal', '0.5', 'mg', 'morphine', '(', 'Group', 'IT0.5', ')', ',', 'intrathecal', '0.1', 'mg', 'morphine', '(', 'Group', 'IT0.1', ')', 'or', '10', 'mg', 'morphine', 'i.v', '.']","(6, 7)","(38, 46)",-1,ss_i,10764172,Abstract,2,test,gold,5107.0
330,"The groups received intrathecal 0.5 mg morphine ( Group IT0.5 ) , intrathecal 0.1 mg",morphine,( Group IT0.1 ) or 10 mg morphine i.v .,"['The', 'groups', 'received', 'intrathecal', '0.5', 'mg', 'morphine', '(', 'Group', 'IT0.5', ')', ',', 'intrathecal', '0.1', 'mg', 'morphine', '(', 'Group', 'IT0.1', ')', 'or', '10', 'mg', 'morphine', 'i.v', '.']","(15, 16)","(84, 92)",-1,ss_i,10764172,Abstract,2,test,gold,5106.0
331,"The groups received intrathecal 0.5 mg morphine ( Group IT0.5 ) , intrathecal 0.1 mg morphine ( Group IT0.1 ) or 10 mg",morphine,i.v .,"['The', 'groups', 'received', 'intrathecal', '0.5', 'mg', 'morphine', '(', 'Group', 'IT0.5', ')', ',', 'intrathecal', '0.1', 'mg', 'morphine', '(', 'Group', 'IT0.1', ')', 'or', '10', 'mg', 'morphine', 'i.v', '.']","(23, 24)","(118, 126)",-1,ss_i,10764172,Abstract,2,test,gold,5105.0
332,The groups received intrathecal 0.5 mg,morphine,"( Group IT0.5 ) , intrathecal 0.1 mg morphine ( Group IT0.1 ) or 10 mg morphine i.v .","['The', 'groups', 'received', 'intrathecal', '0.5', 'mg', 'morphine', '(', 'Group', 'IT0.5', ')', ',', 'intrathecal', '0.1', 'mg', 'morphine', '(', 'Group', 'IT0.1', ')', 'or', '10', 'mg', 'morphine', 'i.v', '.']","(6, 7)","(38, 46)",-1,hl_i,10764172,Abstract,2,test,gold,5104.0
333,"The groups received intrathecal 0.5 mg morphine ( Group IT0.5 ) , intrathecal 0.1 mg",morphine,( Group IT0.1 ) or 10 mg morphine i.v .,"['The', 'groups', 'received', 'intrathecal', '0.5', 'mg', 'morphine', '(', 'Group', 'IT0.5', ')', ',', 'intrathecal', '0.1', 'mg', 'morphine', '(', 'Group', 'IT0.1', ')', 'or', '10', 'mg', 'morphine', 'i.v', '.']","(15, 16)","(84, 92)",-1,hl_i,10764172,Abstract,2,test,gold,5103.0
334,"The groups received intrathecal 0.5 mg morphine ( Group IT0.5 ) , intrathecal 0.1 mg morphine ( Group IT0.1 ) or 10 mg",morphine,i.v .,"['The', 'groups', 'received', 'intrathecal', '0.5', 'mg', 'morphine', '(', 'Group', 'IT0.5', ')', ',', 'intrathecal', '0.1', 'mg', 'morphine', '(', 'Group', 'IT0.1', ')', 'or', '10', 'mg', 'morphine', 'i.v', '.']","(23, 24)","(118, 126)",-1,hl_i,10764172,Abstract,2,test,gold,5102.0
335,( Group IV ) .,,,"['(', 'Group', 'IV', ')', '.']",,,,,10764172,Abstract,3,test,gold,
336,The remaining ten patients served as controls and received inhalation anesthesia alone ( Group C ) .,,,"['The', 'remaining', 'ten', 'patients', 'served', 'as', 'controls', 'and', 'received', 'inhalation', 'anesthesia', 'alone', '(', 'Group', 'C', ')', '.']",,,,,10764172,Abstract,4,test,gold,
337,Blood samples were withdrawn before and two hours after surgery and on postoperative days one and two to determine the,blood NK cell activity,"using a chromium release assay with K562 cells as targets , plasma catecholamines and cortisol levels .","['Blood', 'samples', 'were', 'withdrawn', 'before', 'and', 'two', 'hours', 'after', 'surgery', 'and', 'on', 'postoperative', 'days', 'one', 'and', 'two', 'to', 'determine', 'the', 'blood', 'NK', 'cell', 'activity', 'using', 'a', 'chromium', 'release', 'assay', 'with', 'K562', 'cells', 'as', 'targets', ',', 'plasma', 'catecholamines', 'and', 'cortisol', 'levels', '.']","(20, 24)","(118, 140)",-1,ss_o,10764172,Abstract,5,test,gold,4548.0
338,Blood samples were withdrawn before and two hours after surgery and on postoperative days one and two to determine the blood NK cell activity using a,"chromium release assay with K562 cells as targets , plasma catecholamines and cortisol levels .",,"['Blood', 'samples', 'were', 'withdrawn', 'before', 'and', 'two', 'hours', 'after', 'surgery', 'and', 'on', 'postoperative', 'days', 'one', 'and', 'two', 'to', 'determine', 'the', 'blood', 'NK', 'cell', 'activity', 'using', 'a', 'chromium', 'release', 'assay', 'with', 'K562', 'cells', 'as', 'targets', ',', 'plasma', 'catecholamines', 'and', 'cortisol', 'levels', '.']","(26, 41)","(149, 244)",-1,ss_o,10764172,Abstract,5,test,gold,6531.0
339,The,postoperative pain score and side effects,were studied in the four groups .,"['The', 'postoperative', 'pain', 'score', 'and', 'side', 'effects', 'were', 'studied', 'in', 'the', 'four', 'groups', '.']","(1, 7)","(3, 44)",-1,ss_o,10764172,Abstract,6,test,gold,3666.0
340,The,postoperative pain score and side effects,were studied in the four groups .,"['The', 'postoperative', 'pain', 'score', 'and', 'side', 'effects', 'were', 'studied', 'in', 'the', 'four', 'groups', '.']","(1, 7)","(3, 44)",-1,hl_o,10764172,Abstract,6,test,gold,3667.0
341,"RESULTS In Group IT0.5 , the",NK cell activity,"was lower on postoperative day 1 ( 23.9 +/- 8.4 % ) than the baseline level ( 45.7 +/- 13 % ) before surgery , and recovered on postoperative day 2 .","['RESULTS', 'In', 'Group', 'IT0.5', ',', 'the', 'NK', 'cell', 'activity', 'was', 'lower', 'on', 'postoperative', 'day', '1', '(', '23.9', '+/-', '8.4', '%', ')', 'than', 'the', 'baseline', 'level', '(', '45.7', '+/-', '13', '%', ')', 'before', 'surgery', ',', 'and', 'recovered', 'on', 'postoperative', 'day', '2', '.']","(6, 9)","(28, 44)",-1,ss_o,10764172,Abstract,7,test,gold,4550.0
342,"RESULTS In Group IT0.5 , the",NK cell activity,"was lower on postoperative day 1 ( 23.9 +/- 8.4 % ) than the baseline level ( 45.7 +/- 13 % ) before surgery , and recovered on postoperative day 2 .","['RESULTS', 'In', 'Group', 'IT0.5', ',', 'the', 'NK', 'cell', 'activity', 'was', 'lower', 'on', 'postoperative', 'day', '1', '(', '23.9', '+/-', '8.4', '%', ')', 'than', 'the', 'baseline', 'level', '(', '45.7', '+/-', '13', '%', ')', 'before', 'surgery', ',', 'and', 'recovered', 'on', 'postoperative', 'day', '2', '.']","(6, 9)","(28, 44)",-1,hl_o,10764172,Abstract,7,test,gold,4549.0
343,"In Groups IT0.1 , C and IV , the",NK cell activities,showed no significant changes .,"['In', 'Groups', 'IT0.1', ',', 'C', 'and', 'IV', ',', 'the', 'NK', 'cell', 'activities', 'showed', 'no', 'significant', 'changes', '.']","(9, 12)","(32, 50)",-1,ss_o,10764172,Abstract,8,test,gold,4553.0
344,"In Groups IT0.1 , C and IV , the",NK cell activities,showed no significant changes .,"['In', 'Groups', 'IT0.1', ',', 'C', 'and', 'IV', ',', 'the', 'NK', 'cell', 'activities', 'showed', 'no', 'significant', 'changes', '.']","(9, 12)","(32, 50)",-1,hl_o,10764172,Abstract,8,test,gold,4554.0
345,"In all four groups , neither",plasma adrenaline,nor noradrenaline concentrations changed .,"['In', 'all', 'four', 'groups', ',', 'neither', 'plasma', 'adrenaline', 'nor', 'noradrenaline', 'concentrations', 'changed', '.']","(6, 8)","(28, 45)",-1,ss_o,10764172,Abstract,9,test,gold,4449.0
346,"In all four groups , neither plasma adrenaline nor",noradrenaline concentrations,changed .,"['In', 'all', 'four', 'groups', ',', 'neither', 'plasma', 'adrenaline', 'nor', 'noradrenaline', 'concentrations', 'changed', '.']","(9, 11)","(50, 78)",-1,ss_o,10764172,Abstract,9,test,gold,4513.0
347,"In all four groups , neither",plasma adrenaline,nor noradrenaline concentrations changed .,"['In', 'all', 'four', 'groups', ',', 'neither', 'plasma', 'adrenaline', 'nor', 'noradrenaline', 'concentrations', 'changed', '.']","(6, 8)","(28, 45)",-1,hl_o,10764172,Abstract,9,test,gold,4450.0
348,"In all four groups , neither plasma adrenaline nor",noradrenaline concentrations,changed .,"['In', 'all', 'four', 'groups', ',', 'neither', 'plasma', 'adrenaline', 'nor', 'noradrenaline', 'concentrations', 'changed', '.']","(9, 11)","(50, 78)",-1,hl_o,10764172,Abstract,9,test,gold,4514.0
349,"In all four groups , the",plasma cortisol levels,"increased after surgery , on postoperative days 1 and 2 .","['In', 'all', 'four', 'groups', ',', 'the', 'plasma', 'cortisol', 'levels', 'increased', 'after', 'surgery', ',', 'on', 'postoperative', 'days', '1', 'and', '2', '.']","(6, 9)","(24, 46)",-1,ss_o,10764172,Abstract,10,test,gold,6570.0
350,"In all four groups , the",plasma cortisol levels,"increased after surgery , on postoperative days 1 and 2 .","['In', 'all', 'four', 'groups', ',', 'the', 'plasma', 'cortisol', 'levels', 'increased', 'after', 'surgery', ',', 'on', 'postoperative', 'days', '1', 'and', '2', '.']","(6, 9)","(24, 46)",-1,hl_o,10764172,Abstract,10,test,gold,6571.0
351,The,pain score,was lower two hours after surgery and on postoperative day 1 in Group IT0.5 than in the other groups .,"['The', 'pain', 'score', 'was', 'lower', 'two', 'hours', 'after', 'surgery', 'and', 'on', 'postoperative', 'day', '1', 'in', 'Group', 'IT0.5', 'than', 'in', 'the', 'other', 'groups', '.']","(1, 3)","(3, 13)",-1,ss_o,10764172,Abstract,11,test,gold,2323.0
352,The,pain score,was lower two hours after surgery and on postoperative day 1 in Group IT0.5 than in the other groups .,"['The', 'pain', 'score', 'was', 'lower', 'two', 'hours', 'after', 'surgery', 'and', 'on', 'postoperative', 'day', '1', 'in', 'Group', 'IT0.5', 'than', 'in', 'the', 'other', 'groups', '.']","(1, 3)","(3, 13)",-1,hl_o,10764172,Abstract,11,test,gold,2324.0
353,CONCLUSION These results suggest that long-lasting analgesic effects of intrathecal 0.5 mg morphine suppress the immune response following,abdominal surgery .,,"['CONCLUSION', 'These', 'results', 'suggest', 'that', 'long-lasting', 'analgesic', 'effects', 'of', 'intrathecal', '0.5', 'mg', 'morphine', 'suppress', 'the', 'immune', 'response', 'following', 'abdominal', 'surgery', '.']","(18, 21)","(138, 157)",-1,ss_p,10764172,Abstract,12,test,gold,3665.0
354,CONCLUSION These results suggest that long-lasting analgesic effects of intrathecal 0.5 mg,morphine,suppress the immune response following abdominal surgery .,"['CONCLUSION', 'These', 'results', 'suggest', 'that', 'long-lasting', 'analgesic', 'effects', 'of', 'intrathecal', '0.5', 'mg', 'morphine', 'suppress', 'the', 'immune', 'response', 'following', 'abdominal', 'surgery', '.']","(12, 13)","(90, 98)",-1,ss_i,10764172,Abstract,12,test,gold,5101.0
355,CONCLUSION These results suggest that long-lasting analgesic effects of intrathecal 0.5 mg,morphine,suppress the immune response following abdominal surgery .,"['CONCLUSION', 'These', 'results', 'suggest', 'that', 'long-lasting', 'analgesic', 'effects', 'of', 'intrathecal', '0.5', 'mg', 'morphine', 'suppress', 'the', 'immune', 'response', 'following', 'abdominal', 'surgery', '.']","(12, 13)","(90, 98)",-1,hl_i,10764172,Abstract,12,test,gold,5100.0
356,Effects of low-dose aspirin on clinic and ambulatory blood pressure in,treated hypertensive patients .,,"['Effects', 'of', 'low-dose', 'aspirin', 'on', 'clinic', 'and', 'ambulatory', 'blood', 'pressure', 'in', 'treated', 'hypertensive', 'patients', '.']","(11, 15)","(70, 101)",-1,ss_p,10912743,Title,0,test,gold,6914.0
357,Effects of low-dose,aspirin,on clinic and ambulatory blood pressure in treated hypertensive patients .,"['Effects', 'of', 'low-dose', 'aspirin', 'on', 'clinic', 'and', 'ambulatory', 'blood', 'pressure', 'in', 'treated', 'hypertensive', 'patients', '.']","(3, 4)","(19, 26)",-1,ss_i,10912743,Title,0,test,gold,5342.0
358,Effects of low-dose aspirin on,clinic and ambulatory blood pressure,in treated hypertensive patients .,"['Effects', 'of', 'low-dose', 'aspirin', 'on', 'clinic', 'and', 'ambulatory', 'blood', 'pressure', 'in', 'treated', 'hypertensive', 'patients', '.']","(5, 10)","(30, 66)",-1,ss_o,10912743,Title,0,test,gold,6717.0
359,Effects of low-dose aspirin on clinic and ambulatory blood pressure in,treated hypertensive patients .,,"['Effects', 'of', 'low-dose', 'aspirin', 'on', 'clinic', 'and', 'ambulatory', 'blood', 'pressure', 'in', 'treated', 'hypertensive', 'patients', '.']","(11, 15)","(70, 101)",-1,hl_p,10912743,Title,0,test,gold,6915.0
360,Effects of low-dose,aspirin,on clinic and ambulatory blood pressure in treated hypertensive patients .,"['Effects', 'of', 'low-dose', 'aspirin', 'on', 'clinic', 'and', 'ambulatory', 'blood', 'pressure', 'in', 'treated', 'hypertensive', 'patients', '.']","(3, 4)","(19, 26)",-1,hl_i,10912743,Title,0,test,gold,5343.0
361,Effects of low-dose aspirin on,clinic and ambulatory blood pressure,in treated hypertensive patients .,"['Effects', 'of', 'low-dose', 'aspirin', 'on', 'clinic', 'and', 'ambulatory', 'blood', 'pressure', 'in', 'treated', 'hypertensive', 'patients', '.']","(5, 10)","(30, 66)",-1,hl_o,10912743,Title,0,test,gold,6718.0
362,Collaborative Group of the Primary Prevention Project ( PPP ) -- Hypertension study .,,,"['Collaborative', 'Group', 'of', 'the', 'Primary', 'Prevention', 'Project', '(', 'PPP', ')', '--', 'Hypertension', 'study', '.']",,,,,10912743,Abstract,0,test,gold,
363,Nonsteroidal antiinflammatory drugs may affect blood pressure ( BP ) control in,hypertensive patients receiving drug treatment,", but data on the effects of low-dose aspirin are scanty .","['Nonsteroidal', 'antiinflammatory', 'drugs', 'may', 'affect', 'blood', 'pressure', '(', 'BP', ')', 'control', 'in', 'hypertensive', 'patients', 'receiving', 'drug', 'treatment', ',', 'but', 'data', 'on', 'the', 'effects', 'of', 'low-dose', 'aspirin', 'are', 'scanty', '.']","(12, 17)","(79, 125)",-1,ss_p,10912743,Abstract,1,test,gold,6916.0
364,"Nonsteroidal antiinflammatory drugs may affect blood pressure ( BP ) control in hypertensive patients receiving drug treatment , but data on the effects of low-dose",aspirin,are scanty .,"['Nonsteroidal', 'antiinflammatory', 'drugs', 'may', 'affect', 'blood', 'pressure', '(', 'BP', ')', 'control', 'in', 'hypertensive', 'patients', 'receiving', 'drug', 'treatment', ',', 'but', 'data', 'on', 'the', 'effects', 'of', 'low-dose', 'aspirin', 'are', 'scanty', '.']","(25, 26)","(164, 171)",-1,ss_i,10912743,Abstract,1,test,gold,5341.0
365,Nonsteroidal antiinflammatory drugs may affect,blood pressure ( BP ) control,"in hypertensive patients receiving drug treatment , but data on the effects of low-dose aspirin are scanty .","['Nonsteroidal', 'antiinflammatory', 'drugs', 'may', 'affect', 'blood', 'pressure', '(', 'BP', ')', 'control', 'in', 'hypertensive', 'patients', 'receiving', 'drug', 'treatment', ',', 'but', 'data', 'on', 'the', 'effects', 'of', 'low-dose', 'aspirin', 'are', 'scanty', '.']","(5, 11)","(46, 75)",-1,ss_o,10912743,Abstract,1,test,gold,6698.0
366,Nonsteroidal antiinflammatory drugs may affect blood pressure ( BP ) control in,hypertensive patients receiving drug treatment,", but data on the effects of low-dose aspirin are scanty .","['Nonsteroidal', 'antiinflammatory', 'drugs', 'may', 'affect', 'blood', 'pressure', '(', 'BP', ')', 'control', 'in', 'hypertensive', 'patients', 'receiving', 'drug', 'treatment', ',', 'but', 'data', 'on', 'the', 'effects', 'of', 'low-dose', 'aspirin', 'are', 'scanty', '.']","(12, 17)","(79, 125)",-1,hl_p,10912743,Abstract,1,test,gold,6917.0
367,"Nonsteroidal antiinflammatory drugs may affect blood pressure ( BP ) control in hypertensive patients receiving drug treatment , but data on the effects of low-dose",aspirin,are scanty .,"['Nonsteroidal', 'antiinflammatory', 'drugs', 'may', 'affect', 'blood', 'pressure', '(', 'BP', ')', 'control', 'in', 'hypertensive', 'patients', 'receiving', 'drug', 'treatment', ',', 'but', 'data', 'on', 'the', 'effects', 'of', 'low-dose', 'aspirin', 'are', 'scanty', '.']","(25, 26)","(164, 171)",-1,hl_i,10912743,Abstract,1,test,gold,5340.0
368,Nonsteroidal antiinflammatory drugs may affect,blood pressure ( BP ) control,"in hypertensive patients receiving drug treatment , but data on the effects of low-dose aspirin are scanty .","['Nonsteroidal', 'antiinflammatory', 'drugs', 'may', 'affect', 'blood', 'pressure', '(', 'BP', ')', 'control', 'in', 'hypertensive', 'patients', 'receiving', 'drug', 'treatment', ',', 'but', 'data', 'on', 'the', 'effects', 'of', 'low-dose', 'aspirin', 'are', 'scanty', '.']","(5, 11)","(46, 75)",-1,hl_o,10912743,Abstract,1,test,gold,6699.0
369,This study assessed the effects of chronic treatment with low doses of aspirin ( 100 mg/day ) on clinic and ambulatory systolic ( SBP ) and diastolic ( DBP ) BP in,"hypertensives on chronic , stable antihypertensive therapy .",,"['This', 'study', 'assessed', 'the', 'effects', 'of', 'chronic', 'treatment', 'with', 'low', 'doses', 'of', 'aspirin', '(', '100', 'mg/day', ')', 'on', 'clinic', 'and', 'ambulatory', 'systolic', '(', 'SBP', ')', 'and', 'diastolic', '(', 'DBP', ')', 'BP', 'in', 'hypertensives', 'on', 'chronic', ',', 'stable', 'antihypertensive', 'therapy', '.']","(32, 40)","(163, 223)",-1,ss_p,10912743,Abstract,2,test,gold,6910.0
370,This study assessed the effects of chronic treatment with low doses of,aspirin,"( 100 mg/day ) on clinic and ambulatory systolic ( SBP ) and diastolic ( DBP ) BP in hypertensives on chronic , stable antihypertensive therapy .","['This', 'study', 'assessed', 'the', 'effects', 'of', 'chronic', 'treatment', 'with', 'low', 'doses', 'of', 'aspirin', '(', '100', 'mg/day', ')', 'on', 'clinic', 'and', 'ambulatory', 'systolic', '(', 'SBP', ')', 'and', 'diastolic', '(', 'DBP', ')', 'BP', 'in', 'hypertensives', 'on', 'chronic', ',', 'stable', 'antihypertensive', 'therapy', '.']","(12, 13)","(70, 77)",-1,ss_i,10912743,Abstract,2,test,gold,5339.0
371,This study assessed the effects of chronic treatment with low doses of aspirin ( 100 mg/day ) on,clinic and ambulatory systolic ( SBP ) and diastolic ( DBP ) BP,"in hypertensives on chronic , stable antihypertensive therapy .","['This', 'study', 'assessed', 'the', 'effects', 'of', 'chronic', 'treatment', 'with', 'low', 'doses', 'of', 'aspirin', '(', '100', 'mg/day', ')', 'on', 'clinic', 'and', 'ambulatory', 'systolic', '(', 'SBP', ')', 'and', 'diastolic', '(', 'DBP', ')', 'BP', 'in', 'hypertensives', 'on', 'chronic', ',', 'stable', 'antihypertensive', 'therapy', '.']","(18, 31)","(96, 159)",-1,ss_o,10912743,Abstract,2,test,gold,6696.0
372,This study assessed the effects of chronic treatment with low doses of,aspirin,"( 100 mg/day ) on clinic and ambulatory systolic ( SBP ) and diastolic ( DBP ) BP in hypertensives on chronic , stable antihypertensive therapy .","['This', 'study', 'assessed', 'the', 'effects', 'of', 'chronic', 'treatment', 'with', 'low', 'doses', 'of', 'aspirin', '(', '100', 'mg/day', ')', 'on', 'clinic', 'and', 'ambulatory', 'systolic', '(', 'SBP', ')', 'and', 'diastolic', '(', 'DBP', ')', 'BP', 'in', 'hypertensives', 'on', 'chronic', ',', 'stable', 'antihypertensive', 'therapy', '.']","(12, 13)","(70, 77)",-1,hl_i,10912743,Abstract,2,test,gold,5338.0
373,This study assessed the effects of chronic treatment with low doses of aspirin ( 100 mg/day ) on,clinic and ambulatory systolic ( SBP ) and diastolic ( DBP ) BP,"in hypertensives on chronic , stable antihypertensive therapy .","['This', 'study', 'assessed', 'the', 'effects', 'of', 'chronic', 'treatment', 'with', 'low', 'doses', 'of', 'aspirin', '(', '100', 'mg/day', ')', 'on', 'clinic', 'and', 'ambulatory', 'systolic', '(', 'SBP', ')', 'and', 'diastolic', '(', 'DBP', ')', 'BP', 'in', 'hypertensives', 'on', 'chronic', ',', 'stable', 'antihypertensive', 'therapy', '.']","(18, 31)","(96, 159)",-1,hl_o,10912743,Abstract,2,test,gold,6697.0
374,"The study was conducted in the framework of the Primary Prevention Project ( PPP ) , a randomized , controlled factorial trial on the preventive effect of aspirin or vitamin E in",people with one or more cardiovascular risk factors .,,"['The', 'study', 'was', 'conducted', 'in', 'the', 'framework', 'of', 'the', 'Primary', 'Prevention', 'Project', '(', 'PPP', ')', ',', 'a', 'randomized', ',', 'controlled', 'factorial', 'trial', 'on', 'the', 'preventive', 'effect', 'of', 'aspirin', 'or', 'vitamin', 'E', 'in', 'people', 'with', 'one', 'or', 'more', 'cardiovascular', 'risk', 'factors', '.']","(32, 41)","(178, 231)",-1,ss_p,10912743,Abstract,3,test,gold,6930.0
375,"The study was conducted in the framework of the Primary Prevention Project ( PPP ) , a randomized , controlled factorial trial on the preventive effect of",aspirin,or vitamin E in people with one or more cardiovascular risk factors .,"['The', 'study', 'was', 'conducted', 'in', 'the', 'framework', 'of', 'the', 'Primary', 'Prevention', 'Project', '(', 'PPP', ')', ',', 'a', 'randomized', ',', 'controlled', 'factorial', 'trial', 'on', 'the', 'preventive', 'effect', 'of', 'aspirin', 'or', 'vitamin', 'E', 'in', 'people', 'with', 'one', 'or', 'more', 'cardiovascular', 'risk', 'factors', '.']","(27, 28)","(154, 161)",-1,ss_i,10912743,Abstract,3,test,gold,5337.0
376,"The study was conducted in the framework of the Primary Prevention Project ( PPP ) , a randomized , controlled factorial trial on the preventive effect of aspirin or",vitamin E,in people with one or more cardiovascular risk factors .,"['The', 'study', 'was', 'conducted', 'in', 'the', 'framework', 'of', 'the', 'Primary', 'Prevention', 'Project', '(', 'PPP', ')', ',', 'a', 'randomized', ',', 'controlled', 'factorial', 'trial', 'on', 'the', 'preventive', 'effect', 'of', 'aspirin', 'or', 'vitamin', 'E', 'in', 'people', 'with', 'one', 'or', 'more', 'cardiovascular', 'risk', 'factors', '.']","(29, 31)","(165, 174)",-1,ss_i,10912743,Abstract,3,test,gold,4626.0
377,"The study was conducted in the framework of the Primary Prevention Project ( PPP ) , a randomized , controlled factorial trial on the preventive effect of aspirin or vitamin E in",people with one or more cardiovascular risk factors .,,"['The', 'study', 'was', 'conducted', 'in', 'the', 'framework', 'of', 'the', 'Primary', 'Prevention', 'Project', '(', 'PPP', ')', ',', 'a', 'randomized', ',', 'controlled', 'factorial', 'trial', 'on', 'the', 'preventive', 'effect', 'of', 'aspirin', 'or', 'vitamin', 'E', 'in', 'people', 'with', 'one', 'or', 'more', 'cardiovascular', 'risk', 'factors', '.']","(32, 41)","(178, 231)",-1,hl_p,10912743,Abstract,3,test,gold,6931.0
378,"The study was conducted in the framework of the Primary Prevention Project ( PPP ) , a randomized , controlled factorial trial on the preventive effect of",aspirin,or vitamin E in people with one or more cardiovascular risk factors .,"['The', 'study', 'was', 'conducted', 'in', 'the', 'framework', 'of', 'the', 'Primary', 'Prevention', 'Project', '(', 'PPP', ')', ',', 'a', 'randomized', ',', 'controlled', 'factorial', 'trial', 'on', 'the', 'preventive', 'effect', 'of', 'aspirin', 'or', 'vitamin', 'E', 'in', 'people', 'with', 'one', 'or', 'more', 'cardiovascular', 'risk', 'factors', '.']","(27, 28)","(154, 161)",-1,hl_i,10912743,Abstract,3,test,gold,5336.0
379,"The study was conducted in the framework of the Primary Prevention Project ( PPP ) , a randomized , controlled factorial trial on the preventive effect of aspirin or",vitamin E,in people with one or more cardiovascular risk factors .,"['The', 'study', 'was', 'conducted', 'in', 'the', 'framework', 'of', 'the', 'Primary', 'Prevention', 'Project', '(', 'PPP', ')', ',', 'a', 'randomized', ',', 'controlled', 'factorial', 'trial', 'on', 'the', 'preventive', 'effect', 'of', 'aspirin', 'or', 'vitamin', 'E', 'in', 'people', 'with', 'one', 'or', 'more', 'cardiovascular', 'risk', 'factors', '.']","(29, 31)","(165, 174)",-1,hl_i,10912743,Abstract,3,test,gold,4627.0
380,,"Fifteen Italian hypertension units studied 142 hypertensive patients ( 76 men , 66 women ; mean age 59 +/- 5.9 years ) treated with different antihypertensive drugs :",71 patients were randomized to aspirin and 71 served as controls .,"['Fifteen', 'Italian', 'hypertension', 'units', 'studied', '142', 'hypertensive', 'patients', '(', '76', 'men', ',', '66', 'women', ';', 'mean', 'age', '59', '+/-', '5.9', 'years', ')', 'treated', 'with', 'different', 'antihypertensive', 'drugs', ':', '71', 'patients', 'were', 'randomized', 'to', 'aspirin', 'and', '71', 'served', 'as', 'controls', '.']","(0, 28)","(0, 166)",-1,ss_p,10912743,Abstract,4,test,gold,5907.0
381,"Fifteen Italian hypertension units studied 142 hypertensive patients ( 76 men , 66 women ; mean age 59 +/- 5.9 years ) treated with different antihypertensive drugs : 71 patients were randomized to",aspirin,and 71 served as controls .,"['Fifteen', 'Italian', 'hypertension', 'units', 'studied', '142', 'hypertensive', 'patients', '(', '76', 'men', ',', '66', 'women', ';', 'mean', 'age', '59', '+/-', '5.9', 'years', ')', 'treated', 'with', 'different', 'antihypertensive', 'drugs', ':', '71', 'patients', 'were', 'randomized', 'to', 'aspirin', 'and', '71', 'served', 'as', 'controls', '.']","(33, 34)","(197, 204)",-1,ss_i,10912743,Abstract,4,test,gold,5335.0
382,Fifteen Italian,hypertension,"units studied 142 hypertensive patients ( 76 men , 66 women ; mean age 59 +/- 5.9 years ) treated with different antihypertensive drugs : 71 patients were randomized to aspirin and 71 served as controls .","['Fifteen', 'Italian', 'hypertension', 'units', 'studied', '142', 'hypertensive', 'patients', '(', '76', 'men', ',', '66', 'women', ';', 'mean', 'age', '59', '+/-', '5.9', 'years', ')', 'treated', 'with', 'different', 'antihypertensive', 'drugs', ':', '71', 'patients', 'were', 'randomized', 'to', 'aspirin', 'and', '71', 'served', 'as', 'controls', '.']","(2, 3)","(15, 27)",-1,hl_p,10912743,Abstract,4,test,gold,3459.0
383,Fifteen Italian hypertension units studied,142 hypertensive,"patients ( 76 men , 66 women ; mean age 59 +/- 5.9 years ) treated with different antihypertensive drugs : 71 patients were randomized to aspirin and 71 served as controls .","['Fifteen', 'Italian', 'hypertension', 'units', 'studied', '142', 'hypertensive', 'patients', '(', '76', 'men', ',', '66', 'women', ';', 'mean', 'age', '59', '+/-', '5.9', 'years', ')', 'treated', 'with', 'different', 'antihypertensive', 'drugs', ':', '71', 'patients', 'were', 'randomized', 'to', 'aspirin', 'and', '71', 'served', 'as', 'controls', '.']","(5, 7)","(42, 58)",-1,hl_p,10912743,Abstract,4,test,gold,3454.0
384,Fifteen Italian hypertension units studied 142 hypertensive patients (,76 men,", 66 women ; mean age 59 +/- 5.9 years ) treated with different antihypertensive drugs : 71 patients were randomized to aspirin and 71 served as controls .","['Fifteen', 'Italian', 'hypertension', 'units', 'studied', '142', 'hypertensive', 'patients', '(', '76', 'men', ',', '66', 'women', ';', 'mean', 'age', '59', '+/-', '5.9', 'years', ')', 'treated', 'with', 'different', 'antihypertensive', 'drugs', ':', '71', 'patients', 'were', 'randomized', 'to', 'aspirin', 'and', '71', 'served', 'as', 'controls', '.']","(9, 11)","(70, 76)",-1,hl_p,10912743,Abstract,4,test,gold,2239.0
385,"Fifteen Italian hypertension units studied 142 hypertensive patients ( 76 men ,",66 women,; mean age 59 +/- 5.9 years ) treated with different antihypertensive drugs : 71 patients were randomized to aspirin and 71 served as controls .,"['Fifteen', 'Italian', 'hypertension', 'units', 'studied', '142', 'hypertensive', 'patients', '(', '76', 'men', ',', '66', 'women', ';', 'mean', 'age', '59', '+/-', '5.9', 'years', ')', 'treated', 'with', 'different', 'antihypertensive', 'drugs', ':', '71', 'patients', 'were', 'randomized', 'to', 'aspirin', 'and', '71', 'served', 'as', 'controls', '.']","(12, 14)","(79, 87)",-1,hl_p,10912743,Abstract,4,test,gold,2244.0
386,"Fifteen Italian hypertension units studied 142 hypertensive patients ( 76 men , 66 women ;",mean age 59 +/- 5.9 years,) treated with different antihypertensive drugs : 71 patients were randomized to aspirin and 71 served as controls .,"['Fifteen', 'Italian', 'hypertension', 'units', 'studied', '142', 'hypertensive', 'patients', '(', '76', 'men', ',', '66', 'women', ';', 'mean', 'age', '59', '+/-', '5.9', 'years', ')', 'treated', 'with', 'different', 'antihypertensive', 'drugs', ':', '71', 'patients', 'were', 'randomized', 'to', 'aspirin', 'and', '71', 'served', 'as', 'controls', '.']","(15, 21)","(90, 115)",-1,hl_p,10912743,Abstract,4,test,gold,2015.0
387,"Fifteen Italian hypertension units studied 142 hypertensive patients ( 76 men , 66 women ; mean age 59 +/- 5.9 years )",treated with different antihypertensive drugs,: 71 patients were randomized to aspirin and 71 served as controls .,"['Fifteen', 'Italian', 'hypertension', 'units', 'studied', '142', 'hypertensive', 'patients', '(', '76', 'men', ',', '66', 'women', ';', 'mean', 'age', '59', '+/-', '5.9', 'years', ')', 'treated', 'with', 'different', 'antihypertensive', 'drugs', ':', '71', 'patients', 'were', 'randomized', 'to', 'aspirin', 'and', '71', 'served', 'as', 'controls', '.']","(22, 27)","(118, 163)",-1,hl_p,10912743,Abstract,4,test,gold,6911.0
388,"Fifteen Italian hypertension units studied 142 hypertensive patients ( 76 men , 66 women ; mean age 59 +/- 5.9 years ) treated with different antihypertensive drugs : 71 patients were randomized to",aspirin,and 71 served as controls .,"['Fifteen', 'Italian', 'hypertension', 'units', 'studied', '142', 'hypertensive', 'patients', '(', '76', 'men', ',', '66', 'women', ';', 'mean', 'age', '59', '+/-', '5.9', 'years', ')', 'treated', 'with', 'different', 'antihypertensive', 'drugs', ':', '71', 'patients', 'were', 'randomized', 'to', 'aspirin', 'and', '71', 'served', 'as', 'controls', '.']","(33, 34)","(197, 204)",-1,hl_i,10912743,Abstract,4,test,gold,5334.0
389,"All patients underwent a clinic BP evaluation with an automatic sphygmomanometer and a 24-h ambulatory BP monitoring , at baseline and after 3 months of",aspirin,treatment .,"['All', 'patients', 'underwent', 'a', 'clinic', 'BP', 'evaluation', 'with', 'an', 'automatic', 'sphygmomanometer', 'and', 'a', '24-h', 'ambulatory', 'BP', 'monitoring', ',', 'at', 'baseline', 'and', 'after', '3', 'months', 'of', 'aspirin', 'treatment', '.']","(25, 26)","(152, 159)",-1,ss_i,10912743,Abstract,5,test,gold,5333.0
390,All patients underwent a,clinic BP,"evaluation with an automatic sphygmomanometer and a 24-h ambulatory BP monitoring , at baseline and after 3 months of aspirin treatment .","['All', 'patients', 'underwent', 'a', 'clinic', 'BP', 'evaluation', 'with', 'an', 'automatic', 'sphygmomanometer', 'and', 'a', '24-h', 'ambulatory', 'BP', 'monitoring', ',', 'at', 'baseline', 'and', 'after', '3', 'months', 'of', 'aspirin', 'treatment', '.']","(4, 6)","(24, 33)",-1,ss_o,10912743,Abstract,5,test,gold,1476.0
391,All patients underwent a clinic BP evaluation with an automatic sphygmomanometer and a,24-h ambulatory BP monitoring,", at baseline and after 3 months of aspirin treatment .","['All', 'patients', 'underwent', 'a', 'clinic', 'BP', 'evaluation', 'with', 'an', 'automatic', 'sphygmomanometer', 'and', 'a', '24-h', 'ambulatory', 'BP', 'monitoring', ',', 'at', 'baseline', 'and', 'after', '3', 'months', 'of', 'aspirin', 'treatment', '.']","(13, 17)","(86, 115)",-1,ss_o,10912743,Abstract,5,test,gold,1472.0
392,"All patients underwent a clinic BP evaluation with an automatic sphygmomanometer and a 24-h ambulatory BP monitoring , at baseline and after 3 months of",aspirin,treatment .,"['All', 'patients', 'underwent', 'a', 'clinic', 'BP', 'evaluation', 'with', 'an', 'automatic', 'sphygmomanometer', 'and', 'a', '24-h', 'ambulatory', 'BP', 'monitoring', ',', 'at', 'baseline', 'and', 'after', '3', 'months', 'of', 'aspirin', 'treatment', '.']","(25, 26)","(152, 159)",-1,hl_i,10912743,Abstract,5,test,gold,5332.0
393,All patients underwent a,clinic BP,"evaluation with an automatic sphygmomanometer and a 24-h ambulatory BP monitoring , at baseline and after 3 months of aspirin treatment .","['All', 'patients', 'underwent', 'a', 'clinic', 'BP', 'evaluation', 'with', 'an', 'automatic', 'sphygmomanometer', 'and', 'a', '24-h', 'ambulatory', 'BP', 'monitoring', ',', 'at', 'baseline', 'and', 'after', '3', 'months', 'of', 'aspirin', 'treatment', '.']","(4, 6)","(24, 33)",-1,hl_o,10912743,Abstract,5,test,gold,1477.0
394,All patients underwent a clinic BP evaluation with an automatic sphygmomanometer and a,24-h ambulatory BP monitoring,", at baseline and after 3 months of aspirin treatment .","['All', 'patients', 'underwent', 'a', 'clinic', 'BP', 'evaluation', 'with', 'an', 'automatic', 'sphygmomanometer', 'and', 'a', '24-h', 'ambulatory', 'BP', 'monitoring', ',', 'at', 'baseline', 'and', 'after', '3', 'months', 'of', 'aspirin', 'treatment', '.']","(13, 17)","(86, 115)",-1,hl_o,10912743,Abstract,5,test,gold,1473.0
395,At the end of the study the changes in,clinic SBP and DBP,were not statistically different in treated and untreated subjects .,"['At', 'the', 'end', 'of', 'the', 'study', 'the', 'changes', 'in', 'clinic', 'SBP', 'and', 'DBP', 'were', 'not', 'statistically', 'different', 'in', 'treated', 'and', 'untreated', 'subjects', '.']","(9, 13)","(38, 56)",-1,ss_o,10912743,Abstract,6,test,gold,1682.0
396,At the end of the study the changes in,clinic SBP and DBP,were not statistically different in treated and untreated subjects .,"['At', 'the', 'end', 'of', 'the', 'study', 'the', 'changes', 'in', 'clinic', 'SBP', 'and', 'DBP', 'were', 'not', 'statistically', 'different', 'in', 'treated', 'and', 'untreated', 'subjects', '.']","(9, 13)","(38, 56)",-1,hl_o,10912743,Abstract,6,test,gold,1683.0
397,Ambulatory SBP and DBP after 3 months of,aspirin,treatment were similar to baseline : deltaSBP -0.5 mmHg ( 95 % confidence intervals [ CI ] from -1.9 to +2.9 mm Hg ) and deltaDBP -1.1 mm Hg ( 95 % CI from -2.5 to +0.3 mm Hg ) .,"['Ambulatory', 'SBP', 'and', 'DBP', 'after', '3', 'months', 'of', 'aspirin', 'treatment', 'were', 'similar', 'to', 'baseline', ':', 'deltaSBP', '-0.5', 'mmHg', '(', '95', '%', 'confidence', 'intervals', '[', 'CI', ']', 'from', '-1.9', 'to', '+2.9', 'mm', 'Hg', ')', 'and', 'deltaDBP', '-1.1', 'mm', 'Hg', '(', '95', '%', 'CI', 'from', '-2.5', 'to', '+0.3', 'mm', 'Hg', ')', '.']","(8, 9)","(40, 47)",-1,ss_i,10912743,Abstract,7,test,gold,5331.0
398,,Ambulatory SBP and DBP,after 3 months of aspirin treatment were similar to baseline : deltaSBP -0.5 mmHg ( 95 % confidence intervals [ CI ] from -1.9 to +2.9 mm Hg ) and deltaDBP -1.1 mm Hg ( 95 % CI from -2.5 to +0.3 mm Hg ) .,"['Ambulatory', 'SBP', 'and', 'DBP', 'after', '3', 'months', 'of', 'aspirin', 'treatment', 'were', 'similar', 'to', 'baseline', ':', 'deltaSBP', '-0.5', 'mmHg', '(', '95', '%', 'confidence', 'intervals', '[', 'CI', ']', 'from', '-1.9', 'to', '+2.9', 'mm', 'Hg', ')', 'and', 'deltaDBP', '-1.1', 'mm', 'Hg', '(', '95', '%', 'CI', 'from', '-2.5', 'to', '+0.3', 'mm', 'Hg', ')', '.']","(0, 4)","(0, 22)",-1,ss_o,10912743,Abstract,7,test,gold,1684.0
399,Ambulatory SBP and DBP after 3 months of,aspirin,treatment were similar to baseline : deltaSBP -0.5 mmHg ( 95 % confidence intervals [ CI ] from -1.9 to +2.9 mm Hg ) and deltaDBP -1.1 mm Hg ( 95 % CI from -2.5 to +0.3 mm Hg ) .,"['Ambulatory', 'SBP', 'and', 'DBP', 'after', '3', 'months', 'of', 'aspirin', 'treatment', 'were', 'similar', 'to', 'baseline', ':', 'deltaSBP', '-0.5', 'mmHg', '(', '95', '%', 'confidence', 'intervals', '[', 'CI', ']', 'from', '-1.9', 'to', '+2.9', 'mm', 'Hg', ')', 'and', 'deltaDBP', '-1.1', 'mm', 'Hg', '(', '95', '%', 'CI', 'from', '-2.5', 'to', '+0.3', 'mm', 'Hg', ')', '.']","(8, 9)","(40, 47)",-1,hl_i,10912743,Abstract,7,test,gold,5330.0
400,,Ambulatory SBP and DBP,after 3 months of aspirin treatment were similar to baseline : deltaSBP -0.5 mmHg ( 95 % confidence intervals [ CI ] from -1.9 to +2.9 mm Hg ) and deltaDBP -1.1 mm Hg ( 95 % CI from -2.5 to +0.3 mm Hg ) .,"['Ambulatory', 'SBP', 'and', 'DBP', 'after', '3', 'months', 'of', 'aspirin', 'treatment', 'were', 'similar', 'to', 'baseline', ':', 'deltaSBP', '-0.5', 'mmHg', '(', '95', '%', 'confidence', 'intervals', '[', 'CI', ']', 'from', '-1.9', 'to', '+2.9', 'mm', 'Hg', ')', 'and', 'deltaDBP', '-1.1', 'mm', 'Hg', '(', '95', '%', 'CI', 'from', '-2.5', 'to', '+0.3', 'mm', 'Hg', ')', '.']","(0, 4)","(0, 22)",-1,hl_o,10912743,Abstract,7,test,gold,1685.0
401,The pattern was similar in the control group .,,,"['The', 'pattern', 'was', 'similar', 'in', 'the', 'control', 'group', '.']",,,,,10912743,Abstract,8,test,gold,
402,No interaction was found between,aspirin,and the most used antihypertensive drug classes ( angiotensin converting enzyme inhibitors and calcium antagonists ) .,"['No', 'interaction', 'was', 'found', 'between', 'aspirin', 'and', 'the', 'most', 'used', 'antihypertensive', 'drug', 'classes', '(', 'angiotensin', 'converting', 'enzyme', 'inhibitors', 'and', 'calcium', 'antagonists', ')', '.']","(5, 6)","(32, 39)",-1,ss_i,10912743,Abstract,9,test,gold,5329.0
403,No interaction was found between,aspirin,and the most used antihypertensive drug classes ( angiotensin converting enzyme inhibitors and calcium antagonists ) .,"['No', 'interaction', 'was', 'found', 'between', 'aspirin', 'and', 'the', 'most', 'used', 'antihypertensive', 'drug', 'classes', '(', 'angiotensin', 'converting', 'enzyme', 'inhibitors', 'and', 'calcium', 'antagonists', ')', '.']","(5, 6)","(32, 39)",-1,hl_i,10912743,Abstract,9,test,gold,5328.0
404,Despite the relatively small sample size our results seem to exclude any significant influence of low-dose aspirin on BP control in,hypertensives under treatment .,,"['Despite', 'the', 'relatively', 'small', 'sample', 'size', 'our', 'results', 'seem', 'to', 'exclude', 'any', 'significant', 'influence', 'of', 'low-dose', 'aspirin', 'on', 'BP', 'control', 'in', 'hypertensives', 'under', 'treatment', '.']","(21, 25)","(131, 162)",-1,ss_p,10912743,Abstract,10,test,gold,3982.0
405,Despite the relatively small sample size our results seem to exclude any significant influence of low-dose,aspirin,on BP control in hypertensives under treatment .,"['Despite', 'the', 'relatively', 'small', 'sample', 'size', 'our', 'results', 'seem', 'to', 'exclude', 'any', 'significant', 'influence', 'of', 'low-dose', 'aspirin', 'on', 'BP', 'control', 'in', 'hypertensives', 'under', 'treatment', '.']","(16, 17)","(106, 113)",-1,ss_i,10912743,Abstract,10,test,gold,5327.0
406,Despite the relatively small sample size our results seem to exclude any significant influence of low-dose aspirin on,BP,control in hypertensives under treatment .,"['Despite', 'the', 'relatively', 'small', 'sample', 'size', 'our', 'results', 'seem', 'to', 'exclude', 'any', 'significant', 'influence', 'of', 'low-dose', 'aspirin', 'on', 'BP', 'control', 'in', 'hypertensives', 'under', 'treatment', '.']","(18, 19)","(117, 119)",-1,ss_o,10912743,Abstract,10,test,gold,1474.0
407,Despite the relatively small sample size our results seem to exclude any significant influence of low-dose,aspirin,on BP control in hypertensives under treatment .,"['Despite', 'the', 'relatively', 'small', 'sample', 'size', 'our', 'results', 'seem', 'to', 'exclude', 'any', 'significant', 'influence', 'of', 'low-dose', 'aspirin', 'on', 'BP', 'control', 'in', 'hypertensives', 'under', 'treatment', '.']","(16, 17)","(106, 113)",-1,hl_i,10912743,Abstract,10,test,gold,5326.0
408,Despite the relatively small sample size our results seem to exclude any significant influence of low-dose aspirin on,BP,control in hypertensives under treatment .,"['Despite', 'the', 'relatively', 'small', 'sample', 'size', 'our', 'results', 'seem', 'to', 'exclude', 'any', 'significant', 'influence', 'of', 'low-dose', 'aspirin', 'on', 'BP', 'control', 'in', 'hypertensives', 'under', 'treatment', '.']","(18, 19)","(117, 119)",-1,hl_o,10912743,Abstract,10,test,gold,1475.0
409,Randomized trial of intensive early intervention for,children with pervasive developmental disorder .,,"['Randomized', 'trial', 'of', 'intensive', 'early', 'intervention', 'for', 'children', 'with', 'pervasive', 'developmental', 'disorder', '.']","(7, 13)","(52, 100)",-1,ss_p,10934569,Title,0,test,gold,6180.0
410,Randomized trial of,intensive early intervention,for children with pervasive developmental disorder .,"['Randomized', 'trial', 'of', 'intensive', 'early', 'intervention', 'for', 'children', 'with', 'pervasive', 'developmental', 'disorder', '.']","(3, 6)","(19, 47)",-1,ss_i,10934569,Title,0,test,gold,4002.0
411,Randomized trial of intensive early intervention for,children,with pervasive developmental disorder .,"['Randomized', 'trial', 'of', 'intensive', 'early', 'intervention', 'for', 'children', 'with', 'pervasive', 'developmental', 'disorder', '.']","(7, 8)","(52, 60)",-1,hl_p,10934569,Title,0,test,gold,2148.0
412,Randomized trial of intensive early intervention for children with,pervasive developmental disorder,.,"['Randomized', 'trial', 'of', 'intensive', 'early', 'intervention', 'for', 'children', 'with', 'pervasive', 'developmental', 'disorder', '.']","(9, 12)","(66, 98)",-1,hl_p,10934569,Title,0,test,gold,6178.0
413,Randomized trial of,intensive early intervention,for children with pervasive developmental disorder .,"['Randomized', 'trial', 'of', 'intensive', 'early', 'intervention', 'for', 'children', 'with', 'pervasive', 'developmental', 'disorder', '.']","(3, 6)","(19, 47)",-1,hl_i,10934569,Title,0,test,gold,4003.0
414,,Young children with pervasive developmental disorder,were randomly assigned to intensive treatment or parent training .,"['Young', 'children', 'with', 'pervasive', 'developmental', 'disorder', 'were', 'randomly', 'assigned', 'to', 'intensive', 'treatment', 'or', 'parent', 'training', '.']","(0, 6)","(0, 52)",-1,ss_p,10934569,Abstract,0,test,gold,6181.0
415,Young children with pervasive developmental disorder were randomly assigned to,intensive treatment,or parent training .,"['Young', 'children', 'with', 'pervasive', 'developmental', 'disorder', 'were', 'randomly', 'assigned', 'to', 'intensive', 'treatment', 'or', 'parent', 'training', '.']","(10, 12)","(78, 97)",-1,ss_i,10934569,Abstract,0,test,gold,4000.0
416,Young children with pervasive developmental disorder were randomly assigned to intensive treatment or,parent training .,,"['Young', 'children', 'with', 'pervasive', 'developmental', 'disorder', 'were', 'randomly', 'assigned', 'to', 'intensive', 'treatment', 'or', 'parent', 'training', '.']","(13, 16)","(101, 118)",-1,ss_i,10934569,Abstract,0,test,gold,2842.0
417,,Young children,with pervasive developmental disorder were randomly assigned to intensive treatment or parent training .,"['Young', 'children', 'with', 'pervasive', 'developmental', 'disorder', 'were', 'randomly', 'assigned', 'to', 'intensive', 'treatment', 'or', 'parent', 'training', '.']","(0, 2)","(0, 14)",-1,hl_p,10934569,Abstract,0,test,gold,2157.0
418,Young children with,pervasive developmental disorder,were randomly assigned to intensive treatment or parent training .,"['Young', 'children', 'with', 'pervasive', 'developmental', 'disorder', 'were', 'randomly', 'assigned', 'to', 'intensive', 'treatment', 'or', 'parent', 'training', '.']","(3, 6)","(19, 51)",-1,hl_p,10934569,Abstract,0,test,gold,6179.0
419,Young children with pervasive developmental disorder were randomly assigned to,intensive treatment,or parent training .,"['Young', 'children', 'with', 'pervasive', 'developmental', 'disorder', 'were', 'randomly', 'assigned', 'to', 'intensive', 'treatment', 'or', 'parent', 'training', '.']","(10, 12)","(78, 97)",-1,hl_i,10934569,Abstract,0,test,gold,4001.0
420,Young children with pervasive developmental disorder were randomly assigned to intensive treatment or,parent training .,,"['Young', 'children', 'with', 'pervasive', 'developmental', 'disorder', 'were', 'randomly', 'assigned', 'to', 'intensive', 'treatment', 'or', 'parent', 'training', '.']","(13, 16)","(101, 118)",-1,hl_i,10934569,Abstract,0,test,gold,2843.0
421,The intensive treatment group,"( 7 with autism , 8 with pervasive developmental disorder not otherwise specified -- NOS )","averaged 24.52 hours per week of individual treatment for one year , gradually reducing hours over the next 1 to 2 years .","['The', 'intensive', 'treatment', 'group', '(', '7', 'with', 'autism', ',', '8', 'with', 'pervasive', 'developmental', 'disorder', 'not', 'otherwise', 'specified', '--', 'NOS', ')', 'averaged', '24.52', 'hours', 'per', 'week', 'of', 'individual', 'treatment', 'for', 'one', 'year', ',', 'gradually', 'reducing', 'hours', 'over', 'the', 'next', '1', 'to', '2', 'years', '.']","(4, 20)","(29, 119)",-1,ss_p,10934569,Abstract,1,test,gold,6175.0
422,The,intensive treatment,"group ( 7 with autism , 8 with pervasive developmental disorder not otherwise specified -- NOS ) averaged 24.52 hours per week of individual treatment for one year , gradually reducing hours over the next 1 to 2 years .","['The', 'intensive', 'treatment', 'group', '(', '7', 'with', 'autism', ',', '8', 'with', 'pervasive', 'developmental', 'disorder', 'not', 'otherwise', 'specified', '--', 'NOS', ')', 'averaged', '24.52', 'hours', 'per', 'week', 'of', 'individual', 'treatment', 'for', 'one', 'year', ',', 'gradually', 'reducing', 'hours', 'over', 'the', 'next', '1', 'to', '2', 'years', '.']","(1, 3)","(3, 22)",-1,ss_i,10934569,Abstract,1,test,gold,3999.0
423,The intensive treatment group (,7,"with autism , 8 with pervasive developmental disorder not otherwise specified -- NOS ) averaged 24.52 hours per week of individual treatment for one year , gradually reducing hours over the next 1 to 2 years .","['The', 'intensive', 'treatment', 'group', '(', '7', 'with', 'autism', ',', '8', 'with', 'pervasive', 'developmental', 'disorder', 'not', 'otherwise', 'specified', '--', 'NOS', ')', 'averaged', '24.52', 'hours', 'per', 'week', 'of', 'individual', 'treatment', 'for', 'one', 'year', ',', 'gradually', 'reducing', 'hours', 'over', 'the', 'next', '1', 'to', '2', 'years', '.']","(5, 6)","(31, 32)",-1,hl_p,10934569,Abstract,1,test,gold,1169.0
424,The intensive treatment group ( 7 with,autism,", 8 with pervasive developmental disorder not otherwise specified -- NOS ) averaged 24.52 hours per week of individual treatment for one year , gradually reducing hours over the next 1 to 2 years .","['The', 'intensive', 'treatment', 'group', '(', '7', 'with', 'autism', ',', '8', 'with', 'pervasive', 'developmental', 'disorder', 'not', 'otherwise', 'specified', '--', 'NOS', ')', 'averaged', '24.52', 'hours', 'per', 'week', 'of', 'individual', 'treatment', 'for', 'one', 'year', ',', 'gradually', 'reducing', 'hours', 'over', 'the', 'next', '1', 'to', '2', 'years', '.']","(7, 8)","(38, 44)",-1,hl_p,10934569,Abstract,1,test,gold,6151.0
425,"The intensive treatment group ( 7 with autism ,",8,"with pervasive developmental disorder not otherwise specified -- NOS ) averaged 24.52 hours per week of individual treatment for one year , gradually reducing hours over the next 1 to 2 years .","['The', 'intensive', 'treatment', 'group', '(', '7', 'with', 'autism', ',', '8', 'with', 'pervasive', 'developmental', 'disorder', 'not', 'otherwise', 'specified', '--', 'NOS', ')', 'averaged', '24.52', 'hours', 'per', 'week', 'of', 'individual', 'treatment', 'for', 'one', 'year', ',', 'gradually', 'reducing', 'hours', 'over', 'the', 'next', '1', 'to', '2', 'years', '.']","(9, 10)","(47, 48)",-1,hl_p,10934569,Abstract,1,test,gold,1167.0
426,"The intensive treatment group ( 7 with autism , 8 with",pervasive developmental disorder not otherwise specified -- NOS,") averaged 24.52 hours per week of individual treatment for one year , gradually reducing hours over the next 1 to 2 years .","['The', 'intensive', 'treatment', 'group', '(', '7', 'with', 'autism', ',', '8', 'with', 'pervasive', 'developmental', 'disorder', 'not', 'otherwise', 'specified', '--', 'NOS', ')', 'averaged', '24.52', 'hours', 'per', 'week', 'of', 'individual', 'treatment', 'for', 'one', 'year', ',', 'gradually', 'reducing', 'hours', 'over', 'the', 'next', '1', 'to', '2', 'years', '.']","(11, 19)","(54, 117)",-1,hl_p,10934569,Abstract,1,test,gold,6184.0
427,The,intensive treatment,"group ( 7 with autism , 8 with pervasive developmental disorder not otherwise specified -- NOS ) averaged 24.52 hours per week of individual treatment for one year , gradually reducing hours over the next 1 to 2 years .","['The', 'intensive', 'treatment', 'group', '(', '7', 'with', 'autism', ',', '8', 'with', 'pervasive', 'developmental', 'disorder', 'not', 'otherwise', 'specified', '--', 'NOS', ')', 'averaged', '24.52', 'hours', 'per', 'week', 'of', 'individual', 'treatment', 'for', 'one', 'year', ',', 'gradually', 'reducing', 'hours', 'over', 'the', 'next', '1', 'to', '2', 'years', '.']","(1, 3)","(3, 22)",-1,hl_i,10934569,Abstract,1,test,gold,3998.0
428,The parent training group,"( 7 with autism , 6 with pervasive developmental disorder NOS )",received 3 to 9 months of parent training .,"['The', 'parent', 'training', 'group', '(', '7', 'with', 'autism', ',', '6', 'with', 'pervasive', 'developmental', 'disorder', 'NOS', ')', 'received', '3', 'to', '9', 'months', 'of', 'parent', 'training', '.']","(4, 16)","(25, 88)",-1,ss_p,10934569,Abstract,2,test,gold,6176.0
429,The,parent training,"group ( 7 with autism , 6 with pervasive developmental disorder NOS ) received 3 to 9 months of parent training .","['The', 'parent', 'training', 'group', '(', '7', 'with', 'autism', ',', '6', 'with', 'pervasive', 'developmental', 'disorder', 'NOS', ')', 'received', '3', 'to', '9', 'months', 'of', 'parent', 'training', '.']","(1, 3)","(3, 18)",-1,ss_i,10934569,Abstract,2,test,gold,2841.0
430,"The parent training group ( 7 with autism , 6 with pervasive developmental disorder NOS ) received 3 to 9 months of",parent training .,,"['The', 'parent', 'training', 'group', '(', '7', 'with', 'autism', ',', '6', 'with', 'pervasive', 'developmental', 'disorder', 'NOS', ')', 'received', '3', 'to', '9', 'months', 'of', 'parent', 'training', '.']","(22, 25)","(115, 132)",-1,ss_i,10934569,Abstract,2,test,gold,2840.0
431,The parent training group (,7 with autism,", 6 with pervasive developmental disorder NOS ) received 3 to 9 months of parent training .","['The', 'parent', 'training', 'group', '(', '7', 'with', 'autism', ',', '6', 'with', 'pervasive', 'developmental', 'disorder', 'NOS', ')', 'received', '3', 'to', '9', 'months', 'of', 'parent', 'training', '.']","(5, 8)","(27, 40)",-1,hl_p,10934569,Abstract,2,test,gold,6144.0
432,"The parent training group ( 7 with autism ,",6 with pervasive developmental disorder NOS,) received 3 to 9 months of parent training .,"['The', 'parent', 'training', 'group', '(', '7', 'with', 'autism', ',', '6', 'with', 'pervasive', 'developmental', 'disorder', 'NOS', ')', 'received', '3', 'to', '9', 'months', 'of', 'parent', 'training', '.']","(9, 15)","(43, 86)",-1,hl_p,10934569,Abstract,2,test,gold,6185.0
433,The,parent training,"group ( 7 with autism , 6 with pervasive developmental disorder NOS ) received 3 to 9 months of parent training .","['The', 'parent', 'training', 'group', '(', '7', 'with', 'autism', ',', '6', 'with', 'pervasive', 'developmental', 'disorder', 'NOS', ')', 'received', '3', 'to', '9', 'months', 'of', 'parent', 'training', '.']","(1, 3)","(3, 18)",-1,hl_i,10934569,Abstract,2,test,gold,2839.0
434,"The parent training group ( 7 with autism , 6 with pervasive developmental disorder NOS ) received 3 to 9 months of",parent training .,,"['The', 'parent', 'training', 'group', '(', '7', 'with', 'autism', ',', '6', 'with', 'pervasive', 'developmental', 'disorder', 'NOS', ')', 'received', '3', 'to', '9', 'months', 'of', 'parent', 'training', '.']","(22, 25)","(115, 132)",-1,hl_i,10934569,Abstract,2,test,gold,2838.0
435,"The groups appeared similar at intake on all measures ; however , at follow-up the",intensive treatment,"group outperformed the parent training group on measures of intelligence , visual-spatial skills , language , and academics , though not adaptive functioning or behavior problems .","['The', 'groups', 'appeared', 'similar', 'at', 'intake', 'on', 'all', 'measures', ';', 'however', ',', 'at', 'follow-up', 'the', 'intensive', 'treatment', 'group', 'outperformed', 'the', 'parent', 'training', 'group', 'on', 'measures', 'of', 'intelligence', ',', 'visual-spatial', 'skills', ',', 'language', ',', 'and', 'academics', ',', 'though', 'not', 'adaptive', 'functioning', 'or', 'behavior', 'problems', '.']","(15, 17)","(82, 101)",-1,ss_i,10934569,Abstract,3,test,gold,3997.0
436,"The groups appeared similar at intake on all measures ; however , at follow-up the intensive treatment group outperformed the",parent training,"group on measures of intelligence , visual-spatial skills , language , and academics , though not adaptive functioning or behavior problems .","['The', 'groups', 'appeared', 'similar', 'at', 'intake', 'on', 'all', 'measures', ';', 'however', ',', 'at', 'follow-up', 'the', 'intensive', 'treatment', 'group', 'outperformed', 'the', 'parent', 'training', 'group', 'on', 'measures', 'of', 'intelligence', ',', 'visual-spatial', 'skills', ',', 'language', ',', 'and', 'academics', ',', 'though', 'not', 'adaptive', 'functioning', 'or', 'behavior', 'problems', '.']","(20, 22)","(125, 140)",-1,ss_i,10934569,Abstract,3,test,gold,2837.0
437,"The groups appeared similar at intake on all measures ; however , at follow-up the intensive treatment group outperformed the parent training group on measures of","intelligence , visual-spatial skills , language , and academics",", though not adaptive functioning or behavior problems .","['The', 'groups', 'appeared', 'similar', 'at', 'intake', 'on', 'all', 'measures', ';', 'however', ',', 'at', 'follow-up', 'the', 'intensive', 'treatment', 'group', 'outperformed', 'the', 'parent', 'training', 'group', 'on', 'measures', 'of', 'intelligence', ',', 'visual-spatial', 'skills', ',', 'language', ',', 'and', 'academics', ',', 'though', 'not', 'adaptive', 'functioning', 'or', 'behavior', 'problems', '.']","(26, 35)","(162, 225)",-1,ss_o,10934569,Abstract,3,test,gold,2850.0
438,"The groups appeared similar at intake on all measures ; however , at follow-up the intensive treatment group outperformed the parent training group on measures of intelligence , visual-spatial skills , language , and academics , though not",adaptive functioning,or behavior problems .,"['The', 'groups', 'appeared', 'similar', 'at', 'intake', 'on', 'all', 'measures', ';', 'however', ',', 'at', 'follow-up', 'the', 'intensive', 'treatment', 'group', 'outperformed', 'the', 'parent', 'training', 'group', 'on', 'measures', 'of', 'intelligence', ',', 'visual-spatial', 'skills', ',', 'language', ',', 'and', 'academics', ',', 'though', 'not', 'adaptive', 'functioning', 'or', 'behavior', 'problems', '.']","(38, 40)","(239, 259)",-1,ss_o,10934569,Abstract,3,test,gold,2942.0
439,"The groups appeared similar at intake on all measures ; however , at follow-up the intensive treatment group outperformed the parent training group on measures of intelligence , visual-spatial skills , language , and academics , though not adaptive functioning or",behavior problems .,,"['The', 'groups', 'appeared', 'similar', 'at', 'intake', 'on', 'all', 'measures', ';', 'however', ',', 'at', 'follow-up', 'the', 'intensive', 'treatment', 'group', 'outperformed', 'the', 'parent', 'training', 'group', 'on', 'measures', 'of', 'intelligence', ',', 'visual-spatial', 'skills', ',', 'language', ',', 'and', 'academics', ',', 'though', 'not', 'adaptive', 'functioning', 'or', 'behavior', 'problems', '.']","(41, 44)","(263, 282)",-1,ss_o,10934569,Abstract,3,test,gold,2598.0
440,"The groups appeared similar at intake on all measures ; however , at follow-up the",intensive treatment,"group outperformed the parent training group on measures of intelligence , visual-spatial skills , language , and academics , though not adaptive functioning or behavior problems .","['The', 'groups', 'appeared', 'similar', 'at', 'intake', 'on', 'all', 'measures', ';', 'however', ',', 'at', 'follow-up', 'the', 'intensive', 'treatment', 'group', 'outperformed', 'the', 'parent', 'training', 'group', 'on', 'measures', 'of', 'intelligence', ',', 'visual-spatial', 'skills', ',', 'language', ',', 'and', 'academics', ',', 'though', 'not', 'adaptive', 'functioning', 'or', 'behavior', 'problems', '.']","(15, 17)","(82, 101)",-1,hl_i,10934569,Abstract,3,test,gold,3996.0
441,"The groups appeared similar at intake on all measures ; however , at follow-up the intensive treatment group outperformed the",parent training,"group on measures of intelligence , visual-spatial skills , language , and academics , though not adaptive functioning or behavior problems .","['The', 'groups', 'appeared', 'similar', 'at', 'intake', 'on', 'all', 'measures', ';', 'however', ',', 'at', 'follow-up', 'the', 'intensive', 'treatment', 'group', 'outperformed', 'the', 'parent', 'training', 'group', 'on', 'measures', 'of', 'intelligence', ',', 'visual-spatial', 'skills', ',', 'language', ',', 'and', 'academics', ',', 'though', 'not', 'adaptive', 'functioning', 'or', 'behavior', 'problems', '.']","(20, 22)","(125, 140)",-1,hl_i,10934569,Abstract,3,test,gold,2836.0
442,"The groups appeared similar at intake on all measures ; however , at follow-up the intensive treatment group outperformed the parent training group on measures of",intelligence,", visual-spatial skills , language , and academics , though not adaptive functioning or behavior problems .","['The', 'groups', 'appeared', 'similar', 'at', 'intake', 'on', 'all', 'measures', ';', 'however', ',', 'at', 'follow-up', 'the', 'intensive', 'treatment', 'group', 'outperformed', 'the', 'parent', 'training', 'group', 'on', 'measures', 'of', 'intelligence', ',', 'visual-spatial', 'skills', ',', 'language', ',', 'and', 'academics', ',', 'though', 'not', 'adaptive', 'functioning', 'or', 'behavior', 'problems', '.']","(26, 27)","(162, 174)",-1,hl_o,10934569,Abstract,3,test,gold,1194.0
443,"The groups appeared similar at intake on all measures ; however , at follow-up the intensive treatment group outperformed the parent training group on measures of intelligence ,",visual-spatial skills,", language , and academics , though not adaptive functioning or behavior problems .","['The', 'groups', 'appeared', 'similar', 'at', 'intake', 'on', 'all', 'measures', ';', 'however', ',', 'at', 'follow-up', 'the', 'intensive', 'treatment', 'group', 'outperformed', 'the', 'parent', 'training', 'group', 'on', 'measures', 'of', 'intelligence', ',', 'visual-spatial', 'skills', ',', 'language', ',', 'and', 'academics', ',', 'though', 'not', 'adaptive', 'functioning', 'or', 'behavior', 'problems', '.']","(28, 30)","(177, 198)",-1,hl_o,10934569,Abstract,3,test,gold,2854.0
444,"The groups appeared similar at intake on all measures ; however , at follow-up the intensive treatment group outperformed the parent training group on measures of intelligence , visual-spatial skills ,",language,", and academics , though not adaptive functioning or behavior problems .","['The', 'groups', 'appeared', 'similar', 'at', 'intake', 'on', 'all', 'measures', ';', 'however', ',', 'at', 'follow-up', 'the', 'intensive', 'treatment', 'group', 'outperformed', 'the', 'parent', 'training', 'group', 'on', 'measures', 'of', 'intelligence', ',', 'visual-spatial', 'skills', ',', 'language', ',', 'and', 'academics', ',', 'though', 'not', 'adaptive', 'functioning', 'or', 'behavior', 'problems', '.']","(31, 32)","(201, 209)",-1,hl_o,10934569,Abstract,3,test,gold,2615.0
445,"The groups appeared similar at intake on all measures ; however , at follow-up the intensive treatment group outperformed the parent training group on measures of intelligence , visual-spatial skills , language , and",academics,", though not adaptive functioning or behavior problems .","['The', 'groups', 'appeared', 'similar', 'at', 'intake', 'on', 'all', 'measures', ';', 'however', ',', 'at', 'follow-up', 'the', 'intensive', 'treatment', 'group', 'outperformed', 'the', 'parent', 'training', 'group', 'on', 'measures', 'of', 'intelligence', ',', 'visual-spatial', 'skills', ',', 'language', ',', 'and', 'academics', ',', 'though', 'not', 'adaptive', 'functioning', 'or', 'behavior', 'problems', '.']","(34, 35)","(216, 225)",-1,hl_o,10934569,Abstract,3,test,gold,2188.0
446,"The groups appeared similar at intake on all measures ; however , at follow-up the intensive treatment group outperformed the parent training group on measures of intelligence , visual-spatial skills , language , and academics , though not",adaptive functioning,or behavior problems .,"['The', 'groups', 'appeared', 'similar', 'at', 'intake', 'on', 'all', 'measures', ';', 'however', ',', 'at', 'follow-up', 'the', 'intensive', 'treatment', 'group', 'outperformed', 'the', 'parent', 'training', 'group', 'on', 'measures', 'of', 'intelligence', ',', 'visual-spatial', 'skills', ',', 'language', ',', 'and', 'academics', ',', 'though', 'not', 'adaptive', 'functioning', 'or', 'behavior', 'problems', '.']","(38, 40)","(239, 259)",-1,hl_o,10934569,Abstract,3,test,gold,2943.0
447,"The groups appeared similar at intake on all measures ; however , at follow-up the intensive treatment group outperformed the parent training group on measures of intelligence , visual-spatial skills , language , and academics , though not adaptive functioning or",behavior problems .,,"['The', 'groups', 'appeared', 'similar', 'at', 'intake', 'on', 'all', 'measures', ';', 'however', ',', 'at', 'follow-up', 'the', 'intensive', 'treatment', 'group', 'outperformed', 'the', 'parent', 'training', 'group', 'on', 'measures', 'of', 'intelligence', ',', 'visual-spatial', 'skills', ',', 'language', ',', 'and', 'academics', ',', 'though', 'not', 'adaptive', 'functioning', 'or', 'behavior', 'problems', '.']","(41, 44)","(263, 282)",-1,hl_o,10934569,Abstract,3,test,gold,2599.0
448,,Children with pervasive developmental disorder NOS,may have gained more than those with autism .,"['Children', 'with', 'pervasive', 'developmental', 'disorder', 'NOS', 'may', 'have', 'gained', 'more', 'than', 'those', 'with', 'autism', '.']","(0, 6)","(0, 50)",-1,ss_p,10934569,Abstract,4,test,gold,6186.0
449,Children with pervasive developmental disorder NOS may have gained more than those with,autism .,,"['Children', 'with', 'pervasive', 'developmental', 'disorder', 'NOS', 'may', 'have', 'gained', 'more', 'than', 'those', 'with', 'autism', '.']","(13, 15)","(87, 95)",-1,ss_p,10934569,Abstract,4,test,gold,6152.0
450,,Children,with pervasive developmental disorder NOS may have gained more than those with autism .,"['Children', 'with', 'pervasive', 'developmental', 'disorder', 'NOS', 'may', 'have', 'gained', 'more', 'than', 'those', 'with', 'autism', '.']","(0, 1)","(0, 8)",-1,hl_p,10934569,Abstract,4,test,gold,2177.0
451,Children with,pervasive developmental disorder,NOS may have gained more than those with autism .,"['Children', 'with', 'pervasive', 'developmental', 'disorder', 'NOS', 'may', 'have', 'gained', 'more', 'than', 'those', 'with', 'autism', '.']","(2, 5)","(13, 45)",-1,hl_p,10934569,Abstract,4,test,gold,6177.0
452,Efficacy and safety of selamectin against fleas and heartworms in,dogs and cats presented as veterinary patients in North America .,,"['Efficacy', 'and', 'safety', 'of', 'selamectin', 'against', 'fleas', 'and', 'heartworms', 'in', 'dogs', 'and', 'cats', 'presented', 'as', 'veterinary', 'patients', 'in', 'North', 'America', '.']","(10, 21)","(65, 130)",-1,ss_p,10940525,Title,0,test,gold,6077.0
453,Efficacy and safety of,selamectin,against fleas and heartworms in dogs and cats presented as veterinary patients in North America .,"['Efficacy', 'and', 'safety', 'of', 'selamectin', 'against', 'fleas', 'and', 'heartworms', 'in', 'dogs', 'and', 'cats', 'presented', 'as', 'veterinary', 'patients', 'in', 'North', 'America', '.']","(4, 5)","(22, 32)",-1,ss_i,10940525,Title,0,test,gold,
454,,Efficacy,and safety of selamectin against fleas and heartworms in dogs and cats presented as veterinary patients in North America .,"['Efficacy', 'and', 'safety', 'of', 'selamectin', 'against', 'fleas', 'and', 'heartworms', 'in', 'dogs', 'and', 'cats', 'presented', 'as', 'veterinary', 'patients', 'in', 'North', 'America', '.']","(0, 1)","(0, 8)",-1,ss_o,10940525,Title,0,test,gold,427.0
455,Efficacy and,safety,of selamectin against fleas and heartworms in dogs and cats presented as veterinary patients in North America .,"['Efficacy', 'and', 'safety', 'of', 'selamectin', 'against', 'fleas', 'and', 'heartworms', 'in', 'dogs', 'and', 'cats', 'presented', 'as', 'veterinary', 'patients', 'in', 'North', 'America', '.']","(2, 3)","(12, 18)",-1,ss_o,10940525,Title,0,test,gold,492.0
456,Efficacy and safety of selamectin against fleas and heartworms in,dogs and cats presented as veterinary patients in North America .,,"['Efficacy', 'and', 'safety', 'of', 'selamectin', 'against', 'fleas', 'and', 'heartworms', 'in', 'dogs', 'and', 'cats', 'presented', 'as', 'veterinary', 'patients', 'in', 'North', 'America', '.']","(10, 21)","(65, 130)",-1,hl_p,10940525,Title,0,test,gold,6078.0
457,Efficacy and safety of,selamectin,against fleas and heartworms in dogs and cats presented as veterinary patients in North America .,"['Efficacy', 'and', 'safety', 'of', 'selamectin', 'against', 'fleas', 'and', 'heartworms', 'in', 'dogs', 'and', 'cats', 'presented', 'as', 'veterinary', 'patients', 'in', 'North', 'America', '.']","(4, 5)","(22, 32)",-1,hl_i,10940525,Title,0,test,gold,
458,,Efficacy,and safety of selamectin against fleas and heartworms in dogs and cats presented as veterinary patients in North America .,"['Efficacy', 'and', 'safety', 'of', 'selamectin', 'against', 'fleas', 'and', 'heartworms', 'in', 'dogs', 'and', 'cats', 'presented', 'as', 'veterinary', 'patients', 'in', 'North', 'America', '.']","(0, 1)","(0, 8)",-1,hl_o,10940525,Title,0,test,gold,428.0
459,Efficacy and,safety,of selamectin against fleas and heartworms in dogs and cats presented as veterinary patients in North America .,"['Efficacy', 'and', 'safety', 'of', 'selamectin', 'against', 'fleas', 'and', 'heartworms', 'in', 'dogs', 'and', 'cats', 'presented', 'as', 'veterinary', 'patients', 'in', 'North', 'America', '.']","(2, 3)","(12, 18)",-1,hl_o,10940525,Title,0,test,gold,493.0
460,"A series of randomized , controlled , masked field studies was conducted to assess the efficacy and safety of selamectin in the treatment of flea infestations",on dogs and cats,", and in the prevention of heartworm infection in dogs .","['A', 'series', 'of', 'randomized', ',', 'controlled', ',', 'masked', 'field', 'studies', 'was', 'conducted', 'to', 'assess', 'the', 'efficacy', 'and', 'safety', 'of', 'selamectin', 'in', 'the', 'treatment', 'of', 'flea', 'infestations', 'on', 'dogs', 'and', 'cats', ',', 'and', 'in', 'the', 'prevention', 'of', 'heartworm', 'infection', 'in', 'dogs', '.']","(26, 30)","(158, 174)",-1,ss_p,10940525,Abstract,0,test,gold,6071.0
461,"A series of randomized , controlled , masked field studies was conducted to assess the efficacy and safety of",selamectin,"in the treatment of flea infestations on dogs and cats , and in the prevention of heartworm infection in dogs .","['A', 'series', 'of', 'randomized', ',', 'controlled', ',', 'masked', 'field', 'studies', 'was', 'conducted', 'to', 'assess', 'the', 'efficacy', 'and', 'safety', 'of', 'selamectin', 'in', 'the', 'treatment', 'of', 'flea', 'infestations', 'on', 'dogs', 'and', 'cats', ',', 'and', 'in', 'the', 'prevention', 'of', 'heartworm', 'infection', 'in', 'dogs', '.']","(19, 20)","(109, 119)",-1,ss_i,10940525,Abstract,0,test,gold,
462,"A series of randomized , controlled , masked field studies was conducted to assess the",efficacy,"and safety of selamectin in the treatment of flea infestations on dogs and cats , and in the prevention of heartworm infection in dogs .","['A', 'series', 'of', 'randomized', ',', 'controlled', ',', 'masked', 'field', 'studies', 'was', 'conducted', 'to', 'assess', 'the', 'efficacy', 'and', 'safety', 'of', 'selamectin', 'in', 'the', 'treatment', 'of', 'flea', 'infestations', 'on', 'dogs', 'and', 'cats', ',', 'and', 'in', 'the', 'prevention', 'of', 'heartworm', 'infection', 'in', 'dogs', '.']","(15, 16)","(86, 94)",-1,ss_o,10940525,Abstract,0,test,gold,4839.0
463,"A series of randomized , controlled , masked field studies was conducted to assess the efficacy and",safety,"of selamectin in the treatment of flea infestations on dogs and cats , and in the prevention of heartworm infection in dogs .","['A', 'series', 'of', 'randomized', ',', 'controlled', ',', 'masked', 'field', 'studies', 'was', 'conducted', 'to', 'assess', 'the', 'efficacy', 'and', 'safety', 'of', 'selamectin', 'in', 'the', 'treatment', 'of', 'flea', 'infestations', 'on', 'dogs', 'and', 'cats', ',', 'and', 'in', 'the', 'prevention', 'of', 'heartworm', 'infection', 'in', 'dogs', '.']","(17, 18)","(99, 105)",-1,ss_o,10940525,Abstract,0,test,gold,491.0
464,"A series of randomized , controlled , masked field studies was conducted to assess the efficacy and safety of selamectin in the treatment of flea infestations on",dogs and cats,", and in the prevention of heartworm infection in dogs .","['A', 'series', 'of', 'randomized', ',', 'controlled', ',', 'masked', 'field', 'studies', 'was', 'conducted', 'to', 'assess', 'the', 'efficacy', 'and', 'safety', 'of', 'selamectin', 'in', 'the', 'treatment', 'of', 'flea', 'infestations', 'on', 'dogs', 'and', 'cats', ',', 'and', 'in', 'the', 'prevention', 'of', 'heartworm', 'infection', 'in', 'dogs', '.']","(27, 30)","(161, 174)",-1,hl_p,10940525,Abstract,0,test,gold,6069.0
465,"A series of randomized , controlled , masked field studies was conducted to assess the efficacy and safety of",selamectin,"in the treatment of flea infestations on dogs and cats , and in the prevention of heartworm infection in dogs .","['A', 'series', 'of', 'randomized', ',', 'controlled', ',', 'masked', 'field', 'studies', 'was', 'conducted', 'to', 'assess', 'the', 'efficacy', 'and', 'safety', 'of', 'selamectin', 'in', 'the', 'treatment', 'of', 'flea', 'infestations', 'on', 'dogs', 'and', 'cats', ',', 'and', 'in', 'the', 'prevention', 'of', 'heartworm', 'infection', 'in', 'dogs', '.']","(19, 20)","(109, 119)",-1,hl_i,10940525,Abstract,0,test,gold,
466,"A series of randomized , controlled , masked field studies was conducted to assess the",efficacy,"and safety of selamectin in the treatment of flea infestations on dogs and cats , and in the prevention of heartworm infection in dogs .","['A', 'series', 'of', 'randomized', ',', 'controlled', ',', 'masked', 'field', 'studies', 'was', 'conducted', 'to', 'assess', 'the', 'efficacy', 'and', 'safety', 'of', 'selamectin', 'in', 'the', 'treatment', 'of', 'flea', 'infestations', 'on', 'dogs', 'and', 'cats', ',', 'and', 'in', 'the', 'prevention', 'of', 'heartworm', 'infection', 'in', 'dogs', '.']","(15, 16)","(86, 94)",-1,hl_o,10940525,Abstract,0,test,gold,4838.0
467,"A series of randomized , controlled , masked field studies was conducted to assess the efficacy and",safety,"of selamectin in the treatment of flea infestations on dogs and cats , and in the prevention of heartworm infection in dogs .","['A', 'series', 'of', 'randomized', ',', 'controlled', ',', 'masked', 'field', 'studies', 'was', 'conducted', 'to', 'assess', 'the', 'efficacy', 'and', 'safety', 'of', 'selamectin', 'in', 'the', 'treatment', 'of', 'flea', 'infestations', 'on', 'dogs', 'and', 'cats', ',', 'and', 'in', 'the', 'prevention', 'of', 'heartworm', 'infection', 'in', 'dogs', '.']","(17, 18)","(99, 105)",-1,hl_o,10940525,Abstract,0,test,gold,490.0
468,"In addition , observations were made on the beneficial effect of selamectin treatment on",dogs and cats showing signs of flea allergy dermatitis ( FAD ) .,,"['In', 'addition', ',', 'observations', 'were', 'made', 'on', 'the', 'beneficial', 'effect', 'of', 'selamectin', 'treatment', 'on', 'dogs', 'and', 'cats', 'showing', 'signs', 'of', 'flea', 'allergy', 'dermatitis', '(', 'FAD', ')', '.']","(14, 27)","(88, 152)",-1,ss_p,10940525,Abstract,1,test,gold,6060.0
469,"In addition , observations were made on the beneficial effect of",selamectin,treatment on dogs and cats showing signs of flea allergy dermatitis ( FAD ) .,"['In', 'addition', ',', 'observations', 'were', 'made', 'on', 'the', 'beneficial', 'effect', 'of', 'selamectin', 'treatment', 'on', 'dogs', 'and', 'cats', 'showing', 'signs', 'of', 'flea', 'allergy', 'dermatitis', '(', 'FAD', ')', '.']","(11, 12)","(64, 74)",-1,ss_i,10940525,Abstract,1,test,gold,
470,"In addition , observations were made on the beneficial effect of selamectin treatment on",dogs and cats showing signs of flea allergy dermatitis ( FAD ) .,,"['In', 'addition', ',', 'observations', 'were', 'made', 'on', 'the', 'beneficial', 'effect', 'of', 'selamectin', 'treatment', 'on', 'dogs', 'and', 'cats', 'showing', 'signs', 'of', 'flea', 'allergy', 'dermatitis', '(', 'FAD', ')', '.']","(14, 27)","(88, 152)",-1,hl_p,10940525,Abstract,1,test,gold,6061.0
471,"In addition , observations were made on the beneficial effect of",selamectin,treatment on dogs and cats showing signs of flea allergy dermatitis ( FAD ) .,"['In', 'addition', ',', 'observations', 'were', 'made', 'on', 'the', 'beneficial', 'effect', 'of', 'selamectin', 'treatment', 'on', 'dogs', 'and', 'cats', 'showing', 'signs', 'of', 'flea', 'allergy', 'dermatitis', '(', 'FAD', ')', '.']","(11, 12)","(64, 74)",-1,hl_i,10940525,Abstract,1,test,gold,
472,In all studies,selamectin,"was applied topically , once per month , in unit doses providing a minimum dosage of 6mgkg ( -1 ) .","['In', 'all', 'studies', 'selamectin', 'was', 'applied', 'topically', ',', 'once', 'per', 'month', ',', 'in', 'unit', 'doses', 'providing', 'a', 'minimum', 'dosage', 'of', '6mgkg', '(', '-1', ')', '.']","(3, 4)","(14, 24)",-1,ss_i,10940525,Abstract,2,test,gold,
473,In all studies,selamectin,"was applied topically , once per month , in unit doses providing a minimum dosage of 6mgkg ( -1 ) .","['In', 'all', 'studies', 'selamectin', 'was', 'applied', 'topically', ',', 'once', 'per', 'month', ',', 'in', 'unit', 'doses', 'providing', 'a', 'minimum', 'dosage', 'of', '6mgkg', '(', '-1', ')', '.']","(3, 4)","(14, 24)",-1,hl_i,10940525,Abstract,2,test,gold,
474,,"Dogs and cats with naturally occurring flea infestations , some of which also had signs associated with FAD",", were assigned randomly to receive three months of topical treatment with selamectin ( 220 dogs , 189 cats ) or a positive-control product ( dogs : fenthion , n=81 ; cats : pyrethrins , n=66 ) .","['Dogs', 'and', 'cats', 'with', 'naturally', 'occurring', 'flea', 'infestations', ',', 'some', 'of', 'which', 'also', 'had', 'signs', 'associated', 'with', 'FAD', ',', 'were', 'assigned', 'randomly', 'to', 'receive', 'three', 'months', 'of', 'topical', 'treatment', 'with', 'selamectin', '(', '220', 'dogs', ',', '189', 'cats', ')', 'or', 'a', 'positive-control', 'product', '(', 'dogs', ':', 'fenthion', ',', 'n=81', ';', 'cats', ':', 'pyrethrins', ',', 'n=66', ')', '.']","(0, 18)","(0, 107)",-1,ss_p,10940525,Abstract,3,test,gold,6058.0
475,"Dogs and cats with naturally occurring flea infestations , some of which also had signs associated with FAD , were assigned randomly to receive three months of topical treatment with selamectin","( 220 dogs , 189 cats )","or a positive-control product ( dogs : fenthion , n=81 ; cats : pyrethrins , n=66 ) .","['Dogs', 'and', 'cats', 'with', 'naturally', 'occurring', 'flea', 'infestations', ',', 'some', 'of', 'which', 'also', 'had', 'signs', 'associated', 'with', 'FAD', ',', 'were', 'assigned', 'randomly', 'to', 'receive', 'three', 'months', 'of', 'topical', 'treatment', 'with', 'selamectin', '(', '220', 'dogs', ',', '189', 'cats', ')', 'or', 'a', 'positive-control', 'product', '(', 'dogs', ':', 'fenthion', ',', 'n=81', ';', 'cats', ':', 'pyrethrins', ',', 'n=66', ')', '.']","(31, 38)","(193, 216)",-1,ss_p,10940525,Abstract,3,test,gold,6070.0
476,"Dogs and cats with naturally occurring flea infestations , some of which also had signs associated with FAD , were assigned randomly to receive three months of topical treatment with",selamectin,"( 220 dogs , 189 cats ) or a positive-control product ( dogs : fenthion , n=81 ; cats : pyrethrins , n=66 ) .","['Dogs', 'and', 'cats', 'with', 'naturally', 'occurring', 'flea', 'infestations', ',', 'some', 'of', 'which', 'also', 'had', 'signs', 'associated', 'with', 'FAD', ',', 'were', 'assigned', 'randomly', 'to', 'receive', 'three', 'months', 'of', 'topical', 'treatment', 'with', 'selamectin', '(', '220', 'dogs', ',', '189', 'cats', ')', 'or', 'a', 'positive-control', 'product', '(', 'dogs', ':', 'fenthion', ',', 'n=81', ';', 'cats', ':', 'pyrethrins', ',', 'n=66', ')', '.']","(30, 31)","(182, 192)",-1,ss_i,10940525,Abstract,3,test,gold,
477,"Dogs and cats with naturally occurring flea infestations , some of which also had signs associated with FAD , were assigned randomly to receive three months of topical treatment with selamectin ( 220 dogs , 189 cats ) or a positive-control product ( dogs :",fenthion,", n=81 ; cats : pyrethrins , n=66 ) .","['Dogs', 'and', 'cats', 'with', 'naturally', 'occurring', 'flea', 'infestations', ',', 'some', 'of', 'which', 'also', 'had', 'signs', 'associated', 'with', 'FAD', ',', 'were', 'assigned', 'randomly', 'to', 'receive', 'three', 'months', 'of', 'topical', 'treatment', 'with', 'selamectin', '(', '220', 'dogs', ',', '189', 'cats', ')', 'or', 'a', 'positive-control', 'product', '(', 'dogs', ':', 'fenthion', ',', 'n=81', ';', 'cats', ':', 'pyrethrins', ',', 'n=66', ')', '.']","(45, 46)","(256, 264)",-1,ss_i,10940525,Abstract,3,test,gold,
478,"Dogs and cats with naturally occurring flea infestations , some of which also had signs associated with FAD , were assigned randomly to receive three months of topical treatment with selamectin ( 220 dogs , 189 cats ) or a positive-control product ( dogs : fenthion , n=81 ; cats :",pyrethrins,", n=66 ) .","['Dogs', 'and', 'cats', 'with', 'naturally', 'occurring', 'flea', 'infestations', ',', 'some', 'of', 'which', 'also', 'had', 'signs', 'associated', 'with', 'FAD', ',', 'were', 'assigned', 'randomly', 'to', 'receive', 'three', 'months', 'of', 'topical', 'treatment', 'with', 'selamectin', '(', '220', 'dogs', ',', '189', 'cats', ')', 'or', 'a', 'positive-control', 'product', '(', 'dogs', ':', 'fenthion', ',', 'n=81', ';', 'cats', ':', 'pyrethrins', ',', 'n=66', ')', '.']","(51, 52)","(281, 291)",-1,ss_i,10940525,Abstract,3,test,gold,100.0
479,,"Dogs and cats with naturally occurring flea infestations , some of which also had signs associated with FAD",", were assigned randomly to receive three months of topical treatment with selamectin ( 220 dogs , 189 cats ) or a positive-control product ( dogs : fenthion , n=81 ; cats : pyrethrins , n=66 ) .","['Dogs', 'and', 'cats', 'with', 'naturally', 'occurring', 'flea', 'infestations', ',', 'some', 'of', 'which', 'also', 'had', 'signs', 'associated', 'with', 'FAD', ',', 'were', 'assigned', 'randomly', 'to', 'receive', 'three', 'months', 'of', 'topical', 'treatment', 'with', 'selamectin', '(', '220', 'dogs', ',', '189', 'cats', ')', 'or', 'a', 'positive-control', 'product', '(', 'dogs', ':', 'fenthion', ',', 'n=81', ';', 'cats', ':', 'pyrethrins', ',', 'n=66', ')', '.']","(0, 18)","(0, 107)",-1,hl_p,10940525,Abstract,3,test,gold,6059.0
480,"Dogs and cats with naturally occurring flea infestations , some of which also had signs associated with FAD , were assigned randomly to receive three months of topical treatment with selamectin (","220 dogs , 189 cats",") or a positive-control product ( dogs : fenthion , n=81 ; cats : pyrethrins , n=66 ) .","['Dogs', 'and', 'cats', 'with', 'naturally', 'occurring', 'flea', 'infestations', ',', 'some', 'of', 'which', 'also', 'had', 'signs', 'associated', 'with', 'FAD', ',', 'were', 'assigned', 'randomly', 'to', 'receive', 'three', 'months', 'of', 'topical', 'treatment', 'with', 'selamectin', '(', '220', 'dogs', ',', '189', 'cats', ')', 'or', 'a', 'positive-control', 'product', '(', 'dogs', ':', 'fenthion', ',', 'n=81', ';', 'cats', ':', 'pyrethrins', ',', 'n=66', ')', '.']","(32, 37)","(195, 214)",-1,hl_p,10940525,Abstract,3,test,gold,6068.0
481,"Dogs and cats with naturally occurring flea infestations , some of which also had signs associated with FAD , were assigned randomly to receive three months of topical treatment with",selamectin,"( 220 dogs , 189 cats ) or a positive-control product ( dogs : fenthion , n=81 ; cats : pyrethrins , n=66 ) .","['Dogs', 'and', 'cats', 'with', 'naturally', 'occurring', 'flea', 'infestations', ',', 'some', 'of', 'which', 'also', 'had', 'signs', 'associated', 'with', 'FAD', ',', 'were', 'assigned', 'randomly', 'to', 'receive', 'three', 'months', 'of', 'topical', 'treatment', 'with', 'selamectin', '(', '220', 'dogs', ',', '189', 'cats', ')', 'or', 'a', 'positive-control', 'product', '(', 'dogs', ':', 'fenthion', ',', 'n=81', ';', 'cats', ':', 'pyrethrins', ',', 'n=66', ')', '.']","(30, 31)","(182, 192)",-1,hl_i,10940525,Abstract,3,test,gold,
482,"Dogs and cats with naturally occurring flea infestations , some of which also had signs associated with FAD , were assigned randomly to receive three months of topical treatment with selamectin ( 220 dogs , 189 cats ) or a positive-control product ( dogs :",fenthion,", n=81 ; cats : pyrethrins , n=66 ) .","['Dogs', 'and', 'cats', 'with', 'naturally', 'occurring', 'flea', 'infestations', ',', 'some', 'of', 'which', 'also', 'had', 'signs', 'associated', 'with', 'FAD', ',', 'were', 'assigned', 'randomly', 'to', 'receive', 'three', 'months', 'of', 'topical', 'treatment', 'with', 'selamectin', '(', '220', 'dogs', ',', '189', 'cats', ')', 'or', 'a', 'positive-control', 'product', '(', 'dogs', ':', 'fenthion', ',', 'n=81', ';', 'cats', ':', 'pyrethrins', ',', 'n=66', ')', '.']","(45, 46)","(256, 264)",-1,hl_i,10940525,Abstract,3,test,gold,
483,"Dogs and cats with naturally occurring flea infestations , some of which also had signs associated with FAD , were assigned randomly to receive three months of topical treatment with selamectin ( 220 dogs , 189 cats ) or a positive-control product ( dogs : fenthion , n=81 ; cats :",pyrethrins,", n=66 ) .","['Dogs', 'and', 'cats', 'with', 'naturally', 'occurring', 'flea', 'infestations', ',', 'some', 'of', 'which', 'also', 'had', 'signs', 'associated', 'with', 'FAD', ',', 'were', 'assigned', 'randomly', 'to', 'receive', 'three', 'months', 'of', 'topical', 'treatment', 'with', 'selamectin', '(', '220', 'dogs', ',', '189', 'cats', ')', 'or', 'a', 'positive-control', 'product', '(', 'dogs', ':', 'fenthion', ',', 'n=81', ';', 'cats', ':', 'pyrethrins', ',', 'n=66', ')', '.']","(51, 52)","(281, 291)",-1,hl_i,10940525,Abstract,3,test,gold,101.0
484,,Selamectin,"was administered on days 0 , 30 , and 60 .","['Selamectin', 'was', 'administered', 'on', 'days', '0', ',', '30', ',', 'and', '60', '.']","(0, 1)","(0, 10)",-1,ss_i,10940525,Abstract,4,test,gold,
485,,Selamectin,"was administered on days 0 , 30 , and 60 .","['Selamectin', 'was', 'administered', 'on', 'days', '0', ',', '30', ',', 'and', '60', '.']","(0, 1)","(0, 10)",-1,hl_i,10940525,Abstract,4,test,gold,
486,Day 0 was defined as the day that the animal first received treatment .,,,"['Day', '0', 'was', 'defined', 'as', 'the', 'day', 'that', 'the', 'animal', 'first', 'received', 'treatment', '.']",,,,,10940525,Abstract,5,test,gold,
487,Flea burdens were assessed by,flea comb counts and clinical evaluations of FAD,"were performed before treatment , and on days 14 , 30 , 60 , and 90 .","['Flea', 'burdens', 'were', 'assessed', 'by', 'flea', 'comb', 'counts', 'and', 'clinical', 'evaluations', 'of', 'FAD', 'were', 'performed', 'before', 'treatment', ',', 'and', 'on', 'days', '14', ',', '30', ',', '60', ',', 'and', '90', '.']","(5, 13)","(29, 77)",-1,ss_o,10940525,Abstract,6,test,gold,4743.0
488,Flea burdens were assessed by,flea comb counts,"and clinical evaluations of FAD were performed before treatment , and on days 14 , 30 , 60 , and 90 .","['Flea', 'burdens', 'were', 'assessed', 'by', 'flea', 'comb', 'counts', 'and', 'clinical', 'evaluations', 'of', 'FAD', 'were', 'performed', 'before', 'treatment', ',', 'and', 'on', 'days', '14', ',', '30', ',', '60', ',', 'and', '90', '.']","(5, 8)","(29, 45)",-1,hl_o,10940525,Abstract,6,test,gold,1406.0
489,Flea burdens were assessed by flea comb counts and,clinical evaluations of FAD,"were performed before treatment , and on days 14 , 30 , 60 , and 90 .","['Flea', 'burdens', 'were', 'assessed', 'by', 'flea', 'comb', 'counts', 'and', 'clinical', 'evaluations', 'of', 'FAD', 'were', 'performed', 'before', 'treatment', ',', 'and', 'on', 'days', '14', ',', '30', ',', '60', ',', 'and', '90', '.']","(9, 13)","(50, 77)",-1,hl_o,10940525,Abstract,6,test,gold,4744.0
490,"On days 30 , 60 , and 90 , mean flea counts in",selamectin-treated,"dogs were reduced by 92.1 , 99.0 , and 99.8 % , and mean flea counts in fenthion-treated dogs were reduced by 81.5 , 86.8 , and 86.1 % , respectively , compared with day 0 counts .","['On', 'days', '30', ',', '60', ',', 'and', '90', ',', 'mean', 'flea', 'counts', 'in', 'selamectin-treated', 'dogs', 'were', 'reduced', 'by', '92.1', ',', '99.0', ',', 'and', '99.8', '%', ',', 'and', 'mean', 'flea', 'counts', 'in', 'fenthion-treated', 'dogs', 'were', 'reduced', 'by', '81.5', ',', '86.8', ',', 'and', '86.1', '%', ',', 'respectively', ',', 'compared', 'with', 'day', '0', 'counts', '.']","(13, 14)","(46, 64)",-1,ss_i,10940525,Abstract,7,test,gold,
491,"On days 30 , 60 , and 90 , mean flea counts in selamectin-treated dogs were reduced by 92.1 , 99.0 , and 99.8 % , and mean flea counts in",fenthion-treated,"dogs were reduced by 81.5 , 86.8 , and 86.1 % , respectively , compared with day 0 counts .","['On', 'days', '30', ',', '60', ',', 'and', '90', ',', 'mean', 'flea', 'counts', 'in', 'selamectin-treated', 'dogs', 'were', 'reduced', 'by', '92.1', ',', '99.0', ',', 'and', '99.8', '%', ',', 'and', 'mean', 'flea', 'counts', 'in', 'fenthion-treated', 'dogs', 'were', 'reduced', 'by', '81.5', ',', '86.8', ',', 'and', '86.1', '%', ',', 'respectively', ',', 'compared', 'with', 'day', '0', 'counts', '.']","(31, 32)","(137, 153)",-1,ss_i,10940525,Abstract,7,test,gold,
492,"On days 30 , 60 , and 90 ,",mean flea counts,"in selamectin-treated dogs were reduced by 92.1 , 99.0 , and 99.8 % , and mean flea counts in fenthion-treated dogs were reduced by 81.5 , 86.8 , and 86.1 % , respectively , compared with day 0 counts .","['On', 'days', '30', ',', '60', ',', 'and', '90', ',', 'mean', 'flea', 'counts', 'in', 'selamectin-treated', 'dogs', 'were', 'reduced', 'by', '92.1', ',', '99.0', ',', 'and', '99.8', '%', ',', 'and', 'mean', 'flea', 'counts', 'in', 'fenthion-treated', 'dogs', 'were', 'reduced', 'by', '81.5', ',', '86.8', ',', 'and', '86.1', '%', ',', 'respectively', ',', 'compared', 'with', 'day', '0', 'counts', '.']","(9, 12)","(26, 42)",-1,ss_o,10940525,Abstract,7,test,gold,1413.0
493,"On days 30 , 60 , and 90 , mean flea counts in selamectin-treated dogs were reduced by 92.1 , 99.0 , and 99.8 % , and",mean flea counts,"in fenthion-treated dogs were reduced by 81.5 , 86.8 , and 86.1 % , respectively , compared with day 0 counts .","['On', 'days', '30', ',', '60', ',', 'and', '90', ',', 'mean', 'flea', 'counts', 'in', 'selamectin-treated', 'dogs', 'were', 'reduced', 'by', '92.1', ',', '99.0', ',', 'and', '99.8', '%', ',', 'and', 'mean', 'flea', 'counts', 'in', 'fenthion-treated', 'dogs', 'were', 'reduced', 'by', '81.5', ',', '86.8', ',', 'and', '86.1', '%', ',', 'respectively', ',', 'compared', 'with', 'day', '0', 'counts', '.']","(27, 30)","(117, 133)",-1,ss_o,10940525,Abstract,7,test,gold,1414.0
494,"On days 30 , 60 , and 90 , mean flea counts in",selamectin-treated,"dogs were reduced by 92.1 , 99.0 , and 99.8 % , and mean flea counts in fenthion-treated dogs were reduced by 81.5 , 86.8 , and 86.1 % , respectively , compared with day 0 counts .","['On', 'days', '30', ',', '60', ',', 'and', '90', ',', 'mean', 'flea', 'counts', 'in', 'selamectin-treated', 'dogs', 'were', 'reduced', 'by', '92.1', ',', '99.0', ',', 'and', '99.8', '%', ',', 'and', 'mean', 'flea', 'counts', 'in', 'fenthion-treated', 'dogs', 'were', 'reduced', 'by', '81.5', ',', '86.8', ',', 'and', '86.1', '%', ',', 'respectively', ',', 'compared', 'with', 'day', '0', 'counts', '.']","(13, 14)","(46, 64)",-1,hl_i,10940525,Abstract,7,test,gold,
495,"On days 30 , 60 , and 90 ,",mean flea counts,"in selamectin-treated dogs were reduced by 92.1 , 99.0 , and 99.8 % , and mean flea counts in fenthion-treated dogs were reduced by 81.5 , 86.8 , and 86.1 % , respectively , compared with day 0 counts .","['On', 'days', '30', ',', '60', ',', 'and', '90', ',', 'mean', 'flea', 'counts', 'in', 'selamectin-treated', 'dogs', 'were', 'reduced', 'by', '92.1', ',', '99.0', ',', 'and', '99.8', '%', ',', 'and', 'mean', 'flea', 'counts', 'in', 'fenthion-treated', 'dogs', 'were', 'reduced', 'by', '81.5', ',', '86.8', ',', 'and', '86.1', '%', ',', 'respectively', ',', 'compared', 'with', 'day', '0', 'counts', '.']","(9, 12)","(26, 42)",-1,hl_o,10940525,Abstract,7,test,gold,1412.0
496,"On days 30 , 60 , and 90 , mean flea counts in selamectin-treated dogs were reduced by 92.1 , 99.0 , and 99.8 % , and",mean flea counts,"in fenthion-treated dogs were reduced by 81.5 , 86.8 , and 86.1 % , respectively , compared with day 0 counts .","['On', 'days', '30', ',', '60', ',', 'and', '90', ',', 'mean', 'flea', 'counts', 'in', 'selamectin-treated', 'dogs', 'were', 'reduced', 'by', '92.1', ',', '99.0', ',', 'and', '99.8', '%', ',', 'and', 'mean', 'flea', 'counts', 'in', 'fenthion-treated', 'dogs', 'were', 'reduced', 'by', '81.5', ',', '86.8', ',', 'and', '86.1', '%', ',', 'respectively', ',', 'compared', 'with', 'day', '0', 'counts', '.']","(27, 30)","(117, 133)",-1,hl_o,10940525,Abstract,7,test,gold,1411.0
497,"Also , on days 30 , 60 , and 90 , mean flea counts in",selamectin-treated,"cats were reduced by 92.5 , 98.3 , and 99.3 % , and mean flea counts in pyrethrin-treated cats were reduced by 66.4 , 73.9 , and 81.3 % , respectively , compared with day 0 counts .","['Also', ',', 'on', 'days', '30', ',', '60', ',', 'and', '90', ',', 'mean', 'flea', 'counts', 'in', 'selamectin-treated', 'cats', 'were', 'reduced', 'by', '92.5', ',', '98.3', ',', 'and', '99.3', '%', ',', 'and', 'mean', 'flea', 'counts', 'in', 'pyrethrin-treated', 'cats', 'were', 'reduced', 'by', '66.4', ',', '73.9', ',', 'and', '81.3', '%', ',', 'respectively', ',', 'compared', 'with', 'day', '0', 'counts', '.']","(15, 16)","(53, 71)",-1,ss_i,10940525,Abstract,8,test,gold,
498,"Also , on days 30 , 60 , and 90 , mean flea counts in selamectin-treated cats were reduced by 92.5 , 98.3 , and 99.3 % , and mean flea counts in",pyrethrin-treated,"cats were reduced by 66.4 , 73.9 , and 81.3 % , respectively , compared with day 0 counts .","['Also', ',', 'on', 'days', '30', ',', '60', ',', 'and', '90', ',', 'mean', 'flea', 'counts', 'in', 'selamectin-treated', 'cats', 'were', 'reduced', 'by', '92.5', ',', '98.3', ',', 'and', '99.3', '%', ',', 'and', 'mean', 'flea', 'counts', 'in', 'pyrethrin-treated', 'cats', 'were', 'reduced', 'by', '66.4', ',', '73.9', ',', 'and', '81.3', '%', ',', 'respectively', ',', 'compared', 'with', 'day', '0', 'counts', '.']","(33, 34)","(144, 161)",-1,ss_i,10940525,Abstract,8,test,gold,
499,"Also , on days 30 , 60 , and 90 ,",mean flea counts,"in selamectin-treated cats were reduced by 92.5 , 98.3 , and 99.3 % , and mean flea counts in pyrethrin-treated cats were reduced by 66.4 , 73.9 , and 81.3 % , respectively , compared with day 0 counts .","['Also', ',', 'on', 'days', '30', ',', '60', ',', 'and', '90', ',', 'mean', 'flea', 'counts', 'in', 'selamectin-treated', 'cats', 'were', 'reduced', 'by', '92.5', ',', '98.3', ',', 'and', '99.3', '%', ',', 'and', 'mean', 'flea', 'counts', 'in', 'pyrethrin-treated', 'cats', 'were', 'reduced', 'by', '66.4', ',', '73.9', ',', 'and', '81.3', '%', ',', 'respectively', ',', 'compared', 'with', 'day', '0', 'counts', '.']","(11, 14)","(33, 49)",-1,ss_o,10940525,Abstract,8,test,gold,1410.0
500,"Also , on days 30 , 60 , and 90 , mean flea counts in selamectin-treated cats were reduced by 92.5 , 98.3 , and 99.3 % , and",mean flea counts,"in pyrethrin-treated cats were reduced by 66.4 , 73.9 , and 81.3 % , respectively , compared with day 0 counts .","['Also', ',', 'on', 'days', '30', ',', '60', ',', 'and', '90', ',', 'mean', 'flea', 'counts', 'in', 'selamectin-treated', 'cats', 'were', 'reduced', 'by', '92.5', ',', '98.3', ',', 'and', '99.3', '%', ',', 'and', 'mean', 'flea', 'counts', 'in', 'pyrethrin-treated', 'cats', 'were', 'reduced', 'by', '66.4', ',', '73.9', ',', 'and', '81.3', '%', ',', 'respectively', ',', 'compared', 'with', 'day', '0', 'counts', '.']","(29, 32)","(124, 140)",-1,ss_o,10940525,Abstract,8,test,gold,1409.0
501,"Also , on days 30 , 60 , and 90 ,",mean flea counts,"in selamectin-treated cats were reduced by 92.5 , 98.3 , and 99.3 % , and mean flea counts in pyrethrin-treated cats were reduced by 66.4 , 73.9 , and 81.3 % , respectively , compared with day 0 counts .","['Also', ',', 'on', 'days', '30', ',', '60', ',', 'and', '90', ',', 'mean', 'flea', 'counts', 'in', 'selamectin-treated', 'cats', 'were', 'reduced', 'by', '92.5', ',', '98.3', ',', 'and', '99.3', '%', ',', 'and', 'mean', 'flea', 'counts', 'in', 'pyrethrin-treated', 'cats', 'were', 'reduced', 'by', '66.4', ',', '73.9', ',', 'and', '81.3', '%', ',', 'respectively', ',', 'compared', 'with', 'day', '0', 'counts', '.']","(11, 14)","(33, 49)",-1,hl_o,10940525,Abstract,8,test,gold,1408.0
502,"Also , on days 30 , 60 , and 90 , mean flea counts in selamectin-treated cats were reduced by 92.5 , 98.3 , and 99.3 % , and",mean flea counts,"in pyrethrin-treated cats were reduced by 66.4 , 73.9 , and 81.3 % , respectively , compared with day 0 counts .","['Also', ',', 'on', 'days', '30', ',', '60', ',', 'and', '90', ',', 'mean', 'flea', 'counts', 'in', 'selamectin-treated', 'cats', 'were', 'reduced', 'by', '92.5', ',', '98.3', ',', 'and', '99.3', '%', ',', 'and', 'mean', 'flea', 'counts', 'in', 'pyrethrin-treated', 'cats', 'were', 'reduced', 'by', '66.4', ',', '73.9', ',', 'and', '81.3', '%', ',', 'respectively', ',', 'compared', 'with', 'day', '0', 'counts', '.']","(29, 32)","(124, 140)",-1,hl_o,10940525,Abstract,8,test,gold,1407.0
503,Selamectin also was beneficial in alleviating signs in,dogs and cats diagnosed clinically with FAD .,,"['Selamectin', 'also', 'was', 'beneficial', 'in', 'alleviating', 'signs', 'in', 'dogs', 'and', 'cats', 'diagnosed', 'clinically', 'with', 'FAD', '.']","(8, 16)","(54, 99)",-1,ss_p,10940525,Abstract,9,test,gold,6075.0
504,,Selamectin,also was beneficial in alleviating signs in dogs and cats diagnosed clinically with FAD .,"['Selamectin', 'also', 'was', 'beneficial', 'in', 'alleviating', 'signs', 'in', 'dogs', 'and', 'cats', 'diagnosed', 'clinically', 'with', 'FAD', '.']","(0, 1)","(0, 10)",-1,ss_i,10940525,Abstract,9,test,gold,
505,Selamectin also was beneficial in alleviating,signs,in dogs and cats diagnosed clinically with FAD .,"['Selamectin', 'also', 'was', 'beneficial', 'in', 'alleviating', 'signs', 'in', 'dogs', 'and', 'cats', 'diagnosed', 'clinically', 'with', 'FAD', '.']","(6, 7)","(45, 50)",-1,ss_o,10940525,Abstract,9,test,gold,1293.0
506,Selamectin also was beneficial in alleviating signs in,dogs and cats diagnosed clinically with FAD .,,"['Selamectin', 'also', 'was', 'beneficial', 'in', 'alleviating', 'signs', 'in', 'dogs', 'and', 'cats', 'diagnosed', 'clinically', 'with', 'FAD', '.']","(8, 16)","(54, 99)",-1,hl_p,10940525,Abstract,9,test,gold,6076.0
507,,Selamectin,also was beneficial in alleviating signs in dogs and cats diagnosed clinically with FAD .,"['Selamectin', 'also', 'was', 'beneficial', 'in', 'alleviating', 'signs', 'in', 'dogs', 'and', 'cats', 'diagnosed', 'clinically', 'with', 'FAD', '.']","(0, 1)","(0, 10)",-1,hl_i,10940525,Abstract,9,test,gold,
508,A total of,397 dogs free of adult heartworm infection from four heartworm-endemic areas of the USA,were allocated randomly to six months of treatment with selamectin ( n=298 ) or ivermectin ( n=99 ) .,"['A', 'total', 'of', '397', 'dogs', 'free', 'of', 'adult', 'heartworm', 'infection', 'from', 'four', 'heartworm-endemic', 'areas', 'of', 'the', 'USA', 'were', 'allocated', 'randomly', 'to', 'six', 'months', 'of', 'treatment', 'with', 'selamectin', '(', 'n=298', ')', 'or', 'ivermectin', '(', 'n=99', ')', '.']","(3, 17)","(10, 97)",-1,ss_p,10940525,Abstract,10,test,gold,6073.0
509,A total of 397 dogs free of adult heartworm infection from four heartworm-endemic areas of the USA were allocated randomly to six months of treatment with,selamectin,( n=298 ) or ivermectin ( n=99 ) .,"['A', 'total', 'of', '397', 'dogs', 'free', 'of', 'adult', 'heartworm', 'infection', 'from', 'four', 'heartworm-endemic', 'areas', 'of', 'the', 'USA', 'were', 'allocated', 'randomly', 'to', 'six', 'months', 'of', 'treatment', 'with', 'selamectin', '(', 'n=298', ')', 'or', 'ivermectin', '(', 'n=99', ')', '.']","(26, 27)","(154, 164)",-1,ss_i,10940525,Abstract,10,test,gold,
510,A total of 397 dogs free of adult heartworm infection from four heartworm-endemic areas of the USA were allocated randomly to six months of treatment with selamectin ( n=298 ) or,ivermectin,( n=99 ) .,"['A', 'total', 'of', '397', 'dogs', 'free', 'of', 'adult', 'heartworm', 'infection', 'from', 'four', 'heartworm-endemic', 'areas', 'of', 'the', 'USA', 'were', 'allocated', 'randomly', 'to', 'six', 'months', 'of', 'treatment', 'with', 'selamectin', '(', 'n=298', ')', 'or', 'ivermectin', '(', 'n=99', ')', '.']","(31, 32)","(178, 188)",-1,ss_i,10940525,Abstract,10,test,gold,249.0
511,A total of,397 dogs free of adult heartworm infection from four heartworm-endemic areas of the USA,were allocated randomly to six months of treatment with selamectin ( n=298 ) or ivermectin ( n=99 ) .,"['A', 'total', 'of', '397', 'dogs', 'free', 'of', 'adult', 'heartworm', 'infection', 'from', 'four', 'heartworm-endemic', 'areas', 'of', 'the', 'USA', 'were', 'allocated', 'randomly', 'to', 'six', 'months', 'of', 'treatment', 'with', 'selamectin', '(', 'n=298', ')', 'or', 'ivermectin', '(', 'n=99', ')', '.']","(3, 17)","(10, 97)",-1,hl_p,10940525,Abstract,10,test,gold,6074.0
512,A total of 397 dogs free of adult heartworm infection from four heartworm-endemic areas of the USA were allocated randomly to six months of treatment with,selamectin,( n=298 ) or ivermectin ( n=99 ) .,"['A', 'total', 'of', '397', 'dogs', 'free', 'of', 'adult', 'heartworm', 'infection', 'from', 'four', 'heartworm-endemic', 'areas', 'of', 'the', 'USA', 'were', 'allocated', 'randomly', 'to', 'six', 'months', 'of', 'treatment', 'with', 'selamectin', '(', 'n=298', ')', 'or', 'ivermectin', '(', 'n=99', ')', '.']","(26, 27)","(154, 164)",-1,hl_i,10940525,Abstract,10,test,gold,
513,A total of 397 dogs free of adult heartworm infection from four heartworm-endemic areas of the USA were allocated randomly to six months of treatment with selamectin ( n=298 ) or,ivermectin,( n=99 ) .,"['A', 'total', 'of', '397', 'dogs', 'free', 'of', 'adult', 'heartworm', 'infection', 'from', 'four', 'heartworm-endemic', 'areas', 'of', 'the', 'USA', 'were', 'allocated', 'randomly', 'to', 'six', 'months', 'of', 'treatment', 'with', 'selamectin', '(', 'n=298', ')', 'or', 'ivermectin', '(', 'n=99', ')', '.']","(31, 32)","(178, 188)",-1,hl_i,10940525,Abstract,10,test,gold,250.0
514,,Selamectin,"achieved a heartworm prevention rate of 100 % , with all dogs testing negative for microfilariae and adult heartworm antigen on days 180 and 300 .","['Selamectin', 'achieved', 'a', 'heartworm', 'prevention', 'rate', 'of', '100', '%', ',', 'with', 'all', 'dogs', 'testing', 'negative', 'for', 'microfilariae', 'and', 'adult', 'heartworm', 'antigen', 'on', 'days', '180', 'and', '300', '.']","(0, 1)","(0, 10)",-1,ss_i,10940525,Abstract,11,test,gold,
515,Selamectin achieved a,heartworm prevention rate,"of 100 % , with all dogs testing negative for microfilariae and adult heartworm antigen on days 180 and 300 .","['Selamectin', 'achieved', 'a', 'heartworm', 'prevention', 'rate', 'of', '100', '%', ',', 'with', 'all', 'dogs', 'testing', 'negative', 'for', 'microfilariae', 'and', 'adult', 'heartworm', 'antigen', 'on', 'days', '180', 'and', '300', '.']","(3, 6)","(21, 46)",-1,ss_o,10940525,Abstract,11,test,gold,4034.0
516,"Selamectin achieved a heartworm prevention rate of 100 % , with all dogs testing negative for",microfilariae and adult heartworm antigen,on days 180 and 300 .,"['Selamectin', 'achieved', 'a', 'heartworm', 'prevention', 'rate', 'of', '100', '%', ',', 'with', 'all', 'dogs', 'testing', 'negative', 'for', 'microfilariae', 'and', 'adult', 'heartworm', 'antigen', 'on', 'days', '180', 'and', '300', '.']","(16, 21)","(93, 134)",-1,ss_o,10940525,Abstract,11,test,gold,6660.0
517,,Selamectin,"achieved a heartworm prevention rate of 100 % , with all dogs testing negative for microfilariae and adult heartworm antigen on days 180 and 300 .","['Selamectin', 'achieved', 'a', 'heartworm', 'prevention', 'rate', 'of', '100', '%', ',', 'with', 'all', 'dogs', 'testing', 'negative', 'for', 'microfilariae', 'and', 'adult', 'heartworm', 'antigen', 'on', 'days', '180', 'and', '300', '.']","(0, 1)","(0, 10)",-1,hl_i,10940525,Abstract,11,test,gold,
518,Selamectin achieved a,heartworm prevention rate,"of 100 % , with all dogs testing negative for microfilariae and adult heartworm antigen on days 180 and 300 .","['Selamectin', 'achieved', 'a', 'heartworm', 'prevention', 'rate', 'of', '100', '%', ',', 'with', 'all', 'dogs', 'testing', 'negative', 'for', 'microfilariae', 'and', 'adult', 'heartworm', 'antigen', 'on', 'days', '180', 'and', '300', '.']","(3, 6)","(21, 46)",-1,hl_o,10940525,Abstract,11,test,gold,4035.0
519,Selamectin was administered to a total of,673 dogs and 347 cats having an age range of 6 weeks to 19 years,( 3954 doses ) .,"['Selamectin', 'was', 'administered', 'to', 'a', 'total', 'of', '673', 'dogs', 'and', '347', 'cats', 'having', 'an', 'age', 'range', 'of', '6', 'weeks', 'to', '19', 'years', '(', '3954', 'doses', ')', '.']","(7, 22)","(41, 105)",-1,ss_p,10940525,Abstract,12,test,gold,5836.0
520,,Selamectin,was administered to a total of 673 dogs and 347 cats having an age range of 6 weeks to 19 years ( 3954 doses ) .,"['Selamectin', 'was', 'administered', 'to', 'a', 'total', 'of', '673', 'dogs', 'and', '347', 'cats', 'having', 'an', 'age', 'range', 'of', '6', 'weeks', 'to', '19', 'years', '(', '3954', 'doses', ')', '.']","(0, 1)","(0, 10)",-1,ss_i,10940525,Abstract,12,test,gold,
521,Selamectin was administered to a total of,673 dogs and 347 cats,having an age range of 6 weeks to 19 years ( 3954 doses ) .,"['Selamectin', 'was', 'administered', 'to', 'a', 'total', 'of', '673', 'dogs', 'and', '347', 'cats', 'having', 'an', 'age', 'range', 'of', '6', 'weeks', 'to', '19', 'years', '(', '3954', 'doses', ')', '.']","(7, 12)","(41, 62)",-1,hl_p,10940525,Abstract,12,test,gold,6067.0
522,,Selamectin,was administered to a total of 673 dogs and 347 cats having an age range of 6 weeks to 19 years ( 3954 doses ) .,"['Selamectin', 'was', 'administered', 'to', 'a', 'total', 'of', '673', 'dogs', 'and', '347', 'cats', 'having', 'an', 'age', 'range', 'of', '6', 'weeks', 'to', '19', 'years', '(', '3954', 'doses', ')', '.']","(0, 1)","(0, 10)",-1,hl_i,10940525,Abstract,12,test,gold,
523,The animals included,"19 purebred or crossbred Collies ( Bearded , Border , and unspecified ) .",,"['The', 'animals', 'included', '19', 'purebred', 'or', 'crossbred', 'Collies', '(', 'Bearded', ',', 'Border', ',', 'and', 'unspecified', ')', '.']","(3, 17)","(20, 93)",-1,ss_p,10940525,Abstract,13,test,gold,6062.0
524,The animals included,"19 purebred or crossbred Collies ( Bearded , Border , and unspecified ) .",,"['The', 'animals', 'included', '19', 'purebred', 'or', 'crossbred', 'Collies', '(', 'Bearded', ',', 'Border', ',', 'and', 'unspecified', ')', '.']","(3, 17)","(20, 93)",-1,hl_p,10940525,Abstract,13,test,gold,6063.0
525,There were no serious,adverse events .,,"['There', 'were', 'no', 'serious', 'adverse', 'events', '.']","(4, 7)","(21, 37)",-1,ss_o,10940525,Abstract,14,test,gold,3071.0
526,There were no serious,adverse events .,,"['There', 'were', 'no', 'serious', 'adverse', 'events', '.']","(4, 7)","(21, 37)",-1,hl_o,10940525,Abstract,14,test,gold,3070.0
527,Results of these studies indicated that selamectin was highly effective in the control of flea infestations,in dogs and cats,without the need for simultaneous treatment of the environment or of in-contact animals and also was beneficial in alleviating signs associated with FAD .,"['Results', 'of', 'these', 'studies', 'indicated', 'that', 'selamectin', 'was', 'highly', 'effective', 'in', 'the', 'control', 'of', 'flea', 'infestations', 'in', 'dogs', 'and', 'cats', 'without', 'the', 'need', 'for', 'simultaneous', 'treatment', 'of', 'the', 'environment', 'or', 'of', 'in-contact', 'animals', 'and', 'also', 'was', 'beneficial', 'in', 'alleviating', 'signs', 'associated', 'with', 'FAD', '.']","(16, 20)","(107, 123)",-1,ss_p,10940525,Abstract,15,test,gold,6072.0
528,Results of these studies indicated that,selamectin,was highly effective in the control of flea infestations in dogs and cats without the need for simultaneous treatment of the environment or of in-contact animals and also was beneficial in alleviating signs associated with FAD .,"['Results', 'of', 'these', 'studies', 'indicated', 'that', 'selamectin', 'was', 'highly', 'effective', 'in', 'the', 'control', 'of', 'flea', 'infestations', 'in', 'dogs', 'and', 'cats', 'without', 'the', 'need', 'for', 'simultaneous', 'treatment', 'of', 'the', 'environment', 'or', 'of', 'in-contact', 'animals', 'and', 'also', 'was', 'beneficial', 'in', 'alleviating', 'signs', 'associated', 'with', 'FAD', '.']","(6, 7)","(39, 49)",-1,ss_i,10940525,Abstract,15,test,gold,
529,Results of these studies indicated that selamectin was highly,effective,in the control of flea infestations in dogs and cats without the need for simultaneous treatment of the environment or of in-contact animals and also was beneficial in alleviating signs associated with FAD .,"['Results', 'of', 'these', 'studies', 'indicated', 'that', 'selamectin', 'was', 'highly', 'effective', 'in', 'the', 'control', 'of', 'flea', 'infestations', 'in', 'dogs', 'and', 'cats', 'without', 'the', 'need', 'for', 'simultaneous', 'treatment', 'of', 'the', 'environment', 'or', 'of', 'in-contact', 'animals', 'and', 'also', 'was', 'beneficial', 'in', 'alleviating', 'signs', 'associated', 'with', 'FAD', '.']","(9, 10)","(61, 70)",-1,ss_o,10940525,Abstract,15,test,gold,859.0
530,Results of these studies indicated that selamectin was highly effective in the control of flea infestations in dogs and cats without the need for simultaneous treatment of the environment or of in-contact animals and also was beneficial in alleviating,signs associated with FAD .,,"['Results', 'of', 'these', 'studies', 'indicated', 'that', 'selamectin', 'was', 'highly', 'effective', 'in', 'the', 'control', 'of', 'flea', 'infestations', 'in', 'dogs', 'and', 'cats', 'without', 'the', 'need', 'for', 'simultaneous', 'treatment', 'of', 'the', 'environment', 'or', 'of', 'in-contact', 'animals', 'and', 'also', 'was', 'beneficial', 'in', 'alleviating', 'signs', 'associated', 'with', 'FAD', '.']","(39, 44)","(251, 278)",-1,ss_o,10940525,Abstract,15,test,gold,1869.0
531,Results of these studies indicated that selamectin was highly effective in the control of flea infestations in,dogs and cats,without the need for simultaneous treatment of the environment or of in-contact animals and also was beneficial in alleviating signs associated with FAD .,"['Results', 'of', 'these', 'studies', 'indicated', 'that', 'selamectin', 'was', 'highly', 'effective', 'in', 'the', 'control', 'of', 'flea', 'infestations', 'in', 'dogs', 'and', 'cats', 'without', 'the', 'need', 'for', 'simultaneous', 'treatment', 'of', 'the', 'environment', 'or', 'of', 'in-contact', 'animals', 'and', 'also', 'was', 'beneficial', 'in', 'alleviating', 'signs', 'associated', 'with', 'FAD', '.']","(17, 20)","(110, 123)",-1,hl_p,10940525,Abstract,15,test,gold,6066.0
532,Results of these studies indicated that,selamectin,was highly effective in the control of flea infestations in dogs and cats without the need for simultaneous treatment of the environment or of in-contact animals and also was beneficial in alleviating signs associated with FAD .,"['Results', 'of', 'these', 'studies', 'indicated', 'that', 'selamectin', 'was', 'highly', 'effective', 'in', 'the', 'control', 'of', 'flea', 'infestations', 'in', 'dogs', 'and', 'cats', 'without', 'the', 'need', 'for', 'simultaneous', 'treatment', 'of', 'the', 'environment', 'or', 'of', 'in-contact', 'animals', 'and', 'also', 'was', 'beneficial', 'in', 'alleviating', 'signs', 'associated', 'with', 'FAD', '.']","(6, 7)","(39, 49)",-1,hl_i,10940525,Abstract,15,test,gold,
533,Results of these studies indicated that selamectin was highly,effective,in the control of flea infestations in dogs and cats without the need for simultaneous treatment of the environment or of in-contact animals and also was beneficial in alleviating signs associated with FAD .,"['Results', 'of', 'these', 'studies', 'indicated', 'that', 'selamectin', 'was', 'highly', 'effective', 'in', 'the', 'control', 'of', 'flea', 'infestations', 'in', 'dogs', 'and', 'cats', 'without', 'the', 'need', 'for', 'simultaneous', 'treatment', 'of', 'the', 'environment', 'or', 'of', 'in-contact', 'animals', 'and', 'also', 'was', 'beneficial', 'in', 'alleviating', 'signs', 'associated', 'with', 'FAD', '.']","(9, 10)","(61, 70)",-1,hl_o,10940525,Abstract,15,test,gold,860.0
534,Results of these studies indicated that selamectin was highly effective in the control of flea infestations in dogs and cats without the need for simultaneous treatment of the environment or of in-contact animals and also was beneficial in alleviating,signs associated with FAD .,,"['Results', 'of', 'these', 'studies', 'indicated', 'that', 'selamectin', 'was', 'highly', 'effective', 'in', 'the', 'control', 'of', 'flea', 'infestations', 'in', 'dogs', 'and', 'cats', 'without', 'the', 'need', 'for', 'simultaneous', 'treatment', 'of', 'the', 'environment', 'or', 'of', 'in-contact', 'animals', 'and', 'also', 'was', 'beneficial', 'in', 'alleviating', 'signs', 'associated', 'with', 'FAD', '.']","(39, 44)","(251, 278)",-1,hl_o,10940525,Abstract,15,test,gold,1870.0
535,Selamectin also was 100 % effective in preventing the development of canine heartworms and was safe for topical use in,dogs and cats .,,"['Selamectin', 'also', 'was', '100', '%', 'effective', 'in', 'preventing', 'the', 'development', 'of', 'canine', 'heartworms', 'and', 'was', 'safe', 'for', 'topical', 'use', 'in', 'dogs', 'and', 'cats', '.']","(20, 24)","(118, 133)",-1,ss_p,10940525,Abstract,16,test,gold,6065.0
536,,Selamectin,also was 100 % effective in preventing the development of canine heartworms and was safe for topical use in dogs and cats .,"['Selamectin', 'also', 'was', '100', '%', 'effective', 'in', 'preventing', 'the', 'development', 'of', 'canine', 'heartworms', 'and', 'was', 'safe', 'for', 'topical', 'use', 'in', 'dogs', 'and', 'cats', '.']","(0, 1)","(0, 10)",-1,ss_i,10940525,Abstract,16,test,gold,
537,Selamectin also was 100 %,effective,in preventing the development of canine heartworms and was safe for topical use in dogs and cats .,"['Selamectin', 'also', 'was', '100', '%', 'effective', 'in', 'preventing', 'the', 'development', 'of', 'canine', 'heartworms', 'and', 'was', 'safe', 'for', 'topical', 'use', 'in', 'dogs', 'and', 'cats', '.']","(5, 6)","(25, 34)",-1,ss_o,10940525,Abstract,16,test,gold,858.0
538,Selamectin also was 100 % effective in preventing the development of canine,heartworms,and was safe for topical use in dogs and cats .,"['Selamectin', 'also', 'was', '100', '%', 'effective', 'in', 'preventing', 'the', 'development', 'of', 'canine', 'heartworms', 'and', 'was', 'safe', 'for', 'topical', 'use', 'in', 'dogs', 'and', 'cats', '.']","(12, 13)","(75, 85)",-1,ss_o,10940525,Abstract,16,test,gold,235.0
539,Selamectin also was 100 % effective in preventing the development of canine heartworms and was,safe,for topical use in dogs and cats .,"['Selamectin', 'also', 'was', '100', '%', 'effective', 'in', 'preventing', 'the', 'development', 'of', 'canine', 'heartworms', 'and', 'was', 'safe', 'for', 'topical', 'use', 'in', 'dogs', 'and', 'cats', '.']","(15, 16)","(94, 98)",-1,ss_o,10940525,Abstract,16,test,gold,888.0
540,Selamectin also was 100 % effective in preventing the development of canine heartworms and was safe for topical use in,dogs and cats .,,"['Selamectin', 'also', 'was', '100', '%', 'effective', 'in', 'preventing', 'the', 'development', 'of', 'canine', 'heartworms', 'and', 'was', 'safe', 'for', 'topical', 'use', 'in', 'dogs', 'and', 'cats', '.']","(20, 24)","(118, 133)",-1,hl_p,10940525,Abstract,16,test,gold,6064.0
541,,Selamectin,also was 100 % effective in preventing the development of canine heartworms and was safe for topical use in dogs and cats .,"['Selamectin', 'also', 'was', '100', '%', 'effective', 'in', 'preventing', 'the', 'development', 'of', 'canine', 'heartworms', 'and', 'was', 'safe', 'for', 'topical', 'use', 'in', 'dogs', 'and', 'cats', '.']","(0, 1)","(0, 10)",-1,hl_i,10940525,Abstract,16,test,gold,
542,Selamectin also was 100 % effective in preventing the development of canine,heartworms,and was safe for topical use in dogs and cats .,"['Selamectin', 'also', 'was', '100', '%', 'effective', 'in', 'preventing', 'the', 'development', 'of', 'canine', 'heartworms', 'and', 'was', 'safe', 'for', 'topical', 'use', 'in', 'dogs', 'and', 'cats', '.']","(12, 13)","(75, 85)",-1,hl_o,10940525,Abstract,16,test,gold,236.0
543,Selamectin also was 100 % effective in preventing the development of canine heartworms and was,safe,for topical use in dogs and cats .,"['Selamectin', 'also', 'was', '100', '%', 'effective', 'in', 'preventing', 'the', 'development', 'of', 'canine', 'heartworms', 'and', 'was', 'safe', 'for', 'topical', 'use', 'in', 'dogs', 'and', 'cats', '.']","(15, 16)","(94, 98)",-1,hl_o,10940525,Abstract,16,test,gold,887.0
544,Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of,acute invasive diarrhea in children .,,"['Oral', 'ciprofloxacin', 'vs.', 'intramuscular', 'ceftriaxone', 'as', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'children', '.']","(9, 15)","(72, 109)",-1,ss_p,11099086,Title,0,test,gold,3601.0
545,Oral,ciprofloxacin,vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children .,"['Oral', 'ciprofloxacin', 'vs.', 'intramuscular', 'ceftriaxone', 'as', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'children', '.']","(1, 2)","(4, 17)",-1,ss_i,11099086,Title,0,test,gold,4992.0
546,Oral ciprofloxacin vs. intramuscular,ceftriaxone,as empiric treatment of acute invasive diarrhea in children .,"['Oral', 'ciprofloxacin', 'vs.', 'intramuscular', 'ceftriaxone', 'as', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'children', '.']","(4, 5)","(36, 47)",-1,ss_i,11099086,Title,0,test,gold,5769.0
547,Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of,acute invasive diarrhea,in children .,"['Oral', 'ciprofloxacin', 'vs.', 'intramuscular', 'ceftriaxone', 'as', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'children', '.']","(9, 12)","(72, 95)",-1,hl_p,11099086,Title,0,test,gold,3599.0
548,Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in,children,.,"['Oral', 'ciprofloxacin', 'vs.', 'intramuscular', 'ceftriaxone', 'as', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'children', '.']","(13, 14)","(99, 107)",-1,hl_p,11099086,Title,0,test,gold,2147.0
549,Oral,ciprofloxacin,vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children .,"['Oral', 'ciprofloxacin', 'vs.', 'intramuscular', 'ceftriaxone', 'as', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'children', '.']","(1, 2)","(4, 17)",-1,hl_i,11099086,Title,0,test,gold,4993.0
550,Oral ciprofloxacin vs. intramuscular,ceftriaxone,as empiric treatment of acute invasive diarrhea in children .,"['Oral', 'ciprofloxacin', 'vs.', 'intramuscular', 'ceftriaxone', 'as', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'children', '.']","(4, 5)","(36, 47)",-1,hl_i,11099086,Title,0,test,gold,5770.0
551,BACKGROUND,Acute invasive diarrhea,is a potentially serious condition in children .,"['BACKGROUND', 'Acute', 'invasive', 'diarrhea', 'is', 'a', 'potentially', 'serious', 'condition', 'in', 'children', '.']","(1, 4)","(10, 33)",-1,ss_p,11099086,Abstract,0,test,gold,3598.0
552,BACKGROUND Acute invasive diarrhea is a potentially serious condition,in children .,,"['BACKGROUND', 'Acute', 'invasive', 'diarrhea', 'is', 'a', 'potentially', 'serious', 'condition', 'in', 'children', '.']","(9, 12)","(69, 82)",-1,ss_p,11099086,Abstract,0,test,gold,2152.0
553,BACKGROUND Acute invasive diarrhea is a potentially serious condition in,children .,,"['BACKGROUND', 'Acute', 'invasive', 'diarrhea', 'is', 'a', 'potentially', 'serious', 'condition', 'in', 'children', '.']","(10, 12)","(72, 82)",-1,hl_p,11099086,Abstract,0,test,gold,2146.0
554,"Because of the increasing resistance of enteric pathogens to commonly used oral antibiotics , intramuscular ceftriaxone has become the routine drug in the treatment of",acute invasive diarrhea requiring an emergency visit in southern Israel .,,"['Because', 'of', 'the', 'increasing', 'resistance', 'of', 'enteric', 'pathogens', 'to', 'commonly', 'used', 'oral', 'antibiotics', ',', 'intramuscular', 'ceftriaxone', 'has', 'become', 'the', 'routine', 'drug', 'in', 'the', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'requiring', 'an', 'emergency', 'visit', 'in', 'southern', 'Israel', '.']","(25, 36)","(167, 240)",-1,ss_p,11099086,Abstract,1,test,gold,5881.0
555,"Because of the increasing resistance of enteric pathogens to commonly used oral antibiotics , intramuscular",ceftriaxone,has become the routine drug in the treatment of acute invasive diarrhea requiring an emergency visit in southern Israel .,"['Because', 'of', 'the', 'increasing', 'resistance', 'of', 'enteric', 'pathogens', 'to', 'commonly', 'used', 'oral', 'antibiotics', ',', 'intramuscular', 'ceftriaxone', 'has', 'become', 'the', 'routine', 'drug', 'in', 'the', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'requiring', 'an', 'emergency', 'visit', 'in', 'southern', 'Israel', '.']","(15, 16)","(107, 118)",-1,ss_i,11099086,Abstract,1,test,gold,5768.0
556,"Because of the increasing resistance of enteric pathogens to commonly used oral antibiotics , intramuscular",ceftriaxone,has become the routine drug in the treatment of acute invasive diarrhea requiring an emergency visit in southern Israel .,"['Because', 'of', 'the', 'increasing', 'resistance', 'of', 'enteric', 'pathogens', 'to', 'commonly', 'used', 'oral', 'antibiotics', ',', 'intramuscular', 'ceftriaxone', 'has', 'become', 'the', 'routine', 'drug', 'in', 'the', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'requiring', 'an', 'emergency', 'visit', 'in', 'southern', 'Israel', '.']","(15, 16)","(107, 118)",-1,hl_i,11099086,Abstract,1,test,gold,5767.0
557,The inconvenience of this parenteral regimen created an increased need for oral pediatric formulations for the treatment of,invasive diarrhea .,,"['The', 'inconvenience', 'of', 'this', 'parenteral', 'regimen', 'created', 'an', 'increased', 'need', 'for', 'oral', 'pediatric', 'formulations', 'for', 'the', 'treatment', 'of', 'invasive', 'diarrhea', '.']","(18, 21)","(123, 142)",-1,ss_p,11099086,Abstract,2,test,gold,3597.0
558,OBJECTIVES To evaluate the efficacy and safety of a suspension formulation of ciprofloxacin in the treatment of,acute invasive diarrhea in infants and children .,,"['OBJECTIVES', 'To', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'a', 'suspension', 'formulation', 'of', 'ciprofloxacin', 'in', 'the', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'infants', 'and', 'children', '.']","(17, 25)","(111, 160)",-1,ss_p,11099086,Abstract,3,test,gold,3602.0
559,OBJECTIVES To evaluate the efficacy and safety of a suspension formulation of,ciprofloxacin,in the treatment of acute invasive diarrhea in infants and children .,"['OBJECTIVES', 'To', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'a', 'suspension', 'formulation', 'of', 'ciprofloxacin', 'in', 'the', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'infants', 'and', 'children', '.']","(12, 13)","(77, 90)",-1,ss_i,11099086,Abstract,3,test,gold,4991.0
560,OBJECTIVES To evaluate the,efficacy,and safety of a suspension formulation of ciprofloxacin in the treatment of acute invasive diarrhea in infants and children .,"['OBJECTIVES', 'To', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'a', 'suspension', 'formulation', 'of', 'ciprofloxacin', 'in', 'the', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'infants', 'and', 'children', '.']","(4, 5)","(26, 34)",-1,ss_o,11099086,Abstract,3,test,gold,4837.0
561,OBJECTIVES To evaluate the efficacy and,safety,of a suspension formulation of ciprofloxacin in the treatment of acute invasive diarrhea in infants and children .,"['OBJECTIVES', 'To', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'a', 'suspension', 'formulation', 'of', 'ciprofloxacin', 'in', 'the', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'infants', 'and', 'children', '.']","(6, 7)","(39, 45)",-1,ss_o,11099086,Abstract,3,test,gold,489.0
562,OBJECTIVES To evaluate the efficacy and safety of a suspension formulation of ciprofloxacin in the treatment of,acute invasive diarrhea,in infants and children .,"['OBJECTIVES', 'To', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'a', 'suspension', 'formulation', 'of', 'ciprofloxacin', 'in', 'the', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'infants', 'and', 'children', '.']","(17, 20)","(111, 134)",-1,hl_p,11099086,Abstract,3,test,gold,3600.0
563,OBJECTIVES To evaluate the efficacy and safety of a suspension formulation of ciprofloxacin in the treatment of acute invasive diarrhea in,infants and children,.,"['OBJECTIVES', 'To', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'a', 'suspension', 'formulation', 'of', 'ciprofloxacin', 'in', 'the', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'infants', 'and', 'children', '.']","(21, 24)","(138, 158)",-1,hl_p,11099086,Abstract,3,test,gold,2166.0
564,OBJECTIVES To evaluate the efficacy and safety of a suspension formulation of,ciprofloxacin,in the treatment of acute invasive diarrhea in infants and children .,"['OBJECTIVES', 'To', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'a', 'suspension', 'formulation', 'of', 'ciprofloxacin', 'in', 'the', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'infants', 'and', 'children', '.']","(12, 13)","(77, 90)",-1,hl_i,11099086,Abstract,3,test,gold,4990.0
565,OBJECTIVES To evaluate the,efficacy,and safety of a suspension formulation of ciprofloxacin in the treatment of acute invasive diarrhea in infants and children .,"['OBJECTIVES', 'To', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'a', 'suspension', 'formulation', 'of', 'ciprofloxacin', 'in', 'the', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'infants', 'and', 'children', '.']","(4, 5)","(26, 34)",-1,hl_o,11099086,Abstract,3,test,gold,4836.0
566,OBJECTIVES To evaluate the efficacy and,safety,of a suspension formulation of ciprofloxacin in the treatment of acute invasive diarrhea in infants and children .,"['OBJECTIVES', 'To', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'a', 'suspension', 'formulation', 'of', 'ciprofloxacin', 'in', 'the', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'infants', 'and', 'children', '.']","(6, 7)","(39, 45)",-1,hl_o,11099086,Abstract,3,test,gold,488.0
567,"PATIENTS AND METHODS From July 1996 through December 1997 ,",201 evaluable children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room,were randomized to receive either ciprofloxacin suspension ( 10 mg/kg twice a day + im placebo ; n = 95 ) or im ceftriaxone ( 50 mg/kg/day + placebo suspension ; n = 106 ) for 3 days in a double blind manner .,"['PATIENTS', 'AND', 'METHODS', 'From', 'July', '1996', 'through', 'December', '1997', ',', '201', 'evaluable', 'children', 'ages', '6', 'months', 'to', '10', 'years', '(', '35', '%', '<', '1', 'year', ';', '70', '%', '<', '3', 'years', ')', 'presenting', 'with', 'acute', 'invasive', 'diarrhea', 'at', 'the', 'Pediatric', 'Emergency', 'Room', 'were', 'randomized', 'to', 'receive', 'either', 'ciprofloxacin', 'suspension', '(', '10', 'mg/kg', 'twice', 'a', 'day', '+', 'im', 'placebo', ';', 'n', '=', '95', ')', 'or', 'im', 'ceftriaxone', '(', '50', 'mg/kg/day', '+', 'placebo', 'suspension', ';', 'n', '=', '106', ')', 'for', '3', 'days', 'in', 'a', 'double', 'blind', 'manner', '.']","(10, 42)","(59, 214)",-1,ss_p,11099086,Abstract,4,test,gold,5873.0
568,"PATIENTS AND METHODS From July 1996 through December 1997 , 201 evaluable children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room were randomized to receive either",ciprofloxacin,suspension ( 10 mg/kg twice a day + im placebo ; n = 95 ) or im ceftriaxone ( 50 mg/kg/day + placebo suspension ; n = 106 ) for 3 days in a double blind manner .,"['PATIENTS', 'AND', 'METHODS', 'From', 'July', '1996', 'through', 'December', '1997', ',', '201', 'evaluable', 'children', 'ages', '6', 'months', 'to', '10', 'years', '(', '35', '%', '<', '1', 'year', ';', '70', '%', '<', '3', 'years', ')', 'presenting', 'with', 'acute', 'invasive', 'diarrhea', 'at', 'the', 'Pediatric', 'Emergency', 'Room', 'were', 'randomized', 'to', 'receive', 'either', 'ciprofloxacin', 'suspension', '(', '10', 'mg/kg', 'twice', 'a', 'day', '+', 'im', 'placebo', ';', 'n', '=', '95', ')', 'or', 'im', 'ceftriaxone', '(', '50', 'mg/kg/day', '+', 'placebo', 'suspension', ';', 'n', '=', '106', ')', 'for', '3', 'days', 'in', 'a', 'double', 'blind', 'manner', '.']","(47, 48)","(249, 262)",-1,ss_i,11099086,Abstract,4,test,gold,4989.0
569,"PATIENTS AND METHODS From July 1996 through December 1997 , 201 evaluable children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room were randomized to receive either ciprofloxacin suspension ( 10 mg/kg twice a day + im placebo ; n = 95 ) or im",ceftriaxone,( 50 mg/kg/day + placebo suspension ; n = 106 ) for 3 days in a double blind manner .,"['PATIENTS', 'AND', 'METHODS', 'From', 'July', '1996', 'through', 'December', '1997', ',', '201', 'evaluable', 'children', 'ages', '6', 'months', 'to', '10', 'years', '(', '35', '%', '<', '1', 'year', ';', '70', '%', '<', '3', 'years', ')', 'presenting', 'with', 'acute', 'invasive', 'diarrhea', 'at', 'the', 'Pediatric', 'Emergency', 'Room', 'were', 'randomized', 'to', 'receive', 'either', 'ciprofloxacin', 'suspension', '(', '10', 'mg/kg', 'twice', 'a', 'day', '+', 'im', 'placebo', ';', 'n', '=', '95', ')', 'or', 'im', 'ceftriaxone', '(', '50', 'mg/kg/day', '+', 'placebo', 'suspension', ';', 'n', '=', '106', ')', 'for', '3', 'days', 'in', 'a', 'double', 'blind', 'manner', '.']","(65, 66)","(327, 338)",-1,ss_i,11099086,Abstract,4,test,gold,5766.0
570,"PATIENTS AND METHODS From July 1996 through December 1997 ,",201,evaluable children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room were randomized to receive either ciprofloxacin suspension ( 10 mg/kg twice a day + im placebo ; n = 95 ) or im ceftriaxone ( 50 mg/kg/day + placebo suspension ; n = 106 ) for 3 days in a double blind manner .,"['PATIENTS', 'AND', 'METHODS', 'From', 'July', '1996', 'through', 'December', '1997', ',', '201', 'evaluable', 'children', 'ages', '6', 'months', 'to', '10', 'years', '(', '35', '%', '<', '1', 'year', ';', '70', '%', '<', '3', 'years', ')', 'presenting', 'with', 'acute', 'invasive', 'diarrhea', 'at', 'the', 'Pediatric', 'Emergency', 'Room', 'were', 'randomized', 'to', 'receive', 'either', 'ciprofloxacin', 'suspension', '(', '10', 'mg/kg', 'twice', 'a', 'day', '+', 'im', 'placebo', ';', 'n', '=', '95', ')', 'or', 'im', 'ceftriaxone', '(', '50', 'mg/kg/day', '+', 'placebo', 'suspension', ';', 'n', '=', '106', ')', 'for', '3', 'days', 'in', 'a', 'double', 'blind', 'manner', '.']","(10, 11)","(59, 62)",-1,hl_p,11099086,Abstract,4,test,gold,
571,"PATIENTS AND METHODS From July 1996 through December 1997 , 201 evaluable",children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room,were randomized to receive either ciprofloxacin suspension ( 10 mg/kg twice a day + im placebo ; n = 95 ) or im ceftriaxone ( 50 mg/kg/day + placebo suspension ; n = 106 ) for 3 days in a double blind manner .,"['PATIENTS', 'AND', 'METHODS', 'From', 'July', '1996', 'through', 'December', '1997', ',', '201', 'evaluable', 'children', 'ages', '6', 'months', 'to', '10', 'years', '(', '35', '%', '<', '1', 'year', ';', '70', '%', '<', '3', 'years', ')', 'presenting', 'with', 'acute', 'invasive', 'diarrhea', 'at', 'the', 'Pediatric', 'Emergency', 'Room', 'were', 'randomized', 'to', 'receive', 'either', 'ciprofloxacin', 'suspension', '(', '10', 'mg/kg', 'twice', 'a', 'day', '+', 'im', 'placebo', ';', 'n', '=', '95', ')', 'or', 'im', 'ceftriaxone', '(', '50', 'mg/kg/day', '+', 'placebo', 'suspension', ';', 'n', '=', '106', ')', 'for', '3', 'days', 'in', 'a', 'double', 'blind', 'manner', '.']","(12, 42)","(73, 214)",-1,hl_p,11099086,Abstract,4,test,gold,5874.0
572,"PATIENTS AND METHODS From July 1996 through December 1997 , 201 evaluable children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room were randomized to receive either",ciprofloxacin,suspension ( 10 mg/kg twice a day + im placebo ; n = 95 ) or im ceftriaxone ( 50 mg/kg/day + placebo suspension ; n = 106 ) for 3 days in a double blind manner .,"['PATIENTS', 'AND', 'METHODS', 'From', 'July', '1996', 'through', 'December', '1997', ',', '201', 'evaluable', 'children', 'ages', '6', 'months', 'to', '10', 'years', '(', '35', '%', '<', '1', 'year', ';', '70', '%', '<', '3', 'years', ')', 'presenting', 'with', 'acute', 'invasive', 'diarrhea', 'at', 'the', 'Pediatric', 'Emergency', 'Room', 'were', 'randomized', 'to', 'receive', 'either', 'ciprofloxacin', 'suspension', '(', '10', 'mg/kg', 'twice', 'a', 'day', '+', 'im', 'placebo', ';', 'n', '=', '95', ')', 'or', 'im', 'ceftriaxone', '(', '50', 'mg/kg/day', '+', 'placebo', 'suspension', ';', 'n', '=', '106', ')', 'for', '3', 'days', 'in', 'a', 'double', 'blind', 'manner', '.']","(47, 48)","(249, 262)",-1,hl_i,11099086,Abstract,4,test,gold,4988.0
573,"PATIENTS AND METHODS From July 1996 through December 1997 , 201 evaluable children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room were randomized to receive either ciprofloxacin suspension ( 10 mg/kg twice a day + im placebo ; n = 95 ) or im",ceftriaxone,( 50 mg/kg/day + placebo suspension ; n = 106 ) for 3 days in a double blind manner .,"['PATIENTS', 'AND', 'METHODS', 'From', 'July', '1996', 'through', 'December', '1997', ',', '201', 'evaluable', 'children', 'ages', '6', 'months', 'to', '10', 'years', '(', '35', '%', '<', '1', 'year', ';', '70', '%', '<', '3', 'years', ')', 'presenting', 'with', 'acute', 'invasive', 'diarrhea', 'at', 'the', 'Pediatric', 'Emergency', 'Room', 'were', 'randomized', 'to', 'receive', 'either', 'ciprofloxacin', 'suspension', '(', '10', 'mg/kg', 'twice', 'a', 'day', '+', 'im', 'placebo', ';', 'n', '=', '95', ')', 'or', 'im', 'ceftriaxone', '(', '50', 'mg/kg/day', '+', 'placebo', 'suspension', ';', 'n', '=', '106', ')', 'for', '3', 'days', 'in', 'a', 'double', 'blind', 'manner', '.']","(65, 66)","(327, 338)",-1,hl_i,11099086,Abstract,4,test,gold,5765.0
574,,"Stool cultures for Shigella , Salmonella , Campylobacter spp .",,"['Stool', 'cultures', 'for', 'Shigella', ',', 'Salmonella', ',', 'Campylobacter', 'spp', '.']","(0, 10)","(0, 62)",-1,ss_o,11099086,Abstract,5,test,gold,6643.0
575,,"Stool cultures for Shigella , Salmonella , Campylobacter spp .",,"['Stool', 'cultures', 'for', 'Shigella', ',', 'Salmonella', ',', 'Campylobacter', 'spp', '.']","(0, 10)","(0, 62)",-1,hl_o,11099086,Abstract,5,test,gold,6644.0
576,,and diarrheagenic Escherichia coli,"were obtained on Days 1 , 3 , 4 to 5 and 21 +/- 5 .","['and', 'diarrheagenic', 'Escherichia', 'coli', 'were', 'obtained', 'on', 'Days', '1', ',', '3', ',', '4', 'to', '5', 'and', '21', '+/-', '5', '.']","(0, 4)","(0, 34)",-1,ss_o,11099086,Abstract,6,test,gold,213.0
577,,and diarrheagenic Escherichia coli,"were obtained on Days 1 , 3 , 4 to 5 and 21 +/- 5 .","['and', 'diarrheagenic', 'Escherichia', 'coli', 'were', 'obtained', 'on', 'Days', '1', ',', '3', ',', '4', 'to', '5', 'and', '21', '+/-', '5', '.']","(0, 4)","(0, 34)",-1,hl_o,11099086,Abstract,6,test,gold,214.0
578,,Clinical response and safety,"were assessed on Days 1 , 2 , 3 , 4 to 5 and 21 +/- 5 .","['Clinical', 'response', 'and', 'safety', 'were', 'assessed', 'on', 'Days', '1', ',', '2', ',', '3', ',', '4', 'to', '5', 'and', '21', '+/-', '5', '.']","(0, 4)","(0, 28)",-1,ss_o,11099086,Abstract,7,test,gold,2515.0
579,,Clinical response and safety,"were assessed on Days 1 , 2 , 3 , 4 to 5 and 21 +/- 5 .","['Clinical', 'response', 'and', 'safety', 'were', 'assessed', 'on', 'Days', '1', ',', '2', ',', '3', ',', '4', 'to', '5', 'and', '21', '+/-', '5', '.']","(0, 4)","(0, 28)",-1,hl_o,11099086,Abstract,7,test,gold,2516.0
580,RESULTS We isolated 127 pathogens from 121 ( 60 % ) patients : 73 ( 57 % ) Shigella ; 23 ( 18 % ) Salmonella ; 18 ( 14 % ) E. coli ; and 13 ( 10 % ) Campylobacter .,,,"['RESULTS', 'We', 'isolated', '127', 'pathogens', 'from', '121', '(', '60', '%', ')', 'patients', ':', '73', '(', '57', '%', ')', 'Shigella', ';', '23', '(', '18', '%', ')', 'Salmonella', ';', '18', '(', '14', '%', ')', 'E.', 'coli', ';', 'and', '13', '(', '10', '%', ')', 'Campylobacter', '.']",,,,,11099086,Abstract,8,test,gold,
581,"Overall bacteriologic eradication on Day 4 to 5 was 99 % for Shigella , 77 % for Salmonella and 77 % for Campylobacter , with no difference between the 2 groups .",,,"['Overall', 'bacteriologic', 'eradication', 'on', 'Day', '4', 'to', '5', 'was', '99', '%', 'for', 'Shigella', ',', '77', '%', 'for', 'Salmonella', 'and', '77', '%', 'for', 'Campylobacter', ',', 'with', 'no', 'difference', 'between', 'the', '2', 'groups', '.']",,,,,11099086,Abstract,9,test,gold,
582,Clinical cure or improvement was observed in 100 and 99 % of the,ciprofloxacin,"and ceftriaxone groups , respectively .","['Clinical', 'cure', 'or', 'improvement', 'was', 'observed', 'in', '100', 'and', '99', '%', 'of', 'the', 'ciprofloxacin', 'and', 'ceftriaxone', 'groups', ',', 'respectively', '.']","(13, 14)","(64, 77)",-1,ss_i,11099086,Abstract,10,test,gold,4987.0
583,Clinical cure or improvement was observed in 100 and 99 % of the ciprofloxacin and,ceftriaxone,"groups , respectively .","['Clinical', 'cure', 'or', 'improvement', 'was', 'observed', 'in', '100', 'and', '99', '%', 'of', 'the', 'ciprofloxacin', 'and', 'ceftriaxone', 'groups', ',', 'respectively', '.']","(15, 16)","(82, 93)",-1,ss_i,11099086,Abstract,10,test,gold,5764.0
584,,Clinical cure or improvement,"was observed in 100 and 99 % of the ciprofloxacin and ceftriaxone groups , respectively .","['Clinical', 'cure', 'or', 'improvement', 'was', 'observed', 'in', '100', 'and', '99', '%', 'of', 'the', 'ciprofloxacin', 'and', 'ceftriaxone', 'groups', ',', 'respectively', '.']","(0, 4)","(0, 28)",-1,ss_o,11099086,Abstract,10,test,gold,4759.0
585,Clinical cure or improvement was observed in 100 and 99 % of the,ciprofloxacin,"and ceftriaxone groups , respectively .","['Clinical', 'cure', 'or', 'improvement', 'was', 'observed', 'in', '100', 'and', '99', '%', 'of', 'the', 'ciprofloxacin', 'and', 'ceftriaxone', 'groups', ',', 'respectively', '.']","(13, 14)","(64, 77)",-1,hl_i,11099086,Abstract,10,test,gold,4986.0
586,Clinical cure or improvement was observed in 100 and 99 % of the ciprofloxacin and,ceftriaxone,"groups , respectively .","['Clinical', 'cure', 'or', 'improvement', 'was', 'observed', 'in', '100', 'and', '99', '%', 'of', 'the', 'ciprofloxacin', 'and', 'ceftriaxone', 'groups', ',', 'respectively', '.']","(15, 16)","(82, 93)",-1,hl_i,11099086,Abstract,10,test,gold,5763.0
587,,Clinical cure or improvement,"was observed in 100 and 99 % of the ciprofloxacin and ceftriaxone groups , respectively .","['Clinical', 'cure', 'or', 'improvement', 'was', 'observed', 'in', '100', 'and', '99', '%', 'of', 'the', 'ciprofloxacin', 'and', 'ceftriaxone', 'groups', ',', 'respectively', '.']","(0, 4)","(0, 28)",-1,hl_o,11099086,Abstract,10,test,gold,4760.0
588,Serum,ciprofloxacin,values determined on Day 3 of the treatment were higher in the majority of patients than were the MIC50 and MIC90 values for the Shigella and Salmonella spp .,"['Serum', 'ciprofloxacin', 'values', 'determined', 'on', 'Day', '3', 'of', 'the', 'treatment', 'were', 'higher', 'in', 'the', 'majority', 'of', 'patients', 'than', 'were', 'the', 'MIC50', 'and', 'MIC90', 'values', 'for', 'the', 'Shigella', 'and', 'Salmonella', 'spp', '.']","(1, 2)","(5, 18)",-1,ss_i,11099086,Abstract,11,test,gold,4985.0
589,Serum,ciprofloxacin,values determined on Day 3 of the treatment were higher in the majority of patients than were the MIC50 and MIC90 values for the Shigella and Salmonella spp .,"['Serum', 'ciprofloxacin', 'values', 'determined', 'on', 'Day', '3', 'of', 'the', 'treatment', 'were', 'higher', 'in', 'the', 'majority', 'of', 'patients', 'than', 'were', 'the', 'MIC50', 'and', 'MIC90', 'values', 'for', 'the', 'Shigella', 'and', 'Salmonella', 'spp', '.']","(1, 2)","(5, 18)",-1,hl_i,11099086,Abstract,11,test,gold,4984.0
590,isolated .,,,"['isolated', '.']",,,,,11099086,Abstract,12,test,gold,
591,Possible drug-related adverse events occurred in 13 patients,[ ciprofloxacin,", 8 ( 8 % ) ; ceftriaxone , 5 ( 4.7 % ) ] and were mild and transient .","['Possible', 'drug-related', 'adverse', 'events', 'occurred', 'in', '13', 'patients', '[', 'ciprofloxacin', ',', '8', '(', '8', '%', ')', ';', 'ceftriaxone', ',', '5', '(', '4.7', '%', ')', ']', 'and', 'were', 'mild', 'and', 'transient', '.']","(8, 10)","(60, 75)",-1,ss_i,11099086,Abstract,13,test,gold,4983.0
592,"Possible drug-related adverse events occurred in 13 patients [ ciprofloxacin , 8 ( 8 % ) ;",ceftriaxone,", 5 ( 4.7 % ) ] and were mild and transient .","['Possible', 'drug-related', 'adverse', 'events', 'occurred', 'in', '13', 'patients', '[', 'ciprofloxacin', ',', '8', '(', '8', '%', ')', ';', 'ceftriaxone', ',', '5', '(', '4.7', '%', ')', ']', 'and', 'were', 'mild', 'and', 'transient', '.']","(17, 18)","(90, 101)",-1,ss_i,11099086,Abstract,13,test,gold,5762.0
593,Possible drug-related,adverse events,"occurred in 13 patients [ ciprofloxacin , 8 ( 8 % ) ; ceftriaxone , 5 ( 4.7 % ) ] and were mild and transient .","['Possible', 'drug-related', 'adverse', 'events', 'occurred', 'in', '13', 'patients', '[', 'ciprofloxacin', ',', '8', '(', '8', '%', ')', ';', 'ceftriaxone', ',', '5', '(', '4.7', '%', ')', ']', 'and', 'were', 'mild', 'and', 'transient', '.']","(2, 4)","(21, 35)",-1,ss_o,11099086,Abstract,13,test,gold,3069.0
594,Possible drug-related adverse events occurred in 13 patients [,ciprofloxacin,", 8 ( 8 % ) ; ceftriaxone , 5 ( 4.7 % ) ] and were mild and transient .","['Possible', 'drug-related', 'adverse', 'events', 'occurred', 'in', '13', 'patients', '[', 'ciprofloxacin', ',', '8', '(', '8', '%', ')', ';', 'ceftriaxone', ',', '5', '(', '4.7', '%', ')', ']', 'and', 'were', 'mild', 'and', 'transient', '.']","(9, 10)","(62, 75)",-1,hl_i,11099086,Abstract,13,test,gold,4982.0
595,"Possible drug-related adverse events occurred in 13 patients [ ciprofloxacin , 8 ( 8 % ) ;",ceftriaxone,", 5 ( 4.7 % ) ] and were mild and transient .","['Possible', 'drug-related', 'adverse', 'events', 'occurred', 'in', '13', 'patients', '[', 'ciprofloxacin', ',', '8', '(', '8', '%', ')', ';', 'ceftriaxone', ',', '5', '(', '4.7', '%', ')', ']', 'and', 'were', 'mild', 'and', 'transient', '.']","(17, 18)","(90, 101)",-1,hl_i,11099086,Abstract,13,test,gold,5761.0
596,Possible drug-related,adverse events,"occurred in 13 patients [ ciprofloxacin , 8 ( 8 % ) ; ceftriaxone , 5 ( 4.7 % ) ] and were mild and transient .","['Possible', 'drug-related', 'adverse', 'events', 'occurred', 'in', '13', 'patients', '[', 'ciprofloxacin', ',', '8', '(', '8', '%', ')', ';', 'ceftriaxone', ',', '5', '(', '4.7', '%', ')', ']', 'and', 'were', 'mild', 'and', 'transient', '.']","(2, 4)","(21, 35)",-1,hl_o,11099086,Abstract,13,test,gold,3068.0
597,,Joint examination,was normal during and after completion of therapy in all patients .,"['Joint', 'examination', 'was', 'normal', 'during', 'and', 'after', 'completion', 'of', 'therapy', 'in', 'all', 'patients', '.']","(0, 2)","(0, 17)",-1,ss_o,11099086,Abstract,14,test,gold,920.0
598,,Joint examination,was normal during and after completion of therapy in all patients .,"['Joint', 'examination', 'was', 'normal', 'during', 'and', 'after', 'completion', 'of', 'therapy', 'in', 'all', 'patients', '.']","(0, 2)","(0, 17)",-1,hl_o,11099086,Abstract,14,test,gold,921.0
599,CONCLUSION Oral ciprofloxacin was as safe and effective as intramuscular ceftriaxone for the empiric treatment of,acute invasive diarrhea in ambulatory pediatric patients requiring an emergency room visit .,,"['CONCLUSION', 'Oral', 'ciprofloxacin', 'was', 'as', 'safe', 'and', 'effective', 'as', 'intramuscular', 'ceftriaxone', 'for', 'the', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'ambulatory', 'pediatric', 'patients', 'requiring', 'an', 'emergency', 'room', 'visit', '.']","(16, 29)","(113, 205)",-1,ss_p,11099086,Abstract,15,test,gold,5882.0
600,CONCLUSION Oral,ciprofloxacin,was as safe and effective as intramuscular ceftriaxone for the empiric treatment of acute invasive diarrhea in ambulatory pediatric patients requiring an emergency room visit .,"['CONCLUSION', 'Oral', 'ciprofloxacin', 'was', 'as', 'safe', 'and', 'effective', 'as', 'intramuscular', 'ceftriaxone', 'for', 'the', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'ambulatory', 'pediatric', 'patients', 'requiring', 'an', 'emergency', 'room', 'visit', '.']","(2, 3)","(15, 28)",-1,ss_i,11099086,Abstract,15,test,gold,4981.0
601,CONCLUSION Oral ciprofloxacin was as safe and effective as intramuscular,ceftriaxone,for the empiric treatment of acute invasive diarrhea in ambulatory pediatric patients requiring an emergency room visit .,"['CONCLUSION', 'Oral', 'ciprofloxacin', 'was', 'as', 'safe', 'and', 'effective', 'as', 'intramuscular', 'ceftriaxone', 'for', 'the', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'ambulatory', 'pediatric', 'patients', 'requiring', 'an', 'emergency', 'room', 'visit', '.']","(10, 11)","(72, 83)",-1,ss_i,11099086,Abstract,15,test,gold,5760.0
602,CONCLUSION Oral ciprofloxacin was as,safe and effective,as intramuscular ceftriaxone for the empiric treatment of acute invasive diarrhea in ambulatory pediatric patients requiring an emergency room visit .,"['CONCLUSION', 'Oral', 'ciprofloxacin', 'was', 'as', 'safe', 'and', 'effective', 'as', 'intramuscular', 'ceftriaxone', 'for', 'the', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'ambulatory', 'pediatric', 'patients', 'requiring', 'an', 'emergency', 'room', 'visit', '.']","(5, 8)","(36, 54)",-1,ss_o,11099086,Abstract,15,test,gold,875.0
603,CONCLUSION Oral ciprofloxacin was as safe and effective as intramuscular ceftriaxone for the empiric treatment of acute invasive diarrhea in,ambulatory pediatric patients requiring an emergency room visit .,,"['CONCLUSION', 'Oral', 'ciprofloxacin', 'was', 'as', 'safe', 'and', 'effective', 'as', 'intramuscular', 'ceftriaxone', 'for', 'the', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'ambulatory', 'pediatric', 'patients', 'requiring', 'an', 'emergency', 'room', 'visit', '.']","(20, 29)","(140, 205)",-1,hl_p,11099086,Abstract,15,test,gold,5883.0
604,CONCLUSION Oral,ciprofloxacin,was as safe and effective as intramuscular ceftriaxone for the empiric treatment of acute invasive diarrhea in ambulatory pediatric patients requiring an emergency room visit .,"['CONCLUSION', 'Oral', 'ciprofloxacin', 'was', 'as', 'safe', 'and', 'effective', 'as', 'intramuscular', 'ceftriaxone', 'for', 'the', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'ambulatory', 'pediatric', 'patients', 'requiring', 'an', 'emergency', 'room', 'visit', '.']","(2, 3)","(15, 28)",-1,hl_i,11099086,Abstract,15,test,gold,4980.0
605,CONCLUSION Oral ciprofloxacin was as safe and effective as intramuscular,ceftriaxone,for the empiric treatment of acute invasive diarrhea in ambulatory pediatric patients requiring an emergency room visit .,"['CONCLUSION', 'Oral', 'ciprofloxacin', 'was', 'as', 'safe', 'and', 'effective', 'as', 'intramuscular', 'ceftriaxone', 'for', 'the', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'ambulatory', 'pediatric', 'patients', 'requiring', 'an', 'emergency', 'room', 'visit', '.']","(10, 11)","(72, 83)",-1,hl_i,11099086,Abstract,15,test,gold,5759.0
606,CONCLUSION Oral ciprofloxacin was as,safe,and effective as intramuscular ceftriaxone for the empiric treatment of acute invasive diarrhea in ambulatory pediatric patients requiring an emergency room visit .,"['CONCLUSION', 'Oral', 'ciprofloxacin', 'was', 'as', 'safe', 'and', 'effective', 'as', 'intramuscular', 'ceftriaxone', 'for', 'the', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'ambulatory', 'pediatric', 'patients', 'requiring', 'an', 'emergency', 'room', 'visit', '.']","(5, 6)","(36, 40)",-1,hl_o,11099086,Abstract,15,test,gold,886.0
607,CONCLUSION Oral ciprofloxacin was as safe and,effective,as intramuscular ceftriaxone for the empiric treatment of acute invasive diarrhea in ambulatory pediatric patients requiring an emergency room visit .,"['CONCLUSION', 'Oral', 'ciprofloxacin', 'was', 'as', 'safe', 'and', 'effective', 'as', 'intramuscular', 'ceftriaxone', 'for', 'the', 'empiric', 'treatment', 'of', 'acute', 'invasive', 'diarrhea', 'in', 'ambulatory', 'pediatric', 'patients', 'requiring', 'an', 'emergency', 'room', 'visit', '.']","(7, 8)","(45, 54)",-1,hl_o,11099086,Abstract,15,test,gold,857.0
608,Effect of antipyretic drugs in,children with malaria .,,"['Effect', 'of', 'antipyretic', 'drugs', 'in', 'children', 'with', 'malaria', '.']","(5, 9)","(30, 53)",-1,ss_p,11229858,Title,0,test,gold,3396.0
609,Effect of,antipyretic drugs,in children with malaria .,"['Effect', 'of', 'antipyretic', 'drugs', 'in', 'children', 'with', 'malaria', '.']","(2, 4)","(9, 26)",-1,ss_i,11229858,Title,0,test,gold,5082.0
610,Effect of antipyretic drugs in,children,with malaria .,"['Effect', 'of', 'antipyretic', 'drugs', 'in', 'children', 'with', 'malaria', '.']","(5, 6)","(30, 38)",-1,hl_p,11229858,Title,0,test,gold,2145.0
611,Effect of antipyretic drugs in children with,malaria,.,"['Effect', 'of', 'antipyretic', 'drugs', 'in', 'children', 'with', 'malaria', '.']","(7, 8)","(44, 51)",-1,hl_p,11229858,Title,0,test,gold,3394.0
612,Effect of,antipyretic drugs,in children with malaria .,"['Effect', 'of', 'antipyretic', 'drugs', 'in', 'children', 'with', 'malaria', '.']","(2, 4)","(9, 26)",-1,hl_i,11229858,Title,0,test,gold,5083.0
613,A comparison of different antipyretics in,children with malaria,"showed a small effect of naproxen , but not of metamizol , on the reduction of fever peaks .","['A', 'comparison', 'of', 'different', 'antipyretics', 'in', 'children', 'with', 'malaria', 'showed', 'a', 'small', 'effect', 'of', 'naproxen', ',', 'but', 'not', 'of', 'metamizol', ',', 'on', 'the', 'reduction', 'of', 'fever', 'peaks', '.']","(6, 9)","(41, 62)",-1,ss_p,11229858,Abstract,0,test,gold,3397.0
614,A comparison of different,antipyretics,"in children with malaria showed a small effect of naproxen , but not of metamizol , on the reduction of fever peaks .","['A', 'comparison', 'of', 'different', 'antipyretics', 'in', 'children', 'with', 'malaria', 'showed', 'a', 'small', 'effect', 'of', 'naproxen', ',', 'but', 'not', 'of', 'metamizol', ',', 'on', 'the', 'reduction', 'of', 'fever', 'peaks', '.']","(4, 5)","(25, 37)",-1,ss_i,11229858,Abstract,0,test,gold,139.0
615,A comparison of different antipyretics in children with malaria showed a small effect of,naproxen,", but not of metamizol , on the reduction of fever peaks .","['A', 'comparison', 'of', 'different', 'antipyretics', 'in', 'children', 'with', 'malaria', 'showed', 'a', 'small', 'effect', 'of', 'naproxen', ',', 'but', 'not', 'of', 'metamizol', ',', 'on', 'the', 'reduction', 'of', 'fever', 'peaks', '.']","(14, 15)","(88, 96)",-1,ss_i,11229858,Abstract,0,test,gold,5380.0
616,"A comparison of different antipyretics in children with malaria showed a small effect of naproxen , but not of",metamizol,", on the reduction of fever peaks .","['A', 'comparison', 'of', 'different', 'antipyretics', 'in', 'children', 'with', 'malaria', 'showed', 'a', 'small', 'effect', 'of', 'naproxen', ',', 'but', 'not', 'of', 'metamizol', ',', 'on', 'the', 'reduction', 'of', 'fever', 'peaks', '.']","(19, 20)","(110, 119)",-1,ss_i,11229858,Abstract,0,test,gold,
617,"A comparison of different antipyretics in children with malaria showed a small effect of naproxen , but not of metamizol , on the",reduction of fever peaks .,,"['A', 'comparison', 'of', 'different', 'antipyretics', 'in', 'children', 'with', 'malaria', 'showed', 'a', 'small', 'effect', 'of', 'naproxen', ',', 'but', 'not', 'of', 'metamizol', ',', 'on', 'the', 'reduction', 'of', 'fever', 'peaks', '.']","(23, 28)","(129, 155)",-1,ss_o,11229858,Abstract,0,test,gold,2680.0
618,A comparison of different antipyretics in,children,"with malaria showed a small effect of naproxen , but not of metamizol , on the reduction of fever peaks .","['A', 'comparison', 'of', 'different', 'antipyretics', 'in', 'children', 'with', 'malaria', 'showed', 'a', 'small', 'effect', 'of', 'naproxen', ',', 'but', 'not', 'of', 'metamizol', ',', 'on', 'the', 'reduction', 'of', 'fever', 'peaks', '.']","(6, 7)","(41, 49)",-1,hl_p,11229858,Abstract,0,test,gold,2144.0
619,A comparison of different antipyretics in children with,malaria,"showed a small effect of naproxen , but not of metamizol , on the reduction of fever peaks .","['A', 'comparison', 'of', 'different', 'antipyretics', 'in', 'children', 'with', 'malaria', 'showed', 'a', 'small', 'effect', 'of', 'naproxen', ',', 'but', 'not', 'of', 'metamizol', ',', 'on', 'the', 'reduction', 'of', 'fever', 'peaks', '.']","(8, 9)","(55, 62)",-1,hl_p,11229858,Abstract,0,test,gold,3395.0
620,A comparison of different,antipyretics,"in children with malaria showed a small effect of naproxen , but not of metamizol , on the reduction of fever peaks .","['A', 'comparison', 'of', 'different', 'antipyretics', 'in', 'children', 'with', 'malaria', 'showed', 'a', 'small', 'effect', 'of', 'naproxen', ',', 'but', 'not', 'of', 'metamizol', ',', 'on', 'the', 'reduction', 'of', 'fever', 'peaks', '.']","(4, 5)","(25, 37)",-1,hl_i,11229858,Abstract,0,test,gold,140.0
621,A comparison of different antipyretics in children with malaria showed a small effect of,naproxen,", but not of metamizol , on the reduction of fever peaks .","['A', 'comparison', 'of', 'different', 'antipyretics', 'in', 'children', 'with', 'malaria', 'showed', 'a', 'small', 'effect', 'of', 'naproxen', ',', 'but', 'not', 'of', 'metamizol', ',', 'on', 'the', 'reduction', 'of', 'fever', 'peaks', '.']","(14, 15)","(88, 96)",-1,hl_i,11229858,Abstract,0,test,gold,5381.0
622,"A comparison of different antipyretics in children with malaria showed a small effect of naproxen , but not of",metamizol,", on the reduction of fever peaks .","['A', 'comparison', 'of', 'different', 'antipyretics', 'in', 'children', 'with', 'malaria', 'showed', 'a', 'small', 'effect', 'of', 'naproxen', ',', 'but', 'not', 'of', 'metamizol', ',', 'on', 'the', 'reduction', 'of', 'fever', 'peaks', '.']","(19, 20)","(110, 119)",-1,hl_i,11229858,Abstract,0,test,gold,
623,"A comparison of different antipyretics in children with malaria showed a small effect of naproxen , but not of metamizol , on the",reduction of fever peaks .,,"['A', 'comparison', 'of', 'different', 'antipyretics', 'in', 'children', 'with', 'malaria', 'showed', 'a', 'small', 'effect', 'of', 'naproxen', ',', 'but', 'not', 'of', 'metamizol', ',', 'on', 'the', 'reduction', 'of', 'fever', 'peaks', '.']","(23, 28)","(129, 155)",-1,hl_o,11229858,Abstract,0,test,gold,2681.0
624,Antipyretic treatment had no effect on fever clearance and therefore should be used cautiously in the treatment of,malaria .,,"['Antipyretic', 'treatment', 'had', 'no', 'effect', 'on', 'fever', 'clearance', 'and', 'therefore', 'should', 'be', 'used', 'cautiously', 'in', 'the', 'treatment', 'of', 'malaria', '.']","(18, 20)","(114, 123)",-1,ss_p,11229858,Abstract,1,test,gold,3393.0
625,,Antipyretic,treatment had no effect on fever clearance and therefore should be used cautiously in the treatment of malaria .,"['Antipyretic', 'treatment', 'had', 'no', 'effect', 'on', 'fever', 'clearance', 'and', 'therefore', 'should', 'be', 'used', 'cautiously', 'in', 'the', 'treatment', 'of', 'malaria', '.']","(0, 1)","(0, 11)",-1,ss_i,11229858,Abstract,1,test,gold,
626,Antipyretic treatment had no effect on,fever clearance,and therefore should be used cautiously in the treatment of malaria .,"['Antipyretic', 'treatment', 'had', 'no', 'effect', 'on', 'fever', 'clearance', 'and', 'therefore', 'should', 'be', 'used', 'cautiously', 'in', 'the', 'treatment', 'of', 'malaria', '.']","(6, 8)","(38, 53)",-1,ss_o,11229858,Abstract,1,test,gold,2678.0
627,Antipyretic treatment had no effect on fever clearance and therefore should be used cautiously in the treatment of,malaria .,,"['Antipyretic', 'treatment', 'had', 'no', 'effect', 'on', 'fever', 'clearance', 'and', 'therefore', 'should', 'be', 'used', 'cautiously', 'in', 'the', 'treatment', 'of', 'malaria', '.']","(18, 20)","(114, 123)",-1,hl_p,11229858,Abstract,1,test,gold,3392.0
628,,Antipyretic,treatment had no effect on fever clearance and therefore should be used cautiously in the treatment of malaria .,"['Antipyretic', 'treatment', 'had', 'no', 'effect', 'on', 'fever', 'clearance', 'and', 'therefore', 'should', 'be', 'used', 'cautiously', 'in', 'the', 'treatment', 'of', 'malaria', '.']","(0, 1)","(0, 11)",-1,hl_i,11229858,Abstract,1,test,gold,
629,Antipyretic treatment had no effect on,fever clearance,and therefore should be used cautiously in the treatment of malaria .,"['Antipyretic', 'treatment', 'had', 'no', 'effect', 'on', 'fever', 'clearance', 'and', 'therefore', 'should', 'be', 'used', 'cautiously', 'in', 'the', 'treatment', 'of', 'malaria', '.']","(6, 8)","(38, 53)",-1,hl_o,11229858,Abstract,1,test,gold,2679.0
630,Effect of the,essential oils of garlic and onion,on alimentary hyperlipemia .,"['Effect', 'of', 'the', 'essential', 'oils', 'of', 'garlic', 'and', 'onion', 'on', 'alimentary', 'hyperlipemia', '.']","(3, 9)","(13, 47)",-1,ss_i,1131298,Title,0,test,gold,4577.0
631,Effect of the,essential oils of garlic and onion,on alimentary hyperlipemia .,"['Effect', 'of', 'the', 'essential', 'oils', 'of', 'garlic', 'and', 'onion', 'on', 'alimentary', 'hyperlipemia', '.']","(3, 9)","(13, 47)",-1,hl_i,1131298,Title,0,test,gold,4578.0
632,"SUMMARY The effect of garlic and onion on alimentary hyperlipemia , induced by feeding 100 g butter , has been studied in",10 healthy subjects .,,"['SUMMARY', 'The', 'effect', 'of', 'garlic', 'and', 'onion', 'on', 'alimentary', 'hyperlipemia', ',', 'induced', 'by', 'feeding', '100', 'g', 'butter', ',', 'has', 'been', 'studied', 'in', '10', 'healthy', 'subjects', '.']","(22, 26)","(121, 142)",-1,ss_p,1131298,Abstract,0,test,gold,2261.0
633,SUMMARY The effect of,garlic and onion,"on alimentary hyperlipemia , induced by feeding 100 g butter , has been studied in 10 healthy subjects .","['SUMMARY', 'The', 'effect', 'of', 'garlic', 'and', 'onion', 'on', 'alimentary', 'hyperlipemia', ',', 'induced', 'by', 'feeding', '100', 'g', 'butter', ',', 'has', 'been', 'studied', 'in', '10', 'healthy', 'subjects', '.']","(4, 7)","(21, 37)",-1,ss_i,1131298,Abstract,0,test,gold,4583.0
634,"SUMMARY The effect of garlic and onion on alimentary hyperlipemia , induced by feeding 100 g butter , has been studied in",10 healthy subjects,.,"['SUMMARY', 'The', 'effect', 'of', 'garlic', 'and', 'onion', 'on', 'alimentary', 'hyperlipemia', ',', 'induced', 'by', 'feeding', '100', 'g', 'butter', ',', 'has', 'been', 'studied', 'in', '10', 'healthy', 'subjects', '.']","(22, 25)","(121, 140)",-1,hl_p,1131298,Abstract,0,test,gold,2262.0
635,SUMMARY The effect of,garlic and onion,"on alimentary hyperlipemia , induced by feeding 100 g butter , has been studied in 10 healthy subjects .","['SUMMARY', 'The', 'effect', 'of', 'garlic', 'and', 'onion', 'on', 'alimentary', 'hyperlipemia', ',', 'induced', 'by', 'feeding', '100', 'g', 'butter', ',', 'has', 'been', 'studied', 'in', '10', 'healthy', 'subjects', '.']","(4, 7)","(21, 37)",-1,hl_i,1131298,Abstract,0,test,gold,4584.0
636,The freshly extracted juice of 50 g of,garlic or onion,", as well as an equivalent amount of their ether-extracted essential oils , was administered randomly on four different days during a one-week period .","['The', 'freshly', 'extracted', 'juice', 'of', '50', 'g', 'of', 'garlic', 'or', 'onion', ',', 'as', 'well', 'as', 'an', 'equivalent', 'amount', 'of', 'their', 'ether-extracted', 'essential', 'oils', ',', 'was', 'administered', 'randomly', 'on', 'four', 'different', 'days', 'during', 'a', 'one-week', 'period', '.']","(8, 11)","(38, 53)",-1,ss_i,1131298,Abstract,1,test,gold,4585.0
637,"The freshly extracted juice of 50 g of garlic or onion , as well as an equivalent amount of their ether-extracted",essential oils,", was administered randomly on four different days during a one-week period .","['The', 'freshly', 'extracted', 'juice', 'of', '50', 'g', 'of', 'garlic', 'or', 'onion', ',', 'as', 'well', 'as', 'an', 'equivalent', 'amount', 'of', 'their', 'ether-extracted', 'essential', 'oils', ',', 'was', 'administered', 'randomly', 'on', 'four', 'different', 'days', 'during', 'a', 'one-week', 'period', '.']","(21, 23)","(113, 127)",-1,ss_i,1131298,Abstract,1,test,gold,253.0
638,The freshly extracted juice of 50 g of,garlic or onion,", as well as an equivalent amount of their ether-extracted essential oils , was administered randomly on four different days during a one-week period .","['The', 'freshly', 'extracted', 'juice', 'of', '50', 'g', 'of', 'garlic', 'or', 'onion', ',', 'as', 'well', 'as', 'an', 'equivalent', 'amount', 'of', 'their', 'ether-extracted', 'essential', 'oils', ',', 'was', 'administered', 'randomly', 'on', 'four', 'different', 'days', 'during', 'a', 'one-week', 'period', '.']","(8, 11)","(38, 53)",-1,hl_i,1131298,Abstract,1,test,gold,4586.0
639,"The freshly extracted juice of 50 g of garlic or onion , as well as an equivalent amount of their ether-extracted",essential oils,", was administered randomly on four different days during a one-week period .","['The', 'freshly', 'extracted', 'juice', 'of', '50', 'g', 'of', 'garlic', 'or', 'onion', ',', 'as', 'well', 'as', 'an', 'equivalent', 'amount', 'of', 'their', 'ether-extracted', 'essential', 'oils', ',', 'was', 'administered', 'randomly', 'on', 'four', 'different', 'days', 'during', 'a', 'one-week', 'period', '.']","(21, 23)","(113, 127)",-1,hl_i,1131298,Abstract,1,test,gold,254.0
640,,Garlic and onion,have a significant protective action against fat-induced increases in serum cholesterol and plasma fibrinogen and decreases in coagulation time and fibrinolytic activity .,"['Garlic', 'and', 'onion', 'have', 'a', 'significant', 'protective', 'action', 'against', 'fat-induced', 'increases', 'in', 'serum', 'cholesterol', 'and', 'plasma', 'fibrinogen', 'and', 'decreases', 'in', 'coagulation', 'time', 'and', 'fibrinolytic', 'activity', '.']","(0, 3)","(0, 16)",-1,ss_i,1131298,Abstract,2,test,gold,4579.0
641,Garlic and onion have a significant protective action against fat-induced increases in,serum cholesterol and plasma fibrinogen,and decreases in coagulation time and fibrinolytic activity .,"['Garlic', 'and', 'onion', 'have', 'a', 'significant', 'protective', 'action', 'against', 'fat-induced', 'increases', 'in', 'serum', 'cholesterol', 'and', 'plasma', 'fibrinogen', 'and', 'decreases', 'in', 'coagulation', 'time', 'and', 'fibrinolytic', 'activity', '.']","(12, 17)","(86, 125)",-1,ss_o,1131298,Abstract,2,test,gold,6562.0
642,Garlic and onion have a significant protective action against fat-induced increases in serum cholesterol and plasma fibrinogen and decreases in,coagulation time,and fibrinolytic activity .,"['Garlic', 'and', 'onion', 'have', 'a', 'significant', 'protective', 'action', 'against', 'fat-induced', 'increases', 'in', 'serum', 'cholesterol', 'and', 'plasma', 'fibrinogen', 'and', 'decreases', 'in', 'coagulation', 'time', 'and', 'fibrinolytic', 'activity', '.']","(20, 22)","(143, 159)",-1,ss_o,1131298,Abstract,2,test,gold,3211.0
643,Garlic and onion have a significant protective action against fat-induced increases in serum cholesterol and plasma fibrinogen and decreases in coagulation time and,fibrinolytic activity .,,"['Garlic', 'and', 'onion', 'have', 'a', 'significant', 'protective', 'action', 'against', 'fat-induced', 'increases', 'in', 'serum', 'cholesterol', 'and', 'plasma', 'fibrinogen', 'and', 'decreases', 'in', 'coagulation', 'time', 'and', 'fibrinolytic', 'activity', '.']","(23, 26)","(164, 187)",-1,ss_o,1131298,Abstract,2,test,gold,2906.0
644,,Garlic and onion,have a significant protective action against fat-induced increases in serum cholesterol and plasma fibrinogen and decreases in coagulation time and fibrinolytic activity .,"['Garlic', 'and', 'onion', 'have', 'a', 'significant', 'protective', 'action', 'against', 'fat-induced', 'increases', 'in', 'serum', 'cholesterol', 'and', 'plasma', 'fibrinogen', 'and', 'decreases', 'in', 'coagulation', 'time', 'and', 'fibrinolytic', 'activity', '.']","(0, 3)","(0, 16)",-1,hl_i,1131298,Abstract,2,test,gold,4580.0
645,Garlic and onion have a significant protective action against fat-induced increases in,serum cholesterol and plasma fibrinogen,and decreases in coagulation time and fibrinolytic activity .,"['Garlic', 'and', 'onion', 'have', 'a', 'significant', 'protective', 'action', 'against', 'fat-induced', 'increases', 'in', 'serum', 'cholesterol', 'and', 'plasma', 'fibrinogen', 'and', 'decreases', 'in', 'coagulation', 'time', 'and', 'fibrinolytic', 'activity', '.']","(12, 17)","(86, 125)",-1,hl_o,1131298,Abstract,2,test,gold,6563.0
646,Garlic and onion have a significant protective action against fat-induced increases in serum cholesterol and plasma fibrinogen and decreases in,coagulation time,and fibrinolytic activity .,"['Garlic', 'and', 'onion', 'have', 'a', 'significant', 'protective', 'action', 'against', 'fat-induced', 'increases', 'in', 'serum', 'cholesterol', 'and', 'plasma', 'fibrinogen', 'and', 'decreases', 'in', 'coagulation', 'time', 'and', 'fibrinolytic', 'activity', '.']","(20, 22)","(143, 159)",-1,hl_o,1131298,Abstract,2,test,gold,3212.0
647,Garlic and onion have a significant protective action against fat-induced increases in serum cholesterol and plasma fibrinogen and decreases in coagulation time and,fibrinolytic activity .,,"['Garlic', 'and', 'onion', 'have', 'a', 'significant', 'protective', 'action', 'against', 'fat-induced', 'increases', 'in', 'serum', 'cholesterol', 'and', 'plasma', 'fibrinogen', 'and', 'decreases', 'in', 'coagulation', 'time', 'and', 'fibrinolytic', 'activity', '.']","(23, 26)","(164, 187)",-1,hl_o,1131298,Abstract,2,test,gold,2907.0
648,The,essential oil,"fraction , which contains all the taste and odour , exactly duplicated the beneficial effects of whole garlic and onion .","['The', 'essential', 'oil', 'fraction', ',', 'which', 'contains', 'all', 'the', 'taste', 'and', 'odour', ',', 'exactly', 'duplicated', 'the', 'beneficial', 'effects', 'of', 'whole', 'garlic', 'and', 'onion', '.']","(1, 3)","(3, 16)",-1,ss_i,1131298,Abstract,3,test,gold,255.0
649,"The essential oil fraction , which contains all the taste and odour , exactly duplicated the beneficial effects of whole",garlic,and onion .,"['The', 'essential', 'oil', 'fraction', ',', 'which', 'contains', 'all', 'the', 'taste', 'and', 'odour', ',', 'exactly', 'duplicated', 'the', 'beneficial', 'effects', 'of', 'whole', 'garlic', 'and', 'onion', '.']","(20, 21)","(120, 126)",-1,ss_i,1131298,Abstract,3,test,gold,270.0
650,"The essential oil fraction , which contains all the taste and odour , exactly duplicated the beneficial effects of whole garlic and",onion .,,"['The', 'essential', 'oil', 'fraction', ',', 'which', 'contains', 'all', 'the', 'taste', 'and', 'odour', ',', 'exactly', 'duplicated', 'the', 'beneficial', 'effects', 'of', 'whole', 'garlic', 'and', 'onion', '.']","(22, 24)","(131, 138)",-1,ss_i,1131298,Abstract,3,test,gold,272.0
651,"The essential oil fraction , which contains all the taste and odour , exactly duplicated the beneficial",effects,of whole garlic and onion .,"['The', 'essential', 'oil', 'fraction', ',', 'which', 'contains', 'all', 'the', 'taste', 'and', 'odour', ',', 'exactly', 'duplicated', 'the', 'beneficial', 'effects', 'of', 'whole', 'garlic', 'and', 'onion', '.']","(17, 18)","(103, 110)",-1,ss_o,1131298,Abstract,3,test,gold,2385.0
652,"The essential oil fraction , which contains all the taste and odour , exactly duplicated the beneficial effects of whole",garlic,and onion .,"['The', 'essential', 'oil', 'fraction', ',', 'which', 'contains', 'all', 'the', 'taste', 'and', 'odour', ',', 'exactly', 'duplicated', 'the', 'beneficial', 'effects', 'of', 'whole', 'garlic', 'and', 'onion', '.']","(20, 21)","(120, 126)",-1,hl_i,1131298,Abstract,3,test,gold,271.0
653,"The essential oil fraction , which contains all the taste and odour , exactly duplicated the beneficial effects of whole garlic and",onion .,,"['The', 'essential', 'oil', 'fraction', ',', 'which', 'contains', 'all', 'the', 'taste', 'and', 'odour', ',', 'exactly', 'duplicated', 'the', 'beneficial', 'effects', 'of', 'whole', 'garlic', 'and', 'onion', '.']","(22, 24)","(131, 138)",-1,hl_i,1131298,Abstract,3,test,gold,273.0
654,"The essential oil fraction , which contains all the taste and odour , exactly duplicated the beneficial",effects,of whole garlic and onion .,"['The', 'essential', 'oil', 'fraction', ',', 'which', 'contains', 'all', 'the', 'taste', 'and', 'odour', ',', 'exactly', 'duplicated', 'the', 'beneficial', 'effects', 'of', 'whole', 'garlic', 'and', 'onion', '.']","(17, 18)","(103, 110)",-1,hl_o,1131298,Abstract,3,test,gold,2383.0
655,"It is , therefore , concluded that the active principle of",garlic and onion,"is the essential oil , which chemically is a combination of sulphur-containing compounds , mainly allyl propyl disulphide and diallyl disulphide .","['It', 'is', ',', 'therefore', ',', 'concluded', 'that', 'the', 'active', 'principle', 'of', 'garlic', 'and', 'onion', 'is', 'the', 'essential', 'oil', ',', 'which', 'chemically', 'is', 'a', 'combination', 'of', 'sulphur-containing', 'compounds', ',', 'mainly', 'allyl', 'propyl', 'disulphide', 'and', 'diallyl', 'disulphide', '.']","(11, 14)","(58, 74)",-1,ss_i,1131298,Abstract,4,test,gold,4582.0
656,"It is , therefore , concluded that the active principle of garlic and onion is the",essential oil,", which chemically is a combination of sulphur-containing compounds , mainly allyl propyl disulphide and diallyl disulphide .","['It', 'is', ',', 'therefore', ',', 'concluded', 'that', 'the', 'active', 'principle', 'of', 'garlic', 'and', 'onion', 'is', 'the', 'essential', 'oil', ',', 'which', 'chemically', 'is', 'a', 'combination', 'of', 'sulphur-containing', 'compounds', ',', 'mainly', 'allyl', 'propyl', 'disulphide', 'and', 'diallyl', 'disulphide', '.']","(16, 18)","(82, 95)",-1,ss_i,1131298,Abstract,4,test,gold,256.0
657,"It is , therefore , concluded that the active principle of",garlic and onion,"is the essential oil , which chemically is a combination of sulphur-containing compounds , mainly allyl propyl disulphide and diallyl disulphide .","['It', 'is', ',', 'therefore', ',', 'concluded', 'that', 'the', 'active', 'principle', 'of', 'garlic', 'and', 'onion', 'is', 'the', 'essential', 'oil', ',', 'which', 'chemically', 'is', 'a', 'combination', 'of', 'sulphur-containing', 'compounds', ',', 'mainly', 'allyl', 'propyl', 'disulphide', 'and', 'diallyl', 'disulphide', '.']","(11, 14)","(58, 74)",-1,hl_i,1131298,Abstract,4,test,gold,4581.0
658,Economic evaluation of aquatic exercise for,persons with osteoarthritis .,,"['Economic', 'evaluation', 'of', 'aquatic', 'exercise', 'for', 'persons', 'with', 'osteoarthritis', '.']","(6, 10)","(43, 72)",-1,ss_p,11317090,Title,0,test,gold,3800.0
659,Economic evaluation of,aquatic exercise,for persons with osteoarthritis .,"['Economic', 'evaluation', 'of', 'aquatic', 'exercise', 'for', 'persons', 'with', 'osteoarthritis', '.']","(3, 5)","(22, 38)",-1,ss_i,11317090,Title,0,test,gold,2757.0
660,,Economic evaluation,of aquatic exercise for persons with osteoarthritis .,"['Economic', 'evaluation', 'of', 'aquatic', 'exercise', 'for', 'persons', 'with', 'osteoarthritis', '.']","(0, 2)","(0, 19)",-1,ss_o,11317090,Title,0,test,gold,923.0
661,Economic evaluation of aquatic exercise for,persons with osteoarthritis .,,"['Economic', 'evaluation', 'of', 'aquatic', 'exercise', 'for', 'persons', 'with', 'osteoarthritis', '.']","(6, 10)","(43, 72)",-1,hl_p,11317090,Title,0,test,gold,3801.0
662,Economic evaluation of,aquatic exercise,for persons with osteoarthritis .,"['Economic', 'evaluation', 'of', 'aquatic', 'exercise', 'for', 'persons', 'with', 'osteoarthritis', '.']","(3, 5)","(22, 38)",-1,hl_i,11317090,Title,0,test,gold,2758.0
663,,Economic evaluation,of aquatic exercise for persons with osteoarthritis .,"['Economic', 'evaluation', 'of', 'aquatic', 'exercise', 'for', 'persons', 'with', 'osteoarthritis', '.']","(0, 2)","(0, 19)",-1,hl_o,11317090,Title,0,test,gold,924.0
664,OBJECTIVES To estimate cost and outcomes of the Arthritis Foundation,aquatic exercise classes,from the societal perspective .,"['OBJECTIVES', 'To', 'estimate', 'cost', 'and', 'outcomes', 'of', 'the', 'Arthritis', 'Foundation', 'aquatic', 'exercise', 'classes', 'from', 'the', 'societal', 'perspective', '.']","(10, 13)","(68, 92)",-1,ss_i,11317090,Abstract,0,test,gold,2759.0
665,OBJECTIVES To estimate,cost and outcomes,of the Arthritis Foundation aquatic exercise classes from the societal perspective .,"['OBJECTIVES', 'To', 'estimate', 'cost', 'and', 'outcomes', 'of', 'the', 'Arthritis', 'Foundation', 'aquatic', 'exercise', 'classes', 'from', 'the', 'societal', 'perspective', '.']","(3, 6)","(22, 39)",-1,ss_o,11317090,Abstract,0,test,gold,419.0
666,OBJECTIVES To estimate cost and outcomes of the Arthritis Foundation,aquatic exercise classes,from the societal perspective .,"['OBJECTIVES', 'To', 'estimate', 'cost', 'and', 'outcomes', 'of', 'the', 'Arthritis', 'Foundation', 'aquatic', 'exercise', 'classes', 'from', 'the', 'societal', 'perspective', '.']","(10, 13)","(68, 92)",-1,hl_i,11317090,Abstract,0,test,gold,2760.0
667,OBJECTIVES To estimate,cost,and outcomes of the Arthritis Foundation aquatic exercise classes from the societal perspective .,"['OBJECTIVES', 'To', 'estimate', 'cost', 'and', 'outcomes', 'of', 'the', 'Arthritis', 'Foundation', 'aquatic', 'exercise', 'classes', 'from', 'the', 'societal', 'perspective', '.']","(3, 4)","(22, 26)",-1,hl_o,11317090,Abstract,0,test,gold,1004.0
668,OBJECTIVES To estimate cost and,outcomes,of the Arthritis Foundation aquatic exercise classes from the societal perspective .,"['OBJECTIVES', 'To', 'estimate', 'cost', 'and', 'outcomes', 'of', 'the', 'Arthritis', 'Foundation', 'aquatic', 'exercise', 'classes', 'from', 'the', 'societal', 'perspective', '.']","(5, 6)","(31, 39)",-1,hl_o,11317090,Abstract,0,test,gold,421.0
669,DESIGN Randomized trial of 20-week,aquatic classes .,,"['DESIGN', 'Randomized', 'trial', 'of', '20-week', 'aquatic', 'classes', '.']","(5, 8)","(34, 51)",-1,ss_i,11317090,Abstract,1,test,gold,2753.0
670,DESIGN Randomized trial of 20-week,aquatic classes .,,"['DESIGN', 'Randomized', 'trial', 'of', '20-week', 'aquatic', 'classes', '.']","(5, 8)","(34, 51)",-1,hl_i,11317090,Abstract,1,test,gold,2754.0
671,,Cost per quality-adjusted life year ( QALY ) gained,was estimated using trial data .,"['Cost', 'per', 'quality-adjusted', 'life', 'year', '(', 'QALY', ')', 'gained', 'was', 'estimated', 'using', 'trial', 'data', '.']","(0, 9)","(0, 51)",-1,ss_o,11317090,Abstract,2,test,gold,6474.0
672,,Cost per quality-adjusted life year ( QALY ),gained was estimated using trial data .,"['Cost', 'per', 'quality-adjusted', 'life', 'year', '(', 'QALY', ')', 'gained', 'was', 'estimated', 'using', 'trial', 'data', '.']","(0, 8)","(0, 44)",-1,hl_o,11317090,Abstract,2,test,gold,6475.0
673,Sample size was based on 80 % power to reject the null hypothesis that the,cost/QALY gained,"would not exceed $ 50,000 .","['Sample', 'size', 'was', 'based', 'on', '80', '%', 'power', 'to', 'reject', 'the', 'null', 'hypothesis', 'that', 'the', 'cost/QALY', 'gained', 'would', 'not', 'exceed', '$', '50,000', '.']","(15, 17)","(74, 90)",-1,ss_o,11317090,Abstract,3,test,gold,1162.0
674,Sample size was based on 80 % power to reject the null hypothesis that the,cost/QALY,"gained would not exceed $ 50,000 .","['Sample', 'size', 'was', 'based', 'on', '80', '%', 'power', 'to', 'reject', 'the', 'null', 'hypothesis', 'that', 'the', 'cost/QALY', 'gained', 'would', 'not', 'exceed', '$', '50,000', '.']","(15, 16)","(74, 83)",-1,hl_o,11317090,Abstract,3,test,gold,
675,SUBJECTS AND METHODS Recruited,249 adults from Washington State aged 55 to 75 with a doctor-confirmed diagnosis of osteoarthritis to participate in aquatic classes .,,"['SUBJECTS', 'AND', 'METHODS', 'Recruited', '249', 'adults', 'from', 'Washington', 'State', 'aged', '55', 'to', '75', 'with', 'a', 'doctor-confirmed', 'diagnosis', 'of', 'osteoarthritis', 'to', 'participate', 'in', 'aquatic', 'classes', '.']","(4, 25)","(30, 164)",-1,ss_p,11317090,Abstract,4,test,gold,5832.0
676,SUBJECTS AND METHODS Recruited 249 adults from Washington State aged 55 to 75 with a doctor-confirmed diagnosis of osteoarthritis to participate in,aquatic classes .,,"['SUBJECTS', 'AND', 'METHODS', 'Recruited', '249', 'adults', 'from', 'Washington', 'State', 'aged', '55', 'to', '75', 'with', 'a', 'doctor-confirmed', 'diagnosis', 'of', 'osteoarthritis', 'to', 'participate', 'in', 'aquatic', 'classes', '.']","(22, 25)","(147, 164)",-1,ss_i,11317090,Abstract,4,test,gold,2752.0
677,SUBJECTS AND METHODS Recruited,249 adults from Washington State aged 55 to 75,with a doctor-confirmed diagnosis of osteoarthritis to participate in aquatic classes .,"['SUBJECTS', 'AND', 'METHODS', 'Recruited', '249', 'adults', 'from', 'Washington', 'State', 'aged', '55', 'to', '75', 'with', 'a', 'doctor-confirmed', 'diagnosis', 'of', 'osteoarthritis', 'to', 'participate', 'in', 'aquatic', 'classes', '.']","(4, 13)","(30, 76)",-1,hl_p,11317090,Abstract,4,test,gold,2041.0
678,SUBJECTS AND METHODS Recruited 249 adults from Washington State aged 55 to 75 with a,doctor-confirmed diagnosis of osteoarthritis,to participate in aquatic classes .,"['SUBJECTS', 'AND', 'METHODS', 'Recruited', '249', 'adults', 'from', 'Washington', 'State', 'aged', '55', 'to', '75', 'with', 'a', 'doctor-confirmed', 'diagnosis', 'of', 'osteoarthritis', 'to', 'participate', 'in', 'aquatic', 'classes', '.']","(15, 19)","(84, 128)",-1,hl_p,11317090,Abstract,4,test,gold,3799.0
679,SUBJECTS AND METHODS Recruited 249 adults from Washington State aged 55 to 75 with a doctor-confirmed diagnosis of osteoarthritis to participate in,aquatic classes .,,"['SUBJECTS', 'AND', 'METHODS', 'Recruited', '249', 'adults', 'from', 'Washington', 'State', 'aged', '55', 'to', '75', 'with', 'a', 'doctor-confirmed', 'diagnosis', 'of', 'osteoarthritis', 'to', 'participate', 'in', 'aquatic', 'classes', '.']","(22, 25)","(147, 164)",-1,hl_i,11317090,Abstract,4,test,gold,2751.0
680,The,Quality of Well-Being Scale ( QWB ),"and Current Health Desirability Rating ( CHDR ) were used for economic evaluation , supplemented by the arthritis-specific Health Assessment Questionnaire ( HAQ ) , Center for Epidemiologic Studies-Depression Scale ( CES-D ) , and Perceived Quality of Life Scale ( PQOL ) collected at baseline and postclass .","['The', 'Quality', 'of', 'Well-Being', 'Scale', '(', 'QWB', ')', 'and', 'Current', 'Health', 'Desirability', 'Rating', '(', 'CHDR', ')', 'were', 'used', 'for', 'economic', 'evaluation', ',', 'supplemented', 'by', 'the', 'arthritis-specific', 'Health', 'Assessment', 'Questionnaire', '(', 'HAQ', ')', ',', 'Center', 'for', 'Epidemiologic', 'Studies-Depression', 'Scale', '(', 'CES-D', ')', ',', 'and', 'Perceived', 'Quality', 'of', 'Life', 'Scale', '(', 'PQOL', ')', 'collected', 'at', 'baseline', 'and', 'postclass', '.']","(1, 8)","(3, 38)",-1,ss_o,11317090,Abstract,5,test,gold,6227.0
681,The Quality of Well-Being Scale ( QWB ) and,Current Health Desirability Rating ( CHDR ),"were used for economic evaluation , supplemented by the arthritis-specific Health Assessment Questionnaire ( HAQ ) , Center for Epidemiologic Studies-Depression Scale ( CES-D ) , and Perceived Quality of Life Scale ( PQOL ) collected at baseline and postclass .","['The', 'Quality', 'of', 'Well-Being', 'Scale', '(', 'QWB', ')', 'and', 'Current', 'Health', 'Desirability', 'Rating', '(', 'CHDR', ')', 'were', 'used', 'for', 'economic', 'evaluation', ',', 'supplemented', 'by', 'the', 'arthritis-specific', 'Health', 'Assessment', 'Questionnaire', '(', 'HAQ', ')', ',', 'Center', 'for', 'Epidemiologic', 'Studies-Depression', 'Scale', '(', 'CES-D', ')', ',', 'and', 'Perceived', 'Quality', 'of', 'Life', 'Scale', '(', 'PQOL', ')', 'collected', 'at', 'baseline', 'and', 'postclass', '.']","(9, 16)","(43, 86)",-1,ss_o,11317090,Abstract,5,test,gold,6215.0
682,The Quality of Well-Being Scale ( QWB ) and Current Health Desirability Rating ( CHDR ) were used for,economic evaluation,", supplemented by the arthritis-specific Health Assessment Questionnaire ( HAQ ) , Center for Epidemiologic Studies-Depression Scale ( CES-D ) , and Perceived Quality of Life Scale ( PQOL ) collected at baseline and postclass .","['The', 'Quality', 'of', 'Well-Being', 'Scale', '(', 'QWB', ')', 'and', 'Current', 'Health', 'Desirability', 'Rating', '(', 'CHDR', ')', 'were', 'used', 'for', 'economic', 'evaluation', ',', 'supplemented', 'by', 'the', 'arthritis-specific', 'Health', 'Assessment', 'Questionnaire', '(', 'HAQ', ')', ',', 'Center', 'for', 'Epidemiologic', 'Studies-Depression', 'Scale', '(', 'CES-D', ')', ',', 'and', 'Perceived', 'Quality', 'of', 'Life', 'Scale', '(', 'PQOL', ')', 'collected', 'at', 'baseline', 'and', 'postclass', '.']","(19, 21)","(101, 120)",-1,ss_o,11317090,Abstract,5,test,gold,922.0
683,"The Quality of Well-Being Scale ( QWB ) and Current Health Desirability Rating ( CHDR ) were used for economic evaluation , supplemented by the","arthritis-specific Health Assessment Questionnaire ( HAQ ) , Center for Epidemiologic Studies-Depression Scale ( CES-D )",", and Perceived Quality of Life Scale ( PQOL ) collected at baseline and postclass .","['The', 'Quality', 'of', 'Well-Being', 'Scale', '(', 'QWB', ')', 'and', 'Current', 'Health', 'Desirability', 'Rating', '(', 'CHDR', ')', 'were', 'used', 'for', 'economic', 'evaluation', ',', 'supplemented', 'by', 'the', 'arthritis-specific', 'Health', 'Assessment', 'Questionnaire', '(', 'HAQ', ')', ',', 'Center', 'for', 'Epidemiologic', 'Studies-Depression', 'Scale', '(', 'CES-D', ')', ',', 'and', 'Perceived', 'Quality', 'of', 'Life', 'Scale', '(', 'PQOL', ')', 'collected', 'at', 'baseline', 'and', 'postclass', '.']","(25, 41)","(143, 263)",-1,ss_o,11317090,Abstract,5,test,gold,6274.0
684,"The Quality of Well-Being Scale ( QWB ) and Current Health Desirability Rating ( CHDR ) were used for economic evaluation , supplemented by the arthritis-specific Health Assessment Questionnaire ( HAQ ) , Center for Epidemiologic Studies-Depression Scale ( CES-D ) , and",Perceived Quality of Life Scale ( PQOL ),collected at baseline and postclass .,"['The', 'Quality', 'of', 'Well-Being', 'Scale', '(', 'QWB', ')', 'and', 'Current', 'Health', 'Desirability', 'Rating', '(', 'CHDR', ')', 'were', 'used', 'for', 'economic', 'evaluation', ',', 'supplemented', 'by', 'the', 'arthritis-specific', 'Health', 'Assessment', 'Questionnaire', '(', 'HAQ', ')', ',', 'Center', 'for', 'Epidemiologic', 'Studies-Depression', 'Scale', '(', 'CES-D', ')', ',', 'and', 'Perceived', 'Quality', 'of', 'Life', 'Scale', '(', 'PQOL', ')', 'collected', 'at', 'baseline', 'and', 'postclass', '.']","(43, 51)","(270, 310)",-1,ss_o,11317090,Abstract,5,test,gold,6224.0
685,The,Quality of Well-Being Scale ( QWB ),"and Current Health Desirability Rating ( CHDR ) were used for economic evaluation , supplemented by the arthritis-specific Health Assessment Questionnaire ( HAQ ) , Center for Epidemiologic Studies-Depression Scale ( CES-D ) , and Perceived Quality of Life Scale ( PQOL ) collected at baseline and postclass .","['The', 'Quality', 'of', 'Well-Being', 'Scale', '(', 'QWB', ')', 'and', 'Current', 'Health', 'Desirability', 'Rating', '(', 'CHDR', ')', 'were', 'used', 'for', 'economic', 'evaluation', ',', 'supplemented', 'by', 'the', 'arthritis-specific', 'Health', 'Assessment', 'Questionnaire', '(', 'HAQ', ')', ',', 'Center', 'for', 'Epidemiologic', 'Studies-Depression', 'Scale', '(', 'CES-D', ')', ',', 'and', 'Perceived', 'Quality', 'of', 'Life', 'Scale', '(', 'PQOL', ')', 'collected', 'at', 'baseline', 'and', 'postclass', '.']","(1, 8)","(3, 38)",-1,hl_o,11317090,Abstract,5,test,gold,6228.0
686,The Quality of Well-Being Scale ( QWB ) and,Current Health Desirability Rating ( CHDR ),"were used for economic evaluation , supplemented by the arthritis-specific Health Assessment Questionnaire ( HAQ ) , Center for Epidemiologic Studies-Depression Scale ( CES-D ) , and Perceived Quality of Life Scale ( PQOL ) collected at baseline and postclass .","['The', 'Quality', 'of', 'Well-Being', 'Scale', '(', 'QWB', ')', 'and', 'Current', 'Health', 'Desirability', 'Rating', '(', 'CHDR', ')', 'were', 'used', 'for', 'economic', 'evaluation', ',', 'supplemented', 'by', 'the', 'arthritis-specific', 'Health', 'Assessment', 'Questionnaire', '(', 'HAQ', ')', ',', 'Center', 'for', 'Epidemiologic', 'Studies-Depression', 'Scale', '(', 'CES-D', ')', ',', 'and', 'Perceived', 'Quality', 'of', 'Life', 'Scale', '(', 'PQOL', ')', 'collected', 'at', 'baseline', 'and', 'postclass', '.']","(9, 16)","(43, 86)",-1,hl_o,11317090,Abstract,5,test,gold,6216.0
687,"The Quality of Well-Being Scale ( QWB ) and Current Health Desirability Rating ( CHDR ) were used for economic evaluation , supplemented by the","arthritis-specific Health Assessment Questionnaire ( HAQ ) , Center for Epidemiologic Studies-Depression Scale ( CES-D )",", and Perceived Quality of Life Scale ( PQOL ) collected at baseline and postclass .","['The', 'Quality', 'of', 'Well-Being', 'Scale', '(', 'QWB', ')', 'and', 'Current', 'Health', 'Desirability', 'Rating', '(', 'CHDR', ')', 'were', 'used', 'for', 'economic', 'evaluation', ',', 'supplemented', 'by', 'the', 'arthritis-specific', 'Health', 'Assessment', 'Questionnaire', '(', 'HAQ', ')', ',', 'Center', 'for', 'Epidemiologic', 'Studies-Depression', 'Scale', '(', 'CES-D', ')', ',', 'and', 'Perceived', 'Quality', 'of', 'Life', 'Scale', '(', 'PQOL', ')', 'collected', 'at', 'baseline', 'and', 'postclass', '.']","(25, 41)","(143, 263)",-1,hl_o,11317090,Abstract,5,test,gold,6275.0
688,"The Quality of Well-Being Scale ( QWB ) and Current Health Desirability Rating ( CHDR ) were used for economic evaluation , supplemented by the arthritis-specific Health Assessment Questionnaire ( HAQ ) , Center for Epidemiologic Studies-Depression Scale ( CES-D ) , and",Perceived Quality of Life Scale ( PQOL ),collected at baseline and postclass .,"['The', 'Quality', 'of', 'Well-Being', 'Scale', '(', 'QWB', ')', 'and', 'Current', 'Health', 'Desirability', 'Rating', '(', 'CHDR', ')', 'were', 'used', 'for', 'economic', 'evaluation', ',', 'supplemented', 'by', 'the', 'arthritis-specific', 'Health', 'Assessment', 'Questionnaire', '(', 'HAQ', ')', ',', 'Center', 'for', 'Epidemiologic', 'Studies-Depression', 'Scale', '(', 'CES-D', ')', ',', 'and', 'Perceived', 'Quality', 'of', 'Life', 'Scale', '(', 'PQOL', ')', 'collected', 'at', 'baseline', 'and', 'postclass', '.']","(43, 51)","(270, 310)",-1,hl_o,11317090,Abstract,5,test,gold,6225.0
689,Outcome results applied to,life expectancy tables,were used to estimate QALYs .,"['Outcome', 'results', 'applied', 'to', 'life', 'expectancy', 'tables', 'were', 'used', 'to', 'estimate', 'QALYs', '.']","(4, 7)","(26, 48)",-1,ss_o,11317090,Abstract,6,test,gold,1879.0
690,Outcome results applied to life expectancy tables were used to estimate,QALYs .,,"['Outcome', 'results', 'applied', 'to', 'life', 'expectancy', 'tables', 'were', 'used', 'to', 'estimate', 'QALYs', '.']","(11, 13)","(71, 78)",-1,ss_o,11317090,Abstract,6,test,gold,414.0
691,Outcome results applied to life expectancy tables were used to estimate,QALYs .,,"['Outcome', 'results', 'applied', 'to', 'life', 'expectancy', 'tables', 'were', 'used', 'to', 'estimate', 'QALYs', '.']","(11, 13)","(71, 78)",-1,hl_o,11317090,Abstract,6,test,gold,415.0
692,,Use of health care facilities,was assessed from diaries/questionnaires and Medicare reimbursement rates used to estimate costs .,"['Use', 'of', 'health', 'care', 'facilities', 'was', 'assessed', 'from', 'diaries/questionnaires', 'and', 'Medicare', 'reimbursement', 'rates', 'used', 'to', 'estimate', 'costs', '.']","(0, 5)","(0, 29)",-1,ss_o,11317090,Abstract,7,test,gold,3943.0
693,Use of health care facilities was assessed from,diaries/questionnaires,and Medicare reimbursement rates used to estimate costs .,"['Use', 'of', 'health', 'care', 'facilities', 'was', 'assessed', 'from', 'diaries/questionnaires', 'and', 'Medicare', 'reimbursement', 'rates', 'used', 'to', 'estimate', 'costs', '.']","(8, 9)","(47, 69)",-1,ss_o,11317090,Abstract,7,test,gold,
694,Use of health care facilities was assessed from diaries/questionnaires and,Medicare reimbursement rates,used to estimate costs .,"['Use', 'of', 'health', 'care', 'facilities', 'was', 'assessed', 'from', 'diaries/questionnaires', 'and', 'Medicare', 'reimbursement', 'rates', 'used', 'to', 'estimate', 'costs', '.']","(10, 13)","(74, 102)",-1,ss_o,11317090,Abstract,7,test,gold,3833.0
695,Use of health care facilities was assessed from diaries/questionnaires and Medicare reimbursement rates used to estimate,costs .,,"['Use', 'of', 'health', 'care', 'facilities', 'was', 'assessed', 'from', 'diaries/questionnaires', 'and', 'Medicare', 'reimbursement', 'rates', 'used', 'to', 'estimate', 'costs', '.']","(16, 18)","(120, 127)",-1,ss_o,11317090,Abstract,7,test,gold,1008.0
696,,Use of health care facilities,was assessed from diaries/questionnaires and Medicare reimbursement rates used to estimate costs .,"['Use', 'of', 'health', 'care', 'facilities', 'was', 'assessed', 'from', 'diaries/questionnaires', 'and', 'Medicare', 'reimbursement', 'rates', 'used', 'to', 'estimate', 'costs', '.']","(0, 5)","(0, 29)",-1,hl_o,11317090,Abstract,7,test,gold,3944.0
697,Use of health care facilities was assessed from diaries/questionnaires and,Medicare reimbursement rates,used to estimate costs .,"['Use', 'of', 'health', 'care', 'facilities', 'was', 'assessed', 'from', 'diaries/questionnaires', 'and', 'Medicare', 'reimbursement', 'rates', 'used', 'to', 'estimate', 'costs', '.']","(10, 13)","(74, 102)",-1,hl_o,11317090,Abstract,7,test,gold,3834.0
698,,Nonparametric bootstrap sampling of costs/QALY ratios,established the 95 % CI around the estimates .,"['Nonparametric', 'bootstrap', 'sampling', 'of', 'costs/QALY', 'ratios', 'established', 'the', '95', '%', 'CI', 'around', 'the', 'estimates', '.']","(0, 6)","(0, 53)",-1,ss_o,11317090,Abstract,8,test,gold,1487.0
699,Nonparametric bootstrap sampling of,costs/QALY ratios,established the 95 % CI around the estimates .,"['Nonparametric', 'bootstrap', 'sampling', 'of', 'costs/QALY', 'ratios', 'established', 'the', '95', '%', 'CI', 'around', 'the', 'estimates', '.']","(4, 6)","(35, 52)",-1,hl_o,11317090,Abstract,8,test,gold,1478.0
700,RESULTS,Aquatic exercisers,"reported equal ( QWB ) or better ( CHDR , HAQ , PQOL ) health-related quality of life compared with controls .","['RESULTS', 'Aquatic', 'exercisers', 'reported', 'equal', '(', 'QWB', ')', 'or', 'better', '(', 'CHDR', ',', 'HAQ', ',', 'PQOL', ')', 'health-related', 'quality', 'of', 'life', 'compared', 'with', 'controls', '.']","(1, 3)","(7, 25)",-1,ss_i,11317090,Abstract,9,test,gold,2749.0
701,RESULTS Aquatic exercisers reported equal,( QWB ),"or better ( CHDR , HAQ , PQOL ) health-related quality of life compared with controls .","['RESULTS', 'Aquatic', 'exercisers', 'reported', 'equal', '(', 'QWB', ')', 'or', 'better', '(', 'CHDR', ',', 'HAQ', ',', 'PQOL', ')', 'health-related', 'quality', 'of', 'life', 'compared', 'with', 'controls', '.']","(5, 8)","(41, 48)",-1,ss_o,11317090,Abstract,9,test,gold,
702,RESULTS Aquatic exercisers reported equal ( QWB ) or better,"( CHDR , HAQ , PQOL )",health-related quality of life compared with controls .,"['RESULTS', 'Aquatic', 'exercisers', 'reported', 'equal', '(', 'QWB', ')', 'or', 'better', '(', 'CHDR', ',', 'HAQ', ',', 'PQOL', ')', 'health-related', 'quality', 'of', 'life', 'compared', 'with', 'controls', '.']","(10, 17)","(59, 80)",-1,ss_o,11317090,Abstract,9,test,gold,79.0
703,RESULTS,Aquatic exercisers,"reported equal ( QWB ) or better ( CHDR , HAQ , PQOL ) health-related quality of life compared with controls .","['RESULTS', 'Aquatic', 'exercisers', 'reported', 'equal', '(', 'QWB', ')', 'or', 'better', '(', 'CHDR', ',', 'HAQ', ',', 'PQOL', ')', 'health-related', 'quality', 'of', 'life', 'compared', 'with', 'controls', '.']","(1, 3)","(7, 25)",-1,hl_i,11317090,Abstract,9,test,gold,2750.0
704,RESULTS Aquatic exercisers reported equal,( QWB ),"or better ( CHDR , HAQ , PQOL ) health-related quality of life compared with controls .","['RESULTS', 'Aquatic', 'exercisers', 'reported', 'equal', '(', 'QWB', ')', 'or', 'better', '(', 'CHDR', ',', 'HAQ', ',', 'PQOL', ')', 'health-related', 'quality', 'of', 'life', 'compared', 'with', 'controls', '.']","(5, 8)","(41, 48)",-1,hl_o,11317090,Abstract,9,test,gold,
705,RESULTS Aquatic exercisers reported equal ( QWB ) or better,"( CHDR , HAQ , PQOL )",health-related quality of life compared with controls .,"['RESULTS', 'Aquatic', 'exercisers', 'reported', 'equal', '(', 'QWB', ')', 'or', 'better', '(', 'CHDR', ',', 'HAQ', ',', 'PQOL', ')', 'health-related', 'quality', 'of', 'life', 'compared', 'with', 'controls', '.']","(10, 17)","(59, 80)",-1,hl_o,11317090,Abstract,9,test,gold,80.0
706,Outcomes improved with regular class attendance .,,,"['Outcomes', 'improved', 'with', 'regular', 'class', 'attendance', '.']",,,,,11317090,Abstract,10,test,gold,
707,,Costs/QALY,"gained discounted at 3 % were $ 205,186 using the QWB and $ 32,643 using the CHRD .","['Costs/QALY', 'gained', 'discounted', 'at', '3', '%', 'were', '$', '205,186', 'using', 'the', 'QWB', 'and', '$', '32,643', 'using', 'the', 'CHRD', '.']","(0, 1)","(0, 10)",-1,ss_o,11317090,Abstract,11,test,gold,
708,"Costs/QALY gained discounted at 3 % were $ 205,186 using the",QWB,"and $ 32,643 using the CHRD .","['Costs/QALY', 'gained', 'discounted', 'at', '3', '%', 'were', '$', '205,186', 'using', 'the', 'QWB', 'and', '$', '32,643', 'using', 'the', 'CHRD', '.']","(11, 12)","(60, 63)",-1,ss_o,11317090,Abstract,11,test,gold,
709,"Costs/QALY gained discounted at 3 % were $ 205,186 using the QWB and $ 32,643 using the",CHRD .,,"['Costs/QALY', 'gained', 'discounted', 'at', '3', '%', 'were', '$', '205,186', 'using', 'the', 'QWB', 'and', '$', '32,643', 'using', 'the', 'CHRD', '.']","(17, 19)","(87, 93)",-1,ss_o,11317090,Abstract,11,test,gold,631.0
710,,Costs/QALY,"gained discounted at 3 % were $ 205,186 using the QWB and $ 32,643 using the CHRD .","['Costs/QALY', 'gained', 'discounted', 'at', '3', '%', 'were', '$', '205,186', 'using', 'the', 'QWB', 'and', '$', '32,643', 'using', 'the', 'CHRD', '.']","(0, 1)","(0, 10)",-1,hl_o,11317090,Abstract,11,test,gold,
711,"Costs/QALY gained discounted at 3 % were $ 205,186 using the",QWB,"and $ 32,643 using the CHRD .","['Costs/QALY', 'gained', 'discounted', 'at', '3', '%', 'were', '$', '205,186', 'using', 'the', 'QWB', 'and', '$', '32,643', 'using', 'the', 'CHRD', '.']","(11, 12)","(60, 63)",-1,hl_o,11317090,Abstract,11,test,gold,
712,"Costs/QALY gained discounted at 3 % were $ 205,186 using the QWB and $ 32,643 using the",CHRD .,,"['Costs/QALY', 'gained', 'discounted', 'at', '3', '%', 'were', '$', '205,186', 'using', 'the', 'QWB', 'and', '$', '32,643', 'using', 'the', 'CHRD', '.']","(17, 19)","(87, 93)",-1,hl_o,11317090,Abstract,11,test,gold,632.0
713,CONCLUSION,Aquatic exercise,"exceeded $ 50,000 per QALY gained using the community-weighted outcome but fell below this arbitrary budget constraint when using the participant-weighted measure .","['CONCLUSION', 'Aquatic', 'exercise', 'exceeded', '$', '50,000', 'per', 'QALY', 'gained', 'using', 'the', 'community-weighted', 'outcome', 'but', 'fell', 'below', 'this', 'arbitrary', 'budget', 'constraint', 'when', 'using', 'the', 'participant-weighted', 'measure', '.']","(1, 3)","(10, 26)",-1,ss_i,11317090,Abstract,12,test,gold,2747.0
714,"CONCLUSION Aquatic exercise exceeded $ 50,000 per",QALY gained,using the community-weighted outcome but fell below this arbitrary budget constraint when using the participant-weighted measure .,"['CONCLUSION', 'Aquatic', 'exercise', 'exceeded', '$', '50,000', 'per', 'QALY', 'gained', 'using', 'the', 'community-weighted', 'outcome', 'but', 'fell', 'below', 'this', 'arbitrary', 'budget', 'constraint', 'when', 'using', 'the', 'participant-weighted', 'measure', '.']","(7, 9)","(49, 60)",-1,ss_o,11317090,Abstract,12,test,gold,416.0
715,CONCLUSION,Aquatic exercise,"exceeded $ 50,000 per QALY gained using the community-weighted outcome but fell below this arbitrary budget constraint when using the participant-weighted measure .","['CONCLUSION', 'Aquatic', 'exercise', 'exceeded', '$', '50,000', 'per', 'QALY', 'gained', 'using', 'the', 'community-weighted', 'outcome', 'but', 'fell', 'below', 'this', 'arbitrary', 'budget', 'constraint', 'when', 'using', 'the', 'participant-weighted', 'measure', '.']","(1, 3)","(10, 26)",-1,hl_i,11317090,Abstract,12,test,gold,2748.0
716,"CONCLUSION Aquatic exercise exceeded $ 50,000 per",QALY,gained using the community-weighted outcome but fell below this arbitrary budget constraint when using the participant-weighted measure .,"['CONCLUSION', 'Aquatic', 'exercise', 'exceeded', '$', '50,000', 'per', 'QALY', 'gained', 'using', 'the', 'community-weighted', 'outcome', 'but', 'fell', 'below', 'this', 'arbitrary', 'budget', 'constraint', 'when', 'using', 'the', 'participant-weighted', 'measure', '.']","(7, 8)","(49, 53)",-1,hl_o,11317090,Abstract,12,test,gold,417.0
717,Confidence intervals around these ratios suggested wide variability of cost effectiveness of,aquatic exercise .,,"['Confidence', 'intervals', 'around', 'these', 'ratios', 'suggested', 'wide', 'variability', 'of', 'cost', 'effectiveness', 'of', 'aquatic', 'exercise', '.']","(12, 15)","(92, 110)",-1,ss_i,11317090,Abstract,13,test,gold,2756.0
718,Confidence intervals around these ratios suggested wide variability of cost effectiveness of,aquatic exercise .,,"['Confidence', 'intervals', 'around', 'these', 'ratios', 'suggested', 'wide', 'variability', 'of', 'cost', 'effectiveness', 'of', 'aquatic', 'exercise', '.']","(12, 15)","(92, 110)",-1,hl_i,11317090,Abstract,13,test,gold,2755.0
719,Why were the results of the Heart Outcomes Prevention Evaluation ( HOPE ) trial so astounding ?,,,"['Why', 'were', 'the', 'results', 'of', 'the', 'Heart', 'Outcomes', 'Prevention', 'Evaluation', '(', 'HOPE', ')', 'trial', 'so', 'astounding', '?']",,,,,11381289,Title,0,test,gold,
720,The Heart Outcomes Prevention Evaluation ( HOPE ) study was important because it showed the benefits of ramipril - an angiotensin-converting enzyme ( ACE ) inhibitor - in,patients at high risk for cardiovascular events .,,"['The', 'Heart', 'Outcomes', 'Prevention', 'Evaluation', '(', 'HOPE', ')', 'study', 'was', 'important', 'because', 'it', 'showed', 'the', 'benefits', 'of', 'ramipril', '-', 'an', 'angiotensin-converting', 'enzyme', '(', 'ACE', ')', 'inhibitor', '-', 'in', 'patients', 'at', 'high', 'risk', 'for', 'cardiovascular', 'events', '.']","(28, 36)","(170, 219)",-1,ss_p,11381289,Abstract,0,test,gold,6932.0
721,The Heart Outcomes Prevention Evaluation ( HOPE ) study was important because it showed the benefits of,ramipril,- an angiotensin-converting enzyme ( ACE ) inhibitor - in patients at high risk for cardiovascular events .,"['The', 'Heart', 'Outcomes', 'Prevention', 'Evaluation', '(', 'HOPE', ')', 'study', 'was', 'important', 'because', 'it', 'showed', 'the', 'benefits', 'of', 'ramipril', '-', 'an', 'angiotensin-converting', 'enzyme', '(', 'ACE', ')', 'inhibitor', '-', 'in', 'patients', 'at', 'high', 'risk', 'for', 'cardiovascular', 'events', '.']","(17, 18)","(103, 111)",-1,ss_i,11381289,Abstract,0,test,gold,5396.0
722,The Heart Outcomes Prevention Evaluation ( HOPE ) study was important because it showed the benefits of ramipril - an,angiotensin-converting enzyme ( ACE ) inhibitor,- in patients at high risk for cardiovascular events .,"['The', 'Heart', 'Outcomes', 'Prevention', 'Evaluation', '(', 'HOPE', ')', 'study', 'was', 'important', 'because', 'it', 'showed', 'the', 'benefits', 'of', 'ramipril', '-', 'an', 'angiotensin-converting', 'enzyme', '(', 'ACE', ')', 'inhibitor', '-', 'in', 'patients', 'at', 'high', 'risk', 'for', 'cardiovascular', 'events', '.']","(20, 26)","(117, 164)",-1,ss_i,11381289,Abstract,0,test,gold,4561.0
723,The Heart Outcomes Prevention Evaluation ( HOPE ) study was important because it showed the benefits of ramipril - an angiotensin-converting enzyme ( ACE ) inhibitor - in,patients at high risk for cardiovascular events .,,"['The', 'Heart', 'Outcomes', 'Prevention', 'Evaluation', '(', 'HOPE', ')', 'study', 'was', 'important', 'because', 'it', 'showed', 'the', 'benefits', 'of', 'ramipril', '-', 'an', 'angiotensin-converting', 'enzyme', '(', 'ACE', ')', 'inhibitor', '-', 'in', 'patients', 'at', 'high', 'risk', 'for', 'cardiovascular', 'events', '.']","(28, 36)","(170, 219)",-1,hl_p,11381289,Abstract,0,test,gold,6933.0
724,The Heart Outcomes Prevention Evaluation ( HOPE ) study was important because it showed the benefits of,ramipril,- an angiotensin-converting enzyme ( ACE ) inhibitor - in patients at high risk for cardiovascular events .,"['The', 'Heart', 'Outcomes', 'Prevention', 'Evaluation', '(', 'HOPE', ')', 'study', 'was', 'important', 'because', 'it', 'showed', 'the', 'benefits', 'of', 'ramipril', '-', 'an', 'angiotensin-converting', 'enzyme', '(', 'ACE', ')', 'inhibitor', '-', 'in', 'patients', 'at', 'high', 'risk', 'for', 'cardiovascular', 'events', '.']","(17, 18)","(103, 111)",-1,hl_i,11381289,Abstract,0,test,gold,5397.0
725,The Heart Outcomes Prevention Evaluation ( HOPE ) study was important because it showed the benefits of ramipril - an,angiotensin-converting enzyme ( ACE ) inhibitor,- in patients at high risk for cardiovascular events .,"['The', 'Heart', 'Outcomes', 'Prevention', 'Evaluation', '(', 'HOPE', ')', 'study', 'was', 'important', 'because', 'it', 'showed', 'the', 'benefits', 'of', 'ramipril', '-', 'an', 'angiotensin-converting', 'enzyme', '(', 'ACE', ')', 'inhibitor', '-', 'in', 'patients', 'at', 'high', 'risk', 'for', 'cardiovascular', 'events', '.']","(20, 26)","(117, 164)",-1,hl_i,11381289,Abstract,0,test,gold,4562.0
726,Treatment with,ramipril,"significantly reduced the rates of death , myocardial infarction , stroke , coronary revascularization , cardiac arrest and heart failure , as well as the risk of diabetes-related complications and of diabetes itself .","['Treatment', 'with', 'ramipril', 'significantly', 'reduced', 'the', 'rates', 'of', 'death', ',', 'myocardial', 'infarction', ',', 'stroke', ',', 'coronary', 'revascularization', ',', 'cardiac', 'arrest', 'and', 'heart', 'failure', ',', 'as', 'well', 'as', 'the', 'risk', 'of', 'diabetes-related', 'complications', 'and', 'of', 'diabetes', 'itself', '.']","(2, 3)","(14, 22)",-1,ss_i,11381289,Abstract,1,test,gold,5395.0
727,Treatment with ramipril significantly reduced the,"rates of death , myocardial infarction , stroke , coronary revascularization , cardiac arrest and heart failure",", as well as the risk of diabetes-related complications and of diabetes itself .","['Treatment', 'with', 'ramipril', 'significantly', 'reduced', 'the', 'rates', 'of', 'death', ',', 'myocardial', 'infarction', ',', 'stroke', ',', 'coronary', 'revascularization', ',', 'cardiac', 'arrest', 'and', 'heart', 'failure', ',', 'as', 'well', 'as', 'the', 'risk', 'of', 'diabetes-related', 'complications', 'and', 'of', 'diabetes', 'itself', '.']","(6, 23)","(49, 160)",-1,ss_o,11381289,Abstract,1,test,gold,6002.0
728,"Treatment with ramipril significantly reduced the rates of death , myocardial infarction , stroke , coronary revascularization , cardiac arrest and heart failure , as well as the",risk of diabetes-related complications and of diabetes itself .,,"['Treatment', 'with', 'ramipril', 'significantly', 'reduced', 'the', 'rates', 'of', 'death', ',', 'myocardial', 'infarction', ',', 'stroke', ',', 'coronary', 'revascularization', ',', 'cardiac', 'arrest', 'and', 'heart', 'failure', ',', 'as', 'well', 'as', 'the', 'risk', 'of', 'diabetes-related', 'complications', 'and', 'of', 'diabetes', 'itself', '.']","(28, 37)","(178, 241)",-1,ss_o,11381289,Abstract,1,test,gold,6941.0
729,Treatment with,ramipril,"significantly reduced the rates of death , myocardial infarction , stroke , coronary revascularization , cardiac arrest and heart failure , as well as the risk of diabetes-related complications and of diabetes itself .","['Treatment', 'with', 'ramipril', 'significantly', 'reduced', 'the', 'rates', 'of', 'death', ',', 'myocardial', 'infarction', ',', 'stroke', ',', 'coronary', 'revascularization', ',', 'cardiac', 'arrest', 'and', 'heart', 'failure', ',', 'as', 'well', 'as', 'the', 'risk', 'of', 'diabetes-related', 'complications', 'and', 'of', 'diabetes', 'itself', '.']","(2, 3)","(14, 22)",-1,hl_i,11381289,Abstract,1,test,gold,5394.0
730,Treatment with ramipril significantly reduced the,"rates of death , myocardial infarction , stroke , coronary revascularization , cardiac arrest and heart failure",", as well as the risk of diabetes-related complications and of diabetes itself .","['Treatment', 'with', 'ramipril', 'significantly', 'reduced', 'the', 'rates', 'of', 'death', ',', 'myocardial', 'infarction', ',', 'stroke', ',', 'coronary', 'revascularization', ',', 'cardiac', 'arrest', 'and', 'heart', 'failure', ',', 'as', 'well', 'as', 'the', 'risk', 'of', 'diabetes-related', 'complications', 'and', 'of', 'diabetes', 'itself', '.']","(6, 23)","(49, 160)",-1,hl_o,11381289,Abstract,1,test,gold,6003.0
731,"Treatment with ramipril significantly reduced the rates of death , myocardial infarction , stroke , coronary revascularization , cardiac arrest and heart failure , as well as the",risk of diabetes-related complications and of diabetes itself .,,"['Treatment', 'with', 'ramipril', 'significantly', 'reduced', 'the', 'rates', 'of', 'death', ',', 'myocardial', 'infarction', ',', 'stroke', ',', 'coronary', 'revascularization', ',', 'cardiac', 'arrest', 'and', 'heart', 'failure', ',', 'as', 'well', 'as', 'the', 'risk', 'of', 'diabetes-related', 'complications', 'and', 'of', 'diabetes', 'itself', '.']","(28, 37)","(178, 241)",-1,hl_o,11381289,Abstract,1,test,gold,6942.0
732,The effects of therapy with,vitamin E,"were also evaluated , but no statistical benefits were shown .","['The', 'effects', 'of', 'therapy', 'with', 'vitamin', 'E', 'were', 'also', 'evaluated', ',', 'but', 'no', 'statistical', 'benefits', 'were', 'shown', '.']","(5, 7)","(27, 36)",-1,ss_i,11381289,Abstract,2,test,gold,4625.0
733,The effects of therapy with,vitamin E,"were also evaluated , but no statistical benefits were shown .","['The', 'effects', 'of', 'therapy', 'with', 'vitamin', 'E', 'were', 'also', 'evaluated', ',', 'but', 'no', 'statistical', 'benefits', 'were', 'shown', '.']","(5, 7)","(27, 36)",-1,hl_i,11381289,Abstract,2,test,gold,4624.0
734,The benefits of,ACE inhibitor,"therapy that were observed were likely due to a variety of mechanisms , not just a reduction in blood pressure .","['The', 'benefits', 'of', 'ACE', 'inhibitor', 'therapy', 'that', 'were', 'observed', 'were', 'likely', 'due', 'to', 'a', 'variety', 'of', 'mechanisms', ',', 'not', 'just', 'a', 'reduction', 'in', 'blood', 'pressure', '.']","(3, 5)","(15, 28)",-1,ss_i,11381289,Abstract,3,test,gold,4555.0
735,The benefits of,ACE inhibitor,"therapy that were observed were likely due to a variety of mechanisms , not just a reduction in blood pressure .","['The', 'benefits', 'of', 'ACE', 'inhibitor', 'therapy', 'that', 'were', 'observed', 'were', 'likely', 'due', 'to', 'a', 'variety', 'of', 'mechanisms', ',', 'not', 'just', 'a', 'reduction', 'in', 'blood', 'pressure', '.']","(3, 5)","(15, 28)",-1,hl_i,11381289,Abstract,3,test,gold,4556.0
736,Additive IOP-reducing effect of latanoprost in,patients insufficiently controlled on timolol .,,"['Additive', 'IOP-reducing', 'effect', 'of', 'latanoprost', 'in', 'patients', 'insufficiently', 'controlled', 'on', 'timolol', '.']","(6, 12)","(46, 93)",-1,ss_p,11401641,Title,0,test,gold,3865.0
737,Additive IOP-reducing effect of,latanoprost,in patients insufficiently controlled on timolol .,"['Additive', 'IOP-reducing', 'effect', 'of', 'latanoprost', 'in', 'patients', 'insufficiently', 'controlled', 'on', 'timolol', '.']","(4, 5)","(31, 42)",-1,ss_i,11401641,Title,0,test,gold,5488.0
738,Additive,IOP-reducing,effect of latanoprost in patients insufficiently controlled on timolol .,"['Additive', 'IOP-reducing', 'effect', 'of', 'latanoprost', 'in', 'patients', 'insufficiently', 'controlled', 'on', 'timolol', '.']","(1, 2)","(8, 20)",-1,ss_o,11401641,Title,0,test,gold,
739,Additive IOP-reducing effect of latanoprost in,patients insufficiently controlled on timolol .,,"['Additive', 'IOP-reducing', 'effect', 'of', 'latanoprost', 'in', 'patients', 'insufficiently', 'controlled', 'on', 'timolol', '.']","(6, 12)","(46, 93)",-1,hl_p,11401641,Title,0,test,gold,3866.0
740,Additive,IOP-reducing,effect of latanoprost in patients insufficiently controlled on timolol .,"['Additive', 'IOP-reducing', 'effect', 'of', 'latanoprost', 'in', 'patients', 'insufficiently', 'controlled', 'on', 'timolol', '.']","(1, 2)","(8, 20)",-1,hl_o,11401641,Title,0,test,gold,
741,PURPOSE To evaluate the effect on intraocular pressure ( IOP ) of switching from timolol to latanoprost or adding latanoprost to timolol,in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .,,"['PURPOSE', 'To', 'evaluate', 'the', 'effect', 'on', 'intraocular', 'pressure', '(', 'IOP', ')', 'of', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'or', 'adding', 'latanoprost', 'to', 'timolol', 'in', 'patients', 'with', 'open', 'angle', 'glaucoma', 'or', 'ocular', 'hypertension', 'where', 'IOP', 'is', 'not', 'adequately', 'controlled', 'with', 'timolol', '.']","(22, 40)","(136, 249)",-1,ss_p,11401641,Abstract,0,test,gold,6000.0
742,PURPOSE To evaluate the effect on intraocular pressure ( IOP ) of switching from,timolol,to latanoprost or adding latanoprost to timolol in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .,"['PURPOSE', 'To', 'evaluate', 'the', 'effect', 'on', 'intraocular', 'pressure', '(', 'IOP', ')', 'of', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'or', 'adding', 'latanoprost', 'to', 'timolol', 'in', 'patients', 'with', 'open', 'angle', 'glaucoma', 'or', 'ocular', 'hypertension', 'where', 'IOP', 'is', 'not', 'adequately', 'controlled', 'with', 'timolol', '.']","(14, 15)","(80, 87)",-1,ss_i,11401641,Abstract,0,test,gold,5474.0
743,PURPOSE To evaluate the effect on intraocular pressure ( IOP ) of switching from timolol to,latanoprost,or adding latanoprost to timolol in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .,"['PURPOSE', 'To', 'evaluate', 'the', 'effect', 'on', 'intraocular', 'pressure', '(', 'IOP', ')', 'of', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'or', 'adding', 'latanoprost', 'to', 'timolol', 'in', 'patients', 'with', 'open', 'angle', 'glaucoma', 'or', 'ocular', 'hypertension', 'where', 'IOP', 'is', 'not', 'adequately', 'controlled', 'with', 'timolol', '.']","(16, 17)","(91, 102)",-1,ss_i,11401641,Abstract,0,test,gold,5489.0
744,PURPOSE To evaluate the effect on intraocular pressure ( IOP ) of switching from timolol to latanoprost or adding,latanoprost,to timolol in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .,"['PURPOSE', 'To', 'evaluate', 'the', 'effect', 'on', 'intraocular', 'pressure', '(', 'IOP', ')', 'of', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'or', 'adding', 'latanoprost', 'to', 'timolol', 'in', 'patients', 'with', 'open', 'angle', 'glaucoma', 'or', 'ocular', 'hypertension', 'where', 'IOP', 'is', 'not', 'adequately', 'controlled', 'with', 'timolol', '.']","(19, 20)","(113, 124)",-1,ss_i,11401641,Abstract,0,test,gold,5487.0
745,PURPOSE To evaluate the effect on intraocular pressure ( IOP ) of switching from timolol to latanoprost or adding latanoprost to,timolol,in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .,"['PURPOSE', 'To', 'evaluate', 'the', 'effect', 'on', 'intraocular', 'pressure', '(', 'IOP', ')', 'of', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'or', 'adding', 'latanoprost', 'to', 'timolol', 'in', 'patients', 'with', 'open', 'angle', 'glaucoma', 'or', 'ocular', 'hypertension', 'where', 'IOP', 'is', 'not', 'adequately', 'controlled', 'with', 'timolol', '.']","(21, 22)","(128, 135)",-1,ss_i,11401641,Abstract,0,test,gold,5475.0
746,PURPOSE To evaluate the effect on,intraocular pressure ( IOP ),of switching from timolol to latanoprost or adding latanoprost to timolol in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .,"['PURPOSE', 'To', 'evaluate', 'the', 'effect', 'on', 'intraocular', 'pressure', '(', 'IOP', ')', 'of', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'or', 'adding', 'latanoprost', 'to', 'timolol', 'in', 'patients', 'with', 'open', 'angle', 'glaucoma', 'or', 'ocular', 'hypertension', 'where', 'IOP', 'is', 'not', 'adequately', 'controlled', 'with', 'timolol', '.']","(6, 11)","(33, 61)",-1,ss_o,11401641,Abstract,0,test,gold,1690.0
747,PURPOSE To evaluate the effect on intraocular pressure ( IOP ) of switching from timolol to latanoprost or adding latanoprost to timolol in,patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .,,"['PURPOSE', 'To', 'evaluate', 'the', 'effect', 'on', 'intraocular', 'pressure', '(', 'IOP', ')', 'of', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'or', 'adding', 'latanoprost', 'to', 'timolol', 'in', 'patients', 'with', 'open', 'angle', 'glaucoma', 'or', 'ocular', 'hypertension', 'where', 'IOP', 'is', 'not', 'adequately', 'controlled', 'with', 'timolol', '.']","(23, 40)","(139, 249)",-1,hl_p,11401641,Abstract,0,test,gold,6001.0
748,PURPOSE To evaluate the effect on intraocular pressure ( IOP ) of switching from,timolol,to latanoprost or adding latanoprost to timolol in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .,"['PURPOSE', 'To', 'evaluate', 'the', 'effect', 'on', 'intraocular', 'pressure', '(', 'IOP', ')', 'of', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'or', 'adding', 'latanoprost', 'to', 'timolol', 'in', 'patients', 'with', 'open', 'angle', 'glaucoma', 'or', 'ocular', 'hypertension', 'where', 'IOP', 'is', 'not', 'adequately', 'controlled', 'with', 'timolol', '.']","(14, 15)","(80, 87)",-1,hl_i,11401641,Abstract,0,test,gold,5473.0
749,PURPOSE To evaluate the effect on intraocular pressure ( IOP ) of switching from timolol to,latanoprost,or adding latanoprost to timolol in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .,"['PURPOSE', 'To', 'evaluate', 'the', 'effect', 'on', 'intraocular', 'pressure', '(', 'IOP', ')', 'of', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'or', 'adding', 'latanoprost', 'to', 'timolol', 'in', 'patients', 'with', 'open', 'angle', 'glaucoma', 'or', 'ocular', 'hypertension', 'where', 'IOP', 'is', 'not', 'adequately', 'controlled', 'with', 'timolol', '.']","(16, 17)","(91, 102)",-1,hl_i,11401641,Abstract,0,test,gold,5486.0
750,PURPOSE To evaluate the effect on intraocular pressure ( IOP ) of switching from timolol to latanoprost or adding,latanoprost,to timolol in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .,"['PURPOSE', 'To', 'evaluate', 'the', 'effect', 'on', 'intraocular', 'pressure', '(', 'IOP', ')', 'of', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'or', 'adding', 'latanoprost', 'to', 'timolol', 'in', 'patients', 'with', 'open', 'angle', 'glaucoma', 'or', 'ocular', 'hypertension', 'where', 'IOP', 'is', 'not', 'adequately', 'controlled', 'with', 'timolol', '.']","(19, 20)","(113, 124)",-1,hl_i,11401641,Abstract,0,test,gold,5485.0
751,PURPOSE To evaluate the effect on intraocular pressure ( IOP ) of switching from timolol to latanoprost or adding latanoprost to,timolol,in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .,"['PURPOSE', 'To', 'evaluate', 'the', 'effect', 'on', 'intraocular', 'pressure', '(', 'IOP', ')', 'of', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'or', 'adding', 'latanoprost', 'to', 'timolol', 'in', 'patients', 'with', 'open', 'angle', 'glaucoma', 'or', 'ocular', 'hypertension', 'where', 'IOP', 'is', 'not', 'adequately', 'controlled', 'with', 'timolol', '.']","(21, 22)","(128, 135)",-1,hl_i,11401641,Abstract,0,test,gold,5472.0
752,PURPOSE To evaluate the effect on,intraocular pressure ( IOP ),of switching from timolol to latanoprost or adding latanoprost to timolol in patients with open angle glaucoma or ocular hypertension where IOP is not adequately controlled with timolol .,"['PURPOSE', 'To', 'evaluate', 'the', 'effect', 'on', 'intraocular', 'pressure', '(', 'IOP', ')', 'of', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'or', 'adding', 'latanoprost', 'to', 'timolol', 'in', 'patients', 'with', 'open', 'angle', 'glaucoma', 'or', 'ocular', 'hypertension', 'where', 'IOP', 'is', 'not', 'adequately', 'controlled', 'with', 'timolol', '.']","(6, 11)","(33, 61)",-1,hl_o,11401641,Abstract,0,test,gold,1691.0
753,"METHODS This was a 6-week , double-masked , randomised multi-centre study .",,,"['METHODS', 'This', 'was', 'a', '6-week', ',', 'double-masked', ',', 'randomised', 'multi-centre', 'study', '.']",,,,,11401641,Abstract,1,test,gold,
754,,"53 patients with primary open angle glaucoma , capsular glaucoma , or ocular hypertension with an IOP of at least 21 mmHg on current therapy",were recruited .,"['53', 'patients', 'with', 'primary', 'open', 'angle', 'glaucoma', ',', 'capsular', 'glaucoma', ',', 'or', 'ocular', 'hypertension', 'with', 'an', 'IOP', 'of', 'at', 'least', '21', 'mmHg', 'on', 'current', 'therapy', 'were', 'recruited', '.']","(0, 25)","(0, 140)",-1,ss_p,11401641,Abstract,2,test,gold,5998.0
755,,"53 patients with primary open angle glaucoma , capsular glaucoma , or ocular hypertension with an IOP of at least 21 mmHg on current therapy",were recruited .,"['53', 'patients', 'with', 'primary', 'open', 'angle', 'glaucoma', ',', 'capsular', 'glaucoma', ',', 'or', 'ocular', 'hypertension', 'with', 'an', 'IOP', 'of', 'at', 'least', '21', 'mmHg', 'on', 'current', 'therapy', 'were', 'recruited', '.']","(0, 25)","(0, 140)",-1,hl_p,11401641,Abstract,2,test,gold,5999.0
756,After a run-in period of at least 2 weeks on,timolol,", 5 mg/ml twice daily , patients were randomised to one of three groups .","['After', 'a', 'run-in', 'period', 'of', 'at', 'least', '2', 'weeks', 'on', 'timolol', ',', '5', 'mg/ml', 'twice', 'daily', ',', 'patients', 'were', 'randomised', 'to', 'one', 'of', 'three', 'groups', '.']","(10, 11)","(44, 51)",-1,ss_i,11401641,Abstract,3,test,gold,5471.0
757,After a run-in period of at least 2 weeks on,timolol,", 5 mg/ml twice daily , patients were randomised to one of three groups .","['After', 'a', 'run-in', 'period', 'of', 'at', 'least', '2', 'weeks', 'on', 'timolol', ',', '5', 'mg/ml', 'twice', 'daily', ',', 'patients', 'were', 'randomised', 'to', 'one', 'of', 'three', 'groups', '.']","(10, 11)","(44, 51)",-1,hl_i,11401641,Abstract,3,test,gold,5470.0
758,One group continued on,timolol,", one switched from timolol to latanoprost , 50 microg/ml once daily , and a third group received latanoprost in addition to timolol .","['One', 'group', 'continued', 'on', 'timolol', ',', 'one', 'switched', 'from', 'timolol', 'to', 'latanoprost', ',', '50', 'microg/ml', 'once', 'daily', ',', 'and', 'a', 'third', 'group', 'received', 'latanoprost', 'in', 'addition', 'to', 'timolol', '.']","(4, 5)","(22, 29)",-1,ss_i,11401641,Abstract,4,test,gold,5469.0
759,"One group continued on timolol , one switched from",timolol,"to latanoprost , 50 microg/ml once daily , and a third group received latanoprost in addition to timolol .","['One', 'group', 'continued', 'on', 'timolol', ',', 'one', 'switched', 'from', 'timolol', 'to', 'latanoprost', ',', '50', 'microg/ml', 'once', 'daily', ',', 'and', 'a', 'third', 'group', 'received', 'latanoprost', 'in', 'addition', 'to', 'timolol', '.']","(9, 10)","(50, 57)",-1,ss_i,11401641,Abstract,4,test,gold,5468.0
760,"One group continued on timolol , one switched from timolol to",latanoprost,", 50 microg/ml once daily , and a third group received latanoprost in addition to timolol .","['One', 'group', 'continued', 'on', 'timolol', ',', 'one', 'switched', 'from', 'timolol', 'to', 'latanoprost', ',', '50', 'microg/ml', 'once', 'daily', ',', 'and', 'a', 'third', 'group', 'received', 'latanoprost', 'in', 'addition', 'to', 'timolol', '.']","(11, 12)","(61, 72)",-1,ss_i,11401641,Abstract,4,test,gold,5484.0
761,"One group continued on timolol , one switched from timolol to latanoprost , 50 microg/ml once daily , and a third group received",latanoprost,in addition to timolol .,"['One', 'group', 'continued', 'on', 'timolol', ',', 'one', 'switched', 'from', 'timolol', 'to', 'latanoprost', ',', '50', 'microg/ml', 'once', 'daily', ',', 'and', 'a', 'third', 'group', 'received', 'latanoprost', 'in', 'addition', 'to', 'timolol', '.']","(23, 24)","(128, 139)",-1,ss_i,11401641,Abstract,4,test,gold,5483.0
762,"One group continued on timolol , one switched from timolol to latanoprost , 50 microg/ml once daily , and a third group received latanoprost in addition to",timolol .,,"['One', 'group', 'continued', 'on', 'timolol', ',', 'one', 'switched', 'from', 'timolol', 'to', 'latanoprost', ',', '50', 'microg/ml', 'once', 'daily', ',', 'and', 'a', 'third', 'group', 'received', 'latanoprost', 'in', 'addition', 'to', 'timolol', '.']","(27, 29)","(155, 164)",-1,ss_i,11401641,Abstract,4,test,gold,5467.0
763,One group continued on,timolol,", one switched from timolol to latanoprost , 50 microg/ml once daily , and a third group received latanoprost in addition to timolol .","['One', 'group', 'continued', 'on', 'timolol', ',', 'one', 'switched', 'from', 'timolol', 'to', 'latanoprost', ',', '50', 'microg/ml', 'once', 'daily', ',', 'and', 'a', 'third', 'group', 'received', 'latanoprost', 'in', 'addition', 'to', 'timolol', '.']","(4, 5)","(22, 29)",-1,hl_i,11401641,Abstract,4,test,gold,5466.0
764,"One group continued on timolol , one switched from",timolol,"to latanoprost , 50 microg/ml once daily , and a third group received latanoprost in addition to timolol .","['One', 'group', 'continued', 'on', 'timolol', ',', 'one', 'switched', 'from', 'timolol', 'to', 'latanoprost', ',', '50', 'microg/ml', 'once', 'daily', ',', 'and', 'a', 'third', 'group', 'received', 'latanoprost', 'in', 'addition', 'to', 'timolol', '.']","(9, 10)","(50, 57)",-1,hl_i,11401641,Abstract,4,test,gold,5465.0
765,"One group continued on timolol , one switched from timolol to",latanoprost,", 50 microg/ml once daily , and a third group received latanoprost in addition to timolol .","['One', 'group', 'continued', 'on', 'timolol', ',', 'one', 'switched', 'from', 'timolol', 'to', 'latanoprost', ',', '50', 'microg/ml', 'once', 'daily', ',', 'and', 'a', 'third', 'group', 'received', 'latanoprost', 'in', 'addition', 'to', 'timolol', '.']","(11, 12)","(61, 72)",-1,hl_i,11401641,Abstract,4,test,gold,5482.0
766,"One group continued on timolol , one switched from timolol to latanoprost , 50 microg/ml once daily , and a third group received",latanoprost,in addition to timolol .,"['One', 'group', 'continued', 'on', 'timolol', ',', 'one', 'switched', 'from', 'timolol', 'to', 'latanoprost', ',', '50', 'microg/ml', 'once', 'daily', ',', 'and', 'a', 'third', 'group', 'received', 'latanoprost', 'in', 'addition', 'to', 'timolol', '.']","(23, 24)","(128, 139)",-1,hl_i,11401641,Abstract,4,test,gold,5481.0
767,"One group continued on timolol , one switched from timolol to latanoprost , 50 microg/ml once daily , and a third group received latanoprost in addition to",timolol .,,"['One', 'group', 'continued', 'on', 'timolol', ',', 'one', 'switched', 'from', 'timolol', 'to', 'latanoprost', ',', '50', 'microg/ml', 'once', 'daily', ',', 'and', 'a', 'third', 'group', 'received', 'latanoprost', 'in', 'addition', 'to', 'timolol', '.']","(27, 29)","(155, 164)",-1,hl_i,11401641,Abstract,4,test,gold,5464.0
768,The,efficacy,was evaluated by comparing IOP at 9 AM at baseline and after 6 weeks of treatment .,"['The', 'efficacy', 'was', 'evaluated', 'by', 'comparing', 'IOP', 'at', '9', 'AM', 'at', 'baseline', 'and', 'after', '6', 'weeks', 'of', 'treatment', '.']","(1, 2)","(3, 11)",-1,ss_o,11401641,Abstract,5,test,gold,4835.0
769,The efficacy was evaluated by comparing,IOP,at 9 AM at baseline and after 6 weeks of treatment .,"['The', 'efficacy', 'was', 'evaluated', 'by', 'comparing', 'IOP', 'at', '9', 'AM', 'at', 'baseline', 'and', 'after', '6', 'weeks', 'of', 'treatment', '.']","(6, 7)","(39, 42)",-1,ss_o,11401641,Abstract,5,test,gold,1706.0
770,The efficacy was evaluated by comparing,IOP,at 9 AM at baseline and after 6 weeks of treatment .,"['The', 'efficacy', 'was', 'evaluated', 'by', 'comparing', 'IOP', 'at', '9', 'AM', 'at', 'baseline', 'and', 'after', '6', 'weeks', 'of', 'treatment', '.']","(6, 7)","(39, 42)",-1,hl_o,11401641,Abstract,5,test,gold,1707.0
771,RESULTS IOP at baseline and after 6 weeks of treatment ( mean +/- SEM ) were 24.2 +/- 0.9 and 23.8 +/- 1.0 mmHg ( n = 16 ) for patients continuing on,timolol,", 26.3 +/- 1.2 and 19.6 +/- 1.1 mmHg ( n = 17 ) for patients switching to latanoprost , and 23.2 +/- 1.0 and 17.5 +/- 0.8 mmHg ( n = 17 ) for patients with combined treatment .","['RESULTS', 'IOP', 'at', 'baseline', 'and', 'after', '6', 'weeks', 'of', 'treatment', '(', 'mean', '+/-', 'SEM', ')', 'were', '24.2', '+/-', '0.9', 'and', '23.8', '+/-', '1.0', 'mmHg', '(', 'n', '=', '16', ')', 'for', 'patients', 'continuing', 'on', 'timolol', ',', '26.3', '+/-', '1.2', 'and', '19.6', '+/-', '1.1', 'mmHg', '(', 'n', '=', '17', ')', 'for', 'patients', 'switching', 'to', 'latanoprost', ',', 'and', '23.2', '+/-', '1.0', 'and', '17.5', '+/-', '0.8', 'mmHg', '(', 'n', '=', '17', ')', 'for', 'patients', 'with', 'combined', 'treatment', '.']","(33, 34)","(149, 156)",-1,ss_i,11401641,Abstract,6,test,gold,5463.0
772,"RESULTS IOP at baseline and after 6 weeks of treatment ( mean +/- SEM ) were 24.2 +/- 0.9 and 23.8 +/- 1.0 mmHg ( n = 16 ) for patients continuing on timolol , 26.3 +/- 1.2 and 19.6 +/- 1.1 mmHg ( n = 17 ) for patients switching to",latanoprost,", and 23.2 +/- 1.0 and 17.5 +/- 0.8 mmHg ( n = 17 ) for patients with combined treatment .","['RESULTS', 'IOP', 'at', 'baseline', 'and', 'after', '6', 'weeks', 'of', 'treatment', '(', 'mean', '+/-', 'SEM', ')', 'were', '24.2', '+/-', '0.9', 'and', '23.8', '+/-', '1.0', 'mmHg', '(', 'n', '=', '16', ')', 'for', 'patients', 'continuing', 'on', 'timolol', ',', '26.3', '+/-', '1.2', 'and', '19.6', '+/-', '1.1', 'mmHg', '(', 'n', '=', '17', ')', 'for', 'patients', 'switching', 'to', 'latanoprost', ',', 'and', '23.2', '+/-', '1.0', 'and', '17.5', '+/-', '0.8', 'mmHg', '(', 'n', '=', '17', ')', 'for', 'patients', 'with', 'combined', 'treatment', '.']","(52, 53)","(231, 242)",-1,ss_i,11401641,Abstract,6,test,gold,5480.0
773,RESULTS,IOP,"at baseline and after 6 weeks of treatment ( mean +/- SEM ) were 24.2 +/- 0.9 and 23.8 +/- 1.0 mmHg ( n = 16 ) for patients continuing on timolol , 26.3 +/- 1.2 and 19.6 +/- 1.1 mmHg ( n = 17 ) for patients switching to latanoprost , and 23.2 +/- 1.0 and 17.5 +/- 0.8 mmHg ( n = 17 ) for patients with combined treatment .","['RESULTS', 'IOP', 'at', 'baseline', 'and', 'after', '6', 'weeks', 'of', 'treatment', '(', 'mean', '+/-', 'SEM', ')', 'were', '24.2', '+/-', '0.9', 'and', '23.8', '+/-', '1.0', 'mmHg', '(', 'n', '=', '16', ')', 'for', 'patients', 'continuing', 'on', 'timolol', ',', '26.3', '+/-', '1.2', 'and', '19.6', '+/-', '1.1', 'mmHg', '(', 'n', '=', '17', ')', 'for', 'patients', 'switching', 'to', 'latanoprost', ',', 'and', '23.2', '+/-', '1.0', 'and', '17.5', '+/-', '0.8', 'mmHg', '(', 'n', '=', '17', ')', 'for', 'patients', 'with', 'combined', 'treatment', '.']","(1, 2)","(7, 10)",-1,ss_o,11401641,Abstract,6,test,gold,1705.0
774,RESULTS,IOP,"at baseline and after 6 weeks of treatment ( mean +/- SEM ) were 24.2 +/- 0.9 and 23.8 +/- 1.0 mmHg ( n = 16 ) for patients continuing on timolol , 26.3 +/- 1.2 and 19.6 +/- 1.1 mmHg ( n = 17 ) for patients switching to latanoprost , and 23.2 +/- 1.0 and 17.5 +/- 0.8 mmHg ( n = 17 ) for patients with combined treatment .","['RESULTS', 'IOP', 'at', 'baseline', 'and', 'after', '6', 'weeks', 'of', 'treatment', '(', 'mean', '+/-', 'SEM', ')', 'were', '24.2', '+/-', '0.9', 'and', '23.8', '+/-', '1.0', 'mmHg', '(', 'n', '=', '16', ')', 'for', 'patients', 'continuing', 'on', 'timolol', ',', '26.3', '+/-', '1.2', 'and', '19.6', '+/-', '1.1', 'mmHg', '(', 'n', '=', '17', ')', 'for', 'patients', 'switching', 'to', 'latanoprost', ',', 'and', '23.2', '+/-', '1.0', 'and', '17.5', '+/-', '0.8', 'mmHg', '(', 'n', '=', '17', ')', 'for', 'patients', 'with', 'combined', 'treatment', '.']","(1, 2)","(7, 10)",-1,hl_o,11401641,Abstract,6,test,gold,1704.0
775,Adding,latanoprost,"to timolol reduced IOP with 5.9 +/- 0.9 mmHg ( p < 0.001 ) and switching from timolol to latanoprost reduced IOP with 5.0 +/- 0.9 mmHg ( p < 0.001 ) , which caused in each group a significant IOP reduction of about 25 % .","['Adding', 'latanoprost', 'to', 'timolol', 'reduced', 'IOP', 'with', '5.9', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', 'and', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'reduced', 'IOP', 'with', '5.0', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', ',', 'which', 'caused', 'in', 'each', 'group', 'a', 'significant', 'IOP', 'reduction', 'of', 'about', '25', '%', '.']","(1, 2)","(6, 17)",-1,ss_i,11401641,Abstract,7,test,gold,5479.0
776,Adding latanoprost to,timolol,"reduced IOP with 5.9 +/- 0.9 mmHg ( p < 0.001 ) and switching from timolol to latanoprost reduced IOP with 5.0 +/- 0.9 mmHg ( p < 0.001 ) , which caused in each group a significant IOP reduction of about 25 % .","['Adding', 'latanoprost', 'to', 'timolol', 'reduced', 'IOP', 'with', '5.9', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', 'and', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'reduced', 'IOP', 'with', '5.0', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', ',', 'which', 'caused', 'in', 'each', 'group', 'a', 'significant', 'IOP', 'reduction', 'of', 'about', '25', '%', '.']","(3, 4)","(21, 28)",-1,ss_i,11401641,Abstract,7,test,gold,5462.0
777,Adding latanoprost to timolol reduced IOP with 5.9 +/- 0.9 mmHg ( p < 0.001 ) and switching from,timolol,"to latanoprost reduced IOP with 5.0 +/- 0.9 mmHg ( p < 0.001 ) , which caused in each group a significant IOP reduction of about 25 % .","['Adding', 'latanoprost', 'to', 'timolol', 'reduced', 'IOP', 'with', '5.9', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', 'and', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'reduced', 'IOP', 'with', '5.0', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', ',', 'which', 'caused', 'in', 'each', 'group', 'a', 'significant', 'IOP', 'reduction', 'of', 'about', '25', '%', '.']","(19, 20)","(96, 103)",-1,ss_i,11401641,Abstract,7,test,gold,5461.0
778,Adding latanoprost to timolol reduced IOP with 5.9 +/- 0.9 mmHg ( p < 0.001 ) and switching from timolol to,latanoprost,"reduced IOP with 5.0 +/- 0.9 mmHg ( p < 0.001 ) , which caused in each group a significant IOP reduction of about 25 % .","['Adding', 'latanoprost', 'to', 'timolol', 'reduced', 'IOP', 'with', '5.9', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', 'and', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'reduced', 'IOP', 'with', '5.0', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', ',', 'which', 'caused', 'in', 'each', 'group', 'a', 'significant', 'IOP', 'reduction', 'of', 'about', '25', '%', '.']","(21, 22)","(107, 118)",-1,ss_i,11401641,Abstract,7,test,gold,5478.0
779,Adding latanoprost to timolol reduced,IOP,"with 5.9 +/- 0.9 mmHg ( p < 0.001 ) and switching from timolol to latanoprost reduced IOP with 5.0 +/- 0.9 mmHg ( p < 0.001 ) , which caused in each group a significant IOP reduction of about 25 % .","['Adding', 'latanoprost', 'to', 'timolol', 'reduced', 'IOP', 'with', '5.9', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', 'and', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'reduced', 'IOP', 'with', '5.0', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', ',', 'which', 'caused', 'in', 'each', 'group', 'a', 'significant', 'IOP', 'reduction', 'of', 'about', '25', '%', '.']","(5, 6)","(37, 40)",-1,ss_o,11401641,Abstract,7,test,gold,1703.0
780,Adding latanoprost to timolol reduced IOP with 5.9 +/- 0.9 mmHg ( p < 0.001 ) and switching from timolol to latanoprost reduced,IOP,"with 5.0 +/- 0.9 mmHg ( p < 0.001 ) , which caused in each group a significant IOP reduction of about 25 % .","['Adding', 'latanoprost', 'to', 'timolol', 'reduced', 'IOP', 'with', '5.9', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', 'and', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'reduced', 'IOP', 'with', '5.0', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', ',', 'which', 'caused', 'in', 'each', 'group', 'a', 'significant', 'IOP', 'reduction', 'of', 'about', '25', '%', '.']","(23, 24)","(127, 130)",-1,ss_o,11401641,Abstract,7,test,gold,1702.0
781,"Adding latanoprost to timolol reduced IOP with 5.9 +/- 0.9 mmHg ( p < 0.001 ) and switching from timolol to latanoprost reduced IOP with 5.0 +/- 0.9 mmHg ( p < 0.001 ) , which caused in each group a significant",IOP,reduction of about 25 % .,"['Adding', 'latanoprost', 'to', 'timolol', 'reduced', 'IOP', 'with', '5.9', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', 'and', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'reduced', 'IOP', 'with', '5.0', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', ',', 'which', 'caused', 'in', 'each', 'group', 'a', 'significant', 'IOP', 'reduction', 'of', 'about', '25', '%', '.']","(42, 43)","(210, 213)",-1,ss_o,11401641,Abstract,7,test,gold,1701.0
782,Adding latanoprost to timolol reduced,IOP,"with 5.9 +/- 0.9 mmHg ( p < 0.001 ) and switching from timolol to latanoprost reduced IOP with 5.0 +/- 0.9 mmHg ( p < 0.001 ) , which caused in each group a significant IOP reduction of about 25 % .","['Adding', 'latanoprost', 'to', 'timolol', 'reduced', 'IOP', 'with', '5.9', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', 'and', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'reduced', 'IOP', 'with', '5.0', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', ',', 'which', 'caused', 'in', 'each', 'group', 'a', 'significant', 'IOP', 'reduction', 'of', 'about', '25', '%', '.']","(5, 6)","(37, 40)",-1,hl_o,11401641,Abstract,7,test,gold,1700.0
783,Adding latanoprost to timolol reduced IOP with 5.9 +/- 0.9 mmHg ( p < 0.001 ) and switching from timolol to latanoprost reduced,IOP,"with 5.0 +/- 0.9 mmHg ( p < 0.001 ) , which caused in each group a significant IOP reduction of about 25 % .","['Adding', 'latanoprost', 'to', 'timolol', 'reduced', 'IOP', 'with', '5.9', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', 'and', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'reduced', 'IOP', 'with', '5.0', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', ',', 'which', 'caused', 'in', 'each', 'group', 'a', 'significant', 'IOP', 'reduction', 'of', 'about', '25', '%', '.']","(23, 24)","(127, 130)",-1,hl_o,11401641,Abstract,7,test,gold,1699.0
784,"Adding latanoprost to timolol reduced IOP with 5.9 +/- 0.9 mmHg ( p < 0.001 ) and switching from timolol to latanoprost reduced IOP with 5.0 +/- 0.9 mmHg ( p < 0.001 ) , which caused in each group a significant",IOP,reduction of about 25 % .,"['Adding', 'latanoprost', 'to', 'timolol', 'reduced', 'IOP', 'with', '5.9', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', 'and', 'switching', 'from', 'timolol', 'to', 'latanoprost', 'reduced', 'IOP', 'with', '5.0', '+/-', '0.9', 'mmHg', '(', 'p', '<', '0.001', ')', ',', 'which', 'caused', 'in', 'each', 'group', 'a', 'significant', 'IOP', 'reduction', 'of', 'about', '25', '%', '.']","(42, 43)","(210, 213)",-1,hl_o,11401641,Abstract,7,test,gold,1698.0
785,CONCLUSIONS The effect of,latanoprost,"was additive to that of timolol , and a good effect on IOP reduction was also achieved by switching from timolol to latanoprost , suggesting that a switch in many patients is an effective alternative to combination treatment .","['CONCLUSIONS', 'The', 'effect', 'of', 'latanoprost', 'was', 'additive', 'to', 'that', 'of', 'timolol', ',', 'and', 'a', 'good', 'effect', 'on', 'IOP', 'reduction', 'was', 'also', 'achieved', 'by', 'switching', 'from', 'timolol', 'to', 'latanoprost', ',', 'suggesting', 'that', 'a', 'switch', 'in', 'many', 'patients', 'is', 'an', 'effective', 'alternative', 'to', 'combination', 'treatment', '.']","(4, 5)","(25, 36)",-1,ss_i,11401641,Abstract,8,test,gold,5477.0
786,CONCLUSIONS The effect of latanoprost was additive to that of,timolol,", and a good effect on IOP reduction was also achieved by switching from timolol to latanoprost , suggesting that a switch in many patients is an effective alternative to combination treatment .","['CONCLUSIONS', 'The', 'effect', 'of', 'latanoprost', 'was', 'additive', 'to', 'that', 'of', 'timolol', ',', 'and', 'a', 'good', 'effect', 'on', 'IOP', 'reduction', 'was', 'also', 'achieved', 'by', 'switching', 'from', 'timolol', 'to', 'latanoprost', ',', 'suggesting', 'that', 'a', 'switch', 'in', 'many', 'patients', 'is', 'an', 'effective', 'alternative', 'to', 'combination', 'treatment', '.']","(10, 11)","(61, 68)",-1,ss_i,11401641,Abstract,8,test,gold,5460.0
787,"CONCLUSIONS The effect of latanoprost was additive to that of timolol , and a good effect on IOP reduction was also achieved by switching from",timolol,"to latanoprost , suggesting that a switch in many patients is an effective alternative to combination treatment .","['CONCLUSIONS', 'The', 'effect', 'of', 'latanoprost', 'was', 'additive', 'to', 'that', 'of', 'timolol', ',', 'and', 'a', 'good', 'effect', 'on', 'IOP', 'reduction', 'was', 'also', 'achieved', 'by', 'switching', 'from', 'timolol', 'to', 'latanoprost', ',', 'suggesting', 'that', 'a', 'switch', 'in', 'many', 'patients', 'is', 'an', 'effective', 'alternative', 'to', 'combination', 'treatment', '.']","(25, 26)","(142, 149)",-1,ss_i,11401641,Abstract,8,test,gold,5459.0
788,"CONCLUSIONS The effect of latanoprost was additive to that of timolol , and a good effect on IOP reduction was also achieved by switching from timolol to",latanoprost,", suggesting that a switch in many patients is an effective alternative to combination treatment .","['CONCLUSIONS', 'The', 'effect', 'of', 'latanoprost', 'was', 'additive', 'to', 'that', 'of', 'timolol', ',', 'and', 'a', 'good', 'effect', 'on', 'IOP', 'reduction', 'was', 'also', 'achieved', 'by', 'switching', 'from', 'timolol', 'to', 'latanoprost', ',', 'suggesting', 'that', 'a', 'switch', 'in', 'many', 'patients', 'is', 'an', 'effective', 'alternative', 'to', 'combination', 'treatment', '.']","(27, 28)","(153, 164)",-1,ss_i,11401641,Abstract,8,test,gold,5476.0
789,"CONCLUSIONS The effect of latanoprost was additive to that of timolol , and a good effect on",IOP,"reduction was also achieved by switching from timolol to latanoprost , suggesting that a switch in many patients is an effective alternative to combination treatment .","['CONCLUSIONS', 'The', 'effect', 'of', 'latanoprost', 'was', 'additive', 'to', 'that', 'of', 'timolol', ',', 'and', 'a', 'good', 'effect', 'on', 'IOP', 'reduction', 'was', 'also', 'achieved', 'by', 'switching', 'from', 'timolol', 'to', 'latanoprost', ',', 'suggesting', 'that', 'a', 'switch', 'in', 'many', 'patients', 'is', 'an', 'effective', 'alternative', 'to', 'combination', 'treatment', '.']","(17, 18)","(92, 95)",-1,ss_o,11401641,Abstract,8,test,gold,1697.0
790,"CONCLUSIONS The effect of latanoprost was additive to that of timolol , and a good effect on",IOP,"reduction was also achieved by switching from timolol to latanoprost , suggesting that a switch in many patients is an effective alternative to combination treatment .","['CONCLUSIONS', 'The', 'effect', 'of', 'latanoprost', 'was', 'additive', 'to', 'that', 'of', 'timolol', ',', 'and', 'a', 'good', 'effect', 'on', 'IOP', 'reduction', 'was', 'also', 'achieved', 'by', 'switching', 'from', 'timolol', 'to', 'latanoprost', ',', 'suggesting', 'that', 'a', 'switch', 'in', 'many', 'patients', 'is', 'an', 'effective', 'alternative', 'to', 'combination', 'treatment', '.']","(17, 18)","(92, 95)",-1,hl_o,11401641,Abstract,8,test,gold,1696.0
791,,Recurrent epithelial ovarian carcinoma :,a randomized phase III study of pegylated liposomal doxorubicin versus topotecan .,"['Recurrent', 'epithelial', 'ovarian', 'carcinoma', ':', 'a', 'randomized', 'phase', 'III', 'study', 'of', 'pegylated', 'liposomal', 'doxorubicin', 'versus', 'topotecan', '.']","(0, 5)","(0, 40)",-1,ss_p,11454878,Title,0,test,gold,6865.0
792,Recurrent epithelial ovarian carcinoma : a randomized phase III study of,pegylated liposomal doxorubicin,versus topotecan .,"['Recurrent', 'epithelial', 'ovarian', 'carcinoma', ':', 'a', 'randomized', 'phase', 'III', 'study', 'of', 'pegylated', 'liposomal', 'doxorubicin', 'versus', 'topotecan', '.']","(11, 14)","(72, 103)",-1,ss_i,11454878,Title,0,test,gold,6679.0
793,Recurrent epithelial ovarian carcinoma : a randomized phase III study of pegylated liposomal doxorubicin versus,topotecan .,,"['Recurrent', 'epithelial', 'ovarian', 'carcinoma', ':', 'a', 'randomized', 'phase', 'III', 'study', 'of', 'pegylated', 'liposomal', 'doxorubicin', 'versus', 'topotecan', '.']","(15, 17)","(111, 122)",-1,ss_i,11454878,Title,0,test,gold,5714.0
794,Recurrent epithelial ovarian carcinoma : a randomized phase III study of,pegylated liposomal doxorubicin,versus topotecan .,"['Recurrent', 'epithelial', 'ovarian', 'carcinoma', ':', 'a', 'randomized', 'phase', 'III', 'study', 'of', 'pegylated', 'liposomal', 'doxorubicin', 'versus', 'topotecan', '.']","(11, 14)","(72, 103)",-1,hl_i,11454878,Title,0,test,gold,6680.0
795,Recurrent epithelial ovarian carcinoma : a randomized phase III study of pegylated liposomal doxorubicin versus,topotecan .,,"['Recurrent', 'epithelial', 'ovarian', 'carcinoma', ':', 'a', 'randomized', 'phase', 'III', 'study', 'of', 'pegylated', 'liposomal', 'doxorubicin', 'versus', 'topotecan', '.']","(15, 17)","(111, 122)",-1,hl_i,11454878,Title,0,test,gold,5715.0
796,PURPOSE To compare the efficacy and safety of pegylated liposomal doxorubicin ( PLD ) and topotecan in,"patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy .",,"['PURPOSE', 'To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'pegylated', 'liposomal', 'doxorubicin', '(', 'PLD', ')', 'and', 'topotecan', 'in', 'patients', 'with', 'epithelial', 'ovarian', 'carcinoma', 'that', 'recurred', 'after', 'or', 'did', ""n't"", 'respond', 'to', 'first-line', ',', 'platinum-based', 'chemotherapy', '.']","(17, 35)","(102, 229)",-1,ss_p,11454878,Abstract,0,test,gold,5921.0
797,PURPOSE To compare the efficacy and safety of,pegylated liposomal doxorubicin ( PLD ),"and topotecan in patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy .","['PURPOSE', 'To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'pegylated', 'liposomal', 'doxorubicin', '(', 'PLD', ')', 'and', 'topotecan', 'in', 'patients', 'with', 'epithelial', 'ovarian', 'carcinoma', 'that', 'recurred', 'after', 'or', 'did', ""n't"", 'respond', 'to', 'first-line', ',', 'platinum-based', 'chemotherapy', '.']","(8, 14)","(45, 84)",-1,ss_i,11454878,Abstract,0,test,gold,6681.0
798,PURPOSE To compare the efficacy and safety of pegylated liposomal doxorubicin ( PLD ) and,topotecan,"in patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy .","['PURPOSE', 'To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'pegylated', 'liposomal', 'doxorubicin', '(', 'PLD', ')', 'and', 'topotecan', 'in', 'patients', 'with', 'epithelial', 'ovarian', 'carcinoma', 'that', 'recurred', 'after', 'or', 'did', ""n't"", 'respond', 'to', 'first-line', ',', 'platinum-based', 'chemotherapy', '.']","(15, 16)","(89, 98)",-1,ss_i,11454878,Abstract,0,test,gold,5713.0
799,PURPOSE To compare the,efficacy,"and safety of pegylated liposomal doxorubicin ( PLD ) and topotecan in patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy .","['PURPOSE', 'To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'pegylated', 'liposomal', 'doxorubicin', '(', 'PLD', ')', 'and', 'topotecan', 'in', 'patients', 'with', 'epithelial', 'ovarian', 'carcinoma', 'that', 'recurred', 'after', 'or', 'did', ""n't"", 'respond', 'to', 'first-line', ',', 'platinum-based', 'chemotherapy', '.']","(4, 5)","(22, 30)",-1,ss_o,11454878,Abstract,0,test,gold,4834.0
800,PURPOSE To compare the efficacy and,safety,"of pegylated liposomal doxorubicin ( PLD ) and topotecan in patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy .","['PURPOSE', 'To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'pegylated', 'liposomal', 'doxorubicin', '(', 'PLD', ')', 'and', 'topotecan', 'in', 'patients', 'with', 'epithelial', 'ovarian', 'carcinoma', 'that', 'recurred', 'after', 'or', 'did', ""n't"", 'respond', 'to', 'first-line', ',', 'platinum-based', 'chemotherapy', '.']","(6, 7)","(35, 41)",-1,ss_o,11454878,Abstract,0,test,gold,487.0
801,PURPOSE To compare the efficacy and safety of pegylated liposomal doxorubicin ( PLD ) and topotecan in,"patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy .",,"['PURPOSE', 'To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'pegylated', 'liposomal', 'doxorubicin', '(', 'PLD', ')', 'and', 'topotecan', 'in', 'patients', 'with', 'epithelial', 'ovarian', 'carcinoma', 'that', 'recurred', 'after', 'or', 'did', ""n't"", 'respond', 'to', 'first-line', ',', 'platinum-based', 'chemotherapy', '.']","(17, 35)","(102, 229)",-1,hl_p,11454878,Abstract,0,test,gold,5922.0
802,PURPOSE To compare the efficacy and safety of,pegylated liposomal doxorubicin ( PLD ),"and topotecan in patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy .","['PURPOSE', 'To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'pegylated', 'liposomal', 'doxorubicin', '(', 'PLD', ')', 'and', 'topotecan', 'in', 'patients', 'with', 'epithelial', 'ovarian', 'carcinoma', 'that', 'recurred', 'after', 'or', 'did', ""n't"", 'respond', 'to', 'first-line', ',', 'platinum-based', 'chemotherapy', '.']","(8, 14)","(45, 84)",-1,hl_i,11454878,Abstract,0,test,gold,6682.0
803,PURPOSE To compare the efficacy and safety of pegylated liposomal doxorubicin ( PLD ) and,topotecan,"in patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy .","['PURPOSE', 'To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'pegylated', 'liposomal', 'doxorubicin', '(', 'PLD', ')', 'and', 'topotecan', 'in', 'patients', 'with', 'epithelial', 'ovarian', 'carcinoma', 'that', 'recurred', 'after', 'or', 'did', ""n't"", 'respond', 'to', 'first-line', ',', 'platinum-based', 'chemotherapy', '.']","(15, 16)","(89, 98)",-1,hl_i,11454878,Abstract,0,test,gold,5712.0
804,PURPOSE To compare the,efficacy,"and safety of pegylated liposomal doxorubicin ( PLD ) and topotecan in patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy .","['PURPOSE', 'To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'pegylated', 'liposomal', 'doxorubicin', '(', 'PLD', ')', 'and', 'topotecan', 'in', 'patients', 'with', 'epithelial', 'ovarian', 'carcinoma', 'that', 'recurred', 'after', 'or', 'did', ""n't"", 'respond', 'to', 'first-line', ',', 'platinum-based', 'chemotherapy', '.']","(4, 5)","(22, 30)",-1,hl_o,11454878,Abstract,0,test,gold,4833.0
805,PURPOSE To compare the efficacy and,safety,"of pegylated liposomal doxorubicin ( PLD ) and topotecan in patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy .","['PURPOSE', 'To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'pegylated', 'liposomal', 'doxorubicin', '(', 'PLD', ')', 'and', 'topotecan', 'in', 'patients', 'with', 'epithelial', 'ovarian', 'carcinoma', 'that', 'recurred', 'after', 'or', 'did', ""n't"", 'respond', 'to', 'first-line', ',', 'platinum-based', 'chemotherapy', '.']","(6, 7)","(35, 41)",-1,hl_o,11454878,Abstract,0,test,gold,486.0
806,PATIENTS AND METHODS,Patients with measurable and assessable disease,were randomized to receive either PLD 50 mg/m ( 2 ) as a 1-hour infusion every 4 weeks or topotecan 1.5 mg/m ( 2 ) /d for 5 consecutive days every 3 weeks .,"['PATIENTS', 'AND', 'METHODS', 'Patients', 'with', 'measurable', 'and', 'assessable', 'disease', 'were', 'randomized', 'to', 'receive', 'either', 'PLD', '50', 'mg/m', '(', '2', ')', 'as', 'a', '1-hour', 'infusion', 'every', '4', 'weeks', 'or', 'topotecan', '1.5', 'mg/m', '(', '2', ')', '/d', 'for', '5', 'consecutive', 'days', 'every', '3', 'weeks', '.']","(3, 9)","(20, 67)",-1,ss_p,11454878,Abstract,1,test,gold,6991.0
807,PATIENTS AND METHODS Patients with measurable and assessable disease were randomized to receive either,PLD,50 mg/m ( 2 ) as a 1-hour infusion every 4 weeks or topotecan 1.5 mg/m ( 2 ) /d for 5 consecutive days every 3 weeks .,"['PATIENTS', 'AND', 'METHODS', 'Patients', 'with', 'measurable', 'and', 'assessable', 'disease', 'were', 'randomized', 'to', 'receive', 'either', 'PLD', '50', 'mg/m', '(', '2', ')', 'as', 'a', '1-hour', 'infusion', 'every', '4', 'weeks', 'or', 'topotecan', '1.5', 'mg/m', '(', '2', ')', '/d', 'for', '5', 'consecutive', 'days', 'every', '3', 'weeks', '.']","(14, 15)","(102, 105)",-1,ss_i,11454878,Abstract,1,test,gold,513.0
808,PATIENTS AND METHODS Patients with measurable and assessable disease were randomized to receive either PLD 50 mg/m ( 2 ) as a 1-hour infusion every 4 weeks or,topotecan,1.5 mg/m ( 2 ) /d for 5 consecutive days every 3 weeks .,"['PATIENTS', 'AND', 'METHODS', 'Patients', 'with', 'measurable', 'and', 'assessable', 'disease', 'were', 'randomized', 'to', 'receive', 'either', 'PLD', '50', 'mg/m', '(', '2', ')', 'as', 'a', '1-hour', 'infusion', 'every', '4', 'weeks', 'or', 'topotecan', '1.5', 'mg/m', '(', '2', ')', '/d', 'for', '5', 'consecutive', 'days', 'every', '3', 'weeks', '.']","(28, 29)","(158, 167)",-1,ss_i,11454878,Abstract,1,test,gold,5711.0
809,PATIENTS AND METHODS,Patients with measurable and assessable disease,were randomized to receive either PLD 50 mg/m ( 2 ) as a 1-hour infusion every 4 weeks or topotecan 1.5 mg/m ( 2 ) /d for 5 consecutive days every 3 weeks .,"['PATIENTS', 'AND', 'METHODS', 'Patients', 'with', 'measurable', 'and', 'assessable', 'disease', 'were', 'randomized', 'to', 'receive', 'either', 'PLD', '50', 'mg/m', '(', '2', ')', 'as', 'a', '1-hour', 'infusion', 'every', '4', 'weeks', 'or', 'topotecan', '1.5', 'mg/m', '(', '2', ')', '/d', 'for', '5', 'consecutive', 'days', 'every', '3', 'weeks', '.']","(3, 9)","(20, 67)",-1,hl_p,11454878,Abstract,1,test,gold,6992.0
810,PATIENTS AND METHODS Patients with measurable and assessable disease were randomized to receive either,PLD,50 mg/m ( 2 ) as a 1-hour infusion every 4 weeks or topotecan 1.5 mg/m ( 2 ) /d for 5 consecutive days every 3 weeks .,"['PATIENTS', 'AND', 'METHODS', 'Patients', 'with', 'measurable', 'and', 'assessable', 'disease', 'were', 'randomized', 'to', 'receive', 'either', 'PLD', '50', 'mg/m', '(', '2', ')', 'as', 'a', '1-hour', 'infusion', 'every', '4', 'weeks', 'or', 'topotecan', '1.5', 'mg/m', '(', '2', ')', '/d', 'for', '5', 'consecutive', 'days', 'every', '3', 'weeks', '.']","(14, 15)","(102, 105)",-1,hl_i,11454878,Abstract,1,test,gold,514.0
811,PATIENTS AND METHODS Patients with measurable and assessable disease were randomized to receive either PLD 50 mg/m ( 2 ) as a 1-hour infusion every 4 weeks or,topotecan,1.5 mg/m ( 2 ) /d for 5 consecutive days every 3 weeks .,"['PATIENTS', 'AND', 'METHODS', 'Patients', 'with', 'measurable', 'and', 'assessable', 'disease', 'were', 'randomized', 'to', 'receive', 'either', 'PLD', '50', 'mg/m', '(', '2', ')', 'as', 'a', '1-hour', 'infusion', 'every', '4', 'weeks', 'or', 'topotecan', '1.5', 'mg/m', '(', '2', ')', '/d', 'for', '5', 'consecutive', 'days', 'every', '3', 'weeks', '.']","(28, 29)","(158, 167)",-1,hl_i,11454878,Abstract,1,test,gold,5710.0
812,Patients were stratified prospectively for platinum sensitivity and for the presence or absence of bulky disease .,,,"['Patients', 'were', 'stratified', 'prospectively', 'for', 'platinum', 'sensitivity', 'and', 'for', 'the', 'presence', 'or', 'absence', 'of', 'bulky', 'disease', '.']",,,,,11454878,Abstract,2,test,gold,
813,RESULTS,A total of 474 patients were treated,( 239 PLD and 235 topotecan ) .,"['RESULTS', 'A', 'total', 'of', '474', 'patients', 'were', 'treated', '(', '239', 'PLD', 'and', '235', 'topotecan', ')', '.']","(1, 8)","(7, 43)",-1,ss_p,11454878,Abstract,3,test,gold,2097.0
814,RESULTS A total of 474 patients were treated ( 239,PLD,and 235 topotecan ) .,"['RESULTS', 'A', 'total', 'of', '474', 'patients', 'were', 'treated', '(', '239', 'PLD', 'and', '235', 'topotecan', ')', '.']","(10, 11)","(50, 53)",-1,ss_i,11454878,Abstract,3,test,gold,512.0
815,RESULTS A total of 474 patients were treated ( 239 PLD and 235,topotecan ),.,"['RESULTS', 'A', 'total', 'of', '474', 'patients', 'were', 'treated', '(', '239', 'PLD', 'and', '235', 'topotecan', ')', '.']","(13, 15)","(62, 73)",-1,ss_i,11454878,Abstract,3,test,gold,5709.0
816,RESULTS A total of,474,patients were treated ( 239 PLD and 235 topotecan ) .,"['RESULTS', 'A', 'total', 'of', '474', 'patients', 'were', 'treated', '(', '239', 'PLD', 'and', '235', 'topotecan', ')', '.']","(4, 5)","(18, 21)",-1,hl_p,11454878,Abstract,3,test,gold,
817,RESULTS A total of 474 patients were treated ( 239,PLD,and 235 topotecan ) .,"['RESULTS', 'A', 'total', 'of', '474', 'patients', 'were', 'treated', '(', '239', 'PLD', 'and', '235', 'topotecan', ')', '.']","(10, 11)","(50, 53)",-1,hl_i,11454878,Abstract,3,test,gold,511.0
818,RESULTS A total of 474 patients were treated ( 239 PLD and 235,topotecan,) .,"['RESULTS', 'A', 'total', 'of', '474', 'patients', 'were', 'treated', '(', '239', 'PLD', 'and', '235', 'topotecan', ')', '.']","(13, 14)","(62, 71)",-1,hl_i,11454878,Abstract,3,test,gold,5708.0
819,They comprised the intent-to-treat population .,,,"['They', 'comprised', 'the', 'intent-to-treat', 'population', '.']",,,,,11454878,Abstract,4,test,gold,
820,The,overall progression-free survival rates,were similar between the two arms ( P =.095 ) .,"['The', 'overall', 'progression-free', 'survival', 'rates', 'were', 'similar', 'between', 'the', 'two', 'arms', '(', 'P', '=.095', ')', '.']","(1, 5)","(3, 42)",-1,ss_o,11454878,Abstract,5,test,gold,1954.0
821,The,overall progression-free survival rates,were similar between the two arms ( P =.095 ) .,"['The', 'overall', 'progression-free', 'survival', 'rates', 'were', 'similar', 'between', 'the', 'two', 'arms', '(', 'P', '=.095', ')', '.']","(1, 5)","(3, 42)",-1,hl_o,11454878,Abstract,5,test,gold,1955.0
822,The overall response rates for,PLD,"and topotecan were 19.7 % and 17.0 % , respectively ( P =.390 ) .","['The', 'overall', 'response', 'rates', 'for', 'PLD', 'and', 'topotecan', 'were', '19.7', '%', 'and', '17.0', '%', ',', 'respectively', '(', 'P', '=.390', ')', '.']","(5, 6)","(30, 33)",-1,ss_i,11454878,Abstract,6,test,gold,510.0
823,The overall response rates for PLD and,topotecan,"were 19.7 % and 17.0 % , respectively ( P =.390 ) .","['The', 'overall', 'response', 'rates', 'for', 'PLD', 'and', 'topotecan', 'were', '19.7', '%', 'and', '17.0', '%', ',', 'respectively', '(', 'P', '=.390', ')', '.']","(7, 8)","(38, 47)",-1,ss_i,11454878,Abstract,6,test,gold,5707.0
824,The,overall response rates,"for PLD and topotecan were 19.7 % and 17.0 % , respectively ( P =.390 ) .","['The', 'overall', 'response', 'rates', 'for', 'PLD', 'and', 'topotecan', 'were', '19.7', '%', 'and', '17.0', '%', ',', 'respectively', '(', 'P', '=.390', ')', '.']","(1, 4)","(3, 25)",-1,ss_o,11454878,Abstract,6,test,gold,1920.0
825,The overall response rates for,PLD,"and topotecan were 19.7 % and 17.0 % , respectively ( P =.390 ) .","['The', 'overall', 'response', 'rates', 'for', 'PLD', 'and', 'topotecan', 'were', '19.7', '%', 'and', '17.0', '%', ',', 'respectively', '(', 'P', '=.390', ')', '.']","(5, 6)","(30, 33)",-1,hl_i,11454878,Abstract,6,test,gold,509.0
826,The overall response rates for PLD and,topotecan,"were 19.7 % and 17.0 % , respectively ( P =.390 ) .","['The', 'overall', 'response', 'rates', 'for', 'PLD', 'and', 'topotecan', 'were', '19.7', '%', 'and', '17.0', '%', ',', 'respectively', '(', 'P', '=.390', ')', '.']","(7, 8)","(38, 47)",-1,hl_i,11454878,Abstract,6,test,gold,5706.0
827,The,overall response rates,"for PLD and topotecan were 19.7 % and 17.0 % , respectively ( P =.390 ) .","['The', 'overall', 'response', 'rates', 'for', 'PLD', 'and', 'topotecan', 'were', '19.7', '%', 'and', '17.0', '%', ',', 'respectively', '(', 'P', '=.390', ')', '.']","(1, 4)","(3, 25)",-1,hl_o,11454878,Abstract,6,test,gold,1921.0
828,Median overall survival times were 60 weeks for,PLD,and 56.7 weeks for topotecan .,"['Median', 'overall', 'survival', 'times', 'were', '60', 'weeks', 'for', 'PLD', 'and', '56.7', 'weeks', 'for', 'topotecan', '.']","(8, 9)","(47, 50)",-1,ss_i,11454878,Abstract,7,test,gold,508.0
829,Median overall survival times were 60 weeks for PLD and 56.7 weeks for,topotecan .,,"['Median', 'overall', 'survival', 'times', 'were', '60', 'weeks', 'for', 'PLD', 'and', '56.7', 'weeks', 'for', 'topotecan', '.']","(13, 15)","(70, 81)",-1,ss_i,11454878,Abstract,7,test,gold,5705.0
830,,Median overall survival times,were 60 weeks for PLD and 56.7 weeks for topotecan .,"['Median', 'overall', 'survival', 'times', 'were', '60', 'weeks', 'for', 'PLD', 'and', '56.7', 'weeks', 'for', 'topotecan', '.']","(0, 4)","(0, 29)",-1,ss_o,11454878,Abstract,7,test,gold,1986.0
831,Median overall survival times were 60 weeks for,PLD,and 56.7 weeks for topotecan .,"['Median', 'overall', 'survival', 'times', 'were', '60', 'weeks', 'for', 'PLD', 'and', '56.7', 'weeks', 'for', 'topotecan', '.']","(8, 9)","(47, 50)",-1,hl_i,11454878,Abstract,7,test,gold,507.0
832,Median overall survival times were 60 weeks for PLD and 56.7 weeks for,topotecan,.,"['Median', 'overall', 'survival', 'times', 'were', '60', 'weeks', 'for', 'PLD', 'and', '56.7', 'weeks', 'for', 'topotecan', '.']","(13, 14)","(70, 79)",-1,hl_i,11454878,Abstract,7,test,gold,5704.0
833,,Median overall survival times,were 60 weeks for PLD and 56.7 weeks for topotecan .,"['Median', 'overall', 'survival', 'times', 'were', '60', 'weeks', 'for', 'PLD', 'and', '56.7', 'weeks', 'for', 'topotecan', '.']","(0, 4)","(0, 29)",-1,hl_o,11454878,Abstract,7,test,gold,1987.0
834,Data analyzed in platinum-sensitive patients demonstrated a statistically significant benefit from,PLD,"for progression-free survival ( P =.037 ) , with medians of 28.9 for PLD versus 23.3 weeks for topotecan .","['Data', 'analyzed', 'in', 'platinum-sensitive', 'patients', 'demonstrated', 'a', 'statistically', 'significant', 'benefit', 'from', 'PLD', 'for', 'progression-free', 'survival', '(', 'P', '=.037', ')', ',', 'with', 'medians', 'of', '28.9', 'for', 'PLD', 'versus', '23.3', 'weeks', 'for', 'topotecan', '.']","(11, 12)","(98, 101)",-1,ss_i,11454878,Abstract,8,test,gold,506.0
835,"Data analyzed in platinum-sensitive patients demonstrated a statistically significant benefit from PLD for progression-free survival ( P =.037 ) , with medians of 28.9 for",PLD,versus 23.3 weeks for topotecan .,"['Data', 'analyzed', 'in', 'platinum-sensitive', 'patients', 'demonstrated', 'a', 'statistically', 'significant', 'benefit', 'from', 'PLD', 'for', 'progression-free', 'survival', '(', 'P', '=.037', ')', ',', 'with', 'medians', 'of', '28.9', 'for', 'PLD', 'versus', '23.3', 'weeks', 'for', 'topotecan', '.']","(25, 26)","(171, 174)",-1,ss_i,11454878,Abstract,8,test,gold,505.0
836,"Data analyzed in platinum-sensitive patients demonstrated a statistically significant benefit from PLD for progression-free survival ( P =.037 ) , with medians of 28.9 for PLD versus 23.3 weeks for",topotecan .,,"['Data', 'analyzed', 'in', 'platinum-sensitive', 'patients', 'demonstrated', 'a', 'statistically', 'significant', 'benefit', 'from', 'PLD', 'for', 'progression-free', 'survival', '(', 'P', '=.037', ')', ',', 'with', 'medians', 'of', '28.9', 'for', 'PLD', 'versus', '23.3', 'weeks', 'for', 'topotecan', '.']","(30, 32)","(197, 208)",-1,ss_i,11454878,Abstract,8,test,gold,5703.0
837,Data analyzed in platinum-sensitive patients demonstrated a statistically significant benefit from,PLD,"for progression-free survival ( P =.037 ) , with medians of 28.9 for PLD versus 23.3 weeks for topotecan .","['Data', 'analyzed', 'in', 'platinum-sensitive', 'patients', 'demonstrated', 'a', 'statistically', 'significant', 'benefit', 'from', 'PLD', 'for', 'progression-free', 'survival', '(', 'P', '=.037', ')', ',', 'with', 'medians', 'of', '28.9', 'for', 'PLD', 'versus', '23.3', 'weeks', 'for', 'topotecan', '.']","(11, 12)","(98, 101)",-1,hl_i,11454878,Abstract,8,test,gold,504.0
838,"Data analyzed in platinum-sensitive patients demonstrated a statistically significant benefit from PLD for progression-free survival ( P =.037 ) , with medians of 28.9 for",PLD,versus 23.3 weeks for topotecan .,"['Data', 'analyzed', 'in', 'platinum-sensitive', 'patients', 'demonstrated', 'a', 'statistically', 'significant', 'benefit', 'from', 'PLD', 'for', 'progression-free', 'survival', '(', 'P', '=.037', ')', ',', 'with', 'medians', 'of', '28.9', 'for', 'PLD', 'versus', '23.3', 'weeks', 'for', 'topotecan', '.']","(25, 26)","(171, 174)",-1,hl_i,11454878,Abstract,8,test,gold,503.0
839,"Data analyzed in platinum-sensitive patients demonstrated a statistically significant benefit from PLD for progression-free survival ( P =.037 ) , with medians of 28.9 for PLD versus 23.3 weeks for",topotecan .,,"['Data', 'analyzed', 'in', 'platinum-sensitive', 'patients', 'demonstrated', 'a', 'statistically', 'significant', 'benefit', 'from', 'PLD', 'for', 'progression-free', 'survival', '(', 'P', '=.037', ')', ',', 'with', 'medians', 'of', '28.9', 'for', 'PLD', 'versus', '23.3', 'weeks', 'for', 'topotecan', '.']","(30, 32)","(197, 208)",-1,hl_i,11454878,Abstract,8,test,gold,5702.0
840,"For overall survival ,",PLD,"was significantly superior to topotecan ( P =.008 ) , with a median of 108 weeks versus 71.1 weeks .","['For', 'overall', 'survival', ',', 'PLD', 'was', 'significantly', 'superior', 'to', 'topotecan', '(', 'P', '=.008', ')', ',', 'with', 'a', 'median', 'of', '108', 'weeks', 'versus', '71.1', 'weeks', '.']","(4, 5)","(22, 25)",-1,ss_i,11454878,Abstract,9,test,gold,502.0
841,"For overall survival , PLD was significantly superior to",topotecan,"( P =.008 ) , with a median of 108 weeks versus 71.1 weeks .","['For', 'overall', 'survival', ',', 'PLD', 'was', 'significantly', 'superior', 'to', 'topotecan', '(', 'P', '=.008', ')', ',', 'with', 'a', 'median', 'of', '108', 'weeks', 'versus', '71.1', 'weeks', '.']","(9, 10)","(56, 65)",-1,ss_i,11454878,Abstract,9,test,gold,5701.0
842,For,overall survival,", PLD was significantly superior to topotecan ( P =.008 ) , with a median of 108 weeks versus 71.1 weeks .","['For', 'overall', 'survival', ',', 'PLD', 'was', 'significantly', 'superior', 'to', 'topotecan', '(', 'P', '=.008', ')', ',', 'with', 'a', 'median', 'of', '108', 'weeks', 'versus', '71.1', 'weeks', '.']","(1, 3)","(3, 19)",-1,ss_o,11454878,Abstract,9,test,gold,1976.0
843,"For overall survival ,",PLD,"was significantly superior to topotecan ( P =.008 ) , with a median of 108 weeks versus 71.1 weeks .","['For', 'overall', 'survival', ',', 'PLD', 'was', 'significantly', 'superior', 'to', 'topotecan', '(', 'P', '=.008', ')', ',', 'with', 'a', 'median', 'of', '108', 'weeks', 'versus', '71.1', 'weeks', '.']","(4, 5)","(22, 25)",-1,hl_i,11454878,Abstract,9,test,gold,501.0
844,"For overall survival , PLD was significantly superior to",topotecan,"( P =.008 ) , with a median of 108 weeks versus 71.1 weeks .","['For', 'overall', 'survival', ',', 'PLD', 'was', 'significantly', 'superior', 'to', 'topotecan', '(', 'P', '=.008', ')', ',', 'with', 'a', 'median', 'of', '108', 'weeks', 'versus', '71.1', 'weeks', '.']","(9, 10)","(56, 65)",-1,hl_i,11454878,Abstract,9,test,gold,5700.0
845,For,overall survival,", PLD was significantly superior to topotecan ( P =.008 ) , with a median of 108 weeks versus 71.1 weeks .","['For', 'overall', 'survival', ',', 'PLD', 'was', 'significantly', 'superior', 'to', 'topotecan', '(', 'P', '=.008', ')', ',', 'with', 'a', 'median', 'of', '108', 'weeks', 'versus', '71.1', 'weeks', '.']","(1, 3)","(3, 19)",-1,hl_o,11454878,Abstract,9,test,gold,1977.0
846,The platinum-refractory subgroup demonstrated a nonstatistically significant survival trend in favor of,topotecan,( P =.455 ) .,"['The', 'platinum-refractory', 'subgroup', 'demonstrated', 'a', 'nonstatistically', 'significant', 'survival', 'trend', 'in', 'favor', 'of', 'topotecan', '(', 'P', '=.455', ')', '.']","(12, 13)","(103, 112)",-1,ss_i,11454878,Abstract,10,test,gold,5699.0
847,The platinum-refractory subgroup demonstrated a nonstatistically significant,survival,trend in favor of topotecan ( P =.455 ) .,"['The', 'platinum-refractory', 'subgroup', 'demonstrated', 'a', 'nonstatistically', 'significant', 'survival', 'trend', 'in', 'favor', 'of', 'topotecan', '(', 'P', '=.455', ')', '.']","(7, 8)","(76, 84)",-1,ss_o,11454878,Abstract,10,test,gold,1966.0
848,The platinum-refractory subgroup demonstrated a nonstatistically significant survival trend in favor of,topotecan,( P =.455 ) .,"['The', 'platinum-refractory', 'subgroup', 'demonstrated', 'a', 'nonstatistically', 'significant', 'survival', 'trend', 'in', 'favor', 'of', 'topotecan', '(', 'P', '=.455', ')', '.']","(12, 13)","(103, 112)",-1,hl_i,11454878,Abstract,10,test,gold,5698.0
849,Severe hematologic toxicity was more common with,topotecan,"and was more likely to be associated with dosage modification , or growth factor or blood product utilization .","['Severe', 'hematologic', 'toxicity', 'was', 'more', 'common', 'with', 'topotecan', 'and', 'was', 'more', 'likely', 'to', 'be', 'associated', 'with', 'dosage', 'modification', ',', 'or', 'growth', 'factor', 'or', 'blood', 'product', 'utilization', '.']","(7, 8)","(48, 57)",-1,ss_i,11454878,Abstract,11,test,gold,5697.0
850,,Severe hematologic toxicity,"was more common with topotecan and was more likely to be associated with dosage modification , or growth factor or blood product utilization .","['Severe', 'hematologic', 'toxicity', 'was', 'more', 'common', 'with', 'topotecan', 'and', 'was', 'more', 'likely', 'to', 'be', 'associated', 'with', 'dosage', 'modification', ',', 'or', 'growth', 'factor', 'or', 'blood', 'product', 'utilization', '.']","(0, 3)","(0, 27)",-1,ss_o,11454878,Abstract,11,test,gold,3480.0
851,Severe hematologic toxicity was more common with,topotecan,"and was more likely to be associated with dosage modification , or growth factor or blood product utilization .","['Severe', 'hematologic', 'toxicity', 'was', 'more', 'common', 'with', 'topotecan', 'and', 'was', 'more', 'likely', 'to', 'be', 'associated', 'with', 'dosage', 'modification', ',', 'or', 'growth', 'factor', 'or', 'blood', 'product', 'utilization', '.']","(7, 8)","(48, 57)",-1,hl_i,11454878,Abstract,11,test,gold,5696.0
852,,Severe hematologic toxicity,"was more common with topotecan and was more likely to be associated with dosage modification , or growth factor or blood product utilization .","['Severe', 'hematologic', 'toxicity', 'was', 'more', 'common', 'with', 'topotecan', 'and', 'was', 'more', 'likely', 'to', 'be', 'associated', 'with', 'dosage', 'modification', ',', 'or', 'growth', 'factor', 'or', 'blood', 'product', 'utilization', '.']","(0, 3)","(0, 27)",-1,hl_o,11454878,Abstract,11,test,gold,3481.0
853,"CONCLUSION The comparable efficacy , favorable safety profile , and convenient dosing support the role of",PLD,as a valuable treatment option in this patient population .,"['CONCLUSION', 'The', 'comparable', 'efficacy', ',', 'favorable', 'safety', 'profile', ',', 'and', 'convenient', 'dosing', 'support', 'the', 'role', 'of', 'PLD', 'as', 'a', 'valuable', 'treatment', 'option', 'in', 'this', 'patient', 'population', '.']","(16, 17)","(105, 108)",-1,ss_i,11454878,Abstract,12,test,gold,500.0
854,CONCLUSION The comparable,"efficacy , favorable safety profile",", and convenient dosing support the role of PLD as a valuable treatment option in this patient population .","['CONCLUSION', 'The', 'comparable', 'efficacy', ',', 'favorable', 'safety', 'profile', ',', 'and', 'convenient', 'dosing', 'support', 'the', 'role', 'of', 'PLD', 'as', 'a', 'valuable', 'treatment', 'option', 'in', 'this', 'patient', 'population', '.']","(3, 8)","(25, 60)",-1,ss_o,11454878,Abstract,12,test,gold,4775.0
855,"CONCLUSION The comparable efficacy , favorable safety profile , and",convenient dosing,support the role of PLD as a valuable treatment option in this patient population .,"['CONCLUSION', 'The', 'comparable', 'efficacy', ',', 'favorable', 'safety', 'profile', ',', 'and', 'convenient', 'dosing', 'support', 'the', 'role', 'of', 'PLD', 'as', 'a', 'valuable', 'treatment', 'option', 'in', 'this', 'patient', 'population', '.']","(10, 12)","(67, 84)",-1,ss_o,11454878,Abstract,12,test,gold,5046.0
856,"CONCLUSION The comparable efficacy , favorable safety profile , and convenient dosing support the role of",PLD,as a valuable treatment option in this patient population .,"['CONCLUSION', 'The', 'comparable', 'efficacy', ',', 'favorable', 'safety', 'profile', ',', 'and', 'convenient', 'dosing', 'support', 'the', 'role', 'of', 'PLD', 'as', 'a', 'valuable', 'treatment', 'option', 'in', 'this', 'patient', 'population', '.']","(16, 17)","(105, 108)",-1,hl_i,11454878,Abstract,12,test,gold,499.0
857,CONCLUSION The comparable,efficacy,", favorable safety profile , and convenient dosing support the role of PLD as a valuable treatment option in this patient population .","['CONCLUSION', 'The', 'comparable', 'efficacy', ',', 'favorable', 'safety', 'profile', ',', 'and', 'convenient', 'dosing', 'support', 'the', 'role', 'of', 'PLD', 'as', 'a', 'valuable', 'treatment', 'option', 'in', 'this', 'patient', 'population', '.']","(3, 4)","(25, 33)",-1,hl_o,11454878,Abstract,12,test,gold,4832.0
858,"CONCLUSION The comparable efficacy , favorable",safety,"profile , and convenient dosing support the role of PLD as a valuable treatment option in this patient population .","['CONCLUSION', 'The', 'comparable', 'efficacy', ',', 'favorable', 'safety', 'profile', ',', 'and', 'convenient', 'dosing', 'support', 'the', 'role', 'of', 'PLD', 'as', 'a', 'valuable', 'treatment', 'option', 'in', 'this', 'patient', 'population', '.']","(6, 7)","(46, 52)",-1,hl_o,11454878,Abstract,12,test,gold,485.0
859,Oral contraceptive use is associated with increased cardiovascular reactivity in,nonsmokers .,,"['Oral', 'contraceptive', 'use', 'is', 'associated', 'with', 'increased', 'cardiovascular', 'reactivity', 'in', 'nonsmokers', '.']","(10, 12)","(80, 92)",-1,ss_p,11495215,Title,0,test,gold,2425.0
860,,Oral contraceptive,use is associated with increased cardiovascular reactivity in nonsmokers .,"['Oral', 'contraceptive', 'use', 'is', 'associated', 'with', 'increased', 'cardiovascular', 'reactivity', 'in', 'nonsmokers', '.']","(0, 2)","(0, 18)",-1,ss_i,11495215,Title,0,test,gold,3904.0
861,Oral contraceptive use is associated with increased,cardiovascular reactivity,in nonsmokers .,"['Oral', 'contraceptive', 'use', 'is', 'associated', 'with', 'increased', 'cardiovascular', 'reactivity', 'in', 'nonsmokers', '.']","(7, 9)","(51, 76)",-1,ss_o,11495215,Title,0,test,gold,6952.0
862,,Oral contraceptive,use is associated with increased cardiovascular reactivity in nonsmokers .,"['Oral', 'contraceptive', 'use', 'is', 'associated', 'with', 'increased', 'cardiovascular', 'reactivity', 'in', 'nonsmokers', '.']","(0, 2)","(0, 18)",-1,hl_i,11495215,Title,0,test,gold,3905.0
863,Oral contraceptive use is associated with increased,cardiovascular reactivity,in nonsmokers .,"['Oral', 'contraceptive', 'use', 'is', 'associated', 'with', 'increased', 'cardiovascular', 'reactivity', 'in', 'nonsmokers', '.']","(7, 9)","(51, 76)",-1,hl_o,11495215,Title,0,test,gold,6953.0
864,Women who smoke and take,oral contraceptives ( OCs ),"have significantly increased risk of cardiovascular disease , but the exact mechanismsfor the increased risk are not known .","['Women', 'who', 'smoke', 'and', 'take', 'oral', 'contraceptives', '(', 'OCs', ')', 'have', 'significantly', 'increased', 'risk', 'of', 'cardiovascular', 'disease', ',', 'but', 'the', 'exact', 'mechanismsfor', 'the', 'increased', 'risk', 'are', 'not', 'known', '.']","(5, 10)","(24, 51)",-1,ss_i,11495215,Abstract,0,test,gold,3906.0
865,Women who smoke and take oral contraceptives ( OCs ) have significantly increased risk of,cardiovascular disease,", but the exact mechanismsfor the increased risk are not known .","['Women', 'who', 'smoke', 'and', 'take', 'oral', 'contraceptives', '(', 'OCs', ')', 'have', 'significantly', 'increased', 'risk', 'of', 'cardiovascular', 'disease', ',', 'but', 'the', 'exact', 'mechanismsfor', 'the', 'increased', 'risk', 'are', 'not', 'known', '.']","(15, 17)","(89, 111)",-1,ss_o,11495215,Abstract,0,test,gold,3431.0
866,Women who smoke and take,oral contraceptives ( OCs ),"have significantly increased risk of cardiovascular disease , but the exact mechanismsfor the increased risk are not known .","['Women', 'who', 'smoke', 'and', 'take', 'oral', 'contraceptives', '(', 'OCs', ')', 'have', 'significantly', 'increased', 'risk', 'of', 'cardiovascular', 'disease', ',', 'but', 'the', 'exact', 'mechanismsfor', 'the', 'increased', 'risk', 'are', 'not', 'known', '.']","(5, 10)","(24, 51)",-1,hl_i,11495215,Abstract,0,test,gold,3907.0
867,"Cardiovascular reactivity to psychological stress may be one mechanism for the enhanced risk , but the small number of studies examining whether",OC,users who smoke have greater reactivity have produced mixed results .,"['Cardiovascular', 'reactivity', 'to', 'psychological', 'stress', 'may', 'be', 'one', 'mechanism', 'for', 'the', 'enhanced', 'risk', ',', 'but', 'the', 'small', 'number', 'of', 'studies', 'examining', 'whether', 'OC', 'users', 'who', 'smoke', 'have', 'greater', 'reactivity', 'have', 'produced', 'mixed', 'results', '.']","(22, 23)","(144, 146)",-1,ss_i,11495215,Abstract,1,test,gold,649.0
868,,Cardiovascular reactivity,"to psychological stress may be one mechanism for the enhanced risk , but the small number of studies examining whether OC users who smoke have greater reactivity have produced mixed results .","['Cardiovascular', 'reactivity', 'to', 'psychological', 'stress', 'may', 'be', 'one', 'mechanism', 'for', 'the', 'enhanced', 'risk', ',', 'but', 'the', 'small', 'number', 'of', 'studies', 'examining', 'whether', 'OC', 'users', 'who', 'smoke', 'have', 'greater', 'reactivity', 'have', 'produced', 'mixed', 'results', '.']","(0, 2)","(0, 25)",-1,ss_o,11495215,Abstract,1,test,gold,6949.0
869,The purpose of this study was to examine the effect of chronic,cigarette smoking,", acute nicotine administration , and OC use on cardiovascular and lipid reactivity .","['The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'examine', 'the', 'effect', 'of', 'chronic', 'cigarette', 'smoking', ',', 'acute', 'nicotine', 'administration', ',', 'and', 'OC', 'use', 'on', 'cardiovascular', 'and', 'lipid', 'reactivity', '.']","(12, 14)","(62, 79)",-1,ss_i,11495215,Abstract,2,test,gold,2431.0
870,"The purpose of this study was to examine the effect of chronic cigarette smoking , acute",nicotine,"administration , and OC use on cardiovascular and lipid reactivity .","['The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'examine', 'the', 'effect', 'of', 'chronic', 'cigarette', 'smoking', ',', 'acute', 'nicotine', 'administration', ',', 'and', 'OC', 'use', 'on', 'cardiovascular', 'and', 'lipid', 'reactivity', '.']","(16, 17)","(88, 96)",-1,ss_i,11495215,Abstract,2,test,gold,2419.0
871,"The purpose of this study was to examine the effect of chronic cigarette smoking , acute nicotine administration , and",OC,use on cardiovascular and lipid reactivity .,"['The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'examine', 'the', 'effect', 'of', 'chronic', 'cigarette', 'smoking', ',', 'acute', 'nicotine', 'administration', ',', 'and', 'OC', 'use', 'on', 'cardiovascular', 'and', 'lipid', 'reactivity', '.']","(20, 21)","(118, 120)",-1,ss_i,11495215,Abstract,2,test,gold,650.0
872,"The purpose of this study was to examine the effect of chronic cigarette smoking , acute nicotine administration , and OC use on",cardiovascular and lipid reactivity .,,"['The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'examine', 'the', 'effect', 'of', 'chronic', 'cigarette', 'smoking', ',', 'acute', 'nicotine', 'administration', ',', 'and', 'OC', 'use', 'on', 'cardiovascular', 'and', 'lipid', 'reactivity', '.']","(23, 28)","(128, 165)",-1,ss_o,11495215,Abstract,2,test,gold,6954.0
873,"The purpose of this study was to examine the effect of chronic cigarette smoking , acute nicotine administration , and OC use on",cardiovascular and lipid reactivity .,,"['The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'examine', 'the', 'effect', 'of', 'chronic', 'cigarette', 'smoking', ',', 'acute', 'nicotine', 'administration', ',', 'and', 'OC', 'use', 'on', 'cardiovascular', 'and', 'lipid', 'reactivity', '.']","(23, 28)","(128, 165)",-1,hl_o,11495215,Abstract,2,test,gold,6955.0
874,,"Sixty healthy women , half of whom had been using OCs for at least the previous 6 months",", participated in the study .","['Sixty', 'healthy', 'women', ',', 'half', 'of', 'whom', 'had', 'been', 'using', 'OCs', 'for', 'at', 'least', 'the', 'previous', '6', 'months', ',', 'participated', 'in', 'the', 'study', '.']","(0, 18)","(0, 88)",-1,ss_p,11495215,Abstract,3,test,gold,5825.0
875,"Sixty healthy women , half of whom had been using",OCs,"for at least the previous 6 months , participated in the study .","['Sixty', 'healthy', 'women', ',', 'half', 'of', 'whom', 'had', 'been', 'using', 'OCs', 'for', 'at', 'least', 'the', 'previous', '6', 'months', ',', 'participated', 'in', 'the', 'study', '.']","(10, 11)","(49, 52)",-1,ss_i,11495215,Abstract,3,test,gold,86.0
876,,"Sixty healthy women , half of whom had been using OCs for at least the previous 6 months",", participated in the study .","['Sixty', 'healthy', 'women', ',', 'half', 'of', 'whom', 'had', 'been', 'using', 'OCs', 'for', 'at', 'least', 'the', 'previous', '6', 'months', ',', 'participated', 'in', 'the', 'study', '.']","(0, 18)","(0, 88)",-1,hl_p,11495215,Abstract,3,test,gold,5826.0
877,Approximately,two thirds were smokers,and were randomized to be tested after either a 12-hr nicotine deprivation or administration of nicotine gum .,"['Approximately', 'two', 'thirds', 'were', 'smokers', 'and', 'were', 'randomized', 'to', 'be', 'tested', 'after', 'either', 'a', '12-hr', 'nicotine', 'deprivation', 'or', 'administration', 'of', 'nicotine', 'gum', '.']","(1, 5)","(13, 36)",-1,ss_p,11495215,Abstract,4,test,gold,2421.0
878,Approximately two thirds were smokers and were randomized to be tested after either a 12-hr,nicotine deprivation,or administration of nicotine gum .,"['Approximately', 'two', 'thirds', 'were', 'smokers', 'and', 'were', 'randomized', 'to', 'be', 'tested', 'after', 'either', 'a', '12-hr', 'nicotine', 'deprivation', 'or', 'administration', 'of', 'nicotine', 'gum', '.']","(15, 17)","(91, 111)",-1,ss_i,11495215,Abstract,4,test,gold,2410.0
879,Approximately two thirds were smokers and were randomized to be tested after either a 12-hr nicotine deprivation or administration of,nicotine,gum .,"['Approximately', 'two', 'thirds', 'were', 'smokers', 'and', 'were', 'randomized', 'to', 'be', 'tested', 'after', 'either', 'a', '12-hr', 'nicotine', 'deprivation', 'or', 'administration', 'of', 'nicotine', 'gum', '.']","(20, 21)","(133, 141)",-1,ss_i,11495215,Abstract,4,test,gold,2420.0
880,Approximately,two thirds were smokers,and were randomized to be tested after either a 12-hr nicotine deprivation or administration of nicotine gum .,"['Approximately', 'two', 'thirds', 'were', 'smokers', 'and', 'were', 'randomized', 'to', 'be', 'tested', 'after', 'either', 'a', '12-hr', 'nicotine', 'deprivation', 'or', 'administration', 'of', 'nicotine', 'gum', '.']","(1, 5)","(13, 36)",-1,hl_p,11495215,Abstract,4,test,gold,2422.0
881,Approximately two thirds were smokers and were randomized to be tested after either a 12-hr,nicotine,deprivation or administration of nicotine gum .,"['Approximately', 'two', 'thirds', 'were', 'smokers', 'and', 'were', 'randomized', 'to', 'be', 'tested', 'after', 'either', 'a', '12-hr', 'nicotine', 'deprivation', 'or', 'administration', 'of', 'nicotine', 'gum', '.']","(15, 16)","(91, 99)",-1,hl_i,11495215,Abstract,4,test,gold,2418.0
882,Approximately two thirds were smokers and were randomized to be tested after either a 12-hr nicotine deprivation or administration of,nicotine,gum .,"['Approximately', 'two', 'thirds', 'were', 'smokers', 'and', 'were', 'randomized', 'to', 'be', 'tested', 'after', 'either', 'a', '12-hr', 'nicotine', 'deprivation', 'or', 'administration', 'of', 'nicotine', 'gum', '.']","(20, 21)","(133, 141)",-1,hl_i,11495215,Abstract,4,test,gold,2417.0
883,,One third were nonsmokers .,,"['One', 'third', 'were', 'nonsmokers', '.']","(0, 5)","(0, 27)",-1,ss_p,11495215,Abstract,5,test,gold,2423.0
884,,One third were nonsmokers .,,"['One', 'third', 'were', 'nonsmokers', '.']","(0, 5)","(0, 27)",-1,hl_p,11495215,Abstract,5,test,gold,2424.0
885,,"Heart rate , blood pressure , and lipid measures","were taken at rest , during a videotaped speech task , and during recovery from the task .","['Heart', 'rate', ',', 'blood', 'pressure', ',', 'and', 'lipid', 'measures', 'were', 'taken', 'at', 'rest', ',', 'during', 'a', 'videotaped', 'speech', 'task', ',', 'and', 'during', 'recovery', 'from', 'the', 'task', '.']","(0, 9)","(0, 48)",-1,ss_o,11495215,Abstract,6,test,gold,6728.0
886,,"Heart rate , blood pressure , and lipid measures","were taken at rest , during a videotaped speech task , and during recovery from the task .","['Heart', 'rate', ',', 'blood', 'pressure', ',', 'and', 'lipid', 'measures', 'were', 'taken', 'at', 'rest', ',', 'during', 'a', 'videotaped', 'speech', 'task', ',', 'and', 'during', 'recovery', 'from', 'the', 'task', '.']","(0, 9)","(0, 48)",-1,hl_o,11495215,Abstract,6,test,gold,6729.0
887,"Results indicated that , among",OC,"nonusers , there was no effect of smoking status or nicotine administration on cardiovascular reactivity .","['Results', 'indicated', 'that', ',', 'among', 'OC', 'nonusers', ',', 'there', 'was', 'no', 'effect', 'of', 'smoking', 'status', 'or', 'nicotine', 'administration', 'on', 'cardiovascular', 'reactivity', '.']","(5, 6)","(30, 32)",-1,ss_i,11495215,Abstract,7,test,gold,648.0
888,"Results indicated that , among OC nonusers , there was no effect of smoking status or",nicotine,administration on cardiovascular reactivity .,"['Results', 'indicated', 'that', ',', 'among', 'OC', 'nonusers', ',', 'there', 'was', 'no', 'effect', 'of', 'smoking', 'status', 'or', 'nicotine', 'administration', 'on', 'cardiovascular', 'reactivity', '.']","(16, 17)","(85, 93)",-1,ss_i,11495215,Abstract,7,test,gold,2416.0
889,"Results indicated that , among",OC,"nonusers , there was no effect of smoking status or nicotine administration on cardiovascular reactivity .","['Results', 'indicated', 'that', ',', 'among', 'OC', 'nonusers', ',', 'there', 'was', 'no', 'effect', 'of', 'smoking', 'status', 'or', 'nicotine', 'administration', 'on', 'cardiovascular', 'reactivity', '.']","(5, 6)","(30, 32)",-1,hl_i,11495215,Abstract,7,test,gold,647.0
890,"Results indicated that , among OC nonusers , there was no effect of smoking status or",nicotine,administration on cardiovascular reactivity .,"['Results', 'indicated', 'that', ',', 'among', 'OC', 'nonusers', ',', 'there', 'was', 'no', 'effect', 'of', 'smoking', 'status', 'or', 'nicotine', 'administration', 'on', 'cardiovascular', 'reactivity', '.']","(16, 17)","(85, 93)",-1,hl_i,11495215,Abstract,7,test,gold,2415.0
891,"However , among",OC,"users , nonsmokers had significantly greater heart rate and diastolic blood pressure reactivity to stress .","['However', ',', 'among', 'OC', 'users', ',', 'nonsmokers', 'had', 'significantly', 'greater', 'heart', 'rate', 'and', 'diastolic', 'blood', 'pressure', 'reactivity', 'to', 'stress', '.']","(3, 4)","(15, 17)",-1,ss_i,11495215,Abstract,8,test,gold,646.0
892,"However , among OC users , nonsmokers had significantly greater",heart rate and diastolic blood pressure reactivity,to stress .,"['However', ',', 'among', 'OC', 'users', ',', 'nonsmokers', 'had', 'significantly', 'greater', 'heart', 'rate', 'and', 'diastolic', 'blood', 'pressure', 'reactivity', 'to', 'stress', '.']","(10, 17)","(63, 113)",-1,ss_o,11495215,Abstract,8,test,gold,6731.0
893,"However , among",OC,"users , nonsmokers had significantly greater heart rate and diastolic blood pressure reactivity to stress .","['However', ',', 'among', 'OC', 'users', ',', 'nonsmokers', 'had', 'significantly', 'greater', 'heart', 'rate', 'and', 'diastolic', 'blood', 'pressure', 'reactivity', 'to', 'stress', '.']","(3, 4)","(15, 17)",-1,hl_i,11495215,Abstract,8,test,gold,645.0
894,"However , among OC users , nonsmokers had significantly greater",heart rate and diastolic blood pressure reactivity,to stress .,"['However', ',', 'among', 'OC', 'users', ',', 'nonsmokers', 'had', 'significantly', 'greater', 'heart', 'rate', 'and', 'diastolic', 'blood', 'pressure', 'reactivity', 'to', 'stress', '.']","(10, 17)","(63, 113)",-1,hl_o,11495215,Abstract,8,test,gold,6732.0
895,"These data show that acute nicotine administration , in the form of nicotine gum , has no effect on cardiovascular or lipid stress reactivity in",women .,,"['These', 'data', 'show', 'that', 'acute', 'nicotine', 'administration', ',', 'in', 'the', 'form', 'of', 'nicotine', 'gum', ',', 'has', 'no', 'effect', 'on', 'cardiovascular', 'or', 'lipid', 'stress', 'reactivity', 'in', 'women', '.']","(25, 27)","(144, 151)",-1,ss_p,11495215,Abstract,9,test,gold,2245.0
896,These data show that acute,nicotine,"administration , in the form of nicotine gum , has no effect on cardiovascular or lipid stress reactivity in women .","['These', 'data', 'show', 'that', 'acute', 'nicotine', 'administration', ',', 'in', 'the', 'form', 'of', 'nicotine', 'gum', ',', 'has', 'no', 'effect', 'on', 'cardiovascular', 'or', 'lipid', 'stress', 'reactivity', 'in', 'women', '.']","(5, 6)","(26, 34)",-1,ss_i,11495215,Abstract,9,test,gold,2414.0
897,"These data show that acute nicotine administration , in the form of",nicotine,"gum , has no effect on cardiovascular or lipid stress reactivity in women .","['These', 'data', 'show', 'that', 'acute', 'nicotine', 'administration', ',', 'in', 'the', 'form', 'of', 'nicotine', 'gum', ',', 'has', 'no', 'effect', 'on', 'cardiovascular', 'or', 'lipid', 'stress', 'reactivity', 'in', 'women', '.']","(12, 13)","(67, 75)",-1,ss_i,11495215,Abstract,9,test,gold,2413.0
898,"These data show that acute nicotine administration , in the form of nicotine gum , has no effect on",cardiovascular or lipid stress reactivity,in women .,"['These', 'data', 'show', 'that', 'acute', 'nicotine', 'administration', ',', 'in', 'the', 'form', 'of', 'nicotine', 'gum', ',', 'has', 'no', 'effect', 'on', 'cardiovascular', 'or', 'lipid', 'stress', 'reactivity', 'in', 'women', '.']","(19, 24)","(99, 140)",-1,ss_o,11495215,Abstract,9,test,gold,6956.0
899,These data show that acute,nicotine,"administration , in the form of nicotine gum , has no effect on cardiovascular or lipid stress reactivity in women .","['These', 'data', 'show', 'that', 'acute', 'nicotine', 'administration', ',', 'in', 'the', 'form', 'of', 'nicotine', 'gum', ',', 'has', 'no', 'effect', 'on', 'cardiovascular', 'or', 'lipid', 'stress', 'reactivity', 'in', 'women', '.']","(5, 6)","(26, 34)",-1,hl_i,11495215,Abstract,9,test,gold,2412.0
900,"These data show that acute nicotine administration , in the form of",nicotine,"gum , has no effect on cardiovascular or lipid stress reactivity in women .","['These', 'data', 'show', 'that', 'acute', 'nicotine', 'administration', ',', 'in', 'the', 'form', 'of', 'nicotine', 'gum', ',', 'has', 'no', 'effect', 'on', 'cardiovascular', 'or', 'lipid', 'stress', 'reactivity', 'in', 'women', '.']","(12, 13)","(67, 75)",-1,hl_i,11495215,Abstract,9,test,gold,2411.0
901,"These data show that acute nicotine administration , in the form of nicotine gum , has no effect on",cardiovascular or lipid stress reactivity,in women .,"['These', 'data', 'show', 'that', 'acute', 'nicotine', 'administration', ',', 'in', 'the', 'form', 'of', 'nicotine', 'gum', ',', 'has', 'no', 'effect', 'on', 'cardiovascular', 'or', 'lipid', 'stress', 'reactivity', 'in', 'women', '.']","(19, 24)","(99, 140)",-1,hl_o,11495215,Abstract,9,test,gold,6957.0
902,However OC use among,nonsmoking women,is associated with greater cardiovascular reactivity to stress .,"['However', 'OC', 'use', 'among', 'nonsmoking', 'women', 'is', 'associated', 'with', 'greater', 'cardiovascular', 'reactivity', 'to', 'stress', '.']","(4, 6)","(20, 36)",-1,ss_p,11495215,Abstract,10,test,gold,2426.0
903,However,OC,use among nonsmoking women is associated with greater cardiovascular reactivity to stress .,"['However', 'OC', 'use', 'among', 'nonsmoking', 'women', 'is', 'associated', 'with', 'greater', 'cardiovascular', 'reactivity', 'to', 'stress', '.']","(1, 2)","(7, 9)",-1,ss_i,11495215,Abstract,10,test,gold,644.0
904,However OC use among nonsmoking women is associated with greater,cardiovascular reactivity,to stress .,"['However', 'OC', 'use', 'among', 'nonsmoking', 'women', 'is', 'associated', 'with', 'greater', 'cardiovascular', 'reactivity', 'to', 'stress', '.']","(10, 12)","(64, 89)",-1,ss_o,11495215,Abstract,10,test,gold,6951.0
905,However,OC,use among nonsmoking women is associated with greater cardiovascular reactivity to stress .,"['However', 'OC', 'use', 'among', 'nonsmoking', 'women', 'is', 'associated', 'with', 'greater', 'cardiovascular', 'reactivity', 'to', 'stress', '.']","(1, 2)","(7, 9)",-1,hl_i,11495215,Abstract,10,test,gold,643.0
906,However OC use among nonsmoking women is associated with greater,cardiovascular reactivity,to stress .,"['However', 'OC', 'use', 'among', 'nonsmoking', 'women', 'is', 'associated', 'with', 'greater', 'cardiovascular', 'reactivity', 'to', 'stress', '.']","(10, 12)","(64, 89)",-1,hl_o,11495215,Abstract,10,test,gold,6950.0
907,,[ Neoton,and thrombolytic therapy of myocardial infarction ] .,"['[', 'Neoton', 'and', 'thrombolytic', 'therapy', 'of', 'myocardial', 'infarction', ']', '.']","(0, 2)","(0, 8)",-1,ss_i,11642083,Title,0,test,gold,1063.0
908,[ Neoton and,thrombolytic therapy,of myocardial infarction ] .,"['[', 'Neoton', 'and', 'thrombolytic', 'therapy', 'of', 'myocardial', 'infarction', ']', '.']","(3, 5)","(12, 32)",-1,ss_i,11642083,Title,0,test,gold,4204.0
909,[ Neoton and thrombolytic therapy of,myocardial infarction,] .,"['[', 'Neoton', 'and', 'thrombolytic', 'therapy', 'of', 'myocardial', 'infarction', ']', '.']","(6, 8)","(36, 57)",-1,hl_p,11642083,Title,0,test,gold,6796.0
910,[,Neoton,and thrombolytic therapy of myocardial infarction ] .,"['[', 'Neoton', 'and', 'thrombolytic', 'therapy', 'of', 'myocardial', 'infarction', ']', '.']","(1, 2)","(1, 7)",-1,hl_i,11642083,Title,0,test,gold,1064.0
911,[ Neoton and,thrombolytic therapy,of myocardial infarction ] .,"['[', 'Neoton', 'and', 'thrombolytic', 'therapy', 'of', 'myocardial', 'infarction', ']', '.']","(3, 5)","(12, 32)",-1,hl_i,11642083,Title,0,test,gold,4205.0
912,"AIM To evaluate neoton therapy effects in acute myocardial infarction ( MI ) on systolic function of the left ventricle , arrhythmia and clinical symptoms in",patients on thrombolytic therapy ( TLT ) .,,"['AIM', 'To', 'evaluate', 'neoton', 'therapy', 'effects', 'in', 'acute', 'myocardial', 'infarction', '(', 'MI', ')', 'on', 'systolic', 'function', 'of', 'the', 'left', 'ventricle', ',', 'arrhythmia', 'and', 'clinical', 'symptoms', 'in', 'patients', 'on', 'thrombolytic', 'therapy', '(', 'TLT', ')', '.']","(26, 34)","(157, 199)",-1,ss_p,11642083,Abstract,0,test,gold,4192.0
913,AIM To evaluate,neoton,"therapy effects in acute myocardial infarction ( MI ) on systolic function of the left ventricle , arrhythmia and clinical symptoms in patients on thrombolytic therapy ( TLT ) .","['AIM', 'To', 'evaluate', 'neoton', 'therapy', 'effects', 'in', 'acute', 'myocardial', 'infarction', '(', 'MI', ')', 'on', 'systolic', 'function', 'of', 'the', 'left', 'ventricle', ',', 'arrhythmia', 'and', 'clinical', 'symptoms', 'in', 'patients', 'on', 'thrombolytic', 'therapy', '(', 'TLT', ')', '.']","(3, 4)","(15, 21)",-1,ss_i,11642083,Abstract,0,test,gold,
914,"AIM To evaluate neoton therapy effects in acute myocardial infarction ( MI ) on systolic function of the left ventricle , arrhythmia and clinical symptoms in patients on",thrombolytic therapy ( TLT ),.,"['AIM', 'To', 'evaluate', 'neoton', 'therapy', 'effects', 'in', 'acute', 'myocardial', 'infarction', '(', 'MI', ')', 'on', 'systolic', 'function', 'of', 'the', 'left', 'ventricle', ',', 'arrhythmia', 'and', 'clinical', 'symptoms', 'in', 'patients', 'on', 'thrombolytic', 'therapy', '(', 'TLT', ')', '.']","(28, 33)","(169, 197)",-1,ss_i,11642083,Abstract,0,test,gold,4190.0
915,AIM To evaluate neoton therapy effects in acute myocardial infarction ( MI ) on,"systolic function of the left ventricle , arrhythmia and clinical symptoms",in patients on thrombolytic therapy ( TLT ) .,"['AIM', 'To', 'evaluate', 'neoton', 'therapy', 'effects', 'in', 'acute', 'myocardial', 'infarction', '(', 'MI', ')', 'on', 'systolic', 'function', 'of', 'the', 'left', 'ventricle', ',', 'arrhythmia', 'and', 'clinical', 'symptoms', 'in', 'patients', 'on', 'thrombolytic', 'therapy', '(', 'TLT', ')', '.']","(14, 25)","(79, 153)",-1,ss_o,11642083,Abstract,0,test,gold,5976.0
916,"AIM To evaluate neoton therapy effects in acute myocardial infarction ( MI ) on systolic function of the left ventricle , arrhythmia and clinical symptoms in",patients on thrombolytic therapy ( TLT ) .,,"['AIM', 'To', 'evaluate', 'neoton', 'therapy', 'effects', 'in', 'acute', 'myocardial', 'infarction', '(', 'MI', ')', 'on', 'systolic', 'function', 'of', 'the', 'left', 'ventricle', ',', 'arrhythmia', 'and', 'clinical', 'symptoms', 'in', 'patients', 'on', 'thrombolytic', 'therapy', '(', 'TLT', ')', '.']","(26, 34)","(157, 199)",-1,hl_p,11642083,Abstract,0,test,gold,4193.0
917,AIM To evaluate,neoton,"therapy effects in acute myocardial infarction ( MI ) on systolic function of the left ventricle , arrhythmia and clinical symptoms in patients on thrombolytic therapy ( TLT ) .","['AIM', 'To', 'evaluate', 'neoton', 'therapy', 'effects', 'in', 'acute', 'myocardial', 'infarction', '(', 'MI', ')', 'on', 'systolic', 'function', 'of', 'the', 'left', 'ventricle', ',', 'arrhythmia', 'and', 'clinical', 'symptoms', 'in', 'patients', 'on', 'thrombolytic', 'therapy', '(', 'TLT', ')', '.']","(3, 4)","(15, 21)",-1,hl_i,11642083,Abstract,0,test,gold,
918,"AIM To evaluate neoton therapy effects in acute myocardial infarction ( MI ) on systolic function of the left ventricle , arrhythmia and clinical symptoms in patients on",thrombolytic therapy ( TLT ),.,"['AIM', 'To', 'evaluate', 'neoton', 'therapy', 'effects', 'in', 'acute', 'myocardial', 'infarction', '(', 'MI', ')', 'on', 'systolic', 'function', 'of', 'the', 'left', 'ventricle', ',', 'arrhythmia', 'and', 'clinical', 'symptoms', 'in', 'patients', 'on', 'thrombolytic', 'therapy', '(', 'TLT', ')', '.']","(28, 33)","(169, 197)",-1,hl_i,11642083,Abstract,0,test,gold,4191.0
919,AIM To evaluate neoton therapy effects in acute myocardial infarction ( MI ) on,"systolic function of the left ventricle , arrhythmia and clinical symptoms",in patients on thrombolytic therapy ( TLT ) .,"['AIM', 'To', 'evaluate', 'neoton', 'therapy', 'effects', 'in', 'acute', 'myocardial', 'infarction', '(', 'MI', ')', 'on', 'systolic', 'function', 'of', 'the', 'left', 'ventricle', ',', 'arrhythmia', 'and', 'clinical', 'symptoms', 'in', 'patients', 'on', 'thrombolytic', 'therapy', '(', 'TLT', ')', '.']","(14, 25)","(79, 153)",-1,hl_o,11642083,Abstract,0,test,gold,5977.0
920,MATERIAL AND METHODS,106 males with Q-MI entered the study .,,"['MATERIAL', 'AND', 'METHODS', '106', 'males', 'with', 'Q-MI', 'entered', 'the', 'study', '.']","(3, 11)","(20, 59)",-1,ss_p,11642083,Abstract,1,test,gold,2092.0
921,MATERIAL AND METHODS,106 males,with Q-MI entered the study .,"['MATERIAL', 'AND', 'METHODS', '106', 'males', 'with', 'Q-MI', 'entered', 'the', 'study', '.']","(3, 5)","(20, 29)",-1,hl_p,11642083,Abstract,1,test,gold,2233.0
922,MATERIAL AND METHODS 106 males with,Q-MI,entered the study .,"['MATERIAL', 'AND', 'METHODS', '106', 'males', 'with', 'Q-MI', 'entered', 'the', 'study', '.']","(6, 7)","(35, 39)",-1,hl_p,11642083,Abstract,1,test,gold,
923,47 received treatment without,TLT,"and neoton , 30 patients received TLT with streptokinase preparations , 29 patients were given streptokinase preparations and neoton .","['47', 'received', 'treatment', 'without', 'TLT', 'and', 'neoton', ',', '30', 'patients', 'received', 'TLT', 'with', 'streptokinase', 'preparations', ',', '29', 'patients', 'were', 'given', 'streptokinase', 'preparations', 'and', 'neoton', '.']","(4, 5)","(29, 32)",-1,ss_i,11642083,Abstract,2,test,gold,610.0
924,47 received treatment without TLT and,neoton,", 30 patients received TLT with streptokinase preparations , 29 patients were given streptokinase preparations and neoton .","['47', 'received', 'treatment', 'without', 'TLT', 'and', 'neoton', ',', '30', 'patients', 'received', 'TLT', 'with', 'streptokinase', 'preparations', ',', '29', 'patients', 'were', 'given', 'streptokinase', 'preparations', 'and', 'neoton', '.']","(6, 7)","(37, 43)",-1,ss_i,11642083,Abstract,2,test,gold,
925,"47 received treatment without TLT and neoton , 30 patients received",TLT,"with streptokinase preparations , 29 patients were given streptokinase preparations and neoton .","['47', 'received', 'treatment', 'without', 'TLT', 'and', 'neoton', ',', '30', 'patients', 'received', 'TLT', 'with', 'streptokinase', 'preparations', ',', '29', 'patients', 'were', 'given', 'streptokinase', 'preparations', 'and', 'neoton', '.']","(11, 12)","(67, 70)",-1,ss_i,11642083,Abstract,2,test,gold,611.0
926,"47 received treatment without TLT and neoton , 30 patients received TLT with",streptokinase,"preparations , 29 patients were given streptokinase preparations and neoton .","['47', 'received', 'treatment', 'without', 'TLT', 'and', 'neoton', ',', '30', 'patients', 'received', 'TLT', 'with', 'streptokinase', 'preparations', ',', '29', 'patients', 'were', 'given', 'streptokinase', 'preparations', 'and', 'neoton', '.']","(13, 14)","(76, 89)",-1,ss_i,11642083,Abstract,2,test,gold,170.0
927,"47 received treatment without TLT and neoton , 30 patients received TLT with streptokinase preparations , 29 patients were given",streptokinase preparations,and neoton .,"['47', 'received', 'treatment', 'without', 'TLT', 'and', 'neoton', ',', '30', 'patients', 'received', 'TLT', 'with', 'streptokinase', 'preparations', ',', '29', 'patients', 'were', 'given', 'streptokinase', 'preparations', 'and', 'neoton', '.']","(20, 22)","(128, 154)",-1,ss_i,11642083,Abstract,2,test,gold,5720.0
928,"47 received treatment without TLT and neoton , 30 patients received TLT with streptokinase preparations , 29 patients were given streptokinase preparations and",neoton .,,"['47', 'received', 'treatment', 'without', 'TLT', 'and', 'neoton', ',', '30', 'patients', 'received', 'TLT', 'with', 'streptokinase', 'preparations', ',', '29', 'patients', 'were', 'given', 'streptokinase', 'preparations', 'and', 'neoton', '.']","(23, 25)","(159, 167)",-1,ss_i,11642083,Abstract,2,test,gold,
929,47 received treatment without,TLT,"and neoton , 30 patients received TLT with streptokinase preparations , 29 patients were given streptokinase preparations and neoton .","['47', 'received', 'treatment', 'without', 'TLT', 'and', 'neoton', ',', '30', 'patients', 'received', 'TLT', 'with', 'streptokinase', 'preparations', ',', '29', 'patients', 'were', 'given', 'streptokinase', 'preparations', 'and', 'neoton', '.']","(4, 5)","(29, 32)",-1,hl_i,11642083,Abstract,2,test,gold,609.0
930,47 received treatment without TLT and,neoton,", 30 patients received TLT with streptokinase preparations , 29 patients were given streptokinase preparations and neoton .","['47', 'received', 'treatment', 'without', 'TLT', 'and', 'neoton', ',', '30', 'patients', 'received', 'TLT', 'with', 'streptokinase', 'preparations', ',', '29', 'patients', 'were', 'given', 'streptokinase', 'preparations', 'and', 'neoton', '.']","(6, 7)","(37, 43)",-1,hl_i,11642083,Abstract,2,test,gold,
931,"47 received treatment without TLT and neoton , 30 patients received",TLT,"with streptokinase preparations , 29 patients were given streptokinase preparations and neoton .","['47', 'received', 'treatment', 'without', 'TLT', 'and', 'neoton', ',', '30', 'patients', 'received', 'TLT', 'with', 'streptokinase', 'preparations', ',', '29', 'patients', 'were', 'given', 'streptokinase', 'preparations', 'and', 'neoton', '.']","(11, 12)","(67, 70)",-1,hl_i,11642083,Abstract,2,test,gold,608.0
932,"47 received treatment without TLT and neoton , 30 patients received TLT with",streptokinase,"preparations , 29 patients were given streptokinase preparations and neoton .","['47', 'received', 'treatment', 'without', 'TLT', 'and', 'neoton', ',', '30', 'patients', 'received', 'TLT', 'with', 'streptokinase', 'preparations', ',', '29', 'patients', 'were', 'given', 'streptokinase', 'preparations', 'and', 'neoton', '.']","(13, 14)","(76, 89)",-1,hl_i,11642083,Abstract,2,test,gold,171.0
933,"47 received treatment without TLT and neoton , 30 patients received TLT with streptokinase preparations , 29 patients were given",streptokinase preparations,and neoton .,"['47', 'received', 'treatment', 'without', 'TLT', 'and', 'neoton', ',', '30', 'patients', 'received', 'TLT', 'with', 'streptokinase', 'preparations', ',', '29', 'patients', 'were', 'given', 'streptokinase', 'preparations', 'and', 'neoton', '.']","(20, 22)","(128, 154)",-1,hl_i,11642083,Abstract,2,test,gold,5721.0
934,"47 received treatment without TLT and neoton , 30 patients received TLT with streptokinase preparations , 29 patients were given streptokinase preparations and",neoton .,,"['47', 'received', 'treatment', 'without', 'TLT', 'and', 'neoton', ',', '30', 'patients', 'received', 'TLT', 'with', 'streptokinase', 'preparations', ',', '29', 'patients', 'were', 'given', 'streptokinase', 'preparations', 'and', 'neoton', '.']","(23, 25)","(159, 167)",-1,hl_i,11642083,Abstract,2,test,gold,
935,,Left ventricular systolic function was measured by echocardiography,"on day 1 , 3 , 7 , 14 , 21 and 28 ; arrhythmia was analysed at Holter monitoring in day 1 and 2 of MI .","['Left', 'ventricular', 'systolic', 'function', 'was', 'measured', 'by', 'echocardiography', 'on', 'day', '1', ',', '3', ',', '7', ',', '14', ',', '21', 'and', '28', ';', 'arrhythmia', 'was', 'analysed', 'at', 'Holter', 'monitoring', 'in', 'day', '1', 'and', '2', 'of', 'MI', '.']","(0, 8)","(0, 67)",-1,ss_o,11642083,Abstract,3,test,gold,6770.0
936,"Left ventricular systolic function was measured by echocardiography on day 1 , 3 , 7 , 14 , 21 and 28 ;",arrhythmia was analysed at Holter monitoring,in day 1 and 2 of MI .,"['Left', 'ventricular', 'systolic', 'function', 'was', 'measured', 'by', 'echocardiography', 'on', 'day', '1', ',', '3', ',', '7', ',', '14', ',', '21', 'and', '28', ';', 'arrhythmia', 'was', 'analysed', 'at', 'Holter', 'monitoring', 'in', 'day', '1', 'and', '2', 'of', 'MI', '.']","(22, 28)","(103, 147)",-1,ss_o,11642083,Abstract,3,test,gold,3219.0
937,,Left ventricular systolic function,"was measured by echocardiography on day 1 , 3 , 7 , 14 , 21 and 28 ; arrhythmia was analysed at Holter monitoring in day 1 and 2 of MI .","['Left', 'ventricular', 'systolic', 'function', 'was', 'measured', 'by', 'echocardiography', 'on', 'day', '1', ',', '3', ',', '7', ',', '14', ',', '21', 'and', '28', ';', 'arrhythmia', 'was', 'analysed', 'at', 'Holter', 'monitoring', 'in', 'day', '1', 'and', '2', 'of', 'MI', '.']","(0, 4)","(0, 34)",-1,hl_o,11642083,Abstract,3,test,gold,6773.0
938,"Left ventricular systolic function was measured by echocardiography on day 1 , 3 , 7 , 14 , 21 and 28 ;",arrhythmia,was analysed at Holter monitoring in day 1 and 2 of MI .,"['Left', 'ventricular', 'systolic', 'function', 'was', 'measured', 'by', 'echocardiography', 'on', 'day', '1', ',', '3', ',', '7', ',', '14', ',', '21', 'and', '28', ';', 'arrhythmia', 'was', 'analysed', 'at', 'Holter', 'monitoring', 'in', 'day', '1', 'and', '2', 'of', 'MI', '.']","(22, 23)","(103, 113)",-1,hl_o,11642083,Abstract,3,test,gold,3456.0
939,RESULTS,TLT,failed to arrest progression of left ventricular dilation by the end of the hospital stay .,"['RESULTS', 'TLT', 'failed', 'to', 'arrest', 'progression', 'of', 'left', 'ventricular', 'dilation', 'by', 'the', 'end', 'of', 'the', 'hospital', 'stay', '.']","(1, 2)","(7, 10)",-1,ss_i,11642083,Abstract,4,test,gold,607.0
940,Patients given,neoton,in acute period of MI had no increase in the end systolic and diastolic volumes of the left ventricle in the course of the first months after MI onset .,"['Patients', 'given', 'neoton', 'in', 'acute', 'period', 'of', 'MI', 'had', 'no', 'increase', 'in', 'the', 'end', 'systolic', 'and', 'diastolic', 'volumes', 'of', 'the', 'left', 'ventricle', 'in', 'the', 'course', 'of', 'the', 'first', 'months', 'after', 'MI', 'onset', '.']","(2, 3)","(14, 20)",-1,ss_i,11642083,Abstract,5,test,gold,
941,Patients given neoton in acute period of MI had no increase in the end,systolic and diastolic volumes,of the left ventricle in the course of the first months after MI onset .,"['Patients', 'given', 'neoton', 'in', 'acute', 'period', 'of', 'MI', 'had', 'no', 'increase', 'in', 'the', 'end', 'systolic', 'and', 'diastolic', 'volumes', 'of', 'the', 'left', 'ventricle', 'in', 'the', 'course', 'of', 'the', 'first', 'months', 'after', 'MI', 'onset', '.']","(14, 18)","(70, 100)",-1,ss_o,11642083,Abstract,5,test,gold,6692.0
942,Patients given,neoton,in acute period of MI had no increase in the end systolic and diastolic volumes of the left ventricle in the course of the first months after MI onset .,"['Patients', 'given', 'neoton', 'in', 'acute', 'period', 'of', 'MI', 'had', 'no', 'increase', 'in', 'the', 'end', 'systolic', 'and', 'diastolic', 'volumes', 'of', 'the', 'left', 'ventricle', 'in', 'the', 'course', 'of', 'the', 'first', 'months', 'after', 'MI', 'onset', '.']","(2, 3)","(14, 20)",-1,hl_i,11642083,Abstract,5,test,gold,
943,Patients given neoton in acute period of MI had no increase in the end,systolic and diastolic volumes,of the left ventricle in the course of the first months after MI onset .,"['Patients', 'given', 'neoton', 'in', 'acute', 'period', 'of', 'MI', 'had', 'no', 'increase', 'in', 'the', 'end', 'systolic', 'and', 'diastolic', 'volumes', 'of', 'the', 'left', 'ventricle', 'in', 'the', 'course', 'of', 'the', 'first', 'months', 'after', 'MI', 'onset', '.']","(14, 18)","(70, 100)",-1,hl_o,11642083,Abstract,5,test,gold,6693.0
944,Antiarrhythmic action of,neoton,manifested on MI day 2 .,"['Antiarrhythmic', 'action', 'of', 'neoton', 'manifested', 'on', 'MI', 'day', '2', '.']","(3, 4)","(24, 30)",-1,ss_i,11642083,Abstract,6,test,gold,
945,Antiarrhythmic action of,neoton,manifested on MI day 2 .,"['Antiarrhythmic', 'action', 'of', 'neoton', 'manifested', 'on', 'MI', 'day', '2', '.']","(3, 4)","(24, 30)",-1,hl_i,11642083,Abstract,6,test,gold,
946,CONCLUSION Neoton given to,MI patients receiving TLT,prevents progression of left ventricular systolic dysfunction and establishment of predictors of unfavourable outcome .,"['CONCLUSION', 'Neoton', 'given', 'to', 'MI', 'patients', 'receiving', 'TLT', 'prevents', 'progression', 'of', 'left', 'ventricular', 'systolic', 'dysfunction', 'and', 'establishment', 'of', 'predictors', 'of', 'unfavourable', 'outcome', '.']","(4, 8)","(26, 51)",-1,ss_p,11642083,Abstract,7,test,gold,3870.0
947,CONCLUSION,Neoton,given to MI patients receiving TLT prevents progression of left ventricular systolic dysfunction and establishment of predictors of unfavourable outcome .,"['CONCLUSION', 'Neoton', 'given', 'to', 'MI', 'patients', 'receiving', 'TLT', 'prevents', 'progression', 'of', 'left', 'ventricular', 'systolic', 'dysfunction', 'and', 'establishment', 'of', 'predictors', 'of', 'unfavourable', 'outcome', '.']","(1, 2)","(10, 16)",-1,ss_i,11642083,Abstract,7,test,gold,1062.0
948,CONCLUSION Neoton given to MI patients receiving,TLT,prevents progression of left ventricular systolic dysfunction and establishment of predictors of unfavourable outcome .,"['CONCLUSION', 'Neoton', 'given', 'to', 'MI', 'patients', 'receiving', 'TLT', 'prevents', 'progression', 'of', 'left', 'ventricular', 'systolic', 'dysfunction', 'and', 'establishment', 'of', 'predictors', 'of', 'unfavourable', 'outcome', '.']","(7, 8)","(48, 51)",-1,ss_i,11642083,Abstract,7,test,gold,606.0
949,CONCLUSION Neoton given to MI patients receiving TLT prevents progression of,left ventricular systolic dysfunction,and establishment of predictors of unfavourable outcome .,"['CONCLUSION', 'Neoton', 'given', 'to', 'MI', 'patients', 'receiving', 'TLT', 'prevents', 'progression', 'of', 'left', 'ventricular', 'systolic', 'dysfunction', 'and', 'establishment', 'of', 'predictors', 'of', 'unfavourable', 'outcome', '.']","(11, 15)","(76, 113)",-1,ss_o,11642083,Abstract,7,test,gold,6771.0
950,CONCLUSION,Neoton,given to MI patients receiving TLT prevents progression of left ventricular systolic dysfunction and establishment of predictors of unfavourable outcome .,"['CONCLUSION', 'Neoton', 'given', 'to', 'MI', 'patients', 'receiving', 'TLT', 'prevents', 'progression', 'of', 'left', 'ventricular', 'systolic', 'dysfunction', 'and', 'establishment', 'of', 'predictors', 'of', 'unfavourable', 'outcome', '.']","(1, 2)","(10, 16)",-1,hl_i,11642083,Abstract,7,test,gold,1061.0
951,CONCLUSION Neoton given to MI patients receiving TLT prevents progression of,left ventricular systolic dysfunction,and establishment of predictors of unfavourable outcome .,"['CONCLUSION', 'Neoton', 'given', 'to', 'MI', 'patients', 'receiving', 'TLT', 'prevents', 'progression', 'of', 'left', 'ventricular', 'systolic', 'dysfunction', 'and', 'establishment', 'of', 'predictors', 'of', 'unfavourable', 'outcome', '.']","(11, 15)","(76, 113)",-1,hl_o,11642083,Abstract,7,test,gold,6772.0
952,Antioxidant supplementation and exercise-induced oxidative stress in,the 60-year-old,as measured by antipyrine hydroxylates .,"['Antioxidant', 'supplementation', 'and', 'exercise-induced', 'oxidative', 'stress', 'in', 'the', '60-year-old', 'as', 'measured', 'by', 'antipyrine', 'hydroxylates', '.']","(7, 9)","(68, 83)",-1,ss_p,11737955,Title,0,test,gold,1190.0
953,,Antioxidant supplementation,and exercise-induced oxidative stress in the 60-year-old as measured by antipyrine hydroxylates .,"['Antioxidant', 'supplementation', 'and', 'exercise-induced', 'oxidative', 'stress', 'in', 'the', '60-year-old', 'as', 'measured', 'by', 'antipyrine', 'hydroxylates', '.']","(0, 2)","(0, 27)",-1,ss_i,11737955,Title,0,test,gold,4632.0
954,Antioxidant supplementation and exercise-induced oxidative stress in the 60-year-old as measured by,antipyrine hydroxylates .,,"['Antioxidant', 'supplementation', 'and', 'exercise-induced', 'oxidative', 'stress', 'in', 'the', '60-year-old', 'as', 'measured', 'by', 'antipyrine', 'hydroxylates', '.']","(12, 15)","(99, 124)",-1,ss_i,11737955,Title,0,test,gold,
955,Antioxidant supplementation and,exercise-induced oxidative stress,in the 60-year-old as measured by antipyrine hydroxylates .,"['Antioxidant', 'supplementation', 'and', 'exercise-induced', 'oxidative', 'stress', 'in', 'the', '60-year-old', 'as', 'measured', 'by', 'antipyrine', 'hydroxylates', '.']","(3, 6)","(31, 64)",-1,ss_o,11737955,Title,0,test,gold,2460.0
956,Antioxidant supplementation and exercise-induced oxidative stress in,the 60-year-old,as measured by antipyrine hydroxylates .,"['Antioxidant', 'supplementation', 'and', 'exercise-induced', 'oxidative', 'stress', 'in', 'the', '60-year-old', 'as', 'measured', 'by', 'antipyrine', 'hydroxylates', '.']","(7, 9)","(68, 83)",-1,hl_p,11737955,Title,0,test,gold,1191.0
957,,Antioxidant supplementation,and exercise-induced oxidative stress in the 60-year-old as measured by antipyrine hydroxylates .,"['Antioxidant', 'supplementation', 'and', 'exercise-induced', 'oxidative', 'stress', 'in', 'the', '60-year-old', 'as', 'measured', 'by', 'antipyrine', 'hydroxylates', '.']","(0, 2)","(0, 27)",-1,hl_i,11737955,Title,0,test,gold,4633.0
958,Antioxidant supplementation and exercise-induced oxidative stress in the 60-year-old as measured by,antipyrine,hydroxylates .,"['Antioxidant', 'supplementation', 'and', 'exercise-induced', 'oxidative', 'stress', 'in', 'the', '60-year-old', 'as', 'measured', 'by', 'antipyrine', 'hydroxylates', '.']","(12, 13)","(99, 109)",-1,hl_i,11737955,Title,0,test,gold,
959,The effects of 12 weeks of antioxidant supplementation on exercise-induced oxidative stress were investigated in,older adults ( 60 ( SE 1 ) years ; BMI 26 ( SE 1 ) kg/m ( 2 ) ) .,,"['The', 'effects', 'of', '12', 'weeks', 'of', 'antioxidant', 'supplementation', 'on', 'exercise-induced', 'oxidative', 'stress', 'were', 'investigated', 'in', 'older', 'adults', '(', '60', '(', 'SE', '1', ')', 'years', ';', 'BMI', '26', '(', 'SE', '1', ')', 'kg/m', '(', '2', ')', ')', '.']","(15, 37)","(112, 177)",-1,ss_p,11737955,Abstract,0,test,gold,6450.0
960,The effects of 12 weeks of,antioxidant supplementation,on exercise-induced oxidative stress were investigated in older adults ( 60 ( SE 1 ) years ; BMI 26 ( SE 1 ) kg/m ( 2 ) ) .,"['The', 'effects', 'of', '12', 'weeks', 'of', 'antioxidant', 'supplementation', 'on', 'exercise-induced', 'oxidative', 'stress', 'were', 'investigated', 'in', 'older', 'adults', '(', '60', '(', 'SE', '1', ')', 'years', ';', 'BMI', '26', '(', 'SE', '1', ')', 'kg/m', '(', '2', ')', ')', '.']","(6, 8)","(26, 53)",-1,ss_i,11737955,Abstract,0,test,gold,4636.0
961,The effects of 12 weeks of antioxidant supplementation on,exercise-induced oxidative stress,were investigated in older adults ( 60 ( SE 1 ) years ; BMI 26 ( SE 1 ) kg/m ( 2 ) ) .,"['The', 'effects', 'of', '12', 'weeks', 'of', 'antioxidant', 'supplementation', 'on', 'exercise-induced', 'oxidative', 'stress', 'were', 'investigated', 'in', 'older', 'adults', '(', '60', '(', 'SE', '1', ')', 'years', ';', 'BMI', '26', '(', 'SE', '1', ')', 'kg/m', '(', '2', ')', ')', '.']","(9, 12)","(57, 90)",-1,ss_o,11737955,Abstract,0,test,gold,2461.0
962,The effects of 12 weeks of antioxidant supplementation on exercise-induced oxidative stress were investigated in,older adults ( 60 ( SE 1 ) years ; BMI 26 ( SE 1 ) kg/m ( 2 ) ),.,"['The', 'effects', 'of', '12', 'weeks', 'of', 'antioxidant', 'supplementation', 'on', 'exercise-induced', 'oxidative', 'stress', 'were', 'investigated', 'in', 'older', 'adults', '(', '60', '(', 'SE', '1', ')', 'years', ';', 'BMI', '26', '(', 'SE', '1', ')', 'kg/m', '(', '2', ')', ')', '.']","(15, 36)","(112, 175)",-1,hl_p,11737955,Abstract,0,test,gold,6451.0
963,The effects of 12 weeks of,antioxidant supplementation,on exercise-induced oxidative stress were investigated in older adults ( 60 ( SE 1 ) years ; BMI 26 ( SE 1 ) kg/m ( 2 ) ) .,"['The', 'effects', 'of', '12', 'weeks', 'of', 'antioxidant', 'supplementation', 'on', 'exercise-induced', 'oxidative', 'stress', 'were', 'investigated', 'in', 'older', 'adults', '(', '60', '(', 'SE', '1', ')', 'years', ';', 'BMI', '26', '(', 'SE', '1', ')', 'kg/m', '(', '2', ')', ')', '.']","(6, 8)","(26, 53)",-1,hl_i,11737955,Abstract,0,test,gold,4637.0
964,Subjects were randomly divided in two groups : supplementation ( n 11 ) with 100 mg,dl-alpha-tocopheryl acetate,", 200 mg ascorbic acid , and 2 mg beta-carotene , and placebo ( n 9 ) .","['Subjects', 'were', 'randomly', 'divided', 'in', 'two', 'groups', ':', 'supplementation', '(', 'n', '11', ')', 'with', '100', 'mg', 'dl-alpha-tocopheryl', 'acetate', ',', '200', 'mg', 'ascorbic', 'acid', ',', 'and', '2', 'mg', 'beta-carotene', ',', 'and', 'placebo', '(', 'n', '9', ')', '.']","(16, 18)","(83, 110)",-1,ss_i,11737955,Abstract,1,test,gold,299.0
965,"Subjects were randomly divided in two groups : supplementation ( n 11 ) with 100 mg dl-alpha-tocopheryl acetate , 200 mg",ascorbic acid,", and 2 mg beta-carotene , and placebo ( n 9 ) .","['Subjects', 'were', 'randomly', 'divided', 'in', 'two', 'groups', ':', 'supplementation', '(', 'n', '11', ')', 'with', '100', 'mg', 'dl-alpha-tocopheryl', 'acetate', ',', '200', 'mg', 'ascorbic', 'acid', ',', 'and', '2', 'mg', 'beta-carotene', ',', 'and', 'placebo', '(', 'n', '9', ')', '.']","(21, 23)","(120, 133)",-1,ss_i,11737955,Abstract,1,test,gold,226.0
966,"Subjects were randomly divided in two groups : supplementation ( n 11 ) with 100 mg dl-alpha-tocopheryl acetate , 200 mg ascorbic acid , and 2 mg",beta-carotene,", and placebo ( n 9 ) .","['Subjects', 'were', 'randomly', 'divided', 'in', 'two', 'groups', ':', 'supplementation', '(', 'n', '11', ')', 'with', '100', 'mg', 'dl-alpha-tocopheryl', 'acetate', ',', '200', 'mg', 'ascorbic', 'acid', ',', 'and', '2', 'mg', 'beta-carotene', ',', 'and', 'placebo', '(', 'n', '9', ')', '.']","(27, 28)","(145, 158)",-1,ss_i,11737955,Abstract,1,test,gold,
967,"Subjects were randomly divided in two groups : supplementation ( n 11 ) with 100 mg dl-alpha-tocopheryl acetate , 200 mg ascorbic acid , and 2 mg beta-carotene , and",placebo,( n 9 ) .,"['Subjects', 'were', 'randomly', 'divided', 'in', 'two', 'groups', ':', 'supplementation', '(', 'n', '11', ')', 'with', '100', 'mg', 'dl-alpha-tocopheryl', 'acetate', ',', '200', 'mg', 'ascorbic', 'acid', ',', 'and', '2', 'mg', 'beta-carotene', ',', 'and', 'placebo', '(', 'n', '9', ')', '.']","(30, 31)","(165, 172)",-1,ss_i,11737955,Abstract,1,test,gold,4421.0
968,Subjects were randomly divided in two groups : supplementation ( n 11 ) with 100 mg,dl-alpha-tocopheryl acetate,", 200 mg ascorbic acid , and 2 mg beta-carotene , and placebo ( n 9 ) .","['Subjects', 'were', 'randomly', 'divided', 'in', 'two', 'groups', ':', 'supplementation', '(', 'n', '11', ')', 'with', '100', 'mg', 'dl-alpha-tocopheryl', 'acetate', ',', '200', 'mg', 'ascorbic', 'acid', ',', 'and', '2', 'mg', 'beta-carotene', ',', 'and', 'placebo', '(', 'n', '9', ')', '.']","(16, 18)","(83, 110)",-1,hl_i,11737955,Abstract,1,test,gold,300.0
969,"Subjects were randomly divided in two groups : supplementation ( n 11 ) with 100 mg dl-alpha-tocopheryl acetate , 200 mg",ascorbic acid,", and 2 mg beta-carotene , and placebo ( n 9 ) .","['Subjects', 'were', 'randomly', 'divided', 'in', 'two', 'groups', ':', 'supplementation', '(', 'n', '11', ')', 'with', '100', 'mg', 'dl-alpha-tocopheryl', 'acetate', ',', '200', 'mg', 'ascorbic', 'acid', ',', 'and', '2', 'mg', 'beta-carotene', ',', 'and', 'placebo', '(', 'n', '9', ')', '.']","(21, 23)","(120, 133)",-1,hl_i,11737955,Abstract,1,test,gold,227.0
970,"Subjects were randomly divided in two groups : supplementation ( n 11 ) with 100 mg dl-alpha-tocopheryl acetate , 200 mg ascorbic acid , and 2 mg",beta-carotene,", and placebo ( n 9 ) .","['Subjects', 'were', 'randomly', 'divided', 'in', 'two', 'groups', ':', 'supplementation', '(', 'n', '11', ')', 'with', '100', 'mg', 'dl-alpha-tocopheryl', 'acetate', ',', '200', 'mg', 'ascorbic', 'acid', ',', 'and', '2', 'mg', 'beta-carotene', ',', 'and', 'placebo', '(', 'n', '9', ')', '.']","(27, 28)","(145, 158)",-1,hl_i,11737955,Abstract,1,test,gold,
971,"Subjects were randomly divided in two groups : supplementation ( n 11 ) with 100 mg dl-alpha-tocopheryl acetate , 200 mg ascorbic acid , and 2 mg beta-carotene , and",placebo,( n 9 ) .,"['Subjects', 'were', 'randomly', 'divided', 'in', 'two', 'groups', ':', 'supplementation', '(', 'n', '11', ')', 'with', '100', 'mg', 'dl-alpha-tocopheryl', 'acetate', ',', '200', 'mg', 'ascorbic', 'acid', ',', 'and', '2', 'mg', 'beta-carotene', ',', 'and', 'placebo', '(', 'n', '9', ')', '.']","(30, 31)","(165, 172)",-1,hl_i,11737955,Abstract,1,test,gold,4420.0
972,"Before and after the 12 week supplementation period , subjects cycled for 45 min at submaximal intensity ( 50 % maximal workload capacity ) .",,,"['Before', 'and', 'after', 'the', '12', 'week', 'supplementation', 'period', ',', 'subjects', 'cycled', 'for', '45', 'min', 'at', 'submaximal', 'intensity', '(', '50', '%', 'maximal', 'workload', 'capacity', ')', '.']",,,,,11737955,Abstract,2,test,gold,
973,,Antipyrine,was used as marker for oxidative stress .,"['Antipyrine', 'was', 'used', 'as', 'marker', 'for', 'oxidative', 'stress', '.']","(0, 1)","(0, 10)",-1,ss_i,11737955,Abstract,3,test,gold,
974,,Antipyrine,was used as marker for oxidative stress .,"['Antipyrine', 'was', 'used', 'as', 'marker', 'for', 'oxidative', 'stress', '.']","(0, 1)","(0, 10)",-1,ss_o,11737955,Abstract,3,test,gold,
975,Antipyrine was used as marker for,oxidative stress .,,"['Antipyrine', 'was', 'used', 'as', 'marker', 'for', 'oxidative', 'stress', '.']","(6, 9)","(33, 51)",-1,ss_o,11737955,Abstract,3,test,gold,2459.0
976,,Antipyrine,was used as marker for oxidative stress .,"['Antipyrine', 'was', 'used', 'as', 'marker', 'for', 'oxidative', 'stress', '.']","(0, 1)","(0, 10)",-1,hl_i,11737955,Abstract,3,test,gold,
977,,Antipyrine,reacts quickly with hydroxyl radicals to form para- and ortho-hydroxyantipyrine .,"['Antipyrine', 'reacts', 'quickly', 'with', 'hydroxyl', 'radicals', 'to', 'form', 'para-', 'and', 'ortho-hydroxyantipyrine', '.']","(0, 1)","(0, 10)",-1,ss_i,11737955,Abstract,4,test,gold,
978,,Antipyrine,reacts quickly with hydroxyl radicals to form para- and ortho-hydroxyantipyrine .,"['Antipyrine', 'reacts', 'quickly', 'with', 'hydroxyl', 'radicals', 'to', 'form', 'para-', 'and', 'ortho-hydroxyantipyrine', '.']","(0, 1)","(0, 10)",-1,ss_o,11737955,Abstract,4,test,gold,
979,Antipyrine reacts quickly with hydroxyl radicals to form,para- and ortho-hydroxyantipyrine .,,"['Antipyrine', 'reacts', 'quickly', 'with', 'hydroxyl', 'radicals', 'to', 'form', 'para-', 'and', 'ortho-hydroxyantipyrine', '.']","(8, 12)","(56, 91)",-1,ss_o,11737955,Abstract,4,test,gold,
980,The latter metabolite is not formed in man through the mono-oxygenase pathway of cytochrome P450 .,,,"['The', 'latter', 'metabolite', 'is', 'not', 'formed', 'in', 'man', 'through', 'the', 'mono-oxygenase', 'pathway', 'of', 'cytochrome', 'P450', '.']",,,,,11737955,Abstract,5,test,gold,
981,Daily supplementation significantly increased plasma concentrations of alpha-tocopherol and beta-carotene in the supplemented group ( Delta 14.4 ( SE 3.2 ) and 0.4 ( se 0.1 ) micromol/l ; P < 0.001 and P < 0.01 ) .,,,"['Daily', 'supplementation', 'significantly', 'increased', 'plasma', 'concentrations', 'of', 'alpha-tocopherol', 'and', 'beta-carotene', 'in', 'the', 'supplemented', 'group', '(', 'Delta', '14.4', '(', 'SE', '3.2', ')', 'and', '0.4', '(', 'se', '0.1', ')', 'micromol/l', ';', 'P', '<', '0.001', 'and', 'P', '<', '0.01', ')', '.']",,,,,11737955,Abstract,6,test,gold,
982,"No significant differences , within and between groups , were observed in the exercise-induced increase in the ratios",para- and ortho-hydroxyantipyrine to antipyrine .,,"['No', 'significant', 'differences', ',', 'within', 'and', 'between', 'groups', ',', 'were', 'observed', 'in', 'the', 'exercise-induced', 'increase', 'in', 'the', 'ratios', 'para-', 'and', 'ortho-hydroxyantipyrine', 'to', 'antipyrine', '.']","(18, 24)","(117, 166)",-1,ss_o,11737955,Abstract,7,test,gold,
983,"No significant differences , within and between groups , were observed in the exercise-induced increase in the ratios",para- and ortho-hydroxyantipyrine to antipyrine .,,"['No', 'significant', 'differences', ',', 'within', 'and', 'between', 'groups', ',', 'were', 'observed', 'in', 'the', 'exercise-induced', 'increase', 'in', 'the', 'ratios', 'para-', 'and', 'ortho-hydroxyantipyrine', 'to', 'antipyrine', '.']","(18, 24)","(117, 166)",-1,hl_o,11737955,Abstract,7,test,gold,
984,"In addition , supplementation did not affect the exercise-induced increase in",thiobarbituric acid reactive substances in plasma .,,"['In', 'addition', ',', 'supplementation', 'did', 'not', 'affect', 'the', 'exercise-induced', 'increase', 'in', 'thiobarbituric', 'acid', 'reactive', 'substances', 'in', 'plasma', '.']","(11, 18)","(77, 128)",-1,ss_o,11737955,Abstract,8,test,gold,4667.0
985,"In addition , supplementation did not affect the exercise-induced increase in",thiobarbituric acid reactive substances in plasma .,,"['In', 'addition', ',', 'supplementation', 'did', 'not', 'affect', 'the', 'exercise-induced', 'increase', 'in', 'thiobarbituric', 'acid', 'reactive', 'substances', 'in', 'plasma', '.']","(11, 18)","(77, 128)",-1,hl_o,11737955,Abstract,8,test,gold,4668.0
986,"In conclusion , in",60-year-old subjects,antioxidant supplementation had no effect on the exercise-induced increase in oxidative stress as measured by free radical products of antipyrine .,"['In', 'conclusion', ',', 'in', '60-year-old', 'subjects', 'antioxidant', 'supplementation', 'had', 'no', 'effect', 'on', 'the', 'exercise-induced', 'increase', 'in', 'oxidative', 'stress', 'as', 'measured', 'by', 'free', 'radical', 'products', 'of', 'antipyrine', '.']","(4, 6)","(18, 38)",-1,ss_p,11737955,Abstract,9,test,gold,2076.0
987,"In conclusion , in 60-year-old subjects",antioxidant supplementation,had no effect on the exercise-induced increase in oxidative stress as measured by free radical products of antipyrine .,"['In', 'conclusion', ',', 'in', '60-year-old', 'subjects', 'antioxidant', 'supplementation', 'had', 'no', 'effect', 'on', 'the', 'exercise-induced', 'increase', 'in', 'oxidative', 'stress', 'as', 'measured', 'by', 'free', 'radical', 'products', 'of', 'antipyrine', '.']","(6, 8)","(39, 66)",-1,ss_i,11737955,Abstract,9,test,gold,4635.0
988,"In conclusion , in 60-year-old subjects antioxidant supplementation had no effect on the exercise-induced increase in oxidative stress as measured by",free radical products of antipyrine .,,"['In', 'conclusion', ',', 'in', '60-year-old', 'subjects', 'antioxidant', 'supplementation', 'had', 'no', 'effect', 'on', 'the', 'exercise-induced', 'increase', 'in', 'oxidative', 'stress', 'as', 'measured', 'by', 'free', 'radical', 'products', 'of', 'antipyrine', '.']","(21, 27)","(149, 186)",-1,ss_o,11737955,Abstract,9,test,gold,1791.0
989,"In conclusion , in",60-year-old subjects,antioxidant supplementation had no effect on the exercise-induced increase in oxidative stress as measured by free radical products of antipyrine .,"['In', 'conclusion', ',', 'in', '60-year-old', 'subjects', 'antioxidant', 'supplementation', 'had', 'no', 'effect', 'on', 'the', 'exercise-induced', 'increase', 'in', 'oxidative', 'stress', 'as', 'measured', 'by', 'free', 'radical', 'products', 'of', 'antipyrine', '.']","(4, 6)","(18, 38)",-1,hl_p,11737955,Abstract,9,test,gold,2075.0
990,"In conclusion , in 60-year-old subjects",antioxidant supplementation,had no effect on the exercise-induced increase in oxidative stress as measured by free radical products of antipyrine .,"['In', 'conclusion', ',', 'in', '60-year-old', 'subjects', 'antioxidant', 'supplementation', 'had', 'no', 'effect', 'on', 'the', 'exercise-induced', 'increase', 'in', 'oxidative', 'stress', 'as', 'measured', 'by', 'free', 'radical', 'products', 'of', 'antipyrine', '.']","(6, 8)","(39, 66)",-1,hl_i,11737955,Abstract,9,test,gold,4634.0
991,"In conclusion , in 60-year-old subjects antioxidant supplementation had no effect on the exercise-induced increase in oxidative stress as measured by",free radical products of antipyrine .,,"['In', 'conclusion', ',', 'in', '60-year-old', 'subjects', 'antioxidant', 'supplementation', 'had', 'no', 'effect', 'on', 'the', 'exercise-induced', 'increase', 'in', 'oxidative', 'stress', 'as', 'measured', 'by', 'free', 'radical', 'products', 'of', 'antipyrine', '.']","(21, 27)","(149, 186)",-1,hl_o,11737955,Abstract,9,test,gold,1792.0
992,The course of depression in,recent onset rheumatoid arthritis :,"the predictive role of disability , illness perceptions , pain and coping .","['The', 'course', 'of', 'depression', 'in', 'recent', 'onset', 'rheumatoid', 'arthritis', ':', 'the', 'predictive', 'role', 'of', 'disability', ',', 'illness', 'perceptions', ',', 'pain', 'and', 'coping', '.']","(5, 10)","(27, 62)",-1,ss_p,11750293,Title,0,test,gold,7026.0
993,The course of depression in recent onset rheumatoid arthritis : the predictive,role,"of disability , illness perceptions , pain and coping .","['The', 'course', 'of', 'depression', 'in', 'recent', 'onset', 'rheumatoid', 'arthritis', ':', 'the', 'predictive', 'role', 'of', 'disability', ',', 'illness', 'perceptions', ',', 'pain', 'and', 'coping', '.']","(12, 13)","(78, 82)",-1,ss_o,11750293,Title,0,test,gold,1206.0
994,The course of depression in recent onset rheumatoid arthritis : the predictive role of,"disability , illness perceptions , pain and coping .",,"['The', 'course', 'of', 'depression', 'in', 'recent', 'onset', 'rheumatoid', 'arthritis', ':', 'the', 'predictive', 'role', 'of', 'disability', ',', 'illness', 'perceptions', ',', 'pain', 'and', 'coping', '.']","(14, 23)","(86, 138)",-1,ss_o,11750293,Title,0,test,gold,6417.0
995,The course of depression in,recent onset rheumatoid arthritis :,"the predictive role of disability , illness perceptions , pain and coping .","['The', 'course', 'of', 'depression', 'in', 'recent', 'onset', 'rheumatoid', 'arthritis', ':', 'the', 'predictive', 'role', 'of', 'disability', ',', 'illness', 'perceptions', ',', 'pain', 'and', 'coping', '.']","(5, 10)","(27, 62)",-1,hl_p,11750293,Title,0,test,gold,7027.0
996,The course of depression in recent onset rheumatoid arthritis : the predictive role of,disability,", illness perceptions , pain and coping .","['The', 'course', 'of', 'depression', 'in', 'recent', 'onset', 'rheumatoid', 'arthritis', ':', 'the', 'predictive', 'role', 'of', 'disability', ',', 'illness', 'perceptions', ',', 'pain', 'and', 'coping', '.']","(14, 15)","(86, 96)",-1,hl_o,11750293,Title,0,test,gold,1287.0
997,"The course of depression in recent onset rheumatoid arthritis : the predictive role of disability ,",illness perceptions,", pain and coping .","['The', 'course', 'of', 'depression', 'in', 'recent', 'onset', 'rheumatoid', 'arthritis', ':', 'the', 'predictive', 'role', 'of', 'disability', ',', 'illness', 'perceptions', ',', 'pain', 'and', 'coping', '.']","(16, 18)","(99, 118)",-1,hl_o,11750293,Title,0,test,gold,3426.0
998,"The course of depression in recent onset rheumatoid arthritis : the predictive role of disability , illness perceptions ,",pain,and coping .,"['The', 'course', 'of', 'depression', 'in', 'recent', 'onset', 'rheumatoid', 'arthritis', ':', 'the', 'predictive', 'role', 'of', 'disability', ',', 'illness', 'perceptions', ',', 'pain', 'and', 'coping', '.']","(19, 20)","(121, 125)",-1,hl_o,11750293,Title,0,test,gold,2302.0
999,"The course of depression in recent onset rheumatoid arthritis : the predictive role of disability , illness perceptions , pain and",coping,.,"['The', 'course', 'of', 'depression', 'in', 'recent', 'onset', 'rheumatoid', 'arthritis', ':', 'the', 'predictive', 'role', 'of', 'disability', ',', 'illness', 'perceptions', ',', 'pain', 'and', 'coping', '.']","(21, 22)","(130, 136)",-1,hl_o,11750293,Title,0,test,gold,1294.0
1000,BACKGROUND This study aimed to investigate the course of depression for,patients with recently diagnosed rheumatoid arthritis ( RA ),and to investigate predictors of depression .,"['BACKGROUND', 'This', 'study', 'aimed', 'to', 'investigate', 'the', 'course', 'of', 'depression', 'for', 'patients', 'with', 'recently', 'diagnosed', 'rheumatoid', 'arthritis', '(', 'RA', ')', 'and', 'to', 'investigate', 'predictors', 'of', 'depression', '.']","(11, 20)","(71, 131)",-1,ss_p,11750293,Abstract,0,test,gold,7024.0
1001,BACKGROUND This study aimed to investigate the course of depression for patients with recently diagnosed rheumatoid arthritis ( RA ) and to investigate,predictors of depression .,,"['BACKGROUND', 'This', 'study', 'aimed', 'to', 'investigate', 'the', 'course', 'of', 'depression', 'for', 'patients', 'with', 'recently', 'diagnosed', 'rheumatoid', 'arthritis', '(', 'RA', ')', 'and', 'to', 'investigate', 'predictors', 'of', 'depression', '.']","(23, 27)","(151, 177)",-1,ss_o,11750293,Abstract,0,test,gold,6397.0
1002,BACKGROUND This study aimed to investigate the course of depression for,patients with recently diagnosed rheumatoid arthritis ( RA ),and to investigate predictors of depression .,"['BACKGROUND', 'This', 'study', 'aimed', 'to', 'investigate', 'the', 'course', 'of', 'depression', 'for', 'patients', 'with', 'recently', 'diagnosed', 'rheumatoid', 'arthritis', '(', 'RA', ')', 'and', 'to', 'investigate', 'predictors', 'of', 'depression', '.']","(11, 20)","(71, 131)",-1,hl_p,11750293,Abstract,0,test,gold,7025.0
1003,BACKGROUND This study aimed to investigate the course of depression for patients with recently diagnosed rheumatoid arthritis ( RA ) and to investigate predictors of,depression .,,"['BACKGROUND', 'This', 'study', 'aimed', 'to', 'investigate', 'the', 'course', 'of', 'depression', 'for', 'patients', 'with', 'recently', 'diagnosed', 'rheumatoid', 'arthritis', '(', 'RA', ')', 'and', 'to', 'investigate', 'predictors', 'of', 'depression', '.']","(25, 27)","(165, 177)",-1,hl_o,11750293,Abstract,0,test,gold,2552.0
1004,METHODS,Twenty-two patients with a history of recently diagnosed RA of less than 2 years,were assessed on a variety of clinical outcome and process measures on six assessment occasions over a 21-month period .,"['METHODS', 'Twenty-two', 'patients', 'with', 'a', 'history', 'of', 'recently', 'diagnosed', 'RA', 'of', 'less', 'than', '2', 'years', 'were', 'assessed', 'on', 'a', 'variety', 'of', 'clinical', 'outcome', 'and', 'process', 'measures', 'on', 'six', 'assessment', 'occasions', 'over', 'a', '21-month', 'period', '.']","(1, 15)","(7, 87)",-1,ss_p,11750293,Abstract,1,test,gold,5852.0
1005,METHODS Twenty-two patients with a history of recently diagnosed RA of less than 2 years were assessed on a variety of,clinical outcome and process measures,on six assessment occasions over a 21-month period .,"['METHODS', 'Twenty-two', 'patients', 'with', 'a', 'history', 'of', 'recently', 'diagnosed', 'RA', 'of', 'less', 'than', '2', 'years', 'were', 'assessed', 'on', 'a', 'variety', 'of', 'clinical', 'outcome', 'and', 'process', 'measures', 'on', 'six', 'assessment', 'occasions', 'over', 'a', '21-month', 'period', '.']","(21, 26)","(118, 155)",-1,ss_o,11750293,Abstract,1,test,gold,4751.0
1006,METHODS,Twenty-two patients with a history of recently diagnosed RA of less than 2 years,were assessed on a variety of clinical outcome and process measures on six assessment occasions over a 21-month period .,"['METHODS', 'Twenty-two', 'patients', 'with', 'a', 'history', 'of', 'recently', 'diagnosed', 'RA', 'of', 'less', 'than', '2', 'years', 'were', 'assessed', 'on', 'a', 'variety', 'of', 'clinical', 'outcome', 'and', 'process', 'measures', 'on', 'six', 'assessment', 'occasions', 'over', 'a', '21-month', 'period', '.']","(1, 15)","(7, 87)",-1,hl_p,11750293,Abstract,1,test,gold,5853.0
1007,METHODS Twenty-two patients with a history of recently diagnosed RA of less than 2 years were assessed on a variety of,clinical outcome and process measures,on six assessment occasions over a 21-month period .,"['METHODS', 'Twenty-two', 'patients', 'with', 'a', 'history', 'of', 'recently', 'diagnosed', 'RA', 'of', 'less', 'than', '2', 'years', 'were', 'assessed', 'on', 'a', 'variety', 'of', 'clinical', 'outcome', 'and', 'process', 'measures', 'on', 'six', 'assessment', 'occasions', 'over', 'a', '21-month', 'period', '.']","(21, 26)","(118, 155)",-1,hl_o,11750293,Abstract,1,test,gold,4752.0
1008,These,22 patients,constituted the control group of a controlled trial and received standard outpatient clinic treatment during follow-up .,"['These', '22', 'patients', 'constituted', 'the', 'control', 'group', 'of', 'a', 'controlled', 'trial', 'and', 'received', 'standard', 'outpatient', 'clinic', 'treatment', 'during', 'follow-up', '.']","(1, 3)","(5, 16)",-1,ss_p,11750293,Abstract,2,test,gold,3756.0
1009,These 22 patients constituted the control group of a controlled trial and received,standard outpatient clinic treatment,during follow-up .,"['These', '22', 'patients', 'constituted', 'the', 'control', 'group', 'of', 'a', 'controlled', 'trial', 'and', 'received', 'standard', 'outpatient', 'clinic', 'treatment', 'during', 'follow-up', '.']","(13, 17)","(82, 118)",-1,ss_i,11750293,Abstract,2,test,gold,3835.0
1010,These,22 patients,constituted the control group of a controlled trial and received standard outpatient clinic treatment during follow-up .,"['These', '22', 'patients', 'constituted', 'the', 'control', 'group', 'of', 'a', 'controlled', 'trial', 'and', 'received', 'standard', 'outpatient', 'clinic', 'treatment', 'during', 'follow-up', '.']","(1, 3)","(5, 16)",-1,hl_p,11750293,Abstract,2,test,gold,3754.0
1011,These 22 patients constituted the control group of a controlled trial and received,standard outpatient clinic treatment,during follow-up .,"['These', '22', 'patients', 'constituted', 'the', 'control', 'group', 'of', 'a', 'controlled', 'trial', 'and', 'received', 'standard', 'outpatient', 'clinic', 'treatment', 'during', 'follow-up', '.']","(13, 17)","(82, 118)",-1,hl_i,11750293,Abstract,2,test,gold,3836.0
1012,RESULTS Patients became significantly more depressed over time .,,,"['RESULTS', 'Patients', 'became', 'significantly', 'more', 'depressed', 'over', 'time', '.']",,,,,11750293,Abstract,3,test,gold,
1013,A set of five factors were found to consistently,predict depression,at the following assessment .,"['A', 'set', 'of', 'five', 'factors', 'were', 'found', 'to', 'consistently', 'predict', 'depression', 'at', 'the', 'following', 'assessment', '.']","(9, 11)","(48, 66)",-1,ss_o,11750293,Abstract,4,test,gold,2545.0
1014,A set of five factors were found to consistently,predict depression,at the following assessment .,"['A', 'set', 'of', 'five', 'factors', 'were', 'found', 'to', 'consistently', 'predict', 'depression', 'at', 'the', 'following', 'assessment', '.']","(9, 11)","(48, 66)",-1,hl_o,11750293,Abstract,4,test,gold,2546.0
1015,These were,"initial level of depression , disability , pain , beliefs about the consequences of arthritis and coping strategies .",,"['These', 'were', 'initial', 'level', 'of', 'depression', ',', 'disability', ',', 'pain', ',', 'beliefs', 'about', 'the', 'consequences', 'of', 'arthritis', 'and', 'coping', 'strategies', '.']","(2, 21)","(10, 127)",-1,ss_o,11750293,Abstract,5,test,gold,7116.0
1016,These were initial level of,"depression , disability , pain , beliefs about the consequences of arthritis and coping strategies .",,"['These', 'were', 'initial', 'level', 'of', 'depression', ',', 'disability', ',', 'pain', ',', 'beliefs', 'about', 'the', 'consequences', 'of', 'arthritis', 'and', 'coping', 'strategies', '.']","(5, 21)","(27, 127)",-1,hl_o,11750293,Abstract,5,test,gold,7117.0
1017,CONCLUSIONS The results confirm the importance of psychological factors in early RA and their relative independence from physical findings .,,,"['CONCLUSIONS', 'The', 'results', 'confirm', 'the', 'importance', 'of', 'psychological', 'factors', 'in', 'early', 'RA', 'and', 'their', 'relative', 'independence', 'from', 'physical', 'findings', '.']",,,,,11750293,Abstract,6,test,gold,
1018,This is the first study to document the importance of illness perceptions in,recent onset RA .,,"['This', 'is', 'the', 'first', 'study', 'to', 'document', 'the', 'importance', 'of', 'illness', 'perceptions', 'in', 'recent', 'onset', 'RA', '.']","(13, 17)","(76, 93)",-1,ss_p,11750293,Abstract,7,test,gold,2205.0
1019,A pilot study on the effect of progressive muscle relaxation training of,patients after stoma surgery .,,"['A', 'pilot', 'study', 'on', 'the', 'effect', 'of', 'progressive', 'muscle', 'relaxation', 'training', 'of', 'patients', 'after', 'stoma', 'surgery', '.']","(12, 17)","(72, 102)",-1,ss_p,11829043,Title,0,test,gold,3640.0
1020,A pilot study on the effect of,progressive muscle relaxation training,of patients after stoma surgery .,"['A', 'pilot', 'study', 'on', 'the', 'effect', 'of', 'progressive', 'muscle', 'relaxation', 'training', 'of', 'patients', 'after', 'stoma', 'surgery', '.']","(7, 11)","(30, 68)",-1,ss_i,11829043,Title,0,test,gold,2727.0
1021,A pilot study on the effect of progressive muscle relaxation training of,patients after stoma surgery .,,"['A', 'pilot', 'study', 'on', 'the', 'effect', 'of', 'progressive', 'muscle', 'relaxation', 'training', 'of', 'patients', 'after', 'stoma', 'surgery', '.']","(12, 17)","(72, 102)",-1,hl_p,11829043,Title,0,test,gold,3641.0
1022,A pilot study on the effect of,progressive muscle relaxation training,of patients after stoma surgery .,"['A', 'pilot', 'study', 'on', 'the', 'effect', 'of', 'progressive', 'muscle', 'relaxation', 'training', 'of', 'patients', 'after', 'stoma', 'surgery', '.']","(7, 11)","(30, 68)",-1,hl_i,11829043,Title,0,test,gold,2728.0
1023,,Eighteen patients who had undergone stoma surgery,"were assessed with respect to their anxiety level and self-reported quality of life ( QoL ) on three occasions ; namely , immediately after surgery , 5 weeks after surgery , and 10 weeks after surgery .","['Eighteen', 'patients', 'who', 'had', 'undergone', 'stoma', 'surgery', 'were', 'assessed', 'with', 'respect', 'to', 'their', 'anxiety', 'level', 'and', 'self-reported', 'quality', 'of', 'life', '(', 'QoL', ')', 'on', 'three', 'occasions', ';', 'namely', ',', 'immediately', 'after', 'surgery', ',', '5', 'weeks', 'after', 'surgery', ',', 'and', '10', 'weeks', 'after', 'surgery', '.']","(0, 7)","(0, 49)",-1,ss_p,11829043,Abstract,0,test,gold,3621.0
1024,Eighteen patients who had undergone stoma surgery were assessed with respect to their,anxiety level and self-reported quality of life ( QoL ),"on three occasions ; namely , immediately after surgery , 5 weeks after surgery , and 10 weeks after surgery .","['Eighteen', 'patients', 'who', 'had', 'undergone', 'stoma', 'surgery', 'were', 'assessed', 'with', 'respect', 'to', 'their', 'anxiety', 'level', 'and', 'self-reported', 'quality', 'of', 'life', '(', 'QoL', ')', 'on', 'three', 'occasions', ';', 'namely', ',', 'immediately', 'after', 'surgery', ',', '5', 'weeks', 'after', 'surgery', ',', 'and', '10', 'weeks', 'after', 'surgery', '.']","(13, 23)","(85, 140)",-1,ss_o,11829043,Abstract,0,test,gold,1898.0
1025,,Eighteen patients who had undergone stoma surgery,"were assessed with respect to their anxiety level and self-reported quality of life ( QoL ) on three occasions ; namely , immediately after surgery , 5 weeks after surgery , and 10 weeks after surgery .","['Eighteen', 'patients', 'who', 'had', 'undergone', 'stoma', 'surgery', 'were', 'assessed', 'with', 'respect', 'to', 'their', 'anxiety', 'level', 'and', 'self-reported', 'quality', 'of', 'life', '(', 'QoL', ')', 'on', 'three', 'occasions', ';', 'namely', ',', 'immediately', 'after', 'surgery', ',', '5', 'weeks', 'after', 'surgery', ',', 'and', '10', 'weeks', 'after', 'surgery', '.']","(0, 7)","(0, 49)",-1,hl_p,11829043,Abstract,0,test,gold,3622.0
1026,Eighteen patients who had undergone stoma surgery were assessed with respect to their,anxiety level and self-reported quality of life ( QoL ),"on three occasions ; namely , immediately after surgery , 5 weeks after surgery , and 10 weeks after surgery .","['Eighteen', 'patients', 'who', 'had', 'undergone', 'stoma', 'surgery', 'were', 'assessed', 'with', 'respect', 'to', 'their', 'anxiety', 'level', 'and', 'self-reported', 'quality', 'of', 'life', '(', 'QoL', ')', 'on', 'three', 'occasions', ';', 'namely', ',', 'immediately', 'after', 'surgery', ',', '5', 'weeks', 'after', 'surgery', ',', 'and', '10', 'weeks', 'after', 'surgery', '.']","(13, 23)","(85, 140)",-1,hl_o,11829043,Abstract,0,test,gold,1899.0
1027,The patients were randomised into a control group ( n = 10 ) and an experimental group ( n = 8 ) .,,,"['The', 'patients', 'were', 'randomised', 'into', 'a', 'control', 'group', '(', 'n', '=', '10', ')', 'and', 'an', 'experimental', 'group', '(', 'n', '=', '8', ')', '.']",,,,,11829043,Abstract,1,test,gold,
1028,A 20-min set of audiotaped instructions on,progressive muscle relaxation training ( PMRT ),was given to the patients in the experimental group for home practice .,"['A', '20-min', 'set', 'of', 'audiotaped', 'instructions', 'on', 'progressive', 'muscle', 'relaxation', 'training', '(', 'PMRT', ')', 'was', 'given', 'to', 'the', 'patients', 'in', 'the', 'experimental', 'group', 'for', 'home', 'practice', '.']","(7, 14)","(42, 89)",-1,ss_i,11829043,Abstract,2,test,gold,2726.0
1029,A 20-min set of audiotaped instructions on,progressive muscle relaxation training ( PMRT ),was given to the patients in the experimental group for home practice .,"['A', '20-min', 'set', 'of', 'audiotaped', 'instructions', 'on', 'progressive', 'muscle', 'relaxation', 'training', '(', 'PMRT', ')', 'was', 'given', 'to', 'the', 'patients', 'in', 'the', 'experimental', 'group', 'for', 'home', 'practice', '.']","(7, 14)","(42, 89)",-1,hl_i,11829043,Abstract,2,test,gold,2725.0
1030,Assessment instructions included the,"Chinese State-Trait Anxiety Inventory ( C-STAI ) , the Quality of Life Index for Colostomy ( QoL-Colostomy ) and the Hong Kong Chinese version of the World Health Organisation Quality of Life Scale ( WHOQoL ) .",,"['Assessment', 'instructions', 'included', 'the', 'Chinese', 'State-Trait', 'Anxiety', 'Inventory', '(', 'C-STAI', ')', ',', 'the', 'Quality', 'of', 'Life', 'Index', 'for', 'Colostomy', '(', 'QoL-Colostomy', ')', 'and', 'the', 'Hong', 'Kong', 'Chinese', 'version', 'of', 'the', 'World', 'Health', 'Organisation', 'Quality', 'of', 'Life', 'Scale', '(', 'WHOQoL', ')', '.']","(4, 41)","(36, 246)",-1,ss_o,11829043,Abstract,3,test,gold,6270.0
1031,Assessment instructions included the,"Chinese State-Trait Anxiety Inventory ( C-STAI ) , the Quality of Life Index for Colostomy ( QoL-Colostomy ) and the Hong Kong Chinese version of the World Health Organisation Quality of Life Scale ( WHOQoL ) .",,"['Assessment', 'instructions', 'included', 'the', 'Chinese', 'State-Trait', 'Anxiety', 'Inventory', '(', 'C-STAI', ')', ',', 'the', 'Quality', 'of', 'Life', 'Index', 'for', 'Colostomy', '(', 'QoL-Colostomy', ')', 'and', 'the', 'Hong', 'Kong', 'Chinese', 'version', 'of', 'the', 'World', 'Health', 'Organisation', 'Quality', 'of', 'Life', 'Scale', '(', 'WHOQoL', ')', '.']","(4, 41)","(36, 246)",-1,hl_o,11829043,Abstract,3,test,gold,6271.0
1032,Results indicated that there was a significant decrease in both the,C-STAI score,"( F = 4.66 , P < 0.05 ) and the WHOQoL score ( F = 4.74 , P < 0.05 ) in the experimental group .","['Results', 'indicated', 'that', 'there', 'was', 'a', 'significant', 'decrease', 'in', 'both', 'the', 'C-STAI', 'score', '(', 'F', '=', '4.66', ',', 'P', '<', '0.05', ')', 'and', 'the', 'WHOQoL', 'score', '(', 'F', '=', '4.74', ',', 'P', '<', '0.05', ')', 'in', 'the', 'experimental', 'group', '.']","(11, 13)","(67, 79)",-1,ss_o,11829043,Abstract,4,test,gold,1445.0
1033,"Results indicated that there was a significant decrease in both the C-STAI score ( F = 4.66 , P < 0.05 ) and the",WHOQoL score,"( F = 4.74 , P < 0.05 ) in the experimental group .","['Results', 'indicated', 'that', 'there', 'was', 'a', 'significant', 'decrease', 'in', 'both', 'the', 'C-STAI', 'score', '(', 'F', '=', '4.66', ',', 'P', '<', '0.05', ')', 'and', 'the', 'WHOQoL', 'score', '(', 'F', '=', '4.74', ',', 'P', '<', '0.05', ')', 'in', 'the', 'experimental', 'group', '.']","(24, 26)","(112, 124)",-1,ss_o,11829043,Abstract,4,test,gold,1446.0
1034,Results indicated that there was a significant decrease in both the,C-STAI score,"( F = 4.66 , P < 0.05 ) and the WHOQoL score ( F = 4.74 , P < 0.05 ) in the experimental group .","['Results', 'indicated', 'that', 'there', 'was', 'a', 'significant', 'decrease', 'in', 'both', 'the', 'C-STAI', 'score', '(', 'F', '=', '4.66', ',', 'P', '<', '0.05', ')', 'and', 'the', 'WHOQoL', 'score', '(', 'F', '=', '4.74', ',', 'P', '<', '0.05', ')', 'in', 'the', 'experimental', 'group', '.']","(11, 13)","(67, 79)",-1,hl_o,11829043,Abstract,4,test,gold,1444.0
1035,"Results indicated that there was a significant decrease in both the C-STAI score ( F = 4.66 , P < 0.05 ) and the",WHOQoL score,"( F = 4.74 , P < 0.05 ) in the experimental group .","['Results', 'indicated', 'that', 'there', 'was', 'a', 'significant', 'decrease', 'in', 'both', 'the', 'C-STAI', 'score', '(', 'F', '=', '4.66', ',', 'P', '<', '0.05', ')', 'and', 'the', 'WHOQoL', 'score', '(', 'F', '=', '4.74', ',', 'P', '<', '0.05', ')', 'in', 'the', 'experimental', 'group', '.']","(24, 26)","(112, 124)",-1,hl_o,11829043,Abstract,4,test,gold,1443.0
1036,Among the domains of,WHOQoL,", a significant difference was shown in physical health/independence and general perception of QoL , with the experimental group demonstrating better functioning .","['Among', 'the', 'domains', 'of', 'WHOQoL', ',', 'a', 'significant', 'difference', 'was', 'shown', 'in', 'physical', 'health/independence', 'and', 'general', 'perception', 'of', 'QoL', ',', 'with', 'the', 'experimental', 'group', 'demonstrating', 'better', 'functioning', '.']","(4, 5)","(20, 26)",-1,ss_o,11829043,Abstract,5,test,gold,
1037,"Among the domains of WHOQoL , a significant difference was shown in physical health/independence and general perception of",QoL,", with the experimental group demonstrating better functioning .","['Among', 'the', 'domains', 'of', 'WHOQoL', ',', 'a', 'significant', 'difference', 'was', 'shown', 'in', 'physical', 'health/independence', 'and', 'general', 'perception', 'of', 'QoL', ',', 'with', 'the', 'experimental', 'group', 'demonstrating', 'better', 'functioning', '.']","(18, 19)","(122, 125)",-1,ss_o,11829043,Abstract,5,test,gold,376.0
1038,Among the domains of,WHOQoL,", a significant difference was shown in physical health/independence and general perception of QoL , with the experimental group demonstrating better functioning .","['Among', 'the', 'domains', 'of', 'WHOQoL', ',', 'a', 'significant', 'difference', 'was', 'shown', 'in', 'physical', 'health/independence', 'and', 'general', 'perception', 'of', 'QoL', ',', 'with', 'the', 'experimental', 'group', 'demonstrating', 'better', 'functioning', '.']","(4, 5)","(20, 26)",-1,hl_o,11829043,Abstract,5,test,gold,
1039,"Among the domains of WHOQoL , a significant difference was shown in physical health/independence and general perception of",QoL,", with the experimental group demonstrating better functioning .","['Among', 'the', 'domains', 'of', 'WHOQoL', ',', 'a', 'significant', 'difference', 'was', 'shown', 'in', 'physical', 'health/independence', 'and', 'general', 'perception', 'of', 'QoL', ',', 'with', 'the', 'experimental', 'group', 'demonstrating', 'better', 'functioning', '.']","(18, 19)","(122, 125)",-1,hl_o,11829043,Abstract,5,test,gold,377.0
1040,For the,QoL-Colostomy,", however , there was no significant difference between the control and experimental groups .","['For', 'the', 'QoL-Colostomy', ',', 'however', ',', 'there', 'was', 'no', 'significant', 'difference', 'between', 'the', 'control', 'and', 'experimental', 'groups', '.']","(2, 3)","(7, 20)",-1,ss_o,11829043,Abstract,6,test,gold,
1041,For the,QoL-Colostomy,", however , there was no significant difference between the control and experimental groups .","['For', 'the', 'QoL-Colostomy', ',', 'however', ',', 'there', 'was', 'no', 'significant', 'difference', 'between', 'the', 'control', 'and', 'experimental', 'groups', '.']","(2, 3)","(7, 20)",-1,hl_o,11829043,Abstract,6,test,gold,
1042,The results suggest that the use of PMRT could enhance quality of life and decrease state anxiety in,patients after stoma surgery .,,"['The', 'results', 'suggest', 'that', 'the', 'use', 'of', 'PMRT', 'could', 'enhance', 'quality', 'of', 'life', 'and', 'decrease', 'state', 'anxiety', 'in', 'patients', 'after', 'stoma', 'surgery', '.']","(18, 23)","(100, 130)",-1,ss_p,11829043,Abstract,7,test,gold,3639.0
1043,The results suggest that the use of,PMRT,could enhance quality of life and decrease state anxiety in patients after stoma surgery .,"['The', 'results', 'suggest', 'that', 'the', 'use', 'of', 'PMRT', 'could', 'enhance', 'quality', 'of', 'life', 'and', 'decrease', 'state', 'anxiety', 'in', 'patients', 'after', 'stoma', 'surgery', '.']","(7, 8)","(35, 39)",-1,ss_i,11829043,Abstract,7,test,gold,
1044,The results suggest that the use of PMRT could enhance,quality of life,and decrease state anxiety in patients after stoma surgery .,"['The', 'results', 'suggest', 'that', 'the', 'use', 'of', 'PMRT', 'could', 'enhance', 'quality', 'of', 'life', 'and', 'decrease', 'state', 'anxiety', 'in', 'patients', 'after', 'stoma', 'surgery', '.']","(10, 13)","(54, 69)",-1,ss_o,11829043,Abstract,7,test,gold,1886.0
1045,The results suggest that the use of PMRT could enhance quality of life and decrease state,anxiety,in patients after stoma surgery .,"['The', 'results', 'suggest', 'that', 'the', 'use', 'of', 'PMRT', 'could', 'enhance', 'quality', 'of', 'life', 'and', 'decrease', 'state', 'anxiety', 'in', 'patients', 'after', 'stoma', 'surgery', '.']","(16, 17)","(89, 96)",-1,ss_o,11829043,Abstract,7,test,gold,2443.0
1046,The results suggest that the use of PMRT could enhance quality of life and decrease state anxiety in,patients after stoma surgery .,,"['The', 'results', 'suggest', 'that', 'the', 'use', 'of', 'PMRT', 'could', 'enhance', 'quality', 'of', 'life', 'and', 'decrease', 'state', 'anxiety', 'in', 'patients', 'after', 'stoma', 'surgery', '.']","(18, 23)","(100, 130)",-1,hl_p,11829043,Abstract,7,test,gold,3638.0
1047,The results suggest that the use of,PMRT,could enhance quality of life and decrease state anxiety in patients after stoma surgery .,"['The', 'results', 'suggest', 'that', 'the', 'use', 'of', 'PMRT', 'could', 'enhance', 'quality', 'of', 'life', 'and', 'decrease', 'state', 'anxiety', 'in', 'patients', 'after', 'stoma', 'surgery', '.']","(7, 8)","(35, 39)",-1,hl_i,11829043,Abstract,7,test,gold,
1048,The results suggest that the use of PMRT could enhance,quality of life,and decrease state anxiety in patients after stoma surgery .,"['The', 'results', 'suggest', 'that', 'the', 'use', 'of', 'PMRT', 'could', 'enhance', 'quality', 'of', 'life', 'and', 'decrease', 'state', 'anxiety', 'in', 'patients', 'after', 'stoma', 'surgery', '.']","(10, 13)","(54, 69)",-1,hl_o,11829043,Abstract,7,test,gold,1885.0
1049,The results suggest that the use of PMRT could enhance quality of life and decrease state,anxiety,in patients after stoma surgery .,"['The', 'results', 'suggest', 'that', 'the', 'use', 'of', 'PMRT', 'could', 'enhance', 'quality', 'of', 'life', 'and', 'decrease', 'state', 'anxiety', 'in', 'patients', 'after', 'stoma', 'surgery', '.']","(16, 17)","(89, 96)",-1,hl_o,11829043,Abstract,7,test,gold,2444.0
1050,Comparison of weakness progression in,inclusion body myositis,during treatment with methotrexate or placebo .,"['Comparison', 'of', 'weakness', 'progression', 'in', 'inclusion', 'body', 'myositis', 'during', 'treatment', 'with', 'methotrexate', 'or', 'placebo', '.']","(5, 8)","(37, 60)",-1,ss_p,11891832,Title,0,test,gold,2916.0
1051,Comparison of weakness progression in inclusion body myositis during treatment with,methotrexate,or placebo .,"['Comparison', 'of', 'weakness', 'progression', 'in', 'inclusion', 'body', 'myositis', 'during', 'treatment', 'with', 'methotrexate', 'or', 'placebo', '.']","(11, 12)","(83, 95)",-1,ss_i,11891832,Title,0,test,gold,5149.0
1052,Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or,placebo .,,"['Comparison', 'of', 'weakness', 'progression', 'in', 'inclusion', 'body', 'myositis', 'during', 'treatment', 'with', 'methotrexate', 'or', 'placebo', '.']","(13, 15)","(99, 108)",-1,ss_i,11891832,Title,0,test,gold,4419.0
1053,Comparison of,weakness progression,in inclusion body myositis during treatment with methotrexate or placebo .,"['Comparison', 'of', 'weakness', 'progression', 'in', 'inclusion', 'body', 'myositis', 'during', 'treatment', 'with', 'methotrexate', 'or', 'placebo', '.']","(2, 4)","(13, 33)",-1,ss_o,11891832,Title,0,test,gold,3319.0
1054,Comparison of weakness progression in,inclusion body myositis,during treatment with methotrexate or placebo .,"['Comparison', 'of', 'weakness', 'progression', 'in', 'inclusion', 'body', 'myositis', 'during', 'treatment', 'with', 'methotrexate', 'or', 'placebo', '.']","(5, 8)","(37, 60)",-1,hl_p,11891832,Title,0,test,gold,2917.0
1055,Comparison of weakness progression in inclusion body myositis during treatment with,methotrexate,or placebo .,"['Comparison', 'of', 'weakness', 'progression', 'in', 'inclusion', 'body', 'myositis', 'during', 'treatment', 'with', 'methotrexate', 'or', 'placebo', '.']","(11, 12)","(83, 95)",-1,hl_i,11891832,Title,0,test,gold,5150.0
1056,Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or,placebo .,,"['Comparison', 'of', 'weakness', 'progression', 'in', 'inclusion', 'body', 'myositis', 'during', 'treatment', 'with', 'methotrexate', 'or', 'placebo', '.']","(13, 15)","(99, 108)",-1,hl_i,11891832,Title,0,test,gold,4418.0
1057,Comparison of,weakness progression,in inclusion body myositis during treatment with methotrexate or placebo .,"['Comparison', 'of', 'weakness', 'progression', 'in', 'inclusion', 'body', 'myositis', 'during', 'treatment', 'with', 'methotrexate', 'or', 'placebo', '.']","(2, 4)","(13, 33)",-1,hl_o,11891832,Title,0,test,gold,3320.0
1058,We investigated whether 5 to 20mg per week oral methotrexate could slow down disease progression in,44 patients with inclusion body myositis,in a randomized double-blind placebo-controlled study over 48 weeks .,"['We', 'investigated', 'whether', '5', 'to', '20mg', 'per', 'week', 'oral', 'methotrexate', 'could', 'slow', 'down', 'disease', 'progression', 'in', '44', 'patients', 'with', 'inclusion', 'body', 'myositis', 'in', 'a', 'randomized', 'double-blind', 'placebo-controlled', 'study', 'over', '48', 'weeks', '.']","(16, 22)","(99, 139)",-1,ss_p,11891832,Abstract,0,test,gold,2914.0
1059,We investigated whether 5 to 20mg per week oral,methotrexate,could slow down disease progression in 44 patients with inclusion body myositis in a randomized double-blind placebo-controlled study over 48 weeks .,"['We', 'investigated', 'whether', '5', 'to', '20mg', 'per', 'week', 'oral', 'methotrexate', 'could', 'slow', 'down', 'disease', 'progression', 'in', '44', 'patients', 'with', 'inclusion', 'body', 'myositis', 'in', 'a', 'randomized', 'double-blind', 'placebo-controlled', 'study', 'over', '48', 'weeks', '.']","(9, 10)","(47, 59)",-1,ss_i,11891832,Abstract,0,test,gold,5148.0
1060,We investigated whether 5 to 20mg per week oral methotrexate could slow down,disease progression,in 44 patients with inclusion body myositis in a randomized double-blind placebo-controlled study over 48 weeks .,"['We', 'investigated', 'whether', '5', 'to', '20mg', 'per', 'week', 'oral', 'methotrexate', 'could', 'slow', 'down', 'disease', 'progression', 'in', '44', 'patients', 'with', 'inclusion', 'body', 'myositis', 'in', 'a', 'randomized', 'double-blind', 'placebo-controlled', 'study', 'over', '48', 'weeks', '.']","(13, 15)","(76, 95)",-1,ss_o,11891832,Abstract,0,test,gold,3317.0
1061,We investigated whether 5 to 20mg per week oral methotrexate could slow down disease progression in,44 patients with inclusion body myositis,in a randomized double-blind placebo-controlled study over 48 weeks .,"['We', 'investigated', 'whether', '5', 'to', '20mg', 'per', 'week', 'oral', 'methotrexate', 'could', 'slow', 'down', 'disease', 'progression', 'in', '44', 'patients', 'with', 'inclusion', 'body', 'myositis', 'in', 'a', 'randomized', 'double-blind', 'placebo-controlled', 'study', 'over', '48', 'weeks', '.']","(16, 22)","(99, 139)",-1,hl_p,11891832,Abstract,0,test,gold,2915.0
1062,We investigated whether 5 to 20mg per week oral,methotrexate,could slow down disease progression in 44 patients with inclusion body myositis in a randomized double-blind placebo-controlled study over 48 weeks .,"['We', 'investigated', 'whether', '5', 'to', '20mg', 'per', 'week', 'oral', 'methotrexate', 'could', 'slow', 'down', 'disease', 'progression', 'in', '44', 'patients', 'with', 'inclusion', 'body', 'myositis', 'in', 'a', 'randomized', 'double-blind', 'placebo-controlled', 'study', 'over', '48', 'weeks', '.']","(9, 10)","(47, 59)",-1,hl_i,11891832,Abstract,0,test,gold,5147.0
1063,We investigated whether 5 to 20mg per week oral methotrexate could slow down,disease progression,in 44 patients with inclusion body myositis in a randomized double-blind placebo-controlled study over 48 weeks .,"['We', 'investigated', 'whether', '5', 'to', '20mg', 'per', 'week', 'oral', 'methotrexate', 'could', 'slow', 'down', 'disease', 'progression', 'in', '44', 'patients', 'with', 'inclusion', 'body', 'myositis', 'in', 'a', 'randomized', 'double-blind', 'placebo-controlled', 'study', 'over', '48', 'weeks', '.']","(13, 15)","(76, 95)",-1,hl_o,11891832,Abstract,0,test,gold,3318.0
1064,,Mean change of quantitative muscle strength testing sum scores,was the primary study outcome measure .,"['Mean', 'change', 'of', 'quantitative', 'muscle', 'strength', 'testing', 'sum', 'scores', 'was', 'the', 'primary', 'study', 'outcome', 'measure', '.']","(0, 9)","(0, 62)",-1,ss_o,11891832,Abstract,1,test,gold,6486.0
1065,,Mean change of quantitative muscle strength testing sum scores,was the primary study outcome measure .,"['Mean', 'change', 'of', 'quantitative', 'muscle', 'strength', 'testing', 'sum', 'scores', 'was', 'the', 'primary', 'study', 'outcome', 'measure', '.']","(0, 9)","(0, 62)",-1,hl_o,11891832,Abstract,1,test,gold,6487.0
1066,"Quantitative muscle strength testing sum scores declined in both treatment groups , -0.2 % for",methotrexate,and -3.4 % for placebo ( 95 % confidence interval = -2.5 % to +9.1 % for difference ) .,"['Quantitative', 'muscle', 'strength', 'testing', 'sum', 'scores', 'declined', 'in', 'both', 'treatment', 'groups', ',', '-0.2', '%', 'for', 'methotrexate', 'and', '-3.4', '%', 'for', 'placebo', '(', '95', '%', 'confidence', 'interval', '=', '-2.5', '%', 'to', '+9.1', '%', 'for', 'difference', ')', '.']","(15, 16)","(94, 106)",-1,ss_i,11891832,Abstract,2,test,gold,5146.0
1067,"Quantitative muscle strength testing sum scores declined in both treatment groups , -0.2 % for methotrexate and -3.4 % for",placebo,( 95 % confidence interval = -2.5 % to +9.1 % for difference ) .,"['Quantitative', 'muscle', 'strength', 'testing', 'sum', 'scores', 'declined', 'in', 'both', 'treatment', 'groups', ',', '-0.2', '%', 'for', 'methotrexate', 'and', '-3.4', '%', 'for', 'placebo', '(', '95', '%', 'confidence', 'interval', '=', '-2.5', '%', 'to', '+9.1', '%', 'for', 'difference', ')', '.']","(20, 21)","(122, 129)",-1,ss_i,11891832,Abstract,2,test,gold,4417.0
1068,,Quantitative muscle strength testing sum scores,"declined in both treatment groups , -0.2 % for methotrexate and -3.4 % for placebo ( 95 % confidence interval = -2.5 % to +9.1 % for difference ) .","['Quantitative', 'muscle', 'strength', 'testing', 'sum', 'scores', 'declined', 'in', 'both', 'treatment', 'groups', ',', '-0.2', '%', 'for', 'methotrexate', 'and', '-3.4', '%', 'for', 'placebo', '(', '95', '%', 'confidence', 'interval', '=', '-2.5', '%', 'to', '+9.1', '%', 'for', 'difference', ')', '.']","(0, 6)","(0, 47)",-1,ss_o,11891832,Abstract,2,test,gold,6488.0
1069,"Quantitative muscle strength testing sum scores declined in both treatment groups , -0.2 % for",methotrexate,and -3.4 % for placebo ( 95 % confidence interval = -2.5 % to +9.1 % for difference ) .,"['Quantitative', 'muscle', 'strength', 'testing', 'sum', 'scores', 'declined', 'in', 'both', 'treatment', 'groups', ',', '-0.2', '%', 'for', 'methotrexate', 'and', '-3.4', '%', 'for', 'placebo', '(', '95', '%', 'confidence', 'interval', '=', '-2.5', '%', 'to', '+9.1', '%', 'for', 'difference', ')', '.']","(15, 16)","(94, 106)",-1,hl_i,11891832,Abstract,2,test,gold,5145.0
1070,"Quantitative muscle strength testing sum scores declined in both treatment groups , -0.2 % for methotrexate and -3.4 % for",placebo,( 95 % confidence interval = -2.5 % to +9.1 % for difference ) .,"['Quantitative', 'muscle', 'strength', 'testing', 'sum', 'scores', 'declined', 'in', 'both', 'treatment', 'groups', ',', '-0.2', '%', 'for', 'methotrexate', 'and', '-3.4', '%', 'for', 'placebo', '(', '95', '%', 'confidence', 'interval', '=', '-2.5', '%', 'to', '+9.1', '%', 'for', 'difference', ')', '.']","(20, 21)","(122, 129)",-1,hl_i,11891832,Abstract,2,test,gold,4416.0
1071,,Quantitative muscle strength testing sum scores,"declined in both treatment groups , -0.2 % for methotrexate and -3.4 % for placebo ( 95 % confidence interval = -2.5 % to +9.1 % for difference ) .","['Quantitative', 'muscle', 'strength', 'testing', 'sum', 'scores', 'declined', 'in', 'both', 'treatment', 'groups', ',', '-0.2', '%', 'for', 'methotrexate', 'and', '-3.4', '%', 'for', 'placebo', '(', '95', '%', 'confidence', 'interval', '=', '-2.5', '%', 'to', '+9.1', '%', 'for', 'difference', ')', '.']","(0, 6)","(0, 47)",-1,hl_o,11891832,Abstract,2,test,gold,6489.0
1072,There were also no differences in,"manual muscle testing sum scores , activity scale scores and patients ' own assessments",after 48 weeks of treatment .,"['There', 'were', 'also', 'no', 'differences', 'in', 'manual', 'muscle', 'testing', 'sum', 'scores', ',', 'activity', 'scale', 'scores', 'and', 'patients', ""'"", 'own', 'assessments', 'after', '48', 'weeks', 'of', 'treatment', '.']","(6, 20)","(33, 120)",-1,ss_o,11891832,Abstract,3,test,gold,6484.0
1073,There were also no differences in,"manual muscle testing sum scores , activity scale scores and patients ' own assessments",after 48 weeks of treatment .,"['There', 'were', 'also', 'no', 'differences', 'in', 'manual', 'muscle', 'testing', 'sum', 'scores', ',', 'activity', 'scale', 'scores', 'and', 'patients', ""'"", 'own', 'assessments', 'after', '48', 'weeks', 'of', 'treatment', '.']","(6, 20)","(33, 120)",-1,hl_o,11891832,Abstract,3,test,gold,6485.0
1074,Serum creatine kinase activity decreased significantly in the,methotrexate,group .,"['Serum', 'creatine', 'kinase', 'activity', 'decreased', 'significantly', 'in', 'the', 'methotrexate', 'group', '.']","(8, 9)","(61, 73)",-1,ss_i,11891832,Abstract,4,test,gold,5144.0
1075,,Serum creatine kinase activity,decreased significantly in the methotrexate group .,"['Serum', 'creatine', 'kinase', 'activity', 'decreased', 'significantly', 'in', 'the', 'methotrexate', 'group', '.']","(0, 4)","(0, 30)",-1,ss_o,11891832,Abstract,4,test,gold,6519.0
1076,Serum creatine kinase activity decreased significantly in the,methotrexate,group .,"['Serum', 'creatine', 'kinase', 'activity', 'decreased', 'significantly', 'in', 'the', 'methotrexate', 'group', '.']","(8, 9)","(61, 73)",-1,hl_i,11891832,Abstract,4,test,gold,5143.0
1077,,Serum creatine kinase activity,decreased significantly in the methotrexate group .,"['Serum', 'creatine', 'kinase', 'activity', 'decreased', 'significantly', 'in', 'the', 'methotrexate', 'group', '.']","(0, 4)","(0, 30)",-1,hl_o,11891832,Abstract,4,test,gold,6520.0
1078,We conclude that oral,methotrexate,did not slow down progression of muscle weakness but decreased serum creatine kinase activity .,"['We', 'conclude', 'that', 'oral', 'methotrexate', 'did', 'not', 'slow', 'down', 'progression', 'of', 'muscle', 'weakness', 'but', 'decreased', 'serum', 'creatine', 'kinase', 'activity', '.']","(4, 5)","(21, 33)",-1,ss_i,11891832,Abstract,5,test,gold,5142.0
1079,We conclude that oral methotrexate did not slow down,progression of muscle weakness,but decreased serum creatine kinase activity .,"['We', 'conclude', 'that', 'oral', 'methotrexate', 'did', 'not', 'slow', 'down', 'progression', 'of', 'muscle', 'weakness', 'but', 'decreased', 'serum', 'creatine', 'kinase', 'activity', '.']","(9, 13)","(52, 82)",-1,ss_o,11891832,Abstract,5,test,gold,3321.0
1080,We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased,serum creatine kinase activity .,,"['We', 'conclude', 'that', 'oral', 'methotrexate', 'did', 'not', 'slow', 'down', 'progression', 'of', 'muscle', 'weakness', 'but', 'decreased', 'serum', 'creatine', 'kinase', 'activity', '.']","(15, 20)","(97, 129)",-1,ss_o,11891832,Abstract,5,test,gold,6517.0
1081,We conclude that oral,methotrexate,did not slow down progression of muscle weakness but decreased serum creatine kinase activity .,"['We', 'conclude', 'that', 'oral', 'methotrexate', 'did', 'not', 'slow', 'down', 'progression', 'of', 'muscle', 'weakness', 'but', 'decreased', 'serum', 'creatine', 'kinase', 'activity', '.']","(4, 5)","(21, 33)",-1,hl_i,11891832,Abstract,5,test,gold,5141.0
1082,We conclude that oral methotrexate did not slow down,progression of muscle weakness,but decreased serum creatine kinase activity .,"['We', 'conclude', 'that', 'oral', 'methotrexate', 'did', 'not', 'slow', 'down', 'progression', 'of', 'muscle', 'weakness', 'but', 'decreased', 'serum', 'creatine', 'kinase', 'activity', '.']","(9, 13)","(52, 82)",-1,hl_o,11891832,Abstract,5,test,gold,3322.0
1083,We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased,serum creatine kinase activity .,,"['We', 'conclude', 'that', 'oral', 'methotrexate', 'did', 'not', 'slow', 'down', 'progression', 'of', 'muscle', 'weakness', 'but', 'decreased', 'serum', 'creatine', 'kinase', 'activity', '.']","(15, 20)","(97, 129)",-1,hl_o,11891832,Abstract,5,test,gold,6518.0
1084,[ Limbal epithelial autograft transplantation in treatment of,pterygium ],.,"['[', 'Limbal', 'epithelial', 'autograft', 'transplantation', 'in', 'treatment', 'of', 'pterygium', ']', '.']","(8, 10)","(61, 72)",-1,ss_p,12139812,Title,0,test,gold,291.0
1085,,[ Limbal epithelial autograft transplantation,in treatment of pterygium ] .,"['[', 'Limbal', 'epithelial', 'autograft', 'transplantation', 'in', 'treatment', 'of', 'pterygium', ']', '.']","(0, 5)","(0, 45)",-1,ss_i,12139812,Title,0,test,gold,6669.0
1086,[ Limbal epithelial autograft transplantation in treatment of,pterygium,] .,"['[', 'Limbal', 'epithelial', 'autograft', 'transplantation', 'in', 'treatment', 'of', 'pterygium', ']', '.']","(8, 9)","(61, 70)",-1,hl_p,12139812,Title,0,test,gold,292.0
1087,,[ Limbal epithelial autograft transplantation,in treatment of pterygium ] .,"['[', 'Limbal', 'epithelial', 'autograft', 'transplantation', 'in', 'treatment', 'of', 'pterygium', ']', '.']","(0, 5)","(0, 45)",-1,hl_i,12139812,Title,0,test,gold,6670.0
1088,OBJECTIVE To observe the therapeutic effects of limbal epithelial autograft transplantation and pterygium excision in the treatment of,pterygium .,,"['OBJECTIVE', 'To', 'observe', 'the', 'therapeutic', 'effects', 'of', 'limbal', 'epithelial', 'autograft', 'transplantation', 'and', 'pterygium', 'excision', 'in', 'the', 'treatment', 'of', 'pterygium', '.']","(18, 20)","(134, 145)",-1,ss_p,12139812,Abstract,0,test,gold,290.0
1089,OBJECTIVE To observe the therapeutic effects of,limbal epithelial autograft transplantation,and pterygium excision in the treatment of pterygium .,"['OBJECTIVE', 'To', 'observe', 'the', 'therapeutic', 'effects', 'of', 'limbal', 'epithelial', 'autograft', 'transplantation', 'and', 'pterygium', 'excision', 'in', 'the', 'treatment', 'of', 'pterygium', '.']","(7, 11)","(47, 90)",-1,ss_i,12139812,Abstract,0,test,gold,6673.0
1090,OBJECTIVE To observe the therapeutic effects of limbal epithelial autograft transplantation and,pterygium excision,in the treatment of pterygium .,"['OBJECTIVE', 'To', 'observe', 'the', 'therapeutic', 'effects', 'of', 'limbal', 'epithelial', 'autograft', 'transplantation', 'and', 'pterygium', 'excision', 'in', 'the', 'treatment', 'of', 'pterygium', '.']","(12, 14)","(95, 113)",-1,ss_i,12139812,Abstract,0,test,gold,3107.0
1091,OBJECTIVE To observe the,therapeutic effects,of limbal epithelial autograft transplantation and pterygium excision in the treatment of pterygium .,"['OBJECTIVE', 'To', 'observe', 'the', 'therapeutic', 'effects', 'of', 'limbal', 'epithelial', 'autograft', 'transplantation', 'and', 'pterygium', 'excision', 'in', 'the', 'treatment', 'of', 'pterygium', '.']","(4, 6)","(24, 43)",-1,ss_o,12139812,Abstract,0,test,gold,2350.0
1092,OBJECTIVE To observe the therapeutic effects of limbal epithelial autograft transplantation and pterygium excision in the treatment of,pterygium .,,"['OBJECTIVE', 'To', 'observe', 'the', 'therapeutic', 'effects', 'of', 'limbal', 'epithelial', 'autograft', 'transplantation', 'and', 'pterygium', 'excision', 'in', 'the', 'treatment', 'of', 'pterygium', '.']","(18, 20)","(134, 145)",-1,hl_p,12139812,Abstract,0,test,gold,289.0
1093,OBJECTIVE To observe the therapeutic effects of,limbal epithelial autograft transplantation,and pterygium excision in the treatment of pterygium .,"['OBJECTIVE', 'To', 'observe', 'the', 'therapeutic', 'effects', 'of', 'limbal', 'epithelial', 'autograft', 'transplantation', 'and', 'pterygium', 'excision', 'in', 'the', 'treatment', 'of', 'pterygium', '.']","(7, 11)","(47, 90)",-1,hl_i,12139812,Abstract,0,test,gold,6674.0
1094,OBJECTIVE To observe the therapeutic effects of limbal epithelial autograft transplantation and,pterygium excision,in the treatment of pterygium .,"['OBJECTIVE', 'To', 'observe', 'the', 'therapeutic', 'effects', 'of', 'limbal', 'epithelial', 'autograft', 'transplantation', 'and', 'pterygium', 'excision', 'in', 'the', 'treatment', 'of', 'pterygium', '.']","(12, 14)","(95, 113)",-1,hl_i,12139812,Abstract,0,test,gold,3108.0
1095,METHODS A prospective randomized paired-eye trial was studied .,,,"['METHODS', 'A', 'prospective', 'randomized', 'paired-eye', 'trial', 'was', 'studied', '.']",,,,,12139812,Abstract,1,test,gold,
1096,There were,208 patients ( 229 eyes ) with initial pterygium,", and they were allocated to two groups : excision of pterygium with limbal epithelial autograft transplantation surgery ( A group , 106 cases and 124 eyes ) and simple pterygium excision ( B group , 102 cases and 105 eyes ) .","['There', 'were', '208', 'patients', '(', '229', 'eyes', ')', 'with', 'initial', 'pterygium', ',', 'and', 'they', 'were', 'allocated', 'to', 'two', 'groups', ':', 'excision', 'of', 'pterygium', 'with', 'limbal', 'epithelial', 'autograft', 'transplantation', 'surgery', '(', 'A', 'group', ',', '106', 'cases', 'and', '124', 'eyes', ')', 'and', 'simple', 'pterygium', 'excision', '(', 'B', 'group', ',', '102', 'cases', 'and', '105', 'eyes', ')', '.']","(2, 11)","(10, 58)",-1,ss_p,12139812,Abstract,2,test,gold,3875.0
1097,"There were 208 patients ( 229 eyes ) with initial pterygium , and they were allocated to two groups :",excision of pterygium,"with limbal epithelial autograft transplantation surgery ( A group , 106 cases and 124 eyes ) and simple pterygium excision ( B group , 102 cases and 105 eyes ) .","['There', 'were', '208', 'patients', '(', '229', 'eyes', ')', 'with', 'initial', 'pterygium', ',', 'and', 'they', 'were', 'allocated', 'to', 'two', 'groups', ':', 'excision', 'of', 'pterygium', 'with', 'limbal', 'epithelial', 'autograft', 'transplantation', 'surgery', '(', 'A', 'group', ',', '106', 'cases', 'and', '124', 'eyes', ')', 'and', 'simple', 'pterygium', 'excision', '(', 'B', 'group', ',', '102', 'cases', 'and', '105', 'eyes', ')', '.']","(20, 23)","(101, 122)",-1,ss_i,12139812,Abstract,2,test,gold,3106.0
1098,"There were 208 patients ( 229 eyes ) with initial pterygium , and they were allocated to two groups : excision of pterygium with",limbal epithelial autograft transplantation surgery,"( A group , 106 cases and 124 eyes ) and simple pterygium excision ( B group , 102 cases and 105 eyes ) .","['There', 'were', '208', 'patients', '(', '229', 'eyes', ')', 'with', 'initial', 'pterygium', ',', 'and', 'they', 'were', 'allocated', 'to', 'two', 'groups', ':', 'excision', 'of', 'pterygium', 'with', 'limbal', 'epithelial', 'autograft', 'transplantation', 'surgery', '(', 'A', 'group', ',', '106', 'cases', 'and', '124', 'eyes', ')', 'and', 'simple', 'pterygium', 'excision', '(', 'B', 'group', ',', '102', 'cases', 'and', '105', 'eyes', ')', '.']","(24, 29)","(128, 179)",-1,ss_i,12139812,Abstract,2,test,gold,6667.0
1099,"There were 208 patients ( 229 eyes ) with initial pterygium , and they were allocated to two groups : excision of pterygium with limbal epithelial autograft transplantation surgery ( A group , 106 cases and 124 eyes ) and",simple pterygium excision,"( B group , 102 cases and 105 eyes ) .","['There', 'were', '208', 'patients', '(', '229', 'eyes', ')', 'with', 'initial', 'pterygium', ',', 'and', 'they', 'were', 'allocated', 'to', 'two', 'groups', ':', 'excision', 'of', 'pterygium', 'with', 'limbal', 'epithelial', 'autograft', 'transplantation', 'surgery', '(', 'A', 'group', ',', '106', 'cases', 'and', '124', 'eyes', ')', 'and', 'simple', 'pterygium', 'excision', '(', 'B', 'group', ',', '102', 'cases', 'and', '105', 'eyes', ')', '.']","(40, 43)","(221, 246)",-1,ss_i,12139812,Abstract,2,test,gold,3109.0
1100,There were,208 patients,"( 229 eyes ) with initial pterygium , and they were allocated to two groups : excision of pterygium with limbal epithelial autograft transplantation surgery ( A group , 106 cases and 124 eyes ) and simple pterygium excision ( B group , 102 cases and 105 eyes ) .","['There', 'were', '208', 'patients', '(', '229', 'eyes', ')', 'with', 'initial', 'pterygium', ',', 'and', 'they', 'were', 'allocated', 'to', 'two', 'groups', ':', 'excision', 'of', 'pterygium', 'with', 'limbal', 'epithelial', 'autograft', 'transplantation', 'surgery', '(', 'A', 'group', ',', '106', 'cases', 'and', '124', 'eyes', ')', 'and', 'simple', 'pterygium', 'excision', '(', 'B', 'group', ',', '102', 'cases', 'and', '105', 'eyes', ')', '.']","(2, 4)","(10, 22)",-1,hl_p,12139812,Abstract,2,test,gold,3753.0
1101,There were 208 patients ( 229 eyes ) with,initial pterygium,", and they were allocated to two groups : excision of pterygium with limbal epithelial autograft transplantation surgery ( A group , 106 cases and 124 eyes ) and simple pterygium excision ( B group , 102 cases and 105 eyes ) .","['There', 'were', '208', 'patients', '(', '229', 'eyes', ')', 'with', 'initial', 'pterygium', ',', 'and', 'they', 'were', 'allocated', 'to', 'two', 'groups', ':', 'excision', 'of', 'pterygium', 'with', 'limbal', 'epithelial', 'autograft', 'transplantation', 'surgery', '(', 'A', 'group', ',', '106', 'cases', 'and', '124', 'eyes', ')', 'and', 'simple', 'pterygium', 'excision', '(', 'B', 'group', ',', '102', 'cases', 'and', '105', 'eyes', ')', '.']","(9, 11)","(41, 58)",-1,hl_p,12139812,Abstract,2,test,gold,287.0
1102,"There were 208 patients ( 229 eyes ) with initial pterygium , and they were allocated to two groups :",excision of pterygium,"with limbal epithelial autograft transplantation surgery ( A group , 106 cases and 124 eyes ) and simple pterygium excision ( B group , 102 cases and 105 eyes ) .","['There', 'were', '208', 'patients', '(', '229', 'eyes', ')', 'with', 'initial', 'pterygium', ',', 'and', 'they', 'were', 'allocated', 'to', 'two', 'groups', ':', 'excision', 'of', 'pterygium', 'with', 'limbal', 'epithelial', 'autograft', 'transplantation', 'surgery', '(', 'A', 'group', ',', '106', 'cases', 'and', '124', 'eyes', ')', 'and', 'simple', 'pterygium', 'excision', '(', 'B', 'group', ',', '102', 'cases', 'and', '105', 'eyes', ')', '.']","(20, 23)","(101, 122)",-1,hl_i,12139812,Abstract,2,test,gold,3105.0
1103,"There were 208 patients ( 229 eyes ) with initial pterygium , and they were allocated to two groups : excision of pterygium with",limbal epithelial autograft transplantation surgery,"( A group , 106 cases and 124 eyes ) and simple pterygium excision ( B group , 102 cases and 105 eyes ) .","['There', 'were', '208', 'patients', '(', '229', 'eyes', ')', 'with', 'initial', 'pterygium', ',', 'and', 'they', 'were', 'allocated', 'to', 'two', 'groups', ':', 'excision', 'of', 'pterygium', 'with', 'limbal', 'epithelial', 'autograft', 'transplantation', 'surgery', '(', 'A', 'group', ',', '106', 'cases', 'and', '124', 'eyes', ')', 'and', 'simple', 'pterygium', 'excision', '(', 'B', 'group', ',', '102', 'cases', 'and', '105', 'eyes', ')', '.']","(24, 29)","(128, 179)",-1,hl_i,12139812,Abstract,2,test,gold,6668.0
1104,"There were 208 patients ( 229 eyes ) with initial pterygium , and they were allocated to two groups : excision of pterygium with limbal epithelial autograft transplantation surgery ( A group , 106 cases and 124 eyes ) and",simple pterygium excision,"( B group , 102 cases and 105 eyes ) .","['There', 'were', '208', 'patients', '(', '229', 'eyes', ')', 'with', 'initial', 'pterygium', ',', 'and', 'they', 'were', 'allocated', 'to', 'two', 'groups', ':', 'excision', 'of', 'pterygium', 'with', 'limbal', 'epithelial', 'autograft', 'transplantation', 'surgery', '(', 'A', 'group', ',', '106', 'cases', 'and', '124', 'eyes', ')', 'and', 'simple', 'pterygium', 'excision', '(', 'B', 'group', ',', '102', 'cases', 'and', '105', 'eyes', ')', '.']","(40, 43)","(221, 246)",-1,hl_i,12139812,Abstract,2,test,gold,3110.0
1105,The criteria for recovery were,corneal transparency with stable epithelial healing and no abnormal proliferation of pterygium-like tissue .,,"['The', 'criteria', 'for', 'recovery', 'were', 'corneal', 'transparency', 'with', 'stable', 'epithelial', 'healing', 'and', 'no', 'abnormal', 'proliferation', 'of', 'pterygium-like', 'tissue', '.']","(5, 19)","(30, 138)",-1,ss_o,12139812,Abstract,3,test,gold,6538.0
1106,The criteria for recovery were corneal transparency with stable,epithelial healing,and no abnormal proliferation of pterygium-like tissue .,"['The', 'criteria', 'for', 'recovery', 'were', 'corneal', 'transparency', 'with', 'stable', 'epithelial', 'healing', 'and', 'no', 'abnormal', 'proliferation', 'of', 'pterygium-like', 'tissue', '.']","(9, 11)","(63, 81)",-1,hl_o,12139812,Abstract,3,test,gold,3166.0
1107,The criteria for recovery were corneal transparency with stable epithelial healing and no,abnormal proliferation of pterygium-like tissue .,,"['The', 'criteria', 'for', 'recovery', 'were', 'corneal', 'transparency', 'with', 'stable', 'epithelial', 'healing', 'and', 'no', 'abnormal', 'proliferation', 'of', 'pterygium-like', 'tissue', '.']","(13, 19)","(89, 138)",-1,hl_o,12139812,Abstract,3,test,gold,3165.0
1108,The post-operative follow-up periods ranged from 18 approximately 28 ( 22.4 +/- 4.9 ) months .,,,"['The', 'post-operative', 'follow-up', 'periods', 'ranged', 'from', '18', 'approximately', '28', '(', '22.4', '+/-', '4.9', ')', 'months', '.']",,,,,12139812,Abstract,4,test,gold,
1109,RESULTS Some of the patients lost follow-up .,,,"['RESULTS', 'Some', 'of', 'the', 'patients', 'lost', 'follow-up', '.']",,,,,12139812,Abstract,5,test,gold,
1110,"In the eyes followed up , 5 of 11 2 eyes ( 4.5 % ) in A group and 41 of 96 eyes ( 42.7 % ) in B group were recurred , the difference being very significant ( P < 0.001 ) .",,,"['In', 'the', 'eyes', 'followed', 'up', ',', '5', 'of', '11', '2', 'eyes', '(', '4.5', '%', ')', 'in', 'A', 'group', 'and', '41', 'of', '96', 'eyes', '(', '42.7', '%', ')', 'in', 'B', 'group', 'were', 'recurred', ',', 'the', 'difference', 'being', 'very', 'significant', '(', 'P', '<', '0.001', ')', '.']",,,,,12139812,Abstract,6,test,gold,
1111,"CONCLUSION To provide a new stem cell source , limbal epithelial autograft transplantation , for an injured limb us is a reasonable therapeutic method for the treatment of",pterygium .,,"['CONCLUSION', 'To', 'provide', 'a', 'new', 'stem', 'cell', 'source', ',', 'limbal', 'epithelial', 'autograft', 'transplantation', ',', 'for', 'an', 'injured', 'limb', 'us', 'is', 'a', 'reasonable', 'therapeutic', 'method', 'for', 'the', 'treatment', 'of', 'pterygium', '.']","(28, 30)","(171, 182)",-1,ss_p,12139812,Abstract,7,test,gold,288.0
1112,"CONCLUSION To provide a new stem cell source ,",limbal epithelial autograft transplantation,", for an injured limb us is a reasonable therapeutic method for the treatment of pterygium .","['CONCLUSION', 'To', 'provide', 'a', 'new', 'stem', 'cell', 'source', ',', 'limbal', 'epithelial', 'autograft', 'transplantation', ',', 'for', 'an', 'injured', 'limb', 'us', 'is', 'a', 'reasonable', 'therapeutic', 'method', 'for', 'the', 'treatment', 'of', 'pterygium', '.']","(9, 13)","(46, 89)",-1,ss_i,12139812,Abstract,7,test,gold,6672.0
1113,"CONCLUSION To provide a new stem cell source ,",limbal epithelial autograft transplantation,", for an injured limb us is a reasonable therapeutic method for the treatment of pterygium .","['CONCLUSION', 'To', 'provide', 'a', 'new', 'stem', 'cell', 'source', ',', 'limbal', 'epithelial', 'autograft', 'transplantation', ',', 'for', 'an', 'injured', 'limb', 'us', 'is', 'a', 'reasonable', 'therapeutic', 'method', 'for', 'the', 'treatment', 'of', 'pterygium', '.']","(9, 13)","(46, 89)",-1,hl_i,12139812,Abstract,7,test,gold,6671.0
1114,Clinical performance of the,Reichert AT550 :,a new non-contact tonometer .,"['Clinical', 'performance', 'of', 'the', 'Reichert', 'AT550', ':', 'a', 'new', 'non-contact', 'tonometer', '.']","(4, 7)","(27, 43)",-1,ss_i,12477021,Title,0,test,gold,1120.0
1115,,Clinical performance,of the Reichert AT550 : a new non-contact tonometer .,"['Clinical', 'performance', 'of', 'the', 'Reichert', 'AT550', ':', 'a', 'new', 'non-contact', 'tonometer', '.']","(0, 2)","(0, 20)",-1,ss_o,12477021,Title,0,test,gold,4763.0
1116,Clinical performance of the,Reichert AT550 :,a new non-contact tonometer .,"['Clinical', 'performance', 'of', 'the', 'Reichert', 'AT550', ':', 'a', 'new', 'non-contact', 'tonometer', '.']","(4, 7)","(27, 43)",-1,hl_i,12477021,Title,0,test,gold,1121.0
1117,,Clinical performance,of the Reichert AT550 : a new non-contact tonometer .,"['Clinical', 'performance', 'of', 'the', 'Reichert', 'AT550', ':', 'a', 'new', 'non-contact', 'tonometer', '.']","(0, 2)","(0, 20)",-1,hl_o,12477021,Title,0,test,gold,4764.0
1118,The aim of the present study was to assess the level of accuracy for measurements of intra-ocular pressure ( IOP ) obtained with a new non-contact tonometer ( NCT ) the,Reichert AT550 .,,"['The', 'aim', 'of', 'the', 'present', 'study', 'was', 'to', 'assess', 'the', 'level', 'of', 'accuracy', 'for', 'measurements', 'of', 'intra-ocular', 'pressure', '(', 'IOP', ')', 'obtained', 'with', 'a', 'new', 'non-contact', 'tonometer', '(', 'NCT', ')', 'the', 'Reichert', 'AT550', '.']","(31, 34)","(168, 184)",-1,ss_i,12477021,Abstract,0,test,gold,1119.0
1119,The aim of the present study was to assess the,level of accuracy,for measurements of intra-ocular pressure ( IOP ) obtained with a new non-contact tonometer ( NCT ) the Reichert AT550 .,"['The', 'aim', 'of', 'the', 'present', 'study', 'was', 'to', 'assess', 'the', 'level', 'of', 'accuracy', 'for', 'measurements', 'of', 'intra-ocular', 'pressure', '(', 'IOP', ')', 'obtained', 'with', 'a', 'new', 'non-contact', 'tonometer', '(', 'NCT', ')', 'the', 'Reichert', 'AT550', '.']","(10, 13)","(46, 63)",-1,ss_o,12477021,Abstract,0,test,gold,1814.0
1120,The aim of the present study was to assess the level of accuracy for,measurements of intra-ocular pressure ( IOP ),obtained with a new non-contact tonometer ( NCT ) the Reichert AT550 .,"['The', 'aim', 'of', 'the', 'present', 'study', 'was', 'to', 'assess', 'the', 'level', 'of', 'accuracy', 'for', 'measurements', 'of', 'intra-ocular', 'pressure', '(', 'IOP', ')', 'obtained', 'with', 'a', 'new', 'non-contact', 'tonometer', '(', 'NCT', ')', 'the', 'Reichert', 'AT550', '.']","(14, 21)","(68, 113)",-1,ss_o,12477021,Abstract,0,test,gold,1687.0
1121,The aim of the present study was to assess the level of accuracy for measurements of intra-ocular pressure ( IOP ) obtained with a new non-contact tonometer ( NCT ) the,Reichert AT550 .,,"['The', 'aim', 'of', 'the', 'present', 'study', 'was', 'to', 'assess', 'the', 'level', 'of', 'accuracy', 'for', 'measurements', 'of', 'intra-ocular', 'pressure', '(', 'IOP', ')', 'obtained', 'with', 'a', 'new', 'non-contact', 'tonometer', '(', 'NCT', ')', 'the', 'Reichert', 'AT550', '.']","(31, 34)","(168, 184)",-1,hl_i,12477021,Abstract,0,test,gold,1118.0
1122,The aim of the present study was to assess the,level of accuracy,for measurements of intra-ocular pressure ( IOP ) obtained with a new non-contact tonometer ( NCT ) the Reichert AT550 .,"['The', 'aim', 'of', 'the', 'present', 'study', 'was', 'to', 'assess', 'the', 'level', 'of', 'accuracy', 'for', 'measurements', 'of', 'intra-ocular', 'pressure', '(', 'IOP', ')', 'obtained', 'with', 'a', 'new', 'non-contact', 'tonometer', '(', 'NCT', ')', 'the', 'Reichert', 'AT550', '.']","(10, 13)","(46, 63)",-1,hl_o,12477021,Abstract,0,test,gold,1815.0
1123,The aim of the present study was to assess the level of accuracy for,measurements,of intra-ocular pressure ( IOP ) obtained with a new non-contact tonometer ( NCT ) the Reichert AT550 .,"['The', 'aim', 'of', 'the', 'present', 'study', 'was', 'to', 'assess', 'the', 'level', 'of', 'accuracy', 'for', 'measurements', 'of', 'intra-ocular', 'pressure', '(', 'IOP', ')', 'obtained', 'with', 'a', 'new', 'non-contact', 'tonometer', '(', 'NCT', ')', 'the', 'Reichert', 'AT550', '.']","(14, 15)","(68, 80)",-1,hl_o,12477021,Abstract,0,test,gold,1314.0
1124,Measurements were compared against those obtained with the,"Reichert Xpert Plus , Goldmann applanation tonometer",and Perkins tonometer .,"['Measurements', 'were', 'compared', 'against', 'those', 'obtained', 'with', 'the', 'Reichert', 'Xpert', 'Plus', ',', 'Goldmann', 'applanation', 'tonometer', 'and', 'Perkins', 'tonometer', '.']","(8, 15)","(58, 110)",-1,ss_i,12477021,Abstract,1,test,gold,4097.0
1125,"Measurements were compared against those obtained with the Reichert Xpert Plus , Goldmann applanation tonometer and",Perkins tonometer .,,"['Measurements', 'were', 'compared', 'against', 'those', 'obtained', 'with', 'the', 'Reichert', 'Xpert', 'Plus', ',', 'Goldmann', 'applanation', 'tonometer', 'and', 'Perkins', 'tonometer', '.']","(16, 19)","(115, 134)",-1,ss_i,12477021,Abstract,1,test,gold,1109.0
1126,Measurements were compared against those obtained with the,Reichert Xpert Plus,", Goldmann applanation tonometer and Perkins tonometer .","['Measurements', 'were', 'compared', 'against', 'those', 'obtained', 'with', 'the', 'Reichert', 'Xpert', 'Plus', ',', 'Goldmann', 'applanation', 'tonometer', 'and', 'Perkins', 'tonometer', '.']","(8, 11)","(58, 77)",-1,hl_i,12477021,Abstract,1,test,gold,4098.0
1127,"Measurements were compared against those obtained with the Reichert Xpert Plus ,",Goldmann applanation tonometer,and Perkins tonometer .,"['Measurements', 'were', 'compared', 'against', 'those', 'obtained', 'with', 'the', 'Reichert', 'Xpert', 'Plus', ',', 'Goldmann', 'applanation', 'tonometer', 'and', 'Perkins', 'tonometer', '.']","(12, 15)","(80, 110)",-1,hl_i,12477021,Abstract,1,test,gold,4095.0
1128,"Measurements were compared against those obtained with the Reichert Xpert Plus , Goldmann applanation tonometer and",Perkins tonometer .,,"['Measurements', 'were', 'compared', 'against', 'those', 'obtained', 'with', 'the', 'Reichert', 'Xpert', 'Plus', ',', 'Goldmann', 'applanation', 'tonometer', 'and', 'Perkins', 'tonometer', '.']","(16, 19)","(115, 134)",-1,hl_i,12477021,Abstract,1,test,gold,1110.0
1129,,Thirty-five university students were assessed,"with the four tonometers in a randomised order , with non-contact tonometry performed first .","['Thirty-five', 'university', 'students', 'were', 'assessed', 'with', 'the', 'four', 'tonometers', 'in', 'a', 'randomised', 'order', ',', 'with', 'non-contact', 'tonometry', 'performed', 'first', '.']","(0, 5)","(0, 45)",-1,ss_p,12477021,Abstract,2,test,gold,2181.0
1130,,Thirty-five university students were assessed,"with the four tonometers in a randomised order , with non-contact tonometry performed first .","['Thirty-five', 'university', 'students', 'were', 'assessed', 'with', 'the', 'four', 'tonometers', 'in', 'a', 'randomised', 'order', ',', 'with', 'non-contact', 'tonometry', 'performed', 'first', '.']","(0, 5)","(0, 45)",-1,hl_p,12477021,Abstract,2,test,gold,2182.0
1131,Each of the four measurement devices had its own trained clinical observer .,,,"['Each', 'of', 'the', 'four', 'measurement', 'devices', 'had', 'its', 'own', 'trained', 'clinical', 'observer', '.']",,,,,12477021,Abstract,3,test,gold,
1132,Plots of differences of,IOP,as a function of the mean for each pair of instruments were obtained .,"['Plots', 'of', 'differences', 'of', 'IOP', 'as', 'a', 'function', 'of', 'the', 'mean', 'for', 'each', 'pair', 'of', 'instruments', 'were', 'obtained', '.']","(4, 5)","(23, 26)",-1,ss_o,12477021,Abstract,4,test,gold,1695.0
1133,No statistically significant differences were found when comparing the,AT550 NCT,"with contact applanation tonometry ( AT ) ( p > 0.05 ) , displaying the closest level of agreement ( as represented by the lowest mean difference and the narrowest confidence interval ) with the Goldmann tonometer ( limits of agreement , 0.12+/-2.17 ) .","['No', 'statistically', 'significant', 'differences', 'were', 'found', 'when', 'comparing', 'the', 'AT550', 'NCT', 'with', 'contact', 'applanation', 'tonometry', '(', 'AT', ')', '(', 'p', '>', '0.05', ')', ',', 'displaying', 'the', 'closest', 'level', 'of', 'agreement', '(', 'as', 'represented', 'by', 'the', 'lowest', 'mean', 'difference', 'and', 'the', 'narrowest', 'confidence', 'interval', ')', 'with', 'the', 'Goldmann', 'tonometer', '(', 'limits', 'of', 'agreement', ',', '0.12+/-2.17', ')', '.']","(9, 11)","(70, 79)",-1,ss_i,12477021,Abstract,5,test,gold,677.0
1134,"No statistically significant differences were found when comparing the AT550 NCT with contact applanation tonometry ( AT ) ( p > 0.05 ) , displaying the closest level of agreement ( as represented by the lowest mean difference and the narrowest confidence interval ) with the",Goldmann tonometer,"( limits of agreement , 0.12+/-2.17 ) .","['No', 'statistically', 'significant', 'differences', 'were', 'found', 'when', 'comparing', 'the', 'AT550', 'NCT', 'with', 'contact', 'applanation', 'tonometry', '(', 'AT', ')', '(', 'p', '>', '0.05', ')', ',', 'displaying', 'the', 'closest', 'level', 'of', 'agreement', '(', 'as', 'represented', 'by', 'the', 'lowest', 'mean', 'difference', 'and', 'the', 'narrowest', 'confidence', 'interval', ')', 'with', 'the', 'Goldmann', 'tonometer', '(', 'limits', 'of', 'agreement', ',', '0.12+/-2.17', ')', '.']","(46, 48)","(275, 293)",-1,ss_i,12477021,Abstract,5,test,gold,4096.0
1135,No statistically significant differences were found when comparing the,AT550 NCT,"with contact applanation tonometry ( AT ) ( p > 0.05 ) , displaying the closest level of agreement ( as represented by the lowest mean difference and the narrowest confidence interval ) with the Goldmann tonometer ( limits of agreement , 0.12+/-2.17 ) .","['No', 'statistically', 'significant', 'differences', 'were', 'found', 'when', 'comparing', 'the', 'AT550', 'NCT', 'with', 'contact', 'applanation', 'tonometry', '(', 'AT', ')', '(', 'p', '>', '0.05', ')', ',', 'displaying', 'the', 'closest', 'level', 'of', 'agreement', '(', 'as', 'represented', 'by', 'the', 'lowest', 'mean', 'difference', 'and', 'the', 'narrowest', 'confidence', 'interval', ')', 'with', 'the', 'Goldmann', 'tonometer', '(', 'limits', 'of', 'agreement', ',', '0.12+/-2.17', ')', '.']","(9, 11)","(70, 79)",-1,hl_i,12477021,Abstract,5,test,gold,678.0
1136,"No statistically significant differences were found when comparing the AT550 NCT with contact applanation tonometry ( AT ) ( p > 0.05 ) , displaying the closest level of agreement ( as represented by the lowest mean difference and the narrowest confidence interval ) with the",Goldmann tonometer,"( limits of agreement , 0.12+/-2.17 ) .","['No', 'statistically', 'significant', 'differences', 'were', 'found', 'when', 'comparing', 'the', 'AT550', 'NCT', 'with', 'contact', 'applanation', 'tonometry', '(', 'AT', ')', '(', 'p', '>', '0.05', ')', ',', 'displaying', 'the', 'closest', 'level', 'of', 'agreement', '(', 'as', 'represented', 'by', 'the', 'lowest', 'mean', 'difference', 'and', 'the', 'narrowest', 'confidence', 'interval', ')', 'with', 'the', 'Goldmann', 'tonometer', '(', 'limits', 'of', 'agreement', ',', '0.12+/-2.17', ')', '.']","(46, 48)","(275, 293)",-1,hl_i,12477021,Abstract,5,test,gold,4094.0
1137,"In conclusion , readings of IOP with the",AT550 NCT,are clinically comparable with those obtained with Goldmann tonometry in a population with IOP within the normal range .,"['In', 'conclusion', ',', 'readings', 'of', 'IOP', 'with', 'the', 'AT550', 'NCT', 'are', 'clinically', 'comparable', 'with', 'those', 'obtained', 'with', 'Goldmann', 'tonometry', 'in', 'a', 'population', 'with', 'IOP', 'within', 'the', 'normal', 'range', '.']","(8, 10)","(40, 49)",-1,ss_i,12477021,Abstract,6,test,gold,676.0
1138,"In conclusion , readings of IOP with the AT550 NCT are clinically comparable with those obtained with",Goldmann tonometry,in a population with IOP within the normal range .,"['In', 'conclusion', ',', 'readings', 'of', 'IOP', 'with', 'the', 'AT550', 'NCT', 'are', 'clinically', 'comparable', 'with', 'those', 'obtained', 'with', 'Goldmann', 'tonometry', 'in', 'a', 'population', 'with', 'IOP', 'within', 'the', 'normal', 'range', '.']","(17, 19)","(101, 119)",-1,ss_i,12477021,Abstract,6,test,gold,4092.0
1139,"In conclusion , readings of",IOP,with the AT550 NCT are clinically comparable with those obtained with Goldmann tonometry in a population with IOP within the normal range .,"['In', 'conclusion', ',', 'readings', 'of', 'IOP', 'with', 'the', 'AT550', 'NCT', 'are', 'clinically', 'comparable', 'with', 'those', 'obtained', 'with', 'Goldmann', 'tonometry', 'in', 'a', 'population', 'with', 'IOP', 'within', 'the', 'normal', 'range', '.']","(5, 6)","(27, 30)",-1,ss_o,12477021,Abstract,6,test,gold,1694.0
1140,"In conclusion , readings of IOP with the AT550 NCT are clinically comparable with those obtained with Goldmann tonometry in a population with",IOP,within the normal range .,"['In', 'conclusion', ',', 'readings', 'of', 'IOP', 'with', 'the', 'AT550', 'NCT', 'are', 'clinically', 'comparable', 'with', 'those', 'obtained', 'with', 'Goldmann', 'tonometry', 'in', 'a', 'population', 'with', 'IOP', 'within', 'the', 'normal', 'range', '.']","(23, 24)","(141, 144)",-1,ss_o,12477021,Abstract,6,test,gold,1693.0
1141,"In conclusion , readings of IOP with the",AT550 NCT,are clinically comparable with those obtained with Goldmann tonometry in a population with IOP within the normal range .,"['In', 'conclusion', ',', 'readings', 'of', 'IOP', 'with', 'the', 'AT550', 'NCT', 'are', 'clinically', 'comparable', 'with', 'those', 'obtained', 'with', 'Goldmann', 'tonometry', 'in', 'a', 'population', 'with', 'IOP', 'within', 'the', 'normal', 'range', '.']","(8, 10)","(40, 49)",-1,hl_i,12477021,Abstract,6,test,gold,675.0
1142,"In conclusion , readings of IOP with the AT550 NCT are clinically comparable with those obtained with",Goldmann tonometry,in a population with IOP within the normal range .,"['In', 'conclusion', ',', 'readings', 'of', 'IOP', 'with', 'the', 'AT550', 'NCT', 'are', 'clinically', 'comparable', 'with', 'those', 'obtained', 'with', 'Goldmann', 'tonometry', 'in', 'a', 'population', 'with', 'IOP', 'within', 'the', 'normal', 'range', '.']","(17, 19)","(101, 119)",-1,hl_i,12477021,Abstract,6,test,gold,4093.0
1143,"In conclusion , readings of",IOP,with the AT550 NCT are clinically comparable with those obtained with Goldmann tonometry in a population with IOP within the normal range .,"['In', 'conclusion', ',', 'readings', 'of', 'IOP', 'with', 'the', 'AT550', 'NCT', 'are', 'clinically', 'comparable', 'with', 'those', 'obtained', 'with', 'Goldmann', 'tonometry', 'in', 'a', 'population', 'with', 'IOP', 'within', 'the', 'normal', 'range', '.']","(5, 6)","(27, 30)",-1,hl_o,12477021,Abstract,6,test,gold,1692.0
1144,Is a 2-week duration sufficient for stenting in,endopyelotomy,?,"['Is', 'a', '2-week', 'duration', 'sufficient', 'for', 'stenting', 'in', 'endopyelotomy', '?']","(8, 9)","(47, 60)",-1,ss_p,12576806,Title,0,test,gold,
1145,Is a 2-week duration sufficient for,stenting,in endopyelotomy ?,"['Is', 'a', '2-week', 'duration', 'sufficient', 'for', 'stenting', 'in', 'endopyelotomy', '?']","(6, 7)","(35, 43)",-1,ss_i,12576806,Title,0,test,gold,4060.0
1146,Is a 2-week duration sufficient for stenting in,endopyelotomy,?,"['Is', 'a', '2-week', 'duration', 'sufficient', 'for', 'stenting', 'in', 'endopyelotomy', '?']","(8, 9)","(47, 60)",-1,ss_i,12576806,Title,0,test,gold,
1147,Is a 2-week,duration,sufficient for stenting in endopyelotomy ?,"['Is', 'a', '2-week', 'duration', 'sufficient', 'for', 'stenting', 'in', 'endopyelotomy', '?']","(3, 4)","(11, 19)",-1,ss_o,12576806,Title,0,test,gold,1329.0
1148,Is a 2-week duration sufficient for,stenting,in endopyelotomy ?,"['Is', 'a', '2-week', 'duration', 'sufficient', 'for', 'stenting', 'in', 'endopyelotomy', '?']","(6, 7)","(35, 43)",-1,hl_i,12576806,Title,0,test,gold,4061.0
1149,PURPOSE,Internal stenting,is an integral part of endopyelotomy .,"['PURPOSE', 'Internal', 'stenting', 'is', 'an', 'integral', 'part', 'of', 'endopyelotomy', '.']","(1, 3)","(7, 24)",-1,ss_i,12576806,Abstract,0,test,gold,4062.0
1150,PURPOSE,Internal stenting,is an integral part of endopyelotomy .,"['PURPOSE', 'Internal', 'stenting', 'is', 'an', 'integral', 'part', 'of', 'endopyelotomy', '.']","(1, 3)","(7, 24)",-1,hl_i,12576806,Abstract,0,test,gold,4063.0
1151,Studies in animals show good healing after 1 to 2 weeks of ureterotomy .,,,"['Studies', 'in', 'animals', 'show', 'good', 'healing', 'after', '1', 'to', '2', 'weeks', 'of', 'ureterotomy', '.']",,,,,12576806,Abstract,1,test,gold,
1152,Inherent,stent,related problems warrant a minimum possible duration of stenting without compromising the results of endopyelotomy .,"['Inherent', 'stent', 'related', 'problems', 'warrant', 'a', 'minimum', 'possible', 'duration', 'of', 'stenting', 'without', 'compromising', 'the', 'results', 'of', 'endopyelotomy', '.']","(1, 2)","(8, 13)",-1,ss_i,12576806,Abstract,2,test,gold,4070.0
1153,We performed a prospective randomized trial to evaluate the optimum duration of,stenting,after endopyelotomy .,"['We', 'performed', 'a', 'prospective', 'randomized', 'trial', 'to', 'evaluate', 'the', 'optimum', 'duration', 'of', 'stenting', 'after', 'endopyelotomy', '.']","(12, 13)","(79, 87)",-1,ss_i,12576806,Abstract,3,test,gold,4059.0
1154,We performed a prospective randomized trial to evaluate the,optimum duration of stenting,after endopyelotomy .,"['We', 'performed', 'a', 'prospective', 'randomized', 'trial', 'to', 'evaluate', 'the', 'optimum', 'duration', 'of', 'stenting', 'after', 'endopyelotomy', '.']","(9, 13)","(59, 87)",-1,ss_o,12576806,Abstract,3,test,gold,4056.0
1155,We performed a prospective randomized trial to evaluate the optimum duration of,stenting,after endopyelotomy .,"['We', 'performed', 'a', 'prospective', 'randomized', 'trial', 'to', 'evaluate', 'the', 'optimum', 'duration', 'of', 'stenting', 'after', 'endopyelotomy', '.']","(12, 13)","(79, 87)",-1,hl_i,12576806,Abstract,3,test,gold,4058.0
1156,We performed a prospective randomized trial to evaluate the,optimum duration of stenting,after endopyelotomy .,"['We', 'performed', 'a', 'prospective', 'randomized', 'trial', 'to', 'evaluate', 'the', 'optimum', 'duration', 'of', 'stenting', 'after', 'endopyelotomy', '.']","(9, 13)","(59, 87)",-1,hl_o,12576806,Abstract,3,test,gold,4057.0
1157,MATERIALS AND METHODS,A total of 57 consecutive patients with primary ureteropelvic junction obstruction,were randomized to undergo 7/14Fr internal endopyelotomy stent placement for 2 ( group 1 ) and 4 ( group 2 ) weeks .,"['MATERIALS', 'AND', 'METHODS', 'A', 'total', 'of', '57', 'consecutive', 'patients', 'with', 'primary', 'ureteropelvic', 'junction', 'obstruction', 'were', 'randomized', 'to', 'undergo', '7/14Fr', 'internal', 'endopyelotomy', 'stent', 'placement', 'for', '2', '(', 'group', '1', ')', 'and', '4', '(', 'group', '2', ')', 'weeks', '.']","(3, 14)","(21, 103)",-1,ss_p,12576806,Abstract,4,test,gold,3721.0
1158,MATERIALS AND METHODS A total of 57 consecutive patients with primary ureteropelvic junction obstruction were randomized to undergo,7/14Fr internal endopyelotomy stent placement,for 2 ( group 1 ) and 4 ( group 2 ) weeks .,"['MATERIALS', 'AND', 'METHODS', 'A', 'total', 'of', '57', 'consecutive', 'patients', 'with', 'primary', 'ureteropelvic', 'junction', 'obstruction', 'were', 'randomized', 'to', 'undergo', '7/14Fr', 'internal', 'endopyelotomy', 'stent', 'placement', 'for', '2', '(', 'group', '1', ')', 'and', '4', '(', 'group', '2', ')', 'weeks', '.']","(18, 23)","(131, 176)",-1,ss_i,12576806,Abstract,4,test,gold,4068.0
1159,MATERIALS AND METHODS A total of,57,consecutive patients with primary ureteropelvic junction obstruction were randomized to undergo 7/14Fr internal endopyelotomy stent placement for 2 ( group 1 ) and 4 ( group 2 ) weeks .,"['MATERIALS', 'AND', 'METHODS', 'A', 'total', 'of', '57', 'consecutive', 'patients', 'with', 'primary', 'ureteropelvic', 'junction', 'obstruction', 'were', 'randomized', 'to', 'undergo', '7/14Fr', 'internal', 'endopyelotomy', 'stent', 'placement', 'for', '2', '(', 'group', '1', ')', 'and', '4', '(', 'group', '2', ')', 'weeks', '.']","(6, 7)","(32, 34)",-1,hl_p,12576806,Abstract,4,test,gold,
1160,MATERIALS AND METHODS A total of 57 consecutive,patients with primary ureteropelvic junction obstruction,were randomized to undergo 7/14Fr internal endopyelotomy stent placement for 2 ( group 1 ) and 4 ( group 2 ) weeks .,"['MATERIALS', 'AND', 'METHODS', 'A', 'total', 'of', '57', 'consecutive', 'patients', 'with', 'primary', 'ureteropelvic', 'junction', 'obstruction', 'were', 'randomized', 'to', 'undergo', '7/14Fr', 'internal', 'endopyelotomy', 'stent', 'placement', 'for', '2', '(', 'group', '1', ')', 'and', '4', '(', 'group', '2', ')', 'weeks', '.']","(8, 14)","(47, 103)",-1,hl_p,12576806,Abstract,4,test,gold,3722.0
1161,MATERIALS AND METHODS A total of 57 consecutive patients with primary ureteropelvic junction obstruction were randomized to undergo,7/14Fr internal endopyelotomy stent placement,for 2 ( group 1 ) and 4 ( group 2 ) weeks .,"['MATERIALS', 'AND', 'METHODS', 'A', 'total', 'of', '57', 'consecutive', 'patients', 'with', 'primary', 'ureteropelvic', 'junction', 'obstruction', 'were', 'randomized', 'to', 'undergo', '7/14Fr', 'internal', 'endopyelotomy', 'stent', 'placement', 'for', '2', '(', 'group', '1', ')', 'and', '4', '(', 'group', '2', ')', 'weeks', '.']","(18, 23)","(131, 176)",-1,hl_i,12576806,Abstract,4,test,gold,4069.0
1162,A,symptom based questionnaire,was administered to all patients at stent removal .,"['A', 'symptom', 'based', 'questionnaire', 'was', 'administered', 'to', 'all', 'patients', 'at', 'stent', 'removal', '.']","(1, 4)","(1, 28)",-1,ss_o,12576806,Abstract,5,test,gold,1844.0
1163,Followup was done with,diuretic scanning,"at 3 , 6 , 9 and 12 months and then yearly , and thereafter with diuretic renography .","['Followup', 'was', 'done', 'with', 'diuretic', 'scanning', 'at', '3', ',', '6', ',', '9', 'and', '12', 'months', 'and', 'then', 'yearly', ',', 'and', 'thereafter', 'with', 'diuretic', 'renography', '.']","(4, 6)","(22, 39)",-1,ss_o,12576806,Abstract,6,test,gold,5074.0
1164,"Followup was done with diuretic scanning at 3 , 6 , 9 and 12 months and then yearly , and thereafter with",diuretic renography .,,"['Followup', 'was', 'done', 'with', 'diuretic', 'scanning', 'at', '3', ',', '6', ',', '9', 'and', '12', 'months', 'and', 'then', 'yearly', ',', 'and', 'thereafter', 'with', 'diuretic', 'renography', '.']","(22, 25)","(105, 126)",-1,ss_o,12576806,Abstract,6,test,gold,5075.0
1165,RESULTS In each group 26 patients were available for evaluation .,,,"['RESULTS', 'In', 'each', 'group', '26', 'patients', 'were', 'available', 'for', 'evaluation', '.']",,,,,12576806,Abstract,7,test,gold,
1166,"The 2 groups were comparable in terms of age , sex ,",symptoms and ipsilateral glomerular filtration rate .,,"['The', '2', 'groups', 'were', 'comparable', 'in', 'terms', 'of', 'age', ',', 'sex', ',', 'symptoms', 'and', 'ipsilateral', 'glomerular', 'filtration', 'rate', '.']","(12, 19)","(52, 105)",-1,ss_o,12576806,Abstract,8,test,gold,6811.0
1167,"The 2 groups were comparable in terms of age , sex ,",symptoms,and ipsilateral glomerular filtration rate .,"['The', '2', 'groups', 'were', 'comparable', 'in', 'terms', 'of', 'age', ',', 'sex', ',', 'symptoms', 'and', 'ipsilateral', 'glomerular', 'filtration', 'rate', '.']","(12, 13)","(52, 60)",-1,hl_o,12576806,Abstract,8,test,gold,3281.0
1168,"The 2 groups were comparable in terms of age , sex , symptoms and",ipsilateral glomerular filtration rate .,,"['The', '2', 'groups', 'were', 'comparable', 'in', 'terms', 'of', 'age', ',', 'sex', ',', 'symptoms', 'and', 'ipsilateral', 'glomerular', 'filtration', 'rate', '.']","(14, 19)","(65, 105)",-1,hl_o,12576806,Abstract,8,test,gold,6812.0
1169,"Mean followup was 22.3 ( range 12 to 36 ) and 21.3 months ( range 12 to 35 ) in groups 1 and 2 , respectively .",,,"['Mean', 'followup', 'was', '22.3', '(', 'range', '12', 'to', '36', ')', 'and', '21.3', 'months', '(', 'range', '12', 'to', '35', ')', 'in', 'groups', '1', 'and', '2', ',', 'respectively', '.']",,,,,12576806,Abstract,9,test,gold,
1170,At the end of 1 year 24 group 1 ( 92.3 % ) and 23 group 2 ( 90.3 % ) patients had an improved,drainage pattern .,,"['At', 'the', 'end', 'of', '1', 'year', '24', 'group', '1', '(', '92.3', '%', ')', 'and', '23', 'group', '2', '(', '90.3', '%', ')', 'patients', 'had', 'an', 'improved', 'drainage', 'pattern', '.']","(25, 28)","(93, 111)",-1,ss_o,12576806,Abstract,10,test,gold,2710.0
1171,At the end of 1 year 24 group 1 ( 92.3 % ) and 23 group 2 ( 90.3 % ) patients had an improved,drainage pattern .,,"['At', 'the', 'end', 'of', '1', 'year', '24', 'group', '1', '(', '92.3', '%', ')', 'and', '23', 'group', '2', '(', '90.3', '%', ')', 'patients', 'had', 'an', 'improved', 'drainage', 'pattern', '.']","(25, 28)","(93, 111)",-1,hl_o,12576806,Abstract,10,test,gold,2711.0
1172,This difference was not significant .,,,"['This', 'difference', 'was', 'not', 'significant', '.']",,,,,12576806,Abstract,11,test,gold,
1173,,Stent,"related symptoms were present in a good proportion of patients in groups 1 and 2 but there was a significant difference in the incidence of urinary tract infections ( 11.5 % versus 38.1 % , p = 0.04 ) .","['Stent', 'related', 'symptoms', 'were', 'present', 'in', 'a', 'good', 'proportion', 'of', 'patients', 'in', 'groups', '1', 'and', '2', 'but', 'there', 'was', 'a', 'significant', 'difference', 'in', 'the', 'incidence', 'of', 'urinary', 'tract', 'infections', '(', '11.5', '%', 'versus', '38.1', '%', ',', 'p', '=', '0.04', ')', '.']","(0, 1)","(0, 5)",-1,ss_i,12576806,Abstract,12,test,gold,4071.0
1174,,Stent related symptoms,"were present in a good proportion of patients in groups 1 and 2 but there was a significant difference in the incidence of urinary tract infections ( 11.5 % versus 38.1 % , p = 0.04 ) .","['Stent', 'related', 'symptoms', 'were', 'present', 'in', 'a', 'good', 'proportion', 'of', 'patients', 'in', 'groups', '1', 'and', '2', 'but', 'there', 'was', 'a', 'significant', 'difference', 'in', 'the', 'incidence', 'of', 'urinary', 'tract', 'infections', '(', '11.5', '%', 'versus', '38.1', '%', ',', 'p', '=', '0.04', ')', '.']","(0, 3)","(0, 22)",-1,ss_o,12576806,Abstract,12,test,gold,4064.0
1175,Stent related symptoms were present in a good proportion of patients in groups 1 and 2 but there was a significant difference in the incidence of,urinary tract infections,"( 11.5 % versus 38.1 % , p = 0.04 ) .","['Stent', 'related', 'symptoms', 'were', 'present', 'in', 'a', 'good', 'proportion', 'of', 'patients', 'in', 'groups', '1', 'and', '2', 'but', 'there', 'was', 'a', 'significant', 'difference', 'in', 'the', 'incidence', 'of', 'urinary', 'tract', 'infections', '(', '11.5', '%', 'versus', '38.1', '%', ',', 'p', '=', '0.04', ')', '.']","(26, 29)","(145, 169)",-1,ss_o,12576806,Abstract,12,test,gold,3580.0
1176,,Stent related symptoms,"were present in a good proportion of patients in groups 1 and 2 but there was a significant difference in the incidence of urinary tract infections ( 11.5 % versus 38.1 % , p = 0.04 ) .","['Stent', 'related', 'symptoms', 'were', 'present', 'in', 'a', 'good', 'proportion', 'of', 'patients', 'in', 'groups', '1', 'and', '2', 'but', 'there', 'was', 'a', 'significant', 'difference', 'in', 'the', 'incidence', 'of', 'urinary', 'tract', 'infections', '(', '11.5', '%', 'versus', '38.1', '%', ',', 'p', '=', '0.04', ')', '.']","(0, 3)","(0, 22)",-1,hl_o,12576806,Abstract,12,test,gold,4065.0
1177,Stent related symptoms were present in a good proportion of patients in groups 1 and 2 but there was a significant difference in the incidence of,urinary tract infections,"( 11.5 % versus 38.1 % , p = 0.04 ) .","['Stent', 'related', 'symptoms', 'were', 'present', 'in', 'a', 'good', 'proportion', 'of', 'patients', 'in', 'groups', '1', 'and', '2', 'but', 'there', 'was', 'a', 'significant', 'difference', 'in', 'the', 'incidence', 'of', 'urinary', 'tract', 'infections', '(', '11.5', '%', 'versus', '38.1', '%', ',', 'p', '=', '0.04', ')', '.']","(26, 29)","(145, 169)",-1,hl_o,12576806,Abstract,12,test,gold,3581.0
1178,Of the group 2 patients 64 % preferred 2 weeks of stenting .,,,"['Of', 'the', 'group', '2', 'patients', '64', '%', 'preferred', '2', 'weeks', 'of', 'stenting', '.']",,,,,12576806,Abstract,13,test,gold,
1179,CONCLUSIONS Two weeks seems to be a sufficient duration to allow functional restoration across the ureteropelvic junction after,endopyelotomy,and decrease stent related complications .,"['CONCLUSIONS', 'Two', 'weeks', 'seems', 'to', 'be', 'a', 'sufficient', 'duration', 'to', 'allow', 'functional', 'restoration', 'across', 'the', 'ureteropelvic', 'junction', 'after', 'endopyelotomy', 'and', 'decrease', 'stent', 'related', 'complications', '.']","(18, 19)","(127, 140)",-1,ss_p,12576806,Abstract,14,test,gold,
1180,CONCLUSIONS Two weeks seems to be a sufficient,duration,to allow functional restoration across the ureteropelvic junction after endopyelotomy and decrease stent related complications .,"['CONCLUSIONS', 'Two', 'weeks', 'seems', 'to', 'be', 'a', 'sufficient', 'duration', 'to', 'allow', 'functional', 'restoration', 'across', 'the', 'ureteropelvic', 'junction', 'after', 'endopyelotomy', 'and', 'decrease', 'stent', 'related', 'complications', '.']","(8, 9)","(46, 54)",-1,ss_o,12576806,Abstract,14,test,gold,1330.0
1181,CONCLUSIONS Two weeks seems to be a sufficient duration to allow functional restoration across the ureteropelvic junction after endopyelotomy and decrease,stent related complications .,,"['CONCLUSIONS', 'Two', 'weeks', 'seems', 'to', 'be', 'a', 'sufficient', 'duration', 'to', 'allow', 'functional', 'restoration', 'across', 'the', 'ureteropelvic', 'junction', 'after', 'endopyelotomy', 'and', 'decrease', 'stent', 'related', 'complications', '.']","(21, 25)","(154, 183)",-1,ss_o,12576806,Abstract,14,test,gold,4066.0
1182,CONCLUSIONS Two weeks seems to be a sufficient,duration,to allow functional restoration across the ureteropelvic junction after endopyelotomy and decrease stent related complications .,"['CONCLUSIONS', 'Two', 'weeks', 'seems', 'to', 'be', 'a', 'sufficient', 'duration', 'to', 'allow', 'functional', 'restoration', 'across', 'the', 'ureteropelvic', 'junction', 'after', 'endopyelotomy', 'and', 'decrease', 'stent', 'related', 'complications', '.']","(8, 9)","(46, 54)",-1,hl_o,12576806,Abstract,14,test,gold,1328.0
1183,CONCLUSIONS Two weeks seems to be a sufficient duration to allow functional restoration across the ureteropelvic junction after endopyelotomy and decrease,stent related complications .,,"['CONCLUSIONS', 'Two', 'weeks', 'seems', 'to', 'be', 'a', 'sufficient', 'duration', 'to', 'allow', 'functional', 'restoration', 'across', 'the', 'ureteropelvic', 'junction', 'after', 'endopyelotomy', 'and', 'decrease', 'stent', 'related', 'complications', '.']","(21, 25)","(154, 183)",-1,hl_o,12576806,Abstract,14,test,gold,4067.0
1184,Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for,advanced nasopharyngeal carcinoma :,positive effect on overall and progression-free survival .,"['Phase', 'III', 'study', 'of', 'concurrent', 'chemoradiotherapy', 'versus', 'radiotherapy', 'alone', 'for', 'advanced', 'nasopharyngeal', 'carcinoma', ':', 'positive', 'effect', 'on', 'overall', 'and', 'progression-free', 'survival', '.']","(10, 14)","(77, 112)",-1,ss_p,12586799,Title,0,test,gold,6858.0
1185,Phase III study of,concurrent chemoradiotherapy,versus radiotherapy alone for advanced nasopharyngeal carcinoma : positive effect on overall and progression-free survival .,"['Phase', 'III', 'study', 'of', 'concurrent', 'chemoradiotherapy', 'versus', 'radiotherapy', 'alone', 'for', 'advanced', 'nasopharyngeal', 'carcinoma', ':', 'positive', 'effect', 'on', 'overall', 'and', 'progression-free', 'survival', '.']","(4, 6)","(18, 46)",-1,ss_i,12586799,Title,0,test,gold,5791.0
1186,Phase III study of concurrent chemoradiotherapy versus,radiotherapy,alone for advanced nasopharyngeal carcinoma : positive effect on overall and progression-free survival .,"['Phase', 'III', 'study', 'of', 'concurrent', 'chemoradiotherapy', 'versus', 'radiotherapy', 'alone', 'for', 'advanced', 'nasopharyngeal', 'carcinoma', ':', 'positive', 'effect', 'on', 'overall', 'and', 'progression-free', 'survival', '.']","(7, 8)","(54, 66)",-1,ss_i,12586799,Title,0,test,gold,4256.0
1187,Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma : positive,effect,on overall and progression-free survival .,"['Phase', 'III', 'study', 'of', 'concurrent', 'chemoradiotherapy', 'versus', 'radiotherapy', 'alone', 'for', 'advanced', 'nasopharyngeal', 'carcinoma', ':', 'positive', 'effect', 'on', 'overall', 'and', 'progression-free', 'survival', '.']","(15, 16)","(122, 128)",-1,ss_o,12586799,Title,0,test,gold,2342.0
1188,Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma : positive effect on,overall and progression-free survival .,,"['Phase', 'III', 'study', 'of', 'concurrent', 'chemoradiotherapy', 'versus', 'radiotherapy', 'alone', 'for', 'advanced', 'nasopharyngeal', 'carcinoma', ':', 'positive', 'effect', 'on', 'overall', 'and', 'progression-free', 'survival', '.']","(17, 22)","(132, 171)",-1,ss_o,12586799,Title,0,test,gold,1975.0
1189,Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for,advanced nasopharyngeal carcinoma :,positive effect on overall and progression-free survival .,"['Phase', 'III', 'study', 'of', 'concurrent', 'chemoradiotherapy', 'versus', 'radiotherapy', 'alone', 'for', 'advanced', 'nasopharyngeal', 'carcinoma', ':', 'positive', 'effect', 'on', 'overall', 'and', 'progression-free', 'survival', '.']","(10, 14)","(77, 112)",-1,hl_p,12586799,Title,0,test,gold,6859.0
1190,Phase III study of,concurrent chemoradiotherapy,versus radiotherapy alone for advanced nasopharyngeal carcinoma : positive effect on overall and progression-free survival .,"['Phase', 'III', 'study', 'of', 'concurrent', 'chemoradiotherapy', 'versus', 'radiotherapy', 'alone', 'for', 'advanced', 'nasopharyngeal', 'carcinoma', ':', 'positive', 'effect', 'on', 'overall', 'and', 'progression-free', 'survival', '.']","(4, 6)","(18, 46)",-1,hl_i,12586799,Title,0,test,gold,5792.0
1191,Phase III study of concurrent chemoradiotherapy versus,radiotherapy,alone for advanced nasopharyngeal carcinoma : positive effect on overall and progression-free survival .,"['Phase', 'III', 'study', 'of', 'concurrent', 'chemoradiotherapy', 'versus', 'radiotherapy', 'alone', 'for', 'advanced', 'nasopharyngeal', 'carcinoma', ':', 'positive', 'effect', 'on', 'overall', 'and', 'progression-free', 'survival', '.']","(7, 8)","(54, 66)",-1,hl_i,12586799,Title,0,test,gold,4257.0
1192,Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma : positive effect on,overall and progression-free survival .,,"['Phase', 'III', 'study', 'of', 'concurrent', 'chemoradiotherapy', 'versus', 'radiotherapy', 'alone', 'for', 'advanced', 'nasopharyngeal', 'carcinoma', ':', 'positive', 'effect', 'on', 'overall', 'and', 'progression-free', 'survival', '.']","(17, 22)","(132, 171)",-1,hl_o,12586799,Title,0,test,gold,1974.0
1193,PURPOSE Nasopharyngeal carcinoma ( NPC ) is a radiosensitive and chemosensitive tumor .,,,"['PURPOSE', 'Nasopharyngeal', 'carcinoma', '(', 'NPC', ')', 'is', 'a', 'radiosensitive', 'and', 'chemosensitive', 'tumor', '.']",,,,,12586799,Abstract,0,test,gold,
1194,This randomized phase III trial compared concurrent chemoradiotherapy ( CCRT ) versus radiotherapy ( RT ) alone in,patients with advanced NPC .,,"['This', 'randomized', 'phase', 'III', 'trial', 'compared', 'concurrent', 'chemoradiotherapy', '(', 'CCRT', ')', 'versus', 'radiotherapy', '(', 'RT', ')', 'alone', 'in', 'patients', 'with', 'advanced', 'NPC', '.']","(18, 23)","(114, 142)",-1,ss_p,12586799,Abstract,1,test,gold,3863.0
1195,This randomized phase III trial compared,concurrent chemoradiotherapy ( CCRT ),versus radiotherapy ( RT ) alone in patients with advanced NPC .,"['This', 'randomized', 'phase', 'III', 'trial', 'compared', 'concurrent', 'chemoradiotherapy', '(', 'CCRT', ')', 'versus', 'radiotherapy', '(', 'RT', ')', 'alone', 'in', 'patients', 'with', 'advanced', 'NPC', '.']","(6, 11)","(40, 77)",-1,ss_i,12586799,Abstract,1,test,gold,5793.0
1196,This randomized phase III trial compared concurrent chemoradiotherapy ( CCRT ) versus,radiotherapy ( RT ),alone in patients with advanced NPC .,"['This', 'randomized', 'phase', 'III', 'trial', 'compared', 'concurrent', 'chemoradiotherapy', '(', 'CCRT', ')', 'versus', 'radiotherapy', '(', 'RT', ')', 'alone', 'in', 'patients', 'with', 'advanced', 'NPC', '.']","(12, 16)","(85, 104)",-1,ss_i,12586799,Abstract,1,test,gold,4258.0
1197,This randomized phase III trial compared concurrent chemoradiotherapy ( CCRT ) versus radiotherapy ( RT ) alone in,patients with advanced NPC .,,"['This', 'randomized', 'phase', 'III', 'trial', 'compared', 'concurrent', 'chemoradiotherapy', '(', 'CCRT', ')', 'versus', 'radiotherapy', '(', 'RT', ')', 'alone', 'in', 'patients', 'with', 'advanced', 'NPC', '.']","(18, 23)","(114, 142)",-1,hl_p,12586799,Abstract,1,test,gold,3864.0
1198,This randomized phase III trial compared,concurrent chemoradiotherapy ( CCRT ),versus radiotherapy ( RT ) alone in patients with advanced NPC .,"['This', 'randomized', 'phase', 'III', 'trial', 'compared', 'concurrent', 'chemoradiotherapy', '(', 'CCRT', ')', 'versus', 'radiotherapy', '(', 'RT', ')', 'alone', 'in', 'patients', 'with', 'advanced', 'NPC', '.']","(6, 11)","(40, 77)",-1,hl_i,12586799,Abstract,1,test,gold,5794.0
1199,This randomized phase III trial compared concurrent chemoradiotherapy ( CCRT ) versus,radiotherapy ( RT ),alone in patients with advanced NPC .,"['This', 'randomized', 'phase', 'III', 'trial', 'compared', 'concurrent', 'chemoradiotherapy', '(', 'CCRT', ')', 'versus', 'radiotherapy', '(', 'RT', ')', 'alone', 'in', 'patients', 'with', 'advanced', 'NPC', '.']","(12, 16)","(85, 104)",-1,hl_i,12586799,Abstract,1,test,gold,4259.0
1200,PATIENTS AND METHODS,"From December 1993 to April 1999 , 284 patients with 1992 American Joint Committee on Cancer stage III to IV ( M0 ) NPC",were randomly allocated into two arms .,"['PATIENTS', 'AND', 'METHODS', 'From', 'December', '1993', 'to', 'April', '1999', ',', '284', 'patients', 'with', '1992', 'American', 'Joint', 'Committee', 'on', 'Cancer', 'stage', 'III', 'to', 'IV', '(', 'M0', ')', 'NPC', 'were', 'randomly', 'allocated', 'into', 'two', 'arms', '.']","(3, 27)","(20, 139)",-1,ss_p,12586799,Abstract,2,test,gold,5863.0
1201,PATIENTS AND METHODS,From December 1993 to April 1999,", 284 patients with 1992 American Joint Committee on Cancer stage III to IV ( M0 ) NPC were randomly allocated into two arms .","['PATIENTS', 'AND', 'METHODS', 'From', 'December', '1993', 'to', 'April', '1999', ',', '284', 'patients', 'with', '1992', 'American', 'Joint', 'Committee', 'on', 'Cancer', 'stage', 'III', 'to', 'IV', '(', 'M0', ')', 'NPC', 'were', 'randomly', 'allocated', 'into', 'two', 'arms', '.']","(3, 9)","(20, 52)",-1,hl_p,12586799,Abstract,2,test,gold,1492.0
1202,"PATIENTS AND METHODS From December 1993 to April 1999 ,",284 patients with 1992 American Joint Committee on Cancer stage III to IV ( M0 ) NPC,were randomly allocated into two arms .,"['PATIENTS', 'AND', 'METHODS', 'From', 'December', '1993', 'to', 'April', '1999', ',', '284', 'patients', 'with', '1992', 'American', 'Joint', 'Committee', 'on', 'Cancer', 'stage', 'III', 'to', 'IV', '(', 'M0', ')', 'NPC', 'were', 'randomly', 'allocated', 'into', 'two', 'arms', '.']","(10, 27)","(55, 139)",-1,hl_p,12586799,Abstract,2,test,gold,5864.0
1203,Similar dosage and fractionation of,RT,was administered in both arms .,"['Similar', 'dosage', 'and', 'fractionation', 'of', 'RT', 'was', 'administered', 'in', 'both', 'arms', '.']","(5, 6)","(35, 37)",-1,ss_i,12586799,Abstract,3,test,gold,689.0
1204,The investigational arm received two cycles of concurrent,chemotherapy,with cisplatin 20 mg/m ( 2 ) /d plus fluorouracil 400 mg/m ( 2 ) /d by 96-hour continuous infusion during the weeks 1 and 5 of RT .,"['The', 'investigational', 'arm', 'received', 'two', 'cycles', 'of', 'concurrent', 'chemotherapy', 'with', 'cisplatin', '20', 'mg/m', '(', '2', ')', '/d', 'plus', 'fluorouracil', '400', 'mg/m', '(', '2', ')', '/d', 'by', '96-hour', 'continuous', 'infusion', 'during', 'the', 'weeks', '1', 'and', '5', 'of', 'RT', '.']","(8, 9)","(57, 69)",-1,ss_i,12586799,Abstract,4,test,gold,4252.0
1205,The investigational arm received two cycles of concurrent chemotherapy with,cisplatin,20 mg/m ( 2 ) /d plus fluorouracil 400 mg/m ( 2 ) /d by 96-hour continuous infusion during the weeks 1 and 5 of RT .,"['The', 'investigational', 'arm', 'received', 'two', 'cycles', 'of', 'concurrent', 'chemotherapy', 'with', 'cisplatin', '20', 'mg/m', '(', '2', ')', '/d', 'plus', 'fluorouracil', '400', 'mg/m', '(', '2', ')', '/d', 'by', '96-hour', 'continuous', 'infusion', 'during', 'the', 'weeks', '1', 'and', '5', 'of', 'RT', '.']","(10, 11)","(75, 84)",-1,ss_i,12586799,Abstract,4,test,gold,5748.0
1206,The investigational arm received two cycles of concurrent chemotherapy with cisplatin 20 mg/m ( 2 ) /d plus,fluorouracil,400 mg/m ( 2 ) /d by 96-hour continuous infusion during the weeks 1 and 5 of RT .,"['The', 'investigational', 'arm', 'received', 'two', 'cycles', 'of', 'concurrent', 'chemotherapy', 'with', 'cisplatin', '20', 'mg/m', '(', '2', ')', '/d', 'plus', 'fluorouracil', '400', 'mg/m', '(', '2', ')', '/d', 'by', '96-hour', 'continuous', 'infusion', 'during', 'the', 'weeks', '1', 'and', '5', 'of', 'RT', '.']","(18, 19)","(107, 119)",-1,ss_i,12586799,Abstract,4,test,gold,5742.0
1207,The investigational arm received two cycles of concurrent chemotherapy with cisplatin 20 mg/m ( 2 ) /d plus fluorouracil 400 mg/m ( 2 ) /d by 96-hour continuous infusion during the weeks 1 and 5 of,RT .,,"['The', 'investigational', 'arm', 'received', 'two', 'cycles', 'of', 'concurrent', 'chemotherapy', 'with', 'cisplatin', '20', 'mg/m', '(', '2', ')', '/d', 'plus', 'fluorouracil', '400', 'mg/m', '(', '2', ')', '/d', 'by', '96-hour', 'continuous', 'infusion', 'during', 'the', 'weeks', '1', 'and', '5', 'of', 'RT', '.']","(36, 38)","(197, 201)",-1,ss_i,12586799,Abstract,4,test,gold,690.0
1208,The investigational arm received two cycles of concurrent,chemotherapy,with cisplatin 20 mg/m ( 2 ) /d plus fluorouracil 400 mg/m ( 2 ) /d by 96-hour continuous infusion during the weeks 1 and 5 of RT .,"['The', 'investigational', 'arm', 'received', 'two', 'cycles', 'of', 'concurrent', 'chemotherapy', 'with', 'cisplatin', '20', 'mg/m', '(', '2', ')', '/d', 'plus', 'fluorouracil', '400', 'mg/m', '(', '2', ')', '/d', 'by', '96-hour', 'continuous', 'infusion', 'during', 'the', 'weeks', '1', 'and', '5', 'of', 'RT', '.']","(8, 9)","(57, 69)",-1,hl_i,12586799,Abstract,4,test,gold,4253.0
1209,The investigational arm received two cycles of concurrent chemotherapy with,cisplatin,20 mg/m ( 2 ) /d plus fluorouracil 400 mg/m ( 2 ) /d by 96-hour continuous infusion during the weeks 1 and 5 of RT .,"['The', 'investigational', 'arm', 'received', 'two', 'cycles', 'of', 'concurrent', 'chemotherapy', 'with', 'cisplatin', '20', 'mg/m', '(', '2', ')', '/d', 'plus', 'fluorouracil', '400', 'mg/m', '(', '2', ')', '/d', 'by', '96-hour', 'continuous', 'infusion', 'during', 'the', 'weeks', '1', 'and', '5', 'of', 'RT', '.']","(10, 11)","(75, 84)",-1,hl_i,12586799,Abstract,4,test,gold,5749.0
1210,The investigational arm received two cycles of concurrent chemotherapy with cisplatin 20 mg/m ( 2 ) /d plus,fluorouracil,400 mg/m ( 2 ) /d by 96-hour continuous infusion during the weeks 1 and 5 of RT .,"['The', 'investigational', 'arm', 'received', 'two', 'cycles', 'of', 'concurrent', 'chemotherapy', 'with', 'cisplatin', '20', 'mg/m', '(', '2', ')', '/d', 'plus', 'fluorouracil', '400', 'mg/m', '(', '2', ')', '/d', 'by', '96-hour', 'continuous', 'infusion', 'during', 'the', 'weeks', '1', 'and', '5', 'of', 'RT', '.']","(18, 19)","(107, 119)",-1,hl_i,12586799,Abstract,4,test,gold,5743.0
1211,,Survival analysis was estimated by the Kaplan-Meier method and compared by the log-rank test .,,"['Survival', 'analysis', 'was', 'estimated', 'by', 'the', 'Kaplan-Meier', 'method', 'and', 'compared', 'by', 'the', 'log-rank', 'test', '.']","(0, 15)","(0, 94)",-1,ss_o,12586799,Abstract,5,test,gold,6469.0
1212,,Survival analysis,was estimated by the Kaplan-Meier method and compared by the log-rank test .,"['Survival', 'analysis', 'was', 'estimated', 'by', 'the', 'Kaplan-Meier', 'method', 'and', 'compared', 'by', 'the', 'log-rank', 'test', '.']","(0, 2)","(0, 17)",-1,hl_o,12586799,Abstract,5,test,gold,1970.0
1213,RESULTS Baseline patient characteristics were comparable in both arms .,,,"['RESULTS', 'Baseline', 'patient', 'characteristics', 'were', 'comparable', 'in', 'both', 'arms', '.']",,,,,12586799,Abstract,6,test,gold,
1214,"After a median follow-up of 65 months , 26.2 % ( 37 of 141 ) and 46.2 % ( 66 of 143 ) of patients developed tumor relapse in the",CCRT,"and RT-alone groups , respectively .","['After', 'a', 'median', 'follow-up', 'of', '65', 'months', ',', '26.2', '%', '(', '37', 'of', '141', ')', 'and', '46.2', '%', '(', '66', 'of', '143', ')', 'of', 'patients', 'developed', 'tumor', 'relapse', 'in', 'the', 'CCRT', 'and', 'RT-alone', 'groups', ',', 'respectively', '.']","(30, 31)","(128, 132)",-1,ss_i,12586799,Abstract,7,test,gold,623.0
1215,"After a median follow-up of 65 months , 26.2 % ( 37 of 141 ) and 46.2 % ( 66 of 143 ) of patients developed tumor relapse in the CCRT and",RT-alone,"groups , respectively .","['After', 'a', 'median', 'follow-up', 'of', '65', 'months', ',', '26.2', '%', '(', '37', 'of', '141', ')', 'and', '46.2', '%', '(', '66', 'of', '143', ')', 'of', 'patients', 'developed', 'tumor', 'relapse', 'in', 'the', 'CCRT', 'and', 'RT-alone', 'groups', ',', 'respectively', '.']","(32, 33)","(137, 145)",-1,ss_i,12586799,Abstract,7,test,gold,
1216,"After a median follow-up of 65 months , 26.2 % ( 37 of 141 ) and 46.2 % ( 66 of 143 ) of patients developed",tumor relapse,"in the CCRT and RT-alone groups , respectively .","['After', 'a', 'median', 'follow-up', 'of', '65', 'months', ',', '26.2', '%', '(', '37', 'of', '141', ')', 'and', '46.2', '%', '(', '66', 'of', '143', ')', 'of', 'patients', 'developed', 'tumor', 'relapse', 'in', 'the', 'CCRT', 'and', 'RT-alone', 'groups', ',', 'respectively', '.']","(26, 28)","(107, 120)",-1,ss_o,12586799,Abstract,7,test,gold,6860.0
1217,"After a median follow-up of 65 months , 26.2 % ( 37 of 141 ) and 46.2 % ( 66 of 143 ) of patients developed tumor relapse in the",CCRT,"and RT-alone groups , respectively .","['After', 'a', 'median', 'follow-up', 'of', '65', 'months', ',', '26.2', '%', '(', '37', 'of', '141', ')', 'and', '46.2', '%', '(', '66', 'of', '143', ')', 'of', 'patients', 'developed', 'tumor', 'relapse', 'in', 'the', 'CCRT', 'and', 'RT-alone', 'groups', ',', 'respectively', '.']","(30, 31)","(128, 132)",-1,hl_i,12586799,Abstract,7,test,gold,624.0
1218,"After a median follow-up of 65 months , 26.2 % ( 37 of 141 ) and 46.2 % ( 66 of 143 ) of patients developed tumor relapse in the CCRT and",RT-alone,"groups , respectively .","['After', 'a', 'median', 'follow-up', 'of', '65', 'months', ',', '26.2', '%', '(', '37', 'of', '141', ')', 'and', '46.2', '%', '(', '66', 'of', '143', ')', 'of', 'patients', 'developed', 'tumor', 'relapse', 'in', 'the', 'CCRT', 'and', 'RT-alone', 'groups', ',', 'respectively', '.']","(32, 33)","(137, 145)",-1,hl_i,12586799,Abstract,7,test,gold,
1219,"After a median follow-up of 65 months , 26.2 % ( 37 of 141 ) and 46.2 % ( 66 of 143 ) of patients developed",tumor relapse,"in the CCRT and RT-alone groups , respectively .","['After', 'a', 'median', 'follow-up', 'of', '65', 'months', ',', '26.2', '%', '(', '37', 'of', '141', ')', 'and', '46.2', '%', '(', '66', 'of', '143', ')', 'of', 'patients', 'developed', 'tumor', 'relapse', 'in', 'the', 'CCRT', 'and', 'RT-alone', 'groups', ',', 'respectively', '.']","(26, 28)","(107, 120)",-1,hl_o,12586799,Abstract,7,test,gold,6861.0
1220,The 5-year overall survival rates were 72.3 % for the,CCRT,arm and 54.2 % for the RT-only arm ( P =.0022 ) .,"['The', '5-year', 'overall', 'survival', 'rates', 'were', '72.3', '%', 'for', 'the', 'CCRT', 'arm', 'and', '54.2', '%', 'for', 'the', 'RT-only', 'arm', '(', 'P', '=.0022', ')', '.']","(10, 11)","(53, 57)",-1,ss_i,12586799,Abstract,8,test,gold,622.0
1221,The 5-year overall survival rates were 72.3 % for the CCRT arm and 54.2 % for the,RT-only,arm ( P =.0022 ) .,"['The', '5-year', 'overall', 'survival', 'rates', 'were', '72.3', '%', 'for', 'the', 'CCRT', 'arm', 'and', '54.2', '%', 'for', 'the', 'RT-only', 'arm', '(', 'P', '=.0022', ')', '.']","(17, 18)","(81, 88)",-1,ss_i,12586799,Abstract,8,test,gold,
1222,The,5-year overall survival rates,were 72.3 % for the CCRT arm and 54.2 % for the RT-only arm ( P =.0022 ) .,"['The', '5-year', 'overall', 'survival', 'rates', 'were', '72.3', '%', 'for', 'the', 'CCRT', 'arm', 'and', '54.2', '%', 'for', 'the', 'RT-only', 'arm', '(', 'P', '=.0022', ')', '.']","(1, 5)","(3, 32)",-1,ss_o,12586799,Abstract,8,test,gold,1953.0
1223,The 5-year overall survival rates were 72.3 % for the,CCRT,arm and 54.2 % for the RT-only arm ( P =.0022 ) .,"['The', '5-year', 'overall', 'survival', 'rates', 'were', '72.3', '%', 'for', 'the', 'CCRT', 'arm', 'and', '54.2', '%', 'for', 'the', 'RT-only', 'arm', '(', 'P', '=.0022', ')', '.']","(10, 11)","(53, 57)",-1,hl_i,12586799,Abstract,8,test,gold,621.0
1224,The 5-year overall survival rates were 72.3 % for the CCRT arm and 54.2 % for the,RT-only,arm ( P =.0022 ) .,"['The', '5-year', 'overall', 'survival', 'rates', 'were', '72.3', '%', 'for', 'the', 'CCRT', 'arm', 'and', '54.2', '%', 'for', 'the', 'RT-only', 'arm', '(', 'P', '=.0022', ')', '.']","(17, 18)","(81, 88)",-1,hl_i,12586799,Abstract,8,test,gold,
1225,The,5-year overall survival rates,were 72.3 % for the CCRT arm and 54.2 % for the RT-only arm ( P =.0022 ) .,"['The', '5-year', 'overall', 'survival', 'rates', 'were', '72.3', '%', 'for', 'the', 'CCRT', 'arm', 'and', '54.2', '%', 'for', 'the', 'RT-only', 'arm', '(', 'P', '=.0022', ')', '.']","(1, 5)","(3, 32)",-1,hl_o,12586799,Abstract,8,test,gold,1952.0
1226,The 5-year progression-free survival rates were 71.6 % for the,CCRT,group compared with 53.0 % for the RT-only group ( P =.0012 ) .,"['The', '5-year', 'progression-free', 'survival', 'rates', 'were', '71.6', '%', 'for', 'the', 'CCRT', 'group', 'compared', 'with', '53.0', '%', 'for', 'the', 'RT-only', 'group', '(', 'P', '=.0012', ')', '.']","(10, 11)","(62, 66)",-1,ss_i,12586799,Abstract,9,test,gold,620.0
1227,The 5-year progression-free survival rates were 71.6 % for the CCRT group compared with 53.0 % for the,RT-only,group ( P =.0012 ) .,"['The', '5-year', 'progression-free', 'survival', 'rates', 'were', '71.6', '%', 'for', 'the', 'CCRT', 'group', 'compared', 'with', '53.0', '%', 'for', 'the', 'RT-only', 'group', '(', 'P', '=.0012', ')', '.']","(18, 19)","(102, 109)",-1,ss_i,12586799,Abstract,9,test,gold,
1228,The,5-year progression-free survival rates,were 71.6 % for the CCRT group compared with 53.0 % for the RT-only group ( P =.0012 ) .,"['The', '5-year', 'progression-free', 'survival', 'rates', 'were', '71.6', '%', 'for', 'the', 'CCRT', 'group', 'compared', 'with', '53.0', '%', 'for', 'the', 'RT-only', 'group', '(', 'P', '=.0012', ')', '.']","(1, 5)","(3, 41)",-1,ss_o,12586799,Abstract,9,test,gold,1957.0
1229,The 5-year progression-free survival rates were 71.6 % for the,CCRT,group compared with 53.0 % for the RT-only group ( P =.0012 ) .,"['The', '5-year', 'progression-free', 'survival', 'rates', 'were', '71.6', '%', 'for', 'the', 'CCRT', 'group', 'compared', 'with', '53.0', '%', 'for', 'the', 'RT-only', 'group', '(', 'P', '=.0012', ')', '.']","(10, 11)","(62, 66)",-1,hl_i,12586799,Abstract,9,test,gold,619.0
1230,The 5-year progression-free survival rates were 71.6 % for the CCRT group compared with 53.0 % for the,RT-only,group ( P =.0012 ) .,"['The', '5-year', 'progression-free', 'survival', 'rates', 'were', '71.6', '%', 'for', 'the', 'CCRT', 'group', 'compared', 'with', '53.0', '%', 'for', 'the', 'RT-only', 'group', '(', 'P', '=.0012', ')', '.']","(18, 19)","(102, 109)",-1,hl_i,12586799,Abstract,9,test,gold,
1231,The,5-year progression-free survival rates,were 71.6 % for the CCRT group compared with 53.0 % for the RT-only group ( P =.0012 ) .,"['The', '5-year', 'progression-free', 'survival', 'rates', 'were', '71.6', '%', 'for', 'the', 'CCRT', 'group', 'compared', 'with', '53.0', '%', 'for', 'the', 'RT-only', 'group', '(', 'P', '=.0012', ')', '.']","(1, 5)","(3, 41)",-1,hl_o,12586799,Abstract,9,test,gold,1958.0
1232,Although significantly more toxicity was noted in the,CCRT,"arm , including leukopenia and emesis , compliance with the combined treatment was good .","['Although', 'significantly', 'more', 'toxicity', 'was', 'noted', 'in', 'the', 'CCRT', 'arm', ',', 'including', 'leukopenia', 'and', 'emesis', ',', 'compliance', 'with', 'the', 'combined', 'treatment', 'was', 'good', '.']","(8, 9)","(53, 57)",-1,ss_i,12586799,Abstract,10,test,gold,618.0
1233,Although significantly more,toxicity,"was noted in the CCRT arm , including leukopenia and emesis , compliance with the combined treatment was good .","['Although', 'significantly', 'more', 'toxicity', 'was', 'noted', 'in', 'the', 'CCRT', 'arm', ',', 'including', 'leukopenia', 'and', 'emesis', ',', 'compliance', 'with', 'the', 'combined', 'treatment', 'was', 'good', '.']","(3, 4)","(27, 35)",-1,ss_o,12586799,Abstract,10,test,gold,3498.0
1234,"Although significantly more toxicity was noted in the CCRT arm , including",leukopenia and emesis,", compliance with the combined treatment was good .","['Although', 'significantly', 'more', 'toxicity', 'was', 'noted', 'in', 'the', 'CCRT', 'arm', ',', 'including', 'leukopenia', 'and', 'emesis', ',', 'compliance', 'with', 'the', 'combined', 'treatment', 'was', 'good', '.']","(12, 15)","(74, 95)",-1,ss_o,12586799,Abstract,10,test,gold,3500.0
1235,Although significantly more toxicity was noted in the,CCRT,"arm , including leukopenia and emesis , compliance with the combined treatment was good .","['Although', 'significantly', 'more', 'toxicity', 'was', 'noted', 'in', 'the', 'CCRT', 'arm', ',', 'including', 'leukopenia', 'and', 'emesis', ',', 'compliance', 'with', 'the', 'combined', 'treatment', 'was', 'good', '.']","(8, 9)","(53, 57)",-1,hl_i,12586799,Abstract,10,test,gold,617.0
1236,Although significantly more,toxicity,"was noted in the CCRT arm , including leukopenia and emesis , compliance with the combined treatment was good .","['Although', 'significantly', 'more', 'toxicity', 'was', 'noted', 'in', 'the', 'CCRT', 'arm', ',', 'including', 'leukopenia', 'and', 'emesis', ',', 'compliance', 'with', 'the', 'combined', 'treatment', 'was', 'good', '.']","(3, 4)","(27, 35)",-1,hl_o,12586799,Abstract,10,test,gold,3499.0
1237,"Although significantly more toxicity was noted in the CCRT arm , including",leukopenia,"and emesis , compliance with the combined treatment was good .","['Although', 'significantly', 'more', 'toxicity', 'was', 'noted', 'in', 'the', 'CCRT', 'arm', ',', 'including', 'leukopenia', 'and', 'emesis', ',', 'compliance', 'with', 'the', 'combined', 'treatment', 'was', 'good', '.']","(12, 13)","(74, 84)",-1,hl_o,12586799,Abstract,10,test,gold,3506.0
1238,"Although significantly more toxicity was noted in the CCRT arm , including leukopenia and",emesis,", compliance with the combined treatment was good .","['Although', 'significantly', 'more', 'toxicity', 'was', 'noted', 'in', 'the', 'CCRT', 'arm', ',', 'including', 'leukopenia', 'and', 'emesis', ',', 'compliance', 'with', 'the', 'combined', 'treatment', 'was', 'good', '.']","(14, 15)","(89, 95)",-1,hl_o,12586799,Abstract,10,test,gold,60.0
1239,The second cycle of,concurrent chemotherapy,was refused by nine patients and was delayed for > or = 1 week for another nine patients .,"['The', 'second', 'cycle', 'of', 'concurrent', 'chemotherapy', 'was', 'refused', 'by', 'nine', 'patients', 'and', 'was', 'delayed', 'for', '>', 'or', '=', '1', 'week', 'for', 'another', 'nine', 'patients', '.']","(4, 6)","(19, 42)",-1,ss_i,12586799,Abstract,11,test,gold,4242.0
1240,There were no,treatment-related deaths,in either arm .,"['There', 'were', 'no', 'treatment-related', 'deaths', 'in', 'either', 'arm', '.']","(3, 5)","(13, 37)",-1,ss_o,12586799,Abstract,12,test,gold,2194.0
1241,There were no,treatment-related deaths,in either arm .,"['There', 'were', 'no', 'treatment-related', 'deaths', 'in', 'either', 'arm', '.']","(3, 5)","(13, 37)",-1,hl_o,12586799,Abstract,12,test,gold,2195.0
1242,CONCLUSION We conclude that CCRT is superior to RT alone for,patients with advanced NPC in endemic areas .,,"['CONCLUSION', 'We', 'conclude', 'that', 'CCRT', 'is', 'superior', 'to', 'RT', 'alone', 'for', 'patients', 'with', 'advanced', 'NPC', 'in', 'endemic', 'areas', '.']","(11, 19)","(60, 105)",-1,ss_p,12586799,Abstract,13,test,gold,3861.0
1243,CONCLUSION We conclude that,CCRT,is superior to RT alone for patients with advanced NPC in endemic areas .,"['CONCLUSION', 'We', 'conclude', 'that', 'CCRT', 'is', 'superior', 'to', 'RT', 'alone', 'for', 'patients', 'with', 'advanced', 'NPC', 'in', 'endemic', 'areas', '.']","(4, 5)","(27, 31)",-1,ss_i,12586799,Abstract,13,test,gold,616.0
1244,CONCLUSION We conclude that CCRT is superior to,RT,alone for patients with advanced NPC in endemic areas .,"['CONCLUSION', 'We', 'conclude', 'that', 'CCRT', 'is', 'superior', 'to', 'RT', 'alone', 'for', 'patients', 'with', 'advanced', 'NPC', 'in', 'endemic', 'areas', '.']","(8, 9)","(47, 49)",-1,ss_i,12586799,Abstract,13,test,gold,688.0
1245,CONCLUSION We conclude that CCRT is superior to RT alone for,patients with advanced NPC,in endemic areas .,"['CONCLUSION', 'We', 'conclude', 'that', 'CCRT', 'is', 'superior', 'to', 'RT', 'alone', 'for', 'patients', 'with', 'advanced', 'NPC', 'in', 'endemic', 'areas', '.']","(11, 15)","(60, 86)",-1,hl_p,12586799,Abstract,13,test,gold,3862.0
1246,CONCLUSION We conclude that,CCRT,is superior to RT alone for patients with advanced NPC in endemic areas .,"['CONCLUSION', 'We', 'conclude', 'that', 'CCRT', 'is', 'superior', 'to', 'RT', 'alone', 'for', 'patients', 'with', 'advanced', 'NPC', 'in', 'endemic', 'areas', '.']","(4, 5)","(27, 31)",-1,hl_i,12586799,Abstract,13,test,gold,615.0
1247,CONCLUSION We conclude that CCRT is superior to,RT,alone for patients with advanced NPC in endemic areas .,"['CONCLUSION', 'We', 'conclude', 'that', 'CCRT', 'is', 'superior', 'to', 'RT', 'alone', 'for', 'patients', 'with', 'advanced', 'NPC', 'in', 'endemic', 'areas', '.']","(8, 9)","(47, 49)",-1,hl_i,12586799,Abstract,13,test,gold,687.0
1248,Development of renal disease,in people at high cardiovascular risk :,results of the HOPE randomized study .,"['Development', 'of', 'renal', 'disease', 'in', 'people', 'at', 'high', 'cardiovascular', 'risk', ':', 'results', 'of', 'the', 'HOPE', 'randomized', 'study', '.']","(4, 11)","(28, 67)",-1,ss_p,12595499,Title,0,test,gold,6934.0
1249,,Development of renal disease,in people at high cardiovascular risk : results of the HOPE randomized study .,"['Development', 'of', 'renal', 'disease', 'in', 'people', 'at', 'high', 'cardiovascular', 'risk', ':', 'results', 'of', 'the', 'HOPE', 'randomized', 'study', '.']","(0, 4)","(0, 28)",-1,ss_o,12595499,Title,0,test,gold,3433.0
1250,Development of renal disease in,people at high cardiovascular risk,: results of the HOPE randomized study .,"['Development', 'of', 'renal', 'disease', 'in', 'people', 'at', 'high', 'cardiovascular', 'risk', ':', 'results', 'of', 'the', 'HOPE', 'randomized', 'study', '.']","(5, 10)","(31, 65)",-1,hl_p,12595499,Title,0,test,gold,6935.0
1251,In,people with diabetes,", renal disease tends to progress from microalbuminuria to clinical proteinuria to renal insufficiency .","['In', 'people', 'with', 'diabetes', ',', 'renal', 'disease', 'tends', 'to', 'progress', 'from', 'microalbuminuria', 'to', 'clinical', 'proteinuria', 'to', 'renal', 'insufficiency', '.']","(1, 4)","(2, 22)",-1,ss_p,12595499,Abstract,0,test,gold,3804.0
1252,"In people with diabetes , renal disease tends to",progress from microalbuminuria,to clinical proteinuria to renal insufficiency .,"['In', 'people', 'with', 'diabetes', ',', 'renal', 'disease', 'tends', 'to', 'progress', 'from', 'microalbuminuria', 'to', 'clinical', 'proteinuria', 'to', 'renal', 'insufficiency', '.']","(9, 12)","(48, 78)",-1,ss_o,12595499,Abstract,0,test,gold,3304.0
1253,"In people with diabetes , renal disease tends to progress from microalbuminuria to",clinical proteinuria,to renal insufficiency .,"['In', 'people', 'with', 'diabetes', ',', 'renal', 'disease', 'tends', 'to', 'progress', 'from', 'microalbuminuria', 'to', 'clinical', 'proteinuria', 'to', 'renal', 'insufficiency', '.']","(13, 15)","(82, 102)",-1,ss_o,12595499,Abstract,0,test,gold,4739.0
1254,"In people with diabetes , renal disease tends to progress from microalbuminuria to clinical proteinuria to",renal insufficiency .,,"['In', 'people', 'with', 'diabetes', ',', 'renal', 'disease', 'tends', 'to', 'progress', 'from', 'microalbuminuria', 'to', 'clinical', 'proteinuria', 'to', 'renal', 'insufficiency', '.']","(16, 19)","(106, 127)",-1,ss_o,12595499,Abstract,0,test,gold,3434.0
1255,In,people with diabetes,", renal disease tends to progress from microalbuminuria to clinical proteinuria to renal insufficiency .","['In', 'people', 'with', 'diabetes', ',', 'renal', 'disease', 'tends', 'to', 'progress', 'from', 'microalbuminuria', 'to', 'clinical', 'proteinuria', 'to', 'renal', 'insufficiency', '.']","(1, 4)","(2, 22)",-1,hl_p,12595499,Abstract,0,test,gold,3805.0
1256,Little evidence has been published for the nondiabetic population .,,,"['Little', 'evidence', 'has', 'been', 'published', 'for', 'the', 'nondiabetic', 'population', '.']",,,,,12595499,Abstract,1,test,gold,
1257,"This study retrospectively analyzed changes of proteinuria over 4.5 yr in the HOPE ( Heart Outcomes and Prevention Evaluation ) study , which compared",ramipril 's,"effects to placebo in 9297 participants , including 3577 with diabetes and 1956 with microalbuminuria .","['This', 'study', 'retrospectively', 'analyzed', 'changes', 'of', 'proteinuria', 'over', '4.5', 'yr', 'in', 'the', 'HOPE', '(', 'Heart', 'Outcomes', 'and', 'Prevention', 'Evaluation', ')', 'study', ',', 'which', 'compared', 'ramipril', ""'s"", 'effects', 'to', 'placebo', 'in', '9297', 'participants', ',', 'including', '3577', 'with', 'diabetes', 'and', '1956', 'with', 'microalbuminuria', '.']","(24, 26)","(150, 161)",-1,ss_i,12595499,Abstract,2,test,gold,5393.0
1258,"This study retrospectively analyzed changes of proteinuria over 4.5 yr in the HOPE ( Heart Outcomes and Prevention Evaluation ) study , which compared ramipril 's effects to",placebo,"in 9297 participants , including 3577 with diabetes and 1956 with microalbuminuria .","['This', 'study', 'retrospectively', 'analyzed', 'changes', 'of', 'proteinuria', 'over', '4.5', 'yr', 'in', 'the', 'HOPE', '(', 'Heart', 'Outcomes', 'and', 'Prevention', 'Evaluation', ')', 'study', ',', 'which', 'compared', 'ramipril', ""'s"", 'effects', 'to', 'placebo', 'in', '9297', 'participants', ',', 'including', '3577', 'with', 'diabetes', 'and', '1956', 'with', 'microalbuminuria', '.']","(28, 29)","(173, 180)",-1,ss_i,12595499,Abstract,2,test,gold,4415.0
1259,This study retrospectively analyzed,changes of proteinuria,"over 4.5 yr in the HOPE ( Heart Outcomes and Prevention Evaluation ) study , which compared ramipril 's effects to placebo in 9297 participants , including 3577 with diabetes and 1956 with microalbuminuria .","['This', 'study', 'retrospectively', 'analyzed', 'changes', 'of', 'proteinuria', 'over', '4.5', 'yr', 'in', 'the', 'HOPE', '(', 'Heart', 'Outcomes', 'and', 'Prevention', 'Evaluation', ')', 'study', ',', 'which', 'compared', 'ramipril', ""'s"", 'effects', 'to', 'placebo', 'in', '9297', 'participants', ',', 'including', '3577', 'with', 'diabetes', 'and', '1956', 'with', 'microalbuminuria', '.']","(4, 7)","(35, 57)",-1,ss_o,12595499,Abstract,2,test,gold,3307.0
1260,"This study retrospectively analyzed changes of proteinuria over 4.5 yr in the HOPE ( Heart Outcomes and Prevention Evaluation ) study , which compared",ramipril 's,"effects to placebo in 9297 participants , including 3577 with diabetes and 1956 with microalbuminuria .","['This', 'study', 'retrospectively', 'analyzed', 'changes', 'of', 'proteinuria', 'over', '4.5', 'yr', 'in', 'the', 'HOPE', '(', 'Heart', 'Outcomes', 'and', 'Prevention', 'Evaluation', ')', 'study', ',', 'which', 'compared', 'ramipril', ""'s"", 'effects', 'to', 'placebo', 'in', '9297', 'participants', ',', 'including', '3577', 'with', 'diabetes', 'and', '1956', 'with', 'microalbuminuria', '.']","(24, 26)","(150, 161)",-1,hl_i,12595499,Abstract,2,test,gold,5392.0
1261,"This study retrospectively analyzed changes of proteinuria over 4.5 yr in the HOPE ( Heart Outcomes and Prevention Evaluation ) study , which compared ramipril 's effects to",placebo,"in 9297 participants , including 3577 with diabetes and 1956 with microalbuminuria .","['This', 'study', 'retrospectively', 'analyzed', 'changes', 'of', 'proteinuria', 'over', '4.5', 'yr', 'in', 'the', 'HOPE', '(', 'Heart', 'Outcomes', 'and', 'Prevention', 'Evaluation', ')', 'study', ',', 'which', 'compared', 'ramipril', ""'s"", 'effects', 'to', 'placebo', 'in', '9297', 'participants', ',', 'including', '3577', 'with', 'diabetes', 'and', '1956', 'with', 'microalbuminuria', '.']","(28, 29)","(173, 180)",-1,hl_i,12595499,Abstract,2,test,gold,4414.0
1262,This report is restricted to,7674 participants with albuminuria data at baseline and at follow-up .,,"['This', 'report', 'is', 'restricted', 'to', '7674', 'participants', 'with', 'albuminuria', 'data', 'at', 'baseline', 'and', 'at', 'follow-up', '.']","(5, 16)","(28, 98)",-1,ss_p,12595499,Abstract,3,test,gold,6479.0
1263,This report is restricted to,7674 participants with albuminuria data at baseline and at follow-up,.,"['This', 'report', 'is', 'restricted', 'to', '7674', 'participants', 'with', 'albuminuria', 'data', 'at', 'baseline', 'and', 'at', 'follow-up', '.']","(5, 15)","(28, 96)",-1,hl_p,12595499,Abstract,3,test,gold,6480.0
1264,,"Inclusion criteria were known vascular disease or diabetes plus one other cardiovascular risk factor , exclusion criteria included heart failure or known impaired left ventricular function , dipstick-positive proteinuria ( > 1+ ) , and serum creatinine > 2.3 mg/dl ( 200 microM ) .",,"['Inclusion', 'criteria', 'were', 'known', 'vascular', 'disease', 'or', 'diabetes', 'plus', 'one', 'other', 'cardiovascular', 'risk', 'factor', ',', 'exclusion', 'criteria', 'included', 'heart', 'failure', 'or', 'known', 'impaired', 'left', 'ventricular', 'function', ',', 'dipstick-positive', 'proteinuria', '(', '>', '1+', ')', ',', 'and', 'serum', 'creatinine', '>', '2.3', 'mg/dl', '(', '200', 'microM', ')', '.']","(0, 45)","(0, 281)",-1,ss_p,12595499,Abstract,4,test,gold,6006.0
1265,Baseline microalbuminuria predicted subsequent,clinical proteinuria,"for the study participants overall ( adjusted odds ratio [ OR ] , 17.5 ; 95 % confidence interval [ CI ] , 12.6 to 24.4 ) , in participants without diabetes ( OR , 16.7 ; 95 % CI , 8.6 to 32.4 ) , and in participants with diabetes ( OR , 18.2 ; 95 % CI , 12.4 to 26.7 ) .","['Baseline', 'microalbuminuria', 'predicted', 'subsequent', 'clinical', 'proteinuria', 'for', 'the', 'study', 'participants', 'overall', '(', 'adjusted', 'odds', 'ratio', '[', 'OR', ']', ',', '17.5', ';', '95', '%', 'confidence', 'interval', '[', 'CI', ']', ',', '12.6', 'to', '24.4', ')', ',', 'in', 'participants', 'without', 'diabetes', '(', 'OR', ',', '16.7', ';', '95', '%', 'CI', ',', '8.6', 'to', '32.4', ')', ',', 'and', 'in', 'participants', 'with', 'diabetes', '(', 'OR', ',', '18.2', ';', '95', '%', 'CI', ',', '12.4', 'to', '26.7', ')', '.']","(4, 6)","(46, 66)",-1,ss_o,12595499,Abstract,5,test,gold,4740.0
1266,Baseline microalbuminuria predicted subsequent,clinical proteinuria,"for the study participants overall ( adjusted odds ratio [ OR ] , 17.5 ; 95 % confidence interval [ CI ] , 12.6 to 24.4 ) , in participants without diabetes ( OR , 16.7 ; 95 % CI , 8.6 to 32.4 ) , and in participants with diabetes ( OR , 18.2 ; 95 % CI , 12.4 to 26.7 ) .","['Baseline', 'microalbuminuria', 'predicted', 'subsequent', 'clinical', 'proteinuria', 'for', 'the', 'study', 'participants', 'overall', '(', 'adjusted', 'odds', 'ratio', '[', 'OR', ']', ',', '17.5', ';', '95', '%', 'confidence', 'interval', '[', 'CI', ']', ',', '12.6', 'to', '24.4', ')', ',', 'in', 'participants', 'without', 'diabetes', '(', 'OR', ',', '16.7', ';', '95', '%', 'CI', ',', '8.6', 'to', '32.4', ')', ',', 'and', 'in', 'participants', 'with', 'diabetes', '(', 'OR', ',', '18.2', ';', '95', '%', 'CI', ',', '12.4', 'to', '26.7', ')', '.']","(4, 6)","(46, 66)",-1,hl_o,12595499,Abstract,5,test,gold,4738.0
1267,Any,progression of albuminuria,"( defined as new microalbuminuria or new clinical proteinuria ) occurred in 1859 participants ; 1542 developed new microalbuminuria , and 317 participants developed clinical proteinuria .","['Any', 'progression', 'of', 'albuminuria', '(', 'defined', 'as', 'new', 'microalbuminuria', 'or', 'new', 'clinical', 'proteinuria', ')', 'occurred', 'in', '1859', 'participants', ';', '1542', 'developed', 'new', 'microalbuminuria', ',', 'and', '317', 'participants', 'developed', 'clinical', 'proteinuria', '.']","(1, 4)","(3, 29)",-1,ss_o,12595499,Abstract,6,test,gold,3302.0
1268,Any progression of albuminuria ( defined as,new microalbuminuria or new clinical proteinuria ),"occurred in 1859 participants ; 1542 developed new microalbuminuria , and 317 participants developed clinical proteinuria .","['Any', 'progression', 'of', 'albuminuria', '(', 'defined', 'as', 'new', 'microalbuminuria', 'or', 'new', 'clinical', 'proteinuria', ')', 'occurred', 'in', '1859', 'participants', ';', '1542', 'developed', 'new', 'microalbuminuria', ',', 'and', '317', 'participants', 'developed', 'clinical', 'proteinuria', '.']","(7, 14)","(43, 93)",-1,ss_o,12595499,Abstract,6,test,gold,4734.0
1269,Any progression of albuminuria ( defined as new microalbuminuria or new clinical proteinuria ) occurred in 1859 participants ; 1542 developed,new microalbuminuria,", and 317 participants developed clinical proteinuria .","['Any', 'progression', 'of', 'albuminuria', '(', 'defined', 'as', 'new', 'microalbuminuria', 'or', 'new', 'clinical', 'proteinuria', ')', 'occurred', 'in', '1859', 'participants', ';', '1542', 'developed', 'new', 'microalbuminuria', ',', 'and', '317', 'participants', 'developed', 'clinical', 'proteinuria', '.']","(21, 23)","(141, 161)",-1,ss_o,12595499,Abstract,6,test,gold,3305.0
1270,"Any progression of albuminuria ( defined as new microalbuminuria or new clinical proteinuria ) occurred in 1859 participants ; 1542 developed new microalbuminuria , and 317 participants developed",clinical proteinuria .,,"['Any', 'progression', 'of', 'albuminuria', '(', 'defined', 'as', 'new', 'microalbuminuria', 'or', 'new', 'clinical', 'proteinuria', ')', 'occurred', 'in', '1859', 'participants', ';', '1542', 'developed', 'new', 'microalbuminuria', ',', 'and', '317', 'participants', 'developed', 'clinical', 'proteinuria', '.']","(28, 31)","(195, 217)",-1,ss_o,12595499,Abstract,6,test,gold,4737.0
1271,Any,progression of albuminuria,"( defined as new microalbuminuria or new clinical proteinuria ) occurred in 1859 participants ; 1542 developed new microalbuminuria , and 317 participants developed clinical proteinuria .","['Any', 'progression', 'of', 'albuminuria', '(', 'defined', 'as', 'new', 'microalbuminuria', 'or', 'new', 'clinical', 'proteinuria', ')', 'occurred', 'in', '1859', 'participants', ';', '1542', 'developed', 'new', 'microalbuminuria', ',', 'and', '317', 'participants', 'developed', 'clinical', 'proteinuria', '.']","(1, 4)","(3, 29)",-1,hl_o,12595499,Abstract,6,test,gold,3303.0
1272,Any progression of albuminuria ( defined as new microalbuminuria or new clinical proteinuria ) occurred in 1859 participants ; 1542 developed new,microalbuminuria,", and 317 participants developed clinical proteinuria .","['Any', 'progression', 'of', 'albuminuria', '(', 'defined', 'as', 'new', 'microalbuminuria', 'or', 'new', 'clinical', 'proteinuria', ')', 'occurred', 'in', '1859', 'participants', ';', '1542', 'developed', 'new', 'microalbuminuria', ',', 'and', '317', 'participants', 'developed', 'clinical', 'proteinuria', '.']","(22, 23)","(145, 161)",-1,hl_o,12595499,Abstract,6,test,gold,3306.0
1273,"Any progression of albuminuria ( defined as new microalbuminuria or new clinical proteinuria ) occurred in 1859 participants ; 1542 developed new microalbuminuria , and 317 participants developed",clinical proteinuria .,,"['Any', 'progression', 'of', 'albuminuria', '(', 'defined', 'as', 'new', 'microalbuminuria', 'or', 'new', 'clinical', 'proteinuria', ')', 'occurred', 'in', '1859', 'participants', ';', '1542', 'developed', 'new', 'microalbuminuria', ',', 'and', '317', 'participants', 'developed', 'clinical', 'proteinuria', '.']","(28, 31)","(195, 217)",-1,hl_o,12595499,Abstract,6,test,gold,4736.0
1274,,Ramipril,"reduced the risk for any progression ( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) .","['Ramipril', 'reduced', 'the', 'risk', 'for', 'any', 'progression', '(', 'OR', ',', '0.87', ';', '95', '%', 'CI', ',', '0.78', 'to', '0.97', ';', 'P', '=', '0.0146', ')', '.']","(0, 1)","(0, 8)",-1,ss_i,12595499,Abstract,7,test,gold,153.0
1275,Ramipril reduced the risk for any,progression,"( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) .","['Ramipril', 'reduced', 'the', 'risk', 'for', 'any', 'progression', '(', 'OR', ',', '0.87', ';', '95', '%', 'CI', ',', '0.78', 'to', '0.97', ';', 'P', '=', '0.0146', ')', '.']","(6, 7)","(33, 44)",-1,ss_o,12595499,Abstract,7,test,gold,3330.0
1276,,Ramipril,"reduced the risk for any progression ( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) .","['Ramipril', 'reduced', 'the', 'risk', 'for', 'any', 'progression', '(', 'OR', ',', '0.87', ';', '95', '%', 'CI', ',', '0.78', 'to', '0.97', ';', 'P', '=', '0.0146', ')', '.']","(0, 1)","(0, 8)",-1,hl_i,12595499,Abstract,7,test,gold,154.0
1277,Ramipril reduced the risk for any,progression,"( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) .","['Ramipril', 'reduced', 'the', 'risk', 'for', 'any', 'progression', '(', 'OR', ',', '0.87', ';', '95', '%', 'CI', ',', '0.78', 'to', '0.97', ';', 'P', '=', '0.0146', ')', '.']","(6, 7)","(33, 44)",-1,hl_o,12595499,Abstract,7,test,gold,3331.0
1278,,People without and with diabetes who are at high risk for cardiovascular disease,are also at risk for a progressive rise in albuminuria .,"['People', 'without', 'and', 'with', 'diabetes', 'who', 'are', 'at', 'high', 'risk', 'for', 'cardiovascular', 'disease', 'are', 'also', 'at', 'risk', 'for', 'a', 'progressive', 'rise', 'in', 'albuminuria', '.']","(0, 13)","(0, 80)",-1,ss_p,12595499,Abstract,8,test,gold,5938.0
1279,People without and with diabetes who are at high risk for cardiovascular disease are also at risk for a progressive rise in,albuminuria .,,"['People', 'without', 'and', 'with', 'diabetes', 'who', 'are', 'at', 'high', 'risk', 'for', 'cardiovascular', 'disease', 'are', 'also', 'at', 'risk', 'for', 'a', 'progressive', 'rise', 'in', 'albuminuria', '.']","(22, 24)","(123, 136)",-1,ss_o,12595499,Abstract,8,test,gold,3308.0
1280,People without and with diabetes who are at high risk for cardiovascular disease are also at risk for a progressive rise in,albuminuria .,,"['People', 'without', 'and', 'with', 'diabetes', 'who', 'are', 'at', 'high', 'risk', 'for', 'cardiovascular', 'disease', 'are', 'also', 'at', 'risk', 'for', 'a', 'progressive', 'rise', 'in', 'albuminuria', '.']","(22, 24)","(123, 136)",-1,hl_o,12595499,Abstract,8,test,gold,3309.0
1281,Microalbuminuria itself predicts clinical proteinuria in,nondiabetic and in diabetic people .,,"['Microalbuminuria', 'itself', 'predicts', 'clinical', 'proteinuria', 'in', 'nondiabetic', 'and', 'in', 'diabetic', 'people', '.']","(6, 12)","(56, 92)",-1,ss_p,12595499,Abstract,9,test,gold,3797.0
1282,Microalbuminuria itself predicts,clinical proteinuria,in nondiabetic and in diabetic people .,"['Microalbuminuria', 'itself', 'predicts', 'clinical', 'proteinuria', 'in', 'nondiabetic', 'and', 'in', 'diabetic', 'people', '.']","(3, 5)","(32, 52)",-1,ss_o,12595499,Abstract,9,test,gold,4735.0
1283,Microalbuminuria itself predicts clinical proteinuria in,nondiabetic and in diabetic people .,,"['Microalbuminuria', 'itself', 'predicts', 'clinical', 'proteinuria', 'in', 'nondiabetic', 'and', 'in', 'diabetic', 'people', '.']","(6, 12)","(56, 92)",-1,hl_p,12595499,Abstract,9,test,gold,3798.0
1284,,Ramipril,prevents or delays the progression of albuminuria .,"['Ramipril', 'prevents', 'or', 'delays', 'the', 'progression', 'of', 'albuminuria', '.']","(0, 1)","(0, 8)",-1,ss_i,12595499,Abstract,10,test,gold,152.0
1285,Ramipril prevents or delays the,progression of albuminuria .,,"['Ramipril', 'prevents', 'or', 'delays', 'the', 'progression', 'of', 'albuminuria', '.']","(5, 9)","(31, 59)",-1,ss_o,12595499,Abstract,10,test,gold,3301.0
1286,,Ramipril,prevents or delays the progression of albuminuria .,"['Ramipril', 'prevents', 'or', 'delays', 'the', 'progression', 'of', 'albuminuria', '.']","(0, 1)","(0, 8)",-1,hl_i,12595499,Abstract,10,test,gold,151.0
1287,Ramipril prevents or delays the,progression of albuminuria .,,"['Ramipril', 'prevents', 'or', 'delays', 'the', 'progression', 'of', 'albuminuria', '.']","(5, 9)","(31, 59)",-1,hl_o,12595499,Abstract,10,test,gold,3300.0
1288,"Conscious analgesia/sedation with remifentanil and propofol versus total intravenous anesthesia with fentanyl , midazolam , and propofol for",outpatient colonoscopy .,,"['Conscious', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'versus', 'total', 'intravenous', 'anesthesia', 'with', 'fentanyl', ',', 'midazolam', ',', 'and', 'propofol', 'for', 'outpatient', 'colonoscopy', '.']","(18, 21)","(140, 164)",-1,ss_p,12709693,Title,0,test,gold,4147.0
1289,Conscious analgesia/sedation with,remifentanil,"and propofol versus total intravenous anesthesia with fentanyl , midazolam , and propofol for outpatient colonoscopy .","['Conscious', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'versus', 'total', 'intravenous', 'anesthesia', 'with', 'fentanyl', ',', 'midazolam', ',', 'and', 'propofol', 'for', 'outpatient', 'colonoscopy', '.']","(3, 4)","(33, 45)",-1,ss_i,12709693,Title,0,test,gold,184.0
1290,Conscious analgesia/sedation with remifentanil and,propofol,"versus total intravenous anesthesia with fentanyl , midazolam , and propofol for outpatient colonoscopy .","['Conscious', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'versus', 'total', 'intravenous', 'anesthesia', 'with', 'fentanyl', ',', 'midazolam', ',', 'and', 'propofol', 'for', 'outpatient', 'colonoscopy', '.']","(5, 6)","(50, 58)",-1,ss_i,12709693,Title,0,test,gold,4728.0
1291,Conscious analgesia/sedation with remifentanil and propofol versus total intravenous anesthesia with,"fentanyl , midazolam",", and propofol for outpatient colonoscopy .","['Conscious', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'versus', 'total', 'intravenous', 'anesthesia', 'with', 'fentanyl', ',', 'midazolam', ',', 'and', 'propofol', 'for', 'outpatient', 'colonoscopy', '.']","(11, 14)","(100, 120)",-1,ss_i,12709693,Title,0,test,gold,4948.0
1292,"Conscious analgesia/sedation with remifentanil and propofol versus total intravenous anesthesia with fentanyl , midazolam , and",propofol,for outpatient colonoscopy .,"['Conscious', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'versus', 'total', 'intravenous', 'anesthesia', 'with', 'fentanyl', ',', 'midazolam', ',', 'and', 'propofol', 'for', 'outpatient', 'colonoscopy', '.']","(16, 17)","(127, 135)",-1,ss_i,12709693,Title,0,test,gold,4729.0
1293,"Conscious analgesia/sedation with remifentanil and propofol versus total intravenous anesthesia with fentanyl , midazolam , and propofol for",outpatient colonoscopy .,,"['Conscious', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'versus', 'total', 'intravenous', 'anesthesia', 'with', 'fentanyl', ',', 'midazolam', ',', 'and', 'propofol', 'for', 'outpatient', 'colonoscopy', '.']","(18, 21)","(140, 164)",-1,hl_p,12709693,Title,0,test,gold,4148.0
1294,Conscious analgesia/sedation with,remifentanil,"and propofol versus total intravenous anesthesia with fentanyl , midazolam , and propofol for outpatient colonoscopy .","['Conscious', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'versus', 'total', 'intravenous', 'anesthesia', 'with', 'fentanyl', ',', 'midazolam', ',', 'and', 'propofol', 'for', 'outpatient', 'colonoscopy', '.']","(3, 4)","(33, 45)",-1,hl_i,12709693,Title,0,test,gold,185.0
1295,Conscious analgesia/sedation with remifentanil and,propofol,"versus total intravenous anesthesia with fentanyl , midazolam , and propofol for outpatient colonoscopy .","['Conscious', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'versus', 'total', 'intravenous', 'anesthesia', 'with', 'fentanyl', ',', 'midazolam', ',', 'and', 'propofol', 'for', 'outpatient', 'colonoscopy', '.']","(5, 6)","(50, 58)",-1,hl_i,12709693,Title,0,test,gold,4727.0
1296,Conscious analgesia/sedation with remifentanil and propofol versus total intravenous anesthesia with,fentanyl,", midazolam , and propofol for outpatient colonoscopy .","['Conscious', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'versus', 'total', 'intravenous', 'anesthesia', 'with', 'fentanyl', ',', 'midazolam', ',', 'and', 'propofol', 'for', 'outpatient', 'colonoscopy', '.']","(11, 12)","(100, 108)",-1,hl_i,12709693,Title,0,test,gold,5094.0
1297,"Conscious analgesia/sedation with remifentanil and propofol versus total intravenous anesthesia with fentanyl ,",midazolam,", and propofol for outpatient colonoscopy .","['Conscious', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'versus', 'total', 'intravenous', 'anesthesia', 'with', 'fentanyl', ',', 'midazolam', ',', 'and', 'propofol', 'for', 'outpatient', 'colonoscopy', '.']","(13, 14)","(111, 120)",-1,hl_i,12709693,Title,0,test,gold,4962.0
1298,"Conscious analgesia/sedation with remifentanil and propofol versus total intravenous anesthesia with fentanyl , midazolam , and",propofol,for outpatient colonoscopy .,"['Conscious', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'versus', 'total', 'intravenous', 'anesthesia', 'with', 'fentanyl', ',', 'midazolam', ',', 'and', 'propofol', 'for', 'outpatient', 'colonoscopy', '.']","(16, 17)","(127, 135)",-1,hl_i,12709693,Title,0,test,gold,4726.0
1299,"BACKGROUND This study tested the hypothesis that ,",for colonoscopy,", analgesia/sedation with remifentanil and propofol might be more effective compared with anesthesia by intravenous administration of midazolam , fentanyl , and propofol .","['BACKGROUND', 'This', 'study', 'tested', 'the', 'hypothesis', 'that', ',', 'for', 'colonoscopy', ',', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'might', 'be', 'more', 'effective', 'compared', 'with', 'anesthesia', 'by', 'intravenous', 'administration', 'of', 'midazolam', ',', 'fentanyl', ',', 'and', 'propofol', '.']","(8, 10)","(50, 65)",-1,ss_p,12709693,Abstract,0,test,gold,4149.0
1300,"BACKGROUND This study tested the hypothesis that , for colonoscopy , analgesia/sedation with",remifentanil,"and propofol might be more effective compared with anesthesia by intravenous administration of midazolam , fentanyl , and propofol .","['BACKGROUND', 'This', 'study', 'tested', 'the', 'hypothesis', 'that', ',', 'for', 'colonoscopy', ',', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'might', 'be', 'more', 'effective', 'compared', 'with', 'anesthesia', 'by', 'intravenous', 'administration', 'of', 'midazolam', ',', 'fentanyl', ',', 'and', 'propofol', '.']","(13, 14)","(92, 104)",-1,ss_i,12709693,Abstract,0,test,gold,183.0
1301,"BACKGROUND This study tested the hypothesis that , for colonoscopy , analgesia/sedation with remifentanil and",propofol,"might be more effective compared with anesthesia by intravenous administration of midazolam , fentanyl , and propofol .","['BACKGROUND', 'This', 'study', 'tested', 'the', 'hypothesis', 'that', ',', 'for', 'colonoscopy', ',', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'might', 'be', 'more', 'effective', 'compared', 'with', 'anesthesia', 'by', 'intravenous', 'administration', 'of', 'midazolam', ',', 'fentanyl', ',', 'and', 'propofol', '.']","(15, 16)","(109, 117)",-1,ss_i,12709693,Abstract,0,test,gold,4725.0
1302,"BACKGROUND This study tested the hypothesis that , for colonoscopy , analgesia/sedation with remifentanil and propofol might be more effective compared with anesthesia by intravenous administration of","midazolam , fentanyl",", and propofol .","['BACKGROUND', 'This', 'study', 'tested', 'the', 'hypothesis', 'that', ',', 'for', 'colonoscopy', ',', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'might', 'be', 'more', 'effective', 'compared', 'with', 'anesthesia', 'by', 'intravenous', 'administration', 'of', 'midazolam', ',', 'fentanyl', ',', 'and', 'propofol', '.']","(27, 30)","(200, 220)",-1,ss_i,12709693,Abstract,0,test,gold,4949.0
1303,"BACKGROUND This study tested the hypothesis that , for colonoscopy , analgesia/sedation with remifentanil and propofol might be more effective compared with anesthesia by intravenous administration of midazolam , fentanyl , and",propofol .,,"['BACKGROUND', 'This', 'study', 'tested', 'the', 'hypothesis', 'that', ',', 'for', 'colonoscopy', ',', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'might', 'be', 'more', 'effective', 'compared', 'with', 'anesthesia', 'by', 'intravenous', 'administration', 'of', 'midazolam', ',', 'fentanyl', ',', 'and', 'propofol', '.']","(32, 34)","(227, 237)",-1,ss_i,12709693,Abstract,0,test,gold,4724.0
1304,"BACKGROUND This study tested the hypothesis that , for colonoscopy , analgesia/sedation with remifentanil and propofol might be more",effective,"compared with anesthesia by intravenous administration of midazolam , fentanyl , and propofol .","['BACKGROUND', 'This', 'study', 'tested', 'the', 'hypothesis', 'that', ',', 'for', 'colonoscopy', ',', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'might', 'be', 'more', 'effective', 'compared', 'with', 'anesthesia', 'by', 'intravenous', 'administration', 'of', 'midazolam', ',', 'fentanyl', ',', 'and', 'propofol', '.']","(19, 20)","(132, 141)",-1,ss_o,12709693,Abstract,0,test,gold,856.0
1305,"BACKGROUND This study tested the hypothesis that , for colonoscopy , analgesia/sedation with",remifentanil,"and propofol might be more effective compared with anesthesia by intravenous administration of midazolam , fentanyl , and propofol .","['BACKGROUND', 'This', 'study', 'tested', 'the', 'hypothesis', 'that', ',', 'for', 'colonoscopy', ',', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'might', 'be', 'more', 'effective', 'compared', 'with', 'anesthesia', 'by', 'intravenous', 'administration', 'of', 'midazolam', ',', 'fentanyl', ',', 'and', 'propofol', '.']","(13, 14)","(92, 104)",-1,hl_i,12709693,Abstract,0,test,gold,182.0
1306,"BACKGROUND This study tested the hypothesis that , for colonoscopy , analgesia/sedation with remifentanil and",propofol,"might be more effective compared with anesthesia by intravenous administration of midazolam , fentanyl , and propofol .","['BACKGROUND', 'This', 'study', 'tested', 'the', 'hypothesis', 'that', ',', 'for', 'colonoscopy', ',', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'might', 'be', 'more', 'effective', 'compared', 'with', 'anesthesia', 'by', 'intravenous', 'administration', 'of', 'midazolam', ',', 'fentanyl', ',', 'and', 'propofol', '.']","(15, 16)","(109, 117)",-1,hl_i,12709693,Abstract,0,test,gold,4723.0
1307,"BACKGROUND This study tested the hypothesis that , for colonoscopy , analgesia/sedation with remifentanil and propofol might be more effective compared with anesthesia by intravenous administration of",midazolam,", fentanyl , and propofol .","['BACKGROUND', 'This', 'study', 'tested', 'the', 'hypothesis', 'that', ',', 'for', 'colonoscopy', ',', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'might', 'be', 'more', 'effective', 'compared', 'with', 'anesthesia', 'by', 'intravenous', 'administration', 'of', 'midazolam', ',', 'fentanyl', ',', 'and', 'propofol', '.']","(27, 28)","(200, 209)",-1,hl_i,12709693,Abstract,0,test,gold,4963.0
1308,"BACKGROUND This study tested the hypothesis that , for colonoscopy , analgesia/sedation with remifentanil and propofol might be more effective compared with anesthesia by intravenous administration of midazolam ,",fentanyl,", and propofol .","['BACKGROUND', 'This', 'study', 'tested', 'the', 'hypothesis', 'that', ',', 'for', 'colonoscopy', ',', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'might', 'be', 'more', 'effective', 'compared', 'with', 'anesthesia', 'by', 'intravenous', 'administration', 'of', 'midazolam', ',', 'fentanyl', ',', 'and', 'propofol', '.']","(29, 30)","(212, 220)",-1,hl_i,12709693,Abstract,0,test,gold,5095.0
1309,"BACKGROUND This study tested the hypothesis that , for colonoscopy , analgesia/sedation with remifentanil and propofol might be more effective compared with anesthesia by intravenous administration of midazolam , fentanyl , and",propofol,.,"['BACKGROUND', 'This', 'study', 'tested', 'the', 'hypothesis', 'that', ',', 'for', 'colonoscopy', ',', 'analgesia/sedation', 'with', 'remifentanil', 'and', 'propofol', 'might', 'be', 'more', 'effective', 'compared', 'with', 'anesthesia', 'by', 'intravenous', 'administration', 'of', 'midazolam', ',', 'fentanyl', ',', 'and', 'propofol', '.']","(32, 33)","(227, 235)",-1,hl_i,12709693,Abstract,0,test,gold,4722.0
1310,"METHODS In a prospective , randomized trial ,",100 adult patients,received either conscious analgesia/sedation ( Sedation group ) or total intravenous anesthesia ( TIVA group ) .,"['METHODS', 'In', 'a', 'prospective', ',', 'randomized', 'trial', ',', '100', 'adult', 'patients', 'received', 'either', 'conscious', 'analgesia/sedation', '(', 'Sedation', 'group', ')', 'or', 'total', 'intravenous', 'anesthesia', '(', 'TIVA', 'group', ')', '.']","(8, 11)","(45, 63)",-1,ss_p,12709693,Abstract,1,test,gold,3768.0
1311,"METHODS In a prospective , randomized trial ,",100 adult patients,received either conscious analgesia/sedation ( Sedation group ) or total intravenous anesthesia ( TIVA group ) .,"['METHODS', 'In', 'a', 'prospective', ',', 'randomized', 'trial', ',', '100', 'adult', 'patients', 'received', 'either', 'conscious', 'analgesia/sedation', '(', 'Sedation', 'group', ')', 'or', 'total', 'intravenous', 'anesthesia', '(', 'TIVA', 'group', ')', '.']","(8, 11)","(45, 63)",-1,hl_p,12709693,Abstract,1,test,gold,3769.0
1312,Analgesia/sedation was achieved by infusion of,remifentanil,( 0.20 to 0.25 microg/kg/min ) and propofol in titrated doses .,"['Analgesia/sedation', 'was', 'achieved', 'by', 'infusion', 'of', 'remifentanil', '(', '0.20', 'to', '0.25', 'microg/kg/min', ')', 'and', 'propofol', 'in', 'titrated', 'doses', '.']","(6, 7)","(46, 58)",-1,ss_i,12709693,Abstract,2,test,gold,181.0
1313,Analgesia/sedation was achieved by infusion of remifentanil ( 0.20 to 0.25 microg/kg/min ) and,propofol,in titrated doses .,"['Analgesia/sedation', 'was', 'achieved', 'by', 'infusion', 'of', 'remifentanil', '(', '0.20', 'to', '0.25', 'microg/kg/min', ')', 'and', 'propofol', 'in', 'titrated', 'doses', '.']","(14, 15)","(94, 102)",-1,ss_i,12709693,Abstract,2,test,gold,4721.0
1314,Analgesia/sedation was achieved by infusion of,remifentanil,( 0.20 to 0.25 microg/kg/min ) and propofol in titrated doses .,"['Analgesia/sedation', 'was', 'achieved', 'by', 'infusion', 'of', 'remifentanil', '(', '0.20', 'to', '0.25', 'microg/kg/min', ')', 'and', 'propofol', 'in', 'titrated', 'doses', '.']","(6, 7)","(46, 58)",-1,hl_i,12709693,Abstract,2,test,gold,180.0
1315,Analgesia/sedation was achieved by infusion of remifentanil ( 0.20 to 0.25 microg/kg/min ) and,propofol,in titrated doses .,"['Analgesia/sedation', 'was', 'achieved', 'by', 'infusion', 'of', 'remifentanil', '(', '0.20', 'to', '0.25', 'microg/kg/min', ')', 'and', 'propofol', 'in', 'titrated', 'doses', '.']","(14, 15)","(94, 102)",-1,hl_i,12709693,Abstract,2,test,gold,4720.0
1316,TIVA was induced by intravenous administration of,fentanyl,"( 2 microg/kg ) , midazolam ( 0.05 mg/kg ) and propofol ( dosage titrated ) .","['TIVA', 'was', 'induced', 'by', 'intravenous', 'administration', 'of', 'fentanyl', '(', '2', 'microg/kg', ')', ',', 'midazolam', '(', '0.05', 'mg/kg', ')', 'and', 'propofol', '(', 'dosage', 'titrated', ')', '.']","(7, 8)","(49, 57)",-1,ss_i,12709693,Abstract,3,test,gold,5093.0
1317,"TIVA was induced by intravenous administration of fentanyl ( 2 microg/kg ) ,",midazolam,( 0.05 mg/kg ) and propofol ( dosage titrated ) .,"['TIVA', 'was', 'induced', 'by', 'intravenous', 'administration', 'of', 'fentanyl', '(', '2', 'microg/kg', ')', ',', 'midazolam', '(', '0.05', 'mg/kg', ')', 'and', 'propofol', '(', 'dosage', 'titrated', ')', '.']","(13, 14)","(76, 85)",-1,ss_i,12709693,Abstract,3,test,gold,4961.0
1318,"TIVA was induced by intravenous administration of fentanyl ( 2 microg/kg ) , midazolam ( 0.05 mg/kg ) and",propofol,( dosage titrated ) .,"['TIVA', 'was', 'induced', 'by', 'intravenous', 'administration', 'of', 'fentanyl', '(', '2', 'microg/kg', ')', ',', 'midazolam', '(', '0.05', 'mg/kg', ')', 'and', 'propofol', '(', 'dosage', 'titrated', ')', '.']","(19, 20)","(105, 113)",-1,ss_i,12709693,Abstract,3,test,gold,4719.0
1319,TIVA was induced by intravenous administration of,fentanyl,"( 2 microg/kg ) , midazolam ( 0.05 mg/kg ) and propofol ( dosage titrated ) .","['TIVA', 'was', 'induced', 'by', 'intravenous', 'administration', 'of', 'fentanyl', '(', '2', 'microg/kg', ')', ',', 'midazolam', '(', '0.05', 'mg/kg', ')', 'and', 'propofol', '(', 'dosage', 'titrated', ')', '.']","(7, 8)","(49, 57)",-1,hl_i,12709693,Abstract,3,test,gold,5092.0
1320,"TIVA was induced by intravenous administration of fentanyl ( 2 microg/kg ) ,",midazolam,( 0.05 mg/kg ) and propofol ( dosage titrated ) .,"['TIVA', 'was', 'induced', 'by', 'intravenous', 'administration', 'of', 'fentanyl', '(', '2', 'microg/kg', ')', ',', 'midazolam', '(', '0.05', 'mg/kg', ')', 'and', 'propofol', '(', 'dosage', 'titrated', ')', '.']","(13, 14)","(76, 85)",-1,hl_i,12709693,Abstract,3,test,gold,4960.0
1321,"TIVA was induced by intravenous administration of fentanyl ( 2 microg/kg ) , midazolam ( 0.05 mg/kg ) and",propofol,( dosage titrated ) .,"['TIVA', 'was', 'induced', 'by', 'intravenous', 'administration', 'of', 'fentanyl', '(', '2', 'microg/kg', ')', ',', 'midazolam', '(', '0.05', 'mg/kg', ')', 'and', 'propofol', '(', 'dosage', 'titrated', ')', '.']","(19, 20)","(105, 113)",-1,hl_i,12709693,Abstract,3,test,gold,4718.0
1322,,Cardiorespiratory parameters and bispectral index were monitored and recorded .,,"['Cardiorespiratory', 'parameters', 'and', 'bispectral', 'index', 'were', 'monitored', 'and', 'recorded', '.']","(0, 10)","(0, 79)",-1,ss_o,12709693,Abstract,4,test,gold,2002.0
1323,,Cardiorespiratory parameters,and bispectral index were monitored and recorded .,"['Cardiorespiratory', 'parameters', 'and', 'bispectral', 'index', 'were', 'monitored', 'and', 'recorded', '.']","(0, 2)","(0, 28)",-1,hl_o,12709693,Abstract,4,test,gold,1824.0
1324,Cardiorespiratory parameters and,bispectral index,were monitored and recorded .,"['Cardiorespiratory', 'parameters', 'and', 'bispectral', 'index', 'were', 'monitored', 'and', 'recorded', '.']","(3, 5)","(32, 48)",-1,hl_o,12709693,Abstract,4,test,gold,1997.0
1325,,"The quality of the analgesia was assessed with a Numerical Pain Rating Scale ( NRS ) ; recovery level and return of psychomotor efficiency were evaluated with , respectively , the Aldrete scale and a Modified Post Anesthesia Discharge Scoring ( MPADS ) system .",,"['The', 'quality', 'of', 'the', 'analgesia', 'was', 'assessed', 'with', 'a', 'Numerical', 'Pain', 'Rating', 'Scale', '(', 'NRS', ')', ';', 'recovery', 'level', 'and', 'return', 'of', 'psychomotor', 'efficiency', 'were', 'evaluated', 'with', ',', 'respectively', ',', 'the', 'Aldrete', 'scale', 'and', 'a', 'Modified', 'Post', 'Anesthesia', 'Discharge', 'Scoring', '(', 'MPADS', ')', 'system', '.']","(0, 45)","(0, 261)",-1,ss_o,12709693,Abstract,5,test,gold,5916.0
1326,The quality of the analgesia was assessed with a,Numerical Pain Rating Scale ( NRS ),"; recovery level and return of psychomotor efficiency were evaluated with , respectively , the Aldrete scale and a Modified Post Anesthesia Discharge Scoring ( MPADS ) system .","['The', 'quality', 'of', 'the', 'analgesia', 'was', 'assessed', 'with', 'a', 'Numerical', 'Pain', 'Rating', 'Scale', '(', 'NRS', ')', ';', 'recovery', 'level', 'and', 'return', 'of', 'psychomotor', 'efficiency', 'were', 'evaluated', 'with', ',', 'respectively', ',', 'the', 'Aldrete', 'scale', 'and', 'a', 'Modified', 'Post', 'Anesthesia', 'Discharge', 'Scoring', '(', 'MPADS', ')', 'system', '.']","(9, 16)","(48, 83)",-1,hl_o,12709693,Abstract,5,test,gold,6211.0
1327,The quality of the analgesia was assessed with a Numerical Pain Rating Scale ( NRS ) ;,recovery level,"and return of psychomotor efficiency were evaluated with , respectively , the Aldrete scale and a Modified Post Anesthesia Discharge Scoring ( MPADS ) system .","['The', 'quality', 'of', 'the', 'analgesia', 'was', 'assessed', 'with', 'a', 'Numerical', 'Pain', 'Rating', 'Scale', '(', 'NRS', ')', ';', 'recovery', 'level', 'and', 'return', 'of', 'psychomotor', 'efficiency', 'were', 'evaluated', 'with', ',', 'respectively', ',', 'the', 'Aldrete', 'scale', 'and', 'a', 'Modified', 'Post', 'Anesthesia', 'Discharge', 'Scoring', '(', 'MPADS', ')', 'system', '.']","(17, 19)","(86, 100)",-1,hl_o,12709693,Abstract,5,test,gold,944.0
1328,The quality of the analgesia was assessed with a Numerical Pain Rating Scale ( NRS ) ; recovery level and,return of psychomotor efficiency,"were evaluated with , respectively , the Aldrete scale and a Modified Post Anesthesia Discharge Scoring ( MPADS ) system .","['The', 'quality', 'of', 'the', 'analgesia', 'was', 'assessed', 'with', 'a', 'Numerical', 'Pain', 'Rating', 'Scale', '(', 'NRS', ')', ';', 'recovery', 'level', 'and', 'return', 'of', 'psychomotor', 'efficiency', 'were', 'evaluated', 'with', ',', 'respectively', ',', 'the', 'Aldrete', 'scale', 'and', 'a', 'Modified', 'Post', 'Anesthesia', 'Discharge', 'Scoring', '(', 'MPADS', ')', 'system', '.']","(20, 24)","(105, 137)",-1,hl_o,12709693,Abstract,5,test,gold,1381.0
1329,"The quality of the analgesia was assessed with a Numerical Pain Rating Scale ( NRS ) ; recovery level and return of psychomotor efficiency were evaluated with , respectively , the",Aldrete scale,and a Modified Post Anesthesia Discharge Scoring ( MPADS ) system .,"['The', 'quality', 'of', 'the', 'analgesia', 'was', 'assessed', 'with', 'a', 'Numerical', 'Pain', 'Rating', 'Scale', '(', 'NRS', ')', ';', 'recovery', 'level', 'and', 'return', 'of', 'psychomotor', 'efficiency', 'were', 'evaluated', 'with', ',', 'respectively', ',', 'the', 'Aldrete', 'scale', 'and', 'a', 'Modified', 'Post', 'Anesthesia', 'Discharge', 'Scoring', '(', 'MPADS', ')', 'system', '.']","(31, 33)","(179, 192)",-1,hl_o,12709693,Abstract,5,test,gold,1369.0
1330,"The quality of the analgesia was assessed with a Numerical Pain Rating Scale ( NRS ) ; recovery level and return of psychomotor efficiency were evaluated with , respectively , the Aldrete scale and a",Modified Post Anesthesia Discharge Scoring ( MPADS ) system,.,"['The', 'quality', 'of', 'the', 'analgesia', 'was', 'assessed', 'with', 'a', 'Numerical', 'Pain', 'Rating', 'Scale', '(', 'NRS', ')', ';', 'recovery', 'level', 'and', 'return', 'of', 'psychomotor', 'efficiency', 'were', 'evaluated', 'with', ',', 'respectively', ',', 'the', 'Aldrete', 'scale', 'and', 'a', 'Modified', 'Post', 'Anesthesia', 'Discharge', 'Scoring', '(', 'MPADS', ')', 'system', '.']","(35, 44)","(199, 258)",-1,hl_o,12709693,Abstract,5,test,gold,6210.0
1331,"RESULTS Both groups of 50 patients were comparable with respect to demographic data , initial parameters , and duration of colonoscopy .",,,"['RESULTS', 'Both', 'groups', 'of', '50', 'patients', 'were', 'comparable', 'with', 'respect', 'to', 'demographic', 'data', ',', 'initial', 'parameters', ',', 'and', 'duration', 'of', 'colonoscopy', '.']",,,,,12709693,Abstract,6,test,gold,
1332,All patients in the TIVA group found the colonoscopy painless,( NRS,score 0 ) .,"['All', 'patients', 'in', 'the', 'TIVA', 'group', 'found', 'the', 'colonoscopy', 'painless', '(', 'NRS', 'score', '0', ')', '.']","(10, 12)","(61, 66)",-1,ss_o,12709693,Abstract,7,test,gold,1081.0
1333,"In the Sedation group , the average",pain intensity score,was 0.4 ( 0.8 ) .,"['In', 'the', 'Sedation', 'group', ',', 'the', 'average', 'pain', 'intensity', 'score', 'was', '0.4', '(', '0.8', ')', '.']","(7, 10)","(35, 55)",-1,ss_o,12709693,Abstract,8,test,gold,2316.0
1334,"In the Sedation group , the average",pain intensity score,was 0.4 ( 0.8 ) .,"['In', 'the', 'Sedation', 'group', ',', 'the', 'average', 'pain', 'intensity', 'score', 'was', '0.4', '(', '0.8', ')', '.']","(7, 10)","(35, 55)",-1,hl_o,12709693,Abstract,8,test,gold,2317.0
1335,There was a marked difference between the Sedation and TIVA groups with respect to the time from the end of the procedure until the,maximum MPADS score,"was reached : respectively , -6.9 ( 4.0 ) versus 25.7 ( 8.4 ) minutes ( p < 0.001 ) .","['There', 'was', 'a', 'marked', 'difference', 'between', 'the', 'Sedation', 'and', 'TIVA', 'groups', 'with', 'respect', 'to', 'the', 'time', 'from', 'the', 'end', 'of', 'the', 'procedure', 'until', 'the', 'maximum', 'MPADS', 'score', 'was', 'reached', ':', 'respectively', ',', '-6.9', '(', '4.0', ')', 'versus', '25.7', '(', '8.4', ')', 'minutes', '(', 'p', '<', '0.001', ')', '.']","(24, 27)","(131, 150)",-1,ss_o,12709693,Abstract,9,test,gold,1447.0
1336,There was a marked difference between the Sedation and TIVA groups with respect to the time from the end of the procedure until the,maximum MPADS score,"was reached : respectively , -6.9 ( 4.0 ) versus 25.7 ( 8.4 ) minutes ( p < 0.001 ) .","['There', 'was', 'a', 'marked', 'difference', 'between', 'the', 'Sedation', 'and', 'TIVA', 'groups', 'with', 'respect', 'to', 'the', 'time', 'from', 'the', 'end', 'of', 'the', 'procedure', 'until', 'the', 'maximum', 'MPADS', 'score', 'was', 'reached', ':', 'respectively', ',', '-6.9', '(', '4.0', ')', 'versus', '25.7', '(', '8.4', ')', 'minutes', '(', 'p', '<', '0.001', ')', '.']","(24, 27)","(131, 150)",-1,hl_o,12709693,Abstract,9,test,gold,1448.0
1337,"In the TIVA group , changes in",mean arterial pressure and heart rate and signs of respiratory depression,were significant ( p < 0.05 ) .,"['In', 'the', 'TIVA', 'group', ',', 'changes', 'in', 'mean', 'arterial', 'pressure', 'and', 'heart', 'rate', 'and', 'signs', 'of', 'respiratory', 'depression', 'were', 'significant', '(', 'p', '<', '0.05', ')', '.']","(7, 18)","(30, 103)",-1,ss_o,12709693,Abstract,10,test,gold,6726.0
1338,"In the TIVA group , changes in",mean arterial pressure and heart rate and signs of respiratory depression,were significant ( p < 0.05 ) .,"['In', 'the', 'TIVA', 'group', ',', 'changes', 'in', 'mean', 'arterial', 'pressure', 'and', 'heart', 'rate', 'and', 'signs', 'of', 'respiratory', 'depression', 'were', 'significant', '(', 'p', '<', '0.05', ')', '.']","(7, 18)","(30, 103)",-1,hl_o,12709693,Abstract,10,test,gold,6727.0
1339,CONCLUSIONS Combined administration of remifentanil and propofol for,colonoscopy,"provides sufficient analgesia , satisfactory hemodynamic stability , minor respiratory depression , and rapid recovery , and allows patients to be discharged approximately 15 minutes after the procedure .","['CONCLUSIONS', 'Combined', 'administration', 'of', 'remifentanil', 'and', 'propofol', 'for', 'colonoscopy', 'provides', 'sufficient', 'analgesia', ',', 'satisfactory', 'hemodynamic', 'stability', ',', 'minor', 'respiratory', 'depression', ',', 'and', 'rapid', 'recovery', ',', 'and', 'allows', 'patients', 'to', 'be', 'discharged', 'approximately', '15', 'minutes', 'after', 'the', 'procedure', '.']","(8, 9)","(68, 79)",-1,ss_p,12709693,Abstract,11,test,gold,4150.0
1340,CONCLUSIONS Combined administration of,remifentanil,"and propofol for colonoscopy provides sufficient analgesia , satisfactory hemodynamic stability , minor respiratory depression , and rapid recovery , and allows patients to be discharged approximately 15 minutes after the procedure .","['CONCLUSIONS', 'Combined', 'administration', 'of', 'remifentanil', 'and', 'propofol', 'for', 'colonoscopy', 'provides', 'sufficient', 'analgesia', ',', 'satisfactory', 'hemodynamic', 'stability', ',', 'minor', 'respiratory', 'depression', ',', 'and', 'rapid', 'recovery', ',', 'and', 'allows', 'patients', 'to', 'be', 'discharged', 'approximately', '15', 'minutes', 'after', 'the', 'procedure', '.']","(4, 5)","(38, 50)",-1,ss_i,12709693,Abstract,11,test,gold,179.0
1341,CONCLUSIONS Combined administration of remifentanil and,propofol,"for colonoscopy provides sufficient analgesia , satisfactory hemodynamic stability , minor respiratory depression , and rapid recovery , and allows patients to be discharged approximately 15 minutes after the procedure .","['CONCLUSIONS', 'Combined', 'administration', 'of', 'remifentanil', 'and', 'propofol', 'for', 'colonoscopy', 'provides', 'sufficient', 'analgesia', ',', 'satisfactory', 'hemodynamic', 'stability', ',', 'minor', 'respiratory', 'depression', ',', 'and', 'rapid', 'recovery', ',', 'and', 'allows', 'patients', 'to', 'be', 'discharged', 'approximately', '15', 'minutes', 'after', 'the', 'procedure', '.']","(6, 7)","(55, 63)",-1,ss_i,12709693,Abstract,11,test,gold,4717.0
1342,CONCLUSIONS Combined administration of remifentanil and propofol for colonoscopy provides,sufficient analgesia,", satisfactory hemodynamic stability , minor respiratory depression , and rapid recovery , and allows patients to be discharged approximately 15 minutes after the procedure .","['CONCLUSIONS', 'Combined', 'administration', 'of', 'remifentanil', 'and', 'propofol', 'for', 'colonoscopy', 'provides', 'sufficient', 'analgesia', ',', 'satisfactory', 'hemodynamic', 'stability', ',', 'minor', 'respiratory', 'depression', ',', 'and', 'rapid', 'recovery', ',', 'and', 'allows', 'patients', 'to', 'be', 'discharged', 'approximately', '15', 'minutes', 'after', 'the', 'procedure', '.']","(10, 12)","(89, 109)",-1,ss_o,12709693,Abstract,11,test,gold,5449.0
1343,"CONCLUSIONS Combined administration of remifentanil and propofol for colonoscopy provides sufficient analgesia , satisfactory",hemodynamic stability,", minor respiratory depression , and rapid recovery , and allows patients to be discharged approximately 15 minutes after the procedure .","['CONCLUSIONS', 'Combined', 'administration', 'of', 'remifentanil', 'and', 'propofol', 'for', 'colonoscopy', 'provides', 'sufficient', 'analgesia', ',', 'satisfactory', 'hemodynamic', 'stability', ',', 'minor', 'respiratory', 'depression', ',', 'and', 'rapid', 'recovery', ',', 'and', 'allows', 'patients', 'to', 'be', 'discharged', 'approximately', '15', 'minutes', 'after', 'the', 'procedure', '.']","(14, 16)","(125, 146)",-1,ss_o,12709693,Abstract,11,test,gold,3237.0
1344,"CONCLUSIONS Combined administration of remifentanil and propofol for colonoscopy provides sufficient analgesia , satisfactory hemodynamic stability , minor",respiratory depression,", and rapid recovery , and allows patients to be discharged approximately 15 minutes after the procedure .","['CONCLUSIONS', 'Combined', 'administration', 'of', 'remifentanil', 'and', 'propofol', 'for', 'colonoscopy', 'provides', 'sufficient', 'analgesia', ',', 'satisfactory', 'hemodynamic', 'stability', ',', 'minor', 'respiratory', 'depression', ',', 'and', 'rapid', 'recovery', ',', 'and', 'allows', 'patients', 'to', 'be', 'discharged', 'approximately', '15', 'minutes', 'after', 'the', 'procedure', '.']","(18, 20)","(155, 177)",-1,ss_o,12709693,Abstract,11,test,gold,3447.0
1345,"CONCLUSIONS Combined administration of remifentanil and propofol for colonoscopy provides sufficient analgesia , satisfactory hemodynamic stability , minor respiratory depression , and",rapid recovery,", and allows patients to be discharged approximately 15 minutes after the procedure .","['CONCLUSIONS', 'Combined', 'administration', 'of', 'remifentanil', 'and', 'propofol', 'for', 'colonoscopy', 'provides', 'sufficient', 'analgesia', ',', 'satisfactory', 'hemodynamic', 'stability', ',', 'minor', 'respiratory', 'depression', ',', 'and', 'rapid', 'recovery', ',', 'and', 'allows', 'patients', 'to', 'be', 'discharged', 'approximately', '15', 'minutes', 'after', 'the', 'procedure', '.']","(22, 24)","(184, 198)",-1,ss_o,12709693,Abstract,11,test,gold,942.0
1346,CONCLUSIONS Combined administration of,remifentanil,"and propofol for colonoscopy provides sufficient analgesia , satisfactory hemodynamic stability , minor respiratory depression , and rapid recovery , and allows patients to be discharged approximately 15 minutes after the procedure .","['CONCLUSIONS', 'Combined', 'administration', 'of', 'remifentanil', 'and', 'propofol', 'for', 'colonoscopy', 'provides', 'sufficient', 'analgesia', ',', 'satisfactory', 'hemodynamic', 'stability', ',', 'minor', 'respiratory', 'depression', ',', 'and', 'rapid', 'recovery', ',', 'and', 'allows', 'patients', 'to', 'be', 'discharged', 'approximately', '15', 'minutes', 'after', 'the', 'procedure', '.']","(4, 5)","(38, 50)",-1,hl_i,12709693,Abstract,11,test,gold,178.0
1347,CONCLUSIONS Combined administration of remifentanil and,propofol,"for colonoscopy provides sufficient analgesia , satisfactory hemodynamic stability , minor respiratory depression , and rapid recovery , and allows patients to be discharged approximately 15 minutes after the procedure .","['CONCLUSIONS', 'Combined', 'administration', 'of', 'remifentanil', 'and', 'propofol', 'for', 'colonoscopy', 'provides', 'sufficient', 'analgesia', ',', 'satisfactory', 'hemodynamic', 'stability', ',', 'minor', 'respiratory', 'depression', ',', 'and', 'rapid', 'recovery', ',', 'and', 'allows', 'patients', 'to', 'be', 'discharged', 'approximately', '15', 'minutes', 'after', 'the', 'procedure', '.']","(6, 7)","(55, 63)",-1,hl_i,12709693,Abstract,11,test,gold,4716.0
1348,CONCLUSIONS Combined administration of remifentanil and propofol for colonoscopy provides sufficient,analgesia,", satisfactory hemodynamic stability , minor respiratory depression , and rapid recovery , and allows patients to be discharged approximately 15 minutes after the procedure .","['CONCLUSIONS', 'Combined', 'administration', 'of', 'remifentanil', 'and', 'propofol', 'for', 'colonoscopy', 'provides', 'sufficient', 'analgesia', ',', 'satisfactory', 'hemodynamic', 'stability', ',', 'minor', 'respiratory', 'depression', ',', 'and', 'rapid', 'recovery', ',', 'and', 'allows', 'patients', 'to', 'be', 'discharged', 'approximately', '15', 'minutes', 'after', 'the', 'procedure', '.']","(11, 12)","(100, 109)",-1,hl_o,12709693,Abstract,11,test,gold,5450.0
1349,"CONCLUSIONS Combined administration of remifentanil and propofol for colonoscopy provides sufficient analgesia , satisfactory",hemodynamic stability,", minor respiratory depression , and rapid recovery , and allows patients to be discharged approximately 15 minutes after the procedure .","['CONCLUSIONS', 'Combined', 'administration', 'of', 'remifentanil', 'and', 'propofol', 'for', 'colonoscopy', 'provides', 'sufficient', 'analgesia', ',', 'satisfactory', 'hemodynamic', 'stability', ',', 'minor', 'respiratory', 'depression', ',', 'and', 'rapid', 'recovery', ',', 'and', 'allows', 'patients', 'to', 'be', 'discharged', 'approximately', '15', 'minutes', 'after', 'the', 'procedure', '.']","(14, 16)","(125, 146)",-1,hl_o,12709693,Abstract,11,test,gold,3238.0
1350,"CONCLUSIONS Combined administration of remifentanil and propofol for colonoscopy provides sufficient analgesia , satisfactory hemodynamic stability , minor",respiratory depression,", and rapid recovery , and allows patients to be discharged approximately 15 minutes after the procedure .","['CONCLUSIONS', 'Combined', 'administration', 'of', 'remifentanil', 'and', 'propofol', 'for', 'colonoscopy', 'provides', 'sufficient', 'analgesia', ',', 'satisfactory', 'hemodynamic', 'stability', ',', 'minor', 'respiratory', 'depression', ',', 'and', 'rapid', 'recovery', ',', 'and', 'allows', 'patients', 'to', 'be', 'discharged', 'approximately', '15', 'minutes', 'after', 'the', 'procedure', '.']","(18, 20)","(155, 177)",-1,hl_o,12709693,Abstract,11,test,gold,3448.0
1351,"CONCLUSIONS Combined administration of remifentanil and propofol for colonoscopy provides sufficient analgesia , satisfactory hemodynamic stability , minor respiratory depression , and",rapid recovery,", and allows patients to be discharged approximately 15 minutes after the procedure .","['CONCLUSIONS', 'Combined', 'administration', 'of', 'remifentanil', 'and', 'propofol', 'for', 'colonoscopy', 'provides', 'sufficient', 'analgesia', ',', 'satisfactory', 'hemodynamic', 'stability', ',', 'minor', 'respiratory', 'depression', ',', 'and', 'rapid', 'recovery', ',', 'and', 'allows', 'patients', 'to', 'be', 'discharged', 'approximately', '15', 'minutes', 'after', 'the', 'procedure', '.']","(22, 24)","(184, 198)",-1,hl_o,12709693,Abstract,11,test,gold,943.0
1352,"Reduced platelet thromboxane formation after long-term administration of a dihydropyridine calcium channel blocker : a prospective , double-blind , placebo-controlled study with nitrendipine in",borderline hypertensive patients with IDDM-type diabetes mellitus .,,"['Reduced', 'platelet', 'thromboxane', 'formation', 'after', 'long-term', 'administration', 'of', 'a', 'dihydropyridine', 'calcium', 'channel', 'blocker', ':', 'a', 'prospective', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'with', 'nitrendipine', 'in', 'borderline', 'hypertensive', 'patients', 'with', 'IDDM-type', 'diabetes', 'mellitus', '.']","(24, 32)","(193, 260)",-1,ss_p,1286547,Title,0,test,gold,6918.0
1353,Reduced platelet thromboxane formation after long-term administration of a,dihydropyridine calcium channel blocker :,"a prospective , double-blind , placebo-controlled study with nitrendipine in borderline hypertensive patients with IDDM-type diabetes mellitus .","['Reduced', 'platelet', 'thromboxane', 'formation', 'after', 'long-term', 'administration', 'of', 'a', 'dihydropyridine', 'calcium', 'channel', 'blocker', ':', 'a', 'prospective', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'with', 'nitrendipine', 'in', 'borderline', 'hypertensive', 'patients', 'with', 'IDDM-type', 'diabetes', 'mellitus', '.']","(9, 14)","(74, 115)",-1,ss_i,1286547,Title,0,test,gold,4638.0
1354,"Reduced platelet thromboxane formation after long-term administration of a dihydropyridine calcium channel blocker : a prospective , double-blind , placebo-controlled study with",nitrendipine,in borderline hypertensive patients with IDDM-type diabetes mellitus .,"['Reduced', 'platelet', 'thromboxane', 'formation', 'after', 'long-term', 'administration', 'of', 'a', 'dihydropyridine', 'calcium', 'channel', 'blocker', ':', 'a', 'prospective', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'with', 'nitrendipine', 'in', 'borderline', 'hypertensive', 'patients', 'with', 'IDDM-type', 'diabetes', 'mellitus', '.']","(22, 23)","(177, 189)",-1,ss_i,1286547,Title,0,test,gold,
1355,Reduced,platelet thromboxane formation,"after long-term administration of a dihydropyridine calcium channel blocker : a prospective , double-blind , placebo-controlled study with nitrendipine in borderline hypertensive patients with IDDM-type diabetes mellitus .","['Reduced', 'platelet', 'thromboxane', 'formation', 'after', 'long-term', 'administration', 'of', 'a', 'dihydropyridine', 'calcium', 'channel', 'blocker', ':', 'a', 'prospective', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'with', 'nitrendipine', 'in', 'borderline', 'hypertensive', 'patients', 'with', 'IDDM-type', 'diabetes', 'mellitus', '.']","(1, 4)","(7, 37)",-1,ss_o,1286547,Title,0,test,gold,6630.0
1356,"Reduced platelet thromboxane formation after long-term administration of a dihydropyridine calcium channel blocker : a prospective , double-blind , placebo-controlled study with nitrendipine in",borderline hypertensive patients with IDDM-type diabetes mellitus .,,"['Reduced', 'platelet', 'thromboxane', 'formation', 'after', 'long-term', 'administration', 'of', 'a', 'dihydropyridine', 'calcium', 'channel', 'blocker', ':', 'a', 'prospective', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'with', 'nitrendipine', 'in', 'borderline', 'hypertensive', 'patients', 'with', 'IDDM-type', 'diabetes', 'mellitus', '.']","(24, 32)","(193, 260)",-1,hl_p,1286547,Title,0,test,gold,6919.0
1357,Reduced platelet thromboxane formation after long-term administration of a,dihydropyridine calcium channel blocker,": a prospective , double-blind , placebo-controlled study with nitrendipine in borderline hypertensive patients with IDDM-type diabetes mellitus .","['Reduced', 'platelet', 'thromboxane', 'formation', 'after', 'long-term', 'administration', 'of', 'a', 'dihydropyridine', 'calcium', 'channel', 'blocker', ':', 'a', 'prospective', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'with', 'nitrendipine', 'in', 'borderline', 'hypertensive', 'patients', 'with', 'IDDM-type', 'diabetes', 'mellitus', '.']","(9, 13)","(74, 113)",-1,hl_i,1286547,Title,0,test,gold,4639.0
1358,"Reduced platelet thromboxane formation after long-term administration of a dihydropyridine calcium channel blocker : a prospective , double-blind , placebo-controlled study with",nitrendipine,in borderline hypertensive patients with IDDM-type diabetes mellitus .,"['Reduced', 'platelet', 'thromboxane', 'formation', 'after', 'long-term', 'administration', 'of', 'a', 'dihydropyridine', 'calcium', 'channel', 'blocker', ':', 'a', 'prospective', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'with', 'nitrendipine', 'in', 'borderline', 'hypertensive', 'patients', 'with', 'IDDM-type', 'diabetes', 'mellitus', '.']","(22, 23)","(177, 189)",-1,hl_i,1286547,Title,0,test,gold,
1359,Reduced,platelet thromboxane formation,"after long-term administration of a dihydropyridine calcium channel blocker : a prospective , double-blind , placebo-controlled study with nitrendipine in borderline hypertensive patients with IDDM-type diabetes mellitus .","['Reduced', 'platelet', 'thromboxane', 'formation', 'after', 'long-term', 'administration', 'of', 'a', 'dihydropyridine', 'calcium', 'channel', 'blocker', ':', 'a', 'prospective', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'with', 'nitrendipine', 'in', 'borderline', 'hypertensive', 'patients', 'with', 'IDDM-type', 'diabetes', 'mellitus', '.']","(1, 4)","(7, 37)",-1,hl_o,1286547,Title,0,test,gold,6631.0
1360,,Twenty-nine IDDM patients with borderline hypertension,were randomly allocated to placebo or nitrendipine treatment .,"['Twenty-nine', 'IDDM', 'patients', 'with', 'borderline', 'hypertension', 'were', 'randomly', 'allocated', 'to', 'placebo', 'or', 'nitrendipine', 'treatment', '.']","(0, 6)","(0, 54)",-1,ss_p,1286547,Abstract,0,test,gold,6920.0
1361,Twenty-nine IDDM patients with borderline hypertension were randomly allocated to,placebo,or nitrendipine treatment .,"['Twenty-nine', 'IDDM', 'patients', 'with', 'borderline', 'hypertension', 'were', 'randomly', 'allocated', 'to', 'placebo', 'or', 'nitrendipine', 'treatment', '.']","(10, 11)","(81, 88)",-1,ss_i,1286547,Abstract,0,test,gold,4413.0
1362,Twenty-nine IDDM patients with borderline hypertension were randomly allocated to placebo or,nitrendipine,treatment .,"['Twenty-nine', 'IDDM', 'patients', 'with', 'borderline', 'hypertension', 'were', 'randomly', 'allocated', 'to', 'placebo', 'or', 'nitrendipine', 'treatment', '.']","(12, 13)","(92, 104)",-1,ss_i,1286547,Abstract,0,test,gold,
1363,,Twenty-nine IDDM patients with borderline hypertension,were randomly allocated to placebo or nitrendipine treatment .,"['Twenty-nine', 'IDDM', 'patients', 'with', 'borderline', 'hypertension', 'were', 'randomly', 'allocated', 'to', 'placebo', 'or', 'nitrendipine', 'treatment', '.']","(0, 6)","(0, 54)",-1,hl_p,1286547,Abstract,0,test,gold,6921.0
1364,Twenty-nine IDDM patients with borderline hypertension were randomly allocated to,placebo,or nitrendipine treatment .,"['Twenty-nine', 'IDDM', 'patients', 'with', 'borderline', 'hypertension', 'were', 'randomly', 'allocated', 'to', 'placebo', 'or', 'nitrendipine', 'treatment', '.']","(10, 11)","(81, 88)",-1,hl_i,1286547,Abstract,0,test,gold,4412.0
1365,Twenty-nine IDDM patients with borderline hypertension were randomly allocated to placebo or,nitrendipine,treatment .,"['Twenty-nine', 'IDDM', 'patients', 'with', 'borderline', 'hypertension', 'were', 'randomly', 'allocated', 'to', 'placebo', 'or', 'nitrendipine', 'treatment', '.']","(12, 13)","(92, 104)",-1,hl_i,1286547,Abstract,0,test,gold,
1366,,Nitrendipine,was given orally at a dosage of 20 mg once daily over 4 weeks .,"['Nitrendipine', 'was', 'given', 'orally', 'at', 'a', 'dosage', 'of', '20', 'mg', 'once', 'daily', 'over', '4', 'weeks', '.']","(0, 1)","(0, 12)",-1,ss_i,1286547,Abstract,1,test,gold,
1367,,Nitrendipine,was given orally at a dosage of 20 mg once daily over 4 weeks .,"['Nitrendipine', 'was', 'given', 'orally', 'at', 'a', 'dosage', 'of', '20', 'mg', 'once', 'daily', 'over', '4', 'weeks', '.']","(0, 1)","(0, 12)",-1,hl_i,1286547,Abstract,1,test,gold,
1368,,Stimulated platelet thromboxane formation,"at rest and after standardized , non exhausting exercise was measured by standard methods .","['Stimulated', 'platelet', 'thromboxane', 'formation', 'at', 'rest', 'and', 'after', 'standardized', ',', 'non', 'exhausting', 'exercise', 'was', 'measured', 'by', 'standard', 'methods', '.']","(0, 4)","(0, 41)",-1,ss_o,1286547,Abstract,2,test,gold,6632.0
1369,"Stimulated platelet thromboxane formation at rest and after standardized ,",non exhausting exercise,was measured by standard methods .,"['Stimulated', 'platelet', 'thromboxane', 'formation', 'at', 'rest', 'and', 'after', 'standardized', ',', 'non', 'exhausting', 'exercise', 'was', 'measured', 'by', 'standard', 'methods', '.']","(10, 13)","(74, 97)",-1,ss_o,1286547,Abstract,2,test,gold,2790.0
1370,,Stimulated platelet thromboxane formation,"at rest and after standardized , non exhausting exercise was measured by standard methods .","['Stimulated', 'platelet', 'thromboxane', 'formation', 'at', 'rest', 'and', 'after', 'standardized', ',', 'non', 'exhausting', 'exercise', 'was', 'measured', 'by', 'standard', 'methods', '.']","(0, 4)","(0, 41)",-1,hl_o,1286547,Abstract,2,test,gold,6633.0
1371,"In addition ,",plasma levels of platelet factor 4 and aggregation responses to collagen and ADP,were determined .,"['In', 'addition', ',', 'plasma', 'levels', 'of', 'platelet', 'factor', '4', 'and', 'aggregation', 'responses', 'to', 'collagen', 'and', 'ADP', 'were', 'determined', '.']","(3, 16)","(13, 93)",-1,ss_o,1286547,Abstract,3,test,gold,6536.0
1372,"In addition ,",plasma levels of platelet factor 4 and aggregation responses to collagen and ADP,were determined .,"['In', 'addition', ',', 'plasma', 'levels', 'of', 'platelet', 'factor', '4', 'and', 'aggregation', 'responses', 'to', 'collagen', 'and', 'ADP', 'were', 'determined', '.']","(3, 16)","(13, 93)",-1,hl_o,1286547,Abstract,3,test,gold,6537.0
1373,In the treatment group,thromboxane formation,after stimulation with collagen ( 0.3 and 1.0 micrograms/ml ) and 1 mM arachidonic acid ( AA ) was reduced in the resting state .,"['In', 'the', 'treatment', 'group', 'thromboxane', 'formation', 'after', 'stimulation', 'with', 'collagen', '(', '0.3', 'and', '1.0', 'micrograms/ml', ')', 'and', '1', 'mM', 'arachidonic', 'acid', '(', 'AA', ')', 'was', 'reduced', 'in', 'the', 'resting', 'state', '.']","(4, 6)","(22, 43)",-1,ss_o,1286547,Abstract,4,test,gold,3188.0
1374,In the treatment group,thromboxane formation,after stimulation with collagen ( 0.3 and 1.0 micrograms/ml ) and 1 mM arachidonic acid ( AA ) was reduced in the resting state .,"['In', 'the', 'treatment', 'group', 'thromboxane', 'formation', 'after', 'stimulation', 'with', 'collagen', '(', '0.3', 'and', '1.0', 'micrograms/ml', ')', 'and', '1', 'mM', 'arachidonic', 'acid', '(', 'AA', ')', 'was', 'reduced', 'in', 'the', 'resting', 'state', '.']","(4, 6)","(22, 43)",-1,hl_o,1286547,Abstract,4,test,gold,3189.0
1375,Exercise induced change of thromboxane synthesis in response to 1.0 micrograms/ml collagen was significantly lower as compared to,placebo,( p < 0.05 ) .,"['Exercise', 'induced', 'change', 'of', 'thromboxane', 'synthesis', 'in', 'response', 'to', '1.0', 'micrograms/ml', 'collagen', 'was', 'significantly', 'lower', 'as', 'compared', 'to', 'placebo', '(', 'p', '<', '0.05', ')', '.']","(18, 19)","(129, 136)",-1,ss_i,1286547,Abstract,5,test,gold,4411.0
1376,,Exercise induced change of thromboxane synthesis,in response to 1.0 micrograms/ml collagen was significantly lower as compared to placebo ( p < 0.05 ) .,"['Exercise', 'induced', 'change', 'of', 'thromboxane', 'synthesis', 'in', 'response', 'to', '1.0', 'micrograms/ml', 'collagen', 'was', 'significantly', 'lower', 'as', 'compared', 'to', 'placebo', '(', 'p', '<', '0.05', ')', '.']","(0, 6)","(0, 48)",-1,ss_o,1286547,Abstract,5,test,gold,6628.0
1377,Exercise induced change of thromboxane synthesis in response to 1.0 micrograms/ml collagen was significantly lower as compared to,placebo,( p < 0.05 ) .,"['Exercise', 'induced', 'change', 'of', 'thromboxane', 'synthesis', 'in', 'response', 'to', '1.0', 'micrograms/ml', 'collagen', 'was', 'significantly', 'lower', 'as', 'compared', 'to', 'placebo', '(', 'p', '<', '0.05', ')', '.']","(18, 19)","(129, 136)",-1,hl_i,1286547,Abstract,5,test,gold,4410.0
1378,,Exercise induced change of thromboxane synthesis,in response to 1.0 micrograms/ml collagen was significantly lower as compared to placebo ( p < 0.05 ) .,"['Exercise', 'induced', 'change', 'of', 'thromboxane', 'synthesis', 'in', 'response', 'to', '1.0', 'micrograms/ml', 'collagen', 'was', 'significantly', 'lower', 'as', 'compared', 'to', 'placebo', '(', 'p', '<', '0.05', ')', '.']","(0, 6)","(0, 48)",-1,hl_o,1286547,Abstract,5,test,gold,6629.0
1379,"In parallel ,",PF4 plasma levels,were significantly lowered ( p < 0.05 ) .,"['In', 'parallel', ',', 'PF4', 'plasma', 'levels', 'were', 'significantly', 'lowered', '(', 'p', '<', '0.05', ')', '.']","(3, 6)","(13, 30)",-1,ss_o,1286547,Abstract,6,test,gold,4457.0
1380,"In parallel ,",PF4 plasma levels,were significantly lowered ( p < 0.05 ) .,"['In', 'parallel', ',', 'PF4', 'plasma', 'levels', 'were', 'significantly', 'lowered', '(', 'p', '<', '0.05', ')', '.']","(3, 6)","(13, 30)",-1,hl_o,1286547,Abstract,6,test,gold,4458.0
1381,Whole blood aggregation after collagen stimulation ( 1.0 micrograms/ml ) was reduced after 4 weeks of,nitrendipine,"treatment , but ADP ( 5 microM ) induced aggregation was not .","['Whole', 'blood', 'aggregation', 'after', 'collagen', 'stimulation', '(', '1.0', 'micrograms/ml', ')', 'was', 'reduced', 'after', '4', 'weeks', 'of', 'nitrendipine', 'treatment', ',', 'but', 'ADP', '(', '5', 'microM', ')', 'induced', 'aggregation', 'was', 'not', '.']","(16, 17)","(101, 113)",-1,ss_i,1286547,Abstract,7,test,gold,
1382,,Whole blood aggregation after collagen stimulation,"( 1.0 micrograms/ml ) was reduced after 4 weeks of nitrendipine treatment , but ADP ( 5 microM ) induced aggregation was not .","['Whole', 'blood', 'aggregation', 'after', 'collagen', 'stimulation', '(', '1.0', 'micrograms/ml', ')', 'was', 'reduced', 'after', '4', 'weeks', 'of', 'nitrendipine', 'treatment', ',', 'but', 'ADP', '(', '5', 'microM', ')', 'induced', 'aggregation', 'was', 'not', '.']","(0, 6)","(0, 50)",-1,ss_o,1286547,Abstract,7,test,gold,6624.0
1383,"Whole blood aggregation after collagen stimulation ( 1.0 micrograms/ml ) was reduced after 4 weeks of nitrendipine treatment , but ADP ( 5 microM ) induced",aggregation,was not .,"['Whole', 'blood', 'aggregation', 'after', 'collagen', 'stimulation', '(', '1.0', 'micrograms/ml', ')', 'was', 'reduced', 'after', '4', 'weeks', 'of', 'nitrendipine', 'treatment', ',', 'but', 'ADP', '(', '5', 'microM', ')', 'induced', 'aggregation', 'was', 'not', '.']","(26, 27)","(155, 166)",-1,ss_o,1286547,Abstract,7,test,gold,1264.0
1384,Whole blood aggregation after collagen stimulation ( 1.0 micrograms/ml ) was reduced after 4 weeks of,nitrendipine,"treatment , but ADP ( 5 microM ) induced aggregation was not .","['Whole', 'blood', 'aggregation', 'after', 'collagen', 'stimulation', '(', '1.0', 'micrograms/ml', ')', 'was', 'reduced', 'after', '4', 'weeks', 'of', 'nitrendipine', 'treatment', ',', 'but', 'ADP', '(', '5', 'microM', ')', 'induced', 'aggregation', 'was', 'not', '.']","(16, 17)","(101, 113)",-1,hl_i,1286547,Abstract,7,test,gold,
1385,,Whole blood aggregation after collagen stimulation,"( 1.0 micrograms/ml ) was reduced after 4 weeks of nitrendipine treatment , but ADP ( 5 microM ) induced aggregation was not .","['Whole', 'blood', 'aggregation', 'after', 'collagen', 'stimulation', '(', '1.0', 'micrograms/ml', ')', 'was', 'reduced', 'after', '4', 'weeks', 'of', 'nitrendipine', 'treatment', ',', 'but', 'ADP', '(', '5', 'microM', ')', 'induced', 'aggregation', 'was', 'not', '.']","(0, 6)","(0, 50)",-1,hl_o,1286547,Abstract,7,test,gold,6625.0
1386,"Whole blood aggregation after collagen stimulation ( 1.0 micrograms/ml ) was reduced after 4 weeks of nitrendipine treatment , but ADP ( 5 microM ) induced",aggregation,was not .,"['Whole', 'blood', 'aggregation', 'after', 'collagen', 'stimulation', '(', '1.0', 'micrograms/ml', ')', 'was', 'reduced', 'after', '4', 'weeks', 'of', 'nitrendipine', 'treatment', ',', 'but', 'ADP', '(', '5', 'microM', ')', 'induced', 'aggregation', 'was', 'not', '.']","(26, 27)","(155, 166)",-1,hl_o,1286547,Abstract,7,test,gold,1265.0
1387,These effects of,nitrendipine,were not seen in platelet rich plasma .,"['These', 'effects', 'of', 'nitrendipine', 'were', 'not', 'seen', 'in', 'platelet', 'rich', 'plasma', '.']","(3, 4)","(16, 28)",-1,ss_i,1286547,Abstract,8,test,gold,
1388,These effects of,nitrendipine,were not seen in platelet rich plasma .,"['These', 'effects', 'of', 'nitrendipine', 'were', 'not', 'seen', 'in', 'platelet', 'rich', 'plasma', '.']","(3, 4)","(16, 28)",-1,hl_i,1286547,Abstract,8,test,gold,
1389,In conclusion long-term nitrendipine treatment may inhibit collagen dependent platelet activation in the blood of,diabetic patients with borderline hypertension .,,"['In', 'conclusion', 'long-term', 'nitrendipine', 'treatment', 'may', 'inhibit', 'collagen', 'dependent', 'platelet', 'activation', 'in', 'the', 'blood', 'of', 'diabetic', 'patients', 'with', 'borderline', 'hypertension', '.']","(15, 21)","(113, 161)",-1,ss_p,1286547,Abstract,9,test,gold,6922.0
1390,In conclusion long-term,nitrendipine,treatment may inhibit collagen dependent platelet activation in the blood of diabetic patients with borderline hypertension .,"['In', 'conclusion', 'long-term', 'nitrendipine', 'treatment', 'may', 'inhibit', 'collagen', 'dependent', 'platelet', 'activation', 'in', 'the', 'blood', 'of', 'diabetic', 'patients', 'with', 'borderline', 'hypertension', '.']","(3, 4)","(23, 35)",-1,ss_i,1286547,Abstract,9,test,gold,
1391,In conclusion long-term nitrendipine treatment may inhibit,collagen dependent platelet activation,in the blood of diabetic patients with borderline hypertension .,"['In', 'conclusion', 'long-term', 'nitrendipine', 'treatment', 'may', 'inhibit', 'collagen', 'dependent', 'platelet', 'activation', 'in', 'the', 'blood', 'of', 'diabetic', 'patients', 'with', 'borderline', 'hypertension', '.']","(7, 11)","(58, 96)",-1,ss_o,1286547,Abstract,9,test,gold,6626.0
1392,In conclusion long-term nitrendipine treatment may inhibit collagen dependent platelet activation in the blood of,diabetic patients with borderline hypertension .,,"['In', 'conclusion', 'long-term', 'nitrendipine', 'treatment', 'may', 'inhibit', 'collagen', 'dependent', 'platelet', 'activation', 'in', 'the', 'blood', 'of', 'diabetic', 'patients', 'with', 'borderline', 'hypertension', '.']","(15, 21)","(113, 161)",-1,hl_p,1286547,Abstract,9,test,gold,6923.0
1393,In conclusion long-term,nitrendipine,treatment may inhibit collagen dependent platelet activation in the blood of diabetic patients with borderline hypertension .,"['In', 'conclusion', 'long-term', 'nitrendipine', 'treatment', 'may', 'inhibit', 'collagen', 'dependent', 'platelet', 'activation', 'in', 'the', 'blood', 'of', 'diabetic', 'patients', 'with', 'borderline', 'hypertension', '.']","(3, 4)","(23, 35)",-1,hl_i,1286547,Abstract,9,test,gold,
1394,In conclusion long-term nitrendipine treatment may inhibit,collagen dependent platelet activation,in the blood of diabetic patients with borderline hypertension .,"['In', 'conclusion', 'long-term', 'nitrendipine', 'treatment', 'may', 'inhibit', 'collagen', 'dependent', 'platelet', 'activation', 'in', 'the', 'blood', 'of', 'diabetic', 'patients', 'with', 'borderline', 'hypertension', '.']","(7, 11)","(58, 96)",-1,hl_o,1286547,Abstract,9,test,gold,6627.0
1395,Gastric dysrhythmia in,infants with gastrointestinal diseases,measured by epigastric impedance .,"['Gastric', 'dysrhythmia', 'in', 'infants', 'with', 'gastrointestinal', 'diseases', 'measured', 'by', 'epigastric', 'impedance', '.']","(3, 7)","(22, 60)",-1,ss_p,12960652,Title,0,test,gold,7038.0
1396,,Gastric dysrhythmia,in infants with gastrointestinal diseases measured by epigastric impedance .,"['Gastric', 'dysrhythmia', 'in', 'infants', 'with', 'gastrointestinal', 'diseases', 'measured', 'by', 'epigastric', 'impedance', '.']","(0, 2)","(0, 19)",-1,ss_o,12960652,Title,0,test,gold,3193.0
1397,Gastric dysrhythmia in infants with gastrointestinal diseases measured by,epigastric impedance .,,"['Gastric', 'dysrhythmia', 'in', 'infants', 'with', 'gastrointestinal', 'diseases', 'measured', 'by', 'epigastric', 'impedance', '.']","(9, 12)","(73, 95)",-1,ss_o,12960652,Title,0,test,gold,1749.0
1398,Gastric dysrhythmia in,infants,with gastrointestinal diseases measured by epigastric impedance .,"['Gastric', 'dysrhythmia', 'in', 'infants', 'with', 'gastrointestinal', 'diseases', 'measured', 'by', 'epigastric', 'impedance', '.']","(3, 4)","(22, 29)",-1,hl_p,12960652,Title,0,test,gold,2167.0
1399,Gastric dysrhythmia in infants with,gastrointestinal diseases,measured by epigastric impedance .,"['Gastric', 'dysrhythmia', 'in', 'infants', 'with', 'gastrointestinal', 'diseases', 'measured', 'by', 'epigastric', 'impedance', '.']","(5, 7)","(35, 60)",-1,hl_p,12960652,Title,0,test,gold,3432.0
1400,Gastric dysrhythmia in infants with gastrointestinal diseases measured by,epigastric impedance,.,"['Gastric', 'dysrhythmia', 'in', 'infants', 'with', 'gastrointestinal', 'diseases', 'measured', 'by', 'epigastric', 'impedance', '.']","(9, 11)","(73, 93)",-1,hl_i,12960652,Title,0,test,gold,1750.0
1401,BACKGROUND Gastrointestinal symptoms have been reported in association with,myoelectrical dysrhythmia,", where different types of gastric electrical activity have been described .","['BACKGROUND', 'Gastrointestinal', 'symptoms', 'have', 'been', 'reported', 'in', 'association', 'with', 'myoelectrical', 'dysrhythmia', ',', 'where', 'different', 'types', 'of', 'gastric', 'electrical', 'activity', 'have', 'been', 'described', '.']","(9, 11)","(75, 100)",-1,ss_o,12960652,Abstract,0,test,gold,72.0
1402,"BACKGROUND Gastrointestinal symptoms have been reported in association with myoelectrical dysrhythmia , where different types of",gastric electrical activity,have been described .,"['BACKGROUND', 'Gastrointestinal', 'symptoms', 'have', 'been', 'reported', 'in', 'association', 'with', 'myoelectrical', 'dysrhythmia', ',', 'where', 'different', 'types', 'of', 'gastric', 'electrical', 'activity', 'have', 'been', 'described', '.']","(16, 19)","(128, 155)",-1,ss_o,12960652,Abstract,0,test,gold,3196.0
1403,These types of,gastric myoelectrical activity and dysrhythmia,can be measured by electrogastrography using cutaneous electrodes .,"['These', 'types', 'of', 'gastric', 'myoelectrical', 'activity', 'and', 'dysrhythmia', 'can', 'be', 'measured', 'by', 'electrogastrography', 'using', 'cutaneous', 'electrodes', '.']","(3, 8)","(14, 60)",-1,ss_o,12960652,Abstract,1,test,gold,3194.0
1404,These types of gastric myoelectrical activity and dysrhythmia can be measured by,electrogastrography,using cutaneous electrodes .,"['These', 'types', 'of', 'gastric', 'myoelectrical', 'activity', 'and', 'dysrhythmia', 'can', 'be', 'measured', 'by', 'electrogastrography', 'using', 'cutaneous', 'electrodes', '.']","(12, 13)","(80, 99)",-1,ss_o,12960652,Abstract,1,test,gold,
1405,,Epigastric impedance,is a non-invasive method used to study gastric emptying time and gastric phasic activity .,"['Epigastric', 'impedance', 'is', 'a', 'non-invasive', 'method', 'used', 'to', 'study', 'gastric', 'emptying', 'time', 'and', 'gastric', 'phasic', 'activity', '.']","(0, 2)","(0, 20)",-1,ss_i,12960652,Abstract,2,test,gold,1740.0
1406,,Epigastric impedance,is a non-invasive method used to study gastric emptying time and gastric phasic activity .,"['Epigastric', 'impedance', 'is', 'a', 'non-invasive', 'method', 'used', 'to', 'study', 'gastric', 'emptying', 'time', 'and', 'gastric', 'phasic', 'activity', '.']","(0, 2)","(0, 20)",-1,ss_o,12960652,Abstract,2,test,gold,1741.0
1407,Epigastric impedance is a non-invasive method used to study,gastric emptying time and gastric phasic activity .,,"['Epigastric', 'impedance', 'is', 'a', 'non-invasive', 'method', 'used', 'to', 'study', 'gastric', 'emptying', 'time', 'and', 'gastric', 'phasic', 'activity', '.']","(9, 17)","(59, 110)",-1,ss_o,12960652,Abstract,2,test,gold,7011.0
1408,,Epigastric impedance,is a non-invasive method used to study gastric emptying time and gastric phasic activity .,"['Epigastric', 'impedance', 'is', 'a', 'non-invasive', 'method', 'used', 'to', 'study', 'gastric', 'emptying', 'time', 'and', 'gastric', 'phasic', 'activity', '.']","(0, 2)","(0, 20)",-1,hl_i,12960652,Abstract,2,test,gold,1739.0
1409,"At present no study of gastric dysrhythmia , measured with epigastric impedance , has been presented , and the purpose of the present study was to investigate gastric rhythms by means of impedance gastrography in","control infants , compared to infants with different gastrointestinal diseases , before and after treatment of their disease .",,"['At', 'present', 'no', 'study', 'of', 'gastric', 'dysrhythmia', ',', 'measured', 'with', 'epigastric', 'impedance', ',', 'has', 'been', 'presented', ',', 'and', 'the', 'purpose', 'of', 'the', 'present', 'study', 'was', 'to', 'investigate', 'gastric', 'rhythms', 'by', 'means', 'of', 'impedance', 'gastrography', 'in', 'control', 'infants', ',', 'compared', 'to', 'infants', 'with', 'different', 'gastrointestinal', 'diseases', ',', 'before', 'and', 'after', 'treatment', 'of', 'their', 'disease', '.']","(35, 54)","(212, 338)",-1,ss_p,12960652,Abstract,3,test,gold,5937.0
1410,"At present no study of gastric dysrhythmia , measured with",epigastric impedance,", has been presented , and the purpose of the present study was to investigate gastric rhythms by means of impedance gastrography in control infants , compared to infants with different gastrointestinal diseases , before and after treatment of their disease .","['At', 'present', 'no', 'study', 'of', 'gastric', 'dysrhythmia', ',', 'measured', 'with', 'epigastric', 'impedance', ',', 'has', 'been', 'presented', ',', 'and', 'the', 'purpose', 'of', 'the', 'present', 'study', 'was', 'to', 'investigate', 'gastric', 'rhythms', 'by', 'means', 'of', 'impedance', 'gastrography', 'in', 'control', 'infants', ',', 'compared', 'to', 'infants', 'with', 'different', 'gastrointestinal', 'diseases', ',', 'before', 'and', 'after', 'treatment', 'of', 'their', 'disease', '.']","(10, 12)","(58, 78)",-1,ss_i,12960652,Abstract,3,test,gold,1748.0
1411,At present no study of,gastric dysrhythmia,", measured with epigastric impedance , has been presented , and the purpose of the present study was to investigate gastric rhythms by means of impedance gastrography in control infants , compared to infants with different gastrointestinal diseases , before and after treatment of their disease .","['At', 'present', 'no', 'study', 'of', 'gastric', 'dysrhythmia', ',', 'measured', 'with', 'epigastric', 'impedance', ',', 'has', 'been', 'presented', ',', 'and', 'the', 'purpose', 'of', 'the', 'present', 'study', 'was', 'to', 'investigate', 'gastric', 'rhythms', 'by', 'means', 'of', 'impedance', 'gastrography', 'in', 'control', 'infants', ',', 'compared', 'to', 'infants', 'with', 'different', 'gastrointestinal', 'diseases', ',', 'before', 'and', 'after', 'treatment', 'of', 'their', 'disease', '.']","(5, 7)","(22, 41)",-1,ss_o,12960652,Abstract,3,test,gold,3195.0
1412,"At present no study of gastric dysrhythmia , measured with",epigastric impedance,", has been presented , and the purpose of the present study was to investigate gastric rhythms by means of impedance gastrography in control infants , compared to infants with different gastrointestinal diseases , before and after treatment of their disease .","['At', 'present', 'no', 'study', 'of', 'gastric', 'dysrhythmia', ',', 'measured', 'with', 'epigastric', 'impedance', ',', 'has', 'been', 'presented', ',', 'and', 'the', 'purpose', 'of', 'the', 'present', 'study', 'was', 'to', 'investigate', 'gastric', 'rhythms', 'by', 'means', 'of', 'impedance', 'gastrography', 'in', 'control', 'infants', ',', 'compared', 'to', 'infants', 'with', 'different', 'gastrointestinal', 'diseases', ',', 'before', 'and', 'after', 'treatment', 'of', 'their', 'disease', '.']","(10, 12)","(58, 78)",-1,ss_o,12960652,Abstract,3,test,gold,1747.0
1413,"At present no study of gastric dysrhythmia , measured with epigastric impedance , has been presented , and the purpose of the present study was to investigate",gastric rhythms,"by means of impedance gastrography in control infants , compared to infants with different gastrointestinal diseases , before and after treatment of their disease .","['At', 'present', 'no', 'study', 'of', 'gastric', 'dysrhythmia', ',', 'measured', 'with', 'epigastric', 'impedance', ',', 'has', 'been', 'presented', ',', 'and', 'the', 'purpose', 'of', 'the', 'present', 'study', 'was', 'to', 'investigate', 'gastric', 'rhythms', 'by', 'means', 'of', 'impedance', 'gastrography', 'in', 'control', 'infants', ',', 'compared', 'to', 'infants', 'with', 'different', 'gastrointestinal', 'diseases', ',', 'before', 'and', 'after', 'treatment', 'of', 'their', 'disease', '.']","(27, 29)","(158, 173)",-1,ss_o,12960652,Abstract,3,test,gold,3192.0
1414,"At present no study of gastric dysrhythmia , measured with epigastric impedance , has been presented , and the purpose of the present study was to investigate gastric rhythms by means of",impedance gastrography,"in control infants , compared to infants with different gastrointestinal diseases , before and after treatment of their disease .","['At', 'present', 'no', 'study', 'of', 'gastric', 'dysrhythmia', ',', 'measured', 'with', 'epigastric', 'impedance', ',', 'has', 'been', 'presented', ',', 'and', 'the', 'purpose', 'of', 'the', 'present', 'study', 'was', 'to', 'investigate', 'gastric', 'rhythms', 'by', 'means', 'of', 'impedance', 'gastrography', 'in', 'control', 'infants', ',', 'compared', 'to', 'infants', 'with', 'different', 'gastrointestinal', 'diseases', ',', 'before', 'and', 'after', 'treatment', 'of', 'their', 'disease', '.']","(32, 34)","(186, 208)",-1,ss_o,12960652,Abstract,3,test,gold,1738.0
1415,"At present no study of gastric dysrhythmia , measured with epigastric impedance , has been presented , and the purpose of the present study was to investigate gastric rhythms by means of impedance gastrography in control infants , compared to",infants with different gastrointestinal diseases,", before and after treatment of their disease .","['At', 'present', 'no', 'study', 'of', 'gastric', 'dysrhythmia', ',', 'measured', 'with', 'epigastric', 'impedance', ',', 'has', 'been', 'presented', ',', 'and', 'the', 'purpose', 'of', 'the', 'present', 'study', 'was', 'to', 'investigate', 'gastric', 'rhythms', 'by', 'means', 'of', 'impedance', 'gastrography', 'in', 'control', 'infants', ',', 'compared', 'to', 'infants', 'with', 'different', 'gastrointestinal', 'diseases', ',', 'before', 'and', 'after', 'treatment', 'of', 'their', 'disease', '.']","(40, 45)","(242, 290)",-1,hl_p,12960652,Abstract,3,test,gold,7039.0
1416,"At present no study of gastric dysrhythmia , measured with",epigastric impedance,", has been presented , and the purpose of the present study was to investigate gastric rhythms by means of impedance gastrography in control infants , compared to infants with different gastrointestinal diseases , before and after treatment of their disease .","['At', 'present', 'no', 'study', 'of', 'gastric', 'dysrhythmia', ',', 'measured', 'with', 'epigastric', 'impedance', ',', 'has', 'been', 'presented', ',', 'and', 'the', 'purpose', 'of', 'the', 'present', 'study', 'was', 'to', 'investigate', 'gastric', 'rhythms', 'by', 'means', 'of', 'impedance', 'gastrography', 'in', 'control', 'infants', ',', 'compared', 'to', 'infants', 'with', 'different', 'gastrointestinal', 'diseases', ',', 'before', 'and', 'after', 'treatment', 'of', 'their', 'disease', '.']","(10, 12)","(58, 78)",-1,hl_i,12960652,Abstract,3,test,gold,1746.0
1417,"At present no study of gastric dysrhythmia , measured with",epigastric impedance,", has been presented , and the purpose of the present study was to investigate gastric rhythms by means of impedance gastrography in control infants , compared to infants with different gastrointestinal diseases , before and after treatment of their disease .","['At', 'present', 'no', 'study', 'of', 'gastric', 'dysrhythmia', ',', 'measured', 'with', 'epigastric', 'impedance', ',', 'has', 'been', 'presented', ',', 'and', 'the', 'purpose', 'of', 'the', 'present', 'study', 'was', 'to', 'investigate', 'gastric', 'rhythms', 'by', 'means', 'of', 'impedance', 'gastrography', 'in', 'control', 'infants', ',', 'compared', 'to', 'infants', 'with', 'different', 'gastrointestinal', 'diseases', ',', 'before', 'and', 'after', 'treatment', 'of', 'their', 'disease', '.']","(10, 12)","(58, 78)",-1,hl_o,12960652,Abstract,3,test,gold,1745.0
1418,METHOD,21 patients ( age 0-2 months ) and 40 healthy infants ( age 0-2 months ),were investigated .,"['METHOD', '21', 'patients', '(', 'age', '0-2', 'months', ')', 'and', '40', 'healthy', 'infants', '(', 'age', '0-2', 'months', ')', 'were', 'investigated', '.']","(1, 17)","(6, 78)",-1,ss_p,12960652,Abstract,4,test,gold,5837.0
1419,METHOD,21 patients,( age 0-2 months ) and 40 healthy infants ( age 0-2 months ) were investigated .,"['METHOD', '21', 'patients', '(', 'age', '0-2', 'months', ')', 'and', '40', 'healthy', 'infants', '(', 'age', '0-2', 'months', ')', 'were', 'investigated', '.']","(1, 3)","(6, 17)",-1,hl_p,12960652,Abstract,4,test,gold,3752.0
1420,METHOD 21 patients (,age 0-2 months,) and 40 healthy infants ( age 0-2 months ) were investigated .,"['METHOD', '21', 'patients', '(', 'age', '0-2', 'months', ')', 'and', '40', 'healthy', 'infants', '(', 'age', '0-2', 'months', ')', 'were', 'investigated', '.']","(4, 7)","(20, 34)",-1,hl_p,12960652,Abstract,4,test,gold,2022.0
1421,METHOD 21 patients ( age 0-2 months ) and,40 healthy infants,( age 0-2 months ) were investigated .,"['METHOD', '21', 'patients', '(', 'age', '0-2', 'months', ')', 'and', '40', 'healthy', 'infants', '(', 'age', '0-2', 'months', ')', 'were', 'investigated', '.']","(9, 12)","(41, 59)",-1,hl_p,12960652,Abstract,4,test,gold,2265.0
1422,METHOD 21 patients ( age 0-2 months ) and 40 healthy infants (,age 0-2 months,) were investigated .,"['METHOD', '21', 'patients', '(', 'age', '0-2', 'months', ')', 'and', '40', 'healthy', 'infants', '(', 'age', '0-2', 'months', ')', 'were', 'investigated', '.']","(13, 16)","(62, 76)",-1,hl_p,12960652,Abstract,4,test,gold,2023.0
1423,The,"patients suffered from partial or total intestinal obstruction , necrotizing enterocolitis or pyloric stenosis.All infants were fasting",and studied during periods of at least one hour .,"['The', 'patients', 'suffered', 'from', 'partial', 'or', 'total', 'intestinal', 'obstruction', ',', 'necrotizing', 'enterocolitis', 'or', 'pyloric', 'stenosis.All', 'infants', 'were', 'fasting', 'and', 'studied', 'during', 'periods', 'of', 'at', 'least', 'one', 'hour', '.']","(1, 18)","(3, 138)",-1,ss_p,12960652,Abstract,5,test,gold,5927.0
1424,The,"patients suffered from partial or total intestinal obstruction , necrotizing enterocolitis or pyloric stenosis.All infants were fasting",and studied during periods of at least one hour .,"['The', 'patients', 'suffered', 'from', 'partial', 'or', 'total', 'intestinal', 'obstruction', ',', 'necrotizing', 'enterocolitis', 'or', 'pyloric', 'stenosis.All', 'infants', 'were', 'fasting', 'and', 'studied', 'during', 'periods', 'of', 'at', 'least', 'one', 'hour', '.']","(1, 18)","(3, 138)",-1,hl_p,12960652,Abstract,5,test,gold,5928.0
1425,The patients were examined in the acute state and after treatment when possible .,,,"['The', 'patients', 'were', 'examined', 'in', 'the', 'acute', 'state', 'and', 'after', 'treatment', 'when', 'possible', '.']",,,,,12960652,Abstract,6,test,gold,
1426,RESULTS A pathologic result was found in 90 % of the patients .,,,"['RESULTS', 'A', 'pathologic', 'result', 'was', 'found', 'in', '90', '%', 'of', 'the', 'patients', '.']",,,,,12960652,Abstract,7,test,gold,
1427,A persistent,phasic activity,"pattern was found in 19 of the 21 patients , high frequency phasic activity in 11 of the 21 patients .","['A', 'persistent', 'phasic', 'activity', 'pattern', 'was', 'found', 'in', '19', 'of', 'the', '21', 'patients', ',', 'high', 'frequency', 'phasic', 'activity', 'in', '11', 'of', 'the', '21', 'patients', '.']","(2, 4)","(12, 27)",-1,ss_o,12960652,Abstract,8,test,gold,2912.0
1428,"A persistent phasic activity pattern was found in 19 of the 21 patients , high",frequency phasic activity,in 11 of the 21 patients .,"['A', 'persistent', 'phasic', 'activity', 'pattern', 'was', 'found', 'in', '19', 'of', 'the', '21', 'patients', ',', 'high', 'frequency', 'phasic', 'activity', 'in', '11', 'of', 'the', '21', 'patients', '.']","(15, 18)","(78, 103)",-1,ss_o,12960652,Abstract,8,test,gold,2904.0
1429,A persistent,phasic activity,"pattern was found in 19 of the 21 patients , high frequency phasic activity in 11 of the 21 patients .","['A', 'persistent', 'phasic', 'activity', 'pattern', 'was', 'found', 'in', '19', 'of', 'the', '21', 'patients', ',', 'high', 'frequency', 'phasic', 'activity', 'in', '11', 'of', 'the', '21', 'patients', '.']","(2, 4)","(12, 27)",-1,hl_o,12960652,Abstract,8,test,gold,2913.0
1430,"A persistent phasic activity pattern was found in 19 of the 21 patients , high",frequency phasic activity,in 11 of the 21 patients .,"['A', 'persistent', 'phasic', 'activity', 'pattern', 'was', 'found', 'in', '19', 'of', 'the', '21', 'patients', ',', 'high', 'frequency', 'phasic', 'activity', 'in', '11', 'of', 'the', '21', 'patients', '.']","(15, 18)","(78, 103)",-1,hl_o,12960652,Abstract,8,test,gold,2905.0
1431,Short-term,phasic activity,was only found in 13 out of 40 of the normal infants ( 32.5 % ) .,"['Short-term', 'phasic', 'activity', 'was', 'only', 'found', 'in', '13', 'out', 'of', '40', 'of', 'the', 'normal', 'infants', '(', '32.5', '%', ')', '.']","(1, 3)","(10, 25)",-1,ss_o,12960652,Abstract,9,test,gold,2911.0
1432,Short-term,phasic activity,was only found in 13 out of 40 of the normal infants ( 32.5 % ) .,"['Short-term', 'phasic', 'activity', 'was', 'only', 'found', 'in', '13', 'out', 'of', '40', 'of', 'the', 'normal', 'infants', '(', '32.5', '%', ')', '.']","(1, 3)","(10, 25)",-1,hl_o,12960652,Abstract,9,test,gold,2910.0
1433,CONCLUSION Using epigastric impedance we found that,infants with partial or total intestinal obstruction,"had gastric phasic activity , which was not found in the control infants .","['CONCLUSION', 'Using', 'epigastric', 'impedance', 'we', 'found', 'that', 'infants', 'with', 'partial', 'or', 'total', 'intestinal', 'obstruction', 'had', 'gastric', 'phasic', 'activity', ',', 'which', 'was', 'not', 'found', 'in', 'the', 'control', 'infants', '.']","(7, 14)","(51, 103)",-1,ss_p,12960652,Abstract,10,test,gold,3720.0
1434,CONCLUSION Using,epigastric impedance,"we found that infants with partial or total intestinal obstruction had gastric phasic activity , which was not found in the control infants .","['CONCLUSION', 'Using', 'epigastric', 'impedance', 'we', 'found', 'that', 'infants', 'with', 'partial', 'or', 'total', 'intestinal', 'obstruction', 'had', 'gastric', 'phasic', 'activity', ',', 'which', 'was', 'not', 'found', 'in', 'the', 'control', 'infants', '.']","(2, 4)","(16, 36)",-1,ss_i,12960652,Abstract,10,test,gold,1744.0
1435,CONCLUSION Using,epigastric impedance,"we found that infants with partial or total intestinal obstruction had gastric phasic activity , which was not found in the control infants .","['CONCLUSION', 'Using', 'epigastric', 'impedance', 'we', 'found', 'that', 'infants', 'with', 'partial', 'or', 'total', 'intestinal', 'obstruction', 'had', 'gastric', 'phasic', 'activity', ',', 'which', 'was', 'not', 'found', 'in', 'the', 'control', 'infants', '.']","(2, 4)","(16, 36)",-1,ss_o,12960652,Abstract,10,test,gold,1743.0
1436,CONCLUSION Using,epigastric impedance,"we found that infants with partial or total intestinal obstruction had gastric phasic activity , which was not found in the control infants .","['CONCLUSION', 'Using', 'epigastric', 'impedance', 'we', 'found', 'that', 'infants', 'with', 'partial', 'or', 'total', 'intestinal', 'obstruction', 'had', 'gastric', 'phasic', 'activity', ',', 'which', 'was', 'not', 'found', 'in', 'the', 'control', 'infants', '.']","(2, 4)","(16, 36)",-1,hl_i,12960652,Abstract,10,test,gold,1742.0
1437,The origin of the,gastric phasic activity patterns,"is unknown , but they may be related to electrical control activity .","['The', 'origin', 'of', 'the', 'gastric', 'phasic', 'activity', 'patterns', 'is', 'unknown', ',', 'but', 'they', 'may', 'be', 'related', 'to', 'electrical', 'control', 'activity', '.']","(4, 8)","(17, 49)",-1,ss_o,12960652,Abstract,11,test,gold,3197.0
1438,Prospective study of short and ultrashort regimens of gonadotropin-releasing hormone agonist in an,in vitro fertilization,program .,"['Prospective', 'study', 'of', 'short', 'and', 'ultrashort', 'regimens', 'of', 'gonadotropin-releasing', 'hormone', 'agonist', 'in', 'an', 'in', 'vitro', 'fertilization', 'program', '.']","(13, 16)","(98, 120)",-1,ss_p,1459268,Title,0,test,gold,3891.0
1439,Prospective study of short and ultrashort regimens of,gonadotropin-releasing hormone agonist,in an in vitro fertilization program .,"['Prospective', 'study', 'of', 'short', 'and', 'ultrashort', 'regimens', 'of', 'gonadotropin-releasing', 'hormone', 'agonist', 'in', 'an', 'in', 'vitro', 'fertilization', 'program', '.']","(8, 11)","(53, 91)",-1,ss_i,1459268,Title,0,test,gold,6620.0
1440,Prospective study of short and ultrashort regimens of,gonadotropin-releasing hormone agonist,in an in vitro fertilization program .,"['Prospective', 'study', 'of', 'short', 'and', 'ultrashort', 'regimens', 'of', 'gonadotropin-releasing', 'hormone', 'agonist', 'in', 'an', 'in', 'vitro', 'fertilization', 'program', '.']","(8, 11)","(53, 91)",-1,hl_i,1459268,Title,0,test,gold,6621.0
1441,OBJECTIVE To assess the usefulness of the ultrashort regimen of gonadotropin-releasing hormone agonist ( GnRH-a ) in ovulation induction in an,in vitro fertilization ( IVF ),program .,"['OBJECTIVE', 'To', 'assess', 'the', 'usefulness', 'of', 'the', 'ultrashort', 'regimen', 'of', 'gonadotropin-releasing', 'hormone', 'agonist', '(', 'GnRH-a', ')', 'in', 'ovulation', 'induction', 'in', 'an', 'in', 'vitro', 'fertilization', '(', 'IVF', ')', 'program', '.']","(21, 27)","(142, 172)",-1,ss_p,1459268,Abstract,0,test,gold,3892.0
1442,OBJECTIVE To assess the usefulness of the ultrashort regimen of,gonadotropin-releasing hormone agonist ( GnRH-a ),in ovulation induction in an in vitro fertilization ( IVF ) program .,"['OBJECTIVE', 'To', 'assess', 'the', 'usefulness', 'of', 'the', 'ultrashort', 'regimen', 'of', 'gonadotropin-releasing', 'hormone', 'agonist', '(', 'GnRH-a', ')', 'in', 'ovulation', 'induction', 'in', 'an', 'in', 'vitro', 'fertilization', '(', 'IVF', ')', 'program', '.']","(10, 16)","(63, 112)",-1,ss_i,1459268,Abstract,0,test,gold,6619.0
1443,OBJECTIVE To assess the,usefulness,of the ultrashort regimen of gonadotropin-releasing hormone agonist ( GnRH-a ) in ovulation induction in an in vitro fertilization ( IVF ) program .,"['OBJECTIVE', 'To', 'assess', 'the', 'usefulness', 'of', 'the', 'ultrashort', 'regimen', 'of', 'gonadotropin-releasing', 'hormone', 'agonist', '(', 'GnRH-a', ')', 'in', 'ovulation', 'induction', 'in', 'an', 'in', 'vitro', 'fertilization', '(', 'IVF', ')', 'program', '.']","(4, 5)","(23, 33)",-1,ss_o,1459268,Abstract,0,test,gold,401.0
1444,OBJECTIVE To assess the usefulness of the ultrashort regimen of gonadotropin-releasing hormone agonist ( GnRH-a ) in ovulation induction in an,in vitro fertilization ( IVF ),program .,"['OBJECTIVE', 'To', 'assess', 'the', 'usefulness', 'of', 'the', 'ultrashort', 'regimen', 'of', 'gonadotropin-releasing', 'hormone', 'agonist', '(', 'GnRH-a', ')', 'in', 'ovulation', 'induction', 'in', 'an', 'in', 'vitro', 'fertilization', '(', 'IVF', ')', 'program', '.']","(21, 27)","(142, 172)",-1,hl_p,1459268,Abstract,0,test,gold,3893.0
1445,OBJECTIVE To assess the usefulness of the ultrashort regimen of,gonadotropin-releasing hormone agonist ( GnRH-a ),in ovulation induction in an in vitro fertilization ( IVF ) program .,"['OBJECTIVE', 'To', 'assess', 'the', 'usefulness', 'of', 'the', 'ultrashort', 'regimen', 'of', 'gonadotropin-releasing', 'hormone', 'agonist', '(', 'GnRH-a', ')', 'in', 'ovulation', 'induction', 'in', 'an', 'in', 'vitro', 'fertilization', '(', 'IVF', ')', 'program', '.']","(10, 16)","(63, 112)",-1,hl_i,1459268,Abstract,0,test,gold,6618.0
1446,OBJECTIVE To assess the,usefulness,of the ultrashort regimen of gonadotropin-releasing hormone agonist ( GnRH-a ) in ovulation induction in an in vitro fertilization ( IVF ) program .,"['OBJECTIVE', 'To', 'assess', 'the', 'usefulness', 'of', 'the', 'ultrashort', 'regimen', 'of', 'gonadotropin-releasing', 'hormone', 'agonist', '(', 'GnRH-a', ')', 'in', 'ovulation', 'induction', 'in', 'an', 'in', 'vitro', 'fertilization', '(', 'IVF', ')', 'program', '.']","(4, 5)","(23, 33)",-1,hl_o,1459268,Abstract,0,test,gold,402.0
1447,DESIGN A prospective randomized trial comparing short and ultrashort regimens of,GnRH-a .,,"['DESIGN', 'A', 'prospective', 'randomized', 'trial', 'comparing', 'short', 'and', 'ultrashort', 'regimens', 'of', 'GnRH-a', '.']","(11, 13)","(80, 88)",-1,ss_i,1459268,Abstract,1,test,gold,
1448,DESIGN A prospective randomized trial comparing short and ultrashort regimens of,GnRH-a .,,"['DESIGN', 'A', 'prospective', 'randomized', 'trial', 'comparing', 'short', 'and', 'ultrashort', 'regimens', 'of', 'GnRH-a', '.']","(11, 13)","(80, 88)",-1,hl_i,1459268,Abstract,1,test,gold,
1449,SETTING,Aberdeen Assisted Reproduction Unit .,,"['SETTING', 'Aberdeen', 'Assisted', 'Reproduction', 'Unit', '.']","(1, 6)","(7, 44)",-1,ss_p,1459268,Abstract,2,test,gold,6247.0
1450,PATIENTS,Forty-eight patients having IVF for the first time,were randomized between the two protocols .,"['PATIENTS', 'Forty-eight', 'patients', 'having', 'IVF', 'for', 'the', 'first', 'time', 'were', 'randomized', 'between', 'the', 'two', 'protocols', '.']","(1, 9)","(8, 58)",-1,ss_p,1459268,Abstract,3,test,gold,5859.0
1451,PATIENTS,Forty-eight patients having IVF for the first time,were randomized between the two protocols .,"['PATIENTS', 'Forty-eight', 'patients', 'having', 'IVF', 'for', 'the', 'first', 'time', 'were', 'randomized', 'between', 'the', 'two', 'protocols', '.']","(1, 9)","(8, 58)",-1,hl_p,1459268,Abstract,3,test,gold,5860.0
1452,MAIN OUTCOME MEASURES,Response to ovarian stimulation and occurrence of spontaneous luteinizing hormone ( LH ) surges .,,"['MAIN', 'OUTCOME', 'MEASURES', 'Response', 'to', 'ovarian', 'stimulation', 'and', 'occurrence', 'of', 'spontaneous', 'luteinizing', 'hormone', '(', 'LH', ')', 'surges', '.']","(3, 18)","(21, 118)",-1,ss_o,1459268,Abstract,4,test,gold,6534.0
1453,MAIN OUTCOME MEASURES,Response to ovarian stimulation and occurrence of spontaneous luteinizing hormone ( LH ) surges .,,"['MAIN', 'OUTCOME', 'MEASURES', 'Response', 'to', 'ovarian', 'stimulation', 'and', 'occurrence', 'of', 'spontaneous', 'luteinizing', 'hormone', '(', 'LH', ')', 'surges', '.']","(3, 18)","(21, 118)",-1,hl_o,1459268,Abstract,4,test,gold,6535.0
1454,RESULTS In,"ovulation induction , fertilization , and pregnancy rates",the ultrashort regimen produces results that were no different to the short regimen but it did not always prevent an LH surge .,"['RESULTS', 'In', 'ovulation', 'induction', ',', 'fertilization', ',', 'and', 'pregnancy', 'rates', 'the', 'ultrashort', 'regimen', 'produces', 'results', 'that', 'were', 'no', 'different', 'to', 'the', 'short', 'regimen', 'but', 'it', 'did', 'not', 'always', 'prevent', 'an', 'LH', 'surge', '.']","(2, 10)","(10, 67)",-1,ss_o,1459268,Abstract,5,test,gold,3889.0
1455,"RESULTS In ovulation induction , fertilization , and pregnancy rates the ultrashort regimen produces results that were no different to the short regimen but it did not always prevent an",LH surge .,,"['RESULTS', 'In', 'ovulation', 'induction', ',', 'fertilization', ',', 'and', 'pregnancy', 'rates', 'the', 'ultrashort', 'regimen', 'produces', 'results', 'that', 'were', 'no', 'different', 'to', 'the', 'short', 'regimen', 'but', 'it', 'did', 'not', 'always', 'prevent', 'an', 'LH', 'surge', '.']","(30, 33)","(185, 195)",-1,ss_o,1459268,Abstract,5,test,gold,963.0
1456,RESULTS In,"ovulation induction , fertilization , and pregnancy rates",the ultrashort regimen produces results that were no different to the short regimen but it did not always prevent an LH surge .,"['RESULTS', 'In', 'ovulation', 'induction', ',', 'fertilization', ',', 'and', 'pregnancy', 'rates', 'the', 'ultrashort', 'regimen', 'produces', 'results', 'that', 'were', 'no', 'different', 'to', 'the', 'short', 'regimen', 'but', 'it', 'did', 'not', 'always', 'prevent', 'an', 'LH', 'surge', '.']","(2, 10)","(10, 67)",-1,hl_o,1459268,Abstract,5,test,gold,3890.0
1457,"RESULTS In ovulation induction , fertilization , and pregnancy rates the ultrashort regimen produces results that were no different to the short regimen but it did not always prevent an",LH surge .,,"['RESULTS', 'In', 'ovulation', 'induction', ',', 'fertilization', ',', 'and', 'pregnancy', 'rates', 'the', 'ultrashort', 'regimen', 'produces', 'results', 'that', 'were', 'no', 'different', 'to', 'the', 'short', 'regimen', 'but', 'it', 'did', 'not', 'always', 'prevent', 'an', 'LH', 'surge', '.']","(30, 33)","(185, 195)",-1,hl_o,1459268,Abstract,5,test,gold,964.0
1458,CONCLUSION The ultrashort regimen can be a useful alternative for ovarian stimulation of,patients undergoing IVF .,,"['CONCLUSION', 'The', 'ultrashort', 'regimen', 'can', 'be', 'a', 'useful', 'alternative', 'for', 'ovarian', 'stimulation', 'of', 'patients', 'undergoing', 'IVF', '.']","(13, 17)","(88, 113)",-1,ss_p,1459268,Abstract,6,test,gold,3615.0
1459,CONCLUSION The ultrashort regimen can be a useful alternative for,ovarian stimulation,of patients undergoing IVF .,"['CONCLUSION', 'The', 'ultrashort', 'regimen', 'can', 'be', 'a', 'useful', 'alternative', 'for', 'ovarian', 'stimulation', 'of', 'patients', 'undergoing', 'IVF', '.']","(10, 12)","(65, 84)",-1,ss_o,1459268,Abstract,6,test,gold,6888.0
1460,CONCLUSION The ultrashort regimen can be a useful alternative for ovarian stimulation of patients,undergoing IVF,.,"['CONCLUSION', 'The', 'ultrashort', 'regimen', 'can', 'be', 'a', 'useful', 'alternative', 'for', 'ovarian', 'stimulation', 'of', 'patients', 'undergoing', 'IVF', '.']","(14, 16)","(97, 111)",-1,hl_p,1459268,Abstract,6,test,gold,3616.0
1461,"Long-term survival in a phase III , randomised study of topotecan versus paclitaxel in",advanced epithelial ovarian carcinoma .,,"['Long-term', 'survival', 'in', 'a', 'phase', 'III', ',', 'randomised', 'study', 'of', 'topotecan', 'versus', 'paclitaxel', 'in', 'advanced', 'epithelial', 'ovarian', 'carcinoma', '.']","(14, 19)","(86, 125)",-1,ss_p,14679127,Title,0,test,gold,6866.0
1462,"Long-term survival in a phase III , randomised study of",topotecan,versus paclitaxel in advanced epithelial ovarian carcinoma .,"['Long-term', 'survival', 'in', 'a', 'phase', 'III', ',', 'randomised', 'study', 'of', 'topotecan', 'versus', 'paclitaxel', 'in', 'advanced', 'epithelial', 'ovarian', 'carcinoma', '.']","(10, 11)","(55, 64)",-1,ss_i,14679127,Title,0,test,gold,5695.0
1463,"Long-term survival in a phase III , randomised study of topotecan versus",paclitaxel,in advanced epithelial ovarian carcinoma .,"['Long-term', 'survival', 'in', 'a', 'phase', 'III', ',', 'randomised', 'study', 'of', 'topotecan', 'versus', 'paclitaxel', 'in', 'advanced', 'epithelial', 'ovarian', 'carcinoma', '.']","(12, 13)","(72, 82)",-1,ss_i,14679127,Title,0,test,gold,5162.0
1464,,Long-term survival,"in a phase III , randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma .","['Long-term', 'survival', 'in', 'a', 'phase', 'III', ',', 'randomised', 'study', 'of', 'topotecan', 'versus', 'paclitaxel', 'in', 'advanced', 'epithelial', 'ovarian', 'carcinoma', '.']","(0, 2)","(0, 18)",-1,ss_o,14679127,Title,0,test,gold,1967.0
1465,"Long-term survival in a phase III , randomised study of topotecan versus paclitaxel in",advanced epithelial ovarian carcinoma .,,"['Long-term', 'survival', 'in', 'a', 'phase', 'III', ',', 'randomised', 'study', 'of', 'topotecan', 'versus', 'paclitaxel', 'in', 'advanced', 'epithelial', 'ovarian', 'carcinoma', '.']","(14, 19)","(86, 125)",-1,hl_p,14679127,Title,0,test,gold,6867.0
1466,"Long-term survival in a phase III , randomised study of",topotecan,versus paclitaxel in advanced epithelial ovarian carcinoma .,"['Long-term', 'survival', 'in', 'a', 'phase', 'III', ',', 'randomised', 'study', 'of', 'topotecan', 'versus', 'paclitaxel', 'in', 'advanced', 'epithelial', 'ovarian', 'carcinoma', '.']","(10, 11)","(55, 64)",-1,hl_i,14679127,Title,0,test,gold,5694.0
1467,"Long-term survival in a phase III , randomised study of topotecan versus",paclitaxel,in advanced epithelial ovarian carcinoma .,"['Long-term', 'survival', 'in', 'a', 'phase', 'III', ',', 'randomised', 'study', 'of', 'topotecan', 'versus', 'paclitaxel', 'in', 'advanced', 'epithelial', 'ovarian', 'carcinoma', '.']","(12, 13)","(72, 82)",-1,hl_i,14679127,Title,0,test,gold,5163.0
1468,BACKGROUND We have continued to monitor the survival of patients randomised in a previously reported multicentre phase III study of topotecan versus paclitaxel in,patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen .,,"['BACKGROUND', 'We', 'have', 'continued', 'to', 'monitor', 'the', 'survival', 'of', 'patients', 'randomised', 'in', 'a', 'previously', 'reported', 'multicentre', 'phase', 'III', 'study', 'of', 'topotecan', 'versus', 'paclitaxel', 'in', 'patients', 'with', 'advanced', 'epithelial', 'ovarian', 'cancer', 'who', 'had', 'failed', 'one', 'prior', 'platinum-based', 'regimen', '.']","(24, 38)","(162, 260)",-1,ss_p,14679127,Abstract,0,test,gold,5923.0
1469,BACKGROUND We have continued to monitor the survival of patients randomised in a previously reported multicentre phase III study of,topotecan,versus paclitaxel in patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen .,"['BACKGROUND', 'We', 'have', 'continued', 'to', 'monitor', 'the', 'survival', 'of', 'patients', 'randomised', 'in', 'a', 'previously', 'reported', 'multicentre', 'phase', 'III', 'study', 'of', 'topotecan', 'versus', 'paclitaxel', 'in', 'patients', 'with', 'advanced', 'epithelial', 'ovarian', 'cancer', 'who', 'had', 'failed', 'one', 'prior', 'platinum-based', 'regimen', '.']","(20, 21)","(131, 140)",-1,ss_i,14679127,Abstract,0,test,gold,5693.0
1470,BACKGROUND We have continued to monitor the survival of patients randomised in a previously reported multicentre phase III study of topotecan versus,paclitaxel,in patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen .,"['BACKGROUND', 'We', 'have', 'continued', 'to', 'monitor', 'the', 'survival', 'of', 'patients', 'randomised', 'in', 'a', 'previously', 'reported', 'multicentre', 'phase', 'III', 'study', 'of', 'topotecan', 'versus', 'paclitaxel', 'in', 'patients', 'with', 'advanced', 'epithelial', 'ovarian', 'cancer', 'who', 'had', 'failed', 'one', 'prior', 'platinum-based', 'regimen', '.']","(22, 23)","(148, 158)",-1,ss_i,14679127,Abstract,0,test,gold,5161.0
1471,BACKGROUND We have continued to monitor the,survival,of patients randomised in a previously reported multicentre phase III study of topotecan versus paclitaxel in patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen .,"['BACKGROUND', 'We', 'have', 'continued', 'to', 'monitor', 'the', 'survival', 'of', 'patients', 'randomised', 'in', 'a', 'previously', 'reported', 'multicentre', 'phase', 'III', 'study', 'of', 'topotecan', 'versus', 'paclitaxel', 'in', 'patients', 'with', 'advanced', 'epithelial', 'ovarian', 'cancer', 'who', 'had', 'failed', 'one', 'prior', 'platinum-based', 'regimen', '.']","(7, 8)","(43, 51)",-1,ss_o,14679127,Abstract,0,test,gold,1965.0
1472,BACKGROUND We have continued to monitor the survival of patients randomised in a previously reported multicentre phase III study of topotecan versus paclitaxel in,patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen .,,"['BACKGROUND', 'We', 'have', 'continued', 'to', 'monitor', 'the', 'survival', 'of', 'patients', 'randomised', 'in', 'a', 'previously', 'reported', 'multicentre', 'phase', 'III', 'study', 'of', 'topotecan', 'versus', 'paclitaxel', 'in', 'patients', 'with', 'advanced', 'epithelial', 'ovarian', 'cancer', 'who', 'had', 'failed', 'one', 'prior', 'platinum-based', 'regimen', '.']","(24, 38)","(162, 260)",-1,hl_p,14679127,Abstract,0,test,gold,5924.0
1473,BACKGROUND We have continued to monitor the survival of patients randomised in a previously reported multicentre phase III study of,topotecan,versus paclitaxel in patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen .,"['BACKGROUND', 'We', 'have', 'continued', 'to', 'monitor', 'the', 'survival', 'of', 'patients', 'randomised', 'in', 'a', 'previously', 'reported', 'multicentre', 'phase', 'III', 'study', 'of', 'topotecan', 'versus', 'paclitaxel', 'in', 'patients', 'with', 'advanced', 'epithelial', 'ovarian', 'cancer', 'who', 'had', 'failed', 'one', 'prior', 'platinum-based', 'regimen', '.']","(20, 21)","(131, 140)",-1,hl_i,14679127,Abstract,0,test,gold,5692.0
1474,BACKGROUND We have continued to monitor the survival of patients randomised in a previously reported multicentre phase III study of topotecan versus,paclitaxel,in patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen .,"['BACKGROUND', 'We', 'have', 'continued', 'to', 'monitor', 'the', 'survival', 'of', 'patients', 'randomised', 'in', 'a', 'previously', 'reported', 'multicentre', 'phase', 'III', 'study', 'of', 'topotecan', 'versus', 'paclitaxel', 'in', 'patients', 'with', 'advanced', 'epithelial', 'ovarian', 'cancer', 'who', 'had', 'failed', 'one', 'prior', 'platinum-based', 'regimen', '.']","(22, 23)","(148, 158)",-1,hl_i,14679127,Abstract,0,test,gold,5160.0
1475,PATIENTS AND METHODS,Patients with bidimensionally measurable disease,were randomised to topotecan ( 1.5 mg/m ( 2 ) /day for 5 days ) or paclitaxel ( 175 mg/m ( 2 ) /day as a 3-h infusion ) every 21 days .,"['PATIENTS', 'AND', 'METHODS', 'Patients', 'with', 'bidimensionally', 'measurable', 'disease', 'were', 'randomised', 'to', 'topotecan', '(', '1.5', 'mg/m', '(', '2', ')', '/day', 'for', '5', 'days', ')', 'or', 'paclitaxel', '(', '175', 'mg/m', '(', '2', ')', '/day', 'as', 'a', '3-h', 'infusion', ')', 'every', '21', 'days', '.']","(3, 8)","(20, 68)",-1,ss_p,14679127,Abstract,1,test,gold,6989.0
1476,PATIENTS AND METHODS Patients with bidimensionally measurable disease were randomised to,topotecan,( 1.5 mg/m ( 2 ) /day for 5 days ) or paclitaxel ( 175 mg/m ( 2 ) /day as a 3-h infusion ) every 21 days .,"['PATIENTS', 'AND', 'METHODS', 'Patients', 'with', 'bidimensionally', 'measurable', 'disease', 'were', 'randomised', 'to', 'topotecan', '(', '1.5', 'mg/m', '(', '2', ')', '/day', 'for', '5', 'days', ')', 'or', 'paclitaxel', '(', '175', 'mg/m', '(', '2', ')', '/day', 'as', 'a', '3-h', 'infusion', ')', 'every', '21', 'days', '.']","(11, 12)","(88, 97)",-1,ss_i,14679127,Abstract,1,test,gold,5691.0
1477,PATIENTS AND METHODS Patients with bidimensionally measurable disease were randomised to topotecan ( 1.5 mg/m ( 2 ) /day for 5 days ) or,paclitaxel,( 175 mg/m ( 2 ) /day as a 3-h infusion ) every 21 days .,"['PATIENTS', 'AND', 'METHODS', 'Patients', 'with', 'bidimensionally', 'measurable', 'disease', 'were', 'randomised', 'to', 'topotecan', '(', '1.5', 'mg/m', '(', '2', ')', '/day', 'for', '5', 'days', ')', 'or', 'paclitaxel', '(', '175', 'mg/m', '(', '2', ')', '/day', 'as', 'a', '3-h', 'infusion', ')', 'every', '21', 'days', '.']","(24, 25)","(136, 146)",-1,ss_i,14679127,Abstract,1,test,gold,5159.0
1478,PATIENTS AND METHODS,Patients with bidimensionally measurable disease,were randomised to topotecan ( 1.5 mg/m ( 2 ) /day for 5 days ) or paclitaxel ( 175 mg/m ( 2 ) /day as a 3-h infusion ) every 21 days .,"['PATIENTS', 'AND', 'METHODS', 'Patients', 'with', 'bidimensionally', 'measurable', 'disease', 'were', 'randomised', 'to', 'topotecan', '(', '1.5', 'mg/m', '(', '2', ')', '/day', 'for', '5', 'days', ')', 'or', 'paclitaxel', '(', '175', 'mg/m', '(', '2', ')', '/day', 'as', 'a', '3-h', 'infusion', ')', 'every', '21', 'days', '.']","(3, 8)","(20, 68)",-1,hl_p,14679127,Abstract,1,test,gold,6990.0
1479,PATIENTS AND METHODS Patients with bidimensionally measurable disease were randomised to,topotecan,( 1.5 mg/m ( 2 ) /day for 5 days ) or paclitaxel ( 175 mg/m ( 2 ) /day as a 3-h infusion ) every 21 days .,"['PATIENTS', 'AND', 'METHODS', 'Patients', 'with', 'bidimensionally', 'measurable', 'disease', 'were', 'randomised', 'to', 'topotecan', '(', '1.5', 'mg/m', '(', '2', ')', '/day', 'for', '5', 'days', ')', 'or', 'paclitaxel', '(', '175', 'mg/m', '(', '2', ')', '/day', 'as', 'a', '3-h', 'infusion', ')', 'every', '21', 'days', '.']","(11, 12)","(88, 97)",-1,hl_i,14679127,Abstract,1,test,gold,5690.0
1480,PATIENTS AND METHODS Patients with bidimensionally measurable disease were randomised to topotecan ( 1.5 mg/m ( 2 ) /day for 5 days ) or,paclitaxel,( 175 mg/m ( 2 ) /day as a 3-h infusion ) every 21 days .,"['PATIENTS', 'AND', 'METHODS', 'Patients', 'with', 'bidimensionally', 'measurable', 'disease', 'were', 'randomised', 'to', 'topotecan', '(', '1.5', 'mg/m', '(', '2', ')', '/day', 'for', '5', 'days', ')', 'or', 'paclitaxel', '(', '175', 'mg/m', '(', '2', ')', '/day', 'as', 'a', '3-h', 'infusion', ')', 'every', '21', 'days', '.']","(24, 25)","(136, 146)",-1,hl_i,14679127,Abstract,1,test,gold,5158.0
1481,Patients were eligible for treatment with the alternate therapy at third line .,,,"['Patients', 'were', 'eligible', 'for', 'treatment', 'with', 'the', 'alternate', 'therapy', 'at', 'third', 'line', '.']",,,,,14679127,Abstract,2,test,gold,
1482,,The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire,"was also used to measure eight symptoms at baseline and during each course ( pain , anorexia , diarrhoea , fatigue , nausea and vomiting , dyspnea , constipation and insomnia ) .","['The', 'European', 'Organisation', 'for', 'Research', 'and', 'Treatment', 'of', 'Cancer', 'Quality', 'of', 'Life', '(', 'EORTC', 'QOL', ')', '-C30', 'questionnaire', 'was', 'also', 'used', 'to', 'measure', 'eight', 'symptoms', 'at', 'baseline', 'and', 'during', 'each', 'course', '(', 'pain', ',', 'anorexia', ',', 'diarrhoea', ',', 'fatigue', ',', 'nausea', 'and', 'vomiting', ',', 'dyspnea', ',', 'constipation', 'and', 'insomnia', ')', '.']","(0, 18)","(0, 111)",-1,ss_o,14679127,Abstract,3,test,gold,6272.0
1483,The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire was also used to measure eight symptoms at baseline and during each course,"( pain , anorexia , diarrhoea , fatigue , nausea and vomiting , dyspnea , constipation and insomnia )",.,"['The', 'European', 'Organisation', 'for', 'Research', 'and', 'Treatment', 'of', 'Cancer', 'Quality', 'of', 'Life', '(', 'EORTC', 'QOL', ')', '-C30', 'questionnaire', 'was', 'also', 'used', 'to', 'measure', 'eight', 'symptoms', 'at', 'baseline', 'and', 'during', 'each', 'course', '(', 'pain', ',', 'anorexia', ',', 'diarrhoea', ',', 'fatigue', ',', 'nausea', 'and', 'vomiting', ',', 'dyspnea', ',', 'constipation', 'and', 'insomnia', ')', '.']","(31, 50)","(186, 287)",-1,ss_o,14679127,Abstract,3,test,gold,7126.0
1484,The,European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire,"was also used to measure eight symptoms at baseline and during each course ( pain , anorexia , diarrhoea , fatigue , nausea and vomiting , dyspnea , constipation and insomnia ) .","['The', 'European', 'Organisation', 'for', 'Research', 'and', 'Treatment', 'of', 'Cancer', 'Quality', 'of', 'Life', '(', 'EORTC', 'QOL', ')', '-C30', 'questionnaire', 'was', 'also', 'used', 'to', 'measure', 'eight', 'symptoms', 'at', 'baseline', 'and', 'during', 'each', 'course', '(', 'pain', ',', 'anorexia', ',', 'diarrhoea', ',', 'fatigue', ',', 'nausea', 'and', 'vomiting', ',', 'dyspnea', ',', 'constipation', 'and', 'insomnia', ')', '.']","(1, 18)","(3, 110)",-1,hl_o,14679127,Abstract,3,test,gold,6273.0
1485,The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire was also used to measure eight symptoms at baseline and during each course (,pain,", anorexia , diarrhoea , fatigue , nausea and vomiting , dyspnea , constipation and insomnia ) .","['The', 'European', 'Organisation', 'for', 'Research', 'and', 'Treatment', 'of', 'Cancer', 'Quality', 'of', 'Life', '(', 'EORTC', 'QOL', ')', '-C30', 'questionnaire', 'was', 'also', 'used', 'to', 'measure', 'eight', 'symptoms', 'at', 'baseline', 'and', 'during', 'each', 'course', '(', 'pain', ',', 'anorexia', ',', 'diarrhoea', ',', 'fatigue', ',', 'nausea', 'and', 'vomiting', ',', 'dyspnea', ',', 'constipation', 'and', 'insomnia', ')', '.']","(32, 33)","(188, 192)",-1,hl_o,14679127,Abstract,3,test,gold,2303.0
1486,"The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire was also used to measure eight symptoms at baseline and during each course ( pain ,",anorexia,", diarrhoea , fatigue , nausea and vomiting , dyspnea , constipation and insomnia ) .","['The', 'European', 'Organisation', 'for', 'Research', 'and', 'Treatment', 'of', 'Cancer', 'Quality', 'of', 'Life', '(', 'EORTC', 'QOL', ')', '-C30', 'questionnaire', 'was', 'also', 'used', 'to', 'measure', 'eight', 'symptoms', 'at', 'baseline', 'and', 'during', 'each', 'course', '(', 'pain', ',', 'anorexia', ',', 'diarrhoea', ',', 'fatigue', ',', 'nausea', 'and', 'vomiting', ',', 'dyspnea', ',', 'constipation', 'and', 'insomnia', ')', '.']","(34, 35)","(195, 203)",-1,hl_o,14679127,Abstract,3,test,gold,2556.0
1487,"The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire was also used to measure eight symptoms at baseline and during each course ( pain , anorexia ,",diarrhoea,", fatigue , nausea and vomiting , dyspnea , constipation and insomnia ) .","['The', 'European', 'Organisation', 'for', 'Research', 'and', 'Treatment', 'of', 'Cancer', 'Quality', 'of', 'Life', '(', 'EORTC', 'QOL', ')', '-C30', 'questionnaire', 'was', 'also', 'used', 'to', 'measure', 'eight', 'symptoms', 'at', 'baseline', 'and', 'during', 'each', 'course', '(', 'pain', ',', 'anorexia', ',', 'diarrhoea', ',', 'fatigue', ',', 'nausea', 'and', 'vomiting', ',', 'dyspnea', ',', 'constipation', 'and', 'insomnia', ')', '.']","(36, 37)","(206, 215)",-1,hl_o,14679127,Abstract,3,test,gold,
1488,"The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire was also used to measure eight symptoms at baseline and during each course ( pain , anorexia , diarrhoea ,",fatigue,", nausea and vomiting , dyspnea , constipation and insomnia ) .","['The', 'European', 'Organisation', 'for', 'Research', 'and', 'Treatment', 'of', 'Cancer', 'Quality', 'of', 'Life', '(', 'EORTC', 'QOL', ')', '-C30', 'questionnaire', 'was', 'also', 'used', 'to', 'measure', 'eight', 'symptoms', 'at', 'baseline', 'and', 'during', 'each', 'course', '(', 'pain', ',', 'anorexia', ',', 'diarrhoea', ',', 'fatigue', ',', 'nausea', 'and', 'vomiting', ',', 'dyspnea', ',', 'constipation', 'and', 'insomnia', ')', '.']","(38, 39)","(218, 225)",-1,hl_o,14679127,Abstract,3,test,gold,2704.0
1489,"The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire was also used to measure eight symptoms at baseline and during each course ( pain , anorexia , diarrhoea , fatigue ,",nausea,"and vomiting , dyspnea , constipation and insomnia ) .","['The', 'European', 'Organisation', 'for', 'Research', 'and', 'Treatment', 'of', 'Cancer', 'Quality', 'of', 'Life', '(', 'EORTC', 'QOL', ')', '-C30', 'questionnaire', 'was', 'also', 'used', 'to', 'measure', 'eight', 'symptoms', 'at', 'baseline', 'and', 'during', 'each', 'course', '(', 'pain', ',', 'anorexia', ',', 'diarrhoea', ',', 'fatigue', ',', 'nausea', 'and', 'vomiting', ',', 'dyspnea', ',', 'constipation', 'and', 'insomnia', ')', '.']","(40, 41)","(228, 234)",-1,hl_o,14679127,Abstract,3,test,gold,2695.0
1490,"The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire was also used to measure eight symptoms at baseline and during each course ( pain , anorexia , diarrhoea , fatigue , nausea and",vomiting,", dyspnea , constipation and insomnia ) .","['The', 'European', 'Organisation', 'for', 'Research', 'and', 'Treatment', 'of', 'Cancer', 'Quality', 'of', 'Life', '(', 'EORTC', 'QOL', ')', '-C30', 'questionnaire', 'was', 'also', 'used', 'to', 'measure', 'eight', 'symptoms', 'at', 'baseline', 'and', 'during', 'each', 'course', '(', 'pain', ',', 'anorexia', ',', 'diarrhoea', ',', 'fatigue', ',', 'nausea', 'and', 'vomiting', ',', 'dyspnea', ',', 'constipation', 'and', 'insomnia', ')', '.']","(42, 43)","(239, 247)",-1,hl_o,14679127,Abstract,3,test,gold,2691.0
1491,"The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire was also used to measure eight symptoms at baseline and during each course ( pain , anorexia , diarrhoea , fatigue , nausea and vomiting ,",dyspnea,", constipation and insomnia ) .","['The', 'European', 'Organisation', 'for', 'Research', 'and', 'Treatment', 'of', 'Cancer', 'Quality', 'of', 'Life', '(', 'EORTC', 'QOL', ')', '-C30', 'questionnaire', 'was', 'also', 'used', 'to', 'measure', 'eight', 'symptoms', 'at', 'baseline', 'and', 'during', 'each', 'course', '(', 'pain', ',', 'anorexia', ',', 'diarrhoea', ',', 'fatigue', ',', 'nausea', 'and', 'vomiting', ',', 'dyspnea', ',', 'constipation', 'and', 'insomnia', ')', '.']","(44, 45)","(250, 257)",-1,hl_o,14679127,Abstract,3,test,gold,3510.0
1492,"The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire was also used to measure eight symptoms at baseline and during each course ( pain , anorexia , diarrhoea , fatigue , nausea and vomiting , dyspnea ,",constipation,and insomnia ) .,"['The', 'European', 'Organisation', 'for', 'Research', 'and', 'Treatment', 'of', 'Cancer', 'Quality', 'of', 'Life', '(', 'EORTC', 'QOL', ')', '-C30', 'questionnaire', 'was', 'also', 'used', 'to', 'measure', 'eight', 'symptoms', 'at', 'baseline', 'and', 'during', 'each', 'course', '(', 'pain', ',', 'anorexia', ',', 'diarrhoea', ',', 'fatigue', ',', 'nausea', 'and', 'vomiting', ',', 'dyspnea', ',', 'constipation', 'and', 'insomnia', ')', '.']","(46, 47)","(260, 272)",-1,hl_o,14679127,Abstract,3,test,gold,2696.0
1493,"The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire was also used to measure eight symptoms at baseline and during each course ( pain , anorexia , diarrhoea , fatigue , nausea and vomiting , dyspnea , constipation and",insomnia,) .,"['The', 'European', 'Organisation', 'for', 'Research', 'and', 'Treatment', 'of', 'Cancer', 'Quality', 'of', 'Life', '(', 'EORTC', 'QOL', ')', '-C30', 'questionnaire', 'was', 'also', 'used', 'to', 'measure', 'eight', 'symptoms', 'at', 'baseline', 'and', 'during', 'each', 'course', '(', 'pain', ',', 'anorexia', ',', 'diarrhoea', ',', 'fatigue', ',', 'nausea', 'and', 'vomiting', ',', 'dyspnea', ',', 'constipation', 'and', 'insomnia', ')', '.']","(48, 49)","(277, 285)",-1,hl_o,14679127,Abstract,3,test,gold,2694.0
1494,RESULTS,A total of 226 patients were evaluable for response .,,"['RESULTS', 'A', 'total', 'of', '226', 'patients', 'were', 'evaluable', 'for', 'response', '.']","(1, 11)","(7, 60)",-1,ss_p,14679127,Abstract,4,test,gold,5841.0
1495,RESULTS A total of,226,patients were evaluable for response .,"['RESULTS', 'A', 'total', 'of', '226', 'patients', 'were', 'evaluable', 'for', 'response', '.']","(4, 5)","(18, 21)",-1,hl_p,14679127,Abstract,4,test,gold,
1496,"Demographic characteristics were similar in both treatment groups , as were results of the",EORTC QOL-30 questionnaire .,,"['Demographic', 'characteristics', 'were', 'similar', 'in', 'both', 'treatment', 'groups', ',', 'as', 'were', 'results', 'of', 'the', 'EORTC', 'QOL-30', 'questionnaire', '.']","(14, 18)","(90, 118)",-1,ss_o,14679127,Abstract,5,test,gold,1845.0
1497,For the,topotecan,"group , median time to progression was 18.9 weeks ( range < 1 to 92.6+ weeks ; 25 % censored ) , and , for paclitaxel , 14.7 weeks ( range < 1 to 137.3+ weeks ; 12.3 % censored ) ; P = 0.076 .","['For', 'the', 'topotecan', 'group', ',', 'median', 'time', 'to', 'progression', 'was', '18.9', 'weeks', '(', 'range', '<', '1', 'to', '92.6+', 'weeks', ';', '25', '%', 'censored', ')', ',', 'and', ',', 'for', 'paclitaxel', ',', '14.7', 'weeks', '(', 'range', '<', '1', 'to', '137.3+', 'weeks', ';', '12.3', '%', 'censored', ')', ';', 'P', '=', '0.076', '.']","(2, 3)","(7, 16)",-1,ss_i,14679127,Abstract,6,test,gold,5689.0
1498,"For the topotecan group , median time to progression was 18.9 weeks ( range < 1 to 92.6+ weeks ; 25 % censored ) , and , for",paclitaxel,", 14.7 weeks ( range < 1 to 137.3+ weeks ; 12.3 % censored ) ; P = 0.076 .","['For', 'the', 'topotecan', 'group', ',', 'median', 'time', 'to', 'progression', 'was', '18.9', 'weeks', '(', 'range', '<', '1', 'to', '92.6+', 'weeks', ';', '25', '%', 'censored', ')', ',', 'and', ',', 'for', 'paclitaxel', ',', '14.7', 'weeks', '(', 'range', '<', '1', 'to', '137.3+', 'weeks', ';', '12.3', '%', 'censored', ')', ';', 'P', '=', '0.076', '.']","(28, 29)","(124, 134)",-1,ss_i,14679127,Abstract,6,test,gold,5157.0
1499,"For the topotecan group , median time to",progression,"was 18.9 weeks ( range < 1 to 92.6+ weeks ; 25 % censored ) , and , for paclitaxel , 14.7 weeks ( range < 1 to 137.3+ weeks ; 12.3 % censored ) ; P = 0.076 .","['For', 'the', 'topotecan', 'group', ',', 'median', 'time', 'to', 'progression', 'was', '18.9', 'weeks', '(', 'range', '<', '1', 'to', '92.6+', 'weeks', ';', '25', '%', 'censored', ')', ',', 'and', ',', 'for', 'paclitaxel', ',', '14.7', 'weeks', '(', 'range', '<', '1', 'to', '137.3+', 'weeks', ';', '12.3', '%', 'censored', ')', ';', 'P', '=', '0.076', '.']","(8, 9)","(40, 51)",-1,ss_o,14679127,Abstract,6,test,gold,3329.0
1500,For the,topotecan,"group , median time to progression was 18.9 weeks ( range < 1 to 92.6+ weeks ; 25 % censored ) , and , for paclitaxel , 14.7 weeks ( range < 1 to 137.3+ weeks ; 12.3 % censored ) ; P = 0.076 .","['For', 'the', 'topotecan', 'group', ',', 'median', 'time', 'to', 'progression', 'was', '18.9', 'weeks', '(', 'range', '<', '1', 'to', '92.6+', 'weeks', ';', '25', '%', 'censored', ')', ',', 'and', ',', 'for', 'paclitaxel', ',', '14.7', 'weeks', '(', 'range', '<', '1', 'to', '137.3+', 'weeks', ';', '12.3', '%', 'censored', ')', ';', 'P', '=', '0.076', '.']","(2, 3)","(7, 16)",-1,hl_i,14679127,Abstract,6,test,gold,5688.0
1501,"For the topotecan group , median time to progression was 18.9 weeks ( range < 1 to 92.6+ weeks ; 25 % censored ) , and , for",paclitaxel,", 14.7 weeks ( range < 1 to 137.3+ weeks ; 12.3 % censored ) ; P = 0.076 .","['For', 'the', 'topotecan', 'group', ',', 'median', 'time', 'to', 'progression', 'was', '18.9', 'weeks', '(', 'range', '<', '1', 'to', '92.6+', 'weeks', ';', '25', '%', 'censored', ')', ',', 'and', ',', 'for', 'paclitaxel', ',', '14.7', 'weeks', '(', 'range', '<', '1', 'to', '137.3+', 'weeks', ';', '12.3', '%', 'censored', ')', ';', 'P', '=', '0.076', '.']","(28, 29)","(124, 134)",-1,hl_i,14679127,Abstract,6,test,gold,5156.0
1502,"For the topotecan group , median time to",progression,"was 18.9 weeks ( range < 1 to 92.6+ weeks ; 25 % censored ) , and , for paclitaxel , 14.7 weeks ( range < 1 to 137.3+ weeks ; 12.3 % censored ) ; P = 0.076 .","['For', 'the', 'topotecan', 'group', ',', 'median', 'time', 'to', 'progression', 'was', '18.9', 'weeks', '(', 'range', '<', '1', 'to', '92.6+', 'weeks', ';', '25', '%', 'censored', ')', ',', 'and', ',', 'for', 'paclitaxel', ',', '14.7', 'weeks', '(', 'range', '<', '1', 'to', '137.3+', 'weeks', ';', '12.3', '%', 'censored', ')', ';', 'P', '=', '0.076', '.']","(8, 9)","(40, 51)",-1,hl_o,14679127,Abstract,6,test,gold,3328.0
1503,"At 4 years post-randomisation , median survival in the",topotecan,"group was 63.0 weeks ( range < 1 to 238.4+ weeks ; 20.5 % censored ) and , for paclitaxel , 53.0 weeks ( range < 1 to 226.3+ weeks ; 12.3 % censored ) ; P = 0.44 .","['At', '4', 'years', 'post-randomisation', ',', 'median', 'survival', 'in', 'the', 'topotecan', 'group', 'was', '63.0', 'weeks', '(', 'range', '<', '1', 'to', '238.4+', 'weeks', ';', '20.5', '%', 'censored', ')', 'and', ',', 'for', 'paclitaxel', ',', '53.0', 'weeks', '(', 'range', '<', '1', 'to', '226.3+', 'weeks', ';', '12.3', '%', 'censored', ')', ';', 'P', '=', '0.44', '.']","(9, 10)","(54, 63)",-1,ss_i,14679127,Abstract,7,test,gold,5687.0
1504,"At 4 years post-randomisation , median survival in the topotecan group was 63.0 weeks ( range < 1 to 238.4+ weeks ; 20.5 % censored ) and , for",paclitaxel,", 53.0 weeks ( range < 1 to 226.3+ weeks ; 12.3 % censored ) ; P = 0.44 .","['At', '4', 'years', 'post-randomisation', ',', 'median', 'survival', 'in', 'the', 'topotecan', 'group', 'was', '63.0', 'weeks', '(', 'range', '<', '1', 'to', '238.4+', 'weeks', ';', '20.5', '%', 'censored', ')', 'and', ',', 'for', 'paclitaxel', ',', '53.0', 'weeks', '(', 'range', '<', '1', 'to', '226.3+', 'weeks', ';', '12.3', '%', 'censored', ')', ';', 'P', '=', '0.44', '.']","(29, 30)","(143, 153)",-1,ss_i,14679127,Abstract,7,test,gold,5155.0
1505,"At 4 years post-randomisation ,",median survival,"in the topotecan group was 63.0 weeks ( range < 1 to 238.4+ weeks ; 20.5 % censored ) and , for paclitaxel , 53.0 weeks ( range < 1 to 226.3+ weeks ; 12.3 % censored ) ; P = 0.44 .","['At', '4', 'years', 'post-randomisation', ',', 'median', 'survival', 'in', 'the', 'topotecan', 'group', 'was', '63.0', 'weeks', '(', 'range', '<', '1', 'to', '238.4+', 'weeks', ';', '20.5', '%', 'censored', ')', 'and', ',', 'for', 'paclitaxel', ',', '53.0', 'weeks', '(', 'range', '<', '1', 'to', '226.3+', 'weeks', ';', '12.3', '%', 'censored', ')', ';', 'P', '=', '0.44', '.']","(5, 7)","(31, 46)",-1,ss_o,14679127,Abstract,7,test,gold,1989.0
1506,"At 4 years post-randomisation , median survival in the",topotecan,"group was 63.0 weeks ( range < 1 to 238.4+ weeks ; 20.5 % censored ) and , for paclitaxel , 53.0 weeks ( range < 1 to 226.3+ weeks ; 12.3 % censored ) ; P = 0.44 .","['At', '4', 'years', 'post-randomisation', ',', 'median', 'survival', 'in', 'the', 'topotecan', 'group', 'was', '63.0', 'weeks', '(', 'range', '<', '1', 'to', '238.4+', 'weeks', ';', '20.5', '%', 'censored', ')', 'and', ',', 'for', 'paclitaxel', ',', '53.0', 'weeks', '(', 'range', '<', '1', 'to', '226.3+', 'weeks', ';', '12.3', '%', 'censored', ')', ';', 'P', '=', '0.44', '.']","(9, 10)","(54, 63)",-1,hl_i,14679127,Abstract,7,test,gold,5686.0
1507,"At 4 years post-randomisation , median survival in the topotecan group was 63.0 weeks ( range < 1 to 238.4+ weeks ; 20.5 % censored ) and , for",paclitaxel,", 53.0 weeks ( range < 1 to 226.3+ weeks ; 12.3 % censored ) ; P = 0.44 .","['At', '4', 'years', 'post-randomisation', ',', 'median', 'survival', 'in', 'the', 'topotecan', 'group', 'was', '63.0', 'weeks', '(', 'range', '<', '1', 'to', '238.4+', 'weeks', ';', '20.5', '%', 'censored', ')', 'and', ',', 'for', 'paclitaxel', ',', '53.0', 'weeks', '(', 'range', '<', '1', 'to', '226.3+', 'weeks', ';', '12.3', '%', 'censored', ')', ';', 'P', '=', '0.44', '.']","(29, 30)","(143, 153)",-1,hl_i,14679127,Abstract,7,test,gold,5154.0
1508,"At 4 years post-randomisation ,",median survival,"in the topotecan group was 63.0 weeks ( range < 1 to 238.4+ weeks ; 20.5 % censored ) and , for paclitaxel , 53.0 weeks ( range < 1 to 226.3+ weeks ; 12.3 % censored ) ; P = 0.44 .","['At', '4', 'years', 'post-randomisation', ',', 'median', 'survival', 'in', 'the', 'topotecan', 'group', 'was', '63.0', 'weeks', '(', 'range', '<', '1', 'to', '238.4+', 'weeks', ';', '20.5', '%', 'censored', ')', 'and', ',', 'for', 'paclitaxel', ',', '53.0', 'weeks', '(', 'range', '<', '1', 'to', '226.3+', 'weeks', ';', '12.3', '%', 'censored', ')', ';', 'P', '=', '0.44', '.']","(5, 7)","(31, 46)",-1,hl_o,14679127,Abstract,7,test,gold,1990.0
1509,CONCLUSION,Topotecan,continues to demonstrate comparable efficacy and survival to paclitaxel with manageable and non-cumulative haematological toxicity .,"['CONCLUSION', 'Topotecan', 'continues', 'to', 'demonstrate', 'comparable', 'efficacy', 'and', 'survival', 'to', 'paclitaxel', 'with', 'manageable', 'and', 'non-cumulative', 'haematological', 'toxicity', '.']","(1, 2)","(10, 19)",-1,ss_i,14679127,Abstract,8,test,gold,160.0
1510,CONCLUSION Topotecan continues to demonstrate comparable efficacy and survival to,paclitaxel,with manageable and non-cumulative haematological toxicity .,"['CONCLUSION', 'Topotecan', 'continues', 'to', 'demonstrate', 'comparable', 'efficacy', 'and', 'survival', 'to', 'paclitaxel', 'with', 'manageable', 'and', 'non-cumulative', 'haematological', 'toxicity', '.']","(10, 11)","(81, 91)",-1,ss_i,14679127,Abstract,8,test,gold,5153.0
1511,CONCLUSION Topotecan continues to demonstrate comparable,efficacy,and survival to paclitaxel with manageable and non-cumulative haematological toxicity .,"['CONCLUSION', 'Topotecan', 'continues', 'to', 'demonstrate', 'comparable', 'efficacy', 'and', 'survival', 'to', 'paclitaxel', 'with', 'manageable', 'and', 'non-cumulative', 'haematological', 'toxicity', '.']","(6, 7)","(56, 64)",-1,ss_o,14679127,Abstract,8,test,gold,4831.0
1512,CONCLUSION Topotecan continues to demonstrate comparable efficacy and,survival,to paclitaxel with manageable and non-cumulative haematological toxicity .,"['CONCLUSION', 'Topotecan', 'continues', 'to', 'demonstrate', 'comparable', 'efficacy', 'and', 'survival', 'to', 'paclitaxel', 'with', 'manageable', 'and', 'non-cumulative', 'haematological', 'toxicity', '.']","(8, 9)","(69, 77)",-1,ss_o,14679127,Abstract,8,test,gold,1964.0
1513,CONCLUSION Topotecan continues to demonstrate comparable efficacy and survival to paclitaxel with manageable and non-cumulative,haematological toxicity .,,"['CONCLUSION', 'Topotecan', 'continues', 'to', 'demonstrate', 'comparable', 'efficacy', 'and', 'survival', 'to', 'paclitaxel', 'with', 'manageable', 'and', 'non-cumulative', 'haematological', 'toxicity', '.']","(15, 18)","(127, 152)",-1,ss_o,14679127,Abstract,8,test,gold,3493.0
1514,CONCLUSION,Topotecan,continues to demonstrate comparable efficacy and survival to paclitaxel with manageable and non-cumulative haematological toxicity .,"['CONCLUSION', 'Topotecan', 'continues', 'to', 'demonstrate', 'comparable', 'efficacy', 'and', 'survival', 'to', 'paclitaxel', 'with', 'manageable', 'and', 'non-cumulative', 'haematological', 'toxicity', '.']","(1, 2)","(10, 19)",-1,hl_i,14679127,Abstract,8,test,gold,161.0
1515,CONCLUSION Topotecan continues to demonstrate comparable efficacy and survival to,paclitaxel,with manageable and non-cumulative haematological toxicity .,"['CONCLUSION', 'Topotecan', 'continues', 'to', 'demonstrate', 'comparable', 'efficacy', 'and', 'survival', 'to', 'paclitaxel', 'with', 'manageable', 'and', 'non-cumulative', 'haematological', 'toxicity', '.']","(10, 11)","(81, 91)",-1,hl_i,14679127,Abstract,8,test,gold,5152.0
1516,CONCLUSION Topotecan continues to demonstrate comparable,efficacy,and survival to paclitaxel with manageable and non-cumulative haematological toxicity .,"['CONCLUSION', 'Topotecan', 'continues', 'to', 'demonstrate', 'comparable', 'efficacy', 'and', 'survival', 'to', 'paclitaxel', 'with', 'manageable', 'and', 'non-cumulative', 'haematological', 'toxicity', '.']","(6, 7)","(56, 64)",-1,hl_o,14679127,Abstract,8,test,gold,4830.0
1517,CONCLUSION Topotecan continues to demonstrate comparable efficacy and,survival,to paclitaxel with manageable and non-cumulative haematological toxicity .,"['CONCLUSION', 'Topotecan', 'continues', 'to', 'demonstrate', 'comparable', 'efficacy', 'and', 'survival', 'to', 'paclitaxel', 'with', 'manageable', 'and', 'non-cumulative', 'haematological', 'toxicity', '.']","(8, 9)","(69, 77)",-1,hl_o,14679127,Abstract,8,test,gold,1963.0
1518,CONCLUSION Topotecan continues to demonstrate comparable efficacy and survival to paclitaxel with manageable and non-cumulative,haematological toxicity .,,"['CONCLUSION', 'Topotecan', 'continues', 'to', 'demonstrate', 'comparable', 'efficacy', 'and', 'survival', 'to', 'paclitaxel', 'with', 'manageable', 'and', 'non-cumulative', 'haematological', 'toxicity', '.']","(15, 18)","(127, 152)",-1,hl_o,14679127,Abstract,8,test,gold,3494.0
1519,,Non-haematological toxicity,was generally mild for both groups .,"['Non-haematological', 'toxicity', 'was', 'generally', 'mild', 'for', 'both', 'groups', '.']","(0, 2)","(0, 27)",-1,ss_o,14679127,Abstract,9,test,gold,3497.0
1520,,Non-haematological toxicity,was generally mild for both groups .,"['Non-haematological', 'toxicity', 'was', 'generally', 'mild', 'for', 'both', 'groups', '.']","(0, 2)","(0, 27)",-1,hl_o,14679127,Abstract,9,test,gold,3496.0
1521,The long-term survival rate indicates substantial therapeutic benefit for this group of patients receiving topotecan at relapse of,ovarian cancer .,,"['The', 'long-term', 'survival', 'rate', 'indicates', 'substantial', 'therapeutic', 'benefit', 'for', 'this', 'group', 'of', 'patients', 'receiving', 'topotecan', 'at', 'relapse', 'of', 'ovarian', 'cancer', '.']","(18, 21)","(130, 146)",-1,ss_p,14679127,Abstract,10,test,gold,6889.0
1522,The long-term survival rate indicates substantial therapeutic benefit for this group of patients receiving,topotecan,at relapse of ovarian cancer .,"['The', 'long-term', 'survival', 'rate', 'indicates', 'substantial', 'therapeutic', 'benefit', 'for', 'this', 'group', 'of', 'patients', 'receiving', 'topotecan', 'at', 'relapse', 'of', 'ovarian', 'cancer', '.']","(14, 15)","(106, 115)",-1,ss_i,14679127,Abstract,10,test,gold,5685.0
1523,The,long-term survival rate,indicates substantial therapeutic benefit for this group of patients receiving topotecan at relapse of ovarian cancer .,"['The', 'long-term', 'survival', 'rate', 'indicates', 'substantial', 'therapeutic', 'benefit', 'for', 'this', 'group', 'of', 'patients', 'receiving', 'topotecan', 'at', 'relapse', 'of', 'ovarian', 'cancer', '.']","(1, 4)","(3, 26)",-1,ss_o,14679127,Abstract,10,test,gold,1956.0
1524,The long-term survival rate indicates substantial therapeutic benefit for this group of patients receiving topotecan at relapse of,ovarian cancer .,,"['The', 'long-term', 'survival', 'rate', 'indicates', 'substantial', 'therapeutic', 'benefit', 'for', 'this', 'group', 'of', 'patients', 'receiving', 'topotecan', 'at', 'relapse', 'of', 'ovarian', 'cancer', '.']","(18, 21)","(130, 146)",-1,hl_p,14679127,Abstract,10,test,gold,6890.0
1525,The long-term survival rate indicates substantial therapeutic benefit for this group of patients receiving,topotecan,at relapse of ovarian cancer .,"['The', 'long-term', 'survival', 'rate', 'indicates', 'substantial', 'therapeutic', 'benefit', 'for', 'this', 'group', 'of', 'patients', 'receiving', 'topotecan', 'at', 'relapse', 'of', 'ovarian', 'cancer', '.']","(14, 15)","(106, 115)",-1,hl_i,14679127,Abstract,10,test,gold,5684.0
1526,Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein : an initial multidose study of,torcetrapib .,,"['Raising', 'high-density', 'lipoprotein', 'in', 'humans', 'through', 'inhibition', 'of', 'cholesteryl', 'ester', 'transfer', 'protein', ':', 'an', 'initial', 'multidose', 'study', 'of', 'torcetrapib', '.']","(18, 20)","(131, 144)",-1,ss_i,14739125,Title,0,test,gold,5346.0
1527,Raising,high-density lipoprotein,in humans through inhibition of cholesteryl ester transfer protein : an initial multidose study of torcetrapib .,"['Raising', 'high-density', 'lipoprotein', 'in', 'humans', 'through', 'inhibition', 'of', 'cholesteryl', 'ester', 'transfer', 'protein', ':', 'an', 'initial', 'multidose', 'study', 'of', 'torcetrapib', '.']","(1, 3)","(7, 31)",-1,ss_o,14739125,Title,0,test,gold,1582.0
1528,Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein : an initial multidose study of,torcetrapib .,,"['Raising', 'high-density', 'lipoprotein', 'in', 'humans', 'through', 'inhibition', 'of', 'cholesteryl', 'ester', 'transfer', 'protein', ':', 'an', 'initial', 'multidose', 'study', 'of', 'torcetrapib', '.']","(18, 20)","(131, 144)",-1,hl_i,14739125,Title,0,test,gold,5347.0
1529,"OBJECTIVE The ability of the potent cholesteryl ester transfer protein ( CETP ) inhibitor torcetrapib ( CP-529,414 ) to raise high-density lipoprotein cholesterol ( HDL-C ) levels in",healthy young subjects,was tested in this initial phase 1 multidose study .,"['OBJECTIVE', 'The', 'ability', 'of', 'the', 'potent', 'cholesteryl', 'ester', 'transfer', 'protein', '(', 'CETP', ')', 'inhibitor', 'torcetrapib', '(', 'CP-529,414', ')', 'to', 'raise', 'high-density', 'lipoprotein', 'cholesterol', '(', 'HDL-C', ')', 'levels', 'in', 'healthy', 'young', 'subjects', 'was', 'tested', 'in', 'this', 'initial', 'phase', '1', 'multidose', 'study', '.']","(28, 31)","(182, 204)",-1,ss_p,14739125,Abstract,0,test,gold,2260.0
1530,OBJECTIVE The ability of the potent,"cholesteryl ester transfer protein ( CETP ) inhibitor torcetrapib ( CP-529,414 )",to raise high-density lipoprotein cholesterol ( HDL-C ) levels in healthy young subjects was tested in this initial phase 1 multidose study .,"['OBJECTIVE', 'The', 'ability', 'of', 'the', 'potent', 'cholesteryl', 'ester', 'transfer', 'protein', '(', 'CETP', ')', 'inhibitor', 'torcetrapib', '(', 'CP-529,414', ')', 'to', 'raise', 'high-density', 'lipoprotein', 'cholesterol', '(', 'HDL-C', ')', 'levels', 'in', 'healthy', 'young', 'subjects', 'was', 'tested', 'in', 'this', 'initial', 'phase', '1', 'multidose', 'study', '.']","(6, 18)","(35, 115)",-1,ss_i,14739125,Abstract,0,test,gold,6515.0
1531,"OBJECTIVE The ability of the potent cholesteryl ester transfer protein ( CETP ) inhibitor torcetrapib ( CP-529,414 ) to raise",high-density lipoprotein cholesterol ( HDL-C ) levels,in healthy young subjects was tested in this initial phase 1 multidose study .,"['OBJECTIVE', 'The', 'ability', 'of', 'the', 'potent', 'cholesteryl', 'ester', 'transfer', 'protein', '(', 'CETP', ')', 'inhibitor', 'torcetrapib', '(', 'CP-529,414', ')', 'to', 'raise', 'high-density', 'lipoprotein', 'cholesterol', '(', 'HDL-C', ')', 'levels', 'in', 'healthy', 'young', 'subjects', 'was', 'tested', 'in', 'this', 'initial', 'phase', '1', 'multidose', 'study', '.']","(20, 27)","(125, 178)",-1,ss_o,14739125,Abstract,0,test,gold,6555.0
1532,"OBJECTIVE The ability of the potent cholesteryl ester transfer protein ( CETP ) inhibitor torcetrapib ( CP-529,414 ) to raise high-density lipoprotein cholesterol ( HDL-C ) levels in",healthy young,subjects was tested in this initial phase 1 multidose study .,"['OBJECTIVE', 'The', 'ability', 'of', 'the', 'potent', 'cholesteryl', 'ester', 'transfer', 'protein', '(', 'CETP', ')', 'inhibitor', 'torcetrapib', '(', 'CP-529,414', ')', 'to', 'raise', 'high-density', 'lipoprotein', 'cholesterol', '(', 'HDL-C', ')', 'levels', 'in', 'healthy', 'young', 'subjects', 'was', 'tested', 'in', 'this', 'initial', 'phase', '1', 'multidose', 'study', '.']","(28, 30)","(182, 195)",-1,hl_p,14739125,Abstract,0,test,gold,2263.0
1533,OBJECTIVE The ability of the potent,cholesteryl ester transfer protein ( CETP ) inhibitor torcetrapib,"( CP-529,414 ) to raise high-density lipoprotein cholesterol ( HDL-C ) levels in healthy young subjects was tested in this initial phase 1 multidose study .","['OBJECTIVE', 'The', 'ability', 'of', 'the', 'potent', 'cholesteryl', 'ester', 'transfer', 'protein', '(', 'CETP', ')', 'inhibitor', 'torcetrapib', '(', 'CP-529,414', ')', 'to', 'raise', 'high-density', 'lipoprotein', 'cholesterol', '(', 'HDL-C', ')', 'levels', 'in', 'healthy', 'young', 'subjects', 'was', 'tested', 'in', 'this', 'initial', 'phase', '1', 'multidose', 'study', '.']","(6, 15)","(35, 100)",-1,hl_i,14739125,Abstract,0,test,gold,6516.0
1534,METHODS AND RESULTS,Five groups of 8 subjects each,"were randomized to placebo ( n=2 ) or torcetrapib ( n=6 ) at 10 , 30 , 60 , and 120 mg daily and 120 mg twice daily for 14 days .","['METHODS', 'AND', 'RESULTS', 'Five', 'groups', 'of', '8', 'subjects', 'each', 'were', 'randomized', 'to', 'placebo', '(', 'n=2', ')', 'or', 'torcetrapib', '(', 'n=6', ')', 'at', '10', ',', '30', ',', '60', ',', 'and', '120', 'mg', 'daily', 'and', '120', 'mg', 'twice', 'daily', 'for', '14', 'days', '.']","(3, 9)","(19, 49)",-1,ss_p,14739125,Abstract,1,test,gold,2081.0
1535,METHODS AND RESULTS Five groups of 8 subjects each were randomized to,placebo,"( n=2 ) or torcetrapib ( n=6 ) at 10 , 30 , 60 , and 120 mg daily and 120 mg twice daily for 14 days .","['METHODS', 'AND', 'RESULTS', 'Five', 'groups', 'of', '8', 'subjects', 'each', 'were', 'randomized', 'to', 'placebo', '(', 'n=2', ')', 'or', 'torcetrapib', '(', 'n=6', ')', 'at', '10', ',', '30', ',', '60', ',', 'and', '120', 'mg', 'daily', 'and', '120', 'mg', 'twice', 'daily', 'for', '14', 'days', '.']","(12, 13)","(69, 76)",-1,ss_i,14739125,Abstract,1,test,gold,4409.0
1536,METHODS AND RESULTS Five groups of 8 subjects each were randomized to placebo ( n=2 ) or,torcetrapib,"( n=6 ) at 10 , 30 , 60 , and 120 mg daily and 120 mg twice daily for 14 days .","['METHODS', 'AND', 'RESULTS', 'Five', 'groups', 'of', '8', 'subjects', 'each', 'were', 'randomized', 'to', 'placebo', '(', 'n=2', ')', 'or', 'torcetrapib', '(', 'n=6', ')', 'at', '10', ',', '30', ',', '60', ',', 'and', '120', 'mg', 'daily', 'and', '120', 'mg', 'twice', 'daily', 'for', '14', 'days', '.']","(17, 18)","(88, 99)",-1,ss_i,14739125,Abstract,1,test,gold,5345.0
1537,METHODS AND RESULTS,Five groups of 8 subjects each,"were randomized to placebo ( n=2 ) or torcetrapib ( n=6 ) at 10 , 30 , 60 , and 120 mg daily and 120 mg twice daily for 14 days .","['METHODS', 'AND', 'RESULTS', 'Five', 'groups', 'of', '8', 'subjects', 'each', 'were', 'randomized', 'to', 'placebo', '(', 'n=2', ')', 'or', 'torcetrapib', '(', 'n=6', ')', 'at', '10', ',', '30', ',', '60', ',', 'and', '120', 'mg', 'daily', 'and', '120', 'mg', 'twice', 'daily', 'for', '14', 'days', '.']","(3, 9)","(19, 49)",-1,hl_p,14739125,Abstract,1,test,gold,2082.0
1538,METHODS AND RESULTS Five groups of 8 subjects each were randomized to,placebo,"( n=2 ) or torcetrapib ( n=6 ) at 10 , 30 , 60 , and 120 mg daily and 120 mg twice daily for 14 days .","['METHODS', 'AND', 'RESULTS', 'Five', 'groups', 'of', '8', 'subjects', 'each', 'were', 'randomized', 'to', 'placebo', '(', 'n=2', ')', 'or', 'torcetrapib', '(', 'n=6', ')', 'at', '10', ',', '30', ',', '60', ',', 'and', '120', 'mg', 'daily', 'and', '120', 'mg', 'twice', 'daily', 'for', '14', 'days', '.']","(12, 13)","(69, 76)",-1,hl_i,14739125,Abstract,1,test,gold,4408.0
1539,METHODS AND RESULTS Five groups of 8 subjects each were randomized to placebo ( n=2 ) or,torcetrapib,"( n=6 ) at 10 , 30 , 60 , and 120 mg daily and 120 mg twice daily for 14 days .","['METHODS', 'AND', 'RESULTS', 'Five', 'groups', 'of', '8', 'subjects', 'each', 'were', 'randomized', 'to', 'placebo', '(', 'n=2', ')', 'or', 'torcetrapib', '(', 'n=6', ')', 'at', '10', ',', '30', ',', '60', ',', 'and', '120', 'mg', 'daily', 'and', '120', 'mg', 'twice', 'daily', 'for', '14', 'days', '.']","(17, 18)","(88, 99)",-1,hl_i,14739125,Abstract,1,test,gold,5344.0
1540,,Torcetrapib,"was well tolerated , with all treated subjects completing the study .","['Torcetrapib', 'was', 'well', 'tolerated', ',', 'with', 'all', 'treated', 'subjects', 'completing', 'the', 'study', '.']","(0, 1)","(0, 11)",-1,ss_i,14739125,Abstract,2,test,gold,5563.0
1541,,Torcetrapib,"was well tolerated , with all treated subjects completing the study .","['Torcetrapib', 'was', 'well', 'tolerated', ',', 'with', 'all', 'treated', 'subjects', 'completing', 'the', 'study', '.']","(0, 1)","(0, 11)",-1,hl_i,14739125,Abstract,2,test,gold,5564.0
1542,The correlation of,plasma drug levels,"with inhibition ( EC50=43 nM ) was as expected based on in vitro potency ( IC50 approximately 50 nM ) , and increases in CETP mass were consistent with the proposed mechanism of inhibition .","['The', 'correlation', 'of', 'plasma', 'drug', 'levels', 'with', 'inhibition', '(', 'EC50=43', 'nM', ')', 'was', 'as', 'expected', 'based', 'on', 'in', 'vitro', 'potency', '(', 'IC50', 'approximately', '50', 'nM', ')', ',', 'and', 'increases', 'in', 'CETP', 'mass', 'were', 'consistent', 'with', 'the', 'proposed', 'mechanism', 'of', 'inhibition', '.']","(3, 6)","(18, 36)",-1,ss_o,14739125,Abstract,3,test,gold,4459.0
1543,The correlation of,plasma drug levels,"with inhibition ( EC50=43 nM ) was as expected based on in vitro potency ( IC50 approximately 50 nM ) , and increases in CETP mass were consistent with the proposed mechanism of inhibition .","['The', 'correlation', 'of', 'plasma', 'drug', 'levels', 'with', 'inhibition', '(', 'EC50=43', 'nM', ')', 'was', 'as', 'expected', 'based', 'on', 'in', 'vitro', 'potency', '(', 'IC50', 'approximately', '50', 'nM', ')', ',', 'and', 'increases', 'in', 'CETP', 'mass', 'were', 'consistent', 'with', 'the', 'proposed', 'mechanism', 'of', 'inhibition', '.']","(3, 6)","(18, 36)",-1,hl_o,14739125,Abstract,3,test,gold,4460.0
1544,"CETP inhibition increased with escalating dose , leading to elevations of",HDL-C,of 16 % to 91 % .,"['CETP', 'inhibition', 'increased', 'with', 'escalating', 'dose', ',', 'leading', 'to', 'elevations', 'of', 'HDL-C', 'of', '16', '%', 'to', '91', '%', '.']","(11, 12)","(73, 78)",-1,ss_o,14739125,Abstract,4,test,gold,
1545,,Total plasma cholesterol,"did not change significantly because of a reduction in nonHDL-C , including a 21 % to 42 % lowering of low-density lipoprotein cholesterol at the higher doses .","['Total', 'plasma', 'cholesterol', 'did', 'not', 'change', 'significantly', 'because', 'of', 'a', 'reduction', 'in', 'nonHDL-C', ',', 'including', 'a', '21', '%', 'to', '42', '%', 'lowering', 'of', 'low-density', 'lipoprotein', 'cholesterol', 'at', 'the', 'higher', 'doses', '.']","(0, 3)","(0, 24)",-1,ss_o,14739125,Abstract,5,test,gold,4447.0
1546,Total plasma cholesterol did not change significantly because of a reduction in,nonHDL-C,", including a 21 % to 42 % lowering of low-density lipoprotein cholesterol at the higher doses .","['Total', 'plasma', 'cholesterol', 'did', 'not', 'change', 'significantly', 'because', 'of', 'a', 'reduction', 'in', 'nonHDL-C', ',', 'including', 'a', '21', '%', 'to', '42', '%', 'lowering', 'of', 'low-density', 'lipoprotein', 'cholesterol', 'at', 'the', 'higher', 'doses', '.']","(12, 13)","(79, 87)",-1,ss_o,14739125,Abstract,5,test,gold,
1547,"Total plasma cholesterol did not change significantly because of a reduction in nonHDL-C , including a 21 % to 42 % lowering of",low-density lipoprotein cholesterol,at the higher doses .,"['Total', 'plasma', 'cholesterol', 'did', 'not', 'change', 'significantly', 'because', 'of', 'a', 'reduction', 'in', 'nonHDL-C', ',', 'including', 'a', '21', '%', 'to', '42', '%', 'lowering', 'of', 'low-density', 'lipoprotein', 'cholesterol', 'at', 'the', 'higher', 'doses', '.']","(23, 26)","(127, 162)",-1,ss_o,14739125,Abstract,5,test,gold,6553.0
1548,,Total plasma cholesterol,"did not change significantly because of a reduction in nonHDL-C , including a 21 % to 42 % lowering of low-density lipoprotein cholesterol at the higher doses .","['Total', 'plasma', 'cholesterol', 'did', 'not', 'change', 'significantly', 'because', 'of', 'a', 'reduction', 'in', 'nonHDL-C', ',', 'including', 'a', '21', '%', 'to', '42', '%', 'lowering', 'of', 'low-density', 'lipoprotein', 'cholesterol', 'at', 'the', 'higher', 'doses', '.']","(0, 3)","(0, 24)",-1,hl_o,14739125,Abstract,5,test,gold,4448.0
1549,Total plasma cholesterol did not change significantly because of a reduction in,nonHDL-C,", including a 21 % to 42 % lowering of low-density lipoprotein cholesterol at the higher doses .","['Total', 'plasma', 'cholesterol', 'did', 'not', 'change', 'significantly', 'because', 'of', 'a', 'reduction', 'in', 'nonHDL-C', ',', 'including', 'a', '21', '%', 'to', '42', '%', 'lowering', 'of', 'low-density', 'lipoprotein', 'cholesterol', 'at', 'the', 'higher', 'doses', '.']","(12, 13)","(79, 87)",-1,hl_o,14739125,Abstract,5,test,gold,
1550,"Total plasma cholesterol did not change significantly because of a reduction in nonHDL-C , including a 21 % to 42 % lowering of",low-density lipoprotein cholesterol,at the higher doses .,"['Total', 'plasma', 'cholesterol', 'did', 'not', 'change', 'significantly', 'because', 'of', 'a', 'reduction', 'in', 'nonHDL-C', ',', 'including', 'a', '21', '%', 'to', '42', '%', 'lowering', 'of', 'low-density', 'lipoprotein', 'cholesterol', 'at', 'the', 'higher', 'doses', '.']","(23, 26)","(127, 162)",-1,hl_o,14739125,Abstract,5,test,gold,6554.0
1551,,Apolipoprotein A-I and E,"were elevated 27 % and 66 % , respectively , and apoB was reduced 26 % with 120 mg twice daily .","['Apolipoprotein', 'A-I', 'and', 'E', 'were', 'elevated', '27', '%', 'and', '66', '%', ',', 'respectively', ',', 'and', 'apoB', 'was', 'reduced', '26', '%', 'with', '120', 'mg', 'twice', 'daily', '.']","(0, 4)","(0, 24)",-1,ss_o,14739125,Abstract,6,test,gold,826.0
1552,"Apolipoprotein A-I and E were elevated 27 % and 66 % , respectively , and",apoB,was reduced 26 % with 120 mg twice daily .,"['Apolipoprotein', 'A-I', 'and', 'E', 'were', 'elevated', '27', '%', 'and', '66', '%', ',', 'respectively', ',', 'and', 'apoB', 'was', 'reduced', '26', '%', 'with', '120', 'mg', 'twice', 'daily', '.']","(15, 16)","(73, 77)",-1,ss_o,14739125,Abstract,6,test,gold,1580.0
1553,,Apolipoprotein A-I and E,"were elevated 27 % and 66 % , respectively , and apoB was reduced 26 % with 120 mg twice daily .","['Apolipoprotein', 'A-I', 'and', 'E', 'were', 'elevated', '27', '%', 'and', '66', '%', ',', 'respectively', ',', 'and', 'apoB', 'was', 'reduced', '26', '%', 'with', '120', 'mg', 'twice', 'daily', '.']","(0, 4)","(0, 24)",-1,hl_o,14739125,Abstract,6,test,gold,827.0
1554,"Apolipoprotein A-I and E were elevated 27 % and 66 % , respectively , and",apoB,was reduced 26 % with 120 mg twice daily .,"['Apolipoprotein', 'A-I', 'and', 'E', 'were', 'elevated', '27', '%', 'and', '66', '%', ',', 'respectively', ',', 'and', 'apoB', 'was', 'reduced', '26', '%', 'with', '120', 'mg', 'twice', 'daily', '.']","(15, 16)","(73, 77)",-1,hl_o,14739125,Abstract,6,test,gold,1581.0
1555,,Cholesteryl ester content,"decreased and triglyceride increased in the nonHDL plasma fraction , with contrasting changes occurring in HDL .","['Cholesteryl', 'ester', 'content', 'decreased', 'and', 'triglyceride', 'increased', 'in', 'the', 'nonHDL', 'plasma', 'fraction', ',', 'with', 'contrasting', 'changes', 'occurring', 'in', 'HDL', '.']","(0, 3)","(0, 25)",-1,ss_o,14739125,Abstract,7,test,gold,1603.0
1556,Cholesteryl ester content decreased and,triglyceride,"increased in the nonHDL plasma fraction , with contrasting changes occurring in HDL .","['Cholesteryl', 'ester', 'content', 'decreased', 'and', 'triglyceride', 'increased', 'in', 'the', 'nonHDL', 'plasma', 'fraction', ',', 'with', 'contrasting', 'changes', 'occurring', 'in', 'HDL', '.']","(5, 6)","(39, 51)",-1,ss_o,14739125,Abstract,7,test,gold,1578.0
1557,Cholesteryl ester content decreased and triglyceride increased in the,nonHDL,"plasma fraction , with contrasting changes occurring in HDL .","['Cholesteryl', 'ester', 'content', 'decreased', 'and', 'triglyceride', 'increased', 'in', 'the', 'nonHDL', 'plasma', 'fraction', ',', 'with', 'contrasting', 'changes', 'occurring', 'in', 'HDL', '.']","(9, 10)","(69, 75)",-1,ss_o,14739125,Abstract,7,test,gold,
1558,"Cholesteryl ester content decreased and triglyceride increased in the nonHDL plasma fraction , with contrasting changes occurring in",HDL .,,"['Cholesteryl', 'ester', 'content', 'decreased', 'and', 'triglyceride', 'increased', 'in', 'the', 'nonHDL', 'plasma', 'fraction', ',', 'with', 'contrasting', 'changes', 'occurring', 'in', 'HDL', '.']","(18, 20)","(132, 137)",-1,ss_o,14739125,Abstract,7,test,gold,1573.0
1559,,Cholesteryl ester content,"decreased and triglyceride increased in the nonHDL plasma fraction , with contrasting changes occurring in HDL .","['Cholesteryl', 'ester', 'content', 'decreased', 'and', 'triglyceride', 'increased', 'in', 'the', 'nonHDL', 'plasma', 'fraction', ',', 'with', 'contrasting', 'changes', 'occurring', 'in', 'HDL', '.']","(0, 3)","(0, 25)",-1,hl_o,14739125,Abstract,7,test,gold,1604.0
1560,Cholesteryl ester content decreased and,triglyceride,"increased in the nonHDL plasma fraction , with contrasting changes occurring in HDL .","['Cholesteryl', 'ester', 'content', 'decreased', 'and', 'triglyceride', 'increased', 'in', 'the', 'nonHDL', 'plasma', 'fraction', ',', 'with', 'contrasting', 'changes', 'occurring', 'in', 'HDL', '.']","(5, 6)","(39, 51)",-1,hl_o,14739125,Abstract,7,test,gold,1579.0
1561,CONCLUSIONS These effects of CETP inhibition resemble those observed in partial CETP deficiency .,,,"['CONCLUSIONS', 'These', 'effects', 'of', 'CETP', 'inhibition', 'resemble', 'those', 'observed', 'in', 'partial', 'CETP', 'deficiency', '.']",,,,,14739125,Abstract,8,test,gold,
1562,"This work serves as a prelude to further studies in subjects with low HDL , or combinations of dyslipidemia , in assessing the role of CETP in atherosclerosis .",,,"['This', 'work', 'serves', 'as', 'a', 'prelude', 'to', 'further', 'studies', 'in', 'subjects', 'with', 'low', 'HDL', ',', 'or', 'combinations', 'of', 'dyslipidemia', ',', 'in', 'assessing', 'the', 'role', 'of', 'CETP', 'in', 'atherosclerosis', '.']",,,,,14739125,Abstract,9,test,gold,
1563,"A selective angiotensin receptor antagonist , Valsartan , produced regression of",left ventricular hypertrophy,associated with a reduction of arterial stiffness .,"['A', 'selective', 'angiotensin', 'receptor', 'antagonist', ',', 'Valsartan', ',', 'produced', 'regression', 'of', 'left', 'ventricular', 'hypertrophy', 'associated', 'with', 'a', 'reduction', 'of', 'arterial', 'stiffness', '.']","(11, 14)","(80, 108)",-1,ss_p,14763035,Title,0,test,gold,6778.0
1564,"A selective angiotensin receptor antagonist ,",Valsartan,", produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness .","['A', 'selective', 'angiotensin', 'receptor', 'antagonist', ',', 'Valsartan', ',', 'produced', 'regression', 'of', 'left', 'ventricular', 'hypertrophy', 'associated', 'with', 'a', 'reduction', 'of', 'arterial', 'stiffness', '.']","(6, 7)","(45, 54)",-1,ss_i,14763035,Title,0,test,gold,158.0
1565,"A selective angiotensin receptor antagonist , Valsartan , produced",regression of left ventricular hypertrophy,associated with a reduction of arterial stiffness .,"['A', 'selective', 'angiotensin', 'receptor', 'antagonist', ',', 'Valsartan', ',', 'produced', 'regression', 'of', 'left', 'ventricular', 'hypertrophy', 'associated', 'with', 'a', 'reduction', 'of', 'arterial', 'stiffness', '.']","(9, 14)","(66, 108)",-1,ss_o,14763035,Title,0,test,gold,6777.0
1566,"A selective angiotensin receptor antagonist , Valsartan , produced regression of left ventricular hypertrophy associated with a reduction of",arterial stiffness .,,"['A', 'selective', 'angiotensin', 'receptor', 'antagonist', ',', 'Valsartan', ',', 'produced', 'regression', 'of', 'left', 'ventricular', 'hypertrophy', 'associated', 'with', 'a', 'reduction', 'of', 'arterial', 'stiffness', '.']","(19, 22)","(140, 160)",-1,ss_o,14763035,Title,0,test,gold,3202.0
1567,"A selective angiotensin receptor antagonist , Valsartan , produced regression of",left ventricular hypertrophy,associated with a reduction of arterial stiffness .,"['A', 'selective', 'angiotensin', 'receptor', 'antagonist', ',', 'Valsartan', ',', 'produced', 'regression', 'of', 'left', 'ventricular', 'hypertrophy', 'associated', 'with', 'a', 'reduction', 'of', 'arterial', 'stiffness', '.']","(11, 14)","(80, 108)",-1,hl_p,14763035,Title,0,test,gold,6779.0
1568,"A selective angiotensin receptor antagonist ,",Valsartan,", produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness .","['A', 'selective', 'angiotensin', 'receptor', 'antagonist', ',', 'Valsartan', ',', 'produced', 'regression', 'of', 'left', 'ventricular', 'hypertrophy', 'associated', 'with', 'a', 'reduction', 'of', 'arterial', 'stiffness', '.']","(6, 7)","(45, 54)",-1,hl_i,14763035,Title,0,test,gold,159.0
1569,We investigated whether a selective angiotensin II receptor blocker ( ARB ) would have a regressive effect on left ventricular hypertrophy ( LVH ) in,patients on continuous ambulatory peritoneal dialysis ( CAPD ) .,,"['We', 'investigated', 'whether', 'a', 'selective', 'angiotensin', 'II', 'receptor', 'blocker', '(', 'ARB', ')', 'would', 'have', 'a', 'regressive', 'effect', 'on', 'left', 'ventricular', 'hypertrophy', '(', 'LVH', ')', 'in', 'patients', 'on', 'continuous', 'ambulatory', 'peritoneal', 'dialysis', '(', 'CAPD', ')', '.']","(25, 35)","(149, 213)",-1,ss_p,14763035,Abstract,0,test,gold,5960.0
1570,We investigated whether a,selective angiotensin II receptor blocker ( ARB ),would have a regressive effect on left ventricular hypertrophy ( LVH ) in patients on continuous ambulatory peritoneal dialysis ( CAPD ) .,"['We', 'investigated', 'whether', 'a', 'selective', 'angiotensin', 'II', 'receptor', 'blocker', '(', 'ARB', ')', 'would', 'have', 'a', 'regressive', 'effect', 'on', 'left', 'ventricular', 'hypertrophy', '(', 'LVH', ')', 'in', 'patients', 'on', 'continuous', 'ambulatory', 'peritoneal', 'dialysis', '(', 'CAPD', ')', '.']","(4, 12)","(25, 74)",-1,ss_i,14763035,Abstract,0,test,gold,6513.0
1571,We investigated whether a selective angiotensin II receptor blocker ( ARB ) would have a,regressive effect on left ventricular hypertrophy ( LVH ),in patients on continuous ambulatory peritoneal dialysis ( CAPD ) .,"['We', 'investigated', 'whether', 'a', 'selective', 'angiotensin', 'II', 'receptor', 'blocker', '(', 'ARB', ')', 'would', 'have', 'a', 'regressive', 'effect', 'on', 'left', 'ventricular', 'hypertrophy', '(', 'LVH', ')', 'in', 'patients', 'on', 'continuous', 'ambulatory', 'peritoneal', 'dialysis', '(', 'CAPD', ')', '.']","(15, 24)","(88, 145)",-1,ss_o,14763035,Abstract,0,test,gold,6776.0
1572,We investigated whether a selective angiotensin II receptor blocker ( ARB ) would have a regressive effect on left ventricular hypertrophy ( LVH ) in,patients on continuous ambulatory peritoneal dialysis ( CAPD ) .,,"['We', 'investigated', 'whether', 'a', 'selective', 'angiotensin', 'II', 'receptor', 'blocker', '(', 'ARB', ')', 'would', 'have', 'a', 'regressive', 'effect', 'on', 'left', 'ventricular', 'hypertrophy', '(', 'LVH', ')', 'in', 'patients', 'on', 'continuous', 'ambulatory', 'peritoneal', 'dialysis', '(', 'CAPD', ')', '.']","(25, 35)","(149, 213)",-1,hl_p,14763035,Abstract,0,test,gold,5961.0
1573,We investigated whether a,selective angiotensin II receptor blocker ( ARB ),would have a regressive effect on left ventricular hypertrophy ( LVH ) in patients on continuous ambulatory peritoneal dialysis ( CAPD ) .,"['We', 'investigated', 'whether', 'a', 'selective', 'angiotensin', 'II', 'receptor', 'blocker', '(', 'ARB', ')', 'would', 'have', 'a', 'regressive', 'effect', 'on', 'left', 'ventricular', 'hypertrophy', '(', 'LVH', ')', 'in', 'patients', 'on', 'continuous', 'ambulatory', 'peritoneal', 'dialysis', '(', 'CAPD', ')', '.']","(4, 12)","(25, 74)",-1,hl_i,14763035,Abstract,0,test,gold,6514.0
1574,"In a double-blind study ,",24 CAPD patients with LVH [ left ventricular mass index ( LVMi ) > 110 g/m2 for women and LVMi > 137 g/m2 for men ],were randomized to 12 months ' administration of either the ARB valsartan ( n = 14 ) or a placebo ( n = 10 ) .,"['In', 'a', 'double-blind', 'study', ',', '24', 'CAPD', 'patients', 'with', 'LVH', '[', 'left', 'ventricular', 'mass', 'index', '(', 'LVMi', ')', '>', '110', 'g/m2', 'for', 'women', 'and', 'LVMi', '>', '137', 'g/m2', 'for', 'men', ']', 'were', 'randomized', 'to', '12', 'months', ""'"", 'administration', 'of', 'either', 'the', 'ARB', 'valsartan', '(', 'n', '=', '14', ')', 'or', 'a', 'placebo', '(', 'n', '=', '10', ')', '.']","(5, 31)","(25, 140)",-1,ss_p,14763035,Abstract,1,test,gold,5974.0
1575,"In a double-blind study , 24 CAPD patients with LVH [ left ventricular mass index ( LVMi ) > 110 g/m2 for women and LVMi > 137 g/m2 for men ] were randomized to 12 months ' administration of either the",ARB valsartan,( n = 14 ) or a placebo ( n = 10 ) .,"['In', 'a', 'double-blind', 'study', ',', '24', 'CAPD', 'patients', 'with', 'LVH', '[', 'left', 'ventricular', 'mass', 'index', '(', 'LVMi', ')', '>', '110', 'g/m2', 'for', 'women', 'and', 'LVMi', '>', '137', 'g/m2', 'for', 'men', ']', 'were', 'randomized', 'to', '12', 'months', ""'"", 'administration', 'of', 'either', 'the', 'ARB', 'valsartan', '(', 'n', '=', '14', ')', 'or', 'a', 'placebo', '(', 'n', '=', '10', ')', '.']","(41, 43)","(201, 214)",-1,ss_i,14763035,Abstract,1,test,gold,531.0
1576,"In a double-blind study , 24 CAPD patients with LVH [ left ventricular mass index ( LVMi ) > 110 g/m2 for women and LVMi > 137 g/m2 for men ] were randomized to 12 months ' administration of either the ARB valsartan ( n = 14 ) or a",placebo,( n = 10 ) .,"['In', 'a', 'double-blind', 'study', ',', '24', 'CAPD', 'patients', 'with', 'LVH', '[', 'left', 'ventricular', 'mass', 'index', '(', 'LVMi', ')', '>', '110', 'g/m2', 'for', 'women', 'and', 'LVMi', '>', '137', 'g/m2', 'for', 'men', ']', 'were', 'randomized', 'to', '12', 'months', ""'"", 'administration', 'of', 'either', 'the', 'ARB', 'valsartan', '(', 'n', '=', '14', ')', 'or', 'a', 'placebo', '(', 'n', '=', '10', ')', '.']","(50, 51)","(231, 238)",-1,ss_i,14763035,Abstract,1,test,gold,4407.0
1577,"In a double-blind study , 24 CAPD patients with LVH",[ left ventricular mass index ( LVMi ),> 110 g/m2 for women and LVMi > 137 g/m2 for men ] were randomized to 12 months ' administration of either the ARB valsartan ( n = 14 ) or a placebo ( n = 10 ) .,"['In', 'a', 'double-blind', 'study', ',', '24', 'CAPD', 'patients', 'with', 'LVH', '[', 'left', 'ventricular', 'mass', 'index', '(', 'LVMi', ')', '>', '110', 'g/m2', 'for', 'women', 'and', 'LVMi', '>', '137', 'g/m2', 'for', 'men', ']', 'were', 'randomized', 'to', '12', 'months', ""'"", 'administration', 'of', 'either', 'the', 'ARB', 'valsartan', '(', 'n', '=', '14', ')', 'or', 'a', 'placebo', '(', 'n', '=', '10', ')', '.']","(10, 18)","(51, 89)",-1,ss_o,14763035,Abstract,1,test,gold,6784.0
1578,"In a double-blind study , 24 CAPD patients with LVH [ left ventricular mass index ( LVMi ) > 110 g/m2 for women and",LVMi,> 137 g/m2 for men ] were randomized to 12 months ' administration of either the ARB valsartan ( n = 14 ) or a placebo ( n = 10 ) .,"['In', 'a', 'double-blind', 'study', ',', '24', 'CAPD', 'patients', 'with', 'LVH', '[', 'left', 'ventricular', 'mass', 'index', '(', 'LVMi', ')', '>', '110', 'g/m2', 'for', 'women', 'and', 'LVMi', '>', '137', 'g/m2', 'for', 'men', ']', 'were', 'randomized', 'to', '12', 'months', ""'"", 'administration', 'of', 'either', 'the', 'ARB', 'valsartan', '(', 'n', '=', '14', ')', 'or', 'a', 'placebo', '(', 'n', '=', '10', ')', '.']","(24, 25)","(115, 119)",-1,ss_o,14763035,Abstract,1,test,gold,
1579,"In a double-blind study ,",24 CAPD patients with LVH [ left ventricular mass index ( LVMi ) > 110 g/m2 for women,and LVMi > 137 g/m2 for men ] were randomized to 12 months ' administration of either the ARB valsartan ( n = 14 ) or a placebo ( n = 10 ) .,"['In', 'a', 'double-blind', 'study', ',', '24', 'CAPD', 'patients', 'with', 'LVH', '[', 'left', 'ventricular', 'mass', 'index', '(', 'LVMi', ')', '>', '110', 'g/m2', 'for', 'women', 'and', 'LVMi', '>', '137', 'g/m2', 'for', 'men', ']', 'were', 'randomized', 'to', '12', 'months', ""'"", 'administration', 'of', 'either', 'the', 'ARB', 'valsartan', '(', 'n', '=', '14', ')', 'or', 'a', 'placebo', '(', 'n', '=', '10', ')', '.']","(5, 23)","(25, 110)",-1,hl_p,14763035,Abstract,1,test,gold,5975.0
1580,"In a double-blind study , 24 CAPD patients with LVH [ left ventricular mass index ( LVMi ) > 110 g/m2 for women and",LVMi > 137 g/m2 for men,] were randomized to 12 months ' administration of either the ARB valsartan ( n = 14 ) or a placebo ( n = 10 ) .,"['In', 'a', 'double-blind', 'study', ',', '24', 'CAPD', 'patients', 'with', 'LVH', '[', 'left', 'ventricular', 'mass', 'index', '(', 'LVMi', ')', '>', '110', 'g/m2', 'for', 'women', 'and', 'LVMi', '>', '137', 'g/m2', 'for', 'men', ']', 'were', 'randomized', 'to', '12', 'months', ""'"", 'administration', 'of', 'either', 'the', 'ARB', 'valsartan', '(', 'n', '=', '14', ')', 'or', 'a', 'placebo', '(', 'n', '=', '10', ')', '.']","(24, 30)","(115, 138)",-1,hl_p,14763035,Abstract,1,test,gold,2232.0
1581,"In a double-blind study , 24 CAPD patients with LVH [ left ventricular mass index ( LVMi ) > 110 g/m2 for women and LVMi > 137 g/m2 for men ] were randomized to 12 months ' administration of either the",ARB valsartan,( n = 14 ) or a placebo ( n = 10 ) .,"['In', 'a', 'double-blind', 'study', ',', '24', 'CAPD', 'patients', 'with', 'LVH', '[', 'left', 'ventricular', 'mass', 'index', '(', 'LVMi', ')', '>', '110', 'g/m2', 'for', 'women', 'and', 'LVMi', '>', '137', 'g/m2', 'for', 'men', ']', 'were', 'randomized', 'to', '12', 'months', ""'"", 'administration', 'of', 'either', 'the', 'ARB', 'valsartan', '(', 'n', '=', '14', ')', 'or', 'a', 'placebo', '(', 'n', '=', '10', ')', '.']","(41, 43)","(201, 214)",-1,hl_i,14763035,Abstract,1,test,gold,532.0
1582,"In a double-blind study , 24 CAPD patients with LVH [ left ventricular mass index ( LVMi ) > 110 g/m2 for women and LVMi > 137 g/m2 for men ] were randomized to 12 months ' administration of either the ARB valsartan ( n = 14 ) or a",placebo,( n = 10 ) .,"['In', 'a', 'double-blind', 'study', ',', '24', 'CAPD', 'patients', 'with', 'LVH', '[', 'left', 'ventricular', 'mass', 'index', '(', 'LVMi', ')', '>', '110', 'g/m2', 'for', 'women', 'and', 'LVMi', '>', '137', 'g/m2', 'for', 'men', ']', 'were', 'randomized', 'to', '12', 'months', ""'"", 'administration', 'of', 'either', 'the', 'ARB', 'valsartan', '(', 'n', '=', '14', ')', 'or', 'a', 'placebo', '(', 'n', '=', '10', ')', '.']","(50, 51)","(231, 238)",-1,hl_i,14763035,Abstract,1,test,gold,4406.0
1583,The,target blood pressure ( BP ),was 140/90 mmHg or lower in both groups .,"['The', 'target', 'blood', 'pressure', '(', 'BP', ')', 'was', '140/90', 'mmHg', 'or', 'lower', 'in', 'both', 'groups', '.']","(1, 7)","(3, 31)",-1,ss_o,14763035,Abstract,2,test,gold,6700.0
1584,The target,blood pressure ( BP ),was 140/90 mmHg or lower in both groups .,"['The', 'target', 'blood', 'pressure', '(', 'BP', ')', 'was', '140/90', 'mmHg', 'or', 'lower', 'in', 'both', 'groups', '.']","(2, 7)","(10, 31)",-1,hl_o,14763035,Abstract,2,test,gold,6701.0
1585,The following parameters were measured before and at the end of the study :,aortic and large-artery compliance and arterial wave reflections [ pulse wave velocity ( PWV ) and augmentation index ( AI ) application tonometry ] and cardiac echocardiography .,,"['The', 'following', 'parameters', 'were', 'measured', 'before', 'and', 'at', 'the', 'end', 'of', 'the', 'study', ':', 'aortic', 'and', 'large-artery', 'compliance', 'and', 'arterial', 'wave', 'reflections', '[', 'pulse', 'wave', 'velocity', '(', 'PWV', ')', 'and', 'augmentation', 'index', '(', 'AI', ')', 'application', 'tonometry', ']', 'and', 'cardiac', 'echocardiography', '.']","(14, 42)","(75, 254)",-1,ss_o,14763035,Abstract,3,test,gold,6004.0
1586,The following parameters were measured before and at the end of the study :,aortic and large-artery compliance,and arterial wave reflections [ pulse wave velocity ( PWV ) and augmentation index ( AI ) application tonometry ] and cardiac echocardiography .,"['The', 'following', 'parameters', 'were', 'measured', 'before', 'and', 'at', 'the', 'end', 'of', 'the', 'study', ':', 'aortic', 'and', 'large-artery', 'compliance', 'and', 'arterial', 'wave', 'reflections', '[', 'pulse', 'wave', 'velocity', '(', 'PWV', ')', 'and', 'augmentation', 'index', '(', 'AI', ')', 'application', 'tonometry', ']', 'and', 'cardiac', 'echocardiography', '.']","(14, 18)","(75, 109)",-1,hl_o,14763035,Abstract,3,test,gold,1389.0
1587,The following parameters were measured before and at the end of the study : aortic and large-artery compliance and,arterial wave reflections [ pulse wave velocity ( PWV ),and augmentation index ( AI ) application tonometry ] and cardiac echocardiography .,"['The', 'following', 'parameters', 'were', 'measured', 'before', 'and', 'at', 'the', 'end', 'of', 'the', 'study', ':', 'aortic', 'and', 'large-artery', 'compliance', 'and', 'arterial', 'wave', 'reflections', '[', 'pulse', 'wave', 'velocity', '(', 'PWV', ')', 'and', 'augmentation', 'index', '(', 'AI', ')', 'application', 'tonometry', ']', 'and', 'cardiac', 'echocardiography', '.']","(19, 29)","(114, 169)",-1,hl_o,14763035,Abstract,3,test,gold,1733.0
1588,The following parameters were measured before and at the end of the study : aortic and large-artery compliance and arterial wave reflections [ pulse wave velocity ( PWV ) and,augmentation index ( AI ) application tonometry ],and cardiac echocardiography .,"['The', 'following', 'parameters', 'were', 'measured', 'before', 'and', 'at', 'the', 'end', 'of', 'the', 'study', ':', 'aortic', 'and', 'large-artery', 'compliance', 'and', 'arterial', 'wave', 'reflections', '[', 'pulse', 'wave', 'velocity', '(', 'PWV', ')', 'and', 'augmentation', 'index', '(', 'AI', ')', 'application', 'tonometry', ']', 'and', 'cardiac', 'echocardiography', '.']","(30, 38)","(174, 223)",-1,hl_o,14763035,Abstract,3,test,gold,2003.0
1589,The following parameters were measured before and at the end of the study : aortic and large-artery compliance and arterial wave reflections [ pulse wave velocity ( PWV ) and augmentation index ( AI ) application tonometry ] and,cardiac echocardiography .,,"['The', 'following', 'parameters', 'were', 'measured', 'before', 'and', 'at', 'the', 'end', 'of', 'the', 'study', ':', 'aortic', 'and', 'large-artery', 'compliance', 'and', 'arterial', 'wave', 'reflections', '[', 'pulse', 'wave', 'velocity', '(', 'PWV', ')', 'and', 'augmentation', 'index', '(', 'AI', ')', 'application', 'tonometry', ']', 'and', 'cardiac', 'echocardiography', '.']","(39, 42)","(228, 254)",-1,hl_o,14763035,Abstract,3,test,gold,3220.0
1590,Periodically recorded were,"body weight , BP ( mercury sphygmomanometer ) , serum creatinine , electrolytes , complete blood cell counts , urine volume , drainage volume , and weekly creatinine clearance .",,"['Periodically', 'recorded', 'were', 'body', 'weight', ',', 'BP', '(', 'mercury', 'sphygmomanometer', ')', ',', 'serum', 'creatinine', ',', 'electrolytes', ',', 'complete', 'blood', 'cell', 'counts', ',', 'urine', 'volume', ',', 'drainage', 'volume', ',', 'and', 'weekly', 'creatinine', 'clearance', '.']","(3, 33)","(26, 203)",-1,ss_o,14763035,Abstract,4,test,gold,5809.0
1591,Periodically recorded were,"body weight , BP ( mercury sphygmomanometer ) , serum creatinine , electrolytes , complete blood cell counts , urine volume , drainage volume , and weekly creatinine clearance .",,"['Periodically', 'recorded', 'were', 'body', 'weight', ',', 'BP', '(', 'mercury', 'sphygmomanometer', ')', ',', 'serum', 'creatinine', ',', 'electrolytes', ',', 'complete', 'blood', 'cell', 'counts', ',', 'urine', 'volume', ',', 'drainage', 'volume', ',', 'and', 'weekly', 'creatinine', 'clearance', '.']","(3, 33)","(26, 203)",-1,hl_o,14763035,Abstract,4,test,gold,5810.0
1592,Two-way analysis of variance for repeated measurements was used for statistical analysis .,,,"['Two-way', 'analysis', 'of', 'variance', 'for', 'repeated', 'measurements', 'was', 'used', 'for', 'statistical', 'analysis', '.']",,,,,14763035,Abstract,5,test,gold,
1593,Systolic and diastolic BP were both reduced in patients treated with,ARB .,,"['Systolic', 'and', 'diastolic', 'BP', 'were', 'both', 'reduced', 'in', 'patients', 'treated', 'with', 'ARB', '.']","(11, 13)","(68, 73)",-1,ss_i,14763035,Abstract,6,test,gold,529.0
1594,,Systolic and diastolic BP,were both reduced in patients treated with ARB .,"['Systolic', 'and', 'diastolic', 'BP', 'were', 'both', 'reduced', 'in', 'patients', 'treated', 'with', 'ARB', '.']","(0, 4)","(0, 25)",-1,ss_o,14763035,Abstract,6,test,gold,6683.0
1595,Systolic and diastolic BP were both reduced in patients treated with,ARB .,,"['Systolic', 'and', 'diastolic', 'BP', 'were', 'both', 'reduced', 'in', 'patients', 'treated', 'with', 'ARB', '.']","(11, 13)","(68, 73)",-1,hl_i,14763035,Abstract,6,test,gold,530.0
1596,,Systolic and diastolic BP,were both reduced in patients treated with ARB .,"['Systolic', 'and', 'diastolic', 'BP', 'were', 'both', 'reduced', 'in', 'patients', 'treated', 'with', 'ARB', '.']","(0, 4)","(0, 25)",-1,hl_o,14763035,Abstract,6,test,gold,6684.0
1597,The LVMi was significantly reduced in patients treated with,ARB,"( to 121 +/- 4 from 145 +/- 5 ) but not in those receiving placebo ( to 137 +/- 3 from 152 +/- 3 , p < 0.05 ) .","['The', 'LVMi', 'was', 'significantly', 'reduced', 'in', 'patients', 'treated', 'with', 'ARB', '(', 'to', '121', '+/-', '4', 'from', '145', '+/-', '5', ')', 'but', 'not', 'in', 'those', 'receiving', 'placebo', '(', 'to', '137', '+/-', '3', 'from', '152', '+/-', '3', ',', 'p', '<', '0.05', ')', '.']","(9, 10)","(59, 62)",-1,ss_i,14763035,Abstract,7,test,gold,528.0
1598,The LVMi was significantly reduced in patients treated with ARB ( to 121 +/- 4 from 145 +/- 5 ) but not in those receiving,placebo,"( to 137 +/- 3 from 152 +/- 3 , p < 0.05 ) .","['The', 'LVMi', 'was', 'significantly', 'reduced', 'in', 'patients', 'treated', 'with', 'ARB', '(', 'to', '121', '+/-', '4', 'from', '145', '+/-', '5', ')', 'but', 'not', 'in', 'those', 'receiving', 'placebo', '(', 'to', '137', '+/-', '3', 'from', '152', '+/-', '3', ',', 'p', '<', '0.05', ')', '.']","(25, 26)","(122, 129)",-1,ss_i,14763035,Abstract,7,test,gold,4405.0
1599,The,LVMi,"was significantly reduced in patients treated with ARB ( to 121 +/- 4 from 145 +/- 5 ) but not in those receiving placebo ( to 137 +/- 3 from 152 +/- 3 , p < 0.05 ) .","['The', 'LVMi', 'was', 'significantly', 'reduced', 'in', 'patients', 'treated', 'with', 'ARB', '(', 'to', '121', '+/-', '4', 'from', '145', '+/-', '5', ')', 'but', 'not', 'in', 'those', 'receiving', 'placebo', '(', 'to', '137', '+/-', '3', 'from', '152', '+/-', '3', ',', 'p', '<', '0.05', ')', '.']","(1, 2)","(3, 7)",-1,ss_o,14763035,Abstract,7,test,gold,
1600,The LVMi was significantly reduced in patients treated with,ARB,"( to 121 +/- 4 from 145 +/- 5 ) but not in those receiving placebo ( to 137 +/- 3 from 152 +/- 3 , p < 0.05 ) .","['The', 'LVMi', 'was', 'significantly', 'reduced', 'in', 'patients', 'treated', 'with', 'ARB', '(', 'to', '121', '+/-', '4', 'from', '145', '+/-', '5', ')', 'but', 'not', 'in', 'those', 'receiving', 'placebo', '(', 'to', '137', '+/-', '3', 'from', '152', '+/-', '3', ',', 'p', '<', '0.05', ')', '.']","(9, 10)","(59, 62)",-1,hl_i,14763035,Abstract,7,test,gold,527.0
1601,The LVMi was significantly reduced in patients treated with ARB ( to 121 +/- 4 from 145 +/- 5 ) but not in those receiving,placebo,"( to 137 +/- 3 from 152 +/- 3 , p < 0.05 ) .","['The', 'LVMi', 'was', 'significantly', 'reduced', 'in', 'patients', 'treated', 'with', 'ARB', '(', 'to', '121', '+/-', '4', 'from', '145', '+/-', '5', ')', 'but', 'not', 'in', 'those', 'receiving', 'placebo', '(', 'to', '137', '+/-', '3', 'from', '152', '+/-', '3', ',', 'p', '<', '0.05', ')', '.']","(25, 26)","(122, 129)",-1,hl_i,14763035,Abstract,7,test,gold,4404.0
1602,The,LVMi,"was significantly reduced in patients treated with ARB ( to 121 +/- 4 from 145 +/- 5 ) but not in those receiving placebo ( to 137 +/- 3 from 152 +/- 3 , p < 0.05 ) .","['The', 'LVMi', 'was', 'significantly', 'reduced', 'in', 'patients', 'treated', 'with', 'ARB', '(', 'to', '121', '+/-', '4', 'from', '145', '+/-', '5', ')', 'but', 'not', 'in', 'those', 'receiving', 'placebo', '(', 'to', '137', '+/-', '3', 'from', '152', '+/-', '3', ',', 'p', '<', '0.05', ')', '.']","(1, 2)","(3, 7)",-1,hl_o,14763035,Abstract,7,test,gold,
1603,The decrease in,LVMi,was associated with a reduction in PWV and AI .,"['The', 'decrease', 'in', 'LVMi', 'was', 'associated', 'with', 'a', 'reduction', 'in', 'PWV', 'and', 'AI', '.']","(3, 4)","(15, 19)",-1,ss_o,14763035,Abstract,8,test,gold,
1604,The decrease in LVMi was associated with a reduction in,PWV,and AI .,"['The', 'decrease', 'in', 'LVMi', 'was', 'associated', 'with', 'a', 'reduction', 'in', 'PWV', 'and', 'AI', '.']","(10, 11)","(55, 58)",-1,ss_o,14763035,Abstract,8,test,gold,1082.0
1605,The decrease in LVMi was associated with a reduction in PWV and,AI .,,"['The', 'decrease', 'in', 'LVMi', 'was', 'associated', 'with', 'a', 'reduction', 'in', 'PWV', 'and', 'AI', '.']","(12, 14)","(63, 67)",-1,ss_o,14763035,Abstract,8,test,gold,1090.0
1606,The decrease in,LVMi,was associated with a reduction in PWV and AI .,"['The', 'decrease', 'in', 'LVMi', 'was', 'associated', 'with', 'a', 'reduction', 'in', 'PWV', 'and', 'AI', '.']","(3, 4)","(15, 19)",-1,hl_o,14763035,Abstract,8,test,gold,
1607,The decrease in LVMi was associated with a reduction in,PWV,and AI .,"['The', 'decrease', 'in', 'LVMi', 'was', 'associated', 'with', 'a', 'reduction', 'in', 'PWV', 'and', 'AI', '.']","(10, 11)","(55, 58)",-1,hl_o,14763035,Abstract,8,test,gold,1083.0
1608,The decrease in LVMi was associated with a reduction in PWV and,AI,.,"['The', 'decrease', 'in', 'LVMi', 'was', 'associated', 'with', 'a', 'reduction', 'in', 'PWV', 'and', 'AI', '.']","(12, 13)","(63, 65)",-1,hl_o,14763035,Abstract,8,test,gold,1091.0
1609,In,CAPD patients with LVH,", ARB reduced LVMi in association with alterations in arterial hemodynamics .","['In', 'CAPD', 'patients', 'with', 'LVH', ',', 'ARB', 'reduced', 'LVMi', 'in', 'association', 'with', 'alterations', 'in', 'arterial', 'hemodynamics', '.']","(1, 5)","(2, 24)",-1,ss_p,14763035,Abstract,9,test,gold,3787.0
1610,"In CAPD patients with LVH ,",ARB,reduced LVMi in association with alterations in arterial hemodynamics .,"['In', 'CAPD', 'patients', 'with', 'LVH', ',', 'ARB', 'reduced', 'LVMi', 'in', 'association', 'with', 'alterations', 'in', 'arterial', 'hemodynamics', '.']","(6, 7)","(27, 30)",-1,ss_i,14763035,Abstract,9,test,gold,526.0
1611,"In CAPD patients with LVH , ARB reduced",LVMi,in association with alterations in arterial hemodynamics .,"['In', 'CAPD', 'patients', 'with', 'LVH', ',', 'ARB', 'reduced', 'LVMi', 'in', 'association', 'with', 'alterations', 'in', 'arterial', 'hemodynamics', '.']","(8, 9)","(39, 43)",-1,ss_o,14763035,Abstract,9,test,gold,
1612,"In CAPD patients with LVH , ARB reduced LVMi in association with alterations in",arterial hemodynamics .,,"['In', 'CAPD', 'patients', 'with', 'LVH', ',', 'ARB', 'reduced', 'LVMi', 'in', 'association', 'with', 'alterations', 'in', 'arterial', 'hemodynamics', '.']","(14, 17)","(79, 102)",-1,ss_o,14763035,Abstract,9,test,gold,3203.0
1613,"In CAPD patients with LVH ,",ARB,reduced LVMi in association with alterations in arterial hemodynamics .,"['In', 'CAPD', 'patients', 'with', 'LVH', ',', 'ARB', 'reduced', 'LVMi', 'in', 'association', 'with', 'alterations', 'in', 'arterial', 'hemodynamics', '.']","(6, 7)","(27, 30)",-1,hl_i,14763035,Abstract,9,test,gold,525.0
1614,"In CAPD patients with LVH , ARB reduced",LVMi,in association with alterations in arterial hemodynamics .,"['In', 'CAPD', 'patients', 'with', 'LVH', ',', 'ARB', 'reduced', 'LVMi', 'in', 'association', 'with', 'alterations', 'in', 'arterial', 'hemodynamics', '.']","(8, 9)","(39, 43)",-1,hl_o,14763035,Abstract,9,test,gold,
1615,A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose,interferon,for melanoma .,"['A', 'pooled', 'analysis', 'of', 'eastern', 'cooperative', 'oncology', 'group', 'and', 'intergroup', 'trials', 'of', 'adjuvant', 'high-dose', 'interferon', 'for', 'melanoma', '.']","(14, 15)","(99, 109)",-1,ss_i,15014018,Title,0,test,gold,5744.0
1616,A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose,interferon,for melanoma .,"['A', 'pooled', 'analysis', 'of', 'eastern', 'cooperative', 'oncology', 'group', 'and', 'intergroup', 'trials', 'of', 'adjuvant', 'high-dose', 'interferon', 'for', 'melanoma', '.']","(14, 15)","(99, 109)",-1,hl_i,15014018,Title,0,test,gold,5745.0
1617,PURPOSE,Nearly 2000 patients with stage IIB and III melanoma,"have participated in four multicenter , randomized trials , conducted by the Eastern Cooperative Oncology Group and the Intergroup , investigating adjuvant high-dose IFN-alpha 2b therapy .","['PURPOSE', 'Nearly', '2000', 'patients', 'with', 'stage', 'IIB', 'and', 'III', 'melanoma', 'have', 'participated', 'in', 'four', 'multicenter', ',', 'randomized', 'trials', ',', 'conducted', 'by', 'the', 'Eastern', 'Cooperative', 'Oncology', 'Group', 'and', 'the', 'Intergroup', ',', 'investigating', 'adjuvant', 'high-dose', 'IFN-alpha', '2b', 'therapy', '.']","(1, 10)","(7, 59)",-1,ss_p,15014018,Abstract,0,test,gold,6856.0
1618,"PURPOSE Nearly 2000 patients with stage IIB and III melanoma have participated in four multicenter , randomized trials , conducted by the Eastern Cooperative Oncology Group and the Intergroup , investigating adjuvant high-dose",IFN-alpha 2b,therapy .,"['PURPOSE', 'Nearly', '2000', 'patients', 'with', 'stage', 'IIB', 'and', 'III', 'melanoma', 'have', 'participated', 'in', 'four', 'multicenter', ',', 'randomized', 'trials', ',', 'conducted', 'by', 'the', 'Eastern', 'Cooperative', 'Oncology', 'Group', 'and', 'the', 'Intergroup', ',', 'investigating', 'adjuvant', 'high-dose', 'IFN-alpha', '2b', 'therapy', '.']","(33, 35)","(226, 238)",-1,ss_i,15014018,Abstract,0,test,gold,791.0
1619,PURPOSE,Nearly 2000 patients with stage IIB and III melanoma,"have participated in four multicenter , randomized trials , conducted by the Eastern Cooperative Oncology Group and the Intergroup , investigating adjuvant high-dose IFN-alpha 2b therapy .","['PURPOSE', 'Nearly', '2000', 'patients', 'with', 'stage', 'IIB', 'and', 'III', 'melanoma', 'have', 'participated', 'in', 'four', 'multicenter', ',', 'randomized', 'trials', ',', 'conducted', 'by', 'the', 'Eastern', 'Cooperative', 'Oncology', 'Group', 'and', 'the', 'Intergroup', ',', 'investigating', 'adjuvant', 'high-dose', 'IFN-alpha', '2b', 'therapy', '.']","(1, 10)","(7, 59)",-1,hl_p,15014018,Abstract,0,test,gold,6857.0
1620,"PURPOSE Nearly 2000 patients with stage IIB and III melanoma have participated in four multicenter , randomized trials , conducted by the Eastern Cooperative Oncology Group and the Intergroup , investigating adjuvant high-dose",IFN-alpha 2b,therapy .,"['PURPOSE', 'Nearly', '2000', 'patients', 'with', 'stage', 'IIB', 'and', 'III', 'melanoma', 'have', 'participated', 'in', 'four', 'multicenter', ',', 'randomized', 'trials', ',', 'conducted', 'by', 'the', 'Eastern', 'Cooperative', 'Oncology', 'Group', 'and', 'the', 'Intergroup', ',', 'investigating', 'adjuvant', 'high-dose', 'IFN-alpha', '2b', 'therapy', '.']","(33, 35)","(226, 238)",-1,hl_i,15014018,Abstract,0,test,gold,792.0
1621,The objectives of this study were to update the analyses of each individual trial and to analyze,prognostic factors and treatment effects,based on pooled data .,"['The', 'objectives', 'of', 'this', 'study', 'were', 'to', 'update', 'the', 'analyses', 'of', 'each', 'individual', 'trial', 'and', 'to', 'analyze', 'prognostic', 'factors', 'and', 'treatment', 'effects', 'based', 'on', 'pooled', 'data', '.']","(17, 22)","(96, 136)",-1,ss_o,15014018,Abstract,1,test,gold,6401.0
1622,EXPERIMENTAL DESIGN Survival and disease status were updated to April 2001 .,,,"['EXPERIMENTAL', 'DESIGN', 'Survival', 'and', 'disease', 'status', 'were', 'updated', 'to', 'April', '2001', '.']",,,,,15014018,Abstract,2,test,gold,
1623,Analysis of,prognostic factors using optimized statistical models,"was based on data from patients in E1684 , E1690 , E1694 , and E2696 .","['Analysis', 'of', 'prognostic', 'factors', 'using', 'optimized', 'statistical', 'models', 'was', 'based', 'on', 'data', 'from', 'patients', 'in', 'E1684', ',', 'E1690', ',', 'E1694', ',', 'and', 'E2696', '.']","(2, 8)","(11, 64)",-1,ss_o,15014018,Abstract,3,test,gold,6400.0
1624,Analysis of treatment effects versus,observation ( Obs ),was based on data from 713 patients randomized to high-dose IFN-alpha 2b ( HDI ) or Obs in Trials E1684 and E1690 .,"['Analysis', 'of', 'treatment', 'effects', 'versus', 'observation', '(', 'Obs', ')', 'was', 'based', 'on', 'data', 'from', '713', 'patients', 'randomized', 'to', 'high-dose', 'IFN-alpha', '2b', '(', 'HDI', ')', 'or', 'Obs', 'in', 'Trials', 'E1684', 'and', 'E1690', '.']","(5, 9)","(36, 55)",-1,ss_i,15014018,Abstract,4,test,gold,1098.0
1625,Analysis of treatment effects versus observation ( Obs ) was based on data from 713 patients randomized to high-dose,IFN-alpha 2b ( HDI ),or Obs in Trials E1684 and E1690 .,"['Analysis', 'of', 'treatment', 'effects', 'versus', 'observation', '(', 'Obs', ')', 'was', 'based', 'on', 'data', 'from', '713', 'patients', 'randomized', 'to', 'high-dose', 'IFN-alpha', '2b', '(', 'HDI', ')', 'or', 'Obs', 'in', 'Trials', 'E1684', 'and', 'E1690', '.']","(19, 24)","(116, 136)",-1,ss_i,15014018,Abstract,4,test,gold,793.0
1626,Analysis of treatment effects versus observation ( Obs ) was based on data from 713 patients randomized to high-dose IFN-alpha 2b ( HDI ) or,Obs,in Trials E1684 and E1690 .,"['Analysis', 'of', 'treatment', 'effects', 'versus', 'observation', '(', 'Obs', ')', 'was', 'based', 'on', 'data', 'from', '713', 'patients', 'randomized', 'to', 'high-dose', 'IFN-alpha', '2b', '(', 'HDI', ')', 'or', 'Obs', 'in', 'Trials', 'E1684', 'and', 'E1690', '.']","(25, 26)","(140, 143)",-1,ss_i,15014018,Abstract,4,test,gold,1103.0
1627,Analysis of,treatment effects versus observation ( Obs ),was based on data from 713 patients randomized to high-dose IFN-alpha 2b ( HDI ) or Obs in Trials E1684 and E1690 .,"['Analysis', 'of', 'treatment', 'effects', 'versus', 'observation', '(', 'Obs', ')', 'was', 'based', 'on', 'data', 'from', '713', 'patients', 'randomized', 'to', 'high-dose', 'IFN-alpha', '2b', '(', 'HDI', ')', 'or', 'Obs', 'in', 'Trials', 'E1684', 'and', 'E1690', '.']","(2, 9)","(11, 55)",-1,ss_o,15014018,Abstract,4,test,gold,3881.0
1628,Analysis of treatment effects versus observation ( Obs ) was based on data from 713 patients randomized to high-dose,IFN-alpha 2b ( HDI ),or Obs in Trials E1684 and E1690 .,"['Analysis', 'of', 'treatment', 'effects', 'versus', 'observation', '(', 'Obs', ')', 'was', 'based', 'on', 'data', 'from', '713', 'patients', 'randomized', 'to', 'high-dose', 'IFN-alpha', '2b', '(', 'HDI', ')', 'or', 'Obs', 'in', 'Trials', 'E1684', 'and', 'E1690', '.']","(19, 24)","(116, 136)",-1,hl_i,15014018,Abstract,4,test,gold,794.0
1629,Analysis of treatment effects versus observation ( Obs ) was based on data from 713 patients randomized to high-dose IFN-alpha 2b ( HDI ) or,Obs,in Trials E1684 and E1690 .,"['Analysis', 'of', 'treatment', 'effects', 'versus', 'observation', '(', 'Obs', ')', 'was', 'based', 'on', 'data', 'from', '713', 'patients', 'randomized', 'to', 'high-dose', 'IFN-alpha', '2b', '(', 'HDI', ')', 'or', 'Obs', 'in', 'Trials', 'E1684', 'and', 'E1690', '.']","(25, 26)","(140, 143)",-1,hl_i,15014018,Abstract,4,test,gold,1104.0
1630,"RESULTS Updated analysis of E1684 , E1690 , and E1694 confirmed their original conclusions , now at median follow-up intervals of 2.1-12.6 years .",,,"['RESULTS', 'Updated', 'analysis', 'of', 'E1684', ',', 'E1690', ',', 'and', 'E1694', 'confirmed', 'their', 'original', 'conclusions', ',', 'now', 'at', 'median', 'follow-up', 'intervals', 'of', '2.1-12.6', 'years', '.']",,,,,15014018,Abstract,5,test,gold,
1631,"Based on two-sided univariate log-rank analysis of pooled data from E1684 and E1690 ( median follow-up , 7.2 years ) , relapse-free survival ( RFS ) -but not overall survival ( OS ) -was significantly prolonged ( two-sided log-rank P value = 0.006 ) for patients treated with",HDI,versus Obs .,"['Based', 'on', 'two-sided', 'univariate', 'log-rank', 'analysis', 'of', 'pooled', 'data', 'from', 'E1684', 'and', 'E1690', '(', 'median', 'follow-up', ',', '7.2', 'years', ')', ',', 'relapse-free', 'survival', '(', 'RFS', ')', '-but', 'not', 'overall', 'survival', '(', 'OS', ')', '-was', 'significantly', 'prolonged', '(', 'two-sided', 'log-rank', 'P', 'value', '=', '0.006', ')', 'for', 'patients', 'treated', 'with', 'HDI', 'versus', 'Obs', '.']","(48, 49)","(275, 278)",-1,ss_i,15014018,Abstract,6,test,gold,604.0
1632,"Based on two-sided univariate log-rank analysis of pooled data from E1684 and E1690 ( median follow-up , 7.2 years ) , relapse-free survival ( RFS ) -but not overall survival ( OS ) -was significantly prolonged ( two-sided log-rank P value = 0.006 ) for patients treated with HDI versus",Obs .,,"['Based', 'on', 'two-sided', 'univariate', 'log-rank', 'analysis', 'of', 'pooled', 'data', 'from', 'E1684', 'and', 'E1690', '(', 'median', 'follow-up', ',', '7.2', 'years', ')', ',', 'relapse-free', 'survival', '(', 'RFS', ')', '-but', 'not', 'overall', 'survival', '(', 'OS', ')', '-was', 'significantly', 'prolonged', '(', 'two-sided', 'log-rank', 'P', 'value', '=', '0.006', ')', 'for', 'patients', 'treated', 'with', 'HDI', 'versus', 'Obs', '.']","(50, 52)","(286, 291)",-1,ss_i,15014018,Abstract,6,test,gold,1102.0
1633,"Based on two-sided univariate log-rank analysis of pooled data from E1684 and E1690 ( median follow-up , 7.2 years ) ,",relapse-free survival ( RFS ) -but,not overall survival ( OS ) -was significantly prolonged ( two-sided log-rank P value = 0.006 ) for patients treated with HDI versus Obs .,"['Based', 'on', 'two-sided', 'univariate', 'log-rank', 'analysis', 'of', 'pooled', 'data', 'from', 'E1684', 'and', 'E1690', '(', 'median', 'follow-up', ',', '7.2', 'years', ')', ',', 'relapse-free', 'survival', '(', 'RFS', ')', '-but', 'not', 'overall', 'survival', '(', 'OS', ')', '-was', 'significantly', 'prolonged', '(', 'two-sided', 'log-rank', 'P', 'value', '=', '0.006', ')', 'for', 'patients', 'treated', 'with', 'HDI', 'versus', 'Obs', '.']","(21, 27)","(118, 152)",-1,ss_o,15014018,Abstract,6,test,gold,739.0
1634,"Based on two-sided univariate log-rank analysis of pooled data from E1684 and E1690 ( median follow-up , 7.2 years ) , relapse-free survival ( RFS ) -but not",overall survival ( OS ) -was,significantly prolonged ( two-sided log-rank P value = 0.006 ) for patients treated with HDI versus Obs .,"['Based', 'on', 'two-sided', 'univariate', 'log-rank', 'analysis', 'of', 'pooled', 'data', 'from', 'E1684', 'and', 'E1690', '(', 'median', 'follow-up', ',', '7.2', 'years', ')', ',', 'relapse-free', 'survival', '(', 'RFS', ')', '-but', 'not', 'overall', 'survival', '(', 'OS', ')', '-was', 'significantly', 'prolonged', '(', 'two-sided', 'log-rank', 'P', 'value', '=', '0.006', ')', 'for', 'patients', 'treated', 'with', 'HDI', 'versus', 'Obs', '.']","(28, 34)","(157, 185)",-1,ss_o,15014018,Abstract,6,test,gold,1978.0
1635,"Based on two-sided univariate log-rank analysis of pooled data from E1684 and E1690 ( median follow-up , 7.2 years ) , relapse-free survival ( RFS ) -but not overall survival ( OS ) -was significantly prolonged ( two-sided log-rank P value = 0.006 ) for patients treated with",HDI,versus Obs .,"['Based', 'on', 'two-sided', 'univariate', 'log-rank', 'analysis', 'of', 'pooled', 'data', 'from', 'E1684', 'and', 'E1690', '(', 'median', 'follow-up', ',', '7.2', 'years', ')', ',', 'relapse-free', 'survival', '(', 'RFS', ')', '-but', 'not', 'overall', 'survival', '(', 'OS', ')', '-was', 'significantly', 'prolonged', '(', 'two-sided', 'log-rank', 'P', 'value', '=', '0.006', ')', 'for', 'patients', 'treated', 'with', 'HDI', 'versus', 'Obs', '.']","(48, 49)","(275, 278)",-1,hl_i,15014018,Abstract,6,test,gold,605.0
1636,"Based on two-sided univariate log-rank analysis of pooled data from E1684 and E1690 ( median follow-up , 7.2 years ) , relapse-free survival ( RFS ) -but not overall survival ( OS ) -was significantly prolonged ( two-sided log-rank P value = 0.006 ) for patients treated with HDI versus",Obs,.,"['Based', 'on', 'two-sided', 'univariate', 'log-rank', 'analysis', 'of', 'pooled', 'data', 'from', 'E1684', 'and', 'E1690', '(', 'median', 'follow-up', ',', '7.2', 'years', ')', ',', 'relapse-free', 'survival', '(', 'RFS', ')', '-but', 'not', 'overall', 'survival', '(', 'OS', ')', '-was', 'significantly', 'prolonged', '(', 'two-sided', 'log-rank', 'P', 'value', '=', '0.006', ')', 'for', 'patients', 'treated', 'with', 'HDI', 'versus', 'Obs', '.']","(50, 51)","(286, 289)",-1,hl_i,15014018,Abstract,6,test,gold,1101.0
1637,"Based on two-sided univariate log-rank analysis of pooled data from E1684 and E1690 ( median follow-up , 7.2 years ) ,",relapse-free survival ( RFS ),-but not overall survival ( OS ) -was significantly prolonged ( two-sided log-rank P value = 0.006 ) for patients treated with HDI versus Obs .,"['Based', 'on', 'two-sided', 'univariate', 'log-rank', 'analysis', 'of', 'pooled', 'data', 'from', 'E1684', 'and', 'E1690', '(', 'median', 'follow-up', ',', '7.2', 'years', ')', ',', 'relapse-free', 'survival', '(', 'RFS', ')', '-but', 'not', 'overall', 'survival', '(', 'OS', ')', '-was', 'significantly', 'prolonged', '(', 'two-sided', 'log-rank', 'P', 'value', '=', '0.006', ')', 'for', 'patients', 'treated', 'with', 'HDI', 'versus', 'Obs', '.']","(21, 26)","(118, 147)",-1,hl_o,15014018,Abstract,6,test,gold,740.0
1638,"Based on two-sided univariate log-rank analysis of pooled data from E1684 and E1690 ( median follow-up , 7.2 years ) , relapse-free survival ( RFS ) -but not",overall survival ( OS ),-was significantly prolonged ( two-sided log-rank P value = 0.006 ) for patients treated with HDI versus Obs .,"['Based', 'on', 'two-sided', 'univariate', 'log-rank', 'analysis', 'of', 'pooled', 'data', 'from', 'E1684', 'and', 'E1690', '(', 'median', 'follow-up', ',', '7.2', 'years', ')', ',', 'relapse-free', 'survival', '(', 'RFS', ')', '-but', 'not', 'overall', 'survival', '(', 'OS', ')', '-was', 'significantly', 'prolonged', '(', 'two-sided', 'log-rank', 'P', 'value', '=', '0.006', ')', 'for', 'patients', 'treated', 'with', 'HDI', 'versus', 'Obs', '.']","(28, 33)","(157, 180)",-1,hl_o,15014018,Abstract,6,test,gold,1979.0
1639,"Among all patients ,",prognostic factors,"that significantly negatively impacted RFS and OS included ulceration , recurrent disease at entry , enrollment in E1684 , and age > 49 years .","['Among', 'all', 'patients', ',', 'prognostic', 'factors', 'that', 'significantly', 'negatively', 'impacted', 'RFS', 'and', 'OS', 'included', 'ulceration', ',', 'recurrent', 'disease', 'at', 'entry', ',', 'enrollment', 'in', 'E1684', ',', 'and', 'age', '>', '49', 'years', '.']","(4, 6)","(20, 38)",-1,ss_o,15014018,Abstract,7,test,gold,6402.0
1640,"Among all patients , prognostic factors that significantly negatively impacted RFS and OS included","ulceration , recurrent disease at entry",", enrollment in E1684 , and age > 49 years .","['Among', 'all', 'patients', ',', 'prognostic', 'factors', 'that', 'significantly', 'negatively', 'impacted', 'RFS', 'and', 'OS', 'included', 'ulceration', ',', 'recurrent', 'disease', 'at', 'entry', ',', 'enrollment', 'in', 'E1684', ',', 'and', 'age', '>', '49', 'years', '.']","(14, 20)","(98, 137)",-1,ss_o,15014018,Abstract,7,test,gold,3557.0
1641,"Among all patients , prognostic factors that significantly negatively impacted RFS and OS included ulceration , recurrent disease at entry , enrollment in E1684 , and",age,> 49 years .,"['Among', 'all', 'patients', ',', 'prognostic', 'factors', 'that', 'significantly', 'negatively', 'impacted', 'RFS', 'and', 'OS', 'included', 'ulceration', ',', 'recurrent', 'disease', 'at', 'entry', ',', 'enrollment', 'in', 'E1684', ',', 'and', 'age', '>', '49', 'years', '.']","(26, 27)","(166, 169)",-1,ss_o,15014018,Abstract,7,test,gold,2012.0
1642,Multivariate statistical models adjusting for these factors confirmed the statistically significant RFS benefit of,HDI,versus Obs but did not demonstrate a significant OS benefit in the pooled populations .,"['Multivariate', 'statistical', 'models', 'adjusting', 'for', 'these', 'factors', 'confirmed', 'the', 'statistically', 'significant', 'RFS', 'benefit', 'of', 'HDI', 'versus', 'Obs', 'but', 'did', 'not', 'demonstrate', 'a', 'significant', 'OS', 'benefit', 'in', 'the', 'pooled', 'populations', '.']","(14, 15)","(114, 117)",-1,ss_i,15014018,Abstract,8,test,gold,603.0
1643,Multivariate statistical models adjusting for these factors confirmed the statistically significant RFS benefit of HDI versus,Obs,but did not demonstrate a significant OS benefit in the pooled populations .,"['Multivariate', 'statistical', 'models', 'adjusting', 'for', 'these', 'factors', 'confirmed', 'the', 'statistically', 'significant', 'RFS', 'benefit', 'of', 'HDI', 'versus', 'Obs', 'but', 'did', 'not', 'demonstrate', 'a', 'significant', 'OS', 'benefit', 'in', 'the', 'pooled', 'populations', '.']","(16, 17)","(125, 128)",-1,ss_i,15014018,Abstract,8,test,gold,1100.0
1644,Multivariate statistical models adjusting for these factors confirmed the statistically significant,RFS,benefit of HDI versus Obs but did not demonstrate a significant OS benefit in the pooled populations .,"['Multivariate', 'statistical', 'models', 'adjusting', 'for', 'these', 'factors', 'confirmed', 'the', 'statistically', 'significant', 'RFS', 'benefit', 'of', 'HDI', 'versus', 'Obs', 'but', 'did', 'not', 'demonstrate', 'a', 'significant', 'OS', 'benefit', 'in', 'the', 'pooled', 'populations', '.']","(11, 12)","(99, 102)",-1,ss_o,15014018,Abstract,8,test,gold,737.0
1645,Multivariate statistical models adjusting for these factors confirmed the statistically significant RFS benefit of HDI versus Obs but did not demonstrate a significant,OS,benefit in the pooled populations .,"['Multivariate', 'statistical', 'models', 'adjusting', 'for', 'these', 'factors', 'confirmed', 'the', 'statistically', 'significant', 'RFS', 'benefit', 'of', 'HDI', 'versus', 'Obs', 'but', 'did', 'not', 'demonstrate', 'a', 'significant', 'OS', 'benefit', 'in', 'the', 'pooled', 'populations', '.']","(23, 24)","(167, 169)",-1,ss_o,15014018,Abstract,8,test,gold,1244.0
1646,Multivariate statistical models adjusting for these factors confirmed the statistically significant RFS benefit of,HDI,versus Obs but did not demonstrate a significant OS benefit in the pooled populations .,"['Multivariate', 'statistical', 'models', 'adjusting', 'for', 'these', 'factors', 'confirmed', 'the', 'statistically', 'significant', 'RFS', 'benefit', 'of', 'HDI', 'versus', 'Obs', 'but', 'did', 'not', 'demonstrate', 'a', 'significant', 'OS', 'benefit', 'in', 'the', 'pooled', 'populations', '.']","(14, 15)","(114, 117)",-1,hl_i,15014018,Abstract,8,test,gold,602.0
1647,Multivariate statistical models adjusting for these factors confirmed the statistically significant RFS benefit of HDI versus,Obs,but did not demonstrate a significant OS benefit in the pooled populations .,"['Multivariate', 'statistical', 'models', 'adjusting', 'for', 'these', 'factors', 'confirmed', 'the', 'statistically', 'significant', 'RFS', 'benefit', 'of', 'HDI', 'versus', 'Obs', 'but', 'did', 'not', 'demonstrate', 'a', 'significant', 'OS', 'benefit', 'in', 'the', 'pooled', 'populations', '.']","(16, 17)","(125, 128)",-1,hl_i,15014018,Abstract,8,test,gold,1099.0
1648,Multivariate statistical models adjusting for these factors confirmed the statistically significant,RFS,benefit of HDI versus Obs but did not demonstrate a significant OS benefit in the pooled populations .,"['Multivariate', 'statistical', 'models', 'adjusting', 'for', 'these', 'factors', 'confirmed', 'the', 'statistically', 'significant', 'RFS', 'benefit', 'of', 'HDI', 'versus', 'Obs', 'but', 'did', 'not', 'demonstrate', 'a', 'significant', 'OS', 'benefit', 'in', 'the', 'pooled', 'populations', '.']","(11, 12)","(99, 102)",-1,hl_o,15014018,Abstract,8,test,gold,738.0
1649,Multivariate statistical models adjusting for these factors confirmed the statistically significant RFS benefit of HDI versus Obs but did not demonstrate a significant,OS,benefit in the pooled populations .,"['Multivariate', 'statistical', 'models', 'adjusting', 'for', 'these', 'factors', 'confirmed', 'the', 'statistically', 'significant', 'RFS', 'benefit', 'of', 'HDI', 'versus', 'Obs', 'but', 'did', 'not', 'demonstrate', 'a', 'significant', 'OS', 'benefit', 'in', 'the', 'pooled', 'populations', '.']","(23, 24)","(167, 169)",-1,hl_o,15014018,Abstract,8,test,gold,1245.0
1650,CONCLUSIONS In,patients with high-risk resected melanoma,", HDI is effective adjuvant therapy with strong evidence for improved RFS and evidence for moderate improvement in OS based on two prospective randomized studies but not the pooled analysis .","['CONCLUSIONS', 'In', 'patients', 'with', 'high-risk', 'resected', 'melanoma', ',', 'HDI', 'is', 'effective', 'adjuvant', 'therapy', 'with', 'strong', 'evidence', 'for', 'improved', 'RFS', 'and', 'evidence', 'for', 'moderate', 'improvement', 'in', 'OS', 'based', 'on', 'two', 'prospective', 'randomized', 'studies', 'but', 'not', 'the', 'pooled', 'analysis', '.']","(2, 7)","(14, 55)",-1,ss_p,15014018,Abstract,9,test,gold,6841.0
1651,"CONCLUSIONS In patients with high-risk resected melanoma , HDI is effective adjuvant therapy with strong evidence for improved",RFS,and evidence for moderate improvement in OS based on two prospective randomized studies but not the pooled analysis .,"['CONCLUSIONS', 'In', 'patients', 'with', 'high-risk', 'resected', 'melanoma', ',', 'HDI', 'is', 'effective', 'adjuvant', 'therapy', 'with', 'strong', 'evidence', 'for', 'improved', 'RFS', 'and', 'evidence', 'for', 'moderate', 'improvement', 'in', 'OS', 'based', 'on', 'two', 'prospective', 'randomized', 'studies', 'but', 'not', 'the', 'pooled', 'analysis', '.']","(18, 19)","(126, 129)",-1,ss_o,15014018,Abstract,9,test,gold,736.0
1652,"CONCLUSIONS In patients with high-risk resected melanoma , HDI is effective adjuvant therapy with strong evidence for improved RFS and evidence for moderate improvement in",OS,based on two prospective randomized studies but not the pooled analysis .,"['CONCLUSIONS', 'In', 'patients', 'with', 'high-risk', 'resected', 'melanoma', ',', 'HDI', 'is', 'effective', 'adjuvant', 'therapy', 'with', 'strong', 'evidence', 'for', 'improved', 'RFS', 'and', 'evidence', 'for', 'moderate', 'improvement', 'in', 'OS', 'based', 'on', 'two', 'prospective', 'randomized', 'studies', 'but', 'not', 'the', 'pooled', 'analysis', '.']","(25, 26)","(171, 173)",-1,ss_o,15014018,Abstract,9,test,gold,1243.0
1653,CONCLUSIONS In,patients with high-risk resected melanoma,", HDI is effective adjuvant therapy with strong evidence for improved RFS and evidence for moderate improvement in OS based on two prospective randomized studies but not the pooled analysis .","['CONCLUSIONS', 'In', 'patients', 'with', 'high-risk', 'resected', 'melanoma', ',', 'HDI', 'is', 'effective', 'adjuvant', 'therapy', 'with', 'strong', 'evidence', 'for', 'improved', 'RFS', 'and', 'evidence', 'for', 'moderate', 'improvement', 'in', 'OS', 'based', 'on', 'two', 'prospective', 'randomized', 'studies', 'but', 'not', 'the', 'pooled', 'analysis', '.']","(2, 7)","(14, 55)",-1,hl_p,15014018,Abstract,9,test,gold,6842.0
1654,"CONCLUSIONS In patients with high-risk resected melanoma , HDI is effective adjuvant therapy with strong evidence for improved",RFS,and evidence for moderate improvement in OS based on two prospective randomized studies but not the pooled analysis .,"['CONCLUSIONS', 'In', 'patients', 'with', 'high-risk', 'resected', 'melanoma', ',', 'HDI', 'is', 'effective', 'adjuvant', 'therapy', 'with', 'strong', 'evidence', 'for', 'improved', 'RFS', 'and', 'evidence', 'for', 'moderate', 'improvement', 'in', 'OS', 'based', 'on', 'two', 'prospective', 'randomized', 'studies', 'but', 'not', 'the', 'pooled', 'analysis', '.']","(18, 19)","(126, 129)",-1,hl_o,15014018,Abstract,9,test,gold,735.0
1655,"CONCLUSIONS In patients with high-risk resected melanoma , HDI is effective adjuvant therapy with strong evidence for improved RFS and evidence for moderate improvement in",OS,based on two prospective randomized studies but not the pooled analysis .,"['CONCLUSIONS', 'In', 'patients', 'with', 'high-risk', 'resected', 'melanoma', ',', 'HDI', 'is', 'effective', 'adjuvant', 'therapy', 'with', 'strong', 'evidence', 'for', 'improved', 'RFS', 'and', 'evidence', 'for', 'moderate', 'improvement', 'in', 'OS', 'based', 'on', 'two', 'prospective', 'randomized', 'studies', 'but', 'not', 'the', 'pooled', 'analysis', '.']","(25, 26)","(171, 173)",-1,hl_o,15014018,Abstract,9,test,gold,1242.0
1656,Analyses of,predictors of relapse and response,are now needed to improve the therapeutic value of this modality .,"['Analyses', 'of', 'predictors', 'of', 'relapse', 'and', 'response', 'are', 'now', 'needed', 'to', 'improve', 'the', 'therapeutic', 'value', 'of', 'this', 'modality', '.']","(2, 7)","(11, 45)",-1,ss_o,15014018,Abstract,10,test,gold,6398.0
1657,A randomized comparison of alternative techniques to achieve coronary sinus cannulation during,biventricular implantation procedures .,,"['A', 'randomized', 'comparison', 'of', 'alternative', 'techniques', 'to', 'achieve', 'coronary', 'sinus', 'cannulation', 'during', 'biventricular', 'implantation', 'procedures', '.']","(12, 16)","(94, 133)",-1,ss_p,15133359,Title,0,test,gold,3200.0
1658,A randomized comparison of alternative techniques to achieve coronary sinus cannulation during,biventricular implantation,procedures .,"['A', 'randomized', 'comparison', 'of', 'alternative', 'techniques', 'to', 'achieve', 'coronary', 'sinus', 'cannulation', 'during', 'biventricular', 'implantation', 'procedures', '.']","(12, 14)","(94, 120)",-1,hl_p,15133359,Title,0,test,gold,3201.0
1659,INTRODUCTION Biventricular pacing system implantation is a time-consuming and challenging procedure .,,,"['INTRODUCTION', 'Biventricular', 'pacing', 'system', 'implantation', 'is', 'a', 'time-consuming', 'and', 'challenging', 'procedure', '.']",,,,,15133359,Abstract,0,test,gold,
1660,A critical step in biventricular pacemaker implantation is coronary sinus ( CS ) cannulation .,,,"['A', 'critical', 'step', 'in', 'biventricular', 'pacemaker', 'implantation', 'is', 'coronary', 'sinus', '(', 'CS', ')', 'cannulation', '.']",,,,,15133359,Abstract,1,test,gold,
1661,CS cannulation can be achieved either using dedicated guiding,catheters ( guiding catheter alone,"positioning strategy , GCA ) or with the aid of an electrophysiology catheter advanced inside the guiding catheter ( electrophysiology catheter aided positioning strategy , EPA ) .","['CS', 'cannulation', 'can', 'be', 'achieved', 'either', 'using', 'dedicated', 'guiding', 'catheters', '(', 'guiding', 'catheter', 'alone', 'positioning', 'strategy', ',', 'GCA', ')', 'or', 'with', 'the', 'aid', 'of', 'an', 'electrophysiology', 'catheter', 'advanced', 'inside', 'the', 'guiding', 'catheter', '(', 'electrophysiology', 'catheter', 'aided', 'positioning', 'strategy', ',', 'EPA', ')', '.']","(9, 14)","(61, 95)",-1,ss_i,15133359,Abstract,2,test,gold,4054.0
1662,"CS cannulation can be achieved either using dedicated guiding catheters ( guiding catheter alone positioning strategy , GCA ) or with the aid of an",electrophysiology catheter advanced,"inside the guiding catheter ( electrophysiology catheter aided positioning strategy , EPA ) .","['CS', 'cannulation', 'can', 'be', 'achieved', 'either', 'using', 'dedicated', 'guiding', 'catheters', '(', 'guiding', 'catheter', 'alone', 'positioning', 'strategy', ',', 'GCA', ')', 'or', 'with', 'the', 'aid', 'of', 'an', 'electrophysiology', 'catheter', 'advanced', 'inside', 'the', 'guiding', 'catheter', '(', 'electrophysiology', 'catheter', 'aided', 'positioning', 'strategy', ',', 'EPA', ')', '.']","(25, 28)","(147, 182)",-1,ss_i,15133359,Abstract,2,test,gold,4045.0
1663,"CS cannulation can be achieved either using dedicated guiding catheters ( guiding catheter alone positioning strategy , GCA ) or with the aid of an electrophysiology catheter advanced inside the guiding catheter",( electrophysiology catheter aided,"positioning strategy , EPA ) .","['CS', 'cannulation', 'can', 'be', 'achieved', 'either', 'using', 'dedicated', 'guiding', 'catheters', '(', 'guiding', 'catheter', 'alone', 'positioning', 'strategy', ',', 'GCA', ')', 'or', 'with', 'the', 'aid', 'of', 'an', 'electrophysiology', 'catheter', 'advanced', 'inside', 'the', 'guiding', 'catheter', '(', 'electrophysiology', 'catheter', 'aided', 'positioning', 'strategy', ',', 'EPA', ')', '.']","(32, 36)","(211, 245)",-1,ss_i,15133359,Abstract,2,test,gold,4043.0
1664,CS cannulation can be achieved either using dedicated guiding,catheters,"( guiding catheter alone positioning strategy , GCA ) or with the aid of an electrophysiology catheter advanced inside the guiding catheter ( electrophysiology catheter aided positioning strategy , EPA ) .","['CS', 'cannulation', 'can', 'be', 'achieved', 'either', 'using', 'dedicated', 'guiding', 'catheters', '(', 'guiding', 'catheter', 'alone', 'positioning', 'strategy', ',', 'GCA', ')', 'or', 'with', 'the', 'aid', 'of', 'an', 'electrophysiology', 'catheter', 'advanced', 'inside', 'the', 'guiding', 'catheter', '(', 'electrophysiology', 'catheter', 'aided', 'positioning', 'strategy', ',', 'EPA', ')', '.']","(9, 10)","(61, 70)",-1,hl_i,15133359,Abstract,2,test,gold,4048.0
1665,CS cannulation can be achieved either using dedicated guiding catheters (,guiding catheter alone,"positioning strategy , GCA ) or with the aid of an electrophysiology catheter advanced inside the guiding catheter ( electrophysiology catheter aided positioning strategy , EPA ) .","['CS', 'cannulation', 'can', 'be', 'achieved', 'either', 'using', 'dedicated', 'guiding', 'catheters', '(', 'guiding', 'catheter', 'alone', 'positioning', 'strategy', ',', 'GCA', ')', 'or', 'with', 'the', 'aid', 'of', 'an', 'electrophysiology', 'catheter', 'advanced', 'inside', 'the', 'guiding', 'catheter', '(', 'electrophysiology', 'catheter', 'aided', 'positioning', 'strategy', ',', 'EPA', ')', '.']","(11, 14)","(73, 95)",-1,hl_i,15133359,Abstract,2,test,gold,4055.0
1666,"CS cannulation can be achieved either using dedicated guiding catheters ( guiding catheter alone positioning strategy ,",GCA,") or with the aid of an electrophysiology catheter advanced inside the guiding catheter ( electrophysiology catheter aided positioning strategy , EPA ) .","['CS', 'cannulation', 'can', 'be', 'achieved', 'either', 'using', 'dedicated', 'guiding', 'catheters', '(', 'guiding', 'catheter', 'alone', 'positioning', 'strategy', ',', 'GCA', ')', 'or', 'with', 'the', 'aid', 'of', 'an', 'electrophysiology', 'catheter', 'advanced', 'inside', 'the', 'guiding', 'catheter', '(', 'electrophysiology', 'catheter', 'aided', 'positioning', 'strategy', ',', 'EPA', ')', '.']","(17, 18)","(119, 122)",-1,hl_i,15133359,Abstract,2,test,gold,729.0
1667,"CS cannulation can be achieved either using dedicated guiding catheters ( guiding catheter alone positioning strategy , GCA ) or with the aid of an",electrophysiology catheter advanced,"inside the guiding catheter ( electrophysiology catheter aided positioning strategy , EPA ) .","['CS', 'cannulation', 'can', 'be', 'achieved', 'either', 'using', 'dedicated', 'guiding', 'catheters', '(', 'guiding', 'catheter', 'alone', 'positioning', 'strategy', ',', 'GCA', ')', 'or', 'with', 'the', 'aid', 'of', 'an', 'electrophysiology', 'catheter', 'advanced', 'inside', 'the', 'guiding', 'catheter', '(', 'electrophysiology', 'catheter', 'aided', 'positioning', 'strategy', ',', 'EPA', ')', '.']","(25, 28)","(147, 182)",-1,hl_i,15133359,Abstract,2,test,gold,4046.0
1668,"CS cannulation can be achieved either using dedicated guiding catheters ( guiding catheter alone positioning strategy , GCA ) or with the aid of an electrophysiology catheter advanced inside the guiding catheter (",electrophysiology catheter aided,"positioning strategy , EPA ) .","['CS', 'cannulation', 'can', 'be', 'achieved', 'either', 'using', 'dedicated', 'guiding', 'catheters', '(', 'guiding', 'catheter', 'alone', 'positioning', 'strategy', ',', 'GCA', ')', 'or', 'with', 'the', 'aid', 'of', 'an', 'electrophysiology', 'catheter', 'advanced', 'inside', 'the', 'guiding', 'catheter', '(', 'electrophysiology', 'catheter', 'aided', 'positioning', 'strategy', ',', 'EPA', ')', '.']","(33, 36)","(213, 245)",-1,hl_i,15133359,Abstract,2,test,gold,4044.0
1669,AIM OF THE STUDY To evaluate whether the,EPA,technique is useful for reducing CS cannulation time compared to a conventional GCA technique .,"['AIM', 'OF', 'THE', 'STUDY', 'To', 'evaluate', 'whether', 'the', 'EPA', 'technique', 'is', 'useful', 'for', 'reducing', 'CS', 'cannulation', 'time', 'compared', 'to', 'a', 'conventional', 'GCA', 'technique', '.']","(8, 9)","(40, 43)",-1,ss_i,15133359,Abstract,3,test,gold,523.0
1670,AIM OF THE STUDY To evaluate whether the EPA technique is useful for reducing CS cannulation time compared to a conventional,GCA,technique .,"['AIM', 'OF', 'THE', 'STUDY', 'To', 'evaluate', 'whether', 'the', 'EPA', 'technique', 'is', 'useful', 'for', 'reducing', 'CS', 'cannulation', 'time', 'compared', 'to', 'a', 'conventional', 'GCA', 'technique', '.']","(21, 22)","(124, 127)",-1,ss_i,15133359,Abstract,3,test,gold,730.0
1671,AIM OF THE STUDY To evaluate whether the EPA technique is useful for reducing,CS cannulation time,compared to a conventional GCA technique .,"['AIM', 'OF', 'THE', 'STUDY', 'To', 'evaluate', 'whether', 'the', 'EPA', 'technique', 'is', 'useful', 'for', 'reducing', 'CS', 'cannulation', 'time', 'compared', 'to', 'a', 'conventional', 'GCA', 'technique', '.']","(14, 17)","(77, 96)",-1,ss_o,15133359,Abstract,3,test,gold,4128.0
1672,AIM OF THE STUDY To evaluate whether the,EPA,technique is useful for reducing CS cannulation time compared to a conventional GCA technique .,"['AIM', 'OF', 'THE', 'STUDY', 'To', 'evaluate', 'whether', 'the', 'EPA', 'technique', 'is', 'useful', 'for', 'reducing', 'CS', 'cannulation', 'time', 'compared', 'to', 'a', 'conventional', 'GCA', 'technique', '.']","(8, 9)","(40, 43)",-1,hl_i,15133359,Abstract,3,test,gold,524.0
1673,AIM OF THE STUDY To evaluate whether the EPA technique is useful for reducing CS cannulation time compared to a conventional,GCA,technique .,"['AIM', 'OF', 'THE', 'STUDY', 'To', 'evaluate', 'whether', 'the', 'EPA', 'technique', 'is', 'useful', 'for', 'reducing', 'CS', 'cannulation', 'time', 'compared', 'to', 'a', 'conventional', 'GCA', 'technique', '.']","(21, 22)","(124, 127)",-1,hl_i,15133359,Abstract,3,test,gold,728.0
1674,AIM OF THE STUDY To evaluate whether the EPA technique is useful for reducing,CS cannulation time,compared to a conventional GCA technique .,"['AIM', 'OF', 'THE', 'STUDY', 'To', 'evaluate', 'whether', 'the', 'EPA', 'technique', 'is', 'useful', 'for', 'reducing', 'CS', 'cannulation', 'time', 'compared', 'to', 'a', 'conventional', 'GCA', 'technique', '.']","(14, 17)","(77, 96)",-1,hl_o,15133359,Abstract,3,test,gold,4129.0
1675,METHODS,Thirty-four consecutive patients,were randomly assigned to the GCA ( 18 patients ) or EPA ( 16 patients ) CS cannulation strategy .,"['METHODS', 'Thirty-four', 'consecutive', 'patients', 'were', 'randomly', 'assigned', 'to', 'the', 'GCA', '(', '18', 'patients', ')', 'or', 'EPA', '(', '16', 'patients', ')', 'CS', 'cannulation', 'strategy', '.']","(1, 4)","(7, 39)",-1,ss_p,15133359,Abstract,4,test,gold,3724.0
1676,METHODS Thirty-four consecutive patients were randomly assigned to the,GCA,( 18 patients ) or EPA ( 16 patients ) CS cannulation strategy .,"['METHODS', 'Thirty-four', 'consecutive', 'patients', 'were', 'randomly', 'assigned', 'to', 'the', 'GCA', '(', '18', 'patients', ')', 'or', 'EPA', '(', '16', 'patients', ')', 'CS', 'cannulation', 'strategy', '.']","(9, 10)","(70, 73)",-1,ss_i,15133359,Abstract,4,test,gold,727.0
1677,METHODS Thirty-four consecutive patients were randomly assigned to the GCA ( 18 patients ) or,EPA,( 16 patients ) CS cannulation strategy .,"['METHODS', 'Thirty-four', 'consecutive', 'patients', 'were', 'randomly', 'assigned', 'to', 'the', 'GCA', '(', '18', 'patients', ')', 'or', 'EPA', '(', '16', 'patients', ')', 'CS', 'cannulation', 'strategy', '.']","(15, 16)","(93, 96)",-1,ss_i,15133359,Abstract,4,test,gold,522.0
1678,METHODS,Thirty-four consecutive patients,were randomly assigned to the GCA ( 18 patients ) or EPA ( 16 patients ) CS cannulation strategy .,"['METHODS', 'Thirty-four', 'consecutive', 'patients', 'were', 'randomly', 'assigned', 'to', 'the', 'GCA', '(', '18', 'patients', ')', 'or', 'EPA', '(', '16', 'patients', ')', 'CS', 'cannulation', 'strategy', '.']","(1, 4)","(7, 39)",-1,hl_p,15133359,Abstract,4,test,gold,3725.0
1679,METHODS Thirty-four consecutive patients were randomly assigned to the,GCA,( 18 patients ) or EPA ( 16 patients ) CS cannulation strategy .,"['METHODS', 'Thirty-four', 'consecutive', 'patients', 'were', 'randomly', 'assigned', 'to', 'the', 'GCA', '(', '18', 'patients', ')', 'or', 'EPA', '(', '16', 'patients', ')', 'CS', 'cannulation', 'strategy', '.']","(9, 10)","(70, 73)",-1,hl_i,15133359,Abstract,4,test,gold,726.0
1680,METHODS Thirty-four consecutive patients were randomly assigned to the GCA ( 18 patients ) or,EPA,( 16 patients ) CS cannulation strategy .,"['METHODS', 'Thirty-four', 'consecutive', 'patients', 'were', 'randomly', 'assigned', 'to', 'the', 'GCA', '(', '18', 'patients', ')', 'or', 'EPA', '(', '16', 'patients', ')', 'CS', 'cannulation', 'strategy', '.']","(15, 16)","(93, 96)",-1,hl_i,15133359,Abstract,4,test,gold,521.0
1681,RESULTS Time to successful catheterization of CS was 5.0 +/- 2.4 min in the,EPA,group versus 10.1 +/- 5.4 min in the GCA group p = 0.004 .,"['RESULTS', 'Time', 'to', 'successful', 'catheterization', 'of', 'CS', 'was', '5.0', '+/-', '2.4', 'min', 'in', 'the', 'EPA', 'group', 'versus', '10.1', '+/-', '5.4', 'min', 'in', 'the', 'GCA', 'group', 'p', '=', '0.004', '.']","(14, 15)","(75, 78)",-1,ss_i,15133359,Abstract,5,test,gold,520.0
1682,RESULTS Time to successful catheterization of CS was 5.0 +/- 2.4 min in the EPA group versus 10.1 +/- 5.4 min in the,GCA,group p = 0.004 .,"['RESULTS', 'Time', 'to', 'successful', 'catheterization', 'of', 'CS', 'was', '5.0', '+/-', '2.4', 'min', 'in', 'the', 'EPA', 'group', 'versus', '10.1', '+/-', '5.4', 'min', 'in', 'the', 'GCA', 'group', 'p', '=', '0.004', '.']","(23, 24)","(116, 119)",-1,ss_i,15133359,Abstract,5,test,gold,725.0
1683,RESULTS,Time to successful catheterization of CS,was 5.0 +/- 2.4 min in the EPA group versus 10.1 +/- 5.4 min in the GCA group p = 0.004 .,"['RESULTS', 'Time', 'to', 'successful', 'catheterization', 'of', 'CS', 'was', '5.0', '+/-', '2.4', 'min', 'in', 'the', 'EPA', 'group', 'versus', '10.1', '+/-', '5.4', 'min', 'in', 'the', 'GCA', 'group', 'p', '=', '0.004', '.']","(1, 7)","(7, 47)",-1,ss_o,15133359,Abstract,5,test,gold,4130.0
1684,RESULTS Time to successful catheterization of CS was 5.0 +/- 2.4 min in the,EPA,group versus 10.1 +/- 5.4 min in the GCA group p = 0.004 .,"['RESULTS', 'Time', 'to', 'successful', 'catheterization', 'of', 'CS', 'was', '5.0', '+/-', '2.4', 'min', 'in', 'the', 'EPA', 'group', 'versus', '10.1', '+/-', '5.4', 'min', 'in', 'the', 'GCA', 'group', 'p', '=', '0.004', '.']","(14, 15)","(75, 78)",-1,hl_i,15133359,Abstract,5,test,gold,519.0
1685,RESULTS Time to successful catheterization of CS was 5.0 +/- 2.4 min in the EPA group versus 10.1 +/- 5.4 min in the,GCA,group p = 0.004 .,"['RESULTS', 'Time', 'to', 'successful', 'catheterization', 'of', 'CS', 'was', '5.0', '+/-', '2.4', 'min', 'in', 'the', 'EPA', 'group', 'versus', '10.1', '+/-', '5.4', 'min', 'in', 'the', 'GCA', 'group', 'p', '=', '0.004', '.']","(23, 24)","(116, 119)",-1,hl_i,15133359,Abstract,5,test,gold,724.0
1686,RESULTS,Time to successful catheterization of CS,was 5.0 +/- 2.4 min in the EPA group versus 10.1 +/- 5.4 min in the GCA group p = 0.004 .,"['RESULTS', 'Time', 'to', 'successful', 'catheterization', 'of', 'CS', 'was', '5.0', '+/-', '2.4', 'min', 'in', 'the', 'EPA', 'group', 'versus', '10.1', '+/-', '5.4', 'min', 'in', 'the', 'GCA', 'group', 'p', '=', '0.004', '.']","(1, 7)","(7, 47)",-1,hl_o,15133359,Abstract,5,test,gold,4131.0
1687,Fluoroscopy time was 4.6 +/- 2.3 min in the,EPA,group versus 9.2 +/- 4.9 min in the GCA group p = 0.004 .,"['Fluoroscopy', 'time', 'was', '4.6', '+/-', '2.3', 'min', 'in', 'the', 'EPA', 'group', 'versus', '9.2', '+/-', '4.9', 'min', 'in', 'the', 'GCA', 'group', 'p', '=', '0.004', '.']","(9, 10)","(43, 46)",-1,ss_i,15133359,Abstract,6,test,gold,518.0
1688,Fluoroscopy time was 4.6 +/- 2.3 min in the EPA group versus 9.2 +/- 4.9 min in the,GCA,group p = 0.004 .,"['Fluoroscopy', 'time', 'was', '4.6', '+/-', '2.3', 'min', 'in', 'the', 'EPA', 'group', 'versus', '9.2', '+/-', '4.9', 'min', 'in', 'the', 'GCA', 'group', 'p', '=', '0.004', '.']","(18, 19)","(83, 86)",-1,ss_i,15133359,Abstract,6,test,gold,723.0
1689,,Fluoroscopy time,was 4.6 +/- 2.3 min in the EPA group versus 9.2 +/- 4.9 min in the GCA group p = 0.004 .,"['Fluoroscopy', 'time', 'was', '4.6', '+/-', '2.3', 'min', 'in', 'the', 'EPA', 'group', 'versus', '9.2', '+/-', '4.9', 'min', 'in', 'the', 'GCA', 'group', 'p', '=', '0.004', '.']","(0, 2)","(0, 16)",-1,ss_o,15133359,Abstract,6,test,gold,1105.0
1690,Fluoroscopy time was 4.6 +/- 2.3 min in the,EPA,group versus 9.2 +/- 4.9 min in the GCA group p = 0.004 .,"['Fluoroscopy', 'time', 'was', '4.6', '+/-', '2.3', 'min', 'in', 'the', 'EPA', 'group', 'versus', '9.2', '+/-', '4.9', 'min', 'in', 'the', 'GCA', 'group', 'p', '=', '0.004', '.']","(9, 10)","(43, 46)",-1,hl_i,15133359,Abstract,6,test,gold,517.0
1691,Fluoroscopy time was 4.6 +/- 2.3 min in the EPA group versus 9.2 +/- 4.9 min in the,GCA,group p = 0.004 .,"['Fluoroscopy', 'time', 'was', '4.6', '+/-', '2.3', 'min', 'in', 'the', 'EPA', 'group', 'versus', '9.2', '+/-', '4.9', 'min', 'in', 'the', 'GCA', 'group', 'p', '=', '0.004', '.']","(18, 19)","(83, 86)",-1,hl_i,15133359,Abstract,6,test,gold,722.0
1692,,Fluoroscopy time,was 4.6 +/- 2.3 min in the EPA group versus 9.2 +/- 4.9 min in the GCA group p = 0.004 .,"['Fluoroscopy', 'time', 'was', '4.6', '+/-', '2.3', 'min', 'in', 'the', 'EPA', 'group', 'versus', '9.2', '+/-', '4.9', 'min', 'in', 'the', 'GCA', 'group', 'p', '=', '0.004', '.']","(0, 2)","(0, 16)",-1,hl_o,15133359,Abstract,6,test,gold,1106.0
1693,Total contrast dye volume to search and engage the CS ostium was 0.0 ml in the,EPA,group versus 14.3 +/- 3.4 ml in the GCA group p < 0.001 .,"['Total', 'contrast', 'dye', 'volume', 'to', 'search', 'and', 'engage', 'the', 'CS', 'ostium', 'was', '0.0', 'ml', 'in', 'the', 'EPA', 'group', 'versus', '14.3', '+/-', '3.4', 'ml', 'in', 'the', 'GCA', 'group', 'p', '<', '0.001', '.']","(16, 17)","(78, 81)",-1,ss_i,15133359,Abstract,7,test,gold,516.0
1694,Total contrast dye volume to search and engage the CS ostium was 0.0 ml in the EPA group versus 14.3 +/- 3.4 ml in the,GCA,group p < 0.001 .,"['Total', 'contrast', 'dye', 'volume', 'to', 'search', 'and', 'engage', 'the', 'CS', 'ostium', 'was', '0.0', 'ml', 'in', 'the', 'EPA', 'group', 'versus', '14.3', '+/-', '3.4', 'ml', 'in', 'the', 'GCA', 'group', 'p', '<', '0.001', '.']","(25, 26)","(118, 121)",-1,ss_i,15133359,Abstract,7,test,gold,721.0
1695,Total,contrast dye volume,to search and engage the CS ostium was 0.0 ml in the EPA group versus 14.3 +/- 3.4 ml in the GCA group p < 0.001 .,"['Total', 'contrast', 'dye', 'volume', 'to', 'search', 'and', 'engage', 'the', 'CS', 'ostium', 'was', '0.0', 'ml', 'in', 'the', 'EPA', 'group', 'versus', '14.3', '+/-', '3.4', 'ml', 'in', 'the', 'GCA', 'group', 'p', '<', '0.001', '.']","(1, 4)","(5, 24)",-1,ss_o,15133359,Abstract,7,test,gold,1776.0
1696,Total contrast dye volume to search and engage the CS ostium was 0.0 ml in the,EPA,group versus 14.3 +/- 3.4 ml in the GCA group p < 0.001 .,"['Total', 'contrast', 'dye', 'volume', 'to', 'search', 'and', 'engage', 'the', 'CS', 'ostium', 'was', '0.0', 'ml', 'in', 'the', 'EPA', 'group', 'versus', '14.3', '+/-', '3.4', 'ml', 'in', 'the', 'GCA', 'group', 'p', '<', '0.001', '.']","(16, 17)","(78, 81)",-1,hl_i,15133359,Abstract,7,test,gold,515.0
1697,Total contrast dye volume to search and engage the CS ostium was 0.0 ml in the EPA group versus 14.3 +/- 3.4 ml in the,GCA,group p < 0.001 .,"['Total', 'contrast', 'dye', 'volume', 'to', 'search', 'and', 'engage', 'the', 'CS', 'ostium', 'was', '0.0', 'ml', 'in', 'the', 'EPA', 'group', 'versus', '14.3', '+/-', '3.4', 'ml', 'in', 'the', 'GCA', 'group', 'p', '<', '0.001', '.']","(25, 26)","(118, 121)",-1,hl_i,15133359,Abstract,7,test,gold,720.0
1698,Total,contrast dye volume,to search and engage the CS ostium was 0.0 ml in the EPA group versus 14.3 +/- 3.4 ml in the GCA group p < 0.001 .,"['Total', 'contrast', 'dye', 'volume', 'to', 'search', 'and', 'engage', 'the', 'CS', 'ostium', 'was', '0.0', 'ml', 'in', 'the', 'EPA', 'group', 'versus', '14.3', '+/-', '3.4', 'ml', 'in', 'the', 'GCA', 'group', 'p', '<', '0.001', '.']","(1, 4)","(5, 24)",-1,hl_o,15133359,Abstract,7,test,gold,1777.0
1699,CONCLUSIONS Cannulation of CS with the adjunct of an electrophysiology catheter to dedicated delivery systems significantly reduces,"procedural time , fluoroscopy time and contrast dye volume",compared to a conventional strategy .,"['CONCLUSIONS', 'Cannulation', 'of', 'CS', 'with', 'the', 'adjunct', 'of', 'an', 'electrophysiology', 'catheter', 'to', 'dedicated', 'delivery', 'systems', 'significantly', 'reduces', 'procedural', 'time', ',', 'fluoroscopy', 'time', 'and', 'contrast', 'dye', 'volume', 'compared', 'to', 'a', 'conventional', 'strategy', '.']","(17, 26)","(131, 189)",-1,ss_o,15133359,Abstract,8,test,gold,4126.0
1700,CONCLUSIONS Cannulation of CS with the adjunct of an electrophysiology catheter to dedicated delivery systems significantly reduces,"procedural time , fluoroscopy time",and contrast dye volume compared to a conventional strategy .,"['CONCLUSIONS', 'Cannulation', 'of', 'CS', 'with', 'the', 'adjunct', 'of', 'an', 'electrophysiology', 'catheter', 'to', 'dedicated', 'delivery', 'systems', 'significantly', 'reduces', 'procedural', 'time', ',', 'fluoroscopy', 'time', 'and', 'contrast', 'dye', 'volume', 'compared', 'to', 'a', 'conventional', 'strategy', '.']","(17, 22)","(131, 165)",-1,hl_o,15133359,Abstract,8,test,gold,4127.0
1701,"CONCLUSIONS Cannulation of CS with the adjunct of an electrophysiology catheter to dedicated delivery systems significantly reduces procedural time , fluoroscopy time and",contrast dye volume,compared to a conventional strategy .,"['CONCLUSIONS', 'Cannulation', 'of', 'CS', 'with', 'the', 'adjunct', 'of', 'an', 'electrophysiology', 'catheter', 'to', 'dedicated', 'delivery', 'systems', 'significantly', 'reduces', 'procedural', 'time', ',', 'fluoroscopy', 'time', 'and', 'contrast', 'dye', 'volume', 'compared', 'to', 'a', 'conventional', 'strategy', '.']","(23, 26)","(170, 189)",-1,hl_o,15133359,Abstract,8,test,gold,1775.0
1702,Combined descriptive and explanatory information improves,peers ',perceptions of autism .,"['Combined', 'descriptive', 'and', 'explanatory', 'information', 'improves', 'peers', ""'"", 'perceptions', 'of', 'autism', '.']","(6, 8)","(57, 64)",-1,ss_p,15193668,Title,0,test,gold,2620.0
1703,,Combined descriptive and explanatory information,improves peers ' perceptions of autism .,"['Combined', 'descriptive', 'and', 'explanatory', 'information', 'improves', 'peers', ""'"", 'perceptions', 'of', 'autism', '.']","(0, 5)","(0, 48)",-1,ss_i,15193668,Title,0,test,gold,2977.0
1704,Combined descriptive and explanatory information improves,peers ' perceptions,of autism .,"['Combined', 'descriptive', 'and', 'explanatory', 'information', 'improves', 'peers', ""'"", 'perceptions', 'of', 'autism', '.']","(6, 9)","(57, 76)",-1,ss_o,15193668,Title,0,test,gold,2623.0
1705,Combined descriptive and explanatory information improves,peers,' perceptions of autism .,"['Combined', 'descriptive', 'and', 'explanatory', 'information', 'improves', 'peers', ""'"", 'perceptions', 'of', 'autism', '.']","(6, 7)","(57, 62)",-1,hl_p,15193668,Title,0,test,gold,2621.0
1706,Combined descriptive and explanatory information improves,peers ' perceptions,of autism .,"['Combined', 'descriptive', 'and', 'explanatory', 'information', 'improves', 'peers', ""'"", 'perceptions', 'of', 'autism', '.']","(6, 9)","(57, 76)",-1,hl_o,15193668,Title,0,test,gold,2624.0
1707,Authors examined the combined effects of descriptive and explanatory information on,peers ',perceptions and behavioral intentions toward an unfamiliar child with autism .,"['Authors', 'examined', 'the', 'combined', 'effects', 'of', 'descriptive', 'and', 'explanatory', 'information', 'on', 'peers', ""'"", 'perceptions', 'and', 'behavioral', 'intentions', 'toward', 'an', 'unfamiliar', 'child', 'with', 'autism', '.']","(11, 13)","(83, 90)",-1,ss_p,15193668,Abstract,0,test,gold,2619.0
1708,Authors examined the combined effects of descriptive and explanatory information on peers ' perceptions and behavioral intentions toward an unfamiliar,child with autism .,,"['Authors', 'examined', 'the', 'combined', 'effects', 'of', 'descriptive', 'and', 'explanatory', 'information', 'on', 'peers', ""'"", 'perceptions', 'and', 'behavioral', 'intentions', 'toward', 'an', 'unfamiliar', 'child', 'with', 'autism', '.']","(20, 24)","(150, 169)",-1,ss_p,15193668,Abstract,0,test,gold,6142.0
1709,Authors examined the combined effects of,descriptive and explanatory information,on peers ' perceptions and behavioral intentions toward an unfamiliar child with autism .,"['Authors', 'examined', 'the', 'combined', 'effects', 'of', 'descriptive', 'and', 'explanatory', 'information', 'on', 'peers', ""'"", 'perceptions', 'and', 'behavioral', 'intentions', 'toward', 'an', 'unfamiliar', 'child', 'with', 'autism', '.']","(6, 10)","(40, 79)",-1,ss_i,15193668,Abstract,0,test,gold,2978.0
1710,Authors examined the combined effects of descriptive and explanatory information on,peers ' perceptions and behavioral intentions,toward an unfamiliar child with autism .,"['Authors', 'examined', 'the', 'combined', 'effects', 'of', 'descriptive', 'and', 'explanatory', 'information', 'on', 'peers', ""'"", 'perceptions', 'and', 'behavioral', 'intentions', 'toward', 'an', 'unfamiliar', 'child', 'with', 'autism', '.']","(11, 17)","(83, 128)",-1,ss_o,15193668,Abstract,0,test,gold,2628.0
1711,Authors examined the combined effects of descriptive and explanatory information on,peers,' perceptions and behavioral intentions toward an unfamiliar child with autism .,"['Authors', 'examined', 'the', 'combined', 'effects', 'of', 'descriptive', 'and', 'explanatory', 'information', 'on', 'peers', ""'"", 'perceptions', 'and', 'behavioral', 'intentions', 'toward', 'an', 'unfamiliar', 'child', 'with', 'autism', '.']","(11, 12)","(83, 88)",-1,hl_p,15193668,Abstract,0,test,gold,2618.0
1712,Authors examined the combined effects of descriptive and explanatory information on peers ' perceptions and behavioral intentions toward an unfamiliar,child with autism .,,"['Authors', 'examined', 'the', 'combined', 'effects', 'of', 'descriptive', 'and', 'explanatory', 'information', 'on', 'peers', ""'"", 'perceptions', 'and', 'behavioral', 'intentions', 'toward', 'an', 'unfamiliar', 'child', 'with', 'autism', '.']","(20, 24)","(150, 169)",-1,hl_p,15193668,Abstract,0,test,gold,6143.0
1713,Authors examined the combined effects of descriptive and explanatory information on,peers ' perceptions,and behavioral intentions toward an unfamiliar child with autism .,"['Authors', 'examined', 'the', 'combined', 'effects', 'of', 'descriptive', 'and', 'explanatory', 'information', 'on', 'peers', ""'"", 'perceptions', 'and', 'behavioral', 'intentions', 'toward', 'an', 'unfamiliar', 'child', 'with', 'autism', '.']","(11, 14)","(83, 102)",-1,hl_o,15193668,Abstract,0,test,gold,2622.0
1714,Authors examined the combined effects of descriptive and explanatory information on peers ' perceptions and,behavioral intentions,toward an unfamiliar child with autism .,"['Authors', 'examined', 'the', 'combined', 'effects', 'of', 'descriptive', 'and', 'explanatory', 'information', 'on', 'peers', ""'"", 'perceptions', 'and', 'behavioral', 'intentions', 'toward', 'an', 'unfamiliar', 'child', 'with', 'autism', '.']","(15, 17)","(107, 128)",-1,hl_o,15193668,Abstract,0,test,gold,2626.0
1715,,Children ( N = 576 ; M age = 10.06 ),were randomly assigned to view two videotapes of a boy engaging in typical and autistic behaviors receiving either descriptive ( AUT-D ) or descriptive and explanatory information ( AUT-D + E ) .,"['Children', '(', 'N', '=', '576', ';', 'M', 'age', '=', '10.06', ')', 'were', 'randomly', 'assigned', 'to', 'view', 'two', 'videotapes', 'of', 'a', 'boy', 'engaging', 'in', 'typical', 'and', 'autistic', 'behaviors', 'receiving', 'either', 'descriptive', '(', 'AUT-D', ')', 'or', 'descriptive', 'and', 'explanatory', 'information', '(', 'AUT-D', '+', 'E', ')', '.']","(0, 11)","(0, 36)",-1,ss_p,15193668,Abstract,1,test,gold,6454.0
1716,Children ( N = 576 ; M age = 10.06 ) were randomly assigned to view two videotapes of a boy engaging in typical and autistic behaviors receiving either,descriptive ( AUT-D ),or descriptive and explanatory information ( AUT-D + E ) .,"['Children', '(', 'N', '=', '576', ';', 'M', 'age', '=', '10.06', ')', 'were', 'randomly', 'assigned', 'to', 'view', 'two', 'videotapes', 'of', 'a', 'boy', 'engaging', 'in', 'typical', 'and', 'autistic', 'behaviors', 'receiving', 'either', 'descriptive', '(', 'AUT-D', ')', 'or', 'descriptive', 'and', 'explanatory', 'information', '(', 'AUT-D', '+', 'E', ')', '.']","(29, 33)","(151, 172)",-1,ss_i,15193668,Abstract,1,test,gold,1249.0
1717,Children ( N = 576 ; M age = 10.06 ) were randomly assigned to view two videotapes of a boy engaging in typical and autistic behaviors receiving either descriptive ( AUT-D ) or,descriptive and explanatory information ( AUT-D + E ) .,,"['Children', '(', 'N', '=', '576', ';', 'M', 'age', '=', '10.06', ')', 'were', 'randomly', 'assigned', 'to', 'view', 'two', 'videotapes', 'of', 'a', 'boy', 'engaging', 'in', 'typical', 'and', 'autistic', 'behaviors', 'receiving', 'either', 'descriptive', '(', 'AUT-D', ')', 'or', 'descriptive', 'and', 'explanatory', 'information', '(', 'AUT-D', '+', 'E', ')', '.']","(34, 44)","(176, 231)",-1,ss_i,15193668,Abstract,1,test,gold,2973.0
1718,,Children,( N = 576 ; M age = 10.06 ) were randomly assigned to view two videotapes of a boy engaging in typical and autistic behaviors receiving either descriptive ( AUT-D ) or descriptive and explanatory information ( AUT-D + E ) .,"['Children', '(', 'N', '=', '576', ';', 'M', 'age', '=', '10.06', ')', 'were', 'randomly', 'assigned', 'to', 'view', 'two', 'videotapes', 'of', 'a', 'boy', 'engaging', 'in', 'typical', 'and', 'autistic', 'behaviors', 'receiving', 'either', 'descriptive', '(', 'AUT-D', ')', 'or', 'descriptive', 'and', 'explanatory', 'information', '(', 'AUT-D', '+', 'E', ')', '.']","(0, 1)","(0, 8)",-1,hl_p,15193668,Abstract,1,test,gold,2178.0
1719,Children ( N =,576,; M age = 10.06 ) were randomly assigned to view two videotapes of a boy engaging in typical and autistic behaviors receiving either descriptive ( AUT-D ) or descriptive and explanatory information ( AUT-D + E ) .,"['Children', '(', 'N', '=', '576', ';', 'M', 'age', '=', '10.06', ')', 'were', 'randomly', 'assigned', 'to', 'view', 'two', 'videotapes', 'of', 'a', 'boy', 'engaging', 'in', 'typical', 'and', 'autistic', 'behaviors', 'receiving', 'either', 'descriptive', '(', 'AUT-D', ')', 'or', 'descriptive', 'and', 'explanatory', 'information', '(', 'AUT-D', '+', 'E', ')', '.']","(4, 5)","(14, 17)",-1,hl_p,15193668,Abstract,1,test,gold,
1720,Children ( N = 576 ;,M age = 10.06,) were randomly assigned to view two videotapes of a boy engaging in typical and autistic behaviors receiving either descriptive ( AUT-D ) or descriptive and explanatory information ( AUT-D + E ) .,"['Children', '(', 'N', '=', '576', ';', 'M', 'age', '=', '10.06', ')', 'were', 'randomly', 'assigned', 'to', 'view', 'two', 'videotapes', 'of', 'a', 'boy', 'engaging', 'in', 'typical', 'and', 'autistic', 'behaviors', 'receiving', 'either', 'descriptive', '(', 'AUT-D', ')', 'or', 'descriptive', 'and', 'explanatory', 'information', '(', 'AUT-D', '+', 'E', ')', '.']","(6, 10)","(20, 33)",-1,hl_p,15193668,Abstract,1,test,gold,6456.0
1721,Children ( N = 576 ; M age = 10.06 ) were randomly assigned to view two videotapes of a boy engaging in typical and autistic behaviors receiving either,descriptive ( AUT-D ),or descriptive and explanatory information ( AUT-D + E ) .,"['Children', '(', 'N', '=', '576', ';', 'M', 'age', '=', '10.06', ')', 'were', 'randomly', 'assigned', 'to', 'view', 'two', 'videotapes', 'of', 'a', 'boy', 'engaging', 'in', 'typical', 'and', 'autistic', 'behaviors', 'receiving', 'either', 'descriptive', '(', 'AUT-D', ')', 'or', 'descriptive', 'and', 'explanatory', 'information', '(', 'AUT-D', '+', 'E', ')', '.']","(29, 33)","(151, 172)",-1,hl_i,15193668,Abstract,1,test,gold,1250.0
1722,Children ( N = 576 ; M age = 10.06 ) were randomly assigned to view two videotapes of a boy engaging in typical and autistic behaviors receiving either descriptive ( AUT-D ) or,descriptive and explanatory information ( AUT-D + E ) .,,"['Children', '(', 'N', '=', '576', ';', 'M', 'age', '=', '10.06', ')', 'were', 'randomly', 'assigned', 'to', 'view', 'two', 'videotapes', 'of', 'a', 'boy', 'engaging', 'in', 'typical', 'and', 'autistic', 'behaviors', 'receiving', 'either', 'descriptive', '(', 'AUT-D', ')', 'or', 'descriptive', 'and', 'explanatory', 'information', '(', 'AUT-D', '+', 'E', ')', '.']","(34, 44)","(176, 231)",-1,hl_i,15193668,Abstract,1,test,gold,2974.0
1723,Children responded to,measures of attitudes ( Adjective Checklist ) and behavioral intentions ( Shared Activities Questionnaire ) .,,"['Children', 'responded', 'to', 'measures', 'of', 'attitudes', '(', 'Adjective', 'Checklist', ')', 'and', 'behavioral', 'intentions', '(', 'Shared', 'Activities', 'Questionnaire', ')', '.']","(3, 19)","(21, 130)",-1,ss_o,15193668,Abstract,2,test,gold,6284.0
1724,Children responded to measures of attitudes,( Adjective Checklist ),and behavioral intentions ( Shared Activities Questionnaire ) .,"['Children', 'responded', 'to', 'measures', 'of', 'attitudes', '(', 'Adjective', 'Checklist', ')', 'and', 'behavioral', 'intentions', '(', 'Shared', 'Activities', 'Questionnaire', ')', '.']","(6, 10)","(43, 66)",-1,hl_o,15193668,Abstract,2,test,gold,435.0
1725,Children responded to measures of attitudes ( Adjective Checklist ) and behavioral intentions,( Shared Activities Questionnaire ),.,"['Children', 'responded', 'to', 'measures', 'of', 'attitudes', '(', 'Adjective', 'Checklist', ')', 'and', 'behavioral', 'intentions', '(', 'Shared', 'Activities', 'Questionnaire', ')', '.']","(13, 18)","(93, 128)",-1,hl_o,15193668,Abstract,2,test,gold,6250.0
1726,Children rated the typical boy more favorably than the boy showing autistic symptoms .,,,"['Children', 'rated', 'the', 'typical', 'boy', 'more', 'favorably', 'than', 'the', 'boy', 'showing', 'autistic', 'symptoms', '.']",,,,,15193668,Abstract,3,test,gold,
1727,When compared to,descriptive information,"alone , the combination of descriptive and explanatory information resulted in improved third- and fourth-graders ' but not fifth-graders ' attitudes toward the child with autism .","['When', 'compared', 'to', 'descriptive', 'information', 'alone', ',', 'the', 'combination', 'of', 'descriptive', 'and', 'explanatory', 'information', 'resulted', 'in', 'improved', 'third-', 'and', 'fourth-graders', ""'"", 'but', 'not', 'fifth-graders', ""'"", 'attitudes', 'toward', 'the', 'child', 'with', 'autism', '.']","(3, 5)","(16, 39)",-1,ss_i,15193668,Abstract,4,test,gold,1248.0
1728,"When compared to descriptive information alone , the",combination of descriptive and explanatory information,resulted in improved third- and fourth-graders ' but not fifth-graders ' attitudes toward the child with autism .,"['When', 'compared', 'to', 'descriptive', 'information', 'alone', ',', 'the', 'combination', 'of', 'descriptive', 'and', 'explanatory', 'information', 'resulted', 'in', 'improved', 'third-', 'and', 'fourth-graders', ""'"", 'but', 'not', 'fifth-graders', ""'"", 'attitudes', 'toward', 'the', 'child', 'with', 'autism', '.']","(8, 14)","(52, 106)",-1,ss_i,15193668,Abstract,4,test,gold,2975.0
1729,Combined information improved,behavioral intentions,"across grades ; however , girls ( vs. boys ) were more responsive to information as evidenced by differences in academic intentions .","['Combined', 'information', 'improved', 'behavioral', 'intentions', 'across', 'grades', ';', 'however', ',', 'girls', '(', 'vs.', 'boys', ')', 'were', 'more', 'responsive', 'to', 'information', 'as', 'evidenced', 'by', 'differences', 'in', 'academic', 'intentions', '.']","(3, 5)","(29, 50)",-1,ss_o,15193668,Abstract,5,test,gold,2627.0
1730,"Combined information improved behavioral intentions across grades ; however , girls ( vs. boys ) were more responsive to information as evidenced by differences in",academic intentions .,,"['Combined', 'information', 'improved', 'behavioral', 'intentions', 'across', 'grades', ';', 'however', ',', 'girls', '(', 'vs.', 'boys', ')', 'were', 'more', 'responsive', 'to', 'information', 'as', 'evidenced', 'by', 'differences', 'in', 'academic', 'intentions', '.']","(25, 28)","(163, 184)",-1,ss_o,15193668,Abstract,5,test,gold,2187.0
1731,The combination of descriptive and explanatory information about autism appears to have a positive effect on,children 's,attitudes and behavioral intentions .,"['The', 'combination', 'of', 'descriptive', 'and', 'explanatory', 'information', 'about', 'autism', 'appears', 'to', 'have', 'a', 'positive', 'effect', 'on', 'children', ""'s"", 'attitudes', 'and', 'behavioral', 'intentions', '.']","(16, 18)","(108, 119)",-1,ss_p,15193668,Abstract,6,test,gold,2143.0
1732,The,combination of descriptive and explanatory information,about autism appears to have a positive effect on children 's attitudes and behavioral intentions .,"['The', 'combination', 'of', 'descriptive', 'and', 'explanatory', 'information', 'about', 'autism', 'appears', 'to', 'have', 'a', 'positive', 'effect', 'on', 'children', ""'s"", 'attitudes', 'and', 'behavioral', 'intentions', '.']","(1, 7)","(3, 57)",-1,ss_i,15193668,Abstract,6,test,gold,2976.0
1733,The combination of descriptive and explanatory information about autism appears to have a positive effect on,children 's attitudes and behavioral intentions .,,"['The', 'combination', 'of', 'descriptive', 'and', 'explanatory', 'information', 'about', 'autism', 'appears', 'to', 'have', 'a', 'positive', 'effect', 'on', 'children', ""'s"", 'attitudes', 'and', 'behavioral', 'intentions', '.']","(16, 23)","(108, 157)",-1,ss_o,15193668,Abstract,6,test,gold,2629.0
1734,The combination of descriptive and explanatory information about autism appears to have a positive effect on,children 's,attitudes and behavioral intentions .,"['The', 'combination', 'of', 'descriptive', 'and', 'explanatory', 'information', 'about', 'autism', 'appears', 'to', 'have', 'a', 'positive', 'effect', 'on', 'children', ""'s"", 'attitudes', 'and', 'behavioral', 'intentions', '.']","(16, 18)","(108, 119)",-1,hl_p,15193668,Abstract,6,test,gold,2142.0
1735,The combination of,descriptive and explanatory information,about autism appears to have a positive effect on children 's attitudes and behavioral intentions .,"['The', 'combination', 'of', 'descriptive', 'and', 'explanatory', 'information', 'about', 'autism', 'appears', 'to', 'have', 'a', 'positive', 'effect', 'on', 'children', ""'s"", 'attitudes', 'and', 'behavioral', 'intentions', '.']","(3, 7)","(18, 57)",-1,hl_i,15193668,Abstract,6,test,gold,2979.0
1736,The combination of descriptive and explanatory information about autism appears to have a positive effect on,children 's attitudes,and behavioral intentions .,"['The', 'combination', 'of', 'descriptive', 'and', 'explanatory', 'information', 'about', 'autism', 'appears', 'to', 'have', 'a', 'positive', 'effect', 'on', 'children', ""'s"", 'attitudes', 'and', 'behavioral', 'intentions', '.']","(16, 19)","(108, 129)",-1,hl_o,15193668,Abstract,6,test,gold,2154.0
1737,The combination of descriptive and explanatory information about autism appears to have a positive effect on children 's attitudes and,behavioral intentions,.,"['The', 'combination', 'of', 'descriptive', 'and', 'explanatory', 'information', 'about', 'autism', 'appears', 'to', 'have', 'a', 'positive', 'effect', 'on', 'children', ""'s"", 'attitudes', 'and', 'behavioral', 'intentions', '.']","(20, 22)","(134, 155)",-1,hl_o,15193668,Abstract,6,test,gold,2625.0
1738,Implications of the findings are briefly discussed as well as study limitations and recommendations for future research .,,,"['Implications', 'of', 'the', 'findings', 'are', 'briefly', 'discussed', 'as', 'well', 'as', 'study', 'limitations', 'and', 'recommendations', 'for', 'future', 'research', '.']",,,,,15193668,Abstract,7,test,gold,
1739,Superior visual search in,adults with autism .,,"['Superior', 'visual', 'search', 'in', 'adults', 'with', 'autism', '.']","(4, 8)","(25, 45)",-1,ss_p,15358868,Title,0,test,gold,6130.0
1740,Superior,visual search,in adults with autism .,"['Superior', 'visual', 'search', 'in', 'adults', 'with', 'autism', '.']","(1, 3)","(8, 21)",-1,ss_i,15358868,Title,0,test,gold,2933.0
1741,Superior visual search in,adults with autism .,,"['Superior', 'visual', 'search', 'in', 'adults', 'with', 'autism', '.']","(4, 8)","(25, 45)",-1,hl_p,15358868,Title,0,test,gold,6131.0
1742,Recent studies have suggested that children with autism perform better than matched controls on,visual search,tasks and that this stems from a superior visual discrimination ability .,"['Recent', 'studies', 'have', 'suggested', 'that', 'children', 'with', 'autism', 'perform', 'better', 'than', 'matched', 'controls', 'on', 'visual', 'search', 'tasks', 'and', 'that', 'this', 'stems', 'from', 'a', 'superior', 'visual', 'discrimination', 'ability', '.']","(14, 16)","(95, 108)",-1,ss_i,15358868,Abstract,0,test,gold,2934.0
1743,Recent studies have suggested that children with autism perform better than matched controls on,visual search tasks,and that this stems from a superior visual discrimination ability .,"['Recent', 'studies', 'have', 'suggested', 'that', 'children', 'with', 'autism', 'perform', 'better', 'than', 'matched', 'controls', 'on', 'visual', 'search', 'tasks', 'and', 'that', 'this', 'stems', 'from', 'a', 'superior', 'visual', 'discrimination', 'ability', '.']","(14, 17)","(95, 114)",-1,ss_o,15358868,Abstract,0,test,gold,2932.0
1744,This study assessed whether these findings generalize from children to,adults with autism .,,"['This', 'study', 'assessed', 'whether', 'these', 'findings', 'generalize', 'from', 'children', 'to', 'adults', 'with', 'autism', '.']","(10, 14)","(70, 90)",-1,ss_p,15358868,Abstract,1,test,gold,6129.0
1745,This study assessed whether these findings generalize from children to,adults with autism .,,"['This', 'study', 'assessed', 'whether', 'these', 'findings', 'generalize', 'from', 'children', 'to', 'adults', 'with', 'autism', '.']","(10, 14)","(70, 90)",-1,hl_p,15358868,Abstract,1,test,gold,6128.0
1746,"Experiments 1 and 2 showed that , like children ,",adults with autism,were superior to controls at searching for targets .,"['Experiments', '1', 'and', '2', 'showed', 'that', ',', 'like', 'children', ',', 'adults', 'with', 'autism', 'were', 'superior', 'to', 'controls', 'at', 'searching', 'for', 'targets', '.']","(10, 13)","(49, 67)",-1,ss_p,15358868,Abstract,2,test,gold,6127.0
1747,"Experiments 1 and 2 showed that , like children , adults with autism were superior to controls at",searching for targets .,,"['Experiments', '1', 'and', '2', 'showed', 'that', ',', 'like', 'children', ',', 'adults', 'with', 'autism', 'were', 'superior', 'to', 'controls', 'at', 'searching', 'for', 'targets', '.']","(18, 22)","(97, 120)",-1,ss_o,15358868,Abstract,2,test,gold,1877.0
1748,"Experiments 1 and 2 showed that , like children ,",adults with autism,were superior to controls at searching for targets .,"['Experiments', '1', 'and', '2', 'showed', 'that', ',', 'like', 'children', ',', 'adults', 'with', 'autism', 'were', 'superior', 'to', 'controls', 'at', 'searching', 'for', 'targets', '.']","(10, 13)","(49, 67)",-1,hl_p,15358868,Abstract,2,test,gold,6126.0
1749,"Experiments 1 and 2 showed that , like children , adults with autism were superior to controls at",searching for targets .,,"['Experiments', '1', 'and', '2', 'showed', 'that', ',', 'like', 'children', ',', 'adults', 'with', 'autism', 'were', 'superior', 'to', 'controls', 'at', 'searching', 'for', 'targets', '.']","(18, 22)","(97, 120)",-1,hl_o,15358868,Abstract,2,test,gold,1878.0
1750,"Experiment 3 showed that increases in target-distractor similarity slowed the visual search performance of the control group significantly more than that of the autism group , suggesting that the",adults with autism,have a superior visual discrimination ability .,"['Experiment', '3', 'showed', 'that', 'increases', 'in', 'target-distractor', 'similarity', 'slowed', 'the', 'visual', 'search', 'performance', 'of', 'the', 'control', 'group', 'significantly', 'more', 'than', 'that', 'of', 'the', 'autism', 'group', ',', 'suggesting', 'that', 'the', 'adults', 'with', 'autism', 'have', 'a', 'superior', 'visual', 'discrimination', 'ability', '.']","(29, 32)","(195, 213)",-1,ss_p,15358868,Abstract,3,test,gold,6125.0
1751,Experiment 3 showed that increases in target-distractor similarity slowed the,visual search performance,"of the control group significantly more than that of the autism group , suggesting that the adults with autism have a superior visual discrimination ability .","['Experiment', '3', 'showed', 'that', 'increases', 'in', 'target-distractor', 'similarity', 'slowed', 'the', 'visual', 'search', 'performance', 'of', 'the', 'control', 'group', 'significantly', 'more', 'than', 'that', 'of', 'the', 'autism', 'group', ',', 'suggesting', 'that', 'the', 'adults', 'with', 'autism', 'have', 'a', 'superior', 'visual', 'discrimination', 'ability', '.']","(10, 13)","(77, 102)",-1,ss_o,15358868,Abstract,3,test,gold,2935.0
1752,"Experiment 3 showed that increases in target-distractor similarity slowed the visual search performance of the control group significantly more than that of the autism group , suggesting that the adults with autism have a superior",visual discrimination ability .,,"['Experiment', '3', 'showed', 'that', 'increases', 'in', 'target-distractor', 'similarity', 'slowed', 'the', 'visual', 'search', 'performance', 'of', 'the', 'control', 'group', 'significantly', 'more', 'than', 'that', 'of', 'the', 'autism', 'group', ',', 'suggesting', 'that', 'the', 'adults', 'with', 'autism', 'have', 'a', 'superior', 'visual', 'discrimination', 'ability', '.']","(35, 39)","(230, 261)",-1,ss_o,15358868,Abstract,3,test,gold,2930.0
1753,Experiment 3 showed that increases in target-distractor similarity slowed the,visual search performance,"of the control group significantly more than that of the autism group , suggesting that the adults with autism have a superior visual discrimination ability .","['Experiment', '3', 'showed', 'that', 'increases', 'in', 'target-distractor', 'similarity', 'slowed', 'the', 'visual', 'search', 'performance', 'of', 'the', 'control', 'group', 'significantly', 'more', 'than', 'that', 'of', 'the', 'autism', 'group', ',', 'suggesting', 'that', 'the', 'adults', 'with', 'autism', 'have', 'a', 'superior', 'visual', 'discrimination', 'ability', '.']","(10, 13)","(77, 102)",-1,hl_o,15358868,Abstract,3,test,gold,2936.0
1754,"Experiment 3 showed that increases in target-distractor similarity slowed the visual search performance of the control group significantly more than that of the autism group , suggesting that the adults with autism have a superior",visual discrimination ability .,,"['Experiment', '3', 'showed', 'that', 'increases', 'in', 'target-distractor', 'similarity', 'slowed', 'the', 'visual', 'search', 'performance', 'of', 'the', 'control', 'group', 'significantly', 'more', 'than', 'that', 'of', 'the', 'autism', 'group', ',', 'suggesting', 'that', 'the', 'adults', 'with', 'autism', 'have', 'a', 'superior', 'visual', 'discrimination', 'ability', '.']","(35, 39)","(230, 261)",-1,hl_o,15358868,Abstract,3,test,gold,2931.0
1755,"Thus , these experiments replicate in adults previous findings in children with autism .",,,"['Thus', ',', 'these', 'experiments', 'replicate', 'in', 'adults', 'previous', 'findings', 'in', 'children', 'with', 'autism', '.']",,,,,15358868,Abstract,4,test,gold,
1756,Superior unique item detection in,adults with autism,", stemming from enhanced discrimination , is discussed in the light of the possible role of stimulus processing disturbances in the disorder in general .","['Superior', 'unique', 'item', 'detection', 'in', 'adults', 'with', 'autism', ',', 'stemming', 'from', 'enhanced', 'discrimination', ',', 'is', 'discussed', 'in', 'the', 'light', 'of', 'the', 'possible', 'role', 'of', 'stimulus', 'processing', 'disturbances', 'in', 'the', 'disorder', 'in', 'general', '.']","(5, 8)","(33, 51)",-1,ss_p,15358868,Abstract,5,test,gold,6124.0
1757,Superior,unique item detection,"in adults with autism , stemming from enhanced discrimination , is discussed in the light of the possible role of stimulus processing disturbances in the disorder in general .","['Superior', 'unique', 'item', 'detection', 'in', 'adults', 'with', 'autism', ',', 'stemming', 'from', 'enhanced', 'discrimination', ',', 'is', 'discussed', 'in', 'the', 'light', 'of', 'the', 'possible', 'role', 'of', 'stimulus', 'processing', 'disturbances', 'in', 'the', 'disorder', 'in', 'general', '.']","(1, 4)","(8, 29)",-1,ss_o,15358868,Abstract,5,test,gold,1875.0
1758,"Superior unique item detection in adults with autism , stemming from enhanced",discrimination,", is discussed in the light of the possible role of stimulus processing disturbances in the disorder in general .","['Superior', 'unique', 'item', 'detection', 'in', 'adults', 'with', 'autism', ',', 'stemming', 'from', 'enhanced', 'discrimination', ',', 'is', 'discussed', 'in', 'the', 'light', 'of', 'the', 'possible', 'role', 'of', 'stimulus', 'processing', 'disturbances', 'in', 'the', 'disorder', 'in', 'general', '.']","(12, 13)","(77, 91)",-1,ss_o,15358868,Abstract,5,test,gold,1288.0
1759,Superior,unique item detection,"in adults with autism , stemming from enhanced discrimination , is discussed in the light of the possible role of stimulus processing disturbances in the disorder in general .","['Superior', 'unique', 'item', 'detection', 'in', 'adults', 'with', 'autism', ',', 'stemming', 'from', 'enhanced', 'discrimination', ',', 'is', 'discussed', 'in', 'the', 'light', 'of', 'the', 'possible', 'role', 'of', 'stimulus', 'processing', 'disturbances', 'in', 'the', 'disorder', 'in', 'general', '.']","(1, 4)","(8, 29)",-1,hl_o,15358868,Abstract,5,test,gold,1876.0
1760,[ Postural biofeedback and locomotion reeducation in,stroke patients ],.,"['[', 'Postural', 'biofeedback', 'and', 'locomotion', 'reeducation', 'in', 'stroke', 'patients', ']', '.']","(7, 10)","(52, 69)",-1,ss_p,15848261,Title,0,test,gold,3379.0
1761,[ Postural biofeedback and locomotion reeducation in,stroke patients ],.,"['[', 'Postural', 'biofeedback', 'and', 'locomotion', 'reeducation', 'in', 'stroke', 'patients', ']', '.']","(7, 10)","(52, 69)",-1,hl_p,15848261,Title,0,test,gold,3380.0
1762,"AIMS To compare , in",post-acute hemiparetic patients,", gait improvement after conventional physical therapy alone or with a specialised balance retraining program .","['AIMS', 'To', 'compare', ',', 'in', 'post-acute', 'hemiparetic', 'patients', ',', 'gait', 'improvement', 'after', 'conventional', 'physical', 'therapy', 'alone', 'or', 'with', 'a', 'specialised', 'balance', 'retraining', 'program', '.']","(5, 8)","(20, 51)",-1,ss_p,15848261,Abstract,0,test,gold,3751.0
1763,"AIMS To compare , in post-acute hemiparetic patients , gait improvement after",conventional physical therapy alone,or with a specialised balance retraining program .,"['AIMS', 'To', 'compare', ',', 'in', 'post-acute', 'hemiparetic', 'patients', ',', 'gait', 'improvement', 'after', 'conventional', 'physical', 'therapy', 'alone', 'or', 'with', 'a', 'specialised', 'balance', 'retraining', 'program', '.']","(12, 16)","(77, 112)",-1,ss_i,15848261,Abstract,0,test,gold,4194.0
1764,"AIMS To compare , in post-acute hemiparetic patients , gait improvement after conventional physical therapy alone or",with a specialised balance retraining program .,,"['AIMS', 'To', 'compare', ',', 'in', 'post-acute', 'hemiparetic', 'patients', ',', 'gait', 'improvement', 'after', 'conventional', 'physical', 'therapy', 'alone', 'or', 'with', 'a', 'specialised', 'balance', 'retraining', 'program', '.']","(17, 24)","(116, 163)",-1,ss_i,15848261,Abstract,0,test,gold,2820.0
1765,"AIMS To compare , in post-acute hemiparetic patients ,",gait improvement,after conventional physical therapy alone or with a specialised balance retraining program .,"['AIMS', 'To', 'compare', ',', 'in', 'post-acute', 'hemiparetic', 'patients', ',', 'gait', 'improvement', 'after', 'conventional', 'physical', 'therapy', 'alone', 'or', 'with', 'a', 'specialised', 'balance', 'retraining', 'program', '.']","(9, 11)","(54, 70)",-1,ss_o,15848261,Abstract,0,test,gold,2717.0
1766,"AIMS To compare , in",post-acute hemiparetic patients,", gait improvement after conventional physical therapy alone or with a specialised balance retraining program .","['AIMS', 'To', 'compare', ',', 'in', 'post-acute', 'hemiparetic', 'patients', ',', 'gait', 'improvement', 'after', 'conventional', 'physical', 'therapy', 'alone', 'or', 'with', 'a', 'specialised', 'balance', 'retraining', 'program', '.']","(5, 8)","(20, 51)",-1,hl_p,15848261,Abstract,0,test,gold,3750.0
1767,"AIMS To compare , in post-acute hemiparetic patients , gait improvement after",conventional physical therapy alone,or with a specialised balance retraining program .,"['AIMS', 'To', 'compare', ',', 'in', 'post-acute', 'hemiparetic', 'patients', ',', 'gait', 'improvement', 'after', 'conventional', 'physical', 'therapy', 'alone', 'or', 'with', 'a', 'specialised', 'balance', 'retraining', 'program', '.']","(12, 16)","(77, 112)",-1,hl_i,15848261,Abstract,0,test,gold,4195.0
1768,"AIMS To compare , in post-acute hemiparetic patients , gait improvement after conventional physical therapy alone or with a",specialised balance retraining program,.,"['AIMS', 'To', 'compare', ',', 'in', 'post-acute', 'hemiparetic', 'patients', ',', 'gait', 'improvement', 'after', 'conventional', 'physical', 'therapy', 'alone', 'or', 'with', 'a', 'specialised', 'balance', 'retraining', 'program', '.']","(19, 23)","(123, 161)",-1,hl_i,15848261,Abstract,0,test,gold,2821.0
1769,"AIMS To compare , in post-acute hemiparetic patients ,",gait improvement,after conventional physical therapy alone or with a specialised balance retraining program .,"['AIMS', 'To', 'compare', ',', 'in', 'post-acute', 'hemiparetic', 'patients', ',', 'gait', 'improvement', 'after', 'conventional', 'physical', 'therapy', 'alone', 'or', 'with', 'a', 'specialised', 'balance', 'retraining', 'program', '.']","(9, 11)","(54, 70)",-1,hl_o,15848261,Abstract,0,test,gold,2718.0
1770,PATIENTS,Twenty-six patients within 3 months of onset of stroke,"were randomised to receive physical therapy ( control group ) or therapy and retraining ( experimental group ) , most of the patients in both groups with left hemiplegia .","['PATIENTS', 'Twenty-six', 'patients', 'within', '3', 'months', 'of', 'onset', 'of', 'stroke', 'were', 'randomised', 'to', 'receive', 'physical', 'therapy', '(', 'control', 'group', ')', 'or', 'therapy', 'and', 'retraining', '(', 'experimental', 'group', ')', ',', 'most', 'of', 'the', 'patients', 'in', 'both', 'groups', 'with', 'left', 'hemiplegia', '.']","(1, 10)","(8, 62)",-1,ss_p,15848261,Abstract,1,test,gold,5855.0
1771,PATIENTS Twenty-six patients within 3 months of onset of stroke were randomised to receive,physical therapy,"( control group ) or therapy and retraining ( experimental group ) , most of the patients in both groups with left hemiplegia .","['PATIENTS', 'Twenty-six', 'patients', 'within', '3', 'months', 'of', 'onset', 'of', 'stroke', 'were', 'randomised', 'to', 'receive', 'physical', 'therapy', '(', 'control', 'group', ')', 'or', 'therapy', 'and', 'retraining', '(', 'experimental', 'group', ')', ',', 'most', 'of', 'the', 'patients', 'in', 'both', 'groups', 'with', 'left', 'hemiplegia', '.']","(14, 16)","(90, 106)",-1,ss_i,15848261,Abstract,1,test,gold,4212.0
1772,PATIENTS Twenty-six patients within 3 months of onset of stroke were randomised to receive physical therapy ( control group ) or,therapy and retraining,"( experimental group ) , most of the patients in both groups with left hemiplegia .","['PATIENTS', 'Twenty-six', 'patients', 'within', '3', 'months', 'of', 'onset', 'of', 'stroke', 'were', 'randomised', 'to', 'receive', 'physical', 'therapy', '(', 'control', 'group', ')', 'or', 'therapy', 'and', 'retraining', '(', 'experimental', 'group', ')', ',', 'most', 'of', 'the', 'patients', 'in', 'both', 'groups', 'with', 'left', 'hemiplegia', '.']","(21, 24)","(128, 150)",-1,ss_i,15848261,Abstract,1,test,gold,4206.0
1773,PATIENTS,Twenty-six patients within 3 months of onset of stroke,"were randomised to receive physical therapy ( control group ) or therapy and retraining ( experimental group ) , most of the patients in both groups with left hemiplegia .","['PATIENTS', 'Twenty-six', 'patients', 'within', '3', 'months', 'of', 'onset', 'of', 'stroke', 'were', 'randomised', 'to', 'receive', 'physical', 'therapy', '(', 'control', 'group', ')', 'or', 'therapy', 'and', 'retraining', '(', 'experimental', 'group', ')', ',', 'most', 'of', 'the', 'patients', 'in', 'both', 'groups', 'with', 'left', 'hemiplegia', '.']","(1, 10)","(8, 62)",-1,hl_p,15848261,Abstract,1,test,gold,5856.0
1774,PATIENTS Twenty-six patients within 3 months of onset of stroke were randomised to receive,physical therapy,"( control group ) or therapy and retraining ( experimental group ) , most of the patients in both groups with left hemiplegia .","['PATIENTS', 'Twenty-six', 'patients', 'within', '3', 'months', 'of', 'onset', 'of', 'stroke', 'were', 'randomised', 'to', 'receive', 'physical', 'therapy', '(', 'control', 'group', ')', 'or', 'therapy', 'and', 'retraining', '(', 'experimental', 'group', ')', ',', 'most', 'of', 'the', 'patients', 'in', 'both', 'groups', 'with', 'left', 'hemiplegia', '.']","(14, 16)","(90, 106)",-1,hl_i,15848261,Abstract,1,test,gold,4213.0
1775,PATIENTS Twenty-six patients within 3 months of onset of stroke were randomised to receive physical therapy ( control group ) or,therapy and retraining,"( experimental group ) , most of the patients in both groups with left hemiplegia .","['PATIENTS', 'Twenty-six', 'patients', 'within', '3', 'months', 'of', 'onset', 'of', 'stroke', 'were', 'randomised', 'to', 'receive', 'physical', 'therapy', '(', 'control', 'group', ')', 'or', 'therapy', 'and', 'retraining', '(', 'experimental', 'group', ')', ',', 'most', 'of', 'the', 'patients', 'in', 'both', 'groups', 'with', 'left', 'hemiplegia', '.']","(21, 24)","(128, 150)",-1,hl_i,15848261,Abstract,1,test,gold,4207.0
1776,The experimental group was significantly older than the control group .,,,"['The', 'experimental', 'group', 'was', 'significantly', 'older', 'than', 'the', 'control', 'group', '.']",,,,,15848261,Abstract,2,test,gold,
1777,METHOD Thirteen patients received early,conventional therapy,", and 13 received therapy combined with standing balance training by biofeedback ( BPM Monitor ) .","['METHOD', 'Thirteen', 'patients', 'received', 'early', 'conventional', 'therapy', ',', 'and', '13', 'received', 'therapy', 'combined', 'with', 'standing', 'balance', 'training', 'by', 'biofeedback', '(', 'BPM', 'Monitor', ')', '.']","(5, 7)","(39, 59)",-1,ss_i,15848261,Abstract,3,test,gold,4199.0
1778,"METHOD Thirteen patients received early conventional therapy , and 13 received",therapy combined with standing balance training by biofeedback ( BPM Monitor ) .,,"['METHOD', 'Thirteen', 'patients', 'received', 'early', 'conventional', 'therapy', ',', 'and', '13', 'received', 'therapy', 'combined', 'with', 'standing', 'balance', 'training', 'by', 'biofeedback', '(', 'BPM', 'Monitor', ')', '.']","(11, 24)","(78, 158)",-1,ss_i,15848261,Abstract,3,test,gold,6308.0
1779,METHOD Thirteen patients received early,conventional therapy,", and 13 received therapy combined with standing balance training by biofeedback ( BPM Monitor ) .","['METHOD', 'Thirteen', 'patients', 'received', 'early', 'conventional', 'therapy', ',', 'and', '13', 'received', 'therapy', 'combined', 'with', 'standing', 'balance', 'training', 'by', 'biofeedback', '(', 'BPM', 'Monitor', ')', '.']","(5, 7)","(39, 59)",-1,hl_i,15848261,Abstract,3,test,gold,4200.0
1780,"METHOD Thirteen patients received early conventional therapy , and 13 received",therapy,combined with standing balance training by biofeedback ( BPM Monitor ) .,"['METHOD', 'Thirteen', 'patients', 'received', 'early', 'conventional', 'therapy', ',', 'and', '13', 'received', 'therapy', 'combined', 'with', 'standing', 'balance', 'training', 'by', 'biofeedback', '(', 'BPM', 'Monitor', ')', '.']","(11, 12)","(78, 85)",-1,hl_i,15848261,Abstract,3,test,gold,4217.0
1781,"METHOD Thirteen patients received early conventional therapy , and 13 received therapy combined with",standing balance training by biofeedback ( BPM Monitor ),.,"['METHOD', 'Thirteen', 'patients', 'received', 'early', 'conventional', 'therapy', ',', 'and', '13', 'received', 'therapy', 'combined', 'with', 'standing', 'balance', 'training', 'by', 'biofeedback', '(', 'BPM', 'Monitor', ')', '.']","(14, 23)","(100, 156)",-1,hl_i,15848261,Abstract,3,test,gold,6309.0
1782,,Clinical measures,"were collected at entry ( J0 ) , once when subjects began to walk ( JM ) and 30 days later ( JM + 30 ) .","['Clinical', 'measures', 'were', 'collected', 'at', 'entry', '(', 'J0', ')', ',', 'once', 'when', 'subjects', 'began', 'to', 'walk', '(', 'JM', ')', 'and', '30', 'days', 'later', '(', 'JM', '+', '30', ')', '.']","(0, 2)","(0, 17)",-1,ss_o,15848261,Abstract,4,test,gold,1835.0
1783,,Gait spatiotemporal parameters,were collected by use of the Vicon system at JM and JM + 30 .,"['Gait', 'spatiotemporal', 'parameters', 'were', 'collected', 'by', 'use', 'of', 'the', 'Vicon', 'system', 'at', 'JM', 'and', 'JM', '+', '30', '.']","(0, 3)","(0, 30)",-1,ss_o,15848261,Abstract,5,test,gold,1820.0
1784,,Gait spatiotemporal parameters,were collected by use of the Vicon system at JM and JM + 30 .,"['Gait', 'spatiotemporal', 'parameters', 'were', 'collected', 'by', 'use', 'of', 'the', 'Vicon', 'system', 'at', 'JM', 'and', 'JM', '+', '30', '.']","(0, 3)","(0, 30)",-1,hl_o,15848261,Abstract,5,test,gold,1821.0
1785,"RESULTS Whatever the method of rehabilitation , the",clinical scores,"improved significantly between J0 and JM + 30 , except for spasticity .","['RESULTS', 'Whatever', 'the', 'method', 'of', 'rehabilitation', ',', 'the', 'clinical', 'scores', 'improved', 'significantly', 'between', 'J0', 'and', 'JM', '+', '30', ',', 'except', 'for', 'spasticity', '.']","(8, 10)","(51, 66)",-1,ss_o,15848261,Abstract,6,test,gold,4766.0
1786,"RESULTS Whatever the method of rehabilitation , the",clinical scores,"improved significantly between J0 and JM + 30 , except for spasticity .","['RESULTS', 'Whatever', 'the', 'method', 'of', 'rehabilitation', ',', 'the', 'clinical', 'scores', 'improved', 'significantly', 'between', 'J0', 'and', 'JM', '+', '30', ',', 'except', 'for', 'spasticity', '.']","(8, 10)","(51, 66)",-1,hl_o,15848261,Abstract,6,test,gold,4767.0
1787,The,time between stroke and the beginning of walking,was not significantly different between both groups .,"['The', 'time', 'between', 'stroke', 'and', 'the', 'beginning', 'of', 'walking', 'was', 'not', 'significantly', 'different', 'between', 'both', 'groups', '.']","(1, 9)","(3, 51)",-1,ss_o,15848261,Abstract,7,test,gold,3385.0
1788,The,time between stroke and the beginning of walking,was not significantly different between both groups .,"['The', 'time', 'between', 'stroke', 'and', 'the', 'beginning', 'of', 'walking', 'was', 'not', 'significantly', 'different', 'between', 'both', 'groups', '.']","(1, 9)","(3, 51)",-1,hl_o,15848261,Abstract,7,test,gold,3386.0
1789,,Gait velocity,"increased significantly between JM and JM + 30 in both groups , with no difference between groups .","['Gait', 'velocity', 'increased', 'significantly', 'between', 'JM', 'and', 'JM', '+', '30', 'in', 'both', 'groups', ',', 'with', 'no', 'difference', 'between', 'groups', '.']","(0, 2)","(0, 13)",-1,ss_o,15848261,Abstract,8,test,gold,1818.0
1790,,Gait velocity,"increased significantly between JM and JM + 30 in both groups , with no difference between groups .","['Gait', 'velocity', 'increased', 'significantly', 'between', 'JM', 'and', 'JM', '+', '30', 'in', 'both', 'groups', ',', 'with', 'no', 'difference', 'between', 'groups', '.']","(0, 2)","(0, 13)",-1,hl_o,15848261,Abstract,8,test,gold,1819.0
1791,The,walking pattern,"was improved for both groups , with a significant increase of the duration of the paretic limb single stance .","['The', 'walking', 'pattern', 'was', 'improved', 'for', 'both', 'groups', ',', 'with', 'a', 'significant', 'increase', 'of', 'the', 'duration', 'of', 'the', 'paretic', 'limb', 'single', 'stance', '.']","(1, 3)","(3, 18)",-1,ss_o,15848261,Abstract,9,test,gold,2708.0
1792,"The walking pattern was improved for both groups , with a significant increase of the",duration of the paretic limb single stance .,,"['The', 'walking', 'pattern', 'was', 'improved', 'for', 'both', 'groups', ',', 'with', 'a', 'significant', 'increase', 'of', 'the', 'duration', 'of', 'the', 'paretic', 'limb', 'single', 'stance', '.']","(15, 23)","(85, 129)",-1,ss_o,15848261,Abstract,9,test,gold,3689.0
1793,The,walking pattern,"was improved for both groups , with a significant increase of the duration of the paretic limb single stance .","['The', 'walking', 'pattern', 'was', 'improved', 'for', 'both', 'groups', ',', 'with', 'a', 'significant', 'increase', 'of', 'the', 'duration', 'of', 'the', 'paretic', 'limb', 'single', 'stance', '.']","(1, 3)","(3, 18)",-1,hl_o,15848261,Abstract,9,test,gold,2709.0
1794,"The walking pattern was improved for both groups , with a significant increase of the",duration of the paretic limb single stance .,,"['The', 'walking', 'pattern', 'was', 'improved', 'for', 'both', 'groups', ',', 'with', 'a', 'significant', 'increase', 'of', 'the', 'duration', 'of', 'the', 'paretic', 'limb', 'single', 'stance', '.']","(15, 23)","(85, 129)",-1,hl_o,15848261,Abstract,9,test,gold,3690.0
1795,The experimental group significantly improved the,duration of the reception double stance on the paretic limb,between JM and JM + 30 compared with the control group ( P = 0.03 ) .,"['The', 'experimental', 'group', 'significantly', 'improved', 'the', 'duration', 'of', 'the', 'reception', 'double', 'stance', 'on', 'the', 'paretic', 'limb', 'between', 'JM', 'and', 'JM', '+', '30', 'compared', 'with', 'the', 'control', 'group', '(', 'P', '=', '0.03', ')', '.']","(6, 16)","(49, 108)",-1,ss_o,15848261,Abstract,10,test,gold,3691.0
1796,The experimental group significantly improved the,duration of the reception double stance on the paretic limb,between JM and JM + 30 compared with the control group ( P = 0.03 ) .,"['The', 'experimental', 'group', 'significantly', 'improved', 'the', 'duration', 'of', 'the', 'reception', 'double', 'stance', 'on', 'the', 'paretic', 'limb', 'between', 'JM', 'and', 'JM', '+', '30', 'compared', 'with', 'the', 'control', 'group', '(', 'P', '=', '0.03', ')', '.']","(6, 16)","(49, 108)",-1,hl_o,15848261,Abstract,10,test,gold,3692.0
1797,CONCLUSION Both groups demonstrated improvement in the rehabilitation unit .,,,"['CONCLUSION', 'Both', 'groups', 'demonstrated', 'improvement', 'in', 'the', 'rehabilitation', 'unit', '.']",,,,,15848261,Abstract,11,test,gold,
1798,The benefits of visual biofeedback by forceplate system training suggest particular improvement of anticipation equilibrium with,conventional therapy .,,"['The', 'benefits', 'of', 'visual', 'biofeedback', 'by', 'forceplate', 'system', 'training', 'suggest', 'particular', 'improvement', 'of', 'anticipation', 'equilibrium', 'with', 'conventional', 'therapy', '.']","(16, 19)","(128, 150)",-1,ss_i,15848261,Abstract,12,test,gold,4198.0
1799,The benefits of visual biofeedback by forceplate system training suggest particular improvement of,anticipation equilibrium,with conventional therapy .,"['The', 'benefits', 'of', 'visual', 'biofeedback', 'by', 'forceplate', 'system', 'training', 'suggest', 'particular', 'improvement', 'of', 'anticipation', 'equilibrium', 'with', 'conventional', 'therapy', '.']","(13, 15)","(98, 122)",-1,ss_o,15848261,Abstract,12,test,gold,1236.0
1800,The benefits of visual biofeedback by forceplate system training suggest particular improvement of anticipation equilibrium with,conventional therapy .,,"['The', 'benefits', 'of', 'visual', 'biofeedback', 'by', 'forceplate', 'system', 'training', 'suggest', 'particular', 'improvement', 'of', 'anticipation', 'equilibrium', 'with', 'conventional', 'therapy', '.']","(16, 19)","(128, 150)",-1,hl_i,15848261,Abstract,12,test,gold,4197.0
1801,Cophenylcaine spray vs. placebo in,flexible nasendoscopy :,a prospective double-blind randomised controlled trial .,"['Cophenylcaine', 'spray', 'vs.', 'placebo', 'in', 'flexible', 'nasendoscopy', ':', 'a', 'prospective', 'double-blind', 'randomised', 'controlled', 'trial', '.']","(5, 8)","(34, 57)",-1,ss_p,15854186,Title,0,test,gold,1341.0
1802,,Cophenylcaine spray,vs. placebo in flexible nasendoscopy : a prospective double-blind randomised controlled trial .,"['Cophenylcaine', 'spray', 'vs.', 'placebo', 'in', 'flexible', 'nasendoscopy', ':', 'a', 'prospective', 'double-blind', 'randomised', 'controlled', 'trial', '.']","(0, 2)","(0, 19)",-1,ss_i,15854186,Title,0,test,gold,99.0
1803,Cophenylcaine spray vs.,placebo,in flexible nasendoscopy : a prospective double-blind randomised controlled trial .,"['Cophenylcaine', 'spray', 'vs.', 'placebo', 'in', 'flexible', 'nasendoscopy', ':', 'a', 'prospective', 'double-blind', 'randomised', 'controlled', 'trial', '.']","(3, 4)","(23, 30)",-1,ss_i,15854186,Title,0,test,gold,4403.0
1804,Cophenylcaine spray vs. placebo in,flexible nasendoscopy :,a prospective double-blind randomised controlled trial .,"['Cophenylcaine', 'spray', 'vs.', 'placebo', 'in', 'flexible', 'nasendoscopy', ':', 'a', 'prospective', 'double-blind', 'randomised', 'controlled', 'trial', '.']","(5, 8)","(34, 57)",-1,hl_p,15854186,Title,0,test,gold,1342.0
1805,,Cophenylcaine,spray vs. placebo in flexible nasendoscopy : a prospective double-blind randomised controlled trial .,"['Cophenylcaine', 'spray', 'vs.', 'placebo', 'in', 'flexible', 'nasendoscopy', ':', 'a', 'prospective', 'double-blind', 'randomised', 'controlled', 'trial', '.']","(0, 1)","(0, 13)",-1,hl_i,15854186,Title,0,test,gold,
1806,Cophenylcaine spray vs.,placebo,in flexible nasendoscopy : a prospective double-blind randomised controlled trial .,"['Cophenylcaine', 'spray', 'vs.', 'placebo', 'in', 'flexible', 'nasendoscopy', ':', 'a', 'prospective', 'double-blind', 'randomised', 'controlled', 'trial', '.']","(3, 4)","(23, 30)",-1,hl_i,15854186,Title,0,test,gold,4402.0
1807,Practices vary across the UK on the use of topical preparation prior to flexible fibreoptic nasendoscopy .,,,"['Practices', 'vary', 'across', 'the', 'UK', 'on', 'the', 'use', 'of', 'topical', 'preparation', 'prior', 'to', 'flexible', 'fibreoptic', 'nasendoscopy', '.']",,,,,15854186,Abstract,0,test,gold,
1808,"In this double-blind study , we randomised",98 patients,to receive cophenylcaine or placebo nasal spray before flexible nasendoscopy .,"['In', 'this', 'double-blind', 'study', ',', 'we', 'randomised', '98', 'patients', 'to', 'receive', 'cophenylcaine', 'or', 'placebo', 'nasal', 'spray', 'before', 'flexible', 'nasendoscopy', '.']","(7, 9)","(42, 53)",-1,ss_p,15854186,Abstract,1,test,gold,3749.0
1809,"In this double-blind study , we randomised 98 patients to receive cophenylcaine or placebo nasal spray before",flexible nasendoscopy .,,"['In', 'this', 'double-blind', 'study', ',', 'we', 'randomised', '98', 'patients', 'to', 'receive', 'cophenylcaine', 'or', 'placebo', 'nasal', 'spray', 'before', 'flexible', 'nasendoscopy', '.']","(17, 20)","(109, 132)",-1,ss_p,15854186,Abstract,1,test,gold,1340.0
1810,"In this double-blind study , we randomised 98 patients to receive",cophenylcaine,or placebo nasal spray before flexible nasendoscopy .,"['In', 'this', 'double-blind', 'study', ',', 'we', 'randomised', '98', 'patients', 'to', 'receive', 'cophenylcaine', 'or', 'placebo', 'nasal', 'spray', 'before', 'flexible', 'nasendoscopy', '.']","(11, 12)","(65, 78)",-1,ss_i,15854186,Abstract,1,test,gold,
1811,"In this double-blind study , we randomised 98 patients to receive cophenylcaine or",placebo,nasal spray before flexible nasendoscopy .,"['In', 'this', 'double-blind', 'study', ',', 'we', 'randomised', '98', 'patients', 'to', 'receive', 'cophenylcaine', 'or', 'placebo', 'nasal', 'spray', 'before', 'flexible', 'nasendoscopy', '.']","(13, 14)","(82, 89)",-1,ss_i,15854186,Abstract,1,test,gold,4401.0
1812,"In this double-blind study , we randomised",98 patients,to receive cophenylcaine or placebo nasal spray before flexible nasendoscopy .,"['In', 'this', 'double-blind', 'study', ',', 'we', 'randomised', '98', 'patients', 'to', 'receive', 'cophenylcaine', 'or', 'placebo', 'nasal', 'spray', 'before', 'flexible', 'nasendoscopy', '.']","(7, 9)","(42, 53)",-1,hl_p,15854186,Abstract,1,test,gold,3748.0
1813,"In this double-blind study , we randomised 98 patients to receive cophenylcaine or placebo nasal spray before",flexible nasendoscopy .,,"['In', 'this', 'double-blind', 'study', ',', 'we', 'randomised', '98', 'patients', 'to', 'receive', 'cophenylcaine', 'or', 'placebo', 'nasal', 'spray', 'before', 'flexible', 'nasendoscopy', '.']","(17, 20)","(109, 132)",-1,hl_p,15854186,Abstract,1,test,gold,1339.0
1814,"In this double-blind study , we randomised 98 patients to receive",cophenylcaine,or placebo nasal spray before flexible nasendoscopy .,"['In', 'this', 'double-blind', 'study', ',', 'we', 'randomised', '98', 'patients', 'to', 'receive', 'cophenylcaine', 'or', 'placebo', 'nasal', 'spray', 'before', 'flexible', 'nasendoscopy', '.']","(11, 12)","(65, 78)",-1,hl_i,15854186,Abstract,1,test,gold,
1815,"In this double-blind study , we randomised 98 patients to receive cophenylcaine or",placebo,nasal spray before flexible nasendoscopy .,"['In', 'this', 'double-blind', 'study', ',', 'we', 'randomised', '98', 'patients', 'to', 'receive', 'cophenylcaine', 'or', 'placebo', 'nasal', 'spray', 'before', 'flexible', 'nasendoscopy', '.']","(13, 14)","(82, 89)",-1,hl_i,15854186,Abstract,1,test,gold,4400.0
1816,A,"visual analogue scale ( 1-100 ) was used to record pain , unpleasantness of taste and overall discomfort experienced .",,"['A', 'visual', 'analogue', 'scale', '(', '1-100', ')', 'was', 'used', 'to', 'record', 'pain', ',', 'unpleasantness', 'of', 'taste', 'and', 'overall', 'discomfort', 'experienced', '.']","(1, 21)","(1, 119)",-1,ss_o,15854186,Abstract,2,test,gold,7121.0
1817,A visual analogue scale ( 1-100 ) was used to record,"pain , unpleasantness of taste and overall discomfort experienced .",,"['A', 'visual', 'analogue', 'scale', '(', '1-100', ')', 'was', 'used', 'to', 'record', 'pain', ',', 'unpleasantness', 'of', 'taste', 'and', 'overall', 'discomfort', 'experienced', '.']","(11, 21)","(52, 119)",-1,hl_o,15854186,Abstract,2,test,gold,2274.0
1818,"Overall , the procedure was associated with minimal",pain and discomfort,in both groups .,"['Overall', ',', 'the', 'procedure', 'was', 'associated', 'with', 'minimal', 'pain', 'and', 'discomfort', 'in', 'both', 'groups', '.']","(8, 11)","(51, 70)",-1,ss_o,15854186,Abstract,3,test,gold,2278.0
1819,"Overall , the procedure was associated with minimal",pain and discomfort,in both groups .,"['Overall', ',', 'the', 'procedure', 'was', 'associated', 'with', 'minimal', 'pain', 'and', 'discomfort', 'in', 'both', 'groups', '.']","(8, 11)","(51, 70)",-1,hl_o,15854186,Abstract,3,test,gold,2279.0
1820,"There was no significant difference in pain or overall discomfort experienced between the two groups ; however , the sensation of bad taste was significantly worse in the",cophenylcaine,group .,"['There', 'was', 'no', 'significant', 'difference', 'in', 'pain', 'or', 'overall', 'discomfort', 'experienced', 'between', 'the', 'two', 'groups', ';', 'however', ',', 'the', 'sensation', 'of', 'bad', 'taste', 'was', 'significantly', 'worse', 'in', 'the', 'cophenylcaine', 'group', '.']","(28, 29)","(170, 183)",-1,ss_i,15854186,Abstract,4,test,gold,
1821,There was no significant difference in,pain or overall discomfort,"experienced between the two groups ; however , the sensation of bad taste was significantly worse in the cophenylcaine group .","['There', 'was', 'no', 'significant', 'difference', 'in', 'pain', 'or', 'overall', 'discomfort', 'experienced', 'between', 'the', 'two', 'groups', ';', 'however', ',', 'the', 'sensation', 'of', 'bad', 'taste', 'was', 'significantly', 'worse', 'in', 'the', 'cophenylcaine', 'group', '.']","(6, 10)","(38, 64)",-1,ss_o,15854186,Abstract,4,test,gold,2280.0
1822,"There was no significant difference in pain or overall discomfort experienced between the two groups ; however , the",sensation of bad taste,was significantly worse in the cophenylcaine group .,"['There', 'was', 'no', 'significant', 'difference', 'in', 'pain', 'or', 'overall', 'discomfort', 'experienced', 'between', 'the', 'two', 'groups', ';', 'however', ',', 'the', 'sensation', 'of', 'bad', 'taste', 'was', 'significantly', 'worse', 'in', 'the', 'cophenylcaine', 'group', '.']","(19, 23)","(116, 138)",-1,ss_o,15854186,Abstract,4,test,gold,2669.0
1823,"There was no significant difference in pain or overall discomfort experienced between the two groups ; however , the sensation of bad taste was significantly worse in the",cophenylcaine,group .,"['There', 'was', 'no', 'significant', 'difference', 'in', 'pain', 'or', 'overall', 'discomfort', 'experienced', 'between', 'the', 'two', 'groups', ';', 'however', ',', 'the', 'sensation', 'of', 'bad', 'taste', 'was', 'significantly', 'worse', 'in', 'the', 'cophenylcaine', 'group', '.']","(28, 29)","(170, 183)",-1,hl_i,15854186,Abstract,4,test,gold,
1824,There was no significant difference in,pain or overall discomfort,"experienced between the two groups ; however , the sensation of bad taste was significantly worse in the cophenylcaine group .","['There', 'was', 'no', 'significant', 'difference', 'in', 'pain', 'or', 'overall', 'discomfort', 'experienced', 'between', 'the', 'two', 'groups', ';', 'however', ',', 'the', 'sensation', 'of', 'bad', 'taste', 'was', 'significantly', 'worse', 'in', 'the', 'cophenylcaine', 'group', '.']","(6, 10)","(38, 64)",-1,hl_o,15854186,Abstract,4,test,gold,2281.0
1825,"There was no significant difference in pain or overall discomfort experienced between the two groups ; however , the",sensation of bad taste,was significantly worse in the cophenylcaine group .,"['There', 'was', 'no', 'significant', 'difference', 'in', 'pain', 'or', 'overall', 'discomfort', 'experienced', 'between', 'the', 'two', 'groups', ';', 'however', ',', 'the', 'sensation', 'of', 'bad', 'taste', 'was', 'significantly', 'worse', 'in', 'the', 'cophenylcaine', 'group', '.']","(19, 23)","(116, 138)",-1,hl_o,15854186,Abstract,4,test,gold,2670.0
1826,"In linear regression , factors that predicted the overall",unpleasantness,of the experience were primarily pain experienced and secondarily unpleasantness of taste .,"['In', 'linear', 'regression', ',', 'factors', 'that', 'predicted', 'the', 'overall', 'unpleasantness', 'of', 'the', 'experience', 'were', 'primarily', 'pain', 'experienced', 'and', 'secondarily', 'unpleasantness', 'of', 'taste', '.']","(9, 10)","(57, 71)",-1,ss_o,15854186,Abstract,5,test,gold,2674.0
1827,"In linear regression , factors that predicted the overall unpleasantness of the experience were primarily",pain,experienced and secondarily unpleasantness of taste .,"['In', 'linear', 'regression', ',', 'factors', 'that', 'predicted', 'the', 'overall', 'unpleasantness', 'of', 'the', 'experience', 'were', 'primarily', 'pain', 'experienced', 'and', 'secondarily', 'unpleasantness', 'of', 'taste', '.']","(15, 16)","(105, 109)",-1,ss_o,15854186,Abstract,5,test,gold,2301.0
1828,"In linear regression , factors that predicted the overall unpleasantness of the experience were primarily pain experienced and secondarily",unpleasantness of taste .,,"['In', 'linear', 'regression', ',', 'factors', 'that', 'predicted', 'the', 'overall', 'unpleasantness', 'of', 'the', 'experience', 'were', 'primarily', 'pain', 'experienced', 'and', 'secondarily', 'unpleasantness', 'of', 'taste', '.']","(19, 23)","(138, 163)",-1,ss_o,15854186,Abstract,5,test,gold,2672.0
1829,"In linear regression , factors that predicted the overall",unpleasantness,of the experience were primarily pain experienced and secondarily unpleasantness of taste .,"['In', 'linear', 'regression', ',', 'factors', 'that', 'predicted', 'the', 'overall', 'unpleasantness', 'of', 'the', 'experience', 'were', 'primarily', 'pain', 'experienced', 'and', 'secondarily', 'unpleasantness', 'of', 'taste', '.']","(9, 10)","(57, 71)",-1,hl_o,15854186,Abstract,5,test,gold,2675.0
1830,"In linear regression , factors that predicted the overall unpleasantness of the experience were primarily",pain,experienced and secondarily unpleasantness of taste .,"['In', 'linear', 'regression', ',', 'factors', 'that', 'predicted', 'the', 'overall', 'unpleasantness', 'of', 'the', 'experience', 'were', 'primarily', 'pain', 'experienced', 'and', 'secondarily', 'unpleasantness', 'of', 'taste', '.']","(15, 16)","(105, 109)",-1,hl_o,15854186,Abstract,5,test,gold,2300.0
1831,"In linear regression , factors that predicted the overall unpleasantness of the experience were primarily pain experienced and secondarily",unpleasantness of taste .,,"['In', 'linear', 'regression', ',', 'factors', 'that', 'predicted', 'the', 'overall', 'unpleasantness', 'of', 'the', 'experience', 'were', 'primarily', 'pain', 'experienced', 'and', 'secondarily', 'unpleasantness', 'of', 'taste', '.']","(19, 23)","(138, 163)",-1,hl_o,15854186,Abstract,5,test,gold,2673.0
1832,We conclude that the routine use of cophenylcaine for nasal preparation is not justified before,flexible nasendoscopy .,,"['We', 'conclude', 'that', 'the', 'routine', 'use', 'of', 'cophenylcaine', 'for', 'nasal', 'preparation', 'is', 'not', 'justified', 'before', 'flexible', 'nasendoscopy', '.']","(15, 18)","(95, 118)",-1,ss_p,15854186,Abstract,6,test,gold,1338.0
1833,We conclude that the routine use of,cophenylcaine,for nasal preparation is not justified before flexible nasendoscopy .,"['We', 'conclude', 'that', 'the', 'routine', 'use', 'of', 'cophenylcaine', 'for', 'nasal', 'preparation', 'is', 'not', 'justified', 'before', 'flexible', 'nasendoscopy', '.']","(7, 8)","(35, 48)",-1,ss_i,15854186,Abstract,6,test,gold,
1834,We conclude that the routine use of cophenylcaine for nasal preparation is not justified before,flexible nasendoscopy .,,"['We', 'conclude', 'that', 'the', 'routine', 'use', 'of', 'cophenylcaine', 'for', 'nasal', 'preparation', 'is', 'not', 'justified', 'before', 'flexible', 'nasendoscopy', '.']","(15, 18)","(95, 118)",-1,hl_p,15854186,Abstract,6,test,gold,1337.0
1835,We conclude that the routine use of,cophenylcaine,for nasal preparation is not justified before flexible nasendoscopy .,"['We', 'conclude', 'that', 'the', 'routine', 'use', 'of', 'cophenylcaine', 'for', 'nasal', 'preparation', 'is', 'not', 'justified', 'before', 'flexible', 'nasendoscopy', '.']","(7, 8)","(35, 48)",-1,hl_i,15854186,Abstract,6,test,gold,
1836,Effects of Saccharomyces boulardii in,children with acute diarrhoea .,,"['Effects', 'of', 'Saccharomyces', 'boulardii', 'in', 'children', 'with', 'acute', 'diarrhoea', '.']","(5, 10)","(37, 68)",-1,ss_p,15858959,Title,0,test,gold,3476.0
1837,Effects of,Saccharomyces boulardii,in children with acute diarrhoea .,"['Effects', 'of', 'Saccharomyces', 'boulardii', 'in', 'children', 'with', 'acute', 'diarrhoea', '.']","(2, 4)","(10, 33)",-1,ss_i,15858959,Title,0,test,gold,105.0
1838,Effects of Saccharomyces boulardii in,children,with acute diarrhoea .,"['Effects', 'of', 'Saccharomyces', 'boulardii', 'in', 'children', 'with', 'acute', 'diarrhoea', '.']","(5, 6)","(37, 45)",-1,hl_p,15858959,Title,0,test,gold,2141.0
1839,Effects of Saccharomyces boulardii in children with,acute diarrhoea,.,"['Effects', 'of', 'Saccharomyces', 'boulardii', 'in', 'children', 'with', 'acute', 'diarrhoea', '.']","(7, 9)","(51, 66)",-1,hl_p,15858959,Title,0,test,gold,1215.0
1840,Effects of,Saccharomyces boulardii,in children with acute diarrhoea .,"['Effects', 'of', 'Saccharomyces', 'boulardii', 'in', 'children', 'with', 'acute', 'diarrhoea', '.']","(2, 4)","(10, 33)",-1,hl_i,15858959,Title,0,test,gold,106.0
1841,"AIM Certain probiotic agents , e.g .",,,"['AIM', 'Certain', 'probiotic', 'agents', ',', 'e.g', '.']",,,,,15858959,Abstract,0,test,gold,
1842,"Lactobacillus GG , have shown efficacy in clinical trials for the treatment of",acute childhood diarrhoea,", but few studies have examined the effect of Saccharomyces boulardii .","['Lactobacillus', 'GG', ',', 'have', 'shown', 'efficacy', 'in', 'clinical', 'trials', 'for', 'the', 'treatment', 'of', 'acute', 'childhood', 'diarrhoea', ',', 'but', 'few', 'studies', 'have', 'examined', 'the', 'effect', 'of', 'Saccharomyces', 'boulardii', '.']","(13, 16)","(78, 103)",-1,ss_p,15858959,Abstract,1,test,gold,3474.0
1843,"Lactobacillus GG , have shown efficacy in clinical trials for the treatment of acute childhood diarrhoea , but few studies have examined the effect of",Saccharomyces boulardii .,,"['Lactobacillus', 'GG', ',', 'have', 'shown', 'efficacy', 'in', 'clinical', 'trials', 'for', 'the', 'treatment', 'of', 'acute', 'childhood', 'diarrhoea', ',', 'but', 'few', 'studies', 'have', 'examined', 'the', 'effect', 'of', 'Saccharomyces', 'boulardii', '.']","(25, 28)","(150, 175)",-1,ss_i,15858959,Abstract,1,test,gold,104.0
1844,"Lactobacillus GG , have shown efficacy in clinical trials for the treatment of acute childhood diarrhoea , but few studies have examined the effect of",Saccharomyces boulardii .,,"['Lactobacillus', 'GG', ',', 'have', 'shown', 'efficacy', 'in', 'clinical', 'trials', 'for', 'the', 'treatment', 'of', 'acute', 'childhood', 'diarrhoea', ',', 'but', 'few', 'studies', 'have', 'examined', 'the', 'effect', 'of', 'Saccharomyces', 'boulardii', '.']","(25, 28)","(150, 175)",-1,hl_i,15858959,Abstract,1,test,gold,103.0
1845,We evaluated the effect of S. boulardii in,children with acute diarrhoea .,,"['We', 'evaluated', 'the', 'effect', 'of', 'S.', 'boulardii', 'in', 'children', 'with', 'acute', 'diarrhoea', '.']","(8, 13)","(42, 73)",-1,ss_p,15858959,Abstract,2,test,gold,3477.0
1846,We evaluated the effect of,S. boulardii,in children with acute diarrhoea .,"['We', 'evaluated', 'the', 'effect', 'of', 'S.', 'boulardii', 'in', 'children', 'with', 'acute', 'diarrhoea', '.']","(5, 7)","(26, 38)",-1,ss_i,15858959,Abstract,2,test,gold,779.0
1847,We evaluated the,effect,of S. boulardii in children with acute diarrhoea .,"['We', 'evaluated', 'the', 'effect', 'of', 'S.', 'boulardii', 'in', 'children', 'with', 'acute', 'diarrhoea', '.']","(3, 4)","(16, 22)",-1,ss_o,15858959,Abstract,2,test,gold,2343.0
1848,We evaluated the effect of S. boulardii in,children with acute diarrhoea .,,"['We', 'evaluated', 'the', 'effect', 'of', 'S.', 'boulardii', 'in', 'children', 'with', 'acute', 'diarrhoea', '.']","(8, 13)","(42, 73)",-1,hl_p,15858959,Abstract,2,test,gold,3475.0
1849,We evaluated the effect of,S. boulardii,in children with acute diarrhoea .,"['We', 'evaluated', 'the', 'effect', 'of', 'S.', 'boulardii', 'in', 'children', 'with', 'acute', 'diarrhoea', '.']","(5, 7)","(26, 38)",-1,hl_i,15858959,Abstract,2,test,gold,780.0
1850,METHODS,Two hundred children,were randomized to receive S. boulardii in a granulated form in a daily dose of 250 mg ( S. boulardii group ) or placebo ( placebo group ) for 5 d. Clinical and demographic characteristics on admission were similar between the study groups .,"['METHODS', 'Two', 'hundred', 'children', 'were', 'randomized', 'to', 'receive', 'S.', 'boulardii', 'in', 'a', 'granulated', 'form', 'in', 'a', 'daily', 'dose', 'of', '250', 'mg', '(', 'S.', 'boulardii', 'group', ')', 'or', 'placebo', '(', 'placebo', 'group', ')', 'for', '5', 'd.', 'Clinical', 'and', 'demographic', 'characteristics', 'on', 'admission', 'were', 'similar', 'between', 'the', 'study', 'groups', '.']","(1, 4)","(7, 27)",-1,ss_p,15858959,Abstract,3,test,gold,2064.0
1851,METHODS Two hundred children were randomized to receive,S. boulardii,in a granulated form in a daily dose of 250 mg ( S. boulardii group ) or placebo ( placebo group ) for 5 d. Clinical and demographic characteristics on admission were similar between the study groups .,"['METHODS', 'Two', 'hundred', 'children', 'were', 'randomized', 'to', 'receive', 'S.', 'boulardii', 'in', 'a', 'granulated', 'form', 'in', 'a', 'daily', 'dose', 'of', '250', 'mg', '(', 'S.', 'boulardii', 'group', ')', 'or', 'placebo', '(', 'placebo', 'group', ')', 'for', '5', 'd.', 'Clinical', 'and', 'demographic', 'characteristics', 'on', 'admission', 'were', 'similar', 'between', 'the', 'study', 'groups', '.']","(8, 10)","(55, 67)",-1,ss_i,15858959,Abstract,3,test,gold,778.0
1852,METHODS Two hundred children were randomized to receive S. boulardii in a granulated form in a daily dose of 250 mg,( S. boulardii,group ) or placebo ( placebo group ) for 5 d. Clinical and demographic characteristics on admission were similar between the study groups .,"['METHODS', 'Two', 'hundred', 'children', 'were', 'randomized', 'to', 'receive', 'S.', 'boulardii', 'in', 'a', 'granulated', 'form', 'in', 'a', 'daily', 'dose', 'of', '250', 'mg', '(', 'S.', 'boulardii', 'group', ')', 'or', 'placebo', '(', 'placebo', 'group', ')', 'for', '5', 'd.', 'Clinical', 'and', 'demographic', 'characteristics', 'on', 'admission', 'were', 'similar', 'between', 'the', 'study', 'groups', '.']","(21, 24)","(115, 129)",-1,ss_i,15858959,Abstract,3,test,gold,777.0
1853,METHODS Two hundred children were randomized to receive S. boulardii in a granulated form in a daily dose of 250 mg ( S. boulardii group ) or,placebo ( placebo,group ) for 5 d. Clinical and demographic characteristics on admission were similar between the study groups .,"['METHODS', 'Two', 'hundred', 'children', 'were', 'randomized', 'to', 'receive', 'S.', 'boulardii', 'in', 'a', 'granulated', 'form', 'in', 'a', 'daily', 'dose', 'of', '250', 'mg', '(', 'S.', 'boulardii', 'group', ')', 'or', 'placebo', '(', 'placebo', 'group', ')', 'for', '5', 'd.', 'Clinical', 'and', 'demographic', 'characteristics', 'on', 'admission', 'were', 'similar', 'between', 'the', 'study', 'groups', '.']","(27, 30)","(141, 158)",-1,ss_i,15858959,Abstract,3,test,gold,4437.0
1854,METHODS,Two hundred children,were randomized to receive S. boulardii in a granulated form in a daily dose of 250 mg ( S. boulardii group ) or placebo ( placebo group ) for 5 d. Clinical and demographic characteristics on admission were similar between the study groups .,"['METHODS', 'Two', 'hundred', 'children', 'were', 'randomized', 'to', 'receive', 'S.', 'boulardii', 'in', 'a', 'granulated', 'form', 'in', 'a', 'daily', 'dose', 'of', '250', 'mg', '(', 'S.', 'boulardii', 'group', ')', 'or', 'placebo', '(', 'placebo', 'group', ')', 'for', '5', 'd.', 'Clinical', 'and', 'demographic', 'characteristics', 'on', 'admission', 'were', 'similar', 'between', 'the', 'study', 'groups', '.']","(1, 4)","(7, 27)",-1,hl_p,15858959,Abstract,3,test,gold,2065.0
1855,METHODS Two hundred children were randomized to receive,S. boulardii,in a granulated form in a daily dose of 250 mg ( S. boulardii group ) or placebo ( placebo group ) for 5 d. Clinical and demographic characteristics on admission were similar between the study groups .,"['METHODS', 'Two', 'hundred', 'children', 'were', 'randomized', 'to', 'receive', 'S.', 'boulardii', 'in', 'a', 'granulated', 'form', 'in', 'a', 'daily', 'dose', 'of', '250', 'mg', '(', 'S.', 'boulardii', 'group', ')', 'or', 'placebo', '(', 'placebo', 'group', ')', 'for', '5', 'd.', 'Clinical', 'and', 'demographic', 'characteristics', 'on', 'admission', 'were', 'similar', 'between', 'the', 'study', 'groups', '.']","(8, 10)","(55, 67)",-1,hl_i,15858959,Abstract,3,test,gold,776.0
1856,METHODS Two hundred children were randomized to receive S. boulardii in a granulated form in a daily dose of 250 mg (,S. boulardii,group ) or placebo ( placebo group ) for 5 d. Clinical and demographic characteristics on admission were similar between the study groups .,"['METHODS', 'Two', 'hundred', 'children', 'were', 'randomized', 'to', 'receive', 'S.', 'boulardii', 'in', 'a', 'granulated', 'form', 'in', 'a', 'daily', 'dose', 'of', '250', 'mg', '(', 'S.', 'boulardii', 'group', ')', 'or', 'placebo', '(', 'placebo', 'group', ')', 'for', '5', 'd.', 'Clinical', 'and', 'demographic', 'characteristics', 'on', 'admission', 'were', 'similar', 'between', 'the', 'study', 'groups', '.']","(22, 24)","(117, 129)",-1,hl_i,15858959,Abstract,3,test,gold,775.0
1857,METHODS Two hundred children were randomized to receive S. boulardii in a granulated form in a daily dose of 250 mg ( S. boulardii group ) or,placebo,( placebo group ) for 5 d. Clinical and demographic characteristics on admission were similar between the study groups .,"['METHODS', 'Two', 'hundred', 'children', 'were', 'randomized', 'to', 'receive', 'S.', 'boulardii', 'in', 'a', 'granulated', 'form', 'in', 'a', 'daily', 'dose', 'of', '250', 'mg', '(', 'S.', 'boulardii', 'group', ')', 'or', 'placebo', '(', 'placebo', 'group', ')', 'for', '5', 'd.', 'Clinical', 'and', 'demographic', 'characteristics', 'on', 'admission', 'were', 'similar', 'between', 'the', 'study', 'groups', '.']","(27, 28)","(141, 148)",-1,hl_i,15858959,Abstract,3,test,gold,4399.0
1858,METHODS Two hundred children were randomized to receive S. boulardii in a granulated form in a daily dose of 250 mg ( S. boulardii group ) or placebo (,placebo,group ) for 5 d. Clinical and demographic characteristics on admission were similar between the study groups .,"['METHODS', 'Two', 'hundred', 'children', 'were', 'randomized', 'to', 'receive', 'S.', 'boulardii', 'in', 'a', 'granulated', 'form', 'in', 'a', 'daily', 'dose', 'of', '250', 'mg', '(', 'S.', 'boulardii', 'group', ')', 'or', 'placebo', '(', 'placebo', 'group', ')', 'for', '5', 'd.', 'Clinical', 'and', 'demographic', 'characteristics', 'on', 'admission', 'were', 'similar', 'between', 'the', 'study', 'groups', '.']","(29, 30)","(151, 158)",-1,hl_i,15858959,Abstract,3,test,gold,4398.0
1859,RESULTS The medians of the average stool frequency after the second day of the treatment were significantly lower in the,S. boulardii,group than in the placebo group ( p = 0.003 ) .,"['RESULTS', 'The', 'medians', 'of', 'the', 'average', 'stool', 'frequency', 'after', 'the', 'second', 'day', 'of', 'the', 'treatment', 'were', 'significantly', 'lower', 'in', 'the', 'S.', 'boulardii', 'group', 'than', 'in', 'the', 'placebo', 'group', '(', 'p', '=', '0.003', ')', '.']","(20, 22)","(120, 132)",-1,ss_i,15858959,Abstract,4,test,gold,774.0
1860,RESULTS The medians of the average stool frequency after the second day of the treatment were significantly lower in the S. boulardii group than in the,placebo,group ( p = 0.003 ) .,"['RESULTS', 'The', 'medians', 'of', 'the', 'average', 'stool', 'frequency', 'after', 'the', 'second', 'day', 'of', 'the', 'treatment', 'were', 'significantly', 'lower', 'in', 'the', 'S.', 'boulardii', 'group', 'than', 'in', 'the', 'placebo', 'group', '(', 'p', '=', '0.003', ')', '.']","(26, 27)","(151, 158)",-1,ss_i,15858959,Abstract,4,test,gold,4397.0
1861,RESULTS The medians of the,average stool frequency,after the second day of the treatment were significantly lower in the S. boulardii group than in the placebo group ( p = 0.003 ) .,"['RESULTS', 'The', 'medians', 'of', 'the', 'average', 'stool', 'frequency', 'after', 'the', 'second', 'day', 'of', 'the', 'treatment', 'were', 'significantly', 'lower', 'in', 'the', 'S.', 'boulardii', 'group', 'than', 'in', 'the', 'placebo', 'group', '(', 'p', '=', '0.003', ')', '.']","(5, 8)","(26, 49)",-1,ss_o,15858959,Abstract,4,test,gold,1863.0
1862,RESULTS The medians of the average stool frequency after the second day of the treatment were significantly lower in the,S. boulardii,group than in the placebo group ( p = 0.003 ) .,"['RESULTS', 'The', 'medians', 'of', 'the', 'average', 'stool', 'frequency', 'after', 'the', 'second', 'day', 'of', 'the', 'treatment', 'were', 'significantly', 'lower', 'in', 'the', 'S.', 'boulardii', 'group', 'than', 'in', 'the', 'placebo', 'group', '(', 'p', '=', '0.003', ')', '.']","(20, 22)","(120, 132)",-1,hl_i,15858959,Abstract,4,test,gold,773.0
1863,RESULTS The medians of the average stool frequency after the second day of the treatment were significantly lower in the S. boulardii group than in the,placebo,group ( p = 0.003 ) .,"['RESULTS', 'The', 'medians', 'of', 'the', 'average', 'stool', 'frequency', 'after', 'the', 'second', 'day', 'of', 'the', 'treatment', 'were', 'significantly', 'lower', 'in', 'the', 'S.', 'boulardii', 'group', 'than', 'in', 'the', 'placebo', 'group', '(', 'p', '=', '0.003', ')', '.']","(26, 27)","(151, 158)",-1,hl_i,15858959,Abstract,4,test,gold,4396.0
1864,RESULTS The medians of the,average stool frequency,after the second day of the treatment were significantly lower in the S. boulardii group than in the placebo group ( p = 0.003 ) .,"['RESULTS', 'The', 'medians', 'of', 'the', 'average', 'stool', 'frequency', 'after', 'the', 'second', 'day', 'of', 'the', 'treatment', 'were', 'significantly', 'lower', 'in', 'the', 'S.', 'boulardii', 'group', 'than', 'in', 'the', 'placebo', 'group', '(', 'p', '=', '0.003', ')', '.']","(5, 8)","(26, 49)",-1,hl_o,15858959,Abstract,4,test,gold,1864.0
1865,The duration of diarrhoea significantly reduced in the,S. boulardii,"group compared with the placebo group ( 4.7 vs 5.5 d , p = 0.03 ) .","['The', 'duration', 'of', 'diarrhoea', 'significantly', 'reduced', 'in', 'the', 'S.', 'boulardii', 'group', 'compared', 'with', 'the', 'placebo', 'group', '(', '4.7', 'vs', '5.5', 'd', ',', 'p', '=', '0.03', ')', '.']","(8, 10)","(54, 66)",-1,ss_i,15858959,Abstract,5,test,gold,772.0
1866,The duration of diarrhoea significantly reduced in the S. boulardii group compared with the,placebo,"group ( 4.7 vs 5.5 d , p = 0.03 ) .","['The', 'duration', 'of', 'diarrhoea', 'significantly', 'reduced', 'in', 'the', 'S.', 'boulardii', 'group', 'compared', 'with', 'the', 'placebo', 'group', '(', '4.7', 'vs', '5.5', 'd', ',', 'p', '=', '0.03', ')', '.']","(14, 15)","(91, 98)",-1,ss_i,15858959,Abstract,5,test,gold,4395.0
1867,The,duration of diarrhoea,"significantly reduced in the S. boulardii group compared with the placebo group ( 4.7 vs 5.5 d , p = 0.03 ) .","['The', 'duration', 'of', 'diarrhoea', 'significantly', 'reduced', 'in', 'the', 'S.', 'boulardii', 'group', 'compared', 'with', 'the', 'placebo', 'group', '(', '4.7', 'vs', '5.5', 'd', ',', 'p', '=', '0.03', ')', '.']","(1, 4)","(3, 24)",-1,ss_o,15858959,Abstract,5,test,gold,1327.0
1868,The duration of diarrhoea significantly reduced in the,S. boulardii,"group compared with the placebo group ( 4.7 vs 5.5 d , p = 0.03 ) .","['The', 'duration', 'of', 'diarrhoea', 'significantly', 'reduced', 'in', 'the', 'S.', 'boulardii', 'group', 'compared', 'with', 'the', 'placebo', 'group', '(', '4.7', 'vs', '5.5', 'd', ',', 'p', '=', '0.03', ')', '.']","(8, 10)","(54, 66)",-1,hl_i,15858959,Abstract,5,test,gold,771.0
1869,The duration of diarrhoea significantly reduced in the S. boulardii group compared with the,placebo,"group ( 4.7 vs 5.5 d , p = 0.03 ) .","['The', 'duration', 'of', 'diarrhoea', 'significantly', 'reduced', 'in', 'the', 'S.', 'boulardii', 'group', 'compared', 'with', 'the', 'placebo', 'group', '(', '4.7', 'vs', '5.5', 'd', ',', 'p', '=', '0.03', ')', '.']","(14, 15)","(91, 98)",-1,hl_i,15858959,Abstract,5,test,gold,4394.0
1870,The,duration of diarrhoea,"significantly reduced in the S. boulardii group compared with the placebo group ( 4.7 vs 5.5 d , p = 0.03 ) .","['The', 'duration', 'of', 'diarrhoea', 'significantly', 'reduced', 'in', 'the', 'S.', 'boulardii', 'group', 'compared', 'with', 'the', 'placebo', 'group', '(', '4.7', 'vs', '5.5', 'd', ',', 'p', '=', '0.03', ')', '.']","(1, 4)","(3, 24)",-1,hl_o,15858959,Abstract,5,test,gold,1326.0
1871,The effect of,S. boulardii,on watery diarrhoea became apparent after the second day of the treatment .,"['The', 'effect', 'of', 'S.', 'boulardii', 'on', 'watery', 'diarrhoea', 'became', 'apparent', 'after', 'the', 'second', 'day', 'of', 'the', 'treatment', '.']","(3, 5)","(13, 25)",-1,ss_i,15858959,Abstract,6,test,gold,770.0
1872,The,effect,of S. boulardii on watery diarrhoea became apparent after the second day of the treatment .,"['The', 'effect', 'of', 'S.', 'boulardii', 'on', 'watery', 'diarrhoea', 'became', 'apparent', 'after', 'the', 'second', 'day', 'of', 'the', 'treatment', '.']","(1, 2)","(3, 9)",-1,ss_o,15858959,Abstract,6,test,gold,2341.0
1873,The effect of,S. boulardii,on watery diarrhoea became apparent after the second day of the treatment .,"['The', 'effect', 'of', 'S.', 'boulardii', 'on', 'watery', 'diarrhoea', 'became', 'apparent', 'after', 'the', 'second', 'day', 'of', 'the', 'treatment', '.']","(3, 5)","(13, 25)",-1,hl_i,15858959,Abstract,6,test,gold,769.0
1874,The duration of hospital stay was shorter in the,S. boulardii,"group than in the placebo group ( 2.9 vs 3.9 d , p < 0.001 ) .","['The', 'duration', 'of', 'hospital', 'stay', 'was', 'shorter', 'in', 'the', 'S.', 'boulardii', 'group', 'than', 'in', 'the', 'placebo', 'group', '(', '2.9', 'vs', '3.9', 'd', ',', 'p', '<', '0.001', ')', '.']","(9, 11)","(48, 60)",-1,ss_i,15858959,Abstract,7,test,gold,768.0
1875,The duration of hospital stay was shorter in the S. boulardii group than in the,placebo,"group ( 2.9 vs 3.9 d , p < 0.001 ) .","['The', 'duration', 'of', 'hospital', 'stay', 'was', 'shorter', 'in', 'the', 'S.', 'boulardii', 'group', 'than', 'in', 'the', 'placebo', 'group', '(', '2.9', 'vs', '3.9', 'd', ',', 'p', '<', '0.001', ')', '.']","(15, 16)","(79, 86)",-1,ss_i,15858959,Abstract,7,test,gold,4393.0
1876,The,duration of hospital stay,"was shorter in the S. boulardii group than in the placebo group ( 2.9 vs 3.9 d , p < 0.001 ) .","['The', 'duration', 'of', 'hospital', 'stay', 'was', 'shorter', 'in', 'the', 'S.', 'boulardii', 'group', 'than', 'in', 'the', 'placebo', 'group', '(', '2.9', 'vs', '3.9', 'd', ',', 'p', '<', '0.001', ')', '.']","(1, 5)","(3, 28)",-1,ss_o,15858959,Abstract,7,test,gold,3698.0
1877,The duration of hospital stay was shorter in the,S. boulardii,"group than in the placebo group ( 2.9 vs 3.9 d , p < 0.001 ) .","['The', 'duration', 'of', 'hospital', 'stay', 'was', 'shorter', 'in', 'the', 'S.', 'boulardii', 'group', 'than', 'in', 'the', 'placebo', 'group', '(', '2.9', 'vs', '3.9', 'd', ',', 'p', '<', '0.001', ')', '.']","(9, 11)","(48, 60)",-1,hl_i,15858959,Abstract,7,test,gold,767.0
1878,The duration of hospital stay was shorter in the S. boulardii group than in the,placebo,"group ( 2.9 vs 3.9 d , p < 0.001 ) .","['The', 'duration', 'of', 'hospital', 'stay', 'was', 'shorter', 'in', 'the', 'S.', 'boulardii', 'group', 'than', 'in', 'the', 'placebo', 'group', '(', '2.9', 'vs', '3.9', 'd', ',', 'p', '<', '0.001', ')', '.']","(15, 16)","(79, 86)",-1,hl_i,15858959,Abstract,7,test,gold,4392.0
1879,The,duration of hospital stay,"was shorter in the S. boulardii group than in the placebo group ( 2.9 vs 3.9 d , p < 0.001 ) .","['The', 'duration', 'of', 'hospital', 'stay', 'was', 'shorter', 'in', 'the', 'S.', 'boulardii', 'group', 'than', 'in', 'the', 'placebo', 'group', '(', '2.9', 'vs', '3.9', 'd', ',', 'p', '<', '0.001', ')', '.']","(1, 5)","(3, 28)",-1,hl_o,15858959,Abstract,7,test,gold,3699.0
1880,Four children from the,placebo,group versus only one child from the S. boulardii group had persisting diarrhoea .,"['Four', 'children', 'from', 'the', 'placebo', 'group', 'versus', 'only', 'one', 'child', 'from', 'the', 'S.', 'boulardii', 'group', 'had', 'persisting', 'diarrhoea', '.']","(4, 5)","(22, 29)",-1,ss_i,15858959,Abstract,8,test,gold,4391.0
1881,Four children from the placebo group versus only one child from the,S. boulardii,group had persisting diarrhoea .,"['Four', 'children', 'from', 'the', 'placebo', 'group', 'versus', 'only', 'one', 'child', 'from', 'the', 'S.', 'boulardii', 'group', 'had', 'persisting', 'diarrhoea', '.']","(12, 14)","(67, 79)",-1,ss_i,15858959,Abstract,8,test,gold,766.0
1882,Four children from the,placebo,group versus only one child from the S. boulardii group had persisting diarrhoea .,"['Four', 'children', 'from', 'the', 'placebo', 'group', 'versus', 'only', 'one', 'child', 'from', 'the', 'S.', 'boulardii', 'group', 'had', 'persisting', 'diarrhoea', '.']","(4, 5)","(22, 29)",-1,hl_i,15858959,Abstract,8,test,gold,4390.0
1883,Four children from the placebo group versus only one child from the,S. boulardii,group had persisting diarrhoea .,"['Four', 'children', 'from', 'the', 'placebo', 'group', 'versus', 'only', 'one', 'child', 'from', 'the', 'S.', 'boulardii', 'group', 'had', 'persisting', 'diarrhoea', '.']","(12, 14)","(67, 79)",-1,hl_i,15858959,Abstract,8,test,gold,765.0
1884,CONCLUSION The placebo-controlled study suggested that,S. boulardii,significantly reduced the duration of acute diarrhoea and the duration of hospital stay .,"['CONCLUSION', 'The', 'placebo-controlled', 'study', 'suggested', 'that', 'S.', 'boulardii', 'significantly', 'reduced', 'the', 'duration', 'of', 'acute', 'diarrhoea', 'and', 'the', 'duration', 'of', 'hospital', 'stay', '.']","(6, 8)","(54, 66)",-1,ss_i,15858959,Abstract,9,test,gold,764.0
1885,CONCLUSION The placebo-controlled study suggested that S. boulardii significantly reduced the,duration of acute diarrhoea and the duration of hospital stay .,,"['CONCLUSION', 'The', 'placebo-controlled', 'study', 'suggested', 'that', 'S.', 'boulardii', 'significantly', 'reduced', 'the', 'duration', 'of', 'acute', 'diarrhoea', 'and', 'the', 'duration', 'of', 'hospital', 'stay', '.']","(11, 22)","(93, 156)",-1,ss_o,15858959,Abstract,9,test,gold,3695.0
1886,CONCLUSION The placebo-controlled study suggested that,S. boulardii,significantly reduced the duration of acute diarrhoea and the duration of hospital stay .,"['CONCLUSION', 'The', 'placebo-controlled', 'study', 'suggested', 'that', 'S.', 'boulardii', 'significantly', 'reduced', 'the', 'duration', 'of', 'acute', 'diarrhoea', 'and', 'the', 'duration', 'of', 'hospital', 'stay', '.']","(6, 8)","(54, 66)",-1,hl_i,15858959,Abstract,9,test,gold,763.0
1887,CONCLUSION The placebo-controlled study suggested that S. boulardii significantly reduced the,duration of acute diarrhoea,and the duration of hospital stay .,"['CONCLUSION', 'The', 'placebo-controlled', 'study', 'suggested', 'that', 'S.', 'boulardii', 'significantly', 'reduced', 'the', 'duration', 'of', 'acute', 'diarrhoea', 'and', 'the', 'duration', 'of', 'hospital', 'stay', '.']","(11, 15)","(93, 120)",-1,hl_o,15858959,Abstract,9,test,gold,1323.0
1888,CONCLUSION The placebo-controlled study suggested that S. boulardii significantly reduced the duration of acute diarrhoea and the,duration of hospital stay,.,"['CONCLUSION', 'The', 'placebo-controlled', 'study', 'suggested', 'that', 'S.', 'boulardii', 'significantly', 'reduced', 'the', 'duration', 'of', 'acute', 'diarrhoea', 'and', 'the', 'duration', 'of', 'hospital', 'stay', '.']","(17, 21)","(129, 154)",-1,hl_o,15858959,Abstract,9,test,gold,3697.0
1889,S. boulardii seems to be a promising agent for the amelioration of the course of,acute diarrhoea in children,when used therapeutically .,"['S.', 'boulardii', 'seems', 'to', 'be', 'a', 'promising', 'agent', 'for', 'the', 'amelioration', 'of', 'the', 'course', 'of', 'acute', 'diarrhoea', 'in', 'children', 'when', 'used', 'therapeutically', '.']","(15, 19)","(80, 107)",-1,ss_p,15858959,Abstract,10,test,gold,3478.0
1890,,S. boulardii,seems to be a promising agent for the amelioration of the course of acute diarrhoea in children when used therapeutically .,"['S.', 'boulardii', 'seems', 'to', 'be', 'a', 'promising', 'agent', 'for', 'the', 'amelioration', 'of', 'the', 'course', 'of', 'acute', 'diarrhoea', 'in', 'children', 'when', 'used', 'therapeutically', '.']","(0, 2)","(0, 12)",-1,ss_i,15858959,Abstract,10,test,gold,762.0
1891,S. boulardii seems to be a promising agent for the amelioration of the course of,acute diarrhoea in children,when used therapeutically .,"['S.', 'boulardii', 'seems', 'to', 'be', 'a', 'promising', 'agent', 'for', 'the', 'amelioration', 'of', 'the', 'course', 'of', 'acute', 'diarrhoea', 'in', 'children', 'when', 'used', 'therapeutically', '.']","(15, 19)","(80, 107)",-1,hl_p,15858959,Abstract,10,test,gold,3479.0
1892,,S. boulardii,seems to be a promising agent for the amelioration of the course of acute diarrhoea in children when used therapeutically .,"['S.', 'boulardii', 'seems', 'to', 'be', 'a', 'promising', 'agent', 'for', 'the', 'amelioration', 'of', 'the', 'course', 'of', 'acute', 'diarrhoea', 'in', 'children', 'when', 'used', 'therapeutically', '.']","(0, 2)","(0, 12)",-1,hl_i,15858959,Abstract,10,test,gold,761.0
1893,Interventions in the,initial prodromal states of psychosis in Germany :,concept and recruitment .,"['Interventions', 'in', 'the', 'initial', 'prodromal', 'states', 'of', 'psychosis', 'in', 'Germany', ':', 'concept', 'and', 'recruitment', '.']","(3, 11)","(20, 70)",-1,ss_p,16055807,Title,0,test,gold,3839.0
1894,Interventions in the,initial prodromal states of psychosis,in Germany : concept and recruitment .,"['Interventions', 'in', 'the', 'initial', 'prodromal', 'states', 'of', 'psychosis', 'in', 'Germany', ':', 'concept', 'and', 'recruitment', '.']","(3, 8)","(20, 57)",-1,hl_p,16055807,Title,0,test,gold,3840.0
1895,Interventions in the initial prodromal states of psychosis in,Germany,: concept and recruitment .,"['Interventions', 'in', 'the', 'initial', 'prodromal', 'states', 'of', 'psychosis', 'in', 'Germany', ':', 'concept', 'and', 'recruitment', '.']","(9, 10)","(61, 68)",-1,hl_p,16055807,Title,0,test,gold,1127.0
1896,BACKGROUND The Early Detection and Intervention Programme of the,German,Research Network on Schizophrenia ( GRNS ) investigates the initial prodromal phase of psychosis in a multidimensional approach .,"['BACKGROUND', 'The', 'Early', 'Detection', 'and', 'Intervention', 'Programme', 'of', 'the', 'German', 'Research', 'Network', 'on', 'Schizophrenia', '(', 'GRNS', ')', 'investigates', 'the', 'initial', 'prodromal', 'phase', 'of', 'psychosis', 'in', 'a', 'multidimensional', 'approach', '.']","(9, 10)","(64, 70)",-1,ss_p,16055807,Abstract,0,test,gold,1128.0
1897,BACKGROUND The Early Detection and Intervention Programme of the German Research Network on,Schizophrenia,( GRNS ) investigates the initial prodromal phase of psychosis in a multidimensional approach .,"['BACKGROUND', 'The', 'Early', 'Detection', 'and', 'Intervention', 'Programme', 'of', 'the', 'German', 'Research', 'Network', 'on', 'Schizophrenia', '(', 'GRNS', ')', 'investigates', 'the', 'initial', 'prodromal', 'phase', 'of', 'psychosis', 'in', 'a', 'multidimensional', 'approach', '.']","(13, 14)","(91, 104)",-1,ss_p,16055807,Abstract,0,test,gold,2557.0
1898,Two intervention strategies are being studied by two large-scale multicentre projects .,,,"['Two', 'intervention', 'strategies', 'are', 'being', 'studied', 'by', 'two', 'large-scale', 'multicentre', 'projects', '.']",,,,,16055807,Abstract,1,test,gold,
1899,"AIMS To present the concept of the intervention studies , and to provide an interim report of the recruitment procedure .",,,"['AIMS', 'To', 'present', 'the', 'concept', 'of', 'the', 'intervention', 'studies', ',', 'and', 'to', 'provide', 'an', 'interim', 'report', 'of', 'the', 'recruitment', 'procedure', '.']",,,,,16055807,Abstract,2,test,gold,
1900,METHOD Comprehensive cognitive-behavioural therapy has been developed for,"patients in the "" early initial prodromal state "" .",,"['METHOD', 'Comprehensive', 'cognitive-behavioural', 'therapy', 'has', 'been', 'developed', 'for', 'patients', 'in', 'the', '""', 'early', 'initial', 'prodromal', 'state', '""', '.']","(8, 18)","(73, 124)",-1,ss_p,16055807,Abstract,3,test,gold,3843.0
1901,METHOD,Comprehensive cognitive-behavioural therapy,"has been developed for patients in the "" early initial prodromal state "" .","['METHOD', 'Comprehensive', 'cognitive-behavioural', 'therapy', 'has', 'been', 'developed', 'for', 'patients', 'in', 'the', '""', 'early', 'initial', 'prodromal', 'state', '""', '.']","(1, 4)","(6, 49)",-1,ss_i,16055807,Abstract,3,test,gold,4210.0
1902,METHOD Comprehensive cognitive-behavioural therapy has been developed for patients in the,""" early initial prodromal state """,.,"['METHOD', 'Comprehensive', 'cognitive-behavioural', 'therapy', 'has', 'been', 'developed', 'for', 'patients', 'in', 'the', '""', 'early', 'initial', 'prodromal', 'state', '""', '.']","(11, 17)","(89, 122)",-1,hl_p,16055807,Abstract,3,test,gold,3841.0
1903,METHOD,Comprehensive cognitive-behavioural therapy,"has been developed for patients in the "" early initial prodromal state "" .","['METHOD', 'Comprehensive', 'cognitive-behavioural', 'therapy', 'has', 'been', 'developed', 'for', 'patients', 'in', 'the', '""', 'early', 'initial', 'prodromal', 'state', '""', '.']","(1, 4)","(6, 49)",-1,hl_i,16055807,Abstract,3,test,gold,4211.0
1904,For,"patients in the "" late initial prodromal state """,the atypical neuroleptic amisulpride is explored .,"['For', 'patients', 'in', 'the', '""', 'late', 'initial', 'prodromal', 'state', '""', 'the', 'atypical', 'neuroleptic', 'amisulpride', 'is', 'explored', '.']","(1, 10)","(3, 51)",-1,ss_p,16055807,Abstract,4,test,gold,3844.0
1905,"For patients in the "" late initial prodromal state "" the",atypical neuroleptic amisulpride,is explored .,"['For', 'patients', 'in', 'the', '""', 'late', 'initial', 'prodromal', 'state', '""', 'the', 'atypical', 'neuroleptic', 'amisulpride', 'is', 'explored', '.']","(11, 14)","(56, 88)",-1,ss_i,16055807,Abstract,4,test,gold,3436.0
1906,For patients in the,""" late initial prodromal state """,the atypical neuroleptic amisulpride is explored .,"['For', 'patients', 'in', 'the', '""', 'late', 'initial', 'prodromal', 'state', '""', 'the', 'atypical', 'neuroleptic', 'amisulpride', 'is', 'explored', '.']","(4, 10)","(19, 51)",-1,hl_p,16055807,Abstract,4,test,gold,3842.0
1907,"For patients in the "" late initial prodromal state "" the",atypical neuroleptic amisulpride,is explored .,"['For', 'patients', 'in', 'the', '""', 'late', 'initial', 'prodromal', 'state', '""', 'the', 'atypical', 'neuroleptic', 'amisulpride', 'is', 'explored', '.']","(11, 14)","(56, 88)",-1,hl_i,16055807,Abstract,4,test,gold,3437.0
1908,Both interventions are evaluated in randomised controlled trials using clinical management as the control condition .,,,"['Both', 'interventions', 'are', 'evaluated', 'in', 'randomised', 'controlled', 'trials', 'using', 'clinical', 'management', 'as', 'the', 'control', 'condition', '.']",,,,,16055807,Abstract,5,test,gold,
1909,"RESULTS Between January 2001 and March 2003 ,",1212 individuals seeking help for mental health problems,were screened for putative prodromal symptoms at four university centres .,"['RESULTS', 'Between', 'January', '2001', 'and', 'March', '2003', ',', '1212', 'individuals', 'seeking', 'help', 'for', 'mental', 'health', 'problems', 'were', 'screened', 'for', 'putative', 'prodromal', 'symptoms', 'at', 'four', 'university', 'centres', '.']","(8, 16)","(45, 101)",-1,ss_p,16055807,Abstract,6,test,gold,6415.0
1910,"RESULTS Between January 2001 and March 2003 , 1212 individuals seeking help for mental health problems were screened for putative prodromal symptoms at",four university centres .,,"['RESULTS', 'Between', 'January', '2001', 'and', 'March', '2003', ',', '1212', 'individuals', 'seeking', 'help', 'for', 'mental', 'health', 'problems', 'were', 'screened', 'for', 'putative', 'prodromal', 'symptoms', 'at', 'four', 'university', 'centres', '.']","(23, 27)","(151, 176)",-1,ss_p,16055807,Abstract,6,test,gold,2189.0
1911,"RESULTS Between January 2001 and March 2003 ,",1212 individuals seeking help for mental health problems,were screened for putative prodromal symptoms at four university centres .,"['RESULTS', 'Between', 'January', '2001', 'and', 'March', '2003', ',', '1212', 'individuals', 'seeking', 'help', 'for', 'mental', 'health', 'problems', 'were', 'screened', 'for', 'putative', 'prodromal', 'symptoms', 'at', 'four', 'university', 'centres', '.']","(8, 16)","(45, 101)",-1,hl_p,16055807,Abstract,6,test,gold,6416.0
1912,,More than 388 individuals fulfilled criteria for both interventions and 188 ( 48.5 % ) gave informed consent to participate in the trials .,,"['More', 'than', '388', 'individuals', 'fulfilled', 'criteria', 'for', 'both', 'interventions', 'and', '188', '(', '48.5', '%', ')', 'gave', 'informed', 'consent', 'to', 'participate', 'in', 'the', 'trials', '.']","(0, 24)","(0, 139)",-1,ss_p,16055807,Abstract,7,test,gold,5895.0
1913,,More than 388 individuals fulfilled criteria for both interventions and 188 ( 48.5 % ) gave informed consent to participate in the trials .,,"['More', 'than', '388', 'individuals', 'fulfilled', 'criteria', 'for', 'both', 'interventions', 'and', '188', '(', '48.5', '%', ')', 'gave', 'informed', 'consent', 'to', 'participate', 'in', 'the', 'trials', '.']","(0, 24)","(0, 139)",-1,hl_p,16055807,Abstract,7,test,gold,5896.0
1914,CONCLUSIONS The screening procedure appears to be feasible and trial participation seems to be acceptable to a relevant proportion of,people at increased risk of developing psychosis .,,"['CONCLUSIONS', 'The', 'screening', 'procedure', 'appears', 'to', 'be', 'feasible', 'and', 'trial', 'participation', 'seems', 'to', 'be', 'acceptable', 'to', 'a', 'relevant', 'proportion', 'of', 'people', 'at', 'increased', 'risk', 'of', 'developing', 'psychosis', '.']","(20, 28)","(133, 183)",-1,ss_p,16055807,Abstract,8,test,gold,6936.0
1915,[ Effect of branch chain amino acid enriched formula on postoperative fatigue and nutritional status,after digestive surgery ],.,"['[', 'Effect', 'of', 'branch', 'chain', 'amino', 'acid', 'enriched', 'formula', 'on', 'postoperative', 'fatigue', 'and', 'nutritional', 'status', 'after', 'digestive', 'surgery', ']', '.']","(15, 19)","(100, 125)",-1,ss_p,16167234,Title,0,test,gold,3642.0
1916,[ Effect of,branch chain amino acid enriched formula,on postoperative fatigue and nutritional status after digestive surgery ] .,"['[', 'Effect', 'of', 'branch', 'chain', 'amino', 'acid', 'enriched', 'formula', 'on', 'postoperative', 'fatigue', 'and', 'nutritional', 'status', 'after', 'digestive', 'surgery', ']', '.']","(3, 9)","(11, 51)",-1,ss_i,16167234,Title,0,test,gold,4653.0
1917,[ Effect of branch chain amino acid enriched formula on,postoperative fatigue and nutritional status,after digestive surgery ] .,"['[', 'Effect', 'of', 'branch', 'chain', 'amino', 'acid', 'enriched', 'formula', 'on', 'postoperative', 'fatigue', 'and', 'nutritional', 'status', 'after', 'digestive', 'surgery', ']', '.']","(10, 15)","(55, 99)",-1,ss_o,16167234,Title,0,test,gold,3668.0
1918,[ Effect of branch chain amino acid enriched formula on postoperative fatigue and nutritional status,after digestive surgery ],.,"['[', 'Effect', 'of', 'branch', 'chain', 'amino', 'acid', 'enriched', 'formula', 'on', 'postoperative', 'fatigue', 'and', 'nutritional', 'status', 'after', 'digestive', 'surgery', ']', '.']","(15, 19)","(100, 125)",-1,hl_p,16167234,Title,0,test,gold,3643.0
1919,[ Effect of branch chain,amino acid enriched formula,on postoperative fatigue and nutritional status after digestive surgery ] .,"['[', 'Effect', 'of', 'branch', 'chain', 'amino', 'acid', 'enriched', 'formula', 'on', 'postoperative', 'fatigue', 'and', 'nutritional', 'status', 'after', 'digestive', 'surgery', ']', '.']","(5, 9)","(24, 51)",-1,hl_i,16167234,Title,0,test,gold,4661.0
1920,[ Effect of branch chain amino acid enriched formula on,postoperative fatigue,and nutritional status after digestive surgery ] .,"['[', 'Effect', 'of', 'branch', 'chain', 'amino', 'acid', 'enriched', 'formula', 'on', 'postoperative', 'fatigue', 'and', 'nutritional', 'status', 'after', 'digestive', 'surgery', ']', '.']","(10, 12)","(55, 76)",-1,hl_o,16167234,Title,0,test,gold,3672.0
1921,[ Effect of branch chain amino acid enriched formula on postoperative fatigue and,nutritional status,after digestive surgery ] .,"['[', 'Effect', 'of', 'branch', 'chain', 'amino', 'acid', 'enriched', 'formula', 'on', 'postoperative', 'fatigue', 'and', 'nutritional', 'status', 'after', 'digestive', 'surgery', ']', '.']","(13, 15)","(81, 99)",-1,hl_o,16167234,Title,0,test,gold,1524.0
1922,OBJECTIVE To evaluate the effect of branch chain amino acid ( BCAA ) enriched formula on nutritional status and postoperative fatigue for,digestive surgery patients .,,"['OBJECTIVE', 'To', 'evaluate', 'the', 'effect', 'of', 'branch', 'chain', 'amino', 'acid', '(', 'BCAA', ')', 'enriched', 'formula', 'on', 'nutritional', 'status', 'and', 'postoperative', 'fatigue', 'for', 'digestive', 'surgery', 'patients', '.']","(22, 26)","(137, 165)",-1,ss_p,16167234,Abstract,0,test,gold,3646.0
1923,OBJECTIVE To evaluate the effect of,branch chain amino acid ( BCAA ) enriched formula,on nutritional status and postoperative fatigue for digestive surgery patients .,"['OBJECTIVE', 'To', 'evaluate', 'the', 'effect', 'of', 'branch', 'chain', 'amino', 'acid', '(', 'BCAA', ')', 'enriched', 'formula', 'on', 'nutritional', 'status', 'and', 'postoperative', 'fatigue', 'for', 'digestive', 'surgery', 'patients', '.']","(6, 15)","(35, 84)",-1,ss_i,16167234,Abstract,0,test,gold,4654.0
1924,OBJECTIVE To evaluate the effect of branch chain amino acid ( BCAA ) enriched formula on,nutritional status,and postoperative fatigue for digestive surgery patients .,"['OBJECTIVE', 'To', 'evaluate', 'the', 'effect', 'of', 'branch', 'chain', 'amino', 'acid', '(', 'BCAA', ')', 'enriched', 'formula', 'on', 'nutritional', 'status', 'and', 'postoperative', 'fatigue', 'for', 'digestive', 'surgery', 'patients', '.']","(16, 18)","(88, 106)",-1,ss_o,16167234,Abstract,0,test,gold,1525.0
1925,OBJECTIVE To evaluate the effect of branch chain amino acid ( BCAA ) enriched formula on nutritional status and,postoperative fatigue,for digestive surgery patients .,"['OBJECTIVE', 'To', 'evaluate', 'the', 'effect', 'of', 'branch', 'chain', 'amino', 'acid', '(', 'BCAA', ')', 'enriched', 'formula', 'on', 'nutritional', 'status', 'and', 'postoperative', 'fatigue', 'for', 'digestive', 'surgery', 'patients', '.']","(19, 21)","(111, 132)",-1,ss_o,16167234,Abstract,0,test,gold,3673.0
1926,OBJECTIVE To evaluate the effect of branch chain amino acid ( BCAA ) enriched formula on nutritional status and postoperative fatigue for,digestive surgery patients .,,"['OBJECTIVE', 'To', 'evaluate', 'the', 'effect', 'of', 'branch', 'chain', 'amino', 'acid', '(', 'BCAA', ')', 'enriched', 'formula', 'on', 'nutritional', 'status', 'and', 'postoperative', 'fatigue', 'for', 'digestive', 'surgery', 'patients', '.']","(22, 26)","(137, 165)",-1,hl_p,16167234,Abstract,0,test,gold,3647.0
1927,OBJECTIVE To evaluate the effect of,branch chain amino acid ( BCAA ) enriched formula,on nutritional status and postoperative fatigue for digestive surgery patients .,"['OBJECTIVE', 'To', 'evaluate', 'the', 'effect', 'of', 'branch', 'chain', 'amino', 'acid', '(', 'BCAA', ')', 'enriched', 'formula', 'on', 'nutritional', 'status', 'and', 'postoperative', 'fatigue', 'for', 'digestive', 'surgery', 'patients', '.']","(6, 15)","(35, 84)",-1,hl_i,16167234,Abstract,0,test,gold,4655.0
1928,OBJECTIVE To evaluate the effect of branch chain amino acid ( BCAA ) enriched formula on,nutritional status,and postoperative fatigue for digestive surgery patients .,"['OBJECTIVE', 'To', 'evaluate', 'the', 'effect', 'of', 'branch', 'chain', 'amino', 'acid', '(', 'BCAA', ')', 'enriched', 'formula', 'on', 'nutritional', 'status', 'and', 'postoperative', 'fatigue', 'for', 'digestive', 'surgery', 'patients', '.']","(16, 18)","(88, 106)",-1,hl_o,16167234,Abstract,0,test,gold,1523.0
1929,OBJECTIVE To evaluate the effect of branch chain amino acid ( BCAA ) enriched formula on nutritional status and,postoperative fatigue,for digestive surgery patients .,"['OBJECTIVE', 'To', 'evaluate', 'the', 'effect', 'of', 'branch', 'chain', 'amino', 'acid', '(', 'BCAA', ')', 'enriched', 'formula', 'on', 'nutritional', 'status', 'and', 'postoperative', 'fatigue', 'for', 'digestive', 'surgery', 'patients', '.']","(19, 21)","(111, 132)",-1,hl_o,16167234,Abstract,0,test,gold,3671.0
1930,METHODS,Forty patients who underwent digestive surgery,"were randomly received parenteral nutrition with either BCAA enriched ( study group , n=20 ) or routine amino acid ( control group , n=20 ) for seven consecutive days .","['METHODS', 'Forty', 'patients', 'who', 'underwent', 'digestive', 'surgery', 'were', 'randomly', 'received', 'parenteral', 'nutrition', 'with', 'either', 'BCAA', 'enriched', '(', 'study', 'group', ',', 'n=20', ')', 'or', 'routine', 'amino', 'acid', '(', 'control', 'group', ',', 'n=20', ')', 'for', 'seven', 'consecutive', 'days', '.']","(1, 7)","(7, 53)",-1,ss_p,16167234,Abstract,1,test,gold,3623.0
1931,METHODS Forty patients who underwent digestive surgery were randomly received parenteral nutrition with either,BCAA enriched,"( study group , n=20 ) or routine amino acid ( control group , n=20 ) for seven consecutive days .","['METHODS', 'Forty', 'patients', 'who', 'underwent', 'digestive', 'surgery', 'were', 'randomly', 'received', 'parenteral', 'nutrition', 'with', 'either', 'BCAA', 'enriched', '(', 'study', 'group', ',', 'n=20', ')', 'or', 'routine', 'amino', 'acid', '(', 'control', 'group', ',', 'n=20', ')', 'for', 'seven', 'consecutive', 'days', '.']","(14, 16)","(110, 123)",-1,ss_i,16167234,Abstract,1,test,gold,584.0
1932,"METHODS Forty patients who underwent digestive surgery were randomly received parenteral nutrition with either BCAA enriched ( study group , n=20 ) or",routine amino acid,"( control group , n=20 ) for seven consecutive days .","['METHODS', 'Forty', 'patients', 'who', 'underwent', 'digestive', 'surgery', 'were', 'randomly', 'received', 'parenteral', 'nutrition', 'with', 'either', 'BCAA', 'enriched', '(', 'study', 'group', ',', 'n=20', ')', 'or', 'routine', 'amino', 'acid', '(', 'control', 'group', ',', 'n=20', ')', 'for', 'seven', 'consecutive', 'days', '.']","(23, 26)","(150, 168)",-1,ss_i,16167234,Abstract,1,test,gold,4662.0
1933,METHODS,Forty patients who underwent digestive surgery,"were randomly received parenteral nutrition with either BCAA enriched ( study group , n=20 ) or routine amino acid ( control group , n=20 ) for seven consecutive days .","['METHODS', 'Forty', 'patients', 'who', 'underwent', 'digestive', 'surgery', 'were', 'randomly', 'received', 'parenteral', 'nutrition', 'with', 'either', 'BCAA', 'enriched', '(', 'study', 'group', ',', 'n=20', ')', 'or', 'routine', 'amino', 'acid', '(', 'control', 'group', ',', 'n=20', ')', 'for', 'seven', 'consecutive', 'days', '.']","(1, 7)","(7, 53)",-1,hl_p,16167234,Abstract,1,test,gold,3624.0
1934,METHODS Forty patients who underwent digestive surgery were randomly received parenteral nutrition with either,BCAA enriched,"( study group , n=20 ) or routine amino acid ( control group , n=20 ) for seven consecutive days .","['METHODS', 'Forty', 'patients', 'who', 'underwent', 'digestive', 'surgery', 'were', 'randomly', 'received', 'parenteral', 'nutrition', 'with', 'either', 'BCAA', 'enriched', '(', 'study', 'group', ',', 'n=20', ')', 'or', 'routine', 'amino', 'acid', '(', 'control', 'group', ',', 'n=20', ')', 'for', 'seven', 'consecutive', 'days', '.']","(14, 16)","(110, 123)",-1,hl_i,16167234,Abstract,1,test,gold,585.0
1935,"METHODS Forty patients who underwent digestive surgery were randomly received parenteral nutrition with either BCAA enriched ( study group , n=20 ) or",routine amino acid,"( control group , n=20 ) for seven consecutive days .","['METHODS', 'Forty', 'patients', 'who', 'underwent', 'digestive', 'surgery', 'were', 'randomly', 'received', 'parenteral', 'nutrition', 'with', 'either', 'BCAA', 'enriched', '(', 'study', 'group', ',', 'n=20', ')', 'or', 'routine', 'amino', 'acid', '(', 'control', 'group', ',', 'n=20', ')', 'for', 'seven', 'consecutive', 'days', '.']","(23, 26)","(150, 168)",-1,hl_i,16167234,Abstract,1,test,gold,4663.0
1936,,"Nitrogen balance , serum total protein , albumin , prealbumin , transferrin , retinol binding protein and postoperative fatigue score",were monitored during the postoperative period .,"['Nitrogen', 'balance', ',', 'serum', 'total', 'protein', ',', 'albumin', ',', 'prealbumin', ',', 'transferrin', ',', 'retinol', 'binding', 'protein', 'and', 'postoperative', 'fatigue', 'score', 'were', 'monitored', 'during', 'the', 'postoperative', 'period', '.']","(0, 20)","(0, 133)",-1,ss_o,16167234,Abstract,2,test,gold,5820.0
1937,,"Nitrogen balance , serum total protein , albumin , prealbumin , transferrin , retinol binding protein and postoperative fatigue score",were monitored during the postoperative period .,"['Nitrogen', 'balance', ',', 'serum', 'total', 'protein', ',', 'albumin', ',', 'prealbumin', ',', 'transferrin', ',', 'retinol', 'binding', 'protein', 'and', 'postoperative', 'fatigue', 'score', 'were', 'monitored', 'during', 'the', 'postoperative', 'period', '.']","(0, 20)","(0, 133)",-1,hl_o,16167234,Abstract,2,test,gold,5821.0
1938,RESULTS The cumulative postoperative fatigue scores were lower in,BCAA,"group than that in the control group at the 4th , 5th and 7th day after operation ( P < 0.05 ) .","['RESULTS', 'The', 'cumulative', 'postoperative', 'fatigue', 'scores', 'were', 'lower', 'in', 'BCAA', 'group', 'than', 'that', 'in', 'the', 'control', 'group', 'at', 'the', '4th', ',', '5th', 'and', '7th', 'day', 'after', 'operation', '(', 'P', '<', '0.05', ')', '.']","(9, 10)","(65, 69)",-1,ss_i,16167234,Abstract,3,test,gold,582.0
1939,RESULTS The,cumulative postoperative fatigue scores,"were lower in BCAA group than that in the control group at the 4th , 5th and 7th day after operation ( P < 0.05 ) .","['RESULTS', 'The', 'cumulative', 'postoperative', 'fatigue', 'scores', 'were', 'lower', 'in', 'BCAA', 'group', 'than', 'that', 'in', 'the', 'control', 'group', 'at', 'the', '4th', ',', '5th', 'and', '7th', 'day', 'after', 'operation', '(', 'P', '<', '0.05', ')', '.']","(2, 6)","(11, 50)",-1,ss_o,16167234,Abstract,3,test,gold,3669.0
1940,RESULTS The cumulative postoperative fatigue scores were lower in,BCAA,"group than that in the control group at the 4th , 5th and 7th day after operation ( P < 0.05 ) .","['RESULTS', 'The', 'cumulative', 'postoperative', 'fatigue', 'scores', 'were', 'lower', 'in', 'BCAA', 'group', 'than', 'that', 'in', 'the', 'control', 'group', 'at', 'the', '4th', ',', '5th', 'and', '7th', 'day', 'after', 'operation', '(', 'P', '<', '0.05', ')', '.']","(9, 10)","(65, 69)",-1,hl_i,16167234,Abstract,3,test,gold,583.0
1941,RESULTS The,cumulative postoperative fatigue scores,"were lower in BCAA group than that in the control group at the 4th , 5th and 7th day after operation ( P < 0.05 ) .","['RESULTS', 'The', 'cumulative', 'postoperative', 'fatigue', 'scores', 'were', 'lower', 'in', 'BCAA', 'group', 'than', 'that', 'in', 'the', 'control', 'group', 'at', 'the', '4th', ',', '5th', 'and', '7th', 'day', 'after', 'operation', '(', 'P', '<', '0.05', ')', '.']","(2, 6)","(11, 50)",-1,hl_o,16167234,Abstract,3,test,gold,3670.0
1942,Patients achieved positive,nitrogen balance,"2 days earlier in the study group than that in the control group , but there was no significant difference in cumulative nitrogen balance between the two groups .","['Patients', 'achieved', 'positive', 'nitrogen', 'balance', '2', 'days', 'earlier', 'in', 'the', 'study', 'group', 'than', 'that', 'in', 'the', 'control', 'group', ',', 'but', 'there', 'was', 'no', 'significant', 'difference', 'in', 'cumulative', 'nitrogen', 'balance', 'between', 'the', 'two', 'groups', '.']","(3, 5)","(26, 42)",-1,ss_o,16167234,Abstract,4,test,gold,1761.0
1943,"Patients achieved positive nitrogen balance 2 days earlier in the study group than that in the control group , but there was no significant difference in",cumulative nitrogen balance,between the two groups .,"['Patients', 'achieved', 'positive', 'nitrogen', 'balance', '2', 'days', 'earlier', 'in', 'the', 'study', 'group', 'than', 'that', 'in', 'the', 'control', 'group', ',', 'but', 'there', 'was', 'no', 'significant', 'difference', 'in', 'cumulative', 'nitrogen', 'balance', 'between', 'the', 'two', 'groups', '.']","(26, 29)","(153, 180)",-1,ss_o,16167234,Abstract,4,test,gold,1763.0
1944,Patients achieved positive,nitrogen balance,"2 days earlier in the study group than that in the control group , but there was no significant difference in cumulative nitrogen balance between the two groups .","['Patients', 'achieved', 'positive', 'nitrogen', 'balance', '2', 'days', 'earlier', 'in', 'the', 'study', 'group', 'than', 'that', 'in', 'the', 'control', 'group', ',', 'but', 'there', 'was', 'no', 'significant', 'difference', 'in', 'cumulative', 'nitrogen', 'balance', 'between', 'the', 'two', 'groups', '.']","(3, 5)","(26, 42)",-1,hl_o,16167234,Abstract,4,test,gold,1762.0
1945,"Patients achieved positive nitrogen balance 2 days earlier in the study group than that in the control group , but there was no significant difference in",cumulative nitrogen balance,between the two groups .,"['Patients', 'achieved', 'positive', 'nitrogen', 'balance', '2', 'days', 'earlier', 'in', 'the', 'study', 'group', 'than', 'that', 'in', 'the', 'control', 'group', ',', 'but', 'there', 'was', 'no', 'significant', 'difference', 'in', 'cumulative', 'nitrogen', 'balance', 'between', 'the', 'two', 'groups', '.']","(26, 29)","(153, 180)",-1,hl_o,16167234,Abstract,4,test,gold,1764.0
1946,There was no significant difference in elevation of,"serum total protein , albumin , prealbumin , transferrin","at the 7th day after operation between the two groups ( P > 0.05 ) , compared with those at the first day after operation .","['There', 'was', 'no', 'significant', 'difference', 'in', 'elevation', 'of', 'serum', 'total', 'protein', ',', 'albumin', ',', 'prealbumin', ',', 'transferrin', 'at', 'the', '7th', 'day', 'after', 'operation', 'between', 'the', 'two', 'groups', '(', 'P', '>', '0.05', ')', ',', 'compared', 'with', 'those', 'at', 'the', 'first', 'day', 'after', 'operation', '.']","(8, 17)","(51, 107)",-1,ss_o,16167234,Abstract,5,test,gold,6525.0
1947,There was no significant difference in elevation of,"serum total protein , albumin , prealbumin , transferrin","at the 7th day after operation between the two groups ( P > 0.05 ) , compared with those at the first day after operation .","['There', 'was', 'no', 'significant', 'difference', 'in', 'elevation', 'of', 'serum', 'total', 'protein', ',', 'albumin', ',', 'prealbumin', ',', 'transferrin', 'at', 'the', '7th', 'day', 'after', 'operation', 'between', 'the', 'two', 'groups', '(', 'P', '>', '0.05', ')', ',', 'compared', 'with', 'those', 'at', 'the', 'first', 'day', 'after', 'operation', '.']","(8, 17)","(51, 107)",-1,hl_o,16167234,Abstract,5,test,gold,6526.0
1948,The serum level of retinol binding protein was higher in,BCAA-enriched,group than that in the control group ( P=0.004 ) .,"['The', 'serum', 'level', 'of', 'retinol', 'binding', 'protein', 'was', 'higher', 'in', 'BCAA-enriched', 'group', 'than', 'that', 'in', 'the', 'control', 'group', '(', 'P=0.004', ')', '.']","(10, 11)","(56, 69)",-1,ss_i,16167234,Abstract,6,test,gold,
1949,The,serum level of retinol binding protein,was higher in BCAA-enriched group than that in the control group ( P=0.004 ) .,"['The', 'serum', 'level', 'of', 'retinol', 'binding', 'protein', 'was', 'higher', 'in', 'BCAA-enriched', 'group', 'than', 'that', 'in', 'the', 'control', 'group', '(', 'P=0.004', ')', '.']","(1, 7)","(3, 41)",-1,ss_o,16167234,Abstract,6,test,gold,6523.0
1950,The serum level of retinol binding protein was higher in,BCAA-enriched,group than that in the control group ( P=0.004 ) .,"['The', 'serum', 'level', 'of', 'retinol', 'binding', 'protein', 'was', 'higher', 'in', 'BCAA-enriched', 'group', 'than', 'that', 'in', 'the', 'control', 'group', '(', 'P=0.004', ')', '.']","(10, 11)","(56, 69)",-1,hl_i,16167234,Abstract,6,test,gold,
1951,The,serum level of retinol binding protein,was higher in BCAA-enriched group than that in the control group ( P=0.004 ) .,"['The', 'serum', 'level', 'of', 'retinol', 'binding', 'protein', 'was', 'higher', 'in', 'BCAA-enriched', 'group', 'than', 'that', 'in', 'the', 'control', 'group', '(', 'P=0.004', ')', '.']","(1, 7)","(3, 41)",-1,hl_o,16167234,Abstract,6,test,gold,6524.0
1952,CONCLUSION TPN with BCAA enriched formula can reduce postoperative fatigue score and improve the nutritional status for,digestive surgery patients .,,"['CONCLUSION', 'TPN', 'with', 'BCAA', 'enriched', 'formula', 'can', 'reduce', 'postoperative', 'fatigue', 'score', 'and', 'improve', 'the', 'nutritional', 'status', 'for', 'digestive', 'surgery', 'patients', '.']","(17, 21)","(119, 147)",-1,ss_p,16167234,Abstract,7,test,gold,3645.0
1953,CONCLUSION TPN with,BCAA enriched formula,can reduce postoperative fatigue score and improve the nutritional status for digestive surgery patients .,"['CONCLUSION', 'TPN', 'with', 'BCAA', 'enriched', 'formula', 'can', 'reduce', 'postoperative', 'fatigue', 'score', 'and', 'improve', 'the', 'nutritional', 'status', 'for', 'digestive', 'surgery', 'patients', '.']","(3, 6)","(19, 40)",-1,ss_i,16167234,Abstract,7,test,gold,580.0
1954,CONCLUSION TPN with BCAA enriched formula can reduce,postoperative fatigue score,and improve the nutritional status for digestive surgery patients .,"['CONCLUSION', 'TPN', 'with', 'BCAA', 'enriched', 'formula', 'can', 'reduce', 'postoperative', 'fatigue', 'score', 'and', 'improve', 'the', 'nutritional', 'status', 'for', 'digestive', 'surgery', 'patients', '.']","(8, 11)","(52, 79)",-1,ss_o,16167234,Abstract,7,test,gold,3674.0
1955,CONCLUSION TPN with BCAA enriched formula can reduce postoperative fatigue score and improve the,nutritional status,for digestive surgery patients .,"['CONCLUSION', 'TPN', 'with', 'BCAA', 'enriched', 'formula', 'can', 'reduce', 'postoperative', 'fatigue', 'score', 'and', 'improve', 'the', 'nutritional', 'status', 'for', 'digestive', 'surgery', 'patients', '.']","(14, 16)","(96, 114)",-1,ss_o,16167234,Abstract,7,test,gold,1522.0
1956,CONCLUSION TPN with BCAA enriched formula can reduce postoperative fatigue score and improve the nutritional status for,digestive surgery patients .,,"['CONCLUSION', 'TPN', 'with', 'BCAA', 'enriched', 'formula', 'can', 'reduce', 'postoperative', 'fatigue', 'score', 'and', 'improve', 'the', 'nutritional', 'status', 'for', 'digestive', 'surgery', 'patients', '.']","(17, 21)","(119, 147)",-1,hl_p,16167234,Abstract,7,test,gold,3644.0
1957,CONCLUSION TPN with,BCAA enriched formula,can reduce postoperative fatigue score and improve the nutritional status for digestive surgery patients .,"['CONCLUSION', 'TPN', 'with', 'BCAA', 'enriched', 'formula', 'can', 'reduce', 'postoperative', 'fatigue', 'score', 'and', 'improve', 'the', 'nutritional', 'status', 'for', 'digestive', 'surgery', 'patients', '.']","(3, 6)","(19, 40)",-1,hl_i,16167234,Abstract,7,test,gold,581.0
1958,CONCLUSION TPN with BCAA enriched formula can reduce,postoperative fatigue score,and improve the nutritional status for digestive surgery patients .,"['CONCLUSION', 'TPN', 'with', 'BCAA', 'enriched', 'formula', 'can', 'reduce', 'postoperative', 'fatigue', 'score', 'and', 'improve', 'the', 'nutritional', 'status', 'for', 'digestive', 'surgery', 'patients', '.']","(8, 11)","(52, 79)",-1,hl_o,16167234,Abstract,7,test,gold,3675.0
1959,CONCLUSION TPN with BCAA enriched formula can reduce postoperative fatigue score and improve the,nutritional status,for digestive surgery patients .,"['CONCLUSION', 'TPN', 'with', 'BCAA', 'enriched', 'formula', 'can', 'reduce', 'postoperative', 'fatigue', 'score', 'and', 'improve', 'the', 'nutritional', 'status', 'for', 'digestive', 'surgery', 'patients', '.']","(14, 16)","(96, 114)",-1,hl_o,16167234,Abstract,7,test,gold,1521.0
1960,Intervention pilot for,parents of children with autistic spectrum disorder .,,"['Intervention', 'pilot', 'for', 'parents', 'of', 'children', 'with', 'autistic', 'spectrum', 'disorder', '.']","(3, 11)","(22, 75)",-1,ss_p,16295154,Title,0,test,gold,6051.0
1961,,Intervention,pilot for parents of children with autistic spectrum disorder .,"['Intervention', 'pilot', 'for', 'parents', 'of', 'children', 'with', 'autistic', 'spectrum', 'disorder', '.']","(0, 1)","(0, 12)",-1,ss_i,16295154,Title,0,test,gold,4019.0
1962,Intervention pilot for,parents of children,with autistic spectrum disorder .,"['Intervention', 'pilot', 'for', 'parents', 'of', 'children', 'with', 'autistic', 'spectrum', 'disorder', '.']","(3, 6)","(22, 41)",-1,hl_p,16295154,Title,0,test,gold,2110.0
1963,Intervention pilot for parents of children with,autistic spectrum disorder,.,"['Intervention', 'pilot', 'for', 'parents', 'of', 'children', 'with', 'autistic', 'spectrum', 'disorder', '.']","(7, 10)","(47, 73)",-1,hl_p,16295154,Title,0,test,gold,6009.0
1964,,Intervention,pilot for parents of children with autistic spectrum disorder .,"['Intervention', 'pilot', 'for', 'parents', 'of', 'children', 'with', 'autistic', 'spectrum', 'disorder', '.']","(0, 1)","(0, 12)",-1,hl_i,16295154,Title,0,test,gold,4020.0
1965,,Parents of children who receive the diagnosis of autistic spectrum disorder ( ASD ),"experience a situational crisis related to receiving the diagnosis , which causes feelings of distress and urgency to access services for the affected child .","['Parents', 'of', 'children', 'who', 'receive', 'the', 'diagnosis', 'of', 'autistic', 'spectrum', 'disorder', '(', 'ASD', ')', 'experience', 'a', 'situational', 'crisis', 'related', 'to', 'receiving', 'the', 'diagnosis', ',', 'which', 'causes', 'feelings', 'of', 'distress', 'and', 'urgency', 'to', 'access', 'services', 'for', 'the', 'affected', 'child', '.']","(0, 14)","(0, 83)",-1,ss_p,16295154,Abstract,0,test,gold,6032.0
1966,,Parents of children,"who receive the diagnosis of autistic spectrum disorder ( ASD ) experience a situational crisis related to receiving the diagnosis , which causes feelings of distress and urgency to access services for the affected child .","['Parents', 'of', 'children', 'who', 'receive', 'the', 'diagnosis', 'of', 'autistic', 'spectrum', 'disorder', '(', 'ASD', ')', 'experience', 'a', 'situational', 'crisis', 'related', 'to', 'receiving', 'the', 'diagnosis', ',', 'which', 'causes', 'feelings', 'of', 'distress', 'and', 'urgency', 'to', 'access', 'services', 'for', 'the', 'affected', 'child', '.']","(0, 3)","(0, 19)",-1,hl_p,16295154,Abstract,0,test,gold,2111.0
1967,Parents of children who receive the,diagnosis of autistic spectrum disorder ( ASD ),"experience a situational crisis related to receiving the diagnosis , which causes feelings of distress and urgency to access services for the affected child .","['Parents', 'of', 'children', 'who', 'receive', 'the', 'diagnosis', 'of', 'autistic', 'spectrum', 'disorder', '(', 'ASD', ')', 'experience', 'a', 'situational', 'crisis', 'related', 'to', 'receiving', 'the', 'diagnosis', ',', 'which', 'causes', 'feelings', 'of', 'distress', 'and', 'urgency', 'to', 'access', 'services', 'for', 'the', 'affected', 'child', '.']","(6, 14)","(35, 82)",-1,hl_p,16295154,Abstract,0,test,gold,6045.0
1968,This paper describes a randomized trial ( n = 31 ) that was conducted at a regional diagnostic center of a large metropolitan children 's hospital to ( a ) refine a nursing intervention designed for,parents of children with ASD,and ( b ) to identify methodological revisions for a larger study .,"['This', 'paper', 'describes', 'a', 'randomized', 'trial', '(', 'n', '=', '31', ')', 'that', 'was', 'conducted', 'at', 'a', 'regional', 'diagnostic', 'center', 'of', 'a', 'large', 'metropolitan', 'children', ""'s"", 'hospital', 'to', '(', 'a', ')', 'refine', 'a', 'nursing', 'intervention', 'designed', 'for', 'parents', 'of', 'children', 'with', 'ASD', 'and', '(', 'b', ')', 'to', 'identify', 'methodological', 'revisions', 'for', 'a', 'larger', 'study', '.']","(36, 41)","(198, 226)",-1,ss_p,16295154,Abstract,1,test,gold,6082.0
1969,This paper describes a randomized trial ( n = 31 ) that was conducted at a regional diagnostic center of a large metropolitan children 's hospital to ( a ) refine a,nursing intervention,designed for parents of children with ASD and ( b ) to identify methodological revisions for a larger study .,"['This', 'paper', 'describes', 'a', 'randomized', 'trial', '(', 'n', '=', '31', ')', 'that', 'was', 'conducted', 'at', 'a', 'regional', 'diagnostic', 'center', 'of', 'a', 'large', 'metropolitan', 'children', ""'s"", 'hospital', 'to', '(', 'a', ')', 'refine', 'a', 'nursing', 'intervention', 'designed', 'for', 'parents', 'of', 'children', 'with', 'ASD', 'and', '(', 'b', ')', 'to', 'identify', 'methodological', 'revisions', 'for', 'a', 'larger', 'study', '.']","(32, 34)","(164, 184)",-1,ss_i,16295154,Abstract,1,test,gold,4012.0
1970,This paper describes a randomized trial ( n = 31 ) that was conducted at a regional diagnostic center of a large metropolitan children 's hospital to ( a ) refine a nursing intervention designed for,parents of children with ASD,and ( b ) to identify methodological revisions for a larger study .,"['This', 'paper', 'describes', 'a', 'randomized', 'trial', '(', 'n', '=', '31', ')', 'that', 'was', 'conducted', 'at', 'a', 'regional', 'diagnostic', 'center', 'of', 'a', 'large', 'metropolitan', 'children', ""'s"", 'hospital', 'to', '(', 'a', ')', 'refine', 'a', 'nursing', 'intervention', 'designed', 'for', 'parents', 'of', 'children', 'with', 'ASD', 'and', '(', 'b', ')', 'to', 'identify', 'methodological', 'revisions', 'for', 'a', 'larger', 'study', '.']","(36, 41)","(198, 226)",-1,hl_p,16295154,Abstract,1,test,gold,6083.0
1971,This paper describes a randomized trial ( n = 31 ) that was conducted at a regional diagnostic center of a large metropolitan children 's hospital to ( a ) refine a,nursing intervention,designed for parents of children with ASD and ( b ) to identify methodological revisions for a larger study .,"['This', 'paper', 'describes', 'a', 'randomized', 'trial', '(', 'n', '=', '31', ')', 'that', 'was', 'conducted', 'at', 'a', 'regional', 'diagnostic', 'center', 'of', 'a', 'large', 'metropolitan', 'children', ""'s"", 'hospital', 'to', '(', 'a', ')', 'refine', 'a', 'nursing', 'intervention', 'designed', 'for', 'parents', 'of', 'children', 'with', 'ASD', 'and', '(', 'b', ')', 'to', 'identify', 'methodological', 'revisions', 'for', 'a', 'larger', 'study', '.']","(32, 34)","(164, 184)",-1,hl_i,16295154,Abstract,1,test,gold,4013.0
1972,A secondary purpose was to test the effects of a,post-diagnosis nursing intervention,"on parents ' reports of stress , impact of event ( diagnosis ) , and use of services after a child is newly diagnosed with ASD .","['A', 'secondary', 'purpose', 'was', 'to', 'test', 'the', 'effects', 'of', 'a', 'post-diagnosis', 'nursing', 'intervention', 'on', 'parents', ""'"", 'reports', 'of', 'stress', ',', 'impact', 'of', 'event', '(', 'diagnosis', ')', ',', 'and', 'use', 'of', 'services', 'after', 'a', 'child', 'is', 'newly', 'diagnosed', 'with', 'ASD', '.']","(10, 13)","(48, 83)",-1,ss_i,16295154,Abstract,2,test,gold,4011.0
1973,A secondary purpose was to test the,effects,"of a post-diagnosis nursing intervention on parents ' reports of stress , impact of event ( diagnosis ) , and use of services after a child is newly diagnosed with ASD .","['A', 'secondary', 'purpose', 'was', 'to', 'test', 'the', 'effects', 'of', 'a', 'post-diagnosis', 'nursing', 'intervention', 'on', 'parents', ""'"", 'reports', 'of', 'stress', ',', 'impact', 'of', 'event', '(', 'diagnosis', ')', ',', 'and', 'use', 'of', 'services', 'after', 'a', 'child', 'is', 'newly', 'diagnosed', 'with', 'ASD', '.']","(7, 8)","(35, 42)",-1,ss_o,16295154,Abstract,2,test,gold,2382.0
1974,A secondary purpose was to test the effects of a post-diagnosis nursing intervention on,"parents ' reports of stress , impact of event ( diagnosis ) , and use of services",after a child is newly diagnosed with ASD .,"['A', 'secondary', 'purpose', 'was', 'to', 'test', 'the', 'effects', 'of', 'a', 'post-diagnosis', 'nursing', 'intervention', 'on', 'parents', ""'"", 'reports', 'of', 'stress', ',', 'impact', 'of', 'event', '(', 'diagnosis', ')', ',', 'and', 'use', 'of', 'services', 'after', 'a', 'child', 'is', 'newly', 'diagnosed', 'with', 'ASD', '.']","(14, 31)","(87, 168)",-1,ss_o,16295154,Abstract,2,test,gold,6418.0
1975,A secondary purpose was to test the effects of a,post-diagnosis nursing intervention,"on parents ' reports of stress , impact of event ( diagnosis ) , and use of services after a child is newly diagnosed with ASD .","['A', 'secondary', 'purpose', 'was', 'to', 'test', 'the', 'effects', 'of', 'a', 'post-diagnosis', 'nursing', 'intervention', 'on', 'parents', ""'"", 'reports', 'of', 'stress', ',', 'impact', 'of', 'event', '(', 'diagnosis', ')', ',', 'and', 'use', 'of', 'services', 'after', 'a', 'child', 'is', 'newly', 'diagnosed', 'with', 'ASD', '.']","(10, 13)","(48, 83)",-1,hl_i,16295154,Abstract,2,test,gold,4010.0
1976,A secondary purpose was to test the effects of a post-diagnosis nursing intervention on,parents ' reports of stress,", impact of event ( diagnosis ) , and use of services after a child is newly diagnosed with ASD .","['A', 'secondary', 'purpose', 'was', 'to', 'test', 'the', 'effects', 'of', 'a', 'post-diagnosis', 'nursing', 'intervention', 'on', 'parents', ""'"", 'reports', 'of', 'stress', ',', 'impact', 'of', 'event', '(', 'diagnosis', ')', ',', 'and', 'use', 'of', 'services', 'after', 'a', 'child', 'is', 'newly', 'diagnosed', 'with', 'ASD', '.']","(14, 19)","(87, 114)",-1,hl_o,16295154,Abstract,2,test,gold,2445.0
1977,"A secondary purpose was to test the effects of a post-diagnosis nursing intervention on parents ' reports of stress ,",impact of event ( diagnosis ),", and use of services after a child is newly diagnosed with ASD .","['A', 'secondary', 'purpose', 'was', 'to', 'test', 'the', 'effects', 'of', 'a', 'post-diagnosis', 'nursing', 'intervention', 'on', 'parents', ""'"", 'reports', 'of', 'stress', ',', 'impact', 'of', 'event', '(', 'diagnosis', ')', ',', 'and', 'use', 'of', 'services', 'after', 'a', 'child', 'is', 'newly', 'diagnosed', 'with', 'ASD', '.']","(20, 26)","(117, 146)",-1,hl_o,16295154,Abstract,2,test,gold,955.0
1978,"A secondary purpose was to test the effects of a post-diagnosis nursing intervention on parents ' reports of stress , impact of event ( diagnosis ) , and",use of services,after a child is newly diagnosed with ASD .,"['A', 'secondary', 'purpose', 'was', 'to', 'test', 'the', 'effects', 'of', 'a', 'post-diagnosis', 'nursing', 'intervention', 'on', 'parents', ""'"", 'reports', 'of', 'stress', ',', 'impact', 'of', 'event', '(', 'diagnosis', ')', ',', 'and', 'use', 'of', 'services', 'after', 'a', 'child', 'is', 'newly', 'diagnosed', 'with', 'ASD', '.']","(28, 31)","(153, 168)",-1,hl_o,16295154,Abstract,2,test,gold,1268.0
1979,The intervention consisted of,usual care,"plus 3 hours contact with a pediatric nurse practitioner ( PNP ) for counseling , instruction , and assistance with implementation of the recommended treatment plan .","['The', 'intervention', 'consisted', 'of', 'usual', 'care', 'plus', '3', 'hours', 'contact', 'with', 'a', 'pediatric', 'nurse', 'practitioner', '(', 'PNP', ')', 'for', 'counseling', ',', 'instruction', ',', 'and', 'assistance', 'with', 'implementation', 'of', 'the', 'recommended', 'treatment', 'plan', '.']","(4, 6)","(29, 39)",-1,ss_i,16295154,Abstract,3,test,gold,3927.0
1980,The intervention consisted of usual care plus 3 hours,"contact with a pediatric nurse practitioner ( PNP ) for counseling , instruction , and assistance with implementation of the recommended treatment plan .",,"['The', 'intervention', 'consisted', 'of', 'usual', 'care', 'plus', '3', 'hours', 'contact', 'with', 'a', 'pediatric', 'nurse', 'practitioner', '(', 'PNP', ')', 'for', 'counseling', ',', 'instruction', ',', 'and', 'assistance', 'with', 'implementation', 'of', 'the', 'recommended', 'treatment', 'plan', '.']","(9, 33)","(53, 206)",-1,ss_i,16295154,Abstract,3,test,gold,5879.0
1981,The intervention consisted of,usual care,"plus 3 hours contact with a pediatric nurse practitioner ( PNP ) for counseling , instruction , and assistance with implementation of the recommended treatment plan .","['The', 'intervention', 'consisted', 'of', 'usual', 'care', 'plus', '3', 'hours', 'contact', 'with', 'a', 'pediatric', 'nurse', 'practitioner', '(', 'PNP', ')', 'for', 'counseling', ',', 'instruction', ',', 'and', 'assistance', 'with', 'implementation', 'of', 'the', 'recommended', 'treatment', 'plan', '.']","(4, 6)","(29, 39)",-1,hl_i,16295154,Abstract,3,test,gold,3928.0
1982,The intervention consisted of usual care plus 3 hours,"contact with a pediatric nurse practitioner ( PNP ) for counseling , instruction , and assistance with implementation of the recommended treatment plan",.,"['The', 'intervention', 'consisted', 'of', 'usual', 'care', 'plus', '3', 'hours', 'contact', 'with', 'a', 'pediatric', 'nurse', 'practitioner', '(', 'PNP', ')', 'for', 'counseling', ',', 'instruction', ',', 'and', 'assistance', 'with', 'implementation', 'of', 'the', 'recommended', 'treatment', 'plan', '.']","(9, 32)","(53, 204)",-1,hl_i,16295154,Abstract,3,test,gold,5880.0
1983,The control group received only the,usual care,"post-diagnosis , which consisted of a 1-hour consultation session to receive the results of diagnostic tests and a written copy of the recommended treatment plan provided by a developmental pediatrician and/or PNP .","['The', 'control', 'group', 'received', 'only', 'the', 'usual', 'care', 'post-diagnosis', ',', 'which', 'consisted', 'of', 'a', '1-hour', 'consultation', 'session', 'to', 'receive', 'the', 'results', 'of', 'diagnostic', 'tests', 'and', 'a', 'written', 'copy', 'of', 'the', 'recommended', 'treatment', 'plan', 'provided', 'by', 'a', 'developmental', 'pediatrician', 'and/or', 'PNP', '.']","(6, 8)","(35, 45)",-1,ss_i,16295154,Abstract,4,test,gold,3926.0
1984,"The control group received only the usual care post-diagnosis , which consisted of a 1-hour",consultation session to receive the results of diagnostic tests and a written copy of the recommended treatment plan,provided by a developmental pediatrician and/or PNP .,"['The', 'control', 'group', 'received', 'only', 'the', 'usual', 'care', 'post-diagnosis', ',', 'which', 'consisted', 'of', 'a', '1-hour', 'consultation', 'session', 'to', 'receive', 'the', 'results', 'of', 'diagnostic', 'tests', 'and', 'a', 'written', 'copy', 'of', 'the', 'recommended', 'treatment', 'plan', 'provided', 'by', 'a', 'developmental', 'pediatrician', 'and/or', 'PNP', '.']","(15, 33)","(91, 207)",-1,ss_i,16295154,Abstract,4,test,gold,5900.0
1985,The control group received only the,usual care,"post-diagnosis , which consisted of a 1-hour consultation session to receive the results of diagnostic tests and a written copy of the recommended treatment plan provided by a developmental pediatrician and/or PNP .","['The', 'control', 'group', 'received', 'only', 'the', 'usual', 'care', 'post-diagnosis', ',', 'which', 'consisted', 'of', 'a', '1-hour', 'consultation', 'session', 'to', 'receive', 'the', 'results', 'of', 'diagnostic', 'tests', 'and', 'a', 'written', 'copy', 'of', 'the', 'recommended', 'treatment', 'plan', 'provided', 'by', 'a', 'developmental', 'pediatrician', 'and/or', 'PNP', '.']","(6, 8)","(35, 45)",-1,hl_i,16295154,Abstract,4,test,gold,3925.0
1986,"The control group received only the usual care post-diagnosis , which consisted of a 1-hour",consultation session to receive the results of diagnostic tests and a written copy of the recommended treatment plan,provided by a developmental pediatrician and/or PNP .,"['The', 'control', 'group', 'received', 'only', 'the', 'usual', 'care', 'post-diagnosis', ',', 'which', 'consisted', 'of', 'a', '1-hour', 'consultation', 'session', 'to', 'receive', 'the', 'results', 'of', 'diagnostic', 'tests', 'and', 'a', 'written', 'copy', 'of', 'the', 'recommended', 'treatment', 'plan', 'provided', 'by', 'a', 'developmental', 'pediatrician', 'and/or', 'PNP', '.']","(15, 33)","(91, 207)",-1,hl_i,16295154,Abstract,4,test,gold,5901.0
1987,Between group differences in measures of,""" impact of event ""","and "" perceived stress "" were not statistically significant .","['Between', 'group', 'differences', 'in', 'measures', 'of', '""', 'impact', 'of', 'event', '""', 'and', '""', 'perceived', 'stress', '""', 'were', 'not', 'statistically', 'significant', '.']","(6, 11)","(40, 59)",-1,ss_o,16295154,Abstract,5,test,gold,957.0
1988,"Between group differences in measures of "" impact of event "" and",""" perceived stress """,were not statistically significant .,"['Between', 'group', 'differences', 'in', 'measures', 'of', '""', 'impact', 'of', 'event', '""', 'and', '""', 'perceived', 'stress', '""', 'were', 'not', 'statistically', 'significant', '.']","(12, 16)","(64, 84)",-1,ss_o,16295154,Abstract,5,test,gold,2448.0
1989,Between group differences in measures of,""" impact of event ""","and "" perceived stress "" were not statistically significant .","['Between', 'group', 'differences', 'in', 'measures', 'of', '""', 'impact', 'of', 'event', '""', 'and', '""', 'perceived', 'stress', '""', 'were', 'not', 'statistically', 'significant', '.']","(6, 11)","(40, 59)",-1,hl_o,16295154,Abstract,5,test,gold,958.0
1990,"Between group differences in measures of "" impact of event "" and",""" perceived stress """,were not statistically significant .,"['Between', 'group', 'differences', 'in', 'measures', 'of', '""', 'impact', 'of', 'event', '""', 'and', '""', 'perceived', 'stress', '""', 'were', 'not', 'statistically', 'significant', '.']","(12, 16)","(64, 84)",-1,hl_o,16295154,Abstract,5,test,gold,2449.0
1991,This was attributed to a small sample size .,,,"['This', 'was', 'attributed', 'to', 'a', 'small', 'sample', 'size', '.']",,,,,16295154,Abstract,6,test,gold,
1992,A larger study is feasible and recommended with an expanded,nursing intervention,and a significantly larger sample recruited from an additional recruitment site .,"['A', 'larger', 'study', 'is', 'feasible', 'and', 'recommended', 'with', 'an', 'expanded', 'nursing', 'intervention', 'and', 'a', 'significantly', 'larger', 'sample', 'recruited', 'from', 'an', 'additional', 'recruitment', 'site', '.']","(10, 12)","(59, 79)",-1,ss_i,16295154,Abstract,7,test,gold,4009.0
1993,Nurses working with this special population must recognize that parents have information and counseling needs that begin after they receive the diagnosis of ASD for their child and can address these needs with a standardized,nursing intervention .,,"['Nurses', 'working', 'with', 'this', 'special', 'population', 'must', 'recognize', 'that', 'parents', 'have', 'information', 'and', 'counseling', 'needs', 'that', 'begin', 'after', 'they', 'receive', 'the', 'diagnosis', 'of', 'ASD', 'for', 'their', 'child', 'and', 'can', 'address', 'these', 'needs', 'with', 'a', 'standardized', 'nursing', 'intervention', '.']","(35, 38)","(224, 246)",-1,ss_i,16295154,Abstract,8,test,gold,4008.0
1994,Sleep-anticipating effects of melatonin in the,human,brain .,"['Sleep-anticipating', 'effects', 'of', 'melatonin', 'in', 'the', 'human', 'brain', '.']","(6, 7)","(46, 51)",-1,ss_p,16427787,Title,0,test,gold,1279.0
1995,Sleep-anticipating effects of,melatonin,in the human brain .,"['Sleep-anticipating', 'effects', 'of', 'melatonin', 'in', 'the', 'human', 'brain', '.']","(3, 4)","(29, 38)",-1,ss_i,16427787,Title,0,test,gold,1557.0
1996,Sleep-anticipating,effects,of melatonin in the human brain .,"['Sleep-anticipating', 'effects', 'of', 'melatonin', 'in', 'the', 'human', 'brain', '.']","(1, 2)","(18, 25)",-1,ss_o,16427787,Title,0,test,gold,2381.0
1997,Sleep-anticipating effects of melatonin in the,human,brain .,"['Sleep-anticipating', 'effects', 'of', 'melatonin', 'in', 'the', 'human', 'brain', '.']","(6, 7)","(46, 51)",-1,hl_p,16427787,Title,0,test,gold,1280.0
1998,Sleep-anticipating effects of,melatonin,in the human brain .,"['Sleep-anticipating', 'effects', 'of', 'melatonin', 'in', 'the', 'human', 'brain', '.']","(3, 4)","(29, 38)",-1,hl_i,16427787,Title,0,test,gold,1558.0
1999,Sleep-anticipating,effects,of melatonin in the human brain .,"['Sleep-anticipating', 'effects', 'of', 'melatonin', 'in', 'the', 'human', 'brain', '.']","(1, 2)","(18, 25)",-1,hl_o,16427787,Title,0,test,gold,2380.0
2000,"Melatonin , the hormone produced nocturnally by the pineal gland , is an endogenous regulator of the sleep-wake cycle .",,,"['Melatonin', ',', 'the', 'hormone', 'produced', 'nocturnally', 'by', 'the', 'pineal', 'gland', ',', 'is', 'an', 'endogenous', 'regulator', 'of', 'the', 'sleep-wake', 'cycle', '.']",,,,,16427787,Abstract,0,test,gold,
2001,The effects of,melatonin,"on brain activities and their relation to induction of sleepiness were studied in a randomized , double-blind , placebo controlled functional magnetic resonance imaging ( fMRI ) study .","['The', 'effects', 'of', 'melatonin', 'on', 'brain', 'activities', 'and', 'their', 'relation', 'to', 'induction', 'of', 'sleepiness', 'were', 'studied', 'in', 'a', 'randomized', ',', 'double-blind', ',', 'placebo', 'controlled', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', 'study', '.']","(3, 4)","(14, 23)",-1,ss_i,16427787,Abstract,1,test,gold,1556.0
2002,The effects of melatonin on,brain activities,"and their relation to induction of sleepiness were studied in a randomized , double-blind , placebo controlled functional magnetic resonance imaging ( fMRI ) study .","['The', 'effects', 'of', 'melatonin', 'on', 'brain', 'activities', 'and', 'their', 'relation', 'to', 'induction', 'of', 'sleepiness', 'were', 'studied', 'in', 'a', 'randomized', ',', 'double-blind', ',', 'placebo', 'controlled', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', 'study', '.']","(5, 7)","(27, 43)",-1,ss_o,16427787,Abstract,1,test,gold,2900.0
2003,The effects of melatonin on brain activities and their relation to,induction of sleepiness,"were studied in a randomized , double-blind , placebo controlled functional magnetic resonance imaging ( fMRI ) study .","['The', 'effects', 'of', 'melatonin', 'on', 'brain', 'activities', 'and', 'their', 'relation', 'to', 'induction', 'of', 'sleepiness', 'were', 'studied', 'in', 'a', 'randomized', ',', 'double-blind', ',', 'placebo', 'controlled', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', 'study', '.']","(11, 14)","(66, 89)",-1,ss_o,16427787,Abstract,1,test,gold,1331.0
2004,The effects of,melatonin,"on brain activities and their relation to induction of sleepiness were studied in a randomized , double-blind , placebo controlled functional magnetic resonance imaging ( fMRI ) study .","['The', 'effects', 'of', 'melatonin', 'on', 'brain', 'activities', 'and', 'their', 'relation', 'to', 'induction', 'of', 'sleepiness', 'were', 'studied', 'in', 'a', 'randomized', ',', 'double-blind', ',', 'placebo', 'controlled', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', 'study', '.']","(3, 4)","(14, 23)",-1,hl_i,16427787,Abstract,1,test,gold,1555.0
2005,,Melatonin,", but not placebo , reduced task-related activity in the rostro-medial aspect of the occipital cortex during a visual-search task and in the auditory cortex during a music task .","['Melatonin', ',', 'but', 'not', 'placebo', ',', 'reduced', 'task-related', 'activity', 'in', 'the', 'rostro-medial', 'aspect', 'of', 'the', 'occipital', 'cortex', 'during', 'a', 'visual-search', 'task', 'and', 'in', 'the', 'auditory', 'cortex', 'during', 'a', 'music', 'task', '.']","(0, 1)","(0, 9)",-1,ss_i,16427787,Abstract,2,test,gold,5501.0
2006,"Melatonin , but not",placebo,", reduced task-related activity in the rostro-medial aspect of the occipital cortex during a visual-search task and in the auditory cortex during a music task .","['Melatonin', ',', 'but', 'not', 'placebo', ',', 'reduced', 'task-related', 'activity', 'in', 'the', 'rostro-medial', 'aspect', 'of', 'the', 'occipital', 'cortex', 'during', 'a', 'visual-search', 'task', 'and', 'in', 'the', 'auditory', 'cortex', 'during', 'a', 'music', 'task', '.']","(4, 5)","(19, 26)",-1,ss_i,16427787,Abstract,2,test,gold,4389.0
2007,"Melatonin , but not placebo , reduced",task-related activity,in the rostro-medial aspect of the occipital cortex during a visual-search task and in the auditory cortex during a music task .,"['Melatonin', ',', 'but', 'not', 'placebo', ',', 'reduced', 'task-related', 'activity', 'in', 'the', 'rostro-medial', 'aspect', 'of', 'the', 'occipital', 'cortex', 'during', 'a', 'visual-search', 'task', 'and', 'in', 'the', 'auditory', 'cortex', 'during', 'a', 'music', 'task', '.']","(7, 9)","(37, 58)",-1,ss_o,16427787,Abstract,2,test,gold,2908.0
2008,,Melatonin,", but not placebo , reduced task-related activity in the rostro-medial aspect of the occipital cortex during a visual-search task and in the auditory cortex during a music task .","['Melatonin', ',', 'but', 'not', 'placebo', ',', 'reduced', 'task-related', 'activity', 'in', 'the', 'rostro-medial', 'aspect', 'of', 'the', 'occipital', 'cortex', 'during', 'a', 'visual-search', 'task', 'and', 'in', 'the', 'auditory', 'cortex', 'during', 'a', 'music', 'task', '.']","(0, 1)","(0, 9)",-1,hl_i,16427787,Abstract,2,test,gold,5502.0
2009,"Melatonin , but not",placebo,", reduced task-related activity in the rostro-medial aspect of the occipital cortex during a visual-search task and in the auditory cortex during a music task .","['Melatonin', ',', 'but', 'not', 'placebo', ',', 'reduced', 'task-related', 'activity', 'in', 'the', 'rostro-medial', 'aspect', 'of', 'the', 'occipital', 'cortex', 'during', 'a', 'visual-search', 'task', 'and', 'in', 'the', 'auditory', 'cortex', 'during', 'a', 'music', 'task', '.']","(4, 5)","(19, 26)",-1,hl_i,16427787,Abstract,2,test,gold,4388.0
2010,"Melatonin , but not placebo , reduced",task-related activity,in the rostro-medial aspect of the occipital cortex during a visual-search task and in the auditory cortex during a music task .,"['Melatonin', ',', 'but', 'not', 'placebo', ',', 'reduced', 'task-related', 'activity', 'in', 'the', 'rostro-medial', 'aspect', 'of', 'the', 'occipital', 'cortex', 'during', 'a', 'visual-search', 'task', 'and', 'in', 'the', 'auditory', 'cortex', 'during', 'a', 'music', 'task', '.']","(7, 9)","(37, 58)",-1,hl_o,16427787,Abstract,2,test,gold,2909.0
2011,These effects correlated with,subjective measurements of fatigue .,,"['These', 'effects', 'correlated', 'with', 'subjective', 'measurements', 'of', 'fatigue', '.']","(4, 9)","(29, 65)",-1,ss_o,16427787,Abstract,3,test,gold,6445.0
2012,These effects correlated with,subjective measurements of fatigue .,,"['These', 'effects', 'correlated', 'with', 'subjective', 'measurements', 'of', 'fatigue', '.']","(4, 9)","(29, 65)",-1,hl_o,16427787,Abstract,3,test,gold,6446.0
2013,"In addition ,",melatonin,enhanced the activation in the left parahippocampus in an autobiographic memory task .,"['In', 'addition', ',', 'melatonin', 'enhanced', 'the', 'activation', 'in', 'the', 'left', 'parahippocampus', 'in', 'an', 'autobiographic', 'memory', 'task', '.']","(3, 4)","(13, 22)",-1,ss_i,16427787,Abstract,4,test,gold,1554.0
2014,"In addition , melatonin enhanced the",activation in the left parahippocampus,in an autobiographic memory task .,"['In', 'addition', ',', 'melatonin', 'enhanced', 'the', 'activation', 'in', 'the', 'left', 'parahippocampus', 'in', 'an', 'autobiographic', 'memory', 'task', '.']","(6, 11)","(36, 74)",-1,ss_o,16427787,Abstract,4,test,gold,946.0
2015,"In addition ,",melatonin,enhanced the activation in the left parahippocampus in an autobiographic memory task .,"['In', 'addition', ',', 'melatonin', 'enhanced', 'the', 'activation', 'in', 'the', 'left', 'parahippocampus', 'in', 'an', 'autobiographic', 'memory', 'task', '.']","(3, 4)","(13, 22)",-1,hl_i,16427787,Abstract,4,test,gold,1553.0
2016,"In addition , melatonin enhanced the",activation in the left parahippocampus,in an autobiographic memory task .,"['In', 'addition', ',', 'melatonin', 'enhanced', 'the', 'activation', 'in', 'the', 'left', 'parahippocampus', 'in', 'an', 'autobiographic', 'memory', 'task', '.']","(6, 11)","(36, 74)",-1,hl_o,16427787,Abstract,4,test,gold,947.0
2017,Results demonstrate that,melatonin,modulates brain activity in a manner resembling actual sleep although subjects are fully awake .,"['Results', 'demonstrate', 'that', 'melatonin', 'modulates', 'brain', 'activity', 'in', 'a', 'manner', 'resembling', 'actual', 'sleep', 'although', 'subjects', 'are', 'fully', 'awake', '.']","(3, 4)","(24, 33)",-1,ss_i,16427787,Abstract,5,test,gold,1552.0
2018,Results demonstrate that melatonin modulates,brain activity,in a manner resembling actual sleep although subjects are fully awake .,"['Results', 'demonstrate', 'that', 'melatonin', 'modulates', 'brain', 'activity', 'in', 'a', 'manner', 'resembling', 'actual', 'sleep', 'although', 'subjects', 'are', 'fully', 'awake', '.']","(5, 7)","(44, 58)",-1,ss_o,16427787,Abstract,5,test,gold,2902.0
2019,Results demonstrate that,melatonin,modulates brain activity in a manner resembling actual sleep although subjects are fully awake .,"['Results', 'demonstrate', 'that', 'melatonin', 'modulates', 'brain', 'activity', 'in', 'a', 'manner', 'resembling', 'actual', 'sleep', 'although', 'subjects', 'are', 'fully', 'awake', '.']","(3, 4)","(24, 33)",-1,hl_i,16427787,Abstract,5,test,gold,1551.0
2020,Results demonstrate that melatonin modulates,brain activity,in a manner resembling actual sleep although subjects are fully awake .,"['Results', 'demonstrate', 'that', 'melatonin', 'modulates', 'brain', 'activity', 'in', 'a', 'manner', 'resembling', 'actual', 'sleep', 'although', 'subjects', 'are', 'fully', 'awake', '.']","(5, 7)","(44, 58)",-1,hl_o,16427787,Abstract,5,test,gold,2903.0
2021,"Furthermore , the fatigue inducing effect of",melatonin,on brain activity is essentially different from that of sleep deprivation thus revealing differences between fatigues related to the circadian sleep regulation as opposed to increased homeostatic sleep need .,"['Furthermore', ',', 'the', 'fatigue', 'inducing', 'effect', 'of', 'melatonin', 'on', 'brain', 'activity', 'is', 'essentially', 'different', 'from', 'that', 'of', 'sleep', 'deprivation', 'thus', 'revealing', 'differences', 'between', 'fatigues', 'related', 'to', 'the', 'circadian', 'sleep', 'regulation', 'as', 'opposed', 'to', 'increased', 'homeostatic', 'sleep', 'need', '.']","(7, 8)","(44, 53)",-1,ss_i,16427787,Abstract,6,test,gold,1550.0
2022,"Furthermore , the",fatigue,inducing effect of melatonin on brain activity is essentially different from that of sleep deprivation thus revealing differences between fatigues related to the circadian sleep regulation as opposed to increased homeostatic sleep need .,"['Furthermore', ',', 'the', 'fatigue', 'inducing', 'effect', 'of', 'melatonin', 'on', 'brain', 'activity', 'is', 'essentially', 'different', 'from', 'that', 'of', 'sleep', 'deprivation', 'thus', 'revealing', 'differences', 'between', 'fatigues', 'related', 'to', 'the', 'circadian', 'sleep', 'regulation', 'as', 'opposed', 'to', 'increased', 'homeostatic', 'sleep', 'need', '.']","(3, 4)","(17, 24)",-1,ss_o,16427787,Abstract,6,test,gold,2705.0
2023,"Furthermore , the fatigue inducing",effect,of melatonin on brain activity is essentially different from that of sleep deprivation thus revealing differences between fatigues related to the circadian sleep regulation as opposed to increased homeostatic sleep need .,"['Furthermore', ',', 'the', 'fatigue', 'inducing', 'effect', 'of', 'melatonin', 'on', 'brain', 'activity', 'is', 'essentially', 'different', 'from', 'that', 'of', 'sleep', 'deprivation', 'thus', 'revealing', 'differences', 'between', 'fatigues', 'related', 'to', 'the', 'circadian', 'sleep', 'regulation', 'as', 'opposed', 'to', 'increased', 'homeostatic', 'sleep', 'need', '.']","(5, 6)","(34, 40)",-1,ss_o,16427787,Abstract,6,test,gold,2340.0
2024,"Furthermore , the fatigue inducing effect of melatonin on",brain activity,is essentially different from that of sleep deprivation thus revealing differences between fatigues related to the circadian sleep regulation as opposed to increased homeostatic sleep need .,"['Furthermore', ',', 'the', 'fatigue', 'inducing', 'effect', 'of', 'melatonin', 'on', 'brain', 'activity', 'is', 'essentially', 'different', 'from', 'that', 'of', 'sleep', 'deprivation', 'thus', 'revealing', 'differences', 'between', 'fatigues', 'related', 'to', 'the', 'circadian', 'sleep', 'regulation', 'as', 'opposed', 'to', 'increased', 'homeostatic', 'sleep', 'need', '.']","(9, 11)","(57, 71)",-1,ss_o,16427787,Abstract,6,test,gold,2901.0
2025,"Furthermore , the fatigue inducing effect of",melatonin,on brain activity is essentially different from that of sleep deprivation thus revealing differences between fatigues related to the circadian sleep regulation as opposed to increased homeostatic sleep need .,"['Furthermore', ',', 'the', 'fatigue', 'inducing', 'effect', 'of', 'melatonin', 'on', 'brain', 'activity', 'is', 'essentially', 'different', 'from', 'that', 'of', 'sleep', 'deprivation', 'thus', 'revealing', 'differences', 'between', 'fatigues', 'related', 'to', 'the', 'circadian', 'sleep', 'regulation', 'as', 'opposed', 'to', 'increased', 'homeostatic', 'sleep', 'need', '.']","(7, 8)","(44, 53)",-1,hl_i,16427787,Abstract,6,test,gold,1549.0
2026,"Furthermore , the",fatigue,inducing effect of melatonin on brain activity is essentially different from that of sleep deprivation thus revealing differences between fatigues related to the circadian sleep regulation as opposed to increased homeostatic sleep need .,"['Furthermore', ',', 'the', 'fatigue', 'inducing', 'effect', 'of', 'melatonin', 'on', 'brain', 'activity', 'is', 'essentially', 'different', 'from', 'that', 'of', 'sleep', 'deprivation', 'thus', 'revealing', 'differences', 'between', 'fatigues', 'related', 'to', 'the', 'circadian', 'sleep', 'regulation', 'as', 'opposed', 'to', 'increased', 'homeostatic', 'sleep', 'need', '.']","(3, 4)","(17, 24)",-1,hl_o,16427787,Abstract,6,test,gold,2703.0
2027,Our findings highlight the role of,melatonin,in priming sleep-associated brain activation patterns in anticipation of sleep .,"['Our', 'findings', 'highlight', 'the', 'role', 'of', 'melatonin', 'in', 'priming', 'sleep-associated', 'brain', 'activation', 'patterns', 'in', 'anticipation', 'of', 'sleep', '.']","(6, 7)","(34, 43)",-1,ss_i,16427787,Abstract,7,test,gold,1548.0
2028,Our findings highlight the role of melatonin in priming,sleep-associated brain activation,patterns in anticipation of sleep .,"['Our', 'findings', 'highlight', 'the', 'role', 'of', 'melatonin', 'in', 'priming', 'sleep-associated', 'brain', 'activation', 'patterns', 'in', 'anticipation', 'of', 'sleep', '.']","(9, 12)","(55, 88)",-1,ss_o,16427787,Abstract,7,test,gold,2895.0
2029,Our findings highlight the role of,melatonin,in priming sleep-associated brain activation patterns in anticipation of sleep .,"['Our', 'findings', 'highlight', 'the', 'role', 'of', 'melatonin', 'in', 'priming', 'sleep-associated', 'brain', 'activation', 'patterns', 'in', 'anticipation', 'of', 'sleep', '.']","(6, 7)","(34, 43)",-1,hl_i,16427787,Abstract,7,test,gold,1547.0
2030,Phase III study of two different dosing schedules of erythropoietin in,anemic patients with cancer .,,"['Phase', 'III', 'study', 'of', 'two', 'different', 'dosing', 'schedules', 'of', 'erythropoietin', 'in', 'anemic', 'patients', 'with', 'cancer', '.']","(11, 16)","(70, 99)",-1,ss_p,16505427,Title,0,test,gold,3785.0
2031,Phase III study of two different dosing schedules of,erythropoietin,in anemic patients with cancer .,"['Phase', 'III', 'study', 'of', 'two', 'different', 'dosing', 'schedules', 'of', 'erythropoietin', 'in', 'anemic', 'patients', 'with', 'cancer', '.']","(9, 10)","(52, 66)",-1,ss_i,16505427,Title,0,test,gold,5499.0
2032,Phase III study of two different dosing schedules of erythropoietin in,anemic patients with cancer .,,"['Phase', 'III', 'study', 'of', 'two', 'different', 'dosing', 'schedules', 'of', 'erythropoietin', 'in', 'anemic', 'patients', 'with', 'cancer', '.']","(11, 16)","(70, 99)",-1,hl_p,16505427,Title,0,test,gold,3786.0
2033,Phase III study of two different dosing schedules of,erythropoietin,in anemic patients with cancer .,"['Phase', 'III', 'study', 'of', 'two', 'different', 'dosing', 'schedules', 'of', 'erythropoietin', 'in', 'anemic', 'patients', 'with', 'cancer', '.']","(9, 10)","(52, 66)",-1,hl_i,16505427,Title,0,test,gold,5500.0
2034,PURPOSE To compare maintenance epoetin alfa administered once every 3 weeks with continued weekly epoetin alfa for,patients with cancer-associated anemia .,,"['PURPOSE', 'To', 'compare', 'maintenance', 'epoetin', 'alfa', 'administered', 'once', 'every', '3', 'weeks', 'with', 'continued', 'weekly', 'epoetin', 'alfa', 'for', 'patients', 'with', 'cancer-associated', 'anemia', '.']","(17, 22)","(114, 154)",-1,ss_p,16505427,Abstract,0,test,gold,3424.0
2035,PURPOSE To compare maintenance,epoetin alfa,administered once every 3 weeks with continued weekly epoetin alfa for patients with cancer-associated anemia .,"['PURPOSE', 'To', 'compare', 'maintenance', 'epoetin', 'alfa', 'administered', 'once', 'every', '3', 'weeks', 'with', 'continued', 'weekly', 'epoetin', 'alfa', 'for', 'patients', 'with', 'cancer-associated', 'anemia', '.']","(4, 6)","(30, 42)",-1,ss_i,16505427,Abstract,0,test,gold,5198.0
2036,PURPOSE To compare maintenance epoetin alfa administered once every 3 weeks with continued weekly,epoetin alfa,for patients with cancer-associated anemia .,"['PURPOSE', 'To', 'compare', 'maintenance', 'epoetin', 'alfa', 'administered', 'once', 'every', '3', 'weeks', 'with', 'continued', 'weekly', 'epoetin', 'alfa', 'for', 'patients', 'with', 'cancer-associated', 'anemia', '.']","(14, 16)","(97, 109)",-1,ss_i,16505427,Abstract,0,test,gold,5199.0
2037,PURPOSE To compare maintenance epoetin alfa administered once every 3 weeks with continued weekly epoetin alfa for,patients with cancer-associated anemia .,,"['PURPOSE', 'To', 'compare', 'maintenance', 'epoetin', 'alfa', 'administered', 'once', 'every', '3', 'weeks', 'with', 'continued', 'weekly', 'epoetin', 'alfa', 'for', 'patients', 'with', 'cancer-associated', 'anemia', '.']","(17, 22)","(114, 154)",-1,hl_p,16505427,Abstract,0,test,gold,3425.0
2038,PURPOSE To compare maintenance,epoetin alfa,administered once every 3 weeks with continued weekly epoetin alfa for patients with cancer-associated anemia .,"['PURPOSE', 'To', 'compare', 'maintenance', 'epoetin', 'alfa', 'administered', 'once', 'every', '3', 'weeks', 'with', 'continued', 'weekly', 'epoetin', 'alfa', 'for', 'patients', 'with', 'cancer-associated', 'anemia', '.']","(4, 6)","(30, 42)",-1,hl_i,16505427,Abstract,0,test,gold,5197.0
2039,PURPOSE To compare maintenance epoetin alfa administered once every 3 weeks with continued weekly,epoetin alfa,for patients with cancer-associated anemia .,"['PURPOSE', 'To', 'compare', 'maintenance', 'epoetin', 'alfa', 'administered', 'once', 'every', '3', 'weeks', 'with', 'continued', 'weekly', 'epoetin', 'alfa', 'for', 'patients', 'with', 'cancer-associated', 'anemia', '.']","(14, 16)","(97, 109)",-1,hl_i,16505427,Abstract,0,test,gold,5196.0
2040,PATIENTS AND METHODS Eligible patients were randomly assigned at enrollment to receive three weekly doses of,epoetin alfa,"40,000 U subcutaneously ( SC ) , followed by either standard weekly epoetin alfa ( 40K arm ) or 120,000 U of epoetin alfa ( 120K arm ) SC every 3 weeks for 18 additional weeks .","['PATIENTS', 'AND', 'METHODS', 'Eligible', 'patients', 'were', 'randomly', 'assigned', 'at', 'enrollment', 'to', 'receive', 'three', 'weekly', 'doses', 'of', 'epoetin', 'alfa', '40,000', 'U', 'subcutaneously', '(', 'SC', ')', ',', 'followed', 'by', 'either', 'standard', 'weekly', 'epoetin', 'alfa', '(', '40K', 'arm', ')', 'or', '120,000', 'U', 'of', 'epoetin', 'alfa', '(', '120K', 'arm', ')', 'SC', 'every', '3', 'weeks', 'for', '18', 'additional', 'weeks', '.']","(16, 18)","(108, 120)",-1,ss_i,16505427,Abstract,1,test,gold,5195.0
2041,"PATIENTS AND METHODS Eligible patients were randomly assigned at enrollment to receive three weekly doses of epoetin alfa 40,000 U subcutaneously ( SC ) , followed by either standard weekly",epoetin alfa,"( 40K arm ) or 120,000 U of epoetin alfa ( 120K arm ) SC every 3 weeks for 18 additional weeks .","['PATIENTS', 'AND', 'METHODS', 'Eligible', 'patients', 'were', 'randomly', 'assigned', 'at', 'enrollment', 'to', 'receive', 'three', 'weekly', 'doses', 'of', 'epoetin', 'alfa', '40,000', 'U', 'subcutaneously', '(', 'SC', ')', ',', 'followed', 'by', 'either', 'standard', 'weekly', 'epoetin', 'alfa', '(', '40K', 'arm', ')', 'or', '120,000', 'U', 'of', 'epoetin', 'alfa', '(', '120K', 'arm', ')', 'SC', 'every', '3', 'weeks', 'for', '18', 'additional', 'weeks', '.']","(30, 32)","(189, 201)",-1,ss_i,16505427,Abstract,1,test,gold,5194.0
2042,"PATIENTS AND METHODS Eligible patients were randomly assigned at enrollment to receive three weekly doses of epoetin alfa 40,000 U subcutaneously ( SC ) , followed by either standard weekly epoetin alfa ( 40K arm ) or 120,000 U of",epoetin alfa,( 120K arm ) SC every 3 weeks for 18 additional weeks .,"['PATIENTS', 'AND', 'METHODS', 'Eligible', 'patients', 'were', 'randomly', 'assigned', 'at', 'enrollment', 'to', 'receive', 'three', 'weekly', 'doses', 'of', 'epoetin', 'alfa', '40,000', 'U', 'subcutaneously', '(', 'SC', ')', ',', 'followed', 'by', 'either', 'standard', 'weekly', 'epoetin', 'alfa', '(', '40K', 'arm', ')', 'or', '120,000', 'U', 'of', 'epoetin', 'alfa', '(', '120K', 'arm', ')', 'SC', 'every', '3', 'weeks', 'for', '18', 'additional', 'weeks', '.']","(40, 42)","(230, 242)",-1,ss_i,16505427,Abstract,1,test,gold,5193.0
2043,PATIENTS AND METHODS Eligible patients were randomly assigned at enrollment to receive three weekly doses of,epoetin alfa,"40,000 U subcutaneously ( SC ) , followed by either standard weekly epoetin alfa ( 40K arm ) or 120,000 U of epoetin alfa ( 120K arm ) SC every 3 weeks for 18 additional weeks .","['PATIENTS', 'AND', 'METHODS', 'Eligible', 'patients', 'were', 'randomly', 'assigned', 'at', 'enrollment', 'to', 'receive', 'three', 'weekly', 'doses', 'of', 'epoetin', 'alfa', '40,000', 'U', 'subcutaneously', '(', 'SC', ')', ',', 'followed', 'by', 'either', 'standard', 'weekly', 'epoetin', 'alfa', '(', '40K', 'arm', ')', 'or', '120,000', 'U', 'of', 'epoetin', 'alfa', '(', '120K', 'arm', ')', 'SC', 'every', '3', 'weeks', 'for', '18', 'additional', 'weeks', '.']","(16, 18)","(108, 120)",-1,hl_i,16505427,Abstract,1,test,gold,5192.0
2044,"PATIENTS AND METHODS Eligible patients were randomly assigned at enrollment to receive three weekly doses of epoetin alfa 40,000 U subcutaneously ( SC ) , followed by either standard weekly",epoetin alfa,"( 40K arm ) or 120,000 U of epoetin alfa ( 120K arm ) SC every 3 weeks for 18 additional weeks .","['PATIENTS', 'AND', 'METHODS', 'Eligible', 'patients', 'were', 'randomly', 'assigned', 'at', 'enrollment', 'to', 'receive', 'three', 'weekly', 'doses', 'of', 'epoetin', 'alfa', '40,000', 'U', 'subcutaneously', '(', 'SC', ')', ',', 'followed', 'by', 'either', 'standard', 'weekly', 'epoetin', 'alfa', '(', '40K', 'arm', ')', 'or', '120,000', 'U', 'of', 'epoetin', 'alfa', '(', '120K', 'arm', ')', 'SC', 'every', '3', 'weeks', 'for', '18', 'additional', 'weeks', '.']","(30, 32)","(189, 201)",-1,hl_i,16505427,Abstract,1,test,gold,5191.0
2045,"PATIENTS AND METHODS Eligible patients were randomly assigned at enrollment to receive three weekly doses of epoetin alfa 40,000 U subcutaneously ( SC ) , followed by either standard weekly epoetin alfa ( 40K arm ) or 120,000 U of",epoetin alfa,( 120K arm ) SC every 3 weeks for 18 additional weeks .,"['PATIENTS', 'AND', 'METHODS', 'Eligible', 'patients', 'were', 'randomly', 'assigned', 'at', 'enrollment', 'to', 'receive', 'three', 'weekly', 'doses', 'of', 'epoetin', 'alfa', '40,000', 'U', 'subcutaneously', '(', 'SC', ')', ',', 'followed', 'by', 'either', 'standard', 'weekly', 'epoetin', 'alfa', '(', '40K', 'arm', ')', 'or', '120,000', 'U', 'of', 'epoetin', 'alfa', '(', '120K', 'arm', ')', 'SC', 'every', '3', 'weeks', 'for', '18', 'additional', 'weeks', '.']","(40, 42)","(230, 242)",-1,hl_i,16505427,Abstract,1,test,gold,5190.0
2046,RESULTS,Three hundred sixty-five patients,were enrolled .,"['RESULTS', 'Three', 'hundred', 'sixty-five', 'patients', 'were', 'enrolled', '.']","(1, 5)","(7, 40)",-1,ss_p,16505427,Abstract,2,test,gold,2061.0
2047,RESULTS,Three hundred sixty-five patients,were enrolled .,"['RESULTS', 'Three', 'hundred', 'sixty-five', 'patients', 'were', 'enrolled', '.']","(1, 5)","(7, 40)",-1,hl_p,16505427,Abstract,2,test,gold,2062.0
2048,"One hundred eighty-three patients were assigned to the 40K arm , and 182 were assigned to the 120K arm .",,,"['One', 'hundred', 'eighty-three', 'patients', 'were', 'assigned', 'to', 'the', '40K', 'arm', ',', 'and', '182', 'were', 'assigned', 'to', 'the', '120K', 'arm', '.']",,,,,16505427,Abstract,3,test,gold,
2049,There was no difference in the proportion of patients,requiring transfusions,"during the study ( 23 % in 40K arm and 18 % in 120K arm , P = .22 ) or specifically during the maintenance phase ( 13 % in 40K arm v 15 % in 120K arm , P = .58 ) .","['There', 'was', 'no', 'difference', 'in', 'the', 'proportion', 'of', 'patients', 'requiring', 'transfusions', 'during', 'the', 'study', '(', '23', '%', 'in', '40K', 'arm', 'and', '18', '%', 'in', '120K', 'arm', ',', 'P', '=', '.22', ')', 'or', 'specifically', 'during', 'the', 'maintenance', 'phase', '(', '13', '%', 'in', '40K', 'arm', 'v', '15', '%', 'in', '120K', 'arm', ',', 'P', '=', '.58', ')', '.']","(9, 11)","(53, 75)",-1,ss_o,16505427,Abstract,4,test,gold,4151.0
2050,There was no difference in the proportion of patients,requiring transfusions,"during the study ( 23 % in 40K arm and 18 % in 120K arm , P = .22 ) or specifically during the maintenance phase ( 13 % in 40K arm v 15 % in 120K arm , P = .58 ) .","['There', 'was', 'no', 'difference', 'in', 'the', 'proportion', 'of', 'patients', 'requiring', 'transfusions', 'during', 'the', 'study', '(', '23', '%', 'in', '40K', 'arm', 'and', '18', '%', 'in', '120K', 'arm', ',', 'P', '=', '.22', ')', 'or', 'specifically', 'during', 'the', 'maintenance', 'phase', '(', '13', '%', 'in', '40K', 'arm', 'v', '15', '%', 'in', '120K', 'arm', ',', 'P', '=', '.58', ')', '.']","(9, 11)","(53, 75)",-1,hl_o,16505427,Abstract,4,test,gold,4152.0
2051,Patients randomly assigned to the 40K arm were more likely to have a > or = 2 or > or = 3 g/dL,hemoglobin ( Hb ) increment,", were more likely to have a drug dose held because of high Hb , and had higher mean end-of-study Hb levels .","['Patients', 'randomly', 'assigned', 'to', 'the', '40K', 'arm', 'were', 'more', 'likely', 'to', 'have', 'a', '>', 'or', '=', '2', 'or', '>', 'or', '=', '3', 'g/dL', 'hemoglobin', '(', 'Hb', ')', 'increment', ',', 'were', 'more', 'likely', 'to', 'have', 'a', 'drug', 'dose', 'held', 'because', 'of', 'high', 'Hb', ',', 'and', 'had', 'higher', 'mean', 'end-of-study', 'Hb', 'levels', '.']","(23, 28)","(94, 121)",-1,ss_o,16505427,Abstract,5,test,gold,1644.0
2052,"Patients randomly assigned to the 40K arm were more likely to have a > or = 2 or > or = 3 g/dL hemoglobin ( Hb ) increment , were more likely to have a",drug dose,"held because of high Hb , and had higher mean end-of-study Hb levels .","['Patients', 'randomly', 'assigned', 'to', 'the', '40K', 'arm', 'were', 'more', 'likely', 'to', 'have', 'a', '>', 'or', '=', '2', 'or', '>', 'or', '=', '3', 'g/dL', 'hemoglobin', '(', 'Hb', ')', 'increment', ',', 'were', 'more', 'likely', 'to', 'have', 'a', 'drug', 'dose', 'held', 'because', 'of', 'high', 'Hb', ',', 'and', 'had', 'higher', 'mean', 'end-of-study', 'Hb', 'levels', '.']","(35, 37)","(151, 160)",-1,ss_o,16505427,Abstract,5,test,gold,5049.0
2053,"Patients randomly assigned to the 40K arm were more likely to have a > or = 2 or > or = 3 g/dL hemoglobin ( Hb ) increment , were more likely to have a drug dose held because of high",Hb,", and had higher mean end-of-study Hb levels .","['Patients', 'randomly', 'assigned', 'to', 'the', '40K', 'arm', 'were', 'more', 'likely', 'to', 'have', 'a', '>', 'or', '=', '2', 'or', '>', 'or', '=', '3', 'g/dL', 'hemoglobin', '(', 'Hb', ')', 'increment', ',', 'were', 'more', 'likely', 'to', 'have', 'a', 'drug', 'dose', 'held', 'because', 'of', 'high', 'Hb', ',', 'and', 'had', 'higher', 'mean', 'end-of-study', 'Hb', 'levels', '.']","(41, 42)","(182, 184)",-1,ss_o,16505427,Abstract,5,test,gold,1657.0
2054,"Patients randomly assigned to the 40K arm were more likely to have a > or = 2 or > or = 3 g/dL hemoglobin ( Hb ) increment , were more likely to have a drug dose held because of high Hb , and had higher mean end-of-study",Hb,levels .,"['Patients', 'randomly', 'assigned', 'to', 'the', '40K', 'arm', 'were', 'more', 'likely', 'to', 'have', 'a', '>', 'or', '=', '2', 'or', '>', 'or', '=', '3', 'g/dL', 'hemoglobin', '(', 'Hb', ')', 'increment', ',', 'were', 'more', 'likely', 'to', 'have', 'a', 'drug', 'dose', 'held', 'because', 'of', 'high', 'Hb', ',', 'and', 'had', 'higher', 'mean', 'end-of-study', 'Hb', 'levels', '.']","(48, 49)","(220, 222)",-1,ss_o,16505427,Abstract,5,test,gold,1658.0
2055,Patients randomly assigned to the 40K arm were more likely to have a > or = 2 or > or = 3 g/dL,hemoglobin ( Hb ) increment,", were more likely to have a drug dose held because of high Hb , and had higher mean end-of-study Hb levels .","['Patients', 'randomly', 'assigned', 'to', 'the', '40K', 'arm', 'were', 'more', 'likely', 'to', 'have', 'a', '>', 'or', '=', '2', 'or', '>', 'or', '=', '3', 'g/dL', 'hemoglobin', '(', 'Hb', ')', 'increment', ',', 'were', 'more', 'likely', 'to', 'have', 'a', 'drug', 'dose', 'held', 'because', 'of', 'high', 'Hb', ',', 'and', 'had', 'higher', 'mean', 'end-of-study', 'Hb', 'levels', '.']","(23, 28)","(94, 121)",-1,hl_o,16505427,Abstract,5,test,gold,1645.0
2056,"Patients randomly assigned to the 40K arm were more likely to have a > or = 2 or > or = 3 g/dL hemoglobin ( Hb ) increment , were more likely to have a",drug dose,"held because of high Hb , and had higher mean end-of-study Hb levels .","['Patients', 'randomly', 'assigned', 'to', 'the', '40K', 'arm', 'were', 'more', 'likely', 'to', 'have', 'a', '>', 'or', '=', '2', 'or', '>', 'or', '=', '3', 'g/dL', 'hemoglobin', '(', 'Hb', ')', 'increment', ',', 'were', 'more', 'likely', 'to', 'have', 'a', 'drug', 'dose', 'held', 'because', 'of', 'high', 'Hb', ',', 'and', 'had', 'higher', 'mean', 'end-of-study', 'Hb', 'levels', '.']","(35, 37)","(151, 160)",-1,hl_o,16505427,Abstract,5,test,gold,5050.0
2057,"Patients randomly assigned to the 40K arm were more likely to have a > or = 2 or > or = 3 g/dL hemoglobin ( Hb ) increment , were more likely to have a drug dose held because of high",Hb,", and had higher mean end-of-study Hb levels .","['Patients', 'randomly', 'assigned', 'to', 'the', '40K', 'arm', 'were', 'more', 'likely', 'to', 'have', 'a', '>', 'or', '=', '2', 'or', '>', 'or', '=', '3', 'g/dL', 'hemoglobin', '(', 'Hb', ')', 'increment', ',', 'were', 'more', 'likely', 'to', 'have', 'a', 'drug', 'dose', 'held', 'because', 'of', 'high', 'Hb', ',', 'and', 'had', 'higher', 'mean', 'end-of-study', 'Hb', 'levels', '.']","(41, 42)","(182, 184)",-1,hl_o,16505427,Abstract,5,test,gold,1656.0
2058,"Patients randomly assigned to the 40K arm were more likely to have a > or = 2 or > or = 3 g/dL hemoglobin ( Hb ) increment , were more likely to have a drug dose held because of high Hb , and had higher mean end-of-study",Hb,levels .,"['Patients', 'randomly', 'assigned', 'to', 'the', '40K', 'arm', 'were', 'more', 'likely', 'to', 'have', 'a', '>', 'or', '=', '2', 'or', '>', 'or', '=', '3', 'g/dL', 'hemoglobin', '(', 'Hb', ')', 'increment', ',', 'were', 'more', 'likely', 'to', 'have', 'a', 'drug', 'dose', 'held', 'because', 'of', 'high', 'Hb', ',', 'and', 'had', 'higher', 'mean', 'end-of-study', 'Hb', 'levels', '.']","(48, 49)","(220, 222)",-1,hl_o,16505427,Abstract,5,test,gold,1655.0
2059,,"Toxicities , including thromboembolism",", and overall survival were similar .","['Toxicities', ',', 'including', 'thromboembolism', ',', 'and', 'overall', 'survival', 'were', 'similar', '.']","(0, 4)","(0, 38)",-1,ss_o,16505427,Abstract,6,test,gold,5680.0
2060,"Toxicities , including thromboembolism , and",overall survival,were similar .,"['Toxicities', ',', 'including', 'thromboembolism', ',', 'and', 'overall', 'survival', 'were', 'similar', '.']","(6, 8)","(44, 60)",-1,ss_o,16505427,Abstract,6,test,gold,1973.0
2061,,Toxicities,", including thromboembolism , and overall survival were similar .","['Toxicities', ',', 'including', 'thromboembolism', ',', 'and', 'overall', 'survival', 'were', 'similar', '.']","(0, 1)","(0, 10)",-1,hl_o,16505427,Abstract,6,test,gold,65.0
2062,"Toxicities , including",thromboembolism,", and overall survival were similar .","['Toxicities', ',', 'including', 'thromboembolism', ',', 'and', 'overall', 'survival', 'were', 'similar', '.']","(3, 4)","(22, 37)",-1,hl_o,16505427,Abstract,6,test,gold,56.0
2063,"Toxicities , including thromboembolism , and",overall survival,were similar .,"['Toxicities', ',', 'including', 'thromboembolism', ',', 'and', 'overall', 'survival', 'were', 'similar', '.']","(6, 8)","(44, 60)",-1,hl_o,16505427,Abstract,6,test,gold,1972.0
2064,Patients in the 40K arm had a higher,global quality of life ( QOL ),"at baseline for unclear reasons , whereas patients in the 120K arm had a greater global QOL improvement during the study , so end-of-study QOL was equivalent .","['Patients', 'in', 'the', '40K', 'arm', 'had', 'a', 'higher', 'global', 'quality', 'of', 'life', '(', 'QOL', ')', 'at', 'baseline', 'for', 'unclear', 'reasons', ',', 'whereas', 'patients', 'in', 'the', '120K', 'arm', 'had', 'a', 'greater', 'global', 'QOL', 'improvement', 'during', 'the', 'study', ',', 'so', 'end-of-study', 'QOL', 'was', 'equivalent', '.']","(8, 15)","(36, 66)",-1,ss_o,16505427,Abstract,7,test,gold,1893.0
2065,"Patients in the 40K arm had a higher global quality of life ( QOL ) at baseline for unclear reasons , whereas patients in the 120K arm had a greater",global QOL,"improvement during the study , so end-of-study QOL was equivalent .","['Patients', 'in', 'the', '40K', 'arm', 'had', 'a', 'higher', 'global', 'quality', 'of', 'life', '(', 'QOL', ')', 'at', 'baseline', 'for', 'unclear', 'reasons', ',', 'whereas', 'patients', 'in', 'the', '120K', 'arm', 'had', 'a', 'greater', 'global', 'QOL', 'improvement', 'during', 'the', 'study', ',', 'so', 'end-of-study', 'QOL', 'was', 'equivalent', '.']","(30, 32)","(148, 158)",-1,ss_o,16505427,Abstract,7,test,gold,371.0
2066,"Patients in the 40K arm had a higher global quality of life ( QOL ) at baseline for unclear reasons , whereas patients in the 120K arm had a greater global QOL improvement during the study , so end-of-study",QOL,was equivalent .,"['Patients', 'in', 'the', '40K', 'arm', 'had', 'a', 'higher', 'global', 'quality', 'of', 'life', '(', 'QOL', ')', 'at', 'baseline', 'for', 'unclear', 'reasons', ',', 'whereas', 'patients', 'in', 'the', '120K', 'arm', 'had', 'a', 'greater', 'global', 'QOL', 'improvement', 'during', 'the', 'study', ',', 'so', 'end-of-study', 'QOL', 'was', 'equivalent', '.']","(39, 40)","(206, 209)",-1,ss_o,16505427,Abstract,7,test,gold,369.0
2067,Patients in the 40K arm had a higher,global quality of life ( QOL ),"at baseline for unclear reasons , whereas patients in the 120K arm had a greater global QOL improvement during the study , so end-of-study QOL was equivalent .","['Patients', 'in', 'the', '40K', 'arm', 'had', 'a', 'higher', 'global', 'quality', 'of', 'life', '(', 'QOL', ')', 'at', 'baseline', 'for', 'unclear', 'reasons', ',', 'whereas', 'patients', 'in', 'the', '120K', 'arm', 'had', 'a', 'greater', 'global', 'QOL', 'improvement', 'during', 'the', 'study', ',', 'so', 'end-of-study', 'QOL', 'was', 'equivalent', '.']","(8, 15)","(36, 66)",-1,hl_o,16505427,Abstract,7,test,gold,1894.0
2068,"Patients in the 40K arm had a higher global quality of life ( QOL ) at baseline for unclear reasons , whereas patients in the 120K arm had a greater",global QOL,"improvement during the study , so end-of-study QOL was equivalent .","['Patients', 'in', 'the', '40K', 'arm', 'had', 'a', 'higher', 'global', 'quality', 'of', 'life', '(', 'QOL', ')', 'at', 'baseline', 'for', 'unclear', 'reasons', ',', 'whereas', 'patients', 'in', 'the', '120K', 'arm', 'had', 'a', 'greater', 'global', 'QOL', 'improvement', 'during', 'the', 'study', ',', 'so', 'end-of-study', 'QOL', 'was', 'equivalent', '.']","(30, 32)","(148, 158)",-1,hl_o,16505427,Abstract,7,test,gold,372.0
2069,"Patients in the 40K arm had a higher global quality of life ( QOL ) at baseline for unclear reasons , whereas patients in the 120K arm had a greater global QOL improvement during the study , so end-of-study",QOL,was equivalent .,"['Patients', 'in', 'the', '40K', 'arm', 'had', 'a', 'higher', 'global', 'quality', 'of', 'life', '(', 'QOL', ')', 'at', 'baseline', 'for', 'unclear', 'reasons', ',', 'whereas', 'patients', 'in', 'the', '120K', 'arm', 'had', 'a', 'greater', 'global', 'QOL', 'improvement', 'during', 'the', 'study', ',', 'so', 'end-of-study', 'QOL', 'was', 'equivalent', '.']","(39, 40)","(206, 209)",-1,hl_o,16505427,Abstract,7,test,gold,370.0
2070,CONCLUSION After three weekly doses of,epoetin alfa,"40,000 U , a dose of 120,000 U can be administered safely once every 3 weeks without increasing transfusion needs or sacrificing QOL .","['CONCLUSION', 'After', 'three', 'weekly', 'doses', 'of', 'epoetin', 'alfa', '40,000', 'U', ',', 'a', 'dose', 'of', '120,000', 'U', 'can', 'be', 'administered', 'safely', 'once', 'every', '3', 'weeks', 'without', 'increasing', 'transfusion', 'needs', 'or', 'sacrificing', 'QOL', '.']","(6, 8)","(38, 50)",-1,ss_i,16505427,Abstract,8,test,gold,5189.0
2071,"CONCLUSION After three weekly doses of epoetin alfa 40,000 U , a dose of 120,000 U can be administered",safely,once every 3 weeks without increasing transfusion needs or sacrificing QOL .,"['CONCLUSION', 'After', 'three', 'weekly', 'doses', 'of', 'epoetin', 'alfa', '40,000', 'U', ',', 'a', 'dose', 'of', '120,000', 'U', 'can', 'be', 'administered', 'safely', 'once', 'every', '3', 'weeks', 'without', 'increasing', 'transfusion', 'needs', 'or', 'sacrificing', 'QOL', '.']","(19, 20)","(102, 108)",-1,ss_o,16505427,Abstract,8,test,gold,876.0
2072,"CONCLUSION After three weekly doses of epoetin alfa 40,000 U , a dose of 120,000 U can be administered safely once every 3 weeks without increasing",transfusion needs,or sacrificing QOL .,"['CONCLUSION', 'After', 'three', 'weekly', 'doses', 'of', 'epoetin', 'alfa', '40,000', 'U', ',', 'a', 'dose', 'of', '120,000', 'U', 'can', 'be', 'administered', 'safely', 'once', 'every', '3', 'weeks', 'without', 'increasing', 'transfusion', 'needs', 'or', 'sacrificing', 'QOL', '.']","(26, 28)","(147, 164)",-1,ss_o,16505427,Abstract,8,test,gold,4153.0
2073,"CONCLUSION After three weekly doses of epoetin alfa 40,000 U , a dose of 120,000 U can be administered safely once every 3 weeks without increasing transfusion needs or sacrificing",QOL .,,"['CONCLUSION', 'After', 'three', 'weekly', 'doses', 'of', 'epoetin', 'alfa', '40,000', 'U', ',', 'a', 'dose', 'of', '120,000', 'U', 'can', 'be', 'administered', 'safely', 'once', 'every', '3', 'weeks', 'without', 'increasing', 'transfusion', 'needs', 'or', 'sacrificing', 'QOL', '.']","(30, 32)","(180, 185)",-1,ss_o,16505427,Abstract,8,test,gold,368.0
2074,CONCLUSION After three weekly doses of,epoetin alfa,"40,000 U , a dose of 120,000 U can be administered safely once every 3 weeks without increasing transfusion needs or sacrificing QOL .","['CONCLUSION', 'After', 'three', 'weekly', 'doses', 'of', 'epoetin', 'alfa', '40,000', 'U', ',', 'a', 'dose', 'of', '120,000', 'U', 'can', 'be', 'administered', 'safely', 'once', 'every', '3', 'weeks', 'without', 'increasing', 'transfusion', 'needs', 'or', 'sacrificing', 'QOL', '.']","(6, 8)","(38, 50)",-1,hl_i,16505427,Abstract,8,test,gold,5188.0
2075,"CONCLUSION After three weekly doses of epoetin alfa 40,000 U , a dose of 120,000 U can be administered safely once every 3 weeks without increasing",transfusion needs,or sacrificing QOL .,"['CONCLUSION', 'After', 'three', 'weekly', 'doses', 'of', 'epoetin', 'alfa', '40,000', 'U', ',', 'a', 'dose', 'of', '120,000', 'U', 'can', 'be', 'administered', 'safely', 'once', 'every', '3', 'weeks', 'without', 'increasing', 'transfusion', 'needs', 'or', 'sacrificing', 'QOL', '.']","(26, 28)","(147, 164)",-1,hl_o,16505427,Abstract,8,test,gold,4154.0
2076,"CONCLUSION After three weekly doses of epoetin alfa 40,000 U , a dose of 120,000 U can be administered safely once every 3 weeks without increasing transfusion needs or sacrificing",QOL .,,"['CONCLUSION', 'After', 'three', 'weekly', 'doses', 'of', 'epoetin', 'alfa', '40,000', 'U', ',', 'a', 'dose', 'of', '120,000', 'U', 'can', 'be', 'administered', 'safely', 'once', 'every', '3', 'weeks', 'without', 'increasing', 'transfusion', 'needs', 'or', 'sacrificing', 'QOL', '.']","(30, 32)","(180, 185)",-1,hl_o,16505427,Abstract,8,test,gold,367.0
2077,The Hb increment is somewhat greater with continued weekly,epoetin alfa .,,"['The', 'Hb', 'increment', 'is', 'somewhat', 'greater', 'with', 'continued', 'weekly', 'epoetin', 'alfa', '.']","(9, 12)","(58, 72)",-1,ss_i,16505427,Abstract,9,test,gold,5187.0
2078,The,Hb increment,is somewhat greater with continued weekly epoetin alfa .,"['The', 'Hb', 'increment', 'is', 'somewhat', 'greater', 'with', 'continued', 'weekly', 'epoetin', 'alfa', '.']","(1, 3)","(3, 15)",-1,ss_o,16505427,Abstract,9,test,gold,1652.0
2079,The Hb increment is somewhat greater with continued weekly,epoetin alfa .,,"['The', 'Hb', 'increment', 'is', 'somewhat', 'greater', 'with', 'continued', 'weekly', 'epoetin', 'alfa', '.']","(9, 12)","(58, 72)",-1,hl_i,16505427,Abstract,9,test,gold,5186.0
2080,The,Hb increment,is somewhat greater with continued weekly epoetin alfa .,"['The', 'Hb', 'increment', 'is', 'somewhat', 'greater', 'with', 'continued', 'weekly', 'epoetin', 'alfa', '.']","(1, 3)","(3, 15)",-1,hl_o,16505427,Abstract,9,test,gold,1653.0
2081,Lack of blinding as a result of different treatment schedules may have confounded results .,,,"['Lack', 'of', 'blinding', 'as', 'a', 'result', 'of', 'different', 'treatment', 'schedules', 'may', 'have', 'confounded', 'results', '.']",,,,,16505427,Abstract,10,test,gold,
2082,Local immunotherapy by inhalation of a powder extract in,asthma due to house dust mite Dermatophagoides pteronyssinus :,a double-blind comparison with parenteral immunotherapy .,"['Local', 'immunotherapy', 'by', 'inhalation', 'of', 'a', 'powder', 'extract', 'in', 'asthma', 'due', 'to', 'house', 'dust', 'mite', 'Dermatophagoides', 'pteronyssinus', ':', 'a', 'double-blind', 'comparison', 'with', 'parenteral', 'immunotherapy', '.']","(9, 18)","(56, 118)",-1,ss_p,1669598,Title,0,test,gold,4527.0
2083,Local,immunotherapy,by inhalation of a powder extract in asthma due to house dust mite Dermatophagoides pteronyssinus : a double-blind comparison with parenteral immunotherapy .,"['Local', 'immunotherapy', 'by', 'inhalation', 'of', 'a', 'powder', 'extract', 'in', 'asthma', 'due', 'to', 'house', 'dust', 'mite', 'Dermatophagoides', 'pteronyssinus', ':', 'a', 'double-blind', 'comparison', 'with', 'parenteral', 'immunotherapy', '.']","(1, 2)","(5, 18)",-1,hl_i,1669598,Title,0,test,gold,5657.0
2084,Local immunotherapy by inhalation of a powder extract in asthma due to house dust mite Dermatophagoides pteronyssinus : a double-blind comparison with parenteral,immunotherapy,.,"['Local', 'immunotherapy', 'by', 'inhalation', 'of', 'a', 'powder', 'extract', 'in', 'asthma', 'due', 'to', 'house', 'dust', 'mite', 'Dermatophagoides', 'pteronyssinus', ':', 'a', 'double-blind', 'comparison', 'with', 'parenteral', 'immunotherapy', '.']","(23, 24)","(161, 174)",-1,hl_i,1669598,Title,0,test,gold,5658.0
2085,"To verify the efficacy and the tolerability of local immunotherapy ( LI ) by inhalation of a powder extract of house dust mite ( HDM ) , in comparison with parenteral immunotherapy ( PI ) by injection ,",10 patients with asthma due to HDM,were studied in a blind fashion .,"['To', 'verify', 'the', 'efficacy', 'and', 'the', 'tolerability', 'of', 'local', 'immunotherapy', '(', 'LI', ')', 'by', 'inhalation', 'of', 'a', 'powder', 'extract', 'of', 'house', 'dust', 'mite', '(', 'HDM', ')', ',', 'in', 'comparison', 'with', 'parenteral', 'immunotherapy', '(', 'PI', ')', 'by', 'injection', ',', '10', 'patients', 'with', 'asthma', 'due', 'to', 'HDM', 'were', 'studied', 'in', 'a', 'blind', 'fashion', '.']","(38, 45)","(202, 236)",-1,ss_p,1669598,Abstract,0,test,gold,3809.0
2086,To verify the efficacy and the tolerability of,local immunotherapy,"( LI ) by inhalation of a powder extract of house dust mite ( HDM ) , in comparison with parenteral immunotherapy ( PI ) by injection , 10 patients with asthma due to HDM were studied in a blind fashion .","['To', 'verify', 'the', 'efficacy', 'and', 'the', 'tolerability', 'of', 'local', 'immunotherapy', '(', 'LI', ')', 'by', 'inhalation', 'of', 'a', 'powder', 'extract', 'of', 'house', 'dust', 'mite', '(', 'HDM', ')', ',', 'in', 'comparison', 'with', 'parenteral', 'immunotherapy', '(', 'PI', ')', 'by', 'injection', ',', '10', 'patients', 'with', 'asthma', 'due', 'to', 'HDM', 'were', 'studied', 'in', 'a', 'blind', 'fashion', '.']","(8, 10)","(46, 65)",-1,ss_i,1669598,Abstract,0,test,gold,5659.0
2087,To verify the efficacy and the tolerability of local immunotherapy ( LI ) by inhalation of a,powder extract of house dust mite ( HDM ),", in comparison with parenteral immunotherapy ( PI ) by injection , 10 patients with asthma due to HDM were studied in a blind fashion .","['To', 'verify', 'the', 'efficacy', 'and', 'the', 'tolerability', 'of', 'local', 'immunotherapy', '(', 'LI', ')', 'by', 'inhalation', 'of', 'a', 'powder', 'extract', 'of', 'house', 'dust', 'mite', '(', 'HDM', ')', ',', 'in', 'comparison', 'with', 'parenteral', 'immunotherapy', '(', 'PI', ')', 'by', 'injection', ',', '10', 'patients', 'with', 'asthma', 'due', 'to', 'HDM', 'were', 'studied', 'in', 'a', 'blind', 'fashion', '.']","(17, 26)","(92, 133)",-1,ss_i,1669598,Abstract,0,test,gold,4528.0
2088,"To verify the efficacy and the tolerability of local immunotherapy ( LI ) by inhalation of a powder extract of house dust mite ( HDM ) , in comparison with",parenteral immunotherapy ( PI ),"by injection , 10 patients with asthma due to HDM were studied in a blind fashion .","['To', 'verify', 'the', 'efficacy', 'and', 'the', 'tolerability', 'of', 'local', 'immunotherapy', '(', 'LI', ')', 'by', 'inhalation', 'of', 'a', 'powder', 'extract', 'of', 'house', 'dust', 'mite', '(', 'HDM', ')', ',', 'in', 'comparison', 'with', 'parenteral', 'immunotherapy', '(', 'PI', ')', 'by', 'injection', ',', '10', 'patients', 'with', 'asthma', 'due', 'to', 'HDM', 'were', 'studied', 'in', 'a', 'blind', 'fashion', '.']","(30, 35)","(155, 186)",-1,ss_i,1669598,Abstract,0,test,gold,5655.0
2089,To verify the,efficacy,"and the tolerability of local immunotherapy ( LI ) by inhalation of a powder extract of house dust mite ( HDM ) , in comparison with parenteral immunotherapy ( PI ) by injection , 10 patients with asthma due to HDM were studied in a blind fashion .","['To', 'verify', 'the', 'efficacy', 'and', 'the', 'tolerability', 'of', 'local', 'immunotherapy', '(', 'LI', ')', 'by', 'inhalation', 'of', 'a', 'powder', 'extract', 'of', 'house', 'dust', 'mite', '(', 'HDM', ')', ',', 'in', 'comparison', 'with', 'parenteral', 'immunotherapy', '(', 'PI', ')', 'by', 'injection', ',', '10', 'patients', 'with', 'asthma', 'due', 'to', 'HDM', 'were', 'studied', 'in', 'a', 'blind', 'fashion', '.']","(3, 4)","(13, 21)",-1,ss_o,1669598,Abstract,0,test,gold,4829.0
2090,To verify the efficacy and the,tolerability,"of local immunotherapy ( LI ) by inhalation of a powder extract of house dust mite ( HDM ) , in comparison with parenteral immunotherapy ( PI ) by injection , 10 patients with asthma due to HDM were studied in a blind fashion .","['To', 'verify', 'the', 'efficacy', 'and', 'the', 'tolerability', 'of', 'local', 'immunotherapy', '(', 'LI', ')', 'by', 'inhalation', 'of', 'a', 'powder', 'extract', 'of', 'house', 'dust', 'mite', '(', 'HDM', ')', ',', 'in', 'comparison', 'with', 'parenteral', 'immunotherapy', '(', 'PI', ')', 'by', 'injection', ',', '10', 'patients', 'with', 'asthma', 'due', 'to', 'HDM', 'were', 'studied', 'in', 'a', 'blind', 'fashion', '.']","(6, 7)","(30, 42)",-1,ss_o,1669598,Abstract,0,test,gold,4869.0
2091,"To verify the efficacy and the tolerability of local immunotherapy ( LI ) by inhalation of a powder extract of house dust mite ( HDM ) , in comparison with parenteral immunotherapy ( PI ) by injection ,",10 patients with asthma due to HDM,were studied in a blind fashion .,"['To', 'verify', 'the', 'efficacy', 'and', 'the', 'tolerability', 'of', 'local', 'immunotherapy', '(', 'LI', ')', 'by', 'inhalation', 'of', 'a', 'powder', 'extract', 'of', 'house', 'dust', 'mite', '(', 'HDM', ')', ',', 'in', 'comparison', 'with', 'parenteral', 'immunotherapy', '(', 'PI', ')', 'by', 'injection', ',', '10', 'patients', 'with', 'asthma', 'due', 'to', 'HDM', 'were', 'studied', 'in', 'a', 'blind', 'fashion', '.']","(38, 45)","(202, 236)",-1,hl_p,1669598,Abstract,0,test,gold,3810.0
2092,To verify the efficacy and the tolerability of,local immunotherapy,"( LI ) by inhalation of a powder extract of house dust mite ( HDM ) , in comparison with parenteral immunotherapy ( PI ) by injection , 10 patients with asthma due to HDM were studied in a blind fashion .","['To', 'verify', 'the', 'efficacy', 'and', 'the', 'tolerability', 'of', 'local', 'immunotherapy', '(', 'LI', ')', 'by', 'inhalation', 'of', 'a', 'powder', 'extract', 'of', 'house', 'dust', 'mite', '(', 'HDM', ')', ',', 'in', 'comparison', 'with', 'parenteral', 'immunotherapy', '(', 'PI', ')', 'by', 'injection', ',', '10', 'patients', 'with', 'asthma', 'due', 'to', 'HDM', 'were', 'studied', 'in', 'a', 'blind', 'fashion', '.']","(8, 10)","(46, 65)",-1,hl_i,1669598,Abstract,0,test,gold,5660.0
2093,To verify the efficacy and the tolerability of local immunotherapy ( LI ) by inhalation of a,powder extract of house dust mite ( HDM ),", in comparison with parenteral immunotherapy ( PI ) by injection , 10 patients with asthma due to HDM were studied in a blind fashion .","['To', 'verify', 'the', 'efficacy', 'and', 'the', 'tolerability', 'of', 'local', 'immunotherapy', '(', 'LI', ')', 'by', 'inhalation', 'of', 'a', 'powder', 'extract', 'of', 'house', 'dust', 'mite', '(', 'HDM', ')', ',', 'in', 'comparison', 'with', 'parenteral', 'immunotherapy', '(', 'PI', ')', 'by', 'injection', ',', '10', 'patients', 'with', 'asthma', 'due', 'to', 'HDM', 'were', 'studied', 'in', 'a', 'blind', 'fashion', '.']","(17, 26)","(92, 133)",-1,hl_i,1669598,Abstract,0,test,gold,4529.0
2094,"To verify the efficacy and the tolerability of local immunotherapy ( LI ) by inhalation of a powder extract of house dust mite ( HDM ) , in comparison with",parenteral immunotherapy ( PI ),"by injection , 10 patients with asthma due to HDM were studied in a blind fashion .","['To', 'verify', 'the', 'efficacy', 'and', 'the', 'tolerability', 'of', 'local', 'immunotherapy', '(', 'LI', ')', 'by', 'inhalation', 'of', 'a', 'powder', 'extract', 'of', 'house', 'dust', 'mite', '(', 'HDM', ')', ',', 'in', 'comparison', 'with', 'parenteral', 'immunotherapy', '(', 'PI', ')', 'by', 'injection', ',', '10', 'patients', 'with', 'asthma', 'due', 'to', 'HDM', 'were', 'studied', 'in', 'a', 'blind', 'fashion', '.']","(30, 35)","(155, 186)",-1,hl_i,1669598,Abstract,0,test,gold,5656.0
2095,To verify the,efficacy,"and the tolerability of local immunotherapy ( LI ) by inhalation of a powder extract of house dust mite ( HDM ) , in comparison with parenteral immunotherapy ( PI ) by injection , 10 patients with asthma due to HDM were studied in a blind fashion .","['To', 'verify', 'the', 'efficacy', 'and', 'the', 'tolerability', 'of', 'local', 'immunotherapy', '(', 'LI', ')', 'by', 'inhalation', 'of', 'a', 'powder', 'extract', 'of', 'house', 'dust', 'mite', '(', 'HDM', ')', ',', 'in', 'comparison', 'with', 'parenteral', 'immunotherapy', '(', 'PI', ')', 'by', 'injection', ',', '10', 'patients', 'with', 'asthma', 'due', 'to', 'HDM', 'were', 'studied', 'in', 'a', 'blind', 'fashion', '.']","(3, 4)","(13, 21)",-1,hl_o,1669598,Abstract,0,test,gold,4828.0
2096,To verify the efficacy and the,tolerability,"of local immunotherapy ( LI ) by inhalation of a powder extract of house dust mite ( HDM ) , in comparison with parenteral immunotherapy ( PI ) by injection , 10 patients with asthma due to HDM were studied in a blind fashion .","['To', 'verify', 'the', 'efficacy', 'and', 'the', 'tolerability', 'of', 'local', 'immunotherapy', '(', 'LI', ')', 'by', 'inhalation', 'of', 'a', 'powder', 'extract', 'of', 'house', 'dust', 'mite', '(', 'HDM', ')', ',', 'in', 'comparison', 'with', 'parenteral', 'immunotherapy', '(', 'PI', ')', 'by', 'injection', ',', '10', 'patients', 'with', 'asthma', 'due', 'to', 'HDM', 'were', 'studied', 'in', 'a', 'blind', 'fashion', '.']","(6, 7)","(30, 42)",-1,hl_o,1669598,Abstract,0,test,gold,4868.0
2097,5 patients ( Group A ) underwent LI and subcutaneous injections of,placebo,", 5 patients ( Group B ) underwent PI and inhalation of lactose for 6 months .","['5', 'patients', '(', 'Group', 'A', ')', 'underwent', 'LI', 'and', 'subcutaneous', 'injections', 'of', 'placebo', ',', '5', 'patients', '(', 'Group', 'B', ')', 'underwent', 'PI', 'and', 'inhalation', 'of', 'lactose', 'for', '6', 'months', '.']","(12, 13)","(66, 73)",-1,ss_i,1669598,Abstract,1,test,gold,4387.0
2098,"5 patients ( Group A ) underwent LI and subcutaneous injections of placebo , 5 patients ( Group B ) underwent PI and inhalation of",lactose,for 6 months .,"['5', 'patients', '(', 'Group', 'A', ')', 'underwent', 'LI', 'and', 'subcutaneous', 'injections', 'of', 'placebo', ',', '5', 'patients', '(', 'Group', 'B', ')', 'underwent', 'PI', 'and', 'inhalation', 'of', 'lactose', 'for', '6', 'months', '.']","(25, 26)","(130, 137)",-1,ss_i,1669598,Abstract,1,test,gold,228.0
2099,5 patients ( Group A ) underwent LI and subcutaneous injections of,placebo,", 5 patients ( Group B ) underwent PI and inhalation of lactose for 6 months .","['5', 'patients', '(', 'Group', 'A', ')', 'underwent', 'LI', 'and', 'subcutaneous', 'injections', 'of', 'placebo', ',', '5', 'patients', '(', 'Group', 'B', ')', 'underwent', 'PI', 'and', 'inhalation', 'of', 'lactose', 'for', '6', 'months', '.']","(12, 13)","(66, 73)",-1,hl_i,1669598,Abstract,1,test,gold,4386.0
2100,"5 patients ( Group A ) underwent LI and subcutaneous injections of placebo , 5 patients ( Group B ) underwent PI and inhalation of",lactose,for 6 months .,"['5', 'patients', '(', 'Group', 'A', ')', 'underwent', 'LI', 'and', 'subcutaneous', 'injections', 'of', 'placebo', ',', '5', 'patients', '(', 'Group', 'B', ')', 'underwent', 'PI', 'and', 'inhalation', 'of', 'lactose', 'for', '6', 'months', '.']","(25, 26)","(130, 137)",-1,hl_i,1669598,Abstract,1,test,gold,229.0
2101,In both groups each inhalation was preceded by premedication with,disodium cromoglycate ( DSCG ),( 40 mg ) .,"['In', 'both', 'groups', 'each', 'inhalation', 'was', 'preceded', 'by', 'premedication', 'with', 'disodium', 'cromoglycate', '(', 'DSCG', ')', '(', '40', 'mg', ')', '.']","(10, 15)","(65, 95)",-1,ss_i,1669598,Abstract,2,test,gold,147.0
2102,In both groups each inhalation was preceded by premedication with,disodium cromoglycate ( DSCG ),( 40 mg ) .,"['In', 'both', 'groups', 'each', 'inhalation', 'was', 'preceded', 'by', 'premedication', 'with', 'disodium', 'cromoglycate', '(', 'DSCG', ')', '(', '40', 'mg', ')', '.']","(10, 15)","(65, 95)",-1,hl_i,1669598,Abstract,2,test,gold,148.0
2103,In Group A a significant decrease in,symptoms score,"and in peak expiratory flow ( PEF ) -derived parameters was observed already after 3 months of treatment , and 2 patients lost the late component of the bronchial response to the challenge with HDM .","['In', 'Group', 'A', 'a', 'significant', 'decrease', 'in', 'symptoms', 'score', 'and', 'in', 'peak', 'expiratory', 'flow', '(', 'PEF', ')', '-derived', 'parameters', 'was', 'observed', 'already', 'after', '3', 'months', 'of', 'treatment', ',', 'and', '2', 'patients', 'lost', 'the', 'late', 'component', 'of', 'the', 'bronchial', 'response', 'to', 'the', 'challenge', 'with', 'HDM', '.']","(7, 9)","(36, 50)",-1,ss_o,1669598,Abstract,3,test,gold,3268.0
2104,In Group A a significant decrease in symptoms score and in,peak expiratory flow ( PEF ) -derived parameters,"was observed already after 3 months of treatment , and 2 patients lost the late component of the bronchial response to the challenge with HDM .","['In', 'Group', 'A', 'a', 'significant', 'decrease', 'in', 'symptoms', 'score', 'and', 'in', 'peak', 'expiratory', 'flow', '(', 'PEF', ')', '-derived', 'parameters', 'was', 'observed', 'already', 'after', '3', 'months', 'of', 'treatment', ',', 'and', '2', 'patients', 'lost', 'the', 'late', 'component', 'of', 'the', 'bronchial', 'response', 'to', 'the', 'challenge', 'with', 'HDM', '.']","(11, 19)","(58, 106)",-1,ss_o,1669598,Abstract,3,test,gold,1736.0
2105,"In Group A a significant decrease in symptoms score and in peak expiratory flow ( PEF ) -derived parameters was observed already after 3 months of treatment , and 2 patients lost the late component of the",bronchial response,to the challenge with HDM .,"['In', 'Group', 'A', 'a', 'significant', 'decrease', 'in', 'symptoms', 'score', 'and', 'in', 'peak', 'expiratory', 'flow', '(', 'PEF', ')', '-derived', 'parameters', 'was', 'observed', 'already', 'after', '3', 'months', 'of', 'treatment', ',', 'and', '2', 'patients', 'lost', 'the', 'late', 'component', 'of', 'the', 'bronchial', 'response', 'to', 'the', 'challenge', 'with', 'HDM', '.']","(37, 39)","(204, 222)",-1,ss_o,1669598,Abstract,3,test,gold,2509.0
2106,In Group A a significant decrease in,symptoms score,"and in peak expiratory flow ( PEF ) -derived parameters was observed already after 3 months of treatment , and 2 patients lost the late component of the bronchial response to the challenge with HDM .","['In', 'Group', 'A', 'a', 'significant', 'decrease', 'in', 'symptoms', 'score', 'and', 'in', 'peak', 'expiratory', 'flow', '(', 'PEF', ')', '-derived', 'parameters', 'was', 'observed', 'already', 'after', '3', 'months', 'of', 'treatment', ',', 'and', '2', 'patients', 'lost', 'the', 'late', 'component', 'of', 'the', 'bronchial', 'response', 'to', 'the', 'challenge', 'with', 'HDM', '.']","(7, 9)","(36, 50)",-1,hl_o,1669598,Abstract,3,test,gold,3269.0
2107,In Group A a significant decrease in symptoms score and in,peak expiratory flow ( PEF ) -derived parameters,"was observed already after 3 months of treatment , and 2 patients lost the late component of the bronchial response to the challenge with HDM .","['In', 'Group', 'A', 'a', 'significant', 'decrease', 'in', 'symptoms', 'score', 'and', 'in', 'peak', 'expiratory', 'flow', '(', 'PEF', ')', '-derived', 'parameters', 'was', 'observed', 'already', 'after', '3', 'months', 'of', 'treatment', ',', 'and', '2', 'patients', 'lost', 'the', 'late', 'component', 'of', 'the', 'bronchial', 'response', 'to', 'the', 'challenge', 'with', 'HDM', '.']","(11, 19)","(58, 106)",-1,hl_o,1669598,Abstract,3,test,gold,1737.0
2108,"In Group A a significant decrease in symptoms score and in peak expiratory flow ( PEF ) -derived parameters was observed already after 3 months of treatment , and 2 patients lost the late component of the",bronchial response,to the challenge with HDM .,"['In', 'Group', 'A', 'a', 'significant', 'decrease', 'in', 'symptoms', 'score', 'and', 'in', 'peak', 'expiratory', 'flow', '(', 'PEF', ')', '-derived', 'parameters', 'was', 'observed', 'already', 'after', '3', 'months', 'of', 'treatment', ',', 'and', '2', 'patients', 'lost', 'the', 'late', 'component', 'of', 'the', 'bronchial', 'response', 'to', 'the', 'challenge', 'with', 'HDM', '.']","(37, 39)","(204, 222)",-1,hl_o,1669598,Abstract,3,test,gold,2510.0
2109,No significant variation was found in,bronchial responsiveness,to methacholine and ultrasonically nebulized distilled water ( UNDW ) and in immunologic humoral and cellular parameters in peripheral blood after treatment in either group .,"['No', 'significant', 'variation', 'was', 'found', 'in', 'bronchial', 'responsiveness', 'to', 'methacholine', 'and', 'ultrasonically', 'nebulized', 'distilled', 'water', '(', 'UNDW', ')', 'and', 'in', 'immunologic', 'humoral', 'and', 'cellular', 'parameters', 'in', 'peripheral', 'blood', 'after', 'treatment', 'in', 'either', 'group', '.']","(6, 8)","(37, 61)",-1,ss_o,1669598,Abstract,4,test,gold,2511.0
2110,No significant variation was found in bronchial responsiveness to methacholine and ultrasonically nebulized distilled water ( UNDW ) and in,immunologic humoral and cellular parameters in peripheral blood,after treatment in either group .,"['No', 'significant', 'variation', 'was', 'found', 'in', 'bronchial', 'responsiveness', 'to', 'methacholine', 'and', 'ultrasonically', 'nebulized', 'distilled', 'water', '(', 'UNDW', ')', 'and', 'in', 'immunologic', 'humoral', 'and', 'cellular', 'parameters', 'in', 'peripheral', 'blood', 'after', 'treatment', 'in', 'either', 'group', '.']","(20, 28)","(139, 202)",-1,ss_o,1669598,Abstract,4,test,gold,6540.0
2111,No significant variation was found in,bronchial responsiveness,to methacholine and ultrasonically nebulized distilled water ( UNDW ) and in immunologic humoral and cellular parameters in peripheral blood after treatment in either group .,"['No', 'significant', 'variation', 'was', 'found', 'in', 'bronchial', 'responsiveness', 'to', 'methacholine', 'and', 'ultrasonically', 'nebulized', 'distilled', 'water', '(', 'UNDW', ')', 'and', 'in', 'immunologic', 'humoral', 'and', 'cellular', 'parameters', 'in', 'peripheral', 'blood', 'after', 'treatment', 'in', 'either', 'group', '.']","(6, 8)","(37, 61)",-1,hl_o,1669598,Abstract,4,test,gold,2512.0
2112,No significant variation was found in bronchial responsiveness to methacholine and ultrasonically nebulized distilled water ( UNDW ) and in,immunologic humoral and cellular parameters in peripheral blood,after treatment in either group .,"['No', 'significant', 'variation', 'was', 'found', 'in', 'bronchial', 'responsiveness', 'to', 'methacholine', 'and', 'ultrasonically', 'nebulized', 'distilled', 'water', '(', 'UNDW', ')', 'and', 'in', 'immunologic', 'humoral', 'and', 'cellular', 'parameters', 'in', 'peripheral', 'blood', 'after', 'treatment', 'in', 'either', 'group', '.']","(20, 28)","(139, 202)",-1,hl_o,1669598,Abstract,4,test,gold,6541.0
2113,No,local important adverse reactions,were observed in Group A and no systemic side effects were observed in either group .,"['No', 'local', 'important', 'adverse', 'reactions', 'were', 'observed', 'in', 'Group', 'A', 'and', 'no', 'systemic', 'side', 'effects', 'were', 'observed', 'in', 'either', 'group', '.']","(1, 5)","(2, 35)",-1,ss_o,1669598,Abstract,5,test,gold,3036.0
2114,No local important adverse reactions were observed in Group A and no,systemic side effects,were observed in either group .,"['No', 'local', 'important', 'adverse', 'reactions', 'were', 'observed', 'in', 'Group', 'A', 'and', 'no', 'systemic', 'side', 'effects', 'were', 'observed', 'in', 'either', 'group', '.']","(12, 15)","(68, 89)",-1,ss_o,1669598,Abstract,5,test,gold,2362.0
2115,No,local important adverse reactions,were observed in Group A and no systemic side effects were observed in either group .,"['No', 'local', 'important', 'adverse', 'reactions', 'were', 'observed', 'in', 'Group', 'A', 'and', 'no', 'systemic', 'side', 'effects', 'were', 'observed', 'in', 'either', 'group', '.']","(1, 5)","(2, 35)",-1,hl_o,1669598,Abstract,5,test,gold,3037.0
2116,No local important adverse reactions were observed in Group A and no,systemic side effects,were observed in either group .,"['No', 'local', 'important', 'adverse', 'reactions', 'were', 'observed', 'in', 'Group', 'A', 'and', 'no', 'systemic', 'side', 'effects', 'were', 'observed', 'in', 'either', 'group', '.']","(12, 15)","(68, 89)",-1,hl_o,1669598,Abstract,5,test,gold,2363.0
2117,"We conclude that LI is as effective as PI , but more rapid in its action , in the treatment of",asthma due to HDM .,,"['We', 'conclude', 'that', 'LI', 'is', 'as', 'effective', 'as', 'PI', ',', 'but', 'more', 'rapid', 'in', 'its', 'action', ',', 'in', 'the', 'treatment', 'of', 'asthma', 'due', 'to', 'HDM', '.']","(21, 26)","(94, 113)",-1,ss_p,1669598,Abstract,6,test,gold,3808.0
2118,We conclude that LI is as,effective,"as PI , but more rapid in its action , in the treatment of asthma due to HDM .","['We', 'conclude', 'that', 'LI', 'is', 'as', 'effective', 'as', 'PI', ',', 'but', 'more', 'rapid', 'in', 'its', 'action', ',', 'in', 'the', 'treatment', 'of', 'asthma', 'due', 'to', 'HDM', '.']","(6, 7)","(25, 34)",-1,ss_o,1669598,Abstract,6,test,gold,855.0
2119,"Moreover , LI is locally well tolerated , providing",DSCG,"is inhaled before each therapeutic inhalation , and does not induce systemic side effects .","['Moreover', ',', 'LI', 'is', 'locally', 'well', 'tolerated', ',', 'providing', 'DSCG', 'is', 'inhaled', 'before', 'each', 'therapeutic', 'inhalation', ',', 'and', 'does', 'not', 'induce', 'systemic', 'side', 'effects', '.']","(9, 10)","(51, 55)",-1,ss_i,1669598,Abstract,7,test,gold,
2120,"Moreover , LI is locally well",tolerated,", providing DSCG is inhaled before each therapeutic inhalation , and does not induce systemic side effects .","['Moreover', ',', 'LI', 'is', 'locally', 'well', 'tolerated', ',', 'providing', 'DSCG', 'is', 'inhaled', 'before', 'each', 'therapeutic', 'inhalation', ',', 'and', 'does', 'not', 'induce', 'systemic', 'side', 'effects', '.']","(6, 7)","(29, 38)",-1,ss_o,1669598,Abstract,7,test,gold,862.0
2121,"Moreover , LI is locally well tolerated , providing DSCG is inhaled before each therapeutic inhalation , and does not induce",systemic side effects .,,"['Moreover', ',', 'LI', 'is', 'locally', 'well', 'tolerated', ',', 'providing', 'DSCG', 'is', 'inhaled', 'before', 'each', 'therapeutic', 'inhalation', ',', 'and', 'does', 'not', 'induce', 'systemic', 'side', 'effects', '.']","(21, 25)","(124, 147)",-1,ss_o,1669598,Abstract,7,test,gold,2361.0
2122,"Moreover , LI is locally well tolerated , providing DSCG is inhaled before each therapeutic inhalation , and does not induce",systemic side effects .,,"['Moreover', ',', 'LI', 'is', 'locally', 'well', 'tolerated', ',', 'providing', 'DSCG', 'is', 'inhaled', 'before', 'each', 'therapeutic', 'inhalation', ',', 'and', 'does', 'not', 'induce', 'systemic', 'side', 'effects', '.']","(21, 25)","(124, 147)",-1,hl_o,1669598,Abstract,7,test,gold,2360.0
2123,The safety of,whey protein concentrate,derived from the milk of cows immunized against Clostridium difficile .,"['The', 'safety', 'of', 'whey', 'protein', 'concentrate', 'derived', 'from', 'the', 'milk', 'of', 'cows', 'immunized', 'against', 'Clostridium', 'difficile', '.']","(3, 6)","(13, 37)",-1,ss_i,17293018,Title,0,test,gold,4649.0
2124,The,safety,of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile .,"['The', 'safety', 'of', 'whey', 'protein', 'concentrate', 'derived', 'from', 'the', 'milk', 'of', 'cows', 'immunized', 'against', 'Clostridium', 'difficile', '.']","(1, 2)","(3, 9)",-1,ss_o,17293018,Title,0,test,gold,484.0
2125,The safety of,whey protein concentrate,derived from the milk of cows immunized against Clostridium difficile .,"['The', 'safety', 'of', 'whey', 'protein', 'concentrate', 'derived', 'from', 'the', 'milk', 'of', 'cows', 'immunized', 'against', 'Clostridium', 'difficile', '.']","(3, 6)","(13, 37)",-1,hl_i,17293018,Title,0,test,gold,4650.0
2126,"A whey protein concentrate prepared from the milk of cows that have been immunized against Clostridium difficile ( C. difficile ) and its toxins , toxin A and toxin B , is produced for use as a medical food for the dietary management of",patients with C. difficile-associated diarrhea ( CDAD ),to prevent a relapse of the infection .,"['A', 'whey', 'protein', 'concentrate', 'prepared', 'from', 'the', 'milk', 'of', 'cows', 'that', 'have', 'been', 'immunized', 'against', 'Clostridium', 'difficile', '(', 'C.', 'difficile', ')', 'and', 'its', 'toxins', ',', 'toxin', 'A', 'and', 'toxin', 'B', ',', 'is', 'produced', 'for', 'use', 'as', 'a', 'medical', 'food', 'for', 'the', 'dietary', 'management', 'of', 'patients', 'with', 'C.', 'difficile-associated', 'diarrhea', '(', 'CDAD', ')', 'to', 'prevent', 'a', 'relapse', 'of', 'the', 'infection', '.']","(44, 52)","(236, 291)",-1,ss_p,17293018,Abstract,0,test,gold,3569.0
2127,A,whey protein concentrate,"prepared from the milk of cows that have been immunized against Clostridium difficile ( C. difficile ) and its toxins , toxin A and toxin B , is produced for use as a medical food for the dietary management of patients with C. difficile-associated diarrhea ( CDAD ) to prevent a relapse of the infection .","['A', 'whey', 'protein', 'concentrate', 'prepared', 'from', 'the', 'milk', 'of', 'cows', 'that', 'have', 'been', 'immunized', 'against', 'Clostridium', 'difficile', '(', 'C.', 'difficile', ')', 'and', 'its', 'toxins', ',', 'toxin', 'A', 'and', 'toxin', 'B', ',', 'is', 'produced', 'for', 'use', 'as', 'a', 'medical', 'food', 'for', 'the', 'dietary', 'management', 'of', 'patients', 'with', 'C.', 'difficile-associated', 'diarrhea', '(', 'CDAD', ')', 'to', 'prevent', 'a', 'relapse', 'of', 'the', 'infection', '.']","(1, 4)","(1, 25)",-1,ss_i,17293018,Abstract,0,test,gold,4648.0
2128,A whey protein concentrate prepared from the milk of cows that have been,"immunized against Clostridium difficile ( C. difficile ) and its toxins , toxin A and toxin B",", is produced for use as a medical food for the dietary management of patients with C. difficile-associated diarrhea ( CDAD ) to prevent a relapse of the infection .","['A', 'whey', 'protein', 'concentrate', 'prepared', 'from', 'the', 'milk', 'of', 'cows', 'that', 'have', 'been', 'immunized', 'against', 'Clostridium', 'difficile', '(', 'C.', 'difficile', ')', 'and', 'its', 'toxins', ',', 'toxin', 'A', 'and', 'toxin', 'B', ',', 'is', 'produced', 'for', 'use', 'as', 'a', 'medical', 'food', 'for', 'the', 'dietary', 'management', 'of', 'patients', 'with', 'C.', 'difficile-associated', 'diarrhea', '(', 'CDAD', ')', 'to', 'prevent', 'a', 'relapse', 'of', 'the', 'infection', '.']","(13, 30)","(72, 165)",-1,ss_i,17293018,Abstract,0,test,gold,6642.0
2129,"A whey protein concentrate prepared from the milk of cows that have been immunized against Clostridium difficile ( C. difficile ) and its toxins , toxin A and toxin B , is produced for use as a medical food for the dietary management of",patients with C. difficile-associated diarrhea ( CDAD ),to prevent a relapse of the infection .,"['A', 'whey', 'protein', 'concentrate', 'prepared', 'from', 'the', 'milk', 'of', 'cows', 'that', 'have', 'been', 'immunized', 'against', 'Clostridium', 'difficile', '(', 'C.', 'difficile', ')', 'and', 'its', 'toxins', ',', 'toxin', 'A', 'and', 'toxin', 'B', ',', 'is', 'produced', 'for', 'use', 'as', 'a', 'medical', 'food', 'for', 'the', 'dietary', 'management', 'of', 'patients', 'with', 'C.', 'difficile-associated', 'diarrhea', '(', 'CDAD', ')', 'to', 'prevent', 'a', 'relapse', 'of', 'the', 'infection', '.']","(44, 52)","(236, 291)",-1,hl_p,17293018,Abstract,0,test,gold,3570.0
2130,A,whey protein concentrate,"prepared from the milk of cows that have been immunized against Clostridium difficile ( C. difficile ) and its toxins , toxin A and toxin B , is produced for use as a medical food for the dietary management of patients with C. difficile-associated diarrhea ( CDAD ) to prevent a relapse of the infection .","['A', 'whey', 'protein', 'concentrate', 'prepared', 'from', 'the', 'milk', 'of', 'cows', 'that', 'have', 'been', 'immunized', 'against', 'Clostridium', 'difficile', '(', 'C.', 'difficile', ')', 'and', 'its', 'toxins', ',', 'toxin', 'A', 'and', 'toxin', 'B', ',', 'is', 'produced', 'for', 'use', 'as', 'a', 'medical', 'food', 'for', 'the', 'dietary', 'management', 'of', 'patients', 'with', 'C.', 'difficile-associated', 'diarrhea', '(', 'CDAD', ')', 'to', 'prevent', 'a', 'relapse', 'of', 'the', 'infection', '.']","(1, 4)","(1, 25)",-1,hl_i,17293018,Abstract,0,test,gold,4647.0
2131,A whey protein concentrate prepared from the milk of cows that have been,immunized against Clostridium difficile ( C.,"difficile ) and its toxins , toxin A and toxin B , is produced for use as a medical food for the dietary management of patients with C. difficile-associated diarrhea ( CDAD ) to prevent a relapse of the infection .","['A', 'whey', 'protein', 'concentrate', 'prepared', 'from', 'the', 'milk', 'of', 'cows', 'that', 'have', 'been', 'immunized', 'against', 'Clostridium', 'difficile', '(', 'C.', 'difficile', ')', 'and', 'its', 'toxins', ',', 'toxin', 'A', 'and', 'toxin', 'B', ',', 'is', 'produced', 'for', 'use', 'as', 'a', 'medical', 'food', 'for', 'the', 'dietary', 'management', 'of', 'patients', 'with', 'C.', 'difficile-associated', 'diarrhea', '(', 'CDAD', ')', 'to', 'prevent', 'a', 'relapse', 'of', 'the', 'infection', '.']","(13, 19)","(72, 116)",-1,hl_i,17293018,Abstract,0,test,gold,5648.0
2132,The safety of,anti-C. difficile whey protein concentrate ( anti-CD WPC ),"is supported by analytical data comparing the composition of raw milk from immunized cows versus that from non-immunized cows , and the composition of anti-CD WPC versus that of regular whey protein concentrate .","['The', 'safety', 'of', 'anti-C.', 'difficile', 'whey', 'protein', 'concentrate', '(', 'anti-CD', 'WPC', ')', 'is', 'supported', 'by', 'analytical', 'data', 'comparing', 'the', 'composition', 'of', 'raw', 'milk', 'from', 'immunized', 'cows', 'versus', 'that', 'from', 'non-immunized', 'cows', ',', 'and', 'the', 'composition', 'of', 'anti-CD', 'WPC', 'versus', 'that', 'of', 'regular', 'whey', 'protein', 'concentrate', '.']","(3, 12)","(13, 71)",-1,ss_i,17293018,Abstract,1,test,gold,4645.0
2133,"The safety of anti-C. difficile whey protein concentrate ( anti-CD WPC ) is supported by analytical data comparing the composition of raw milk from immunized cows versus that from non-immunized cows , and the composition of",anti-CD WPC,versus that of regular whey protein concentrate .,"['The', 'safety', 'of', 'anti-C.', 'difficile', 'whey', 'protein', 'concentrate', '(', 'anti-CD', 'WPC', ')', 'is', 'supported', 'by', 'analytical', 'data', 'comparing', 'the', 'composition', 'of', 'raw', 'milk', 'from', 'immunized', 'cows', 'versus', 'that', 'from', 'non-immunized', 'cows', ',', 'and', 'the', 'composition', 'of', 'anti-CD', 'WPC', 'versus', 'that', 'of', 'regular', 'whey', 'protein', 'concentrate', '.']","(36, 38)","(223, 234)",-1,ss_i,17293018,Abstract,1,test,gold,708.0
2134,"The safety of anti-C. difficile whey protein concentrate ( anti-CD WPC ) is supported by analytical data comparing the composition of raw milk from immunized cows versus that from non-immunized cows , and the composition of anti-CD WPC versus that of",regular whey protein concentrate .,,"['The', 'safety', 'of', 'anti-C.', 'difficile', 'whey', 'protein', 'concentrate', '(', 'anti-CD', 'WPC', ')', 'is', 'supported', 'by', 'analytical', 'data', 'comparing', 'the', 'composition', 'of', 'raw', 'milk', 'from', 'immunized', 'cows', 'versus', 'that', 'from', 'non-immunized', 'cows', ',', 'and', 'the', 'composition', 'of', 'anti-CD', 'WPC', 'versus', 'that', 'of', 'regular', 'whey', 'protein', 'concentrate', '.']","(41, 46)","(250, 284)",-1,ss_i,17293018,Abstract,1,test,gold,4651.0
2135,The,safety,"of anti-C. difficile whey protein concentrate ( anti-CD WPC ) is supported by analytical data comparing the composition of raw milk from immunized cows versus that from non-immunized cows , and the composition of anti-CD WPC versus that of regular whey protein concentrate .","['The', 'safety', 'of', 'anti-C.', 'difficile', 'whey', 'protein', 'concentrate', '(', 'anti-CD', 'WPC', ')', 'is', 'supported', 'by', 'analytical', 'data', 'comparing', 'the', 'composition', 'of', 'raw', 'milk', 'from', 'immunized', 'cows', 'versus', 'that', 'from', 'non-immunized', 'cows', ',', 'and', 'the', 'composition', 'of', 'anti-CD', 'WPC', 'versus', 'that', 'of', 'regular', 'whey', 'protein', 'concentrate', '.']","(1, 2)","(3, 9)",-1,ss_o,17293018,Abstract,1,test,gold,483.0
2136,The safety of,anti-C. difficile whey protein concentrate ( anti-CD WPC ),"is supported by analytical data comparing the composition of raw milk from immunized cows versus that from non-immunized cows , and the composition of anti-CD WPC versus that of regular whey protein concentrate .","['The', 'safety', 'of', 'anti-C.', 'difficile', 'whey', 'protein', 'concentrate', '(', 'anti-CD', 'WPC', ')', 'is', 'supported', 'by', 'analytical', 'data', 'comparing', 'the', 'composition', 'of', 'raw', 'milk', 'from', 'immunized', 'cows', 'versus', 'that', 'from', 'non-immunized', 'cows', ',', 'and', 'the', 'composition', 'of', 'anti-CD', 'WPC', 'versus', 'that', 'of', 'regular', 'whey', 'protein', 'concentrate', '.']","(3, 12)","(13, 71)",-1,hl_i,17293018,Abstract,1,test,gold,4646.0
2137,"The safety of anti-C. difficile whey protein concentrate ( anti-CD WPC ) is supported by analytical data comparing the composition of raw milk from immunized cows versus that from non-immunized cows , and the composition of",anti-CD WPC,versus that of regular whey protein concentrate .,"['The', 'safety', 'of', 'anti-C.', 'difficile', 'whey', 'protein', 'concentrate', '(', 'anti-CD', 'WPC', ')', 'is', 'supported', 'by', 'analytical', 'data', 'comparing', 'the', 'composition', 'of', 'raw', 'milk', 'from', 'immunized', 'cows', 'versus', 'that', 'from', 'non-immunized', 'cows', ',', 'and', 'the', 'composition', 'of', 'anti-CD', 'WPC', 'versus', 'that', 'of', 'regular', 'whey', 'protein', 'concentrate', '.']","(36, 38)","(223, 234)",-1,hl_i,17293018,Abstract,1,test,gold,709.0
2138,"The safety of anti-C. difficile whey protein concentrate ( anti-CD WPC ) is supported by analytical data comparing the composition of raw milk from immunized cows versus that from non-immunized cows , and the composition of anti-CD WPC versus that of",regular whey protein concentrate .,,"['The', 'safety', 'of', 'anti-C.', 'difficile', 'whey', 'protein', 'concentrate', '(', 'anti-CD', 'WPC', ')', 'is', 'supported', 'by', 'analytical', 'data', 'comparing', 'the', 'composition', 'of', 'raw', 'milk', 'from', 'immunized', 'cows', 'versus', 'that', 'from', 'non-immunized', 'cows', ',', 'and', 'the', 'composition', 'of', 'anti-CD', 'WPC', 'versus', 'that', 'of', 'regular', 'whey', 'protein', 'concentrate', '.']","(41, 46)","(250, 284)",-1,hl_i,17293018,Abstract,1,test,gold,4652.0
2139,"Additionally , a prospective clinical study was conducted in",77 patients with CDAD,to demonstrate the safety of consuming anti-CD WPC to prevent relapse of the infection .,"['Additionally', ',', 'a', 'prospective', 'clinical', 'study', 'was', 'conducted', 'in', '77', 'patients', 'with', 'CDAD', 'to', 'demonstrate', 'the', 'safety', 'of', 'consuming', 'anti-CD', 'WPC', 'to', 'prevent', 'relapse', 'of', 'the', 'infection', '.']","(9, 13)","(60, 81)",-1,ss_p,17293018,Abstract,2,test,gold,3573.0
2140,"Additionally , a prospective clinical study was conducted in 77 patients with CDAD to demonstrate the safety of consuming",anti-CD WPC,to prevent relapse of the infection .,"['Additionally', ',', 'a', 'prospective', 'clinical', 'study', 'was', 'conducted', 'in', '77', 'patients', 'with', 'CDAD', 'to', 'demonstrate', 'the', 'safety', 'of', 'consuming', 'anti-CD', 'WPC', 'to', 'prevent', 'relapse', 'of', 'the', 'infection', '.']","(19, 21)","(121, 132)",-1,ss_i,17293018,Abstract,2,test,gold,707.0
2141,"Additionally , a prospective clinical study was conducted in 77 patients with CDAD to demonstrate the",safety,of consuming anti-CD WPC to prevent relapse of the infection .,"['Additionally', ',', 'a', 'prospective', 'clinical', 'study', 'was', 'conducted', 'in', '77', 'patients', 'with', 'CDAD', 'to', 'demonstrate', 'the', 'safety', 'of', 'consuming', 'anti-CD', 'WPC', 'to', 'prevent', 'relapse', 'of', 'the', 'infection', '.']","(16, 17)","(101, 107)",-1,ss_o,17293018,Abstract,2,test,gold,482.0
2142,"Additionally , a prospective clinical study was conducted in 77 patients with CDAD to demonstrate the safety of consuming anti-CD WPC to prevent",relapse of the infection .,,"['Additionally', ',', 'a', 'prospective', 'clinical', 'study', 'was', 'conducted', 'in', '77', 'patients', 'with', 'CDAD', 'to', 'demonstrate', 'the', 'safety', 'of', 'consuming', 'anti-CD', 'WPC', 'to', 'prevent', 'relapse', 'of', 'the', 'infection', '.']","(23, 28)","(144, 170)",-1,ss_o,17293018,Abstract,2,test,gold,3428.0
2143,"Additionally , a prospective clinical study was conducted in",77 patients with CDAD,to demonstrate the safety of consuming anti-CD WPC to prevent relapse of the infection .,"['Additionally', ',', 'a', 'prospective', 'clinical', 'study', 'was', 'conducted', 'in', '77', 'patients', 'with', 'CDAD', 'to', 'demonstrate', 'the', 'safety', 'of', 'consuming', 'anti-CD', 'WPC', 'to', 'prevent', 'relapse', 'of', 'the', 'infection', '.']","(9, 13)","(60, 81)",-1,hl_p,17293018,Abstract,2,test,gold,3574.0
2144,"Additionally , a prospective clinical study was conducted in 77 patients with CDAD to demonstrate the safety of consuming",anti-CD WPC,to prevent relapse of the infection .,"['Additionally', ',', 'a', 'prospective', 'clinical', 'study', 'was', 'conducted', 'in', '77', 'patients', 'with', 'CDAD', 'to', 'demonstrate', 'the', 'safety', 'of', 'consuming', 'anti-CD', 'WPC', 'to', 'prevent', 'relapse', 'of', 'the', 'infection', '.']","(19, 21)","(121, 132)",-1,hl_i,17293018,Abstract,2,test,gold,706.0
2145,"This study , which included adverse event monitoring , physical examinations , and extensive hematological and biochemical assessments , showed that anti-CD WPC is safe to consume by",patients with CDAD .,,"['This', 'study', ',', 'which', 'included', 'adverse', 'event', 'monitoring', ',', 'physical', 'examinations', ',', 'and', 'extensive', 'hematological', 'and', 'biochemical', 'assessments', ',', 'showed', 'that', 'anti-CD', 'WPC', 'is', 'safe', 'to', 'consume', 'by', 'patients', 'with', 'CDAD', '.']","(28, 32)","(182, 202)",-1,ss_p,17293018,Abstract,3,test,gold,3572.0
2146,"This study , which included adverse event monitoring , physical examinations , and extensive hematological and biochemical assessments , showed that",anti-CD WPC,is safe to consume by patients with CDAD .,"['This', 'study', ',', 'which', 'included', 'adverse', 'event', 'monitoring', ',', 'physical', 'examinations', ',', 'and', 'extensive', 'hematological', 'and', 'biochemical', 'assessments', ',', 'showed', 'that', 'anti-CD', 'WPC', 'is', 'safe', 'to', 'consume', 'by', 'patients', 'with', 'CDAD', '.']","(21, 23)","(148, 159)",-1,ss_i,17293018,Abstract,3,test,gold,705.0
2147,"This study , which included","adverse event monitoring , physical examinations , and extensive hematological and biochemical assessments",", showed that anti-CD WPC is safe to consume by patients with CDAD .","['This', 'study', ',', 'which', 'included', 'adverse', 'event', 'monitoring', ',', 'physical', 'examinations', ',', 'and', 'extensive', 'hematological', 'and', 'biochemical', 'assessments', ',', 'showed', 'that', 'anti-CD', 'WPC', 'is', 'safe', 'to', 'consume', 'by', 'patients', 'with', 'CDAD', '.']","(5, 18)","(27, 133)",-1,ss_o,17293018,Abstract,3,test,gold,5970.0
2148,"This study , which included adverse event monitoring , physical examinations , and extensive hematological and biochemical assessments , showed that anti-CD WPC is",safe,to consume by patients with CDAD .,"['This', 'study', ',', 'which', 'included', 'adverse', 'event', 'monitoring', ',', 'physical', 'examinations', ',', 'and', 'extensive', 'hematological', 'and', 'biochemical', 'assessments', ',', 'showed', 'that', 'anti-CD', 'WPC', 'is', 'safe', 'to', 'consume', 'by', 'patients', 'with', 'CDAD', '.']","(24, 25)","(163, 167)",-1,ss_o,17293018,Abstract,3,test,gold,885.0
2149,"This study , which included adverse event monitoring , physical examinations , and extensive hematological and biochemical assessments , showed that anti-CD WPC is safe to consume by",patients with CDAD .,,"['This', 'study', ',', 'which', 'included', 'adverse', 'event', 'monitoring', ',', 'physical', 'examinations', ',', 'and', 'extensive', 'hematological', 'and', 'biochemical', 'assessments', ',', 'showed', 'that', 'anti-CD', 'WPC', 'is', 'safe', 'to', 'consume', 'by', 'patients', 'with', 'CDAD', '.']","(28, 32)","(182, 202)",-1,hl_p,17293018,Abstract,3,test,gold,3571.0
2150,"This study , which included adverse event monitoring , physical examinations , and extensive hematological and biochemical assessments , showed that",anti-CD WPC,is safe to consume by patients with CDAD .,"['This', 'study', ',', 'which', 'included', 'adverse', 'event', 'monitoring', ',', 'physical', 'examinations', ',', 'and', 'extensive', 'hematological', 'and', 'biochemical', 'assessments', ',', 'showed', 'that', 'anti-CD', 'WPC', 'is', 'safe', 'to', 'consume', 'by', 'patients', 'with', 'CDAD', '.']","(21, 23)","(148, 159)",-1,hl_i,17293018,Abstract,3,test,gold,704.0
2151,"This study , which included adverse event monitoring , physical examinations , and extensive hematological and biochemical assessments , showed that anti-CD WPC is",safe,to consume by patients with CDAD .,"['This', 'study', ',', 'which', 'included', 'adverse', 'event', 'monitoring', ',', 'physical', 'examinations', ',', 'and', 'extensive', 'hematological', 'and', 'biochemical', 'assessments', ',', 'showed', 'that', 'anti-CD', 'WPC', 'is', 'safe', 'to', 'consume', 'by', 'patients', 'with', 'CDAD', '.']","(24, 25)","(163, 167)",-1,hl_o,17293018,Abstract,3,test,gold,884.0
2152,The available analytical and clinical evidence demonstrate that anti-CD WPC is safe for use by,individuals with CDAD,", under the described conditions of use .","['The', 'available', 'analytical', 'and', 'clinical', 'evidence', 'demonstrate', 'that', 'anti-CD', 'WPC', 'is', 'safe', 'for', 'use', 'by', 'individuals', 'with', 'CDAD', ',', 'under', 'the', 'described', 'conditions', 'of', 'use', '.']","(15, 18)","(94, 115)",-1,ss_p,17293018,Abstract,4,test,gold,3575.0
2153,The available analytical and clinical evidence demonstrate that,anti-CD WPC,"is safe for use by individuals with CDAD , under the described conditions of use .","['The', 'available', 'analytical', 'and', 'clinical', 'evidence', 'demonstrate', 'that', 'anti-CD', 'WPC', 'is', 'safe', 'for', 'use', 'by', 'individuals', 'with', 'CDAD', ',', 'under', 'the', 'described', 'conditions', 'of', 'use', '.']","(8, 10)","(63, 74)",-1,ss_i,17293018,Abstract,4,test,gold,703.0
2154,The available analytical and clinical evidence demonstrate that anti-CD WPC is,safe,"for use by individuals with CDAD , under the described conditions of use .","['The', 'available', 'analytical', 'and', 'clinical', 'evidence', 'demonstrate', 'that', 'anti-CD', 'WPC', 'is', 'safe', 'for', 'use', 'by', 'individuals', 'with', 'CDAD', ',', 'under', 'the', 'described', 'conditions', 'of', 'use', '.']","(11, 12)","(78, 82)",-1,ss_o,17293018,Abstract,4,test,gold,883.0
2155,The available analytical and clinical evidence demonstrate that anti-CD WPC is safe for use by,individuals with CDAD,", under the described conditions of use .","['The', 'available', 'analytical', 'and', 'clinical', 'evidence', 'demonstrate', 'that', 'anti-CD', 'WPC', 'is', 'safe', 'for', 'use', 'by', 'individuals', 'with', 'CDAD', ',', 'under', 'the', 'described', 'conditions', 'of', 'use', '.']","(15, 18)","(94, 115)",-1,hl_p,17293018,Abstract,4,test,gold,3576.0
2156,The available analytical and clinical evidence demonstrate that,anti-CD WPC,"is safe for use by individuals with CDAD , under the described conditions of use .","['The', 'available', 'analytical', 'and', 'clinical', 'evidence', 'demonstrate', 'that', 'anti-CD', 'WPC', 'is', 'safe', 'for', 'use', 'by', 'individuals', 'with', 'CDAD', ',', 'under', 'the', 'described', 'conditions', 'of', 'use', '.']","(8, 10)","(63, 74)",-1,hl_i,17293018,Abstract,4,test,gold,702.0
2157,The available analytical and clinical evidence demonstrate that anti-CD WPC is,safe,"for use by individuals with CDAD , under the described conditions of use .","['The', 'available', 'analytical', 'and', 'clinical', 'evidence', 'demonstrate', 'that', 'anti-CD', 'WPC', 'is', 'safe', 'for', 'use', 'by', 'individuals', 'with', 'CDAD', ',', 'under', 'the', 'described', 'conditions', 'of', 'use', '.']","(11, 12)","(78, 82)",-1,hl_o,17293018,Abstract,4,test,gold,882.0
2158,The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in,patients with acute myeloid leukemia and myelodysplastic syndromes :,"a Japanese multicenter randomized , controlled study .","['The', 'prophylactic', 'effect', 'of', 'itraconazole', 'capsules', 'and', 'fluconazole', 'capsules', 'for', 'systemic', 'fungal', 'infections', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', 'and', 'myelodysplastic', 'syndromes', ':', 'a', 'Japanese', 'multicenter', 'randomized', ',', 'controlled', 'study', '.']","(14, 23)","(107, 175)",-1,ss_p,17321989,Title,0,test,gold,7049.0
2159,The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes : a,Japanese,"multicenter randomized , controlled study .","['The', 'prophylactic', 'effect', 'of', 'itraconazole', 'capsules', 'and', 'fluconazole', 'capsules', 'for', 'systemic', 'fungal', 'infections', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', 'and', 'myelodysplastic', 'syndromes', ':', 'a', 'Japanese', 'multicenter', 'randomized', ',', 'controlled', 'study', '.']","(24, 25)","(178, 186)",-1,ss_p,17321989,Title,0,test,gold,2228.0
2160,The prophylactic effect of,itraconazole,"capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes : a Japanese multicenter randomized , controlled study .","['The', 'prophylactic', 'effect', 'of', 'itraconazole', 'capsules', 'and', 'fluconazole', 'capsules', 'for', 'systemic', 'fungal', 'infections', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', 'and', 'myelodysplastic', 'syndromes', ':', 'a', 'Japanese', 'multicenter', 'randomized', ',', 'controlled', 'study', '.']","(4, 5)","(26, 38)",-1,ss_i,17321989,Title,0,test,gold,5517.0
2161,The prophylactic effect of itraconazole capsules and,fluconazole,"capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes : a Japanese multicenter randomized , controlled study .","['The', 'prophylactic', 'effect', 'of', 'itraconazole', 'capsules', 'and', 'fluconazole', 'capsules', 'for', 'systemic', 'fungal', 'infections', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', 'and', 'myelodysplastic', 'syndromes', ':', 'a', 'Japanese', 'multicenter', 'randomized', ',', 'controlled', 'study', '.']","(7, 8)","(52, 63)",-1,ss_i,17321989,Title,0,test,gold,5757.0
2162,The,prophylactic effect,"of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes : a Japanese multicenter randomized , controlled study .","['The', 'prophylactic', 'effect', 'of', 'itraconazole', 'capsules', 'and', 'fluconazole', 'capsules', 'for', 'systemic', 'fungal', 'infections', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', 'and', 'myelodysplastic', 'syndromes', ':', 'a', 'Japanese', 'multicenter', 'randomized', ',', 'controlled', 'study', '.']","(1, 3)","(3, 22)",-1,ss_o,17321989,Title,0,test,gold,2331.0
2163,The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in,patients with acute myeloid leukemia and myelodysplastic syndromes :,"a Japanese multicenter randomized , controlled study .","['The', 'prophylactic', 'effect', 'of', 'itraconazole', 'capsules', 'and', 'fluconazole', 'capsules', 'for', 'systemic', 'fungal', 'infections', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', 'and', 'myelodysplastic', 'syndromes', ':', 'a', 'Japanese', 'multicenter', 'randomized', ',', 'controlled', 'study', '.']","(14, 23)","(107, 175)",-1,hl_p,17321989,Title,0,test,gold,7050.0
2164,The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes : a,Japanese,"multicenter randomized , controlled study .","['The', 'prophylactic', 'effect', 'of', 'itraconazole', 'capsules', 'and', 'fluconazole', 'capsules', 'for', 'systemic', 'fungal', 'infections', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', 'and', 'myelodysplastic', 'syndromes', ':', 'a', 'Japanese', 'multicenter', 'randomized', ',', 'controlled', 'study', '.']","(24, 25)","(178, 186)",-1,hl_p,17321989,Title,0,test,gold,2229.0
2165,The prophylactic effect of,itraconazole,"capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes : a Japanese multicenter randomized , controlled study .","['The', 'prophylactic', 'effect', 'of', 'itraconazole', 'capsules', 'and', 'fluconazole', 'capsules', 'for', 'systemic', 'fungal', 'infections', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', 'and', 'myelodysplastic', 'syndromes', ':', 'a', 'Japanese', 'multicenter', 'randomized', ',', 'controlled', 'study', '.']","(4, 5)","(26, 38)",-1,hl_i,17321989,Title,0,test,gold,5518.0
2166,The prophylactic effect of itraconazole capsules and,fluconazole,"capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes : a Japanese multicenter randomized , controlled study .","['The', 'prophylactic', 'effect', 'of', 'itraconazole', 'capsules', 'and', 'fluconazole', 'capsules', 'for', 'systemic', 'fungal', 'infections', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', 'and', 'myelodysplastic', 'syndromes', ':', 'a', 'Japanese', 'multicenter', 'randomized', ',', 'controlled', 'study', '.']","(7, 8)","(52, 63)",-1,hl_i,17321989,Title,0,test,gold,5758.0
2167,"We performed a randomized , controlled study comparing the prophylactic effects of capsule forms of fluconazole ( n = 110 ) and itraconazole ( n = 108 ) in",patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) during and after chemotherapy .,,"['We', 'performed', 'a', 'randomized', ',', 'controlled', 'study', 'comparing', 'the', 'prophylactic', 'effects', 'of', 'capsule', 'forms', 'of', 'fluconazole', '(', 'n', '=', '110', ')', 'and', 'itraconazole', '(', 'n', '=', '108', ')', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', '(', 'AML', ')', 'or', 'myelodysplastic', 'syndromes', '(', 'MDS', ')', 'during', 'and', 'after', 'chemotherapy', '.']","(29, 48)","(155, 268)",-1,ss_p,17321989,Abstract,0,test,gold,5919.0
2168,"We performed a randomized , controlled study comparing the prophylactic effects of capsule forms of",fluconazole,( n = 110 ) and itraconazole ( n = 108 ) in patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) during and after chemotherapy .,"['We', 'performed', 'a', 'randomized', ',', 'controlled', 'study', 'comparing', 'the', 'prophylactic', 'effects', 'of', 'capsule', 'forms', 'of', 'fluconazole', '(', 'n', '=', '110', ')', 'and', 'itraconazole', '(', 'n', '=', '108', ')', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', '(', 'AML', ')', 'or', 'myelodysplastic', 'syndromes', '(', 'MDS', ')', 'during', 'and', 'after', 'chemotherapy', '.']","(15, 16)","(99, 110)",-1,ss_i,17321989,Abstract,0,test,gold,5756.0
2169,"We performed a randomized , controlled study comparing the prophylactic effects of capsule forms of fluconazole ( n = 110 ) and",itraconazole,( n = 108 ) in patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) during and after chemotherapy .,"['We', 'performed', 'a', 'randomized', ',', 'controlled', 'study', 'comparing', 'the', 'prophylactic', 'effects', 'of', 'capsule', 'forms', 'of', 'fluconazole', '(', 'n', '=', '110', ')', 'and', 'itraconazole', '(', 'n', '=', '108', ')', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', '(', 'AML', ')', 'or', 'myelodysplastic', 'syndromes', '(', 'MDS', ')', 'during', 'and', 'after', 'chemotherapy', '.']","(22, 23)","(127, 139)",-1,ss_i,17321989,Abstract,0,test,gold,5516.0
2170,"We performed a randomized , controlled study comparing the",prophylactic effects,of capsule forms of fluconazole ( n = 110 ) and itraconazole ( n = 108 ) in patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) during and after chemotherapy .,"['We', 'performed', 'a', 'randomized', ',', 'controlled', 'study', 'comparing', 'the', 'prophylactic', 'effects', 'of', 'capsule', 'forms', 'of', 'fluconazole', '(', 'n', '=', '110', ')', 'and', 'itraconazole', '(', 'n', '=', '108', ')', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', '(', 'AML', ')', 'or', 'myelodysplastic', 'syndromes', '(', 'MDS', ')', 'during', 'and', 'after', 'chemotherapy', '.']","(9, 11)","(58, 78)",-1,ss_o,17321989,Abstract,0,test,gold,2332.0
2171,"We performed a randomized , controlled study comparing the prophylactic effects of capsule forms of fluconazole ( n = 110 ) and itraconazole ( n = 108 ) in",patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) during and after chemotherapy .,,"['We', 'performed', 'a', 'randomized', ',', 'controlled', 'study', 'comparing', 'the', 'prophylactic', 'effects', 'of', 'capsule', 'forms', 'of', 'fluconazole', '(', 'n', '=', '110', ')', 'and', 'itraconazole', '(', 'n', '=', '108', ')', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', '(', 'AML', ')', 'or', 'myelodysplastic', 'syndromes', '(', 'MDS', ')', 'during', 'and', 'after', 'chemotherapy', '.']","(29, 48)","(155, 268)",-1,hl_p,17321989,Abstract,0,test,gold,5920.0
2172,"We performed a randomized , controlled study comparing the prophylactic effects of capsule forms of",fluconazole,( n = 110 ) and itraconazole ( n = 108 ) in patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) during and after chemotherapy .,"['We', 'performed', 'a', 'randomized', ',', 'controlled', 'study', 'comparing', 'the', 'prophylactic', 'effects', 'of', 'capsule', 'forms', 'of', 'fluconazole', '(', 'n', '=', '110', ')', 'and', 'itraconazole', '(', 'n', '=', '108', ')', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', '(', 'AML', ')', 'or', 'myelodysplastic', 'syndromes', '(', 'MDS', ')', 'during', 'and', 'after', 'chemotherapy', '.']","(15, 16)","(99, 110)",-1,hl_i,17321989,Abstract,0,test,gold,5755.0
2173,"We performed a randomized , controlled study comparing the prophylactic effects of capsule forms of fluconazole ( n = 110 ) and",itraconazole,( n = 108 ) in patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) during and after chemotherapy .,"['We', 'performed', 'a', 'randomized', ',', 'controlled', 'study', 'comparing', 'the', 'prophylactic', 'effects', 'of', 'capsule', 'forms', 'of', 'fluconazole', '(', 'n', '=', '110', ')', 'and', 'itraconazole', '(', 'n', '=', '108', ')', 'in', 'patients', 'with', 'acute', 'myeloid', 'leukemia', '(', 'AML', ')', 'or', 'myelodysplastic', 'syndromes', '(', 'MDS', ')', 'during', 'and', 'after', 'chemotherapy', '.']","(22, 23)","(127, 139)",-1,hl_i,17321989,Abstract,0,test,gold,5515.0
2174,There were 4 cases with possible systemic fungal infection in the,itraconazole,"group , and there were 8 possible and 3 probable cases in the fluconazole group .","['There', 'were', '4', 'cases', 'with', 'possible', 'systemic', 'fungal', 'infection', 'in', 'the', 'itraconazole', 'group', ',', 'and', 'there', 'were', '8', 'possible', 'and', '3', 'probable', 'cases', 'in', 'the', 'fluconazole', 'group', '.']","(11, 12)","(65, 77)",-1,ss_i,17321989,Abstract,1,test,gold,5514.0
2175,"There were 4 cases with possible systemic fungal infection in the itraconazole group , and there were 8 possible and 3 probable cases in the",fluconazole,group .,"['There', 'were', '4', 'cases', 'with', 'possible', 'systemic', 'fungal', 'infection', 'in', 'the', 'itraconazole', 'group', ',', 'and', 'there', 'were', '8', 'possible', 'and', '3', 'probable', 'cases', 'in', 'the', 'fluconazole', 'group', '.']","(25, 26)","(140, 151)",-1,ss_i,17321989,Abstract,1,test,gold,5754.0
2176,There were 4 cases with possible systemic fungal infection in the,itraconazole,"group , and there were 8 possible and 3 probable cases in the fluconazole group .","['There', 'were', '4', 'cases', 'with', 'possible', 'systemic', 'fungal', 'infection', 'in', 'the', 'itraconazole', 'group', ',', 'and', 'there', 'were', '8', 'possible', 'and', '3', 'probable', 'cases', 'in', 'the', 'fluconazole', 'group', '.']","(11, 12)","(65, 77)",-1,hl_i,17321989,Abstract,1,test,gold,5513.0
2177,"There were 4 cases with possible systemic fungal infection in the itraconazole group , and there were 8 possible and 3 probable cases in the",fluconazole,group .,"['There', 'were', '4', 'cases', 'with', 'possible', 'systemic', 'fungal', 'infection', 'in', 'the', 'itraconazole', 'group', ',', 'and', 'there', 'were', '8', 'possible', 'and', '3', 'probable', 'cases', 'in', 'the', 'fluconazole', 'group', '.']","(25, 26)","(140, 151)",-1,hl_i,17321989,Abstract,1,test,gold,5753.0
2178,,Adverse events,did not significantly differ in the 2 groups .,"['Adverse', 'events', 'did', 'not', 'significantly', 'differ', 'in', 'the', '2', 'groups', '.']","(0, 2)","(0, 14)",-1,ss_o,17321989,Abstract,2,test,gold,3043.0
2179,,Adverse events,did not significantly differ in the 2 groups .,"['Adverse', 'events', 'did', 'not', 'significantly', 'differ', 'in', 'the', '2', 'groups', '.']","(0, 2)","(0, 14)",-1,hl_o,17321989,Abstract,2,test,gold,3044.0
2180,"In patients with MDS or in the remission-induction phase of chemotherapy , the numbers of cases with probable or possible infections were lower in the",itraconazole,"group than in the fluconazole group , whereas no difference was seen in patients with AML or in the consolidation phase of therapy .","['In', 'patients', 'with', 'MDS', 'or', 'in', 'the', 'remission-induction', 'phase', 'of', 'chemotherapy', ',', 'the', 'numbers', 'of', 'cases', 'with', 'probable', 'or', 'possible', 'infections', 'were', 'lower', 'in', 'the', 'itraconazole', 'group', 'than', 'in', 'the', 'fluconazole', 'group', ',', 'whereas', 'no', 'difference', 'was', 'seen', 'in', 'patients', 'with', 'AML', 'or', 'in', 'the', 'consolidation', 'phase', 'of', 'therapy', '.']","(25, 26)","(150, 162)",-1,ss_i,17321989,Abstract,3,test,gold,5512.0
2181,"In patients with MDS or in the remission-induction phase of chemotherapy , the numbers of cases with probable or possible infections were lower in the itraconazole group than in the",fluconazole,"group , whereas no difference was seen in patients with AML or in the consolidation phase of therapy .","['In', 'patients', 'with', 'MDS', 'or', 'in', 'the', 'remission-induction', 'phase', 'of', 'chemotherapy', ',', 'the', 'numbers', 'of', 'cases', 'with', 'probable', 'or', 'possible', 'infections', 'were', 'lower', 'in', 'the', 'itraconazole', 'group', 'than', 'in', 'the', 'fluconazole', 'group', ',', 'whereas', 'no', 'difference', 'was', 'seen', 'in', 'patients', 'with', 'AML', 'or', 'in', 'the', 'consolidation', 'phase', 'of', 'therapy', '.']","(30, 31)","(181, 192)",-1,ss_i,17321989,Abstract,3,test,gold,5752.0
2182,"In patients with MDS or in the remission-induction phase of chemotherapy , the numbers of",cases with probable or possible infections,"were lower in the itraconazole group than in the fluconazole group , whereas no difference was seen in patients with AML or in the consolidation phase of therapy .","['In', 'patients', 'with', 'MDS', 'or', 'in', 'the', 'remission-induction', 'phase', 'of', 'chemotherapy', ',', 'the', 'numbers', 'of', 'cases', 'with', 'probable', 'or', 'possible', 'infections', 'were', 'lower', 'in', 'the', 'itraconazole', 'group', 'than', 'in', 'the', 'fluconazole', 'group', ',', 'whereas', 'no', 'difference', 'was', 'seen', 'in', 'patients', 'with', 'AML', 'or', 'in', 'the', 'consolidation', 'phase', 'of', 'therapy', '.']","(15, 21)","(89, 131)",-1,ss_o,17321989,Abstract,3,test,gold,3577.0
2183,"In patients with MDS or in the remission-induction phase of chemotherapy , the numbers of cases with",probable or possible infections,"were lower in the itraconazole group than in the fluconazole group , whereas no difference was seen in patients with AML or in the consolidation phase of therapy .","['In', 'patients', 'with', 'MDS', 'or', 'in', 'the', 'remission-induction', 'phase', 'of', 'chemotherapy', ',', 'the', 'numbers', 'of', 'cases', 'with', 'probable', 'or', 'possible', 'infections', 'were', 'lower', 'in', 'the', 'itraconazole', 'group', 'than', 'in', 'the', 'fluconazole', 'group', ',', 'whereas', 'no', 'difference', 'was', 'seen', 'in', 'patients', 'with', 'AML', 'or', 'in', 'the', 'consolidation', 'phase', 'of', 'therapy', '.']","(17, 21)","(100, 131)",-1,hl_o,17321989,Abstract,3,test,gold,3578.0
2184,"In patients with neutrophil counts of > 0.1 x 10 ( 9 ) /L lasting for more than 4 weeks , the frequency of infection in the",fluconazole,group ( 5 of 9 patients ) was significantly higher than in the itraconazole group ( 0 of 7 patients ; P = .03 ) .,"['In', 'patients', 'with', 'neutrophil', 'counts', 'of', '>', '0.1', 'x', '10', '(', '9', ')', '/L', 'lasting', 'for', 'more', 'than', '4', 'weeks', ',', 'the', 'frequency', 'of', 'infection', 'in', 'the', 'fluconazole', 'group', '(', '5', 'of', '9', 'patients', ')', 'was', 'significantly', 'higher', 'than', 'in', 'the', 'itraconazole', 'group', '(', '0', 'of', '7', 'patients', ';', 'P', '=', '.03', ')', '.']","(27, 28)","(123, 134)",-1,ss_i,17321989,Abstract,4,test,gold,5751.0
2185,"In patients with neutrophil counts of > 0.1 x 10 ( 9 ) /L lasting for more than 4 weeks , the frequency of infection in the fluconazole group ( 5 of 9 patients ) was significantly higher than in the",itraconazole,group ( 0 of 7 patients ; P = .03 ) .,"['In', 'patients', 'with', 'neutrophil', 'counts', 'of', '>', '0.1', 'x', '10', '(', '9', ')', '/L', 'lasting', 'for', 'more', 'than', '4', 'weeks', ',', 'the', 'frequency', 'of', 'infection', 'in', 'the', 'fluconazole', 'group', '(', '5', 'of', '9', 'patients', ')', 'was', 'significantly', 'higher', 'than', 'in', 'the', 'itraconazole', 'group', '(', '0', 'of', '7', 'patients', ';', 'P', '=', '.03', ')', '.']","(41, 42)","(198, 210)",-1,ss_i,17321989,Abstract,4,test,gold,5511.0
2186,"In patients with neutrophil counts of > 0.1 x 10 ( 9 ) /L lasting for more than 4 weeks , the",frequency of infection,in the fluconazole group ( 5 of 9 patients ) was significantly higher than in the itraconazole group ( 0 of 7 patients ; P = .03 ) .,"['In', 'patients', 'with', 'neutrophil', 'counts', 'of', '>', '0.1', 'x', '10', '(', '9', ')', '/L', 'lasting', 'for', 'more', 'than', '4', 'weeks', ',', 'the', 'frequency', 'of', 'infection', 'in', 'the', 'fluconazole', 'group', '(', '5', 'of', '9', 'patients', ')', 'was', 'significantly', 'higher', 'than', 'in', 'the', 'itraconazole', 'group', '(', '0', 'of', '7', 'patients', ';', 'P', '=', '.03', ')', '.']","(22, 25)","(93, 115)",-1,ss_o,17321989,Abstract,4,test,gold,3429.0
2187,"In patients with neutrophil counts of > 0.1 x 10 ( 9 ) /L lasting for more than 4 weeks , the",frequency of infection,in the fluconazole group ( 5 of 9 patients ) was significantly higher than in the itraconazole group ( 0 of 7 patients ; P = .03 ) .,"['In', 'patients', 'with', 'neutrophil', 'counts', 'of', '>', '0.1', 'x', '10', '(', '9', ')', '/L', 'lasting', 'for', 'more', 'than', '4', 'weeks', ',', 'the', 'frequency', 'of', 'infection', 'in', 'the', 'fluconazole', 'group', '(', '5', 'of', '9', 'patients', ')', 'was', 'significantly', 'higher', 'than', 'in', 'the', 'itraconazole', 'group', '(', '0', 'of', '7', 'patients', ';', 'P', '=', '.03', ')', '.']","(22, 25)","(93, 115)",-1,hl_o,17321989,Abstract,4,test,gold,3430.0
2188,Our results suggest that both drugs were well tolerated in,patients with AML or MDS who received chemotherapy,and that the efficacy of itraconazole for prophylaxis against systemic fungal disease is not inferior to that of fluconazole .,"['Our', 'results', 'suggest', 'that', 'both', 'drugs', 'were', 'well', 'tolerated', 'in', 'patients', 'with', 'AML', 'or', 'MDS', 'who', 'received', 'chemotherapy', 'and', 'that', 'the', 'efficacy', 'of', 'itraconazole', 'for', 'prophylaxis', 'against', 'systemic', 'fungal', 'disease', 'is', 'not', 'inferior', 'to', 'that', 'of', 'fluconazole', '.']","(10, 18)","(58, 108)",-1,ss_p,17321989,Abstract,5,test,gold,6854.0
2189,Our results suggest that both drugs were well tolerated in patients with AML or MDS who received chemotherapy and that the efficacy of,itraconazole,for prophylaxis against systemic fungal disease is not inferior to that of fluconazole .,"['Our', 'results', 'suggest', 'that', 'both', 'drugs', 'were', 'well', 'tolerated', 'in', 'patients', 'with', 'AML', 'or', 'MDS', 'who', 'received', 'chemotherapy', 'and', 'that', 'the', 'efficacy', 'of', 'itraconazole', 'for', 'prophylaxis', 'against', 'systemic', 'fungal', 'disease', 'is', 'not', 'inferior', 'to', 'that', 'of', 'fluconazole', '.']","(23, 24)","(134, 146)",-1,ss_i,17321989,Abstract,5,test,gold,5510.0
2190,Our results suggest that both drugs were well tolerated in patients with AML or MDS who received chemotherapy and that the efficacy of itraconazole for prophylaxis against systemic fungal disease is not inferior to that of,fluconazole .,,"['Our', 'results', 'suggest', 'that', 'both', 'drugs', 'were', 'well', 'tolerated', 'in', 'patients', 'with', 'AML', 'or', 'MDS', 'who', 'received', 'chemotherapy', 'and', 'that', 'the', 'efficacy', 'of', 'itraconazole', 'for', 'prophylaxis', 'against', 'systemic', 'fungal', 'disease', 'is', 'not', 'inferior', 'to', 'that', 'of', 'fluconazole', '.']","(36, 38)","(222, 235)",-1,ss_i,17321989,Abstract,5,test,gold,5750.0
2191,Our results suggest that both drugs were well tolerated in patients with AML or MDS who received chemotherapy and that the,efficacy,of itraconazole for prophylaxis against systemic fungal disease is not inferior to that of fluconazole .,"['Our', 'results', 'suggest', 'that', 'both', 'drugs', 'were', 'well', 'tolerated', 'in', 'patients', 'with', 'AML', 'or', 'MDS', 'who', 'received', 'chemotherapy', 'and', 'that', 'the', 'efficacy', 'of', 'itraconazole', 'for', 'prophylaxis', 'against', 'systemic', 'fungal', 'disease', 'is', 'not', 'inferior', 'to', 'that', 'of', 'fluconazole', '.']","(21, 22)","(122, 130)",-1,ss_o,17321989,Abstract,5,test,gold,4827.0
2192,Our results suggest that both drugs were well tolerated in,patients with AML or MDS who received chemotherapy,and that the efficacy of itraconazole for prophylaxis against systemic fungal disease is not inferior to that of fluconazole .,"['Our', 'results', 'suggest', 'that', 'both', 'drugs', 'were', 'well', 'tolerated', 'in', 'patients', 'with', 'AML', 'or', 'MDS', 'who', 'received', 'chemotherapy', 'and', 'that', 'the', 'efficacy', 'of', 'itraconazole', 'for', 'prophylaxis', 'against', 'systemic', 'fungal', 'disease', 'is', 'not', 'inferior', 'to', 'that', 'of', 'fluconazole', '.']","(10, 18)","(58, 108)",-1,hl_p,17321989,Abstract,5,test,gold,6855.0
2193,[ Intravenous treatment of,postpartum anemia,with trivalent ferrum preparation ] .,"['[', 'Intravenous', 'treatment', 'of', 'postpartum', 'anemia', 'with', 'trivalent', 'ferrum', 'preparation', ']', '.']","(4, 6)","(26, 43)",-1,ss_p,17616069,Title,0,test,gold,3420.0
2194,[ Intravenous treatment of postpartum anemia with,trivalent ferrum preparation ],.,"['[', 'Intravenous', 'treatment', 'of', 'postpartum', 'anemia', 'with', 'trivalent', 'ferrum', 'preparation', ']', '.']","(7, 11)","(49, 79)",-1,ss_i,17616069,Title,0,test,gold,5718.0
2195,[ Intravenous treatment of,postpartum,anemia with trivalent ferrum preparation ] .,"['[', 'Intravenous', 'treatment', 'of', 'postpartum', 'anemia', 'with', 'trivalent', 'ferrum', 'preparation', ']', '.']","(4, 5)","(26, 36)",-1,hl_p,17616069,Title,0,test,gold,3421.0
2196,[ Intravenous treatment of postpartum anemia with,trivalent ferrum preparation ],.,"['[', 'Intravenous', 'treatment', 'of', 'postpartum', 'anemia', 'with', 'trivalent', 'ferrum', 'preparation', ']', '.']","(7, 11)","(49, 79)",-1,hl_i,17616069,Title,0,test,gold,5719.0
2197,AIM OF THE STUDY To assess the effectivity and safeness of intravenous treatment of,pospartal anemia,with trivalent ferrum preparation .,"['AIM', 'OF', 'THE', 'STUDY', 'To', 'assess', 'the', 'effectivity', 'and', 'safeness', 'of', 'intravenous', 'treatment', 'of', 'pospartal', 'anemia', 'with', 'trivalent', 'ferrum', 'preparation', '.']","(14, 16)","(83, 99)",-1,ss_p,17616069,Abstract,0,test,gold,3422.0
2198,AIM OF THE STUDY To assess the effectivity and safeness of intravenous treatment of pospartal anemia with,trivalent ferrum preparation .,,"['AIM', 'OF', 'THE', 'STUDY', 'To', 'assess', 'the', 'effectivity', 'and', 'safeness', 'of', 'intravenous', 'treatment', 'of', 'pospartal', 'anemia', 'with', 'trivalent', 'ferrum', 'preparation', '.']","(17, 21)","(105, 135)",-1,ss_i,17616069,Abstract,0,test,gold,5717.0
2199,AIM OF THE STUDY To assess the,effectivity,and safeness of intravenous treatment of pospartal anemia with trivalent ferrum preparation .,"['AIM', 'OF', 'THE', 'STUDY', 'To', 'assess', 'the', 'effectivity', 'and', 'safeness', 'of', 'intravenous', 'treatment', 'of', 'pospartal', 'anemia', 'with', 'trivalent', 'ferrum', 'preparation', '.']","(7, 8)","(30, 41)",-1,ss_o,17616069,Abstract,0,test,gold,1010.0
2200,AIM OF THE STUDY To assess the effectivity and,safeness,of intravenous treatment of pospartal anemia with trivalent ferrum preparation .,"['AIM', 'OF', 'THE', 'STUDY', 'To', 'assess', 'the', 'effectivity', 'and', 'safeness', 'of', 'intravenous', 'treatment', 'of', 'pospartal', 'anemia', 'with', 'trivalent', 'ferrum', 'preparation', '.']","(9, 10)","(46, 54)",-1,ss_o,17616069,Abstract,0,test,gold,1226.0
2201,AIM OF THE STUDY To assess the effectivity and safeness of intravenous treatment of pospartal anemia with,trivalent ferrum preparation .,,"['AIM', 'OF', 'THE', 'STUDY', 'To', 'assess', 'the', 'effectivity', 'and', 'safeness', 'of', 'intravenous', 'treatment', 'of', 'pospartal', 'anemia', 'with', 'trivalent', 'ferrum', 'preparation', '.']","(17, 21)","(105, 135)",-1,hl_i,17616069,Abstract,0,test,gold,5716.0
2202,AIM OF THE STUDY To assess the,effectivity,and safeness of intravenous treatment of pospartal anemia with trivalent ferrum preparation .,"['AIM', 'OF', 'THE', 'STUDY', 'To', 'assess', 'the', 'effectivity', 'and', 'safeness', 'of', 'intravenous', 'treatment', 'of', 'pospartal', 'anemia', 'with', 'trivalent', 'ferrum', 'preparation', '.']","(7, 8)","(30, 41)",-1,hl_o,17616069,Abstract,0,test,gold,1011.0
2203,AIM OF THE STUDY To assess the effectivity and,safeness,of intravenous treatment of pospartal anemia with trivalent ferrum preparation .,"['AIM', 'OF', 'THE', 'STUDY', 'To', 'assess', 'the', 'effectivity', 'and', 'safeness', 'of', 'intravenous', 'treatment', 'of', 'pospartal', 'anemia', 'with', 'trivalent', 'ferrum', 'preparation', '.']","(9, 10)","(46, 54)",-1,hl_o,17616069,Abstract,0,test,gold,1227.0
2204,TYPE OF THE STUDY Prospective randomized study .,,,"['TYPE', 'OF', 'THE', 'STUDY', 'Prospective', 'randomized', 'study', '.']",,,,,17616069,Abstract,1,test,gold,
2205,"SETTING Department of Obstetric and Gynecology 2nd Medical Faculty Charles University and Teaching Hospital Motol ,",Prague,", and Department of Obstetric and Gynecology 1st Medical Faculty and Teaching Hospital Bulovka , Prague .","['SETTING', 'Department', 'of', 'Obstetric', 'and', 'Gynecology', '2nd', 'Medical', 'Faculty', 'Charles', 'University', 'and', 'Teaching', 'Hospital', 'Motol', ',', 'Prague', ',', 'and', 'Department', 'of', 'Obstetric', 'and', 'Gynecology', '1st', 'Medical', 'Faculty', 'and', 'Teaching', 'Hospital', 'Bulovka', ',', 'Prague', '.']","(16, 17)","(115, 121)",-1,ss_p,17616069,Abstract,2,test,gold,1124.0
2206,"SETTING Department of Obstetric and Gynecology 2nd Medical Faculty Charles University and Teaching Hospital Motol , Prague , and Department of Obstetric and Gynecology 1st Medical Faculty and Teaching Hospital Bulovka ,",Prague .,,"['SETTING', 'Department', 'of', 'Obstetric', 'and', 'Gynecology', '2nd', 'Medical', 'Faculty', 'Charles', 'University', 'and', 'Teaching', 'Hospital', 'Motol', ',', 'Prague', ',', 'and', 'Department', 'of', 'Obstetric', 'and', 'Gynecology', '1st', 'Medical', 'Faculty', 'and', 'Teaching', 'Hospital', 'Bulovka', ',', 'Prague', '.']","(32, 34)","(219, 227)",-1,ss_p,17616069,Abstract,2,test,gold,1125.0
2207,"SETTING Department of Obstetric and Gynecology 2nd Medical Faculty Charles University and Teaching Hospital Motol ,",Prague,", and Department of Obstetric and Gynecology 1st Medical Faculty and Teaching Hospital Bulovka , Prague .","['SETTING', 'Department', 'of', 'Obstetric', 'and', 'Gynecology', '2nd', 'Medical', 'Faculty', 'Charles', 'University', 'and', 'Teaching', 'Hospital', 'Motol', ',', 'Prague', ',', 'and', 'Department', 'of', 'Obstetric', 'and', 'Gynecology', '1st', 'Medical', 'Faculty', 'and', 'Teaching', 'Hospital', 'Bulovka', ',', 'Prague', '.']","(16, 17)","(115, 121)",-1,hl_p,17616069,Abstract,2,test,gold,1123.0
2208,"SETTING Department of Obstetric and Gynecology 2nd Medical Faculty Charles University and Teaching Hospital Motol , Prague , and Department of Obstetric and Gynecology 1st Medical Faculty and Teaching Hospital Bulovka ,",Prague,.,"['SETTING', 'Department', 'of', 'Obstetric', 'and', 'Gynecology', '2nd', 'Medical', 'Faculty', 'Charles', 'University', 'and', 'Teaching', 'Hospital', 'Motol', ',', 'Prague', ',', 'and', 'Department', 'of', 'Obstetric', 'and', 'Gynecology', '1st', 'Medical', 'Faculty', 'and', 'Teaching', 'Hospital', 'Bulovka', ',', 'Prague', '.']","(32, 33)","(219, 225)",-1,hl_p,17616069,Abstract,2,test,gold,1122.0
2209,METHODS 500 mg of sacharose ferric oxide ( Venofer ) was intravenously administered in two days regimen to,50 women with clinical and lab signs of postpartal anemia .,,"['METHODS', '500', 'mg', 'of', 'sacharose', 'ferric', 'oxide', '(', 'Venofer', ')', 'was', 'intravenously', 'administered', 'in', 'two', 'days', 'regimen', 'to', '50', 'women', 'with', 'clinical', 'and', 'lab', 'signs', 'of', 'postpartal', 'anemia', '.']","(18, 29)","(106, 165)",-1,ss_p,17616069,Abstract,3,test,gold,4741.0
2210,METHODS 500 mg of,sacharose ferric oxide ( Venofer ),was intravenously administered in two days regimen to 50 women with clinical and lab signs of postpartal anemia .,"['METHODS', '500', 'mg', 'of', 'sacharose', 'ferric', 'oxide', '(', 'Venofer', ')', 'was', 'intravenously', 'administered', 'in', 'two', 'days', 'regimen', 'to', '50', 'women', 'with', 'clinical', 'and', 'lab', 'signs', 'of', 'postpartal', 'anemia', '.']","(4, 10)","(17, 51)",-1,ss_i,17616069,Abstract,3,test,gold,4678.0
2211,METHODS 500 mg of sacharose ferric oxide ( Venofer ) was intravenously administered in two days regimen to,50 women,with clinical and lab signs of postpartal anemia .,"['METHODS', '500', 'mg', 'of', 'sacharose', 'ferric', 'oxide', '(', 'Venofer', ')', 'was', 'intravenously', 'administered', 'in', 'two', 'days', 'regimen', 'to', '50', 'women', 'with', 'clinical', 'and', 'lab', 'signs', 'of', 'postpartal', 'anemia', '.']","(18, 20)","(106, 114)",-1,hl_p,17616069,Abstract,3,test,gold,2243.0
2212,METHODS 500 mg of sacharose ferric oxide ( Venofer ) was intravenously administered in two days regimen to 50 women with,clinical and lab signs of postpartal anemia,.,"['METHODS', '500', 'mg', 'of', 'sacharose', 'ferric', 'oxide', '(', 'Venofer', ')', 'was', 'intravenously', 'administered', 'in', 'two', 'days', 'regimen', 'to', '50', 'women', 'with', 'clinical', 'and', 'lab', 'signs', 'of', 'postpartal', 'anemia', '.']","(21, 28)","(120, 163)",-1,hl_p,17616069,Abstract,3,test,gold,4742.0
2213,METHODS 500 mg of,sacharose ferric oxide ( Venofer ),was intravenously administered in two days regimen to 50 women with clinical and lab signs of postpartal anemia .,"['METHODS', '500', 'mg', 'of', 'sacharose', 'ferric', 'oxide', '(', 'Venofer', ')', 'was', 'intravenously', 'administered', 'in', 'two', 'days', 'regimen', 'to', '50', 'women', 'with', 'clinical', 'and', 'lab', 'signs', 'of', 'postpartal', 'anemia', '.']","(4, 10)","(17, 51)",-1,hl_i,17616069,Abstract,3,test,gold,4679.0
2214,The effect of administered drug was determined by comparsion of,values of red blood count,"recovered before the treatment , 2nd or 3rd day post administration and two weeks later .","['The', 'effect', 'of', 'administered', 'drug', 'was', 'determined', 'by', 'comparsion', 'of', 'values', 'of', 'red', 'blood', 'count', 'recovered', 'before', 'the', 'treatment', ',', '2nd', 'or', '3rd', 'day', 'post', 'administration', 'and', 'two', 'weeks', 'later', '.']","(10, 15)","(63, 88)",-1,ss_o,17616069,Abstract,4,test,gold,2659.0
2215,The effect of administered drug was determined by comparsion of,values of red blood count,"recovered before the treatment , 2nd or 3rd day post administration and two weeks later .","['The', 'effect', 'of', 'administered', 'drug', 'was', 'determined', 'by', 'comparsion', 'of', 'values', 'of', 'red', 'blood', 'count', 'recovered', 'before', 'the', 'treatment', ',', '2nd', 'or', '3rd', 'day', 'post', 'administration', 'and', 'two', 'weeks', 'later', '.']","(10, 15)","(63, 88)",-1,hl_o,17616069,Abstract,4,test,gold,2660.0
2216,The,serum values of soluble transferrin receptors and ferritin,"were observed as markers of iron cell saturation and body iron reserves , too .","['The', 'serum', 'values', 'of', 'soluble', 'transferrin', 'receptors', 'and', 'ferritin', 'were', 'observed', 'as', 'markers', 'of', 'iron', 'cell', 'saturation', 'and', 'body', 'iron', 'reserves', ',', 'too', '.']","(1, 9)","(3, 61)",-1,ss_o,17616069,Abstract,5,test,gold,6521.0
2217,The serum values of soluble transferrin receptors and ferritin were observed as markers of,iron cell saturation and body iron reserves,", too .","['The', 'serum', 'values', 'of', 'soluble', 'transferrin', 'receptors', 'and', 'ferritin', 'were', 'observed', 'as', 'markers', 'of', 'iron', 'cell', 'saturation', 'and', 'body', 'iron', 'reserves', ',', 'too', '.']","(14, 21)","(90, 133)",-1,ss_o,17616069,Abstract,5,test,gold,1765.0
2218,The,serum values of soluble transferrin receptors and ferritin,"were observed as markers of iron cell saturation and body iron reserves , too .","['The', 'serum', 'values', 'of', 'soluble', 'transferrin', 'receptors', 'and', 'ferritin', 'were', 'observed', 'as', 'markers', 'of', 'iron', 'cell', 'saturation', 'and', 'body', 'iron', 'reserves', ',', 'too', '.']","(1, 9)","(3, 61)",-1,hl_o,17616069,Abstract,5,test,gold,6522.0
2219,The serum values of soluble transferrin receptors and ferritin were observed as markers of,iron cell saturation,"and body iron reserves , too .","['The', 'serum', 'values', 'of', 'soluble', 'transferrin', 'receptors', 'and', 'ferritin', 'were', 'observed', 'as', 'markers', 'of', 'iron', 'cell', 'saturation', 'and', 'body', 'iron', 'reserves', ',', 'too', '.']","(14, 17)","(90, 110)",-1,hl_o,17616069,Abstract,5,test,gold,3185.0
2220,The serum values of soluble transferrin receptors and ferritin were observed as markers of iron cell saturation and,body iron reserves,", too .","['The', 'serum', 'values', 'of', 'soluble', 'transferrin', 'receptors', 'and', 'ferritin', 'were', 'observed', 'as', 'markers', 'of', 'iron', 'cell', 'saturation', 'and', 'body', 'iron', 'reserves', ',', 'too', '.']","(18, 21)","(115, 133)",-1,hl_o,17616069,Abstract,5,test,gold,1766.0
2221,Integral part of the study was the monitoring of,adverse events,during the treatment .,"['Integral', 'part', 'of', 'the', 'study', 'was', 'the', 'monitoring', 'of', 'adverse', 'events', 'during', 'the', 'treatment', '.']","(9, 11)","(48, 62)",-1,ss_o,17616069,Abstract,6,test,gold,3067.0
2222,Integral part of the study was the monitoring of,adverse events,during the treatment .,"['Integral', 'part', 'of', 'the', 'study', 'was', 'the', 'monitoring', 'of', 'adverse', 'events', 'during', 'the', 'treatment', '.']","(9, 11)","(48, 62)",-1,hl_o,17616069,Abstract,6,test,gold,3066.0
2223,RESULTS Venofer came in sight as effective drug in the treatment of,pospartal anemia,and could become as the alternative to blood transfusion in mid-severe cases .,"['RESULTS', 'Venofer', 'came', 'in', 'sight', 'as', 'effective', 'drug', 'in', 'the', 'treatment', 'of', 'pospartal', 'anemia', 'and', 'could', 'become', 'as', 'the', 'alternative', 'to', 'blood', 'transfusion', 'in', 'mid-severe', 'cases', '.']","(12, 14)","(67, 83)",-1,ss_p,17616069,Abstract,7,test,gold,3423.0
2224,RESULTS,Venofer,came in sight as effective drug in the treatment of pospartal anemia and could become as the alternative to blood transfusion in mid-severe cases .,"['RESULTS', 'Venofer', 'came', 'in', 'sight', 'as', 'effective', 'drug', 'in', 'the', 'treatment', 'of', 'pospartal', 'anemia', 'and', 'could', 'become', 'as', 'the', 'alternative', 'to', 'blood', 'transfusion', 'in', 'mid-severe', 'cases', '.']","(1, 2)","(7, 14)",-1,ss_i,17616069,Abstract,7,test,gold,137.0
2225,RESULTS Venofer came in sight as,effective,drug in the treatment of pospartal anemia and could become as the alternative to blood transfusion in mid-severe cases .,"['RESULTS', 'Venofer', 'came', 'in', 'sight', 'as', 'effective', 'drug', 'in', 'the', 'treatment', 'of', 'pospartal', 'anemia', 'and', 'could', 'become', 'as', 'the', 'alternative', 'to', 'blood', 'transfusion', 'in', 'mid-severe', 'cases', '.']","(6, 7)","(32, 41)",-1,ss_o,17616069,Abstract,7,test,gold,854.0
2226,RESULTS,Venofer,came in sight as effective drug in the treatment of pospartal anemia and could become as the alternative to blood transfusion in mid-severe cases .,"['RESULTS', 'Venofer', 'came', 'in', 'sight', 'as', 'effective', 'drug', 'in', 'the', 'treatment', 'of', 'pospartal', 'anemia', 'and', 'could', 'become', 'as', 'the', 'alternative', 'to', 'blood', 'transfusion', 'in', 'mid-severe', 'cases', '.']","(1, 2)","(7, 14)",-1,hl_i,17616069,Abstract,7,test,gold,138.0
2227,RESULTS Venofer came in sight as,effective,drug in the treatment of pospartal anemia and could become as the alternative to blood transfusion in mid-severe cases .,"['RESULTS', 'Venofer', 'came', 'in', 'sight', 'as', 'effective', 'drug', 'in', 'the', 'treatment', 'of', 'pospartal', 'anemia', 'and', 'could', 'become', 'as', 'the', 'alternative', 'to', 'blood', 'transfusion', 'in', 'mid-severe', 'cases', '.']","(6, 7)","(32, 41)",-1,hl_o,17616069,Abstract,7,test,gold,853.0
2228,It should be emphasized that we have not encountered any serious adverse event with intravenous,trivalent saccharose ferric oxide,treatment .,"['It', 'should', 'be', 'emphasized', 'that', 'we', 'have', 'not', 'encountered', 'any', 'serious', 'adverse', 'event', 'with', 'intravenous', 'trivalent', 'saccharose', 'ferric', 'oxide', 'treatment', '.']","(15, 19)","(95, 128)",-1,ss_i,17616069,Abstract,8,test,gold,4680.0
2229,It should be emphasized that we have not encountered any,serious adverse event,with intravenous trivalent saccharose ferric oxide treatment .,"['It', 'should', 'be', 'emphasized', 'that', 'we', 'have', 'not', 'encountered', 'any', 'serious', 'adverse', 'event', 'with', 'intravenous', 'trivalent', 'saccharose', 'ferric', 'oxide', 'treatment', '.']","(10, 13)","(56, 77)",-1,ss_o,17616069,Abstract,8,test,gold,3048.0
2230,It should be emphasized that we have not encountered any serious adverse event with intravenous,trivalent saccharose ferric oxide,treatment .,"['It', 'should', 'be', 'emphasized', 'that', 'we', 'have', 'not', 'encountered', 'any', 'serious', 'adverse', 'event', 'with', 'intravenous', 'trivalent', 'saccharose', 'ferric', 'oxide', 'treatment', '.']","(15, 19)","(95, 128)",-1,hl_i,17616069,Abstract,8,test,gold,4681.0
2231,It should be emphasized that we have not encountered any,serious adverse event,with intravenous trivalent saccharose ferric oxide treatment .,"['It', 'should', 'be', 'emphasized', 'that', 'we', 'have', 'not', 'encountered', 'any', 'serious', 'adverse', 'event', 'with', 'intravenous', 'trivalent', 'saccharose', 'ferric', 'oxide', 'treatment', '.']","(10, 13)","(56, 77)",-1,hl_o,17616069,Abstract,8,test,gold,3049.0
2232,[ Clinical study of the efficacy of and tolerance to nimesulide in suppository formulation in,"pain-inflammatory pathologies of the ear , nose , and throat ]",.,"['[', 'Clinical', 'study', 'of', 'the', 'efficacy', 'of', 'and', 'tolerance', 'to', 'nimesulide', 'in', 'suppository', 'formulation', 'in', 'pain-inflammatory', 'pathologies', 'of', 'the', 'ear', ',', 'nose', ',', 'and', 'throat', ']', '.']","(15, 26)","(93, 155)",-1,ss_p,1780092,Title,0,test,gold,3124.0
2233,[ Clinical study of the efficacy of and tolerance to,nimesulide,"in suppository formulation in pain-inflammatory pathologies of the ear , nose , and throat ] .","['[', 'Clinical', 'study', 'of', 'the', 'efficacy', 'of', 'and', 'tolerance', 'to', 'nimesulide', 'in', 'suppository', 'formulation', 'in', 'pain-inflammatory', 'pathologies', 'of', 'the', 'ear', ',', 'nose', ',', 'and', 'throat', ']', '.']","(10, 11)","(52, 62)",-1,ss_i,1780092,Title,0,test,gold,126.0
2234,[ Clinical study of the,efficacy,"of and tolerance to nimesulide in suppository formulation in pain-inflammatory pathologies of the ear , nose , and throat ] .","['[', 'Clinical', 'study', 'of', 'the', 'efficacy', 'of', 'and', 'tolerance', 'to', 'nimesulide', 'in', 'suppository', 'formulation', 'in', 'pain-inflammatory', 'pathologies', 'of', 'the', 'ear', ',', 'nose', ',', 'and', 'throat', ']', '.']","(5, 6)","(23, 31)",-1,ss_o,1780092,Title,0,test,gold,4826.0
2235,[ Clinical study of the efficacy of and,tolerance,"to nimesulide in suppository formulation in pain-inflammatory pathologies of the ear , nose , and throat ] .","['[', 'Clinical', 'study', 'of', 'the', 'efficacy', 'of', 'and', 'tolerance', 'to', 'nimesulide', 'in', 'suppository', 'formulation', 'in', 'pain-inflammatory', 'pathologies', 'of', 'the', 'ear', ',', 'nose', ',', 'and', 'throat', ']', '.']","(8, 9)","(39, 48)",-1,ss_o,1780092,Title,0,test,gold,1356.0
2236,[ Clinical study of the efficacy of and tolerance to,nimesulide,"in suppository formulation in pain-inflammatory pathologies of the ear , nose , and throat ] .","['[', 'Clinical', 'study', 'of', 'the', 'efficacy', 'of', 'and', 'tolerance', 'to', 'nimesulide', 'in', 'suppository', 'formulation', 'in', 'pain-inflammatory', 'pathologies', 'of', 'the', 'ear', ',', 'nose', ',', 'and', 'throat', ']', '.']","(10, 11)","(52, 62)",-1,hl_i,1780092,Title,0,test,gold,127.0
2237,[ Clinical study of the,efficacy,"of and tolerance to nimesulide in suppository formulation in pain-inflammatory pathologies of the ear , nose , and throat ] .","['[', 'Clinical', 'study', 'of', 'the', 'efficacy', 'of', 'and', 'tolerance', 'to', 'nimesulide', 'in', 'suppository', 'formulation', 'in', 'pain-inflammatory', 'pathologies', 'of', 'the', 'ear', ',', 'nose', ',', 'and', 'throat', ']', '.']","(5, 6)","(23, 31)",-1,hl_o,1780092,Title,0,test,gold,4825.0
2238,[ Clinical study of the efficacy of and,tolerance,"to nimesulide in suppository formulation in pain-inflammatory pathologies of the ear , nose , and throat ] .","['[', 'Clinical', 'study', 'of', 'the', 'efficacy', 'of', 'and', 'tolerance', 'to', 'nimesulide', 'in', 'suppository', 'formulation', 'in', 'pain-inflammatory', 'pathologies', 'of', 'the', 'ear', ',', 'nose', ',', 'and', 'throat', ']', '.']","(8, 9)","(39, 48)",-1,hl_o,1780092,Title,0,test,gold,1357.0
2239,The efficacy and tolerability of a new pharmaceutical form of the,non-steroid anti-inflammatory drug .,,"['The', 'efficacy', 'and', 'tolerability', 'of', 'a', 'new', 'pharmaceutical', 'form', 'of', 'the', 'non-steroid', 'anti-inflammatory', 'drug', '.']","(11, 15)","(65, 101)",-1,ss_i,1780092,Abstract,0,test,gold,5081.0
2240,The,efficacy,and tolerability of a new pharmaceutical form of the non-steroid anti-inflammatory drug .,"['The', 'efficacy', 'and', 'tolerability', 'of', 'a', 'new', 'pharmaceutical', 'form', 'of', 'the', 'non-steroid', 'anti-inflammatory', 'drug', '.']","(1, 2)","(3, 11)",-1,ss_o,1780092,Abstract,0,test,gold,4824.0
2241,The efficacy and,tolerability,of a new pharmaceutical form of the non-steroid anti-inflammatory drug .,"['The', 'efficacy', 'and', 'tolerability', 'of', 'a', 'new', 'pharmaceutical', 'form', 'of', 'the', 'non-steroid', 'anti-inflammatory', 'drug', '.']","(3, 4)","(16, 28)",-1,ss_o,1780092,Abstract,0,test,gold,4867.0
2242,The,efficacy,and tolerability of a new pharmaceutical form of the non-steroid anti-inflammatory drug .,"['The', 'efficacy', 'and', 'tolerability', 'of', 'a', 'new', 'pharmaceutical', 'form', 'of', 'the', 'non-steroid', 'anti-inflammatory', 'drug', '.']","(1, 2)","(3, 11)",-1,hl_o,1780092,Abstract,0,test,gold,4823.0
2243,The efficacy and,tolerability,of a new pharmaceutical form of the non-steroid anti-inflammatory drug .,"['The', 'efficacy', 'and', 'tolerability', 'of', 'a', 'new', 'pharmaceutical', 'form', 'of', 'the', 'non-steroid', 'anti-inflammatory', 'drug', '.']","(3, 4)","(16, 28)",-1,hl_o,1780092,Abstract,0,test,gold,4866.0
2244,"Nimesulide have been studied in a double blind study compared with flurbiprofen , in",98 patients aged between 18 and 75 suffering from pain-inflammatory pathologies of ENT nature .,,"['Nimesulide', 'have', 'been', 'studied', 'in', 'a', 'double', 'blind', 'study', 'compared', 'with', 'flurbiprofen', ',', 'in', '98', 'patients', 'aged', 'between', '18', 'and', '75', 'suffering', 'from', 'pain-inflammatory', 'pathologies', 'of', 'ENT', 'nature', '.']","(14, 29)","(84, 179)",-1,ss_p,1780092,Abstract,1,test,gold,7019.0
2245,,Nimesulide,"have been studied in a double blind study compared with flurbiprofen , in 98 patients aged between 18 and 75 suffering from pain-inflammatory pathologies of ENT nature .","['Nimesulide', 'have', 'been', 'studied', 'in', 'a', 'double', 'blind', 'study', 'compared', 'with', 'flurbiprofen', ',', 'in', '98', 'patients', 'aged', 'between', '18', 'and', '75', 'suffering', 'from', 'pain-inflammatory', 'pathologies', 'of', 'ENT', 'nature', '.']","(0, 1)","(0, 10)",-1,ss_i,1780092,Abstract,1,test,gold,124.0
2246,Nimesulide have been studied in a double blind study compared with,flurbiprofen,", in 98 patients aged between 18 and 75 suffering from pain-inflammatory pathologies of ENT nature .","['Nimesulide', 'have', 'been', 'studied', 'in', 'a', 'double', 'blind', 'study', 'compared', 'with', 'flurbiprofen', ',', 'in', '98', 'patients', 'aged', 'between', '18', 'and', '75', 'suffering', 'from', 'pain-inflammatory', 'pathologies', 'of', 'ENT', 'nature', '.']","(11, 12)","(66, 78)",-1,ss_i,1780092,Abstract,1,test,gold,1044.0
2247,"Nimesulide have been studied in a double blind study compared with flurbiprofen , in",98,patients aged between 18 and 75 suffering from pain-inflammatory pathologies of ENT nature .,"['Nimesulide', 'have', 'been', 'studied', 'in', 'a', 'double', 'blind', 'study', 'compared', 'with', 'flurbiprofen', ',', 'in', '98', 'patients', 'aged', 'between', '18', 'and', '75', 'suffering', 'from', 'pain-inflammatory', 'pathologies', 'of', 'ENT', 'nature', '.']","(14, 15)","(84, 86)",-1,hl_p,1780092,Abstract,1,test,gold,
2248,"Nimesulide have been studied in a double blind study compared with flurbiprofen , in 98 patients",aged between 18 and 75,suffering from pain-inflammatory pathologies of ENT nature .,"['Nimesulide', 'have', 'been', 'studied', 'in', 'a', 'double', 'blind', 'study', 'compared', 'with', 'flurbiprofen', ',', 'in', '98', 'patients', 'aged', 'between', '18', 'and', '75', 'suffering', 'from', 'pain-inflammatory', 'pathologies', 'of', 'ENT', 'nature', '.']","(16, 21)","(96, 118)",-1,hl_p,1780092,Abstract,1,test,gold,2030.0
2249,"Nimesulide have been studied in a double blind study compared with flurbiprofen , in 98 patients aged between 18 and 75 suffering from",pain-inflammatory pathologies of ENT nature .,,"['Nimesulide', 'have', 'been', 'studied', 'in', 'a', 'double', 'blind', 'study', 'compared', 'with', 'flurbiprofen', ',', 'in', '98', 'patients', 'aged', 'between', '18', 'and', '75', 'suffering', 'from', 'pain-inflammatory', 'pathologies', 'of', 'ENT', 'nature', '.']","(23, 29)","(134, 179)",-1,hl_p,1780092,Abstract,1,test,gold,3435.0
2250,,Nimesulide,"have been studied in a double blind study compared with flurbiprofen , in 98 patients aged between 18 and 75 suffering from pain-inflammatory pathologies of ENT nature .","['Nimesulide', 'have', 'been', 'studied', 'in', 'a', 'double', 'blind', 'study', 'compared', 'with', 'flurbiprofen', ',', 'in', '98', 'patients', 'aged', 'between', '18', 'and', '75', 'suffering', 'from', 'pain-inflammatory', 'pathologies', 'of', 'ENT', 'nature', '.']","(0, 1)","(0, 10)",-1,hl_i,1780092,Abstract,1,test,gold,125.0
2251,Nimesulide have been studied in a double blind study compared with,flurbiprofen,", in 98 patients aged between 18 and 75 suffering from pain-inflammatory pathologies of ENT nature .","['Nimesulide', 'have', 'been', 'studied', 'in', 'a', 'double', 'blind', 'study', 'compared', 'with', 'flurbiprofen', ',', 'in', '98', 'patients', 'aged', 'between', '18', 'and', '75', 'suffering', 'from', 'pain-inflammatory', 'pathologies', 'of', 'ENT', 'nature', '.']","(11, 12)","(66, 78)",-1,hl_i,1780092,Abstract,1,test,gold,1045.0
2252,"Both drugs , administered in a dose of one suppository twice a day for 7 days , showed marked","anti-inflammatory , analgesic and antipyretic activity","and produced a significant , progressive improvement in the typical symptoms of the inflammatory state up to their complete remission .","['Both', 'drugs', ',', 'administered', 'in', 'a', 'dose', 'of', 'one', 'suppository', 'twice', 'a', 'day', 'for', '7', 'days', ',', 'showed', 'marked', 'anti-inflammatory', ',', 'analgesic', 'and', 'antipyretic', 'activity', 'and', 'produced', 'a', 'significant', ',', 'progressive', 'improvement', 'in', 'the', 'typical', 'symptoms', 'of', 'the', 'inflammatory', 'state', 'up', 'to', 'their', 'complete', 'remission', '.']","(19, 25)","(93, 147)",-1,ss_o,1780092,Abstract,2,test,gold,5055.0
2253,"Both drugs , administered in a dose of one suppository twice a day for 7 days , showed marked anti-inflammatory , analgesic and antipyretic activity and produced a significant , progressive improvement in the typical",symptoms of the inflammatory state,up to their complete remission .,"['Both', 'drugs', ',', 'administered', 'in', 'a', 'dose', 'of', 'one', 'suppository', 'twice', 'a', 'day', 'for', '7', 'days', ',', 'showed', 'marked', 'anti-inflammatory', ',', 'analgesic', 'and', 'antipyretic', 'activity', 'and', 'produced', 'a', 'significant', ',', 'progressive', 'improvement', 'in', 'the', 'typical', 'symptoms', 'of', 'the', 'inflammatory', 'state', 'up', 'to', 'their', 'complete', 'remission', '.']","(35, 40)","(216, 250)",-1,ss_o,1780092,Abstract,2,test,gold,3287.0
2254,"Both drugs , administered in a dose of one suppository twice a day for 7 days , showed marked","anti-inflammatory , analgesic and antipyretic activity","and produced a significant , progressive improvement in the typical symptoms of the inflammatory state up to their complete remission .","['Both', 'drugs', ',', 'administered', 'in', 'a', 'dose', 'of', 'one', 'suppository', 'twice', 'a', 'day', 'for', '7', 'days', ',', 'showed', 'marked', 'anti-inflammatory', ',', 'analgesic', 'and', 'antipyretic', 'activity', 'and', 'produced', 'a', 'significant', ',', 'progressive', 'improvement', 'in', 'the', 'typical', 'symptoms', 'of', 'the', 'inflammatory', 'state', 'up', 'to', 'their', 'complete', 'remission', '.']","(19, 25)","(93, 147)",-1,hl_o,1780092,Abstract,2,test,gold,5056.0
2255,"Both drugs , administered in a dose of one suppository twice a day for 7 days , showed marked anti-inflammatory , analgesic and antipyretic activity and produced a significant , progressive improvement in the typical",symptoms of the inflammatory state,up to their complete remission .,"['Both', 'drugs', ',', 'administered', 'in', 'a', 'dose', 'of', 'one', 'suppository', 'twice', 'a', 'day', 'for', '7', 'days', ',', 'showed', 'marked', 'anti-inflammatory', ',', 'analgesic', 'and', 'antipyretic', 'activity', 'and', 'produced', 'a', 'significant', ',', 'progressive', 'improvement', 'in', 'the', 'typical', 'symptoms', 'of', 'the', 'inflammatory', 'state', 'up', 'to', 'their', 'complete', 'remission', '.']","(35, 40)","(216, 250)",-1,hl_o,1780092,Abstract,2,test,gold,3288.0
2256,,Nimesulide,evidenced greater speed and duration of therapeutic action .,"['Nimesulide', 'evidenced', 'greater', 'speed', 'and', 'duration', 'of', 'therapeutic', 'action', '.']","(0, 1)","(0, 10)",-1,ss_i,1780092,Abstract,3,test,gold,123.0
2257,Nimesulide evidenced greater speed and,duration,of therapeutic action .,"['Nimesulide', 'evidenced', 'greater', 'speed', 'and', 'duration', 'of', 'therapeutic', 'action', '.']","(5, 6)","(38, 46)",-1,ss_o,1780092,Abstract,3,test,gold,1325.0
2258,,Nimesulide,evidenced greater speed and duration of therapeutic action .,"['Nimesulide', 'evidenced', 'greater', 'speed', 'and', 'duration', 'of', 'therapeutic', 'action', '.']","(0, 1)","(0, 10)",-1,hl_i,1780092,Abstract,3,test,gold,122.0
2259,Nimesulide evidenced greater speed and,duration,of therapeutic action .,"['Nimesulide', 'evidenced', 'greater', 'speed', 'and', 'duration', 'of', 'therapeutic', 'action', '.']","(5, 6)","(38, 46)",-1,hl_o,1780092,Abstract,3,test,gold,1324.0
2260,Assessment on the,effectiveness,and tolerability as expressed separately by the physician and patient were positive in almost all cases of both treatments .,"['Assessment', 'on', 'the', 'effectiveness', 'and', 'tolerability', 'as', 'expressed', 'separately', 'by', 'the', 'physician', 'and', 'patient', 'were', 'positive', 'in', 'almost', 'all', 'cases', 'of', 'both', 'treatments', '.']","(3, 4)","(17, 30)",-1,ss_o,1780092,Abstract,4,test,gold,399.0
2261,Assessment on the effectiveness and,tolerability,as expressed separately by the physician and patient were positive in almost all cases of both treatments .,"['Assessment', 'on', 'the', 'effectiveness', 'and', 'tolerability', 'as', 'expressed', 'separately', 'by', 'the', 'physician', 'and', 'patient', 'were', 'positive', 'in', 'almost', 'all', 'cases', 'of', 'both', 'treatments', '.']","(5, 6)","(35, 47)",-1,ss_o,1780092,Abstract,4,test,gold,4865.0
2262,Assessment on the,effectiveness,and tolerability as expressed separately by the physician and patient were positive in almost all cases of both treatments .,"['Assessment', 'on', 'the', 'effectiveness', 'and', 'tolerability', 'as', 'expressed', 'separately', 'by', 'the', 'physician', 'and', 'patient', 'were', 'positive', 'in', 'almost', 'all', 'cases', 'of', 'both', 'treatments', '.']","(3, 4)","(17, 30)",-1,hl_o,1780092,Abstract,4,test,gold,400.0
2263,Assessment on the effectiveness and,tolerability,as expressed separately by the physician and patient were positive in almost all cases of both treatments .,"['Assessment', 'on', 'the', 'effectiveness', 'and', 'tolerability', 'as', 'expressed', 'separately', 'by', 'the', 'physician', 'and', 'patient', 'were', 'positive', 'in', 'almost', 'all', 'cases', 'of', 'both', 'treatments', '.']","(5, 6)","(35, 47)",-1,hl_o,1780092,Abstract,4,test,gold,4864.0
2264,Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast : a randomised controlled trial investigating the effects on airway inflammation in,asthma .,,"['Salmeterol', 'plus', 'fluticasone', 'propionate', 'versus', 'fluticasone', 'propionate', 'plus', 'montelukast', ':', 'a', 'randomised', 'controlled', 'trial', 'investigating', 'the', 'effects', 'on', 'airway', 'inflammation', 'in', 'asthma', '.']","(21, 23)","(169, 177)",-1,ss_p,17897478,Title,0,test,gold,3457.0
2265,,Salmeterol,plus fluticasone propionate versus fluticasone propionate plus montelukast : a randomised controlled trial investigating the effects on airway inflammation in asthma .,"['Salmeterol', 'plus', 'fluticasone', 'propionate', 'versus', 'fluticasone', 'propionate', 'plus', 'montelukast', ':', 'a', 'randomised', 'controlled', 'trial', 'investigating', 'the', 'effects', 'on', 'airway', 'inflammation', 'in', 'asthma', '.']","(0, 1)","(0, 10)",-1,ss_i,17897478,Title,0,test,gold,162.0
2266,Salmeterol plus,fluticasone propionate,versus fluticasone propionate plus montelukast : a randomised controlled trial investigating the effects on airway inflammation in asthma .,"['Salmeterol', 'plus', 'fluticasone', 'propionate', 'versus', 'fluticasone', 'propionate', 'plus', 'montelukast', ':', 'a', 'randomised', 'controlled', 'trial', 'investigating', 'the', 'effects', 'on', 'airway', 'inflammation', 'in', 'asthma', '.']","(2, 4)","(15, 37)",-1,ss_i,17897478,Title,0,test,gold,5204.0
2267,Salmeterol plus fluticasone propionate versus,fluticasone propionate,plus montelukast : a randomised controlled trial investigating the effects on airway inflammation in asthma .,"['Salmeterol', 'plus', 'fluticasone', 'propionate', 'versus', 'fluticasone', 'propionate', 'plus', 'montelukast', ':', 'a', 'randomised', 'controlled', 'trial', 'investigating', 'the', 'effects', 'on', 'airway', 'inflammation', 'in', 'asthma', '.']","(5, 7)","(45, 67)",-1,ss_i,17897478,Title,0,test,gold,5205.0
2268,Salmeterol plus fluticasone propionate versus fluticasone propionate plus,montelukast :,a randomised controlled trial investigating the effects on airway inflammation in asthma .,"['Salmeterol', 'plus', 'fluticasone', 'propionate', 'versus', 'fluticasone', 'propionate', 'plus', 'montelukast', ':', 'a', 'randomised', 'controlled', 'trial', 'investigating', 'the', 'effects', 'on', 'airway', 'inflammation', 'in', 'asthma', '.']","(8, 10)","(73, 86)",-1,ss_i,17897478,Title,0,test,gold,5607.0
2269,Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast : a randomised controlled trial investigating the,effects on airway inflammation,in asthma .,"['Salmeterol', 'plus', 'fluticasone', 'propionate', 'versus', 'fluticasone', 'propionate', 'plus', 'montelukast', ':', 'a', 'randomised', 'controlled', 'trial', 'investigating', 'the', 'effects', 'on', 'airway', 'inflammation', 'in', 'asthma', '.']","(16, 20)","(135, 165)",-1,ss_o,17897478,Title,0,test,gold,3133.0
2270,,Salmeterol,plus fluticasone propionate versus fluticasone propionate plus montelukast : a randomised controlled trial investigating the effects on airway inflammation in asthma .,"['Salmeterol', 'plus', 'fluticasone', 'propionate', 'versus', 'fluticasone', 'propionate', 'plus', 'montelukast', ':', 'a', 'randomised', 'controlled', 'trial', 'investigating', 'the', 'effects', 'on', 'airway', 'inflammation', 'in', 'asthma', '.']","(0, 1)","(0, 10)",-1,hl_i,17897478,Title,0,test,gold,163.0
2271,Salmeterol plus,fluticasone propionate,versus fluticasone propionate plus montelukast : a randomised controlled trial investigating the effects on airway inflammation in asthma .,"['Salmeterol', 'plus', 'fluticasone', 'propionate', 'versus', 'fluticasone', 'propionate', 'plus', 'montelukast', ':', 'a', 'randomised', 'controlled', 'trial', 'investigating', 'the', 'effects', 'on', 'airway', 'inflammation', 'in', 'asthma', '.']","(2, 4)","(15, 37)",-1,hl_i,17897478,Title,0,test,gold,5203.0
2272,Salmeterol plus fluticasone propionate versus,fluticasone propionate,plus montelukast : a randomised controlled trial investigating the effects on airway inflammation in asthma .,"['Salmeterol', 'plus', 'fluticasone', 'propionate', 'versus', 'fluticasone', 'propionate', 'plus', 'montelukast', ':', 'a', 'randomised', 'controlled', 'trial', 'investigating', 'the', 'effects', 'on', 'airway', 'inflammation', 'in', 'asthma', '.']","(5, 7)","(45, 67)",-1,hl_i,17897478,Title,0,test,gold,5202.0
2273,Salmeterol plus fluticasone propionate versus fluticasone propionate plus,montelukast :,a randomised controlled trial investigating the effects on airway inflammation in asthma .,"['Salmeterol', 'plus', 'fluticasone', 'propionate', 'versus', 'fluticasone', 'propionate', 'plus', 'montelukast', ':', 'a', 'randomised', 'controlled', 'trial', 'investigating', 'the', 'effects', 'on', 'airway', 'inflammation', 'in', 'asthma', '.']","(8, 10)","(73, 86)",-1,hl_i,17897478,Title,0,test,gold,5608.0
2274,Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast : a randomised controlled trial investigating the effects on,airway inflammation,in asthma .,"['Salmeterol', 'plus', 'fluticasone', 'propionate', 'versus', 'fluticasone', 'propionate', 'plus', 'montelukast', ':', 'a', 'randomised', 'controlled', 'trial', 'investigating', 'the', 'effects', 'on', 'airway', 'inflammation', 'in', 'asthma', '.']","(18, 20)","(146, 165)",-1,hl_o,17897478,Title,0,test,gold,3134.0
2275,BACKGROUND Few studies have compared treatment strategies in,patients with asthma poorly controlled on low dose inhaled corticosteroids,", and little is known about the effects of different treatments on airway inflammation .","['BACKGROUND', 'Few', 'studies', 'have', 'compared', 'treatment', 'strategies', 'in', 'patients', 'with', 'asthma', 'poorly', 'controlled', 'on', 'low', 'dose', 'inhaled', 'corticosteroids', ',', 'and', 'little', 'is', 'known', 'about', 'the', 'effects', 'of', 'different', 'treatments', 'on', 'airway', 'inflammation', '.']","(8, 18)","(60, 134)",-1,ss_p,17897478,Abstract,0,test,gold,7107.0
2276,BACKGROUND Few studies have compared treatment strategies in patients with asthma poorly controlled on low dose inhaled,corticosteroids,", and little is known about the effects of different treatments on airway inflammation .","['BACKGROUND', 'Few', 'studies', 'have', 'compared', 'treatment', 'strategies', 'in', 'patients', 'with', 'asthma', 'poorly', 'controlled', 'on', 'low', 'dose', 'inhaled', 'corticosteroids', ',', 'and', 'little', 'is', 'known', 'about', 'the', 'effects', 'of', 'different', 'treatments', 'on', 'airway', 'inflammation', '.']","(17, 18)","(119, 134)",-1,ss_i,17897478,Abstract,0,test,gold,5602.0
2277,BACKGROUND Few studies have compared treatment strategies in,patients with asthma,"poorly controlled on low dose inhaled corticosteroids , and little is known about the effects of different treatments on airway inflammation .","['BACKGROUND', 'Few', 'studies', 'have', 'compared', 'treatment', 'strategies', 'in', 'patients', 'with', 'asthma', 'poorly', 'controlled', 'on', 'low', 'dose', 'inhaled', 'corticosteroids', ',', 'and', 'little', 'is', 'known', 'about', 'the', 'effects', 'of', 'different', 'treatments', 'on', 'airway', 'inflammation', '.']","(8, 11)","(60, 80)",-1,hl_p,17897478,Abstract,0,test,gold,3811.0
2278,"In this double-blind , placebo-controlled , parallel group study , we compared the effects of salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and FP plus montelukast ( FP/M ) on sputum inflammatory markers , airway responsiveness , lung function , and symptoms in",adult asthmatics .,,"['In', 'this', 'double-blind', ',', 'placebo-controlled', ',', 'parallel', 'group', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'salmeterol', 'plus', 'fluticasone', 'propionate', '(', 'FP', ')', '(', 'Seretide', ';', 'SFC', ')', 'and', 'FP', 'plus', 'montelukast', '(', 'FP/M', ')', 'on', 'sputum', 'inflammatory', 'markers', ',', 'airway', 'responsiveness', ',', 'lung', 'function', ',', 'and', 'symptoms', 'in', 'adult', 'asthmatics', '.']","(48, 51)","(280, 298)",-1,ss_p,17897478,Abstract,1,test,gold,3813.0
2279,"In this double-blind , placebo-controlled , parallel group study , we compared the effects of",salmeterol,"plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and FP plus montelukast ( FP/M ) on sputum inflammatory markers , airway responsiveness , lung function , and symptoms in adult asthmatics .","['In', 'this', 'double-blind', ',', 'placebo-controlled', ',', 'parallel', 'group', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'salmeterol', 'plus', 'fluticasone', 'propionate', '(', 'FP', ')', '(', 'Seretide', ';', 'SFC', ')', 'and', 'FP', 'plus', 'montelukast', '(', 'FP/M', ')', 'on', 'sputum', 'inflammatory', 'markers', ',', 'airway', 'responsiveness', ',', 'lung', 'function', ',', 'and', 'symptoms', 'in', 'adult', 'asthmatics', '.']","(15, 16)","(93, 103)",-1,ss_i,17897478,Abstract,1,test,gold,5609.0
2280,"In this double-blind , placebo-controlled , parallel group study , we compared the effects of salmeterol plus",fluticasone propionate ( FP ) ( Seretide ; SFC ),"and FP plus montelukast ( FP/M ) on sputum inflammatory markers , airway responsiveness , lung function , and symptoms in adult asthmatics .","['In', 'this', 'double-blind', ',', 'placebo-controlled', ',', 'parallel', 'group', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'salmeterol', 'plus', 'fluticasone', 'propionate', '(', 'FP', ')', '(', 'Seretide', ';', 'SFC', ')', 'and', 'FP', 'plus', 'montelukast', '(', 'FP/M', ')', 'on', 'sputum', 'inflammatory', 'markers', ',', 'airway', 'responsiveness', ',', 'lung', 'function', ',', 'and', 'symptoms', 'in', 'adult', 'asthmatics', '.']","(17, 27)","(109, 157)",-1,ss_i,17897478,Abstract,1,test,gold,5200.0
2281,"In this double-blind , placebo-controlled , parallel group study , we compared the effects of salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and",FP,"plus montelukast ( FP/M ) on sputum inflammatory markers , airway responsiveness , lung function , and symptoms in adult asthmatics .","['In', 'this', 'double-blind', ',', 'placebo-controlled', ',', 'parallel', 'group', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'salmeterol', 'plus', 'fluticasone', 'propionate', '(', 'FP', ')', '(', 'Seretide', ';', 'SFC', ')', 'and', 'FP', 'plus', 'montelukast', '(', 'FP/M', ')', 'on', 'sputum', 'inflammatory', 'markers', ',', 'airway', 'responsiveness', ',', 'lung', 'function', ',', 'and', 'symptoms', 'in', 'adult', 'asthmatics', '.']","(28, 29)","(162, 164)",-1,ss_i,17897478,Abstract,1,test,gold,696.0
2282,"In this double-blind , placebo-controlled , parallel group study , we compared the effects of salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and FP plus",montelukast ( FP/M ),"on sputum inflammatory markers , airway responsiveness , lung function , and symptoms in adult asthmatics .","['In', 'this', 'double-blind', ',', 'placebo-controlled', ',', 'parallel', 'group', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'salmeterol', 'plus', 'fluticasone', 'propionate', '(', 'FP', ')', '(', 'Seretide', ';', 'SFC', ')', 'and', 'FP', 'plus', 'montelukast', '(', 'FP/M', ')', 'on', 'sputum', 'inflammatory', 'markers', ',', 'airway', 'responsiveness', ',', 'lung', 'function', ',', 'and', 'symptoms', 'in', 'adult', 'asthmatics', '.']","(30, 34)","(170, 190)",-1,ss_i,17897478,Abstract,1,test,gold,5606.0
2283,"In this double-blind , placebo-controlled , parallel group study , we compared the effects of salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and FP plus montelukast ( FP/M ) on","sputum inflammatory markers , airway responsiveness , lung function , and symptoms",in adult asthmatics .,"['In', 'this', 'double-blind', ',', 'placebo-controlled', ',', 'parallel', 'group', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'salmeterol', 'plus', 'fluticasone', 'propionate', '(', 'FP', ')', '(', 'Seretide', ';', 'SFC', ')', 'and', 'FP', 'plus', 'montelukast', '(', 'FP/M', ')', 'on', 'sputum', 'inflammatory', 'markers', ',', 'airway', 'responsiveness', ',', 'lung', 'function', ',', 'and', 'symptoms', 'in', 'adult', 'asthmatics', '.']","(35, 47)","(194, 276)",-1,ss_o,17897478,Abstract,1,test,gold,5988.0
2284,"In this double-blind , placebo-controlled , parallel group study , we compared the effects of salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and FP plus montelukast ( FP/M ) on sputum inflammatory markers , airway responsiveness , lung function , and symptoms in",adult asthmatics .,,"['In', 'this', 'double-blind', ',', 'placebo-controlled', ',', 'parallel', 'group', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'salmeterol', 'plus', 'fluticasone', 'propionate', '(', 'FP', ')', '(', 'Seretide', ';', 'SFC', ')', 'and', 'FP', 'plus', 'montelukast', '(', 'FP/M', ')', 'on', 'sputum', 'inflammatory', 'markers', ',', 'airway', 'responsiveness', ',', 'lung', 'function', ',', 'and', 'symptoms', 'in', 'adult', 'asthmatics', '.']","(48, 51)","(280, 298)",-1,hl_p,17897478,Abstract,1,test,gold,3814.0
2285,"In this double-blind , placebo-controlled , parallel group study , we compared the effects of",salmeterol,"plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and FP plus montelukast ( FP/M ) on sputum inflammatory markers , airway responsiveness , lung function , and symptoms in adult asthmatics .","['In', 'this', 'double-blind', ',', 'placebo-controlled', ',', 'parallel', 'group', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'salmeterol', 'plus', 'fluticasone', 'propionate', '(', 'FP', ')', '(', 'Seretide', ';', 'SFC', ')', 'and', 'FP', 'plus', 'montelukast', '(', 'FP/M', ')', 'on', 'sputum', 'inflammatory', 'markers', ',', 'airway', 'responsiveness', ',', 'lung', 'function', ',', 'and', 'symptoms', 'in', 'adult', 'asthmatics', '.']","(15, 16)","(93, 103)",-1,hl_i,17897478,Abstract,1,test,gold,5610.0
2286,"In this double-blind , placebo-controlled , parallel group study , we compared the effects of salmeterol plus",fluticasone propionate ( FP ) ( Seretide ; SFC ),"and FP plus montelukast ( FP/M ) on sputum inflammatory markers , airway responsiveness , lung function , and symptoms in adult asthmatics .","['In', 'this', 'double-blind', ',', 'placebo-controlled', ',', 'parallel', 'group', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'salmeterol', 'plus', 'fluticasone', 'propionate', '(', 'FP', ')', '(', 'Seretide', ';', 'SFC', ')', 'and', 'FP', 'plus', 'montelukast', '(', 'FP/M', ')', 'on', 'sputum', 'inflammatory', 'markers', ',', 'airway', 'responsiveness', ',', 'lung', 'function', ',', 'and', 'symptoms', 'in', 'adult', 'asthmatics', '.']","(17, 27)","(109, 157)",-1,hl_i,17897478,Abstract,1,test,gold,5201.0
2287,"In this double-blind , placebo-controlled , parallel group study , we compared the effects of salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and",FP,"plus montelukast ( FP/M ) on sputum inflammatory markers , airway responsiveness , lung function , and symptoms in adult asthmatics .","['In', 'this', 'double-blind', ',', 'placebo-controlled', ',', 'parallel', 'group', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'salmeterol', 'plus', 'fluticasone', 'propionate', '(', 'FP', ')', '(', 'Seretide', ';', 'SFC', ')', 'and', 'FP', 'plus', 'montelukast', '(', 'FP/M', ')', 'on', 'sputum', 'inflammatory', 'markers', ',', 'airway', 'responsiveness', ',', 'lung', 'function', ',', 'and', 'symptoms', 'in', 'adult', 'asthmatics', '.']","(28, 29)","(162, 164)",-1,hl_i,17897478,Abstract,1,test,gold,697.0
2288,"In this double-blind , placebo-controlled , parallel group study , we compared the effects of salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and FP plus",montelukast ( FP/M ),"on sputum inflammatory markers , airway responsiveness , lung function , and symptoms in adult asthmatics .","['In', 'this', 'double-blind', ',', 'placebo-controlled', ',', 'parallel', 'group', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'salmeterol', 'plus', 'fluticasone', 'propionate', '(', 'FP', ')', '(', 'Seretide', ';', 'SFC', ')', 'and', 'FP', 'plus', 'montelukast', '(', 'FP/M', ')', 'on', 'sputum', 'inflammatory', 'markers', ',', 'airway', 'responsiveness', ',', 'lung', 'function', ',', 'and', 'symptoms', 'in', 'adult', 'asthmatics', '.']","(30, 34)","(170, 190)",-1,hl_i,17897478,Abstract,1,test,gold,5605.0
2289,"In this double-blind , placebo-controlled , parallel group study , we compared the effects of salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and FP plus montelukast ( FP/M ) on",sputum inflammatory markers,", airway responsiveness , lung function , and symptoms in adult asthmatics .","['In', 'this', 'double-blind', ',', 'placebo-controlled', ',', 'parallel', 'group', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'salmeterol', 'plus', 'fluticasone', 'propionate', '(', 'FP', ')', '(', 'Seretide', ';', 'SFC', ')', 'and', 'FP', 'plus', 'montelukast', '(', 'FP/M', ')', 'on', 'sputum', 'inflammatory', 'markers', ',', 'airway', 'responsiveness', ',', 'lung', 'function', ',', 'and', 'symptoms', 'in', 'adult', 'asthmatics', '.']","(35, 38)","(194, 221)",-1,hl_o,17897478,Abstract,1,test,gold,4541.0
2290,"In this double-blind , placebo-controlled , parallel group study , we compared the effects of salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and FP plus montelukast ( FP/M ) on sputum inflammatory markers ,","airway responsiveness , lung function",", and symptoms in adult asthmatics .","['In', 'this', 'double-blind', ',', 'placebo-controlled', ',', 'parallel', 'group', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'salmeterol', 'plus', 'fluticasone', 'propionate', '(', 'FP', ')', '(', 'Seretide', ';', 'SFC', ')', 'and', 'FP', 'plus', 'montelukast', '(', 'FP/M', ')', 'on', 'sputum', 'inflammatory', 'markers', ',', 'airway', 'responsiveness', ',', 'lung', 'function', ',', 'and', 'symptoms', 'in', 'adult', 'asthmatics', '.']","(39, 44)","(224, 261)",-1,hl_o,17897478,Abstract,1,test,gold,3139.0
2291,"In this double-blind , placebo-controlled , parallel group study , we compared the effects of salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC ) and FP plus montelukast ( FP/M ) on sputum inflammatory markers , airway responsiveness , lung function , and",symptoms,in adult asthmatics .,"['In', 'this', 'double-blind', ',', 'placebo-controlled', ',', 'parallel', 'group', 'study', ',', 'we', 'compared', 'the', 'effects', 'of', 'salmeterol', 'plus', 'fluticasone', 'propionate', '(', 'FP', ')', '(', 'Seretide', ';', 'SFC', ')', 'and', 'FP', 'plus', 'montelukast', '(', 'FP/M', ')', 'on', 'sputum', 'inflammatory', 'markers', ',', 'airway', 'responsiveness', ',', 'lung', 'function', ',', 'and', 'symptoms', 'in', 'adult', 'asthmatics', '.']","(46, 47)","(268, 276)",-1,hl_o,17897478,Abstract,1,test,gold,3282.0
2292,METHODS,Sixty-six subjects,were randomised to SFC or FP/M for 12 weeks .,"['METHODS', 'Sixty-six', 'subjects', 'were', 'randomised', 'to', 'SFC', 'or', 'FP/M', 'for', '12', 'weeks', '.']","(1, 3)","(7, 25)",-1,ss_p,17897478,Abstract,2,test,gold,2074.0
2293,METHODS Sixty-six subjects were randomised to,SFC,or FP/M for 12 weeks .,"['METHODS', 'Sixty-six', 'subjects', 'were', 'randomised', 'to', 'SFC', 'or', 'FP/M', 'for', '12', 'weeks', '.']","(6, 7)","(45, 48)",-1,ss_i,17897478,Abstract,2,test,gold,657.0
2294,METHODS Sixty-six subjects were randomised to SFC or,FP/M,for 12 weeks .,"['METHODS', 'Sixty-six', 'subjects', 'were', 'randomised', 'to', 'SFC', 'or', 'FP/M', 'for', '12', 'weeks', '.']","(8, 9)","(52, 56)",-1,ss_i,17897478,Abstract,2,test,gold,
2295,METHODS,Sixty-six subjects,were randomised to SFC or FP/M for 12 weeks .,"['METHODS', 'Sixty-six', 'subjects', 'were', 'randomised', 'to', 'SFC', 'or', 'FP/M', 'for', '12', 'weeks', '.']","(1, 3)","(7, 25)",-1,hl_p,17897478,Abstract,2,test,gold,2073.0
2296,METHODS Sixty-six subjects were randomised to,SFC,or FP/M for 12 weeks .,"['METHODS', 'Sixty-six', 'subjects', 'were', 'randomised', 'to', 'SFC', 'or', 'FP/M', 'for', '12', 'weeks', '.']","(6, 7)","(45, 48)",-1,hl_i,17897478,Abstract,2,test,gold,658.0
2297,METHODS Sixty-six subjects were randomised to SFC or,FP/M,for 12 weeks .,"['METHODS', 'Sixty-six', 'subjects', 'were', 'randomised', 'to', 'SFC', 'or', 'FP/M', 'for', '12', 'weeks', '.']","(8, 9)","(52, 56)",-1,hl_i,17897478,Abstract,2,test,gold,
2298,The primary outcome was,"changes in neutrophil , eosinophil , macrophage , lymphocyte , and epithelial cell levels in induced sputum .",,"['The', 'primary', 'outcome', 'was', 'changes', 'in', 'neutrophil', ',', 'eosinophil', ',', 'macrophage', ',', 'lymphocyte', ',', 'and', 'epithelial', 'cell', 'levels', 'in', 'induced', 'sputum', '.']","(4, 22)","(23, 132)",-1,ss_o,17897478,Abstract,3,test,gold,5801.0
2299,The primary outcome was,"changes in neutrophil , eosinophil , macrophage , lymphocyte , and epithelial cell levels in induced sputum .",,"['The', 'primary', 'outcome', 'was', 'changes', 'in', 'neutrophil', ',', 'eosinophil', ',', 'macrophage', ',', 'lymphocyte', ',', 'and', 'epithelial', 'cell', 'levels', 'in', 'induced', 'sputum', '.']","(4, 22)","(23, 132)",-1,hl_o,17897478,Abstract,3,test,gold,5802.0
2300,Additional outcomes included the,"change in other sputum markers of airway inflammation , airway responsiveness , symptom control , and lung function .",,"['Additional', 'outcomes', 'included', 'the', 'change', 'in', 'other', 'sputum', 'markers', 'of', 'airway', 'inflammation', ',', 'airway', 'responsiveness', ',', 'symptom', 'control', ',', 'and', 'lung', 'function', '.']","(4, 23)","(32, 149)",-1,ss_o,17897478,Abstract,4,test,gold,5989.0
2301,Additional outcomes included the,"change in other sputum markers of airway inflammation , airway responsiveness , symptom control , and lung function .",,"['Additional', 'outcomes', 'included', 'the', 'change', 'in', 'other', 'sputum', 'markers', 'of', 'airway', 'inflammation', ',', 'airway', 'responsiveness', ',', 'symptom', 'control', ',', 'and', 'lung', 'function', '.']","(4, 23)","(32, 149)",-1,hl_o,17897478,Abstract,4,test,gold,5990.0
2302,RESULTS Both treatments had no significant effect on,induced sputum inflammatory cells,", although there was a trend for a reduction in sputum eosinophils .","['RESULTS', 'Both', 'treatments', 'had', 'no', 'significant', 'effect', 'on', 'induced', 'sputum', 'inflammatory', 'cells', ',', 'although', 'there', 'was', 'a', 'trend', 'for', 'a', 'reduction', 'in', 'sputum', 'eosinophils', '.']","(8, 12)","(52, 85)",-1,ss_o,17897478,Abstract,5,test,gold,4540.0
2303,"RESULTS Both treatments had no significant effect on induced sputum inflammatory cells , although there was a trend for a reduction in",sputum eosinophils .,,"['RESULTS', 'Both', 'treatments', 'had', 'no', 'significant', 'effect', 'on', 'induced', 'sputum', 'inflammatory', 'cells', ',', 'although', 'there', 'was', 'a', 'trend', 'for', 'a', 'reduction', 'in', 'sputum', 'eosinophils', '.']","(22, 25)","(134, 154)",-1,ss_o,17897478,Abstract,5,test,gold,4538.0
2304,RESULTS Both treatments had no significant effect on induced,sputum inflammatory,"cells , although there was a trend for a reduction in sputum eosinophils .","['RESULTS', 'Both', 'treatments', 'had', 'no', 'significant', 'effect', 'on', 'induced', 'sputum', 'inflammatory', 'cells', ',', 'although', 'there', 'was', 'a', 'trend', 'for', 'a', 'reduction', 'in', 'sputum', 'eosinophils', '.']","(9, 11)","(60, 79)",-1,hl_o,17897478,Abstract,5,test,gold,4542.0
2305,"RESULTS Both treatments had no significant effect on induced sputum inflammatory cells , although there was a trend for a reduction in",sputum eosinophils .,,"['RESULTS', 'Both', 'treatments', 'had', 'no', 'significant', 'effect', 'on', 'induced', 'sputum', 'inflammatory', 'cells', ',', 'although', 'there', 'was', 'a', 'trend', 'for', 'a', 'reduction', 'in', 'sputum', 'eosinophils', '.']","(22, 25)","(134, 154)",-1,hl_o,17897478,Abstract,5,test,gold,4539.0
2306,"Both treatments significantly improved airway responsiveness , whereas",SFC,generally led to greater improvements in symptom control and lung function than FP/M .,"['Both', 'treatments', 'significantly', 'improved', 'airway', 'responsiveness', ',', 'whereas', 'SFC', 'generally', 'led', 'to', 'greater', 'improvements', 'in', 'symptom', 'control', 'and', 'lung', 'function', 'than', 'FP/M', '.']","(8, 9)","(70, 73)",-1,ss_i,17897478,Abstract,6,test,gold,656.0
2307,"Both treatments significantly improved airway responsiveness , whereas SFC generally led to greater improvements in symptom control and lung function than",FP/M .,,"['Both', 'treatments', 'significantly', 'improved', 'airway', 'responsiveness', ',', 'whereas', 'SFC', 'generally', 'led', 'to', 'greater', 'improvements', 'in', 'symptom', 'control', 'and', 'lung', 'function', 'than', 'FP/M', '.']","(21, 23)","(154, 160)",-1,ss_i,17897478,Abstract,6,test,gold,
2308,Both treatments significantly improved,airway responsiveness,", whereas SFC generally led to greater improvements in symptom control and lung function than FP/M .","['Both', 'treatments', 'significantly', 'improved', 'airway', 'responsiveness', ',', 'whereas', 'SFC', 'generally', 'led', 'to', 'greater', 'improvements', 'in', 'symptom', 'control', 'and', 'lung', 'function', 'than', 'FP/M', '.']","(4, 6)","(38, 59)",-1,ss_o,17897478,Abstract,6,test,gold,3140.0
2309,"Both treatments significantly improved airway responsiveness , whereas SFC generally led to greater improvements in",symptom control and lung function,than FP/M .,"['Both', 'treatments', 'significantly', 'improved', 'airway', 'responsiveness', ',', 'whereas', 'SFC', 'generally', 'led', 'to', 'greater', 'improvements', 'in', 'symptom', 'control', 'and', 'lung', 'function', 'than', 'FP/M', '.']","(15, 20)","(115, 148)",-1,ss_o,17897478,Abstract,6,test,gold,3152.0
2310,"Both treatments significantly improved airway responsiveness , whereas",SFC,generally led to greater improvements in symptom control and lung function than FP/M .,"['Both', 'treatments', 'significantly', 'improved', 'airway', 'responsiveness', ',', 'whereas', 'SFC', 'generally', 'led', 'to', 'greater', 'improvements', 'in', 'symptom', 'control', 'and', 'lung', 'function', 'than', 'FP/M', '.']","(8, 9)","(70, 73)",-1,hl_i,17897478,Abstract,6,test,gold,655.0
2311,"Both treatments significantly improved airway responsiveness , whereas SFC generally led to greater improvements in symptom control and lung function than",FP/M .,,"['Both', 'treatments', 'significantly', 'improved', 'airway', 'responsiveness', ',', 'whereas', 'SFC', 'generally', 'led', 'to', 'greater', 'improvements', 'in', 'symptom', 'control', 'and', 'lung', 'function', 'than', 'FP/M', '.']","(21, 23)","(154, 160)",-1,hl_i,17897478,Abstract,6,test,gold,
2312,Both treatments significantly improved,airway responsiveness,", whereas SFC generally led to greater improvements in symptom control and lung function than FP/M .","['Both', 'treatments', 'significantly', 'improved', 'airway', 'responsiveness', ',', 'whereas', 'SFC', 'generally', 'led', 'to', 'greater', 'improvements', 'in', 'symptom', 'control', 'and', 'lung', 'function', 'than', 'FP/M', '.']","(4, 6)","(38, 59)",-1,hl_o,17897478,Abstract,6,test,gold,3141.0
2313,"Both treatments significantly improved airway responsiveness , whereas SFC generally led to greater improvements in",symptom control and lung function,than FP/M .,"['Both', 'treatments', 'significantly', 'improved', 'airway', 'responsiveness', ',', 'whereas', 'SFC', 'generally', 'led', 'to', 'greater', 'improvements', 'in', 'symptom', 'control', 'and', 'lung', 'function', 'than', 'FP/M', '.']","(15, 20)","(115, 148)",-1,hl_o,17897478,Abstract,6,test,gold,3153.0
2314,,FP/M,"led to significantly greater reductions in sputum cysteinyl leukotrienes than SFC ( treatment ratio 1.80 ; 95 % CI 1.09 , 2.94 ) .","['FP/M', 'led', 'to', 'significantly', 'greater', 'reductions', 'in', 'sputum', 'cysteinyl', 'leukotrienes', 'than', 'SFC', '(', 'treatment', 'ratio', '1.80', ';', '95', '%', 'CI', '1.09', ',', '2.94', ')', '.']","(0, 1)","(0, 4)",-1,ss_i,17897478,Abstract,7,test,gold,
2315,FP/M led to significantly greater reductions in sputum cysteinyl leukotrienes than,SFC,"( treatment ratio 1.80 ; 95 % CI 1.09 , 2.94 ) .","['FP/M', 'led', 'to', 'significantly', 'greater', 'reductions', 'in', 'sputum', 'cysteinyl', 'leukotrienes', 'than', 'SFC', '(', 'treatment', 'ratio', '1.80', ';', '95', '%', 'CI', '1.09', ',', '2.94', ')', '.']","(11, 12)","(82, 85)",-1,ss_i,17897478,Abstract,7,test,gold,654.0
2316,FP/M led to significantly greater reductions in,sputum cysteinyl leukotrienes,"than SFC ( treatment ratio 1.80 ; 95 % CI 1.09 , 2.94 ) .","['FP/M', 'led', 'to', 'significantly', 'greater', 'reductions', 'in', 'sputum', 'cysteinyl', 'leukotrienes', 'than', 'SFC', '(', 'treatment', 'ratio', '1.80', ';', '95', '%', 'CI', '1.09', ',', '2.94', ')', '.']","(7, 10)","(47, 76)",-1,ss_o,17897478,Abstract,7,test,gold,4536.0
2317,,FP/M,"led to significantly greater reductions in sputum cysteinyl leukotrienes than SFC ( treatment ratio 1.80 ; 95 % CI 1.09 , 2.94 ) .","['FP/M', 'led', 'to', 'significantly', 'greater', 'reductions', 'in', 'sputum', 'cysteinyl', 'leukotrienes', 'than', 'SFC', '(', 'treatment', 'ratio', '1.80', ';', '95', '%', 'CI', '1.09', ',', '2.94', ')', '.']","(0, 1)","(0, 4)",-1,hl_i,17897478,Abstract,7,test,gold,
2318,FP/M led to significantly greater reductions in sputum cysteinyl leukotrienes than,SFC,"( treatment ratio 1.80 ; 95 % CI 1.09 , 2.94 ) .","['FP/M', 'led', 'to', 'significantly', 'greater', 'reductions', 'in', 'sputum', 'cysteinyl', 'leukotrienes', 'than', 'SFC', '(', 'treatment', 'ratio', '1.80', ';', '95', '%', 'CI', '1.09', ',', '2.94', ')', '.']","(11, 12)","(82, 85)",-1,hl_i,17897478,Abstract,7,test,gold,653.0
2319,FP/M led to significantly greater reductions in,sputum cysteinyl leukotrienes,"than SFC ( treatment ratio 1.80 ; 95 % CI 1.09 , 2.94 ) .","['FP/M', 'led', 'to', 'significantly', 'greater', 'reductions', 'in', 'sputum', 'cysteinyl', 'leukotrienes', 'than', 'SFC', '(', 'treatment', 'ratio', '1.80', ';', '95', '%', 'CI', '1.09', ',', '2.94', ')', '.']","(7, 10)","(47, 76)",-1,hl_o,17897478,Abstract,7,test,gold,4537.0
2320,"CONCLUSION Both treatments led to similar control of eosinophilic airway inflammation , although PEF and symptom control were better with",SFC .,,"['CONCLUSION', 'Both', 'treatments', 'led', 'to', 'similar', 'control', 'of', 'eosinophilic', 'airway', 'inflammation', ',', 'although', 'PEF', 'and', 'symptom', 'control', 'were', 'better', 'with', 'SFC', '.']","(20, 22)","(137, 142)",-1,ss_i,17897478,Abstract,8,test,gold,652.0
2321,CONCLUSION Both treatments led to similar control of,eosinophilic airway inflammation,", although PEF and symptom control were better with SFC .","['CONCLUSION', 'Both', 'treatments', 'led', 'to', 'similar', 'control', 'of', 'eosinophilic', 'airway', 'inflammation', ',', 'although', 'PEF', 'and', 'symptom', 'control', 'were', 'better', 'with', 'SFC', '.']","(8, 11)","(52, 84)",-1,ss_o,17897478,Abstract,8,test,gold,3135.0
2322,"CONCLUSION Both treatments led to similar control of eosinophilic airway inflammation , although PEF and",symptom control,were better with SFC .,"['CONCLUSION', 'Both', 'treatments', 'led', 'to', 'similar', 'control', 'of', 'eosinophilic', 'airway', 'inflammation', ',', 'although', 'PEF', 'and', 'symptom', 'control', 'were', 'better', 'with', 'SFC', '.']","(15, 17)","(104, 119)",-1,ss_o,17897478,Abstract,8,test,gold,3361.0
2323,"CONCLUSION Both treatments led to similar control of eosinophilic airway inflammation , although PEF and symptom control were better with",SFC .,,"['CONCLUSION', 'Both', 'treatments', 'led', 'to', 'similar', 'control', 'of', 'eosinophilic', 'airway', 'inflammation', ',', 'although', 'PEF', 'and', 'symptom', 'control', 'were', 'better', 'with', 'SFC', '.']","(20, 22)","(137, 142)",-1,hl_i,17897478,Abstract,8,test,gold,651.0
2324,CONCLUSION Both treatments led to similar control of,eosinophilic airway inflammation,", although PEF and symptom control were better with SFC .","['CONCLUSION', 'Both', 'treatments', 'led', 'to', 'similar', 'control', 'of', 'eosinophilic', 'airway', 'inflammation', ',', 'although', 'PEF', 'and', 'symptom', 'control', 'were', 'better', 'with', 'SFC', '.']","(8, 11)","(52, 84)",-1,hl_o,17897478,Abstract,8,test,gold,3136.0
2325,STUDY NUMBER : SAM40030 ( SOLTA ) .,,,"['STUDY', 'NUMBER', ':', 'SAM40030', '(', 'SOLTA', ')', '.']",,,,,17897478,Abstract,9,test,gold,
2326,"A double-blind , randomized , controlled , multicenter safety and immunogenicity study of a refrigerator-stable formulation of",Zostavax .,,"['A', 'double-blind', ',', 'randomized', ',', 'controlled', ',', 'multicenter', 'safety', 'and', 'immunogenicity', 'study', 'of', 'a', 'refrigerator-stable', 'formulation', 'of', 'Zostavax', '.']","(17, 19)","(126, 136)",-1,ss_i,18077611,Title,0,test,gold,5646.0
2327,"A double-blind , randomized , controlled , multicenter",safety,and immunogenicity study of a refrigerator-stable formulation of Zostavax .,"['A', 'double-blind', ',', 'randomized', ',', 'controlled', ',', 'multicenter', 'safety', 'and', 'immunogenicity', 'study', 'of', 'a', 'refrigerator-stable', 'formulation', 'of', 'Zostavax', '.']","(8, 9)","(54, 60)",-1,ss_o,18077611,Title,0,test,gold,481.0
2328,"A double-blind , randomized , controlled , multicenter safety and",immunogenicity,study of a refrigerator-stable formulation of Zostavax .,"['A', 'double-blind', ',', 'randomized', ',', 'controlled', ',', 'multicenter', 'safety', 'and', 'immunogenicity', 'study', 'of', 'a', 'refrigerator-stable', 'formulation', 'of', 'Zostavax', '.']","(10, 11)","(65, 79)",-1,ss_o,18077611,Title,0,test,gold,4885.0
2329,"A double-blind , randomized , controlled , multicenter safety and immunogenicity study of a refrigerator-stable formulation of",Zostavax .,,"['A', 'double-blind', ',', 'randomized', ',', 'controlled', ',', 'multicenter', 'safety', 'and', 'immunogenicity', 'study', 'of', 'a', 'refrigerator-stable', 'formulation', 'of', 'Zostavax', '.']","(17, 19)","(126, 136)",-1,hl_i,18077611,Title,0,test,gold,5647.0
2330,The vaccine,Zostavax,has been shown to prevent herpes zoster ( HZ ) and postherpetic neuralgia and is recommended for individuals > or =60 years of age .,"['The', 'vaccine', 'Zostavax', 'has', 'been', 'shown', 'to', 'prevent', 'herpes', 'zoster', '(', 'HZ', ')', 'and', 'postherpetic', 'neuralgia', 'and', 'is', 'recommended', 'for', 'individuals', '>', 'or', '=60', 'years', 'of', 'age', '.']","(2, 3)","(11, 19)",-1,ss_i,18077611,Abstract,0,test,gold,5645.0
2331,The vaccine,Zostavax,has been shown to prevent herpes zoster ( HZ ) and postherpetic neuralgia and is recommended for individuals > or =60 years of age .,"['The', 'vaccine', 'Zostavax', 'has', 'been', 'shown', 'to', 'prevent', 'herpes', 'zoster', '(', 'HZ', ')', 'and', 'postherpetic', 'neuralgia', 'and', 'is', 'recommended', 'for', 'individuals', '>', 'or', '=60', 'years', 'of', 'age', '.']","(2, 3)","(11, 19)",-1,hl_i,18077611,Abstract,0,test,gold,5644.0
2332,This study compared the safety and the immunogenicity of a refrigerator-stable formulation ( Zostavax refrigerated ) with those of the current formulation ( Zostavax frozen ) in,subjects > or =50 years of age .,,"['This', 'study', 'compared', 'the', 'safety', 'and', 'the', 'immunogenicity', 'of', 'a', 'refrigerator-stable', 'formulation', '(', 'Zostavax', 'refrigerated', ')', 'with', 'those', 'of', 'the', 'current', 'formulation', '(', 'Zostavax', 'frozen', ')', 'in', 'subjects', '>', 'or', '=50', 'years', 'of', 'age', '.']","(27, 35)","(177, 209)",-1,ss_p,18077611,Abstract,1,test,gold,2048.0
2333,This study compared the safety and the immunogenicity of a refrigerator-stable formulation,( Zostavax,refrigerated ) with those of the current formulation ( Zostavax frozen ) in subjects > or =50 years of age .,"['This', 'study', 'compared', 'the', 'safety', 'and', 'the', 'immunogenicity', 'of', 'a', 'refrigerator-stable', 'formulation', '(', 'Zostavax', 'refrigerated', ')', 'with', 'those', 'of', 'the', 'current', 'formulation', '(', 'Zostavax', 'frozen', ')', 'in', 'subjects', '>', 'or', '=50', 'years', 'of', 'age', '.']","(12, 14)","(90, 100)",-1,ss_i,18077611,Abstract,1,test,gold,5643.0
2334,This study compared the safety and the immunogenicity of a refrigerator-stable formulation ( Zostavax refrigerated ) with those of the current formulation,( Zostavax,frozen ) in subjects > or =50 years of age .,"['This', 'study', 'compared', 'the', 'safety', 'and', 'the', 'immunogenicity', 'of', 'a', 'refrigerator-stable', 'formulation', '(', 'Zostavax', 'refrigerated', ')', 'with', 'those', 'of', 'the', 'current', 'formulation', '(', 'Zostavax', 'frozen', ')', 'in', 'subjects', '>', 'or', '=50', 'years', 'of', 'age', '.']","(22, 24)","(154, 164)",-1,ss_i,18077611,Abstract,1,test,gold,5642.0
2335,This study compared the,safety,and the immunogenicity of a refrigerator-stable formulation ( Zostavax refrigerated ) with those of the current formulation ( Zostavax frozen ) in subjects > or =50 years of age .,"['This', 'study', 'compared', 'the', 'safety', 'and', 'the', 'immunogenicity', 'of', 'a', 'refrigerator-stable', 'formulation', '(', 'Zostavax', 'refrigerated', ')', 'with', 'those', 'of', 'the', 'current', 'formulation', '(', 'Zostavax', 'frozen', ')', 'in', 'subjects', '>', 'or', '=50', 'years', 'of', 'age', '.']","(4, 5)","(23, 29)",-1,ss_o,18077611,Abstract,1,test,gold,480.0
2336,This study compared the safety and the,immunogenicity,of a refrigerator-stable formulation ( Zostavax refrigerated ) with those of the current formulation ( Zostavax frozen ) in subjects > or =50 years of age .,"['This', 'study', 'compared', 'the', 'safety', 'and', 'the', 'immunogenicity', 'of', 'a', 'refrigerator-stable', 'formulation', '(', 'Zostavax', 'refrigerated', ')', 'with', 'those', 'of', 'the', 'current', 'formulation', '(', 'Zostavax', 'frozen', ')', 'in', 'subjects', '>', 'or', '=50', 'years', 'of', 'age', '.']","(7, 8)","(38, 52)",-1,ss_o,18077611,Abstract,1,test,gold,4886.0
2337,This study compared the safety and the immunogenicity of a refrigerator-stable formulation ( Zostavax refrigerated ) with those of the current formulation ( Zostavax frozen ) in,subjects > or =50 years of age .,,"['This', 'study', 'compared', 'the', 'safety', 'and', 'the', 'immunogenicity', 'of', 'a', 'refrigerator-stable', 'formulation', '(', 'Zostavax', 'refrigerated', ')', 'with', 'those', 'of', 'the', 'current', 'formulation', '(', 'Zostavax', 'frozen', ')', 'in', 'subjects', '>', 'or', '=50', 'years', 'of', 'age', '.']","(27, 35)","(177, 209)",-1,hl_p,18077611,Abstract,1,test,gold,2049.0
2338,This study compared the safety and the immunogenicity of a refrigerator-stable formulation (,Zostavax,refrigerated ) with those of the current formulation ( Zostavax frozen ) in subjects > or =50 years of age .,"['This', 'study', 'compared', 'the', 'safety', 'and', 'the', 'immunogenicity', 'of', 'a', 'refrigerator-stable', 'formulation', '(', 'Zostavax', 'refrigerated', ')', 'with', 'those', 'of', 'the', 'current', 'formulation', '(', 'Zostavax', 'frozen', ')', 'in', 'subjects', '>', 'or', '=50', 'years', 'of', 'age', '.']","(13, 14)","(92, 100)",-1,hl_i,18077611,Abstract,1,test,gold,5641.0
2339,This study compared the safety and the immunogenicity of a refrigerator-stable formulation ( Zostavax refrigerated ) with those of the current formulation (,Zostavax,frozen ) in subjects > or =50 years of age .,"['This', 'study', 'compared', 'the', 'safety', 'and', 'the', 'immunogenicity', 'of', 'a', 'refrigerator-stable', 'formulation', '(', 'Zostavax', 'refrigerated', ')', 'with', 'those', 'of', 'the', 'current', 'formulation', '(', 'Zostavax', 'frozen', ')', 'in', 'subjects', '>', 'or', '=50', 'years', 'of', 'age', '.']","(23, 24)","(156, 164)",-1,hl_i,18077611,Abstract,1,test,gold,5640.0
2340,This study compared the,safety,and the immunogenicity of a refrigerator-stable formulation ( Zostavax refrigerated ) with those of the current formulation ( Zostavax frozen ) in subjects > or =50 years of age .,"['This', 'study', 'compared', 'the', 'safety', 'and', 'the', 'immunogenicity', 'of', 'a', 'refrigerator-stable', 'formulation', '(', 'Zostavax', 'refrigerated', ')', 'with', 'those', 'of', 'the', 'current', 'formulation', '(', 'Zostavax', 'frozen', ')', 'in', 'subjects', '>', 'or', '=50', 'years', 'of', 'age', '.']","(4, 5)","(23, 29)",-1,hl_o,18077611,Abstract,1,test,gold,479.0
2341,This study compared the safety and the,immunogenicity,of a refrigerator-stable formulation ( Zostavax refrigerated ) with those of the current formulation ( Zostavax frozen ) in subjects > or =50 years of age .,"['This', 'study', 'compared', 'the', 'safety', 'and', 'the', 'immunogenicity', 'of', 'a', 'refrigerator-stable', 'formulation', '(', 'Zostavax', 'refrigerated', ')', 'with', 'those', 'of', 'the', 'current', 'formulation', '(', 'Zostavax', 'frozen', ')', 'in', 'subjects', '>', 'or', '=50', 'years', 'of', 'age', '.']","(7, 8)","(38, 52)",-1,hl_o,18077611,Abstract,1,test,gold,4884.0
2342,,Subjects with a negative history for HZ,were randomized 1:1 to receive one dose of either formulation .,"['Subjects', 'with', 'a', 'negative', 'history', 'for', 'HZ', 'were', 'randomized', '1:1', 'to', 'receive', 'one', 'dose', 'of', 'either', 'formulation', '.']","(0, 7)","(0, 39)",-1,ss_p,18077611,Abstract,2,test,gold,2066.0
2343,,Subjects with a negative history for HZ,were randomized 1:1 to receive one dose of either formulation .,"['Subjects', 'with', 'a', 'negative', 'history', 'for', 'HZ', 'were', 'randomized', '1:1', 'to', 'receive', 'one', 'dose', 'of', 'either', 'formulation', '.']","(0, 7)","(0, 39)",-1,hl_p,18077611,Abstract,2,test,gold,2067.0
2344,,Enrollment was stratified 1:2 by age ( 50 to 59 years and > or =60 years ),.,"['Enrollment', 'was', 'stratified', '1:2', 'by', 'age', '(', '50', 'to', '59', 'years', 'and', '>', 'or', '=60', 'years', ')', '.']","(0, 17)","(0, 74)",-1,ss_p,18077611,Abstract,3,test,gold,5827.0
2345,,Enrollment was stratified 1:2 by age ( 50 to 59 years and > or =60 years ),.,"['Enrollment', 'was', 'stratified', '1:2', 'by', 'age', '(', '50', 'to', '59', 'years', 'and', '>', 'or', '=60', 'years', ')', '.']","(0, 17)","(0, 74)",-1,hl_p,18077611,Abstract,3,test,gold,5828.0
2346,,Safety,was evaluated for 28 days postvaccination .,"['Safety', 'was', 'evaluated', 'for', '28', 'days', 'postvaccination', '.']","(0, 1)","(0, 6)",-1,ss_o,18077611,Abstract,4,test,gold,447.0
2347,,Safety,was evaluated for 28 days postvaccination .,"['Safety', 'was', 'evaluated', 'for', '28', 'days', 'postvaccination', '.']","(0, 1)","(0, 6)",-1,hl_o,18077611,Abstract,4,test,gold,448.0
2348,,Varicella-zoster virus ( VZV ) antibody responses,were measured by a glycoprotein enzyme-linked immunosorbent assay ( gpELISA ) .,"['Varicella-zoster', 'virus', '(', 'VZV', ')', 'antibody', 'responses', 'were', 'measured', 'by', 'a', 'glycoprotein', 'enzyme-linked', 'immunosorbent', 'assay', '(', 'gpELISA', ')', '.']","(0, 7)","(0, 49)",-1,ss_o,18077611,Abstract,5,test,gold,6661.0
2349,Varicella-zoster virus ( VZV ) antibody responses were measured by a,glycoprotein enzyme-linked immunosorbent assay ( gpELISA ) .,,"['Varicella-zoster', 'virus', '(', 'VZV', ')', 'antibody', 'responses', 'were', 'measured', 'by', 'a', 'glycoprotein', 'enzyme-linked', 'immunosorbent', 'assay', '(', 'gpELISA', ')', '.']","(11, 19)","(68, 128)",-1,ss_o,18077611,Abstract,5,test,gold,4474.0
2350,,Varicella-zoster virus ( VZV ) antibody responses,were measured by a glycoprotein enzyme-linked immunosorbent assay ( gpELISA ) .,"['Varicella-zoster', 'virus', '(', 'VZV', ')', 'antibody', 'responses', 'were', 'measured', 'by', 'a', 'glycoprotein', 'enzyme-linked', 'immunosorbent', 'assay', '(', 'gpELISA', ')', '.']","(0, 7)","(0, 49)",-1,hl_o,18077611,Abstract,5,test,gold,6662.0
2351,The primary endpoints were the,VZV antibody geometric mean titer ( GMT ;,"day 28 ) , the VZV antibody geometric mean rise ( GMR ; days 1 to 28 ) , and the incidence of vaccine-related serious adverse experiences ( AEs ) over 28 days .","['The', 'primary', 'endpoints', 'were', 'the', 'VZV', 'antibody', 'geometric', 'mean', 'titer', '(', 'GMT', ';', 'day', '28', ')', ',', 'the', 'VZV', 'antibody', 'geometric', 'mean', 'rise', '(', 'GMR', ';', 'days', '1', 'to', '28', ')', ',', 'and', 'the', 'incidence', 'of', 'vaccine-related', 'serious', 'adverse', 'experiences', '(', 'AEs', ')', 'over', '28', 'days', '.']","(5, 13)","(30, 71)",-1,ss_o,18077611,Abstract,6,test,gold,6665.0
2352,"The primary endpoints were the VZV antibody geometric mean titer ( GMT ; day 28 ) , the",VZV antibody geometric mean rise ( GMR ;,"days 1 to 28 ) , and the incidence of vaccine-related serious adverse experiences ( AEs ) over 28 days .","['The', 'primary', 'endpoints', 'were', 'the', 'VZV', 'antibody', 'geometric', 'mean', 'titer', '(', 'GMT', ';', 'day', '28', ')', ',', 'the', 'VZV', 'antibody', 'geometric', 'mean', 'rise', '(', 'GMR', ';', 'days', '1', 'to', '28', ')', ',', 'and', 'the', 'incidence', 'of', 'vaccine-related', 'serious', 'adverse', 'experiences', '(', 'AEs', ')', 'over', '28', 'days', '.']","(18, 26)","(87, 127)",-1,ss_o,18077611,Abstract,6,test,gold,6663.0
2353,"The primary endpoints were the VZV antibody geometric mean titer ( GMT ; day 28 ) , the VZV antibody geometric mean rise ( GMR ; days 1 to 28 ) , and the",incidence of vaccine-related serious adverse experiences ( AEs ),over 28 days .,"['The', 'primary', 'endpoints', 'were', 'the', 'VZV', 'antibody', 'geometric', 'mean', 'titer', '(', 'GMT', ';', 'day', '28', ')', ',', 'the', 'VZV', 'antibody', 'geometric', 'mean', 'rise', '(', 'GMR', ';', 'days', '1', 'to', '28', ')', ',', 'and', 'the', 'incidence', 'of', 'vaccine-related', 'serious', 'adverse', 'experiences', '(', 'AEs', ')', 'over', '28', 'days', '.']","(34, 43)","(153, 217)",-1,ss_o,18077611,Abstract,6,test,gold,3093.0
2354,The primary endpoints were the,VZV antibody geometric mean titer ( GMT,"; day 28 ) , the VZV antibody geometric mean rise ( GMR ; days 1 to 28 ) , and the incidence of vaccine-related serious adverse experiences ( AEs ) over 28 days .","['The', 'primary', 'endpoints', 'were', 'the', 'VZV', 'antibody', 'geometric', 'mean', 'titer', '(', 'GMT', ';', 'day', '28', ')', ',', 'the', 'VZV', 'antibody', 'geometric', 'mean', 'rise', '(', 'GMR', ';', 'days', '1', 'to', '28', ')', ',', 'and', 'the', 'incidence', 'of', 'vaccine-related', 'serious', 'adverse', 'experiences', '(', 'AEs', ')', 'over', '28', 'days', '.']","(5, 12)","(30, 69)",-1,hl_o,18077611,Abstract,6,test,gold,6666.0
2355,"The primary endpoints were the VZV antibody geometric mean titer ( GMT ; day 28 ) , the",VZV antibody geometric mean rise ( GMR,"; days 1 to 28 ) , and the incidence of vaccine-related serious adverse experiences ( AEs ) over 28 days .","['The', 'primary', 'endpoints', 'were', 'the', 'VZV', 'antibody', 'geometric', 'mean', 'titer', '(', 'GMT', ';', 'day', '28', ')', ',', 'the', 'VZV', 'antibody', 'geometric', 'mean', 'rise', '(', 'GMR', ';', 'days', '1', 'to', '28', ')', ',', 'and', 'the', 'incidence', 'of', 'vaccine-related', 'serious', 'adverse', 'experiences', '(', 'AEs', ')', 'over', '28', 'days', '.']","(18, 25)","(87, 125)",-1,hl_o,18077611,Abstract,6,test,gold,6664.0
2356,"The primary endpoints were the VZV antibody geometric mean titer ( GMT ; day 28 ) , the VZV antibody geometric mean rise ( GMR ; days 1 to 28 ) , and the",incidence of vaccine-related serious adverse experiences ( AEs ),over 28 days .,"['The', 'primary', 'endpoints', 'were', 'the', 'VZV', 'antibody', 'geometric', 'mean', 'titer', '(', 'GMT', ';', 'day', '28', ')', ',', 'the', 'VZV', 'antibody', 'geometric', 'mean', 'rise', '(', 'GMR', ';', 'days', '1', 'to', '28', ')', ',', 'and', 'the', 'incidence', 'of', 'vaccine-related', 'serious', 'adverse', 'experiences', '(', 'AEs', ')', 'over', '28', 'days', '.']","(34, 43)","(153, 217)",-1,hl_o,18077611,Abstract,6,test,gold,3094.0
2357,The refrigerated ( n = 182 ) and frozen ( n = 185 ) formulations induced similar,GMTs,"( 727.4 and 834.4 gpELISA units/ml , respectively ) ; the estimated GMT ratio ( refrigerated formulation/frozen formulation ) was 0.87 ( 95 % confidence interval , 0.71 to 1.07 ) .","['The', 'refrigerated', '(', 'n', '=', '182', ')', 'and', 'frozen', '(', 'n', '=', '185', ')', 'formulations', 'induced', 'similar', 'GMTs', '(', '727.4', 'and', '834.4', 'gpELISA', 'units/ml', ',', 'respectively', ')', ';', 'the', 'estimated', 'GMT', 'ratio', '(', 'refrigerated', 'formulation/frozen', 'formulation', ')', 'was', '0.87', '(', '95', '%', 'confidence', 'interval', ',', '0.71', 'to', '1.07', ')', '.']","(17, 18)","(80, 84)",-1,ss_o,18077611,Abstract,7,test,gold,1030.0
2358,The refrigerated ( n = 182 ) and frozen ( n = 185 ) formulations induced similar GMTs ( 727.4 and 834.4,gpELISA,"units/ml , respectively ) ; the estimated GMT ratio ( refrigerated formulation/frozen formulation ) was 0.87 ( 95 % confidence interval , 0.71 to 1.07 ) .","['The', 'refrigerated', '(', 'n', '=', '182', ')', 'and', 'frozen', '(', 'n', '=', '185', ')', 'formulations', 'induced', 'similar', 'GMTs', '(', '727.4', 'and', '834.4', 'gpELISA', 'units/ml', ',', 'respectively', ')', ';', 'the', 'estimated', 'GMT', 'ratio', '(', 'refrigerated', 'formulation/frozen', 'formulation', ')', 'was', '0.87', '(', '95', '%', 'confidence', 'interval', ',', '0.71', 'to', '1.07', ')', '.']","(22, 23)","(103, 110)",-1,ss_o,18077611,Abstract,7,test,gold,
2359,"The refrigerated ( n = 182 ) and frozen ( n = 185 ) formulations induced similar GMTs ( 727.4 and 834.4 gpELISA units/ml , respectively ) ; the estimated",GMT,"ratio ( refrigerated formulation/frozen formulation ) was 0.87 ( 95 % confidence interval , 0.71 to 1.07 ) .","['The', 'refrigerated', '(', 'n', '=', '182', ')', 'and', 'frozen', '(', 'n', '=', '185', ')', 'formulations', 'induced', 'similar', 'GMTs', '(', '727.4', 'and', '834.4', 'gpELISA', 'units/ml', ',', 'respectively', ')', ';', 'the', 'estimated', 'GMT', 'ratio', '(', 'refrigerated', 'formulation/frozen', 'formulation', ')', 'was', '0.87', '(', '95', '%', 'confidence', 'interval', ',', '0.71', 'to', '1.07', ')', '.']","(30, 31)","(153, 156)",-1,ss_o,18077611,Abstract,7,test,gold,1490.0
2360,The refrigerated ( n = 182 ) and frozen ( n = 185 ) formulations induced similar,GMTs,"( 727.4 and 834.4 gpELISA units/ml , respectively ) ; the estimated GMT ratio ( refrigerated formulation/frozen formulation ) was 0.87 ( 95 % confidence interval , 0.71 to 1.07 ) .","['The', 'refrigerated', '(', 'n', '=', '182', ')', 'and', 'frozen', '(', 'n', '=', '185', ')', 'formulations', 'induced', 'similar', 'GMTs', '(', '727.4', 'and', '834.4', 'gpELISA', 'units/ml', ',', 'respectively', ')', ';', 'the', 'estimated', 'GMT', 'ratio', '(', 'refrigerated', 'formulation/frozen', 'formulation', ')', 'was', '0.87', '(', '95', '%', 'confidence', 'interval', ',', '0.71', 'to', '1.07', ')', '.']","(17, 18)","(80, 84)",-1,hl_o,18077611,Abstract,7,test,gold,1031.0
2361,"The refrigerated ( n = 182 ) and frozen ( n = 185 ) formulations induced similar GMTs ( 727.4 and 834.4 gpELISA units/ml , respectively ) ; the estimated",GMT,"ratio ( refrigerated formulation/frozen formulation ) was 0.87 ( 95 % confidence interval , 0.71 to 1.07 ) .","['The', 'refrigerated', '(', 'n', '=', '182', ')', 'and', 'frozen', '(', 'n', '=', '185', ')', 'formulations', 'induced', 'similar', 'GMTs', '(', '727.4', 'and', '834.4', 'gpELISA', 'units/ml', ',', 'respectively', ')', ';', 'the', 'estimated', 'GMT', 'ratio', '(', 'refrigerated', 'formulation/frozen', 'formulation', ')', 'was', '0.87', '(', '95', '%', 'confidence', 'interval', ',', '0.71', 'to', '1.07', ')', '.']","(30, 31)","(153, 156)",-1,hl_o,18077611,Abstract,7,test,gold,1491.0
2362,The,GMRs,"were 2.6- and 2.9-fold , respectively .","['The', 'GMRs', 'were', '2.6-', 'and', '2.9-fold', ',', 'respectively', '.']","(1, 2)","(3, 7)",-1,ss_o,18077611,Abstract,8,test,gold,
2363,The,GMRs,"were 2.6- and 2.9-fold , respectively .","['The', 'GMRs', 'were', '2.6-', 'and', '2.9-fold', ',', 'respectively', '.']","(1, 2)","(3, 7)",-1,hl_o,18077611,Abstract,8,test,gold,
2364,No,vaccine-related serious AEs,"were reported in either group , and the safety profiles of the formulations were generally similar .","['No', 'vaccine-related', 'serious', 'AEs', 'were', 'reported', 'in', 'either', 'group', ',', 'and', 'the', 'safety', 'profiles', 'of', 'the', 'formulations', 'were', 'generally', 'similar', '.']","(1, 4)","(2, 29)",-1,ss_o,18077611,Abstract,9,test,gold,3082.0
2365,"No vaccine-related serious AEs were reported in either group , and the",safety,profiles of the formulations were generally similar .,"['No', 'vaccine-related', 'serious', 'AEs', 'were', 'reported', 'in', 'either', 'group', ',', 'and', 'the', 'safety', 'profiles', 'of', 'the', 'formulations', 'were', 'generally', 'similar', '.']","(12, 13)","(70, 76)",-1,ss_o,18077611,Abstract,9,test,gold,478.0
2366,No,vaccine-related serious AEs,"were reported in either group , and the safety profiles of the formulations were generally similar .","['No', 'vaccine-related', 'serious', 'AEs', 'were', 'reported', 'in', 'either', 'group', ',', 'and', 'the', 'safety', 'profiles', 'of', 'the', 'formulations', 'were', 'generally', 'similar', '.']","(1, 4)","(2, 29)",-1,hl_o,18077611,Abstract,9,test,gold,3083.0
2367,"No vaccine-related serious AEs were reported in either group , and the",safety,profiles of the formulations were generally similar .,"['No', 'vaccine-related', 'serious', 'AEs', 'were', 'reported', 'in', 'either', 'group', ',', 'and', 'the', 'safety', 'profiles', 'of', 'the', 'formulations', 'were', 'generally', 'similar', '.']","(12, 13)","(70, 76)",-1,hl_o,18077611,Abstract,9,test,gold,477.0
2368,The frequencies of,injection-site AEs,"during follow-up were 35.6 % and 46.4 % in the refrigerated and the frozen formulation groups , respectively , and were generally mild .","['The', 'frequencies', 'of', 'injection-site', 'AEs', 'during', 'follow-up', 'were', '35.6', '%', 'and', '46.4', '%', 'in', 'the', 'refrigerated', 'and', 'the', 'frozen', 'formulation', 'groups', ',', 'respectively', ',', 'and', 'were', 'generally', 'mild', '.']","(3, 5)","(18, 36)",-1,ss_o,18077611,Abstract,10,test,gold,3080.0
2369,The frequencies of,injection-site AEs,"during follow-up were 35.6 % and 46.4 % in the refrigerated and the frozen formulation groups , respectively , and were generally mild .","['The', 'frequencies', 'of', 'injection-site', 'AEs', 'during', 'follow-up', 'were', '35.6', '%', 'and', '46.4', '%', 'in', 'the', 'refrigerated', 'and', 'the', 'frozen', 'formulation', 'groups', ',', 'respectively', ',', 'and', 'were', 'generally', 'mild', '.']","(3, 5)","(18, 36)",-1,hl_o,18077611,Abstract,10,test,gold,3081.0
2370,The frequencies of,systemic AEs,"were similar in the two groups , and those of vaccine-related AEs were approximately 6 % in both groups .","['The', 'frequencies', 'of', 'systemic', 'AEs', 'were', 'similar', 'in', 'the', 'two', 'groups', ',', 'and', 'those', 'of', 'vaccine-related', 'AEs', 'were', 'approximately', '6', '%', 'in', 'both', 'groups', '.']","(3, 5)","(18, 30)",-1,ss_o,18077611,Abstract,11,test,gold,3087.0
2371,"The frequencies of systemic AEs were similar in the two groups , and those of",vaccine-related AEs,were approximately 6 % in both groups .,"['The', 'frequencies', 'of', 'systemic', 'AEs', 'were', 'similar', 'in', 'the', 'two', 'groups', ',', 'and', 'those', 'of', 'vaccine-related', 'AEs', 'were', 'approximately', '6', '%', 'in', 'both', 'groups', '.']","(15, 17)","(77, 96)",-1,ss_o,18077611,Abstract,11,test,gold,3079.0
2372,The frequencies of,systemic AEs,"were similar in the two groups , and those of vaccine-related AEs were approximately 6 % in both groups .","['The', 'frequencies', 'of', 'systemic', 'AEs', 'were', 'similar', 'in', 'the', 'two', 'groups', ',', 'and', 'those', 'of', 'vaccine-related', 'AEs', 'were', 'approximately', '6', '%', 'in', 'both', 'groups', '.']","(3, 5)","(18, 30)",-1,hl_o,18077611,Abstract,11,test,gold,3088.0
2373,"The frequencies of systemic AEs were similar in the two groups , and those of",vaccine-related AEs,were approximately 6 % in both groups .,"['The', 'frequencies', 'of', 'systemic', 'AEs', 'were', 'similar', 'in', 'the', 'two', 'groups', ',', 'and', 'those', 'of', 'vaccine-related', 'AEs', 'were', 'approximately', '6', '%', 'in', 'both', 'groups', '.']","(15, 17)","(77, 96)",-1,hl_o,18077611,Abstract,11,test,gold,3078.0
2374,The refrigerator-stable formulation of,Zostavax,"has an acceptable safety profile and is as immunogenic as the frozen formulation ; thus , the vaccine may be used in clinical settings where freezer availability is limited .","['The', 'refrigerator-stable', 'formulation', 'of', 'Zostavax', 'has', 'an', 'acceptable', 'safety', 'profile', 'and', 'is', 'as', 'immunogenic', 'as', 'the', 'frozen', 'formulation', ';', 'thus', ',', 'the', 'vaccine', 'may', 'be', 'used', 'in', 'clinical', 'settings', 'where', 'freezer', 'availability', 'is', 'limited', '.']","(4, 5)","(38, 46)",-1,ss_i,18077611,Abstract,12,test,gold,5639.0
2375,The refrigerator-stable formulation of Zostavax has an acceptable,safety,"profile and is as immunogenic as the frozen formulation ; thus , the vaccine may be used in clinical settings where freezer availability is limited .","['The', 'refrigerator-stable', 'formulation', 'of', 'Zostavax', 'has', 'an', 'acceptable', 'safety', 'profile', 'and', 'is', 'as', 'immunogenic', 'as', 'the', 'frozen', 'formulation', ';', 'thus', ',', 'the', 'vaccine', 'may', 'be', 'used', 'in', 'clinical', 'settings', 'where', 'freezer', 'availability', 'is', 'limited', '.']","(8, 9)","(65, 71)",-1,ss_o,18077611,Abstract,12,test,gold,476.0
2376,The refrigerator-stable formulation of Zostavax has an acceptable safety profile and is as,immunogenic,"as the frozen formulation ; thus , the vaccine may be used in clinical settings where freezer availability is limited .","['The', 'refrigerator-stable', 'formulation', 'of', 'Zostavax', 'has', 'an', 'acceptable', 'safety', 'profile', 'and', 'is', 'as', 'immunogenic', 'as', 'the', 'frozen', 'formulation', ';', 'thus', ',', 'the', 'vaccine', 'may', 'be', 'used', 'in', 'clinical', 'settings', 'where', 'freezer', 'availability', 'is', 'limited', '.']","(13, 14)","(90, 101)",-1,ss_o,18077611,Abstract,12,test,gold,5725.0
2377,The refrigerator-stable formulation of,Zostavax,"has an acceptable safety profile and is as immunogenic as the frozen formulation ; thus , the vaccine may be used in clinical settings where freezer availability is limited .","['The', 'refrigerator-stable', 'formulation', 'of', 'Zostavax', 'has', 'an', 'acceptable', 'safety', 'profile', 'and', 'is', 'as', 'immunogenic', 'as', 'the', 'frozen', 'formulation', ';', 'thus', ',', 'the', 'vaccine', 'may', 'be', 'used', 'in', 'clinical', 'settings', 'where', 'freezer', 'availability', 'is', 'limited', '.']","(4, 5)","(38, 46)",-1,hl_i,18077611,Abstract,12,test,gold,5638.0
2378,The refrigerator-stable formulation of Zostavax has an acceptable,safety,"profile and is as immunogenic as the frozen formulation ; thus , the vaccine may be used in clinical settings where freezer availability is limited .","['The', 'refrigerator-stable', 'formulation', 'of', 'Zostavax', 'has', 'an', 'acceptable', 'safety', 'profile', 'and', 'is', 'as', 'immunogenic', 'as', 'the', 'frozen', 'formulation', ';', 'thus', ',', 'the', 'vaccine', 'may', 'be', 'used', 'in', 'clinical', 'settings', 'where', 'freezer', 'availability', 'is', 'limited', '.']","(8, 9)","(65, 71)",-1,hl_o,18077611,Abstract,12,test,gold,475.0
2379,The refrigerator-stable formulation of Zostavax has an acceptable safety profile and is as,immunogenic,"as the frozen formulation ; thus , the vaccine may be used in clinical settings where freezer availability is limited .","['The', 'refrigerator-stable', 'formulation', 'of', 'Zostavax', 'has', 'an', 'acceptable', 'safety', 'profile', 'and', 'is', 'as', 'immunogenic', 'as', 'the', 'frozen', 'formulation', ';', 'thus', ',', 'the', 'vaccine', 'may', 'be', 'used', 'in', 'clinical', 'settings', 'where', 'freezer', 'availability', 'is', 'limited', '.']","(13, 14)","(90, 101)",-1,hl_o,18077611,Abstract,12,test,gold,5726.0
2380,Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in,patients with early breast cancer :,results from a randomised study of the Central European Cooperative Oncology Group ( CECOG ) .,"['Feasibility', 'of', 'two', 'dose-dense', 'FEC', 'regimens', 'with', 'growth', 'factor', 'support', 'for', 'adjuvant', 'therapy', 'in', 'patients', 'with', 'early', 'breast', 'cancer', ':', 'results', 'from', 'a', 'randomised', 'study', 'of', 'the', 'Central', 'European', 'Cooperative', 'Oncology', 'Group', '(', 'CECOG', ')', '.']","(14, 20)","(93, 128)",-1,ss_p,18189160,Title,0,test,gold,6831.0
2381,Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer : results from a randomised study of the Central,European,Cooperative Oncology Group ( CECOG ) .,"['Feasibility', 'of', 'two', 'dose-dense', 'FEC', 'regimens', 'with', 'growth', 'factor', 'support', 'for', 'adjuvant', 'therapy', 'in', 'patients', 'with', 'early', 'breast', 'cancer', ':', 'results', 'from', 'a', 'randomised', 'study', 'of', 'the', 'Central', 'European', 'Cooperative', 'Oncology', 'Group', '(', 'CECOG', ')', '.']","(28, 29)","(176, 184)",-1,ss_p,18189160,Title,0,test,gold,1126.0
2382,Feasibility of two dose-dense,FEC,regimens with growth factor support for adjuvant therapy in patients with early breast cancer : results from a randomised study of the Central European Cooperative Oncology Group ( CECOG ) .,"['Feasibility', 'of', 'two', 'dose-dense', 'FEC', 'regimens', 'with', 'growth', 'factor', 'support', 'for', 'adjuvant', 'therapy', 'in', 'patients', 'with', 'early', 'breast', 'cancer', ':', 'results', 'from', 'a', 'randomised', 'study', 'of', 'the', 'Central', 'European', 'Cooperative', 'Oncology', 'Group', '(', 'CECOG', ')', '.']","(4, 5)","(29, 32)",-1,ss_i,18189160,Title,0,test,gold,27.0
2383,,Feasibility,of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer : results from a randomised study of the Central European Cooperative Oncology Group ( CECOG ) .,"['Feasibility', 'of', 'two', 'dose-dense', 'FEC', 'regimens', 'with', 'growth', 'factor', 'support', 'for', 'adjuvant', 'therapy', 'in', 'patients', 'with', 'early', 'breast', 'cancer', ':', 'results', 'from', 'a', 'randomised', 'study', 'of', 'the', 'Central', 'European', 'Cooperative', 'Oncology', 'Group', '(', 'CECOG', ')', '.']","(0, 1)","(0, 11)",-1,ss_o,18189160,Title,0,test,gold,908.0
2384,Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in,patients with early breast cancer :,results from a randomised study of the Central European Cooperative Oncology Group ( CECOG ) .,"['Feasibility', 'of', 'two', 'dose-dense', 'FEC', 'regimens', 'with', 'growth', 'factor', 'support', 'for', 'adjuvant', 'therapy', 'in', 'patients', 'with', 'early', 'breast', 'cancer', ':', 'results', 'from', 'a', 'randomised', 'study', 'of', 'the', 'Central', 'European', 'Cooperative', 'Oncology', 'Group', '(', 'CECOG', ')', '.']","(14, 20)","(93, 128)",-1,hl_p,18189160,Title,0,test,gold,6832.0
2385,Feasibility of two dose-dense,FEC,regimens with growth factor support for adjuvant therapy in patients with early breast cancer : results from a randomised study of the Central European Cooperative Oncology Group ( CECOG ) .,"['Feasibility', 'of', 'two', 'dose-dense', 'FEC', 'regimens', 'with', 'growth', 'factor', 'support', 'for', 'adjuvant', 'therapy', 'in', 'patients', 'with', 'early', 'breast', 'cancer', ':', 'results', 'from', 'a', 'randomised', 'study', 'of', 'the', 'Central', 'European', 'Cooperative', 'Oncology', 'Group', '(', 'CECOG', ')', '.']","(4, 5)","(29, 32)",-1,hl_i,18189160,Title,0,test,gold,28.0
2386,Addition of epirubicin to adjuvant chemotherapy can provide important benefits for,patients with early breast cancer,", but the optimal dose remains unclear .","['Addition', 'of', 'epirubicin', 'to', 'adjuvant', 'chemotherapy', 'can', 'provide', 'important', 'benefits', 'for', 'patients', 'with', 'early', 'breast', 'cancer', ',', 'but', 'the', 'optimal', 'dose', 'remains', 'unclear', '.']","(11, 16)","(82, 115)",-1,ss_p,18189160,Abstract,0,test,gold,6830.0
2387,Addition of,epirubicin,"to adjuvant chemotherapy can provide important benefits for patients with early breast cancer , but the optimal dose remains unclear .","['Addition', 'of', 'epirubicin', 'to', 'adjuvant', 'chemotherapy', 'can', 'provide', 'important', 'benefits', 'for', 'patients', 'with', 'early', 'breast', 'cancer', ',', 'but', 'the', 'optimal', 'dose', 'remains', 'unclear', '.']","(2, 3)","(11, 21)",-1,ss_i,18189160,Abstract,0,test,gold,5740.0
2388,Addition of epirubicin to adjuvant chemotherapy can provide important benefits for,patients with early breast cancer,", but the optimal dose remains unclear .","['Addition', 'of', 'epirubicin', 'to', 'adjuvant', 'chemotherapy', 'can', 'provide', 'important', 'benefits', 'for', 'patients', 'with', 'early', 'breast', 'cancer', ',', 'but', 'the', 'optimal', 'dose', 'remains', 'unclear', '.']","(11, 16)","(82, 115)",-1,hl_p,18189160,Abstract,0,test,gold,6829.0
2389,Addition of,epirubicin,"to adjuvant chemotherapy can provide important benefits for patients with early breast cancer , but the optimal dose remains unclear .","['Addition', 'of', 'epirubicin', 'to', 'adjuvant', 'chemotherapy', 'can', 'provide', 'important', 'benefits', 'for', 'patients', 'with', 'early', 'breast', 'cancer', ',', 'but', 'the', 'optimal', 'dose', 'remains', 'unclear', '.']","(2, 3)","(11, 21)",-1,hl_i,18189160,Abstract,0,test,gold,5741.0
2390,"Further improvements can be achieved with dose-dense regimens , but densification of",fluorouracil/epirubicin/cyclophosphamide ( FEC ),"has proved difficult , with FEC ( 60 ) providing little benefit over standard chemotherapy and FEC ( 100 ) associated with toxicity .","['Further', 'improvements', 'can', 'be', 'achieved', 'with', 'dose-dense', 'regimens', ',', 'but', 'densification', 'of', 'fluorouracil/epirubicin/cyclophosphamide', '(', 'FEC', ')', 'has', 'proved', 'difficult', ',', 'with', 'FEC', '(', '60', ')', 'providing', 'little', 'benefit', 'over', 'standard', 'chemotherapy', 'and', 'FEC', '(', '100', ')', 'associated', 'with', 'toxicity', '.']","(12, 16)","(84, 132)",-1,ss_i,18189160,Abstract,1,test,gold,26.0
2391,"Further improvements can be achieved with dose-dense regimens , but densification of fluorouracil/epirubicin/cyclophosphamide ( FEC ) has proved difficult , with",FEC ( 60 ),providing little benefit over standard chemotherapy and FEC ( 100 ) associated with toxicity .,"['Further', 'improvements', 'can', 'be', 'achieved', 'with', 'dose-dense', 'regimens', ',', 'but', 'densification', 'of', 'fluorouracil/epirubicin/cyclophosphamide', '(', 'FEC', ')', 'has', 'proved', 'difficult', ',', 'with', 'FEC', '(', '60', ')', 'providing', 'little', 'benefit', 'over', 'standard', 'chemotherapy', 'and', 'FEC', '(', '100', ')', 'associated', 'with', 'toxicity', '.']","(21, 25)","(161, 171)",-1,ss_i,18189160,Abstract,1,test,gold,25.0
2392,"Further improvements can be achieved with dose-dense regimens , but densification of fluorouracil/epirubicin/cyclophosphamide ( FEC ) has proved difficult , with FEC ( 60 ) providing little benefit over standard chemotherapy and",FEC ( 100 ),associated with toxicity .,"['Further', 'improvements', 'can', 'be', 'achieved', 'with', 'dose-dense', 'regimens', ',', 'but', 'densification', 'of', 'fluorouracil/epirubicin/cyclophosphamide', '(', 'FEC', ')', 'has', 'proved', 'difficult', ',', 'with', 'FEC', '(', '60', ')', 'providing', 'little', 'benefit', 'over', 'standard', 'chemotherapy', 'and', 'FEC', '(', '100', ')', 'associated', 'with', 'toxicity', '.']","(32, 36)","(228, 239)",-1,ss_i,18189160,Abstract,1,test,gold,24.0
2393,"Further improvements can be achieved with dose-dense regimens , but densification of",fluorouracil/epirubicin/cyclophosphamide ( FEC ),"has proved difficult , with FEC ( 60 ) providing little benefit over standard chemotherapy and FEC ( 100 ) associated with toxicity .","['Further', 'improvements', 'can', 'be', 'achieved', 'with', 'dose-dense', 'regimens', ',', 'but', 'densification', 'of', 'fluorouracil/epirubicin/cyclophosphamide', '(', 'FEC', ')', 'has', 'proved', 'difficult', ',', 'with', 'FEC', '(', '60', ')', 'providing', 'little', 'benefit', 'over', 'standard', 'chemotherapy', 'and', 'FEC', '(', '100', ')', 'associated', 'with', 'toxicity', '.']","(12, 16)","(84, 132)",-1,hl_i,18189160,Abstract,1,test,gold,23.0
2394,"Further improvements can be achieved with dose-dense regimens , but densification of fluorouracil/epirubicin/cyclophosphamide ( FEC ) has proved difficult , with FEC ( 60 ) providing little benefit over standard chemotherapy and",FEC ( 100 ),associated with toxicity .,"['Further', 'improvements', 'can', 'be', 'achieved', 'with', 'dose-dense', 'regimens', ',', 'but', 'densification', 'of', 'fluorouracil/epirubicin/cyclophosphamide', '(', 'FEC', ')', 'has', 'proved', 'difficult', ',', 'with', 'FEC', '(', '60', ')', 'providing', 'little', 'benefit', 'over', 'standard', 'chemotherapy', 'and', 'FEC', '(', '100', ')', 'associated', 'with', 'toxicity', '.']","(32, 36)","(228, 239)",-1,hl_i,18189160,Abstract,1,test,gold,22.0
2395,We investigated the feasibility of two intermediate dose-dense,FEC,regimens .,"['We', 'investigated', 'the', 'feasibility', 'of', 'two', 'intermediate', 'dose-dense', 'FEC', 'regimens', '.']","(8, 9)","(62, 65)",-1,ss_i,18189160,Abstract,2,test,gold,21.0
2396,We investigated the,feasibility,of two intermediate dose-dense FEC regimens .,"['We', 'investigated', 'the', 'feasibility', 'of', 'two', 'intermediate', 'dose-dense', 'FEC', 'regimens', '.']","(3, 4)","(19, 30)",-1,ss_o,18189160,Abstract,2,test,gold,912.0
2397,We investigated the feasibility of two intermediate dose-dense,FEC,regimens .,"['We', 'investigated', 'the', 'feasibility', 'of', 'two', 'intermediate', 'dose-dense', 'FEC', 'regimens', '.']","(8, 9)","(62, 65)",-1,hl_i,18189160,Abstract,2,test,gold,20.0
2398,Patients were randomised to six cycles of,FEC ( 75 ),"or FEC ( 90 ) , with all three drugs given on day 1 of each 14-day cycle .","['Patients', 'were', 'randomised', 'to', 'six', 'cycles', 'of', 'FEC', '(', '75', ')', 'or', 'FEC', '(', '90', ')', ',', 'with', 'all', 'three', 'drugs', 'given', 'on', 'day', '1', 'of', 'each', '14-day', 'cycle', '.']","(7, 11)","(41, 51)",-1,ss_i,18189160,Abstract,3,test,gold,19.0
2399,Patients were randomised to six cycles of FEC ( 75 ) or,FEC ( 90 ),", with all three drugs given on day 1 of each 14-day cycle .","['Patients', 'were', 'randomised', 'to', 'six', 'cycles', 'of', 'FEC', '(', '75', ')', 'or', 'FEC', '(', '90', ')', ',', 'with', 'all', 'three', 'drugs', 'given', 'on', 'day', '1', 'of', 'each', '14-day', 'cycle', '.']","(12, 16)","(55, 65)",-1,ss_i,18189160,Abstract,3,test,gold,18.0
2400,Patients were randomised to six cycles of,FEC ( 75 ),"or FEC ( 90 ) , with all three drugs given on day 1 of each 14-day cycle .","['Patients', 'were', 'randomised', 'to', 'six', 'cycles', 'of', 'FEC', '(', '75', ')', 'or', 'FEC', '(', '90', ')', ',', 'with', 'all', 'three', 'drugs', 'given', 'on', 'day', '1', 'of', 'each', '14-day', 'cycle', '.']","(7, 11)","(41, 51)",-1,hl_i,18189160,Abstract,3,test,gold,17.0
2401,Patients were randomised to six cycles of FEC ( 75 ) or,FEC ( 90 ),", with all three drugs given on day 1 of each 14-day cycle .","['Patients', 'were', 'randomised', 'to', 'six', 'cycles', 'of', 'FEC', '(', '75', ')', 'or', 'FEC', '(', '90', ')', ',', 'with', 'all', 'three', 'drugs', 'given', 'on', 'day', '1', 'of', 'each', '14-day', 'cycle', '.']","(12, 16)","(55, 65)",-1,hl_i,18189160,Abstract,3,test,gold,16.0
2402,Patients also received,pegfilgrastim,6 mg as a single subcutaneous injection on day 2 of each cycle .,"['Patients', 'also', 'received', 'pegfilgrastim', '6', 'mg', 'as', 'a', 'single', 'subcutaneous', 'injection', 'on', 'day', '2', 'of', 'each', 'cycle', '.']","(3, 4)","(22, 35)",-1,ss_i,18189160,Abstract,4,test,gold,156.0
2403,Patients also received,pegfilgrastim,6 mg as a single subcutaneous injection on day 2 of each cycle .,"['Patients', 'also', 'received', 'pegfilgrastim', '6', 'mg', 'as', 'a', 'single', 'subcutaneous', 'injection', 'on', 'day', '2', 'of', 'each', 'cycle', '.']","(3, 4)","(22, 35)",-1,hl_i,18189160,Abstract,4,test,gold,157.0
2404,The primary efficacy endpoint was the proportion of subjects receiving > or =85 % relative dose intensity and was achieved by 96 % and 88 % of patients in the,FEC ( 75 ),"and FEC ( 90 ) arms , respectively .","['The', 'primary', 'efficacy', 'endpoint', 'was', 'the', 'proportion', 'of', 'subjects', 'receiving', '>', 'or', '=85', '%', 'relative', 'dose', 'intensity', 'and', 'was', 'achieved', 'by', '96', '%', 'and', '88', '%', 'of', 'patients', 'in', 'the', 'FEC', '(', '75', ')', 'and', 'FEC', '(', '90', ')', 'arms', ',', 'respectively', '.']","(30, 34)","(158, 168)",-1,ss_i,18189160,Abstract,5,test,gold,15.0
2405,The primary efficacy endpoint was the proportion of subjects receiving > or =85 % relative dose intensity and was achieved by 96 % and 88 % of patients in the FEC ( 75 ) and,FEC ( 90 ),"arms , respectively .","['The', 'primary', 'efficacy', 'endpoint', 'was', 'the', 'proportion', 'of', 'subjects', 'receiving', '>', 'or', '=85', '%', 'relative', 'dose', 'intensity', 'and', 'was', 'achieved', 'by', '96', '%', 'and', '88', '%', 'of', 'patients', 'in', 'the', 'FEC', '(', '75', ')', 'and', 'FEC', '(', '90', ')', 'arms', ',', 'respectively', '.']","(35, 39)","(173, 183)",-1,ss_i,18189160,Abstract,5,test,gold,14.0
2406,The primary,efficacy,"endpoint was the proportion of subjects receiving > or =85 % relative dose intensity and was achieved by 96 % and 88 % of patients in the FEC ( 75 ) and FEC ( 90 ) arms , respectively .","['The', 'primary', 'efficacy', 'endpoint', 'was', 'the', 'proportion', 'of', 'subjects', 'receiving', '>', 'or', '=85', '%', 'relative', 'dose', 'intensity', 'and', 'was', 'achieved', 'by', '96', '%', 'and', '88', '%', 'of', 'patients', 'in', 'the', 'FEC', '(', '75', ')', 'and', 'FEC', '(', '90', ')', 'arms', ',', 'respectively', '.']","(2, 3)","(11, 19)",-1,ss_o,18189160,Abstract,5,test,gold,4822.0
2407,The primary efficacy endpoint was the,proportion of subjects receiving > or =85 % relative dose intensity,"and was achieved by 96 % and 88 % of patients in the FEC ( 75 ) and FEC ( 90 ) arms , respectively .","['The', 'primary', 'efficacy', 'endpoint', 'was', 'the', 'proportion', 'of', 'subjects', 'receiving', '>', 'or', '=85', '%', 'relative', 'dose', 'intensity', 'and', 'was', 'achieved', 'by', '96', '%', 'and', '88', '%', 'of', 'patients', 'in', 'the', 'FEC', '(', '75', ')', 'and', 'FEC', '(', '90', ')', 'arms', ',', 'respectively', '.']","(6, 17)","(37, 104)",-1,ss_o,18189160,Abstract,5,test,gold,6463.0
2408,The primary efficacy endpoint was the,proportion of subjects receiving > or =85 % relative dose intensity,"and was achieved by 96 % and 88 % of patients in the FEC ( 75 ) and FEC ( 90 ) arms , respectively .","['The', 'primary', 'efficacy', 'endpoint', 'was', 'the', 'proportion', 'of', 'subjects', 'receiving', '>', 'or', '=85', '%', 'relative', 'dose', 'intensity', 'and', 'was', 'achieved', 'by', '96', '%', 'and', '88', '%', 'of', 'patients', 'in', 'the', 'FEC', '(', '75', ')', 'and', 'FEC', '(', '90', ')', 'arms', ',', 'respectively', '.']","(6, 17)","(37, 104)",-1,hl_o,18189160,Abstract,5,test,gold,6464.0
2409,Of 147,FEC ( 75 ),"infusions , 4.1 % were delayed , while 9.8 % of 143 FEC ( 90 ) infusions were delayed .","['Of', '147', 'FEC', '(', '75', ')', 'infusions', ',', '4.1', '%', 'were', 'delayed', ',', 'while', '9.8', '%', 'of', '143', 'FEC', '(', '90', ')', 'infusions', 'were', 'delayed', '.']","(2, 6)","(6, 16)",-1,ss_i,18189160,Abstract,6,test,gold,13.0
2410,"Of 147 FEC ( 75 ) infusions , 4.1 % were delayed , while 9.8 % of 143",FEC ( 90 ),infusions were delayed .,"['Of', '147', 'FEC', '(', '75', ')', 'infusions', ',', '4.1', '%', 'were', 'delayed', ',', 'while', '9.8', '%', 'of', '143', 'FEC', '(', '90', ')', 'infusions', 'were', 'delayed', '.']","(18, 22)","(69, 79)",-1,ss_i,18189160,Abstract,6,test,gold,12.0
2411,Of 147,FEC ( 75 ),"infusions , 4.1 % were delayed , while 9.8 % of 143 FEC ( 90 ) infusions were delayed .","['Of', '147', 'FEC', '(', '75', ')', 'infusions', ',', '4.1', '%', 'were', 'delayed', ',', 'while', '9.8', '%', 'of', '143', 'FEC', '(', '90', ')', 'infusions', 'were', 'delayed', '.']","(2, 6)","(6, 16)",-1,hl_i,18189160,Abstract,6,test,gold,11.0
2412,"Of 147 FEC ( 75 ) infusions , 4.1 % were delayed , while 9.8 % of 143",FEC ( 90 ),infusions were delayed .,"['Of', '147', 'FEC', '(', '75', ')', 'infusions', ',', '4.1', '%', 'were', 'delayed', ',', 'while', '9.8', '%', 'of', '143', 'FEC', '(', '90', ')', 'infusions', 'were', 'delayed', '.']","(18, 22)","(69, 79)",-1,hl_i,18189160,Abstract,6,test,gold,10.0
2413,The most common reasons for delay were,adverse events,and personal/logistical reasons .,"['The', 'most', 'common', 'reasons', 'for', 'delay', 'were', 'adverse', 'events', 'and', 'personal/logistical', 'reasons', '.']","(7, 9)","(38, 52)",-1,ss_o,18189160,Abstract,7,test,gold,3065.0
2414,The most common reasons for delay were,adverse events,and personal/logistical reasons .,"['The', 'most', 'common', 'reasons', 'for', 'delay', 'were', 'adverse', 'events', 'and', 'personal/logistical', 'reasons', '.']","(7, 9)","(38, 52)",-1,hl_o,18189160,Abstract,7,test,gold,3064.0
2415,One dose reduction occurred during the study,( FEC ( 90 ) ),", related to diarrhoea .","['One', 'dose', 'reduction', 'occurred', 'during', 'the', 'study', '(', 'FEC', '(', '90', ')', ')', ',', 'related', 'to', 'diarrhoea', '.']","(7, 13)","(44, 58)",-1,ss_i,18189160,Abstract,8,test,gold,9.0
2416,"One dose reduction occurred during the study ( FEC ( 90 ) ) , related to",diarrhoea .,,"['One', 'dose', 'reduction', 'occurred', 'during', 'the', 'study', '(', 'FEC', '(', '90', ')', ')', ',', 'related', 'to', 'diarrhoea', '.']","(16, 18)","(72, 83)",-1,ss_o,18189160,Abstract,8,test,gold,
2417,One dose reduction occurred during the study (,FEC ( 90 ),") , related to diarrhoea .","['One', 'dose', 'reduction', 'occurred', 'during', 'the', 'study', '(', 'FEC', '(', '90', ')', ')', ',', 'related', 'to', 'diarrhoea', '.']","(8, 12)","(46, 56)",-1,hl_i,18189160,Abstract,8,test,gold,8.0
2418,"One dose reduction occurred during the study ( FEC ( 90 ) ) , related to",diarrhoea .,,"['One', 'dose', 'reduction', 'occurred', 'during', 'the', 'study', '(', 'FEC', '(', '90', ')', ')', ',', 'related', 'to', 'diarrhoea', '.']","(16, 18)","(72, 83)",-1,hl_o,18189160,Abstract,8,test,gold,
2419,Grade 3-4 haematological toxicities were reported in two patients in the,FEC ( 90 ),arm .,"['Grade', '3-4', 'haematological', 'toxicities', 'were', 'reported', 'in', 'two', 'patients', 'in', 'the', 'FEC', '(', '90', ')', 'arm', '.']","(11, 15)","(72, 82)",-1,ss_i,18189160,Abstract,9,test,gold,7.0
2420,Grade 3-4,haematological toxicities,were reported in two patients in the FEC ( 90 ) arm .,"['Grade', '3-4', 'haematological', 'toxicities', 'were', 'reported', 'in', 'two', 'patients', 'in', 'the', 'FEC', '(', '90', ')', 'arm', '.']","(2, 4)","(9, 34)",-1,ss_o,18189160,Abstract,9,test,gold,3482.0
2421,Grade 3-4 haematological toxicities were reported in two patients in the,FEC ( 90 ),arm .,"['Grade', '3-4', 'haematological', 'toxicities', 'were', 'reported', 'in', 'two', 'patients', 'in', 'the', 'FEC', '(', '90', ')', 'arm', '.']","(11, 15)","(72, 82)",-1,hl_i,18189160,Abstract,9,test,gold,6.0
2422,Grade 3-4,haematological toxicities,were reported in two patients in the FEC ( 90 ) arm .,"['Grade', '3-4', 'haematological', 'toxicities', 'were', 'reported', 'in', 'two', 'patients', 'in', 'the', 'FEC', '(', '90', ')', 'arm', '.']","(2, 4)","(9, 34)",-1,hl_o,18189160,Abstract,9,test,gold,3483.0
2423,There were no incidences of,febrile neutropenia,during the study .,"['There', 'were', 'no', 'incidences', 'of', 'febrile', 'neutropenia', 'during', 'the', 'study', '.']","(5, 7)","(27, 46)",-1,ss_o,18189160,Abstract,10,test,gold,3522.0
2424,There were no incidences of,febrile neutropenia,during the study .,"['There', 'were', 'no', 'incidences', 'of', 'febrile', 'neutropenia', 'during', 'the', 'study', '.']","(5, 7)","(27, 46)",-1,hl_o,18189160,Abstract,10,test,gold,3523.0
2425,The most common,adverse events,were increases in liver enzymes and gastrointestinal events ; no event resulted in discontinuation .,"['The', 'most', 'common', 'adverse', 'events', 'were', 'increases', 'in', 'liver', 'enzymes', 'and', 'gastrointestinal', 'events', ';', 'no', 'event', 'resulted', 'in', 'discontinuation', '.']","(3, 5)","(15, 29)",-1,ss_o,18189160,Abstract,11,test,gold,3063.0
2426,The most common adverse events were,increases in liver enzymes and gastrointestinal events ;,no event resulted in discontinuation .,"['The', 'most', 'common', 'adverse', 'events', 'were', 'increases', 'in', 'liver', 'enzymes', 'and', 'gastrointestinal', 'events', ';', 'no', 'event', 'resulted', 'in', 'discontinuation', '.']","(6, 14)","(35, 91)",-1,ss_o,18189160,Abstract,11,test,gold,6636.0
2427,The most common adverse events were increases in,liver enzymes and gastrointestinal events,; no event resulted in discontinuation .,"['The', 'most', 'common', 'adverse', 'events', 'were', 'increases', 'in', 'liver', 'enzymes', 'and', 'gastrointestinal', 'events', ';', 'no', 'event', 'resulted', 'in', 'discontinuation', '.']","(8, 13)","(48, 89)",-1,hl_o,18189160,Abstract,11,test,gold,6637.0
2428,Only one patient,( FEC ( 90 ) ),experienced serious adverse events ( vomiting and throat oedema ) .,"['Only', 'one', 'patient', '(', 'FEC', '(', '90', ')', ')', 'experienced', 'serious', 'adverse', 'events', '(', 'vomiting', 'and', 'throat', 'oedema', ')', '.']","(3, 9)","(16, 30)",-1,ss_i,18189160,Abstract,12,test,gold,5.0
2429,Only one patient ( FEC ( 90 ) ) experienced,serious adverse events ( vomiting and throat oedema ) .,,"['Only', 'one', 'patient', '(', 'FEC', '(', '90', ')', ')', 'experienced', 'serious', 'adverse', 'events', '(', 'vomiting', 'and', 'throat', 'oedema', ')', '.']","(10, 20)","(43, 98)",-1,ss_o,18189160,Abstract,12,test,gold,7086.0
2430,Only one patient,( FEC ( 90 ) ),experienced serious adverse events ( vomiting and throat oedema ) .,"['Only', 'one', 'patient', '(', 'FEC', '(', '90', ')', ')', 'experienced', 'serious', 'adverse', 'events', '(', 'vomiting', 'and', 'throat', 'oedema', ')', '.']","(3, 9)","(16, 30)",-1,hl_i,18189160,Abstract,12,test,gold,4.0
2431,Only one patient ( FEC ( 90 ) ) experienced,serious adverse events ( vomiting and throat oedema ) .,,"['Only', 'one', 'patient', '(', 'FEC', '(', '90', ')', ')', 'experienced', 'serious', 'adverse', 'events', '(', 'vomiting', 'and', 'throat', 'oedema', ')', '.']","(10, 20)","(43, 98)",-1,hl_o,18189160,Abstract,12,test,gold,7087.0
2432,"In conclusion , dose-dense",FEC ( 75,) and FEC ( 90 ) are feasible with pegfilgrastim support .,"['In', 'conclusion', ',', 'dose-dense', 'FEC', '(', '75', ')', 'and', 'FEC', '(', '90', ')', 'are', 'feasible', 'with', 'pegfilgrastim', 'support', '.']","(4, 7)","(26, 34)",-1,ss_i,18189160,Abstract,13,test,gold,3.0
2433,"In conclusion , dose-dense FEC ( 75 ) and",FEC ( 90 ),are feasible with pegfilgrastim support .,"['In', 'conclusion', ',', 'dose-dense', 'FEC', '(', '75', ')', 'and', 'FEC', '(', '90', ')', 'are', 'feasible', 'with', 'pegfilgrastim', 'support', '.']","(9, 13)","(41, 51)",-1,ss_i,18189160,Abstract,13,test,gold,2.0
2434,"In conclusion , dose-dense FEC ( 75 ) and FEC ( 90 ) are feasible with",pegfilgrastim,support .,"['In', 'conclusion', ',', 'dose-dense', 'FEC', '(', '75', ')', 'and', 'FEC', '(', '90', ')', 'are', 'feasible', 'with', 'pegfilgrastim', 'support', '.']","(16, 17)","(70, 83)",-1,ss_i,18189160,Abstract,13,test,gold,155.0
2435,"In conclusion , dose-dense FEC ( 75 ) and FEC ( 90 ) are",feasible,with pegfilgrastim support .,"['In', 'conclusion', ',', 'dose-dense', 'FEC', '(', '75', ')', 'and', 'FEC', '(', '90', ')', 'are', 'feasible', 'with', 'pegfilgrastim', 'support', '.']","(14, 15)","(56, 64)",-1,ss_o,18189160,Abstract,13,test,gold,867.0
2436,"In conclusion , dose-dense",FEC ( 75,) and FEC ( 90 ) are feasible with pegfilgrastim support .,"['In', 'conclusion', ',', 'dose-dense', 'FEC', '(', '75', ')', 'and', 'FEC', '(', '90', ')', 'are', 'feasible', 'with', 'pegfilgrastim', 'support', '.']","(4, 7)","(26, 34)",-1,hl_i,18189160,Abstract,13,test,gold,1.0
2437,"In conclusion , dose-dense FEC ( 75 ) and",FEC ( 90 ),are feasible with pegfilgrastim support .,"['In', 'conclusion', ',', 'dose-dense', 'FEC', '(', '75', ')', 'and', 'FEC', '(', '90', ')', 'are', 'feasible', 'with', 'pegfilgrastim', 'support', '.']","(9, 13)","(41, 51)",-1,hl_i,18189160,Abstract,13,test,gold,0.0
2438,These regimens are associated with a very low risk of Grade 3-4 toxicity .,,,"['These', 'regimens', 'are', 'associated', 'with', 'a', 'very', 'low', 'risk', 'of', 'Grade', '3-4', 'toxicity', '.']",,,,,18189160,Abstract,14,test,gold,
2439,Language outcome in,autism :,randomized comparison of joint attention and play interventions .,"['Language', 'outcome', 'in', 'autism', ':', 'randomized', 'comparison', 'of', 'joint', 'attention', 'and', 'play', 'interventions', '.']","(3, 5)","(19, 27)",-1,ss_p,18229990,Title,0,test,gold,6150.0
2440,Language outcome in autism : randomized comparison of,joint attention,and play interventions .,"['Language', 'outcome', 'in', 'autism', ':', 'randomized', 'comparison', 'of', 'joint', 'attention', 'and', 'play', 'interventions', '.']","(8, 10)","(53, 68)",-1,ss_i,18229990,Title,0,test,gold,925.0
2441,Language outcome in autism : randomized comparison of joint attention and,play interventions .,,"['Language', 'outcome', 'in', 'autism', ':', 'randomized', 'comparison', 'of', 'joint', 'attention', 'and', 'play', 'interventions', '.']","(11, 14)","(73, 93)",-1,ss_i,18229990,Title,0,test,gold,2584.0
2442,,Language outcome,in autism : randomized comparison of joint attention and play interventions .,"['Language', 'outcome', 'in', 'autism', ':', 'randomized', 'comparison', 'of', 'joint', 'attention', 'and', 'play', 'interventions', '.']","(0, 2)","(0, 16)",-1,ss_o,18229990,Title,0,test,gold,2607.0
2443,Language outcome in,autism :,randomized comparison of joint attention and play interventions .,"['Language', 'outcome', 'in', 'autism', ':', 'randomized', 'comparison', 'of', 'joint', 'attention', 'and', 'play', 'interventions', '.']","(3, 5)","(19, 27)",-1,hl_p,18229990,Title,0,test,gold,6149.0
2444,Language outcome in autism : randomized comparison of,joint attention,and play interventions .,"['Language', 'outcome', 'in', 'autism', ':', 'randomized', 'comparison', 'of', 'joint', 'attention', 'and', 'play', 'interventions', '.']","(8, 10)","(53, 68)",-1,hl_i,18229990,Title,0,test,gold,926.0
2445,Language outcome in autism : randomized comparison of joint attention and,play interventions .,,"['Language', 'outcome', 'in', 'autism', ':', 'randomized', 'comparison', 'of', 'joint', 'attention', 'and', 'play', 'interventions', '.']","(11, 14)","(73, 93)",-1,hl_i,18229990,Title,0,test,gold,2585.0
2446,,Language outcome,in autism : randomized comparison of joint attention and play interventions .,"['Language', 'outcome', 'in', 'autism', ':', 'randomized', 'comparison', 'of', 'joint', 'attention', 'and', 'play', 'interventions', '.']","(0, 2)","(0, 16)",-1,hl_o,18229990,Title,0,test,gold,2608.0
2447,This study reports results of a randomized controlled trial aimed at joint attention ( JA ) and symbolic play ( SP ) in,preschool children with autism,", with prediction to language outcome 12 months later .","['This', 'study', 'reports', 'results', 'of', 'a', 'randomized', 'controlled', 'trial', 'aimed', 'at', 'joint', 'attention', '(', 'JA', ')', 'and', 'symbolic', 'play', '(', 'SP', ')', 'in', 'preschool', 'children', 'with', 'autism', ',', 'with', 'prediction', 'to', 'language', 'outcome', '12', 'months', 'later', '.']","(23, 27)","(119, 149)",-1,ss_p,18229990,Abstract,0,test,gold,6122.0
2448,This study reports results of a randomized controlled trial aimed at,joint attention ( JA ),"and symbolic play ( SP ) in preschool children with autism , with prediction to language outcome 12 months later .","['This', 'study', 'reports', 'results', 'of', 'a', 'randomized', 'controlled', 'trial', 'aimed', 'at', 'joint', 'attention', '(', 'JA', ')', 'and', 'symbolic', 'play', '(', 'SP', ')', 'in', 'preschool', 'children', 'with', 'autism', ',', 'with', 'prediction', 'to', 'language', 'outcome', '12', 'months', 'later', '.']","(11, 16)","(68, 90)",-1,ss_i,18229990,Abstract,0,test,gold,927.0
2449,This study reports results of a randomized controlled trial aimed at joint attention ( JA ) and,symbolic play ( SP ),"in preschool children with autism , with prediction to language outcome 12 months later .","['This', 'study', 'reports', 'results', 'of', 'a', 'randomized', 'controlled', 'trial', 'aimed', 'at', 'joint', 'attention', '(', 'JA', ')', 'and', 'symbolic', 'play', '(', 'SP', ')', 'in', 'preschool', 'children', 'with', 'autism', ',', 'with', 'prediction', 'to', 'language', 'outcome', '12', 'months', 'later', '.']","(17, 22)","(95, 115)",-1,ss_i,18229990,Abstract,0,test,gold,718.0
2450,"This study reports results of a randomized controlled trial aimed at joint attention ( JA ) and symbolic play ( SP ) in preschool children with autism , with prediction to",language outcome,12 months later .,"['This', 'study', 'reports', 'results', 'of', 'a', 'randomized', 'controlled', 'trial', 'aimed', 'at', 'joint', 'attention', '(', 'JA', ')', 'and', 'symbolic', 'play', '(', 'SP', ')', 'in', 'preschool', 'children', 'with', 'autism', ',', 'with', 'prediction', 'to', 'language', 'outcome', '12', 'months', 'later', '.']","(31, 33)","(171, 187)",-1,ss_o,18229990,Abstract,0,test,gold,2605.0
2451,This study reports results of a randomized controlled trial aimed at joint attention ( JA ) and symbolic play ( SP ) in,preschool children with autism,", with prediction to language outcome 12 months later .","['This', 'study', 'reports', 'results', 'of', 'a', 'randomized', 'controlled', 'trial', 'aimed', 'at', 'joint', 'attention', '(', 'JA', ')', 'and', 'symbolic', 'play', '(', 'SP', ')', 'in', 'preschool', 'children', 'with', 'autism', ',', 'with', 'prediction', 'to', 'language', 'outcome', '12', 'months', 'later', '.']","(23, 27)","(119, 149)",-1,hl_p,18229990,Abstract,0,test,gold,6123.0
2452,This study reports results of a randomized controlled trial aimed at,joint attention ( JA ),"and symbolic play ( SP ) in preschool children with autism , with prediction to language outcome 12 months later .","['This', 'study', 'reports', 'results', 'of', 'a', 'randomized', 'controlled', 'trial', 'aimed', 'at', 'joint', 'attention', '(', 'JA', ')', 'and', 'symbolic', 'play', '(', 'SP', ')', 'in', 'preschool', 'children', 'with', 'autism', ',', 'with', 'prediction', 'to', 'language', 'outcome', '12', 'months', 'later', '.']","(11, 16)","(68, 90)",-1,hl_i,18229990,Abstract,0,test,gold,928.0
2453,This study reports results of a randomized controlled trial aimed at joint attention ( JA ) and,symbolic play ( SP ),"in preschool children with autism , with prediction to language outcome 12 months later .","['This', 'study', 'reports', 'results', 'of', 'a', 'randomized', 'controlled', 'trial', 'aimed', 'at', 'joint', 'attention', '(', 'JA', ')', 'and', 'symbolic', 'play', '(', 'SP', ')', 'in', 'preschool', 'children', 'with', 'autism', ',', 'with', 'prediction', 'to', 'language', 'outcome', '12', 'months', 'later', '.']","(17, 22)","(95, 115)",-1,hl_i,18229990,Abstract,0,test,gold,719.0
2454,"This study reports results of a randomized controlled trial aimed at joint attention ( JA ) and symbolic play ( SP ) in preschool children with autism , with prediction to",language outcome,12 months later .,"['This', 'study', 'reports', 'results', 'of', 'a', 'randomized', 'controlled', 'trial', 'aimed', 'at', 'joint', 'attention', '(', 'JA', ')', 'and', 'symbolic', 'play', '(', 'SP', ')', 'in', 'preschool', 'children', 'with', 'autism', ',', 'with', 'prediction', 'to', 'language', 'outcome', '12', 'months', 'later', '.']","(31, 33)","(171, 187)",-1,hl_o,18229990,Abstract,0,test,gold,2606.0
2455,,Participants were 58 children ( 46 boys ) with autism between 3 and 4 years of age .,,"['Participants', 'were', '58', 'children', '(', '46', 'boys', ')', 'with', 'autism', 'between', '3', 'and', '4', 'years', 'of', 'age', '.']","(0, 18)","(0, 84)",-1,ss_p,18229990,Abstract,1,test,gold,5834.0
2456,Participants were,58 children,( 46 boys ) with autism between 3 and 4 years of age .,"['Participants', 'were', '58', 'children', '(', '46', 'boys', ')', 'with', 'autism', 'between', '3', 'and', '4', 'years', 'of', 'age', '.']","(2, 4)","(17, 28)",-1,hl_p,18229990,Abstract,1,test,gold,2140.0
2457,Participants were 58 children (,46,boys ) with autism between 3 and 4 years of age .,"['Participants', 'were', '58', 'children', '(', '46', 'boys', ')', 'with', 'autism', 'between', '3', 'and', '4', 'years', 'of', 'age', '.']","(5, 6)","(31, 33)",-1,hl_p,18229990,Abstract,1,test,gold,
2458,Participants were 58 children ( 46 boys ) with,autism between 3 and 4 years of age,.,"['Participants', 'were', '58', 'children', '(', '46', 'boys', ')', 'with', 'autism', 'between', '3', 'and', '4', 'years', 'of', 'age', '.']","(9, 17)","(46, 81)",-1,hl_p,18229990,Abstract,1,test,gold,6201.0
2459,Children were randomized to a,JA,"intervention , an SP intervention , or control group .","['Children', 'were', 'randomized', 'to', 'a', 'JA', 'intervention', ',', 'an', 'SP', 'intervention', ',', 'or', 'control', 'group', '.']","(5, 6)","(29, 31)",-1,ss_i,18229990,Abstract,2,test,gold,673.0
2460,"Children were randomized to a JA intervention , an",SP,"intervention , or control group .","['Children', 'were', 'randomized', 'to', 'a', 'JA', 'intervention', ',', 'an', 'SP', 'intervention', ',', 'or', 'control', 'group', '.']","(9, 10)","(50, 52)",-1,ss_i,18229990,Abstract,2,test,gold,716.0
2461,Children were randomized to a,JA,"intervention , an SP intervention , or control group .","['Children', 'were', 'randomized', 'to', 'a', 'JA', 'intervention', ',', 'an', 'SP', 'intervention', ',', 'or', 'control', 'group', '.']","(5, 6)","(29, 31)",-1,hl_i,18229990,Abstract,2,test,gold,674.0
2462,"Children were randomized to a JA intervention , an",SP,"intervention , or control group .","['Children', 'were', 'randomized', 'to', 'a', 'JA', 'intervention', ',', 'an', 'SP', 'intervention', ',', 'or', 'control', 'group', '.']","(9, 10)","(50, 52)",-1,hl_i,18229990,Abstract,2,test,gold,717.0
2463,Interventions were conducted 30 min daily for 5-6 weeks .,,,"['Interventions', 'were', 'conducted', '30', 'min', 'daily', 'for', '5-6', 'weeks', '.']",,,,,18229990,Abstract,3,test,gold,
2464,Assessments of,JA,"skills , SP skills , mother-child interactions , and language development were collected at 4 time points : pre- and postintervention and 6 and 12 months postintervention by independent testers .","['Assessments', 'of', 'JA', 'skills', ',', 'SP', 'skills', ',', 'mother-child', 'interactions', ',', 'and', 'language', 'development', 'were', 'collected', 'at', '4', 'time', 'points', ':', 'pre-', 'and', 'postintervention', 'and', '6', 'and', '12', 'months', 'postintervention', 'by', 'independent', 'testers', '.']","(2, 3)","(14, 16)",-1,ss_i,18229990,Abstract,4,test,gold,672.0
2465,"Assessments of JA skills ,",SP,"skills , mother-child interactions , and language development were collected at 4 time points : pre- and postintervention and 6 and 12 months postintervention by independent testers .","['Assessments', 'of', 'JA', 'skills', ',', 'SP', 'skills', ',', 'mother-child', 'interactions', ',', 'and', 'language', 'development', 'were', 'collected', 'at', '4', 'time', 'points', ':', 'pre-', 'and', 'postintervention', 'and', '6', 'and', '12', 'months', 'postintervention', 'by', 'independent', 'testers', '.']","(5, 6)","(26, 28)",-1,ss_i,18229990,Abstract,4,test,gold,715.0
2466,Assessments of,"JA skills , SP skills , mother-child interactions , and language development",were collected at 4 time points : pre- and postintervention and 6 and 12 months postintervention by independent testers .,"['Assessments', 'of', 'JA', 'skills', ',', 'SP', 'skills', ',', 'mother-child', 'interactions', ',', 'and', 'language', 'development', 'were', 'collected', 'at', '4', 'time', 'points', ':', 'pre-', 'and', 'postintervention', 'and', '6', 'and', '12', 'months', 'postintervention', 'by', 'independent', 'testers', '.']","(2, 14)","(14, 90)",-1,ss_o,18229990,Abstract,4,test,gold,2846.0
2467,Assessments of,JA,"skills , SP skills , mother-child interactions , and language development were collected at 4 time points : pre- and postintervention and 6 and 12 months postintervention by independent testers .","['Assessments', 'of', 'JA', 'skills', ',', 'SP', 'skills', ',', 'mother-child', 'interactions', ',', 'and', 'language', 'development', 'were', 'collected', 'at', '4', 'time', 'points', ':', 'pre-', 'and', 'postintervention', 'and', '6', 'and', '12', 'months', 'postintervention', 'by', 'independent', 'testers', '.']","(2, 3)","(14, 16)",-1,hl_i,18229990,Abstract,4,test,gold,671.0
2468,"Assessments of JA skills ,",SP,"skills , mother-child interactions , and language development were collected at 4 time points : pre- and postintervention and 6 and 12 months postintervention by independent testers .","['Assessments', 'of', 'JA', 'skills', ',', 'SP', 'skills', ',', 'mother-child', 'interactions', ',', 'and', 'language', 'development', 'were', 'collected', 'at', '4', 'time', 'points', ':', 'pre-', 'and', 'postintervention', 'and', '6', 'and', '12', 'months', 'postintervention', 'by', 'independent', 'testers', '.']","(5, 6)","(26, 28)",-1,hl_i,18229990,Abstract,4,test,gold,714.0
2469,Assessments of,"JA skills , SP skills , mother-child interactions , and language development",were collected at 4 time points : pre- and postintervention and 6 and 12 months postintervention by independent testers .,"['Assessments', 'of', 'JA', 'skills', ',', 'SP', 'skills', ',', 'mother-child', 'interactions', ',', 'and', 'language', 'development', 'were', 'collected', 'at', '4', 'time', 'points', ':', 'pre-', 'and', 'postintervention', 'and', '6', 'and', '12', 'months', 'postintervention', 'by', 'independent', 'testers', '.']","(2, 14)","(14, 90)",-1,hl_o,18229990,Abstract,4,test,gold,2847.0
2470,Results indicate that,expressive language gains,"were greater for both treatment groups compared with the control group , and results could not be explained by differences in other interventions in which children participated .","['Results', 'indicate', 'that', 'expressive', 'language', 'gains', 'were', 'greater', 'for', 'both', 'treatment', 'groups', 'compared', 'with', 'the', 'control', 'group', ',', 'and', 'results', 'could', 'not', 'be', 'explained', 'by', 'differences', 'in', 'other', 'interventions', 'in', 'which', 'children', 'participated', '.']","(3, 6)","(21, 46)",-1,ss_o,18229990,Abstract,5,test,gold,2611.0
2471,Results indicate that,expressive language gains,"were greater for both treatment groups compared with the control group , and results could not be explained by differences in other interventions in which children participated .","['Results', 'indicate', 'that', 'expressive', 'language', 'gains', 'were', 'greater', 'for', 'both', 'treatment', 'groups', 'compared', 'with', 'the', 'control', 'group', ',', 'and', 'results', 'could', 'not', 'be', 'explained', 'by', 'differences', 'in', 'other', 'interventions', 'in', 'which', 'children', 'participated', '.']","(3, 6)","(21, 46)",-1,hl_o,18229990,Abstract,5,test,gold,2612.0
2472,"For children beginning treatment with the lowest language levels , the",JA,intervention improved language outcome significantly more than did the SP or control interventions .,"['For', 'children', 'beginning', 'treatment', 'with', 'the', 'lowest', 'language', 'levels', ',', 'the', 'JA', 'intervention', 'improved', 'language', 'outcome', 'significantly', 'more', 'than', 'did', 'the', 'SP', 'or', 'control', 'interventions', '.']","(11, 12)","(70, 72)",-1,ss_i,18229990,Abstract,6,test,gold,670.0
2473,"For children beginning treatment with the lowest language levels , the JA intervention improved language outcome significantly more than did the",SP,or control interventions .,"['For', 'children', 'beginning', 'treatment', 'with', 'the', 'lowest', 'language', 'levels', ',', 'the', 'JA', 'intervention', 'improved', 'language', 'outcome', 'significantly', 'more', 'than', 'did', 'the', 'SP', 'or', 'control', 'interventions', '.']","(21, 22)","(144, 146)",-1,ss_i,18229990,Abstract,6,test,gold,713.0
2474,"For children beginning treatment with the lowest language levels , the JA intervention improved",language outcome,significantly more than did the SP or control interventions .,"['For', 'children', 'beginning', 'treatment', 'with', 'the', 'lowest', 'language', 'levels', ',', 'the', 'JA', 'intervention', 'improved', 'language', 'outcome', 'significantly', 'more', 'than', 'did', 'the', 'SP', 'or', 'control', 'interventions', '.']","(14, 16)","(95, 111)",-1,ss_o,18229990,Abstract,6,test,gold,2604.0
2475,"For children beginning treatment with the lowest language levels , the",JA,intervention improved language outcome significantly more than did the SP or control interventions .,"['For', 'children', 'beginning', 'treatment', 'with', 'the', 'lowest', 'language', 'levels', ',', 'the', 'JA', 'intervention', 'improved', 'language', 'outcome', 'significantly', 'more', 'than', 'did', 'the', 'SP', 'or', 'control', 'interventions', '.']","(11, 12)","(70, 72)",-1,hl_i,18229990,Abstract,6,test,gold,669.0
2476,"For children beginning treatment with the lowest language levels , the JA intervention improved language outcome significantly more than did the",SP,or control interventions .,"['For', 'children', 'beginning', 'treatment', 'with', 'the', 'lowest', 'language', 'levels', ',', 'the', 'JA', 'intervention', 'improved', 'language', 'outcome', 'significantly', 'more', 'than', 'did', 'the', 'SP', 'or', 'control', 'interventions', '.']","(21, 22)","(144, 146)",-1,hl_i,18229990,Abstract,6,test,gold,712.0
2477,"For children beginning treatment with the lowest language levels , the JA intervention improved",language outcome,significantly more than did the SP or control interventions .,"['For', 'children', 'beginning', 'treatment', 'with', 'the', 'lowest', 'language', 'levels', ',', 'the', 'JA', 'intervention', 'improved', 'language', 'outcome', 'significantly', 'more', 'than', 'did', 'the', 'SP', 'or', 'control', 'interventions', '.']","(14, 16)","(95, 111)",-1,hl_o,18229990,Abstract,6,test,gold,2603.0
2478,These findings suggest clinically significant benefits of actively treating JA and SP skills in,young children with autism .,,"['These', 'findings', 'suggest', 'clinically', 'significant', 'benefits', 'of', 'actively', 'treating', 'JA', 'and', 'SP', 'skills', 'in', 'young', 'children', 'with', 'autism', '.']","(14, 19)","(95, 123)",-1,ss_p,18229990,Abstract,7,test,gold,6120.0
2479,These findings suggest clinically significant benefits of actively treating,JA,and SP skills in young children with autism .,"['These', 'findings', 'suggest', 'clinically', 'significant', 'benefits', 'of', 'actively', 'treating', 'JA', 'and', 'SP', 'skills', 'in', 'young', 'children', 'with', 'autism', '.']","(9, 10)","(75, 77)",-1,ss_i,18229990,Abstract,7,test,gold,668.0
2480,These findings suggest clinically significant benefits of actively treating JA and,SP,skills in young children with autism .,"['These', 'findings', 'suggest', 'clinically', 'significant', 'benefits', 'of', 'actively', 'treating', 'JA', 'and', 'SP', 'skills', 'in', 'young', 'children', 'with', 'autism', '.']","(11, 12)","(82, 84)",-1,ss_i,18229990,Abstract,7,test,gold,711.0
2481,These findings suggest clinically significant benefits of actively treating JA and SP skills in,young children with autism .,,"['These', 'findings', 'suggest', 'clinically', 'significant', 'benefits', 'of', 'actively', 'treating', 'JA', 'and', 'SP', 'skills', 'in', 'young', 'children', 'with', 'autism', '.']","(14, 19)","(95, 123)",-1,hl_p,18229990,Abstract,7,test,gold,6121.0
2482,These findings suggest clinically significant benefits of actively treating,JA,and SP skills in young children with autism .,"['These', 'findings', 'suggest', 'clinically', 'significant', 'benefits', 'of', 'actively', 'treating', 'JA', 'and', 'SP', 'skills', 'in', 'young', 'children', 'with', 'autism', '.']","(9, 10)","(75, 77)",-1,hl_i,18229990,Abstract,7,test,gold,667.0
2483,These findings suggest clinically significant benefits of actively treating JA and,SP,skills in young children with autism .,"['These', 'findings', 'suggest', 'clinically', 'significant', 'benefits', 'of', 'actively', 'treating', 'JA', 'and', 'SP', 'skills', 'in', 'young', 'children', 'with', 'autism', '.']","(11, 12)","(82, 84)",-1,hl_i,18229990,Abstract,7,test,gold,710.0
2484,Once-daily amoxicillin versus twice-daily penicillin V in,group A beta-haemolytic streptococcal pharyngitis .,,"['Once-daily', 'amoxicillin', 'versus', 'twice-daily', 'penicillin', 'V', 'in', 'group', 'A', 'beta-haemolytic', 'streptococcal', 'pharyngitis', '.']","(7, 13)","(57, 108)",-1,ss_p,18337284,Title,0,test,gold,3565.0
2485,Once-daily,amoxicillin,versus twice-daily penicillin V in group A beta-haemolytic streptococcal pharyngitis .,"['Once-daily', 'amoxicillin', 'versus', 'twice-daily', 'penicillin', 'V', 'in', 'group', 'A', 'beta-haemolytic', 'streptococcal', 'pharyngitis', '.']","(1, 2)","(10, 21)",-1,ss_i,18337284,Title,0,test,gold,5008.0
2486,Once-daily amoxicillin versus twice-daily,penicillin V,in group A beta-haemolytic streptococcal pharyngitis .,"['Once-daily', 'amoxicillin', 'versus', 'twice-daily', 'penicillin', 'V', 'in', 'group', 'A', 'beta-haemolytic', 'streptococcal', 'pharyngitis', '.']","(4, 6)","(41, 53)",-1,ss_i,18337284,Title,0,test,gold,4978.0
2487,Once-daily amoxicillin versus twice-daily penicillin V in group A,beta-haemolytic streptococcal pharyngitis .,,"['Once-daily', 'amoxicillin', 'versus', 'twice-daily', 'penicillin', 'V', 'in', 'group', 'A', 'beta-haemolytic', 'streptococcal', 'pharyngitis', '.']","(9, 13)","(65, 108)",-1,hl_p,18337284,Title,0,test,gold,3566.0
2488,Once-daily,amoxicillin,versus twice-daily penicillin V in group A beta-haemolytic streptococcal pharyngitis .,"['Once-daily', 'amoxicillin', 'versus', 'twice-daily', 'penicillin', 'V', 'in', 'group', 'A', 'beta-haemolytic', 'streptococcal', 'pharyngitis', '.']","(1, 2)","(10, 21)",-1,hl_i,18337284,Title,0,test,gold,5009.0
2489,Once-daily amoxicillin versus twice-daily,penicillin V,in group A beta-haemolytic streptococcal pharyngitis .,"['Once-daily', 'amoxicillin', 'versus', 'twice-daily', 'penicillin', 'V', 'in', 'group', 'A', 'beta-haemolytic', 'streptococcal', 'pharyngitis', '.']","(4, 6)","(41, 53)",-1,hl_i,18337284,Title,0,test,gold,4979.0
2490,BACKGROUND Rheumatic fever is a preventable chronic disease preceded by group A beta-haemolytic streptococcal ( GABHS ) pharyngitis .,,,"['BACKGROUND', 'Rheumatic', 'fever', 'is', 'a', 'preventable', 'chronic', 'disease', 'preceded', 'by', 'group', 'A', 'beta-haemolytic', 'streptococcal', '(', 'GABHS', ')', 'pharyngitis', '.']",,,,,18337284,Abstract,0,test,gold,
2491,OBJECTIVE To test the non-inferiority of once-daily ( QD ) oral amoxicillin to the recommended twice-daily ( BID ) oral penicillin V in,GABHS pharyngitis .,,"['OBJECTIVE', 'To', 'test', 'the', 'non-inferiority', 'of', 'once-daily', '(', 'QD', ')', 'oral', 'amoxicillin', 'to', 'the', 'recommended', 'twice-daily', '(', 'BID', ')', 'oral', 'penicillin', 'V', 'in', 'GABHS', 'pharyngitis', '.']","(23, 26)","(135, 154)",-1,ss_p,18337284,Abstract,1,test,gold,3567.0
2492,OBJECTIVE To test the non-inferiority of once-daily ( QD ) oral,amoxicillin,to the recommended twice-daily ( BID ) oral penicillin V in GABHS pharyngitis .,"['OBJECTIVE', 'To', 'test', 'the', 'non-inferiority', 'of', 'once-daily', '(', 'QD', ')', 'oral', 'amoxicillin', 'to', 'the', 'recommended', 'twice-daily', '(', 'BID', ')', 'oral', 'penicillin', 'V', 'in', 'GABHS', 'pharyngitis', '.']","(11, 12)","(63, 74)",-1,ss_i,18337284,Abstract,1,test,gold,5007.0
2493,OBJECTIVE To test the non-inferiority of once-daily ( QD ) oral amoxicillin to the recommended twice-daily ( BID ) oral,penicillin V,in GABHS pharyngitis .,"['OBJECTIVE', 'To', 'test', 'the', 'non-inferiority', 'of', 'once-daily', '(', 'QD', ')', 'oral', 'amoxicillin', 'to', 'the', 'recommended', 'twice-daily', '(', 'BID', ')', 'oral', 'penicillin', 'V', 'in', 'GABHS', 'pharyngitis', '.']","(20, 22)","(119, 131)",-1,ss_i,18337284,Abstract,1,test,gold,4977.0
2494,OBJECTIVE To test the,non-inferiority,of once-daily ( QD ) oral amoxicillin to the recommended twice-daily ( BID ) oral penicillin V in GABHS pharyngitis .,"['OBJECTIVE', 'To', 'test', 'the', 'non-inferiority', 'of', 'once-daily', '(', 'QD', ')', 'oral', 'amoxicillin', 'to', 'the', 'recommended', 'twice-daily', '(', 'BID', ')', 'oral', 'penicillin', 'V', 'in', 'GABHS', 'pharyngitis', '.']","(4, 5)","(21, 36)",-1,ss_o,18337284,Abstract,1,test,gold,
2495,OBJECTIVE To test the non-inferiority of once-daily ( QD ) oral,amoxicillin,to the recommended twice-daily ( BID ) oral penicillin V in GABHS pharyngitis .,"['OBJECTIVE', 'To', 'test', 'the', 'non-inferiority', 'of', 'once-daily', '(', 'QD', ')', 'oral', 'amoxicillin', 'to', 'the', 'recommended', 'twice-daily', '(', 'BID', ')', 'oral', 'penicillin', 'V', 'in', 'GABHS', 'pharyngitis', '.']","(11, 12)","(63, 74)",-1,hl_i,18337284,Abstract,1,test,gold,5006.0
2496,OBJECTIVE To test the non-inferiority of once-daily ( QD ) oral amoxicillin to the recommended twice-daily ( BID ) oral,penicillin V,in GABHS pharyngitis .,"['OBJECTIVE', 'To', 'test', 'the', 'non-inferiority', 'of', 'once-daily', '(', 'QD', ')', 'oral', 'amoxicillin', 'to', 'the', 'recommended', 'twice-daily', '(', 'BID', ')', 'oral', 'penicillin', 'V', 'in', 'GABHS', 'pharyngitis', '.']","(20, 22)","(119, 131)",-1,hl_i,18337284,Abstract,1,test,gold,4976.0
2497,OBJECTIVE To test the,non-inferiority,of once-daily ( QD ) oral amoxicillin to the recommended twice-daily ( BID ) oral penicillin V in GABHS pharyngitis .,"['OBJECTIVE', 'To', 'test', 'the', 'non-inferiority', 'of', 'once-daily', '(', 'QD', ')', 'oral', 'amoxicillin', 'to', 'the', 'recommended', 'twice-daily', '(', 'BID', ')', 'oral', 'penicillin', 'V', 'in', 'GABHS', 'pharyngitis', '.']","(4, 5)","(21, 36)",-1,hl_o,18337284,Abstract,1,test,gold,
2498,METHODS This was a randomised non-inferiority trial carried out in a,school-based clinic in New Zealand .,,"['METHODS', 'This', 'was', 'a', 'randomised', 'non-inferiority', 'trial', 'carried', 'out', 'in', 'a', 'school-based', 'clinic', 'in', 'New', 'Zealand', '.']","(11, 17)","(68, 104)",-1,ss_p,18337284,Abstract,2,test,gold,1454.0
2499,METHODS This was a randomised,non-inferiority,trial carried out in a school-based clinic in New Zealand .,"['METHODS', 'This', 'was', 'a', 'randomised', 'non-inferiority', 'trial', 'carried', 'out', 'in', 'a', 'school-based', 'clinic', 'in', 'New', 'Zealand', '.']","(5, 6)","(29, 44)",-1,ss_o,18337284,Abstract,2,test,gold,
2500,METHODS This was a randomised non-inferiority trial carried out in a,school-based clinic in New Zealand,.,"['METHODS', 'This', 'was', 'a', 'randomised', 'non-inferiority', 'trial', 'carried', 'out', 'in', 'a', 'school-based', 'clinic', 'in', 'New', 'Zealand', '.']","(11, 16)","(68, 102)",-1,hl_p,18337284,Abstract,2,test,gold,1455.0
2501,METHODS This was a randomised,non-inferiority,trial carried out in a school-based clinic in New Zealand .,"['METHODS', 'This', 'was', 'a', 'randomised', 'non-inferiority', 'trial', 'carried', 'out', 'in', 'a', 'school-based', 'clinic', 'in', 'New', 'Zealand', '.']","(5, 6)","(29, 44)",-1,hl_o,18337284,Abstract,2,test,gold,
2502,,Children presenting with GABHS pharyngitis,were randomised to oral amoxicillin 1500 mg QD ( or 750 mg if bodyweight was < or=30 kg ) or to oral penicillin V 500 mg BID ( or 250 mg if bodyweight was < or=20 kg ) for 10 days .,"['Children', 'presenting', 'with', 'GABHS', 'pharyngitis', 'were', 'randomised', 'to', 'oral', 'amoxicillin', '1500', 'mg', 'QD', '(', 'or', '750', 'mg', 'if', 'bodyweight', 'was', '<', 'or=30', 'kg', ')', 'or', 'to', 'oral', 'penicillin', 'V', '500', 'mg', 'BID', '(', 'or', '250', 'mg', 'if', 'bodyweight', 'was', '<', 'or=20', 'kg', ')', 'for', '10', 'days', '.']","(0, 5)","(0, 42)",-1,ss_p,18337284,Abstract,3,test,gold,3562.0
2503,Children presenting with GABHS pharyngitis were randomised to oral,amoxicillin,1500 mg QD ( or 750 mg if bodyweight was < or=30 kg ) or to oral penicillin V 500 mg BID ( or 250 mg if bodyweight was < or=20 kg ) for 10 days .,"['Children', 'presenting', 'with', 'GABHS', 'pharyngitis', 'were', 'randomised', 'to', 'oral', 'amoxicillin', '1500', 'mg', 'QD', '(', 'or', '750', 'mg', 'if', 'bodyweight', 'was', '<', 'or=30', 'kg', ')', 'or', 'to', 'oral', 'penicillin', 'V', '500', 'mg', 'BID', '(', 'or', '250', 'mg', 'if', 'bodyweight', 'was', '<', 'or=20', 'kg', ')', 'for', '10', 'days', '.']","(9, 10)","(66, 77)",-1,ss_i,18337284,Abstract,3,test,gold,5005.0
2504,Children presenting with GABHS pharyngitis were randomised to oral amoxicillin 1500 mg QD ( or 750 mg if bodyweight was < or=30 kg ) or to oral,penicillin,V 500 mg BID ( or 250 mg if bodyweight was < or=20 kg ) for 10 days .,"['Children', 'presenting', 'with', 'GABHS', 'pharyngitis', 'were', 'randomised', 'to', 'oral', 'amoxicillin', '1500', 'mg', 'QD', '(', 'or', '750', 'mg', 'if', 'bodyweight', 'was', '<', 'or=30', 'kg', ')', 'or', 'to', 'oral', 'penicillin', 'V', '500', 'mg', 'BID', '(', 'or', '250', 'mg', 'if', 'bodyweight', 'was', '<', 'or=20', 'kg', ')', 'for', '10', 'days', '.']","(27, 28)","(143, 153)",-1,ss_i,18337284,Abstract,3,test,gold,4974.0
2505,,Children,presenting with GABHS pharyngitis were randomised to oral amoxicillin 1500 mg QD ( or 750 mg if bodyweight was < or=30 kg ) or to oral penicillin V 500 mg BID ( or 250 mg if bodyweight was < or=20 kg ) for 10 days .,"['Children', 'presenting', 'with', 'GABHS', 'pharyngitis', 'were', 'randomised', 'to', 'oral', 'amoxicillin', '1500', 'mg', 'QD', '(', 'or', '750', 'mg', 'if', 'bodyweight', 'was', '<', 'or=30', 'kg', ')', 'or', 'to', 'oral', 'penicillin', 'V', '500', 'mg', 'BID', '(', 'or', '250', 'mg', 'if', 'bodyweight', 'was', '<', 'or=20', 'kg', ')', 'for', '10', 'days', '.']","(0, 1)","(0, 8)",-1,hl_p,18337284,Abstract,3,test,gold,2176.0
2506,Children presenting with,GABHS pharyngitis,were randomised to oral amoxicillin 1500 mg QD ( or 750 mg if bodyweight was < or=30 kg ) or to oral penicillin V 500 mg BID ( or 250 mg if bodyweight was < or=20 kg ) for 10 days .,"['Children', 'presenting', 'with', 'GABHS', 'pharyngitis', 'were', 'randomised', 'to', 'oral', 'amoxicillin', '1500', 'mg', 'QD', '(', 'or', '750', 'mg', 'if', 'bodyweight', 'was', '<', 'or=30', 'kg', ')', 'or', 'to', 'oral', 'penicillin', 'V', '500', 'mg', 'BID', '(', 'or', '250', 'mg', 'if', 'bodyweight', 'was', '<', 'or=20', 'kg', ')', 'for', '10', 'days', '.']","(3, 5)","(24, 41)",-1,hl_p,18337284,Abstract,3,test,gold,3568.0
2507,Children presenting with GABHS pharyngitis were randomised to oral,amoxicillin,1500 mg QD ( or 750 mg if bodyweight was < or=30 kg ) or to oral penicillin V 500 mg BID ( or 250 mg if bodyweight was < or=20 kg ) for 10 days .,"['Children', 'presenting', 'with', 'GABHS', 'pharyngitis', 'were', 'randomised', 'to', 'oral', 'amoxicillin', '1500', 'mg', 'QD', '(', 'or', '750', 'mg', 'if', 'bodyweight', 'was', '<', 'or=30', 'kg', ')', 'or', 'to', 'oral', 'penicillin', 'V', '500', 'mg', 'BID', '(', 'or', '250', 'mg', 'if', 'bodyweight', 'was', '<', 'or=20', 'kg', ')', 'for', '10', 'days', '.']","(9, 10)","(66, 77)",-1,hl_i,18337284,Abstract,3,test,gold,5004.0
2508,Children presenting with GABHS pharyngitis were randomised to oral amoxicillin 1500 mg QD ( or 750 mg if bodyweight was < or=30 kg ) or to oral,penicillin,V 500 mg BID ( or 250 mg if bodyweight was < or=20 kg ) for 10 days .,"['Children', 'presenting', 'with', 'GABHS', 'pharyngitis', 'were', 'randomised', 'to', 'oral', 'amoxicillin', '1500', 'mg', 'QD', '(', 'or', '750', 'mg', 'if', 'bodyweight', 'was', '<', 'or=30', 'kg', ')', 'or', 'to', 'oral', 'penicillin', 'V', '500', 'mg', 'BID', '(', 'or', '250', 'mg', 'if', 'bodyweight', 'was', '<', 'or=20', 'kg', ')', 'for', '10', 'days', '.']","(27, 28)","(143, 153)",-1,hl_i,18337284,Abstract,3,test,gold,4975.0
2509,Observed,medication and weekend diary cards,were used to monitor adherence .,"['Observed', 'medication', 'and', 'weekend', 'diary', 'cards', 'were', 'used', 'to', 'monitor', 'adherence', '.']","(1, 6)","(8, 42)",-1,ss_o,18337284,Abstract,4,test,gold,5061.0
2510,OUTCOME,Eradication of GABHS,", determined with follow-up throat cultures on days 3-6 , 12-16 and 26-36 .","['OUTCOME', 'Eradication', 'of', 'GABHS', ',', 'determined', 'with', 'follow-up', 'throat', 'cultures', 'on', 'days', '3-6', ',', '12-16', 'and', '26-36', '.']","(1, 4)","(7, 27)",-1,ss_o,18337284,Abstract,5,test,gold,232.0
2511,"OUTCOME Eradication of GABHS , determined with",follow-up throat cultures,"on days 3-6 , 12-16 and 26-36 .","['OUTCOME', 'Eradication', 'of', 'GABHS', ',', 'determined', 'with', 'follow-up', 'throat', 'cultures', 'on', 'days', '3-6', ',', '12-16', 'and', '26-36', '.']","(7, 10)","(46, 71)",-1,ss_o,18337284,Abstract,5,test,gold,293.0
2512,OUTCOME,Eradication of GABHS,", determined with follow-up throat cultures on days 3-6 , 12-16 and 26-36 .","['OUTCOME', 'Eradication', 'of', 'GABHS', ',', 'determined', 'with', 'follow-up', 'throat', 'cultures', 'on', 'days', '3-6', ',', '12-16', 'and', '26-36', '.']","(1, 4)","(7, 27)",-1,hl_o,18337284,Abstract,5,test,gold,233.0
2513,,GABHS isolates were serotyped,to distinguish bacteriological treatment failures ( and relapses ) from new acquisitions .,"['GABHS', 'isolates', 'were', 'serotyped', 'to', 'distinguish', 'bacteriological', 'treatment', 'failures', '(', 'and', 'relapses', ')', 'from', 'new', 'acquisitions', '.']","(0, 4)","(0, 29)",-1,ss_o,18337284,Abstract,6,test,gold,212.0
2514,GABHS isolates were serotyped to distinguish,bacteriological treatment failures,( and relapses ) from new acquisitions .,"['GABHS', 'isolates', 'were', 'serotyped', 'to', 'distinguish', 'bacteriological', 'treatment', 'failures', '(', 'and', 'relapses', ')', 'from', 'new', 'acquisitions', '.']","(6, 9)","(44, 78)",-1,ss_o,18337284,Abstract,6,test,gold,3980.0
2515,GABHS isolates were serotyped to distinguish bacteriological treatment failures ( and,relapses ),from new acquisitions .,"['GABHS', 'isolates', 'were', 'serotyped', 'to', 'distinguish', 'bacteriological', 'treatment', 'failures', '(', 'and', 'relapses', ')', 'from', 'new', 'acquisitions', '.']","(11, 13)","(85, 95)",-1,ss_o,18337284,Abstract,6,test,gold,2537.0
2516,GABHS isolates were serotyped to distinguish bacteriological treatment failures ( and relapses ) from,new acquisitions .,,"['GABHS', 'isolates', 'were', 'serotyped', 'to', 'distinguish', 'bacteriological', 'treatment', 'failures', '(', 'and', 'relapses', ')', 'from', 'new', 'acquisitions', '.']","(14, 17)","(101, 119)",-1,ss_o,18337284,Abstract,6,test,gold,995.0
2517,GABHS isolates were serotyped to distinguish,bacteriological treatment failures,( and relapses ) from new acquisitions .,"['GABHS', 'isolates', 'were', 'serotyped', 'to', 'distinguish', 'bacteriological', 'treatment', 'failures', '(', 'and', 'relapses', ')', 'from', 'new', 'acquisitions', '.']","(6, 9)","(44, 78)",-1,hl_o,18337284,Abstract,6,test,gold,3981.0
2518,GABHS isolates were serotyped to distinguish bacteriological treatment failures ( and,relapses,) from new acquisitions .,"['GABHS', 'isolates', 'were', 'serotyped', 'to', 'distinguish', 'bacteriological', 'treatment', 'failures', '(', 'and', 'relapses', ')', 'from', 'new', 'acquisitions', '.']","(11, 12)","(85, 93)",-1,hl_o,18337284,Abstract,6,test,gold,2538.0
2519,Non-inferiority was defined as an upper 95 % confidence limit ( CL ) for the difference in success of eradication in the,amoxicillin,and penicillin V treatment groups of < or=10 % .,"['Non-inferiority', 'was', 'defined', 'as', 'an', 'upper', '95', '%', 'confidence', 'limit', '(', 'CL', ')', 'for', 'the', 'difference', 'in', 'success', 'of', 'eradication', 'in', 'the', 'amoxicillin', 'and', 'penicillin', 'V', 'treatment', 'groups', 'of', '<', 'or=10', '%', '.']","(22, 23)","(120, 131)",-1,ss_i,18337284,Abstract,7,test,gold,5003.0
2520,Non-inferiority was defined as an upper 95 % confidence limit ( CL ) for the difference in success of eradication in the amoxicillin and,penicillin,V treatment groups of < or=10 % .,"['Non-inferiority', 'was', 'defined', 'as', 'an', 'upper', '95', '%', 'confidence', 'limit', '(', 'CL', ')', 'for', 'the', 'difference', 'in', 'success', 'of', 'eradication', 'in', 'the', 'amoxicillin', 'and', 'penicillin', 'V', 'treatment', 'groups', 'of', '<', 'or=10', '%', '.']","(24, 25)","(136, 146)",-1,ss_i,18337284,Abstract,7,test,gold,4973.0
2521,,Non-inferiority,was defined as an upper 95 % confidence limit ( CL ) for the difference in success of eradication in the amoxicillin and penicillin V treatment groups of < or=10 % .,"['Non-inferiority', 'was', 'defined', 'as', 'an', 'upper', '95', '%', 'confidence', 'limit', '(', 'CL', ')', 'for', 'the', 'difference', 'in', 'success', 'of', 'eradication', 'in', 'the', 'amoxicillin', 'and', 'penicillin', 'V', 'treatment', 'groups', 'of', '<', 'or=10', '%', '.']","(0, 1)","(0, 15)",-1,ss_o,18337284,Abstract,7,test,gold,
2522,Non-inferiority was defined as an,upper 95 % confidence limit ( CL ) for the difference in success of eradication,in the amoxicillin and penicillin V treatment groups of < or=10 % .,"['Non-inferiority', 'was', 'defined', 'as', 'an', 'upper', '95', '%', 'confidence', 'limit', '(', 'CL', ')', 'for', 'the', 'difference', 'in', 'success', 'of', 'eradication', 'in', 'the', 'amoxicillin', 'and', 'penicillin', 'V', 'treatment', 'groups', 'of', '<', 'or=10', '%', '.']","(5, 20)","(33, 112)",-1,ss_o,18337284,Abstract,7,test,gold,6472.0
2523,Non-inferiority was defined as an upper 95 % confidence limit ( CL ) for the difference in success of eradication in the,amoxicillin,and penicillin V treatment groups of < or=10 % .,"['Non-inferiority', 'was', 'defined', 'as', 'an', 'upper', '95', '%', 'confidence', 'limit', '(', 'CL', ')', 'for', 'the', 'difference', 'in', 'success', 'of', 'eradication', 'in', 'the', 'amoxicillin', 'and', 'penicillin', 'V', 'treatment', 'groups', 'of', '<', 'or=10', '%', '.']","(22, 23)","(120, 131)",-1,hl_i,18337284,Abstract,7,test,gold,5002.0
2524,Non-inferiority was defined as an upper 95 % confidence limit ( CL ) for the difference in success of eradication in the amoxicillin and,penicillin,V treatment groups of < or=10 % .,"['Non-inferiority', 'was', 'defined', 'as', 'an', 'upper', '95', '%', 'confidence', 'limit', '(', 'CL', ')', 'for', 'the', 'difference', 'in', 'success', 'of', 'eradication', 'in', 'the', 'amoxicillin', 'and', 'penicillin', 'V', 'treatment', 'groups', 'of', '<', 'or=10', '%', '.']","(24, 25)","(136, 146)",-1,hl_i,18337284,Abstract,7,test,gold,4972.0
2525,,Non-inferiority,was defined as an upper 95 % confidence limit ( CL ) for the difference in success of eradication in the amoxicillin and penicillin V treatment groups of < or=10 % .,"['Non-inferiority', 'was', 'defined', 'as', 'an', 'upper', '95', '%', 'confidence', 'limit', '(', 'CL', ')', 'for', 'the', 'difference', 'in', 'success', 'of', 'eradication', 'in', 'the', 'amoxicillin', 'and', 'penicillin', 'V', 'treatment', 'groups', 'of', '<', 'or=10', '%', '.']","(0, 1)","(0, 15)",-1,hl_o,18337284,Abstract,7,test,gold,
2526,RESULTS,353 children with positive throat swabs for GABHS,were randomised to amoxicillin ( n = 177 ) or penicillin V ( n = 176 ) .,"['RESULTS', '353', 'children', 'with', 'positive', 'throat', 'swabs', 'for', 'GABHS', 'were', 'randomised', 'to', 'amoxicillin', '(', 'n', '=', '177', ')', 'or', 'penicillin', 'V', '(', 'n', '=', '176', ')', '.']","(1, 9)","(7, 56)",-1,ss_p,18337284,Abstract,8,test,gold,3712.0
2527,RESULTS 353 children with positive throat swabs for GABHS were randomised to,amoxicillin,( n = 177 ) or penicillin V ( n = 176 ) .,"['RESULTS', '353', 'children', 'with', 'positive', 'throat', 'swabs', 'for', 'GABHS', 'were', 'randomised', 'to', 'amoxicillin', '(', 'n', '=', '177', ')', 'or', 'penicillin', 'V', '(', 'n', '=', '176', ')', '.']","(12, 13)","(76, 87)",-1,ss_i,18337284,Abstract,8,test,gold,5001.0
2528,RESULTS 353 children with positive throat swabs for GABHS were randomised to amoxicillin ( n = 177 ) or,penicillin,V ( n = 176 ) .,"['RESULTS', '353', 'children', 'with', 'positive', 'throat', 'swabs', 'for', 'GABHS', 'were', 'randomised', 'to', 'amoxicillin', '(', 'n', '=', '177', ')', 'or', 'penicillin', 'V', '(', 'n', '=', '176', ')', '.']","(19, 20)","(103, 113)",-1,ss_i,18337284,Abstract,8,test,gold,4971.0
2529,RESULTS,353 children with positive throat swabs for GABHS,were randomised to amoxicillin ( n = 177 ) or penicillin V ( n = 176 ) .,"['RESULTS', '353', 'children', 'with', 'positive', 'throat', 'swabs', 'for', 'GABHS', 'were', 'randomised', 'to', 'amoxicillin', '(', 'n', '=', '177', ')', 'or', 'penicillin', 'V', '(', 'n', '=', '176', ')', '.']","(1, 9)","(7, 56)",-1,hl_p,18337284,Abstract,8,test,gold,3713.0
2530,RESULTS 353 children with positive throat swabs for GABHS were randomised to,amoxicillin,( n = 177 ) or penicillin V ( n = 176 ) .,"['RESULTS', '353', 'children', 'with', 'positive', 'throat', 'swabs', 'for', 'GABHS', 'were', 'randomised', 'to', 'amoxicillin', '(', 'n', '=', '177', ')', 'or', 'penicillin', 'V', '(', 'n', '=', '176', ')', '.']","(12, 13)","(76, 87)",-1,hl_i,18337284,Abstract,8,test,gold,5000.0
2531,RESULTS 353 children with positive throat swabs for GABHS were randomised to amoxicillin ( n = 177 ) or,penicillin,V ( n = 176 ) .,"['RESULTS', '353', 'children', 'with', 'positive', 'throat', 'swabs', 'for', 'GABHS', 'were', 'randomised', 'to', 'amoxicillin', '(', 'n', '=', '177', ')', 'or', 'penicillin', 'V', '(', 'n', '=', '176', ')', '.']","(19, 20)","(103, 113)",-1,hl_i,18337284,Abstract,8,test,gold,4970.0
2532,The,upper 95 % CL,"for the differences in positive cultures between the antibiotics was 4.9 % at days 3-6 , 6.5 % at days 12-16 and 8.5 % at days 26-36 .","['The', 'upper', '95', '%', 'CL', 'for', 'the', 'differences', 'in', 'positive', 'cultures', 'between', 'the', 'antibiotics', 'was', '4.9', '%', 'at', 'days', '3-6', ',', '6.5', '%', 'at', 'days', '12-16', 'and', '8.5', '%', 'at', 'days', '26-36', '.']","(1, 5)","(3, 16)",-1,ss_o,18337284,Abstract,9,test,gold,1501.0
2533,"Treatment failures ( including relapses ) occurred at each visit in 5.8 % , 12.7 % and 10.7 % of",amoxicillin,"recipients and 6.2 % , 11.9 % and 11.3 % of penicillin V recipients , respectively .","['Treatment', 'failures', '(', 'including', 'relapses', ')', 'occurred', 'at', 'each', 'visit', 'in', '5.8', '%', ',', '12.7', '%', 'and', '10.7', '%', 'of', 'amoxicillin', 'recipients', 'and', '6.2', '%', ',', '11.9', '%', 'and', '11.3', '%', 'of', 'penicillin', 'V', 'recipients', ',', 'respectively', '.']","(20, 21)","(96, 107)",-1,ss_i,18337284,Abstract,10,test,gold,4999.0
2534,"Treatment failures ( including relapses ) occurred at each visit in 5.8 % , 12.7 % and 10.7 % of amoxicillin recipients and 6.2 % , 11.9 % and 11.3 % of",penicillin,"V recipients , respectively .","['Treatment', 'failures', '(', 'including', 'relapses', ')', 'occurred', 'at', 'each', 'visit', 'in', '5.8', '%', ',', '12.7', '%', 'and', '10.7', '%', 'of', 'amoxicillin', 'recipients', 'and', '6.2', '%', ',', '11.9', '%', 'and', '11.3', '%', 'of', 'penicillin', 'V', 'recipients', ',', 'respectively', '.']","(32, 33)","(152, 162)",-1,ss_i,18337284,Abstract,10,test,gold,4969.0
2535,,Treatment failures,"( including relapses ) occurred at each visit in 5.8 % , 12.7 % and 10.7 % of amoxicillin recipients and 6.2 % , 11.9 % and 11.3 % of penicillin V recipients , respectively .","['Treatment', 'failures', '(', 'including', 'relapses', ')', 'occurred', 'at', 'each', 'visit', 'in', '5.8', '%', ',', '12.7', '%', 'and', '10.7', '%', 'of', 'amoxicillin', 'recipients', 'and', '6.2', '%', ',', '11.9', '%', 'and', '11.3', '%', 'of', 'penicillin', 'V', 'recipients', ',', 'respectively', '.']","(0, 2)","(0, 18)",-1,ss_o,18337284,Abstract,10,test,gold,3978.0
2536,Treatment failures ( including,relapses ),"occurred at each visit in 5.8 % , 12.7 % and 10.7 % of amoxicillin recipients and 6.2 % , 11.9 % and 11.3 % of penicillin V recipients , respectively .","['Treatment', 'failures', '(', 'including', 'relapses', ')', 'occurred', 'at', 'each', 'visit', 'in', '5.8', '%', ',', '12.7', '%', 'and', '10.7', '%', 'of', 'amoxicillin', 'recipients', 'and', '6.2', '%', ',', '11.9', '%', 'and', '11.3', '%', 'of', 'penicillin', 'V', 'recipients', ',', 'respectively', '.']","(4, 6)","(30, 40)",-1,ss_o,18337284,Abstract,10,test,gold,2536.0
2537,"Treatment failures ( including relapses ) occurred at each visit in 5.8 % , 12.7 % and 10.7 % of",amoxicillin,"recipients and 6.2 % , 11.9 % and 11.3 % of penicillin V recipients , respectively .","['Treatment', 'failures', '(', 'including', 'relapses', ')', 'occurred', 'at', 'each', 'visit', 'in', '5.8', '%', ',', '12.7', '%', 'and', '10.7', '%', 'of', 'amoxicillin', 'recipients', 'and', '6.2', '%', ',', '11.9', '%', 'and', '11.3', '%', 'of', 'penicillin', 'V', 'recipients', ',', 'respectively', '.']","(20, 21)","(96, 107)",-1,hl_i,18337284,Abstract,10,test,gold,4998.0
2538,"Treatment failures ( including relapses ) occurred at each visit in 5.8 % , 12.7 % and 10.7 % of amoxicillin recipients and 6.2 % , 11.9 % and 11.3 % of",penicillin,"V recipients , respectively .","['Treatment', 'failures', '(', 'including', 'relapses', ')', 'occurred', 'at', 'each', 'visit', 'in', '5.8', '%', ',', '12.7', '%', 'and', '10.7', '%', 'of', 'amoxicillin', 'recipients', 'and', '6.2', '%', ',', '11.9', '%', 'and', '11.3', '%', 'of', 'penicillin', 'V', 'recipients', ',', 'respectively', '.']","(32, 33)","(152, 162)",-1,hl_i,18337284,Abstract,10,test,gold,4968.0
2539,,Treatment failures,"( including relapses ) occurred at each visit in 5.8 % , 12.7 % and 10.7 % of amoxicillin recipients and 6.2 % , 11.9 % and 11.3 % of penicillin V recipients , respectively .","['Treatment', 'failures', '(', 'including', 'relapses', ')', 'occurred', 'at', 'each', 'visit', 'in', '5.8', '%', ',', '12.7', '%', 'and', '10.7', '%', 'of', 'amoxicillin', 'recipients', 'and', '6.2', '%', ',', '11.9', '%', 'and', '11.3', '%', 'of', 'penicillin', 'V', 'recipients', ',', 'respectively', '.']","(0, 2)","(0, 18)",-1,hl_o,18337284,Abstract,10,test,gold,3979.0
2540,Treatment failures ( including,relapses,") occurred at each visit in 5.8 % , 12.7 % and 10.7 % of amoxicillin recipients and 6.2 % , 11.9 % and 11.3 % of penicillin V recipients , respectively .","['Treatment', 'failures', '(', 'including', 'relapses', ')', 'occurred', 'at', 'each', 'visit', 'in', '5.8', '%', ',', '12.7', '%', 'and', '10.7', '%', 'of', 'amoxicillin', 'recipients', 'and', '6.2', '%', ',', '11.9', '%', 'and', '11.3', '%', 'of', 'penicillin', 'V', 'recipients', ',', 'respectively', '.']","(4, 5)","(30, 38)",-1,hl_o,18337284,Abstract,10,test,gold,2535.0
2541,No significant differences in,resolution of symptoms,were noted between treatment groups .,"['No', 'significant', 'differences', 'in', 'resolution', 'of', 'symptoms', 'were', 'noted', 'between', 'treatment', 'groups', '.']","(4, 7)","(29, 51)",-1,ss_o,18337284,Abstract,11,test,gold,3264.0
2542,No significant differences in,resolution of symptoms,were noted between treatment groups .,"['No', 'significant', 'differences', 'in', 'resolution', 'of', 'symptoms', 'were', 'noted', 'between', 'treatment', 'groups', '.']","(4, 7)","(29, 51)",-1,hl_o,18337284,Abstract,11,test,gold,3265.0
2543,One case of unsubstantiated acute rheumatic fever occurred after 7 days of,amoxicillin .,,"['One', 'case', 'of', 'unsubstantiated', 'acute', 'rheumatic', 'fever', 'occurred', 'after', '7', 'days', 'of', 'amoxicillin', '.']","(12, 14)","(74, 87)",-1,ss_i,18337284,Abstract,12,test,gold,4997.0
2544,One case of unsubstantiated acute rheumatic fever occurred after 7 days of,amoxicillin .,,"['One', 'case', 'of', 'unsubstantiated', 'acute', 'rheumatic', 'fever', 'occurred', 'after', '7', 'days', 'of', 'amoxicillin', '.']","(12, 14)","(74, 87)",-1,hl_i,18337284,Abstract,12,test,gold,4996.0
2545,"CONCLUSION In this adequately powered study , once-daily oral amoxicillin is not inferior to twice-daily penicillin V for the treatment and eradication of",GABHS in children with pharyngitis .,,"['CONCLUSION', 'In', 'this', 'adequately', 'powered', 'study', ',', 'once-daily', 'oral', 'amoxicillin', 'is', 'not', 'inferior', 'to', 'twice-daily', 'penicillin', 'V', 'for', 'the', 'treatment', 'and', 'eradication', 'of', 'GABHS', 'in', 'children', 'with', 'pharyngitis', '.']","(23, 29)","(154, 190)",-1,ss_p,18337284,Abstract,13,test,gold,3563.0
2546,"CONCLUSION In this adequately powered study , once-daily oral",amoxicillin,is not inferior to twice-daily penicillin V for the treatment and eradication of GABHS in children with pharyngitis .,"['CONCLUSION', 'In', 'this', 'adequately', 'powered', 'study', ',', 'once-daily', 'oral', 'amoxicillin', 'is', 'not', 'inferior', 'to', 'twice-daily', 'penicillin', 'V', 'for', 'the', 'treatment', 'and', 'eradication', 'of', 'GABHS', 'in', 'children', 'with', 'pharyngitis', '.']","(9, 10)","(61, 72)",-1,ss_i,18337284,Abstract,13,test,gold,4995.0
2547,"CONCLUSION In this adequately powered study , once-daily oral amoxicillin is not inferior to twice-daily",penicillin,V for the treatment and eradication of GABHS in children with pharyngitis .,"['CONCLUSION', 'In', 'this', 'adequately', 'powered', 'study', ',', 'once-daily', 'oral', 'amoxicillin', 'is', 'not', 'inferior', 'to', 'twice-daily', 'penicillin', 'V', 'for', 'the', 'treatment', 'and', 'eradication', 'of', 'GABHS', 'in', 'children', 'with', 'pharyngitis', '.']","(15, 16)","(104, 114)",-1,ss_i,18337284,Abstract,13,test,gold,4967.0
2548,"CONCLUSION In this adequately powered study , once-daily oral amoxicillin is",not inferior,to twice-daily penicillin V for the treatment and eradication of GABHS in children with pharyngitis .,"['CONCLUSION', 'In', 'this', 'adequately', 'powered', 'study', ',', 'once-daily', 'oral', 'amoxicillin', 'is', 'not', 'inferior', 'to', 'twice-daily', 'penicillin', 'V', 'for', 'the', 'treatment', 'and', 'eradication', 'of', 'GABHS', 'in', 'children', 'with', 'pharyngitis', '.']","(11, 13)","(76, 88)",-1,ss_o,18337284,Abstract,13,test,gold,1157.0
2549,"CONCLUSION In this adequately powered study , once-daily oral amoxicillin is not inferior to twice-daily penicillin V for the treatment and eradication of",GABHS in children with pharyngitis .,,"['CONCLUSION', 'In', 'this', 'adequately', 'powered', 'study', ',', 'once-daily', 'oral', 'amoxicillin', 'is', 'not', 'inferior', 'to', 'twice-daily', 'penicillin', 'V', 'for', 'the', 'treatment', 'and', 'eradication', 'of', 'GABHS', 'in', 'children', 'with', 'pharyngitis', '.']","(23, 29)","(154, 190)",-1,hl_p,18337284,Abstract,13,test,gold,3564.0
2550,"CONCLUSION In this adequately powered study , once-daily oral",amoxicillin,is not inferior to twice-daily penicillin V for the treatment and eradication of GABHS in children with pharyngitis .,"['CONCLUSION', 'In', 'this', 'adequately', 'powered', 'study', ',', 'once-daily', 'oral', 'amoxicillin', 'is', 'not', 'inferior', 'to', 'twice-daily', 'penicillin', 'V', 'for', 'the', 'treatment', 'and', 'eradication', 'of', 'GABHS', 'in', 'children', 'with', 'pharyngitis', '.']","(9, 10)","(61, 72)",-1,hl_i,18337284,Abstract,13,test,gold,4994.0
2551,"CONCLUSION In this adequately powered study , once-daily oral amoxicillin is not inferior to twice-daily",penicillin,V for the treatment and eradication of GABHS in children with pharyngitis .,"['CONCLUSION', 'In', 'this', 'adequately', 'powered', 'study', ',', 'once-daily', 'oral', 'amoxicillin', 'is', 'not', 'inferior', 'to', 'twice-daily', 'penicillin', 'V', 'for', 'the', 'treatment', 'and', 'eradication', 'of', 'GABHS', 'in', 'children', 'with', 'pharyngitis', '.']","(15, 16)","(104, 114)",-1,hl_i,18337284,Abstract,13,test,gold,4966.0
2552,A multi-component social skills intervention for,children with Asperger syndrome :,the Junior Detective Training Program .,"['A', 'multi-component', 'social', 'skills', 'intervention', 'for', 'children', 'with', 'Asperger', 'syndrome', ':', 'the', 'Junior', 'Detective', 'Training', 'Program', '.']","(6, 11)","(48, 81)",-1,ss_p,18503531,Title,0,test,gold,6168.0
2553,A,multi-component social skills intervention,for children with Asperger syndrome : the Junior Detective Training Program .,"['A', 'multi-component', 'social', 'skills', 'intervention', 'for', 'children', 'with', 'Asperger', 'syndrome', ':', 'the', 'Junior', 'Detective', 'Training', 'Program', '.']","(1, 5)","(1, 43)",-1,ss_i,18503531,Title,0,test,gold,2862.0
2554,A multi-component social skills intervention for children with Asperger syndrome : the,Junior Detective Training Program .,,"['A', 'multi-component', 'social', 'skills', 'intervention', 'for', 'children', 'with', 'Asperger', 'syndrome', ':', 'the', 'Junior', 'Detective', 'Training', 'Program', '.']","(12, 17)","(86, 121)",-1,ss_i,18503531,Title,0,test,gold,6243.0
2555,A multi-component social skills intervention for,children,with Asperger syndrome : the Junior Detective Training Program .,"['A', 'multi-component', 'social', 'skills', 'intervention', 'for', 'children', 'with', 'Asperger', 'syndrome', ':', 'the', 'Junior', 'Detective', 'Training', 'Program', '.']","(6, 7)","(48, 56)",-1,hl_p,18503531,Title,0,test,gold,2139.0
2556,A multi-component social skills intervention for children with,Asperger syndrome,: the Junior Detective Training Program .,"['A', 'multi-component', 'social', 'skills', 'intervention', 'for', 'children', 'with', 'Asperger', 'syndrome', ':', 'the', 'Junior', 'Detective', 'Training', 'Program', '.']","(8, 10)","(62, 79)",-1,hl_p,18503531,Title,0,test,gold,6166.0
2557,A,multi-component social skills intervention,for children with Asperger syndrome : the Junior Detective Training Program .,"['A', 'multi-component', 'social', 'skills', 'intervention', 'for', 'children', 'with', 'Asperger', 'syndrome', ':', 'the', 'Junior', 'Detective', 'Training', 'Program', '.']","(1, 5)","(1, 43)",-1,hl_i,18503531,Title,0,test,gold,2863.0
2558,A multi-component social skills intervention for children with Asperger syndrome : the,Junior Detective Training Program .,,"['A', 'multi-component', 'social', 'skills', 'intervention', 'for', 'children', 'with', 'Asperger', 'syndrome', ':', 'the', 'Junior', 'Detective', 'Training', 'Program', '.']","(12, 17)","(86, 121)",-1,hl_i,18503531,Title,0,test,gold,6244.0
2559,BACKGROUND The study aimed to investigate the effectiveness of a new multi-component social skills intervention for,children with Asperger syndrome ( AS ) :,The Junior Detective Training Program .,"['BACKGROUND', 'The', 'study', 'aimed', 'to', 'investigate', 'the', 'effectiveness', 'of', 'a', 'new', 'multi-component', 'social', 'skills', 'intervention', 'for', 'children', 'with', 'Asperger', 'syndrome', '(', 'AS', ')', ':', 'The', 'Junior', 'Detective', 'Training', 'Program', '.']","(16, 24)","(115, 155)",-1,ss_p,18503531,Abstract,0,test,gold,6169.0
2560,BACKGROUND The study aimed to investigate the effectiveness of a new,multi-component social skills intervention,for children with Asperger syndrome ( AS ) : The Junior Detective Training Program .,"['BACKGROUND', 'The', 'study', 'aimed', 'to', 'investigate', 'the', 'effectiveness', 'of', 'a', 'new', 'multi-component', 'social', 'skills', 'intervention', 'for', 'children', 'with', 'Asperger', 'syndrome', '(', 'AS', ')', ':', 'The', 'Junior', 'Detective', 'Training', 'Program', '.']","(11, 15)","(68, 110)",-1,ss_i,18503531,Abstract,0,test,gold,2861.0
2561,BACKGROUND The study aimed to investigate the,effectiveness,of a new multi-component social skills intervention for children with Asperger syndrome ( AS ) : The Junior Detective Training Program .,"['BACKGROUND', 'The', 'study', 'aimed', 'to', 'investigate', 'the', 'effectiveness', 'of', 'a', 'new', 'multi-component', 'social', 'skills', 'intervention', 'for', 'children', 'with', 'Asperger', 'syndrome', '(', 'AS', ')', ':', 'The', 'Junior', 'Detective', 'Training', 'Program', '.']","(7, 8)","(45, 58)",-1,ss_o,18503531,Abstract,0,test,gold,398.0
2562,BACKGROUND The study aimed to investigate the effectiveness of a new multi-component social skills intervention for,children,with Asperger syndrome ( AS ) : The Junior Detective Training Program .,"['BACKGROUND', 'The', 'study', 'aimed', 'to', 'investigate', 'the', 'effectiveness', 'of', 'a', 'new', 'multi-component', 'social', 'skills', 'intervention', 'for', 'children', 'with', 'Asperger', 'syndrome', '(', 'AS', ')', ':', 'The', 'Junior', 'Detective', 'Training', 'Program', '.']","(16, 17)","(115, 123)",-1,hl_p,18503531,Abstract,0,test,gold,2138.0
2563,BACKGROUND The study aimed to investigate the effectiveness of a new multi-component social skills intervention for children with,Asperger syndrome ( AS ),: The Junior Detective Training Program .,"['BACKGROUND', 'The', 'study', 'aimed', 'to', 'investigate', 'the', 'effectiveness', 'of', 'a', 'new', 'multi-component', 'social', 'skills', 'intervention', 'for', 'children', 'with', 'Asperger', 'syndrome', '(', 'AS', ')', ':', 'The', 'Junior', 'Detective', 'Training', 'Program', '.']","(18, 23)","(129, 153)",-1,hl_p,18503531,Abstract,0,test,gold,6167.0
2564,BACKGROUND The study aimed to investigate the effectiveness of a new,multi-component social skills intervention,for children with Asperger syndrome ( AS ) : The Junior Detective Training Program .,"['BACKGROUND', 'The', 'study', 'aimed', 'to', 'investigate', 'the', 'effectiveness', 'of', 'a', 'new', 'multi-component', 'social', 'skills', 'intervention', 'for', 'children', 'with', 'Asperger', 'syndrome', '(', 'AS', ')', ':', 'The', 'Junior', 'Detective', 'Training', 'Program', '.']","(11, 15)","(68, 110)",-1,hl_i,18503531,Abstract,0,test,gold,2860.0
2565,BACKGROUND The study aimed to investigate the,effectiveness,of a new multi-component social skills intervention for children with Asperger syndrome ( AS ) : The Junior Detective Training Program .,"['BACKGROUND', 'The', 'study', 'aimed', 'to', 'investigate', 'the', 'effectiveness', 'of', 'a', 'new', 'multi-component', 'social', 'skills', 'intervention', 'for', 'children', 'with', 'Asperger', 'syndrome', '(', 'AS', ')', ':', 'The', 'Junior', 'Detective', 'Training', 'Program', '.']","(7, 8)","(45, 58)",-1,hl_o,18503531,Abstract,0,test,gold,397.0
2566,"This 7-week program included a computer game ,","small group sessions , parent training sessions",and teacher handouts .,"['This', '7-week', 'program', 'included', 'a', 'computer', 'game', ',', 'small', 'group', 'sessions', ',', 'parent', 'training', 'sessions', 'and', 'teacher', 'handouts', '.']","(8, 15)","(46, 93)",-1,ss_i,18503531,Abstract,1,test,gold,2832.0
2567,"This 7-week program included a computer game , small group sessions , parent training sessions and",teacher handouts .,,"['This', '7-week', 'program', 'included', 'a', 'computer', 'game', ',', 'small', 'group', 'sessions', ',', 'parent', 'training', 'sessions', 'and', 'teacher', 'handouts', '.']","(16, 19)","(98, 116)",-1,ss_i,18503531,Abstract,1,test,gold,2190.0
2568,METHOD,Forty-nine children with AS,were recruited to participate and randomly assigned to intervention ( n = 26 ) or wait-list control ( n = 23 ) conditions .,"['METHOD', 'Forty-nine', 'children', 'with', 'AS', 'were', 'recruited', 'to', 'participate', 'and', 'randomly', 'assigned', 'to', 'intervention', '(', 'n', '=', '26', ')', 'or', 'wait-list', 'control', '(', 'n', '=', '23', ')', 'conditions', '.']","(1, 5)","(6, 33)",-1,ss_p,18503531,Abstract,2,test,gold,2203.0
2569,METHOD,Forty-nine children with AS,were recruited to participate and randomly assigned to intervention ( n = 26 ) or wait-list control ( n = 23 ) conditions .,"['METHOD', 'Forty-nine', 'children', 'with', 'AS', 'were', 'recruited', 'to', 'participate', 'and', 'randomly', 'assigned', 'to', 'intervention', '(', 'n', '=', '26', ')', 'or', 'wait-list', 'control', '(', 'n', '=', '23', ')', 'conditions', '.']","(1, 5)","(6, 33)",-1,hl_p,18503531,Abstract,2,test,gold,2204.0
2570,"RESULTS Relative to children in the wait-list group , program participants showed greater",improvements in social skills,"over the course of the intervention , as indicated by parent-report measures .","['RESULTS', 'Relative', 'to', 'children', 'in', 'the', 'wait-list', 'group', ',', 'program', 'participants', 'showed', 'greater', 'improvements', 'in', 'social', 'skills', 'over', 'the', 'course', 'of', 'the', 'intervention', ',', 'as', 'indicated', 'by', 'parent-report', 'measures', '.']","(13, 17)","(89, 118)",-1,ss_o,18503531,Abstract,3,test,gold,2864.0
2571,"RESULTS Relative to children in the wait-list group , program participants showed greater improvements in social skills over the course of the intervention , as indicated by",parent-report measures .,,"['RESULTS', 'Relative', 'to', 'children', 'in', 'the', 'wait-list', 'group', ',', 'program', 'participants', 'showed', 'greater', 'improvements', 'in', 'social', 'skills', 'over', 'the', 'course', 'of', 'the', 'intervention', ',', 'as', 'indicated', 'by', 'parent-report', 'measures', '.']","(27, 30)","(173, 197)",-1,ss_o,18503531,Abstract,3,test,gold,1298.0
2572,"RESULTS Relative to children in the wait-list group , program participants showed greater",improvements in social skills,"over the course of the intervention , as indicated by parent-report measures .","['RESULTS', 'Relative', 'to', 'children', 'in', 'the', 'wait-list', 'group', ',', 'program', 'participants', 'showed', 'greater', 'improvements', 'in', 'social', 'skills', 'over', 'the', 'course', 'of', 'the', 'intervention', ',', 'as', 'indicated', 'by', 'parent-report', 'measures', '.']","(13, 17)","(89, 118)",-1,hl_o,18503531,Abstract,3,test,gold,2865.0
2573,,Teacher-report data,also confirmed that children receiving the intervention made significant improvements in social functioning from pre- to post-treatment .,"['Teacher-report', 'data', 'also', 'confirmed', 'that', 'children', 'receiving', 'the', 'intervention', 'made', 'significant', 'improvements', 'in', 'social', 'functioning', 'from', 'pre-', 'to', 'post-treatment', '.']","(0, 2)","(0, 19)",-1,ss_o,18503531,Abstract,4,test,gold,1257.0
2574,Teacher-report data also confirmed that children receiving the intervention made significant improvements in,social functioning,from pre- to post-treatment .,"['Teacher-report', 'data', 'also', 'confirmed', 'that', 'children', 'receiving', 'the', 'intervention', 'made', 'significant', 'improvements', 'in', 'social', 'functioning', 'from', 'pre-', 'to', 'post-treatment', '.']","(13, 15)","(108, 126)",-1,ss_o,18503531,Abstract,4,test,gold,2946.0
2575,Teacher-report data also confirmed that children receiving the intervention made significant improvements in,social functioning,from pre- to post-treatment .,"['Teacher-report', 'data', 'also', 'confirmed', 'that', 'children', 'receiving', 'the', 'intervention', 'made', 'significant', 'improvements', 'in', 'social', 'functioning', 'from', 'pre-', 'to', 'post-treatment', '.']","(13, 15)","(108, 126)",-1,hl_o,18503531,Abstract,4,test,gold,2947.0
2576,Treatment group participants were better able to suggest appropriate,emotion-management strategies,"for story characters at post-intervention than at pre-intervention , whereas control participants were not .","['Treatment', 'group', 'participants', 'were', 'better', 'able', 'to', 'suggest', 'appropriate', 'emotion-management', 'strategies', 'for', 'story', 'characters', 'at', 'post-intervention', 'than', 'at', 'pre-intervention', ',', 'whereas', 'control', 'participants', 'were', 'not', '.']","(9, 11)","(68, 97)",-1,ss_o,18503531,Abstract,5,test,gold,1302.0
2577,Treatment group participants were better able to suggest appropriate,emotion-management strategies,"for story characters at post-intervention than at pre-intervention , whereas control participants were not .","['Treatment', 'group', 'participants', 'were', 'better', 'able', 'to', 'suggest', 'appropriate', 'emotion-management', 'strategies', 'for', 'story', 'characters', 'at', 'post-intervention', 'than', 'at', 'pre-intervention', ',', 'whereas', 'control', 'participants', 'were', 'not', '.']","(9, 11)","(68, 97)",-1,hl_o,18503531,Abstract,5,test,gold,1303.0
2578,"However , there was no difference in the improvements made by children in the intervention and control conditions on",facial expression and body-posture recognition measures .,,"['However', ',', 'there', 'was', 'no', 'difference', 'in', 'the', 'improvements', 'made', 'by', 'children', 'in', 'the', 'intervention', 'and', 'control', 'conditions', 'on', 'facial', 'expression', 'and', 'body-posture', 'recognition', 'measures', '.']","(19, 26)","(116, 173)",-1,ss_o,18503531,Abstract,6,test,gold,2918.0
2579,"However , there was no difference in the improvements made by children in the intervention and control conditions on",facial expression and body-posture recognition measures .,,"['However', ',', 'there', 'was', 'no', 'difference', 'in', 'the', 'improvements', 'made', 'by', 'children', 'in', 'the', 'intervention', 'and', 'control', 'conditions', 'on', 'facial', 'expression', 'and', 'body-posture', 'recognition', 'measures', '.']","(19, 26)","(116, 173)",-1,hl_o,18503531,Abstract,6,test,gold,2919.0
2580,Follow-up data suggested that treatment gains were maintained by children at 5-months post-intervention .,,,"['Follow-up', 'data', 'suggested', 'that', 'treatment', 'gains', 'were', 'maintained', 'by', 'children', 'at', '5-months', 'post-intervention', '.']",,,,,18503531,Abstract,7,test,gold,
2581,CONCLUSIONS The Junior Detective Training Program appeared to be effective in enhancing the social skills and emotional understanding of,children with AS .,,"['CONCLUSIONS', 'The', 'Junior', 'Detective', 'Training', 'Program', 'appeared', 'to', 'be', 'effective', 'in', 'enhancing', 'the', 'social', 'skills', 'and', 'emotional', 'understanding', 'of', 'children', 'with', 'AS', '.']","(19, 23)","(136, 154)",-1,ss_p,18503531,Abstract,8,test,gold,2202.0
2582,CONCLUSIONS The,Junior Detective Training Program,appeared to be effective in enhancing the social skills and emotional understanding of children with AS .,"['CONCLUSIONS', 'The', 'Junior', 'Detective', 'Training', 'Program', 'appeared', 'to', 'be', 'effective', 'in', 'enhancing', 'the', 'social', 'skills', 'and', 'emotional', 'understanding', 'of', 'children', 'with', 'AS', '.']","(2, 6)","(15, 48)",-1,ss_i,18503531,Abstract,8,test,gold,6242.0
2583,CONCLUSIONS The Junior Detective Training Program appeared to be,effective,in enhancing the social skills and emotional understanding of children with AS .,"['CONCLUSIONS', 'The', 'Junior', 'Detective', 'Training', 'Program', 'appeared', 'to', 'be', 'effective', 'in', 'enhancing', 'the', 'social', 'skills', 'and', 'emotional', 'understanding', 'of', 'children', 'with', 'AS', '.']","(9, 10)","(64, 73)",-1,ss_o,18503531,Abstract,8,test,gold,852.0
2584,CONCLUSIONS The Junior Detective Training Program appeared to be effective in enhancing the,social skills and emotional understanding,of children with AS .,"['CONCLUSIONS', 'The', 'Junior', 'Detective', 'Training', 'Program', 'appeared', 'to', 'be', 'effective', 'in', 'enhancing', 'the', 'social', 'skills', 'and', 'emotional', 'understanding', 'of', 'children', 'with', 'AS', '.']","(13, 18)","(91, 132)",-1,ss_o,18503531,Abstract,8,test,gold,2858.0
2585,CONCLUSIONS The Junior Detective Training Program appeared to be effective in enhancing the social skills and emotional understanding of,children with AS .,,"['CONCLUSIONS', 'The', 'Junior', 'Detective', 'Training', 'Program', 'appeared', 'to', 'be', 'effective', 'in', 'enhancing', 'the', 'social', 'skills', 'and', 'emotional', 'understanding', 'of', 'children', 'with', 'AS', '.']","(19, 23)","(136, 154)",-1,hl_p,18503531,Abstract,8,test,gold,2201.0
2586,CONCLUSIONS The,Junior Detective Training Program,appeared to be effective in enhancing the social skills and emotional understanding of children with AS .,"['CONCLUSIONS', 'The', 'Junior', 'Detective', 'Training', 'Program', 'appeared', 'to', 'be', 'effective', 'in', 'enhancing', 'the', 'social', 'skills', 'and', 'emotional', 'understanding', 'of', 'children', 'with', 'AS', '.']","(2, 6)","(15, 48)",-1,hl_i,18503531,Abstract,8,test,gold,6241.0
2587,CONCLUSIONS The Junior Detective Training Program appeared to be effective in enhancing the,social skills and emotional understanding,of children with AS .,"['CONCLUSIONS', 'The', 'Junior', 'Detective', 'Training', 'Program', 'appeared', 'to', 'be', 'effective', 'in', 'enhancing', 'the', 'social', 'skills', 'and', 'emotional', 'understanding', 'of', 'children', 'with', 'AS', '.']","(13, 18)","(91, 132)",-1,hl_o,18503531,Abstract,8,test,gold,2859.0
2588,Limitations and suggestions for future research are discussed .,,,"['Limitations', 'and', 'suggestions', 'for', 'future', 'research', 'are', 'discussed', '.']",,,,,18503531,Abstract,9,test,gold,
2589,In,school-aged children,a combination of galacto-oligosaccharides and Lactobacillus GG increases bifidobacteria more than Lactobacillus GG on its own .,"['In', 'school-aged', 'children', 'a', 'combination', 'of', 'galacto-oligosaccharides', 'and', 'Lactobacillus', 'GG', 'increases', 'bifidobacteria', 'more', 'than', 'Lactobacillus', 'GG', 'on', 'its', 'own', '.']","(1, 3)","(2, 22)",-1,ss_p,18544974,Title,0,test,gold,2137.0
2590,In school-aged children a combination of,galacto-oligosaccharides and Lactobacillus GG,increases bifidobacteria more than Lactobacillus GG on its own .,"['In', 'school-aged', 'children', 'a', 'combination', 'of', 'galacto-oligosaccharides', 'and', 'Lactobacillus', 'GG', 'increases', 'bifidobacteria', 'more', 'than', 'Lactobacillus', 'GG', 'on', 'its', 'own', '.']","(6, 10)","(40, 85)",-1,ss_i,18544974,Title,0,test,gold,4565.0
2591,In school-aged children a combination of galacto-oligosaccharides and Lactobacillus GG increases bifidobacteria more than,Lactobacillus GG,on its own .,"['In', 'school-aged', 'children', 'a', 'combination', 'of', 'galacto-oligosaccharides', 'and', 'Lactobacillus', 'GG', 'increases', 'bifidobacteria', 'more', 'than', 'Lactobacillus', 'GG', 'on', 'its', 'own', '.']","(14, 16)","(121, 137)",-1,ss_i,18544974,Title,0,test,gold,4566.0
2592,In school-aged children a combination of galacto-oligosaccharides and Lactobacillus GG increases,bifidobacteria,more than Lactobacillus GG on its own .,"['In', 'school-aged', 'children', 'a', 'combination', 'of', 'galacto-oligosaccharides', 'and', 'Lactobacillus', 'GG', 'increases', 'bifidobacteria', 'more', 'than', 'Lactobacillus', 'GG', 'on', 'its', 'own', '.']","(11, 12)","(96, 110)",-1,ss_o,18544974,Title,0,test,gold,221.0
2593,In,school-aged children,a combination of galacto-oligosaccharides and Lactobacillus GG increases bifidobacteria more than Lactobacillus GG on its own .,"['In', 'school-aged', 'children', 'a', 'combination', 'of', 'galacto-oligosaccharides', 'and', 'Lactobacillus', 'GG', 'increases', 'bifidobacteria', 'more', 'than', 'Lactobacillus', 'GG', 'on', 'its', 'own', '.']","(1, 3)","(2, 22)",-1,hl_p,18544974,Title,0,test,gold,2136.0
2594,In school-aged children a combination of,galacto-oligosaccharides,and Lactobacillus GG increases bifidobacteria more than Lactobacillus GG on its own .,"['In', 'school-aged', 'children', 'a', 'combination', 'of', 'galacto-oligosaccharides', 'and', 'Lactobacillus', 'GG', 'increases', 'bifidobacteria', 'more', 'than', 'Lactobacillus', 'GG', 'on', 'its', 'own', '.']","(6, 7)","(40, 64)",-1,hl_i,18544974,Title,0,test,gold,
2595,In school-aged children a combination of galacto-oligosaccharides and,Lactobacillus GG,increases bifidobacteria more than Lactobacillus GG on its own .,"['In', 'school-aged', 'children', 'a', 'combination', 'of', 'galacto-oligosaccharides', 'and', 'Lactobacillus', 'GG', 'increases', 'bifidobacteria', 'more', 'than', 'Lactobacillus', 'GG', 'on', 'its', 'own', '.']","(8, 10)","(69, 85)",-1,hl_i,18544974,Title,0,test,gold,4564.0
2596,In school-aged children a combination of galacto-oligosaccharides and Lactobacillus GG increases bifidobacteria more than,Lactobacillus GG,on its own .,"['In', 'school-aged', 'children', 'a', 'combination', 'of', 'galacto-oligosaccharides', 'and', 'Lactobacillus', 'GG', 'increases', 'bifidobacteria', 'more', 'than', 'Lactobacillus', 'GG', 'on', 'its', 'own', '.']","(14, 16)","(121, 137)",-1,hl_i,18544974,Title,0,test,gold,4563.0
2597,"The aim of this study was to compare a combination of Lactobacillus GG ( LGG ) and galacto-oligosaccharides ( GOS ) with LGG on its own , and their effects on the intestinal microbiota in",school-aged children .,,"['The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'a', 'combination', 'of', 'Lactobacillus', 'GG', '(', 'LGG', ')', 'and', 'galacto-oligosaccharides', '(', 'GOS', ')', 'with', 'LGG', 'on', 'its', 'own', ',', 'and', 'their', 'effects', 'on', 'the', 'intestinal', 'microbiota', 'in', 'school-aged', 'children', '.']","(35, 38)","(187, 209)",-1,ss_p,18544974,Abstract,0,test,gold,2135.0
2598,The aim of this study was to compare a combination of,Lactobacillus GG ( LGG ) and galacto-oligosaccharides ( GOS ),"with LGG on its own , and their effects on the intestinal microbiota in school-aged children .","['The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'a', 'combination', 'of', 'Lactobacillus', 'GG', '(', 'LGG', ')', 'and', 'galacto-oligosaccharides', '(', 'GOS', ')', 'with', 'LGG', 'on', 'its', 'own', ',', 'and', 'their', 'effects', 'on', 'the', 'intestinal', 'microbiota', 'in', 'school-aged', 'children', '.']","(11, 21)","(53, 114)",-1,ss_i,18544974,Abstract,0,test,gold,4567.0
2599,The aim of this study was to compare a combination of Lactobacillus GG ( LGG ) and galacto-oligosaccharides ( GOS ) with,LGG,"on its own , and their effects on the intestinal microbiota in school-aged children .","['The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'a', 'combination', 'of', 'Lactobacillus', 'GG', '(', 'LGG', ')', 'and', 'galacto-oligosaccharides', '(', 'GOS', ')', 'with', 'LGG', 'on', 'its', 'own', ',', 'and', 'their', 'effects', 'on', 'the', 'intestinal', 'microbiota', 'in', 'school-aged', 'children', '.']","(22, 23)","(120, 123)",-1,ss_i,18544974,Abstract,0,test,gold,209.0
2600,"The aim of this study was to compare a combination of Lactobacillus GG ( LGG ) and galacto-oligosaccharides ( GOS ) with LGG on its own , and their effects on the",intestinal microbiota,in school-aged children .,"['The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'a', 'combination', 'of', 'Lactobacillus', 'GG', '(', 'LGG', ')', 'and', 'galacto-oligosaccharides', '(', 'GOS', ')', 'with', 'LGG', 'on', 'its', 'own', ',', 'and', 'their', 'effects', 'on', 'the', 'intestinal', 'microbiota', 'in', 'school-aged', 'children', '.']","(32, 34)","(162, 183)",-1,ss_o,18544974,Abstract,0,test,gold,3167.0
2601,The aim of this study was to compare a combination of,Lactobacillus GG ( LGG ),"and galacto-oligosaccharides ( GOS ) with LGG on its own , and their effects on the intestinal microbiota in school-aged children .","['The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'a', 'combination', 'of', 'Lactobacillus', 'GG', '(', 'LGG', ')', 'and', 'galacto-oligosaccharides', '(', 'GOS', ')', 'with', 'LGG', 'on', 'its', 'own', ',', 'and', 'their', 'effects', 'on', 'the', 'intestinal', 'microbiota', 'in', 'school-aged', 'children', '.']","(11, 16)","(53, 77)",-1,hl_i,18544974,Abstract,0,test,gold,4568.0
2602,The aim of this study was to compare a combination of Lactobacillus GG ( LGG ) and,galacto-oligosaccharides ( GOS ),"with LGG on its own , and their effects on the intestinal microbiota in school-aged children .","['The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'a', 'combination', 'of', 'Lactobacillus', 'GG', '(', 'LGG', ')', 'and', 'galacto-oligosaccharides', '(', 'GOS', ')', 'with', 'LGG', 'on', 'its', 'own', ',', 'and', 'their', 'effects', 'on', 'the', 'intestinal', 'microbiota', 'in', 'school-aged', 'children', '.']","(17, 21)","(82, 114)",-1,hl_i,18544974,Abstract,0,test,gold,802.0
2603,The aim of this study was to compare a combination of Lactobacillus GG ( LGG ) and galacto-oligosaccharides ( GOS ) with,LGG,"on its own , and their effects on the intestinal microbiota in school-aged children .","['The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'a', 'combination', 'of', 'Lactobacillus', 'GG', '(', 'LGG', ')', 'and', 'galacto-oligosaccharides', '(', 'GOS', ')', 'with', 'LGG', 'on', 'its', 'own', ',', 'and', 'their', 'effects', 'on', 'the', 'intestinal', 'microbiota', 'in', 'school-aged', 'children', '.']","(22, 23)","(120, 123)",-1,hl_i,18544974,Abstract,0,test,gold,210.0
2604,"The randomized , double-blinded , crossover study comprised",30 healthy children .,,"['The', 'randomized', ',', 'double-blinded', ',', 'crossover', 'study', 'comprised', '30', 'healthy', 'children', '.']","(8, 12)","(59, 80)",-1,ss_p,18544974,Abstract,1,test,gold,2266.0
2605,"The randomized , double-blinded , crossover study comprised",30 healthy,children .,"['The', 'randomized', ',', 'double-blinded', ',', 'crossover', 'study', 'comprised', '30', 'healthy', 'children', '.']","(8, 10)","(59, 69)",-1,hl_p,18544974,Abstract,1,test,gold,2264.0
2606,There were two 3-week study periods with a 4-week wash-out period in between .,,,"['There', 'were', 'two', '3-week', 'study', 'periods', 'with', 'a', '4-week', 'wash-out', 'period', 'in', 'between', '.']",,,,,18544974,Abstract,2,test,gold,
2607,The children ingested daily 65 ml of milk-based fruit juice containing either,LGG,alone ( 6.5 x 10 ( 9 ) CFU ) or LGG plus 2 g of GOS .,"['The', 'children', 'ingested', 'daily', '65', 'ml', 'of', 'milk-based', 'fruit', 'juice', 'containing', 'either', 'LGG', 'alone', '(', '6.5', 'x', '10', '(', '9', ')', 'CFU', ')', 'or', 'LGG', 'plus', '2', 'g', 'of', 'GOS', '.']","(12, 13)","(77, 80)",-1,ss_i,18544974,Abstract,3,test,gold,208.0
2608,The children ingested daily 65 ml of milk-based fruit juice containing either LGG alone ( 6.5 x 10 ( 9 ) CFU ) or,LGG,plus 2 g of GOS .,"['The', 'children', 'ingested', 'daily', '65', 'ml', 'of', 'milk-based', 'fruit', 'juice', 'containing', 'either', 'LGG', 'alone', '(', '6.5', 'x', '10', '(', '9', ')', 'CFU', ')', 'or', 'LGG', 'plus', '2', 'g', 'of', 'GOS', '.']","(24, 25)","(113, 116)",-1,ss_i,18544974,Abstract,3,test,gold,207.0
2609,The children ingested daily 65 ml of milk-based fruit juice containing either LGG alone ( 6.5 x 10 ( 9 ) CFU ) or LGG plus 2 g of,GOS .,,"['The', 'children', 'ingested', 'daily', '65', 'ml', 'of', 'milk-based', 'fruit', 'juice', 'containing', 'either', 'LGG', 'alone', '(', '6.5', 'x', '10', '(', '9', ')', 'CFU', ')', 'or', 'LGG', 'plus', '2', 'g', 'of', 'GOS', '.']","(29, 31)","(129, 134)",-1,ss_i,18544974,Abstract,3,test,gold,803.0
2610,The children ingested daily 65 ml of milk-based fruit juice containing either,LGG,alone ( 6.5 x 10 ( 9 ) CFU ) or LGG plus 2 g of GOS .,"['The', 'children', 'ingested', 'daily', '65', 'ml', 'of', 'milk-based', 'fruit', 'juice', 'containing', 'either', 'LGG', 'alone', '(', '6.5', 'x', '10', '(', '9', ')', 'CFU', ')', 'or', 'LGG', 'plus', '2', 'g', 'of', 'GOS', '.']","(12, 13)","(77, 80)",-1,hl_i,18544974,Abstract,3,test,gold,206.0
2611,The children ingested daily 65 ml of milk-based fruit juice containing either LGG alone ( 6.5 x 10 ( 9 ) CFU ) or,LGG,plus 2 g of GOS .,"['The', 'children', 'ingested', 'daily', '65', 'ml', 'of', 'milk-based', 'fruit', 'juice', 'containing', 'either', 'LGG', 'alone', '(', '6.5', 'x', '10', '(', '9', ')', 'CFU', ')', 'or', 'LGG', 'plus', '2', 'g', 'of', 'GOS', '.']","(24, 25)","(113, 116)",-1,hl_i,18544974,Abstract,3,test,gold,205.0
2612,The children ingested daily 65 ml of milk-based fruit juice containing either LGG alone ( 6.5 x 10 ( 9 ) CFU ) or LGG plus 2 g of,GOS .,,"['The', 'children', 'ingested', 'daily', '65', 'ml', 'of', 'milk-based', 'fruit', 'juice', 'containing', 'either', 'LGG', 'alone', '(', '6.5', 'x', '10', '(', '9', ')', 'CFU', ')', 'or', 'LGG', 'plus', '2', 'g', 'of', 'GOS', '.']","(29, 31)","(129, 134)",-1,hl_i,18544974,Abstract,3,test,gold,801.0
2613,,Symptom,diaries were filled during the study periods .,"['Symptom', 'diaries', 'were', 'filled', 'during', 'the', 'study', 'periods', '.']","(0, 1)","(0, 7)",-1,ss_o,18544974,Abstract,4,test,gold,441.0
2614,,Fecal samples,were collected at the beginning and end of both study periods .,"['Fecal', 'samples', 'were', 'collected', 'at', 'the', 'beginning', 'and', 'end', 'of', 'both', 'study', 'periods', '.']","(0, 2)","(0, 13)",-1,ss_o,18544974,Abstract,5,test,gold,4522.0
2615,"At the end of both study periods , the amount of bifidobacteria was significantly greater after the ingestion of",LGG + GOS,"compared with LGG alone ( geometric mean 9.33 x 10 ( 9 ) vs. 4.28 x 10 ( 9 ) CFU/g , p < 0.001 ) .","['At', 'the', 'end', 'of', 'both', 'study', 'periods', ',', 'the', 'amount', 'of', 'bifidobacteria', 'was', 'significantly', 'greater', 'after', 'the', 'ingestion', 'of', 'LGG', '+', 'GOS', 'compared', 'with', 'LGG', 'alone', '(', 'geometric', 'mean', '9.33', 'x', '10', '(', '9', ')', 'vs.', '4.28', 'x', '10', '(', '9', ')', 'CFU/g', ',', 'p', '<', '0.001', ')', '.']","(19, 22)","(112, 121)",-1,ss_i,18544974,Abstract,6,test,gold,804.0
2616,"At the end of both study periods , the amount of bifidobacteria was significantly greater after the ingestion of LGG + GOS compared with",LGG,"alone ( geometric mean 9.33 x 10 ( 9 ) vs. 4.28 x 10 ( 9 ) CFU/g , p < 0.001 ) .","['At', 'the', 'end', 'of', 'both', 'study', 'periods', ',', 'the', 'amount', 'of', 'bifidobacteria', 'was', 'significantly', 'greater', 'after', 'the', 'ingestion', 'of', 'LGG', '+', 'GOS', 'compared', 'with', 'LGG', 'alone', '(', 'geometric', 'mean', '9.33', 'x', '10', '(', '9', ')', 'vs.', '4.28', 'x', '10', '(', '9', ')', 'CFU/g', ',', 'p', '<', '0.001', ')', '.']","(24, 25)","(136, 139)",-1,ss_i,18544974,Abstract,6,test,gold,204.0
2617,"At the end of both study periods , the",amount of bifidobacteria,"was significantly greater after the ingestion of LGG + GOS compared with LGG alone ( geometric mean 9.33 x 10 ( 9 ) vs. 4.28 x 10 ( 9 ) CFU/g , p < 0.001 ) .","['At', 'the', 'end', 'of', 'both', 'study', 'periods', ',', 'the', 'amount', 'of', 'bifidobacteria', 'was', 'significantly', 'greater', 'after', 'the', 'ingestion', 'of', 'LGG', '+', 'GOS', 'compared', 'with', 'LGG', 'alone', '(', 'geometric', 'mean', '9.33', 'x', '10', '(', '9', ')', 'vs.', '4.28', 'x', '10', '(', '9', ')', 'CFU/g', ',', 'p', '<', '0.001', ')', '.']","(9, 12)","(38, 62)",-1,ss_o,18544974,Abstract,6,test,gold,218.0
2618,"At the end of both study periods , the amount of bifidobacteria was significantly greater after the ingestion of",LGG + GOS,"compared with LGG alone ( geometric mean 9.33 x 10 ( 9 ) vs. 4.28 x 10 ( 9 ) CFU/g , p < 0.001 ) .","['At', 'the', 'end', 'of', 'both', 'study', 'periods', ',', 'the', 'amount', 'of', 'bifidobacteria', 'was', 'significantly', 'greater', 'after', 'the', 'ingestion', 'of', 'LGG', '+', 'GOS', 'compared', 'with', 'LGG', 'alone', '(', 'geometric', 'mean', '9.33', 'x', '10', '(', '9', ')', 'vs.', '4.28', 'x', '10', '(', '9', ')', 'CFU/g', ',', 'p', '<', '0.001', ')', '.']","(19, 22)","(112, 121)",-1,hl_i,18544974,Abstract,6,test,gold,805.0
2619,"At the end of both study periods , the amount of bifidobacteria was significantly greater after the ingestion of LGG + GOS compared with",LGG,"alone ( geometric mean 9.33 x 10 ( 9 ) vs. 4.28 x 10 ( 9 ) CFU/g , p < 0.001 ) .","['At', 'the', 'end', 'of', 'both', 'study', 'periods', ',', 'the', 'amount', 'of', 'bifidobacteria', 'was', 'significantly', 'greater', 'after', 'the', 'ingestion', 'of', 'LGG', '+', 'GOS', 'compared', 'with', 'LGG', 'alone', '(', 'geometric', 'mean', '9.33', 'x', '10', '(', '9', ')', 'vs.', '4.28', 'x', '10', '(', '9', ')', 'CFU/g', ',', 'p', '<', '0.001', ')', '.']","(24, 25)","(136, 139)",-1,hl_i,18544974,Abstract,6,test,gold,203.0
2620,"At the end of both study periods , the",amount of bifidobacteria,"was significantly greater after the ingestion of LGG + GOS compared with LGG alone ( geometric mean 9.33 x 10 ( 9 ) vs. 4.28 x 10 ( 9 ) CFU/g , p < 0.001 ) .","['At', 'the', 'end', 'of', 'both', 'study', 'periods', ',', 'the', 'amount', 'of', 'bifidobacteria', 'was', 'significantly', 'greater', 'after', 'the', 'ingestion', 'of', 'LGG', '+', 'GOS', 'compared', 'with', 'LGG', 'alone', '(', 'geometric', 'mean', '9.33', 'x', '10', '(', '9', ')', 'vs.', '4.28', 'x', '10', '(', '9', ')', 'CFU/g', ',', 'p', '<', '0.001', ')', '.']","(9, 12)","(38, 62)",-1,hl_o,18544974,Abstract,6,test,gold,219.0
2621,No significant differences were seen in the amount of lactobacilli or,LGG,", nor did gastrointestinal symptoms , defecation frequency , consistency of stools or ease of defecation differ between the two study periods .","['No', 'significant', 'differences', 'were', 'seen', 'in', 'the', 'amount', 'of', 'lactobacilli', 'or', 'LGG', ',', 'nor', 'did', 'gastrointestinal', 'symptoms', ',', 'defecation', 'frequency', ',', 'consistency', 'of', 'stools', 'or', 'ease', 'of', 'defecation', 'differ', 'between', 'the', 'two', 'study', 'periods', '.']","(11, 12)","(69, 72)",-1,ss_i,18544974,Abstract,7,test,gold,202.0
2622,No significant differences were seen in the amount of,lactobacilli,"or LGG , nor did gastrointestinal symptoms , defecation frequency , consistency of stools or ease of defecation differ between the two study periods .","['No', 'significant', 'differences', 'were', 'seen', 'in', 'the', 'amount', 'of', 'lactobacilli', 'or', 'LGG', ',', 'nor', 'did', 'gastrointestinal', 'symptoms', ',', 'defecation', 'frequency', ',', 'consistency', 'of', 'stools', 'or', 'ease', 'of', 'defecation', 'differ', 'between', 'the', 'two', 'study', 'periods', '.']","(9, 10)","(53, 65)",-1,ss_o,18544974,Abstract,7,test,gold,223.0
2623,"No significant differences were seen in the amount of lactobacilli or LGG , nor did","gastrointestinal symptoms , defecation frequency , consistency of stools or ease of defecation",differ between the two study periods .,"['No', 'significant', 'differences', 'were', 'seen', 'in', 'the', 'amount', 'of', 'lactobacilli', 'or', 'LGG', ',', 'nor', 'did', 'gastrointestinal', 'symptoms', ',', 'defecation', 'frequency', ',', 'consistency', 'of', 'stools', 'or', 'ease', 'of', 'defecation', 'differ', 'between', 'the', 'two', 'study', 'periods', '.']","(15, 28)","(83, 177)",-1,ss_o,18544974,Abstract,7,test,gold,7123.0
2624,No significant differences were seen in the amount of lactobacilli or,LGG,", nor did gastrointestinal symptoms , defecation frequency , consistency of stools or ease of defecation differ between the two study periods .","['No', 'significant', 'differences', 'were', 'seen', 'in', 'the', 'amount', 'of', 'lactobacilli', 'or', 'LGG', ',', 'nor', 'did', 'gastrointestinal', 'symptoms', ',', 'defecation', 'frequency', ',', 'consistency', 'of', 'stools', 'or', 'ease', 'of', 'defecation', 'differ', 'between', 'the', 'two', 'study', 'periods', '.']","(11, 12)","(69, 72)",-1,hl_i,18544974,Abstract,7,test,gold,201.0
2625,No significant differences were seen in the amount of,lactobacilli,"or LGG , nor did gastrointestinal symptoms , defecation frequency , consistency of stools or ease of defecation differ between the two study periods .","['No', 'significant', 'differences', 'were', 'seen', 'in', 'the', 'amount', 'of', 'lactobacilli', 'or', 'LGG', ',', 'nor', 'did', 'gastrointestinal', 'symptoms', ',', 'defecation', 'frequency', ',', 'consistency', 'of', 'stools', 'or', 'ease', 'of', 'defecation', 'differ', 'between', 'the', 'two', 'study', 'periods', '.']","(9, 10)","(53, 65)",-1,hl_o,18544974,Abstract,7,test,gold,224.0
2626,"No significant differences were seen in the amount of lactobacilli or LGG , nor did","gastrointestinal symptoms , defecation frequency , consistency of stools or ease of defecation",differ between the two study periods .,"['No', 'significant', 'differences', 'were', 'seen', 'in', 'the', 'amount', 'of', 'lactobacilli', 'or', 'LGG', ',', 'nor', 'did', 'gastrointestinal', 'symptoms', ',', 'defecation', 'frequency', ',', 'consistency', 'of', 'stools', 'or', 'ease', 'of', 'defecation', 'differ', 'between', 'the', 'two', 'study', 'periods', '.']","(15, 28)","(83, 177)",-1,hl_o,18544974,Abstract,7,test,gold,7124.0
2627,Ingestion of,LGG,combined with 2 g of GOS increased the bifidobacteria more than LGG on its own and thus GOS clearly has a prebiotic effect in children .,"['Ingestion', 'of', 'LGG', 'combined', 'with', '2', 'g', 'of', 'GOS', 'increased', 'the', 'bifidobacteria', 'more', 'than', 'LGG', 'on', 'its', 'own', 'and', 'thus', 'GOS', 'clearly', 'has', 'a', 'prebiotic', 'effect', 'in', 'children', '.']","(2, 3)","(12, 15)",-1,ss_i,18544974,Abstract,8,test,gold,200.0
2628,Ingestion of LGG combined with 2 g of,GOS,increased the bifidobacteria more than LGG on its own and thus GOS clearly has a prebiotic effect in children .,"['Ingestion', 'of', 'LGG', 'combined', 'with', '2', 'g', 'of', 'GOS', 'increased', 'the', 'bifidobacteria', 'more', 'than', 'LGG', 'on', 'its', 'own', 'and', 'thus', 'GOS', 'clearly', 'has', 'a', 'prebiotic', 'effect', 'in', 'children', '.']","(8, 9)","(37, 40)",-1,ss_i,18544974,Abstract,8,test,gold,800.0
2629,Ingestion of LGG combined with 2 g of GOS increased the bifidobacteria more than,LGG,on its own and thus GOS clearly has a prebiotic effect in children .,"['Ingestion', 'of', 'LGG', 'combined', 'with', '2', 'g', 'of', 'GOS', 'increased', 'the', 'bifidobacteria', 'more', 'than', 'LGG', 'on', 'its', 'own', 'and', 'thus', 'GOS', 'clearly', 'has', 'a', 'prebiotic', 'effect', 'in', 'children', '.']","(14, 15)","(80, 83)",-1,ss_i,18544974,Abstract,8,test,gold,199.0
2630,Ingestion of LGG combined with 2 g of GOS increased the bifidobacteria more than LGG on its own and thus,GOS,clearly has a prebiotic effect in children .,"['Ingestion', 'of', 'LGG', 'combined', 'with', '2', 'g', 'of', 'GOS', 'increased', 'the', 'bifidobacteria', 'more', 'than', 'LGG', 'on', 'its', 'own', 'and', 'thus', 'GOS', 'clearly', 'has', 'a', 'prebiotic', 'effect', 'in', 'children', '.']","(20, 21)","(104, 107)",-1,ss_i,18544974,Abstract,8,test,gold,799.0
2631,Ingestion of LGG combined with 2 g of GOS increased the,bifidobacteria,more than LGG on its own and thus GOS clearly has a prebiotic effect in children .,"['Ingestion', 'of', 'LGG', 'combined', 'with', '2', 'g', 'of', 'GOS', 'increased', 'the', 'bifidobacteria', 'more', 'than', 'LGG', 'on', 'its', 'own', 'and', 'thus', 'GOS', 'clearly', 'has', 'a', 'prebiotic', 'effect', 'in', 'children', '.']","(11, 12)","(55, 69)",-1,ss_o,18544974,Abstract,8,test,gold,222.0
2632,Ingestion of LGG combined with 2 g of GOS increased the bifidobacteria more than LGG on its own and thus GOS clearly has a,prebiotic effect,in children .,"['Ingestion', 'of', 'LGG', 'combined', 'with', '2', 'g', 'of', 'GOS', 'increased', 'the', 'bifidobacteria', 'more', 'than', 'LGG', 'on', 'its', 'own', 'and', 'thus', 'GOS', 'clearly', 'has', 'a', 'prebiotic', 'effect', 'in', 'children', '.']","(24, 26)","(122, 138)",-1,ss_o,18544974,Abstract,8,test,gold,2346.0
2633,Ingestion of,LGG,combined with 2 g of GOS increased the bifidobacteria more than LGG on its own and thus GOS clearly has a prebiotic effect in children .,"['Ingestion', 'of', 'LGG', 'combined', 'with', '2', 'g', 'of', 'GOS', 'increased', 'the', 'bifidobacteria', 'more', 'than', 'LGG', 'on', 'its', 'own', 'and', 'thus', 'GOS', 'clearly', 'has', 'a', 'prebiotic', 'effect', 'in', 'children', '.']","(2, 3)","(12, 15)",-1,hl_i,18544974,Abstract,8,test,gold,198.0
2634,Ingestion of LGG combined with 2 g of,GOS,increased the bifidobacteria more than LGG on its own and thus GOS clearly has a prebiotic effect in children .,"['Ingestion', 'of', 'LGG', 'combined', 'with', '2', 'g', 'of', 'GOS', 'increased', 'the', 'bifidobacteria', 'more', 'than', 'LGG', 'on', 'its', 'own', 'and', 'thus', 'GOS', 'clearly', 'has', 'a', 'prebiotic', 'effect', 'in', 'children', '.']","(8, 9)","(37, 40)",-1,hl_i,18544974,Abstract,8,test,gold,798.0
2635,Ingestion of LGG combined with 2 g of GOS increased the bifidobacteria more than,LGG,on its own and thus GOS clearly has a prebiotic effect in children .,"['Ingestion', 'of', 'LGG', 'combined', 'with', '2', 'g', 'of', 'GOS', 'increased', 'the', 'bifidobacteria', 'more', 'than', 'LGG', 'on', 'its', 'own', 'and', 'thus', 'GOS', 'clearly', 'has', 'a', 'prebiotic', 'effect', 'in', 'children', '.']","(14, 15)","(80, 83)",-1,hl_i,18544974,Abstract,8,test,gold,197.0
2636,Ingestion of LGG combined with 2 g of GOS increased the bifidobacteria more than LGG on its own and thus,GOS,clearly has a prebiotic effect in children .,"['Ingestion', 'of', 'LGG', 'combined', 'with', '2', 'g', 'of', 'GOS', 'increased', 'the', 'bifidobacteria', 'more', 'than', 'LGG', 'on', 'its', 'own', 'and', 'thus', 'GOS', 'clearly', 'has', 'a', 'prebiotic', 'effect', 'in', 'children', '.']","(20, 21)","(104, 107)",-1,hl_i,18544974,Abstract,8,test,gold,797.0
2637,Ingestion of LGG combined with 2 g of GOS increased the,bifidobacteria,more than LGG on its own and thus GOS clearly has a prebiotic effect in children .,"['Ingestion', 'of', 'LGG', 'combined', 'with', '2', 'g', 'of', 'GOS', 'increased', 'the', 'bifidobacteria', 'more', 'than', 'LGG', 'on', 'its', 'own', 'and', 'thus', 'GOS', 'clearly', 'has', 'a', 'prebiotic', 'effect', 'in', 'children', '.']","(11, 12)","(55, 69)",-1,hl_o,18544974,Abstract,8,test,gold,220.0
2638,The children tolerated well a daily intake of 2 g of,GOS .,,"['The', 'children', 'tolerated', 'well', 'a', 'daily', 'intake', 'of', '2', 'g', 'of', 'GOS', '.']","(11, 13)","(52, 57)",-1,ss_i,18544974,Abstract,9,test,gold,796.0
2639,The children,tolerated,well a daily intake of 2 g of GOS .,"['The', 'children', 'tolerated', 'well', 'a', 'daily', 'intake', 'of', '2', 'g', 'of', 'GOS', '.']","(2, 3)","(12, 21)",-1,ss_o,18544974,Abstract,9,test,gold,863.0
2640,The children tolerated well a daily intake of 2 g of,GOS .,,"['The', 'children', 'tolerated', 'well', 'a', 'daily', 'intake', 'of', '2', 'g', 'of', 'GOS', '.']","(11, 13)","(52, 57)",-1,hl_i,18544974,Abstract,9,test,gold,795.0
2641,,Vibrotactile -- auditory interactions,are post-perceptual .,"['Vibrotactile', '--', 'auditory', 'interactions', 'are', 'post-perceptual', '.']","(0, 4)","(0, 37)",-1,ss_p,18773733,Title,0,test,gold,2928.0
2642,,Vibrotactile stimuli,"can elicit compelling auditory sensations , even when sound energy levels are minimal and undetectable .","['Vibrotactile', 'stimuli', 'can', 'elicit', 'compelling', 'auditory', 'sensations', ',', 'even', 'when', 'sound', 'energy', 'levels', 'are', 'minimal', 'and', 'undetectable', '.']","(0, 2)","(0, 20)",-1,ss_i,18773733,Abstract,0,test,gold,2572.0
2643,Vibrotactile stimuli can elicit,compelling auditory sensations,", even when sound energy levels are minimal and undetectable .","['Vibrotactile', 'stimuli', 'can', 'elicit', 'compelling', 'auditory', 'sensations', ',', 'even', 'when', 'sound', 'energy', 'levels', 'are', 'minimal', 'and', 'undetectable', '.']","(4, 7)","(31, 61)",-1,ss_o,18773733,Abstract,0,test,gold,2927.0
2644,,Vibrotactile stimuli,"can elicit compelling auditory sensations , even when sound energy levels are minimal and undetectable .","['Vibrotactile', 'stimuli', 'can', 'elicit', 'compelling', 'auditory', 'sensations', ',', 'even', 'when', 'sound', 'energy', 'levels', 'are', 'minimal', 'and', 'undetectable', '.']","(0, 2)","(0, 20)",-1,hl_i,18773733,Abstract,0,test,gold,2573.0
2645,It has previously been shown that subjects judge auditory tones embedded in white noise to be louder when they are accompanied by a,vibrotactile stimulus,of the same frequency .,"['It', 'has', 'previously', 'been', 'shown', 'that', 'subjects', 'judge', 'auditory', 'tones', 'embedded', 'in', 'white', 'noise', 'to', 'be', 'louder', 'when', 'they', 'are', 'accompanied', 'by', 'a', 'vibrotactile', 'stimulus', 'of', 'the', 'same', 'frequency', '.']","(23, 25)","(131, 152)",-1,ss_i,18773733,Abstract,1,test,gold,2568.0
2646,It has previously been shown that subjects judge,auditory tones,embedded in white noise to be louder when they are accompanied by a vibrotactile stimulus of the same frequency .,"['It', 'has', 'previously', 'been', 'shown', 'that', 'subjects', 'judge', 'auditory', 'tones', 'embedded', 'in', 'white', 'noise', 'to', 'be', 'louder', 'when', 'they', 'are', 'accompanied', 'by', 'a', 'vibrotactile', 'stimulus', 'of', 'the', 'same', 'frequency', '.']","(8, 10)","(48, 62)",-1,ss_o,18773733,Abstract,1,test,gold,2925.0
2647,It has previously been shown that subjects judge auditory tones embedded in white noise to be louder when they are accompanied by a,vibrotactile stimulus,of the same frequency .,"['It', 'has', 'previously', 'been', 'shown', 'that', 'subjects', 'judge', 'auditory', 'tones', 'embedded', 'in', 'white', 'noise', 'to', 'be', 'louder', 'when', 'they', 'are', 'accompanied', 'by', 'a', 'vibrotactile', 'stimulus', 'of', 'the', 'same', 'frequency', '.']","(23, 25)","(131, 152)",-1,hl_i,18773733,Abstract,1,test,gold,2569.0
2648,A first experiment replicated this result at four different levels of,auditory stimulation,"( no tone , tone at detection threshold , tone at 5 dB above threshold , and tone at 10 dB above threshold ) .","['A', 'first', 'experiment', 'replicated', 'this', 'result', 'at', 'four', 'different', 'levels', 'of', 'auditory', 'stimulation', '(', 'no', 'tone', ',', 'tone', 'at', 'detection', 'threshold', ',', 'tone', 'at', '5', 'dB', 'above', 'threshold', ',', 'and', 'tone', 'at', '10', 'dB', 'above', 'threshold', ')', '.']","(11, 13)","(69, 89)",-1,ss_p,18773733,Abstract,2,test,gold,2929.0
2649,A first experiment replicated this result at four different levels of,"auditory stimulation ( no tone , tone at detection threshold , tone at 5 dB above threshold , and tone at 10 dB above threshold ) .",,"['A', 'first', 'experiment', 'replicated', 'this', 'result', 'at', 'four', 'different', 'levels', 'of', 'auditory', 'stimulation', '(', 'no', 'tone', ',', 'tone', 'at', 'detection', 'threshold', ',', 'tone', 'at', '5', 'dB', 'above', 'threshold', ',', 'and', 'tone', 'at', '10', 'dB', 'above', 'threshold', ')', '.']","(11, 38)","(69, 200)",-1,ss_o,18773733,Abstract,2,test,gold,5991.0
2650,The presence of a,vibrotactile stimulus,induced an increase in the perceived loudness of auditory tones at three of the four values in this range .,"['The', 'presence', 'of', 'a', 'vibrotactile', 'stimulus', 'induced', 'an', 'increase', 'in', 'the', 'perceived', 'loudness', 'of', 'auditory', 'tones', 'at', 'three', 'of', 'the', 'four', 'values', 'in', 'this', 'range', '.']","(4, 6)","(17, 38)",-1,ss_i,18773733,Abstract,3,test,gold,2567.0
2651,The presence of a vibrotactile stimulus induced an increase in the perceived loudness of,auditory tones,at three of the four values in this range .,"['The', 'presence', 'of', 'a', 'vibrotactile', 'stimulus', 'induced', 'an', 'increase', 'in', 'the', 'perceived', 'loudness', 'of', 'auditory', 'tones', 'at', 'three', 'of', 'the', 'four', 'values', 'in', 'this', 'range', '.']","(14, 16)","(88, 102)",-1,ss_o,18773733,Abstract,3,test,gold,2926.0
2652,The presence of a,vibrotactile stimulus,induced an increase in the perceived loudness of auditory tones at three of the four values in this range .,"['The', 'presence', 'of', 'a', 'vibrotactile', 'stimulus', 'induced', 'an', 'increase', 'in', 'the', 'perceived', 'loudness', 'of', 'auditory', 'tones', 'at', 'three', 'of', 'the', 'four', 'values', 'in', 'this', 'range', '.']","(4, 6)","(17, 38)",-1,hl_i,18773733,Abstract,3,test,gold,2566.0
2653,The presence of a vibrotactile stimulus induced an increase in the perceived loudness of,auditory tones,at three of the four values in this range .,"['The', 'presence', 'of', 'a', 'vibrotactile', 'stimulus', 'induced', 'an', 'increase', 'in', 'the', 'perceived', 'loudness', 'of', 'auditory', 'tones', 'at', 'three', 'of', 'the', 'four', 'values', 'in', 'this', 'range', '.']","(14, 16)","(88, 102)",-1,hl_o,18773733,Abstract,3,test,gold,2924.0
2654,"In two further experiments , a 2-interval forced-choice procedure was used to assess the",nature of this cross-modal interaction .,,"['In', 'two', 'further', 'experiments', ',', 'a', '2-interval', 'forced-choice', 'procedure', 'was', 'used', 'to', 'assess', 'the', 'nature', 'of', 'this', 'cross-modal', 'interaction', '.']","(14, 20)","(88, 128)",-1,ss_o,18773733,Abstract,4,test,gold,2962.0
2655,Subjects were biased when,vibrotaction,"was applied in one interval , but applying vibrotaction in both intervals produced performance comparable to conditions without vibrotactile stimuli .","['Subjects', 'were', 'biased', 'when', 'vibrotaction', 'was', 'applied', 'in', 'one', 'interval', ',', 'but', 'applying', 'vibrotaction', 'in', 'both', 'intervals', 'produced', 'performance', 'comparable', 'to', 'conditions', 'without', 'vibrotactile', 'stimuli', '.']","(4, 5)","(25, 37)",-1,ss_i,18773733,Abstract,5,test,gold,
2656,"Subjects were biased when vibrotaction was applied in one interval , but applying",vibrotaction,in both intervals produced performance comparable to conditions without vibrotactile stimuli .,"['Subjects', 'were', 'biased', 'when', 'vibrotaction', 'was', 'applied', 'in', 'one', 'interval', ',', 'but', 'applying', 'vibrotaction', 'in', 'both', 'intervals', 'produced', 'performance', 'comparable', 'to', 'conditions', 'without', 'vibrotactile', 'stimuli', '.']","(13, 14)","(81, 93)",-1,ss_i,18773733,Abstract,5,test,gold,
2657,"Subjects were biased when vibrotaction was applied in one interval , but applying vibrotaction in both intervals produced performance comparable to conditions without",vibrotactile stimuli .,,"['Subjects', 'were', 'biased', 'when', 'vibrotaction', 'was', 'applied', 'in', 'one', 'interval', ',', 'but', 'applying', 'vibrotaction', 'in', 'both', 'intervals', 'produced', 'performance', 'comparable', 'to', 'conditions', 'without', 'vibrotactile', 'stimuli', '.']","(23, 26)","(166, 188)",-1,ss_i,18773733,Abstract,5,test,gold,2571.0
2658,,Subjects,"were biased when vibrotaction was applied in one interval , but applying vibrotaction in both intervals produced performance comparable to conditions without vibrotactile stimuli .","['Subjects', 'were', 'biased', 'when', 'vibrotaction', 'was', 'applied', 'in', 'one', 'interval', ',', 'but', 'applying', 'vibrotaction', 'in', 'both', 'intervals', 'produced', 'performance', 'comparable', 'to', 'conditions', 'without', 'vibrotactile', 'stimuli', '.']","(0, 1)","(0, 8)",-1,hl_p,18773733,Abstract,5,test,gold,2069.0
2659,Subjects were biased when,vibrotaction,"was applied in one interval , but applying vibrotaction in both intervals produced performance comparable to conditions without vibrotactile stimuli .","['Subjects', 'were', 'biased', 'when', 'vibrotaction', 'was', 'applied', 'in', 'one', 'interval', ',', 'but', 'applying', 'vibrotaction', 'in', 'both', 'intervals', 'produced', 'performance', 'comparable', 'to', 'conditions', 'without', 'vibrotactile', 'stimuli', '.']","(4, 5)","(25, 37)",-1,hl_i,18773733,Abstract,5,test,gold,
2660,"Subjects were biased when vibrotaction was applied in one interval , but applying",vibrotaction,in both intervals produced performance comparable to conditions without vibrotactile stimuli .,"['Subjects', 'were', 'biased', 'when', 'vibrotaction', 'was', 'applied', 'in', 'one', 'interval', ',', 'but', 'applying', 'vibrotaction', 'in', 'both', 'intervals', 'produced', 'performance', 'comparable', 'to', 'conditions', 'without', 'vibrotactile', 'stimuli', '.']","(13, 14)","(81, 93)",-1,hl_i,18773733,Abstract,5,test,gold,
2661,"Subjects were biased when vibrotaction was applied in one interval , but applying vibrotaction in both intervals produced performance comparable to conditions without",vibrotactile stimuli .,,"['Subjects', 'were', 'biased', 'when', 'vibrotaction', 'was', 'applied', 'in', 'one', 'interval', ',', 'but', 'applying', 'vibrotaction', 'in', 'both', 'intervals', 'produced', 'performance', 'comparable', 'to', 'conditions', 'without', 'vibrotactile', 'stimuli', '.']","(23, 26)","(166, 188)",-1,hl_i,18773733,Abstract,5,test,gold,2570.0
2662,This demonstrates that,vibrotaction,is sometimes ignored when judging the presence of an auditory tone .,"['This', 'demonstrates', 'that', 'vibrotaction', 'is', 'sometimes', 'ignored', 'when', 'judging', 'the', 'presence', 'of', 'an', 'auditory', 'tone', '.']","(3, 4)","(22, 34)",-1,ss_i,18773733,Abstract,6,test,gold,
2663,This demonstrates that vibrotaction is sometimes ignored when judging the presence of an,auditory tone .,,"['This', 'demonstrates', 'that', 'vibrotaction', 'is', 'sometimes', 'ignored', 'when', 'judging', 'the', 'presence', 'of', 'an', 'auditory', 'tone', '.']","(13, 16)","(88, 103)",-1,ss_o,18773733,Abstract,6,test,gold,2923.0
2664,This demonstrates that,vibrotaction,is sometimes ignored when judging the presence of an auditory tone .,"['This', 'demonstrates', 'that', 'vibrotaction', 'is', 'sometimes', 'ignored', 'when', 'judging', 'the', 'presence', 'of', 'an', 'auditory', 'tone', '.']","(3, 4)","(22, 34)",-1,hl_i,18773733,Abstract,6,test,gold,
2665,Hence the interaction between,vibrotaction,and audition does not appear to occur at an early perceptual level .,"['Hence', 'the', 'interaction', 'between', 'vibrotaction', 'and', 'audition', 'does', 'not', 'appear', 'to', 'occur', 'at', 'an', 'early', 'perceptual', 'level', '.']","(4, 5)","(29, 41)",-1,ss_i,18773733,Abstract,7,test,gold,
2666,Hence the interaction between,vibrotaction,and audition does not appear to occur at an early perceptual level .,"['Hence', 'the', 'interaction', 'between', 'vibrotaction', 'and', 'audition', 'does', 'not', 'appear', 'to', 'occur', 'at', 'an', 'early', 'perceptual', 'level', '.']","(4, 5)","(29, 41)",-1,hl_i,18773733,Abstract,7,test,gold,
2667,Psychological mediators of bupropion sustained-release treatment for,smoking cessation .,,"['Psychological', 'mediators', 'of', 'bupropion', 'sustained-release', 'treatment', 'for', 'smoking', 'cessation', '.']","(7, 10)","(68, 87)",-1,ss_p,18783504,Title,0,test,gold,2432.0
2668,Psychological mediators of,bupropion sustained-release,treatment for smoking cessation .,"['Psychological', 'mediators', 'of', 'bupropion', 'sustained-release', 'treatment', 'for', 'smoking', 'cessation', '.']","(3, 5)","(26, 53)",-1,ss_i,18783504,Title,0,test,gold,5245.0
2669,,Psychological mediators,of bupropion sustained-release treatment for smoking cessation .,"['Psychological', 'mediators', 'of', 'bupropion', 'sustained-release', 'treatment', 'for', 'smoking', 'cessation', '.']","(0, 2)","(0, 23)",-1,ss_o,18783504,Title,0,test,gold,1272.0
2670,Psychological mediators of,bupropion sustained-release,treatment for smoking cessation .,"['Psychological', 'mediators', 'of', 'bupropion', 'sustained-release', 'treatment', 'for', 'smoking', 'cessation', '.']","(3, 5)","(26, 53)",-1,hl_i,18783504,Title,0,test,gold,5246.0
2671,AIM The study aimed to test simultaneously our understanding of the effects of,bupropion sustained-release ( SR ),"treatment on putative mediators and our understanding of determinants of post-quit abstinence , including withdrawal distress , cigarette craving , positive affect and subjective reactions to cigarettes smoked during a lapse .","['AIM', 'The', 'study', 'aimed', 'to', 'test', 'simultaneously', 'our', 'understanding', 'of', 'the', 'effects', 'of', 'bupropion', 'sustained-release', '(', 'SR', ')', 'treatment', 'on', 'putative', 'mediators', 'and', 'our', 'understanding', 'of', 'determinants', 'of', 'post-quit', 'abstinence', ',', 'including', 'withdrawal', 'distress', ',', 'cigarette', 'craving', ',', 'positive', 'affect', 'and', 'subjective', 'reactions', 'to', 'cigarettes', 'smoked', 'during', 'a', 'lapse', '.']","(13, 18)","(78, 112)",-1,ss_i,18783504,Abstract,0,test,gold,5259.0
2672,AIM The study aimed to test simultaneously our understanding of the effects of bupropion sustained-release ( SR ) treatment on,putative mediators,"and our understanding of determinants of post-quit abstinence , including withdrawal distress , cigarette craving , positive affect and subjective reactions to cigarettes smoked during a lapse .","['AIM', 'The', 'study', 'aimed', 'to', 'test', 'simultaneously', 'our', 'understanding', 'of', 'the', 'effects', 'of', 'bupropion', 'sustained-release', '(', 'SR', ')', 'treatment', 'on', 'putative', 'mediators', 'and', 'our', 'understanding', 'of', 'determinants', 'of', 'post-quit', 'abstinence', ',', 'including', 'withdrawal', 'distress', ',', 'cigarette', 'craving', ',', 'positive', 'affect', 'and', 'subjective', 'reactions', 'to', 'cigarettes', 'smoked', 'during', 'a', 'lapse', '.']","(20, 22)","(126, 144)",-1,ss_o,18783504,Abstract,0,test,gold,1273.0
2673,AIM The study aimed to test simultaneously our understanding of the effects of bupropion sustained-release ( SR ) treatment on putative mediators and our understanding of determinants of,"post-quit abstinence , including withdrawal distress , cigarette craving , positive affect and subjective reactions to cigarettes smoked during a lapse .",,"['AIM', 'The', 'study', 'aimed', 'to', 'test', 'simultaneously', 'our', 'understanding', 'of', 'the', 'effects', 'of', 'bupropion', 'sustained-release', '(', 'SR', ')', 'treatment', 'on', 'putative', 'mediators', 'and', 'our', 'understanding', 'of', 'determinants', 'of', 'post-quit', 'abstinence', ',', 'including', 'withdrawal', 'distress', ',', 'cigarette', 'craving', ',', 'positive', 'affect', 'and', 'subjective', 'reactions', 'to', 'cigarettes', 'smoked', 'during', 'a', 'lapse', '.']","(28, 50)","(186, 339)",-1,ss_o,18783504,Abstract,0,test,gold,7111.0
2674,AIM The study aimed to test simultaneously our understanding of the effects of,bupropion sustained-release ( SR ),"treatment on putative mediators and our understanding of determinants of post-quit abstinence , including withdrawal distress , cigarette craving , positive affect and subjective reactions to cigarettes smoked during a lapse .","['AIM', 'The', 'study', 'aimed', 'to', 'test', 'simultaneously', 'our', 'understanding', 'of', 'the', 'effects', 'of', 'bupropion', 'sustained-release', '(', 'SR', ')', 'treatment', 'on', 'putative', 'mediators', 'and', 'our', 'understanding', 'of', 'determinants', 'of', 'post-quit', 'abstinence', ',', 'including', 'withdrawal', 'distress', ',', 'cigarette', 'craving', ',', 'positive', 'affect', 'and', 'subjective', 'reactions', 'to', 'cigarettes', 'smoked', 'during', 'a', 'lapse', '.']","(13, 18)","(78, 112)",-1,hl_i,18783504,Abstract,0,test,gold,5260.0
2675,The specificity of,bupropion SR,effects was also tested in exploratory analyses .,"['The', 'specificity', 'of', 'bupropion', 'SR', 'effects', 'was', 'also', 'tested', 'in', 'exploratory', 'analyses', '.']","(3, 5)","(18, 30)",-1,ss_i,18783504,Abstract,1,test,gold,5258.0
2676,The,specificity,of bupropion SR effects was also tested in exploratory analyses .,"['The', 'specificity', 'of', 'bupropion', 'SR', 'effects', 'was', 'also', 'tested', 'in', 'exploratory', 'analyses', '.']","(1, 2)","(3, 14)",-1,ss_o,18783504,Abstract,1,test,gold,1398.0
2677,The specificity of,bupropion SR,effects was also tested in exploratory analyses .,"['The', 'specificity', 'of', 'bupropion', 'SR', 'effects', 'was', 'also', 'tested', 'in', 'exploratory', 'analyses', '.']","(3, 5)","(18, 30)",-1,hl_i,18783504,Abstract,1,test,gold,5257.0
2678,"DESIGN Data from a randomized , placebo-controlled clinical trial of",bupropion SR,were submitted to mediation analyses .,"['DESIGN', 'Data', 'from', 'a', 'randomized', ',', 'placebo-controlled', 'clinical', 'trial', 'of', 'bupropion', 'SR', 'were', 'submitted', 'to', 'mediation', 'analyses', '.']","(10, 12)","(68, 80)",-1,ss_i,18783504,Abstract,2,test,gold,5256.0
2679,"DESIGN Data from a randomized , placebo-controlled clinical trial of",bupropion SR,were submitted to mediation analyses .,"['DESIGN', 'Data', 'from', 'a', 'randomized', ',', 'placebo-controlled', 'clinical', 'trial', 'of', 'bupropion', 'SR', 'were', 'submitted', 'to', 'mediation', 'analyses', '.']","(10, 12)","(68, 80)",-1,hl_i,18783504,Abstract,2,test,gold,5255.0
2680,"SETTING Center for Tobacco Research and Intervention ,","Madison , WI , USA .",,"['SETTING', 'Center', 'for', 'Tobacco', 'Research', 'and', 'Intervention', ',', 'Madison', ',', 'WI', ',', 'USA', '.']","(8, 14)","(54, 74)",-1,ss_p,18783504,Abstract,3,test,gold,1452.0
2681,"SETTING Center for Tobacco Research and Intervention ,","Madison , WI , USA",.,"['SETTING', 'Center', 'for', 'Tobacco', 'Research', 'and', 'Intervention', ',', 'Madison', ',', 'WI', ',', 'USA', '.']","(8, 13)","(54, 72)",-1,hl_p,18783504,Abstract,3,test,gold,1453.0
2682,PARTICIPANTS A total of,"403 adult , daily smokers without contraindications to bupropion SR use .",,"['PARTICIPANTS', 'A', 'total', 'of', '403', 'adult', ',', 'daily', 'smokers', 'without', 'contraindications', 'to', 'bupropion', 'SR', 'use', '.']","(4, 16)","(23, 96)",-1,ss_p,18783504,Abstract,4,test,gold,7081.0
2683,"PARTICIPANTS A total of 403 adult , daily smokers without contraindications to",bupropion SR,use .,"['PARTICIPANTS', 'A', 'total', 'of', '403', 'adult', ',', 'daily', 'smokers', 'without', 'contraindications', 'to', 'bupropion', 'SR', 'use', '.']","(12, 14)","(78, 90)",-1,ss_i,18783504,Abstract,4,test,gold,5254.0
2684,PARTICIPANTS A total of,"403 adult , daily smokers without contraindications to bupropion SR use",.,"['PARTICIPANTS', 'A', 'total', 'of', '403', 'adult', ',', 'daily', 'smokers', 'without', 'contraindications', 'to', 'bupropion', 'SR', 'use', '.']","(4, 15)","(23, 94)",-1,hl_p,18783504,Abstract,4,test,gold,7082.0
2685,"PARTICIPANTS A total of 403 adult , daily smokers without contraindications to",bupropion SR,use .,"['PARTICIPANTS', 'A', 'total', 'of', '403', 'adult', ',', 'daily', 'smokers', 'without', 'contraindications', 'to', 'bupropion', 'SR', 'use', '.']","(12, 14)","(78, 90)",-1,hl_i,18783504,Abstract,4,test,gold,5253.0
2686,INTERVENTION Participants were assigned randomly to receive a 9-week course of,bupropion SR,or placebo pill and to receive eight brief individual counseling sessions or no counseling .,"['INTERVENTION', 'Participants', 'were', 'assigned', 'randomly', 'to', 'receive', 'a', '9-week', 'course', 'of', 'bupropion', 'SR', 'or', 'placebo', 'pill', 'and', 'to', 'receive', 'eight', 'brief', 'individual', 'counseling', 'sessions', 'or', 'no', 'counseling', '.']","(11, 13)","(78, 90)",-1,ss_i,18783504,Abstract,5,test,gold,5252.0
2687,INTERVENTION Participants were assigned randomly to receive a 9-week course of bupropion SR or,placebo,pill and to receive eight brief individual counseling sessions or no counseling .,"['INTERVENTION', 'Participants', 'were', 'assigned', 'randomly', 'to', 'receive', 'a', '9-week', 'course', 'of', 'bupropion', 'SR', 'or', 'placebo', 'pill', 'and', 'to', 'receive', 'eight', 'brief', 'individual', 'counseling', 'sessions', 'or', 'no', 'counseling', '.']","(14, 15)","(94, 101)",-1,ss_i,18783504,Abstract,5,test,gold,4385.0
2688,INTERVENTION Participants were assigned randomly to receive a 9-week course of,bupropion SR,or placebo pill and to receive eight brief individual counseling sessions or no counseling .,"['INTERVENTION', 'Participants', 'were', 'assigned', 'randomly', 'to', 'receive', 'a', '9-week', 'course', 'of', 'bupropion', 'SR', 'or', 'placebo', 'pill', 'and', 'to', 'receive', 'eight', 'brief', 'individual', 'counseling', 'sessions', 'or', 'no', 'counseling', '.']","(11, 13)","(78, 90)",-1,hl_i,18783504,Abstract,5,test,gold,5251.0
2689,INTERVENTION Participants were assigned randomly to receive a 9-week course of bupropion SR or,placebo,pill and to receive eight brief individual counseling sessions or no counseling .,"['INTERVENTION', 'Participants', 'were', 'assigned', 'randomly', 'to', 'receive', 'a', '9-week', 'course', 'of', 'bupropion', 'SR', 'or', 'placebo', 'pill', 'and', 'to', 'receive', 'eight', 'brief', 'individual', 'counseling', 'sessions', 'or', 'no', 'counseling', '.']","(14, 15)","(94, 101)",-1,hl_i,18783504,Abstract,5,test,gold,4384.0
2690,MEASUREMENTS,Ecological momentary assessment ratings of smoking behavior and putative mediators,were collected pre- and post-quit .,"['MEASUREMENTS', 'Ecological', 'momentary', 'assessment', 'ratings', 'of', 'smoking', 'behavior', 'and', 'putative', 'mediators', 'were', 'collected', 'pre-', 'and', 'post-quit', '.']","(1, 11)","(12, 94)",-1,ss_o,18783504,Abstract,6,test,gold,6429.0
2691,MEASUREMENTS,Ecological momentary assessment ratings of smoking behavior and putative mediators,were collected pre- and post-quit .,"['MEASUREMENTS', 'Ecological', 'momentary', 'assessment', 'ratings', 'of', 'smoking', 'behavior', 'and', 'putative', 'mediators', 'were', 'collected', 'pre-', 'and', 'post-quit', '.']","(1, 11)","(12, 94)",-1,hl_o,18783504,Abstract,6,test,gold,6430.0
2692,FINDINGS Results of structural equation and hierarchical linear models did not support the hypothesis that,bupropion SR,"treatment improves short-term abstinence by reducing withdrawal distress or affecting the subjective effects of a lapse cigarette , but provided partial support for mediation by cigarette craving reduction and enhanced positive affect .","['FINDINGS', 'Results', 'of', 'structural', 'equation', 'and', 'hierarchical', 'linear', 'models', 'did', 'not', 'support', 'the', 'hypothesis', 'that', 'bupropion', 'SR', 'treatment', 'improves', 'short-term', 'abstinence', 'by', 'reducing', 'withdrawal', 'distress', 'or', 'affecting', 'the', 'subjective', 'effects', 'of', 'a', 'lapse', 'cigarette', ',', 'but', 'provided', 'partial', 'support', 'for', 'mediation', 'by', 'cigarette', 'craving', 'reduction', 'and', 'enhanced', 'positive', 'affect', '.']","(15, 17)","(106, 118)",-1,ss_i,18783504,Abstract,7,test,gold,5250.0
2693,FINDINGS Results of structural equation and hierarchical linear models did not support the hypothesis that bupropion SR treatment improves,short-term abstinence,"by reducing withdrawal distress or affecting the subjective effects of a lapse cigarette , but provided partial support for mediation by cigarette craving reduction and enhanced positive affect .","['FINDINGS', 'Results', 'of', 'structural', 'equation', 'and', 'hierarchical', 'linear', 'models', 'did', 'not', 'support', 'the', 'hypothesis', 'that', 'bupropion', 'SR', 'treatment', 'improves', 'short-term', 'abstinence', 'by', 'reducing', 'withdrawal', 'distress', 'or', 'affecting', 'the', 'subjective', 'effects', 'of', 'a', 'lapse', 'cigarette', ',', 'but', 'provided', 'partial', 'support', 'for', 'mediation', 'by', 'cigarette', 'craving', 'reduction', 'and', 'enhanced', 'positive', 'affect', '.']","(19, 21)","(138, 159)",-1,ss_o,18783504,Abstract,7,test,gold,3911.0
2694,FINDINGS Results of structural equation and hierarchical linear models did not support the hypothesis that bupropion SR treatment improves short-term abstinence by reducing,withdrawal distress,"or affecting the subjective effects of a lapse cigarette , but provided partial support for mediation by cigarette craving reduction and enhanced positive affect .","['FINDINGS', 'Results', 'of', 'structural', 'equation', 'and', 'hierarchical', 'linear', 'models', 'did', 'not', 'support', 'the', 'hypothesis', 'that', 'bupropion', 'SR', 'treatment', 'improves', 'short-term', 'abstinence', 'by', 'reducing', 'withdrawal', 'distress', 'or', 'affecting', 'the', 'subjective', 'effects', 'of', 'a', 'lapse', 'cigarette', ',', 'but', 'provided', 'partial', 'support', 'for', 'mediation', 'by', 'cigarette', 'craving', 'reduction', 'and', 'enhanced', 'positive', 'affect', '.']","(23, 25)","(172, 191)",-1,ss_o,18783504,Abstract,7,test,gold,2595.0
2695,FINDINGS Results of structural equation and hierarchical linear models did not support the hypothesis that bupropion SR treatment improves short-term abstinence by reducing withdrawal distress or affecting the,subjective effects of a lapse cigarette,", but provided partial support for mediation by cigarette craving reduction and enhanced positive affect .","['FINDINGS', 'Results', 'of', 'structural', 'equation', 'and', 'hierarchical', 'linear', 'models', 'did', 'not', 'support', 'the', 'hypothesis', 'that', 'bupropion', 'SR', 'treatment', 'improves', 'short-term', 'abstinence', 'by', 'reducing', 'withdrawal', 'distress', 'or', 'affecting', 'the', 'subjective', 'effects', 'of', 'a', 'lapse', 'cigarette', ',', 'but', 'provided', 'partial', 'support', 'for', 'mediation', 'by', 'cigarette', 'craving', 'reduction', 'and', 'enhanced', 'positive', 'affect', '.']","(28, 34)","(209, 248)",-1,ss_o,18783504,Abstract,7,test,gold,6444.0
2696,"FINDINGS Results of structural equation and hierarchical linear models did not support the hypothesis that bupropion SR treatment improves short-term abstinence by reducing withdrawal distress or affecting the subjective effects of a lapse cigarette , but provided partial support for mediation by",cigarette craving reduction,and enhanced positive affect .,"['FINDINGS', 'Results', 'of', 'structural', 'equation', 'and', 'hierarchical', 'linear', 'models', 'did', 'not', 'support', 'the', 'hypothesis', 'that', 'bupropion', 'SR', 'treatment', 'improves', 'short-term', 'abstinence', 'by', 'reducing', 'withdrawal', 'distress', 'or', 'affecting', 'the', 'subjective', 'effects', 'of', 'a', 'lapse', 'cigarette', ',', 'but', 'provided', 'partial', 'support', 'for', 'mediation', 'by', 'cigarette', 'craving', 'reduction', 'and', 'enhanced', 'positive', 'affect', '.']","(42, 45)","(297, 324)",-1,ss_o,18783504,Abstract,7,test,gold,2429.0
2697,"FINDINGS Results of structural equation and hierarchical linear models did not support the hypothesis that bupropion SR treatment improves short-term abstinence by reducing withdrawal distress or affecting the subjective effects of a lapse cigarette , but provided partial support for mediation by cigarette craving reduction and enhanced",positive affect .,,"['FINDINGS', 'Results', 'of', 'structural', 'equation', 'and', 'hierarchical', 'linear', 'models', 'did', 'not', 'support', 'the', 'hypothesis', 'that', 'bupropion', 'SR', 'treatment', 'improves', 'short-term', 'abstinence', 'by', 'reducing', 'withdrawal', 'distress', 'or', 'affecting', 'the', 'subjective', 'effects', 'of', 'a', 'lapse', 'cigarette', ',', 'but', 'provided', 'partial', 'support', 'for', 'mediation', 'by', 'cigarette', 'craving', 'reduction', 'and', 'enhanced', 'positive', 'affect', '.']","(47, 50)","(338, 355)",-1,ss_o,18783504,Abstract,7,test,gold,959.0
2698,FINDINGS Results of structural equation and hierarchical linear models did not support the hypothesis that bupropion SR treatment improves,short-term abstinence,"by reducing withdrawal distress or affecting the subjective effects of a lapse cigarette , but provided partial support for mediation by cigarette craving reduction and enhanced positive affect .","['FINDINGS', 'Results', 'of', 'structural', 'equation', 'and', 'hierarchical', 'linear', 'models', 'did', 'not', 'support', 'the', 'hypothesis', 'that', 'bupropion', 'SR', 'treatment', 'improves', 'short-term', 'abstinence', 'by', 'reducing', 'withdrawal', 'distress', 'or', 'affecting', 'the', 'subjective', 'effects', 'of', 'a', 'lapse', 'cigarette', ',', 'but', 'provided', 'partial', 'support', 'for', 'mediation', 'by', 'cigarette', 'craving', 'reduction', 'and', 'enhanced', 'positive', 'affect', '.']","(19, 21)","(138, 159)",-1,hl_o,18783504,Abstract,7,test,gold,3912.0
2699,"FINDINGS Results of structural equation and hierarchical linear models did not support the hypothesis that bupropion SR treatment improves short-term abstinence by reducing withdrawal distress or affecting the subjective effects of a lapse cigarette , but provided partial support for mediation by",cigarette craving reduction,and enhanced positive affect .,"['FINDINGS', 'Results', 'of', 'structural', 'equation', 'and', 'hierarchical', 'linear', 'models', 'did', 'not', 'support', 'the', 'hypothesis', 'that', 'bupropion', 'SR', 'treatment', 'improves', 'short-term', 'abstinence', 'by', 'reducing', 'withdrawal', 'distress', 'or', 'affecting', 'the', 'subjective', 'effects', 'of', 'a', 'lapse', 'cigarette', ',', 'but', 'provided', 'partial', 'support', 'for', 'mediation', 'by', 'cigarette', 'craving', 'reduction', 'and', 'enhanced', 'positive', 'affect', '.']","(42, 45)","(297, 324)",-1,hl_o,18783504,Abstract,7,test,gold,2430.0
2700,"FINDINGS Results of structural equation and hierarchical linear models did not support the hypothesis that bupropion SR treatment improves short-term abstinence by reducing withdrawal distress or affecting the subjective effects of a lapse cigarette , but provided partial support for mediation by cigarette craving reduction and enhanced",positive affect .,,"['FINDINGS', 'Results', 'of', 'structural', 'equation', 'and', 'hierarchical', 'linear', 'models', 'did', 'not', 'support', 'the', 'hypothesis', 'that', 'bupropion', 'SR', 'treatment', 'improves', 'short-term', 'abstinence', 'by', 'reducing', 'withdrawal', 'distress', 'or', 'affecting', 'the', 'subjective', 'effects', 'of', 'a', 'lapse', 'cigarette', ',', 'but', 'provided', 'partial', 'support', 'for', 'mediation', 'by', 'cigarette', 'craving', 'reduction', 'and', 'enhanced', 'positive', 'affect', '.']","(47, 50)","(338, 355)",-1,hl_o,18783504,Abstract,7,test,gold,960.0
2701,,Bupropion SR,effects on point-prevalence abstinence at 1 month post-quit were also mediated partially by enhanced motivation to quit and self-efficacy .,"['Bupropion', 'SR', 'effects', 'on', 'point-prevalence', 'abstinence', 'at', '1', 'month', 'post-quit', 'were', 'also', 'mediated', 'partially', 'by', 'enhanced', 'motivation', 'to', 'quit', 'and', 'self-efficacy', '.']","(0, 2)","(0, 12)",-1,ss_i,18783504,Abstract,8,test,gold,5261.0
2702,Bupropion SR effects on,point-prevalence abstinence,at 1 month post-quit were also mediated partially by enhanced motivation to quit and self-efficacy .,"['Bupropion', 'SR', 'effects', 'on', 'point-prevalence', 'abstinence', 'at', '1', 'month', 'post-quit', 'were', 'also', 'mediated', 'partially', 'by', 'enhanced', 'motivation', 'to', 'quit', 'and', 'self-efficacy', '.']","(4, 6)","(23, 50)",-1,ss_o,18783504,Abstract,8,test,gold,3910.0
2703,Bupropion SR effects on point-prevalence abstinence at 1 month post-quit were also mediated partially by enhanced,motivation,to quit and self-efficacy .,"['Bupropion', 'SR', 'effects', 'on', 'point-prevalence', 'abstinence', 'at', '1', 'month', 'post-quit', 'were', 'also', 'mediated', 'partially', 'by', 'enhanced', 'motivation', 'to', 'quit', 'and', 'self-efficacy', '.']","(16, 17)","(113, 123)",-1,ss_o,18783504,Abstract,8,test,gold,1225.0
2704,Bupropion SR effects on point-prevalence abstinence at 1 month post-quit were also mediated partially by enhanced motivation to quit and,self-efficacy .,,"['Bupropion', 'SR', 'effects', 'on', 'point-prevalence', 'abstinence', 'at', '1', 'month', 'post-quit', 'were', 'also', 'mediated', 'partially', 'by', 'enhanced', 'motivation', 'to', 'quit', 'and', 'self-efficacy', '.']","(20, 22)","(136, 151)",-1,ss_o,18783504,Abstract,8,test,gold,
2705,,Bupropion SR,effects on point-prevalence abstinence at 1 month post-quit were also mediated partially by enhanced motivation to quit and self-efficacy .,"['Bupropion', 'SR', 'effects', 'on', 'point-prevalence', 'abstinence', 'at', '1', 'month', 'post-quit', 'were', 'also', 'mediated', 'partially', 'by', 'enhanced', 'motivation', 'to', 'quit', 'and', 'self-efficacy', '.']","(0, 2)","(0, 12)",-1,hl_i,18783504,Abstract,8,test,gold,5262.0
2706,Bupropion SR effects on point-prevalence,abstinence,at 1 month post-quit were also mediated partially by enhanced motivation to quit and self-efficacy .,"['Bupropion', 'SR', 'effects', 'on', 'point-prevalence', 'abstinence', 'at', '1', 'month', 'post-quit', 'were', 'also', 'mediated', 'partially', 'by', 'enhanced', 'motivation', 'to', 'quit', 'and', 'self-efficacy', '.']","(5, 6)","(40, 50)",-1,hl_o,18783504,Abstract,8,test,gold,3909.0
2707,CONCLUSIONS Results provided some support for models of,bupropion SR,treatment and relapse and suggested that motivational processes may partially account for bupropion SR efficacy .,"['CONCLUSIONS', 'Results', 'provided', 'some', 'support', 'for', 'models', 'of', 'bupropion', 'SR', 'treatment', 'and', 'relapse', 'and', 'suggested', 'that', 'motivational', 'processes', 'may', 'partially', 'account', 'for', 'bupropion', 'SR', 'efficacy', '.']","(8, 10)","(55, 67)",-1,ss_i,18783504,Abstract,9,test,gold,5249.0
2708,CONCLUSIONS Results provided some support for models of bupropion SR treatment and relapse and suggested that motivational processes may partially account for,bupropion SR,efficacy .,"['CONCLUSIONS', 'Results', 'provided', 'some', 'support', 'for', 'models', 'of', 'bupropion', 'SR', 'treatment', 'and', 'relapse', 'and', 'suggested', 'that', 'motivational', 'processes', 'may', 'partially', 'account', 'for', 'bupropion', 'SR', 'efficacy', '.']","(22, 24)","(158, 170)",-1,ss_i,18783504,Abstract,9,test,gold,5248.0
2709,CONCLUSIONS Results provided some support for models of bupropion SR treatment and relapse and suggested that motivational processes may partially account for bupropion SR,efficacy .,,"['CONCLUSIONS', 'Results', 'provided', 'some', 'support', 'for', 'models', 'of', 'bupropion', 'SR', 'treatment', 'and', 'relapse', 'and', 'suggested', 'that', 'motivational', 'processes', 'may', 'partially', 'account', 'for', 'bupropion', 'SR', 'efficacy', '.']","(24, 26)","(171, 181)",-1,ss_o,18783504,Abstract,9,test,gold,4821.0
2710,CONCLUSIONS Results provided some support for models of,bupropion SR,treatment and relapse and suggested that motivational processes may partially account for bupropion SR efficacy .,"['CONCLUSIONS', 'Results', 'provided', 'some', 'support', 'for', 'models', 'of', 'bupropion', 'SR', 'treatment', 'and', 'relapse', 'and', 'suggested', 'that', 'motivational', 'processes', 'may', 'partially', 'account', 'for', 'bupropion', 'SR', 'efficacy', '.']","(8, 10)","(55, 67)",-1,hl_i,18783504,Abstract,9,test,gold,5247.0
2711,Identifying patients at high risk for neutropenic complications during chemotherapy for,metastatic breast cancer,with doxorubicin or pegylated liposomal doxorubicin : the development of a prediction model .,"['Identifying', 'patients', 'at', 'high', 'risk', 'for', 'neutropenic', 'complications', 'during', 'chemotherapy', 'for', 'metastatic', 'breast', 'cancer', 'with', 'doxorubicin', 'or', 'pegylated', 'liposomal', 'doxorubicin', ':', 'the', 'development', 'of', 'a', 'prediction', 'model', '.']","(11, 14)","(87, 111)",-1,ss_p,18845996,Title,0,test,gold,6837.0
2712,Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with,doxorubicin,or pegylated liposomal doxorubicin : the development of a prediction model .,"['Identifying', 'patients', 'at', 'high', 'risk', 'for', 'neutropenic', 'complications', 'during', 'chemotherapy', 'for', 'metastatic', 'breast', 'cancer', 'with', 'doxorubicin', 'or', 'pegylated', 'liposomal', 'doxorubicin', ':', 'the', 'development', 'of', 'a', 'prediction', 'model', '.']","(15, 16)","(117, 128)",-1,ss_i,18845996,Title,0,test,gold,5172.0
2713,Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or,pegylated liposomal doxorubicin :,the development of a prediction model .,"['Identifying', 'patients', 'at', 'high', 'risk', 'for', 'neutropenic', 'complications', 'during', 'chemotherapy', 'for', 'metastatic', 'breast', 'cancer', 'with', 'doxorubicin', 'or', 'pegylated', 'liposomal', 'doxorubicin', ':', 'the', 'development', 'of', 'a', 'prediction', 'model', '.']","(17, 21)","(132, 165)",-1,ss_i,18845996,Title,0,test,gold,6678.0
2714,,Identifying patients at high risk for neutropenic complications,during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin : the development of a prediction model .,"['Identifying', 'patients', 'at', 'high', 'risk', 'for', 'neutropenic', 'complications', 'during', 'chemotherapy', 'for', 'metastatic', 'breast', 'cancer', 'with', 'doxorubicin', 'or', 'pegylated', 'liposomal', 'doxorubicin', ':', 'the', 'development', 'of', 'a', 'prediction', 'model', '.']","(0, 8)","(0, 63)",-1,ss_o,18845996,Title,0,test,gold,6937.0
2715,Identifying patients at high risk for neutropenic complications during chemotherapy for,metastatic breast cancer,with doxorubicin or pegylated liposomal doxorubicin : the development of a prediction model .,"['Identifying', 'patients', 'at', 'high', 'risk', 'for', 'neutropenic', 'complications', 'during', 'chemotherapy', 'for', 'metastatic', 'breast', 'cancer', 'with', 'doxorubicin', 'or', 'pegylated', 'liposomal', 'doxorubicin', ':', 'the', 'development', 'of', 'a', 'prediction', 'model', '.']","(11, 14)","(87, 111)",-1,hl_p,18845996,Title,0,test,gold,6838.0
2716,Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with,doxorubicin,or pegylated liposomal doxorubicin : the development of a prediction model .,"['Identifying', 'patients', 'at', 'high', 'risk', 'for', 'neutropenic', 'complications', 'during', 'chemotherapy', 'for', 'metastatic', 'breast', 'cancer', 'with', 'doxorubicin', 'or', 'pegylated', 'liposomal', 'doxorubicin', ':', 'the', 'development', 'of', 'a', 'prediction', 'model', '.']","(15, 16)","(117, 128)",-1,hl_i,18845996,Title,0,test,gold,5173.0
2717,Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or,pegylated liposomal doxorubicin,: the development of a prediction model .,"['Identifying', 'patients', 'at', 'high', 'risk', 'for', 'neutropenic', 'complications', 'during', 'chemotherapy', 'for', 'metastatic', 'breast', 'cancer', 'with', 'doxorubicin', 'or', 'pegylated', 'liposomal', 'doxorubicin', ':', 'the', 'development', 'of', 'a', 'prediction', 'model', '.']","(17, 20)","(132, 163)",-1,hl_i,18845996,Title,0,test,gold,6677.0
2718,Identifying patients at high risk for,neutropenic complications,during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin : the development of a prediction model .,"['Identifying', 'patients', 'at', 'high', 'risk', 'for', 'neutropenic', 'complications', 'during', 'chemotherapy', 'for', 'metastatic', 'breast', 'cancer', 'with', 'doxorubicin', 'or', 'pegylated', 'liposomal', 'doxorubicin', ':', 'the', 'development', 'of', 'a', 'prediction', 'model', '.']","(6, 8)","(37, 62)",-1,hl_o,18845996,Title,0,test,gold,3439.0
2719,OBJECTIVE To develop a cycle-based risk prediction model for neutropenic complications ( NC ) during chemotherapy with doxorubicin ( DOX ) or a pegylated liposomal formulation ( PLD ) for,patients with metastatic breast cancer ( MBC ) .,,"['OBJECTIVE', 'To', 'develop', 'a', 'cycle-based', 'risk', 'prediction', 'model', 'for', 'neutropenic', 'complications', '(', 'NC', ')', 'during', 'chemotherapy', 'with', 'doxorubicin', '(', 'DOX', ')', 'or', 'a', 'pegylated', 'liposomal', 'formulation', '(', 'PLD', ')', 'for', 'patients', 'with', 'metastatic', 'breast', 'cancer', '(', 'MBC', ')', '.']","(30, 39)","(187, 235)",-1,ss_p,18845996,Abstract,0,test,gold,6839.0
2720,OBJECTIVE To develop a cycle-based risk prediction model for neutropenic complications ( NC ) during chemotherapy with,doxorubicin ( DOX ),or a pegylated liposomal formulation ( PLD ) for patients with metastatic breast cancer ( MBC ) .,"['OBJECTIVE', 'To', 'develop', 'a', 'cycle-based', 'risk', 'prediction', 'model', 'for', 'neutropenic', 'complications', '(', 'NC', ')', 'during', 'chemotherapy', 'with', 'doxorubicin', '(', 'DOX', ')', 'or', 'a', 'pegylated', 'liposomal', 'formulation', '(', 'PLD', ')', 'for', 'patients', 'with', 'metastatic', 'breast', 'cancer', '(', 'MBC', ')', '.']","(17, 21)","(118, 137)",-1,ss_i,18845996,Abstract,0,test,gold,5174.0
2721,OBJECTIVE To develop a cycle-based risk prediction model for neutropenic complications ( NC ) during chemotherapy with doxorubicin ( DOX ) or a,pegylated liposomal formulation ( PLD ),for patients with metastatic breast cancer ( MBC ) .,"['OBJECTIVE', 'To', 'develop', 'a', 'cycle-based', 'risk', 'prediction', 'model', 'for', 'neutropenic', 'complications', '(', 'NC', ')', 'during', 'chemotherapy', 'with', 'doxorubicin', '(', 'DOX', ')', 'or', 'a', 'pegylated', 'liposomal', 'formulation', '(', 'PLD', ')', 'for', 'patients', 'with', 'metastatic', 'breast', 'cancer', '(', 'MBC', ')', '.']","(23, 29)","(143, 182)",-1,ss_i,18845996,Abstract,0,test,gold,6675.0
2722,OBJECTIVE To develop a,cycle-based risk prediction model for neutropenic complications ( NC ),during chemotherapy with doxorubicin ( DOX ) or a pegylated liposomal formulation ( PLD ) for patients with metastatic breast cancer ( MBC ) .,"['OBJECTIVE', 'To', 'develop', 'a', 'cycle-based', 'risk', 'prediction', 'model', 'for', 'neutropenic', 'complications', '(', 'NC', ')', 'during', 'chemotherapy', 'with', 'doxorubicin', '(', 'DOX', ')', 'or', 'a', 'pegylated', 'liposomal', 'formulation', '(', 'PLD', ')', 'for', 'patients', 'with', 'metastatic', 'breast', 'cancer', '(', 'MBC', ')', '.']","(4, 14)","(22, 92)",-1,ss_o,18845996,Abstract,0,test,gold,6940.0
2723,OBJECTIVE To develop a cycle-based risk prediction model for neutropenic complications ( NC ) during chemotherapy with doxorubicin ( DOX ) or a pegylated liposomal formulation ( PLD ) for,patients with metastatic breast cancer ( MBC ) .,,"['OBJECTIVE', 'To', 'develop', 'a', 'cycle-based', 'risk', 'prediction', 'model', 'for', 'neutropenic', 'complications', '(', 'NC', ')', 'during', 'chemotherapy', 'with', 'doxorubicin', '(', 'DOX', ')', 'or', 'a', 'pegylated', 'liposomal', 'formulation', '(', 'PLD', ')', 'for', 'patients', 'with', 'metastatic', 'breast', 'cancer', '(', 'MBC', ')', '.']","(30, 39)","(187, 235)",-1,hl_p,18845996,Abstract,0,test,gold,6840.0
2724,OBJECTIVE To develop a cycle-based risk prediction model for neutropenic complications ( NC ) during chemotherapy with,doxorubicin ( DOX ),or a pegylated liposomal formulation ( PLD ) for patients with metastatic breast cancer ( MBC ) .,"['OBJECTIVE', 'To', 'develop', 'a', 'cycle-based', 'risk', 'prediction', 'model', 'for', 'neutropenic', 'complications', '(', 'NC', ')', 'during', 'chemotherapy', 'with', 'doxorubicin', '(', 'DOX', ')', 'or', 'a', 'pegylated', 'liposomal', 'formulation', '(', 'PLD', ')', 'for', 'patients', 'with', 'metastatic', 'breast', 'cancer', '(', 'MBC', ')', '.']","(17, 21)","(118, 137)",-1,hl_i,18845996,Abstract,0,test,gold,5175.0
2725,OBJECTIVE To develop a cycle-based risk prediction model for neutropenic complications ( NC ) during chemotherapy with doxorubicin ( DOX ) or a,pegylated liposomal formulation ( PLD ),for patients with metastatic breast cancer ( MBC ) .,"['OBJECTIVE', 'To', 'develop', 'a', 'cycle-based', 'risk', 'prediction', 'model', 'for', 'neutropenic', 'complications', '(', 'NC', ')', 'during', 'chemotherapy', 'with', 'doxorubicin', '(', 'DOX', ')', 'or', 'a', 'pegylated', 'liposomal', 'formulation', '(', 'PLD', ')', 'for', 'patients', 'with', 'metastatic', 'breast', 'cancer', '(', 'MBC', ')', '.']","(23, 29)","(143, 182)",-1,hl_i,18845996,Abstract,0,test,gold,6676.0
2726,OBJECTIVE To develop a cycle-based risk prediction model for,neutropenic complications ( NC ),during chemotherapy with doxorubicin ( DOX ) or a pegylated liposomal formulation ( PLD ) for patients with metastatic breast cancer ( MBC ) .,"['OBJECTIVE', 'To', 'develop', 'a', 'cycle-based', 'risk', 'prediction', 'model', 'for', 'neutropenic', 'complications', '(', 'NC', ')', 'during', 'chemotherapy', 'with', 'doxorubicin', '(', 'DOX', ')', 'or', 'a', 'pegylated', 'liposomal', 'formulation', '(', 'PLD', ')', 'for', 'patients', 'with', 'metastatic', 'breast', 'cancer', '(', 'MBC', ')', '.']","(9, 14)","(60, 92)",-1,hl_o,18845996,Abstract,0,test,gold,3440.0
2727,"METHODS Data analyzed was from a phase III , randomized clinical trial of DOX ( 60 mg/m ( 2 ) every 3 weeks ) or PLD ( 50 mg/m ( 2 ) every 4 weeks ) for the first line therapy for",MBC ( n = 509 ),"( O'Brien et al , Ann Oncol .","['METHODS', 'Data', 'analyzed', 'was', 'from', 'a', 'phase', 'III', ',', 'randomized', 'clinical', 'trial', 'of', 'DOX', '(', '60', 'mg/m', '(', '2', ')', 'every', '3', 'weeks', ')', 'or', 'PLD', '(', '50', 'mg/m', '(', '2', ')', 'every', '4', 'weeks', ')', 'for', 'the', 'first', 'line', 'therapy', 'for', 'MBC', '(', 'n', '=', '509', ')', '(', ""O'Brien"", 'et', 'al', ',', 'Ann', 'Oncol', '.']","(42, 48)","(179, 194)",-1,ss_p,18845996,Abstract,1,test,gold,820.0
2728,"METHODS Data analyzed was from a phase III , randomized clinical trial of",DOX,"( 60 mg/m ( 2 ) every 3 weeks ) or PLD ( 50 mg/m ( 2 ) every 4 weeks ) for the first line therapy for MBC ( n = 509 ) ( O'Brien et al , Ann Oncol .","['METHODS', 'Data', 'analyzed', 'was', 'from', 'a', 'phase', 'III', ',', 'randomized', 'clinical', 'trial', 'of', 'DOX', '(', '60', 'mg/m', '(', '2', ')', 'every', '3', 'weeks', ')', 'or', 'PLD', '(', '50', 'mg/m', '(', '2', ')', 'every', '4', 'weeks', ')', 'for', 'the', 'first', 'line', 'therapy', 'for', 'MBC', '(', 'n', '=', '509', ')', '(', ""O'Brien"", 'et', 'al', ',', 'Ann', 'Oncol', '.']","(13, 14)","(73, 76)",-1,ss_i,18845996,Abstract,1,test,gold,629.0
2729,"METHODS Data analyzed was from a phase III , randomized clinical trial of DOX ( 60 mg/m ( 2 ) every 3 weeks ) or",PLD,"( 50 mg/m ( 2 ) every 4 weeks ) for the first line therapy for MBC ( n = 509 ) ( O'Brien et al , Ann Oncol .","['METHODS', 'Data', 'analyzed', 'was', 'from', 'a', 'phase', 'III', ',', 'randomized', 'clinical', 'trial', 'of', 'DOX', '(', '60', 'mg/m', '(', '2', ')', 'every', '3', 'weeks', ')', 'or', 'PLD', '(', '50', 'mg/m', '(', '2', ')', 'every', '4', 'weeks', ')', 'for', 'the', 'first', 'line', 'therapy', 'for', 'MBC', '(', 'n', '=', '509', ')', '(', ""O'Brien"", 'et', 'al', ',', 'Ann', 'Oncol', '.']","(25, 26)","(112, 115)",-1,ss_i,18845996,Abstract,1,test,gold,498.0
2730,"METHODS Data analyzed was from a phase III , randomized clinical trial of",DOX,"( 60 mg/m ( 2 ) every 3 weeks ) or PLD ( 50 mg/m ( 2 ) every 4 weeks ) for the first line therapy for MBC ( n = 509 ) ( O'Brien et al , Ann Oncol .","['METHODS', 'Data', 'analyzed', 'was', 'from', 'a', 'phase', 'III', ',', 'randomized', 'clinical', 'trial', 'of', 'DOX', '(', '60', 'mg/m', '(', '2', ')', 'every', '3', 'weeks', ')', 'or', 'PLD', '(', '50', 'mg/m', '(', '2', ')', 'every', '4', 'weeks', ')', 'for', 'the', 'first', 'line', 'therapy', 'for', 'MBC', '(', 'n', '=', '509', ')', '(', ""O'Brien"", 'et', 'al', ',', 'Ann', 'Oncol', '.']","(13, 14)","(73, 76)",-1,hl_i,18845996,Abstract,1,test,gold,630.0
2731,"METHODS Data analyzed was from a phase III , randomized clinical trial of DOX ( 60 mg/m ( 2 ) every 3 weeks ) or",PLD,"( 50 mg/m ( 2 ) every 4 weeks ) for the first line therapy for MBC ( n = 509 ) ( O'Brien et al , Ann Oncol .","['METHODS', 'Data', 'analyzed', 'was', 'from', 'a', 'phase', 'III', ',', 'randomized', 'clinical', 'trial', 'of', 'DOX', '(', '60', 'mg/m', '(', '2', ')', 'every', '3', 'weeks', ')', 'or', 'PLD', '(', '50', 'mg/m', '(', '2', ')', 'every', '4', 'weeks', ')', 'for', 'the', 'first', 'line', 'therapy', 'for', 'MBC', '(', 'n', '=', '509', ')', '(', ""O'Brien"", 'et', 'al', ',', 'Ann', 'Oncol', '.']","(25, 26)","(112, 115)",-1,hl_i,18845996,Abstract,1,test,gold,497.0
2732,2004 ; 15:440-449 ) .,,,"['2004', ';', '15:440-449', ')', '.']",,,,,18845996,Abstract,2,test,gold,
2733,,NC,"were defined as an absolute neutrophil count < or =1.5 x 10 ( 9 ) cells/L ( ie , > or =grade II ) before the next cycle , febrile neutropenia or neutropenia with a documented infection .","['NC', 'were', 'defined', 'as', 'an', 'absolute', 'neutrophil', 'count', '<', 'or', '=1.5', 'x', '10', '(', '9', ')', 'cells/L', '(', 'ie', ',', '>', 'or', '=grade', 'II', ')', 'before', 'the', 'next', 'cycle', ',', 'febrile', 'neutropenia', 'or', 'neutropenia', 'with', 'a', 'documented', 'infection', '.']","(0, 1)","(0, 2)",-1,ss_o,18845996,Abstract,3,test,gold,636.0
2734,NC were defined as an,"absolute neutrophil count < or =1.5 x 10 ( 9 ) cells/L ( ie , > or =grade II ) before the next cycle , febrile neutropenia or neutropenia with a documented infection .",,"['NC', 'were', 'defined', 'as', 'an', 'absolute', 'neutrophil', 'count', '<', 'or', '=1.5', 'x', '10', '(', '9', ')', 'cells/L', '(', 'ie', ',', '>', 'or', '=grade', 'II', ')', 'before', 'the', 'next', 'cycle', ',', 'febrile', 'neutropenia', 'or', 'neutropenia', 'with', 'a', 'documented', 'infection', '.']","(5, 39)","(21, 188)",-1,ss_o,18845996,Abstract,3,test,gold,5871.0
2735,,NC,"were defined as an absolute neutrophil count < or =1.5 x 10 ( 9 ) cells/L ( ie , > or =grade II ) before the next cycle , febrile neutropenia or neutropenia with a documented infection .","['NC', 'were', 'defined', 'as', 'an', 'absolute', 'neutrophil', 'count', '<', 'or', '=1.5', 'x', '10', '(', '9', ')', 'cells/L', '(', 'ie', ',', '>', 'or', '=grade', 'II', ')', 'before', 'the', 'next', 'cycle', ',', 'febrile', 'neutropenia', 'or', 'neutropenia', 'with', 'a', 'documented', 'infection', '.']","(0, 1)","(0, 2)",-1,hl_o,18845996,Abstract,3,test,gold,637.0
2736,NC were defined as an,absolute neutrophil count < or =1.5 x 10 ( 9 ) cells/L,"( ie , > or =grade II ) before the next cycle , febrile neutropenia or neutropenia with a documented infection .","['NC', 'were', 'defined', 'as', 'an', 'absolute', 'neutrophil', 'count', '<', 'or', '=1.5', 'x', '10', '(', '9', ')', 'cells/L', '(', 'ie', ',', '>', 'or', '=grade', 'II', ')', 'before', 'the', 'next', 'cycle', ',', 'febrile', 'neutropenia', 'or', 'neutropenia', 'with', 'a', 'documented', 'infection', '.']","(5, 17)","(21, 75)",-1,hl_o,18845996,Abstract,3,test,gold,6476.0
2737,"NC were defined as an absolute neutrophil count < or =1.5 x 10 ( 9 ) cells/L ( ie , > or =grade II ) before the next cycle ,",febrile neutropenia or neutropenia with a documented infection .,,"['NC', 'were', 'defined', 'as', 'an', 'absolute', 'neutrophil', 'count', '<', 'or', '=1.5', 'x', '10', '(', '9', ')', 'cells/L', '(', 'ie', ',', '>', 'or', '=grade', 'II', ')', 'before', 'the', 'next', 'cycle', ',', 'febrile', 'neutropenia', 'or', 'neutropenia', 'with', 'a', 'documented', 'infection', '.']","(30, 39)","(124, 188)",-1,hl_o,18845996,Abstract,3,test,gold,7094.0
2738,,Patient and hematologic factors potentially associated with NC,were evaluated .,"['Patient', 'and', 'hematologic', 'factors', 'potentially', 'associated', 'with', 'NC', 'were', 'evaluated', '.']","(0, 8)","(0, 62)",-1,ss_o,18845996,Abstract,4,test,gold,6399.0
2739,Factors with a P value of < or =0.25 within a cycle were included in a generalized estimating equations regression model .,,,"['Factors', 'with', 'a', 'P', 'value', 'of', '<', 'or', '=0.25', 'within', 'a', 'cycle', 'were', 'included', 'in', 'a', 'generalized', 'estimating', 'equations', 'regression', 'model', '.']",,,,,18845996,Abstract,5,test,gold,
2740,"Using backward elimination , we derived a",risk scoring algorithm,( range 0-63 ) from the final reduced model .,"['Using', 'backward', 'elimination', ',', 'we', 'derived', 'a', 'risk', 'scoring', 'algorithm', '(', 'range', '0-63', ')', 'from', 'the', 'final', 'reduced', 'model', '.']","(7, 10)","(41, 63)",-1,ss_o,18845996,Abstract,6,test,gold,1436.0
2741,"RESULTS Risk factors retained in the model included poor performance status , absolute neutrophil count < or =2.0 x 10 ( 9 ) cells/L in the previous cycle , the first cycle of chemotherapy ,",DOX,versus PLD and advanced age .,"['RESULTS', 'Risk', 'factors', 'retained', 'in', 'the', 'model', 'included', 'poor', 'performance', 'status', ',', 'absolute', 'neutrophil', 'count', '<', 'or', '=2.0', 'x', '10', '(', '9', ')', 'cells/L', 'in', 'the', 'previous', 'cycle', ',', 'the', 'first', 'cycle', 'of', 'chemotherapy', ',', 'DOX', 'versus', 'PLD', 'and', 'advanced', 'age', '.']","(35, 36)","(190, 193)",-1,ss_i,18845996,Abstract,7,test,gold,628.0
2742,"RESULTS Risk factors retained in the model included poor performance status , absolute neutrophil count < or =2.0 x 10 ( 9 ) cells/L in the previous cycle , the first cycle of chemotherapy , DOX versus",PLD,and advanced age .,"['RESULTS', 'Risk', 'factors', 'retained', 'in', 'the', 'model', 'included', 'poor', 'performance', 'status', ',', 'absolute', 'neutrophil', 'count', '<', 'or', '=2.0', 'x', '10', '(', '9', ')', 'cells/L', 'in', 'the', 'previous', 'cycle', ',', 'the', 'first', 'cycle', 'of', 'chemotherapy', ',', 'DOX', 'versus', 'PLD', 'and', 'advanced', 'age', '.']","(37, 38)","(201, 204)",-1,ss_i,18845996,Abstract,7,test,gold,496.0
2743,RESULTS,Risk factors,"retained in the model included poor performance status , absolute neutrophil count < or =2.0 x 10 ( 9 ) cells/L in the previous cycle , the first cycle of chemotherapy , DOX versus PLD and advanced age .","['RESULTS', 'Risk', 'factors', 'retained', 'in', 'the', 'model', 'included', 'poor', 'performance', 'status', ',', 'absolute', 'neutrophil', 'count', '<', 'or', '=2.0', 'x', '10', '(', '9', ')', 'cells/L', 'in', 'the', 'previous', 'cycle', ',', 'the', 'first', 'cycle', 'of', 'chemotherapy', ',', 'DOX', 'versus', 'PLD', 'and', 'advanced', 'age', '.']","(1, 3)","(7, 19)",-1,ss_o,18845996,Abstract,7,test,gold,2503.0
2744,RESULTS Risk factors retained in the model included,"poor performance status , absolute neutrophil count < or =2.0 x 10 ( 9 ) cells/L","in the previous cycle , the first cycle of chemotherapy , DOX versus PLD and advanced age .","['RESULTS', 'Risk', 'factors', 'retained', 'in', 'the', 'model', 'included', 'poor', 'performance', 'status', ',', 'absolute', 'neutrophil', 'count', '<', 'or', '=2.0', 'x', '10', '(', '9', ')', 'cells/L', 'in', 'the', 'previous', 'cycle', ',', 'the', 'first', 'cycle', 'of', 'chemotherapy', ',', 'DOX', 'versus', 'PLD', 'and', 'advanced', 'age', '.']","(8, 24)","(51, 131)",-1,ss_o,18845996,Abstract,7,test,gold,6477.0
2745,"RESULTS Risk factors retained in the model included poor performance status , absolute neutrophil count < or =2.0 x 10 ( 9 ) cells/L in the previous cycle , the first cycle of chemotherapy , DOX versus PLD and advanced",age .,,"['RESULTS', 'Risk', 'factors', 'retained', 'in', 'the', 'model', 'included', 'poor', 'performance', 'status', ',', 'absolute', 'neutrophil', 'count', '<', 'or', '=2.0', 'x', '10', '(', '9', ')', 'cells/L', 'in', 'the', 'previous', 'cycle', ',', 'the', 'first', 'cycle', 'of', 'chemotherapy', ',', 'DOX', 'versus', 'PLD', 'and', 'advanced', 'age', '.']","(40, 42)","(218, 223)",-1,ss_o,18845996,Abstract,7,test,gold,2013.0
2746,"RESULTS Risk factors retained in the model included poor performance status , absolute neutrophil count < or =2.0 x 10 ( 9 ) cells/L in the previous cycle , the first cycle of chemotherapy ,",DOX,versus PLD and advanced age .,"['RESULTS', 'Risk', 'factors', 'retained', 'in', 'the', 'model', 'included', 'poor', 'performance', 'status', ',', 'absolute', 'neutrophil', 'count', '<', 'or', '=2.0', 'x', '10', '(', '9', ')', 'cells/L', 'in', 'the', 'previous', 'cycle', ',', 'the', 'first', 'cycle', 'of', 'chemotherapy', ',', 'DOX', 'versus', 'PLD', 'and', 'advanced', 'age', '.']","(35, 36)","(190, 193)",-1,hl_i,18845996,Abstract,7,test,gold,627.0
2747,"RESULTS Risk factors retained in the model included poor performance status , absolute neutrophil count < or =2.0 x 10 ( 9 ) cells/L in the previous cycle , the first cycle of chemotherapy , DOX versus",PLD,and advanced age .,"['RESULTS', 'Risk', 'factors', 'retained', 'in', 'the', 'model', 'included', 'poor', 'performance', 'status', ',', 'absolute', 'neutrophil', 'count', '<', 'or', '=2.0', 'x', '10', '(', '9', ')', 'cells/L', 'in', 'the', 'previous', 'cycle', ',', 'the', 'first', 'cycle', 'of', 'chemotherapy', ',', 'DOX', 'versus', 'PLD', 'and', 'advanced', 'age', '.']","(37, 38)","(201, 204)",-1,hl_i,18845996,Abstract,7,test,gold,495.0
2748,RESULTS Risk factors retained in the model included,"poor performance status , absolute neutrophil count < or =2.0 x 10 ( 9 ) cells/L","in the previous cycle , the first cycle of chemotherapy , DOX versus PLD and advanced age .","['RESULTS', 'Risk', 'factors', 'retained', 'in', 'the', 'model', 'included', 'poor', 'performance', 'status', ',', 'absolute', 'neutrophil', 'count', '<', 'or', '=2.0', 'x', '10', '(', '9', ')', 'cells/L', 'in', 'the', 'previous', 'cycle', ',', 'the', 'first', 'cycle', 'of', 'chemotherapy', ',', 'DOX', 'versus', 'PLD', 'and', 'advanced', 'age', '.']","(8, 24)","(51, 131)",-1,hl_o,18845996,Abstract,7,test,gold,6478.0
2749,"RESULTS Risk factors retained in the model included poor performance status , absolute neutrophil count < or =2.0 x 10 ( 9 ) cells/L in the previous cycle , the first cycle of chemotherapy , DOX versus PLD and advanced",age,.,"['RESULTS', 'Risk', 'factors', 'retained', 'in', 'the', 'model', 'included', 'poor', 'performance', 'status', ',', 'absolute', 'neutrophil', 'count', '<', 'or', '=2.0', 'x', '10', '(', '9', ')', 'cells/L', 'in', 'the', 'previous', 'cycle', ',', 'the', 'first', 'cycle', 'of', 'chemotherapy', ',', 'DOX', 'versus', 'PLD', 'and', 'advanced', 'age', '.']","(40, 41)","(218, 221)",-1,hl_o,18845996,Abstract,7,test,gold,2011.0
2750,A,precycle risk score,from > or =25 to < 40 for a given patient was identified as being the optimal threshold for sensitivity ( 58.0 % ) and specificity ( 78.7 % ) .,"['A', 'precycle', 'risk', 'score', 'from', '>', 'or', '=25', 'to', '<', '40', 'for', 'a', 'given', 'patient', 'was', 'identified', 'as', 'being', 'the', 'optimal', 'threshold', 'for', 'sensitivity', '(', '58.0', '%', ')', 'and', 'specificity', '(', '78.7', '%', ')', '.']","(1, 4)","(1, 20)",-1,ss_o,18845996,Abstract,8,test,gold,1437.0
2751,A,precycle risk score,from > or =25 to < 40 for a given patient was identified as being the optimal threshold for sensitivity ( 58.0 % ) and specificity ( 78.7 % ) .,"['A', 'precycle', 'risk', 'score', 'from', '>', 'or', '=25', 'to', '<', '40', 'for', 'a', 'given', 'patient', 'was', 'identified', 'as', 'being', 'the', 'optimal', 'threshold', 'for', 'sensitivity', '(', '58.0', '%', ')', 'and', 'specificity', '(', '78.7', '%', ')', '.']","(1, 4)","(1, 20)",-1,hl_o,18845996,Abstract,8,test,gold,1438.0
2752,Patients with a score at or beyond this threshold would be considered at high,risk,for developing NC in later cycles .,"['Patients', 'with', 'a', 'score', 'at', 'or', 'beyond', 'this', 'threshold', 'would', 'be', 'considered', 'at', 'high', 'risk', 'for', 'developing', 'NC', 'in', 'later', 'cycles', '.']","(14, 15)","(77, 81)",-1,ss_o,18845996,Abstract,9,test,gold,2498.0
2753,Patients with a score at or beyond this threshold would be considered at high risk for developing,NC,in later cycles .,"['Patients', 'with', 'a', 'score', 'at', 'or', 'beyond', 'this', 'threshold', 'would', 'be', 'considered', 'at', 'high', 'risk', 'for', 'developing', 'NC', 'in', 'later', 'cycles', '.']","(17, 18)","(97, 99)",-1,ss_o,18845996,Abstract,9,test,gold,635.0
2754,Patients with a score at or beyond this threshold would be considered at high,risk,for developing NC in later cycles .,"['Patients', 'with', 'a', 'score', 'at', 'or', 'beyond', 'this', 'threshold', 'would', 'be', 'considered', 'at', 'high', 'risk', 'for', 'developing', 'NC', 'in', 'later', 'cycles', '.']","(14, 15)","(77, 81)",-1,hl_o,18845996,Abstract,9,test,gold,2499.0
2755,"CONCLUSION The use of this model may enhance patient care by targeting preventative therapies ( eg , granulocyte colony stimulating factor or PLD ) to those",MBC patients,most likely to experience NC during anthracycline-based chemotherapy .,"['CONCLUSION', 'The', 'use', 'of', 'this', 'model', 'may', 'enhance', 'patient', 'care', 'by', 'targeting', 'preventative', 'therapies', '(', 'eg', ',', 'granulocyte', 'colony', 'stimulating', 'factor', 'or', 'PLD', ')', 'to', 'those', 'MBC', 'patients', 'most', 'likely', 'to', 'experience', 'NC', 'during', 'anthracycline-based', 'chemotherapy', '.']","(26, 28)","(156, 168)",-1,ss_p,18845996,Abstract,10,test,gold,3732.0
2756,"CONCLUSION The use of this model may enhance patient care by targeting preventative therapies ( eg , granulocyte colony stimulating factor or",PLD ),to those MBC patients most likely to experience NC during anthracycline-based chemotherapy .,"['CONCLUSION', 'The', 'use', 'of', 'this', 'model', 'may', 'enhance', 'patient', 'care', 'by', 'targeting', 'preventative', 'therapies', '(', 'eg', ',', 'granulocyte', 'colony', 'stimulating', 'factor', 'or', 'PLD', ')', 'to', 'those', 'MBC', 'patients', 'most', 'likely', 'to', 'experience', 'NC', 'during', 'anthracycline-based', 'chemotherapy', '.']","(22, 24)","(141, 146)",-1,ss_i,18845996,Abstract,10,test,gold,494.0
2757,"CONCLUSION The use of this model may enhance patient care by targeting preventative therapies ( eg , granulocyte colony stimulating factor or PLD ) to those MBC patients most likely to experience",NC,during anthracycline-based chemotherapy .,"['CONCLUSION', 'The', 'use', 'of', 'this', 'model', 'may', 'enhance', 'patient', 'care', 'by', 'targeting', 'preventative', 'therapies', '(', 'eg', ',', 'granulocyte', 'colony', 'stimulating', 'factor', 'or', 'PLD', ')', 'to', 'those', 'MBC', 'patients', 'most', 'likely', 'to', 'experience', 'NC', 'during', 'anthracycline-based', 'chemotherapy', '.']","(32, 33)","(195, 197)",-1,ss_o,18845996,Abstract,10,test,gold,634.0
2758,"CONCLUSION The use of this model may enhance patient care by targeting preventative therapies ( eg , granulocyte colony stimulating factor or PLD ) to those MBC",patients,most likely to experience NC during anthracycline-based chemotherapy .,"['CONCLUSION', 'The', 'use', 'of', 'this', 'model', 'may', 'enhance', 'patient', 'care', 'by', 'targeting', 'preventative', 'therapies', '(', 'eg', ',', 'granulocyte', 'colony', 'stimulating', 'factor', 'or', 'PLD', ')', 'to', 'those', 'MBC', 'patients', 'most', 'likely', 'to', 'experience', 'NC', 'during', 'anthracycline-based', 'chemotherapy', '.']","(27, 28)","(160, 168)",-1,hl_p,18845996,Abstract,10,test,gold,3747.0
2759,"CONCLUSION The use of this model may enhance patient care by targeting preventative therapies ( eg , granulocyte colony stimulating factor or PLD ) to those MBC patients most likely to experience",NC,during anthracycline-based chemotherapy .,"['CONCLUSION', 'The', 'use', 'of', 'this', 'model', 'may', 'enhance', 'patient', 'care', 'by', 'targeting', 'preventative', 'therapies', '(', 'eg', ',', 'granulocyte', 'colony', 'stimulating', 'factor', 'or', 'PLD', ')', 'to', 'those', 'MBC', 'patients', 'most', 'likely', 'to', 'experience', 'NC', 'during', 'anthracycline-based', 'chemotherapy', '.']","(32, 33)","(195, 197)",-1,hl_o,18845996,Abstract,10,test,gold,633.0
2760,,Neural basis of self and other representation,in autism : an FMRI study of self-face recognition .,"['Neural', 'basis', 'of', 'self', 'and', 'other', 'representation', 'in', 'autism', ':', 'an', 'FMRI', 'study', 'of', 'self-face', 'recognition', '.']","(0, 7)","(0, 45)",-1,ss_o,18958161,Title,0,test,gold,2920.0
2761,Neural basis of self and other representation in autism : an,FMRI,study of self-face recognition .,"['Neural', 'basis', 'of', 'self', 'and', 'other', 'representation', 'in', 'autism', ':', 'an', 'FMRI', 'study', 'of', 'self-face', 'recognition', '.']","(11, 12)","(60, 64)",-1,ss_o,18958161,Title,0,test,gold,1032.0
2762,Neural basis of self and other representation in autism : an FMRI study of,self-face recognition .,,"['Neural', 'basis', 'of', 'self', 'and', 'other', 'representation', 'in', 'autism', ':', 'an', 'FMRI', 'study', 'of', 'self-face', 'recognition', '.']","(14, 17)","(74, 97)",-1,ss_o,18958161,Title,0,test,gold,1376.0
2763,Neural basis of self and other representation in,autism,: an FMRI study of self-face recognition .,"['Neural', 'basis', 'of', 'self', 'and', 'other', 'representation', 'in', 'autism', ':', 'an', 'FMRI', 'study', 'of', 'self-face', 'recognition', '.']","(8, 9)","(48, 54)",-1,hl_p,18958161,Title,0,test,gold,6148.0
2764,Neural basis of self and other representation in autism : an FMRI study of,self-face recognition,.,"['Neural', 'basis', 'of', 'self', 'and', 'other', 'representation', 'in', 'autism', ':', 'an', 'FMRI', 'study', 'of', 'self-face', 'recognition', '.']","(14, 16)","(74, 95)",-1,hl_o,18958161,Title,0,test,gold,1377.0
2765,BACKGROUND Autism is a developmental disorder characterized by decreased interest and engagement in social interactions and by enhanced self-focus .,,,"['BACKGROUND', 'Autism', 'is', 'a', 'developmental', 'disorder', 'characterized', 'by', 'decreased', 'interest', 'and', 'engagement', 'in', 'social', 'interactions', 'and', 'by', 'enhanced', 'self-focus', '.']",,,,,18958161,Abstract,0,test,gold,
2766,"While previous theoretical approaches to understanding autism have emphasized social impairments and altered interpersonal interactions , there is a recent shift towards understanding the nature of the representation of the self in",individuals with autism spectrum disorders ( ASD ) .,,"['While', 'previous', 'theoretical', 'approaches', 'to', 'understanding', 'autism', 'have', 'emphasized', 'social', 'impairments', 'and', 'altered', 'interpersonal', 'interactions', ',', 'there', 'is', 'a', 'recent', 'shift', 'towards', 'understanding', 'the', 'nature', 'of', 'the', 'representation', 'of', 'the', 'self', 'in', 'individuals', 'with', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', '.']","(32, 41)","(231, 283)",-1,ss_p,18958161,Abstract,1,test,gold,6037.0
2767,"While previous theoretical approaches to understanding autism have emphasized social impairments and altered interpersonal interactions , there is a recent shift towards understanding the nature of the representation of the self in",individuals with autism spectrum disorders ( ASD ) .,,"['While', 'previous', 'theoretical', 'approaches', 'to', 'understanding', 'autism', 'have', 'emphasized', 'social', 'impairments', 'and', 'altered', 'interpersonal', 'interactions', ',', 'there', 'is', 'a', 'recent', 'shift', 'towards', 'understanding', 'the', 'nature', 'of', 'the', 'representation', 'of', 'the', 'self', 'in', 'individuals', 'with', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', '.']","(32, 41)","(231, 283)",-1,hl_p,18958161,Abstract,1,test,gold,6038.0
2768,"Still , the",neural mechanisms,subserving self-representations in ASD are relatively unexplored .,"['Still', ',', 'the', 'neural', 'mechanisms', 'subserving', 'self-representations', 'in', 'ASD', 'are', 'relatively', 'unexplored', '.']","(3, 5)","(11, 28)",-1,ss_o,18958161,Abstract,2,test,gold,2921.0
2769,METHODOLOGY/PRINCIPAL FINDINGS We used event-related fMRI to investigate brain responsiveness to,images of the subjects ' own face and to faces of others .,,"['METHODOLOGY/PRINCIPAL', 'FINDINGS', 'We', 'used', 'event-related', 'fMRI', 'to', 'investigate', 'brain', 'responsiveness', 'to', 'images', 'of', 'the', 'subjects', ""'"", 'own', 'face', 'and', 'to', 'faces', 'of', 'others', '.']","(11, 24)","(96, 154)",-1,ss_i,18958161,Abstract,3,test,gold,3705.0
2770,METHODOLOGY/PRINCIPAL FINDINGS We used event-related,fMRI,to investigate brain responsiveness to images of the subjects ' own face and to faces of others .,"['METHODOLOGY/PRINCIPAL', 'FINDINGS', 'We', 'used', 'event-related', 'fMRI', 'to', 'investigate', 'brain', 'responsiveness', 'to', 'images', 'of', 'the', 'subjects', ""'"", 'own', 'face', 'and', 'to', 'faces', 'of', 'others', '.']","(5, 6)","(52, 56)",-1,ss_o,18958161,Abstract,3,test,gold,2574.0
2771,METHODOLOGY/PRINCIPAL FINDINGS We used event-related fMRI to investigate,brain responsiveness to images of the subjects ' own face and to faces of others .,,"['METHODOLOGY/PRINCIPAL', 'FINDINGS', 'We', 'used', 'event-related', 'fMRI', 'to', 'investigate', 'brain', 'responsiveness', 'to', 'images', 'of', 'the', 'subjects', ""'"", 'own', 'face', 'and', 'to', 'faces', 'of', 'others', '.']","(8, 24)","(72, 154)",-1,ss_o,18958161,Abstract,3,test,gold,3706.0
2772,METHODOLOGY/PRINCIPAL FINDINGS We used event-related fMRI to investigate,brain responsiveness,to images of the subjects ' own face and to faces of others .,"['METHODOLOGY/PRINCIPAL', 'FINDINGS', 'We', 'used', 'event-related', 'fMRI', 'to', 'investigate', 'brain', 'responsiveness', 'to', 'images', 'of', 'the', 'subjects', ""'"", 'own', 'face', 'and', 'to', 'faces', 'of', 'others', '.']","(8, 10)","(72, 92)",-1,hl_o,18958161,Abstract,3,test,gold,2899.0
2773,,Children with ASD and typically developing ( TD ) children,"viewed randomly presented digital morphs between their own face and a gender-matched other face , and made "" self/other "" judgments .","['Children', 'with', 'ASD', 'and', 'typically', 'developing', '(', 'TD', ')', 'children', 'viewed', 'randomly', 'presented', 'digital', 'morphs', 'between', 'their', 'own', 'face', 'and', 'a', 'gender-matched', 'other', 'face', ',', 'and', 'made', '""', 'self/other', '""', 'judgments', '.']","(0, 10)","(0, 58)",-1,ss_p,18958161,Abstract,4,test,gold,6190.0
2774,Children with ASD and typically developing ( TD ) children viewed randomly presented digital morphs between,their own face and a gender-matched other face,", and made "" self/other "" judgments .","['Children', 'with', 'ASD', 'and', 'typically', 'developing', '(', 'TD', ')', 'children', 'viewed', 'randomly', 'presented', 'digital', 'morphs', 'between', 'their', 'own', 'face', 'and', 'a', 'gender-matched', 'other', 'face', ',', 'and', 'made', '""', 'self/other', '""', 'judgments', '.']","(16, 24)","(107, 153)",-1,ss_i,18958161,Abstract,4,test,gold,3703.0
2775,,Children,"with ASD and typically developing ( TD ) children viewed randomly presented digital morphs between their own face and a gender-matched other face , and made "" self/other "" judgments .","['Children', 'with', 'ASD', 'and', 'typically', 'developing', '(', 'TD', ')', 'children', 'viewed', 'randomly', 'presented', 'digital', 'morphs', 'between', 'their', 'own', 'face', 'and', 'a', 'gender-matched', 'other', 'face', ',', 'and', 'made', '""', 'self/other', '""', 'judgments', '.']","(0, 1)","(0, 8)",-1,hl_p,18958161,Abstract,4,test,gold,2175.0
2776,Children with,ASD and typically developing ( TD ) children,"viewed randomly presented digital morphs between their own face and a gender-matched other face , and made "" self/other "" judgments .","['Children', 'with', 'ASD', 'and', 'typically', 'developing', '(', 'TD', ')', 'children', 'viewed', 'randomly', 'presented', 'digital', 'morphs', 'between', 'their', 'own', 'face', 'and', 'a', 'gender-matched', 'other', 'face', ',', 'and', 'made', '""', 'self/other', '""', 'judgments', '.']","(2, 10)","(13, 57)",-1,hl_p,18958161,Abstract,4,test,gold,6191.0
2777,Children with ASD and typically developing ( TD ) children viewed randomly presented digital morphs between,their own face and a gender-matched other face,", and made "" self/other "" judgments .","['Children', 'with', 'ASD', 'and', 'typically', 'developing', '(', 'TD', ')', 'children', 'viewed', 'randomly', 'presented', 'digital', 'morphs', 'between', 'their', 'own', 'face', 'and', 'a', 'gender-matched', 'other', 'face', ',', 'and', 'made', '""', 'self/other', '""', 'judgments', '.']","(16, 24)","(107, 153)",-1,hl_i,18958161,Abstract,4,test,gold,3704.0
2778,Both groups of children activated a right premotor/prefrontal system when identifying,images,containing a greater percentage of the self face .,"['Both', 'groups', 'of', 'children', 'activated', 'a', 'right', 'premotor/prefrontal', 'system', 'when', 'identifying', 'images', 'containing', 'a', 'greater', 'percentage', 'of', 'the', 'self', 'face', '.']","(11, 12)","(85, 91)",-1,ss_i,18958161,Abstract,5,test,gold,1259.0
2779,Both groups of children activated a,right premotor/prefrontal system,when identifying images containing a greater percentage of the self face .,"['Both', 'groups', 'of', 'children', 'activated', 'a', 'right', 'premotor/prefrontal', 'system', 'when', 'identifying', 'images', 'containing', 'a', 'greater', 'percentage', 'of', 'the', 'self', 'face', '.']","(6, 9)","(35, 67)",-1,ss_o,18958161,Abstract,5,test,gold,1262.0
2780,Both groups of children activated a,right premotor/prefrontal system,when identifying images containing a greater percentage of the self face .,"['Both', 'groups', 'of', 'children', 'activated', 'a', 'right', 'premotor/prefrontal', 'system', 'when', 'identifying', 'images', 'containing', 'a', 'greater', 'percentage', 'of', 'the', 'self', 'face', '.']","(6, 9)","(35, 67)",-1,hl_o,18958161,Abstract,5,test,gold,1263.0
2781,"However , while TD children showed activation of this system during both",self- and other-processing,", children with ASD only recruited this system while viewing images containing mostly their own face .","['However', ',', 'while', 'TD', 'children', 'showed', 'activation', 'of', 'this', 'system', 'during', 'both', 'self-', 'and', 'other-processing', ',', 'children', 'with', 'ASD', 'only', 'recruited', 'this', 'system', 'while', 'viewing', 'images', 'containing', 'mostly', 'their', 'own', 'face', '.']","(12, 15)","(72, 98)",-1,ss_i,18958161,Abstract,6,test,gold,
2782,"However , while TD children showed activation of this system during both self- and other-processing , children with ASD only recruited this system while viewing",images,containing mostly their own face .,"['However', ',', 'while', 'TD', 'children', 'showed', 'activation', 'of', 'this', 'system', 'during', 'both', 'self-', 'and', 'other-processing', ',', 'children', 'with', 'ASD', 'only', 'recruited', 'this', 'system', 'while', 'viewing', 'images', 'containing', 'mostly', 'their', 'own', 'face', '.']","(25, 26)","(160, 166)",-1,ss_i,18958161,Abstract,6,test,gold,1260.0
2783,"However , while TD children showed activation of this",system,"during both self- and other-processing , children with ASD only recruited this system while viewing images containing mostly their own face .","['However', ',', 'while', 'TD', 'children', 'showed', 'activation', 'of', 'this', 'system', 'during', 'both', 'self-', 'and', 'other-processing', ',', 'children', 'with', 'ASD', 'only', 'recruited', 'this', 'system', 'while', 'viewing', 'images', 'containing', 'mostly', 'their', 'own', 'face', '.']","(9, 10)","(53, 59)",-1,ss_o,18958161,Abstract,6,test,gold,1261.0
2784,"CONCLUSIONS/SIGNIFICANCE This functional dissociation between the representation of self versus others points to a potential neural substrate for the characteristic self-focus and decreased social understanding exhibited by these individuals , and suggests that individuals with ASD lack the shared",neural representations for self and others,that TD children and adults possess and may use to understand others .,"['CONCLUSIONS/SIGNIFICANCE', 'This', 'functional', 'dissociation', 'between', 'the', 'representation', 'of', 'self', 'versus', 'others', 'points', 'to', 'a', 'potential', 'neural', 'substrate', 'for', 'the', 'characteristic', 'self-focus', 'and', 'decreased', 'social', 'understanding', 'exhibited', 'by', 'these', 'individuals', ',', 'and', 'suggests', 'that', 'individuals', 'with', 'ASD', 'lack', 'the', 'shared', 'neural', 'representations', 'for', 'self', 'and', 'others', 'that', 'TD', 'children', 'and', 'adults', 'possess', 'and', 'may', 'use', 'to', 'understand', 'others', '.']","(39, 45)","(298, 340)",-1,ss_o,18958161,Abstract,7,test,gold,2922.0
2785,Bolus injection of contrast agents with various iodine concentrations and delivery rates for intracranial three-dimensional CT angiography : evaluation of,intracranial arteriovenous contrast,using a multidetector-row CT scanner .,"['Bolus', 'injection', 'of', 'contrast', 'agents', 'with', 'various', 'iodine', 'concentrations', 'and', 'delivery', 'rates', 'for', 'intracranial', 'three-dimensional', 'CT', 'angiography', ':', 'evaluation', 'of', 'intracranial', 'arteriovenous', 'contrast', 'using', 'a', 'multidetector-row', 'CT', 'scanner', '.']","(20, 23)","(154, 189)",-1,ss_o,18975051,Title,0,test,gold,1779.0
2786,Bolus injection of contrast agents with various iodine concentrations and delivery rates for intracranial three-dimensional CT angiography : evaluation of,intracranial arteriovenous contrast,using a multidetector-row CT scanner .,"['Bolus', 'injection', 'of', 'contrast', 'agents', 'with', 'various', 'iodine', 'concentrations', 'and', 'delivery', 'rates', 'for', 'intracranial', 'three-dimensional', 'CT', 'angiography', ':', 'evaluation', 'of', 'intracranial', 'arteriovenous', 'contrast', 'using', 'a', 'multidetector-row', 'CT', 'scanner', '.']","(20, 23)","(154, 189)",-1,hl_o,18975051,Title,0,test,gold,1780.0
2787,PURPOSE We evaluated the,difference,in computed tomography ( CT ) attenuation values of the intracranial arterial and venous systems among the various contrast injection protocols ( higher iodine delivery rate or higher concentration of the agent ) on the source images of intracranial three-dimensional CT angiography ( 3D-CTA ) using a multidetector-row CT ( MDCT ) scanner .,"['PURPOSE', 'We', 'evaluated', 'the', 'difference', 'in', 'computed', 'tomography', '(', 'CT', ')', 'attenuation', 'values', 'of', 'the', 'intracranial', 'arterial', 'and', 'venous', 'systems', 'among', 'the', 'various', 'contrast', 'injection', 'protocols', '(', 'higher', 'iodine', 'delivery', 'rate', 'or', 'higher', 'concentration', 'of', 'the', 'agent', ')', 'on', 'the', 'source', 'images', 'of', 'intracranial', 'three-dimensional', 'CT', 'angiography', '(', '3D-CTA', ')', 'using', 'a', 'multidetector-row', 'CT', '(', 'MDCT', ')', 'scanner', '.']","(4, 5)","(24, 34)",-1,ss_o,18975051,Abstract,0,test,gold,971.0
2788,PURPOSE We evaluated the,difference,in computed tomography ( CT ) attenuation values of the intracranial arterial and venous systems among the various contrast injection protocols ( higher iodine delivery rate or higher concentration of the agent ) on the source images of intracranial three-dimensional CT angiography ( 3D-CTA ) using a multidetector-row CT ( MDCT ) scanner .,"['PURPOSE', 'We', 'evaluated', 'the', 'difference', 'in', 'computed', 'tomography', '(', 'CT', ')', 'attenuation', 'values', 'of', 'the', 'intracranial', 'arterial', 'and', 'venous', 'systems', 'among', 'the', 'various', 'contrast', 'injection', 'protocols', '(', 'higher', 'iodine', 'delivery', 'rate', 'or', 'higher', 'concentration', 'of', 'the', 'agent', ')', 'on', 'the', 'source', 'images', 'of', 'intracranial', 'three-dimensional', 'CT', 'angiography', '(', '3D-CTA', ')', 'using', 'a', 'multidetector-row', 'CT', '(', 'MDCT', ')', 'scanner', '.']","(4, 5)","(24, 34)",-1,hl_o,18975051,Abstract,0,test,gold,972.0
2789,MATERIALS AND METHODS We used 100 ml of,iopamidol,"300 at an injection rate of 3.0 ml/s , 100 ml of iopamidol 300 at an injection rate of 3.7 ml/s , and 80 ml of iopamidol 370 at an injection rate of 3.0 ml/s .","['MATERIALS', 'AND', 'METHODS', 'We', 'used', '100', 'ml', 'of', 'iopamidol', '300', 'at', 'an', 'injection', 'rate', 'of', '3.0', 'ml/s', ',', '100', 'ml', 'of', 'iopamidol', '300', 'at', 'an', 'injection', 'rate', 'of', '3.7', 'ml/s', ',', 'and', '80', 'ml', 'of', 'iopamidol', '370', 'at', 'an', 'injection', 'rate', 'of', '3.0', 'ml/s', '.']","(8, 9)","(39, 48)",-1,ss_i,18975051,Abstract,1,test,gold,
2790,"MATERIALS AND METHODS We used 100 ml of iopamidol 300 at an injection rate of 3.0 ml/s , 100 ml of",iopamidol,"300 at an injection rate of 3.7 ml/s , and 80 ml of iopamidol 370 at an injection rate of 3.0 ml/s .","['MATERIALS', 'AND', 'METHODS', 'We', 'used', '100', 'ml', 'of', 'iopamidol', '300', 'at', 'an', 'injection', 'rate', 'of', '3.0', 'ml/s', ',', '100', 'ml', 'of', 'iopamidol', '300', 'at', 'an', 'injection', 'rate', 'of', '3.7', 'ml/s', ',', 'and', '80', 'ml', 'of', 'iopamidol', '370', 'at', 'an', 'injection', 'rate', 'of', '3.0', 'ml/s', '.']","(21, 22)","(98, 107)",-1,ss_i,18975051,Abstract,1,test,gold,
2791,"MATERIALS AND METHODS We used 100 ml of iopamidol 300 at an injection rate of 3.0 ml/s , 100 ml of iopamidol 300 at an injection rate of 3.7 ml/s , and 80 ml of",iopamidol,370 at an injection rate of 3.0 ml/s .,"['MATERIALS', 'AND', 'METHODS', 'We', 'used', '100', 'ml', 'of', 'iopamidol', '300', 'at', 'an', 'injection', 'rate', 'of', '3.0', 'ml/s', ',', '100', 'ml', 'of', 'iopamidol', '300', 'at', 'an', 'injection', 'rate', 'of', '3.7', 'ml/s', ',', 'and', '80', 'ml', 'of', 'iopamidol', '370', 'at', 'an', 'injection', 'rate', 'of', '3.0', 'ml/s', '.']","(35, 36)","(160, 169)",-1,ss_i,18975051,Abstract,1,test,gold,
2792,MATERIALS AND METHODS We used 100 ml of,iopamidol,"300 at an injection rate of 3.0 ml/s , 100 ml of iopamidol 300 at an injection rate of 3.7 ml/s , and 80 ml of iopamidol 370 at an injection rate of 3.0 ml/s .","['MATERIALS', 'AND', 'METHODS', 'We', 'used', '100', 'ml', 'of', 'iopamidol', '300', 'at', 'an', 'injection', 'rate', 'of', '3.0', 'ml/s', ',', '100', 'ml', 'of', 'iopamidol', '300', 'at', 'an', 'injection', 'rate', 'of', '3.7', 'ml/s', ',', 'and', '80', 'ml', 'of', 'iopamidol', '370', 'at', 'an', 'injection', 'rate', 'of', '3.0', 'ml/s', '.']","(8, 9)","(39, 48)",-1,hl_i,18975051,Abstract,1,test,gold,
2793,"MATERIALS AND METHODS We used 100 ml of iopamidol 300 at an injection rate of 3.0 ml/s , 100 ml of",iopamidol,"300 at an injection rate of 3.7 ml/s , and 80 ml of iopamidol 370 at an injection rate of 3.0 ml/s .","['MATERIALS', 'AND', 'METHODS', 'We', 'used', '100', 'ml', 'of', 'iopamidol', '300', 'at', 'an', 'injection', 'rate', 'of', '3.0', 'ml/s', ',', '100', 'ml', 'of', 'iopamidol', '300', 'at', 'an', 'injection', 'rate', 'of', '3.7', 'ml/s', ',', 'and', '80', 'ml', 'of', 'iopamidol', '370', 'at', 'an', 'injection', 'rate', 'of', '3.0', 'ml/s', '.']","(21, 22)","(98, 107)",-1,hl_i,18975051,Abstract,1,test,gold,
2794,"MATERIALS AND METHODS We used 100 ml of iopamidol 300 at an injection rate of 3.0 ml/s , 100 ml of iopamidol 300 at an injection rate of 3.7 ml/s , and 80 ml of",iopamidol,370 at an injection rate of 3.0 ml/s .,"['MATERIALS', 'AND', 'METHODS', 'We', 'used', '100', 'ml', 'of', 'iopamidol', '300', 'at', 'an', 'injection', 'rate', 'of', '3.0', 'ml/s', ',', '100', 'ml', 'of', 'iopamidol', '300', 'at', 'an', 'injection', 'rate', 'of', '3.7', 'ml/s', ',', 'and', '80', 'ml', 'of', 'iopamidol', '370', 'at', 'an', 'injection', 'rate', 'of', '3.0', 'ml/s', '.']","(35, 36)","(160, 169)",-1,hl_i,18975051,Abstract,1,test,gold,
2795,There were,10 patients in each group .,,"['There', 'were', '10', 'patients', 'in', 'each', 'group', '.']","(2, 8)","(10, 37)",-1,ss_p,18975051,Abstract,2,test,gold,3873.0
2796,There were,10 patients in each group .,,"['There', 'were', '10', 'patients', 'in', 'each', 'group', '.']","(2, 8)","(10, 37)",-1,hl_p,18975051,Abstract,2,test,gold,3874.0
2797,,"Attenuation values of the bilateral internal carotid arteries ( ICAs ) , basilar artery trunk , bilateral cavernous sinuses ( CSs ) , and Galenic vein",were measured quantitatively on the axial CT angiographic source images obtained by four-channel MDCT .,"['Attenuation', 'values', 'of', 'the', 'bilateral', 'internal', 'carotid', 'arteries', '(', 'ICAs', ')', ',', 'basilar', 'artery', 'trunk', ',', 'bilateral', 'cavernous', 'sinuses', '(', 'CSs', ')', ',', 'and', 'Galenic', 'vein', 'were', 'measured', 'quantitatively', 'on', 'the', 'axial', 'CT', 'angiographic', 'source', 'images', 'obtained', 'by', 'four-channel', 'MDCT', '.']","(0, 26)","(0, 150)",-1,ss_o,18975051,Abstract,3,test,gold,5986.0
2798,"Attenuation values of the bilateral internal carotid arteries ( ICAs ) , basilar artery trunk , bilateral cavernous sinuses ( CSs ) , and Galenic vein were measured quantitatively on the axial CT angiographic source images obtained by",four-channel MDCT .,,"['Attenuation', 'values', 'of', 'the', 'bilateral', 'internal', 'carotid', 'arteries', '(', 'ICAs', ')', ',', 'basilar', 'artery', 'trunk', ',', 'bilateral', 'cavernous', 'sinuses', '(', 'CSs', ')', ',', 'and', 'Galenic', 'vein', 'were', 'measured', 'quantitatively', 'on', 'the', 'axial', 'CT', 'angiographic', 'source', 'images', 'obtained', 'by', 'four-channel', 'MDCT', '.']","(38, 41)","(234, 253)",-1,ss_o,18975051,Abstract,3,test,gold,76.0
2799,,"Attenuation values of the bilateral internal carotid arteries ( ICAs ) , basilar artery trunk , bilateral cavernous sinuses ( CSs ) , and Galenic vein",were measured quantitatively on the axial CT angiographic source images obtained by four-channel MDCT .,"['Attenuation', 'values', 'of', 'the', 'bilateral', 'internal', 'carotid', 'arteries', '(', 'ICAs', ')', ',', 'basilar', 'artery', 'trunk', ',', 'bilateral', 'cavernous', 'sinuses', '(', 'CSs', ')', ',', 'and', 'Galenic', 'vein', 'were', 'measured', 'quantitatively', 'on', 'the', 'axial', 'CT', 'angiographic', 'source', 'images', 'obtained', 'by', 'four-channel', 'MDCT', '.']","(0, 26)","(0, 150)",-1,hl_o,18975051,Abstract,3,test,gold,5987.0
2800,RESULTS Injection of the high-concentration contrast with a higher iodine-delivery rate achieved good,arteriovenous contrast at the cavernous portion .,,"['RESULTS', 'Injection', 'of', 'the', 'high-concentration', 'contrast', 'with', 'a', 'higher', 'iodine-delivery', 'rate', 'achieved', 'good', 'arteriovenous', 'contrast', 'at', 'the', 'cavernous', 'portion', '.']","(13, 20)","(101, 150)",-1,ss_o,18975051,Abstract,4,test,gold,1778.0
2801,RESULTS Injection of the high-concentration contrast with a higher iodine-delivery rate achieved good,arteriovenous contrast,at the cavernous portion .,"['RESULTS', 'Injection', 'of', 'the', 'high-concentration', 'contrast', 'with', 'a', 'higher', 'iodine-delivery', 'rate', 'achieved', 'good', 'arteriovenous', 'contrast', 'at', 'the', 'cavernous', 'portion', '.']","(13, 15)","(101, 123)",-1,hl_o,18975051,Abstract,4,test,gold,1781.0
2802,"With the same rate of iodine delivery , injection of the intermediate concentrate agent increased the",CT value,of not only the ICAs but also the CSs .,"['With', 'the', 'same', 'rate', 'of', 'iodine', 'delivery', ',', 'injection', 'of', 'the', 'intermediate', 'concentrate', 'agent', 'increased', 'the', 'CT', 'value', 'of', 'not', 'only', 'the', 'ICAs', 'but', 'also', 'the', 'CSs', '.']","(16, 18)","(101, 109)",-1,ss_o,18975051,Abstract,5,test,gold,1393.0
2803,"With the same rate of iodine delivery , injection of the intermediate concentrate agent increased the",CT value,of not only the ICAs but also the CSs .,"['With', 'the', 'same', 'rate', 'of', 'iodine', 'delivery', ',', 'injection', 'of', 'the', 'intermediate', 'concentrate', 'agent', 'increased', 'the', 'CT', 'value', 'of', 'not', 'only', 'the', 'ICAs', 'but', 'also', 'the', 'CSs', '.']","(16, 18)","(101, 109)",-1,hl_o,18975051,Abstract,5,test,gold,1394.0
2804,CONCLUSION High-concentration contrast could increase,ICA attenuation,"without intracavernous attenuation gain during the "" first-pass "" phase .","['CONCLUSION', 'High-concentration', 'contrast', 'could', 'increase', 'ICA', 'attenuation', 'without', 'intracavernous', 'attenuation', 'gain', 'during', 'the', '""', 'first-pass', '""', 'phase', '.']","(5, 7)","(53, 68)",-1,ss_o,18975051,Abstract,6,test,gold,1348.0
2805,CONCLUSION High-concentration contrast could increase ICA attenuation without,intracavernous attenuation,"gain during the "" first-pass "" phase .","['CONCLUSION', 'High-concentration', 'contrast', 'could', 'increase', 'ICA', 'attenuation', 'without', 'intracavernous', 'attenuation', 'gain', 'during', 'the', '""', 'first-pass', '""', 'phase', '.']","(8, 10)","(77, 103)",-1,ss_o,18975051,Abstract,6,test,gold,1346.0
2806,CONCLUSION High-concentration contrast could increase,ICA attenuation,"without intracavernous attenuation gain during the "" first-pass "" phase .","['CONCLUSION', 'High-concentration', 'contrast', 'could', 'increase', 'ICA', 'attenuation', 'without', 'intracavernous', 'attenuation', 'gain', 'during', 'the', '""', 'first-pass', '""', 'phase', '.']","(5, 7)","(53, 68)",-1,hl_o,18975051,Abstract,6,test,gold,1349.0
2807,CONCLUSION High-concentration contrast could increase ICA attenuation without,intracavernous attenuation,"gain during the "" first-pass "" phase .","['CONCLUSION', 'High-concentration', 'contrast', 'could', 'increase', 'ICA', 'attenuation', 'without', 'intracavernous', 'attenuation', 'gain', 'during', 'the', '""', 'first-pass', '""', 'phase', '.']","(8, 10)","(77, 103)",-1,hl_o,18975051,Abstract,6,test,gold,1347.0
2808,Trial design challenges when combining medication and parent training in,children with pervasive developmental disorders .,,"['Trial', 'design', 'challenges', 'when', 'combining', 'medication', 'and', 'parent', 'training', 'in', 'children', 'with', 'pervasive', 'developmental', 'disorders', '.']","(10, 16)","(72, 121)",-1,ss_p,19096921,Title,0,test,gold,6182.0
2809,Trial design challenges when combining,medication,and parent training in children with pervasive developmental disorders .,"['Trial', 'design', 'challenges', 'when', 'combining', 'medication', 'and', 'parent', 'training', 'in', 'children', 'with', 'pervasive', 'developmental', 'disorders', '.']","(5, 6)","(38, 48)",-1,ss_i,19096921,Title,0,test,gold,5072.0
2810,Trial design challenges when combining medication and,parent training,in children with pervasive developmental disorders .,"['Trial', 'design', 'challenges', 'when', 'combining', 'medication', 'and', 'parent', 'training', 'in', 'children', 'with', 'pervasive', 'developmental', 'disorders', '.']","(7, 9)","(53, 68)",-1,ss_i,19096921,Title,0,test,gold,2835.0
2811,Trial design challenges when combining medication and parent training in,children,with pervasive developmental disorders .,"['Trial', 'design', 'challenges', 'when', 'combining', 'medication', 'and', 'parent', 'training', 'in', 'children', 'with', 'pervasive', 'developmental', 'disorders', '.']","(10, 11)","(72, 80)",-1,hl_p,19096921,Title,0,test,gold,2134.0
2812,Trial design challenges when combining medication and parent training in children with,pervasive developmental disorders,.,"['Trial', 'design', 'challenges', 'when', 'combining', 'medication', 'and', 'parent', 'training', 'in', 'children', 'with', 'pervasive', 'developmental', 'disorders', '.']","(12, 15)","(86, 119)",-1,hl_p,19096921,Title,0,test,gold,6183.0
2813,Trial design challenges when combining,medication,and parent training in children with pervasive developmental disorders .,"['Trial', 'design', 'challenges', 'when', 'combining', 'medication', 'and', 'parent', 'training', 'in', 'children', 'with', 'pervasive', 'developmental', 'disorders', '.']","(5, 6)","(38, 48)",-1,hl_i,19096921,Title,0,test,gold,5073.0
2814,Trial design challenges when combining medication and,parent training,in children with pervasive developmental disorders .,"['Trial', 'design', 'challenges', 'when', 'combining', 'medication', 'and', 'parent', 'training', 'in', 'children', 'with', 'pervasive', 'developmental', 'disorders', '.']","(7, 9)","(53, 68)",-1,hl_i,19096921,Title,0,test,gold,2834.0
2815,"This paper presents the rationale for a 24-week , randomized trial designed to test whether",risperidone,"plus structured parent training would be superior to risperidone only on measures of noncompliance , irritability and adaptive functioning .","['This', 'paper', 'presents', 'the', 'rationale', 'for', 'a', '24-week', ',', 'randomized', 'trial', 'designed', 'to', 'test', 'whether', 'risperidone', 'plus', 'structured', 'parent', 'training', 'would', 'be', 'superior', 'to', 'risperidone', 'only', 'on', 'measures', 'of', 'noncompliance', ',', 'irritability', 'and', 'adaptive', 'functioning', '.']","(15, 16)","(91, 102)",-1,ss_i,19096921,Abstract,0,test,gold,5302.0
2816,"This paper presents the rationale for a 24-week , randomized trial designed to test whether risperidone plus",structured parent training,"would be superior to risperidone only on measures of noncompliance , irritability and adaptive functioning .","['This', 'paper', 'presents', 'the', 'rationale', 'for', 'a', '24-week', ',', 'randomized', 'trial', 'designed', 'to', 'test', 'whether', 'risperidone', 'plus', 'structured', 'parent', 'training', 'would', 'be', 'superior', 'to', 'risperidone', 'only', 'on', 'measures', 'of', 'noncompliance', ',', 'irritability', 'and', 'adaptive', 'functioning', '.']","(17, 20)","(108, 134)",-1,ss_i,19096921,Abstract,0,test,gold,2844.0
2817,"This paper presents the rationale for a 24-week , randomized trial designed to test whether risperidone plus structured parent training would be superior to",risperidone,"only on measures of noncompliance , irritability and adaptive functioning .","['This', 'paper', 'presents', 'the', 'rationale', 'for', 'a', '24-week', ',', 'randomized', 'trial', 'designed', 'to', 'test', 'whether', 'risperidone', 'plus', 'structured', 'parent', 'training', 'would', 'be', 'superior', 'to', 'risperidone', 'only', 'on', 'measures', 'of', 'noncompliance', ',', 'irritability', 'and', 'adaptive', 'functioning', '.']","(24, 25)","(156, 167)",-1,ss_i,19096921,Abstract,0,test,gold,5303.0
2818,"This paper presents the rationale for a 24-week , randomized trial designed to test whether risperidone plus structured parent training would be superior to risperidone only on measures of","noncompliance , irritability and adaptive functioning .",,"['This', 'paper', 'presents', 'the', 'rationale', 'for', 'a', '24-week', ',', 'randomized', 'trial', 'designed', 'to', 'test', 'whether', 'risperidone', 'plus', 'structured', 'parent', 'training', 'would', 'be', 'superior', 'to', 'risperidone', 'only', 'on', 'measures', 'of', 'noncompliance', ',', 'irritability', 'and', 'adaptive', 'functioning', '.']","(29, 36)","(188, 243)",-1,ss_o,19096921,Abstract,0,test,gold,2937.0
2819,"This paper presents the rationale for a 24-week , randomized trial designed to test whether",risperidone,"plus structured parent training would be superior to risperidone only on measures of noncompliance , irritability and adaptive functioning .","['This', 'paper', 'presents', 'the', 'rationale', 'for', 'a', '24-week', ',', 'randomized', 'trial', 'designed', 'to', 'test', 'whether', 'risperidone', 'plus', 'structured', 'parent', 'training', 'would', 'be', 'superior', 'to', 'risperidone', 'only', 'on', 'measures', 'of', 'noncompliance', ',', 'irritability', 'and', 'adaptive', 'functioning', '.']","(15, 16)","(91, 102)",-1,hl_i,19096921,Abstract,0,test,gold,5301.0
2820,"This paper presents the rationale for a 24-week , randomized trial designed to test whether risperidone plus",structured parent training,"would be superior to risperidone only on measures of noncompliance , irritability and adaptive functioning .","['This', 'paper', 'presents', 'the', 'rationale', 'for', 'a', '24-week', ',', 'randomized', 'trial', 'designed', 'to', 'test', 'whether', 'risperidone', 'plus', 'structured', 'parent', 'training', 'would', 'be', 'superior', 'to', 'risperidone', 'only', 'on', 'measures', 'of', 'noncompliance', ',', 'irritability', 'and', 'adaptive', 'functioning', '.']","(17, 20)","(108, 134)",-1,hl_i,19096921,Abstract,0,test,gold,2845.0
2821,"This paper presents the rationale for a 24-week , randomized trial designed to test whether risperidone plus structured parent training would be superior to",risperidone,"only on measures of noncompliance , irritability and adaptive functioning .","['This', 'paper', 'presents', 'the', 'rationale', 'for', 'a', '24-week', ',', 'randomized', 'trial', 'designed', 'to', 'test', 'whether', 'risperidone', 'plus', 'structured', 'parent', 'training', 'would', 'be', 'superior', 'to', 'risperidone', 'only', 'on', 'measures', 'of', 'noncompliance', ',', 'irritability', 'and', 'adaptive', 'functioning', '.']","(24, 25)","(156, 167)",-1,hl_i,19096921,Abstract,0,test,gold,5300.0
2822,"This paper presents the rationale for a 24-week , randomized trial designed to test whether risperidone plus structured parent training would be superior to risperidone only on measures of",noncompliance,", irritability and adaptive functioning .","['This', 'paper', 'presents', 'the', 'rationale', 'for', 'a', '24-week', ',', 'randomized', 'trial', 'designed', 'to', 'test', 'whether', 'risperidone', 'plus', 'structured', 'parent', 'training', 'would', 'be', 'superior', 'to', 'risperidone', 'only', 'on', 'measures', 'of', 'noncompliance', ',', 'irritability', 'and', 'adaptive', 'functioning', '.']","(29, 30)","(188, 201)",-1,hl_o,19096921,Abstract,0,test,gold,1390.0
2823,"This paper presents the rationale for a 24-week , randomized trial designed to test whether risperidone plus structured parent training would be superior to risperidone only on measures of noncompliance ,",irritability,and adaptive functioning .,"['This', 'paper', 'presents', 'the', 'rationale', 'for', 'a', '24-week', ',', 'randomized', 'trial', 'designed', 'to', 'test', 'whether', 'risperidone', 'plus', 'structured', 'parent', 'training', 'would', 'be', 'superior', 'to', 'risperidone', 'only', 'on', 'measures', 'of', 'noncompliance', ',', 'irritability', 'and', 'adaptive', 'functioning', '.']","(31, 32)","(204, 216)",-1,hl_o,19096921,Abstract,0,test,gold,2693.0
2824,"This paper presents the rationale for a 24-week , randomized trial designed to test whether risperidone plus structured parent training would be superior to risperidone only on measures of noncompliance , irritability and",adaptive functioning,.,"['This', 'paper', 'presents', 'the', 'rationale', 'for', 'a', '24-week', ',', 'randomized', 'trial', 'designed', 'to', 'test', 'whether', 'risperidone', 'plus', 'structured', 'parent', 'training', 'would', 'be', 'superior', 'to', 'risperidone', 'only', 'on', 'measures', 'of', 'noncompliance', ',', 'irritability', 'and', 'adaptive', 'functioning', '.']","(33, 35)","(221, 241)",-1,hl_o,19096921,Abstract,0,test,gold,2941.0
2825,"In this model , medication reduces","tantrums , aggression and self-injury ;",parent training promotes improvement in noncompliance and adaptive functioning .,"['In', 'this', 'model', ',', 'medication', 'reduces', 'tantrums', ',', 'aggression', 'and', 'self-injury', ';', 'parent', 'training', 'promotes', 'improvement', 'in', 'noncompliance', 'and', 'adaptive', 'functioning', '.']","(6, 12)","(34, 73)",-1,ss_o,19096921,Abstract,1,test,gold,2593.0
2826,"In this model , medication reduces tantrums , aggression and self-injury ; parent training promotes improvement in",noncompliance and adaptive functioning .,,"['In', 'this', 'model', ',', 'medication', 'reduces', 'tantrums', ',', 'aggression', 'and', 'self-injury', ';', 'parent', 'training', 'promotes', 'improvement', 'in', 'noncompliance', 'and', 'adaptive', 'functioning', '.']","(17, 22)","(114, 154)",-1,ss_o,19096921,Abstract,1,test,gold,2938.0
2827,"In this model , medication reduces",tantrums,", aggression and self-injury ; parent training promotes improvement in noncompliance and adaptive functioning .","['In', 'this', 'model', ',', 'medication', 'reduces', 'tantrums', ',', 'aggression', 'and', 'self-injury', ';', 'parent', 'training', 'promotes', 'improvement', 'in', 'noncompliance', 'and', 'adaptive', 'functioning', '.']","(6, 7)","(34, 42)",-1,hl_o,19096921,Abstract,1,test,gold,2594.0
2828,"In this model , medication reduces tantrums ,",aggression,and self-injury ; parent training promotes improvement in noncompliance and adaptive functioning .,"['In', 'this', 'model', ',', 'medication', 'reduces', 'tantrums', ',', 'aggression', 'and', 'self-injury', ';', 'parent', 'training', 'promotes', 'improvement', 'in', 'noncompliance', 'and', 'adaptive', 'functioning', '.']","(8, 9)","(45, 55)",-1,hl_o,19096921,Abstract,1,test,gold,2591.0
2829,"In this model , medication reduces tantrums , aggression and",self-injury,; parent training promotes improvement in noncompliance and adaptive functioning .,"['In', 'this', 'model', ',', 'medication', 'reduces', 'tantrums', ',', 'aggression', 'and', 'self-injury', ';', 'parent', 'training', 'promotes', 'improvement', 'in', 'noncompliance', 'and', 'adaptive', 'functioning', '.']","(10, 11)","(60, 71)",-1,hl_o,19096921,Abstract,1,test,gold,
2830,"In this model , medication reduces tantrums , aggression and self-injury ; parent training promotes improvement in",noncompliance and adaptive functioning .,,"['In', 'this', 'model', ',', 'medication', 'reduces', 'tantrums', ',', 'aggression', 'and', 'self-injury', ';', 'parent', 'training', 'promotes', 'improvement', 'in', 'noncompliance', 'and', 'adaptive', 'functioning', '.']","(17, 22)","(114, 154)",-1,hl_o,19096921,Abstract,1,test,gold,2939.0
2831,"Thus ,",medication,"and parent training target related , but separate , outcomes .","['Thus', ',', 'medication', 'and', 'parent', 'training', 'target', 'related', ',', 'but', 'separate', ',', 'outcomes', '.']","(2, 3)","(6, 16)",-1,ss_i,19096921,Abstract,2,test,gold,5071.0
2832,"Thus , medication and",parent training,"target related , but separate , outcomes .","['Thus', ',', 'medication', 'and', 'parent', 'training', 'target', 'related', ',', 'but', 'separate', ',', 'outcomes', '.']","(4, 6)","(21, 36)",-1,ss_i,19096921,Abstract,2,test,gold,2833.0
2833,"At week 24 , the",medication,was gradually withdrawn to determine whether subjects in the combined treatment group could be managed on a lower dose or off medication without relapse .,"['At', 'week', '24', ',', 'the', 'medication', 'was', 'gradually', 'withdrawn', 'to', 'determine', 'whether', 'subjects', 'in', 'the', 'combined', 'treatment', 'group', 'could', 'be', 'managed', 'on', 'a', 'lower', 'dose', 'or', 'off', 'medication', 'without', 'relapse', '.']","(5, 6)","(16, 26)",-1,ss_i,19096921,Abstract,3,test,gold,5070.0
2834,Both,symptom,reduction and functional improvement are important clinical treatment targets .,"['Both', 'symptom', 'reduction', 'and', 'functional', 'improvement', 'are', 'important', 'clinical', 'treatment', 'targets', '.']","(1, 2)","(4, 11)",-1,ss_o,19096921,Abstract,4,test,gold,3363.0
2835,Both symptom reduction and,functional,improvement are important clinical treatment targets .,"['Both', 'symptom', 'reduction', 'and', 'functional', 'improvement', 'are', 'important', 'clinical', 'treatment', 'targets', '.']","(4, 5)","(26, 36)",-1,ss_o,19096921,Abstract,4,test,gold,1364.0
2836,Both,symptom,reduction and functional improvement are important clinical treatment targets .,"['Both', 'symptom', 'reduction', 'and', 'functional', 'improvement', 'are', 'important', 'clinical', 'treatment', 'targets', '.']","(1, 2)","(4, 11)",-1,hl_o,19096921,Abstract,4,test,gold,3364.0
2837,Both symptom reduction and,functional,improvement are important clinical treatment targets .,"['Both', 'symptom', 'reduction', 'and', 'functional', 'improvement', 'are', 'important', 'clinical', 'treatment', 'targets', '.']","(4, 5)","(26, 36)",-1,hl_o,19096921,Abstract,4,test,gold,1365.0
2838,"Thus , experimental evidence on the beneficial",effects,of combining pharmacotherapy and exportable behavioral interventions is needed to guide clinical practice .,"['Thus', ',', 'experimental', 'evidence', 'on', 'the', 'beneficial', 'effects', 'of', 'combining', 'pharmacotherapy', 'and', 'exportable', 'behavioral', 'interventions', 'is', 'needed', 'to', 'guide', 'clinical', 'practice', '.']","(7, 8)","(46, 53)",-1,ss_o,19096921,Abstract,5,test,gold,2379.0
2839,"Comparison of propofol , droperidol , and metoclopramide for prophylaxis of postoperative nausea and vomiting after",breast cancer surgery :,"a prospective , randomized , double-blind , placebo-controlled study in Japanese patients .","['Comparison', 'of', 'propofol', ',', 'droperidol', ',', 'and', 'metoclopramide', 'for', 'prophylaxis', 'of', 'postoperative', 'nausea', 'and', 'vomiting', 'after', 'breast', 'cancer', 'surgery', ':', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'Japanese', 'patients', '.']","(16, 20)","(115, 138)",-1,ss_p,19108790,Title,0,test,gold,6874.0
2840,"Comparison of propofol , droperidol , and metoclopramide for prophylaxis of postoperative nausea and vomiting after breast cancer surgery : a prospective , randomized , double-blind , placebo-controlled study in",Japanese patients .,,"['Comparison', 'of', 'propofol', ',', 'droperidol', ',', 'and', 'metoclopramide', 'for', 'prophylaxis', 'of', 'postoperative', 'nausea', 'and', 'vomiting', 'after', 'breast', 'cancer', 'surgery', ':', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'Japanese', 'patients', '.']","(30, 33)","(211, 230)",-1,ss_p,19108790,Title,0,test,gold,2226.0
2841,Comparison of,"propofol , droperidol",", and metoclopramide for prophylaxis of postoperative nausea and vomiting after breast cancer surgery : a prospective , randomized , double-blind , placebo-controlled study in Japanese patients .","['Comparison', 'of', 'propofol', ',', 'droperidol', ',', 'and', 'metoclopramide', 'for', 'prophylaxis', 'of', 'postoperative', 'nausea', 'and', 'vomiting', 'after', 'breast', 'cancer', 'surgery', ':', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'Japanese', 'patients', '.']","(2, 5)","(13, 34)",-1,ss_i,19108790,Title,0,test,gold,4684.0
2842,"Comparison of propofol , droperidol , and",metoclopramide,"for prophylaxis of postoperative nausea and vomiting after breast cancer surgery : a prospective , randomized , double-blind , placebo-controlled study in Japanese patients .","['Comparison', 'of', 'propofol', ',', 'droperidol', ',', 'and', 'metoclopramide', 'for', 'prophylaxis', 'of', 'postoperative', 'nausea', 'and', 'vomiting', 'after', 'breast', 'cancer', 'surgery', ':', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'Japanese', 'patients', '.']","(7, 8)","(41, 55)",-1,ss_i,19108790,Title,0,test,gold,5324.0
2843,"Comparison of propofol , droperidol , and metoclopramide for",prophylaxis of postoperative nausea and vomiting,"after breast cancer surgery : a prospective , randomized , double-blind , placebo-controlled study in Japanese patients .","['Comparison', 'of', 'propofol', ',', 'droperidol', ',', 'and', 'metoclopramide', 'for', 'prophylaxis', 'of', 'postoperative', 'nausea', 'and', 'vomiting', 'after', 'breast', 'cancer', 'surgery', ':', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'Japanese', 'patients', '.']","(9, 15)","(60, 108)",-1,ss_o,19108790,Title,0,test,gold,7132.0
2844,"Comparison of propofol , droperidol , and metoclopramide for prophylaxis of postoperative nausea and vomiting after",breast cancer surgery :,"a prospective , randomized , double-blind , placebo-controlled study in Japanese patients .","['Comparison', 'of', 'propofol', ',', 'droperidol', ',', 'and', 'metoclopramide', 'for', 'prophylaxis', 'of', 'postoperative', 'nausea', 'and', 'vomiting', 'after', 'breast', 'cancer', 'surgery', ':', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'Japanese', 'patients', '.']","(16, 20)","(115, 138)",-1,hl_p,19108790,Title,0,test,gold,6875.0
2845,"Comparison of propofol , droperidol , and metoclopramide for prophylaxis of postoperative nausea and vomiting after breast cancer surgery : a prospective , randomized , double-blind , placebo-controlled study in",Japanese patients .,,"['Comparison', 'of', 'propofol', ',', 'droperidol', ',', 'and', 'metoclopramide', 'for', 'prophylaxis', 'of', 'postoperative', 'nausea', 'and', 'vomiting', 'after', 'breast', 'cancer', 'surgery', ':', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'Japanese', 'patients', '.']","(30, 33)","(211, 230)",-1,hl_p,19108790,Title,0,test,gold,2227.0
2846,Comparison of,propofol,", droperidol , and metoclopramide for prophylaxis of postoperative nausea and vomiting after breast cancer surgery : a prospective , randomized , double-blind , placebo-controlled study in Japanese patients .","['Comparison', 'of', 'propofol', ',', 'droperidol', ',', 'and', 'metoclopramide', 'for', 'prophylaxis', 'of', 'postoperative', 'nausea', 'and', 'vomiting', 'after', 'breast', 'cancer', 'surgery', ':', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'Japanese', 'patients', '.']","(2, 3)","(13, 21)",-1,hl_i,19108790,Title,0,test,gold,4715.0
2847,"Comparison of propofol ,",droperidol,", and metoclopramide for prophylaxis of postoperative nausea and vomiting after breast cancer surgery : a prospective , randomized , double-blind , placebo-controlled study in Japanese patients .","['Comparison', 'of', 'propofol', ',', 'droperidol', ',', 'and', 'metoclopramide', 'for', 'prophylaxis', 'of', 'postoperative', 'nausea', 'and', 'vomiting', 'after', 'breast', 'cancer', 'surgery', ':', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'Japanese', 'patients', '.']","(4, 5)","(24, 34)",-1,hl_i,19108790,Title,0,test,gold,48.0
2848,"Comparison of propofol , droperidol , and",metoclopramide,"for prophylaxis of postoperative nausea and vomiting after breast cancer surgery : a prospective , randomized , double-blind , placebo-controlled study in Japanese patients .","['Comparison', 'of', 'propofol', ',', 'droperidol', ',', 'and', 'metoclopramide', 'for', 'prophylaxis', 'of', 'postoperative', 'nausea', 'and', 'vomiting', 'after', 'breast', 'cancer', 'surgery', ':', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'Japanese', 'patients', '.']","(7, 8)","(41, 55)",-1,hl_i,19108790,Title,0,test,gold,5325.0
2849,"Comparison of propofol , droperidol , and metoclopramide for prophylaxis of",postoperative nausea and vomiting,"after breast cancer surgery : a prospective , randomized , double-blind , placebo-controlled study in Japanese patients .","['Comparison', 'of', 'propofol', ',', 'droperidol', ',', 'and', 'metoclopramide', 'for', 'prophylaxis', 'of', 'postoperative', 'nausea', 'and', 'vomiting', 'after', 'breast', 'cancer', 'surgery', ':', 'a', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'Japanese', 'patients', '.']","(11, 15)","(75, 108)",-1,hl_o,19108790,Title,0,test,gold,7133.0
2850,BACKGROUND Breast cancer surgery performed with the patient under general anesthesia has been associated with a relatively high,incidence of postoperative nausea and vomiting ( PONV ) .,,"['BACKGROUND', 'Breast', 'cancer', 'surgery', 'performed', 'with', 'the', 'patient', 'under', 'general', 'anesthesia', 'has', 'been', 'associated', 'with', 'a', 'relatively', 'high', 'incidence', 'of', 'postoperative', 'nausea', 'and', 'vomiting', '(', 'PONV', ')', '.']","(18, 28)","(127, 184)",-1,ss_o,19108790,Abstract,0,test,gold,7131.0
2851,BACKGROUND Breast cancer surgery performed with the patient under general anesthesia has been associated with a relatively high incidence of,postoperative nausea and vomiting ( PONV ),.,"['BACKGROUND', 'Breast', 'cancer', 'surgery', 'performed', 'with', 'the', 'patient', 'under', 'general', 'anesthesia', 'has', 'been', 'associated', 'with', 'a', 'relatively', 'high', 'incidence', 'of', 'postoperative', 'nausea', 'and', 'vomiting', '(', 'PONV', ')', '.']","(20, 27)","(140, 182)",-1,hl_o,19108790,Abstract,0,test,gold,7134.0
2852,Between 60 % and 80 % of patients who undergo mastectomy ( with axillary dissection ) experience,PONV .,,"['Between', '60', '%', 'and', '80', '%', 'of', 'patients', 'who', 'undergo', 'mastectomy', '(', 'with', 'axillary', 'dissection', ')', 'experience', 'PONV', '.']","(17, 19)","(96, 102)",-1,ss_o,19108790,Abstract,1,test,gold,3416.0
2853,Between 60 % and 80 % of patients who undergo mastectomy ( with axillary dissection ) experience,PONV .,,"['Between', '60', '%', 'and', '80', '%', 'of', 'patients', 'who', 'undergo', 'mastectomy', '(', 'with', 'axillary', 'dissection', ')', 'experience', 'PONV', '.']","(17, 19)","(96, 102)",-1,hl_o,19108790,Abstract,1,test,gold,3417.0
2854,We previously reported that,propofol,at a subhypnotic dose of 0.5 mg/kg was more effective than placebo in preventing PONV in women who undergo mastectomy .,"['We', 'previously', 'reported', 'that', 'propofol', 'at', 'a', 'subhypnotic', 'dose', 'of', '0.5', 'mg/kg', 'was', 'more', 'effective', 'than', 'placebo', 'in', 'preventing', 'PONV', 'in', 'women', 'who', 'undergo', 'mastectomy', '.']","(4, 5)","(27, 35)",-1,ss_i,19108790,Abstract,2,test,gold,4714.0
2855,We previously reported that propofol at a subhypnotic dose of 0.5 mg/kg was more effective than,placebo,in preventing PONV in women who undergo mastectomy .,"['We', 'previously', 'reported', 'that', 'propofol', 'at', 'a', 'subhypnotic', 'dose', 'of', '0.5', 'mg/kg', 'was', 'more', 'effective', 'than', 'placebo', 'in', 'preventing', 'PONV', 'in', 'women', 'who', 'undergo', 'mastectomy', '.']","(16, 17)","(95, 102)",-1,ss_i,19108790,Abstract,2,test,gold,4383.0
2856,We previously reported that propofol at a subhypnotic dose of 0.5 mg/kg was more effective than placebo in preventing,PONV,in women who undergo mastectomy .,"['We', 'previously', 'reported', 'that', 'propofol', 'at', 'a', 'subhypnotic', 'dose', 'of', '0.5', 'mg/kg', 'was', 'more', 'effective', 'than', 'placebo', 'in', 'preventing', 'PONV', 'in', 'women', 'who', 'undergo', 'mastectomy', '.']","(19, 20)","(117, 121)",-1,ss_o,19108790,Abstract,2,test,gold,3415.0
2857,We previously reported that,propofol,at a subhypnotic dose of 0.5 mg/kg was more effective than placebo in preventing PONV in women who undergo mastectomy .,"['We', 'previously', 'reported', 'that', 'propofol', 'at', 'a', 'subhypnotic', 'dose', 'of', '0.5', 'mg/kg', 'was', 'more', 'effective', 'than', 'placebo', 'in', 'preventing', 'PONV', 'in', 'women', 'who', 'undergo', 'mastectomy', '.']","(4, 5)","(27, 35)",-1,hl_i,19108790,Abstract,2,test,gold,4713.0
2858,We previously reported that propofol at a subhypnotic dose of 0.5 mg/kg was more effective than,placebo,in preventing PONV in women who undergo mastectomy .,"['We', 'previously', 'reported', 'that', 'propofol', 'at', 'a', 'subhypnotic', 'dose', 'of', '0.5', 'mg/kg', 'was', 'more', 'effective', 'than', 'placebo', 'in', 'preventing', 'PONV', 'in', 'women', 'who', 'undergo', 'mastectomy', '.']","(16, 17)","(95, 102)",-1,hl_i,19108790,Abstract,2,test,gold,4382.0
2859,We previously reported that propofol at a subhypnotic dose of 0.5 mg/kg was more effective than placebo in preventing,PONV,in women who undergo mastectomy .,"['We', 'previously', 'reported', 'that', 'propofol', 'at', 'a', 'subhypnotic', 'dose', 'of', '0.5', 'mg/kg', 'was', 'more', 'effective', 'than', 'placebo', 'in', 'preventing', 'PONV', 'in', 'women', 'who', 'undergo', 'mastectomy', '.']","(19, 20)","(117, 121)",-1,hl_o,19108790,Abstract,2,test,gold,3414.0
2860,OBJECTIVE The purpose of this study was to compare the efficacy of a subhypnotic dose of propofol with the conventional antiemetics droperidol and metoclopramide for the prophylaxis of PONV after,breast cancer surgery in Japanese patients .,,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'of', 'a', 'subhypnotic', 'dose', 'of', 'propofol', 'with', 'the', 'conventional', 'antiemetics', 'droperidol', 'and', 'metoclopramide', 'for', 'the', 'prophylaxis', 'of', 'PONV', 'after', 'breast', 'cancer', 'surgery', 'in', 'Japanese', 'patients', '.']","(30, 37)","(195, 239)",-1,ss_p,19108790,Abstract,3,test,gold,6824.0
2861,OBJECTIVE The purpose of this study was to compare the efficacy of a subhypnotic dose of,propofol,with the conventional antiemetics droperidol and metoclopramide for the prophylaxis of PONV after breast cancer surgery in Japanese patients .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'of', 'a', 'subhypnotic', 'dose', 'of', 'propofol', 'with', 'the', 'conventional', 'antiemetics', 'droperidol', 'and', 'metoclopramide', 'for', 'the', 'prophylaxis', 'of', 'PONV', 'after', 'breast', 'cancer', 'surgery', 'in', 'Japanese', 'patients', '.']","(16, 17)","(88, 96)",-1,ss_i,19108790,Abstract,3,test,gold,4712.0
2862,OBJECTIVE The purpose of this study was to compare the efficacy of a subhypnotic dose of propofol with the conventional antiemetics,droperidol,and metoclopramide for the prophylaxis of PONV after breast cancer surgery in Japanese patients .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'of', 'a', 'subhypnotic', 'dose', 'of', 'propofol', 'with', 'the', 'conventional', 'antiemetics', 'droperidol', 'and', 'metoclopramide', 'for', 'the', 'prophylaxis', 'of', 'PONV', 'after', 'breast', 'cancer', 'surgery', 'in', 'Japanese', 'patients', '.']","(21, 22)","(131, 141)",-1,ss_i,19108790,Abstract,3,test,gold,49.0
2863,OBJECTIVE The purpose of this study was to compare the efficacy of a subhypnotic dose of propofol with the conventional antiemetics droperidol and,metoclopramide,for the prophylaxis of PONV after breast cancer surgery in Japanese patients .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'of', 'a', 'subhypnotic', 'dose', 'of', 'propofol', 'with', 'the', 'conventional', 'antiemetics', 'droperidol', 'and', 'metoclopramide', 'for', 'the', 'prophylaxis', 'of', 'PONV', 'after', 'breast', 'cancer', 'surgery', 'in', 'Japanese', 'patients', '.']","(23, 24)","(146, 160)",-1,ss_i,19108790,Abstract,3,test,gold,5323.0
2864,OBJECTIVE The purpose of this study was to compare the,efficacy,of a subhypnotic dose of propofol with the conventional antiemetics droperidol and metoclopramide for the prophylaxis of PONV after breast cancer surgery in Japanese patients .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'of', 'a', 'subhypnotic', 'dose', 'of', 'propofol', 'with', 'the', 'conventional', 'antiemetics', 'droperidol', 'and', 'metoclopramide', 'for', 'the', 'prophylaxis', 'of', 'PONV', 'after', 'breast', 'cancer', 'surgery', 'in', 'Japanese', 'patients', '.']","(10, 11)","(54, 62)",-1,ss_o,19108790,Abstract,3,test,gold,4820.0
2865,OBJECTIVE The purpose of this study was to compare the efficacy of a subhypnotic dose of propofol with the conventional antiemetics droperidol and metoclopramide for the,prophylaxis of PONV,after breast cancer surgery in Japanese patients .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'of', 'a', 'subhypnotic', 'dose', 'of', 'propofol', 'with', 'the', 'conventional', 'antiemetics', 'droperidol', 'and', 'metoclopramide', 'for', 'the', 'prophylaxis', 'of', 'PONV', 'after', 'breast', 'cancer', 'surgery', 'in', 'Japanese', 'patients', '.']","(26, 29)","(169, 188)",-1,ss_o,19108790,Abstract,3,test,gold,3418.0
2866,OBJECTIVE The purpose of this study was to compare the efficacy of a subhypnotic dose of propofol with the conventional antiemetics droperidol and metoclopramide for the prophylaxis of PONV after,breast cancer surgery in Japanese patients .,,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'of', 'a', 'subhypnotic', 'dose', 'of', 'propofol', 'with', 'the', 'conventional', 'antiemetics', 'droperidol', 'and', 'metoclopramide', 'for', 'the', 'prophylaxis', 'of', 'PONV', 'after', 'breast', 'cancer', 'surgery', 'in', 'Japanese', 'patients', '.']","(30, 37)","(195, 239)",-1,hl_p,19108790,Abstract,3,test,gold,6825.0
2867,OBJECTIVE The purpose of this study was to compare the efficacy of a subhypnotic dose of,propofol,with the conventional antiemetics droperidol and metoclopramide for the prophylaxis of PONV after breast cancer surgery in Japanese patients .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'of', 'a', 'subhypnotic', 'dose', 'of', 'propofol', 'with', 'the', 'conventional', 'antiemetics', 'droperidol', 'and', 'metoclopramide', 'for', 'the', 'prophylaxis', 'of', 'PONV', 'after', 'breast', 'cancer', 'surgery', 'in', 'Japanese', 'patients', '.']","(16, 17)","(88, 96)",-1,hl_i,19108790,Abstract,3,test,gold,4711.0
2868,OBJECTIVE The purpose of this study was to compare the efficacy of a subhypnotic dose of propofol with the conventional antiemetics,droperidol,and metoclopramide for the prophylaxis of PONV after breast cancer surgery in Japanese patients .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'of', 'a', 'subhypnotic', 'dose', 'of', 'propofol', 'with', 'the', 'conventional', 'antiemetics', 'droperidol', 'and', 'metoclopramide', 'for', 'the', 'prophylaxis', 'of', 'PONV', 'after', 'breast', 'cancer', 'surgery', 'in', 'Japanese', 'patients', '.']","(21, 22)","(131, 141)",-1,hl_i,19108790,Abstract,3,test,gold,47.0
2869,OBJECTIVE The purpose of this study was to compare the efficacy of a subhypnotic dose of propofol with the conventional antiemetics droperidol and,metoclopramide,for the prophylaxis of PONV after breast cancer surgery in Japanese patients .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'of', 'a', 'subhypnotic', 'dose', 'of', 'propofol', 'with', 'the', 'conventional', 'antiemetics', 'droperidol', 'and', 'metoclopramide', 'for', 'the', 'prophylaxis', 'of', 'PONV', 'after', 'breast', 'cancer', 'surgery', 'in', 'Japanese', 'patients', '.']","(23, 24)","(146, 160)",-1,hl_i,19108790,Abstract,3,test,gold,5322.0
2870,OBJECTIVE The purpose of this study was to compare the,efficacy,of a subhypnotic dose of propofol with the conventional antiemetics droperidol and metoclopramide for the prophylaxis of PONV after breast cancer surgery in Japanese patients .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'of', 'a', 'subhypnotic', 'dose', 'of', 'propofol', 'with', 'the', 'conventional', 'antiemetics', 'droperidol', 'and', 'metoclopramide', 'for', 'the', 'prophylaxis', 'of', 'PONV', 'after', 'breast', 'cancer', 'surgery', 'in', 'Japanese', 'patients', '.']","(10, 11)","(54, 62)",-1,hl_o,19108790,Abstract,3,test,gold,4819.0
2871,OBJECTIVE The purpose of this study was to compare the efficacy of a subhypnotic dose of propofol with the conventional antiemetics droperidol and metoclopramide for the prophylaxis of,PONV,after breast cancer surgery in Japanese patients .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'of', 'a', 'subhypnotic', 'dose', 'of', 'propofol', 'with', 'the', 'conventional', 'antiemetics', 'droperidol', 'and', 'metoclopramide', 'for', 'the', 'prophylaxis', 'of', 'PONV', 'after', 'breast', 'cancer', 'surgery', 'in', 'Japanese', 'patients', '.']","(28, 29)","(184, 188)",-1,hl_o,19108790,Abstract,3,test,gold,3413.0
2872,"METHODS In this prospective , randomized , double-blind , placebo-controlled study ,",Japanese women,"were randomized to 1 of 4 groups to receive IV administration of propofol 0.5 mg/kg , droperidol 20 microg/kg , metoclopramide 0.2 mg/kg , or placebo ( isotonic saline ) immediately after skin suture .","['METHODS', 'In', 'this', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', ',', 'Japanese', 'women', 'were', 'randomized', 'to', '1', 'of', '4', 'groups', 'to', 'receive', 'IV', 'administration', 'of', 'propofol', '0.5', 'mg/kg', ',', 'droperidol', '20', 'microg/kg', ',', 'metoclopramide', '0.2', 'mg/kg', ',', 'or', 'placebo', '(', 'isotonic', 'saline', ')', 'immediately', 'after', 'skin', 'suture', '.']","(12, 14)","(84, 98)",-1,ss_p,19108790,Abstract,4,test,gold,2230.0
2873,"METHODS In this prospective , randomized , double-blind , placebo-controlled study , Japanese women were randomized to 1 of 4 groups to receive IV administration of",propofol,"0.5 mg/kg , droperidol 20 microg/kg , metoclopramide 0.2 mg/kg , or placebo ( isotonic saline ) immediately after skin suture .","['METHODS', 'In', 'this', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', ',', 'Japanese', 'women', 'were', 'randomized', 'to', '1', 'of', '4', 'groups', 'to', 'receive', 'IV', 'administration', 'of', 'propofol', '0.5', 'mg/kg', ',', 'droperidol', '20', 'microg/kg', ',', 'metoclopramide', '0.2', 'mg/kg', ',', 'or', 'placebo', '(', 'isotonic', 'saline', ')', 'immediately', 'after', 'skin', 'suture', '.']","(26, 27)","(164, 172)",-1,ss_i,19108790,Abstract,4,test,gold,4710.0
2874,"METHODS In this prospective , randomized , double-blind , placebo-controlled study , Japanese women were randomized to 1 of 4 groups to receive IV administration of propofol 0.5 mg/kg ,",droperidol,"20 microg/kg , metoclopramide 0.2 mg/kg , or placebo ( isotonic saline ) immediately after skin suture .","['METHODS', 'In', 'this', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', ',', 'Japanese', 'women', 'were', 'randomized', 'to', '1', 'of', '4', 'groups', 'to', 'receive', 'IV', 'administration', 'of', 'propofol', '0.5', 'mg/kg', ',', 'droperidol', '20', 'microg/kg', ',', 'metoclopramide', '0.2', 'mg/kg', ',', 'or', 'placebo', '(', 'isotonic', 'saline', ')', 'immediately', 'after', 'skin', 'suture', '.']","(30, 31)","(185, 195)",-1,ss_i,19108790,Abstract,4,test,gold,46.0
2875,"METHODS In this prospective , randomized , double-blind , placebo-controlled study , Japanese women were randomized to 1 of 4 groups to receive IV administration of propofol 0.5 mg/kg , droperidol 20 microg/kg ,",metoclopramide,"0.2 mg/kg , or placebo ( isotonic saline ) immediately after skin suture .","['METHODS', 'In', 'this', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', ',', 'Japanese', 'women', 'were', 'randomized', 'to', '1', 'of', '4', 'groups', 'to', 'receive', 'IV', 'administration', 'of', 'propofol', '0.5', 'mg/kg', ',', 'droperidol', '20', 'microg/kg', ',', 'metoclopramide', '0.2', 'mg/kg', ',', 'or', 'placebo', '(', 'isotonic', 'saline', ')', 'immediately', 'after', 'skin', 'suture', '.']","(34, 35)","(211, 225)",-1,ss_i,19108790,Abstract,4,test,gold,5321.0
2876,"METHODS In this prospective , randomized , double-blind , placebo-controlled study , Japanese women were randomized to 1 of 4 groups to receive IV administration of propofol 0.5 mg/kg , droperidol 20 microg/kg , metoclopramide 0.2 mg/kg , or",placebo ( isotonic saline ),immediately after skin suture .,"['METHODS', 'In', 'this', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', ',', 'Japanese', 'women', 'were', 'randomized', 'to', '1', 'of', '4', 'groups', 'to', 'receive', 'IV', 'administration', 'of', 'propofol', '0.5', 'mg/kg', ',', 'droperidol', '20', 'microg/kg', ',', 'metoclopramide', '0.2', 'mg/kg', ',', 'or', 'placebo', '(', 'isotonic', 'saline', ')', 'immediately', 'after', 'skin', 'suture', '.']","(39, 44)","(241, 268)",-1,ss_i,19108790,Abstract,4,test,gold,4434.0
2877,"METHODS In this prospective , randomized , double-blind , placebo-controlled study ,",Japanese women,"were randomized to 1 of 4 groups to receive IV administration of propofol 0.5 mg/kg , droperidol 20 microg/kg , metoclopramide 0.2 mg/kg , or placebo ( isotonic saline ) immediately after skin suture .","['METHODS', 'In', 'this', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', ',', 'Japanese', 'women', 'were', 'randomized', 'to', '1', 'of', '4', 'groups', 'to', 'receive', 'IV', 'administration', 'of', 'propofol', '0.5', 'mg/kg', ',', 'droperidol', '20', 'microg/kg', ',', 'metoclopramide', '0.2', 'mg/kg', ',', 'or', 'placebo', '(', 'isotonic', 'saline', ')', 'immediately', 'after', 'skin', 'suture', '.']","(12, 14)","(84, 98)",-1,hl_p,19108790,Abstract,4,test,gold,2231.0
2878,"METHODS In this prospective , randomized , double-blind , placebo-controlled study , Japanese women were randomized to 1 of 4 groups to receive IV administration of",propofol,"0.5 mg/kg , droperidol 20 microg/kg , metoclopramide 0.2 mg/kg , or placebo ( isotonic saline ) immediately after skin suture .","['METHODS', 'In', 'this', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', ',', 'Japanese', 'women', 'were', 'randomized', 'to', '1', 'of', '4', 'groups', 'to', 'receive', 'IV', 'administration', 'of', 'propofol', '0.5', 'mg/kg', ',', 'droperidol', '20', 'microg/kg', ',', 'metoclopramide', '0.2', 'mg/kg', ',', 'or', 'placebo', '(', 'isotonic', 'saline', ')', 'immediately', 'after', 'skin', 'suture', '.']","(26, 27)","(164, 172)",-1,hl_i,19108790,Abstract,4,test,gold,4709.0
2879,"METHODS In this prospective , randomized , double-blind , placebo-controlled study , Japanese women were randomized to 1 of 4 groups to receive IV administration of propofol 0.5 mg/kg ,",droperidol,"20 microg/kg , metoclopramide 0.2 mg/kg , or placebo ( isotonic saline ) immediately after skin suture .","['METHODS', 'In', 'this', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', ',', 'Japanese', 'women', 'were', 'randomized', 'to', '1', 'of', '4', 'groups', 'to', 'receive', 'IV', 'administration', 'of', 'propofol', '0.5', 'mg/kg', ',', 'droperidol', '20', 'microg/kg', ',', 'metoclopramide', '0.2', 'mg/kg', ',', 'or', 'placebo', '(', 'isotonic', 'saline', ')', 'immediately', 'after', 'skin', 'suture', '.']","(30, 31)","(185, 195)",-1,hl_i,19108790,Abstract,4,test,gold,45.0
2880,"METHODS In this prospective , randomized , double-blind , placebo-controlled study , Japanese women were randomized to 1 of 4 groups to receive IV administration of propofol 0.5 mg/kg , droperidol 20 microg/kg ,",metoclopramide,"0.2 mg/kg , or placebo ( isotonic saline ) immediately after skin suture .","['METHODS', 'In', 'this', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', ',', 'Japanese', 'women', 'were', 'randomized', 'to', '1', 'of', '4', 'groups', 'to', 'receive', 'IV', 'administration', 'of', 'propofol', '0.5', 'mg/kg', ',', 'droperidol', '20', 'microg/kg', ',', 'metoclopramide', '0.2', 'mg/kg', ',', 'or', 'placebo', '(', 'isotonic', 'saline', ')', 'immediately', 'after', 'skin', 'suture', '.']","(34, 35)","(211, 225)",-1,hl_i,19108790,Abstract,4,test,gold,5320.0
2881,"METHODS In this prospective , randomized , double-blind , placebo-controlled study , Japanese women were randomized to 1 of 4 groups to receive IV administration of propofol 0.5 mg/kg , droperidol 20 microg/kg , metoclopramide 0.2 mg/kg , or",placebo ( isotonic saline ),immediately after skin suture .,"['METHODS', 'In', 'this', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', ',', 'Japanese', 'women', 'were', 'randomized', 'to', '1', 'of', '4', 'groups', 'to', 'receive', 'IV', 'administration', 'of', 'propofol', '0.5', 'mg/kg', ',', 'droperidol', '20', 'microg/kg', ',', 'metoclopramide', '0.2', 'mg/kg', ',', 'or', 'placebo', '(', 'isotonic', 'saline', ')', 'immediately', 'after', 'skin', 'suture', '.']","(39, 44)","(241, 268)",-1,hl_i,19108790,Abstract,4,test,gold,4435.0
2882,"A standard general anesthetic technique , including",sevoflurane,"and air in oxygen , was used .","['A', 'standard', 'general', 'anesthetic', 'technique', ',', 'including', 'sevoflurane', 'and', 'air', 'in', 'oxygen', ',', 'was', 'used', '.']","(7, 8)","(51, 62)",-1,ss_i,19108790,Abstract,5,test,gold,5421.0
2883,"A standard general anesthetic technique , including sevoflurane and air in",oxygen,", was used .","['A', 'standard', 'general', 'anesthetic', 'technique', ',', 'including', 'sevoflurane', 'and', 'air', 'in', 'oxygen', ',', 'was', 'used', '.']","(11, 12)","(74, 80)",-1,ss_i,19108790,Abstract,5,test,gold,258.0
2884,All,episodes of PONV during the first 24 hours after anesthesia administration,were recorded by an investigator who was blinded to treatment assignment .,"['All', 'episodes', 'of', 'PONV', 'during', 'the', 'first', '24', 'hours', 'after', 'anesthesia', 'administration', 'were', 'recorded', 'by', 'an', 'investigator', 'who', 'was', 'blinded', 'to', 'treatment', 'assignment', '.']","(1, 12)","(3, 77)",-1,ss_o,19108790,Abstract,6,test,gold,5857.0
2885,All episodes of,PONV,during the first 24 hours after anesthesia administration were recorded by an investigator who was blinded to treatment assignment .,"['All', 'episodes', 'of', 'PONV', 'during', 'the', 'first', '24', 'hours', 'after', 'anesthesia', 'administration', 'were', 'recorded', 'by', 'an', 'investigator', 'who', 'was', 'blinded', 'to', 'treatment', 'assignment', '.']","(3, 4)","(15, 19)",-1,hl_o,19108790,Abstract,6,test,gold,3412.0
2886,The investigator questioned the patients as to whether they experienced,extrapyramidal symptoms .,,"['The', 'investigator', 'questioned', 'the', 'patients', 'as', 'to', 'whether', 'they', 'experienced', 'extrapyramidal', 'symptoms', '.']","(10, 13)","(71, 96)",-1,ss_o,19108790,Abstract,7,test,gold,3270.0
2887,The investigator questioned the patients as to whether they experienced,extrapyramidal symptoms .,,"['The', 'investigator', 'questioned', 'the', 'patients', 'as', 'to', 'whether', 'they', 'experienced', 'extrapyramidal', 'symptoms', '.']","(10, 13)","(71, 96)",-1,hl_o,19108790,Abstract,7,test,gold,3271.0
2888,"To maintain the integrity of the study results , none of the patients received preanesthetic medication .",,,"['To', 'maintain', 'the', 'integrity', 'of', 'the', 'study', 'results', ',', 'none', 'of', 'the', 'patients', 'received', 'preanesthetic', 'medication', '.']",,,,,19108790,Abstract,8,test,gold,
2889,RESULTS,"A total of 100 women ( mean [ SD ] age , 52 [ 7 ] years ; height , 154 [ 6 ] cm ; weight , 54 [ 7 ] kg )",were included in the study .,"['RESULTS', 'A', 'total', 'of', '100', 'women', '(', 'mean', '[', 'SD', ']', 'age', ',', '52', '[', '7', ']', 'years', ';', 'height', ',', '154', '[', '6', ']', 'cm', ';', 'weight', ',', '54', '[', '7', ']', 'kg', ')', 'were', 'included', 'in', 'the', 'study', '.']","(1, 35)","(7, 111)",-1,ss_p,19108790,Abstract,9,test,gold,6449.0
2890,RESULTS A total of,100,"women ( mean [ SD ] age , 52 [ 7 ] years ; height , 154 [ 6 ] cm ; weight , 54 [ 7 ] kg ) were included in the study .","['RESULTS', 'A', 'total', 'of', '100', 'women', '(', 'mean', '[', 'SD', ']', 'age', ',', '52', '[', '7', ']', 'years', ';', 'height', ',', '154', '[', '6', ']', 'cm', ';', 'weight', ',', '54', '[', '7', ']', 'kg', ')', 'were', 'included', 'in', 'the', 'study', '.']","(4, 5)","(18, 21)",-1,hl_p,19108790,Abstract,9,test,gold,
2891,RESULTS A total of 100 women (,"mean [ SD ] age , 52 [ 7 ] years","; height , 154 [ 6 ] cm ; weight , 54 [ 7 ] kg ) were included in the study .","['RESULTS', 'A', 'total', 'of', '100', 'women', '(', 'mean', '[', 'SD', ']', 'age', ',', '52', '[', '7', ']', 'years', ';', 'height', ',', '154', '[', '6', ']', 'cm', ';', 'weight', ',', '54', '[', '7', ']', 'kg', ')', 'were', 'included', 'in', 'the', 'study', '.']","(7, 18)","(30, 62)",-1,hl_p,19108790,Abstract,9,test,gold,2004.0
2892,"RESULTS A total of 100 women ( mean [ SD ] age , 52 [ 7 ] years ;","height , 154 [ 6 ] cm","; weight , 54 [ 7 ] kg ) were included in the study .","['RESULTS', 'A', 'total', 'of', '100', 'women', '(', 'mean', '[', 'SD', ']', 'age', ',', '52', '[', '7', ']', 'years', ';', 'height', ',', '154', '[', '6', ']', 'cm', ';', 'weight', ',', '54', '[', '7', ']', 'kg', ')', 'were', 'included', 'in', 'the', 'study', '.']","(19, 26)","(65, 86)",-1,hl_p,19108790,Abstract,9,test,gold,1496.0
2893,"RESULTS A total of 100 women ( mean [ SD ] age , 52 [ 7 ] years ; height , 154 [ 6 ] cm ;","weight , 54 [ 7 ] kg",) were included in the study .,"['RESULTS', 'A', 'total', 'of', '100', 'women', '(', 'mean', '[', 'SD', ']', 'age', ',', '52', '[', '7', ']', 'years', ';', 'height', ',', '154', '[', '6', ']', 'cm', ';', 'weight', ',', '54', '[', '7', ']', 'kg', ')', 'were', 'included', 'in', 'the', 'study', '.']","(27, 34)","(89, 109)",-1,hl_p,19108790,Abstract,9,test,gold,1497.0
2894,Each study group comprised 25 patients .,,,"['Each', 'study', 'group', 'comprised', '25', 'patients', '.']",,,,,19108790,Abstract,10,test,gold,
2895,There were no significant differences between treatment groups with regard to,"patient demographics , surgery type , or awakening time .",,"['There', 'were', 'no', 'significant', 'differences', 'between', 'treatment', 'groups', 'with', 'regard', 'to', 'patient', 'demographics', ',', 'surgery', 'type', ',', 'or', 'awakening', 'time', '.']","(11, 21)","(77, 134)",-1,ss_o,19108790,Abstract,11,test,gold,3878.0
2896,The prevalences of PONV 0 to 24 hours after anesthesia were 28 % with,propofol,"( P = 0.005 ) , 32 % with droperidol ( P = 0.011 ) , and 60 % with metoclopramide ( P = NS ) , compared with placebo ( 68 % ) .","['The', 'prevalences', 'of', 'PONV', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'were', '28', '%', 'with', 'propofol', '(', 'P', '=', '0.005', ')', ',', '32', '%', 'with', 'droperidol', '(', 'P', '=', '0.011', ')', ',', 'and', '60', '%', 'with', 'metoclopramide', '(', 'P', '=', 'NS', ')', ',', 'compared', 'with', 'placebo', '(', '68', '%', ')', '.']","(14, 15)","(69, 77)",-1,ss_i,19108790,Abstract,12,test,gold,4708.0
2897,"The prevalences of PONV 0 to 24 hours after anesthesia were 28 % with propofol ( P = 0.005 ) , 32 % with",droperidol,"( P = 0.011 ) , and 60 % with metoclopramide ( P = NS ) , compared with placebo ( 68 % ) .","['The', 'prevalences', 'of', 'PONV', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'were', '28', '%', 'with', 'propofol', '(', 'P', '=', '0.005', ')', ',', '32', '%', 'with', 'droperidol', '(', 'P', '=', '0.011', ')', ',', 'and', '60', '%', 'with', 'metoclopramide', '(', 'P', '=', 'NS', ')', ',', 'compared', 'with', 'placebo', '(', '68', '%', ')', '.']","(24, 25)","(104, 114)",-1,ss_i,19108790,Abstract,12,test,gold,44.0
2898,"The prevalences of PONV 0 to 24 hours after anesthesia were 28 % with propofol ( P = 0.005 ) , 32 % with droperidol ( P = 0.011 ) , and 60 % with",metoclopramide,"( P = NS ) , compared with placebo ( 68 % ) .","['The', 'prevalences', 'of', 'PONV', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'were', '28', '%', 'with', 'propofol', '(', 'P', '=', '0.005', ')', ',', '32', '%', 'with', 'droperidol', '(', 'P', '=', '0.011', ')', ',', 'and', '60', '%', 'with', 'metoclopramide', '(', 'P', '=', 'NS', ')', ',', 'compared', 'with', 'placebo', '(', '68', '%', ')', '.']","(35, 36)","(145, 159)",-1,ss_i,19108790,Abstract,12,test,gold,5319.0
2899,"The prevalences of PONV 0 to 24 hours after anesthesia were 28 % with propofol ( P = 0.005 ) , 32 % with droperidol ( P = 0.011 ) , and 60 % with metoclopramide ( P = NS ) , compared with",placebo,( 68 % ) .,"['The', 'prevalences', 'of', 'PONV', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'were', '28', '%', 'with', 'propofol', '(', 'P', '=', '0.005', ')', ',', '32', '%', 'with', 'droperidol', '(', 'P', '=', '0.011', ')', ',', 'and', '60', '%', 'with', 'metoclopramide', '(', 'P', '=', 'NS', ')', ',', 'compared', 'with', 'placebo', '(', '68', '%', ')', '.']","(44, 45)","(187, 194)",-1,ss_i,19108790,Abstract,12,test,gold,4381.0
2900,The,prevalences of PONV 0 to 24 hours,"after anesthesia were 28 % with propofol ( P = 0.005 ) , 32 % with droperidol ( P = 0.011 ) , and 60 % with metoclopramide ( P = NS ) , compared with placebo ( 68 % ) .","['The', 'prevalences', 'of', 'PONV', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'were', '28', '%', 'with', 'propofol', '(', 'P', '=', '0.005', ')', ',', '32', '%', 'with', 'droperidol', '(', 'P', '=', '0.011', ')', ',', 'and', '60', '%', 'with', 'metoclopramide', '(', 'P', '=', 'NS', ')', ',', 'compared', 'with', 'placebo', '(', '68', '%', ')', '.']","(1, 8)","(3, 36)",-1,ss_o,19108790,Abstract,12,test,gold,3401.0
2901,The prevalences of PONV 0 to 24 hours after anesthesia were 28 % with,propofol,"( P = 0.005 ) , 32 % with droperidol ( P = 0.011 ) , and 60 % with metoclopramide ( P = NS ) , compared with placebo ( 68 % ) .","['The', 'prevalences', 'of', 'PONV', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'were', '28', '%', 'with', 'propofol', '(', 'P', '=', '0.005', ')', ',', '32', '%', 'with', 'droperidol', '(', 'P', '=', '0.011', ')', ',', 'and', '60', '%', 'with', 'metoclopramide', '(', 'P', '=', 'NS', ')', ',', 'compared', 'with', 'placebo', '(', '68', '%', ')', '.']","(14, 15)","(69, 77)",-1,hl_i,19108790,Abstract,12,test,gold,4707.0
2902,"The prevalences of PONV 0 to 24 hours after anesthesia were 28 % with propofol ( P = 0.005 ) , 32 % with",droperidol,"( P = 0.011 ) , and 60 % with metoclopramide ( P = NS ) , compared with placebo ( 68 % ) .","['The', 'prevalences', 'of', 'PONV', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'were', '28', '%', 'with', 'propofol', '(', 'P', '=', '0.005', ')', ',', '32', '%', 'with', 'droperidol', '(', 'P', '=', '0.011', ')', ',', 'and', '60', '%', 'with', 'metoclopramide', '(', 'P', '=', 'NS', ')', ',', 'compared', 'with', 'placebo', '(', '68', '%', ')', '.']","(24, 25)","(104, 114)",-1,hl_i,19108790,Abstract,12,test,gold,43.0
2903,"The prevalences of PONV 0 to 24 hours after anesthesia were 28 % with propofol ( P = 0.005 ) , 32 % with droperidol ( P = 0.011 ) , and 60 % with",metoclopramide,"( P = NS ) , compared with placebo ( 68 % ) .","['The', 'prevalences', 'of', 'PONV', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'were', '28', '%', 'with', 'propofol', '(', 'P', '=', '0.005', ')', ',', '32', '%', 'with', 'droperidol', '(', 'P', '=', '0.011', ')', ',', 'and', '60', '%', 'with', 'metoclopramide', '(', 'P', '=', 'NS', ')', ',', 'compared', 'with', 'placebo', '(', '68', '%', ')', '.']","(35, 36)","(145, 159)",-1,hl_i,19108790,Abstract,12,test,gold,5318.0
2904,"The prevalences of PONV 0 to 24 hours after anesthesia were 28 % with propofol ( P = 0.005 ) , 32 % with droperidol ( P = 0.011 ) , and 60 % with metoclopramide ( P = NS ) , compared with",placebo,( 68 % ) .,"['The', 'prevalences', 'of', 'PONV', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'were', '28', '%', 'with', 'propofol', '(', 'P', '=', '0.005', ')', ',', '32', '%', 'with', 'droperidol', '(', 'P', '=', '0.011', ')', ',', 'and', '60', '%', 'with', 'metoclopramide', '(', 'P', '=', 'NS', ')', ',', 'compared', 'with', 'placebo', '(', '68', '%', ')', '.']","(44, 45)","(187, 194)",-1,hl_i,19108790,Abstract,12,test,gold,4380.0
2905,The prevalences of,PONV,"0 to 24 hours after anesthesia were 28 % with propofol ( P = 0.005 ) , 32 % with droperidol ( P = 0.011 ) , and 60 % with metoclopramide ( P = NS ) , compared with placebo ( 68 % ) .","['The', 'prevalences', 'of', 'PONV', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'were', '28', '%', 'with', 'propofol', '(', 'P', '=', '0.005', ')', ',', '32', '%', 'with', 'droperidol', '(', 'P', '=', '0.011', ')', ',', 'and', '60', '%', 'with', 'metoclopramide', '(', 'P', '=', 'NS', ')', ',', 'compared', 'with', 'placebo', '(', '68', '%', ')', '.']","(3, 4)","(18, 22)",-1,hl_o,19108790,Abstract,12,test,gold,3411.0
2906,No significant difference in the prevalence of PONV was found between patients receiving,propofol,"and those receiving droperidol , and propofol and droperidol were associated with significantly lower prevalences of PONV compared with metoclopramide ( P = 0.022 and P = 0.043 , respectively ) .","['No', 'significant', 'difference', 'in', 'the', 'prevalence', 'of', 'PONV', 'was', 'found', 'between', 'patients', 'receiving', 'propofol', 'and', 'those', 'receiving', 'droperidol', ',', 'and', 'propofol', 'and', 'droperidol', 'were', 'associated', 'with', 'significantly', 'lower', 'prevalences', 'of', 'PONV', 'compared', 'with', 'metoclopramide', '(', 'P', '=', '0.022', 'and', 'P', '=', '0.043', ',', 'respectively', ')', '.']","(13, 14)","(88, 96)",-1,ss_i,19108790,Abstract,13,test,gold,4706.0
2907,No significant difference in the prevalence of PONV was found between patients receiving propofol and those receiving,droperidol,", and propofol and droperidol were associated with significantly lower prevalences of PONV compared with metoclopramide ( P = 0.022 and P = 0.043 , respectively ) .","['No', 'significant', 'difference', 'in', 'the', 'prevalence', 'of', 'PONV', 'was', 'found', 'between', 'patients', 'receiving', 'propofol', 'and', 'those', 'receiving', 'droperidol', ',', 'and', 'propofol', 'and', 'droperidol', 'were', 'associated', 'with', 'significantly', 'lower', 'prevalences', 'of', 'PONV', 'compared', 'with', 'metoclopramide', '(', 'P', '=', '0.022', 'and', 'P', '=', '0.043', ',', 'respectively', ')', '.']","(17, 18)","(117, 127)",-1,ss_i,19108790,Abstract,13,test,gold,42.0
2908,"No significant difference in the prevalence of PONV was found between patients receiving propofol and those receiving droperidol , and",propofol,"and droperidol were associated with significantly lower prevalences of PONV compared with metoclopramide ( P = 0.022 and P = 0.043 , respectively ) .","['No', 'significant', 'difference', 'in', 'the', 'prevalence', 'of', 'PONV', 'was', 'found', 'between', 'patients', 'receiving', 'propofol', 'and', 'those', 'receiving', 'droperidol', ',', 'and', 'propofol', 'and', 'droperidol', 'were', 'associated', 'with', 'significantly', 'lower', 'prevalences', 'of', 'PONV', 'compared', 'with', 'metoclopramide', '(', 'P', '=', '0.022', 'and', 'P', '=', '0.043', ',', 'respectively', ')', '.']","(20, 21)","(134, 142)",-1,ss_i,19108790,Abstract,13,test,gold,4705.0
2909,"No significant difference in the prevalence of PONV was found between patients receiving propofol and those receiving droperidol , and propofol and",droperidol,"were associated with significantly lower prevalences of PONV compared with metoclopramide ( P = 0.022 and P = 0.043 , respectively ) .","['No', 'significant', 'difference', 'in', 'the', 'prevalence', 'of', 'PONV', 'was', 'found', 'between', 'patients', 'receiving', 'propofol', 'and', 'those', 'receiving', 'droperidol', ',', 'and', 'propofol', 'and', 'droperidol', 'were', 'associated', 'with', 'significantly', 'lower', 'prevalences', 'of', 'PONV', 'compared', 'with', 'metoclopramide', '(', 'P', '=', '0.022', 'and', 'P', '=', '0.043', ',', 'respectively', ')', '.']","(22, 23)","(147, 157)",-1,ss_i,19108790,Abstract,13,test,gold,41.0
2910,"No significant difference in the prevalence of PONV was found between patients receiving propofol and those receiving droperidol , and propofol and droperidol were associated with significantly lower prevalences of PONV compared with",metoclopramide,"( P = 0.022 and P = 0.043 , respectively ) .","['No', 'significant', 'difference', 'in', 'the', 'prevalence', 'of', 'PONV', 'was', 'found', 'between', 'patients', 'receiving', 'propofol', 'and', 'those', 'receiving', 'droperidol', ',', 'and', 'propofol', 'and', 'droperidol', 'were', 'associated', 'with', 'significantly', 'lower', 'prevalences', 'of', 'PONV', 'compared', 'with', 'metoclopramide', '(', 'P', '=', '0.022', 'and', 'P', '=', '0.043', ',', 'respectively', ')', '.']","(33, 34)","(233, 247)",-1,ss_i,19108790,Abstract,13,test,gold,5317.0
2911,No significant difference in the,prevalence of PONV,"was found between patients receiving propofol and those receiving droperidol , and propofol and droperidol were associated with significantly lower prevalences of PONV compared with metoclopramide ( P = 0.022 and P = 0.043 , respectively ) .","['No', 'significant', 'difference', 'in', 'the', 'prevalence', 'of', 'PONV', 'was', 'found', 'between', 'patients', 'receiving', 'propofol', 'and', 'those', 'receiving', 'droperidol', ',', 'and', 'propofol', 'and', 'droperidol', 'were', 'associated', 'with', 'significantly', 'lower', 'prevalences', 'of', 'PONV', 'compared', 'with', 'metoclopramide', '(', 'P', '=', '0.022', 'and', 'P', '=', '0.043', ',', 'respectively', ')', '.']","(5, 8)","(32, 50)",-1,ss_o,19108790,Abstract,13,test,gold,3402.0
2912,"No significant difference in the prevalence of PONV was found between patients receiving propofol and those receiving droperidol , and propofol and droperidol were associated with significantly lower",prevalences of PONV,"compared with metoclopramide ( P = 0.022 and P = 0.043 , respectively ) .","['No', 'significant', 'difference', 'in', 'the', 'prevalence', 'of', 'PONV', 'was', 'found', 'between', 'patients', 'receiving', 'propofol', 'and', 'those', 'receiving', 'droperidol', ',', 'and', 'propofol', 'and', 'droperidol', 'were', 'associated', 'with', 'significantly', 'lower', 'prevalences', 'of', 'PONV', 'compared', 'with', 'metoclopramide', '(', 'P', '=', '0.022', 'and', 'P', '=', '0.043', ',', 'respectively', ')', '.']","(28, 31)","(199, 218)",-1,ss_o,19108790,Abstract,13,test,gold,3404.0
2913,No significant difference in the prevalence of PONV was found between patients receiving,propofol,"and those receiving droperidol , and propofol and droperidol were associated with significantly lower prevalences of PONV compared with metoclopramide ( P = 0.022 and P = 0.043 , respectively ) .","['No', 'significant', 'difference', 'in', 'the', 'prevalence', 'of', 'PONV', 'was', 'found', 'between', 'patients', 'receiving', 'propofol', 'and', 'those', 'receiving', 'droperidol', ',', 'and', 'propofol', 'and', 'droperidol', 'were', 'associated', 'with', 'significantly', 'lower', 'prevalences', 'of', 'PONV', 'compared', 'with', 'metoclopramide', '(', 'P', '=', '0.022', 'and', 'P', '=', '0.043', ',', 'respectively', ')', '.']","(13, 14)","(88, 96)",-1,hl_i,19108790,Abstract,13,test,gold,4704.0
2914,No significant difference in the prevalence of PONV was found between patients receiving propofol and those receiving,droperidol,", and propofol and droperidol were associated with significantly lower prevalences of PONV compared with metoclopramide ( P = 0.022 and P = 0.043 , respectively ) .","['No', 'significant', 'difference', 'in', 'the', 'prevalence', 'of', 'PONV', 'was', 'found', 'between', 'patients', 'receiving', 'propofol', 'and', 'those', 'receiving', 'droperidol', ',', 'and', 'propofol', 'and', 'droperidol', 'were', 'associated', 'with', 'significantly', 'lower', 'prevalences', 'of', 'PONV', 'compared', 'with', 'metoclopramide', '(', 'P', '=', '0.022', 'and', 'P', '=', '0.043', ',', 'respectively', ')', '.']","(17, 18)","(117, 127)",-1,hl_i,19108790,Abstract,13,test,gold,40.0
2915,"No significant difference in the prevalence of PONV was found between patients receiving propofol and those receiving droperidol , and",propofol,"and droperidol were associated with significantly lower prevalences of PONV compared with metoclopramide ( P = 0.022 and P = 0.043 , respectively ) .","['No', 'significant', 'difference', 'in', 'the', 'prevalence', 'of', 'PONV', 'was', 'found', 'between', 'patients', 'receiving', 'propofol', 'and', 'those', 'receiving', 'droperidol', ',', 'and', 'propofol', 'and', 'droperidol', 'were', 'associated', 'with', 'significantly', 'lower', 'prevalences', 'of', 'PONV', 'compared', 'with', 'metoclopramide', '(', 'P', '=', '0.022', 'and', 'P', '=', '0.043', ',', 'respectively', ')', '.']","(20, 21)","(134, 142)",-1,hl_i,19108790,Abstract,13,test,gold,4703.0
2916,"No significant difference in the prevalence of PONV was found between patients receiving propofol and those receiving droperidol , and propofol and",droperidol,"were associated with significantly lower prevalences of PONV compared with metoclopramide ( P = 0.022 and P = 0.043 , respectively ) .","['No', 'significant', 'difference', 'in', 'the', 'prevalence', 'of', 'PONV', 'was', 'found', 'between', 'patients', 'receiving', 'propofol', 'and', 'those', 'receiving', 'droperidol', ',', 'and', 'propofol', 'and', 'droperidol', 'were', 'associated', 'with', 'significantly', 'lower', 'prevalences', 'of', 'PONV', 'compared', 'with', 'metoclopramide', '(', 'P', '=', '0.022', 'and', 'P', '=', '0.043', ',', 'respectively', ')', '.']","(22, 23)","(147, 157)",-1,hl_i,19108790,Abstract,13,test,gold,39.0
2917,"No significant difference in the prevalence of PONV was found between patients receiving propofol and those receiving droperidol , and propofol and droperidol were associated with significantly lower prevalences of PONV compared with",metoclopramide,"( P = 0.022 and P = 0.043 , respectively ) .","['No', 'significant', 'difference', 'in', 'the', 'prevalence', 'of', 'PONV', 'was', 'found', 'between', 'patients', 'receiving', 'propofol', 'and', 'those', 'receiving', 'droperidol', ',', 'and', 'propofol', 'and', 'droperidol', 'were', 'associated', 'with', 'significantly', 'lower', 'prevalences', 'of', 'PONV', 'compared', 'with', 'metoclopramide', '(', 'P', '=', '0.022', 'and', 'P', '=', '0.043', ',', 'respectively', ')', '.']","(33, 34)","(233, 247)",-1,hl_i,19108790,Abstract,13,test,gold,5316.0
2918,No significant difference in the prevalence of,PONV,"was found between patients receiving propofol and those receiving droperidol , and propofol and droperidol were associated with significantly lower prevalences of PONV compared with metoclopramide ( P = 0.022 and P = 0.043 , respectively ) .","['No', 'significant', 'difference', 'in', 'the', 'prevalence', 'of', 'PONV', 'was', 'found', 'between', 'patients', 'receiving', 'propofol', 'and', 'those', 'receiving', 'droperidol', ',', 'and', 'propofol', 'and', 'droperidol', 'were', 'associated', 'with', 'significantly', 'lower', 'prevalences', 'of', 'PONV', 'compared', 'with', 'metoclopramide', '(', 'P', '=', '0.022', 'and', 'P', '=', '0.043', ',', 'respectively', ')', '.']","(7, 8)","(46, 50)",-1,hl_o,19108790,Abstract,13,test,gold,3410.0
2919,"No significant difference in the prevalence of PONV was found between patients receiving propofol and those receiving droperidol , and propofol and droperidol were associated with significantly lower prevalences of",PONV,"compared with metoclopramide ( P = 0.022 and P = 0.043 , respectively ) .","['No', 'significant', 'difference', 'in', 'the', 'prevalence', 'of', 'PONV', 'was', 'found', 'between', 'patients', 'receiving', 'propofol', 'and', 'those', 'receiving', 'droperidol', ',', 'and', 'propofol', 'and', 'droperidol', 'were', 'associated', 'with', 'significantly', 'lower', 'prevalences', 'of', 'PONV', 'compared', 'with', 'metoclopramide', '(', 'P', '=', '0.022', 'and', 'P', '=', '0.043', ',', 'respectively', ')', '.']","(30, 31)","(214, 218)",-1,hl_o,19108790,Abstract,13,test,gold,3409.0
2920,,Extrapyramidal symptoms,were not reported in any of the groups .,"['Extrapyramidal', 'symptoms', 'were', 'not', 'reported', 'in', 'any', 'of', 'the', 'groups', '.']","(0, 2)","(0, 23)",-1,ss_o,19108790,Abstract,14,test,gold,3280.0
2921,,Extrapyramidal symptoms,were not reported in any of the groups .,"['Extrapyramidal', 'symptoms', 'were', 'not', 'reported', 'in', 'any', 'of', 'the', 'groups', '.']","(0, 2)","(0, 23)",-1,hl_o,19108790,Abstract,14,test,gold,3279.0
2922,"CONCLUSIONS The prevalences of PONV were not significantly different between propofol 0.5 mg/kg and droperidol 20 microg/kg 0 to 24 hours after anesthesia in this small , select group of",Japanese women who underwent breast cancer surgery .,,"['CONCLUSIONS', 'The', 'prevalences', 'of', 'PONV', 'were', 'not', 'significantly', 'different', 'between', 'propofol', '0.5', 'mg/kg', 'and', 'droperidol', '20', 'microg/kg', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'in', 'this', 'small', ',', 'select', 'group', 'of', 'Japanese', 'women', 'who', 'underwent', 'breast', 'cancer', 'surgery', '.']","(30, 38)","(186, 238)",-1,ss_p,19108790,Abstract,15,test,gold,6823.0
2923,CONCLUSIONS The prevalences of PONV were not significantly different between,propofol,"0.5 mg/kg and droperidol 20 microg/kg 0 to 24 hours after anesthesia in this small , select group of Japanese women who underwent breast cancer surgery .","['CONCLUSIONS', 'The', 'prevalences', 'of', 'PONV', 'were', 'not', 'significantly', 'different', 'between', 'propofol', '0.5', 'mg/kg', 'and', 'droperidol', '20', 'microg/kg', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'in', 'this', 'small', ',', 'select', 'group', 'of', 'Japanese', 'women', 'who', 'underwent', 'breast', 'cancer', 'surgery', '.']","(10, 11)","(76, 84)",-1,ss_i,19108790,Abstract,15,test,gold,4702.0
2924,CONCLUSIONS The prevalences of PONV were not significantly different between propofol 0.5 mg/kg and,droperidol,"20 microg/kg 0 to 24 hours after anesthesia in this small , select group of Japanese women who underwent breast cancer surgery .","['CONCLUSIONS', 'The', 'prevalences', 'of', 'PONV', 'were', 'not', 'significantly', 'different', 'between', 'propofol', '0.5', 'mg/kg', 'and', 'droperidol', '20', 'microg/kg', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'in', 'this', 'small', ',', 'select', 'group', 'of', 'Japanese', 'women', 'who', 'underwent', 'breast', 'cancer', 'surgery', '.']","(14, 15)","(99, 109)",-1,ss_i,19108790,Abstract,15,test,gold,38.0
2925,CONCLUSIONS The,prevalences of PONV,"were not significantly different between propofol 0.5 mg/kg and droperidol 20 microg/kg 0 to 24 hours after anesthesia in this small , select group of Japanese women who underwent breast cancer surgery .","['CONCLUSIONS', 'The', 'prevalences', 'of', 'PONV', 'were', 'not', 'significantly', 'different', 'between', 'propofol', '0.5', 'mg/kg', 'and', 'droperidol', '20', 'microg/kg', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'in', 'this', 'small', ',', 'select', 'group', 'of', 'Japanese', 'women', 'who', 'underwent', 'breast', 'cancer', 'surgery', '.']","(2, 5)","(15, 34)",-1,ss_o,19108790,Abstract,15,test,gold,3405.0
2926,CONCLUSIONS The prevalences of PONV were not significantly different between,propofol,"0.5 mg/kg and droperidol 20 microg/kg 0 to 24 hours after anesthesia in this small , select group of Japanese women who underwent breast cancer surgery .","['CONCLUSIONS', 'The', 'prevalences', 'of', 'PONV', 'were', 'not', 'significantly', 'different', 'between', 'propofol', '0.5', 'mg/kg', 'and', 'droperidol', '20', 'microg/kg', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'in', 'this', 'small', ',', 'select', 'group', 'of', 'Japanese', 'women', 'who', 'underwent', 'breast', 'cancer', 'surgery', '.']","(10, 11)","(76, 84)",-1,hl_i,19108790,Abstract,15,test,gold,4701.0
2927,CONCLUSIONS The prevalences of PONV were not significantly different between propofol 0.5 mg/kg and,droperidol,"20 microg/kg 0 to 24 hours after anesthesia in this small , select group of Japanese women who underwent breast cancer surgery .","['CONCLUSIONS', 'The', 'prevalences', 'of', 'PONV', 'were', 'not', 'significantly', 'different', 'between', 'propofol', '0.5', 'mg/kg', 'and', 'droperidol', '20', 'microg/kg', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'in', 'this', 'small', ',', 'select', 'group', 'of', 'Japanese', 'women', 'who', 'underwent', 'breast', 'cancer', 'surgery', '.']","(14, 15)","(99, 109)",-1,hl_i,19108790,Abstract,15,test,gold,37.0
2928,CONCLUSIONS The prevalences of,PONV,"were not significantly different between propofol 0.5 mg/kg and droperidol 20 microg/kg 0 to 24 hours after anesthesia in this small , select group of Japanese women who underwent breast cancer surgery .","['CONCLUSIONS', 'The', 'prevalences', 'of', 'PONV', 'were', 'not', 'significantly', 'different', 'between', 'propofol', '0.5', 'mg/kg', 'and', 'droperidol', '20', 'microg/kg', '0', 'to', '24', 'hours', 'after', 'anesthesia', 'in', 'this', 'small', ',', 'select', 'group', 'of', 'Japanese', 'women', 'who', 'underwent', 'breast', 'cancer', 'surgery', '.']","(4, 5)","(30, 34)",-1,hl_o,19108790,Abstract,15,test,gold,3408.0
2929,The prevalences of PONV were significantly lower with,propofol,and droperidol compared with metoclopramide 0.2 mg/kg and placebo .,"['The', 'prevalences', 'of', 'PONV', 'were', 'significantly', 'lower', 'with', 'propofol', 'and', 'droperidol', 'compared', 'with', 'metoclopramide', '0.2', 'mg/kg', 'and', 'placebo', '.']","(8, 9)","(53, 61)",-1,ss_i,19108790,Abstract,16,test,gold,4700.0
2930,The prevalences of PONV were significantly lower with propofol and,droperidol,compared with metoclopramide 0.2 mg/kg and placebo .,"['The', 'prevalences', 'of', 'PONV', 'were', 'significantly', 'lower', 'with', 'propofol', 'and', 'droperidol', 'compared', 'with', 'metoclopramide', '0.2', 'mg/kg', 'and', 'placebo', '.']","(10, 11)","(66, 76)",-1,ss_i,19108790,Abstract,16,test,gold,36.0
2931,The prevalences of PONV were significantly lower with propofol and droperidol compared with,metoclopramide,0.2 mg/kg and placebo .,"['The', 'prevalences', 'of', 'PONV', 'were', 'significantly', 'lower', 'with', 'propofol', 'and', 'droperidol', 'compared', 'with', 'metoclopramide', '0.2', 'mg/kg', 'and', 'placebo', '.']","(13, 14)","(91, 105)",-1,ss_i,19108790,Abstract,16,test,gold,5315.0
2932,The prevalences of PONV were significantly lower with propofol and droperidol compared with metoclopramide 0.2 mg/kg and,placebo .,,"['The', 'prevalences', 'of', 'PONV', 'were', 'significantly', 'lower', 'with', 'propofol', 'and', 'droperidol', 'compared', 'with', 'metoclopramide', '0.2', 'mg/kg', 'and', 'placebo', '.']","(17, 19)","(120, 129)",-1,ss_i,19108790,Abstract,16,test,gold,4379.0
2933,The,prevalences of PONV,were significantly lower with propofol and droperidol compared with metoclopramide 0.2 mg/kg and placebo .,"['The', 'prevalences', 'of', 'PONV', 'were', 'significantly', 'lower', 'with', 'propofol', 'and', 'droperidol', 'compared', 'with', 'metoclopramide', '0.2', 'mg/kg', 'and', 'placebo', '.']","(1, 4)","(3, 22)",-1,ss_o,19108790,Abstract,16,test,gold,3403.0
2934,The prevalences of PONV were significantly lower with,propofol,and droperidol compared with metoclopramide 0.2 mg/kg and placebo .,"['The', 'prevalences', 'of', 'PONV', 'were', 'significantly', 'lower', 'with', 'propofol', 'and', 'droperidol', 'compared', 'with', 'metoclopramide', '0.2', 'mg/kg', 'and', 'placebo', '.']","(8, 9)","(53, 61)",-1,hl_i,19108790,Abstract,16,test,gold,4699.0
2935,The prevalences of PONV were significantly lower with propofol and,droperidol,compared with metoclopramide 0.2 mg/kg and placebo .,"['The', 'prevalences', 'of', 'PONV', 'were', 'significantly', 'lower', 'with', 'propofol', 'and', 'droperidol', 'compared', 'with', 'metoclopramide', '0.2', 'mg/kg', 'and', 'placebo', '.']","(10, 11)","(66, 76)",-1,hl_i,19108790,Abstract,16,test,gold,35.0
2936,The prevalences of PONV were significantly lower with propofol and droperidol compared with,metoclopramide,0.2 mg/kg and placebo .,"['The', 'prevalences', 'of', 'PONV', 'were', 'significantly', 'lower', 'with', 'propofol', 'and', 'droperidol', 'compared', 'with', 'metoclopramide', '0.2', 'mg/kg', 'and', 'placebo', '.']","(13, 14)","(91, 105)",-1,hl_i,19108790,Abstract,16,test,gold,5314.0
2937,The prevalences of PONV were significantly lower with propofol and droperidol compared with metoclopramide 0.2 mg/kg and,placebo .,,"['The', 'prevalences', 'of', 'PONV', 'were', 'significantly', 'lower', 'with', 'propofol', 'and', 'droperidol', 'compared', 'with', 'metoclopramide', '0.2', 'mg/kg', 'and', 'placebo', '.']","(17, 19)","(120, 129)",-1,hl_i,19108790,Abstract,16,test,gold,4378.0
2938,The prevalences of,PONV,were significantly lower with propofol and droperidol compared with metoclopramide 0.2 mg/kg and placebo .,"['The', 'prevalences', 'of', 'PONV', 'were', 'significantly', 'lower', 'with', 'propofol', 'and', 'droperidol', 'compared', 'with', 'metoclopramide', '0.2', 'mg/kg', 'and', 'placebo', '.']","(3, 4)","(18, 22)",-1,hl_o,19108790,Abstract,16,test,gold,3407.0
2939,To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat,patients with primary Raynaud 's phenomenon in South Korea ;,Korean Raynaud study ( KOARA study ) .,"['To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', 'with', 'Ginkgo', 'biloba', 'extract', 'to', 'treat', 'patients', 'with', 'primary', 'Raynaud', ""'s"", 'phenomenon', 'in', 'South', 'Korea', ';', 'Korean', 'Raynaud', 'study', '(', 'KOARA', 'study', ')', '.']","(16, 26)","(102, 162)",-1,ss_p,19159999,Title,0,test,gold,3339.0
2940,To compare the efficacy and safety of,nifedipine sustained release,with Ginkgo biloba extract to treat patients with primary Raynaud 's phenomenon in South Korea ; Korean Raynaud study ( KOARA study ) .,"['To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', 'with', 'Ginkgo', 'biloba', 'extract', 'to', 'treat', 'patients', 'with', 'primary', 'Raynaud', ""'s"", 'phenomenon', 'in', 'South', 'Korea', ';', 'Korean', 'Raynaud', 'study', '(', 'KOARA', 'study', ')', '.']","(7, 10)","(37, 65)",-1,ss_i,19159999,Title,0,test,gold,3524.0
2941,To compare the efficacy and safety of nifedipine sustained release with,Ginkgo biloba extract,to treat patients with primary Raynaud 's phenomenon in South Korea ; Korean Raynaud study ( KOARA study ) .,"['To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', 'with', 'Ginkgo', 'biloba', 'extract', 'to', 'treat', 'patients', 'with', 'primary', 'Raynaud', ""'s"", 'phenomenon', 'in', 'South', 'Korea', ';', 'Korean', 'Raynaud', 'study', '(', 'KOARA', 'study', ')', '.']","(11, 14)","(71, 92)",-1,ss_i,19159999,Title,0,test,gold,4603.0
2942,To compare the,efficacy,and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud 's phenomenon in South Korea ; Korean Raynaud study ( KOARA study ) .,"['To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', 'with', 'Ginkgo', 'biloba', 'extract', 'to', 'treat', 'patients', 'with', 'primary', 'Raynaud', ""'s"", 'phenomenon', 'in', 'South', 'Korea', ';', 'Korean', 'Raynaud', 'study', '(', 'KOARA', 'study', ')', '.']","(3, 4)","(14, 22)",-1,ss_o,19159999,Title,0,test,gold,4818.0
2943,To compare the efficacy and,safety,of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud 's phenomenon in South Korea ; Korean Raynaud study ( KOARA study ) .,"['To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', 'with', 'Ginkgo', 'biloba', 'extract', 'to', 'treat', 'patients', 'with', 'primary', 'Raynaud', ""'s"", 'phenomenon', 'in', 'South', 'Korea', ';', 'Korean', 'Raynaud', 'study', '(', 'KOARA', 'study', ')', '.']","(5, 6)","(27, 33)",-1,ss_o,19159999,Title,0,test,gold,474.0
2944,To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat,patients with primary Raynaud 's phenomenon in South Korea ;,Korean Raynaud study ( KOARA study ) .,"['To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', 'with', 'Ginkgo', 'biloba', 'extract', 'to', 'treat', 'patients', 'with', 'primary', 'Raynaud', ""'s"", 'phenomenon', 'in', 'South', 'Korea', ';', 'Korean', 'Raynaud', 'study', '(', 'KOARA', 'study', ')', '.']","(16, 26)","(102, 162)",-1,hl_p,19159999,Title,0,test,gold,3340.0
2945,To compare the efficacy and safety of,nifedipine sustained release,with Ginkgo biloba extract to treat patients with primary Raynaud 's phenomenon in South Korea ; Korean Raynaud study ( KOARA study ) .,"['To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', 'with', 'Ginkgo', 'biloba', 'extract', 'to', 'treat', 'patients', 'with', 'primary', 'Raynaud', ""'s"", 'phenomenon', 'in', 'South', 'Korea', ';', 'Korean', 'Raynaud', 'study', '(', 'KOARA', 'study', ')', '.']","(7, 10)","(37, 65)",-1,hl_i,19159999,Title,0,test,gold,3525.0
2946,To compare the efficacy and safety of nifedipine sustained release with,Ginkgo biloba extract,to treat patients with primary Raynaud 's phenomenon in South Korea ; Korean Raynaud study ( KOARA study ) .,"['To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', 'with', 'Ginkgo', 'biloba', 'extract', 'to', 'treat', 'patients', 'with', 'primary', 'Raynaud', ""'s"", 'phenomenon', 'in', 'South', 'Korea', ';', 'Korean', 'Raynaud', 'study', '(', 'KOARA', 'study', ')', '.']","(11, 14)","(71, 92)",-1,hl_i,19159999,Title,0,test,gold,4604.0
2947,To compare the,efficacy,and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud 's phenomenon in South Korea ; Korean Raynaud study ( KOARA study ) .,"['To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', 'with', 'Ginkgo', 'biloba', 'extract', 'to', 'treat', 'patients', 'with', 'primary', 'Raynaud', ""'s"", 'phenomenon', 'in', 'South', 'Korea', ';', 'Korean', 'Raynaud', 'study', '(', 'KOARA', 'study', ')', '.']","(3, 4)","(14, 22)",-1,hl_o,19159999,Title,0,test,gold,4817.0
2948,To compare the efficacy and,safety,of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud 's phenomenon in South Korea ; Korean Raynaud study ( KOARA study ) .,"['To', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', 'with', 'Ginkgo', 'biloba', 'extract', 'to', 'treat', 'patients', 'with', 'primary', 'Raynaud', ""'s"", 'phenomenon', 'in', 'South', 'Korea', ';', 'Korean', 'Raynaud', 'study', '(', 'KOARA', 'study', ')', '.']","(5, 6)","(27, 33)",-1,hl_o,19159999,Title,0,test,gold,473.0
2949,This study examined the efficacy and safety of nifedipine sustained release ( nifedipine SR ) compared with Ginkgo biloba extract as treatment for,primary Raynaud 's phenomenon ( RP ) in Korea .,,"['This', 'study', 'examined', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', '(', 'nifedipine', 'SR', ')', 'compared', 'with', 'Ginkgo', 'biloba', 'extract', 'as', 'treatment', 'for', 'primary', 'Raynaud', ""'s"", 'phenomenon', '(', 'RP', ')', 'in', 'Korea', '.']","(23, 33)","(146, 193)",-1,ss_p,19159999,Abstract,0,test,gold,3338.0
2950,This study examined the efficacy and safety of,nifedipine sustained release ( nifedipine SR ),compared with Ginkgo biloba extract as treatment for primary Raynaud 's phenomenon ( RP ) in Korea .,"['This', 'study', 'examined', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', '(', 'nifedipine', 'SR', ')', 'compared', 'with', 'Ginkgo', 'biloba', 'extract', 'as', 'treatment', 'for', 'primary', 'Raynaud', ""'s"", 'phenomenon', '(', 'RP', ')', 'in', 'Korea', '.']","(8, 15)","(46, 92)",-1,ss_i,19159999,Abstract,0,test,gold,3526.0
2951,This study examined the efficacy and safety of nifedipine sustained release ( nifedipine SR ) compared with,Ginkgo biloba extract,as treatment for primary Raynaud 's phenomenon ( RP ) in Korea .,"['This', 'study', 'examined', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', '(', 'nifedipine', 'SR', ')', 'compared', 'with', 'Ginkgo', 'biloba', 'extract', 'as', 'treatment', 'for', 'primary', 'Raynaud', ""'s"", 'phenomenon', '(', 'RP', ')', 'in', 'Korea', '.']","(17, 20)","(107, 128)",-1,ss_i,19159999,Abstract,0,test,gold,4602.0
2952,This study examined the,efficacy,and safety of nifedipine sustained release ( nifedipine SR ) compared with Ginkgo biloba extract as treatment for primary Raynaud 's phenomenon ( RP ) in Korea .,"['This', 'study', 'examined', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', '(', 'nifedipine', 'SR', ')', 'compared', 'with', 'Ginkgo', 'biloba', 'extract', 'as', 'treatment', 'for', 'primary', 'Raynaud', ""'s"", 'phenomenon', '(', 'RP', ')', 'in', 'Korea', '.']","(4, 5)","(23, 31)",-1,ss_o,19159999,Abstract,0,test,gold,4816.0
2953,This study examined the efficacy and,safety,of nifedipine sustained release ( nifedipine SR ) compared with Ginkgo biloba extract as treatment for primary Raynaud 's phenomenon ( RP ) in Korea .,"['This', 'study', 'examined', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', '(', 'nifedipine', 'SR', ')', 'compared', 'with', 'Ginkgo', 'biloba', 'extract', 'as', 'treatment', 'for', 'primary', 'Raynaud', ""'s"", 'phenomenon', '(', 'RP', ')', 'in', 'Korea', '.']","(6, 7)","(36, 42)",-1,ss_o,19159999,Abstract,0,test,gold,472.0
2954,This study examined the efficacy and safety of,nifedipine sustained release ( nifedipine SR ),compared with Ginkgo biloba extract as treatment for primary Raynaud 's phenomenon ( RP ) in Korea .,"['This', 'study', 'examined', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', '(', 'nifedipine', 'SR', ')', 'compared', 'with', 'Ginkgo', 'biloba', 'extract', 'as', 'treatment', 'for', 'primary', 'Raynaud', ""'s"", 'phenomenon', '(', 'RP', ')', 'in', 'Korea', '.']","(8, 15)","(46, 92)",-1,hl_i,19159999,Abstract,0,test,gold,3527.0
2955,This study examined the efficacy and safety of nifedipine sustained release ( nifedipine SR ) compared with,Ginkgo biloba extract,as treatment for primary Raynaud 's phenomenon ( RP ) in Korea .,"['This', 'study', 'examined', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', '(', 'nifedipine', 'SR', ')', 'compared', 'with', 'Ginkgo', 'biloba', 'extract', 'as', 'treatment', 'for', 'primary', 'Raynaud', ""'s"", 'phenomenon', '(', 'RP', ')', 'in', 'Korea', '.']","(17, 20)","(107, 128)",-1,hl_i,19159999,Abstract,0,test,gold,4601.0
2956,This study examined the,efficacy,and safety of nifedipine sustained release ( nifedipine SR ) compared with Ginkgo biloba extract as treatment for primary Raynaud 's phenomenon ( RP ) in Korea .,"['This', 'study', 'examined', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', '(', 'nifedipine', 'SR', ')', 'compared', 'with', 'Ginkgo', 'biloba', 'extract', 'as', 'treatment', 'for', 'primary', 'Raynaud', ""'s"", 'phenomenon', '(', 'RP', ')', 'in', 'Korea', '.']","(4, 5)","(23, 31)",-1,hl_o,19159999,Abstract,0,test,gold,4815.0
2957,This study examined the efficacy and,safety,of nifedipine sustained release ( nifedipine SR ) compared with Ginkgo biloba extract as treatment for primary Raynaud 's phenomenon ( RP ) in Korea .,"['This', 'study', 'examined', 'the', 'efficacy', 'and', 'safety', 'of', 'nifedipine', 'sustained', 'release', '(', 'nifedipine', 'SR', ')', 'compared', 'with', 'Ginkgo', 'biloba', 'extract', 'as', 'treatment', 'for', 'primary', 'Raynaud', ""'s"", 'phenomenon', '(', 'RP', ')', 'in', 'Korea', '.']","(6, 7)","(36, 42)",-1,hl_o,19159999,Abstract,0,test,gold,471.0
2958,Primary RP were screened and assigned to either the,nifedipine SR,group ( Group N ) or the Ginkgo biloba extract group ( Group G ) in the ratio of 2:1 .,"['Primary', 'RP', 'were', 'screened', 'and', 'assigned', 'to', 'either', 'the', 'nifedipine', 'SR', 'group', '(', 'Group', 'N', ')', 'or', 'the', 'Ginkgo', 'biloba', 'extract', 'group', '(', 'Group', 'G', ')', 'in', 'the', 'ratio', 'of', '2:1', '.']","(9, 11)","(51, 64)",-1,ss_i,19159999,Abstract,1,test,gold,5265.0
2959,Primary RP were screened and assigned to either the nifedipine SR group ( Group N ) or the,Ginkgo biloba extract,group ( Group G ) in the ratio of 2:1 .,"['Primary', 'RP', 'were', 'screened', 'and', 'assigned', 'to', 'either', 'the', 'nifedipine', 'SR', 'group', '(', 'Group', 'N', ')', 'or', 'the', 'Ginkgo', 'biloba', 'extract', 'group', '(', 'Group', 'G', ')', 'in', 'the', 'ratio', 'of', '2:1', '.']","(18, 21)","(90, 111)",-1,ss_i,19159999,Abstract,1,test,gold,4600.0
2960,Primary RP were screened and assigned to either the,nifedipine SR,group ( Group N ) or the Ginkgo biloba extract group ( Group G ) in the ratio of 2:1 .,"['Primary', 'RP', 'were', 'screened', 'and', 'assigned', 'to', 'either', 'the', 'nifedipine', 'SR', 'group', '(', 'Group', 'N', ')', 'or', 'the', 'Ginkgo', 'biloba', 'extract', 'group', '(', 'Group', 'G', ')', 'in', 'the', 'ratio', 'of', '2:1', '.']","(9, 11)","(51, 64)",-1,hl_i,19159999,Abstract,1,test,gold,5266.0
2961,Primary RP were screened and assigned to either the nifedipine SR group ( Group N ) or the,Ginkgo biloba extract,group ( Group G ) in the ratio of 2:1 .,"['Primary', 'RP', 'were', 'screened', 'and', 'assigned', 'to', 'either', 'the', 'nifedipine', 'SR', 'group', '(', 'Group', 'N', ')', 'or', 'the', 'Ginkgo', 'biloba', 'extract', 'group', '(', 'Group', 'G', ')', 'in', 'the', 'ratio', 'of', '2:1', '.']","(18, 21)","(90, 111)",-1,hl_i,19159999,Abstract,1,test,gold,4599.0
2962,"After a run-in period of 2 weeks , patients received treatment for 8 weeks .",,,"['After', 'a', 'run-in', 'period', 'of', '2', 'weeks', ',', 'patients', 'received', 'treatment', 'for', '8', 'weeks', '.']",,,,,19159999,Abstract,2,test,gold,
2963,We observed the,percent improvement of the RP attack rate between before and after the 8-week treatment .,,"['We', 'observed', 'the', 'percent', 'improvement', 'of', 'the', 'RP', 'attack', 'rate', 'between', 'before', 'and', 'after', 'the', '8-week', 'treatment', '.']","(3, 18)","(15, 104)",-1,ss_o,19159999,Abstract,3,test,gold,6470.0
2964,We observed the,percent improvement of the RP attack rate,between before and after the 8-week treatment .,"['We', 'observed', 'the', 'percent', 'improvement', 'of', 'the', 'RP', 'attack', 'rate', 'between', 'before', 'and', 'after', 'the', '8-week', 'treatment', '.']","(3, 10)","(15, 56)",-1,hl_o,19159999,Abstract,3,test,gold,6471.0
2965,,Ninety-three subjects,were randomly assigned .,"['Ninety-three', 'subjects', 'were', 'randomly', 'assigned', '.']","(0, 2)","(0, 21)",-1,ss_p,19159999,Abstract,4,test,gold,2072.0
2966,,Ninety-three subjects,were randomly assigned .,"['Ninety-three', 'subjects', 'were', 'randomly', 'assigned', '.']","(0, 2)","(0, 21)",-1,hl_p,19159999,Abstract,4,test,gold,2071.0
2967,The,percent improvement,"in Group N was 50.1 % at 8 weeks after treatment , while it was 31.0 % in Group G ( p = 0.03 ) .","['The', 'percent', 'improvement', 'in', 'Group', 'N', 'was', '50.1', '%', 'at', '8', 'weeks', 'after', 'treatment', ',', 'while', 'it', 'was', '31.0', '%', 'in', 'Group', 'G', '(', 'p', '=', '0.03', ')', '.']","(1, 3)","(3, 22)",-1,ss_o,19159999,Abstract,5,test,gold,974.0
2968,No,serious adverse events,"occurred , and almost adverse events were mild and improved without specific treatment .","['No', 'serious', 'adverse', 'events', 'occurred', ',', 'and', 'almost', 'adverse', 'events', 'were', 'mild', 'and', 'improved', 'without', 'specific', 'treatment', '.']","(1, 4)","(2, 24)",-1,ss_o,19159999,Abstract,6,test,gold,3050.0
2969,"No serious adverse events occurred , and almost",adverse events,were mild and improved without specific treatment .,"['No', 'serious', 'adverse', 'events', 'occurred', ',', 'and', 'almost', 'adverse', 'events', 'were', 'mild', 'and', 'improved', 'without', 'specific', 'treatment', '.']","(8, 10)","(47, 61)",-1,ss_o,19159999,Abstract,6,test,gold,3062.0
2970,No,serious adverse events,"occurred , and almost adverse events were mild and improved without specific treatment .","['No', 'serious', 'adverse', 'events', 'occurred', ',', 'and', 'almost', 'adverse', 'events', 'were', 'mild', 'and', 'improved', 'without', 'specific', 'treatment', '.']","(1, 4)","(2, 24)",-1,hl_o,19159999,Abstract,6,test,gold,3051.0
2971,"No serious adverse events occurred , and almost",adverse events,were mild and improved without specific treatment .,"['No', 'serious', 'adverse', 'events', 'occurred', ',', 'and', 'almost', 'adverse', 'events', 'were', 'mild', 'and', 'improved', 'without', 'specific', 'treatment', '.']","(8, 10)","(47, 61)",-1,hl_o,19159999,Abstract,6,test,gold,3061.0
2972,nifedipine SR was more effective than Ginkgo biloba extract for treatment of,primary RP in Korean patients .,,"['nifedipine', 'SR', 'was', 'more', 'effective', 'than', 'Ginkgo', 'biloba', 'extract', 'for', 'treatment', 'of', 'primary', 'RP', 'in', 'Korean', 'patients', '.']","(12, 18)","(76, 107)",-1,ss_p,19159999,Abstract,7,test,gold,3867.0
2973,,nifedipine SR,was more effective than Ginkgo biloba extract for treatment of primary RP in Korean patients .,"['nifedipine', 'SR', 'was', 'more', 'effective', 'than', 'Ginkgo', 'biloba', 'extract', 'for', 'treatment', 'of', 'primary', 'RP', 'in', 'Korean', 'patients', '.']","(0, 2)","(0, 13)",-1,ss_i,19159999,Abstract,7,test,gold,5264.0
2974,nifedipine SR was more effective than,Ginkgo biloba extract,for treatment of primary RP in Korean patients .,"['nifedipine', 'SR', 'was', 'more', 'effective', 'than', 'Ginkgo', 'biloba', 'extract', 'for', 'treatment', 'of', 'primary', 'RP', 'in', 'Korean', 'patients', '.']","(6, 9)","(37, 58)",-1,ss_i,19159999,Abstract,7,test,gold,4598.0
2975,nifedipine SR was more,effective,than Ginkgo biloba extract for treatment of primary RP in Korean patients .,"['nifedipine', 'SR', 'was', 'more', 'effective', 'than', 'Ginkgo', 'biloba', 'extract', 'for', 'treatment', 'of', 'primary', 'RP', 'in', 'Korean', 'patients', '.']","(4, 5)","(22, 31)",-1,ss_o,19159999,Abstract,7,test,gold,851.0
2976,nifedipine SR was more effective than Ginkgo biloba extract for treatment of primary RP in,Korean patients .,,"['nifedipine', 'SR', 'was', 'more', 'effective', 'than', 'Ginkgo', 'biloba', 'extract', 'for', 'treatment', 'of', 'primary', 'RP', 'in', 'Korean', 'patients', '.']","(15, 18)","(90, 107)",-1,hl_p,19159999,Abstract,7,test,gold,2225.0
2977,,nifedipine SR,was more effective than Ginkgo biloba extract for treatment of primary RP in Korean patients .,"['nifedipine', 'SR', 'was', 'more', 'effective', 'than', 'Ginkgo', 'biloba', 'extract', 'for', 'treatment', 'of', 'primary', 'RP', 'in', 'Korean', 'patients', '.']","(0, 2)","(0, 13)",-1,hl_i,19159999,Abstract,7,test,gold,5263.0
2978,nifedipine SR was more effective than,Ginkgo biloba extract,for treatment of primary RP in Korean patients .,"['nifedipine', 'SR', 'was', 'more', 'effective', 'than', 'Ginkgo', 'biloba', 'extract', 'for', 'treatment', 'of', 'primary', 'RP', 'in', 'Korean', 'patients', '.']","(6, 9)","(37, 58)",-1,hl_i,19159999,Abstract,7,test,gold,4597.0
2979,nifedipine SR was more,effective,than Ginkgo biloba extract for treatment of primary RP in Korean patients .,"['nifedipine', 'SR', 'was', 'more', 'effective', 'than', 'Ginkgo', 'biloba', 'extract', 'for', 'treatment', 'of', 'primary', 'RP', 'in', 'Korean', 'patients', '.']","(4, 5)","(22, 31)",-1,hl_o,19159999,Abstract,7,test,gold,850.0
2980,Both drugs were tolerable with,primary RP patients .,,"['Both', 'drugs', 'were', 'tolerable', 'with', 'primary', 'RP', 'patients', '.']","(5, 9)","(30, 51)",-1,ss_p,19159999,Abstract,8,test,gold,3868.0
2981,Both drugs were,tolerable,with primary RP patients .,"['Both', 'drugs', 'were', 'tolerable', 'with', 'primary', 'RP', 'patients', '.']","(3, 4)","(15, 24)",-1,ss_o,19159999,Abstract,8,test,gold,869.0
2982,Both drugs were tolerable with primary,RP patients .,,"['Both', 'drugs', 'were', 'tolerable', 'with', 'primary', 'RP', 'patients', '.']","(6, 9)","(38, 51)",-1,hl_p,19159999,Abstract,8,test,gold,3869.0
2983,Both drugs were,tolerable,with primary RP patients .,"['Both', 'drugs', 'were', 'tolerable', 'with', 'primary', 'RP', 'patients', '.']","(3, 4)","(15, 24)",-1,hl_o,19159999,Abstract,8,test,gold,870.0
2984,A comparison of continuous femoral nerve block ( CFNB ) and continuous epidural infusion ( CEI ) in postoperative analgesia and knee rehabilitation,after total knee arthroplasty ( TKA ) .,,"['A', 'comparison', 'of', 'continuous', 'femoral', 'nerve', 'block', '(', 'CFNB', ')', 'and', 'continuous', 'epidural', 'infusion', '(', 'CEI', ')', 'in', 'postoperative', 'analgesia', 'and', 'knee', 'rehabilitation', 'after', 'total', 'knee', 'arthroplasty', '(', 'TKA', ')', '.']","(23, 31)","(147, 186)",-1,ss_p,19301724,Title,0,test,gold,3681.0
2985,A comparison of,continuous femoral nerve block ( CFNB ),and continuous epidural infusion ( CEI ) in postoperative analgesia and knee rehabilitation after total knee arthroplasty ( TKA ) .,"['A', 'comparison', 'of', 'continuous', 'femoral', 'nerve', 'block', '(', 'CFNB', ')', 'and', 'continuous', 'epidural', 'infusion', '(', 'CEI', ')', 'in', 'postoperative', 'analgesia', 'and', 'knee', 'rehabilitation', 'after', 'total', 'knee', 'arthroplasty', '(', 'TKA', ')', '.']","(3, 10)","(15, 54)",-1,ss_i,19301724,Title,0,test,gold,3101.0
2986,A comparison of continuous femoral nerve block ( CFNB ) and,continuous epidural infusion ( CEI ),in postoperative analgesia and knee rehabilitation after total knee arthroplasty ( TKA ) .,"['A', 'comparison', 'of', 'continuous', 'femoral', 'nerve', 'block', '(', 'CFNB', ')', 'and', 'continuous', 'epidural', 'infusion', '(', 'CEI', ')', 'in', 'postoperative', 'analgesia', 'and', 'knee', 'rehabilitation', 'after', 'total', 'knee', 'arthroplasty', '(', 'TKA', ')', '.']","(11, 17)","(59, 95)",-1,ss_i,19301724,Title,0,test,gold,4946.0
2987,A comparison of continuous femoral nerve block ( CFNB ) and continuous epidural infusion ( CEI ) in postoperative analgesia and knee rehabilitation after,total knee arthroplasty ( TKA ) .,,"['A', 'comparison', 'of', 'continuous', 'femoral', 'nerve', 'block', '(', 'CFNB', ')', 'and', 'continuous', 'epidural', 'infusion', '(', 'CEI', ')', 'in', 'postoperative', 'analgesia', 'and', 'knee', 'rehabilitation', 'after', 'total', 'knee', 'arthroplasty', '(', 'TKA', ')', '.']","(24, 31)","(153, 186)",-1,hl_p,19301724,Title,0,test,gold,3683.0
2988,A comparison of,continuous femoral nerve block ( CFNB ),and continuous epidural infusion ( CEI ) in postoperative analgesia and knee rehabilitation after total knee arthroplasty ( TKA ) .,"['A', 'comparison', 'of', 'continuous', 'femoral', 'nerve', 'block', '(', 'CFNB', ')', 'and', 'continuous', 'epidural', 'infusion', '(', 'CEI', ')', 'in', 'postoperative', 'analgesia', 'and', 'knee', 'rehabilitation', 'after', 'total', 'knee', 'arthroplasty', '(', 'TKA', ')', '.']","(3, 10)","(15, 54)",-1,hl_i,19301724,Title,0,test,gold,3102.0
2989,A comparison of continuous femoral nerve block ( CFNB ) and,continuous epidural infusion ( CEI ),in postoperative analgesia and knee rehabilitation after total knee arthroplasty ( TKA ) .,"['A', 'comparison', 'of', 'continuous', 'femoral', 'nerve', 'block', '(', 'CFNB', ')', 'and', 'continuous', 'epidural', 'infusion', '(', 'CEI', ')', 'in', 'postoperative', 'analgesia', 'and', 'knee', 'rehabilitation', 'after', 'total', 'knee', 'arthroplasty', '(', 'TKA', ')', '.']","(11, 17)","(59, 95)",-1,hl_i,19301724,Title,0,test,gold,4947.0
2990,BACKGROUND Postoperative epidural analgesia ( EA ) and,femoral nerve block ( FNB ),"provided effective pain relief However , EA has common side effects such as nausea , vomiting , pruritus , dizziness , and hypotension .","['BACKGROUND', 'Postoperative', 'epidural', 'analgesia', '(', 'EA', ')', 'and', 'femoral', 'nerve', 'block', '(', 'FNB', ')', 'provided', 'effective', 'pain', 'relief', 'However', ',', 'EA', 'has', 'common', 'side', 'effects', 'such', 'as', 'nausea', ',', 'vomiting', ',', 'pruritus', ',', 'dizziness', ',', 'and', 'hypotension', '.']","(8, 14)","(54, 81)",-1,ss_i,19301724,Abstract,0,test,gold,3103.0
2991,BACKGROUND Postoperative epidural analgesia ( EA ) and femoral nerve block ( FNB ) provided effective,pain relief,"However , EA has common side effects such as nausea , vomiting , pruritus , dizziness , and hypotension .","['BACKGROUND', 'Postoperative', 'epidural', 'analgesia', '(', 'EA', ')', 'and', 'femoral', 'nerve', 'block', '(', 'FNB', ')', 'provided', 'effective', 'pain', 'relief', 'However', ',', 'EA', 'has', 'common', 'side', 'effects', 'such', 'as', 'nausea', ',', 'vomiting', ',', 'pruritus', ',', 'dizziness', ',', 'and', 'hypotension', '.']","(16, 18)","(101, 112)",-1,ss_o,19301724,Abstract,0,test,gold,2306.0
2992,"BACKGROUND Postoperative epidural analgesia ( EA ) and femoral nerve block ( FNB ) provided effective pain relief However , EA has common",side effects,"such as nausea , vomiting , pruritus , dizziness , and hypotension .","['BACKGROUND', 'Postoperative', 'epidural', 'analgesia', '(', 'EA', ')', 'and', 'femoral', 'nerve', 'block', '(', 'FNB', ')', 'provided', 'effective', 'pain', 'relief', 'However', ',', 'EA', 'has', 'common', 'side', 'effects', 'such', 'as', 'nausea', ',', 'vomiting', ',', 'pruritus', ',', 'dizziness', ',', 'and', 'hypotension', '.']","(23, 25)","(137, 149)",-1,ss_o,19301724,Abstract,0,test,gold,2373.0
2993,"BACKGROUND Postoperative epidural analgesia ( EA ) and femoral nerve block ( FNB ) provided effective pain relief However , EA has common side effects such as","nausea , vomiting , pruritus , dizziness , and hypotension .",,"['BACKGROUND', 'Postoperative', 'epidural', 'analgesia', '(', 'EA', ')', 'and', 'femoral', 'nerve', 'block', '(', 'FNB', ')', 'provided', 'effective', 'pain', 'relief', 'However', ',', 'EA', 'has', 'common', 'side', 'effects', 'such', 'as', 'nausea', ',', 'vomiting', ',', 'pruritus', ',', 'dizziness', ',', 'and', 'hypotension', '.']","(27, 38)","(158, 218)",-1,ss_o,19301724,Abstract,0,test,gold,7127.0
2994,BACKGROUND Postoperative epidural analgesia ( EA ) and,femoral nerve block ( FNB ),"provided effective pain relief However , EA has common side effects such as nausea , vomiting , pruritus , dizziness , and hypotension .","['BACKGROUND', 'Postoperative', 'epidural', 'analgesia', '(', 'EA', ')', 'and', 'femoral', 'nerve', 'block', '(', 'FNB', ')', 'provided', 'effective', 'pain', 'relief', 'However', ',', 'EA', 'has', 'common', 'side', 'effects', 'such', 'as', 'nausea', ',', 'vomiting', ',', 'pruritus', ',', 'dizziness', ',', 'and', 'hypotension', '.']","(8, 14)","(54, 81)",-1,hl_i,19301724,Abstract,0,test,gold,3104.0
2995,Some investigations found that those side effects were less in FNB than in EA .,,,"['Some', 'investigations', 'found', 'that', 'those', 'side', 'effects', 'were', 'less', 'in', 'FNB', 'than', 'in', 'EA', '.']",,,,,19301724,Abstract,1,test,gold,
2996,However the analgesic equivalent of both techniques have not been confirmed .,,,"['However', 'the', 'analgesic', 'equivalent', 'of', 'both', 'techniques', 'have', 'not', 'been', 'confirmed', '.']",,,,,19301724,Abstract,2,test,gold,
2997,OBJECTIVE The authors compared,continuous epidural infusion ( CEI ),"with continuous femoral nerve block ( CFNB ) regarding the postoperative analgesic efficacy , side effects , postoperative knee rehabilitation , and hospital length of stay ( LOS ) .","['OBJECTIVE', 'The', 'authors', 'compared', 'continuous', 'epidural', 'infusion', '(', 'CEI', ')', 'with', 'continuous', 'femoral', 'nerve', 'block', '(', 'CFNB', ')', 'regarding', 'the', 'postoperative', 'analgesic', 'efficacy', ',', 'side', 'effects', ',', 'postoperative', 'knee', 'rehabilitation', ',', 'and', 'hospital', 'length', 'of', 'stay', '(', 'LOS', ')', '.']","(4, 10)","(30, 66)",-1,ss_i,19301724,Abstract,3,test,gold,4945.0
2998,OBJECTIVE The authors compared continuous epidural infusion ( CEI ) with,continuous femoral nerve block ( CFNB ),"regarding the postoperative analgesic efficacy , side effects , postoperative knee rehabilitation , and hospital length of stay ( LOS ) .","['OBJECTIVE', 'The', 'authors', 'compared', 'continuous', 'epidural', 'infusion', '(', 'CEI', ')', 'with', 'continuous', 'femoral', 'nerve', 'block', '(', 'CFNB', ')', 'regarding', 'the', 'postoperative', 'analgesic', 'efficacy', ',', 'side', 'effects', ',', 'postoperative', 'knee', 'rehabilitation', ',', 'and', 'hospital', 'length', 'of', 'stay', '(', 'LOS', ')', '.']","(11, 18)","(72, 111)",-1,ss_i,19301724,Abstract,3,test,gold,3100.0
2999,OBJECTIVE The authors compared continuous epidural infusion ( CEI ) with continuous femoral nerve block ( CFNB ) regarding the,"postoperative analgesic efficacy , side effects , postoperative knee rehabilitation , and hospital length of stay ( LOS ) .",,"['OBJECTIVE', 'The', 'authors', 'compared', 'continuous', 'epidural', 'infusion', '(', 'CEI', ')', 'with', 'continuous', 'femoral', 'nerve', 'block', '(', 'CFNB', ')', 'regarding', 'the', 'postoperative', 'analgesic', 'efficacy', ',', 'side', 'effects', ',', 'postoperative', 'knee', 'rehabilitation', ',', 'and', 'hospital', 'length', 'of', 'stay', '(', 'LOS', ')', '.']","(20, 40)","(126, 249)",-1,ss_o,19301724,Abstract,3,test,gold,5944.0
3000,OBJECTIVE The authors compared,continuous epidural infusion ( CEI ),"with continuous femoral nerve block ( CFNB ) regarding the postoperative analgesic efficacy , side effects , postoperative knee rehabilitation , and hospital length of stay ( LOS ) .","['OBJECTIVE', 'The', 'authors', 'compared', 'continuous', 'epidural', 'infusion', '(', 'CEI', ')', 'with', 'continuous', 'femoral', 'nerve', 'block', '(', 'CFNB', ')', 'regarding', 'the', 'postoperative', 'analgesic', 'efficacy', ',', 'side', 'effects', ',', 'postoperative', 'knee', 'rehabilitation', ',', 'and', 'hospital', 'length', 'of', 'stay', '(', 'LOS', ')', '.']","(4, 10)","(30, 66)",-1,hl_i,19301724,Abstract,3,test,gold,4944.0
3001,OBJECTIVE The authors compared continuous epidural infusion ( CEI ) with,continuous femoral nerve block ( CFNB ),"regarding the postoperative analgesic efficacy , side effects , postoperative knee rehabilitation , and hospital length of stay ( LOS ) .","['OBJECTIVE', 'The', 'authors', 'compared', 'continuous', 'epidural', 'infusion', '(', 'CEI', ')', 'with', 'continuous', 'femoral', 'nerve', 'block', '(', 'CFNB', ')', 'regarding', 'the', 'postoperative', 'analgesic', 'efficacy', ',', 'side', 'effects', ',', 'postoperative', 'knee', 'rehabilitation', ',', 'and', 'hospital', 'length', 'of', 'stay', '(', 'LOS', ')', '.']","(11, 18)","(72, 111)",-1,hl_i,19301724,Abstract,3,test,gold,3099.0
3002,OBJECTIVE The authors compared continuous epidural infusion ( CEI ) with continuous femoral nerve block ( CFNB ) regarding the,postoperative analgesic efficacy,", side effects , postoperative knee rehabilitation , and hospital length of stay ( LOS ) .","['OBJECTIVE', 'The', 'authors', 'compared', 'continuous', 'epidural', 'infusion', '(', 'CEI', ')', 'with', 'continuous', 'femoral', 'nerve', 'block', '(', 'CFNB', ')', 'regarding', 'the', 'postoperative', 'analgesic', 'efficacy', ',', 'side', 'effects', ',', 'postoperative', 'knee', 'rehabilitation', ',', 'and', 'hospital', 'length', 'of', 'stay', '(', 'LOS', ')', '.']","(20, 23)","(126, 158)",-1,hl_o,19301724,Abstract,3,test,gold,4853.0
3003,"OBJECTIVE The authors compared continuous epidural infusion ( CEI ) with continuous femoral nerve block ( CFNB ) regarding the postoperative analgesic efficacy ,",side effects,", postoperative knee rehabilitation , and hospital length of stay ( LOS ) .","['OBJECTIVE', 'The', 'authors', 'compared', 'continuous', 'epidural', 'infusion', '(', 'CEI', ')', 'with', 'continuous', 'femoral', 'nerve', 'block', '(', 'CFNB', ')', 'regarding', 'the', 'postoperative', 'analgesic', 'efficacy', ',', 'side', 'effects', ',', 'postoperative', 'knee', 'rehabilitation', ',', 'and', 'hospital', 'length', 'of', 'stay', '(', 'LOS', ')', '.']","(24, 26)","(161, 173)",-1,hl_o,19301724,Abstract,3,test,gold,2374.0
3004,"OBJECTIVE The authors compared continuous epidural infusion ( CEI ) with continuous femoral nerve block ( CFNB ) regarding the postoperative analgesic efficacy , side effects ,",postoperative knee rehabilitation,", and hospital length of stay ( LOS ) .","['OBJECTIVE', 'The', 'authors', 'compared', 'continuous', 'epidural', 'infusion', '(', 'CEI', ')', 'with', 'continuous', 'femoral', 'nerve', 'block', '(', 'CFNB', ')', 'regarding', 'the', 'postoperative', 'analgesic', 'efficacy', ',', 'side', 'effects', ',', 'postoperative', 'knee', 'rehabilitation', ',', 'and', 'hospital', 'length', 'of', 'stay', '(', 'LOS', ')', '.']","(27, 30)","(176, 209)",-1,hl_o,19301724,Abstract,3,test,gold,3677.0
3005,"OBJECTIVE The authors compared continuous epidural infusion ( CEI ) with continuous femoral nerve block ( CFNB ) regarding the postoperative analgesic efficacy , side effects , postoperative knee rehabilitation , and",hospital length of stay ( LOS ),.,"['OBJECTIVE', 'The', 'authors', 'compared', 'continuous', 'epidural', 'infusion', '(', 'CEI', ')', 'with', 'continuous', 'femoral', 'nerve', 'block', '(', 'CFNB', ')', 'regarding', 'the', 'postoperative', 'analgesic', 'efficacy', ',', 'side', 'effects', ',', 'postoperative', 'knee', 'rehabilitation', ',', 'and', 'hospital', 'length', 'of', 'stay', '(', 'LOS', ')', '.']","(32, 39)","(216, 247)",-1,hl_o,19301724,Abstract,3,test,gold,3701.0
3006,"MATERIAL AND METHOD In this prospective , randomized controlled study ,",61 ASA physical status I-III patients scheduled for elective unilateral total knee arthroplasty ( TKA ) under spinal anesthesia ( SA ),participated .,"['MATERIAL', 'AND', 'METHOD', 'In', 'this', 'prospective', ',', 'randomized', 'controlled', 'study', ',', '61', 'ASA', 'physical', 'status', 'I-III', 'patients', 'scheduled', 'for', 'elective', 'unilateral', 'total', 'knee', 'arthroplasty', '(', 'TKA', ')', 'under', 'spinal', 'anesthesia', '(', 'SA', ')', 'participated', '.']","(11, 33)","(71, 205)",-1,ss_p,19301724,Abstract,4,test,gold,5942.0
3007,"MATERIAL AND METHOD In this prospective , randomized controlled study ,",61 ASA physical status I-III patients scheduled for elective unilateral total knee arthroplasty ( TKA ) under spinal anesthesia ( SA ),participated .,"['MATERIAL', 'AND', 'METHOD', 'In', 'this', 'prospective', ',', 'randomized', 'controlled', 'study', ',', '61', 'ASA', 'physical', 'status', 'I-III', 'patients', 'scheduled', 'for', 'elective', 'unilateral', 'total', 'knee', 'arthroplasty', '(', 'TKA', ')', 'under', 'spinal', 'anesthesia', '(', 'SA', ')', 'participated', '.']","(11, 33)","(71, 205)",-1,hl_p,19301724,Abstract,4,test,gold,5943.0
3008,The patients were allocated into two groups .,,,"['The', 'patients', 'were', 'allocated', 'into', 'two', 'groups', '.']",,,,,19301724,Abstract,5,test,gold,
3009,"In the ward , patients in Group I",( CEI ),"were maintained by continuous infusion of 0.125 % levobupivacaine with morphine 0.0125 mg/ml ( 4 ml/hr ) , Group II ( CFNB ) were maintained by 0.125 % levobupivacaine ( 8 ml/hr ) .","['In', 'the', 'ward', ',', 'patients', 'in', 'Group', 'I', '(', 'CEI', ')', 'were', 'maintained', 'by', 'continuous', 'infusion', 'of', '0.125', '%', 'levobupivacaine', 'with', 'morphine', '0.0125', 'mg/ml', '(', '4', 'ml/hr', ')', ',', 'Group', 'II', '(', 'CFNB', ')', 'were', 'maintained', 'by', '0.125', '%', 'levobupivacaine', '(', '8', 'ml/hr', ')', '.']","(8, 11)","(33, 40)",-1,ss_i,19301724,Abstract,6,test,gold,600.0
3010,"In the ward , patients in Group I ( CEI ) were maintained by continuous infusion of 0.125 %",levobupivacaine,"with morphine 0.0125 mg/ml ( 4 ml/hr ) , Group II ( CFNB ) were maintained by 0.125 % levobupivacaine ( 8 ml/hr ) .","['In', 'the', 'ward', ',', 'patients', 'in', 'Group', 'I', '(', 'CEI', ')', 'were', 'maintained', 'by', 'continuous', 'infusion', 'of', '0.125', '%', 'levobupivacaine', 'with', 'morphine', '0.0125', 'mg/ml', '(', '4', 'ml/hr', ')', ',', 'Group', 'II', '(', 'CFNB', ')', 'were', 'maintained', 'by', '0.125', '%', 'levobupivacaine', '(', '8', 'ml/hr', ')', '.']","(19, 20)","(91, 106)",-1,ss_i,19301724,Abstract,6,test,gold,
3011,"In the ward , patients in Group I ( CEI ) were maintained by continuous infusion of 0.125 % levobupivacaine with",morphine,"0.0125 mg/ml ( 4 ml/hr ) , Group II ( CFNB ) were maintained by 0.125 % levobupivacaine ( 8 ml/hr ) .","['In', 'the', 'ward', ',', 'patients', 'in', 'Group', 'I', '(', 'CEI', ')', 'were', 'maintained', 'by', 'continuous', 'infusion', 'of', '0.125', '%', 'levobupivacaine', 'with', 'morphine', '0.0125', 'mg/ml', '(', '4', 'ml/hr', ')', ',', 'Group', 'II', '(', 'CFNB', ')', 'were', 'maintained', 'by', '0.125', '%', 'levobupivacaine', '(', '8', 'ml/hr', ')', '.']","(21, 22)","(112, 120)",-1,ss_i,19301724,Abstract,6,test,gold,5099.0
3012,"In the ward , patients in Group I ( CEI ) were maintained by continuous infusion of 0.125 % levobupivacaine with morphine 0.0125 mg/ml ( 4 ml/hr ) , Group II",( CFNB ),were maintained by 0.125 % levobupivacaine ( 8 ml/hr ) .,"['In', 'the', 'ward', ',', 'patients', 'in', 'Group', 'I', '(', 'CEI', ')', 'were', 'maintained', 'by', 'continuous', 'infusion', 'of', '0.125', '%', 'levobupivacaine', 'with', 'morphine', '0.0125', 'mg/ml', '(', '4', 'ml/hr', ')', ',', 'Group', 'II', '(', 'CFNB', ')', 'were', 'maintained', 'by', '0.125', '%', 'levobupivacaine', '(', '8', 'ml/hr', ')', '.']","(31, 34)","(157, 165)",-1,ss_i,19301724,Abstract,6,test,gold,1027.0
3013,"In the ward , patients in Group I ( CEI ) were maintained by continuous infusion of 0.125 % levobupivacaine with morphine 0.0125 mg/ml ( 4 ml/hr ) , Group II ( CFNB ) were maintained by 0.125 %",levobupivacaine,( 8 ml/hr ) .,"['In', 'the', 'ward', ',', 'patients', 'in', 'Group', 'I', '(', 'CEI', ')', 'were', 'maintained', 'by', 'continuous', 'infusion', 'of', '0.125', '%', 'levobupivacaine', 'with', 'morphine', '0.0125', 'mg/ml', '(', '4', 'ml/hr', ')', ',', 'Group', 'II', '(', 'CFNB', ')', 'were', 'maintained', 'by', '0.125', '%', 'levobupivacaine', '(', '8', 'ml/hr', ')', '.']","(39, 40)","(193, 208)",-1,ss_i,19301724,Abstract,6,test,gold,
3014,"In the ward , patients in Group I",( CEI ),"were maintained by continuous infusion of 0.125 % levobupivacaine with morphine 0.0125 mg/ml ( 4 ml/hr ) , Group II ( CFNB ) were maintained by 0.125 % levobupivacaine ( 8 ml/hr ) .","['In', 'the', 'ward', ',', 'patients', 'in', 'Group', 'I', '(', 'CEI', ')', 'were', 'maintained', 'by', 'continuous', 'infusion', 'of', '0.125', '%', 'levobupivacaine', 'with', 'morphine', '0.0125', 'mg/ml', '(', '4', 'ml/hr', ')', ',', 'Group', 'II', '(', 'CFNB', ')', 'were', 'maintained', 'by', '0.125', '%', 'levobupivacaine', '(', '8', 'ml/hr', ')', '.']","(8, 11)","(33, 40)",-1,hl_i,19301724,Abstract,6,test,gold,601.0
3015,"In the ward , patients in Group I ( CEI ) were maintained by continuous infusion of 0.125 %",levobupivacaine,"with morphine 0.0125 mg/ml ( 4 ml/hr ) , Group II ( CFNB ) were maintained by 0.125 % levobupivacaine ( 8 ml/hr ) .","['In', 'the', 'ward', ',', 'patients', 'in', 'Group', 'I', '(', 'CEI', ')', 'were', 'maintained', 'by', 'continuous', 'infusion', 'of', '0.125', '%', 'levobupivacaine', 'with', 'morphine', '0.0125', 'mg/ml', '(', '4', 'ml/hr', ')', ',', 'Group', 'II', '(', 'CFNB', ')', 'were', 'maintained', 'by', '0.125', '%', 'levobupivacaine', '(', '8', 'ml/hr', ')', '.']","(19, 20)","(91, 106)",-1,hl_i,19301724,Abstract,6,test,gold,
3016,"In the ward , patients in Group I ( CEI ) were maintained by continuous infusion of 0.125 % levobupivacaine with",morphine,"0.0125 mg/ml ( 4 ml/hr ) , Group II ( CFNB ) were maintained by 0.125 % levobupivacaine ( 8 ml/hr ) .","['In', 'the', 'ward', ',', 'patients', 'in', 'Group', 'I', '(', 'CEI', ')', 'were', 'maintained', 'by', 'continuous', 'infusion', 'of', '0.125', '%', 'levobupivacaine', 'with', 'morphine', '0.0125', 'mg/ml', '(', '4', 'ml/hr', ')', ',', 'Group', 'II', '(', 'CFNB', ')', 'were', 'maintained', 'by', '0.125', '%', 'levobupivacaine', '(', '8', 'ml/hr', ')', '.']","(21, 22)","(112, 120)",-1,hl_i,19301724,Abstract,6,test,gold,5098.0
3017,"In the ward , patients in Group I ( CEI ) were maintained by continuous infusion of 0.125 % levobupivacaine with morphine 0.0125 mg/ml ( 4 ml/hr ) , Group II",( CFNB ),were maintained by 0.125 % levobupivacaine ( 8 ml/hr ) .,"['In', 'the', 'ward', ',', 'patients', 'in', 'Group', 'I', '(', 'CEI', ')', 'were', 'maintained', 'by', 'continuous', 'infusion', 'of', '0.125', '%', 'levobupivacaine', 'with', 'morphine', '0.0125', 'mg/ml', '(', '4', 'ml/hr', ')', ',', 'Group', 'II', '(', 'CFNB', ')', 'were', 'maintained', 'by', '0.125', '%', 'levobupivacaine', '(', '8', 'ml/hr', ')', '.']","(31, 34)","(157, 165)",-1,hl_i,19301724,Abstract,6,test,gold,1028.0
3018,"In the ward , patients in Group I ( CEI ) were maintained by continuous infusion of 0.125 % levobupivacaine with morphine 0.0125 mg/ml ( 4 ml/hr ) , Group II ( CFNB ) were maintained by 0.125 %",levobupivacaine,( 8 ml/hr ) .,"['In', 'the', 'ward', ',', 'patients', 'in', 'Group', 'I', '(', 'CEI', ')', 'were', 'maintained', 'by', 'continuous', 'infusion', 'of', '0.125', '%', 'levobupivacaine', 'with', 'morphine', '0.0125', 'mg/ml', '(', '4', 'ml/hr', ')', ',', 'Group', 'II', '(', 'CFNB', ')', 'were', 'maintained', 'by', '0.125', '%', 'levobupivacaine', '(', '8', 'ml/hr', ')', '.']","(39, 40)","(193, 208)",-1,hl_i,19301724,Abstract,6,test,gold,
3019,RESULTS Patients in the,CFNB,"group , the VAS scores at PO6-12 hr and tramadol IV requirement were significantly greater than the CEI group ( VAS : PO6 hr p-value = 0.001 , PO12 hr p-value = 0.004 ) .","['RESULTS', 'Patients', 'in', 'the', 'CFNB', 'group', ',', 'the', 'VAS', 'scores', 'at', 'PO6-12', 'hr', 'and', 'tramadol', 'IV', 'requirement', 'were', 'significantly', 'greater', 'than', 'the', 'CEI', 'group', '(', 'VAS', ':', 'PO6', 'hr', 'p-value', '=', '0.001', ',', 'PO12', 'hr', 'p-value', '=', '0.004', ')', '.']","(4, 5)","(23, 27)",-1,ss_i,19301724,Abstract,7,test,gold,1026.0
3020,"RESULTS Patients in the CFNB group , the VAS scores at PO6-12 hr and tramadol IV requirement were significantly greater than the",CEI,"group ( VAS : PO6 hr p-value = 0.001 , PO12 hr p-value = 0.004 ) .","['RESULTS', 'Patients', 'in', 'the', 'CFNB', 'group', ',', 'the', 'VAS', 'scores', 'at', 'PO6-12', 'hr', 'and', 'tramadol', 'IV', 'requirement', 'were', 'significantly', 'greater', 'than', 'the', 'CEI', 'group', '(', 'VAS', ':', 'PO6', 'hr', 'p-value', '=', '0.001', ',', 'PO12', 'hr', 'p-value', '=', '0.004', ')', '.']","(22, 23)","(128, 131)",-1,ss_i,19301724,Abstract,7,test,gold,599.0
3021,"RESULTS Patients in the CFNB group , the",VAS scores,"at PO6-12 hr and tramadol IV requirement were significantly greater than the CEI group ( VAS : PO6 hr p-value = 0.001 , PO12 hr p-value = 0.004 ) .","['RESULTS', 'Patients', 'in', 'the', 'CFNB', 'group', ',', 'the', 'VAS', 'scores', 'at', 'PO6-12', 'hr', 'and', 'tramadol', 'IV', 'requirement', 'were', 'significantly', 'greater', 'than', 'the', 'CEI', 'group', '(', 'VAS', ':', 'PO6', 'hr', 'p-value', '=', '0.001', ',', 'PO12', 'hr', 'p-value', '=', '0.004', ')', '.']","(8, 10)","(40, 50)",-1,ss_o,19301724,Abstract,7,test,gold,380.0
3022,"RESULTS Patients in the CFNB group , the VAS scores at PO6-12 hr and",tramadol IV requirement,"were significantly greater than the CEI group ( VAS : PO6 hr p-value = 0.001 , PO12 hr p-value = 0.004 ) .","['RESULTS', 'Patients', 'in', 'the', 'CFNB', 'group', ',', 'the', 'VAS', 'scores', 'at', 'PO6-12', 'hr', 'and', 'tramadol', 'IV', 'requirement', 'were', 'significantly', 'greater', 'than', 'the', 'CEI', 'group', '(', 'VAS', ':', 'PO6', 'hr', 'p-value', '=', '0.001', ',', 'PO12', 'hr', 'p-value', '=', '0.004', ')', '.']","(14, 17)","(68, 91)",-1,ss_o,19301724,Abstract,7,test,gold,5022.0
3023,RESULTS Patients in the,CFNB,"group , the VAS scores at PO6-12 hr and tramadol IV requirement were significantly greater than the CEI group ( VAS : PO6 hr p-value = 0.001 , PO12 hr p-value = 0.004 ) .","['RESULTS', 'Patients', 'in', 'the', 'CFNB', 'group', ',', 'the', 'VAS', 'scores', 'at', 'PO6-12', 'hr', 'and', 'tramadol', 'IV', 'requirement', 'were', 'significantly', 'greater', 'than', 'the', 'CEI', 'group', '(', 'VAS', ':', 'PO6', 'hr', 'p-value', '=', '0.001', ',', 'PO12', 'hr', 'p-value', '=', '0.004', ')', '.']","(4, 5)","(23, 27)",-1,hl_i,19301724,Abstract,7,test,gold,1025.0
3024,"RESULTS Patients in the CFNB group , the VAS scores at PO6-12 hr and tramadol IV requirement were significantly greater than the",CEI,"group ( VAS : PO6 hr p-value = 0.001 , PO12 hr p-value = 0.004 ) .","['RESULTS', 'Patients', 'in', 'the', 'CFNB', 'group', ',', 'the', 'VAS', 'scores', 'at', 'PO6-12', 'hr', 'and', 'tramadol', 'IV', 'requirement', 'were', 'significantly', 'greater', 'than', 'the', 'CEI', 'group', '(', 'VAS', ':', 'PO6', 'hr', 'p-value', '=', '0.001', ',', 'PO12', 'hr', 'p-value', '=', '0.004', ')', '.']","(22, 23)","(128, 131)",-1,hl_i,19301724,Abstract,7,test,gold,598.0
3025,"RESULTS Patients in the CFNB group , the",VAS scores,"at PO6-12 hr and tramadol IV requirement were significantly greater than the CEI group ( VAS : PO6 hr p-value = 0.001 , PO12 hr p-value = 0.004 ) .","['RESULTS', 'Patients', 'in', 'the', 'CFNB', 'group', ',', 'the', 'VAS', 'scores', 'at', 'PO6-12', 'hr', 'and', 'tramadol', 'IV', 'requirement', 'were', 'significantly', 'greater', 'than', 'the', 'CEI', 'group', '(', 'VAS', ':', 'PO6', 'hr', 'p-value', '=', '0.001', ',', 'PO12', 'hr', 'p-value', '=', '0.004', ')', '.']","(8, 10)","(40, 50)",-1,hl_o,19301724,Abstract,7,test,gold,381.0
3026,"RESULTS Patients in the CFNB group , the VAS scores at PO6-12 hr and",tramadol IV requirement,"were significantly greater than the CEI group ( VAS : PO6 hr p-value = 0.001 , PO12 hr p-value = 0.004 ) .","['RESULTS', 'Patients', 'in', 'the', 'CFNB', 'group', ',', 'the', 'VAS', 'scores', 'at', 'PO6-12', 'hr', 'and', 'tramadol', 'IV', 'requirement', 'were', 'significantly', 'greater', 'than', 'the', 'CEI', 'group', '(', 'VAS', ':', 'PO6', 'hr', 'p-value', '=', '0.001', ',', 'PO12', 'hr', 'p-value', '=', '0.004', ')', '.']","(14, 17)","(68, 91)",-1,hl_o,19301724,Abstract,7,test,gold,5023.0
3027,Patients in the,CEI,"group experienced dizziness , pruritus , and PONV more than the CFNB group significantly .","['Patients', 'in', 'the', 'CEI', 'group', 'experienced', 'dizziness', ',', 'pruritus', ',', 'and', 'PONV', 'more', 'than', 'the', 'CFNB', 'group', 'significantly', '.']","(3, 4)","(15, 18)",-1,ss_i,19301724,Abstract,8,test,gold,597.0
3028,"Patients in the CEI group experienced dizziness , pruritus , and PONV more than the",CFNB,group significantly .,"['Patients', 'in', 'the', 'CEI', 'group', 'experienced', 'dizziness', ',', 'pruritus', ',', 'and', 'PONV', 'more', 'than', 'the', 'CFNB', 'group', 'significantly', '.']","(15, 16)","(83, 87)",-1,ss_i,19301724,Abstract,8,test,gold,1024.0
3029,Patients in the CEI group experienced,"dizziness , pruritus , and PONV",more than the CFNB group significantly .,"['Patients', 'in', 'the', 'CEI', 'group', 'experienced', 'dizziness', ',', 'pruritus', ',', 'and', 'PONV', 'more', 'than', 'the', 'CFNB', 'group', 'significantly', '.']","(6, 12)","(37, 68)",-1,ss_o,19301724,Abstract,8,test,gold,7130.0
3030,Patients in the,CEI,"group experienced dizziness , pruritus , and PONV more than the CFNB group significantly .","['Patients', 'in', 'the', 'CEI', 'group', 'experienced', 'dizziness', ',', 'pruritus', ',', 'and', 'PONV', 'more', 'than', 'the', 'CFNB', 'group', 'significantly', '.']","(3, 4)","(15, 18)",-1,hl_i,19301724,Abstract,8,test,gold,596.0
3031,"Patients in the CEI group experienced dizziness , pruritus , and PONV more than the",CFNB,group significantly .,"['Patients', 'in', 'the', 'CEI', 'group', 'experienced', 'dizziness', ',', 'pruritus', ',', 'and', 'PONV', 'more', 'than', 'the', 'CFNB', 'group', 'significantly', '.']","(15, 16)","(83, 87)",-1,hl_i,19301724,Abstract,8,test,gold,1023.0
3032,Patients in the CEI group experienced,dizziness,", pruritus , and PONV more than the CFNB group significantly .","['Patients', 'in', 'the', 'CEI', 'group', 'experienced', 'dizziness', ',', 'pruritus', ',', 'and', 'PONV', 'more', 'than', 'the', 'CFNB', 'group', 'significantly', '.']","(6, 7)","(37, 46)",-1,hl_o,19301724,Abstract,8,test,gold,2692.0
3033,"Patients in the CEI group experienced dizziness ,",pruritus,", and PONV more than the CFNB group significantly .","['Patients', 'in', 'the', 'CEI', 'group', 'experienced', 'dizziness', ',', 'pruritus', ',', 'and', 'PONV', 'more', 'than', 'the', 'CFNB', 'group', 'significantly', '.']","(8, 9)","(49, 57)",-1,hl_o,19301724,Abstract,8,test,gold,3512.0
3034,"Patients in the CEI group experienced dizziness , pruritus , and",PONV,more than the CFNB group significantly .,"['Patients', 'in', 'the', 'CEI', 'group', 'experienced', 'dizziness', ',', 'pruritus', ',', 'and', 'PONV', 'more', 'than', 'the', 'CFNB', 'group', 'significantly', '.']","(11, 12)","(64, 68)",-1,hl_o,19301724,Abstract,8,test,gold,3406.0
3035,Patient satisfaction was greater with the,CFNB,group although postoperative knee rehabilitation and the hospital LOS were not different .,"['Patient', 'satisfaction', 'was', 'greater', 'with', 'the', 'CFNB', 'group', 'although', 'postoperative', 'knee', 'rehabilitation', 'and', 'the', 'hospital', 'LOS', 'were', 'not', 'different', '.']","(6, 7)","(41, 45)",-1,ss_i,19301724,Abstract,9,test,gold,1022.0
3036,,Patient satisfaction,was greater with the CFNB group although postoperative knee rehabilitation and the hospital LOS were not different .,"['Patient', 'satisfaction', 'was', 'greater', 'with', 'the', 'CFNB', 'group', 'although', 'postoperative', 'knee', 'rehabilitation', 'and', 'the', 'hospital', 'LOS', 'were', 'not', 'different', '.']","(0, 2)","(0, 20)",-1,ss_o,19301724,Abstract,9,test,gold,3851.0
3037,Patient satisfaction was greater with the CFNB group although,postoperative knee rehabilitation and the hospital LOS,were not different .,"['Patient', 'satisfaction', 'was', 'greater', 'with', 'the', 'CFNB', 'group', 'although', 'postoperative', 'knee', 'rehabilitation', 'and', 'the', 'hospital', 'LOS', 'were', 'not', 'different', '.']","(9, 16)","(61, 115)",-1,ss_o,19301724,Abstract,9,test,gold,3676.0
3038,Patient satisfaction was greater with the,CFNB,group although postoperative knee rehabilitation and the hospital LOS were not different .,"['Patient', 'satisfaction', 'was', 'greater', 'with', 'the', 'CFNB', 'group', 'although', 'postoperative', 'knee', 'rehabilitation', 'and', 'the', 'hospital', 'LOS', 'were', 'not', 'different', '.']","(6, 7)","(41, 45)",-1,hl_i,19301724,Abstract,9,test,gold,1021.0
3039,,Patient satisfaction,was greater with the CFNB group although postoperative knee rehabilitation and the hospital LOS were not different .,"['Patient', 'satisfaction', 'was', 'greater', 'with', 'the', 'CFNB', 'group', 'although', 'postoperative', 'knee', 'rehabilitation', 'and', 'the', 'hospital', 'LOS', 'were', 'not', 'different', '.']","(0, 2)","(0, 20)",-1,hl_o,19301724,Abstract,9,test,gold,3852.0
3040,Patient satisfaction was greater with the CFNB group although,postoperative knee rehabilitation,and the hospital LOS were not different .,"['Patient', 'satisfaction', 'was', 'greater', 'with', 'the', 'CFNB', 'group', 'although', 'postoperative', 'knee', 'rehabilitation', 'and', 'the', 'hospital', 'LOS', 'were', 'not', 'different', '.']","(9, 12)","(61, 94)",-1,hl_o,19301724,Abstract,9,test,gold,3678.0
3041,Patient satisfaction was greater with the CFNB group although postoperative knee rehabilitation and the,hospital LOS,were not different .,"['Patient', 'satisfaction', 'was', 'greater', 'with', 'the', 'CFNB', 'group', 'although', 'postoperative', 'knee', 'rehabilitation', 'and', 'the', 'hospital', 'LOS', 'were', 'not', 'different', '.']","(14, 16)","(103, 115)",-1,hl_o,19301724,Abstract,9,test,gold,3702.0
3042,CONCLUSION,CFNB,"represents the optimal analgesia with fewer side effects and greater patient , satisfaction .","['CONCLUSION', 'CFNB', 'represents', 'the', 'optimal', 'analgesia', 'with', 'fewer', 'side', 'effects', 'and', 'greater', 'patient', ',', 'satisfaction', '.']","(1, 2)","(10, 14)",-1,ss_i,19301724,Abstract,10,test,gold,1020.0
3043,CONCLUSION CFNB represents the optimal analgesia with fewer,side effects,"and greater patient , satisfaction .","['CONCLUSION', 'CFNB', 'represents', 'the', 'optimal', 'analgesia', 'with', 'fewer', 'side', 'effects', 'and', 'greater', 'patient', ',', 'satisfaction', '.']","(8, 10)","(59, 71)",-1,ss_o,19301724,Abstract,10,test,gold,2372.0
3044,CONCLUSION CFNB represents the optimal analgesia with fewer side effects and greater,"patient , satisfaction .",,"['CONCLUSION', 'CFNB', 'represents', 'the', 'optimal', 'analgesia', 'with', 'fewer', 'side', 'effects', 'and', 'greater', 'patient', ',', 'satisfaction', '.']","(12, 16)","(84, 108)",-1,ss_o,19301724,Abstract,10,test,gold,3848.0
3045,CONCLUSION,CFNB,"represents the optimal analgesia with fewer side effects and greater patient , satisfaction .","['CONCLUSION', 'CFNB', 'represents', 'the', 'optimal', 'analgesia', 'with', 'fewer', 'side', 'effects', 'and', 'greater', 'patient', ',', 'satisfaction', '.']","(1, 2)","(10, 14)",-1,hl_i,19301724,Abstract,10,test,gold,1019.0
3046,CONCLUSION CFNB represents the optimal analgesia with fewer,side effects,"and greater patient , satisfaction .","['CONCLUSION', 'CFNB', 'represents', 'the', 'optimal', 'analgesia', 'with', 'fewer', 'side', 'effects', 'and', 'greater', 'patient', ',', 'satisfaction', '.']","(8, 10)","(59, 71)",-1,hl_o,19301724,Abstract,10,test,gold,2371.0
3047,CONCLUSION CFNB represents the optimal analgesia with fewer side effects and greater,"patient , satisfaction",.,"['CONCLUSION', 'CFNB', 'represents', 'the', 'optimal', 'analgesia', 'with', 'fewer', 'side', 'effects', 'and', 'greater', 'patient', ',', 'satisfaction', '.']","(12, 15)","(84, 106)",-1,hl_o,19301724,Abstract,10,test,gold,3849.0
3048,The,rehabilitation indices and duration of hospital stay,are comparable in both groups .,"['The', 'rehabilitation', 'indices', 'and', 'duration', 'of', 'hospital', 'stay', 'are', 'comparable', 'in', 'both', 'groups', '.']","(1, 8)","(3, 55)",-1,ss_o,19301724,Abstract,11,test,gold,2000.0
3049,The,rehabilitation indices,and duration of hospital stay are comparable in both groups .,"['The', 'rehabilitation', 'indices', 'and', 'duration', 'of', 'hospital', 'stay', 'are', 'comparable', 'in', 'both', 'groups', '.']","(1, 3)","(3, 25)",-1,hl_o,19301724,Abstract,11,test,gold,2001.0
3050,The rehabilitation indices and,duration of hospital stay,are comparable in both groups .,"['The', 'rehabilitation', 'indices', 'and', 'duration', 'of', 'hospital', 'stay', 'are', 'comparable', 'in', 'both', 'groups', '.']","(4, 8)","(30, 55)",-1,hl_o,19301724,Abstract,11,test,gold,3696.0
3051,"Rationale and design of RE-LY : randomized evaluation of long-term anticoagulant therapy ,",warfarin,", compared with dabigatran .","['Rationale', 'and', 'design', 'of', 'RE-LY', ':', 'randomized', 'evaluation', 'of', 'long-term', 'anticoagulant', 'therapy', ',', 'warfarin', ',', 'compared', 'with', 'dabigatran', '.']","(13, 14)","(90, 98)",-1,ss_i,19376304,Title,0,test,gold,5377.0
3052,"Rationale and design of RE-LY : randomized evaluation of long-term anticoagulant therapy , warfarin , compared with",dabigatran .,,"['Rationale', 'and', 'design', 'of', 'RE-LY', ':', 'randomized', 'evaluation', 'of', 'long-term', 'anticoagulant', 'therapy', ',', 'warfarin', ',', 'compared', 'with', 'dabigatran', '.']","(17, 19)","(115, 127)",-1,ss_i,19376304,Title,0,test,gold,5367.0
3053,"Rationale and design of RE-LY : randomized evaluation of long-term anticoagulant therapy ,",warfarin,", compared with dabigatran .","['Rationale', 'and', 'design', 'of', 'RE-LY', ':', 'randomized', 'evaluation', 'of', 'long-term', 'anticoagulant', 'therapy', ',', 'warfarin', ',', 'compared', 'with', 'dabigatran', '.']","(13, 14)","(90, 98)",-1,hl_i,19376304,Title,0,test,gold,5378.0
3054,"Rationale and design of RE-LY : randomized evaluation of long-term anticoagulant therapy , warfarin , compared with",dabigatran .,,"['Rationale', 'and', 'design', 'of', 'RE-LY', ':', 'randomized', 'evaluation', 'of', 'long-term', 'anticoagulant', 'therapy', ',', 'warfarin', ',', 'compared', 'with', 'dabigatran', '.']","(17, 19)","(115, 127)",-1,hl_i,19376304,Title,0,test,gold,5368.0
3055,Vitamin K antagonists ( VKAs ) are effective for stroke prevention in,patients with atrial fibrillation ( AF ),but are difficult to use .,"['Vitamin', 'K', 'antagonists', '(', 'VKAs', ')', 'are', 'effective', 'for', 'stroke', 'prevention', 'in', 'patients', 'with', 'atrial', 'fibrillation', '(', 'AF', ')', 'but', 'are', 'difficult', 'to', 'use', '.']","(12, 19)","(69, 109)",-1,ss_p,19376304,Abstract,0,test,gold,6787.0
3056,,Vitamin K antagonists,( VKAs ) are effective for stroke prevention in patients with atrial fibrillation ( AF ) but are difficult to use .,"['Vitamin', 'K', 'antagonists', '(', 'VKAs', ')', 'are', 'effective', 'for', 'stroke', 'prevention', 'in', 'patients', 'with', 'atrial', 'fibrillation', '(', 'AF', ')', 'but', 'are', 'difficult', 'to', 'use', '.']","(0, 3)","(0, 21)",-1,ss_i,19376304,Abstract,0,test,gold,4623.0
3057,Vitamin K antagonists ( VKAs ) are effective for,stroke prevention,in patients with atrial fibrillation ( AF ) but are difficult to use .,"['Vitamin', 'K', 'antagonists', '(', 'VKAs', ')', 'are', 'effective', 'for', 'stroke', 'prevention', 'in', 'patients', 'with', 'atrial', 'fibrillation', '(', 'AF', ')', 'but', 'are', 'difficult', 'to', 'use', '.']","(9, 11)","(48, 65)",-1,ss_o,19376304,Abstract,0,test,gold,3377.0
3058,Vitamin K antagonists ( VKAs ) are effective for stroke prevention in patients with,atrial fibrillation,( AF ) but are difficult to use .,"['Vitamin', 'K', 'antagonists', '(', 'VKAs', ')', 'are', 'effective', 'for', 'stroke', 'prevention', 'in', 'patients', 'with', 'atrial', 'fibrillation', '(', 'AF', ')', 'but', 'are', 'difficult', 'to', 'use', '.']","(14, 16)","(83, 102)",-1,hl_p,19376304,Abstract,0,test,gold,6788.0
3059,Vitamin K antagonists ( VKAs ) are effective for stroke prevention in patients with atrial fibrillation (,AF,) but are difficult to use .,"['Vitamin', 'K', 'antagonists', '(', 'VKAs', ')', 'are', 'effective', 'for', 'stroke', 'prevention', 'in', 'patients', 'with', 'atrial', 'fibrillation', '(', 'AF', ')', 'but', 'are', 'difficult', 'to', 'use', '.']","(17, 18)","(105, 107)",-1,hl_p,19376304,Abstract,0,test,gold,698.0
3060,,Dabigatran etexilate,is a prodrug that is rapidly converted to the active direct thrombin inhibitor dabigatran .,"['Dabigatran', 'etexilate', 'is', 'a', 'prodrug', 'that', 'is', 'rapidly', 'converted', 'to', 'the', 'active', 'direct', 'thrombin', 'inhibitor', 'dabigatran', '.']","(0, 2)","(0, 20)",-1,ss_i,19376304,Abstract,1,test,gold,164.0
3061,Dabigatran etexilate is a prodrug that is rapidly converted to the active direct thrombin inhibitor,dabigatran .,,"['Dabigatran', 'etexilate', 'is', 'a', 'prodrug', 'that', 'is', 'rapidly', 'converted', 'to', 'the', 'active', 'direct', 'thrombin', 'inhibitor', 'dabigatran', '.']","(15, 17)","(99, 111)",-1,ss_i,19376304,Abstract,1,test,gold,5366.0
3062,,Dabigatran etexilate,is a prodrug that is rapidly converted to the active direct thrombin inhibitor dabigatran .,"['Dabigatran', 'etexilate', 'is', 'a', 'prodrug', 'that', 'is', 'rapidly', 'converted', 'to', 'the', 'active', 'direct', 'thrombin', 'inhibitor', 'dabigatran', '.']","(0, 2)","(0, 20)",-1,hl_i,19376304,Abstract,1,test,gold,165.0
3063,Dabigatran etexilate is a prodrug that is rapidly converted to the active direct thrombin inhibitor,dabigatran .,,"['Dabigatran', 'etexilate', 'is', 'a', 'prodrug', 'that', 'is', 'rapidly', 'converted', 'to', 'the', 'active', 'direct', 'thrombin', 'inhibitor', 'dabigatran', '.']","(15, 17)","(99, 111)",-1,hl_i,19376304,Abstract,1,test,gold,5365.0
3064,It is administered in a fixed dose without laboratory monitoring and is being compared with,warfarin,( international normalized ratio 2-3 ) in the RE-LY trial .,"['It', 'is', 'administered', 'in', 'a', 'fixed', 'dose', 'without', 'laboratory', 'monitoring', 'and', 'is', 'being', 'compared', 'with', 'warfarin', '(', 'international', 'normalized', 'ratio', '2-3', ')', 'in', 'the', 'RE-LY', 'trial', '.']","(15, 16)","(91, 99)",-1,ss_i,19376304,Abstract,2,test,gold,5376.0
3065,It is administered in a fixed dose without laboratory monitoring and is being compared with,warfarin,( international normalized ratio 2-3 ) in the RE-LY trial .,"['It', 'is', 'administered', 'in', 'a', 'fixed', 'dose', 'without', 'laboratory', 'monitoring', 'and', 'is', 'being', 'compared', 'with', 'warfarin', '(', 'international', 'normalized', 'ratio', '2-3', ')', 'in', 'the', 'RE-LY', 'trial', '.']","(15, 16)","(91, 99)",-1,hl_i,19376304,Abstract,2,test,gold,5375.0
3066,Two doses of,dabigatran,( 110 and 150 mg BID ) are being evaluated .,"['Two', 'doses', 'of', 'dabigatran', '(', '110', 'and', '150', 'mg', 'BID', ')', 'are', 'being', 'evaluated', '.']","(3, 4)","(12, 22)",-1,ss_i,19376304,Abstract,3,test,gold,5364.0
3067,Two doses of,dabigatran,( 110 and 150 mg BID ) are being evaluated .,"['Two', 'doses', 'of', 'dabigatran', '(', '110', 'and', '150', 'mg', 'BID', ')', 'are', 'being', 'evaluated', '.']","(3, 4)","(12, 22)",-1,hl_i,19376304,Abstract,3,test,gold,5363.0
3068,"RE-LY is a phase 3 , prospective , randomized , open-label multinational ( 44 countries ) trial of",patients with nonvalvular AF and at least 1 risk factor for stroke .,,"['RE-LY', 'is', 'a', 'phase', '3', ',', 'prospective', ',', 'randomized', ',', 'open-label', 'multinational', '(', '44', 'countries', ')', 'trial', 'of', 'patients', 'with', 'nonvalvular', 'AF', 'and', 'at', 'least', '1', 'risk', 'factor', 'for', 'stroke', '.']","(18, 31)","(98, 166)",-1,ss_p,19376304,Abstract,4,test,gold,5854.0
3069,,"Recruitment concluded with a total of 18,113 patients .",,"['Recruitment', 'concluded', 'with', 'a', 'total', 'of', '18,113', 'patients', '.']","(0, 9)","(0, 55)",-1,ss_p,19376304,Abstract,5,test,gold,3876.0
3070,Recruitment concluded with a total of,"18,113",patients .,"['Recruitment', 'concluded', 'with', 'a', 'total', 'of', '18,113', 'patients', '.']","(6, 7)","(37, 43)",-1,hl_p,19376304,Abstract,5,test,gold,
3071,,Patients who were VKA-naive and experienced are included in balanced proportions .,,"['Patients', 'who', 'were', 'VKA-naive', 'and', 'experienced', 'are', 'included', 'in', 'balanced', 'proportions', '.']","(0, 12)","(0, 82)",-1,ss_p,19376304,Abstract,6,test,gold,3709.0
3072,The primary outcome is,stroke ( including hemorrhagic ) or systemic embolism .,,"['The', 'primary', 'outcome', 'is', 'stroke', '(', 'including', 'hemorrhagic', ')', 'or', 'systemic', 'embolism', '.']","(4, 13)","(22, 77)",-1,ss_o,19376304,Abstract,7,test,gold,7088.0
3073,The primary outcome is,stroke ( including hemorrhagic ),or systemic embolism .,"['The', 'primary', 'outcome', 'is', 'stroke', '(', 'including', 'hemorrhagic', ')', 'or', 'systemic', 'embolism', '.']","(4, 9)","(22, 54)",-1,hl_o,19376304,Abstract,7,test,gold,3383.0
3074,The primary outcome is stroke ( including hemorrhagic ) or,systemic embolism,.,"['The', 'primary', 'outcome', 'is', 'stroke', '(', 'including', 'hemorrhagic', ')', 'or', 'systemic', 'embolism', '.']","(10, 12)","(58, 75)",-1,hl_o,19376304,Abstract,7,test,gold,3438.0
3075,,Safety,"outcomes are bleeding , liver function abnormalities , and other adverse events .","['Safety', 'outcomes', 'are', 'bleeding', ',', 'liver', 'function', 'abnormalities', ',', 'and', 'other', 'adverse', 'events', '.']","(0, 1)","(0, 6)",-1,ss_o,19376304,Abstract,8,test,gold,446.0
3076,Safety outcomes are,"bleeding , liver function abnormalities , and other adverse events .",,"['Safety', 'outcomes', 'are', 'bleeding', ',', 'liver', 'function', 'abnormalities', ',', 'and', 'other', 'adverse', 'events', '.']","(3, 14)","(19, 87)",-1,ss_o,19376304,Abstract,8,test,gold,7089.0
3077,Safety outcomes are,bleeding,", liver function abnormalities , and other adverse events .","['Safety', 'outcomes', 'are', 'bleeding', ',', 'liver', 'function', 'abnormalities', ',', 'and', 'other', 'adverse', 'events', '.']","(3, 4)","(19, 27)",-1,hl_o,19376304,Abstract,8,test,gold,2653.0
3078,"Safety outcomes are bleeding ,",liver function abnormalities,", and other adverse events .","['Safety', 'outcomes', 'are', 'bleeding', ',', 'liver', 'function', 'abnormalities', ',', 'and', 'other', 'adverse', 'events', '.']","(5, 8)","(30, 58)",-1,hl_o,19376304,Abstract,8,test,gold,3154.0
3079,"Safety outcomes are bleeding , liver function abnormalities , and",other adverse events,.,"['Safety', 'outcomes', 'are', 'bleeding', ',', 'liver', 'function', 'abnormalities', ',', 'and', 'other', 'adverse', 'events', '.']","(10, 13)","(65, 85)",-1,hl_o,19376304,Abstract,8,test,gold,3055.0
3080,Adjudication of end points is blinded to drug assignment .,,,"['Adjudication', 'of', 'end', 'points', 'is', 'blinded', 'to', 'drug', 'assignment', '.']",,,,,19376304,Abstract,9,test,gold,
3081,The trial is expected to accrue a minimum of 450 events with a minimum 1-year of follow-up .,,,"['The', 'trial', 'is', 'expected', 'to', 'accrue', 'a', 'minimum', 'of', '450', 'events', 'with', 'a', 'minimum', '1-year', 'of', 'follow-up', '.']",,,,,19376304,Abstract,10,test,gold,
3082,RE-LY is the largest AF,stroke,prevention trial yet undertaken .,"['RE-LY', 'is', 'the', 'largest', 'AF', 'stroke', 'prevention', 'trial', 'yet', 'undertaken', '.']","(5, 6)","(23, 29)",-1,ss_o,19376304,Abstract,11,test,gold,3375.0
3083,It is unique because it includes equal numbers of VKA-experienced and naive patients and evaluates 2 different dosages of,dabigatran,", which may allow tailoring of dosing to individual patient needs .","['It', 'is', 'unique', 'because', 'it', 'includes', 'equal', 'numbers', 'of', 'VKA-experienced', 'and', 'naive', 'patients', 'and', 'evaluates', '2', 'different', 'dosages', 'of', 'dabigatran', ',', 'which', 'may', 'allow', 'tailoring', 'of', 'dosing', 'to', 'individual', 'patient', 'needs', '.']","(19, 20)","(121, 131)",-1,ss_i,19376304,Abstract,12,test,gold,5362.0
3084,It is unique because it includes equal numbers of VKA-experienced and naive patients and evaluates 2 different dosages of,dabigatran,", which may allow tailoring of dosing to individual patient needs .","['It', 'is', 'unique', 'because', 'it', 'includes', 'equal', 'numbers', 'of', 'VKA-experienced', 'and', 'naive', 'patients', 'and', 'evaluates', '2', 'different', 'dosages', 'of', 'dabigatran', ',', 'which', 'may', 'allow', 'tailoring', 'of', 'dosing', 'to', 'individual', 'patient', 'needs', '.']","(19, 20)","(121, 131)",-1,hl_i,19376304,Abstract,12,test,gold,5361.0
3085,The worldwide site distribution and broad range of stroke risk further increase the general applicability of the trial .,,,"['The', 'worldwide', 'site', 'distribution', 'and', 'broad', 'range', 'of', 'stroke', 'risk', 'further', 'increase', 'the', 'general', 'applicability', 'of', 'the', 'trial', '.']",,,,,19376304,Abstract,13,test,gold,
3086,Results are expected in 2009 .,,,"['Results', 'are', 'expected', 'in', '2009', '.']",,,,,19376304,Abstract,14,test,gold,
3087,Effects of cuff inflation on,self-recorded blood pressure .,,"['Effects', 'of', 'cuff', 'inflation', 'on', 'self-recorded', 'blood', 'pressure', '.']","(5, 9)","(28, 58)",-1,ss_o,1968178,Title,0,test,gold,6708.0
3088,Effects of,cuff inflation,on self-recorded blood pressure .,"['Effects', 'of', 'cuff', 'inflation', 'on', 'self-recorded', 'blood', 'pressure', '.']","(2, 4)","(10, 24)",-1,hl_i,1968178,Title,0,test,gold,2641.0
3089,Effects of cuff inflation on,self-recorded blood pressure .,,"['Effects', 'of', 'cuff', 'inflation', 'on', 'self-recorded', 'blood', 'pressure', '.']","(5, 9)","(28, 58)",-1,hl_o,1968178,Title,0,test,gold,6709.0
3090,Changes in continuously recorded 'Finapres ' finger blood pressure in,ten normotensive and seven hypertensive subjects,induced by self-inflation of the cuff or just wearing the inflated cuff were studied .,"['Changes', 'in', 'continuously', 'recorded', ""'Finapres"", ""'"", 'finger', 'blood', 'pressure', 'in', 'ten', 'normotensive', 'and', 'seven', 'hypertensive', 'subjects', 'induced', 'by', 'self-inflation', 'of', 'the', 'cuff', 'or', 'just', 'wearing', 'the', 'inflated', 'cuff', 'were', 'studied', '.']","(10, 16)","(69, 117)",-1,ss_p,1968178,Abstract,0,test,gold,6912.0
3091,Changes in continuously recorded 'Finapres ' finger blood pressure in ten normotensive and seven hypertensive subjects induced by,self-inflation of the cuff,or just wearing the inflated cuff were studied .,"['Changes', 'in', 'continuously', 'recorded', ""'Finapres"", ""'"", 'finger', 'blood', 'pressure', 'in', 'ten', 'normotensive', 'and', 'seven', 'hypertensive', 'subjects', 'induced', 'by', 'self-inflation', 'of', 'the', 'cuff', 'or', 'just', 'wearing', 'the', 'inflated', 'cuff', 'were', 'studied', '.']","(18, 22)","(129, 155)",-1,ss_i,1968178,Abstract,0,test,gold,2635.0
3092,Changes in continuously recorded 'Finapres ' finger blood pressure in ten normotensive and seven hypertensive subjects induced by self-inflation of the cuff or,just wearing the inflated cuff,were studied .,"['Changes', 'in', 'continuously', 'recorded', ""'Finapres"", ""'"", 'finger', 'blood', 'pressure', 'in', 'ten', 'normotensive', 'and', 'seven', 'hypertensive', 'subjects', 'induced', 'by', 'self-inflation', 'of', 'the', 'cuff', 'or', 'just', 'wearing', 'the', 'inflated', 'cuff', 'were', 'studied', '.']","(23, 28)","(159, 189)",-1,ss_i,1968178,Abstract,0,test,gold,2630.0
3093,Changes in,continuously recorded 'Finapres ' finger blood pressure,in ten normotensive and seven hypertensive subjects induced by self-inflation of the cuff or just wearing the inflated cuff were studied .,"['Changes', 'in', 'continuously', 'recorded', ""'Finapres"", ""'"", 'finger', 'blood', 'pressure', 'in', 'ten', 'normotensive', 'and', 'seven', 'hypertensive', 'subjects', 'induced', 'by', 'self-inflation', 'of', 'the', 'cuff', 'or', 'just', 'wearing', 'the', 'inflated', 'cuff', 'were', 'studied', '.']","(2, 9)","(10, 65)",-1,ss_o,1968178,Abstract,0,test,gold,6702.0
3094,Changes in continuously recorded 'Finapres ' finger blood pressure in,ten normotensive,and seven hypertensive subjects induced by self-inflation of the cuff or just wearing the inflated cuff were studied .,"['Changes', 'in', 'continuously', 'recorded', ""'Finapres"", ""'"", 'finger', 'blood', 'pressure', 'in', 'ten', 'normotensive', 'and', 'seven', 'hypertensive', 'subjects', 'induced', 'by', 'self-inflation', 'of', 'the', 'cuff', 'or', 'just', 'wearing', 'the', 'inflated', 'cuff', 'were', 'studied', '.']","(10, 12)","(69, 85)",-1,hl_p,1968178,Abstract,0,test,gold,87.0
3095,Changes in continuously recorded 'Finapres ' finger blood pressure in ten normotensive and,seven hypertensive,subjects induced by self-inflation of the cuff or just wearing the inflated cuff were studied .,"['Changes', 'in', 'continuously', 'recorded', ""'Finapres"", ""'"", 'finger', 'blood', 'pressure', 'in', 'ten', 'normotensive', 'and', 'seven', 'hypertensive', 'subjects', 'induced', 'by', 'self-inflation', 'of', 'the', 'cuff', 'or', 'just', 'wearing', 'the', 'inflated', 'cuff', 'were', 'studied', '.']","(13, 15)","(90, 108)",-1,hl_p,1968178,Abstract,0,test,gold,3455.0
3096,Changes in continuously recorded 'Finapres ' finger blood pressure in ten normotensive and seven hypertensive subjects induced by,self-inflation of the cuff,or just wearing the inflated cuff were studied .,"['Changes', 'in', 'continuously', 'recorded', ""'Finapres"", ""'"", 'finger', 'blood', 'pressure', 'in', 'ten', 'normotensive', 'and', 'seven', 'hypertensive', 'subjects', 'induced', 'by', 'self-inflation', 'of', 'the', 'cuff', 'or', 'just', 'wearing', 'the', 'inflated', 'cuff', 'were', 'studied', '.']","(18, 22)","(129, 155)",-1,hl_i,1968178,Abstract,0,test,gold,2636.0
3097,Changes in continuously recorded 'Finapres ' finger blood pressure in ten normotensive and seven hypertensive subjects induced by self-inflation of the cuff or,just wearing the inflated cuff,were studied .,"['Changes', 'in', 'continuously', 'recorded', ""'Finapres"", ""'"", 'finger', 'blood', 'pressure', 'in', 'ten', 'normotensive', 'and', 'seven', 'hypertensive', 'subjects', 'induced', 'by', 'self-inflation', 'of', 'the', 'cuff', 'or', 'just', 'wearing', 'the', 'inflated', 'cuff', 'were', 'studied', '.']","(23, 28)","(159, 189)",-1,hl_i,1968178,Abstract,0,test,gold,2631.0
3098,Changes in continuously recorded,'Finapres ' finger blood pressure,in ten normotensive and seven hypertensive subjects induced by self-inflation of the cuff or just wearing the inflated cuff were studied .,"['Changes', 'in', 'continuously', 'recorded', ""'Finapres"", ""'"", 'finger', 'blood', 'pressure', 'in', 'ten', 'normotensive', 'and', 'seven', 'hypertensive', 'subjects', 'induced', 'by', 'self-inflation', 'of', 'the', 'cuff', 'or', 'just', 'wearing', 'the', 'inflated', 'cuff', 'were', 'studied', '.']","(4, 9)","(32, 65)",-1,hl_o,1968178,Abstract,0,test,gold,6703.0
3099,Inflating the cuff caused an instantaneous rise in systolic blood pressure of 13 and 12 mm Hg,( hypertensive and normotensive subjects,", respectively ) .","['Inflating', 'the', 'cuff', 'caused', 'an', 'instantaneous', 'rise', 'in', 'systolic', 'blood', 'pressure', 'of', '13', 'and', '12', 'mm', 'Hg', '(', 'hypertensive', 'and', 'normotensive', 'subjects', ',', 'respectively', ')', '.']","(17, 22)","(93, 133)",-1,ss_p,1968178,Abstract,1,test,gold,6913.0
3100,,Inflating the cuff,"caused an instantaneous rise in systolic blood pressure of 13 and 12 mm Hg ( hypertensive and normotensive subjects , respectively ) .","['Inflating', 'the', 'cuff', 'caused', 'an', 'instantaneous', 'rise', 'in', 'systolic', 'blood', 'pressure', 'of', '13', 'and', '12', 'mm', 'Hg', '(', 'hypertensive', 'and', 'normotensive', 'subjects', ',', 'respectively', ')', '.']","(0, 3)","(0, 18)",-1,ss_i,1968178,Abstract,1,test,gold,2637.0
3101,Inflating the cuff caused an instantaneous rise in,systolic blood pressure,"of 13 and 12 mm Hg ( hypertensive and normotensive subjects , respectively ) .","['Inflating', 'the', 'cuff', 'caused', 'an', 'instantaneous', 'rise', 'in', 'systolic', 'blood', 'pressure', 'of', '13', 'and', '12', 'mm', 'Hg', '(', 'hypertensive', 'and', 'normotensive', 'subjects', ',', 'respectively', ')', '.']","(8, 11)","(50, 73)",-1,ss_o,1968178,Abstract,1,test,gold,6715.0
3102,,Inflating the cuff,"caused an instantaneous rise in systolic blood pressure of 13 and 12 mm Hg ( hypertensive and normotensive subjects , respectively ) .","['Inflating', 'the', 'cuff', 'caused', 'an', 'instantaneous', 'rise', 'in', 'systolic', 'blood', 'pressure', 'of', '13', 'and', '12', 'mm', 'Hg', '(', 'hypertensive', 'and', 'normotensive', 'subjects', ',', 'respectively', ')', '.']","(0, 3)","(0, 18)",-1,hl_i,1968178,Abstract,1,test,gold,2638.0
3103,Inflating the cuff caused an instantaneous rise in,systolic blood pressure,"of 13 and 12 mm Hg ( hypertensive and normotensive subjects , respectively ) .","['Inflating', 'the', 'cuff', 'caused', 'an', 'instantaneous', 'rise', 'in', 'systolic', 'blood', 'pressure', 'of', '13', 'and', '12', 'mm', 'Hg', '(', 'hypertensive', 'and', 'normotensive', 'subjects', ',', 'respectively', ')', '.']","(8, 11)","(50, 73)",-1,hl_o,1968178,Abstract,1,test,gold,6716.0
3104,Wearing the,inflated cuff,did not change blood pressure .,"['Wearing', 'the', 'inflated', 'cuff', 'did', 'not', 'change', 'blood', 'pressure', '.']","(2, 4)","(11, 24)",-1,ss_i,1968178,Abstract,2,test,gold,2633.0
3105,Wearing the inflated cuff did not change,blood pressure .,,"['Wearing', 'the', 'inflated', 'cuff', 'did', 'not', 'change', 'blood', 'pressure', '.']","(7, 10)","(40, 56)",-1,ss_o,1968178,Abstract,2,test,gold,6707.0
3106,Wearing the,inflated cuff,did not change blood pressure .,"['Wearing', 'the', 'inflated', 'cuff', 'did', 'not', 'change', 'blood', 'pressure', '.']","(2, 4)","(11, 24)",-1,hl_i,1968178,Abstract,2,test,gold,2634.0
3107,Wearing the inflated cuff did not change,blood pressure .,,"['Wearing', 'the', 'inflated', 'cuff', 'did', 'not', 'change', 'blood', 'pressure', '.']","(7, 10)","(40, 56)",-1,hl_o,1968178,Abstract,2,test,gold,6706.0
3108,Thus the rise in pressure was related to the muscular activity required for,cuff inflation .,,"['Thus', 'the', 'rise', 'in', 'pressure', 'was', 'related', 'to', 'the', 'muscular', 'activity', 'required', 'for', 'cuff', 'inflation', '.']","(13, 16)","(75, 91)",-1,ss_i,1968178,Abstract,3,test,gold,2642.0
3109,Thus the rise in,pressure,was related to the muscular activity required for cuff inflation .,"['Thus', 'the', 'rise', 'in', 'pressure', 'was', 'related', 'to', 'the', 'muscular', 'activity', 'required', 'for', 'cuff', 'inflation', '.']","(4, 5)","(16, 24)",-1,ss_o,1968178,Abstract,3,test,gold,1234.0
3110,Thus the rise in pressure was related to the muscular activity required for,cuff inflation .,,"['Thus', 'the', 'rise', 'in', 'pressure', 'was', 'related', 'to', 'the', 'muscular', 'activity', 'required', 'for', 'cuff', 'inflation', '.']","(13, 16)","(75, 91)",-1,hl_i,1968178,Abstract,3,test,gold,2640.0
3111,Thus the rise in,pressure,was related to the muscular activity required for cuff inflation .,"['Thus', 'the', 'rise', 'in', 'pressure', 'was', 'related', 'to', 'the', 'muscular', 'activity', 'required', 'for', 'cuff', 'inflation', '.']","(4, 5)","(16, 24)",-1,hl_o,1968178,Abstract,3,test,gold,1235.0
3112,Systolic blood pressure took on average 7 s and at most 21 s to return to baseline level after stopping,cuff inflation .,,"['Systolic', 'blood', 'pressure', 'took', 'on', 'average', '7', 's', 'and', 'at', 'most', '21', 's', 'to', 'return', 'to', 'baseline', 'level', 'after', 'stopping', 'cuff', 'inflation', '.']","(20, 23)","(103, 119)",-1,ss_i,1968178,Abstract,4,test,gold,2639.0
3113,,Systolic blood pressure,took on average 7 s and at most 21 s to return to baseline level after stopping cuff inflation .,"['Systolic', 'blood', 'pressure', 'took', 'on', 'average', '7', 's', 'and', 'at', 'most', '21', 's', 'to', 'return', 'to', 'baseline', 'level', 'after', 'stopping', 'cuff', 'inflation', '.']","(0, 3)","(0, 23)",-1,ss_o,1968178,Abstract,4,test,gold,6710.0
3114,,Systolic blood pressure,took on average 7 s and at most 21 s to return to baseline level after stopping cuff inflation .,"['Systolic', 'blood', 'pressure', 'took', 'on', 'average', '7', 's', 'and', 'at', 'most', '21', 's', 'to', 'return', 'to', 'baseline', 'level', 'after', 'stopping', 'cuff', 'inflation', '.']","(0, 3)","(0, 23)",-1,hl_o,1968178,Abstract,4,test,gold,6711.0
3115,"Since first Korotkoff sounds may already be heard after 10-15 s when following recommended procedures , self-recorded systolic blood pressure may be recorded as too high when subjects",inflate their cuff,at too low a pressure or deflate it too fast .,"['Since', 'first', 'Korotkoff', 'sounds', 'may', 'already', 'be', 'heard', 'after', '10-15', 's', 'when', 'following', 'recommended', 'procedures', ',', 'self-recorded', 'systolic', 'blood', 'pressure', 'may', 'be', 'recorded', 'as', 'too', 'high', 'when', 'subjects', 'inflate', 'their', 'cuff', 'at', 'too', 'low', 'a', 'pressure', 'or', 'deflate', 'it', 'too', 'fast', '.']","(28, 31)","(183, 201)",-1,ss_i,1968178,Abstract,5,test,gold,2632.0
3116,"Since first Korotkoff sounds may already be heard after 10-15 s when following recommended procedures ,",self-recorded systolic blood pressure,may be recorded as too high when subjects inflate their cuff at too low a pressure or deflate it too fast .,"['Since', 'first', 'Korotkoff', 'sounds', 'may', 'already', 'be', 'heard', 'after', '10-15', 's', 'when', 'following', 'recommended', 'procedures', ',', 'self-recorded', 'systolic', 'blood', 'pressure', 'may', 'be', 'recorded', 'as', 'too', 'high', 'when', 'subjects', 'inflate', 'their', 'cuff', 'at', 'too', 'low', 'a', 'pressure', 'or', 'deflate', 'it', 'too', 'fast', '.']","(16, 20)","(103, 140)",-1,ss_o,1968178,Abstract,5,test,gold,6714.0
3117,"Since first Korotkoff sounds may already be heard after 10-15 s when following recommended procedures ,",self-recorded systolic blood pressure,may be recorded as too high when subjects inflate their cuff at too low a pressure or deflate it too fast .,"['Since', 'first', 'Korotkoff', 'sounds', 'may', 'already', 'be', 'heard', 'after', '10-15', 's', 'when', 'following', 'recommended', 'procedures', ',', 'self-recorded', 'systolic', 'blood', 'pressure', 'may', 'be', 'recorded', 'as', 'too', 'high', 'when', 'subjects', 'inflate', 'their', 'cuff', 'at', 'too', 'low', 'a', 'pressure', 'or', 'deflate', 'it', 'too', 'fast', '.']","(16, 20)","(103, 140)",-1,hl_o,1968178,Abstract,5,test,gold,6713.0
3118,[ Effect of transcranial electrostimulation on clinical and laboratory characteristics in,patients with gastric ulcer ],.,"['[', 'Effect', 'of', 'transcranial', 'electrostimulation', 'on', 'clinical', 'and', 'laboratory', 'characteristics', 'in', 'patients', 'with', 'gastric', 'ulcer', ']', '.']","(11, 16)","(89, 118)",-1,ss_p,19708562,Title,0,test,gold,7007.0
3119,[ Effect of,transcranial electrostimulation,on clinical and laboratory characteristics in patients with gastric ulcer ] .,"['[', 'Effect', 'of', 'transcranial', 'electrostimulation', 'on', 'clinical', 'and', 'laboratory', 'characteristics', 'in', 'patients', 'with', 'gastric', 'ulcer', ']', '.']","(3, 5)","(11, 42)",-1,ss_i,19708562,Title,0,test,gold,4106.0
3120,[ Effect of transcranial electrostimulation on clinical and laboratory characteristics in,patients with gastric ulcer ],.,"['[', 'Effect', 'of', 'transcranial', 'electrostimulation', 'on', 'clinical', 'and', 'laboratory', 'characteristics', 'in', 'patients', 'with', 'gastric', 'ulcer', ']', '.']","(11, 16)","(89, 118)",-1,hl_p,19708562,Title,0,test,gold,7008.0
3121,[ Effect of,transcranial electrostimulation,on clinical and laboratory characteristics in patients with gastric ulcer ] .,"['[', 'Effect', 'of', 'transcranial', 'electrostimulation', 'on', 'clinical', 'and', 'laboratory', 'characteristics', 'in', 'patients', 'with', 'gastric', 'ulcer', ']', '.']","(3, 5)","(11, 42)",-1,hl_i,19708562,Title,0,test,gold,4107.0
3122,The study included,100 patients with gastric ulcer aged from 16 to 60 years .,,"['The', 'study', 'included', '100', 'patients', 'with', 'gastric', 'ulcer', 'aged', 'from', '16', 'to', '60', 'years', '.']","(3, 15)","(18, 76)",-1,ss_p,19708562,Abstract,0,test,gold,7009.0
3123,The study included,100 patients with gastric ulcer aged from 16 to 60 years,.,"['The', 'study', 'included', '100', 'patients', 'with', 'gastric', 'ulcer', 'aged', 'from', '16', 'to', '60', 'years', '.']","(3, 14)","(18, 74)",-1,hl_p,19708562,Abstract,0,test,gold,7010.0
3124,"In 58 patients ,",traditional treatment,was supplemented by transcranial electrotherapy using a TRANSAIR-02 apparatus .,"['In', '58', 'patients', ',', 'traditional', 'treatment', 'was', 'supplemented', 'by', 'transcranial', 'electrotherapy', 'using', 'a', 'TRANSAIR-02', 'apparatus', '.']","(4, 6)","(16, 37)",-1,ss_i,19708562,Abstract,1,test,gold,3984.0
3125,"In 58 patients , traditional treatment was supplemented by",transcranial electrotherapy,using a TRANSAIR-02 apparatus .,"['In', '58', 'patients', ',', 'traditional', 'treatment', 'was', 'supplemented', 'by', 'transcranial', 'electrotherapy', 'using', 'a', 'TRANSAIR-02', 'apparatus', '.']","(9, 11)","(58, 85)",-1,ss_i,19708562,Abstract,1,test,gold,4108.0
3126,"In 58 patients ,",traditional treatment,was supplemented by transcranial electrotherapy using a TRANSAIR-02 apparatus .,"['In', '58', 'patients', ',', 'traditional', 'treatment', 'was', 'supplemented', 'by', 'transcranial', 'electrotherapy', 'using', 'a', 'TRANSAIR-02', 'apparatus', '.']","(4, 6)","(16, 37)",-1,hl_i,19708562,Abstract,1,test,gold,3985.0
3127,"In 58 patients , traditional treatment was supplemented by",transcranial electrotherapy,using a TRANSAIR-02 apparatus .,"['In', '58', 'patients', ',', 'traditional', 'treatment', 'was', 'supplemented', 'by', 'transcranial', 'electrotherapy', 'using', 'a', 'TRANSAIR-02', 'apparatus', '.']","(9, 11)","(58, 85)",-1,hl_i,19708562,Abstract,1,test,gold,4109.0
3128,,Laboratory studies,"included measurements of lactoferrin ( LF ) and tumour necrosis factor-alpha ( TNF-alpha ) , besides standard analyses .","['Laboratory', 'studies', 'included', 'measurements', 'of', 'lactoferrin', '(', 'LF', ')', 'and', 'tumour', 'necrosis', 'factor-alpha', '(', 'TNF-alpha', ')', ',', 'besides', 'standard', 'analyses', '.']","(0, 2)","(0, 18)",-1,ss_o,19708562,Abstract,2,test,gold,2086.0
3129,Laboratory studies included,"measurements of lactoferrin ( LF ) and tumour necrosis factor-alpha ( TNF-alpha ) , besides standard analyses .",,"['Laboratory', 'studies', 'included', 'measurements', 'of', 'lactoferrin', '(', 'LF', ')', 'and', 'tumour', 'necrosis', 'factor-alpha', '(', 'TNF-alpha', ')', ',', 'besides', 'standard', 'analyses', '.']","(3, 21)","(27, 138)",-1,ss_o,19708562,Abstract,2,test,gold,6810.0
3130,Laboratory studies included measurements of,lactoferrin ( LF ),"and tumour necrosis factor-alpha ( TNF-alpha ) , besides standard analyses .","['Laboratory', 'studies', 'included', 'measurements', 'of', 'lactoferrin', '(', 'LF', ')', 'and', 'tumour', 'necrosis', 'factor-alpha', '(', 'TNF-alpha', ')', ',', 'besides', 'standard', 'analyses', '.']","(5, 9)","(43, 61)",-1,hl_o,19708562,Abstract,2,test,gold,216.0
3131,Laboratory studies included measurements of lactoferrin ( LF ) and,tumour necrosis factor-alpha ( TNF-alpha ),", besides standard analyses .","['Laboratory', 'studies', 'included', 'measurements', 'of', 'lactoferrin', '(', 'LF', ')', 'and', 'tumour', 'necrosis', 'factor-alpha', '(', 'TNF-alpha', ')', ',', 'besides', 'standard', 'analyses', '.']","(10, 16)","(66, 108)",-1,hl_o,19708562,Abstract,2,test,gold,77.0
3132,Combined treatment,( traditional therapy plus electrostimulation ),"resulted in a significant reduction in duration of the main symptoms of the gastric ulcer depending on the severity of ulceration process , patients ' age and sex .","['Combined', 'treatment', '(', 'traditional', 'therapy', 'plus', 'electrostimulation', ')', 'resulted', 'in', 'a', 'significant', 'reduction', 'in', 'duration', 'of', 'the', 'main', 'symptoms', 'of', 'the', 'gastric', 'ulcer', 'depending', 'on', 'the', 'severity', 'of', 'ulceration', 'process', ',', 'patients', ""'"", 'age', 'and', 'sex', '.']","(2, 8)","(18, 65)",-1,ss_i,19708562,Abstract,3,test,gold,4201.0
3133,Combined treatment ( traditional therapy plus electrostimulation ) resulted in a significant reduction in,duration of the main symptoms of the gastric ulcer,"depending on the severity of ulceration process , patients ' age and sex .","['Combined', 'treatment', '(', 'traditional', 'therapy', 'plus', 'electrostimulation', ')', 'resulted', 'in', 'a', 'significant', 'reduction', 'in', 'duration', 'of', 'the', 'main', 'symptoms', 'of', 'the', 'gastric', 'ulcer', 'depending', 'on', 'the', 'severity', 'of', 'ulceration', 'process', ',', 'patients', ""'"", 'age', 'and', 'sex', '.']","(14, 23)","(105, 155)",-1,ss_o,19708562,Abstract,3,test,gold,7012.0
3134,"Combined treatment ( traditional therapy plus electrostimulation ) resulted in a significant reduction in duration of the main symptoms of the gastric ulcer depending on the severity of ulceration process ,",patients ' age and sex .,,"['Combined', 'treatment', '(', 'traditional', 'therapy', 'plus', 'electrostimulation', ')', 'resulted', 'in', 'a', 'significant', 'reduction', 'in', 'duration', 'of', 'the', 'main', 'symptoms', 'of', 'the', 'gastric', 'ulcer', 'depending', 'on', 'the', 'severity', 'of', 'ulceration', 'process', ',', 'patients', ""'"", 'age', 'and', 'sex', '.']","(31, 37)","(206, 230)",-1,ss_o,19708562,Abstract,3,test,gold,3765.0
3135,Combined treatment,( traditional therapy,"plus electrostimulation ) resulted in a significant reduction in duration of the main symptoms of the gastric ulcer depending on the severity of ulceration process , patients ' age and sex .","['Combined', 'treatment', '(', 'traditional', 'therapy', 'plus', 'electrostimulation', ')', 'resulted', 'in', 'a', 'significant', 'reduction', 'in', 'duration', 'of', 'the', 'main', 'symptoms', 'of', 'the', 'gastric', 'ulcer', 'depending', 'on', 'the', 'severity', 'of', 'ulceration', 'process', ',', 'patients', ""'"", 'age', 'and', 'sex', '.']","(2, 5)","(18, 39)",-1,hl_i,19708562,Abstract,3,test,gold,4196.0
3136,Combined treatment ( traditional therapy plus,electrostimulation,") resulted in a significant reduction in duration of the main symptoms of the gastric ulcer depending on the severity of ulceration process , patients ' age and sex .","['Combined', 'treatment', '(', 'traditional', 'therapy', 'plus', 'electrostimulation', ')', 'resulted', 'in', 'a', 'significant', 'reduction', 'in', 'duration', 'of', 'the', 'main', 'symptoms', 'of', 'the', 'gastric', 'ulcer', 'depending', 'on', 'the', 'severity', 'of', 'ulceration', 'process', ',', 'patients', ""'"", 'age', 'and', 'sex', '.']","(6, 7)","(45, 63)",-1,hl_i,19708562,Abstract,3,test,gold,74.0
3137,Combined treatment ( traditional therapy plus electrostimulation ) resulted in a significant reduction in,duration of the main symptoms,"of the gastric ulcer depending on the severity of ulceration process , patients ' age and sex .","['Combined', 'treatment', '(', 'traditional', 'therapy', 'plus', 'electrostimulation', ')', 'resulted', 'in', 'a', 'significant', 'reduction', 'in', 'duration', 'of', 'the', 'main', 'symptoms', 'of', 'the', 'gastric', 'ulcer', 'depending', 'on', 'the', 'severity', 'of', 'ulceration', 'process', ',', 'patients', ""'"", 'age', 'and', 'sex', '.']","(14, 19)","(105, 134)",-1,hl_o,19708562,Abstract,3,test,gold,3289.0
3138,"Moreover , it facilitated",ulcer scarring,and had beneficial effect on dynamics of serum LF and TNF-alpha levels .,"['Moreover', ',', 'it', 'facilitated', 'ulcer', 'scarring', 'and', 'had', 'beneficial', 'effect', 'on', 'dynamics', 'of', 'serum', 'LF', 'and', 'TNF-alpha', 'levels', '.']","(4, 6)","(25, 39)",-1,ss_o,19708562,Abstract,4,test,gold,3111.0
3139,"Moreover , it facilitated ulcer scarring and had beneficial effect on dynamics of",serum LF and TNF-alpha levels .,,"['Moreover', ',', 'it', 'facilitated', 'ulcer', 'scarring', 'and', 'had', 'beneficial', 'effect', 'on', 'dynamics', 'of', 'serum', 'LF', 'and', 'TNF-alpha', 'levels', '.']","(13, 19)","(81, 112)",-1,ss_o,19708562,Abstract,4,test,gold,4480.0
3140,"Moreover , it facilitated",ulcer scarring,and had beneficial effect on dynamics of serum LF and TNF-alpha levels .,"['Moreover', ',', 'it', 'facilitated', 'ulcer', 'scarring', 'and', 'had', 'beneficial', 'effect', 'on', 'dynamics', 'of', 'serum', 'LF', 'and', 'TNF-alpha', 'levels', '.']","(4, 6)","(25, 39)",-1,hl_o,19708562,Abstract,4,test,gold,3112.0
3141,"Moreover , it facilitated ulcer scarring and had beneficial effect on dynamics of",serum LF and TNF-alpha levels .,,"['Moreover', ',', 'it', 'facilitated', 'ulcer', 'scarring', 'and', 'had', 'beneficial', 'effect', 'on', 'dynamics', 'of', 'serum', 'LF', 'and', 'TNF-alpha', 'levels', '.']","(13, 19)","(81, 112)",-1,hl_o,19708562,Abstract,4,test,gold,4481.0
3142,[ Effects of auditory integrative training on,autistic children ],.,"['[', 'Effects', 'of', 'auditory', 'integrative', 'training', 'on', 'autistic', 'children', ']', '.']","(7, 10)","(45, 64)",-1,ss_p,19727232,Title,0,test,gold,6157.0
3143,[ Effects of,auditory integrative training,on autistic children ] .,"['[', 'Effects', 'of', 'auditory', 'integrative', 'training', 'on', 'autistic', 'children', ']', '.']","(3, 6)","(12, 41)",-1,ss_i,19727232,Title,0,test,gold,6316.0
3144,[ Effects of auditory integrative training on,autistic children,] .,"['[', 'Effects', 'of', 'auditory', 'integrative', 'training', 'on', 'autistic', 'children', ']', '.']","(7, 9)","(45, 62)",-1,hl_p,19727232,Title,0,test,gold,6158.0
3145,[ Effects of,auditory integrative training,on autistic children ] .,"['[', 'Effects', 'of', 'auditory', 'integrative', 'training', 'on', 'autistic', 'children', ']', '.']","(3, 6)","(12, 41)",-1,hl_i,19727232,Title,0,test,gold,6317.0
3146,OBJECTIVE To explore the short-term treatment effect of the auditory integrative training on,autistic children,and provide them with clinical support for rehabilitative treatment .,"['OBJECTIVE', 'To', 'explore', 'the', 'short-term', 'treatment', 'effect', 'of', 'the', 'auditory', 'integrative', 'training', 'on', 'autistic', 'children', 'and', 'provide', 'them', 'with', 'clinical', 'support', 'for', 'rehabilitative', 'treatment', '.']","(13, 15)","(92, 109)",-1,ss_p,19727232,Abstract,0,test,gold,6156.0
3147,OBJECTIVE To explore the short-term treatment effect of the,auditory integrative training,on autistic children and provide them with clinical support for rehabilitative treatment .,"['OBJECTIVE', 'To', 'explore', 'the', 'short-term', 'treatment', 'effect', 'of', 'the', 'auditory', 'integrative', 'training', 'on', 'autistic', 'children', 'and', 'provide', 'them', 'with', 'clinical', 'support', 'for', 'rehabilitative', 'treatment', '.']","(9, 12)","(59, 88)",-1,ss_i,19727232,Abstract,0,test,gold,6315.0
3148,OBJECTIVE To explore the short-term treatment,effect,of the auditory integrative training on autistic children and provide them with clinical support for rehabilitative treatment .,"['OBJECTIVE', 'To', 'explore', 'the', 'short-term', 'treatment', 'effect', 'of', 'the', 'auditory', 'integrative', 'training', 'on', 'autistic', 'children', 'and', 'provide', 'them', 'with', 'clinical', 'support', 'for', 'rehabilitative', 'treatment', '.']","(6, 7)","(45, 51)",-1,ss_o,19727232,Abstract,0,test,gold,2339.0
3149,OBJECTIVE To explore the short-term treatment effect of the auditory integrative training on,autistic children,and provide them with clinical support for rehabilitative treatment .,"['OBJECTIVE', 'To', 'explore', 'the', 'short-term', 'treatment', 'effect', 'of', 'the', 'auditory', 'integrative', 'training', 'on', 'autistic', 'children', 'and', 'provide', 'them', 'with', 'clinical', 'support', 'for', 'rehabilitative', 'treatment', '.']","(13, 15)","(92, 109)",-1,hl_p,19727232,Abstract,0,test,gold,6155.0
3150,OBJECTIVE To explore the short-term treatment effect of the,auditory integrative training,on autistic children and provide them with clinical support for rehabilitative treatment .,"['OBJECTIVE', 'To', 'explore', 'the', 'short-term', 'treatment', 'effect', 'of', 'the', 'auditory', 'integrative', 'training', 'on', 'autistic', 'children', 'and', 'provide', 'them', 'with', 'clinical', 'support', 'for', 'rehabilitative', 'treatment', '.']","(9, 12)","(59, 88)",-1,hl_i,19727232,Abstract,0,test,gold,6314.0
3151,METHODS A total of,81 cases of autistic children were selected,through the standard of DSM-4 and clinical case study was used .,"['METHODS', 'A', 'total', 'of', '81', 'cases', 'of', 'autistic', 'children', 'were', 'selected', 'through', 'the', 'standard', 'of', 'DSM-4', 'and', 'clinical', 'case', 'study', 'was', 'used', '.']","(4, 11)","(18, 61)",-1,ss_p,19727232,Abstract,1,test,gold,6159.0
3152,METHODS A total of,81 cases of autistic children,were selected through the standard of DSM-4 and clinical case study was used .,"['METHODS', 'A', 'total', 'of', '81', 'cases', 'of', 'autistic', 'children', 'were', 'selected', 'through', 'the', 'standard', 'of', 'DSM-4', 'and', 'clinical', 'case', 'study', 'was', 'used', '.']","(4, 9)","(18, 47)",-1,hl_p,19727232,Abstract,1,test,gold,6160.0
3153,"They were divided randomly into experimental group and control one , and respectively received",auditory integrative training,and no training based on the multiple therapies .,"['They', 'were', 'divided', 'randomly', 'into', 'experimental', 'group', 'and', 'control', 'one', ',', 'and', 'respectively', 'received', 'auditory', 'integrative', 'training', 'and', 'no', 'training', 'based', 'on', 'the', 'multiple', 'therapies', '.']","(14, 17)","(94, 123)",-1,ss_i,19727232,Abstract,2,test,gold,6313.0
3154,"They were divided randomly into experimental group and control one , and respectively received",auditory integrative training,and no training based on the multiple therapies .,"['They', 'were', 'divided', 'randomly', 'into', 'experimental', 'group', 'and', 'control', 'one', ',', 'and', 'respectively', 'received', 'auditory', 'integrative', 'training', 'and', 'no', 'training', 'based', 'on', 'the', 'multiple', 'therapies', '.']","(14, 17)","(94, 123)",-1,hl_i,19727232,Abstract,2,test,gold,6312.0
3155,The patients were investigated using,clinical manifestation and Autism Behavior Checklist ( ABC ) and intelligence quotient ( IQ ),before and after six months of treatment .,"['The', 'patients', 'were', 'investigated', 'using', 'clinical', 'manifestation', 'and', 'Autism', 'Behavior', 'Checklist', '(', 'ABC', ')', 'and', 'intelligence', 'quotient', '(', 'IQ', ')', 'before', 'and', 'after', 'six', 'months', 'of', 'treatment', '.']","(5, 20)","(36, 129)",-1,ss_o,19727232,Abstract,3,test,gold,6290.0
3156,The patients were investigated using,clinical manifestation,and Autism Behavior Checklist ( ABC ) and intelligence quotient ( IQ ) before and after six months of treatment .,"['The', 'patients', 'were', 'investigated', 'using', 'clinical', 'manifestation', 'and', 'Autism', 'Behavior', 'Checklist', '(', 'ABC', ')', 'and', 'intelligence', 'quotient', '(', 'IQ', ')', 'before', 'and', 'after', 'six', 'months', 'of', 'treatment', '.']","(5, 7)","(36, 58)",-1,hl_o,19727232,Abstract,3,test,gold,4769.0
3157,The patients were investigated using clinical manifestation and,Autism Behavior Checklist ( ABC ),and intelligence quotient ( IQ ) before and after six months of treatment .,"['The', 'patients', 'were', 'investigated', 'using', 'clinical', 'manifestation', 'and', 'Autism', 'Behavior', 'Checklist', '(', 'ABC', ')', 'and', 'intelligence', 'quotient', '(', 'IQ', ')', 'before', 'and', 'after', 'six', 'months', 'of', 'treatment', '.']","(8, 14)","(63, 96)",-1,hl_o,19727232,Abstract,3,test,gold,6287.0
3158,The patients were investigated using clinical manifestation and Autism Behavior Checklist ( ABC ) and,intelligence quotient ( IQ ),before and after six months of treatment .,"['The', 'patients', 'were', 'investigated', 'using', 'clinical', 'manifestation', 'and', 'Autism', 'Behavior', 'Checklist', '(', 'ABC', ')', 'and', 'intelligence', 'quotient', '(', 'IQ', ')', 'before', 'and', 'after', 'six', 'months', 'of', 'treatment', '.']","(15, 20)","(101, 129)",-1,hl_o,19727232,Abstract,3,test,gold,1417.0
3159,The effect was evaluated through the,changes of clinical manifestations and scores of ABC and IQ .,,"['The', 'effect', 'was', 'evaluated', 'through', 'the', 'changes', 'of', 'clinical', 'manifestations', 'and', 'scores', 'of', 'ABC', 'and', 'IQ', '.']","(6, 17)","(36, 97)",-1,ss_o,19727232,Abstract,4,test,gold,6379.0
3160,The effect was evaluated through the,changes of clinical manifestations,and scores of ABC and IQ .,"['The', 'effect', 'was', 'evaluated', 'through', 'the', 'changes', 'of', 'clinical', 'manifestations', 'and', 'scores', 'of', 'ABC', 'and', 'IQ', '.']","(6, 10)","(36, 70)",-1,hl_o,19727232,Abstract,4,test,gold,4765.0
3161,The effect was evaluated through the changes of clinical manifestations and scores of,ABC,and IQ .,"['The', 'effect', 'was', 'evaluated', 'through', 'the', 'changes', 'of', 'clinical', 'manifestations', 'and', 'scores', 'of', 'ABC', 'and', 'IQ', '.']","(13, 14)","(85, 88)",-1,hl_o,19727232,Abstract,4,test,gold,1423.0
3162,The effect was evaluated through the changes of clinical manifestations and scores of ABC and,IQ .,,"['The', 'effect', 'was', 'evaluated', 'through', 'the', 'changes', 'of', 'clinical', 'manifestations', 'and', 'scores', 'of', 'ABC', 'and', 'IQ', '.']","(15, 17)","(93, 97)",-1,hl_o,19727232,Abstract,4,test,gold,1419.0
3163,The,changes of scores of IQ were determined with Gesell and WPPSI or WISC-R .,,"['The', 'changes', 'of', 'scores', 'of', 'IQ', 'were', 'determined', 'with', 'Gesell', 'and', 'WPPSI', 'or', 'WISC-R', '.']","(1, 15)","(3, 76)",-1,ss_o,19727232,Abstract,5,test,gold,6377.0
3164,The changes of scores of,IQ,were determined with Gesell and WPPSI or WISC-R .,"['The', 'changes', 'of', 'scores', 'of', 'IQ', 'were', 'determined', 'with', 'Gesell', 'and', 'WPPSI', 'or', 'WISC-R', '.']","(5, 6)","(24, 26)",-1,hl_o,19727232,Abstract,5,test,gold,1420.0
3165,RESULTS Compared with 40 patients of the control group after the six months of the,auditory integrative training,", 41 of the experimental group had greatly improved in many aspects , such as the disorders of their language , social interactions and typical behavior symptoms while they had not changed in their abnormal behaviors .","['RESULTS', 'Compared', 'with', '40', 'patients', 'of', 'the', 'control', 'group', 'after', 'the', 'six', 'months', 'of', 'the', 'auditory', 'integrative', 'training', ',', '41', 'of', 'the', 'experimental', 'group', 'had', 'greatly', 'improved', 'in', 'many', 'aspects', ',', 'such', 'as', 'the', 'disorders', 'of', 'their', 'language', ',', 'social', 'interactions', 'and', 'typical', 'behavior', 'symptoms', 'while', 'they', 'had', 'not', 'changed', 'in', 'their', 'abnormal', 'behaviors', '.']","(15, 18)","(82, 111)",-1,ss_i,19727232,Abstract,6,test,gold,6311.0
3166,"RESULTS Compared with 40 patients of the control group after the six months of the auditory integrative training , 41 of the experimental group had greatly improved in many aspects , such as the","disorders of their language , social interactions and typical behavior symptoms",while they had not changed in their abnormal behaviors .,"['RESULTS', 'Compared', 'with', '40', 'patients', 'of', 'the', 'control', 'group', 'after', 'the', 'six', 'months', 'of', 'the', 'auditory', 'integrative', 'training', ',', '41', 'of', 'the', 'experimental', 'group', 'had', 'greatly', 'improved', 'in', 'many', 'aspects', ',', 'such', 'as', 'the', 'disorders', 'of', 'their', 'language', ',', 'social', 'interactions', 'and', 'typical', 'behavior', 'symptoms', 'while', 'they', 'had', 'not', 'changed', 'in', 'their', 'abnormal', 'behaviors', '.']","(34, 45)","(194, 273)",-1,ss_o,19727232,Abstract,6,test,gold,7114.0
3167,"RESULTS Compared with 40 patients of the control group after the six months of the auditory integrative training , 41 of the experimental group had greatly improved in many aspects , such as the disorders of their language , social interactions and typical behavior symptoms while they had not changed in their",abnormal behaviors .,,"['RESULTS', 'Compared', 'with', '40', 'patients', 'of', 'the', 'control', 'group', 'after', 'the', 'six', 'months', 'of', 'the', 'auditory', 'integrative', 'training', ',', '41', 'of', 'the', 'experimental', 'group', 'had', 'greatly', 'improved', 'in', 'many', 'aspects', ',', 'such', 'as', 'the', 'disorders', 'of', 'their', 'language', ',', 'social', 'interactions', 'and', 'typical', 'behavior', 'symptoms', 'while', 'they', 'had', 'not', 'changed', 'in', 'their', 'abnormal', 'behaviors', '.']","(52, 55)","(310, 330)",-1,ss_o,19727232,Abstract,6,test,gold,6411.0
3168,RESULTS Compared with 40 patients of the control group after the six months of the,auditory integrative training,", 41 of the experimental group had greatly improved in many aspects , such as the disorders of their language , social interactions and typical behavior symptoms while they had not changed in their abnormal behaviors .","['RESULTS', 'Compared', 'with', '40', 'patients', 'of', 'the', 'control', 'group', 'after', 'the', 'six', 'months', 'of', 'the', 'auditory', 'integrative', 'training', ',', '41', 'of', 'the', 'experimental', 'group', 'had', 'greatly', 'improved', 'in', 'many', 'aspects', ',', 'such', 'as', 'the', 'disorders', 'of', 'their', 'language', ',', 'social', 'interactions', 'and', 'typical', 'behavior', 'symptoms', 'while', 'they', 'had', 'not', 'changed', 'in', 'their', 'abnormal', 'behaviors', '.']","(15, 18)","(82, 111)",-1,hl_i,19727232,Abstract,6,test,gold,6310.0
3169,"RESULTS Compared with 40 patients of the control group after the six months of the auditory integrative training , 41 of the experimental group had greatly improved in many aspects , such as the",disorders of their language,", social interactions and typical behavior symptoms while they had not changed in their abnormal behaviors .","['RESULTS', 'Compared', 'with', '40', 'patients', 'of', 'the', 'control', 'group', 'after', 'the', 'six', 'months', 'of', 'the', 'auditory', 'integrative', 'training', ',', '41', 'of', 'the', 'experimental', 'group', 'had', 'greatly', 'improved', 'in', 'many', 'aspects', ',', 'such', 'as', 'the', 'disorders', 'of', 'their', 'language', ',', 'social', 'interactions', 'and', 'typical', 'behavior', 'symptoms', 'while', 'they', 'had', 'not', 'changed', 'in', 'their', 'abnormal', 'behaviors', '.']","(34, 38)","(194, 221)",-1,hl_o,19727232,Abstract,6,test,gold,2613.0
3170,"RESULTS Compared with 40 patients of the control group after the six months of the auditory integrative training , 41 of the experimental group had greatly improved in many aspects , such as the disorders of their language ,",social interactions,and typical behavior symptoms while they had not changed in their abnormal behaviors .,"['RESULTS', 'Compared', 'with', '40', 'patients', 'of', 'the', 'control', 'group', 'after', 'the', 'six', 'months', 'of', 'the', 'auditory', 'integrative', 'training', ',', '41', 'of', 'the', 'experimental', 'group', 'had', 'greatly', 'improved', 'in', 'many', 'aspects', ',', 'such', 'as', 'the', 'disorders', 'of', 'their', 'language', ',', 'social', 'interactions', 'and', 'typical', 'behavior', 'symptoms', 'while', 'they', 'had', 'not', 'changed', 'in', 'their', 'abnormal', 'behaviors', '.']","(39, 41)","(224, 243)",-1,hl_o,19727232,Abstract,6,test,gold,2963.0
3171,"RESULTS Compared with 40 patients of the control group after the six months of the auditory integrative training , 41 of the experimental group had greatly improved in many aspects , such as the disorders of their language , social interactions and",typical behavior symptoms,while they had not changed in their abnormal behaviors .,"['RESULTS', 'Compared', 'with', '40', 'patients', 'of', 'the', 'control', 'group', 'after', 'the', 'six', 'months', 'of', 'the', 'auditory', 'integrative', 'training', ',', '41', 'of', 'the', 'experimental', 'group', 'had', 'greatly', 'improved', 'in', 'many', 'aspects', ',', 'such', 'as', 'the', 'disorders', 'of', 'their', 'language', ',', 'social', 'interactions', 'and', 'typical', 'behavior', 'symptoms', 'while', 'they', 'had', 'not', 'changed', 'in', 'their', 'abnormal', 'behaviors', '.']","(42, 45)","(248, 273)",-1,hl_o,19727232,Abstract,6,test,gold,3290.0
3172,"RESULTS Compared with 40 patients of the control group after the six months of the auditory integrative training , 41 of the experimental group had greatly improved in many aspects , such as the disorders of their language , social interactions and typical behavior symptoms while they had not changed in their",abnormal behaviors .,,"['RESULTS', 'Compared', 'with', '40', 'patients', 'of', 'the', 'control', 'group', 'after', 'the', 'six', 'months', 'of', 'the', 'auditory', 'integrative', 'training', ',', '41', 'of', 'the', 'experimental', 'group', 'had', 'greatly', 'improved', 'in', 'many', 'aspects', ',', 'such', 'as', 'the', 'disorders', 'of', 'their', 'language', ',', 'social', 'interactions', 'and', 'typical', 'behavior', 'symptoms', 'while', 'they', 'had', 'not', 'changed', 'in', 'their', 'abnormal', 'behaviors', '.']","(52, 55)","(310, 330)",-1,hl_o,19727232,Abstract,6,test,gold,6412.0
3173,The,scores of IQ or DQ,had increased and scores of ABC had dropped .,"['The', 'scores', 'of', 'IQ', 'or', 'DQ', 'had', 'increased', 'and', 'scores', 'of', 'ABC', 'had', 'dropped', '.']","(1, 6)","(3, 21)",-1,ss_o,19727232,Abstract,7,test,gold,1415.0
3174,The scores of IQ or DQ had increased and,scores of ABC,had dropped .,"['The', 'scores', 'of', 'IQ', 'or', 'DQ', 'had', 'increased', 'and', 'scores', 'of', 'ABC', 'had', 'dropped', '.']","(9, 12)","(40, 53)",-1,ss_o,19727232,Abstract,7,test,gold,1428.0
3175,The,scores of IQ or DQ,had increased and scores of ABC had dropped .,"['The', 'scores', 'of', 'IQ', 'or', 'DQ', 'had', 'increased', 'and', 'scores', 'of', 'ABC', 'had', 'dropped', '.']","(1, 6)","(3, 21)",-1,hl_o,19727232,Abstract,7,test,gold,1416.0
3176,The scores of IQ or DQ had increased and scores of,ABC,had dropped .,"['The', 'scores', 'of', 'IQ', 'or', 'DQ', 'had', 'increased', 'and', 'scores', 'of', 'ABC', 'had', 'dropped', '.']","(11, 12)","(50, 53)",-1,hl_o,19727232,Abstract,7,test,gold,1424.0
3177,The differences between the two groups were greatly significant in statistics ( P < 0.01 ) .,,,"['The', 'differences', 'between', 'the', 'two', 'groups', 'were', 'greatly', 'significant', 'in', 'statistics', '(', 'P', '<', '0.01', ')', '.']",,,,,19727232,Abstract,8,test,gold,
3178,The decreasing level of both,ABC scores,"and the increasing level of the IQ scores were negatively correlated with age , and the decreasing level of ABC scores was in line regression ( positive correlation ) with base IQ .","['The', 'decreasing', 'level', 'of', 'both', 'ABC', 'scores', 'and', 'the', 'increasing', 'level', 'of', 'the', 'IQ', 'scores', 'were', 'negatively', 'correlated', 'with', 'age', ',', 'and', 'the', 'decreasing', 'level', 'of', 'ABC', 'scores', 'was', 'in', 'line', 'regression', '(', 'positive', 'correlation', ')', 'with', 'base', 'IQ', '.']","(5, 7)","(28, 38)",-1,ss_o,19727232,Abstract,9,test,gold,1429.0
3179,The decreasing level of both ABC scores and the increasing level of the,IQ scores,"were negatively correlated with age , and the decreasing level of ABC scores was in line regression ( positive correlation ) with base IQ .","['The', 'decreasing', 'level', 'of', 'both', 'ABC', 'scores', 'and', 'the', 'increasing', 'level', 'of', 'the', 'IQ', 'scores', 'were', 'negatively', 'correlated', 'with', 'age', ',', 'and', 'the', 'decreasing', 'level', 'of', 'ABC', 'scores', 'was', 'in', 'line', 'regression', '(', 'positive', 'correlation', ')', 'with', 'base', 'IQ', '.']","(13, 15)","(71, 80)",-1,ss_o,19727232,Abstract,9,test,gold,1421.0
3180,"The decreasing level of both ABC scores and the increasing level of the IQ scores were negatively correlated with age , and the decreasing level of",ABC scores,was in line regression ( positive correlation ) with base IQ .,"['The', 'decreasing', 'level', 'of', 'both', 'ABC', 'scores', 'and', 'the', 'increasing', 'level', 'of', 'the', 'IQ', 'scores', 'were', 'negatively', 'correlated', 'with', 'age', ',', 'and', 'the', 'decreasing', 'level', 'of', 'ABC', 'scores', 'was', 'in', 'line', 'regression', '(', 'positive', 'correlation', ')', 'with', 'base', 'IQ', '.']","(26, 28)","(147, 157)",-1,ss_o,19727232,Abstract,9,test,gold,1427.0
3181,The decreasing level of both,ABC scores,"and the increasing level of the IQ scores were negatively correlated with age , and the decreasing level of ABC scores was in line regression ( positive correlation ) with base IQ .","['The', 'decreasing', 'level', 'of', 'both', 'ABC', 'scores', 'and', 'the', 'increasing', 'level', 'of', 'the', 'IQ', 'scores', 'were', 'negatively', 'correlated', 'with', 'age', ',', 'and', 'the', 'decreasing', 'level', 'of', 'ABC', 'scores', 'was', 'in', 'line', 'regression', '(', 'positive', 'correlation', ')', 'with', 'base', 'IQ', '.']","(5, 7)","(28, 38)",-1,hl_o,19727232,Abstract,9,test,gold,1426.0
3182,The decreasing level of both ABC scores and the increasing level of the,IQ scores,"were negatively correlated with age , and the decreasing level of ABC scores was in line regression ( positive correlation ) with base IQ .","['The', 'decreasing', 'level', 'of', 'both', 'ABC', 'scores', 'and', 'the', 'increasing', 'level', 'of', 'the', 'IQ', 'scores', 'were', 'negatively', 'correlated', 'with', 'age', ',', 'and', 'the', 'decreasing', 'level', 'of', 'ABC', 'scores', 'was', 'in', 'line', 'regression', '(', 'positive', 'correlation', ')', 'with', 'base', 'IQ', '.']","(13, 15)","(71, 80)",-1,hl_o,19727232,Abstract,9,test,gold,1422.0
3183,"The decreasing level of both ABC scores and the increasing level of the IQ scores were negatively correlated with age , and the decreasing level of",ABC scores,was in line regression ( positive correlation ) with base IQ .,"['The', 'decreasing', 'level', 'of', 'both', 'ABC', 'scores', 'and', 'the', 'increasing', 'level', 'of', 'the', 'IQ', 'scores', 'were', 'negatively', 'correlated', 'with', 'age', ',', 'and', 'the', 'decreasing', 'level', 'of', 'ABC', 'scores', 'was', 'in', 'line', 'regression', '(', 'positive', 'correlation', ')', 'with', 'base', 'IQ', '.']","(26, 28)","(147, 157)",-1,hl_o,19727232,Abstract,9,test,gold,1425.0
3184,"CONCLUSION The treatment of auditory integrative training ( AIT ) could greatly improve on language disorders , the difficulties of social interactions , typical behavior symptoms and developmental levels , therefore it is positive to the",autistic children,in its short-term treatment effect .,"['CONCLUSION', 'The', 'treatment', 'of', 'auditory', 'integrative', 'training', '(', 'AIT', ')', 'could', 'greatly', 'improve', 'on', 'language', 'disorders', ',', 'the', 'difficulties', 'of', 'social', 'interactions', ',', 'typical', 'behavior', 'symptoms', 'and', 'developmental', 'levels', ',', 'therefore', 'it', 'is', 'positive', 'to', 'the', 'autistic', 'children', 'in', 'its', 'short-term', 'treatment', 'effect', '.']","(36, 38)","(238, 255)",-1,ss_p,19727232,Abstract,10,test,gold,6154.0
3185,CONCLUSION The treatment of,auditory integrative training ( AIT ),"could greatly improve on language disorders , the difficulties of social interactions , typical behavior symptoms and developmental levels , therefore it is positive to the autistic children in its short-term treatment effect .","['CONCLUSION', 'The', 'treatment', 'of', 'auditory', 'integrative', 'training', '(', 'AIT', ')', 'could', 'greatly', 'improve', 'on', 'language', 'disorders', ',', 'the', 'difficulties', 'of', 'social', 'interactions', ',', 'typical', 'behavior', 'symptoms', 'and', 'developmental', 'levels', ',', 'therefore', 'it', 'is', 'positive', 'to', 'the', 'autistic', 'children', 'in', 'its', 'short-term', 'treatment', 'effect', '.']","(4, 10)","(27, 64)",-1,ss_i,19727232,Abstract,10,test,gold,6318.0
3186,CONCLUSION The treatment of auditory integrative training ( AIT ) could greatly improve on,"language disorders , the difficulties of social interactions , typical behavior symptoms and developmental levels",", therefore it is positive to the autistic children in its short-term treatment effect .","['CONCLUSION', 'The', 'treatment', 'of', 'auditory', 'integrative', 'training', '(', 'AIT', ')', 'could', 'greatly', 'improve', 'on', 'language', 'disorders', ',', 'the', 'difficulties', 'of', 'social', 'interactions', ',', 'typical', 'behavior', 'symptoms', 'and', 'developmental', 'levels', ',', 'therefore', 'it', 'is', 'positive', 'to', 'the', 'autistic', 'children', 'in', 'its', 'short-term', 'treatment', 'effect', '.']","(14, 29)","(90, 203)",-1,ss_o,19727232,Abstract,10,test,gold,7115.0
3187,"CONCLUSION The treatment of auditory integrative training ( AIT ) could greatly improve on language disorders , the difficulties of social interactions , typical behavior symptoms and developmental levels , therefore it is positive to the autistic children in its short-term treatment",effect .,,"['CONCLUSION', 'The', 'treatment', 'of', 'auditory', 'integrative', 'training', '(', 'AIT', ')', 'could', 'greatly', 'improve', 'on', 'language', 'disorders', ',', 'the', 'difficulties', 'of', 'social', 'interactions', ',', 'typical', 'behavior', 'symptoms', 'and', 'developmental', 'levels', ',', 'therefore', 'it', 'is', 'positive', 'to', 'the', 'autistic', 'children', 'in', 'its', 'short-term', 'treatment', 'effect', '.']","(42, 44)","(284, 292)",-1,ss_o,19727232,Abstract,10,test,gold,2338.0
3188,"CONCLUSION The treatment of auditory integrative training ( AIT ) could greatly improve on language disorders , the difficulties of social interactions , typical behavior symptoms and developmental levels , therefore it is positive to the",autistic children,in its short-term treatment effect .,"['CONCLUSION', 'The', 'treatment', 'of', 'auditory', 'integrative', 'training', '(', 'AIT', ')', 'could', 'greatly', 'improve', 'on', 'language', 'disorders', ',', 'the', 'difficulties', 'of', 'social', 'interactions', ',', 'typical', 'behavior', 'symptoms', 'and', 'developmental', 'levels', ',', 'therefore', 'it', 'is', 'positive', 'to', 'the', 'autistic', 'children', 'in', 'its', 'short-term', 'treatment', 'effect', '.']","(36, 38)","(238, 255)",-1,hl_p,19727232,Abstract,10,test,gold,6153.0
3189,CONCLUSION The treatment of,auditory integrative training ( AIT ),"could greatly improve on language disorders , the difficulties of social interactions , typical behavior symptoms and developmental levels , therefore it is positive to the autistic children in its short-term treatment effect .","['CONCLUSION', 'The', 'treatment', 'of', 'auditory', 'integrative', 'training', '(', 'AIT', ')', 'could', 'greatly', 'improve', 'on', 'language', 'disorders', ',', 'the', 'difficulties', 'of', 'social', 'interactions', ',', 'typical', 'behavior', 'symptoms', 'and', 'developmental', 'levels', ',', 'therefore', 'it', 'is', 'positive', 'to', 'the', 'autistic', 'children', 'in', 'its', 'short-term', 'treatment', 'effect', '.']","(4, 10)","(27, 64)",-1,hl_i,19727232,Abstract,10,test,gold,6319.0
3190,CONCLUSION The treatment of auditory integrative training ( AIT ) could greatly improve on,language disorders,", the difficulties of social interactions , typical behavior symptoms and developmental levels , therefore it is positive to the autistic children in its short-term treatment effect .","['CONCLUSION', 'The', 'treatment', 'of', 'auditory', 'integrative', 'training', '(', 'AIT', ')', 'could', 'greatly', 'improve', 'on', 'language', 'disorders', ',', 'the', 'difficulties', 'of', 'social', 'interactions', ',', 'typical', 'behavior', 'symptoms', 'and', 'developmental', 'levels', ',', 'therefore', 'it', 'is', 'positive', 'to', 'the', 'autistic', 'children', 'in', 'its', 'short-term', 'treatment', 'effect', '.']","(14, 16)","(90, 108)",-1,hl_o,19727232,Abstract,10,test,gold,2614.0
3191,"CONCLUSION The treatment of auditory integrative training ( AIT ) could greatly improve on language disorders , the",difficulties of social interactions,", typical behavior symptoms and developmental levels , therefore it is positive to the autistic children in its short-term treatment effect .","['CONCLUSION', 'The', 'treatment', 'of', 'auditory', 'integrative', 'training', '(', 'AIT', ')', 'could', 'greatly', 'improve', 'on', 'language', 'disorders', ',', 'the', 'difficulties', 'of', 'social', 'interactions', ',', 'typical', 'behavior', 'symptoms', 'and', 'developmental', 'levels', ',', 'therefore', 'it', 'is', 'positive', 'to', 'the', 'autistic', 'children', 'in', 'its', 'short-term', 'treatment', 'effect', '.']","(18, 22)","(115, 150)",-1,hl_o,19727232,Abstract,10,test,gold,2964.0
3192,"CONCLUSION The treatment of auditory integrative training ( AIT ) could greatly improve on language disorders , the difficulties of social interactions ,",typical behavior symptoms,"and developmental levels , therefore it is positive to the autistic children in its short-term treatment effect .","['CONCLUSION', 'The', 'treatment', 'of', 'auditory', 'integrative', 'training', '(', 'AIT', ')', 'could', 'greatly', 'improve', 'on', 'language', 'disorders', ',', 'the', 'difficulties', 'of', 'social', 'interactions', ',', 'typical', 'behavior', 'symptoms', 'and', 'developmental', 'levels', ',', 'therefore', 'it', 'is', 'positive', 'to', 'the', 'autistic', 'children', 'in', 'its', 'short-term', 'treatment', 'effect', '.']","(23, 26)","(153, 178)",-1,hl_o,19727232,Abstract,10,test,gold,3291.0
3193,"CONCLUSION The treatment of auditory integrative training ( AIT ) could greatly improve on language disorders , the difficulties of social interactions , typical behavior symptoms and",developmental levels,", therefore it is positive to the autistic children in its short-term treatment effect .","['CONCLUSION', 'The', 'treatment', 'of', 'auditory', 'integrative', 'training', '(', 'AIT', ')', 'could', 'greatly', 'improve', 'on', 'language', 'disorders', ',', 'the', 'difficulties', 'of', 'social', 'interactions', ',', 'typical', 'behavior', 'symptoms', 'and', 'developmental', 'levels', ',', 'therefore', 'it', 'is', 'positive', 'to', 'the', 'autistic', 'children', 'in', 'its', 'short-term', 'treatment', 'effect', '.']","(27, 29)","(183, 203)",-1,hl_o,19727232,Abstract,10,test,gold,1382.0
3194,The effect of weight training on bone mineral density and bone turnover in,postmenopausal breast cancer survivors with bone loss :,a 24-month randomized controlled trial .,"['The', 'effect', 'of', 'weight', 'training', 'on', 'bone', 'mineral', 'density', 'and', 'bone', 'turnover', 'in', 'postmenopausal', 'breast', 'cancer', 'survivors', 'with', 'bone', 'loss', ':', 'a', '24-month', 'randomized', 'controlled', 'trial', '.']","(13, 21)","(74, 129)",-1,ss_p,19802506,Title,0,test,gold,6819.0
3195,The effect of,weight training,on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss : a 24-month randomized controlled trial .,"['The', 'effect', 'of', 'weight', 'training', 'on', 'bone', 'mineral', 'density', 'and', 'bone', 'turnover', 'in', 'postmenopausal', 'breast', 'cancer', 'survivors', 'with', 'bone', 'loss', ':', 'a', '24-month', 'randomized', 'controlled', 'trial', '.']","(3, 5)","(13, 28)",-1,ss_i,19802506,Title,0,test,gold,2733.0
3196,The effect of weight training on,bone mineral density and bone turnover,in postmenopausal breast cancer survivors with bone loss : a 24-month randomized controlled trial .,"['The', 'effect', 'of', 'weight', 'training', 'on', 'bone', 'mineral', 'density', 'and', 'bone', 'turnover', 'in', 'postmenopausal', 'breast', 'cancer', 'survivors', 'with', 'bone', 'loss', ':', 'a', '24-month', 'randomized', 'controlled', 'trial', '.']","(6, 12)","(32, 70)",-1,ss_o,19802506,Title,0,test,gold,1625.0
3197,The effect of weight training on bone mineral density and bone turnover in,postmenopausal breast cancer survivors with bone loss :,a 24-month randomized controlled trial .,"['The', 'effect', 'of', 'weight', 'training', 'on', 'bone', 'mineral', 'density', 'and', 'bone', 'turnover', 'in', 'postmenopausal', 'breast', 'cancer', 'survivors', 'with', 'bone', 'loss', ':', 'a', '24-month', 'randomized', 'controlled', 'trial', '.']","(13, 21)","(74, 129)",-1,hl_p,19802506,Title,0,test,gold,6820.0
3198,The effect of,weight training,on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss : a 24-month randomized controlled trial .,"['The', 'effect', 'of', 'weight', 'training', 'on', 'bone', 'mineral', 'density', 'and', 'bone', 'turnover', 'in', 'postmenopausal', 'breast', 'cancer', 'survivors', 'with', 'bone', 'loss', ':', 'a', '24-month', 'randomized', 'controlled', 'trial', '.']","(3, 5)","(13, 28)",-1,hl_i,19802506,Title,0,test,gold,2734.0
3199,The effect of weight training on,bone mineral density,and bone turnover in postmenopausal breast cancer survivors with bone loss : a 24-month randomized controlled trial .,"['The', 'effect', 'of', 'weight', 'training', 'on', 'bone', 'mineral', 'density', 'and', 'bone', 'turnover', 'in', 'postmenopausal', 'breast', 'cancer', 'survivors', 'with', 'bone', 'loss', ':', 'a', '24-month', 'randomized', 'controlled', 'trial', '.']","(6, 9)","(32, 52)",-1,hl_o,19802506,Title,0,test,gold,1626.0
3200,The effect of weight training on bone mineral density and,bone turnover,in postmenopausal breast cancer survivors with bone loss : a 24-month randomized controlled trial .,"['The', 'effect', 'of', 'weight', 'training', 'on', 'bone', 'mineral', 'density', 'and', 'bone', 'turnover', 'in', 'postmenopausal', 'breast', 'cancer', 'survivors', 'with', 'bone', 'loss', ':', 'a', '24-month', 'randomized', 'controlled', 'trial', '.']","(10, 12)","(57, 70)",-1,hl_o,19802506,Title,0,test,gold,1637.0
3201,"SUMMARY This study examined whether 24 months of weight training exercises enhanced the effectiveness of risedronate , calcium , and vitamin D in maintaining or improving bone mineral density ( BMD ) in",223 postmenopausal breast cancer survivors .,,"['SUMMARY', 'This', 'study', 'examined', 'whether', '24', 'months', 'of', 'weight', 'training', 'exercises', 'enhanced', 'the', 'effectiveness', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'in', 'maintaining', 'or', 'improving', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'in', '223', 'postmenopausal', 'breast', 'cancer', 'survivors', '.']","(33, 39)","(202, 246)",-1,ss_p,19802506,Abstract,0,test,gold,6817.0
3202,SUMMARY This study examined whether 24 months of,weight training exercises,"enhanced the effectiveness of risedronate , calcium , and vitamin D in maintaining or improving bone mineral density ( BMD ) in 223 postmenopausal breast cancer survivors .","['SUMMARY', 'This', 'study', 'examined', 'whether', '24', 'months', 'of', 'weight', 'training', 'exercises', 'enhanced', 'the', 'effectiveness', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'in', 'maintaining', 'or', 'improving', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'in', '223', 'postmenopausal', 'breast', 'cancer', 'survivors', '.']","(8, 11)","(48, 73)",-1,ss_i,19802506,Abstract,0,test,gold,2735.0
3203,SUMMARY This study examined whether 24 months of weight training exercises enhanced the,effectiveness,"of risedronate , calcium , and vitamin D in maintaining or improving bone mineral density ( BMD ) in 223 postmenopausal breast cancer survivors .","['SUMMARY', 'This', 'study', 'examined', 'whether', '24', 'months', 'of', 'weight', 'training', 'exercises', 'enhanced', 'the', 'effectiveness', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'in', 'maintaining', 'or', 'improving', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'in', '223', 'postmenopausal', 'breast', 'cancer', 'survivors', '.']","(13, 14)","(87, 100)",-1,ss_o,19802506,Abstract,0,test,gold,396.0
3204,"SUMMARY This study examined whether 24 months of weight training exercises enhanced the effectiveness of risedronate , calcium , and vitamin D in maintaining or improving",bone mineral density ( BMD ),in 223 postmenopausal breast cancer survivors .,"['SUMMARY', 'This', 'study', 'examined', 'whether', '24', 'months', 'of', 'weight', 'training', 'exercises', 'enhanced', 'the', 'effectiveness', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'in', 'maintaining', 'or', 'improving', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'in', '223', 'postmenopausal', 'breast', 'cancer', 'survivors', '.']","(26, 32)","(170, 198)",-1,ss_o,19802506,Abstract,0,test,gold,1628.0
3205,"SUMMARY This study examined whether 24 months of weight training exercises enhanced the effectiveness of risedronate , calcium , and vitamin D in maintaining or improving bone mineral density ( BMD ) in",223 postmenopausal breast cancer survivors,.,"['SUMMARY', 'This', 'study', 'examined', 'whether', '24', 'months', 'of', 'weight', 'training', 'exercises', 'enhanced', 'the', 'effectiveness', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'in', 'maintaining', 'or', 'improving', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'in', '223', 'postmenopausal', 'breast', 'cancer', 'survivors', '.']","(33, 38)","(202, 244)",-1,hl_p,19802506,Abstract,0,test,gold,6818.0
3206,SUMMARY This study examined whether 24 months of,weight training exercises,"enhanced the effectiveness of risedronate , calcium , and vitamin D in maintaining or improving bone mineral density ( BMD ) in 223 postmenopausal breast cancer survivors .","['SUMMARY', 'This', 'study', 'examined', 'whether', '24', 'months', 'of', 'weight', 'training', 'exercises', 'enhanced', 'the', 'effectiveness', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'in', 'maintaining', 'or', 'improving', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'in', '223', 'postmenopausal', 'breast', 'cancer', 'survivors', '.']","(8, 11)","(48, 73)",-1,hl_i,19802506,Abstract,0,test,gold,2736.0
3207,"SUMMARY This study examined whether 24 months of weight training exercises enhanced the effectiveness of risedronate , calcium , and vitamin D in maintaining or improving",bone mineral density ( BMD ),in 223 postmenopausal breast cancer survivors .,"['SUMMARY', 'This', 'study', 'examined', 'whether', '24', 'months', 'of', 'weight', 'training', 'exercises', 'enhanced', 'the', 'effectiveness', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'in', 'maintaining', 'or', 'improving', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'in', '223', 'postmenopausal', 'breast', 'cancer', 'survivors', '.']","(26, 32)","(170, 198)",-1,hl_o,19802506,Abstract,0,test,gold,1629.0
3208,Subjects who were > or =50 % adherent to exercise had no improvement in,BMD,but were less likely to lose BMD .,"['Subjects', 'who', 'were', '>', 'or', '=50', '%', 'adherent', 'to', 'exercise', 'had', 'no', 'improvement', 'in', 'BMD', 'but', 'were', 'less', 'likely', 'to', 'lose', 'BMD', '.']","(14, 15)","(71, 74)",-1,ss_o,19802506,Abstract,1,test,gold,1623.0
3209,Subjects who were > or =50 % adherent to exercise had no improvement in BMD but were less likely to lose,BMD .,,"['Subjects', 'who', 'were', '>', 'or', '=50', '%', 'adherent', 'to', 'exercise', 'had', 'no', 'improvement', 'in', 'BMD', 'but', 'were', 'less', 'likely', 'to', 'lose', 'BMD', '.']","(21, 23)","(104, 109)",-1,ss_o,19802506,Abstract,1,test,gold,1624.0
3210,Subjects who were > or =50 % adherent to exercise had no improvement in,BMD,but were less likely to lose BMD .,"['Subjects', 'who', 'were', '>', 'or', '=50', '%', 'adherent', 'to', 'exercise', 'had', 'no', 'improvement', 'in', 'BMD', 'but', 'were', 'less', 'likely', 'to', 'lose', 'BMD', '.']","(14, 15)","(71, 74)",-1,hl_o,19802506,Abstract,1,test,gold,1622.0
3211,Subjects who were > or =50 % adherent to exercise had no improvement in BMD but were less likely to lose,BMD .,,"['Subjects', 'who', 'were', '>', 'or', '=50', '%', 'adherent', 'to', 'exercise', 'had', 'no', 'improvement', 'in', 'BMD', 'but', 'were', 'less', 'likely', 'to', 'lose', 'BMD', '.']","(21, 23)","(104, 109)",-1,hl_o,19802506,Abstract,1,test,gold,1621.0
3212,INTRODUCTION This study examined whether ( 1 ),postmenopausal breast cancer survivors ( BCS ) with bone loss,"taking 24 months of risedronate , calcium , and vitamin D had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in BMD and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .","['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(8, 18)","(46, 107)",-1,ss_p,19802506,Abstract,2,test,gold,6821.0
3213,INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of,"risedronate , calcium",", and vitamin D had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in BMD and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .","['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(22, 25)","(128, 149)",-1,ss_i,19802506,Abstract,2,test,gold,1598.0
3214,"INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of risedronate , calcium , and",vitamin D,"had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in BMD and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .","['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(27, 29)","(156, 165)",-1,ss_i,19802506,Abstract,2,test,gold,4630.0
3215,"INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of risedronate , calcium , and vitamin D had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in",strength/weight training ( ST ) exercises,had greater increases in BMD and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .,"['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(68, 74)","(358, 399)",-1,ss_i,19802506,Abstract,2,test,gold,2731.0
3216,"INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of risedronate , calcium , and vitamin D had increased","bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius","and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in BMD and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .","['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(31, 50)","(180, 269)",-1,ss_o,19802506,Abstract,2,test,gold,5996.0
3217,"INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of risedronate , calcium , and vitamin D had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased",bone turnover ;,( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in BMD and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .,"['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(57, 60)","(302, 317)",-1,ss_o,19802506,Abstract,2,test,gold,1638.0
3218,"INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of risedronate , calcium , and vitamin D had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in",BMD,and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .,"['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(78, 79)","(425, 428)",-1,ss_o,19802506,Abstract,2,test,gold,1620.0
3219,"INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of risedronate , calcium , and vitamin D had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in BMD and greater decreases in",bone turnover ;,and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .,"['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(83, 86)","(454, 469)",-1,ss_o,19802506,Abstract,2,test,gold,1636.0
3220,"INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of risedronate , calcium , and vitamin D had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in BMD and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain )",BMD .,,"['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(104, 106)","(559, 564)",-1,ss_o,19802506,Abstract,2,test,gold,1619.0
3221,INTRODUCTION This study examined whether ( 1 ),postmenopausal breast cancer survivors ( BCS ) with bone loss,"taking 24 months of risedronate , calcium , and vitamin D had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in BMD and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .","['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(8, 18)","(46, 107)",-1,hl_p,19802506,Abstract,2,test,gold,6822.0
3222,INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of,risedronate,", calcium , and vitamin D had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in BMD and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .","['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(22, 23)","(128, 139)",-1,hl_i,19802506,Abstract,2,test,gold,82.0
3223,"INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of risedronate ,",calcium,", and vitamin D had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in BMD and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .","['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(24, 25)","(142, 149)",-1,hl_i,19802506,Abstract,2,test,gold,1600.0
3224,"INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of risedronate , calcium , and",vitamin D,"had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in BMD and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .","['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(27, 29)","(156, 165)",-1,hl_i,19802506,Abstract,2,test,gold,4631.0
3225,"INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of risedronate , calcium , and vitamin D had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in",strength/weight training ( ST ) exercises,had greater increases in BMD and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .,"['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(68, 74)","(358, 399)",-1,hl_i,19802506,Abstract,2,test,gold,2732.0
3226,"INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of risedronate , calcium , and vitamin D had increased",bone mineral density ( BMD ),"at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in BMD and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .","['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(31, 37)","(180, 208)",-1,hl_o,19802506,Abstract,2,test,gold,1627.0
3227,"INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of risedronate , calcium , and vitamin D had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased",bone turnover ;,( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in BMD and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .,"['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(57, 60)","(302, 317)",-1,hl_o,19802506,Abstract,2,test,gold,1635.0
3228,"INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of risedronate , calcium , and vitamin D had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in",BMD,and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .,"['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(78, 79)","(425, 428)",-1,hl_o,19802506,Abstract,2,test,gold,1618.0
3229,"INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of risedronate , calcium , and vitamin D had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in BMD and greater decreases in",bone turnover ;,and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain ) BMD .,"['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(83, 86)","(454, 469)",-1,hl_o,19802506,Abstract,2,test,gold,1634.0
3230,"INTRODUCTION This study examined whether ( 1 ) postmenopausal breast cancer survivors ( BCS ) with bone loss taking 24 months of risedronate , calcium , and vitamin D had increased bone mineral density ( BMD ) at the total hip , femoral neck , L1-L4 spine , total radius and 33 % radius , and decreased bone turnover ; ( 2 ) subjects who also participated in strength/weight training ( ST ) exercises had greater increases in BMD and greater decreases in bone turnover ; and ( 3 ) subjects who also exercised were more likely to preserve ( at least maintain )",BMD .,,"['INTRODUCTION', 'This', 'study', 'examined', 'whether', '(', '1', ')', 'postmenopausal', 'breast', 'cancer', 'survivors', '(', 'BCS', ')', 'with', 'bone', 'loss', 'taking', '24', 'months', 'of', 'risedronate', ',', 'calcium', ',', 'and', 'vitamin', 'D', 'had', 'increased', 'bone', 'mineral', 'density', '(', 'BMD', ')', 'at', 'the', 'total', 'hip', ',', 'femoral', 'neck', ',', 'L1-L4', 'spine', ',', 'total', 'radius', 'and', '33', '%', 'radius', ',', 'and', 'decreased', 'bone', 'turnover', ';', '(', '2', ')', 'subjects', 'who', 'also', 'participated', 'in', 'strength/weight', 'training', '(', 'ST', ')', 'exercises', 'had', 'greater', 'increases', 'in', 'BMD', 'and', 'greater', 'decreases', 'in', 'bone', 'turnover', ';', 'and', '(', '3', ')', 'subjects', 'who', 'also', 'exercised', 'were', 'more', 'likely', 'to', 'preserve', '(', 'at', 'least', 'maintain', ')', 'BMD', '.']","(104, 106)","(559, 564)",-1,hl_o,19802506,Abstract,2,test,gold,1617.0
3231,METHODS,Postmenopausal BCS ( 223 ),were randomly assigned to exercise plus medication or medication only groups .,"['METHODS', 'Postmenopausal', 'BCS', '(', '223', ')', 'were', 'randomly', 'assigned', 'to', 'exercise', 'plus', 'medication', 'or', 'medication', 'only', 'groups', '.']","(1, 6)","(7, 33)",-1,ss_p,19802506,Abstract,3,test,gold,429.0
3232,METHODS Postmenopausal BCS ( 223 ) were randomly assigned to,exercise plus medication,or medication only groups .,"['METHODS', 'Postmenopausal', 'BCS', '(', '223', ')', 'were', 'randomly', 'assigned', 'to', 'exercise', 'plus', 'medication', 'or', 'medication', 'only', 'groups', '.']","(10, 13)","(60, 84)",-1,ss_i,19802506,Abstract,3,test,gold,5063.0
3233,METHODS Postmenopausal BCS ( 223 ) were randomly assigned to exercise plus medication or,medication,only groups .,"['METHODS', 'Postmenopausal', 'BCS', '(', '223', ')', 'were', 'randomly', 'assigned', 'to', 'exercise', 'plus', 'medication', 'or', 'medication', 'only', 'groups', '.']","(14, 15)","(88, 98)",-1,ss_i,19802506,Abstract,3,test,gold,5069.0
3234,METHODS,Postmenopausal BCS,( 223 ) were randomly assigned to exercise plus medication or medication only groups .,"['METHODS', 'Postmenopausal', 'BCS', '(', '223', ')', 'were', 'randomly', 'assigned', 'to', 'exercise', 'plus', 'medication', 'or', 'medication', 'only', 'groups', '.']","(1, 3)","(7, 25)",-1,hl_p,19802506,Abstract,3,test,gold,430.0
3235,METHODS Postmenopausal BCS (,223,) were randomly assigned to exercise plus medication or medication only groups .,"['METHODS', 'Postmenopausal', 'BCS', '(', '223', ')', 'were', 'randomly', 'assigned', 'to', 'exercise', 'plus', 'medication', 'or', 'medication', 'only', 'groups', '.']","(4, 5)","(28, 31)",-1,hl_p,19802506,Abstract,3,test,gold,
3236,METHODS Postmenopausal BCS ( 223 ) were randomly assigned to,exercise,plus medication or medication only groups .,"['METHODS', 'Postmenopausal', 'BCS', '(', '223', ')', 'were', 'randomly', 'assigned', 'to', 'exercise', 'plus', 'medication', 'or', 'medication', 'only', 'groups', '.']","(10, 11)","(60, 68)",-1,hl_i,19802506,Abstract,3,test,gold,2776.0
3237,METHODS Postmenopausal BCS ( 223 ) were randomly assigned to exercise plus,medication,or medication only groups .,"['METHODS', 'Postmenopausal', 'BCS', '(', '223', ')', 'were', 'randomly', 'assigned', 'to', 'exercise', 'plus', 'medication', 'or', 'medication', 'only', 'groups', '.']","(12, 13)","(74, 84)",-1,hl_i,19802506,Abstract,3,test,gold,5068.0
3238,METHODS Postmenopausal BCS ( 223 ) were randomly assigned to exercise plus medication or,medication,only groups .,"['METHODS', 'Postmenopausal', 'BCS', '(', '223', ')', 'were', 'randomly', 'assigned', 'to', 'exercise', 'plus', 'medication', 'or', 'medication', 'only', 'groups', '.']","(14, 15)","(88, 98)",-1,hl_i,19802506,Abstract,3,test,gold,5067.0
3239,"Both groups received 24 months of 1,200 mg of",calcium,"and 400 IU of vitamin D daily and 35 mg of risedronate weekly , and the exercise group additionally had ST exercises twice weekly .","['Both', 'groups', 'received', '24', 'months', 'of', '1,200', 'mg', 'of', 'calcium', 'and', '400', 'IU', 'of', 'vitamin', 'D', 'daily', 'and', '35', 'mg', 'of', 'risedronate', 'weekly', ',', 'and', 'the', 'exercise', 'group', 'additionally', 'had', 'ST', 'exercises', 'twice', 'weekly', '.']","(9, 10)","(45, 52)",-1,ss_i,19802506,Abstract,4,test,gold,1601.0
3240,"Both groups received 24 months of 1,200 mg of calcium and 400 IU of",vitamin D,"daily and 35 mg of risedronate weekly , and the exercise group additionally had ST exercises twice weekly .","['Both', 'groups', 'received', '24', 'months', 'of', '1,200', 'mg', 'of', 'calcium', 'and', '400', 'IU', 'of', 'vitamin', 'D', 'daily', 'and', '35', 'mg', 'of', 'risedronate', 'weekly', ',', 'and', 'the', 'exercise', 'group', 'additionally', 'had', 'ST', 'exercises', 'twice', 'weekly', '.']","(14, 16)","(67, 76)",-1,ss_i,19802506,Abstract,4,test,gold,4629.0
3241,"Both groups received 24 months of 1,200 mg of calcium and 400 IU of vitamin D daily and 35 mg of",risedronate,"weekly , and the exercise group additionally had ST exercises twice weekly .","['Both', 'groups', 'received', '24', 'months', 'of', '1,200', 'mg', 'of', 'calcium', 'and', '400', 'IU', 'of', 'vitamin', 'D', 'daily', 'and', '35', 'mg', 'of', 'risedronate', 'weekly', ',', 'and', 'the', 'exercise', 'group', 'additionally', 'had', 'ST', 'exercises', 'twice', 'weekly', '.']","(21, 22)","(96, 107)",-1,ss_i,19802506,Abstract,4,test,gold,83.0
3242,"Both groups received 24 months of 1,200 mg of calcium and 400 IU of vitamin D daily and 35 mg of risedronate weekly , and the",exercise,group additionally had ST exercises twice weekly .,"['Both', 'groups', 'received', '24', 'months', 'of', '1,200', 'mg', 'of', 'calcium', 'and', '400', 'IU', 'of', 'vitamin', 'D', 'daily', 'and', '35', 'mg', 'of', 'risedronate', 'weekly', ',', 'and', 'the', 'exercise', 'group', 'additionally', 'had', 'ST', 'exercises', 'twice', 'weekly', '.']","(26, 27)","(125, 133)",-1,ss_i,19802506,Abstract,4,test,gold,2777.0
3243,"Both groups received 24 months of 1,200 mg of calcium and 400 IU of vitamin D daily and 35 mg of risedronate weekly , and the exercise group additionally had",ST exercises,twice weekly .,"['Both', 'groups', 'received', '24', 'months', 'of', '1,200', 'mg', 'of', 'calcium', 'and', '400', 'IU', 'of', 'vitamin', 'D', 'daily', 'and', '35', 'mg', 'of', 'risedronate', 'weekly', ',', 'and', 'the', 'exercise', 'group', 'additionally', 'had', 'ST', 'exercises', 'twice', 'weekly', '.']","(30, 32)","(157, 169)",-1,ss_i,19802506,Abstract,4,test,gold,2729.0
3244,"Both groups received 24 months of 1,200 mg of",calcium,"and 400 IU of vitamin D daily and 35 mg of risedronate weekly , and the exercise group additionally had ST exercises twice weekly .","['Both', 'groups', 'received', '24', 'months', 'of', '1,200', 'mg', 'of', 'calcium', 'and', '400', 'IU', 'of', 'vitamin', 'D', 'daily', 'and', '35', 'mg', 'of', 'risedronate', 'weekly', ',', 'and', 'the', 'exercise', 'group', 'additionally', 'had', 'ST', 'exercises', 'twice', 'weekly', '.']","(9, 10)","(45, 52)",-1,hl_i,19802506,Abstract,4,test,gold,1599.0
3245,"Both groups received 24 months of 1,200 mg of calcium and 400 IU of",vitamin D,"daily and 35 mg of risedronate weekly , and the exercise group additionally had ST exercises twice weekly .","['Both', 'groups', 'received', '24', 'months', 'of', '1,200', 'mg', 'of', 'calcium', 'and', '400', 'IU', 'of', 'vitamin', 'D', 'daily', 'and', '35', 'mg', 'of', 'risedronate', 'weekly', ',', 'and', 'the', 'exercise', 'group', 'additionally', 'had', 'ST', 'exercises', 'twice', 'weekly', '.']","(14, 16)","(67, 76)",-1,hl_i,19802506,Abstract,4,test,gold,4628.0
3246,"Both groups received 24 months of 1,200 mg of calcium and 400 IU of vitamin D daily and 35 mg of",risedronate,"weekly , and the exercise group additionally had ST exercises twice weekly .","['Both', 'groups', 'received', '24', 'months', 'of', '1,200', 'mg', 'of', 'calcium', 'and', '400', 'IU', 'of', 'vitamin', 'D', 'daily', 'and', '35', 'mg', 'of', 'risedronate', 'weekly', ',', 'and', 'the', 'exercise', 'group', 'additionally', 'had', 'ST', 'exercises', 'twice', 'weekly', '.']","(21, 22)","(96, 107)",-1,hl_i,19802506,Abstract,4,test,gold,81.0
3247,"Both groups received 24 months of 1,200 mg of calcium and 400 IU of vitamin D daily and 35 mg of risedronate weekly , and the",exercise,group additionally had ST exercises twice weekly .,"['Both', 'groups', 'received', '24', 'months', 'of', '1,200', 'mg', 'of', 'calcium', 'and', '400', 'IU', 'of', 'vitamin', 'D', 'daily', 'and', '35', 'mg', 'of', 'risedronate', 'weekly', ',', 'and', 'the', 'exercise', 'group', 'additionally', 'had', 'ST', 'exercises', 'twice', 'weekly', '.']","(26, 27)","(125, 133)",-1,hl_i,19802506,Abstract,4,test,gold,2775.0
3248,"Both groups received 24 months of 1,200 mg of calcium and 400 IU of vitamin D daily and 35 mg of risedronate weekly , and the exercise group additionally had",ST exercises,twice weekly .,"['Both', 'groups', 'received', '24', 'months', 'of', '1,200', 'mg', 'of', 'calcium', 'and', '400', 'IU', 'of', 'vitamin', 'D', 'daily', 'and', '35', 'mg', 'of', 'risedronate', 'weekly', ',', 'and', 'the', 'exercise', 'group', 'additionally', 'had', 'ST', 'exercises', 'twice', 'weekly', '.']","(30, 32)","(157, 169)",-1,hl_i,19802506,Abstract,4,test,gold,2730.0
3249,"RESULTS After 24 months , women who took",medications,without exercising had significant improvements in BMD at the total hip ( +1.81 % ) and spine ( +2.85 % ) and significant decreases in Alkphase B ( -8.7 % ) and serum NTx ( -16.7 % ) .,"['RESULTS', 'After', '24', 'months', ',', 'women', 'who', 'took', 'medications', 'without', 'exercising', 'had', 'significant', 'improvements', 'in', 'BMD', 'at', 'the', 'total', 'hip', '(', '+1.81', '%', ')', 'and', 'spine', '(', '+2.85', '%', ')', 'and', 'significant', 'decreases', 'in', 'Alkphase', 'B', '(', '-8.7', '%', ')', 'and', 'serum', 'NTx', '(', '-16.7', '%', ')', '.']","(8, 9)","(40, 51)",-1,ss_i,19802506,Abstract,5,test,gold,5064.0
3250,"RESULTS After 24 months , women who took medications without",exercising,had significant improvements in BMD at the total hip ( +1.81 % ) and spine ( +2.85 % ) and significant decreases in Alkphase B ( -8.7 % ) and serum NTx ( -16.7 % ) .,"['RESULTS', 'After', '24', 'months', ',', 'women', 'who', 'took', 'medications', 'without', 'exercising', 'had', 'significant', 'improvements', 'in', 'BMD', 'at', 'the', 'total', 'hip', '(', '+1.81', '%', ')', 'and', 'spine', '(', '+2.85', '%', ')', 'and', 'significant', 'decreases', 'in', 'Alkphase', 'B', '(', '-8.7', '%', ')', 'and', 'serum', 'NTx', '(', '-16.7', '%', ')', '.']","(10, 11)","(60, 70)",-1,ss_i,19802506,Abstract,5,test,gold,2778.0
3251,"RESULTS After 24 months , women who took medications without exercising had significant improvements in",BMD,at the total hip ( +1.81 % ) and spine ( +2.85 % ) and significant decreases in Alkphase B ( -8.7 % ) and serum NTx ( -16.7 % ) .,"['RESULTS', 'After', '24', 'months', ',', 'women', 'who', 'took', 'medications', 'without', 'exercising', 'had', 'significant', 'improvements', 'in', 'BMD', 'at', 'the', 'total', 'hip', '(', '+1.81', '%', ')', 'and', 'spine', '(', '+2.85', '%', ')', 'and', 'significant', 'decreases', 'in', 'Alkphase', 'B', '(', '-8.7', '%', ')', 'and', 'serum', 'NTx', '(', '-16.7', '%', ')', '.']","(15, 16)","(103, 106)",-1,ss_o,19802506,Abstract,5,test,gold,1616.0
3252,"RESULTS After 24 months , women who took medications without exercising had significant improvements in BMD at the total hip ( +1.81 % ) and spine ( +2.85 % ) and significant decreases in",Alkphase B,( -8.7 % ) and serum NTx ( -16.7 % ) .,"['RESULTS', 'After', '24', 'months', ',', 'women', 'who', 'took', 'medications', 'without', 'exercising', 'had', 'significant', 'improvements', 'in', 'BMD', 'at', 'the', 'total', 'hip', '(', '+1.81', '%', ')', 'and', 'spine', '(', '+2.85', '%', ')', 'and', 'significant', 'decreases', 'in', 'Alkphase', 'B', '(', '-8.7', '%', ')', 'and', 'serum', 'NTx', '(', '-16.7', '%', ')', '.']","(34, 36)","(187, 197)",-1,ss_o,19802506,Abstract,5,test,gold,832.0
3253,"RESULTS After 24 months , women who took medications without exercising had significant improvements in BMD at the total hip ( +1.81 % ) and spine ( +2.85 % ) and significant decreases in Alkphase B ( -8.7 % ) and",serum NTx,( -16.7 % ) .,"['RESULTS', 'After', '24', 'months', ',', 'women', 'who', 'took', 'medications', 'without', 'exercising', 'had', 'significant', 'improvements', 'in', 'BMD', 'at', 'the', 'total', 'hip', '(', '+1.81', '%', ')', 'and', 'spine', '(', '+2.85', '%', ')', 'and', 'significant', 'decreases', 'in', 'Alkphase', 'B', '(', '-8.7', '%', ')', 'and', 'serum', 'NTx', '(', '-16.7', '%', ')', '.']","(41, 43)","(213, 222)",-1,ss_o,19802506,Abstract,5,test,gold,4489.0
3254,"RESULTS After 24 months , women who took",medications,without exercising had significant improvements in BMD at the total hip ( +1.81 % ) and spine ( +2.85 % ) and significant decreases in Alkphase B ( -8.7 % ) and serum NTx ( -16.7 % ) .,"['RESULTS', 'After', '24', 'months', ',', 'women', 'who', 'took', 'medications', 'without', 'exercising', 'had', 'significant', 'improvements', 'in', 'BMD', 'at', 'the', 'total', 'hip', '(', '+1.81', '%', ')', 'and', 'spine', '(', '+2.85', '%', ')', 'and', 'significant', 'decreases', 'in', 'Alkphase', 'B', '(', '-8.7', '%', ')', 'and', 'serum', 'NTx', '(', '-16.7', '%', ')', '.']","(8, 9)","(40, 51)",-1,hl_i,19802506,Abstract,5,test,gold,5065.0
3255,"RESULTS After 24 months , women who took medications without",exercising,had significant improvements in BMD at the total hip ( +1.81 % ) and spine ( +2.85 % ) and significant decreases in Alkphase B ( -8.7 % ) and serum NTx ( -16.7 % ) .,"['RESULTS', 'After', '24', 'months', ',', 'women', 'who', 'took', 'medications', 'without', 'exercising', 'had', 'significant', 'improvements', 'in', 'BMD', 'at', 'the', 'total', 'hip', '(', '+1.81', '%', ')', 'and', 'spine', '(', '+2.85', '%', ')', 'and', 'significant', 'decreases', 'in', 'Alkphase', 'B', '(', '-8.7', '%', ')', 'and', 'serum', 'NTx', '(', '-16.7', '%', ')', '.']","(10, 11)","(60, 70)",-1,hl_i,19802506,Abstract,5,test,gold,2779.0
3256,"RESULTS After 24 months , women who took medications without exercising had significant improvements in",BMD,at the total hip ( +1.81 % ) and spine ( +2.85 % ) and significant decreases in Alkphase B ( -8.7 % ) and serum NTx ( -16.7 % ) .,"['RESULTS', 'After', '24', 'months', ',', 'women', 'who', 'took', 'medications', 'without', 'exercising', 'had', 'significant', 'improvements', 'in', 'BMD', 'at', 'the', 'total', 'hip', '(', '+1.81', '%', ')', 'and', 'spine', '(', '+2.85', '%', ')', 'and', 'significant', 'decreases', 'in', 'Alkphase', 'B', '(', '-8.7', '%', ')', 'and', 'serum', 'NTx', '(', '-16.7', '%', ')', '.']","(15, 16)","(103, 106)",-1,hl_o,19802506,Abstract,5,test,gold,1615.0
3257,"RESULTS After 24 months , women who took medications without exercising had significant improvements in BMD at the total hip ( +1.81 % ) and spine ( +2.85 % ) and significant decreases in",Alkphase B,( -8.7 % ) and serum NTx ( -16.7 % ) .,"['RESULTS', 'After', '24', 'months', ',', 'women', 'who', 'took', 'medications', 'without', 'exercising', 'had', 'significant', 'improvements', 'in', 'BMD', 'at', 'the', 'total', 'hip', '(', '+1.81', '%', ')', 'and', 'spine', '(', '+2.85', '%', ')', 'and', 'significant', 'decreases', 'in', 'Alkphase', 'B', '(', '-8.7', '%', ')', 'and', 'serum', 'NTx', '(', '-16.7', '%', ')', '.']","(34, 36)","(187, 197)",-1,hl_o,19802506,Abstract,5,test,gold,833.0
3258,"RESULTS After 24 months , women who took medications without exercising had significant improvements in BMD at the total hip ( +1.81 % ) and spine ( +2.85 % ) and significant decreases in Alkphase B ( -8.7 % ) and",serum NTx,( -16.7 % ) .,"['RESULTS', 'After', '24', 'months', ',', 'women', 'who', 'took', 'medications', 'without', 'exercising', 'had', 'significant', 'improvements', 'in', 'BMD', 'at', 'the', 'total', 'hip', '(', '+1.81', '%', ')', 'and', 'spine', '(', '+2.85', '%', ')', 'and', 'significant', 'decreases', 'in', 'Alkphase', 'B', '(', '-8.7', '%', ')', 'and', 'serum', 'NTx', '(', '-16.7', '%', ')', '.']","(41, 43)","(213, 222)",-1,hl_o,19802506,Abstract,5,test,gold,4490.0
3259,Women who also,exercised,"had additional increases in BMD at the femoral neck ( +0.29 % ) , total hip ( +0.34 % ) , spine ( +0.23 % ) , total radius ( +0.30 % ) , and additional decreases in Alkphase B ( -2.4 % ) and Serum NTx ( -6.5 % ) .","['Women', 'who', 'also', 'exercised', 'had', 'additional', 'increases', 'in', 'BMD', 'at', 'the', 'femoral', 'neck', '(', '+0.29', '%', ')', ',', 'total', 'hip', '(', '+0.34', '%', ')', ',', 'spine', '(', '+0.23', '%', ')', ',', 'total', 'radius', '(', '+0.30', '%', ')', ',', 'and', 'additional', 'decreases', 'in', 'Alkphase', 'B', '(', '-2.4', '%', ')', 'and', 'Serum', 'NTx', '(', '-6.5', '%', ')', '.']","(3, 4)","(14, 23)",-1,ss_i,19802506,Abstract,6,test,gold,2780.0
3260,Women who also exercised had additional increases in,BMD,"at the femoral neck ( +0.29 % ) , total hip ( +0.34 % ) , spine ( +0.23 % ) , total radius ( +0.30 % ) , and additional decreases in Alkphase B ( -2.4 % ) and Serum NTx ( -6.5 % ) .","['Women', 'who', 'also', 'exercised', 'had', 'additional', 'increases', 'in', 'BMD', 'at', 'the', 'femoral', 'neck', '(', '+0.29', '%', ')', ',', 'total', 'hip', '(', '+0.34', '%', ')', ',', 'spine', '(', '+0.23', '%', ')', ',', 'total', 'radius', '(', '+0.30', '%', ')', ',', 'and', 'additional', 'decreases', 'in', 'Alkphase', 'B', '(', '-2.4', '%', ')', 'and', 'Serum', 'NTx', '(', '-6.5', '%', ')', '.']","(8, 9)","(52, 55)",-1,ss_o,19802506,Abstract,6,test,gold,1614.0
3261,"Women who also exercised had additional increases in BMD at the femoral neck ( +0.29 % ) , total hip ( +0.34 % ) , spine ( +0.23 % ) , total radius ( +0.30 % ) , and additional decreases in",Alkphase B,( -2.4 % ) and Serum NTx ( -6.5 % ) .,"['Women', 'who', 'also', 'exercised', 'had', 'additional', 'increases', 'in', 'BMD', 'at', 'the', 'femoral', 'neck', '(', '+0.29', '%', ')', ',', 'total', 'hip', '(', '+0.34', '%', ')', ',', 'spine', '(', '+0.23', '%', ')', ',', 'total', 'radius', '(', '+0.30', '%', ')', ',', 'and', 'additional', 'decreases', 'in', 'Alkphase', 'B', '(', '-2.4', '%', ')', 'and', 'Serum', 'NTx', '(', '-6.5', '%', ')', '.']","(42, 44)","(189, 199)",-1,ss_o,19802506,Abstract,6,test,gold,831.0
3262,"Women who also exercised had additional increases in BMD at the femoral neck ( +0.29 % ) , total hip ( +0.34 % ) , spine ( +0.23 % ) , total radius ( +0.30 % ) , and additional decreases in Alkphase B ( -2.4 % ) and",Serum NTx,( -6.5 % ) .,"['Women', 'who', 'also', 'exercised', 'had', 'additional', 'increases', 'in', 'BMD', 'at', 'the', 'femoral', 'neck', '(', '+0.29', '%', ')', ',', 'total', 'hip', '(', '+0.34', '%', ')', ',', 'spine', '(', '+0.23', '%', ')', ',', 'total', 'radius', '(', '+0.30', '%', ')', ',', 'and', 'additional', 'decreases', 'in', 'Alkphase', 'B', '(', '-2.4', '%', ')', 'and', 'Serum', 'NTx', '(', '-6.5', '%', ')', '.']","(49, 51)","(215, 224)",-1,ss_o,19802506,Abstract,6,test,gold,4494.0
3263,Women who also,exercised,"had additional increases in BMD at the femoral neck ( +0.29 % ) , total hip ( +0.34 % ) , spine ( +0.23 % ) , total radius ( +0.30 % ) , and additional decreases in Alkphase B ( -2.4 % ) and Serum NTx ( -6.5 % ) .","['Women', 'who', 'also', 'exercised', 'had', 'additional', 'increases', 'in', 'BMD', 'at', 'the', 'femoral', 'neck', '(', '+0.29', '%', ')', ',', 'total', 'hip', '(', '+0.34', '%', ')', ',', 'spine', '(', '+0.23', '%', ')', ',', 'total', 'radius', '(', '+0.30', '%', ')', ',', 'and', 'additional', 'decreases', 'in', 'Alkphase', 'B', '(', '-2.4', '%', ')', 'and', 'Serum', 'NTx', '(', '-6.5', '%', ')', '.']","(3, 4)","(14, 23)",-1,hl_i,19802506,Abstract,6,test,gold,2781.0
3264,Women who also exercised had additional increases in,BMD,"at the femoral neck ( +0.29 % ) , total hip ( +0.34 % ) , spine ( +0.23 % ) , total radius ( +0.30 % ) , and additional decreases in Alkphase B ( -2.4 % ) and Serum NTx ( -6.5 % ) .","['Women', 'who', 'also', 'exercised', 'had', 'additional', 'increases', 'in', 'BMD', 'at', 'the', 'femoral', 'neck', '(', '+0.29', '%', ')', ',', 'total', 'hip', '(', '+0.34', '%', ')', ',', 'spine', '(', '+0.23', '%', ')', ',', 'total', 'radius', '(', '+0.30', '%', ')', ',', 'and', 'additional', 'decreases', 'in', 'Alkphase', 'B', '(', '-2.4', '%', ')', 'and', 'Serum', 'NTx', '(', '-6.5', '%', ')', '.']","(8, 9)","(52, 55)",-1,hl_o,19802506,Abstract,6,test,gold,1613.0
3265,"Women who also exercised had additional increases in BMD at the femoral neck ( +0.29 % ) , total hip ( +0.34 % ) , spine ( +0.23 % ) , total radius ( +0.30 % ) , and additional decreases in",Alkphase B,( -2.4 % ) and Serum NTx ( -6.5 % ) .,"['Women', 'who', 'also', 'exercised', 'had', 'additional', 'increases', 'in', 'BMD', 'at', 'the', 'femoral', 'neck', '(', '+0.29', '%', ')', ',', 'total', 'hip', '(', '+0.34', '%', ')', ',', 'spine', '(', '+0.23', '%', ')', ',', 'total', 'radius', '(', '+0.30', '%', ')', ',', 'and', 'additional', 'decreases', 'in', 'Alkphase', 'B', '(', '-2.4', '%', ')', 'and', 'Serum', 'NTx', '(', '-6.5', '%', ')', '.']","(42, 44)","(189, 199)",-1,hl_o,19802506,Abstract,6,test,gold,830.0
3266,"Women who also exercised had additional increases in BMD at the femoral neck ( +0.29 % ) , total hip ( +0.34 % ) , spine ( +0.23 % ) , total radius ( +0.30 % ) , and additional decreases in Alkphase B ( -2.4 % ) and",Serum NTx,( -6.5 % ) .,"['Women', 'who', 'also', 'exercised', 'had', 'additional', 'increases', 'in', 'BMD', 'at', 'the', 'femoral', 'neck', '(', '+0.29', '%', ')', ',', 'total', 'hip', '(', '+0.34', '%', ')', ',', 'spine', '(', '+0.23', '%', ')', ',', 'total', 'radius', '(', '+0.30', '%', ')', ',', 'and', 'additional', 'decreases', 'in', 'Alkphase', 'B', '(', '-2.4', '%', ')', 'and', 'Serum', 'NTx', '(', '-6.5', '%', ')', '.']","(49, 51)","(215, 224)",-1,hl_o,19802506,Abstract,6,test,gold,4495.0
3267,Additional changes in BMD and bone turnover with,exercise,were not significant .,"['Additional', 'changes', 'in', 'BMD', 'and', 'bone', 'turnover', 'with', 'exercise', 'were', 'not', 'significant', '.']","(8, 9)","(48, 56)",-1,ss_i,19802506,Abstract,7,test,gold,2774.0
3268,Additional,changes in BMD and bone turnover,with exercise were not significant .,"['Additional', 'changes', 'in', 'BMD', 'and', 'bone', 'turnover', 'with', 'exercise', 'were', 'not', 'significant', '.']","(1, 7)","(10, 42)",-1,ss_o,19802506,Abstract,7,test,gold,1630.0
3269,Additional changes in,BMD,and bone turnover with exercise were not significant .,"['Additional', 'changes', 'in', 'BMD', 'and', 'bone', 'turnover', 'with', 'exercise', 'were', 'not', 'significant', '.']","(3, 4)","(21, 24)",-1,hl_o,19802506,Abstract,7,test,gold,1612.0
3270,Additional changes in BMD and,bone turnover,with exercise were not significant .,"['Additional', 'changes', 'in', 'BMD', 'and', 'bone', 'turnover', 'with', 'exercise', 'were', 'not', 'significant', '.']","(5, 7)","(29, 42)",-1,hl_o,19802506,Abstract,7,test,gold,1633.0
3271,Subjects who were > or =50 % adherent to,exercise,"were less likely to lose BMD at the total hip ( chi-square [ 1 ] = 4.66 , p = 0.03 ) and femoral neck ( chi-square [ 1 ] = 4.63 , p = 0.03 ) .","['Subjects', 'who', 'were', '>', 'or', '=50', '%', 'adherent', 'to', 'exercise', 'were', 'less', 'likely', 'to', 'lose', 'BMD', 'at', 'the', 'total', 'hip', '(', 'chi-square', '[', '1', ']', '=', '4.66', ',', 'p', '=', '0.03', ')', 'and', 'femoral', 'neck', '(', 'chi-square', '[', '1', ']', '=', '4.63', ',', 'p', '=', '0.03', ')', '.']","(9, 10)","(40, 48)",-1,ss_i,19802506,Abstract,8,test,gold,2773.0
3272,Subjects who were > or =50 % adherent to exercise were less likely to lose,BMD,"at the total hip ( chi-square [ 1 ] = 4.66 , p = 0.03 ) and femoral neck ( chi-square [ 1 ] = 4.63 , p = 0.03 ) .","['Subjects', 'who', 'were', '>', 'or', '=50', '%', 'adherent', 'to', 'exercise', 'were', 'less', 'likely', 'to', 'lose', 'BMD', 'at', 'the', 'total', 'hip', '(', 'chi-square', '[', '1', ']', '=', '4.66', ',', 'p', '=', '0.03', ')', 'and', 'femoral', 'neck', '(', 'chi-square', '[', '1', ']', '=', '4.63', ',', 'p', '=', '0.03', ')', '.']","(15, 16)","(74, 77)",-1,ss_o,19802506,Abstract,8,test,gold,1611.0
3273,Subjects who were > or =50 % adherent to,exercise,"were less likely to lose BMD at the total hip ( chi-square [ 1 ] = 4.66 , p = 0.03 ) and femoral neck ( chi-square [ 1 ] = 4.63 , p = 0.03 ) .","['Subjects', 'who', 'were', '>', 'or', '=50', '%', 'adherent', 'to', 'exercise', 'were', 'less', 'likely', 'to', 'lose', 'BMD', 'at', 'the', 'total', 'hip', '(', 'chi-square', '[', '1', ']', '=', '4.66', ',', 'p', '=', '0.03', ')', 'and', 'femoral', 'neck', '(', 'chi-square', '[', '1', ']', '=', '4.63', ',', 'p', '=', '0.03', ')', '.']","(9, 10)","(40, 48)",-1,hl_i,19802506,Abstract,8,test,gold,2772.0
3274,Subjects who were > or =50 % adherent to exercise were less likely to lose,BMD,"at the total hip ( chi-square [ 1 ] = 4.66 , p = 0.03 ) and femoral neck ( chi-square [ 1 ] = 4.63 , p = 0.03 ) .","['Subjects', 'who', 'were', '>', 'or', '=50', '%', 'adherent', 'to', 'exercise', 'were', 'less', 'likely', 'to', 'lose', 'BMD', 'at', 'the', 'total', 'hip', '(', 'chi-square', '[', '1', ']', '=', '4.66', ',', 'p', '=', '0.03', ')', 'and', 'femoral', 'neck', '(', 'chi-square', '[', '1', ']', '=', '4.63', ',', 'p', '=', '0.03', ')', '.']","(15, 16)","(74, 77)",-1,hl_o,19802506,Abstract,8,test,gold,1610.0
3275,CONCLUSION Strength/weight training exercises may prevent loss of BMD in,postmenopausal BCS at risk for bone loss .,,"['CONCLUSION', 'Strength/weight', 'training', 'exercises', 'may', 'prevent', 'loss', 'of', 'BMD', 'in', 'postmenopausal', 'BCS', 'at', 'risk', 'for', 'bone', 'loss', '.']","(10, 18)","(72, 114)",-1,ss_p,19802506,Abstract,9,test,gold,6816.0
3276,CONCLUSION,Strength/weight training exercises,may prevent loss of BMD in postmenopausal BCS at risk for bone loss .,"['CONCLUSION', 'Strength/weight', 'training', 'exercises', 'may', 'prevent', 'loss', 'of', 'BMD', 'in', 'postmenopausal', 'BCS', 'at', 'risk', 'for', 'bone', 'loss', '.']","(1, 4)","(10, 44)",-1,ss_i,19802506,Abstract,9,test,gold,2741.0
3277,CONCLUSION Strength/weight training exercises may prevent loss of,BMD,in postmenopausal BCS at risk for bone loss .,"['CONCLUSION', 'Strength/weight', 'training', 'exercises', 'may', 'prevent', 'loss', 'of', 'BMD', 'in', 'postmenopausal', 'BCS', 'at', 'risk', 'for', 'bone', 'loss', '.']","(8, 9)","(65, 68)",-1,ss_o,19802506,Abstract,9,test,gold,1609.0
3278,CONCLUSION,Strength/weight training exercises,may prevent loss of BMD in postmenopausal BCS at risk for bone loss .,"['CONCLUSION', 'Strength/weight', 'training', 'exercises', 'may', 'prevent', 'loss', 'of', 'BMD', 'in', 'postmenopausal', 'BCS', 'at', 'risk', 'for', 'bone', 'loss', '.']","(1, 4)","(10, 44)",-1,hl_i,19802506,Abstract,9,test,gold,2742.0
3279,CONCLUSION Strength/weight training exercises may prevent loss of,BMD,in postmenopausal BCS at risk for bone loss .,"['CONCLUSION', 'Strength/weight', 'training', 'exercises', 'may', 'prevent', 'loss', 'of', 'BMD', 'in', 'postmenopausal', 'BCS', 'at', 'risk', 'for', 'bone', 'loss', '.']","(8, 9)","(65, 68)",-1,hl_o,19802506,Abstract,9,test,gold,1608.0
3280,Randomized phase II study of two different schedules of gemcitabine and oral S-1 in,chemo-naïve patients with advanced non-small cell lung cancer,.,"['Randomized', 'phase', 'II', 'study', 'of', 'two', 'different', 'schedules', 'of', 'gemcitabine', 'and', 'oral', 'S-1', 'in', 'chemo-naïve', 'patients', 'with', 'advanced', 'non-small', 'cell', 'lung', 'cancer', '.']","(14, 22)","(83, 144)",-1,ss_p,20147856,Title,0,test,gold,6851.0
3281,Randomized phase II study of two different schedules of,gemcitabine,and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer .,"['Randomized', 'phase', 'II', 'study', 'of', 'two', 'different', 'schedules', 'of', 'gemcitabine', 'and', 'oral', 'S-1', 'in', 'chemo-naïve', 'patients', 'with', 'advanced', 'non-small', 'cell', 'lung', 'cancer', '.']","(9, 10)","(55, 66)",-1,ss_i,20147856,Title,0,test,gold,5170.0
3282,Randomized phase II study of two different schedules of gemcitabine and oral,S-1,in chemo-naïve patients with advanced non-small cell lung cancer .,"['Randomized', 'phase', 'II', 'study', 'of', 'two', 'different', 'schedules', 'of', 'gemcitabine', 'and', 'oral', 'S-1', 'in', 'chemo-naïve', 'patients', 'with', 'advanced', 'non-small', 'cell', 'lung', 'cancer', '.']","(12, 13)","(76, 79)",-1,ss_i,20147856,Title,0,test,gold,
3283,Randomized phase II study of two different schedules of gemcitabine and oral S-1 in,chemo-naïve,patients with advanced non-small cell lung cancer .,"['Randomized', 'phase', 'II', 'study', 'of', 'two', 'different', 'schedules', 'of', 'gemcitabine', 'and', 'oral', 'S-1', 'in', 'chemo-naïve', 'patients', 'with', 'advanced', 'non-small', 'cell', 'lung', 'cancer', '.']","(14, 15)","(83, 94)",-1,hl_p,20147856,Title,0,test,gold,
3284,Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with,advanced non-small cell lung cancer,.,"['Randomized', 'phase', 'II', 'study', 'of', 'two', 'different', 'schedules', 'of', 'gemcitabine', 'and', 'oral', 'S-1', 'in', 'chemo-naïve', 'patients', 'with', 'advanced', 'non-small', 'cell', 'lung', 'cancer', '.']","(17, 22)","(109, 144)",-1,hl_p,20147856,Title,0,test,gold,6849.0
3285,Randomized phase II study of two different schedules of,gemcitabine,and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer .,"['Randomized', 'phase', 'II', 'study', 'of', 'two', 'different', 'schedules', 'of', 'gemcitabine', 'and', 'oral', 'S-1', 'in', 'chemo-naïve', 'patients', 'with', 'advanced', 'non-small', 'cell', 'lung', 'cancer', '.']","(9, 10)","(55, 66)",-1,hl_i,20147856,Title,0,test,gold,5171.0
3286,Randomized phase II study of two different schedules of gemcitabine and oral,S-1,in chemo-naïve patients with advanced non-small cell lung cancer .,"['Randomized', 'phase', 'II', 'study', 'of', 'two', 'different', 'schedules', 'of', 'gemcitabine', 'and', 'oral', 'S-1', 'in', 'chemo-naïve', 'patients', 'with', 'advanced', 'non-small', 'cell', 'lung', 'cancer', '.']","(12, 13)","(76, 79)",-1,hl_i,20147856,Title,0,test,gold,
3287,INTRODUCTION This study was conducted to evaluate the efficacy and safety and to compare dosing schedules of gemcitabine combined with S-1,in chemo-naïve non-small cell lung cancer patients,.,"['INTRODUCTION', 'This', 'study', 'was', 'conducted', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'and', 'to', 'compare', 'dosing', 'schedules', 'of', 'gemcitabine', 'combined', 'with', 'S-1', 'in', 'chemo-naïve', 'non-small', 'cell', 'lung', 'cancer', 'patients', '.']","(21, 28)","(138, 188)",-1,ss_p,20147856,Abstract,0,test,gold,6852.0
3288,INTRODUCTION This study was conducted to evaluate the efficacy and safety and to compare dosing schedules,of gemcitabine,combined with S-1 in chemo-naïve non-small cell lung cancer patients .,"['INTRODUCTION', 'This', 'study', 'was', 'conducted', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'and', 'to', 'compare', 'dosing', 'schedules', 'of', 'gemcitabine', 'combined', 'with', 'S-1', 'in', 'chemo-naïve', 'non-small', 'cell', 'lung', 'cancer', 'patients', '.']","(16, 18)","(105, 119)",-1,ss_i,20147856,Abstract,0,test,gold,5169.0
3289,INTRODUCTION This study was conducted to evaluate the efficacy and safety and to compare dosing schedules of gemcitabine combined,with S-1,in chemo-naïve non-small cell lung cancer patients .,"['INTRODUCTION', 'This', 'study', 'was', 'conducted', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'and', 'to', 'compare', 'dosing', 'schedules', 'of', 'gemcitabine', 'combined', 'with', 'S-1', 'in', 'chemo-naïve', 'non-small', 'cell', 'lung', 'cancer', 'patients', '.']","(19, 21)","(129, 137)",-1,ss_i,20147856,Abstract,0,test,gold,1180.0
3290,INTRODUCTION This study was conducted to evaluate,the efficacy and safety,and to compare dosing schedules of gemcitabine combined with S-1 in chemo-naïve non-small cell lung cancer patients .,"['INTRODUCTION', 'This', 'study', 'was', 'conducted', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'and', 'to', 'compare', 'dosing', 'schedules', 'of', 'gemcitabine', 'combined', 'with', 'S-1', 'in', 'chemo-naïve', 'non-small', 'cell', 'lung', 'cancer', 'patients', '.']","(7, 11)","(49, 72)",-1,ss_o,20147856,Abstract,0,test,gold,4777.0
3291,INTRODUCTION This study was conducted to evaluate the efficacy and safety and,to compare dosing schedules,of gemcitabine combined with S-1 in chemo-naïve non-small cell lung cancer patients .,"['INTRODUCTION', 'This', 'study', 'was', 'conducted', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'and', 'to', 'compare', 'dosing', 'schedules', 'of', 'gemcitabine', 'combined', 'with', 'S-1', 'in', 'chemo-naïve', 'non-small', 'cell', 'lung', 'cancer', 'patients', '.']","(12, 16)","(77, 104)",-1,ss_o,20147856,Abstract,0,test,gold,5047.0
3292,INTRODUCTION This study was conducted to evaluate the efficacy and safety and to compare dosing schedules of gemcitabine combined with S-1 in,chemo-naïve non-small cell lung cancer patients,.,"['INTRODUCTION', 'This', 'study', 'was', 'conducted', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'and', 'to', 'compare', 'dosing', 'schedules', 'of', 'gemcitabine', 'combined', 'with', 'S-1', 'in', 'chemo-naïve', 'non-small', 'cell', 'lung', 'cancer', 'patients', '.']","(22, 28)","(141, 188)",-1,hl_p,20147856,Abstract,0,test,gold,6853.0
3293,INTRODUCTION This study was conducted to evaluate the efficacy and safety and to compare dosing schedules of,gemcitabine,combined with S-1 in chemo-naïve non-small cell lung cancer patients .,"['INTRODUCTION', 'This', 'study', 'was', 'conducted', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'and', 'to', 'compare', 'dosing', 'schedules', 'of', 'gemcitabine', 'combined', 'with', 'S-1', 'in', 'chemo-naïve', 'non-small', 'cell', 'lung', 'cancer', 'patients', '.']","(17, 18)","(108, 119)",-1,hl_i,20147856,Abstract,0,test,gold,5168.0
3294,INTRODUCTION This study was conducted to evaluate the efficacy and safety and to compare dosing schedules of gemcitabine combined with,S-1,in chemo-naïve non-small cell lung cancer patients .,"['INTRODUCTION', 'This', 'study', 'was', 'conducted', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'and', 'to', 'compare', 'dosing', 'schedules', 'of', 'gemcitabine', 'combined', 'with', 'S-1', 'in', 'chemo-naïve', 'non-small', 'cell', 'lung', 'cancer', 'patients', '.']","(20, 21)","(134, 137)",-1,hl_i,20147856,Abstract,0,test,gold,
3295,INTRODUCTION This study was conducted to evaluate the,efficacy,and safety and to compare dosing schedules of gemcitabine combined with S-1 in chemo-naïve non-small cell lung cancer patients .,"['INTRODUCTION', 'This', 'study', 'was', 'conducted', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'and', 'to', 'compare', 'dosing', 'schedules', 'of', 'gemcitabine', 'combined', 'with', 'S-1', 'in', 'chemo-naïve', 'non-small', 'cell', 'lung', 'cancer', 'patients', '.']","(8, 9)","(53, 61)",-1,hl_o,20147856,Abstract,0,test,gold,4814.0
3296,INTRODUCTION This study was conducted to evaluate the efficacy and,safety,and to compare dosing schedules of gemcitabine combined with S-1 in chemo-naïve non-small cell lung cancer patients .,"['INTRODUCTION', 'This', 'study', 'was', 'conducted', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'and', 'to', 'compare', 'dosing', 'schedules', 'of', 'gemcitabine', 'combined', 'with', 'S-1', 'in', 'chemo-naïve', 'non-small', 'cell', 'lung', 'cancer', 'patients', '.']","(10, 11)","(66, 72)",-1,hl_o,20147856,Abstract,0,test,gold,470.0
3297,,METHODS Patients with chemo-naïve stage IIIB/IV non-small cell lung cancer,were randomized into two treatment arms .,"['METHODS', 'Patients', 'with', 'chemo-naïve', 'stage', 'IIIB/IV', 'non-small', 'cell', 'lung', 'cancer', 'were', 'randomized', 'into', 'two', 'treatment', 'arms', '.']","(0, 10)","(0, 74)",-1,ss_p,20147856,Abstract,1,test,gold,6848.0
3298,METHODS Patients with,chemo-naïve stage IIIB/IV non-small cell lung cancer,were randomized into two treatment arms .,"['METHODS', 'Patients', 'with', 'chemo-naïve', 'stage', 'IIIB/IV', 'non-small', 'cell', 'lung', 'cancer', 'were', 'randomized', 'into', 'two', 'treatment', 'arms', '.']","(3, 10)","(21, 73)",-1,hl_p,20147856,Abstract,1,test,gold,6850.0
3299,Patients were given,oral S-1,"( 60 mg/m/d , twice a day ) from days 1 to 14 with gemcitabine ( 1000 mg/m/d ) on days 1 and 8 ( arm A ) or on days 8 and 15 ( arm B ) .","['Patients', 'were', 'given', 'oral', 'S-1', '(', '60', 'mg/m/d', ',', 'twice', 'a', 'day', ')', 'from', 'days', '1', 'to', '14', 'with', 'gemcitabine', '(', '1000', 'mg/m/d', ')', 'on', 'days', '1', 'and', '8', '(', 'arm', 'A', ')', 'or', 'on', 'days', '8', 'and', '15', '(', 'arm', 'B', ')', '.']","(3, 5)","(19, 27)",-1,ss_i,20147856,Abstract,2,test,gold,5438.0
3300,"Patients were given oral S-1 ( 60 mg/m/d , twice a day ) from days 1 to 14",with gemcitabine,( 1000 mg/m/d ) on days 1 and 8 ( arm A ) or on days 8 and 15 ( arm B ) .,"['Patients', 'were', 'given', 'oral', 'S-1', '(', '60', 'mg/m/d', ',', 'twice', 'a', 'day', ')', 'from', 'days', '1', 'to', '14', 'with', 'gemcitabine', '(', '1000', 'mg/m/d', ')', 'on', 'days', '1', 'and', '8', '(', 'arm', 'A', ')', 'or', 'on', 'days', '8', 'and', '15', '(', 'arm', 'B', ')', '.']","(18, 20)","(74, 90)",-1,ss_i,20147856,Abstract,2,test,gold,5164.0
3301,Patients were given oral,S-1,"( 60 mg/m/d , twice a day ) from days 1 to 14 with gemcitabine ( 1000 mg/m/d ) on days 1 and 8 ( arm A ) or on days 8 and 15 ( arm B ) .","['Patients', 'were', 'given', 'oral', 'S-1', '(', '60', 'mg/m/d', ',', 'twice', 'a', 'day', ')', 'from', 'days', '1', 'to', '14', 'with', 'gemcitabine', '(', '1000', 'mg/m/d', ')', 'on', 'days', '1', 'and', '8', '(', 'arm', 'A', ')', 'or', 'on', 'days', '8', 'and', '15', '(', 'arm', 'B', ')', '.']","(4, 5)","(24, 27)",-1,hl_i,20147856,Abstract,2,test,gold,
3302,"Patients were given oral S-1 ( 60 mg/m/d , twice a day ) from days 1 to 14 with",gemcitabine,( 1000 mg/m/d ) on days 1 and 8 ( arm A ) or on days 8 and 15 ( arm B ) .,"['Patients', 'were', 'given', 'oral', 'S-1', '(', '60', 'mg/m/d', ',', 'twice', 'a', 'day', ')', 'from', 'days', '1', 'to', '14', 'with', 'gemcitabine', '(', '1000', 'mg/m/d', ')', 'on', 'days', '1', 'and', '8', '(', 'arm', 'A', ')', 'or', 'on', 'days', '8', 'and', '15', '(', 'arm', 'B', ')', '.']","(19, 20)","(79, 90)",-1,hl_i,20147856,Abstract,2,test,gold,5167.0
3303,This cycle was repeated every 21 days .,,,"['This', 'cycle', 'was', 'repeated', 'every', '21', 'days', '.']",,,,,20147856,Abstract,3,test,gold,
3304,,RESULTS A total of 80 patients were entered in this trial,.,"['RESULTS', 'A', 'total', 'of', '80', 'patients', 'were', 'entered', 'in', 'this', 'trial', '.']","(0, 11)","(0, 57)",-1,ss_p,20147856,Abstract,4,test,gold,5842.0
3305,RESULTS A total of,80,patients were entered in this trial .,"['RESULTS', 'A', 'total', 'of', '80', 'patients', 'were', 'entered', 'in', 'this', 'trial', '.']","(4, 5)","(18, 20)",-1,hl_p,20147856,Abstract,4,test,gold,
3306,The primary end point of this study,was response rate,.,"['The', 'primary', 'end', 'point', 'of', 'this', 'study', 'was', 'response', 'rate', '.']","(7, 10)","(35, 52)",-1,ss_o,20147856,Abstract,5,test,gold,1924.0
3307,The primary end point of this study was,response rate,.,"['The', 'primary', 'end', 'point', 'of', 'this', 'study', 'was', 'response', 'rate', '.']","(8, 10)","(39, 52)",-1,hl_o,20147856,Abstract,5,test,gold,1927.0
3308,,The response rates,"of arm A and arm B were 22.0 and 28.9 % , respectively ( p = 0.606 ) .","['The', 'response', 'rates', 'of', 'arm', 'A', 'and', 'arm', 'B', 'were', '22.0', 'and', '28.9', '%', ',', 'respectively', '(', 'p', '=', '0.606', ')', '.']","(0, 3)","(0, 18)",-1,ss_o,20147856,Abstract,6,test,gold,1922.0
3309,"The response rates of arm A and arm B were 22.0 and 28.9 % , respectively ( p =",0.606 ) .,,"['The', 'response', 'rates', 'of', 'arm', 'A', 'and', 'arm', 'B', 'were', '22.0', 'and', '28.9', '%', ',', 'respectively', '(', 'p', '=', '0.606', ')', '.']","(19, 22)","(79, 88)",-1,ss_o,20147856,Abstract,6,test,gold,
3310,The,response rates,"of arm A and arm B were 22.0 and 28.9 % , respectively ( p = 0.606 ) .","['The', 'response', 'rates', 'of', 'arm', 'A', 'and', 'arm', 'B', 'were', '22.0', 'and', '28.9', '%', ',', 'respectively', '(', 'p', '=', '0.606', ')', '.']","(1, 3)","(3, 17)",-1,hl_o,20147856,Abstract,6,test,gold,1923.0
3311,,Median time to treatment failure,in arm A was 3.6 months and 4.8 months in arm B .,"['Median', 'time', 'to', 'treatment', 'failure', 'in', 'arm', 'A', 'was', '3.6', 'months', 'and', '4.8', 'months', 'in', 'arm', 'B', '.']","(0, 5)","(0, 32)",-1,ss_o,20147856,Abstract,7,test,gold,1982.0
3312,Median time to treatment failure in arm A was 3.6 months and 4.8 months in arm,B .,,"['Median', 'time', 'to', 'treatment', 'failure', 'in', 'arm', 'A', 'was', '3.6', 'months', 'and', '4.8', 'months', 'in', 'arm', 'B', '.']","(16, 18)","(78, 81)",-1,ss_o,20147856,Abstract,7,test,gold,829.0
3313,,Median time to treatment failure,in arm A was 3.6 months and 4.8 months in arm B .,"['Median', 'time', 'to', 'treatment', 'failure', 'in', 'arm', 'A', 'was', '3.6', 'months', 'and', '4.8', 'months', 'in', 'arm', 'B', '.']","(0, 5)","(0, 32)",-1,hl_o,20147856,Abstract,7,test,gold,1983.0
3314,,Median time to progression,in arm A was 4.1 months and 5.5 months in arm B .,"['Median', 'time', 'to', 'progression', 'in', 'arm', 'A', 'was', '4.1', 'months', 'and', '5.5', 'months', 'in', 'arm', 'B', '.']","(0, 4)","(0, 26)",-1,ss_o,20147856,Abstract,8,test,gold,1980.0
3315,Median time to progression in arm A was 4.1 months and 5.5 months in arm,B .,,"['Median', 'time', 'to', 'progression', 'in', 'arm', 'A', 'was', '4.1', 'months', 'and', '5.5', 'months', 'in', 'arm', 'B', '.']","(15, 17)","(72, 75)",-1,ss_o,20147856,Abstract,8,test,gold,828.0
3316,,Median time to progression,in arm A was 4.1 months and 5.5 months in arm B .,"['Median', 'time', 'to', 'progression', 'in', 'arm', 'A', 'was', '4.1', 'months', 'and', '5.5', 'months', 'in', 'arm', 'B', '.']","(0, 4)","(0, 26)",-1,hl_o,20147856,Abstract,8,test,gold,1981.0
3317,,Median survival time,"in arm A and arm B was 15.5 months and 18.8 months , respectively .","['Median', 'survival', 'time', 'in', 'arm', 'A', 'and', 'arm', 'B', 'was', '15.5', 'months', 'and', '18.8', 'months', ',', 'respectively', '.']","(0, 3)","(0, 20)",-1,ss_o,20147856,Abstract,9,test,gold,1984.0
3318,,Median survival time,"in arm A and arm B was 15.5 months and 18.8 months , respectively .","['Median', 'survival', 'time', 'in', 'arm', 'A', 'and', 'arm', 'B', 'was', '15.5', 'months', 'and', '18.8', 'months', ',', 'respectively', '.']","(0, 3)","(0, 20)",-1,hl_o,20147856,Abstract,9,test,gold,1985.0
3319,,The toxicity profile,was relatively mild and did not differ very much between two arms .,"['The', 'toxicity', 'profile', 'was', 'relatively', 'mild', 'and', 'did', 'not', 'differ', 'very', 'much', 'between', 'two', 'arms', '.']","(0, 3)","(0, 20)",-1,ss_o,20147856,Abstract,10,test,gold,3491.0
3320,The,toxicity profile,was relatively mild and did not differ very much between two arms .,"['The', 'toxicity', 'profile', 'was', 'relatively', 'mild', 'and', 'did', 'not', 'differ', 'very', 'much', 'between', 'two', 'arms', '.']","(1, 3)","(3, 19)",-1,hl_o,20147856,Abstract,10,test,gold,3492.0
3321,CONCLUSION The combination,of gemcitabine and S-1,was determined to be feasible and effective for advanced non-small cell lung cancer .,"['CONCLUSION', 'The', 'combination', 'of', 'gemcitabine', 'and', 'S-1', 'was', 'determined', 'to', 'be', 'feasible', 'and', 'effective', 'for', 'advanced', 'non-small', 'cell', 'lung', 'cancer', '.']","(3, 7)","(26, 48)",-1,ss_i,20147856,Abstract,11,test,gold,5166.0
3322,CONCLUSION The combination of gemcitabine and S-1 was determined to,be feasible and effective,for advanced non-small cell lung cancer .,"['CONCLUSION', 'The', 'combination', 'of', 'gemcitabine', 'and', 'S-1', 'was', 'determined', 'to', 'be', 'feasible', 'and', 'effective', 'for', 'advanced', 'non-small', 'cell', 'lung', 'cancer', '.']","(10, 14)","(67, 92)",-1,ss_o,20147856,Abstract,11,test,gold,864.0
3323,CONCLUSION The combination of,gemcitabine,and S-1 was determined to be feasible and effective for advanced non-small cell lung cancer .,"['CONCLUSION', 'The', 'combination', 'of', 'gemcitabine', 'and', 'S-1', 'was', 'determined', 'to', 'be', 'feasible', 'and', 'effective', 'for', 'advanced', 'non-small', 'cell', 'lung', 'cancer', '.']","(4, 5)","(29, 40)",-1,hl_i,20147856,Abstract,11,test,gold,5165.0
3324,CONCLUSION The combination of gemcitabine and,S-1,was determined to be feasible and effective for advanced non-small cell lung cancer .,"['CONCLUSION', 'The', 'combination', 'of', 'gemcitabine', 'and', 'S-1', 'was', 'determined', 'to', 'be', 'feasible', 'and', 'effective', 'for', 'advanced', 'non-small', 'cell', 'lung', 'cancer', '.']","(6, 7)","(45, 48)",-1,hl_i,20147856,Abstract,11,test,gold,
3325,CONCLUSION The combination of gemcitabine and S-1 was determined to be,feasible,and effective for advanced non-small cell lung cancer .,"['CONCLUSION', 'The', 'combination', 'of', 'gemcitabine', 'and', 'S-1', 'was', 'determined', 'to', 'be', 'feasible', 'and', 'effective', 'for', 'advanced', 'non-small', 'cell', 'lung', 'cancer', '.']","(11, 12)","(70, 78)",-1,hl_o,20147856,Abstract,11,test,gold,868.0
3326,CONCLUSION The combination of gemcitabine and S-1 was determined to be feasible and,effective,for advanced non-small cell lung cancer .,"['CONCLUSION', 'The', 'combination', 'of', 'gemcitabine', 'and', 'S-1', 'was', 'determined', 'to', 'be', 'feasible', 'and', 'effective', 'for', 'advanced', 'non-small', 'cell', 'lung', 'cancer', '.']","(13, 14)","(83, 92)",-1,hl_o,20147856,Abstract,11,test,gold,849.0
3327,We selected arm B for further studies because of its,higher response rate and survival data,.,"['We', 'selected', 'arm', 'B', 'for', 'further', 'studies', 'because', 'of', 'its', 'higher', 'response', 'rate', 'and', 'survival', 'data', '.']","(10, 16)","(52, 90)",-1,ss_o,20147856,Abstract,12,test,gold,1951.0
3328,We selected arm B for further studies because of its higher,response rate,and survival data .,"['We', 'selected', 'arm', 'B', 'for', 'further', 'studies', 'because', 'of', 'its', 'higher', 'response', 'rate', 'and', 'survival', 'data', '.']","(11, 13)","(59, 72)",-1,hl_o,20147856,Abstract,12,test,gold,1928.0
3329,We selected arm B for further studies because of its higher response rate and,survival data,.,"['We', 'selected', 'arm', 'B', 'for', 'further', 'studies', 'because', 'of', 'its', 'higher', 'response', 'rate', 'and', 'survival', 'data', '.']","(14, 16)","(77, 90)",-1,hl_o,20147856,Abstract,12,test,gold,1971.0
3330,"Remote ischaemic conditioning before hospital admission , as a complement to angioplasty , and effect on myocardial salvage in",patients with acute myocardial infarction :,a randomised trial .,"['Remote', 'ischaemic', 'conditioning', 'before', 'hospital', 'admission', ',', 'as', 'a', 'complement', 'to', 'angioplasty', ',', 'and', 'effect', 'on', 'myocardial', 'salvage', 'in', 'patients', 'with', 'acute', 'myocardial', 'infarction', ':', 'a', 'randomised', 'trial', '.']","(19, 25)","(126, 169)",-1,ss_p,20189026,Title,0,test,gold,6798.0
3331,,Remote ischaemic conditioning,"before hospital admission , as a complement to angioplasty , and effect on myocardial salvage in patients with acute myocardial infarction : a randomised trial .","['Remote', 'ischaemic', 'conditioning', 'before', 'hospital', 'admission', ',', 'as', 'a', 'complement', 'to', 'angioplasty', ',', 'and', 'effect', 'on', 'myocardial', 'salvage', 'in', 'patients', 'with', 'acute', 'myocardial', 'infarction', ':', 'a', 'randomised', 'trial', '.']","(0, 3)","(0, 29)",-1,ss_i,20189026,Title,0,test,gold,2806.0
3332,"Remote ischaemic conditioning before hospital admission , as a complement to angioplasty , and effect on",myocardial salvage,in patients with acute myocardial infarction : a randomised trial .,"['Remote', 'ischaemic', 'conditioning', 'before', 'hospital', 'admission', ',', 'as', 'a', 'complement', 'to', 'angioplasty', ',', 'and', 'effect', 'on', 'myocardial', 'salvage', 'in', 'patients', 'with', 'acute', 'myocardial', 'infarction', ':', 'a', 'randomised', 'trial', '.']","(16, 18)","(104, 122)",-1,ss_o,20189026,Title,0,test,gold,3229.0
3333,"Remote ischaemic conditioning before hospital admission , as a complement to angioplasty , and effect on myocardial salvage in",patients with acute myocardial infarction :,a randomised trial .,"['Remote', 'ischaemic', 'conditioning', 'before', 'hospital', 'admission', ',', 'as', 'a', 'complement', 'to', 'angioplasty', ',', 'and', 'effect', 'on', 'myocardial', 'salvage', 'in', 'patients', 'with', 'acute', 'myocardial', 'infarction', ':', 'a', 'randomised', 'trial', '.']","(19, 25)","(126, 169)",-1,hl_p,20189026,Title,0,test,gold,6799.0
3334,,Remote ischaemic conditioning,"before hospital admission , as a complement to angioplasty , and effect on myocardial salvage in patients with acute myocardial infarction : a randomised trial .","['Remote', 'ischaemic', 'conditioning', 'before', 'hospital', 'admission', ',', 'as', 'a', 'complement', 'to', 'angioplasty', ',', 'and', 'effect', 'on', 'myocardial', 'salvage', 'in', 'patients', 'with', 'acute', 'myocardial', 'infarction', ':', 'a', 'randomised', 'trial', '.']","(0, 3)","(0, 29)",-1,hl_i,20189026,Title,0,test,gold,2807.0
3335,"Remote ischaemic conditioning before hospital admission , as a complement to angioplasty , and effect on",myocardial salvage,in patients with acute myocardial infarction : a randomised trial .,"['Remote', 'ischaemic', 'conditioning', 'before', 'hospital', 'admission', ',', 'as', 'a', 'complement', 'to', 'angioplasty', ',', 'and', 'effect', 'on', 'myocardial', 'salvage', 'in', 'patients', 'with', 'acute', 'myocardial', 'infarction', ':', 'a', 'randomised', 'trial', '.']","(16, 18)","(104, 122)",-1,hl_o,20189026,Title,0,test,gold,3230.0
3336,BACKGROUND,Remote ischaemic preconditioning,attenuates cardiac injury at elective surgery and angioplasty .,"['BACKGROUND', 'Remote', 'ischaemic', 'preconditioning', 'attenuates', 'cardiac', 'injury', 'at', 'elective', 'surgery', 'and', 'angioplasty', '.']","(1, 4)","(10, 42)",-1,ss_i,20189026,Abstract,0,test,gold,4100.0
3337,BACKGROUND,Remote ischaemic preconditioning,attenuates cardiac injury at elective surgery and angioplasty .,"['BACKGROUND', 'Remote', 'ischaemic', 'preconditioning', 'attenuates', 'cardiac', 'injury', 'at', 'elective', 'surgery', 'and', 'angioplasty', '.']","(1, 4)","(10, 42)",-1,hl_i,20189026,Abstract,0,test,gold,4101.0
3338,We tested the hypothesis that remote ischaemic conditioning during evolving,ST-elevation myocardial infarction,", and done before primary percutaneous coronary intervention , increases myocardial salvage .","['We', 'tested', 'the', 'hypothesis', 'that', 'remote', 'ischaemic', 'conditioning', 'during', 'evolving', 'ST-elevation', 'myocardial', 'infarction', ',', 'and', 'done', 'before', 'primary', 'percutaneous', 'coronary', 'intervention', ',', 'increases', 'myocardial', 'salvage', '.']","(10, 13)","(75, 109)",-1,ss_p,20189026,Abstract,1,test,gold,6797.0
3339,We tested the hypothesis that,remote ischaemic conditioning,"during evolving ST-elevation myocardial infarction , and done before primary percutaneous coronary intervention , increases myocardial salvage .","['We', 'tested', 'the', 'hypothesis', 'that', 'remote', 'ischaemic', 'conditioning', 'during', 'evolving', 'ST-elevation', 'myocardial', 'infarction', ',', 'and', 'done', 'before', 'primary', 'percutaneous', 'coronary', 'intervention', ',', 'increases', 'myocardial', 'salvage', '.']","(5, 8)","(29, 58)",-1,ss_i,20189026,Abstract,1,test,gold,2802.0
3340,"We tested the hypothesis that remote ischaemic conditioning during evolving ST-elevation myocardial infarction , and done before primary percutaneous coronary intervention , increases",myocardial salvage .,,"['We', 'tested', 'the', 'hypothesis', 'that', 'remote', 'ischaemic', 'conditioning', 'during', 'evolving', 'ST-elevation', 'myocardial', 'infarction', ',', 'and', 'done', 'before', 'primary', 'percutaneous', 'coronary', 'intervention', ',', 'increases', 'myocardial', 'salvage', '.']","(23, 26)","(183, 203)",-1,ss_o,20189026,Abstract,1,test,gold,3228.0
3341,We tested the hypothesis that,remote ischaemic conditioning,"during evolving ST-elevation myocardial infarction , and done before primary percutaneous coronary intervention , increases myocardial salvage .","['We', 'tested', 'the', 'hypothesis', 'that', 'remote', 'ischaemic', 'conditioning', 'during', 'evolving', 'ST-elevation', 'myocardial', 'infarction', ',', 'and', 'done', 'before', 'primary', 'percutaneous', 'coronary', 'intervention', ',', 'increases', 'myocardial', 'salvage', '.']","(5, 8)","(29, 58)",-1,hl_i,20189026,Abstract,1,test,gold,2803.0
3342,"We tested the hypothesis that remote ischaemic conditioning during evolving ST-elevation myocardial infarction , and done before primary percutaneous coronary intervention , increases",myocardial salvage .,,"['We', 'tested', 'the', 'hypothesis', 'that', 'remote', 'ischaemic', 'conditioning', 'during', 'evolving', 'ST-elevation', 'myocardial', 'infarction', ',', 'and', 'done', 'before', 'primary', 'percutaneous', 'coronary', 'intervention', ',', 'increases', 'myocardial', 'salvage', '.']","(23, 26)","(183, 203)",-1,hl_o,20189026,Abstract,1,test,gold,3227.0
3343,METHODS,333 consecutive adult patients with a suspected first acute myocardial infarction,were randomly assigned in a 1:1 ratio by computerised block randomisation to receive primary percutaneous coronary intervention with ( n=166 patients ) versus without ( n=167 ) remote conditioning ( intermittent arm ischaemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff ) .,"['METHODS', '333', 'consecutive', 'adult', 'patients', 'with', 'a', 'suspected', 'first', 'acute', 'myocardial', 'infarction', 'were', 'randomly', 'assigned', 'in', 'a', '1:1', 'ratio', 'by', 'computerised', 'block', 'randomisation', 'to', 'receive', 'primary', 'percutaneous', 'coronary', 'intervention', 'with', '(', 'n=166', 'patients', ')', 'versus', 'without', '(', 'n=167', ')', 'remote', 'conditioning', '(', 'intermittent', 'arm', 'ischaemia', 'through', 'four', 'cycles', 'of', '5-min', 'inflation', 'and', '5-min', 'deflation', 'of', 'a', 'blood-pressure', 'cuff', ')', '.']","(1, 12)","(7, 88)",-1,ss_p,20189026,Abstract,2,test,gold,5984.0
3344,METHODS 333 consecutive adult patients with a suspected first acute myocardial infarction were randomly assigned in a 1:1 ratio by computerised block randomisation to receive primary percutaneous coronary intervention with ( n=166 patients ) versus without ( n=167 ),remote conditioning,( intermittent arm ischaemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff ) .,"['METHODS', '333', 'consecutive', 'adult', 'patients', 'with', 'a', 'suspected', 'first', 'acute', 'myocardial', 'infarction', 'were', 'randomly', 'assigned', 'in', 'a', '1:1', 'ratio', 'by', 'computerised', 'block', 'randomisation', 'to', 'receive', 'primary', 'percutaneous', 'coronary', 'intervention', 'with', '(', 'n=166', 'patients', ')', 'versus', 'without', '(', 'n=167', ')', 'remote', 'conditioning', '(', 'intermittent', 'arm', 'ischaemia', 'through', 'four', 'cycles', 'of', '5-min', 'inflation', 'and', '5-min', 'deflation', 'of', 'a', 'blood-pressure', 'cuff', ')', '.']","(39, 41)","(266, 285)",-1,ss_i,20189026,Abstract,2,test,gold,2801.0
3345,METHODS,333 consecutive adult patients with a suspected first acute myocardial infarction,were randomly assigned in a 1:1 ratio by computerised block randomisation to receive primary percutaneous coronary intervention with ( n=166 patients ) versus without ( n=167 ) remote conditioning ( intermittent arm ischaemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff ) .,"['METHODS', '333', 'consecutive', 'adult', 'patients', 'with', 'a', 'suspected', 'first', 'acute', 'myocardial', 'infarction', 'were', 'randomly', 'assigned', 'in', 'a', '1:1', 'ratio', 'by', 'computerised', 'block', 'randomisation', 'to', 'receive', 'primary', 'percutaneous', 'coronary', 'intervention', 'with', '(', 'n=166', 'patients', ')', 'versus', 'without', '(', 'n=167', ')', 'remote', 'conditioning', '(', 'intermittent', 'arm', 'ischaemia', 'through', 'four', 'cycles', 'of', '5-min', 'inflation', 'and', '5-min', 'deflation', 'of', 'a', 'blood-pressure', 'cuff', ')', '.']","(1, 12)","(7, 88)",-1,hl_p,20189026,Abstract,2,test,gold,5985.0
3346,METHODS 333 consecutive adult patients with a suspected first acute myocardial infarction were randomly assigned in a 1:1 ratio by computerised block randomisation to receive primary percutaneous coronary intervention with ( n=166 patients ) versus without ( n=167 ),remote conditioning,( intermittent arm ischaemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff ) .,"['METHODS', '333', 'consecutive', 'adult', 'patients', 'with', 'a', 'suspected', 'first', 'acute', 'myocardial', 'infarction', 'were', 'randomly', 'assigned', 'in', 'a', '1:1', 'ratio', 'by', 'computerised', 'block', 'randomisation', 'to', 'receive', 'primary', 'percutaneous', 'coronary', 'intervention', 'with', '(', 'n=166', 'patients', ')', 'versus', 'without', '(', 'n=167', ')', 'remote', 'conditioning', '(', 'intermittent', 'arm', 'ischaemia', 'through', 'four', 'cycles', 'of', '5-min', 'inflation', 'and', '5-min', 'deflation', 'of', 'a', 'blood-pressure', 'cuff', ')', '.']","(39, 41)","(266, 285)",-1,hl_i,20189026,Abstract,2,test,gold,2800.0
3347,Allocation was concealed with opaque sealed envelopes .,,,"['Allocation', 'was', 'concealed', 'with', 'opaque', 'sealed', 'envelopes', '.']",,,,,20189026,Abstract,3,test,gold,
3348,Patients received,remote conditioning,"during transport to hospital , and primary percutaneous coronary intervention in hospital .","['Patients', 'received', 'remote', 'conditioning', 'during', 'transport', 'to', 'hospital', ',', 'and', 'primary', 'percutaneous', 'coronary', 'intervention', 'in', 'hospital', '.']","(2, 4)","(17, 36)",-1,ss_i,20189026,Abstract,4,test,gold,2799.0
3349,Patients received,remote conditioning,"during transport to hospital , and primary percutaneous coronary intervention in hospital .","['Patients', 'received', 'remote', 'conditioning', 'during', 'transport', 'to', 'hospital', ',', 'and', 'primary', 'percutaneous', 'coronary', 'intervention', 'in', 'hospital', '.']","(2, 4)","(17, 36)",-1,hl_i,20189026,Abstract,4,test,gold,2798.0
3350,The primary endpoint was,"myocardial salvage index at 30 days after primary percutaneous coronary intervention , measured by myocardial perfusion imaging",as the proportion of the area at risk salvaged by treatment ; analysis was per protocol .,"['The', 'primary', 'endpoint', 'was', 'myocardial', 'salvage', 'index', 'at', '30', 'days', 'after', 'primary', 'percutaneous', 'coronary', 'intervention', ',', 'measured', 'by', 'myocardial', 'perfusion', 'imaging', 'as', 'the', 'proportion', 'of', 'the', 'area', 'at', 'risk', 'salvaged', 'by', 'treatment', ';', 'analysis', 'was', 'per', 'protocol', '.']","(4, 21)","(24, 151)",-1,ss_o,20189026,Abstract,5,test,gold,6005.0
3351,"The primary endpoint was myocardial salvage index at 30 days after primary percutaneous coronary intervention , measured by myocardial perfusion imaging as the",proportion of the area at risk salvaged by treatment ;,analysis was per protocol .,"['The', 'primary', 'endpoint', 'was', 'myocardial', 'salvage', 'index', 'at', '30', 'days', 'after', 'primary', 'percutaneous', 'coronary', 'intervention', ',', 'measured', 'by', 'myocardial', 'perfusion', 'imaging', 'as', 'the', 'proportion', 'of', 'the', 'area', 'at', 'risk', 'salvaged', 'by', 'treatment', ';', 'analysis', 'was', 'per', 'protocol', '.']","(23, 33)","(159, 213)",-1,ss_o,20189026,Abstract,5,test,gold,2096.0
3352,The primary endpoint was,myocardial salvage index,"at 30 days after primary percutaneous coronary intervention , measured by myocardial perfusion imaging as the proportion of the area at risk salvaged by treatment ; analysis was per protocol .","['The', 'primary', 'endpoint', 'was', 'myocardial', 'salvage', 'index', 'at', '30', 'days', 'after', 'primary', 'percutaneous', 'coronary', 'intervention', ',', 'measured', 'by', 'myocardial', 'perfusion', 'imaging', 'as', 'the', 'proportion', 'of', 'the', 'area', 'at', 'risk', 'salvaged', 'by', 'treatment', ';', 'analysis', 'was', 'per', 'protocol', '.']","(4, 7)","(24, 48)",-1,hl_o,20189026,Abstract,5,test,gold,3223.0
3353,"The primary endpoint was myocardial salvage index at 30 days after primary percutaneous coronary intervention , measured by",myocardial perfusion imaging,as the proportion of the area at risk salvaged by treatment ; analysis was per protocol .,"['The', 'primary', 'endpoint', 'was', 'myocardial', 'salvage', 'index', 'at', '30', 'days', 'after', 'primary', 'percutaneous', 'coronary', 'intervention', ',', 'measured', 'by', 'myocardial', 'perfusion', 'imaging', 'as', 'the', 'proportion', 'of', 'the', 'area', 'at', 'risk', 'salvaged', 'by', 'treatment', ';', 'analysis', 'was', 'per', 'protocol', '.']","(18, 21)","(123, 151)",-1,hl_o,20189026,Abstract,5,test,gold,6793.0
3354,"This study is registered with ClinicalTrials.gov , number NCT00435266 .",,,"['This', 'study', 'is', 'registered', 'with', 'ClinicalTrials.gov', ',', 'number', 'NCT00435266', '.']",,,,,20189026,Abstract,6,test,gold,
3355,FINDINGS,"82 patients were excluded on arrival at hospital because they did not meet inclusion criteria , 32 were lost to follow-up , and 77 did not complete the follow-up",with data for salvage index .,"['FINDINGS', '82', 'patients', 'were', 'excluded', 'on', 'arrival', 'at', 'hospital', 'because', 'they', 'did', 'not', 'meet', 'inclusion', 'criteria', ',', '32', 'were', 'lost', 'to', 'follow-up', ',', 'and', '77', 'did', 'not', 'complete', 'the', 'follow-up', 'with', 'data', 'for', 'salvage', 'index', '.']","(1, 30)","(8, 169)",-1,ss_p,20189026,Abstract,7,test,gold,5891.0
3356,"FINDINGS 82 patients were excluded on arrival at hospital because they did not meet inclusion criteria , 32 were lost to follow-up , and 77 did not complete the follow-up with data for",salvage index .,,"['FINDINGS', '82', 'patients', 'were', 'excluded', 'on', 'arrival', 'at', 'hospital', 'because', 'they', 'did', 'not', 'meet', 'inclusion', 'criteria', ',', '32', 'were', 'lost', 'to', 'follow-up', ',', 'and', '77', 'did', 'not', 'complete', 'the', 'follow-up', 'with', 'data', 'for', 'salvage', 'index', '.']","(33, 36)","(184, 199)",-1,ss_o,20189026,Abstract,7,test,gold,1993.0
3357,FINDINGS,"82 patients were excluded on arrival at hospital because they did not meet inclusion criteria , 32 were lost to follow-up , and 77 did not complete the follow-up",with data for salvage index .,"['FINDINGS', '82', 'patients', 'were', 'excluded', 'on', 'arrival', 'at', 'hospital', 'because', 'they', 'did', 'not', 'meet', 'inclusion', 'criteria', ',', '32', 'were', 'lost', 'to', 'follow-up', ',', 'and', '77', 'did', 'not', 'complete', 'the', 'follow-up', 'with', 'data', 'for', 'salvage', 'index', '.']","(1, 30)","(8, 169)",-1,hl_p,20189026,Abstract,7,test,gold,5892.0
3358,"Median salvage index was 0.75 ( IQR 0.50-0.93 , n=73 ) in the",remote conditioning,"group versus 0.55 ( 0.35-0.88 , n=69 ) in the control group , with median difference of 0.10 ( 95 % CI 0.01-0.22 ; p=0.0333 ) ; mean salvage index was 0.69 ( SD 0.27 ) versus 0.57 ( 0.26 ) , with mean difference of 0.12 ( 95 % CI 0.01-0.21 ; p=0.0333 ) .","['Median', 'salvage', 'index', 'was', '0.75', '(', 'IQR', '0.50-0.93', ',', 'n=73', ')', 'in', 'the', 'remote', 'conditioning', 'group', 'versus', '0.55', '(', '0.35-0.88', ',', 'n=69', ')', 'in', 'the', 'control', 'group', ',', 'with', 'median', 'difference', 'of', '0.10', '(', '95', '%', 'CI', '0.01-0.22', ';', 'p=0.0333', ')', ';', 'mean', 'salvage', 'index', 'was', '0.69', '(', 'SD', '0.27', ')', 'versus', '0.57', '(', '0.26', ')', ',', 'with', 'mean', 'difference', 'of', '0.12', '(', '95', '%', 'CI', '0.01-0.21', ';', 'p=0.0333', ')', '.']","(13, 15)","(61, 80)",-1,ss_i,20189026,Abstract,8,test,gold,2797.0
3359,,Median salvage index,"was 0.75 ( IQR 0.50-0.93 , n=73 ) in the remote conditioning group versus 0.55 ( 0.35-0.88 , n=69 ) in the control group , with median difference of 0.10 ( 95 % CI 0.01-0.22 ; p=0.0333 ) ; mean salvage index was 0.69 ( SD 0.27 ) versus 0.57 ( 0.26 ) , with mean difference of 0.12 ( 95 % CI 0.01-0.21 ; p=0.0333 ) .","['Median', 'salvage', 'index', 'was', '0.75', '(', 'IQR', '0.50-0.93', ',', 'n=73', ')', 'in', 'the', 'remote', 'conditioning', 'group', 'versus', '0.55', '(', '0.35-0.88', ',', 'n=69', ')', 'in', 'the', 'control', 'group', ',', 'with', 'median', 'difference', 'of', '0.10', '(', '95', '%', 'CI', '0.01-0.22', ';', 'p=0.0333', ')', ';', 'mean', 'salvage', 'index', 'was', '0.69', '(', 'SD', '0.27', ')', 'versus', '0.57', '(', '0.26', ')', ',', 'with', 'mean', 'difference', 'of', '0.12', '(', '95', '%', 'CI', '0.01-0.21', ';', 'p=0.0333', ')', '.']","(0, 3)","(0, 20)",-1,ss_o,20189026,Abstract,8,test,gold,1991.0
3360,"Median salvage index was 0.75 ( IQR 0.50-0.93 , n=73 ) in the remote conditioning group versus 0.55 ( 0.35-0.88 , n=69 ) in the control group , with",median difference,"of 0.10 ( 95 % CI 0.01-0.22 ; p=0.0333 ) ; mean salvage index was 0.69 ( SD 0.27 ) versus 0.57 ( 0.26 ) , with mean difference of 0.12 ( 95 % CI 0.01-0.21 ; p=0.0333 ) .","['Median', 'salvage', 'index', 'was', '0.75', '(', 'IQR', '0.50-0.93', ',', 'n=73', ')', 'in', 'the', 'remote', 'conditioning', 'group', 'versus', '0.55', '(', '0.35-0.88', ',', 'n=69', ')', 'in', 'the', 'control', 'group', ',', 'with', 'median', 'difference', 'of', '0.10', '(', '95', '%', 'CI', '0.01-0.22', ';', 'p=0.0333', ')', ';', 'mean', 'salvage', 'index', 'was', '0.69', '(', 'SD', '0.27', ')', 'versus', '0.57', '(', '0.26', ')', ',', 'with', 'mean', 'difference', 'of', '0.12', '(', '95', '%', 'CI', '0.01-0.21', ';', 'p=0.0333', ')', '.']","(29, 31)","(148, 165)",-1,ss_o,20189026,Abstract,8,test,gold,1988.0
3361,"Median salvage index was 0.75 ( IQR 0.50-0.93 , n=73 ) in the remote conditioning group versus 0.55 ( 0.35-0.88 , n=69 ) in the control group , with median difference of 0.10 ( 95 % CI 0.01-0.22 ; p=0.0333 ) ;",mean salvage index,"was 0.69 ( SD 0.27 ) versus 0.57 ( 0.26 ) , with mean difference of 0.12 ( 95 % CI 0.01-0.21 ; p=0.0333 ) .","['Median', 'salvage', 'index', 'was', '0.75', '(', 'IQR', '0.50-0.93', ',', 'n=73', ')', 'in', 'the', 'remote', 'conditioning', 'group', 'versus', '0.55', '(', '0.35-0.88', ',', 'n=69', ')', 'in', 'the', 'control', 'group', ',', 'with', 'median', 'difference', 'of', '0.10', '(', '95', '%', 'CI', '0.01-0.22', ';', 'p=0.0333', ')', ';', 'mean', 'salvage', 'index', 'was', '0.69', '(', 'SD', '0.27', ')', 'versus', '0.57', '(', '0.26', ')', ',', 'with', 'mean', 'difference', 'of', '0.12', '(', '95', '%', 'CI', '0.01-0.21', ';', 'p=0.0333', ')', '.']","(42, 45)","(209, 227)",-1,ss_o,20189026,Abstract,8,test,gold,1994.0
3362,"Median salvage index was 0.75 ( IQR 0.50-0.93 , n=73 ) in the remote conditioning group versus 0.55 ( 0.35-0.88 , n=69 ) in the control group , with median difference of 0.10 ( 95 % CI 0.01-0.22 ; p=0.0333 ) ; mean salvage index was 0.69 ( SD 0.27 ) versus 0.57 ( 0.26 ) , with",mean difference,of 0.12 ( 95 % CI 0.01-0.21 ; p=0.0333 ) .,"['Median', 'salvage', 'index', 'was', '0.75', '(', 'IQR', '0.50-0.93', ',', 'n=73', ')', 'in', 'the', 'remote', 'conditioning', 'group', 'versus', '0.55', '(', '0.35-0.88', ',', 'n=69', ')', 'in', 'the', 'control', 'group', ',', 'with', 'median', 'difference', 'of', '0.10', '(', '95', '%', 'CI', '0.01-0.22', ';', 'p=0.0333', ')', ';', 'mean', 'salvage', 'index', 'was', '0.69', '(', 'SD', '0.27', ')', 'versus', '0.57', '(', '0.26', ')', ',', 'with', 'mean', 'difference', 'of', '0.12', '(', '95', '%', 'CI', '0.01-0.21', ';', 'p=0.0333', ')', '.']","(58, 60)","(277, 292)",-1,ss_o,20189026,Abstract,8,test,gold,970.0
3363,"Median salvage index was 0.75 ( IQR 0.50-0.93 , n=73 ) in the",remote conditioning,"group versus 0.55 ( 0.35-0.88 , n=69 ) in the control group , with median difference of 0.10 ( 95 % CI 0.01-0.22 ; p=0.0333 ) ; mean salvage index was 0.69 ( SD 0.27 ) versus 0.57 ( 0.26 ) , with mean difference of 0.12 ( 95 % CI 0.01-0.21 ; p=0.0333 ) .","['Median', 'salvage', 'index', 'was', '0.75', '(', 'IQR', '0.50-0.93', ',', 'n=73', ')', 'in', 'the', 'remote', 'conditioning', 'group', 'versus', '0.55', '(', '0.35-0.88', ',', 'n=69', ')', 'in', 'the', 'control', 'group', ',', 'with', 'median', 'difference', 'of', '0.10', '(', '95', '%', 'CI', '0.01-0.22', ';', 'p=0.0333', ')', ';', 'mean', 'salvage', 'index', 'was', '0.69', '(', 'SD', '0.27', ')', 'versus', '0.57', '(', '0.26', ')', ',', 'with', 'mean', 'difference', 'of', '0.12', '(', '95', '%', 'CI', '0.01-0.21', ';', 'p=0.0333', ')', '.']","(13, 15)","(61, 80)",-1,hl_i,20189026,Abstract,8,test,gold,2796.0
3364,,Median salvage index,"was 0.75 ( IQR 0.50-0.93 , n=73 ) in the remote conditioning group versus 0.55 ( 0.35-0.88 , n=69 ) in the control group , with median difference of 0.10 ( 95 % CI 0.01-0.22 ; p=0.0333 ) ; mean salvage index was 0.69 ( SD 0.27 ) versus 0.57 ( 0.26 ) , with mean difference of 0.12 ( 95 % CI 0.01-0.21 ; p=0.0333 ) .","['Median', 'salvage', 'index', 'was', '0.75', '(', 'IQR', '0.50-0.93', ',', 'n=73', ')', 'in', 'the', 'remote', 'conditioning', 'group', 'versus', '0.55', '(', '0.35-0.88', ',', 'n=69', ')', 'in', 'the', 'control', 'group', ',', 'with', 'median', 'difference', 'of', '0.10', '(', '95', '%', 'CI', '0.01-0.22', ';', 'p=0.0333', ')', ';', 'mean', 'salvage', 'index', 'was', '0.69', '(', 'SD', '0.27', ')', 'versus', '0.57', '(', '0.26', ')', ',', 'with', 'mean', 'difference', 'of', '0.12', '(', '95', '%', 'CI', '0.01-0.21', ';', 'p=0.0333', ')', '.']","(0, 3)","(0, 20)",-1,hl_o,20189026,Abstract,8,test,gold,1992.0
3365,"Median salvage index was 0.75 ( IQR 0.50-0.93 , n=73 ) in the remote conditioning group versus 0.55 ( 0.35-0.88 , n=69 ) in the control group , with median difference of 0.10 ( 95 % CI 0.01-0.22 ; p=0.0333 ) ;",mean salvage index,"was 0.69 ( SD 0.27 ) versus 0.57 ( 0.26 ) , with mean difference of 0.12 ( 95 % CI 0.01-0.21 ; p=0.0333 ) .","['Median', 'salvage', 'index', 'was', '0.75', '(', 'IQR', '0.50-0.93', ',', 'n=73', ')', 'in', 'the', 'remote', 'conditioning', 'group', 'versus', '0.55', '(', '0.35-0.88', ',', 'n=69', ')', 'in', 'the', 'control', 'group', ',', 'with', 'median', 'difference', 'of', '0.10', '(', '95', '%', 'CI', '0.01-0.22', ';', 'p=0.0333', ')', ';', 'mean', 'salvage', 'index', 'was', '0.69', '(', 'SD', '0.27', ')', 'versus', '0.57', '(', '0.26', ')', ',', 'with', 'mean', 'difference', 'of', '0.12', '(', '95', '%', 'CI', '0.01-0.21', ';', 'p=0.0333', ')', '.']","(42, 45)","(209, 227)",-1,hl_o,20189026,Abstract,8,test,gold,1995.0
3366,,Major adverse coronary events,"were death ( n=3 per group ) , reinfarction ( n=1 per group ) , and heart failure ( n=3 per group ) .","['Major', 'adverse', 'coronary', 'events', 'were', 'death', '(', 'n=3', 'per', 'group', ')', ',', 'reinfarction', '(', 'n=1', 'per', 'group', ')', ',', 'and', 'heart', 'failure', '(', 'n=3', 'per', 'group', ')', '.']","(0, 4)","(0, 29)",-1,ss_o,20189026,Abstract,9,test,gold,3040.0
3367,Major adverse coronary events were,death,"( n=3 per group ) , reinfarction ( n=1 per group ) , and heart failure ( n=3 per group ) .","['Major', 'adverse', 'coronary', 'events', 'were', 'death', '(', 'n=3', 'per', 'group', ')', ',', 'reinfarction', '(', 'n=1', 'per', 'group', ')', ',', 'and', 'heart', 'failure', '(', 'n=3', 'per', 'group', ')', '.']","(5, 6)","(34, 39)",-1,ss_o,20189026,Abstract,9,test,gold,2196.0
3368,"Major adverse coronary events were death ( n=3 per group ) ,",reinfarction,"( n=1 per group ) , and heart failure ( n=3 per group ) .","['Major', 'adverse', 'coronary', 'events', 'were', 'death', '(', 'n=3', 'per', 'group', ')', ',', 'reinfarction', '(', 'n=1', 'per', 'group', ')', ',', 'and', 'heart', 'failure', '(', 'n=3', 'per', 'group', ')', '.']","(12, 13)","(60, 72)",-1,ss_o,20189026,Abstract,9,test,gold,54.0
3369,"Major adverse coronary events were death ( n=3 per group ) , reinfarction ( n=1 per group ) , and",heart failure,( n=3 per group ) .,"['Major', 'adverse', 'coronary', 'events', 'were', 'death', '(', 'n=3', 'per', 'group', ')', ',', 'reinfarction', '(', 'n=1', 'per', 'group', ')', ',', 'and', 'heart', 'failure', '(', 'n=3', 'per', 'group', ')', '.']","(20, 22)","(97, 110)",-1,ss_o,20189026,Abstract,9,test,gold,7067.0
3370,,Major adverse coronary events,"were death ( n=3 per group ) , reinfarction ( n=1 per group ) , and heart failure ( n=3 per group ) .","['Major', 'adverse', 'coronary', 'events', 'were', 'death', '(', 'n=3', 'per', 'group', ')', ',', 'reinfarction', '(', 'n=1', 'per', 'group', ')', ',', 'and', 'heart', 'failure', '(', 'n=3', 'per', 'group', ')', '.']","(0, 4)","(0, 29)",-1,hl_o,20189026,Abstract,9,test,gold,3041.0
3371,Major adverse coronary events were,death,"( n=3 per group ) , reinfarction ( n=1 per group ) , and heart failure ( n=3 per group ) .","['Major', 'adverse', 'coronary', 'events', 'were', 'death', '(', 'n=3', 'per', 'group', ')', ',', 'reinfarction', '(', 'n=1', 'per', 'group', ')', ',', 'and', 'heart', 'failure', '(', 'n=3', 'per', 'group', ')', '.']","(5, 6)","(34, 39)",-1,hl_o,20189026,Abstract,9,test,gold,2197.0
3372,"Major adverse coronary events were death ( n=3 per group ) ,",reinfarction,"( n=1 per group ) , and heart failure ( n=3 per group ) .","['Major', 'adverse', 'coronary', 'events', 'were', 'death', '(', 'n=3', 'per', 'group', ')', ',', 'reinfarction', '(', 'n=1', 'per', 'group', ')', ',', 'and', 'heart', 'failure', '(', 'n=3', 'per', 'group', ')', '.']","(12, 13)","(60, 72)",-1,hl_o,20189026,Abstract,9,test,gold,55.0
3373,"Major adverse coronary events were death ( n=3 per group ) , reinfarction ( n=1 per group ) , and",heart failure,( n=3 per group ) .,"['Major', 'adverse', 'coronary', 'events', 'were', 'death', '(', 'n=3', 'per', 'group', ')', ',', 'reinfarction', '(', 'n=1', 'per', 'group', ')', ',', 'and', 'heart', 'failure', '(', 'n=3', 'per', 'group', ')', '.']","(20, 22)","(97, 110)",-1,hl_o,20189026,Abstract,9,test,gold,7068.0
3374,INTERPRETATION,Remote ischaemic conditioning,"before hospital admission increases myocardial salvage , and has a favourable safety profile .","['INTERPRETATION', 'Remote', 'ischaemic', 'conditioning', 'before', 'hospital', 'admission', 'increases', 'myocardial', 'salvage', ',', 'and', 'has', 'a', 'favourable', 'safety', 'profile', '.']","(1, 4)","(14, 43)",-1,ss_i,20189026,Abstract,10,test,gold,2805.0
3375,INTERPRETATION Remote ischaemic conditioning before hospital admission increases,myocardial salvage,", and has a favourable safety profile .","['INTERPRETATION', 'Remote', 'ischaemic', 'conditioning', 'before', 'hospital', 'admission', 'increases', 'myocardial', 'salvage', ',', 'and', 'has', 'a', 'favourable', 'safety', 'profile', '.']","(8, 10)","(80, 98)",-1,ss_o,20189026,Abstract,10,test,gold,3226.0
3376,"INTERPRETATION Remote ischaemic conditioning before hospital admission increases myocardial salvage , and has a favourable",safety profile .,,"['INTERPRETATION', 'Remote', 'ischaemic', 'conditioning', 'before', 'hospital', 'admission', 'increases', 'myocardial', 'salvage', ',', 'and', 'has', 'a', 'favourable', 'safety', 'profile', '.']","(15, 18)","(122, 138)",-1,ss_o,20189026,Abstract,10,test,gold,451.0
3377,INTERPRETATION,Remote ischaemic conditioning,"before hospital admission increases myocardial salvage , and has a favourable safety profile .","['INTERPRETATION', 'Remote', 'ischaemic', 'conditioning', 'before', 'hospital', 'admission', 'increases', 'myocardial', 'salvage', ',', 'and', 'has', 'a', 'favourable', 'safety', 'profile', '.']","(1, 4)","(14, 43)",-1,hl_i,20189026,Abstract,10,test,gold,2804.0
3378,INTERPRETATION Remote ischaemic conditioning before hospital admission increases,myocardial salvage,", and has a favourable safety profile .","['INTERPRETATION', 'Remote', 'ischaemic', 'conditioning', 'before', 'hospital', 'admission', 'increases', 'myocardial', 'salvage', ',', 'and', 'has', 'a', 'favourable', 'safety', 'profile', '.']","(8, 10)","(80, 98)",-1,hl_o,20189026,Abstract,10,test,gold,3225.0
3379,"INTERPRETATION Remote ischaemic conditioning before hospital admission increases myocardial salvage , and has a favourable",safety,profile .,"['INTERPRETATION', 'Remote', 'ischaemic', 'conditioning', 'before', 'hospital', 'admission', 'increases', 'myocardial', 'salvage', ',', 'and', 'has', 'a', 'favourable', 'safety', 'profile', '.']","(15, 16)","(122, 128)",-1,hl_o,20189026,Abstract,10,test,gold,469.0
3380,Our findings merit a larger trial to establish the effect of,remote conditioning,on clinical outcomes .,"['Our', 'findings', 'merit', 'a', 'larger', 'trial', 'to', 'establish', 'the', 'effect', 'of', 'remote', 'conditioning', 'on', 'clinical', 'outcomes', '.']","(11, 13)","(60, 79)",-1,ss_i,20189026,Abstract,11,test,gold,2795.0
3381,Our findings merit a larger trial to establish the effect of,remote conditioning,on clinical outcomes .,"['Our', 'findings', 'merit', 'a', 'larger', 'trial', 'to', 'establish', 'the', 'effect', 'of', 'remote', 'conditioning', 'on', 'clinical', 'outcomes', '.']","(11, 13)","(60, 79)",-1,hl_i,20189026,Abstract,11,test,gold,2794.0
3382,FUNDING Fondation Leducq .,,,"['FUNDING', 'Fondation', 'Leducq', '.']",,,,,20189026,Abstract,12,test,gold,
3383,Cryoprobe biopsy increases the diagnostic yield in,endobronchial tumor lesions .,,"['Cryoprobe', 'biopsy', 'increases', 'the', 'diagnostic', 'yield', 'in', 'endobronchial', 'tumor', 'lesions', '.']","(7, 11)","(50, 79)",-1,ss_p,20226474,Title,0,test,gold,6862.0
3384,,Cryoprobe biopsy,increases the diagnostic yield in endobronchial tumor lesions .,"['Cryoprobe', 'biopsy', 'increases', 'the', 'diagnostic', 'yield', 'in', 'endobronchial', 'tumor', 'lesions', '.']","(0, 2)","(0, 16)",-1,ss_i,20226474,Title,0,test,gold,4145.0
3385,Cryoprobe biopsy increases the,diagnostic yield,in endobronchial tumor lesions .,"['Cryoprobe', 'biopsy', 'increases', 'the', 'diagnostic', 'yield', 'in', 'endobronchial', 'tumor', 'lesions', '.']","(4, 6)","(30, 46)",-1,ss_o,20226474,Title,0,test,gold,1808.0
3386,Cryoprobe biopsy increases the diagnostic yield in,endobronchial tumor lesions .,,"['Cryoprobe', 'biopsy', 'increases', 'the', 'diagnostic', 'yield', 'in', 'endobronchial', 'tumor', 'lesions', '.']","(7, 11)","(50, 79)",-1,hl_p,20226474,Title,0,test,gold,6863.0
3387,,Cryoprobe biopsy,increases the diagnostic yield in endobronchial tumor lesions .,"['Cryoprobe', 'biopsy', 'increases', 'the', 'diagnostic', 'yield', 'in', 'endobronchial', 'tumor', 'lesions', '.']","(0, 2)","(0, 16)",-1,hl_i,20226474,Title,0,test,gold,4146.0
3388,OBJECTIVE Forceps biopsy is the standard method to obtain specimens in endoscopically visible lesions .,,,"['OBJECTIVE', 'Forceps', 'biopsy', 'is', 'the', 'standard', 'method', 'to', 'obtain', 'specimens', 'in', 'endoscopically', 'visible', 'lesions', '.']",,,,,20226474,Abstract,0,test,gold,
3389,It is common to combine forceps biopsy with cytology methods to increase the,diagnostic yield .,,"['It', 'is', 'common', 'to', 'combine', 'forceps', 'biopsy', 'with', 'cytology', 'methods', 'to', 'increase', 'the', 'diagnostic', 'yield', '.']","(13, 16)","(76, 94)",-1,ss_o,20226474,Abstract,1,test,gold,1809.0
3390,Although the flexible,cryoprobe,"has been established for bronchoscopic interventions in malignant stenosis , the obtained biopsies , called "" cryobiopsies , "" have not been investigated in a large cohort of patients .","['Although', 'the', 'flexible', 'cryoprobe', 'has', 'been', 'established', 'for', 'bronchoscopic', 'interventions', 'in', 'malignant', 'stenosis', ',', 'the', 'obtained', 'biopsies', ',', 'called', '""', 'cryobiopsies', ',', '""', 'have', 'not', 'been', 'investigated', 'in', 'a', 'large', 'cohort', 'of', 'patients', '.']","(3, 4)","(21, 30)",-1,ss_i,20226474,Abstract,2,test,gold,1033.0
3391,"Although the flexible cryoprobe has been established for bronchoscopic interventions in malignant stenosis , the obtained biopsies , called",""" cryobiopsies",", "" have not been investigated in a large cohort of patients .","['Although', 'the', 'flexible', 'cryoprobe', 'has', 'been', 'established', 'for', 'bronchoscopic', 'interventions', 'in', 'malignant', 'stenosis', ',', 'the', 'obtained', 'biopsies', ',', 'called', '""', 'cryobiopsies', ',', '""', 'have', 'not', 'been', 'investigated', 'in', 'a', 'large', 'cohort', 'of', 'patients', '.']","(19, 21)","(139, 153)",-1,ss_i,20226474,Abstract,2,test,gold,
3392,Although the flexible,cryoprobe,"has been established for bronchoscopic interventions in malignant stenosis , the obtained biopsies , called "" cryobiopsies , "" have not been investigated in a large cohort of patients .","['Although', 'the', 'flexible', 'cryoprobe', 'has', 'been', 'established', 'for', 'bronchoscopic', 'interventions', 'in', 'malignant', 'stenosis', ',', 'the', 'obtained', 'biopsies', ',', 'called', '""', 'cryobiopsies', ',', '""', 'have', 'not', 'been', 'investigated', 'in', 'a', 'large', 'cohort', 'of', 'patients', '.']","(3, 4)","(21, 30)",-1,hl_i,20226474,Abstract,2,test,gold,1034.0
3393,The aim of this feasibility study was to prospectively evaluate the diagnostic yield and safety of,cryobiopsy,and forceps biopsy .,"['The', 'aim', 'of', 'this', 'feasibility', 'study', 'was', 'to', 'prospectively', 'evaluate', 'the', 'diagnostic', 'yield', 'and', 'safety', 'of', 'cryobiopsy', 'and', 'forceps', 'biopsy', '.']","(16, 17)","(98, 108)",-1,ss_i,20226474,Abstract,3,test,gold,
3394,The aim of this feasibility study was to prospectively evaluate the diagnostic yield and safety of cryobiopsy and,forceps biopsy .,,"['The', 'aim', 'of', 'this', 'feasibility', 'study', 'was', 'to', 'prospectively', 'evaluate', 'the', 'diagnostic', 'yield', 'and', 'safety', 'of', 'cryobiopsy', 'and', 'forceps', 'biopsy', '.']","(18, 21)","(113, 129)",-1,ss_i,20226474,Abstract,3,test,gold,3636.0
3395,The aim of this feasibility study was to prospectively evaluate the,diagnostic yield,and safety of cryobiopsy and forceps biopsy .,"['The', 'aim', 'of', 'this', 'feasibility', 'study', 'was', 'to', 'prospectively', 'evaluate', 'the', 'diagnostic', 'yield', 'and', 'safety', 'of', 'cryobiopsy', 'and', 'forceps', 'biopsy', '.']","(11, 13)","(67, 83)",-1,ss_o,20226474,Abstract,3,test,gold,1807.0
3396,The aim of this feasibility study was to prospectively evaluate the diagnostic yield and,safety,of cryobiopsy and forceps biopsy .,"['The', 'aim', 'of', 'this', 'feasibility', 'study', 'was', 'to', 'prospectively', 'evaluate', 'the', 'diagnostic', 'yield', 'and', 'safety', 'of', 'cryobiopsy', 'and', 'forceps', 'biopsy', '.']","(14, 15)","(88, 94)",-1,ss_o,20226474,Abstract,3,test,gold,468.0
3397,The aim of this feasibility study was to prospectively evaluate the diagnostic yield and safety of,cryobiopsy,and forceps biopsy .,"['The', 'aim', 'of', 'this', 'feasibility', 'study', 'was', 'to', 'prospectively', 'evaluate', 'the', 'diagnostic', 'yield', 'and', 'safety', 'of', 'cryobiopsy', 'and', 'forceps', 'biopsy', '.']","(16, 17)","(98, 108)",-1,hl_i,20226474,Abstract,3,test,gold,
3398,The aim of this feasibility study was to prospectively evaluate the diagnostic yield and safety of cryobiopsy and,forceps biopsy .,,"['The', 'aim', 'of', 'this', 'feasibility', 'study', 'was', 'to', 'prospectively', 'evaluate', 'the', 'diagnostic', 'yield', 'and', 'safety', 'of', 'cryobiopsy', 'and', 'forceps', 'biopsy', '.']","(18, 21)","(113, 129)",-1,hl_i,20226474,Abstract,3,test,gold,3637.0
3399,"METHODS During a 6-year period ,",296 patients with visible endoluminal tumor lesions were included,in the study at the bronchoscopy unit of a university hospital .,"['METHODS', 'During', 'a', '6-year', 'period', ',', '296', 'patients', 'with', 'visible', 'endoluminal', 'tumor', 'lesions', 'were', 'included', 'in', 'the', 'study', 'at', 'the', 'bronchoscopy', 'unit', 'of', 'a', 'university', 'hospital', '.']","(6, 15)","(32, 97)",-1,ss_p,20226474,Abstract,4,test,gold,5958.0
3400,"METHODS During a 6-year period , 296 patients with visible endoluminal tumor lesions were included in the study at the",bronchoscopy unit of a university hospital .,,"['METHODS', 'During', 'a', '6-year', 'period', ',', '296', 'patients', 'with', 'visible', 'endoluminal', 'tumor', 'lesions', 'were', 'included', 'in', 'the', 'study', 'at', 'the', 'bronchoscopy', 'unit', 'of', 'a', 'university', 'hospital', '.']","(20, 27)","(118, 162)",-1,ss_p,20226474,Abstract,4,test,gold,3824.0
3401,"METHODS During a 6-year period ,",296 patients with visible endoluminal tumor lesions were included,in the study at the bronchoscopy unit of a university hospital .,"['METHODS', 'During', 'a', '6-year', 'period', ',', '296', 'patients', 'with', 'visible', 'endoluminal', 'tumor', 'lesions', 'were', 'included', 'in', 'the', 'study', 'at', 'the', 'bronchoscopy', 'unit', 'of', 'a', 'university', 'hospital', '.']","(6, 15)","(32, 97)",-1,hl_p,20226474,Abstract,4,test,gold,5959.0
3402,"METHODS During a 6-year period , 296 patients with visible endoluminal tumor lesions were included in the study at the",bronchoscopy unit of a university hospital .,,"['METHODS', 'During', 'a', '6-year', 'period', ',', '296', 'patients', 'with', 'visible', 'endoluminal', 'tumor', 'lesions', 'were', 'included', 'in', 'the', 'study', 'at', 'the', 'bronchoscopy', 'unit', 'of', 'a', 'university', 'hospital', '.']","(20, 27)","(118, 162)",-1,hl_p,20226474,Abstract,4,test,gold,3825.0
3403,"In the first consecutively conducted 55 cases , both techniques ,",forceps biopsy and cryobiopsy,", were applied simultaneously .","['In', 'the', 'first', 'consecutively', 'conducted', '55', 'cases', ',', 'both', 'techniques', ',', 'forceps', 'biopsy', 'and', 'cryobiopsy', ',', 'were', 'applied', 'simultaneously', '.']","(11, 15)","(65, 94)",-1,ss_i,20226474,Abstract,5,test,gold,3635.0
3404,"In the first consecutively conducted 55 cases , both techniques ,",forceps biopsy,"and cryobiopsy , were applied simultaneously .","['In', 'the', 'first', 'consecutively', 'conducted', '55', 'cases', ',', 'both', 'techniques', ',', 'forceps', 'biopsy', 'and', 'cryobiopsy', ',', 'were', 'applied', 'simultaneously', '.']","(11, 13)","(65, 79)",-1,hl_i,20226474,Abstract,5,test,gold,3634.0
3405,"In the first consecutively conducted 55 cases , both techniques , forceps biopsy and",cryobiopsy,", were applied simultaneously .","['In', 'the', 'first', 'consecutively', 'conducted', '55', 'cases', ',', 'both', 'techniques', ',', 'forceps', 'biopsy', 'and', 'cryobiopsy', ',', 'were', 'applied', 'simultaneously', '.']","(14, 15)","(84, 94)",-1,hl_i,20226474,Abstract,5,test,gold,
3406,,Pathologic and quantitative image analyses,were performed to evaluate the size and quality of the obtained specimens .,"['Pathologic', 'and', 'quantitative', 'image', 'analyses', 'were', 'performed', 'to', 'evaluate', 'the', 'size', 'and', 'quality', 'of', 'the', 'obtained', 'specimens', '.']","(0, 5)","(0, 42)",-1,ss_o,20226474,Abstract,6,test,gold,1842.0
3407,Pathologic and quantitative image analyses were performed to evaluate the,size and quality of the obtained specimens .,,"['Pathologic', 'and', 'quantitative', 'image', 'analyses', 'were', 'performed', 'to', 'evaluate', 'the', 'size', 'and', 'quality', 'of', 'the', 'obtained', 'specimens', '.']","(10, 18)","(73, 117)",-1,ss_o,20226474,Abstract,6,test,gold,1850.0
3408,We evaluated the safety and diagnostic yield to describe the feasibility of,cryobiopsy .,,"['We', 'evaluated', 'the', 'safety', 'and', 'diagnostic', 'yield', 'to', 'describe', 'the', 'feasibility', 'of', 'cryobiopsy', '.']","(12, 14)","(75, 87)",-1,ss_i,20226474,Abstract,7,test,gold,
3409,We evaluated the,safety,and diagnostic yield to describe the feasibility of cryobiopsy .,"['We', 'evaluated', 'the', 'safety', 'and', 'diagnostic', 'yield', 'to', 'describe', 'the', 'feasibility', 'of', 'cryobiopsy', '.']","(3, 4)","(16, 22)",-1,ss_o,20226474,Abstract,7,test,gold,467.0
3410,We evaluated the safety and,diagnostic yield,to describe the feasibility of cryobiopsy .,"['We', 'evaluated', 'the', 'safety', 'and', 'diagnostic', 'yield', 'to', 'describe', 'the', 'feasibility', 'of', 'cryobiopsy', '.']","(5, 7)","(27, 43)",-1,ss_o,20226474,Abstract,7,test,gold,1806.0
3411,We evaluated the safety and diagnostic yield to describe the,feasibility,of cryobiopsy .,"['We', 'evaluated', 'the', 'safety', 'and', 'diagnostic', 'yield', 'to', 'describe', 'the', 'feasibility', 'of', 'cryobiopsy', '.']","(10, 11)","(60, 71)",-1,ss_o,20226474,Abstract,7,test,gold,913.0
3412,We evaluated the safety and diagnostic yield to describe the feasibility of,cryobiopsy .,,"['We', 'evaluated', 'the', 'safety', 'and', 'diagnostic', 'yield', 'to', 'describe', 'the', 'feasibility', 'of', 'cryobiopsy', '.']","(12, 14)","(75, 87)",-1,hl_i,20226474,Abstract,7,test,gold,
3413,We evaluated the,safety,and diagnostic yield to describe the feasibility of cryobiopsy .,"['We', 'evaluated', 'the', 'safety', 'and', 'diagnostic', 'yield', 'to', 'describe', 'the', 'feasibility', 'of', 'cryobiopsy', '.']","(3, 4)","(16, 22)",-1,hl_o,20226474,Abstract,7,test,gold,466.0
3414,We evaluated the safety and,diagnostic yield,to describe the feasibility of cryobiopsy .,"['We', 'evaluated', 'the', 'safety', 'and', 'diagnostic', 'yield', 'to', 'describe', 'the', 'feasibility', 'of', 'cryobiopsy', '.']","(5, 7)","(27, 43)",-1,hl_o,20226474,Abstract,7,test,gold,1805.0
3415,RESULTS Comparative analysis of the first conducted and randomly assigned 55 cases revealed a significantly higher diagnostic yield for,cryobiopsy,"compared with forceps biopsy ( 89.1 % vs 65.5 % , P < .05 ) .","['RESULTS', 'Comparative', 'analysis', 'of', 'the', 'first', 'conducted', 'and', 'randomly', 'assigned', '55', 'cases', 'revealed', 'a', 'significantly', 'higher', 'diagnostic', 'yield', 'for', 'cryobiopsy', 'compared', 'with', 'forceps', 'biopsy', '(', '89.1', '%', 'vs', '65.5', '%', ',', 'P', '<', '.05', ')', '.']","(19, 20)","(135, 145)",-1,ss_i,20226474,Abstract,8,test,gold,
3416,RESULTS Comparative analysis of the first conducted and randomly assigned 55 cases revealed a significantly higher diagnostic yield for cryobiopsy compared with,forceps biopsy,"( 89.1 % vs 65.5 % , P < .05 ) .","['RESULTS', 'Comparative', 'analysis', 'of', 'the', 'first', 'conducted', 'and', 'randomly', 'assigned', '55', 'cases', 'revealed', 'a', 'significantly', 'higher', 'diagnostic', 'yield', 'for', 'cryobiopsy', 'compared', 'with', 'forceps', 'biopsy', '(', '89.1', '%', 'vs', '65.5', '%', ',', 'P', '<', '.05', ')', '.']","(22, 24)","(160, 174)",-1,ss_i,20226474,Abstract,8,test,gold,3633.0
3417,RESULTS Comparative analysis of the first conducted and randomly assigned 55 cases revealed a significantly higher,diagnostic yield,"for cryobiopsy compared with forceps biopsy ( 89.1 % vs 65.5 % , P < .05 ) .","['RESULTS', 'Comparative', 'analysis', 'of', 'the', 'first', 'conducted', 'and', 'randomly', 'assigned', '55', 'cases', 'revealed', 'a', 'significantly', 'higher', 'diagnostic', 'yield', 'for', 'cryobiopsy', 'compared', 'with', 'forceps', 'biopsy', '(', '89.1', '%', 'vs', '65.5', '%', ',', 'P', '<', '.05', ')', '.']","(16, 18)","(114, 130)",-1,ss_o,20226474,Abstract,8,test,gold,1804.0
3418,RESULTS Comparative analysis of the first conducted and randomly assigned 55 cases revealed a significantly higher diagnostic yield for,cryobiopsy,"compared with forceps biopsy ( 89.1 % vs 65.5 % , P < .05 ) .","['RESULTS', 'Comparative', 'analysis', 'of', 'the', 'first', 'conducted', 'and', 'randomly', 'assigned', '55', 'cases', 'revealed', 'a', 'significantly', 'higher', 'diagnostic', 'yield', 'for', 'cryobiopsy', 'compared', 'with', 'forceps', 'biopsy', '(', '89.1', '%', 'vs', '65.5', '%', ',', 'P', '<', '.05', ')', '.']","(19, 20)","(135, 145)",-1,hl_i,20226474,Abstract,8,test,gold,
3419,RESULTS Comparative analysis of the first conducted and randomly assigned 55 cases revealed a significantly higher diagnostic yield for cryobiopsy compared with,forceps biopsy,"( 89.1 % vs 65.5 % , P < .05 ) .","['RESULTS', 'Comparative', 'analysis', 'of', 'the', 'first', 'conducted', 'and', 'randomly', 'assigned', '55', 'cases', 'revealed', 'a', 'significantly', 'higher', 'diagnostic', 'yield', 'for', 'cryobiopsy', 'compared', 'with', 'forceps', 'biopsy', '(', '89.1', '%', 'vs', '65.5', '%', ',', 'P', '<', '.05', ')', '.']","(22, 24)","(160, 174)",-1,hl_i,20226474,Abstract,8,test,gold,3632.0
3420,RESULTS Comparative analysis of the first conducted and randomly assigned 55 cases revealed a significantly higher,diagnostic yield,"for cryobiopsy compared with forceps biopsy ( 89.1 % vs 65.5 % , P < .05 ) .","['RESULTS', 'Comparative', 'analysis', 'of', 'the', 'first', 'conducted', 'and', 'randomly', 'assigned', '55', 'cases', 'revealed', 'a', 'significantly', 'higher', 'diagnostic', 'yield', 'for', 'cryobiopsy', 'compared', 'with', 'forceps', 'biopsy', '(', '89.1', '%', 'vs', '65.5', '%', ',', 'P', '<', '.05', ')', '.']","(16, 18)","(114, 130)",-1,hl_o,20226474,Abstract,8,test,gold,1803.0
3421,"In this cohort , quantitative image analysis showed significantly larger biopsies regarding size and artifact-free tissue sections for",cryobiopsy,compared with forceps biopsy ( P < .0001 ) .,"['In', 'this', 'cohort', ',', 'quantitative', 'image', 'analysis', 'showed', 'significantly', 'larger', 'biopsies', 'regarding', 'size', 'and', 'artifact-free', 'tissue', 'sections', 'for', 'cryobiopsy', 'compared', 'with', 'forceps', 'biopsy', '(', 'P', '<', '.0001', ')', '.']","(18, 19)","(134, 144)",-1,ss_i,20226474,Abstract,9,test,gold,
3422,"In this cohort , quantitative image analysis showed significantly larger biopsies regarding size and artifact-free tissue sections for cryobiopsy compared with",forceps biopsy,( P < .0001 ) .,"['In', 'this', 'cohort', ',', 'quantitative', 'image', 'analysis', 'showed', 'significantly', 'larger', 'biopsies', 'regarding', 'size', 'and', 'artifact-free', 'tissue', 'sections', 'for', 'cryobiopsy', 'compared', 'with', 'forceps', 'biopsy', '(', 'P', '<', '.0001', ')', '.']","(21, 23)","(159, 173)",-1,ss_i,20226474,Abstract,9,test,gold,3631.0
3423,"In this cohort ,",quantitative image analysis,showed significantly larger biopsies regarding size and artifact-free tissue sections for cryobiopsy compared with forceps biopsy ( P < .0001 ) .,"['In', 'this', 'cohort', ',', 'quantitative', 'image', 'analysis', 'showed', 'significantly', 'larger', 'biopsies', 'regarding', 'size', 'and', 'artifact-free', 'tissue', 'sections', 'for', 'cryobiopsy', 'compared', 'with', 'forceps', 'biopsy', '(', 'P', '<', '.0001', ')', '.']","(4, 7)","(16, 43)",-1,ss_o,20226474,Abstract,9,test,gold,1843.0
3424,"In this cohort , quantitative image analysis showed significantly larger biopsies regarding",size,and artifact-free tissue sections for cryobiopsy compared with forceps biopsy ( P < .0001 ) .,"['In', 'this', 'cohort', ',', 'quantitative', 'image', 'analysis', 'showed', 'significantly', 'larger', 'biopsies', 'regarding', 'size', 'and', 'artifact-free', 'tissue', 'sections', 'for', 'cryobiopsy', 'compared', 'with', 'forceps', 'biopsy', '(', 'P', '<', '.0001', ')', '.']","(12, 13)","(91, 95)",-1,ss_o,20226474,Abstract,9,test,gold,1370.0
3425,"In this cohort , quantitative image analysis showed significantly larger biopsies regarding size and artifact-free tissue sections for",cryobiopsy,compared with forceps biopsy ( P < .0001 ) .,"['In', 'this', 'cohort', ',', 'quantitative', 'image', 'analysis', 'showed', 'significantly', 'larger', 'biopsies', 'regarding', 'size', 'and', 'artifact-free', 'tissue', 'sections', 'for', 'cryobiopsy', 'compared', 'with', 'forceps', 'biopsy', '(', 'P', '<', '.0001', ')', '.']","(18, 19)","(134, 144)",-1,hl_i,20226474,Abstract,9,test,gold,
3426,"In this cohort , quantitative image analysis showed significantly larger biopsies regarding size and artifact-free tissue sections for cryobiopsy compared with",forceps biopsy,( P < .0001 ) .,"['In', 'this', 'cohort', ',', 'quantitative', 'image', 'analysis', 'showed', 'significantly', 'larger', 'biopsies', 'regarding', 'size', 'and', 'artifact-free', 'tissue', 'sections', 'for', 'cryobiopsy', 'compared', 'with', 'forceps', 'biopsy', '(', 'P', '<', '.0001', ')', '.']","(21, 23)","(159, 173)",-1,hl_i,20226474,Abstract,9,test,gold,3630.0
3427,"In this cohort , quantitative image analysis showed significantly larger biopsies regarding",size,and artifact-free tissue sections for cryobiopsy compared with forceps biopsy ( P < .0001 ) .,"['In', 'this', 'cohort', ',', 'quantitative', 'image', 'analysis', 'showed', 'significantly', 'larger', 'biopsies', 'regarding', 'size', 'and', 'artifact-free', 'tissue', 'sections', 'for', 'cryobiopsy', 'compared', 'with', 'forceps', 'biopsy', '(', 'P', '<', '.0001', ')', '.']","(12, 13)","(91, 95)",-1,hl_o,20226474,Abstract,9,test,gold,1371.0
3428,The overall diagnostic yield of,cryobiopsy,was 89.5 % .,"['The', 'overall', 'diagnostic', 'yield', 'of', 'cryobiopsy', 'was', '89.5', '%', '.']","(5, 6)","(31, 41)",-1,ss_i,20226474,Abstract,10,test,gold,
3429,The,overall diagnostic yield,of cryobiopsy was 89.5 % .,"['The', 'overall', 'diagnostic', 'yield', 'of', 'cryobiopsy', 'was', '89.5', '%', '.']","(1, 4)","(3, 27)",-1,ss_o,20226474,Abstract,10,test,gold,1799.0
3430,The overall diagnostic yield of,cryobiopsy,was 89.5 % .,"['The', 'overall', 'diagnostic', 'yield', 'of', 'cryobiopsy', 'was', '89.5', '%', '.']","(5, 6)","(31, 41)",-1,hl_i,20226474,Abstract,10,test,gold,
3431,The overall,diagnostic yield,of cryobiopsy was 89.5 % .,"['The', 'overall', 'diagnostic', 'yield', 'of', 'cryobiopsy', 'was', '89.5', '%', '.']","(2, 4)","(11, 27)",-1,hl_o,20226474,Abstract,10,test,gold,1802.0
3432,Mild,bleeding,"occurred in 11 cases ( 3.7 % ) , moderate bleeding occurred in 3 cases ( 1.0 % ) , and severe bleeding occurred in 1 case ( 0.3 % ) .","['Mild', 'bleeding', 'occurred', 'in', '11', 'cases', '(', '3.7', '%', ')', ',', 'moderate', 'bleeding', 'occurred', 'in', '3', 'cases', '(', '1.0', '%', ')', ',', 'and', 'severe', 'bleeding', 'occurred', 'in', '1', 'case', '(', '0.3', '%', ')', '.']","(1, 2)","(4, 12)",-1,ss_o,20226474,Abstract,11,test,gold,2654.0
3433,"Mild bleeding occurred in 11 cases ( 3.7 % ) , moderate",bleeding,"occurred in 3 cases ( 1.0 % ) , and severe bleeding occurred in 1 case ( 0.3 % ) .","['Mild', 'bleeding', 'occurred', 'in', '11', 'cases', '(', '3.7', '%', ')', ',', 'moderate', 'bleeding', 'occurred', 'in', '3', 'cases', '(', '1.0', '%', ')', ',', 'and', 'severe', 'bleeding', 'occurred', 'in', '1', 'case', '(', '0.3', '%', ')', '.']","(12, 13)","(55, 63)",-1,ss_o,20226474,Abstract,11,test,gold,2652.0
3434,"Mild bleeding occurred in 11 cases ( 3.7 % ) , moderate bleeding occurred in 3 cases ( 1.0 % ) , and severe",bleeding,occurred in 1 case ( 0.3 % ) .,"['Mild', 'bleeding', 'occurred', 'in', '11', 'cases', '(', '3.7', '%', ')', ',', 'moderate', 'bleeding', 'occurred', 'in', '3', 'cases', '(', '1.0', '%', ')', ',', 'and', 'severe', 'bleeding', 'occurred', 'in', '1', 'case', '(', '0.3', '%', ')', '.']","(24, 25)","(107, 115)",-1,ss_o,20226474,Abstract,11,test,gold,2651.0
3435,Mild,bleeding,"occurred in 11 cases ( 3.7 % ) , moderate bleeding occurred in 3 cases ( 1.0 % ) , and severe bleeding occurred in 1 case ( 0.3 % ) .","['Mild', 'bleeding', 'occurred', 'in', '11', 'cases', '(', '3.7', '%', ')', ',', 'moderate', 'bleeding', 'occurred', 'in', '3', 'cases', '(', '1.0', '%', ')', ',', 'and', 'severe', 'bleeding', 'occurred', 'in', '1', 'case', '(', '0.3', '%', ')', '.']","(1, 2)","(4, 12)",-1,hl_o,20226474,Abstract,11,test,gold,2650.0
3436,"Mild bleeding occurred in 11 cases ( 3.7 % ) , moderate",bleeding,"occurred in 3 cases ( 1.0 % ) , and severe bleeding occurred in 1 case ( 0.3 % ) .","['Mild', 'bleeding', 'occurred', 'in', '11', 'cases', '(', '3.7', '%', ')', ',', 'moderate', 'bleeding', 'occurred', 'in', '3', 'cases', '(', '1.0', '%', ')', ',', 'and', 'severe', 'bleeding', 'occurred', 'in', '1', 'case', '(', '0.3', '%', ')', '.']","(12, 13)","(55, 63)",-1,hl_o,20226474,Abstract,11,test,gold,2649.0
3437,"Mild bleeding occurred in 11 cases ( 3.7 % ) , moderate bleeding occurred in 3 cases ( 1.0 % ) , and severe",bleeding,occurred in 1 case ( 0.3 % ) .,"['Mild', 'bleeding', 'occurred', 'in', '11', 'cases', '(', '3.7', '%', ')', ',', 'moderate', 'bleeding', 'occurred', 'in', '3', 'cases', '(', '1.0', '%', ')', ',', 'and', 'severe', 'bleeding', 'occurred', 'in', '1', 'case', '(', '0.3', '%', ')', '.']","(24, 25)","(107, 115)",-1,hl_o,20226474,Abstract,11,test,gold,2648.0
3438,CONCLUSION,Cryobiopsy,is safe and increases the diagnostic yield in endobronchial tumor lesions .,"['CONCLUSION', 'Cryobiopsy', 'is', 'safe', 'and', 'increases', 'the', 'diagnostic', 'yield', 'in', 'endobronchial', 'tumor', 'lesions', '.']","(1, 2)","(10, 20)",-1,ss_i,20226474,Abstract,12,test,gold,
3439,CONCLUSION Cryobiopsy is,safe,and increases the diagnostic yield in endobronchial tumor lesions .,"['CONCLUSION', 'Cryobiopsy', 'is', 'safe', 'and', 'increases', 'the', 'diagnostic', 'yield', 'in', 'endobronchial', 'tumor', 'lesions', '.']","(3, 4)","(24, 28)",-1,ss_o,20226474,Abstract,12,test,gold,881.0
3440,CONCLUSION Cryobiopsy is safe and increases the,diagnostic yield,in endobronchial tumor lesions .,"['CONCLUSION', 'Cryobiopsy', 'is', 'safe', 'and', 'increases', 'the', 'diagnostic', 'yield', 'in', 'endobronchial', 'tumor', 'lesions', '.']","(7, 9)","(47, 63)",-1,ss_o,20226474,Abstract,12,test,gold,1801.0
3441,CONCLUSION,Cryobiopsy,is safe and increases the diagnostic yield in endobronchial tumor lesions .,"['CONCLUSION', 'Cryobiopsy', 'is', 'safe', 'and', 'increases', 'the', 'diagnostic', 'yield', 'in', 'endobronchial', 'tumor', 'lesions', '.']","(1, 2)","(10, 20)",-1,hl_i,20226474,Abstract,12,test,gold,
3442,CONCLUSION Cryobiopsy is,safe,and increases the diagnostic yield in endobronchial tumor lesions .,"['CONCLUSION', 'Cryobiopsy', 'is', 'safe', 'and', 'increases', 'the', 'diagnostic', 'yield', 'in', 'endobronchial', 'tumor', 'lesions', '.']","(3, 4)","(24, 28)",-1,hl_o,20226474,Abstract,12,test,gold,880.0
3443,CONCLUSION Cryobiopsy is safe and increases the,diagnostic yield,in endobronchial tumor lesions .,"['CONCLUSION', 'Cryobiopsy', 'is', 'safe', 'and', 'increases', 'the', 'diagnostic', 'yield', 'in', 'endobronchial', 'tumor', 'lesions', '.']","(7, 9)","(47, 63)",-1,hl_o,20226474,Abstract,12,test,gold,1800.0
3444,The method also is,feasible,under routine conditions .,"['The', 'method', 'also', 'is', 'feasible', 'under', 'routine', 'conditions', '.']","(4, 5)","(18, 26)",-1,ss_o,20226474,Abstract,13,test,gold,866.0
3445,The method also is,feasible,under routine conditions .,"['The', 'method', 'also', 'is', 'feasible', 'under', 'routine', 'conditions', '.']","(4, 5)","(18, 26)",-1,hl_o,20226474,Abstract,13,test,gold,865.0
3446,Virtual reality hypnosis for pain associated with recovery from,physical trauma .,,"['Virtual', 'reality', 'hypnosis', 'for', 'pain', 'associated', 'with', 'recovery', 'from', 'physical', 'trauma', '.']","(9, 12)","(63, 80)",-1,ss_p,20509069,Title,0,test,gold,2564.0
3447,,Virtual reality hypnosis,for pain associated with recovery from physical trauma .,"['Virtual', 'reality', 'hypnosis', 'for', 'pain', 'associated', 'with', 'recovery', 'from', 'physical', 'trauma', '.']","(0, 3)","(0, 24)",-1,ss_i,20509069,Title,0,test,gold,4170.0
3448,Virtual reality hypnosis for pain associated with recovery from,physical trauma .,,"['Virtual', 'reality', 'hypnosis', 'for', 'pain', 'associated', 'with', 'recovery', 'from', 'physical', 'trauma', '.']","(9, 12)","(63, 80)",-1,hl_p,20509069,Title,0,test,gold,2565.0
3449,,Virtual reality hypnosis,for pain associated with recovery from physical trauma .,"['Virtual', 'reality', 'hypnosis', 'for', 'pain', 'associated', 'with', 'recovery', 'from', 'physical', 'trauma', '.']","(0, 3)","(0, 24)",-1,hl_i,20509069,Title,0,test,gold,4171.0
3450,"Pain following traumatic injuries is common , can impair injury recovery and is often inadequately treated .",,,"['Pain', 'following', 'traumatic', 'injuries', 'is', 'common', ',', 'can', 'impair', 'injury', 'recovery', 'and', 'is', 'often', 'inadequately', 'treated', '.']",,,,,20509069,Abstract,0,test,gold,
3451,"In particular , the role of adjunctive nonpharmacologic analgesic techniques is unclear .",,,"['In', 'particular', ',', 'the', 'role', 'of', 'adjunctive', 'nonpharmacologic', 'analgesic', 'techniques', 'is', 'unclear', '.']",,,,,20509069,Abstract,1,test,gold,
3452,"The authors report a randomized , controlled study of",21 hospitalized trauma patients,to assess the analgesic efficacy of virtual reality hypnosis ( VRH ) -hypnotic induction and analgesic suggestion delivered by customized virtual reality ( VR ) hardware/software .,"['The', 'authors', 'report', 'a', 'randomized', ',', 'controlled', 'study', 'of', '21', 'hospitalized', 'trauma', 'patients', 'to', 'assess', 'the', 'analgesic', 'efficacy', 'of', 'virtual', 'reality', 'hypnosis', '(', 'VRH', ')', '-hypnotic', 'induction', 'and', 'analgesic', 'suggestion', 'delivered', 'by', 'customized', 'virtual', 'reality', '(', 'VR', ')', 'hardware/software', '.']","(9, 13)","(53, 84)",-1,ss_p,20509069,Abstract,2,test,gold,3826.0
3453,"The authors report a randomized , controlled study of 21 hospitalized trauma patients to assess the analgesic efficacy of",virtual reality hypnosis ( VRH ) -hypnotic induction,and analgesic suggestion delivered by customized virtual reality ( VR ) hardware/software .,"['The', 'authors', 'report', 'a', 'randomized', ',', 'controlled', 'study', 'of', '21', 'hospitalized', 'trauma', 'patients', 'to', 'assess', 'the', 'analgesic', 'efficacy', 'of', 'virtual', 'reality', 'hypnosis', '(', 'VRH', ')', '-hypnotic', 'induction', 'and', 'analgesic', 'suggestion', 'delivered', 'by', 'customized', 'virtual', 'reality', '(', 'VR', ')', 'hardware/software', '.']","(19, 27)","(121, 173)",-1,ss_i,20509069,Abstract,2,test,gold,4167.0
3454,"The authors report a randomized , controlled study of 21 hospitalized trauma patients to assess the",analgesic efficacy,of virtual reality hypnosis ( VRH ) -hypnotic induction and analgesic suggestion delivered by customized virtual reality ( VR ) hardware/software .,"['The', 'authors', 'report', 'a', 'randomized', ',', 'controlled', 'study', 'of', '21', 'hospitalized', 'trauma', 'patients', 'to', 'assess', 'the', 'analgesic', 'efficacy', 'of', 'virtual', 'reality', 'hypnosis', '(', 'VRH', ')', '-hypnotic', 'induction', 'and', 'analgesic', 'suggestion', 'delivered', 'by', 'customized', 'virtual', 'reality', '(', 'VR', ')', 'hardware/software', '.']","(16, 18)","(99, 117)",-1,ss_o,20509069,Abstract,2,test,gold,4856.0
3455,"The authors report a randomized , controlled study of 21 hospitalized trauma patients to assess the analgesic efficacy of virtual reality hypnosis ( VRH ) -hypnotic induction and",analgesic suggestion,delivered by customized virtual reality ( VR ) hardware/software .,"['The', 'authors', 'report', 'a', 'randomized', ',', 'controlled', 'study', 'of', '21', 'hospitalized', 'trauma', 'patients', 'to', 'assess', 'the', 'analgesic', 'efficacy', 'of', 'virtual', 'reality', 'hypnosis', '(', 'VRH', ')', '-hypnotic', 'induction', 'and', 'analgesic', 'suggestion', 'delivered', 'by', 'customized', 'virtual', 'reality', '(', 'VR', ')', 'hardware/software', '.']","(28, 30)","(178, 198)",-1,ss_o,20509069,Abstract,2,test,gold,5600.0
3456,"The authors report a randomized , controlled study of",21 hospitalized trauma patients,to assess the analgesic efficacy of virtual reality hypnosis ( VRH ) -hypnotic induction and analgesic suggestion delivered by customized virtual reality ( VR ) hardware/software .,"['The', 'authors', 'report', 'a', 'randomized', ',', 'controlled', 'study', 'of', '21', 'hospitalized', 'trauma', 'patients', 'to', 'assess', 'the', 'analgesic', 'efficacy', 'of', 'virtual', 'reality', 'hypnosis', '(', 'VRH', ')', '-hypnotic', 'induction', 'and', 'analgesic', 'suggestion', 'delivered', 'by', 'customized', 'virtual', 'reality', '(', 'VR', ')', 'hardware/software', '.']","(9, 13)","(53, 84)",-1,hl_p,20509069,Abstract,2,test,gold,3827.0
3457,"The authors report a randomized , controlled study of 21 hospitalized trauma patients to assess the analgesic efficacy of",virtual reality hypnosis ( VRH ) -hypnotic induction,and analgesic suggestion delivered by customized virtual reality ( VR ) hardware/software .,"['The', 'authors', 'report', 'a', 'randomized', ',', 'controlled', 'study', 'of', '21', 'hospitalized', 'trauma', 'patients', 'to', 'assess', 'the', 'analgesic', 'efficacy', 'of', 'virtual', 'reality', 'hypnosis', '(', 'VRH', ')', '-hypnotic', 'induction', 'and', 'analgesic', 'suggestion', 'delivered', 'by', 'customized', 'virtual', 'reality', '(', 'VR', ')', 'hardware/software', '.']","(19, 27)","(121, 173)",-1,hl_i,20509069,Abstract,2,test,gold,4168.0
3458,Subjective pain ratings were obtained immediately and 8 hours after,VRH,( used as an adjunct to standard analgesic care ) and compared to both adjunctive VR without hypnosis and standard care alone .,"['Subjective', 'pain', 'ratings', 'were', 'obtained', 'immediately', 'and', '8', 'hours', 'after', 'VRH', '(', 'used', 'as', 'an', 'adjunct', 'to', 'standard', 'analgesic', 'care', ')', 'and', 'compared', 'to', 'both', 'adjunctive', 'VR', 'without', 'hypnosis', 'and', 'standard', 'care', 'alone', '.']","(10, 11)","(67, 70)",-1,ss_i,20509069,Abstract,3,test,gold,1067.0
3459,Subjective pain ratings were obtained immediately and 8 hours after VRH ( used as an adjunct to standard analgesic care ) and compared to both adjunctive,VR without hypnosis,and standard care alone .,"['Subjective', 'pain', 'ratings', 'were', 'obtained', 'immediately', 'and', '8', 'hours', 'after', 'VRH', '(', 'used', 'as', 'an', 'adjunct', 'to', 'standard', 'analgesic', 'care', ')', 'and', 'compared', 'to', 'both', 'adjunctive', 'VR', 'without', 'hypnosis', 'and', 'standard', 'care', 'alone', '.']","(26, 29)","(153, 172)",-1,ss_i,20509069,Abstract,3,test,gold,4169.0
3460,Subjective pain ratings were obtained immediately and 8 hours after VRH ( used as an adjunct to standard analgesic care ) and compared to both adjunctive VR without hypnosis and,standard care,alone .,"['Subjective', 'pain', 'ratings', 'were', 'obtained', 'immediately', 'and', '8', 'hours', 'after', 'VRH', '(', 'used', 'as', 'an', 'adjunct', 'to', 'standard', 'analgesic', 'care', ')', 'and', 'compared', 'to', 'both', 'adjunctive', 'VR', 'without', 'hypnosis', 'and', 'standard', 'care', 'alone', '.']","(30, 32)","(177, 190)",-1,ss_i,20509069,Abstract,3,test,gold,3954.0
3461,,Subjective pain ratings,were obtained immediately and 8 hours after VRH ( used as an adjunct to standard analgesic care ) and compared to both adjunctive VR without hypnosis and standard care alone .,"['Subjective', 'pain', 'ratings', 'were', 'obtained', 'immediately', 'and', '8', 'hours', 'after', 'VRH', '(', 'used', 'as', 'an', 'adjunct', 'to', 'standard', 'analgesic', 'care', ')', 'and', 'compared', 'to', 'both', 'adjunctive', 'VR', 'without', 'hypnosis', 'and', 'standard', 'care', 'alone', '.']","(0, 3)","(0, 23)",-1,ss_o,20509069,Abstract,3,test,gold,6232.0
3462,,Subjective pain ratings,were obtained immediately and 8 hours after VRH ( used as an adjunct to standard analgesic care ) and compared to both adjunctive VR without hypnosis and standard care alone .,"['Subjective', 'pain', 'ratings', 'were', 'obtained', 'immediately', 'and', '8', 'hours', 'after', 'VRH', '(', 'used', 'as', 'an', 'adjunct', 'to', 'standard', 'analgesic', 'care', ')', 'and', 'compared', 'to', 'both', 'adjunctive', 'VR', 'without', 'hypnosis', 'and', 'standard', 'care', 'alone', '.']","(0, 3)","(0, 23)",-1,hl_o,20509069,Abstract,3,test,gold,6233.0
3463,,VRH,patients reported less pain intensity and less pain unpleasantness compared to control groups .,"['VRH', 'patients', 'reported', 'less', 'pain', 'intensity', 'and', 'less', 'pain', 'unpleasantness', 'compared', 'to', 'control', 'groups', '.']","(0, 1)","(0, 3)",-1,ss_i,20509069,Abstract,4,test,gold,1068.0
3464,VRH patients reported less,pain intensity,and less pain unpleasantness compared to control groups .,"['VRH', 'patients', 'reported', 'less', 'pain', 'intensity', 'and', 'less', 'pain', 'unpleasantness', 'compared', 'to', 'control', 'groups', '.']","(4, 6)","(26, 40)",-1,ss_o,20509069,Abstract,4,test,gold,2314.0
3465,VRH patients reported less pain intensity and less,pain unpleasantness,compared to control groups .,"['VRH', 'patients', 'reported', 'less', 'pain', 'intensity', 'and', 'less', 'pain', 'unpleasantness', 'compared', 'to', 'control', 'groups', '.']","(8, 10)","(50, 69)",-1,ss_o,20509069,Abstract,4,test,gold,2676.0
3466,VRH patients reported less,pain intensity,and less pain unpleasantness compared to control groups .,"['VRH', 'patients', 'reported', 'less', 'pain', 'intensity', 'and', 'less', 'pain', 'unpleasantness', 'compared', 'to', 'control', 'groups', '.']","(4, 6)","(26, 40)",-1,hl_o,20509069,Abstract,4,test,gold,2315.0
3467,VRH patients reported less pain intensity and less,pain unpleasantness,compared to control groups .,"['VRH', 'patients', 'reported', 'less', 'pain', 'intensity', 'and', 'less', 'pain', 'unpleasantness', 'compared', 'to', 'control', 'groups', '.']","(8, 10)","(50, 69)",-1,hl_o,20509069,Abstract,4,test,gold,2677.0
3468,These preliminary findings suggest that,VRH,"analgesia is a novel technology worthy of further study , both to improve pain management and to increase availability of hypnotic analgesia to populations without access to therapist-provided hypnosis and suggestion .","['These', 'preliminary', 'findings', 'suggest', 'that', 'VRH', 'analgesia', 'is', 'a', 'novel', 'technology', 'worthy', 'of', 'further', 'study', ',', 'both', 'to', 'improve', 'pain', 'management', 'and', 'to', 'increase', 'availability', 'of', 'hypnotic', 'analgesia', 'to', 'populations', 'without', 'access', 'to', 'therapist-provided', 'hypnosis', 'and', 'suggestion', '.']","(5, 6)","(39, 42)",-1,ss_i,20509069,Abstract,5,test,gold,1066.0
3469,"These preliminary findings suggest that VRH analgesia is a novel technology worthy of further study , both to improve",pain management,and to increase availability of hypnotic analgesia to populations without access to therapist-provided hypnosis and suggestion .,"['These', 'preliminary', 'findings', 'suggest', 'that', 'VRH', 'analgesia', 'is', 'a', 'novel', 'technology', 'worthy', 'of', 'further', 'study', ',', 'both', 'to', 'improve', 'pain', 'management', 'and', 'to', 'increase', 'availability', 'of', 'hypnotic', 'analgesia', 'to', 'populations', 'without', 'access', 'to', 'therapist-provided', 'hypnosis', 'and', 'suggestion', '.']","(19, 21)","(117, 132)",-1,ss_o,20509069,Abstract,5,test,gold,2304.0
3470,These preliminary findings suggest that,VRH,"analgesia is a novel technology worthy of further study , both to improve pain management and to increase availability of hypnotic analgesia to populations without access to therapist-provided hypnosis and suggestion .","['These', 'preliminary', 'findings', 'suggest', 'that', 'VRH', 'analgesia', 'is', 'a', 'novel', 'technology', 'worthy', 'of', 'further', 'study', ',', 'both', 'to', 'improve', 'pain', 'management', 'and', 'to', 'increase', 'availability', 'of', 'hypnotic', 'analgesia', 'to', 'populations', 'without', 'access', 'to', 'therapist-provided', 'hypnosis', 'and', 'suggestion', '.']","(5, 6)","(39, 42)",-1,hl_i,20509069,Abstract,5,test,gold,1065.0
3471,"These preliminary findings suggest that VRH analgesia is a novel technology worthy of further study , both to improve",pain management,and to increase availability of hypnotic analgesia to populations without access to therapist-provided hypnosis and suggestion .,"['These', 'preliminary', 'findings', 'suggest', 'that', 'VRH', 'analgesia', 'is', 'a', 'novel', 'technology', 'worthy', 'of', 'further', 'study', ',', 'both', 'to', 'improve', 'pain', 'management', 'and', 'to', 'increase', 'availability', 'of', 'hypnotic', 'analgesia', 'to', 'populations', 'without', 'access', 'to', 'therapist-provided', 'hypnosis', 'and', 'suggestion', '.']","(19, 21)","(117, 132)",-1,hl_o,20509069,Abstract,5,test,gold,2305.0
3472,Influence of diets rich in,Maillard reaction products,on calcium bioavailability .,"['Influence', 'of', 'diets', 'rich', 'in', 'Maillard', 'reaction', 'products', 'on', 'calcium', 'bioavailability', '.']","(5, 8)","(26, 52)",-1,ss_i,20560622,Title,0,test,gold,2505.0
3473,Influence of diets rich in Maillard reaction products on,calcium bioavailability .,,"['Influence', 'of', 'diets', 'rich', 'in', 'Maillard', 'reaction', 'products', 'on', 'calcium', 'bioavailability', '.']","(9, 12)","(56, 81)",-1,ss_o,20560622,Title,0,test,gold,4643.0
3474,Influence of diets rich in,Maillard reaction products,on calcium bioavailability .,"['Influence', 'of', 'diets', 'rich', 'in', 'Maillard', 'reaction', 'products', 'on', 'calcium', 'bioavailability', '.']","(5, 8)","(26, 52)",-1,hl_i,20560622,Title,0,test,gold,2506.0
3475,Influence of diets rich in Maillard reaction products on,calcium bioavailability .,,"['Influence', 'of', 'diets', 'rich', 'in', 'Maillard', 'reaction', 'products', 'on', 'calcium', 'bioavailability', '.']","(9, 12)","(56, 81)",-1,hl_o,20560622,Title,0,test,gold,4644.0
3476,Assays in,male adolescents,and in Caco-2 cells .,"['Assays', 'in', 'male', 'adolescents', 'and', 'in', 'Caco-2', 'cells', '.']","(2, 4)","(9, 25)",-1,ss_p,20560622,Abstract,0,test,gold,2102.0
3477,Assays in,male adolescents,and in Caco-2 cells .,"['Assays', 'in', 'male', 'adolescents', 'and', 'in', 'Caco-2', 'cells', '.']","(2, 4)","(9, 25)",-1,hl_p,20560622,Abstract,0,test,gold,2103.0
3478,The effects of the high intake of Maillard reaction products ( MRP ) on calcium availability in,adolescents,and across Caco-2 cell monolayers were examined .,"['The', 'effects', 'of', 'the', 'high', 'intake', 'of', 'Maillard', 'reaction', 'products', '(', 'MRP', ')', 'on', 'calcium', 'availability', 'in', 'adolescents', 'and', 'across', 'Caco-2', 'cell', 'monolayers', 'were', 'examined', '.']","(17, 18)","(95, 106)",-1,ss_p,20560622,Abstract,1,test,gold,2164.0
3479,The effects of the high intake of,Maillard reaction products ( MRP ),on calcium availability in adolescents and across Caco-2 cell monolayers were examined .,"['The', 'effects', 'of', 'the', 'high', 'intake', 'of', 'Maillard', 'reaction', 'products', '(', 'MRP', ')', 'on', 'calcium', 'availability', 'in', 'adolescents', 'and', 'across', 'Caco-2', 'cell', 'monolayers', 'were', 'examined', '.']","(7, 13)","(33, 67)",-1,ss_i,20560622,Abstract,1,test,gold,2507.0
3480,The effects of the high intake of Maillard reaction products ( MRP ) on,calcium availability,in adolescents and across Caco-2 cell monolayers were examined .,"['The', 'effects', 'of', 'the', 'high', 'intake', 'of', 'Maillard', 'reaction', 'products', '(', 'MRP', ')', 'on', 'calcium', 'availability', 'in', 'adolescents', 'and', 'across', 'Caco-2', 'cell', 'monolayers', 'were', 'examined', '.']","(14, 16)","(71, 91)",-1,ss_o,20560622,Abstract,1,test,gold,1596.0
3481,The effects of the high intake of Maillard reaction products ( MRP ) on calcium availability in,adolescents,and across Caco-2 cell monolayers were examined .,"['The', 'effects', 'of', 'the', 'high', 'intake', 'of', 'Maillard', 'reaction', 'products', '(', 'MRP', ')', 'on', 'calcium', 'availability', 'in', 'adolescents', 'and', 'across', 'Caco-2', 'cell', 'monolayers', 'were', 'examined', '.']","(17, 18)","(95, 106)",-1,hl_p,20560622,Abstract,1,test,gold,2165.0
3482,The effects of the high intake of,Maillard reaction products ( MRP ),on calcium availability in adolescents and across Caco-2 cell monolayers were examined .,"['The', 'effects', 'of', 'the', 'high', 'intake', 'of', 'Maillard', 'reaction', 'products', '(', 'MRP', ')', 'on', 'calcium', 'availability', 'in', 'adolescents', 'and', 'across', 'Caco-2', 'cell', 'monolayers', 'were', 'examined', '.']","(7, 13)","(33, 67)",-1,hl_i,20560622,Abstract,1,test,gold,2508.0
3483,The effects of the high intake of Maillard reaction products ( MRP ) on,calcium availability,in adolescents and across Caco-2 cell monolayers were examined .,"['The', 'effects', 'of', 'the', 'high', 'intake', 'of', 'Maillard', 'reaction', 'products', '(', 'MRP', ')', 'on', 'calcium', 'availability', 'in', 'adolescents', 'and', 'across', 'Caco-2', 'cell', 'monolayers', 'were', 'examined', '.']","(14, 16)","(71, 91)",-1,hl_o,20560622,Abstract,1,test,gold,1597.0
3484,"In a 2 week randomized two-period crossover trial ,",18 male adolescents,"consumed two diets , named white diet ( WD ) and brown diet ( BD ) , which were poor and rich in MRP , respectively .","['In', 'a', '2', 'week', 'randomized', 'two-period', 'crossover', 'trial', ',', '18', 'male', 'adolescents', 'consumed', 'two', 'diets', ',', 'named', 'white', 'diet', '(', 'WD', ')', 'and', 'brown', 'diet', '(', 'BD', ')', ',', 'which', 'were', 'poor', 'and', 'rich', 'in', 'MRP', ',', 'respectively', '.']","(9, 12)","(51, 70)",-1,ss_p,20560622,Abstract,2,test,gold,2101.0
3485,"In a 2 week randomized two-period crossover trial , 18 male adolescents consumed two diets , named",white diet ( WD ),"and brown diet ( BD ) , which were poor and rich in MRP , respectively .","['In', 'a', '2', 'week', 'randomized', 'two-period', 'crossover', 'trial', ',', '18', 'male', 'adolescents', 'consumed', 'two', 'diets', ',', 'named', 'white', 'diet', '(', 'WD', ')', 'and', 'brown', 'diet', '(', 'BD', ')', ',', 'which', 'were', 'poor', 'and', 'rich', 'in', 'MRP', ',', 'respectively', '.']","(17, 22)","(98, 115)",-1,ss_i,20560622,Abstract,2,test,gold,1545.0
3486,"In a 2 week randomized two-period crossover trial , 18 male adolescents consumed two diets , named white diet ( WD ) and",brown diet ( BD ),", which were poor and rich in MRP , respectively .","['In', 'a', '2', 'week', 'randomized', 'two-period', 'crossover', 'trial', ',', '18', 'male', 'adolescents', 'consumed', 'two', 'diets', ',', 'named', 'white', 'diet', '(', 'WD', ')', 'and', 'brown', 'diet', '(', 'BD', ')', ',', 'which', 'were', 'poor', 'and', 'rich', 'in', 'MRP', ',', 'respectively', '.']","(23, 28)","(120, 137)",-1,ss_i,20560622,Abstract,2,test,gold,1543.0
3487,"In a 2 week randomized two-period crossover trial , 18 male adolescents consumed two diets , named white diet ( WD ) and brown diet ( BD ) , which were poor and rich in",MRP,", respectively .","['In', 'a', '2', 'week', 'randomized', 'two-period', 'crossover', 'trial', ',', '18', 'male', 'adolescents', 'consumed', 'two', 'diets', ',', 'named', 'white', 'diet', '(', 'WD', ')', 'and', 'brown', 'diet', '(', 'BD', ')', ',', 'which', 'were', 'poor', 'and', 'rich', 'in', 'MRP', ',', 'respectively', '.']","(35, 36)","(168, 171)",-1,ss_i,20560622,Abstract,2,test,gold,1014.0
3488,"In a 2 week randomized two-period crossover trial ,",18 male adolescents,"consumed two diets , named white diet ( WD ) and brown diet ( BD ) , which were poor and rich in MRP , respectively .","['In', 'a', '2', 'week', 'randomized', 'two-period', 'crossover', 'trial', ',', '18', 'male', 'adolescents', 'consumed', 'two', 'diets', ',', 'named', 'white', 'diet', '(', 'WD', ')', 'and', 'brown', 'diet', '(', 'BD', ')', ',', 'which', 'were', 'poor', 'and', 'rich', 'in', 'MRP', ',', 'respectively', '.']","(9, 12)","(51, 70)",-1,hl_p,20560622,Abstract,2,test,gold,2100.0
3489,"In a 2 week randomized two-period crossover trial , 18 male adolescents consumed two diets , named",white diet ( WD ),"and brown diet ( BD ) , which were poor and rich in MRP , respectively .","['In', 'a', '2', 'week', 'randomized', 'two-period', 'crossover', 'trial', ',', '18', 'male', 'adolescents', 'consumed', 'two', 'diets', ',', 'named', 'white', 'diet', '(', 'WD', ')', 'and', 'brown', 'diet', '(', 'BD', ')', ',', 'which', 'were', 'poor', 'and', 'rich', 'in', 'MRP', ',', 'respectively', '.']","(17, 22)","(98, 115)",-1,hl_i,20560622,Abstract,2,test,gold,1546.0
3490,"In a 2 week randomized two-period crossover trial , 18 male adolescents consumed two diets , named white diet ( WD ) and",brown diet ( BD ),", which were poor and rich in MRP , respectively .","['In', 'a', '2', 'week', 'randomized', 'two-period', 'crossover', 'trial', ',', '18', 'male', 'adolescents', 'consumed', 'two', 'diets', ',', 'named', 'white', 'diet', '(', 'WD', ')', 'and', 'brown', 'diet', '(', 'BD', ')', ',', 'which', 'were', 'poor', 'and', 'rich', 'in', 'MRP', ',', 'respectively', '.']","(23, 28)","(120, 137)",-1,hl_i,20560622,Abstract,2,test,gold,1544.0
3491,"In a 2 week randomized two-period crossover trial , 18 male adolescents consumed two diets , named white diet ( WD ) and brown diet ( BD ) , which were poor and rich in",MRP,", respectively .","['In', 'a', '2', 'week', 'randomized', 'two-period', 'crossover', 'trial', ',', '18', 'male', 'adolescents', 'consumed', 'two', 'diets', ',', 'named', 'white', 'diet', '(', 'WD', ')', 'and', 'brown', 'diet', '(', 'BD', ')', ',', 'which', 'were', 'poor', 'and', 'rich', 'in', 'MRP', ',', 'respectively', '.']","(35, 36)","(168, 171)",-1,hl_i,20560622,Abstract,2,test,gold,1015.0
3492,"A 3 day balance was performed at the end of each period , and",fasting blood samples,were collected .,"['A', '3', 'day', 'balance', 'was', 'performed', 'at', 'the', 'end', 'of', 'each', 'period', ',', 'and', 'fasting', 'blood', 'samples', 'were', 'collected', '.']","(14, 17)","(61, 82)",-1,ss_o,20560622,Abstract,3,test,gold,4517.0
3493,"A 3 day balance was performed at the end of each period , and",fasting blood samples,were collected .,"['A', '3', 'day', 'balance', 'was', 'performed', 'at', 'the', 'end', 'of', 'each', 'period', ',', 'and', 'fasting', 'blood', 'samples', 'were', 'collected', '.']","(14, 17)","(61, 82)",-1,hl_o,20560622,Abstract,3,test,gold,4518.0
3494,,Calcium solubility and absorption across Caco-2 cells,were studied after the in vitro digestion of the diets .,"['Calcium', 'solubility', 'and', 'absorption', 'across', 'Caco-2', 'cells', 'were', 'studied', 'after', 'the', 'in', 'vitro', 'digestion', 'of', 'the', 'diets', '.']","(0, 7)","(0, 53)",-1,ss_o,20560622,Abstract,4,test,gold,4640.0
3495,,Calcium solubility,and absorption across Caco-2 cells were studied after the in vitro digestion of the diets .,"['Calcium', 'solubility', 'and', 'absorption', 'across', 'Caco-2', 'cells', 'were', 'studied', 'after', 'the', 'in', 'vitro', 'digestion', 'of', 'the', 'diets', '.']","(0, 2)","(0, 18)",-1,hl_o,20560622,Abstract,4,test,gold,1605.0
3496,Calcium solubility and,absorption across Caco-2 cells,were studied after the in vitro digestion of the diets .,"['Calcium', 'solubility', 'and', 'absorption', 'across', 'Caco-2', 'cells', 'were', 'studied', 'after', 'the', 'in', 'vitro', 'digestion', 'of', 'the', 'diets', '.']","(3, 7)","(22, 52)",-1,hl_o,20560622,Abstract,4,test,gold,3186.0
3497,The in vitro assay showed similar,solubility,after the in vitro digestion and similar transport across Caco-2 cells .,"['The', 'in', 'vitro', 'assay', 'showed', 'similar', 'solubility', 'after', 'the', 'in', 'vitro', 'digestion', 'and', 'similar', 'transport', 'across', 'Caco-2', 'cells', '.']","(6, 7)","(33, 43)",-1,ss_o,20560622,Abstract,5,test,gold,1606.0
3498,The in vitro assay showed similar,solubility,after the in vitro digestion and similar transport across Caco-2 cells .,"['The', 'in', 'vitro', 'assay', 'showed', 'similar', 'solubility', 'after', 'the', 'in', 'vitro', 'digestion', 'and', 'similar', 'transport', 'across', 'Caco-2', 'cells', '.']","(6, 7)","(33, 43)",-1,hl_o,20560622,Abstract,5,test,gold,1607.0
3499,"In accordance ,",calcium bioavailability,"in adolescents did not vary between the diets ( % WD = 40.4 +/- 5.1 , % BD = 38.2 +/- 3.6 ) .","['In', 'accordance', ',', 'calcium', 'bioavailability', 'in', 'adolescents', 'did', 'not', 'vary', 'between', 'the', 'diets', '(', '%', 'WD', '=', '40.4', '+/-', '5.1', ',', '%', 'BD', '=', '38.2', '+/-', '3.6', ')', '.']","(3, 5)","(15, 38)",-1,ss_o,20560622,Abstract,6,test,gold,4642.0
3500,"In accordance ,",calcium bioavailability,"in adolescents did not vary between the diets ( % WD = 40.4 +/- 5.1 , % BD = 38.2 +/- 3.6 ) .","['In', 'accordance', ',', 'calcium', 'bioavailability', 'in', 'adolescents', 'did', 'not', 'vary', 'between', 'the', 'diets', '(', '%', 'WD', '=', '40.4', '+/-', '5.1', ',', '%', 'BD', '=', '38.2', '+/-', '3.6', ')', '.']","(3, 5)","(15, 38)",-1,hl_o,20560622,Abstract,6,test,gold,4641.0
3501,,Serum and urine biochemical parameters related to calcium status and bone metabolism,remained unaltered .,"['Serum', 'and', 'urine', 'biochemical', 'parameters', 'related', 'to', 'calcium', 'status', 'and', 'bone', 'metabolism', 'remained', 'unaltered', '.']","(0, 12)","(0, 84)",-1,ss_o,20560622,Abstract,7,test,gold,6527.0
3502,,Serum and urine biochemical parameters related to calcium status and bone metabolism,remained unaltered .,"['Serum', 'and', 'urine', 'biochemical', 'parameters', 'related', 'to', 'calcium', 'status', 'and', 'bone', 'metabolism', 'remained', 'unaltered', '.']","(0, 12)","(0, 84)",-1,hl_o,20560622,Abstract,7,test,gold,6528.0
3503,Only,deoxypyridinoline,"values were significantly lower after consumption of the BD ( 13.0 +/- 1.1 compared to 18.3 +/- 2.1 nM/Mm Cr in the WD ) , possibly indicative of less efficient bone turnover during this period .","['Only', 'deoxypyridinoline', 'values', 'were', 'significantly', 'lower', 'after', 'consumption', 'of', 'the', 'BD', '(', '13.0', '+/-', '1.1', 'compared', 'to', '18.3', '+/-', '2.1', 'nM/Mm', 'Cr', 'in', 'the', 'WD', ')', ',', 'possibly', 'indicative', 'of', 'less', 'efficient', 'bone', 'turnover', 'during', 'this', 'period', '.']","(1, 2)","(4, 21)",-1,ss_o,20560622,Abstract,8,test,gold,
3504,"Only deoxypyridinoline values were significantly lower after consumption of the BD ( 13.0 +/- 1.1 compared to 18.3 +/- 2.1 nM/Mm Cr in the WD ) , possibly indicative of less efficient",bone turnover,during this period .,"['Only', 'deoxypyridinoline', 'values', 'were', 'significantly', 'lower', 'after', 'consumption', 'of', 'the', 'BD', '(', '13.0', '+/-', '1.1', 'compared', 'to', '18.3', '+/-', '2.1', 'nM/Mm', 'Cr', 'in', 'the', 'WD', ')', ',', 'possibly', 'indicative', 'of', 'less', 'efficient', 'bone', 'turnover', 'during', 'this', 'period', '.']","(32, 34)","(183, 196)",-1,ss_o,20560622,Abstract,8,test,gold,1632.0
3505,Only,deoxypyridinoline,"values were significantly lower after consumption of the BD ( 13.0 +/- 1.1 compared to 18.3 +/- 2.1 nM/Mm Cr in the WD ) , possibly indicative of less efficient bone turnover during this period .","['Only', 'deoxypyridinoline', 'values', 'were', 'significantly', 'lower', 'after', 'consumption', 'of', 'the', 'BD', '(', '13.0', '+/-', '1.1', 'compared', 'to', '18.3', '+/-', '2.1', 'nM/Mm', 'Cr', 'in', 'the', 'WD', ')', ',', 'possibly', 'indicative', 'of', 'less', 'efficient', 'bone', 'turnover', 'during', 'this', 'period', '.']","(1, 2)","(4, 21)",-1,hl_o,20560622,Abstract,8,test,gold,
3506,"Only deoxypyridinoline values were significantly lower after consumption of the BD ( 13.0 +/- 1.1 compared to 18.3 +/- 2.1 nM/Mm Cr in the WD ) , possibly indicative of less efficient",bone turnover,during this period .,"['Only', 'deoxypyridinoline', 'values', 'were', 'significantly', 'lower', 'after', 'consumption', 'of', 'the', 'BD', '(', '13.0', '+/-', '1.1', 'compared', 'to', '18.3', '+/-', '2.1', 'nM/Mm', 'Cr', 'in', 'the', 'WD', ')', ',', 'possibly', 'indicative', 'of', 'less', 'efficient', 'bone', 'turnover', 'during', 'this', 'period', '.']","(32, 34)","(183, 196)",-1,hl_o,20560622,Abstract,8,test,gold,1631.0
3507,"As calcium acquired during adolescence is essential to maximize peak bone mass and to prevent osteoporosis , possible long-term effects of excessive",MRP,intake during this period warrant attention .,"['As', 'calcium', 'acquired', 'during', 'adolescence', 'is', 'essential', 'to', 'maximize', 'peak', 'bone', 'mass', 'and', 'to', 'prevent', 'osteoporosis', ',', 'possible', 'long-term', 'effects', 'of', 'excessive', 'MRP', 'intake', 'during', 'this', 'period', 'warrant', 'attention', '.']","(22, 23)","(148, 151)",-1,ss_i,20560622,Abstract,9,test,gold,1013.0
3508,"As calcium acquired during adolescence is essential to maximize peak bone mass and to prevent osteoporosis , possible long-term effects of excessive",MRP,intake during this period warrant attention .,"['As', 'calcium', 'acquired', 'during', 'adolescence', 'is', 'essential', 'to', 'maximize', 'peak', 'bone', 'mass', 'and', 'to', 'prevent', 'osteoporosis', ',', 'possible', 'long-term', 'effects', 'of', 'excessive', 'MRP', 'intake', 'during', 'this', 'period', 'warrant', 'attention', '.']","(22, 23)","(148, 151)",-1,hl_i,20560622,Abstract,9,test,gold,1012.0
3509,Effectiveness of hygienic-dietary recommendations as enhancers of antidepressant treatment in,patients with depression :,study protocol of a randomized controlled trial .,"['Effectiveness', 'of', 'hygienic-dietary', 'recommendations', 'as', 'enhancers', 'of', 'antidepressant', 'treatment', 'in', 'patients', 'with', 'depression', ':', 'study', 'protocol', 'of', 'a', 'randomized', 'controlled', 'trial', '.']","(10, 14)","(93, 119)",-1,ss_p,20618920,Title,0,test,gold,6980.0
3510,Effectiveness of,hygienic-dietary recommendations,as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial .,"['Effectiveness', 'of', 'hygienic-dietary', 'recommendations', 'as', 'enhancers', 'of', 'antidepressant', 'treatment', 'in', 'patients', 'with', 'depression', ':', 'study', 'protocol', 'of', 'a', 'randomized', 'controlled', 'trial', '.']","(2, 4)","(16, 48)",-1,ss_i,20618920,Title,0,test,gold,935.0
3511,,Effectiveness,of hygienic-dietary recommendations as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial .,"['Effectiveness', 'of', 'hygienic-dietary', 'recommendations', 'as', 'enhancers', 'of', 'antidepressant', 'treatment', 'in', 'patients', 'with', 'depression', ':', 'study', 'protocol', 'of', 'a', 'randomized', 'controlled', 'trial', '.']","(0, 1)","(0, 13)",-1,ss_o,20618920,Title,0,test,gold,438.0
3512,Effectiveness of hygienic-dietary recommendations as enhancers of antidepressant treatment in,patients with depression :,study protocol of a randomized controlled trial .,"['Effectiveness', 'of', 'hygienic-dietary', 'recommendations', 'as', 'enhancers', 'of', 'antidepressant', 'treatment', 'in', 'patients', 'with', 'depression', ':', 'study', 'protocol', 'of', 'a', 'randomized', 'controlled', 'trial', '.']","(10, 14)","(93, 119)",-1,hl_p,20618920,Title,0,test,gold,6981.0
3513,Effectiveness of,hygienic-dietary recommendations,as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial .,"['Effectiveness', 'of', 'hygienic-dietary', 'recommendations', 'as', 'enhancers', 'of', 'antidepressant', 'treatment', 'in', 'patients', 'with', 'depression', ':', 'study', 'protocol', 'of', 'a', 'randomized', 'controlled', 'trial', '.']","(2, 4)","(16, 48)",-1,hl_i,20618920,Title,0,test,gold,936.0
3514,,Effectiveness,of hygienic-dietary recommendations as enhancers of antidepressant treatment in patients with depression : study protocol of a randomized controlled trial .,"['Effectiveness', 'of', 'hygienic-dietary', 'recommendations', 'as', 'enhancers', 'of', 'antidepressant', 'treatment', 'in', 'patients', 'with', 'depression', ':', 'study', 'protocol', 'of', 'a', 'randomized', 'controlled', 'trial', '.']","(0, 1)","(0, 13)",-1,hl_o,20618920,Title,0,test,gold,439.0
3515,BACKGROUND In recent years some studies have been published supporting the,efficacy,"of light exposure , physical activity , sleep control and a Mediterranean diet pattern on the improvement or prevention of depression .","['BACKGROUND', 'In', 'recent', 'years', 'some', 'studies', 'have', 'been', 'published', 'supporting', 'the', 'efficacy', 'of', 'light', 'exposure', ',', 'physical', 'activity', ',', 'sleep', 'control', 'and', 'a', 'Mediterranean', 'diet', 'pattern', 'on', 'the', 'improvement', 'or', 'prevention', 'of', 'depression', '.']","(11, 12)","(74, 82)",-1,ss_o,20618920,Abstract,0,test,gold,4813.0
3516,"BACKGROUND In recent years some studies have been published supporting the efficacy of light exposure , physical activity , sleep control and a",Mediterranean diet,pattern on the improvement or prevention of depression .,"['BACKGROUND', 'In', 'recent', 'years', 'some', 'studies', 'have', 'been', 'published', 'supporting', 'the', 'efficacy', 'of', 'light', 'exposure', ',', 'physical', 'activity', ',', 'sleep', 'control', 'and', 'a', 'Mediterranean', 'diet', 'pattern', 'on', 'the', 'improvement', 'or', 'prevention', 'of', 'depression', '.']","(23, 25)","(143, 161)",-1,hl_i,20618920,Abstract,0,test,gold,1526.0
3517,"However , to our knowledge , there have been no studies using all these measures together as an adjuvant antidepressant strategy .",,,"['However', ',', 'to', 'our', 'knowledge', ',', 'there', 'have', 'been', 'no', 'studies', 'using', 'all', 'these', 'measures', 'together', 'as', 'an', 'adjuvant', 'antidepressant', 'strategy', '.']",,,,,20618920,Abstract,1,test,gold,
3518,"METHODS Multicenter , randomized , controlled , two arm-parallel , clinical trial .",,,"['METHODS', 'Multicenter', ',', 'randomized', ',', 'controlled', ',', 'two', 'arm-parallel', ',', 'clinical', 'trial', '.']",,,,,20618920,Abstract,2,test,gold,
3519,,Eighty depressed patients undergoing standard antidepressant treatment,"will be advised to follow four additional hygienic-dietary recommendations about exercise , diet , sunlight exposure and sleep .","['Eighty', 'depressed', 'patients', 'undergoing', 'standard', 'antidepressant', 'treatment', 'will', 'be', 'advised', 'to', 'follow', 'four', 'additional', 'hygienic-dietary', 'recommendations', 'about', 'exercise', ',', 'diet', ',', 'sunlight', 'exposure', 'and', 'sleep', '.']","(0, 7)","(0, 70)",-1,ss_p,20618920,Abstract,3,test,gold,7077.0
3520,Eighty depressed patients undergoing standard,antidepressant,"treatment will be advised to follow four additional hygienic-dietary recommendations about exercise , diet , sunlight exposure and sleep .","['Eighty', 'depressed', 'patients', 'undergoing', 'standard', 'antidepressant', 'treatment', 'will', 'be', 'advised', 'to', 'follow', 'four', 'additional', 'hygienic-dietary', 'recommendations', 'about', 'exercise', ',', 'diet', ',', 'sunlight', 'exposure', 'and', 'sleep', '.']","(5, 6)","(45, 59)",-1,ss_i,20618920,Abstract,3,test,gold,5084.0
3521,Eighty depressed patients undergoing standard antidepressant treatment will be advised to follow four additional,hygienic-dietary recommendations,"about exercise , diet , sunlight exposure and sleep .","['Eighty', 'depressed', 'patients', 'undergoing', 'standard', 'antidepressant', 'treatment', 'will', 'be', 'advised', 'to', 'follow', 'four', 'additional', 'hygienic-dietary', 'recommendations', 'about', 'exercise', ',', 'diet', ',', 'sunlight', 'exposure', 'and', 'sleep', '.']","(14, 16)","(112, 144)",-1,ss_i,20618920,Abstract,3,test,gold,934.0
3522,,Eighty depressed patients undergoing standard antidepressant treatment,"will be advised to follow four additional hygienic-dietary recommendations about exercise , diet , sunlight exposure and sleep .","['Eighty', 'depressed', 'patients', 'undergoing', 'standard', 'antidepressant', 'treatment', 'will', 'be', 'advised', 'to', 'follow', 'four', 'additional', 'hygienic-dietary', 'recommendations', 'about', 'exercise', ',', 'diet', ',', 'sunlight', 'exposure', 'and', 'sleep', '.']","(0, 7)","(0, 70)",-1,hl_p,20618920,Abstract,3,test,gold,7078.0
3523,Eighty depressed patients undergoing standard antidepressant treatment will be advised to follow four additional,hygienic-dietary recommendations,"about exercise , diet , sunlight exposure and sleep .","['Eighty', 'depressed', 'patients', 'undergoing', 'standard', 'antidepressant', 'treatment', 'will', 'be', 'advised', 'to', 'follow', 'four', 'additional', 'hygienic-dietary', 'recommendations', 'about', 'exercise', ',', 'diet', ',', 'sunlight', 'exposure', 'and', 'sleep', '.']","(14, 16)","(112, 144)",-1,hl_i,20618920,Abstract,3,test,gold,933.0
3524,,Outcome measures,will be assessed before and after the 6 month intervention period .,"['Outcome', 'measures', 'will', 'be', 'assessed', 'before', 'and', 'after', 'the', '6', 'month', 'intervention', 'period', '.']","(0, 2)","(0, 16)",-1,ss_o,20618920,Abstract,4,test,gold,1836.0
3525,DISCUSSION We expect the patients in the active recommendations group to experience a greater improvement in their,depressive symptoms .,,"['DISCUSSION', 'We', 'expect', 'the', 'patients', 'in', 'the', 'active', 'recommendations', 'group', 'to', 'experience', 'a', 'greater', 'improvement', 'in', 'their', 'depressive', 'symptoms', '.']","(17, 20)","(114, 135)",-1,ss_o,20618920,Abstract,5,test,gold,3254.0
3526,DISCUSSION We expect the patients in the active recommendations group to experience a greater improvement in their,depressive symptoms .,,"['DISCUSSION', 'We', 'expect', 'the', 'patients', 'in', 'the', 'active', 'recommendations', 'group', 'to', 'experience', 'a', 'greater', 'improvement', 'in', 'their', 'depressive', 'symptoms', '.']","(17, 20)","(114, 135)",-1,hl_o,20618920,Abstract,5,test,gold,3255.0
3527,"If so , this would be a great support for doctors who might systematically recommend these simple and costless measures , especially in primary care .",,,"['If', 'so', ',', 'this', 'would', 'be', 'a', 'great', 'support', 'for', 'doctors', 'who', 'might', 'systematically', 'recommend', 'these', 'simple', 'and', 'costless', 'measures', ',', 'especially', 'in', 'primary', 'care', '.']",,,,,20618920,Abstract,6,test,gold,
3528,TRIAL REGISTRATION ISRCTN59506583 .,,,"['TRIAL', 'REGISTRATION', 'ISRCTN59506583', '.']",,,,,20618920,Abstract,7,test,gold,
3529,Therapeutic effects of combined treatment using tetracycline-immobilized collagen film and root planing in,periodontal furcation pockets .,,"['Therapeutic', 'effects', 'of', 'combined', 'treatment', 'using', 'tetracycline-immobilized', 'collagen', 'film', 'and', 'root', 'planing', 'in', 'periodontal', 'furcation', 'pockets', '.']","(13, 17)","(106, 137)",-1,ss_p,2066441,Title,0,test,gold,4084.0
3530,Therapeutic effects of combined treatment using,tetracycline-immobilized collagen film and root planing,in periodontal furcation pockets .,"['Therapeutic', 'effects', 'of', 'combined', 'treatment', 'using', 'tetracycline-immobilized', 'collagen', 'film', 'and', 'root', 'planing', 'in', 'periodontal', 'furcation', 'pockets', '.']","(6, 12)","(47, 102)",-1,ss_i,2066441,Title,0,test,gold,4674.0
3531,,Therapeutic effects,of combined treatment using tetracycline-immobilized collagen film and root planing in periodontal furcation pockets .,"['Therapeutic', 'effects', 'of', 'combined', 'treatment', 'using', 'tetracycline-immobilized', 'collagen', 'film', 'and', 'root', 'planing', 'in', 'periodontal', 'furcation', 'pockets', '.']","(0, 2)","(0, 19)",-1,ss_o,2066441,Title,0,test,gold,2349.0
3532,Therapeutic effects of combined treatment using tetracycline-immobilized collagen film and root planing in,periodontal furcation pockets .,,"['Therapeutic', 'effects', 'of', 'combined', 'treatment', 'using', 'tetracycline-immobilized', 'collagen', 'film', 'and', 'root', 'planing', 'in', 'periodontal', 'furcation', 'pockets', '.']","(13, 17)","(106, 137)",-1,hl_p,2066441,Title,0,test,gold,4085.0
3533,Therapeutic effects of combined treatment using,tetracycline-immobilized collagen film,and root planing in periodontal furcation pockets .,"['Therapeutic', 'effects', 'of', 'combined', 'treatment', 'using', 'tetracycline-immobilized', 'collagen', 'film', 'and', 'root', 'planing', 'in', 'periodontal', 'furcation', 'pockets', '.']","(6, 9)","(47, 85)",-1,hl_i,2066441,Title,0,test,gold,4675.0
3534,Therapeutic effects of combined treatment using tetracycline-immobilized collagen film and,root planing,in periodontal furcation pockets .,"['Therapeutic', 'effects', 'of', 'combined', 'treatment', 'using', 'tetracycline-immobilized', 'collagen', 'film', 'and', 'root', 'planing', 'in', 'periodontal', 'furcation', 'pockets', '.']","(10, 12)","(90, 102)",-1,hl_i,2066441,Title,0,test,gold,1773.0
3535,,46 upper and lower molars with furcation grade II involvement,were selected from 16 patients with periodontal disease .,"['46', 'upper', 'and', 'lower', 'molars', 'with', 'furcation', 'grade', 'II', 'involvement', 'were', 'selected', 'from', '16', 'patients', 'with', 'periodontal', 'disease', '.']","(0, 10)","(0, 61)",-1,ss_p,2066441,Abstract,0,test,gold,5869.0
3536,46 upper and lower molars with furcation grade II involvement were selected from,16 patients with periodontal disease .,,"['46', 'upper', 'and', 'lower', 'molars', 'with', 'furcation', 'grade', 'II', 'involvement', 'were', 'selected', 'from', '16', 'patients', 'with', 'periodontal', 'disease', '.']","(13, 19)","(80, 118)",-1,ss_p,2066441,Abstract,0,test,gold,7042.0
3537,,46 upper and lower molars with furcation grade II involvement,were selected from 16 patients with periodontal disease .,"['46', 'upper', 'and', 'lower', 'molars', 'with', 'furcation', 'grade', 'II', 'involvement', 'were', 'selected', 'from', '16', 'patients', 'with', 'periodontal', 'disease', '.']","(0, 10)","(0, 61)",-1,hl_p,2066441,Abstract,0,test,gold,5870.0
3538,46 upper and lower molars with furcation grade II involvement were selected from,16 patients with periodontal disease,.,"['46', 'upper', 'and', 'lower', 'molars', 'with', 'furcation', 'grade', 'II', 'involvement', 'were', 'selected', 'from', '16', 'patients', 'with', 'periodontal', 'disease', '.']","(13, 18)","(80, 116)",-1,hl_p,2066441,Abstract,0,test,gold,7043.0
3539,The teeth were randomly allocated to the following groups according to treatment ; ( 1 ) 4 consecutive administrations of,tetracycline-immobilized cross-linked collagen film ( TC film ),at intervals of 1 week ( TC group ) ; ( 2 ) 1 root planing treatment ( RP group ) ; ( 3 ) combination treatment ( TC + RP group ) ; ( 4 ) no treatment ( control group ) .,"['The', 'teeth', 'were', 'randomly', 'allocated', 'to', 'the', 'following', 'groups', 'according', 'to', 'treatment', ';', '(', '1', ')', '4', 'consecutive', 'administrations', 'of', 'tetracycline-immobilized', 'cross-linked', 'collagen', 'film', '(', 'TC', 'film', ')', 'at', 'intervals', 'of', '1', 'week', '(', 'TC', 'group', ')', ';', '(', '2', ')', '1', 'root', 'planing', 'treatment', '(', 'RP', 'group', ')', ';', '(', '3', ')', 'combination', 'treatment', '(', 'TC', '+', 'RP', 'group', ')', ';', '(', '4', ')', 'no', 'treatment', '(', 'control', 'group', ')', '.']","(20, 28)","(121, 184)",-1,ss_i,2066441,Abstract,1,test,gold,4672.0
3540,The teeth were randomly allocated to the following groups according to treatment ; ( 1 ) 4 consecutive administrations of tetracycline-immobilized cross-linked collagen film ( TC film ) at intervals of 1 week ( TC group ) ; ( 2 ) 1,root planing treatment ( RP,group ) ; ( 3 ) combination treatment ( TC + RP group ) ; ( 4 ) no treatment ( control group ) .,"['The', 'teeth', 'were', 'randomly', 'allocated', 'to', 'the', 'following', 'groups', 'according', 'to', 'treatment', ';', '(', '1', ')', '4', 'consecutive', 'administrations', 'of', 'tetracycline-immobilized', 'cross-linked', 'collagen', 'film', '(', 'TC', 'film', ')', 'at', 'intervals', 'of', '1', 'week', '(', 'TC', 'group', ')', ';', '(', '2', ')', '1', 'root', 'planing', 'treatment', '(', 'RP', 'group', ')', ';', '(', '3', ')', 'combination', 'treatment', '(', 'TC', '+', 'RP', 'group', ')', ';', '(', '4', ')', 'no', 'treatment', '(', 'control', 'group', ')', '.']","(42, 47)","(231, 258)",-1,ss_i,2066441,Abstract,1,test,gold,1770.0
3541,The teeth were randomly allocated to the following groups according to treatment ; ( 1 ) 4 consecutive administrations of tetracycline-immobilized cross-linked collagen film ( TC film ) at intervals of 1 week ( TC group ) ; ( 2 ) 1 root planing treatment ( RP group ) ; ( 3 ) combination treatment,( TC + RP,group ) ; ( 4 ) no treatment ( control group ) .,"['The', 'teeth', 'were', 'randomly', 'allocated', 'to', 'the', 'following', 'groups', 'according', 'to', 'treatment', ';', '(', '1', ')', '4', 'consecutive', 'administrations', 'of', 'tetracycline-immobilized', 'cross-linked', 'collagen', 'film', '(', 'TC', 'film', ')', 'at', 'intervals', 'of', '1', 'week', '(', 'TC', 'group', ')', ';', '(', '2', ')', '1', 'root', 'planing', 'treatment', '(', 'RP', 'group', ')', ';', '(', '3', ')', 'combination', 'treatment', '(', 'TC', '+', 'RP', 'group', ')', ';', '(', '4', ')', 'no', 'treatment', '(', 'control', 'group', ')', '.']","(55, 59)","(297, 306)",-1,ss_i,2066441,Abstract,1,test,gold,789.0
3542,The teeth were randomly allocated to the following groups according to treatment ; ( 1 ) 4 consecutive administrations of,tetracycline-immobilized cross-linked collagen film ( TC film ),at intervals of 1 week ( TC group ) ; ( 2 ) 1 root planing treatment ( RP group ) ; ( 3 ) combination treatment ( TC + RP group ) ; ( 4 ) no treatment ( control group ) .,"['The', 'teeth', 'were', 'randomly', 'allocated', 'to', 'the', 'following', 'groups', 'according', 'to', 'treatment', ';', '(', '1', ')', '4', 'consecutive', 'administrations', 'of', 'tetracycline-immobilized', 'cross-linked', 'collagen', 'film', '(', 'TC', 'film', ')', 'at', 'intervals', 'of', '1', 'week', '(', 'TC', 'group', ')', ';', '(', '2', ')', '1', 'root', 'planing', 'treatment', '(', 'RP', 'group', ')', ';', '(', '3', ')', 'combination', 'treatment', '(', 'TC', '+', 'RP', 'group', ')', ';', '(', '4', ')', 'no', 'treatment', '(', 'control', 'group', ')', '.']","(20, 28)","(121, 184)",-1,hl_i,2066441,Abstract,1,test,gold,4673.0
3543,The teeth were randomly allocated to the following groups according to treatment ; ( 1 ) 4 consecutive administrations of tetracycline-immobilized cross-linked collagen film ( TC film ) at intervals of 1 week ( TC group ) ; ( 2 ) 1,root planing treatment ( RP,group ) ; ( 3 ) combination treatment ( TC + RP group ) ; ( 4 ) no treatment ( control group ) .,"['The', 'teeth', 'were', 'randomly', 'allocated', 'to', 'the', 'following', 'groups', 'according', 'to', 'treatment', ';', '(', '1', ')', '4', 'consecutive', 'administrations', 'of', 'tetracycline-immobilized', 'cross-linked', 'collagen', 'film', '(', 'TC', 'film', ')', 'at', 'intervals', 'of', '1', 'week', '(', 'TC', 'group', ')', ';', '(', '2', ')', '1', 'root', 'planing', 'treatment', '(', 'RP', 'group', ')', ';', '(', '3', ')', 'combination', 'treatment', '(', 'TC', '+', 'RP', 'group', ')', ';', '(', '4', ')', 'no', 'treatment', '(', 'control', 'group', ')', '.']","(42, 47)","(231, 258)",-1,hl_i,2066441,Abstract,1,test,gold,1771.0
3544,The teeth were randomly allocated to the following groups according to treatment ; ( 1 ) 4 consecutive administrations of tetracycline-immobilized cross-linked collagen film ( TC film ) at intervals of 1 week ( TC group ) ; ( 2 ) 1 root planing treatment ( RP group ) ; ( 3 ) combination treatment (,TC + RP,group ) ; ( 4 ) no treatment ( control group ) .,"['The', 'teeth', 'were', 'randomly', 'allocated', 'to', 'the', 'following', 'groups', 'according', 'to', 'treatment', ';', '(', '1', ')', '4', 'consecutive', 'administrations', 'of', 'tetracycline-immobilized', 'cross-linked', 'collagen', 'film', '(', 'TC', 'film', ')', 'at', 'intervals', 'of', '1', 'week', '(', 'TC', 'group', ')', ';', '(', '2', ')', '1', 'root', 'planing', 'treatment', '(', 'RP', 'group', ')', ';', '(', '3', ')', 'combination', 'treatment', '(', 'TC', '+', 'RP', 'group', ')', ';', '(', '4', ')', 'no', 'treatment', '(', 'control', 'group', ')', '.']","(56, 59)","(299, 306)",-1,hl_i,2066441,Abstract,1,test,gold,790.0
3545,The,therapeutic effects,of each treatment were compared both clinically and microbiologically .,"['The', 'therapeutic', 'effects', 'of', 'each', 'treatment', 'were', 'compared', 'both', 'clinically', 'and', 'microbiologically', '.']","(1, 3)","(3, 22)",-1,ss_o,2066441,Abstract,2,test,gold,2351.0
3546,Records of,"plaque index , gingival index , bleeding on probing , probing depth , probing attachment level and microscopic counts","were obtained at 0 , 4 , 6 and 8 weeks .","['Records', 'of', 'plaque', 'index', ',', 'gingival', 'index', ',', 'bleeding', 'on', 'probing', ',', 'probing', 'depth', ',', 'probing', 'attachment', 'level', 'and', 'microscopic', 'counts', 'were', 'obtained', 'at', '0', ',', '4', ',', '6', 'and', '8', 'weeks', '.']","(2, 21)","(10, 127)",-1,ss_o,2066441,Abstract,3,test,gold,6363.0
3547,Records of,"plaque index , gingival index , bleeding on probing , probing depth , probing attachment level and microscopic counts","were obtained at 0 , 4 , 6 and 8 weeks .","['Records', 'of', 'plaque', 'index', ',', 'gingival', 'index', ',', 'bleeding', 'on', 'probing', ',', 'probing', 'depth', ',', 'probing', 'attachment', 'level', 'and', 'microscopic', 'counts', 'were', 'obtained', 'at', '0', ',', '4', ',', '6', 'and', '8', 'weeks', '.']","(2, 21)","(10, 127)",-1,hl_o,2066441,Abstract,3,test,gold,6364.0
3548,The results showed marked decreases in probing depth and density of micro-organisms in both the,RP,and TC + RP groups .,"['The', 'results', 'showed', 'marked', 'decreases', 'in', 'probing', 'depth', 'and', 'density', 'of', 'micro-organisms', 'in', 'both', 'the', 'RP', 'and', 'TC', '+', 'RP', 'groups', '.']","(15, 16)","(95, 97)",-1,ss_i,2066441,Abstract,4,test,gold,1093.0
3549,The results showed marked decreases in probing depth and density of micro-organisms in both the RP and,TC + RP,groups .,"['The', 'results', 'showed', 'marked', 'decreases', 'in', 'probing', 'depth', 'and', 'density', 'of', 'micro-organisms', 'in', 'both', 'the', 'RP', 'and', 'TC', '+', 'RP', 'groups', '.']","(17, 20)","(102, 109)",-1,ss_i,2066441,Abstract,4,test,gold,788.0
3550,The results showed marked decreases in,probing depth and density of micro-organisms,in both the RP and TC + RP groups .,"['The', 'results', 'showed', 'marked', 'decreases', 'in', 'probing', 'depth', 'and', 'density', 'of', 'micro-organisms', 'in', 'both', 'the', 'RP', 'and', 'TC', '+', 'RP', 'groups', '.']","(6, 12)","(38, 82)",-1,ss_o,2066441,Abstract,4,test,gold,1873.0
3551,The results showed marked decreases in probing depth and density of micro-organisms in both the,RP,and TC + RP groups .,"['The', 'results', 'showed', 'marked', 'decreases', 'in', 'probing', 'depth', 'and', 'density', 'of', 'micro-organisms', 'in', 'both', 'the', 'RP', 'and', 'TC', '+', 'RP', 'groups', '.']","(15, 16)","(95, 97)",-1,hl_i,2066441,Abstract,4,test,gold,1094.0
3552,The results showed marked decreases in probing depth and density of micro-organisms in both the RP and,TC + RP,groups .,"['The', 'results', 'showed', 'marked', 'decreases', 'in', 'probing', 'depth', 'and', 'density', 'of', 'micro-organisms', 'in', 'both', 'the', 'RP', 'and', 'TC', '+', 'RP', 'groups', '.']","(17, 20)","(102, 109)",-1,hl_i,2066441,Abstract,4,test,gold,787.0
3553,The results showed marked decreases in,probing depth and density of micro-organisms,in both the RP and TC + RP groups .,"['The', 'results', 'showed', 'marked', 'decreases', 'in', 'probing', 'depth', 'and', 'density', 'of', 'micro-organisms', 'in', 'both', 'the', 'RP', 'and', 'TC', '+', 'RP', 'groups', '.']","(6, 12)","(38, 82)",-1,hl_o,2066441,Abstract,4,test,gold,1874.0
3554,"In particular , the",TC + RP,group was characterized by a decreased rate of bleeding on pocket probing and an increased probing attachment gain .,"['In', 'particular', ',', 'the', 'TC', '+', 'RP', 'group', 'was', 'characterized', 'by', 'a', 'decreased', 'rate', 'of', 'bleeding', 'on', 'pocket', 'probing', 'and', 'an', 'increased', 'probing', 'attachment', 'gain', '.']","(4, 7)","(19, 26)",-1,ss_i,2066441,Abstract,5,test,gold,786.0
3555,"In particular , the TC + RP group was characterized by a decreased",rate of bleeding on pocket probing,and an increased probing attachment gain .,"['In', 'particular', ',', 'the', 'TC', '+', 'RP', 'group', 'was', 'characterized', 'by', 'a', 'decreased', 'rate', 'of', 'bleeding', 'on', 'pocket', 'probing', 'and', 'an', 'increased', 'probing', 'attachment', 'gain', '.']","(13, 19)","(66, 100)",-1,ss_o,2066441,Abstract,5,test,gold,6370.0
3556,"In particular , the TC + RP group was characterized by a decreased rate of bleeding on pocket probing and an increased",probing attachment gain .,,"['In', 'particular', ',', 'the', 'TC', '+', 'RP', 'group', 'was', 'characterized', 'by', 'a', 'decreased', 'rate', 'of', 'bleeding', 'on', 'pocket', 'probing', 'and', 'an', 'increased', 'probing', 'attachment', 'gain', '.']","(22, 26)","(118, 143)",-1,ss_o,2066441,Abstract,5,test,gold,1871.0
3557,"In particular , the",TC + RP,group was characterized by a decreased rate of bleeding on pocket probing and an increased probing attachment gain .,"['In', 'particular', ',', 'the', 'TC', '+', 'RP', 'group', 'was', 'characterized', 'by', 'a', 'decreased', 'rate', 'of', 'bleeding', 'on', 'pocket', 'probing', 'and', 'an', 'increased', 'probing', 'attachment', 'gain', '.']","(4, 7)","(19, 26)",-1,hl_i,2066441,Abstract,5,test,gold,785.0
3558,"In particular , the TC + RP group was characterized by a decreased",rate of bleeding on pocket probing,and an increased probing attachment gain .,"['In', 'particular', ',', 'the', 'TC', '+', 'RP', 'group', 'was', 'characterized', 'by', 'a', 'decreased', 'rate', 'of', 'bleeding', 'on', 'pocket', 'probing', 'and', 'an', 'increased', 'probing', 'attachment', 'gain', '.']","(13, 19)","(66, 100)",-1,hl_o,2066441,Abstract,5,test,gold,6371.0
3559,"In particular , the TC + RP group was characterized by a decreased rate of bleeding on pocket probing and an increased",probing attachment gain .,,"['In', 'particular', ',', 'the', 'TC', '+', 'RP', 'group', 'was', 'characterized', 'by', 'a', 'decreased', 'rate', 'of', 'bleeding', 'on', 'pocket', 'probing', 'and', 'an', 'increased', 'probing', 'attachment', 'gain', '.']","(22, 26)","(118, 143)",-1,hl_o,2066441,Abstract,5,test,gold,1872.0
3560,The above findings demonstrated that,root planning,is effective in the treatment of furcation involvement and that the effects are enhanced by the local administration of TC films .,"['The', 'above', 'findings', 'demonstrated', 'that', 'root', 'planning', 'is', 'effective', 'in', 'the', 'treatment', 'of', 'furcation', 'involvement', 'and', 'that', 'the', 'effects', 'are', 'enhanced', 'by', 'the', 'local', 'administration', 'of', 'TC', 'films', '.']","(5, 7)","(36, 49)",-1,ss_i,2066441,Abstract,6,test,gold,1774.0
3561,The above findings demonstrated that root planning is effective in the treatment of furcation involvement and that the effects are enhanced by the local administration of,TC films .,,"['The', 'above', 'findings', 'demonstrated', 'that', 'root', 'planning', 'is', 'effective', 'in', 'the', 'treatment', 'of', 'furcation', 'involvement', 'and', 'that', 'the', 'effects', 'are', 'enhanced', 'by', 'the', 'local', 'administration', 'of', 'TC', 'films', '.']","(26, 29)","(170, 180)",-1,ss_i,2066441,Abstract,6,test,gold,679.0
3562,The above findings demonstrated that root planning is effective in the treatment of furcation involvement and that the effects are enhanced by the local administration of,TC,films .,"['The', 'above', 'findings', 'demonstrated', 'that', 'root', 'planning', 'is', 'effective', 'in', 'the', 'treatment', 'of', 'furcation', 'involvement', 'and', 'that', 'the', 'effects', 'are', 'enhanced', 'by', 'the', 'local', 'administration', 'of', 'TC', 'films', '.']","(26, 27)","(170, 172)",-1,hl_i,2066441,Abstract,6,test,gold,685.0
3563,Eltrombopag for management of,chronic immune thrombocytopenia,"( RAISE ) : a 6-month , randomised , phase 3 study .","['Eltrombopag', 'for', 'management', 'of', 'chronic', 'immune', 'thrombocytopenia', '(', 'RAISE', ')', ':', 'a', '6-month', ',', 'randomised', ',', 'phase', '3', 'study', '.']","(4, 7)","(29, 60)",-1,ss_p,20739054,Title,0,test,gold,7096.0
3564,,Eltrombopag,"for management of chronic immune thrombocytopenia ( RAISE ) : a 6-month , randomised , phase 3 study .","['Eltrombopag', 'for', 'management', 'of', 'chronic', 'immune', 'thrombocytopenia', '(', 'RAISE', ')', ':', 'a', '6-month', ',', 'randomised', ',', 'phase', '3', 'study', '.']","(0, 1)","(0, 11)",-1,ss_i,20739054,Title,0,test,gold,5570.0
3565,Eltrombopag for management of,chronic immune thrombocytopenia,"( RAISE ) : a 6-month , randomised , phase 3 study .","['Eltrombopag', 'for', 'management', 'of', 'chronic', 'immune', 'thrombocytopenia', '(', 'RAISE', ')', ':', 'a', '6-month', ',', 'randomised', ',', 'phase', '3', 'study', '.']","(4, 7)","(29, 60)",-1,hl_p,20739054,Title,0,test,gold,7097.0
3566,,Eltrombopag,"for management of chronic immune thrombocytopenia ( RAISE ) : a 6-month , randomised , phase 3 study .","['Eltrombopag', 'for', 'management', 'of', 'chronic', 'immune', 'thrombocytopenia', '(', 'RAISE', ')', ':', 'a', '6-month', ',', 'randomised', ',', 'phase', '3', 'study', '.']","(0, 1)","(0, 11)",-1,hl_i,20739054,Title,0,test,gold,5571.0
3567,BACKGROUND,Eltrombopag,is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia .,"['BACKGROUND', 'Eltrombopag', 'is', 'an', 'oral', 'thrombopoietin', 'receptor', 'agonist', 'for', 'the', 'treatment', 'of', 'thrombocytopenia', '.']","(1, 2)","(10, 21)",-1,ss_i,20739054,Abstract,0,test,gold,5569.0
3568,BACKGROUND,Eltrombopag,is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia .,"['BACKGROUND', 'Eltrombopag', 'is', 'an', 'oral', 'thrombopoietin', 'receptor', 'agonist', 'for', 'the', 'treatment', 'of', 'thrombocytopenia', '.']","(1, 2)","(10, 21)",-1,hl_i,20739054,Abstract,0,test,gold,5568.0
3569,We aimed to compare the response to once daily eltrombopag versus placebo in,patients with chronic immune thrombocytopenia,during a 6-month period .,"['We', 'aimed', 'to', 'compare', 'the', 'response', 'to', 'once', 'daily', 'eltrombopag', 'versus', 'placebo', 'in', 'patients', 'with', 'chronic', 'immune', 'thrombocytopenia', 'during', 'a', '6-month', 'period', '.']","(13, 18)","(76, 121)",-1,ss_p,20739054,Abstract,1,test,gold,7098.0
3570,We aimed to compare the response to once daily,eltrombopag,versus placebo in patients with chronic immune thrombocytopenia during a 6-month period .,"['We', 'aimed', 'to', 'compare', 'the', 'response', 'to', 'once', 'daily', 'eltrombopag', 'versus', 'placebo', 'in', 'patients', 'with', 'chronic', 'immune', 'thrombocytopenia', 'during', 'a', '6-month', 'period', '.']","(9, 10)","(46, 57)",-1,ss_i,20739054,Abstract,1,test,gold,5672.0
3571,We aimed to compare the response to once daily eltrombopag versus,placebo,in patients with chronic immune thrombocytopenia during a 6-month period .,"['We', 'aimed', 'to', 'compare', 'the', 'response', 'to', 'once', 'daily', 'eltrombopag', 'versus', 'placebo', 'in', 'patients', 'with', 'chronic', 'immune', 'thrombocytopenia', 'during', 'a', '6-month', 'period', '.']","(11, 12)","(65, 72)",-1,ss_i,20739054,Abstract,1,test,gold,4377.0
3572,We aimed to compare the,response,to once daily eltrombopag versus placebo in patients with chronic immune thrombocytopenia during a 6-month period .,"['We', 'aimed', 'to', 'compare', 'the', 'response', 'to', 'once', 'daily', 'eltrombopag', 'versus', 'placebo', 'in', 'patients', 'with', 'chronic', 'immune', 'thrombocytopenia', 'during', 'a', '6-month', 'period', '.']","(5, 6)","(23, 31)",-1,ss_o,20739054,Abstract,1,test,gold,2526.0
3573,We aimed to compare the response to once daily eltrombopag versus placebo in,patients with chronic immune thrombocytopenia,during a 6-month period .,"['We', 'aimed', 'to', 'compare', 'the', 'response', 'to', 'once', 'daily', 'eltrombopag', 'versus', 'placebo', 'in', 'patients', 'with', 'chronic', 'immune', 'thrombocytopenia', 'during', 'a', '6-month', 'period', '.']","(13, 18)","(76, 121)",-1,hl_p,20739054,Abstract,1,test,gold,7099.0
3574,We aimed to compare the response to once daily,eltrombopag,versus placebo in patients with chronic immune thrombocytopenia during a 6-month period .,"['We', 'aimed', 'to', 'compare', 'the', 'response', 'to', 'once', 'daily', 'eltrombopag', 'versus', 'placebo', 'in', 'patients', 'with', 'chronic', 'immune', 'thrombocytopenia', 'during', 'a', '6-month', 'period', '.']","(9, 10)","(46, 57)",-1,hl_i,20739054,Abstract,1,test,gold,5673.0
3575,We aimed to compare the response to once daily eltrombopag versus,placebo,in patients with chronic immune thrombocytopenia during a 6-month period .,"['We', 'aimed', 'to', 'compare', 'the', 'response', 'to', 'once', 'daily', 'eltrombopag', 'versus', 'placebo', 'in', 'patients', 'with', 'chronic', 'immune', 'thrombocytopenia', 'during', 'a', '6-month', 'period', '.']","(11, 12)","(65, 72)",-1,hl_i,20739054,Abstract,1,test,gold,4376.0
3576,We aimed to compare the,response,to once daily eltrombopag versus placebo in patients with chronic immune thrombocytopenia during a 6-month period .,"['We', 'aimed', 'to', 'compare', 'the', 'response', 'to', 'once', 'daily', 'eltrombopag', 'versus', 'placebo', 'in', 'patients', 'with', 'chronic', 'immune', 'thrombocytopenia', 'during', 'a', '6-month', 'period', '.']","(5, 6)","(23, 31)",-1,hl_o,20739054,Abstract,1,test,gold,2527.0
3577,"METHODS We undertook a phase 3 , double-blind , placebo-controlled study in","adults with previously treated immune thrombocytopenia of more than 6 months ' duration who had baseline platelet counts lower than 30,000 per μL",.,"['METHODS', 'We', 'undertook', 'a', 'phase', '3', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'adults', 'with', 'previously', 'treated', 'immune', 'thrombocytopenia', 'of', 'more', 'than', '6', 'months', ""'"", 'duration', 'who', 'had', 'baseline', 'platelet', 'counts', 'lower', 'than', '30,000', 'per', 'μL', '.']","(12, 35)","(75, 220)",-1,ss_p,20739054,Abstract,2,test,gold,5872.0
3578,"METHODS We undertook a phase 3 , double-blind , placebo-controlled study in",adults,"with previously treated immune thrombocytopenia of more than 6 months ' duration who had baseline platelet counts lower than 30,000 per μL .","['METHODS', 'We', 'undertook', 'a', 'phase', '3', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'adults', 'with', 'previously', 'treated', 'immune', 'thrombocytopenia', 'of', 'more', 'than', '6', 'months', ""'"", 'duration', 'who', 'had', 'baseline', 'platelet', 'counts', 'lower', 'than', '30,000', 'per', 'μL', '.']","(12, 13)","(75, 81)",-1,hl_p,20739054,Abstract,2,test,gold,2162.0
3579,"METHODS We undertook a phase 3 , double-blind , placebo-controlled study in adults with",previously treated immune thrombocytopenia of more than 6 months ' duration,"who had baseline platelet counts lower than 30,000 per μL .","['METHODS', 'We', 'undertook', 'a', 'phase', '3', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'adults', 'with', 'previously', 'treated', 'immune', 'thrombocytopenia', 'of', 'more', 'than', '6', 'months', ""'"", 'duration', 'who', 'had', 'baseline', 'platelet', 'counts', 'lower', 'than', '30,000', 'per', 'μL', '.']","(14, 25)","(87, 162)",-1,hl_p,20739054,Abstract,2,test,gold,7095.0
3580,"METHODS We undertook a phase 3 , double-blind , placebo-controlled study in adults with previously treated immune thrombocytopenia of more than 6 months ' duration who had","baseline platelet counts lower than 30,000 per μL",.,"['METHODS', 'We', 'undertook', 'a', 'phase', '3', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'adults', 'with', 'previously', 'treated', 'immune', 'thrombocytopenia', 'of', 'more', 'than', '6', 'months', ""'"", 'duration', 'who', 'had', 'baseline', 'platelet', 'counts', 'lower', 'than', '30,000', 'per', 'μL', '.']","(27, 35)","(171, 220)",-1,hl_p,20739054,Abstract,2,test,gold,6482.0
3581,"METHODS We undertook a phase 3 , double-blind ,",placebo-controlled,"study in adults with previously treated immune thrombocytopenia of more than 6 months ' duration who had baseline platelet counts lower than 30,000 per μL .","['METHODS', 'We', 'undertook', 'a', 'phase', '3', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'in', 'adults', 'with', 'previously', 'treated', 'immune', 'thrombocytopenia', 'of', 'more', 'than', '6', 'months', ""'"", 'duration', 'who', 'had', 'baseline', 'platelet', 'counts', 'lower', 'than', '30,000', 'per', 'μL', '.']","(9, 10)","(47, 65)",-1,hl_i,20739054,Abstract,2,test,gold,
3582,Patients were randomly allocated ( in a 2:1 ratio ) treatment with local standard of care plus 50,mg eltrombopag,or matching placebo once daily for 6 months .,"['Patients', 'were', 'randomly', 'allocated', '(', 'in', 'a', '2:1', 'ratio', ')', 'treatment', 'with', 'local', 'standard', 'of', 'care', 'plus', '50', 'mg', 'eltrombopag', 'or', 'matching', 'placebo', 'once', 'daily', 'for', '6', 'months', '.']","(18, 20)","(97, 111)",-1,ss_i,20739054,Abstract,3,test,gold,4440.0
3583,Patients were randomly allocated ( in a 2:1 ratio ) treatment with local standard of care plus 50 mg eltrombopag or,matching placebo,once daily for 6 months .,"['Patients', 'were', 'randomly', 'allocated', '(', 'in', 'a', '2:1', 'ratio', ')', 'treatment', 'with', 'local', 'standard', 'of', 'care', 'plus', '50', 'mg', 'eltrombopag', 'or', 'matching', 'placebo', 'once', 'daily', 'for', '6', 'months', '.']","(21, 23)","(115, 131)",-1,ss_i,20739054,Abstract,3,test,gold,4424.0
3584,Patients were randomly allocated ( in a 2:1 ratio ) treatment with local standard of care plus 50 mg,eltrombopag,or matching placebo once daily for 6 months .,"['Patients', 'were', 'randomly', 'allocated', '(', 'in', 'a', '2:1', 'ratio', ')', 'treatment', 'with', 'local', 'standard', 'of', 'care', 'plus', '50', 'mg', 'eltrombopag', 'or', 'matching', 'placebo', 'once', 'daily', 'for', '6', 'months', '.']","(19, 20)","(100, 111)",-1,hl_i,20739054,Abstract,3,test,gold,5671.0
3585,Patients were randomly allocated ( in a 2:1 ratio ) treatment with local standard of care plus 50 mg eltrombopag or matching,placebo,once daily for 6 months .,"['Patients', 'were', 'randomly', 'allocated', '(', 'in', 'a', '2:1', 'ratio', ')', 'treatment', 'with', 'local', 'standard', 'of', 'care', 'plus', '50', 'mg', 'eltrombopag', 'or', 'matching', 'placebo', 'once', 'daily', 'for', '6', 'months', '.']","(22, 23)","(124, 131)",-1,hl_i,20739054,Abstract,3,test,gold,4375.0
3586,"Randomisation was done centrally with a computer-generated randomisation schedule and was stratified by baseline platelet count ( ≤ 15,000 per μL ) , use of treatment for immune thrombocytopenia , and splenectomy status .",,,"['Randomisation', 'was', 'done', 'centrally', 'with', 'a', 'computer-generated', 'randomisation', 'schedule', 'and', 'was', 'stratified', 'by', 'baseline', 'platelet', 'count', '(', '≤', '15,000', 'per', 'μL', ')', ',', 'use', 'of', 'treatment', 'for', 'immune', 'thrombocytopenia', ',', 'and', 'splenectomy', 'status', '.']",,,,,20739054,Abstract,4,test,gold,
3587,"Patients , investigators , and those assessing data were masked to allocation .",,,"['Patients', ',', 'investigators', ',', 'and', 'those', 'assessing', 'data', 'were', 'masked', 'to', 'allocation', '.']",,,,,20739054,Abstract,5,test,gold,
3588,Dose modifications were made on the basis of platelet response .,,,"['Dose', 'modifications', 'were', 'made', 'on', 'the', 'basis', 'of', 'platelet', 'response', '.']",,,,,20739054,Abstract,6,test,gold,
3589,"Patients were assessed for response to treatment ( defined as a platelet count of 50,000-400,000 per μL ) weekly during the first 6 weeks and at least once every 4 weeks thereafter ; the primary endpoint was the odds of",response to eltrombopag versus placebo,.,"['Patients', 'were', 'assessed', 'for', 'response', 'to', 'treatment', '(', 'defined', 'as', 'a', 'platelet', 'count', 'of', '50,000-400,000', 'per', 'μL', ')', 'weekly', 'during', 'the', 'first', '6', 'weeks', 'and', 'at', 'least', 'once', 'every', '4', 'weeks', 'thereafter', ';', 'the', 'primary', 'endpoint', 'was', 'the', 'odds', 'of', 'response', 'to', 'eltrombopag', 'versus', 'placebo', '.']","(40, 45)","(219, 257)",-1,ss_i,20739054,Abstract,7,test,gold,4441.0
3590,Patients were assessed,"for response to treatment ( defined as a platelet count of 50,000-400,000 per",μL ) weekly during the first 6 weeks and at least once every 4 weeks thereafter ; the primary endpoint was the odds of response to eltrombopag versus placebo .,"['Patients', 'were', 'assessed', 'for', 'response', 'to', 'treatment', '(', 'defined', 'as', 'a', 'platelet', 'count', 'of', '50,000-400,000', 'per', 'μL', ')', 'weekly', 'during', 'the', 'first', '6', 'weeks', 'and', 'at', 'least', 'once', 'every', '4', 'weeks', 'thereafter', ';', 'the', 'primary', 'endpoint', 'was', 'the', 'odds', 'of', 'response', 'to', 'eltrombopag', 'versus', 'placebo', '.']","(3, 16)","(22, 99)",-1,ss_o,20739054,Abstract,7,test,gold,6483.0
3591,"Patients were assessed for response to treatment ( defined as a platelet count of 50,000-400,000 per μL ) weekly during the first 6 weeks and at least once every 4 weeks thereafter ; the primary endpoint",was the odds of response,to eltrombopag versus placebo .,"['Patients', 'were', 'assessed', 'for', 'response', 'to', 'treatment', '(', 'defined', 'as', 'a', 'platelet', 'count', 'of', '50,000-400,000', 'per', 'μL', ')', 'weekly', 'during', 'the', 'first', '6', 'weeks', 'and', 'at', 'least', 'once', 'every', '4', 'weeks', 'thereafter', ';', 'the', 'primary', 'endpoint', 'was', 'the', 'odds', 'of', 'response', 'to', 'eltrombopag', 'versus', 'placebo', '.']","(36, 41)","(203, 227)",-1,ss_o,20739054,Abstract,7,test,gold,2517.0
3592,"Patients were assessed for response to treatment ( defined as a platelet count of 50,000-400,000 per μL ) weekly during the first 6 weeks and at least once every 4 weeks thereafter ; the primary endpoint was the odds of response to",eltrombopag,versus placebo .,"['Patients', 'were', 'assessed', 'for', 'response', 'to', 'treatment', '(', 'defined', 'as', 'a', 'platelet', 'count', 'of', '50,000-400,000', 'per', 'μL', ')', 'weekly', 'during', 'the', 'first', '6', 'weeks', 'and', 'at', 'least', 'once', 'every', '4', 'weeks', 'thereafter', ';', 'the', 'primary', 'endpoint', 'was', 'the', 'odds', 'of', 'response', 'to', 'eltrombopag', 'versus', 'placebo', '.']","(42, 43)","(231, 242)",-1,hl_i,20739054,Abstract,7,test,gold,5670.0
3593,"Patients were assessed for response to treatment ( defined as a platelet count of 50,000-400,000 per μL ) weekly during the first 6 weeks and at least once every 4 weeks thereafter ; the primary endpoint was the odds of response to eltrombopag versus",placebo,.,"['Patients', 'were', 'assessed', 'for', 'response', 'to', 'treatment', '(', 'defined', 'as', 'a', 'platelet', 'count', 'of', '50,000-400,000', 'per', 'μL', ')', 'weekly', 'during', 'the', 'first', '6', 'weeks', 'and', 'at', 'least', 'once', 'every', '4', 'weeks', 'thereafter', ';', 'the', 'primary', 'endpoint', 'was', 'the', 'odds', 'of', 'response', 'to', 'eltrombopag', 'versus', 'placebo', '.']","(44, 45)","(250, 257)",-1,hl_i,20739054,Abstract,7,test,gold,4374.0
3594,Patients were assessed for,response to treatment,"( defined as a platelet count of 50,000-400,000 per μL ) weekly during the first 6 weeks and at least once every 4 weeks thereafter ; the primary endpoint was the odds of response to eltrombopag versus placebo .","['Patients', 'were', 'assessed', 'for', 'response', 'to', 'treatment', '(', 'defined', 'as', 'a', 'platelet', 'count', 'of', '50,000-400,000', 'per', 'μL', ')', 'weekly', 'during', 'the', 'first', '6', 'weeks', 'and', 'at', 'least', 'once', 'every', '4', 'weeks', 'thereafter', ';', 'the', 'primary', 'endpoint', 'was', 'the', 'odds', 'of', 'response', 'to', 'eltrombopag', 'versus', 'placebo', '.']","(4, 7)","(26, 47)",-1,hl_o,20739054,Abstract,7,test,gold,2533.0
3595,Patients were assessed for response to treatment ( defined as a,platelet count,"of 50,000-400,000 per μL ) weekly during the first 6 weeks and at least once every 4 weeks thereafter ; the primary endpoint was the odds of response to eltrombopag versus placebo .","['Patients', 'were', 'assessed', 'for', 'response', 'to', 'treatment', '(', 'defined', 'as', 'a', 'platelet', 'count', 'of', '50,000-400,000', 'per', 'μL', ')', 'weekly', 'during', 'the', 'first', '6', 'weeks', 'and', 'at', 'least', 'once', 'every', '4', 'weeks', 'thereafter', ';', 'the', 'primary', 'endpoint', 'was', 'the', 'odds', 'of', 'response', 'to', 'eltrombopag', 'versus', 'placebo', '.']","(11, 13)","(63, 77)",-1,hl_o,20739054,Abstract,7,test,gold,5498.0
3596,Analysis was by intention to treat .,,,"['Analysis', 'was', 'by', 'intention', 'to', 'treat', '.']",,,,,20739054,Abstract,8,test,gold,
3597,"This study is registered at ClinicalTrials.gov , number NCT00370331 .",,,"['This', 'study', 'is', 'registered', 'at', 'ClinicalTrials.gov', ',', 'number', 'NCT00370331', '.']",,,,,20739054,Abstract,9,test,gold,
3598,,"FINDINGS Between Nov 22 , 2006 , and July 31 , 2007 , 197 patients","were randomly allocated to treatment groups and were included in the intention-to-treat analysis ( 135 eltrombopag , 62 placebo ) .","['FINDINGS', 'Between', 'Nov', '22', ',', '2006', ',', 'and', 'July', '31', ',', '2007', ',', '197', 'patients', 'were', 'randomly', 'allocated', 'to', 'treatment', 'groups', 'and', 'were', 'included', 'in', 'the', 'intention-to-treat', 'analysis', '(', '135', 'eltrombopag', ',', '62', 'placebo', ')', '.']","(0, 15)","(0, 66)",-1,ss_p,20739054,Abstract,10,test,gold,1493.0
3599,"FINDINGS Between Nov 22 , 2006 , and July 31 , 2007 , 197 patients were randomly allocated to treatment groups and were included in the intention-to-treat analysis","( 135 eltrombopag , 62 placebo )",.,"['FINDINGS', 'Between', 'Nov', '22', ',', '2006', ',', 'and', 'July', '31', ',', '2007', ',', '197', 'patients', 'were', 'randomly', 'allocated', 'to', 'treatment', 'groups', 'and', 'were', 'included', 'in', 'the', 'intention-to-treat', 'analysis', '(', '135', 'eltrombopag', ',', '62', 'placebo', ')', '.']","(28, 35)","(163, 195)",-1,ss_i,20739054,Abstract,10,test,gold,4442.0
3600,"FINDINGS Between Nov 22 , 2006 , and July 31 , 2007 ,",197,"patients were randomly allocated to treatment groups and were included in the intention-to-treat analysis ( 135 eltrombopag , 62 placebo ) .","['FINDINGS', 'Between', 'Nov', '22', ',', '2006', ',', 'and', 'July', '31', ',', '2007', ',', '197', 'patients', 'were', 'randomly', 'allocated', 'to', 'treatment', 'groups', 'and', 'were', 'included', 'in', 'the', 'intention-to-treat', 'analysis', '(', '135', 'eltrombopag', ',', '62', 'placebo', ')', '.']","(13, 14)","(53, 56)",-1,hl_p,20739054,Abstract,10,test,gold,
3601,"FINDINGS Between Nov 22 , 2006 , and July 31 , 2007 , 197 patients were randomly allocated to treatment groups and were included in the intention-to-treat analysis ( 135",eltrombopag,", 62 placebo ) .","['FINDINGS', 'Between', 'Nov', '22', ',', '2006', ',', 'and', 'July', '31', ',', '2007', ',', '197', 'patients', 'were', 'randomly', 'allocated', 'to', 'treatment', 'groups', 'and', 'were', 'included', 'in', 'the', 'intention-to-treat', 'analysis', '(', '135', 'eltrombopag', ',', '62', 'placebo', ')', '.']","(30, 31)","(169, 180)",-1,hl_i,20739054,Abstract,10,test,gold,5669.0
3602,"FINDINGS Between Nov 22 , 2006 , and July 31 , 2007 , 197 patients were randomly allocated to treatment groups and were included in the intention-to-treat analysis ( 135 eltrombopag , 62",placebo,) .,"['FINDINGS', 'Between', 'Nov', '22', ',', '2006', ',', 'and', 'July', '31', ',', '2007', ',', '197', 'patients', 'were', 'randomly', 'allocated', 'to', 'treatment', 'groups', 'and', 'were', 'included', 'in', 'the', 'intention-to-treat', 'analysis', '(', '135', 'eltrombopag', ',', '62', 'placebo', ')', '.']","(33, 34)","(186, 193)",-1,hl_i,20739054,Abstract,10,test,gold,4373.0
3603,106 ( 79 % ) patients,in the eltrombopag,"group responded to treatment at least once during the study , compared with 17 ( 28 % ) patients in the placebo group .","['106', '(', '79', '%', ')', 'patients', 'in', 'the', 'eltrombopag', 'group', 'responded', 'to', 'treatment', 'at', 'least', 'once', 'during', 'the', 'study', ',', 'compared', 'with', '17', '(', '28', '%', ')', 'patients', 'in', 'the', 'placebo', 'group', '.']","(6, 9)","(21, 39)",-1,ss_i,20739054,Abstract,11,test,gold,5674.0
3604,"106 ( 79 % ) patients in the eltrombopag group responded to treatment at least once during the study , compared with 17 ( 28 % ) patients",in the placebo,group .,"['106', '(', '79', '%', ')', 'patients', 'in', 'the', 'eltrombopag', 'group', 'responded', 'to', 'treatment', 'at', 'least', 'once', 'during', 'the', 'study', ',', 'compared', 'with', '17', '(', '28', '%', ')', 'patients', 'in', 'the', 'placebo', 'group', '.']","(28, 31)","(137, 151)",-1,ss_i,20739054,Abstract,11,test,gold,4427.0
3605,106 ( 79 % ) patients in the eltrombopag,group responded,"to treatment at least once during the study , compared with 17 ( 28 % ) patients in the placebo group .","['106', '(', '79', '%', ')', 'patients', 'in', 'the', 'eltrombopag', 'group', 'responded', 'to', 'treatment', 'at', 'least', 'once', 'during', 'the', 'study', ',', 'compared', 'with', '17', '(', '28', '%', ')', 'patients', 'in', 'the', 'placebo', 'group', '.']","(9, 11)","(40, 55)",-1,ss_o,20739054,Abstract,11,test,gold,1160.0
3606,"106 ( 79 % ) patients in the eltrombopag group responded to treatment at least once during the study , compared with 17 ( 28 % ) patients in the placebo group",.,,"['106', '(', '79', '%', ')', 'patients', 'in', 'the', 'eltrombopag', 'group', 'responded', 'to', 'treatment', 'at', 'least', 'once', 'during', 'the', 'study', ',', 'compared', 'with', '17', '(', '28', '%', ')', 'patients', 'in', 'the', 'placebo', 'group', '.']","(32, 33)","(158, 159)",-1,ss_o,20739054,Abstract,11,test,gold,
3607,106 ( 79 % ) patients in the,eltrombopag,"group responded to treatment at least once during the study , compared with 17 ( 28 % ) patients in the placebo group .","['106', '(', '79', '%', ')', 'patients', 'in', 'the', 'eltrombopag', 'group', 'responded', 'to', 'treatment', 'at', 'least', 'once', 'during', 'the', 'study', ',', 'compared', 'with', '17', '(', '28', '%', ')', 'patients', 'in', 'the', 'placebo', 'group', '.']","(8, 9)","(28, 39)",-1,hl_i,20739054,Abstract,11,test,gold,5668.0
3608,106 ( 79 % ) patients in the eltrombopag group,responded to treatment,"at least once during the study , compared with 17 ( 28 % ) patients in the placebo group .","['106', '(', '79', '%', ')', 'patients', 'in', 'the', 'eltrombopag', 'group', 'responded', 'to', 'treatment', 'at', 'least', 'once', 'during', 'the', 'study', ',', 'compared', 'with', '17', '(', '28', '%', ')', 'patients', 'in', 'the', 'placebo', 'group', '.']","(10, 13)","(46, 68)",-1,hl_o,20739054,Abstract,11,test,gold,1161.0
3609,The odds of responding were greater in patients,in the eltrombopag,"group compared with those in the placebo group throughout the 6-month treatment period ( odds ratio 8·2 , 99 % CI 3·59-18·73 ; p < 0·0001 ) .","['The', 'odds', 'of', 'responding', 'were', 'greater', 'in', 'patients', 'in', 'the', 'eltrombopag', 'group', 'compared', 'with', 'those', 'in', 'the', 'placebo', 'group', 'throughout', 'the', '6-month', 'treatment', 'period', '(', 'odds', 'ratio', '8·2', ',', '99', '%', 'CI', '3·59-18·73', ';', 'p', '<', '0·0001', ')', '.']","(8, 11)","(47, 65)",-1,ss_i,20739054,Abstract,12,test,gold,5675.0
3610,The odds of responding were greater in patients in the eltrombopag group compared with those,in the placebo,"group throughout the 6-month treatment period ( odds ratio 8·2 , 99 % CI 3·59-18·73 ; p < 0·0001 ) .","['The', 'odds', 'of', 'responding', 'were', 'greater', 'in', 'patients', 'in', 'the', 'eltrombopag', 'group', 'compared', 'with', 'those', 'in', 'the', 'placebo', 'group', 'throughout', 'the', '6-month', 'treatment', 'period', '(', 'odds', 'ratio', '8·2', ',', '99', '%', 'CI', '3·59-18·73', ';', 'p', '<', '0·0001', ')', '.']","(15, 18)","(92, 106)",-1,ss_i,20739054,Abstract,12,test,gold,4428.0
3611,,The odds of responding,"were greater in patients in the eltrombopag group compared with those in the placebo group throughout the 6-month treatment period ( odds ratio 8·2 , 99 % CI 3·59-18·73 ; p < 0·0001 ) .","['The', 'odds', 'of', 'responding', 'were', 'greater', 'in', 'patients', 'in', 'the', 'eltrombopag', 'group', 'compared', 'with', 'those', 'in', 'the', 'placebo', 'group', 'throughout', 'the', '6-month', 'treatment', 'period', '(', 'odds', 'ratio', '8·2', ',', '99', '%', 'CI', '3·59-18·73', ';', 'p', '<', '0·0001', ')', '.']","(0, 4)","(0, 22)",-1,ss_o,20739054,Abstract,12,test,gold,2518.0
3612,The odds of responding were greater in patients in the,eltrombopag,"group compared with those in the placebo group throughout the 6-month treatment period ( odds ratio 8·2 , 99 % CI 3·59-18·73 ; p < 0·0001 ) .","['The', 'odds', 'of', 'responding', 'were', 'greater', 'in', 'patients', 'in', 'the', 'eltrombopag', 'group', 'compared', 'with', 'those', 'in', 'the', 'placebo', 'group', 'throughout', 'the', '6-month', 'treatment', 'period', '(', 'odds', 'ratio', '8·2', ',', '99', '%', 'CI', '3·59-18·73', ';', 'p', '<', '0·0001', ')', '.']","(10, 11)","(54, 65)",-1,hl_i,20739054,Abstract,12,test,gold,5667.0
3613,The odds of responding were greater in patients in the eltrombopag group compared with those in the,placebo,"group throughout the 6-month treatment period ( odds ratio 8·2 , 99 % CI 3·59-18·73 ; p < 0·0001 ) .","['The', 'odds', 'of', 'responding', 'were', 'greater', 'in', 'patients', 'in', 'the', 'eltrombopag', 'group', 'compared', 'with', 'those', 'in', 'the', 'placebo', 'group', 'throughout', 'the', '6-month', 'treatment', 'period', '(', 'odds', 'ratio', '8·2', ',', '99', '%', 'CI', '3·59-18·73', ';', 'p', '<', '0·0001', ')', '.']","(17, 18)","(99, 106)",-1,hl_i,20739054,Abstract,12,test,gold,4372.0
3614,37 ( 59 % ) patients,receiving eltrombopag,reduced concomitant treatment versus ten ( 32 % ) patients receiving placebo ( p=0·016 ) .,"['37', '(', '59', '%', ')', 'patients', 'receiving', 'eltrombopag', 'reduced', 'concomitant', 'treatment', 'versus', 'ten', '(', '32', '%', ')', 'patients', 'receiving', 'placebo', '(', 'p=0·016', ')', '.']","(6, 8)","(20, 41)",-1,ss_i,20739054,Abstract,13,test,gold,5678.0
3615,37 ( 59 % ) patients receiving eltrombopag reduced concomitant treatment versus ten ( 32 % ) patients,receiving,placebo ( p=0·016 ) .,"['37', '(', '59', '%', ')', 'patients', 'receiving', 'eltrombopag', 'reduced', 'concomitant', 'treatment', 'versus', 'ten', '(', '32', '%', ')', 'patients', 'receiving', 'placebo', '(', 'p=0·016', ')', '.']","(18, 19)","(101, 110)",-1,ss_i,20739054,Abstract,13,test,gold,1163.0
3616,37 ( 59 % ) patients receiving,eltrombopag reduced concomitant treatment,versus ten ( 32 % ) patients receiving placebo ( p=0·016 ) .,"['37', '(', '59', '%', ')', 'patients', 'receiving', 'eltrombopag', 'reduced', 'concomitant', 'treatment', 'versus', 'ten', '(', '32', '%', ')', 'patients', 'receiving', 'placebo', '(', 'p=0·016', ')', '.']","(7, 11)","(30, 71)",-1,ss_o,20739054,Abstract,13,test,gold,5676.0
3617,37 ( 59 % ) patients receiving,eltrombopag,reduced concomitant treatment versus ten ( 32 % ) patients receiving placebo ( p=0·016 ) .,"['37', '(', '59', '%', ')', 'patients', 'receiving', 'eltrombopag', 'reduced', 'concomitant', 'treatment', 'versus', 'ten', '(', '32', '%', ')', 'patients', 'receiving', 'placebo', '(', 'p=0·016', ')', '.']","(7, 8)","(30, 41)",-1,hl_i,20739054,Abstract,13,test,gold,5666.0
3618,24 ( 18 % ) patients,receiving eltrombopag,needed rescue treatment compared with 25 ( 40 % ) patients receiving placebo ( p=0·001 ) .,"['24', '(', '18', '%', ')', 'patients', 'receiving', 'eltrombopag', 'needed', 'rescue', 'treatment', 'compared', 'with', '25', '(', '40', '%', ')', 'patients', 'receiving', 'placebo', '(', 'p=0·001', ')', '.']","(6, 8)","(20, 41)",-1,ss_i,20739054,Abstract,14,test,gold,5679.0
3619,24 ( 18 % ) patients receiving eltrombopag needed rescue treatment compared with 25 ( 40 % ) patients,receiving,placebo ( p=0·001 ) .,"['24', '(', '18', '%', ')', 'patients', 'receiving', 'eltrombopag', 'needed', 'rescue', 'treatment', 'compared', 'with', '25', '(', '40', '%', ')', 'patients', 'receiving', 'placebo', '(', 'p=0·001', ')', '.']","(19, 20)","(101, 110)",-1,ss_i,20739054,Abstract,14,test,gold,1164.0
3620,24 ( 18 % ) patients receiving,eltrombopag needed rescue,treatment compared with 25 ( 40 % ) patients receiving placebo ( p=0·001 ) .,"['24', '(', '18', '%', ')', 'patients', 'receiving', 'eltrombopag', 'needed', 'rescue', 'treatment', 'compared', 'with', '25', '(', '40', '%', ')', 'patients', 'receiving', 'placebo', '(', 'p=0·001', ')', '.']","(7, 10)","(30, 55)",-1,ss_o,20739054,Abstract,14,test,gold,5661.0
3621,24 ( 18 % ) patients receiving,eltrombopag,needed rescue treatment compared with 25 ( 40 % ) patients receiving placebo ( p=0·001 ) .,"['24', '(', '18', '%', ')', 'patients', 'receiving', 'eltrombopag', 'needed', 'rescue', 'treatment', 'compared', 'with', '25', '(', '40', '%', ')', 'patients', 'receiving', 'placebo', '(', 'p=0·001', ')', '.']","(7, 8)","(30, 41)",-1,hl_i,20739054,Abstract,14,test,gold,5665.0
3622,Three ( 2 % ),patients receiving eltrombopag,had thromboembolic events compared with none in patients on placebo .,"['Three', '(', '2', '%', ')', 'patients', 'receiving', 'eltrombopag', 'had', 'thromboembolic', 'events', 'compared', 'with', 'none', 'in', 'patients', 'on', 'placebo', '.']","(5, 8)","(13, 43)",-1,ss_i,20739054,Abstract,15,test,gold,5677.0
3623,Three ( 2 % ) patients receiving eltrombopag had thromboembolic events compared with none in,patients,on placebo .,"['Three', '(', '2', '%', ')', 'patients', 'receiving', 'eltrombopag', 'had', 'thromboembolic', 'events', 'compared', 'with', 'none', 'in', 'patients', 'on', 'placebo', '.']","(15, 16)","(92, 100)",-1,ss_i,20739054,Abstract,15,test,gold,3746.0
3624,Three ( 2 % ) patients receiving eltrombopag had thromboembolic events compared with none in patients on placebo,.,,"['Three', '(', '2', '%', ')', 'patients', 'receiving', 'eltrombopag', 'had', 'thromboembolic', 'events', 'compared', 'with', 'none', 'in', 'patients', 'on', 'placebo', '.']","(18, 19)","(112, 113)",-1,ss_i,20739054,Abstract,15,test,gold,
3625,Three ( 2 % ) patients receiving,eltrombopag had thromboembolic,events compared with none in patients on placebo .,"['Three', '(', '2', '%', ')', 'patients', 'receiving', 'eltrombopag', 'had', 'thromboembolic', 'events', 'compared', 'with', 'none', 'in', 'patients', 'on', 'placebo', '.']","(7, 10)","(32, 62)",-1,ss_o,20739054,Abstract,15,test,gold,5681.0
3626,Three ( 2 % ) patients receiving,eltrombopag,had thromboembolic events compared with none in patients on placebo .,"['Three', '(', '2', '%', ')', 'patients', 'receiving', 'eltrombopag', 'had', 'thromboembolic', 'events', 'compared', 'with', 'none', 'in', 'patients', 'on', 'placebo', '.']","(7, 8)","(32, 43)",-1,hl_i,20739054,Abstract,15,test,gold,5664.0
3627,Three ( 2 % ) patients receiving eltrombopag had,thromboembolic,events compared with none in patients on placebo .,"['Three', '(', '2', '%', ')', 'patients', 'receiving', 'eltrombopag', 'had', 'thromboembolic', 'events', 'compared', 'with', 'none', 'in', 'patients', 'on', 'placebo', '.']","(9, 10)","(48, 62)",-1,hl_o,20739054,Abstract,15,test,gold,57.0
3628,,Nine ( 7 % ) eltrombopag-treated,"patients and two ( 3 % ) in the placebo group had mild increases in alanine aminotransferase concentration , and five ( 4 % ) eltrombopag-treated patients ( vs none allocated to placebo ) had increases in total bilirubin .","['Nine', '(', '7', '%', ')', 'eltrombopag-treated', 'patients', 'and', 'two', '(', '3', '%', ')', 'in', 'the', 'placebo', 'group', 'had', 'mild', 'increases', 'in', 'alanine', 'aminotransferase', 'concentration', ',', 'and', 'five', '(', '4', '%', ')', 'eltrombopag-treated', 'patients', '(', 'vs', 'none', 'allocated', 'to', 'placebo', ')', 'had', 'increases', 'in', 'total', 'bilirubin', '.']","(0, 6)","(0, 32)",-1,ss_i,20739054,Abstract,16,test,gold,1498.0
3629,Nine ( 7 % ) eltrombopag-treated patients and two,( 3 % ) in the,"placebo group had mild increases in alanine aminotransferase concentration , and five ( 4 % ) eltrombopag-treated patients ( vs none allocated to placebo ) had increases in total bilirubin .","['Nine', '(', '7', '%', ')', 'eltrombopag-treated', 'patients', 'and', 'two', '(', '3', '%', ')', 'in', 'the', 'placebo', 'group', 'had', 'mild', 'increases', 'in', 'alanine', 'aminotransferase', 'concentration', ',', 'and', 'five', '(', '4', '%', ')', 'eltrombopag-treated', 'patients', '(', 'vs', 'none', 'allocated', 'to', 'placebo', ')', 'had', 'increases', 'in', 'total', 'bilirubin', '.']","(9, 15)","(49, 63)",-1,ss_i,20739054,Abstract,16,test,gold,1499.0
3630,"Nine ( 7 % ) eltrombopag-treated patients and two ( 3 % ) in the placebo group had mild increases in alanine aminotransferase concentration ,",and five ( 4 % ) eltrombopag-treated,patients ( vs none allocated to placebo ) had increases in total bilirubin .,"['Nine', '(', '7', '%', ')', 'eltrombopag-treated', 'patients', 'and', 'two', '(', '3', '%', ')', 'in', 'the', 'placebo', 'group', 'had', 'mild', 'increases', 'in', 'alanine', 'aminotransferase', 'concentration', ',', 'and', 'five', '(', '4', '%', ')', 'eltrombopag-treated', 'patients', '(', 'vs', 'none', 'allocated', 'to', 'placebo', ')', 'had', 'increases', 'in', 'total', 'bilirubin', '.']","(25, 32)","(141, 177)",-1,ss_i,20739054,Abstract,16,test,gold,1500.0
3631,"Nine ( 7 % ) eltrombopag-treated patients and two ( 3 % ) in the placebo group had mild increases in alanine aminotransferase concentration , and five ( 4 % ) eltrombopag-treated patients ( vs none",allocated,to placebo ) had increases in total bilirubin .,"['Nine', '(', '7', '%', ')', 'eltrombopag-treated', 'patients', 'and', 'two', '(', '3', '%', ')', 'in', 'the', 'placebo', 'group', 'had', 'mild', 'increases', 'in', 'alanine', 'aminotransferase', 'concentration', ',', 'and', 'five', '(', '4', '%', ')', 'eltrombopag-treated', 'patients', '(', 'vs', 'none', 'allocated', 'to', 'placebo', ')', 'had', 'increases', 'in', 'total', 'bilirubin', '.']","(36, 37)","(197, 206)",-1,ss_i,20739054,Abstract,16,test,gold,1213.0
3632,Nine ( 7 % ) eltrombopag-treated patients and two ( 3 % ) in the placebo group had mild,increases in alanine aminotransferase concentration,", and five ( 4 % ) eltrombopag-treated patients ( vs none allocated to placebo ) had increases in total bilirubin .","['Nine', '(', '7', '%', ')', 'eltrombopag-treated', 'patients', 'and', 'two', '(', '3', '%', ')', 'in', 'the', 'placebo', 'group', 'had', 'mild', 'increases', 'in', 'alanine', 'aminotransferase', 'concentration', ',', 'and', 'five', '(', '4', '%', ')', 'eltrombopag-treated', 'patients', '(', 'vs', 'none', 'allocated', 'to', 'placebo', ')', 'had', 'increases', 'in', 'total', 'bilirubin', '.']","(19, 24)","(87, 138)",-1,ss_o,20739054,Abstract,16,test,gold,4505.0
3633,"Nine ( 7 % ) eltrombopag-treated patients and two ( 3 % ) in the placebo group had mild increases in alanine aminotransferase concentration , and five ( 4 % ) eltrombopag-treated patients ( vs none allocated to placebo ) had",increases in total,bilirubin .,"['Nine', '(', '7', '%', ')', 'eltrombopag-treated', 'patients', 'and', 'two', '(', '3', '%', ')', 'in', 'the', 'placebo', 'group', 'had', 'mild', 'increases', 'in', 'alanine', 'aminotransferase', 'concentration', ',', 'and', 'five', '(', '4', '%', ')', 'eltrombopag-treated', 'patients', '(', 'vs', 'none', 'allocated', 'to', 'placebo', ')', 'had', 'increases', 'in', 'total', 'bilirubin', '.']","(41, 44)","(224, 242)",-1,ss_o,20739054,Abstract,16,test,gold,980.0
3634,Nine ( 7 % ),eltrombopag-treated,"patients and two ( 3 % ) in the placebo group had mild increases in alanine aminotransferase concentration , and five ( 4 % ) eltrombopag-treated patients ( vs none allocated to placebo ) had increases in total bilirubin .","['Nine', '(', '7', '%', ')', 'eltrombopag-treated', 'patients', 'and', 'two', '(', '3', '%', ')', 'in', 'the', 'placebo', 'group', 'had', 'mild', 'increases', 'in', 'alanine', 'aminotransferase', 'concentration', ',', 'and', 'five', '(', '4', '%', ')', 'eltrombopag-treated', 'patients', '(', 'vs', 'none', 'allocated', 'to', 'placebo', ')', 'had', 'increases', 'in', 'total', 'bilirubin', '.']","(5, 6)","(12, 31)",-1,hl_i,20739054,Abstract,16,test,gold,
3635,"Nine ( 7 % ) eltrombopag-treated patients and two ( 3 % ) in the placebo group had mild increases in alanine aminotransferase concentration , and five ( 4 % )",eltrombopag-treated,patients ( vs none allocated to placebo ) had increases in total bilirubin .,"['Nine', '(', '7', '%', ')', 'eltrombopag-treated', 'patients', 'and', 'two', '(', '3', '%', ')', 'in', 'the', 'placebo', 'group', 'had', 'mild', 'increases', 'in', 'alanine', 'aminotransferase', 'concentration', ',', 'and', 'five', '(', '4', '%', ')', 'eltrombopag-treated', 'patients', '(', 'vs', 'none', 'allocated', 'to', 'placebo', ')', 'had', 'increases', 'in', 'total', 'bilirubin', '.']","(31, 32)","(158, 177)",-1,hl_i,20739054,Abstract,16,test,gold,
3636,Four ( 7 % ),patients taking,"placebo had serious bleeding events , compared with one ( < 1 % ) patient treated with eltrombopag .","['Four', '(', '7', '%', ')', 'patients', 'taking', 'placebo', 'had', 'serious', 'bleeding', 'events', ',', 'compared', 'with', 'one', '(', '<', '1', '%', ')', 'patient', 'treated', 'with', 'eltrombopag', '.']","(5, 7)","(12, 27)",-1,ss_i,20739054,Abstract,17,test,gold,3734.0
3637,"Four ( 7 % ) patients taking placebo had serious bleeding events , compared with one ( < 1 % ) patient",treated with eltrombopag,.,"['Four', '(', '7', '%', ')', 'patients', 'taking', 'placebo', 'had', 'serious', 'bleeding', 'events', ',', 'compared', 'with', 'one', '(', '<', '1', '%', ')', 'patient', 'treated', 'with', 'eltrombopag', '.']","(22, 25)","(102, 126)",-1,ss_i,20739054,Abstract,17,test,gold,5682.0
3638,Four ( 7 % ) patients taking,placebo had serious bleeding,"events , compared with one ( < 1 % ) patient treated with eltrombopag .","['Four', '(', '7', '%', ')', 'patients', 'taking', 'placebo', 'had', 'serious', 'bleeding', 'events', ',', 'compared', 'with', 'one', '(', '<', '1', '%', ')', 'patient', 'treated', 'with', 'eltrombopag', '.']","(7, 11)","(28, 56)",-1,ss_o,20739054,Abstract,17,test,gold,4439.0
3639,"Four ( 7 % ) patients taking placebo had serious bleeding events , compared with one ( < 1 % ) patient treated with",eltrombopag,.,"['Four', '(', '7', '%', ')', 'patients', 'taking', 'placebo', 'had', 'serious', 'bleeding', 'events', ',', 'compared', 'with', 'one', '(', '<', '1', '%', ')', 'patient', 'treated', 'with', 'eltrombopag', '.']","(24, 25)","(115, 126)",-1,hl_i,20739054,Abstract,17,test,gold,5663.0
3640,Four ( 7 % ) patients taking placebo had,serious bleeding,"events , compared with one ( < 1 % ) patient treated with eltrombopag .","['Four', '(', '7', '%', ')', 'patients', 'taking', 'placebo', 'had', 'serious', 'bleeding', 'events', ',', 'compared', 'with', 'one', '(', '<', '1', '%', ')', 'patient', 'treated', 'with', 'eltrombopag', '.']","(9, 11)","(40, 56)",-1,hl_o,20739054,Abstract,17,test,gold,2647.0
3641,,INTERPRETATION Eltrombopag,"is effective for management of chronic immune thrombocytopenia , and could be particularly beneficial for patients who have not responded to splenectomy or previous treatment .","['INTERPRETATION', 'Eltrombopag', 'is', 'effective', 'for', 'management', 'of', 'chronic', 'immune', 'thrombocytopenia', ',', 'and', 'could', 'be', 'particularly', 'beneficial', 'for', 'patients', 'who', 'have', 'not', 'responded', 'to', 'splenectomy', 'or', 'previous', 'treatment', '.']","(0, 2)","(0, 26)",-1,ss_i,20739054,Abstract,18,test,gold,5566.0
3642,INTERPRETATION,Eltrombopag is,"effective for management of chronic immune thrombocytopenia , and could be particularly beneficial for patients who have not responded to splenectomy or previous treatment .","['INTERPRETATION', 'Eltrombopag', 'is', 'effective', 'for', 'management', 'of', 'chronic', 'immune', 'thrombocytopenia', ',', 'and', 'could', 'be', 'particularly', 'beneficial', 'for', 'patients', 'who', 'have', 'not', 'responded', 'to', 'splenectomy', 'or', 'previous', 'treatment', '.']","(1, 3)","(14, 28)",-1,ss_o,20739054,Abstract,18,test,gold,5565.0
3643,INTERPRETATION,Eltrombopag,"is effective for management of chronic immune thrombocytopenia , and could be particularly beneficial for patients who have not responded to splenectomy or previous treatment .","['INTERPRETATION', 'Eltrombopag', 'is', 'effective', 'for', 'management', 'of', 'chronic', 'immune', 'thrombocytopenia', ',', 'and', 'could', 'be', 'particularly', 'beneficial', 'for', 'patients', 'who', 'have', 'not', 'responded', 'to', 'splenectomy', 'or', 'previous', 'treatment', '.']","(1, 2)","(14, 25)",-1,hl_i,20739054,Abstract,18,test,gold,5567.0
3644,These benefits should be balanced with the potential risks,associated with eltrombopag,treatment .,"['These', 'benefits', 'should', 'be', 'balanced', 'with', 'the', 'potential', 'risks', 'associated', 'with', 'eltrombopag', 'treatment', '.']","(9, 12)","(58, 85)",-1,ss_i,20739054,Abstract,19,test,gold,5683.0
3645,These benefits should be balanced with the potential risks associated with,eltrombopag,treatment .,"['These', 'benefits', 'should', 'be', 'balanced', 'with', 'the', 'potential', 'risks', 'associated', 'with', 'eltrombopag', 'treatment', '.']","(11, 12)","(74, 85)",-1,hl_i,20739054,Abstract,19,test,gold,5662.0
3646,FUNDING GlaxoSmithKline .,,,"['FUNDING', 'GlaxoSmithKline', '.']",,,,,20739054,Abstract,20,test,gold,
3647,Randomized controlled trial of acupuncture versus sham acupuncture in,autism spectrum disorder .,,"['Randomized', 'controlled', 'trial', 'of', 'acupuncture', 'versus', 'sham', 'acupuncture', 'in', 'autism', 'spectrum', 'disorder', '.']","(9, 13)","(69, 95)",-1,ss_p,20804366,Title,0,test,gold,6014.0
3648,Randomized controlled trial of,acupuncture,versus sham acupuncture in autism spectrum disorder .,"['Randomized', 'controlled', 'trial', 'of', 'acupuncture', 'versus', 'sham', 'acupuncture', 'in', 'autism', 'spectrum', 'disorder', '.']","(4, 5)","(30, 41)",-1,ss_i,20804366,Title,0,test,gold,4176.0
3649,Randomized controlled trial of acupuncture versus,sham acupuncture,in autism spectrum disorder .,"['Randomized', 'controlled', 'trial', 'of', 'acupuncture', 'versus', 'sham', 'acupuncture', 'in', 'autism', 'spectrum', 'disorder', '.']","(6, 8)","(49, 65)",-1,ss_i,20804366,Title,0,test,gold,4180.0
3650,Randomized controlled trial of acupuncture versus sham acupuncture in,autism spectrum disorder .,,"['Randomized', 'controlled', 'trial', 'of', 'acupuncture', 'versus', 'sham', 'acupuncture', 'in', 'autism', 'spectrum', 'disorder', '.']","(9, 13)","(69, 95)",-1,hl_p,20804366,Title,0,test,gold,6015.0
3651,Randomized controlled trial of,acupuncture,versus sham acupuncture in autism spectrum disorder .,"['Randomized', 'controlled', 'trial', 'of', 'acupuncture', 'versus', 'sham', 'acupuncture', 'in', 'autism', 'spectrum', 'disorder', '.']","(4, 5)","(30, 41)",-1,hl_i,20804366,Title,0,test,gold,4177.0
3652,Randomized controlled trial of acupuncture versus,sham acupuncture,in autism spectrum disorder .,"['Randomized', 'controlled', 'trial', 'of', 'acupuncture', 'versus', 'sham', 'acupuncture', 'in', 'autism', 'spectrum', 'disorder', '.']","(6, 8)","(49, 65)",-1,hl_i,20804366,Title,0,test,gold,4181.0
3653,OBJECTIVE We aim to study the efficacy of acupuncture versus sham acupuncture in,children with autism spectrum disorder .,,"['OBJECTIVE', 'We', 'aim', 'to', 'study', 'the', 'efficacy', 'of', 'acupuncture', 'versus', 'sham', 'acupuncture', 'in', 'children', 'with', 'autism', 'spectrum', 'disorder', '.']","(13, 19)","(80, 120)",-1,ss_p,20804366,Abstract,0,test,gold,6052.0
3654,OBJECTIVE We aim to study the efficacy of,acupuncture,versus sham acupuncture in children with autism spectrum disorder .,"['OBJECTIVE', 'We', 'aim', 'to', 'study', 'the', 'efficacy', 'of', 'acupuncture', 'versus', 'sham', 'acupuncture', 'in', 'children', 'with', 'autism', 'spectrum', 'disorder', '.']","(8, 9)","(41, 52)",-1,ss_i,20804366,Abstract,0,test,gold,4175.0
3655,OBJECTIVE We aim to study the efficacy of acupuncture versus,sham acupuncture,in children with autism spectrum disorder .,"['OBJECTIVE', 'We', 'aim', 'to', 'study', 'the', 'efficacy', 'of', 'acupuncture', 'versus', 'sham', 'acupuncture', 'in', 'children', 'with', 'autism', 'spectrum', 'disorder', '.']","(10, 12)","(60, 76)",-1,ss_i,20804366,Abstract,0,test,gold,4179.0
3656,OBJECTIVE We aim to study the,efficacy,of acupuncture versus sham acupuncture in children with autism spectrum disorder .,"['OBJECTIVE', 'We', 'aim', 'to', 'study', 'the', 'efficacy', 'of', 'acupuncture', 'versus', 'sham', 'acupuncture', 'in', 'children', 'with', 'autism', 'spectrum', 'disorder', '.']","(6, 7)","(29, 37)",-1,ss_o,20804366,Abstract,0,test,gold,4812.0
3657,OBJECTIVE We aim to study the efficacy of acupuncture versus sham acupuncture in,children,with autism spectrum disorder .,"['OBJECTIVE', 'We', 'aim', 'to', 'study', 'the', 'efficacy', 'of', 'acupuncture', 'versus', 'sham', 'acupuncture', 'in', 'children', 'with', 'autism', 'spectrum', 'disorder', '.']","(13, 14)","(80, 88)",-1,hl_p,20804366,Abstract,0,test,gold,2133.0
3658,OBJECTIVE We aim to study the efficacy of acupuncture versus sham acupuncture in children with,autism spectrum disorder,.,"['OBJECTIVE', 'We', 'aim', 'to', 'study', 'the', 'efficacy', 'of', 'acupuncture', 'versus', 'sham', 'acupuncture', 'in', 'children', 'with', 'autism', 'spectrum', 'disorder', '.']","(15, 18)","(94, 118)",-1,hl_p,20804366,Abstract,0,test,gold,6013.0
3659,OBJECTIVE We aim to study the efficacy of,acupuncture,versus sham acupuncture in children with autism spectrum disorder .,"['OBJECTIVE', 'We', 'aim', 'to', 'study', 'the', 'efficacy', 'of', 'acupuncture', 'versus', 'sham', 'acupuncture', 'in', 'children', 'with', 'autism', 'spectrum', 'disorder', '.']","(8, 9)","(41, 52)",-1,hl_i,20804366,Abstract,0,test,gold,4174.0
3660,OBJECTIVE We aim to study the efficacy of acupuncture versus,sham acupuncture,in children with autism spectrum disorder .,"['OBJECTIVE', 'We', 'aim', 'to', 'study', 'the', 'efficacy', 'of', 'acupuncture', 'versus', 'sham', 'acupuncture', 'in', 'children', 'with', 'autism', 'spectrum', 'disorder', '.']","(10, 12)","(60, 76)",-1,hl_i,20804366,Abstract,0,test,gold,4178.0
3661,OBJECTIVE We aim to study the,efficacy,of acupuncture versus sham acupuncture in children with autism spectrum disorder .,"['OBJECTIVE', 'We', 'aim', 'to', 'study', 'the', 'efficacy', 'of', 'acupuncture', 'versus', 'sham', 'acupuncture', 'in', 'children', 'with', 'autism', 'spectrum', 'disorder', '.']","(6, 7)","(29, 37)",-1,hl_o,20804366,Abstract,0,test,gold,4811.0
3662,METHODS A single-blind randomized control trial was conducted in,50 children .,,"['METHODS', 'A', 'single-blind', 'randomized', 'control', 'trial', 'was', 'conducted', 'in', '50', 'children', '.']","(9, 12)","(64, 77)",-1,ss_p,20804366,Abstract,1,test,gold,2132.0
3663,METHODS A single-blind randomized control trial was conducted in,50 children,.,"['METHODS', 'A', 'single-blind', 'randomized', 'control', 'trial', 'was', 'conducted', 'in', '50', 'children', '.']","(9, 11)","(64, 75)",-1,hl_p,20804366,Abstract,1,test,gold,2131.0
3664,These children were randomly assigned to the treatment group with,tongue acupuncture,( 40 sessions over 8 weeks ) or the control group ( sham tongue acupuncture to nonacupoints in the tongue ) .,"['These', 'children', 'were', 'randomly', 'assigned', 'to', 'the', 'treatment', 'group', 'with', 'tongue', 'acupuncture', '(', '40', 'sessions', 'over', '8', 'weeks', ')', 'or', 'the', 'control', 'group', '(', 'sham', 'tongue', 'acupuncture', 'to', 'nonacupoints', 'in', 'the', 'tongue', ')', '.']","(10, 12)","(65, 83)",-1,ss_i,20804366,Abstract,2,test,gold,4182.0
3665,These children were randomly assigned to the treatment group with tongue acupuncture ( 40 sessions over 8 weeks ) or the control group,( sham tongue acupuncture,to nonacupoints in the tongue ) .,"['These', 'children', 'were', 'randomly', 'assigned', 'to', 'the', 'treatment', 'group', 'with', 'tongue', 'acupuncture', '(', '40', 'sessions', 'over', '8', 'weeks', ')', 'or', 'the', 'control', 'group', '(', 'sham', 'tongue', 'acupuncture', 'to', 'nonacupoints', 'in', 'the', 'tongue', ')', '.']","(23, 27)","(134, 159)",-1,ss_i,20804366,Abstract,2,test,gold,4184.0
3666,These children were randomly assigned to the treatment group with,tongue acupuncture,( 40 sessions over 8 weeks ) or the control group ( sham tongue acupuncture to nonacupoints in the tongue ) .,"['These', 'children', 'were', 'randomly', 'assigned', 'to', 'the', 'treatment', 'group', 'with', 'tongue', 'acupuncture', '(', '40', 'sessions', 'over', '8', 'weeks', ')', 'or', 'the', 'control', 'group', '(', 'sham', 'tongue', 'acupuncture', 'to', 'nonacupoints', 'in', 'the', 'tongue', ')', '.']","(10, 12)","(65, 83)",-1,hl_i,20804366,Abstract,2,test,gold,4183.0
3667,These children were randomly assigned to the treatment group with tongue acupuncture ( 40 sessions over 8 weeks ) or the control group (,sham tongue acupuncture,to nonacupoints in the tongue ) .,"['These', 'children', 'were', 'randomly', 'assigned', 'to', 'the', 'treatment', 'group', 'with', 'tongue', 'acupuncture', '(', '40', 'sessions', 'over', '8', 'weeks', ')', 'or', 'the', 'control', 'group', '(', 'sham', 'tongue', 'acupuncture', 'to', 'nonacupoints', 'in', 'the', 'tongue', ')', '.']","(24, 27)","(136, 159)",-1,hl_i,20804366,Abstract,2,test,gold,4185.0
3668,RESULTS There was improvement in both the treatment and control groups in all assessed measures but more so in the treatment than in the control group : ( 1 ),"eye-hand coordination , performance , and practical reasoning of Griffiths Mental Developmental Scale ; ( 2 ) sensory-motor , social , affectual , language , and total score of Ritvo-Freeman Real Life Scale ; ( 3 ) Comprehension Language age in the Reynell Language Developmental Scale ; and ( 4 ) Total Score and Mental Age in Symbolic Play Test .",,"['RESULTS', 'There', 'was', 'improvement', 'in', 'both', 'the', 'treatment', 'and', 'control', 'groups', 'in', 'all', 'assessed', 'measures', 'but', 'more', 'so', 'in', 'the', 'treatment', 'than', 'in', 'the', 'control', 'group', ':', '(', '1', ')', 'eye-hand', 'coordination', ',', 'performance', ',', 'and', 'practical', 'reasoning', 'of', 'Griffiths', 'Mental', 'Developmental', 'Scale', ';', '(', '2', ')', 'sensory-motor', ',', 'social', ',', 'affectual', ',', 'language', ',', 'and', 'total', 'score', 'of', 'Ritvo-Freeman', 'Real', 'Life', 'Scale', ';', '(', '3', ')', 'Comprehension', 'Language', 'age', 'in', 'the', 'Reynell', 'Language', 'Developmental', 'Scale', ';', 'and', '(', '4', ')', 'Total', 'Score', 'and', 'Mental', 'Age', 'in', 'Symbolic', 'Play', 'Test', '.']","(30, 91)","(158, 506)",-1,ss_o,20804366,Abstract,3,test,gold,5915.0
3669,RESULTS There was improvement in both the treatment and control groups in all assessed measures but more so in the treatment than in the control group : ( 1 ),"eye-hand coordination , performance , and practical reasoning of Griffiths Mental Developmental Scale","; ( 2 ) sensory-motor , social , affectual , language , and total score of Ritvo-Freeman Real Life Scale ; ( 3 ) Comprehension Language age in the Reynell Language Developmental Scale ; and ( 4 ) Total Score and Mental Age in Symbolic Play Test .","['RESULTS', 'There', 'was', 'improvement', 'in', 'both', 'the', 'treatment', 'and', 'control', 'groups', 'in', 'all', 'assessed', 'measures', 'but', 'more', 'so', 'in', 'the', 'treatment', 'than', 'in', 'the', 'control', 'group', ':', '(', '1', ')', 'eye-hand', 'coordination', ',', 'performance', ',', 'and', 'practical', 'reasoning', 'of', 'Griffiths', 'Mental', 'Developmental', 'Scale', ';', '(', '2', ')', 'sensory-motor', ',', 'social', ',', 'affectual', ',', 'language', ',', 'and', 'total', 'score', 'of', 'Ritvo-Freeman', 'Real', 'Life', 'Scale', ';', '(', '3', ')', 'Comprehension', 'Language', 'age', 'in', 'the', 'Reynell', 'Language', 'Developmental', 'Scale', ';', 'and', '(', '4', ')', 'Total', 'Score', 'and', 'Mental', 'Age', 'in', 'Symbolic', 'Play', 'Test', '.']","(30, 43)","(158, 259)",-1,hl_o,20804366,Abstract,3,test,gold,6268.0
3670,"RESULTS There was improvement in both the treatment and control groups in all assessed measures but more so in the treatment than in the control group : ( 1 ) eye-hand coordination , performance , and practical reasoning of Griffiths Mental Developmental Scale ; ( 2 )","sensory-motor , social , affectual , language , and total score of Ritvo-Freeman Real Life Scale",; ( 3 ) Comprehension Language age in the Reynell Language Developmental Scale ; and ( 4 ) Total Score and Mental Age in Symbolic Play Test .,"['RESULTS', 'There', 'was', 'improvement', 'in', 'both', 'the', 'treatment', 'and', 'control', 'groups', 'in', 'all', 'assessed', 'measures', 'but', 'more', 'so', 'in', 'the', 'treatment', 'than', 'in', 'the', 'control', 'group', ':', '(', '1', ')', 'eye-hand', 'coordination', ',', 'performance', ',', 'and', 'practical', 'reasoning', 'of', 'Griffiths', 'Mental', 'Developmental', 'Scale', ';', '(', '2', ')', 'sensory-motor', ',', 'social', ',', 'affectual', ',', 'language', ',', 'and', 'total', 'score', 'of', 'Ritvo-Freeman', 'Real', 'Life', 'Scale', ';', '(', '3', ')', 'Comprehension', 'Language', 'age', 'in', 'the', 'Reynell', 'Language', 'Developmental', 'Scale', ';', 'and', '(', '4', ')', 'Total', 'Score', 'and', 'Mental', 'Age', 'in', 'Symbolic', 'Play', 'Test', '.']","(47, 63)","(268, 364)",-1,hl_o,20804366,Abstract,3,test,gold,6223.0
3671,"RESULTS There was improvement in both the treatment and control groups in all assessed measures but more so in the treatment than in the control group : ( 1 ) eye-hand coordination , performance , and practical reasoning of Griffiths Mental Developmental Scale ; ( 2 ) sensory-motor , social , affectual , language , and total score of Ritvo-Freeman Real Life Scale ; ( 3 )",Comprehension Language age in the Reynell Language Developmental Scale,; and ( 4 ) Total Score and Mental Age in Symbolic Play Test .,"['RESULTS', 'There', 'was', 'improvement', 'in', 'both', 'the', 'treatment', 'and', 'control', 'groups', 'in', 'all', 'assessed', 'measures', 'but', 'more', 'so', 'in', 'the', 'treatment', 'than', 'in', 'the', 'control', 'group', ':', '(', '1', ')', 'eye-hand', 'coordination', ',', 'performance', ',', 'and', 'practical', 'reasoning', 'of', 'Griffiths', 'Mental', 'Developmental', 'Scale', ';', '(', '2', ')', 'sensory-motor', ',', 'social', ',', 'affectual', ',', 'language', ',', 'and', 'total', 'score', 'of', 'Ritvo-Freeman', 'Real', 'Life', 'Scale', ';', '(', '3', ')', 'Comprehension', 'Language', 'age', 'in', 'the', 'Reynell', 'Language', 'Developmental', 'Scale', ';', 'and', '(', '4', ')', 'Total', 'Score', 'and', 'Mental', 'Age', 'in', 'Symbolic', 'Play', 'Test', '.']","(67, 76)","(373, 443)",-1,hl_o,20804366,Abstract,3,test,gold,6269.0
3672,"RESULTS There was improvement in both the treatment and control groups in all assessed measures but more so in the treatment than in the control group : ( 1 ) eye-hand coordination , performance , and practical reasoning of Griffiths Mental Developmental Scale ; ( 2 ) sensory-motor , social , affectual , language , and total score of Ritvo-Freeman Real Life Scale ; ( 3 ) Comprehension Language age in the Reynell Language Developmental Scale ; and ( 4 )",Total Score and Mental Age in Symbolic Play Test,.,"['RESULTS', 'There', 'was', 'improvement', 'in', 'both', 'the', 'treatment', 'and', 'control', 'groups', 'in', 'all', 'assessed', 'measures', 'but', 'more', 'so', 'in', 'the', 'treatment', 'than', 'in', 'the', 'control', 'group', ':', '(', '1', ')', 'eye-hand', 'coordination', ',', 'performance', ',', 'and', 'practical', 'reasoning', 'of', 'Griffiths', 'Mental', 'Developmental', 'Scale', ';', '(', '2', ')', 'sensory-motor', ',', 'social', ',', 'affectual', ',', 'language', ',', 'and', 'total', 'score', 'of', 'Ritvo-Freeman', 'Real', 'Life', 'Scale', ';', '(', '3', ')', 'Comprehension', 'Language', 'age', 'in', 'the', 'Reynell', 'Language', 'Developmental', 'Scale', ';', 'and', '(', '4', ')', 'Total', 'Score', 'and', 'Mental', 'Age', 'in', 'Symbolic', 'Play', 'Test', '.']","(81, 90)","(456, 504)",-1,hl_o,20804366,Abstract,3,test,gold,6267.0
3673,The only statistically significant improvement in the treatment as compared to the control group was seen in self-care and cognition domains of the Functional Independence Measure for,children .,,"['The', 'only', 'statistically', 'significant', 'improvement', 'in', 'the', 'treatment', 'as', 'compared', 'to', 'the', 'control', 'group', 'was', 'seen', 'in', 'self-care', 'and', 'cognition', 'domains', 'of', 'the', 'Functional', 'Independence', 'Measure', 'for', 'children', '.']","(27, 29)","(183, 193)",-1,ss_p,20804366,Abstract,4,test,gold,2130.0
3674,The only statistically significant improvement in the treatment as compared to the control group was seen in,self-care and cognition domains of the Functional Independence Measure for children .,,"['The', 'only', 'statistically', 'significant', 'improvement', 'in', 'the', 'treatment', 'as', 'compared', 'to', 'the', 'control', 'group', 'was', 'seen', 'in', 'self-care', 'and', 'cognition', 'domains', 'of', 'the', 'Functional', 'Independence', 'Measure', 'for', 'children', '.']","(17, 29)","(108, 193)",-1,ss_o,20804366,Abstract,4,test,gold,6265.0
3675,The only statistically significant improvement in the treatment as compared to the control group was seen in,self-care and cognition domains of the Functional Independence Measure for children .,,"['The', 'only', 'statistically', 'significant', 'improvement', 'in', 'the', 'treatment', 'as', 'compared', 'to', 'the', 'control', 'group', 'was', 'seen', 'in', 'self-care', 'and', 'cognition', 'domains', 'of', 'the', 'Functional', 'Independence', 'Measure', 'for', 'children', '.']","(17, 29)","(108, 193)",-1,hl_o,20804366,Abstract,4,test,gold,6266.0
3676,CONCLUSIONS We had demonstrated that a short course of acupuncture had efficacy in improving various developmental and behavioral aspects of,children with autism .,,"['CONCLUSIONS', 'We', 'had', 'demonstrated', 'that', 'a', 'short', 'course', 'of', 'acupuncture', 'had', 'efficacy', 'in', 'improving', 'various', 'developmental', 'and', 'behavioral', 'aspects', 'of', 'children', 'with', 'autism', '.']","(20, 24)","(140, 162)",-1,ss_p,20804366,Abstract,5,test,gold,6140.0
3677,CONCLUSIONS We had demonstrated that a short course of,acupuncture,had efficacy in improving various developmental and behavioral aspects of children with autism .,"['CONCLUSIONS', 'We', 'had', 'demonstrated', 'that', 'a', 'short', 'course', 'of', 'acupuncture', 'had', 'efficacy', 'in', 'improving', 'various', 'developmental', 'and', 'behavioral', 'aspects', 'of', 'children', 'with', 'autism', '.']","(9, 10)","(54, 65)",-1,ss_i,20804366,Abstract,5,test,gold,4173.0
3678,CONCLUSIONS We had demonstrated that a short course of acupuncture had,efficacy,in improving various developmental and behavioral aspects of children with autism .,"['CONCLUSIONS', 'We', 'had', 'demonstrated', 'that', 'a', 'short', 'course', 'of', 'acupuncture', 'had', 'efficacy', 'in', 'improving', 'various', 'developmental', 'and', 'behavioral', 'aspects', 'of', 'children', 'with', 'autism', '.']","(11, 12)","(70, 78)",-1,ss_o,20804366,Abstract,5,test,gold,4810.0
3679,CONCLUSIONS We had demonstrated that a short course of acupuncture had efficacy in improving various developmental and behavioral aspects of,children with autism .,,"['CONCLUSIONS', 'We', 'had', 'demonstrated', 'that', 'a', 'short', 'course', 'of', 'acupuncture', 'had', 'efficacy', 'in', 'improving', 'various', 'developmental', 'and', 'behavioral', 'aspects', 'of', 'children', 'with', 'autism', '.']","(20, 24)","(140, 162)",-1,hl_p,20804366,Abstract,5,test,gold,6141.0
3680,CONCLUSIONS We had demonstrated that a short course of,acupuncture,had efficacy in improving various developmental and behavioral aspects of children with autism .,"['CONCLUSIONS', 'We', 'had', 'demonstrated', 'that', 'a', 'short', 'course', 'of', 'acupuncture', 'had', 'efficacy', 'in', 'improving', 'various', 'developmental', 'and', 'behavioral', 'aspects', 'of', 'children', 'with', 'autism', '.']","(9, 10)","(54, 65)",-1,hl_i,20804366,Abstract,5,test,gold,4172.0
3681,The long-term,efficacy,in functional gain needs to be further explored .,"['The', 'long-term', 'efficacy', 'in', 'functional', 'gain', 'needs', 'to', 'be', 'further', 'explored', '.']","(2, 3)","(13, 21)",-1,ss_o,20804366,Abstract,6,test,gold,4809.0
3682,The immediate efficacy of adjunctive doxycycline in treatment of,localized juvenile periodontitis .,,"['The', 'immediate', 'efficacy', 'of', 'adjunctive', 'doxycycline', 'in', 'treatment', 'of', 'localized', 'juvenile', 'periodontitis', '.']","(9, 13)","(64, 98)",-1,ss_p,2088233,Title,0,test,gold,3540.0
3683,The immediate efficacy of adjunctive,doxycycline,in treatment of localized juvenile periodontitis .,"['The', 'immediate', 'efficacy', 'of', 'adjunctive', 'doxycycline', 'in', 'treatment', 'of', 'localized', 'juvenile', 'periodontitis', '.']","(5, 6)","(36, 47)",-1,ss_i,2088233,Title,0,test,gold,5020.0
3684,The,immediate efficacy,of adjunctive doxycycline in treatment of localized juvenile periodontitis .,"['The', 'immediate', 'efficacy', 'of', 'adjunctive', 'doxycycline', 'in', 'treatment', 'of', 'localized', 'juvenile', 'periodontitis', '.']","(1, 3)","(3, 21)",-1,ss_o,2088233,Title,0,test,gold,4851.0
3685,The immediate efficacy of adjunctive doxycycline in treatment of,localized juvenile periodontitis .,,"['The', 'immediate', 'efficacy', 'of', 'adjunctive', 'doxycycline', 'in', 'treatment', 'of', 'localized', 'juvenile', 'periodontitis', '.']","(9, 13)","(64, 98)",-1,hl_p,2088233,Title,0,test,gold,3541.0
3686,The immediate efficacy of adjunctive,doxycycline,in treatment of localized juvenile periodontitis .,"['The', 'immediate', 'efficacy', 'of', 'adjunctive', 'doxycycline', 'in', 'treatment', 'of', 'localized', 'juvenile', 'periodontitis', '.']","(5, 6)","(36, 47)",-1,hl_i,2088233,Title,0,test,gold,5021.0
3687,The,immediate efficacy,of adjunctive doxycycline in treatment of localized juvenile periodontitis .,"['The', 'immediate', 'efficacy', 'of', 'adjunctive', 'doxycycline', 'in', 'treatment', 'of', 'localized', 'juvenile', 'periodontitis', '.']","(1, 3)","(3, 21)",-1,hl_o,2088233,Title,0,test,gold,4852.0
3688,"A randomized , double-blind , placebo-controlled study on the immediate clinical and microbiological efficacy of doxycycline ( 100 mg for 14 days ) was carried out to determine the benefit of adjunctive medication in",16 patients with localized juvenile periodontitis .,,"['A', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'on', 'the', 'immediate', 'clinical', 'and', 'microbiological', 'efficacy', 'of', 'doxycycline', '(', '100', 'mg', 'for', '14', 'days', ')', 'was', 'carried', 'out', 'to', 'determine', 'the', 'benefit', 'of', 'adjunctive', 'medication', 'in', '16', 'patients', 'with', 'localized', 'juvenile', 'periodontitis', '.']","(34, 41)","(216, 267)",-1,ss_p,2088233,Abstract,0,test,gold,3544.0
3689,"A randomized , double-blind , placebo-controlled study on the immediate clinical and microbiological efficacy of",doxycycline,( 100 mg for 14 days ) was carried out to determine the benefit of adjunctive medication in 16 patients with localized juvenile periodontitis .,"['A', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'on', 'the', 'immediate', 'clinical', 'and', 'microbiological', 'efficacy', 'of', 'doxycycline', '(', '100', 'mg', 'for', '14', 'days', ')', 'was', 'carried', 'out', 'to', 'determine', 'the', 'benefit', 'of', 'adjunctive', 'medication', 'in', '16', 'patients', 'with', 'localized', 'juvenile', 'periodontitis', '.']","(15, 16)","(112, 123)",-1,ss_i,2088233,Abstract,0,test,gold,5019.0
3690,"A randomized , double-blind , placebo-controlled study on the",immediate clinical and microbiological efficacy,of doxycycline ( 100 mg for 14 days ) was carried out to determine the benefit of adjunctive medication in 16 patients with localized juvenile periodontitis .,"['A', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'on', 'the', 'immediate', 'clinical', 'and', 'microbiological', 'efficacy', 'of', 'doxycycline', '(', '100', 'mg', 'for', '14', 'days', ')', 'was', 'carried', 'out', 'to', 'determine', 'the', 'benefit', 'of', 'adjunctive', 'medication', 'in', '16', 'patients', 'with', 'localized', 'juvenile', 'periodontitis', '.']","(9, 14)","(61, 108)",-1,ss_o,2088233,Abstract,0,test,gold,4732.0
3691,"A randomized , double-blind , placebo-controlled study on the immediate clinical and microbiological efficacy of doxycycline ( 100 mg for 14 days ) was carried out to determine the benefit of adjunctive medication in",16 patients with localized juvenile periodontitis,.,"['A', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'on', 'the', 'immediate', 'clinical', 'and', 'microbiological', 'efficacy', 'of', 'doxycycline', '(', '100', 'mg', 'for', '14', 'days', ')', 'was', 'carried', 'out', 'to', 'determine', 'the', 'benefit', 'of', 'adjunctive', 'medication', 'in', '16', 'patients', 'with', 'localized', 'juvenile', 'periodontitis', '.']","(34, 40)","(216, 265)",-1,hl_p,2088233,Abstract,0,test,gold,3545.0
3692,"A randomized , double-blind , placebo-controlled study on the immediate clinical and microbiological efficacy of",doxycycline,( 100 mg for 14 days ) was carried out to determine the benefit of adjunctive medication in 16 patients with localized juvenile periodontitis .,"['A', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'on', 'the', 'immediate', 'clinical', 'and', 'microbiological', 'efficacy', 'of', 'doxycycline', '(', '100', 'mg', 'for', '14', 'days', ')', 'was', 'carried', 'out', 'to', 'determine', 'the', 'benefit', 'of', 'adjunctive', 'medication', 'in', '16', 'patients', 'with', 'localized', 'juvenile', 'periodontitis', '.']","(15, 16)","(112, 123)",-1,hl_i,2088233,Abstract,0,test,gold,5018.0
3693,"A randomized , double-blind , placebo-controlled study on the",immediate clinical and microbiological efficacy,of doxycycline ( 100 mg for 14 days ) was carried out to determine the benefit of adjunctive medication in 16 patients with localized juvenile periodontitis .,"['A', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', 'on', 'the', 'immediate', 'clinical', 'and', 'microbiological', 'efficacy', 'of', 'doxycycline', '(', '100', 'mg', 'for', '14', 'days', ')', 'was', 'carried', 'out', 'to', 'determine', 'the', 'benefit', 'of', 'adjunctive', 'medication', 'in', '16', 'patients', 'with', 'localized', 'juvenile', 'periodontitis', '.']","(9, 14)","(61, 108)",-1,hl_o,2088233,Abstract,0,test,gold,4733.0
3694,Measurements of,"gingival fluid flow , probing depths , bleeding on probing and suppuration","were determined at 2 periodontal sites with and 2 without radiographic attachment loss , at weeks 0 , 1 , 3 and 8 .","['Measurements', 'of', 'gingival', 'fluid', 'flow', ',', 'probing', 'depths', ',', 'bleeding', 'on', 'probing', 'and', 'suppuration', 'were', 'determined', 'at', '2', 'periodontal', 'sites', 'with', 'and', '2', 'without', 'radiographic', 'attachment', 'loss', ',', 'at', 'weeks', '0', ',', '1', ',', '3', 'and', '8', '.']","(2, 14)","(15, 89)",-1,ss_o,2088233,Abstract,1,test,gold,6375.0
3695,"Measurements of gingival fluid flow , probing depths , bleeding on probing and suppuration were determined at 2 periodontal sites with and 2 without",radiographic attachment loss,", at weeks 0 , 1 , 3 and 8 .","['Measurements', 'of', 'gingival', 'fluid', 'flow', ',', 'probing', 'depths', ',', 'bleeding', 'on', 'probing', 'and', 'suppuration', 'were', 'determined', 'at', '2', 'periodontal', 'sites', 'with', 'and', '2', 'without', 'radiographic', 'attachment', 'loss', ',', 'at', 'weeks', '0', ',', '1', ',', '3', 'and', '8', '.']","(24, 27)","(148, 176)",-1,ss_o,2088233,Abstract,1,test,gold,3168.0
3696,Measurements of,"gingival fluid flow , probing depths , bleeding on probing and suppuration","were determined at 2 periodontal sites with and 2 without radiographic attachment loss , at weeks 0 , 1 , 3 and 8 .","['Measurements', 'of', 'gingival', 'fluid', 'flow', ',', 'probing', 'depths', ',', 'bleeding', 'on', 'probing', 'and', 'suppuration', 'were', 'determined', 'at', '2', 'periodontal', 'sites', 'with', 'and', '2', 'without', 'radiographic', 'attachment', 'loss', ',', 'at', 'weeks', '0', ',', '1', ',', '3', 'and', '8', '.']","(2, 14)","(15, 89)",-1,hl_o,2088233,Abstract,1,test,gold,6376.0
3697,,Subgingival bacterial samples,were taken with curettes from the same sites .,"['Subgingival', 'bacterial', 'samples', 'were', 'taken', 'with', 'curettes', 'from', 'the', 'same', 'sites', '.']","(0, 3)","(0, 29)",-1,ss_o,2088233,Abstract,2,test,gold,4519.0
3698,,Subgingival bacterial samples,were taken with curettes from the same sites .,"['Subgingival', 'bacterial', 'samples', 'were', 'taken', 'with', 'curettes', 'from', 'the', 'same', 'sites', '.']","(0, 3)","(0, 29)",-1,hl_o,2088233,Abstract,2,test,gold,4520.0
3699,,Spirochaetes,were searched for by dark-field microscopy .,"['Spirochaetes', 'were', 'searched', 'for', 'by', 'dark-field', 'microscopy', '.']","(0, 1)","(0, 12)",-1,ss_o,2088233,Abstract,3,test,gold,
3700,Spirochaetes were searched for by,dark-field microscopy .,,"['Spirochaetes', 'were', 'searched', 'for', 'by', 'dark-field', 'microscopy', '.']","(5, 8)","(33, 56)",-1,ss_o,2088233,Abstract,3,test,gold,318.0
3701,,Spirochaetes,were searched for by dark-field microscopy .,"['Spirochaetes', 'were', 'searched', 'for', 'by', 'dark-field', 'microscopy', '.']","(0, 1)","(0, 12)",-1,hl_o,2088233,Abstract,3,test,gold,
3702,Spirochaetes were searched for by,dark-field microscopy .,,"['Spirochaetes', 'were', 'searched', 'for', 'by', 'dark-field', 'microscopy', '.']","(5, 8)","(33, 56)",-1,hl_o,2088233,Abstract,3,test,gold,319.0
3703,,"Actinobacillus actinomycetemcomitans , pigmented and non-pigmented Bacteroides spp.",", Capnocytophaga , Fusobacterium and Actinomyces spp .","['Actinobacillus', 'actinomycetemcomitans', ',', 'pigmented', 'and', 'non-pigmented', 'Bacteroides', 'spp.', ',', 'Capnocytophaga', ',', 'Fusobacterium', 'and', 'Actinomyces', 'spp', '.']","(0, 8)","(0, 83)",-1,ss_o,2088233,Abstract,4,test,gold,217.0
3704,"Actinobacillus actinomycetemcomitans , pigmented and non-pigmented Bacteroides spp. ,","Capnocytophaga , Fusobacterium and Actinomyces spp .",,"['Actinobacillus', 'actinomycetemcomitans', ',', 'pigmented', 'and', 'non-pigmented', 'Bacteroides', 'spp.', ',', 'Capnocytophaga', ',', 'Fusobacterium', 'and', 'Actinomyces', 'spp', '.']","(9, 16)","(85, 137)",-1,ss_o,2088233,Abstract,4,test,gold,102.0
3705,were cultured on various selective and non-selective media .,,,"['were', 'cultured', 'on', 'various', 'selective', 'and', 'non-selective', 'media', '.']",,,,,2088233,Abstract,5,test,gold,
3706,,Bacterial species,found at least in 50 % of the patients and comprising on average 5 % or more of the cultivable flora were included in the analysis .,"['Bacterial', 'species', 'found', 'at', 'least', 'in', '50', '%', 'of', 'the', 'patients', 'and', 'comprising', 'on', 'average', '5', '%', 'or', 'more', 'of', 'the', 'cultivable', 'flora', 'were', 'included', 'in', 'the', 'analysis', '.']","(0, 2)","(0, 17)",-1,ss_o,2088233,Abstract,6,test,gold,211.0
3707,Neither short-term clinical nor microbiological efficacy beyond that of a course of mechanical debridement alone was found by using systemic medication with doxycycline in,patients with localized juvenile periodontitis .,,"['Neither', 'short-term', 'clinical', 'nor', 'microbiological', 'efficacy', 'beyond', 'that', 'of', 'a', 'course', 'of', 'mechanical', 'debridement', 'alone', 'was', 'found', 'by', 'using', 'systemic', 'medication', 'with', 'doxycycline', 'in', 'patients', 'with', 'localized', 'juvenile', 'periodontitis', '.']","(24, 30)","(171, 219)",-1,ss_p,2088233,Abstract,7,test,gold,3543.0
3708,Neither short-term clinical nor microbiological efficacy beyond that of a course of mechanical debridement alone was found by using systemic medication with,doxycycline,in patients with localized juvenile periodontitis .,"['Neither', 'short-term', 'clinical', 'nor', 'microbiological', 'efficacy', 'beyond', 'that', 'of', 'a', 'course', 'of', 'mechanical', 'debridement', 'alone', 'was', 'found', 'by', 'using', 'systemic', 'medication', 'with', 'doxycycline', 'in', 'patients', 'with', 'localized', 'juvenile', 'periodontitis', '.']","(22, 23)","(156, 167)",-1,ss_i,2088233,Abstract,7,test,gold,5017.0
3709,Neither,short-term clinical nor microbiological efficacy,beyond that of a course of mechanical debridement alone was found by using systemic medication with doxycycline in patients with localized juvenile periodontitis .,"['Neither', 'short-term', 'clinical', 'nor', 'microbiological', 'efficacy', 'beyond', 'that', 'of', 'a', 'course', 'of', 'mechanical', 'debridement', 'alone', 'was', 'found', 'by', 'using', 'systemic', 'medication', 'with', 'doxycycline', 'in', 'patients', 'with', 'localized', 'juvenile', 'periodontitis', '.']","(1, 6)","(7, 55)",-1,ss_o,2088233,Abstract,7,test,gold,4730.0
3710,Neither short-term clinical nor microbiological efficacy beyond that of a course of mechanical debridement alone was found by using systemic medication with doxycycline in,patients with localized juvenile periodontitis .,,"['Neither', 'short-term', 'clinical', 'nor', 'microbiological', 'efficacy', 'beyond', 'that', 'of', 'a', 'course', 'of', 'mechanical', 'debridement', 'alone', 'was', 'found', 'by', 'using', 'systemic', 'medication', 'with', 'doxycycline', 'in', 'patients', 'with', 'localized', 'juvenile', 'periodontitis', '.']","(24, 30)","(171, 219)",-1,hl_p,2088233,Abstract,7,test,gold,3542.0
3711,Neither short-term clinical nor microbiological efficacy beyond that of a course of mechanical debridement alone was found by using systemic medication with,doxycycline,in patients with localized juvenile periodontitis .,"['Neither', 'short-term', 'clinical', 'nor', 'microbiological', 'efficacy', 'beyond', 'that', 'of', 'a', 'course', 'of', 'mechanical', 'debridement', 'alone', 'was', 'found', 'by', 'using', 'systemic', 'medication', 'with', 'doxycycline', 'in', 'patients', 'with', 'localized', 'juvenile', 'periodontitis', '.']","(22, 23)","(156, 167)",-1,hl_i,2088233,Abstract,7,test,gold,5016.0
3712,Neither,short-term clinical nor microbiological efficacy,beyond that of a course of mechanical debridement alone was found by using systemic medication with doxycycline in patients with localized juvenile periodontitis .,"['Neither', 'short-term', 'clinical', 'nor', 'microbiological', 'efficacy', 'beyond', 'that', 'of', 'a', 'course', 'of', 'mechanical', 'debridement', 'alone', 'was', 'found', 'by', 'using', 'systemic', 'medication', 'with', 'doxycycline', 'in', 'patients', 'with', 'localized', 'juvenile', 'periodontitis', '.']","(1, 6)","(7, 55)",-1,hl_o,2088233,Abstract,7,test,gold,4731.0
3713,Visual and kinesthetic locomotor imagery training integrated with auditory step rhythm for walking performance of,patients with chronic stroke .,,"['Visual', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'integrated', 'with', 'auditory', 'step', 'rhythm', 'for', 'walking', 'performance', 'of', 'patients', 'with', 'chronic', 'stroke', '.']","(15, 20)","(113, 143)",-1,ss_p,20943715,Title,0,test,gold,3381.0
3714,,Visual and kinesthetic locomotor imagery training integrated with auditory step rhythm,for walking performance of patients with chronic stroke .,"['Visual', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'integrated', 'with', 'auditory', 'step', 'rhythm', 'for', 'walking', 'performance', 'of', 'patients', 'with', 'chronic', 'stroke', '.']","(0, 11)","(0, 86)",-1,ss_i,20943715,Title,0,test,gold,6293.0
3715,Visual and kinesthetic locomotor imagery training integrated with auditory step rhythm for,walking performance,of patients with chronic stroke .,"['Visual', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'integrated', 'with', 'auditory', 'step', 'rhythm', 'for', 'walking', 'performance', 'of', 'patients', 'with', 'chronic', 'stroke', '.']","(12, 14)","(90, 109)",-1,ss_o,20943715,Title,0,test,gold,2714.0
3716,Visual and kinesthetic locomotor imagery training integrated with auditory step rhythm for walking performance of,patients with chronic stroke .,,"['Visual', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'integrated', 'with', 'auditory', 'step', 'rhythm', 'for', 'walking', 'performance', 'of', 'patients', 'with', 'chronic', 'stroke', '.']","(15, 20)","(113, 143)",-1,hl_p,20943715,Title,0,test,gold,3382.0
3717,,Visual and kinesthetic locomotor imagery training,integrated with auditory step rhythm for walking performance of patients with chronic stroke .,"['Visual', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'integrated', 'with', 'auditory', 'step', 'rhythm', 'for', 'walking', 'performance', 'of', 'patients', 'with', 'chronic', 'stroke', '.']","(0, 6)","(0, 49)",-1,hl_i,20943715,Title,0,test,gold,6339.0
3718,Visual and kinesthetic locomotor imagery training integrated with,auditory step rhythm,for walking performance of patients with chronic stroke .,"['Visual', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'integrated', 'with', 'auditory', 'step', 'rhythm', 'for', 'walking', 'performance', 'of', 'patients', 'with', 'chronic', 'stroke', '.']","(8, 11)","(65, 85)",-1,hl_i,20943715,Title,0,test,gold,6306.0
3719,OBJECTIVE To compare the effect of,visual and kinesthetic locomotor imagery training,on walking performance and to determine the clinical feasibility of incorporating auditory step rhythm into the training .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'visual', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'on', 'walking', 'performance', 'and', 'to', 'determine', 'the', 'clinical', 'feasibility', 'of', 'incorporating', 'auditory', 'step', 'rhythm', 'into', 'the', 'training', '.']","(6, 12)","(34, 83)",-1,ss_i,20943715,Abstract,0,test,gold,6340.0
3720,OBJECTIVE To compare the effect of visual and kinesthetic locomotor imagery training on walking performance and to determine the clinical feasibility of incorporating,auditory step rhythm,into the training .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'visual', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'on', 'walking', 'performance', 'and', 'to', 'determine', 'the', 'clinical', 'feasibility', 'of', 'incorporating', 'auditory', 'step', 'rhythm', 'into', 'the', 'training', '.']","(23, 26)","(166, 186)",-1,ss_i,20943715,Abstract,0,test,gold,6307.0
3721,OBJECTIVE To compare the effect of visual and kinesthetic locomotor imagery training on,walking performance,and to determine the clinical feasibility of incorporating auditory step rhythm into the training .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'visual', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'on', 'walking', 'performance', 'and', 'to', 'determine', 'the', 'clinical', 'feasibility', 'of', 'incorporating', 'auditory', 'step', 'rhythm', 'into', 'the', 'training', '.']","(13, 15)","(87, 106)",-1,ss_o,20943715,Abstract,0,test,gold,2715.0
3722,OBJECTIVE To compare the effect of,visual and kinesthetic locomotor imagery training,on walking performance and to determine the clinical feasibility of incorporating auditory step rhythm into the training .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'visual', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'on', 'walking', 'performance', 'and', 'to', 'determine', 'the', 'clinical', 'feasibility', 'of', 'incorporating', 'auditory', 'step', 'rhythm', 'into', 'the', 'training', '.']","(6, 12)","(34, 83)",-1,hl_i,20943715,Abstract,0,test,gold,6341.0
3723,OBJECTIVE To compare the effect of visual and kinesthetic locomotor imagery training on walking performance and to determine the clinical feasibility of incorporating,auditory step rhythm,into the training .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'visual', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'on', 'walking', 'performance', 'and', 'to', 'determine', 'the', 'clinical', 'feasibility', 'of', 'incorporating', 'auditory', 'step', 'rhythm', 'into', 'the', 'training', '.']","(23, 26)","(166, 186)",-1,hl_i,20943715,Abstract,0,test,gold,6305.0
3724,OBJECTIVE To compare the effect of visual and kinesthetic locomotor imagery training on,walking performance,and to determine the clinical feasibility of incorporating auditory step rhythm into the training .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'visual', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'on', 'walking', 'performance', 'and', 'to', 'determine', 'the', 'clinical', 'feasibility', 'of', 'incorporating', 'auditory', 'step', 'rhythm', 'into', 'the', 'training', '.']","(13, 15)","(87, 106)",-1,hl_o,20943715,Abstract,0,test,gold,2713.0
3725,DESIGN Randomized crossover trial .,,,"['DESIGN', 'Randomized', 'crossover', 'trial', '.']",,,,,20943715,Abstract,1,test,gold,
3726,SETTING Laboratory of a Department of Physical Therapy .,,,"['SETTING', 'Laboratory', 'of', 'a', 'Department', 'of', 'Physical', 'Therapy', '.']",,,,,20943715,Abstract,2,test,gold,
3727,SUBJECTS,Fifteen subjects with post-stroke hemiparesis .,,"['SUBJECTS', 'Fifteen', 'subjects', 'with', 'post-stroke', 'hemiparesis', '.']","(1, 7)","(8, 55)",-1,ss_p,20943715,Abstract,3,test,gold,2079.0
3728,SUBJECTS,Fifteen subjects with post-stroke hemiparesis,.,"['SUBJECTS', 'Fifteen', 'subjects', 'with', 'post-stroke', 'hemiparesis', '.']","(1, 6)","(8, 53)",-1,hl_p,20943715,Abstract,3,test,gold,2080.0
3729,INTERVENTION Four,locomotor imagery trainings,"on walking performance : visual locomotor imagery training , kinesthetic locomotor imagery training , visual locomotor imagery training with auditory step rhythm and kinesthetic locomotor imagery training with auditory step rhythm .","['INTERVENTION', 'Four', 'locomotor', 'imagery', 'trainings', 'on', 'walking', 'performance', ':', 'visual', 'locomotor', 'imagery', 'training', ',', 'kinesthetic', 'locomotor', 'imagery', 'training', ',', 'visual', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '.']","(2, 5)","(17, 44)",-1,ss_i,20943715,Abstract,4,test,gold,6358.0
3730,INTERVENTION Four locomotor imagery trainings on walking performance :,"visual locomotor imagery training , kinesthetic locomotor imagery training , visual locomotor imagery training with auditory step rhythm",and kinesthetic locomotor imagery training with auditory step rhythm .,"['INTERVENTION', 'Four', 'locomotor', 'imagery', 'trainings', 'on', 'walking', 'performance', ':', 'visual', 'locomotor', 'imagery', 'training', ',', 'kinesthetic', 'locomotor', 'imagery', 'training', ',', 'visual', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '.']","(9, 27)","(70, 206)",-1,ss_i,20943715,Abstract,4,test,gold,6292.0
3731,"INTERVENTION Four locomotor imagery trainings on walking performance : visual locomotor imagery training , kinesthetic locomotor imagery training , visual locomotor imagery training with auditory step rhythm and",kinesthetic locomotor imagery training with auditory step rhythm .,,"['INTERVENTION', 'Four', 'locomotor', 'imagery', 'trainings', 'on', 'walking', 'performance', ':', 'visual', 'locomotor', 'imagery', 'training', ',', 'kinesthetic', 'locomotor', 'imagery', 'training', ',', 'visual', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '.']","(28, 37)","(211, 277)",-1,ss_i,20943715,Abstract,4,test,gold,6295.0
3732,INTERVENTION Four,locomotor imagery trainings,"on walking performance : visual locomotor imagery training , kinesthetic locomotor imagery training , visual locomotor imagery training with auditory step rhythm and kinesthetic locomotor imagery training with auditory step rhythm .","['INTERVENTION', 'Four', 'locomotor', 'imagery', 'trainings', 'on', 'walking', 'performance', ':', 'visual', 'locomotor', 'imagery', 'training', ',', 'kinesthetic', 'locomotor', 'imagery', 'training', ',', 'visual', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '.']","(2, 5)","(17, 44)",-1,hl_i,20943715,Abstract,4,test,gold,6359.0
3733,INTERVENTION Four locomotor imagery trainings on walking performance :,visual locomotor imagery training,", kinesthetic locomotor imagery training , visual locomotor imagery training with auditory step rhythm and kinesthetic locomotor imagery training with auditory step rhythm .","['INTERVENTION', 'Four', 'locomotor', 'imagery', 'trainings', 'on', 'walking', 'performance', ':', 'visual', 'locomotor', 'imagery', 'training', ',', 'kinesthetic', 'locomotor', 'imagery', 'training', ',', 'visual', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '.']","(9, 13)","(70, 103)",-1,hl_i,20943715,Abstract,4,test,gold,6353.0
3734,"INTERVENTION Four locomotor imagery trainings on walking performance : visual locomotor imagery training ,",kinesthetic locomotor imagery training,", visual locomotor imagery training with auditory step rhythm and kinesthetic locomotor imagery training with auditory step rhythm .","['INTERVENTION', 'Four', 'locomotor', 'imagery', 'trainings', 'on', 'walking', 'performance', ':', 'visual', 'locomotor', 'imagery', 'training', ',', 'kinesthetic', 'locomotor', 'imagery', 'training', ',', 'visual', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '.']","(14, 18)","(106, 144)",-1,hl_i,20943715,Abstract,4,test,gold,6345.0
3735,"INTERVENTION Four locomotor imagery trainings on walking performance : visual locomotor imagery training , kinesthetic locomotor imagery training ,",visual locomotor imagery training with auditory step rhythm,and kinesthetic locomotor imagery training with auditory step rhythm .,"['INTERVENTION', 'Four', 'locomotor', 'imagery', 'trainings', 'on', 'walking', 'performance', ':', 'visual', 'locomotor', 'imagery', 'training', ',', 'kinesthetic', 'locomotor', 'imagery', 'training', ',', 'visual', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '.']","(19, 27)","(147, 206)",-1,hl_i,20943715,Abstract,4,test,gold,6294.0
3736,"INTERVENTION Four locomotor imagery trainings on walking performance : visual locomotor imagery training , kinesthetic locomotor imagery training , visual locomotor imagery training with auditory step rhythm and",kinesthetic locomotor imagery training with auditory step rhythm,.,"['INTERVENTION', 'Four', 'locomotor', 'imagery', 'trainings', 'on', 'walking', 'performance', ':', 'visual', 'locomotor', 'imagery', 'training', ',', 'kinesthetic', 'locomotor', 'imagery', 'training', ',', 'visual', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', 'and', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '.']","(28, 36)","(211, 275)",-1,hl_i,20943715,Abstract,4,test,gold,6296.0
3737,MAIN OUTCOME MEASURES,The timed up-and-go test and electromyographic and kinematic analyses of the affected lower limb,during one gait cycle .,"['MAIN', 'OUTCOME', 'MEASURES', 'The', 'timed', 'up-and-go', 'test', 'and', 'electromyographic', 'and', 'kinematic', 'analyses', 'of', 'the', 'affected', 'lower', 'limb', 'during', 'one', 'gait', 'cycle', '.']","(3, 17)","(21, 117)",-1,ss_o,20943715,Abstract,5,test,gold,6494.0
3738,MAIN OUTCOME MEASURES,The timed up-and-go test and electromyographic and kinematic analyses of the affected lower limb,during one gait cycle .,"['MAIN', 'OUTCOME', 'MEASURES', 'The', 'timed', 'up-and-go', 'test', 'and', 'electromyographic', 'and', 'kinematic', 'analyses', 'of', 'the', 'affected', 'lower', 'limb', 'during', 'one', 'gait', 'cycle', '.']","(3, 17)","(21, 117)",-1,hl_o,20943715,Abstract,5,test,gold,6495.0
3739,"RESULTS After the interventions , significant differences were found in the timed up-and-go test results between the",visual locomotor imagery training,( 25.69 ± 16.16 to 23.97 ± 14.30 ) and the kinesthetic locomotor imagery training with auditory step rhythm ( 22.68 ± 12.35 to 15.77 ± 8.58 ) ( P < 0.05 ) .,"['RESULTS', 'After', 'the', 'interventions', ',', 'significant', 'differences', 'were', 'found', 'in', 'the', 'timed', 'up-and-go', 'test', 'results', 'between', 'the', 'visual', 'locomotor', 'imagery', 'training', '(', '25.69', '±', '16.16', 'to', '23.97', '±', '14.30', ')', 'and', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '(', '22.68', '±', '12.35', 'to', '15.77', '±', '8.58', ')', '(', 'P', '<', '0.05', ')', '.']","(17, 21)","(116, 149)",-1,ss_i,20943715,Abstract,6,test,gold,6354.0
3740,"RESULTS After the interventions , significant differences were found in the timed up-and-go test results between the visual locomotor imagery training ( 25.69 ± 16.16 to 23.97 ± 14.30 ) and",the kinesthetic locomotor imagery training with auditory step rhythm,( 22.68 ± 12.35 to 15.77 ± 8.58 ) ( P < 0.05 ) .,"['RESULTS', 'After', 'the', 'interventions', ',', 'significant', 'differences', 'were', 'found', 'in', 'the', 'timed', 'up-and-go', 'test', 'results', 'between', 'the', 'visual', 'locomotor', 'imagery', 'training', '(', '25.69', '±', '16.16', 'to', '23.97', '±', '14.30', ')', 'and', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '(', '22.68', '±', '12.35', 'to', '15.77', '±', '8.58', ')', '(', 'P', '<', '0.05', ')', '.']","(31, 40)","(189, 257)",-1,ss_i,20943715,Abstract,6,test,gold,6297.0
3741,"RESULTS After the interventions , significant differences were found in the",timed up-and-go test,results between the visual locomotor imagery training ( 25.69 ± 16.16 to 23.97 ± 14.30 ) and the kinesthetic locomotor imagery training with auditory step rhythm ( 22.68 ± 12.35 to 15.77 ± 8.58 ) ( P < 0.05 ) .,"['RESULTS', 'After', 'the', 'interventions', ',', 'significant', 'differences', 'were', 'found', 'in', 'the', 'timed', 'up-and-go', 'test', 'results', 'between', 'the', 'visual', 'locomotor', 'imagery', 'training', '(', '25.69', '±', '16.16', 'to', '23.97', '±', '14.30', ')', 'and', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '(', '22.68', '±', '12.35', 'to', '15.77', '±', '8.58', ')', '(', 'P', '<', '0.05', ')', '.']","(11, 14)","(75, 95)",-1,ss_o,20943715,Abstract,6,test,gold,1855.0
3742,"RESULTS After the interventions , significant differences were found in the timed up-and-go test results between the",visual locomotor imagery training,( 25.69 ± 16.16 to 23.97 ± 14.30 ) and the kinesthetic locomotor imagery training with auditory step rhythm ( 22.68 ± 12.35 to 15.77 ± 8.58 ) ( P < 0.05 ) .,"['RESULTS', 'After', 'the', 'interventions', ',', 'significant', 'differences', 'were', 'found', 'in', 'the', 'timed', 'up-and-go', 'test', 'results', 'between', 'the', 'visual', 'locomotor', 'imagery', 'training', '(', '25.69', '±', '16.16', 'to', '23.97', '±', '14.30', ')', 'and', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '(', '22.68', '±', '12.35', 'to', '15.77', '±', '8.58', ')', '(', 'P', '<', '0.05', ')', '.']","(17, 21)","(116, 149)",-1,hl_i,20943715,Abstract,6,test,gold,6352.0
3743,"RESULTS After the interventions , significant differences were found in the timed up-and-go test results between the visual locomotor imagery training ( 25.69 ± 16.16 to 23.97 ± 14.30 ) and the",kinesthetic locomotor imagery training,with auditory step rhythm ( 22.68 ± 12.35 to 15.77 ± 8.58 ) ( P < 0.05 ) .,"['RESULTS', 'After', 'the', 'interventions', ',', 'significant', 'differences', 'were', 'found', 'in', 'the', 'timed', 'up-and-go', 'test', 'results', 'between', 'the', 'visual', 'locomotor', 'imagery', 'training', '(', '25.69', '±', '16.16', 'to', '23.97', '±', '14.30', ')', 'and', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '(', '22.68', '±', '12.35', 'to', '15.77', '±', '8.58', ')', '(', 'P', '<', '0.05', ')', '.']","(32, 36)","(193, 231)",-1,hl_i,20943715,Abstract,6,test,gold,6346.0
3744,"RESULTS After the interventions , significant differences were found in the timed up-and-go test results between the visual locomotor imagery training ( 25.69 ± 16.16 to 23.97 ± 14.30 ) and the kinesthetic locomotor imagery training with",auditory step rhythm,( 22.68 ± 12.35 to 15.77 ± 8.58 ) ( P < 0.05 ) .,"['RESULTS', 'After', 'the', 'interventions', ',', 'significant', 'differences', 'were', 'found', 'in', 'the', 'timed', 'up-and-go', 'test', 'results', 'between', 'the', 'visual', 'locomotor', 'imagery', 'training', '(', '25.69', '±', '16.16', 'to', '23.97', '±', '14.30', ')', 'and', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '(', '22.68', '±', '12.35', 'to', '15.77', '±', '8.58', ')', '(', 'P', '<', '0.05', ')', '.']","(37, 40)","(237, 257)",-1,hl_i,20943715,Abstract,6,test,gold,6304.0
3745,"RESULTS After the interventions , significant differences were found in the",timed up-and-go test,results between the visual locomotor imagery training ( 25.69 ± 16.16 to 23.97 ± 14.30 ) and the kinesthetic locomotor imagery training with auditory step rhythm ( 22.68 ± 12.35 to 15.77 ± 8.58 ) ( P < 0.05 ) .,"['RESULTS', 'After', 'the', 'interventions', ',', 'significant', 'differences', 'were', 'found', 'in', 'the', 'timed', 'up-and-go', 'test', 'results', 'between', 'the', 'visual', 'locomotor', 'imagery', 'training', '(', '25.69', '±', '16.16', 'to', '23.97', '±', '14.30', ')', 'and', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '(', '22.68', '±', '12.35', 'to', '15.77', '±', '8.58', ')', '(', 'P', '<', '0.05', ')', '.']","(11, 14)","(75, 95)",-1,hl_o,20943715,Abstract,6,test,gold,1856.0
3746,"During the swing and stance phases ,",the kinesthetic locomotor imagery training,"exhibited significantly increased activation in a greater number of muscles and increased angular displacement of the knee and ankle joints compared with the visual locomotor imagery training , and these effects were more prominent when auditory step rhythm was integrated into each form of locomotor imagery training .","['During', 'the', 'swing', 'and', 'stance', 'phases', ',', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'exhibited', 'significantly', 'increased', 'activation', 'in', 'a', 'greater', 'number', 'of', 'muscles', 'and', 'increased', 'angular', 'displacement', 'of', 'the', 'knee', 'and', 'ankle', 'joints', 'compared', 'with', 'the', 'visual', 'locomotor', 'imagery', 'training', ',', 'and', 'these', 'effects', 'were', 'more', 'prominent', 'when', 'auditory', 'step', 'rhythm', 'was', 'integrated', 'into', 'each', 'form', 'of', 'locomotor', 'imagery', 'training', '.']","(7, 12)","(36, 78)",-1,ss_i,20943715,Abstract,7,test,gold,6347.0
3747,"During the swing and stance phases , the kinesthetic locomotor imagery training exhibited significantly increased activation in a greater number of muscles and increased angular displacement of the knee and ankle joints compared with",the visual locomotor imagery training,", and these effects were more prominent when auditory step rhythm was integrated into each form of locomotor imagery training .","['During', 'the', 'swing', 'and', 'stance', 'phases', ',', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'exhibited', 'significantly', 'increased', 'activation', 'in', 'a', 'greater', 'number', 'of', 'muscles', 'and', 'increased', 'angular', 'displacement', 'of', 'the', 'knee', 'and', 'ankle', 'joints', 'compared', 'with', 'the', 'visual', 'locomotor', 'imagery', 'training', ',', 'and', 'these', 'effects', 'were', 'more', 'prominent', 'when', 'auditory', 'step', 'rhythm', 'was', 'integrated', 'into', 'each', 'form', 'of', 'locomotor', 'imagery', 'training', '.']","(34, 39)","(233, 270)",-1,ss_i,20943715,Abstract,7,test,gold,6356.0
3748,"During the swing and stance phases , the kinesthetic locomotor imagery training exhibited significantly increased activation in a greater number of muscles and increased angular displacement of the knee and ankle joints compared with the visual locomotor imagery training , and these effects were more prominent",when auditory step rhythm,was integrated into each form of locomotor imagery training .,"['During', 'the', 'swing', 'and', 'stance', 'phases', ',', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'exhibited', 'significantly', 'increased', 'activation', 'in', 'a', 'greater', 'number', 'of', 'muscles', 'and', 'increased', 'angular', 'displacement', 'of', 'the', 'knee', 'and', 'ankle', 'joints', 'compared', 'with', 'the', 'visual', 'locomotor', 'imagery', 'training', ',', 'and', 'these', 'effects', 'were', 'more', 'prominent', 'when', 'auditory', 'step', 'rhythm', 'was', 'integrated', 'into', 'each', 'form', 'of', 'locomotor', 'imagery', 'training', '.']","(46, 50)","(311, 336)",-1,ss_i,20943715,Abstract,7,test,gold,6301.0
3749,"During the swing and stance phases , the kinesthetic locomotor imagery training exhibited significantly increased activation in a greater number of muscles and increased angular displacement of the knee and ankle joints compared with the visual locomotor imagery training , and these effects were more prominent when auditory step rhythm was integrated into each",form of locomotor imagery training,.,"['During', 'the', 'swing', 'and', 'stance', 'phases', ',', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'exhibited', 'significantly', 'increased', 'activation', 'in', 'a', 'greater', 'number', 'of', 'muscles', 'and', 'increased', 'angular', 'displacement', 'of', 'the', 'knee', 'and', 'ankle', 'joints', 'compared', 'with', 'the', 'visual', 'locomotor', 'imagery', 'training', ',', 'and', 'these', 'effects', 'were', 'more', 'prominent', 'when', 'auditory', 'step', 'rhythm', 'was', 'integrated', 'into', 'each', 'form', 'of', 'locomotor', 'imagery', 'training', '.']","(54, 59)","(362, 396)",-1,ss_i,20943715,Abstract,7,test,gold,6360.0
3750,"During the swing and stance phases , the kinesthetic locomotor imagery training exhibited significantly increased activation in a",greater number of muscles,"and increased angular displacement of the knee and ankle joints compared with the visual locomotor imagery training , and these effects were more prominent when auditory step rhythm was integrated into each form of locomotor imagery training .","['During', 'the', 'swing', 'and', 'stance', 'phases', ',', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'exhibited', 'significantly', 'increased', 'activation', 'in', 'a', 'greater', 'number', 'of', 'muscles', 'and', 'increased', 'angular', 'displacement', 'of', 'the', 'knee', 'and', 'ankle', 'joints', 'compared', 'with', 'the', 'visual', 'locomotor', 'imagery', 'training', ',', 'and', 'these', 'effects', 'were', 'more', 'prominent', 'when', 'auditory', 'step', 'rhythm', 'was', 'integrated', 'into', 'each', 'form', 'of', 'locomotor', 'imagery', 'training', '.']","(18, 22)","(129, 154)",-1,ss_o,20943715,Abstract,7,test,gold,983.0
3751,"During the swing and stance phases , the kinesthetic locomotor imagery training exhibited significantly increased activation in a greater number of muscles and",increased angular displacement of the knee and ankle joints,"compared with the visual locomotor imagery training , and these effects were more prominent when auditory step rhythm was integrated into each form of locomotor imagery training .","['During', 'the', 'swing', 'and', 'stance', 'phases', ',', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'exhibited', 'significantly', 'increased', 'activation', 'in', 'a', 'greater', 'number', 'of', 'muscles', 'and', 'increased', 'angular', 'displacement', 'of', 'the', 'knee', 'and', 'ankle', 'joints', 'compared', 'with', 'the', 'visual', 'locomotor', 'imagery', 'training', ',', 'and', 'these', 'effects', 'were', 'more', 'prominent', 'when', 'auditory', 'step', 'rhythm', 'was', 'integrated', 'into', 'each', 'form', 'of', 'locomotor', 'imagery', 'training', '.']","(23, 32)","(159, 218)",-1,ss_o,20943715,Abstract,7,test,gold,3685.0
3752,"During the swing and stance phases , the",kinesthetic locomotor imagery,"training exhibited significantly increased activation in a greater number of muscles and increased angular displacement of the knee and ankle joints compared with the visual locomotor imagery training , and these effects were more prominent when auditory step rhythm was integrated into each form of locomotor imagery training .","['During', 'the', 'swing', 'and', 'stance', 'phases', ',', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'exhibited', 'significantly', 'increased', 'activation', 'in', 'a', 'greater', 'number', 'of', 'muscles', 'and', 'increased', 'angular', 'displacement', 'of', 'the', 'knee', 'and', 'ankle', 'joints', 'compared', 'with', 'the', 'visual', 'locomotor', 'imagery', 'training', ',', 'and', 'these', 'effects', 'were', 'more', 'prominent', 'when', 'auditory', 'step', 'rhythm', 'was', 'integrated', 'into', 'each', 'form', 'of', 'locomotor', 'imagery', 'training', '.']","(8, 11)","(40, 69)",-1,hl_i,20943715,Abstract,7,test,gold,6342.0
3753,"During the swing and stance phases , the kinesthetic locomotor imagery training exhibited significantly increased activation in a greater number of muscles and increased angular displacement of the knee and ankle joints compared with the",visual locomotor imagery training,", and these effects were more prominent when auditory step rhythm was integrated into each form of locomotor imagery training .","['During', 'the', 'swing', 'and', 'stance', 'phases', ',', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'exhibited', 'significantly', 'increased', 'activation', 'in', 'a', 'greater', 'number', 'of', 'muscles', 'and', 'increased', 'angular', 'displacement', 'of', 'the', 'knee', 'and', 'ankle', 'joints', 'compared', 'with', 'the', 'visual', 'locomotor', 'imagery', 'training', ',', 'and', 'these', 'effects', 'were', 'more', 'prominent', 'when', 'auditory', 'step', 'rhythm', 'was', 'integrated', 'into', 'each', 'form', 'of', 'locomotor', 'imagery', 'training', '.']","(35, 39)","(237, 270)",-1,hl_i,20943715,Abstract,7,test,gold,6351.0
3754,"During the swing and stance phases , the kinesthetic locomotor imagery training exhibited significantly increased activation in a greater number of muscles and increased angular displacement of the knee and ankle joints compared with the visual locomotor imagery training , and these effects were more prominent when auditory",step rhythm,was integrated into each form of locomotor imagery training .,"['During', 'the', 'swing', 'and', 'stance', 'phases', ',', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'exhibited', 'significantly', 'increased', 'activation', 'in', 'a', 'greater', 'number', 'of', 'muscles', 'and', 'increased', 'angular', 'displacement', 'of', 'the', 'knee', 'and', 'ankle', 'joints', 'compared', 'with', 'the', 'visual', 'locomotor', 'imagery', 'training', ',', 'and', 'these', 'effects', 'were', 'more', 'prominent', 'when', 'auditory', 'step', 'rhythm', 'was', 'integrated', 'into', 'each', 'form', 'of', 'locomotor', 'imagery', 'training', '.']","(48, 50)","(325, 336)",-1,hl_i,20943715,Abstract,7,test,gold,6299.0
3755,"The activation of the hamstring during the swing phase and the gastrocnemius during the stance phase , as well as kinematic data of the knee joint , were significantly different for posttest values between",the visual locomotor imagery training,and the kinesthetic locomotor imagery training with auditory step rhythm ( P < 0.05 ) .,"['The', 'activation', 'of', 'the', 'hamstring', 'during', 'the', 'swing', 'phase', 'and', 'the', 'gastrocnemius', 'during', 'the', 'stance', 'phase', ',', 'as', 'well', 'as', 'kinematic', 'data', 'of', 'the', 'knee', 'joint', ',', 'were', 'significantly', 'different', 'for', 'posttest', 'values', 'between', 'the', 'visual', 'locomotor', 'imagery', 'training', 'and', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '(', 'P', '<', '0.05', ')', '.']","(34, 39)","(205, 242)",-1,ss_i,20943715,Abstract,8,test,gold,6357.0
3756,"The activation of the hamstring during the swing phase and the gastrocnemius during the stance phase , as well as kinematic data of the knee joint , were significantly different for posttest values between the visual locomotor imagery training and",the kinesthetic locomotor imagery training with auditory step rhythm,( P < 0.05 ) .,"['The', 'activation', 'of', 'the', 'hamstring', 'during', 'the', 'swing', 'phase', 'and', 'the', 'gastrocnemius', 'during', 'the', 'stance', 'phase', ',', 'as', 'well', 'as', 'kinematic', 'data', 'of', 'the', 'knee', 'joint', ',', 'were', 'significantly', 'different', 'for', 'posttest', 'values', 'between', 'the', 'visual', 'locomotor', 'imagery', 'training', 'and', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '(', 'P', '<', '0.05', ')', '.']","(40, 49)","(247, 315)",-1,ss_i,20943715,Abstract,8,test,gold,6298.0
3757,"The activation of the hamstring during the swing phase and the gastrocnemius during the stance phase , as",well as kinematic data of the knee joint,", were significantly different for posttest values between the visual locomotor imagery training and the kinesthetic locomotor imagery training with auditory step rhythm ( P < 0.05 ) .","['The', 'activation', 'of', 'the', 'hamstring', 'during', 'the', 'swing', 'phase', 'and', 'the', 'gastrocnemius', 'during', 'the', 'stance', 'phase', ',', 'as', 'well', 'as', 'kinematic', 'data', 'of', 'the', 'knee', 'joint', ',', 'were', 'significantly', 'different', 'for', 'posttest', 'values', 'between', 'the', 'visual', 'locomotor', 'imagery', 'training', 'and', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '(', 'P', '<', '0.05', ')', '.']","(18, 26)","(105, 145)",-1,ss_o,20943715,Abstract,8,test,gold,3686.0
3758,"The activation of the hamstring during the swing phase and the gastrocnemius during the stance phase , as well as kinematic data of the knee joint , were significantly different for posttest values between the",visual locomotor imagery training,and the kinesthetic locomotor imagery training with auditory step rhythm ( P < 0.05 ) .,"['The', 'activation', 'of', 'the', 'hamstring', 'during', 'the', 'swing', 'phase', 'and', 'the', 'gastrocnemius', 'during', 'the', 'stance', 'phase', ',', 'as', 'well', 'as', 'kinematic', 'data', 'of', 'the', 'knee', 'joint', ',', 'were', 'significantly', 'different', 'for', 'posttest', 'values', 'between', 'the', 'visual', 'locomotor', 'imagery', 'training', 'and', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '(', 'P', '<', '0.05', ')', '.']","(35, 39)","(209, 242)",-1,hl_i,20943715,Abstract,8,test,gold,6350.0
3759,"The activation of the hamstring during the swing phase and the gastrocnemius during the stance phase , as well as kinematic data of the knee joint , were significantly different for posttest values between the visual locomotor imagery training and the",kinesthetic locomotor imagery training,with auditory step rhythm ( P < 0.05 ) .,"['The', 'activation', 'of', 'the', 'hamstring', 'during', 'the', 'swing', 'phase', 'and', 'the', 'gastrocnemius', 'during', 'the', 'stance', 'phase', ',', 'as', 'well', 'as', 'kinematic', 'data', 'of', 'the', 'knee', 'joint', ',', 'were', 'significantly', 'different', 'for', 'posttest', 'values', 'between', 'the', 'visual', 'locomotor', 'imagery', 'training', 'and', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '(', 'P', '<', '0.05', ')', '.']","(41, 45)","(251, 289)",-1,hl_i,20943715,Abstract,8,test,gold,6344.0
3760,"The activation of the hamstring during the swing phase and the gastrocnemius during the stance phase , as well as kinematic data of the knee joint , were significantly different for posttest values between the visual locomotor imagery training and the kinesthetic locomotor imagery training with",auditory step rhythm,( P < 0.05 ) .,"['The', 'activation', 'of', 'the', 'hamstring', 'during', 'the', 'swing', 'phase', 'and', 'the', 'gastrocnemius', 'during', 'the', 'stance', 'phase', ',', 'as', 'well', 'as', 'kinematic', 'data', 'of', 'the', 'knee', 'joint', ',', 'were', 'significantly', 'different', 'for', 'posttest', 'values', 'between', 'the', 'visual', 'locomotor', 'imagery', 'training', 'and', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'with', 'auditory', 'step', 'rhythm', '(', 'P', '<', '0.05', ')', '.']","(46, 49)","(295, 315)",-1,hl_i,20943715,Abstract,8,test,gold,6303.0
3761,CONCLUSIONS The therapeutic effect may be further enhanced in,the kinesthetic locomotor imagery training,than in the visual locomotor imagery training .,"['CONCLUSIONS', 'The', 'therapeutic', 'effect', 'may', 'be', 'further', 'enhanced', 'in', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'than', 'in', 'the', 'visual', 'locomotor', 'imagery', 'training', '.']","(9, 14)","(61, 103)",-1,ss_i,20943715,Abstract,9,test,gold,6348.0
3762,CONCLUSIONS The therapeutic effect may be further enhanced in the kinesthetic locomotor imagery training than in,the visual locomotor imagery training,.,"['CONCLUSIONS', 'The', 'therapeutic', 'effect', 'may', 'be', 'further', 'enhanced', 'in', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'than', 'in', 'the', 'visual', 'locomotor', 'imagery', 'training', '.']","(16, 21)","(112, 149)",-1,ss_i,20943715,Abstract,9,test,gold,6355.0
3763,CONCLUSIONS,The therapeutic effect,may be further enhanced in the kinesthetic locomotor imagery training than in the visual locomotor imagery training .,"['CONCLUSIONS', 'The', 'therapeutic', 'effect', 'may', 'be', 'further', 'enhanced', 'in', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'than', 'in', 'the', 'visual', 'locomotor', 'imagery', 'training', '.']","(1, 4)","(11, 33)",-1,ss_o,20943715,Abstract,9,test,gold,2348.0
3764,CONCLUSIONS The therapeutic effect may be further enhanced in the,kinesthetic locomotor imagery training,than in the visual locomotor imagery training .,"['CONCLUSIONS', 'The', 'therapeutic', 'effect', 'may', 'be', 'further', 'enhanced', 'in', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'than', 'in', 'the', 'visual', 'locomotor', 'imagery', 'training', '.']","(10, 14)","(65, 103)",-1,hl_i,20943715,Abstract,9,test,gold,6343.0
3765,CONCLUSIONS The therapeutic effect may be further enhanced in the kinesthetic locomotor imagery training than in the,visual locomotor imagery training,.,"['CONCLUSIONS', 'The', 'therapeutic', 'effect', 'may', 'be', 'further', 'enhanced', 'in', 'the', 'kinesthetic', 'locomotor', 'imagery', 'training', 'than', 'in', 'the', 'visual', 'locomotor', 'imagery', 'training', '.']","(17, 21)","(116, 149)",-1,hl_i,20943715,Abstract,9,test,gold,6349.0
3766,The auditory step rhythm together with the locomotor imagery training produces a greater positive effect in improving the walking,performance of patients with post-stroke hemiparesis,.,"['The', 'auditory', 'step', 'rhythm', 'together', 'with', 'the', 'locomotor', 'imagery', 'training', 'produces', 'a', 'greater', 'positive', 'effect', 'in', 'improving', 'the', 'walking', 'performance', 'of', 'patients', 'with', 'post-stroke', 'hemiparesis', '.']","(19, 25)","(129, 181)",-1,ss_p,20943715,Abstract,10,test,gold,3790.0
3767,,The auditory step rhythm,together with the locomotor imagery training produces a greater positive effect in improving the walking performance of patients with post-stroke hemiparesis .,"['The', 'auditory', 'step', 'rhythm', 'together', 'with', 'the', 'locomotor', 'imagery', 'training', 'produces', 'a', 'greater', 'positive', 'effect', 'in', 'improving', 'the', 'walking', 'performance', 'of', 'patients', 'with', 'post-stroke', 'hemiparesis', '.']","(0, 4)","(0, 24)",-1,ss_i,20943715,Abstract,10,test,gold,6300.0
3768,The auditory step rhythm together with,the locomotor imagery training,produces a greater positive effect in improving the walking performance of patients with post-stroke hemiparesis .,"['The', 'auditory', 'step', 'rhythm', 'together', 'with', 'the', 'locomotor', 'imagery', 'training', 'produces', 'a', 'greater', 'positive', 'effect', 'in', 'improving', 'the', 'walking', 'performance', 'of', 'patients', 'with', 'post-stroke', 'hemiparesis', '.']","(6, 10)","(38, 68)",-1,ss_i,20943715,Abstract,10,test,gold,6361.0
3769,The auditory step rhythm together with the locomotor imagery training produces a greater positive effect in improving,the walking performance,of patients with post-stroke hemiparesis .,"['The', 'auditory', 'step', 'rhythm', 'together', 'with', 'the', 'locomotor', 'imagery', 'training', 'produces', 'a', 'greater', 'positive', 'effect', 'in', 'improving', 'the', 'walking', 'performance', 'of', 'patients', 'with', 'post-stroke', 'hemiparesis', '.']","(17, 20)","(117, 140)",-1,ss_o,20943715,Abstract,10,test,gold,2712.0
3770,The auditory step rhythm together with the locomotor imagery training produces a greater positive effect in improving the walking performance of patients with,post-stroke hemiparesis,.,"['The', 'auditory', 'step', 'rhythm', 'together', 'with', 'the', 'locomotor', 'imagery', 'training', 'produces', 'a', 'greater', 'positive', 'effect', 'in', 'improving', 'the', 'walking', 'performance', 'of', 'patients', 'with', 'post-stroke', 'hemiparesis', '.']","(23, 25)","(158, 181)",-1,hl_p,20943715,Abstract,10,test,gold,75.0
3771,The,auditory step rhythm,together with the locomotor imagery training produces a greater positive effect in improving the walking performance of patients with post-stroke hemiparesis .,"['The', 'auditory', 'step', 'rhythm', 'together', 'with', 'the', 'locomotor', 'imagery', 'training', 'produces', 'a', 'greater', 'positive', 'effect', 'in', 'improving', 'the', 'walking', 'performance', 'of', 'patients', 'with', 'post-stroke', 'hemiparesis', '.']","(1, 4)","(3, 23)",-1,hl_i,20943715,Abstract,10,test,gold,6302.0
3772,The auditory step rhythm together with the,locomotor imagery training,produces a greater positive effect in improving the walking performance of patients with post-stroke hemiparesis .,"['The', 'auditory', 'step', 'rhythm', 'together', 'with', 'the', 'locomotor', 'imagery', 'training', 'produces', 'a', 'greater', 'positive', 'effect', 'in', 'improving', 'the', 'walking', 'performance', 'of', 'patients', 'with', 'post-stroke', 'hemiparesis', '.']","(7, 10)","(42, 68)",-1,hl_i,20943715,Abstract,10,test,gold,6362.0
3773,[ Efficacy of paliperidone extended-release tablets in the improvement of social functions in,schizophrenics :,a randomized and controlled study ] .,"['[', 'Efficacy', 'of', 'paliperidone', 'extended-release', 'tablets', 'in', 'the', 'improvement', 'of', 'social', 'functions', 'in', 'schizophrenics', ':', 'a', 'randomized', 'and', 'controlled', 'study', ']', '.']","(13, 15)","(93, 109)",-1,ss_p,21029638,Title,0,test,gold,2543.0
3774,[ Efficacy of,paliperidone,extended-release tablets in the improvement of social functions in schizophrenics : a randomized and controlled study ] .,"['[', 'Efficacy', 'of', 'paliperidone', 'extended-release', 'tablets', 'in', 'the', 'improvement', 'of', 'social', 'functions', 'in', 'schizophrenics', ':', 'a', 'randomized', 'and', 'controlled', 'study', ']', '.']","(3, 4)","(13, 25)",-1,ss_i,21029638,Title,0,test,gold,5561.0
3775,,[ Efficacy,of paliperidone extended-release tablets in the improvement of social functions in schizophrenics : a randomized and controlled study ] .,"['[', 'Efficacy', 'of', 'paliperidone', 'extended-release', 'tablets', 'in', 'the', 'improvement', 'of', 'social', 'functions', 'in', 'schizophrenics', ':', 'a', 'randomized', 'and', 'controlled', 'study', ']', '.']","(0, 2)","(0, 10)",-1,ss_o,21029638,Title,0,test,gold,426.0
3776,[ Efficacy of paliperidone extended-release tablets in the improvement of,social functions,in schizophrenics : a randomized and controlled study ] .,"['[', 'Efficacy', 'of', 'paliperidone', 'extended-release', 'tablets', 'in', 'the', 'improvement', 'of', 'social', 'functions', 'in', 'schizophrenics', ':', 'a', 'randomized', 'and', 'controlled', 'study', ']', '.']","(10, 12)","(73, 89)",-1,ss_o,21029638,Title,0,test,gold,2971.0
3777,[ Efficacy of paliperidone extended-release tablets in the improvement of social functions in,schizophrenics,: a randomized and controlled study ] .,"['[', 'Efficacy', 'of', 'paliperidone', 'extended-release', 'tablets', 'in', 'the', 'improvement', 'of', 'social', 'functions', 'in', 'schizophrenics', ':', 'a', 'randomized', 'and', 'controlled', 'study', ']', '.']","(13, 14)","(93, 107)",-1,hl_p,21029638,Title,0,test,gold,2544.0
3778,[ Efficacy of,paliperidone,extended-release tablets in the improvement of social functions in schizophrenics : a randomized and controlled study ] .,"['[', 'Efficacy', 'of', 'paliperidone', 'extended-release', 'tablets', 'in', 'the', 'improvement', 'of', 'social', 'functions', 'in', 'schizophrenics', ':', 'a', 'randomized', 'and', 'controlled', 'study', ']', '.']","(3, 4)","(13, 25)",-1,hl_i,21029638,Title,0,test,gold,5562.0
3779,[ Efficacy of paliperidone extended-release tablets in the improvement of,social functions,in schizophrenics : a randomized and controlled study ] .,"['[', 'Efficacy', 'of', 'paliperidone', 'extended-release', 'tablets', 'in', 'the', 'improvement', 'of', 'social', 'functions', 'in', 'schizophrenics', ':', 'a', 'randomized', 'and', 'controlled', 'study', ']', '.']","(10, 12)","(73, 89)",-1,hl_o,21029638,Title,0,test,gold,2972.0
3780,OBJECTIVE To explore the efficacy of paliperidone extended-release tablets in the improvement of social functions in,schizophrenics .,,"['OBJECTIVE', 'To', 'explore', 'the', 'efficacy', 'of', 'paliperidone', 'extended-release', 'tablets', 'in', 'the', 'improvement', 'of', 'social', 'functions', 'in', 'schizophrenics', '.']","(16, 18)","(116, 132)",-1,ss_p,21029638,Abstract,0,test,gold,2542.0
3781,OBJECTIVE To explore the efficacy of,paliperidone,extended-release tablets in the improvement of social functions in schizophrenics .,"['OBJECTIVE', 'To', 'explore', 'the', 'efficacy', 'of', 'paliperidone', 'extended-release', 'tablets', 'in', 'the', 'improvement', 'of', 'social', 'functions', 'in', 'schizophrenics', '.']","(6, 7)","(36, 48)",-1,ss_i,21029638,Abstract,0,test,gold,5560.0
3782,OBJECTIVE To explore the,efficacy,of paliperidone extended-release tablets in the improvement of social functions in schizophrenics .,"['OBJECTIVE', 'To', 'explore', 'the', 'efficacy', 'of', 'paliperidone', 'extended-release', 'tablets', 'in', 'the', 'improvement', 'of', 'social', 'functions', 'in', 'schizophrenics', '.']","(4, 5)","(24, 32)",-1,ss_o,21029638,Abstract,0,test,gold,4808.0
3783,OBJECTIVE To explore the efficacy of paliperidone extended-release tablets in the improvement of,social functions,in schizophrenics .,"['OBJECTIVE', 'To', 'explore', 'the', 'efficacy', 'of', 'paliperidone', 'extended-release', 'tablets', 'in', 'the', 'improvement', 'of', 'social', 'functions', 'in', 'schizophrenics', '.']","(13, 15)","(96, 112)",-1,ss_o,21029638,Abstract,0,test,gold,2970.0
3784,OBJECTIVE To explore the efficacy of paliperidone extended-release tablets in the improvement of social functions in,schizophrenics .,,"['OBJECTIVE', 'To', 'explore', 'the', 'efficacy', 'of', 'paliperidone', 'extended-release', 'tablets', 'in', 'the', 'improvement', 'of', 'social', 'functions', 'in', 'schizophrenics', '.']","(16, 18)","(116, 132)",-1,hl_p,21029638,Abstract,0,test,gold,2541.0
3785,OBJECTIVE To explore the efficacy of,paliperidone,extended-release tablets in the improvement of social functions in schizophrenics .,"['OBJECTIVE', 'To', 'explore', 'the', 'efficacy', 'of', 'paliperidone', 'extended-release', 'tablets', 'in', 'the', 'improvement', 'of', 'social', 'functions', 'in', 'schizophrenics', '.']","(6, 7)","(36, 48)",-1,hl_i,21029638,Abstract,0,test,gold,5559.0
3786,OBJECTIVE To explore the efficacy of paliperidone extended-release tablets in the improvement of,social functions,in schizophrenics .,"['OBJECTIVE', 'To', 'explore', 'the', 'efficacy', 'of', 'paliperidone', 'extended-release', 'tablets', 'in', 'the', 'improvement', 'of', 'social', 'functions', 'in', 'schizophrenics', '.']","(13, 15)","(96, 112)",-1,hl_o,21029638,Abstract,0,test,gold,2969.0
3787,METHODS A,total of 81 schizophrenics,were randomly divided into study group with paliperidone extended-release tablets and control group with risperidone for a 12-week treatment .,"['METHODS', 'A', 'total', 'of', '81', 'schizophrenics', 'were', 'randomly', 'divided', 'into', 'study', 'group', 'with', 'paliperidone', 'extended-release', 'tablets', 'and', 'control', 'group', 'with', 'risperidone', 'for', 'a', '12-week', 'treatment', '.']","(2, 6)","(9, 35)",-1,ss_p,21029638,Abstract,1,test,gold,2539.0
3788,METHODS A total of 81 schizophrenics were randomly divided into study group with,paliperidone,extended-release tablets and control group with risperidone for a 12-week treatment .,"['METHODS', 'A', 'total', 'of', '81', 'schizophrenics', 'were', 'randomly', 'divided', 'into', 'study', 'group', 'with', 'paliperidone', 'extended-release', 'tablets', 'and', 'control', 'group', 'with', 'risperidone', 'for', 'a', '12-week', 'treatment', '.']","(13, 14)","(80, 92)",-1,ss_i,21029638,Abstract,1,test,gold,5558.0
3789,METHODS A total of 81 schizophrenics were randomly divided into study group with paliperidone extended-release tablets and control group with,risperidone,for a 12-week treatment .,"['METHODS', 'A', 'total', 'of', '81', 'schizophrenics', 'were', 'randomly', 'divided', 'into', 'study', 'group', 'with', 'paliperidone', 'extended-release', 'tablets', 'and', 'control', 'group', 'with', 'risperidone', 'for', 'a', '12-week', 'treatment', '.']","(20, 21)","(141, 152)",-1,ss_i,21029638,Abstract,1,test,gold,5299.0
3790,METHODS A total of,81 schizophrenics,were randomly divided into study group with paliperidone extended-release tablets and control group with risperidone for a 12-week treatment .,"['METHODS', 'A', 'total', 'of', '81', 'schizophrenics', 'were', 'randomly', 'divided', 'into', 'study', 'group', 'with', 'paliperidone', 'extended-release', 'tablets', 'and', 'control', 'group', 'with', 'risperidone', 'for', 'a', '12-week', 'treatment', '.']","(4, 6)","(18, 35)",-1,hl_p,21029638,Abstract,1,test,gold,2540.0
3791,METHODS A total of 81 schizophrenics were randomly divided into study group with,paliperidone,extended-release tablets and control group with risperidone for a 12-week treatment .,"['METHODS', 'A', 'total', 'of', '81', 'schizophrenics', 'were', 'randomly', 'divided', 'into', 'study', 'group', 'with', 'paliperidone', 'extended-release', 'tablets', 'and', 'control', 'group', 'with', 'risperidone', 'for', 'a', '12-week', 'treatment', '.']","(13, 14)","(80, 92)",-1,hl_i,21029638,Abstract,1,test,gold,5557.0
3792,METHODS A total of 81 schizophrenics were randomly divided into study group with paliperidone extended-release tablets and control group with,risperidone,for a 12-week treatment .,"['METHODS', 'A', 'total', 'of', '81', 'schizophrenics', 'were', 'randomly', 'divided', 'into', 'study', 'group', 'with', 'paliperidone', 'extended-release', 'tablets', 'and', 'control', 'group', 'with', 'risperidone', 'for', 'a', '12-week', 'treatment', '.']","(20, 21)","(141, 152)",-1,hl_i,21029638,Abstract,1,test,gold,5298.0
3793,They were assessed and analyzed by,"positive and negative symptoms scales ( PANSS ) , social disability screening schedule ( SDSS ) and treatment emergent symptom scale ( TESS )","at baseline , 6 ( th ) weekend and 12 ( th ) weekend .","['They', 'were', 'assessed', 'and', 'analyzed', 'by', 'positive', 'and', 'negative', 'symptoms', 'scales', '(', 'PANSS', ')', ',', 'social', 'disability', 'screening', 'schedule', '(', 'SDSS', ')', 'and', 'treatment', 'emergent', 'symptom', 'scale', '(', 'TESS', ')', 'at', 'baseline', ',', '6', '(', 'th', ')', 'weekend', 'and', '12', '(', 'th', ')', 'weekend', '.']","(6, 30)","(34, 175)",-1,ss_o,21029638,Abstract,2,test,gold,5913.0
3794,They were assessed and analyzed by,positive and negative symptoms scales ( PANSS ),", social disability screening schedule ( SDSS ) and treatment emergent symptom scale ( TESS ) at baseline , 6 ( th ) weekend and 12 ( th ) weekend .","['They', 'were', 'assessed', 'and', 'analyzed', 'by', 'positive', 'and', 'negative', 'symptoms', 'scales', '(', 'PANSS', ')', ',', 'social', 'disability', 'screening', 'schedule', '(', 'SDSS', ')', 'and', 'treatment', 'emergent', 'symptom', 'scale', '(', 'TESS', ')', 'at', 'baseline', ',', '6', '(', 'th', ')', 'weekend', 'and', '12', '(', 'th', ')', 'weekend', '.']","(6, 14)","(34, 81)",-1,hl_o,21029638,Abstract,2,test,gold,6384.0
3795,"They were assessed and analyzed by positive and negative symptoms scales ( PANSS ) ,",social disability screening schedule ( SDSS ),"and treatment emergent symptom scale ( TESS ) at baseline , 6 ( th ) weekend and 12 ( th ) weekend .","['They', 'were', 'assessed', 'and', 'analyzed', 'by', 'positive', 'and', 'negative', 'symptoms', 'scales', '(', 'PANSS', ')', ',', 'social', 'disability', 'screening', 'schedule', '(', 'SDSS', ')', 'and', 'treatment', 'emergent', 'symptom', 'scale', '(', 'TESS', ')', 'at', 'baseline', ',', '6', '(', 'th', ')', 'weekend', 'and', '12', '(', 'th', ')', 'weekend', '.']","(15, 22)","(84, 129)",-1,hl_o,21029638,Abstract,2,test,gold,6419.0
3796,"They were assessed and analyzed by positive and negative symptoms scales ( PANSS ) , social disability screening schedule ( SDSS ) and",treatment emergent symptom scale ( TESS ),"at baseline , 6 ( th ) weekend and 12 ( th ) weekend .","['They', 'were', 'assessed', 'and', 'analyzed', 'by', 'positive', 'and', 'negative', 'symptoms', 'scales', '(', 'PANSS', ')', ',', 'social', 'disability', 'screening', 'schedule', '(', 'SDSS', ')', 'and', 'treatment', 'emergent', 'symptom', 'scale', '(', 'TESS', ')', 'at', 'baseline', ',', '6', '(', 'th', ')', 'weekend', 'and', '12', '(', 'th', ')', 'weekend', '.']","(23, 30)","(134, 175)",-1,hl_o,21029638,Abstract,2,test,gold,3882.0
3797,"RESULTS In study group , the",factors and total scores of PANSS,"in the 12 ( th ) weekend of treatment [ ( 12.0 ± 2.8 ) , ( 12.1 ± 3.6 ) , ( 26.2 ± 5.0 ) , ( 50.2 ± 8.7 ) ] were all significantly lower than those at baseline [ ( 24.7 ± 5.3 ) , ( 23.8 ± 3.6 ) , ( 45.0 ± 2.9 ) , ( 93.5 ± 6.8 ) ] ( t = 9.60-16.78 , P < 0.05 ) .","['RESULTS', 'In', 'study', 'group', ',', 'the', 'factors', 'and', 'total', 'scores', 'of', 'PANSS', 'in', 'the', '12', '(', 'th', ')', 'weekend', 'of', 'treatment', '[', '(', '12.0', '±', '2.8', ')', ',', '(', '12.1', '±', '3.6', ')', ',', '(', '26.2', '±', '5.0', ')', ',', '(', '50.2', '±', '8.7', ')', ']', 'were', 'all', 'significantly', 'lower', 'than', 'those', 'at', 'baseline', '[', '(', '24.7', '±', '5.3', ')', ',', '(', '23.8', '±', '3.6', ')', ',', '(', '45.0', '±', '2.9', ')', ',', '(', '93.5', '±', '6.8', ')', ']', '(', 't', '=', '9.60-16.78', ',', 'P', '<', '0.05', ')', '.']","(6, 12)","(28, 61)",-1,ss_o,21029638,Abstract,3,test,gold,6382.0
3798,"RESULTS In study group , the",factors and total scores of PANSS,"in the 12 ( th ) weekend of treatment [ ( 12.0 ± 2.8 ) , ( 12.1 ± 3.6 ) , ( 26.2 ± 5.0 ) , ( 50.2 ± 8.7 ) ] were all significantly lower than those at baseline [ ( 24.7 ± 5.3 ) , ( 23.8 ± 3.6 ) , ( 45.0 ± 2.9 ) , ( 93.5 ± 6.8 ) ] ( t = 9.60-16.78 , P < 0.05 ) .","['RESULTS', 'In', 'study', 'group', ',', 'the', 'factors', 'and', 'total', 'scores', 'of', 'PANSS', 'in', 'the', '12', '(', 'th', ')', 'weekend', 'of', 'treatment', '[', '(', '12.0', '±', '2.8', ')', ',', '(', '12.1', '±', '3.6', ')', ',', '(', '26.2', '±', '5.0', ')', ',', '(', '50.2', '±', '8.7', ')', ']', 'were', 'all', 'significantly', 'lower', 'than', 'those', 'at', 'baseline', '[', '(', '24.7', '±', '5.3', ')', ',', '(', '23.8', '±', '3.6', ')', ',', '(', '45.0', '±', '2.9', ')', ',', '(', '93.5', '±', '6.8', ')', ']', '(', 't', '=', '9.60-16.78', ',', 'P', '<', '0.05', ')', '.']","(6, 12)","(28, 61)",-1,hl_o,21029638,Abstract,3,test,gold,6383.0
3799,In study,"group , the positive factor , negative factor and total scores of","PANSS in the 12 ( th ) weekend of treatment [ ( 12.0 ± 2.8 ) , ( 12.1 ± 3.6 ) , ( 50.2 ± 8.7 ) ] were all significantly lower than those in the 6 ( th ) weekend of treatment [ ( 14.2 ± 1.8 ) , ( 14.6 ± 2.4 ) , ( 56.5 ± 6.4 ) ] ( t = 2.58-4.26 , P < 0.05 ) .","['In', 'study', 'group', ',', 'the', 'positive', 'factor', ',', 'negative', 'factor', 'and', 'total', 'scores', 'of', 'PANSS', 'in', 'the', '12', '(', 'th', ')', 'weekend', 'of', 'treatment', '[', '(', '12.0', '±', '2.8', ')', ',', '(', '12.1', '±', '3.6', ')', ',', '(', '50.2', '±', '8.7', ')', ']', 'were', 'all', 'significantly', 'lower', 'than', 'those', 'in', 'the', '6', '(', 'th', ')', 'weekend', 'of', 'treatment', '[', '(', '14.2', '±', '1.8', ')', ',', '(', '14.6', '±', '2.4', ')', ',', '(', '56.5', '±', '6.4', ')', ']', '(', 't', '=', '2.58-4.26', ',', 'P', '<', '0.05', ')', '.']","(2, 14)","(8, 73)",-1,ss_o,21029638,Abstract,4,test,gold,6385.0
3800,In the 12 ( th ) weekend of,"treatment , the factors and total scores","of PANSS in study group [ ( 12.0 ± 2.8 ) , ( 12.1 ± 3.6 ) , ( 26.2 ± 5.0 ) , ( 50.2 ± 8.7 ) ] were all significantly lower than those in control group [ ( 16.9 ± 4.9 ) , ( 18.7 ± 5.3 ) , ( 32.5 ± 5.1 ) , ( 68.1 ± 13.0 ) ] ( t = -4.28 -- 5.67 , P < 0.05 ) .","['In', 'the', '12', '(', 'th', ')', 'weekend', 'of', 'treatment', ',', 'the', 'factors', 'and', 'total', 'scores', 'of', 'PANSS', 'in', 'study', 'group', '[', '(', '12.0', '±', '2.8', ')', ',', '(', '12.1', '±', '3.6', ')', ',', '(', '26.2', '±', '5.0', ')', ',', '(', '50.2', '±', '8.7', ')', ']', 'were', 'all', 'significantly', 'lower', 'than', 'those', 'in', 'control', 'group', '[', '(', '16.9', '±', '4.9', ')', ',', '(', '18.7', '±', '5.3', ')', ',', '(', '32.5', '±', '5.1', ')', ',', '(', '68.1', '±', '13.0', ')', ']', '(', 't', '=', '-4.28', '--', '5.67', ',', 'P', '<', '0.05', ')', '.']","(8, 15)","(27, 67)",-1,ss_o,21029638,Abstract,5,test,gold,6381.0
3801,In,"study group , the","total scores of SDSS in the 12 ( th ) weekend of treatment ( 5.93 ± 2.78 ) were significantly lower than those at baseline ( 13.9 ± 3.4 ) ( t = 10.83 , P < 0.05 ) .","['In', 'study', 'group', ',', 'the', 'total', 'scores', 'of', 'SDSS', 'in', 'the', '12', '(', 'th', ')', 'weekend', 'of', 'treatment', '(', '5.93', '±', '2.78', ')', 'were', 'significantly', 'lower', 'than', 'those', 'at', 'baseline', '(', '13.9', '±', '3.4', ')', '(', 't', '=', '10.83', ',', 'P', '<', '0.05', ')', '.']","(1, 5)","(2, 19)",-1,ss_o,21029638,Abstract,6,test,gold,2088.0
3802,,"In study group , the","total scores of SDSS in the 12 ( th ) weekend of treatment ( 5.9 ± 2.8 ) were significantly lower than those in the 6 ( th ) weekend of treatment ( 7.6 ± 2.9 ) ( t = 5.21 , P < 0.05 ) .","['In', 'study', 'group', ',', 'the', 'total', 'scores', 'of', 'SDSS', 'in', 'the', '12', '(', 'th', ')', 'weekend', 'of', 'treatment', '(', '5.9', '±', '2.8', ')', 'were', 'significantly', 'lower', 'than', 'those', 'in', 'the', '6', '(', 'th', ')', 'weekend', 'of', 'treatment', '(', '7.6', '±', '2.9', ')', '(', 't', '=', '5.21', ',', 'P', '<', '0.05', ')', '.']","(0, 5)","(0, 20)",-1,ss_o,21029638,Abstract,7,test,gold,2087.0
3803,"But there was no significant improvement in control group ( t = 1.88 , P > 0.05 ) .",,,"['But', 'there', 'was', 'no', 'significant', 'improvement', 'in', 'control', 'group', '(', 't', '=', '1.88', ',', 'P', '>', '0.05', ')', '.']",,,,,21029638,Abstract,8,test,gold,
3804,In the 12 ( th ),weekend of treatment,", the total scores of SDSS in study group ( 5.9 ± 2.8 ) were significantly lower than those in control group ( 8.8 ± 2.9 ) ( t = -4.49 , P < 0.05 ) .","['In', 'the', '12', '(', 'th', ')', 'weekend', 'of', 'treatment', ',', 'the', 'total', 'scores', 'of', 'SDSS', 'in', 'study', 'group', '(', '5.9', '±', '2.8', ')', 'were', 'significantly', 'lower', 'than', 'those', 'in', 'control', 'group', '(', '8.8', '±', '2.9', ')', '(', 't', '=', '-4.49', ',', 'P', '<', '0.05', ')', '.']","(6, 9)","(16, 36)",-1,ss_o,21029638,Abstract,9,test,gold,3990.0
3805,"In the 12 ( th ) weekend of treatment , the total scores of SDSS in study group ( 5.9 ± 2.8 ) were significantly lower than those in control group ( 8.8 ±","2.9 ) ( t = -4.49 , P < 0.05 )",.,"['In', 'the', '12', '(', 'th', ')', 'weekend', 'of', 'treatment', ',', 'the', 'total', 'scores', 'of', 'SDSS', 'in', 'study', 'group', '(', '5.9', '±', '2.8', ')', 'were', 'significantly', 'lower', 'than', 'those', 'in', 'control', 'group', '(', '8.8', '±', '2.9', ')', '(', 't', '=', '-4.49', ',', 'P', '<', '0.05', ')', '.']","(34, 45)","(154, 184)",-1,ss_o,21029638,Abstract,9,test,gold,819.0
3806,No severe adverse effect was reported,in either group,.,"['No', 'severe', 'adverse', 'effect', 'was', 'reported', 'in', 'either', 'group', '.']","(6, 9)","(37, 52)",-1,ss_i,21029638,Abstract,10,test,gold,1086.0
3807,CONCLUSION Paliperidone extended-release tablets are effective to improve social functions,and psychiatric,symptoms of schizophrenics .,"['CONCLUSION', 'Paliperidone', 'extended-release', 'tablets', 'are', 'effective', 'to', 'improve', 'social', 'functions', 'and', 'psychiatric', 'symptoms', 'of', 'schizophrenics', '.']","(10, 12)","(90, 105)",-1,ss_p,21029638,Abstract,11,test,gold,3830.0
3808,CONCLUSION Paliperidone,extended-release tablets are effective,to improve social functions and psychiatric symptoms of schizophrenics .,"['CONCLUSION', 'Paliperidone', 'extended-release', 'tablets', 'are', 'effective', 'to', 'improve', 'social', 'functions', 'and', 'psychiatric', 'symptoms', 'of', 'schizophrenics', '.']","(2, 6)","(23, 61)",-1,ss_o,21029638,Abstract,11,test,gold,836.0
3809,CONCLUSION Paliperidone extended-release tablets are effective to,improve social functions,and psychiatric symptoms of schizophrenics .,"['CONCLUSION', 'Paliperidone', 'extended-release', 'tablets', 'are', 'effective', 'to', 'improve', 'social', 'functions', 'and', 'psychiatric', 'symptoms', 'of', 'schizophrenics', '.']","(7, 10)","(65, 89)",-1,ss_o,21029638,Abstract,11,test,gold,2968.0
3810,Time-varying smoking abstinence predicts lower,depressive symptoms,following smoking cessation treatment .,"['Time-varying', 'smoking', 'abstinence', 'predicts', 'lower', 'depressive', 'symptoms', 'following', 'smoking', 'cessation', 'treatment', '.']","(5, 7)","(46, 65)",-1,ss_o,21106663,Title,0,test,gold,3253.0
3811,Time-varying smoking abstinence predicts lower,depressive symptoms,following smoking cessation treatment .,"['Time-varying', 'smoking', 'abstinence', 'predicts', 'lower', 'depressive', 'symptoms', 'following', 'smoking', 'cessation', 'treatment', '.']","(5, 7)","(46, 65)",-1,hl_o,21106663,Title,0,test,gold,3252.0
3812,INTRODUCTION The question of whether abstinence during the months following a planned quit attempt exacerbates or improves,depressive symptoms,is an important clinical issue .,"['INTRODUCTION', 'The', 'question', 'of', 'whether', 'abstinence', 'during', 'the', 'months', 'following', 'a', 'planned', 'quit', 'attempt', 'exacerbates', 'or', 'improves', 'depressive', 'symptoms', 'is', 'an', 'important', 'clinical', 'issue', '.']","(17, 19)","(122, 141)",-1,ss_o,21106663,Abstract,0,test,gold,3251.0
3813,INTRODUCTION The question of whether abstinence during the months following a planned quit attempt exacerbates or improves,depressive symptoms,is an important clinical issue .,"['INTRODUCTION', 'The', 'question', 'of', 'whether', 'abstinence', 'during', 'the', 'months', 'following', 'a', 'planned', 'quit', 'attempt', 'exacerbates', 'or', 'improves', 'depressive', 'symptoms', 'is', 'an', 'important', 'clinical', 'issue', '.']","(17, 19)","(122, 141)",-1,hl_o,21106663,Abstract,0,test,gold,3250.0
3814,Extant research has primarily modeled between-person covariation between postquit,abstinence and depressive symptom,trajectories .,"['Extant', 'research', 'has', 'primarily', 'modeled', 'between-person', 'covariation', 'between', 'postquit', 'abstinence', 'and', 'depressive', 'symptom', 'trajectories', '.']","(9, 13)","(81, 114)",-1,ss_o,21106663,Abstract,1,test,gold,3913.0
3815,"However , this approach can not account for potential third variables between participants that may affect both smoking and depression .",,,"['However', ',', 'this', 'approach', 'can', 'not', 'account', 'for', 'potential', 'third', 'variables', 'between', 'participants', 'that', 'may', 'affect', 'both', 'smoking', 'and', 'depression', '.']",,,,,21106663,Abstract,2,test,gold,
3816,"Accordingly , the current study examined within-person covariation between",time-varying abstinence and depressive symptom,"in a multilevel model ( MLM ) , which allowed for transitions between smoking statuses within a participant .","['Accordingly', ',', 'the', 'current', 'study', 'examined', 'within-person', 'covariation', 'between', 'time-varying', 'abstinence', 'and', 'depressive', 'symptom', 'in', 'a', 'multilevel', 'model', '(', 'MLM', ')', ',', 'which', 'allowed', 'for', 'transitions', 'between', 'smoking', 'statuses', 'within', 'a', 'participant', '.']","(9, 14)","(74, 120)",-1,ss_o,21106663,Abstract,3,test,gold,3914.0
3817,"Accordingly , the current study examined within-person covariation between time-varying abstinence and",depressive symptom,"in a multilevel model ( MLM ) , which allowed for transitions between smoking statuses within a participant .","['Accordingly', ',', 'the', 'current', 'study', 'examined', 'within-person', 'covariation', 'between', 'time-varying', 'abstinence', 'and', 'depressive', 'symptom', 'in', 'a', 'multilevel', 'model', '(', 'MLM', ')', ',', 'which', 'allowed', 'for', 'transitions', 'between', 'smoking', 'statuses', 'within', 'a', 'participant', '.']","(12, 14)","(102, 120)",-1,hl_o,21106663,Abstract,3,test,gold,3359.0
3818,METHODS,Participants were 236 heavy drinking smokers,in a randomized clinical trial testing the efficacy of incorporating brief alcohol intervention into smoking cessation treatment .,"['METHODS', 'Participants', 'were', '236', 'heavy', 'drinking', 'smokers', 'in', 'a', 'randomized', 'clinical', 'trial', 'testing', 'the', 'efficacy', 'of', 'incorporating', 'brief', 'alcohol', 'intervention', 'into', 'smoking', 'cessation', 'treatment', '.']","(1, 7)","(7, 51)",-1,ss_p,21106663,Abstract,4,test,gold,2427.0
3819,METHODS Participants were 236 heavy drinking smokers in a randomized clinical trial testing the efficacy of incorporating brief,alcohol intervention,into smoking cessation treatment .,"['METHODS', 'Participants', 'were', '236', 'heavy', 'drinking', 'smokers', 'in', 'a', 'randomized', 'clinical', 'trial', 'testing', 'the', 'efficacy', 'of', 'incorporating', 'brief', 'alcohol', 'intervention', 'into', 'smoking', 'cessation', 'treatment', '.']","(18, 20)","(127, 147)",-1,ss_i,21106663,Abstract,4,test,gold,4017.0
3820,METHODS Participants were 236 heavy drinking smokers in a randomized clinical trial testing the,efficacy,of incorporating brief alcohol intervention into smoking cessation treatment .,"['METHODS', 'Participants', 'were', '236', 'heavy', 'drinking', 'smokers', 'in', 'a', 'randomized', 'clinical', 'trial', 'testing', 'the', 'efficacy', 'of', 'incorporating', 'brief', 'alcohol', 'intervention', 'into', 'smoking', 'cessation', 'treatment', '.']","(14, 15)","(95, 103)",-1,ss_o,21106663,Abstract,4,test,gold,4807.0
3821,METHODS Participants were,236 heavy drinking smokers,in a randomized clinical trial testing the efficacy of incorporating brief alcohol intervention into smoking cessation treatment .,"['METHODS', 'Participants', 'were', '236', 'heavy', 'drinking', 'smokers', 'in', 'a', 'randomized', 'clinical', 'trial', 'testing', 'the', 'efficacy', 'of', 'incorporating', 'brief', 'alcohol', 'intervention', 'into', 'smoking', 'cessation', 'treatment', '.']","(3, 7)","(25, 51)",-1,hl_p,21106663,Abstract,4,test,gold,2428.0
3822,METHODS Participants were 236 heavy drinking smokers in a randomized clinical trial testing the efficacy of incorporating brief,alcohol intervention,into smoking cessation treatment .,"['METHODS', 'Participants', 'were', '236', 'heavy', 'drinking', 'smokers', 'in', 'a', 'randomized', 'clinical', 'trial', 'testing', 'the', 'efficacy', 'of', 'incorporating', 'brief', 'alcohol', 'intervention', 'into', 'smoking', 'cessation', 'treatment', '.']","(18, 20)","(127, 147)",-1,hl_i,21106663,Abstract,4,test,gold,4018.0
3823,,Depressive symptoms and biochemically verified abstinence,"were assessed 1 week prior to and 2 , 8 , 16 , and 26 weeks after quit date .","['Depressive', 'symptoms', 'and', 'biochemically', 'verified', 'abstinence', 'were', 'assessed', '1', 'week', 'prior', 'to', 'and', '2', ',', '8', ',', '16', ',', 'and', '26', 'weeks', 'after', 'quit', 'date', '.']","(0, 6)","(0, 57)",-1,ss_o,21106663,Abstract,5,test,gold,3915.0
3824,,Depressive symptoms,"and biochemically verified abstinence were assessed 1 week prior to and 2 , 8 , 16 , and 26 weeks after quit date .","['Depressive', 'symptoms', 'and', 'biochemically', 'verified', 'abstinence', 'were', 'assessed', '1', 'week', 'prior', 'to', 'and', '2', ',', '8', ',', '16', ',', 'and', '26', 'weeks', 'after', 'quit', 'date', '.']","(0, 2)","(0, 19)",-1,hl_o,21106663,Abstract,5,test,gold,3285.0
3825,Depressive symptoms and,biochemically verified abstinence,"were assessed 1 week prior to and 2 , 8 , 16 , and 26 weeks after quit date .","['Depressive', 'symptoms', 'and', 'biochemically', 'verified', 'abstinence', 'were', 'assessed', '1', 'week', 'prior', 'to', 'and', '2', ',', '8', ',', '16', ',', 'and', '26', 'weeks', 'after', 'quit', 'date', '.']","(3, 6)","(23, 56)",-1,hl_o,21106663,Abstract,5,test,gold,3916.0
3826,RESULTS MLMs indicated a slight increase in,depressive symptoms,over time in the sample as a whole .,"['RESULTS', 'MLMs', 'indicated', 'a', 'slight', 'increase', 'in', 'depressive', 'symptoms', 'over', 'time', 'in', 'the', 'sample', 'as', 'a', 'whole', '.']","(7, 9)","(43, 62)",-1,ss_o,21106663,Abstract,6,test,gold,3249.0
3827,RESULTS MLMs indicated a slight increase in,depressive symptoms,over time in the sample as a whole .,"['RESULTS', 'MLMs', 'indicated', 'a', 'slight', 'increase', 'in', 'depressive', 'symptoms', 'over', 'time', 'in', 'the', 'sample', 'as', 'a', 'whole', '.']","(7, 9)","(43, 62)",-1,hl_o,21106663,Abstract,6,test,gold,3248.0
3828,"However , there was an inverse relation between",time-varying abstinence ( vs. smoking ),"and concurrent level of depressive symptoms , indicating that transitions from smoking to abstinence within individuals were associated with reductions in depressive symptoms .","['However', ',', 'there', 'was', 'an', 'inverse', 'relation', 'between', 'time-varying', 'abstinence', '(', 'vs.', 'smoking', ')', 'and', 'concurrent', 'level', 'of', 'depressive', 'symptoms', ',', 'indicating', 'that', 'transitions', 'from', 'smoking', 'to', 'abstinence', 'within', 'individuals', 'were', 'associated', 'with', 'reductions', 'in', 'depressive', 'symptoms', '.']","(8, 14)","(47, 86)",-1,ss_o,21106663,Abstract,7,test,gold,3908.0
3829,"However , there was an inverse relation between time-varying abstinence ( vs. smoking ) and concurrent",level of depressive symptoms,", indicating that transitions from smoking to abstinence within individuals were associated with reductions in depressive symptoms .","['However', ',', 'there', 'was', 'an', 'inverse', 'relation', 'between', 'time-varying', 'abstinence', '(', 'vs.', 'smoking', ')', 'and', 'concurrent', 'level', 'of', 'depressive', 'symptoms', ',', 'indicating', 'that', 'transitions', 'from', 'smoking', 'to', 'abstinence', 'within', 'individuals', 'were', 'associated', 'with', 'reductions', 'in', 'depressive', 'symptoms', '.']","(16, 20)","(102, 130)",-1,ss_o,21106663,Abstract,7,test,gold,3256.0
3830,"However , there was an inverse relation between time-varying abstinence ( vs. smoking ) and concurrent level of depressive symptoms , indicating that transitions from smoking to abstinence within individuals were associated with reductions in",depressive symptoms .,,"['However', ',', 'there', 'was', 'an', 'inverse', 'relation', 'between', 'time-varying', 'abstinence', '(', 'vs.', 'smoking', ')', 'and', 'concurrent', 'level', 'of', 'depressive', 'symptoms', ',', 'indicating', 'that', 'transitions', 'from', 'smoking', 'to', 'abstinence', 'within', 'individuals', 'were', 'associated', 'with', 'reductions', 'in', 'depressive', 'symptoms', '.']","(35, 38)","(242, 263)",-1,ss_o,21106663,Abstract,7,test,gold,3247.0
3831,"However , there was an inverse relation between time-varying abstinence ( vs. smoking ) and concurrent",level of depressive symptoms,", indicating that transitions from smoking to abstinence within individuals were associated with reductions in depressive symptoms .","['However', ',', 'there', 'was', 'an', 'inverse', 'relation', 'between', 'time-varying', 'abstinence', '(', 'vs.', 'smoking', ')', 'and', 'concurrent', 'level', 'of', 'depressive', 'symptoms', ',', 'indicating', 'that', 'transitions', 'from', 'smoking', 'to', 'abstinence', 'within', 'individuals', 'were', 'associated', 'with', 'reductions', 'in', 'depressive', 'symptoms', '.']","(16, 20)","(102, 130)",-1,hl_o,21106663,Abstract,7,test,gold,3257.0
3832,"However , there was an inverse relation between time-varying abstinence ( vs. smoking ) and concurrent level of depressive symptoms , indicating that transitions from smoking to abstinence within individuals were associated with reductions in",depressive symptoms .,,"['However', ',', 'there', 'was', 'an', 'inverse', 'relation', 'between', 'time-varying', 'abstinence', '(', 'vs.', 'smoking', ')', 'and', 'concurrent', 'level', 'of', 'depressive', 'symptoms', ',', 'indicating', 'that', 'transitions', 'from', 'smoking', 'to', 'abstinence', 'within', 'individuals', 'were', 'associated', 'with', 'reductions', 'in', 'depressive', 'symptoms', '.']","(35, 38)","(242, 263)",-1,hl_o,21106663,Abstract,7,test,gold,3246.0
3833,"CONCLUSIONS During the first 6 months following a planned quit attempt , being abstinent in a particular week appears to be associated with lower levels of concurrent",depressive symptoms .,,"['CONCLUSIONS', 'During', 'the', 'first', '6', 'months', 'following', 'a', 'planned', 'quit', 'attempt', ',', 'being', 'abstinent', 'in', 'a', 'particular', 'week', 'appears', 'to', 'be', 'associated', 'with', 'lower', 'levels', 'of', 'concurrent', 'depressive', 'symptoms', '.']","(27, 30)","(166, 187)",-1,ss_o,21106663,Abstract,8,test,gold,3245.0
3834,"CONCLUSIONS During the first 6 months following a planned quit attempt , being abstinent in a particular week appears to be associated with lower levels of concurrent",depressive symptoms .,,"['CONCLUSIONS', 'During', 'the', 'first', '6', 'months', 'following', 'a', 'planned', 'quit', 'attempt', ',', 'being', 'abstinent', 'in', 'a', 'particular', 'week', 'appears', 'to', 'be', 'associated', 'with', 'lower', 'levels', 'of', 'concurrent', 'depressive', 'symptoms', '.']","(27, 30)","(166, 187)",-1,hl_o,21106663,Abstract,8,test,gold,3244.0
3835,These results are not concordant with the view that intentional smoking abstinence exacerbates,depressive symptoms .,,"['These', 'results', 'are', 'not', 'concordant', 'with', 'the', 'view', 'that', 'intentional', 'smoking', 'abstinence', 'exacerbates', 'depressive', 'symptoms', '.']","(13, 16)","(94, 115)",-1,ss_o,21106663,Abstract,9,test,gold,3243.0
3836,These results are not concordant with the view that intentional smoking abstinence exacerbates,depressive symptoms .,,"['These', 'results', 'are', 'not', 'concordant', 'with', 'the', 'view', 'that', 'intentional', 'smoking', 'abstinence', 'exacerbates', 'depressive', 'symptoms', '.']","(13, 16)","(94, 115)",-1,hl_o,21106663,Abstract,9,test,gold,3242.0
3837,Efforts to promote smoking cessation should highlight that individuals are likely to feel more rather than less psychologically healthy when they successfully quit smoking .,,,"['Efforts', 'to', 'promote', 'smoking', 'cessation', 'should', 'highlight', 'that', 'individuals', 'are', 'likely', 'to', 'feel', 'more', 'rather', 'than', 'less', 'psychologically', 'healthy', 'when', 'they', 'successfully', 'quit', 'smoking', '.']",,,,,21106663,Abstract,10,test,gold,
3838,Serum biochemical characteristics of,"Beluga , Huso huso ( L. )",", in response to blood sampling after clove powder solution exposure .","['Serum', 'biochemical', 'characteristics', 'of', 'Beluga', ',', 'Huso', 'huso', '(', 'L.', ')', ',', 'in', 'response', 'to', 'blood', 'sampling', 'after', 'clove', 'powder', 'solution', 'exposure', '.']","(4, 11)","(36, 61)",-1,ss_p,21170734,Title,0,test,gold,783.0
3839,,Serum biochemical characteristics,"of Beluga , Huso huso ( L. ) , in response to blood sampling after clove powder solution exposure .","['Serum', 'biochemical', 'characteristics', 'of', 'Beluga', ',', 'Huso', 'huso', '(', 'L.', ')', ',', 'in', 'response', 'to', 'blood', 'sampling', 'after', 'clove', 'powder', 'solution', 'exposure', '.']","(0, 3)","(0, 33)",-1,ss_o,21170734,Title,0,test,gold,4493.0
3840,Serum biochemical characteristics of,"Beluga , Huso huso ( L. )",", in response to blood sampling after clove powder solution exposure .","['Serum', 'biochemical', 'characteristics', 'of', 'Beluga', ',', 'Huso', 'huso', '(', 'L.', ')', ',', 'in', 'response', 'to', 'blood', 'sampling', 'after', 'clove', 'powder', 'solution', 'exposure', '.']","(4, 11)","(36, 61)",-1,hl_p,21170734,Title,0,test,gold,784.0
3841,"In order to investigate the effect of anesthesia on serum parameters ,","Beluga , Huso huso ( L. )","were blood-sampled immediately without anesthesia ( control ) or subjected to following anesthesia procedure : 40 , 120 , and 240 s exposure to 3,000 , 700 , and 500 mg l⁻¹ clove solution , respectively .","['In', 'order', 'to', 'investigate', 'the', 'effect', 'of', 'anesthesia', 'on', 'serum', 'parameters', ',', 'Beluga', ',', 'Huso', 'huso', '(', 'L.', ')', 'were', 'blood-sampled', 'immediately', 'without', 'anesthesia', '(', 'control', ')', 'or', 'subjected', 'to', 'following', 'anesthesia', 'procedure', ':', '40', ',', '120', ',', 'and', '240', 's', 'exposure', 'to', '3,000', ',', '700', ',', 'and', '500', 'mg', 'l⁻¹', 'clove', 'solution', ',', 'respectively', '.']","(12, 19)","(70, 95)",-1,ss_p,21170734,Abstract,0,test,gold,782.0
3842,In order to investigate the effect of,anesthesia,"on serum parameters , Beluga , Huso huso ( L. ) were blood-sampled immediately without anesthesia ( control ) or subjected to following anesthesia procedure : 40 , 120 , and 240 s exposure to 3,000 , 700 , and 500 mg l⁻¹ clove solution , respectively .","['In', 'order', 'to', 'investigate', 'the', 'effect', 'of', 'anesthesia', 'on', 'serum', 'parameters', ',', 'Beluga', ',', 'Huso', 'huso', '(', 'L.', ')', 'were', 'blood-sampled', 'immediately', 'without', 'anesthesia', '(', 'control', ')', 'or', 'subjected', 'to', 'following', 'anesthesia', 'procedure', ':', '40', ',', '120', ',', 'and', '240', 's', 'exposure', 'to', '3,000', ',', '700', ',', 'and', '500', 'mg', 'l⁻¹', 'clove', 'solution', ',', 'respectively', '.']","(7, 8)","(37, 47)",-1,ss_i,21170734,Abstract,0,test,gold,4117.0
3843,"In order to investigate the effect of anesthesia on serum parameters , Beluga , Huso huso ( L. ) were blood-sampled immediately without",anesthesia,"( control ) or subjected to following anesthesia procedure : 40 , 120 , and 240 s exposure to 3,000 , 700 , and 500 mg l⁻¹ clove solution , respectively .","['In', 'order', 'to', 'investigate', 'the', 'effect', 'of', 'anesthesia', 'on', 'serum', 'parameters', ',', 'Beluga', ',', 'Huso', 'huso', '(', 'L.', ')', 'were', 'blood-sampled', 'immediately', 'without', 'anesthesia', '(', 'control', ')', 'or', 'subjected', 'to', 'following', 'anesthesia', 'procedure', ':', '40', ',', '120', ',', 'and', '240', 's', 'exposure', 'to', '3,000', ',', '700', ',', 'and', '500', 'mg', 'l⁻¹', 'clove', 'solution', ',', 'respectively', '.']","(23, 24)","(135, 145)",-1,ss_i,21170734,Abstract,0,test,gold,4118.0
3844,"In order to investigate the effect of anesthesia on serum parameters , Beluga , Huso huso ( L. ) were blood-sampled immediately without anesthesia ( control ) or subjected to following",anesthesia,"procedure : 40 , 120 , and 240 s exposure to 3,000 , 700 , and 500 mg l⁻¹ clove solution , respectively .","['In', 'order', 'to', 'investigate', 'the', 'effect', 'of', 'anesthesia', 'on', 'serum', 'parameters', ',', 'Beluga', ',', 'Huso', 'huso', '(', 'L.', ')', 'were', 'blood-sampled', 'immediately', 'without', 'anesthesia', '(', 'control', ')', 'or', 'subjected', 'to', 'following', 'anesthesia', 'procedure', ':', '40', ',', '120', ',', 'and', '240', 's', 'exposure', 'to', '3,000', ',', '700', ',', 'and', '500', 'mg', 'l⁻¹', 'clove', 'solution', ',', 'respectively', '.']","(31, 32)","(184, 194)",-1,ss_i,21170734,Abstract,0,test,gold,4116.0
3845,"In order to investigate the effect of anesthesia on serum parameters , Beluga , Huso huso ( L. ) were blood-sampled immediately without anesthesia ( control ) or subjected to following anesthesia procedure : 40 , 120 , and 240 s exposure to 3,000 , 700 , and 500 mg",l⁻¹ clove solution,", respectively .","['In', 'order', 'to', 'investigate', 'the', 'effect', 'of', 'anesthesia', 'on', 'serum', 'parameters', ',', 'Beluga', ',', 'Huso', 'huso', '(', 'L.', ')', 'were', 'blood-sampled', 'immediately', 'without', 'anesthesia', '(', 'control', ')', 'or', 'subjected', 'to', 'following', 'anesthesia', 'procedure', ':', '40', ',', '120', ',', 'and', '240', 's', 'exposure', 'to', '3,000', ',', '700', ',', 'and', '500', 'mg', 'l⁻¹', 'clove', 'solution', ',', 'respectively', '.']","(50, 53)","(265, 283)",-1,ss_i,21170734,Abstract,0,test,gold,301.0
3846,In order to investigate the effect of anesthesia on,serum parameters,", Beluga , Huso huso ( L. ) were blood-sampled immediately without anesthesia ( control ) or subjected to following anesthesia procedure : 40 , 120 , and 240 s exposure to 3,000 , 700 , and 500 mg l⁻¹ clove solution , respectively .","['In', 'order', 'to', 'investigate', 'the', 'effect', 'of', 'anesthesia', 'on', 'serum', 'parameters', ',', 'Beluga', ',', 'Huso', 'huso', '(', 'L.', ')', 'were', 'blood-sampled', 'immediately', 'without', 'anesthesia', '(', 'control', ')', 'or', 'subjected', 'to', 'following', 'anesthesia', 'procedure', ':', '40', ',', '120', ',', 'and', '240', 's', 'exposure', 'to', '3,000', ',', '700', ',', 'and', '500', 'mg', 'l⁻¹', 'clove', 'solution', ',', 'respectively', '.']","(9, 11)","(51, 67)",-1,ss_o,21170734,Abstract,0,test,gold,4486.0
3847,"In order to investigate the effect of anesthesia on serum parameters , Beluga , Huso huso ( L. ) were blood-sampled immediately without anesthesia ( control ) or subjected to following anesthesia procedure : 40 , 120 , and 240 s exposure to 3,000 , 700 , and 500 mg l⁻¹ clove solution ,",respectively .,,"['In', 'order', 'to', 'investigate', 'the', 'effect', 'of', 'anesthesia', 'on', 'serum', 'parameters', ',', 'Beluga', ',', 'Huso', 'huso', '(', 'L.', ')', 'were', 'blood-sampled', 'immediately', 'without', 'anesthesia', '(', 'control', ')', 'or', 'subjected', 'to', 'following', 'anesthesia', 'procedure', ':', '40', ',', '120', ',', 'and', '240', 's', 'exposure', 'to', '3,000', ',', '700', ',', 'and', '500', 'mg', 'l⁻¹', 'clove', 'solution', ',', 'respectively', '.']","(54, 56)","(286, 300)",-1,ss_o,21170734,Abstract,0,test,gold,1172.0
3848,"In order to investigate the effect of anesthesia on serum parameters ,","Beluga , Huso huso ( L. )","were blood-sampled immediately without anesthesia ( control ) or subjected to following anesthesia procedure : 40 , 120 , and 240 s exposure to 3,000 , 700 , and 500 mg l⁻¹ clove solution , respectively .","['In', 'order', 'to', 'investigate', 'the', 'effect', 'of', 'anesthesia', 'on', 'serum', 'parameters', ',', 'Beluga', ',', 'Huso', 'huso', '(', 'L.', ')', 'were', 'blood-sampled', 'immediately', 'without', 'anesthesia', '(', 'control', ')', 'or', 'subjected', 'to', 'following', 'anesthesia', 'procedure', ':', '40', ',', '120', ',', 'and', '240', 's', 'exposure', 'to', '3,000', ',', '700', ',', 'and', '500', 'mg', 'l⁻¹', 'clove', 'solution', ',', 'respectively', '.']","(12, 19)","(70, 95)",-1,hl_p,21170734,Abstract,0,test,gold,781.0
3849,"In order to investigate the effect of anesthesia on serum parameters , Beluga , Huso huso ( L. ) were blood-sampled immediately without",anesthesia,"( control ) or subjected to following anesthesia procedure : 40 , 120 , and 240 s exposure to 3,000 , 700 , and 500 mg l⁻¹ clove solution , respectively .","['In', 'order', 'to', 'investigate', 'the', 'effect', 'of', 'anesthesia', 'on', 'serum', 'parameters', ',', 'Beluga', ',', 'Huso', 'huso', '(', 'L.', ')', 'were', 'blood-sampled', 'immediately', 'without', 'anesthesia', '(', 'control', ')', 'or', 'subjected', 'to', 'following', 'anesthesia', 'procedure', ':', '40', ',', '120', ',', 'and', '240', 's', 'exposure', 'to', '3,000', ',', '700', ',', 'and', '500', 'mg', 'l⁻¹', 'clove', 'solution', ',', 'respectively', '.']","(23, 24)","(135, 145)",-1,hl_i,21170734,Abstract,0,test,gold,4115.0
3850,"In order to investigate the effect of anesthesia on serum parameters , Beluga , Huso huso ( L. ) were blood-sampled immediately without anesthesia ( control ) or subjected to following",anesthesia,"procedure : 40 , 120 , and 240 s exposure to 3,000 , 700 , and 500 mg l⁻¹ clove solution , respectively .","['In', 'order', 'to', 'investigate', 'the', 'effect', 'of', 'anesthesia', 'on', 'serum', 'parameters', ',', 'Beluga', ',', 'Huso', 'huso', '(', 'L.', ')', 'were', 'blood-sampled', 'immediately', 'without', 'anesthesia', '(', 'control', ')', 'or', 'subjected', 'to', 'following', 'anesthesia', 'procedure', ':', '40', ',', '120', ',', 'and', '240', 's', 'exposure', 'to', '3,000', ',', '700', ',', 'and', '500', 'mg', 'l⁻¹', 'clove', 'solution', ',', 'respectively', '.']","(31, 32)","(184, 194)",-1,hl_i,21170734,Abstract,0,test,gold,4114.0
3851,,Blood samples,"were collected after these periods , when fish were immobile and reached stage 4 anesthesia .","['Blood', 'samples', 'were', 'collected', 'after', 'these', 'periods', ',', 'when', 'fish', 'were', 'immobile', 'and', 'reached', 'stage', '4', 'anesthesia', '.']","(0, 2)","(0, 13)",-1,ss_o,21170734,Abstract,1,test,gold,4523.0
3852,Results showed,that cortisol and glucose levels,"were significantly high in 700 and 500 but not 3,000 mg l⁻¹ group compared to control .","['Results', 'showed', 'that', 'cortisol', 'and', 'glucose', 'levels', 'were', 'significantly', 'high', 'in', '700', 'and', '500', 'but', 'not', '3,000', 'mg', 'l⁻¹', 'group', 'compared', 'to', 'control', '.']","(2, 7)","(14, 46)",-1,ss_o,21170734,Abstract,2,test,gold,6569.0
3853,"Results showed that cortisol and glucose levels were significantly high in 700 and 500 but not 3,000 mg l⁻¹ group compared to",control .,,"['Results', 'showed', 'that', 'cortisol', 'and', 'glucose', 'levels', 'were', 'significantly', 'high', 'in', '700', 'and', '500', 'but', 'not', '3,000', 'mg', 'l⁻¹', 'group', 'compared', 'to', 'control', '.']","(22, 24)","(125, 134)",-1,ss_o,21170734,Abstract,2,test,gold,902.0
3854,,Serum lactate levels,were significantly high in 500 mg l⁻¹ group compared to control group .,"['Serum', 'lactate', 'levels', 'were', 'significantly', 'high', 'in', '500', 'mg', 'l⁻¹', 'group', 'compared', 'to', 'control', 'group', '.']","(0, 3)","(0, 20)",-1,ss_o,21170734,Abstract,3,test,gold,4491.0
3855,Serum lactate levels were significantly high in 500 mg l⁻¹ group compared to,control group .,,"['Serum', 'lactate', 'levels', 'were', 'significantly', 'high', 'in', '500', 'mg', 'l⁻¹', 'group', 'compared', 'to', 'control', 'group', '.']","(13, 16)","(76, 91)",-1,ss_o,21170734,Abstract,3,test,gold,891.0
3856,,Lactate,"levels were not significantly differed between control , 3,000 , and 700 mg l⁻¹ groups .","['Lactate', 'levels', 'were', 'not', 'significantly', 'differed', 'between', 'control', ',', '3,000', ',', 'and', '700', 'mg', 'l⁻¹', 'groups', '.']","(0, 1)","(0, 7)",-1,ss_o,21170734,Abstract,4,test,gold,134.0
3857,There were no significant,"differences in serum levels of cholesterol , total protein , lactate dehydrogenase , aspartate aminotransferase , alanine aminotransferase , Na⁺ , Cl⁻",", K⁺ , and Ca²⁺ .","['There', 'were', 'no', 'significant', 'differences', 'in', 'serum', 'levels', 'of', 'cholesterol', ',', 'total', 'protein', ',', 'lactate', 'dehydrogenase', ',', 'aspartate', 'aminotransferase', ',', 'alanine', 'aminotransferase', ',', 'Na⁺', ',', 'Cl⁻', ',', 'K⁺', ',', 'and', 'Ca²⁺', '.']","(4, 26)","(25, 175)",-1,ss_o,21170734,Abstract,5,test,gold,5819.0
3858,Results suggest that rapid anesthesia with higher dose is better than slow anesthesia with lower dose,for blood,sampling in Beluga .,"['Results', 'suggest', 'that', 'rapid', 'anesthesia', 'with', 'higher', 'dose', 'is', 'better', 'than', 'slow', 'anesthesia', 'with', 'lower', 'dose', 'for', 'blood', 'sampling', 'in', 'Beluga', '.']","(16, 18)","(101, 110)",-1,ss_p,21170734,Abstract,6,test,gold,2662.0
3859,,Results suggest that,rapid anesthesia with higher dose is better than slow anesthesia with lower dose for blood sampling in Beluga .,"['Results', 'suggest', 'that', 'rapid', 'anesthesia', 'with', 'higher', 'dose', 'is', 'better', 'than', 'slow', 'anesthesia', 'with', 'lower', 'dose', 'for', 'blood', 'sampling', 'in', 'Beluga', '.']","(0, 3)","(0, 20)",-1,ss_i,21170734,Abstract,6,test,gold,1858.0
3860,Results suggest that rapid anesthesia with higher,dose is better,than slow anesthesia with lower dose for blood sampling in Beluga .,"['Results', 'suggest', 'that', 'rapid', 'anesthesia', 'with', 'higher', 'dose', 'is', 'better', 'than', 'slow', 'anesthesia', 'with', 'lower', 'dose', 'for', 'blood', 'sampling', 'in', 'Beluga', '.']","(7, 10)","(49, 63)",-1,ss_i,21170734,Abstract,6,test,gold,5051.0
3861,Results suggest that rapid anesthesia with higher dose is better than slow,anesthesia with lower dose,for blood sampling in Beluga .,"['Results', 'suggest', 'that', 'rapid', 'anesthesia', 'with', 'higher', 'dose', 'is', 'better', 'than', 'slow', 'anesthesia', 'with', 'lower', 'dose', 'for', 'blood', 'sampling', 'in', 'Beluga', '.']","(12, 16)","(74, 100)",-1,ss_o,21170734,Abstract,6,test,gold,4110.0
3862,Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in,diabetic patients :,insights from the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['Lowering', 'the', 'triglyceride/high-density', 'lipoprotein', 'cholesterol', 'ratio', 'is', 'associated', 'with', 'the', 'beneficial', 'impact', 'of', 'pioglitazone', 'on', 'progression', 'of', 'coronary', 'atherosclerosis', 'in', 'diabetic', 'patients', ':', 'insights', 'from', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(20, 23)","(171, 190)",-1,ss_p,21211686,Title,0,test,gold,3795.0
3863,Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of,pioglitazone,on progression of coronary atherosclerosis in diabetic patients : insights from the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['Lowering', 'the', 'triglyceride/high-density', 'lipoprotein', 'cholesterol', 'ratio', 'is', 'associated', 'with', 'the', 'beneficial', 'impact', 'of', 'pioglitazone', 'on', 'progression', 'of', 'coronary', 'atherosclerosis', 'in', 'diabetic', 'patients', ':', 'insights', 'from', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(13, 14)","(112, 124)",-1,ss_i,21211686,Title,0,test,gold,5390.0
3864,Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients : insights from the PERISCOPE,( Pioglitazone,Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['Lowering', 'the', 'triglyceride/high-density', 'lipoprotein', 'cholesterol', 'ratio', 'is', 'associated', 'with', 'the', 'beneficial', 'impact', 'of', 'pioglitazone', 'on', 'progression', 'of', 'coronary', 'atherosclerosis', 'in', 'diabetic', 'patients', ':', 'insights', 'from', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(27, 29)","(219, 233)",-1,ss_i,21211686,Title,0,test,gold,5574.0
3865,Lowering the,triglyceride/high-density lipoprotein cholesterol ratio,is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients : insights from the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['Lowering', 'the', 'triglyceride/high-density', 'lipoprotein', 'cholesterol', 'ratio', 'is', 'associated', 'with', 'the', 'beneficial', 'impact', 'of', 'pioglitazone', 'on', 'progression', 'of', 'coronary', 'atherosclerosis', 'in', 'diabetic', 'patients', ':', 'insights', 'from', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(2, 6)","(12, 67)",-1,ss_o,21211686,Title,0,test,gold,6547.0
3866,Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on,progression of coronary atherosclerosis,in diabetic patients : insights from the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['Lowering', 'the', 'triglyceride/high-density', 'lipoprotein', 'cholesterol', 'ratio', 'is', 'associated', 'with', 'the', 'beneficial', 'impact', 'of', 'pioglitazone', 'on', 'progression', 'of', 'coronary', 'atherosclerosis', 'in', 'diabetic', 'patients', ':', 'insights', 'from', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(15, 19)","(128, 167)",-1,ss_o,21211686,Title,0,test,gold,6742.0
3867,Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in,diabetic patients,: insights from the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['Lowering', 'the', 'triglyceride/high-density', 'lipoprotein', 'cholesterol', 'ratio', 'is', 'associated', 'with', 'the', 'beneficial', 'impact', 'of', 'pioglitazone', 'on', 'progression', 'of', 'coronary', 'atherosclerosis', 'in', 'diabetic', 'patients', ':', 'insights', 'from', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(20, 22)","(171, 188)",-1,hl_p,21211686,Title,0,test,gold,3796.0
3868,Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of,pioglitazone,on progression of coronary atherosclerosis in diabetic patients : insights from the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['Lowering', 'the', 'triglyceride/high-density', 'lipoprotein', 'cholesterol', 'ratio', 'is', 'associated', 'with', 'the', 'beneficial', 'impact', 'of', 'pioglitazone', 'on', 'progression', 'of', 'coronary', 'atherosclerosis', 'in', 'diabetic', 'patients', ':', 'insights', 'from', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(13, 14)","(112, 124)",-1,hl_i,21211686,Title,0,test,gold,5391.0
3869,Lowering the,triglyceride/high-density lipoprotein cholesterol ratio,is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients : insights from the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['Lowering', 'the', 'triglyceride/high-density', 'lipoprotein', 'cholesterol', 'ratio', 'is', 'associated', 'with', 'the', 'beneficial', 'impact', 'of', 'pioglitazone', 'on', 'progression', 'of', 'coronary', 'atherosclerosis', 'in', 'diabetic', 'patients', ':', 'insights', 'from', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(2, 6)","(12, 67)",-1,hl_o,21211686,Title,0,test,gold,6548.0
3870,Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of,coronary atherosclerosis,in diabetic patients : insights from the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['Lowering', 'the', 'triglyceride/high-density', 'lipoprotein', 'cholesterol', 'ratio', 'is', 'associated', 'with', 'the', 'beneficial', 'impact', 'of', 'pioglitazone', 'on', 'progression', 'of', 'coronary', 'atherosclerosis', 'in', 'diabetic', 'patients', ':', 'insights', 'from', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(17, 19)","(143, 167)",-1,hl_o,21211686,Title,0,test,gold,6745.0
3871,OBJECTIVES The purpose of this study was to determine the factors associated with the favorable effect of,pioglitazone,on atheroma progression .,"['OBJECTIVES', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'determine', 'the', 'factors', 'associated', 'with', 'the', 'favorable', 'effect', 'of', 'pioglitazone', 'on', 'atheroma', 'progression', '.']","(17, 18)","(105, 117)",-1,ss_i,21211686,Abstract,0,test,gold,5389.0
3872,OBJECTIVES The purpose of this study was to determine the factors associated with the favorable,effect,of pioglitazone on atheroma progression .,"['OBJECTIVES', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'determine', 'the', 'factors', 'associated', 'with', 'the', 'favorable', 'effect', 'of', 'pioglitazone', 'on', 'atheroma', 'progression', '.']","(15, 16)","(95, 101)",-1,ss_o,21211686,Abstract,0,test,gold,2337.0
3873,OBJECTIVES The purpose of this study was to determine the factors associated with the favorable effect of pioglitazone on,atheroma progression .,,"['OBJECTIVES', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'determine', 'the', 'factors', 'associated', 'with', 'the', 'favorable', 'effect', 'of', 'pioglitazone', 'on', 'atheroma', 'progression', '.']","(19, 22)","(121, 143)",-1,ss_o,21211686,Abstract,0,test,gold,3296.0
3874,OBJECTIVES The purpose of this study was to determine the factors associated with the favorable effect of,pioglitazone,on atheroma progression .,"['OBJECTIVES', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'determine', 'the', 'factors', 'associated', 'with', 'the', 'favorable', 'effect', 'of', 'pioglitazone', 'on', 'atheroma', 'progression', '.']","(17, 18)","(105, 117)",-1,hl_i,21211686,Abstract,0,test,gold,5388.0
3875,BACKGROUND Diabetes mellitus is associated with accelerated,coronary atheroma progression .,,"['BACKGROUND', 'Diabetes', 'mellitus', 'is', 'associated', 'with', 'accelerated', 'coronary', 'atheroma', 'progression', '.']","(7, 11)","(59, 90)",-1,ss_o,21211686,Abstract,1,test,gold,3298.0
3876,,Pioglitazone,slowed progression compared with glimepiride in this population .,"['Pioglitazone', 'slowed', 'progression', 'compared', 'with', 'glimepiride', 'in', 'this', 'population', '.']","(0, 1)","(0, 12)",-1,ss_i,21211686,Abstract,2,test,gold,5575.0
3877,Pioglitazone slowed progression compared with,glimepiride,in this population .,"['Pioglitazone', 'slowed', 'progression', 'compared', 'with', 'glimepiride', 'in', 'this', 'population', '.']","(5, 6)","(45, 56)",-1,ss_i,21211686,Abstract,2,test,gold,5401.0
3878,Pioglitazone slowed,progression,compared with glimepiride in this population .,"['Pioglitazone', 'slowed', 'progression', 'compared', 'with', 'glimepiride', 'in', 'this', 'population', '.']","(2, 3)","(19, 30)",-1,ss_o,21211686,Abstract,2,test,gold,3327.0
3879,,Pioglitazone,slowed progression compared with glimepiride in this population .,"['Pioglitazone', 'slowed', 'progression', 'compared', 'with', 'glimepiride', 'in', 'this', 'population', '.']","(0, 1)","(0, 12)",-1,hl_i,21211686,Abstract,2,test,gold,5573.0
3880,"METHODS In all ,",360 diabetic patients with coronary artery disease,were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['METHODS', 'In', 'all', ',', '360', 'diabetic', 'patients', 'with', 'coronary', 'artery', 'disease', 'were', 'treated', 'with', 'pioglitazone', 'or', 'glimepiride', 'for', '18', 'months', 'in', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(4, 11)","(16, 66)",-1,ss_p,21211686,Abstract,3,test,gold,6739.0
3881,"METHODS In all , 360 diabetic patients with coronary artery disease were treated with",pioglitazone,or glimepiride for 18 months in the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['METHODS', 'In', 'all', ',', '360', 'diabetic', 'patients', 'with', 'coronary', 'artery', 'disease', 'were', 'treated', 'with', 'pioglitazone', 'or', 'glimepiride', 'for', '18', 'months', 'in', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(14, 15)","(85, 97)",-1,ss_i,21211686,Abstract,3,test,gold,5387.0
3882,"METHODS In all , 360 diabetic patients with coronary artery disease were treated with pioglitazone or",glimepiride,for 18 months in the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['METHODS', 'In', 'all', ',', '360', 'diabetic', 'patients', 'with', 'coronary', 'artery', 'disease', 'were', 'treated', 'with', 'pioglitazone', 'or', 'glimepiride', 'for', '18', 'months', 'in', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(16, 17)","(101, 112)",-1,ss_i,21211686,Abstract,3,test,gold,5402.0
3883,"METHODS In all , 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE",( Pioglitazone,Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['METHODS', 'In', 'all', ',', '360', 'diabetic', 'patients', 'with', 'coronary', 'artery', 'disease', 'were', 'treated', 'with', 'pioglitazone', 'or', 'glimepiride', 'for', '18', 'months', 'in', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(23, 25)","(144, 158)",-1,ss_i,21211686,Abstract,3,test,gold,5572.0
3884,"METHODS In all ,",360 diabetic patients with coronary artery disease,were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['METHODS', 'In', 'all', ',', '360', 'diabetic', 'patients', 'with', 'coronary', 'artery', 'disease', 'were', 'treated', 'with', 'pioglitazone', 'or', 'glimepiride', 'for', '18', 'months', 'in', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(4, 11)","(16, 66)",-1,hl_p,21211686,Abstract,3,test,gold,6740.0
3885,"METHODS In all , 360 diabetic patients with coronary artery disease were treated with",pioglitazone,or glimepiride for 18 months in the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['METHODS', 'In', 'all', ',', '360', 'diabetic', 'patients', 'with', 'coronary', 'artery', 'disease', 'were', 'treated', 'with', 'pioglitazone', 'or', 'glimepiride', 'for', '18', 'months', 'in', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(14, 15)","(85, 97)",-1,hl_i,21211686,Abstract,3,test,gold,5386.0
3886,"METHODS In all , 360 diabetic patients with coronary artery disease were treated with pioglitazone or",glimepiride,for 18 months in the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study .,"['METHODS', 'In', 'all', ',', '360', 'diabetic', 'patients', 'with', 'coronary', 'artery', 'disease', 'were', 'treated', 'with', 'pioglitazone', 'or', 'glimepiride', 'for', '18', 'months', 'in', 'the', 'PERISCOPE', '(', 'Pioglitazone', 'Effect', 'on', 'Regression', 'of', 'Intravascular', 'Sonographic', 'Coronary', 'Obstruction', 'Prospective', 'Evaluation', ')', 'study', '.']","(16, 17)","(101, 112)",-1,hl_i,21211686,Abstract,3,test,gold,5400.0
3887,,Coronary atheroma progression was evaluated by serial intravascular ultrasound .,,"['Coronary', 'atheroma', 'progression', 'was', 'evaluated', 'by', 'serial', 'intravascular', 'ultrasound', '.']","(0, 10)","(0, 80)",-1,ss_o,21211686,Abstract,4,test,gold,5964.0
3888,,Coronary atheroma progression,was evaluated by serial intravascular ultrasound .,"['Coronary', 'atheroma', 'progression', 'was', 'evaluated', 'by', 'serial', 'intravascular', 'ultrasound', '.']","(0, 3)","(0, 29)",-1,hl_o,21211686,Abstract,4,test,gold,3299.0
3889,The relationship between,"changes in biochemical parameters , percent atheroma volume , and total atheroma volume",was investigated .,"['The', 'relationship', 'between', 'changes', 'in', 'biochemical', 'parameters', ',', 'percent', 'atheroma', 'volume', ',', 'and', 'total', 'atheroma', 'volume', 'was', 'investigated', '.']","(3, 16)","(24, 111)",-1,ss_o,21211686,Abstract,5,test,gold,6465.0
3890,The relationship between,changes in biochemical parameters,", percent atheroma volume , and total atheroma volume was investigated .","['The', 'relationship', 'between', 'changes', 'in', 'biochemical', 'parameters', ',', 'percent', 'atheroma', 'volume', ',', 'and', 'total', 'atheroma', 'volume', 'was', 'investigated', '.']","(3, 7)","(24, 57)",-1,hl_o,21211686,Abstract,5,test,gold,1828.0
3891,"The relationship between changes in biochemical parameters ,",percent atheroma volume,", and total atheroma volume was investigated .","['The', 'relationship', 'between', 'changes', 'in', 'biochemical', 'parameters', ',', 'percent', 'atheroma', 'volume', ',', 'and', 'total', 'atheroma', 'volume', 'was', 'investigated', '.']","(8, 11)","(60, 83)",-1,hl_o,21211686,Abstract,5,test,gold,1721.0
3892,"The relationship between changes in biochemical parameters , percent atheroma volume , and",total atheroma volume,was investigated .,"['The', 'relationship', 'between', 'changes', 'in', 'biochemical', 'parameters', ',', 'percent', 'atheroma', 'volume', ',', 'and', 'total', 'atheroma', 'volume', 'was', 'investigated', '.']","(13, 16)","(90, 111)",-1,hl_o,21211686,Abstract,5,test,gold,1717.0
3893,RESULTS,Pioglitazone-treated,"patients demonstrated greater increases in high-density lipoprotein cholesterol ( HDL-C ) and reductions in glycated hemoglobin , triglycerides , and C-reactive protein .","['RESULTS', 'Pioglitazone-treated', 'patients', 'demonstrated', 'greater', 'increases', 'in', 'high-density', 'lipoprotein', 'cholesterol', '(', 'HDL-C', ')', 'and', 'reductions', 'in', 'glycated', 'hemoglobin', ',', 'triglycerides', ',', 'and', 'C-reactive', 'protein', '.']","(1, 2)","(7, 27)",-1,ss_i,21211686,Abstract,6,test,gold,
3894,RESULTS Pioglitazone-treated patients demonstrated greater increases in,high-density lipoprotein cholesterol ( HDL-C ),"and reductions in glycated hemoglobin , triglycerides , and C-reactive protein .","['RESULTS', 'Pioglitazone-treated', 'patients', 'demonstrated', 'greater', 'increases', 'in', 'high-density', 'lipoprotein', 'cholesterol', '(', 'HDL-C', ')', 'and', 'reductions', 'in', 'glycated', 'hemoglobin', ',', 'triglycerides', ',', 'and', 'C-reactive', 'protein', '.']","(7, 13)","(71, 117)",-1,ss_o,21211686,Abstract,6,test,gold,6552.0
3895,RESULTS Pioglitazone-treated patients demonstrated greater increases in high-density lipoprotein cholesterol ( HDL-C ) and reductions in,"glycated hemoglobin , triglycerides , and C-reactive protein .",,"['RESULTS', 'Pioglitazone-treated', 'patients', 'demonstrated', 'greater', 'increases', 'in', 'high-density', 'lipoprotein', 'cholesterol', '(', 'HDL-C', ')', 'and', 'reductions', 'in', 'glycated', 'hemoglobin', ',', 'triglycerides', ',', 'and', 'C-reactive', 'protein', '.']","(16, 25)","(136, 198)",-1,ss_o,21211686,Abstract,6,test,gold,6560.0
3896,RESULTS,Pioglitazone-treated,"patients demonstrated greater increases in high-density lipoprotein cholesterol ( HDL-C ) and reductions in glycated hemoglobin , triglycerides , and C-reactive protein .","['RESULTS', 'Pioglitazone-treated', 'patients', 'demonstrated', 'greater', 'increases', 'in', 'high-density', 'lipoprotein', 'cholesterol', '(', 'HDL-C', ')', 'and', 'reductions', 'in', 'glycated', 'hemoglobin', ',', 'triglycerides', ',', 'and', 'C-reactive', 'protein', '.']","(1, 2)","(7, 27)",-1,hl_i,21211686,Abstract,6,test,gold,
3897,RESULTS Pioglitazone-treated patients demonstrated greater increases in,high-density lipoprotein cholesterol ( HDL-C ),"and reductions in glycated hemoglobin , triglycerides , and C-reactive protein .","['RESULTS', 'Pioglitazone-treated', 'patients', 'demonstrated', 'greater', 'increases', 'in', 'high-density', 'lipoprotein', 'cholesterol', '(', 'HDL-C', ')', 'and', 'reductions', 'in', 'glycated', 'hemoglobin', ',', 'triglycerides', ',', 'and', 'C-reactive', 'protein', '.']","(7, 13)","(71, 117)",-1,hl_o,21211686,Abstract,6,test,gold,6551.0
3898,RESULTS Pioglitazone-treated patients demonstrated greater increases in high-density lipoprotein cholesterol ( HDL-C ) and reductions in,glycated hemoglobin,", triglycerides , and C-reactive protein .","['RESULTS', 'Pioglitazone-treated', 'patients', 'demonstrated', 'greater', 'increases', 'in', 'high-density', 'lipoprotein', 'cholesterol', '(', 'HDL-C', ')', 'and', 'reductions', 'in', 'glycated', 'hemoglobin', ',', 'triglycerides', ',', 'and', 'C-reactive', 'protein', '.']","(16, 18)","(136, 155)",-1,hl_o,21211686,Abstract,6,test,gold,1642.0
3899,"RESULTS Pioglitazone-treated patients demonstrated greater increases in high-density lipoprotein cholesterol ( HDL-C ) and reductions in glycated hemoglobin ,",triglycerides,", and C-reactive protein .","['RESULTS', 'Pioglitazone-treated', 'patients', 'demonstrated', 'greater', 'increases', 'in', 'high-density', 'lipoprotein', 'cholesterol', '(', 'HDL-C', ')', 'and', 'reductions', 'in', 'glycated', 'hemoglobin', ',', 'triglycerides', ',', 'and', 'C-reactive', 'protein', '.']","(19, 20)","(158, 171)",-1,hl_o,21211686,Abstract,6,test,gold,1576.0
3900,"RESULTS Pioglitazone-treated patients demonstrated greater increases in high-density lipoprotein cholesterol ( HDL-C ) and reductions in glycated hemoglobin , triglycerides , and",C-reactive protein,.,"['RESULTS', 'Pioglitazone-treated', 'patients', 'demonstrated', 'greater', 'increases', 'in', 'high-density', 'lipoprotein', 'cholesterol', '(', 'HDL-C', ')', 'and', 'reductions', 'in', 'glycated', 'hemoglobin', ',', 'triglycerides', ',', 'and', 'C-reactive', 'protein', '.']","(22, 24)","(178, 196)",-1,hl_o,21211686,Abstract,6,test,gold,5508.0
3901,"Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) , triglyceride/HDL-C ratio ( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with",pioglitazone,", and changes in low-density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and apolipoprotein A-I ( r = -0.20 , p = 0.01 ) with glimepiride .","['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(47, 48)","(229, 241)",-1,ss_i,21211686,Abstract,7,test,gold,5385.0
3902,"Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) , triglyceride/HDL-C ratio ( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in low-density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and apolipoprotein A-I ( r = -0.20 , p = 0.01 ) with",glimepiride .,,"['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(90, 92)","(419, 432)",-1,ss_i,21211686,Abstract,7,test,gold,5399.0
3903,Significant correlations were observed between changes in,percent atheroma volume and triglycerides,"( r = 0.15 , p = 0.04 ) , triglyceride/HDL-C ratio ( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in low-density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and apolipoprotein A-I ( r = -0.20 , p = 0.01 ) with glimepiride .","['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(7, 12)","(57, 98)",-1,ss_o,21211686,Abstract,7,test,gold,1713.0
3904,"Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) ,",triglyceride/HDL-C ratio,"( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in low-density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and apolipoprotein A-I ( r = -0.20 , p = 0.01 ) with glimepiride .","['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(22, 24)","(125, 149)",-1,ss_o,21211686,Abstract,7,test,gold,1485.0
3905,"Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) , triglyceride/HDL-C ratio ( r = 0.16 , p = 0.03 ) , and",glycated hemoglobin,"( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in low-density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and apolipoprotein A-I ( r = -0.20 , p = 0.01 ) with glimepiride .","['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(35, 37)","(180, 199)",-1,ss_o,21211686,Abstract,7,test,gold,1643.0
3906,"Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) , triglyceride/HDL-C ratio ( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in",low-density lipoprotein cholesterol,"( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and apolipoprotein A-I ( r = -0.20 , p = 0.01 ) with glimepiride .","['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(52, 55)","(259, 294)",-1,ss_o,21211686,Abstract,7,test,gold,6550.0
3907,"Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) , triglyceride/HDL-C ratio ( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in low-density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) ,",apolipoprotein B,"( r = -0.16 , p = 0.04 ) , and apolipoprotein A-I ( r = -0.20 , p = 0.01 ) with glimepiride .","['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(65, 67)","(322, 338)",-1,ss_o,21211686,Abstract,7,test,gold,824.0
3908,"Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) , triglyceride/HDL-C ratio ( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in low-density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and",apolipoprotein A-I,"( r = -0.20 , p = 0.01 ) with glimepiride .","['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(78, 80)","(370, 388)",-1,ss_o,21211686,Abstract,7,test,gold,822.0
3909,"Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) , triglyceride/HDL-C ratio ( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with",pioglitazone,", and changes in low-density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and apolipoprotein A-I ( r = -0.20 , p = 0.01 ) with glimepiride .","['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(47, 48)","(229, 241)",-1,hl_i,21211686,Abstract,7,test,gold,5384.0
3910,"Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) , triglyceride/HDL-C ratio ( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in low-density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and apolipoprotein A-I ( r = -0.20 , p = 0.01 ) with",glimepiride .,,"['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(90, 92)","(419, 432)",-1,hl_i,21211686,Abstract,7,test,gold,5398.0
3911,Significant correlations were observed between changes in,percent atheroma volume and triglycerides,"( r = 0.15 , p = 0.04 ) , triglyceride/HDL-C ratio ( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in low-density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and apolipoprotein A-I ( r = -0.20 , p = 0.01 ) with glimepiride .","['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(7, 12)","(57, 98)",-1,hl_o,21211686,Abstract,7,test,gold,1714.0
3912,"Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) ,",triglyceride/HDL-C ratio,"( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in low-density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and apolipoprotein A-I ( r = -0.20 , p = 0.01 ) with glimepiride .","['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(22, 24)","(125, 149)",-1,hl_o,21211686,Abstract,7,test,gold,1486.0
3913,"Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) , triglyceride/HDL-C ratio ( r = 0.16 , p = 0.03 ) , and",glycated hemoglobin,"( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in low-density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and apolipoprotein A-I ( r = -0.20 , p = 0.01 ) with glimepiride .","['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(35, 37)","(180, 199)",-1,hl_o,21211686,Abstract,7,test,gold,1641.0
3914,"Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) , triglyceride/HDL-C ratio ( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in",low-density lipoprotein cholesterol,"( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and apolipoprotein A-I ( r = -0.20 , p = 0.01 ) with glimepiride .","['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(52, 55)","(259, 294)",-1,hl_o,21211686,Abstract,7,test,gold,6549.0
3915,"Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) , triglyceride/HDL-C ratio ( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in low-density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) ,",apolipoprotein B,"( r = -0.16 , p = 0.04 ) , and apolipoprotein A-I ( r = -0.20 , p = 0.01 ) with glimepiride .","['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(65, 67)","(322, 338)",-1,hl_o,21211686,Abstract,7,test,gold,825.0
3916,"Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) , triglyceride/HDL-C ratio ( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in low-density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and",apolipoprotein A-I,"( r = -0.20 , p = 0.01 ) with glimepiride .","['Significant', 'correlations', 'were', 'observed', 'between', 'changes', 'in', 'percent', 'atheroma', 'volume', 'and', 'triglycerides', '(', 'r', '=', '0.15', ',', 'p', '=', '0.04', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', ',', 'and', 'glycated', 'hemoglobin', '(', 'r', '=', '0.16', ',', 'p', '=', '0.03', ')', 'with', 'pioglitazone', ',', 'and', 'changes', 'in', 'low-density', 'lipoprotein', 'cholesterol', '(', 'r', '=', '-0.15', ',', 'p', '=', '0.05', ')', ',', 'apolipoprotein', 'B', '(', 'r', '=', '-0.16', ',', 'p', '=', '0.04', ')', ',', 'and', 'apolipoprotein', 'A-I', '(', 'r', '=', '-0.20', ',', 'p', '=', '0.01', ')', 'with', 'glimepiride', '.']","(78, 80)","(370, 388)",-1,hl_o,21211686,Abstract,7,test,gold,823.0
3917,,Substantial atheroma regression,", compared to progression , was associated with greater relative increases in HDL-C ( 14.2 % vs. 7.8 % , p = 0.04 ) , relative decreases in triglycerides ( -13.3 % vs. -1.9 % , p = 0.045 ) , triglyceride/HDL-C ratio ( -22.5 vs. -9.9 % , p = 0.05 ) , and decrease in glycated hemoglobin ( -0.6 % vs. -0.3 % , p = 0.01 ) .","['Substantial', 'atheroma', 'regression', ',', 'compared', 'to', 'progression', ',', 'was', 'associated', 'with', 'greater', 'relative', 'increases', 'in', 'HDL-C', '(', '14.2', '%', 'vs.', '7.8', '%', ',', 'p', '=', '0.04', ')', ',', 'relative', 'decreases', 'in', 'triglycerides', '(', '-13.3', '%', 'vs.', '-1.9', '%', ',', 'p', '=', '0.045', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', '-22.5', 'vs.', '-9.9', '%', ',', 'p', '=', '0.05', ')', ',', 'and', 'decrease', 'in', 'glycated', 'hemoglobin', '(', '-0.6', '%', 'vs.', '-0.3', '%', ',', 'p', '=', '0.01', ')', '.']","(0, 3)","(0, 31)",-1,ss_o,21211686,Abstract,8,test,gold,3292.0
3918,"Substantial atheroma regression , compared to",progression,", was associated with greater relative increases in HDL-C ( 14.2 % vs. 7.8 % , p = 0.04 ) , relative decreases in triglycerides ( -13.3 % vs. -1.9 % , p = 0.045 ) , triglyceride/HDL-C ratio ( -22.5 vs. -9.9 % , p = 0.05 ) , and decrease in glycated hemoglobin ( -0.6 % vs. -0.3 % , p = 0.01 ) .","['Substantial', 'atheroma', 'regression', ',', 'compared', 'to', 'progression', ',', 'was', 'associated', 'with', 'greater', 'relative', 'increases', 'in', 'HDL-C', '(', '14.2', '%', 'vs.', '7.8', '%', ',', 'p', '=', '0.04', ')', ',', 'relative', 'decreases', 'in', 'triglycerides', '(', '-13.3', '%', 'vs.', '-1.9', '%', ',', 'p', '=', '0.045', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', '-22.5', 'vs.', '-9.9', '%', ',', 'p', '=', '0.05', ')', ',', 'and', 'decrease', 'in', 'glycated', 'hemoglobin', '(', '-0.6', '%', 'vs.', '-0.3', '%', ',', 'p', '=', '0.01', ')', '.']","(6, 7)","(45, 56)",-1,ss_o,21211686,Abstract,8,test,gold,3326.0
3919,"Substantial atheroma regression , compared to progression , was associated with greater relative increases in",HDL-C,"( 14.2 % vs. 7.8 % , p = 0.04 ) , relative decreases in triglycerides ( -13.3 % vs. -1.9 % , p = 0.045 ) , triglyceride/HDL-C ratio ( -22.5 vs. -9.9 % , p = 0.05 ) , and decrease in glycated hemoglobin ( -0.6 % vs. -0.3 % , p = 0.01 ) .","['Substantial', 'atheroma', 'regression', ',', 'compared', 'to', 'progression', ',', 'was', 'associated', 'with', 'greater', 'relative', 'increases', 'in', 'HDL-C', '(', '14.2', '%', 'vs.', '7.8', '%', ',', 'p', '=', '0.04', ')', ',', 'relative', 'decreases', 'in', 'triglycerides', '(', '-13.3', '%', 'vs.', '-1.9', '%', ',', 'p', '=', '0.045', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', '-22.5', 'vs.', '-9.9', '%', ',', 'p', '=', '0.05', ')', ',', 'and', 'decrease', 'in', 'glycated', 'hemoglobin', '(', '-0.6', '%', 'vs.', '-0.3', '%', ',', 'p', '=', '0.01', ')', '.']","(15, 16)","(109, 114)",-1,ss_o,21211686,Abstract,8,test,gold,
3920,"Substantial atheroma regression , compared to progression , was associated with greater relative increases in HDL-C ( 14.2 % vs. 7.8 % , p = 0.04 ) , relative decreases in",triglycerides,"( -13.3 % vs. -1.9 % , p = 0.045 ) , triglyceride/HDL-C ratio ( -22.5 vs. -9.9 % , p = 0.05 ) , and decrease in glycated hemoglobin ( -0.6 % vs. -0.3 % , p = 0.01 ) .","['Substantial', 'atheroma', 'regression', ',', 'compared', 'to', 'progression', ',', 'was', 'associated', 'with', 'greater', 'relative', 'increases', 'in', 'HDL-C', '(', '14.2', '%', 'vs.', '7.8', '%', ',', 'p', '=', '0.04', ')', ',', 'relative', 'decreases', 'in', 'triglycerides', '(', '-13.3', '%', 'vs.', '-1.9', '%', ',', 'p', '=', '0.045', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', '-22.5', 'vs.', '-9.9', '%', ',', 'p', '=', '0.05', ')', ',', 'and', 'decrease', 'in', 'glycated', 'hemoglobin', '(', '-0.6', '%', 'vs.', '-0.3', '%', ',', 'p', '=', '0.01', ')', '.']","(31, 32)","(171, 184)",-1,ss_o,21211686,Abstract,8,test,gold,1577.0
3921,"Substantial atheroma regression , compared to progression , was associated with greater relative increases in HDL-C ( 14.2 % vs. 7.8 % , p = 0.04 ) , relative decreases in triglycerides ( -13.3 % vs. -1.9 % , p = 0.045 ) ,",triglyceride/HDL-C ratio,"( -22.5 vs. -9.9 % , p = 0.05 ) , and decrease in glycated hemoglobin ( -0.6 % vs. -0.3 % , p = 0.01 ) .","['Substantial', 'atheroma', 'regression', ',', 'compared', 'to', 'progression', ',', 'was', 'associated', 'with', 'greater', 'relative', 'increases', 'in', 'HDL-C', '(', '14.2', '%', 'vs.', '7.8', '%', ',', 'p', '=', '0.04', ')', ',', 'relative', 'decreases', 'in', 'triglycerides', '(', '-13.3', '%', 'vs.', '-1.9', '%', ',', 'p', '=', '0.045', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', '-22.5', 'vs.', '-9.9', '%', ',', 'p', '=', '0.05', ')', ',', 'and', 'decrease', 'in', 'glycated', 'hemoglobin', '(', '-0.6', '%', 'vs.', '-0.3', '%', ',', 'p', '=', '0.01', ')', '.']","(44, 46)","(222, 246)",-1,ss_o,21211686,Abstract,8,test,gold,1484.0
3922,"Substantial atheroma regression , compared to progression , was associated with greater relative increases in HDL-C ( 14.2 % vs. 7.8 % , p = 0.04 ) , relative decreases in triglycerides ( -13.3 % vs. -1.9 % , p = 0.045 ) , triglyceride/HDL-C ratio ( -22.5 vs. -9.9 % , p = 0.05 ) , and decrease in",glycated hemoglobin,"( -0.6 % vs. -0.3 % , p = 0.01 ) .","['Substantial', 'atheroma', 'regression', ',', 'compared', 'to', 'progression', ',', 'was', 'associated', 'with', 'greater', 'relative', 'increases', 'in', 'HDL-C', '(', '14.2', '%', 'vs.', '7.8', '%', ',', 'p', '=', '0.04', ')', ',', 'relative', 'decreases', 'in', 'triglycerides', '(', '-13.3', '%', 'vs.', '-1.9', '%', ',', 'p', '=', '0.045', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', '-22.5', 'vs.', '-9.9', '%', ',', 'p', '=', '0.05', ')', ',', 'and', 'decrease', 'in', 'glycated', 'hemoglobin', '(', '-0.6', '%', 'vs.', '-0.3', '%', ',', 'p', '=', '0.01', ')', '.']","(60, 62)","(297, 316)",-1,ss_o,21211686,Abstract,8,test,gold,1640.0
3923,"Substantial atheroma regression , compared to progression , was associated with greater relative increases in",HDL-C,"( 14.2 % vs. 7.8 % , p = 0.04 ) , relative decreases in triglycerides ( -13.3 % vs. -1.9 % , p = 0.045 ) , triglyceride/HDL-C ratio ( -22.5 vs. -9.9 % , p = 0.05 ) , and decrease in glycated hemoglobin ( -0.6 % vs. -0.3 % , p = 0.01 ) .","['Substantial', 'atheroma', 'regression', ',', 'compared', 'to', 'progression', ',', 'was', 'associated', 'with', 'greater', 'relative', 'increases', 'in', 'HDL-C', '(', '14.2', '%', 'vs.', '7.8', '%', ',', 'p', '=', '0.04', ')', ',', 'relative', 'decreases', 'in', 'triglycerides', '(', '-13.3', '%', 'vs.', '-1.9', '%', ',', 'p', '=', '0.045', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', '-22.5', 'vs.', '-9.9', '%', ',', 'p', '=', '0.05', ')', ',', 'and', 'decrease', 'in', 'glycated', 'hemoglobin', '(', '-0.6', '%', 'vs.', '-0.3', '%', ',', 'p', '=', '0.01', ')', '.']","(15, 16)","(109, 114)",-1,hl_o,21211686,Abstract,8,test,gold,
3924,"Substantial atheroma regression , compared to progression , was associated with greater relative increases in HDL-C ( 14.2 % vs. 7.8 % , p = 0.04 ) , relative decreases in",triglycerides,"( -13.3 % vs. -1.9 % , p = 0.045 ) , triglyceride/HDL-C ratio ( -22.5 vs. -9.9 % , p = 0.05 ) , and decrease in glycated hemoglobin ( -0.6 % vs. -0.3 % , p = 0.01 ) .","['Substantial', 'atheroma', 'regression', ',', 'compared', 'to', 'progression', ',', 'was', 'associated', 'with', 'greater', 'relative', 'increases', 'in', 'HDL-C', '(', '14.2', '%', 'vs.', '7.8', '%', ',', 'p', '=', '0.04', ')', ',', 'relative', 'decreases', 'in', 'triglycerides', '(', '-13.3', '%', 'vs.', '-1.9', '%', ',', 'p', '=', '0.045', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', '-22.5', 'vs.', '-9.9', '%', ',', 'p', '=', '0.05', ')', ',', 'and', 'decrease', 'in', 'glycated', 'hemoglobin', '(', '-0.6', '%', 'vs.', '-0.3', '%', ',', 'p', '=', '0.01', ')', '.']","(31, 32)","(171, 184)",-1,hl_o,21211686,Abstract,8,test,gold,1575.0
3925,"Substantial atheroma regression , compared to progression , was associated with greater relative increases in HDL-C ( 14.2 % vs. 7.8 % , p = 0.04 ) , relative decreases in triglycerides ( -13.3 % vs. -1.9 % , p = 0.045 ) ,",triglyceride/HDL-C ratio,"( -22.5 vs. -9.9 % , p = 0.05 ) , and decrease in glycated hemoglobin ( -0.6 % vs. -0.3 % , p = 0.01 ) .","['Substantial', 'atheroma', 'regression', ',', 'compared', 'to', 'progression', ',', 'was', 'associated', 'with', 'greater', 'relative', 'increases', 'in', 'HDL-C', '(', '14.2', '%', 'vs.', '7.8', '%', ',', 'p', '=', '0.04', ')', ',', 'relative', 'decreases', 'in', 'triglycerides', '(', '-13.3', '%', 'vs.', '-1.9', '%', ',', 'p', '=', '0.045', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', '-22.5', 'vs.', '-9.9', '%', ',', 'p', '=', '0.05', ')', ',', 'and', 'decrease', 'in', 'glycated', 'hemoglobin', '(', '-0.6', '%', 'vs.', '-0.3', '%', ',', 'p', '=', '0.01', ')', '.']","(44, 46)","(222, 246)",-1,hl_o,21211686,Abstract,8,test,gold,1483.0
3926,"Substantial atheroma regression , compared to progression , was associated with greater relative increases in HDL-C ( 14.2 % vs. 7.8 % , p = 0.04 ) , relative decreases in triglycerides ( -13.3 % vs. -1.9 % , p = 0.045 ) , triglyceride/HDL-C ratio ( -22.5 vs. -9.9 % , p = 0.05 ) , and decrease in",glycated hemoglobin,"( -0.6 % vs. -0.3 % , p = 0.01 ) .","['Substantial', 'atheroma', 'regression', ',', 'compared', 'to', 'progression', ',', 'was', 'associated', 'with', 'greater', 'relative', 'increases', 'in', 'HDL-C', '(', '14.2', '%', 'vs.', '7.8', '%', ',', 'p', '=', '0.04', ')', ',', 'relative', 'decreases', 'in', 'triglycerides', '(', '-13.3', '%', 'vs.', '-1.9', '%', ',', 'p', '=', '0.045', ')', ',', 'triglyceride/HDL-C', 'ratio', '(', '-22.5', 'vs.', '-9.9', '%', ',', 'p', '=', '0.05', ')', ',', 'and', 'decrease', 'in', 'glycated', 'hemoglobin', '(', '-0.6', '%', 'vs.', '-0.3', '%', ',', 'p', '=', '0.01', ')', '.']","(60, 62)","(297, 316)",-1,hl_o,21211686,Abstract,8,test,gold,1639.0
3927,Multivariable analysis revealed that,pioglitazone-induced,effects on triglyceride/HDL-C were associated with changes in percent atheroma volume ( p = 0.03 ) and total atheroma volume ( p = 0.02 ) .,"['Multivariable', 'analysis', 'revealed', 'that', 'pioglitazone-induced', 'effects', 'on', 'triglyceride/HDL-C', 'were', 'associated', 'with', 'changes', 'in', 'percent', 'atheroma', 'volume', '(', 'p', '=', '0.03', ')', 'and', 'total', 'atheroma', 'volume', '(', 'p', '=', '0.02', ')', '.']","(4, 5)","(36, 56)",-1,ss_i,21211686,Abstract,9,test,gold,
3928,Multivariable analysis revealed that pioglitazone-induced effects on,triglyceride/HDL-C,were associated with changes in percent atheroma volume ( p = 0.03 ) and total atheroma volume ( p = 0.02 ) .,"['Multivariable', 'analysis', 'revealed', 'that', 'pioglitazone-induced', 'effects', 'on', 'triglyceride/HDL-C', 'were', 'associated', 'with', 'changes', 'in', 'percent', 'atheroma', 'volume', '(', 'p', '=', '0.03', ')', 'and', 'total', 'atheroma', 'volume', '(', 'p', '=', '0.02', ')', '.']","(7, 8)","(68, 86)",-1,ss_o,21211686,Abstract,9,test,gold,
3929,Multivariable analysis revealed that pioglitazone-induced effects on triglyceride/HDL-C were associated with changes in,percent atheroma volume,( p = 0.03 ) and total atheroma volume ( p = 0.02 ) .,"['Multivariable', 'analysis', 'revealed', 'that', 'pioglitazone-induced', 'effects', 'on', 'triglyceride/HDL-C', 'were', 'associated', 'with', 'changes', 'in', 'percent', 'atheroma', 'volume', '(', 'p', '=', '0.03', ')', 'and', 'total', 'atheroma', 'volume', '(', 'p', '=', '0.02', ')', '.']","(13, 16)","(119, 142)",-1,ss_o,21211686,Abstract,9,test,gold,1722.0
3930,Multivariable analysis revealed that pioglitazone-induced effects on triglyceride/HDL-C were associated with changes in percent atheroma volume ( p = 0.03 ) and,total atheroma volume,( p = 0.02 ) .,"['Multivariable', 'analysis', 'revealed', 'that', 'pioglitazone-induced', 'effects', 'on', 'triglyceride/HDL-C', 'were', 'associated', 'with', 'changes', 'in', 'percent', 'atheroma', 'volume', '(', 'p', '=', '0.03', ')', 'and', 'total', 'atheroma', 'volume', '(', 'p', '=', '0.02', ')', '.']","(22, 25)","(160, 181)",-1,ss_o,21211686,Abstract,9,test,gold,1718.0
3931,Multivariable analysis revealed that,pioglitazone-induced,effects on triglyceride/HDL-C were associated with changes in percent atheroma volume ( p = 0.03 ) and total atheroma volume ( p = 0.02 ) .,"['Multivariable', 'analysis', 'revealed', 'that', 'pioglitazone-induced', 'effects', 'on', 'triglyceride/HDL-C', 'were', 'associated', 'with', 'changes', 'in', 'percent', 'atheroma', 'volume', '(', 'p', '=', '0.03', ')', 'and', 'total', 'atheroma', 'volume', '(', 'p', '=', '0.02', ')', '.']","(4, 5)","(36, 56)",-1,hl_i,21211686,Abstract,9,test,gold,
3932,Multivariable analysis revealed that pioglitazone-induced effects on,triglyceride/HDL-C,were associated with changes in percent atheroma volume ( p = 0.03 ) and total atheroma volume ( p = 0.02 ) .,"['Multivariable', 'analysis', 'revealed', 'that', 'pioglitazone-induced', 'effects', 'on', 'triglyceride/HDL-C', 'were', 'associated', 'with', 'changes', 'in', 'percent', 'atheroma', 'volume', '(', 'p', '=', '0.03', ')', 'and', 'total', 'atheroma', 'volume', '(', 'p', '=', '0.02', ')', '.']","(7, 8)","(68, 86)",-1,hl_o,21211686,Abstract,9,test,gold,
3933,Multivariable analysis revealed that pioglitazone-induced effects on triglyceride/HDL-C were associated with changes in,percent atheroma volume,( p = 0.03 ) and total atheroma volume ( p = 0.02 ) .,"['Multivariable', 'analysis', 'revealed', 'that', 'pioglitazone-induced', 'effects', 'on', 'triglyceride/HDL-C', 'were', 'associated', 'with', 'changes', 'in', 'percent', 'atheroma', 'volume', '(', 'p', '=', '0.03', ')', 'and', 'total', 'atheroma', 'volume', '(', 'p', '=', '0.02', ')', '.']","(13, 16)","(119, 142)",-1,hl_o,21211686,Abstract,9,test,gold,1720.0
3934,Multivariable analysis revealed that pioglitazone-induced effects on triglyceride/HDL-C were associated with changes in percent atheroma volume ( p = 0.03 ) and,total atheroma volume,( p = 0.02 ) .,"['Multivariable', 'analysis', 'revealed', 'that', 'pioglitazone-induced', 'effects', 'on', 'triglyceride/HDL-C', 'were', 'associated', 'with', 'changes', 'in', 'percent', 'atheroma', 'volume', '(', 'p', '=', '0.03', ')', 'and', 'total', 'atheroma', 'volume', '(', 'p', '=', '0.02', ')', '.']","(22, 25)","(160, 181)",-1,hl_o,21211686,Abstract,9,test,gold,1716.0
3935,CONCLUSIONS Favorable effects of pioglitazone on the triglyceride/HDL-C ratio correlated with delayed atheroma progression in,diabetic patients .,,"['CONCLUSIONS', 'Favorable', 'effects', 'of', 'pioglitazone', 'on', 'the', 'triglyceride/HDL-C', 'ratio', 'correlated', 'with', 'delayed', 'atheroma', 'progression', 'in', 'diabetic', 'patients', '.']","(15, 18)","(125, 144)",-1,ss_p,21211686,Abstract,10,test,gold,3794.0
3936,CONCLUSIONS Favorable effects of,pioglitazone,on the triglyceride/HDL-C ratio correlated with delayed atheroma progression in diabetic patients .,"['CONCLUSIONS', 'Favorable', 'effects', 'of', 'pioglitazone', 'on', 'the', 'triglyceride/HDL-C', 'ratio', 'correlated', 'with', 'delayed', 'atheroma', 'progression', 'in', 'diabetic', 'patients', '.']","(4, 5)","(32, 44)",-1,ss_i,21211686,Abstract,10,test,gold,5383.0
3937,CONCLUSIONS Favorable effects of pioglitazone on the,triglyceride/HDL-C ratio,correlated with delayed atheroma progression in diabetic patients .,"['CONCLUSIONS', 'Favorable', 'effects', 'of', 'pioglitazone', 'on', 'the', 'triglyceride/HDL-C', 'ratio', 'correlated', 'with', 'delayed', 'atheroma', 'progression', 'in', 'diabetic', 'patients', '.']","(7, 9)","(52, 76)",-1,ss_o,21211686,Abstract,10,test,gold,1482.0
3938,CONCLUSIONS Favorable effects of pioglitazone on the triglyceride/HDL-C ratio correlated with delayed,atheroma progression,in diabetic patients .,"['CONCLUSIONS', 'Favorable', 'effects', 'of', 'pioglitazone', 'on', 'the', 'triglyceride/HDL-C', 'ratio', 'correlated', 'with', 'delayed', 'atheroma', 'progression', 'in', 'diabetic', 'patients', '.']","(12, 14)","(101, 121)",-1,ss_o,21211686,Abstract,10,test,gold,3297.0
3939,CONCLUSIONS Favorable effects of pioglitazone on the triglyceride/HDL-C ratio correlated with delayed atheroma progression in,diabetic patients .,,"['CONCLUSIONS', 'Favorable', 'effects', 'of', 'pioglitazone', 'on', 'the', 'triglyceride/HDL-C', 'ratio', 'correlated', 'with', 'delayed', 'atheroma', 'progression', 'in', 'diabetic', 'patients', '.']","(15, 18)","(125, 144)",-1,hl_p,21211686,Abstract,10,test,gold,3793.0
3940,CONCLUSIONS Favorable effects of,pioglitazone,on the triglyceride/HDL-C ratio correlated with delayed atheroma progression in diabetic patients .,"['CONCLUSIONS', 'Favorable', 'effects', 'of', 'pioglitazone', 'on', 'the', 'triglyceride/HDL-C', 'ratio', 'correlated', 'with', 'delayed', 'atheroma', 'progression', 'in', 'diabetic', 'patients', '.']","(4, 5)","(32, 44)",-1,hl_i,21211686,Abstract,10,test,gold,5382.0
3941,CONCLUSIONS Favorable effects of pioglitazone on the,triglyceride/HDL-C ratio,correlated with delayed atheroma progression in diabetic patients .,"['CONCLUSIONS', 'Favorable', 'effects', 'of', 'pioglitazone', 'on', 'the', 'triglyceride/HDL-C', 'ratio', 'correlated', 'with', 'delayed', 'atheroma', 'progression', 'in', 'diabetic', 'patients', '.']","(7, 9)","(52, 76)",-1,hl_o,21211686,Abstract,10,test,gold,1481.0
3942,CONCLUSIONS Favorable effects of pioglitazone on the triglyceride/HDL-C ratio correlated with delayed,atheroma progression,in diabetic patients .,"['CONCLUSIONS', 'Favorable', 'effects', 'of', 'pioglitazone', 'on', 'the', 'triglyceride/HDL-C', 'ratio', 'correlated', 'with', 'delayed', 'atheroma', 'progression', 'in', 'diabetic', 'patients', '.']","(12, 14)","(101, 121)",-1,hl_o,21211686,Abstract,10,test,gold,3295.0
3943,This finding highlights the potential importance of targeting atherogenic dyslipidemia in,diabetic patients with coronary artery disease .,,"['This', 'finding', 'highlights', 'the', 'potential', 'importance', 'of', 'targeting', 'atherogenic', 'dyslipidemia', 'in', 'diabetic', 'patients', 'with', 'coronary', 'artery', 'disease', '.']","(11, 18)","(89, 137)",-1,ss_p,21211686,Abstract,11,test,gold,6738.0
3944,This finding highlights the potential importance of targeting atherogenic dyslipidemia in,diabetic patients with coronary artery disease .,,"['This', 'finding', 'highlights', 'the', 'potential', 'importance', 'of', 'targeting', 'atherogenic', 'dyslipidemia', 'in', 'diabetic', 'patients', 'with', 'coronary', 'artery', 'disease', '.']","(11, 18)","(89, 137)",-1,hl_p,21211686,Abstract,11,test,gold,6737.0
3945,Distinct fast and slow processes contribute to the selection of preferred step frequency during,human,walking .,"['Distinct', 'fast', 'and', 'slow', 'processes', 'contribute', 'to', 'the', 'selection', 'of', 'preferred', 'step', 'frequency', 'during', 'human', 'walking', '.']","(14, 15)","(95, 100)",-1,ss_p,21393467,Title,0,test,gold,1278.0
3946,Distinct fast and slow processes contribute to the selection of preferred step frequency during,human,walking .,"['Distinct', 'fast', 'and', 'slow', 'processes', 'contribute', 'to', 'the', 'selection', 'of', 'preferred', 'step', 'frequency', 'during', 'human', 'walking', '.']","(14, 15)","(95, 100)",-1,hl_p,21393467,Title,0,test,gold,1277.0
3947,Humans spontaneously select a,step frequency,that minimizes the energy expenditure of walking .,"['Humans', 'spontaneously', 'select', 'a', 'step', 'frequency', 'that', 'minimizes', 'the', 'energy', 'expenditure', 'of', 'walking', '.']","(4, 6)","(29, 43)",-1,ss_o,21393467,Abstract,0,test,gold,1867.0
3948,This selection might be embedded within the neural circuits that generate gait so that the optimum is pre-programmed for a given walking speed .,,,"['This', 'selection', 'might', 'be', 'embedded', 'within', 'the', 'neural', 'circuits', 'that', 'generate', 'gait', 'so', 'that', 'the', 'optimum', 'is', 'pre-programmed', 'for', 'a', 'given', 'walking', 'speed', '.']",,,,,21393467,Abstract,1,test,gold,
3949,"Or perhaps step frequency is directly optimized , based on sensed feedback of energy expenditure .",,,"['Or', 'perhaps', 'step', 'frequency', 'is', 'directly', 'optimized', ',', 'based', 'on', 'sensed', 'feedback', 'of', 'energy', 'expenditure', '.']",,,,,21393467,Abstract,2,test,gold,
3950,"Direct optimization is expected to be slow due to the compounded effect of delays and iteration , whereas a pre-programmed mechanism presumably allows for faster step frequency selection , albeit dependent on prior experience .",,,"['Direct', 'optimization', 'is', 'expected', 'to', 'be', 'slow', 'due', 'to', 'the', 'compounded', 'effect', 'of', 'delays', 'and', 'iteration', ',', 'whereas', 'a', 'pre-programmed', 'mechanism', 'presumably', 'allows', 'for', 'faster', 'step', 'frequency', 'selection', ',', 'albeit', 'dependent', 'on', 'prior', 'experience', '.']",,,,,21393467,Abstract,3,test,gold,
3951,"To test for both pre-programmed selection and direct optimization , we applied",perturbations to treadmill walking,to elicit transient changes in step frequency .,"['To', 'test', 'for', 'both', 'pre-programmed', 'selection', 'and', 'direct', 'optimization', ',', 'we', 'applied', 'perturbations', 'to', 'treadmill', 'walking', 'to', 'elicit', 'transient', 'changes', 'in', 'step', 'frequency', '.']","(12, 16)","(78, 112)",-1,ss_i,21393467,Abstract,4,test,gold,2706.0
3952,"To test for both pre-programmed selection and direct optimization , we applied",perturbations to treadmill walking,to elicit transient changes in step frequency .,"['To', 'test', 'for', 'both', 'pre-programmed', 'selection', 'and', 'direct', 'optimization', ',', 'we', 'applied', 'perturbations', 'to', 'treadmill', 'walking', 'to', 'elicit', 'transient', 'changes', 'in', 'step', 'frequency', '.']","(12, 16)","(78, 112)",-1,hl_i,21393467,Abstract,4,test,gold,2707.0
3953,We found that,human step frequency adjustments,"( n = 7 ) occurred with two components , the first dominating the response ( 66 ± 10 % of total amplitude change ; mean ± SD ) and occurring quite quickly ( 1.44 ± 1.14 s to complete 95 % of total change ) .","['We', 'found', 'that', 'human', 'step', 'frequency', 'adjustments', '(', 'n', '=', '7', ')', 'occurred', 'with', 'two', 'components', ',', 'the', 'first', 'dominating', 'the', 'response', '(', '66', '±', '10', '%', 'of', 'total', 'amplitude', 'change', ';', 'mean', '±', 'SD', ')', 'and', 'occurring', 'quite', 'quickly', '(', '1.44', '±', '1.14', 's', 'to', 'complete', '95', '%', 'of', 'total', 'change', ')', '.']","(3, 7)","(13, 45)",-1,ss_o,21393467,Abstract,5,test,gold,1865.0
3954,"We found that human step frequency adjustments ( n = 7 ) occurred with two components , the first dominating the response ( 66 ± 10 % of total amplitude change ; mean ± SD ) and occurring",quite quickly,( 1.44 ± 1.14 s to complete 95 % of total change ) .,"['We', 'found', 'that', 'human', 'step', 'frequency', 'adjustments', '(', 'n', '=', '7', ')', 'occurred', 'with', 'two', 'components', ',', 'the', 'first', 'dominating', 'the', 'response', '(', '66', '±', '10', '%', 'of', 'total', 'amplitude', 'change', ';', 'mean', '±', 'SD', ')', 'and', 'occurring', 'quite', 'quickly', '(', '1.44', '±', '1.14', 's', 'to', 'complete', '95', '%', 'of', 'total', 'change', ')', '.']","(38, 40)","(187, 200)",-1,ss_o,21393467,Abstract,5,test,gold,1155.0
3955,We found that,human step frequency adjustments,"( n = 7 ) occurred with two components , the first dominating the response ( 66 ± 10 % of total amplitude change ; mean ± SD ) and occurring quite quickly ( 1.44 ± 1.14 s to complete 95 % of total change ) .","['We', 'found', 'that', 'human', 'step', 'frequency', 'adjustments', '(', 'n', '=', '7', ')', 'occurred', 'with', 'two', 'components', ',', 'the', 'first', 'dominating', 'the', 'response', '(', '66', '±', '10', '%', 'of', 'total', 'amplitude', 'change', ';', 'mean', '±', 'SD', ')', 'and', 'occurring', 'quite', 'quickly', '(', '1.44', '±', '1.14', 's', 'to', 'complete', '95', '%', 'of', 'total', 'change', ')', '.']","(3, 7)","(13, 45)",-1,hl_o,21393467,Abstract,5,test,gold,1866.0
3956,The other component was of,smaller amplitude,( 35 ± 10 % of total change ) and took tens of seconds ( 27.56 ± 16.18 s for 95 % completion ) .,"['The', 'other', 'component', 'was', 'of', 'smaller', 'amplitude', '(', '35', '±', '10', '%', 'of', 'total', 'change', ')', 'and', 'took', 'tens', 'of', 'seconds', '(', '27.56', '±', '16.18', 's', 'for', '95', '%', 'completion', ')', '.']","(5, 7)","(26, 43)",-1,ss_o,21393467,Abstract,6,test,gold,1350.0
3957,The other component was of smaller amplitude ( 35 ± 10 % of total change ) and took,tens of seconds,( 27.56 ± 16.18 s for 95 % completion ) .,"['The', 'other', 'component', 'was', 'of', 'smaller', 'amplitude', '(', '35', '±', '10', '%', 'of', 'total', 'change', ')', 'and', 'took', 'tens', 'of', 'seconds', '(', '27.56', '±', '16.18', 's', 'for', '95', '%', 'completion', ')', '.']","(18, 21)","(83, 98)",-1,ss_o,21393467,Abstract,6,test,gold,1144.0
3958,The fast process appeared to be too fast for direct optimization and more indicative of a pre-programmed response .,,,"['The', 'fast', 'process', 'appeared', 'to', 'be', 'too', 'fast', 'for', 'direct', 'optimization', 'and', 'more', 'indicative', 'of', 'a', 'pre-programmed', 'response', '.']",,,,,21393467,Abstract,7,test,gold,
3959,It also persisted even with unusual closed-loop perturbations that conflicted with prior experience and rendered the response energetically suboptimal .,,,"['It', 'also', 'persisted', 'even', 'with', 'unusual', 'closed-loop', 'perturbations', 'that', 'conflicted', 'with', 'prior', 'experience', 'and', 'rendered', 'the', 'response', 'energetically', 'suboptimal', '.']",,,,,21393467,Abstract,8,test,gold,
3960,The slow process was more consistent with the timing expected for direct optimization .,,,"['The', 'slow', 'process', 'was', 'more', 'consistent', 'with', 'the', 'timing', 'expected', 'for', 'direct', 'optimization', '.']",,,,,21393467,Abstract,9,test,gold,
3961,Our interpretation of these results is that humans may rely heavily on pre-programmed gaits to rapidly select their,preferred step frequency,and then gradually fine-tune that selection with direct optimization .,"['Our', 'interpretation', 'of', 'these', 'results', 'is', 'that', 'humans', 'may', 'rely', 'heavily', 'on', 'pre-programmed', 'gaits', 'to', 'rapidly', 'select', 'their', 'preferred', 'step', 'frequency', 'and', 'then', 'gradually', 'fine-tune', 'that', 'selection', 'with', 'direct', 'optimization', '.']","(18, 21)","(115, 139)",-1,ss_o,21393467,Abstract,10,test,gold,1868.0
3962,A novel approach to the use of subgingival controlled-release chlorhexidine delivery in,chronic periodontitis :,a randomized clinical trial .,"['A', 'novel', 'approach', 'to', 'the', 'use', 'of', 'subgingival', 'controlled-release', 'chlorhexidine', 'delivery', 'in', 'chronic', 'periodontitis', ':', 'a', 'randomized', 'clinical', 'trial', '.']","(12, 15)","(87, 110)",-1,ss_p,21491990,Title,0,test,gold,3560.0
3963,A novel approach to the use of subgingival controlled-release,chlorhexidine,delivery in chronic periodontitis : a randomized clinical trial .,"['A', 'novel', 'approach', 'to', 'the', 'use', 'of', 'subgingival', 'controlled-release', 'chlorhexidine', 'delivery', 'in', 'chronic', 'periodontitis', ':', 'a', 'randomized', 'clinical', 'trial', '.']","(9, 10)","(61, 74)",-1,ss_i,21491990,Title,0,test,gold,5440.0
3964,A novel approach to the use of subgingival controlled-release chlorhexidine delivery in,chronic periodontitis :,a randomized clinical trial .,"['A', 'novel', 'approach', 'to', 'the', 'use', 'of', 'subgingival', 'controlled-release', 'chlorhexidine', 'delivery', 'in', 'chronic', 'periodontitis', ':', 'a', 'randomized', 'clinical', 'trial', '.']","(12, 15)","(87, 110)",-1,hl_p,21491990,Title,0,test,gold,3561.0
3965,A novel approach to the use of subgingival controlled-release,chlorhexidine,delivery in chronic periodontitis : a randomized clinical trial .,"['A', 'novel', 'approach', 'to', 'the', 'use', 'of', 'subgingival', 'controlled-release', 'chlorhexidine', 'delivery', 'in', 'chronic', 'periodontitis', ':', 'a', 'randomized', 'clinical', 'trial', '.']","(9, 10)","(61, 74)",-1,hl_i,21491990,Title,0,test,gold,5441.0
3966,"BACKGROUND We aimed to analyze clinical , microbiologic , and serologic effects of",chlorhexidine ( CHX ),chips used as a subgingival controlled-release delivery device before and immediately after scaling and root planing ( SRP ) .,"['BACKGROUND', 'We', 'aimed', 'to', 'analyze', 'clinical', ',', 'microbiologic', ',', 'and', 'serologic', 'effects', 'of', 'chlorhexidine', '(', 'CHX', ')', 'chips', 'used', 'as', 'a', 'subgingival', 'controlled-release', 'delivery', 'device', 'before', 'and', 'immediately', 'after', 'scaling', 'and', 'root', 'planing', '(', 'SRP', ')', '.']","(13, 17)","(82, 103)",-1,ss_i,21491990,Abstract,0,test,gold,5442.0
3967,BACKGROUND We aimed to analyze,"clinical , microbiologic , and serologic effects",of chlorhexidine ( CHX ) chips used as a subgingival controlled-release delivery device before and immediately after scaling and root planing ( SRP ) .,"['BACKGROUND', 'We', 'aimed', 'to', 'analyze', 'clinical', ',', 'microbiologic', ',', 'and', 'serologic', 'effects', 'of', 'chlorhexidine', '(', 'CHX', ')', 'chips', 'used', 'as', 'a', 'subgingival', 'controlled-release', 'delivery', 'device', 'before', 'and', 'immediately', 'after', 'scaling', 'and', 'root', 'planing', '(', 'SRP', ')', '.']","(5, 12)","(30, 78)",-1,ss_o,21491990,Abstract,0,test,gold,4749.0
3968,"BACKGROUND We aimed to analyze clinical , microbiologic , and serologic effects of",chlorhexidine ( CHX ),chips used as a subgingival controlled-release delivery device before and immediately after scaling and root planing ( SRP ) .,"['BACKGROUND', 'We', 'aimed', 'to', 'analyze', 'clinical', ',', 'microbiologic', ',', 'and', 'serologic', 'effects', 'of', 'chlorhexidine', '(', 'CHX', ')', 'chips', 'used', 'as', 'a', 'subgingival', 'controlled-release', 'delivery', 'device', 'before', 'and', 'immediately', 'after', 'scaling', 'and', 'root', 'planing', '(', 'SRP', ')', '.']","(13, 17)","(82, 103)",-1,hl_i,21491990,Abstract,0,test,gold,5443.0
3969,BACKGROUND We aimed to analyze,clinical,", microbiologic , and serologic effects of chlorhexidine ( CHX ) chips used as a subgingival controlled-release delivery device before and immediately after scaling and root planing ( SRP ) .","['BACKGROUND', 'We', 'aimed', 'to', 'analyze', 'clinical', ',', 'microbiologic', ',', 'and', 'serologic', 'effects', 'of', 'chlorhexidine', '(', 'CHX', ')', 'chips', 'used', 'as', 'a', 'subgingival', 'controlled-release', 'delivery', 'device', 'before', 'and', 'immediately', 'after', 'scaling', 'and', 'root', 'planing', '(', 'SRP', ')', '.']","(5, 6)","(30, 38)",-1,hl_o,21491990,Abstract,0,test,gold,4771.0
3970,"BACKGROUND We aimed to analyze clinical ,",microbiologic,", and serologic effects of chlorhexidine ( CHX ) chips used as a subgingival controlled-release delivery device before and immediately after scaling and root planing ( SRP ) .","['BACKGROUND', 'We', 'aimed', 'to', 'analyze', 'clinical', ',', 'microbiologic', ',', 'and', 'serologic', 'effects', 'of', 'chlorhexidine', '(', 'CHX', ')', 'chips', 'used', 'as', 'a', 'subgingival', 'controlled-release', 'delivery', 'device', 'before', 'and', 'immediately', 'after', 'scaling', 'and', 'root', 'planing', '(', 'SRP', ')', '.']","(7, 8)","(41, 54)",-1,hl_o,21491990,Abstract,0,test,gold,63.0
3971,"BACKGROUND We aimed to analyze clinical , microbiologic , and",serologic effects,of chlorhexidine ( CHX ) chips used as a subgingival controlled-release delivery device before and immediately after scaling and root planing ( SRP ) .,"['BACKGROUND', 'We', 'aimed', 'to', 'analyze', 'clinical', ',', 'microbiologic', ',', 'and', 'serologic', 'effects', 'of', 'chlorhexidine', '(', 'CHX', ')', 'chips', 'used', 'as', 'a', 'subgingival', 'controlled-release', 'delivery', 'device', 'before', 'and', 'immediately', 'after', 'scaling', 'and', 'root', 'planing', '(', 'SRP', ')', '.']","(10, 12)","(61, 78)",-1,hl_o,21491990,Abstract,0,test,gold,2386.0
3972,METHODS,Twenty-four patients presenting with ≥12 teeth with probing depth ( PD ) ≥5 mm and bleeding on probing,were assigned in test or control groups .,"['METHODS', 'Twenty-four', 'patients', 'presenting', 'with', '≥12', 'teeth', 'with', 'probing', 'depth', '(', 'PD', ')', '≥5', 'mm', 'and', 'bleeding', 'on', 'probing', 'were', 'assigned', 'in', 'test', 'or', 'control', 'groups', '.']","(1, 19)","(7, 109)",-1,ss_p,21491990,Abstract,1,test,gold,6374.0
3973,METHODS,Twenty-four patients,presenting with ≥12 teeth with probing depth ( PD ) ≥5 mm and bleeding on probing were assigned in test or control groups .,"['METHODS', 'Twenty-four', 'patients', 'presenting', 'with', '≥12', 'teeth', 'with', 'probing', 'depth', '(', 'PD', ')', '≥5', 'mm', 'and', 'bleeding', 'on', 'probing', 'were', 'assigned', 'in', 'test', 'or', 'control', 'groups', '.']","(1, 3)","(7, 27)",-1,hl_p,21491990,Abstract,1,test,gold,3745.0
3974,After,"prophylaxis , CHX chips ( test ) or placebo",chips ( control ) were placed in pockets with PD ≥5 mm .,"['After', 'prophylaxis', ',', 'CHX', 'chips', '(', 'test', ')', 'or', 'placebo', 'chips', '(', 'control', ')', 'were', 'placed', 'in', 'pockets', 'with', 'PD', '≥5', 'mm', '.']","(1, 10)","(5, 48)",-1,ss_i,21491990,Abstract,2,test,gold,4436.0
3975,"After prophylaxis , CHX chips ( test ) or",placebo,chips ( control ) were placed in pockets with PD ≥5 mm .,"['After', 'prophylaxis', ',', 'CHX', 'chips', '(', 'test', ')', 'or', 'placebo', 'chips', '(', 'control', ')', 'were', 'placed', 'in', 'pockets', 'with', 'PD', '≥5', 'mm', '.']","(9, 10)","(41, 48)",-1,hl_i,21491990,Abstract,2,test,gold,4371.0
3976,"Ten days later , SRP was performed in all teeth with PD ≥4 mm in a single appointment .",,,"['Ten', 'days', 'later', ',', 'SRP', 'was', 'performed', 'in', 'all', 'teeth', 'with', 'PD', '≥4', 'mm', 'in', 'a', 'single', 'appointment', '.']",,,,,21491990,Abstract,3,test,gold,
3977,"Immediately after SRP , new chips were inserted in all pockets with",PD ≥5 mm .,,"['Immediately', 'after', 'SRP', ',', 'new', 'chips', 'were', 'inserted', 'in', 'all', 'pockets', 'with', 'PD', '≥5', 'mm', '.']","(12, 16)","(67, 77)",-1,ss_o,21491990,Abstract,4,test,gold,1351.0
3978,,Parameters,"were assessed at baseline ; beginning of SRP ; and 1 , 3 , and 6 months after treatment .","['Parameters', 'were', 'assessed', 'at', 'baseline', ';', 'beginning', 'of', 'SRP', ';', 'and', '1', ',', '3', ',', 'and', '6', 'months', 'after', 'treatment', '.']","(0, 1)","(0, 10)",-1,ss_o,21491990,Abstract,5,test,gold,1312.0
3979,"Parameters were assessed at baseline ; beginning of SRP ; and 1 , 3 , and 6 months after",treatment .,,"['Parameters', 'were', 'assessed', 'at', 'baseline', ';', 'beginning', 'of', 'SRP', ';', 'and', '1', ',', '3', ',', 'and', '6', 'months', 'after', 'treatment', '.']","(19, 21)","(88, 99)",-1,ss_o,21491990,Abstract,5,test,gold,3994.0
3980,,Subgingival,samples were obtained at baseline ; beginning of SRP ; and at 1 month after treatment .,"['Subgingival', 'samples', 'were', 'obtained', 'at', 'baseline', ';', 'beginning', 'of', 'SRP', ';', 'and', 'at', '1', 'month', 'after', 'treatment', '.']","(0, 1)","(0, 11)",-1,ss_o,21491990,Abstract,6,test,gold,
3981,Subgingival samples were obtained at baseline ; beginning of SRP ; and at 1 month after,treatment .,,"['Subgingival', 'samples', 'were', 'obtained', 'at', 'baseline', ';', 'beginning', 'of', 'SRP', ';', 'and', 'at', '1', 'month', 'after', 'treatment', '.']","(16, 18)","(87, 98)",-1,ss_o,21491990,Abstract,6,test,gold,3995.0
3982,,"Periodontal pathogens Aggregatibacter actinomycetemcomitans , Porphyromonas gingivalis , Prevotella intermedia , Tannerella forsythia , and Treponema",denticola were analyzed .,"['Periodontal', 'pathogens', 'Aggregatibacter', 'actinomycetemcomitans', ',', 'Porphyromonas', 'gingivalis', ',', 'Prevotella', 'intermedia', ',', 'Tannerella', 'forsythia', ',', 'and', 'Treponema', 'denticola', 'were', 'analyzed', '.']","(0, 16)","(0, 149)",-1,ss_o,21491990,Abstract,7,test,gold,6645.0
3983,"Periodontal pathogens Aggregatibacter actinomycetemcomitans , Porphyromonas gingivalis , Prevotella intermedia , Tannerella forsythia , and Treponema denticola were",analyzed .,,"['Periodontal', 'pathogens', 'Aggregatibacter', 'actinomycetemcomitans', ',', 'Porphyromonas', 'gingivalis', ',', 'Prevotella', 'intermedia', ',', 'Tannerella', 'forsythia', ',', 'and', 'Treponema', 'denticola', 'were', 'analyzed', '.']","(18, 20)","(164, 174)",-1,ss_o,21491990,Abstract,7,test,gold,1307.0
3984,,Serum levels of high sensitive C-reactive and lipopolysaccharide-binding,proteins were measured .,"['Serum', 'levels', 'of', 'high', 'sensitive', 'C-reactive', 'and', 'lipopolysaccharide-binding', 'proteins', 'were', 'measured', '.']","(0, 8)","(0, 72)",-1,ss_o,21491990,Abstract,8,test,gold,4492.0
3985,The,changes of the parameters,between and within the groups were tested by Mann-Whitney U test ( P < 0.05 ) .,"['The', 'changes', 'of', 'the', 'parameters', 'between', 'and', 'within', 'the', 'groups', 'were', 'tested', 'by', 'Mann-Whitney', 'U', 'test', '(', 'P', '<', '0.05', ')', '.']","(1, 5)","(3, 28)",-1,ss_o,21491990,Abstract,9,test,gold,1829.0
3986,The changes of the parameters between and within the groups were,tested by Mann-Whitney,U test ( P < 0.05 ) .,"['The', 'changes', 'of', 'the', 'parameters', 'between', 'and', 'within', 'the', 'groups', 'were', 'tested', 'by', 'Mann-Whitney', 'U', 'test', '(', 'P', '<', '0.05', ')', '.']","(11, 14)","(64, 86)",-1,ss_o,21491990,Abstract,9,test,gold,1861.0
3987,,RESULTS All clinical and serologic parameters,improved in both groups over time .,"['RESULTS', 'All', 'clinical', 'and', 'serologic', 'parameters', 'improved', 'in', 'both', 'groups', 'over', 'time', '.']","(0, 6)","(0, 45)",-1,ss_o,21491990,Abstract,10,test,gold,4750.0
3988,There was a significant,difference in clinical attachment level,( CAL ) gain from baseline to 6 months between groups ( 1.17 mm in the test group versus 0.79 mm in the placebo group ) ( P < 0.05 ) .,"['There', 'was', 'a', 'significant', 'difference', 'in', 'clinical', 'attachment', 'level', '(', 'CAL', ')', 'gain', 'from', 'baseline', 'to', '6', 'months', 'between', 'groups', '(', '1.17', 'mm', 'in', 'the', 'test', 'group', 'versus', '0.79', 'mm', 'in', 'the', 'placebo', 'group', ')', '(', 'P', '<', '0.05', ')', '.']","(4, 9)","(23, 62)",-1,ss_o,21491990,Abstract,11,test,gold,4761.0
3989,There was a significant difference in,clinical attachment level ( CAL ),gain from baseline to 6 months between groups ( 1.17 mm in the test group versus 0.79 mm in the placebo group ) ( P < 0.05 ) .,"['There', 'was', 'a', 'significant', 'difference', 'in', 'clinical', 'attachment', 'level', '(', 'CAL', ')', 'gain', 'from', 'baseline', 'to', '6', 'months', 'between', 'groups', '(', '1.17', 'mm', 'in', 'the', 'test', 'group', 'versus', '0.79', 'mm', 'in', 'the', 'placebo', 'group', ')', '(', 'P', '<', '0.05', ')', '.']","(6, 12)","(37, 70)",-1,hl_o,21491990,Abstract,11,test,gold,4762.0
3990,The,treatment with,"CHX chips showed a greater reduction of the microorganisms of the "" red complex "" after 1 month ( P = 0.02 ) .","['The', 'treatment', 'with', 'CHX', 'chips', 'showed', 'a', 'greater', 'reduction', 'of', 'the', 'microorganisms', 'of', 'the', '""', 'red', 'complex', '""', 'after', '1', 'month', '(', 'P', '=', '0.02', ')', '.']","(1, 3)","(3, 17)",-1,ss_i,21491990,Abstract,12,test,gold,3991.0
3991,The treatment with CHX chips showed,"a greater reduction of the microorganisms of the "" red","complex "" after 1 month ( P = 0.02 ) .","['The', 'treatment', 'with', 'CHX', 'chips', 'showed', 'a', 'greater', 'reduction', 'of', 'the', 'microorganisms', 'of', 'the', '""', 'red', 'complex', '""', 'after', '1', 'month', '(', 'P', '=', '0.02', ')', '.']","(6, 16)","(35, 89)",-1,ss_o,21491990,Abstract,12,test,gold,1757.0
3992,The treatment with CHX chips showed a greater,"reduction of the microorganisms of the "" red","complex "" after 1 month ( P = 0.02 ) .","['The', 'treatment', 'with', 'CHX', 'chips', 'showed', 'a', 'greater', 'reduction', 'of', 'the', 'microorganisms', 'of', 'the', '""', 'red', 'complex', '""', 'after', '1', 'month', '(', 'P', '=', '0.02', ')', '.']","(8, 16)","(45, 89)",-1,hl_o,21491990,Abstract,12,test,gold,1758.0
3993,CONCLUSION The use of CHX chips before and immediately after SRP improved CAL and reduced the subgingival microorganisms of the red complex in the,treatment of chronic periodontitis,.,"['CONCLUSION', 'The', 'use', 'of', 'CHX', 'chips', 'before', 'and', 'immediately', 'after', 'SRP', 'improved', 'CAL', 'and', 'reduced', 'the', 'subgingival', 'microorganisms', 'of', 'the', 'red', 'complex', 'in', 'the', 'treatment', 'of', 'chronic', 'periodontitis', '.']","(24, 28)","(146, 180)",-1,ss_p,21491990,Abstract,13,test,gold,3559.0
3994,CONCLUSION,The use of,CHX chips before and immediately after SRP improved CAL and reduced the subgingival microorganisms of the red complex in the treatment of chronic periodontitis .,"['CONCLUSION', 'The', 'use', 'of', 'CHX', 'chips', 'before', 'and', 'immediately', 'after', 'SRP', 'improved', 'CAL', 'and', 'reduced', 'the', 'subgingival', 'microorganisms', 'of', 'the', 'red', 'complex', 'in', 'the', 'treatment', 'of', 'chronic', 'periodontitis', '.']","(1, 4)","(10, 20)",-1,ss_i,21491990,Abstract,13,test,gold,1174.0
3995,CONCLUSION The use of CHX chips before and immediately after,SRP improved,CAL and reduced the subgingival microorganisms of the red complex in the treatment of chronic periodontitis .,"['CONCLUSION', 'The', 'use', 'of', 'CHX', 'chips', 'before', 'and', 'immediately', 'after', 'SRP', 'improved', 'CAL', 'and', 'reduced', 'the', 'subgingival', 'microorganisms', 'of', 'the', 'red', 'complex', 'in', 'the', 'treatment', 'of', 'chronic', 'periodontitis', '.']","(10, 12)","(60, 72)",-1,ss_o,21491990,Abstract,13,test,gold,973.0
3996,CONCLUSION The use of CHX chips before and immediately after SRP improved CAL and,reduced the subgingival microorganisms of the red,complex in the treatment of chronic periodontitis .,"['CONCLUSION', 'The', 'use', 'of', 'CHX', 'chips', 'before', 'and', 'immediately', 'after', 'SRP', 'improved', 'CAL', 'and', 'reduced', 'the', 'subgingival', 'microorganisms', 'of', 'the', 'red', 'complex', 'in', 'the', 'treatment', 'of', 'chronic', 'periodontitis', '.']","(14, 21)","(81, 130)",-1,ss_o,21491990,Abstract,13,test,gold,1759.0
3997,CONCLUSION The use of CHX chips before and immediately after SRP improved CAL and reduced the,subgingival microorganisms of the red,complex in the treatment of chronic periodontitis .,"['CONCLUSION', 'The', 'use', 'of', 'CHX', 'chips', 'before', 'and', 'immediately', 'after', 'SRP', 'improved', 'CAL', 'and', 'reduced', 'the', 'subgingival', 'microorganisms', 'of', 'the', 'red', 'complex', 'in', 'the', 'treatment', 'of', 'chronic', 'periodontitis', '.']","(16, 21)","(93, 130)",-1,hl_o,21491990,Abstract,13,test,gold,1760.0
3998,Intervention to lower household wood smoke exposure in,Guatemala,reduces ST-segment depression on electrocardiograms .,"['Intervention', 'to', 'lower', 'household', 'wood', 'smoke', 'exposure', 'in', 'Guatemala', 'reduces', 'ST-segment', 'depression', 'on', 'electrocardiograms', '.']","(8, 9)","(54, 63)",-1,ss_p,21669557,Title,0,test,gold,1092.0
3999,Intervention to lower household wood smoke exposure in Guatemala reduces,ST-segment depression,on electrocardiograms .,"['Intervention', 'to', 'lower', 'household', 'wood', 'smoke', 'exposure', 'in', 'Guatemala', 'reduces', 'ST-segment', 'depression', 'on', 'electrocardiograms', '.']","(10, 12)","(72, 93)",-1,ss_o,21669557,Title,0,test,gold,2553.0
4000,Intervention to lower household wood smoke exposure in Guatemala reduces,ST-segment depression,on electrocardiograms .,"['Intervention', 'to', 'lower', 'household', 'wood', 'smoke', 'exposure', 'in', 'Guatemala', 'reduces', 'ST-segment', 'depression', 'on', 'electrocardiograms', '.']","(10, 12)","(72, 93)",-1,hl_o,21669557,Title,0,test,gold,2551.0
4001,"BACKGROUND A large body of evidence suggests that fine particulate matter ( PM ) air pollution is a cause of cardiovascular disease , but little is known in particular about the cardiovascular effects of indoor air pollution from household use of solid fuels in developing countries .",,,"['BACKGROUND', 'A', 'large', 'body', 'of', 'evidence', 'suggests', 'that', 'fine', 'particulate', 'matter', '(', 'PM', ')', 'air', 'pollution', 'is', 'a', 'cause', 'of', 'cardiovascular', 'disease', ',', 'but', 'little', 'is', 'known', 'in', 'particular', 'about', 'the', 'cardiovascular', 'effects', 'of', 'indoor', 'air', 'pollution', 'from', 'household', 'use', 'of', 'solid', 'fuels', 'in', 'developing', 'countries', '.']",,,,,21669557,Abstract,0,test,gold,
4002,RESPIRE ( Randomized Exposure Study of Pollution Indoors and Respiratory Effects ) was a randomized trial of a,chimney woodstove,that reduces wood smoke exposure .,"['RESPIRE', '(', 'Randomized', 'Exposure', 'Study', 'of', 'Pollution', 'Indoors', 'and', 'Respiratory', 'Effects', ')', 'was', 'a', 'randomized', 'trial', 'of', 'a', 'chimney', 'woodstove', 'that', 'reduces', 'wood', 'smoke', 'exposure', '.']","(18, 20)","(110, 127)",-1,ss_i,21669557,Abstract,1,test,gold,2401.0
4003,RESPIRE ( Randomized Exposure Study of Pollution Indoors and Respiratory Effects ) was a randomized trial of a,chimney woodstove,that reduces wood smoke exposure .,"['RESPIRE', '(', 'Randomized', 'Exposure', 'Study', 'of', 'Pollution', 'Indoors', 'and', 'Respiratory', 'Effects', ')', 'was', 'a', 'randomized', 'trial', 'of', 'a', 'chimney', 'woodstove', 'that', 'reduces', 'wood', 'smoke', 'exposure', '.']","(18, 20)","(110, 127)",-1,hl_i,21669557,Abstract,1,test,gold,2402.0
4004,OBJECTIVES We tested the hypotheses that the,stove intervention,", compared with open fire use , would reduce ST-segment depression and increase heart rate variability ( HRV ) .","['OBJECTIVES', 'We', 'tested', 'the', 'hypotheses', 'that', 'the', 'stove', 'intervention', ',', 'compared', 'with', 'open', 'fire', 'use', ',', 'would', 'reduce', 'ST-segment', 'depression', 'and', 'increase', 'heart', 'rate', 'variability', '(', 'HRV', ')', '.']","(7, 9)","(44, 62)",-1,ss_i,21669557,Abstract,2,test,gold,2404.0
4005,"OBJECTIVES We tested the hypotheses that the stove intervention , compared with",open fire,"use , would reduce ST-segment depression and increase heart rate variability ( HRV ) .","['OBJECTIVES', 'We', 'tested', 'the', 'hypotheses', 'that', 'the', 'stove', 'intervention', ',', 'compared', 'with', 'open', 'fire', 'use', ',', 'would', 'reduce', 'ST-segment', 'depression', 'and', 'increase', 'heart', 'rate', 'variability', '(', 'HRV', ')', '.']","(12, 14)","(79, 88)",-1,ss_i,21669557,Abstract,2,test,gold,731.0
4006,"OBJECTIVES We tested the hypotheses that the stove intervention , compared with open fire use , would reduce",ST-segment depression,and increase heart rate variability ( HRV ) .,"['OBJECTIVES', 'We', 'tested', 'the', 'hypotheses', 'that', 'the', 'stove', 'intervention', ',', 'compared', 'with', 'open', 'fire', 'use', ',', 'would', 'reduce', 'ST-segment', 'depression', 'and', 'increase', 'heart', 'rate', 'variability', '(', 'HRV', ')', '.']","(18, 20)","(108, 129)",-1,ss_o,21669557,Abstract,2,test,gold,2550.0
4007,"OBJECTIVES We tested the hypotheses that the stove intervention , compared with open fire use , would reduce ST-segment depression and increase",heart rate variability ( HRV ) .,,"['OBJECTIVES', 'We', 'tested', 'the', 'hypotheses', 'that', 'the', 'stove', 'intervention', ',', 'compared', 'with', 'open', 'fire', 'use', ',', 'would', 'reduce', 'ST-segment', 'depression', 'and', 'increase', 'heart', 'rate', 'variability', '(', 'HRV', ')', '.']","(22, 29)","(143, 175)",-1,ss_o,21669557,Abstract,2,test,gold,1929.0
4008,OBJECTIVES We tested the hypotheses that the,stove intervention,", compared with open fire use , would reduce ST-segment depression and increase heart rate variability ( HRV ) .","['OBJECTIVES', 'We', 'tested', 'the', 'hypotheses', 'that', 'the', 'stove', 'intervention', ',', 'compared', 'with', 'open', 'fire', 'use', ',', 'would', 'reduce', 'ST-segment', 'depression', 'and', 'increase', 'heart', 'rate', 'variability', '(', 'HRV', ')', '.']","(7, 9)","(44, 62)",-1,hl_i,21669557,Abstract,2,test,gold,2405.0
4009,"OBJECTIVES We tested the hypotheses that the stove intervention , compared with",open fire,"use , would reduce ST-segment depression and increase heart rate variability ( HRV ) .","['OBJECTIVES', 'We', 'tested', 'the', 'hypotheses', 'that', 'the', 'stove', 'intervention', ',', 'compared', 'with', 'open', 'fire', 'use', ',', 'would', 'reduce', 'ST-segment', 'depression', 'and', 'increase', 'heart', 'rate', 'variability', '(', 'HRV', ')', '.']","(12, 14)","(79, 88)",-1,hl_i,21669557,Abstract,2,test,gold,732.0
4010,"OBJECTIVES We tested the hypotheses that the stove intervention , compared with open fire use , would reduce",ST-segment depression,and increase heart rate variability ( HRV ) .,"['OBJECTIVES', 'We', 'tested', 'the', 'hypotheses', 'that', 'the', 'stove', 'intervention', ',', 'compared', 'with', 'open', 'fire', 'use', ',', 'would', 'reduce', 'ST-segment', 'depression', 'and', 'increase', 'heart', 'rate', 'variability', '(', 'HRV', ')', '.']","(18, 20)","(108, 129)",-1,hl_o,21669557,Abstract,2,test,gold,2549.0
4011,"OBJECTIVES We tested the hypotheses that the stove intervention , compared with open fire use , would reduce ST-segment depression and increase",heart rate variability ( HRV ) .,,"['OBJECTIVES', 'We', 'tested', 'the', 'hypotheses', 'that', 'the', 'stove', 'intervention', ',', 'compared', 'with', 'open', 'fire', 'use', ',', 'would', 'reduce', 'ST-segment', 'depression', 'and', 'increase', 'heart', 'rate', 'variability', '(', 'HRV', ')', '.']","(22, 29)","(143, 175)",-1,hl_o,21669557,Abstract,2,test,gold,1930.0
4012,METHODS We used two complementary study designs : a ) between-groups comparisons based on randomized,stove,"assignment , and b ) before-and-after comparisons within control subjects who used open fires during the trial and received chimney stoves after the trial .","['METHODS', 'We', 'used', 'two', 'complementary', 'study', 'designs', ':', 'a', ')', 'between-groups', 'comparisons', 'based', 'on', 'randomized', 'stove', 'assignment', ',', 'and', 'b', ')', 'before-and-after', 'comparisons', 'within', 'control', 'subjects', 'who', 'used', 'open', 'fires', 'during', 'the', 'trial', 'and', 'received', 'chimney', 'stoves', 'after', 'the', 'trial', '.']","(15, 16)","(100, 105)",-1,ss_i,21669557,Abstract,3,test,gold,2406.0
4013,"METHODS We used two complementary study designs : a ) between-groups comparisons based on randomized stove assignment , and b ) before-and-after comparisons within control subjects who used",open fires,during the trial and received chimney stoves after the trial .,"['METHODS', 'We', 'used', 'two', 'complementary', 'study', 'designs', ':', 'a', ')', 'between-groups', 'comparisons', 'based', 'on', 'randomized', 'stove', 'assignment', ',', 'and', 'b', ')', 'before-and-after', 'comparisons', 'within', 'control', 'subjects', 'who', 'used', 'open', 'fires', 'during', 'the', 'trial', 'and', 'received', 'chimney', 'stoves', 'after', 'the', 'trial', '.']","(28, 30)","(189, 199)",-1,ss_i,21669557,Abstract,3,test,gold,733.0
4014,"METHODS We used two complementary study designs : a ) between-groups comparisons based on randomized stove assignment , and b ) before-and-after comparisons within control subjects who used open fires during the trial and received",chimney stoves,after the trial .,"['METHODS', 'We', 'used', 'two', 'complementary', 'study', 'designs', ':', 'a', ')', 'between-groups', 'comparisons', 'based', 'on', 'randomized', 'stove', 'assignment', ',', 'and', 'b', ')', 'before-and-after', 'comparisons', 'within', 'control', 'subjects', 'who', 'used', 'open', 'fires', 'during', 'the', 'trial', 'and', 'received', 'chimney', 'stoves', 'after', 'the', 'trial', '.']","(35, 37)","(230, 244)",-1,ss_i,21669557,Abstract,3,test,gold,2399.0
4015,METHODS We used two complementary study designs : a ) between-groups comparisons based on randomized,stove,"assignment , and b ) before-and-after comparisons within control subjects who used open fires during the trial and received chimney stoves after the trial .","['METHODS', 'We', 'used', 'two', 'complementary', 'study', 'designs', ':', 'a', ')', 'between-groups', 'comparisons', 'based', 'on', 'randomized', 'stove', 'assignment', ',', 'and', 'b', ')', 'before-and-after', 'comparisons', 'within', 'control', 'subjects', 'who', 'used', 'open', 'fires', 'during', 'the', 'trial', 'and', 'received', 'chimney', 'stoves', 'after', 'the', 'trial', '.']","(15, 16)","(100, 105)",-1,hl_i,21669557,Abstract,3,test,gold,2407.0
4016,"METHODS We used two complementary study designs : a ) between-groups comparisons based on randomized stove assignment , and b ) before-and-after comparisons within control subjects who used",open fires,during the trial and received chimney stoves after the trial .,"['METHODS', 'We', 'used', 'two', 'complementary', 'study', 'designs', ':', 'a', ')', 'between-groups', 'comparisons', 'based', 'on', 'randomized', 'stove', 'assignment', ',', 'and', 'b', ')', 'before-and-after', 'comparisons', 'within', 'control', 'subjects', 'who', 'used', 'open', 'fires', 'during', 'the', 'trial', 'and', 'received', 'chimney', 'stoves', 'after', 'the', 'trial', '.']","(28, 30)","(189, 199)",-1,hl_i,21669557,Abstract,3,test,gold,734.0
4017,"METHODS We used two complementary study designs : a ) between-groups comparisons based on randomized stove assignment , and b ) before-and-after comparisons within control subjects who used open fires during the trial and received",chimney stoves,after the trial .,"['METHODS', 'We', 'used', 'two', 'complementary', 'study', 'designs', ':', 'a', ')', 'between-groups', 'comparisons', 'based', 'on', 'randomized', 'stove', 'assignment', ',', 'and', 'b', ')', 'before-and-after', 'comparisons', 'within', 'control', 'subjects', 'who', 'used', 'open', 'fires', 'during', 'the', 'trial', 'and', 'received', 'chimney', 'stoves', 'after', 'the', 'trial', '.']","(35, 37)","(230, 244)",-1,hl_i,21669557,Abstract,3,test,gold,2400.0
4018,Electrocardiogram sessions that lasted 20 hr were repeated up to three times among,"49 intervention and 70 control women 38-84 years of age , and 55 control subjects were also assessed after receiving stoves .",,"['Electrocardiogram', 'sessions', 'that', 'lasted', '20', 'hr', 'were', 'repeated', 'up', 'to', 'three', 'times', 'among', '49', 'intervention', 'and', '70', 'control', 'women', '38-84', 'years', 'of', 'age', ',', 'and', '55', 'control', 'subjects', 'were', 'also', 'assessed', 'after', 'receiving', 'stoves', '.']","(13, 35)","(82, 207)",-1,ss_p,21669557,Abstract,4,test,gold,5839.0
4019,"Electrocardiogram sessions that lasted 20 hr were repeated up to three times among 49 intervention and 70 control women 38-84 years of age , and 55 control subjects were also assessed after receiving",stoves .,,"['Electrocardiogram', 'sessions', 'that', 'lasted', '20', 'hr', 'were', 'repeated', 'up', 'to', 'three', 'times', 'among', '49', 'intervention', 'and', '70', 'control', 'women', '38-84', 'years', 'of', 'age', ',', 'and', '55', 'control', 'subjects', 'were', 'also', 'assessed', 'after', 'receiving', 'stoves', '.']","(33, 35)","(199, 207)",-1,ss_i,21669557,Abstract,4,test,gold,2408.0
4020,,Electrocardiogram sessions,"that lasted 20 hr were repeated up to three times among 49 intervention and 70 control women 38-84 years of age , and 55 control subjects were also assessed after receiving stoves .","['Electrocardiogram', 'sessions', 'that', 'lasted', '20', 'hr', 'were', 'repeated', 'up', 'to', 'three', 'times', 'among', '49', 'intervention', 'and', '70', 'control', 'women', '38-84', 'years', 'of', 'age', ',', 'and', '55', 'control', 'subjects', 'were', 'also', 'assessed', 'after', 'receiving', 'stoves', '.']","(0, 2)","(0, 26)",-1,ss_o,21669557,Abstract,4,test,gold,1274.0
4021,Electrocardiogram sessions that lasted 20 hr were repeated up to three times among,49,"intervention and 70 control women 38-84 years of age , and 55 control subjects were also assessed after receiving stoves .","['Electrocardiogram', 'sessions', 'that', 'lasted', '20', 'hr', 'were', 'repeated', 'up', 'to', 'three', 'times', 'among', '49', 'intervention', 'and', '70', 'control', 'women', '38-84', 'years', 'of', 'age', ',', 'and', '55', 'control', 'subjects', 'were', 'also', 'assessed', 'after', 'receiving', 'stoves', '.']","(13, 14)","(82, 84)",-1,hl_p,21669557,Abstract,4,test,gold,
4022,Electrocardiogram sessions that lasted 20 hr were repeated up to three times among 49 intervention and,70,"control women 38-84 years of age , and 55 control subjects were also assessed after receiving stoves .","['Electrocardiogram', 'sessions', 'that', 'lasted', '20', 'hr', 'were', 'repeated', 'up', 'to', 'three', 'times', 'among', '49', 'intervention', 'and', '70', 'control', 'women', '38-84', 'years', 'of', 'age', ',', 'and', '55', 'control', 'subjects', 'were', 'also', 'assessed', 'after', 'receiving', 'stoves', '.']","(16, 17)","(102, 104)",-1,hl_p,21669557,Abstract,4,test,gold,
4023,Electrocardiogram sessions that lasted 20 hr were repeated up to three times among 49 intervention and 70 control women,38-84 years of age,", and 55 control subjects were also assessed after receiving stoves .","['Electrocardiogram', 'sessions', 'that', 'lasted', '20', 'hr', 'were', 'repeated', 'up', 'to', 'three', 'times', 'among', '49', 'intervention', 'and', '70', 'control', 'women', '38-84', 'years', 'of', 'age', ',', 'and', '55', 'control', 'subjects', 'were', 'also', 'assessed', 'after', 'receiving', 'stoves', '.']","(19, 23)","(119, 137)",-1,hl_p,21669557,Abstract,4,test,gold,2020.0
4024,"Electrocardiogram sessions that lasted 20 hr were repeated up to three times among 49 intervention and 70 control women 38-84 years of age , and",55,control subjects were also assessed after receiving stoves .,"['Electrocardiogram', 'sessions', 'that', 'lasted', '20', 'hr', 'were', 'repeated', 'up', 'to', 'three', 'times', 'among', '49', 'intervention', 'and', '70', 'control', 'women', '38-84', 'years', 'of', 'age', ',', 'and', '55', 'control', 'subjects', 'were', 'also', 'assessed', 'after', 'receiving', 'stoves', '.']","(25, 26)","(144, 146)",-1,hl_p,21669557,Abstract,4,test,gold,
4025,"Electrocardiogram sessions that lasted 20 hr were repeated up to three times among 49 intervention and 70 control women 38-84 years of age , and 55 control subjects were also assessed after receiving",stoves .,,"['Electrocardiogram', 'sessions', 'that', 'lasted', '20', 'hr', 'were', 'repeated', 'up', 'to', 'three', 'times', 'among', '49', 'intervention', 'and', '70', 'control', 'women', '38-84', 'years', 'of', 'age', ',', 'and', '55', 'control', 'subjects', 'were', 'also', 'assessed', 'after', 'receiving', 'stoves', '.']","(33, 35)","(199, 207)",-1,hl_i,21669557,Abstract,4,test,gold,2409.0
4026,,HRV and ST-segment values,were assessed for each 30-min period .,"['HRV', 'and', 'ST-segment', 'values', 'were', 'assessed', 'for', 'each', '30-min', 'period', '.']","(0, 4)","(0, 25)",-1,ss_o,21669557,Abstract,5,test,gold,1352.0
4027,,HRV and ST-segment values,were assessed for each 30-min period .,"['HRV', 'and', 'ST-segment', 'values', 'were', 'assessed', 'for', 'each', '30-min', 'period', '.']","(0, 4)","(0, 25)",-1,hl_o,21669557,Abstract,5,test,gold,1353.0
4028,,ST-segment depression was defined as an average value below -1.00 mm .,,"['ST-segment', 'depression', 'was', 'defined', 'as', 'an', 'average', 'value', 'below', '-1.00', 'mm', '.']","(0, 12)","(0, 70)",-1,ss_o,21669557,Abstract,6,test,gold,6481.0
4029,,ST-segment depression,was defined as an average value below -1.00 mm .,"['ST-segment', 'depression', 'was', 'defined', 'as', 'an', 'average', 'value', 'below', '-1.00', 'mm', '.']","(0, 2)","(0, 21)",-1,hl_o,21669557,Abstract,6,test,gold,2548.0
4030,,Personal fine PM [ aerodynamic diameter ≤ 2.5 μm ( PM₂.₅ ] exposures,were measured for 24 hr before each electrocardiogram .,"['Personal', 'fine', 'PM', '[', 'aerodynamic', 'diameter', '≤', '2.5', 'μm', '(', 'PM₂.₅', ']', 'exposures', 'were', 'measured', 'for', '24', 'hr', 'before', 'each', 'electrocardiogram', '.']","(0, 13)","(0, 68)",-1,ss_o,21669557,Abstract,7,test,gold,6493.0
4031,Personal fine PM [ aerodynamic diameter ≤ 2.5 μm ( PM₂.₅ ] exposures were measured for 24 hr,before each electrocardiogram,.,"['Personal', 'fine', 'PM', '[', 'aerodynamic', 'diameter', '≤', '2.5', 'μm', '(', 'PM₂.₅', ']', 'exposures', 'were', 'measured', 'for', '24', 'hr', 'before', 'each', 'electrocardiogram', '.']","(18, 21)","(92, 121)",-1,ss_o,21669557,Abstract,7,test,gold,3214.0
4032,,RESULTS PM₂.₅,"exposure means were 266 and 102 μg/m³ during the trial period in the control and intervention groups , respectively .","['RESULTS', 'PM₂.₅', 'exposure', 'means', 'were', '266', 'and', '102', 'μg/m³', 'during', 'the', 'trial', 'period', 'in', 'the', 'control', 'and', 'intervention', 'groups', ',', 'respectively', '.']","(0, 2)","(0, 13)",-1,ss_o,21669557,Abstract,8,test,gold,364.0
4033,During,"the trial , the stove","intervention was associated with an odds ratio of 0.26 ( 95 % confidence interval , 0.08-0.90 ) for ST-segment depression .","['During', 'the', 'trial', ',', 'the', 'stove', 'intervention', 'was', 'associated', 'with', 'an', 'odds', 'ratio', 'of', '0.26', '(', '95', '%', 'confidence', 'interval', ',', '0.08-0.90', ')', 'for', 'ST-segment', 'depression', '.']","(1, 6)","(6, 27)",-1,ss_i,21669557,Abstract,9,test,gold,2403.0
4034,"During the trial , the stove intervention was associated with an odds ratio of 0.26 ( 95 % confidence interval ,",0.08-0.90 ) for ST-segment,depression .,"['During', 'the', 'trial', ',', 'the', 'stove', 'intervention', 'was', 'associated', 'with', 'an', 'odds', 'ratio', 'of', '0.26', '(', '95', '%', 'confidence', 'interval', ',', '0.08-0.90', ')', 'for', 'ST-segment', 'depression', '.']","(21, 25)","(112, 138)",-1,ss_o,21669557,Abstract,9,test,gold,1189.0
4035,We found similar associations with the before-and-after comparison .,,,"['We', 'found', 'similar', 'associations', 'with', 'the', 'before-and-after', 'comparison', '.']",,,,,21669557,Abstract,10,test,gold,
4036,The intervention was not significantly,associated,with HRV .,"['The', 'intervention', 'was', 'not', 'significantly', 'associated', 'with', 'HRV', '.']","(5, 6)","(38, 48)",-1,ss_o,21669557,Abstract,11,test,gold,1210.0
4037,,CONCLUSIONS The stove,"intervention was associated with reduced occurrence of nonspecific ST-segment depression , suggesting that household wood smoke exposures affect ventricular repolarization and potentially cardiovascular health .","['CONCLUSIONS', 'The', 'stove', 'intervention', 'was', 'associated', 'with', 'reduced', 'occurrence', 'of', 'nonspecific', 'ST-segment', 'depression', ',', 'suggesting', 'that', 'household', 'wood', 'smoke', 'exposures', 'affect', 'ventricular', 'repolarization', 'and', 'potentially', 'cardiovascular', 'health', '.']","(0, 3)","(0, 21)",-1,ss_i,21669557,Abstract,12,test,gold,431.0
4038,CONCLUSIONS The stove intervention was associated with reduced occurrence,of nonspecific ST-segment,"depression , suggesting that household wood smoke exposures affect ventricular repolarization and potentially cardiovascular health .","['CONCLUSIONS', 'The', 'stove', 'intervention', 'was', 'associated', 'with', 'reduced', 'occurrence', 'of', 'nonspecific', 'ST-segment', 'depression', ',', 'suggesting', 'that', 'household', 'wood', 'smoke', 'exposures', 'affect', 'ventricular', 'repolarization', 'and', 'potentially', 'cardiovascular', 'health', '.']","(9, 12)","(73, 98)",-1,ss_o,21669557,Abstract,12,test,gold,1397.0
4039,Insulin pump therapy started at the time of diagnosis : effects on glycemic control and pancreatic β-cell function,in type 1 diabetes,.,"['Insulin', 'pump', 'therapy', 'started', 'at', 'the', 'time', 'of', 'diagnosis', ':', 'effects', 'on', 'glycemic', 'control', 'and', 'pancreatic', 'β-cell', 'function', 'in', 'type', '1', 'diabetes', '.']","(18, 22)","(114, 132)",-1,ss_p,21718094,Title,0,test,gold,6901.0
4040,,Insulin pump,therapy started at the time of diagnosis : effects on glycemic control and pancreatic β-cell function in type 1 diabetes .,"['Insulin', 'pump', 'therapy', 'started', 'at', 'the', 'time', 'of', 'diagnosis', ':', 'effects', 'on', 'glycemic', 'control', 'and', 'pancreatic', 'β-cell', 'function', 'in', 'type', '1', 'diabetes', '.']","(0, 2)","(0, 12)",-1,ss_i,21718094,Title,0,test,gold,4893.0
4041,Insulin pump therapy started at the time of diagnosis : effects on,glycemic control and pancreatic β-cell function,in type 1 diabetes .,"['Insulin', 'pump', 'therapy', 'started', 'at', 'the', 'time', 'of', 'diagnosis', ':', 'effects', 'on', 'glycemic', 'control', 'and', 'pancreatic', 'β-cell', 'function', 'in', 'type', '1', 'diabetes', '.']","(12, 18)","(66, 113)",-1,ss_o,21718094,Title,0,test,gold,1559.0
4042,Insulin pump therapy started at the time of diagnosis : effects on glycemic control and pancreatic β-cell function in,type 1 diabetes,.,"['Insulin', 'pump', 'therapy', 'started', 'at', 'the', 'time', 'of', 'diagnosis', ':', 'effects', 'on', 'glycemic', 'control', 'and', 'pancreatic', 'β-cell', 'function', 'in', 'type', '1', 'diabetes', '.']","(19, 22)","(117, 132)",-1,hl_p,21718094,Title,0,test,gold,6902.0
4043,,Insulin pump,therapy started at the time of diagnosis : effects on glycemic control and pancreatic β-cell function in type 1 diabetes .,"['Insulin', 'pump', 'therapy', 'started', 'at', 'the', 'time', 'of', 'diagnosis', ':', 'effects', 'on', 'glycemic', 'control', 'and', 'pancreatic', 'β-cell', 'function', 'in', 'type', '1', 'diabetes', '.']","(0, 2)","(0, 12)",-1,hl_i,21718094,Title,0,test,gold,4894.0
4044,Insulin pump therapy started at the time of diagnosis : effects on,glycemic control,and pancreatic β-cell function in type 1 diabetes .,"['Insulin', 'pump', 'therapy', 'started', 'at', 'the', 'time', 'of', 'diagnosis', ':', 'effects', 'on', 'glycemic', 'control', 'and', 'pancreatic', 'β-cell', 'function', 'in', 'type', '1', 'diabetes', '.']","(12, 14)","(66, 82)",-1,hl_o,21718094,Title,0,test,gold,1561.0
4045,Insulin pump therapy started at the time of diagnosis : effects on glycemic control and,pancreatic β-cell function,in type 1 diabetes .,"['Insulin', 'pump', 'therapy', 'started', 'at', 'the', 'time', 'of', 'diagnosis', ':', 'effects', 'on', 'glycemic', 'control', 'and', 'pancreatic', 'β-cell', 'function', 'in', 'type', '1', 'diabetes', '.']","(15, 18)","(87, 113)",-1,hl_o,21718094,Title,0,test,gold,1366.0
4046,BACKGROUND In the interest of preserving residual insulin secretory capacity present at the time of diagnosis,with type 1 diabetes ( T1D ),", we compared the efficacy of starting insulin pump therapy at diagnosis with standard multiple daily insulin injections ( MDIs ) .","['BACKGROUND', 'In', 'the', 'interest', 'of', 'preserving', 'residual', 'insulin', 'secretory', 'capacity', 'present', 'at', 'the', 'time', 'of', 'diagnosis', 'with', 'type', '1', 'diabetes', '(', 'T1D', ')', ',', 'we', 'compared', 'the', 'efficacy', 'of', 'starting', 'insulin', 'pump', 'therapy', 'at', 'diagnosis', 'with', 'standard', 'multiple', 'daily', 'insulin', 'injections', '(', 'MDIs', ')', '.']","(16, 23)","(109, 137)",-1,ss_p,21718094,Abstract,0,test,gold,6904.0
4047,"BACKGROUND In the interest of preserving residual insulin secretory capacity present at the time of diagnosis with type 1 diabetes ( T1D ) , we compared the efficacy of",starting insulin pump,therapy at diagnosis with standard multiple daily insulin injections ( MDIs ) .,"['BACKGROUND', 'In', 'the', 'interest', 'of', 'preserving', 'residual', 'insulin', 'secretory', 'capacity', 'present', 'at', 'the', 'time', 'of', 'diagnosis', 'with', 'type', '1', 'diabetes', '(', 'T1D', ')', ',', 'we', 'compared', 'the', 'efficacy', 'of', 'starting', 'insulin', 'pump', 'therapy', 'at', 'diagnosis', 'with', 'standard', 'multiple', 'daily', 'insulin', 'injections', '(', 'MDIs', ')', '.']","(29, 32)","(168, 189)",-1,ss_i,21718094,Abstract,0,test,gold,4897.0
4048,"BACKGROUND In the interest of preserving residual insulin secretory capacity present at the time of diagnosis with type 1 diabetes ( T1D ) , we compared the efficacy of starting insulin pump therapy at diagnosis with standard multiple",daily insulin,injections ( MDIs ) .,"['BACKGROUND', 'In', 'the', 'interest', 'of', 'preserving', 'residual', 'insulin', 'secretory', 'capacity', 'present', 'at', 'the', 'time', 'of', 'diagnosis', 'with', 'type', '1', 'diabetes', '(', 'T1D', ')', ',', 'we', 'compared', 'the', 'efficacy', 'of', 'starting', 'insulin', 'pump', 'therapy', 'at', 'diagnosis', 'with', 'standard', 'multiple', 'daily', 'insulin', 'injections', '(', 'MDIs', ')', '.']","(38, 40)","(234, 247)",-1,ss_i,21718094,Abstract,0,test,gold,4898.0
4049,"BACKGROUND In the interest of preserving residual insulin secretory capacity present at the time of diagnosis with type 1 diabetes ( T1D ) , we compared",the efficacy,of starting insulin pump therapy at diagnosis with standard multiple daily insulin injections ( MDIs ) .,"['BACKGROUND', 'In', 'the', 'interest', 'of', 'preserving', 'residual', 'insulin', 'secretory', 'capacity', 'present', 'at', 'the', 'time', 'of', 'diagnosis', 'with', 'type', '1', 'diabetes', '(', 'T1D', ')', ',', 'we', 'compared', 'the', 'efficacy', 'of', 'starting', 'insulin', 'pump', 'therapy', 'at', 'diagnosis', 'with', 'standard', 'multiple', 'daily', 'insulin', 'injections', '(', 'MDIs', ')', '.']","(26, 28)","(152, 164)",-1,ss_o,21718094,Abstract,0,test,gold,4779.0
4050,BACKGROUND In the interest of preserving residual insulin secretory capacity present at the time of diagnosis with,type 1 diabetes ( T1D ),", we compared the efficacy of starting insulin pump therapy at diagnosis with standard multiple daily insulin injections ( MDIs ) .","['BACKGROUND', 'In', 'the', 'interest', 'of', 'preserving', 'residual', 'insulin', 'secretory', 'capacity', 'present', 'at', 'the', 'time', 'of', 'diagnosis', 'with', 'type', '1', 'diabetes', '(', 'T1D', ')', ',', 'we', 'compared', 'the', 'efficacy', 'of', 'starting', 'insulin', 'pump', 'therapy', 'at', 'diagnosis', 'with', 'standard', 'multiple', 'daily', 'insulin', 'injections', '(', 'MDIs', ')', '.']","(17, 23)","(114, 137)",-1,hl_p,21718094,Abstract,0,test,gold,6905.0
4051,"METHODS We conducted a prospective , randomized , pilot trial comparing MDI therapy with continuous subcutaneous insulin therapy ( pump therapy )","in 24 patients , 8-18 years old , with newly diagnosed T1D",.,"['METHODS', 'We', 'conducted', 'a', 'prospective', ',', 'randomized', ',', 'pilot', 'trial', 'comparing', 'MDI', 'therapy', 'with', 'continuous', 'subcutaneous', 'insulin', 'therapy', '(', 'pump', 'therapy', ')', 'in', '24', 'patients', ',', '8-18', 'years', 'old', ',', 'with', 'newly', 'diagnosed', 'T1D', '.']","(22, 34)","(145, 203)",-1,ss_p,21718094,Abstract,1,test,gold,7005.0
4052,"METHODS We conducted a prospective , randomized , pilot trial",comparing MDI,"therapy with continuous subcutaneous insulin therapy ( pump therapy ) in 24 patients , 8-18 years old , with newly diagnosed T1D .","['METHODS', 'We', 'conducted', 'a', 'prospective', ',', 'randomized', ',', 'pilot', 'trial', 'comparing', 'MDI', 'therapy', 'with', 'continuous', 'subcutaneous', 'insulin', 'therapy', '(', 'pump', 'therapy', ')', 'in', '24', 'patients', ',', '8-18', 'years', 'old', ',', 'with', 'newly', 'diagnosed', 'T1D', '.']","(10, 12)","(61, 74)",-1,ss_i,21718094,Abstract,1,test,gold,1310.0
4053,"METHODS We conducted a prospective , randomized , pilot trial comparing MDI therapy with continuous",subcutaneous insulin therapy ( pump therapy ),"in 24 patients , 8-18 years old , with newly diagnosed T1D .","['METHODS', 'We', 'conducted', 'a', 'prospective', ',', 'randomized', ',', 'pilot', 'trial', 'comparing', 'MDI', 'therapy', 'with', 'continuous', 'subcutaneous', 'insulin', 'therapy', '(', 'pump', 'therapy', ')', 'in', '24', 'patients', ',', '8-18', 'years', 'old', ',', 'with', 'newly', 'diagnosed', 'T1D', '.']","(15, 22)","(99, 144)",-1,ss_i,21718094,Abstract,1,test,gold,4887.0
4054,"METHODS We conducted a prospective , randomized , pilot trial comparing MDI therapy with continuous subcutaneous insulin therapy ( pump therapy ) in",24,"patients , 8-18 years old , with newly diagnosed T1D .","['METHODS', 'We', 'conducted', 'a', 'prospective', ',', 'randomized', ',', 'pilot', 'trial', 'comparing', 'MDI', 'therapy', 'with', 'continuous', 'subcutaneous', 'insulin', 'therapy', '(', 'pump', 'therapy', ')', 'in', '24', 'patients', ',', '8-18', 'years', 'old', ',', 'with', 'newly', 'diagnosed', 'T1D', '.']","(23, 24)","(148, 150)",-1,hl_p,21718094,Abstract,1,test,gold,
4055,"METHODS We conducted a prospective , randomized , pilot trial comparing MDI therapy with continuous subcutaneous insulin therapy ( pump therapy ) in 24 patients ,",8-18 years old,", with newly diagnosed T1D .","['METHODS', 'We', 'conducted', 'a', 'prospective', ',', 'randomized', ',', 'pilot', 'trial', 'comparing', 'MDI', 'therapy', 'with', 'continuous', 'subcutaneous', 'insulin', 'therapy', '(', 'pump', 'therapy', ')', 'in', '24', 'patients', ',', '8-18', 'years', 'old', ',', 'with', 'newly', 'diagnosed', 'T1D', '.']","(26, 29)","(162, 176)",-1,hl_p,21718094,Abstract,1,test,gold,2025.0
4056,"METHODS We conducted a prospective , randomized , pilot trial comparing MDI therapy with continuous subcutaneous insulin therapy ( pump therapy ) in 24 patients , 8-18 years old , with",newly diagnosed T1D,.,"['METHODS', 'We', 'conducted', 'a', 'prospective', ',', 'randomized', ',', 'pilot', 'trial', 'comparing', 'MDI', 'therapy', 'with', 'continuous', 'subcutaneous', 'insulin', 'therapy', '(', 'pump', 'therapy', ')', 'in', '24', 'patients', ',', '8-18', 'years', 'old', ',', 'with', 'newly', 'diagnosed', 'T1D', '.']","(31, 34)","(184, 203)",-1,hl_p,21718094,Abstract,1,test,gold,7006.0
4057,"METHODS We conducted a prospective , randomized , pilot trial comparing MDI therapy with continuous subcutaneous",insulin therapy ( pump therapy ),"in 24 patients , 8-18 years old , with newly diagnosed T1D .","['METHODS', 'We', 'conducted', 'a', 'prospective', ',', 'randomized', ',', 'pilot', 'trial', 'comparing', 'MDI', 'therapy', 'with', 'continuous', 'subcutaneous', 'insulin', 'therapy', '(', 'pump', 'therapy', ')', 'in', '24', 'patients', ',', '8-18', 'years', 'old', ',', 'with', 'newly', 'diagnosed', 'T1D', '.']","(16, 22)","(112, 144)",-1,hl_i,21718094,Abstract,1,test,gold,4888.0
4058,"Subjects were evaluated at enrollment and 1 , 3 , 6 , 9 , and 12 months after initial diagnosis of T1D",.,,"['Subjects', 'were', 'evaluated', 'at', 'enrollment', 'and', '1', ',', '3', ',', '6', ',', '9', ',', 'and', '12', 'months', 'after', 'initial', 'diagnosis', 'of', 'T1D', '.']","(22, 23)","(102, 103)",-1,ss_o,21718094,Abstract,2,test,gold,
4059,,"Preservation of insulin secretion , measured by mixed-meal-stimulated C-peptide secretion",", was compared after 6 and 12 months of treatment .","['Preservation', 'of', 'insulin', 'secretion', ',', 'measured', 'by', 'mixed-meal-stimulated', 'C-peptide', 'secretion', ',', 'was', 'compared', 'after', '6', 'and', '12', 'months', 'of', 'treatment', '.']","(0, 10)","(0, 89)",-1,ss_o,21718094,Abstract,3,test,gold,6603.0
4060,,Preservation of insulin secretion,", measured by mixed-meal-stimulated C-peptide secretion , was compared after 6 and 12 months of treatment .","['Preservation', 'of', 'insulin', 'secretion', ',', 'measured', 'by', 'mixed-meal-stimulated', 'C-peptide', 'secretion', ',', 'was', 'compared', 'after', '6', 'and', '12', 'months', 'of', 'treatment', '.']","(0, 4)","(0, 33)",-1,hl_o,21718094,Abstract,3,test,gold,6604.0
4061,"Preservation of insulin secretion , measured",by mixed-meal-stimulated C-peptide secretion,", was compared after 6 and 12 months of treatment .","['Preservation', 'of', 'insulin', 'secretion', ',', 'measured', 'by', 'mixed-meal-stimulated', 'C-peptide', 'secretion', ',', 'was', 'compared', 'after', '6', 'and', '12', 'months', 'of', 'treatment', '.']","(6, 10)","(44, 88)",-1,hl_o,21718094,Abstract,3,test,gold,3176.0
4062,Between-group differences,"in glycosylated hemoglobin ( HbA1c ) , continuous glucose sensor data , insulin utilization , anthropometric measures , and patient satisfaction with therapy",were also compared at multiple time points .,"['Between-group', 'differences', 'in', 'glycosylated', 'hemoglobin', '(', 'HbA1c', ')', ',', 'continuous', 'glucose', 'sensor', 'data', ',', 'insulin', 'utilization', ',', 'anthropometric', 'measures', ',', 'and', 'patient', 'satisfaction', 'with', 'therapy', 'were', 'also', 'compared', 'at', 'multiple', 'time', 'points', '.']","(2, 25)","(25, 182)",-1,ss_o,21718094,Abstract,4,test,gold,5813.0
4063,Between-group differences in,"glycosylated hemoglobin ( HbA1c ) , continuous glucose sensor data , insulin utilization , anthropometric measures , and patient satisfaction",with therapy were also compared at multiple time points .,"['Between-group', 'differences', 'in', 'glycosylated', 'hemoglobin', '(', 'HbA1c', ')', ',', 'continuous', 'glucose', 'sensor', 'data', ',', 'insulin', 'utilization', ',', 'anthropometric', 'measures', ',', 'and', 'patient', 'satisfaction', 'with', 'therapy', 'were', 'also', 'compared', 'at', 'multiple', 'time', 'points', '.']","(3, 23)","(28, 169)",-1,hl_o,21718094,Abstract,4,test,gold,5814.0
4064,RESULTS Initiation,of pump therapy,"within 1 month of diagnosis resulted in consistently higher mixed-meal tolerance test-stimulated C-peptide values at all time points , although these differences were not statistically significant .","['RESULTS', 'Initiation', 'of', 'pump', 'therapy', 'within', '1', 'month', 'of', 'diagnosis', 'resulted', 'in', 'consistently', 'higher', 'mixed-meal', 'tolerance', 'test-stimulated', 'C-peptide', 'values', 'at', 'all', 'time', 'points', ',', 'although', 'these', 'differences', 'were', 'not', 'statistically', 'significant', '.']","(2, 5)","(18, 33)",-1,ss_i,21718094,Abstract,5,test,gold,4214.0
4065,RESULTS Initiation of pump therapy within 1 month of diagnosis resulted in consistently,higher mixed-meal tolerance test-stimulated C-peptide values,"at all time points , although these differences were not statistically significant .","['RESULTS', 'Initiation', 'of', 'pump', 'therapy', 'within', '1', 'month', 'of', 'diagnosis', 'resulted', 'in', 'consistently', 'higher', 'mixed-meal', 'tolerance', 'test-stimulated', 'C-peptide', 'values', 'at', 'all', 'time', 'points', ',', 'although', 'these', 'differences', 'were', 'not', 'statistically', 'significant', '.']","(13, 19)","(87, 147)",-1,ss_o,21718094,Abstract,5,test,gold,1354.0
4066,RESULTS Initiation of pump therapy within 1 month of diagnosis resulted in consistently higher,mixed-meal tolerance,"test-stimulated C-peptide values at all time points , although these differences were not statistically significant .","['RESULTS', 'Initiation', 'of', 'pump', 'therapy', 'within', '1', 'month', 'of', 'diagnosis', 'resulted', 'in', 'consistently', 'higher', 'mixed-meal', 'tolerance', 'test-stimulated', 'C-peptide', 'values', 'at', 'all', 'time', 'points', ',', 'although', 'these', 'differences', 'were', 'not', 'statistically', 'significant', '.']","(14, 16)","(94, 114)",-1,hl_o,21718094,Abstract,5,test,gold,1355.0
4067,RESULTS Initiation of pump therapy within 1 month of diagnosis resulted in consistently higher mixed-meal tolerance test-stimulated,C-peptide values,"at all time points , although these differences were not statistically significant .","['RESULTS', 'Initiation', 'of', 'pump', 'therapy', 'within', '1', 'month', 'of', 'diagnosis', 'resulted', 'in', 'consistently', 'higher', 'mixed-meal', 'tolerance', 'test-stimulated', 'C-peptide', 'values', 'at', 'all', 'time', 'points', ',', 'although', 'these', 'differences', 'were', 'not', 'statistically', 'significant', '.']","(17, 19)","(131, 147)",-1,hl_o,21718094,Abstract,5,test,gold,1196.0
4068,"Nonetheless , improved glycemic control was observed",in insulin,"pump-treated subjects ( more time spent with normoglycemia , better mean HbA1c ) , and pump-treated subjects reported comparatively greater satisfaction with route of treatment administration .","['Nonetheless', ',', 'improved', 'glycemic', 'control', 'was', 'observed', 'in', 'insulin', 'pump-treated', 'subjects', '(', 'more', 'time', 'spent', 'with', 'normoglycemia', ',', 'better', 'mean', 'HbA1c', ')', ',', 'and', 'pump-treated', 'subjects', 'reported', 'comparatively', 'greater', 'satisfaction', 'with', 'route', 'of', 'treatment', 'administration', '.']","(7, 9)","(52, 62)",-1,ss_i,21718094,Abstract,6,test,gold,4899.0
4069,"Nonetheless ,",improved glycemic control,"was observed in insulin pump-treated subjects ( more time spent with normoglycemia , better mean HbA1c ) , and pump-treated subjects reported comparatively greater satisfaction with route of treatment administration .","['Nonetheless', ',', 'improved', 'glycemic', 'control', 'was', 'observed', 'in', 'insulin', 'pump-treated', 'subjects', '(', 'more', 'time', 'spent', 'with', 'normoglycemia', ',', 'better', 'mean', 'HbA1c', ')', ',', 'and', 'pump-treated', 'subjects', 'reported', 'comparatively', 'greater', 'satisfaction', 'with', 'route', 'of', 'treatment', 'administration', '.']","(2, 5)","(13, 38)",-1,ss_o,21718094,Abstract,6,test,gold,1563.0
4070,"Nonetheless , improved glycemic control was observed in insulin pump-treated subjects ( more time spent with normoglycemia , better",mean HbA1c ),", and pump-treated subjects reported comparatively greater satisfaction with route of treatment administration .","['Nonetheless', ',', 'improved', 'glycemic', 'control', 'was', 'observed', 'in', 'insulin', 'pump-treated', 'subjects', '(', 'more', 'time', 'spent', 'with', 'normoglycemia', ',', 'better', 'mean', 'HbA1c', ')', ',', 'and', 'pump-treated', 'subjects', 'reported', 'comparatively', 'greater', 'satisfaction', 'with', 'route', 'of', 'treatment', 'administration', '.']","(19, 22)","(131, 143)",-1,ss_o,21718094,Abstract,6,test,gold,1661.0
4071,"Nonetheless , improved glycemic control was observed in insulin pump-treated subjects ( more time spent with normoglycemia , better mean HbA1c ) , and pump-treated subjects reported comparatively",greater satisfaction,with route of treatment administration .,"['Nonetheless', ',', 'improved', 'glycemic', 'control', 'was', 'observed', 'in', 'insulin', 'pump-treated', 'subjects', '(', 'more', 'time', 'spent', 'with', 'normoglycemia', ',', 'better', 'mean', 'HbA1c', ')', ',', 'and', 'pump-treated', 'subjects', 'reported', 'comparatively', 'greater', 'satisfaction', 'with', 'route', 'of', 'treatment', 'administration', '.']","(28, 30)","(195, 215)",-1,ss_o,21718094,Abstract,6,test,gold,984.0
4072,"Nonetheless , improved",glycemic control,"was observed in insulin pump-treated subjects ( more time spent with normoglycemia , better mean HbA1c ) , and pump-treated subjects reported comparatively greater satisfaction with route of treatment administration .","['Nonetheless', ',', 'improved', 'glycemic', 'control', 'was', 'observed', 'in', 'insulin', 'pump-treated', 'subjects', '(', 'more', 'time', 'spent', 'with', 'normoglycemia', ',', 'better', 'mean', 'HbA1c', ')', ',', 'and', 'pump-treated', 'subjects', 'reported', 'comparatively', 'greater', 'satisfaction', 'with', 'route', 'of', 'treatment', 'administration', '.']","(3, 5)","(22, 38)",-1,hl_o,21718094,Abstract,6,test,gold,1562.0
4073,CONCLUSIONS Initiation,of insulin pump therapy,"at diagnosis improved glycemic control , was well tolerated , and contributed to improved patient satisfaction with treatment .","['CONCLUSIONS', 'Initiation', 'of', 'insulin', 'pump', 'therapy', 'at', 'diagnosis', 'improved', 'glycemic', 'control', ',', 'was', 'well', 'tolerated', ',', 'and', 'contributed', 'to', 'improved', 'patient', 'satisfaction', 'with', 'treatment', '.']","(2, 6)","(22, 45)",-1,ss_i,21718094,Abstract,7,test,gold,4889.0
4074,CONCLUSIONS Initiation of insulin pump therapy at diagnosis,improved glycemic control,", was well tolerated , and contributed to improved patient satisfaction with treatment .","['CONCLUSIONS', 'Initiation', 'of', 'insulin', 'pump', 'therapy', 'at', 'diagnosis', 'improved', 'glycemic', 'control', ',', 'was', 'well', 'tolerated', ',', 'and', 'contributed', 'to', 'improved', 'patient', 'satisfaction', 'with', 'treatment', '.']","(8, 11)","(59, 84)",-1,ss_o,21718094,Abstract,7,test,gold,1564.0
4075,"CONCLUSIONS Initiation of insulin pump therapy at diagnosis improved glycemic control , was well tolerated , and contributed to",improved patient satisfaction,with treatment .,"['CONCLUSIONS', 'Initiation', 'of', 'insulin', 'pump', 'therapy', 'at', 'diagnosis', 'improved', 'glycemic', 'control', ',', 'was', 'well', 'tolerated', ',', 'and', 'contributed', 'to', 'improved', 'patient', 'satisfaction', 'with', 'treatment', '.']","(19, 22)","(127, 156)",-1,ss_o,21718094,Abstract,7,test,gold,3845.0
4076,CONCLUSIONS Initiation of,insulin pump therapy,"at diagnosis improved glycemic control , was well tolerated , and contributed to improved patient satisfaction with treatment .","['CONCLUSIONS', 'Initiation', 'of', 'insulin', 'pump', 'therapy', 'at', 'diagnosis', 'improved', 'glycemic', 'control', ',', 'was', 'well', 'tolerated', ',', 'and', 'contributed', 'to', 'improved', 'patient', 'satisfaction', 'with', 'treatment', '.']","(3, 6)","(25, 45)",-1,hl_i,21718094,Abstract,7,test,gold,4890.0
4077,CONCLUSIONS Initiation of insulin pump therapy at diagnosis improved,glycemic control,", was well tolerated , and contributed to improved patient satisfaction with treatment .","['CONCLUSIONS', 'Initiation', 'of', 'insulin', 'pump', 'therapy', 'at', 'diagnosis', 'improved', 'glycemic', 'control', ',', 'was', 'well', 'tolerated', ',', 'and', 'contributed', 'to', 'improved', 'patient', 'satisfaction', 'with', 'treatment', '.']","(9, 11)","(68, 84)",-1,hl_o,21718094,Abstract,7,test,gold,1560.0
4078,This study also suggests that earlier use of pump therapy might help to,preserve residual β-cell function,", although a larger clinical trial would be required to confirm this .","['This', 'study', 'also', 'suggests', 'that', 'earlier', 'use', 'of', 'pump', 'therapy', 'might', 'help', 'to', 'preserve', 'residual', 'β-cell', 'function', ',', 'although', 'a', 'larger', 'clinical', 'trial', 'would', 'be', 'required', 'to', 'confirm', 'this', '.']","(13, 17)","(71, 104)",-1,ss_o,21718094,Abstract,8,test,gold,1367.0
4079,[ Clinical study on treatment of,endometriosis-related infertility patients,by laparoscopic surgery in combination of quyu jiedu recipe ] .,"['[', 'Clinical', 'study', 'on', 'treatment', 'of', 'endometriosis-related', 'infertility', 'patients', 'by', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'quyu', 'jiedu', 'recipe', ']', '.']","(6, 9)","(32, 74)",-1,ss_p,21866656,Title,0,test,gold,3783.0
4080,[ Clinical study on treatment of endometriosis-related infertility patients by,laparoscopic surgery,in combination of quyu jiedu recipe ] .,"['[', 'Clinical', 'study', 'on', 'treatment', 'of', 'endometriosis-related', 'infertility', 'patients', 'by', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'quyu', 'jiedu', 'recipe', ']', '.']","(10, 12)","(78, 98)",-1,ss_i,21866656,Title,0,test,gold,3653.0
4081,[ Clinical study on treatment of endometriosis-related infertility patients by laparoscopic surgery in combination of,quyu jiedu recipe ],.,"['[', 'Clinical', 'study', 'on', 'treatment', 'of', 'endometriosis-related', 'infertility', 'patients', 'by', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'quyu', 'jiedu', 'recipe', ']', '.']","(15, 19)","(117, 136)",-1,ss_i,21866656,Title,0,test,gold,262.0
4082,[ Clinical study on treatment of,endometriosis-related infertility patients,by laparoscopic surgery in combination of quyu jiedu recipe ] .,"['[', 'Clinical', 'study', 'on', 'treatment', 'of', 'endometriosis-related', 'infertility', 'patients', 'by', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'quyu', 'jiedu', 'recipe', ']', '.']","(6, 9)","(32, 74)",-1,hl_p,21866656,Title,0,test,gold,3784.0
4083,[ Clinical study on treatment of endometriosis-related infertility patients by,laparoscopic surgery,in combination of quyu jiedu recipe ] .,"['[', 'Clinical', 'study', 'on', 'treatment', 'of', 'endometriosis-related', 'infertility', 'patients', 'by', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'quyu', 'jiedu', 'recipe', ']', '.']","(10, 12)","(78, 98)",-1,hl_i,21866656,Title,0,test,gold,3654.0
4084,[ Clinical study on treatment of endometriosis-related infertility patients by laparoscopic surgery in combination of,quyu jiedu recipe ],.,"['[', 'Clinical', 'study', 'on', 'treatment', 'of', 'endometriosis-related', 'infertility', 'patients', 'by', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'quyu', 'jiedu', 'recipe', ']', '.']","(15, 19)","(117, 136)",-1,hl_i,21866656,Title,0,test,gold,263.0
4085,OBJECTIVE To study the clinical efficacy of the laparoscopic surgery in combination of Quyu Jiedu Recipe ( QYJDR ) on,endometriosis ( EMs ) -related infertility patients .,,"['OBJECTIVE', 'To', 'study', 'the', 'clinical', 'efficacy', 'of', 'the', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'Quyu', 'Jiedu', 'Recipe', '(', 'QYJDR', ')', 'on', 'endometriosis', '(', 'EMs', ')', '-related', 'infertility', 'patients', '.']","(20, 28)","(117, 170)",-1,ss_p,21866656,Abstract,0,test,gold,7051.0
4086,OBJECTIVE To study the clinical efficacy of the,laparoscopic surgery,in combination of Quyu Jiedu Recipe ( QYJDR ) on endometriosis ( EMs ) -related infertility patients .,"['OBJECTIVE', 'To', 'study', 'the', 'clinical', 'efficacy', 'of', 'the', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'Quyu', 'Jiedu', 'Recipe', '(', 'QYJDR', ')', 'on', 'endometriosis', '(', 'EMs', ')', '-related', 'infertility', 'patients', '.']","(8, 10)","(47, 67)",-1,ss_i,21866656,Abstract,0,test,gold,3652.0
4087,OBJECTIVE To study the clinical efficacy of the laparoscopic surgery in combination of,Quyu Jiedu Recipe ( QYJDR ),on endometriosis ( EMs ) -related infertility patients .,"['OBJECTIVE', 'To', 'study', 'the', 'clinical', 'efficacy', 'of', 'the', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'Quyu', 'Jiedu', 'Recipe', '(', 'QYJDR', ')', 'on', 'endometriosis', '(', 'EMs', ')', '-related', 'infertility', 'patients', '.']","(13, 19)","(86, 113)",-1,ss_i,21866656,Abstract,0,test,gold,264.0
4088,OBJECTIVE To study the,clinical efficacy,of the laparoscopic surgery in combination of Quyu Jiedu Recipe ( QYJDR ) on endometriosis ( EMs ) -related infertility patients .,"['OBJECTIVE', 'To', 'study', 'the', 'clinical', 'efficacy', 'of', 'the', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'Quyu', 'Jiedu', 'Recipe', '(', 'QYJDR', ')', 'on', 'endometriosis', '(', 'EMs', ')', '-related', 'infertility', 'patients', '.']","(4, 6)","(22, 39)",-1,ss_o,21866656,Abstract,0,test,gold,4854.0
4089,OBJECTIVE To study the clinical efficacy of the laparoscopic surgery in combination of Quyu Jiedu Recipe ( QYJDR ) on,endometriosis ( EMs ) -related infertility patients .,,"['OBJECTIVE', 'To', 'study', 'the', 'clinical', 'efficacy', 'of', 'the', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'Quyu', 'Jiedu', 'Recipe', '(', 'QYJDR', ')', 'on', 'endometriosis', '(', 'EMs', ')', '-related', 'infertility', 'patients', '.']","(20, 28)","(117, 170)",-1,hl_p,21866656,Abstract,0,test,gold,7052.0
4090,OBJECTIVE To study the clinical efficacy of the,laparoscopic surgery,in combination of Quyu Jiedu Recipe ( QYJDR ) on endometriosis ( EMs ) -related infertility patients .,"['OBJECTIVE', 'To', 'study', 'the', 'clinical', 'efficacy', 'of', 'the', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'Quyu', 'Jiedu', 'Recipe', '(', 'QYJDR', ')', 'on', 'endometriosis', '(', 'EMs', ')', '-related', 'infertility', 'patients', '.']","(8, 10)","(47, 67)",-1,hl_i,21866656,Abstract,0,test,gold,3651.0
4091,OBJECTIVE To study the clinical efficacy of the laparoscopic surgery in combination of,Quyu Jiedu Recipe ( QYJDR ),on endometriosis ( EMs ) -related infertility patients .,"['OBJECTIVE', 'To', 'study', 'the', 'clinical', 'efficacy', 'of', 'the', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'Quyu', 'Jiedu', 'Recipe', '(', 'QYJDR', ')', 'on', 'endometriosis', '(', 'EMs', ')', '-related', 'infertility', 'patients', '.']","(13, 19)","(86, 113)",-1,hl_i,21866656,Abstract,0,test,gold,265.0
4092,OBJECTIVE To study the,clinical efficacy,of the laparoscopic surgery in combination of Quyu Jiedu Recipe ( QYJDR ) on endometriosis ( EMs ) -related infertility patients .,"['OBJECTIVE', 'To', 'study', 'the', 'clinical', 'efficacy', 'of', 'the', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'Quyu', 'Jiedu', 'Recipe', '(', 'QYJDR', ')', 'on', 'endometriosis', '(', 'EMs', ')', '-related', 'infertility', 'patients', '.']","(4, 6)","(22, 39)",-1,hl_o,21866656,Abstract,0,test,gold,4855.0
4093,METHODS,130 EMs-related infertility patients of blood stasis and toxin accumulation syndrome diagnosed and treated by laparoscopic surgery,"were randomly assigned to two groups , i.e. , the test group ( 75 cases ) and the control group ( 55 cases ) .","['METHODS', '130', 'EMs-related', 'infertility', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', 'diagnosed', 'and', 'treated', 'by', 'laparoscopic', 'surgery', 'were', 'randomly', 'assigned', 'to', 'two', 'groups', ',', 'i.e.', ',', 'the', 'test', 'group', '(', '75', 'cases', ')', 'and', 'the', 'control', 'group', '(', '55', 'cases', ')', '.']","(1, 18)","(7, 137)",-1,ss_p,21866656,Abstract,1,test,gold,5929.0
4094,METHODS,130 EMs-related infertility patients,"of blood stasis and toxin accumulation syndrome diagnosed and treated by laparoscopic surgery were randomly assigned to two groups , i.e. , the test group ( 75 cases ) and the control group ( 55 cases ) .","['METHODS', '130', 'EMs-related', 'infertility', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', 'diagnosed', 'and', 'treated', 'by', 'laparoscopic', 'surgery', 'were', 'randomly', 'assigned', 'to', 'two', 'groups', ',', 'i.e.', ',', 'the', 'test', 'group', '(', '75', 'cases', ')', 'and', 'the', 'control', 'group', '(', '55', 'cases', ')', '.']","(1, 5)","(7, 43)",-1,hl_p,21866656,Abstract,1,test,gold,3782.0
4095,METHODS 130 EMs-related infertility patients of,blood stasis and toxin accumulation syndrome diagnosed and treated by laparoscopic surgery,"were randomly assigned to two groups , i.e. , the test group ( 75 cases ) and the control group ( 55 cases ) .","['METHODS', '130', 'EMs-related', 'infertility', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', 'diagnosed', 'and', 'treated', 'by', 'laparoscopic', 'surgery', 'were', 'randomly', 'assigned', 'to', 'two', 'groups', ',', 'i.e.', ',', 'the', 'test', 'group', '(', '75', 'cases', ')', 'and', 'the', 'control', 'group', '(', '55', 'cases', ')', '.']","(6, 18)","(47, 137)",-1,hl_p,21866656,Abstract,1,test,gold,5930.0
4096,All patients received routine,progesterone,treatment after laparoscopic surgery .,"['All', 'patients', 'received', 'routine', 'progesterone', 'treatment', 'after', 'laparoscopic', 'surgery', '.']","(4, 5)","(29, 41)",-1,ss_i,21866656,Abstract,2,test,gold,5503.0
4097,All patients received routine,progesterone,treatment after laparoscopic surgery .,"['All', 'patients', 'received', 'routine', 'progesterone', 'treatment', 'after', 'laparoscopic', 'surgery', '.']","(4, 5)","(29, 41)",-1,hl_i,21866656,Abstract,2,test,gold,5504.0
4098,,QYJDR,"was given to patients in the test group after laparoscopic surgery , lasting for twelve months .","['QYJDR', 'was', 'given', 'to', 'patients', 'in', 'the', 'test', 'group', 'after', 'laparoscopic', 'surgery', ',', 'lasting', 'for', 'twelve', 'months', '.']","(0, 1)","(0, 5)",-1,ss_i,21866656,Abstract,3,test,gold,
4099,,QYJDR,"was given to patients in the test group after laparoscopic surgery , lasting for twelve months .","['QYJDR', 'was', 'given', 'to', 'patients', 'in', 'the', 'test', 'group', 'after', 'laparoscopic', 'surgery', ',', 'lasting', 'for', 'twelve', 'months', '.']","(0, 1)","(0, 5)",-1,hl_i,21866656,Abstract,3,test,gold,
4100,QYJDR was given to patients in the test group after,laparoscopic surgery,", lasting for twelve months .","['QYJDR', 'was', 'given', 'to', 'patients', 'in', 'the', 'test', 'group', 'after', 'laparoscopic', 'surgery', ',', 'lasting', 'for', 'twelve', 'months', '.']","(10, 12)","(51, 71)",-1,hl_i,21866656,Abstract,3,test,gold,3650.0
4101,The,pregnancy rate within one year after laparoscopic surgery,were compared between the two groups .,"['The', 'pregnancy', 'rate', 'within', 'one', 'year', 'after', 'laparoscopic', 'surgery', 'were', 'compared', 'between', 'the', 'two', 'groups', '.']","(1, 9)","(3, 60)",-1,ss_o,21866656,Abstract,4,test,gold,5858.0
4102,The,pregnancy rate,within one year after laparoscopic surgery were compared between the two groups .,"['The', 'pregnancy', 'rate', 'within', 'one', 'year', 'after', 'laparoscopic', 'surgery', 'were', 'compared', 'between', 'the', 'two', 'groups', '.']","(1, 3)","(3, 17)",-1,hl_o,21866656,Abstract,4,test,gold,1932.0
4103,The,"Chinese medicine syndrome integrals , serum endometrium antibody ( EMAb ) and cancer antigen 125 ( CA125 ) levels",were compared between before drug therapy and three months after drug therapy .,"['The', 'Chinese', 'medicine', 'syndrome', 'integrals', ',', 'serum', 'endometrium', 'antibody', '(', 'EMAb', ')', 'and', 'cancer', 'antigen', '125', '(', 'CA125', ')', 'levels', 'were', 'compared', 'between', 'before', 'drug', 'therapy', 'and', 'three', 'months', 'after', 'drug', 'therapy', '.']","(1, 20)","(3, 116)",-1,ss_o,21866656,Abstract,5,test,gold,5807.0
4104,The,"Chinese medicine syndrome integrals , serum endometrium antibody ( EMAb ) and cancer antigen 125 ( CA125 ) levels",were compared between before drug therapy and three months after drug therapy .,"['The', 'Chinese', 'medicine', 'syndrome', 'integrals', ',', 'serum', 'endometrium', 'antibody', '(', 'EMAb', ')', 'and', 'cancer', 'antigen', '125', '(', 'CA125', ')', 'levels', 'were', 'compared', 'between', 'before', 'drug', 'therapy', 'and', 'three', 'months', 'after', 'drug', 'therapy', '.']","(1, 20)","(3, 116)",-1,hl_o,21866656,Abstract,5,test,gold,5808.0
4105,RESULTS The,pregnancy rate,"within one year after laparoscopic surgery was higher in the test group than in the control group [ 61.33 % ( 46/75 ) vs 45.45 % ( 25/55 ) ] , showing significant difference ( P < 0.05 ) .","['RESULTS', 'The', 'pregnancy', 'rate', 'within', 'one', 'year', 'after', 'laparoscopic', 'surgery', 'was', 'higher', 'in', 'the', 'test', 'group', 'than', 'in', 'the', 'control', 'group', '[', '61.33', '%', '(', '46/75', ')', 'vs', '45.45', '%', '(', '25/55', ')', ']', ',', 'showing', 'significant', 'difference', '(', 'P', '<', '0.05', ')', '.']","(2, 4)","(11, 25)",-1,ss_o,21866656,Abstract,6,test,gold,1933.0
4106,RESULTS The,pregnancy rate,"within one year after laparoscopic surgery was higher in the test group than in the control group [ 61.33 % ( 46/75 ) vs 45.45 % ( 25/55 ) ] , showing significant difference ( P < 0.05 ) .","['RESULTS', 'The', 'pregnancy', 'rate', 'within', 'one', 'year', 'after', 'laparoscopic', 'surgery', 'was', 'higher', 'in', 'the', 'test', 'group', 'than', 'in', 'the', 'control', 'group', '[', '61.33', '%', '(', '46/75', ')', 'vs', '45.45', '%', '(', '25/55', ')', ']', ',', 'showing', 'significant', 'difference', '(', 'P', '<', '0.05', ')', '.']","(2, 4)","(11, 25)",-1,hl_o,21866656,Abstract,6,test,gold,1931.0
4107,The,Chinese medicine syndrome integral,"was ( 16.07 +/- 6.77 ) score and ( 7.25 +/- 3.27 ) score before and 3 months after drug therapy in the test group , while it was ( 15.92 +/- 7.51 ) score and ( 12.73 +/- 6.12 ) score in the control group .","['The', 'Chinese', 'medicine', 'syndrome', 'integral', 'was', '(', '16.07', '+/-', '6.77', ')', 'score', 'and', '(', '7.25', '+/-', '3.27', ')', 'score', 'before', 'and', '3', 'months', 'after', 'drug', 'therapy', 'in', 'the', 'test', 'group', ',', 'while', 'it', 'was', '(', '15.92', '+/-', '7.51', ')', 'score', 'and', '(', '12.73', '+/-', '6.12', ')', 'score', 'in', 'the', 'control', 'group', '.']","(1, 5)","(3, 37)",-1,ss_o,21866656,Abstract,7,test,gold,3336.0
4108,The,Chinese medicine syndrome integral,"was ( 16.07 +/- 6.77 ) score and ( 7.25 +/- 3.27 ) score before and 3 months after drug therapy in the test group , while it was ( 15.92 +/- 7.51 ) score and ( 12.73 +/- 6.12 ) score in the control group .","['The', 'Chinese', 'medicine', 'syndrome', 'integral', 'was', '(', '16.07', '+/-', '6.77', ')', 'score', 'and', '(', '7.25', '+/-', '3.27', ')', 'score', 'before', 'and', '3', 'months', 'after', 'drug', 'therapy', 'in', 'the', 'test', 'group', ',', 'while', 'it', 'was', '(', '15.92', '+/-', '7.51', ')', 'score', 'and', '(', '12.73', '+/-', '6.12', ')', 'score', 'in', 'the', 'control', 'group', '.']","(1, 5)","(3, 37)",-1,hl_o,21866656,Abstract,7,test,gold,3337.0
4109,The,Chinese medicine syndrome integral,after drug therapy was lower than that before drug therapy in the same group .,"['The', 'Chinese', 'medicine', 'syndrome', 'integral', 'after', 'drug', 'therapy', 'was', 'lower', 'than', 'that', 'before', 'drug', 'therapy', 'in', 'the', 'same', 'group', '.']","(1, 5)","(3, 37)",-1,ss_o,21866656,Abstract,8,test,gold,3335.0
4110,The,Chinese medicine syndrome integral,after drug therapy was lower than that before drug therapy in the same group .,"['The', 'Chinese', 'medicine', 'syndrome', 'integral', 'after', 'drug', 'therapy', 'was', 'lower', 'than', 'that', 'before', 'drug', 'therapy', 'in', 'the', 'same', 'group', '.']","(1, 5)","(3, 37)",-1,hl_o,21866656,Abstract,8,test,gold,3334.0
4111,"Besides , the",integral,"difference between before and after drug therapy was higher in the test group than in the control group [ ( 9.12 +/- 6.16 ) score vs ( 3.48 +/- 2.06 ) score ) ] , showing statistical difference ( P < 0.05 ) .","['Besides', ',', 'the', 'integral', 'difference', 'between', 'before', 'and', 'after', 'drug', 'therapy', 'was', 'higher', 'in', 'the', 'test', 'group', 'than', 'in', 'the', 'control', 'group', '[', '(', '9.12', '+/-', '6.16', ')', 'score', 'vs', '(', '3.48', '+/-', '2.06', ')', 'score', ')', ']', ',', 'showing', 'statistical', 'difference', '(', 'P', '<', '0.05', ')', '.']","(3, 4)","(13, 21)",-1,ss_o,21866656,Abstract,9,test,gold,1205.0
4112,"After three-month drug therapy , the",serum EMAb,"negative conversion rate was obviously higher in the test group than in the control group ( 44.44 % vs 15.62 % ) , showing statistical difference ( P < 0.05 ) .","['After', 'three-month', 'drug', 'therapy', ',', 'the', 'serum', 'EMAb', 'negative', 'conversion', 'rate', 'was', 'obviously', 'higher', 'in', 'the', 'test', 'group', 'than', 'in', 'the', 'control', 'group', '(', '44.44', '%', 'vs', '15.62', '%', ')', ',', 'showing', 'statistical', 'difference', '(', 'P', '<', '0.05', ')', '.']","(6, 8)","(36, 46)",-1,ss_o,21866656,Abstract,10,test,gold,4487.0
4113,"After three-month drug therapy , the",serum EMAb,"negative conversion rate was obviously higher in the test group than in the control group ( 44.44 % vs 15.62 % ) , showing statistical difference ( P < 0.05 ) .","['After', 'three-month', 'drug', 'therapy', ',', 'the', 'serum', 'EMAb', 'negative', 'conversion', 'rate', 'was', 'obviously', 'higher', 'in', 'the', 'test', 'group', 'than', 'in', 'the', 'control', 'group', '(', '44.44', '%', 'vs', '15.62', '%', ')', ',', 'showing', 'statistical', 'difference', '(', 'P', '<', '0.05', ')', '.']","(6, 8)","(36, 46)",-1,hl_o,21866656,Abstract,10,test,gold,4488.0
4114,The,serum CA125 level,"was ( 31.88 +/- 15.78 ) U/mL before drug therapy and ( 18.82 +/- 10.08 ) U/mL three months after drug therapy in the test group , while it was ( 30.63 +/- 19.28 ) U/mL and ( 18.05 +/- 11.20 ) U/mL respectively in the control group .","['The', 'serum', 'CA125', 'level', 'was', '(', '31.88', '+/-', '15.78', ')', 'U/mL', 'before', 'drug', 'therapy', 'and', '(', '18.82', '+/-', '10.08', ')', 'U/mL', 'three', 'months', 'after', 'drug', 'therapy', 'in', 'the', 'test', 'group', ',', 'while', 'it', 'was', '(', '30.63', '+/-', '19.28', ')', 'U/mL', 'and', '(', '18.05', '+/-', '11.20', ')', 'U/mL', 'respectively', 'in', 'the', 'control', 'group', '.']","(1, 4)","(3, 20)",-1,ss_o,21866656,Abstract,11,test,gold,4482.0
4115,The,serum CA125 level,"was ( 31.88 +/- 15.78 ) U/mL before drug therapy and ( 18.82 +/- 10.08 ) U/mL three months after drug therapy in the test group , while it was ( 30.63 +/- 19.28 ) U/mL and ( 18.05 +/- 11.20 ) U/mL respectively in the control group .","['The', 'serum', 'CA125', 'level', 'was', '(', '31.88', '+/-', '15.78', ')', 'U/mL', 'before', 'drug', 'therapy', 'and', '(', '18.82', '+/-', '10.08', ')', 'U/mL', 'three', 'months', 'after', 'drug', 'therapy', 'in', 'the', 'test', 'group', ',', 'while', 'it', 'was', '(', '30.63', '+/-', '19.28', ')', 'U/mL', 'and', '(', '18.05', '+/-', '11.20', ')', 'U/mL', 'respectively', 'in', 'the', 'control', 'group', '.']","(1, 4)","(3, 20)",-1,hl_o,21866656,Abstract,11,test,gold,4483.0
4116,It was lowered after drug therapy in the two groups with statistical difference ( P < 0.05 ) .,,,"['It', 'was', 'lowered', 'after', 'drug', 'therapy', 'in', 'the', 'two', 'groups', 'with', 'statistical', 'difference', '(', 'P', '<', '0.05', ')', '.']",,,,,21866656,Abstract,12,test,gold,
4117,There was no statistical difference between the two groups after drug therapy ( P > 0.05 ) .,,,"['There', 'was', 'no', 'statistical', 'difference', 'between', 'the', 'two', 'groups', 'after', 'drug', 'therapy', '(', 'P', '>', '0.05', ')', '.']",,,,,21866656,Abstract,13,test,gold,
4118,CONCLUSIONS The laparoscopic surgery in combination of QYJDR could effectively improve clinical symptoms of,EMs patients of blood stasis and toxin accumulation syndrome,", promote negative conversion of EMAb , lower serum CA125 levels , and elevate the clinical pregnancy rate .","['CONCLUSIONS', 'The', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'QYJDR', 'could', 'effectively', 'improve', 'clinical', 'symptoms', 'of', 'EMs', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', ',', 'promote', 'negative', 'conversion', 'of', 'EMAb', ',', 'lower', 'serum', 'CA125', 'levels', ',', 'and', 'elevate', 'the', 'clinical', 'pregnancy', 'rate', '.']","(14, 23)","(107, 167)",-1,ss_p,21866656,Abstract,14,test,gold,4524.0
4119,CONCLUSIONS The,laparoscopic surgery,"in combination of QYJDR could effectively improve clinical symptoms of EMs patients of blood stasis and toxin accumulation syndrome , promote negative conversion of EMAb , lower serum CA125 levels , and elevate the clinical pregnancy rate .","['CONCLUSIONS', 'The', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'QYJDR', 'could', 'effectively', 'improve', 'clinical', 'symptoms', 'of', 'EMs', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', ',', 'promote', 'negative', 'conversion', 'of', 'EMAb', ',', 'lower', 'serum', 'CA125', 'levels', ',', 'and', 'elevate', 'the', 'clinical', 'pregnancy', 'rate', '.']","(2, 4)","(15, 35)",-1,ss_i,21866656,Abstract,14,test,gold,3649.0
4120,CONCLUSIONS The laparoscopic surgery in combination of,QYJDR,"could effectively improve clinical symptoms of EMs patients of blood stasis and toxin accumulation syndrome , promote negative conversion of EMAb , lower serum CA125 levels , and elevate the clinical pregnancy rate .","['CONCLUSIONS', 'The', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'QYJDR', 'could', 'effectively', 'improve', 'clinical', 'symptoms', 'of', 'EMs', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', ',', 'promote', 'negative', 'conversion', 'of', 'EMAb', ',', 'lower', 'serum', 'CA125', 'levels', ',', 'and', 'elevate', 'the', 'clinical', 'pregnancy', 'rate', '.']","(7, 8)","(54, 59)",-1,ss_i,21866656,Abstract,14,test,gold,
4121,CONCLUSIONS The laparoscopic surgery in combination of QYJDR could effectively improve,clinical symptoms,"of EMs patients of blood stasis and toxin accumulation syndrome , promote negative conversion of EMAb , lower serum CA125 levels , and elevate the clinical pregnancy rate .","['CONCLUSIONS', 'The', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'QYJDR', 'could', 'effectively', 'improve', 'clinical', 'symptoms', 'of', 'EMs', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', ',', 'promote', 'negative', 'conversion', 'of', 'EMAb', ',', 'lower', 'serum', 'CA125', 'levels', ',', 'and', 'elevate', 'the', 'clinical', 'pregnancy', 'rate', '.']","(11, 13)","(86, 103)",-1,ss_o,21866656,Abstract,14,test,gold,3284.0
4122,CONCLUSIONS The laparoscopic surgery in combination of QYJDR could effectively improve clinical symptoms of EMs patients of,blood stasis and toxin accumulation syndrome,", promote negative conversion of EMAb , lower serum CA125 levels , and elevate the clinical pregnancy rate .","['CONCLUSIONS', 'The', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'QYJDR', 'could', 'effectively', 'improve', 'clinical', 'symptoms', 'of', 'EMs', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', ',', 'promote', 'negative', 'conversion', 'of', 'EMAb', ',', 'lower', 'serum', 'CA125', 'levels', ',', 'and', 'elevate', 'the', 'clinical', 'pregnancy', 'rate', '.']","(17, 23)","(123, 167)",-1,ss_o,21866656,Abstract,14,test,gold,4525.0
4123,"CONCLUSIONS The laparoscopic surgery in combination of QYJDR could effectively improve clinical symptoms of EMs patients of blood stasis and toxin accumulation syndrome , promote",negative conversion of EMAb,", lower serum CA125 levels , and elevate the clinical pregnancy rate .","['CONCLUSIONS', 'The', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'QYJDR', 'could', 'effectively', 'improve', 'clinical', 'symptoms', 'of', 'EMs', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', ',', 'promote', 'negative', 'conversion', 'of', 'EMAb', ',', 'lower', 'serum', 'CA125', 'levels', ',', 'and', 'elevate', 'the', 'clinical', 'pregnancy', 'rate', '.']","(25, 29)","(178, 205)",-1,ss_o,21866656,Abstract,14,test,gold,961.0
4124,"CONCLUSIONS The laparoscopic surgery in combination of QYJDR could effectively improve clinical symptoms of EMs patients of blood stasis and toxin accumulation syndrome , promote negative conversion of EMAb , lower",serum CA125 levels,", and elevate the clinical pregnancy rate .","['CONCLUSIONS', 'The', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'QYJDR', 'could', 'effectively', 'improve', 'clinical', 'symptoms', 'of', 'EMs', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', ',', 'promote', 'negative', 'conversion', 'of', 'EMAb', ',', 'lower', 'serum', 'CA125', 'levels', ',', 'and', 'elevate', 'the', 'clinical', 'pregnancy', 'rate', '.']","(31, 34)","(214, 232)",-1,ss_o,21866656,Abstract,14,test,gold,4484.0
4125,"CONCLUSIONS The laparoscopic surgery in combination of QYJDR could effectively improve clinical symptoms of EMs patients of blood stasis and toxin accumulation syndrome , promote negative conversion of EMAb , lower serum CA125 levels , and elevate the",clinical pregnancy rate .,,"['CONCLUSIONS', 'The', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'QYJDR', 'could', 'effectively', 'improve', 'clinical', 'symptoms', 'of', 'EMs', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', ',', 'promote', 'negative', 'conversion', 'of', 'EMAb', ',', 'lower', 'serum', 'CA125', 'levels', ',', 'and', 'elevate', 'the', 'clinical', 'pregnancy', 'rate', '.']","(38, 42)","(251, 276)",-1,ss_o,21866656,Abstract,14,test,gold,1934.0
4126,CONCLUSIONS The,laparoscopic surgery,"in combination of QYJDR could effectively improve clinical symptoms of EMs patients of blood stasis and toxin accumulation syndrome , promote negative conversion of EMAb , lower serum CA125 levels , and elevate the clinical pregnancy rate .","['CONCLUSIONS', 'The', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'QYJDR', 'could', 'effectively', 'improve', 'clinical', 'symptoms', 'of', 'EMs', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', ',', 'promote', 'negative', 'conversion', 'of', 'EMAb', ',', 'lower', 'serum', 'CA125', 'levels', ',', 'and', 'elevate', 'the', 'clinical', 'pregnancy', 'rate', '.']","(2, 4)","(15, 35)",-1,hl_i,21866656,Abstract,14,test,gold,3648.0
4127,CONCLUSIONS The laparoscopic surgery in combination of,QYJDR,"could effectively improve clinical symptoms of EMs patients of blood stasis and toxin accumulation syndrome , promote negative conversion of EMAb , lower serum CA125 levels , and elevate the clinical pregnancy rate .","['CONCLUSIONS', 'The', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'QYJDR', 'could', 'effectively', 'improve', 'clinical', 'symptoms', 'of', 'EMs', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', ',', 'promote', 'negative', 'conversion', 'of', 'EMAb', ',', 'lower', 'serum', 'CA125', 'levels', ',', 'and', 'elevate', 'the', 'clinical', 'pregnancy', 'rate', '.']","(7, 8)","(54, 59)",-1,hl_i,21866656,Abstract,14,test,gold,
4128,CONCLUSIONS The laparoscopic surgery in combination of QYJDR could effectively improve clinical symptoms of EMs patients of,blood stasis,"and toxin accumulation syndrome , promote negative conversion of EMAb , lower serum CA125 levels , and elevate the clinical pregnancy rate .","['CONCLUSIONS', 'The', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'QYJDR', 'could', 'effectively', 'improve', 'clinical', 'symptoms', 'of', 'EMs', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', ',', 'promote', 'negative', 'conversion', 'of', 'EMAb', ',', 'lower', 'serum', 'CA125', 'levels', ',', 'and', 'elevate', 'the', 'clinical', 'pregnancy', 'rate', '.']","(17, 19)","(123, 135)",-1,hl_o,21866656,Abstract,14,test,gold,2663.0
4129,CONCLUSIONS The laparoscopic surgery in combination of QYJDR could effectively improve clinical symptoms of EMs patients of blood stasis and,toxin accumulation syndrome,", promote negative conversion of EMAb , lower serum CA125 levels , and elevate the clinical pregnancy rate .","['CONCLUSIONS', 'The', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'QYJDR', 'could', 'effectively', 'improve', 'clinical', 'symptoms', 'of', 'EMs', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', ',', 'promote', 'negative', 'conversion', 'of', 'EMAb', ',', 'lower', 'serum', 'CA125', 'levels', ',', 'and', 'elevate', 'the', 'clinical', 'pregnancy', 'rate', '.']","(20, 23)","(140, 167)",-1,hl_o,21866656,Abstract,14,test,gold,4526.0
4130,"CONCLUSIONS The laparoscopic surgery in combination of QYJDR could effectively improve clinical symptoms of EMs patients of blood stasis and toxin accumulation syndrome , promote",negative conversion of EMAb,", lower serum CA125 levels , and elevate the clinical pregnancy rate .","['CONCLUSIONS', 'The', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'QYJDR', 'could', 'effectively', 'improve', 'clinical', 'symptoms', 'of', 'EMs', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', ',', 'promote', 'negative', 'conversion', 'of', 'EMAb', ',', 'lower', 'serum', 'CA125', 'levels', ',', 'and', 'elevate', 'the', 'clinical', 'pregnancy', 'rate', '.']","(25, 29)","(178, 205)",-1,hl_o,21866656,Abstract,14,test,gold,962.0
4131,"CONCLUSIONS The laparoscopic surgery in combination of QYJDR could effectively improve clinical symptoms of EMs patients of blood stasis and toxin accumulation syndrome , promote negative conversion of EMAb , lower",serum CA125 levels,", and elevate the clinical pregnancy rate .","['CONCLUSIONS', 'The', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'QYJDR', 'could', 'effectively', 'improve', 'clinical', 'symptoms', 'of', 'EMs', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', ',', 'promote', 'negative', 'conversion', 'of', 'EMAb', ',', 'lower', 'serum', 'CA125', 'levels', ',', 'and', 'elevate', 'the', 'clinical', 'pregnancy', 'rate', '.']","(31, 34)","(214, 232)",-1,hl_o,21866656,Abstract,14,test,gold,4485.0
4132,"CONCLUSIONS The laparoscopic surgery in combination of QYJDR could effectively improve clinical symptoms of EMs patients of blood stasis and toxin accumulation syndrome , promote negative conversion of EMAb , lower serum CA125 levels , and elevate the",clinical pregnancy rate .,,"['CONCLUSIONS', 'The', 'laparoscopic', 'surgery', 'in', 'combination', 'of', 'QYJDR', 'could', 'effectively', 'improve', 'clinical', 'symptoms', 'of', 'EMs', 'patients', 'of', 'blood', 'stasis', 'and', 'toxin', 'accumulation', 'syndrome', ',', 'promote', 'negative', 'conversion', 'of', 'EMAb', ',', 'lower', 'serum', 'CA125', 'levels', ',', 'and', 'elevate', 'the', 'clinical', 'pregnancy', 'rate', '.']","(38, 42)","(251, 276)",-1,hl_o,21866656,Abstract,14,test,gold,1935.0
4133,QYJDR is an effective formula in treatment of,EMs-related infertility .,,"['QYJDR', 'is', 'an', 'effective', 'formula', 'in', 'treatment', 'of', 'EMs-related', 'infertility', '.']","(8, 11)","(45, 70)",-1,ss_p,21866656,Abstract,15,test,gold,3781.0
4134,,QYJDR,is an effective formula in treatment of EMs-related infertility .,"['QYJDR', 'is', 'an', 'effective', 'formula', 'in', 'treatment', 'of', 'EMs-related', 'infertility', '.']","(0, 1)","(0, 5)",-1,ss_i,21866656,Abstract,15,test,gold,
4135,,QYJDR,is an effective formula in treatment of EMs-related infertility .,"['QYJDR', 'is', 'an', 'effective', 'formula', 'in', 'treatment', 'of', 'EMs-related', 'infertility', '.']","(0, 1)","(0, 5)",-1,hl_i,21866656,Abstract,15,test,gold,
4136,Chronic vasodilator therapy with flosequinan in,congestive heart failure .,,"['Chronic', 'vasodilator', 'therapy', 'with', 'flosequinan', 'in', 'congestive', 'heart', 'failure', '.']","(6, 10)","(47, 73)",-1,ss_p,2188766,Title,0,test,gold,7064.0
4137,Chronic vasodilator therapy with,flosequinan,in congestive heart failure .,"['Chronic', 'vasodilator', 'therapy', 'with', 'flosequinan', 'in', 'congestive', 'heart', 'failure', '.']","(4, 5)","(32, 43)",-1,ss_i,2188766,Title,0,test,gold,
4138,Chronic vasodilator therapy with flosequinan in,congestive heart failure .,,"['Chronic', 'vasodilator', 'therapy', 'with', 'flosequinan', 'in', 'congestive', 'heart', 'failure', '.']","(6, 10)","(47, 73)",-1,hl_p,2188766,Title,0,test,gold,7065.0
4139,Chronic vasodilator therapy with,flosequinan,in congestive heart failure .,"['Chronic', 'vasodilator', 'therapy', 'with', 'flosequinan', 'in', 'congestive', 'heart', 'failure', '.']","(4, 5)","(32, 43)",-1,hl_i,2188766,Title,0,test,gold,
4140,"This study was conducted to determine the long-term effect of flosequinan , a new orally administered arterial and venous dilator , on the clinical course of",patients with moderate to severe congestive heart failure .,,"['This', 'study', 'was', 'conducted', 'to', 'determine', 'the', 'long-term', 'effect', 'of', 'flosequinan', ',', 'a', 'new', 'orally', 'administered', 'arterial', 'and', 'venous', 'dilator', ',', 'on', 'the', 'clinical', 'course', 'of', 'patients', 'with', 'moderate', 'to', 'severe', 'congestive', 'heart', 'failure', '.']","(26, 35)","(157, 216)",-1,ss_p,2188766,Abstract,0,test,gold,7062.0
4141,This study was conducted to determine the long-term effect of,flosequinan,", a new orally administered arterial and venous dilator , on the clinical course of patients with moderate to severe congestive heart failure .","['This', 'study', 'was', 'conducted', 'to', 'determine', 'the', 'long-term', 'effect', 'of', 'flosequinan', ',', 'a', 'new', 'orally', 'administered', 'arterial', 'and', 'venous', 'dilator', ',', 'on', 'the', 'clinical', 'course', 'of', 'patients', 'with', 'moderate', 'to', 'severe', 'congestive', 'heart', 'failure', '.']","(10, 11)","(61, 72)",-1,ss_i,2188766,Abstract,0,test,gold,
4142,This study was conducted to determine the,long-term effect,"of flosequinan , a new orally administered arterial and venous dilator , on the clinical course of patients with moderate to severe congestive heart failure .","['This', 'study', 'was', 'conducted', 'to', 'determine', 'the', 'long-term', 'effect', 'of', 'flosequinan', ',', 'a', 'new', 'orally', 'administered', 'arterial', 'and', 'venous', 'dilator', ',', 'on', 'the', 'clinical', 'course', 'of', 'patients', 'with', 'moderate', 'to', 'severe', 'congestive', 'heart', 'failure', '.']","(7, 9)","(41, 57)",-1,ss_o,2188766,Abstract,0,test,gold,2336.0
4143,"This study was conducted to determine the long-term effect of flosequinan , a new orally administered arterial and venous dilator , on the",clinical course,of patients with moderate to severe congestive heart failure .,"['This', 'study', 'was', 'conducted', 'to', 'determine', 'the', 'long-term', 'effect', 'of', 'flosequinan', ',', 'a', 'new', 'orally', 'administered', 'arterial', 'and', 'venous', 'dilator', ',', 'on', 'the', 'clinical', 'course', 'of', 'patients', 'with', 'moderate', 'to', 'severe', 'congestive', 'heart', 'failure', '.']","(23, 25)","(138, 153)",-1,ss_o,2188766,Abstract,0,test,gold,4772.0
4144,"This study was conducted to determine the long-term effect of flosequinan , a new orally administered arterial and venous dilator , on the clinical course of",patients with moderate to severe congestive heart failure .,,"['This', 'study', 'was', 'conducted', 'to', 'determine', 'the', 'long-term', 'effect', 'of', 'flosequinan', ',', 'a', 'new', 'orally', 'administered', 'arterial', 'and', 'venous', 'dilator', ',', 'on', 'the', 'clinical', 'course', 'of', 'patients', 'with', 'moderate', 'to', 'severe', 'congestive', 'heart', 'failure', '.']","(26, 35)","(157, 216)",-1,hl_p,2188766,Abstract,0,test,gold,7063.0
4145,This study was conducted to determine the long-term effect of,flosequinan,", a new orally administered arterial and venous dilator , on the clinical course of patients with moderate to severe congestive heart failure .","['This', 'study', 'was', 'conducted', 'to', 'determine', 'the', 'long-term', 'effect', 'of', 'flosequinan', ',', 'a', 'new', 'orally', 'administered', 'arterial', 'and', 'venous', 'dilator', ',', 'on', 'the', 'clinical', 'course', 'of', 'patients', 'with', 'moderate', 'to', 'severe', 'congestive', 'heart', 'failure', '.']","(10, 11)","(61, 72)",-1,hl_i,2188766,Abstract,0,test,gold,
4146,This study was conducted to determine the,long-term effect,"of flosequinan , a new orally administered arterial and venous dilator , on the clinical course of patients with moderate to severe congestive heart failure .","['This', 'study', 'was', 'conducted', 'to', 'determine', 'the', 'long-term', 'effect', 'of', 'flosequinan', ',', 'a', 'new', 'orally', 'administered', 'arterial', 'and', 'venous', 'dilator', ',', 'on', 'the', 'clinical', 'course', 'of', 'patients', 'with', 'moderate', 'to', 'severe', 'congestive', 'heart', 'failure', '.']","(7, 9)","(41, 57)",-1,hl_o,2188766,Abstract,0,test,gold,2335.0
4147,,Seventeen patients on chronic digitalis and diuretic therapy,were randomized to receive either flosequinan ( n = 9 ) or placebo ( n = 8 ) in a double-blind fashion .,"['Seventeen', 'patients', 'on', 'chronic', 'digitalis', 'and', 'diuretic', 'therapy', 'were', 'randomized', 'to', 'receive', 'either', 'flosequinan', '(', 'n', '=', '9', ')', 'or', 'placebo', '(', 'n', '=', '8', ')', 'in', 'a', 'double-blind', 'fashion', '.']","(0, 8)","(0, 60)",-1,ss_p,2188766,Abstract,1,test,gold,7079.0
4148,Seventeen patients on chronic digitalis and diuretic therapy were randomized to receive either,flosequinan,( n = 9 ) or placebo ( n = 8 ) in a double-blind fashion .,"['Seventeen', 'patients', 'on', 'chronic', 'digitalis', 'and', 'diuretic', 'therapy', 'were', 'randomized', 'to', 'receive', 'either', 'flosequinan', '(', 'n', '=', '9', ')', 'or', 'placebo', '(', 'n', '=', '8', ')', 'in', 'a', 'double-blind', 'fashion', '.']","(13, 14)","(94, 105)",-1,ss_i,2188766,Abstract,1,test,gold,
4149,Seventeen patients on chronic digitalis and diuretic therapy were randomized to receive either flosequinan ( n = 9 ) or,placebo,( n = 8 ) in a double-blind fashion .,"['Seventeen', 'patients', 'on', 'chronic', 'digitalis', 'and', 'diuretic', 'therapy', 'were', 'randomized', 'to', 'receive', 'either', 'flosequinan', '(', 'n', '=', '9', ')', 'or', 'placebo', '(', 'n', '=', '8', ')', 'in', 'a', 'double-blind', 'fashion', '.']","(20, 21)","(119, 126)",-1,ss_i,2188766,Abstract,1,test,gold,4370.0
4150,,Seventeen patients on chronic digitalis and diuretic therapy,were randomized to receive either flosequinan ( n = 9 ) or placebo ( n = 8 ) in a double-blind fashion .,"['Seventeen', 'patients', 'on', 'chronic', 'digitalis', 'and', 'diuretic', 'therapy', 'were', 'randomized', 'to', 'receive', 'either', 'flosequinan', '(', 'n', '=', '9', ')', 'or', 'placebo', '(', 'n', '=', '8', ')', 'in', 'a', 'double-blind', 'fashion', '.']","(0, 8)","(0, 60)",-1,hl_p,2188766,Abstract,1,test,gold,7080.0
4151,Seventeen patients on chronic digitalis and diuretic therapy were randomized to receive either,flosequinan,( n = 9 ) or placebo ( n = 8 ) in a double-blind fashion .,"['Seventeen', 'patients', 'on', 'chronic', 'digitalis', 'and', 'diuretic', 'therapy', 'were', 'randomized', 'to', 'receive', 'either', 'flosequinan', '(', 'n', '=', '9', ')', 'or', 'placebo', '(', 'n', '=', '8', ')', 'in', 'a', 'double-blind', 'fashion', '.']","(13, 14)","(94, 105)",-1,hl_i,2188766,Abstract,1,test,gold,
4152,Seventeen patients on chronic digitalis and diuretic therapy were randomized to receive either flosequinan ( n = 9 ) or,placebo,( n = 8 ) in a double-blind fashion .,"['Seventeen', 'patients', 'on', 'chronic', 'digitalis', 'and', 'diuretic', 'therapy', 'were', 'randomized', 'to', 'receive', 'either', 'flosequinan', '(', 'n', '=', '9', ')', 'or', 'placebo', '(', 'n', '=', '8', ')', 'in', 'a', 'double-blind', 'fashion', '.']","(20, 21)","(119, 126)",-1,hl_i,2188766,Abstract,1,test,gold,4369.0
4153,,"Changes in symptomatology , exercise performance , and left ventricular function",were assessed serially during the two-month treatment period .,"['Changes', 'in', 'symptomatology', ',', 'exercise', 'performance', ',', 'and', 'left', 'ventricular', 'function', 'were', 'assessed', 'serially', 'during', 'the', 'two-month', 'treatment', 'period', '.']","(0, 11)","(0, 80)",-1,ss_o,2188766,Abstract,2,test,gold,6780.0
4154,Changes in,symptomatology,", exercise performance , and left ventricular function were assessed serially during the two-month treatment period .","['Changes', 'in', 'symptomatology', ',', 'exercise', 'performance', ',', 'and', 'left', 'ventricular', 'function', 'were', 'assessed', 'serially', 'during', 'the', 'two-month', 'treatment', 'period', '.']","(2, 3)","(10, 24)",-1,hl_o,2188766,Abstract,2,test,gold,64.0
4155,"Changes in symptomatology ,",exercise performance,", and left ventricular function were assessed serially during the two-month treatment period .","['Changes', 'in', 'symptomatology', ',', 'exercise', 'performance', ',', 'and', 'left', 'ventricular', 'function', 'were', 'assessed', 'serially', 'during', 'the', 'two-month', 'treatment', 'period', '.']","(4, 6)","(27, 47)",-1,hl_o,2188766,Abstract,2,test,gold,2761.0
4156,"Changes in symptomatology , exercise performance , and",left ventricular function,were assessed serially during the two-month treatment period .,"['Changes', 'in', 'symptomatology', ',', 'exercise', 'performance', ',', 'and', 'left', 'ventricular', 'function', 'were', 'assessed', 'serially', 'during', 'the', 'two-month', 'treatment', 'period', '.']","(8, 11)","(54, 79)",-1,hl_o,2188766,Abstract,2,test,gold,6785.0
4157,"During the course of therapy , a modest improvement in the symptom scores and functional classification of the",flosequinan-treated,patients was observed .,"['During', 'the', 'course', 'of', 'therapy', ',', 'a', 'modest', 'improvement', 'in', 'the', 'symptom', 'scores', 'and', 'functional', 'classification', 'of', 'the', 'flosequinan-treated', 'patients', 'was', 'observed', '.']","(18, 19)","(110, 129)",-1,ss_i,2188766,Abstract,3,test,gold,
4158,"During the course of therapy , a modest improvement in the",symptom scores and functional classification,of the flosequinan-treated patients was observed .,"['During', 'the', 'course', 'of', 'therapy', ',', 'a', 'modest', 'improvement', 'in', 'the', 'symptom', 'scores', 'and', 'functional', 'classification', 'of', 'the', 'flosequinan-treated', 'patients', 'was', 'observed', '.']","(11, 16)","(58, 102)",-1,ss_o,2188766,Abstract,3,test,gold,3357.0
4159,"During the course of therapy , a modest improvement in the",symptom scores,and functional classification of the flosequinan-treated patients was observed .,"['During', 'the', 'course', 'of', 'therapy', ',', 'a', 'modest', 'improvement', 'in', 'the', 'symptom', 'scores', 'and', 'functional', 'classification', 'of', 'the', 'flosequinan-treated', 'patients', 'was', 'observed', '.']","(11, 13)","(58, 72)",-1,hl_o,2188766,Abstract,3,test,gold,3362.0
4160,"During the course of therapy , a modest improvement in the symptom scores and",functional classification,of the flosequinan-treated patients was observed .,"['During', 'the', 'course', 'of', 'therapy', ',', 'a', 'modest', 'improvement', 'in', 'the', 'symptom', 'scores', 'and', 'functional', 'classification', 'of', 'the', 'flosequinan-treated', 'patients', 'was', 'observed', '.']","(14, 16)","(77, 102)",-1,hl_o,2188766,Abstract,3,test,gold,1362.0
4161,,Flosequinan,evoked a significant increase in maximal exercise capacity .,"['Flosequinan', 'evoked', 'a', 'significant', 'increase', 'in', 'maximal', 'exercise', 'capacity', '.']","(0, 1)","(0, 11)",-1,ss_i,2188766,Abstract,4,test,gold,
4162,Flosequinan evoked a significant increase in,maximal exercise capacity .,,"['Flosequinan', 'evoked', 'a', 'significant', 'increase', 'in', 'maximal', 'exercise', 'capacity', '.']","(6, 10)","(44, 71)",-1,ss_o,2188766,Abstract,4,test,gold,1680.0
4163,,Flosequinan,evoked a significant increase in maximal exercise capacity .,"['Flosequinan', 'evoked', 'a', 'significant', 'increase', 'in', 'maximal', 'exercise', 'capacity', '.']","(0, 1)","(0, 11)",-1,hl_i,2188766,Abstract,4,test,gold,
4164,Flosequinan evoked a significant increase in,maximal exercise capacity .,,"['Flosequinan', 'evoked', 'a', 'significant', 'increase', 'in', 'maximal', 'exercise', 'capacity', '.']","(6, 10)","(44, 71)",-1,hl_o,2188766,Abstract,4,test,gold,1681.0
4165,While long-term,flosequinan,"administration also effected a progressive increase in resting heart rate , it did not consistently improve indices of left ventricular systolic function .","['While', 'long-term', 'flosequinan', 'administration', 'also', 'effected', 'a', 'progressive', 'increase', 'in', 'resting', 'heart', 'rate', ',', 'it', 'did', 'not', 'consistently', 'improve', 'indices', 'of', 'left', 'ventricular', 'systolic', 'function', '.']","(2, 3)","(15, 26)",-1,ss_i,2188766,Abstract,5,test,gold,
4166,While long-term flosequinan administration also effected a progressive increase in,resting heart rate,", it did not consistently improve indices of left ventricular systolic function .","['While', 'long-term', 'flosequinan', 'administration', 'also', 'effected', 'a', 'progressive', 'increase', 'in', 'resting', 'heart', 'rate', ',', 'it', 'did', 'not', 'consistently', 'improve', 'indices', 'of', 'left', 'ventricular', 'systolic', 'function', '.']","(10, 13)","(82, 100)",-1,ss_o,2188766,Abstract,5,test,gold,1936.0
4167,"While long-term flosequinan administration also effected a progressive increase in resting heart rate , it did not consistently improve indices of",left ventricular systolic function .,,"['While', 'long-term', 'flosequinan', 'administration', 'also', 'effected', 'a', 'progressive', 'increase', 'in', 'resting', 'heart', 'rate', ',', 'it', 'did', 'not', 'consistently', 'improve', 'indices', 'of', 'left', 'ventricular', 'systolic', 'function', '.']","(21, 26)","(146, 182)",-1,ss_o,2188766,Abstract,5,test,gold,6774.0
4168,While long-term,flosequinan,"administration also effected a progressive increase in resting heart rate , it did not consistently improve indices of left ventricular systolic function .","['While', 'long-term', 'flosequinan', 'administration', 'also', 'effected', 'a', 'progressive', 'increase', 'in', 'resting', 'heart', 'rate', ',', 'it', 'did', 'not', 'consistently', 'improve', 'indices', 'of', 'left', 'ventricular', 'systolic', 'function', '.']","(2, 3)","(15, 26)",-1,hl_i,2188766,Abstract,5,test,gold,
4169,While long-term flosequinan administration also effected a progressive increase in,resting heart rate,", it did not consistently improve indices of left ventricular systolic function .","['While', 'long-term', 'flosequinan', 'administration', 'also', 'effected', 'a', 'progressive', 'increase', 'in', 'resting', 'heart', 'rate', ',', 'it', 'did', 'not', 'consistently', 'improve', 'indices', 'of', 'left', 'ventricular', 'systolic', 'function', '.']","(10, 13)","(82, 100)",-1,hl_o,2188766,Abstract,5,test,gold,1937.0
4170,"While long-term flosequinan administration also effected a progressive increase in resting heart rate , it did not consistently improve indices of",left ventricular systolic function .,,"['While', 'long-term', 'flosequinan', 'administration', 'also', 'effected', 'a', 'progressive', 'increase', 'in', 'resting', 'heart', 'rate', ',', 'it', 'did', 'not', 'consistently', 'improve', 'indices', 'of', 'left', 'ventricular', 'systolic', 'function', '.']","(21, 26)","(146, 182)",-1,hl_o,2188766,Abstract,5,test,gold,6775.0
4171,The addition of chronic vasodilator therapy with flosequinan to standard digitalis-diuretic regimens is capable of inducing clinical improvement in,patients with moderate to severe chronic heart failure .,,"['The', 'addition', 'of', 'chronic', 'vasodilator', 'therapy', 'with', 'flosequinan', 'to', 'standard', 'digitalis-diuretic', 'regimens', 'is', 'capable', 'of', 'inducing', 'clinical', 'improvement', 'in', 'patients', 'with', 'moderate', 'to', 'severe', 'chronic', 'heart', 'failure', '.']","(19, 28)","(147, 203)",-1,ss_p,2188766,Abstract,6,test,gold,7060.0
4172,The addition of chronic vasodilator therapy with,flosequinan,to standard digitalis-diuretic regimens is capable of inducing clinical improvement in patients with moderate to severe chronic heart failure .,"['The', 'addition', 'of', 'chronic', 'vasodilator', 'therapy', 'with', 'flosequinan', 'to', 'standard', 'digitalis-diuretic', 'regimens', 'is', 'capable', 'of', 'inducing', 'clinical', 'improvement', 'in', 'patients', 'with', 'moderate', 'to', 'severe', 'chronic', 'heart', 'failure', '.']","(7, 8)","(48, 59)",-1,ss_i,2188766,Abstract,6,test,gold,
4173,The addition of chronic vasodilator therapy with flosequinan to standard digitalis-diuretic regimens is capable of inducing clinical improvement in,patients with moderate to severe chronic heart failure .,,"['The', 'addition', 'of', 'chronic', 'vasodilator', 'therapy', 'with', 'flosequinan', 'to', 'standard', 'digitalis-diuretic', 'regimens', 'is', 'capable', 'of', 'inducing', 'clinical', 'improvement', 'in', 'patients', 'with', 'moderate', 'to', 'severe', 'chronic', 'heart', 'failure', '.']","(19, 28)","(147, 203)",-1,hl_p,2188766,Abstract,6,test,gold,7061.0
4174,The addition of chronic vasodilator therapy with,flosequinan,to standard digitalis-diuretic regimens is capable of inducing clinical improvement in patients with moderate to severe chronic heart failure .,"['The', 'addition', 'of', 'chronic', 'vasodilator', 'therapy', 'with', 'flosequinan', 'to', 'standard', 'digitalis-diuretic', 'regimens', 'is', 'capable', 'of', 'inducing', 'clinical', 'improvement', 'in', 'patients', 'with', 'moderate', 'to', 'severe', 'chronic', 'heart', 'failure', '.']","(7, 8)","(48, 59)",-1,hl_i,2188766,Abstract,6,test,gold,
4175,"Trials involving larger patient populations will be necessary to confirm the results of this preliminary study and to determine the extent of clinical improvement , subpopulations benefited , role in heart failure therapeutics , and so forth .",,,"['Trials', 'involving', 'larger', 'patient', 'populations', 'will', 'be', 'necessary', 'to', 'confirm', 'the', 'results', 'of', 'this', 'preliminary', 'study', 'and', 'to', 'determine', 'the', 'extent', 'of', 'clinical', 'improvement', ',', 'subpopulations', 'benefited', ',', 'role', 'in', 'heart', 'failure', 'therapeutics', ',', 'and', 'so', 'forth', '.']",,,,,2188766,Abstract,7,test,gold,
4176,A,physiotherapy service,to an emergency extended care unit does not decrease admission rates to hospital : a randomised trial .,"['A', 'physiotherapy', 'service', 'to', 'an', 'emergency', 'extended', 'care', 'unit', 'does', 'not', 'decrease', 'admission', 'rates', 'to', 'hospital', ':', 'a', 'randomised', 'trial', '.']","(1, 3)","(1, 22)",-1,ss_i,21896676,Title,0,test,gold,4222.0
4177,A physiotherapy service to an emergency extended care unit does not decrease,admission rates to hospital :,a randomised trial .,"['A', 'physiotherapy', 'service', 'to', 'an', 'emergency', 'extended', 'care', 'unit', 'does', 'not', 'decrease', 'admission', 'rates', 'to', 'hospital', ':', 'a', 'randomised', 'trial', '.']","(12, 17)","(76, 105)",-1,ss_o,21896676,Title,0,test,gold,3817.0
4178,A,physiotherapy service,to an emergency extended care unit does not decrease admission rates to hospital : a randomised trial .,"['A', 'physiotherapy', 'service', 'to', 'an', 'emergency', 'extended', 'care', 'unit', 'does', 'not', 'decrease', 'admission', 'rates', 'to', 'hospital', ':', 'a', 'randomised', 'trial', '.']","(1, 3)","(1, 22)",-1,hl_i,21896676,Title,0,test,gold,4223.0
4179,A physiotherapy service to an emergency extended care unit does not decrease,admission rates to hospital :,a randomised trial .,"['A', 'physiotherapy', 'service', 'to', 'an', 'emergency', 'extended', 'care', 'unit', 'does', 'not', 'decrease', 'admission', 'rates', 'to', 'hospital', ':', 'a', 'randomised', 'trial', '.']","(12, 17)","(76, 105)",-1,hl_o,21896676,Title,0,test,gold,3818.0
4180,BACKGROUND One of the reasons,physiotherapy,services are provided to emergency departments ( EDs ) and emergency extended care units ( EECUs ) is to review patients ' mobility to ensure they are safe to be discharged home .,"['BACKGROUND', 'One', 'of', 'the', 'reasons', 'physiotherapy', 'services', 'are', 'provided', 'to', 'emergency', 'departments', '(', 'EDs', ')', 'and', 'emergency', 'extended', 'care', 'units', '(', 'EECUs', ')', 'is', 'to', 'review', 'patients', ""'"", 'mobility', 'to', 'ensure', 'they', 'are', 'safe', 'to', 'be', 'discharged', 'home', '.']","(5, 6)","(29, 42)",-1,ss_i,21896676,Abstract,0,test,gold,4234.0
4181,BACKGROUND One of the reasons,physiotherapy,services are provided to emergency departments ( EDs ) and emergency extended care units ( EECUs ) is to review patients ' mobility to ensure they are safe to be discharged home .,"['BACKGROUND', 'One', 'of', 'the', 'reasons', 'physiotherapy', 'services', 'are', 'provided', 'to', 'emergency', 'departments', '(', 'EDs', ')', 'and', 'emergency', 'extended', 'care', 'units', '(', 'EECUs', ')', 'is', 'to', 'review', 'patients', ""'"", 'mobility', 'to', 'ensure', 'they', 'are', 'safe', 'to', 'be', 'discharged', 'home', '.']","(5, 6)","(29, 42)",-1,hl_i,21896676,Abstract,0,test,gold,4235.0
4182,AIM To investigate whether a,physiotherapy service,"to an EECU altered the rate of hospital admission , rate of re-presentation to the ED , visits to community healthcare practitioners , return to usual work/home/leisure activities and patient satisfaction .","['AIM', 'To', 'investigate', 'whether', 'a', 'physiotherapy', 'service', 'to', 'an', 'EECU', 'altered', 'the', 'rate', 'of', 'hospital', 'admission', ',', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'visits', 'to', 'community', 'healthcare', 'practitioners', ',', 'return', 'to', 'usual', 'work/home/leisure', 'activities', 'and', 'patient', 'satisfaction', '.']","(5, 7)","(28, 49)",-1,ss_i,21896676,Abstract,1,test,gold,4221.0
4183,AIM To investigate whether a physiotherapy service to an EECU altered the,"rate of hospital admission , rate of re-presentation to the ED , visits to community healthcare practitioners , return to usual work/home/leisure activities and patient satisfaction .",,"['AIM', 'To', 'investigate', 'whether', 'a', 'physiotherapy', 'service', 'to', 'an', 'EECU', 'altered', 'the', 'rate', 'of', 'hospital', 'admission', ',', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'visits', 'to', 'community', 'healthcare', 'practitioners', ',', 'return', 'to', 'usual', 'work/home/leisure', 'activities', 'and', 'patient', 'satisfaction', '.']","(12, 39)","(73, 256)",-1,ss_o,21896676,Abstract,1,test,gold,5889.0
4184,AIM To investigate whether a,physiotherapy service,"to an EECU altered the rate of hospital admission , rate of re-presentation to the ED , visits to community healthcare practitioners , return to usual work/home/leisure activities and patient satisfaction .","['AIM', 'To', 'investigate', 'whether', 'a', 'physiotherapy', 'service', 'to', 'an', 'EECU', 'altered', 'the', 'rate', 'of', 'hospital', 'admission', ',', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'visits', 'to', 'community', 'healthcare', 'practitioners', ',', 'return', 'to', 'usual', 'work/home/leisure', 'activities', 'and', 'patient', 'satisfaction', '.']","(5, 7)","(28, 49)",-1,hl_i,21896676,Abstract,1,test,gold,4220.0
4185,AIM To investigate whether a physiotherapy service to an EECU altered the,rate of hospital admission,", rate of re-presentation to the ED , visits to community healthcare practitioners , return to usual work/home/leisure activities and patient satisfaction .","['AIM', 'To', 'investigate', 'whether', 'a', 'physiotherapy', 'service', 'to', 'an', 'EECU', 'altered', 'the', 'rate', 'of', 'hospital', 'admission', ',', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'visits', 'to', 'community', 'healthcare', 'practitioners', ',', 'return', 'to', 'usual', 'work/home/leisure', 'activities', 'and', 'patient', 'satisfaction', '.']","(12, 16)","(73, 99)",-1,hl_o,21896676,Abstract,1,test,gold,3820.0
4186,"AIM To investigate whether a physiotherapy service to an EECU altered the rate of hospital admission ,",rate of re-presentation to the ED,", visits to community healthcare practitioners , return to usual work/home/leisure activities and patient satisfaction .","['AIM', 'To', 'investigate', 'whether', 'a', 'physiotherapy', 'service', 'to', 'an', 'EECU', 'altered', 'the', 'rate', 'of', 'hospital', 'admission', ',', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'visits', 'to', 'community', 'healthcare', 'practitioners', ',', 'return', 'to', 'usual', 'work/home/leisure', 'activities', 'and', 'patient', 'satisfaction', '.']","(17, 23)","(102, 135)",-1,hl_o,21896676,Abstract,1,test,gold,1949.0
4187,"AIM To investigate whether a physiotherapy service to an EECU altered the rate of hospital admission , rate of re-presentation to the ED ,",visits to community healthcare practitioners,", return to usual work/home/leisure activities and patient satisfaction .","['AIM', 'To', 'investigate', 'whether', 'a', 'physiotherapy', 'service', 'to', 'an', 'EECU', 'altered', 'the', 'rate', 'of', 'hospital', 'admission', ',', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'visits', 'to', 'community', 'healthcare', 'practitioners', ',', 'return', 'to', 'usual', 'work/home/leisure', 'activities', 'and', 'patient', 'satisfaction', '.']","(24, 29)","(138, 182)",-1,hl_o,21896676,Abstract,1,test,gold,3939.0
4188,"AIM To investigate whether a physiotherapy service to an EECU altered the rate of hospital admission , rate of re-presentation to the ED , visits to community healthcare practitioners ,",return to usual work/home/leisure activities,and patient satisfaction .,"['AIM', 'To', 'investigate', 'whether', 'a', 'physiotherapy', 'service', 'to', 'an', 'EECU', 'altered', 'the', 'rate', 'of', 'hospital', 'admission', ',', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'visits', 'to', 'community', 'healthcare', 'practitioners', ',', 'return', 'to', 'usual', 'work/home/leisure', 'activities', 'and', 'patient', 'satisfaction', '.']","(30, 35)","(185, 229)",-1,hl_o,21896676,Abstract,1,test,gold,3931.0
4189,"AIM To investigate whether a physiotherapy service to an EECU altered the rate of hospital admission , rate of re-presentation to the ED , visits to community healthcare practitioners , return to usual work/home/leisure activities and",patient satisfaction,.,"['AIM', 'To', 'investigate', 'whether', 'a', 'physiotherapy', 'service', 'to', 'an', 'EECU', 'altered', 'the', 'rate', 'of', 'hospital', 'admission', ',', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'visits', 'to', 'community', 'healthcare', 'practitioners', ',', 'return', 'to', 'usual', 'work/home/leisure', 'activities', 'and', 'patient', 'satisfaction', '.']","(36, 38)","(234, 254)",-1,hl_o,21896676,Abstract,1,test,gold,3847.0
4190,"METHODS A randomised trial with concealed allocation , assessor blinding and intention-to-treat analysis was undertaken in an EECU .",,,"['METHODS', 'A', 'randomised', 'trial', 'with', 'concealed', 'allocation', ',', 'assessor', 'blinding', 'and', 'intention-to-treat', 'analysis', 'was', 'undertaken', 'in', 'an', 'EECU', '.']",,,,,21896676,Abstract,2,test,gold,
4191,,"The sample comprised 186 patients ( mean age 70 years , 123 ( 66 % ) female patients , 130 ( 70 % ) trauma ) who were referred for physiotherapy assessment/intervention .",,"['The', 'sample', 'comprised', '186', 'patients', '(', 'mean', 'age', '70', 'years', ',', '123', '(', '66', '%', ')', 'female', 'patients', ',', '130', '(', '70', '%', ')', 'trauma', ')', 'who', 'were', 'referred', 'for', 'physiotherapy', 'assessment/intervention', '.']","(0, 33)","(0, 170)",-1,ss_p,21896676,Abstract,3,test,gold,5908.0
4192,"The sample comprised 186 patients ( mean age 70 years , 123 ( 66 % ) female patients , 130 ( 70 % ) trauma ) who were referred for",physiotherapy assessment/intervention .,,"['The', 'sample', 'comprised', '186', 'patients', '(', 'mean', 'age', '70', 'years', ',', '123', '(', '66', '%', ')', 'female', 'patients', ',', '130', '(', '70', '%', ')', 'trauma', ')', 'who', 'were', 'referred', 'for', 'physiotherapy', 'assessment/intervention', '.']","(30, 33)","(130, 169)",-1,ss_i,21896676,Abstract,3,test,gold,4233.0
4193,The sample comprised,186,"patients ( mean age 70 years , 123 ( 66 % ) female patients , 130 ( 70 % ) trauma ) who were referred for physiotherapy assessment/intervention .","['The', 'sample', 'comprised', '186', 'patients', '(', 'mean', 'age', '70', 'years', ',', '123', '(', '66', '%', ')', 'female', 'patients', ',', '130', '(', '70', '%', ')', 'trauma', ')', 'who', 'were', 'referred', 'for', 'physiotherapy', 'assessment/intervention', '.']","(3, 4)","(20, 23)",-1,hl_p,21896676,Abstract,3,test,gold,
4194,The sample comprised 186 patients (,mean age 70 years,", 123 ( 66 % ) female patients , 130 ( 70 % ) trauma ) who were referred for physiotherapy assessment/intervention .","['The', 'sample', 'comprised', '186', 'patients', '(', 'mean', 'age', '70', 'years', ',', '123', '(', '66', '%', ')', 'female', 'patients', ',', '130', '(', '70', '%', ')', 'trauma', ')', 'who', 'were', 'referred', 'for', 'physiotherapy', 'assessment/intervention', '.']","(6, 10)","(35, 52)",-1,hl_p,21896676,Abstract,3,test,gold,2016.0
4195,"The sample comprised 186 patients ( mean age 70 years ,",123,"( 66 % ) female patients , 130 ( 70 % ) trauma ) who were referred for physiotherapy assessment/intervention .","['The', 'sample', 'comprised', '186', 'patients', '(', 'mean', 'age', '70', 'years', ',', '123', '(', '66', '%', ')', 'female', 'patients', ',', '130', '(', '70', '%', ')', 'trauma', ')', 'who', 'were', 'referred', 'for', 'physiotherapy', 'assessment/intervention', '.']","(11, 12)","(55, 58)",-1,hl_p,21896676,Abstract,3,test,gold,
4196,"The sample comprised 186 patients ( mean age 70 years , 123 ( 66 % )",female,"patients , 130 ( 70 % ) trauma ) who were referred for physiotherapy assessment/intervention .","['The', 'sample', 'comprised', '186', 'patients', '(', 'mean', 'age', '70', 'years', ',', '123', '(', '66', '%', ')', 'female', 'patients', ',', '130', '(', '70', '%', ')', 'trauma', ')', 'who', 'were', 'referred', 'for', 'physiotherapy', 'assessment/intervention', '.']","(16, 17)","(68, 74)",-1,hl_p,21896676,Abstract,3,test,gold,2234.0
4197,"The sample comprised 186 patients ( mean age 70 years , 123 ( 66 % ) female patients ,",130,( 70 % ) trauma ) who were referred for physiotherapy assessment/intervention .,"['The', 'sample', 'comprised', '186', 'patients', '(', 'mean', 'age', '70', 'years', ',', '123', '(', '66', '%', ')', 'female', 'patients', ',', '130', '(', '70', '%', ')', 'trauma', ')', 'who', 'were', 'referred', 'for', 'physiotherapy', 'assessment/intervention', '.']","(19, 20)","(86, 89)",-1,hl_p,21896676,Abstract,3,test,gold,
4198,"The sample comprised 186 patients ( mean age 70 years , 123 ( 66 % ) female patients , 130 ( 70 % )",trauma,) who were referred for physiotherapy assessment/intervention .,"['The', 'sample', 'comprised', '186', 'patients', '(', 'mean', 'age', '70', 'years', ',', '123', '(', '66', '%', ')', 'female', 'patients', ',', '130', '(', '70', '%', ')', 'trauma', ')', 'who', 'were', 'referred', 'for', 'physiotherapy', 'assessment/intervention', '.']","(24, 25)","(99, 105)",-1,hl_p,21896676,Abstract,3,test,gold,2563.0
4199,"The sample comprised 186 patients ( mean age 70 years , 123 ( 66 % ) female patients , 130 ( 70 % ) trauma ) who were",referred for physiotherapy assessment/intervention,.,"['The', 'sample', 'comprised', '186', 'patients', '(', 'mean', 'age', '70', 'years', ',', '123', '(', '66', '%', ')', 'female', 'patients', ',', '130', '(', '70', '%', ')', 'trauma', ')', 'who', 'were', 'referred', 'for', 'physiotherapy', 'assessment/intervention', '.']","(28, 32)","(117, 167)",-1,hl_p,21896676,Abstract,3,test,gold,4224.0
4200,"The sample comprised 186 patients ( mean age 70 years , 123 ( 66 % ) female patients , 130 ( 70 % ) trauma ) who were referred for",physiotherapy assessment/intervention,.,"['The', 'sample', 'comprised', '186', 'patients', '(', 'mean', 'age', '70', 'years', ',', '123', '(', '66', '%', ')', 'female', 'patients', ',', '130', '(', '70', '%', ')', 'trauma', ')', 'who', 'were', 'referred', 'for', 'physiotherapy', 'assessment/intervention', '.']","(30, 32)","(130, 167)",-1,hl_i,21896676,Abstract,3,test,gold,4232.0
4201,Referral occurred at any stage of the patients ' EECU admission .,,,"['Referral', 'occurred', 'at', 'any', 'stage', 'of', 'the', 'patients', ""'"", 'EECU', 'admission', '.']",,,,,21896676,Abstract,4,test,gold,
4202,All participants received medical/nursing care as required .,,,"['All', 'participants', 'received', 'medical/nursing', 'care', 'as', 'required', '.']",,,,,21896676,Abstract,5,test,gold,
4203,The,physiotherapy,group also received physiotherapy assessment/intervention .,"['The', 'physiotherapy', 'group', 'also', 'received', 'physiotherapy', 'assessment/intervention', '.']","(1, 2)","(3, 16)",-1,ss_i,21896676,Abstract,6,test,gold,4231.0
4204,The physiotherapy group also received,physiotherapy assessment/intervention .,,"['The', 'physiotherapy', 'group', 'also', 'received', 'physiotherapy', 'assessment/intervention', '.']","(5, 8)","(37, 76)",-1,ss_i,21896676,Abstract,6,test,gold,4230.0
4205,The,physiotherapy,group also received physiotherapy assessment/intervention .,"['The', 'physiotherapy', 'group', 'also', 'received', 'physiotherapy', 'assessment/intervention', '.']","(1, 2)","(3, 16)",-1,hl_i,21896676,Abstract,6,test,gold,4229.0
4206,The physiotherapy group also received,physiotherapy assessment/intervention,.,"['The', 'physiotherapy', 'group', 'also', 'received', 'physiotherapy', 'assessment/intervention', '.']","(5, 7)","(37, 74)",-1,hl_i,21896676,Abstract,6,test,gold,4228.0
4207,RESULTS The,physiotherapy,"group had a 4 % ( 95 % CI -18 % to 9 % ) lower rate of admission to hospital than the control group and a 4 % ( 95 % CI -6 % to 13 % ) higher rate of re-presentation to the ED , which were statistically non-significant ( p≥0.45 ) .","['RESULTS', 'The', 'physiotherapy', 'group', 'had', 'a', '4', '%', '(', '95', '%', 'CI', '-18', '%', 'to', '9', '%', ')', 'lower', 'rate', 'of', 'admission', 'to', 'hospital', 'than', 'the', 'control', 'group', 'and', 'a', '4', '%', '(', '95', '%', 'CI', '-6', '%', 'to', '13', '%', ')', 'higher', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'which', 'were', 'statistically', 'non-significant', '(', 'p≥0.45', ')', '.']","(2, 3)","(11, 24)",-1,ss_i,21896676,Abstract,7,test,gold,4227.0
4208,RESULTS The physiotherapy group had a 4 % ( 95 % CI -18 % to 9 % ) lower,rate of admission to hospital,"than the control group and a 4 % ( 95 % CI -6 % to 13 % ) higher rate of re-presentation to the ED , which were statistically non-significant ( p≥0.45 ) .","['RESULTS', 'The', 'physiotherapy', 'group', 'had', 'a', '4', '%', '(', '95', '%', 'CI', '-18', '%', 'to', '9', '%', ')', 'lower', 'rate', 'of', 'admission', 'to', 'hospital', 'than', 'the', 'control', 'group', 'and', 'a', '4', '%', '(', '95', '%', 'CI', '-6', '%', 'to', '13', '%', ')', 'higher', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'which', 'were', 'statistically', 'non-significant', '(', 'p≥0.45', ')', '.']","(19, 24)","(72, 101)",-1,ss_o,21896676,Abstract,7,test,gold,3821.0
4209,RESULTS The physiotherapy group had a 4 % ( 95 % CI -18 % to 9 % ) lower rate of admission to hospital than the control group and a 4 % ( 95 % CI -6 % to 13 % ) higher,rate of re-presentation to the ED,", which were statistically non-significant ( p≥0.45 ) .","['RESULTS', 'The', 'physiotherapy', 'group', 'had', 'a', '4', '%', '(', '95', '%', 'CI', '-18', '%', 'to', '9', '%', ')', 'lower', 'rate', 'of', 'admission', 'to', 'hospital', 'than', 'the', 'control', 'group', 'and', 'a', '4', '%', '(', '95', '%', 'CI', '-6', '%', 'to', '13', '%', ')', 'higher', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'which', 'were', 'statistically', 'non-significant', '(', 'p≥0.45', ')', '.']","(43, 49)","(167, 200)",-1,ss_o,21896676,Abstract,7,test,gold,1950.0
4210,RESULTS The,physiotherapy,"group had a 4 % ( 95 % CI -18 % to 9 % ) lower rate of admission to hospital than the control group and a 4 % ( 95 % CI -6 % to 13 % ) higher rate of re-presentation to the ED , which were statistically non-significant ( p≥0.45 ) .","['RESULTS', 'The', 'physiotherapy', 'group', 'had', 'a', '4', '%', '(', '95', '%', 'CI', '-18', '%', 'to', '9', '%', ')', 'lower', 'rate', 'of', 'admission', 'to', 'hospital', 'than', 'the', 'control', 'group', 'and', 'a', '4', '%', '(', '95', '%', 'CI', '-6', '%', 'to', '13', '%', ')', 'higher', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'which', 'were', 'statistically', 'non-significant', '(', 'p≥0.45', ')', '.']","(2, 3)","(11, 24)",-1,hl_i,21896676,Abstract,7,test,gold,4226.0
4211,RESULTS The physiotherapy group had a 4 % ( 95 % CI -18 % to 9 % ) lower,rate of admission to hospital,"than the control group and a 4 % ( 95 % CI -6 % to 13 % ) higher rate of re-presentation to the ED , which were statistically non-significant ( p≥0.45 ) .","['RESULTS', 'The', 'physiotherapy', 'group', 'had', 'a', '4', '%', '(', '95', '%', 'CI', '-18', '%', 'to', '9', '%', ')', 'lower', 'rate', 'of', 'admission', 'to', 'hospital', 'than', 'the', 'control', 'group', 'and', 'a', '4', '%', '(', '95', '%', 'CI', '-6', '%', 'to', '13', '%', ')', 'higher', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'which', 'were', 'statistically', 'non-significant', '(', 'p≥0.45', ')', '.']","(19, 24)","(72, 101)",-1,hl_o,21896676,Abstract,7,test,gold,3819.0
4212,RESULTS The physiotherapy group had a 4 % ( 95 % CI -18 % to 9 % ) lower rate of admission to hospital than the control group and a 4 % ( 95 % CI -6 % to 13 % ) higher,rate of re-presentation to the ED,", which were statistically non-significant ( p≥0.45 ) .","['RESULTS', 'The', 'physiotherapy', 'group', 'had', 'a', '4', '%', '(', '95', '%', 'CI', '-18', '%', 'to', '9', '%', ')', 'lower', 'rate', 'of', 'admission', 'to', 'hospital', 'than', 'the', 'control', 'group', 'and', 'a', '4', '%', '(', '95', '%', 'CI', '-6', '%', 'to', '13', '%', ')', 'higher', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'which', 'were', 'statistically', 'non-significant', '(', 'p≥0.45', ')', '.']","(43, 49)","(167, 200)",-1,hl_o,21896676,Abstract,7,test,gold,1948.0
4213,Differences between groups,"for use of community healthcare resources , return to usual work/home/leisure activities and satisfaction with their EECU care",were small and not significant .,"['Differences', 'between', 'groups', 'for', 'use', 'of', 'community', 'healthcare', 'resources', ',', 'return', 'to', 'usual', 'work/home/leisure', 'activities', 'and', 'satisfaction', 'with', 'their', 'EECU', 'care', 'were', 'small', 'and', 'not', 'significant', '.']","(3, 21)","(26, 152)",-1,ss_o,21896676,Abstract,8,test,gold,5886.0
4214,CONCLUSION,A physiotherapy service,"for EECU patients , as provided in this study , did not reduce the rate of hospital admission , rate of re-presentation to the ED , use of community healthcare resources , or improve the rate of return to usual work/home/leisure activities or patient satisfaction .","['CONCLUSION', 'A', 'physiotherapy', 'service', 'for', 'EECU', 'patients', ',', 'as', 'provided', 'in', 'this', 'study', ',', 'did', 'not', 'reduce', 'the', 'rate', 'of', 'hospital', 'admission', ',', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'use', 'of', 'community', 'healthcare', 'resources', ',', 'or', 'improve', 'the', 'rate', 'of', 'return', 'to', 'usual', 'work/home/leisure', 'activities', 'or', 'patient', 'satisfaction', '.']","(1, 4)","(10, 33)",-1,ss_i,21896676,Abstract,9,test,gold,4219.0
4215,"CONCLUSION A physiotherapy service for EECU patients , as provided in this study , did not reduce","the rate of hospital admission , rate of re-presentation to the ED , use of community healthcare resources",", or improve the rate of return to usual work/home/leisure activities or patient satisfaction .","['CONCLUSION', 'A', 'physiotherapy', 'service', 'for', 'EECU', 'patients', ',', 'as', 'provided', 'in', 'this', 'study', ',', 'did', 'not', 'reduce', 'the', 'rate', 'of', 'hospital', 'admission', ',', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'use', 'of', 'community', 'healthcare', 'resources', ',', 'or', 'improve', 'the', 'rate', 'of', 'return', 'to', 'usual', 'work/home/leisure', 'activities', 'or', 'patient', 'satisfaction', '.']","(17, 35)","(97, 203)",-1,ss_o,21896676,Abstract,9,test,gold,5890.0
4216,"CONCLUSION A physiotherapy service for EECU patients , as provided in this study , did not reduce the rate of hospital admission , rate of re-presentation to the ED , use of community healthcare resources , or improve",the rate of return to usual work/home/leisure activities or patient satisfaction,.,"['CONCLUSION', 'A', 'physiotherapy', 'service', 'for', 'EECU', 'patients', ',', 'as', 'provided', 'in', 'this', 'study', ',', 'did', 'not', 'reduce', 'the', 'rate', 'of', 'hospital', 'admission', ',', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'use', 'of', 'community', 'healthcare', 'resources', ',', 'or', 'improve', 'the', 'rate', 'of', 'return', 'to', 'usual', 'work/home/leisure', 'activities', 'or', 'patient', 'satisfaction', '.']","(38, 49)","(217, 297)",-1,ss_o,21896676,Abstract,9,test,gold,3877.0
4217,CONCLUSION A,physiotherapy,"service for EECU patients , as provided in this study , did not reduce the rate of hospital admission , rate of re-presentation to the ED , use of community healthcare resources , or improve the rate of return to usual work/home/leisure activities or patient satisfaction .","['CONCLUSION', 'A', 'physiotherapy', 'service', 'for', 'EECU', 'patients', ',', 'as', 'provided', 'in', 'this', 'study', ',', 'did', 'not', 'reduce', 'the', 'rate', 'of', 'hospital', 'admission', ',', 'rate', 'of', 're-presentation', 'to', 'the', 'ED', ',', 'use', 'of', 'community', 'healthcare', 'resources', ',', 'or', 'improve', 'the', 'rate', 'of', 'return', 'to', 'usual', 'work/home/leisure', 'activities', 'or', 'patient', 'satisfaction', '.']","(2, 3)","(12, 25)",-1,hl_i,21896676,Abstract,9,test,gold,4225.0
4218,Trial registration number ANZCTRN12609000106235 .,,,"['Trial', 'registration', 'number', 'ANZCTRN12609000106235', '.']",,,,,21896676,Abstract,10,test,gold,
4219,,Cancer information,and anxiety : applying the extended parallel process model .,"['Cancer', 'information', 'and', 'anxiety', ':', 'applying', 'the', 'extended', 'parallel', 'process', 'model', '.']","(0, 2)","(0, 18)",-1,ss_i,21914768,Title,0,test,gold,6883.0
4220,Cancer information and,anxiety :,applying the extended parallel process model .,"['Cancer', 'information', 'and', 'anxiety', ':', 'applying', 'the', 'extended', 'parallel', 'process', 'model', '.']","(3, 5)","(22, 31)",-1,ss_o,21914768,Title,0,test,gold,2442.0
4221,Cancer information and,anxiety :,applying the extended parallel process model .,"['Cancer', 'information', 'and', 'anxiety', ':', 'applying', 'the', 'extended', 'parallel', 'process', 'model', '.']","(3, 5)","(22, 31)",-1,hl_o,21914768,Title,0,test,gold,2441.0
4222,There is concern that,public education about testicular cancer ( TC ),may cause unnecessary anxiety .,"['There', 'is', 'concern', 'that', 'public', 'education', 'about', 'testicular', 'cancer', '(', 'TC', ')', 'may', 'cause', 'unnecessary', 'anxiety', '.']","(4, 12)","(21, 68)",-1,ss_i,21914768,Abstract,0,test,gold,6891.0
4223,There is concern that public education about testicular cancer ( TC ) may cause unnecessary,anxiety .,,"['There', 'is', 'concern', 'that', 'public', 'education', 'about', 'testicular', 'cancer', '(', 'TC', ')', 'may', 'cause', 'unnecessary', 'anxiety', '.']","(15, 17)","(91, 100)",-1,ss_o,21914768,Abstract,0,test,gold,2440.0
4224,"Psychological theory suggests that if threat ( eg , TC ) information is accompanied with","threat control strategies ( eg , testicular self-examination ; TSE )",anxiety is less likely .,"['Psychological', 'theory', 'suggests', 'that', 'if', 'threat', '(', 'eg', ',', 'TC', ')', 'information', 'is', 'accompanied', 'with', 'threat', 'control', 'strategies', '(', 'eg', ',', 'testicular', 'self-examination', ';', 'TSE', ')', 'anxiety', 'is', 'less', 'likely', '.']","(15, 26)","(88, 156)",-1,ss_i,21914768,Abstract,1,test,gold,3151.0
4225,"Psychological theory suggests that if threat ( eg , TC ) information is accompanied with threat control strategies ( eg , testicular self-examination ; TSE )",anxiety,is less likely .,"['Psychological', 'theory', 'suggests', 'that', 'if', 'threat', '(', 'eg', ',', 'TC', ')', 'information', 'is', 'accompanied', 'with', 'threat', 'control', 'strategies', '(', 'eg', ',', 'testicular', 'self-examination', ';', 'TSE', ')', 'anxiety', 'is', 'less', 'likely', '.']","(26, 27)","(157, 164)",-1,ss_o,21914768,Abstract,1,test,gold,2439.0
4226,"Psychological theory suggests that if threat ( eg , TC ) information is accompanied with threat control strategies ( eg ,",testicular self-examination ;,TSE ) anxiety is less likely .,"['Psychological', 'theory', 'suggests', 'that', 'if', 'threat', '(', 'eg', ',', 'TC', ')', 'information', 'is', 'accompanied', 'with', 'threat', 'control', 'strategies', '(', 'eg', ',', 'testicular', 'self-examination', ';', 'TSE', ')', 'anxiety', 'is', 'less', 'likely', '.']","(21, 24)","(121, 150)",-1,hl_i,21914768,Abstract,1,test,gold,78.0
4227,,Male students ( N=443 ),"were randomized to either a TC or TC +TSE information group or a no information control group , and assessed at three time points .","['Male', 'students', '(', 'N=443', ')', 'were', 'randomized', 'to', 'either', 'a', 'TC', 'or', 'TC', '+TSE', 'information', 'group', 'or', 'a', 'no', 'information', 'control', 'group', ',', 'and', 'assessed', 'at', 'three', 'time', 'points', '.']","(0, 5)","(0, 23)",-1,ss_p,21914768,Abstract,2,test,gold,2185.0
4228,Male students ( N=443 ) were randomized to either a,TC,"or TC +TSE information group or a no information control group , and assessed at three time points .","['Male', 'students', '(', 'N=443', ')', 'were', 'randomized', 'to', 'either', 'a', 'TC', 'or', 'TC', '+TSE', 'information', 'group', 'or', 'a', 'no', 'information', 'control', 'group', ',', 'and', 'assessed', 'at', 'three', 'time', 'points', '.']","(10, 11)","(51, 53)",-1,ss_i,21914768,Abstract,2,test,gold,686.0
4229,Male students ( N=443 ) were randomized to either a TC or,TC +TSE,"information group or a no information control group , and assessed at three time points .","['Male', 'students', '(', 'N=443', ')', 'were', 'randomized', 'to', 'either', 'a', 'TC', 'or', 'TC', '+TSE', 'information', 'group', 'or', 'a', 'no', 'information', 'control', 'group', ',', 'and', 'assessed', 'at', 'three', 'time', 'points', '.']","(12, 14)","(57, 64)",-1,ss_i,21914768,Abstract,2,test,gold,684.0
4230,,Male students,"( N=443 ) were randomized to either a TC or TC +TSE information group or a no information control group , and assessed at three time points .","['Male', 'students', '(', 'N=443', ')', 'were', 'randomized', 'to', 'either', 'a', 'TC', 'or', 'TC', '+TSE', 'information', 'group', 'or', 'a', 'no', 'information', 'control', 'group', ',', 'and', 'assessed', 'at', 'three', 'time', 'points', '.']","(0, 2)","(0, 13)",-1,hl_p,21914768,Abstract,2,test,gold,2186.0
4231,Male students (,N=443,") were randomized to either a TC or TC +TSE information group or a no information control group , and assessed at three time points .","['Male', 'students', '(', 'N=443', ')', 'were', 'randomized', 'to', 'either', 'a', 'TC', 'or', 'TC', '+TSE', 'information', 'group', 'or', 'a', 'no', 'information', 'control', 'group', ',', 'and', 'assessed', 'at', 'three', 'time', 'points', '.']","(3, 4)","(15, 20)",-1,hl_p,21914768,Abstract,2,test,gold,
4232,Male students ( N=443 ) were randomized to either a,TC,"or TC +TSE information group or a no information control group , and assessed at three time points .","['Male', 'students', '(', 'N=443', ')', 'were', 'randomized', 'to', 'either', 'a', 'TC', 'or', 'TC', '+TSE', 'information', 'group', 'or', 'a', 'no', 'information', 'control', 'group', ',', 'and', 'assessed', 'at', 'three', 'time', 'points', '.']","(10, 11)","(51, 53)",-1,hl_i,21914768,Abstract,2,test,gold,683.0
4233,Male students ( N=443 ) were randomized to either a TC or,TC +TSE,"information group or a no information control group , and assessed at three time points .","['Male', 'students', '(', 'N=443', ')', 'were', 'randomized', 'to', 'either', 'a', 'TC', 'or', 'TC', '+TSE', 'information', 'group', 'or', 'a', 'no', 'information', 'control', 'group', ',', 'and', 'assessed', 'at', 'three', 'time', 'points', '.']","(12, 14)","(57, 64)",-1,hl_i,21914768,Abstract,2,test,gold,682.0
4234,Anxiety levels did not differ between the groups and exposure to,TC+TSE,"resulted in greater perceived message benefit , increased intention to self-examine and lower message denigration .","['Anxiety', 'levels', 'did', 'not', 'differ', 'between', 'the', 'groups', 'and', 'exposure', 'to', 'TC+TSE', 'resulted', 'in', 'greater', 'perceived', 'message', 'benefit', ',', 'increased', 'intention', 'to', 'self-examine', 'and', 'lower', 'message', 'denigration', '.']","(11, 12)","(64, 70)",-1,ss_i,21914768,Abstract,3,test,gold,
4235,,Anxiety levels,"did not differ between the groups and exposure to TC+TSE resulted in greater perceived message benefit , increased intention to self-examine and lower message denigration .","['Anxiety', 'levels', 'did', 'not', 'differ', 'between', 'the', 'groups', 'and', 'exposure', 'to', 'TC+TSE', 'resulted', 'in', 'greater', 'perceived', 'message', 'benefit', ',', 'increased', 'intention', 'to', 'self-examine', 'and', 'lower', 'message', 'denigration', '.']","(0, 2)","(0, 14)",-1,ss_o,21914768,Abstract,3,test,gold,2451.0
4236,Anxiety levels did not differ between the groups and exposure to TC+TSE resulted in greater,perceived message benefit,", increased intention to self-examine and lower message denigration .","['Anxiety', 'levels', 'did', 'not', 'differ', 'between', 'the', 'groups', 'and', 'exposure', 'to', 'TC+TSE', 'resulted', 'in', 'greater', 'perceived', 'message', 'benefit', ',', 'increased', 'intention', 'to', 'self-examine', 'and', 'lower', 'message', 'denigration', '.']","(15, 18)","(91, 116)",-1,ss_o,21914768,Abstract,3,test,gold,2993.0
4237,"Anxiety levels did not differ between the groups and exposure to TC+TSE resulted in greater perceived message benefit , increased",intention to self-examine,and lower message denigration .,"['Anxiety', 'levels', 'did', 'not', 'differ', 'between', 'the', 'groups', 'and', 'exposure', 'to', 'TC+TSE', 'resulted', 'in', 'greater', 'perceived', 'message', 'benefit', ',', 'increased', 'intention', 'to', 'self-examine', 'and', 'lower', 'message', 'denigration', '.']","(20, 23)","(129, 154)",-1,ss_o,21914768,Abstract,3,test,gold,1228.0
4238,"Anxiety levels did not differ between the groups and exposure to TC+TSE resulted in greater perceived message benefit , increased intention to self-examine and lower",message denigration .,,"['Anxiety', 'levels', 'did', 'not', 'differ', 'between', 'the', 'groups', 'and', 'exposure', 'to', 'TC+TSE', 'resulted', 'in', 'greater', 'perceived', 'message', 'benefit', ',', 'increased', 'intention', 'to', 'self-examine', 'and', 'lower', 'message', 'denigration', '.']","(25, 28)","(165, 186)",-1,ss_o,21914768,Abstract,3,test,gold,2995.0
4239,,Anxiety levels,"did not differ between the groups and exposure to TC+TSE resulted in greater perceived message benefit , increased intention to self-examine and lower message denigration .","['Anxiety', 'levels', 'did', 'not', 'differ', 'between', 'the', 'groups', 'and', 'exposure', 'to', 'TC+TSE', 'resulted', 'in', 'greater', 'perceived', 'message', 'benefit', ',', 'increased', 'intention', 'to', 'self-examine', 'and', 'lower', 'message', 'denigration', '.']","(0, 2)","(0, 14)",-1,hl_o,21914768,Abstract,3,test,gold,2452.0
4240,Anxiety levels did not differ between the groups and exposure to TC+TSE resulted in greater,perceived message benefit,", increased intention to self-examine and lower message denigration .","['Anxiety', 'levels', 'did', 'not', 'differ', 'between', 'the', 'groups', 'and', 'exposure', 'to', 'TC+TSE', 'resulted', 'in', 'greater', 'perceived', 'message', 'benefit', ',', 'increased', 'intention', 'to', 'self-examine', 'and', 'lower', 'message', 'denigration', '.']","(15, 18)","(91, 116)",-1,hl_o,21914768,Abstract,3,test,gold,2994.0
4241,"Anxiety levels did not differ between the groups and exposure to TC+TSE resulted in greater perceived message benefit , increased",intention to self-examine,and lower message denigration .,"['Anxiety', 'levels', 'did', 'not', 'differ', 'between', 'the', 'groups', 'and', 'exposure', 'to', 'TC+TSE', 'resulted', 'in', 'greater', 'perceived', 'message', 'benefit', ',', 'increased', 'intention', 'to', 'self-examine', 'and', 'lower', 'message', 'denigration', '.']","(20, 23)","(129, 154)",-1,hl_o,21914768,Abstract,3,test,gold,1229.0
4242,"Anxiety levels did not differ between the groups and exposure to TC+TSE resulted in greater perceived message benefit , increased intention to self-examine and lower",message denigration .,,"['Anxiety', 'levels', 'did', 'not', 'differ', 'between', 'the', 'groups', 'and', 'exposure', 'to', 'TC+TSE', 'resulted', 'in', 'greater', 'perceived', 'message', 'benefit', ',', 'increased', 'intention', 'to', 'self-examine', 'and', 'lower', 'message', 'denigration', '.']","(25, 28)","(165, 186)",-1,hl_o,21914768,Abstract,3,test,gold,2996.0
4243,This suggests,TC,"information is not anxiogenic , but inclusion of TSE information may improve acceptance of disease awareness information .","['This', 'suggests', 'TC', 'information', 'is', 'not', 'anxiogenic', ',', 'but', 'inclusion', 'of', 'TSE', 'information', 'may', 'improve', 'acceptance', 'of', 'disease', 'awareness', 'information', '.']","(2, 3)","(13, 15)",-1,ss_i,21914768,Abstract,4,test,gold,681.0
4244,"This suggests TC information is not anxiogenic , but inclusion of",TSE,information may improve acceptance of disease awareness information .,"['This', 'suggests', 'TC', 'information', 'is', 'not', 'anxiogenic', ',', 'but', 'inclusion', 'of', 'TSE', 'information', 'may', 'improve', 'acceptance', 'of', 'disease', 'awareness', 'information', '.']","(11, 12)","(65, 68)",-1,ss_i,21914768,Abstract,4,test,gold,1095.0
4245,This suggests TC information is not,anxiogenic,", but inclusion of TSE information may improve acceptance of disease awareness information .","['This', 'suggests', 'TC', 'information', 'is', 'not', 'anxiogenic', ',', 'but', 'inclusion', 'of', 'TSE', 'information', 'may', 'improve', 'acceptance', 'of', 'disease', 'awareness', 'information', '.']","(6, 7)","(35, 45)",-1,ss_o,21914768,Abstract,4,test,gold,
4246,"This suggests TC information is not anxiogenic , but inclusion of TSE information may improve",acceptance of disease awareness information .,,"['This', 'suggests', 'TC', 'information', 'is', 'not', 'anxiogenic', ',', 'but', 'inclusion', 'of', 'TSE', 'information', 'may', 'improve', 'acceptance', 'of', 'disease', 'awareness', 'information', '.']","(15, 21)","(93, 138)",-1,ss_o,21914768,Abstract,4,test,gold,6420.0
4247,This suggests,TC,"information is not anxiogenic , but inclusion of TSE information may improve acceptance of disease awareness information .","['This', 'suggests', 'TC', 'information', 'is', 'not', 'anxiogenic', ',', 'but', 'inclusion', 'of', 'TSE', 'information', 'may', 'improve', 'acceptance', 'of', 'disease', 'awareness', 'information', '.']","(2, 3)","(13, 15)",-1,hl_i,21914768,Abstract,4,test,gold,680.0
4248,Quality of individual INR control and the risk of stroke and bleeding events in,atrial fibrillation patients :,a nested case control analysis of the ACTIVE W study .,"['Quality', 'of', 'individual', 'INR', 'control', 'and', 'the', 'risk', 'of', 'stroke', 'and', 'bleeding', 'events', 'in', 'atrial', 'fibrillation', 'patients', ':', 'a', 'nested', 'case', 'control', 'analysis', 'of', 'the', 'ACTIVE', 'W', 'study', '.']","(14, 18)","(79, 109)",-1,ss_p,21924760,Title,0,test,gold,6789.0
4249,Quality of individual INR control and the,risk of stroke and bleeding events,in atrial fibrillation patients : a nested case control analysis of the ACTIVE W study .,"['Quality', 'of', 'individual', 'INR', 'control', 'and', 'the', 'risk', 'of', 'stroke', 'and', 'bleeding', 'events', 'in', 'atrial', 'fibrillation', 'patients', ':', 'a', 'nested', 'case', 'control', 'analysis', 'of', 'the', 'ACTIVE', 'W', 'study', '.']","(7, 13)","(41, 75)",-1,ss_o,21924760,Title,0,test,gold,3372.0
4250,Quality of individual INR control and the risk of stroke and bleeding events in,atrial fibrillation patients :,a nested case control analysis of the ACTIVE W study .,"['Quality', 'of', 'individual', 'INR', 'control', 'and', 'the', 'risk', 'of', 'stroke', 'and', 'bleeding', 'events', 'in', 'atrial', 'fibrillation', 'patients', ':', 'a', 'nested', 'case', 'control', 'analysis', 'of', 'the', 'ACTIVE', 'W', 'study', '.']","(14, 18)","(79, 109)",-1,hl_p,21924760,Title,0,test,gold,6790.0
4251,INTRODUCTION,Time in therapeutic range ( TTR ),"for international normalized ratio ( INR ) is an accepted quality measure of anticoagulation control in patient populations , but its usefulness for predicting stroke and bleeding in individuals is not well understood .","['INTRODUCTION', 'Time', 'in', 'therapeutic', 'range', '(', 'TTR', ')', 'for', 'international', 'normalized', 'ratio', '(', 'INR', ')', 'is', 'an', 'accepted', 'quality', 'measure', 'of', 'anticoagulation', 'control', 'in', 'patient', 'populations', ',', 'but', 'its', 'usefulness', 'for', 'predicting', 'stroke', 'and', 'bleeding', 'in', 'individuals', 'is', 'not', 'well', 'understood', '.']","(1, 8)","(12, 45)",-1,ss_i,21924760,Abstract,0,test,gold,4188.0
4252,INTRODUCTION,Time in therapeutic range ( TTR ),"for international normalized ratio ( INR ) is an accepted quality measure of anticoagulation control in patient populations , but its usefulness for predicting stroke and bleeding in individuals is not well understood .","['INTRODUCTION', 'Time', 'in', 'therapeutic', 'range', '(', 'TTR', ')', 'for', 'international', 'normalized', 'ratio', '(', 'INR', ')', 'is', 'an', 'accepted', 'quality', 'measure', 'of', 'anticoagulation', 'control', 'in', 'patient', 'populations', ',', 'but', 'its', 'usefulness', 'for', 'predicting', 'stroke', 'and', 'bleeding', 'in', 'individuals', 'is', 'not', 'well', 'understood', '.']","(1, 8)","(12, 45)",-1,ss_o,21924760,Abstract,0,test,gold,4189.0
4253,"INTRODUCTION Time in therapeutic range ( TTR ) for international normalized ratio ( INR ) is an accepted quality measure of anticoagulation control in patient populations , but its usefulness for predicting",stroke and bleeding,in individuals is not well understood .,"['INTRODUCTION', 'Time', 'in', 'therapeutic', 'range', '(', 'TTR', ')', 'for', 'international', 'normalized', 'ratio', '(', 'INR', ')', 'is', 'an', 'accepted', 'quality', 'measure', 'of', 'anticoagulation', 'control', 'in', 'patient', 'populations', ',', 'but', 'its', 'usefulness', 'for', 'predicting', 'stroke', 'and', 'bleeding', 'in', 'individuals', 'is', 'not', 'well', 'understood', '.']","(32, 35)","(206, 225)",-1,ss_o,21924760,Abstract,0,test,gold,3373.0
4254,INTRODUCTION,Time in therapeutic range ( TTR ),"for international normalized ratio ( INR ) is an accepted quality measure of anticoagulation control in patient populations , but its usefulness for predicting stroke and bleeding in individuals is not well understood .","['INTRODUCTION', 'Time', 'in', 'therapeutic', 'range', '(', 'TTR', ')', 'for', 'international', 'normalized', 'ratio', '(', 'INR', ')', 'is', 'an', 'accepted', 'quality', 'measure', 'of', 'anticoagulation', 'control', 'in', 'patient', 'populations', ',', 'but', 'its', 'usefulness', 'for', 'predicting', 'stroke', 'and', 'bleeding', 'in', 'individuals', 'is', 'not', 'well', 'understood', '.']","(1, 8)","(12, 45)",-1,hl_i,21924760,Abstract,0,test,gold,4187.0
4255,INTRODUCTION,Time in therapeutic range ( TTR ),"for international normalized ratio ( INR ) is an accepted quality measure of anticoagulation control in patient populations , but its usefulness for predicting stroke and bleeding in individuals is not well understood .","['INTRODUCTION', 'Time', 'in', 'therapeutic', 'range', '(', 'TTR', ')', 'for', 'international', 'normalized', 'ratio', '(', 'INR', ')', 'is', 'an', 'accepted', 'quality', 'measure', 'of', 'anticoagulation', 'control', 'in', 'patient', 'populations', ',', 'but', 'its', 'usefulness', 'for', 'predicting', 'stroke', 'and', 'bleeding', 'in', 'individuals', 'is', 'not', 'well', 'understood', '.']","(1, 8)","(12, 45)",-1,hl_o,21924760,Abstract,0,test,gold,4186.0
4256,MATERIALS AND METHODS In a nested case control analysis among,"ACTIVE W study patients , cases with stroke and cases with bleeding were separately matched with controls .",,"['MATERIALS', 'AND', 'METHODS', 'In', 'a', 'nested', 'case', 'control', 'analysis', 'among', 'ACTIVE', 'W', 'study', 'patients', ',', 'cases', 'with', 'stroke', 'and', 'cases', 'with', 'bleeding', 'were', 'separately', 'matched', 'with', 'controls', '.']","(10, 28)","(61, 168)",-1,ss_p,21924760,Abstract,1,test,gold,5905.0
4257,MATERIALS AND METHODS In a nested case control analysis among,"ACTIVE W study patients , cases with stroke and cases with bleeding were separately matched with controls .",,"['MATERIALS', 'AND', 'METHODS', 'In', 'a', 'nested', 'case', 'control', 'analysis', 'among', 'ACTIVE', 'W', 'study', 'patients', ',', 'cases', 'with', 'stroke', 'and', 'cases', 'with', 'bleeding', 'were', 'separately', 'matched', 'with', 'controls', '.']","(10, 28)","(61, 168)",-1,hl_p,21924760,Abstract,1,test,gold,5906.0
4258,Several,anticoagulation quality measures,"were compared , overall and in a time-dependent manner .","['Several', 'anticoagulation', 'quality', 'measures', 'were', 'compared', ',', 'overall', 'and', 'in', 'a', 'time-dependent', 'manner', '.']","(1, 4)","(7, 39)",-1,ss_o,21924760,Abstract,2,test,gold,1834.0
4259,RESULTS,32 cases with ischemic stroke and 234 cases with bleeding in the analysis were matched,"in a 4:1 ratio to 122 and 865 controls , respectively .","['RESULTS', '32', 'cases', 'with', 'ischemic', 'stroke', 'and', '234', 'cases', 'with', 'bleeding', 'in', 'the', 'analysis', 'were', 'matched', 'in', 'a', '4:1', 'ratio', 'to', '122', 'and', '865', 'controls', ',', 'respectively', '.']","(1, 16)","(7, 93)",-1,ss_p,21924760,Abstract,3,test,gold,5904.0
4260,RESULTS 32 cases with ischemic stroke and 234 cases with bleeding in the analysis were matched in a 4:1 ratio to,122 and 865 controls,", respectively .","['RESULTS', '32', 'cases', 'with', 'ischemic', 'stroke', 'and', '234', 'cases', 'with', 'bleeding', 'in', 'the', 'analysis', 'were', 'matched', 'in', 'a', '4:1', 'ratio', 'to', '122', 'and', '865', 'controls', ',', 'respectively', '.']","(21, 25)","(112, 132)",-1,ss_p,21924760,Abstract,3,test,gold,1299.0
4261,RESULTS,32 cases with ischemic stroke,"and 234 cases with bleeding in the analysis were matched in a 4:1 ratio to 122 and 865 controls , respectively .","['RESULTS', '32', 'cases', 'with', 'ischemic', 'stroke', 'and', '234', 'cases', 'with', 'bleeding', 'in', 'the', 'analysis', 'were', 'matched', 'in', 'a', '4:1', 'ratio', 'to', '122', 'and', '865', 'controls', ',', 'respectively', '.']","(1, 6)","(7, 36)",-1,hl_p,21924760,Abstract,3,test,gold,3384.0
4262,RESULTS 32 cases with ischemic stroke and,234 cases with bleeding,"in the analysis were matched in a 4:1 ratio to 122 and 865 controls , respectively .","['RESULTS', '32', 'cases', 'with', 'ischemic', 'stroke', 'and', '234', 'cases', 'with', 'bleeding', 'in', 'the', 'analysis', 'were', 'matched', 'in', 'a', '4:1', 'ratio', 'to', '122', 'and', '865', 'controls', ',', 'respectively', '.']","(7, 11)","(41, 64)",-1,hl_p,21924760,Abstract,3,test,gold,2645.0
4263,Follow-up duration was 257±154days for,the stroke analysis,and 222±146days for the bleeding analysis .,"['Follow-up', 'duration', 'was', '257±154days', 'for', 'the', 'stroke', 'analysis', 'and', '222±146days', 'for', 'the', 'bleeding', 'analysis', '.']","(5, 8)","(38, 57)",-1,ss_o,21924760,Abstract,4,test,gold,3374.0
4264,Follow-up duration was 257±154days for the stroke analysis and 222±146days for,the bleeding analysis,.,"['Follow-up', 'duration', 'was', '257±154days', 'for', 'the', 'stroke', 'analysis', 'and', '222±146days', 'for', 'the', 'bleeding', 'analysis', '.']","(11, 14)","(78, 99)",-1,ss_o,21924760,Abstract,4,test,gold,2646.0
4265,"Compared with their respective controls , the study",mean TTR,of both stroke cases ( 53.9 % ±25.1 vs 63.4 % ±24.8 ; p=0.055 ) and bleeding cases ( 56.2 % ±25.4 vs 63.4 % ±26.8 ; p < 0.001 ) was lower .,"['Compared', 'with', 'their', 'respective', 'controls', ',', 'the', 'study', 'mean', 'TTR', 'of', 'both', 'stroke', 'cases', '(', '53.9', '%', '±25.1', 'vs', '63.4', '%', '±24.8', ';', 'p=0.055', ')', 'and', 'bleeding', 'cases', '(', '56.2', '%', '±25.4', 'vs', '63.4', '%', '±26.8', ';', 'p', '<', '0.001', ')', 'was', 'lower', '.']","(8, 10)","(51, 59)",-1,ss_i,21924760,Abstract,5,test,gold,1335.0
4266,"Compared with their respective controls , the study",mean TTR,of both stroke cases ( 53.9 % ±25.1 vs 63.4 % ±24.8 ; p=0.055 ) and bleeding cases ( 56.2 % ±25.4 vs 63.4 % ±26.8 ; p < 0.001 ) was lower .,"['Compared', 'with', 'their', 'respective', 'controls', ',', 'the', 'study', 'mean', 'TTR', 'of', 'both', 'stroke', 'cases', '(', '53.9', '%', '±25.1', 'vs', '63.4', '%', '±24.8', ';', 'p=0.055', ')', 'and', 'bleeding', 'cases', '(', '56.2', '%', '±25.4', 'vs', '63.4', '%', '±26.8', ';', 'p', '<', '0.001', ')', 'was', 'lower', '.']","(8, 10)","(51, 59)",-1,ss_o,21924760,Abstract,5,test,gold,1336.0
4267,"Compared with their respective controls , the study mean TTR of both stroke cases ( 53.9 % ±25.1 vs 63.4 % ±24.8 ; p=0.055 ) and bleeding cases ( 56.2 % ±25.4 vs 63.4 % ±26.8 ; p < 0.001 ) was",lower .,,"['Compared', 'with', 'their', 'respective', 'controls', ',', 'the', 'study', 'mean', 'TTR', 'of', 'both', 'stroke', 'cases', '(', '53.9', '%', '±25.1', 'vs', '63.4', '%', '±24.8', ';', 'p=0.055', ')', 'and', 'bleeding', 'cases', '(', '56.2', '%', '±25.4', 'vs', '63.4', '%', '±26.8', ';', 'p', '<', '0.001', ')', 'was', 'lower', '.']","(42, 44)","(192, 199)",-1,ss_o,21924760,Abstract,5,test,gold,1223.0
4268,"Compared with their respective controls , the study mean",TTR,of both stroke cases ( 53.9 % ±25.1 vs 63.4 % ±24.8 ; p=0.055 ) and bleeding cases ( 56.2 % ±25.4 vs 63.4 % ±26.8 ; p < 0.001 ) was lower .,"['Compared', 'with', 'their', 'respective', 'controls', ',', 'the', 'study', 'mean', 'TTR', 'of', 'both', 'stroke', 'cases', '(', '53.9', '%', '±25.1', 'vs', '63.4', '%', '±24.8', ';', 'p=0.055', ')', 'and', 'bleeding', 'cases', '(', '56.2', '%', '±25.4', 'vs', '63.4', '%', '±26.8', ';', 'p', '<', '0.001', ')', 'was', 'lower', '.']","(9, 10)","(56, 59)",-1,hl_i,21924760,Abstract,5,test,gold,1334.0
4269,Time below range for,stroke and,"time above range for bleeding were only greater in the last month leading up to the event , not over the entire study period .","['Time', 'below', 'range', 'for', 'stroke', 'and', 'time', 'above', 'range', 'for', 'bleeding', 'were', 'only', 'greater', 'in', 'the', 'last', 'month', 'leading', 'up', 'to', 'the', 'event', ',', 'not', 'over', 'the', 'entire', 'study', 'period', '.']","(4, 6)","(20, 30)",-1,ss_o,21924760,Abstract,6,test,gold,3376.0
4270,,Time below range for stroke,"and time above range for bleeding were only greater in the last month leading up to the event , not over the entire study period .","['Time', 'below', 'range', 'for', 'stroke', 'and', 'time', 'above', 'range', 'for', 'bleeding', 'were', 'only', 'greater', 'in', 'the', 'last', 'month', 'leading', 'up', 'to', 'the', 'event', ',', 'not', 'over', 'the', 'entire', 'study', 'period', '.']","(0, 5)","(0, 27)",-1,hl_o,21924760,Abstract,6,test,gold,3387.0
4271,Time below range for stroke and,time above range for bleeding,"were only greater in the last month leading up to the event , not over the entire study period .","['Time', 'below', 'range', 'for', 'stroke', 'and', 'time', 'above', 'range', 'for', 'bleeding', 'were', 'only', 'greater', 'in', 'the', 'last', 'month', 'leading', 'up', 'to', 'the', 'event', ',', 'not', 'over', 'the', 'entire', 'study', 'period', '.']","(6, 11)","(31, 60)",-1,hl_o,21924760,Abstract,6,test,gold,3388.0
4272,"Rather , over the entire study period bleeding cases",spent more,time below range than controls ( 26.8 % ±25.9 vs 20.8 % ±24.0 ; p=0.001 ) .,"['Rather', ',', 'over', 'the', 'entire', 'study', 'period', 'bleeding', 'cases', 'spent', 'more', 'time', 'below', 'range', 'than', 'controls', '(', '26.8', '%', '±25.9', 'vs', '20.8', '%', '±24.0', ';', 'p=0.001', ')', '.']","(9, 11)","(52, 62)",-1,ss_o,21924760,Abstract,7,test,gold,1152.0
4273,CONCLUSIONS TTR was,lower in individual AF patients,"with stroke or bleeding compared with matched controls in ACTIVE W. Maintaining a high TTR , with equal importance to avoid low and high INRs , is a relevant goal of individual patient treatment to prevent stroke and bleeding .","['CONCLUSIONS', 'TTR', 'was', 'lower', 'in', 'individual', 'AF', 'patients', 'with', 'stroke', 'or', 'bleeding', 'compared', 'with', 'matched', 'controls', 'in', 'ACTIVE', 'W.', 'Maintaining', 'a', 'high', 'TTR', ',', 'with', 'equal', 'importance', 'to', 'avoid', 'low', 'and', 'high', 'INRs', ',', 'is', 'a', 'relevant', 'goal', 'of', 'individual', 'patient', 'treatment', 'to', 'prevent', 'stroke', 'and', 'bleeding', '.']","(3, 8)","(19, 50)",-1,ss_p,21924760,Abstract,8,test,gold,3871.0
4274,,CONCLUSIONS,"TTR was lower in individual AF patients with stroke or bleeding compared with matched controls in ACTIVE W. Maintaining a high TTR , with equal importance to avoid low and high INRs , is a relevant goal of individual patient treatment to prevent stroke and bleeding .","['CONCLUSIONS', 'TTR', 'was', 'lower', 'in', 'individual', 'AF', 'patients', 'with', 'stroke', 'or', 'bleeding', 'compared', 'with', 'matched', 'controls', 'in', 'ACTIVE', 'W.', 'Maintaining', 'a', 'high', 'TTR', ',', 'with', 'equal', 'importance', 'to', 'avoid', 'low', 'and', 'high', 'INRs', ',', 'is', 'a', 'relevant', 'goal', 'of', 'individual', 'patient', 'treatment', 'to', 'prevent', 'stroke', 'and', 'bleeding', '.']","(0, 1)","(0, 11)",-1,ss_i,21924760,Abstract,8,test,gold,433.0
4275,CONCLUSIONS TTR was lower in individual AF patients with stroke or bleeding compared with matched controls in ACTIVE W.,Maintaining a high,"TTR , with equal importance to avoid low and high INRs , is a relevant goal of individual patient treatment to prevent stroke and bleeding .","['CONCLUSIONS', 'TTR', 'was', 'lower', 'in', 'individual', 'AF', 'patients', 'with', 'stroke', 'or', 'bleeding', 'compared', 'with', 'matched', 'controls', 'in', 'ACTIVE', 'W.', 'Maintaining', 'a', 'high', 'TTR', ',', 'with', 'equal', 'importance', 'to', 'avoid', 'low', 'and', 'high', 'INRs', ',', 'is', 'a', 'relevant', 'goal', 'of', 'individual', 'patient', 'treatment', 'to', 'prevent', 'stroke', 'and', 'bleeding', '.']","(19, 22)","(119, 137)",-1,ss_i,21924760,Abstract,8,test,gold,977.0
4276,,CONCLUSIONS,"TTR was lower in individual AF patients with stroke or bleeding compared with matched controls in ACTIVE W. Maintaining a high TTR , with equal importance to avoid low and high INRs , is a relevant goal of individual patient treatment to prevent stroke and bleeding .","['CONCLUSIONS', 'TTR', 'was', 'lower', 'in', 'individual', 'AF', 'patients', 'with', 'stroke', 'or', 'bleeding', 'compared', 'with', 'matched', 'controls', 'in', 'ACTIVE', 'W.', 'Maintaining', 'a', 'high', 'TTR', ',', 'with', 'equal', 'importance', 'to', 'avoid', 'low', 'and', 'high', 'INRs', ',', 'is', 'a', 'relevant', 'goal', 'of', 'individual', 'patient', 'treatment', 'to', 'prevent', 'stroke', 'and', 'bleeding', '.']","(0, 1)","(0, 11)",-1,ss_o,21924760,Abstract,8,test,gold,434.0
4277,CONCLUSIONS TTR was lower in individual AF patients with stroke or bleeding compared with matched controls in ACTIVE W.,Maintaining a high,"TTR , with equal importance to avoid low and high INRs , is a relevant goal of individual patient treatment to prevent stroke and bleeding .","['CONCLUSIONS', 'TTR', 'was', 'lower', 'in', 'individual', 'AF', 'patients', 'with', 'stroke', 'or', 'bleeding', 'compared', 'with', 'matched', 'controls', 'in', 'ACTIVE', 'W.', 'Maintaining', 'a', 'high', 'TTR', ',', 'with', 'equal', 'importance', 'to', 'avoid', 'low', 'and', 'high', 'INRs', ',', 'is', 'a', 'relevant', 'goal', 'of', 'individual', 'patient', 'treatment', 'to', 'prevent', 'stroke', 'and', 'bleeding', '.']","(19, 22)","(119, 137)",-1,ss_o,21924760,Abstract,8,test,gold,978.0
4278,"CONCLUSIONS TTR was lower in individual AF patients with stroke or bleeding compared with matched controls in ACTIVE W. Maintaining a high TTR , with equal importance to avoid low and high INRs , is a relevant goal of individual patient",treatment to prevent stroke and bleeding,.,"['CONCLUSIONS', 'TTR', 'was', 'lower', 'in', 'individual', 'AF', 'patients', 'with', 'stroke', 'or', 'bleeding', 'compared', 'with', 'matched', 'controls', 'in', 'ACTIVE', 'W.', 'Maintaining', 'a', 'high', 'TTR', ',', 'with', 'equal', 'importance', 'to', 'avoid', 'low', 'and', 'high', 'INRs', ',', 'is', 'a', 'relevant', 'goal', 'of', 'individual', 'patient', 'treatment', 'to', 'prevent', 'stroke', 'and', 'bleeding', '.']","(41, 47)","(236, 276)",-1,ss_o,21924760,Abstract,8,test,gold,3371.0
4279,Use of,hormonal contraceptives,and risk of HIV-1 transmission : a prospective cohort study .,"['Use', 'of', 'hormonal', 'contraceptives', 'and', 'risk', 'of', 'HIV-1', 'transmission', ':', 'a', 'prospective', 'cohort', 'study', '.']","(2, 4)","(6, 29)",-1,ss_i,21975269,Title,0,test,gold,3898.0
4280,Use of hormonal contraceptives and,risk of HIV-1 transmission :,a prospective cohort study .,"['Use', 'of', 'hormonal', 'contraceptives', 'and', 'risk', 'of', 'HIV-1', 'transmission', ':', 'a', 'prospective', 'cohort', 'study', '.']","(5, 10)","(34, 62)",-1,ss_o,21975269,Title,0,test,gold,991.0
4281,Use of,hormonal contraceptives,and risk of HIV-1 transmission : a prospective cohort study .,"['Use', 'of', 'hormonal', 'contraceptives', 'and', 'risk', 'of', 'HIV-1', 'transmission', ':', 'a', 'prospective', 'cohort', 'study', '.']","(2, 4)","(6, 29)",-1,hl_i,21975269,Title,0,test,gold,3899.0
4282,BACKGROUND,Hormonal contraceptives,are used widely but their effects on HIV-1 risk are unclear .,"['BACKGROUND', 'Hormonal', 'contraceptives', 'are', 'used', 'widely', 'but', 'their', 'effects', 'on', 'HIV-1', 'risk', 'are', 'unclear', '.']","(1, 3)","(10, 33)",-1,ss_i,21975269,Abstract,0,test,gold,3894.0
4283,BACKGROUND,Hormonal contraceptives,are used widely but their effects on HIV-1 risk are unclear .,"['BACKGROUND', 'Hormonal', 'contraceptives', 'are', 'used', 'widely', 'but', 'their', 'effects', 'on', 'HIV-1', 'risk', 'are', 'unclear', '.']","(1, 3)","(10, 33)",-1,hl_i,21975269,Abstract,0,test,gold,3895.0
4284,We aimed to assess the association between,hormonal contraceptive,use and risk of HIV-1 acquisition by women and HIV-1 transmission from HIV-1-infected women to their male partners .,"['We', 'aimed', 'to', 'assess', 'the', 'association', 'between', 'hormonal', 'contraceptive', 'use', 'and', 'risk', 'of', 'HIV-1', 'acquisition', 'by', 'women', 'and', 'HIV-1', 'transmission', 'from', 'HIV-1-infected', 'women', 'to', 'their', 'male', 'partners', '.']","(7, 9)","(42, 64)",-1,ss_i,21975269,Abstract,1,test,gold,3902.0
4285,We aimed to assess the association between hormonal contraceptive use and,risk of HIV-1 acquisition,by women and HIV-1 transmission from HIV-1-infected women to their male partners .,"['We', 'aimed', 'to', 'assess', 'the', 'association', 'between', 'hormonal', 'contraceptive', 'use', 'and', 'risk', 'of', 'HIV-1', 'acquisition', 'by', 'women', 'and', 'HIV-1', 'transmission', 'from', 'HIV-1-infected', 'women', 'to', 'their', 'male', 'partners', '.']","(11, 15)","(73, 98)",-1,ss_o,21975269,Abstract,1,test,gold,999.0
4286,We aimed to assess the association between hormonal contraceptive use and risk of HIV-1 acquisition by women and,HIV-1 transmission,from HIV-1-infected women to their male partners .,"['We', 'aimed', 'to', 'assess', 'the', 'association', 'between', 'hormonal', 'contraceptive', 'use', 'and', 'risk', 'of', 'HIV-1', 'acquisition', 'by', 'women', 'and', 'HIV-1', 'transmission', 'from', 'HIV-1-infected', 'women', 'to', 'their', 'male', 'partners', '.']","(18, 20)","(112, 130)",-1,ss_o,21975269,Abstract,1,test,gold,993.0
4287,We aimed to assess the association between,hormonal contraceptive,use and risk of HIV-1 acquisition by women and HIV-1 transmission from HIV-1-infected women to their male partners .,"['We', 'aimed', 'to', 'assess', 'the', 'association', 'between', 'hormonal', 'contraceptive', 'use', 'and', 'risk', 'of', 'HIV-1', 'acquisition', 'by', 'women', 'and', 'HIV-1', 'transmission', 'from', 'HIV-1-infected', 'women', 'to', 'their', 'male', 'partners', '.']","(7, 9)","(42, 64)",-1,hl_i,21975269,Abstract,1,test,gold,3903.0
4288,"METHODS In this prospective study , we followed up",3790 heterosexual HIV-1-serodiscordant couples participating in two longitudinal studies of HIV-1 incidence in seven African countries .,,"['METHODS', 'In', 'this', 'prospective', 'study', ',', 'we', 'followed', 'up', '3790', 'heterosexual', 'HIV-1-serodiscordant', 'couples', 'participating', 'in', 'two', 'longitudinal', 'studies', 'of', 'HIV-1', 'incidence', 'in', 'seven', 'African', 'countries', '.']","(9, 26)","(50, 186)",-1,ss_p,21975269,Abstract,2,test,gold,5822.0
4289,"METHODS In this prospective study , we followed up",3790 heterosexual HIV-1-serodiscordant couples participating in two longitudinal studies of HIV-1 incidence in seven African countries,.,"['METHODS', 'In', 'this', 'prospective', 'study', ',', 'we', 'followed', 'up', '3790', 'heterosexual', 'HIV-1-serodiscordant', 'couples', 'participating', 'in', 'two', 'longitudinal', 'studies', 'of', 'HIV-1', 'incidence', 'in', 'seven', 'African', 'countries', '.']","(9, 25)","(50, 184)",-1,hl_p,21975269,Abstract,2,test,gold,5823.0
4290,Among injectable and oral,hormonal contraceptive,"users and non-users , we compared rates of HIV-1 acquisition by women and HIV-1 transmission from women to men .","['Among', 'injectable', 'and', 'oral', 'hormonal', 'contraceptive', 'users', 'and', 'non-users', ',', 'we', 'compared', 'rates', 'of', 'HIV-1', 'acquisition', 'by', 'women', 'and', 'HIV-1', 'transmission', 'from', 'women', 'to', 'men', '.']","(4, 6)","(25, 47)",-1,ss_i,21975269,Abstract,3,test,gold,3901.0
4291,"Among injectable and oral hormonal contraceptive users and non-users , we compared",rates of HIV-1 acquisition,by women and HIV-1 transmission from women to men .,"['Among', 'injectable', 'and', 'oral', 'hormonal', 'contraceptive', 'users', 'and', 'non-users', ',', 'we', 'compared', 'rates', 'of', 'HIV-1', 'acquisition', 'by', 'women', 'and', 'HIV-1', 'transmission', 'from', 'women', 'to', 'men', '.']","(12, 16)","(82, 108)",-1,ss_o,21975269,Abstract,3,test,gold,1918.0
4292,"Among injectable and oral hormonal contraceptive users and non-users , we compared rates of HIV-1 acquisition by women and",HIV-1 transmission,from women to men .,"['Among', 'injectable', 'and', 'oral', 'hormonal', 'contraceptive', 'users', 'and', 'non-users', ',', 'we', 'compared', 'rates', 'of', 'HIV-1', 'acquisition', 'by', 'women', 'and', 'HIV-1', 'transmission', 'from', 'women', 'to', 'men', '.']","(19, 21)","(122, 140)",-1,ss_o,21975269,Abstract,3,test,gold,994.0
4293,Among injectable and oral,hormonal contraceptive,"users and non-users , we compared rates of HIV-1 acquisition by women and HIV-1 transmission from women to men .","['Among', 'injectable', 'and', 'oral', 'hormonal', 'contraceptive', 'users', 'and', 'non-users', ',', 'we', 'compared', 'rates', 'of', 'HIV-1', 'acquisition', 'by', 'women', 'and', 'HIV-1', 'transmission', 'from', 'women', 'to', 'men', '.']","(4, 6)","(25, 47)",-1,hl_i,21975269,Abstract,3,test,gold,3900.0
4294,The primary outcome measure was,HIV-1 seroconversion .,,"['The', 'primary', 'outcome', 'measure', 'was', 'HIV-1', 'seroconversion', '.']","(5, 8)","(31, 53)",-1,ss_o,21975269,Abstract,4,test,gold,85.0
4295,We used Cox proportional hazards regression and marginal structural modelling to assess the effect of contraceptive use on,HIV-1 risk .,,"['We', 'used', 'Cox', 'proportional', 'hazards', 'regression', 'and', 'marginal', 'structural', 'modelling', 'to', 'assess', 'the', 'effect', 'of', 'contraceptive', 'use', 'on', 'HIV-1', 'risk', '.']","(18, 21)","(122, 134)",-1,ss_o,21975269,Abstract,5,test,gold,2497.0
4296,FINDINGS,Among 1314 couples in which the HIV-1-seronegative partner was female,"( median follow-up 18·0 [ IQR 12·6-24·2 ] months ) , rates of HIV-1 acquisition were 6·61 per 100 person-years in women who used hormonal contraception and 3·78 per 100 person-years in those who did not ( adjusted hazard ratio 1·98 , 95 % CI 1·06-3·68 , p=0·03 ) .","['FINDINGS', 'Among', '1314', 'couples', 'in', 'which', 'the', 'HIV-1-seronegative', 'partner', 'was', 'female', '(', 'median', 'follow-up', '18·0', '[', 'IQR', '12·6-24·2', ']', 'months', ')', ',', 'rates', 'of', 'HIV-1', 'acquisition', 'were', '6·61', 'per', '100', 'person-years', 'in', 'women', 'who', 'used', 'hormonal', 'contraception', 'and', '3·78', 'per', '100', 'person-years', 'in', 'those', 'who', 'did', 'not', '(', 'adjusted', 'hazard', 'ratio', '1·98', ',', '95', '%', 'CI', '1·06-3·68', ',', 'p=0·03', ')', '.']","(1, 11)","(8, 77)",-1,ss_p,21975269,Abstract,6,test,gold,2083.0
4297,"FINDINGS Among 1314 couples in which the HIV-1-seronegative partner was female ( median follow-up 18·0 [ IQR 12·6-24·2 ] months ) , rates of HIV-1 acquisition were 6·61 per 100 person-years in women who used hormonal contraception and 3·78 per 100 person-years in those who did not ( adjusted hazard ratio 1·98 , 95 % CI 1·06-3·68 ,",p=0·03 ) .,,"['FINDINGS', 'Among', '1314', 'couples', 'in', 'which', 'the', 'HIV-1-seronegative', 'partner', 'was', 'female', '(', 'median', 'follow-up', '18·0', '[', 'IQR', '12·6-24·2', ']', 'months', ')', ',', 'rates', 'of', 'HIV-1', 'acquisition', 'were', '6·61', 'per', '100', 'person-years', 'in', 'women', 'who', 'used', 'hormonal', 'contraception', 'and', '3·78', 'per', '100', 'person-years', 'in', 'those', 'who', 'did', 'not', '(', 'adjusted', 'hazard', 'ratio', '1·98', ',', '95', '%', 'CI', '1·06-3·68', ',', 'p=0·03', ')', '.']","(58, 61)","(332, 342)",-1,ss_p,21975269,Abstract,6,test,gold,
4298,"FINDINGS Among 1314 couples in which the HIV-1-seronegative partner was female ( median follow-up 18·0 [ IQR 12·6-24·2 ] months ) , rates of HIV-1 acquisition were 6·61 per 100 person-years in women who",used hormonal contraception,"and 3·78 per 100 person-years in those who did not ( adjusted hazard ratio 1·98 , 95 % CI 1·06-3·68 , p=0·03 ) .","['FINDINGS', 'Among', '1314', 'couples', 'in', 'which', 'the', 'HIV-1-seronegative', 'partner', 'was', 'female', '(', 'median', 'follow-up', '18·0', '[', 'IQR', '12·6-24·2', ']', 'months', ')', ',', 'rates', 'of', 'HIV-1', 'acquisition', 'were', '6·61', 'per', '100', 'person-years', 'in', 'women', 'who', 'used', 'hormonal', 'contraception', 'and', '3·78', 'per', '100', 'person-years', 'in', 'those', 'who', 'did', 'not', '(', 'adjusted', 'hazard', 'ratio', '1·98', ',', '95', '%', 'CI', '1·06-3·68', ',', 'p=0·03', ')', '.']","(34, 37)","(202, 229)",-1,ss_i,21975269,Abstract,6,test,gold,3896.0
4299,"FINDINGS Among 1314 couples in which the HIV-1-seronegative partner was female ( median follow-up 18·0 [ IQR 12·6-24·2 ] months ) , rates",of HIV-1 acquisition,"were 6·61 per 100 person-years in women who used hormonal contraception and 3·78 per 100 person-years in those who did not ( adjusted hazard ratio 1·98 , 95 % CI 1·06-3·68 , p=0·03 ) .","['FINDINGS', 'Among', '1314', 'couples', 'in', 'which', 'the', 'HIV-1-seronegative', 'partner', 'was', 'female', '(', 'median', 'follow-up', '18·0', '[', 'IQR', '12·6-24·2', ']', 'months', ')', ',', 'rates', 'of', 'HIV-1', 'acquisition', 'were', '6·61', 'per', '100', 'person-years', 'in', 'women', 'who', 'used', 'hormonal', 'contraception', 'and', '3·78', 'per', '100', 'person-years', 'in', 'those', 'who', 'did', 'not', '(', 'adjusted', 'hazard', 'ratio', '1·98', ',', '95', '%', 'CI', '1·06-3·68', ',', 'p=0·03', ')', '.']","(23, 26)","(137, 157)",-1,ss_o,21975269,Abstract,6,test,gold,996.0
4300,FINDINGS Among,1314 couples in which the HIV-1-seronegative partner,"was female ( median follow-up 18·0 [ IQR 12·6-24·2 ] months ) , rates of HIV-1 acquisition were 6·61 per 100 person-years in women who used hormonal contraception and 3·78 per 100 person-years in those who did not ( adjusted hazard ratio 1·98 , 95 % CI 1·06-3·68 , p=0·03 ) .","['FINDINGS', 'Among', '1314', 'couples', 'in', 'which', 'the', 'HIV-1-seronegative', 'partner', 'was', 'female', '(', 'median', 'follow-up', '18·0', '[', 'IQR', '12·6-24·2', ']', 'months', ')', ',', 'rates', 'of', 'HIV-1', 'acquisition', 'were', '6·61', 'per', '100', 'person-years', 'in', 'women', 'who', 'used', 'hormonal', 'contraception', 'and', '3·78', 'per', '100', 'person-years', 'in', 'those', 'who', 'did', 'not', '(', 'adjusted', 'hazard', 'ratio', '1·98', ',', '95', '%', 'CI', '1·06-3·68', ',', 'p=0·03', ')', '.']","(2, 9)","(14, 66)",-1,hl_p,21975269,Abstract,6,test,gold,2084.0
4301,FINDINGS Among 1314 couples in which the HIV-1-seronegative partner was,female,"( median follow-up 18·0 [ IQR 12·6-24·2 ] months ) , rates of HIV-1 acquisition were 6·61 per 100 person-years in women who used hormonal contraception and 3·78 per 100 person-years in those who did not ( adjusted hazard ratio 1·98 , 95 % CI 1·06-3·68 , p=0·03 ) .","['FINDINGS', 'Among', '1314', 'couples', 'in', 'which', 'the', 'HIV-1-seronegative', 'partner', 'was', 'female', '(', 'median', 'follow-up', '18·0', '[', 'IQR', '12·6-24·2', ']', 'months', ')', ',', 'rates', 'of', 'HIV-1', 'acquisition', 'were', '6·61', 'per', '100', 'person-years', 'in', 'women', 'who', 'used', 'hormonal', 'contraception', 'and', '3·78', 'per', '100', 'person-years', 'in', 'those', 'who', 'did', 'not', '(', 'adjusted', 'hazard', 'ratio', '1·98', ',', '95', '%', 'CI', '1·06-3·68', ',', 'p=0·03', ')', '.']","(10, 11)","(71, 77)",-1,hl_p,21975269,Abstract,6,test,gold,2235.0
4302,"FINDINGS Among 1314 couples in which the HIV-1-seronegative partner was female ( median follow-up 18·0 [ IQR 12·6-24·2 ] months ) , rates of",HIV-1 acquisition,"were 6·61 per 100 person-years in women who used hormonal contraception and 3·78 per 100 person-years in those who did not ( adjusted hazard ratio 1·98 , 95 % CI 1·06-3·68 , p=0·03 ) .","['FINDINGS', 'Among', '1314', 'couples', 'in', 'which', 'the', 'HIV-1-seronegative', 'partner', 'was', 'female', '(', 'median', 'follow-up', '18·0', '[', 'IQR', '12·6-24·2', ']', 'months', ')', ',', 'rates', 'of', 'HIV-1', 'acquisition', 'were', '6·61', 'per', '100', 'person-years', 'in', 'women', 'who', 'used', 'hormonal', 'contraception', 'and', '3·78', 'per', '100', 'person-years', 'in', 'those', 'who', 'did', 'not', '(', 'adjusted', 'hazard', 'ratio', '1·98', ',', '95', '%', 'CI', '1·06-3·68', ',', 'p=0·03', ')', '.']","(24, 26)","(140, 157)",-1,hl_o,21975269,Abstract,6,test,gold,997.0
4303,,Among 2476 couples in which the HIV-1-seronegative partner,"was male ( median follow-up 18·7 [ IQR 12·8-24·2 ] months ) , rates of HIV-1 transmission from women to men were 2·61 per 100 person-years in couples in which women used hormonal contraception and 1·51 per 100 person-years in couples in which women did not use hormonal contraception ( adjusted hazard ratio 1·97 , 95 % CI 1·12-3·45 , p=0·02 ) .","['Among', '2476', 'couples', 'in', 'which', 'the', 'HIV-1-seronegative', 'partner', 'was', 'male', '(', 'median', 'follow-up', '18·7', '[', 'IQR', '12·8-24·2', ']', 'months', ')', ',', 'rates', 'of', 'HIV-1', 'transmission', 'from', 'women', 'to', 'men', 'were', '2·61', 'per', '100', 'person-years', 'in', 'couples', 'in', 'which', 'women', 'used', 'hormonal', 'contraception', 'and', '1·51', 'per', '100', 'person-years', 'in', 'couples', 'in', 'which', 'women', 'did', 'not', 'use', 'hormonal', 'contraception', '(', 'adjusted', 'hazard', 'ratio', '1·97', ',', '95', '%', 'CI', '1·12-3·45', ',', 'p=0·02', ')', '.']","(0, 8)","(0, 58)",-1,ss_p,21975269,Abstract,7,test,gold,2085.0
4304,"Among 2476 couples in which the HIV-1-seronegative partner was male ( median follow-up 18·7 [ IQR 12·8-24·2 ] months ) , rates of HIV-1 transmission from women to men were 2·61 per 100 person-years in couples in",which women used hormonal contraception,"and 1·51 per 100 person-years in couples in which women did not use hormonal contraception ( adjusted hazard ratio 1·97 , 95 % CI 1·12-3·45 , p=0·02 ) .","['Among', '2476', 'couples', 'in', 'which', 'the', 'HIV-1-seronegative', 'partner', 'was', 'male', '(', 'median', 'follow-up', '18·7', '[', 'IQR', '12·8-24·2', ']', 'months', ')', ',', 'rates', 'of', 'HIV-1', 'transmission', 'from', 'women', 'to', 'men', 'were', '2·61', 'per', '100', 'person-years', 'in', 'couples', 'in', 'which', 'women', 'used', 'hormonal', 'contraception', 'and', '1·51', 'per', '100', 'person-years', 'in', 'couples', 'in', 'which', 'women', 'did', 'not', 'use', 'hormonal', 'contraception', '(', 'adjusted', 'hazard', 'ratio', '1·97', ',', '95', '%', 'CI', '1·12-3·45', ',', 'p=0·02', ')', '.']","(37, 42)","(211, 250)",-1,ss_i,21975269,Abstract,7,test,gold,3897.0
4305,"Among 2476 couples in which the HIV-1-seronegative partner was male ( median follow-up 18·7 [ IQR 12·8-24·2 ] months ) , rates of HIV-1 transmission from women to men were 2·61 per 100 person-years in couples in which women used hormonal contraception and 1·51 per 100 person-years in couples in which",women did not use hormonal,"contraception ( adjusted hazard ratio 1·97 , 95 % CI 1·12-3·45 , p=0·02 ) .","['Among', '2476', 'couples', 'in', 'which', 'the', 'HIV-1-seronegative', 'partner', 'was', 'male', '(', 'median', 'follow-up', '18·7', '[', 'IQR', '12·8-24·2', ']', 'months', ')', ',', 'rates', 'of', 'HIV-1', 'transmission', 'from', 'women', 'to', 'men', 'were', '2·61', 'per', '100', 'person-years', 'in', 'couples', 'in', 'which', 'women', 'used', 'hormonal', 'contraception', 'and', '1·51', 'per', '100', 'person-years', 'in', 'couples', 'in', 'which', 'women', 'did', 'not', 'use', 'hormonal', 'contraception', '(', 'adjusted', 'hazard', 'ratio', '1·97', ',', '95', '%', 'CI', '1·12-3·45', ',', 'p=0·02', ')', '.']","(51, 56)","(301, 327)",-1,ss_i,21975269,Abstract,7,test,gold,2462.0
4306,Among 2476 couples in which the HIV-1-seronegative partner was male ( median follow-up 18·7 [ IQR 12·8-24·2 ],"months ) , rates of HIV-1 transmission","from women to men were 2·61 per 100 person-years in couples in which women used hormonal contraception and 1·51 per 100 person-years in couples in which women did not use hormonal contraception ( adjusted hazard ratio 1·97 , 95 % CI 1·12-3·45 , p=0·02 ) .","['Among', '2476', 'couples', 'in', 'which', 'the', 'HIV-1-seronegative', 'partner', 'was', 'male', '(', 'median', 'follow-up', '18·7', '[', 'IQR', '12·8-24·2', ']', 'months', ')', ',', 'rates', 'of', 'HIV-1', 'transmission', 'from', 'women', 'to', 'men', 'were', '2·61', 'per', '100', 'person-years', 'in', 'couples', 'in', 'which', 'women', 'used', 'hormonal', 'contraception', 'and', '1·51', 'per', '100', 'person-years', 'in', 'couples', 'in', 'which', 'women', 'did', 'not', 'use', 'hormonal', 'contraception', '(', 'adjusted', 'hazard', 'ratio', '1·97', ',', '95', '%', 'CI', '1·12-3·45', ',', 'p=0·02', ')', '.']","(18, 25)","(109, 147)",-1,ss_o,21975269,Abstract,7,test,gold,990.0
4307,"Among 2476 couples in which the HIV-1-seronegative partner was male ( median follow-up 18·7 [ IQR 12·8-24·2 ] months ) , rates of",HIV-1 transmission,"from women to men were 2·61 per 100 person-years in couples in which women used hormonal contraception and 1·51 per 100 person-years in couples in which women did not use hormonal contraception ( adjusted hazard ratio 1·97 , 95 % CI 1·12-3·45 , p=0·02 ) .","['Among', '2476', 'couples', 'in', 'which', 'the', 'HIV-1-seronegative', 'partner', 'was', 'male', '(', 'median', 'follow-up', '18·7', '[', 'IQR', '12·8-24·2', ']', 'months', ')', ',', 'rates', 'of', 'HIV-1', 'transmission', 'from', 'women', 'to', 'men', 'were', '2·61', 'per', '100', 'person-years', 'in', 'couples', 'in', 'which', 'women', 'used', 'hormonal', 'contraception', 'and', '1·51', 'per', '100', 'person-years', 'in', 'couples', 'in', 'which', 'women', 'did', 'not', 'use', 'hormonal', 'contraception', '(', 'adjusted', 'hazard', 'ratio', '1·97', ',', '95', '%', 'CI', '1·12-3·45', ',', 'p=0·02', ')', '.']","(23, 25)","(129, 147)",-1,hl_o,21975269,Abstract,7,test,gold,992.0
4308,Marginal structural model analyses generated much the same results to the Cox proportional hazards regression .,,,"['Marginal', 'structural', 'model', 'analyses', 'generated', 'much', 'the', 'same', 'results', 'to', 'the', 'Cox', 'proportional', 'hazards', 'regression', '.']",,,,,21975269,Abstract,8,test,gold,
4309,INTERPRETATION Women should be counselled about potentially increased risk of HIV-1 acquisition and,transmission with hormonal,"contraception , especially injectable methods , and about the importance of dual protection with condoms to decrease HIV-1 risk .","['INTERPRETATION', 'Women', 'should', 'be', 'counselled', 'about', 'potentially', 'increased', 'risk', 'of', 'HIV-1', 'acquisition', 'and', 'transmission', 'with', 'hormonal', 'contraception', ',', 'especially', 'injectable', 'methods', ',', 'and', 'about', 'the', 'importance', 'of', 'dual', 'protection', 'with', 'condoms', 'to', 'decrease', 'HIV-1', 'risk', '.']","(13, 16)","(99, 125)",-1,ss_i,21975269,Abstract,9,test,gold,2463.0
4310,INTERPRETATION Women should be counselled about,potentially increased risk of HIV-1 acquisition,"and transmission with hormonal contraception , especially injectable methods , and about the importance of dual protection with condoms to decrease HIV-1 risk .","['INTERPRETATION', 'Women', 'should', 'be', 'counselled', 'about', 'potentially', 'increased', 'risk', 'of', 'HIV-1', 'acquisition', 'and', 'transmission', 'with', 'hormonal', 'contraception', ',', 'especially', 'injectable', 'methods', ',', 'and', 'about', 'the', 'importance', 'of', 'dual', 'protection', 'with', 'condoms', 'to', 'decrease', 'HIV-1', 'risk', '.']","(6, 12)","(47, 94)",-1,ss_o,21975269,Abstract,9,test,gold,998.0
4311,INTERPRETATION Women should be counselled about potentially increased,risk of HIV-1 acquisition,"and transmission with hormonal contraception , especially injectable methods , and about the importance of dual protection with condoms to decrease HIV-1 risk .","['INTERPRETATION', 'Women', 'should', 'be', 'counselled', 'about', 'potentially', 'increased', 'risk', 'of', 'HIV-1', 'acquisition', 'and', 'transmission', 'with', 'hormonal', 'contraception', ',', 'especially', 'injectable', 'methods', ',', 'and', 'about', 'the', 'importance', 'of', 'dual', 'protection', 'with', 'condoms', 'to', 'decrease', 'HIV-1', 'risk', '.']","(8, 12)","(69, 94)",-1,hl_o,21975269,Abstract,9,test,gold,1000.0
4312,,Non-hormonal or low-dose hormonal,contraceptive methods should be considered for women with or at-risk for HIV-1 .,"['Non-hormonal', 'or', 'low-dose', 'hormonal', 'contraceptive', 'methods', 'should', 'be', 'considered', 'for', 'women', 'with', 'or', 'at-risk', 'for', 'HIV-1', '.']","(0, 4)","(0, 33)",-1,ss_i,21975269,Abstract,10,test,gold,2465.0
4313,FUNDING US National Institutes of Health and the Bill & Melinda Gates Foundation .,,,"['FUNDING', 'US', 'National', 'Institutes', 'of', 'Health', 'and', 'the', 'Bill', '&', 'Melinda', 'Gates', 'Foundation', '.']",,,,,21975269,Abstract,11,test,gold,
4314,"A double-blind , randomized , controlled , multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in",patients with chronic heart failure after myocardial infarction .,,"['A', 'double-blind', ',', 'randomized', ',', 'controlled', ',', 'multicenter', 'study', 'to', 'assess', 'the', 'safety', 'and', 'cardiovascular', 'effects', 'of', 'skeletal', 'myoblast', 'implantation', 'by', 'catheter', 'delivery', 'in', 'patients', 'with', 'chronic', 'heart', 'failure', 'after', 'myocardial', 'infarction', '.']","(24, 33)","(166, 231)",-1,ss_p,21982657,Title,0,test,gold,5982.0
4315,"A double-blind , randomized , controlled , multicenter study to assess the safety and cardiovascular effects of",skeletal myoblast implantation,by catheter delivery in patients with chronic heart failure after myocardial infarction .,"['A', 'double-blind', ',', 'randomized', ',', 'controlled', ',', 'multicenter', 'study', 'to', 'assess', 'the', 'safety', 'and', 'cardiovascular', 'effects', 'of', 'skeletal', 'myoblast', 'implantation', 'by', 'catheter', 'delivery', 'in', 'patients', 'with', 'chronic', 'heart', 'failure', 'after', 'myocardial', 'infarction', '.']","(17, 20)","(111, 141)",-1,ss_i,21982657,Title,0,test,gold,3198.0
4316,"A double-blind , randomized , controlled , multicenter study to assess the",safety,and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction .,"['A', 'double-blind', ',', 'randomized', ',', 'controlled', ',', 'multicenter', 'study', 'to', 'assess', 'the', 'safety', 'and', 'cardiovascular', 'effects', 'of', 'skeletal', 'myoblast', 'implantation', 'by', 'catheter', 'delivery', 'in', 'patients', 'with', 'chronic', 'heart', 'failure', 'after', 'myocardial', 'infarction', '.']","(12, 13)","(74, 80)",-1,ss_o,21982657,Title,0,test,gold,465.0
4317,"A double-blind , randomized , controlled , multicenter study to assess the safety and",cardiovascular effects,of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction .,"['A', 'double-blind', ',', 'randomized', ',', 'controlled', ',', 'multicenter', 'study', 'to', 'assess', 'the', 'safety', 'and', 'cardiovascular', 'effects', 'of', 'skeletal', 'myoblast', 'implantation', 'by', 'catheter', 'delivery', 'in', 'patients', 'with', 'chronic', 'heart', 'failure', 'after', 'myocardial', 'infarction', '.']","(14, 16)","(85, 107)",-1,ss_o,21982657,Title,0,test,gold,2358.0
4318,"A double-blind , randomized , controlled , multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in",patients with chronic heart failure after myocardial infarction .,,"['A', 'double-blind', ',', 'randomized', ',', 'controlled', ',', 'multicenter', 'study', 'to', 'assess', 'the', 'safety', 'and', 'cardiovascular', 'effects', 'of', 'skeletal', 'myoblast', 'implantation', 'by', 'catheter', 'delivery', 'in', 'patients', 'with', 'chronic', 'heart', 'failure', 'after', 'myocardial', 'infarction', '.']","(24, 33)","(166, 231)",-1,hl_p,21982657,Title,0,test,gold,5983.0
4319,"A double-blind , randomized , controlled , multicenter study to assess the safety and cardiovascular effects of",skeletal myoblast implantation,by catheter delivery in patients with chronic heart failure after myocardial infarction .,"['A', 'double-blind', ',', 'randomized', ',', 'controlled', ',', 'multicenter', 'study', 'to', 'assess', 'the', 'safety', 'and', 'cardiovascular', 'effects', 'of', 'skeletal', 'myoblast', 'implantation', 'by', 'catheter', 'delivery', 'in', 'patients', 'with', 'chronic', 'heart', 'failure', 'after', 'myocardial', 'infarction', '.']","(17, 20)","(111, 141)",-1,hl_i,21982657,Title,0,test,gold,3199.0
4320,"A double-blind , randomized , controlled , multicenter study to assess the",safety,and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction .,"['A', 'double-blind', ',', 'randomized', ',', 'controlled', ',', 'multicenter', 'study', 'to', 'assess', 'the', 'safety', 'and', 'cardiovascular', 'effects', 'of', 'skeletal', 'myoblast', 'implantation', 'by', 'catheter', 'delivery', 'in', 'patients', 'with', 'chronic', 'heart', 'failure', 'after', 'myocardial', 'infarction', '.']","(12, 13)","(74, 80)",-1,hl_o,21982657,Title,0,test,gold,464.0
4321,"A double-blind , randomized , controlled , multicenter study to assess the safety and",cardiovascular effects,of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction .,"['A', 'double-blind', ',', 'randomized', ',', 'controlled', ',', 'multicenter', 'study', 'to', 'assess', 'the', 'safety', 'and', 'cardiovascular', 'effects', 'of', 'skeletal', 'myoblast', 'implantation', 'by', 'catheter', 'delivery', 'in', 'patients', 'with', 'chronic', 'heart', 'failure', 'after', 'myocardial', 'infarction', '.']","(14, 16)","(85, 107)",-1,hl_o,21982657,Title,0,test,gold,2359.0
4322,BACKGROUND We sought to determine the safety and preliminary efficacy of transcatheter intramyocardial administration of myoblasts in,patients with heart failure ( HF ) .,,"['BACKGROUND', 'We', 'sought', 'to', 'determine', 'the', 'safety', 'and', 'preliminary', 'efficacy', 'of', 'transcatheter', 'intramyocardial', 'administration', 'of', 'myoblasts', 'in', 'patients', 'with', 'heart', 'failure', '(', 'HF', ')', '.']","(17, 25)","(133, 169)",-1,ss_p,21982657,Abstract,0,test,gold,7069.0
4323,BACKGROUND We sought to determine the safety and preliminary efficacy of transcatheter intramyocardial administration of,myoblasts,in patients with heart failure ( HF ) .,"['BACKGROUND', 'We', 'sought', 'to', 'determine', 'the', 'safety', 'and', 'preliminary', 'efficacy', 'of', 'transcatheter', 'intramyocardial', 'administration', 'of', 'myoblasts', 'in', 'patients', 'with', 'heart', 'failure', '(', 'HF', ')', '.']","(15, 16)","(120, 129)",-1,ss_i,21982657,Abstract,0,test,gold,3163.0
4324,BACKGROUND We sought to determine the,safety,and preliminary efficacy of transcatheter intramyocardial administration of myoblasts in patients with heart failure ( HF ) .,"['BACKGROUND', 'We', 'sought', 'to', 'determine', 'the', 'safety', 'and', 'preliminary', 'efficacy', 'of', 'transcatheter', 'intramyocardial', 'administration', 'of', 'myoblasts', 'in', 'patients', 'with', 'heart', 'failure', '(', 'HF', ')', '.']","(6, 7)","(37, 43)",-1,ss_o,21982657,Abstract,0,test,gold,463.0
4325,BACKGROUND We sought to determine the safety and,preliminary efficacy,of transcatheter intramyocardial administration of myoblasts in patients with heart failure ( HF ) .,"['BACKGROUND', 'We', 'sought', 'to', 'determine', 'the', 'safety', 'and', 'preliminary', 'efficacy', 'of', 'transcatheter', 'intramyocardial', 'administration', 'of', 'myoblasts', 'in', 'patients', 'with', 'heart', 'failure', '(', 'HF', ')', '.']","(8, 10)","(48, 68)",-1,ss_o,21982657,Abstract,0,test,gold,4850.0
4326,BACKGROUND We sought to determine the safety and preliminary efficacy of transcatheter intramyocardial administration of myoblasts in,patients with heart failure ( HF ) .,,"['BACKGROUND', 'We', 'sought', 'to', 'determine', 'the', 'safety', 'and', 'preliminary', 'efficacy', 'of', 'transcatheter', 'intramyocardial', 'administration', 'of', 'myoblasts', 'in', 'patients', 'with', 'heart', 'failure', '(', 'HF', ')', '.']","(17, 25)","(133, 169)",-1,hl_p,21982657,Abstract,0,test,gold,7070.0
4327,BACKGROUND We sought to determine the safety and preliminary efficacy of transcatheter intramyocardial administration of,myoblasts,in patients with heart failure ( HF ) .,"['BACKGROUND', 'We', 'sought', 'to', 'determine', 'the', 'safety', 'and', 'preliminary', 'efficacy', 'of', 'transcatheter', 'intramyocardial', 'administration', 'of', 'myoblasts', 'in', 'patients', 'with', 'heart', 'failure', '(', 'HF', ')', '.']","(15, 16)","(120, 129)",-1,hl_i,21982657,Abstract,0,test,gold,3164.0
4328,BACKGROUND We sought to determine the,safety,and preliminary efficacy of transcatheter intramyocardial administration of myoblasts in patients with heart failure ( HF ) .,"['BACKGROUND', 'We', 'sought', 'to', 'determine', 'the', 'safety', 'and', 'preliminary', 'efficacy', 'of', 'transcatheter', 'intramyocardial', 'administration', 'of', 'myoblasts', 'in', 'patients', 'with', 'heart', 'failure', '(', 'HF', ')', '.']","(6, 7)","(37, 43)",-1,hl_o,21982657,Abstract,0,test,gold,462.0
4329,BACKGROUND We sought to determine the safety and preliminary,efficacy,of transcatheter intramyocardial administration of myoblasts in patients with heart failure ( HF ) .,"['BACKGROUND', 'We', 'sought', 'to', 'determine', 'the', 'safety', 'and', 'preliminary', 'efficacy', 'of', 'transcatheter', 'intramyocardial', 'administration', 'of', 'myoblasts', 'in', 'patients', 'with', 'heart', 'failure', '(', 'HF', ')', '.']","(9, 10)","(60, 68)",-1,hl_o,21982657,Abstract,0,test,gold,4806.0
4330,"METHODS MARVEL is a randomized placebo-controlled trial of image-guided , catheter-based intramyocardial injection of placebo or myoblasts ( 400 or 800 million ) in",patients with class II to IV HF and ejection fraction < 35 % .,,"['METHODS', 'MARVEL', 'is', 'a', 'randomized', 'placebo-controlled', 'trial', 'of', 'image-guided', ',', 'catheter-based', 'intramyocardial', 'injection', 'of', 'placebo', 'or', 'myoblasts', '(', '400', 'or', '800', 'million', ')', 'in', 'patients', 'with', 'class', 'II', 'to', 'IV', 'HF', 'and', 'ejection', 'fraction', '<', '35', '%', '.']","(24, 38)","(164, 226)",-1,ss_p,21982657,Abstract,1,test,gold,5867.0
4331,"METHODS MARVEL is a randomized placebo-controlled trial of image-guided , catheter-based intramyocardial injection of",placebo,or myoblasts ( 400 or 800 million ) in patients with class II to IV HF and ejection fraction < 35 % .,"['METHODS', 'MARVEL', 'is', 'a', 'randomized', 'placebo-controlled', 'trial', 'of', 'image-guided', ',', 'catheter-based', 'intramyocardial', 'injection', 'of', 'placebo', 'or', 'myoblasts', '(', '400', 'or', '800', 'million', ')', 'in', 'patients', 'with', 'class', 'II', 'to', 'IV', 'HF', 'and', 'ejection', 'fraction', '<', '35', '%', '.']","(14, 15)","(117, 124)",-1,ss_i,21982657,Abstract,1,test,gold,4368.0
4332,"METHODS MARVEL is a randomized placebo-controlled trial of image-guided , catheter-based intramyocardial injection of placebo or",myoblasts,( 400 or 800 million ) in patients with class II to IV HF and ejection fraction < 35 % .,"['METHODS', 'MARVEL', 'is', 'a', 'randomized', 'placebo-controlled', 'trial', 'of', 'image-guided', ',', 'catheter-based', 'intramyocardial', 'injection', 'of', 'placebo', 'or', 'myoblasts', '(', '400', 'or', '800', 'million', ')', 'in', 'patients', 'with', 'class', 'II', 'to', 'IV', 'HF', 'and', 'ejection', 'fraction', '<', '35', '%', '.']","(16, 17)","(128, 137)",-1,ss_i,21982657,Abstract,1,test,gold,3162.0
4333,"METHODS MARVEL is a randomized placebo-controlled trial of image-guided , catheter-based intramyocardial injection of placebo or myoblasts ( 400 or 800 million ) in",patients with class II to IV HF and ejection fraction < 35 % .,,"['METHODS', 'MARVEL', 'is', 'a', 'randomized', 'placebo-controlled', 'trial', 'of', 'image-guided', ',', 'catheter-based', 'intramyocardial', 'injection', 'of', 'placebo', 'or', 'myoblasts', '(', '400', 'or', '800', 'million', ')', 'in', 'patients', 'with', 'class', 'II', 'to', 'IV', 'HF', 'and', 'ejection', 'fraction', '<', '35', '%', '.']","(24, 38)","(164, 226)",-1,hl_p,21982657,Abstract,1,test,gold,5868.0
4334,"METHODS MARVEL is a randomized placebo-controlled trial of image-guided , catheter-based intramyocardial injection of",placebo,or myoblasts ( 400 or 800 million ) in patients with class II to IV HF and ejection fraction < 35 % .,"['METHODS', 'MARVEL', 'is', 'a', 'randomized', 'placebo-controlled', 'trial', 'of', 'image-guided', ',', 'catheter-based', 'intramyocardial', 'injection', 'of', 'placebo', 'or', 'myoblasts', '(', '400', 'or', '800', 'million', ')', 'in', 'patients', 'with', 'class', 'II', 'to', 'IV', 'HF', 'and', 'ejection', 'fraction', '<', '35', '%', '.']","(14, 15)","(117, 124)",-1,hl_i,21982657,Abstract,1,test,gold,4367.0
4335,"METHODS MARVEL is a randomized placebo-controlled trial of image-guided , catheter-based intramyocardial injection of placebo or",myoblasts,( 400 or 800 million ) in patients with class II to IV HF and ejection fraction < 35 % .,"['METHODS', 'MARVEL', 'is', 'a', 'randomized', 'placebo-controlled', 'trial', 'of', 'image-guided', ',', 'catheter-based', 'intramyocardial', 'injection', 'of', 'placebo', 'or', 'myoblasts', '(', '400', 'or', '800', 'million', ')', 'in', 'patients', 'with', 'class', 'II', 'to', 'IV', 'HF', 'and', 'ejection', 'fraction', '<', '35', '%', '.']","(16, 17)","(128, 137)",-1,hl_i,21982657,Abstract,1,test,gold,3161.0
4336,Primary end points were,frequency of serious adverse events ( safety ) and changes in 6-minute walk test and Minnesota Living With HF score ( efficacy ) .,,"['Primary', 'end', 'points', 'were', 'frequency', 'of', 'serious', 'adverse', 'events', '(', 'safety', ')', 'and', 'changes', 'in', '6-minute', 'walk', 'test', 'and', 'Minnesota', 'Living', 'With', 'HF', 'score', '(', 'efficacy', ')', '.']","(4, 28)","(23, 153)",-1,ss_o,21982657,Abstract,2,test,gold,7092.0
4337,Primary end points were,frequency of serious adverse events ( safety ),and changes in 6-minute walk test and Minnesota Living With HF score ( efficacy ) .,"['Primary', 'end', 'points', 'were', 'frequency', 'of', 'serious', 'adverse', 'events', '(', 'safety', ')', 'and', 'changes', 'in', '6-minute', 'walk', 'test', 'and', 'Minnesota', 'Living', 'With', 'HF', 'score', '(', 'efficacy', ')', '.']","(4, 12)","(23, 69)",-1,hl_o,21982657,Abstract,2,test,gold,3045.0
4338,Primary end points were frequency of serious adverse events ( safety ) and,changes in 6-minute walk test,and Minnesota Living With HF score ( efficacy ) .,"['Primary', 'end', 'points', 'were', 'frequency', 'of', 'serious', 'adverse', 'events', '(', 'safety', ')', 'and', 'changes', 'in', '6-minute', 'walk', 'test', 'and', 'Minnesota', 'Living', 'With', 'HF', 'score', '(', 'efficacy', ')', '.']","(13, 18)","(74, 103)",-1,hl_o,21982657,Abstract,2,test,gold,965.0
4339,Primary end points were frequency of serious adverse events ( safety ) and changes in 6-minute walk test and,Minnesota Living With HF score ( efficacy ),.,"['Primary', 'end', 'points', 'were', 'frequency', 'of', 'serious', 'adverse', 'events', '(', 'safety', ')', 'and', 'changes', 'in', '6-minute', 'walk', 'test', 'and', 'Minnesota', 'Living', 'With', 'HF', 'score', '(', 'efficacy', ')', '.']","(19, 27)","(108, 151)",-1,hl_o,21982657,Abstract,2,test,gold,1449.0
4340,,"Of 330 patients intended for enrollment , 23 were randomized ( MARVEL-1 ) before stopping the study for financial reasons .",,"['Of', '330', 'patients', 'intended', 'for', 'enrollment', ',', '23', 'were', 'randomized', '(', 'MARVEL-1', ')', 'before', 'stopping', 'the', 'study', 'for', 'financial', 'reasons', '.']","(0, 21)","(0, 123)",-1,ss_p,21982657,Abstract,3,test,gold,5849.0
4341,Of,330,"patients intended for enrollment , 23 were randomized ( MARVEL-1 ) before stopping the study for financial reasons .","['Of', '330', 'patients', 'intended', 'for', 'enrollment', ',', '23', 'were', 'randomized', '(', 'MARVEL-1', ')', 'before', 'stopping', 'the', 'study', 'for', 'financial', 'reasons', '.']","(1, 2)","(2, 5)",-1,hl_p,21982657,Abstract,3,test,gold,
4342,"Of 330 patients intended for enrollment ,",23,were randomized ( MARVEL-1 ) before stopping the study for financial reasons .,"['Of', '330', 'patients', 'intended', 'for', 'enrollment', ',', '23', 'were', 'randomized', '(', 'MARVEL-1', ')', 'before', 'stopping', 'the', 'study', 'for', 'financial', 'reasons', '.']","(7, 8)","(41, 43)",-1,hl_p,21982657,Abstract,3,test,gold,
4343,"RESULTS At 6 months , similar numbers of events occurred in each group : 8",( placebo ),", 7 ( low dose ) , and 8 ( high dose ) , without deaths .","['RESULTS', 'At', '6', 'months', ',', 'similar', 'numbers', 'of', 'events', 'occurred', 'in', 'each', 'group', ':', '8', '(', 'placebo', ')', ',', '7', '(', 'low', 'dose', ')', ',', 'and', '8', '(', 'high', 'dose', ')', ',', 'without', 'deaths', '.']","(15, 18)","(74, 85)",-1,ss_i,21982657,Abstract,4,test,gold,4366.0
4344,"RESULTS At 6 months , similar numbers of events occurred in each group : 8",( placebo ),", 7 ( low dose ) , and 8 ( high dose ) , without deaths .","['RESULTS', 'At', '6', 'months', ',', 'similar', 'numbers', 'of', 'events', 'occurred', 'in', 'each', 'group', ':', '8', '(', 'placebo', ')', ',', '7', '(', 'low', 'dose', ')', ',', 'and', '8', '(', 'high', 'dose', ')', ',', 'without', 'deaths', '.']","(15, 18)","(74, 85)",-1,hl_i,21982657,Abstract,4,test,gold,4365.0
4345,Ventricular tachycardia responsive to amiodarone was more frequent in,myoblast-treated,"patients : 1 ( placebo ) , 3 ( low dose ) , and 4 ( high dose ) .","['Ventricular', 'tachycardia', 'responsive', 'to', 'amiodarone', 'was', 'more', 'frequent', 'in', 'myoblast-treated', 'patients', ':', '1', '(', 'placebo', ')', ',', '3', '(', 'low', 'dose', ')', ',', 'and', '4', '(', 'high', 'dose', ')', '.']","(9, 10)","(69, 85)",-1,ss_i,21982657,Abstract,5,test,gold,
4346,Ventricular tachycardia responsive to amiodarone was more frequent in myoblast-treated patients : 1,( placebo ),", 3 ( low dose ) , and 4 ( high dose ) .","['Ventricular', 'tachycardia', 'responsive', 'to', 'amiodarone', 'was', 'more', 'frequent', 'in', 'myoblast-treated', 'patients', ':', '1', '(', 'placebo', ')', ',', '3', '(', 'low', 'dose', ')', ',', 'and', '4', '(', 'high', 'dose', ')', '.']","(13, 16)","(99, 110)",-1,ss_i,21982657,Abstract,5,test,gold,4364.0
4347,,Ventricular tachycardia responsive,"to amiodarone was more frequent in myoblast-treated patients : 1 ( placebo ) , 3 ( low dose ) , and 4 ( high dose ) .","['Ventricular', 'tachycardia', 'responsive', 'to', 'amiodarone', 'was', 'more', 'frequent', 'in', 'myoblast-treated', 'patients', ':', '1', '(', 'placebo', ')', ',', '3', '(', 'low', 'dose', ')', ',', 'and', '4', '(', 'high', 'dose', ')', '.']","(0, 3)","(0, 34)",-1,ss_o,21982657,Abstract,5,test,gold,3528.0
4348,Ventricular tachycardia responsive to amiodarone was more frequent in,myoblast-treated,"patients : 1 ( placebo ) , 3 ( low dose ) , and 4 ( high dose ) .","['Ventricular', 'tachycardia', 'responsive', 'to', 'amiodarone', 'was', 'more', 'frequent', 'in', 'myoblast-treated', 'patients', ':', '1', '(', 'placebo', ')', ',', '3', '(', 'low', 'dose', ')', ',', 'and', '4', '(', 'high', 'dose', ')', '.']","(9, 10)","(69, 85)",-1,hl_i,21982657,Abstract,5,test,gold,
4349,Ventricular tachycardia responsive to amiodarone was more frequent in myoblast-treated patients : 1,( placebo ),", 3 ( low dose ) , and 4 ( high dose ) .","['Ventricular', 'tachycardia', 'responsive', 'to', 'amiodarone', 'was', 'more', 'frequent', 'in', 'myoblast-treated', 'patients', ':', '1', '(', 'placebo', ')', ',', '3', '(', 'low', 'dose', ')', ',', 'and', '4', '(', 'high', 'dose', ')', '.']","(13, 16)","(99, 110)",-1,hl_i,21982657,Abstract,5,test,gold,4363.0
4350,,Ventricular tachycardia responsive,"to amiodarone was more frequent in myoblast-treated patients : 1 ( placebo ) , 3 ( low dose ) , and 4 ( high dose ) .","['Ventricular', 'tachycardia', 'responsive', 'to', 'amiodarone', 'was', 'more', 'frequent', 'in', 'myoblast-treated', 'patients', ':', '1', '(', 'placebo', ')', ',', '3', '(', 'low', 'dose', ')', ',', 'and', '4', '(', 'high', 'dose', ')', '.']","(0, 3)","(0, 34)",-1,hl_o,21982657,Abstract,5,test,gold,3529.0
4351,A trend toward improvement in functional capacity was noted in,myoblast-treated,groups ( Δ6-minute walk test of -3.6 vs +95.6 vs +85.5 m [ placebo vs low dose vs high dose ; P = .50 ] ) without significant changes in Minnesota Living With HF scores .,"['A', 'trend', 'toward', 'improvement', 'in', 'functional', 'capacity', 'was', 'noted', 'in', 'myoblast-treated', 'groups', '(', 'Δ6-minute', 'walk', 'test', 'of', '-3.6', 'vs', '+95.6', 'vs', '+85.5', 'm', '[', 'placebo', 'vs', 'low', 'dose', 'vs', 'high', 'dose', ';', 'P', '=', '.50', ']', ')', 'without', 'significant', 'changes', 'in', 'Minnesota', 'Living', 'With', 'HF', 'scores', '.']","(10, 11)","(62, 78)",-1,ss_i,21982657,Abstract,6,test,gold,
4352,A trend toward improvement in,functional capacity,was noted in myoblast-treated groups ( Δ6-minute walk test of -3.6 vs +95.6 vs +85.5 m [ placebo vs low dose vs high dose ; P = .50 ] ) without significant changes in Minnesota Living With HF scores .,"['A', 'trend', 'toward', 'improvement', 'in', 'functional', 'capacity', 'was', 'noted', 'in', 'myoblast-treated', 'groups', '(', 'Δ6-minute', 'walk', 'test', 'of', '-3.6', 'vs', '+95.6', 'vs', '+85.5', 'm', '[', 'placebo', 'vs', 'low', 'dose', 'vs', 'high', 'dose', ';', 'P', '=', '.50', ']', ')', 'without', 'significant', 'changes', 'in', 'Minnesota', 'Living', 'With', 'HF', 'scores', '.']","(5, 7)","(29, 48)",-1,ss_o,21982657,Abstract,6,test,gold,1360.0
4353,A trend toward improvement in functional capacity was noted in myoblast-treated groups ( Δ6-minute walk test of -3.6 vs +95.6 vs +85.5 m [ placebo vs low dose vs high dose ; P = .50 ] ) without significant changes,in Minnesota Living With HF scores,.,"['A', 'trend', 'toward', 'improvement', 'in', 'functional', 'capacity', 'was', 'noted', 'in', 'myoblast-treated', 'groups', '(', 'Δ6-minute', 'walk', 'test', 'of', '-3.6', 'vs', '+95.6', 'vs', '+85.5', 'm', '[', 'placebo', 'vs', 'low', 'dose', 'vs', 'high', 'dose', ';', 'P', '=', '.50', ']', ')', 'without', 'significant', 'changes', 'in', 'Minnesota', 'Living', 'With', 'HF', 'scores', '.']","(40, 46)","(213, 247)",-1,ss_o,21982657,Abstract,6,test,gold,1450.0
4354,A trend toward improvement in functional capacity was noted in,myoblast-treated,groups ( Δ6-minute walk test of -3.6 vs +95.6 vs +85.5 m [ placebo vs low dose vs high dose ; P = .50 ] ) without significant changes in Minnesota Living With HF scores .,"['A', 'trend', 'toward', 'improvement', 'in', 'functional', 'capacity', 'was', 'noted', 'in', 'myoblast-treated', 'groups', '(', 'Δ6-minute', 'walk', 'test', 'of', '-3.6', 'vs', '+95.6', 'vs', '+85.5', 'm', '[', 'placebo', 'vs', 'low', 'dose', 'vs', 'high', 'dose', ';', 'P', '=', '.50', ']', ')', 'without', 'significant', 'changes', 'in', 'Minnesota', 'Living', 'With', 'HF', 'scores', '.']","(10, 11)","(62, 78)",-1,hl_i,21982657,Abstract,6,test,gold,
4355,A trend toward improvement in,functional capacity,was noted in myoblast-treated groups ( Δ6-minute walk test of -3.6 vs +95.6 vs +85.5 m [ placebo vs low dose vs high dose ; P = .50 ] ) without significant changes in Minnesota Living With HF scores .,"['A', 'trend', 'toward', 'improvement', 'in', 'functional', 'capacity', 'was', 'noted', 'in', 'myoblast-treated', 'groups', '(', 'Δ6-minute', 'walk', 'test', 'of', '-3.6', 'vs', '+95.6', 'vs', '+85.5', 'm', '[', 'placebo', 'vs', 'low', 'dose', 'vs', 'high', 'dose', ';', 'P', '=', '.50', ']', ')', 'without', 'significant', 'changes', 'in', 'Minnesota', 'Living', 'With', 'HF', 'scores', '.']","(5, 7)","(29, 48)",-1,hl_o,21982657,Abstract,6,test,gold,1361.0
4356,CONCLUSIONS,In HF patients with chronic postinfarction cardiomyopathy,", transcatheter administration of myoblasts in doses of 400 to 800 million cells is feasible and may lead to important clinical benefits .","['CONCLUSIONS', 'In', 'HF', 'patients', 'with', 'chronic', 'postinfarction', 'cardiomyopathy', ',', 'transcatheter', 'administration', 'of', 'myoblasts', 'in', 'doses', 'of', '400', 'to', '800', 'million', 'cells', 'is', 'feasible', 'and', 'may', 'lead', 'to', 'important', 'clinical', 'benefits', '.']","(1, 8)","(11, 68)",-1,ss_p,21982657,Abstract,7,test,gold,7003.0
4357,"CONCLUSIONS In HF patients with chronic postinfarction cardiomyopathy , transcatheter administration",of myoblasts,in doses of 400 to 800 million cells is feasible and may lead to important clinical benefits .,"['CONCLUSIONS', 'In', 'HF', 'patients', 'with', 'chronic', 'postinfarction', 'cardiomyopathy', ',', 'transcatheter', 'administration', 'of', 'myoblasts', 'in', 'doses', 'of', '400', 'to', '800', 'million', 'cells', 'is', 'feasible', 'and', 'may', 'lead', 'to', 'important', 'clinical', 'benefits', '.']","(11, 13)","(100, 112)",-1,ss_i,21982657,Abstract,7,test,gold,3160.0
4358,"CONCLUSIONS In HF patients with chronic postinfarction cardiomyopathy , transcatheter administration of",myoblasts,in doses of 400 to 800 million cells is feasible and may lead to important clinical benefits .,"['CONCLUSIONS', 'In', 'HF', 'patients', 'with', 'chronic', 'postinfarction', 'cardiomyopathy', ',', 'transcatheter', 'administration', 'of', 'myoblasts', 'in', 'doses', 'of', '400', 'to', '800', 'million', 'cells', 'is', 'feasible', 'and', 'may', 'lead', 'to', 'important', 'clinical', 'benefits', '.']","(12, 13)","(103, 112)",-1,hl_i,21982657,Abstract,7,test,gold,3159.0
4359,Ventricular tachycardia may be provoked,by myoblast,injection but appears to be a transient and treatable problem .,"['Ventricular', 'tachycardia', 'may', 'be', 'provoked', 'by', 'myoblast', 'injection', 'but', 'appears', 'to', 'be', 'a', 'transient', 'and', 'treatable', 'problem', '.']","(5, 7)","(39, 50)",-1,ss_i,21982657,Abstract,8,test,gold,120.0
4360,A large-scale outcome trial of myoblast administration,in HF patients with postinfarction cardiomyopathy,is feasible and warranted .,"['A', 'large-scale', 'outcome', 'trial', 'of', 'myoblast', 'administration', 'in', 'HF', 'patients', 'with', 'postinfarction', 'cardiomyopathy', 'is', 'feasible', 'and', 'warranted', '.']","(7, 13)","(54, 103)",-1,ss_p,21982657,Abstract,9,test,gold,7004.0
4361,A large-scale outcome trial,of myoblast,administration in HF patients with postinfarction cardiomyopathy is feasible and warranted .,"['A', 'large-scale', 'outcome', 'trial', 'of', 'myoblast', 'administration', 'in', 'HF', 'patients', 'with', 'postinfarction', 'cardiomyopathy', 'is', 'feasible', 'and', 'warranted', '.']","(4, 6)","(27, 38)",-1,ss_i,21982657,Abstract,9,test,gold,121.0
4362,"Safety , tolerability , and immunogenicity after 1 and 2 doses of zoster vaccine in",healthy adults ≥60 years of age,.,"['Safety', ',', 'tolerability', ',', 'and', 'immunogenicity', 'after', '1', 'and', '2', 'doses', 'of', 'zoster', 'vaccine', 'in', 'healthy', 'adults', '≥60', 'years', 'of', 'age', '.']","(15, 21)","(83, 114)",-1,ss_p,22154769,Title,0,test,gold,2042.0
4363,"Safety , tolerability , and immunogenicity after 1 and 2 doses of",zoster vaccine,in healthy adults ≥60 years of age .,"['Safety', ',', 'tolerability', ',', 'and', 'immunogenicity', 'after', '1', 'and', '2', 'doses', 'of', 'zoster', 'vaccine', 'in', 'healthy', 'adults', '≥60', 'years', 'of', 'age', '.']","(12, 14)","(65, 79)",-1,ss_i,22154769,Title,0,test,gold,5651.0
4364,,"Safety , tolerability , and immunogenicity",after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age .,"['Safety', ',', 'tolerability', ',', 'and', 'immunogenicity', 'after', '1', 'and', '2', 'doses', 'of', 'zoster', 'vaccine', 'in', 'healthy', 'adults', '≥60', 'years', 'of', 'age', '.']","(0, 6)","(0, 42)",-1,ss_o,22154769,Title,0,test,gold,4878.0
4365,"Safety , tolerability , and immunogenicity after 1 and 2 doses of zoster vaccine in",healthy adults ≥60 years of age,.,"['Safety', ',', 'tolerability', ',', 'and', 'immunogenicity', 'after', '1', 'and', '2', 'doses', 'of', 'zoster', 'vaccine', 'in', 'healthy', 'adults', '≥60', 'years', 'of', 'age', '.']","(15, 21)","(83, 114)",-1,hl_p,22154769,Title,0,test,gold,2043.0
4366,"Safety , tolerability , and immunogenicity after 1 and 2 doses of",zoster vaccine,in healthy adults ≥60 years of age .,"['Safety', ',', 'tolerability', ',', 'and', 'immunogenicity', 'after', '1', 'and', '2', 'doses', 'of', 'zoster', 'vaccine', 'in', 'healthy', 'adults', '≥60', 'years', 'of', 'age', '.']","(12, 14)","(65, 79)",-1,hl_i,22154769,Title,0,test,gold,5652.0
4367,,Safety,", tolerability , and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age .","['Safety', ',', 'tolerability', ',', 'and', 'immunogenicity', 'after', '1', 'and', '2', 'doses', 'of', 'zoster', 'vaccine', 'in', 'healthy', 'adults', '≥60', 'years', 'of', 'age', '.']","(0, 1)","(0, 6)",-1,hl_o,22154769,Title,0,test,gold,445.0
4368,"Safety ,",tolerability,", and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age .","['Safety', ',', 'tolerability', ',', 'and', 'immunogenicity', 'after', '1', 'and', '2', 'doses', 'of', 'zoster', 'vaccine', 'in', 'healthy', 'adults', '≥60', 'years', 'of', 'age', '.']","(2, 3)","(8, 20)",-1,hl_o,22154769,Title,0,test,gold,4863.0
4369,"Safety , tolerability , and",immunogenicity,after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age .,"['Safety', ',', 'tolerability', ',', 'and', 'immunogenicity', 'after', '1', 'and', '2', 'doses', 'of', 'zoster', 'vaccine', 'in', 'healthy', 'adults', '≥60', 'years', 'of', 'age', '.']","(5, 6)","(27, 41)",-1,hl_o,22154769,Title,0,test,gold,4883.0
4370,"BACKGROUND Incidence and severity of herpes zoster ( HZ ) and postherpetic neuralgia increase with age , associated with age-related decrease in immunity to varicella-zoster virus ( VZV ) .",,,"['BACKGROUND', 'Incidence', 'and', 'severity', 'of', 'herpes', 'zoster', '(', 'HZ', ')', 'and', 'postherpetic', 'neuralgia', 'increase', 'with', 'age', ',', 'associated', 'with', 'age-related', 'decrease', 'in', 'immunity', 'to', 'varicella-zoster', 'virus', '(', 'VZV', ')', '.']",,,,,22154769,Abstract,0,test,gold,
4371,One dose,of zoster vaccine ( ZV ),has demonstrated substantial protection against HZ ; this study examined impact of a second dose of ZV .,"['One', 'dose', 'of', 'zoster', 'vaccine', '(', 'ZV', ')', 'has', 'demonstrated', 'substantial', 'protection', 'against', 'HZ', ';', 'this', 'study', 'examined', 'impact', 'of', 'a', 'second', 'dose', 'of', 'ZV', '.']","(2, 8)","(8, 32)",-1,ss_i,22154769,Abstract,1,test,gold,5653.0
4372,One dose of zoster vaccine ( ZV ) has demonstrated substantial protection against HZ ; this study examined impact of a second dose,of ZV,.,"['One', 'dose', 'of', 'zoster', 'vaccine', '(', 'ZV', ')', 'has', 'demonstrated', 'substantial', 'protection', 'against', 'HZ', ';', 'this', 'study', 'examined', 'impact', 'of', 'a', 'second', 'dose', 'of', 'ZV', '.']","(23, 25)","(130, 135)",-1,ss_i,22154769,Abstract,1,test,gold,1052.0
4373,One dose of,zoster vaccine ( ZV ),has demonstrated substantial protection against HZ ; this study examined impact of a second dose of ZV .,"['One', 'dose', 'of', 'zoster', 'vaccine', '(', 'ZV', ')', 'has', 'demonstrated', 'substantial', 'protection', 'against', 'HZ', ';', 'this', 'study', 'examined', 'impact', 'of', 'a', 'second', 'dose', 'of', 'ZV', '.']","(3, 8)","(11, 32)",-1,hl_i,22154769,Abstract,1,test,gold,5654.0
4374,"METHODS Randomized , double-blind , multicenter study",with 210 subjects ≥60 years,"old compared immunity and safety profiles after one and two doses of ZV , separated by 6 weeks , vs. placebo .","['METHODS', 'Randomized', ',', 'double-blind', ',', 'multicenter', 'study', 'with', '210', 'subjects', '≥60', 'years', 'old', 'compared', 'immunity', 'and', 'safety', 'profiles', 'after', 'one', 'and', 'two', 'doses', 'of', 'ZV', ',', 'separated', 'by', '6', 'weeks', ',', 'vs.', 'placebo', '.']","(7, 12)","(53, 80)",-1,ss_p,22154769,Abstract,2,test,gold,2070.0
4375,"METHODS Randomized , double-blind , multicenter study with 210 subjects ≥60 years old compared immunity and safety profiles after one and two",doses of,"ZV , separated by 6 weeks , vs. placebo .","['METHODS', 'Randomized', ',', 'double-blind', ',', 'multicenter', 'study', 'with', '210', 'subjects', '≥60', 'years', 'old', 'compared', 'immunity', 'and', 'safety', 'profiles', 'after', 'one', 'and', 'two', 'doses', 'of', 'ZV', ',', 'separated', 'by', '6', 'weeks', ',', 'vs.', 'placebo', '.']","(22, 24)","(141, 149)",-1,ss_i,22154769,Abstract,2,test,gold,5052.0
4376,"METHODS Randomized , double-blind , multicenter study with 210 subjects ≥60 years old compared immunity and safety profiles after one and two doses of ZV , separated by 6 weeks ,",vs. placebo,.,"['METHODS', 'Randomized', ',', 'double-blind', ',', 'multicenter', 'study', 'with', '210', 'subjects', '≥60', 'years', 'old', 'compared', 'immunity', 'and', 'safety', 'profiles', 'after', 'one', 'and', 'two', 'doses', 'of', 'ZV', ',', 'separated', 'by', '6', 'weeks', ',', 'vs.', 'placebo', '.']","(31, 33)","(178, 189)",-1,ss_i,22154769,Abstract,2,test,gold,4429.0
4377,"METHODS Randomized , double-blind , multicenter study with 210 subjects ≥60 years old",compared immunity and safety profiles,"after one and two doses of ZV , separated by 6 weeks , vs. placebo .","['METHODS', 'Randomized', ',', 'double-blind', ',', 'multicenter', 'study', 'with', '210', 'subjects', '≥60', 'years', 'old', 'compared', 'immunity', 'and', 'safety', 'profiles', 'after', 'one', 'and', 'two', 'doses', 'of', 'ZV', ',', 'separated', 'by', '6', 'weeks', ',', 'vs.', 'placebo', '.']","(13, 18)","(85, 122)",-1,ss_o,22154769,Abstract,2,test,gold,4773.0
4378,"METHODS Randomized , double-blind , multicenter study with 210 subjects ≥60 years old compared immunity and safety profiles after one and two doses of ZV , separated by 6 weeks , vs.",placebo .,,"['METHODS', 'Randomized', ',', 'double-blind', ',', 'multicenter', 'study', 'with', '210', 'subjects', '≥60', 'years', 'old', 'compared', 'immunity', 'and', 'safety', 'profiles', 'after', 'one', 'and', 'two', 'doses', 'of', 'ZV', ',', 'separated', 'by', '6', 'weeks', ',', 'vs.', 'placebo', '.']","(32, 34)","(182, 191)",-1,ss_o,22154769,Abstract,2,test,gold,4362.0
4379,"METHODS Randomized , double-blind , multicenter study with",210,"subjects ≥60 years old compared immunity and safety profiles after one and two doses of ZV , separated by 6 weeks , vs. placebo .","['METHODS', 'Randomized', ',', 'double-blind', ',', 'multicenter', 'study', 'with', '210', 'subjects', '≥60', 'years', 'old', 'compared', 'immunity', 'and', 'safety', 'profiles', 'after', 'one', 'and', 'two', 'doses', 'of', 'ZV', ',', 'separated', 'by', '6', 'weeks', ',', 'vs.', 'placebo', '.']","(8, 9)","(58, 61)",-1,hl_p,22154769,Abstract,2,test,gold,
4380,"METHODS Randomized , double-blind , multicenter study with 210 subjects",≥60 years,"old compared immunity and safety profiles after one and two doses of ZV , separated by 6 weeks , vs. placebo .","['METHODS', 'Randomized', ',', 'double-blind', ',', 'multicenter', 'study', 'with', '210', 'subjects', '≥60', 'years', 'old', 'compared', 'immunity', 'and', 'safety', 'profiles', 'after', 'one', 'and', 'two', 'doses', 'of', 'ZV', ',', 'separated', 'by', '6', 'weeks', ',', 'vs.', 'placebo', '.']","(10, 12)","(71, 80)",-1,hl_p,22154769,Abstract,2,test,gold,2026.0
4381,"METHODS Randomized , double-blind , multicenter study with 210 subjects ≥60 years old compared immunity and safety profiles after one and two doses of ZV , separated by 6 weeks , vs.",placebo,.,"['METHODS', 'Randomized', ',', 'double-blind', ',', 'multicenter', 'study', 'with', '210', 'subjects', '≥60', 'years', 'old', 'compared', 'immunity', 'and', 'safety', 'profiles', 'after', 'one', 'and', 'two', 'doses', 'of', 'ZV', ',', 'separated', 'by', '6', 'weeks', ',', 'vs.', 'placebo', '.']","(32, 33)","(182, 189)",-1,hl_i,22154769,Abstract,2,test,gold,4361.0
4382,"METHODS Randomized , double-blind , multicenter study with 210 subjects ≥60 years old compared",immunity,"and safety profiles after one and two doses of ZV , separated by 6 weeks , vs. placebo .","['METHODS', 'Randomized', ',', 'double-blind', ',', 'multicenter', 'study', 'with', '210', 'subjects', '≥60', 'years', 'old', 'compared', 'immunity', 'and', 'safety', 'profiles', 'after', 'one', 'and', 'two', 'doses', 'of', 'ZV', ',', 'separated', 'by', '6', 'weeks', ',', 'vs.', 'placebo', '.']","(14, 15)","(94, 102)",-1,hl_o,22154769,Abstract,2,test,gold,1232.0
4383,"METHODS Randomized , double-blind , multicenter study with 210 subjects ≥60 years old compared immunity and",safety,"profiles after one and two doses of ZV , separated by 6 weeks , vs. placebo .","['METHODS', 'Randomized', ',', 'double-blind', ',', 'multicenter', 'study', 'with', '210', 'subjects', '≥60', 'years', 'old', 'compared', 'immunity', 'and', 'safety', 'profiles', 'after', 'one', 'and', 'two', 'doses', 'of', 'ZV', ',', 'separated', 'by', '6', 'weeks', ',', 'vs.', 'placebo', '.']","(16, 17)","(107, 113)",-1,hl_o,22154769,Abstract,2,test,gold,461.0
4384,,Immunogenicity was evaluated using VZV interferon-gamma ( IFN-γ ) enzyme-linked immunospot ( ELISPOT ) assay and VZV glycoprotein enzyme-linked immunosorbent antibody ( gpELISA ) assay .,,"['Immunogenicity', 'was', 'evaluated', 'using', 'VZV', 'interferon-gamma', '(', 'IFN-γ', ')', 'enzyme-linked', 'immunospot', '(', 'ELISPOT', ')', 'assay', 'and', 'VZV', 'glycoprotein', 'enzyme-linked', 'immunosorbent', 'antibody', '(', 'gpELISA', ')', 'assay', '.']","(0, 26)","(0, 186)",-1,ss_o,22154769,Abstract,3,test,gold,5806.0
4385,,Immunogenicity,was evaluated using VZV interferon-gamma ( IFN-γ ) enzyme-linked immunospot ( ELISPOT ) assay and VZV glycoprotein enzyme-linked immunosorbent antibody ( gpELISA ) assay .,"['Immunogenicity', 'was', 'evaluated', 'using', 'VZV', 'interferon-gamma', '(', 'IFN-γ', ')', 'enzyme-linked', 'immunospot', '(', 'ELISPOT', ')', 'assay', 'and', 'VZV', 'glycoprotein', 'enzyme-linked', 'immunosorbent', 'antibody', '(', 'gpELISA', ')', 'assay', '.']","(0, 1)","(0, 14)",-1,hl_o,22154769,Abstract,3,test,gold,132.0
4386,,Adverse experiences ( AEs ),were recorded on a standardized Vaccination Report Card .,"['Adverse', 'experiences', '(', 'AEs', ')', 'were', 'recorded', 'on', 'a', 'standardized', 'Vaccination', 'Report', 'Card', '.']","(0, 5)","(0, 27)",-1,ss_o,22154769,Abstract,4,test,gold,3090.0
4387,Adverse experiences ( AEs ) were recorded,on a standardized Vaccination Report,Card .,"['Adverse', 'experiences', '(', 'AEs', ')', 'were', 'recorded', 'on', 'a', 'standardized', 'Vaccination', 'Report', 'Card', '.']","(7, 12)","(41, 77)",-1,ss_o,22154769,Abstract,4,test,gold,3398.0
4388,,Adverse experiences ( AEs ),were recorded on a standardized Vaccination Report Card .,"['Adverse', 'experiences', '(', 'AEs', ')', 'were', 'recorded', 'on', 'a', 'standardized', 'Vaccination', 'Report', 'Card', '.']","(0, 5)","(0, 27)",-1,hl_o,22154769,Abstract,4,test,gold,3091.0
4389,,RESULTS No serious vaccine-related,AEs occurred .,"['RESULTS', 'No', 'serious', 'vaccine-related', 'AEs', 'occurred', '.']","(0, 4)","(0, 34)",-1,ss_o,22154769,Abstract,5,test,gold,360.0
4390,RESULTS No serious vaccine-related AEs,occurred .,,"['RESULTS', 'No', 'serious', 'vaccine-related', 'AEs', 'occurred', '.']","(5, 7)","(38, 48)",-1,ss_o,22154769,Abstract,5,test,gold,1208.0
4391,RESULTS No,serious vaccine-related,AEs occurred .,"['RESULTS', 'No', 'serious', 'vaccine-related', 'AEs', 'occurred', '.']","(2, 4)","(10, 33)",-1,hl_o,22154769,Abstract,5,test,gold,1216.0
4392,VZV IFN-γ ELISPOT geometric mean count ( GMC ) of spot-forming cells per 10 ( 6 ) peripheral blood mononuclear cells increased,in the,"ZV group from 16.9 prevaccination to 49.5 and 32.8 at 2 and 6 weeks postdose 1 , respectively .","['VZV', 'IFN-γ', 'ELISPOT', 'geometric', 'mean', 'count', '(', 'GMC', ')', 'of', 'spot-forming', 'cells', 'per', '10', '(', '6', ')', 'peripheral', 'blood', 'mononuclear', 'cells', 'increased', 'in', 'the', 'ZV', 'group', 'from', '16.9', 'prevaccination', 'to', '49.5', 'and', '32.8', 'at', '2', 'and', '6', 'weeks', 'postdose', '1', ',', 'respectively', '.']","(22, 24)","(126, 132)",-1,ss_i,22154769,Abstract,6,test,gold,1187.0
4393,,VZV IFN-γ ELISPOT geometric mean count ( GMC ) of spot-forming cells per 10 ( 6 ) peripheral blood mononuclear,"cells increased in the ZV group from 16.9 prevaccination to 49.5 and 32.8 at 2 and 6 weeks postdose 1 , respectively .","['VZV', 'IFN-γ', 'ELISPOT', 'geometric', 'mean', 'count', '(', 'GMC', ')', 'of', 'spot-forming', 'cells', 'per', '10', '(', '6', ')', 'peripheral', 'blood', 'mononuclear', 'cells', 'increased', 'in', 'the', 'ZV', 'group', 'from', '16.9', 'prevaccination', 'to', '49.5', 'and', '32.8', 'at', '2', 'and', '6', 'weeks', 'postdose', '1', ',', 'respectively', '.']","(0, 20)","(0, 110)",-1,ss_o,22154769,Abstract,6,test,gold,6539.0
4394,"Two weeks , 6 weeks and 6 months postdose 2 , GMC was 44.3 , 42.9 , and 36.5 ,",respectively,.,"['Two', 'weeks', ',', '6', 'weeks', 'and', '6', 'months', 'postdose', '2', ',', 'GMC', 'was', '44.3', ',', '42.9', ',', 'and', '36.5', ',', 'respectively', '.']","(20, 21)","(78, 90)",-1,ss_o,22154769,Abstract,7,test,gold,1173.0
4395,GMC,in the placebo,group did not change during the study .,"['GMC', 'in', 'the', 'placebo', 'group', 'did', 'not', 'change', 'during', 'the', 'study', '.']","(1, 4)","(3, 17)",-1,ss_i,22154769,Abstract,8,test,gold,4426.0
4396,GMC in the placebo group did not change during the,study .,,"['GMC', 'in', 'the', 'placebo', 'group', 'did', 'not', 'change', 'during', 'the', 'study', '.']","(10, 12)","(50, 57)",-1,ss_o,22154769,Abstract,8,test,gold,2089.0
4397,GMC in the,placebo,group did not change during the study .,"['GMC', 'in', 'the', 'placebo', 'group', 'did', 'not', 'change', 'during', 'the', 'study', '.']","(3, 4)","(10, 17)",-1,hl_i,22154769,Abstract,8,test,gold,4360.0
4398,The peak ELISPOT response occurred ∼2 weeks,after,each ZV dose .,"['The', 'peak', 'ELISPOT', 'response', 'occurred', '∼2', 'weeks', 'after', 'each', 'ZV', 'dose', '.']","(7, 8)","(43, 48)",-1,ss_i,22154769,Abstract,9,test,gold,1192.0
4399,,The peak ELISPOT response,occurred ∼2 weeks after each ZV dose .,"['The', 'peak', 'ELISPOT', 'response', 'occurred', '∼2', 'weeks', 'after', 'each', 'ZV', 'dose', '.']","(0, 4)","(0, 25)",-1,ss_o,22154769,Abstract,9,test,gold,2531.0
4400,The peak ELISPOT response occurred ∼2 weeks after each ZV,dose .,,"['The', 'peak', 'ELISPOT', 'response', 'occurred', '∼2', 'weeks', 'after', 'each', 'ZV', 'dose', '.']","(10, 12)","(57, 63)",-1,ss_o,22154769,Abstract,9,test,gold,5053.0
4401,The gpELISA geometric mean titers,( GMTs ) in,the ZV group were higher than in the placebo group at 6 weeks after each dose .,"['The', 'gpELISA', 'geometric', 'mean', 'titers', '(', 'GMTs', ')', 'in', 'the', 'ZV', 'group', 'were', 'higher', 'than', 'in', 'the', 'placebo', 'group', 'at', '6', 'weeks', 'after', 'each', 'dose', '.']","(5, 9)","(33, 44)",-1,ss_i,22154769,Abstract,10,test,gold,1029.0
4402,The gpELISA geometric mean titers ( GMTs ) in the ZV group were higher,than in the,placebo group at 6 weeks after each dose .,"['The', 'gpELISA', 'geometric', 'mean', 'titers', '(', 'GMTs', ')', 'in', 'the', 'ZV', 'group', 'were', 'higher', 'than', 'in', 'the', 'placebo', 'group', 'at', '6', 'weeks', 'after', 'each', 'dose', '.']","(14, 17)","(70, 81)",-1,ss_i,22154769,Abstract,10,test,gold,1153.0
4403,,The gpELISA geometric mean titers,( GMTs ) in the ZV group were higher than in the placebo group at 6 weeks after each dose .,"['The', 'gpELISA', 'geometric', 'mean', 'titers', '(', 'GMTs', ')', 'in', 'the', 'ZV', 'group', 'were', 'higher', 'than', 'in', 'the', 'placebo', 'group', 'at', '6', 'weeks', 'after', 'each', 'dose', '.']","(0, 5)","(0, 33)",-1,ss_o,22154769,Abstract,10,test,gold,1664.0
4404,Correlation,between the IFN-γ ELISPOT and gpELISA,assays was poor .,"['Correlation', 'between', 'the', 'IFN-γ', 'ELISPOT', 'and', 'gpELISA', 'assays', 'was', 'poor', '.']","(1, 7)","(11, 48)",-1,ss_o,22154769,Abstract,11,test,gold,119.0
4405,CONCLUSIONS ZV was generally well-tolerated and,immunogenic in adults ≥60,years old .,"['CONCLUSIONS', 'ZV', 'was', 'generally', 'well-tolerated', 'and', 'immunogenic', 'in', 'adults', '≥60', 'years', 'old', '.']","(6, 10)","(47, 72)",-1,ss_p,22154769,Abstract,12,test,gold,5724.0
4406,,CONCLUSIONS,ZV was generally well-tolerated and immunogenic in adults ≥60 years old .,"['CONCLUSIONS', 'ZV', 'was', 'generally', 'well-tolerated', 'and', 'immunogenic', 'in', 'adults', '≥60', 'years', 'old', '.']","(0, 1)","(0, 11)",-1,ss_i,22154769,Abstract,12,test,gold,432.0
4407,A,second,"dose of ZV was generally safe , but did not boost VZV-specific immunity beyond levels achieved postdose 1 .","['A', 'second', 'dose', 'of', 'ZV', 'was', 'generally', 'safe', ',', 'but', 'did', 'not', 'boost', 'VZV-specific', 'immunity', 'beyond', 'levels', 'achieved', 'postdose', '1', '.']","(1, 2)","(1, 7)",-1,ss_i,22154769,Abstract,13,test,gold,1193.0
4408,A second dose of ZV,was generally,"safe , but did not boost VZV-specific immunity beyond levels achieved postdose 1 .","['A', 'second', 'dose', 'of', 'ZV', 'was', 'generally', 'safe', ',', 'but', 'did', 'not', 'boost', 'VZV-specific', 'immunity', 'beyond', 'levels', 'achieved', 'postdose', '1', '.']","(5, 7)","(19, 32)",-1,ss_o,22154769,Abstract,13,test,gold,1156.0
4409,"A second dose of ZV was generally safe , but did not boost",VZV-specific,immunity beyond levels achieved postdose 1 .,"['A', 'second', 'dose', 'of', 'ZV', 'was', 'generally', 'safe', ',', 'but', 'did', 'not', 'boost', 'VZV-specific', 'immunity', 'beyond', 'levels', 'achieved', 'postdose', '1', '.']","(13, 14)","(58, 70)",-1,ss_o,22154769,Abstract,13,test,gold,
4410,Effect of different rates of infusion of propofol for induction of anaesthesia in,elderly patients .,,"['Effect', 'of', 'different', 'rates', 'of', 'infusion', 'of', 'propofol', 'for', 'induction', 'of', 'anaesthesia', 'in', 'elderly', 'patients', '.']","(13, 16)","(81, 99)",-1,ss_p,2223363,Title,0,test,gold,3763.0
4411,Effect of different rates of infusion of,propofol,for induction of anaesthesia in elderly patients .,"['Effect', 'of', 'different', 'rates', 'of', 'infusion', 'of', 'propofol', 'for', 'induction', 'of', 'anaesthesia', 'in', 'elderly', 'patients', '.']","(7, 8)","(40, 48)",-1,ss_i,2223363,Title,0,test,gold,4698.0
4412,Effect of different rates of infusion of propofol for induction of anaesthesia in,elderly patients .,,"['Effect', 'of', 'different', 'rates', 'of', 'infusion', 'of', 'propofol', 'for', 'induction', 'of', 'anaesthesia', 'in', 'elderly', 'patients', '.']","(13, 16)","(81, 99)",-1,hl_p,2223363,Title,0,test,gold,3764.0
4413,Effect of different rates of infusion of,propofol,for induction of anaesthesia in elderly patients .,"['Effect', 'of', 'different', 'rates', 'of', 'infusion', 'of', 'propofol', 'for', 'induction', 'of', 'anaesthesia', 'in', 'elderly', 'patients', '.']","(7, 8)","(40, 48)",-1,hl_i,2223363,Title,0,test,gold,4697.0
4414,The effect of changing the rate of infusion of propofol for induction of anaesthesia was studied in,60 elderly patients .,,"['The', 'effect', 'of', 'changing', 'the', 'rate', 'of', 'infusion', 'of', 'propofol', 'for', 'induction', 'of', 'anaesthesia', 'was', 'studied', 'in', '60', 'elderly', 'patients', '.']","(17, 21)","(99, 120)",-1,ss_p,2223363,Abstract,0,test,gold,3762.0
4415,The effect of changing the rate of infusion of,propofol,for induction of anaesthesia was studied in 60 elderly patients .,"['The', 'effect', 'of', 'changing', 'the', 'rate', 'of', 'infusion', 'of', 'propofol', 'for', 'induction', 'of', 'anaesthesia', 'was', 'studied', 'in', '60', 'elderly', 'patients', '.']","(9, 10)","(46, 54)",-1,ss_i,2223363,Abstract,0,test,gold,4696.0
4416,The effect of changing the rate of infusion of propofol for induction of anaesthesia was studied in,60 elderly patients,.,"['The', 'effect', 'of', 'changing', 'the', 'rate', 'of', 'infusion', 'of', 'propofol', 'for', 'induction', 'of', 'anaesthesia', 'was', 'studied', 'in', '60', 'elderly', 'patients', '.']","(17, 20)","(99, 118)",-1,hl_p,2223363,Abstract,0,test,gold,3761.0
4417,The effect of changing the rate of infusion of,propofol,for induction of anaesthesia was studied in 60 elderly patients .,"['The', 'effect', 'of', 'changing', 'the', 'rate', 'of', 'infusion', 'of', 'propofol', 'for', 'induction', 'of', 'anaesthesia', 'was', 'studied', 'in', '60', 'elderly', 'patients', '.']","(9, 10)","(46, 54)",-1,hl_i,2223363,Abstract,0,test,gold,4695.0
4418,,Propofol,"was administered at 300 , 600 or 1200 ml h-1 until loss of consciousness ( as judged by loss of verbal contact with the patient ) had been achieved .","['Propofol', 'was', 'administered', 'at', '300', ',', '600', 'or', '1200', 'ml', 'h-1', 'until', 'loss', 'of', 'consciousness', '(', 'as', 'judged', 'by', 'loss', 'of', 'verbal', 'contact', 'with', 'the', 'patient', ')', 'had', 'been', 'achieved', '.']","(0, 1)","(0, 8)",-1,ss_i,2223363,Abstract,1,test,gold,4682.0
4419,"Propofol was administered at 300 , 600 or 1200 ml h-1 until",loss of consciousness ( as judged by loss of verbal contact with the patient ),had been achieved .,"['Propofol', 'was', 'administered', 'at', '300', ',', '600', 'or', '1200', 'ml', 'h-1', 'until', 'loss', 'of', 'consciousness', '(', 'as', 'judged', 'by', 'loss', 'of', 'verbal', 'contact', 'with', 'the', 'patient', ')', 'had', 'been', 'achieved', '.']","(12, 27)","(59, 137)",-1,ss_o,2223363,Abstract,1,test,gold,3718.0
4420,,Propofol,"was administered at 300 , 600 or 1200 ml h-1 until loss of consciousness ( as judged by loss of verbal contact with the patient ) had been achieved .","['Propofol', 'was', 'administered', 'at', '300', ',', '600', 'or', '1200', 'ml', 'h-1', 'until', 'loss', 'of', 'consciousness', '(', 'as', 'judged', 'by', 'loss', 'of', 'verbal', 'contact', 'with', 'the', 'patient', ')', 'had', 'been', 'achieved', '.']","(0, 1)","(0, 8)",-1,hl_i,2223363,Abstract,1,test,gold,4683.0
4421,"Propofol was administered at 300 , 600 or 1200 ml h-1 until",loss of consciousness,( as judged by loss of verbal contact with the patient ) had been achieved .,"['Propofol', 'was', 'administered', 'at', '300', ',', '600', 'or', '1200', 'ml', 'h-1', 'until', 'loss', 'of', 'consciousness', '(', 'as', 'judged', 'by', 'loss', 'of', 'verbal', 'contact', 'with', 'the', 'patient', ')', 'had', 'been', 'achieved', '.']","(12, 15)","(59, 80)",-1,hl_o,2223363,Abstract,1,test,gold,2664.0
4422,"Propofol was administered at 300 , 600 or 1200 ml h-1 until loss of consciousness ( as judged by",loss of verbal contact with the patient ),had been achieved .,"['Propofol', 'was', 'administered', 'at', '300', ',', '600', 'or', '1200', 'ml', 'h-1', 'until', 'loss', 'of', 'consciousness', '(', 'as', 'judged', 'by', 'loss', 'of', 'verbal', 'contact', 'with', 'the', 'patient', ')', 'had', 'been', 'achieved', '.']","(19, 27)","(96, 137)",-1,hl_o,2223363,Abstract,1,test,gold,3719.0
4423,The,duration of induction,"was significantly longer ( P less than 0.001 ) with the slower infusion rates ( 104 , 68 and 51 s ) , but the total dose used was significantly less ( P less than 0.001 ) in these patients ( 1.2 , 1.6 and 2.5 mg kg-1 , respectively ) .","['The', 'duration', 'of', 'induction', 'was', 'significantly', 'longer', '(', 'P', 'less', 'than', '0.001', ')', 'with', 'the', 'slower', 'infusion', 'rates', '(', '104', ',', '68', 'and', '51', 's', ')', ',', 'but', 'the', 'total', 'dose', 'used', 'was', 'significantly', 'less', '(', 'P', 'less', 'than', '0.001', ')', 'in', 'these', 'patients', '(', '1.2', ',', '1.6', 'and', '2.5', 'mg', 'kg-1', ',', 'respectively', ')', '.']","(1, 4)","(3, 24)",-1,ss_o,2223363,Abstract,2,test,gold,1332.0
4424,The duration of induction was significantly longer ( P less than 0.001 ) with the slower,infusion rates,"( 104 , 68 and 51 s ) , but the total dose used was significantly less ( P less than 0.001 ) in these patients ( 1.2 , 1.6 and 2.5 mg kg-1 , respectively ) .","['The', 'duration', 'of', 'induction', 'was', 'significantly', 'longer', '(', 'P', 'less', 'than', '0.001', ')', 'with', 'the', 'slower', 'infusion', 'rates', '(', '104', ',', '68', 'and', '51', 's', ')', ',', 'but', 'the', 'total', 'dose', 'used', 'was', 'significantly', 'less', '(', 'P', 'less', 'than', '0.001', ')', 'in', 'these', 'patients', '(', '1.2', ',', '1.6', 'and', '2.5', 'mg', 'kg-1', ',', 'respectively', ')', '.']","(16, 18)","(88, 102)",-1,ss_o,2223363,Abstract,2,test,gold,1917.0
4425,"The duration of induction was significantly longer ( P less than 0.001 ) with the slower infusion rates ( 104 , 68 and 51 s ) , but the",total dose,"used was significantly less ( P less than 0.001 ) in these patients ( 1.2 , 1.6 and 2.5 mg kg-1 , respectively ) .","['The', 'duration', 'of', 'induction', 'was', 'significantly', 'longer', '(', 'P', 'less', 'than', '0.001', ')', 'with', 'the', 'slower', 'infusion', 'rates', '(', '104', ',', '68', 'and', '51', 's', ')', ',', 'but', 'the', 'total', 'dose', 'used', 'was', 'significantly', 'less', '(', 'P', 'less', 'than', '0.001', ')', 'in', 'these', 'patients', '(', '1.2', ',', '1.6', 'and', '2.5', 'mg', 'kg-1', ',', 'respectively', ')', '.']","(29, 31)","(135, 145)",-1,ss_o,2223363,Abstract,2,test,gold,5054.0
4426,The,duration of induction,"was significantly longer ( P less than 0.001 ) with the slower infusion rates ( 104 , 68 and 51 s ) , but the total dose used was significantly less ( P less than 0.001 ) in these patients ( 1.2 , 1.6 and 2.5 mg kg-1 , respectively ) .","['The', 'duration', 'of', 'induction', 'was', 'significantly', 'longer', '(', 'P', 'less', 'than', '0.001', ')', 'with', 'the', 'slower', 'infusion', 'rates', '(', '104', ',', '68', 'and', '51', 's', ')', ',', 'but', 'the', 'total', 'dose', 'used', 'was', 'significantly', 'less', '(', 'P', 'less', 'than', '0.001', ')', 'in', 'these', 'patients', '(', '1.2', ',', '1.6', 'and', '2.5', 'mg', 'kg-1', ',', 'respectively', ')', '.']","(1, 4)","(3, 24)",-1,hl_o,2223363,Abstract,2,test,gold,1333.0
4427,The decrease in,systolic and diastolic arterial pressure,was significantly less in the 300-ml h-1 group at the end of induction and immediately after induction ( P less than 0.01 ) .,"['The', 'decrease', 'in', 'systolic', 'and', 'diastolic', 'arterial', 'pressure', 'was', 'significantly', 'less', 'in', 'the', '300-ml', 'h-1', 'group', 'at', 'the', 'end', 'of', 'induction', 'and', 'immediately', 'after', 'induction', '(', 'P', 'less', 'than', '0.01', ')', '.']","(3, 8)","(15, 55)",-1,ss_o,2223363,Abstract,3,test,gold,6689.0
4428,The decrease in,systolic and diastolic arterial pressure,was significantly less in the 300-ml h-1 group at the end of induction and immediately after induction ( P less than 0.01 ) .,"['The', 'decrease', 'in', 'systolic', 'and', 'diastolic', 'arterial', 'pressure', 'was', 'significantly', 'less', 'in', 'the', '300-ml', 'h-1', 'group', 'at', 'the', 'end', 'of', 'induction', 'and', 'immediately', 'after', 'induction', '(', 'P', 'less', 'than', '0.01', ')', '.']","(3, 8)","(15, 55)",-1,hl_o,2223363,Abstract,3,test,gold,6690.0
4429,The,incidence of apnoea,was also significantly less in the slower infusion group .,"['The', 'incidence', 'of', 'apnoea', 'was', 'also', 'significantly', 'less', 'in', 'the', 'slower', 'infusion', 'group', '.']","(1, 4)","(3, 22)",-1,ss_o,2223363,Abstract,4,test,gold,3350.0
4430,The,incidence of apnoea,was also significantly less in the slower infusion group .,"['The', 'incidence', 'of', 'apnoea', 'was', 'also', 'significantly', 'less', 'in', 'the', 'slower', 'infusion', 'group', '.']","(1, 4)","(3, 22)",-1,hl_o,2223363,Abstract,4,test,gold,3351.0
4431,Randomized controlled study of chemoimmunotherapy with bestatin of,acute nonlymphocytic leukemia in adults .,,"['Randomized', 'controlled', 'study', 'of', 'chemoimmunotherapy', 'with', 'bestatin', 'of', 'acute', 'nonlymphocytic', 'leukemia', 'in', 'adults', '.']","(8, 14)","(66, 107)",-1,ss_p,2224060,Title,0,test,gold,3470.0
4432,Randomized controlled study of chemoimmunotherapy with,bestatin,of acute nonlymphocytic leukemia in adults .,"['Randomized', 'controlled', 'study', 'of', 'chemoimmunotherapy', 'with', 'bestatin', 'of', 'acute', 'nonlymphocytic', 'leukemia', 'in', 'adults', '.']","(6, 7)","(54, 62)",-1,ss_i,2224060,Title,0,test,gold,
4433,Randomized controlled study of chemoimmunotherapy with bestatin of,acute nonlymphocytic leukemia,in adults .,"['Randomized', 'controlled', 'study', 'of', 'chemoimmunotherapy', 'with', 'bestatin', 'of', 'acute', 'nonlymphocytic', 'leukemia', 'in', 'adults', '.']","(8, 11)","(66, 95)",-1,hl_p,2224060,Title,0,test,gold,3471.0
4434,Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlymphocytic leukemia in,adults,.,"['Randomized', 'controlled', 'study', 'of', 'chemoimmunotherapy', 'with', 'bestatin', 'of', 'acute', 'nonlymphocytic', 'leukemia', 'in', 'adults', '.']","(12, 13)","(99, 105)",-1,hl_p,2224060,Title,0,test,gold,2163.0
4435,Randomized controlled study of chemoimmunotherapy with,bestatin,of acute nonlymphocytic leukemia in adults .,"['Randomized', 'controlled', 'study', 'of', 'chemoimmunotherapy', 'with', 'bestatin', 'of', 'acute', 'nonlymphocytic', 'leukemia', 'in', 'adults', '.']","(6, 7)","(54, 62)",-1,hl_i,2224060,Title,0,test,gold,
4436,"A new immunomodulating agent ,",bestatin,( INN : Ubenimex has low toxicity even after long-term oral administration and has significant modifications in immunological response .,"['A', 'new', 'immunomodulating', 'agent', ',', 'bestatin', '(', 'INN', ':', 'Ubenimex', 'has', 'low', 'toxicity', 'even', 'after', 'long-term', 'oral', 'administration', 'and', 'has', 'significant', 'modifications', 'in', 'immunological', 'response', '.']","(5, 6)","(30, 38)",-1,ss_i,2224060,Abstract,0,test,gold,
4437,"A new immunomodulating agent ,",bestatin,( INN : Ubenimex has low toxicity even after long-term oral administration and has significant modifications in immunological response .,"['A', 'new', 'immunomodulating', 'agent', ',', 'bestatin', '(', 'INN', ':', 'Ubenimex', 'has', 'low', 'toxicity', 'even', 'after', 'long-term', 'oral', 'administration', 'and', 'has', 'significant', 'modifications', 'in', 'immunological', 'response', '.']","(5, 6)","(30, 38)",-1,hl_i,2224060,Abstract,0,test,gold,
4438,A cooperative randomized controlled study of bestatin immunotherapy in combination with remission maintenance chemotherapy for,adult acute nonlymphocytic leukemia ( ANLL ),was performed .,"['A', 'cooperative', 'randomized', 'controlled', 'study', 'of', 'bestatin', 'immunotherapy', 'in', 'combination', 'with', 'remission', 'maintenance', 'chemotherapy', 'for', 'adult', 'acute', 'nonlymphocytic', 'leukemia', '(', 'ANLL', ')', 'was', 'performed', '.']","(15, 22)","(126, 170)",-1,ss_p,2224060,Abstract,1,test,gold,3472.0
4439,A cooperative randomized controlled study of,bestatin,immunotherapy in combination with remission maintenance chemotherapy for adult acute nonlymphocytic leukemia ( ANLL ) was performed .,"['A', 'cooperative', 'randomized', 'controlled', 'study', 'of', 'bestatin', 'immunotherapy', 'in', 'combination', 'with', 'remission', 'maintenance', 'chemotherapy', 'for', 'adult', 'acute', 'nonlymphocytic', 'leukemia', '(', 'ANLL', ')', 'was', 'performed', '.']","(6, 7)","(44, 52)",-1,ss_i,2224060,Abstract,1,test,gold,
4440,A cooperative randomized controlled study of bestatin immunotherapy in combination with remission maintenance chemotherapy for,adult acute nonlymphocytic leukemia ( ANLL ),was performed .,"['A', 'cooperative', 'randomized', 'controlled', 'study', 'of', 'bestatin', 'immunotherapy', 'in', 'combination', 'with', 'remission', 'maintenance', 'chemotherapy', 'for', 'adult', 'acute', 'nonlymphocytic', 'leukemia', '(', 'ANLL', ')', 'was', 'performed', '.']","(15, 22)","(126, 170)",-1,hl_p,2224060,Abstract,1,test,gold,3473.0
4441,A cooperative randomized controlled study of,bestatin,immunotherapy in combination with remission maintenance chemotherapy for adult acute nonlymphocytic leukemia ( ANLL ) was performed .,"['A', 'cooperative', 'randomized', 'controlled', 'study', 'of', 'bestatin', 'immunotherapy', 'in', 'combination', 'with', 'remission', 'maintenance', 'chemotherapy', 'for', 'adult', 'acute', 'nonlymphocytic', 'leukemia', '(', 'ANLL', ')', 'was', 'performed', '.']","(6, 7)","(44, 52)",-1,hl_i,2224060,Abstract,1,test,gold,
4442,"After induction of complete remission , patients were randomized to the",bestatin,group ( 30 mg/bw per os ( po ) daily ) and the control group .,"['After', 'induction', 'of', 'complete', 'remission', ',', 'patients', 'were', 'randomized', 'to', 'the', 'bestatin', 'group', '(', '30', 'mg/bw', 'per', 'os', '(', 'po', ')', 'daily', ')', 'and', 'the', 'control', 'group', '.']","(11, 12)","(71, 79)",-1,ss_i,2224060,Abstract,2,test,gold,
4443,"After induction of complete remission , patients were randomized to the",bestatin,group ( 30 mg/bw per os ( po ) daily ) and the control group .,"['After', 'induction', 'of', 'complete', 'remission', ',', 'patients', 'were', 'randomized', 'to', 'the', 'bestatin', 'group', '(', '30', 'mg/bw', 'per', 'os', '(', 'po', ')', 'daily', ')', 'and', 'the', 'control', 'group', '.']","(11, 12)","(71, 79)",-1,hl_i,2224060,Abstract,2,test,gold,
4444,,"The 101 eligible cases ( bestatin : 48 , control : 53 )",were analyzed ; the bestatin group achieved longer remission than the control group and a statistically significant longer survival .,"['The', '101', 'eligible', 'cases', '(', 'bestatin', ':', '48', ',', 'control', ':', '53', ')', 'were', 'analyzed', ';', 'the', 'bestatin', 'group', 'achieved', 'longer', 'remission', 'than', 'the', 'control', 'group', 'and', 'a', 'statistically', 'significant', 'longer', 'survival', '.']","(0, 13)","(0, 55)",-1,ss_p,2224060,Abstract,3,test,gold,2050.0
4445,The 101 eligible cases,( bestatin :,"48 , control : 53 ) were analyzed ; the bestatin group achieved longer remission than the control group and a statistically significant longer survival .","['The', '101', 'eligible', 'cases', '(', 'bestatin', ':', '48', ',', 'control', ':', '53', ')', 'were', 'analyzed', ';', 'the', 'bestatin', 'group', 'achieved', 'longer', 'remission', 'than', 'the', 'control', 'group', 'and', 'a', 'statistically', 'significant', 'longer', 'survival', '.']","(4, 7)","(22, 34)",-1,ss_i,2224060,Abstract,3,test,gold,
4446,"The 101 eligible cases ( bestatin : 48 , control : 53 ) were analyzed ; the",bestatin,group achieved longer remission than the control group and a statistically significant longer survival .,"['The', '101', 'eligible', 'cases', '(', 'bestatin', ':', '48', ',', 'control', ':', '53', ')', 'were', 'analyzed', ';', 'the', 'bestatin', 'group', 'achieved', 'longer', 'remission', 'than', 'the', 'control', 'group', 'and', 'a', 'statistically', 'significant', 'longer', 'survival', '.']","(17, 18)","(75, 83)",-1,ss_i,2224060,Abstract,3,test,gold,
4447,"The 101 eligible cases ( bestatin : 48 , control : 53 ) were analyzed ; the bestatin group achieved",longer remission,than the control group and a statistically significant longer survival .,"['The', '101', 'eligible', 'cases', '(', 'bestatin', ':', '48', ',', 'control', ':', '53', ')', 'were', 'analyzed', ';', 'the', 'bestatin', 'group', 'achieved', 'longer', 'remission', 'than', 'the', 'control', 'group', 'and', 'a', 'statistically', 'significant', 'longer', 'survival', '.']","(20, 22)","(99, 115)",-1,ss_o,2224060,Abstract,3,test,gold,4236.0
4448,"The 101 eligible cases ( bestatin : 48 , control : 53 ) were analyzed ; the bestatin group achieved longer remission than the control group and a statistically significant",longer survival .,,"['The', '101', 'eligible', 'cases', '(', 'bestatin', ':', '48', ',', 'control', ':', '53', ')', 'were', 'analyzed', ';', 'the', 'bestatin', 'group', 'achieved', 'longer', 'remission', 'than', 'the', 'control', 'group', 'and', 'a', 'statistically', 'significant', 'longer', 'survival', '.']","(30, 33)","(171, 188)",-1,ss_o,2224060,Abstract,3,test,gold,1968.0
4449,The,101,"eligible cases ( bestatin : 48 , control : 53 ) were analyzed ; the bestatin group achieved longer remission than the control group and a statistically significant longer survival .","['The', '101', 'eligible', 'cases', '(', 'bestatin', ':', '48', ',', 'control', ':', '53', ')', 'were', 'analyzed', ';', 'the', 'bestatin', 'group', 'achieved', 'longer', 'remission', 'than', 'the', 'control', 'group', 'and', 'a', 'statistically', 'significant', 'longer', 'survival', '.']","(1, 2)","(3, 6)",-1,hl_p,2224060,Abstract,3,test,gold,
4450,The 101 eligible cases ( bestatin :,48,", control : 53 ) were analyzed ; the bestatin group achieved longer remission than the control group and a statistically significant longer survival .","['The', '101', 'eligible', 'cases', '(', 'bestatin', ':', '48', ',', 'control', ':', '53', ')', 'were', 'analyzed', ';', 'the', 'bestatin', 'group', 'achieved', 'longer', 'remission', 'than', 'the', 'control', 'group', 'and', 'a', 'statistically', 'significant', 'longer', 'survival', '.']","(7, 8)","(35, 37)",-1,hl_p,2224060,Abstract,3,test,gold,
4451,"The 101 eligible cases ( bestatin : 48 , control :",53,) were analyzed ; the bestatin group achieved longer remission than the control group and a statistically significant longer survival .,"['The', '101', 'eligible', 'cases', '(', 'bestatin', ':', '48', ',', 'control', ':', '53', ')', 'were', 'analyzed', ';', 'the', 'bestatin', 'group', 'achieved', 'longer', 'remission', 'than', 'the', 'control', 'group', 'and', 'a', 'statistically', 'significant', 'longer', 'survival', '.']","(11, 12)","(50, 52)",-1,hl_p,2224060,Abstract,3,test,gold,
4452,The 101 eligible cases (,bestatin,": 48 , control : 53 ) were analyzed ; the bestatin group achieved longer remission than the control group and a statistically significant longer survival .","['The', '101', 'eligible', 'cases', '(', 'bestatin', ':', '48', ',', 'control', ':', '53', ')', 'were', 'analyzed', ';', 'the', 'bestatin', 'group', 'achieved', 'longer', 'remission', 'than', 'the', 'control', 'group', 'and', 'a', 'statistically', 'significant', 'longer', 'survival', '.']","(5, 6)","(24, 32)",-1,hl_i,2224060,Abstract,3,test,gold,
4453,"The 101 eligible cases ( bestatin : 48 , control : 53 ) were analyzed ; the",bestatin,group achieved longer remission than the control group and a statistically significant longer survival .,"['The', '101', 'eligible', 'cases', '(', 'bestatin', ':', '48', ',', 'control', ':', '53', ')', 'were', 'analyzed', ';', 'the', 'bestatin', 'group', 'achieved', 'longer', 'remission', 'than', 'the', 'control', 'group', 'and', 'a', 'statistically', 'significant', 'longer', 'survival', '.']","(17, 18)","(75, 83)",-1,hl_i,2224060,Abstract,3,test,gold,
4454,"The 101 eligible cases ( bestatin : 48 , control : 53 ) were analyzed ; the bestatin group achieved longer",remission,than the control group and a statistically significant longer survival .,"['The', '101', 'eligible', 'cases', '(', 'bestatin', ':', '48', ',', 'control', ':', '53', ')', 'were', 'analyzed', ';', 'the', 'bestatin', 'group', 'achieved', 'longer', 'remission', 'than', 'the', 'control', 'group', 'and', 'a', 'statistically', 'significant', 'longer', 'survival', '.']","(21, 22)","(106, 115)",-1,hl_o,2224060,Abstract,3,test,gold,4237.0
4455,"The 101 eligible cases ( bestatin : 48 , control : 53 ) were analyzed ; the bestatin group achieved longer remission than the control group and a statistically significant longer",survival .,,"['The', '101', 'eligible', 'cases', '(', 'bestatin', ':', '48', ',', 'control', ':', '53', ')', 'were', 'analyzed', ';', 'the', 'bestatin', 'group', 'achieved', 'longer', 'remission', 'than', 'the', 'control', 'group', 'and', 'a', 'statistically', 'significant', 'longer', 'survival', '.']","(31, 33)","(178, 188)",-1,hl_o,2224060,Abstract,3,test,gold,1962.0
4456,Though this prolongation of remission was not significant in the,bestatin,"group compared to the control group in the 15-49 yr age group , in the 50-65 yr age group it was significantly longer .","['Though', 'this', 'prolongation', 'of', 'remission', 'was', 'not', 'significant', 'in', 'the', 'bestatin', 'group', 'compared', 'to', 'the', 'control', 'group', 'in', 'the', '15-49', 'yr', 'age', 'group', ',', 'in', 'the', '50-65', 'yr', 'age', 'group', 'it', 'was', 'significantly', 'longer', '.']","(10, 11)","(64, 72)",-1,ss_i,2224060,Abstract,4,test,gold,
4457,Though this,prolongation of remission,"was not significant in the bestatin group compared to the control group in the 15-49 yr age group , in the 50-65 yr age group it was significantly longer .","['Though', 'this', 'prolongation', 'of', 'remission', 'was', 'not', 'significant', 'in', 'the', 'bestatin', 'group', 'compared', 'to', 'the', 'control', 'group', 'in', 'the', '15-49', 'yr', 'age', 'group', ',', 'in', 'the', '50-65', 'yr', 'age', 'group', 'it', 'was', 'significantly', 'longer', '.']","(2, 5)","(11, 36)",-1,ss_o,2224060,Abstract,4,test,gold,4240.0
4458,Though this prolongation of remission was not significant in the,bestatin,"group compared to the control group in the 15-49 yr age group , in the 50-65 yr age group it was significantly longer .","['Though', 'this', 'prolongation', 'of', 'remission', 'was', 'not', 'significant', 'in', 'the', 'bestatin', 'group', 'compared', 'to', 'the', 'control', 'group', 'in', 'the', '15-49', 'yr', 'age', 'group', ',', 'in', 'the', '50-65', 'yr', 'age', 'group', 'it', 'was', 'significantly', 'longer', '.']","(10, 11)","(64, 72)",-1,hl_i,2224060,Abstract,4,test,gold,
4459,Though this,prolongation of remission,"was not significant in the bestatin group compared to the control group in the 15-49 yr age group , in the 50-65 yr age group it was significantly longer .","['Though', 'this', 'prolongation', 'of', 'remission', 'was', 'not', 'significant', 'in', 'the', 'bestatin', 'group', 'compared', 'to', 'the', 'control', 'group', 'in', 'the', '15-49', 'yr', 'age', 'group', ',', 'in', 'the', '50-65', 'yr', 'age', 'group', 'it', 'was', 'significantly', 'longer', '.']","(2, 5)","(11, 36)",-1,hl_o,2224060,Abstract,4,test,gold,4241.0
4460,,Bestatin,"is shown to be a clinically useful drug for immunotherapy of adult ANLL , since it has prolonged survival and remission especially in elderly patients , with few side-effects .","['Bestatin', 'is', 'shown', 'to', 'be', 'a', 'clinically', 'useful', 'drug', 'for', 'immunotherapy', 'of', 'adult', 'ANLL', ',', 'since', 'it', 'has', 'prolonged', 'survival', 'and', 'remission', 'especially', 'in', 'elderly', 'patients', ',', 'with', 'few', 'side-effects', '.']","(0, 1)","(0, 8)",-1,ss_i,2224060,Abstract,5,test,gold,
4461,"Bestatin is shown to be a clinically useful drug for immunotherapy of adult ANLL , since it has",prolonged survival and remission,"especially in elderly patients , with few side-effects .","['Bestatin', 'is', 'shown', 'to', 'be', 'a', 'clinically', 'useful', 'drug', 'for', 'immunotherapy', 'of', 'adult', 'ANLL', ',', 'since', 'it', 'has', 'prolonged', 'survival', 'and', 'remission', 'especially', 'in', 'elderly', 'patients', ',', 'with', 'few', 'side-effects', '.']","(18, 22)","(95, 127)",-1,ss_o,2224060,Abstract,5,test,gold,4239.0
4462,"Bestatin is shown to be a clinically useful drug for immunotherapy of adult ANLL , since it has prolonged survival and remission especially in elderly patients , with few",side-effects .,,"['Bestatin', 'is', 'shown', 'to', 'be', 'a', 'clinically', 'useful', 'drug', 'for', 'immunotherapy', 'of', 'adult', 'ANLL', ',', 'since', 'it', 'has', 'prolonged', 'survival', 'and', 'remission', 'especially', 'in', 'elderly', 'patients', ',', 'with', 'few', 'side-effects', '.']","(29, 31)","(170, 184)",-1,ss_o,2224060,Abstract,5,test,gold,
4463,,Bestatin,"is shown to be a clinically useful drug for immunotherapy of adult ANLL , since it has prolonged survival and remission especially in elderly patients , with few side-effects .","['Bestatin', 'is', 'shown', 'to', 'be', 'a', 'clinically', 'useful', 'drug', 'for', 'immunotherapy', 'of', 'adult', 'ANLL', ',', 'since', 'it', 'has', 'prolonged', 'survival', 'and', 'remission', 'especially', 'in', 'elderly', 'patients', ',', 'with', 'few', 'side-effects', '.']","(0, 1)","(0, 8)",-1,hl_i,2224060,Abstract,5,test,gold,
4464,"Bestatin is shown to be a clinically useful drug for immunotherapy of adult ANLL , since it has prolonged",survival,"and remission especially in elderly patients , with few side-effects .","['Bestatin', 'is', 'shown', 'to', 'be', 'a', 'clinically', 'useful', 'drug', 'for', 'immunotherapy', 'of', 'adult', 'ANLL', ',', 'since', 'it', 'has', 'prolonged', 'survival', 'and', 'remission', 'especially', 'in', 'elderly', 'patients', ',', 'with', 'few', 'side-effects', '.']","(19, 20)","(105, 113)",-1,hl_o,2224060,Abstract,5,test,gold,1961.0
4465,"Bestatin is shown to be a clinically useful drug for immunotherapy of adult ANLL , since it has prolonged survival and",remission,"especially in elderly patients , with few side-effects .","['Bestatin', 'is', 'shown', 'to', 'be', 'a', 'clinically', 'useful', 'drug', 'for', 'immunotherapy', 'of', 'adult', 'ANLL', ',', 'since', 'it', 'has', 'prolonged', 'survival', 'and', 'remission', 'especially', 'in', 'elderly', 'patients', ',', 'with', 'few', 'side-effects', '.']","(21, 22)","(118, 127)",-1,hl_o,2224060,Abstract,5,test,gold,4238.0
4466,"Bestatin is shown to be a clinically useful drug for immunotherapy of adult ANLL , since it has prolonged survival and remission especially in elderly patients , with few",side-effects .,,"['Bestatin', 'is', 'shown', 'to', 'be', 'a', 'clinically', 'useful', 'drug', 'for', 'immunotherapy', 'of', 'adult', 'ANLL', ',', 'since', 'it', 'has', 'prolonged', 'survival', 'and', 'remission', 'especially', 'in', 'elderly', 'patients', ',', 'with', 'few', 'side-effects', '.']","(29, 31)","(170, 184)",-1,hl_o,2224060,Abstract,5,test,gold,
4467,Goal attainment scaling as an outcome measure in randomized controlled trials of psychosocial interventions in,autism .,,"['Goal', 'attainment', 'scaling', 'as', 'an', 'outcome', 'measure', 'in', 'randomized', 'controlled', 'trials', 'of', 'psychosocial', 'interventions', 'in', 'autism', '.']","(15, 17)","(110, 118)",-1,ss_p,22271197,Title,0,test,gold,6147.0
4468,Goal attainment scaling as an outcome measure in randomized controlled trials of,psychosocial interventions,in autism .,"['Goal', 'attainment', 'scaling', 'as', 'an', 'outcome', 'measure', 'in', 'randomized', 'controlled', 'trials', 'of', 'psychosocial', 'interventions', 'in', 'autism', '.']","(12, 14)","(80, 106)",-1,ss_i,22271197,Title,0,test,gold,4006.0
4469,,Goal attainment scaling,as an outcome measure in randomized controlled trials of psychosocial interventions in autism .,"['Goal', 'attainment', 'scaling', 'as', 'an', 'outcome', 'measure', 'in', 'randomized', 'controlled', 'trials', 'of', 'psychosocial', 'interventions', 'in', 'autism', '.']","(0, 3)","(0, 23)",-1,ss_o,22271197,Title,0,test,gold,351.0
4470,Goal attainment scaling as an outcome measure in randomized controlled trials of psychosocial interventions in,autism .,,"['Goal', 'attainment', 'scaling', 'as', 'an', 'outcome', 'measure', 'in', 'randomized', 'controlled', 'trials', 'of', 'psychosocial', 'interventions', 'in', 'autism', '.']","(15, 17)","(110, 118)",-1,hl_p,22271197,Title,0,test,gold,6146.0
4471,Goal attainment scaling as an outcome measure in randomized controlled trials of,psychosocial interventions,in autism .,"['Goal', 'attainment', 'scaling', 'as', 'an', 'outcome', 'measure', 'in', 'randomized', 'controlled', 'trials', 'of', 'psychosocial', 'interventions', 'in', 'autism', '.']","(12, 14)","(80, 106)",-1,hl_i,22271197,Title,0,test,gold,4007.0
4472,,Goal attainment scaling,as an outcome measure in randomized controlled trials of psychosocial interventions in autism .,"['Goal', 'attainment', 'scaling', 'as', 'an', 'outcome', 'measure', 'in', 'randomized', 'controlled', 'trials', 'of', 'psychosocial', 'interventions', 'in', 'autism', '.']","(0, 3)","(0, 23)",-1,hl_o,22271197,Title,0,test,gold,352.0
4473,Goal attainment scaling ( GAS ) holds promise as an idiographic approach for measuring outcomes of,psychosocial interventions,in community settings .,"['Goal', 'attainment', 'scaling', '(', 'GAS', ')', 'holds', 'promise', 'as', 'an', 'idiographic', 'approach', 'for', 'measuring', 'outcomes', 'of', 'psychosocial', 'interventions', 'in', 'community', 'settings', '.']","(16, 18)","(98, 124)",-1,ss_i,22271197,Abstract,0,test,gold,4005.0
4474,,Goal attainment scaling ( GAS ),holds promise as an idiographic approach for measuring outcomes of psychosocial interventions in community settings .,"['Goal', 'attainment', 'scaling', '(', 'GAS', ')', 'holds', 'promise', 'as', 'an', 'idiographic', 'approach', 'for', 'measuring', 'outcomes', 'of', 'psychosocial', 'interventions', 'in', 'community', 'settings', '.']","(0, 6)","(0, 31)",-1,ss_o,22271197,Abstract,0,test,gold,353.0
4475,Goal attainment scaling ( GAS ) holds promise as an idiographic approach for measuring outcomes of,psychosocial interventions,in community settings .,"['Goal', 'attainment', 'scaling', '(', 'GAS', ')', 'holds', 'promise', 'as', 'an', 'idiographic', 'approach', 'for', 'measuring', 'outcomes', 'of', 'psychosocial', 'interventions', 'in', 'community', 'settings', '.']","(16, 18)","(98, 124)",-1,hl_i,22271197,Abstract,0,test,gold,4004.0
4476,,Goal attainment scaling ( GAS ),holds promise as an idiographic approach for measuring outcomes of psychosocial interventions in community settings .,"['Goal', 'attainment', 'scaling', '(', 'GAS', ')', 'holds', 'promise', 'as', 'an', 'idiographic', 'approach', 'for', 'measuring', 'outcomes', 'of', 'psychosocial', 'interventions', 'in', 'community', 'settings', '.']","(0, 6)","(0, 31)",-1,hl_o,22271197,Abstract,0,test,gold,354.0
4477,GAS has been criticized for untested assumptions of,scaling level,"( i.e. , interval or ordinal ) , inter-individual equivalence and comparability , and reliability of coding across different behavioral observation methods .","['GAS', 'has', 'been', 'criticized', 'for', 'untested', 'assumptions', 'of', 'scaling', 'level', '(', 'i.e.', ',', 'interval', 'or', 'ordinal', ')', ',', 'inter-individual', 'equivalence', 'and', 'comparability', ',', 'and', 'reliability', 'of', 'coding', 'across', 'different', 'behavioral', 'observation', 'methods', '.']","(8, 10)","(51, 64)",-1,ss_o,22271197,Abstract,1,test,gold,1383.0
4478,"GAS has been criticized for untested assumptions of scaling level ( i.e. , interval or ordinal ) ,",inter-individual equivalence,"and comparability , and reliability of coding across different behavioral observation methods .","['GAS', 'has', 'been', 'criticized', 'for', 'untested', 'assumptions', 'of', 'scaling', 'level', '(', 'i.e.', ',', 'interval', 'or', 'ordinal', ')', ',', 'inter-individual', 'equivalence', 'and', 'comparability', ',', 'and', 'reliability', 'of', 'coding', 'across', 'different', 'behavioral', 'observation', 'methods', '.']","(18, 20)","(98, 126)",-1,ss_o,22271197,Abstract,1,test,gold,1201.0
4479,"GAS has been criticized for untested assumptions of scaling level ( i.e. , interval or ordinal ) , inter-individual equivalence and",comparability,", and reliability of coding across different behavioral observation methods .","['GAS', 'has', 'been', 'criticized', 'for', 'untested', 'assumptions', 'of', 'scaling', 'level', '(', 'i.e.', ',', 'interval', 'or', 'ordinal', ')', ',', 'inter-individual', 'equivalence', 'and', 'comparability', ',', 'and', 'reliability', 'of', 'coding', 'across', 'different', 'behavioral', 'observation', 'methods', '.']","(21, 22)","(131, 144)",-1,ss_o,22271197,Abstract,1,test,gold,1358.0
4480,"GAS has been criticized for untested assumptions of scaling level ( i.e. , interval or ordinal ) , inter-individual equivalence and comparability , and",reliability of coding across different behavioral observation methods .,,"['GAS', 'has', 'been', 'criticized', 'for', 'untested', 'assumptions', 'of', 'scaling', 'level', '(', 'i.e.', ',', 'interval', 'or', 'ordinal', ')', ',', 'inter-individual', 'equivalence', 'and', 'comparability', ',', 'and', 'reliability', 'of', 'coding', 'across', 'different', 'behavioral', 'observation', 'methods', '.']","(24, 33)","(151, 222)",-1,ss_o,22271197,Abstract,1,test,gold,6424.0
4481,We tested,assumptions of equality,"between GAS descriptions for outcome measurement in a randomized trial ( i.e. , measurability , equidistance , level of difficulty , comparability of behavior samples collected from teachers vs. researchers and live vs. videotape ) .","['We', 'tested', 'assumptions', 'of', 'equality', 'between', 'GAS', 'descriptions', 'for', 'outcome', 'measurement', 'in', 'a', 'randomized', 'trial', '(', 'i.e.', ',', 'measurability', ',', 'equidistance', ',', 'level', 'of', 'difficulty', ',', 'comparability', 'of', 'behavior', 'samples', 'collected', 'from', 'teachers', 'vs.', 'researchers', 'and', 'live', 'vs.', 'videotape', ')', '.']","(2, 5)","(9, 32)",-1,ss_o,22271197,Abstract,2,test,gold,1359.0
4482,"We tested assumptions of equality between GAS descriptions for outcome measurement in a randomized trial ( i.e. ,","measurability , equidistance , level of difficulty , comparability of behavior samples collected from teachers vs. researchers and live vs. videotape )",.,"['We', 'tested', 'assumptions', 'of', 'equality', 'between', 'GAS', 'descriptions', 'for', 'outcome', 'measurement', 'in', 'a', 'randomized', 'trial', '(', 'i.e.', ',', 'measurability', ',', 'equidistance', ',', 'level', 'of', 'difficulty', ',', 'comparability', 'of', 'behavior', 'samples', 'collected', 'from', 'teachers', 'vs.', 'researchers', 'and', 'live', 'vs.', 'videotape', ')', '.']","(18, 40)","(113, 264)",-1,ss_o,22271197,Abstract,2,test,gold,5897.0
4483,Results suggest,GAS,"descriptions can be evaluated for equivalency , that teacher collected behavior samples are representative , and that varied sources of behavior samples can be reliably coded .","['Results', 'suggest', 'GAS', 'descriptions', 'can', 'be', 'evaluated', 'for', 'equivalency', ',', 'that', 'teacher', 'collected', 'behavior', 'samples', 'are', 'representative', ',', 'and', 'that', 'varied', 'sources', 'of', 'behavior', 'samples', 'can', 'be', 'reliably', 'coded', '.']","(2, 3)","(15, 18)",-1,ss_o,22271197,Abstract,3,test,gold,694.0
4484,,GAS,is a promising measurement approach .,"['GAS', 'is', 'a', 'promising', 'measurement', 'approach', '.']","(0, 1)","(0, 3)",-1,ss_o,22271197,Abstract,4,test,gold,695.0
4485,Recommendations are provided to ensure methodological quality .,,,"['Recommendations', 'are', 'provided', 'to', 'ensure', 'methodological', 'quality', '.']",,,,,22271197,Abstract,5,test,gold,
4486,Intermediate-term mortality and cardiac transplantation in,infants with single-ventricle lesions :,risk factors and their interaction with shunt type .,"['Intermediate-term', 'mortality', 'and', 'cardiac', 'transplantation', 'in', 'infants', 'with', 'single-ventricle', 'lesions', ':', 'risk', 'factors', 'and', 'their', 'interaction', 'with', 'shunt', 'type', '.']","(6, 11)","(58, 97)",-1,ss_p,22341427,Title,0,test,gold,3170.0
4487,Intermediate-term mortality and,cardiac transplantation,in infants with single-ventricle lesions : risk factors and their interaction with shunt type .,"['Intermediate-term', 'mortality', 'and', 'cardiac', 'transplantation', 'in', 'infants', 'with', 'single-ventricle', 'lesions', ':', 'risk', 'factors', 'and', 'their', 'interaction', 'with', 'shunt', 'type', '.']","(3, 5)","(31, 54)",-1,ss_i,22341427,Title,0,test,gold,6757.0
4488,,Intermediate-term mortality and cardiac transplantation,in infants with single-ventricle lesions : risk factors and their interaction with shunt type .,"['Intermediate-term', 'mortality', 'and', 'cardiac', 'transplantation', 'in', 'infants', 'with', 'single-ventricle', 'lesions', ':', 'risk', 'factors', 'and', 'their', 'interaction', 'with', 'shunt', 'type', '.']","(0, 5)","(0, 55)",-1,ss_o,22341427,Title,0,test,gold,6753.0
4489,Intermediate-term mortality and cardiac transplantation in infants with single-ventricle lesions :,risk factors,and their interaction with shunt type .,"['Intermediate-term', 'mortality', 'and', 'cardiac', 'transplantation', 'in', 'infants', 'with', 'single-ventricle', 'lesions', ':', 'risk', 'factors', 'and', 'their', 'interaction', 'with', 'shunt', 'type', '.']","(11, 13)","(98, 110)",-1,ss_o,22341427,Title,0,test,gold,2504.0
4490,Intermediate-term mortality and cardiac transplantation in,infants,with single-ventricle lesions : risk factors and their interaction with shunt type .,"['Intermediate-term', 'mortality', 'and', 'cardiac', 'transplantation', 'in', 'infants', 'with', 'single-ventricle', 'lesions', ':', 'risk', 'factors', 'and', 'their', 'interaction', 'with', 'shunt', 'type', '.']","(6, 7)","(58, 65)",-1,hl_p,22341427,Title,0,test,gold,2168.0
4491,Intermediate-term mortality and cardiac transplantation in infants with,single-ventricle lesions,: risk factors and their interaction with shunt type .,"['Intermediate-term', 'mortality', 'and', 'cardiac', 'transplantation', 'in', 'infants', 'with', 'single-ventricle', 'lesions', ':', 'risk', 'factors', 'and', 'their', 'interaction', 'with', 'shunt', 'type', '.']","(8, 10)","(71, 95)",-1,hl_p,22341427,Title,0,test,gold,3171.0
4492,Intermediate-term mortality and,cardiac transplantation,in infants with single-ventricle lesions : risk factors and their interaction with shunt type .,"['Intermediate-term', 'mortality', 'and', 'cardiac', 'transplantation', 'in', 'infants', 'with', 'single-ventricle', 'lesions', ':', 'risk', 'factors', 'and', 'their', 'interaction', 'with', 'shunt', 'type', '.']","(3, 5)","(31, 54)",-1,hl_i,22341427,Title,0,test,gold,6758.0
4493,OBJECTIVE The study objective was to identify factors associated with death and cardiac transplantation in,infants undergoing the Norwood procedure,and to determine differences in associations that might favor the modified Blalock-Taussig shunt or a right ventricle-to-pulmonary artery shunt .,"['OBJECTIVE', 'The', 'study', 'objective', 'was', 'to', 'identify', 'factors', 'associated', 'with', 'death', 'and', 'cardiac', 'transplantation', 'in', 'infants', 'undergoing', 'the', 'Norwood', 'procedure', 'and', 'to', 'determine', 'differences', 'in', 'associations', 'that', 'might', 'favor', 'the', 'modified', 'Blalock-Taussig', 'shunt', 'or', 'a', 'right', 'ventricle-to-pulmonary', 'artery', 'shunt', '.']","(15, 20)","(106, 146)",-1,ss_p,22341427,Abstract,0,test,gold,3606.0
4494,OBJECTIVE The study objective was to identify factors associated with death and,cardiac transplantation,in infants undergoing the Norwood procedure and to determine differences in associations that might favor the modified Blalock-Taussig shunt or a right ventricle-to-pulmonary artery shunt .,"['OBJECTIVE', 'The', 'study', 'objective', 'was', 'to', 'identify', 'factors', 'associated', 'with', 'death', 'and', 'cardiac', 'transplantation', 'in', 'infants', 'undergoing', 'the', 'Norwood', 'procedure', 'and', 'to', 'determine', 'differences', 'in', 'associations', 'that', 'might', 'favor', 'the', 'modified', 'Blalock-Taussig', 'shunt', 'or', 'a', 'right', 'ventricle-to-pulmonary', 'artery', 'shunt', '.']","(12, 14)","(79, 102)",-1,ss_i,22341427,Abstract,0,test,gold,6756.0
4495,OBJECTIVE The study objective was to identify,factors associated with death and cardiac transplantation,in infants undergoing the Norwood procedure and to determine differences in associations that might favor the modified Blalock-Taussig shunt or a right ventricle-to-pulmonary artery shunt .,"['OBJECTIVE', 'The', 'study', 'objective', 'was', 'to', 'identify', 'factors', 'associated', 'with', 'death', 'and', 'cardiac', 'transplantation', 'in', 'infants', 'undergoing', 'the', 'Norwood', 'procedure', 'and', 'to', 'determine', 'differences', 'in', 'associations', 'that', 'might', 'favor', 'the', 'modified', 'Blalock-Taussig', 'shunt', 'or', 'a', 'right', 'ventricle-to-pulmonary', 'artery', 'shunt', '.']","(7, 14)","(45, 102)",-1,ss_o,22341427,Abstract,0,test,gold,6752.0
4496,OBJECTIVE The study objective was to identify factors associated with death and cardiac transplantation in,infants undergoing the Norwood procedure,and to determine differences in associations that might favor the modified Blalock-Taussig shunt or a right ventricle-to-pulmonary artery shunt .,"['OBJECTIVE', 'The', 'study', 'objective', 'was', 'to', 'identify', 'factors', 'associated', 'with', 'death', 'and', 'cardiac', 'transplantation', 'in', 'infants', 'undergoing', 'the', 'Norwood', 'procedure', 'and', 'to', 'determine', 'differences', 'in', 'associations', 'that', 'might', 'favor', 'the', 'modified', 'Blalock-Taussig', 'shunt', 'or', 'a', 'right', 'ventricle-to-pulmonary', 'artery', 'shunt', '.']","(15, 20)","(106, 146)",-1,hl_p,22341427,Abstract,0,test,gold,3607.0
4497,OBJECTIVE The study objective was to identify factors associated with death and,cardiac transplantation,in infants undergoing the Norwood procedure and to determine differences in associations that might favor the modified Blalock-Taussig shunt or a right ventricle-to-pulmonary artery shunt .,"['OBJECTIVE', 'The', 'study', 'objective', 'was', 'to', 'identify', 'factors', 'associated', 'with', 'death', 'and', 'cardiac', 'transplantation', 'in', 'infants', 'undergoing', 'the', 'Norwood', 'procedure', 'and', 'to', 'determine', 'differences', 'in', 'associations', 'that', 'might', 'favor', 'the', 'modified', 'Blalock-Taussig', 'shunt', 'or', 'a', 'right', 'ventricle-to-pulmonary', 'artery', 'shunt', '.']","(12, 14)","(79, 102)",-1,hl_i,22341427,Abstract,0,test,gold,6755.0
4498,"METHODS We used competing risks methodology to analyze death without transplantation ,",cardiac transplantation,", and survival without transplantation .","['METHODS', 'We', 'used', 'competing', 'risks', 'methodology', 'to', 'analyze', 'death', 'without', 'transplantation', ',', 'cardiac', 'transplantation', ',', 'and', 'survival', 'without', 'transplantation', '.']","(12, 14)","(86, 109)",-1,ss_i,22341427,Abstract,1,test,gold,6754.0
4499,METHODS We used competing risks methodology to analyze,"death without transplantation , cardiac transplantation , and survival without transplantation .",,"['METHODS', 'We', 'used', 'competing', 'risks', 'methodology', 'to', 'analyze', 'death', 'without', 'transplantation', ',', 'cardiac', 'transplantation', ',', 'and', 'survival', 'without', 'transplantation', '.']","(8, 20)","(54, 150)",-1,ss_o,22341427,Abstract,1,test,gold,6751.0
4500,,Parametric time-to-event modeling and bootstrapping were used to identify independent predictors .,,"['Parametric', 'time-to-event', 'modeling', 'and', 'bootstrapping', 'were', 'used', 'to', 'identify', 'independent', 'predictors', '.']","(0, 12)","(0, 98)",-1,ss_o,22341427,Abstract,2,test,gold,6393.0
4501,RESULTS Data from,"549 subjects ( follow-up , 2.7 ± 0.9 years )",were analyzed .,"['RESULTS', 'Data', 'from', '549', 'subjects', '(', 'follow-up', ',', '2.7', '±', '0.9', 'years', ')', 'were', 'analyzed', '.']","(3, 13)","(17, 61)",-1,ss_p,22341427,Abstract,3,test,gold,2068.0
4502,"RESULTS Data from 549 subjects ( follow-up , 2.7 ± 0.9 years ) were analyzed",.,,"['RESULTS', 'Data', 'from', '549', 'subjects', '(', 'follow-up', ',', '2.7', '±', '0.9', 'years', ')', 'were', 'analyzed', '.']","(15, 16)","(76, 77)",-1,ss_o,22341427,Abstract,3,test,gold,
4503,RESULTS Data from,549,"subjects ( follow-up , 2.7 ± 0.9 years ) were analyzed .","['RESULTS', 'Data', 'from', '549', 'subjects', '(', 'follow-up', ',', '2.7', '±', '0.9', 'years', ')', 'were', 'analyzed', '.']","(3, 4)","(17, 20)",-1,hl_p,22341427,Abstract,3,test,gold,
4504,,Mortality risk,was characterized by early and constant phases ; transplant was characterized by only a constant phase .,"['Mortality', 'risk', 'was', 'characterized', 'by', 'early', 'and', 'constant', 'phases', ';', 'transplant', 'was', 'characterized', 'by', 'only', 'a', 'constant', 'phase', '.']","(0, 2)","(0, 14)",-1,ss_o,22341427,Abstract,4,test,gold,2500.0
4505,,Mortality risk,was characterized by early and constant phases ; transplant was characterized by only a constant phase .,"['Mortality', 'risk', 'was', 'characterized', 'by', 'early', 'and', 'constant', 'phases', ';', 'transplant', 'was', 'characterized', 'by', 'only', 'a', 'constant', 'phase', '.']","(0, 2)","(0, 14)",-1,hl_o,22341427,Abstract,4,test,gold,2501.0
4506,Early phase factors associated,with death,"included lower socioeconomic status ( P = .01 ) , obstructed pulmonary venous return ( P < .001 ) , smaller ascending aorta ( P = .02 ) , and anatomic subtype .","['Early', 'phase', 'factors', 'associated', 'with', 'death', 'included', 'lower', 'socioeconomic', 'status', '(', 'P', '=', '.01', ')', ',', 'obstructed', 'pulmonary', 'venous', 'return', '(', 'P', '<', '.001', ')', ',', 'smaller', 'ascending', 'aorta', '(', 'P', '=', '.02', ')', ',', 'and', 'anatomic', 'subtype', '.']","(4, 6)","(30, 40)",-1,ss_o,22341427,Abstract,5,test,gold,2199.0
4507,Early phase factors associated with death included,lower socioeconomic status,"( P = .01 ) , obstructed pulmonary venous return ( P < .001 ) , smaller ascending aorta ( P = .02 ) , and anatomic subtype .","['Early', 'phase', 'factors', 'associated', 'with', 'death', 'included', 'lower', 'socioeconomic', 'status', '(', 'P', '=', '.01', ')', ',', 'obstructed', 'pulmonary', 'venous', 'return', '(', 'P', '<', '.001', ')', ',', 'smaller', 'ascending', 'aorta', '(', 'P', '=', '.02', ')', ',', 'and', 'anatomic', 'subtype', '.']","(7, 10)","(50, 76)",-1,ss_o,22341427,Abstract,5,test,gold,1375.0
4508,"Early phase factors associated with death included lower socioeconomic status ( P = .01 ) ,",obstructed pulmonary venous return,"( P < .001 ) , smaller ascending aorta ( P = .02 ) , and anatomic subtype .","['Early', 'phase', 'factors', 'associated', 'with', 'death', 'included', 'lower', 'socioeconomic', 'status', '(', 'P', '=', '.01', ')', ',', 'obstructed', 'pulmonary', 'venous', 'return', '(', 'P', '<', '.001', ')', ',', 'smaller', 'ascending', 'aorta', '(', 'P', '=', '.02', ')', ',', 'and', 'anatomic', 'subtype', '.']","(16, 20)","(91, 125)",-1,ss_o,22341427,Abstract,5,test,gold,6808.0
4509,"Early phase factors associated with death included lower socioeconomic status ( P = .01 ) , obstructed pulmonary venous return ( P < .001 ) ,",smaller ascending aorta,"( P = .02 ) , and anatomic subtype .","['Early', 'phase', 'factors', 'associated', 'with', 'death', 'included', 'lower', 'socioeconomic', 'status', '(', 'P', '=', '.01', ')', ',', 'obstructed', 'pulmonary', 'venous', 'return', '(', 'P', '<', '.001', ')', ',', 'smaller', 'ascending', 'aorta', '(', 'P', '=', '.02', ')', ',', 'and', 'anatomic', 'subtype', '.']","(26, 29)","(141, 164)",-1,ss_o,22341427,Abstract,5,test,gold,3216.0
4510,"Early phase factors associated with death included lower socioeconomic status ( P = .01 ) , obstructed pulmonary venous return ( P < .001 ) , smaller ascending aorta ( P = .02 ) ,",and anatomic subtype,.,"['Early', 'phase', 'factors', 'associated', 'with', 'death', 'included', 'lower', 'socioeconomic', 'status', '(', 'P', '=', '.01', ')', ',', 'obstructed', 'pulmonary', 'venous', 'return', '(', 'P', '<', '.001', ')', ',', 'smaller', 'ascending', 'aorta', '(', 'P', '=', '.02', ')', ',', 'and', 'anatomic', 'subtype', '.']","(35, 38)","(179, 199)",-1,ss_o,22341427,Abstract,5,test,gold,3169.0
4511,Early phase factors associated,with death,"included lower socioeconomic status ( P = .01 ) , obstructed pulmonary venous return ( P < .001 ) , smaller ascending aorta ( P = .02 ) , and anatomic subtype .","['Early', 'phase', 'factors', 'associated', 'with', 'death', 'included', 'lower', 'socioeconomic', 'status', '(', 'P', '=', '.01', ')', ',', 'obstructed', 'pulmonary', 'venous', 'return', '(', 'P', '<', '.001', ')', ',', 'smaller', 'ascending', 'aorta', '(', 'P', '=', '.02', ')', ',', 'and', 'anatomic', 'subtype', '.']","(4, 6)","(30, 40)",-1,hl_o,22341427,Abstract,5,test,gold,2200.0
4512,Constant phase factors associated,with death included genetic syndrome,( P < .001 ) and lower gestational age ( P < .001 ) .,"['Constant', 'phase', 'factors', 'associated', 'with', 'death', 'included', 'genetic', 'syndrome', '(', 'P', '<', '.001', ')', 'and', 'lower', 'gestational', 'age', '(', 'P', '<', '.001', ')', '.']","(4, 9)","(33, 69)",-1,ss_o,22341427,Abstract,6,test,gold,6421.0
4513,Constant phase factors associated with death included genetic syndrome ( P < .001 ) and,lower gestational age,( P < .001 ) .,"['Constant', 'phase', 'factors', 'associated', 'with', 'death', 'included', 'genetic', 'syndrome', '(', 'P', '<', '.001', ')', 'and', 'lower', 'gestational', 'age', '(', 'P', '<', '.001', ')', '.']","(15, 18)","(87, 108)",-1,ss_o,22341427,Abstract,6,test,gold,2008.0
4514,Constant phase factors associated,with death,included genetic syndrome ( P < .001 ) and lower gestational age ( P < .001 ) .,"['Constant', 'phase', 'factors', 'associated', 'with', 'death', 'included', 'genetic', 'syndrome', '(', 'P', '<', '.001', ')', 'and', 'lower', 'gestational', 'age', '(', 'P', '<', '.001', ')', '.']","(4, 6)","(33, 43)",-1,hl_o,22341427,Abstract,6,test,gold,2198.0
4515,The right ventricle-to-pulmonary artery shunt demonstrated,better survival,in the 51 % of subjects who were full term with aortic atresia ( P < .001 ) .,"['The', 'right', 'ventricle-to-pulmonary', 'artery', 'shunt', 'demonstrated', 'better', 'survival', 'in', 'the', '51', '%', 'of', 'subjects', 'who', 'were', 'full', 'term', 'with', 'aortic', 'atresia', '(', 'P', '<', '.001', ')', '.']","(6, 8)","(58, 73)",-1,ss_o,22341427,Abstract,7,test,gold,1969.0
4516,The right ventricle-to-pulmonary artery shunt demonstrated better,survival,in the 51 % of subjects who were full term with aortic atresia ( P < .001 ) .,"['The', 'right', 'ventricle-to-pulmonary', 'artery', 'shunt', 'demonstrated', 'better', 'survival', 'in', 'the', '51', '%', 'of', 'subjects', 'who', 'were', 'full', 'term', 'with', 'aortic', 'atresia', '(', 'P', '<', '.001', ')', '.']","(7, 8)","(65, 73)",-1,hl_o,22341427,Abstract,7,test,gold,1960.0
4517,The modified Blalock-Taussig shunt was better among the 4 % of subjects who were preterm with a patent aortic valve ( P = .003 ) .,,,"['The', 'modified', 'Blalock-Taussig', 'shunt', 'was', 'better', 'among', 'the', '4', '%', 'of', 'subjects', 'who', 'were', 'preterm', 'with', 'a', 'patent', 'aortic', 'valve', '(', 'P', '=', '.003', ')', '.']",,,,,22341427,Abstract,8,test,gold,
4518,,"Lower pre-Norwood right ventricular fractional area change , pre-Norwood surgery , and anatomy other than hypoplastic left heart syndrome","were independently associated with transplantation ( all P < .03 ) , but shunt type was not ( P = .43 ) .","['Lower', 'pre-Norwood', 'right', 'ventricular', 'fractional', 'area', 'change', ',', 'pre-Norwood', 'surgery', ',', 'and', 'anatomy', 'other', 'than', 'hypoplastic', 'left', 'heart', 'syndrome', 'were', 'independently', 'associated', 'with', 'transplantation', '(', 'all', 'P', '<', '.03', ')', ',', 'but', 'shunt', 'type', 'was', 'not', '(', 'P', '=', '.43', ')', '.']","(0, 19)","(0, 137)",-1,ss_o,22341427,Abstract,9,test,gold,5978.0
4519,CONCLUSIONS,Independent risk factors for intermediate-term mortality,"include lower socioeconomic status , anatomy , genetic syndrome , and lower gestational age .","['CONCLUSIONS', 'Independent', 'risk', 'factors', 'for', 'intermediate-term', 'mortality', 'include', 'lower', 'socioeconomic', 'status', ',', 'anatomy', ',', 'genetic', 'syndrome', ',', 'and', 'lower', 'gestational', 'age', '.']","(1, 7)","(11, 67)",-1,ss_o,22341427,Abstract,10,test,gold,2502.0
4520,"Term infants with aortic atresia benefited from a right ventricle-to-pulmonary artery shunt , and preterm infants with a patent aortic valve benefited from a modified Blalock-Taussig shunt",.,,"['Term', 'infants', 'with', 'aortic', 'atresia', 'benefited', 'from', 'a', 'right', 'ventricle-to-pulmonary', 'artery', 'shunt', ',', 'and', 'preterm', 'infants', 'with', 'a', 'patent', 'aortic', 'valve', 'benefited', 'from', 'a', 'modified', 'Blalock-Taussig', 'shunt', '.']","(27, 28)","(188, 189)",-1,ss_o,22341427,Abstract,11,test,gold,
4521,,Right ventricular function and anatomy,", but not shunt type , were associated with transplantation .","['Right', 'ventricular', 'function', 'and', 'anatomy', ',', 'but', 'not', 'shunt', 'type', ',', 'were', 'associated', 'with', 'transplantation', '.']","(0, 5)","(0, 38)",-1,ss_o,22341427,Abstract,12,test,gold,6786.0
4522,"Right ventricular function and anatomy , but",not shunt type,", were associated with transplantation .","['Right', 'ventricular', 'function', 'and', 'anatomy', ',', 'but', 'not', 'shunt', 'type', ',', 'were', 'associated', 'with', 'transplantation', '.']","(7, 10)","(44, 58)",-1,ss_o,22341427,Abstract,12,test,gold,1151.0
4523,,Preschoolers,acquire general knowledge by sharing in pretense .,"['Preschoolers', 'acquire', 'general', 'knowledge', 'by', 'sharing', 'in', 'pretense', '.']","(0, 1)","(0, 12)",-1,ss_p,22416755,Title,0,test,gold,2169.0
4524,Preschoolers acquire general knowledge by sharing in,pretense .,,"['Preschoolers', 'acquire', 'general', 'knowledge', 'by', 'sharing', 'in', 'pretense', '.']","(7, 9)","(52, 62)",-1,ss_i,22416755,Title,0,test,gold,1131.0
4525,Preschoolers acquire,general knowledge,by sharing in pretense .,"['Preschoolers', 'acquire', 'general', 'knowledge', 'by', 'sharing', 'in', 'pretense', '.']","(2, 4)","(20, 37)",-1,ss_o,22416755,Title,0,test,gold,1133.0
4526,,Preschoolers,acquire general knowledge by sharing in pretense .,"['Preschoolers', 'acquire', 'general', 'knowledge', 'by', 'sharing', 'in', 'pretense', '.']","(0, 1)","(0, 12)",-1,hl_p,22416755,Title,0,test,gold,2170.0
4527,Preschoolers acquire general knowledge by sharing in,pretense .,,"['Preschoolers', 'acquire', 'general', 'knowledge', 'by', 'sharing', 'in', 'pretense', '.']","(7, 9)","(52, 62)",-1,hl_i,22416755,Title,0,test,gold,1132.0
4528,Children acquire,general knowledge,"about many kinds of things , but there are few known means by which this knowledge is acquired .","['Children', 'acquire', 'general', 'knowledge', 'about', 'many', 'kinds', 'of', 'things', ',', 'but', 'there', 'are', 'few', 'known', 'means', 'by', 'which', 'this', 'knowledge', 'is', 'acquired', '.']","(2, 4)","(16, 33)",-1,ss_o,22416755,Abstract,0,test,gold,1134.0
4529,"In this article , it is proposed that",children,acquire generic knowledge by sharing in pretend play .,"['In', 'this', 'article', ',', 'it', 'is', 'proposed', 'that', 'children', 'acquire', 'generic', 'knowledge', 'by', 'sharing', 'in', 'pretend', 'play', '.']","(8, 9)","(37, 45)",-1,ss_p,22416755,Abstract,1,test,gold,2129.0
4530,"In this article , it is proposed that children acquire generic knowledge by sharing in",pretend play .,,"['In', 'this', 'article', ',', 'it', 'is', 'proposed', 'that', 'children', 'acquire', 'generic', 'knowledge', 'by', 'sharing', 'in', 'pretend', 'play', '.']","(15, 18)","(86, 100)",-1,ss_i,22416755,Abstract,1,test,gold,2586.0
4531,"In this article , it is proposed that children acquire",generic knowledge,by sharing in pretend play .,"['In', 'this', 'article', ',', 'it', 'is', 'proposed', 'that', 'children', 'acquire', 'generic', 'knowledge', 'by', 'sharing', 'in', 'pretend', 'play', '.']","(10, 12)","(54, 71)",-1,ss_o,22416755,Abstract,1,test,gold,1135.0
4532,"In this article , it is proposed that children acquire generic knowledge by sharing in",pretend play .,,"['In', 'this', 'article', ',', 'it', 'is', 'proposed', 'that', 'children', 'acquire', 'generic', 'knowledge', 'by', 'sharing', 'in', 'pretend', 'play', '.']","(15, 18)","(86, 100)",-1,hl_i,22416755,Abstract,1,test,gold,2587.0
4533,"In Experiment 1 ,",twenty-two 3- to 4-year-olds,"watched pretense in which a puppet represented a "" nerp "" ( an unfamiliar kind of animal ) .","['In', 'Experiment', '1', ',', 'twenty-two', '3-', 'to', '4-year-olds', 'watched', 'pretense', 'in', 'which', 'a', 'puppet', 'represented', 'a', '""', 'nerp', '""', '(', 'an', 'unfamiliar', 'kind', 'of', 'animal', ')', '.']","(4, 8)","(17, 45)",-1,ss_p,22416755,Abstract,2,test,gold,
4534,"In Experiment 1 , twenty-two 3- to 4-year-olds watched",pretense,"in which a puppet represented a "" nerp "" ( an unfamiliar kind of animal ) .","['In', 'Experiment', '1', ',', 'twenty-two', '3-', 'to', '4-year-olds', 'watched', 'pretense', 'in', 'which', 'a', 'puppet', 'represented', 'a', '""', 'nerp', '""', '(', 'an', 'unfamiliar', 'kind', 'of', 'animal', ')', '.']","(9, 10)","(54, 62)",-1,ss_i,22416755,Abstract,2,test,gold,1130.0
4535,"In Experiment 1 ,",twenty-two 3- to 4-year-olds,"watched pretense in which a puppet represented a "" nerp "" ( an unfamiliar kind of animal ) .","['In', 'Experiment', '1', ',', 'twenty-two', '3-', 'to', '4-year-olds', 'watched', 'pretense', 'in', 'which', 'a', 'puppet', 'represented', 'a', '""', 'nerp', '""', '(', 'an', 'unfamiliar', 'kind', 'of', 'animal', ')', '.']","(4, 8)","(17, 45)",-1,hl_p,22416755,Abstract,2,test,gold,
4536,"In Experiment 1 , twenty-two 3- to 4-year-olds watched",pretense,"in which a puppet represented a "" nerp "" ( an unfamiliar kind of animal ) .","['In', 'Experiment', '1', ',', 'twenty-two', '3-', 'to', '4-year-olds', 'watched', 'pretense', 'in', 'which', 'a', 'puppet', 'represented', 'a', '""', 'nerp', '""', '(', 'an', 'unfamiliar', 'kind', 'of', 'animal', ')', '.']","(9, 10)","(54, 62)",-1,hl_i,22416755,Abstract,2,test,gold,1129.0
4537,"For instance , in one scenario , the nerp ate and disliked a carrot .",,,"['For', 'instance', ',', 'in', 'one', 'scenario', ',', 'the', 'nerp', 'ate', 'and', 'disliked', 'a', 'carrot', '.']",,,,,22416755,Abstract,3,test,gold,
4538,"When subsequently asked generic questions about real nerps ,",children 's responses,"suggested that they had learned general facts ( e.g. , nerps dislike carrots ) .","['When', 'subsequently', 'asked', 'generic', 'questions', 'about', 'real', 'nerps', ',', 'children', ""'s"", 'responses', 'suggested', 'that', 'they', 'had', 'learned', 'general', 'facts', '(', 'e.g.', ',', 'nerps', 'dislike', 'carrots', ')', '.']","(9, 12)","(60, 81)",-1,ss_o,22416755,Abstract,4,test,gold,2529.0
4539,"When subsequently asked generic questions about real nerps , children 's",responses,"suggested that they had learned general facts ( e.g. , nerps dislike carrots ) .","['When', 'subsequently', 'asked', 'generic', 'questions', 'about', 'real', 'nerps', ',', 'children', ""'s"", 'responses', 'suggested', 'that', 'they', 'had', 'learned', 'general', 'facts', '(', 'e.g.', ',', 'nerps', 'dislike', 'carrots', ')', '.']","(11, 12)","(72, 81)",-1,hl_o,22416755,Abstract,4,test,gold,2530.0
4540,"In Experiment 2 ,",thirty-two 4- to 5-year-olds,learned from scenarios lacking pretend speech or sound effects .,"['In', 'Experiment', '2', ',', 'thirty-two', '4-', 'to', '5-year-olds', 'learned', 'from', 'scenarios', 'lacking', 'pretend', 'speech', 'or', 'sound', 'effects', '.']","(4, 8)","(17, 45)",-1,ss_p,22416755,Abstract,5,test,gold,
4541,"In Experiment 2 , thirty-two 4- to 5-year-olds learned from",scenarios lacking pretend speech or sound effects .,,"['In', 'Experiment', '2', ',', 'thirty-two', '4-', 'to', '5-year-olds', 'learned', 'from', 'scenarios', 'lacking', 'pretend', 'speech', 'or', 'sound', 'effects', '.']","(10, 18)","(59, 110)",-1,ss_i,22416755,Abstract,5,test,gold,6422.0
4542,"In Experiment 2 ,",thirty-two 4- to 5-year-olds,learned from scenarios lacking pretend speech or sound effects .,"['In', 'Experiment', '2', ',', 'thirty-two', '4-', 'to', '5-year-olds', 'learned', 'from', 'scenarios', 'lacking', 'pretend', 'speech', 'or', 'sound', 'effects', '.']","(4, 8)","(17, 45)",-1,hl_p,22416755,Abstract,5,test,gold,
4543,"In Experiment 2 , thirty-two 4- to 5-year-olds learned from",scenarios lacking pretend speech or sound effects .,,"['In', 'Experiment', '2', ',', 'thirty-two', '4-', 'to', '5-year-olds', 'learned', 'from', 'scenarios', 'lacking', 'pretend', 'speech', 'or', 'sound', 'effects', '.']","(10, 18)","(59, 110)",-1,hl_i,22416755,Abstract,5,test,gold,6423.0
4544,The findings reveal a long overlooked means by which children can acquire,generic knowledge .,,"['The', 'findings', 'reveal', 'a', 'long', 'overlooked', 'means', 'by', 'which', 'children', 'can', 'acquire', 'generic', 'knowledge', '.']","(12, 15)","(73, 92)",-1,ss_o,22416755,Abstract,6,test,gold,1136.0
4545,Training referential communicative skills to,individuals with autism spectrum disorder :,a pilot study .,"['Training', 'referential', 'communicative', 'skills', 'to', 'individuals', 'with', 'autism', 'spectrum', 'disorder', ':', 'a', 'pilot', 'study', '.']","(5, 11)","(44, 87)",-1,ss_p,22420121,Title,0,test,gold,6017.0
4546,Training,referential communicative skills,to individuals with autism spectrum disorder : a pilot study .,"['Training', 'referential', 'communicative', 'skills', 'to', 'individuals', 'with', 'autism', 'spectrum', 'disorder', ':', 'a', 'pilot', 'study', '.']","(1, 4)","(8, 40)",-1,ss_i,22420121,Title,0,test,gold,2952.0
4547,Training referential communicative skills to,individuals with autism spectrum disorder :,a pilot study .,"['Training', 'referential', 'communicative', 'skills', 'to', 'individuals', 'with', 'autism', 'spectrum', 'disorder', ':', 'a', 'pilot', 'study', '.']","(5, 11)","(44, 87)",-1,hl_p,22420121,Title,0,test,gold,6018.0
4548,Training,referential communicative skills,to individuals with autism spectrum disorder : a pilot study .,"['Training', 'referential', 'communicative', 'skills', 'to', 'individuals', 'with', 'autism', 'spectrum', 'disorder', ':', 'a', 'pilot', 'study', '.']","(1, 4)","(8, 40)",-1,hl_i,22420121,Title,0,test,gold,2953.0
4549,The present study reports the effects of referential communication training in,individuals formally diagnosed with autism spectrum disorder ( ASD ) .,,"['The', 'present', 'study', 'reports', 'the', 'effects', 'of', 'referential', 'communication', 'training', 'in', 'individuals', 'formally', 'diagnosed', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', '.']","(11, 22)","(78, 148)",-1,ss_p,22420121,Abstract,0,test,gold,6047.0
4550,The present study reports the effects of,referential communication training,in individuals formally diagnosed with autism spectrum disorder ( ASD ) .,"['The', 'present', 'study', 'reports', 'the', 'effects', 'of', 'referential', 'communication', 'training', 'in', 'individuals', 'formally', 'diagnosed', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', '.']","(7, 10)","(40, 74)",-1,ss_i,22420121,Abstract,0,test,gold,2957.0
4551,The present study reports the effects of referential communication training in,individuals formally diagnosed with autism spectrum disorder ( ASD ) .,,"['The', 'present', 'study', 'reports', 'the', 'effects', 'of', 'referential', 'communication', 'training', 'in', 'individuals', 'formally', 'diagnosed', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', '.']","(11, 22)","(78, 148)",-1,hl_p,22420121,Abstract,0,test,gold,6048.0
4552,The present study reports the effects of,referential communication training,in individuals formally diagnosed with autism spectrum disorder ( ASD ) .,"['The', 'present', 'study', 'reports', 'the', 'effects', 'of', 'referential', 'communication', 'training', 'in', 'individuals', 'formally', 'diagnosed', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', '.']","(7, 10)","(40, 74)",-1,hl_i,22420121,Abstract,0,test,gold,2958.0
4553,Participants were,20 children with ASD ( M age = 14.3 yr.,", SD = 4.2 ; 6 girls , 14 boys ) in the role of speakers and 20 control children , who acted as listeners .","['Participants', 'were', '20', 'children', 'with', 'ASD', '(', 'M', 'age', '=', '14.3', 'yr.', ',', 'SD', '=', '4.2', ';', '6', 'girls', ',', '14', 'boys', ')', 'in', 'the', 'role', 'of', 'speakers', 'and', '20', 'control', 'children', ',', 'who', 'acted', 'as', 'listeners', '.']","(2, 12)","(17, 56)",-1,ss_p,22420121,Abstract,1,test,gold,6455.0
4554,"Participants were 20 children with ASD ( M age = 14.3 yr. ,","SD = 4.2 ; 6 girls , 14 boys ) in the role of speakers and 20 control children , who acted as listeners .",,"['Participants', 'were', '20', 'children', 'with', 'ASD', '(', 'M', 'age', '=', '14.3', 'yr.', ',', 'SD', '=', '4.2', ';', '6', 'girls', ',', '14', 'boys', ')', 'in', 'the', 'role', 'of', 'speakers', 'and', '20', 'control', 'children', ',', 'who', 'acted', 'as', 'listeners', '.']","(13, 38)","(59, 164)",-1,ss_p,22420121,Abstract,1,test,gold,5831.0
4555,Participants were,20 children,"with ASD ( M age = 14.3 yr. , SD = 4.2 ; 6 girls , 14 boys ) in the role of speakers and 20 control children , who acted as listeners .","['Participants', 'were', '20', 'children', 'with', 'ASD', '(', 'M', 'age', '=', '14.3', 'yr.', ',', 'SD', '=', '4.2', ';', '6', 'girls', ',', '14', 'boys', ')', 'in', 'the', 'role', 'of', 'speakers', 'and', '20', 'control', 'children', ',', 'who', 'acted', 'as', 'listeners', '.']","(2, 4)","(17, 28)",-1,hl_p,22420121,Abstract,1,test,gold,2128.0
4556,Participants were 20 children with,ASD,"( M age = 14.3 yr. , SD = 4.2 ; 6 girls , 14 boys ) in the role of speakers and 20 control children , who acted as listeners .","['Participants', 'were', '20', 'children', 'with', 'ASD', '(', 'M', 'age', '=', '14.3', 'yr.', ',', 'SD', '=', '4.2', ';', '6', 'girls', ',', '14', 'boys', ')', 'in', 'the', 'role', 'of', 'speakers', 'and', '20', 'control', 'children', ',', 'who', 'acted', 'as', 'listeners', '.']","(5, 6)","(34, 37)",-1,hl_p,22420121,Abstract,1,test,gold,6101.0
4557,Participants were 20 children with ASD (,M age = 14.3 yr.,", SD = 4.2 ; 6 girls , 14 boys ) in the role of speakers and 20 control children , who acted as listeners .","['Participants', 'were', '20', 'children', 'with', 'ASD', '(', 'M', 'age', '=', '14.3', 'yr.', ',', 'SD', '=', '4.2', ';', '6', 'girls', ',', '14', 'boys', ')', 'in', 'the', 'role', 'of', 'speakers', 'and', '20', 'control', 'children', ',', 'who', 'acted', 'as', 'listeners', '.']","(7, 12)","(40, 56)",-1,hl_p,22420121,Abstract,1,test,gold,6457.0
4558,"Participants were 20 children with ASD ( M age = 14.3 yr. ,",SD = 4.2,"; 6 girls , 14 boys ) in the role of speakers and 20 control children , who acted as listeners .","['Participants', 'were', '20', 'children', 'with', 'ASD', '(', 'M', 'age', '=', '14.3', 'yr.', ',', 'SD', '=', '4.2', ';', '6', 'girls', ',', '14', 'boys', ')', 'in', 'the', 'role', 'of', 'speakers', 'and', '20', 'control', 'children', ',', 'who', 'acted', 'as', 'listeners', '.']","(13, 16)","(59, 67)",-1,hl_p,22420121,Abstract,1,test,gold,821.0
4559,"Participants were 20 children with ASD ( M age = 14.3 yr. , SD = 4.2 ;",6,"girls , 14 boys ) in the role of speakers and 20 control children , who acted as listeners .","['Participants', 'were', '20', 'children', 'with', 'ASD', '(', 'M', 'age', '=', '14.3', 'yr.', ',', 'SD', '=', '4.2', ';', '6', 'girls', ',', '14', 'boys', ')', 'in', 'the', 'role', 'of', 'speakers', 'and', '20', 'control', 'children', ',', 'who', 'acted', 'as', 'listeners', '.']","(17, 18)","(70, 71)",-1,hl_p,22420121,Abstract,1,test,gold,1170.0
4560,"Participants were 20 children with ASD ( M age = 14.3 yr. , SD = 4.2 ; 6 girls ,",14,"boys ) in the role of speakers and 20 control children , who acted as listeners .","['Participants', 'were', '20', 'children', 'with', 'ASD', '(', 'M', 'age', '=', '14.3', 'yr.', ',', 'SD', '=', '4.2', ';', '6', 'girls', ',', '14', 'boys', ')', 'in', 'the', 'role', 'of', 'speakers', 'and', '20', 'control', 'children', ',', 'who', 'acted', 'as', 'listeners', '.']","(20, 21)","(80, 82)",-1,hl_p,22420121,Abstract,1,test,gold,
4561,"Participants were 20 children with ASD ( M age = 14.3 yr. , SD = 4.2 ; 6 girls , 14 boys ) in the role of speakers and",20,"control children , who acted as listeners .","['Participants', 'were', '20', 'children', 'with', 'ASD', '(', 'M', 'age', '=', '14.3', 'yr.', ',', 'SD', '=', '4.2', ';', '6', 'girls', ',', '14', 'boys', ')', 'in', 'the', 'role', 'of', 'speakers', 'and', '20', 'control', 'children', ',', 'who', 'acted', 'as', 'listeners', '.']","(29, 30)","(118, 120)",-1,hl_p,22420121,Abstract,1,test,gold,
4562,"Participants were 20 children with ASD ( M age = 14.3 yr. , SD = 4.2 ; 6 girls , 14 boys ) in the role of speakers and 20 control",children,", who acted as listeners .","['Participants', 'were', '20', 'children', 'with', 'ASD', '(', 'M', 'age', '=', '14.3', 'yr.', ',', 'SD', '=', '4.2', ';', '6', 'girls', ',', '14', 'boys', ')', 'in', 'the', 'role', 'of', 'speakers', 'and', '20', 'control', 'children', ',', 'who', 'acted', 'as', 'listeners', '.']","(31, 32)","(129, 137)",-1,hl_p,22420121,Abstract,1,test,gold,2127.0
4563,They were all enrolled in mainstream compulsory education .,,,"['They', 'were', 'all', 'enrolled', 'in', 'mainstream', 'compulsory', 'education', '.']",,,,,22420121,Abstract,2,test,gold,
4564,,"Inclusion/exclusion criteria were defined according to the clinical diagnosis of ASD , the presence or absence of additional or associated disability , previous training in referential communication , and any drug treatment .",,"['Inclusion/exclusion', 'criteria', 'were', 'defined', 'according', 'to', 'the', 'clinical', 'diagnosis', 'of', 'ASD', ',', 'the', 'presence', 'or', 'absence', 'of', 'additional', 'or', 'associated', 'disability', ',', 'previous', 'training', 'in', 'referential', 'communication', ',', 'and', 'any', 'drug', 'treatment', '.']","(0, 33)","(0, 225)",-1,ss_p,22420121,Abstract,3,test,gold,5914.0
4565,"Inclusion/exclusion criteria were defined according to the clinical diagnosis of ASD , the presence or absence of additional or associated disability , previous training in",referential communication,", and any drug treatment .","['Inclusion/exclusion', 'criteria', 'were', 'defined', 'according', 'to', 'the', 'clinical', 'diagnosis', 'of', 'ASD', ',', 'the', 'presence', 'or', 'absence', 'of', 'additional', 'or', 'associated', 'disability', ',', 'previous', 'training', 'in', 'referential', 'communication', ',', 'and', 'any', 'drug', 'treatment', '.']","(25, 27)","(172, 197)",-1,ss_i,22420121,Abstract,3,test,gold,2955.0
4566,Speakers were randomly assigned to one of two groups ( trained vs untrained ) .,,,"['Speakers', 'were', 'randomly', 'assigned', 'to', 'one', 'of', 'two', 'groups', '(', 'trained', 'vs', 'untrained', ')', '.']",,,,,22420121,Abstract,4,test,gold,
4567,,"Linguistic age , cognitive level and autistic symptoms","were analyzed , respectively , with the Peabody Picture Vocabulary Test ( PPVT ) , the Wechsler Intelligence Scale ( WISC-R or WAIS-III ) , and the Autistic Behavior Checklist ( ABC ) .","['Linguistic', 'age', ',', 'cognitive', 'level', 'and', 'autistic', 'symptoms', 'were', 'analyzed', ',', 'respectively', ',', 'with', 'the', 'Peabody', 'Picture', 'Vocabulary', 'Test', '(', 'PPVT', ')', ',', 'the', 'Wechsler', 'Intelligence', 'Scale', '(', 'WISC-R', 'or', 'WAIS-III', ')', ',', 'and', 'the', 'Autistic', 'Behavior', 'Checklist', '(', 'ABC', ')', '.']","(0, 8)","(0, 54)",-1,ss_o,22420121,Abstract,5,test,gold,7112.0
4568,"Linguistic age , cognitive level and autistic symptoms were analyzed , respectively , with the","Peabody Picture Vocabulary Test ( PPVT ) , the Wechsler Intelligence Scale ( WISC-R or WAIS-III ) , and the Autistic Behavior Checklist ( ABC ) .",,"['Linguistic', 'age', ',', 'cognitive', 'level', 'and', 'autistic', 'symptoms', 'were', 'analyzed', ',', 'respectively', ',', 'with', 'the', 'Peabody', 'Picture', 'Vocabulary', 'Test', '(', 'PPVT', ')', ',', 'the', 'Wechsler', 'Intelligence', 'Scale', '(', 'WISC-R', 'or', 'WAIS-III', ')', ',', 'and', 'the', 'Autistic', 'Behavior', 'Checklist', '(', 'ABC', ')', '.']","(15, 42)","(94, 239)",-1,ss_o,22420121,Abstract,5,test,gold,6282.0
4569,,"Linguistic age , cognitive level and autistic symptoms","were analyzed , respectively , with the Peabody Picture Vocabulary Test ( PPVT ) , the Wechsler Intelligence Scale ( WISC-R or WAIS-III ) , and the Autistic Behavior Checklist ( ABC ) .","['Linguistic', 'age', ',', 'cognitive', 'level', 'and', 'autistic', 'symptoms', 'were', 'analyzed', ',', 'respectively', ',', 'with', 'the', 'Peabody', 'Picture', 'Vocabulary', 'Test', '(', 'PPVT', ')', ',', 'the', 'Wechsler', 'Intelligence', 'Scale', '(', 'WISC-R', 'or', 'WAIS-III', ')', ',', 'and', 'the', 'Autistic', 'Behavior', 'Checklist', '(', 'ABC', ')', '.']","(0, 8)","(0, 54)",-1,hl_o,22420121,Abstract,5,test,gold,7113.0
4570,"Linguistic age , cognitive level and autistic symptoms were analyzed , respectively , with the","Peabody Picture Vocabulary Test ( PPVT ) , the Wechsler Intelligence Scale ( WISC-R or WAIS-III ) , and the Autistic Behavior Checklist ( ABC ) .",,"['Linguistic', 'age', ',', 'cognitive', 'level', 'and', 'autistic', 'symptoms', 'were', 'analyzed', ',', 'respectively', ',', 'with', 'the', 'Peabody', 'Picture', 'Vocabulary', 'Test', '(', 'PPVT', ')', ',', 'the', 'Wechsler', 'Intelligence', 'Scale', '(', 'WISC-R', 'or', 'WAIS-III', ')', ',', 'and', 'the', 'Autistic', 'Behavior', 'Checklist', '(', 'ABC', ')', '.']","(15, 42)","(94, 239)",-1,hl_o,22420121,Abstract,5,test,gold,6283.0
4571,,Communicative abilities,were analyzed through two indexes related to message complexity and self-regulation .,"['Communicative', 'abilities', 'were', 'analyzed', 'through', 'two', 'indexes', 'related', 'to', 'message', 'complexity', 'and', 'self-regulation', '.']","(0, 2)","(0, 23)",-1,ss_o,22420121,Abstract,6,test,gold,2851.0
4572,Communicative abilities were analyzed through two,indexes related to message complexity and self-regulation .,,"['Communicative', 'abilities', 'were', 'analyzed', 'through', 'two', 'indexes', 'related', 'to', 'message', 'complexity', 'and', 'self-regulation', '.']","(6, 14)","(49, 108)",-1,ss_o,22420121,Abstract,6,test,gold,2997.0
4573,,Communicative abilities,were analyzed through two indexes related to message complexity and self-regulation .,"['Communicative', 'abilities', 'were', 'analyzed', 'through', 'two', 'indexes', 'related', 'to', 'message', 'complexity', 'and', 'self-regulation', '.']","(0, 2)","(0, 23)",-1,hl_o,22420121,Abstract,6,test,gold,2852.0
4574,The trained group was trained in,"referential communication tasks ( task analysis , role taking",", and task evaluation ) , while the untrained group took part in a communicative game but without any specific communicative training .","['The', 'trained', 'group', 'was', 'trained', 'in', 'referential', 'communication', 'tasks', '(', 'task', 'analysis', ',', 'role', 'taking', ',', 'and', 'task', 'evaluation', ')', ',', 'while', 'the', 'untrained', 'group', 'took', 'part', 'in', 'a', 'communicative', 'game', 'but', 'without', 'any', 'specific', 'communicative', 'training', '.']","(6, 15)","(32, 93)",-1,ss_i,22420121,Abstract,7,test,gold,6431.0
4575,"The trained group was trained in referential communication tasks ( task analysis , role taking , and",task evaluation ),", while the untrained group took part in a communicative game but without any specific communicative training .","['The', 'trained', 'group', 'was', 'trained', 'in', 'referential', 'communication', 'tasks', '(', 'task', 'analysis', ',', 'role', 'taking', ',', 'and', 'task', 'evaluation', ')', ',', 'while', 'the', 'untrained', 'group', 'took', 'part', 'in', 'a', 'communicative', 'game', 'but', 'without', 'any', 'specific', 'communicative', 'training', '.']","(17, 20)","(100, 117)",-1,ss_i,22420121,Abstract,7,test,gold,916.0
4576,"The trained group was trained in referential communication tasks ( task analysis , role taking , and task evaluation ) , while the untrained group took part in a",communicative game,but without any specific communicative training .,"['The', 'trained', 'group', 'was', 'trained', 'in', 'referential', 'communication', 'tasks', '(', 'task', 'analysis', ',', 'role', 'taking', ',', 'and', 'task', 'evaluation', ')', ',', 'while', 'the', 'untrained', 'group', 'took', 'part', 'in', 'a', 'communicative', 'game', 'but', 'without', 'any', 'specific', 'communicative', 'training', '.']","(29, 31)","(161, 179)",-1,ss_i,22420121,Abstract,7,test,gold,2582.0
4577,The trained group was trained in,"referential communication tasks ( task analysis , role taking",", and task evaluation ) , while the untrained group took part in a communicative game but without any specific communicative training .","['The', 'trained', 'group', 'was', 'trained', 'in', 'referential', 'communication', 'tasks', '(', 'task', 'analysis', ',', 'role', 'taking', ',', 'and', 'task', 'evaluation', ')', ',', 'while', 'the', 'untrained', 'group', 'took', 'part', 'in', 'a', 'communicative', 'game', 'but', 'without', 'any', 'specific', 'communicative', 'training', '.']","(6, 15)","(32, 93)",-1,hl_i,22420121,Abstract,7,test,gold,6432.0
4578,"The trained group was trained in referential communication tasks ( task analysis , role taking , and",task evaluation ),", while the untrained group took part in a communicative game but without any specific communicative training .","['The', 'trained', 'group', 'was', 'trained', 'in', 'referential', 'communication', 'tasks', '(', 'task', 'analysis', ',', 'role', 'taking', ',', 'and', 'task', 'evaluation', ')', ',', 'while', 'the', 'untrained', 'group', 'took', 'part', 'in', 'a', 'communicative', 'game', 'but', 'without', 'any', 'specific', 'communicative', 'training', '.']","(17, 20)","(100, 117)",-1,hl_i,22420121,Abstract,7,test,gold,917.0
4579,"The trained group was trained in referential communication tasks ( task analysis , role taking , and task evaluation ) , while the untrained group took part in a",communicative game,but without any specific communicative training .,"['The', 'trained', 'group', 'was', 'trained', 'in', 'referential', 'communication', 'tasks', '(', 'task', 'analysis', ',', 'role', 'taking', ',', 'and', 'task', 'evaluation', ')', ',', 'while', 'the', 'untrained', 'group', 'took', 'part', 'in', 'a', 'communicative', 'game', 'but', 'without', 'any', 'specific', 'communicative', 'training', '.']","(29, 31)","(161, 179)",-1,hl_i,22420121,Abstract,7,test,gold,2583.0
4580,The results showed that the,complexity of emitted messages,had improved statistically significantly in the trained group as an effect of training .,"['The', 'results', 'showed', 'that', 'the', 'complexity', 'of', 'emitted', 'messages', 'had', 'improved', 'statistically', 'significantly', 'in', 'the', 'trained', 'group', 'as', 'an', 'effect', 'of', 'training', '.']","(5, 9)","(27, 57)",-1,ss_o,22420121,Abstract,8,test,gold,2998.0
4581,The results showed that the,complexity of emitted messages,had improved statistically significantly in the trained group as an effect of training .,"['The', 'results', 'showed', 'that', 'the', 'complexity', 'of', 'emitted', 'messages', 'had', 'improved', 'statistically', 'significantly', 'in', 'the', 'trained', 'group', 'as', 'an', 'effect', 'of', 'training', '.']","(5, 9)","(27, 57)",-1,hl_o,22420121,Abstract,8,test,gold,2999.0
4582,Ecological referential communication is shown to be an appropriate paradigm for studying the communicative process and its products and could be used to develop and implement a training program focused on those skills in which,individuals with ASD,are most deficient .,"['Ecological', 'referential', 'communication', 'is', 'shown', 'to', 'be', 'an', 'appropriate', 'paradigm', 'for', 'studying', 'the', 'communicative', 'process', 'and', 'its', 'products', 'and', 'could', 'be', 'used', 'to', 'develop', 'and', 'implement', 'a', 'training', 'program', 'focused', 'on', 'those', 'skills', 'in', 'which', 'individuals', 'with', 'ASD', 'are', 'most', 'deficient', '.']","(35, 38)","(226, 246)",-1,ss_p,22420121,Abstract,9,test,gold,6094.0
4583,Ecological,referential communication,is shown to be an appropriate paradigm for studying the communicative process and its products and could be used to develop and implement a training program focused on those skills in which individuals with ASD are most deficient .,"['Ecological', 'referential', 'communication', 'is', 'shown', 'to', 'be', 'an', 'appropriate', 'paradigm', 'for', 'studying', 'the', 'communicative', 'process', 'and', 'its', 'products', 'and', 'could', 'be', 'used', 'to', 'develop', 'and', 'implement', 'a', 'training', 'program', 'focused', 'on', 'those', 'skills', 'in', 'which', 'individuals', 'with', 'ASD', 'are', 'most', 'deficient', '.']","(1, 3)","(10, 35)",-1,ss_i,22420121,Abstract,9,test,gold,2956.0
4584,Ecological referential communication is shown to be an appropriate paradigm for studying the communicative process and its products and could be used to develop and implement a training program focused on those skills in which,individuals with ASD,are most deficient .,"['Ecological', 'referential', 'communication', 'is', 'shown', 'to', 'be', 'an', 'appropriate', 'paradigm', 'for', 'studying', 'the', 'communicative', 'process', 'and', 'its', 'products', 'and', 'could', 'be', 'used', 'to', 'develop', 'and', 'implement', 'a', 'training', 'program', 'focused', 'on', 'those', 'skills', 'in', 'which', 'individuals', 'with', 'ASD', 'are', 'most', 'deficient', '.']","(35, 38)","(226, 246)",-1,hl_p,22420121,Abstract,9,test,gold,6095.0
4585,Ecological,referential communication,is shown to be an appropriate paradigm for studying the communicative process and its products and could be used to develop and implement a training program focused on those skills in which individuals with ASD are most deficient .,"['Ecological', 'referential', 'communication', 'is', 'shown', 'to', 'be', 'an', 'appropriate', 'paradigm', 'for', 'studying', 'the', 'communicative', 'process', 'and', 'its', 'products', 'and', 'could', 'be', 'used', 'to', 'develop', 'and', 'implement', 'a', 'training', 'program', 'focused', 'on', 'those', 'skills', 'in', 'which', 'individuals', 'with', 'ASD', 'are', 'most', 'deficient', '.']","(1, 3)","(10, 35)",-1,hl_i,22420121,Abstract,9,test,gold,2954.0
4586,Group cognitive behavior therapy for,children with high-functioning autism spectrum disorders and anxiety :,a randomized trial .,"['Group', 'cognitive', 'behavior', 'therapy', 'for', 'children', 'with', 'high-functioning', 'autism', 'spectrum', 'disorders', 'and', 'anxiety', ':', 'a', 'randomized', 'trial', '.']","(5, 14)","(36, 106)",-1,ss_p,22435114,Title,0,test,gold,6019.0
4587,,Group cognitive behavior therapy,for children with high-functioning autism spectrum disorders and anxiety : a randomized trial .,"['Group', 'cognitive', 'behavior', 'therapy', 'for', 'children', 'with', 'high-functioning', 'autism', 'spectrum', 'disorders', 'and', 'anxiety', ':', 'a', 'randomized', 'trial', '.']","(0, 4)","(0, 32)",-1,ss_i,22435114,Title,0,test,gold,6320.0
4588,Group cognitive behavior therapy for,children,with high-functioning autism spectrum disorders and anxiety : a randomized trial .,"['Group', 'cognitive', 'behavior', 'therapy', 'for', 'children', 'with', 'high-functioning', 'autism', 'spectrum', 'disorders', 'and', 'anxiety', ':', 'a', 'randomized', 'trial', '.']","(5, 6)","(36, 44)",-1,hl_p,22435114,Title,0,test,gold,2126.0
4589,Group cognitive behavior therapy for children with,high-functioning autism spectrum disorders and anxiety,: a randomized trial .,"['Group', 'cognitive', 'behavior', 'therapy', 'for', 'children', 'with', 'high-functioning', 'autism', 'spectrum', 'disorders', 'and', 'anxiety', ':', 'a', 'randomized', 'trial', '.']","(7, 13)","(50, 104)",-1,hl_p,22435114,Title,0,test,gold,6020.0
4590,,Group cognitive behavior therapy,for children with high-functioning autism spectrum disorders and anxiety : a randomized trial .,"['Group', 'cognitive', 'behavior', 'therapy', 'for', 'children', 'with', 'high-functioning', 'autism', 'spectrum', 'disorders', 'and', 'anxiety', ':', 'a', 'randomized', 'trial', '.']","(0, 4)","(0, 32)",-1,hl_i,22435114,Title,0,test,gold,6321.0
4591,BACKGROUND Children with high-functioning autism spectrum disorders ( ASD ) are at high risk for developing significant anxiety .,,,"['BACKGROUND', 'Children', 'with', 'high-functioning', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', 'are', 'at', 'high', 'risk', 'for', 'developing', 'significant', 'anxiety', '.']",,,,,22435114,Abstract,0,test,gold,
4592,"Anxiety can adversely impact functioning across school , home and community environments .",,,"['Anxiety', 'can', 'adversely', 'impact', 'functioning', 'across', 'school', ',', 'home', 'and', 'community', 'environments', '.']",,,,,22435114,Abstract,1,test,gold,
4593,,Cognitive behavioral therapies ( CBT ),are frequently used with success for children with anxiety symptoms .,"['Cognitive', 'behavioral', 'therapies', '(', 'CBT', ')', 'are', 'frequently', 'used', 'with', 'success', 'for', 'children', 'with', 'anxiety', 'symptoms', '.']","(0, 6)","(0, 38)",-1,ss_i,22435114,Abstract,2,test,gold,6326.0
4594,Cognitive behavioral therapies ( CBT ) are frequently used with success for children with,anxiety symptoms .,,"['Cognitive', 'behavioral', 'therapies', '(', 'CBT', ')', 'are', 'frequently', 'used', 'with', 'success', 'for', 'children', 'with', 'anxiety', 'symptoms', '.']","(14, 17)","(89, 107)",-1,ss_o,22435114,Abstract,2,test,gold,3260.0
4595,,Cognitive behavioral therapies ( CBT ),are frequently used with success for children with anxiety symptoms .,"['Cognitive', 'behavioral', 'therapies', '(', 'CBT', ')', 'are', 'frequently', 'used', 'with', 'success', 'for', 'children', 'with', 'anxiety', 'symptoms', '.']","(0, 6)","(0, 38)",-1,hl_i,22435114,Abstract,2,test,gold,6327.0
4596,Cognitive behavioral therapies ( CBT ) are frequently used with success for children with,anxiety symptoms .,,"['Cognitive', 'behavioral', 'therapies', '(', 'CBT', ')', 'are', 'frequently', 'used', 'with', 'success', 'for', 'children', 'with', 'anxiety', 'symptoms', '.']","(14, 17)","(89, 107)",-1,hl_o,22435114,Abstract,2,test,gold,3261.0
4597,Modified,CBT,interventions for anxiety in children with ASD have also yielded promising results .,"['Modified', 'CBT', 'interventions', 'for', 'anxiety', 'in', 'children', 'with', 'ASD', 'have', 'also', 'yielded', 'promising', 'results', '.']","(1, 2)","(8, 11)",-1,ss_i,22435114,Abstract,3,test,gold,346.0
4598,Modified,CBT,interventions for anxiety in children with ASD have also yielded promising results .,"['Modified', 'CBT', 'interventions', 'for', 'anxiety', 'in', 'children', 'with', 'ASD', 'have', 'also', 'yielded', 'promising', 'results', '.']","(1, 2)","(8, 11)",-1,hl_i,22435114,Abstract,3,test,gold,347.0
4599,METHODS,Fifty children with high-functioning ASD and anxiety,were randomizedto group CBT or treatment-as-usual ( TAU ) for 12 weeks .,"['METHODS', 'Fifty', 'children', 'with', 'high-functioning', 'ASD', 'and', 'anxiety', 'were', 'randomizedto', 'group', 'CBT', 'or', 'treatment-as-usual', '(', 'TAU', ')', 'for', '12', 'weeks', '.']","(1, 8)","(7, 59)",-1,ss_p,22435114,Abstract,4,test,gold,6202.0
4600,METHODS Fifty children with high-functioning ASD and anxiety were randomizedto group,CBT,or treatment-as-usual ( TAU ) for 12 weeks .,"['METHODS', 'Fifty', 'children', 'with', 'high-functioning', 'ASD', 'and', 'anxiety', 'were', 'randomizedto', 'group', 'CBT', 'or', 'treatment-as-usual', '(', 'TAU', ')', 'for', '12', 'weeks', '.']","(11, 12)","(84, 87)",-1,ss_i,22435114,Abstract,4,test,gold,345.0
4601,METHODS Fifty children with high-functioning ASD and anxiety were randomizedto group CBT or,treatment-as-usual ( TAU ),for 12 weeks .,"['METHODS', 'Fifty', 'children', 'with', 'high-functioning', 'ASD', 'and', 'anxiety', 'were', 'randomizedto', 'group', 'CBT', 'or', 'treatment-as-usual', '(', 'TAU', ')', 'for', '12', 'weeks', '.']","(13, 17)","(91, 117)",-1,ss_i,22435114,Abstract,4,test,gold,542.0
4602,METHODS,Fifty children,with high-functioning ASD and anxiety were randomizedto group CBT or treatment-as-usual ( TAU ) for 12 weeks .,"['METHODS', 'Fifty', 'children', 'with', 'high-functioning', 'ASD', 'and', 'anxiety', 'were', 'randomizedto', 'group', 'CBT', 'or', 'treatment-as-usual', '(', 'TAU', ')', 'for', '12', 'weeks', '.']","(1, 3)","(7, 21)",-1,hl_p,22435114,Abstract,4,test,gold,2056.0
4603,METHODS Fifty children with,high-functioning ASD and anxiety,were randomizedto group CBT or treatment-as-usual ( TAU ) for 12 weeks .,"['METHODS', 'Fifty', 'children', 'with', 'high-functioning', 'ASD', 'and', 'anxiety', 'were', 'randomizedto', 'group', 'CBT', 'or', 'treatment-as-usual', '(', 'TAU', ')', 'for', '12', 'weeks', '.']","(4, 8)","(27, 59)",-1,hl_p,22435114,Abstract,4,test,gold,6100.0
4604,METHODS Fifty children with high-functioning ASD and anxiety were randomizedto group,CBT,or treatment-as-usual ( TAU ) for 12 weeks .,"['METHODS', 'Fifty', 'children', 'with', 'high-functioning', 'ASD', 'and', 'anxiety', 'were', 'randomizedto', 'group', 'CBT', 'or', 'treatment-as-usual', '(', 'TAU', ')', 'for', '12', 'weeks', '.']","(11, 12)","(84, 87)",-1,hl_i,22435114,Abstract,4,test,gold,344.0
4605,METHODS Fifty children with high-functioning ASD and anxiety were randomizedto group CBT or,treatment-as-usual ( TAU ),for 12 weeks .,"['METHODS', 'Fifty', 'children', 'with', 'high-functioning', 'ASD', 'and', 'anxiety', 'were', 'randomizedto', 'group', 'CBT', 'or', 'treatment-as-usual', '(', 'TAU', ')', 'for', '12', 'weeks', '.']","(13, 17)","(91, 117)",-1,hl_i,22435114,Abstract,4,test,gold,543.0
4606,"Independent clinical evaluators , blind to condition , completed",structured interviews ( Anxiety Disorders Interview Schedule – Parent Version ; ADIS-P ),pre- and post-intervention condition .,"['Independent', 'clinical', 'evaluators', ',', 'blind', 'to', 'condition', ',', 'completed', 'structured', 'interviews', '(', 'Anxiety', 'Disorders', 'Interview', 'Schedule', '–', 'Parent', 'Version', ';', 'ADIS-P', ')', 'pre-', 'and', 'post-intervention', 'condition', '.']","(9, 22)","(64, 152)",-1,ss_o,22435114,Abstract,5,test,gold,6286.0
4607,,RESULTS Forty-seven children completed either the CBT or TAU condition,.,"['RESULTS', 'Forty-seven', 'children', 'completed', 'either', 'the', 'CBT', 'or', 'TAU', 'condition', '.']","(0, 10)","(0, 70)",-1,ss_p,22435114,Abstract,6,test,gold,5843.0
4608,RESULTS Forty-seven children completed either,the CBT or TAU,condition .,"['RESULTS', 'Forty-seven', 'children', 'completed', 'either', 'the', 'CBT', 'or', 'TAU', 'condition', '.']","(5, 9)","(45, 59)",-1,ss_i,22435114,Abstract,6,test,gold,533.0
4609,RESULTS,Forty-seven children,completed either the CBT or TAU condition .,"['RESULTS', 'Forty-seven', 'children', 'completed', 'either', 'the', 'CBT', 'or', 'TAU', 'condition', '.']","(1, 3)","(7, 27)",-1,hl_p,22435114,Abstract,6,test,gold,2125.0
4610,RESULTS Forty-seven children completed either the,CBT,or TAU condition .,"['RESULTS', 'Forty-seven', 'children', 'completed', 'either', 'the', 'CBT', 'or', 'TAU', 'condition', '.']","(6, 7)","(49, 52)",-1,hl_i,22435114,Abstract,6,test,gold,343.0
4611,RESULTS Forty-seven children completed either the CBT or,TAU,condition .,"['RESULTS', 'Forty-seven', 'children', 'completed', 'either', 'the', 'CBT', 'or', 'TAU', 'condition', '.']","(8, 9)","(56, 59)",-1,hl_i,22435114,Abstract,6,test,gold,541.0
4612,Results indicated markedly better outcomes for,the CBT,group .,"['Results', 'indicated', 'markedly', 'better', 'outcomes', 'for', 'the', 'CBT', 'group', '.']","(6, 8)","(46, 53)",-1,ss_i,22435114,Abstract,7,test,gold,349.0
4613,Results indicated markedly better outcomes for the,CBT,group .,"['Results', 'indicated', 'markedly', 'better', 'outcomes', 'for', 'the', 'CBT', 'group', '.']","(7, 8)","(50, 53)",-1,hl_i,22435114,Abstract,7,test,gold,342.0
4614,Significant differences by group were noted,"in Clinician Severity Ratings , diagnostic status , and clinician ratings of global improvement",.,"['Significant', 'differences', 'by', 'group', 'were', 'noted', 'in', 'Clinician', 'Severity', 'Ratings', ',', 'diagnostic', 'status', ',', 'and', 'clinician', 'ratings', 'of', 'global', 'improvement', '.']","(6, 20)","(43, 138)",-1,ss_o,22435114,Abstract,8,test,gold,6278.0
4615,"In the intent-to-treat sample , 10 of 20 children ( 50 % ) in",the CBT,"group had a clinically meaningful positive treatment response , compared to 2 of 23 children ( 8.7 % ) in the TAU group .","['In', 'the', 'intent-to-treat', 'sample', ',', '10', 'of', '20', 'children', '(', '50', '%', ')', 'in', 'the', 'CBT', 'group', 'had', 'a', 'clinically', 'meaningful', 'positive', 'treatment', 'response', ',', 'compared', 'to', '2', 'of', '23', 'children', '(', '8.7', '%', ')', 'in', 'the', 'TAU', 'group', '.']","(14, 16)","(61, 68)",-1,ss_i,22435114,Abstract,9,test,gold,350.0
4616,"In the intent-to-treat sample , 10 of 20 children ( 50 % ) in the CBT group had a clinically meaningful positive treatment response , compared to 2 of 23 children ( 8.7 % ) in",the TAU,group .,"['In', 'the', 'intent-to-treat', 'sample', ',', '10', 'of', '20', 'children', '(', '50', '%', ')', 'in', 'the', 'CBT', 'group', 'had', 'a', 'clinically', 'meaningful', 'positive', 'treatment', 'response', ',', 'compared', 'to', '2', 'of', '23', 'children', '(', '8.7', '%', ')', 'in', 'the', 'TAU', 'group', '.']","(36, 38)","(175, 182)",-1,ss_i,22435114,Abstract,9,test,gold,534.0
4617,"In the intent-to-treat sample , 10 of 20 children ( 50 % ) in the CBT group had a clinically meaningful",positive treatment response,", compared to 2 of 23 children ( 8.7 % ) in the TAU group .","['In', 'the', 'intent-to-treat', 'sample', ',', '10', 'of', '20', 'children', '(', '50', '%', ')', 'in', 'the', 'CBT', 'group', 'had', 'a', 'clinically', 'meaningful', 'positive', 'treatment', 'response', ',', 'compared', 'to', '2', 'of', '23', 'children', '(', '8.7', '%', ')', 'in', 'the', 'TAU', 'group', '.']","(21, 24)","(103, 130)",-1,ss_o,22435114,Abstract,9,test,gold,2532.0
4618,"In the intent-to-treat sample , 10 of 20 children ( 50 % ) in the",CBT,"group had a clinically meaningful positive treatment response , compared to 2 of 23 children ( 8.7 % ) in the TAU group .","['In', 'the', 'intent-to-treat', 'sample', ',', '10', 'of', '20', 'children', '(', '50', '%', ')', 'in', 'the', 'CBT', 'group', 'had', 'a', 'clinically', 'meaningful', 'positive', 'treatment', 'response', ',', 'compared', 'to', '2', 'of', '23', 'children', '(', '8.7', '%', ')', 'in', 'the', 'TAU', 'group', '.']","(15, 16)","(65, 68)",-1,hl_i,22435114,Abstract,9,test,gold,341.0
4619,"CONCLUSIONS Initial results from this randomized , designed treatment study suggest that agroup CBT intervention specifically developed",for children with ASD,may be effective in decreasing anxiety .,"['CONCLUSIONS', 'Initial', 'results', 'from', 'this', 'randomized', ',', 'designed', 'treatment', 'study', 'suggest', 'that', 'agroup', 'CBT', 'intervention', 'specifically', 'developed', 'for', 'children', 'with', 'ASD', 'may', 'be', 'effective', 'in', 'decreasing', 'anxiety', '.']","(17, 21)","(135, 156)",-1,ss_p,22435114,Abstract,10,test,gold,6088.0
4620,"CONCLUSIONS Initial results from this randomized , designed treatment study suggest that",agroup CBT,intervention specifically developed for children with ASD may be effective in decreasing anxiety .,"['CONCLUSIONS', 'Initial', 'results', 'from', 'this', 'randomized', ',', 'designed', 'treatment', 'study', 'suggest', 'that', 'agroup', 'CBT', 'intervention', 'specifically', 'developed', 'for', 'children', 'with', 'ASD', 'may', 'be', 'effective', 'in', 'decreasing', 'anxiety', '.']","(12, 14)","(88, 98)",-1,ss_i,22435114,Abstract,10,test,gold,348.0
4621,"CONCLUSIONS Initial results from this randomized , designed treatment study suggest that agroup",CBT,intervention specifically developed for children with ASD may be effective in decreasing anxiety .,"['CONCLUSIONS', 'Initial', 'results', 'from', 'this', 'randomized', ',', 'designed', 'treatment', 'study', 'suggest', 'that', 'agroup', 'CBT', 'intervention', 'specifically', 'developed', 'for', 'children', 'with', 'ASD', 'may', 'be', 'effective', 'in', 'decreasing', 'anxiety', '.']","(13, 14)","(95, 98)",-1,hl_i,22435114,Abstract,10,test,gold,340.0
4622,"Limitations of this study include small sample size , lack of an attention control group , and use of outcome measures normed with typically developing children",,,"['Limitations', 'of', 'this', 'study', 'include', 'small', 'sample', 'size', ',', 'lack', 'of', 'an', 'attention', 'control', 'group', ',', 'and', 'use', 'of', 'outcome', 'measures', 'normed', 'with', 'typically', 'developing', 'children']",,,,,22435114,Abstract,11,test,gold,
4623,Spotty calcification as a marker of accelerated,progression of coronary atherosclerosis :,insights from serial intravascular ultrasound .,"['Spotty', 'calcification', 'as', 'a', 'marker', 'of', 'accelerated', 'progression', 'of', 'coronary', 'atherosclerosis', ':', 'insights', 'from', 'serial', 'intravascular', 'ultrasound', '.']","(7, 12)","(47, 88)",-1,ss_o,22538329,Title,0,test,gold,6743.0
4624,Spotty calcification as a marker of accelerated,progression of coronary atherosclerosis :,insights from serial intravascular ultrasound .,"['Spotty', 'calcification', 'as', 'a', 'marker', 'of', 'accelerated', 'progression', 'of', 'coronary', 'atherosclerosis', ':', 'insights', 'from', 'serial', 'intravascular', 'ultrasound', '.']","(7, 12)","(47, 88)",-1,hl_o,22538329,Title,0,test,gold,6741.0
4625,OBJECTIVES The purpose of this study was to determine atheroma progression in,patients with spotty calcification .,,"['OBJECTIVES', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'determine', 'atheroma', 'progression', 'in', 'patients', 'with', 'spotty', 'calcification', '.']","(12, 17)","(77, 113)",-1,ss_p,22538329,Abstract,0,test,gold,3548.0
4626,OBJECTIVES The purpose of this study was to determine,atheroma progression,in patients with spotty calcification .,"['OBJECTIVES', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'determine', 'atheroma', 'progression', 'in', 'patients', 'with', 'spotty', 'calcification', '.']","(9, 11)","(53, 73)",-1,ss_o,22538329,Abstract,0,test,gold,3294.0
4627,OBJECTIVES The purpose of this study was to determine atheroma progression in,patients with spotty calcification .,,"['OBJECTIVES', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'determine', 'atheroma', 'progression', 'in', 'patients', 'with', 'spotty', 'calcification', '.']","(12, 17)","(77, 113)",-1,hl_p,22538329,Abstract,0,test,gold,3549.0
4628,OBJECTIVES The purpose of this study was to determine,atheroma progression,in patients with spotty calcification .,"['OBJECTIVES', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'determine', 'atheroma', 'progression', 'in', 'patients', 'with', 'spotty', 'calcification', '.']","(9, 11)","(53, 73)",-1,hl_o,22538329,Abstract,0,test,gold,3293.0
4629,"BACKGROUND Although extensively calcified atherosclerotic lesions have been proposed to be clinically quiescent , the presence of spotty calcification within plaque has been reported to be associated with an increased incidence of ischemic cardiovascular events .",,,"['BACKGROUND', 'Although', 'extensively', 'calcified', 'atherosclerotic', 'lesions', 'have', 'been', 'proposed', 'to', 'be', 'clinically', 'quiescent', ',', 'the', 'presence', 'of', 'spotty', 'calcification', 'within', 'plaque', 'has', 'been', 'reported', 'to', 'be', 'associated', 'with', 'an', 'increased', 'incidence', 'of', 'ischemic', 'cardiovascular', 'events', '.']",,,,,22538329,Abstract,1,test,gold,
4630,The relationship between,spotty calcification,and disease progression has not been investigated .,"['The', 'relationship', 'between', 'spotty', 'calcification', 'and', 'disease', 'progression', 'has', 'not', 'been', 'investigated', '.']","(3, 5)","(24, 44)",-1,ss_o,22538329,Abstract,2,test,gold,3547.0
4631,The relationship between spotty calcification and,disease progression,has not been investigated .,"['The', 'relationship', 'between', 'spotty', 'calcification', 'and', 'disease', 'progression', 'has', 'not', 'been', 'investigated', '.']","(6, 8)","(49, 68)",-1,ss_o,22538329,Abstract,2,test,gold,3316.0
4632,The relationship between spotty calcification and,disease progression,has not been investigated .,"['The', 'relationship', 'between', 'spotty', 'calcification', 'and', 'disease', 'progression', 'has', 'not', 'been', 'investigated', '.']","(6, 8)","(49, 68)",-1,hl_o,22538329,Abstract,2,test,gold,3315.0
4633,METHODS,"A total of 1,347 stable patients with angiographic coronary artery disease",underwent serial evaluation of atheroma burden with intravascular ultrasound imaging .,"['METHODS', 'A', 'total', 'of', '1,347', 'stable', 'patients', 'with', 'angiographic', 'coronary', 'artery', 'disease', 'underwent', 'serial', 'evaluation', 'of', 'atheroma', 'burden', 'with', 'intravascular', 'ultrasound', 'imaging', '.']","(1, 12)","(7, 81)",-1,ss_p,22538329,Abstract,3,test,gold,6733.0
4634,"METHODS A total of 1,347 stable patients with angiographic coronary artery disease underwent",serial evaluation of atheroma burden with intravascular ultrasound imaging .,,"['METHODS', 'A', 'total', 'of', '1,347', 'stable', 'patients', 'with', 'angiographic', 'coronary', 'artery', 'disease', 'underwent', 'serial', 'evaluation', 'of', 'atheroma', 'burden', 'with', 'intravascular', 'ultrasound', 'imaging', '.']","(13, 23)","(92, 168)",-1,ss_i,22538329,Abstract,3,test,gold,5966.0
4635,"METHODS A total of 1,347 stable patients with angiographic coronary artery disease underwent serial evaluation of",atheroma burden with intravascular ultrasound imaging .,,"['METHODS', 'A', 'total', 'of', '1,347', 'stable', 'patients', 'with', 'angiographic', 'coronary', 'artery', 'disease', 'underwent', 'serial', 'evaluation', 'of', 'atheroma', 'burden', 'with', 'intravascular', 'ultrasound', 'imaging', '.']","(16, 23)","(113, 168)",-1,ss_o,22538329,Abstract,3,test,gold,5965.0
4636,METHODS A total of,"1,347 stable patients with angiographic coronary artery disease",underwent serial evaluation of atheroma burden with intravascular ultrasound imaging .,"['METHODS', 'A', 'total', 'of', '1,347', 'stable', 'patients', 'with', 'angiographic', 'coronary', 'artery', 'disease', 'underwent', 'serial', 'evaluation', 'of', 'atheroma', 'burden', 'with', 'intravascular', 'ultrasound', 'imaging', '.']","(4, 12)","(18, 81)",-1,hl_p,22538329,Abstract,3,test,gold,6734.0
4637,"METHODS A total of 1,347 stable patients with angiographic coronary artery disease underwent",serial evaluation of atheroma burden with intravascular ultrasound imaging .,,"['METHODS', 'A', 'total', 'of', '1,347', 'stable', 'patients', 'with', 'angiographic', 'coronary', 'artery', 'disease', 'underwent', 'serial', 'evaluation', 'of', 'atheroma', 'burden', 'with', 'intravascular', 'ultrasound', 'imaging', '.']","(13, 23)","(92, 168)",-1,hl_i,22538329,Abstract,3,test,gold,5967.0
4638,"METHODS A total of 1,347 stable patients with angiographic coronary artery disease underwent serial evaluation of",atheroma burden,with intravascular ultrasound imaging .,"['METHODS', 'A', 'total', 'of', '1,347', 'stable', 'patients', 'with', 'angiographic', 'coronary', 'artery', 'disease', 'underwent', 'serial', 'evaluation', 'of', 'atheroma', 'burden', 'with', 'intravascular', 'ultrasound', 'imaging', '.']","(16, 18)","(113, 128)",-1,hl_o,22538329,Abstract,3,test,gold,2476.0
4639,,Patients with spotty calcification were identified based on the presence of lesions ( 1 to 4 mm in length ) containing an arc of calcification of < 90°,.,"['Patients', 'with', 'spotty', 'calcification', 'were', 'identified', 'based', 'on', 'the', 'presence', 'of', 'lesions', '(', '1', 'to', '4', 'mm', 'in', 'length', ')', 'containing', 'an', 'arc', 'of', 'calcification', 'of', '<', '90°', '.']","(0, 28)","(0, 151)",-1,ss_p,22538329,Abstract,4,test,gold,5997.0
4640,Patients with spotty calcification were identified based on the presence of lesions ( 1 to 4 mm in length ) containing an arc of calcification of < 90°,.,,"['Patients', 'with', 'spotty', 'calcification', 'were', 'identified', 'based', 'on', 'the', 'presence', 'of', 'lesions', '(', '1', 'to', '4', 'mm', 'in', 'length', ')', 'containing', 'an', 'arc', 'of', 'calcification', 'of', '<', '90°', '.']","(28, 29)","(151, 152)",-1,ss_o,22538329,Abstract,4,test,gold,
4641,,Clinical characteristics and disease progression,were compared between patients with spotty calcification ( n = 922 ) and those with no calcification ( n = 425 ) .,"['Clinical', 'characteristics', 'and', 'disease', 'progression', 'were', 'compared', 'between', 'patients', 'with', 'spotty', 'calcification', '(', 'n', '=', '922', ')', 'and', 'those', 'with', 'no', 'calcification', '(', 'n', '=', '425', ')', '.']","(0, 5)","(0, 48)",-1,ss_o,22538329,Abstract,5,test,gold,3313.0
4642,,"RESULTS Patients with spotty calcification were older ( age 56 years vs. 54 years ; p = 0.001 ) , more likely to be male ( 68 % vs. 54 % ;","p = 0.01 ) , and have a history of diabetes mellitus ( 30 % vs. 24 % ; p = 0.01 ) and myocardial infarction ( 28 % vs. 20 % ; p = 0.004 ) , and have lower on-treatment high-density lipoprotein cholesterol levels ( 48 ± 16 mg/dl vs. 51 ± 17 mg/dl ; p = 0.001 ) .","['RESULTS', 'Patients', 'with', 'spotty', 'calcification', 'were', 'older', '(', 'age', '56', 'years', 'vs.', '54', 'years', ';', 'p', '=', '0.001', ')', ',', 'more', 'likely', 'to', 'be', 'male', '(', '68', '%', 'vs.', '54', '%', ';', 'p', '=', '0.01', ')', ',', 'and', 'have', 'a', 'history', 'of', 'diabetes', 'mellitus', '(', '30', '%', 'vs.', '24', '%', ';', 'p', '=', '0.01', ')', 'and', 'myocardial', 'infarction', '(', '28', '%', 'vs.', '20', '%', ';', 'p', '=', '0.004', ')', ',', 'and', 'have', 'lower', 'on-treatment', 'high-density', 'lipoprotein', 'cholesterol', 'levels', '(', '48', '±', '16', 'mg/dl', 'vs.', '51', '±', '17', 'mg/dl', ';', 'p', '=', '0.001', ')', '.']","(0, 32)","(0, 138)",-1,ss_p,22538329,Abstract,6,test,gold,5875.0
4643,"RESULTS Patients with spotty calcification were older ( age 56 years vs. 54 years ; p = 0.001 ) , more likely to be male ( 68 % vs. 54 % ; p = 0.01 ) , and have a history of diabetes mellitus ( 30 % vs. 24 % ; p = 0.01 ) and myocardial infarction ( 28 % vs. 20 % ; p = 0.004 ) , and have lower on-treatment high-density lipoprotein cholesterol levels ( 48 ± 16 mg/dl vs. 51 ± 17 mg/dl ; p =",0.001 ),.,"['RESULTS', 'Patients', 'with', 'spotty', 'calcification', 'were', 'older', '(', 'age', '56', 'years', 'vs.', '54', 'years', ';', 'p', '=', '0.001', ')', ',', 'more', 'likely', 'to', 'be', 'male', '(', '68', '%', 'vs.', '54', '%', ';', 'p', '=', '0.01', ')', ',', 'and', 'have', 'a', 'history', 'of', 'diabetes', 'mellitus', '(', '30', '%', 'vs.', '24', '%', ';', 'p', '=', '0.01', ')', 'and', 'myocardial', 'infarction', '(', '28', '%', 'vs.', '20', '%', ';', 'p', '=', '0.004', ')', ',', 'and', 'have', 'lower', 'on-treatment', 'high-density', 'lipoprotein', 'cholesterol', 'levels', '(', '48', '±', '16', 'mg/dl', 'vs.', '51', '±', '17', 'mg/dl', ';', 'p', '=', '0.001', ')', '.']","(91, 93)","(390, 397)",-1,ss_p,22538329,Abstract,6,test,gold,
4644,"RESULTS Patients with spotty calcification were older ( age 56 years vs. 54 years ; p = 0.001 ) , more likely to be male ( 68 % vs. 54 % ; p = 0.01 ) , and have a history of diabetes mellitus ( 30 % vs. 24 % ; p = 0.01 ) and myocardial infarction ( 28 % vs. 20 % ; p = 0.004 ) , and have lower",on-treatment high-density lipoprotein cholesterol levels,( 48 ± 16 mg/dl vs. 51 ± 17 mg/dl ; p = 0.001 ) .,"['RESULTS', 'Patients', 'with', 'spotty', 'calcification', 'were', 'older', '(', 'age', '56', 'years', 'vs.', '54', 'years', ';', 'p', '=', '0.001', ')', ',', 'more', 'likely', 'to', 'be', 'male', '(', '68', '%', 'vs.', '54', '%', ';', 'p', '=', '0.01', ')', ',', 'and', 'have', 'a', 'history', 'of', 'diabetes', 'mellitus', '(', '30', '%', 'vs.', '24', '%', ';', 'p', '=', '0.01', ')', 'and', 'myocardial', 'infarction', '(', '28', '%', 'vs.', '20', '%', ';', 'p', '=', '0.004', ')', ',', 'and', 'have', 'lower', 'on-treatment', 'high-density', 'lipoprotein', 'cholesterol', 'levels', '(', '48', '±', '16', 'mg/dl', 'vs.', '51', '±', '17', 'mg/dl', ';', 'p', '=', '0.001', ')', '.']","(73, 78)","(293, 349)",-1,ss_o,22538329,Abstract,6,test,gold,6556.0
4645,Patients with spotty calcification demonstrated a,greater percent atheroma volume ( PAV ),( 36.0 ± 7.6 % vs. 29.0 ± 8.5 % ; p < 0.001 ) and total atheroma volume ( 174.6 ± 71.9 mm ( 3 ) vs. 133.9 ± 64.9 mm ( 3 ) ; p < 0.001 ) .,"['Patients', 'with', 'spotty', 'calcification', 'demonstrated', 'a', 'greater', 'percent', 'atheroma', 'volume', '(', 'PAV', ')', '(', '36.0', '±', '7.6', '%', 'vs.', '29.0', '±', '8.5', '%', ';', 'p', '<', '0.001', ')', 'and', 'total', 'atheroma', 'volume', '(', '174.6', '±', '71.9', 'mm', '(', '3', ')', 'vs.', '133.9', '±', '64.9', 'mm', '(', '3', ')', ';', 'p', '<', '0.001', ')', '.']","(6, 13)","(49, 88)",-1,ss_o,22538329,Abstract,7,test,gold,1719.0
4646,Patients with spotty calcification demonstrated a greater percent atheroma volume ( PAV ) ( 36.0 ± 7.6 % vs. 29.0 ± 8.5 % ; p <,0.001 ) and total atheroma volume,( 174.6 ± 71.9 mm ( 3 ) vs. 133.9 ± 64.9 mm ( 3 ) ; p < 0.001 ) .,"['Patients', 'with', 'spotty', 'calcification', 'demonstrated', 'a', 'greater', 'percent', 'atheroma', 'volume', '(', 'PAV', ')', '(', '36.0', '±', '7.6', '%', 'vs.', '29.0', '±', '8.5', '%', ';', 'p', '<', '0.001', ')', 'and', 'total', 'atheroma', 'volume', '(', '174.6', '±', '71.9', 'mm', '(', '3', ')', 'vs.', '133.9', '±', '64.9', 'mm', '(', '3', ')', ';', 'p', '<', '0.001', ')', '.']","(26, 32)","(127, 160)",-1,ss_o,22538329,Abstract,7,test,gold,1715.0
4647,"On serial evaluation , spotty calcification was associated with",greater progression,of PAV ( +0.43 ± 0.07 % vs. +0.02 ± 0.11 % ; p = 0.002 ) .,"['On', 'serial', 'evaluation', ',', 'spotty', 'calcification', 'was', 'associated', 'with', 'greater', 'progression', 'of', 'PAV', '(', '+0.43', '±', '0.07', '%', 'vs.', '+0.02', '±', '0.11', '%', ';', 'p', '=', '0.002', ')', '.']","(9, 11)","(63, 82)",-1,ss_o,22538329,Abstract,8,test,gold,3332.0
4648,"On serial evaluation , spotty calcification was associated with",greater progression,of PAV ( +0.43 ± 0.07 % vs. +0.02 ± 0.11 % ; p = 0.002 ) .,"['On', 'serial', 'evaluation', ',', 'spotty', 'calcification', 'was', 'associated', 'with', 'greater', 'progression', 'of', 'PAV', '(', '+0.43', '±', '0.07', '%', 'vs.', '+0.02', '±', '0.11', '%', ';', 'p', '=', '0.002', ')', '.']","(9, 11)","(63, 82)",-1,hl_o,22538329,Abstract,8,test,gold,3333.0
4649,"Although intensive low-density lipoprotein cholesterol and blood pressure lowering therapy slowed disease progression , these efficacies were",attenuated in patients with spotty calcification,.,"['Although', 'intensive', 'low-density', 'lipoprotein', 'cholesterol', 'and', 'blood', 'pressure', 'lowering', 'therapy', 'slowed', 'disease', 'progression', ',', 'these', 'efficacies', 'were', 'attenuated', 'in', 'patients', 'with', 'spotty', 'calcification', '.']","(17, 23)","(141, 189)",-1,ss_p,22538329,Abstract,9,test,gold,3546.0
4650,CONCLUSIONS The presence of spotty calcification is associated with more extensive,and diffuse coronary atherosclerosis,and accelerated disease progression despite use of medical therapies .,"['CONCLUSIONS', 'The', 'presence', 'of', 'spotty', 'calcification', 'is', 'associated', 'with', 'more', 'extensive', 'and', 'diffuse', 'coronary', 'atherosclerosis', 'and', 'accelerated', 'disease', 'progression', 'despite', 'use', 'of', 'medical', 'therapies', '.']","(11, 15)","(82, 118)",-1,ss_o,22538329,Abstract,10,test,gold,6744.0
4651,CONCLUSIONS The presence of spotty calcification is associated with more extensive and diffuse coronary atherosclerosis and,accelerated disease progression,despite use of medical therapies .,"['CONCLUSIONS', 'The', 'presence', 'of', 'spotty', 'calcification', 'is', 'associated', 'with', 'more', 'extensive', 'and', 'diffuse', 'coronary', 'atherosclerosis', 'and', 'accelerated', 'disease', 'progression', 'despite', 'use', 'of', 'medical', 'therapies', '.']","(16, 19)","(123, 154)",-1,ss_o,22538329,Abstract,10,test,gold,3314.0
4652,CONCLUSIONS The presence of spotty calcification is associated with more extensive and diffuse,coronary atherosclerosis,and accelerated disease progression despite use of medical therapies .,"['CONCLUSIONS', 'The', 'presence', 'of', 'spotty', 'calcification', 'is', 'associated', 'with', 'more', 'extensive', 'and', 'diffuse', 'coronary', 'atherosclerosis', 'and', 'accelerated', 'disease', 'progression', 'despite', 'use', 'of', 'medical', 'therapies', '.']","(13, 15)","(94, 118)",-1,hl_o,22538329,Abstract,10,test,gold,6746.0
4653,Effects of guided imagery with relaxation training on anxiety and quality of life among,patients with inflammatory bowel disease .,,"['Effects', 'of', 'guided', 'imagery', 'with', 'relaxation', 'training', 'on', 'anxiety', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'inflammatory', 'bowel', 'disease', '.']","(14, 20)","(87, 129)",-1,ss_p,22646975,Title,0,test,gold,7040.0
4654,Effects of guided imagery with,relaxation training,on anxiety and quality of life among patients with inflammatory bowel disease .,"['Effects', 'of', 'guided', 'imagery', 'with', 'relaxation', 'training', 'on', 'anxiety', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'inflammatory', 'bowel', 'disease', '.']","(5, 7)","(30, 49)",-1,ss_i,22646975,Title,0,test,gold,2828.0
4655,Effects of guided imagery with relaxation training on,anxiety,and quality of life among patients with inflammatory bowel disease .,"['Effects', 'of', 'guided', 'imagery', 'with', 'relaxation', 'training', 'on', 'anxiety', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'inflammatory', 'bowel', 'disease', '.']","(8, 9)","(53, 60)",-1,ss_o,22646975,Title,0,test,gold,2438.0
4656,Effects of guided imagery with relaxation training on anxiety and,quality of life,among patients with inflammatory bowel disease .,"['Effects', 'of', 'guided', 'imagery', 'with', 'relaxation', 'training', 'on', 'anxiety', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'inflammatory', 'bowel', 'disease', '.']","(10, 13)","(65, 80)",-1,ss_o,22646975,Title,0,test,gold,1884.0
4657,Effects of guided imagery with relaxation training on anxiety and quality of life among,patients with inflammatory bowel disease .,,"['Effects', 'of', 'guided', 'imagery', 'with', 'relaxation', 'training', 'on', 'anxiety', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'inflammatory', 'bowel', 'disease', '.']","(14, 20)","(87, 129)",-1,hl_p,22646975,Title,0,test,gold,7041.0
4658,Effects of guided imagery with,relaxation training,on anxiety and quality of life among patients with inflammatory bowel disease .,"['Effects', 'of', 'guided', 'imagery', 'with', 'relaxation', 'training', 'on', 'anxiety', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'inflammatory', 'bowel', 'disease', '.']","(5, 7)","(30, 49)",-1,hl_i,22646975,Title,0,test,gold,2829.0
4659,Effects of guided imagery with relaxation training on,anxiety,and quality of life among patients with inflammatory bowel disease .,"['Effects', 'of', 'guided', 'imagery', 'with', 'relaxation', 'training', 'on', 'anxiety', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'inflammatory', 'bowel', 'disease', '.']","(8, 9)","(53, 60)",-1,hl_o,22646975,Title,0,test,gold,2437.0
4660,Effects of guided imagery with relaxation training on anxiety and,quality of life,among patients with inflammatory bowel disease .,"['Effects', 'of', 'guided', 'imagery', 'with', 'relaxation', 'training', 'on', 'anxiety', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'inflammatory', 'bowel', 'disease', '.']","(10, 13)","(65, 80)",-1,hl_o,22646975,Title,0,test,gold,1883.0
4661,BACKGROUND Inflammatory Bowel Disease ( IBD ) impacts,quality of life ( QoL ) .,,"['BACKGROUND', 'Inflammatory', 'Bowel', 'Disease', '(', 'IBD', ')', 'impacts', 'quality', 'of', 'life', '(', 'QoL', ')', '.']","(8, 15)","(53, 78)",-1,ss_o,22646975,Abstract,0,test,gold,1896.0
4662,BACKGROUND Inflammatory Bowel Disease ( IBD ) impacts,quality of life ( QoL ) .,,"['BACKGROUND', 'Inflammatory', 'Bowel', 'Disease', '(', 'IBD', ')', 'impacts', 'quality', 'of', 'life', '(', 'QoL', ')', '.']","(8, 15)","(53, 78)",-1,hl_o,22646975,Abstract,0,test,gold,1897.0
4663,Psychological factors influence the course of the disease and should be targeted for intervention .,,,"['Psychological', 'factors', 'influence', 'the', 'course', 'of', 'the', 'disease', 'and', 'should', 'be', 'targeted', 'for', 'intervention', '.']",,,,,22646975,Abstract,1,test,gold,
4664,"METHODS Our study was a prospective , randomised control trial .",,,"['METHODS', 'Our', 'study', 'was', 'a', 'prospective', ',', 'randomised', 'control', 'trial', '.']",,,,,22646975,Abstract,2,test,gold,
4665,,Fifty-six outpatients,were randomly chosen and allocated to a treatment group or a waiting-list control group .,"['Fifty-six', 'outpatients', 'were', 'randomly', 'chosen', 'and', 'allocated', 'to', 'a', 'treatment', 'group', 'or', 'a', 'waiting-list', 'control', 'group', '.']","(0, 2)","(0, 21)",-1,ss_p,22646975,Abstract,3,test,gold,3728.0
4666,,Fifty-six outpatients,were randomly chosen and allocated to a treatment group or a waiting-list control group .,"['Fifty-six', 'outpatients', 'were', 'randomly', 'chosen', 'and', 'allocated', 'to', 'a', 'treatment', 'group', 'or', 'a', 'waiting-list', 'control', 'group', '.']","(0, 2)","(0, 21)",-1,hl_p,22646975,Abstract,3,test,gold,3729.0
4667,Treatment group patients attended three,relaxation-training sessions,and received an audio disc for home practice .,"['Treatment', 'group', 'patients', 'attended', 'three', 'relaxation-training', 'sessions', 'and', 'received', 'an', 'audio', 'disc', 'for', 'home', 'practice', '.']","(5, 7)","(39, 67)",-1,ss_i,22646975,Abstract,4,test,gold,1275.0
4668,Treatment group patients attended three,relaxation-training sessions,and received an audio disc for home practice .,"['Treatment', 'group', 'patients', 'attended', 'three', 'relaxation-training', 'sessions', 'and', 'received', 'an', 'audio', 'disc', 'for', 'home', 'practice', '.']","(5, 7)","(39, 67)",-1,hl_i,22646975,Abstract,4,test,gold,1276.0
4669,Evaluations performed pre and post-treatment :,"state anxiety was assessed with the State-Trait Anxiety Inventory , QoL with the IBD Questionnaire .",,"['Evaluations', 'performed', 'pre', 'and', 'post-treatment', ':', 'state', 'anxiety', 'was', 'assessed', 'with', 'the', 'State-Trait', 'Anxiety', 'Inventory', ',', 'QoL', 'with', 'the', 'IBD', 'Questionnaire', '.']","(6, 22)","(46, 146)",-1,ss_o,22646975,Abstract,5,test,gold,6276.0
4670,Evaluations performed pre and post-treatment :,state anxiety,"was assessed with the State-Trait Anxiety Inventory , QoL with the IBD Questionnaire .","['Evaluations', 'performed', 'pre', 'and', 'post-treatment', ':', 'state', 'anxiety', 'was', 'assessed', 'with', 'the', 'State-Trait', 'Anxiety', 'Inventory', ',', 'QoL', 'with', 'the', 'IBD', 'Questionnaire', '.']","(6, 8)","(46, 59)",-1,hl_o,22646975,Abstract,5,test,gold,2434.0
4671,Evaluations performed pre and post-treatment : state anxiety was assessed with the,"State-Trait Anxiety Inventory , QoL with the IBD Questionnaire .",,"['Evaluations', 'performed', 'pre', 'and', 'post-treatment', ':', 'state', 'anxiety', 'was', 'assessed', 'with', 'the', 'State-Trait', 'Anxiety', 'Inventory', ',', 'QoL', 'with', 'the', 'IBD', 'Questionnaire', '.']","(12, 22)","(82, 146)",-1,hl_o,22646975,Abstract,5,test,gold,6277.0
4672,,"The Visual Analogue Scale assessed pain , depression , stress and mood .",,"['The', 'Visual', 'Analogue', 'Scale', 'assessed', 'pain', ',', 'depression', ',', 'stress', 'and', 'mood', '.']","(0, 13)","(0, 72)",-1,ss_o,22646975,Abstract,6,test,gold,7120.0
4673,The,Visual Analogue Scale,"assessed pain , depression , stress and mood .","['The', 'Visual', 'Analogue', 'Scale', 'assessed', 'pain', ',', 'depression', ',', 'stress', 'and', 'mood', '.']","(1, 4)","(3, 24)",-1,hl_o,22646975,Abstract,6,test,gold,6226.0
4674,The Visual Analogue Scale assessed,pain,", depression , stress and mood .","['The', 'Visual', 'Analogue', 'Scale', 'assessed', 'pain', ',', 'depression', ',', 'stress', 'and', 'mood', '.']","(5, 6)","(34, 38)",-1,hl_o,22646975,Abstract,6,test,gold,2299.0
4675,"The Visual Analogue Scale assessed pain ,",depression,", stress and mood .","['The', 'Visual', 'Analogue', 'Scale', 'assessed', 'pain', ',', 'depression', ',', 'stress', 'and', 'mood', '.']","(7, 8)","(41, 51)",-1,hl_o,22646975,Abstract,6,test,gold,2547.0
4676,"The Visual Analogue Scale assessed pain , depression ,",stress,and mood .,"['The', 'Visual', 'Analogue', 'Scale', 'assessed', 'pain', ',', 'depression', ',', 'stress', 'and', 'mood', '.']","(9, 10)","(54, 60)",-1,hl_o,22646975,Abstract,6,test,gold,2447.0
4677,"The Visual Analogue Scale assessed pain , depression , stress and",mood,.,"['The', 'Visual', 'Analogue', 'Scale', 'assessed', 'pain', ',', 'depression', ',', 'stress', 'and', 'mood', '.']","(11, 12)","(65, 69)",-1,hl_o,22646975,Abstract,6,test,gold,1239.0
4678,Patients completed a,symptom monitoring diary .,,"['Patients', 'completed', 'a', 'symptom', 'monitoring', 'diary', '.']","(3, 7)","(20, 46)",-1,ss_o,22646975,Abstract,7,test,gold,3358.0
4679,The control group 's symptoms were monitored without study-related treatment .,,,"['The', 'control', 'group', ""'s"", 'symptoms', 'were', 'monitored', 'without', 'study-related', 'treatment', '.']",,,,,22646975,Abstract,8,test,gold,
4680,RESULTS,Thirty-nine subjects completed the study,and were included in the data analysis .,"['RESULTS', 'Thirty-nine', 'subjects', 'completed', 'the', 'study', 'and', 'were', 'included', 'in', 'the', 'data', 'analysis', '.']","(1, 6)","(7, 47)",-1,ss_p,22646975,Abstract,9,test,gold,2090.0
4681,RESULTS,Thirty-nine subjects completed the study,and were included in the data analysis .,"['RESULTS', 'Thirty-nine', 'subjects', 'completed', 'the', 'study', 'and', 'were', 'included', 'in', 'the', 'data', 'analysis', '.']","(1, 6)","(7, 47)",-1,hl_p,22646975,Abstract,9,test,gold,2091.0
4682,Following the,relaxation-training,"intervention , the treatment group 's ( n = 18 ) measured results showed a statistically significant improvement as compared to the control group ( n = 21 ) ( time by treatment interaction ) : anxiety levels decreased ( p < 0.01 ) , QoL and mood improved ( p < 0.05 ) , while levels of pain and stress decreased ( p < 0.01 ) .","['Following', 'the', 'relaxation-training', 'intervention', ',', 'the', 'treatment', 'group', ""'s"", '(', 'n', '=', '18', ')', 'measured', 'results', 'showed', 'a', 'statistically', 'significant', 'improvement', 'as', 'compared', 'to', 'the', 'control', 'group', '(', 'n', '=', '21', ')', '(', 'time', 'by', 'treatment', 'interaction', ')', ':', 'anxiety', 'levels', 'decreased', '(', 'p', '<', '0.01', ')', ',', 'QoL', 'and', 'mood', 'improved', '(', 'p', '<', '0.05', ')', ',', 'while', 'levels', 'of', 'pain', 'and', 'stress', 'decreased', '(', 'p', '<', '0.01', ')', '.']","(2, 3)","(13, 32)",-1,ss_i,22646975,Abstract,10,test,gold,
4683,"Following the relaxation-training intervention , the treatment group 's ( n = 18 ) measured results showed a statistically significant improvement as compared to the control group ( n = 21 ) ( time by treatment",interaction ) : anxiety,"levels decreased ( p < 0.01 ) , QoL and mood improved ( p < 0.05 ) , while levels of pain and stress decreased ( p < 0.01 ) .","['Following', 'the', 'relaxation-training', 'intervention', ',', 'the', 'treatment', 'group', ""'s"", '(', 'n', '=', '18', ')', 'measured', 'results', 'showed', 'a', 'statistically', 'significant', 'improvement', 'as', 'compared', 'to', 'the', 'control', 'group', '(', 'n', '=', '21', ')', '(', 'time', 'by', 'treatment', 'interaction', ')', ':', 'anxiety', 'levels', 'decreased', '(', 'p', '<', '0.01', ')', ',', 'QoL', 'and', 'mood', 'improved', '(', 'p', '<', '0.05', ')', ',', 'while', 'levels', 'of', 'pain', 'and', 'stress', 'decreased', '(', 'p', '<', '0.01', ')', '.']","(36, 40)","(210, 233)",-1,ss_o,22646975,Abstract,10,test,gold,2433.0
4684,"Following the relaxation-training intervention , the treatment group 's ( n = 18 ) measured results showed a statistically significant improvement as compared to the control group ( n = 21 ) ( time by treatment interaction ) : anxiety levels decreased","( p < 0.01 ) , QoL","and mood improved ( p < 0.05 ) , while levels of pain and stress decreased ( p < 0.01 ) .","['Following', 'the', 'relaxation-training', 'intervention', ',', 'the', 'treatment', 'group', ""'s"", '(', 'n', '=', '18', ')', 'measured', 'results', 'showed', 'a', 'statistically', 'significant', 'improvement', 'as', 'compared', 'to', 'the', 'control', 'group', '(', 'n', '=', '21', ')', '(', 'time', 'by', 'treatment', 'interaction', ')', ':', 'anxiety', 'levels', 'decreased', '(', 'p', '<', '0.01', ')', ',', 'QoL', 'and', 'mood', 'improved', '(', 'p', '<', '0.05', ')', ',', 'while', 'levels', 'of', 'pain', 'and', 'stress', 'decreased', '(', 'p', '<', '0.01', ')', '.']","(42, 49)","(251, 269)",-1,ss_o,22646975,Abstract,10,test,gold,373.0
4685,"Following the relaxation-training intervention , the treatment group 's ( n = 18 ) measured results showed a statistically significant improvement as compared to the control group ( n = 21 ) ( time by treatment interaction ) : anxiety levels decreased ( p < 0.01 ) , QoL and mood improved","( p < 0.05 ) , while levels of",pain and stress decreased ( p < 0.01 ) .,"['Following', 'the', 'relaxation-training', 'intervention', ',', 'the', 'treatment', 'group', ""'s"", '(', 'n', '=', '18', ')', 'measured', 'results', 'showed', 'a', 'statistically', 'significant', 'improvement', 'as', 'compared', 'to', 'the', 'control', 'group', '(', 'n', '=', '21', ')', '(', 'time', 'by', 'treatment', 'interaction', ')', ':', 'anxiety', 'levels', 'decreased', '(', 'p', '<', '0.01', ')', ',', 'QoL', 'and', 'mood', 'improved', '(', 'p', '<', '0.05', ')', ',', 'while', 'levels', 'of', 'pain', 'and', 'stress', 'decreased', '(', 'p', '<', '0.01', ')', '.']","(52, 61)","(288, 318)",-1,ss_o,22646975,Abstract,10,test,gold,816.0
4686,Following the,relaxation-training,"intervention , the treatment group 's ( n = 18 ) measured results showed a statistically significant improvement as compared to the control group ( n = 21 ) ( time by treatment interaction ) : anxiety levels decreased ( p < 0.01 ) , QoL and mood improved ( p < 0.05 ) , while levels of pain and stress decreased ( p < 0.01 ) .","['Following', 'the', 'relaxation-training', 'intervention', ',', 'the', 'treatment', 'group', ""'s"", '(', 'n', '=', '18', ')', 'measured', 'results', 'showed', 'a', 'statistically', 'significant', 'improvement', 'as', 'compared', 'to', 'the', 'control', 'group', '(', 'n', '=', '21', ')', '(', 'time', 'by', 'treatment', 'interaction', ')', ':', 'anxiety', 'levels', 'decreased', '(', 'p', '<', '0.01', ')', ',', 'QoL', 'and', 'mood', 'improved', '(', 'p', '<', '0.05', ')', ',', 'while', 'levels', 'of', 'pain', 'and', 'stress', 'decreased', '(', 'p', '<', '0.01', ')', '.']","(2, 3)","(13, 32)",-1,hl_i,22646975,Abstract,10,test,gold,
4687,CONCLUSIONS Findings indicate IBD,patients may benefit from,relaxation training in their holistic care .,"['CONCLUSIONS', 'Findings', 'indicate', 'IBD', 'patients', 'may', 'benefit', 'from', 'relaxation', 'training', 'in', 'their', 'holistic', 'care', '.']","(4, 8)","(33, 58)",-1,ss_i,22646975,Abstract,11,test,gold,3872.0
4688,New studies as well as further investigation of the subject are warranted .,,,"['New', 'studies', 'as', 'well', 'as', 'further', 'investigation', 'of', 'the', 'subject', 'are', 'warranted', '.']",,,,,22646975,Abstract,12,test,gold,
4689,Parent-implemented enhanced milieu teaching with,preschool children who have intellectual disabilities .,,"['Parent-implemented', 'enhanced', 'milieu', 'teaching', 'with', 'preschool', 'children', 'who', 'have', 'intellectual', 'disabilities', '.']","(5, 12)","(48, 103)",-1,ss_p,22744141,Title,0,test,gold,6206.0
4690,Parent-implemented,enhanced milieu teaching,with preschool children who have intellectual disabilities .,"['Parent-implemented', 'enhanced', 'milieu', 'teaching', 'with', 'preschool', 'children', 'who', 'have', 'intellectual', 'disabilities', '.']","(1, 4)","(18, 42)",-1,ss_i,22744141,Title,0,test,gold,2808.0
4691,Parent-implemented enhanced milieu teaching with,preschool children who have intellectual disabilities .,,"['Parent-implemented', 'enhanced', 'milieu', 'teaching', 'with', 'preschool', 'children', 'who', 'have', 'intellectual', 'disabilities', '.']","(5, 12)","(48, 103)",-1,hl_p,22744141,Title,0,test,gold,6207.0
4692,Parent-implemented,enhanced milieu teaching,with preschool children who have intellectual disabilities .,"['Parent-implemented', 'enhanced', 'milieu', 'teaching', 'with', 'preschool', 'children', 'who', 'have', 'intellectual', 'disabilities', '.']","(1, 4)","(18, 42)",-1,hl_i,22744141,Title,0,test,gold,2809.0
4693,PURPOSE The purpose of this study was to compare the effects of enhanced milieu teaching ( EMT ) implemented by parents and therapists versus therapists only on the language skills of,"preschool children with intellectual disabilities ( IDs ) , including children with Down syndrome and children with autism spectrum disorders .",,"['PURPOSE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'effects', 'of', 'enhanced', 'milieu', 'teaching', '(', 'EMT', ')', 'implemented', 'by', 'parents', 'and', 'therapists', 'versus', 'therapists', 'only', 'on', 'the', 'language', 'skills', 'of', 'preschool', 'children', 'with', 'intellectual', 'disabilities', '(', 'IDs', ')', ',', 'including', 'children', 'with', 'Down', 'syndrome', 'and', 'children', 'with', 'autism', 'spectrum', 'disorders', '.']","(31, 52)","(183, 326)",-1,ss_p,22744141,Abstract,0,test,gold,6056.0
4694,PURPOSE The purpose of this study was to compare the effects of,enhanced milieu teaching ( EMT ),"implemented by parents and therapists versus therapists only on the language skills of preschool children with intellectual disabilities ( IDs ) , including children with Down syndrome and children with autism spectrum disorders .","['PURPOSE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'effects', 'of', 'enhanced', 'milieu', 'teaching', '(', 'EMT', ')', 'implemented', 'by', 'parents', 'and', 'therapists', 'versus', 'therapists', 'only', 'on', 'the', 'language', 'skills', 'of', 'preschool', 'children', 'with', 'intellectual', 'disabilities', '(', 'IDs', ')', ',', 'including', 'children', 'with', 'Down', 'syndrome', 'and', 'children', 'with', 'autism', 'spectrum', 'disorders', '.']","(12, 18)","(63, 95)",-1,ss_i,22744141,Abstract,0,test,gold,2810.0
4695,PURPOSE The purpose of this study was to compare the effects of enhanced milieu teaching ( EMT ) implemented by parents and therapists versus therapists only on the,language skills,"of preschool children with intellectual disabilities ( IDs ) , including children with Down syndrome and children with autism spectrum disorders .","['PURPOSE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'effects', 'of', 'enhanced', 'milieu', 'teaching', '(', 'EMT', ')', 'implemented', 'by', 'parents', 'and', 'therapists', 'versus', 'therapists', 'only', 'on', 'the', 'language', 'skills', 'of', 'preschool', 'children', 'with', 'intellectual', 'disabilities', '(', 'IDs', ')', ',', 'including', 'children', 'with', 'Down', 'syndrome', 'and', 'children', 'with', 'autism', 'spectrum', 'disorders', '.']","(28, 30)","(164, 179)",-1,ss_o,22744141,Abstract,0,test,gold,2855.0
4696,PURPOSE The purpose of this study was to compare the effects of enhanced milieu teaching ( EMT ) implemented by parents and therapists versus therapists only on the language skills of,"preschool children with intellectual disabilities ( IDs ) , including children with Down syndrome and children with autism spectrum disorders .",,"['PURPOSE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'effects', 'of', 'enhanced', 'milieu', 'teaching', '(', 'EMT', ')', 'implemented', 'by', 'parents', 'and', 'therapists', 'versus', 'therapists', 'only', 'on', 'the', 'language', 'skills', 'of', 'preschool', 'children', 'with', 'intellectual', 'disabilities', '(', 'IDs', ')', ',', 'including', 'children', 'with', 'Down', 'syndrome', 'and', 'children', 'with', 'autism', 'spectrum', 'disorders', '.']","(31, 52)","(183, 326)",-1,hl_p,22744141,Abstract,0,test,gold,6057.0
4697,PURPOSE The purpose of this study was to compare the effects of,enhanced milieu teaching ( EMT ),"implemented by parents and therapists versus therapists only on the language skills of preschool children with intellectual disabilities ( IDs ) , including children with Down syndrome and children with autism spectrum disorders .","['PURPOSE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'effects', 'of', 'enhanced', 'milieu', 'teaching', '(', 'EMT', ')', 'implemented', 'by', 'parents', 'and', 'therapists', 'versus', 'therapists', 'only', 'on', 'the', 'language', 'skills', 'of', 'preschool', 'children', 'with', 'intellectual', 'disabilities', '(', 'IDs', ')', ',', 'including', 'children', 'with', 'Down', 'syndrome', 'and', 'children', 'with', 'autism', 'spectrum', 'disorders', '.']","(12, 18)","(63, 95)",-1,hl_i,22744141,Abstract,0,test,gold,2811.0
4698,METHOD,Seventy-seven children,were randomly assigned to 2 treatments ( parent + therapist EMT or therapist-only EMT ) and received 36 intervention sessions .,"['METHOD', 'Seventy-seven', 'children', 'were', 'randomly', 'assigned', 'to', '2', 'treatments', '(', 'parent', '+', 'therapist', 'EMT', 'or', 'therapist-only', 'EMT', ')', 'and', 'received', '36', 'intervention', 'sessions', '.']","(1, 3)","(6, 28)",-1,ss_p,22744141,Abstract,1,test,gold,2124.0
4699,METHOD Seventy-seven children were randomly assigned to 2 treatments,( parent + therapist EMT,or therapist-only EMT ) and received 36 intervention sessions .,"['METHOD', 'Seventy-seven', 'children', 'were', 'randomly', 'assigned', 'to', '2', 'treatments', '(', 'parent', '+', 'therapist', 'EMT', 'or', 'therapist-only', 'EMT', ')', 'and', 'received', '36', 'intervention', 'sessions', '.']","(9, 14)","(68, 92)",-1,ss_i,22744141,Abstract,1,test,gold,2812.0
4700,METHOD Seventy-seven children were randomly assigned to 2 treatments ( parent + therapist EMT or,therapist-only EMT ),and received 36 intervention sessions .,"['METHOD', 'Seventy-seven', 'children', 'were', 'randomly', 'assigned', 'to', '2', 'treatments', '(', 'parent', '+', 'therapist', 'EMT', 'or', 'therapist-only', 'EMT', ')', 'and', 'received', '36', 'intervention', 'sessions', '.']","(15, 18)","(96, 116)",-1,ss_i,22744141,Abstract,1,test,gold,2816.0
4701,METHOD,Seventy-seven children,were randomly assigned to 2 treatments ( parent + therapist EMT or therapist-only EMT ) and received 36 intervention sessions .,"['METHOD', 'Seventy-seven', 'children', 'were', 'randomly', 'assigned', 'to', '2', 'treatments', '(', 'parent', '+', 'therapist', 'EMT', 'or', 'therapist-only', 'EMT', ')', 'and', 'received', '36', 'intervention', 'sessions', '.']","(1, 3)","(6, 28)",-1,hl_p,22744141,Abstract,1,test,gold,2123.0
4702,METHOD Seventy-seven children were randomly assigned to 2 treatments (,parent + therapist EMT,or therapist-only EMT ) and received 36 intervention sessions .,"['METHOD', 'Seventy-seven', 'children', 'were', 'randomly', 'assigned', 'to', '2', 'treatments', '(', 'parent', '+', 'therapist', 'EMT', 'or', 'therapist-only', 'EMT', ')', 'and', 'received', '36', 'intervention', 'sessions', '.']","(10, 14)","(70, 92)",-1,hl_i,22744141,Abstract,1,test,gold,2813.0
4703,METHOD Seventy-seven children were randomly assigned to 2 treatments ( parent + therapist EMT or,therapist-only EMT,) and received 36 intervention sessions .,"['METHOD', 'Seventy-seven', 'children', 'were', 'randomly', 'assigned', 'to', '2', 'treatments', '(', 'parent', '+', 'therapist', 'EMT', 'or', 'therapist-only', 'EMT', ')', 'and', 'received', '36', 'intervention', 'sessions', '.']","(15, 17)","(96, 114)",-1,hl_i,22744141,Abstract,1,test,gold,2817.0
4704,"Children were assessed before , immediately after , 6 months after , and 12 months after intervention .",,,"['Children', 'were', 'assessed', 'before', ',', 'immediately', 'after', ',', '6', 'months', 'after', ',', 'and', '12', 'months', 'after', 'intervention', '.']",,,,,22744141,Abstract,2,test,gold,
4705,Separate linear regressions were conducted for each,standardized and observational measure,at each time point .,"['Separate', 'linear', 'regressions', 'were', 'conducted', 'for', 'each', 'standardized', 'and', 'observational', 'measure', 'at', 'each', 'time', 'point', '.']","(7, 11)","(51, 89)",-1,ss_o,22744141,Abstract,3,test,gold,1839.0
4706,RESULTS Parents in the parent + therapist group demonstrated greater use of,EMT,"strategies at home than untrained parents in the therapist-only group , and these effects maintained over time .","['RESULTS', 'Parents', 'in', 'the', 'parent', '+', 'therapist', 'group', 'demonstrated', 'greater', 'use', 'of', 'EMT', 'strategies', 'at', 'home', 'than', 'untrained', 'parents', 'in', 'the', 'therapist-only', 'group', ',', 'and', 'these', 'effects', 'maintained', 'over', 'time', '.']","(12, 13)","(75, 78)",-1,ss_i,22744141,Abstract,4,test,gold,2815.0
4707,RESULTS Parents in the parent + therapist group demonstrated greater,use of EMT strategies,"at home than untrained parents in the therapist-only group , and these effects maintained over time .","['RESULTS', 'Parents', 'in', 'the', 'parent', '+', 'therapist', 'group', 'demonstrated', 'greater', 'use', 'of', 'EMT', 'strategies', 'at', 'home', 'than', 'untrained', 'parents', 'in', 'the', 'therapist-only', 'group', ',', 'and', 'these', 'effects', 'maintained', 'over', 'time', '.']","(10, 14)","(68, 89)",-1,ss_o,22744141,Abstract,4,test,gold,2818.0
4708,RESULTS Parents in the parent + therapist group demonstrated greater use of,EMT,"strategies at home than untrained parents in the therapist-only group , and these effects maintained over time .","['RESULTS', 'Parents', 'in', 'the', 'parent', '+', 'therapist', 'group', 'demonstrated', 'greater', 'use', 'of', 'EMT', 'strategies', 'at', 'home', 'than', 'untrained', 'parents', 'in', 'the', 'therapist-only', 'group', ',', 'and', 'these', 'effects', 'maintained', 'over', 'time', '.']","(12, 13)","(75, 78)",-1,hl_i,22744141,Abstract,4,test,gold,2814.0
4709,RESULTS Parents in the parent + therapist group demonstrated greater use of,EMT strategies,"at home than untrained parents in the therapist-only group , and these effects maintained over time .","['RESULTS', 'Parents', 'in', 'the', 'parent', '+', 'therapist', 'group', 'demonstrated', 'greater', 'use', 'of', 'EMT', 'strategies', 'at', 'home', 'than', 'untrained', 'parents', 'in', 'the', 'therapist-only', 'group', ',', 'and', 'these', 'effects', 'maintained', 'over', 'time', '.']","(12, 14)","(75, 89)",-1,hl_o,22744141,Abstract,4,test,gold,2819.0
4710,Effect sizes for,observational measures,"ranged from d = 0.10 to d = 1.32 favoring the parent + therapist group , with the largest effect sizes found 12 months after intervention .","['Effect', 'sizes', 'for', 'observational', 'measures', 'ranged', 'from', 'd', '=', '0.10', 'to', 'd', '=', '1.32', 'favoring', 'the', 'parent', '+', 'therapist', 'group', ',', 'with', 'the', 'largest', 'effect', 'sizes', 'found', '12', 'months', 'after', 'intervention', '.']","(3, 5)","(16, 38)",-1,ss_o,22744141,Abstract,5,test,gold,1840.0
4711,Effect sizes for,observational measures,"ranged from d = 0.10 to d = 1.32 favoring the parent + therapist group , with the largest effect sizes found 12 months after intervention .","['Effect', 'sizes', 'for', 'observational', 'measures', 'ranged', 'from', 'd', '=', '0.10', 'to', 'd', '=', '1.32', 'favoring', 'the', 'parent', '+', 'therapist', 'group', ',', 'with', 'the', 'largest', 'effect', 'sizes', 'found', '12', 'months', 'after', 'intervention', '.']","(3, 5)","(16, 38)",-1,hl_o,22744141,Abstract,5,test,gold,1841.0
4712,CONCLUSION Findings from this study indicate generally that there are benefits to training parents to implement naturalistic language intervention strategies with,preschool children who have ID and significant language impairments .,,"['CONCLUSION', 'Findings', 'from', 'this', 'study', 'indicate', 'generally', 'that', 'there', 'are', 'benefits', 'to', 'training', 'parents', 'to', 'implement', 'naturalistic', 'language', 'intervention', 'strategies', 'with', 'preschool', 'children', 'who', 'have', 'ID', 'and', 'significant', 'language', 'impairments', '.']","(21, 31)","(162, 231)",-1,ss_p,22744141,Abstract,6,test,gold,6204.0
4713,CONCLUSION Findings from this study indicate generally that there are benefits to training parents to implement naturalistic language intervention strategies with,preschool children who have ID and significant language impairments .,,"['CONCLUSION', 'Findings', 'from', 'this', 'study', 'indicate', 'generally', 'that', 'there', 'are', 'benefits', 'to', 'training', 'parents', 'to', 'implement', 'naturalistic', 'language', 'intervention', 'strategies', 'with', 'preschool', 'children', 'who', 'have', 'ID', 'and', 'significant', 'language', 'impairments', '.']","(21, 31)","(162, 231)",-1,hl_p,22744141,Abstract,6,test,gold,6205.0
4714,RESPECT-PTSD : re-engineering systems for the primary care treatment of,PTSD,", a randomized controlled trial .","['RESPECT-PTSD', ':', 're-engineering', 'systems', 'for', 'the', 'primary', 'care', 'treatment', 'of', 'PTSD', ',', 'a', 'randomized', 'controlled', 'trial', '.']","(10, 11)","(71, 75)",-1,ss_p,22865017,Title,0,test,gold,2561.0
4715,RESPECT-PTSD : re-engineering systems for the primary care treatment of,PTSD,", a randomized controlled trial .","['RESPECT-PTSD', ':', 're-engineering', 'systems', 'for', 'the', 'primary', 'care', 'treatment', 'of', 'PTSD', ',', 'a', 'randomized', 'controlled', 'trial', '.']","(10, 11)","(71, 75)",-1,hl_p,22865017,Title,0,test,gold,2562.0
4716,"BACKGROUND Although collaborative care is effective for treating depression and other mental disorders in primary care , there have been no randomized trials of collaborative care specifically for",patients with Posttraumatic stress disorder ( PTSD ) .,,"['BACKGROUND', 'Although', 'collaborative', 'care', 'is', 'effective', 'for', 'treating', 'depression', 'and', 'other', 'mental', 'disorders', 'in', 'primary', 'care', ',', 'there', 'have', 'been', 'no', 'randomized', 'trials', 'of', 'collaborative', 'care', 'specifically', 'for', 'patients', 'with', 'Posttraumatic', 'stress', 'disorder', '(', 'PTSD', ')', '.']","(28, 37)","(196, 250)",-1,ss_p,22865017,Abstract,0,test,gold,6965.0
4717,BACKGROUND Although,collaborative care,"is effective for treating depression and other mental disorders in primary care , there have been no randomized trials of collaborative care specifically for patients with Posttraumatic stress disorder ( PTSD ) .","['BACKGROUND', 'Although', 'collaborative', 'care', 'is', 'effective', 'for', 'treating', 'depression', 'and', 'other', 'mental', 'disorders', 'in', 'primary', 'care', ',', 'there', 'have', 'been', 'no', 'randomized', 'trials', 'of', 'collaborative', 'care', 'specifically', 'for', 'patients', 'with', 'Posttraumatic', 'stress', 'disorder', '(', 'PTSD', ')', '.']","(2, 4)","(19, 37)",-1,ss_i,22865017,Abstract,0,test,gold,3952.0
4718,"BACKGROUND Although collaborative care is effective for treating depression and other mental disorders in primary care , there have been no randomized trials of collaborative care specifically for",patients with Posttraumatic stress disorder ( PTSD ) .,,"['BACKGROUND', 'Although', 'collaborative', 'care', 'is', 'effective', 'for', 'treating', 'depression', 'and', 'other', 'mental', 'disorders', 'in', 'primary', 'care', ',', 'there', 'have', 'been', 'no', 'randomized', 'trials', 'of', 'collaborative', 'care', 'specifically', 'for', 'patients', 'with', 'Posttraumatic', 'stress', 'disorder', '(', 'PTSD', ')', '.']","(28, 37)","(196, 250)",-1,hl_p,22865017,Abstract,0,test,gold,6966.0
4719,"OBJECTIVE To compare a collaborative approach , the Three Component Model ( 3CM ) , with usual care for treating",PTSD,in primary care .,"['OBJECTIVE', 'To', 'compare', 'a', 'collaborative', 'approach', ',', 'the', 'Three', 'Component', 'Model', '(', '3CM', ')', ',', 'with', 'usual', 'care', 'for', 'treating', 'PTSD', 'in', 'primary', 'care', '.']","(20, 21)","(112, 116)",-1,ss_p,22865017,Abstract,1,test,gold,2560.0
4720,"OBJECTIVE To compare a collaborative approach , the",Three Component Model ( 3CM ),", with usual care for treating PTSD in primary care .","['OBJECTIVE', 'To', 'compare', 'a', 'collaborative', 'approach', ',', 'the', 'Three', 'Component', 'Model', '(', '3CM', ')', ',', 'with', 'usual', 'care', 'for', 'treating', 'PTSD', 'in', 'primary', 'care', '.']","(8, 14)","(51, 80)",-1,ss_i,22865017,Abstract,1,test,gold,592.0
4721,"OBJECTIVE To compare a collaborative approach , the Three Component Model ( 3CM ) , with",usual care,for treating PTSD in primary care .,"['OBJECTIVE', 'To', 'compare', 'a', 'collaborative', 'approach', ',', 'the', 'Three', 'Component', 'Model', '(', '3CM', ')', ',', 'with', 'usual', 'care', 'for', 'treating', 'PTSD', 'in', 'primary', 'care', '.']","(16, 18)","(88, 98)",-1,ss_i,22865017,Abstract,1,test,gold,3924.0
4722,"OBJECTIVE To compare a collaborative approach , the",Three Component Model ( 3CM ),", with usual care for treating PTSD in primary care .","['OBJECTIVE', 'To', 'compare', 'a', 'collaborative', 'approach', ',', 'the', 'Three', 'Component', 'Model', '(', '3CM', ')', ',', 'with', 'usual', 'care', 'for', 'treating', 'PTSD', 'in', 'primary', 'care', '.']","(8, 14)","(51, 80)",-1,hl_i,22865017,Abstract,1,test,gold,593.0
4723,"OBJECTIVE To compare a collaborative approach , the Three Component Model ( 3CM ) , with",usual care,for treating PTSD in primary care .,"['OBJECTIVE', 'To', 'compare', 'a', 'collaborative', 'approach', ',', 'the', 'Three', 'Component', 'Model', '(', '3CM', ')', ',', 'with', 'usual', 'care', 'for', 'treating', 'PTSD', 'in', 'primary', 'care', '.']","(16, 18)","(88, 98)",-1,hl_i,22865017,Abstract,1,test,gold,3923.0
4724,"DESIGN The study was a two-arm , parallel randomized clinical trial .",,,"['DESIGN', 'The', 'study', 'was', 'a', 'two-arm', ',', 'parallel', 'randomized', 'clinical', 'trial', '.']",,,,,22865017,Abstract,2,test,gold,
4725,,PTSD patients were recruited from five primary care clinics at four Veterans Affairs healthcare facilities,and randomized to receive usual care or usual care plus 3CM .,"['PTSD', 'patients', 'were', 'recruited', 'from', 'five', 'primary', 'care', 'clinics', 'at', 'four', 'Veterans', 'Affairs', 'healthcare', 'facilities', 'and', 'randomized', 'to', 'receive', 'usual', 'care', 'or', 'usual', 'care', 'plus', '3CM', '.']","(0, 15)","(0, 106)",-1,ss_p,22865017,Abstract,3,test,gold,5884.0
4726,PTSD patients were recruited from five primary care clinics at four Veterans Affairs healthcare facilities and randomized to receive,usual care,or usual care plus 3CM .,"['PTSD', 'patients', 'were', 'recruited', 'from', 'five', 'primary', 'care', 'clinics', 'at', 'four', 'Veterans', 'Affairs', 'healthcare', 'facilities', 'and', 'randomized', 'to', 'receive', 'usual', 'care', 'or', 'usual', 'care', 'plus', '3CM', '.']","(19, 21)","(132, 142)",-1,ss_i,22865017,Abstract,3,test,gold,3922.0
4727,PTSD patients were recruited from five primary care clinics at four Veterans Affairs healthcare facilities and randomized to receive usual care or,usual care plus 3CM .,,"['PTSD', 'patients', 'were', 'recruited', 'from', 'five', 'primary', 'care', 'clinics', 'at', 'four', 'Veterans', 'Affairs', 'healthcare', 'facilities', 'and', 'randomized', 'to', 'receive', 'usual', 'care', 'or', 'usual', 'care', 'plus', '3CM', '.']","(22, 27)","(146, 167)",-1,ss_i,22865017,Abstract,3,test,gold,3917.0
4728,,PTSD,patients were recruited from five primary care clinics at four Veterans Affairs healthcare facilities and randomized to receive usual care or usual care plus 3CM .,"['PTSD', 'patients', 'were', 'recruited', 'from', 'five', 'primary', 'care', 'clinics', 'at', 'four', 'Veterans', 'Affairs', 'healthcare', 'facilities', 'and', 'randomized', 'to', 'receive', 'usual', 'care', 'or', 'usual', 'care', 'plus', '3CM', '.']","(0, 1)","(0, 4)",-1,hl_p,22865017,Abstract,3,test,gold,2559.0
4729,PTSD patients were recruited from,five primary care clinics at four Veterans Affairs healthcare facilities,and randomized to receive usual care or usual care plus 3CM .,"['PTSD', 'patients', 'were', 'recruited', 'from', 'five', 'primary', 'care', 'clinics', 'at', 'four', 'Veterans', 'Affairs', 'healthcare', 'facilities', 'and', 'randomized', 'to', 'receive', 'usual', 'care', 'or', 'usual', 'care', 'plus', '3CM', '.']","(5, 15)","(33, 105)",-1,hl_p,22865017,Abstract,3,test,gold,5885.0
4730,PTSD patients were recruited from five primary care clinics at four Veterans Affairs healthcare facilities and randomized to receive,usual care,or usual care plus 3CM .,"['PTSD', 'patients', 'were', 'recruited', 'from', 'five', 'primary', 'care', 'clinics', 'at', 'four', 'Veterans', 'Affairs', 'healthcare', 'facilities', 'and', 'randomized', 'to', 'receive', 'usual', 'care', 'or', 'usual', 'care', 'plus', '3CM', '.']","(19, 21)","(132, 142)",-1,hl_i,22865017,Abstract,3,test,gold,3921.0
4731,PTSD patients were recruited from five primary care clinics at four Veterans Affairs healthcare facilities and randomized to receive usual care or,usual care,plus 3CM .,"['PTSD', 'patients', 'were', 'recruited', 'from', 'five', 'primary', 'care', 'clinics', 'at', 'four', 'Veterans', 'Affairs', 'healthcare', 'facilities', 'and', 'randomized', 'to', 'receive', 'usual', 'care', 'or', 'usual', 'care', 'plus', '3CM', '.']","(22, 24)","(146, 156)",-1,hl_i,22865017,Abstract,3,test,gold,3920.0
4732,PTSD patients were recruited from five primary care clinics at four Veterans Affairs healthcare facilities and randomized to receive usual care or usual care plus,3CM,.,"['PTSD', 'patients', 'were', 'recruited', 'from', 'five', 'primary', 'care', 'clinics', 'at', 'four', 'Veterans', 'Affairs', 'healthcare', 'facilities', 'and', 'randomized', 'to', 'receive', 'usual', 'care', 'or', 'usual', 'care', 'plus', '3CM', '.']","(25, 26)","(162, 165)",-1,hl_i,22865017,Abstract,3,test,gold,
4733,Blinded assessors collected data at baseline and 3-month and 6-month follow-up .,,,"['Blinded', 'assessors', 'collected', 'data', 'at', 'baseline', 'and', '3-month', 'and', '6-month', 'follow-up', '.']",,,,,22865017,Abstract,4,test,gold,
4734,PARTICIPANTS,Participants were 195 Veterans .,,"['PARTICIPANTS', 'Participants', 'were', '195', 'Veterans', '.']","(1, 6)","(12, 44)",-1,ss_p,22865017,Abstract,5,test,gold,2173.0
4735,PARTICIPANTS Participants were,195 Veterans,.,"['PARTICIPANTS', 'Participants', 'were', '195', 'Veterans', '.']","(3, 5)","(30, 42)",-1,hl_p,22865017,Abstract,5,test,gold,2179.0
4736,,"Their average age was 45 years , 91 % were male , 58 % were white , 40 % served in Iraq or Afghanistan , and 42 % served in Vietnam .",,"['Their', 'average', 'age', 'was', '45', 'years', ',', '91', '%', 'were', 'male', ',', '58', '%', 'were', 'white', ',', '40', '%', 'served', 'in', 'Iraq', 'or', 'Afghanistan', ',', 'and', '42', '%', 'served', 'in', 'Vietnam', '.']","(0, 32)","(0, 133)",-1,ss_p,22865017,Abstract,6,test,gold,5876.0
4737,Their,average age was 45 years,", 91 % were male , 58 % were white , 40 % served in Iraq or Afghanistan , and 42 % served in Vietnam .","['Their', 'average', 'age', 'was', '45', 'years', ',', '91', '%', 'were', 'male', ',', '58', '%', 'were', 'white', ',', '40', '%', 'served', 'in', 'Iraq', 'or', 'Afghanistan', ',', 'and', '42', '%', 'served', 'in', 'Vietnam', '.']","(1, 6)","(5, 29)",-1,hl_p,22865017,Abstract,6,test,gold,2014.0
4738,"Their average age was 45 years ,",91 % were male,", 58 % were white , 40 % served in Iraq or Afghanistan , and 42 % served in Vietnam .","['Their', 'average', 'age', 'was', '45', 'years', ',', '91', '%', 'were', 'male', ',', '58', '%', 'were', 'white', ',', '40', '%', 'served', 'in', 'Iraq', 'or', 'Afghanistan', ',', 'and', '42', '%', 'served', 'in', 'Vietnam', '.']","(7, 11)","(32, 46)",-1,hl_p,22865017,Abstract,6,test,gold,1502.0
4739,INTERVENTION All participants received,usual care,.,"['INTERVENTION', 'All', 'participants', 'received', 'usual', 'care', '.']","(4, 6)","(38, 48)",-1,hl_i,22865017,Abstract,7,test,gold,3919.0
4740,Participants assigned to,3CM,also received telephone care management .,"['Participants', 'assigned', 'to', '3CM', 'also', 'received', 'telephone', 'care', 'management', '.']","(3, 4)","(24, 27)",-1,ss_i,22865017,Abstract,8,test,gold,
4741,Participants assigned to 3CM also received,telephone care management .,,"['Participants', 'assigned', 'to', '3CM', 'also', 'received', 'telephone', 'care', 'management', '.']","(6, 10)","(42, 69)",-1,ss_i,22865017,Abstract,8,test,gold,3945.0
4742,Participants assigned to,3CM,also received telephone care management .,"['Participants', 'assigned', 'to', '3CM', 'also', 'received', 'telephone', 'care', 'management', '.']","(3, 4)","(24, 27)",-1,hl_i,22865017,Abstract,8,test,gold,
4743,Participants assigned to 3CM also received,telephone care management .,,"['Participants', 'assigned', 'to', '3CM', 'also', 'received', 'telephone', 'care', 'management', '.']","(6, 10)","(42, 69)",-1,hl_i,22865017,Abstract,8,test,gold,3946.0
4744,Care managers received supervision from a psychiatrist .,,,"['Care', 'managers', 'received', 'supervision', 'from', 'a', 'psychiatrist', '.']",,,,,22865017,Abstract,9,test,gold,
4745,MAIN MEASURES,PTSD symptom severity,was the primary outcome .,"['MAIN', 'MEASURES', 'PTSD', 'symptom', 'severity', 'was', 'the', 'primary', 'outcome', '.']","(2, 5)","(13, 34)",-1,ss_o,22865017,Abstract,10,test,gold,3369.0
4746,MAIN MEASURES,PTSD symptom severity,was the primary outcome .,"['MAIN', 'MEASURES', 'PTSD', 'symptom', 'severity', 'was', 'the', 'primary', 'outcome', '.']","(2, 5)","(13, 34)",-1,hl_o,22865017,Abstract,10,test,gold,3370.0
4747,,"Depression , functioning , perceived quality of care , utilization , and costs",were secondary outcomes .,"['Depression', ',', 'functioning', ',', 'perceived', 'quality', 'of', 'care', ',', 'utilization', ',', 'and', 'costs', 'were', 'secondary', 'outcomes', '.']","(0, 13)","(0, 78)",-1,ss_o,22865017,Abstract,11,test,gold,6426.0
4748,,Depression,", functioning , perceived quality of care , utilization , and costs were secondary outcomes .","['Depression', ',', 'functioning', ',', 'perceived', 'quality', 'of', 'care', ',', 'utilization', ',', 'and', 'costs', 'were', 'secondary', 'outcomes', '.']","(0, 1)","(0, 10)",-1,hl_o,22865017,Abstract,11,test,gold,2554.0
4749,"Depression ,",functioning,", perceived quality of care , utilization , and costs were secondary outcomes .","['Depression', ',', 'functioning', ',', 'perceived', 'quality', 'of', 'care', ',', 'utilization', ',', 'and', 'costs', 'were', 'secondary', 'outcomes', '.']","(2, 3)","(12, 23)",-1,hl_o,22865017,Abstract,11,test,gold,2950.0
4750,"Depression , functioning ,",perceived quality of care,", utilization , and costs were secondary outcomes .","['Depression', ',', 'functioning', ',', 'perceived', 'quality', 'of', 'care', ',', 'utilization', ',', 'and', 'costs', 'were', 'secondary', 'outcomes', '.']","(4, 8)","(26, 51)",-1,hl_o,22865017,Abstract,11,test,gold,3957.0
4751,"Depression , functioning , perceived quality of care ,",utilization,", and costs were secondary outcomes .","['Depression', ',', 'functioning', ',', 'perceived', 'quality', 'of', 'care', ',', 'utilization', ',', 'and', 'costs', 'were', 'secondary', 'outcomes', '.']","(9, 10)","(54, 65)",-1,hl_o,22865017,Abstract,11,test,gold,1386.0
4752,"Depression , functioning , perceived quality of care , utilization , and",costs,were secondary outcomes .,"['Depression', ',', 'functioning', ',', 'perceived', 'quality', 'of', 'care', ',', 'utilization', ',', 'and', 'costs', 'were', 'secondary', 'outcomes', '.']","(12, 13)","(72, 77)",-1,hl_o,22865017,Abstract,11,test,gold,1009.0
4753,KEY RESULTS There were no differences between,3CM,and usual care in symptoms or functioning .,"['KEY', 'RESULTS', 'There', 'were', 'no', 'differences', 'between', '3CM', 'and', 'usual', 'care', 'in', 'symptoms', 'or', 'functioning', '.']","(7, 8)","(45, 48)",-1,ss_i,22865017,Abstract,12,test,gold,
4754,KEY RESULTS There were no differences between 3CM and,usual care,in symptoms or functioning .,"['KEY', 'RESULTS', 'There', 'were', 'no', 'differences', 'between', '3CM', 'and', 'usual', 'care', 'in', 'symptoms', 'or', 'functioning', '.']","(9, 11)","(53, 63)",-1,ss_i,22865017,Abstract,12,test,gold,3918.0
4755,KEY RESULTS There were no differences between 3CM and usual care in,symptoms or functioning .,,"['KEY', 'RESULTS', 'There', 'were', 'no', 'differences', 'between', '3CM', 'and', 'usual', 'care', 'in', 'symptoms', 'or', 'functioning', '.']","(12, 16)","(67, 92)",-1,ss_o,22865017,Abstract,12,test,gold,3283.0
4756,KEY RESULTS There were no differences between 3CM and usual care in,symptoms,or functioning .,"['KEY', 'RESULTS', 'There', 'were', 'no', 'differences', 'between', '3CM', 'and', 'usual', 'care', 'in', 'symptoms', 'or', 'functioning', '.']","(12, 13)","(67, 75)",-1,hl_o,22865017,Abstract,12,test,gold,3278.0
4757,KEY RESULTS There were no differences between 3CM and usual care in symptoms or,functioning .,,"['KEY', 'RESULTS', 'There', 'were', 'no', 'differences', 'between', '3CM', 'and', 'usual', 'care', 'in', 'symptoms', 'or', 'functioning', '.']","(14, 16)","(79, 92)",-1,hl_o,22865017,Abstract,12,test,gold,2951.0
4758,Participants assigned to,3CM,"were more likely to have a mental health visit , fill an antidepressant prescription , and have adequate antidepressant refills .","['Participants', 'assigned', 'to', '3CM', 'were', 'more', 'likely', 'to', 'have', 'a', 'mental', 'health', 'visit', ',', 'fill', 'an', 'antidepressant', 'prescription', ',', 'and', 'have', 'adequate', 'antidepressant', 'refills', '.']","(3, 4)","(24, 27)",-1,ss_i,22865017,Abstract,13,test,gold,
4759,Participants assigned to 3CM were more likely to have a,"mental health visit , fill an antidepressant prescription",", and have adequate antidepressant refills .","['Participants', 'assigned', 'to', '3CM', 'were', 'more', 'likely', 'to', 'have', 'a', 'mental', 'health', 'visit', ',', 'fill', 'an', 'antidepressant', 'prescription', ',', 'and', 'have', 'adequate', 'antidepressant', 'refills', '.']","(10, 18)","(55, 112)",-1,ss_o,22865017,Abstract,13,test,gold,7084.0
4760,"Participants assigned to 3CM were more likely to have a mental health visit , fill an antidepressant prescription , and have",adequate antidepressant refills .,,"['Participants', 'assigned', 'to', '3CM', 'were', 'more', 'likely', 'to', 'have', 'a', 'mental', 'health', 'visit', ',', 'fill', 'an', 'antidepressant', 'prescription', ',', 'and', 'have', 'adequate', 'antidepressant', 'refills', '.']","(21, 25)","(124, 157)",-1,ss_o,22865017,Abstract,13,test,gold,5059.0
4761,Participants assigned to,3CM,"were more likely to have a mental health visit , fill an antidepressant prescription , and have adequate antidepressant refills .","['Participants', 'assigned', 'to', '3CM', 'were', 'more', 'likely', 'to', 'have', 'a', 'mental', 'health', 'visit', ',', 'fill', 'an', 'antidepressant', 'prescription', ',', 'and', 'have', 'adequate', 'antidepressant', 'refills', '.']","(3, 4)","(24, 27)",-1,hl_i,22865017,Abstract,13,test,gold,
4762,Participants assigned to 3CM were more likely to have a,"mental health visit , fill an antidepressant prescription",", and have adequate antidepressant refills .","['Participants', 'assigned', 'to', '3CM', 'were', 'more', 'likely', 'to', 'have', 'a', 'mental', 'health', 'visit', ',', 'fill', 'an', 'antidepressant', 'prescription', ',', 'and', 'have', 'adequate', 'antidepressant', 'refills', '.']","(10, 18)","(55, 112)",-1,hl_o,22865017,Abstract,13,test,gold,7085.0
4763,"Participants assigned to 3CM were more likely to have a mental health visit , fill an antidepressant prescription , and have",adequate antidepressant refills .,,"['Participants', 'assigned', 'to', '3CM', 'were', 'more', 'likely', 'to', 'have', 'a', 'mental', 'health', 'visit', ',', 'fill', 'an', 'antidepressant', 'prescription', ',', 'and', 'have', 'adequate', 'antidepressant', 'refills', '.']","(21, 25)","(124, 157)",-1,hl_o,22865017,Abstract,13,test,gold,5060.0
4764,,3CM,participants also had more mental health visits and higher outpatient pharmacy costs .,"['3CM', 'participants', 'also', 'had', 'more', 'mental', 'health', 'visits', 'and', 'higher', 'outpatient', 'pharmacy', 'costs', '.']","(0, 1)","(0, 3)",-1,ss_i,22865017,Abstract,14,test,gold,
4765,3CM participants also had more,mental health visits,and higher outpatient pharmacy costs .,"['3CM', 'participants', 'also', 'had', 'more', 'mental', 'health', 'visits', 'and', 'higher', 'outpatient', 'pharmacy', 'costs', '.']","(5, 8)","(30, 50)",-1,ss_o,22865017,Abstract,14,test,gold,3941.0
4766,3CM participants also had more mental health visits and higher,outpatient pharmacy costs .,,"['3CM', 'participants', 'also', 'had', 'more', 'mental', 'health', 'visits', 'and', 'higher', 'outpatient', 'pharmacy', 'costs', '.']","(10, 14)","(62, 89)",-1,ss_o,22865017,Abstract,14,test,gold,3837.0
4767,,3CM,participants also had more mental health visits and higher outpatient pharmacy costs .,"['3CM', 'participants', 'also', 'had', 'more', 'mental', 'health', 'visits', 'and', 'higher', 'outpatient', 'pharmacy', 'costs', '.']","(0, 1)","(0, 3)",-1,hl_i,22865017,Abstract,14,test,gold,
4768,3CM participants also had more,mental health visits,and higher outpatient pharmacy costs .,"['3CM', 'participants', 'also', 'had', 'more', 'mental', 'health', 'visits', 'and', 'higher', 'outpatient', 'pharmacy', 'costs', '.']","(5, 8)","(30, 50)",-1,hl_o,22865017,Abstract,14,test,gold,3942.0
4769,3CM participants also had more mental health visits and higher,outpatient pharmacy costs .,,"['3CM', 'participants', 'also', 'had', 'more', 'mental', 'health', 'visits', 'and', 'higher', 'outpatient', 'pharmacy', 'costs', '.']","(10, 14)","(62, 89)",-1,hl_o,22865017,Abstract,14,test,gold,3838.0
4770,CONCLUSIONS Results suggest the need for careful examination of the way that,collaborative care,"models are implemented for treating PTSD , and for additional supports to encourage primary care providers to manage PTSD .","['CONCLUSIONS', 'Results', 'suggest', 'the', 'need', 'for', 'careful', 'examination', 'of', 'the', 'way', 'that', 'collaborative', 'care', 'models', 'are', 'implemented', 'for', 'treating', 'PTSD', ',', 'and', 'for', 'additional', 'supports', 'to', 'encourage', 'primary', 'care', 'providers', 'to', 'manage', 'PTSD', '.']","(12, 14)","(76, 94)",-1,ss_i,22865017,Abstract,15,test,gold,3953.0
4771,Teaching emotion recognition skills to,young children with autism :,a randomised controlled trial of an emotion training programme .,"['Teaching', 'emotion', 'recognition', 'skills', 'to', 'young', 'children', 'with', 'autism', ':', 'a', 'randomised', 'controlled', 'trial', 'of', 'an', 'emotion', 'training', 'programme', '.']","(5, 10)","(38, 66)",-1,ss_p,22881991,Title,0,test,gold,6119.0
4772,Teaching,emotion recognition,skills to young children with autism : a randomised controlled trial of an emotion training programme .,"['Teaching', 'emotion', 'recognition', 'skills', 'to', 'young', 'children', 'with', 'autism', ':', 'a', 'randomised', 'controlled', 'trial', 'of', 'an', 'emotion', 'training', 'programme', '.']","(1, 3)","(8, 27)",-1,ss_i,22881991,Title,0,test,gold,3031.0
4773,Teaching emotion recognition skills to young children with autism : a randomised controlled trial of an,emotion training programme .,,"['Teaching', 'emotion', 'recognition', 'skills', 'to', 'young', 'children', 'with', 'autism', ':', 'a', 'randomised', 'controlled', 'trial', 'of', 'an', 'emotion', 'training', 'programme', '.']","(16, 20)","(103, 131)",-1,ss_i,22881991,Title,0,test,gold,3028.0
4774,Teaching emotion recognition skills to,young children with autism :,a randomised controlled trial of an emotion training programme .,"['Teaching', 'emotion', 'recognition', 'skills', 'to', 'young', 'children', 'with', 'autism', ':', 'a', 'randomised', 'controlled', 'trial', 'of', 'an', 'emotion', 'training', 'programme', '.']","(5, 10)","(38, 66)",-1,hl_p,22881991,Title,0,test,gold,6118.0
4775,Teaching,emotion recognition,skills to young children with autism : a randomised controlled trial of an emotion training programme .,"['Teaching', 'emotion', 'recognition', 'skills', 'to', 'young', 'children', 'with', 'autism', ':', 'a', 'randomised', 'controlled', 'trial', 'of', 'an', 'emotion', 'training', 'programme', '.']","(1, 3)","(8, 27)",-1,hl_i,22881991,Title,0,test,gold,3032.0
4776,Teaching emotion recognition skills to young children with autism : a randomised controlled trial of an,emotion training programme .,,"['Teaching', 'emotion', 'recognition', 'skills', 'to', 'young', 'children', 'with', 'autism', ':', 'a', 'randomised', 'controlled', 'trial', 'of', 'an', 'emotion', 'training', 'programme', '.']","(16, 20)","(103, 131)",-1,hl_i,22881991,Title,0,test,gold,3029.0
4777,BACKGROUND Children with autism have difficulties in emotion recognition and a number of interventions have been designed to target these problems .,,,"['BACKGROUND', 'Children', 'with', 'autism', 'have', 'difficulties', 'in', 'emotion', 'recognition', 'and', 'a', 'number', 'of', 'interventions', 'have', 'been', 'designed', 'to', 'target', 'these', 'problems', '.']",,,,,22881991,Abstract,0,test,gold,
4778,"However , few",emotion training,interventions have been trialled with young children with autism and co-morbid ID .,"['However', ',', 'few', 'emotion', 'training', 'interventions', 'have', 'been', 'trialled', 'with', 'young', 'children', 'with', 'autism', 'and', 'co-morbid', 'ID', '.']","(3, 5)","(13, 29)",-1,ss_i,22881991,Abstract,1,test,gold,3027.0
4779,"However , few",emotion training,interventions have been trialled with young children with autism and co-morbid ID .,"['However', ',', 'few', 'emotion', 'training', 'interventions', 'have', 'been', 'trialled', 'with', 'young', 'children', 'with', 'autism', 'and', 'co-morbid', 'ID', '.']","(3, 5)","(13, 29)",-1,hl_i,22881991,Abstract,1,test,gold,3026.0
4780,This study aimed to evaluate the efficacy of an emotion training programme for a group of,young children with autism with a range of intellectual ability .,,"['This', 'study', 'aimed', 'to', 'evaluate', 'the', 'efficacy', 'of', 'an', 'emotion', 'training', 'programme', 'for', 'a', 'group', 'of', 'young', 'children', 'with', 'autism', 'with', 'a', 'range', 'of', 'intellectual', 'ability', '.']","(16, 27)","(89, 154)",-1,ss_p,22881991,Abstract,2,test,gold,6208.0
4781,This study aimed to evaluate the efficacy of an,emotion training programme,for a group of young children with autism with a range of intellectual ability .,"['This', 'study', 'aimed', 'to', 'evaluate', 'the', 'efficacy', 'of', 'an', 'emotion', 'training', 'programme', 'for', 'a', 'group', 'of', 'young', 'children', 'with', 'autism', 'with', 'a', 'range', 'of', 'intellectual', 'ability', '.']","(9, 12)","(47, 73)",-1,ss_i,22881991,Abstract,2,test,gold,3025.0
4782,This study aimed to evaluate the,efficacy,of an emotion training programme for a group of young children with autism with a range of intellectual ability .,"['This', 'study', 'aimed', 'to', 'evaluate', 'the', 'efficacy', 'of', 'an', 'emotion', 'training', 'programme', 'for', 'a', 'group', 'of', 'young', 'children', 'with', 'autism', 'with', 'a', 'range', 'of', 'intellectual', 'ability', '.']","(6, 7)","(32, 40)",-1,ss_o,22881991,Abstract,2,test,gold,4805.0
4783,This study aimed to evaluate the efficacy of an emotion training programme for a group of,young children,with autism with a range of intellectual ability .,"['This', 'study', 'aimed', 'to', 'evaluate', 'the', 'efficacy', 'of', 'an', 'emotion', 'training', 'programme', 'for', 'a', 'group', 'of', 'young', 'children', 'with', 'autism', 'with', 'a', 'range', 'of', 'intellectual', 'ability', '.']","(16, 18)","(89, 103)",-1,hl_p,22881991,Abstract,2,test,gold,2158.0
4784,This study aimed to evaluate the efficacy of an emotion training programme for a group of young children with,autism with a range of intellectual ability,.,"['This', 'study', 'aimed', 'to', 'evaluate', 'the', 'efficacy', 'of', 'an', 'emotion', 'training', 'programme', 'for', 'a', 'group', 'of', 'young', 'children', 'with', 'autism', 'with', 'a', 'range', 'of', 'intellectual', 'ability', '.']","(19, 26)","(109, 152)",-1,hl_p,22881991,Abstract,2,test,gold,6209.0
4785,This study aimed to evaluate the efficacy of an,emotion training programme,for a group of young children with autism with a range of intellectual ability .,"['This', 'study', 'aimed', 'to', 'evaluate', 'the', 'efficacy', 'of', 'an', 'emotion', 'training', 'programme', 'for', 'a', 'group', 'of', 'young', 'children', 'with', 'autism', 'with', 'a', 'range', 'of', 'intellectual', 'ability', '.']","(9, 12)","(47, 73)",-1,hl_i,22881991,Abstract,2,test,gold,3024.0
4786,This study aimed to evaluate the,efficacy,of an emotion training programme for a group of young children with autism with a range of intellectual ability .,"['This', 'study', 'aimed', 'to', 'evaluate', 'the', 'efficacy', 'of', 'an', 'emotion', 'training', 'programme', 'for', 'a', 'group', 'of', 'young', 'children', 'with', 'autism', 'with', 'a', 'range', 'of', 'intellectual', 'ability', '.']","(6, 7)","(32, 40)",-1,hl_o,22881991,Abstract,2,test,gold,4804.0
4787,METHODS,"Participants were 55 children with autistic disorder , aged 4-7 years ( FSIQ 42-107 ) .",,"['METHODS', 'Participants', 'were', '55', 'children', 'with', 'autistic', 'disorder', ',', 'aged', '4-7', 'years', '(', 'FSIQ', '42-107', ')', '.']","(1, 17)","(7, 94)",-1,ss_p,22881991,Abstract,3,test,gold,5835.0
4788,METHODS Participants were,55 children with autistic disorder,", aged 4-7 years ( FSIQ 42-107 ) .","['METHODS', 'Participants', 'were', '55', 'children', 'with', 'autistic', 'disorder', ',', 'aged', '4-7', 'years', '(', 'FSIQ', '42-107', ')', '.']","(3, 8)","(25, 59)",-1,hl_p,22881991,Abstract,3,test,gold,6105.0
4789,"METHODS Participants were 55 children with autistic disorder ,",aged 4-7 years,( FSIQ 42-107 ) .,"['METHODS', 'Participants', 'were', '55', 'children', 'with', 'autistic', 'disorder', ',', 'aged', '4-7', 'years', '(', 'FSIQ', '42-107', ')', '.']","(9, 12)","(62, 76)",-1,hl_p,22881991,Abstract,3,test,gold,2029.0
4790,Children were randomly assigned to an intervention ( n = 28 ) or control group ( n = 27 ) .,,,"['Children', 'were', 'randomly', 'assigned', 'to', 'an', 'intervention', '(', 'n', '=', '28', ')', 'or', 'control', 'group', '(', 'n', '=', '27', ')', '.']",,,,,22881991,Abstract,4,test,gold,
4791,Participants in the intervention group watched a DVD designed to teach,emotion recognition skills,"to children with autism ( the Transporters ) , whereas the control group watched a DVD of Thomas the Tank Engine .","['Participants', 'in', 'the', 'intervention', 'group', 'watched', 'a', 'DVD', 'designed', 'to', 'teach', 'emotion', 'recognition', 'skills', 'to', 'children', 'with', 'autism', '(', 'the', 'Transporters', ')', ',', 'whereas', 'the', 'control', 'group', 'watched', 'a', 'DVD', 'of', 'Thomas', 'the', 'Tank', 'Engine', '.']","(11, 14)","(70, 96)",-1,ss_i,22881991,Abstract,5,test,gold,3034.0
4792,Participants in the intervention group watched a DVD designed to teach emotion recognition skills to children with autism,( the Transporters ),", whereas the control group watched a DVD of Thomas the Tank Engine .","['Participants', 'in', 'the', 'intervention', 'group', 'watched', 'a', 'DVD', 'designed', 'to', 'teach', 'emotion', 'recognition', 'skills', 'to', 'children', 'with', 'autism', '(', 'the', 'Transporters', ')', ',', 'whereas', 'the', 'control', 'group', 'watched', 'a', 'DVD', 'of', 'Thomas', 'the', 'Tank', 'Engine', '.']","(18, 22)","(121, 141)",-1,ss_i,22881991,Abstract,5,test,gold,590.0
4793,"Participants in the intervention group watched a DVD designed to teach emotion recognition skills to children with autism ( the Transporters ) , whereas the control group watched a DVD of",Thomas the Tank Engine .,,"['Participants', 'in', 'the', 'intervention', 'group', 'watched', 'a', 'DVD', 'designed', 'to', 'teach', 'emotion', 'recognition', 'skills', 'to', 'children', 'with', 'autism', '(', 'the', 'Transporters', ')', ',', 'whereas', 'the', 'control', 'group', 'watched', 'a', 'DVD', 'of', 'Thomas', 'the', 'Tank', 'Engine', '.']","(31, 36)","(187, 211)",-1,ss_i,22881991,Abstract,5,test,gold,594.0
4794,Participants in the intervention group watched a DVD designed to teach,emotion recognition skills,"to children with autism ( the Transporters ) , whereas the control group watched a DVD of Thomas the Tank Engine .","['Participants', 'in', 'the', 'intervention', 'group', 'watched', 'a', 'DVD', 'designed', 'to', 'teach', 'emotion', 'recognition', 'skills', 'to', 'children', 'with', 'autism', '(', 'the', 'Transporters', ')', ',', 'whereas', 'the', 'control', 'group', 'watched', 'a', 'DVD', 'of', 'Thomas', 'the', 'Tank', 'Engine', '.']","(11, 14)","(70, 96)",-1,hl_i,22881991,Abstract,5,test,gold,3035.0
4795,Participants in the intervention group watched a DVD designed to teach emotion recognition skills to children with autism (,the Transporters,") , whereas the control group watched a DVD of Thomas the Tank Engine .","['Participants', 'in', 'the', 'intervention', 'group', 'watched', 'a', 'DVD', 'designed', 'to', 'teach', 'emotion', 'recognition', 'skills', 'to', 'children', 'with', 'autism', '(', 'the', 'Transporters', ')', ',', 'whereas', 'the', 'control', 'group', 'watched', 'a', 'DVD', 'of', 'Thomas', 'the', 'Tank', 'Engine', '.']","(19, 21)","(123, 139)",-1,hl_i,22881991,Abstract,5,test,gold,591.0
4796,"Participants in the intervention group watched a DVD designed to teach emotion recognition skills to children with autism ( the Transporters ) , whereas the",control,group watched a DVD of Thomas the Tank Engine .,"['Participants', 'in', 'the', 'intervention', 'group', 'watched', 'a', 'DVD', 'designed', 'to', 'teach', 'emotion', 'recognition', 'skills', 'to', 'children', 'with', 'autism', '(', 'the', 'Transporters', ')', ',', 'whereas', 'the', 'control', 'group', 'watched', 'a', 'DVD', 'of', 'Thomas', 'the', 'Tank', 'Engine', '.']","(25, 26)","(156, 163)",-1,hl_i,22881991,Abstract,5,test,gold,903.0
4797,"Participants in the intervention group watched a DVD designed to teach emotion recognition skills to children with autism ( the Transporters ) , whereas the control group watched a DVD of",Thomas the Tank Engine .,,"['Participants', 'in', 'the', 'intervention', 'group', 'watched', 'a', 'DVD', 'designed', 'to', 'teach', 'emotion', 'recognition', 'skills', 'to', 'children', 'with', 'autism', '(', 'the', 'Transporters', ')', ',', 'whereas', 'the', 'control', 'group', 'watched', 'a', 'DVD', 'of', 'Thomas', 'the', 'Tank', 'Engine', '.']","(31, 36)","(187, 211)",-1,hl_i,22881991,Abstract,5,test,gold,595.0
4798,Participants were assessed on their,"ability to complete basic emotion recognition tasks , mindreading and theory of mind ( TOM ) tasks","before and after the 4-week intervention period , and at 3-month follow-up .","['Participants', 'were', 'assessed', 'on', 'their', 'ability', 'to', 'complete', 'basic', 'emotion', 'recognition', 'tasks', ',', 'mindreading', 'and', 'theory', 'of', 'mind', '(', 'TOM', ')', 'tasks', 'before', 'and', 'after', 'the', '4-week', 'intervention', 'period', ',', 'and', 'at', '3-month', 'follow-up', '.']","(5, 22)","(35, 133)",-1,ss_o,22881991,Abstract,6,test,gold,6433.0
4799,Participants were assessed on their ability to complete,basic emotion recognition tasks,", mindreading and theory of mind ( TOM ) tasks before and after the 4-week intervention period , and at 3-month follow-up .","['Participants', 'were', 'assessed', 'on', 'their', 'ability', 'to', 'complete', 'basic', 'emotion', 'recognition', 'tasks', ',', 'mindreading', 'and', 'theory', 'of', 'mind', '(', 'TOM', ')', 'tasks', 'before', 'and', 'after', 'the', '4-week', 'intervention', 'period', ',', 'and', 'at', '3-month', 'follow-up', '.']","(8, 12)","(55, 86)",-1,hl_o,22881991,Abstract,6,test,gold,3030.0
4800,"Participants were assessed on their ability to complete basic emotion recognition tasks ,",mindreading and theory of mind ( TOM ) tasks,"before and after the 4-week intervention period , and at 3-month follow-up .","['Participants', 'were', 'assessed', 'on', 'their', 'ability', 'to', 'complete', 'basic', 'emotion', 'recognition', 'tasks', ',', 'mindreading', 'and', 'theory', 'of', 'mind', '(', 'TOM', ')', 'tasks', 'before', 'and', 'after', 'the', '4-week', 'intervention', 'period', ',', 'and', 'at', '3-month', 'follow-up', '.']","(13, 22)","(89, 133)",-1,hl_o,22881991,Abstract,6,test,gold,6434.0
4801,"RESULTS Analyses controlled for the effect of chronological age , verbal intelligence , gender and DVD viewing time on outcomes .",,,"['RESULTS', 'Analyses', 'controlled', 'for', 'the', 'effect', 'of', 'chronological', 'age', ',', 'verbal', 'intelligence', ',', 'gender', 'and', 'DVD', 'viewing', 'time', 'on', 'outcomes', '.']",,,,,22881991,Abstract,7,test,gold,
4802,Children in the intervention group showed improved performance in the,recognition of anger,"compared with the control group , with few improvements maintained at 3-month follow-up .","['Children', 'in', 'the', 'intervention', 'group', 'showed', 'improved', 'performance', 'in', 'the', 'recognition', 'of', 'anger', 'compared', 'with', 'the', 'control', 'group', ',', 'with', 'few', 'improvements', 'maintained', 'at', '3-month', 'follow-up', '.']","(10, 13)","(69, 89)",-1,ss_o,22881991,Abstract,8,test,gold,3022.0
4803,Children in the intervention group showed improved performance in the,recognition of anger,"compared with the control group , with few improvements maintained at 3-month follow-up .","['Children', 'in', 'the', 'intervention', 'group', 'showed', 'improved', 'performance', 'in', 'the', 'recognition', 'of', 'anger', 'compared', 'with', 'the', 'control', 'group', ',', 'with', 'few', 'improvements', 'maintained', 'at', '3-month', 'follow-up', '.']","(10, 13)","(69, 89)",-1,hl_o,22881991,Abstract,8,test,gold,3023.0
4804,There was no generalisation of skills to,TOM or social skills .,,"['There', 'was', 'no', 'generalisation', 'of', 'skills', 'to', 'TOM', 'or', 'social', 'skills', '.']","(7, 12)","(40, 62)",-1,ss_o,22881991,Abstract,9,test,gold,2866.0
4805,There was no generalisation of skills to,TOM,or social skills .,"['There', 'was', 'no', 'generalisation', 'of', 'skills', 'to', 'TOM', 'or', 'social', 'skills', '.']","(7, 8)","(40, 43)",-1,hl_o,22881991,Abstract,9,test,gold,693.0
4806,There was no generalisation of skills to TOM or,social skills .,,"['There', 'was', 'no', 'generalisation', 'of', 'skills', 'to', 'TOM', 'or', 'social', 'skills', '.']","(9, 12)","(47, 62)",-1,hl_o,22881991,Abstract,9,test,gold,2876.0
4807,CONCLUSIONS The Transporters programme showed limited efficacy in teaching basic emotion recognition skills to,young children with autism,with a lower range of cognitive ability .,"['CONCLUSIONS', 'The', 'Transporters', 'programme', 'showed', 'limited', 'efficacy', 'in', 'teaching', 'basic', 'emotion', 'recognition', 'skills', 'to', 'young', 'children', 'with', 'autism', 'with', 'a', 'lower', 'range', 'of', 'cognitive', 'ability', '.']","(14, 18)","(110, 136)",-1,ss_p,22881991,Abstract,10,test,gold,6117.0
4808,CONCLUSIONS,The Transporters,programme showed limited efficacy in teaching basic emotion recognition skills to young children with autism with a lower range of cognitive ability .,"['CONCLUSIONS', 'The', 'Transporters', 'programme', 'showed', 'limited', 'efficacy', 'in', 'teaching', 'basic', 'emotion', 'recognition', 'skills', 'to', 'young', 'children', 'with', 'autism', 'with', 'a', 'lower', 'range', 'of', 'cognitive', 'ability', '.']","(1, 3)","(11, 27)",-1,ss_i,22881991,Abstract,10,test,gold,586.0
4809,CONCLUSIONS The Transporters programme showed limited,efficacy,in teaching basic emotion recognition skills to young children with autism with a lower range of cognitive ability .,"['CONCLUSIONS', 'The', 'Transporters', 'programme', 'showed', 'limited', 'efficacy', 'in', 'teaching', 'basic', 'emotion', 'recognition', 'skills', 'to', 'young', 'children', 'with', 'autism', 'with', 'a', 'lower', 'range', 'of', 'cognitive', 'ability', '.']","(6, 7)","(53, 61)",-1,ss_o,22881991,Abstract,10,test,gold,4803.0
4810,CONCLUSIONS The Transporters programme showed limited efficacy in teaching basic,emotion recognition skills,to young children with autism with a lower range of cognitive ability .,"['CONCLUSIONS', 'The', 'Transporters', 'programme', 'showed', 'limited', 'efficacy', 'in', 'teaching', 'basic', 'emotion', 'recognition', 'skills', 'to', 'young', 'children', 'with', 'autism', 'with', 'a', 'lower', 'range', 'of', 'cognitive', 'ability', '.']","(10, 13)","(80, 106)",-1,ss_o,22881991,Abstract,10,test,gold,3033.0
4811,CONCLUSIONS The Transporters programme showed limited efficacy in teaching basic emotion recognition skills to,young children with autism,with a lower range of cognitive ability .,"['CONCLUSIONS', 'The', 'Transporters', 'programme', 'showed', 'limited', 'efficacy', 'in', 'teaching', 'basic', 'emotion', 'recognition', 'skills', 'to', 'young', 'children', 'with', 'autism', 'with', 'a', 'lower', 'range', 'of', 'cognitive', 'ability', '.']","(14, 18)","(110, 136)",-1,hl_p,22881991,Abstract,10,test,gold,6116.0
4812,CONCLUSIONS,The Transporters,programme showed limited efficacy in teaching basic emotion recognition skills to young children with autism with a lower range of cognitive ability .,"['CONCLUSIONS', 'The', 'Transporters', 'programme', 'showed', 'limited', 'efficacy', 'in', 'teaching', 'basic', 'emotion', 'recognition', 'skills', 'to', 'young', 'children', 'with', 'autism', 'with', 'a', 'lower', 'range', 'of', 'cognitive', 'ability', '.']","(1, 3)","(11, 27)",-1,hl_i,22881991,Abstract,10,test,gold,587.0
4813,CONCLUSIONS The Transporters programme showed limited,efficacy,in teaching basic emotion recognition skills to young children with autism with a lower range of cognitive ability .,"['CONCLUSIONS', 'The', 'Transporters', 'programme', 'showed', 'limited', 'efficacy', 'in', 'teaching', 'basic', 'emotion', 'recognition', 'skills', 'to', 'young', 'children', 'with', 'autism', 'with', 'a', 'lower', 'range', 'of', 'cognitive', 'ability', '.']","(6, 7)","(53, 61)",-1,hl_o,22881991,Abstract,10,test,gold,4802.0
4814,Improvements were limited to the,recognition of expressions of anger,", with poor maintenance of these skills at follow-up .","['Improvements', 'were', 'limited', 'to', 'the', 'recognition', 'of', 'expressions', 'of', 'anger', ',', 'with', 'poor', 'maintenance', 'of', 'these', 'skills', 'at', 'follow-up', '.']","(5, 10)","(32, 67)",-1,ss_o,22881991,Abstract,11,test,gold,3021.0
4815,These findings provide limited support for the efficacy of the Transporters programme for,young children with autism,of a lower cognitive range .,"['These', 'findings', 'provide', 'limited', 'support', 'for', 'the', 'efficacy', 'of', 'the', 'Transporters', 'programme', 'for', 'young', 'children', 'with', 'autism', 'of', 'a', 'lower', 'cognitive', 'range', '.']","(13, 17)","(89, 115)",-1,ss_p,22881991,Abstract,12,test,gold,6115.0
4816,These findings provide limited support for the efficacy of,the Transporters,programme for young children with autism of a lower cognitive range .,"['These', 'findings', 'provide', 'limited', 'support', 'for', 'the', 'efficacy', 'of', 'the', 'Transporters', 'programme', 'for', 'young', 'children', 'with', 'autism', 'of', 'a', 'lower', 'cognitive', 'range', '.']","(9, 11)","(58, 74)",-1,ss_i,22881991,Abstract,12,test,gold,589.0
4817,These findings provide limited support for the,efficacy,of the Transporters programme for young children with autism of a lower cognitive range .,"['These', 'findings', 'provide', 'limited', 'support', 'for', 'the', 'efficacy', 'of', 'the', 'Transporters', 'programme', 'for', 'young', 'children', 'with', 'autism', 'of', 'a', 'lower', 'cognitive', 'range', '.']","(7, 8)","(46, 54)",-1,ss_o,22881991,Abstract,12,test,gold,4801.0
4818,These findings provide limited support for the efficacy of the Transporters programme for,young children with autism,of a lower cognitive range .,"['These', 'findings', 'provide', 'limited', 'support', 'for', 'the', 'efficacy', 'of', 'the', 'Transporters', 'programme', 'for', 'young', 'children', 'with', 'autism', 'of', 'a', 'lower', 'cognitive', 'range', '.']","(13, 17)","(89, 115)",-1,hl_p,22881991,Abstract,12,test,gold,6114.0
4819,These findings provide limited support for the efficacy of the,Transporters,programme for young children with autism of a lower cognitive range .,"['These', 'findings', 'provide', 'limited', 'support', 'for', 'the', 'efficacy', 'of', 'the', 'Transporters', 'programme', 'for', 'young', 'children', 'with', 'autism', 'of', 'a', 'lower', 'cognitive', 'range', '.']","(10, 11)","(62, 74)",-1,hl_i,22881991,Abstract,12,test,gold,588.0
4820,Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile,in patients with mixed dyslipidaemia and metabolic syndrome,.,"['Effect', 'of', 'rosuvastatin', 'monotherapy', 'or', 'in', 'combination', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'metabolic', 'syndrome', '.']","(17, 25)","(123, 182)",-1,ss_p,22897461,Title,0,test,gold,6993.0
4821,Effect of,rosuvastatin,monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome .,"['Effect', 'of', 'rosuvastatin', 'monotherapy', 'or', 'in', 'combination', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'metabolic', 'syndrome', '.']","(2, 3)","(9, 21)",-1,ss_i,22897461,Title,0,test,gold,5354.0
4822,Effect of rosuvastatin monotherapy or in combination with,fenofibrate,or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome .,"['Effect', 'of', 'rosuvastatin', 'monotherapy', 'or', 'in', 'combination', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'metabolic', 'syndrome', '.']","(8, 9)","(57, 68)",-1,ss_i,22897461,Title,0,test,gold,5359.0
4823,Effect of rosuvastatin monotherapy or in combination with fenofibrate or,ω-3 fatty acids,on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome .,"['Effect', 'of', 'rosuvastatin', 'monotherapy', 'or', 'in', 'combination', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'metabolic', 'syndrome', '.']","(10, 13)","(72, 87)",-1,ss_i,22897461,Title,0,test,gold,4611.0
4824,Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids,on lipoprotein subfraction profile,in patients with mixed dyslipidaemia and metabolic syndrome .,"['Effect', 'of', 'rosuvastatin', 'monotherapy', 'or', 'in', 'combination', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'metabolic', 'syndrome', '.']","(13, 17)","(88, 122)",-1,ss_o,22897461,Title,0,test,gold,1565.0
4825,Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in,patients with mixed dyslipidaemia and metabolic syndrome,.,"['Effect', 'of', 'rosuvastatin', 'monotherapy', 'or', 'in', 'combination', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'metabolic', 'syndrome', '.']","(18, 25)","(126, 182)",-1,hl_p,22897461,Title,0,test,gold,6994.0
4826,Effect of,rosuvastatin,monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome .,"['Effect', 'of', 'rosuvastatin', 'monotherapy', 'or', 'in', 'combination', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'metabolic', 'syndrome', '.']","(2, 3)","(9, 21)",-1,hl_i,22897461,Title,0,test,gold,5355.0
4827,Effect of rosuvastatin monotherapy or in combination with,fenofibrate,or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome .,"['Effect', 'of', 'rosuvastatin', 'monotherapy', 'or', 'in', 'combination', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'metabolic', 'syndrome', '.']","(8, 9)","(57, 68)",-1,hl_i,22897461,Title,0,test,gold,5360.0
4828,Effect of rosuvastatin monotherapy or in combination with fenofibrate or,ω-3 fatty acids,on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome .,"['Effect', 'of', 'rosuvastatin', 'monotherapy', 'or', 'in', 'combination', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'metabolic', 'syndrome', '.']","(10, 13)","(72, 87)",-1,hl_i,22897461,Title,0,test,gold,4612.0
4829,Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on,lipoprotein subfraction profile,in patients with mixed dyslipidaemia and metabolic syndrome .,"['Effect', 'of', 'rosuvastatin', 'monotherapy', 'or', 'in', 'combination', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'metabolic', 'syndrome', '.']","(14, 17)","(91, 122)",-1,hl_o,22897461,Title,0,test,gold,1567.0
4830,"BACKGROUND Raised triglycerides ( TG ) , decreased high-density lipoprotein cholesterol ( HDL-C ) levels and a predominance of small dense low density lipoproteins ( sdLDL ) are characteristics of the metabolic syndrome ( MetS ) .",,,"['BACKGROUND', 'Raised', 'triglycerides', '(', 'TG', ')', ',', 'decreased', 'high-density', 'lipoprotein', 'cholesterol', '(', 'HDL-C', ')', 'levels', 'and', 'a', 'predominance', 'of', 'small', 'dense', 'low', 'density', 'lipoproteins', '(', 'sdLDL', ')', 'are', 'characteristics', 'of', 'the', 'metabolic', 'syndrome', '(', 'MetS', ')', '.']",,,,,22897461,Abstract,0,test,gold,
4831,OBJECTIVE To compare the effect of high-dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on the lipoprotein subfraction profile,in patients with mixed dyslipidaemia and MetS,.,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'high-dose', 'rosuvastatin', 'monotherapy', 'with', 'moderate', 'dosing', 'combined', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'the', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'MetS', '.']","(24, 31)","(174, 219)",-1,ss_p,22897461,Abstract,1,test,gold,6996.0
4832,OBJECTIVE To compare the effect of,high-dose rosuvastatin,monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on the lipoprotein subfraction profile in patients with mixed dyslipidaemia and MetS .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'high-dose', 'rosuvastatin', 'monotherapy', 'with', 'moderate', 'dosing', 'combined', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'the', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'MetS', '.']","(6, 8)","(34, 56)",-1,ss_i,22897461,Abstract,1,test,gold,5353.0
4833,OBJECTIVE To compare the effect of high-dose rosuvastatin monotherapy with moderate dosing combined,with fenofibrate or ω-3 fatty acids,on the lipoprotein subfraction profile in patients with mixed dyslipidaemia and MetS .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'high-dose', 'rosuvastatin', 'monotherapy', 'with', 'moderate', 'dosing', 'combined', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'the', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'MetS', '.']","(13, 19)","(99, 134)",-1,ss_i,22897461,Abstract,1,test,gold,4615.0
4834,OBJECTIVE To compare the effect of high-dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on,the lipoprotein subfraction profile,in patients with mixed dyslipidaemia and MetS .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'high-dose', 'rosuvastatin', 'monotherapy', 'with', 'moderate', 'dosing', 'combined', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'the', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'MetS', '.']","(20, 24)","(138, 173)",-1,ss_o,22897461,Abstract,1,test,gold,1566.0
4835,OBJECTIVE To compare the effect of high-dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on the lipoprotein subfraction profile in,patients with mixed dyslipidaemia and MetS,.,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'high-dose', 'rosuvastatin', 'monotherapy', 'with', 'moderate', 'dosing', 'combined', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'the', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'MetS', '.']","(25, 31)","(177, 219)",-1,hl_p,22897461,Abstract,1,test,gold,6997.0
4836,OBJECTIVE To compare the effect of high-dose,rosuvastatin,monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on the lipoprotein subfraction profile in patients with mixed dyslipidaemia and MetS .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'high-dose', 'rosuvastatin', 'monotherapy', 'with', 'moderate', 'dosing', 'combined', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'the', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'MetS', '.']","(7, 8)","(44, 56)",-1,hl_i,22897461,Abstract,1,test,gold,5352.0
4837,OBJECTIVE To compare the effect of high-dose rosuvastatin monotherapy with moderate dosing combined with,fenofibrate,or ω-3 fatty acids on the lipoprotein subfraction profile in patients with mixed dyslipidaemia and MetS .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'high-dose', 'rosuvastatin', 'monotherapy', 'with', 'moderate', 'dosing', 'combined', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'the', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'MetS', '.']","(14, 15)","(104, 115)",-1,hl_i,22897461,Abstract,1,test,gold,5358.0
4838,OBJECTIVE To compare the effect of high-dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or,ω-3 fatty acids,on the lipoprotein subfraction profile in patients with mixed dyslipidaemia and MetS .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'high-dose', 'rosuvastatin', 'monotherapy', 'with', 'moderate', 'dosing', 'combined', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'the', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'MetS', '.']","(16, 19)","(119, 134)",-1,hl_i,22897461,Abstract,1,test,gold,4610.0
4839,OBJECTIVE To compare the effect of high-dose rosuvastatin monotherapy with moderate dosing combined with fenofibrate or ω-3 fatty acids on the,lipoprotein subfraction profile,in patients with mixed dyslipidaemia and MetS .,"['OBJECTIVE', 'To', 'compare', 'the', 'effect', 'of', 'high-dose', 'rosuvastatin', 'monotherapy', 'with', 'moderate', 'dosing', 'combined', 'with', 'fenofibrate', 'or', 'ω-3', 'fatty', 'acids', 'on', 'the', 'lipoprotein', 'subfraction', 'profile', 'in', 'patients', 'with', 'mixed', 'dyslipidaemia', 'and', 'MetS', '.']","(21, 24)","(142, 173)",-1,hl_o,22897461,Abstract,1,test,gold,1568.0
4840,METHODS We previously randomised patients with low-density lipoprotein cholesterol ( LDL-C ) > 160 and TG >,200 mg/dl to rosuvastatin,"monotherapy 40 mg/day ( R group , n = 30 ) or rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day ( RF group , n = 30 ) or ω-3 fatty acids 2 g/day ( Rω group , n = 30 ) .","['METHODS', 'We', 'previously', 'randomised', 'patients', 'with', 'low-density', 'lipoprotein', 'cholesterol', '(', 'LDL-C', ')', '>', '160', 'and', 'TG', '>', '200', 'mg/dl', 'to', 'rosuvastatin', 'monotherapy', '40', 'mg/day', '(', 'R', 'group', ',', 'n', '=', '30', ')', 'or', 'rosuvastatin', '10', 'mg/day', 'combined', 'with', 'fenofibrate', '200', 'mg/day', '(', 'RF', 'group', ',', 'n', '=', '30', ')', 'or', 'ω-3', 'fatty', 'acids', '2', 'g/day', '(', 'Rω', 'group', ',', 'n', '=', '30', ')', '.']","(17, 21)","(107, 132)",-1,ss_i,22897461,Abstract,2,test,gold,5351.0
4841,"METHODS We previously randomised patients with low-density lipoprotein cholesterol ( LDL-C ) > 160 and TG > 200 mg/dl to rosuvastatin monotherapy 40 mg/day ( R group , n =",30 ) or rosuvastatin,"10 mg/day combined with fenofibrate 200 mg/day ( RF group , n = 30 ) or ω-3 fatty acids 2 g/day ( Rω group , n = 30 ) .","['METHODS', 'We', 'previously', 'randomised', 'patients', 'with', 'low-density', 'lipoprotein', 'cholesterol', '(', 'LDL-C', ')', '>', '160', 'and', 'TG', '>', '200', 'mg/dl', 'to', 'rosuvastatin', 'monotherapy', '40', 'mg/day', '(', 'R', 'group', ',', 'n', '=', '30', ')', 'or', 'rosuvastatin', '10', 'mg/day', 'combined', 'with', 'fenofibrate', '200', 'mg/day', '(', 'RF', 'group', ',', 'n', '=', '30', ')', 'or', 'ω-3', 'fatty', 'acids', '2', 'g/day', '(', 'Rω', 'group', ',', 'n', '=', '30', ')', '.']","(30, 34)","(171, 191)",-1,ss_i,22897461,Abstract,2,test,gold,5348.0
4842,"METHODS We previously randomised patients with low-density lipoprotein cholesterol ( LDL-C ) > 160 and TG > 200 mg/dl to rosuvastatin monotherapy 40 mg/day ( R group , n = 30 ) or rosuvastatin 10 mg/day",combined with fenofibrate,"200 mg/day ( RF group , n = 30 ) or ω-3 fatty acids 2 g/day ( Rω group , n = 30 ) .","['METHODS', 'We', 'previously', 'randomised', 'patients', 'with', 'low-density', 'lipoprotein', 'cholesterol', '(', 'LDL-C', ')', '>', '160', 'and', 'TG', '>', '200', 'mg/dl', 'to', 'rosuvastatin', 'monotherapy', '40', 'mg/day', '(', 'R', 'group', ',', 'n', '=', '30', ')', 'or', 'rosuvastatin', '10', 'mg/day', 'combined', 'with', 'fenofibrate', '200', 'mg/day', '(', 'RF', 'group', ',', 'n', '=', '30', ')', 'or', 'ω-3', 'fatty', 'acids', '2', 'g/day', '(', 'Rω', 'group', ',', 'n', '=', '30', ')', '.']","(36, 39)","(202, 227)",-1,ss_i,22897461,Abstract,2,test,gold,5356.0
4843,"METHODS We previously randomised patients with low-density lipoprotein cholesterol ( LDL-C ) > 160 and TG > 200 mg/dl to rosuvastatin monotherapy 40 mg/day ( R group , n = 30 ) or rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day ( RF group , n =",30 ) or ω-3 fatty,"acids 2 g/day ( Rω group , n = 30 ) .","['METHODS', 'We', 'previously', 'randomised', 'patients', 'with', 'low-density', 'lipoprotein', 'cholesterol', '(', 'LDL-C', ')', '>', '160', 'and', 'TG', '>', '200', 'mg/dl', 'to', 'rosuvastatin', 'monotherapy', '40', 'mg/day', '(', 'R', 'group', ',', 'n', '=', '30', ')', 'or', 'rosuvastatin', '10', 'mg/day', 'combined', 'with', 'fenofibrate', '200', 'mg/day', '(', 'RF', 'group', ',', 'n', '=', '30', ')', 'or', 'ω-3', 'fatty', 'acids', '2', 'g/day', '(', 'Rω', 'group', ',', 'n', '=', '30', ')', '.']","(47, 52)","(256, 273)",-1,ss_i,22897461,Abstract,2,test,gold,230.0
4844,METHODS We previously randomised,patients with low-density lipoprotein cholesterol ( LDL-C ) > 160 and TG > 200 mg/dl,"to rosuvastatin monotherapy 40 mg/day ( R group , n = 30 ) or rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day ( RF group , n = 30 ) or ω-3 fatty acids 2 g/day ( Rω group , n = 30 ) .","['METHODS', 'We', 'previously', 'randomised', 'patients', 'with', 'low-density', 'lipoprotein', 'cholesterol', '(', 'LDL-C', ')', '>', '160', 'and', 'TG', '>', '200', 'mg/dl', 'to', 'rosuvastatin', 'monotherapy', '40', 'mg/day', '(', 'R', 'group', ',', 'n', '=', '30', ')', 'or', 'rosuvastatin', '10', 'mg/day', 'combined', 'with', 'fenofibrate', '200', 'mg/day', '(', 'RF', 'group', ',', 'n', '=', '30', ')', 'or', 'ω-3', 'fatty', 'acids', '2', 'g/day', '(', 'Rω', 'group', ',', 'n', '=', '30', ')', '.']","(4, 19)","(32, 116)",-1,hl_p,22897461,Abstract,2,test,gold,6546.0
4845,METHODS We previously randomised patients with low-density lipoprotein cholesterol ( LDL-C ) > 160 and TG > 200 mg/dl to,rosuvastatin,"monotherapy 40 mg/day ( R group , n = 30 ) or rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day ( RF group , n = 30 ) or ω-3 fatty acids 2 g/day ( Rω group , n = 30 ) .","['METHODS', 'We', 'previously', 'randomised', 'patients', 'with', 'low-density', 'lipoprotein', 'cholesterol', '(', 'LDL-C', ')', '>', '160', 'and', 'TG', '>', '200', 'mg/dl', 'to', 'rosuvastatin', 'monotherapy', '40', 'mg/day', '(', 'R', 'group', ',', 'n', '=', '30', ')', 'or', 'rosuvastatin', '10', 'mg/day', 'combined', 'with', 'fenofibrate', '200', 'mg/day', '(', 'RF', 'group', ',', 'n', '=', '30', ')', 'or', 'ω-3', 'fatty', 'acids', '2', 'g/day', '(', 'Rω', 'group', ',', 'n', '=', '30', ')', '.']","(20, 21)","(120, 132)",-1,hl_i,22897461,Abstract,2,test,gold,5350.0
4846,"METHODS We previously randomised patients with low-density lipoprotein cholesterol ( LDL-C ) > 160 and TG > 200 mg/dl to rosuvastatin monotherapy 40 mg/day ( R group , n = 30 ) or",rosuvastatin,"10 mg/day combined with fenofibrate 200 mg/day ( RF group , n = 30 ) or ω-3 fatty acids 2 g/day ( Rω group , n = 30 ) .","['METHODS', 'We', 'previously', 'randomised', 'patients', 'with', 'low-density', 'lipoprotein', 'cholesterol', '(', 'LDL-C', ')', '>', '160', 'and', 'TG', '>', '200', 'mg/dl', 'to', 'rosuvastatin', 'monotherapy', '40', 'mg/day', '(', 'R', 'group', ',', 'n', '=', '30', ')', 'or', 'rosuvastatin', '10', 'mg/day', 'combined', 'with', 'fenofibrate', '200', 'mg/day', '(', 'RF', 'group', ',', 'n', '=', '30', ')', 'or', 'ω-3', 'fatty', 'acids', '2', 'g/day', '(', 'Rω', 'group', ',', 'n', '=', '30', ')', '.']","(33, 34)","(179, 191)",-1,hl_i,22897461,Abstract,2,test,gold,5349.0
4847,"METHODS We previously randomised patients with low-density lipoprotein cholesterol ( LDL-C ) > 160 and TG > 200 mg/dl to rosuvastatin monotherapy 40 mg/day ( R group , n = 30 ) or rosuvastatin 10 mg/day combined with",fenofibrate,"200 mg/day ( RF group , n = 30 ) or ω-3 fatty acids 2 g/day ( Rω group , n = 30 ) .","['METHODS', 'We', 'previously', 'randomised', 'patients', 'with', 'low-density', 'lipoprotein', 'cholesterol', '(', 'LDL-C', ')', '>', '160', 'and', 'TG', '>', '200', 'mg/dl', 'to', 'rosuvastatin', 'monotherapy', '40', 'mg/day', '(', 'R', 'group', ',', 'n', '=', '30', ')', 'or', 'rosuvastatin', '10', 'mg/day', 'combined', 'with', 'fenofibrate', '200', 'mg/day', '(', 'RF', 'group', ',', 'n', '=', '30', ')', 'or', 'ω-3', 'fatty', 'acids', '2', 'g/day', '(', 'Rω', 'group', ',', 'n', '=', '30', ')', '.']","(38, 39)","(216, 227)",-1,hl_i,22897461,Abstract,2,test,gold,5357.0
4848,"METHODS We previously randomised patients with low-density lipoprotein cholesterol ( LDL-C ) > 160 and TG > 200 mg/dl to rosuvastatin monotherapy 40 mg/day ( R group , n = 30 ) or rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day ( RF group , n = 30 ) or",ω-3 fatty,"acids 2 g/day ( Rω group , n = 30 ) .","['METHODS', 'We', 'previously', 'randomised', 'patients', 'with', 'low-density', 'lipoprotein', 'cholesterol', '(', 'LDL-C', ')', '>', '160', 'and', 'TG', '>', '200', 'mg/dl', 'to', 'rosuvastatin', 'monotherapy', '40', 'mg/day', '(', 'R', 'group', ',', 'n', '=', '30', ')', 'or', 'rosuvastatin', '10', 'mg/day', 'combined', 'with', 'fenofibrate', '200', 'mg/day', '(', 'RF', 'group', ',', 'n', '=', '30', ')', 'or', 'ω-3', 'fatty', 'acids', '2', 'g/day', '(', 'Rω', 'group', ',', 'n', '=', '30', ')', '.']","(50, 52)","(264, 273)",-1,hl_i,22897461,Abstract,2,test,gold,231.0
4849,In the present,"study , only patients with MetS were included","( 24 , 23 and 24 in the R , RF and Rω groups respectively ) .","['In', 'the', 'present', 'study', ',', 'only', 'patients', 'with', 'MetS', 'were', 'included', '(', '24', ',', '23', 'and', '24', 'in', 'the', 'R', ',', 'RF', 'and', 'Rω', 'groups', 'respectively', ')', '.']","(3, 11)","(14, 59)",-1,ss_p,22897461,Abstract,3,test,gold,6995.0
4850,"In the present study , only patients with MetS were included ( 24 , 23 and 24",in the,"R , RF and Rω groups respectively ) .","['In', 'the', 'present', 'study', ',', 'only', 'patients', 'with', 'MetS', 'were', 'included', '(', '24', ',', '23', 'and', '24', 'in', 'the', 'R', ',', 'RF', 'and', 'Rω', 'groups', 'respectively', ')', '.']","(17, 19)","(77, 83)",-1,ss_i,22897461,Abstract,3,test,gold,1188.0
4851,"In the present study , only patients with MetS were included ( 24 , 23 and 24 in the R ,",RF,and Rω groups respectively ) .,"['In', 'the', 'present', 'study', ',', 'only', 'patients', 'with', 'MetS', 'were', 'included', '(', '24', ',', '23', 'and', '24', 'in', 'the', 'R', ',', 'RF', 'and', 'Rω', 'groups', 'respectively', ')', '.']","(21, 22)","(88, 90)",-1,ss_i,22897461,Abstract,3,test,gold,115.0
4852,"In the present study , only",patients with MetS,"were included ( 24 , 23 and 24 in the R , RF and Rω groups respectively ) .","['In', 'the', 'present', 'study', ',', 'only', 'patients', 'with', 'MetS', 'were', 'included', '(', '24', ',', '23', 'and', '24', 'in', 'the', 'R', ',', 'RF', 'and', 'Rω', 'groups', 'respectively', ')', '.']","(6, 9)","(27, 45)",-1,hl_p,22897461,Abstract,3,test,gold,3791.0
4853,At baseline and after 12 weeks of,"treatment , the lipoprotein subfraction profile was determined by polyacrylamide 3 % gel electrophoresis",.,"['At', 'baseline', 'and', 'after', '12', 'weeks', 'of', 'treatment', ',', 'the', 'lipoprotein', 'subfraction', 'profile', 'was', 'determined', 'by', 'polyacrylamide', '3', '%', 'gel', 'electrophoresis', '.']","(7, 21)","(33, 137)",-1,ss_o,22897461,Abstract,4,test,gold,6466.0
4854,"At baseline and after 12 weeks of treatment , the",lipoprotein subfraction,profile was determined by polyacrylamide 3 % gel electrophoresis .,"['At', 'baseline', 'and', 'after', '12', 'weeks', 'of', 'treatment', ',', 'the', 'lipoprotein', 'subfraction', 'profile', 'was', 'determined', 'by', 'polyacrylamide', '3', '%', 'gel', 'electrophoresis', '.']","(10, 12)","(49, 72)",-1,hl_o,22897461,Abstract,4,test,gold,1583.0
4855,,RESULTS The mean,LDL size was significantly increased in all groups .,"['RESULTS', 'The', 'mean', 'LDL', 'size', 'was', 'significantly', 'increased', 'in', 'all', 'groups', '.']","(0, 3)","(0, 16)",-1,ss_o,22897461,Abstract,5,test,gold,365.0
4856,RESULTS The,mean,LDL size was significantly increased in all groups .,"['RESULTS', 'The', 'mean', 'LDL', 'size', 'was', 'significantly', 'increased', 'in', 'all', 'groups', '.']","(2, 3)","(11, 15)",-1,hl_o,22897461,Abstract,5,test,gold,1221.0
4857,This change was more,prominent,with RF than with other treatments in parallel with its greater hypotriglyceridemic capacity ( p < 0.05 compared with R and Rω ) .,"['This', 'change', 'was', 'more', 'prominent', 'with', 'RF', 'than', 'with', 'other', 'treatments', 'in', 'parallel', 'with', 'its', 'greater', 'hypotriglyceridemic', 'capacity', '(', 'p', '<', '0.05', 'compared', 'with', 'R', 'and', 'Rω', ')', '.']","(4, 5)","(20, 29)",-1,ss_i,22897461,Abstract,6,test,gold,1217.0
4858,This change was more prominent with RF than with other treatments in parallel with its greater hypotriglyceridemic capacity ( p < 0.05,compared with,R and Rω ) .,"['This', 'change', 'was', 'more', 'prominent', 'with', 'RF', 'than', 'with', 'other', 'treatments', 'in', 'parallel', 'with', 'its', 'greater', 'hypotriglyceridemic', 'capacity', '(', 'p', '<', '0.05', 'compared', 'with', 'R', 'and', 'Rω', ')', '.']","(22, 24)","(134, 147)",-1,ss_i,22897461,Abstract,6,test,gold,1171.0
4859,This change was more prominent with RF than with other treatments in parallel with,its greater hypotriglyceridemic,capacity ( p < 0.05 compared with R and Rω ) .,"['This', 'change', 'was', 'more', 'prominent', 'with', 'RF', 'than', 'with', 'other', 'treatments', 'in', 'parallel', 'with', 'its', 'greater', 'hypotriglyceridemic', 'capacity', '(', 'p', '<', '0.05', 'compared', 'with', 'R', 'and', 'Rω', ')', '.']","(14, 17)","(82, 113)",-1,ss_o,22897461,Abstract,6,test,gold,985.0
4860,A decrease in insulin,resistance,by RF was also noted .,"['A', 'decrease', 'in', 'insulin', 'resistance', 'by', 'RF', 'was', 'also', 'noted', '.']","(4, 5)","(21, 31)",-1,ss_i,22897461,Abstract,7,test,gold,1233.0
4861,A decrease in insulin resistance by RF was also,noted,.,"['A', 'decrease', 'in', 'insulin', 'resistance', 'by', 'RF', 'was', 'also', 'noted', '.']","(9, 10)","(47, 52)",-1,ss_i,22897461,Abstract,7,test,gold,1218.0
4862,A,decrease in insulin resistance,by RF was also noted .,"['A', 'decrease', 'in', 'insulin', 'resistance', 'by', 'RF', 'was', 'also', 'noted', '.']","(1, 5)","(1, 31)",-1,ss_o,22897461,Abstract,7,test,gold,4891.0
4863,A decrease in,insulin resistance,by RF was also noted .,"['A', 'decrease', 'in', 'insulin', 'resistance', 'by', 'RF', 'was', 'also', 'noted', '.']","(3, 5)","(13, 31)",-1,hl_o,22897461,Abstract,7,test,gold,4892.0
4864,Only RF,significantly raised HDL-C,"levels ( by 7.7 % , p < 0.05 ) by increasing the cholesterol of small HDL particles .","['Only', 'RF', 'significantly', 'raised', 'HDL-C', 'levels', '(', 'by', '7.7', '%', ',', 'p', '<', '0.05', ')', 'by', 'increasing', 'the', 'cholesterol', 'of', 'small', 'HDL', 'particles', '.']","(2, 5)","(7, 33)",-1,ss_o,22897461,Abstract,8,test,gold,979.0
4865,"Only RF significantly raised HDL-C levels ( by 7.7 % , p < 0.05 ) by",increasing the cholesterol of small HDL particles .,,"['Only', 'RF', 'significantly', 'raised', 'HDL-C', 'levels', '(', 'by', '7.7', '%', ',', 'p', '<', '0.05', ')', 'by', 'increasing', 'the', 'cholesterol', 'of', 'small', 'HDL', 'particles', '.']","(16, 24)","(68, 119)",-1,ss_o,22897461,Abstract,8,test,gold,6557.0
4866,The cholesterol of larger HDL subclasses was significantly,increased by,R and Rω .,"['The', 'cholesterol', 'of', 'larger', 'HDL', 'subclasses', 'was', 'significantly', 'increased', 'by', 'R', 'and', 'Rω', '.']","(8, 10)","(58, 70)",-1,ss_i,22897461,Abstract,9,test,gold,981.0
4867,,The cholesterol of larger HDL subclasses,was significantly increased by R and Rω .,"['The', 'cholesterol', 'of', 'larger', 'HDL', 'subclasses', 'was', 'significantly', 'increased', 'by', 'R', 'and', 'Rω', '.']","(0, 6)","(0, 40)",-1,ss_o,22897461,Abstract,9,test,gold,6558.0
4868,The,cholesterol of larger HDL,subclasses was significantly increased by R and Rω .,"['The', 'cholesterol', 'of', 'larger', 'HDL', 'subclasses', 'was', 'significantly', 'increased', 'by', 'R', 'and', 'Rω', '.']","(1, 5)","(3, 28)",-1,hl_o,22897461,Abstract,9,test,gold,6559.0
4869,CONCLUSIONS All regimens increased,mean LDL,size ; RF was the most effective .,"['CONCLUSIONS', 'All', 'regimens', 'increased', 'mean', 'LDL', 'size', ';', 'RF', 'was', 'the', 'most', 'effective', '.']","(4, 6)","(34, 42)",-1,ss_i,22897461,Abstract,10,test,gold,1572.0
4870,CONCLUSIONS All,regimens increased mean,LDL size ; RF was the most effective .,"['CONCLUSIONS', 'All', 'regimens', 'increased', 'mean', 'LDL', 'size', ';', 'RF', 'was', 'the', 'most', 'effective', '.']","(2, 5)","(15, 38)",-1,ss_o,22897461,Abstract,10,test,gold,5598.0
4871,A differential effect of treatments was,noted on the HDL subfraction,profile .,"['A', 'differential', 'effect', 'of', 'treatments', 'was', 'noted', 'on', 'the', 'HDL', 'subfraction', 'profile', '.']","(6, 11)","(39, 67)",-1,ss_o,22897461,Abstract,11,test,gold,1574.0
4872,A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy,for breast cancer,.,"['A', 'randomized', 'double-blind', 'placebo-controlled', 'cross-over', 'trial', 'of', 'the', 'impact', 'on', 'quality', 'of', 'life', 'of', 'continuing', 'dexamethasone', 'beyond', '24', 'h', 'following', 'adjuvant', 'chemotherapy', 'for', 'breast', 'cancer', '.']","(22, 25)","(166, 183)",-1,ss_p,22956006,Title,0,test,gold,6880.0
4873,A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing,dexamethasone,beyond 24 h following adjuvant chemotherapy for breast cancer .,"['A', 'randomized', 'double-blind', 'placebo-controlled', 'cross-over', 'trial', 'of', 'the', 'impact', 'on', 'quality', 'of', 'life', 'of', 'continuing', 'dexamethasone', 'beyond', '24', 'h', 'following', 'adjuvant', 'chemotherapy', 'for', 'breast', 'cancer', '.']","(15, 16)","(108, 121)",-1,ss_i,22956006,Title,0,test,gold,5132.0
4874,A randomized double-blind placebo-controlled cross-over trial of the impact on,quality of life,of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer .,"['A', 'randomized', 'double-blind', 'placebo-controlled', 'cross-over', 'trial', 'of', 'the', 'impact', 'on', 'quality', 'of', 'life', 'of', 'continuing', 'dexamethasone', 'beyond', '24', 'h', 'following', 'adjuvant', 'chemotherapy', 'for', 'breast', 'cancer', '.']","(10, 13)","(78, 93)",-1,ss_o,22956006,Title,0,test,gold,1882.0
4875,A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for,breast cancer,.,"['A', 'randomized', 'double-blind', 'placebo-controlled', 'cross-over', 'trial', 'of', 'the', 'impact', 'on', 'quality', 'of', 'life', 'of', 'continuing', 'dexamethasone', 'beyond', '24', 'h', 'following', 'adjuvant', 'chemotherapy', 'for', 'breast', 'cancer', '.']","(23, 25)","(170, 183)",-1,hl_p,22956006,Title,0,test,gold,6881.0
4876,A randomized double-blind,placebo-controlled,cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer .,"['A', 'randomized', 'double-blind', 'placebo-controlled', 'cross-over', 'trial', 'of', 'the', 'impact', 'on', 'quality', 'of', 'life', 'of', 'continuing', 'dexamethasone', 'beyond', '24', 'h', 'following', 'adjuvant', 'chemotherapy', 'for', 'breast', 'cancer', '.']","(3, 4)","(25, 43)",-1,hl_i,22956006,Title,0,test,gold,
4877,A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing,dexamethasone,beyond 24 h following adjuvant chemotherapy for breast cancer .,"['A', 'randomized', 'double-blind', 'placebo-controlled', 'cross-over', 'trial', 'of', 'the', 'impact', 'on', 'quality', 'of', 'life', 'of', 'continuing', 'dexamethasone', 'beyond', '24', 'h', 'following', 'adjuvant', 'chemotherapy', 'for', 'breast', 'cancer', '.']","(15, 16)","(108, 121)",-1,hl_i,22956006,Title,0,test,gold,5133.0
4878,A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant,chemotherapy,for breast cancer .,"['A', 'randomized', 'double-blind', 'placebo-controlled', 'cross-over', 'trial', 'of', 'the', 'impact', 'on', 'quality', 'of', 'life', 'of', 'continuing', 'dexamethasone', 'beyond', '24', 'h', 'following', 'adjuvant', 'chemotherapy', 'for', 'breast', 'cancer', '.']","(21, 22)","(153, 165)",-1,hl_i,22956006,Title,0,test,gold,4251.0
4879,A randomized double-blind placebo-controlled cross-over trial of the impact on,quality of life,of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer .,"['A', 'randomized', 'double-blind', 'placebo-controlled', 'cross-over', 'trial', 'of', 'the', 'impact', 'on', 'quality', 'of', 'life', 'of', 'continuing', 'dexamethasone', 'beyond', '24', 'h', 'following', 'adjuvant', 'chemotherapy', 'for', 'breast', 'cancer', '.']","(10, 13)","(78, 93)",-1,hl_o,22956006,Title,0,test,gold,1881.0
4880,Uncertainty remains about the optimal anti-emetic regimen for control of delayed nausea and vomiting after adjuvant,chemotherapy,for breast cancer .,"['Uncertainty', 'remains', 'about', 'the', 'optimal', 'anti-emetic', 'regimen', 'for', 'control', 'of', 'delayed', 'nausea', 'and', 'vomiting', 'after', 'adjuvant', 'chemotherapy', 'for', 'breast', 'cancer', '.']","(16, 17)","(115, 127)",-1,hl_i,22956006,Abstract,0,test,gold,4250.0
4881,Many patients,receive dexamethasone,"but complain of insomnia , anxiety/agitation , and indigestion .","['Many', 'patients', 'receive', 'dexamethasone', 'but', 'complain', 'of', 'insomnia', ',', 'anxiety/agitation', ',', 'and', 'indigestion', '.']","(2, 4)","(13, 34)",-1,ss_i,22956006,Abstract,1,test,gold,5137.0
4882,Many patients receive,dexamethasone,"but complain of insomnia , anxiety/agitation , and indigestion .","['Many', 'patients', 'receive', 'dexamethasone', 'but', 'complain', 'of', 'insomnia', ',', 'anxiety/agitation', ',', 'and', 'indigestion', '.']","(3, 4)","(21, 34)",-1,hl_i,22956006,Abstract,1,test,gold,5131.0
4883,The aim was to determine,if patients receiving chemotherapy for breast cancer,"prefer treatment with dexamethasone or placebo for prophylaxis against delayed nausea and vomiting , and to compare quality of life ( QOL ) between the two treatments .","['The', 'aim', 'was', 'to', 'determine', 'if', 'patients', 'receiving', 'chemotherapy', 'for', 'breast', 'cancer', 'prefer', 'treatment', 'with', 'dexamethasone', 'or', 'placebo', 'for', 'prophylaxis', 'against', 'delayed', 'nausea', 'and', 'vomiting', ',', 'and', 'to', 'compare', 'quality', 'of', 'life', '(', 'QOL', ')', 'between', 'the', 'two', 'treatments', '.']","(5, 12)","(24, 76)",-1,ss_p,22956006,Abstract,2,test,gold,6828.0
4884,The aim was to determine if patients receiving chemotherapy for breast cancer prefer treatment,with dexamethasone or placebo,"for prophylaxis against delayed nausea and vomiting , and to compare quality of life ( QOL ) between the two treatments .","['The', 'aim', 'was', 'to', 'determine', 'if', 'patients', 'receiving', 'chemotherapy', 'for', 'breast', 'cancer', 'prefer', 'treatment', 'with', 'dexamethasone', 'or', 'placebo', 'for', 'prophylaxis', 'against', 'delayed', 'nausea', 'and', 'vomiting', ',', 'and', 'to', 'compare', 'quality', 'of', 'life', '(', 'QOL', ')', 'between', 'the', 'two', 'treatments', '.']","(14, 18)","(94, 123)",-1,ss_i,22956006,Abstract,2,test,gold,4438.0
4885,The aim was to determine if patients receiving chemotherapy for breast,cancer prefer,"treatment with dexamethasone or placebo for prophylaxis against delayed nausea and vomiting , and to compare quality of life ( QOL ) between the two treatments .","['The', 'aim', 'was', 'to', 'determine', 'if', 'patients', 'receiving', 'chemotherapy', 'for', 'breast', 'cancer', 'prefer', 'treatment', 'with', 'dexamethasone', 'or', 'placebo', 'for', 'prophylaxis', 'against', 'delayed', 'nausea', 'and', 'vomiting', ',', 'and', 'to', 'compare', 'quality', 'of', 'life', '(', 'QOL', ')', 'between', 'the', 'two', 'treatments', '.']","(11, 13)","(70, 83)",-1,ss_o,22956006,Abstract,2,test,gold,6884.0
4886,"The aim was to determine if patients receiving chemotherapy for breast cancer prefer treatment with dexamethasone or placebo for prophylaxis against delayed nausea and vomiting , and to",compare quality of life ( QOL ),between the two treatments .,"['The', 'aim', 'was', 'to', 'determine', 'if', 'patients', 'receiving', 'chemotherapy', 'for', 'breast', 'cancer', 'prefer', 'treatment', 'with', 'dexamethasone', 'or', 'placebo', 'for', 'prophylaxis', 'against', 'delayed', 'nausea', 'and', 'vomiting', ',', 'and', 'to', 'compare', 'quality', 'of', 'life', '(', 'QOL', ')', 'between', 'the', 'two', 'treatments', '.']","(28, 35)","(185, 216)",-1,ss_o,22956006,Abstract,2,test,gold,1891.0
4887,The aim was to determine if patients receiving chemotherapy for,breast cancer,"prefer treatment with dexamethasone or placebo for prophylaxis against delayed nausea and vomiting , and to compare quality of life ( QOL ) between the two treatments .","['The', 'aim', 'was', 'to', 'determine', 'if', 'patients', 'receiving', 'chemotherapy', 'for', 'breast', 'cancer', 'prefer', 'treatment', 'with', 'dexamethasone', 'or', 'placebo', 'for', 'prophylaxis', 'against', 'delayed', 'nausea', 'and', 'vomiting', ',', 'and', 'to', 'compare', 'quality', 'of', 'life', '(', 'QOL', ')', 'between', 'the', 'two', 'treatments', '.']","(10, 12)","(63, 76)",-1,hl_p,22956006,Abstract,2,test,gold,6882.0
4888,The aim was to determine if patients receiving,chemotherapy,"for breast cancer prefer treatment with dexamethasone or placebo for prophylaxis against delayed nausea and vomiting , and to compare quality of life ( QOL ) between the two treatments .","['The', 'aim', 'was', 'to', 'determine', 'if', 'patients', 'receiving', 'chemotherapy', 'for', 'breast', 'cancer', 'prefer', 'treatment', 'with', 'dexamethasone', 'or', 'placebo', 'for', 'prophylaxis', 'against', 'delayed', 'nausea', 'and', 'vomiting', ',', 'and', 'to', 'compare', 'quality', 'of', 'life', '(', 'QOL', ')', 'between', 'the', 'two', 'treatments', '.']","(8, 9)","(46, 58)",-1,hl_i,22956006,Abstract,2,test,gold,4249.0
4889,The aim was to determine if patients receiving chemotherapy for breast cancer prefer treatment with,dexamethasone,"or placebo for prophylaxis against delayed nausea and vomiting , and to compare quality of life ( QOL ) between the two treatments .","['The', 'aim', 'was', 'to', 'determine', 'if', 'patients', 'receiving', 'chemotherapy', 'for', 'breast', 'cancer', 'prefer', 'treatment', 'with', 'dexamethasone', 'or', 'placebo', 'for', 'prophylaxis', 'against', 'delayed', 'nausea', 'and', 'vomiting', ',', 'and', 'to', 'compare', 'quality', 'of', 'life', '(', 'QOL', ')', 'between', 'the', 'two', 'treatments', '.']","(15, 16)","(99, 112)",-1,hl_i,22956006,Abstract,2,test,gold,5130.0
4890,The aim was to determine if patients receiving chemotherapy for breast cancer prefer treatment with dexamethasone or,placebo,"for prophylaxis against delayed nausea and vomiting , and to compare quality of life ( QOL ) between the two treatments .","['The', 'aim', 'was', 'to', 'determine', 'if', 'patients', 'receiving', 'chemotherapy', 'for', 'breast', 'cancer', 'prefer', 'treatment', 'with', 'dexamethasone', 'or', 'placebo', 'for', 'prophylaxis', 'against', 'delayed', 'nausea', 'and', 'vomiting', ',', 'and', 'to', 'compare', 'quality', 'of', 'life', '(', 'QOL', ')', 'between', 'the', 'two', 'treatments', '.']","(17, 18)","(116, 123)",-1,hl_i,22956006,Abstract,2,test,gold,4359.0
4891,"The aim was to determine if patients receiving chemotherapy for breast cancer prefer treatment with dexamethasone or placebo for prophylaxis against delayed nausea and vomiting , and to compare",quality of life ( QOL ),between the two treatments .,"['The', 'aim', 'was', 'to', 'determine', 'if', 'patients', 'receiving', 'chemotherapy', 'for', 'breast', 'cancer', 'prefer', 'treatment', 'with', 'dexamethasone', 'or', 'placebo', 'for', 'prophylaxis', 'against', 'delayed', 'nausea', 'and', 'vomiting', ',', 'and', 'to', 'compare', 'quality', 'of', 'life', '(', 'QOL', ')', 'between', 'the', 'two', 'treatments', '.']","(29, 35)","(193, 216)",-1,hl_o,22956006,Abstract,2,test,gold,1892.0
4892,"In this randomized , double-blind , cross-over trial , we compared oral dexamethasone ( 4 mg twice daily for 2 days ) versus placebo",for chemotherapy-naïve patients with breast cancer,.,"['In', 'this', 'randomized', ',', 'double-blind', ',', 'cross-over', 'trial', ',', 'we', 'compared', 'oral', 'dexamethasone', '(', '4', 'mg', 'twice', 'daily', 'for', '2', 'days', ')', 'versus', 'placebo', 'for', 'chemotherapy-naïve', 'patients', 'with', 'breast', 'cancer', '.']","(24, 30)","(132, 182)",-1,ss_p,22956006,Abstract,3,test,gold,6833.0
4893,"In this randomized , double-blind , cross-over trial , we compared",oral dexamethasone,( 4 mg twice daily for 2 days ) versus placebo for chemotherapy-naïve patients with breast cancer .,"['In', 'this', 'randomized', ',', 'double-blind', ',', 'cross-over', 'trial', ',', 'we', 'compared', 'oral', 'dexamethasone', '(', '4', 'mg', 'twice', 'daily', 'for', '2', 'days', ')', 'versus', 'placebo', 'for', 'chemotherapy-naïve', 'patients', 'with', 'breast', 'cancer', '.']","(11, 13)","(66, 84)",-1,ss_i,22956006,Abstract,3,test,gold,5437.0
4894,"In this randomized , double-blind , cross-over trial , we compared oral dexamethasone ( 4 mg twice daily for 2 days )",versus placebo,for chemotherapy-naïve patients with breast cancer .,"['In', 'this', 'randomized', ',', 'double-blind', ',', 'cross-over', 'trial', ',', 'we', 'compared', 'oral', 'dexamethasone', '(', '4', 'mg', 'twice', 'daily', 'for', '2', 'days', ')', 'versus', 'placebo', 'for', 'chemotherapy-naïve', 'patients', 'with', 'breast', 'cancer', '.']","(22, 24)","(117, 131)",-1,ss_i,22956006,Abstract,3,test,gold,4430.0
4895,"In this randomized , double-blind , cross-over trial , we compared oral dexamethasone ( 4 mg twice daily for 2 days ) versus placebo for",chemotherapy-naïve patients with breast cancer,.,"['In', 'this', 'randomized', ',', 'double-blind', ',', 'cross-over', 'trial', ',', 'we', 'compared', 'oral', 'dexamethasone', '(', '4', 'mg', 'twice', 'daily', 'for', '2', 'days', ')', 'versus', 'placebo', 'for', 'chemotherapy-naïve', 'patients', 'with', 'breast', 'cancer', '.']","(25, 30)","(136, 182)",-1,hl_p,22956006,Abstract,3,test,gold,6834.0
4896,"In this randomized , double-blind , cross-over trial , we compared oral",dexamethasone,( 4 mg twice daily for 2 days ) versus placebo for chemotherapy-naïve patients with breast cancer .,"['In', 'this', 'randomized', ',', 'double-blind', ',', 'cross-over', 'trial', ',', 'we', 'compared', 'oral', 'dexamethasone', '(', '4', 'mg', 'twice', 'daily', 'for', '2', 'days', ')', 'versus', 'placebo', 'for', 'chemotherapy-naïve', 'patients', 'with', 'breast', 'cancer', '.']","(12, 13)","(71, 84)",-1,hl_i,22956006,Abstract,3,test,gold,5129.0
4897,"In this randomized , double-blind , cross-over trial , we compared oral dexamethasone ( 4 mg twice daily for 2 days ) versus",placebo,for chemotherapy-naïve patients with breast cancer .,"['In', 'this', 'randomized', ',', 'double-blind', ',', 'cross-over', 'trial', ',', 'we', 'compared', 'oral', 'dexamethasone', '(', '4', 'mg', 'twice', 'daily', 'for', '2', 'days', ')', 'versus', 'placebo', 'for', 'chemotherapy-naïve', 'patients', 'with', 'breast', 'cancer', '.']","(23, 24)","(124, 131)",-1,hl_i,22956006,Abstract,3,test,gold,4358.0
4898,All patients received,intravenous granisetron and dexamethasone,pre-chemotherapy and oral granisetron on day 2 .,"['All', 'patients', 'received', 'intravenous', 'granisetron', 'and', 'dexamethasone', 'pre-chemotherapy', 'and', 'oral', 'granisetron', 'on', 'day', '2', '.']","(3, 7)","(21, 62)",-1,ss_i,22956006,Abstract,4,test,gold,4433.0
4899,All patients received intravenous granisetron and dexamethasone pre-chemotherapy and,oral granisetron,on day 2 .,"['All', 'patients', 'received', 'intravenous', 'granisetron', 'and', 'dexamethasone', 'pre-chemotherapy', 'and', 'oral', 'granisetron', 'on', 'day', '2', '.']","(9, 11)","(84, 100)",-1,ss_i,22956006,Abstract,4,test,gold,5439.0
4900,All patients received intravenous,granisetron,and dexamethasone pre-chemotherapy and oral granisetron on day 2 .,"['All', 'patients', 'received', 'intravenous', 'granisetron', 'and', 'dexamethasone', 'pre-chemotherapy', 'and', 'oral', 'granisetron', 'on', 'day', '2', '.']","(4, 5)","(33, 44)",-1,hl_i,22956006,Abstract,4,test,gold,5426.0
4901,All patients received intravenous granisetron and,dexamethasone pre-chemotherapy,and oral granisetron on day 2 .,"['All', 'patients', 'received', 'intravenous', 'granisetron', 'and', 'dexamethasone', 'pre-chemotherapy', 'and', 'oral', 'granisetron', 'on', 'day', '2', '.']","(6, 8)","(49, 79)",-1,hl_i,22956006,Abstract,4,test,gold,5128.0
4902,All patients received intravenous granisetron and dexamethasone pre-chemotherapy and oral,granisetron,on day 2 .,"['All', 'patients', 'received', 'intravenous', 'granisetron', 'and', 'dexamethasone', 'pre-chemotherapy', 'and', 'oral', 'granisetron', 'on', 'day', '2', '.']","(10, 11)","(89, 100)",-1,hl_i,22956006,Abstract,4,test,gold,5425.0
4903,Primary endpoints were : ( i ) patient preference ; ( ii ) difference between cycles in change of QOL from days 1,to 8 .,,"['Primary', 'endpoints', 'were', ':', '(', 'i', ')', 'patient', 'preference', ';', '(', 'ii', ')', 'difference', 'between', 'cycles', 'in', 'change', 'of', 'QOL', 'from', 'days', '1', 'to', '8', '.']","(23, 26)","(113, 119)",-1,ss_p,22956006,Abstract,5,test,gold,1168.0
4904,Primary endpoints were :,( i ) patient preference ;,( ii ) difference between cycles in change of QOL from days 1 to 8 .,"['Primary', 'endpoints', 'were', ':', '(', 'i', ')', 'patient', 'preference', ';', '(', 'ii', ')', 'difference', 'between', 'cycles', 'in', 'change', 'of', 'QOL', 'from', 'days', '1', 'to', '8', '.']","(4, 10)","(24, 50)",-1,ss_o,22956006,Abstract,5,test,gold,3858.0
4905,Primary endpoints were : ( i ) patient preference ; ( ii ) difference between,cycles in change of,QOL from days 1 to 8 .,"['Primary', 'endpoints', 'were', ':', '(', 'i', ')', 'patient', 'preference', ';', '(', 'ii', ')', 'difference', 'between', 'cycles', 'in', 'change', 'of', 'QOL', 'from', 'days', '1', 'to', '8', '.']","(15, 19)","(77, 96)",-1,ss_o,22956006,Abstract,5,test,gold,968.0
4906,Primary endpoints were : ( i ),patient preference,; ( ii ) difference between cycles in change of QOL from days 1 to 8 .,"['Primary', 'endpoints', 'were', ':', '(', 'i', ')', 'patient', 'preference', ';', '(', 'ii', ')', 'difference', 'between', 'cycles', 'in', 'change', 'of', 'QOL', 'from', 'days', '1', 'to', '8', '.']","(7, 9)","(30, 48)",-1,hl_o,22956006,Abstract,5,test,gold,3859.0
4907,,Median age of the 94 women was 51 years ( range 27-76 ) :,79 received fluorouracil/epirubicin/cyclophosphamide and 15 received doxorubicin/cyclophosphamide .,"['Median', 'age', 'of', 'the', '94', 'women', 'was', '51', 'years', '(', 'range', '27-76', ')', ':', '79', 'received', 'fluorouracil/epirubicin/cyclophosphamide', 'and', '15', 'received', 'doxorubicin/cyclophosphamide', '.']","(0, 14)","(0, 57)",-1,ss_p,22956006,Abstract,6,test,gold,2047.0
4908,Median age of the 94 women was 51 years ( range 27-76 ) : 79,received fluorouracil/epirubicin/cyclophosphamide,and 15 received doxorubicin/cyclophosphamide .,"['Median', 'age', 'of', 'the', '94', 'women', 'was', '51', 'years', '(', 'range', '27-76', ')', ':', '79', 'received', 'fluorouracil/epirubicin/cyclophosphamide', 'and', '15', 'received', 'doxorubicin/cyclophosphamide', '.']","(15, 17)","(60, 109)",-1,ss_i,22956006,Abstract,6,test,gold,1165.0
4909,Median age of the 94 women was 51 years ( range 27-76 ) : 79 received fluorouracil/epirubicin/cyclophosphamide and 15,received doxorubicin/cyclophosphamide,.,"['Median', 'age', 'of', 'the', '94', 'women', 'was', '51', 'years', '(', 'range', '27-76', ')', ':', '79', 'received', 'fluorouracil/epirubicin/cyclophosphamide', 'and', '15', 'received', 'doxorubicin/cyclophosphamide', '.']","(19, 21)","(117, 154)",-1,ss_i,22956006,Abstract,6,test,gold,1166.0
4910,Median age of the,94 women,was 51 years ( range 27-76 ) : 79 received fluorouracil/epirubicin/cyclophosphamide and 15 received doxorubicin/cyclophosphamide .,"['Median', 'age', 'of', 'the', '94', 'women', 'was', '51', 'years', '(', 'range', '27-76', ')', ':', '79', 'received', 'fluorouracil/epirubicin/cyclophosphamide', 'and', '15', 'received', 'doxorubicin/cyclophosphamide', '.']","(4, 6)","(17, 25)",-1,hl_p,22956006,Abstract,6,test,gold,2242.0
4911,Median age of the 94 women was,51 years ( range 27-76 ),: 79 received fluorouracil/epirubicin/cyclophosphamide and 15 received doxorubicin/cyclophosphamide .,"['Median', 'age', 'of', 'the', '94', 'women', 'was', '51', 'years', '(', 'range', '27-76', ')', ':', '79', 'received', 'fluorouracil/epirubicin/cyclophosphamide', 'and', '15', 'received', 'doxorubicin/cyclophosphamide', '.']","(7, 13)","(30, 54)",-1,hl_p,22956006,Abstract,6,test,gold,2024.0
4912,Median age of the 94 women was 51 years ( range 27-76 ) : 79 received,fluorouracil/epirubicin/cyclophosphamide,and 15 received doxorubicin/cyclophosphamide .,"['Median', 'age', 'of', 'the', '94', 'women', 'was', '51', 'years', '(', 'range', '27-76', ')', ':', '79', 'received', 'fluorouracil/epirubicin/cyclophosphamide', 'and', '15', 'received', 'doxorubicin/cyclophosphamide', '.']","(16, 17)","(69, 109)",-1,hl_i,22956006,Abstract,6,test,gold,
4913,Median age of the 94 women was 51 years ( range 27-76 ) : 79 received fluorouracil/epirubicin/cyclophosphamide and 15 received,doxorubicin/cyclophosphamide,.,"['Median', 'age', 'of', 'the', '94', 'women', 'was', '51', 'years', '(', 'range', '27-76', ')', ':', '79', 'received', 'fluorouracil/epirubicin/cyclophosphamide', 'and', '15', 'received', 'doxorubicin/cyclophosphamide', '.']","(20, 21)","(126, 154)",-1,hl_i,22956006,Abstract,6,test,gold,
4914,Thirteen withdrew pre-cycle 2 with no differences between arms .,,,"['Thirteen', 'withdrew', 'pre-cycle', '2', 'with', 'no', 'differences', 'between', 'arms', '.']",,,,,22956006,Abstract,7,test,gold,
4915,"Of 80 patients stating a preference , 31",preferred placebo,"( 39 % , 95 % CI : 28-50 % ) and 37 ( 46 % , 95 % CI : 35-58 % ) preferred dexamethasone ; 12 had no preference .","['Of', '80', 'patients', 'stating', 'a', 'preference', ',', '31', 'preferred', 'placebo', '(', '39', '%', ',', '95', '%', 'CI', ':', '28-50', '%', ')', 'and', '37', '(', '46', '%', ',', '95', '%', 'CI', ':', '35-58', '%', ')', 'preferred', 'dexamethasone', ';', '12', 'had', 'no', 'preference', '.']","(8, 10)","(40, 57)",-1,ss_i,22956006,Abstract,8,test,gold,4425.0
4916,"Of 80 patients stating a preference , 31 preferred placebo ( 39 % , 95 % CI : 28-50 % ) and 37 ( 46 % , 95 % CI :",35-58 % ) preferred dexamethasone ;,12 had no preference .,"['Of', '80', 'patients', 'stating', 'a', 'preference', ',', '31', 'preferred', 'placebo', '(', '39', '%', ',', '95', '%', 'CI', ':', '28-50', '%', ')', 'and', '37', '(', '46', '%', ',', '95', '%', 'CI', ':', '35-58', '%', ')', 'preferred', 'dexamethasone', ';', '12', 'had', 'no', 'preference', '.']","(31, 37)","(113, 148)",-1,ss_i,22956006,Abstract,8,test,gold,5136.0
4917,Of 80 patients,"stating a preference , 31 preferred","placebo ( 39 % , 95 % CI : 28-50 % ) and 37 ( 46 % , 95 % CI : 35-58 % ) preferred dexamethasone ; 12 had no preference .","['Of', '80', 'patients', 'stating', 'a', 'preference', ',', '31', 'preferred', 'placebo', '(', '39', '%', ',', '95', '%', 'CI', ':', '28-50', '%', ')', 'and', '37', '(', '46', '%', ',', '95', '%', 'CI', ':', '35-58', '%', ')', 'preferred', 'dexamethasone', ';', '12', 'had', 'no', 'preference', '.']","(3, 9)","(14, 49)",-1,ss_o,22956006,Abstract,8,test,gold,3856.0
4918,"Of 80 patients stating a preference , 31 preferred placebo ( 39 % , 95 % CI : 28-50 % ) and 37 ( 46 % , 95 %",CI : 35-58 % ),preferred dexamethasone ; 12 had no preference .,"['Of', '80', 'patients', 'stating', 'a', 'preference', ',', '31', 'preferred', 'placebo', '(', '39', '%', ',', '95', '%', 'CI', ':', '28-50', '%', ')', 'and', '37', '(', '46', '%', ',', '95', '%', 'CI', ':', '35-58', '%', ')', 'preferred', 'dexamethasone', ';', '12', 'had', 'no', 'preference', '.']","(29, 34)","(108, 122)",-1,ss_o,22956006,Abstract,8,test,gold,1503.0
4919,"Of 80 patients stating a preference , 31 preferred placebo ( 39 % , 95 % CI : 28-50 % ) and 37 ( 46 % , 95 % CI : 35-58 % ) preferred",dexamethasone ; 12 had no,preference .,"['Of', '80', 'patients', 'stating', 'a', 'preference', ',', '31', 'preferred', 'placebo', '(', '39', '%', ',', '95', '%', 'CI', ':', '28-50', '%', ')', 'and', '37', '(', '46', '%', ',', '95', '%', 'CI', ':', '35-58', '%', ')', 'preferred', 'dexamethasone', ';', '12', 'had', 'no', 'preference', '.']","(35, 40)","(133, 158)",-1,ss_o,22956006,Abstract,8,test,gold,5134.0
4920,"Of 80 patients stating a preference , 31 preferred",placebo,"( 39 % , 95 % CI : 28-50 % ) and 37 ( 46 % , 95 % CI : 35-58 % ) preferred dexamethasone ; 12 had no preference .","['Of', '80', 'patients', 'stating', 'a', 'preference', ',', '31', 'preferred', 'placebo', '(', '39', '%', ',', '95', '%', 'CI', ':', '28-50', '%', ')', 'and', '37', '(', '46', '%', ',', '95', '%', 'CI', ':', '35-58', '%', ')', 'preferred', 'dexamethasone', ';', '12', 'had', 'no', 'preference', '.']","(9, 10)","(50, 57)",-1,hl_i,22956006,Abstract,8,test,gold,4357.0
4921,"Of 80 patients stating a preference , 31 preferred placebo ( 39 % , 95 % CI : 28-50 % ) and 37 ( 46 % , 95 % CI : 35-58 % ) preferred",dexamethasone,; 12 had no preference .,"['Of', '80', 'patients', 'stating', 'a', 'preference', ',', '31', 'preferred', 'placebo', '(', '39', '%', ',', '95', '%', 'CI', ':', '28-50', '%', ')', 'and', '37', '(', '46', '%', ',', '95', '%', 'CI', ':', '35-58', '%', ')', 'preferred', 'dexamethasone', ';', '12', 'had', 'no', 'preference', '.']","(35, 36)","(133, 146)",-1,hl_i,22956006,Abstract,8,test,gold,5127.0
4922,There were no,"differences in intensity of vomiting , nausea , or time to onset of",vomiting .,"['There', 'were', 'no', 'differences', 'in', 'intensity', 'of', 'vomiting', ',', 'nausea', ',', 'or', 'time', 'to', 'onset', 'of', 'vomiting', '.']","(3, 16)","(13, 80)",-1,ss_o,22956006,Abstract,9,test,gold,7137.0
4923,There was greater decrease in global QOL ( p = 0.06 ) when,patients received dexamethasone,.,"['There', 'was', 'greater', 'decrease', 'in', 'global', 'QOL', '(', 'p', '=', '0.06', ')', 'when', 'patients', 'received', 'dexamethasone', '.']","(13, 16)","(58, 89)",-1,ss_i,22956006,Abstract,10,test,gold,5138.0
4924,There was greater,decrease in,global QOL ( p = 0.06 ) when patients received dexamethasone .,"['There', 'was', 'greater', 'decrease', 'in', 'global', 'QOL', '(', 'p', '=', '0.06', ')', 'when', 'patients', 'received', 'dexamethasone', '.']","(3, 5)","(17, 28)",-1,ss_o,22956006,Abstract,10,test,gold,982.0
4925,There was greater decrease in global QOL ( p = 0.06 ) when patients received,dexamethasone .,,"['There', 'was', 'greater', 'decrease', 'in', 'global', 'QOL', '(', 'p', '=', '0.06', ')', 'when', 'patients', 'received', 'dexamethasone', '.']","(15, 17)","(76, 91)",-1,ss_o,22956006,Abstract,10,test,gold,5126.0
4926,There was greater decrease in global QOL ( p = 0.06 ) when patients received,dexamethasone,.,"['There', 'was', 'greater', 'decrease', 'in', 'global', 'QOL', '(', 'p', '=', '0.06', ')', 'when', 'patients', 'received', 'dexamethasone', '.']","(15, 16)","(76, 89)",-1,hl_i,22956006,Abstract,10,test,gold,5125.0
4927,,No other,symptom/QOL domains differed significantly .,"['No', 'other', 'symptom/QOL', 'domains', 'differed', 'significantly', '.']","(0, 2)","(0, 8)",-1,ss_o,22956006,Abstract,11,test,gold,1137.0
4928,No other,symptom/QOL,domains differed significantly .,"['No', 'other', 'symptom/QOL', 'domains', 'differed', 'significantly', '.']","(2, 3)","(8, 19)",-1,hl_o,22956006,Abstract,11,test,gold,
4929,"In conclusion , no significant difference was found in patient preference , QOL , or symptoms",regardless of whether dexamethasone,or placebo was used after adjuvant chemotherapy .,"['In', 'conclusion', ',', 'no', 'significant', 'difference', 'was', 'found', 'in', 'patient', 'preference', ',', 'QOL', ',', 'or', 'symptoms', 'regardless', 'of', 'whether', 'dexamethasone', 'or', 'placebo', 'was', 'used', 'after', 'adjuvant', 'chemotherapy', '.']","(16, 20)","(93, 128)",-1,ss_i,22956006,Abstract,12,test,gold,5135.0
4930,"In conclusion , no significant difference","was found in patient preference , QOL",", or symptoms regardless of whether dexamethasone or placebo was used after adjuvant chemotherapy .","['In', 'conclusion', ',', 'no', 'significant', 'difference', 'was', 'found', 'in', 'patient', 'preference', ',', 'QOL', ',', 'or', 'symptoms', 'regardless', 'of', 'whether', 'dexamethasone', 'or', 'placebo', 'was', 'used', 'after', 'adjuvant', 'chemotherapy', '.']","(6, 13)","(41, 78)",-1,ss_o,22956006,Abstract,12,test,gold,3880.0
4931,"In conclusion , no significant difference was found in patient preference , QOL , or symptoms regardless of whether",dexamethasone,or placebo was used after adjuvant chemotherapy .,"['In', 'conclusion', ',', 'no', 'significant', 'difference', 'was', 'found', 'in', 'patient', 'preference', ',', 'QOL', ',', 'or', 'symptoms', 'regardless', 'of', 'whether', 'dexamethasone', 'or', 'placebo', 'was', 'used', 'after', 'adjuvant', 'chemotherapy', '.']","(19, 20)","(115, 128)",-1,hl_i,22956006,Abstract,12,test,gold,5124.0
4932,"In conclusion , no significant difference was found in",patient preference,", QOL , or symptoms regardless of whether dexamethasone or placebo was used after adjuvant chemotherapy .","['In', 'conclusion', ',', 'no', 'significant', 'difference', 'was', 'found', 'in', 'patient', 'preference', ',', 'QOL', ',', 'or', 'symptoms', 'regardless', 'of', 'whether', 'dexamethasone', 'or', 'placebo', 'was', 'used', 'after', 'adjuvant', 'chemotherapy', '.']","(9, 11)","(54, 72)",-1,hl_o,22956006,Abstract,12,test,gold,3860.0
4933,"In conclusion , no significant difference was found in patient preference ,",QOL,", or symptoms regardless of whether dexamethasone or placebo was used after adjuvant chemotherapy .","['In', 'conclusion', ',', 'no', 'significant', 'difference', 'was', 'found', 'in', 'patient', 'preference', ',', 'QOL', ',', 'or', 'symptoms', 'regardless', 'of', 'whether', 'dexamethasone', 'or', 'placebo', 'was', 'used', 'after', 'adjuvant', 'chemotherapy', '.']","(12, 13)","(75, 78)",-1,hl_o,22956006,Abstract,12,test,gold,366.0
4934,Adherence to lifestyle recommendations by,patients with depression .,,"['Adherence', 'to', 'lifestyle', 'recommendations', 'by', 'patients', 'with', 'depression', '.']","(5, 9)","(41, 67)",-1,ss_p,23021296,Title,0,test,gold,6979.0
4935,Adherence to,lifestyle recommendations,by patients with depression .,"['Adherence', 'to', 'lifestyle', 'recommendations', 'by', 'patients', 'with', 'depression', '.']","(2, 4)","(12, 37)",-1,ss_i,23021296,Title,0,test,gold,937.0
4936,,Adherence,to lifestyle recommendations by patients with depression .,"['Adherence', 'to', 'lifestyle', 'recommendations', 'by', 'patients', 'with', 'depression', '.']","(0, 1)","(0, 9)",-1,ss_o,23021296,Title,0,test,gold,408.0
4937,Adherence to lifestyle recommendations by,patients with depression .,,"['Adherence', 'to', 'lifestyle', 'recommendations', 'by', 'patients', 'with', 'depression', '.']","(5, 9)","(41, 67)",-1,hl_p,23021296,Title,0,test,gold,6978.0
4938,Adherence to,lifestyle,recommendations by patients with depression .,"['Adherence', 'to', 'lifestyle', 'recommendations', 'by', 'patients', 'with', 'depression', '.']","(2, 3)","(12, 21)",-1,hl_i,23021296,Title,0,test,gold,1197.0
4939,,Adherence,to lifestyle recommendations by patients with depression .,"['Adherence', 'to', 'lifestyle', 'recommendations', 'by', 'patients', 'with', 'depression', '.']","(0, 1)","(0, 9)",-1,hl_o,23021296,Title,0,test,gold,409.0
4940,INTRODUCTION There is an increasing amount of evidence showing that physical activity and sun exposure are effective coadjuvant treatments for,patients with mild to moderate depression .,,"['INTRODUCTION', 'There', 'is', 'an', 'increasing', 'amount', 'of', 'evidence', 'showing', 'that', 'physical', 'activity', 'and', 'sun', 'exposure', 'are', 'effective', 'coadjuvant', 'treatments', 'for', 'patients', 'with', 'mild', 'to', 'moderate', 'depression', '.']","(20, 27)","(142, 185)",-1,ss_p,23021296,Abstract,0,test,gold,6976.0
4941,INTRODUCTION There is an increasing amount of evidence showing that physical activity and sun exposure are effective coadjuvant treatments for,patients with mild to moderate depression .,,"['INTRODUCTION', 'There', 'is', 'an', 'increasing', 'amount', 'of', 'evidence', 'showing', 'that', 'physical', 'activity', 'and', 'sun', 'exposure', 'are', 'effective', 'coadjuvant', 'treatments', 'for', 'patients', 'with', 'mild', 'to', 'moderate', 'depression', '.']","(20, 27)","(142, 185)",-1,hl_p,23021296,Abstract,0,test,gold,6977.0
4942,INTRODUCTION There is an increasing amount of evidence showing that,physical activity,and sun exposure are effective coadjuvant treatments for patients with mild to moderate depression .,"['INTRODUCTION', 'There', 'is', 'an', 'increasing', 'amount', 'of', 'evidence', 'showing', 'that', 'physical', 'activity', 'and', 'sun', 'exposure', 'are', 'effective', 'coadjuvant', 'treatments', 'for', 'patients', 'with', 'mild', 'to', 'moderate', 'depression', '.']","(10, 12)","(67, 84)",-1,hl_i,23021296,Abstract,0,test,gold,2887.0
4943,"However , there is a lack of information regarding",patient 's adherence,to these recommendations in daily clinical practice .,"['However', ',', 'there', 'is', 'a', 'lack', 'of', 'information', 'regarding', 'patient', ""'s"", 'adherence', 'to', 'these', 'recommendations', 'in', 'daily', 'clinical', 'practice', '.']","(9, 12)","(50, 70)",-1,ss_o,23021296,Abstract,1,test,gold,411.0
4944,"However , there is a lack of information regarding patient 's",adherence,to these recommendations in daily clinical practice .,"['However', ',', 'there', 'is', 'a', 'lack', 'of', 'information', 'regarding', 'patient', ""'s"", 'adherence', 'to', 'these', 'recommendations', 'in', 'daily', 'clinical', 'practice', '.']","(11, 12)","(61, 70)",-1,hl_o,23021296,Abstract,1,test,gold,406.0
4945,METHODS We conducted a study including,15 depressive patients who had been under antidepressant treatment for at least one month .,,"['METHODS', 'We', 'conducted', 'a', 'study', 'including', '15', 'depressive', 'patients', 'who', 'had', 'been', 'under', 'antidepressant', 'treatment', 'for', 'at', 'least', 'one', 'month', '.']","(6, 21)","(38, 129)",-1,ss_p,23021296,Abstract,2,test,gold,7075.0
4946,METHODS We conducted a study including,15 depressive patients who had been under antidepressant treatment for at least one month,.,"['METHODS', 'We', 'conducted', 'a', 'study', 'including', '15', 'depressive', 'patients', 'who', 'had', 'been', 'under', 'antidepressant', 'treatment', 'for', 'at', 'least', 'one', 'month', '.']","(6, 20)","(38, 127)",-1,hl_p,23021296,Abstract,2,test,gold,7076.0
4947,They wore a wrist-watch-like actimetry sensor to measure,physical activity,and sun exposure 24 hours a day .,"['They', 'wore', 'a', 'wrist-watch-like', 'actimetry', 'sensor', 'to', 'measure', 'physical', 'activity', 'and', 'sun', 'exposure', '24', 'hours', 'a', 'day', '.']","(8, 10)","(56, 73)",-1,ss_i,23021296,Abstract,3,test,gold,2888.0
4948,They wore a wrist-watch-like actimetry sensor to measure physical activity and,sun exposure,24 hours a day .,"['They', 'wore', 'a', 'wrist-watch-like', 'actimetry', 'sensor', 'to', 'measure', 'physical', 'activity', 'and', 'sun', 'exposure', '24', 'hours', 'a', 'day', '.']","(11, 13)","(78, 90)",-1,ss_i,23021296,Abstract,3,test,gold,2394.0
4949,They wore a wrist-watch-like actimetry sensor to measure,physical activity and sun exposure,24 hours a day .,"['They', 'wore', 'a', 'wrist-watch-like', 'actimetry', 'sensor', 'to', 'measure', 'physical', 'activity', 'and', 'sun', 'exposure', '24', 'hours', 'a', 'day', '.']","(8, 13)","(56, 90)",-1,ss_o,23021296,Abstract,3,test,gold,2389.0
4950,They wore a wrist-watch-like actimetry sensor to measure,physical activity,and sun exposure 24 hours a day .,"['They', 'wore', 'a', 'wrist-watch-like', 'actimetry', 'sensor', 'to', 'measure', 'physical', 'activity', 'and', 'sun', 'exposure', '24', 'hours', 'a', 'day', '.']","(8, 10)","(56, 73)",-1,hl_o,23021296,Abstract,3,test,gold,2886.0
4951,They wore a wrist-watch-like actimetry sensor to measure physical activity and,sun exposure,24 hours a day .,"['They', 'wore', 'a', 'wrist-watch-like', 'actimetry', 'sensor', 'to', 'measure', 'physical', 'activity', 'and', 'sun', 'exposure', '24', 'hours', 'a', 'day', '.']","(11, 13)","(78, 90)",-1,hl_o,23021296,Abstract,3,test,gold,2395.0
4952,"After one week of baseline assessment , patients were randomised into one of the two arms of the study .",,,"['After', 'one', 'week', 'of', 'baseline', 'assessment', ',', 'patients', 'were', 'randomised', 'into', 'one', 'of', 'the', 'two', 'arms', 'of', 'the', 'study', '.']",,,,,23021296,Abstract,4,test,gold,
4953,Patients in the experimental group received a brief note in which they were explicitly asked to increase both their,physical activity,"level and time of sun exposure , while control group patients did not receive these explicit recommendations .","['Patients', 'in', 'the', 'experimental', 'group', 'received', 'a', 'brief', 'note', 'in', 'which', 'they', 'were', 'explicitly', 'asked', 'to', 'increase', 'both', 'their', 'physical', 'activity', 'level', 'and', 'time', 'of', 'sun', 'exposure', ',', 'while', 'control', 'group', 'patients', 'did', 'not', 'receive', 'these', 'explicit', 'recommendations', '.']","(19, 21)","(115, 132)",-1,ss_i,23021296,Abstract,5,test,gold,2885.0
4954,Patients in the experimental group received a brief note in which they were explicitly asked to increase both their physical activity level and time of,sun exposure,", while control group patients did not receive these explicit recommendations .","['Patients', 'in', 'the', 'experimental', 'group', 'received', 'a', 'brief', 'note', 'in', 'which', 'they', 'were', 'explicitly', 'asked', 'to', 'increase', 'both', 'their', 'physical', 'activity', 'level', 'and', 'time', 'of', 'sun', 'exposure', ',', 'while', 'control', 'group', 'patients', 'did', 'not', 'receive', 'these', 'explicit', 'recommendations', '.']","(25, 27)","(151, 163)",-1,ss_i,23021296,Abstract,5,test,gold,2393.0
4955,"Patients in the experimental group received a brief note in which they were explicitly asked to increase both their physical activity level and time of sun exposure , while",control,group patients did not receive these explicit recommendations .,"['Patients', 'in', 'the', 'experimental', 'group', 'received', 'a', 'brief', 'note', 'in', 'which', 'they', 'were', 'explicitly', 'asked', 'to', 'increase', 'both', 'their', 'physical', 'activity', 'level', 'and', 'time', 'of', 'sun', 'exposure', ',', 'while', 'control', 'group', 'patients', 'did', 'not', 'receive', 'these', 'explicit', 'recommendations', '.']","(29, 30)","(172, 179)",-1,ss_i,23021296,Abstract,5,test,gold,901.0
4956,"Patients in the experimental group received a brief note in which they were explicitly asked to increase both their physical activity level and time of sun exposure , while control group patients",did not receive these explicit recommendations .,,"['Patients', 'in', 'the', 'experimental', 'group', 'received', 'a', 'brief', 'note', 'in', 'which', 'they', 'were', 'explicitly', 'asked', 'to', 'increase', 'both', 'their', 'physical', 'activity', 'level', 'and', 'time', 'of', 'sun', 'exposure', ',', 'while', 'control', 'group', 'patients', 'did', 'not', 'receive', 'these', 'explicit', 'recommendations', '.']","(32, 39)","(195, 243)",-1,ss_i,23021296,Abstract,5,test,gold,2989.0
4957,Patients in the experimental group received a brief note in which they were explicitly asked to increase both their,physical activity level,"and time of sun exposure , while control group patients did not receive these explicit recommendations .","['Patients', 'in', 'the', 'experimental', 'group', 'received', 'a', 'brief', 'note', 'in', 'which', 'they', 'were', 'explicitly', 'asked', 'to', 'increase', 'both', 'their', 'physical', 'activity', 'level', 'and', 'time', 'of', 'sun', 'exposure', ',', 'while', 'control', 'group', 'patients', 'did', 'not', 'receive', 'these', 'explicit', 'recommendations', '.']","(19, 22)","(115, 138)",-1,ss_o,23021296,Abstract,5,test,gold,2889.0
4958,Patients in the experimental group received a brief note in which they were explicitly asked to increase both their physical activity level and,time of sun exposure,", while control group patients did not receive these explicit recommendations .","['Patients', 'in', 'the', 'experimental', 'group', 'received', 'a', 'brief', 'note', 'in', 'which', 'they', 'were', 'explicitly', 'asked', 'to', 'increase', 'both', 'their', 'physical', 'activity', 'level', 'and', 'time', 'of', 'sun', 'exposure', ',', 'while', 'control', 'group', 'patients', 'did', 'not', 'receive', 'these', 'explicit', 'recommendations', '.']","(23, 27)","(143, 163)",-1,ss_o,23021296,Abstract,5,test,gold,2397.0
4959,Patients in the experimental group received a brief note in which they were explicitly asked to increase both their,physical activity,"level and time of sun exposure , while control group patients did not receive these explicit recommendations .","['Patients', 'in', 'the', 'experimental', 'group', 'received', 'a', 'brief', 'note', 'in', 'which', 'they', 'were', 'explicitly', 'asked', 'to', 'increase', 'both', 'their', 'physical', 'activity', 'level', 'and', 'time', 'of', 'sun', 'exposure', ',', 'while', 'control', 'group', 'patients', 'did', 'not', 'receive', 'these', 'explicit', 'recommendations', '.']","(19, 21)","(115, 132)",-1,hl_i,23021296,Abstract,5,test,gold,2884.0
4960,Patients in the experimental group received a brief note in which they were explicitly asked to increase both their physical activity level and time of,sun exposure,", while control group patients did not receive these explicit recommendations .","['Patients', 'in', 'the', 'experimental', 'group', 'received', 'a', 'brief', 'note', 'in', 'which', 'they', 'were', 'explicitly', 'asked', 'to', 'increase', 'both', 'their', 'physical', 'activity', 'level', 'and', 'time', 'of', 'sun', 'exposure', ',', 'while', 'control', 'group', 'patients', 'did', 'not', 'receive', 'these', 'explicit', 'recommendations', '.']","(25, 27)","(151, 163)",-1,hl_i,23021296,Abstract,5,test,gold,2392.0
4961,"Patients in the experimental group received a brief note in which they were explicitly asked to increase both their physical activity level and time of sun exposure , while",control,group patients did not receive these explicit recommendations .,"['Patients', 'in', 'the', 'experimental', 'group', 'received', 'a', 'brief', 'note', 'in', 'which', 'they', 'were', 'explicitly', 'asked', 'to', 'increase', 'both', 'their', 'physical', 'activity', 'level', 'and', 'time', 'of', 'sun', 'exposure', ',', 'while', 'control', 'group', 'patients', 'did', 'not', 'receive', 'these', 'explicit', 'recommendations', '.']","(29, 30)","(172, 179)",-1,hl_i,23021296,Abstract,5,test,gold,900.0
4962,"Patients in the experimental group received a brief note in which they were explicitly asked to increase both their physical activity level and time of sun exposure , while control group patients did",not receive these explicit recommendations,.,"['Patients', 'in', 'the', 'experimental', 'group', 'received', 'a', 'brief', 'note', 'in', 'which', 'they', 'were', 'explicitly', 'asked', 'to', 'increase', 'both', 'their', 'physical', 'activity', 'level', 'and', 'time', 'of', 'sun', 'exposure', ',', 'while', 'control', 'group', 'patients', 'did', 'not', 'receive', 'these', 'explicit', 'recommendations', '.']","(33, 38)","(199, 241)",-1,hl_i,23021296,Abstract,5,test,gold,2990.0
4963,Patients in the experimental group received a brief note in which they were explicitly asked to increase both their,physical activity level,"and time of sun exposure , while control group patients did not receive these explicit recommendations .","['Patients', 'in', 'the', 'experimental', 'group', 'received', 'a', 'brief', 'note', 'in', 'which', 'they', 'were', 'explicitly', 'asked', 'to', 'increase', 'both', 'their', 'physical', 'activity', 'level', 'and', 'time', 'of', 'sun', 'exposure', ',', 'while', 'control', 'group', 'patients', 'did', 'not', 'receive', 'these', 'explicit', 'recommendations', '.']","(19, 22)","(115, 138)",-1,hl_o,23021296,Abstract,5,test,gold,2890.0
4964,Patients in the experimental group received a brief note in which they were explicitly asked to increase both their physical activity level and,time of sun exposure,", while control group patients did not receive these explicit recommendations .","['Patients', 'in', 'the', 'experimental', 'group', 'received', 'a', 'brief', 'note', 'in', 'which', 'they', 'were', 'explicitly', 'asked', 'to', 'increase', 'both', 'their', 'physical', 'activity', 'level', 'and', 'time', 'of', 'sun', 'exposure', ',', 'while', 'control', 'group', 'patients', 'did', 'not', 'receive', 'these', 'explicit', 'recommendations', '.']","(23, 27)","(143, 163)",-1,hl_o,23021296,Abstract,5,test,gold,2398.0
4965,"RESULTS One week after recommendations were delivered , only patients in the experimental group had increased time of",sun exposure,"and physical activity ( 25.8 % and 14.3 % , respectively ) .","['RESULTS', 'One', 'week', 'after', 'recommendations', 'were', 'delivered', ',', 'only', 'patients', 'in', 'the', 'experimental', 'group', 'had', 'increased', 'time', 'of', 'sun', 'exposure', 'and', 'physical', 'activity', '(', '25.8', '%', 'and', '14.3', '%', ',', 'respectively', ')', '.']","(18, 20)","(117, 129)",-1,ss_i,23021296,Abstract,6,test,gold,2391.0
4966,"RESULTS One week after recommendations were delivered , only patients in the experimental group had increased time of sun exposure and",physical activity,"( 25.8 % and 14.3 % , respectively ) .","['RESULTS', 'One', 'week', 'after', 'recommendations', 'were', 'delivered', ',', 'only', 'patients', 'in', 'the', 'experimental', 'group', 'had', 'increased', 'time', 'of', 'sun', 'exposure', 'and', 'physical', 'activity', '(', '25.8', '%', 'and', '14.3', '%', ',', 'respectively', ')', '.']","(21, 23)","(134, 151)",-1,ss_i,23021296,Abstract,6,test,gold,2883.0
4967,"RESULTS One week after recommendations were delivered , only patients in the experimental group had increased",time of sun exposure and physical activity,"( 25.8 % and 14.3 % , respectively ) .","['RESULTS', 'One', 'week', 'after', 'recommendations', 'were', 'delivered', ',', 'only', 'patients', 'in', 'the', 'experimental', 'group', 'had', 'increased', 'time', 'of', 'sun', 'exposure', 'and', 'physical', 'activity', '(', '25.8', '%', 'and', '14.3', '%', ',', 'respectively', ')', '.']","(16, 23)","(109, 151)",-1,ss_o,23021296,Abstract,6,test,gold,2390.0
4968,"RESULTS One week after recommendations were delivered , only patients in the experimental group had increased",time of sun exposure,"and physical activity ( 25.8 % and 14.3 % , respectively ) .","['RESULTS', 'One', 'week', 'after', 'recommendations', 'were', 'delivered', ',', 'only', 'patients', 'in', 'the', 'experimental', 'group', 'had', 'increased', 'time', 'of', 'sun', 'exposure', 'and', 'physical', 'activity', '(', '25.8', '%', 'and', '14.3', '%', ',', 'respectively', ')', '.']","(16, 20)","(109, 129)",-1,hl_o,23021296,Abstract,6,test,gold,2396.0
4969,"RESULTS One week after recommendations were delivered , only patients in the experimental group had increased time of sun exposure and",physical activity,"( 25.8 % and 14.3 % , respectively ) .","['RESULTS', 'One', 'week', 'after', 'recommendations', 'were', 'delivered', ',', 'only', 'patients', 'in', 'the', 'experimental', 'group', 'had', 'increased', 'time', 'of', 'sun', 'exposure', 'and', 'physical', 'activity', '(', '25.8', '%', 'and', '14.3', '%', ',', 'respectively', ')', '.']","(21, 23)","(134, 151)",-1,hl_o,23021296,Abstract,6,test,gold,2882.0
4970,CONCLUSIONS,Depressive patients,are able to follow prescribed lifestyle recommendations in the short-term .,"['CONCLUSIONS', 'Depressive', 'patients', 'are', 'able', 'to', 'follow', 'prescribed', 'lifestyle', 'recommendations', 'in', 'the', 'short-term', '.']","(1, 3)","(11, 30)",-1,ss_p,23021296,Abstract,7,test,gold,3726.0
4971,CONCLUSIONS Depressive patients are able to follow prescribed,lifestyle recommendations,in the short-term .,"['CONCLUSIONS', 'Depressive', 'patients', 'are', 'able', 'to', 'follow', 'prescribed', 'lifestyle', 'recommendations', 'in', 'the', 'short-term', '.']","(8, 10)","(61, 86)",-1,ss_i,23021296,Abstract,7,test,gold,938.0
4972,CONCLUSIONS,Depressive patients,are able to follow prescribed lifestyle recommendations in the short-term .,"['CONCLUSIONS', 'Depressive', 'patients', 'are', 'able', 'to', 'follow', 'prescribed', 'lifestyle', 'recommendations', 'in', 'the', 'short-term', '.']","(1, 3)","(11, 30)",-1,hl_p,23021296,Abstract,7,test,gold,3727.0
4973,Role of posterior tibial nerve stimulation in the treatment of,refractory monosymptomatic nocturnal enuresis :,a pilot study .,"['Role', 'of', 'posterior', 'tibial', 'nerve', 'stimulation', 'in', 'the', 'treatment', 'of', 'refractory', 'monosymptomatic', 'nocturnal', 'enuresis', ':', 'a', 'pilot', 'study', '.']","(10, 15)","(62, 109)",-1,ss_p,23103798,Title,0,test,gold,7100.0
4974,Role of,posterior tibial nerve stimulation,in the treatment of refractory monosymptomatic nocturnal enuresis : a pilot study .,"['Role', 'of', 'posterior', 'tibial', 'nerve', 'stimulation', 'in', 'the', 'treatment', 'of', 'refractory', 'monosymptomatic', 'nocturnal', 'enuresis', ':', 'a', 'pilot', 'study', '.']","(2, 6)","(7, 41)",-1,ss_i,23103798,Title,0,test,gold,6768.0
4975,Role of,posterior tibial nerve stimulation,in the treatment of refractory monosymptomatic nocturnal enuresis : a pilot study .,"['Role', 'of', 'posterior', 'tibial', 'nerve', 'stimulation', 'in', 'the', 'treatment', 'of', 'refractory', 'monosymptomatic', 'nocturnal', 'enuresis', ':', 'a', 'pilot', 'study', '.']","(2, 6)","(7, 41)",-1,hl_i,23103798,Title,0,test,gold,6769.0
4976,PURPOSE We evaluated the early clinical and urodynamic results of posterior tibial nerve stimulation in,patients with refractory monosymptomatic nocturnal enuresis .,,"['PURPOSE', 'We', 'evaluated', 'the', 'early', 'clinical', 'and', 'urodynamic', 'results', 'of', 'posterior', 'tibial', 'nerve', 'stimulation', 'in', 'patients', 'with', 'refractory', 'monosymptomatic', 'nocturnal', 'enuresis', '.']","(15, 22)","(103, 164)",-1,ss_p,23103798,Abstract,0,test,gold,7102.0
4977,PURPOSE We evaluated the early clinical and urodynamic results of,posterior tibial nerve stimulation,in patients with refractory monosymptomatic nocturnal enuresis .,"['PURPOSE', 'We', 'evaluated', 'the', 'early', 'clinical', 'and', 'urodynamic', 'results', 'of', 'posterior', 'tibial', 'nerve', 'stimulation', 'in', 'patients', 'with', 'refractory', 'monosymptomatic', 'nocturnal', 'enuresis', '.']","(10, 14)","(65, 99)",-1,ss_i,23103798,Abstract,0,test,gold,6767.0
4978,PURPOSE We evaluated the,early clinical and urodynamic results,of posterior tibial nerve stimulation in patients with refractory monosymptomatic nocturnal enuresis .,"['PURPOSE', 'We', 'evaluated', 'the', 'early', 'clinical', 'and', 'urodynamic', 'results', 'of', 'posterior', 'tibial', 'nerve', 'stimulation', 'in', 'patients', 'with', 'refractory', 'monosymptomatic', 'nocturnal', 'enuresis', '.']","(4, 9)","(24, 61)",-1,ss_o,23103798,Abstract,0,test,gold,4747.0
4979,PURPOSE We evaluated the early clinical and urodynamic results of,posterior tibial nerve stimulation,in patients with refractory monosymptomatic nocturnal enuresis .,"['PURPOSE', 'We', 'evaluated', 'the', 'early', 'clinical', 'and', 'urodynamic', 'results', 'of', 'posterior', 'tibial', 'nerve', 'stimulation', 'in', 'patients', 'with', 'refractory', 'monosymptomatic', 'nocturnal', 'enuresis', '.']","(10, 14)","(65, 99)",-1,hl_i,23103798,Abstract,0,test,gold,6766.0
4980,MATERIALS AND METHODS We randomly assigned,28 patients with refractory monosymptomatic nocturnal enuresis,to 2 equal groups .,"['MATERIALS', 'AND', 'METHODS', 'We', 'randomly', 'assigned', '28', 'patients', 'with', 'refractory', 'monosymptomatic', 'nocturnal', 'enuresis', 'to', '2', 'equal', 'groups', '.']","(6, 13)","(42, 104)",-1,ss_p,23103798,Abstract,1,test,gold,7103.0
4981,MATERIALS AND METHODS We randomly assigned,28,patients with refractory monosymptomatic nocturnal enuresis to 2 equal groups .,"['MATERIALS', 'AND', 'METHODS', 'We', 'randomly', 'assigned', '28', 'patients', 'with', 'refractory', 'monosymptomatic', 'nocturnal', 'enuresis', 'to', '2', 'equal', 'groups', '.']","(6, 7)","(42, 44)",-1,hl_p,23103798,Abstract,1,test,gold,
4982,Group 1 received a weekly session of,posterior tibial nerve stimulation,for 12 weeks and group 2 was the placebo group .,"['Group', '1', 'received', 'a', 'weekly', 'session', 'of', 'posterior', 'tibial', 'nerve', 'stimulation', 'for', '12', 'weeks', 'and', 'group', '2', 'was', 'the', 'placebo', 'group', '.']","(7, 11)","(36, 70)",-1,ss_i,23103798,Abstract,2,test,gold,6765.0
4983,Group 1 received a weekly session of posterior tibial nerve stimulation for 12 weeks and group 2 was the,placebo,group .,"['Group', '1', 'received', 'a', 'weekly', 'session', 'of', 'posterior', 'tibial', 'nerve', 'stimulation', 'for', '12', 'weeks', 'and', 'group', '2', 'was', 'the', 'placebo', 'group', '.']","(19, 20)","(104, 111)",-1,ss_i,23103798,Abstract,2,test,gold,4356.0
4984,Group 1 received a weekly session of,posterior tibial nerve stimulation,for 12 weeks and group 2 was the placebo group .,"['Group', '1', 'received', 'a', 'weekly', 'session', 'of', 'posterior', 'tibial', 'nerve', 'stimulation', 'for', '12', 'weeks', 'and', 'group', '2', 'was', 'the', 'placebo', 'group', '.']","(7, 11)","(36, 70)",-1,hl_i,23103798,Abstract,2,test,gold,6764.0
4985,Group 1 received a weekly session of posterior tibial nerve stimulation for 12 weeks and group 2 was the,placebo,group .,"['Group', '1', 'received', 'a', 'weekly', 'session', 'of', 'posterior', 'tibial', 'nerve', 'stimulation', 'for', '12', 'weeks', 'and', 'group', '2', 'was', 'the', 'placebo', 'group', '.']","(19, 20)","(104, 111)",-1,hl_i,23103798,Abstract,2,test,gold,4355.0
4986,Evaluation was performed in each group at baseline and after,posterior tibial nerve stimulation,to compare clinical and urodynamic findings .,"['Evaluation', 'was', 'performed', 'in', 'each', 'group', 'at', 'baseline', 'and', 'after', 'posterior', 'tibial', 'nerve', 'stimulation', 'to', 'compare', 'clinical', 'and', 'urodynamic', 'findings', '.']","(10, 14)","(60, 94)",-1,ss_i,23103798,Abstract,3,test,gold,6763.0
4987,Evaluation was performed in each group at baseline and after posterior tibial nerve stimulation to compare,clinical and urodynamic findings .,,"['Evaluation', 'was', 'performed', 'in', 'each', 'group', 'at', 'baseline', 'and', 'after', 'posterior', 'tibial', 'nerve', 'stimulation', 'to', 'compare', 'clinical', 'and', 'urodynamic', 'findings', '.']","(16, 21)","(106, 140)",-1,ss_o,23103798,Abstract,3,test,gold,4748.0
4988,Another clinical assessment was done 3 months after the first followup .,,,"['Another', 'clinical', 'assessment', 'was', 'done', '3', 'months', 'after', 'the', 'first', 'followup', '.']",,,,,23103798,Abstract,4,test,gold,
4989,RESULTS The 2 groups were comparable in,baseline clinical and urodynamic data .,,"['RESULTS', 'The', '2', 'groups', 'were', 'comparable', 'in', 'baseline', 'clinical', 'and', 'urodynamic', 'data', '.']","(7, 13)","(39, 78)",-1,ss_o,23103798,Abstract,5,test,gold,4745.0
4990,"Overall , 13 patients ( 46.4 % ) had",detrusor overactivity,and 14 ( 50 % ) had decreased bladder capacity .,"['Overall', ',', '13', 'patients', '(', '46.4', '%', ')', 'had', 'detrusor', 'overactivity', 'and', '14', '(', '50', '%', ')', 'had', 'decreased', 'bladder', 'capacity', '.']","(9, 11)","(36, 57)",-1,ss_o,23103798,Abstract,6,test,gold,3179.0
4991,"Overall , 13 patients ( 46.4 % ) had detrusor overactivity and 14 ( 50 % ) had decreased",bladder capacity .,,"['Overall', ',', '13', 'patients', '(', '46.4', '%', ')', 'had', 'detrusor', 'overactivity', 'and', '14', '(', '50', '%', ')', 'had', 'decreased', 'bladder', 'capacity', '.']","(19, 22)","(88, 106)",-1,ss_o,23103798,Abstract,6,test,gold,1678.0
4992,"Overall , 13 patients ( 46.4 % ) had",detrusor overactivity,and 14 ( 50 % ) had decreased bladder capacity .,"['Overall', ',', '13', 'patients', '(', '46.4', '%', ')', 'had', 'detrusor', 'overactivity', 'and', '14', '(', '50', '%', ')', 'had', 'decreased', 'bladder', 'capacity', '.']","(9, 11)","(36, 57)",-1,hl_o,23103798,Abstract,6,test,gold,3180.0
4993,"Overall , 13 patients ( 46.4 % ) had detrusor overactivity and 14 ( 50 % ) had decreased",bladder capacity .,,"['Overall', ',', '13', 'patients', '(', '46.4', '%', ')', 'had', 'detrusor', 'overactivity', 'and', '14', '(', '50', '%', ')', 'had', 'decreased', 'bladder', 'capacity', '.']","(19, 22)","(88, 106)",-1,hl_o,23103798,Abstract,6,test,gold,1679.0
4994,After treatment 11 group 1 patients ( 78.6 % ) had a partial or full response to,posterior tibial nerve stimulation,but only 2 ( 14.3 % ) in group 2 had a partial response ( p = 0.002 ) .,"['After', 'treatment', '11', 'group', '1', 'patients', '(', '78.6', '%', ')', 'had', 'a', 'partial', 'or', 'full', 'response', 'to', 'posterior', 'tibial', 'nerve', 'stimulation', 'but', 'only', '2', '(', '14.3', '%', ')', 'in', 'group', '2', 'had', 'a', 'partial', 'response', '(', 'p', '=', '0.002', ')', '.']","(17, 21)","(80, 114)",-1,ss_i,23103798,Abstract,7,test,gold,6762.0
4995,After treatment 11 group 1 patients ( 78.6 % ) had a partial or full,response to posterior tibial nerve stimulation,but only 2 ( 14.3 % ) in group 2 had a partial response ( p = 0.002 ) .,"['After', 'treatment', '11', 'group', '1', 'patients', '(', '78.6', '%', ')', 'had', 'a', 'partial', 'or', 'full', 'response', 'to', 'posterior', 'tibial', 'nerve', 'stimulation', 'but', 'only', '2', '(', '14.3', '%', ')', 'in', 'group', '2', 'had', 'a', 'partial', 'response', '(', 'p', '=', '0.002', ')', '.']","(15, 21)","(68, 114)",-1,ss_o,23103798,Abstract,7,test,gold,6761.0
4996,After treatment 11 group 1 patients ( 78.6 % ) had a partial or full response to posterior tibial nerve stimulation but only 2 ( 14.3 % ) in group 2 had a partial,response,( p = 0.002 ) .,"['After', 'treatment', '11', 'group', '1', 'patients', '(', '78.6', '%', ')', 'had', 'a', 'partial', 'or', 'full', 'response', 'to', 'posterior', 'tibial', 'nerve', 'stimulation', 'but', 'only', '2', '(', '14.3', '%', ')', 'in', 'group', '2', 'had', 'a', 'partial', 'response', '(', 'p', '=', '0.002', ')', '.']","(34, 35)","(162, 170)",-1,ss_o,23103798,Abstract,7,test,gold,2525.0
4997,After treatment 11 group 1 patients ( 78.6 % ) had a partial or full,response,to posterior tibial nerve stimulation but only 2 ( 14.3 % ) in group 2 had a partial response ( p = 0.002 ) .,"['After', 'treatment', '11', 'group', '1', 'patients', '(', '78.6', '%', ')', 'had', 'a', 'partial', 'or', 'full', 'response', 'to', 'posterior', 'tibial', 'nerve', 'stimulation', 'but', 'only', '2', '(', '14.3', '%', ')', 'in', 'group', '2', 'had', 'a', 'partial', 'response', '(', 'p', '=', '0.002', ')', '.']","(15, 16)","(68, 76)",-1,hl_o,23103798,Abstract,7,test,gold,2524.0
4998,After treatment 11 group 1 patients ( 78.6 % ) had a partial or full response to posterior tibial nerve stimulation but only 2 ( 14.3 % ) in group 2 had a partial,response,( p = 0.002 ) .,"['After', 'treatment', '11', 'group', '1', 'patients', '(', '78.6', '%', ')', 'had', 'a', 'partial', 'or', 'full', 'response', 'to', 'posterior', 'tibial', 'nerve', 'stimulation', 'but', 'only', '2', '(', '14.3', '%', ')', 'in', 'group', '2', 'had', 'a', 'partial', 'response', '(', 'p', '=', '0.002', ')', '.']","(34, 35)","(162, 170)",-1,hl_o,23103798,Abstract,7,test,gold,2523.0
4999,"Also , the average",number of wet nights,in group 1 was significantly lower than at baseline ( p = 0.002 ) .,"['Also', ',', 'the', 'average', 'number', 'of', 'wet', 'nights', 'in', 'group', '1', 'was', 'significantly', 'lower', 'than', 'at', 'baseline', '(', 'p', '=', '0.002', ')', '.']","(4, 8)","(18, 38)",-1,ss_o,23103798,Abstract,8,test,gold,2723.0
5000,"Also , the average",number of wet nights,in group 1 was significantly lower than at baseline ( p = 0.002 ) .,"['Also', ',', 'the', 'average', 'number', 'of', 'wet', 'nights', 'in', 'group', '1', 'was', 'significantly', 'lower', 'than', 'at', 'baseline', '(', 'p', '=', '0.002', ')', '.']","(4, 8)","(18, 38)",-1,hl_o,23103798,Abstract,8,test,gold,2724.0
5001,All,urodynamic parameters,significantly improved in group 1 .,"['All', 'urodynamic', 'parameters', 'significantly', 'improved', 'in', 'group', '1', '.']","(1, 3)","(3, 24)",-1,ss_o,23103798,Abstract,9,test,gold,1826.0
5002,All,urodynamic parameters,significantly improved in group 1 .,"['All', 'urodynamic', 'parameters', 'significantly', 'improved', 'in', 'group', '1', '.']","(1, 3)","(3, 24)",-1,hl_o,23103798,Abstract,9,test,gold,1827.0
5003,"In contrast , the",number of wet nights and urodynamic parameters,did not change significantly in group 2 .,"['In', 'contrast', ',', 'the', 'number', 'of', 'wet', 'nights', 'and', 'urodynamic', 'parameters', 'did', 'not', 'change', 'significantly', 'in', 'group', '2', '.']","(4, 11)","(17, 63)",-1,ss_o,23103798,Abstract,10,test,gold,2721.0
5004,"In contrast , the number of",wet nights,and urodynamic parameters did not change significantly in group 2 .,"['In', 'contrast', ',', 'the', 'number', 'of', 'wet', 'nights', 'and', 'urodynamic', 'parameters', 'did', 'not', 'change', 'significantly', 'in', 'group', '2', '.']","(6, 8)","(27, 37)",-1,hl_o,23103798,Abstract,10,test,gold,2722.0
5005,"In contrast , the number of wet nights and",urodynamic parameters,did not change significantly in group 2 .,"['In', 'contrast', ',', 'the', 'number', 'of', 'wet', 'nights', 'and', 'urodynamic', 'parameters', 'did', 'not', 'change', 'significantly', 'in', 'group', '2', '.']","(9, 11)","(42, 63)",-1,hl_o,23103798,Abstract,10,test,gold,1825.0
5006,At 3-month followup the number of patients with a partial or full,response,in group 1 had decreased from 11 ( 78.6 % ) to 6 ( 42.9 % ) .,"['At', '3-month', 'followup', 'the', 'number', 'of', 'patients', 'with', 'a', 'partial', 'or', 'full', 'response', 'in', 'group', '1', 'had', 'decreased', 'from', '11', '(', '78.6', '%', ')', 'to', '6', '(', '42.9', '%', ')', '.']","(12, 13)","(65, 73)",-1,ss_o,23103798,Abstract,11,test,gold,2522.0
5007,At 3-month followup the number of patients with a partial or full,response,in group 1 had decreased from 11 ( 78.6 % ) to 6 ( 42.9 % ) .,"['At', '3-month', 'followup', 'the', 'number', 'of', 'patients', 'with', 'a', 'partial', 'or', 'full', 'response', 'in', 'group', '1', 'had', 'decreased', 'from', '11', '(', '78.6', '%', ')', 'to', '6', '(', '42.9', '%', ')', '.']","(12, 13)","(65, 73)",-1,hl_o,23103798,Abstract,11,test,gold,2521.0
5008,No change was evident in group 2 .,,,"['No', 'change', 'was', 'evident', 'in', 'group', '2', '.']",,,,,23103798,Abstract,12,test,gold,
5009,CONCLUSIONS Posterior tibial nerve stimulation can be a viable treatment option in some,patients with refractory monosymptomatic nocturnal enuresis .,,"['CONCLUSIONS', 'Posterior', 'tibial', 'nerve', 'stimulation', 'can', 'be', 'a', 'viable', 'treatment', 'option', 'in', 'some', 'patients', 'with', 'refractory', 'monosymptomatic', 'nocturnal', 'enuresis', '.']","(13, 20)","(87, 148)",-1,ss_p,23103798,Abstract,13,test,gold,7101.0
5010,CONCLUSIONS,Posterior tibial nerve stimulation,can be a viable treatment option in some patients with refractory monosymptomatic nocturnal enuresis .,"['CONCLUSIONS', 'Posterior', 'tibial', 'nerve', 'stimulation', 'can', 'be', 'a', 'viable', 'treatment', 'option', 'in', 'some', 'patients', 'with', 'refractory', 'monosymptomatic', 'nocturnal', 'enuresis', '.']","(1, 5)","(11, 45)",-1,ss_i,23103798,Abstract,13,test,gold,6759.0
5011,CONCLUSIONS,Posterior tibial nerve stimulation,can be a viable treatment option in some patients with refractory monosymptomatic nocturnal enuresis .,"['CONCLUSIONS', 'Posterior', 'tibial', 'nerve', 'stimulation', 'can', 'be', 'a', 'viable', 'treatment', 'option', 'in', 'some', 'patients', 'with', 'refractory', 'monosymptomatic', 'nocturnal', 'enuresis', '.']","(1, 5)","(11, 45)",-1,hl_i,23103798,Abstract,13,test,gold,6760.0
5012,"However , deterioration in some responders with time suggests the need for maintenance protocols .",,,"['However', ',', 'deterioration', 'in', 'some', 'responders', 'with', 'time', 'suggests', 'the', 'need', 'for', 'maintenance', 'protocols', '.']",,,,,23103798,Abstract,14,test,gold,
5013,Custom-fit minimally invasive,total knee arthroplasty :,effect on blood loss and early clinical outcomes .,"['Custom-fit', 'minimally', 'invasive', 'total', 'knee', 'arthroplasty', ':', 'effect', 'on', 'blood', 'loss', 'and', 'early', 'clinical', 'outcomes', '.']","(3, 7)","(29, 54)",-1,ss_i,23114870,Title,0,test,gold,3679.0
5014,Custom-fit minimally invasive total knee arthroplasty : effect on,blood loss and early clinical outcomes .,,"['Custom-fit', 'minimally', 'invasive', 'total', 'knee', 'arthroplasty', ':', 'effect', 'on', 'blood', 'loss', 'and', 'early', 'clinical', 'outcomes', '.']","(9, 16)","(65, 105)",-1,ss_o,23114870,Title,0,test,gold,4757.0
5015,Custom-fit minimally invasive,total knee arthroplasty :,effect on blood loss and early clinical outcomes .,"['Custom-fit', 'minimally', 'invasive', 'total', 'knee', 'arthroplasty', ':', 'effect', 'on', 'blood', 'loss', 'and', 'early', 'clinical', 'outcomes', '.']","(3, 7)","(29, 54)",-1,hl_i,23114870,Title,0,test,gold,3680.0
5016,Custom-fit minimally invasive total knee arthroplasty : effect on,blood loss,and early clinical outcomes .,"['Custom-fit', 'minimally', 'invasive', 'total', 'knee', 'arthroplasty', ':', 'effect', 'on', 'blood', 'loss', 'and', 'early', 'clinical', 'outcomes', '.']","(9, 11)","(65, 75)",-1,hl_o,23114870,Title,0,test,gold,2667.0
5017,Custom-fit minimally invasive total knee arthroplasty : effect on blood loss and,early clinical outcomes,.,"['Custom-fit', 'minimally', 'invasive', 'total', 'knee', 'arthroplasty', ':', 'effect', 'on', 'blood', 'loss', 'and', 'early', 'clinical', 'outcomes', '.']","(12, 15)","(80, 103)",-1,hl_o,23114870,Title,0,test,gold,4755.0
5018,"PURPOSE Recently , new custom-fit pin guides in",total knee arthroplasty ( TKA ),have been introduced .,"['PURPOSE', 'Recently', ',', 'new', 'custom-fit', 'pin', 'guides', 'in', 'total', 'knee', 'arthroplasty', '(', 'TKA', ')', 'have', 'been', 'introduced', '.']","(8, 14)","(47, 78)",-1,ss_i,23114870,Abstract,0,test,gold,3684.0
5019,"PURPOSE Recently , new custom-fit pin guides in",total knee arthroplasty ( TKA ),have been introduced .,"['PURPOSE', 'Recently', ',', 'new', 'custom-fit', 'pin', 'guides', 'in', 'total', 'knee', 'arthroplasty', '(', 'TKA', ')', 'have', 'been', 'introduced', '.']","(8, 14)","(47, 78)",-1,hl_i,23114870,Abstract,0,test,gold,3682.0
5020,Use of these guides may reduce operating time .,,,"['Use', 'of', 'these', 'guides', 'may', 'reduce', 'operating', 'time', '.']",,,,,23114870,Abstract,1,test,gold,
5021,Use of the guides combined with the absence of intramedullary alignment jigs may lead to reduced,blood loss,and improved early outcomes .,"['Use', 'of', 'the', 'guides', 'combined', 'with', 'the', 'absence', 'of', 'intramedullary', 'alignment', 'jigs', 'may', 'lead', 'to', 'reduced', 'blood', 'loss', 'and', 'improved', 'early', 'outcomes', '.']","(16, 18)","(96, 106)",-1,ss_o,23114870,Abstract,2,test,gold,2668.0
5022,Use of the guides combined with the absence of intramedullary alignment jigs may lead to reduced blood loss and improved,early outcomes .,,"['Use', 'of', 'the', 'guides', 'combined', 'with', 'the', 'absence', 'of', 'intramedullary', 'alignment', 'jigs', 'may', 'lead', 'to', 'reduced', 'blood', 'loss', 'and', 'improved', 'early', 'outcomes', '.']","(20, 23)","(120, 136)",-1,ss_o,23114870,Abstract,2,test,gold,423.0
5023,Use of the guides combined with the absence of intramedullary alignment jigs may lead to reduced,blood loss,and improved early outcomes .,"['Use', 'of', 'the', 'guides', 'combined', 'with', 'the', 'absence', 'of', 'intramedullary', 'alignment', 'jigs', 'may', 'lead', 'to', 'reduced', 'blood', 'loss', 'and', 'improved', 'early', 'outcomes', '.']","(16, 18)","(96, 106)",-1,hl_o,23114870,Abstract,2,test,gold,2666.0
5024,Use of the guides combined with the absence of intramedullary alignment jigs may lead to reduced blood loss and improved,early outcomes .,,"['Use', 'of', 'the', 'guides', 'combined', 'with', 'the', 'absence', 'of', 'intramedullary', 'alignment', 'jigs', 'may', 'lead', 'to', 'reduced', 'blood', 'loss', 'and', 'improved', 'early', 'outcomes', '.']","(20, 23)","(120, 136)",-1,hl_o,23114870,Abstract,2,test,gold,424.0
5025,Our aim was to evaluate blood loss and early clinical outcomes in,patients undergoing minimally invasive TKA,using custom-fit magnetic resonance imaging ( MRI ) -based pin guides .,"['Our', 'aim', 'was', 'to', 'evaluate', 'blood', 'loss', 'and', 'early', 'clinical', 'outcomes', 'in', 'patients', 'undergoing', 'minimally', 'invasive', 'TKA', 'using', 'custom-fit', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', '-based', 'pin', 'guides', '.']","(12, 17)","(65, 107)",-1,ss_p,23114870,Abstract,3,test,gold,3604.0
5026,Our aim was to evaluate blood loss and early clinical outcomes in patients undergoing minimally invasive TKA using,custom-fit magnetic resonance imaging ( MRI ) -based pin guides .,,"['Our', 'aim', 'was', 'to', 'evaluate', 'blood', 'loss', 'and', 'early', 'clinical', 'outcomes', 'in', 'patients', 'undergoing', 'minimally', 'invasive', 'TKA', 'using', 'custom-fit', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', '-based', 'pin', 'guides', '.']","(18, 29)","(114, 179)",-1,ss_i,23114870,Abstract,3,test,gold,6491.0
5027,Our aim was to evaluate,blood loss and early clinical outcomes,in patients undergoing minimally invasive TKA using custom-fit magnetic resonance imaging ( MRI ) -based pin guides .,"['Our', 'aim', 'was', 'to', 'evaluate', 'blood', 'loss', 'and', 'early', 'clinical', 'outcomes', 'in', 'patients', 'undergoing', 'minimally', 'invasive', 'TKA', 'using', 'custom-fit', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', '-based', 'pin', 'guides', '.']","(5, 11)","(23, 61)",-1,ss_o,23114870,Abstract,3,test,gold,4758.0
5028,Our aim was to evaluate blood loss and early clinical outcomes in,patients undergoing minimally invasive TKA,using custom-fit magnetic resonance imaging ( MRI ) -based pin guides .,"['Our', 'aim', 'was', 'to', 'evaluate', 'blood', 'loss', 'and', 'early', 'clinical', 'outcomes', 'in', 'patients', 'undergoing', 'minimally', 'invasive', 'TKA', 'using', 'custom-fit', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', '-based', 'pin', 'guides', '.']","(12, 17)","(65, 107)",-1,hl_p,23114870,Abstract,3,test,gold,3605.0
5029,Our aim was to evaluate blood loss and early clinical outcomes in patients undergoing,minimally invasive TKA,using custom-fit magnetic resonance imaging ( MRI ) -based pin guides .,"['Our', 'aim', 'was', 'to', 'evaluate', 'blood', 'loss', 'and', 'early', 'clinical', 'outcomes', 'in', 'patients', 'undergoing', 'minimally', 'invasive', 'TKA', 'using', 'custom-fit', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', '-based', 'pin', 'guides', '.']","(14, 17)","(85, 107)",-1,hl_i,23114870,Abstract,3,test,gold,3603.0
5030,Our aim was to evaluate blood loss and early clinical outcomes in patients undergoing minimally invasive TKA using,custom-fit magnetic resonance imaging ( MRI ) -based pin guides .,,"['Our', 'aim', 'was', 'to', 'evaluate', 'blood', 'loss', 'and', 'early', 'clinical', 'outcomes', 'in', 'patients', 'undergoing', 'minimally', 'invasive', 'TKA', 'using', 'custom-fit', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', '-based', 'pin', 'guides', '.']","(18, 29)","(114, 179)",-1,hl_i,23114870,Abstract,3,test,gold,6492.0
5031,Our aim was to evaluate,blood loss,and early clinical outcomes in patients undergoing minimally invasive TKA using custom-fit magnetic resonance imaging ( MRI ) -based pin guides .,"['Our', 'aim', 'was', 'to', 'evaluate', 'blood', 'loss', 'and', 'early', 'clinical', 'outcomes', 'in', 'patients', 'undergoing', 'minimally', 'invasive', 'TKA', 'using', 'custom-fit', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', '-based', 'pin', 'guides', '.']","(5, 7)","(23, 33)",-1,hl_o,23114870,Abstract,3,test,gold,2665.0
5032,Our aim was to evaluate blood loss and,early clinical outcomes,in patients undergoing minimally invasive TKA using custom-fit magnetic resonance imaging ( MRI ) -based pin guides .,"['Our', 'aim', 'was', 'to', 'evaluate', 'blood', 'loss', 'and', 'early', 'clinical', 'outcomes', 'in', 'patients', 'undergoing', 'minimally', 'invasive', 'TKA', 'using', 'custom-fit', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', '-based', 'pin', 'guides', '.']","(8, 11)","(38, 61)",-1,hl_o,23114870,Abstract,3,test,gold,4756.0
5033,METHODS A prospective study in,80 patients,was carried out .,"['METHODS', 'A', 'prospective', 'study', 'in', '80', 'patients', 'was', 'carried', 'out', '.']","(5, 7)","(30, 41)",-1,ss_p,23114870,Abstract,4,test,gold,3744.0
5034,METHODS A prospective study in,80 patients,was carried out .,"['METHODS', 'A', 'prospective', 'study', 'in', '80', 'patients', 'was', 'carried', 'out', '.']","(5, 7)","(30, 41)",-1,hl_p,23114870,Abstract,4,test,gold,3743.0
5035,Patients were divided randomly into 2 equal groups .,,,"['Patients', 'were', 'divided', 'randomly', 'into', '2', 'equal', 'groups', '.']",,,,,23114870,Abstract,5,test,gold,
5036,"In one group ,",intramedullary alignment jigs,were used .,"['In', 'one', 'group', ',', 'intramedullary', 'alignment', 'jigs', 'were', 'used', '.']","(4, 7)","(14, 43)",-1,ss_i,23114870,Abstract,6,test,gold,1767.0
5037,"In one group ,",intramedullary alignment jigs,were used .,"['In', 'one', 'group', ',', 'intramedullary', 'alignment', 'jigs', 'were', 'used', '.']","(4, 7)","(14, 43)",-1,hl_i,23114870,Abstract,6,test,gold,1768.0
5038,"In the second group ,",custom-fit MRI-based pin guides,were used .,"['In', 'the', 'second', 'group', ',', 'custom-fit', 'MRI-based', 'pin', 'guides', 'were', 'used', '.']","(5, 9)","(21, 52)",-1,ss_i,23114870,Abstract,7,test,gold,1402.0
5039,"In the second group ,",custom-fit MRI-based pin guides,were used .,"['In', 'the', 'second', 'group', ',', 'custom-fit', 'MRI-based', 'pin', 'guides', 'were', 'used', '.']","(5, 9)","(21, 52)",-1,hl_i,23114870,Abstract,7,test,gold,1403.0
5040,All patients received the same,cemented posterior-stabilized implant,through a mini-midvastus approach .,"['All', 'patients', 'received', 'the', 'same', 'cemented', 'posterior-stabilized', 'implant', 'through', 'a', 'mini-midvastus', 'approach', '.']","(5, 8)","(30, 67)",-1,ss_i,23114870,Abstract,8,test,gold,4074.0
5041,All patients received the same,cemented posterior-stabilized implant,through a mini-midvastus approach .,"['All', 'patients', 'received', 'the', 'same', 'cemented', 'posterior-stabilized', 'implant', 'through', 'a', 'mini-midvastus', 'approach', '.']","(5, 8)","(30, 67)",-1,hl_i,23114870,Abstract,8,test,gold,4075.0
5042,The,volume in the drain bottles,was recorded after 48 h. Hb loss was estimated by subtracting the postoperative from the preoperative Hb level .,"['The', 'volume', 'in', 'the', 'drain', 'bottles', 'was', 'recorded', 'after', '48', 'h.', 'Hb', 'loss', 'was', 'estimated', 'by', 'subtracting', 'the', 'postoperative', 'from', 'the', 'preoperative', 'Hb', 'level', '.']","(1, 6)","(3, 30)",-1,ss_o,23114870,Abstract,9,test,gold,1724.0
5043,The volume in the drain bottles was recorded after 48 h.,Hb loss,was estimated by subtracting the postoperative from the preoperative Hb level .,"['The', 'volume', 'in', 'the', 'drain', 'bottles', 'was', 'recorded', 'after', '48', 'h.', 'Hb', 'loss', 'was', 'estimated', 'by', 'subtracting', 'the', 'postoperative', 'from', 'the', 'preoperative', 'Hb', 'level', '.']","(11, 13)","(56, 63)",-1,ss_o,23114870,Abstract,9,test,gold,1650.0
5044,The volume in the drain bottles was recorded after 48 h. Hb loss was estimated by subtracting the postoperative from the preoperative,Hb level .,,"['The', 'volume', 'in', 'the', 'drain', 'bottles', 'was', 'recorded', 'after', '48', 'h.', 'Hb', 'loss', 'was', 'estimated', 'by', 'subtracting', 'the', 'postoperative', 'from', 'the', 'preoperative', 'Hb', 'level', '.']","(22, 25)","(133, 143)",-1,ss_o,23114870,Abstract,9,test,gold,1654.0
5045,The volume in the drain bottles was recorded after 48 h.,Hb loss,was estimated by subtracting the postoperative from the preoperative Hb level .,"['The', 'volume', 'in', 'the', 'drain', 'bottles', 'was', 'recorded', 'after', '48', 'h.', 'Hb', 'loss', 'was', 'estimated', 'by', 'subtracting', 'the', 'postoperative', 'from', 'the', 'preoperative', 'Hb', 'level', '.']","(11, 13)","(56, 63)",-1,hl_o,23114870,Abstract,9,test,gold,1651.0
5046,,Transfusion requirements and surgical time,were recorded .,"['Transfusion', 'requirements', 'and', 'surgical', 'time', 'were', 'recorded', '.']","(0, 5)","(0, 42)",-1,ss_o,23114870,Abstract,10,test,gold,4157.0
5047,,Transfusion requirements,and surgical time were recorded .,"['Transfusion', 'requirements', 'and', 'surgical', 'time', 'were', 'recorded', '.']","(0, 2)","(0, 24)",-1,hl_o,23114870,Abstract,10,test,gold,4158.0
5048,Transfusion requirements and,surgical time,were recorded .,"['Transfusion', 'requirements', 'and', 'surgical', 'time', 'were', 'recorded', '.']","(3, 5)","(28, 41)",-1,hl_o,23114870,Abstract,10,test,gold,4159.0
5049,Outcome measures were,"Knee Society Scores ( KSS ) , knee flexion , knee swelling and pain .",,"['Outcome', 'measures', 'were', 'Knee', 'Society', 'Scores', '(', 'KSS', ')', ',', 'knee', 'flexion', ',', 'knee', 'swelling', 'and', 'pain', '.']","(3, 18)","(21, 90)",-1,ss_o,23114870,Abstract,11,test,gold,5940.0
5050,Outcome measures were,"Knee Society Scores ( KSS ) , knee flexion , knee swelling and pain .",,"['Outcome', 'measures', 'were', 'Knee', 'Society', 'Scores', '(', 'KSS', ')', ',', 'knee', 'flexion', ',', 'knee', 'swelling', 'and', 'pain', '.']","(3, 18)","(21, 90)",-1,hl_o,23114870,Abstract,11,test,gold,5941.0
5051,RESULTS There was lower mean drainage of blood in the,custom-fit,group ( 391 ml vs. 603 ml ; p < 0.0001 ) .,"['RESULTS', 'There', 'was', 'lower', 'mean', 'drainage', 'of', 'blood', 'in', 'the', 'custom-fit', 'group', '(', '391', 'ml', 'vs.', '603', 'ml', ';', 'p', '<', '0.0001', ')', '.']","(10, 11)","(53, 63)",-1,ss_i,23114870,Abstract,12,test,gold,
5052,RESULTS There was lower mean,drainage of blood,in the custom-fit group ( 391 ml vs. 603 ml ; p < 0.0001 ) .,"['RESULTS', 'There', 'was', 'lower', 'mean', 'drainage', 'of', 'blood', 'in', 'the', 'custom-fit', 'group', '(', '391', 'ml', 'vs.', '603', 'ml', ';', 'p', '<', '0.0001', ')', '.']","(5, 8)","(28, 45)",-1,ss_o,23114870,Abstract,12,test,gold,2657.0
5053,RESULTS There was lower mean drainage of blood in the,custom-fit,group ( 391 ml vs. 603 ml ; p < 0.0001 ) .,"['RESULTS', 'There', 'was', 'lower', 'mean', 'drainage', 'of', 'blood', 'in', 'the', 'custom-fit', 'group', '(', '391', 'ml', 'vs.', '603', 'ml', ';', 'p', '<', '0.0001', ')', '.']","(10, 11)","(53, 63)",-1,hl_i,23114870,Abstract,12,test,gold,
5054,RESULTS There was lower mean,drainage of blood,in the custom-fit group ( 391 ml vs. 603 ml ; p < 0.0001 ) .,"['RESULTS', 'There', 'was', 'lower', 'mean', 'drainage', 'of', 'blood', 'in', 'the', 'custom-fit', 'group', '(', '391', 'ml', 'vs.', '603', 'ml', ';', 'p', '<', '0.0001', ')', '.']","(5, 8)","(28, 45)",-1,hl_o,23114870,Abstract,12,test,gold,2658.0
5055,There was no difference in estimated,loss of Hb,( 3.6 g/dl vs. 4.1 g/dl ; n.s . ),"['There', 'was', 'no', 'difference', 'in', 'estimated', 'loss', 'of', 'Hb', '(', '3.6', 'g/dl', 'vs.', '4.1', 'g/dl', ';', 'n.s', '.', ')']","(6, 9)","(36, 46)",-1,ss_o,23114870,Abstract,13,test,gold,1649.0
5056,There was no difference in estimated,loss of Hb,( 3.6 g/dl vs. 4.1 g/dl ; n.s . ),"['There', 'was', 'no', 'difference', 'in', 'estimated', 'loss', 'of', 'Hb', '(', '3.6', 'g/dl', 'vs.', '4.1', 'g/dl', ';', 'n.s', '.', ')']","(6, 9)","(36, 46)",-1,hl_o,23114870,Abstract,13,test,gold,1648.0
5057,and in transfusion requirements ( 7.5 % vs. 10 % ; n.s. ) .,,,"['and', 'in', 'transfusion', 'requirements', '(', '7.5', '%', 'vs.', '10', '%', ';', 'n.s.', ')', '.']",,,,,23114870,Abstract,14,test,gold,
5058,Surgical time was reduced in the,custom-fit,group ( 12 min less ; p = 0.001 ) .,"['Surgical', 'time', 'was', 'reduced', 'in', 'the', 'custom-fit', 'group', '(', '12', 'min', 'less', ';', 'p', '=', '0.001', ')', '.']","(6, 7)","(32, 42)",-1,ss_i,23114870,Abstract,15,test,gold,
5059,,Surgical time,was reduced in the custom-fit group ( 12 min less ; p = 0.001 ) .,"['Surgical', 'time', 'was', 'reduced', 'in', 'the', 'custom-fit', 'group', '(', '12', 'min', 'less', ';', 'p', '=', '0.001', ')', '.']","(0, 2)","(0, 13)",-1,ss_o,23114870,Abstract,15,test,gold,4162.0
5060,Surgical time was reduced in the,custom-fit,group ( 12 min less ; p = 0.001 ) .,"['Surgical', 'time', 'was', 'reduced', 'in', 'the', 'custom-fit', 'group', '(', '12', 'min', 'less', ';', 'p', '=', '0.001', ')', '.']","(6, 7)","(32, 42)",-1,hl_i,23114870,Abstract,15,test,gold,
5061,,Surgical time,was reduced in the custom-fit group ( 12 min less ; p = 0.001 ) .,"['Surgical', 'time', 'was', 'reduced', 'in', 'the', 'custom-fit', 'group', '(', '12', 'min', 'less', ';', 'p', '=', '0.001', ')', '.']","(0, 2)","(0, 13)",-1,hl_o,23114870,Abstract,15,test,gold,4163.0
5062,,KSS,"measured at week 2 , 6 and 12 showed no significant difference between groups .","['KSS', 'measured', 'at', 'week', '2', ',', '6', 'and', '12', 'showed', 'no', 'significant', 'difference', 'between', 'groups', '.']","(0, 1)","(0, 3)",-1,ss_o,23114870,Abstract,16,test,gold,625.0
5063,,KSS,"measured at week 2 , 6 and 12 showed no significant difference between groups .","['KSS', 'measured', 'at', 'week', '2', ',', '6', 'and', '12', 'showed', 'no', 'significant', 'difference', 'between', 'groups', '.']","(0, 1)","(0, 3)",-1,hl_o,23114870,Abstract,16,test,gold,626.0
5064,,Knee flexion,"measured on days 7 , 10 and at week 6 , 12 and knee swelling and pain measured on days 1 , 3 , 10 and at week 6 , 12 showed no significant difference between groups .","['Knee', 'flexion', 'measured', 'on', 'days', '7', ',', '10', 'and', 'at', 'week', '6', ',', '12', 'and', 'knee', 'swelling', 'and', 'pain', 'measured', 'on', 'days', '1', ',', '3', ',', '10', 'and', 'at', 'week', '6', ',', '12', 'showed', 'no', 'significant', 'difference', 'between', 'groups', '.']","(0, 2)","(0, 12)",-1,ss_o,23114870,Abstract,17,test,gold,3687.0
5065,"Knee flexion measured on days 7 , 10 and at week 6 , 12 and",knee swelling,"and pain measured on days 1 , 3 , 10 and at week 6 , 12 showed no significant difference between groups .","['Knee', 'flexion', 'measured', 'on', 'days', '7', ',', '10', 'and', 'at', 'week', '6', ',', '12', 'and', 'knee', 'swelling', 'and', 'pain', 'measured', 'on', 'days', '1', ',', '3', ',', '10', 'and', 'at', 'week', '6', ',', '12', 'showed', 'no', 'significant', 'difference', 'between', 'groups', '.']","(15, 17)","(59, 72)",-1,ss_o,23114870,Abstract,17,test,gold,3655.0
5066,"Knee flexion measured on days 7 , 10 and at week 6 , 12 and knee swelling and",pain,"measured on days 1 , 3 , 10 and at week 6 , 12 showed no significant difference between groups .","['Knee', 'flexion', 'measured', 'on', 'days', '7', ',', '10', 'and', 'at', 'week', '6', ',', '12', 'and', 'knee', 'swelling', 'and', 'pain', 'measured', 'on', 'days', '1', ',', '3', ',', '10', 'and', 'at', 'week', '6', ',', '12', 'showed', 'no', 'significant', 'difference', 'between', 'groups', '.']","(18, 19)","(77, 81)",-1,ss_o,23114870,Abstract,17,test,gold,2298.0
5067,,Knee flexion,"measured on days 7 , 10 and at week 6 , 12 and knee swelling and pain measured on days 1 , 3 , 10 and at week 6 , 12 showed no significant difference between groups .","['Knee', 'flexion', 'measured', 'on', 'days', '7', ',', '10', 'and', 'at', 'week', '6', ',', '12', 'and', 'knee', 'swelling', 'and', 'pain', 'measured', 'on', 'days', '1', ',', '3', ',', '10', 'and', 'at', 'week', '6', ',', '12', 'showed', 'no', 'significant', 'difference', 'between', 'groups', '.']","(0, 2)","(0, 12)",-1,hl_o,23114870,Abstract,17,test,gold,3688.0
5068,"Knee flexion measured on days 7 , 10 and at week 6 , 12 and",knee swelling,"and pain measured on days 1 , 3 , 10 and at week 6 , 12 showed no significant difference between groups .","['Knee', 'flexion', 'measured', 'on', 'days', '7', ',', '10', 'and', 'at', 'week', '6', ',', '12', 'and', 'knee', 'swelling', 'and', 'pain', 'measured', 'on', 'days', '1', ',', '3', ',', '10', 'and', 'at', 'week', '6', ',', '12', 'showed', 'no', 'significant', 'difference', 'between', 'groups', '.']","(15, 17)","(59, 72)",-1,hl_o,23114870,Abstract,17,test,gold,3656.0
5069,"Knee flexion measured on days 7 , 10 and at week 6 , 12 and knee swelling and",pain,"measured on days 1 , 3 , 10 and at week 6 , 12 showed no significant difference between groups .","['Knee', 'flexion', 'measured', 'on', 'days', '7', ',', '10', 'and', 'at', 'week', '6', ',', '12', 'and', 'knee', 'swelling', 'and', 'pain', 'measured', 'on', 'days', '1', ',', '3', ',', '10', 'and', 'at', 'week', '6', ',', '12', 'showed', 'no', 'significant', 'difference', 'between', 'groups', '.']","(18, 19)","(77, 81)",-1,hl_o,23114870,Abstract,17,test,gold,2297.0
5070,CONCLUSIONS Using,custom-fit pin guides,"reduces blood drainage , but not the estimated Hb loss in minimally invasive TKA and does not affect transfusion rate .","['CONCLUSIONS', 'Using', 'custom-fit', 'pin', 'guides', 'reduces', 'blood', 'drainage', ',', 'but', 'not', 'the', 'estimated', 'Hb', 'loss', 'in', 'minimally', 'invasive', 'TKA', 'and', 'does', 'not', 'affect', 'transfusion', 'rate', '.']","(2, 5)","(17, 38)",-1,ss_i,23114870,Abstract,18,test,gold,1401.0
5071,CONCLUSIONS Using custom-fit pin guides reduces,blood drainage,", but not the estimated Hb loss in minimally invasive TKA and does not affect transfusion rate .","['CONCLUSIONS', 'Using', 'custom-fit', 'pin', 'guides', 'reduces', 'blood', 'drainage', ',', 'but', 'not', 'the', 'estimated', 'Hb', 'loss', 'in', 'minimally', 'invasive', 'TKA', 'and', 'does', 'not', 'affect', 'transfusion', 'rate', '.']","(6, 8)","(47, 61)",-1,ss_o,23114870,Abstract,18,test,gold,2656.0
5072,"CONCLUSIONS Using custom-fit pin guides reduces blood drainage , but not the estimated",Hb loss,in minimally invasive TKA and does not affect transfusion rate .,"['CONCLUSIONS', 'Using', 'custom-fit', 'pin', 'guides', 'reduces', 'blood', 'drainage', ',', 'but', 'not', 'the', 'estimated', 'Hb', 'loss', 'in', 'minimally', 'invasive', 'TKA', 'and', 'does', 'not', 'affect', 'transfusion', 'rate', '.']","(13, 15)","(86, 93)",-1,ss_o,23114870,Abstract,18,test,gold,1647.0
5073,"CONCLUSIONS Using custom-fit pin guides reduces blood drainage , but not the estimated Hb loss in minimally invasive TKA and does not affect",transfusion rate .,,"['CONCLUSIONS', 'Using', 'custom-fit', 'pin', 'guides', 'reduces', 'blood', 'drainage', ',', 'but', 'not', 'the', 'estimated', 'Hb', 'loss', 'in', 'minimally', 'invasive', 'TKA', 'and', 'does', 'not', 'affect', 'transfusion', 'rate', '.']","(23, 26)","(140, 158)",-1,ss_o,23114870,Abstract,18,test,gold,4155.0
5074,CONCLUSIONS Using,custom-fit pin guides,"reduces blood drainage , but not the estimated Hb loss in minimally invasive TKA and does not affect transfusion rate .","['CONCLUSIONS', 'Using', 'custom-fit', 'pin', 'guides', 'reduces', 'blood', 'drainage', ',', 'but', 'not', 'the', 'estimated', 'Hb', 'loss', 'in', 'minimally', 'invasive', 'TKA', 'and', 'does', 'not', 'affect', 'transfusion', 'rate', '.']","(2, 5)","(17, 38)",-1,hl_i,23114870,Abstract,18,test,gold,1400.0
5075,CONCLUSIONS Using custom-fit pin guides reduces,blood drainage,", but not the estimated Hb loss in minimally invasive TKA and does not affect transfusion rate .","['CONCLUSIONS', 'Using', 'custom-fit', 'pin', 'guides', 'reduces', 'blood', 'drainage', ',', 'but', 'not', 'the', 'estimated', 'Hb', 'loss', 'in', 'minimally', 'invasive', 'TKA', 'and', 'does', 'not', 'affect', 'transfusion', 'rate', '.']","(6, 8)","(47, 61)",-1,hl_o,23114870,Abstract,18,test,gold,2655.0
5076,"CONCLUSIONS Using custom-fit pin guides reduces blood drainage , but not the estimated",Hb loss,in minimally invasive TKA and does not affect transfusion rate .,"['CONCLUSIONS', 'Using', 'custom-fit', 'pin', 'guides', 'reduces', 'blood', 'drainage', ',', 'but', 'not', 'the', 'estimated', 'Hb', 'loss', 'in', 'minimally', 'invasive', 'TKA', 'and', 'does', 'not', 'affect', 'transfusion', 'rate', '.']","(13, 15)","(86, 93)",-1,hl_o,23114870,Abstract,18,test,gold,1646.0
5077,"CONCLUSIONS Using custom-fit pin guides reduces blood drainage , but not the estimated Hb loss in minimally invasive TKA and does not affect",transfusion rate .,,"['CONCLUSIONS', 'Using', 'custom-fit', 'pin', 'guides', 'reduces', 'blood', 'drainage', ',', 'but', 'not', 'the', 'estimated', 'Hb', 'loss', 'in', 'minimally', 'invasive', 'TKA', 'and', 'does', 'not', 'affect', 'transfusion', 'rate', '.']","(23, 26)","(140, 158)",-1,hl_o,23114870,Abstract,18,test,gold,4156.0
5078,,Surgical time,is reduced .,"['Surgical', 'time', 'is', 'reduced', '.']","(0, 2)","(0, 13)",-1,ss_o,23114870,Abstract,19,test,gold,4161.0
5079,,Surgical time,is reduced .,"['Surgical', 'time', 'is', 'reduced', '.']","(0, 2)","(0, 13)",-1,hl_o,23114870,Abstract,19,test,gold,4160.0
5080,There is no effect on the,early clinical outcomes .,,"['There', 'is', 'no', 'effect', 'on', 'the', 'early', 'clinical', 'outcomes', '.']","(6, 10)","(25, 50)",-1,ss_o,23114870,Abstract,20,test,gold,4754.0
5081,There is no effect on the,early clinical outcomes .,,"['There', 'is', 'no', 'effect', 'on', 'the', 'early', 'clinical', 'outcomes', '.']","(6, 10)","(25, 50)",-1,hl_o,23114870,Abstract,20,test,gold,4753.0
5082,"LEVEL OF EVIDENCE Therapeutic study , Level I .",,,"['LEVEL', 'OF', 'EVIDENCE', 'Therapeutic', 'study', ',', 'Level', 'I', '.']",,,,,23114870,Abstract,21,test,gold,
5083,Influence of lime juice on the severity of,sickle cell anemia .,,"['Influence', 'of', 'lime', 'juice', 'on', 'the', 'severity', 'of', 'sickle', 'cell', 'anemia', '.']","(8, 12)","(42, 62)",-1,ss_p,23356250,Title,0,test,gold,4544.0
5084,Influence of,lime juice,on the severity of sickle cell anemia .,"['Influence', 'of', 'lime', 'juice', 'on', 'the', 'severity', 'of', 'sickle', 'cell', 'anemia', '.']","(2, 4)","(12, 22)",-1,ss_i,23356250,Title,0,test,gold,4595.0
5085,Influence of lime juice on the severity of,sickle cell anemia .,,"['Influence', 'of', 'lime', 'juice', 'on', 'the', 'severity', 'of', 'sickle', 'cell', 'anemia', '.']","(8, 12)","(42, 62)",-1,hl_p,23356250,Title,0,test,gold,4545.0
5086,Influence of,lime juice,on the severity of sickle cell anemia .,"['Influence', 'of', 'lime', 'juice', 'on', 'the', 'severity', 'of', 'sickle', 'cell', 'anemia', '.']","(2, 4)","(12, 22)",-1,hl_i,23356250,Title,0,test,gold,4596.0
5087,BACKGROUND AND OBJECTIVES The pain in,sickle cell anemia ( SCA ),"is often triggered by dehydration , acidosis , and fever that are usually due to malaria .","['BACKGROUND', 'AND', 'OBJECTIVES', 'The', 'pain', 'in', 'sickle', 'cell', 'anemia', '(', 'SCA', ')', 'is', 'often', 'triggered', 'by', 'dehydration', ',', 'acidosis', ',', 'and', 'fever', 'that', 'are', 'usually', 'due', 'to', 'malaria', '.']","(6, 12)","(37, 63)",-1,ss_p,23356250,Abstract,0,test,gold,4543.0
5088,Intake of,lime juice,was recently demonstrated to facilitate clearance of the malaria parasite .,"['Intake', 'of', 'lime', 'juice', 'was', 'recently', 'demonstrated', 'to', 'facilitate', 'clearance', 'of', 'the', 'malaria', 'parasite', '.']","(2, 4)","(9, 19)",-1,ss_i,23356250,Abstract,1,test,gold,4594.0
5089,Intake of,lime juice,was recently demonstrated to facilitate clearance of the malaria parasite .,"['Intake', 'of', 'lime', 'juice', 'was', 'recently', 'demonstrated', 'to', 'facilitate', 'clearance', 'of', 'the', 'malaria', 'parasite', '.']","(2, 4)","(9, 19)",-1,hl_i,23356250,Abstract,1,test,gold,4593.0
5090,It was therefore sought to determine whether regular intake of,lime juice,"will ameliorate crisis , especially recurrent bone pain .","['It', 'was', 'therefore', 'sought', 'to', 'determine', 'whether', 'regular', 'intake', 'of', 'lime', 'juice', 'will', 'ameliorate', 'crisis', ',', 'especially', 'recurrent', 'bone', 'pain', '.']","(10, 12)","(62, 72)",-1,ss_i,23356250,Abstract,2,test,gold,4592.0
5091,It was therefore sought to determine whether regular intake of lime juice will ameliorate,crisis,", especially recurrent bone pain .","['It', 'was', 'therefore', 'sought', 'to', 'determine', 'whether', 'regular', 'intake', 'of', 'lime', 'juice', 'will', 'ameliorate', 'crisis', ',', 'especially', 'recurrent', 'bone', 'pain', '.']","(14, 15)","(89, 95)",-1,ss_o,23356250,Abstract,2,test,gold,2555.0
5092,"It was therefore sought to determine whether regular intake of lime juice will ameliorate crisis , especially",recurrent bone pain .,,"['It', 'was', 'therefore', 'sought', 'to', 'determine', 'whether', 'regular', 'intake', 'of', 'lime', 'juice', 'will', 'ameliorate', 'crisis', ',', 'especially', 'recurrent', 'bone', 'pain', '.']","(17, 21)","(109, 130)",-1,ss_o,23356250,Abstract,2,test,gold,3119.0
5093,It was therefore sought to determine whether regular intake of,lime juice,"will ameliorate crisis , especially recurrent bone pain .","['It', 'was', 'therefore', 'sought', 'to', 'determine', 'whether', 'regular', 'intake', 'of', 'lime', 'juice', 'will', 'ameliorate', 'crisis', ',', 'especially', 'recurrent', 'bone', 'pain', '.']","(10, 12)","(62, 72)",-1,hl_i,23356250,Abstract,2,test,gold,4591.0
5094,"It was therefore sought to determine whether regular intake of lime juice will ameliorate crisis , especially",recurrent bone pain .,,"['It', 'was', 'therefore', 'sought', 'to', 'determine', 'whether', 'regular', 'intake', 'of', 'lime', 'juice', 'will', 'ameliorate', 'crisis', ',', 'especially', 'recurrent', 'bone', 'pain', '.']","(17, 21)","(109, 130)",-1,hl_o,23356250,Abstract,2,test,gold,3120.0
5095,"DESIGN In this preliminary , open-labeled , randomized study , the effects of lime juice on the clinical and some laboratory characteristics of",children with SCA,were tested .,"['DESIGN', 'In', 'this', 'preliminary', ',', 'open-labeled', ',', 'randomized', 'study', ',', 'the', 'effects', 'of', 'lime', 'juice', 'on', 'the', 'clinical', 'and', 'some', 'laboratory', 'characteristics', 'of', 'children', 'with', 'SCA', 'were', 'tested', '.']","(23, 26)","(143, 160)",-1,ss_p,23356250,Abstract,3,test,gold,2212.0
5096,"DESIGN In this preliminary , open-labeled , randomized study , the effects of",lime juice,on the clinical and some laboratory characteristics of children with SCA were tested .,"['DESIGN', 'In', 'this', 'preliminary', ',', 'open-labeled', ',', 'randomized', 'study', ',', 'the', 'effects', 'of', 'lime', 'juice', 'on', 'the', 'clinical', 'and', 'some', 'laboratory', 'characteristics', 'of', 'children', 'with', 'SCA', 'were', 'tested', '.']","(13, 15)","(77, 87)",-1,ss_i,23356250,Abstract,3,test,gold,4590.0
5097,"DESIGN In this preliminary , open-labeled , randomized study , the effects of lime juice on the",clinical and some laboratory characteristics,of children with SCA were tested .,"['DESIGN', 'In', 'this', 'preliminary', ',', 'open-labeled', ',', 'randomized', 'study', ',', 'the', 'effects', 'of', 'lime', 'juice', 'on', 'the', 'clinical', 'and', 'some', 'laboratory', 'characteristics', 'of', 'children', 'with', 'SCA', 'were', 'tested', '.']","(17, 22)","(95, 139)",-1,ss_o,23356250,Abstract,3,test,gold,4746.0
5098,"DESIGN In this preliminary , open-labeled , randomized study , the effects of lime juice on the clinical and some laboratory characteristics of",children,with SCA were tested .,"['DESIGN', 'In', 'this', 'preliminary', ',', 'open-labeled', ',', 'randomized', 'study', ',', 'the', 'effects', 'of', 'lime', 'juice', 'on', 'the', 'clinical', 'and', 'some', 'laboratory', 'characteristics', 'of', 'children', 'with', 'SCA', 'were', 'tested', '.']","(23, 24)","(143, 151)",-1,hl_p,23356250,Abstract,3,test,gold,2122.0
5099,"DESIGN In this preliminary , open-labeled , randomized study , the effects of lime juice on the clinical and some laboratory characteristics of children with",SCA,were tested .,"['DESIGN', 'In', 'this', 'preliminary', ',', 'open-labeled', ',', 'randomized', 'study', ',', 'the', 'effects', 'of', 'lime', 'juice', 'on', 'the', 'clinical', 'and', 'some', 'laboratory', 'characteristics', 'of', 'children', 'with', 'SCA', 'were', 'tested', '.']","(25, 26)","(157, 160)",-1,hl_p,23356250,Abstract,3,test,gold,2210.0
5100,"DESIGN In this preliminary , open-labeled , randomized study , the effects of",lime juice,on the clinical and some laboratory characteristics of children with SCA were tested .,"['DESIGN', 'In', 'this', 'preliminary', ',', 'open-labeled', ',', 'randomized', 'study', ',', 'the', 'effects', 'of', 'lime', 'juice', 'on', 'the', 'clinical', 'and', 'some', 'laboratory', 'characteristics', 'of', 'children', 'with', 'SCA', 'were', 'tested', '.']","(13, 15)","(77, 87)",-1,hl_i,23356250,Abstract,3,test,gold,4589.0
5101,RESULTS Among the,113 children with SCA studied in two hospitals,", the 58 receiving lime treatment had lower rates of significant painful episodes than the 55 without lime ( 37 versus 83 crises in 6 months , and 0.64±0.11 versus 1.51±0.34 average rates per child , p < 0.001 ) .","['RESULTS', 'Among', 'the', '113', 'children', 'with', 'SCA', 'studied', 'in', 'two', 'hospitals', ',', 'the', '58', 'receiving', 'lime', 'treatment', 'had', 'lower', 'rates', 'of', 'significant', 'painful', 'episodes', 'than', 'the', '55', 'without', 'lime', '(', '37', 'versus', '83', 'crises', 'in', '6', 'months', ',', 'and', '0.64±0.11', 'versus', '1.51±0.34', 'average', 'rates', 'per', 'child', ',', 'p', '<', '0.001', ')', '.']","(3, 11)","(17, 63)",-1,ss_p,23356250,Abstract,4,test,gold,6195.0
5102,"RESULTS Among the 113 children with SCA studied in two hospitals , the 58 receiving",lime,"treatment had lower rates of significant painful episodes than the 55 without lime ( 37 versus 83 crises in 6 months , and 0.64±0.11 versus 1.51±0.34 average rates per child , p < 0.001 ) .","['RESULTS', 'Among', 'the', '113', 'children', 'with', 'SCA', 'studied', 'in', 'two', 'hospitals', ',', 'the', '58', 'receiving', 'lime', 'treatment', 'had', 'lower', 'rates', 'of', 'significant', 'painful', 'episodes', 'than', 'the', '55', 'without', 'lime', '(', '37', 'versus', '83', 'crises', 'in', '6', 'months', ',', 'and', '0.64±0.11', 'versus', '1.51±0.34', 'average', 'rates', 'per', 'child', ',', 'p', '<', '0.001', ')', '.']","(15, 16)","(83, 87)",-1,ss_i,23356250,Abstract,4,test,gold,268.0
5103,"RESULTS Among the 113 children with SCA studied in two hospitals , the 58 receiving lime treatment had lower rates of significant painful episodes than the 55",without lime,"( 37 versus 83 crises in 6 months , and 0.64±0.11 versus 1.51±0.34 average rates per child , p < 0.001 ) .","['RESULTS', 'Among', 'the', '113', 'children', 'with', 'SCA', 'studied', 'in', 'two', 'hospitals', ',', 'the', '58', 'receiving', 'lime', 'treatment', 'had', 'lower', 'rates', 'of', 'significant', 'painful', 'episodes', 'than', 'the', '55', 'without', 'lime', '(', '37', 'versus', '83', 'crises', 'in', '6', 'months', ',', 'and', '0.64±0.11', 'versus', '1.51±0.34', 'average', 'rates', 'per', 'child', ',', 'p', '<', '0.001', ')', '.']","(27, 29)","(158, 170)",-1,ss_i,23356250,Abstract,4,test,gold,266.0
5104,"RESULTS Among the 113 children with SCA studied in two hospitals , the 58 receiving lime treatment had lower",rates of significant painful episodes,"than the 55 without lime ( 37 versus 83 crises in 6 months , and 0.64±0.11 versus 1.51±0.34 average rates per child , p < 0.001 ) .","['RESULTS', 'Among', 'the', '113', 'children', 'with', 'SCA', 'studied', 'in', 'two', 'hospitals', ',', 'the', '58', 'receiving', 'lime', 'treatment', 'had', 'lower', 'rates', 'of', 'significant', 'painful', 'episodes', 'than', 'the', '55', 'without', 'lime', '(', '37', 'versus', '83', 'crises', 'in', '6', 'months', ',', 'and', '0.64±0.11', 'versus', '1.51±0.34', 'average', 'rates', 'per', 'child', ',', 'p', '<', '0.001', ')', '.']","(19, 24)","(108, 145)",-1,ss_o,23356250,Abstract,4,test,gold,3463.0
5105,RESULTS Among the,113 children,"with SCA studied in two hospitals , the 58 receiving lime treatment had lower rates of significant painful episodes than the 55 without lime ( 37 versus 83 crises in 6 months , and 0.64±0.11 versus 1.51±0.34 average rates per child , p < 0.001 ) .","['RESULTS', 'Among', 'the', '113', 'children', 'with', 'SCA', 'studied', 'in', 'two', 'hospitals', ',', 'the', '58', 'receiving', 'lime', 'treatment', 'had', 'lower', 'rates', 'of', 'significant', 'painful', 'episodes', 'than', 'the', '55', 'without', 'lime', '(', '37', 'versus', '83', 'crises', 'in', '6', 'months', ',', 'and', '0.64±0.11', 'versus', '1.51±0.34', 'average', 'rates', 'per', 'child', ',', 'p', '<', '0.001', ')', '.']","(3, 5)","(17, 29)",-1,hl_p,23356250,Abstract,4,test,gold,2121.0
5106,RESULTS Among the 113 children with,SCA,"studied in two hospitals , the 58 receiving lime treatment had lower rates of significant painful episodes than the 55 without lime ( 37 versus 83 crises in 6 months , and 0.64±0.11 versus 1.51±0.34 average rates per child , p < 0.001 ) .","['RESULTS', 'Among', 'the', '113', 'children', 'with', 'SCA', 'studied', 'in', 'two', 'hospitals', ',', 'the', '58', 'receiving', 'lime', 'treatment', 'had', 'lower', 'rates', 'of', 'significant', 'painful', 'episodes', 'than', 'the', '55', 'without', 'lime', '(', '37', 'versus', '83', 'crises', 'in', '6', 'months', ',', 'and', '0.64±0.11', 'versus', '1.51±0.34', 'average', 'rates', 'per', 'child', ',', 'p', '<', '0.001', ')', '.']","(6, 7)","(35, 38)",-1,hl_p,23356250,Abstract,4,test,gold,2211.0
5107,"RESULTS Among the 113 children with SCA studied in two hospitals , the 58 receiving lime treatment had lower rates of significant painful episodes than the 55",without lime,"( 37 versus 83 crises in 6 months , and 0.64±0.11 versus 1.51±0.34 average rates per child , p < 0.001 ) .","['RESULTS', 'Among', 'the', '113', 'children', 'with', 'SCA', 'studied', 'in', 'two', 'hospitals', ',', 'the', '58', 'receiving', 'lime', 'treatment', 'had', 'lower', 'rates', 'of', 'significant', 'painful', 'episodes', 'than', 'the', '55', 'without', 'lime', '(', '37', 'versus', '83', 'crises', 'in', '6', 'months', ',', 'and', '0.64±0.11', 'versus', '1.51±0.34', 'average', 'rates', 'per', 'child', ',', 'p', '<', '0.001', ')', '.']","(27, 29)","(158, 170)",-1,hl_i,23356250,Abstract,4,test,gold,267.0
5108,"RESULTS Among the 113 children with SCA studied in two hospitals , the 58 receiving lime treatment had lower rates of",significant painful episodes,"than the 55 without lime ( 37 versus 83 crises in 6 months , and 0.64±0.11 versus 1.51±0.34 average rates per child , p < 0.001 ) .","['RESULTS', 'Among', 'the', '113', 'children', 'with', 'SCA', 'studied', 'in', 'two', 'hospitals', ',', 'the', '58', 'receiving', 'lime', 'treatment', 'had', 'lower', 'rates', 'of', 'significant', 'painful', 'episodes', 'than', 'the', '55', 'without', 'lime', '(', '37', 'versus', '83', 'crises', 'in', '6', 'months', ',', 'and', '0.64±0.11', 'versus', '1.51±0.34', 'average', 'rates', 'per', 'child', ',', 'p', '<', '0.001', ')', '.']","(21, 24)","(117, 145)",-1,hl_o,23356250,Abstract,4,test,gold,3464.0
5109,"Also , fewer subjects than the controls",had significant painful episodes,( 50.0 % versus 92.7 % ) ; febrile illness ( 46.6 % versus 87.3 % ) and admission rate ( 3.4 % versus 34.5 % ) ( p < 0.001 ) .,"['Also', ',', 'fewer', 'subjects', 'than', 'the', 'controls', 'had', 'significant', 'painful', 'episodes', '(', '50.0', '%', 'versus', '92.7', '%', ')', ';', 'febrile', 'illness', '(', '46.6', '%', 'versus', '87.3', '%', ')', 'and', 'admission', 'rate', '(', '3.4', '%', 'versus', '34.5', '%', ')', '(', 'p', '<', '0.001', ')', '.']","(7, 11)","(39, 71)",-1,ss_o,23356250,Abstract,5,test,gold,3465.0
5110,"Also , fewer subjects than the controls had significant painful episodes ( 50.0 % versus",92.7 % ) ; febrile illness,( 46.6 % versus 87.3 % ) and admission rate ( 3.4 % versus 34.5 % ) ( p < 0.001 ) .,"['Also', ',', 'fewer', 'subjects', 'than', 'the', 'controls', 'had', 'significant', 'painful', 'episodes', '(', '50.0', '%', 'versus', '92.7', '%', ')', ';', 'febrile', 'illness', '(', '46.6', '%', 'versus', '87.3', '%', ')', 'and', 'admission', 'rate', '(', '3.4', '%', 'versus', '34.5', '%', ')', '(', 'p', '<', '0.001', ')', '.']","(15, 21)","(88, 114)",-1,ss_o,23356250,Abstract,5,test,gold,3427.0
5111,"Also , fewer subjects than the controls had significant painful episodes ( 50.0 % versus 92.7 % ) ; febrile illness ( 46.6 % versus 87.3 % )",and admission rate,( 3.4 % versus 34.5 % ) ( p < 0.001 ) .,"['Also', ',', 'fewer', 'subjects', 'than', 'the', 'controls', 'had', 'significant', 'painful', 'episodes', '(', '50.0', '%', 'versus', '92.7', '%', ')', ';', 'febrile', 'illness', '(', '46.6', '%', 'versus', '87.3', '%', ')', 'and', 'admission', 'rate', '(', '3.4', '%', 'versus', '34.5', '%', ')', '(', 'p', '<', '0.001', ')', '.']","(28, 31)","(140, 158)",-1,ss_o,23356250,Abstract,5,test,gold,3822.0
5112,,The mean hematocrit,"of the subjects ( 26.23±2.03 % ) at the end of the study was also higher , p < 0.001 .","['The', 'mean', 'hematocrit', 'of', 'the', 'subjects', '(', '26.23±2.03', '%', ')', 'at', 'the', 'end', 'of', 'the', 'study', 'was', 'also', 'higher', ',', 'p', '<', '0.001', '.']","(0, 3)","(0, 19)",-1,ss_o,23356250,Abstract,6,test,gold,1665.0
5113,,"However , transfusion rate , presence of hepatomegaly , splenomegaly , and jaundice",was similar .,"['However', ',', 'transfusion', 'rate', ',', 'presence', 'of', 'hepatomegaly', ',', 'splenomegaly', ',', 'and', 'jaundice', 'was', 'similar', '.']","(0, 13)","(0, 83)",-1,ss_o,23356250,Abstract,7,test,gold,7109.0
5114,Treatment,with lime,did not cause any significant side-effect .,"['Treatment', 'with', 'lime', 'did', 'not', 'cause', 'any', 'significant', 'side-effect', '.']","(1, 3)","(9, 18)",-1,ss_i,23356250,Abstract,8,test,gold,269.0
5115,Treatment with lime did not cause,any significant side-effect,.,"['Treatment', 'with', 'lime', 'did', 'not', 'cause', 'any', 'significant', 'side-effect', '.']","(6, 9)","(33, 60)",-1,ss_o,23356250,Abstract,8,test,gold,1158.0
5116,CONCLUSIONS Regular intake of lime juice may be of great therapeutic and nutritional relevance,in children with SCA,.,"['CONCLUSIONS', 'Regular', 'intake', 'of', 'lime', 'juice', 'may', 'be', 'of', 'great', 'therapeutic', 'and', 'nutritional', 'relevance', 'in', 'children', 'with', 'SCA', '.']","(14, 18)","(94, 114)",-1,ss_p,23356250,Abstract,9,test,gold,2213.0
5117,CONCLUSIONS Regular intake,of lime juice,may be of great therapeutic and nutritional relevance in children with SCA .,"['CONCLUSIONS', 'Regular', 'intake', 'of', 'lime', 'juice', 'may', 'be', 'of', 'great', 'therapeutic', 'and', 'nutritional', 'relevance', 'in', 'children', 'with', 'SCA', '.']","(3, 6)","(26, 39)",-1,ss_i,23356250,Abstract,9,test,gold,4588.0
5118,CONCLUSIONS Regular intake of lime juice may be of great therapeutic and nutritional relevance in,children,with SCA .,"['CONCLUSIONS', 'Regular', 'intake', 'of', 'lime', 'juice', 'may', 'be', 'of', 'great', 'therapeutic', 'and', 'nutritional', 'relevance', 'in', 'children', 'with', 'SCA', '.']","(15, 16)","(97, 105)",-1,hl_p,23356250,Abstract,9,test,gold,2120.0
5119,CONCLUSIONS Regular intake of lime juice may be of great therapeutic and nutritional relevance in children with,SCA,.,"['CONCLUSIONS', 'Regular', 'intake', 'of', 'lime', 'juice', 'may', 'be', 'of', 'great', 'therapeutic', 'and', 'nutritional', 'relevance', 'in', 'children', 'with', 'SCA', '.']","(17, 18)","(111, 114)",-1,hl_p,23356250,Abstract,9,test,gold,2209.0
5120,CONCLUSIONS Regular intake of,lime juice,may be of great therapeutic and nutritional relevance in children with SCA .,"['CONCLUSIONS', 'Regular', 'intake', 'of', 'lime', 'juice', 'may', 'be', 'of', 'great', 'therapeutic', 'and', 'nutritional', 'relevance', 'in', 'children', 'with', 'SCA', '.']","(4, 6)","(29, 39)",-1,hl_i,23356250,Abstract,9,test,gold,4587.0
5121,The effect of cognitive-behavioral therapy versus treatment as usual for anxiety in,children with autism spectrum disorders :,"a randomized , controlled trial .","['The', 'effect', 'of', 'cognitive-behavioral', 'therapy', 'versus', 'treatment', 'as', 'usual', 'for', 'anxiety', 'in', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'a', 'randomized', ',', 'controlled', 'trial', '.']","(12, 18)","(83, 124)",-1,ss_p,23357440,Title,0,test,gold,6022.0
5122,The effect of,cognitive-behavioral therapy,"versus treatment as usual for anxiety in children with autism spectrum disorders : a randomized , controlled trial .","['The', 'effect', 'of', 'cognitive-behavioral', 'therapy', 'versus', 'treatment', 'as', 'usual', 'for', 'anxiety', 'in', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'a', 'randomized', ',', 'controlled', 'trial', '.']","(3, 5)","(13, 41)",-1,ss_i,23357440,Title,0,test,gold,4218.0
5123,The effect of cognitive-behavioral therapy versus,treatment as usual,"for anxiety in children with autism spectrum disorders : a randomized , controlled trial .","['The', 'effect', 'of', 'cognitive-behavioral', 'therapy', 'versus', 'treatment', 'as', 'usual', 'for', 'anxiety', 'in', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'a', 'randomized', ',', 'controlled', 'trial', '.']","(6, 9)","(49, 67)",-1,ss_i,23357440,Title,0,test,gold,3932.0
5124,The effect of cognitive-behavioral therapy versus treatment as usual for anxiety in,children,"with autism spectrum disorders : a randomized , controlled trial .","['The', 'effect', 'of', 'cognitive-behavioral', 'therapy', 'versus', 'treatment', 'as', 'usual', 'for', 'anxiety', 'in', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'a', 'randomized', ',', 'controlled', 'trial', '.']","(12, 13)","(83, 91)",-1,hl_p,23357440,Title,0,test,gold,2119.0
5125,The effect of cognitive-behavioral therapy versus treatment as usual for anxiety in children with,autism spectrum disorders,": a randomized , controlled trial .","['The', 'effect', 'of', 'cognitive-behavioral', 'therapy', 'versus', 'treatment', 'as', 'usual', 'for', 'anxiety', 'in', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'a', 'randomized', ',', 'controlled', 'trial', '.']","(14, 17)","(97, 122)",-1,hl_p,23357440,Title,0,test,gold,6025.0
5126,The effect of,cognitive-behavioral therapy,"versus treatment as usual for anxiety in children with autism spectrum disorders : a randomized , controlled trial .","['The', 'effect', 'of', 'cognitive-behavioral', 'therapy', 'versus', 'treatment', 'as', 'usual', 'for', 'anxiety', 'in', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'a', 'randomized', ',', 'controlled', 'trial', '.']","(3, 5)","(13, 41)",-1,hl_i,23357440,Title,0,test,gold,4216.0
5127,The effect of cognitive-behavioral therapy versus,treatment as usual,"for anxiety in children with autism spectrum disorders : a randomized , controlled trial .","['The', 'effect', 'of', 'cognitive-behavioral', 'therapy', 'versus', 'treatment', 'as', 'usual', 'for', 'anxiety', 'in', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'a', 'randomized', ',', 'controlled', 'trial', '.']","(6, 9)","(49, 67)",-1,hl_i,23357440,Title,0,test,gold,3933.0
5128,OBJECTIVE To examine the efficacy of a modular cognitive-behavioral therapy ( CBT ) protocol relative to treatment as usual ( TAU ) among,children with high-functioning autism spectrum disorders ( ASD ) and clinically significant anxiety .,,"['OBJECTIVE', 'To', 'examine', 'the', 'efficacy', 'of', 'a', 'modular', 'cognitive-behavioral', 'therapy', '(', 'CBT', ')', 'protocol', 'relative', 'to', 'treatment', 'as', 'usual', '(', 'TAU', ')', 'among', 'children', 'with', 'high-functioning', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', 'and', 'clinically', 'significant', 'anxiety', '.']","(23, 37)","(137, 238)",-1,ss_p,23357440,Abstract,0,test,gold,6030.0
5129,OBJECTIVE To examine the efficacy of a modular,cognitive-behavioral therapy ( CBT ),protocol relative to treatment as usual ( TAU ) among children with high-functioning autism spectrum disorders ( ASD ) and clinically significant anxiety .,"['OBJECTIVE', 'To', 'examine', 'the', 'efficacy', 'of', 'a', 'modular', 'cognitive-behavioral', 'therapy', '(', 'CBT', ')', 'protocol', 'relative', 'to', 'treatment', 'as', 'usual', '(', 'TAU', ')', 'among', 'children', 'with', 'high-functioning', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', 'and', 'clinically', 'significant', 'anxiety', '.']","(8, 13)","(46, 82)",-1,ss_i,23357440,Abstract,0,test,gold,4208.0
5130,OBJECTIVE To examine the efficacy of a modular cognitive-behavioral therapy ( CBT ) protocol relative to,treatment as usual ( TAU ),among children with high-functioning autism spectrum disorders ( ASD ) and clinically significant anxiety .,"['OBJECTIVE', 'To', 'examine', 'the', 'efficacy', 'of', 'a', 'modular', 'cognitive-behavioral', 'therapy', '(', 'CBT', ')', 'protocol', 'relative', 'to', 'treatment', 'as', 'usual', '(', 'TAU', ')', 'among', 'children', 'with', 'high-functioning', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', 'and', 'clinically', 'significant', 'anxiety', '.']","(16, 22)","(104, 130)",-1,ss_i,23357440,Abstract,0,test,gold,3929.0
5131,OBJECTIVE To examine the,efficacy,of a modular cognitive-behavioral therapy ( CBT ) protocol relative to treatment as usual ( TAU ) among children with high-functioning autism spectrum disorders ( ASD ) and clinically significant anxiety .,"['OBJECTIVE', 'To', 'examine', 'the', 'efficacy', 'of', 'a', 'modular', 'cognitive-behavioral', 'therapy', '(', 'CBT', ')', 'protocol', 'relative', 'to', 'treatment', 'as', 'usual', '(', 'TAU', ')', 'among', 'children', 'with', 'high-functioning', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', 'and', 'clinically', 'significant', 'anxiety', '.']","(4, 5)","(24, 32)",-1,ss_o,23357440,Abstract,0,test,gold,4800.0
5132,OBJECTIVE To examine the efficacy of a modular cognitive-behavioral therapy ( CBT ) protocol relative to treatment as usual ( TAU ) among,children,with high-functioning autism spectrum disorders ( ASD ) and clinically significant anxiety .,"['OBJECTIVE', 'To', 'examine', 'the', 'efficacy', 'of', 'a', 'modular', 'cognitive-behavioral', 'therapy', '(', 'CBT', ')', 'protocol', 'relative', 'to', 'treatment', 'as', 'usual', '(', 'TAU', ')', 'among', 'children', 'with', 'high-functioning', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', 'and', 'clinically', 'significant', 'anxiety', '.']","(23, 24)","(137, 145)",-1,hl_p,23357440,Abstract,0,test,gold,2118.0
5133,OBJECTIVE To examine the efficacy of a modular cognitive-behavioral therapy ( CBT ) protocol relative to treatment as usual ( TAU ) among children with,high-functioning autism spectrum disorders ( ASD ) and clinically significant anxiety,.,"['OBJECTIVE', 'To', 'examine', 'the', 'efficacy', 'of', 'a', 'modular', 'cognitive-behavioral', 'therapy', '(', 'CBT', ')', 'protocol', 'relative', 'to', 'treatment', 'as', 'usual', '(', 'TAU', ')', 'among', 'children', 'with', 'high-functioning', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', 'and', 'clinically', 'significant', 'anxiety', '.']","(25, 36)","(151, 236)",-1,hl_p,23357440,Abstract,0,test,gold,6031.0
5134,OBJECTIVE To examine the efficacy of a modular,cognitive-behavioral therapy ( CBT ),protocol relative to treatment as usual ( TAU ) among children with high-functioning autism spectrum disorders ( ASD ) and clinically significant anxiety .,"['OBJECTIVE', 'To', 'examine', 'the', 'efficacy', 'of', 'a', 'modular', 'cognitive-behavioral', 'therapy', '(', 'CBT', ')', 'protocol', 'relative', 'to', 'treatment', 'as', 'usual', '(', 'TAU', ')', 'among', 'children', 'with', 'high-functioning', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', 'and', 'clinically', 'significant', 'anxiety', '.']","(8, 13)","(46, 82)",-1,hl_i,23357440,Abstract,0,test,gold,4209.0
5135,OBJECTIVE To examine the efficacy of a modular cognitive-behavioral therapy ( CBT ) protocol relative to,treatment as usual ( TAU ),among children with high-functioning autism spectrum disorders ( ASD ) and clinically significant anxiety .,"['OBJECTIVE', 'To', 'examine', 'the', 'efficacy', 'of', 'a', 'modular', 'cognitive-behavioral', 'therapy', '(', 'CBT', ')', 'protocol', 'relative', 'to', 'treatment', 'as', 'usual', '(', 'TAU', ')', 'among', 'children', 'with', 'high-functioning', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', 'and', 'clinically', 'significant', 'anxiety', '.']","(16, 22)","(104, 130)",-1,hl_i,23357440,Abstract,0,test,gold,3930.0
5136,OBJECTIVE To examine the,efficacy,of a modular cognitive-behavioral therapy ( CBT ) protocol relative to treatment as usual ( TAU ) among children with high-functioning autism spectrum disorders ( ASD ) and clinically significant anxiety .,"['OBJECTIVE', 'To', 'examine', 'the', 'efficacy', 'of', 'a', 'modular', 'cognitive-behavioral', 'therapy', '(', 'CBT', ')', 'protocol', 'relative', 'to', 'treatment', 'as', 'usual', '(', 'TAU', ')', 'among', 'children', 'with', 'high-functioning', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', 'and', 'clinically', 'significant', 'anxiety', '.']","(4, 5)","(24, 32)",-1,hl_o,23357440,Abstract,0,test,gold,4799.0
5137,METHOD A total of,45 children ( 7-11 years of age ) with high-functioning ASD and clinically significant anxiety,were randomized to receive 16 sessions of weekly CBT or TAU for an equivalent duration .,"['METHOD', 'A', 'total', 'of', '45', 'children', '(', '7-11', 'years', 'of', 'age', ')', 'with', 'high-functioning', 'ASD', 'and', 'clinically', 'significant', 'anxiety', 'were', 'randomized', 'to', 'receive', '16', 'sessions', 'of', 'weekly', 'CBT', 'or', 'TAU', 'for', 'an', 'equivalent', 'duration', '.']","(4, 19)","(17, 111)",-1,ss_p,23357440,Abstract,1,test,gold,6199.0
5138,METHOD A total of 45 children ( 7-11 years of age ) with high-functioning ASD and clinically significant anxiety were randomized to receive 16 sessions of weekly,CBT,or TAU for an equivalent duration .,"['METHOD', 'A', 'total', 'of', '45', 'children', '(', '7-11', 'years', 'of', 'age', ')', 'with', 'high-functioning', 'ASD', 'and', 'clinically', 'significant', 'anxiety', 'were', 'randomized', 'to', 'receive', '16', 'sessions', 'of', 'weekly', 'CBT', 'or', 'TAU', 'for', 'an', 'equivalent', 'duration', '.']","(27, 28)","(161, 164)",-1,ss_i,23357440,Abstract,1,test,gold,339.0
5139,METHOD A total of 45 children ( 7-11 years of age ) with high-functioning ASD and clinically significant anxiety were randomized to receive 16 sessions of weekly CBT or,TAU,for an equivalent duration .,"['METHOD', 'A', 'total', 'of', '45', 'children', '(', '7-11', 'years', 'of', 'age', ')', 'with', 'high-functioning', 'ASD', 'and', 'clinically', 'significant', 'anxiety', 'were', 'randomized', 'to', 'receive', '16', 'sessions', 'of', 'weekly', 'CBT', 'or', 'TAU', 'for', 'an', 'equivalent', 'duration', '.']","(29, 30)","(168, 171)",-1,ss_i,23357440,Abstract,1,test,gold,540.0
5140,METHOD A total of,45 children ( 7-11 years of age ),with high-functioning ASD and clinically significant anxiety were randomized to receive 16 sessions of weekly CBT or TAU for an equivalent duration .,"['METHOD', 'A', 'total', 'of', '45', 'children', '(', '7-11', 'years', 'of', 'age', ')', 'with', 'high-functioning', 'ASD', 'and', 'clinically', 'significant', 'anxiety', 'were', 'randomized', 'to', 'receive', '16', 'sessions', 'of', 'weekly', 'CBT', 'or', 'TAU', 'for', 'an', 'equivalent', 'duration', '.']","(4, 12)","(17, 50)",-1,hl_p,23357440,Abstract,1,test,gold,2045.0
5141,METHOD A total of 45 children ( 7-11 years of age ) with,high-functioning ASD and clinically significant anxiety,were randomized to receive 16 sessions of weekly CBT or TAU for an equivalent duration .,"['METHOD', 'A', 'total', 'of', '45', 'children', '(', '7-11', 'years', 'of', 'age', ')', 'with', 'high-functioning', 'ASD', 'and', 'clinically', 'significant', 'anxiety', 'were', 'randomized', 'to', 'receive', '16', 'sessions', 'of', 'weekly', 'CBT', 'or', 'TAU', 'for', 'an', 'equivalent', 'duration', '.']","(13, 19)","(56, 111)",-1,hl_p,23357440,Abstract,1,test,gold,6098.0
5142,METHOD A total of 45 children ( 7-11 years of age ) with high-functioning ASD and clinically significant anxiety were randomized to receive 16 sessions of weekly,CBT,or TAU for an equivalent duration .,"['METHOD', 'A', 'total', 'of', '45', 'children', '(', '7-11', 'years', 'of', 'age', ')', 'with', 'high-functioning', 'ASD', 'and', 'clinically', 'significant', 'anxiety', 'were', 'randomized', 'to', 'receive', '16', 'sessions', 'of', 'weekly', 'CBT', 'or', 'TAU', 'for', 'an', 'equivalent', 'duration', '.']","(27, 28)","(161, 164)",-1,hl_i,23357440,Abstract,1,test,gold,338.0
5143,METHOD A total of 45 children ( 7-11 years of age ) with high-functioning ASD and clinically significant anxiety were randomized to receive 16 sessions of weekly CBT or,TAU,for an equivalent duration .,"['METHOD', 'A', 'total', 'of', '45', 'children', '(', '7-11', 'years', 'of', 'age', ')', 'with', 'high-functioning', 'ASD', 'and', 'clinically', 'significant', 'anxiety', 'were', 'randomized', 'to', 'receive', '16', 'sessions', 'of', 'weekly', 'CBT', 'or', 'TAU', 'for', 'an', 'equivalent', 'duration', '.']","(29, 30)","(168, 171)",-1,hl_i,23357440,Abstract,1,test,gold,539.0
5144,"After screening , assessments were conducted at baseline , post-treatment , and 3-month follow-up .",,,"['After', 'screening', ',', 'assessments', 'were', 'conducted', 'at', 'baseline', ',', 'post-treatment', ',', 'and', '3-month', 'follow-up', '.']",,,,,23357440,Abstract,2,test,gold,
5145,Raters were blind to treatment condition .,,,"['Raters', 'were', 'blind', 'to', 'treatment', 'condition', '.']",,,,,23357440,Abstract,3,test,gold,
5146,RESULTS Youth receiving,CBT,showed substantial improvement relative to TAU on primary anxiety outcomes .,"['RESULTS', 'Youth', 'receiving', 'CBT', 'showed', 'substantial', 'improvement', 'relative', 'to', 'TAU', 'on', 'primary', 'anxiety', 'outcomes', '.']","(3, 4)","(23, 26)",-1,ss_i,23357440,Abstract,4,test,gold,337.0
5147,RESULTS Youth receiving CBT showed substantial improvement relative to,TAU,on primary anxiety outcomes .,"['RESULTS', 'Youth', 'receiving', 'CBT', 'showed', 'substantial', 'improvement', 'relative', 'to', 'TAU', 'on', 'primary', 'anxiety', 'outcomes', '.']","(9, 10)","(70, 73)",-1,ss_i,23357440,Abstract,4,test,gold,538.0
5148,RESULTS Youth receiving CBT showed substantial improvement relative to TAU on,primary anxiety outcomes .,,"['RESULTS', 'Youth', 'receiving', 'CBT', 'showed', 'substantial', 'improvement', 'relative', 'to', 'TAU', 'on', 'primary', 'anxiety', 'outcomes', '.']","(11, 15)","(77, 103)",-1,ss_o,23357440,Abstract,4,test,gold,2455.0
5149,RESULTS Youth receiving,CBT,showed substantial improvement relative to TAU on primary anxiety outcomes .,"['RESULTS', 'Youth', 'receiving', 'CBT', 'showed', 'substantial', 'improvement', 'relative', 'to', 'TAU', 'on', 'primary', 'anxiety', 'outcomes', '.']","(3, 4)","(23, 26)",-1,hl_i,23357440,Abstract,4,test,gold,336.0
5150,RESULTS Youth receiving CBT showed substantial improvement relative to,TAU,on primary anxiety outcomes .,"['RESULTS', 'Youth', 'receiving', 'CBT', 'showed', 'substantial', 'improvement', 'relative', 'to', 'TAU', 'on', 'primary', 'anxiety', 'outcomes', '.']","(9, 10)","(70, 73)",-1,hl_i,23357440,Abstract,4,test,gold,537.0
5151,RESULTS Youth receiving CBT showed substantial improvement relative to TAU on,primary anxiety outcomes .,,"['RESULTS', 'Youth', 'receiving', 'CBT', 'showed', 'substantial', 'improvement', 'relative', 'to', 'TAU', 'on', 'primary', 'anxiety', 'outcomes', '.']","(11, 15)","(77, 103)",-1,hl_o,23357440,Abstract,4,test,gold,2456.0
5152,Of 24 children randomized to the,CBT,"arm , 18 ( 75 % ) were treatment responders , versus only 3 of 21 children ( 14 % ) in the TAU arm .","['Of', '24', 'children', 'randomized', 'to', 'the', 'CBT', 'arm', ',', '18', '(', '75', '%', ')', 'were', 'treatment', 'responders', ',', 'versus', 'only', '3', 'of', '21', 'children', '(', '14', '%', ')', 'in', 'the', 'TAU', 'arm', '.']","(6, 7)","(32, 35)",-1,ss_i,23357440,Abstract,5,test,gold,335.0
5153,"Of 24 children randomized to the CBT arm , 18 ( 75 % ) were treatment responders , versus only 3 of 21 children ( 14 % ) in the",TAU,arm .,"['Of', '24', 'children', 'randomized', 'to', 'the', 'CBT', 'arm', ',', '18', '(', '75', '%', ')', 'were', 'treatment', 'responders', ',', 'versus', 'only', '3', 'of', '21', 'children', '(', '14', '%', ')', 'in', 'the', 'TAU', 'arm', '.']","(30, 31)","(127, 130)",-1,ss_i,23357440,Abstract,5,test,gold,536.0
5154,"Of 24 children randomized to the CBT arm , 18 ( 75 % ) were",treatment responders,", versus only 3 of 21 children ( 14 % ) in the TAU arm .","['Of', '24', 'children', 'randomized', 'to', 'the', 'CBT', 'arm', ',', '18', '(', '75', '%', ')', 'were', 'treatment', 'responders', ',', 'versus', 'only', '3', 'of', '21', 'children', '(', '14', '%', ')', 'in', 'the', 'TAU', 'arm', '.']","(15, 17)","(59, 79)",-1,ss_o,23357440,Abstract,5,test,gold,3960.0
5155,Of 24 children randomized to the,CBT,"arm , 18 ( 75 % ) were treatment responders , versus only 3 of 21 children ( 14 % ) in the TAU arm .","['Of', '24', 'children', 'randomized', 'to', 'the', 'CBT', 'arm', ',', '18', '(', '75', '%', ')', 'were', 'treatment', 'responders', ',', 'versus', 'only', '3', 'of', '21', 'children', '(', '14', '%', ')', 'in', 'the', 'TAU', 'arm', '.']","(6, 7)","(32, 35)",-1,hl_i,23357440,Abstract,5,test,gold,334.0
5156,"Of 24 children randomized to the CBT arm , 18 ( 75 % ) were treatment responders , versus only 3 of 21 children ( 14 % ) in the",TAU,arm .,"['Of', '24', 'children', 'randomized', 'to', 'the', 'CBT', 'arm', ',', '18', '(', '75', '%', ')', 'were', 'treatment', 'responders', ',', 'versus', 'only', '3', 'of', '21', 'children', '(', '14', '%', ')', 'in', 'the', 'TAU', 'arm', '.']","(30, 31)","(127, 130)",-1,hl_i,23357440,Abstract,5,test,gold,535.0
5157,Gains were generally maintained at 3-month follow-up for,CBT,responders .,"['Gains', 'were', 'generally', 'maintained', 'at', '3-month', 'follow-up', 'for', 'CBT', 'responders', '.']","(8, 9)","(56, 59)",-1,ss_i,23357440,Abstract,6,test,gold,333.0
5158,Gains were generally maintained at 3-month follow-up for,CBT,responders .,"['Gains', 'were', 'generally', 'maintained', 'at', '3-month', 'follow-up', 'for', 'CBT', 'responders', '.']","(8, 9)","(56, 59)",-1,hl_i,23357440,Abstract,6,test,gold,332.0
5159,"CONCLUSIONS Relative to usual care ,",CBT,adapted for anxious youth with high-functioning ASD demonstrates large effects in reducing anxiety symptoms .,"['CONCLUSIONS', 'Relative', 'to', 'usual', 'care', ',', 'CBT', 'adapted', 'for', 'anxious', 'youth', 'with', 'high-functioning', 'ASD', 'demonstrates', 'large', 'effects', 'in', 'reducing', 'anxiety', 'symptoms', '.']","(6, 7)","(36, 39)",-1,ss_i,23357440,Abstract,7,test,gold,331.0
5160,"CONCLUSIONS Relative to usual care , CBT adapted for anxious youth with high-functioning ASD demonstrates large effects in reducing",anxiety symptoms .,,"['CONCLUSIONS', 'Relative', 'to', 'usual', 'care', ',', 'CBT', 'adapted', 'for', 'anxious', 'youth', 'with', 'high-functioning', 'ASD', 'demonstrates', 'large', 'effects', 'in', 'reducing', 'anxiety', 'symptoms', '.']","(19, 22)","(131, 149)",-1,ss_o,23357440,Abstract,7,test,gold,3259.0
5161,"CONCLUSIONS Relative to usual care ,",CBT,adapted for anxious youth with high-functioning ASD demonstrates large effects in reducing anxiety symptoms .,"['CONCLUSIONS', 'Relative', 'to', 'usual', 'care', ',', 'CBT', 'adapted', 'for', 'anxious', 'youth', 'with', 'high-functioning', 'ASD', 'demonstrates', 'large', 'effects', 'in', 'reducing', 'anxiety', 'symptoms', '.']","(6, 7)","(36, 39)",-1,hl_i,23357440,Abstract,7,test,gold,330.0
5162,"CONCLUSIONS Relative to usual care , CBT adapted for anxious youth with high-functioning ASD demonstrates large effects in reducing",anxiety symptoms .,,"['CONCLUSIONS', 'Relative', 'to', 'usual', 'care', ',', 'CBT', 'adapted', 'for', 'anxious', 'youth', 'with', 'high-functioning', 'ASD', 'demonstrates', 'large', 'effects', 'in', 'reducing', 'anxiety', 'symptoms', '.']","(19, 22)","(131, 149)",-1,hl_o,23357440,Abstract,7,test,gold,3258.0
5163,This study contributes to the growing literature supporting adapted CBT approaches for treating anxiety in,youth with ASD .,,"['This', 'study', 'contributes', 'to', 'the', 'growing', 'literature', 'supporting', 'adapted', 'CBT', 'approaches', 'for', 'treating', 'anxiety', 'in', 'youth', 'with', 'ASD', '.']","(15, 19)","(106, 122)",-1,ss_p,23357440,Abstract,8,test,gold,6096.0
5164,This study contributes to the growing literature supporting adapted,CBT,approaches for treating anxiety in youth with ASD .,"['This', 'study', 'contributes', 'to', 'the', 'growing', 'literature', 'supporting', 'adapted', 'CBT', 'approaches', 'for', 'treating', 'anxiety', 'in', 'youth', 'with', 'ASD', '.']","(9, 10)","(67, 70)",-1,ss_i,23357440,Abstract,8,test,gold,329.0
5165,This study contributes to the growing literature supporting adapted,CBT,approaches for treating anxiety in youth with ASD .,"['This', 'study', 'contributes', 'to', 'the', 'growing', 'literature', 'supporting', 'adapted', 'CBT', 'approaches', 'for', 'treating', 'anxiety', 'in', 'youth', 'with', 'ASD', '.']","(9, 10)","(67, 70)",-1,hl_i,23357440,Abstract,8,test,gold,328.0
5166,Plasma AGE-peptides and C-peptide in,early-stage diabetic nephropathy patients,on thiamine and pyridoxine therapy .,"['Plasma', 'AGE-peptides', 'and', 'C-peptide', 'in', 'early-stage', 'diabetic', 'nephropathy', 'patients', 'on', 'thiamine', 'and', 'pyridoxine', 'therapy', '.']","(5, 9)","(36, 77)",-1,ss_p,23392542,Title,0,test,gold,6928.0
5167,Plasma AGE-peptides and C-peptide in early-stage diabetic nephropathy patients on,thiamine,and pyridoxine therapy .,"['Plasma', 'AGE-peptides', 'and', 'C-peptide', 'in', 'early-stage', 'diabetic', 'nephropathy', 'patients', 'on', 'thiamine', 'and', 'pyridoxine', 'therapy', '.']","(10, 11)","(81, 89)",-1,ss_i,23392542,Title,0,test,gold,5507.0
5168,Plasma AGE-peptides and C-peptide in early-stage diabetic nephropathy patients on thiamine and,pyridoxine,therapy .,"['Plasma', 'AGE-peptides', 'and', 'C-peptide', 'in', 'early-stage', 'diabetic', 'nephropathy', 'patients', 'on', 'thiamine', 'and', 'pyridoxine', 'therapy', '.']","(12, 13)","(94, 104)",-1,ss_i,23392542,Title,0,test,gold,135.0
5169,,Plasma AGE-peptides and C-peptide,in early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy .,"['Plasma', 'AGE-peptides', 'and', 'C-peptide', 'in', 'early-stage', 'diabetic', 'nephropathy', 'patients', 'on', 'thiamine', 'and', 'pyridoxine', 'therapy', '.']","(0, 4)","(0, 33)",-1,ss_o,23392542,Title,0,test,gold,4453.0
5170,Plasma AGE-peptides and C-peptide in,early-stage diabetic nephropathy patients,on thiamine and pyridoxine therapy .,"['Plasma', 'AGE-peptides', 'and', 'C-peptide', 'in', 'early-stage', 'diabetic', 'nephropathy', 'patients', 'on', 'thiamine', 'and', 'pyridoxine', 'therapy', '.']","(5, 9)","(36, 77)",-1,hl_p,23392542,Title,0,test,gold,6929.0
5171,,Plasma AGE-peptides and C-peptide,in early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy .,"['Plasma', 'AGE-peptides', 'and', 'C-peptide', 'in', 'early-stage', 'diabetic', 'nephropathy', 'patients', 'on', 'thiamine', 'and', 'pyridoxine', 'therapy', '.']","(0, 4)","(0, 33)",-1,hl_o,23392542,Title,0,test,gold,4454.0
5172,AIM The aim of the study was to evaluate circulatory AGE-peptide levels in,diabetic nephropathy,and to observe the effects of thiamine ( vitamin B1 ) and pyridoxine ( vitamin B6 ) therapy .,"['AIM', 'The', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'circulatory', 'AGE-peptide', 'levels', 'in', 'diabetic', 'nephropathy', 'and', 'to', 'observe', 'the', 'effects', 'of', 'thiamine', '(', 'vitamin', 'B1', ')', 'and', 'pyridoxine', '(', 'vitamin', 'B6', ')', 'therapy', '.']","(13, 15)","(74, 94)",-1,ss_p,23392542,Abstract,0,test,gold,6927.0
5173,AIM The aim of the study was to evaluate circulatory AGE-peptide levels in diabetic nephropathy and to observe the effects of,thiamine ( vitamin B1 ),and pyridoxine ( vitamin B6 ) therapy .,"['AIM', 'The', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'circulatory', 'AGE-peptide', 'levels', 'in', 'diabetic', 'nephropathy', 'and', 'to', 'observe', 'the', 'effects', 'of', 'thiamine', '(', 'vitamin', 'B1', ')', 'and', 'pyridoxine', '(', 'vitamin', 'B6', ')', 'therapy', '.']","(21, 26)","(125, 148)",-1,ss_i,23392542,Abstract,0,test,gold,4621.0
5174,AIM The aim of the study was to evaluate circulatory AGE-peptide levels in diabetic nephropathy and to observe the effects of thiamine ( vitamin B1 ) and,pyridoxine ( vitamin B6 ),therapy .,"['AIM', 'The', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'circulatory', 'AGE-peptide', 'levels', 'in', 'diabetic', 'nephropathy', 'and', 'to', 'observe', 'the', 'effects', 'of', 'thiamine', '(', 'vitamin', 'B1', ')', 'and', 'pyridoxine', '(', 'vitamin', 'B6', ')', 'therapy', '.']","(27, 32)","(153, 178)",-1,ss_i,23392542,Abstract,0,test,gold,4619.0
5175,AIM The aim of the study was to evaluate,circulatory AGE-peptide levels,in diabetic nephropathy and to observe the effects of thiamine ( vitamin B1 ) and pyridoxine ( vitamin B6 ) therapy .,"['AIM', 'The', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'circulatory', 'AGE-peptide', 'levels', 'in', 'diabetic', 'nephropathy', 'and', 'to', 'observe', 'the', 'effects', 'of', 'thiamine', '(', 'vitamin', 'B1', ')', 'and', 'pyridoxine', '(', 'vitamin', 'B6', ')', 'therapy', '.']","(9, 12)","(40, 70)",-1,ss_o,23392542,Abstract,0,test,gold,3217.0
5176,AIM The aim of the study was to evaluate circulatory AGE-peptide levels in diabetic nephropathy and to observe the effects of,thiamine ( vitamin B1 ),and pyridoxine ( vitamin B6 ) therapy .,"['AIM', 'The', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'circulatory', 'AGE-peptide', 'levels', 'in', 'diabetic', 'nephropathy', 'and', 'to', 'observe', 'the', 'effects', 'of', 'thiamine', '(', 'vitamin', 'B1', ')', 'and', 'pyridoxine', '(', 'vitamin', 'B6', ')', 'therapy', '.']","(21, 26)","(125, 148)",-1,hl_i,23392542,Abstract,0,test,gold,4622.0
5177,AIM The aim of the study was to evaluate circulatory AGE-peptide levels in diabetic nephropathy and to observe the effects of thiamine ( vitamin B1 ) and,pyridoxine ( vitamin B6 ),therapy .,"['AIM', 'The', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'circulatory', 'AGE-peptide', 'levels', 'in', 'diabetic', 'nephropathy', 'and', 'to', 'observe', 'the', 'effects', 'of', 'thiamine', '(', 'vitamin', 'B1', ')', 'and', 'pyridoxine', '(', 'vitamin', 'B6', ')', 'therapy', '.']","(27, 32)","(153, 178)",-1,hl_i,23392542,Abstract,0,test,gold,4620.0
5178,AIM The aim of the study was to evaluate,circulatory AGE-peptide levels,in diabetic nephropathy and to observe the effects of thiamine ( vitamin B1 ) and pyridoxine ( vitamin B6 ) therapy .,"['AIM', 'The', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'circulatory', 'AGE-peptide', 'levels', 'in', 'diabetic', 'nephropathy', 'and', 'to', 'observe', 'the', 'effects', 'of', 'thiamine', '(', 'vitamin', 'B1', ')', 'and', 'pyridoxine', '(', 'vitamin', 'B6', ')', 'therapy', '.']","(9, 12)","(40, 70)",-1,hl_o,23392542,Abstract,0,test,gold,3218.0
5179,METHODS,Type 2 diabetic patients ( N.=57 ) were divided,"into two groups as "" with nephropathy "" ( N.=27 ) and "" without nephropathy "" ( N.=30 ) .","['METHODS', 'Type', '2', 'diabetic', 'patients', '(', 'N.=57', ')', 'were', 'divided', 'into', 'two', 'groups', 'as', '""', 'with', 'nephropathy', '""', '(', 'N.=27', ')', 'and', '""', 'without', 'nephropathy', '""', '(', 'N.=30', ')', '.']","(1, 10)","(7, 54)",-1,ss_p,23392542,Abstract,1,test,gold,6898.0
5180,METHODS,Type 2 diabetic patients,"( N.=57 ) were divided into two groups as "" with nephropathy "" ( N.=27 ) and "" without nephropathy "" ( N.=30 ) .","['METHODS', 'Type', '2', 'diabetic', 'patients', '(', 'N.=57', ')', 'were', 'divided', 'into', 'two', 'groups', 'as', '""', 'with', 'nephropathy', '""', '(', 'N.=27', ')', 'and', '""', 'without', 'nephropathy', '""', '(', 'N.=30', ')', '.']","(1, 5)","(7, 31)",-1,hl_p,23392542,Abstract,1,test,gold,6899.0
5181,METHODS Type 2 diabetic patients (,N.=57,") were divided into two groups as "" with nephropathy "" ( N.=27 ) and "" without nephropathy "" ( N.=30 ) .","['METHODS', 'Type', '2', 'diabetic', 'patients', '(', 'N.=57', ')', 'were', 'divided', 'into', 'two', 'groups', 'as', '""', 'with', 'nephropathy', '""', '(', 'N.=27', ')', 'and', '""', 'without', 'nephropathy', '""', '(', 'N.=30', ')', '.']","(6, 7)","(34, 39)",-1,hl_p,23392542,Abstract,1,test,gold,
5182,,Diabetic nephropathy patients,"were treated with either B6 ( N.=12 ) ( 250 mg/day ) or B1+B6 ( N.=15 ) ( 250 mg/day , each ) for five months .","['Diabetic', 'nephropathy', 'patients', 'were', 'treated', 'with', 'either', 'B6', '(', 'N.=12', ')', '(', '250', 'mg/day', ')', 'or', 'B1+B6', '(', 'N.=15', ')', '(', '250', 'mg/day', ',', 'each', ')', 'for', 'five', 'months', '.']","(0, 3)","(0, 29)",-1,ss_p,23392542,Abstract,2,test,gold,6925.0
5183,Diabetic nephropathy patients were treated with either,B6,"( N.=12 ) ( 250 mg/day ) or B1+B6 ( N.=15 ) ( 250 mg/day , each ) for five months .","['Diabetic', 'nephropathy', 'patients', 'were', 'treated', 'with', 'either', 'B6', '(', 'N.=12', ')', '(', '250', 'mg/day', ')', 'or', 'B1+B6', '(', 'N.=15', ')', '(', '250', 'mg/day', ',', 'each', ')', 'for', 'five', 'months', '.']","(7, 8)","(54, 56)",-1,ss_i,23392542,Abstract,2,test,gold,814.0
5184,Diabetic nephropathy patients were treated with either B6 ( N.=12 ) ( 250 mg/day ) or,B1+B6,"( N.=15 ) ( 250 mg/day , each ) for five months .","['Diabetic', 'nephropathy', 'patients', 'were', 'treated', 'with', 'either', 'B6', '(', 'N.=12', ')', '(', '250', 'mg/day', ')', 'or', 'B1+B6', '(', 'N.=15', ')', '(', '250', 'mg/day', ',', 'each', ')', 'for', 'five', 'months', '.']","(16, 17)","(85, 90)",-1,ss_i,23392542,Abstract,2,test,gold,
5185,,Diabetic nephropathy patients,"were treated with either B6 ( N.=12 ) ( 250 mg/day ) or B1+B6 ( N.=15 ) ( 250 mg/day , each ) for five months .","['Diabetic', 'nephropathy', 'patients', 'were', 'treated', 'with', 'either', 'B6', '(', 'N.=12', ')', '(', '250', 'mg/day', ')', 'or', 'B1+B6', '(', 'N.=15', ')', '(', '250', 'mg/day', ',', 'each', ')', 'for', 'five', 'months', '.']","(0, 3)","(0, 29)",-1,hl_p,23392542,Abstract,2,test,gold,6926.0
5186,Diabetic nephropathy patients were treated with either,B6,"( N.=12 ) ( 250 mg/day ) or B1+B6 ( N.=15 ) ( 250 mg/day , each ) for five months .","['Diabetic', 'nephropathy', 'patients', 'were', 'treated', 'with', 'either', 'B6', '(', 'N.=12', ')', '(', '250', 'mg/day', ')', 'or', 'B1+B6', '(', 'N.=15', ')', '(', '250', 'mg/day', ',', 'each', ')', 'for', 'five', 'months', '.']","(7, 8)","(54, 56)",-1,hl_i,23392542,Abstract,2,test,gold,815.0
5187,Diabetic nephropathy patients were treated with either B6 ( N.=12 ) ( 250 mg/day ) or,B1+B6,"( N.=15 ) ( 250 mg/day , each ) for five months .","['Diabetic', 'nephropathy', 'patients', 'were', 'treated', 'with', 'either', 'B6', '(', 'N.=12', ')', '(', '250', 'mg/day', ')', 'or', 'B1+B6', '(', 'N.=15', ')', '(', '250', 'mg/day', ',', 'each', ')', 'for', 'five', 'months', '.']","(16, 17)","(85, 90)",-1,hl_i,23392542,Abstract,2,test,gold,
5188,"At the beginning and the end of the experimentation period ,","glucose , HbA1c , triglyceride , cholesterol , insulin , C-peptide , thiamine pyrophosphate , pyridoxal phosphate and AGE- peptides",were measured .,"['At', 'the', 'beginning', 'and', 'the', 'end', 'of', 'the', 'experimentation', 'period', ',', 'glucose', ',', 'HbA1c', ',', 'triglyceride', ',', 'cholesterol', ',', 'insulin', ',', 'C-peptide', ',', 'thiamine', 'pyrophosphate', ',', 'pyridoxal', 'phosphate', 'and', 'AGE-', 'peptides', 'were', 'measured', '.']","(11, 31)","(60, 191)",-1,ss_o,23392542,Abstract,3,test,gold,5817.0
5189,"At the beginning and the end of the experimentation period ,","glucose , HbA1c , triglyceride , cholesterol , insulin , C-peptide , thiamine pyrophosphate , pyridoxal phosphate and AGE- peptides",were measured .,"['At', 'the', 'beginning', 'and', 'the', 'end', 'of', 'the', 'experimentation', 'period', ',', 'glucose', ',', 'HbA1c', ',', 'triglyceride', ',', 'cholesterol', ',', 'insulin', ',', 'C-peptide', ',', 'thiamine', 'pyrophosphate', ',', 'pyridoxal', 'phosphate', 'and', 'AGE-', 'peptides', 'were', 'measured', '.']","(11, 31)","(60, 191)",-1,hl_o,23392542,Abstract,3,test,gold,5818.0
5190,RESULTS,AGE-peptides,were higher in the diabetic group with nephropathy than without nephropathy ( P=0.005 ) .,"['RESULTS', 'AGE-peptides', 'were', 'higher', 'in', 'the', 'diabetic', 'group', 'with', 'nephropathy', 'than', 'without', 'nephropathy', '(', 'P=0.005', ')', '.']","(1, 2)","(7, 19)",-1,ss_o,23392542,Abstract,4,test,gold,
5191,RESULTS,AGE-peptides,were higher in the diabetic group with nephropathy than without nephropathy ( P=0.005 ) .,"['RESULTS', 'AGE-peptides', 'were', 'higher', 'in', 'the', 'diabetic', 'group', 'with', 'nephropathy', 'than', 'without', 'nephropathy', '(', 'P=0.005', ')', '.']","(1, 2)","(7, 19)",-1,hl_o,23392542,Abstract,4,test,gold,
5192,Within five months AGE-peptides increased in the diabetic group without nephropathy ( P=0.042 ) but not in the group with nephropathy treated either with,B1+B6,or B6 .,"['Within', 'five', 'months', 'AGE-peptides', 'increased', 'in', 'the', 'diabetic', 'group', 'without', 'nephropathy', '(', 'P=0.042', ')', 'but', 'not', 'in', 'the', 'group', 'with', 'nephropathy', 'treated', 'either', 'with', 'B1+B6', 'or', 'B6', '.']","(24, 25)","(153, 158)",-1,ss_i,23392542,Abstract,5,test,gold,
5193,Within five months AGE-peptides increased in the diabetic group without nephropathy ( P=0.042 ) but not in the group with nephropathy treated either with B1+B6 or,B6 .,,"['Within', 'five', 'months', 'AGE-peptides', 'increased', 'in', 'the', 'diabetic', 'group', 'without', 'nephropathy', '(', 'P=0.042', ')', 'but', 'not', 'in', 'the', 'group', 'with', 'nephropathy', 'treated', 'either', 'with', 'B1+B6', 'or', 'B6', '.']","(26, 28)","(162, 166)",-1,ss_i,23392542,Abstract,5,test,gold,813.0
5194,Within five months,AGE-peptides,increased in the diabetic group without nephropathy ( P=0.042 ) but not in the group with nephropathy treated either with B1+B6 or B6 .,"['Within', 'five', 'months', 'AGE-peptides', 'increased', 'in', 'the', 'diabetic', 'group', 'without', 'nephropathy', '(', 'P=0.042', ')', 'but', 'not', 'in', 'the', 'group', 'with', 'nephropathy', 'treated', 'either', 'with', 'B1+B6', 'or', 'B6', '.']","(3, 4)","(18, 30)",-1,ss_o,23392542,Abstract,5,test,gold,
5195,Within five months AGE-peptides increased in the diabetic group without nephropathy ( P=0.042 ) but not in the group with nephropathy treated either with,B1+B6,or B6 .,"['Within', 'five', 'months', 'AGE-peptides', 'increased', 'in', 'the', 'diabetic', 'group', 'without', 'nephropathy', '(', 'P=0.042', ')', 'but', 'not', 'in', 'the', 'group', 'with', 'nephropathy', 'treated', 'either', 'with', 'B1+B6', 'or', 'B6', '.']","(24, 25)","(153, 158)",-1,hl_i,23392542,Abstract,5,test,gold,
5196,Within five months AGE-peptides increased in the diabetic group without nephropathy ( P=0.042 ) but not in the group with nephropathy treated either with B1+B6 or,B6 .,,"['Within', 'five', 'months', 'AGE-peptides', 'increased', 'in', 'the', 'diabetic', 'group', 'without', 'nephropathy', '(', 'P=0.042', ')', 'but', 'not', 'in', 'the', 'group', 'with', 'nephropathy', 'treated', 'either', 'with', 'B1+B6', 'or', 'B6', '.']","(26, 28)","(162, 166)",-1,hl_i,23392542,Abstract,5,test,gold,812.0
5197,Within five months,AGE-peptides,increased in the diabetic group without nephropathy ( P=0.042 ) but not in the group with nephropathy treated either with B1+B6 or B6 .,"['Within', 'five', 'months', 'AGE-peptides', 'increased', 'in', 'the', 'diabetic', 'group', 'without', 'nephropathy', '(', 'P=0.042', ')', 'but', 'not', 'in', 'the', 'group', 'with', 'nephropathy', 'treated', 'either', 'with', 'B1+B6', 'or', 'B6', '.']","(3, 4)","(18, 30)",-1,hl_o,23392542,Abstract,5,test,gold,
5198,In,B6,treated group a substantial decrease was observed in HbA1c ( P=0.033 ) .,"['In', 'B6', 'treated', 'group', 'a', 'substantial', 'decrease', 'was', 'observed', 'in', 'HbA1c', '(', 'P=0.033', ')', '.']","(1, 2)","(2, 4)",-1,ss_i,23392542,Abstract,6,test,gold,811.0
5199,In B6 treated group a substantial decrease was observed in,HbA1c,( P=0.033 ) .,"['In', 'B6', 'treated', 'group', 'a', 'substantial', 'decrease', 'was', 'observed', 'in', 'HbA1c', '(', 'P=0.033', ')', '.']","(10, 11)","(58, 63)",-1,ss_o,23392542,Abstract,6,test,gold,1662.0
5200,In,B6,treated group a substantial decrease was observed in HbA1c ( P=0.033 ) .,"['In', 'B6', 'treated', 'group', 'a', 'substantial', 'decrease', 'was', 'observed', 'in', 'HbA1c', '(', 'P=0.033', ')', '.']","(1, 2)","(2, 4)",-1,hl_i,23392542,Abstract,6,test,gold,810.0
5201,In B6 treated group a substantial decrease was observed in,HbA1c,( P=0.033 ) .,"['In', 'B6', 'treated', 'group', 'a', 'substantial', 'decrease', 'was', 'observed', 'in', 'HbA1c', '(', 'P=0.033', ')', '.']","(10, 11)","(58, 63)",-1,hl_o,23392542,Abstract,6,test,gold,1663.0
5202,,B1+B6,"or B6 treatment both caused an increase in C-peptide ( P=0.006 , P=0.004 ) .","['B1+B6', 'or', 'B6', 'treatment', 'both', 'caused', 'an', 'increase', 'in', 'C-peptide', '(', 'P=0.006', ',', 'P=0.004', ')', '.']","(0, 1)","(0, 5)",-1,ss_i,23392542,Abstract,7,test,gold,
5203,B1+B6 or,B6,"treatment both caused an increase in C-peptide ( P=0.006 , P=0.004 ) .","['B1+B6', 'or', 'B6', 'treatment', 'both', 'caused', 'an', 'increase', 'in', 'C-peptide', '(', 'P=0.006', ',', 'P=0.004', ')', '.']","(2, 3)","(8, 10)",-1,ss_i,23392542,Abstract,7,test,gold,809.0
5204,B1+B6 or B6 treatment both caused an increase in,C-peptide,"( P=0.006 , P=0.004 ) .","['B1+B6', 'or', 'B6', 'treatment', 'both', 'caused', 'an', 'increase', 'in', 'C-peptide', '(', 'P=0.006', ',', 'P=0.004', ')', '.']","(9, 10)","(48, 57)",-1,ss_o,23392542,Abstract,7,test,gold,
5205,,B1+B6,"or B6 treatment both caused an increase in C-peptide ( P=0.006 , P=0.004 ) .","['B1+B6', 'or', 'B6', 'treatment', 'both', 'caused', 'an', 'increase', 'in', 'C-peptide', '(', 'P=0.006', ',', 'P=0.004', ')', '.']","(0, 1)","(0, 5)",-1,hl_i,23392542,Abstract,7,test,gold,
5206,B1+B6 or,B6,"treatment both caused an increase in C-peptide ( P=0.006 , P=0.004 ) .","['B1+B6', 'or', 'B6', 'treatment', 'both', 'caused', 'an', 'increase', 'in', 'C-peptide', '(', 'P=0.006', ',', 'P=0.004', ')', '.']","(2, 3)","(8, 10)",-1,hl_i,23392542,Abstract,7,test,gold,808.0
5207,B1+B6 or B6 treatment both caused an increase in,C-peptide,"( P=0.006 , P=0.004 ) .","['B1+B6', 'or', 'B6', 'treatment', 'both', 'caused', 'an', 'increase', 'in', 'C-peptide', '(', 'P=0.006', ',', 'P=0.004', ')', '.']","(9, 10)","(48, 57)",-1,hl_o,23392542,Abstract,7,test,gold,
5208,"CONCLUSION Among the parameters measured , plasma AGE-peptides was the only parameter found to be higher in","type 2 diabetes mellitus patients "" with nephropathy ""","than "" without nephropathy "" .","['CONCLUSION', 'Among', 'the', 'parameters', 'measured', ',', 'plasma', 'AGE-peptides', 'was', 'the', 'only', 'parameter', 'found', 'to', 'be', 'higher', 'in', 'type', '2', 'diabetes', 'mellitus', 'patients', '""', 'with', 'nephropathy', '""', 'than', '""', 'without', 'nephropathy', '""', '.']","(17, 26)","(107, 161)",-1,ss_p,23392542,Abstract,8,test,gold,6924.0
5209,"CONCLUSION Among the parameters measured ,",plasma AGE-peptides,"was the only parameter found to be higher in type 2 diabetes mellitus patients "" with nephropathy "" than "" without nephropathy "" .","['CONCLUSION', 'Among', 'the', 'parameters', 'measured', ',', 'plasma', 'AGE-peptides', 'was', 'the', 'only', 'parameter', 'found', 'to', 'be', 'higher', 'in', 'type', '2', 'diabetes', 'mellitus', 'patients', '""', 'with', 'nephropathy', '""', 'than', '""', 'without', 'nephropathy', '""', '.']","(6, 8)","(42, 61)",-1,ss_o,23392542,Abstract,8,test,gold,4451.0
5210,"CONCLUSION Among the parameters measured , plasma AGE-peptides was the only parameter found to be higher in",type 2 diabetes mellitus patients,""" with nephropathy "" than "" without nephropathy "" .","['CONCLUSION', 'Among', 'the', 'parameters', 'measured', ',', 'plasma', 'AGE-peptides', 'was', 'the', 'only', 'parameter', 'found', 'to', 'be', 'higher', 'in', 'type', '2', 'diabetes', 'mellitus', 'patients', '""', 'with', 'nephropathy', '""', 'than', '""', 'without', 'nephropathy', '""', '.']","(17, 22)","(107, 140)",-1,hl_p,23392542,Abstract,8,test,gold,6903.0
5211,"CONCLUSION Among the parameters measured ,",plasma AGE-peptides,"was the only parameter found to be higher in type 2 diabetes mellitus patients "" with nephropathy "" than "" without nephropathy "" .","['CONCLUSION', 'Among', 'the', 'parameters', 'measured', ',', 'plasma', 'AGE-peptides', 'was', 'the', 'only', 'parameter', 'found', 'to', 'be', 'higher', 'in', 'type', '2', 'diabetes', 'mellitus', 'patients', '""', 'with', 'nephropathy', '""', 'than', '""', 'without', 'nephropathy', '""', '.']","(6, 8)","(42, 61)",-1,hl_o,23392542,Abstract,8,test,gold,4452.0
5212,"However ,",patients with nephropathy,treated with B1+B6 or B6 did not display any further increase in AGE-peptides within five months .,"['However', ',', 'patients', 'with', 'nephropathy', 'treated', 'with', 'B1+B6', 'or', 'B6', 'did', 'not', 'display', 'any', 'further', 'increase', 'in', 'AGE-peptides', 'within', 'five', 'months', '.']","(2, 5)","(9, 34)",-1,ss_p,23392542,Abstract,9,test,gold,3792.0
5213,"However , patients with nephropathy treated with",B1+B6,or B6 did not display any further increase in AGE-peptides within five months .,"['However', ',', 'patients', 'with', 'nephropathy', 'treated', 'with', 'B1+B6', 'or', 'B6', 'did', 'not', 'display', 'any', 'further', 'increase', 'in', 'AGE-peptides', 'within', 'five', 'months', '.']","(7, 8)","(48, 53)",-1,ss_i,23392542,Abstract,9,test,gold,
5214,"However , patients with nephropathy treated with B1+B6 or",B6,did not display any further increase in AGE-peptides within five months .,"['However', ',', 'patients', 'with', 'nephropathy', 'treated', 'with', 'B1+B6', 'or', 'B6', 'did', 'not', 'display', 'any', 'further', 'increase', 'in', 'AGE-peptides', 'within', 'five', 'months', '.']","(9, 10)","(57, 59)",-1,ss_i,23392542,Abstract,9,test,gold,807.0
5215,"However , patients with nephropathy treated with B1+B6 or B6 did not display any further increase in",AGE-peptides,within five months .,"['However', ',', 'patients', 'with', 'nephropathy', 'treated', 'with', 'B1+B6', 'or', 'B6', 'did', 'not', 'display', 'any', 'further', 'increase', 'in', 'AGE-peptides', 'within', 'five', 'months', '.']","(17, 18)","(100, 112)",-1,ss_o,23392542,Abstract,9,test,gold,
5216,"However ,",patients,with nephropathy treated with B1+B6 or B6 did not display any further increase in AGE-peptides within five months .,"['However', ',', 'patients', 'with', 'nephropathy', 'treated', 'with', 'B1+B6', 'or', 'B6', 'did', 'not', 'display', 'any', 'further', 'increase', 'in', 'AGE-peptides', 'within', 'five', 'months', '.']","(2, 3)","(9, 17)",-1,hl_p,23392542,Abstract,9,test,gold,3742.0
5217,"However , patients with nephropathy treated with",B1+B6,or B6 did not display any further increase in AGE-peptides within five months .,"['However', ',', 'patients', 'with', 'nephropathy', 'treated', 'with', 'B1+B6', 'or', 'B6', 'did', 'not', 'display', 'any', 'further', 'increase', 'in', 'AGE-peptides', 'within', 'five', 'months', '.']","(7, 8)","(48, 53)",-1,hl_i,23392542,Abstract,9,test,gold,
5218,"However , patients with nephropathy treated with B1+B6 or",B6,did not display any further increase in AGE-peptides within five months .,"['However', ',', 'patients', 'with', 'nephropathy', 'treated', 'with', 'B1+B6', 'or', 'B6', 'did', 'not', 'display', 'any', 'further', 'increase', 'in', 'AGE-peptides', 'within', 'five', 'months', '.']","(9, 10)","(57, 59)",-1,hl_i,23392542,Abstract,9,test,gold,806.0
5219,"However , patients with nephropathy treated with B1+B6 or B6 did not display any further increase in",AGE-peptides,within five months .,"['However', ',', 'patients', 'with', 'nephropathy', 'treated', 'with', 'B1+B6', 'or', 'B6', 'did', 'not', 'display', 'any', 'further', 'increase', 'in', 'AGE-peptides', 'within', 'five', 'months', '.']","(17, 18)","(100, 112)",-1,hl_o,23392542,Abstract,9,test,gold,
5220,Both of the treatments caused an increase in,C-peptide .,,"['Both', 'of', 'the', 'treatments', 'caused', 'an', 'increase', 'in', 'C-peptide', '.']","(8, 10)","(44, 55)",-1,ss_o,23392542,Abstract,10,test,gold,
5221,Both of the treatments caused an increase in,C-peptide .,,"['Both', 'of', 'the', 'treatments', 'caused', 'an', 'increase', 'in', 'C-peptide', '.']","(8, 10)","(44, 55)",-1,hl_o,23392542,Abstract,10,test,gold,
5222,Social skills improvement in,children with high-functioning autism :,a pilot randomized controlled trial .,"['Social', 'skills', 'improvement', 'in', 'children', 'with', 'high-functioning', 'autism', ':', 'a', 'pilot', 'randomized', 'controlled', 'trial', '.']","(4, 9)","(28, 67)",-1,ss_p,23417625,Title,0,test,gold,6139.0
5223,,Social skills,improvement in children with high-functioning autism : a pilot randomized controlled trial .,"['Social', 'skills', 'improvement', 'in', 'children', 'with', 'high-functioning', 'autism', ':', 'a', 'pilot', 'randomized', 'controlled', 'trial', '.']","(0, 2)","(0, 13)",-1,ss_i,23417625,Title,0,test,gold,2867.0
5224,,Social skills,improvement in children with high-functioning autism : a pilot randomized controlled trial .,"['Social', 'skills', 'improvement', 'in', 'children', 'with', 'high-functioning', 'autism', ':', 'a', 'pilot', 'randomized', 'controlled', 'trial', '.']","(0, 2)","(0, 13)",-1,ss_o,23417625,Title,0,test,gold,2868.0
5225,Social skills improvement in,children,with high-functioning autism : a pilot randomized controlled trial .,"['Social', 'skills', 'improvement', 'in', 'children', 'with', 'high-functioning', 'autism', ':', 'a', 'pilot', 'randomized', 'controlled', 'trial', '.']","(4, 5)","(28, 36)",-1,hl_p,23417625,Title,0,test,gold,2117.0
5226,Social skills improvement in children with,high-functioning autism,: a pilot randomized controlled trial .,"['Social', 'skills', 'improvement', 'in', 'children', 'with', 'high-functioning', 'autism', ':', 'a', 'pilot', 'randomized', 'controlled', 'trial', '.']","(6, 8)","(42, 65)",-1,hl_p,23417625,Title,0,test,gold,6145.0
5227,High-functioning autism ( HFA ) is characterized by persistent impairment in social interaction despite the absence of mental retardation .,,,"['High-functioning', 'autism', '(', 'HFA', ')', 'is', 'characterized', 'by', 'persistent', 'impairment', 'in', 'social', 'interaction', 'despite', 'the', 'absence', 'of', 'mental', 'retardation', '.']",,,,,23417625,Abstract,0,test,gold,
5228,Although an increasing number of group-based programs for the improvement of,social skills,"have been described , randomized controlled trials are needed to evaluate their efficacy .","['Although', 'an', 'increasing', 'number', 'of', 'group-based', 'programs', 'for', 'the', 'improvement', 'of', 'social', 'skills', 'have', 'been', 'described', ',', 'randomized', 'controlled', 'trials', 'are', 'needed', 'to', 'evaluate', 'their', 'efficacy', '.']","(11, 13)","(76, 89)",-1,ss_o,23417625,Abstract,1,test,gold,2877.0
5229,"Although an increasing number of group-based programs for the improvement of social skills have been described , randomized controlled trials are needed to evaluate their",efficacy .,,"['Although', 'an', 'increasing', 'number', 'of', 'group-based', 'programs', 'for', 'the', 'improvement', 'of', 'social', 'skills', 'have', 'been', 'described', ',', 'randomized', 'controlled', 'trials', 'are', 'needed', 'to', 'evaluate', 'their', 'efficacy', '.']","(25, 27)","(170, 180)",-1,ss_o,23417625,Abstract,1,test,gold,4798.0
5230,To compare the effect of a Social Skills Training Group-based Program ( SST-GP ) and a Leisure Activities Group-based Program ( LA-GP ) on the perception of facial emotions and quality of life ( QoL ) in,young people with HFA .,,"['To', 'compare', 'the', 'effect', 'of', 'a', 'Social', 'Skills', 'Training', 'Group-based', 'Program', '(', 'SST-GP', ')', 'and', 'a', 'Leisure', 'Activities', 'Group-based', 'Program', '(', 'LA-GP', ')', 'on', 'the', 'perception', 'of', 'facial', 'emotions', 'and', 'quality', 'of', 'life', '(', 'QoL', ')', 'in', 'young', 'people', 'with', 'HFA', '.']","(37, 42)","(203, 226)",-1,ss_p,23417625,Abstract,2,test,gold,2216.0
5231,To compare the effect of a,Social Skills Training Group-based Program ( SST-GP ),and a Leisure Activities Group-based Program ( LA-GP ) on the perception of facial emotions and quality of life ( QoL ) in young people with HFA .,"['To', 'compare', 'the', 'effect', 'of', 'a', 'Social', 'Skills', 'Training', 'Group-based', 'Program', '(', 'SST-GP', ')', 'and', 'a', 'Leisure', 'Activities', 'Group-based', 'Program', '(', 'LA-GP', ')', 'on', 'the', 'perception', 'of', 'facial', 'emotions', 'and', 'quality', 'of', 'life', '(', 'QoL', ')', 'in', 'young', 'people', 'with', 'HFA', '.']","(6, 14)","(26, 79)",-1,ss_i,23417625,Abstract,2,test,gold,6245.0
5232,To compare the effect of a Social Skills Training Group-based Program ( SST-GP ) and a,Leisure Activities Group-based Program ( LA-GP ),on the perception of facial emotions and quality of life ( QoL ) in young people with HFA .,"['To', 'compare', 'the', 'effect', 'of', 'a', 'Social', 'Skills', 'Training', 'Group-based', 'Program', '(', 'SST-GP', ')', 'and', 'a', 'Leisure', 'Activities', 'Group-based', 'Program', '(', 'LA-GP', ')', 'on', 'the', 'perception', 'of', 'facial', 'emotions', 'and', 'quality', 'of', 'life', '(', 'QoL', ')', 'in', 'young', 'people', 'with', 'HFA', '.']","(16, 23)","(86, 134)",-1,ss_i,23417625,Abstract,2,test,gold,6248.0
5233,To compare the effect of a Social Skills Training Group-based Program ( SST-GP ) and a Leisure Activities Group-based Program ( LA-GP ) on the,perception of facial emotions and quality of life ( QoL ),in young people with HFA .,"['To', 'compare', 'the', 'effect', 'of', 'a', 'Social', 'Skills', 'Training', 'Group-based', 'Program', '(', 'SST-GP', ')', 'and', 'a', 'Leisure', 'Activities', 'Group-based', 'Program', '(', 'LA-GP', ')', 'on', 'the', 'perception', 'of', 'facial', 'emotions', 'and', 'quality', 'of', 'life', '(', 'QoL', ')', 'in', 'young', 'people', 'with', 'HFA', '.']","(25, 36)","(142, 199)",-1,ss_o,23417625,Abstract,2,test,gold,1895.0
5234,To compare the effect of a,Social Skills Training Group-based Program ( SST-GP ),and a Leisure Activities Group-based Program ( LA-GP ) on the perception of facial emotions and quality of life ( QoL ) in young people with HFA .,"['To', 'compare', 'the', 'effect', 'of', 'a', 'Social', 'Skills', 'Training', 'Group-based', 'Program', '(', 'SST-GP', ')', 'and', 'a', 'Leisure', 'Activities', 'Group-based', 'Program', '(', 'LA-GP', ')', 'on', 'the', 'perception', 'of', 'facial', 'emotions', 'and', 'quality', 'of', 'life', '(', 'QoL', ')', 'in', 'young', 'people', 'with', 'HFA', '.']","(6, 14)","(26, 79)",-1,hl_i,23417625,Abstract,2,test,gold,6246.0
5235,To compare the effect of a Social Skills Training Group-based Program ( SST-GP ) and a,Leisure Activities Group-based Program ( LA-GP ),on the perception of facial emotions and quality of life ( QoL ) in young people with HFA .,"['To', 'compare', 'the', 'effect', 'of', 'a', 'Social', 'Skills', 'Training', 'Group-based', 'Program', '(', 'SST-GP', ')', 'and', 'a', 'Leisure', 'Activities', 'Group-based', 'Program', '(', 'LA-GP', ')', 'on', 'the', 'perception', 'of', 'facial', 'emotions', 'and', 'quality', 'of', 'life', '(', 'QoL', ')', 'in', 'young', 'people', 'with', 'HFA', '.']","(16, 23)","(86, 134)",-1,hl_i,23417625,Abstract,2,test,gold,6249.0
5236,,Eligible patients were children and adolescents with HFA .,,"['Eligible', 'patients', 'were', 'children', 'and', 'adolescents', 'with', 'HFA', '.']","(0, 9)","(0, 58)",-1,ss_p,23417625,Abstract,3,test,gold,6194.0
5237,Eligible patients were,children and adolescents,with HFA .,"['Eligible', 'patients', 'were', 'children', 'and', 'adolescents', 'with', 'HFA', '.']","(3, 6)","(22, 46)",-1,hl_p,23417625,Abstract,3,test,gold,2106.0
5238,Eligible patients were children and adolescents with,HFA,.,"['Eligible', 'patients', 'were', 'children', 'and', 'adolescents', 'with', 'HFA', '.']","(7, 8)","(52, 55)",-1,hl_p,23417625,Abstract,3,test,gold,2217.0
5239,Participants were randomized to the,SST,or LA group .,"['Participants', 'were', 'randomized', 'to', 'the', 'SST', 'or', 'LA', 'group', '.']","(5, 6)","(35, 38)",-1,ss_i,23417625,Abstract,4,test,gold,578.0
5240,Participants were randomized to the SST or,LA,group .,"['Participants', 'were', 'randomized', 'to', 'the', 'SST', 'or', 'LA', 'group', '.']","(7, 8)","(42, 44)",-1,ss_i,23417625,Abstract,4,test,gold,640.0
5241,Participants were randomized to the,SST,or LA group .,"['Participants', 'were', 'randomized', 'to', 'the', 'SST', 'or', 'LA', 'group', '.']","(5, 6)","(35, 38)",-1,hl_i,23417625,Abstract,4,test,gold,579.0
5242,Participants were randomized to the SST or,LA,group .,"['Participants', 'were', 'randomized', 'to', 'the', 'SST', 'or', 'LA', 'group', '.']","(7, 8)","(42, 44)",-1,hl_i,23417625,Abstract,4,test,gold,641.0
5243,The primary outcome was defined as an,improvement of 2 points in error rates for facial emotion labeling ( DANVA2 ) from baseline .,,"['The', 'primary', 'outcome', 'was', 'defined', 'as', 'an', 'improvement', 'of', '2', 'points', 'in', 'error', 'rates', 'for', 'facial', 'emotion', 'labeling', '(', 'DANVA2', ')', 'from', 'baseline', '.']","(7, 24)","(37, 130)",-1,ss_o,23417625,Abstract,5,test,gold,6467.0
5244,The primary outcome was defined as an improvement of 2 points in,error rates for facial emotion labeling ( DANVA2 ),from baseline .,"['The', 'primary', 'outcome', 'was', 'defined', 'as', 'an', 'improvement', 'of', '2', 'points', 'in', 'error', 'rates', 'for', 'facial', 'emotion', 'labeling', '(', 'DANVA2', ')', 'from', 'baseline', '.']","(12, 21)","(64, 114)",-1,hl_o,23417625,Abstract,5,test,gold,6468.0
5245,"After the 6-month training period , the",SST,"Group made fewer errors in labeling anger on adult faces , whereas error rates in the LA Group remained stable .","['After', 'the', '6-month', 'training', 'period', ',', 'the', 'SST', 'Group', 'made', 'fewer', 'errors', 'in', 'labeling', 'anger', 'on', 'adult', 'faces', ',', 'whereas', 'error', 'rates', 'in', 'the', 'LA', 'Group', 'remained', 'stable', '.']","(7, 8)","(39, 42)",-1,ss_i,23417625,Abstract,6,test,gold,577.0
5246,"After the 6-month training period , the SST Group made fewer errors in labeling anger on adult faces , whereas error rates in the",LA,Group remained stable .,"['After', 'the', '6-month', 'training', 'period', ',', 'the', 'SST', 'Group', 'made', 'fewer', 'errors', 'in', 'labeling', 'anger', 'on', 'adult', 'faces', ',', 'whereas', 'error', 'rates', 'in', 'the', 'LA', 'Group', 'remained', 'stable', '.']","(24, 25)","(129, 131)",-1,ss_i,23417625,Abstract,6,test,gold,639.0
5247,"After the 6-month training period , the SST Group made fewer errors in",labeling anger,"on adult faces , whereas error rates in the LA Group remained stable .","['After', 'the', '6-month', 'training', 'period', ',', 'the', 'SST', 'Group', 'made', 'fewer', 'errors', 'in', 'labeling', 'anger', 'on', 'adult', 'faces', ',', 'whereas', 'error', 'rates', 'in', 'the', 'LA', 'Group', 'remained', 'stable', '.']","(13, 15)","(70, 84)",-1,ss_o,23417625,Abstract,6,test,gold,3020.0
5248,"After the 6-month training period , the",SST,"Group made fewer errors in labeling anger on adult faces , whereas error rates in the LA Group remained stable .","['After', 'the', '6-month', 'training', 'period', ',', 'the', 'SST', 'Group', 'made', 'fewer', 'errors', 'in', 'labeling', 'anger', 'on', 'adult', 'faces', ',', 'whereas', 'error', 'rates', 'in', 'the', 'LA', 'Group', 'remained', 'stable', '.']","(7, 8)","(39, 42)",-1,hl_i,23417625,Abstract,6,test,gold,576.0
5249,"After the 6-month training period , the SST Group made fewer errors in labeling anger on adult faces , whereas error rates in the",LA,Group remained stable .,"['After', 'the', '6-month', 'training', 'period', ',', 'the', 'SST', 'Group', 'made', 'fewer', 'errors', 'in', 'labeling', 'anger', 'on', 'adult', 'faces', ',', 'whereas', 'error', 'rates', 'in', 'the', 'LA', 'Group', 'remained', 'stable', '.']","(24, 25)","(129, 131)",-1,hl_i,23417625,Abstract,6,test,gold,638.0
5250,Progress in the ability to recognize anger in the,SST,Group was due to better recognition of low intensity stimuli on adult faces .,"['Progress', 'in', 'the', 'ability', 'to', 'recognize', 'anger', 'in', 'the', 'SST', 'Group', 'was', 'due', 'to', 'better', 'recognition', 'of', 'low', 'intensity', 'stimuli', 'on', 'adult', 'faces', '.']","(9, 10)","(49, 52)",-1,ss_i,23417625,Abstract,7,test,gold,575.0
5251,Progress in the,ability to recognize anger,in the SST Group was due to better recognition of low intensity stimuli on adult faces .,"['Progress', 'in', 'the', 'ability', 'to', 'recognize', 'anger', 'in', 'the', 'SST', 'Group', 'was', 'due', 'to', 'better', 'recognition', 'of', 'low', 'intensity', 'stimuli', 'on', 'adult', 'faces', '.']","(3, 7)","(15, 41)",-1,ss_o,23417625,Abstract,7,test,gold,3018.0
5252,Progress in the ability to recognize anger in the,SST,Group was due to better recognition of low intensity stimuli on adult faces .,"['Progress', 'in', 'the', 'ability', 'to', 'recognize', 'anger', 'in', 'the', 'SST', 'Group', 'was', 'due', 'to', 'better', 'recognition', 'of', 'low', 'intensity', 'stimuli', 'on', 'adult', 'faces', '.']","(9, 10)","(49, 52)",-1,hl_i,23417625,Abstract,7,test,gold,574.0
5253,Progress in the,ability to recognize anger,in the SST Group was due to better recognition of low intensity stimuli on adult faces .,"['Progress', 'in', 'the', 'ability', 'to', 'recognize', 'anger', 'in', 'the', 'SST', 'Group', 'was', 'due', 'to', 'better', 'recognition', 'of', 'low', 'intensity', 'stimuli', 'on', 'adult', 'faces', '.']","(3, 7)","(15, 41)",-1,hl_o,23417625,Abstract,7,test,gold,3019.0
5254,QoL increased in the,SST,"Group in the dimension of school environment , as a marker of the transfer of skills acquired in the treatment setting to their use in the community .","['QoL', 'increased', 'in', 'the', 'SST', 'Group', 'in', 'the', 'dimension', 'of', 'school', 'environment', ',', 'as', 'a', 'marker', 'of', 'the', 'transfer', 'of', 'skills', 'acquired', 'in', 'the', 'treatment', 'setting', 'to', 'their', 'use', 'in', 'the', 'community', '.']","(4, 5)","(20, 23)",-1,ss_i,23417625,Abstract,8,test,gold,573.0
5255,,QoL,"increased in the SST Group in the dimension of school environment , as a marker of the transfer of skills acquired in the treatment setting to their use in the community .","['QoL', 'increased', 'in', 'the', 'SST', 'Group', 'in', 'the', 'dimension', 'of', 'school', 'environment', ',', 'as', 'a', 'marker', 'of', 'the', 'transfer', 'of', 'skills', 'acquired', 'in', 'the', 'treatment', 'setting', 'to', 'their', 'use', 'in', 'the', 'community', '.']","(0, 1)","(0, 3)",-1,ss_o,23417625,Abstract,8,test,gold,375.0
5256,QoL increased in the,SST,"Group in the dimension of school environment , as a marker of the transfer of skills acquired in the treatment setting to their use in the community .","['QoL', 'increased', 'in', 'the', 'SST', 'Group', 'in', 'the', 'dimension', 'of', 'school', 'environment', ',', 'as', 'a', 'marker', 'of', 'the', 'transfer', 'of', 'skills', 'acquired', 'in', 'the', 'treatment', 'setting', 'to', 'their', 'use', 'in', 'the', 'community', '.']","(4, 5)","(20, 23)",-1,hl_i,23417625,Abstract,8,test,gold,572.0
5257,,QoL,"increased in the SST Group in the dimension of school environment , as a marker of the transfer of skills acquired in the treatment setting to their use in the community .","['QoL', 'increased', 'in', 'the', 'SST', 'Group', 'in', 'the', 'dimension', 'of', 'school', 'environment', ',', 'as', 'a', 'marker', 'of', 'the', 'transfer', 'of', 'skills', 'acquired', 'in', 'the', 'treatment', 'setting', 'to', 'their', 'use', 'in', 'the', 'community', '.']","(0, 1)","(0, 3)",-1,hl_o,23417625,Abstract,8,test,gold,374.0
5258,The,SST-GP,had higher efficacy than the LA-GP .,"['The', 'SST-GP', 'had', 'higher', 'efficacy', 'than', 'the', 'LA-GP', '.']","(1, 2)","(3, 9)",-1,ss_i,23417625,Abstract,9,test,gold,
5259,The SST-GP had higher efficacy than the,LA-GP .,,"['The', 'SST-GP', 'had', 'higher', 'efficacy', 'than', 'the', 'LA-GP', '.']","(7, 9)","(39, 46)",-1,ss_i,23417625,Abstract,9,test,gold,
5260,The SST-GP had higher,efficacy,than the LA-GP .,"['The', 'SST-GP', 'had', 'higher', 'efficacy', 'than', 'the', 'LA-GP', '.']","(4, 5)","(21, 29)",-1,ss_o,23417625,Abstract,9,test,gold,4797.0
5261,The,SST-GP,had higher efficacy than the LA-GP .,"['The', 'SST-GP', 'had', 'higher', 'efficacy', 'than', 'the', 'LA-GP', '.']","(1, 2)","(3, 9)",-1,hl_i,23417625,Abstract,9,test,gold,
5262,The SST-GP had higher efficacy than the,LA-GP .,,"['The', 'SST-GP', 'had', 'higher', 'efficacy', 'than', 'the', 'LA-GP', '.']","(7, 9)","(39, 46)",-1,hl_i,23417625,Abstract,9,test,gold,
5263,The SST-GP had higher,efficacy,than the LA-GP .,"['The', 'SST-GP', 'had', 'higher', 'efficacy', 'than', 'the', 'LA-GP', '.']","(4, 5)","(21, 29)",-1,hl_o,23417625,Abstract,9,test,gold,4796.0
5264,Data justify replication using larger samples .,,,"['Data', 'justify', 'replication', 'using', 'larger', 'samples', '.']",,,,,23417625,Abstract,10,test,gold,
5265,"Effect of duloxetine on pain , function , and quality of life among",patients with chemotherapy-induced painful peripheral neuropathy :,a randomized clinical trial .,"['Effect', 'of', 'duloxetine', 'on', 'pain', ',', 'function', ',', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'chemotherapy-induced', 'painful', 'peripheral', 'neuropathy', ':', 'a', 'randomized', 'clinical', 'trial', '.']","(13, 20)","(67, 133)",-1,ss_p,23549581,Title,0,test,gold,7015.0
5266,Effect of,duloxetine,"on pain , function , and quality of life among patients with chemotherapy-induced painful peripheral neuropathy : a randomized clinical trial .","['Effect', 'of', 'duloxetine', 'on', 'pain', ',', 'function', ',', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'chemotherapy-induced', 'painful', 'peripheral', 'neuropathy', ':', 'a', 'randomized', 'clinical', 'trial', '.']","(2, 3)","(9, 19)",-1,ss_i,23549581,Title,0,test,gold,5286.0
5267,Effect of duloxetine on,"pain , function , and quality of life",among patients with chemotherapy-induced painful peripheral neuropathy : a randomized clinical trial .,"['Effect', 'of', 'duloxetine', 'on', 'pain', ',', 'function', ',', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'chemotherapy-induced', 'painful', 'peripheral', 'neuropathy', ':', 'a', 'randomized', 'clinical', 'trial', '.']","(4, 12)","(23, 60)",-1,ss_o,23549581,Title,0,test,gold,2309.0
5268,"Effect of duloxetine on pain , function , and quality of life among",patients with chemotherapy-induced painful peripheral neuropathy :,a randomized clinical trial .,"['Effect', 'of', 'duloxetine', 'on', 'pain', ',', 'function', ',', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'chemotherapy-induced', 'painful', 'peripheral', 'neuropathy', ':', 'a', 'randomized', 'clinical', 'trial', '.']","(13, 20)","(67, 133)",-1,hl_p,23549581,Title,0,test,gold,7016.0
5269,Effect of,duloxetine,"on pain , function , and quality of life among patients with chemotherapy-induced painful peripheral neuropathy : a randomized clinical trial .","['Effect', 'of', 'duloxetine', 'on', 'pain', ',', 'function', ',', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'chemotherapy-induced', 'painful', 'peripheral', 'neuropathy', ':', 'a', 'randomized', 'clinical', 'trial', '.']","(2, 3)","(9, 19)",-1,hl_i,23549581,Title,0,test,gold,5287.0
5270,Effect of duloxetine on,pain,", function , and quality of life among patients with chemotherapy-induced painful peripheral neuropathy : a randomized clinical trial .","['Effect', 'of', 'duloxetine', 'on', 'pain', ',', 'function', ',', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'chemotherapy-induced', 'painful', 'peripheral', 'neuropathy', ':', 'a', 'randomized', 'clinical', 'trial', '.']","(4, 5)","(23, 27)",-1,hl_o,23549581,Title,0,test,gold,2296.0
5271,"Effect of duloxetine on pain ,",function,", and quality of life among patients with chemotherapy-induced painful peripheral neuropathy : a randomized clinical trial .","['Effect', 'of', 'duloxetine', 'on', 'pain', ',', 'function', ',', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'chemotherapy-induced', 'painful', 'peripheral', 'neuropathy', ':', 'a', 'randomized', 'clinical', 'trial', '.']","(6, 7)","(30, 38)",-1,hl_o,23549581,Title,0,test,gold,1363.0
5272,"Effect of duloxetine on pain , function , and",quality of life,among patients with chemotherapy-induced painful peripheral neuropathy : a randomized clinical trial .,"['Effect', 'of', 'duloxetine', 'on', 'pain', ',', 'function', ',', 'and', 'quality', 'of', 'life', 'among', 'patients', 'with', 'chemotherapy-induced', 'painful', 'peripheral', 'neuropathy', ':', 'a', 'randomized', 'clinical', 'trial', '.']","(9, 12)","(45, 60)",-1,hl_o,23549581,Title,0,test,gold,1880.0
5273,IMPORTANCE There are no known effective treatments for painful chemotherapy-induced peripheral neuropathy .,,,"['IMPORTANCE', 'There', 'are', 'no', 'known', 'effective', 'treatments', 'for', 'painful', 'chemotherapy-induced', 'peripheral', 'neuropathy', '.']",,,,,23549581,Abstract,0,test,gold,
5274,OBJECTIVE To determine the effect of,duloxetine,", 60 mg daily , on average pain severity .","['OBJECTIVE', 'To', 'determine', 'the', 'effect', 'of', 'duloxetine', ',', '60', 'mg', 'daily', ',', 'on', 'average', 'pain', 'severity', '.']","(6, 7)","(36, 46)",-1,ss_i,23549581,Abstract,1,test,gold,5285.0
5275,"OBJECTIVE To determine the effect of duloxetine , 60 mg daily , on",average pain severity .,,"['OBJECTIVE', 'To', 'determine', 'the', 'effect', 'of', 'duloxetine', ',', '60', 'mg', 'daily', ',', 'on', 'average', 'pain', 'severity', '.']","(13, 17)","(66, 89)",-1,ss_o,23549581,Abstract,1,test,gold,2319.0
5276,OBJECTIVE To determine the effect of,duloxetine,", 60 mg daily , on average pain severity .","['OBJECTIVE', 'To', 'determine', 'the', 'effect', 'of', 'duloxetine', ',', '60', 'mg', 'daily', ',', 'on', 'average', 'pain', 'severity', '.']","(6, 7)","(36, 46)",-1,hl_i,23549581,Abstract,1,test,gold,5284.0
5277,"OBJECTIVE To determine the effect of duloxetine , 60 mg daily , on",average pain severity .,,"['OBJECTIVE', 'To', 'determine', 'the', 'effect', 'of', 'duloxetine', ',', '60', 'mg', 'daily', ',', 'on', 'average', 'pain', 'severity', '.']","(13, 17)","(66, 89)",-1,hl_o,23549581,Abstract,1,test,gold,2320.0
5278,"DESIGN , SETTING , AND PATIENTS Randomized , double-blind , placebo-controlled crossover trial at 8 National Cancer Institute ( NCI ) -funded cooperative research networks that enrolled",231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011 .,,"['DESIGN', ',', 'SETTING', ',', 'AND', 'PATIENTS', 'Randomized', ',', 'double-blind', ',', 'placebo-controlled', 'crossover', 'trial', 'at', '8', 'National', 'Cancer', 'Institute', '(', 'NCI', ')', '-funded', 'cooperative', 'research', 'networks', 'that', 'enrolled', '231', 'patients', 'who', 'were', '25', 'years', 'or', 'older', 'being', 'treated', 'at', 'community', 'and', 'academic', 'settings', 'between', 'April', '2008', 'and', 'March', '2011', '.']","(27, 49)","(185, 309)",-1,ss_p,23549581,Abstract,2,test,gold,5829.0
5279,"DESIGN , SETTING , AND PATIENTS Randomized , double-blind , placebo-controlled crossover trial at 8 National Cancer Institute ( NCI ) -funded cooperative research networks that enrolled",231 patients who were 25 years or older,being treated at community and academic settings between April 2008 and March 2011 .,"['DESIGN', ',', 'SETTING', ',', 'AND', 'PATIENTS', 'Randomized', ',', 'double-blind', ',', 'placebo-controlled', 'crossover', 'trial', 'at', '8', 'National', 'Cancer', 'Institute', '(', 'NCI', ')', '-funded', 'cooperative', 'research', 'networks', 'that', 'enrolled', '231', 'patients', 'who', 'were', '25', 'years', 'or', 'older', 'being', 'treated', 'at', 'community', 'and', 'academic', 'settings', 'between', 'April', '2008', 'and', 'March', '2011', '.']","(27, 35)","(185, 224)",-1,hl_p,23549581,Abstract,2,test,gold,2040.0
5280,"DESIGN , SETTING , AND PATIENTS Randomized , double-blind , placebo-controlled crossover trial at 8 National Cancer Institute ( NCI ) -funded cooperative research networks that enrolled 231 patients who were 25 years or older being",treated at community and academic settings between April 2008 and March 2011,.,"['DESIGN', ',', 'SETTING', ',', 'AND', 'PATIENTS', 'Randomized', ',', 'double-blind', ',', 'placebo-controlled', 'crossover', 'trial', 'at', '8', 'National', 'Cancer', 'Institute', '(', 'NCI', ')', '-funded', 'cooperative', 'research', 'networks', 'that', 'enrolled', '231', 'patients', 'who', 'were', '25', 'years', 'or', 'older', 'being', 'treated', 'at', 'community', 'and', 'academic', 'settings', 'between', 'April', '2008', 'and', 'March', '2011', '.']","(36, 48)","(231, 307)",-1,hl_p,23549581,Abstract,2,test,gold,5830.0
5281,Study follow-up was completed July 2012 .,,,"['Study', 'follow-up', 'was', 'completed', 'July', '2012', '.']",,,,,23549581,Abstract,3,test,gold,
5282,"Stratified by chemotherapeutic drug and comorbid pain risk , patients were randomized to receive either",duloxetine,followed by placebo or placebo followed by duloxetine .,"['Stratified', 'by', 'chemotherapeutic', 'drug', 'and', 'comorbid', 'pain', 'risk', ',', 'patients', 'were', 'randomized', 'to', 'receive', 'either', 'duloxetine', 'followed', 'by', 'placebo', 'or', 'placebo', 'followed', 'by', 'duloxetine', '.']","(15, 16)","(103, 113)",-1,ss_i,23549581,Abstract,4,test,gold,5283.0
5283,"Stratified by chemotherapeutic drug and comorbid pain risk , patients were randomized to receive either duloxetine followed by",placebo,or placebo followed by duloxetine .,"['Stratified', 'by', 'chemotherapeutic', 'drug', 'and', 'comorbid', 'pain', 'risk', ',', 'patients', 'were', 'randomized', 'to', 'receive', 'either', 'duloxetine', 'followed', 'by', 'placebo', 'or', 'placebo', 'followed', 'by', 'duloxetine', '.']","(18, 19)","(126, 133)",-1,ss_i,23549581,Abstract,4,test,gold,4354.0
5284,"Stratified by chemotherapeutic drug and comorbid pain risk , patients were randomized to receive either duloxetine followed by placebo or",placebo,followed by duloxetine .,"['Stratified', 'by', 'chemotherapeutic', 'drug', 'and', 'comorbid', 'pain', 'risk', ',', 'patients', 'were', 'randomized', 'to', 'receive', 'either', 'duloxetine', 'followed', 'by', 'placebo', 'or', 'placebo', 'followed', 'by', 'duloxetine', '.']","(20, 21)","(137, 144)",-1,ss_i,23549581,Abstract,4,test,gold,4353.0
5285,"Stratified by chemotherapeutic drug and comorbid pain risk , patients were randomized to receive either duloxetine followed by placebo or placebo followed by",duloxetine .,,"['Stratified', 'by', 'chemotherapeutic', 'drug', 'and', 'comorbid', 'pain', 'risk', ',', 'patients', 'were', 'randomized', 'to', 'receive', 'either', 'duloxetine', 'followed', 'by', 'placebo', 'or', 'placebo', 'followed', 'by', 'duloxetine', '.']","(23, 25)","(157, 169)",-1,ss_i,23549581,Abstract,4,test,gold,5282.0
5286,"Stratified by chemotherapeutic drug and comorbid pain risk , patients were randomized to receive either",duloxetine,followed by placebo or placebo followed by duloxetine .,"['Stratified', 'by', 'chemotherapeutic', 'drug', 'and', 'comorbid', 'pain', 'risk', ',', 'patients', 'were', 'randomized', 'to', 'receive', 'either', 'duloxetine', 'followed', 'by', 'placebo', 'or', 'placebo', 'followed', 'by', 'duloxetine', '.']","(15, 16)","(103, 113)",-1,hl_i,23549581,Abstract,4,test,gold,5281.0
5287,"Stratified by chemotherapeutic drug and comorbid pain risk , patients were randomized to receive either duloxetine followed by",placebo,or placebo followed by duloxetine .,"['Stratified', 'by', 'chemotherapeutic', 'drug', 'and', 'comorbid', 'pain', 'risk', ',', 'patients', 'were', 'randomized', 'to', 'receive', 'either', 'duloxetine', 'followed', 'by', 'placebo', 'or', 'placebo', 'followed', 'by', 'duloxetine', '.']","(18, 19)","(126, 133)",-1,hl_i,23549581,Abstract,4,test,gold,4352.0
5288,"Stratified by chemotherapeutic drug and comorbid pain risk , patients were randomized to receive either duloxetine followed by placebo or",placebo,followed by duloxetine .,"['Stratified', 'by', 'chemotherapeutic', 'drug', 'and', 'comorbid', 'pain', 'risk', ',', 'patients', 'were', 'randomized', 'to', 'receive', 'either', 'duloxetine', 'followed', 'by', 'placebo', 'or', 'placebo', 'followed', 'by', 'duloxetine', '.']","(20, 21)","(137, 144)",-1,hl_i,23549581,Abstract,4,test,gold,4351.0
5289,"Stratified by chemotherapeutic drug and comorbid pain risk , patients were randomized to receive either duloxetine followed by placebo or placebo followed by",duloxetine .,,"['Stratified', 'by', 'chemotherapeutic', 'drug', 'and', 'comorbid', 'pain', 'risk', ',', 'patients', 'were', 'randomized', 'to', 'receive', 'either', 'duloxetine', 'followed', 'by', 'placebo', 'or', 'placebo', 'followed', 'by', 'duloxetine', '.']","(23, 25)","(157, 169)",-1,hl_i,23549581,Abstract,4,test,gold,5280.0
5290,Eligibility required that patients have,"grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10 , representing average chemotherapy-induced pain , after paclitaxel , other taxane , or oxaliplatin treatment .",,"['Eligibility', 'required', 'that', 'patients', 'have', 'grade', '1', 'or', 'higher', 'sensory', 'neuropathy', 'according', 'to', 'the', 'NCI', 'Common', 'Terminology', 'Criteria', 'for', 'Adverse', 'Events', 'and', 'at', 'least', '4', 'on', 'a', 'scale', 'of', '0', 'to', '10', ',', 'representing', 'average', 'chemotherapy-induced', 'pain', ',', 'after', 'paclitaxel', ',', 'other', 'taxane', ',', 'or', 'oxaliplatin', 'treatment', '.']","(5, 48)","(39, 292)",-1,ss_p,23549581,Abstract,5,test,gold,5917.0
5291,"Eligibility required that patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10 , representing average chemotherapy-induced pain , after",paclitaxel,", other taxane , or oxaliplatin treatment .","['Eligibility', 'required', 'that', 'patients', 'have', 'grade', '1', 'or', 'higher', 'sensory', 'neuropathy', 'according', 'to', 'the', 'NCI', 'Common', 'Terminology', 'Criteria', 'for', 'Adverse', 'Events', 'and', 'at', 'least', '4', 'on', 'a', 'scale', 'of', '0', 'to', '10', ',', 'representing', 'average', 'chemotherapy-induced', 'pain', ',', 'after', 'paclitaxel', ',', 'other', 'taxane', ',', 'or', 'oxaliplatin', 'treatment', '.']","(39, 40)","(238, 248)",-1,ss_i,23549581,Abstract,5,test,gold,5151.0
5292,"Eligibility required that patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10 , representing average chemotherapy-induced pain , after paclitaxel , other",taxane,", or oxaliplatin treatment .","['Eligibility', 'required', 'that', 'patients', 'have', 'grade', '1', 'or', 'higher', 'sensory', 'neuropathy', 'according', 'to', 'the', 'NCI', 'Common', 'Terminology', 'Criteria', 'for', 'Adverse', 'Events', 'and', 'at', 'least', '4', 'on', 'a', 'scale', 'of', '0', 'to', '10', ',', 'representing', 'average', 'chemotherapy-induced', 'pain', ',', 'after', 'paclitaxel', ',', 'other', 'taxane', ',', 'or', 'oxaliplatin', 'treatment', '.']","(42, 43)","(257, 263)",-1,ss_i,23549581,Abstract,5,test,gold,5739.0
5293,"Eligibility required that patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10 , representing average chemotherapy-induced pain , after paclitaxel , other taxane , or",oxaliplatin,treatment .,"['Eligibility', 'required', 'that', 'patients', 'have', 'grade', '1', 'or', 'higher', 'sensory', 'neuropathy', 'according', 'to', 'the', 'NCI', 'Common', 'Terminology', 'Criteria', 'for', 'Adverse', 'Events', 'and', 'at', 'least', '4', 'on', 'a', 'scale', 'of', '0', 'to', '10', ',', 'representing', 'average', 'chemotherapy-induced', 'pain', ',', 'after', 'paclitaxel', ',', 'other', 'taxane', ',', 'or', 'oxaliplatin', 'treatment', '.']","(45, 46)","(269, 280)",-1,ss_i,23549581,Abstract,5,test,gold,5731.0
5294,Eligibility required that patients have,"grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10 , representing average chemotherapy-induced pain , after paclitaxel , other taxane , or oxaliplatin treatment .",,"['Eligibility', 'required', 'that', 'patients', 'have', 'grade', '1', 'or', 'higher', 'sensory', 'neuropathy', 'according', 'to', 'the', 'NCI', 'Common', 'Terminology', 'Criteria', 'for', 'Adverse', 'Events', 'and', 'at', 'least', '4', 'on', 'a', 'scale', 'of', '0', 'to', '10', ',', 'representing', 'average', 'chemotherapy-induced', 'pain', ',', 'after', 'paclitaxel', ',', 'other', 'taxane', ',', 'or', 'oxaliplatin', 'treatment', '.']","(5, 48)","(39, 292)",-1,hl_p,23549581,Abstract,5,test,gold,5918.0
5295,INTERVENTIONS The initial treatment consisted of taking 1 capsule daily of either 30 mg of,duloxetine,or placebo for the first week and 2 capsules of either 30 mg of duloxetine or placebo daily for 4 additional weeks .,"['INTERVENTIONS', 'The', 'initial', 'treatment', 'consisted', 'of', 'taking', '1', 'capsule', 'daily', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'for', 'the', 'first', 'week', 'and', '2', 'capsules', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'daily', 'for', '4', 'additional', 'weeks', '.']","(15, 16)","(90, 100)",-1,ss_i,23549581,Abstract,6,test,gold,5279.0
5296,INTERVENTIONS The initial treatment consisted of taking 1 capsule daily of either 30 mg of duloxetine or,placebo,for the first week and 2 capsules of either 30 mg of duloxetine or placebo daily for 4 additional weeks .,"['INTERVENTIONS', 'The', 'initial', 'treatment', 'consisted', 'of', 'taking', '1', 'capsule', 'daily', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'for', 'the', 'first', 'week', 'and', '2', 'capsules', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'daily', 'for', '4', 'additional', 'weeks', '.']","(17, 18)","(104, 111)",-1,ss_i,23549581,Abstract,6,test,gold,4350.0
5297,INTERVENTIONS The initial treatment consisted of taking 1 capsule daily of either 30 mg of duloxetine or placebo for the first week and 2 capsules of either 30 mg of,duloxetine,or placebo daily for 4 additional weeks .,"['INTERVENTIONS', 'The', 'initial', 'treatment', 'consisted', 'of', 'taking', '1', 'capsule', 'daily', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'for', 'the', 'first', 'week', 'and', '2', 'capsules', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'daily', 'for', '4', 'additional', 'weeks', '.']","(30, 31)","(165, 175)",-1,ss_i,23549581,Abstract,6,test,gold,5278.0
5298,INTERVENTIONS The initial treatment consisted of taking 1 capsule daily of either 30 mg of duloxetine or placebo for the first week and 2 capsules of either 30 mg of duloxetine or,placebo,daily for 4 additional weeks .,"['INTERVENTIONS', 'The', 'initial', 'treatment', 'consisted', 'of', 'taking', '1', 'capsule', 'daily', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'for', 'the', 'first', 'week', 'and', '2', 'capsules', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'daily', 'for', '4', 'additional', 'weeks', '.']","(32, 33)","(179, 186)",-1,ss_i,23549581,Abstract,6,test,gold,4349.0
5299,INTERVENTIONS The initial treatment consisted of taking 1 capsule daily of either 30 mg of,duloxetine,or placebo for the first week and 2 capsules of either 30 mg of duloxetine or placebo daily for 4 additional weeks .,"['INTERVENTIONS', 'The', 'initial', 'treatment', 'consisted', 'of', 'taking', '1', 'capsule', 'daily', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'for', 'the', 'first', 'week', 'and', '2', 'capsules', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'daily', 'for', '4', 'additional', 'weeks', '.']","(15, 16)","(90, 100)",-1,hl_i,23549581,Abstract,6,test,gold,5277.0
5300,INTERVENTIONS The initial treatment consisted of taking 1 capsule daily of either 30 mg of duloxetine or,placebo,for the first week and 2 capsules of either 30 mg of duloxetine or placebo daily for 4 additional weeks .,"['INTERVENTIONS', 'The', 'initial', 'treatment', 'consisted', 'of', 'taking', '1', 'capsule', 'daily', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'for', 'the', 'first', 'week', 'and', '2', 'capsules', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'daily', 'for', '4', 'additional', 'weeks', '.']","(17, 18)","(104, 111)",-1,hl_i,23549581,Abstract,6,test,gold,4348.0
5301,INTERVENTIONS The initial treatment consisted of taking 1 capsule daily of either 30 mg of duloxetine or placebo for the first week and 2 capsules of either 30 mg of,duloxetine,or placebo daily for 4 additional weeks .,"['INTERVENTIONS', 'The', 'initial', 'treatment', 'consisted', 'of', 'taking', '1', 'capsule', 'daily', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'for', 'the', 'first', 'week', 'and', '2', 'capsules', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'daily', 'for', '4', 'additional', 'weeks', '.']","(30, 31)","(165, 175)",-1,hl_i,23549581,Abstract,6,test,gold,5276.0
5302,INTERVENTIONS The initial treatment consisted of taking 1 capsule daily of either 30 mg of duloxetine or placebo for the first week and 2 capsules of either 30 mg of duloxetine or,placebo,daily for 4 additional weeks .,"['INTERVENTIONS', 'The', 'initial', 'treatment', 'consisted', 'of', 'taking', '1', 'capsule', 'daily', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'for', 'the', 'first', 'week', 'and', '2', 'capsules', 'of', 'either', '30', 'mg', 'of', 'duloxetine', 'or', 'placebo', 'daily', 'for', '4', 'additional', 'weeks', '.']","(32, 33)","(179, 186)",-1,hl_i,23549581,Abstract,6,test,gold,4347.0
5303,MAIN OUTCOME MEASURES The primary hypothesis was that,duloxetine,would be more effective than placebo in decreasing chemotherapy-induced peripheral neuropathic pain .,"['MAIN', 'OUTCOME', 'MEASURES', 'The', 'primary', 'hypothesis', 'was', 'that', 'duloxetine', 'would', 'be', 'more', 'effective', 'than', 'placebo', 'in', 'decreasing', 'chemotherapy-induced', 'peripheral', 'neuropathic', 'pain', '.']","(8, 9)","(53, 63)",-1,ss_i,23549581,Abstract,7,test,gold,5275.0
5304,MAIN OUTCOME MEASURES The primary hypothesis was that duloxetine would be more effective than,placebo,in decreasing chemotherapy-induced peripheral neuropathic pain .,"['MAIN', 'OUTCOME', 'MEASURES', 'The', 'primary', 'hypothesis', 'was', 'that', 'duloxetine', 'would', 'be', 'more', 'effective', 'than', 'placebo', 'in', 'decreasing', 'chemotherapy-induced', 'peripheral', 'neuropathic', 'pain', '.']","(14, 15)","(93, 100)",-1,ss_i,23549581,Abstract,7,test,gold,4346.0
5305,MAIN OUTCOME MEASURES The primary hypothesis was that duloxetine would be more,effective,than placebo in decreasing chemotherapy-induced peripheral neuropathic pain .,"['MAIN', 'OUTCOME', 'MEASURES', 'The', 'primary', 'hypothesis', 'was', 'that', 'duloxetine', 'would', 'be', 'more', 'effective', 'than', 'placebo', 'in', 'decreasing', 'chemotherapy-induced', 'peripheral', 'neuropathic', 'pain', '.']","(12, 13)","(78, 87)",-1,ss_o,23549581,Abstract,7,test,gold,848.0
5306,MAIN OUTCOME MEASURES The primary hypothesis was that duloxetine would be more effective than placebo in decreasing,chemotherapy-induced peripheral neuropathic pain .,,"['MAIN', 'OUTCOME', 'MEASURES', 'The', 'primary', 'hypothesis', 'was', 'that', 'duloxetine', 'would', 'be', 'more', 'effective', 'than', 'placebo', 'in', 'decreasing', 'chemotherapy-induced', 'peripheral', 'neuropathic', 'pain', '.']","(17, 22)","(115, 165)",-1,ss_o,23549581,Abstract,7,test,gold,3117.0
5307,MAIN OUTCOME MEASURES The primary hypothesis was that,duloxetine,would be more effective than placebo in decreasing chemotherapy-induced peripheral neuropathic pain .,"['MAIN', 'OUTCOME', 'MEASURES', 'The', 'primary', 'hypothesis', 'was', 'that', 'duloxetine', 'would', 'be', 'more', 'effective', 'than', 'placebo', 'in', 'decreasing', 'chemotherapy-induced', 'peripheral', 'neuropathic', 'pain', '.']","(8, 9)","(53, 63)",-1,hl_i,23549581,Abstract,7,test,gold,5274.0
5308,MAIN OUTCOME MEASURES The primary hypothesis was that duloxetine would be more effective than,placebo,in decreasing chemotherapy-induced peripheral neuropathic pain .,"['MAIN', 'OUTCOME', 'MEASURES', 'The', 'primary', 'hypothesis', 'was', 'that', 'duloxetine', 'would', 'be', 'more', 'effective', 'than', 'placebo', 'in', 'decreasing', 'chemotherapy-induced', 'peripheral', 'neuropathic', 'pain', '.']","(14, 15)","(93, 100)",-1,hl_i,23549581,Abstract,7,test,gold,4345.0
5309,MAIN OUTCOME MEASURES The primary hypothesis was that duloxetine would be more effective than placebo in decreasing,chemotherapy-induced peripheral neuropathic pain .,,"['MAIN', 'OUTCOME', 'MEASURES', 'The', 'primary', 'hypothesis', 'was', 'that', 'duloxetine', 'would', 'be', 'more', 'effective', 'than', 'placebo', 'in', 'decreasing', 'chemotherapy-induced', 'peripheral', 'neuropathic', 'pain', '.']","(17, 22)","(115, 165)",-1,hl_o,23549581,Abstract,7,test,gold,3118.0
5310,,"Pain severity was assessed using the Brief Pain Inventory-Short Form "" average pain "" item with 0 representing no pain and 10 representing as bad as can be imagined .",,"['Pain', 'severity', 'was', 'assessed', 'using', 'the', 'Brief', 'Pain', 'Inventory-Short', 'Form', '""', 'average', 'pain', '""', 'item', 'with', '0', 'representing', 'no', 'pain', 'and', '10', 'representing', 'as', 'bad', 'as', 'can', 'be', 'imagined', '.']","(0, 30)","(0, 166)",-1,ss_o,23549581,Abstract,8,test,gold,5910.0
5311,,Pain severity,"was assessed using the Brief Pain Inventory-Short Form "" average pain "" item with 0 representing no pain and 10 representing as bad as can be imagined .","['Pain', 'severity', 'was', 'assessed', 'using', 'the', 'Brief', 'Pain', 'Inventory-Short', 'Form', '""', 'average', 'pain', '""', 'item', 'with', '0', 'representing', 'no', 'pain', 'and', '10', 'representing', 'as', 'bad', 'as', 'can', 'be', 'imagined', '.']","(0, 2)","(0, 13)",-1,hl_o,23549581,Abstract,8,test,gold,2318.0
5312,Pain severity was assessed using the,"Brief Pain Inventory-Short Form "" average pain "" item",with 0 representing no pain and 10 representing as bad as can be imagined .,"['Pain', 'severity', 'was', 'assessed', 'using', 'the', 'Brief', 'Pain', 'Inventory-Short', 'Form', '""', 'average', 'pain', '""', 'item', 'with', '0', 'representing', 'no', 'pain', 'and', '10', 'representing', 'as', 'bad', 'as', 'can', 'be', 'imagined', '.']","(6, 15)","(36, 89)",-1,hl_o,23549581,Abstract,8,test,gold,6234.0
5313,"Pain severity was assessed using the Brief Pain Inventory-Short Form "" average pain "" item with 0 representing no",pain,and 10 representing as bad as can be imagined .,"['Pain', 'severity', 'was', 'assessed', 'using', 'the', 'Brief', 'Pain', 'Inventory-Short', 'Form', '""', 'average', 'pain', '""', 'item', 'with', '0', 'representing', 'no', 'pain', 'and', '10', 'representing', 'as', 'bad', 'as', 'can', 'be', 'imagined', '.']","(19, 20)","(113, 117)",-1,hl_o,23549581,Abstract,8,test,gold,2295.0
5314,RESULTS Individuals receiving,duloxetine,"as their initial 5-week treatment reported a mean decrease in average pain of 1.06 ( 95 % CI , 0.72-1.40 ) vs 0.34 ( 95 % CI , 0.01-0.66 ) among those who received placebo ( P = .003 ; effect size , 0.513 ) .","['RESULTS', 'Individuals', 'receiving', 'duloxetine', 'as', 'their', 'initial', '5-week', 'treatment', 'reported', 'a', 'mean', 'decrease', 'in', 'average', 'pain', 'of', '1.06', '(', '95', '%', 'CI', ',', '0.72-1.40', ')', 'vs', '0.34', '(', '95', '%', 'CI', ',', '0.01-0.66', ')', 'among', 'those', 'who', 'received', 'placebo', '(', 'P', '=', '.003', ';', 'effect', 'size', ',', '0.513', ')', '.']","(3, 4)","(29, 39)",-1,ss_i,23549581,Abstract,9,test,gold,5273.0
5315,"RESULTS Individuals receiving duloxetine as their initial 5-week treatment reported a mean decrease in average pain of 1.06 ( 95 % CI , 0.72-1.40 ) vs 0.34 ( 95 % CI , 0.01-0.66 ) among those who received",placebo,"( P = .003 ; effect size , 0.513 ) .","['RESULTS', 'Individuals', 'receiving', 'duloxetine', 'as', 'their', 'initial', '5-week', 'treatment', 'reported', 'a', 'mean', 'decrease', 'in', 'average', 'pain', 'of', '1.06', '(', '95', '%', 'CI', ',', '0.72-1.40', ')', 'vs', '0.34', '(', '95', '%', 'CI', ',', '0.01-0.66', ')', 'among', 'those', 'who', 'received', 'placebo', '(', 'P', '=', '.003', ';', 'effect', 'size', ',', '0.513', ')', '.']","(38, 39)","(204, 211)",-1,ss_i,23549581,Abstract,9,test,gold,4344.0
5316,RESULTS Individuals receiving duloxetine as their initial 5-week treatment reported a mean decrease in,average pain,"of 1.06 ( 95 % CI , 0.72-1.40 ) vs 0.34 ( 95 % CI , 0.01-0.66 ) among those who received placebo ( P = .003 ; effect size , 0.513 ) .","['RESULTS', 'Individuals', 'receiving', 'duloxetine', 'as', 'their', 'initial', '5-week', 'treatment', 'reported', 'a', 'mean', 'decrease', 'in', 'average', 'pain', 'of', '1.06', '(', '95', '%', 'CI', ',', '0.72-1.40', ')', 'vs', '0.34', '(', '95', '%', 'CI', ',', '0.01-0.66', ')', 'among', 'those', 'who', 'received', 'placebo', '(', 'P', '=', '.003', ';', 'effect', 'size', ',', '0.513', ')', '.']","(14, 16)","(102, 114)",-1,ss_o,23549581,Abstract,9,test,gold,2325.0
5317,RESULTS Individuals receiving duloxetine as their initial 5-week treatment reported a mean decrease in,average pain,"of 1.06 ( 95 % CI , 0.72-1.40 ) vs 0.34 ( 95 % CI , 0.01-0.66 ) among those who received placebo ( P = .003 ; effect size , 0.513 ) .","['RESULTS', 'Individuals', 'receiving', 'duloxetine', 'as', 'their', 'initial', '5-week', 'treatment', 'reported', 'a', 'mean', 'decrease', 'in', 'average', 'pain', 'of', '1.06', '(', '95', '%', 'CI', ',', '0.72-1.40', ')', 'vs', '0.34', '(', '95', '%', 'CI', ',', '0.01-0.66', ')', 'among', 'those', 'who', 'received', 'placebo', '(', 'P', '=', '.003', ';', 'effect', 'size', ',', '0.513', ')', '.']","(14, 16)","(102, 114)",-1,hl_o,23549581,Abstract,9,test,gold,2326.0
5318,The observed mean difference in the average pain score between,duloxetine,"and placebo was 0.73 ( 95 % CI , 0.26-1.20 ) .","['The', 'observed', 'mean', 'difference', 'in', 'the', 'average', 'pain', 'score', 'between', 'duloxetine', 'and', 'placebo', 'was', '0.73', '(', '95', '%', 'CI', ',', '0.26-1.20', ')', '.']","(10, 11)","(62, 72)",-1,ss_i,23549581,Abstract,10,test,gold,5272.0
5319,The observed mean difference in the average pain score between duloxetine and,placebo,"was 0.73 ( 95 % CI , 0.26-1.20 ) .","['The', 'observed', 'mean', 'difference', 'in', 'the', 'average', 'pain', 'score', 'between', 'duloxetine', 'and', 'placebo', 'was', '0.73', '(', '95', '%', 'CI', ',', '0.26-1.20', ')', '.']","(12, 13)","(77, 84)",-1,ss_i,23549581,Abstract,10,test,gold,4343.0
5320,The observed mean difference in the,average pain score,"between duloxetine and placebo was 0.73 ( 95 % CI , 0.26-1.20 ) .","['The', 'observed', 'mean', 'difference', 'in', 'the', 'average', 'pain', 'score', 'between', 'duloxetine', 'and', 'placebo', 'was', '0.73', '(', '95', '%', 'CI', ',', '0.26-1.20', ')', '.']","(6, 9)","(35, 53)",-1,ss_o,23549581,Abstract,10,test,gold,2327.0
5321,The observed mean difference in the average pain score between,duloxetine,"and placebo was 0.73 ( 95 % CI , 0.26-1.20 ) .","['The', 'observed', 'mean', 'difference', 'in', 'the', 'average', 'pain', 'score', 'between', 'duloxetine', 'and', 'placebo', 'was', '0.73', '(', '95', '%', 'CI', ',', '0.26-1.20', ')', '.']","(10, 11)","(62, 72)",-1,hl_i,23549581,Abstract,10,test,gold,5271.0
5322,The observed mean difference in the average pain score between duloxetine and,placebo,"was 0.73 ( 95 % CI , 0.26-1.20 ) .","['The', 'observed', 'mean', 'difference', 'in', 'the', 'average', 'pain', 'score', 'between', 'duloxetine', 'and', 'placebo', 'was', '0.73', '(', '95', '%', 'CI', ',', '0.26-1.20', ')', '.']","(12, 13)","(77, 84)",-1,hl_i,23549581,Abstract,10,test,gold,4342.0
5323,The observed mean difference in the,average pain score,"between duloxetine and placebo was 0.73 ( 95 % CI , 0.26-1.20 ) .","['The', 'observed', 'mean', 'difference', 'in', 'the', 'average', 'pain', 'score', 'between', 'duloxetine', 'and', 'placebo', 'was', '0.73', '(', '95', '%', 'CI', ',', '0.26-1.20', ')', '.']","(6, 9)","(35, 53)",-1,hl_o,23549581,Abstract,10,test,gold,2328.0
5324,Fifty-nine percent of those initially receiving,duloxetine,vs 38 % of those initially receiving placebo reported decreased pain of any amount .,"['Fifty-nine', 'percent', 'of', 'those', 'initially', 'receiving', 'duloxetine', 'vs', '38', '%', 'of', 'those', 'initially', 'receiving', 'placebo', 'reported', 'decreased', 'pain', 'of', 'any', 'amount', '.']","(6, 7)","(47, 57)",-1,ss_i,23549581,Abstract,11,test,gold,5270.0
5325,Fifty-nine percent of those initially receiving duloxetine vs 38 % of those initially receiving,placebo,reported decreased pain of any amount .,"['Fifty-nine', 'percent', 'of', 'those', 'initially', 'receiving', 'duloxetine', 'vs', '38', '%', 'of', 'those', 'initially', 'receiving', 'placebo', 'reported', 'decreased', 'pain', 'of', 'any', 'amount', '.']","(14, 15)","(95, 102)",-1,ss_i,23549581,Abstract,11,test,gold,4341.0
5326,Fifty-nine percent of those initially receiving duloxetine vs 38 % of those initially receiving placebo reported decreased,pain,of any amount .,"['Fifty-nine', 'percent', 'of', 'those', 'initially', 'receiving', 'duloxetine', 'vs', '38', '%', 'of', 'those', 'initially', 'receiving', 'placebo', 'reported', 'decreased', 'pain', 'of', 'any', 'amount', '.']","(17, 18)","(122, 126)",-1,ss_o,23549581,Abstract,11,test,gold,2294.0
5327,Fifty-nine percent of those initially receiving,duloxetine,vs 38 % of those initially receiving placebo reported decreased pain of any amount .,"['Fifty-nine', 'percent', 'of', 'those', 'initially', 'receiving', 'duloxetine', 'vs', '38', '%', 'of', 'those', 'initially', 'receiving', 'placebo', 'reported', 'decreased', 'pain', 'of', 'any', 'amount', '.']","(6, 7)","(47, 57)",-1,hl_i,23549581,Abstract,11,test,gold,5269.0
5328,Fifty-nine percent of those initially receiving duloxetine vs 38 % of those initially receiving placebo reported decreased,pain,of any amount .,"['Fifty-nine', 'percent', 'of', 'those', 'initially', 'receiving', 'duloxetine', 'vs', '38', '%', 'of', 'those', 'initially', 'receiving', 'placebo', 'reported', 'decreased', 'pain', 'of', 'any', 'amount', '.']","(17, 18)","(122, 126)",-1,hl_o,23549581,Abstract,11,test,gold,2293.0
5329,CONCLUSION AND RELEVANCE Among,patients with painful chemotherapy-induced peripheral neuropathy,", the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain .","['CONCLUSION', 'AND', 'RELEVANCE', 'Among', 'patients', 'with', 'painful', 'chemotherapy-induced', 'peripheral', 'neuropathy', ',', 'the', 'use', 'of', 'duloxetine', 'compared', 'with', 'placebo', 'for', '5', 'weeks', 'resulted', 'in', 'a', 'greater', 'reduction', 'in', 'pain', '.']","(4, 10)","(30, 94)",-1,ss_p,23549581,Abstract,12,test,gold,7014.0
5330,"CONCLUSION AND RELEVANCE Among patients with painful chemotherapy-induced peripheral neuropathy , the use of",duloxetine,compared with placebo for 5 weeks resulted in a greater reduction in pain .,"['CONCLUSION', 'AND', 'RELEVANCE', 'Among', 'patients', 'with', 'painful', 'chemotherapy-induced', 'peripheral', 'neuropathy', ',', 'the', 'use', 'of', 'duloxetine', 'compared', 'with', 'placebo', 'for', '5', 'weeks', 'resulted', 'in', 'a', 'greater', 'reduction', 'in', 'pain', '.']","(14, 15)","(108, 118)",-1,ss_i,23549581,Abstract,12,test,gold,5268.0
5331,"CONCLUSION AND RELEVANCE Among patients with painful chemotherapy-induced peripheral neuropathy , the use of duloxetine compared with",placebo,for 5 weeks resulted in a greater reduction in pain .,"['CONCLUSION', 'AND', 'RELEVANCE', 'Among', 'patients', 'with', 'painful', 'chemotherapy-induced', 'peripheral', 'neuropathy', ',', 'the', 'use', 'of', 'duloxetine', 'compared', 'with', 'placebo', 'for', '5', 'weeks', 'resulted', 'in', 'a', 'greater', 'reduction', 'in', 'pain', '.']","(17, 18)","(133, 140)",-1,ss_i,23549581,Abstract,12,test,gold,4340.0
5332,CONCLUSION AND RELEVANCE Among patients with painful,chemotherapy-induced peripheral neuropathy,", the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain .","['CONCLUSION', 'AND', 'RELEVANCE', 'Among', 'patients', 'with', 'painful', 'chemotherapy-induced', 'peripheral', 'neuropathy', ',', 'the', 'use', 'of', 'duloxetine', 'compared', 'with', 'placebo', 'for', '5', 'weeks', 'resulted', 'in', 'a', 'greater', 'reduction', 'in', 'pain', '.']","(7, 10)","(52, 94)",-1,ss_o,23549581,Abstract,12,test,gold,3116.0
5333,"CONCLUSION AND RELEVANCE Among patients with painful chemotherapy-induced peripheral neuropathy , the use of duloxetine compared with placebo for 5 weeks resulted in a greater",reduction in pain .,,"['CONCLUSION', 'AND', 'RELEVANCE', 'Among', 'patients', 'with', 'painful', 'chemotherapy-induced', 'peripheral', 'neuropathy', ',', 'the', 'use', 'of', 'duloxetine', 'compared', 'with', 'placebo', 'for', '5', 'weeks', 'resulted', 'in', 'a', 'greater', 'reduction', 'in', 'pain', '.']","(25, 29)","(175, 194)",-1,ss_o,23549581,Abstract,12,test,gold,2307.0
5334,CONCLUSION AND RELEVANCE Among,patients with painful chemotherapy-induced peripheral neuropathy,", the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain .","['CONCLUSION', 'AND', 'RELEVANCE', 'Among', 'patients', 'with', 'painful', 'chemotherapy-induced', 'peripheral', 'neuropathy', ',', 'the', 'use', 'of', 'duloxetine', 'compared', 'with', 'placebo', 'for', '5', 'weeks', 'resulted', 'in', 'a', 'greater', 'reduction', 'in', 'pain', '.']","(4, 10)","(30, 94)",-1,hl_p,23549581,Abstract,12,test,gold,7013.0
5335,"CONCLUSION AND RELEVANCE Among patients with painful chemotherapy-induced peripheral neuropathy , the use of",duloxetine,compared with placebo for 5 weeks resulted in a greater reduction in pain .,"['CONCLUSION', 'AND', 'RELEVANCE', 'Among', 'patients', 'with', 'painful', 'chemotherapy-induced', 'peripheral', 'neuropathy', ',', 'the', 'use', 'of', 'duloxetine', 'compared', 'with', 'placebo', 'for', '5', 'weeks', 'resulted', 'in', 'a', 'greater', 'reduction', 'in', 'pain', '.']","(14, 15)","(108, 118)",-1,hl_i,23549581,Abstract,12,test,gold,5267.0
5336,"CONCLUSION AND RELEVANCE Among patients with painful chemotherapy-induced peripheral neuropathy , the use of duloxetine compared with",placebo,for 5 weeks resulted in a greater reduction in pain .,"['CONCLUSION', 'AND', 'RELEVANCE', 'Among', 'patients', 'with', 'painful', 'chemotherapy-induced', 'peripheral', 'neuropathy', ',', 'the', 'use', 'of', 'duloxetine', 'compared', 'with', 'placebo', 'for', '5', 'weeks', 'resulted', 'in', 'a', 'greater', 'reduction', 'in', 'pain', '.']","(17, 18)","(133, 140)",-1,hl_i,23549581,Abstract,12,test,gold,4339.0
5337,"CONCLUSION AND RELEVANCE Among patients with painful chemotherapy-induced peripheral neuropathy , the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in",pain .,,"['CONCLUSION', 'AND', 'RELEVANCE', 'Among', 'patients', 'with', 'painful', 'chemotherapy-induced', 'peripheral', 'neuropathy', ',', 'the', 'use', 'of', 'duloxetine', 'compared', 'with', 'placebo', 'for', '5', 'weeks', 'resulted', 'in', 'a', 'greater', 'reduction', 'in', 'pain', '.']","(27, 29)","(188, 194)",-1,hl_o,23549581,Abstract,12,test,gold,2292.0
5338,TRIAL REGISTRATION clinicaltrials.gov Identifier : NCT00489411 .,,,"['TRIAL', 'REGISTRATION', 'clinicaltrials.gov', 'Identifier', ':', 'NCT00489411', '.']",,,,,23549581,Abstract,13,test,gold,
5339,Teacher and child predictors of achieving IEP goals of,children with autism .,,"['Teacher', 'and', 'child', 'predictors', 'of', 'achieving', 'IEP', 'goals', 'of', 'children', 'with', 'autism', '.']","(9, 13)","(54, 76)",-1,ss_p,23838728,Title,0,test,gold,6138.0
5340,Teacher and child predictors of achieving IEP goals of,children with autism .,,"['Teacher', 'and', 'child', 'predictors', 'of', 'achieving', 'IEP', 'goals', 'of', 'children', 'with', 'autism', '.']","(9, 13)","(54, 76)",-1,hl_p,23838728,Title,0,test,gold,6137.0
5341,It is encouraging that,children with autism,"show a strong response to early intervention , yet more research is needed for understanding the variability in responsiveness to specialized programs .","['It', 'is', 'encouraging', 'that', 'children', 'with', 'autism', 'show', 'a', 'strong', 'response', 'to', 'early', 'intervention', ',', 'yet', 'more', 'research', 'is', 'needed', 'for', 'understanding', 'the', 'variability', 'in', 'responsiveness', 'to', 'specialized', 'programs', '.']","(4, 7)","(22, 42)",-1,ss_p,23838728,Abstract,0,test,gold,6136.0
5342,It is encouraging that,children with autism,"show a strong response to early intervention , yet more research is needed for understanding the variability in responsiveness to specialized programs .","['It', 'is', 'encouraging', 'that', 'children', 'with', 'autism', 'show', 'a', 'strong', 'response', 'to', 'early', 'intervention', ',', 'yet', 'more', 'research', 'is', 'needed', 'for', 'understanding', 'the', 'variability', 'in', 'responsiveness', 'to', 'specialized', 'programs', '.']","(4, 7)","(22, 42)",-1,hl_p,23838728,Abstract,0,test,gold,6135.0
5343,Treatment predictor variables from,47 teachers and children,who were randomized to receive the COMPASS intervention ( Ruble et al .,"['Treatment', 'predictor', 'variables', 'from', '47', 'teachers', 'and', 'children', 'who', 'were', 'randomized', 'to', 'receive', 'the', 'COMPASS', 'intervention', '(', 'Ruble', 'et', 'al', '.']","(4, 8)","(34, 58)",-1,ss_p,23838728,Abstract,1,test,gold,2108.0
5344,Treatment predictor variables from 47 teachers and children who were randomized to receive the,COMPASS intervention,( Ruble et al .,"['Treatment', 'predictor', 'variables', 'from', '47', 'teachers', 'and', 'children', 'who', 'were', 'randomized', 'to', 'receive', 'the', 'COMPASS', 'intervention', '(', 'Ruble', 'et', 'al', '.']","(14, 16)","(94, 114)",-1,ss_i,23838728,Abstract,1,test,gold,4021.0
5345,,Treatment predictor variables,from 47 teachers and children who were randomized to receive the COMPASS intervention ( Ruble et al .,"['Treatment', 'predictor', 'variables', 'from', '47', 'teachers', 'and', 'children', 'who', 'were', 'randomized', 'to', 'receive', 'the', 'COMPASS', 'intervention', '(', 'Ruble', 'et', 'al', '.']","(0, 3)","(0, 29)",-1,ss_o,23838728,Abstract,1,test,gold,6395.0
5346,Treatment predictor variables from,47 teachers and children,who were randomized to receive the COMPASS intervention ( Ruble et al .,"['Treatment', 'predictor', 'variables', 'from', '47', 'teachers', 'and', 'children', 'who', 'were', 'randomized', 'to', 'receive', 'the', 'COMPASS', 'intervention', '(', 'Ruble', 'et', 'al', '.']","(4, 8)","(34, 58)",-1,hl_p,23838728,Abstract,1,test,gold,2109.0
5347,Treatment predictor variables from 47 teachers and children who were randomized to receive the,COMPASS intervention,( Ruble et al .,"['Treatment', 'predictor', 'variables', 'from', '47', 'teachers', 'and', 'children', 'who', 'were', 'randomized', 'to', 'receive', 'the', 'COMPASS', 'intervention', '(', 'Ruble', 'et', 'al', '.']","(14, 16)","(94, 114)",-1,hl_i,23838728,Abstract,1,test,gold,4022.0
5348,in,The collaborative model for promoting competence and success,for students with ASD .,"['in', 'The', 'collaborative', 'model', 'for', 'promoting', 'competence', 'and', 'success', 'for', 'students', 'with', 'ASD', '.']","(1, 9)","(2, 62)",-1,ss_i,23838728,Abstract,2,test,gold,6425.0
5349,"Springer , New York , 2012a ) were analyzed .",,,"['Springer', ',', 'New', 'York', ',', '2012a', ')', 'were', 'analyzed', '.']",,,,,23838728,Abstract,3,test,gold,
5350,,Predictors,"evaluated against child IEP goal attainment included child , teacher , intervention practice , and implementation practice variables based on an implementation science framework ( Dunst and Trivette in J Soc Sci 8:143-148 , 2012 ) .","['Predictors', 'evaluated', 'against', 'child', 'IEP', 'goal', 'attainment', 'included', 'child', ',', 'teacher', ',', 'intervention', 'practice', ',', 'and', 'implementation', 'practice', 'variables', 'based', 'on', 'an', 'implementation', 'science', 'framework', '(', 'Dunst', 'and', 'Trivette', 'in', 'J', 'Soc', 'Sci', '8:143-148', ',', '2012', ')', '.']","(0, 1)","(0, 10)",-1,ss_o,23838728,Abstract,4,test,gold,442.0
5351,Predictors evaluated against child IEP goal attainment included,"child , teacher , intervention practice , and implementation practice variables based on an implementation science framework","( Dunst and Trivette in J Soc Sci 8:143-148 , 2012 ) .","['Predictors', 'evaluated', 'against', 'child', 'IEP', 'goal', 'attainment', 'included', 'child', ',', 'teacher', ',', 'intervention', 'practice', ',', 'and', 'implementation', 'practice', 'variables', 'based', 'on', 'an', 'implementation', 'science', 'framework', '(', 'Dunst', 'and', 'Trivette', 'in', 'J', 'Soc', 'Sci', '8:143-148', ',', '2012', ')', '.']","(8, 25)","(63, 187)",-1,ss_o,23838728,Abstract,4,test,gold,6428.0
5352,"Findings revealed one child ( engagement ) , one teacher ( exhaustion ) , two",intervention quality ( IEP quality for targeted and not targeted elements ),", and no implementation quality variables accounted for variance in child outcomes when analyzed separately .","['Findings', 'revealed', 'one', 'child', '(', 'engagement', ')', ',', 'one', 'teacher', '(', 'exhaustion', ')', ',', 'two', 'intervention', 'quality', '(', 'IEP', 'quality', 'for', 'targeted', 'and', 'not', 'targeted', 'elements', ')', ',', 'and', 'no', 'implementation', 'quality', 'variables', 'accounted', 'for', 'variance', 'in', 'child', 'outcomes', 'when', 'analyzed', 'separately', '.']","(15, 27)","(77, 152)",-1,ss_o,23838728,Abstract,5,test,gold,6427.0
5353,"Findings revealed one child ( engagement ) , one teacher ( exhaustion ) , two intervention quality ( IEP quality for targeted and not targeted elements ) , and no",implementation quality variables,accounted for variance in child outcomes when analyzed separately .,"['Findings', 'revealed', 'one', 'child', '(', 'engagement', ')', ',', 'one', 'teacher', '(', 'exhaustion', ')', ',', 'two', 'intervention', 'quality', '(', 'IEP', 'quality', 'for', 'targeted', 'and', 'not', 'targeted', 'elements', ')', ',', 'and', 'no', 'implementation', 'quality', 'variables', 'accounted', 'for', 'variance', 'in', 'child', 'outcomes', 'when', 'analyzed', 'separately', '.']","(30, 33)","(162, 194)",-1,ss_o,23838728,Abstract,5,test,gold,1830.0
5354,"When the four significant variables were compared against each other in a single regression analysis , IEP quality accounted for one quarter of the variance in child outcomes .",,,"['When', 'the', 'four', 'significant', 'variables', 'were', 'compared', 'against', 'each', 'other', 'in', 'a', 'single', 'regression', 'analysis', ',', 'IEP', 'quality', 'accounted', 'for', 'one', 'quarter', 'of', 'the', 'variance', 'in', 'child', 'outcomes', '.']",,,,,23838728,Abstract,6,test,gold,
5355,Bayesian adaptive trials offer advantages in comparative effectiveness trials : an example in,status epilepticus .,,"['Bayesian', 'adaptive', 'trials', 'offer', 'advantages', 'in', 'comparative', 'effectiveness', 'trials', ':', 'an', 'example', 'in', 'status', 'epilepticus', '.']","(13, 16)","(93, 113)",-1,ss_p,23849147,Title,0,test,gold,1379.0
5356,,Bayesian adaptive trials,offer advantages in comparative effectiveness trials : an example in status epilepticus .,"['Bayesian', 'adaptive', 'trials', 'offer', 'advantages', 'in', 'comparative', 'effectiveness', 'trials', ':', 'an', 'example', 'in', 'status', 'epilepticus', '.']","(0, 3)","(0, 24)",-1,ss_i,23849147,Title,0,test,gold,6330.0
5357,Bayesian adaptive trials offer advantages in comparative,effectiveness,trials : an example in status epilepticus .,"['Bayesian', 'adaptive', 'trials', 'offer', 'advantages', 'in', 'comparative', 'effectiveness', 'trials', ':', 'an', 'example', 'in', 'status', 'epilepticus', '.']","(7, 8)","(56, 69)",-1,ss_o,23849147,Title,0,test,gold,395.0
5358,Bayesian adaptive trials offer advantages in comparative effectiveness trials : an example in,status epilepticus .,,"['Bayesian', 'adaptive', 'trials', 'offer', 'advantages', 'in', 'comparative', 'effectiveness', 'trials', ':', 'an', 'example', 'in', 'status', 'epilepticus', '.']","(13, 16)","(93, 113)",-1,hl_p,23849147,Title,0,test,gold,1380.0
5359,,Bayesian adaptive,trials offer advantages in comparative effectiveness trials : an example in status epilepticus .,"['Bayesian', 'adaptive', 'trials', 'offer', 'advantages', 'in', 'comparative', 'effectiveness', 'trials', ':', 'an', 'example', 'in', 'status', 'epilepticus', '.']","(0, 2)","(0, 17)",-1,hl_i,23849147,Title,0,test,gold,6331.0
5360,OBJECTIVE We present a novel Bayesian adaptive comparative effectiveness trial comparing three treatments for,status epilepticus,that uses adaptive randomization with potential early stopping .,"['OBJECTIVE', 'We', 'present', 'a', 'novel', 'Bayesian', 'adaptive', 'comparative', 'effectiveness', 'trial', 'comparing', 'three', 'treatments', 'for', 'status', 'epilepticus', 'that', 'uses', 'adaptive', 'randomization', 'with', 'potential', 'early', 'stopping', '.']","(14, 16)","(109, 127)",-1,ss_p,23849147,Abstract,0,test,gold,1378.0
5361,OBJECTIVE We present a novel,Bayesian adaptive comparative effectiveness trial,comparing three treatments for status epilepticus that uses adaptive randomization with potential early stopping .,"['OBJECTIVE', 'We', 'present', 'a', 'novel', 'Bayesian', 'adaptive', 'comparative', 'effectiveness', 'trial', 'comparing', 'three', 'treatments', 'for', 'status', 'epilepticus', 'that', 'uses', 'adaptive', 'randomization', 'with', 'potential', 'early', 'stopping', '.']","(5, 10)","(28, 77)",-1,ss_i,23849147,Abstract,0,test,gold,6335.0
5362,OBJECTIVE We present a novel Bayesian adaptive comparative,effectiveness,trial comparing three treatments for status epilepticus that uses adaptive randomization with potential early stopping .,"['OBJECTIVE', 'We', 'present', 'a', 'novel', 'Bayesian', 'adaptive', 'comparative', 'effectiveness', 'trial', 'comparing', 'three', 'treatments', 'for', 'status', 'epilepticus', 'that', 'uses', 'adaptive', 'randomization', 'with', 'potential', 'early', 'stopping', '.']","(8, 9)","(58, 71)",-1,ss_o,23849147,Abstract,0,test,gold,394.0
5363,OBJECTIVE We present a novel,Bayesian adaptive,comparative effectiveness trial comparing three treatments for status epilepticus that uses adaptive randomization with potential early stopping .,"['OBJECTIVE', 'We', 'present', 'a', 'novel', 'Bayesian', 'adaptive', 'comparative', 'effectiveness', 'trial', 'comparing', 'three', 'treatments', 'for', 'status', 'epilepticus', 'that', 'uses', 'adaptive', 'randomization', 'with', 'potential', 'early', 'stopping', '.']","(5, 7)","(28, 45)",-1,hl_i,23849147,Abstract,0,test,gold,6332.0
5364,STUDY DESIGN AND SETTING The trial will enroll,720 unique patients in emergency departments and uses a Bayesian adaptive design .,,"['STUDY', 'DESIGN', 'AND', 'SETTING', 'The', 'trial', 'will', 'enroll', '720', 'unique', 'patients', 'in', 'emergency', 'departments', 'and', 'uses', 'a', 'Bayesian', 'adaptive', 'design', '.']","(8, 21)","(46, 128)",-1,ss_p,23849147,Abstract,1,test,gold,6328.0
5365,STUDY DESIGN AND SETTING The trial will enroll 720 unique patients in emergency departments and uses a,Bayesian adaptive design .,,"['STUDY', 'DESIGN', 'AND', 'SETTING', 'The', 'trial', 'will', 'enroll', '720', 'unique', 'patients', 'in', 'emergency', 'departments', 'and', 'uses', 'a', 'Bayesian', 'adaptive', 'design', '.']","(17, 21)","(102, 128)",-1,ss_i,23849147,Abstract,1,test,gold,6333.0
5366,STUDY DESIGN AND SETTING The trial will enroll,720,unique patients in emergency departments and uses a Bayesian adaptive design .,"['STUDY', 'DESIGN', 'AND', 'SETTING', 'The', 'trial', 'will', 'enroll', '720', 'unique', 'patients', 'in', 'emergency', 'departments', 'and', 'uses', 'a', 'Bayesian', 'adaptive', 'design', '.']","(8, 9)","(46, 49)",-1,hl_p,23849147,Abstract,1,test,gold,
5367,STUDY DESIGN AND SETTING The trial will enroll 720 unique,patients in emergency departments and uses a Bayesian adaptive design,.,"['STUDY', 'DESIGN', 'AND', 'SETTING', 'The', 'trial', 'will', 'enroll', '720', 'unique', 'patients', 'in', 'emergency', 'departments', 'and', 'uses', 'a', 'Bayesian', 'adaptive', 'design', '.']","(10, 20)","(57, 126)",-1,hl_p,23849147,Abstract,1,test,gold,6329.0
5368,STUDY DESIGN AND SETTING The trial will enroll 720 unique patients in emergency departments and uses a,Bayesian adaptive design .,,"['STUDY', 'DESIGN', 'AND', 'SETTING', 'The', 'trial', 'will', 'enroll', '720', 'unique', 'patients', 'in', 'emergency', 'departments', 'and', 'uses', 'a', 'Bayesian', 'adaptive', 'design', '.']","(17, 21)","(102, 128)",-1,hl_i,23849147,Abstract,1,test,gold,6334.0
5369,RESULTS The trial design is compared to a,trial without adaptive randomization,and produces an efficient trial in which a higher proportion of patients are likely to be randomized to the most effective treatment arm while generally using fewer total patients and offers higher power than an analogous trial with fixed randomization when identifying a superior treatment .,"['RESULTS', 'The', 'trial', 'design', 'is', 'compared', 'to', 'a', 'trial', 'without', 'adaptive', 'randomization', 'and', 'produces', 'an', 'efficient', 'trial', 'in', 'which', 'a', 'higher', 'proportion', 'of', 'patients', 'are', 'likely', 'to', 'be', 'randomized', 'to', 'the', 'most', 'effective', 'treatment', 'arm', 'while', 'generally', 'using', 'fewer', 'total', 'patients', 'and', 'offers', 'higher', 'power', 'than', 'an', 'analogous', 'trial', 'with', 'fixed', 'randomization', 'when', 'identifying', 'a', 'superior', 'treatment', '.']","(8, 12)","(41, 77)",-1,ss_i,23849147,Abstract,2,test,gold,6336.0
5370,RESULTS The trial design is compared to a trial without adaptive randomization and produces an efficient trial in which a higher,proportion of patients,are likely to be randomized to the most effective treatment arm while generally using fewer total patients and offers higher power than an analogous trial with fixed randomization when identifying a superior treatment .,"['RESULTS', 'The', 'trial', 'design', 'is', 'compared', 'to', 'a', 'trial', 'without', 'adaptive', 'randomization', 'and', 'produces', 'an', 'efficient', 'trial', 'in', 'which', 'a', 'higher', 'proportion', 'of', 'patients', 'are', 'likely', 'to', 'be', 'randomized', 'to', 'the', 'most', 'effective', 'treatment', 'arm', 'while', 'generally', 'using', 'fewer', 'total', 'patients', 'and', 'offers', 'higher', 'power', 'than', 'an', 'analogous', 'trial', 'with', 'fixed', 'randomization', 'when', 'identifying', 'a', 'superior', 'treatment', '.']","(21, 24)","(128, 150)",-1,ss_o,23849147,Abstract,2,test,gold,3730.0
5371,RESULTS The trial design is compared to a trial without adaptive randomization and produces an efficient trial in which a higher proportion of patients are likely to be randomized to the most effective treatment arm while generally using fewer,total patients,and offers higher power than an analogous trial with fixed randomization when identifying a superior treatment .,"['RESULTS', 'The', 'trial', 'design', 'is', 'compared', 'to', 'a', 'trial', 'without', 'adaptive', 'randomization', 'and', 'produces', 'an', 'efficient', 'trial', 'in', 'which', 'a', 'higher', 'proportion', 'of', 'patients', 'are', 'likely', 'to', 'be', 'randomized', 'to', 'the', 'most', 'effective', 'treatment', 'arm', 'while', 'generally', 'using', 'fewer', 'total', 'patients', 'and', 'offers', 'higher', 'power', 'than', 'an', 'analogous', 'trial', 'with', 'fixed', 'randomization', 'when', 'identifying', 'a', 'superior', 'treatment', '.']","(39, 41)","(243, 257)",-1,ss_o,23849147,Abstract,2,test,gold,3731.0
5372,"CONCLUSION When one treatment is superior to the other two , the trial design provides better",patient care,", higher power , and a lower expected sample size .","['CONCLUSION', 'When', 'one', 'treatment', 'is', 'superior', 'to', 'the', 'other', 'two', ',', 'the', 'trial', 'design', 'provides', 'better', 'patient', 'care', ',', 'higher', 'power', ',', 'and', 'a', 'lower', 'expected', 'sample', 'size', '.']","(16, 18)","(93, 105)",-1,ss_o,23849147,Abstract,3,test,gold,3958.0
5373,"CONCLUSION When one treatment is superior to the other two , the trial design provides better patient care , higher",power,", and a lower expected sample size .","['CONCLUSION', 'When', 'one', 'treatment', 'is', 'superior', 'to', 'the', 'other', 'two', ',', 'the', 'trial', 'design', 'provides', 'better', 'patient', 'care', ',', 'higher', 'power', ',', 'and', 'a', 'lower', 'expected', 'sample', 'size', '.']","(20, 21)","(115, 120)",-1,ss_o,23849147,Abstract,3,test,gold,1202.0
5374,"CONCLUSION When one treatment is superior to the other two , the trial design provides better patient care , higher power , and a lower",expected sample size .,,"['CONCLUSION', 'When', 'one', 'treatment', 'is', 'superior', 'to', 'the', 'other', 'two', ',', 'the', 'trial', 'design', 'provides', 'better', 'patient', 'care', ',', 'higher', 'power', ',', 'and', 'a', 'lower', 'expected', 'sample', 'size', '.']","(25, 29)","(135, 157)",-1,ss_o,23849147,Abstract,3,test,gold,1851.0
5375,"CONCLUSION When one treatment is superior to the other two , the trial design provides better",patient care,", higher power , and a lower expected sample size .","['CONCLUSION', 'When', 'one', 'treatment', 'is', 'superior', 'to', 'the', 'other', 'two', ',', 'the', 'trial', 'design', 'provides', 'better', 'patient', 'care', ',', 'higher', 'power', ',', 'and', 'a', 'lower', 'expected', 'sample', 'size', '.']","(16, 18)","(93, 105)",-1,hl_o,23849147,Abstract,3,test,gold,3959.0
5376,"CONCLUSION When one treatment is superior to the other two , the trial design provides better patient care , higher",power,", and a lower expected sample size .","['CONCLUSION', 'When', 'one', 'treatment', 'is', 'superior', 'to', 'the', 'other', 'two', ',', 'the', 'trial', 'design', 'provides', 'better', 'patient', 'care', ',', 'higher', 'power', ',', 'and', 'a', 'lower', 'expected', 'sample', 'size', '.']","(20, 21)","(115, 120)",-1,hl_o,23849147,Abstract,3,test,gold,1203.0
5377,"CONCLUSION When one treatment is superior to the other two , the trial design provides better patient care , higher power , and a lower",expected sample size .,,"['CONCLUSION', 'When', 'one', 'treatment', 'is', 'superior', 'to', 'the', 'other', 'two', ',', 'the', 'trial', 'design', 'provides', 'better', 'patient', 'care', ',', 'higher', 'power', ',', 'and', 'a', 'lower', 'expected', 'sample', 'size', '.']","(25, 29)","(135, 157)",-1,hl_o,23849147,Abstract,3,test,gold,1852.0
5378,[ Impact of CCND1 A870G polymorphism on acute adverse events in,postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy ],.,"['[', 'Impact', 'of', 'CCND1', 'A870G', 'polymorphism', 'on', 'acute', 'adverse', 'events', 'in', 'postoperative', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', ']', '.']","(11, 21)","(63, 152)",-1,ss_p,23985254,Title,0,test,gold,5953.0
5379,[ Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent,chemoradiotherapy ],.,"['[', 'Impact', 'of', 'CCND1', 'A870G', 'polymorphism', 'on', 'acute', 'adverse', 'events', 'in', 'postoperative', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', ']', '.']","(19, 21)","(133, 152)",-1,ss_i,23985254,Title,0,test,gold,5797.0
5380,[ Impact of CCND1 A870G polymorphism on,acute adverse events,in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy ] .,"['[', 'Impact', 'of', 'CCND1', 'A870G', 'polymorphism', 'on', 'acute', 'adverse', 'events', 'in', 'postoperative', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', ']', '.']","(7, 10)","(39, 59)",-1,ss_o,23985254,Title,0,test,gold,3046.0
5381,[ Impact of CCND1 A870G polymorphism on acute adverse events in,postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy ],.,"['[', 'Impact', 'of', 'CCND1', 'A870G', 'polymorphism', 'on', 'acute', 'adverse', 'events', 'in', 'postoperative', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', ']', '.']","(11, 21)","(63, 152)",-1,hl_p,23985254,Title,0,test,gold,5954.0
5382,[ Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent,chemoradiotherapy,] .,"['[', 'Impact', 'of', 'CCND1', 'A870G', 'polymorphism', 'on', 'acute', 'adverse', 'events', 'in', 'postoperative', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', ']', '.']","(19, 20)","(133, 150)",-1,hl_i,23985254,Title,0,test,gold,5798.0
5383,[ Impact of CCND1 A870G polymorphism on,acute adverse events,in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy ] .,"['[', 'Impact', 'of', 'CCND1', 'A870G', 'polymorphism', 'on', 'acute', 'adverse', 'events', 'in', 'postoperative', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', ']', '.']","(7, 10)","(39, 59)",-1,hl_o,23985254,Title,0,test,gold,3047.0
5384,OBJECTIVE The purpose of this study was to investigate the association between single nucleotide polymorphism ( SNP ) of CCND1 A870G and acute adverse events ( AEs ) in,postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy ( CRT ) .,,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'association', 'between', 'single', 'nucleotide', 'polymorphism', '(', 'SNP', ')', 'of', 'CCND1', 'A870G', 'and', 'acute', 'adverse', 'events', '(', 'AEs', ')', 'in', 'postoperative', 'rectal', 'cancer', 'patients', 'who', 'received', 'capecitabine-based', 'postoperative', 'chemoradiotherapy', '(', 'CRT', ')', '.']","(29, 42)","(168, 278)",-1,ss_p,23985254,Abstract,0,test,gold,5951.0
5385,OBJECTIVE The purpose of this study was to investigate the association between single nucleotide polymorphism ( SNP ) of CCND1 A870G and acute adverse events ( AEs ) in postoperative rectal cancer patients who received,capecitabine-based,postoperative chemoradiotherapy ( CRT ) .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'association', 'between', 'single', 'nucleotide', 'polymorphism', '(', 'SNP', ')', 'of', 'CCND1', 'A870G', 'and', 'acute', 'adverse', 'events', '(', 'AEs', ')', 'in', 'postoperative', 'rectal', 'cancer', 'patients', 'who', 'received', 'capecitabine-based', 'postoperative', 'chemoradiotherapy', '(', 'CRT', ')', '.']","(35, 36)","(218, 236)",-1,ss_i,23985254,Abstract,0,test,gold,
5386,OBJECTIVE The purpose of this study was to investigate the association between single nucleotide polymorphism ( SNP ) of CCND1 A870G and acute adverse events ( AEs ) in postoperative rectal cancer patients who received capecitabine-based postoperative,chemoradiotherapy ( CRT ),.,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'association', 'between', 'single', 'nucleotide', 'polymorphism', '(', 'SNP', ')', 'of', 'CCND1', 'A870G', 'and', 'acute', 'adverse', 'events', '(', 'AEs', ')', 'in', 'postoperative', 'rectal', 'cancer', 'patients', 'who', 'received', 'capecitabine-based', 'postoperative', 'chemoradiotherapy', '(', 'CRT', ')', '.']","(37, 41)","(251, 276)",-1,ss_i,23985254,Abstract,0,test,gold,5799.0
5387,OBJECTIVE The purpose of this study was to investigate the,association,between single nucleotide polymorphism ( SNP ) of CCND1 A870G and acute adverse events ( AEs ) in postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy ( CRT ) .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'association', 'between', 'single', 'nucleotide', 'polymorphism', '(', 'SNP', ')', 'of', 'CCND1', 'A870G', 'and', 'acute', 'adverse', 'events', '(', 'AEs', ')', 'in', 'postoperative', 'rectal', 'cancer', 'patients', 'who', 'received', 'capecitabine-based', 'postoperative', 'chemoradiotherapy', '(', 'CRT', ')', '.']","(10, 11)","(58, 69)",-1,ss_o,23985254,Abstract,0,test,gold,1079.0
5388,OBJECTIVE The purpose of this study was to investigate the association between,single nucleotide polymorphism ( SNP ) of CCND1 A870G and acute adverse events ( AEs ),in postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy ( CRT ) .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'association', 'between', 'single', 'nucleotide', 'polymorphism', '(', 'SNP', ')', 'of', 'CCND1', 'A870G', 'and', 'acute', 'adverse', 'events', '(', 'AEs', ')', 'in', 'postoperative', 'rectal', 'cancer', 'patients', 'who', 'received', 'capecitabine-based', 'postoperative', 'chemoradiotherapy', '(', 'CRT', ')', '.']","(12, 28)","(78, 164)",-1,ss_o,23985254,Abstract,0,test,gold,7093.0
5389,OBJECTIVE The purpose of this study was to investigate the association between single nucleotide polymorphism ( SNP ) of CCND1 A870G and acute adverse events ( AEs ) in,postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy ( CRT ) .,,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'association', 'between', 'single', 'nucleotide', 'polymorphism', '(', 'SNP', ')', 'of', 'CCND1', 'A870G', 'and', 'acute', 'adverse', 'events', '(', 'AEs', ')', 'in', 'postoperative', 'rectal', 'cancer', 'patients', 'who', 'received', 'capecitabine-based', 'postoperative', 'chemoradiotherapy', '(', 'CRT', ')', '.']","(29, 42)","(168, 278)",-1,hl_p,23985254,Abstract,0,test,gold,5952.0
5390,OBJECTIVE The purpose of this study was to investigate the association between single nucleotide polymorphism ( SNP ) of CCND1 A870G and acute adverse events ( AEs ) in postoperative rectal cancer patients who received,capecitabine-based,postoperative chemoradiotherapy ( CRT ) .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'association', 'between', 'single', 'nucleotide', 'polymorphism', '(', 'SNP', ')', 'of', 'CCND1', 'A870G', 'and', 'acute', 'adverse', 'events', '(', 'AEs', ')', 'in', 'postoperative', 'rectal', 'cancer', 'patients', 'who', 'received', 'capecitabine-based', 'postoperative', 'chemoradiotherapy', '(', 'CRT', ')', '.']","(35, 36)","(218, 236)",-1,hl_i,23985254,Abstract,0,test,gold,
5391,OBJECTIVE The purpose of this study was to investigate the association between single nucleotide polymorphism ( SNP ) of CCND1 A870G and acute adverse events ( AEs ) in postoperative rectal cancer patients who received capecitabine-based postoperative,chemoradiotherapy ( CRT ),.,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'association', 'between', 'single', 'nucleotide', 'polymorphism', '(', 'SNP', ')', 'of', 'CCND1', 'A870G', 'and', 'acute', 'adverse', 'events', '(', 'AEs', ')', 'in', 'postoperative', 'rectal', 'cancer', 'patients', 'who', 'received', 'capecitabine-based', 'postoperative', 'chemoradiotherapy', '(', 'CRT', ')', '.']","(37, 41)","(251, 276)",-1,hl_i,23985254,Abstract,0,test,gold,5800.0
5392,OBJECTIVE The purpose of this study was to investigate the association between single nucleotide polymorphism ( SNP ) of CCND1 A870G and,acute adverse events ( AEs ),in postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy ( CRT ) .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'association', 'between', 'single', 'nucleotide', 'polymorphism', '(', 'SNP', ')', 'of', 'CCND1', 'A870G', 'and', 'acute', 'adverse', 'events', '(', 'AEs', ')', 'in', 'postoperative', 'rectal', 'cancer', 'patients', 'who', 'received', 'capecitabine-based', 'postoperative', 'chemoradiotherapy', '(', 'CRT', ')', '.']","(22, 28)","(136, 164)",-1,hl_o,23985254,Abstract,0,test,gold,3092.0
5393,METHODS,Four hundred patients with stage II and III rectal cancer received postoperative CRT,of capecitabine with or without oxaliplatin were accumulated and prostectively studied in this study .,"['METHODS', 'Four', 'hundred', 'patients', 'with', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'received', 'postoperative', 'CRT', 'of', 'capecitabine', 'with', 'or', 'without', 'oxaliplatin', 'were', 'accumulated', 'and', 'prostectively', 'studied', 'in', 'this', 'study', '.']","(1, 14)","(7, 91)",-1,ss_p,23985254,Abstract,1,test,gold,5949.0
5394,METHODS Four hundred patients with stage II and III rectal cancer received postoperative CRT of,capecitabine,with or without oxaliplatin were accumulated and prostectively studied in this study .,"['METHODS', 'Four', 'hundred', 'patients', 'with', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'received', 'postoperative', 'CRT', 'of', 'capecitabine', 'with', 'or', 'without', 'oxaliplatin', 'were', 'accumulated', 'and', 'prostectively', 'studied', 'in', 'this', 'study', '.']","(15, 16)","(95, 107)",-1,ss_i,23985254,Abstract,1,test,gold,5182.0
5395,METHODS Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine with or without,oxaliplatin,were accumulated and prostectively studied in this study .,"['METHODS', 'Four', 'hundred', 'patients', 'with', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'received', 'postoperative', 'CRT', 'of', 'capecitabine', 'with', 'or', 'without', 'oxaliplatin', 'were', 'accumulated', 'and', 'prostectively', 'studied', 'in', 'this', 'study', '.']","(19, 20)","(124, 135)",-1,ss_i,23985254,Abstract,1,test,gold,5732.0
5396,METHODS,Four hundred patients with stage II and III rectal cancer received postoperative CRT,of capecitabine with or without oxaliplatin were accumulated and prostectively studied in this study .,"['METHODS', 'Four', 'hundred', 'patients', 'with', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'received', 'postoperative', 'CRT', 'of', 'capecitabine', 'with', 'or', 'without', 'oxaliplatin', 'were', 'accumulated', 'and', 'prostectively', 'studied', 'in', 'this', 'study', '.']","(1, 14)","(7, 91)",-1,hl_p,23985254,Abstract,1,test,gold,5950.0
5397,METHODS Four hundred patients with stage II and III rectal cancer received postoperative CRT of,capecitabine,with or without oxaliplatin were accumulated and prostectively studied in this study .,"['METHODS', 'Four', 'hundred', 'patients', 'with', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'received', 'postoperative', 'CRT', 'of', 'capecitabine', 'with', 'or', 'without', 'oxaliplatin', 'were', 'accumulated', 'and', 'prostectively', 'studied', 'in', 'this', 'study', '.']","(15, 16)","(95, 107)",-1,hl_i,23985254,Abstract,1,test,gold,5183.0
5398,METHODS Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine with or without,oxaliplatin,were accumulated and prostectively studied in this study .,"['METHODS', 'Four', 'hundred', 'patients', 'with', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'received', 'postoperative', 'CRT', 'of', 'capecitabine', 'with', 'or', 'without', 'oxaliplatin', 'were', 'accumulated', 'and', 'prostectively', 'studied', 'in', 'this', 'study', '.']","(19, 20)","(124, 135)",-1,hl_i,23985254,Abstract,1,test,gold,5730.0
5399,The patients were randomly divided into two groups .,,,"['The', 'patients', 'were', 'randomly', 'divided', 'into', 'two', 'groups', '.']",,,,,23985254,Abstract,2,test,gold,
5400,Two hundred and twenty-eight patients were treated with concurrent,capecitabine and radiotherapy ( Cap-CRT ),", and 172 patients were treated with capecitabine and oxaliplatin plus radiotherapy ( Cap-Oxa-CRT ) .","['Two', 'hundred', 'and', 'twenty-eight', 'patients', 'were', 'treated', 'with', 'concurrent', 'capecitabine', 'and', 'radiotherapy', '(', 'Cap-CRT', ')', ',', 'and', '172', 'patients', 'were', 'treated', 'with', 'capecitabine', 'and', 'oxaliplatin', 'plus', 'radiotherapy', '(', 'Cap-Oxa-CRT', ')', '.']","(9, 15)","(66, 107)",-1,ss_i,23985254,Abstract,3,test,gold,5184.0
5401,"Two hundred and twenty-eight patients were treated with concurrent capecitabine and radiotherapy ( Cap-CRT ) , and 172 patients were treated with",capecitabine and oxaliplatin plus radiotherapy ( Cap-Oxa-CRT ) .,,"['Two', 'hundred', 'and', 'twenty-eight', 'patients', 'were', 'treated', 'with', 'concurrent', 'capecitabine', 'and', 'radiotherapy', '(', 'Cap-CRT', ')', ',', 'and', '172', 'patients', 'were', 'treated', 'with', 'capecitabine', 'and', 'oxaliplatin', 'plus', 'radiotherapy', '(', 'Cap-Oxa-CRT', ')', '.']","(22, 31)","(145, 209)",-1,ss_i,23985254,Abstract,3,test,gold,5185.0
5402,Two hundred and twenty-eight patients were treated with concurrent,capecitabine,"and radiotherapy ( Cap-CRT ) , and 172 patients were treated with capecitabine and oxaliplatin plus radiotherapy ( Cap-Oxa-CRT ) .","['Two', 'hundred', 'and', 'twenty-eight', 'patients', 'were', 'treated', 'with', 'concurrent', 'capecitabine', 'and', 'radiotherapy', '(', 'Cap-CRT', ')', ',', 'and', '172', 'patients', 'were', 'treated', 'with', 'capecitabine', 'and', 'oxaliplatin', 'plus', 'radiotherapy', '(', 'Cap-Oxa-CRT', ')', '.']","(9, 10)","(66, 78)",-1,hl_i,23985254,Abstract,3,test,gold,5181.0
5403,Two hundred and twenty-eight patients were treated with concurrent capecitabine and,radiotherapy,"( Cap-CRT ) , and 172 patients were treated with capecitabine and oxaliplatin plus radiotherapy ( Cap-Oxa-CRT ) .","['Two', 'hundred', 'and', 'twenty-eight', 'patients', 'were', 'treated', 'with', 'concurrent', 'capecitabine', 'and', 'radiotherapy', '(', 'Cap-CRT', ')', ',', 'and', '172', 'patients', 'were', 'treated', 'with', 'capecitabine', 'and', 'oxaliplatin', 'plus', 'radiotherapy', '(', 'Cap-Oxa-CRT', ')', '.']","(11, 12)","(83, 95)",-1,hl_i,23985254,Abstract,3,test,gold,4255.0
5404,Two hundred and twenty-eight patients were treated with concurrent capecitabine and radiotherapy (,Cap-CRT,") , and 172 patients were treated with capecitabine and oxaliplatin plus radiotherapy ( Cap-Oxa-CRT ) .","['Two', 'hundred', 'and', 'twenty-eight', 'patients', 'were', 'treated', 'with', 'concurrent', 'capecitabine', 'and', 'radiotherapy', '(', 'Cap-CRT', ')', ',', 'and', '172', 'patients', 'were', 'treated', 'with', 'capecitabine', 'and', 'oxaliplatin', 'plus', 'radiotherapy', '(', 'Cap-Oxa-CRT', ')', '.']","(13, 14)","(98, 105)",-1,hl_i,23985254,Abstract,3,test,gold,
5405,"Two hundred and twenty-eight patients were treated with concurrent capecitabine and radiotherapy ( Cap-CRT ) , and 172 patients were treated with",capecitabine,and oxaliplatin plus radiotherapy ( Cap-Oxa-CRT ) .,"['Two', 'hundred', 'and', 'twenty-eight', 'patients', 'were', 'treated', 'with', 'concurrent', 'capecitabine', 'and', 'radiotherapy', '(', 'Cap-CRT', ')', ',', 'and', '172', 'patients', 'were', 'treated', 'with', 'capecitabine', 'and', 'oxaliplatin', 'plus', 'radiotherapy', '(', 'Cap-Oxa-CRT', ')', '.']","(22, 23)","(145, 157)",-1,hl_i,23985254,Abstract,3,test,gold,5180.0
5406,"Two hundred and twenty-eight patients were treated with concurrent capecitabine and radiotherapy ( Cap-CRT ) , and 172 patients were treated with capecitabine and",oxaliplatin,plus radiotherapy ( Cap-Oxa-CRT ) .,"['Two', 'hundred', 'and', 'twenty-eight', 'patients', 'were', 'treated', 'with', 'concurrent', 'capecitabine', 'and', 'radiotherapy', '(', 'Cap-CRT', ')', ',', 'and', '172', 'patients', 'were', 'treated', 'with', 'capecitabine', 'and', 'oxaliplatin', 'plus', 'radiotherapy', '(', 'Cap-Oxa-CRT', ')', '.']","(24, 25)","(162, 173)",-1,hl_i,23985254,Abstract,3,test,gold,5729.0
5407,"Two hundred and twenty-eight patients were treated with concurrent capecitabine and radiotherapy ( Cap-CRT ) , and 172 patients were treated with capecitabine and oxaliplatin plus",radiotherapy,( Cap-Oxa-CRT ) .,"['Two', 'hundred', 'and', 'twenty-eight', 'patients', 'were', 'treated', 'with', 'concurrent', 'capecitabine', 'and', 'radiotherapy', '(', 'Cap-CRT', ')', ',', 'and', '172', 'patients', 'were', 'treated', 'with', 'capecitabine', 'and', 'oxaliplatin', 'plus', 'radiotherapy', '(', 'Cap-Oxa-CRT', ')', '.']","(26, 27)","(179, 191)",-1,hl_i,23985254,Abstract,3,test,gold,4254.0
5408,"Two hundred and twenty-eight patients were treated with concurrent capecitabine and radiotherapy ( Cap-CRT ) , and 172 patients were treated with capecitabine and oxaliplatin plus radiotherapy (",Cap-Oxa-CRT,) .,"['Two', 'hundred', 'and', 'twenty-eight', 'patients', 'were', 'treated', 'with', 'concurrent', 'capecitabine', 'and', 'radiotherapy', '(', 'Cap-CRT', ')', ',', 'and', '172', 'patients', 'were', 'treated', 'with', 'capecitabine', 'and', 'oxaliplatin', 'plus', 'radiotherapy', '(', 'Cap-Oxa-CRT', ')', '.']","(28, 29)","(194, 205)",-1,hl_i,23985254,Abstract,3,test,gold,
5409,,"Adverse events were graded according to the Common Terminology Criteria for Adverse Events , v. 3.0 ( CTCAE v3.0 ) .",,"['Adverse', 'events', 'were', 'graded', 'according', 'to', 'the', 'Common', 'Terminology', 'Criteria', 'for', 'Adverse', 'Events', ',', 'v.', '3.0', '(', 'CTCAE', 'v3.0', ')', '.']","(0, 21)","(0, 116)",-1,ss_o,23985254,Abstract,4,test,gold,6280.0
5410,,Adverse events,"were graded according to the Common Terminology Criteria for Adverse Events , v. 3.0 ( CTCAE v3.0 ) .","['Adverse', 'events', 'were', 'graded', 'according', 'to', 'the', 'Common', 'Terminology', 'Criteria', 'for', 'Adverse', 'Events', ',', 'v.', '3.0', '(', 'CTCAE', 'v3.0', ')', '.']","(0, 2)","(0, 14)",-1,hl_o,23985254,Abstract,4,test,gold,3042.0
5411,Adverse events were graded according to the,"Common Terminology Criteria for Adverse Events , v.",3.0 ( CTCAE v3.0 ) .,"['Adverse', 'events', 'were', 'graded', 'according', 'to', 'the', 'Common', 'Terminology', 'Criteria', 'for', 'Adverse', 'Events', ',', 'v.', '3.0', '(', 'CTCAE', 'v3.0', ')', '.']","(7, 15)","(43, 94)",-1,hl_o,23985254,Abstract,4,test,gold,6281.0
5412,The,genotype of CCND1 A870G,in the patients was detected by polymerase chain reaction-based restriction fragment length polymorphism ( PCR-RFLP ) analysis .,"['The', 'genotype', 'of', 'CCND1', 'A870G', 'in', 'the', 'patients', 'was', 'detected', 'by', 'polymerase', 'chain', 'reaction-based', 'restriction', 'fragment', 'length', 'polymorphism', '(', 'PCR-RFLP', ')', 'analysis', '.']","(1, 5)","(3, 26)",-1,ss_o,23985254,Abstract,5,test,gold,4574.0
5413,The genotype of CCND1 A870G in the patients was detected by,polymerase chain reaction-based restriction fragment length polymorphism ( PCR-RFLP ) analysis .,,"['The', 'genotype', 'of', 'CCND1', 'A870G', 'in', 'the', 'patients', 'was', 'detected', 'by', 'polymerase', 'chain', 'reaction-based', 'restriction', 'fragment', 'length', 'polymorphism', '(', 'PCR-RFLP', ')', 'analysis', '.']","(11, 23)","(59, 155)",-1,ss_o,23985254,Abstract,5,test,gold,6648.0
5414,The,associations between the SNP and acute AEs,"were indicated by odds ratios ( ORs ) and 95 % confidence intervals ( CIs ) , which were computed with logistic regression model .","['The', 'associations', 'between', 'the', 'SNP', 'and', 'acute', 'AEs', 'were', 'indicated', 'by', 'odds', 'ratios', '(', 'ORs', ')', 'and', '95', '%', 'confidence', 'intervals', '(', 'CIs', ')', ',', 'which', 'were', 'computed', 'with', 'logistic', 'regression', 'model', '.']","(1, 8)","(3, 45)",-1,ss_o,23985254,Abstract,6,test,gold,3089.0
5415,The associations between the SNP and acute AEs were indicated by,odds ratios ( ORs ),"and 95 % confidence intervals ( CIs ) , which were computed with logistic regression model .","['The', 'associations', 'between', 'the', 'SNP', 'and', 'acute', 'AEs', 'were', 'indicated', 'by', 'odds', 'ratios', '(', 'ORs', ')', 'and', '95', '%', 'confidence', 'intervals', '(', 'CIs', ')', ',', 'which', 'were', 'computed', 'with', 'logistic', 'regression', 'model', '.']","(11, 16)","(64, 83)",-1,ss_o,23985254,Abstract,6,test,gold,1488.0
5416,The associations between the SNP and acute AEs were indicated by odds ratios ( ORs ) and 95 %,confidence intervals ( CIs ),", which were computed with logistic regression model .","['The', 'associations', 'between', 'the', 'SNP', 'and', 'acute', 'AEs', 'were', 'indicated', 'by', 'odds', 'ratios', '(', 'ORs', ')', 'and', '95', '%', 'confidence', 'intervals', '(', 'CIs', ')', ',', 'which', 'were', 'computed', 'with', 'logistic', 'regression', 'model', '.']","(19, 24)","(93, 121)",-1,ss_o,23985254,Abstract,6,test,gold,3215.0
5417,"The associations between the SNP and acute AEs were indicated by odds ratios ( ORs ) and 95 % confidence intervals ( CIs ) , which were computed with",logistic regression model .,,"['The', 'associations', 'between', 'the', 'SNP', 'and', 'acute', 'AEs', 'were', 'indicated', 'by', 'odds', 'ratios', '(', 'ORs', ')', 'and', '95', '%', 'confidence', 'intervals', '(', 'CIs', ')', ',', 'which', 'were', 'computed', 'with', 'logistic', 'regression', 'model', '.']","(29, 33)","(149, 176)",-1,ss_o,23985254,Abstract,6,test,gold,953.0
5418,The associations between the SNP and,acute AEs,"were indicated by odds ratios ( ORs ) and 95 % confidence intervals ( CIs ) , which were computed with logistic regression model .","['The', 'associations', 'between', 'the', 'SNP', 'and', 'acute', 'AEs', 'were', 'indicated', 'by', 'odds', 'ratios', '(', 'ORs', ')', 'and', '95', '%', 'confidence', 'intervals', '(', 'CIs', ')', ',', 'which', 'were', 'computed', 'with', 'logistic', 'regression', 'model', '.']","(6, 8)","(36, 45)",-1,hl_o,23985254,Abstract,6,test,gold,3085.0
5419,RESULTS A total of 136 patients presented severe,AEs .,,"['RESULTS', 'A', 'total', 'of', '136', 'patients', 'presented', 'severe', 'AEs', '.']","(8, 10)","(48, 53)",-1,ss_o,23985254,Abstract,7,test,gold,3077.0
5420,RESULTS A total of 136 patients presented severe,AEs .,,"['RESULTS', 'A', 'total', 'of', '136', 'patients', 'presented', 'severe', 'AEs', '.']","(8, 10)","(48, 53)",-1,hl_o,23985254,Abstract,7,test,gold,3076.0
5421,Among them the frequencies of the three,genotypes,"GG , GA and AA were 16.9 % , 50.7 % and 32.4 % , compared with 24.6 % , 48.1 % and 27.3 % , respectively , among the patients without severe AEs .","['Among', 'them', 'the', 'frequencies', 'of', 'the', 'three', 'genotypes', 'GG', ',', 'GA', 'and', 'AA', 'were', '16.9', '%', ',', '50.7', '%', 'and', '32.4', '%', ',', 'compared', 'with', '24.6', '%', ',', '48.1', '%', 'and', '27.3', '%', ',', 'respectively', ',', 'among', 'the', 'patients', 'without', 'severe', 'AEs', '.']","(7, 8)","(39, 48)",-1,ss_o,23985254,Abstract,8,test,gold,4575.0
5422,"Among them the frequencies of the three genotypes GG , GA and AA were 16.9 % , 50.7 % and 32.4 % , compared with 24.6 % , 48.1 % and 27.3 % , respectively , among the patients without severe",AEs .,,"['Among', 'them', 'the', 'frequencies', 'of', 'the', 'three', 'genotypes', 'GG', ',', 'GA', 'and', 'AA', 'were', '16.9', '%', ',', '50.7', '%', 'and', '32.4', '%', ',', 'compared', 'with', '24.6', '%', ',', '48.1', '%', 'and', '27.3', '%', ',', 'respectively', ',', 'among', 'the', 'patients', 'without', 'severe', 'AEs', '.']","(41, 43)","(190, 195)",-1,ss_o,23985254,Abstract,8,test,gold,3075.0
5423,"Among them the frequencies of the three genotypes GG , GA and AA were 16.9 % , 50.7 % and 32.4 % , compared with 24.6 % , 48.1 % and 27.3 % , respectively , among the patients without severe",AEs .,,"['Among', 'them', 'the', 'frequencies', 'of', 'the', 'three', 'genotypes', 'GG', ',', 'GA', 'and', 'AA', 'were', '16.9', '%', ',', '50.7', '%', 'and', '32.4', '%', ',', 'compared', 'with', '24.6', '%', ',', '48.1', '%', 'and', '27.3', '%', ',', 'respectively', ',', 'among', 'the', 'patients', 'without', 'severe', 'AEs', '.']","(41, 43)","(190, 195)",-1,hl_o,23985254,Abstract,8,test,gold,3074.0
5424,,Diarrhea,"was the most common AE , and severe diarrhea occurred in 109 patients .","['Diarrhea', 'was', 'the', 'most', 'common', 'AE', ',', 'and', 'severe', 'diarrhea', 'occurred', 'in', '109', 'patients', '.']","(0, 1)","(0, 8)",-1,ss_o,23985254,Abstract,9,test,gold,2686.0
5425,Diarrhea was the most common,AE,", and severe diarrhea occurred in 109 patients .","['Diarrhea', 'was', 'the', 'most', 'common', 'AE', ',', 'and', 'severe', 'diarrhea', 'occurred', 'in', '109', 'patients', '.']","(5, 6)","(28, 30)",-1,ss_o,23985254,Abstract,9,test,gold,700.0
5426,"Diarrhea was the most common AE , and",severe diarrhea,occurred in 109 patients .,"['Diarrhea', 'was', 'the', 'most', 'common', 'AE', ',', 'and', 'severe', 'diarrhea', 'occurred', 'in', '109', 'patients', '.']","(8, 10)","(37, 52)",-1,ss_o,23985254,Abstract,9,test,gold,3595.0
5427,,Diarrhea,"was the most common AE , and severe diarrhea occurred in 109 patients .","['Diarrhea', 'was', 'the', 'most', 'common', 'AE', ',', 'and', 'severe', 'diarrhea', 'occurred', 'in', '109', 'patients', '.']","(0, 1)","(0, 8)",-1,hl_o,23985254,Abstract,9,test,gold,2687.0
5428,Diarrhea was the most common,AE,", and severe diarrhea occurred in 109 patients .","['Diarrhea', 'was', 'the', 'most', 'common', 'AE', ',', 'and', 'severe', 'diarrhea', 'occurred', 'in', '109', 'patients', '.']","(5, 6)","(28, 30)",-1,hl_o,23985254,Abstract,9,test,gold,701.0
5429,"Diarrhea was the most common AE , and",severe diarrhea,occurred in 109 patients .,"['Diarrhea', 'was', 'the', 'most', 'common', 'AE', ',', 'and', 'severe', 'diarrhea', 'occurred', 'in', '109', 'patients', '.']","(8, 10)","(37, 52)",-1,hl_o,23985254,Abstract,9,test,gold,3596.0
5430,The frequencies of the three,genotypes,"GG , GA and AA were 15.6 % , 47.7 % and 36.7 % among these patients , compared with 24.4 % , 49.5 % and 26.1 % , respectively , among patients without severe diarrhea .","['The', 'frequencies', 'of', 'the', 'three', 'genotypes', 'GG', ',', 'GA', 'and', 'AA', 'were', '15.6', '%', ',', '47.7', '%', 'and', '36.7', '%', 'among', 'these', 'patients', ',', 'compared', 'with', '24.4', '%', ',', '49.5', '%', 'and', '26.1', '%', ',', 'respectively', ',', 'among', 'patients', 'without', 'severe', 'diarrhea', '.']","(5, 6)","(28, 37)",-1,ss_o,23985254,Abstract,10,test,gold,4576.0
5431,"The frequencies of the three genotypes GG , GA and AA were 15.6 % , 47.7 % and 36.7 % among these patients , compared with 24.4 % , 49.5 % and 26.1 % , respectively , among patients without",severe diarrhea .,,"['The', 'frequencies', 'of', 'the', 'three', 'genotypes', 'GG', ',', 'GA', 'and', 'AA', 'were', '15.6', '%', ',', '47.7', '%', 'and', '36.7', '%', 'among', 'these', 'patients', ',', 'compared', 'with', '24.4', '%', ',', '49.5', '%', 'and', '26.1', '%', ',', 'respectively', ',', 'among', 'patients', 'without', 'severe', 'diarrhea', '.']","(40, 43)","(189, 206)",-1,ss_o,23985254,Abstract,10,test,gold,3594.0
5432,"The frequencies of the three genotypes GG , GA and AA were 15.6 % , 47.7 % and 36.7 % among these patients , compared with 24.4 % , 49.5 % and 26.1 % , respectively , among patients without",severe diarrhea .,,"['The', 'frequencies', 'of', 'the', 'three', 'genotypes', 'GG', ',', 'GA', 'and', 'AA', 'were', '15.6', '%', ',', '47.7', '%', 'and', '36.7', '%', 'among', 'these', 'patients', ',', 'compared', 'with', '24.4', '%', ',', '49.5', '%', 'and', '26.1', '%', ',', 'respectively', ',', 'among', 'patients', 'without', 'severe', 'diarrhea', '.']","(40, 43)","(189, 206)",-1,hl_o,23985254,Abstract,10,test,gold,3593.0
5433,Multivariate logistic regression analysis showed a 1.66-fold increased risk for,severe diarrhea,"in patients with AA genotype ( 95 % CI 1.03 - 2.67 , P = 0.038 ) compared with the cases with GG or GA genotypes .","['Multivariate', 'logistic', 'regression', 'analysis', 'showed', 'a', '1.66-fold', 'increased', 'risk', 'for', 'severe', 'diarrhea', 'in', 'patients', 'with', 'AA', 'genotype', '(', '95', '%', 'CI', '1.03', '-', '2.67', ',', 'P', '=', '0.038', ')', 'compared', 'with', 'the', 'cases', 'with', 'GG', 'or', 'GA', 'genotypes', '.']","(10, 12)","(79, 94)",-1,ss_o,23985254,Abstract,11,test,gold,3592.0
5434,Multivariate logistic regression analysis showed a 1.66-fold increased risk for,severe diarrhea,"in patients with AA genotype ( 95 % CI 1.03 - 2.67 , P = 0.038 ) compared with the cases with GG or GA genotypes .","['Multivariate', 'logistic', 'regression', 'analysis', 'showed', 'a', '1.66-fold', 'increased', 'risk', 'for', 'severe', 'diarrhea', 'in', 'patients', 'with', 'AA', 'genotype', '(', '95', '%', 'CI', '1.03', '-', '2.67', ',', 'P', '=', '0.038', ')', 'compared', 'with', 'the', 'cases', 'with', 'GG', 'or', 'GA', 'genotypes', '.']","(10, 12)","(79, 94)",-1,hl_o,23985254,Abstract,11,test,gold,3591.0
5435,Stratified analysis showed that in the,Cap-Oxa-CRT,"group , patients with AA genotype showed a 2.34-fold increased risk for severe diarrhea ( 95 % CI 1.16 - 4.76 , P = 0.018 ) compared with those with GG or GA genotypes , but in the Cap-CRT group , the SNP was not associated with the risk of severe diarrhea .","['Stratified', 'analysis', 'showed', 'that', 'in', 'the', 'Cap-Oxa-CRT', 'group', ',', 'patients', 'with', 'AA', 'genotype', 'showed', 'a', '2.34-fold', 'increased', 'risk', 'for', 'severe', 'diarrhea', '(', '95', '%', 'CI', '1.16', '-', '4.76', ',', 'P', '=', '0.018', ')', 'compared', 'with', 'those', 'with', 'GG', 'or', 'GA', 'genotypes', ',', 'but', 'in', 'the', 'Cap-CRT', 'group', ',', 'the', 'SNP', 'was', 'not', 'associated', 'with', 'the', 'risk', 'of', 'severe', 'diarrhea', '.']","(6, 7)","(38, 49)",-1,ss_i,23985254,Abstract,12,test,gold,
5436,"Stratified analysis showed that in the Cap-Oxa-CRT group , patients with AA genotype showed a 2.34-fold increased risk for severe diarrhea ( 95 % CI 1.16 - 4.76 , P = 0.018 ) compared with those with GG or GA genotypes , but in the",Cap-CRT,"group , the SNP was not associated with the risk of severe diarrhea .","['Stratified', 'analysis', 'showed', 'that', 'in', 'the', 'Cap-Oxa-CRT', 'group', ',', 'patients', 'with', 'AA', 'genotype', 'showed', 'a', '2.34-fold', 'increased', 'risk', 'for', 'severe', 'diarrhea', '(', '95', '%', 'CI', '1.16', '-', '4.76', ',', 'P', '=', '0.018', ')', 'compared', 'with', 'those', 'with', 'GG', 'or', 'GA', 'genotypes', ',', 'but', 'in', 'the', 'Cap-CRT', 'group', ',', 'the', 'SNP', 'was', 'not', 'associated', 'with', 'the', 'risk', 'of', 'severe', 'diarrhea', '.']","(45, 46)","(231, 238)",-1,ss_i,23985254,Abstract,12,test,gold,
5437,"Stratified analysis showed that in the Cap-Oxa-CRT group , patients with AA genotype showed a 2.34-fold increased risk for",severe diarrhea,"( 95 % CI 1.16 - 4.76 , P = 0.018 ) compared with those with GG or GA genotypes , but in the Cap-CRT group , the SNP was not associated with the risk of severe diarrhea .","['Stratified', 'analysis', 'showed', 'that', 'in', 'the', 'Cap-Oxa-CRT', 'group', ',', 'patients', 'with', 'AA', 'genotype', 'showed', 'a', '2.34-fold', 'increased', 'risk', 'for', 'severe', 'diarrhea', '(', '95', '%', 'CI', '1.16', '-', '4.76', ',', 'P', '=', '0.018', ')', 'compared', 'with', 'those', 'with', 'GG', 'or', 'GA', 'genotypes', ',', 'but', 'in', 'the', 'Cap-CRT', 'group', ',', 'the', 'SNP', 'was', 'not', 'associated', 'with', 'the', 'risk', 'of', 'severe', 'diarrhea', '.']","(19, 21)","(122, 137)",-1,ss_o,23985254,Abstract,12,test,gold,3590.0
5438,"Stratified analysis showed that in the Cap-Oxa-CRT group , patients with AA genotype showed a 2.34-fold increased risk for severe diarrhea ( 95 % CI 1.16 - 4.76 , P = 0.018 ) compared with those with GG or GA genotypes , but in the Cap-CRT group , the SNP was not associated with the risk of",severe diarrhea .,,"['Stratified', 'analysis', 'showed', 'that', 'in', 'the', 'Cap-Oxa-CRT', 'group', ',', 'patients', 'with', 'AA', 'genotype', 'showed', 'a', '2.34-fold', 'increased', 'risk', 'for', 'severe', 'diarrhea', '(', '95', '%', 'CI', '1.16', '-', '4.76', ',', 'P', '=', '0.018', ')', 'compared', 'with', 'those', 'with', 'GG', 'or', 'GA', 'genotypes', ',', 'but', 'in', 'the', 'Cap-CRT', 'group', ',', 'the', 'SNP', 'was', 'not', 'associated', 'with', 'the', 'risk', 'of', 'severe', 'diarrhea', '.']","(57, 60)","(291, 308)",-1,ss_o,23985254,Abstract,12,test,gold,3589.0
5439,Stratified analysis showed that in the,Cap-Oxa-CRT,"group , patients with AA genotype showed a 2.34-fold increased risk for severe diarrhea ( 95 % CI 1.16 - 4.76 , P = 0.018 ) compared with those with GG or GA genotypes , but in the Cap-CRT group , the SNP was not associated with the risk of severe diarrhea .","['Stratified', 'analysis', 'showed', 'that', 'in', 'the', 'Cap-Oxa-CRT', 'group', ',', 'patients', 'with', 'AA', 'genotype', 'showed', 'a', '2.34-fold', 'increased', 'risk', 'for', 'severe', 'diarrhea', '(', '95', '%', 'CI', '1.16', '-', '4.76', ',', 'P', '=', '0.018', ')', 'compared', 'with', 'those', 'with', 'GG', 'or', 'GA', 'genotypes', ',', 'but', 'in', 'the', 'Cap-CRT', 'group', ',', 'the', 'SNP', 'was', 'not', 'associated', 'with', 'the', 'risk', 'of', 'severe', 'diarrhea', '.']","(6, 7)","(38, 49)",-1,hl_i,23985254,Abstract,12,test,gold,
5440,"Stratified analysis showed that in the Cap-Oxa-CRT group , patients with AA genotype showed a 2.34-fold increased risk for severe diarrhea ( 95 % CI 1.16 - 4.76 , P = 0.018 ) compared with those with GG or GA genotypes , but in the",Cap-CRT,"group , the SNP was not associated with the risk of severe diarrhea .","['Stratified', 'analysis', 'showed', 'that', 'in', 'the', 'Cap-Oxa-CRT', 'group', ',', 'patients', 'with', 'AA', 'genotype', 'showed', 'a', '2.34-fold', 'increased', 'risk', 'for', 'severe', 'diarrhea', '(', '95', '%', 'CI', '1.16', '-', '4.76', ',', 'P', '=', '0.018', ')', 'compared', 'with', 'those', 'with', 'GG', 'or', 'GA', 'genotypes', ',', 'but', 'in', 'the', 'Cap-CRT', 'group', ',', 'the', 'SNP', 'was', 'not', 'associated', 'with', 'the', 'risk', 'of', 'severe', 'diarrhea', '.']","(45, 46)","(231, 238)",-1,hl_i,23985254,Abstract,12,test,gold,
5441,"Stratified analysis showed that in the Cap-Oxa-CRT group , patients with AA genotype showed a 2.34-fold increased risk for",severe diarrhea,"( 95 % CI 1.16 - 4.76 , P = 0.018 ) compared with those with GG or GA genotypes , but in the Cap-CRT group , the SNP was not associated with the risk of severe diarrhea .","['Stratified', 'analysis', 'showed', 'that', 'in', 'the', 'Cap-Oxa-CRT', 'group', ',', 'patients', 'with', 'AA', 'genotype', 'showed', 'a', '2.34-fold', 'increased', 'risk', 'for', 'severe', 'diarrhea', '(', '95', '%', 'CI', '1.16', '-', '4.76', ',', 'P', '=', '0.018', ')', 'compared', 'with', 'those', 'with', 'GG', 'or', 'GA', 'genotypes', ',', 'but', 'in', 'the', 'Cap-CRT', 'group', ',', 'the', 'SNP', 'was', 'not', 'associated', 'with', 'the', 'risk', 'of', 'severe', 'diarrhea', '.']","(19, 21)","(122, 137)",-1,hl_o,23985254,Abstract,12,test,gold,3588.0
5442,"Stratified analysis showed that in the Cap-Oxa-CRT group , patients with AA genotype showed a 2.34-fold increased risk for severe diarrhea ( 95 % CI 1.16 - 4.76 , P = 0.018 ) compared with those with GG or GA genotypes , but in the Cap-CRT group , the SNP was not associated with the risk of",severe diarrhea .,,"['Stratified', 'analysis', 'showed', 'that', 'in', 'the', 'Cap-Oxa-CRT', 'group', ',', 'patients', 'with', 'AA', 'genotype', 'showed', 'a', '2.34-fold', 'increased', 'risk', 'for', 'severe', 'diarrhea', '(', '95', '%', 'CI', '1.16', '-', '4.76', ',', 'P', '=', '0.018', ')', 'compared', 'with', 'those', 'with', 'GG', 'or', 'GA', 'genotypes', ',', 'but', 'in', 'the', 'Cap-CRT', 'group', ',', 'the', 'SNP', 'was', 'not', 'associated', 'with', 'the', 'risk', 'of', 'severe', 'diarrhea', '.']","(57, 60)","(291, 308)",-1,hl_o,23985254,Abstract,12,test,gold,3587.0
5443,CONCLUSIONS The genetic polymorphism of CCND1 A870G might be a potential biomarker for predicting acute AEs in,postoperative stage II and III rectal cancer patients,treated with adjuvant concurrent chemoradiotherapy of capecitabine and oxaliplatin .,"['CONCLUSIONS', 'The', 'genetic', 'polymorphism', 'of', 'CCND1', 'A870G', 'might', 'be', 'a', 'potential', 'biomarker', 'for', 'predicting', 'acute', 'AEs', 'in', 'postoperative', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', 'of', 'capecitabine', 'and', 'oxaliplatin', '.']","(17, 25)","(110, 163)",-1,ss_p,23985254,Abstract,13,test,gold,5947.0
5444,CONCLUSIONS The genetic polymorphism of CCND1 A870G might be a potential biomarker for predicting acute AEs in postoperative stage II and III rectal cancer patients treated with adjuvant concurrent,chemoradiotherapy,of capecitabine and oxaliplatin .,"['CONCLUSIONS', 'The', 'genetic', 'polymorphism', 'of', 'CCND1', 'A870G', 'might', 'be', 'a', 'potential', 'biomarker', 'for', 'predicting', 'acute', 'AEs', 'in', 'postoperative', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', 'of', 'capecitabine', 'and', 'oxaliplatin', '.']","(29, 30)","(197, 214)",-1,ss_i,23985254,Abstract,13,test,gold,5796.0
5445,CONCLUSIONS The genetic polymorphism of CCND1 A870G might be a potential biomarker for predicting acute AEs in postoperative stage II and III rectal cancer patients treated with adjuvant concurrent chemoradiotherapy of,capecitabine,and oxaliplatin .,"['CONCLUSIONS', 'The', 'genetic', 'polymorphism', 'of', 'CCND1', 'A870G', 'might', 'be', 'a', 'potential', 'biomarker', 'for', 'predicting', 'acute', 'AEs', 'in', 'postoperative', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', 'of', 'capecitabine', 'and', 'oxaliplatin', '.']","(31, 32)","(218, 230)",-1,ss_i,23985254,Abstract,13,test,gold,5179.0
5446,CONCLUSIONS The genetic polymorphism of CCND1 A870G might be a potential biomarker for predicting acute AEs in postoperative stage II and III rectal cancer patients treated with adjuvant concurrent chemoradiotherapy of capecitabine and,oxaliplatin .,,"['CONCLUSIONS', 'The', 'genetic', 'polymorphism', 'of', 'CCND1', 'A870G', 'might', 'be', 'a', 'potential', 'biomarker', 'for', 'predicting', 'acute', 'AEs', 'in', 'postoperative', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', 'of', 'capecitabine', 'and', 'oxaliplatin', '.']","(33, 35)","(235, 248)",-1,ss_i,23985254,Abstract,13,test,gold,5728.0
5447,CONCLUSIONS The,genetic polymorphism of CCND1 A870G,might be a potential biomarker for predicting acute AEs in postoperative stage II and III rectal cancer patients treated with adjuvant concurrent chemoradiotherapy of capecitabine and oxaliplatin .,"['CONCLUSIONS', 'The', 'genetic', 'polymorphism', 'of', 'CCND1', 'A870G', 'might', 'be', 'a', 'potential', 'biomarker', 'for', 'predicting', 'acute', 'AEs', 'in', 'postoperative', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', 'of', 'capecitabine', 'and', 'oxaliplatin', '.']","(2, 7)","(15, 50)",-1,ss_o,23985254,Abstract,13,test,gold,4569.0
5448,CONCLUSIONS The genetic polymorphism of CCND1 A870G might be a potential biomarker for predicting,acute AEs,in postoperative stage II and III rectal cancer patients treated with adjuvant concurrent chemoradiotherapy of capecitabine and oxaliplatin .,"['CONCLUSIONS', 'The', 'genetic', 'polymorphism', 'of', 'CCND1', 'A870G', 'might', 'be', 'a', 'potential', 'biomarker', 'for', 'predicting', 'acute', 'AEs', 'in', 'postoperative', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', 'of', 'capecitabine', 'and', 'oxaliplatin', '.']","(14, 16)","(97, 106)",-1,ss_o,23985254,Abstract,13,test,gold,3086.0
5449,CONCLUSIONS The genetic polymorphism of CCND1 A870G might be a potential biomarker for predicting acute AEs in,postoperative stage II and III rectal cancer patients,treated with adjuvant concurrent chemoradiotherapy of capecitabine and oxaliplatin .,"['CONCLUSIONS', 'The', 'genetic', 'polymorphism', 'of', 'CCND1', 'A870G', 'might', 'be', 'a', 'potential', 'biomarker', 'for', 'predicting', 'acute', 'AEs', 'in', 'postoperative', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', 'of', 'capecitabine', 'and', 'oxaliplatin', '.']","(17, 25)","(110, 163)",-1,hl_p,23985254,Abstract,13,test,gold,5948.0
5450,CONCLUSIONS The genetic polymorphism of CCND1 A870G might be a potential biomarker for predicting acute AEs in postoperative stage II and III rectal cancer patients treated with adjuvant concurrent,chemoradiotherapy,of capecitabine and oxaliplatin .,"['CONCLUSIONS', 'The', 'genetic', 'polymorphism', 'of', 'CCND1', 'A870G', 'might', 'be', 'a', 'potential', 'biomarker', 'for', 'predicting', 'acute', 'AEs', 'in', 'postoperative', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', 'of', 'capecitabine', 'and', 'oxaliplatin', '.']","(29, 30)","(197, 214)",-1,hl_i,23985254,Abstract,13,test,gold,5795.0
5451,CONCLUSIONS The genetic polymorphism of CCND1 A870G might be a potential biomarker for predicting acute AEs in postoperative stage II and III rectal cancer patients treated with adjuvant concurrent chemoradiotherapy of,capecitabine,and oxaliplatin .,"['CONCLUSIONS', 'The', 'genetic', 'polymorphism', 'of', 'CCND1', 'A870G', 'might', 'be', 'a', 'potential', 'biomarker', 'for', 'predicting', 'acute', 'AEs', 'in', 'postoperative', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', 'of', 'capecitabine', 'and', 'oxaliplatin', '.']","(31, 32)","(218, 230)",-1,hl_i,23985254,Abstract,13,test,gold,5178.0
5452,CONCLUSIONS The genetic polymorphism of CCND1 A870G might be a potential biomarker for predicting acute AEs in postoperative stage II and III rectal cancer patients treated with adjuvant concurrent chemoradiotherapy of capecitabine and,oxaliplatin .,,"['CONCLUSIONS', 'The', 'genetic', 'polymorphism', 'of', 'CCND1', 'A870G', 'might', 'be', 'a', 'potential', 'biomarker', 'for', 'predicting', 'acute', 'AEs', 'in', 'postoperative', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', 'of', 'capecitabine', 'and', 'oxaliplatin', '.']","(33, 35)","(235, 248)",-1,hl_i,23985254,Abstract,13,test,gold,5727.0
5453,CONCLUSIONS The genetic polymorphism of CCND1 A870G might be a potential biomarker for predicting,acute AEs,in postoperative stage II and III rectal cancer patients treated with adjuvant concurrent chemoradiotherapy of capecitabine and oxaliplatin .,"['CONCLUSIONS', 'The', 'genetic', 'polymorphism', 'of', 'CCND1', 'A870G', 'might', 'be', 'a', 'potential', 'biomarker', 'for', 'predicting', 'acute', 'AEs', 'in', 'postoperative', 'stage', 'II', 'and', 'III', 'rectal', 'cancer', 'patients', 'treated', 'with', 'adjuvant', 'concurrent', 'chemoradiotherapy', 'of', 'capecitabine', 'and', 'oxaliplatin', '.']","(14, 16)","(97, 106)",-1,hl_o,23985254,Abstract,13,test,gold,3084.0
5454,Data mining the ScanBrit study of a gluten- and casein-free dietary intervention for,children with autism spectrum disorders :,behavioural and psychometric measures of dietary response .,"['Data', 'mining', 'the', 'ScanBrit', 'study', 'of', 'a', 'gluten-', 'and', 'casein-free', 'dietary', 'intervention', 'for', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'behavioural', 'and', 'psychometric', 'measures', 'of', 'dietary', 'response', '.']","(13, 19)","(84, 125)",-1,ss_p,24075141,Title,0,test,gold,6023.0
5455,Data mining the ScanBrit study of a,gluten- and casein-free dietary intervention,for children with autism spectrum disorders : behavioural and psychometric measures of dietary response .,"['Data', 'mining', 'the', 'ScanBrit', 'study', 'of', 'a', 'gluten-', 'and', 'casein-free', 'dietary', 'intervention', 'for', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'behavioural', 'and', 'psychometric', 'measures', 'of', 'dietary', 'response', '.']","(7, 12)","(35, 79)",-1,ss_i,24075141,Title,0,test,gold,3972.0
5456,Data mining the ScanBrit study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders :,behavioural and psychometric measures of dietary response .,,"['Data', 'mining', 'the', 'ScanBrit', 'study', 'of', 'a', 'gluten-', 'and', 'casein-free', 'dietary', 'intervention', 'for', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'behavioural', 'and', 'psychometric', 'measures', 'of', 'dietary', 'response', '.']","(19, 27)","(126, 185)",-1,ss_o,24075141,Title,0,test,gold,3974.0
5457,Data mining the ScanBrit study of a gluten- and casein-free dietary intervention for,children,with autism spectrum disorders : behavioural and psychometric measures of dietary response .,"['Data', 'mining', 'the', 'ScanBrit', 'study', 'of', 'a', 'gluten-', 'and', 'casein-free', 'dietary', 'intervention', 'for', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'behavioural', 'and', 'psychometric', 'measures', 'of', 'dietary', 'response', '.']","(13, 14)","(84, 92)",-1,hl_p,24075141,Title,0,test,gold,2116.0
5458,Data mining the ScanBrit study of a gluten- and casein-free dietary intervention for children with,autism spectrum disorders,: behavioural and psychometric measures of dietary response .,"['Data', 'mining', 'the', 'ScanBrit', 'study', 'of', 'a', 'gluten-', 'and', 'casein-free', 'dietary', 'intervention', 'for', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'behavioural', 'and', 'psychometric', 'measures', 'of', 'dietary', 'response', '.']","(15, 18)","(98, 123)",-1,hl_p,24075141,Title,0,test,gold,6026.0
5459,Data mining the ScanBrit study of a,gluten- and casein-free dietary intervention,for children with autism spectrum disorders : behavioural and psychometric measures of dietary response .,"['Data', 'mining', 'the', 'ScanBrit', 'study', 'of', 'a', 'gluten-', 'and', 'casein-free', 'dietary', 'intervention', 'for', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'behavioural', 'and', 'psychometric', 'measures', 'of', 'dietary', 'response', '.']","(7, 12)","(35, 79)",-1,hl_i,24075141,Title,0,test,gold,3973.0
5460,Data mining the ScanBrit study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders :,behavioural and psychometric measures,of dietary response .,"['Data', 'mining', 'the', 'ScanBrit', 'study', 'of', 'a', 'gluten-', 'and', 'casein-free', 'dietary', 'intervention', 'for', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'behavioural', 'and', 'psychometric', 'measures', 'of', 'dietary', 'response', '.']","(19, 23)","(126, 163)",-1,hl_o,24075141,Title,0,test,gold,1837.0
5461,We previously reported results based on the examination of a gluten- and casein-free diet as an intervention for,children diagnosed with an autism spectrum disorder,as part of the ScanBrit collaboration .,"['We', 'previously', 'reported', 'results', 'based', 'on', 'the', 'examination', 'of', 'a', 'gluten-', 'and', 'casein-free', 'diet', 'as', 'an', 'intervention', 'for', 'children', 'diagnosed', 'with', 'an', 'autism', 'spectrum', 'disorder', 'as', 'part', 'of', 'the', 'ScanBrit', 'collaboration', '.']","(18, 25)","(112, 163)",-1,ss_p,24075141,Abstract,0,test,gold,6049.0
5462,We previously reported results based on the examination of a,gluten- and casein-free diet,as an intervention for children diagnosed with an autism spectrum disorder as part of the ScanBrit collaboration .,"['We', 'previously', 'reported', 'results', 'based', 'on', 'the', 'examination', 'of', 'a', 'gluten-', 'and', 'casein-free', 'diet', 'as', 'an', 'intervention', 'for', 'children', 'diagnosed', 'with', 'an', 'autism', 'spectrum', 'disorder', 'as', 'part', 'of', 'the', 'ScanBrit', 'collaboration', '.']","(10, 14)","(60, 88)",-1,ss_i,24075141,Abstract,0,test,gold,1541.0
5463,We previously reported results based on the examination of a gluten- and casein-free diet as an intervention for,children diagnosed with an autism spectrum disorder,as part of the ScanBrit collaboration .,"['We', 'previously', 'reported', 'results', 'based', 'on', 'the', 'examination', 'of', 'a', 'gluten-', 'and', 'casein-free', 'diet', 'as', 'an', 'intervention', 'for', 'children', 'diagnosed', 'with', 'an', 'autism', 'spectrum', 'disorder', 'as', 'part', 'of', 'the', 'ScanBrit', 'collaboration', '.']","(18, 25)","(112, 163)",-1,hl_p,24075141,Abstract,0,test,gold,6050.0
5464,We previously reported results based on the examination of a,gluten- and casein-free diet,as an intervention for children diagnosed with an autism spectrum disorder as part of the ScanBrit collaboration .,"['We', 'previously', 'reported', 'results', 'based', 'on', 'the', 'examination', 'of', 'a', 'gluten-', 'and', 'casein-free', 'diet', 'as', 'an', 'intervention', 'for', 'children', 'diagnosed', 'with', 'an', 'autism', 'spectrum', 'disorder', 'as', 'part', 'of', 'the', 'ScanBrit', 'collaboration', '.']","(10, 14)","(60, 88)",-1,hl_i,24075141,Abstract,0,test,gold,1542.0
5465,Analysis based on grouped results indicated several significant differences between dietary and non-dietary participants across various core and peripheral areas of functioning .,,,"['Analysis', 'based', 'on', 'grouped', 'results', 'indicated', 'several', 'significant', 'differences', 'between', 'dietary', 'and', 'non-dietary', 'participants', 'across', 'various', 'core', 'and', 'peripheral', 'areas', 'of', 'functioning', '.']",,,,,24075141,Abstract,1,test,gold,
5466,Results also indicated some disparity in individual,responses to dietary modification,potentially indicative of responder and non-responder differences .,"['Results', 'also', 'indicated', 'some', 'disparity', 'in', 'individual', 'responses', 'to', 'dietary', 'modification', 'potentially', 'indicative', 'of', 'responder', 'and', 'non-responder', 'differences', '.']","(7, 11)","(51, 84)",-1,ss_o,24075141,Abstract,2,test,gold,3975.0
5467,"Further examination of the behavioural and psychometric data garnered from participants was undertaken , with a view to determining potential factors pertinent to response to",dietary intervention .,,"['Further', 'examination', 'of', 'the', 'behavioural', 'and', 'psychometric', 'data', 'garnered', 'from', 'participants', 'was', 'undertaken', ',', 'with', 'a', 'view', 'to', 'determining', 'potential', 'factors', 'pertinent', 'to', 'response', 'to', 'dietary', 'intervention', '.']","(25, 28)","(174, 196)",-1,ss_i,24075141,Abstract,3,test,gold,3971.0
5468,Further examination of the,behavioural and psychometric data,"garnered from participants was undertaken , with a view to determining potential factors pertinent to response to dietary intervention .","['Further', 'examination', 'of', 'the', 'behavioural', 'and', 'psychometric', 'data', 'garnered', 'from', 'participants', 'was', 'undertaken', ',', 'with', 'a', 'view', 'to', 'determining', 'potential', 'factors', 'pertinent', 'to', 'response', 'to', 'dietary', 'intervention', '.']","(4, 8)","(26, 59)",-1,ss_o,24075141,Abstract,3,test,gold,1838.0
5469,"Further examination of the behavioural and psychometric data garnered from participants was undertaken , with a view to determining potential factors pertinent to",response to dietary intervention .,,"['Further', 'examination', 'of', 'the', 'behavioural', 'and', 'psychometric', 'data', 'garnered', 'from', 'participants', 'was', 'undertaken', ',', 'with', 'a', 'view', 'to', 'determining', 'potential', 'factors', 'pertinent', 'to', 'response', 'to', 'dietary', 'intervention', '.']","(23, 28)","(162, 196)",-1,ss_o,24075141,Abstract,3,test,gold,3976.0
5470,"Further examination of the behavioural and psychometric data garnered from participants was undertaken , with a view to determining potential factors pertinent to response to",dietary intervention .,,"['Further', 'examination', 'of', 'the', 'behavioural', 'and', 'psychometric', 'data', 'garnered', 'from', 'participants', 'was', 'undertaken', ',', 'with', 'a', 'view', 'to', 'determining', 'potential', 'factors', 'pertinent', 'to', 'response', 'to', 'dietary', 'intervention', '.']","(25, 28)","(174, 196)",-1,hl_i,24075141,Abstract,3,test,gold,3970.0
5471,Participants with clinically significant scores indicative of inattention and hyperactivity behaviours and who had a significant positive changes to said scores were defined as responders to the,dietary intervention .,,"['Participants', 'with', 'clinically', 'significant', 'scores', 'indicative', 'of', 'inattention', 'and', 'hyperactivity', 'behaviours', 'and', 'who', 'had', 'a', 'significant', 'positive', 'changes', 'to', 'said', 'scores', 'were', 'defined', 'as', 'responders', 'to', 'the', 'dietary', 'intervention', '.']","(27, 30)","(194, 216)",-1,ss_i,24075141,Abstract,4,test,gold,3969.0
5472,Participants with clinically significant scores indicative of,inattention and hyperactivity behaviours,and who had a significant positive changes to said scores were defined as responders to the dietary intervention .,"['Participants', 'with', 'clinically', 'significant', 'scores', 'indicative', 'of', 'inattention', 'and', 'hyperactivity', 'behaviours', 'and', 'who', 'had', 'a', 'significant', 'positive', 'changes', 'to', 'said', 'scores', 'were', 'defined', 'as', 'responders', 'to', 'the', 'dietary', 'intervention', '.']","(7, 11)","(61, 101)",-1,ss_o,24075141,Abstract,4,test,gold,2588.0
5473,Participants with clinically significant scores indicative of inattention and hyperactivity behaviours and who had a significant positive changes to said scores were defined as,responders to the dietary intervention .,,"['Participants', 'with', 'clinically', 'significant', 'scores', 'indicative', 'of', 'inattention', 'and', 'hyperactivity', 'behaviours', 'and', 'who', 'had', 'a', 'significant', 'positive', 'changes', 'to', 'said', 'scores', 'were', 'defined', 'as', 'responders', 'to', 'the', 'dietary', 'intervention', '.']","(24, 30)","(176, 216)",-1,ss_o,24075141,Abstract,4,test,gold,3961.0
5474,Participants with clinically significant scores indicative of inattention and hyperactivity behaviours and who had a significant positive changes to said scores were defined as responders to the,dietary intervention .,,"['Participants', 'with', 'clinically', 'significant', 'scores', 'indicative', 'of', 'inattention', 'and', 'hyperactivity', 'behaviours', 'and', 'who', 'had', 'a', 'significant', 'positive', 'changes', 'to', 'said', 'scores', 'were', 'defined', 'as', 'responders', 'to', 'the', 'dietary', 'intervention', '.']","(27, 30)","(194, 216)",-1,hl_i,24075141,Abstract,4,test,gold,3968.0
5475,Participants with clinically significant scores indicative of,inattention and hyperactivity behaviours,and who had a significant positive changes to said scores were defined as responders to the dietary intervention .,"['Participants', 'with', 'clinically', 'significant', 'scores', 'indicative', 'of', 'inattention', 'and', 'hyperactivity', 'behaviours', 'and', 'who', 'had', 'a', 'significant', 'positive', 'changes', 'to', 'said', 'scores', 'were', 'defined', 'as', 'responders', 'to', 'the', 'dietary', 'intervention', '.']","(7, 11)","(61, 101)",-1,hl_o,24075141,Abstract,4,test,gold,2589.0
5476,Analyses indicated several factors to be potentially pertinent to a positive response to,dietary intervention,in terms of symptom presentation .,"['Analyses', 'indicated', 'several', 'factors', 'to', 'be', 'potentially', 'pertinent', 'to', 'a', 'positive', 'response', 'to', 'dietary', 'intervention', 'in', 'terms', 'of', 'symptom', 'presentation', '.']","(13, 15)","(88, 108)",-1,ss_i,24075141,Abstract,5,test,gold,3967.0
5477,Analyses indicated several factors to be potentially pertinent to a positive,response to dietary intervention,in terms of symptom presentation .,"['Analyses', 'indicated', 'several', 'factors', 'to', 'be', 'potentially', 'pertinent', 'to', 'a', 'positive', 'response', 'to', 'dietary', 'intervention', 'in', 'terms', 'of', 'symptom', 'presentation', '.']","(11, 15)","(76, 108)",-1,ss_o,24075141,Abstract,5,test,gold,3977.0
5478,Analyses indicated several factors to be potentially pertinent to a positive response to dietary intervention in terms of,symptom presentation .,,"['Analyses', 'indicated', 'several', 'factors', 'to', 'be', 'potentially', 'pertinent', 'to', 'a', 'positive', 'response', 'to', 'dietary', 'intervention', 'in', 'terms', 'of', 'symptom', 'presentation', '.']","(18, 21)","(121, 143)",-1,ss_o,24075141,Abstract,5,test,gold,3360.0
5479,Analyses indicated several factors to be potentially pertinent to a positive response to,dietary intervention,in terms of symptom presentation .,"['Analyses', 'indicated', 'several', 'factors', 'to', 'be', 'potentially', 'pertinent', 'to', 'a', 'positive', 'response', 'to', 'dietary', 'intervention', 'in', 'terms', 'of', 'symptom', 'presentation', '.']","(13, 15)","(88, 108)",-1,hl_i,24075141,Abstract,5,test,gold,3966.0
5480,Analyses indicated several factors to be potentially pertinent to a positive,response,to dietary intervention in terms of symptom presentation .,"['Analyses', 'indicated', 'several', 'factors', 'to', 'be', 'potentially', 'pertinent', 'to', 'a', 'positive', 'response', 'to', 'dietary', 'intervention', 'in', 'terms', 'of', 'symptom', 'presentation', '.']","(11, 12)","(76, 84)",-1,hl_o,24075141,Abstract,5,test,gold,2520.0
5481,"Chronological age was found to be the strongest predictor of response , where those participants aged between 7 and 9 years seemed to derive most benefit from",dietary intervention .,,"['Chronological', 'age', 'was', 'found', 'to', 'be', 'the', 'strongest', 'predictor', 'of', 'response', ',', 'where', 'those', 'participants', 'aged', 'between', '7', 'and', '9', 'years', 'seemed', 'to', 'derive', 'most', 'benefit', 'from', 'dietary', 'intervention', '.']","(27, 30)","(158, 180)",-1,ss_i,24075141,Abstract,6,test,gold,3965.0
5482,,Chronological age,"was found to be the strongest predictor of response , where those participants aged between 7 and 9 years seemed to derive most benefit from dietary intervention .","['Chronological', 'age', 'was', 'found', 'to', 'be', 'the', 'strongest', 'predictor', 'of', 'response', ',', 'where', 'those', 'participants', 'aged', 'between', '7', 'and', '9', 'years', 'seemed', 'to', 'derive', 'most', 'benefit', 'from', 'dietary', 'intervention', '.']","(0, 2)","(0, 17)",-1,ss_o,24075141,Abstract,6,test,gold,2009.0
5483,"Chronological age was found to be the strongest predictor of response , where those participants aged between 7 and 9 years seemed to derive most benefit from",dietary intervention .,,"['Chronological', 'age', 'was', 'found', 'to', 'be', 'the', 'strongest', 'predictor', 'of', 'response', ',', 'where', 'those', 'participants', 'aged', 'between', '7', 'and', '9', 'years', 'seemed', 'to', 'derive', 'most', 'benefit', 'from', 'dietary', 'intervention', '.']","(27, 30)","(158, 180)",-1,ss_o,24075141,Abstract,6,test,gold,3964.0
5484,"Chronological age was found to be the strongest predictor of response , where those participants aged between 7 and 9 years seemed to derive most benefit from",dietary intervention .,,"['Chronological', 'age', 'was', 'found', 'to', 'be', 'the', 'strongest', 'predictor', 'of', 'response', ',', 'where', 'those', 'participants', 'aged', 'between', '7', 'and', '9', 'years', 'seemed', 'to', 'derive', 'most', 'benefit', 'from', 'dietary', 'intervention', '.']","(27, 30)","(158, 180)",-1,hl_i,24075141,Abstract,6,test,gold,3963.0
5485,Further analysis based on the criteria for original study inclusion on the presence of the,"urine compound , trans-indolyl-3-acryloylglycine",may also merit further investigation .,"['Further', 'analysis', 'based', 'on', 'the', 'criteria', 'for', 'original', 'study', 'inclusion', 'on', 'the', 'presence', 'of', 'the', 'urine', 'compound', ',', 'trans-indolyl-3-acryloylglycine', 'may', 'also', 'merit', 'further', 'investigation', '.']","(15, 19)","(90, 138)",-1,ss_o,24075141,Abstract,7,test,gold,225.0
5486,These preliminary observations on potential best responder characteristics to a gluten- and casein-free diet for,children with autism,require independent replication .,"['These', 'preliminary', 'observations', 'on', 'potential', 'best', 'responder', 'characteristics', 'to', 'a', 'gluten-', 'and', 'casein-free', 'diet', 'for', 'children', 'with', 'autism', 'require', 'independent', 'replication', '.']","(15, 18)","(112, 132)",-1,ss_p,24075141,Abstract,8,test,gold,6134.0
5487,These preliminary observations on potential best responder characteristics to a,gluten- and casein-free diet,for children with autism require independent replication .,"['These', 'preliminary', 'observations', 'on', 'potential', 'best', 'responder', 'characteristics', 'to', 'a', 'gluten-', 'and', 'casein-free', 'diet', 'for', 'children', 'with', 'autism', 'require', 'independent', 'replication', '.']","(10, 14)","(79, 107)",-1,ss_i,24075141,Abstract,8,test,gold,1540.0
5488,These preliminary observations on potential best responder characteristics to a,gluten- and casein-free diet,for children with autism require independent replication .,"['These', 'preliminary', 'observations', 'on', 'potential', 'best', 'responder', 'characteristics', 'to', 'a', 'gluten-', 'and', 'casein-free', 'diet', 'for', 'children', 'with', 'autism', 'require', 'independent', 'replication', '.']","(10, 14)","(79, 107)",-1,hl_i,24075141,Abstract,8,test,gold,1539.0
5489,Effect of simvastatin on hemostasis in,patients with isolated hypertriglyceridemia .,,"['Effect', 'of', 'simvastatin', 'on', 'hemostasis', 'in', 'patients', 'with', 'isolated', 'hypertriglyceridemia', '.']","(6, 11)","(38, 83)",-1,ss_p,24080592,Title,0,test,gold,7001.0
5490,Effect of,simvastatin,on hemostasis in patients with isolated hypertriglyceridemia .,"['Effect', 'of', 'simvastatin', 'on', 'hemostasis', 'in', 'patients', 'with', 'isolated', 'hypertriglyceridemia', '.']","(2, 3)","(9, 20)",-1,ss_i,24080592,Title,0,test,gold,5373.0
5491,Effect of simvastatin on,hemostasis,in patients with isolated hypertriglyceridemia .,"['Effect', 'of', 'simvastatin', 'on', 'hemostasis', 'in', 'patients', 'with', 'isolated', 'hypertriglyceridemia', '.']","(4, 5)","(24, 34)",-1,ss_o,24080592,Title,0,test,gold,3210.0
5492,Effect of simvastatin on hemostasis in,patients with isolated hypertriglyceridemia .,,"['Effect', 'of', 'simvastatin', 'on', 'hemostasis', 'in', 'patients', 'with', 'isolated', 'hypertriglyceridemia', '.']","(6, 11)","(38, 83)",-1,hl_p,24080592,Title,0,test,gold,7002.0
5493,Effect of,simvastatin,on hemostasis in patients with isolated hypertriglyceridemia .,"['Effect', 'of', 'simvastatin', 'on', 'hemostasis', 'in', 'patients', 'with', 'isolated', 'hypertriglyceridemia', '.']","(2, 3)","(9, 20)",-1,hl_i,24080592,Title,0,test,gold,5374.0
5494,BACKGROUNDS/AIMS Elevated triglyceride levels seem to predispose to the earlier development and accelerated progression of coronary artery disease .,,,"['BACKGROUNDS/AIMS', 'Elevated', 'triglyceride', 'levels', 'seem', 'to', 'predispose', 'to', 'the', 'earlier', 'development', 'and', 'accelerated', 'progression', 'of', 'coronary', 'artery', 'disease', '.']",,,,,24080592,Abstract,0,test,gold,
5495,"In our study , we assessed for the first time whether simvastatin treatment affects coagulation and fibrinolysis in",patients with isolated hypertriglyceridemia .,,"['In', 'our', 'study', ',', 'we', 'assessed', 'for', 'the', 'first', 'time', 'whether', 'simvastatin', 'treatment', 'affects', 'coagulation', 'and', 'fibrinolysis', 'in', 'patients', 'with', 'isolated', 'hypertriglyceridemia', '.']","(18, 23)","(115, 160)",-1,ss_p,24080592,Abstract,1,test,gold,7000.0
5496,"In our study , we assessed for the first time whether",simvastatin,treatment affects coagulation and fibrinolysis in patients with isolated hypertriglyceridemia .,"['In', 'our', 'study', ',', 'we', 'assessed', 'for', 'the', 'first', 'time', 'whether', 'simvastatin', 'treatment', 'affects', 'coagulation', 'and', 'fibrinolysis', 'in', 'patients', 'with', 'isolated', 'hypertriglyceridemia', '.']","(11, 12)","(53, 64)",-1,ss_i,24080592,Abstract,1,test,gold,5372.0
5497,"In our study , we assessed for the first time whether simvastatin treatment affects",coagulation and fibrinolysis,in patients with isolated hypertriglyceridemia .,"['In', 'our', 'study', ',', 'we', 'assessed', 'for', 'the', 'first', 'time', 'whether', 'simvastatin', 'treatment', 'affects', 'coagulation', 'and', 'fibrinolysis', 'in', 'patients', 'with', 'isolated', 'hypertriglyceridemia', '.']","(14, 17)","(83, 111)",-1,ss_o,24080592,Abstract,1,test,gold,3208.0
5498,"In our study , we assessed for the first time whether simvastatin treatment affects coagulation and fibrinolysis in",patients with isolated hypertriglyceridemia .,,"['In', 'our', 'study', ',', 'we', 'assessed', 'for', 'the', 'first', 'time', 'whether', 'simvastatin', 'treatment', 'affects', 'coagulation', 'and', 'fibrinolysis', 'in', 'patients', 'with', 'isolated', 'hypertriglyceridemia', '.']","(18, 23)","(115, 160)",-1,hl_p,24080592,Abstract,1,test,gold,6999.0
5499,"In our study , we assessed for the first time whether",simvastatin,treatment affects coagulation and fibrinolysis in patients with isolated hypertriglyceridemia .,"['In', 'our', 'study', ',', 'we', 'assessed', 'for', 'the', 'first', 'time', 'whether', 'simvastatin', 'treatment', 'affects', 'coagulation', 'and', 'fibrinolysis', 'in', 'patients', 'with', 'isolated', 'hypertriglyceridemia', '.']","(11, 12)","(53, 64)",-1,hl_i,24080592,Abstract,1,test,gold,5371.0
5500,"In our study , we assessed for the first time whether simvastatin treatment affects",coagulation and fibrinolysis,in patients with isolated hypertriglyceridemia .,"['In', 'our', 'study', ',', 'we', 'assessed', 'for', 'the', 'first', 'time', 'whether', 'simvastatin', 'treatment', 'affects', 'coagulation', 'and', 'fibrinolysis', 'in', 'patients', 'with', 'isolated', 'hypertriglyceridemia', '.']","(14, 17)","(83, 111)",-1,hl_o,24080592,Abstract,1,test,gold,3209.0
5501,METHODS The study included,39 patients with elevated triglyceride levels and peripheral artery sclerosis,", treated for 90 days with either simvastatin ( 40 mg daily ) or placebo .","['METHODS', 'The', 'study', 'included', '39', 'patients', 'with', 'elevated', 'triglyceride', 'levels', 'and', 'peripheral', 'artery', 'sclerosis', ',', 'treated', 'for', '90', 'days', 'with', 'either', 'simvastatin', '(', '40', 'mg', 'daily', ')', 'or', 'placebo', '.']","(4, 14)","(26, 103)",-1,ss_p,24080592,Abstract,2,test,gold,5980.0
5502,"METHODS The study included 39 patients with elevated triglyceride levels and peripheral artery sclerosis , treated for 90 days with either",simvastatin,( 40 mg daily ) or placebo .,"['METHODS', 'The', 'study', 'included', '39', 'patients', 'with', 'elevated', 'triglyceride', 'levels', 'and', 'peripheral', 'artery', 'sclerosis', ',', 'treated', 'for', '90', 'days', 'with', 'either', 'simvastatin', '(', '40', 'mg', 'daily', ')', 'or', 'placebo', '.']","(21, 22)","(138, 149)",-1,ss_i,24080592,Abstract,2,test,gold,5370.0
5503,"METHODS The study included 39 patients with elevated triglyceride levels and peripheral artery sclerosis , treated for 90 days with either simvastatin ( 40 mg daily ) or",placebo .,,"['METHODS', 'The', 'study', 'included', '39', 'patients', 'with', 'elevated', 'triglyceride', 'levels', 'and', 'peripheral', 'artery', 'sclerosis', ',', 'treated', 'for', '90', 'days', 'with', 'either', 'simvastatin', '(', '40', 'mg', 'daily', ')', 'or', 'placebo', '.']","(28, 30)","(169, 178)",-1,ss_i,24080592,Abstract,2,test,gold,4338.0
5504,METHODS The study included,39 patients with elevated triglyceride levels and peripheral artery sclerosis,", treated for 90 days with either simvastatin ( 40 mg daily ) or placebo .","['METHODS', 'The', 'study', 'included', '39', 'patients', 'with', 'elevated', 'triglyceride', 'levels', 'and', 'peripheral', 'artery', 'sclerosis', ',', 'treated', 'for', '90', 'days', 'with', 'either', 'simvastatin', '(', '40', 'mg', 'daily', ')', 'or', 'placebo', '.']","(4, 14)","(26, 103)",-1,hl_p,24080592,Abstract,2,test,gold,5981.0
5505,"METHODS The study included 39 patients with elevated triglyceride levels and peripheral artery sclerosis , treated for 90 days with either",simvastatin,( 40 mg daily ) or placebo .,"['METHODS', 'The', 'study', 'included', '39', 'patients', 'with', 'elevated', 'triglyceride', 'levels', 'and', 'peripheral', 'artery', 'sclerosis', ',', 'treated', 'for', '90', 'days', 'with', 'either', 'simvastatin', '(', '40', 'mg', 'daily', ')', 'or', 'placebo', '.']","(21, 22)","(138, 149)",-1,hl_i,24080592,Abstract,2,test,gold,5369.0
5506,"METHODS The study included 39 patients with elevated triglyceride levels and peripheral artery sclerosis , treated for 90 days with either simvastatin ( 40 mg daily ) or",placebo .,,"['METHODS', 'The', 'study', 'included', '39', 'patients', 'with', 'elevated', 'triglyceride', 'levels', 'and', 'peripheral', 'artery', 'sclerosis', ',', 'treated', 'for', '90', 'days', 'with', 'either', 'simvastatin', '(', '40', 'mg', 'daily', ')', 'or', 'placebo', '.']","(28, 30)","(169, 178)",-1,hl_i,24080592,Abstract,2,test,gold,4337.0
5507,,"Plasma lipids , glucose homeostasis markers and hemostasic variables",were assessed at baseline and after treatment .,"['Plasma', 'lipids', ',', 'glucose', 'homeostasis', 'markers', 'and', 'hemostasic', 'variables', 'were', 'assessed', 'at', 'baseline', 'and', 'after', 'treatment', '.']","(0, 9)","(0, 68)",-1,ss_o,24080592,Abstract,3,test,gold,6529.0
5508,,"Plasma lipids , glucose homeostasis markers",and hemostasic variables were assessed at baseline and after treatment .,"['Plasma', 'lipids', ',', 'glucose', 'homeostasis', 'markers', 'and', 'hemostasic', 'variables', 'were', 'assessed', 'at', 'baseline', 'and', 'after', 'treatment', '.']","(0, 6)","(0, 43)",-1,hl_o,24080592,Abstract,3,test,gold,6530.0
5509,"Plasma lipids , glucose homeostasis markers and",hemostasic variables,were assessed at baseline and after treatment .,"['Plasma', 'lipids', ',', 'glucose', 'homeostasis', 'markers', 'and', 'hemostasic', 'variables', 'were', 'assessed', 'at', 'baseline', 'and', 'after', 'treatment', '.']","(7, 9)","(47, 67)",-1,hl_o,24080592,Abstract,3,test,gold,1315.0
5510,RESULTS,Simvastatin,", but not placebo , administered to these patients reduced plasma levels/activity of fibrinogen ( from 3.5 ± 0.4 to 2.8 ± 0.3 g/l , p < 0.01 ) , factor VII ( from 144.2 ± 16.9 to 112.5 ± 14.0 % , p < 0.01 ) and plasminogen activator inhibitor-1 ( from 76.9 ± 13.5 to 50.2 ± 9.2 ng/ml , p < 0.001 ) , without a significant reduction in von Willebrand factor levels , and tended to prolong the prothrombin and partial thromboplastin times .","['RESULTS', 'Simvastatin', ',', 'but', 'not', 'placebo', ',', 'administered', 'to', 'these', 'patients', 'reduced', 'plasma', 'levels/activity', 'of', 'fibrinogen', '(', 'from', '3.5', '±', '0.4', 'to', '2.8', '±', '0.3', 'g/l', ',', 'p', '<', '0.01', ')', ',', 'factor', 'VII', '(', 'from', '144.2', '±', '16.9', 'to', '112.5', '±', '14.0', '%', ',', 'p', '<', '0.01', ')', 'and', 'plasminogen', 'activator', 'inhibitor-1', '(', 'from', '76.9', '±', '13.5', 'to', '50.2', '±', '9.2', 'ng/ml', ',', 'p', '<', '0.001', ')', ',', 'without', 'a', 'significant', 'reduction', 'in', 'von', 'Willebrand', 'factor', 'levels', ',', 'and', 'tended', 'to', 'prolong', 'the', 'prothrombin', 'and', 'partial', 'thromboplastin', 'times', '.']","(1, 2)","(7, 18)",-1,ss_i,24080592,Abstract,4,test,gold,5578.0
5511,"RESULTS Simvastatin , but not",placebo,", administered to these patients reduced plasma levels/activity of fibrinogen ( from 3.5 ± 0.4 to 2.8 ± 0.3 g/l , p < 0.01 ) , factor VII ( from 144.2 ± 16.9 to 112.5 ± 14.0 % , p < 0.01 ) and plasminogen activator inhibitor-1 ( from 76.9 ± 13.5 to 50.2 ± 9.2 ng/ml , p < 0.001 ) , without a significant reduction in von Willebrand factor levels , and tended to prolong the prothrombin and partial thromboplastin times .","['RESULTS', 'Simvastatin', ',', 'but', 'not', 'placebo', ',', 'administered', 'to', 'these', 'patients', 'reduced', 'plasma', 'levels/activity', 'of', 'fibrinogen', '(', 'from', '3.5', '±', '0.4', 'to', '2.8', '±', '0.3', 'g/l', ',', 'p', '<', '0.01', ')', ',', 'factor', 'VII', '(', 'from', '144.2', '±', '16.9', 'to', '112.5', '±', '14.0', '%', ',', 'p', '<', '0.01', ')', 'and', 'plasminogen', 'activator', 'inhibitor-1', '(', 'from', '76.9', '±', '13.5', 'to', '50.2', '±', '9.2', 'ng/ml', ',', 'p', '<', '0.001', ')', ',', 'without', 'a', 'significant', 'reduction', 'in', 'von', 'Willebrand', 'factor', 'levels', ',', 'and', 'tended', 'to', 'prolong', 'the', 'prothrombin', 'and', 'partial', 'thromboplastin', 'times', '.']","(5, 6)","(29, 36)",-1,ss_i,24080592,Abstract,4,test,gold,4336.0
5512,"RESULTS Simvastatin , but not placebo , administered to these patients reduced",plasma levels/activity of fibrinogen,"( from 3.5 ± 0.4 to 2.8 ± 0.3 g/l , p < 0.01 ) , factor VII ( from 144.2 ± 16.9 to 112.5 ± 14.0 % , p < 0.01 ) and plasminogen activator inhibitor-1 ( from 76.9 ± 13.5 to 50.2 ± 9.2 ng/ml , p < 0.001 ) , without a significant reduction in von Willebrand factor levels , and tended to prolong the prothrombin and partial thromboplastin times .","['RESULTS', 'Simvastatin', ',', 'but', 'not', 'placebo', ',', 'administered', 'to', 'these', 'patients', 'reduced', 'plasma', 'levels/activity', 'of', 'fibrinogen', '(', 'from', '3.5', '±', '0.4', 'to', '2.8', '±', '0.3', 'g/l', ',', 'p', '<', '0.01', ')', ',', 'factor', 'VII', '(', 'from', '144.2', '±', '16.9', 'to', '112.5', '±', '14.0', '%', ',', 'p', '<', '0.01', ')', 'and', 'plasminogen', 'activator', 'inhibitor-1', '(', 'from', '76.9', '±', '13.5', 'to', '50.2', '±', '9.2', 'ng/ml', ',', 'p', '<', '0.001', ')', ',', 'without', 'a', 'significant', 'reduction', 'in', 'von', 'Willebrand', 'factor', 'levels', ',', 'and', 'tended', 'to', 'prolong', 'the', 'prothrombin', 'and', 'partial', 'thromboplastin', 'times', '.']","(12, 16)","(78, 114)",-1,ss_o,24080592,Abstract,4,test,gold,4455.0
5513,"RESULTS Simvastatin , but not placebo , administered to these patients reduced plasma levels/activity of fibrinogen ( from 3.5 ± 0.4 to 2.8 ± 0.3 g/l , p <","0.01 ) , factor VII","( from 144.2 ± 16.9 to 112.5 ± 14.0 % , p < 0.01 ) and plasminogen activator inhibitor-1 ( from 76.9 ± 13.5 to 50.2 ± 9.2 ng/ml , p < 0.001 ) , without a significant reduction in von Willebrand factor levels , and tended to prolong the prothrombin and partial thromboplastin times .","['RESULTS', 'Simvastatin', ',', 'but', 'not', 'placebo', ',', 'administered', 'to', 'these', 'patients', 'reduced', 'plasma', 'levels/activity', 'of', 'fibrinogen', '(', 'from', '3.5', '±', '0.4', 'to', '2.8', '±', '0.3', 'g/l', ',', 'p', '<', '0.01', ')', ',', 'factor', 'VII', '(', 'from', '144.2', '±', '16.9', 'to', '112.5', '±', '14.0', '%', ',', 'p', '<', '0.01', ')', 'and', 'plasminogen', 'activator', 'inhibitor-1', '(', 'from', '76.9', '±', '13.5', 'to', '50.2', '±', '9.2', 'ng/ml', ',', 'p', '<', '0.001', ')', ',', 'without', 'a', 'significant', 'reduction', 'in', 'von', 'Willebrand', 'factor', 'levels', ',', 'and', 'tended', 'to', 'prolong', 'the', 'prothrombin', 'and', 'partial', 'thromboplastin', 'times', '.']","(29, 34)","(155, 174)",-1,ss_o,24080592,Abstract,4,test,gold,1309.0
5514,"RESULTS Simvastatin , but not placebo , administered to these patients reduced plasma levels/activity of fibrinogen ( from 3.5 ± 0.4 to 2.8 ± 0.3 g/l , p < 0.01 ) , factor VII ( from 144.2 ± 16.9 to 112.5 ± 14.0 % , p < 0.01 )",and plasminogen activator inhibitor-1,"( from 76.9 ± 13.5 to 50.2 ± 9.2 ng/ml , p < 0.001 ) , without a significant reduction in von Willebrand factor levels , and tended to prolong the prothrombin and partial thromboplastin times .","['RESULTS', 'Simvastatin', ',', 'but', 'not', 'placebo', ',', 'administered', 'to', 'these', 'patients', 'reduced', 'plasma', 'levels/activity', 'of', 'fibrinogen', '(', 'from', '3.5', '±', '0.4', 'to', '2.8', '±', '0.3', 'g/l', ',', 'p', '<', '0.01', ')', ',', 'factor', 'VII', '(', 'from', '144.2', '±', '16.9', 'to', '112.5', '±', '14.0', '%', ',', 'p', '<', '0.01', ')', 'and', 'plasminogen', 'activator', 'inhibitor-1', '(', 'from', '76.9', '±', '13.5', 'to', '50.2', '±', '9.2', 'ng/ml', ',', 'p', '<', '0.001', ')', ',', 'without', 'a', 'significant', 'reduction', 'in', 'von', 'Willebrand', 'factor', 'levels', ',', 'and', 'tended', 'to', 'prolong', 'the', 'prothrombin', 'and', 'partial', 'thromboplastin', 'times', '.']","(49, 53)","(226, 263)",-1,ss_o,24080592,Abstract,4,test,gold,3181.0
5515,"RESULTS Simvastatin , but not placebo , administered to these patients reduced plasma levels/activity of fibrinogen ( from 3.5 ± 0.4 to 2.8 ± 0.3 g/l , p < 0.01 ) , factor VII ( from 144.2 ± 16.9 to 112.5 ± 14.0 % , p < 0.01 ) and plasminogen activator inhibitor-1 ( from 76.9 ± 13.5 to 50.2 ± 9.2 ng/ml , p < 0.001 ) , without a significant",reduction in von Willebrand factor levels,", and tended to prolong the prothrombin and partial thromboplastin times .","['RESULTS', 'Simvastatin', ',', 'but', 'not', 'placebo', ',', 'administered', 'to', 'these', 'patients', 'reduced', 'plasma', 'levels/activity', 'of', 'fibrinogen', '(', 'from', '3.5', '±', '0.4', 'to', '2.8', '±', '0.3', 'g/l', ',', 'p', '<', '0.01', ')', ',', 'factor', 'VII', '(', 'from', '144.2', '±', '16.9', 'to', '112.5', '±', '14.0', '%', ',', 'p', '<', '0.01', ')', 'and', 'plasminogen', 'activator', 'inhibitor-1', '(', 'from', '76.9', '±', '13.5', 'to', '50.2', '±', '9.2', 'ng/ml', ',', 'p', '<', '0.001', ')', ',', 'without', 'a', 'significant', 'reduction', 'in', 'von', 'Willebrand', 'factor', 'levels', ',', 'and', 'tended', 'to', 'prolong', 'the', 'prothrombin', 'and', 'partial', 'thromboplastin', 'times', '.']","(72, 78)","(341, 382)",-1,ss_o,24080592,Abstract,4,test,gold,1731.0
5516,"RESULTS Simvastatin , but not placebo , administered to these patients reduced plasma levels/activity of fibrinogen ( from 3.5 ± 0.4 to 2.8 ± 0.3 g/l , p < 0.01 ) , factor VII ( from 144.2 ± 16.9 to 112.5 ± 14.0 % , p < 0.01 ) and plasminogen activator inhibitor-1 ( from 76.9 ± 13.5 to 50.2 ± 9.2 ng/ml , p < 0.001 ) , without a significant reduction in von Willebrand factor levels , and tended to",prolong the prothrombin and partial thromboplastin,times .,"['RESULTS', 'Simvastatin', ',', 'but', 'not', 'placebo', ',', 'administered', 'to', 'these', 'patients', 'reduced', 'plasma', 'levels/activity', 'of', 'fibrinogen', '(', 'from', '3.5', '±', '0.4', 'to', '2.8', '±', '0.3', 'g/l', ',', 'p', '<', '0.01', ')', ',', 'factor', 'VII', '(', 'from', '144.2', '±', '16.9', 'to', '112.5', '±', '14.0', '%', ',', 'p', '<', '0.01', ')', 'and', 'plasminogen', 'activator', 'inhibitor-1', '(', 'from', '76.9', '±', '13.5', 'to', '50.2', '±', '9.2', 'ng/ml', ',', 'p', '<', '0.001', ')', ',', 'without', 'a', 'significant', 'reduction', 'in', 'von', 'Willebrand', 'factor', 'levels', ',', 'and', 'tended', 'to', 'prolong', 'the', 'prothrombin', 'and', 'partial', 'thromboplastin', 'times', '.']","(82, 88)","(399, 449)",-1,ss_o,24080592,Abstract,4,test,gold,3213.0
5517,RESULTS,Simvastatin,", but not placebo , administered to these patients reduced plasma levels/activity of fibrinogen ( from 3.5 ± 0.4 to 2.8 ± 0.3 g/l , p < 0.01 ) , factor VII ( from 144.2 ± 16.9 to 112.5 ± 14.0 % , p < 0.01 ) and plasminogen activator inhibitor-1 ( from 76.9 ± 13.5 to 50.2 ± 9.2 ng/ml , p < 0.001 ) , without a significant reduction in von Willebrand factor levels , and tended to prolong the prothrombin and partial thromboplastin times .","['RESULTS', 'Simvastatin', ',', 'but', 'not', 'placebo', ',', 'administered', 'to', 'these', 'patients', 'reduced', 'plasma', 'levels/activity', 'of', 'fibrinogen', '(', 'from', '3.5', '±', '0.4', 'to', '2.8', '±', '0.3', 'g/l', ',', 'p', '<', '0.01', ')', ',', 'factor', 'VII', '(', 'from', '144.2', '±', '16.9', 'to', '112.5', '±', '14.0', '%', ',', 'p', '<', '0.01', ')', 'and', 'plasminogen', 'activator', 'inhibitor-1', '(', 'from', '76.9', '±', '13.5', 'to', '50.2', '±', '9.2', 'ng/ml', ',', 'p', '<', '0.001', ')', ',', 'without', 'a', 'significant', 'reduction', 'in', 'von', 'Willebrand', 'factor', 'levels', ',', 'and', 'tended', 'to', 'prolong', 'the', 'prothrombin', 'and', 'partial', 'thromboplastin', 'times', '.']","(1, 2)","(7, 18)",-1,hl_i,24080592,Abstract,4,test,gold,5579.0
5518,"RESULTS Simvastatin , but not",placebo,", administered to these patients reduced plasma levels/activity of fibrinogen ( from 3.5 ± 0.4 to 2.8 ± 0.3 g/l , p < 0.01 ) , factor VII ( from 144.2 ± 16.9 to 112.5 ± 14.0 % , p < 0.01 ) and plasminogen activator inhibitor-1 ( from 76.9 ± 13.5 to 50.2 ± 9.2 ng/ml , p < 0.001 ) , without a significant reduction in von Willebrand factor levels , and tended to prolong the prothrombin and partial thromboplastin times .","['RESULTS', 'Simvastatin', ',', 'but', 'not', 'placebo', ',', 'administered', 'to', 'these', 'patients', 'reduced', 'plasma', 'levels/activity', 'of', 'fibrinogen', '(', 'from', '3.5', '±', '0.4', 'to', '2.8', '±', '0.3', 'g/l', ',', 'p', '<', '0.01', ')', ',', 'factor', 'VII', '(', 'from', '144.2', '±', '16.9', 'to', '112.5', '±', '14.0', '%', ',', 'p', '<', '0.01', ')', 'and', 'plasminogen', 'activator', 'inhibitor-1', '(', 'from', '76.9', '±', '13.5', 'to', '50.2', '±', '9.2', 'ng/ml', ',', 'p', '<', '0.001', ')', ',', 'without', 'a', 'significant', 'reduction', 'in', 'von', 'Willebrand', 'factor', 'levels', ',', 'and', 'tended', 'to', 'prolong', 'the', 'prothrombin', 'and', 'partial', 'thromboplastin', 'times', '.']","(5, 6)","(29, 36)",-1,hl_i,24080592,Abstract,4,test,gold,4335.0
5519,"RESULTS Simvastatin , but not placebo , administered to these patients reduced",plasma levels/activity of fibrinogen,"( from 3.5 ± 0.4 to 2.8 ± 0.3 g/l , p < 0.01 ) , factor VII ( from 144.2 ± 16.9 to 112.5 ± 14.0 % , p < 0.01 ) and plasminogen activator inhibitor-1 ( from 76.9 ± 13.5 to 50.2 ± 9.2 ng/ml , p < 0.001 ) , without a significant reduction in von Willebrand factor levels , and tended to prolong the prothrombin and partial thromboplastin times .","['RESULTS', 'Simvastatin', ',', 'but', 'not', 'placebo', ',', 'administered', 'to', 'these', 'patients', 'reduced', 'plasma', 'levels/activity', 'of', 'fibrinogen', '(', 'from', '3.5', '±', '0.4', 'to', '2.8', '±', '0.3', 'g/l', ',', 'p', '<', '0.01', ')', ',', 'factor', 'VII', '(', 'from', '144.2', '±', '16.9', 'to', '112.5', '±', '14.0', '%', ',', 'p', '<', '0.01', ')', 'and', 'plasminogen', 'activator', 'inhibitor-1', '(', 'from', '76.9', '±', '13.5', 'to', '50.2', '±', '9.2', 'ng/ml', ',', 'p', '<', '0.001', ')', ',', 'without', 'a', 'significant', 'reduction', 'in', 'von', 'Willebrand', 'factor', 'levels', ',', 'and', 'tended', 'to', 'prolong', 'the', 'prothrombin', 'and', 'partial', 'thromboplastin', 'times', '.']","(12, 16)","(78, 114)",-1,hl_o,24080592,Abstract,4,test,gold,4456.0
5520,CONCLUSION Our results suggest that statin treatment produces a multidirectional effect on coagulation and,fibrinolysis in patients with isolated hypertriglyceridemia,and that this treatment may bring some benefits to patients with elevated triglyceride levels .,"['CONCLUSION', 'Our', 'results', 'suggest', 'that', 'statin', 'treatment', 'produces', 'a', 'multidirectional', 'effect', 'on', 'coagulation', 'and', 'fibrinolysis', 'in', 'patients', 'with', 'isolated', 'hypertriglyceridemia', 'and', 'that', 'this', 'treatment', 'may', 'bring', 'some', 'benefits', 'to', 'patients', 'with', 'elevated', 'triglyceride', 'levels', '.']","(14, 20)","(106, 165)",-1,ss_p,24080592,Abstract,5,test,gold,6998.0
5521,CONCLUSION Our results suggest that statin treatment produces a multidirectional effect on coagulation and fibrinolysis in patients with isolated hypertriglyceridemia and that this treatment may bring some,benefits to patients with elevated triglyceride levels,.,"['CONCLUSION', 'Our', 'results', 'suggest', 'that', 'statin', 'treatment', 'produces', 'a', 'multidirectional', 'effect', 'on', 'coagulation', 'and', 'fibrinolysis', 'in', 'patients', 'with', 'isolated', 'hypertriglyceridemia', 'and', 'that', 'this', 'treatment', 'may', 'bring', 'some', 'benefits', 'to', 'patients', 'with', 'elevated', 'triglyceride', 'levels', '.']","(27, 34)","(205, 259)",-1,ss_p,24080592,Abstract,5,test,gold,6568.0
5522,CONCLUSION Our results,suggest that statin,treatment produces a multidirectional effect on coagulation and fibrinolysis in patients with isolated hypertriglyceridemia and that this treatment may bring some benefits to patients with elevated triglyceride levels .,"['CONCLUSION', 'Our', 'results', 'suggest', 'that', 'statin', 'treatment', 'produces', 'a', 'multidirectional', 'effect', 'on', 'coagulation', 'and', 'fibrinolysis', 'in', 'patients', 'with', 'isolated', 'hypertriglyceridemia', 'and', 'that', 'this', 'treatment', 'may', 'bring', 'some', 'benefits', 'to', 'patients', 'with', 'elevated', 'triglyceride', 'levels', '.']","(3, 6)","(22, 41)",-1,ss_i,24080592,Abstract,5,test,gold,5379.0
5523,CONCLUSION Our results suggest that statin treatment produces a multidirectional,effect on coagulation and fibrinolysis,in patients with isolated hypertriglyceridemia and that this treatment may bring some benefits to patients with elevated triglyceride levels .,"['CONCLUSION', 'Our', 'results', 'suggest', 'that', 'statin', 'treatment', 'produces', 'a', 'multidirectional', 'effect', 'on', 'coagulation', 'and', 'fibrinolysis', 'in', 'patients', 'with', 'isolated', 'hypertriglyceridemia', 'and', 'that', 'this', 'treatment', 'may', 'bring', 'some', 'benefits', 'to', 'patients', 'with', 'elevated', 'triglyceride', 'levels', '.']","(10, 15)","(80, 118)",-1,ss_o,24080592,Abstract,5,test,gold,3207.0
5524,The effect of four different irrigation systems in the removal of a root canal sealer .,,,"['The', 'effect', 'of', 'four', 'different', 'irrigation', 'systems', 'in', 'the', 'removal', 'of', 'a', 'root', 'canal', 'sealer', '.']",,,,,24317958,Title,0,test,gold,
5525,"OBJECTIVES The aim of this study was to compare the efficiency of sonic , ultrasonic , and hydrodynamic devices in the removal of a",root canal,sealer from the surface and from simulated irregularities of root canals .,"['OBJECTIVES', 'The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficiency', 'of', 'sonic', ',', 'ultrasonic', ',', 'and', 'hydrodynamic', 'devices', 'in', 'the', 'removal', 'of', 'a', 'root', 'canal', 'sealer', 'from', 'the', 'surface', 'and', 'from', 'simulated', 'irregularities', 'of', 'root', 'canals', '.']","(24, 26)","(131, 141)",-1,ss_p,24317958,Abstract,0,test,gold,1772.0
5526,OBJECTIVES The aim of this study was to compare the efficiency of,"sonic , ultrasonic , and hydrodynamic devices",in the removal of a root canal sealer from the surface and from simulated irregularities of root canals .,"['OBJECTIVES', 'The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficiency', 'of', 'sonic', ',', 'ultrasonic', ',', 'and', 'hydrodynamic', 'devices', 'in', 'the', 'removal', 'of', 'a', 'root', 'canal', 'sealer', 'from', 'the', 'surface', 'and', 'from', 'simulated', 'irregularities', 'of', 'root', 'canals', '.']","(12, 19)","(65, 110)",-1,ss_i,24317958,Abstract,0,test,gold,1751.0
5527,OBJECTIVES The aim of this study was to compare the,efficiency,"of sonic , ultrasonic , and hydrodynamic devices in the removal of a root canal sealer from the surface and from simulated irregularities of root canals .","['OBJECTIVES', 'The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficiency', 'of', 'sonic', ',', 'ultrasonic', ',', 'and', 'hydrodynamic', 'devices', 'in', 'the', 'removal', 'of', 'a', 'root', 'canal', 'sealer', 'from', 'the', 'surface', 'and', 'from', 'simulated', 'irregularities', 'of', 'root', 'canals', '.']","(10, 11)","(51, 61)",-1,ss_o,24317958,Abstract,0,test,gold,1387.0
5528,OBJECTIVES The aim of this study was to compare the efficiency of,"sonic , ultrasonic , and hydrodynamic devices",in the removal of a root canal sealer from the surface and from simulated irregularities of root canals .,"['OBJECTIVES', 'The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficiency', 'of', 'sonic', ',', 'ultrasonic', ',', 'and', 'hydrodynamic', 'devices', 'in', 'the', 'removal', 'of', 'a', 'root', 'canal', 'sealer', 'from', 'the', 'surface', 'and', 'from', 'simulated', 'irregularities', 'of', 'root', 'canals', '.']","(12, 19)","(65, 110)",-1,hl_i,24317958,Abstract,0,test,gold,1752.0
5529,OBJECTIVES The aim of this study was to compare the,efficiency,"of sonic , ultrasonic , and hydrodynamic devices in the removal of a root canal sealer from the surface and from simulated irregularities of root canals .","['OBJECTIVES', 'The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficiency', 'of', 'sonic', ',', 'ultrasonic', ',', 'and', 'hydrodynamic', 'devices', 'in', 'the', 'removal', 'of', 'a', 'root', 'canal', 'sealer', 'from', 'the', 'surface', 'and', 'from', 'simulated', 'irregularities', 'of', 'root', 'canals', '.']","(10, 11)","(51, 61)",-1,hl_o,24317958,Abstract,0,test,gold,1388.0
5530,MATERIALS AND METHODS,Fifty-three root canals with two standardized grooves in the apical and coronal parts of longitudinally split roots,were covered with AH Plus root canal sealer .,"['MATERIALS', 'AND', 'METHODS', 'Fifty-three', 'root', 'canals', 'with', 'two', 'standardized', 'grooves', 'in', 'the', 'apical', 'and', 'coronal', 'parts', 'of', 'longitudinally', 'split', 'roots', 'were', 'covered', 'with', 'AH', 'Plus', 'root', 'canal', 'sealer', '.']","(3, 20)","(21, 136)",-1,ss_p,24317958,Abstract,1,test,gold,5992.0
5531,MATERIALS AND METHODS,Fifty-three root canals with two standardized grooves in the apical and coronal parts of longitudinally split roots,were covered with AH Plus root canal sealer .,"['MATERIALS', 'AND', 'METHODS', 'Fifty-three', 'root', 'canals', 'with', 'two', 'standardized', 'grooves', 'in', 'the', 'apical', 'and', 'coronal', 'parts', 'of', 'longitudinally', 'split', 'roots', 'were', 'covered', 'with', 'AH', 'Plus', 'root', 'canal', 'sealer', '.']","(3, 20)","(21, 136)",-1,hl_p,24317958,Abstract,1,test,gold,5993.0
5532,Compared were the effects of ( control ),syringe irrigation,", ( 1 ) CanalBrush , ( 2 ) passive ultrasonic irrigation , ( 3 ) EndoActivator , and ( 4 ) RinsEndo on the removal of the sealer .","['Compared', 'were', 'the', 'effects', 'of', '(', 'control', ')', 'syringe', 'irrigation', ',', '(', '1', ')', 'CanalBrush', ',', '(', '2', ')', 'passive', 'ultrasonic', 'irrigation', ',', '(', '3', ')', 'EndoActivator', ',', 'and', '(', '4', ')', 'RinsEndo', 'on', 'the', 'removal', 'of', 'the', 'sealer', '.']","(8, 10)","(40, 58)",-1,ss_i,24317958,Abstract,2,test,gold,4907.0
5533,"Compared were the effects of ( control ) syringe irrigation , ( 1 )",CanalBrush,", ( 2 ) passive ultrasonic irrigation , ( 3 ) EndoActivator , and ( 4 ) RinsEndo on the removal of the sealer .","['Compared', 'were', 'the', 'effects', 'of', '(', 'control', ')', 'syringe', 'irrigation', ',', '(', '1', ')', 'CanalBrush', ',', '(', '2', ')', 'passive', 'ultrasonic', 'irrigation', ',', '(', '3', ')', 'EndoActivator', ',', 'and', '(', '4', ')', 'RinsEndo', 'on', 'the', 'removal', 'of', 'the', 'sealer', '.']","(14, 15)","(67, 77)",-1,ss_i,24317958,Abstract,2,test,gold,
5534,"Compared were the effects of ( control ) syringe irrigation , ( 1 ) CanalBrush , ( 2 )",passive ultrasonic irrigation,", ( 3 ) EndoActivator , and ( 4 ) RinsEndo on the removal of the sealer .","['Compared', 'were', 'the', 'effects', 'of', '(', 'control', ')', 'syringe', 'irrigation', ',', '(', '1', ')', 'CanalBrush', ',', '(', '2', ')', 'passive', 'ultrasonic', 'irrigation', ',', '(', '3', ')', 'EndoActivator', ',', 'and', '(', '4', ')', 'RinsEndo', 'on', 'the', 'removal', 'of', 'the', 'sealer', '.']","(19, 22)","(86, 115)",-1,ss_i,24317958,Abstract,2,test,gold,1755.0
5535,"Compared were the effects of ( control ) syringe irrigation , ( 1 ) CanalBrush , ( 2 ) passive ultrasonic irrigation , ( 3 )",EndoActivator,", and ( 4 ) RinsEndo on the removal of the sealer .","['Compared', 'were', 'the', 'effects', 'of', '(', 'control', ')', 'syringe', 'irrigation', ',', '(', '1', ')', 'CanalBrush', ',', '(', '2', ')', 'passive', 'ultrasonic', 'irrigation', ',', '(', '3', ')', 'EndoActivator', ',', 'and', '(', '4', ')', 'RinsEndo', 'on', 'the', 'removal', 'of', 'the', 'sealer', '.']","(26, 27)","(124, 137)",-1,ss_i,24317958,Abstract,2,test,gold,
5536,"Compared were the effects of ( control ) syringe irrigation , ( 1 ) CanalBrush , ( 2 ) passive ultrasonic irrigation , ( 3 ) EndoActivator , and ( 4 )",RinsEndo,on the removal of the sealer .,"['Compared', 'were', 'the', 'effects', 'of', '(', 'control', ')', 'syringe', 'irrigation', ',', '(', '1', ')', 'CanalBrush', ',', '(', '2', ')', 'passive', 'ultrasonic', 'irrigation', ',', '(', '3', ')', 'EndoActivator', ',', 'and', '(', '4', ')', 'RinsEndo', 'on', 'the', 'removal', 'of', 'the', 'sealer', '.']","(32, 33)","(150, 158)",-1,ss_i,24317958,Abstract,2,test,gold,
5537,Compared were the effects of ( control ),syringe irrigation,", ( 1 ) CanalBrush , ( 2 ) passive ultrasonic irrigation , ( 3 ) EndoActivator , and ( 4 ) RinsEndo on the removal of the sealer .","['Compared', 'were', 'the', 'effects', 'of', '(', 'control', ')', 'syringe', 'irrigation', ',', '(', '1', ')', 'CanalBrush', ',', '(', '2', ')', 'passive', 'ultrasonic', 'irrigation', ',', '(', '3', ')', 'EndoActivator', ',', 'and', '(', '4', ')', 'RinsEndo', 'on', 'the', 'removal', 'of', 'the', 'sealer', '.']","(8, 10)","(40, 58)",-1,hl_i,24317958,Abstract,2,test,gold,4908.0
5538,"Compared were the effects of ( control ) syringe irrigation , ( 1 )",CanalBrush,", ( 2 ) passive ultrasonic irrigation , ( 3 ) EndoActivator , and ( 4 ) RinsEndo on the removal of the sealer .","['Compared', 'were', 'the', 'effects', 'of', '(', 'control', ')', 'syringe', 'irrigation', ',', '(', '1', ')', 'CanalBrush', ',', '(', '2', ')', 'passive', 'ultrasonic', 'irrigation', ',', '(', '3', ')', 'EndoActivator', ',', 'and', '(', '4', ')', 'RinsEndo', 'on', 'the', 'removal', 'of', 'the', 'sealer', '.']","(14, 15)","(67, 77)",-1,hl_i,24317958,Abstract,2,test,gold,
5539,"Compared were the effects of ( control ) syringe irrigation , ( 1 ) CanalBrush , ( 2 )",passive ultrasonic irrigation,", ( 3 ) EndoActivator , and ( 4 ) RinsEndo on the removal of the sealer .","['Compared', 'were', 'the', 'effects', 'of', '(', 'control', ')', 'syringe', 'irrigation', ',', '(', '1', ')', 'CanalBrush', ',', '(', '2', ')', 'passive', 'ultrasonic', 'irrigation', ',', '(', '3', ')', 'EndoActivator', ',', 'and', '(', '4', ')', 'RinsEndo', 'on', 'the', 'removal', 'of', 'the', 'sealer', '.']","(19, 22)","(86, 115)",-1,hl_i,24317958,Abstract,2,test,gold,1756.0
5540,"Compared were the effects of ( control ) syringe irrigation , ( 1 ) CanalBrush , ( 2 ) passive ultrasonic irrigation , ( 3 )",EndoActivator,", and ( 4 ) RinsEndo on the removal of the sealer .","['Compared', 'were', 'the', 'effects', 'of', '(', 'control', ')', 'syringe', 'irrigation', ',', '(', '1', ')', 'CanalBrush', ',', '(', '2', ')', 'passive', 'ultrasonic', 'irrigation', ',', '(', '3', ')', 'EndoActivator', ',', 'and', '(', '4', ')', 'RinsEndo', 'on', 'the', 'removal', 'of', 'the', 'sealer', '.']","(26, 27)","(124, 137)",-1,hl_i,24317958,Abstract,2,test,gold,
5541,"Compared were the effects of ( control ) syringe irrigation , ( 1 ) CanalBrush , ( 2 ) passive ultrasonic irrigation , ( 3 ) EndoActivator , and ( 4 )",RinsEndo,on the removal of the sealer .,"['Compared', 'were', 'the', 'effects', 'of', '(', 'control', ')', 'syringe', 'irrigation', ',', '(', '1', ')', 'CanalBrush', ',', '(', '2', ')', 'passive', 'ultrasonic', 'irrigation', ',', '(', '3', ')', 'EndoActivator', ',', 'and', '(', '4', ')', 'RinsEndo', 'on', 'the', 'removal', 'of', 'the', 'sealer', '.']","(32, 33)","(150, 158)",-1,hl_i,24317958,Abstract,2,test,gold,
5542,The specimens were divided into four groups ( N = 12 ) and one control group ( N = 5 ) via,randomization .,,"['The', 'specimens', 'were', 'divided', 'into', 'four', 'groups', '(', 'N', '=', '12', ')', 'and', 'one', 'control', 'group', '(', 'N', '=', '5', ')', 'via', 'randomization', '.']","(22, 24)","(90, 105)",-1,ss_o,24317958,Abstract,3,test,gold,84.0
5543,,The amount of remaining sealer in the root canal irregularities was evaluated under a microscope using a 4-grade scoring,"system , whereas the remaining sealer on the root canal surface was evaluated with a 7-grade scoring system .","['The', 'amount', 'of', 'remaining', 'sealer', 'in', 'the', 'root', 'canal', 'irregularities', 'was', 'evaluated', 'under', 'a', 'microscope', 'using', 'a', '4-grade', 'scoring', 'system', ',', 'whereas', 'the', 'remaining', 'sealer', 'on', 'the', 'root', 'canal', 'surface', 'was', 'evaluated', 'with', 'a', '7-grade', 'scoring', 'system', '.']","(0, 19)","(0, 120)",-1,ss_o,24317958,Abstract,4,test,gold,6368.0
5544,"The amount of remaining sealer in the root canal irregularities was evaluated under a microscope using a 4-grade scoring system ,",whereas the remaining sealer on the root canal surface was evaluated with a 7-grade scoring,system .,"['The', 'amount', 'of', 'remaining', 'sealer', 'in', 'the', 'root', 'canal', 'irregularities', 'was', 'evaluated', 'under', 'a', 'microscope', 'using', 'a', '4-grade', 'scoring', 'system', ',', 'whereas', 'the', 'remaining', 'sealer', 'on', 'the', 'root', 'canal', 'surface', 'was', 'evaluated', 'with', 'a', '7-grade', 'scoring', 'system', '.']","(21, 36)","(129, 220)",-1,ss_o,24317958,Abstract,4,test,gold,6369.0
5545,The,amount of remaining sealer in the root canal irregularities,"was evaluated under a microscope using a 4-grade scoring system , whereas the remaining sealer on the root canal surface was evaluated with a 7-grade scoring system .","['The', 'amount', 'of', 'remaining', 'sealer', 'in', 'the', 'root', 'canal', 'irregularities', 'was', 'evaluated', 'under', 'a', 'microscope', 'using', 'a', '4-grade', 'scoring', 'system', ',', 'whereas', 'the', 'remaining', 'sealer', 'on', 'the', 'root', 'canal', 'surface', 'was', 'evaluated', 'with', 'a', '7-grade', 'scoring', 'system', '.']","(1, 10)","(3, 62)",-1,hl_o,24317958,Abstract,4,test,gold,6365.0
5546,,RESULTS Passive ultrasonic irrigation,is more effective than the other tested irrigation systems or syringe irrigation in removing sealer from root canal walls ( p < 0.01 ) .,"['RESULTS', 'Passive', 'ultrasonic', 'irrigation', 'is', 'more', 'effective', 'than', 'the', 'other', 'tested', 'irrigation', 'systems', 'or', 'syringe', 'irrigation', 'in', 'removing', 'sealer', 'from', 'root', 'canal', 'walls', '(', 'p', '<', '0.01', ')', '.']","(0, 4)","(0, 37)",-1,ss_i,24317958,Abstract,5,test,gold,1753.0
5547,RESULTS Passive ultrasonic irrigation is more effective than the,other tested irrigation systems or syringe irrigation,in removing sealer from root canal walls ( p < 0.01 ) .,"['RESULTS', 'Passive', 'ultrasonic', 'irrigation', 'is', 'more', 'effective', 'than', 'the', 'other', 'tested', 'irrigation', 'systems', 'or', 'syringe', 'irrigation', 'in', 'removing', 'sealer', 'from', 'root', 'canal', 'walls', '(', 'p', '<', '0.01', ')', '.']","(9, 16)","(64, 117)",-1,ss_i,24317958,Abstract,5,test,gold,4904.0
5548,RESULTS Passive ultrasonic irrigation is more effective than the other tested irrigation systems or syringe,irrigation in removing sealer from root canal,walls ( p < 0.01 ) .,"['RESULTS', 'Passive', 'ultrasonic', 'irrigation', 'is', 'more', 'effective', 'than', 'the', 'other', 'tested', 'irrigation', 'systems', 'or', 'syringe', 'irrigation', 'in', 'removing', 'sealer', 'from', 'root', 'canal', 'walls', '(', 'p', '<', '0.01', ')', '.']","(15, 22)","(107, 152)",-1,ss_o,24317958,Abstract,5,test,gold,6366.0
5549,RESULTS,Passive ultrasonic irrigation,is more effective than the other tested irrigation systems or syringe irrigation in removing sealer from root canal walls ( p < 0.01 ) .,"['RESULTS', 'Passive', 'ultrasonic', 'irrigation', 'is', 'more', 'effective', 'than', 'the', 'other', 'tested', 'irrigation', 'systems', 'or', 'syringe', 'irrigation', 'in', 'removing', 'sealer', 'from', 'root', 'canal', 'walls', '(', 'p', '<', '0.01', ')', '.']","(1, 4)","(7, 36)",-1,hl_i,24317958,Abstract,5,test,gold,1754.0
5550,RESULTS Passive ultrasonic irrigation is more effective than the other tested,irrigation systems,or syringe irrigation in removing sealer from root canal walls ( p < 0.01 ) .,"['RESULTS', 'Passive', 'ultrasonic', 'irrigation', 'is', 'more', 'effective', 'than', 'the', 'other', 'tested', 'irrigation', 'systems', 'or', 'syringe', 'irrigation', 'in', 'removing', 'sealer', 'from', 'root', 'canal', 'walls', '(', 'p', '<', '0.01', ')', '.']","(11, 13)","(77, 95)",-1,hl_i,24317958,Abstract,5,test,gold,4905.0
5551,RESULTS Passive ultrasonic irrigation is more effective than the other tested irrigation systems or,syringe irrigation,in removing sealer from root canal walls ( p < 0.01 ) .,"['RESULTS', 'Passive', 'ultrasonic', 'irrigation', 'is', 'more', 'effective', 'than', 'the', 'other', 'tested', 'irrigation', 'systems', 'or', 'syringe', 'irrigation', 'in', 'removing', 'sealer', 'from', 'root', 'canal', 'walls', '(', 'p', '<', '0.01', ')', '.']","(14, 16)","(99, 117)",-1,hl_i,24317958,Abstract,5,test,gold,4906.0
5552,None of the techniques had a,significant effect on cleaning the lateral,grooves .,"['None', 'of', 'the', 'techniques', 'had', 'a', 'significant', 'effect', 'on', 'cleaning', 'the', 'lateral', 'grooves', '.']","(6, 12)","(28, 70)",-1,ss_o,24317958,Abstract,6,test,gold,1797.0
5553,CONCLUSIONS Within the limitations of this,study protocol ultrasonic,irrigation shows a superior effect on sealer removal from the root canal surface during endodontic retreatment .,"['CONCLUSIONS', 'Within', 'the', 'limitations', 'of', 'this', 'study', 'protocol', 'ultrasonic', 'irrigation', 'shows', 'a', 'superior', 'effect', 'on', 'sealer', 'removal', 'from', 'the', 'root', 'canal', 'surface', 'during', 'endodontic', 'retreatment', '.']","(6, 9)","(42, 67)",-1,ss_i,24317958,Abstract,7,test,gold,4104.0
5554,CONCLUSIONS Within the limitations of this study protocol ultrasonic irrigation shows a,superior effect on sealer removal from the root canal,surface during endodontic retreatment .,"['CONCLUSIONS', 'Within', 'the', 'limitations', 'of', 'this', 'study', 'protocol', 'ultrasonic', 'irrigation', 'shows', 'a', 'superior', 'effect', 'on', 'sealer', 'removal', 'from', 'the', 'root', 'canal', 'surface', 'during', 'endodontic', 'retreatment', '.']","(12, 21)","(87, 140)",-1,ss_o,24317958,Abstract,7,test,gold,6367.0
5555,CONCLUSIONS Within the limitations of this study protocol,ultrasonic,irrigation shows a superior effect on sealer removal from the root canal surface during endodontic retreatment .,"['CONCLUSIONS', 'Within', 'the', 'limitations', 'of', 'this', 'study', 'protocol', 'ultrasonic', 'irrigation', 'shows', 'a', 'superior', 'effect', 'on', 'sealer', 'removal', 'from', 'the', 'root', 'canal', 'surface', 'during', 'endodontic', 'retreatment', '.']","(8, 9)","(57, 67)",-1,hl_i,24317958,Abstract,7,test,gold,4105.0
5556,Cleaning of lateral grooves seems not to be possible with one of the techniques investigated .,,,"['Cleaning', 'of', 'lateral', 'grooves', 'seems', 'not', 'to', 'be', 'possible', 'with', 'one', 'of', 'the', 'techniques', 'investigated', '.']",,,,,24317958,Abstract,8,test,gold,
5557,CLINICAL RELEVANCE Incomplete removal of root canal sealer during re-treatment may cause,treatment failure .,,"['CLINICAL', 'RELEVANCE', 'Incomplete', 'removal', 'of', 'root', 'canal', 'sealer', 'during', 're-treatment', 'may', 'cause', 'treatment', 'failure', '.']","(12, 15)","(88, 107)",-1,ss_i,24317958,Abstract,9,test,gold,3988.0
5558,CLINICAL,RELEVANCE Incomplete removal of root canal,sealer during re-treatment may cause treatment failure .,"['CLINICAL', 'RELEVANCE', 'Incomplete', 'removal', 'of', 'root', 'canal', 'sealer', 'during', 're-treatment', 'may', 'cause', 'treatment', 'failure', '.']","(1, 7)","(8, 50)",-1,ss_o,24317958,Abstract,9,test,gold,1769.0
5559,,Passive Ultrasonic,irrigation seems to be the most effective system to remove sealer from a root canal .,"['Passive', 'Ultrasonic', 'irrigation', 'seems', 'to', 'be', 'the', 'most', 'effective', 'system', 'to', 'remove', 'sealer', 'from', 'a', 'root', 'canal', '.']","(0, 2)","(0, 18)",-1,ss_i,24317958,Abstract,10,test,gold,4102.0
5560,Passive Ultrasonic irrigation seems to be the most,effective system to remove sealer from a,root canal .,"['Passive', 'Ultrasonic', 'irrigation', 'seems', 'to', 'be', 'the', 'most', 'effective', 'system', 'to', 'remove', 'sealer', 'from', 'a', 'root', 'canal', '.']","(8, 15)","(50, 90)",-1,ss_o,24317958,Abstract,10,test,gold,1798.0
5561,,Passive Ultrasonic,irrigation seems to be the most effective system to remove sealer from a root canal .,"['Passive', 'Ultrasonic', 'irrigation', 'seems', 'to', 'be', 'the', 'most', 'effective', 'system', 'to', 'remove', 'sealer', 'from', 'a', 'root', 'canal', '.']","(0, 2)","(0, 18)",-1,hl_i,24317958,Abstract,10,test,gold,4103.0
5562,An open-label extension study of the safety and efficacy of risperidone in,children and adolescents with autistic disorder .,,"['An', 'open-label', 'extension', 'study', 'of', 'the', 'safety', 'and', 'efficacy', 'of', 'risperidone', 'in', 'children', 'and', 'adolescents', 'with', 'autistic', 'disorder', '.']","(12, 19)","(74, 123)",-1,ss_p,24350813,Title,0,test,gold,6112.0
5563,An open-label extension study of the safety and efficacy of,risperidone,in children and adolescents with autistic disorder .,"['An', 'open-label', 'extension', 'study', 'of', 'the', 'safety', 'and', 'efficacy', 'of', 'risperidone', 'in', 'children', 'and', 'adolescents', 'with', 'autistic', 'disorder', '.']","(10, 11)","(59, 70)",-1,ss_i,24350813,Title,0,test,gold,5297.0
5564,An open-label extension study of the,safety,and efficacy of risperidone in children and adolescents with autistic disorder .,"['An', 'open-label', 'extension', 'study', 'of', 'the', 'safety', 'and', 'efficacy', 'of', 'risperidone', 'in', 'children', 'and', 'adolescents', 'with', 'autistic', 'disorder', '.']","(6, 7)","(36, 42)",-1,ss_o,24350813,Title,0,test,gold,460.0
5565,An open-label extension study of the safety and,efficacy,of risperidone in children and adolescents with autistic disorder .,"['An', 'open-label', 'extension', 'study', 'of', 'the', 'safety', 'and', 'efficacy', 'of', 'risperidone', 'in', 'children', 'and', 'adolescents', 'with', 'autistic', 'disorder', '.']","(8, 9)","(47, 55)",-1,ss_o,24350813,Title,0,test,gold,4795.0
5566,An open-label extension study of the safety and efficacy of risperidone in,children and adolescents,with autistic disorder .,"['An', 'open-label', 'extension', 'study', 'of', 'the', 'safety', 'and', 'efficacy', 'of', 'risperidone', 'in', 'children', 'and', 'adolescents', 'with', 'autistic', 'disorder', '.']","(12, 15)","(74, 98)",-1,hl_p,24350813,Title,0,test,gold,2107.0
5567,An open-label extension study of the safety and efficacy of risperidone in children and adolescents with,autistic disorder,.,"['An', 'open-label', 'extension', 'study', 'of', 'the', 'safety', 'and', 'efficacy', 'of', 'risperidone', 'in', 'children', 'and', 'adolescents', 'with', 'autistic', 'disorder', '.']","(16, 18)","(104, 121)",-1,hl_p,24350813,Title,0,test,gold,6164.0
5568,An open-label extension study of the safety and efficacy of,risperidone,in children and adolescents with autistic disorder .,"['An', 'open-label', 'extension', 'study', 'of', 'the', 'safety', 'and', 'efficacy', 'of', 'risperidone', 'in', 'children', 'and', 'adolescents', 'with', 'autistic', 'disorder', '.']","(10, 11)","(59, 70)",-1,hl_i,24350813,Title,0,test,gold,5296.0
5569,OBJECTIVE The purpose of this study was to evaluate the long-term safety and efficacy of risperidone in treating irritability and related behaviors in,children and adolescents with autistic disorders .,,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'evaluate', 'the', 'long-term', 'safety', 'and', 'efficacy', 'of', 'risperidone', 'in', 'treating', 'irritability', 'and', 'related', 'behaviors', 'in', 'children', 'and', 'adolescents', 'with', 'autistic', 'disorders', '.']","(23, 30)","(150, 200)",-1,ss_p,24350813,Abstract,0,test,gold,6113.0
5570,OBJECTIVE The purpose of this study was to evaluate the long-term safety and efficacy of,risperidone,in treating irritability and related behaviors in children and adolescents with autistic disorders .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'evaluate', 'the', 'long-term', 'safety', 'and', 'efficacy', 'of', 'risperidone', 'in', 'treating', 'irritability', 'and', 'related', 'behaviors', 'in', 'children', 'and', 'adolescents', 'with', 'autistic', 'disorders', '.']","(15, 16)","(88, 99)",-1,ss_i,24350813,Abstract,0,test,gold,5295.0
5571,OBJECTIVE The purpose of this study was to evaluate the,long-term safety and efficacy,of risperidone in treating irritability and related behaviors in children and adolescents with autistic disorders .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'evaluate', 'the', 'long-term', 'safety', 'and', 'efficacy', 'of', 'risperidone', 'in', 'treating', 'irritability', 'and', 'related', 'behaviors', 'in', 'children', 'and', 'adolescents', 'with', 'autistic', 'disorders', '.']","(10, 14)","(55, 84)",-1,ss_o,24350813,Abstract,0,test,gold,4778.0
5572,OBJECTIVE The purpose of this study was to evaluate the long-term safety and efficacy of risperidone in treating irritability and related behaviors in,children and adolescents,with autistic disorders .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'evaluate', 'the', 'long-term', 'safety', 'and', 'efficacy', 'of', 'risperidone', 'in', 'treating', 'irritability', 'and', 'related', 'behaviors', 'in', 'children', 'and', 'adolescents', 'with', 'autistic', 'disorders', '.']","(23, 26)","(150, 174)",-1,hl_p,24350813,Abstract,0,test,gold,2105.0
5573,OBJECTIVE The purpose of this study was to evaluate the long-term safety and efficacy of risperidone in treating irritability and related behaviors in children and adolescents with,autistic disorders,.,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'evaluate', 'the', 'long-term', 'safety', 'and', 'efficacy', 'of', 'risperidone', 'in', 'treating', 'irritability', 'and', 'related', 'behaviors', 'in', 'children', 'and', 'adolescents', 'with', 'autistic', 'disorders', '.']","(27, 29)","(180, 198)",-1,hl_p,24350813,Abstract,0,test,gold,6162.0
5574,OBJECTIVE The purpose of this study was to evaluate the long-term safety and efficacy of,risperidone,in treating irritability and related behaviors in children and adolescents with autistic disorders .,"['OBJECTIVE', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'evaluate', 'the', 'long-term', 'safety', 'and', 'efficacy', 'of', 'risperidone', 'in', 'treating', 'irritability', 'and', 'related', 'behaviors', 'in', 'children', 'and', 'adolescents', 'with', 'autistic', 'disorders', '.']","(15, 16)","(88, 99)",-1,hl_i,24350813,Abstract,0,test,gold,5294.0
5575,"METHODS In this 6 month ( 26 week ) open-label extension ( OLE ) study ,","patients ( 5-17 years of age , who completed the previous fixed-dose , 6 week , double-blind [ DB ] phase )",were flexibly dosed with risperidone based on body weight .,"['METHODS', 'In', 'this', '6', 'month', '(', '26', 'week', ')', 'open-label', 'extension', '(', 'OLE', ')', 'study', ',', 'patients', '(', '5-17', 'years', 'of', 'age', ',', 'who', 'completed', 'the', 'previous', 'fixed-dose', ',', '6', 'week', ',', 'double-blind', '[', 'DB', ']', 'phase', ')', 'were', 'flexibly', 'dosed', 'with', 'risperidone', 'based', 'on', 'body', 'weight', '.']","(16, 38)","(72, 179)",-1,ss_p,24350813,Abstract,1,test,gold,5861.0
5576,"METHODS In this 6 month ( 26 week ) open-label extension ( OLE ) study , patients ( 5-17 years of age , who completed the previous fixed-dose , 6 week , double-blind [ DB ] phase ) were flexibly dosed with",risperidone,based on body weight .,"['METHODS', 'In', 'this', '6', 'month', '(', '26', 'week', ')', 'open-label', 'extension', '(', 'OLE', ')', 'study', ',', 'patients', '(', '5-17', 'years', 'of', 'age', ',', 'who', 'completed', 'the', 'previous', 'fixed-dose', ',', '6', 'week', ',', 'double-blind', '[', 'DB', ']', 'phase', ')', 'were', 'flexibly', 'dosed', 'with', 'risperidone', 'based', 'on', 'body', 'weight', '.']","(42, 43)","(205, 216)",-1,ss_i,24350813,Abstract,1,test,gold,5293.0
5577,"METHODS In this 6 month ( 26 week ) open-label extension ( OLE ) study , patients (",5-17 years of age,", who completed the previous fixed-dose , 6 week , double-blind [ DB ] phase ) were flexibly dosed with risperidone based on body weight .","['METHODS', 'In', 'this', '6', 'month', '(', '26', 'week', ')', 'open-label', 'extension', '(', 'OLE', ')', 'study', ',', 'patients', '(', '5-17', 'years', 'of', 'age', ',', 'who', 'completed', 'the', 'previous', 'fixed-dose', ',', '6', 'week', ',', 'double-blind', '[', 'DB', ']', 'phase', ')', 'were', 'flexibly', 'dosed', 'with', 'risperidone', 'based', 'on', 'body', 'weight', '.']","(18, 22)","(83, 100)",-1,hl_p,24350813,Abstract,1,test,gold,2021.0
5578,"METHODS In this 6 month ( 26 week ) open-label extension ( OLE ) study , patients ( 5-17 years of age , who completed the previous fixed-dose , 6 week , double-blind [ DB ] phase ) were flexibly dosed with",risperidone,based on body weight .,"['METHODS', 'In', 'this', '6', 'month', '(', '26', 'week', ')', 'open-label', 'extension', '(', 'OLE', ')', 'study', ',', 'patients', '(', '5-17', 'years', 'of', 'age', ',', 'who', 'completed', 'the', 'previous', 'fixed-dose', ',', '6', 'week', ',', 'double-blind', '[', 'DB', ']', 'phase', ')', 'were', 'flexibly', 'dosed', 'with', 'risperidone', 'based', 'on', 'body', 'weight', '.']","(42, 43)","(205, 216)",-1,hl_i,24350813,Abstract,1,test,gold,5292.0
5579,"The maximum allowed dose was 1.25 mg/day for those weighing 20 to < 45 kg , and 1.75 mg/day for those weighing ≥ 45 kg .",,,"['The', 'maximum', 'allowed', 'dose', 'was', '1.25', 'mg/day', 'for', 'those', 'weighing', '20', 'to', '<', '45', 'kg', ',', 'and', '1.75', 'mg/day', 'for', 'those', 'weighing', '≥', '45', 'kg', '.']",,,,,24350813,Abstract,2,test,gold,
5580,The study primarily,assessed risperidone 's,safety ; efficacy was assessed as a secondary end-point .,"['The', 'study', 'primarily', 'assessed', 'risperidone', ""'s"", 'safety', ';', 'efficacy', 'was', 'assessed', 'as', 'a', 'secondary', 'end-point', '.']","(3, 6)","(19, 42)",-1,ss_i,24350813,Abstract,3,test,gold,5288.0
5581,The study primarily assessed,risperidone 's safety ; efficacy,was assessed as a secondary end-point .,"['The', 'study', 'primarily', 'assessed', 'risperidone', ""'s"", 'safety', ';', 'efficacy', 'was', 'assessed', 'as', 'a', 'secondary', 'end-point', '.']","(4, 9)","(28, 60)",-1,ss_o,24350813,Abstract,3,test,gold,4774.0
5582,The study primarily assessed,risperidone,'s safety ; efficacy was assessed as a secondary end-point .,"['The', 'study', 'primarily', 'assessed', 'risperidone', ""'s"", 'safety', ';', 'efficacy', 'was', 'assessed', 'as', 'a', 'secondary', 'end-point', '.']","(4, 5)","(28, 39)",-1,hl_i,24350813,Abstract,3,test,gold,5291.0
5583,The study primarily assessed risperidone 's,safety,; efficacy was assessed as a secondary end-point .,"['The', 'study', 'primarily', 'assessed', 'risperidone', ""'s"", 'safety', ';', 'efficacy', 'was', 'assessed', 'as', 'a', 'secondary', 'end-point', '.']","(6, 7)","(43, 49)",-1,hl_o,24350813,Abstract,3,test,gold,459.0
5584,The study primarily assessed risperidone 's safety ;,efficacy,was assessed as a secondary end-point .,"['The', 'study', 'primarily', 'assessed', 'risperidone', ""'s"", 'safety', ';', 'efficacy', 'was', 'assessed', 'as', 'a', 'secondary', 'end-point', '.']","(8, 9)","(52, 60)",-1,hl_o,24350813,Abstract,3,test,gold,4794.0
5585,,RESULTS Fifty-six ( 71 % ) out of 79 enrolled patients completed the OLE ;,the most common discontinuations were for insufficient response ( 7 [ 9 % ] ) or adverse events ( AE ) ( 5 [ 6 % ] ) .,"['RESULTS', 'Fifty-six', '(', '71', '%', ')', 'out', 'of', '79', 'enrolled', 'patients', 'completed', 'the', 'OLE', ';', 'the', 'most', 'common', 'discontinuations', 'were', 'for', 'insufficient', 'response', '(', '7', '[', '9', '%', ']', ')', 'or', 'adverse', 'events', '(', 'AE', ')', '(', '5', '[', '6', '%', ']', ')', '.']","(0, 15)","(0, 74)",-1,ss_p,24350813,Abstract,4,test,gold,5844.0
5586,RESULTS Fifty-six ( 71 % ) out of 79 enrolled patients completed the OLE ; the most common discontinuations were for insufficient response ( 7 [ 9 % ] ),or adverse events ( AE ),( 5 [ 6 % ] ) .,"['RESULTS', 'Fifty-six', '(', '71', '%', ')', 'out', 'of', '79', 'enrolled', 'patients', 'completed', 'the', 'OLE', ';', 'the', 'most', 'common', 'discontinuations', 'were', 'for', 'insufficient', 'response', '(', '7', '[', '9', '%', ']', ')', 'or', 'adverse', 'events', '(', 'AE', ')', '(', '5', '[', '6', '%', ']', ')', '.']","(30, 36)","(152, 176)",-1,ss_o,24350813,Abstract,4,test,gold,3054.0
5587,RESULTS Fifty-six ( 71 % ) out of 79 enrolled patients completed the OLE ; the most common discontinuations were for insufficient response ( 7 [ 9 % ] ) or,adverse events,( AE ) ( 5 [ 6 % ] ) .,"['RESULTS', 'Fifty-six', '(', '71', '%', ')', 'out', 'of', '79', 'enrolled', 'patients', 'completed', 'the', 'OLE', ';', 'the', 'most', 'common', 'discontinuations', 'were', 'for', 'insufficient', 'response', '(', '7', '[', '9', '%', ']', ')', 'or', 'adverse', 'events', '(', 'AE', ')', '(', '5', '[', '6', '%', ']', ')', '.']","(31, 33)","(155, 169)",-1,hl_o,24350813,Abstract,4,test,gold,3060.0
5588,The most common ( ≥ 5 % frequency in the total,group ),"AEs were increased appetite ( 11 % [ n=9 ] ) ; increased weight and vomiting ( 9 % [ n=7 ] each ) ; sedation , pyrexia , and upper respiratory tract infection ( 8 % [ n=6 ] each ) ; nasopharyngitis ( 6 % [ n=5 ] ) ; and somnolence and fatigue ( 5 % [ n=4 ] each ) .","['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(11, 13)","(46, 53)",-1,ss_o,24350813,Abstract,5,test,gold,1087.0
5589,The most common ( ≥ 5 % frequency in the total group ) AEs,were increased appetite,"( 11 % [ n=9 ] ) ; increased weight and vomiting ( 9 % [ n=7 ] each ) ; sedation , pyrexia , and upper respiratory tract infection ( 8 % [ n=6 ] each ) ; nasopharyngitis ( 6 % [ n=5 ] ) ; and somnolence and fatigue ( 5 % [ n=4 ] each ) .","['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(14, 17)","(58, 81)",-1,ss_o,24350813,Abstract,5,test,gold,1911.0
5590,The most common ( ≥ 5 % frequency in the total group ) AEs were increased appetite ( 11 %,[ n=9 ] ) ; increased weight and vomiting,"( 9 % [ n=7 ] each ) ; sedation , pyrexia , and upper respiratory tract infection ( 8 % [ n=6 ] each ) ; nasopharyngitis ( 6 % [ n=5 ] ) ; and somnolence and fatigue ( 5 % [ n=4 ] each ) .","['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(20, 29)","(89, 130)",-1,ss_o,24350813,Abstract,5,test,gold,1907.0
5591,The most common ( ≥ 5 % frequency in the total group ) AEs were increased appetite ( 11 % [ n=9 ] ) ; increased weight and vomiting ( 9 % [ n=7 ],"each ) ; sedation , pyrexia , and upper respiratory tract infection",( 8 % [ n=6 ] each ) ; nasopharyngitis ( 6 % [ n=5 ] ) ; and somnolence and fatigue ( 5 % [ n=4 ] each ) .,"['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(35, 47)","(145, 212)",-1,ss_o,24350813,Abstract,5,test,gold,7108.0
5592,"The most common ( ≥ 5 % frequency in the total group ) AEs were increased appetite ( 11 % [ n=9 ] ) ; increased weight and vomiting ( 9 % [ n=7 ] each ) ; sedation , pyrexia , and upper respiratory tract infection ( 8 % [ n=6 ]",each ) ; nasopharyngitis,( 6 % [ n=5 ] ) ; and somnolence and fatigue ( 5 % [ n=4 ] each ) .,"['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(53, 57)","(227, 251)",-1,ss_o,24350813,Abstract,5,test,gold,3514.0
5593,"The most common ( ≥ 5 % frequency in the total group ) AEs were increased appetite ( 11 % [ n=9 ] ) ; increased weight and vomiting ( 9 % [ n=7 ] each ) ; sedation , pyrexia , and upper respiratory tract infection ( 8 % [ n=6 ] each ) ; nasopharyngitis ( 6 % [ n=5 ] ) ;",and somnolence and fatigue,( 5 % [ n=4 ] each ) .,"['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(65, 69)","(270, 296)",-1,ss_o,24350813,Abstract,5,test,gold,3508.0
5594,"The most common ( ≥ 5 % frequency in the total group ) AEs were increased appetite ( 11 % [ n=9 ] ) ; increased weight and vomiting ( 9 % [ n=7 ] each ) ; sedation , pyrexia , and upper respiratory tract infection ( 8 % [ n=6 ] each ) ; nasopharyngitis ( 6 % [ n=5 ] ) ; and somnolence and fatigue ( 5 % [ n=4 ]",each ) .,,"['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(75, 78)","(311, 319)",-1,ss_o,24350813,Abstract,5,test,gold,1182.0
5595,The most common ( ≥ 5 % frequency in the total group ) AEs were,increased appetite,"( 11 % [ n=9 ] ) ; increased weight and vomiting ( 9 % [ n=7 ] each ) ; sedation , pyrexia , and upper respiratory tract infection ( 8 % [ n=6 ] each ) ; nasopharyngitis ( 6 % [ n=5 ] ) ; and somnolence and fatigue ( 5 % [ n=4 ] each ) .","['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(15, 17)","(63, 81)",-1,hl_o,24350813,Abstract,5,test,gold,1912.0
5596,The most common ( ≥ 5 % frequency in the total group ) AEs were increased appetite ( 11 % [ n=9 ] ) ;,increased weight,"and vomiting ( 9 % [ n=7 ] each ) ; sedation , pyrexia , and upper respiratory tract infection ( 8 % [ n=6 ] each ) ; nasopharyngitis ( 6 % [ n=5 ] ) ; and somnolence and fatigue ( 5 % [ n=4 ] each ) .","['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(25, 27)","(101, 117)",-1,hl_o,24350813,Abstract,5,test,gold,1909.0
5597,The most common ( ≥ 5 % frequency in the total group ) AEs were increased appetite ( 11 % [ n=9 ] ) ; increased weight and,vomiting,"( 9 % [ n=7 ] each ) ; sedation , pyrexia , and upper respiratory tract infection ( 8 % [ n=6 ] each ) ; nasopharyngitis ( 6 % [ n=5 ] ) ; and somnolence and fatigue ( 5 % [ n=4 ] each ) .","['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(28, 29)","(122, 130)",-1,hl_o,24350813,Abstract,5,test,gold,2689.0
5598,The most common ( ≥ 5 % frequency in the total group ) AEs were increased appetite ( 11 % [ n=9 ] ) ; increased weight and vomiting ( 9 % [ n=7 ] each ) ;,sedation,", pyrexia , and upper respiratory tract infection ( 8 % [ n=6 ] each ) ; nasopharyngitis ( 6 % [ n=5 ] ) ; and somnolence and fatigue ( 5 % [ n=4 ] each ) .","['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(38, 39)","(154, 162)",-1,hl_o,24350813,Abstract,5,test,gold,4122.0
5599,"The most common ( ≥ 5 % frequency in the total group ) AEs were increased appetite ( 11 % [ n=9 ] ) ; increased weight and vomiting ( 9 % [ n=7 ] each ) ; sedation ,",pyrexia,", and upper respiratory tract infection ( 8 % [ n=6 ] each ) ; nasopharyngitis ( 6 % [ n=5 ] ) ; and somnolence and fatigue ( 5 % [ n=4 ] each ) .","['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(40, 41)","(165, 172)",-1,hl_o,24350813,Abstract,5,test,gold,3513.0
5600,"The most common ( ≥ 5 % frequency in the total group ) AEs were increased appetite ( 11 % [ n=9 ] ) ; increased weight and vomiting ( 9 % [ n=7 ] each ) ; sedation , pyrexia , and",upper respiratory tract infection,( 8 % [ n=6 ] each ) ; nasopharyngitis ( 6 % [ n=5 ] ) ; and somnolence and fatigue ( 5 % [ n=4 ] each ) .,"['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(43, 47)","(179, 212)",-1,hl_o,24350813,Abstract,5,test,gold,3579.0
5601,"The most common ( ≥ 5 % frequency in the total group ) AEs were increased appetite ( 11 % [ n=9 ] ) ; increased weight and vomiting ( 9 % [ n=7 ] each ) ; sedation , pyrexia , and upper respiratory tract infection ( 8 % [ n=6 ] each ) ;",nasopharyngitis,( 6 % [ n=5 ] ) ; and somnolence and fatigue ( 5 % [ n=4 ] each ) .,"['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(56, 57)","(236, 251)",-1,hl_o,24350813,Abstract,5,test,gold,3515.0
5602,"The most common ( ≥ 5 % frequency in the total group ) AEs were increased appetite ( 11 % [ n=9 ] ) ; increased weight and vomiting ( 9 % [ n=7 ] each ) ; sedation , pyrexia , and upper respiratory tract infection ( 8 % [ n=6 ] each ) ; nasopharyngitis ( 6 % [ n=5 ] ) ; and",somnolence,and fatigue ( 5 % [ n=4 ] each ) .,"['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(66, 67)","(274, 284)",-1,hl_o,24350813,Abstract,5,test,gold,3509.0
5603,"The most common ( ≥ 5 % frequency in the total group ) AEs were increased appetite ( 11 % [ n=9 ] ) ; increased weight and vomiting ( 9 % [ n=7 ] each ) ; sedation , pyrexia , and upper respiratory tract infection ( 8 % [ n=6 ] each ) ; nasopharyngitis ( 6 % [ n=5 ] ) ; and somnolence and",fatigue,( 5 % [ n=4 ] each ) .,"['The', 'most', 'common', '(', '≥', '5', '%', 'frequency', 'in', 'the', 'total', 'group', ')', 'AEs', 'were', 'increased', 'appetite', '(', '11', '%', '[', 'n=9', ']', ')', ';', 'increased', 'weight', 'and', 'vomiting', '(', '9', '%', '[', 'n=7', ']', 'each', ')', ';', 'sedation', ',', 'pyrexia', ',', 'and', 'upper', 'respiratory', 'tract', 'infection', '(', '8', '%', '[', 'n=6', ']', 'each', ')', ';', 'nasopharyngitis', '(', '6', '%', '[', 'n=5', ']', ')', ';', 'and', 'somnolence', 'and', 'fatigue', '(', '5', '%', '[', 'n=4', ']', 'each', ')', '.']","(68, 69)","(289, 296)",-1,hl_o,24350813,Abstract,5,test,gold,2702.0
5604,,Extrapyramidal,AEs were reported in 6 ( 8 % ) patients .,"['Extrapyramidal', 'AEs', 'were', 'reported', 'in', '6', '(', '8', '%', ')', 'patients', '.']","(0, 1)","(0, 14)",-1,ss_o,24350813,Abstract,6,test,gold,
5605,Extrapyramidal AEs were reported in 6 ( 8 % ),patients .,,"['Extrapyramidal', 'AEs', 'were', 'reported', 'in', '6', '(', '8', '%', ')', 'patients', '.']","(10, 12)","(45, 55)",-1,ss_o,24350813,Abstract,6,test,gold,3741.0
5606,,Extrapyramidal,AEs were reported in 6 ( 8 % ) patients .,"['Extrapyramidal', 'AEs', 'were', 'reported', 'in', '6', '(', '8', '%', ')', 'patients', '.']","(0, 1)","(0, 14)",-1,hl_o,24350813,Abstract,6,test,gold,
5607,,Increase in mean weight,( 11-15 % ) and body mass index ( 5-10 % ) occurred ; one patient discontinued because of weight increase .,"['Increase', 'in', 'mean', 'weight', '(', '11-15', '%', ')', 'and', 'body', 'mass', 'index', '(', '5-10', '%', ')', 'occurred', ';', 'one', 'patient', 'discontinued', 'because', 'of', 'weight', 'increase', '.']","(0, 4)","(0, 23)",-1,ss_o,24350813,Abstract,7,test,gold,1906.0
5608,Increase in mean weight ( 11-15 % ),and body mass index,( 5-10 % ) occurred ; one patient discontinued because of weight increase .,"['Increase', 'in', 'mean', 'weight', '(', '11-15', '%', ')', 'and', 'body', 'mass', 'index', '(', '5-10', '%', ')', 'occurred', ';', 'one', 'patient', 'discontinued', 'because', 'of', 'weight', 'increase', '.']","(8, 12)","(35, 54)",-1,ss_o,24350813,Abstract,7,test,gold,1996.0
5609,Increase in mean weight ( 11-15 % ) and body mass index ( 5-10 % ) occurred ; one patient discontinued,because of weight increase,.,"['Increase', 'in', 'mean', 'weight', '(', '11-15', '%', ')', 'and', 'body', 'mass', 'index', '(', '5-10', '%', ')', 'occurred', ';', 'one', 'patient', 'discontinued', 'because', 'of', 'weight', 'increase', '.']","(21, 25)","(102, 128)",-1,ss_o,24350813,Abstract,7,test,gold,1910.0
5610,Increase in mean weight ( 11-15 % ) and body mass index ( 5-10 % ) occurred ; one patient discontinued because of,weight,increase .,"['Increase', 'in', 'mean', 'weight', '(', '11-15', '%', ')', 'and', 'body', 'mass', 'index', '(', '5-10', '%', ')', 'occurred', ';', 'one', 'patient', 'discontinued', 'because', 'of', 'weight', 'increase', '.']","(23, 24)","(113, 119)",-1,hl_o,24350813,Abstract,7,test,gold,1908.0
5611,One,potentially prolactin-related AE ( irregular menstruation ),was reported .,"['One', 'potentially', 'prolactin-related', 'AE', '(', 'irregular', 'menstruation', ')', 'was', 'reported', '.']","(1, 8)","(3, 62)",-1,ss_o,24350813,Abstract,8,test,gold,3190.0
5612,One potentially,prolactin-related AE,( irregular menstruation ) was reported .,"['One', 'potentially', 'prolactin-related', 'AE', '(', 'irregular', 'menstruation', ')', 'was', 'reported', '.']","(2, 4)","(15, 35)",-1,hl_o,24350813,Abstract,8,test,gold,699.0
5613,One potentially prolactin-related AE (,irregular menstruation,) was reported .,"['One', 'potentially', 'prolactin-related', 'AE', '(', 'irregular', 'menstruation', ')', 'was', 'reported', '.']","(5, 7)","(38, 60)",-1,hl_o,24350813,Abstract,8,test,gold,3191.0
5614,,The risperidone,high-dose group had the greatest mean improvement in sleep visual analog scale ( 24.6 ) .,"['The', 'risperidone', 'high-dose', 'group', 'had', 'the', 'greatest', 'mean', 'improvement', 'in', 'sleep', 'visual', 'analog', 'scale', '(', '24.6', ')', '.']","(0, 2)","(0, 15)",-1,ss_i,24350813,Abstract,9,test,gold,5289.0
5615,The risperidone high-dose group had the,greatest mean improvement in sleep visual analog scale,( 24.6 ) .,"['The', 'risperidone', 'high-dose', 'group', 'had', 'the', 'greatest', 'mean', 'improvement', 'in', 'sleep', 'visual', 'analog', 'scale', '(', '24.6', ')', '.']","(6, 14)","(39, 93)",-1,ss_o,24350813,Abstract,9,test,gold,6435.0
5616,The,risperidone,high-dose group had the greatest mean improvement in sleep visual analog scale ( 24.6 ) .,"['The', 'risperidone', 'high-dose', 'group', 'had', 'the', 'greatest', 'mean', 'improvement', 'in', 'sleep', 'visual', 'analog', 'scale', '(', '24.6', ')', '.']","(1, 2)","(3, 14)",-1,hl_i,24350813,Abstract,9,test,gold,5290.0
5617,The risperidone high-dose group had the greatest mean improvement in,sleep visual analog scale,( 24.6 ) .,"['The', 'risperidone', 'high-dose', 'group', 'had', 'the', 'greatest', 'mean', 'improvement', 'in', 'sleep', 'visual', 'analog', 'scale', '(', '24.6', ')', '.']","(10, 14)","(68, 93)",-1,hl_o,24350813,Abstract,9,test,gold,6436.0
5618,All groups showed additional,improvement in efficacy scale scores,during the OLE .,"['All', 'groups', 'showed', 'additional', 'improvement', 'in', 'efficacy', 'scale', 'scores', 'during', 'the', 'OLE', '.']","(4, 9)","(28, 64)",-1,ss_o,24350813,Abstract,10,test,gold,3883.0
5619,All groups showed additional improvement in,efficacy,scale scores during the OLE .,"['All', 'groups', 'showed', 'additional', 'improvement', 'in', 'efficacy', 'scale', 'scores', 'during', 'the', 'OLE', '.']","(6, 7)","(43, 51)",-1,hl_o,24350813,Abstract,10,test,gold,4793.0
5620,"CONCLUSIONS During this OLE , safety findings",with risperidone,"treatment ( maximum weight-based dose of 1.25 mg/day or 1.75 mg/day ) were consistent with those observed in the DB phase , and with the current safety information for risperidone in autistic , psychiatric , and behavioral disorders .","['CONCLUSIONS', 'During', 'this', 'OLE', ',', 'safety', 'findings', 'with', 'risperidone', 'treatment', '(', 'maximum', 'weight-based', 'dose', 'of', '1.25', 'mg/day', 'or', '1.75', 'mg/day', ')', 'were', 'consistent', 'with', 'those', 'observed', 'in', 'the', 'DB', 'phase', ',', 'and', 'with', 'the', 'current', 'safety', 'information', 'for', 'risperidone', 'in', 'autistic', ',', 'psychiatric', ',', 'and', 'behavioral', 'disorders', '.']","(7, 9)","(45, 61)",-1,ss_i,24350813,Abstract,11,test,gold,5304.0
5621,"CONCLUSIONS During this OLE , safety findings with risperidone treatment ( maximum weight-based dose of 1.25 mg/day or 1.75 mg/day ) were consistent with those observed in the DB phase , and with the current safety information",for risperidone,"in autistic , psychiatric , and behavioral disorders .","['CONCLUSIONS', 'During', 'this', 'OLE', ',', 'safety', 'findings', 'with', 'risperidone', 'treatment', '(', 'maximum', 'weight-based', 'dose', 'of', '1.25', 'mg/day', 'or', '1.75', 'mg/day', ')', 'were', 'consistent', 'with', 'those', 'observed', 'in', 'the', 'DB', 'phase', ',', 'and', 'with', 'the', 'current', 'safety', 'information', 'for', 'risperidone', 'in', 'autistic', ',', 'psychiatric', ',', 'and', 'behavioral', 'disorders', '.']","(37, 39)","(226, 241)",-1,ss_i,24350813,Abstract,11,test,gold,5305.0
5622,CONCLUSIONS During this,"OLE , safety","findings with risperidone treatment ( maximum weight-based dose of 1.25 mg/day or 1.75 mg/day ) were consistent with those observed in the DB phase , and with the current safety information for risperidone in autistic , psychiatric , and behavioral disorders .","['CONCLUSIONS', 'During', 'this', 'OLE', ',', 'safety', 'findings', 'with', 'risperidone', 'treatment', '(', 'maximum', 'weight-based', 'dose', 'of', '1.25', 'mg/day', 'or', '1.75', 'mg/day', ')', 'were', 'consistent', 'with', 'those', 'observed', 'in', 'the', 'DB', 'phase', ',', 'and', 'with', 'the', 'current', 'safety', 'information', 'for', 'risperidone', 'in', 'autistic', ',', 'psychiatric', ',', 'and', 'behavioral', 'disorders', '.']","(3, 6)","(23, 35)",-1,ss_o,24350813,Abstract,11,test,gold,450.0
5623,"CONCLUSIONS During this OLE , safety findings with risperidone treatment ( maximum weight-based dose of 1.25 mg/day or 1.75 mg/day ) were consistent with those observed in the DB phase , and with the",current safety,"information for risperidone in autistic , psychiatric , and behavioral disorders .","['CONCLUSIONS', 'During', 'this', 'OLE', ',', 'safety', 'findings', 'with', 'risperidone', 'treatment', '(', 'maximum', 'weight-based', 'dose', 'of', '1.25', 'mg/day', 'or', '1.75', 'mg/day', ')', 'were', 'consistent', 'with', 'those', 'observed', 'in', 'the', 'DB', 'phase', ',', 'and', 'with', 'the', 'current', 'safety', 'information', 'for', 'risperidone', 'in', 'autistic', ',', 'psychiatric', ',', 'and', 'behavioral', 'disorders', '.']","(34, 36)","(199, 213)",-1,ss_o,24350813,Abstract,11,test,gold,452.0
5624,Patients experienced some additional,improvement in irritability and related behaviors,.,"['Patients', 'experienced', 'some', 'additional', 'improvement', 'in', 'irritability', 'and', 'related', 'behaviors', '.']","(4, 10)","(36, 85)",-1,ss_o,24350813,Abstract,12,test,gold,6378.0
5625,CLINICAL TRIALS REGISTRY This phase-4 study is registered at ClinicalTrials.gov ( NCT00576732 ) .,,,"['CLINICAL', 'TRIALS', 'REGISTRY', 'This', 'phase-4', 'study', 'is', 'registered', 'at', 'ClinicalTrials.gov', '(', 'NCT00576732', ')', '.']",,,,,24350813,Abstract,13,test,gold,
5626,Inverse Effect of Fluoxetine on Medial Prefrontal Cortex Activation During Reward Reversal in,ADHD and Autism .,,"['Inverse', 'Effect', 'of', 'Fluoxetine', 'on', 'Medial', 'Prefrontal', 'Cortex', 'Activation', 'During', 'Reward', 'Reversal', 'in', 'ADHD', 'and', 'Autism', '.']","(13, 17)","(93, 110)",-1,ss_p,24451919,Title,0,test,gold,6170.0
5627,Inverse Effect of,Fluoxetine,on Medial Prefrontal Cortex Activation During Reward Reversal in ADHD and Autism .,"['Inverse', 'Effect', 'of', 'Fluoxetine', 'on', 'Medial', 'Prefrontal', 'Cortex', 'Activation', 'During', 'Reward', 'Reversal', 'in', 'ADHD', 'and', 'Autism', '.']","(3, 4)","(17, 27)",-1,ss_i,24451919,Title,0,test,gold,5547.0
5628,Inverse Effect of Fluoxetine on,Medial Prefrontal Cortex Activation,During Reward Reversal in ADHD and Autism .,"['Inverse', 'Effect', 'of', 'Fluoxetine', 'on', 'Medial', 'Prefrontal', 'Cortex', 'Activation', 'During', 'Reward', 'Reversal', 'in', 'ADHD', 'and', 'Autism', '.']","(5, 9)","(31, 66)",-1,ss_o,24451919,Title,0,test,gold,4099.0
5629,Inverse Effect of Fluoxetine on Medial Prefrontal Cortex Activation During Reward Reversal in,ADHD and Autism .,,"['Inverse', 'Effect', 'of', 'Fluoxetine', 'on', 'Medial', 'Prefrontal', 'Cortex', 'Activation', 'During', 'Reward', 'Reversal', 'in', 'ADHD', 'and', 'Autism', '.']","(13, 17)","(93, 110)",-1,hl_p,24451919,Title,0,test,gold,6171.0
5630,Inverse Effect of,Fluoxetine,on Medial Prefrontal Cortex Activation During Reward Reversal in ADHD and Autism .,"['Inverse', 'Effect', 'of', 'Fluoxetine', 'on', 'Medial', 'Prefrontal', 'Cortex', 'Activation', 'During', 'Reward', 'Reversal', 'in', 'ADHD', 'and', 'Autism', '.']","(3, 4)","(17, 27)",-1,hl_i,24451919,Title,0,test,gold,5548.0
5631,,Attention deficit hyperactivity disorder ( ADHD ) and autism spectrum disorder ( ASD ),share brain function abnormalities during cognitive flexibility .,"['Attention', 'deficit', 'hyperactivity', 'disorder', '(', 'ADHD', ')', 'and', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'share', 'brain', 'function', 'abnormalities', 'during', 'cognitive', 'flexibility', '.']","(0, 14)","(0, 86)",-1,ss_p,24451919,Abstract,0,test,gold,6054.0
5632,,Attention deficit hyperactivity disorder ( ADHD ) and autism spectrum disorder ( ASD ),share brain function abnormalities during cognitive flexibility .,"['Attention', 'deficit', 'hyperactivity', 'disorder', '(', 'ADHD', ')', 'and', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'share', 'brain', 'function', 'abnormalities', 'during', 'cognitive', 'flexibility', '.']","(0, 14)","(0, 86)",-1,hl_p,24451919,Abstract,0,test,gold,6055.0
5633,"Serotonin is involved in both disorders , and selective serotonin reuptake inhibitors ( SSRIs ) can modulate cognitive flexibility and improve behavior in both disorders .",,,"['Serotonin', 'is', 'involved', 'in', 'both', 'disorders', ',', 'and', 'selective', 'serotonin', 'reuptake', 'inhibitors', '(', 'SSRIs', ')', 'can', 'modulate', 'cognitive', 'flexibility', 'and', 'improve', 'behavior', 'in', 'both', 'disorders', '.']",,,,,24451919,Abstract,1,test,gold,
5634,"Thus , this study investigates",shared and disorder-specific brain dysfunctions,"in these 2 disorders during reward reversal , and the acute effects of an SSRI on these .","['Thus', ',', 'this', 'study', 'investigates', 'shared', 'and', 'disorder-specific', 'brain', 'dysfunctions', 'in', 'these', '2', 'disorders', 'during', 'reward', 'reversal', ',', 'and', 'the', 'acute', 'effects', 'of', 'an', 'SSRI', 'on', 'these', '.']","(5, 10)","(30, 77)",-1,ss_o,24451919,Abstract,2,test,gold,2898.0
5635,,"Age-matched boys with ADHD ( 15 ) , ASD ( 18 ) , and controls ( 21 )",were compared with functional magnetic resonance imaging ( fMRI ) during a reversal task .,"['Age-matched', 'boys', 'with', 'ADHD', '(', '15', ')', ',', 'ASD', '(', '18', ')', ',', 'and', 'controls', '(', '21', ')', 'were', 'compared', 'with', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', 'during', 'a', 'reversal', 'task', '.']","(0, 18)","(0, 68)",-1,ss_p,24451919,Abstract,3,test,gold,6172.0
5636,"Age-matched boys with ADHD ( 15 ) , ASD ( 18 ) , and controls ( 21 ) were compared with",functional magnetic resonance imaging ( fMRI ),during a reversal task .,"['Age-matched', 'boys', 'with', 'ADHD', '(', '15', ')', ',', 'ASD', '(', '18', ')', ',', 'and', 'controls', '(', '21', ')', 'were', 'compared', 'with', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', 'during', 'a', 'reversal', 'task', '.']","(21, 28)","(87, 133)",-1,ss_o,24451919,Abstract,3,test,gold,6490.0
5637,Age-matched boys with ADHD (,15,") , ASD ( 18 ) , and controls ( 21 ) were compared with functional magnetic resonance imaging ( fMRI ) during a reversal task .","['Age-matched', 'boys', 'with', 'ADHD', '(', '15', ')', ',', 'ASD', '(', '18', ')', ',', 'and', 'controls', '(', '21', ')', 'were', 'compared', 'with', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', 'during', 'a', 'reversal', 'task', '.']","(5, 6)","(28, 30)",-1,hl_p,24451919,Abstract,3,test,gold,
5638,"Age-matched boys with ADHD ( 15 ) , ASD (",18,") , and controls ( 21 ) were compared with functional magnetic resonance imaging ( fMRI ) during a reversal task .","['Age-matched', 'boys', 'with', 'ADHD', '(', '15', ')', ',', 'ASD', '(', '18', ')', ',', 'and', 'controls', '(', '21', ')', 'were', 'compared', 'with', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', 'during', 'a', 'reversal', 'task', '.']","(10, 11)","(41, 43)",-1,hl_p,24451919,Abstract,3,test,gold,
5639,"Age-matched boys with ADHD ( 15 ) , ASD ( 18 ) , and controls (",21,) were compared with functional magnetic resonance imaging ( fMRI ) during a reversal task .,"['Age-matched', 'boys', 'with', 'ADHD', '(', '15', ')', ',', 'ASD', '(', '18', ')', ',', 'and', 'controls', '(', '21', ')', 'were', 'compared', 'with', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', 'during', 'a', 'reversal', 'task', '.']","(16, 17)","(63, 65)",-1,hl_p,24451919,Abstract,3,test,gold,
5640,"Patients were scanned twice , under either an acute dose of",Fluoxetine,"or placebo in a double-blind , placebo-controlled randomized design .","['Patients', 'were', 'scanned', 'twice', ',', 'under', 'either', 'an', 'acute', 'dose', 'of', 'Fluoxetine', 'or', 'placebo', 'in', 'a', 'double-blind', ',', 'placebo-controlled', 'randomized', 'design', '.']","(11, 12)","(59, 69)",-1,ss_i,24451919,Abstract,4,test,gold,5546.0
5641,"Patients were scanned twice , under either an acute dose of Fluoxetine or",placebo,"in a double-blind , placebo-controlled randomized design .","['Patients', 'were', 'scanned', 'twice', ',', 'under', 'either', 'an', 'acute', 'dose', 'of', 'Fluoxetine', 'or', 'placebo', 'in', 'a', 'double-blind', ',', 'placebo-controlled', 'randomized', 'design', '.']","(13, 14)","(73, 80)",-1,ss_i,24451919,Abstract,4,test,gold,4334.0
5642,"Patients were scanned twice , under either an acute dose of",Fluoxetine,"or placebo in a double-blind , placebo-controlled randomized design .","['Patients', 'were', 'scanned', 'twice', ',', 'under', 'either', 'an', 'acute', 'dose', 'of', 'Fluoxetine', 'or', 'placebo', 'in', 'a', 'double-blind', ',', 'placebo-controlled', 'randomized', 'design', '.']","(11, 12)","(59, 69)",-1,hl_i,24451919,Abstract,4,test,gold,5545.0
5643,"Patients were scanned twice , under either an acute dose of Fluoxetine or",placebo,"in a double-blind , placebo-controlled randomized design .","['Patients', 'were', 'scanned', 'twice', ',', 'under', 'either', 'an', 'acute', 'dose', 'of', 'Fluoxetine', 'or', 'placebo', 'in', 'a', 'double-blind', ',', 'placebo-controlled', 'randomized', 'design', '.']","(13, 14)","(73, 80)",-1,hl_i,24451919,Abstract,4,test,gold,4333.0
5644,Repeated-measures analyses within patients assessed drug effects .,,,"['Repeated-measures', 'analyses', 'within', 'patients', 'assessed', 'drug', 'effects', '.']",,,,,24451919,Abstract,5,test,gold,
5645,Patients under each drug condition were compared with controls to assess normalization effects .,,,"['Patients', 'under', 'each', 'drug', 'condition', 'were', 'compared', 'with', 'controls', 'to', 'assess', 'normalization', 'effects', '.']",,,,,24451919,Abstract,6,test,gold,
5646,"fMRI data showed that , under",placebo,", ASD boys underactivated medial prefrontal cortex ( mPFC ) , compared with control and ADHD boys .","['fMRI', 'data', 'showed', 'that', ',', 'under', 'placebo', ',', 'ASD', 'boys', 'underactivated', 'medial', 'prefrontal', 'cortex', '(', 'mPFC', ')', ',', 'compared', 'with', 'control', 'and', 'ADHD', 'boys', '.']","(6, 7)","(29, 36)",-1,ss_i,24451919,Abstract,7,test,gold,4332.0
5647,,fMRI,"data showed that , under placebo , ASD boys underactivated medial prefrontal cortex ( mPFC ) , compared with control and ADHD boys .","['fMRI', 'data', 'showed', 'that', ',', 'under', 'placebo', ',', 'ASD', 'boys', 'underactivated', 'medial', 'prefrontal', 'cortex', '(', 'mPFC', ')', ',', 'compared', 'with', 'control', 'and', 'ADHD', 'boys', '.']","(0, 1)","(0, 4)",-1,ss_o,24451919,Abstract,7,test,gold,2575.0
5648,"fMRI data showed that , under placebo , ASD boys underactivated",medial prefrontal cortex ( mPFC ),", compared with control and ADHD boys .","['fMRI', 'data', 'showed', 'that', ',', 'under', 'placebo', ',', 'ASD', 'boys', 'underactivated', 'medial', 'prefrontal', 'cortex', '(', 'mPFC', ')', ',', 'compared', 'with', 'control', 'and', 'ADHD', 'boys', '.']","(11, 17)","(63, 96)",-1,ss_o,24451919,Abstract,7,test,gold,6634.0
5649,"fMRI data showed that , under",placebo,", ASD boys underactivated medial prefrontal cortex ( mPFC ) , compared with control and ADHD boys .","['fMRI', 'data', 'showed', 'that', ',', 'under', 'placebo', ',', 'ASD', 'boys', 'underactivated', 'medial', 'prefrontal', 'cortex', '(', 'mPFC', ')', ',', 'compared', 'with', 'control', 'and', 'ADHD', 'boys', '.']","(6, 7)","(29, 36)",-1,hl_i,24451919,Abstract,7,test,gold,4331.0
5650,"fMRI data showed that , under placebo , ASD boys underactivated",medial prefrontal cortex ( mPFC ),", compared with control and ADHD boys .","['fMRI', 'data', 'showed', 'that', ',', 'under', 'placebo', ',', 'ASD', 'boys', 'underactivated', 'medial', 'prefrontal', 'cortex', '(', 'mPFC', ')', ',', 'compared', 'with', 'control', 'and', 'ADHD', 'boys', '.']","(11, 17)","(63, 96)",-1,hl_o,24451919,Abstract,7,test,gold,6635.0
5651,Both patient groups shared decreased,precuneus activation .,,"['Both', 'patient', 'groups', 'shared', 'decreased', 'precuneus', 'activation', '.']","(5, 8)","(36, 58)",-1,ss_o,24451919,Abstract,8,test,gold,2896.0
5652,Both patient groups shared decreased,precuneus activation .,,"['Both', 'patient', 'groups', 'shared', 'decreased', 'precuneus', 'activation', '.']","(5, 8)","(36, 58)",-1,hl_o,24451919,Abstract,8,test,gold,2897.0
5653,Under,Fluoxetine,", mPFC activation was up-regulated and normalized in ASD boys relative to controls , but down-regulated in ADHD boys relative to placebo , which was concomitant with worse task performance in ADHD .","['Under', 'Fluoxetine', ',', 'mPFC', 'activation', 'was', 'up-regulated', 'and', 'normalized', 'in', 'ASD', 'boys', 'relative', 'to', 'controls', ',', 'but', 'down-regulated', 'in', 'ADHD', 'boys', 'relative', 'to', 'placebo', ',', 'which', 'was', 'concomitant', 'with', 'worse', 'task', 'performance', 'in', 'ADHD', '.']","(1, 2)","(5, 15)",-1,ss_i,24451919,Abstract,9,test,gold,5544.0
5654,"Under Fluoxetine , mPFC activation was up-regulated and normalized in ASD boys relative to controls , but down-regulated in ADHD boys relative to",placebo,", which was concomitant with worse task performance in ADHD .","['Under', 'Fluoxetine', ',', 'mPFC', 'activation', 'was', 'up-regulated', 'and', 'normalized', 'in', 'ASD', 'boys', 'relative', 'to', 'controls', ',', 'but', 'down-regulated', 'in', 'ADHD', 'boys', 'relative', 'to', 'placebo', ',', 'which', 'was', 'concomitant', 'with', 'worse', 'task', 'performance', 'in', 'ADHD', '.']","(23, 24)","(145, 152)",-1,ss_i,24451919,Abstract,9,test,gold,4330.0
5655,"Under Fluoxetine ,",mPFC activation,"was up-regulated and normalized in ASD boys relative to controls , but down-regulated in ADHD boys relative to placebo , which was concomitant with worse task performance in ADHD .","['Under', 'Fluoxetine', ',', 'mPFC', 'activation', 'was', 'up-regulated', 'and', 'normalized', 'in', 'ASD', 'boys', 'relative', 'to', 'controls', ',', 'but', 'down-regulated', 'in', 'ADHD', 'boys', 'relative', 'to', 'placebo', ',', 'which', 'was', 'concomitant', 'with', 'worse', 'task', 'performance', 'in', 'ADHD', '.']","(3, 5)","(18, 33)",-1,ss_o,24451919,Abstract,9,test,gold,2893.0
5656,"Under Fluoxetine , mPFC activation was up-regulated and normalized in ASD boys relative to controls , but down-regulated in ADHD boys relative to placebo , which was concomitant with worse",task performance,in ADHD .,"['Under', 'Fluoxetine', ',', 'mPFC', 'activation', 'was', 'up-regulated', 'and', 'normalized', 'in', 'ASD', 'boys', 'relative', 'to', 'controls', ',', 'but', 'down-regulated', 'in', 'ADHD', 'boys', 'relative', 'to', 'placebo', ',', 'which', 'was', 'concomitant', 'with', 'worse', 'task', 'performance', 'in', 'ADHD', '.']","(30, 32)","(188, 204)",-1,ss_o,24451919,Abstract,9,test,gold,914.0
5657,Under,Fluoxetine,", mPFC activation was up-regulated and normalized in ASD boys relative to controls , but down-regulated in ADHD boys relative to placebo , which was concomitant with worse task performance in ADHD .","['Under', 'Fluoxetine', ',', 'mPFC', 'activation', 'was', 'up-regulated', 'and', 'normalized', 'in', 'ASD', 'boys', 'relative', 'to', 'controls', ',', 'but', 'down-regulated', 'in', 'ADHD', 'boys', 'relative', 'to', 'placebo', ',', 'which', 'was', 'concomitant', 'with', 'worse', 'task', 'performance', 'in', 'ADHD', '.']","(1, 2)","(5, 15)",-1,hl_i,24451919,Abstract,9,test,gold,5543.0
5658,"Under Fluoxetine , mPFC activation was up-regulated and normalized in ASD boys relative to controls , but down-regulated in ADHD boys relative to",placebo,", which was concomitant with worse task performance in ADHD .","['Under', 'Fluoxetine', ',', 'mPFC', 'activation', 'was', 'up-regulated', 'and', 'normalized', 'in', 'ASD', 'boys', 'relative', 'to', 'controls', ',', 'but', 'down-regulated', 'in', 'ADHD', 'boys', 'relative', 'to', 'placebo', ',', 'which', 'was', 'concomitant', 'with', 'worse', 'task', 'performance', 'in', 'ADHD', '.']","(23, 24)","(145, 152)",-1,hl_i,24451919,Abstract,9,test,gold,4329.0
5659,"Under Fluoxetine ,",mPFC activation,"was up-regulated and normalized in ASD boys relative to controls , but down-regulated in ADHD boys relative to placebo , which was concomitant with worse task performance in ADHD .","['Under', 'Fluoxetine', ',', 'mPFC', 'activation', 'was', 'up-regulated', 'and', 'normalized', 'in', 'ASD', 'boys', 'relative', 'to', 'controls', ',', 'but', 'down-regulated', 'in', 'ADHD', 'boys', 'relative', 'to', 'placebo', ',', 'which', 'was', 'concomitant', 'with', 'worse', 'task', 'performance', 'in', 'ADHD', '.']","(3, 5)","(18, 33)",-1,hl_o,24451919,Abstract,9,test,gold,2894.0
5660,"Under Fluoxetine , mPFC activation was up-regulated and normalized in ASD boys relative to controls , but down-regulated in ADHD boys relative to placebo , which was concomitant with worse",task performance,in ADHD .,"['Under', 'Fluoxetine', ',', 'mPFC', 'activation', 'was', 'up-regulated', 'and', 'normalized', 'in', 'ASD', 'boys', 'relative', 'to', 'controls', ',', 'but', 'down-regulated', 'in', 'ADHD', 'boys', 'relative', 'to', 'placebo', ',', 'which', 'was', 'concomitant', 'with', 'worse', 'task', 'performance', 'in', 'ADHD', '.']","(30, 32)","(188, 204)",-1,hl_o,24451919,Abstract,9,test,gold,915.0
5661,,Fluoxetine,"therefore has inverse effects on mPFC activation in ASD and ADHD during reversal learning , suggesting dissociated underlying serotonin abnormalities .","['Fluoxetine', 'therefore', 'has', 'inverse', 'effects', 'on', 'mPFC', 'activation', 'in', 'ASD', 'and', 'ADHD', 'during', 'reversal', 'learning', ',', 'suggesting', 'dissociated', 'underlying', 'serotonin', 'abnormalities', '.']","(0, 1)","(0, 10)",-1,ss_i,24451919,Abstract,10,test,gold,5542.0
5662,Fluoxetine therefore has inverse,effects,"on mPFC activation in ASD and ADHD during reversal learning , suggesting dissociated underlying serotonin abnormalities .","['Fluoxetine', 'therefore', 'has', 'inverse', 'effects', 'on', 'mPFC', 'activation', 'in', 'ASD', 'and', 'ADHD', 'during', 'reversal', 'learning', ',', 'suggesting', 'dissociated', 'underlying', 'serotonin', 'abnormalities', '.']","(4, 5)","(32, 39)",-1,ss_o,24451919,Abstract,10,test,gold,2378.0
5663,Fluoxetine therefore has inverse effects on,mPFC activation,"in ASD and ADHD during reversal learning , suggesting dissociated underlying serotonin abnormalities .","['Fluoxetine', 'therefore', 'has', 'inverse', 'effects', 'on', 'mPFC', 'activation', 'in', 'ASD', 'and', 'ADHD', 'during', 'reversal', 'learning', ',', 'suggesting', 'dissociated', 'underlying', 'serotonin', 'abnormalities', '.']","(6, 8)","(43, 58)",-1,ss_o,24451919,Abstract,10,test,gold,2892.0
5664,,Fluoxetine,"therefore has inverse effects on mPFC activation in ASD and ADHD during reversal learning , suggesting dissociated underlying serotonin abnormalities .","['Fluoxetine', 'therefore', 'has', 'inverse', 'effects', 'on', 'mPFC', 'activation', 'in', 'ASD', 'and', 'ADHD', 'during', 'reversal', 'learning', ',', 'suggesting', 'dissociated', 'underlying', 'serotonin', 'abnormalities', '.']","(0, 1)","(0, 10)",-1,hl_i,24451919,Abstract,10,test,gold,5541.0
5665,Fluoxetine therefore has inverse effects on,mPFC activation,"in ASD and ADHD during reversal learning , suggesting dissociated underlying serotonin abnormalities .","['Fluoxetine', 'therefore', 'has', 'inverse', 'effects', 'on', 'mPFC', 'activation', 'in', 'ASD', 'and', 'ADHD', 'during', 'reversal', 'learning', ',', 'suggesting', 'dissociated', 'underlying', 'serotonin', 'abnormalities', '.']","(6, 8)","(43, 58)",-1,hl_o,24451919,Abstract,10,test,gold,2891.0
5666,Economic burden of,childhood autism spectrum disorders .,,"['Economic', 'burden', 'of', 'childhood', 'autism', 'spectrum', 'disorders', '.']","(3, 8)","(18, 55)",-1,ss_p,24515505,Title,0,test,gold,6028.0
5667,Economic burden of,childhood autism spectrum disorders .,,"['Economic', 'burden', 'of', 'childhood', 'autism', 'spectrum', 'disorders', '.']","(3, 8)","(18, 55)",-1,ss_i,24515505,Title,0,test,gold,6029.0
5668,,Economic burden,of childhood autism spectrum disorders .,"['Economic', 'burden', 'of', 'childhood', 'autism', 'spectrum', 'disorders', '.']","(0, 2)","(0, 15)",-1,ss_o,24515505,Title,0,test,gold,2477.0
5669,Economic burden of,childhood autism spectrum disorders,.,"['Economic', 'burden', 'of', 'childhood', 'autism', 'spectrum', 'disorders', '.']","(3, 7)","(18, 53)",-1,hl_p,24515505,Title,0,test,gold,6027.0
5670,OBJECTIVE To estimate the associations between,autism spectrum disorder ( ASD ),"diagnoses and service use , caregiver time , and cost outcomes .","['OBJECTIVE', 'To', 'estimate', 'the', 'associations', 'between', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'diagnoses', 'and', 'service', 'use', ',', 'caregiver', 'time', ',', 'and', 'cost', 'outcomes', '.']","(6, 12)","(46, 78)",-1,ss_p,24515505,Abstract,0,test,gold,6043.0
5671,OBJECTIVE To estimate the associations between,autism spectrum disorder ( ASD ) diagnoses,"and service use , caregiver time , and cost outcomes .","['OBJECTIVE', 'To', 'estimate', 'the', 'associations', 'between', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'diagnoses', 'and', 'service', 'use', ',', 'caregiver', 'time', ',', 'and', 'cost', 'outcomes', '.']","(6, 13)","(46, 88)",-1,ss_i,24515505,Abstract,0,test,gold,6046.0
5672,OBJECTIVE To estimate the associations between autism spectrum disorder ( ASD ) diagnoses and,"service use , caregiver time , and cost outcomes .",,"['OBJECTIVE', 'To', 'estimate', 'the', 'associations', 'between', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'diagnoses', 'and', 'service', 'use', ',', 'caregiver', 'time', ',', 'and', 'cost', 'outcomes', '.']","(14, 24)","(93, 143)",-1,ss_o,24515505,Abstract,0,test,gold,3934.0
5673,OBJECTIVE To estimate the associations between,autism spectrum disorder ( ASD ),"diagnoses and service use , caregiver time , and cost outcomes .","['OBJECTIVE', 'To', 'estimate', 'the', 'associations', 'between', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'diagnoses', 'and', 'service', 'use', ',', 'caregiver', 'time', ',', 'and', 'cost', 'outcomes', '.']","(6, 12)","(46, 78)",-1,hl_p,24515505,Abstract,0,test,gold,6044.0
5674,OBJECTIVE To estimate the associations between autism spectrum disorder ( ASD ) diagnoses and,service use,", caregiver time , and cost outcomes .","['OBJECTIVE', 'To', 'estimate', 'the', 'associations', 'between', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'diagnoses', 'and', 'service', 'use', ',', 'caregiver', 'time', ',', 'and', 'cost', 'outcomes', '.']","(14, 16)","(93, 104)",-1,hl_o,24515505,Abstract,0,test,gold,1269.0
5675,"OBJECTIVE To estimate the associations between autism spectrum disorder ( ASD ) diagnoses and service use ,",caregiver time,", and cost outcomes .","['OBJECTIVE', 'To', 'estimate', 'the', 'associations', 'between', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'diagnoses', 'and', 'service', 'use', ',', 'caregiver', 'time', ',', 'and', 'cost', 'outcomes', '.']","(17, 19)","(107, 121)",-1,hl_o,24515505,Abstract,0,test,gold,3935.0
5676,"OBJECTIVE To estimate the associations between autism spectrum disorder ( ASD ) diagnoses and service use , caregiver time , and",cost outcomes,.,"['OBJECTIVE', 'To', 'estimate', 'the', 'associations', 'between', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'diagnoses', 'and', 'service', 'use', ',', 'caregiver', 'time', ',', 'and', 'cost', 'outcomes', '.']","(21, 23)","(128, 141)",-1,hl_o,24515505,Abstract,0,test,gold,420.0
5677,"METHODS We used national data from the Medical Expenditure Panel Survey linked to the National Health Interview Survey and a study-specific survey to estimate the annual utilization and costs for health care , school , ASD-related therapy , family-coordinated services , as well as caregiver time in","children aged 3 to 17 years , with and without parent-reported ASD .",,"['METHODS', 'We', 'used', 'national', 'data', 'from', 'the', 'Medical', 'Expenditure', 'Panel', 'Survey', 'linked', 'to', 'the', 'National', 'Health', 'Interview', 'Survey', 'and', 'a', 'study-specific', 'survey', 'to', 'estimate', 'the', 'annual', 'utilization', 'and', 'costs', 'for', 'health', 'care', ',', 'school', ',', 'ASD-related', 'therapy', ',', 'family-coordinated', 'services', ',', 'as', 'well', 'as', 'caregiver', 'time', 'in', 'children', 'aged', '3', 'to', '17', 'years', ',', 'with', 'and', 'without', 'parent-reported', 'ASD', '.']","(47, 60)","(299, 367)",-1,ss_p,24515505,Abstract,1,test,gold,6203.0
5678,"METHODS We used national data from the Medical Expenditure Panel Survey linked to the National Health Interview Survey and a study-specific survey to estimate the annual utilization and costs for health care , school , ASD-related therapy , family-coordinated services , as well as caregiver time in children aged 3 to 17 years ,",with and without parent-reported ASD .,,"['METHODS', 'We', 'used', 'national', 'data', 'from', 'the', 'Medical', 'Expenditure', 'Panel', 'Survey', 'linked', 'to', 'the', 'National', 'Health', 'Interview', 'Survey', 'and', 'a', 'study-specific', 'survey', 'to', 'estimate', 'the', 'annual', 'utilization', 'and', 'costs', 'for', 'health', 'care', ',', 'school', ',', 'ASD-related', 'therapy', ',', 'family-coordinated', 'services', ',', 'as', 'well', 'as', 'caregiver', 'time', 'in', 'children', 'aged', '3', 'to', '17', 'years', ',', 'with', 'and', 'without', 'parent-reported', 'ASD', '.']","(54, 60)","(329, 367)",-1,ss_i,24515505,Abstract,1,test,gold,6093.0
5679,METHODS We used national data from the Medical Expenditure Panel Survey linked to the National Health Interview Survey and a study-specific survey to estimate the,"annual utilization and costs for health care , school , ASD-related therapy , family-coordinated services , as well as caregiver time","in children aged 3 to 17 years , with and without parent-reported ASD .","['METHODS', 'We', 'used', 'national', 'data', 'from', 'the', 'Medical', 'Expenditure', 'Panel', 'Survey', 'linked', 'to', 'the', 'National', 'Health', 'Interview', 'Survey', 'and', 'a', 'study-specific', 'survey', 'to', 'estimate', 'the', 'annual', 'utilization', 'and', 'costs', 'for', 'health', 'care', ',', 'school', ',', 'ASD-related', 'therapy', ',', 'family-coordinated', 'services', ',', 'as', 'well', 'as', 'caregiver', 'time', 'in', 'children', 'aged', '3', 'to', '17', 'years', ',', 'with', 'and', 'without', 'parent-reported', 'ASD', '.']","(25, 46)","(162, 295)",-1,ss_o,24515505,Abstract,1,test,gold,5887.0
5680,"METHODS We used national data from the Medical Expenditure Panel Survey linked to the National Health Interview Survey and a study-specific survey to estimate the annual utilization and costs for health care , school , ASD-related therapy , family-coordinated services , as well as caregiver time in",children aged 3 to 17 years,", with and without parent-reported ASD .","['METHODS', 'We', 'used', 'national', 'data', 'from', 'the', 'Medical', 'Expenditure', 'Panel', 'Survey', 'linked', 'to', 'the', 'National', 'Health', 'Interview', 'Survey', 'and', 'a', 'study-specific', 'survey', 'to', 'estimate', 'the', 'annual', 'utilization', 'and', 'costs', 'for', 'health', 'care', ',', 'school', ',', 'ASD-related', 'therapy', ',', 'family-coordinated', 'services', ',', 'as', 'well', 'as', 'caregiver', 'time', 'in', 'children', 'aged', '3', 'to', '17', 'years', ',', 'with', 'and', 'without', 'parent-reported', 'ASD', '.']","(47, 53)","(299, 326)",-1,hl_p,24515505,Abstract,1,test,gold,2046.0
5681,"METHODS We used national data from the Medical Expenditure Panel Survey linked to the National Health Interview Survey and a study-specific survey to estimate the annual utilization and costs for health care , school , ASD-related therapy , family-coordinated services , as well as caregiver time in children aged 3 to 17 years , with and without",parent-reported ASD,.,"['METHODS', 'We', 'used', 'national', 'data', 'from', 'the', 'Medical', 'Expenditure', 'Panel', 'Survey', 'linked', 'to', 'the', 'National', 'Health', 'Interview', 'Survey', 'and', 'a', 'study-specific', 'survey', 'to', 'estimate', 'the', 'annual', 'utilization', 'and', 'costs', 'for', 'health', 'care', ',', 'school', ',', 'ASD-related', 'therapy', ',', 'family-coordinated', 'services', ',', 'as', 'well', 'as', 'caregiver', 'time', 'in', 'children', 'aged', '3', 'to', '17', 'years', ',', 'with', 'and', 'without', 'parent-reported', 'ASD', '.']","(57, 59)","(346, 365)",-1,hl_p,24515505,Abstract,1,test,gold,6102.0
5682,METHODS We used national data from the Medical Expenditure Panel Survey linked to the National Health Interview Survey and a study-specific survey to estimate the,annual utilization and costs,"for health care , school , ASD-related therapy , family-coordinated services , as well as caregiver time in children aged 3 to 17 years , with and without parent-reported ASD .","['METHODS', 'We', 'used', 'national', 'data', 'from', 'the', 'Medical', 'Expenditure', 'Panel', 'Survey', 'linked', 'to', 'the', 'National', 'Health', 'Interview', 'Survey', 'and', 'a', 'study-specific', 'survey', 'to', 'estimate', 'the', 'annual', 'utilization', 'and', 'costs', 'for', 'health', 'care', ',', 'school', ',', 'ASD-related', 'therapy', ',', 'family-coordinated', 'services', ',', 'as', 'well', 'as', 'caregiver', 'time', 'in', 'children', 'aged', '3', 'to', '17', 'years', ',', 'with', 'and', 'without', 'parent-reported', 'ASD', '.']","(25, 29)","(162, 190)",-1,hl_o,24515505,Abstract,1,test,gold,1003.0
5683,METHODS We used national data from the Medical Expenditure Panel Survey linked to the National Health Interview Survey and a study-specific survey to estimate the annual utilization and costs for,health care,", school , ASD-related therapy , family-coordinated services , as well as caregiver time in children aged 3 to 17 years , with and without parent-reported ASD .","['METHODS', 'We', 'used', 'national', 'data', 'from', 'the', 'Medical', 'Expenditure', 'Panel', 'Survey', 'linked', 'to', 'the', 'National', 'Health', 'Interview', 'Survey', 'and', 'a', 'study-specific', 'survey', 'to', 'estimate', 'the', 'annual', 'utilization', 'and', 'costs', 'for', 'health', 'care', ',', 'school', ',', 'ASD-related', 'therapy', ',', 'family-coordinated', 'services', ',', 'as', 'well', 'as', 'caregiver', 'time', 'in', 'children', 'aged', '3', 'to', '17', 'years', ',', 'with', 'and', 'without', 'parent-reported', 'ASD', '.']","(30, 32)","(195, 206)",-1,hl_o,24515505,Abstract,1,test,gold,3949.0
5684,"METHODS We used national data from the Medical Expenditure Panel Survey linked to the National Health Interview Survey and a study-specific survey to estimate the annual utilization and costs for health care ,",school,", ASD-related therapy , family-coordinated services , as well as caregiver time in children aged 3 to 17 years , with and without parent-reported ASD .","['METHODS', 'We', 'used', 'national', 'data', 'from', 'the', 'Medical', 'Expenditure', 'Panel', 'Survey', 'linked', 'to', 'the', 'National', 'Health', 'Interview', 'Survey', 'and', 'a', 'study-specific', 'survey', 'to', 'estimate', 'the', 'annual', 'utilization', 'and', 'costs', 'for', 'health', 'care', ',', 'school', ',', 'ASD-related', 'therapy', ',', 'family-coordinated', 'services', ',', 'as', 'well', 'as', 'caregiver', 'time', 'in', 'children', 'aged', '3', 'to', '17', 'years', ',', 'with', 'and', 'without', 'parent-reported', 'ASD', '.']","(33, 34)","(209, 215)",-1,hl_o,24515505,Abstract,1,test,gold,2191.0
5685,"METHODS We used national data from the Medical Expenditure Panel Survey linked to the National Health Interview Survey and a study-specific survey to estimate the annual utilization and costs for health care , school ,",ASD-related therapy,", family-coordinated services , as well as caregiver time in children aged 3 to 17 years , with and without parent-reported ASD .","['METHODS', 'We', 'used', 'national', 'data', 'from', 'the', 'Medical', 'Expenditure', 'Panel', 'Survey', 'linked', 'to', 'the', 'National', 'Health', 'Interview', 'Survey', 'and', 'a', 'study-specific', 'survey', 'to', 'estimate', 'the', 'annual', 'utilization', 'and', 'costs', 'for', 'health', 'care', ',', 'school', ',', 'ASD-related', 'therapy', ',', 'family-coordinated', 'services', ',', 'as', 'well', 'as', 'caregiver', 'time', 'in', 'children', 'aged', '3', 'to', '17', 'years', ',', 'with', 'and', 'without', 'parent-reported', 'ASD', '.']","(35, 37)","(218, 237)",-1,hl_o,24515505,Abstract,1,test,gold,4215.0
5686,"METHODS We used national data from the Medical Expenditure Panel Survey linked to the National Health Interview Survey and a study-specific survey to estimate the annual utilization and costs for health care , school , ASD-related therapy ,",family-coordinated services,", as well as caregiver time in children aged 3 to 17 years , with and without parent-reported ASD .","['METHODS', 'We', 'used', 'national', 'data', 'from', 'the', 'Medical', 'Expenditure', 'Panel', 'Survey', 'linked', 'to', 'the', 'National', 'Health', 'Interview', 'Survey', 'and', 'a', 'study-specific', 'survey', 'to', 'estimate', 'the', 'annual', 'utilization', 'and', 'costs', 'for', 'health', 'care', ',', 'school', ',', 'ASD-related', 'therapy', ',', 'family-coordinated', 'services', ',', 'as', 'well', 'as', 'caregiver', 'time', 'in', 'children', 'aged', '3', 'to', '17', 'years', ',', 'with', 'and', 'without', 'parent-reported', 'ASD', '.']","(38, 40)","(240, 267)",-1,hl_o,24515505,Abstract,1,test,gold,1267.0
5687,"METHODS We used national data from the Medical Expenditure Panel Survey linked to the National Health Interview Survey and a study-specific survey to estimate the annual utilization and costs for health care , school , ASD-related therapy , family-coordinated services , as well as",caregiver time,"in children aged 3 to 17 years , with and without parent-reported ASD .","['METHODS', 'We', 'used', 'national', 'data', 'from', 'the', 'Medical', 'Expenditure', 'Panel', 'Survey', 'linked', 'to', 'the', 'National', 'Health', 'Interview', 'Survey', 'and', 'a', 'study-specific', 'survey', 'to', 'estimate', 'the', 'annual', 'utilization', 'and', 'costs', 'for', 'health', 'care', ',', 'school', ',', 'ASD-related', 'therapy', ',', 'family-coordinated', 'services', ',', 'as', 'well', 'as', 'caregiver', 'time', 'in', 'children', 'aged', '3', 'to', '17', 'years', ',', 'with', 'and', 'without', 'parent-reported', 'ASD', '.']","(44, 46)","(281, 295)",-1,hl_o,24515505,Abstract,1,test,gold,3936.0
5688,Regression analyses estimated the association between,ASD diagnosis,"and cost , controlling for child gender , age , race/ethnicity , insurance status , household income , country region and urban/rural classification , and non-ASD-related illnesses .","['Regression', 'analyses', 'estimated', 'the', 'association', 'between', 'ASD', 'diagnosis', 'and', 'cost', ',', 'controlling', 'for', 'child', 'gender', ',', 'age', ',', 'race/ethnicity', ',', 'insurance', 'status', ',', 'household', 'income', ',', 'country', 'region', 'and', 'urban/rural', 'classification', ',', 'and', 'non-ASD-related', 'illnesses', '.']","(6, 8)","(53, 66)",-1,ss_i,24515505,Abstract,2,test,gold,6099.0
5689,,Regression analyses,"estimated the association between ASD diagnosis and cost , controlling for child gender , age , race/ethnicity , insurance status , household income , country region and urban/rural classification , and non-ASD-related illnesses .","['Regression', 'analyses', 'estimated', 'the', 'association', 'between', 'ASD', 'diagnosis', 'and', 'cost', ',', 'controlling', 'for', 'child', 'gender', ',', 'age', ',', 'race/ethnicity', ',', 'insurance', 'status', ',', 'household', 'income', ',', 'country', 'region', 'and', 'urban/rural', 'classification', ',', 'and', 'non-ASD-related', 'illnesses', '.']","(0, 2)","(0, 19)",-1,ss_o,24515505,Abstract,2,test,gold,440.0
5690,Regression analyses estimated the,"association between ASD diagnosis and cost , controlling for child gender , age , race/ethnicity , insurance status , household income , country region and urban/rural classification , and non-ASD-related illnesses .",,"['Regression', 'analyses', 'estimated', 'the', 'association', 'between', 'ASD', 'diagnosis', 'and', 'cost', ',', 'controlling', 'for', 'child', 'gender', ',', 'age', ',', 'race/ethnicity', ',', 'insurance', 'status', ',', 'household', 'income', ',', 'country', 'region', 'and', 'urban/rural', 'classification', ',', 'and', 'non-ASD-related', 'illnesses', '.']","(4, 36)","(33, 249)",-1,ss_o,24515505,Abstract,2,test,gold,5911.0
5691,Regression analyses estimated the association between ASD diagnosis and,cost,", controlling for child gender , age , race/ethnicity , insurance status , household income , country region and urban/rural classification , and non-ASD-related illnesses .","['Regression', 'analyses', 'estimated', 'the', 'association', 'between', 'ASD', 'diagnosis', 'and', 'cost', ',', 'controlling', 'for', 'child', 'gender', ',', 'age', ',', 'race/ethnicity', ',', 'insurance', 'status', ',', 'household', 'income', ',', 'country', 'region', 'and', 'urban/rural', 'classification', ',', 'and', 'non-ASD-related', 'illnesses', '.']","(9, 10)","(71, 75)",-1,hl_o,24515505,Abstract,2,test,gold,1005.0
5692,RESULTS,Children with parent-reported ASD,had higher levels of health care office visits and prescription drug use compared with children without ASD ( P < .05 ) .,"['RESULTS', 'Children', 'with', 'parent-reported', 'ASD', 'had', 'higher', 'levels', 'of', 'health', 'care', 'office', 'visits', 'and', 'prescription', 'drug', 'use', 'compared', 'with', 'children', 'without', 'ASD', '(', 'P', '<', '.05', ')', '.']","(1, 5)","(7, 40)",-1,ss_p,24515505,Abstract,3,test,gold,6080.0
5693,RESULTS,Children with parent-reported ASD,had higher levels of health care office visits and prescription drug use compared with children without ASD ( P < .05 ) .,"['RESULTS', 'Children', 'with', 'parent-reported', 'ASD', 'had', 'higher', 'levels', 'of', 'health', 'care', 'office', 'visits', 'and', 'prescription', 'drug', 'use', 'compared', 'with', 'children', 'without', 'ASD', '(', 'P', '<', '.05', ')', '.']","(1, 5)","(7, 40)",-1,ss_i,24515505,Abstract,3,test,gold,6081.0
5694,RESULTS Children with parent-reported ASD had higher levels of health care office visits and prescription drug use compared with,children without ASD,( P < .05 ) .,"['RESULTS', 'Children', 'with', 'parent-reported', 'ASD', 'had', 'higher', 'levels', 'of', 'health', 'care', 'office', 'visits', 'and', 'prescription', 'drug', 'use', 'compared', 'with', 'children', 'without', 'ASD', '(', 'P', '<', '.05', ')', '.']","(19, 22)","(128, 148)",-1,ss_i,24515505,Abstract,3,test,gold,6086.0
5695,RESULTS Children with parent-reported ASD had higher levels of,health care office visits and prescription drug use,compared with children without ASD ( P < .05 ) .,"['RESULTS', 'Children', 'with', 'parent-reported', 'ASD', 'had', 'higher', 'levels', 'of', 'health', 'care', 'office', 'visits', 'and', 'prescription', 'drug', 'use', 'compared', 'with', 'children', 'without', 'ASD', '(', 'P', '<', '.05', ')', '.']","(9, 17)","(62, 113)",-1,ss_o,24515505,Abstract,3,test,gold,7083.0
5696,RESULTS,Children with parent-reported ASD,had higher levels of health care office visits and prescription drug use compared with children without ASD ( P < .05 ) .,"['RESULTS', 'Children', 'with', 'parent-reported', 'ASD', 'had', 'higher', 'levels', 'of', 'health', 'care', 'office', 'visits', 'and', 'prescription', 'drug', 'use', 'compared', 'with', 'children', 'without', 'ASD', '(', 'P', '<', '.05', ')', '.']","(1, 5)","(7, 40)",-1,hl_p,24515505,Abstract,3,test,gold,6079.0
5697,RESULTS Children with parent-reported ASD had higher levels of,health care office visits,and prescription drug use compared with children without ASD ( P < .05 ) .,"['RESULTS', 'Children', 'with', 'parent-reported', 'ASD', 'had', 'higher', 'levels', 'of', 'health', 'care', 'office', 'visits', 'and', 'prescription', 'drug', 'use', 'compared', 'with', 'children', 'without', 'ASD', '(', 'P', '<', '.05', ')', '.']","(9, 13)","(62, 87)",-1,hl_o,24515505,Abstract,3,test,gold,3940.0
5698,RESULTS Children with parent-reported ASD had higher levels of health care office visits and,prescription drug use,compared with children without ASD ( P < .05 ) .,"['RESULTS', 'Children', 'with', 'parent-reported', 'ASD', 'had', 'higher', 'levels', 'of', 'health', 'care', 'office', 'visits', 'and', 'prescription', 'drug', 'use', 'compared', 'with', 'children', 'without', 'ASD', '(', 'P', '<', '.05', ')', '.']","(14, 17)","(92, 113)",-1,hl_o,24515505,Abstract,3,test,gold,5080.0
5699,A greater proportion of,children in the ASD,"group used special educational services ( 76 % vs. 7 % in the control group , P < .05 ) .","['A', 'greater', 'proportion', 'of', 'children', 'in', 'the', 'ASD', 'group', 'used', 'special', 'educational', 'services', '(', '76', '%', 'vs.', '7', '%', 'in', 'the', 'control', 'group', ',', 'P', '<', '.05', ')', '.']","(4, 8)","(23, 42)",-1,ss_i,24515505,Abstract,4,test,gold,6087.0
5700,A greater proportion of children in the ASD group used special educational services ( 76 % vs. 7 % in the,control,"group , P < .05 ) .","['A', 'greater', 'proportion', 'of', 'children', 'in', 'the', 'ASD', 'group', 'used', 'special', 'educational', 'services', '(', '76', '%', 'vs.', '7', '%', 'in', 'the', 'control', 'group', ',', 'P', '<', '.05', ')', '.']","(21, 22)","(105, 112)",-1,ss_i,24515505,Abstract,4,test,gold,899.0
5701,A greater proportion of children in the ASD group used,special educational services,"( 76 % vs. 7 % in the control group , P < .05 ) .","['A', 'greater', 'proportion', 'of', 'children', 'in', 'the', 'ASD', 'group', 'used', 'special', 'educational', 'services', '(', '76', '%', 'vs.', '7', '%', 'in', 'the', 'control', 'group', ',', 'P', '<', '.05', ')', '.']","(10, 13)","(54, 82)",-1,ss_o,24515505,Abstract,4,test,gold,2966.0
5702,A greater proportion of children in the ASD group used,special educational services,"( 76 % vs. 7 % in the control group , P < .05 ) .","['A', 'greater', 'proportion', 'of', 'children', 'in', 'the', 'ASD', 'group', 'used', 'special', 'educational', 'services', '(', '76', '%', 'vs.', '7', '%', 'in', 'the', 'control', 'group', ',', 'P', '<', '.05', ')', '.']","(10, 13)","(54, 82)",-1,hl_o,24515505,Abstract,4,test,gold,2967.0
5703,"After adjusting for child demographic characteristics and non-ASD-associated illnesses , ASD was associated with $ 3020 ( 95 % confidence interval [ CI ] : $ 1017- $ 4259 ) higher",health care costs,"and $ 14,061 ( 95 % CI : $ 4390- $ 24,302 ) higher aggregate non-health care costs , including $ 8610 ( 95 % CI : $ 6595- $ 10,421 ) higher school costs .","['After', 'adjusting', 'for', 'child', 'demographic', 'characteristics', 'and', 'non-ASD-associated', 'illnesses', ',', 'ASD', 'was', 'associated', 'with', '$', '3020', '(', '95', '%', 'confidence', 'interval', '[', 'CI', ']', ':', '$', '1017-', '$', '4259', ')', 'higher', 'health', 'care', 'costs', 'and', '$', '14,061', '(', '95', '%', 'CI', ':', '$', '4390-', '$', '24,302', ')', 'higher', 'aggregate', 'non-health', 'care', 'costs', ',', 'including', '$', '8610', '(', '95', '%', 'CI', ':', '$', '6595-', '$', '10,421', ')', 'higher', 'school', 'costs', '.']","(31, 34)","(179, 196)",-1,ss_o,24515505,Abstract,5,test,gold,3950.0
5704,"After adjusting for child demographic characteristics and non-ASD-associated illnesses , ASD was associated with $ 3020 ( 95 % confidence interval [ CI ] : $ 1017- $ 4259 ) higher health care costs and $ 14,061 ( 95 % CI : $ 4390- $ 24,302 ) higher aggregate",non-health care costs,", including $ 8610 ( 95 % CI : $ 6595- $ 10,421 ) higher school costs .","['After', 'adjusting', 'for', 'child', 'demographic', 'characteristics', 'and', 'non-ASD-associated', 'illnesses', ',', 'ASD', 'was', 'associated', 'with', '$', '3020', '(', '95', '%', 'confidence', 'interval', '[', 'CI', ']', ':', '$', '1017-', '$', '4259', ')', 'higher', 'health', 'care', 'costs', 'and', '$', '14,061', '(', '95', '%', 'CI', ':', '$', '4390-', '$', '24,302', ')', 'higher', 'aggregate', 'non-health', 'care', 'costs', ',', 'including', '$', '8610', '(', '95', '%', 'CI', ':', '$', '6595-', '$', '10,421', ')', 'higher', 'school', 'costs', '.']","(49, 52)","(258, 279)",-1,ss_o,24515505,Abstract,5,test,gold,3947.0
5705,"After adjusting for child demographic characteristics and non-ASD-associated illnesses , ASD was associated with $ 3020 ( 95 % confidence interval [ CI ] : $ 1017- $ 4259 ) higher health care costs and $ 14,061 ( 95 % CI : $ 4390- $ 24,302 ) higher aggregate non-health care costs , including $ 8610 ( 95 % CI : $ 6595- $ 10,421 )",higher school costs .,,"['After', 'adjusting', 'for', 'child', 'demographic', 'characteristics', 'and', 'non-ASD-associated', 'illnesses', ',', 'ASD', 'was', 'associated', 'with', '$', '3020', '(', '95', '%', 'confidence', 'interval', '[', 'CI', ']', ':', '$', '1017-', '$', '4259', ')', 'higher', 'health', 'care', 'costs', 'and', '$', '14,061', '(', '95', '%', 'CI', ':', '$', '4390-', '$', '24,302', ')', 'higher', 'aggregate', 'non-health', 'care', 'costs', ',', 'including', '$', '8610', '(', '95', '%', 'CI', ':', '$', '6595-', '$', '10,421', ')', 'higher', 'school', 'costs', '.']","(66, 70)","(330, 351)",-1,ss_o,24515505,Abstract,5,test,gold,1001.0
5706,"After adjusting for child demographic characteristics and non-ASD-associated illnesses , ASD was associated with $ 3020 ( 95 % confidence interval [ CI ] : $ 1017- $ 4259 ) higher",health care costs,"and $ 14,061 ( 95 % CI : $ 4390- $ 24,302 ) higher aggregate non-health care costs , including $ 8610 ( 95 % CI : $ 6595- $ 10,421 ) higher school costs .","['After', 'adjusting', 'for', 'child', 'demographic', 'characteristics', 'and', 'non-ASD-associated', 'illnesses', ',', 'ASD', 'was', 'associated', 'with', '$', '3020', '(', '95', '%', 'confidence', 'interval', '[', 'CI', ']', ':', '$', '1017-', '$', '4259', ')', 'higher', 'health', 'care', 'costs', 'and', '$', '14,061', '(', '95', '%', 'CI', ':', '$', '4390-', '$', '24,302', ')', 'higher', 'aggregate', 'non-health', 'care', 'costs', ',', 'including', '$', '8610', '(', '95', '%', 'CI', ':', '$', '6595-', '$', '10,421', ')', 'higher', 'school', 'costs', '.']","(31, 34)","(179, 196)",-1,hl_o,24515505,Abstract,5,test,gold,3951.0
5707,"After adjusting for child demographic characteristics and non-ASD-associated illnesses , ASD was associated with $ 3020 ( 95 % confidence interval [ CI ] : $ 1017- $ 4259 ) higher health care costs and $ 14,061 ( 95 % CI : $ 4390- $ 24,302 ) higher aggregate",non-health care costs,", including $ 8610 ( 95 % CI : $ 6595- $ 10,421 ) higher school costs .","['After', 'adjusting', 'for', 'child', 'demographic', 'characteristics', 'and', 'non-ASD-associated', 'illnesses', ',', 'ASD', 'was', 'associated', 'with', '$', '3020', '(', '95', '%', 'confidence', 'interval', '[', 'CI', ']', ':', '$', '1017-', '$', '4259', ')', 'higher', 'health', 'care', 'costs', 'and', '$', '14,061', '(', '95', '%', 'CI', ':', '$', '4390-', '$', '24,302', ')', 'higher', 'aggregate', 'non-health', 'care', 'costs', ',', 'including', '$', '8610', '(', '95', '%', 'CI', ':', '$', '6595-', '$', '10,421', ')', 'higher', 'school', 'costs', '.']","(49, 52)","(258, 279)",-1,hl_o,24515505,Abstract,5,test,gold,3948.0
5708,"After adjusting for child demographic characteristics and non-ASD-associated illnesses , ASD was associated with $ 3020 ( 95 % confidence interval [ CI ] : $ 1017- $ 4259 ) higher health care costs and $ 14,061 ( 95 % CI : $ 4390- $ 24,302 ) higher aggregate non-health care costs , including $ 8610 ( 95 % CI : $ 6595- $ 10,421 )",higher school costs .,,"['After', 'adjusting', 'for', 'child', 'demographic', 'characteristics', 'and', 'non-ASD-associated', 'illnesses', ',', 'ASD', 'was', 'associated', 'with', '$', '3020', '(', '95', '%', 'confidence', 'interval', '[', 'CI', ']', ':', '$', '1017-', '$', '4259', ')', 'higher', 'health', 'care', 'costs', 'and', '$', '14,061', '(', '95', '%', 'CI', ':', '$', '4390-', '$', '24,302', ')', 'higher', 'aggregate', 'non-health', 'care', 'costs', ',', 'including', '$', '8610', '(', '95', '%', 'CI', ':', '$', '6595-', '$', '10,421', ')', 'higher', 'school', 'costs', '.']","(66, 70)","(330, 351)",-1,hl_o,24515505,Abstract,5,test,gold,1002.0
5709,"In adjusted analyses ,",parents who reported that their child had ASD,did not have significantly higher out-of-pocket costs or spend more time on caregiving activities compared with control parents .,"['In', 'adjusted', 'analyses', ',', 'parents', 'who', 'reported', 'that', 'their', 'child', 'had', 'ASD', 'did', 'not', 'have', 'significantly', 'higher', 'out-of-pocket', 'costs', 'or', 'spend', 'more', 'time', 'on', 'caregiving', 'activities', 'compared', 'with', 'control', 'parents', '.']","(4, 12)","(22, 67)",-1,ss_i,24515505,Abstract,6,test,gold,6196.0
5710,"In adjusted analyses , parents who reported that their child had ASD did not have significantly higher out-of-pocket costs or spend more time on caregiving activities compared with",control,parents .,"['In', 'adjusted', 'analyses', ',', 'parents', 'who', 'reported', 'that', 'their', 'child', 'had', 'ASD', 'did', 'not', 'have', 'significantly', 'higher', 'out-of-pocket', 'costs', 'or', 'spend', 'more', 'time', 'on', 'caregiving', 'activities', 'compared', 'with', 'control', 'parents', '.']","(28, 29)","(180, 187)",-1,ss_i,24515505,Abstract,6,test,gold,898.0
5711,"In adjusted analyses , parents who reported that their child had ASD did not have significantly higher",out-of-pocket costs,or spend more time on caregiving activities compared with control parents .,"['In', 'adjusted', 'analyses', ',', 'parents', 'who', 'reported', 'that', 'their', 'child', 'had', 'ASD', 'did', 'not', 'have', 'significantly', 'higher', 'out-of-pocket', 'costs', 'or', 'spend', 'more', 'time', 'on', 'caregiving', 'activities', 'compared', 'with', 'control', 'parents', '.']","(17, 19)","(102, 121)",-1,ss_o,24515505,Abstract,6,test,gold,1007.0
5712,"In adjusted analyses , parents who reported that their child had ASD did not have significantly higher out-of-pocket costs or spend more",time on caregiving activities,compared with control parents .,"['In', 'adjusted', 'analyses', ',', 'parents', 'who', 'reported', 'that', 'their', 'child', 'had', 'ASD', 'did', 'not', 'have', 'significantly', 'higher', 'out-of-pocket', 'costs', 'or', 'spend', 'more', 'time', 'on', 'caregiving', 'activities', 'compared', 'with', 'control', 'parents', '.']","(22, 26)","(136, 165)",-1,ss_o,24515505,Abstract,6,test,gold,3937.0
5713,"In adjusted analyses , parents who reported that their child had ASD did not have significantly higher",out-of-pocket costs,or spend more time on caregiving activities compared with control parents .,"['In', 'adjusted', 'analyses', ',', 'parents', 'who', 'reported', 'that', 'their', 'child', 'had', 'ASD', 'did', 'not', 'have', 'significantly', 'higher', 'out-of-pocket', 'costs', 'or', 'spend', 'more', 'time', 'on', 'caregiving', 'activities', 'compared', 'with', 'control', 'parents', '.']","(17, 19)","(102, 121)",-1,hl_o,24515505,Abstract,6,test,gold,1006.0
5714,"In adjusted analyses , parents who reported that their child had ASD did not have significantly higher out-of-pocket costs or spend more",time on caregiving activities,compared with control parents .,"['In', 'adjusted', 'analyses', ',', 'parents', 'who', 'reported', 'that', 'their', 'child', 'had', 'ASD', 'did', 'not', 'have', 'significantly', 'higher', 'out-of-pocket', 'costs', 'or', 'spend', 'more', 'time', 'on', 'caregiving', 'activities', 'compared', 'with', 'control', 'parents', '.']","(22, 26)","(136, 165)",-1,hl_o,24515505,Abstract,6,test,gold,3938.0
5715,CONCLUSIONS The,economic burden,associated with ASD is substantial and can be measured across multiple sectors of our society .,"['CONCLUSIONS', 'The', 'economic', 'burden', 'associated', 'with', 'ASD', 'is', 'substantial', 'and', 'can', 'be', 'measured', 'across', 'multiple', 'sectors', 'of', 'our', 'society', '.']","(2, 4)","(15, 30)",-1,ss_o,24515505,Abstract,7,test,gold,2478.0
5716,Previous analyses that focused on health care underestimated this,economic burden,", particularly for school systems .","['Previous', 'analyses', 'that', 'focused', 'on', 'health', 'care', 'underestimated', 'this', 'economic', 'burden', ',', 'particularly', 'for', 'school', 'systems', '.']","(9, 11)","(65, 80)",-1,ss_o,24515505,Abstract,8,test,gold,2479.0
5717,Assessment of acute bronchodilator effects from specific airway resistance changes in,stable COPD patients .,,"['Assessment', 'of', 'acute', 'bronchodilator', 'effects', 'from', 'specific', 'airway', 'resistance', 'changes', 'in', 'stable', 'COPD', 'patients', '.']","(11, 15)","(85, 107)",-1,ss_p,24726342,Title,0,test,gold,3776.0
5718,Assessment of acute,bronchodilator,effects from specific airway resistance changes in stable COPD patients .,"['Assessment', 'of', 'acute', 'bronchodilator', 'effects', 'from', 'specific', 'airway', 'resistance', 'changes', 'in', 'stable', 'COPD', 'patients', '.']","(3, 4)","(19, 33)",-1,ss_i,24726342,Title,0,test,gold,5603.0
5719,Assessment of acute bronchodilator,effects,from specific airway resistance changes in stable COPD patients .,"['Assessment', 'of', 'acute', 'bronchodilator', 'effects', 'from', 'specific', 'airway', 'resistance', 'changes', 'in', 'stable', 'COPD', 'patients', '.']","(4, 5)","(34, 41)",-1,ss_o,24726342,Title,0,test,gold,2377.0
5720,Assessment of acute bronchodilator effects from specific airway resistance changes in,stable COPD patients .,,"['Assessment', 'of', 'acute', 'bronchodilator', 'effects', 'from', 'specific', 'airway', 'resistance', 'changes', 'in', 'stable', 'COPD', 'patients', '.']","(11, 15)","(85, 107)",-1,hl_p,24726342,Title,0,test,gold,3777.0
5721,BACKGROUND In,COPD patients,", reversibility is currently evaluated from the changes of forced expiratory volume at 1s ( ΔFEV1 ) and forced vital capacity ( ΔFVC ) .","['BACKGROUND', 'In', 'COPD', 'patients', ',', 'reversibility', 'is', 'currently', 'evaluated', 'from', 'the', 'changes', 'of', 'forced', 'expiratory', 'volume', 'at', '1s', '(', 'ΔFEV1', ')', 'and', 'forced', 'vital', 'capacity', '(', 'ΔFVC', ')', '.']","(2, 4)","(13, 26)",-1,ss_p,24726342,Abstract,0,test,gold,3779.0
5722,"BACKGROUND In COPD patients , reversibility is currently evaluated from the changes of",forced expiratory volume at 1s ( ΔFEV1 ) and forced vital capacity ( ΔFVC ),.,"['BACKGROUND', 'In', 'COPD', 'patients', ',', 'reversibility', 'is', 'currently', 'evaluated', 'from', 'the', 'changes', 'of', 'forced', 'expiratory', 'volume', 'at', '1s', '(', 'ΔFEV1', ')', 'and', 'forced', 'vital', 'capacity', '(', 'ΔFVC', ')', '.']","(13, 28)","(86, 161)",-1,ss_o,24726342,Abstract,0,test,gold,1723.0
5723,BACKGROUND In,COPD patients,", reversibility is currently evaluated from the changes of forced expiratory volume at 1s ( ΔFEV1 ) and forced vital capacity ( ΔFVC ) .","['BACKGROUND', 'In', 'COPD', 'patients', ',', 'reversibility', 'is', 'currently', 'evaluated', 'from', 'the', 'changes', 'of', 'forced', 'expiratory', 'volume', 'at', '1s', '(', 'ΔFEV1', ')', 'and', 'forced', 'vital', 'capacity', '(', 'ΔFVC', ')', '.']","(2, 4)","(13, 26)",-1,hl_p,24726342,Abstract,0,test,gold,3780.0
5724,By lowering peripheral airway smooth muscle,"tone , bronchodilators","should decrease dynamic hyperinflation , gas trapping , and possibly dyspnea at rest .","['By', 'lowering', 'peripheral', 'airway', 'smooth', 'muscle', 'tone', ',', 'bronchodilators', 'should', 'decrease', 'dynamic', 'hyperinflation', ',', 'gas', 'trapping', ',', 'and', 'possibly', 'dyspnea', 'at', 'rest', '.']","(6, 9)","(43, 65)",-1,ss_i,24726342,Abstract,1,test,gold,5601.0
5725,"By lowering peripheral airway smooth muscle tone , bronchodilators should","decrease dynamic hyperinflation , gas trapping",", and possibly dyspnea at rest .","['By', 'lowering', 'peripheral', 'airway', 'smooth', 'muscle', 'tone', ',', 'bronchodilators', 'should', 'decrease', 'dynamic', 'hyperinflation', ',', 'gas', 'trapping', ',', 'and', 'possibly', 'dyspnea', 'at', 'rest', '.']","(10, 16)","(73, 119)",-1,ss_o,24726342,Abstract,1,test,gold,1730.0
5726,"By lowering peripheral airway smooth muscle tone , bronchodilators should decrease dynamic hyperinflation , gas trapping , and",possibly dyspnea at rest,.,"['By', 'lowering', 'peripheral', 'airway', 'smooth', 'muscle', 'tone', ',', 'bronchodilators', 'should', 'decrease', 'dynamic', 'hyperinflation', ',', 'gas', 'trapping', ',', 'and', 'possibly', 'dyspnea', 'at', 'rest', '.']","(18, 22)","(126, 150)",-1,ss_o,24726342,Abstract,1,test,gold,3511.0
5727,"Hence , we hypothesize that specific airway resistance changes ( ΔsRAW ) should better characterize the acute response",to bronchodilators,.,"['Hence', ',', 'we', 'hypothesize', 'that', 'specific', 'airway', 'resistance', 'changes', '(', 'ΔsRAW', ')', 'should', 'better', 'characterize', 'the', 'acute', 'response', 'to', 'bronchodilators', '.']","(18, 20)","(118, 136)",-1,ss_i,24726342,Abstract,2,test,gold,5604.0
5728,"Hence , we hypothesize",that specific airway resistance changes ( ΔsRAW ),should better characterize the acute response to bronchodilators .,"['Hence', ',', 'we', 'hypothesize', 'that', 'specific', 'airway', 'resistance', 'changes', '(', 'ΔsRAW', ')', 'should', 'better', 'characterize', 'the', 'acute', 'response', 'to', 'bronchodilators', '.']","(4, 12)","(22, 71)",-1,ss_o,24726342,Abstract,2,test,gold,3137.0
5729,"Hence , we hypothesize that",specific airway resistance changes ( ΔsRAW ),should better characterize the acute response to bronchodilators .,"['Hence', ',', 'we', 'hypothesize', 'that', 'specific', 'airway', 'resistance', 'changes', '(', 'ΔsRAW', ')', 'should', 'better', 'characterize', 'the', 'acute', 'response', 'to', 'bronchodilators', '.']","(5, 12)","(27, 71)",-1,hl_o,24726342,Abstract,2,test,gold,3138.0
5730,METHODS On two,"days , 60 COPD patients",underwent dyspnea evaluation ( VAS score ) and pulmonary function testing at baseline and one hour after placebo or 300μg indacaterol administration .,"['METHODS', 'On', 'two', 'days', ',', '60', 'COPD', 'patients', 'underwent', 'dyspnea', 'evaluation', '(', 'VAS', 'score', ')', 'and', 'pulmonary', 'function', 'testing', 'at', 'baseline', 'and', 'one', 'hour', 'after', 'placebo', 'or', '300μg', 'indacaterol', 'administration', '.']","(3, 8)","(14, 37)",-1,ss_p,24726342,Abstract,3,test,gold,3778.0
5731,"METHODS On two days , 60 COPD patients underwent dyspnea evaluation ( VAS score ) and pulmonary function testing at baseline and one hour",after placebo,or 300μg indacaterol administration .,"['METHODS', 'On', 'two', 'days', ',', '60', 'COPD', 'patients', 'underwent', 'dyspnea', 'evaluation', '(', 'VAS', 'score', ')', 'and', 'pulmonary', 'function', 'testing', 'at', 'baseline', 'and', 'one', 'hour', 'after', 'placebo', 'or', '300μg', 'indacaterol', 'administration', '.']","(24, 26)","(137, 150)",-1,ss_i,24726342,Abstract,3,test,gold,4260.0
5732,"METHODS On two days , 60 COPD patients underwent dyspnea evaluation ( VAS score ) and pulmonary function testing at baseline and one hour after placebo or",300μg indacaterol,administration .,"['METHODS', 'On', 'two', 'days', ',', '60', 'COPD', 'patients', 'underwent', 'dyspnea', 'evaluation', '(', 'VAS', 'score', ')', 'and', 'pulmonary', 'function', 'testing', 'at', 'baseline', 'and', 'one', 'hour', 'after', 'placebo', 'or', '300μg', 'indacaterol', 'administration', '.']","(27, 29)","(154, 171)",-1,ss_i,24726342,Abstract,3,test,gold,5576.0
5733,"METHODS On two days , 60 COPD patients",underwent dyspnea evaluation ( VAS score ) and pulmonary function testing,at baseline and one hour after placebo or 300μg indacaterol administration .,"['METHODS', 'On', 'two', 'days', ',', '60', 'COPD', 'patients', 'underwent', 'dyspnea', 'evaluation', '(', 'VAS', 'score', ')', 'and', 'pulmonary', 'function', 'testing', 'at', 'baseline', 'and', 'one', 'hour', 'after', 'placebo', 'or', '300μg', 'indacaterol', 'administration', '.']","(8, 19)","(38, 111)",-1,ss_o,24726342,Abstract,3,test,gold,5971.0
5734,"METHODS On two days ,",60 COPD,patients underwent dyspnea evaluation ( VAS score ) and pulmonary function testing at baseline and one hour after placebo or 300μg indacaterol administration .,"['METHODS', 'On', 'two', 'days', ',', '60', 'COPD', 'patients', 'underwent', 'dyspnea', 'evaluation', '(', 'VAS', 'score', ')', 'and', 'pulmonary', 'function', 'testing', 'at', 'baseline', 'and', 'one', 'hour', 'after', 'placebo', 'or', '300μg', 'indacaterol', 'administration', '.']","(5, 7)","(21, 28)",-1,hl_p,24726342,Abstract,3,test,gold,3460.0
5735,"METHODS On two days , 60 COPD patients underwent dyspnea evaluation ( VAS score ) and pulmonary function testing at baseline and one hour after",placebo,or 300μg indacaterol administration .,"['METHODS', 'On', 'two', 'days', ',', '60', 'COPD', 'patients', 'underwent', 'dyspnea', 'evaluation', '(', 'VAS', 'score', ')', 'and', 'pulmonary', 'function', 'testing', 'at', 'baseline', 'and', 'one', 'hour', 'after', 'placebo', 'or', '300μg', 'indacaterol', 'administration', '.']","(25, 26)","(143, 150)",-1,hl_i,24726342,Abstract,3,test,gold,4328.0
5736,"METHODS On two days , 60 COPD patients underwent dyspnea evaluation ( VAS score ) and pulmonary function testing at baseline and one hour after placebo or 300μg",indacaterol,administration .,"['METHODS', 'On', 'two', 'days', ',', '60', 'COPD', 'patients', 'underwent', 'dyspnea', 'evaluation', '(', 'VAS', 'score', ')', 'and', 'pulmonary', 'function', 'testing', 'at', 'baseline', 'and', 'one', 'hour', 'after', 'placebo', 'or', '300μg', 'indacaterol', 'administration', '.']","(28, 29)","(160, 171)",-1,hl_i,24726342,Abstract,3,test,gold,5577.0
5737,"METHODS On two days , 60 COPD patients underwent",dyspnea evaluation ( VAS score ),and pulmonary function testing at baseline and one hour after placebo or 300μg indacaterol administration .,"['METHODS', 'On', 'two', 'days', ',', '60', 'COPD', 'patients', 'underwent', 'dyspnea', 'evaluation', '(', 'VAS', 'score', ')', 'and', 'pulmonary', 'function', 'testing', 'at', 'baseline', 'and', 'one', 'hour', 'after', 'placebo', 'or', '300μg', 'indacaterol', 'administration', '.']","(9, 15)","(48, 80)",-1,hl_o,24726342,Abstract,3,test,gold,382.0
5738,"METHODS On two days , 60 COPD patients underwent dyspnea evaluation ( VAS score ) and",pulmonary function,testing at baseline and one hour after placebo or 300μg indacaterol administration .,"['METHODS', 'On', 'two', 'days', ',', '60', 'COPD', 'patients', 'underwent', 'dyspnea', 'evaluation', '(', 'VAS', 'score', ')', 'and', 'pulmonary', 'function', 'testing', 'at', 'baseline', 'and', 'one', 'hour', 'after', 'placebo', 'or', '300μg', 'indacaterol', 'administration', '.']","(16, 18)","(85, 103)",-1,hl_o,24726342,Abstract,3,test,gold,3147.0
5739,,RESULTS Spirographic and ΔsRAW-based criteria,"identified as responders 24 and 45 patients , respectively .","['RESULTS', 'Spirographic', 'and', 'ΔsRAW-based', 'criteria', 'identified', 'as', 'responders', '24', 'and', '45', 'patients', ',', 'respectively', '.']","(0, 5)","(0, 45)",-1,ss_o,24726342,Abstract,4,test,gold,363.0
5740,RESULTS,Spirographic,"and ΔsRAW-based criteria identified as responders 24 and 45 patients , respectively .","['RESULTS', 'Spirographic', 'and', 'ΔsRAW-based', 'criteria', 'identified', 'as', 'responders', '24', 'and', '45', 'patients', ',', 'respectively', '.']","(1, 2)","(7, 19)",-1,hl_o,24726342,Abstract,4,test,gold,
5741,RESULTS Spirographic and,ΔsRAW-based,"criteria identified as responders 24 and 45 patients , respectively .","['RESULTS', 'Spirographic', 'and', 'ΔsRAW-based', 'criteria', 'identified', 'as', 'responders', '24', 'and', '45', 'patients', ',', 'respectively', '.']","(3, 4)","(24, 35)",-1,hl_o,24726342,Abstract,4,test,gold,
5742,ΔsRAW correlated with,changes of intrathoracic gas volume ( ΔITGV ),"( r=0.61 ; p < 0.001 ) , residual volume ( ΔRV ) ( r=0.60 ; p < 0.001 ) , ΔFVC ( r=0.44 ; p=0.001 ) , and ΔVAS ( r=0.73 ; p < 0.001 ) , while ΔFEV1 correlated only with ΔFVC ( r=0.34 ; p=0.008 ) .","['ΔsRAW', 'correlated', 'with', 'changes', 'of', 'intrathoracic', 'gas', 'volume', '(', 'ΔITGV', ')', '(', 'r=0.61', ';', 'p', '<', '0.001', ')', ',', 'residual', 'volume', '(', 'ΔRV', ')', '(', 'r=0.60', ';', 'p', '<', '0.001', ')', ',', 'ΔFVC', '(', 'r=0.44', ';', 'p=0.001', ')', ',', 'and', 'ΔVAS', '(', 'r=0.73', ';', 'p', '<', '0.001', ')', ',', 'while', 'ΔFEV1', 'correlated', 'only', 'with', 'ΔFVC', '(', 'r=0.34', ';', 'p=0.008', ')', '.']","(3, 11)","(21, 66)",-1,ss_o,24726342,Abstract,5,test,gold,1725.0
5743,ΔsRAW correlated with changes of intrathoracic gas volume ( ΔITGV ) ( r=0.61 ;,"p < 0.001 ) , residual volume","( ΔRV ) ( r=0.60 ; p < 0.001 ) , ΔFVC ( r=0.44 ; p=0.001 ) , and ΔVAS ( r=0.73 ; p < 0.001 ) , while ΔFEV1 correlated only with ΔFVC ( r=0.34 ; p=0.008 ) .","['ΔsRAW', 'correlated', 'with', 'changes', 'of', 'intrathoracic', 'gas', 'volume', '(', 'ΔITGV', ')', '(', 'r=0.61', ';', 'p', '<', '0.001', ')', ',', 'residual', 'volume', '(', 'ΔRV', ')', '(', 'r=0.60', ';', 'p', '<', '0.001', ')', ',', 'ΔFVC', '(', 'r=0.44', ';', 'p=0.001', ')', ',', 'and', 'ΔVAS', '(', 'r=0.73', ';', 'p', '<', '0.001', ')', ',', 'while', 'ΔFEV1', 'correlated', 'only', 'with', 'ΔFVC', '(', 'r=0.34', ';', 'p=0.008', ')', '.']","(14, 21)","(78, 107)",-1,ss_o,24726342,Abstract,5,test,gold,1728.0
5744,"ΔsRAW correlated with changes of intrathoracic gas volume ( ΔITGV ) ( r=0.61 ; p < 0.001 ) , residual volume ( ΔRV ) ( r=0.60 ;",p < 0.001 ),", ΔFVC ( r=0.44 ; p=0.001 ) , and ΔVAS ( r=0.73 ; p < 0.001 ) , while ΔFEV1 correlated only with ΔFVC ( r=0.34 ; p=0.008 ) .","['ΔsRAW', 'correlated', 'with', 'changes', 'of', 'intrathoracic', 'gas', 'volume', '(', 'ΔITGV', ')', '(', 'r=0.61', ';', 'p', '<', '0.001', ')', ',', 'residual', 'volume', '(', 'ΔRV', ')', '(', 'r=0.60', ';', 'p', '<', '0.001', ')', ',', 'ΔFVC', '(', 'r=0.44', ';', 'p=0.001', ')', ',', 'and', 'ΔVAS', '(', 'r=0.73', ';', 'p', '<', '0.001', ')', ',', 'while', 'ΔFEV1', 'correlated', 'only', 'with', 'ΔFVC', '(', 'r=0.34', ';', 'p=0.008', ')', '.']","(27, 31)","(127, 138)",-1,ss_o,24726342,Abstract,5,test,gold,817.0
5745,"ΔsRAW correlated with changes of intrathoracic gas volume ( ΔITGV ) ( r=0.61 ; p < 0.001 ) , residual volume ( ΔRV ) ( r=0.60 ; p < 0.001 ) , ΔFVC ( r=0.44 ;",p=0.001 ),", and ΔVAS ( r=0.73 ; p < 0.001 ) , while ΔFEV1 correlated only with ΔFVC ( r=0.34 ; p=0.008 ) .","['ΔsRAW', 'correlated', 'with', 'changes', 'of', 'intrathoracic', 'gas', 'volume', '(', 'ΔITGV', ')', '(', 'r=0.61', ';', 'p', '<', '0.001', ')', ',', 'residual', 'volume', '(', 'ΔRV', ')', '(', 'r=0.60', ';', 'p', '<', '0.001', ')', ',', 'ΔFVC', '(', 'r=0.44', ';', 'p=0.001', ')', ',', 'and', 'ΔVAS', '(', 'r=0.73', ';', 'p', '<', '0.001', ')', ',', 'while', 'ΔFEV1', 'correlated', 'only', 'with', 'ΔFVC', '(', 'r=0.34', ';', 'p=0.008', ')', '.']","(36, 38)","(157, 166)",-1,ss_o,24726342,Abstract,5,test,gold,
5746,"ΔsRAW correlated with changes of intrathoracic gas volume ( ΔITGV ) ( r=0.61 ; p < 0.001 ) , residual volume ( ΔRV ) ( r=0.60 ; p < 0.001 ) , ΔFVC ( r=0.44 ; p=0.001 ) , and ΔVAS ( r=0.73 ;","p < 0.001 ) , while",ΔFEV1 correlated only with ΔFVC ( r=0.34 ; p=0.008 ) .,"['ΔsRAW', 'correlated', 'with', 'changes', 'of', 'intrathoracic', 'gas', 'volume', '(', 'ΔITGV', ')', '(', 'r=0.61', ';', 'p', '<', '0.001', ')', ',', 'residual', 'volume', '(', 'ΔRV', ')', '(', 'r=0.60', ';', 'p', '<', '0.001', ')', ',', 'ΔFVC', '(', 'r=0.44', ';', 'p=0.001', ')', ',', 'and', 'ΔVAS', '(', 'r=0.73', ';', 'p', '<', '0.001', ')', ',', 'while', 'ΔFEV1', 'correlated', 'only', 'with', 'ΔFVC', '(', 'r=0.34', ';', 'p=0.008', ')', '.']","(44, 50)","(189, 208)",-1,ss_o,24726342,Abstract,5,test,gold,818.0
5747,"ΔsRAW correlated with changes of intrathoracic gas volume ( ΔITGV ) ( r=0.61 ; p < 0.001 ) , residual volume ( ΔRV ) ( r=0.60 ; p < 0.001 ) , ΔFVC ( r=0.44 ; p=0.001 ) , and ΔVAS ( r=0.73 ; p < 0.001 ) , while ΔFEV1",correlated only,with ΔFVC ( r=0.34 ; p=0.008 ) .,"['ΔsRAW', 'correlated', 'with', 'changes', 'of', 'intrathoracic', 'gas', 'volume', '(', 'ΔITGV', ')', '(', 'r=0.61', ';', 'p', '<', '0.001', ')', ',', 'residual', 'volume', '(', 'ΔRV', ')', '(', 'r=0.60', ';', 'p', '<', '0.001', ')', ',', 'ΔFVC', '(', 'r=0.44', ';', 'p=0.001', ')', ',', 'and', 'ΔVAS', '(', 'r=0.73', ';', 'p', '<', '0.001', ')', ',', 'while', 'ΔFEV1', 'correlated', 'only', 'with', 'ΔFVC', '(', 'r=0.34', ';', 'p=0.008', ')', '.']","(51, 53)","(215, 230)",-1,ss_o,24726342,Abstract,5,test,gold,1306.0
5748,,ΔsRAW,"correlated with changes of intrathoracic gas volume ( ΔITGV ) ( r=0.61 ; p < 0.001 ) , residual volume ( ΔRV ) ( r=0.60 ; p < 0.001 ) , ΔFVC ( r=0.44 ; p=0.001 ) , and ΔVAS ( r=0.73 ; p < 0.001 ) , while ΔFEV1 correlated only with ΔFVC ( r=0.34 ; p=0.008 ) .","['ΔsRAW', 'correlated', 'with', 'changes', 'of', 'intrathoracic', 'gas', 'volume', '(', 'ΔITGV', ')', '(', 'r=0.61', ';', 'p', '<', '0.001', ')', ',', 'residual', 'volume', '(', 'ΔRV', ')', '(', 'r=0.60', ';', 'p', '<', '0.001', ')', ',', 'ΔFVC', '(', 'r=0.44', ';', 'p=0.001', ')', ',', 'and', 'ΔVAS', '(', 'r=0.73', ';', 'p', '<', '0.001', ')', ',', 'while', 'ΔFEV1', 'correlated', 'only', 'with', 'ΔFVC', '(', 'r=0.34', ';', 'p=0.008', ')', '.']","(0, 1)","(0, 5)",-1,hl_o,24726342,Abstract,5,test,gold,
5749,ΔsRAW correlated with changes of,intrathoracic gas volume ( ΔITGV ),"( r=0.61 ; p < 0.001 ) , residual volume ( ΔRV ) ( r=0.60 ; p < 0.001 ) , ΔFVC ( r=0.44 ; p=0.001 ) , and ΔVAS ( r=0.73 ; p < 0.001 ) , while ΔFEV1 correlated only with ΔFVC ( r=0.34 ; p=0.008 ) .","['ΔsRAW', 'correlated', 'with', 'changes', 'of', 'intrathoracic', 'gas', 'volume', '(', 'ΔITGV', ')', '(', 'r=0.61', ';', 'p', '<', '0.001', ')', ',', 'residual', 'volume', '(', 'ΔRV', ')', '(', 'r=0.60', ';', 'p', '<', '0.001', ')', ',', 'ΔFVC', '(', 'r=0.44', ';', 'p=0.001', ')', ',', 'and', 'ΔVAS', '(', 'r=0.73', ';', 'p', '<', '0.001', ')', ',', 'while', 'ΔFEV1', 'correlated', 'only', 'with', 'ΔFVC', '(', 'r=0.34', ';', 'p=0.008', ')', '.']","(5, 11)","(32, 66)",-1,hl_o,24726342,Abstract,5,test,gold,1726.0
5750,"ΔsRAW correlated with changes of intrathoracic gas volume ( ΔITGV ) ( r=0.61 ; p < 0.001 ) ,",residual volume,"( ΔRV ) ( r=0.60 ; p < 0.001 ) , ΔFVC ( r=0.44 ; p=0.001 ) , and ΔVAS ( r=0.73 ; p < 0.001 ) , while ΔFEV1 correlated only with ΔFVC ( r=0.34 ; p=0.008 ) .","['ΔsRAW', 'correlated', 'with', 'changes', 'of', 'intrathoracic', 'gas', 'volume', '(', 'ΔITGV', ')', '(', 'r=0.61', ';', 'p', '<', '0.001', ')', ',', 'residual', 'volume', '(', 'ΔRV', ')', '(', 'r=0.60', ';', 'p', '<', '0.001', ')', ',', 'ΔFVC', '(', 'r=0.44', ';', 'p=0.001', ')', ',', 'and', 'ΔVAS', '(', 'r=0.73', ';', 'p', '<', '0.001', ')', ',', 'while', 'ΔFEV1', 'correlated', 'only', 'with', 'ΔFVC', '(', 'r=0.34', ';', 'p=0.008', ')', '.']","(19, 21)","(92, 107)",-1,hl_o,24726342,Abstract,5,test,gold,1729.0
5751,Significant differences,in terms,"of ΔITGV ( p=0.002 ) , ΔRV ( p=0.023 ) , and ΔVAS ( p < 0.001 ) occurred only if patients were stratified according to ΔsRAW .","['Significant', 'differences', 'in', 'terms', 'of', 'ΔITGV', '(', 'p=0.002', ')', ',', 'ΔRV', '(', 'p=0.023', ')', ',', 'and', 'ΔVAS', '(', 'p', '<', '0.001', ')', 'occurred', 'only', 'if', 'patients', 'were', 'stratified', 'according', 'to', 'ΔsRAW', '.']","(2, 4)","(23, 31)",-1,ss_o,24726342,Abstract,6,test,gold,1185.0
5752,Significant differences in terms of,ΔITGV ( p=0.002 ),", ΔRV ( p=0.023 ) , and ΔVAS ( p < 0.001 ) occurred only if patients were stratified according to ΔsRAW .","['Significant', 'differences', 'in', 'terms', 'of', 'ΔITGV', '(', 'p=0.002', ')', ',', 'ΔRV', '(', 'p=0.023', ')', ',', 'and', 'ΔVAS', '(', 'p', '<', '0.001', ')', 'occurred', 'only', 'if', 'patients', 'were', 'stratified', 'according', 'to', 'ΔsRAW', '.']","(5, 9)","(35, 52)",-1,ss_o,24726342,Abstract,6,test,gold,
5753,"Significant differences in terms of ΔITGV ( p=0.002 ) , ΔRV",( p=0.023 ),", and ΔVAS ( p < 0.001 ) occurred only if patients were stratified according to ΔsRAW .","['Significant', 'differences', 'in', 'terms', 'of', 'ΔITGV', '(', 'p=0.002', ')', ',', 'ΔRV', '(', 'p=0.023', ')', ',', 'and', 'ΔVAS', '(', 'p', '<', '0.001', ')', 'occurred', 'only', 'if', 'patients', 'were', 'stratified', 'according', 'to', 'ΔsRAW', '.']","(11, 14)","(59, 70)",-1,ss_o,24726342,Abstract,6,test,gold,
5754,"Significant differences in terms of ΔITGV ( p=0.002 ) , ΔRV ( p=0.023 ) , and ΔVAS ( p < 0.001 ) occurred only if patients were",stratified according,to ΔsRAW .,"['Significant', 'differences', 'in', 'terms', 'of', 'ΔITGV', '(', 'p=0.002', ')', ',', 'ΔRV', '(', 'p=0.023', ')', ',', 'and', 'ΔVAS', '(', 'p', '<', '0.001', ')', 'occurred', 'only', 'if', 'patients', 'were', 'stratified', 'according', 'to', 'ΔsRAW', '.']","(27, 29)","(127, 147)",-1,ss_o,24726342,Abstract,6,test,gold,1305.0
5755,CONCLUSIONS In assessing the acute,functional effect of,"bronchodilators , ΔsRAW-based criterion is preferable to FEV1-FVC-based criteria , being more closely related to bronchodilator-induced improvements of lung mechanics and dyspnea at rest .","['CONCLUSIONS', 'In', 'assessing', 'the', 'acute', 'functional', 'effect', 'of', 'bronchodilators', ',', 'ΔsRAW-based', 'criterion', 'is', 'preferable', 'to', 'FEV1-FVC-based', 'criteria', ',', 'being', 'more', 'closely', 'related', 'to', 'bronchodilator-induced', 'improvements', 'of', 'lung', 'mechanics', 'and', 'dyspnea', 'at', 'rest', '.']","(5, 8)","(34, 54)",-1,ss_i,24726342,Abstract,7,test,gold,2333.0
5756,"CONCLUSIONS In assessing the acute functional effect of bronchodilators , ΔsRAW-based criterion is preferable to FEV1-FVC-based criteria , being more",closely related to,bronchodilator-induced improvements of lung mechanics and dyspnea at rest .,"['CONCLUSIONS', 'In', 'assessing', 'the', 'acute', 'functional', 'effect', 'of', 'bronchodilators', ',', 'ΔsRAW-based', 'criterion', 'is', 'preferable', 'to', 'FEV1-FVC-based', 'criteria', ',', 'being', 'more', 'closely', 'related', 'to', 'bronchodilator-induced', 'improvements', 'of', 'lung', 'mechanics', 'and', 'dyspnea', 'at', 'rest', '.']","(20, 23)","(149, 167)",-1,ss_i,24726342,Abstract,7,test,gold,1304.0
5757,"CONCLUSIONS In assessing the acute functional effect of bronchodilators , ΔsRAW-based criterion is preferable to FEV1-FVC-based criteria , being more closely related to",bronchodilator-induced improvements of lung mechanics and,dyspnea at rest .,"['CONCLUSIONS', 'In', 'assessing', 'the', 'acute', 'functional', 'effect', 'of', 'bronchodilators', ',', 'ΔsRAW-based', 'criterion', 'is', 'preferable', 'to', 'FEV1-FVC-based', 'criteria', ',', 'being', 'more', 'closely', 'related', 'to', 'bronchodilator-induced', 'improvements', 'of', 'lung', 'mechanics', 'and', 'dyspnea', 'at', 'rest', '.']","(23, 29)","(168, 225)",-1,ss_o,24726342,Abstract,7,test,gold,2716.0
5758,"CONCLUSIONS In assessing the acute functional effect of bronchodilators ,",ΔsRAW-based,"criterion is preferable to FEV1-FVC-based criteria , being more closely related to bronchodilator-induced improvements of lung mechanics and dyspnea at rest .","['CONCLUSIONS', 'In', 'assessing', 'the', 'acute', 'functional', 'effect', 'of', 'bronchodilators', ',', 'ΔsRAW-based', 'criterion', 'is', 'preferable', 'to', 'FEV1-FVC-based', 'criteria', ',', 'being', 'more', 'closely', 'related', 'to', 'bronchodilator-induced', 'improvements', 'of', 'lung', 'mechanics', 'and', 'dyspnea', 'at', 'rest', '.']","(10, 11)","(73, 84)",-1,hl_o,24726342,Abstract,7,test,gold,
5759,"CONCLUSIONS In assessing the acute functional effect of bronchodilators , ΔsRAW-based criterion is preferable to",FEV1-FVC-based,"criteria , being more closely related to bronchodilator-induced improvements of lung mechanics and dyspnea at rest .","['CONCLUSIONS', 'In', 'assessing', 'the', 'acute', 'functional', 'effect', 'of', 'bronchodilators', ',', 'ΔsRAW-based', 'criterion', 'is', 'preferable', 'to', 'FEV1-FVC-based', 'criteria', ',', 'being', 'more', 'closely', 'related', 'to', 'bronchodilator-induced', 'improvements', 'of', 'lung', 'mechanics', 'and', 'dyspnea', 'at', 'rest', '.']","(15, 16)","(112, 126)",-1,hl_o,24726342,Abstract,7,test,gold,
5760,,Youth with autism spectrum disorder,comprehend lexicalized and novel primary conceptual metaphors .,"['Youth', 'with', 'autism', 'spectrum', 'disorder', 'comprehend', 'lexicalized', 'and', 'novel', 'primary', 'conceptual', 'metaphors', '.']","(0, 5)","(0, 35)",-1,ss_p,24803369,Title,0,test,gold,6016.0
5761,Youth with autism spectrum disorder comprehend,lexicalized,and novel primary conceptual metaphors .,"['Youth', 'with', 'autism', 'spectrum', 'disorder', 'comprehend', 'lexicalized', 'and', 'novel', 'primary', 'conceptual', 'metaphors', '.']","(6, 7)","(46, 57)",-1,ss_i,24803369,Title,0,test,gold,
5762,Youth with autism spectrum disorder comprehend lexicalized and novel,primary conceptual metaphors .,,"['Youth', 'with', 'autism', 'spectrum', 'disorder', 'comprehend', 'lexicalized', 'and', 'novel', 'primary', 'conceptual', 'metaphors', '.']","(9, 13)","(68, 98)",-1,ss_i,24803369,Title,0,test,gold,3008.0
5763,,Youth,with autism spectrum disorder comprehend lexicalized and novel primary conceptual metaphors .,"['Youth', 'with', 'autism', 'spectrum', 'disorder', 'comprehend', 'lexicalized', 'and', 'novel', 'primary', 'conceptual', 'metaphors', '.']","(0, 1)","(0, 5)",-1,hl_p,24803369,Title,0,test,gold,2180.0
5764,Youth with,autism spectrum disorder,comprehend lexicalized and novel primary conceptual metaphors .,"['Youth', 'with', 'autism', 'spectrum', 'disorder', 'comprehend', 'lexicalized', 'and', 'novel', 'primary', 'conceptual', 'metaphors', '.']","(2, 5)","(10, 34)",-1,hl_p,24803369,Title,0,test,gold,6012.0
5765,Youth with autism spectrum disorder comprehend,lexicalized,and novel primary conceptual metaphors .,"['Youth', 'with', 'autism', 'spectrum', 'disorder', 'comprehend', 'lexicalized', 'and', 'novel', 'primary', 'conceptual', 'metaphors', '.']","(6, 7)","(46, 57)",-1,hl_i,24803369,Title,0,test,gold,
5766,Youth with autism spectrum disorder comprehend lexicalized and novel,primary conceptual metaphors .,,"['Youth', 'with', 'autism', 'spectrum', 'disorder', 'comprehend', 'lexicalized', 'and', 'novel', 'primary', 'conceptual', 'metaphors', '.']","(9, 13)","(68, 98)",-1,hl_i,24803369,Title,0,test,gold,3009.0
5767,,Individuals with autism spectrum disorder ( ASD ),have difficulty comprehending metaphors .,"['Individuals', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'have', 'difficulty', 'comprehending', 'metaphors', '.']","(0, 8)","(0, 49)",-1,ss_p,24803369,Abstract,0,test,gold,6039.0
5768,Individuals with autism spectrum disorder ( ASD ) have difficulty comprehending,metaphors .,,"['Individuals', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'have', 'difficulty', 'comprehending', 'metaphors', '.']","(11, 13)","(79, 90)",-1,ss_i,24803369,Abstract,0,test,gold,3016.0
5769,Individuals with autism spectrum disorder ( ASD ) have difficulty,comprehending metaphors .,,"['Individuals', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'have', 'difficulty', 'comprehending', 'metaphors', '.']","(10, 13)","(65, 90)",-1,ss_o,24803369,Abstract,0,test,gold,3010.0
5770,,Individuals with autism spectrum disorder ( ASD ),have difficulty comprehending metaphors .,"['Individuals', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'have', 'difficulty', 'comprehending', 'metaphors', '.']","(0, 8)","(0, 49)",-1,hl_p,24803369,Abstract,0,test,gold,6040.0
5771,Individuals with autism spectrum disorder ( ASD ) have difficulty comprehending,metaphors .,,"['Individuals', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'have', 'difficulty', 'comprehending', 'metaphors', '.']","(11, 13)","(79, 90)",-1,hl_i,24803369,Abstract,0,test,gold,3017.0
5772,Individuals with autism spectrum disorder ( ASD ) have difficulty,comprehending metaphors,.,"['Individuals', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'have', 'difficulty', 'comprehending', 'metaphors', '.']","(10, 12)","(65, 88)",-1,hl_o,24803369,Abstract,0,test,gold,3011.0
5773,"However , no study to date has examined whether or not they understand",conceptual metaphors,( i.e .,"['However', ',', 'no', 'study', 'to', 'date', 'has', 'examined', 'whether', 'or', 'not', 'they', 'understand', 'conceptual', 'metaphors', '(', 'i.e', '.']","(13, 15)","(70, 90)",-1,ss_i,24803369,Abstract,1,test,gold,3006.0
5774,"However , no study to date has examined whether or not they understand",conceptual metaphors,( i.e .,"['However', ',', 'no', 'study', 'to', 'date', 'has', 'examined', 'whether', 'or', 'not', 'they', 'understand', 'conceptual', 'metaphors', '(', 'i.e', '.']","(13, 15)","(70, 90)",-1,ss_o,24803369,Abstract,1,test,gold,3007.0
5775,"However , no study to date has examined whether or not they understand",conceptual metaphors,( i.e .,"['However', ',', 'no', 'study', 'to', 'date', 'has', 'examined', 'whether', 'or', 'not', 'they', 'understand', 'conceptual', 'metaphors', '(', 'i.e', '.']","(13, 15)","(70, 90)",-1,hl_i,24803369,Abstract,1,test,gold,3005.0
5776,"However , no study to date has examined whether or not they understand",conceptual metaphors,( i.e .,"['However', ',', 'no', 'study', 'to', 'date', 'has', 'examined', 'whether', 'or', 'not', 'they', 'understand', 'conceptual', 'metaphors', '(', 'i.e', '.']","(13, 15)","(70, 90)",-1,hl_o,24803369,Abstract,1,test,gold,3004.0
5777,"mappings between conceptual structures ) , which could be the building blocks of metaphoric thinking and understanding .",,,"['mappings', 'between', 'conceptual', 'structures', ')', ',', 'which', 'could', 'be', 'the', 'building', 'blocks', 'of', 'metaphoric', 'thinking', 'and', 'understanding', '.']",,,,,24803369,Abstract,2,test,gold,
5778,We investigated whether,13 participants with ASD ( age 7 ; 03-22 ; 03 ) and 13 age-matched typically developing ( TD ) controls,"could comprehend lexicalized conceptual metaphors ( e.g. , Susan is a warm person ) and novel ones ( e.g. , Susan is a toasty person ) .","['We', 'investigated', 'whether', '13', 'participants', 'with', 'ASD', '(', 'age', '7', ';', '03-22', ';', '03', ')', 'and', '13', 'age-matched', 'typically', 'developing', '(', 'TD', ')', 'controls', 'could', 'comprehend', 'lexicalized', 'conceptual', 'metaphors', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'warm', 'person', ')', 'and', 'novel', 'ones', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'toasty', 'person', ')', '.']","(3, 24)","(23, 126)",-1,ss_p,24803369,Abstract,3,test,gold,6189.0
5779,We investigated whether 13 participants with ASD ( age 7 ; 03-22 ; 03 ) and 13 age-matched typically developing ( TD ) controls could comprehend lexicalized,conceptual metaphors,"( e.g. , Susan is a warm person ) and novel ones ( e.g. , Susan is a toasty person ) .","['We', 'investigated', 'whether', '13', 'participants', 'with', 'ASD', '(', 'age', '7', ';', '03-22', ';', '03', ')', 'and', '13', 'age-matched', 'typically', 'developing', '(', 'TD', ')', 'controls', 'could', 'comprehend', 'lexicalized', 'conceptual', 'metaphors', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'warm', 'person', ')', 'and', 'novel', 'ones', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'toasty', 'person', ')', '.']","(27, 29)","(156, 176)",-1,ss_i,24803369,Abstract,3,test,gold,3003.0
5780,We investigated whether 13 participants with ASD ( age 7 ; 03-22 ; 03 ) and 13 age-matched typically developing ( TD ) controls could comprehend,lexicalized conceptual metaphors,"( e.g. , Susan is a warm person ) and novel ones ( e.g. , Susan is a toasty person ) .","['We', 'investigated', 'whether', '13', 'participants', 'with', 'ASD', '(', 'age', '7', ';', '03-22', ';', '03', ')', 'and', '13', 'age-matched', 'typically', 'developing', '(', 'TD', ')', 'controls', 'could', 'comprehend', 'lexicalized', 'conceptual', 'metaphors', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'warm', 'person', ')', 'and', 'novel', 'ones', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'toasty', 'person', ')', '.']","(26, 29)","(144, 176)",-1,ss_o,24803369,Abstract,3,test,gold,3002.0
5781,"We investigated whether 13 participants with ASD ( age 7 ; 03-22 ; 03 ) and 13 age-matched typically developing ( TD ) controls could comprehend lexicalized conceptual metaphors ( e.g. , Susan is a warm person ) and",novel ones,"( e.g. , Susan is a toasty person ) .","['We', 'investigated', 'whether', '13', 'participants', 'with', 'ASD', '(', 'age', '7', ';', '03-22', ';', '03', ')', 'and', '13', 'age-matched', 'typically', 'developing', '(', 'TD', ')', 'controls', 'could', 'comprehend', 'lexicalized', 'conceptual', 'metaphors', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'warm', 'person', ')', 'and', 'novel', 'ones', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'toasty', 'person', ')', '.']","(39, 41)","(215, 225)",-1,ss_o,24803369,Abstract,3,test,gold,1246.0
5782,We investigated whether,13 participants with ASD,"( age 7 ; 03-22 ; 03 ) and 13 age-matched typically developing ( TD ) controls could comprehend lexicalized conceptual metaphors ( e.g. , Susan is a warm person ) and novel ones ( e.g. , Susan is a toasty person ) .","['We', 'investigated', 'whether', '13', 'participants', 'with', 'ASD', '(', 'age', '7', ';', '03-22', ';', '03', ')', 'and', '13', 'age-matched', 'typically', 'developing', '(', 'TD', ')', 'controls', 'could', 'comprehend', 'lexicalized', 'conceptual', 'metaphors', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'warm', 'person', ')', 'and', 'novel', 'ones', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'toasty', 'person', ')', '.']","(3, 7)","(23, 47)",-1,hl_p,24803369,Abstract,3,test,gold,6097.0
5783,We investigated whether 13 participants with ASD (,age 7 ; 03-22 ; 03,") and 13 age-matched typically developing ( TD ) controls could comprehend lexicalized conceptual metaphors ( e.g. , Susan is a warm person ) and novel ones ( e.g. , Susan is a toasty person ) .","['We', 'investigated', 'whether', '13', 'participants', 'with', 'ASD', '(', 'age', '7', ';', '03-22', ';', '03', ')', 'and', '13', 'age-matched', 'typically', 'developing', '(', 'TD', ')', 'controls', 'could', 'comprehend', 'lexicalized', 'conceptual', 'metaphors', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'warm', 'person', ')', 'and', 'novel', 'ones', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'toasty', 'person', ')', '.']","(8, 14)","(50, 68)",-1,hl_p,24803369,Abstract,3,test,gold,2010.0
5784,We investigated whether 13 participants with ASD ( age 7 ; 03-22 ; 03 ) and,13 age-matched typically developing ( TD ) controls,"could comprehend lexicalized conceptual metaphors ( e.g. , Susan is a warm person ) and novel ones ( e.g. , Susan is a toasty person ) .","['We', 'investigated', 'whether', '13', 'participants', 'with', 'ASD', '(', 'age', '7', ';', '03-22', ';', '03', ')', 'and', '13', 'age-matched', 'typically', 'developing', '(', 'TD', ')', 'controls', 'could', 'comprehend', 'lexicalized', 'conceptual', 'metaphors', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'warm', 'person', ')', 'and', 'novel', 'ones', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'toasty', 'person', ')', '.']","(16, 24)","(75, 126)",-1,hl_p,24803369,Abstract,3,test,gold,904.0
5785,We investigated whether 13 participants with ASD ( age 7 ; 03-22 ; 03 ) and 13 age-matched typically developing ( TD ) controls could comprehend,lexicalized conceptual metaphors,"( e.g. , Susan is a warm person ) and novel ones ( e.g. , Susan is a toasty person ) .","['We', 'investigated', 'whether', '13', 'participants', 'with', 'ASD', '(', 'age', '7', ';', '03-22', ';', '03', ')', 'and', '13', 'age-matched', 'typically', 'developing', '(', 'TD', ')', 'controls', 'could', 'comprehend', 'lexicalized', 'conceptual', 'metaphors', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'warm', 'person', ')', 'and', 'novel', 'ones', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'toasty', 'person', ')', '.']","(26, 29)","(144, 176)",-1,hl_i,24803369,Abstract,3,test,gold,3001.0
5786,We investigated whether 13 participants with ASD ( age 7 ; 03-22 ; 03 ) and 13 age-matched typically developing ( TD ) controls could comprehend,lexicalized conceptual metaphors,"( e.g. , Susan is a warm person ) and novel ones ( e.g. , Susan is a toasty person ) .","['We', 'investigated', 'whether', '13', 'participants', 'with', 'ASD', '(', 'age', '7', ';', '03-22', ';', '03', ')', 'and', '13', 'age-matched', 'typically', 'developing', '(', 'TD', ')', 'controls', 'could', 'comprehend', 'lexicalized', 'conceptual', 'metaphors', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'warm', 'person', ')', 'and', 'novel', 'ones', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'toasty', 'person', ')', '.']","(26, 29)","(144, 176)",-1,hl_o,24803369,Abstract,3,test,gold,3000.0
5787,"We investigated whether 13 participants with ASD ( age 7 ; 03-22 ; 03 ) and 13 age-matched typically developing ( TD ) controls could comprehend lexicalized conceptual metaphors ( e.g. , Susan is a warm person ) and",novel ones,"( e.g. , Susan is a toasty person ) .","['We', 'investigated', 'whether', '13', 'participants', 'with', 'ASD', '(', 'age', '7', ';', '03-22', ';', '03', ')', 'and', '13', 'age-matched', 'typically', 'developing', '(', 'TD', ')', 'controls', 'could', 'comprehend', 'lexicalized', 'conceptual', 'metaphors', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'warm', 'person', ')', 'and', 'novel', 'ones', '(', 'e.g.', ',', 'Susan', 'is', 'a', 'toasty', 'person', ')', '.']","(39, 41)","(215, 225)",-1,hl_o,24803369,Abstract,3,test,gold,1247.0
5788,,Individuals with ASD,"performed at greater than chance levels on both metaphor types , although their performance was lower than TD participants .","['Individuals', 'with', 'ASD', 'performed', 'at', 'greater', 'than', 'chance', 'levels', 'on', 'both', 'metaphor', 'types', ',', 'although', 'their', 'performance', 'was', 'lower', 'than', 'TD', 'participants', '.']","(0, 3)","(0, 20)",-1,ss_p,24803369,Abstract,4,test,gold,6091.0
5789,Individuals with ASD performed at greater than chance levels on both,metaphor,"types , although their performance was lower than TD participants .","['Individuals', 'with', 'ASD', 'performed', 'at', 'greater', 'than', 'chance', 'levels', 'on', 'both', 'metaphor', 'types', ',', 'although', 'their', 'performance', 'was', 'lower', 'than', 'TD', 'participants', '.']","(11, 12)","(68, 76)",-1,ss_i,24803369,Abstract,4,test,gold,3014.0
5790,Individuals with ASD performed at greater than chance levels on both,metaphor,"types , although their performance was lower than TD participants .","['Individuals', 'with', 'ASD', 'performed', 'at', 'greater', 'than', 'chance', 'levels', 'on', 'both', 'metaphor', 'types', ',', 'although', 'their', 'performance', 'was', 'lower', 'than', 'TD', 'participants', '.']","(11, 12)","(68, 76)",-1,ss_o,24803369,Abstract,4,test,gold,3015.0
5791,,Individuals with ASD,"performed at greater than chance levels on both metaphor types , although their performance was lower than TD participants .","['Individuals', 'with', 'ASD', 'performed', 'at', 'greater', 'than', 'chance', 'levels', 'on', 'both', 'metaphor', 'types', ',', 'although', 'their', 'performance', 'was', 'lower', 'than', 'TD', 'participants', '.']","(0, 3)","(0, 20)",-1,hl_p,24803369,Abstract,4,test,gold,6092.0
5792,Individuals with ASD performed at greater than chance levels on both,metaphor,"types , although their performance was lower than TD participants .","['Individuals', 'with', 'ASD', 'performed', 'at', 'greater', 'than', 'chance', 'levels', 'on', 'both', 'metaphor', 'types', ',', 'although', 'their', 'performance', 'was', 'lower', 'than', 'TD', 'participants', '.']","(11, 12)","(68, 76)",-1,hl_i,24803369,Abstract,4,test,gold,3013.0
5793,Individuals with ASD performed at greater than chance levels on both,metaphor,"types , although their performance was lower than TD participants .","['Individuals', 'with', 'ASD', 'performed', 'at', 'greater', 'than', 'chance', 'levels', 'on', 'both', 'metaphor', 'types', ',', 'although', 'their', 'performance', 'was', 'lower', 'than', 'TD', 'participants', '.']","(11, 12)","(68, 76)",-1,hl_o,24803369,Abstract,4,test,gold,3012.0
5794,We discuss the theoretical relevance of these findings and educational implications .,,,"['We', 'discuss', 'the', 'theoretical', 'relevance', 'of', 'these', 'findings', 'and', 'educational', 'implications', '.']",,,,,24803369,Abstract,5,test,gold,
5795,Paternal RHD zygosity determination in,Tunisians :,evaluation of three molecular tests .,"['Paternal', 'RHD', 'zygosity', 'determination', 'in', 'Tunisians', ':', 'evaluation', 'of', 'three', 'molecular', 'tests', '.']","(5, 7)","(38, 49)",-1,ss_p,24960665,Title,0,test,gold,2219.0
5796,Paternal RHD zygosity determination in Tunisians : evaluation of three,molecular tests .,,"['Paternal', 'RHD', 'zygosity', 'determination', 'in', 'Tunisians', ':', 'evaluation', 'of', 'three', 'molecular', 'tests', '.']","(10, 13)","(70, 87)",-1,ss_i,24960665,Title,0,test,gold,1848.0
5797,,Paternal RHD zygosity,determination in Tunisians : evaluation of three molecular tests .,"['Paternal', 'RHD', 'zygosity', 'determination', 'in', 'Tunisians', ':', 'evaluation', 'of', 'three', 'molecular', 'tests', '.']","(0, 3)","(0, 21)",-1,ss_o,24960665,Title,0,test,gold,988.0
5798,Paternal RHD zygosity determination in,Tunisians :,evaluation of three molecular tests .,"['Paternal', 'RHD', 'zygosity', 'determination', 'in', 'Tunisians', ':', 'evaluation', 'of', 'three', 'molecular', 'tests', '.']","(5, 7)","(38, 49)",-1,hl_p,24960665,Title,0,test,gold,2220.0
5799,BACKGROUND The choice of a,molecular test,"for first intention determination of paternal RHD zygosity , before entering into invasive diagnostics , is important for the management of pregnancies at risk of haemolytic disease of the foetus and newborn related to anti-RhD .","['BACKGROUND', 'The', 'choice', 'of', 'a', 'molecular', 'test', 'for', 'first', 'intention', 'determination', 'of', 'paternal', 'RHD', 'zygosity', ',', 'before', 'entering', 'into', 'invasive', 'diagnostics', ',', 'is', 'important', 'for', 'the', 'management', 'of', 'pregnancies', 'at', 'risk', 'of', 'haemolytic', 'disease', 'of', 'the', 'foetus', 'and', 'newborn', 'related', 'to', 'anti-RhD', '.']","(5, 7)","(26, 40)",-1,ss_i,24960665,Abstract,0,test,gold,1846.0
5800,BACKGROUND The choice of a molecular test for first intention determination of,paternal RHD zygosity,", before entering into invasive diagnostics , is important for the management of pregnancies at risk of haemolytic disease of the foetus and newborn related to anti-RhD .","['BACKGROUND', 'The', 'choice', 'of', 'a', 'molecular', 'test', 'for', 'first', 'intention', 'determination', 'of', 'paternal', 'RHD', 'zygosity', ',', 'before', 'entering', 'into', 'invasive', 'diagnostics', ',', 'is', 'important', 'for', 'the', 'management', 'of', 'pregnancies', 'at', 'risk', 'of', 'haemolytic', 'disease', 'of', 'the', 'foetus', 'and', 'newborn', 'related', 'to', 'anti-RhD', '.']","(12, 15)","(78, 99)",-1,ss_o,24960665,Abstract,0,test,gold,986.0
5801,BACKGROUND The choice of a,molecular test,"for first intention determination of paternal RHD zygosity , before entering into invasive diagnostics , is important for the management of pregnancies at risk of haemolytic disease of the foetus and newborn related to anti-RhD .","['BACKGROUND', 'The', 'choice', 'of', 'a', 'molecular', 'test', 'for', 'first', 'intention', 'determination', 'of', 'paternal', 'RHD', 'zygosity', ',', 'before', 'entering', 'into', 'invasive', 'diagnostics', ',', 'is', 'important', 'for', 'the', 'management', 'of', 'pregnancies', 'at', 'risk', 'of', 'haemolytic', 'disease', 'of', 'the', 'foetus', 'and', 'newborn', 'related', 'to', 'anti-RhD', '.']","(5, 7)","(26, 40)",-1,hl_i,24960665,Abstract,0,test,gold,1847.0
5802,MATERIALS AND METHODS RHD zygosity was evaluated in,370 RH:1 Tunisian donors,by polymerase chain reaction - sequence-specific polymorphism ( PCR-SSP ) analysis and polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP ) amplification of hybrid Rhesus box and by real time quantitative polymerase chain reaction ( RQ-PCR ) specific for RHD exon 5 .,"['MATERIALS', 'AND', 'METHODS', 'RHD', 'zygosity', 'was', 'evaluated', 'in', '370', 'RH:1', 'Tunisian', 'donors', 'by', 'polymerase', 'chain', 'reaction', '-', 'sequence-specific', 'polymorphism', '(', 'PCR-SSP', ')', 'analysis', 'and', 'polymerase', 'chain', 'reaction', '-', 'restriction', 'fragment', 'length', 'polymorphism', '(', 'PCR-RFLP', ')', 'amplification', 'of', 'hybrid', 'Rhesus', 'box', 'and', 'by', 'real', 'time', 'quantitative', 'polymerase', 'chain', 'reaction', '(', 'RQ-PCR', ')', 'specific', 'for', 'RHD', 'exon', '5', '.']","(8, 12)","(51, 75)",-1,ss_p,24960665,Abstract,1,test,gold,2223.0
5803,MATERIALS AND METHODS RHD zygosity was evaluated in 370 RH:1 Tunisian donors by,polymerase chain reaction - sequence-specific polymorphism ( PCR-SSP ),analysis and polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP ) amplification of hybrid Rhesus box and by real time quantitative polymerase chain reaction ( RQ-PCR ) specific for RHD exon 5 .,"['MATERIALS', 'AND', 'METHODS', 'RHD', 'zygosity', 'was', 'evaluated', 'in', '370', 'RH:1', 'Tunisian', 'donors', 'by', 'polymerase', 'chain', 'reaction', '-', 'sequence-specific', 'polymorphism', '(', 'PCR-SSP', ')', 'analysis', 'and', 'polymerase', 'chain', 'reaction', '-', 'restriction', 'fragment', 'length', 'polymorphism', '(', 'PCR-RFLP', ')', 'amplification', 'of', 'hybrid', 'Rhesus', 'box', 'and', 'by', 'real', 'time', 'quantitative', 'polymerase', 'chain', 'reaction', '(', 'RQ-PCR', ')', 'specific', 'for', 'RHD', 'exon', '5', '.']","(13, 22)","(79, 149)",-1,ss_i,24960665,Abstract,1,test,gold,6651.0
5804,MATERIALS AND METHODS RHD zygosity was evaluated in 370 RH:1 Tunisian donors by polymerase chain reaction - sequence-specific polymorphism ( PCR-SSP ) analysis and,polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP ),amplification of hybrid Rhesus box and by real time quantitative polymerase chain reaction ( RQ-PCR ) specific for RHD exon 5 .,"['MATERIALS', 'AND', 'METHODS', 'RHD', 'zygosity', 'was', 'evaluated', 'in', '370', 'RH:1', 'Tunisian', 'donors', 'by', 'polymerase', 'chain', 'reaction', '-', 'sequence-specific', 'polymorphism', '(', 'PCR-SSP', ')', 'analysis', 'and', 'polymerase', 'chain', 'reaction', '-', 'restriction', 'fragment', 'length', 'polymorphism', '(', 'PCR-RFLP', ')', 'amplification', 'of', 'hybrid', 'Rhesus', 'box', 'and', 'by', 'real', 'time', 'quantitative', 'polymerase', 'chain', 'reaction', '(', 'RQ-PCR', ')', 'specific', 'for', 'RHD', 'exon', '5', '.']","(24, 35)","(163, 244)",-1,ss_i,24960665,Abstract,1,test,gold,6649.0
5805,MATERIALS AND METHODS RHD zygosity was evaluated in 370 RH:1 Tunisian donors by polymerase chain reaction - sequence-specific polymorphism ( PCR-SSP ) analysis and polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP ) amplification of,hybrid Rhesus box and by real time quantitative polymerase chain reaction ( RQ-PCR ),specific for RHD exon 5 .,"['MATERIALS', 'AND', 'METHODS', 'RHD', 'zygosity', 'was', 'evaluated', 'in', '370', 'RH:1', 'Tunisian', 'donors', 'by', 'polymerase', 'chain', 'reaction', '-', 'sequence-specific', 'polymorphism', '(', 'PCR-SSP', ')', 'analysis', 'and', 'polymerase', 'chain', 'reaction', '-', 'restriction', 'fragment', 'length', 'polymorphism', '(', 'PCR-RFLP', ')', 'amplification', 'of', 'hybrid', 'Rhesus', 'box', 'and', 'by', 'real', 'time', 'quantitative', 'polymerase', 'chain', 'reaction', '(', 'RQ-PCR', ')', 'specific', 'for', 'RHD', 'exon', '5', '.']","(37, 51)","(262, 346)",-1,ss_i,24960665,Abstract,1,test,gold,6653.0
5806,MATERIALS AND METHODS,RHD zygosity,was evaluated in 370 RH:1 Tunisian donors by polymerase chain reaction - sequence-specific polymorphism ( PCR-SSP ) analysis and polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP ) amplification of hybrid Rhesus box and by real time quantitative polymerase chain reaction ( RQ-PCR ) specific for RHD exon 5 .,"['MATERIALS', 'AND', 'METHODS', 'RHD', 'zygosity', 'was', 'evaluated', 'in', '370', 'RH:1', 'Tunisian', 'donors', 'by', 'polymerase', 'chain', 'reaction', '-', 'sequence-specific', 'polymorphism', '(', 'PCR-SSP', ')', 'analysis', 'and', 'polymerase', 'chain', 'reaction', '-', 'restriction', 'fragment', 'length', 'polymorphism', '(', 'PCR-RFLP', ')', 'amplification', 'of', 'hybrid', 'Rhesus', 'box', 'and', 'by', 'real', 'time', 'quantitative', 'polymerase', 'chain', 'reaction', '(', 'RQ-PCR', ')', 'specific', 'for', 'RHD', 'exon', '5', '.']","(3, 5)","(21, 33)",-1,ss_o,24960665,Abstract,1,test,gold,989.0
5807,MATERIALS AND METHODS RHD zygosity was evaluated in 370 RH:1 Tunisian donors by,polymerase chain reaction - sequence-specific polymorphism ( PCR-SSP ),analysis and polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP ) amplification of hybrid Rhesus box and by real time quantitative polymerase chain reaction ( RQ-PCR ) specific for RHD exon 5 .,"['MATERIALS', 'AND', 'METHODS', 'RHD', 'zygosity', 'was', 'evaluated', 'in', '370', 'RH:1', 'Tunisian', 'donors', 'by', 'polymerase', 'chain', 'reaction', '-', 'sequence-specific', 'polymorphism', '(', 'PCR-SSP', ')', 'analysis', 'and', 'polymerase', 'chain', 'reaction', '-', 'restriction', 'fragment', 'length', 'polymorphism', '(', 'PCR-RFLP', ')', 'amplification', 'of', 'hybrid', 'Rhesus', 'box', 'and', 'by', 'real', 'time', 'quantitative', 'polymerase', 'chain', 'reaction', '(', 'RQ-PCR', ')', 'specific', 'for', 'RHD', 'exon', '5', '.']","(13, 22)","(79, 149)",-1,ss_o,24960665,Abstract,1,test,gold,6652.0
5808,MATERIALS AND METHODS RHD zygosity was evaluated in 370 RH:1 Tunisian donors by polymerase chain reaction - sequence-specific polymorphism ( PCR-SSP ) analysis and,polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP ) amplification of hybrid Rhesus box and by real time quantitative polymerase chain reaction ( RQ-PCR ) specific for RHD exon 5 .,,"['MATERIALS', 'AND', 'METHODS', 'RHD', 'zygosity', 'was', 'evaluated', 'in', '370', 'RH:1', 'Tunisian', 'donors', 'by', 'polymerase', 'chain', 'reaction', '-', 'sequence-specific', 'polymorphism', '(', 'PCR-SSP', ')', 'analysis', 'and', 'polymerase', 'chain', 'reaction', '-', 'restriction', 'fragment', 'length', 'polymorphism', '(', 'PCR-RFLP', ')', 'amplification', 'of', 'hybrid', 'Rhesus', 'box', 'and', 'by', 'real', 'time', 'quantitative', 'polymerase', 'chain', 'reaction', '(', 'RQ-PCR', ')', 'specific', 'for', 'RHD', 'exon', '5', '.']","(24, 57)","(163, 372)",-1,ss_o,24960665,Abstract,1,test,gold,5805.0
5809,MATERIALS AND METHODS RHD zygosity was evaluated in,370 RH:1 Tunisian donors,by polymerase chain reaction - sequence-specific polymorphism ( PCR-SSP ) analysis and polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP ) amplification of hybrid Rhesus box and by real time quantitative polymerase chain reaction ( RQ-PCR ) specific for RHD exon 5 .,"['MATERIALS', 'AND', 'METHODS', 'RHD', 'zygosity', 'was', 'evaluated', 'in', '370', 'RH:1', 'Tunisian', 'donors', 'by', 'polymerase', 'chain', 'reaction', '-', 'sequence-specific', 'polymorphism', '(', 'PCR-SSP', ')', 'analysis', 'and', 'polymerase', 'chain', 'reaction', '-', 'restriction', 'fragment', 'length', 'polymorphism', '(', 'PCR-RFLP', ')', 'amplification', 'of', 'hybrid', 'Rhesus', 'box', 'and', 'by', 'real', 'time', 'quantitative', 'polymerase', 'chain', 'reaction', '(', 'RQ-PCR', ')', 'specific', 'for', 'RHD', 'exon', '5', '.']","(8, 12)","(51, 75)",-1,hl_p,24960665,Abstract,1,test,gold,2224.0
5810,MATERIALS AND METHODS RHD zygosity was evaluated in 370 RH:1 Tunisian donors by polymerase chain reaction - sequence-specific polymorphism ( PCR-SSP ) analysis and,polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP ),amplification of hybrid Rhesus box and by real time quantitative polymerase chain reaction ( RQ-PCR ) specific for RHD exon 5 .,"['MATERIALS', 'AND', 'METHODS', 'RHD', 'zygosity', 'was', 'evaluated', 'in', '370', 'RH:1', 'Tunisian', 'donors', 'by', 'polymerase', 'chain', 'reaction', '-', 'sequence-specific', 'polymorphism', '(', 'PCR-SSP', ')', 'analysis', 'and', 'polymerase', 'chain', 'reaction', '-', 'restriction', 'fragment', 'length', 'polymorphism', '(', 'PCR-RFLP', ')', 'amplification', 'of', 'hybrid', 'Rhesus', 'box', 'and', 'by', 'real', 'time', 'quantitative', 'polymerase', 'chain', 'reaction', '(', 'RQ-PCR', ')', 'specific', 'for', 'RHD', 'exon', '5', '.']","(24, 35)","(163, 244)",-1,hl_i,24960665,Abstract,1,test,gold,6650.0
5811,MATERIALS AND METHODS RHD zygosity was evaluated in 370 RH:1 Tunisian donors by polymerase chain reaction - sequence-specific polymorphism ( PCR-SSP ) analysis and polymerase chain reaction - restriction fragment length polymorphism ( PCR-RFLP ) amplification of hybrid Rhesus box and by,real time quantitative polymerase chain reaction ( RQ-PCR ),specific for RHD exon 5 .,"['MATERIALS', 'AND', 'METHODS', 'RHD', 'zygosity', 'was', 'evaluated', 'in', '370', 'RH:1', 'Tunisian', 'donors', 'by', 'polymerase', 'chain', 'reaction', '-', 'sequence-specific', 'polymorphism', '(', 'PCR-SSP', ')', 'analysis', 'and', 'polymerase', 'chain', 'reaction', '-', 'restriction', 'fragment', 'length', 'polymorphism', '(', 'PCR-RFLP', ')', 'amplification', 'of', 'hybrid', 'Rhesus', 'box', 'and', 'by', 'real', 'time', 'quantitative', 'polymerase', 'chain', 'reaction', '(', 'RQ-PCR', ')', 'specific', 'for', 'RHD', 'exon', '5', '.']","(42, 51)","(287, 346)",-1,hl_i,24960665,Abstract,1,test,gold,6654.0
5812,To evaluate the accuracy of,molecular tests,"in the cases of discordant results , the ten exons of RHD and Rhesus boxes were amplified by PCR and sequenced .","['To', 'evaluate', 'the', 'accuracy', 'of', 'molecular', 'tests', 'in', 'the', 'cases', 'of', 'discordant', 'results', ',', 'the', 'ten', 'exons', 'of', 'RHD', 'and', 'Rhesus', 'boxes', 'were', 'amplified', 'by', 'PCR', 'and', 'sequenced', '.']","(5, 7)","(27, 42)",-1,ss_i,24960665,Abstract,2,test,gold,1849.0
5813,"To evaluate the accuracy of molecular tests in the cases of discordant results , the ten exons of RHD and Rhesus boxes were amplified by",PCR,and sequenced .,"['To', 'evaluate', 'the', 'accuracy', 'of', 'molecular', 'tests', 'in', 'the', 'cases', 'of', 'discordant', 'results', ',', 'the', 'ten', 'exons', 'of', 'RHD', 'and', 'Rhesus', 'boxes', 'were', 'amplified', 'by', 'PCR', 'and', 'sequenced', '.']","(25, 26)","(136, 139)",-1,ss_i,24960665,Abstract,2,test,gold,116.0
5814,RESULTS Molecular investigations revealed that our,370 donors,comprise 193 dizygous and 145 hemizygous individuals and 32 subjects whose zygosity remains unknown .,"['RESULTS', 'Molecular', 'investigations', 'revealed', 'that', 'our', '370', 'donors', 'comprise', '193', 'dizygous', 'and', '145', 'hemizygous', 'individuals', 'and', '32', 'subjects', 'whose', 'zygosity', 'remains', 'unknown', '.']","(6, 8)","(50, 60)",-1,ss_p,24960665,Abstract,3,test,gold,2221.0
5815,RESULTS Molecular investigations revealed that our,370 donors,comprise 193 dizygous and 145 hemizygous individuals and 32 subjects whose zygosity remains unknown .,"['RESULTS', 'Molecular', 'investigations', 'revealed', 'that', 'our', '370', 'donors', 'comprise', '193', 'dizygous', 'and', '145', 'hemizygous', 'individuals', 'and', '32', 'subjects', 'whose', 'zygosity', 'remains', 'unknown', '.']","(6, 8)","(50, 60)",-1,hl_p,24960665,Abstract,3,test,gold,2222.0
5816,"Positive predictive values were higher than 99 % for all the methods , reaching 100 % for",RQ-PCR .,,"['Positive', 'predictive', 'values', 'were', 'higher', 'than', '99', '%', 'for', 'all', 'the', 'methods', ',', 'reaching', '100', '%', 'for', 'RQ-PCR', '.']","(17, 19)","(89, 97)",-1,ss_i,24960665,Abstract,4,test,gold,
5817,,Positive predictive values,"were higher than 99 % for all the methods , reaching 100 % for RQ-PCR .","['Positive', 'predictive', 'values', 'were', 'higher', 'than', '99', '%', 'for', 'all', 'the', 'methods', ',', 'reaching', '100', '%', 'for', 'RQ-PCR', '.']","(0, 3)","(0, 26)",-1,ss_o,24960665,Abstract,4,test,gold,6389.0
5818,,Positive predictive values,"were higher than 99 % for all the methods , reaching 100 % for RQ-PCR .","['Positive', 'predictive', 'values', 'were', 'higher', 'than', '99', '%', 'for', 'all', 'the', 'methods', ',', 'reaching', '100', '%', 'for', 'RQ-PCR', '.']","(0, 3)","(0, 26)",-1,hl_o,24960665,Abstract,4,test,gold,6390.0
5819,"Negative predictive values were 83.24 % , 87.27 % and 98 % for","PCR-SSP , PCR-RFLP and RQ-PCR",respectively .,"['Negative', 'predictive', 'values', 'were', '83.24', '%', ',', '87.27', '%', 'and', '98', '%', 'for', 'PCR-SSP', ',', 'PCR-RFLP', 'and', 'RQ-PCR', 'respectively', '.']","(13, 18)","(62, 91)",-1,ss_i,24960665,Abstract,5,test,gold,
5820,,Negative predictive values,"were 83.24 % , 87.27 % and 98 % for PCR-SSP , PCR-RFLP and RQ-PCR respectively .","['Negative', 'predictive', 'values', 'were', '83.24', '%', ',', '87.27', '%', 'and', '98', '%', 'for', 'PCR-SSP', ',', 'PCR-RFLP', 'and', 'RQ-PCR', 'respectively', '.']","(0, 3)","(0, 26)",-1,ss_o,24960665,Abstract,5,test,gold,6391.0
5821,,Negative predictive values,"were 83.24 % , 87.27 % and 98 % for PCR-SSP , PCR-RFLP and RQ-PCR respectively .","['Negative', 'predictive', 'values', 'were', '83.24', '%', ',', '87.27', '%', 'and', '98', '%', 'for', 'PCR-SSP', ',', 'PCR-RFLP', 'and', 'RQ-PCR', 'respectively', '.']","(0, 3)","(0, 26)",-1,hl_o,24960665,Abstract,5,test,gold,6392.0
5822,This study also revealed 19 novel,Rhesus box polymorphisms,"and three novel RHD alleles : RHD ( Trp185Stop ) , RHD ( Ala176Thr ) and RHD ( Ile342Ile ) .","['This', 'study', 'also', 'revealed', '19', 'novel', 'Rhesus', 'box', 'polymorphisms', 'and', 'three', 'novel', 'RHD', 'alleles', ':', 'RHD', '(', 'Trp185Stop', ')', ',', 'RHD', '(', 'Ala176Thr', ')', 'and', 'RHD', '(', 'Ile342Ile', ')', '.']","(6, 9)","(33, 57)",-1,ss_o,24960665,Abstract,6,test,gold,4570.0
5823,This study also revealed 19 novel Rhesus box polymorphisms and three novel,RHD alleles :,"RHD ( Trp185Stop ) , RHD ( Ala176Thr ) and RHD ( Ile342Ile ) .","['This', 'study', 'also', 'revealed', '19', 'novel', 'Rhesus', 'box', 'polymorphisms', 'and', 'three', 'novel', 'RHD', 'alleles', ':', 'RHD', '(', 'Trp185Stop', ')', ',', 'RHD', '(', 'Ala176Thr', ')', 'and', 'RHD', '(', 'Ile342Ile', ')', '.']","(12, 15)","(74, 87)",-1,ss_o,24960665,Abstract,6,test,gold,4572.0
5824,This study also revealed 19 novel,Rhesus box polymorphisms,"and three novel RHD alleles : RHD ( Trp185Stop ) , RHD ( Ala176Thr ) and RHD ( Ile342Ile ) .","['This', 'study', 'also', 'revealed', '19', 'novel', 'Rhesus', 'box', 'polymorphisms', 'and', 'three', 'novel', 'RHD', 'alleles', ':', 'RHD', '(', 'Trp185Stop', ')', ',', 'RHD', '(', 'Ala176Thr', ')', 'and', 'RHD', '(', 'Ile342Ile', ')', '.']","(6, 9)","(33, 57)",-1,hl_o,24960665,Abstract,6,test,gold,4571.0
5825,This study also revealed 19 novel Rhesus box polymorphisms and three novel,RHD alleles :,"RHD ( Trp185Stop ) , RHD ( Ala176Thr ) and RHD ( Ile342Ile ) .","['This', 'study', 'also', 'revealed', '19', 'novel', 'Rhesus', 'box', 'polymorphisms', 'and', 'three', 'novel', 'RHD', 'alleles', ':', 'RHD', '(', 'Trp185Stop', ')', ',', 'RHD', '(', 'Ala176Thr', ')', 'and', 'RHD', '(', 'Ile342Ile', ')', '.']","(12, 15)","(74, 87)",-1,hl_o,24960665,Abstract,6,test,gold,4573.0
5826,DISCUSSION RQ-PCR is the most convenient method for first intention determination of paternal RHD zygosity in,Tunisians .,,"['DISCUSSION', 'RQ-PCR', 'is', 'the', 'most', 'convenient', 'method', 'for', 'first', 'intention', 'determination', 'of', 'paternal', 'RHD', 'zygosity', 'in', 'Tunisians', '.']","(16, 18)","(109, 120)",-1,ss_p,24960665,Abstract,7,test,gold,2218.0
5827,DISCUSSION,RQ-PCR,is the most convenient method for first intention determination of paternal RHD zygosity in Tunisians .,"['DISCUSSION', 'RQ-PCR', 'is', 'the', 'most', 'convenient', 'method', 'for', 'first', 'intention', 'determination', 'of', 'paternal', 'RHD', 'zygosity', 'in', 'Tunisians', '.']","(1, 2)","(10, 16)",-1,ss_i,24960665,Abstract,7,test,gold,
5828,DISCUSSION RQ-PCR is the most convenient method for first intention determination of,paternal RHD zygosity,in Tunisians .,"['DISCUSSION', 'RQ-PCR', 'is', 'the', 'most', 'convenient', 'method', 'for', 'first', 'intention', 'determination', 'of', 'paternal', 'RHD', 'zygosity', 'in', 'Tunisians', '.']","(12, 15)","(84, 105)",-1,ss_o,24960665,Abstract,7,test,gold,987.0
5829,DISCUSSION,RQ-PCR,is the most convenient method for first intention determination of paternal RHD zygosity in Tunisians .,"['DISCUSSION', 'RQ-PCR', 'is', 'the', 'most', 'convenient', 'method', 'for', 'first', 'intention', 'determination', 'of', 'paternal', 'RHD', 'zygosity', 'in', 'Tunisians', '.']","(1, 2)","(10, 16)",-1,hl_i,24960665,Abstract,7,test,gold,
5830,"However , taking into account positive and negative predictive values ,",PCR-RFLP,could be an alternative despite the heterogeneity of Rhesus boxes and the complexity of RHD .,"['However', ',', 'taking', 'into', 'account', 'positive', 'and', 'negative', 'predictive', 'values', ',', 'PCR-RFLP', 'could', 'be', 'an', 'alternative', 'despite', 'the', 'heterogeneity', 'of', 'Rhesus', 'boxes', 'and', 'the', 'complexity', 'of', 'RHD', '.']","(11, 12)","(71, 79)",-1,ss_i,24960665,Abstract,8,test,gold,
5831,"However , taking into account positive and negative predictive values ,",PCR-RFLP,could be an alternative despite the heterogeneity of Rhesus boxes and the complexity of RHD .,"['However', ',', 'taking', 'into', 'account', 'positive', 'and', 'negative', 'predictive', 'values', ',', 'PCR-RFLP', 'could', 'be', 'an', 'alternative', 'despite', 'the', 'heterogeneity', 'of', 'Rhesus', 'boxes', 'and', 'the', 'complexity', 'of', 'RHD', '.']","(11, 12)","(71, 79)",-1,ss_o,24960665,Abstract,8,test,gold,
5832,"However , taking into account positive and negative predictive values ,",PCR-RFLP,could be an alternative despite the heterogeneity of Rhesus boxes and the complexity of RHD .,"['However', ',', 'taking', 'into', 'account', 'positive', 'and', 'negative', 'predictive', 'values', ',', 'PCR-RFLP', 'could', 'be', 'an', 'alternative', 'despite', 'the', 'heterogeneity', 'of', 'Rhesus', 'boxes', 'and', 'the', 'complexity', 'of', 'RHD', '.']","(11, 12)","(71, 79)",-1,hl_i,24960665,Abstract,8,test,gold,
5833,A randomized controlled study of a social skills training for,preadolescent children with autism spectrum disorders :,generalization of skills by training parents and teachers ?,"['A', 'randomized', 'controlled', 'study', 'of', 'a', 'social', 'skills', 'training', 'for', 'preadolescent', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'generalization', 'of', 'skills', 'by', 'training', 'parents', 'and', 'teachers', '?']","(10, 17)","(61, 116)",-1,ss_p,24989854,Title,0,test,gold,6021.0
5834,A randomized controlled study of a,social skills training,for preadolescent children with autism spectrum disorders : generalization of skills by training parents and teachers ?,"['A', 'randomized', 'controlled', 'study', 'of', 'a', 'social', 'skills', 'training', 'for', 'preadolescent', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'generalization', 'of', 'skills', 'by', 'training', 'parents', 'and', 'teachers', '?']","(6, 9)","(34, 56)",-1,ss_i,24989854,Title,0,test,gold,2869.0
5835,A randomized controlled study of a social skills training for,preadolescent children,with autism spectrum disorders : generalization of skills by training parents and teachers ?,"['A', 'randomized', 'controlled', 'study', 'of', 'a', 'social', 'skills', 'training', 'for', 'preadolescent', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'generalization', 'of', 'skills', 'by', 'training', 'parents', 'and', 'teachers', '?']","(10, 12)","(61, 83)",-1,hl_p,24989854,Title,0,test,gold,2155.0
5836,A randomized controlled study of a social skills training for preadolescent children with,autism spectrum disorders,: generalization of skills by training parents and teachers ?,"['A', 'randomized', 'controlled', 'study', 'of', 'a', 'social', 'skills', 'training', 'for', 'preadolescent', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'generalization', 'of', 'skills', 'by', 'training', 'parents', 'and', 'teachers', '?']","(13, 16)","(89, 114)",-1,hl_p,24989854,Title,0,test,gold,6024.0
5837,A randomized controlled study of a,social skills training,for preadolescent children with autism spectrum disorders : generalization of skills by training parents and teachers ?,"['A', 'randomized', 'controlled', 'study', 'of', 'a', 'social', 'skills', 'training', 'for', 'preadolescent', 'children', 'with', 'autism', 'spectrum', 'disorders', ':', 'generalization', 'of', 'skills', 'by', 'training', 'parents', 'and', 'teachers', '?']","(6, 9)","(34, 56)",-1,hl_i,24989854,Title,0,test,gold,2870.0
5838,BACKGROUND Social skills training ( SST ) is a common intervention for,children with autism spectrum disorders ( ASDs ),to improve their social and communication skills .,"['BACKGROUND', 'Social', 'skills', 'training', '(', 'SST', ')', 'is', 'a', 'common', 'intervention', 'for', 'children', 'with', 'autism', 'spectrum', 'disorders', '(', 'ASDs', ')', 'to', 'improve', 'their', 'social', 'and', 'communication', 'skills', '.']","(12, 20)","(70, 118)",-1,ss_p,24989854,Abstract,0,test,gold,6034.0
5839,BACKGROUND,Social skills training ( SST ),is a common intervention for children with autism spectrum disorders ( ASDs ) to improve their social and communication skills .,"['BACKGROUND', 'Social', 'skills', 'training', '(', 'SST', ')', 'is', 'a', 'common', 'intervention', 'for', 'children', 'with', 'autism', 'spectrum', 'disorders', '(', 'ASDs', ')', 'to', 'improve', 'their', 'social', 'and', 'communication', 'skills', '.']","(1, 7)","(10, 40)",-1,ss_i,24989854,Abstract,0,test,gold,2856.0
5840,BACKGROUND Social skills training ( SST ) is a common intervention for children with autism spectrum disorders ( ASDs ) to improve their,social and communication skills .,,"['BACKGROUND', 'Social', 'skills', 'training', '(', 'SST', ')', 'is', 'a', 'common', 'intervention', 'for', 'children', 'with', 'autism', 'spectrum', 'disorders', '(', 'ASDs', ')', 'to', 'improve', 'their', 'social', 'and', 'communication', 'skills', '.']","(23, 28)","(136, 169)",-1,ss_o,24989854,Abstract,0,test,gold,2875.0
5841,BACKGROUND Social skills training ( SST ) is a common intervention for,children with autism spectrum disorders ( ASDs ),to improve their social and communication skills .,"['BACKGROUND', 'Social', 'skills', 'training', '(', 'SST', ')', 'is', 'a', 'common', 'intervention', 'for', 'children', 'with', 'autism', 'spectrum', 'disorders', '(', 'ASDs', ')', 'to', 'improve', 'their', 'social', 'and', 'communication', 'skills', '.']","(12, 20)","(70, 118)",-1,hl_p,24989854,Abstract,0,test,gold,6035.0
5842,BACKGROUND,Social skills training ( SST ),is a common intervention for children with autism spectrum disorders ( ASDs ) to improve their social and communication skills .,"['BACKGROUND', 'Social', 'skills', 'training', '(', 'SST', ')', 'is', 'a', 'common', 'intervention', 'for', 'children', 'with', 'autism', 'spectrum', 'disorders', '(', 'ASDs', ')', 'to', 'improve', 'their', 'social', 'and', 'communication', 'skills', '.']","(1, 7)","(10, 40)",-1,hl_i,24989854,Abstract,0,test,gold,2857.0
5843,"Despite the fact that SSTs are often applied in clinical practice , the evidence for the effectiveness of these trainings for",children with ASD,is inconclusive .,"['Despite', 'the', 'fact', 'that', 'SSTs', 'are', 'often', 'applied', 'in', 'clinical', 'practice', ',', 'the', 'evidence', 'for', 'the', 'effectiveness', 'of', 'these', 'trainings', 'for', 'children', 'with', 'ASD', 'is', 'inconclusive', '.']","(21, 24)","(125, 142)",-1,ss_p,24989854,Abstract,1,test,gold,6089.0
5844,Despite the fact that,SSTs,"are often applied in clinical practice , the evidence for the effectiveness of these trainings for children with ASD is inconclusive .","['Despite', 'the', 'fact', 'that', 'SSTs', 'are', 'often', 'applied', 'in', 'clinical', 'practice', ',', 'the', 'evidence', 'for', 'the', 'effectiveness', 'of', 'these', 'trainings', 'for', 'children', 'with', 'ASD', 'is', 'inconclusive', '.']","(4, 5)","(21, 25)",-1,ss_i,24989854,Abstract,1,test,gold,1319.0
5845,"Despite the fact that SSTs are often applied in clinical practice , the evidence for the",effectiveness,of these trainings for children with ASD is inconclusive .,"['Despite', 'the', 'fact', 'that', 'SSTs', 'are', 'often', 'applied', 'in', 'clinical', 'practice', ',', 'the', 'evidence', 'for', 'the', 'effectiveness', 'of', 'these', 'trainings', 'for', 'children', 'with', 'ASD', 'is', 'inconclusive', '.']","(16, 17)","(88, 101)",-1,ss_o,24989854,Abstract,1,test,gold,393.0
5846,"Despite the fact that SSTs are often applied in clinical practice , the evidence for the effectiveness of these trainings for",children with ASD,is inconclusive .,"['Despite', 'the', 'fact', 'that', 'SSTs', 'are', 'often', 'applied', 'in', 'clinical', 'practice', ',', 'the', 'evidence', 'for', 'the', 'effectiveness', 'of', 'these', 'trainings', 'for', 'children', 'with', 'ASD', 'is', 'inconclusive', '.']","(21, 24)","(125, 142)",-1,hl_p,24989854,Abstract,1,test,gold,6090.0
5847,Despite the fact that,SSTs,"are often applied in clinical practice , the evidence for the effectiveness of these trainings for children with ASD is inconclusive .","['Despite', 'the', 'fact', 'that', 'SSTs', 'are', 'often', 'applied', 'in', 'clinical', 'practice', ',', 'the', 'evidence', 'for', 'the', 'effectiveness', 'of', 'these', 'trainings', 'for', 'children', 'with', 'ASD', 'is', 'inconclusive', '.']","(4, 5)","(21, 25)",-1,hl_i,24989854,Abstract,1,test,gold,1320.0
5848,"Moreover ,",long term outcome,and generalization of learned skills are little evaluated .,"['Moreover', ',', 'long', 'term', 'outcome', 'and', 'generalization', 'of', 'learned', 'skills', 'are', 'little', 'evaluated', '.']","(2, 5)","(10, 27)",-1,ss_o,24989854,Abstract,2,test,gold,418.0
5849,"Moreover , long term outcome and",generalization of learned skills,are little evaluated .,"['Moreover', ',', 'long', 'term', 'outcome', 'and', 'generalization', 'of', 'learned', 'skills', 'are', 'little', 'evaluated', '.']","(6, 10)","(32, 64)",-1,ss_o,24989854,Abstract,2,test,gold,2853.0
5850,"Additionally , there is no research on the influence of involvement of parents and teachers on effectiveness of",SST,and on the generalization of learned social skills to daily life .,"['Additionally', ',', 'there', 'is', 'no', 'research', 'on', 'the', 'influence', 'of', 'involvement', 'of', 'parents', 'and', 'teachers', 'on', 'effectiveness', 'of', 'SST', 'and', 'on', 'the', 'generalization', 'of', 'learned', 'social', 'skills', 'to', 'daily', 'life', '.']","(18, 19)","(111, 114)",-1,ss_i,24989854,Abstract,3,test,gold,571.0
5851,"Additionally , there is no research on the influence of involvement of parents and teachers on",effectiveness,of SST and on the generalization of learned social skills to daily life .,"['Additionally', ',', 'there', 'is', 'no', 'research', 'on', 'the', 'influence', 'of', 'involvement', 'of', 'parents', 'and', 'teachers', 'on', 'effectiveness', 'of', 'SST', 'and', 'on', 'the', 'generalization', 'of', 'learned', 'social', 'skills', 'to', 'daily', 'life', '.']","(16, 17)","(94, 107)",-1,ss_o,24989854,Abstract,3,test,gold,392.0
5852,"Additionally , there is no research on the influence of involvement of parents and teachers on effectiveness of SST and on the",generalization of learned social skills to daily life .,,"['Additionally', ',', 'there', 'is', 'no', 'research', 'on', 'the', 'influence', 'of', 'involvement', 'of', 'parents', 'and', 'teachers', 'on', 'effectiveness', 'of', 'SST', 'and', 'on', 'the', 'generalization', 'of', 'learned', 'social', 'skills', 'to', 'daily', 'life', '.']","(22, 31)","(126, 181)",-1,ss_o,24989854,Abstract,3,test,gold,2848.0
5853,"Additionally , there is no research on the influence of involvement of parents and teachers on effectiveness of",SST,and on the generalization of learned social skills to daily life .,"['Additionally', ',', 'there', 'is', 'no', 'research', 'on', 'the', 'influence', 'of', 'involvement', 'of', 'parents', 'and', 'teachers', 'on', 'effectiveness', 'of', 'SST', 'and', 'on', 'the', 'generalization', 'of', 'learned', 'social', 'skills', 'to', 'daily', 'life', '.']","(18, 19)","(111, 114)",-1,hl_i,24989854,Abstract,3,test,gold,570.0
5854,We expect parent and teacher involvement in,SST,to enhance treatment efficacy and to facilitate generalization of learned skills to daily life .,"['We', 'expect', 'parent', 'and', 'teacher', 'involvement', 'in', 'SST', 'to', 'enhance', 'treatment', 'efficacy', 'and', 'to', 'facilitate', 'generalization', 'of', 'learned', 'skills', 'to', 'daily', 'life', '.']","(7, 8)","(43, 46)",-1,ss_i,24989854,Abstract,4,test,gold,569.0
5855,We expect parent and teacher involvement in SST to enhance,treatment efficacy,and to facilitate generalization of learned skills to daily life .,"['We', 'expect', 'parent', 'and', 'teacher', 'involvement', 'in', 'SST', 'to', 'enhance', 'treatment', 'efficacy', 'and', 'to', 'facilitate', 'generalization', 'of', 'learned', 'skills', 'to', 'daily', 'life', '.']","(10, 12)","(58, 76)",-1,ss_o,24989854,Abstract,4,test,gold,4857.0
5856,We expect parent and teacher involvement in SST to enhance treatment efficacy and to facilitate,generalization of learned skills to daily life .,,"['We', 'expect', 'parent', 'and', 'teacher', 'involvement', 'in', 'SST', 'to', 'enhance', 'treatment', 'efficacy', 'and', 'to', 'facilitate', 'generalization', 'of', 'learned', 'skills', 'to', 'daily', 'life', '.']","(15, 23)","(95, 143)",-1,ss_o,24989854,Abstract,4,test,gold,2849.0
5857,We expect parent and teacher involvement in,SST,to enhance treatment efficacy and to facilitate generalization of learned skills to daily life .,"['We', 'expect', 'parent', 'and', 'teacher', 'involvement', 'in', 'SST', 'to', 'enhance', 'treatment', 'efficacy', 'and', 'to', 'facilitate', 'generalization', 'of', 'learned', 'skills', 'to', 'daily', 'life', '.']","(7, 8)","(43, 46)",-1,hl_i,24989854,Abstract,4,test,gold,568.0
5858,"METHOD/DESIGN In a randomized controlled trial ( RCT ) with three conditions ,",120 participants with ASD at the end of primary school ( 10-12 years of calendar age ),"have been randomized to SST , SST-PTI ( SST with Parent & Teacher Involvement ) , or care-as-usual .","['METHOD/DESIGN', 'In', 'a', 'randomized', 'controlled', 'trial', '(', 'RCT', ')', 'with', 'three', 'conditions', ',', '120', 'participants', 'with', 'ASD', 'at', 'the', 'end', 'of', 'primary', 'school', '(', '10-12', 'years', 'of', 'calendar', 'age', ')', 'have', 'been', 'randomized', 'to', 'SST', ',', 'SST-PTI', '(', 'SST', 'with', 'Parent', '&', 'Teacher', 'Involvement', ')', ',', 'or', 'care-as-usual', '.']","(13, 30)","(78, 164)",-1,ss_p,24989854,Abstract,5,test,gold,6192.0
5859,"METHOD/DESIGN In a randomized controlled trial ( RCT ) with three conditions , 120 participants with ASD at the end of primary school ( 10-12 years of calendar age ) have been randomized to","SST , SST-PTI ( SST with Parent & Teacher Involvement )",", or care-as-usual .","['METHOD/DESIGN', 'In', 'a', 'randomized', 'controlled', 'trial', '(', 'RCT', ')', 'with', 'three', 'conditions', ',', '120', 'participants', 'with', 'ASD', 'at', 'the', 'end', 'of', 'primary', 'school', '(', '10-12', 'years', 'of', 'calendar', 'age', ')', 'have', 'been', 'randomized', 'to', 'SST', ',', 'SST-PTI', '(', 'SST', 'with', 'Parent', '&', 'Teacher', 'Involvement', ')', ',', 'or', 'care-as-usual', '.']","(34, 45)","(189, 244)",-1,ss_i,24989854,Abstract,5,test,gold,6239.0
5860,"METHOD/DESIGN In a randomized controlled trial ( RCT ) with three conditions , 120 participants with ASD at the end of primary school ( 10-12 years of calendar age ) have been randomized to SST , SST-PTI ( SST with Parent & Teacher Involvement ) , or",care-as-usual .,,"['METHOD/DESIGN', 'In', 'a', 'randomized', 'controlled', 'trial', '(', 'RCT', ')', 'with', 'three', 'conditions', ',', '120', 'participants', 'with', 'ASD', 'at', 'the', 'end', 'of', 'primary', 'school', '(', '10-12', 'years', 'of', 'calendar', 'age', ')', 'have', 'been', 'randomized', 'to', 'SST', ',', 'SST-PTI', '(', 'SST', 'with', 'Parent', '&', 'Teacher', 'Involvement', ')', ',', 'or', 'care-as-usual', '.']","(47, 49)","(250, 265)",-1,ss_i,24989854,Abstract,5,test,gold,
5861,"METHOD/DESIGN In a randomized controlled trial ( RCT ) with three conditions ,",120 participants with ASD at the end of primary school,"( 10-12 years of calendar age ) have been randomized to SST , SST-PTI ( SST with Parent & Teacher Involvement ) , or care-as-usual .","['METHOD/DESIGN', 'In', 'a', 'randomized', 'controlled', 'trial', '(', 'RCT', ')', 'with', 'three', 'conditions', ',', '120', 'participants', 'with', 'ASD', 'at', 'the', 'end', 'of', 'primary', 'school', '(', '10-12', 'years', 'of', 'calendar', 'age', ')', 'have', 'been', 'randomized', 'to', 'SST', ',', 'SST-PTI', '(', 'SST', 'with', 'Parent', '&', 'Teacher', 'Involvement', ')', ',', 'or', 'care-as-usual', '.']","(13, 23)","(78, 132)",-1,hl_p,24989854,Abstract,5,test,gold,6193.0
5862,"METHOD/DESIGN In a randomized controlled trial ( RCT ) with three conditions , 120 participants with ASD at the end of primary school (",10-12 years of calendar age,") have been randomized to SST , SST-PTI ( SST with Parent & Teacher Involvement ) , or care-as-usual .","['METHOD/DESIGN', 'In', 'a', 'randomized', 'controlled', 'trial', '(', 'RCT', ')', 'with', 'three', 'conditions', ',', '120', 'participants', 'with', 'ASD', 'at', 'the', 'end', 'of', 'primary', 'school', '(', '10-12', 'years', 'of', 'calendar', 'age', ')', 'have', 'been', 'randomized', 'to', 'SST', ',', 'SST-PTI', '(', 'SST', 'with', 'Parent', '&', 'Teacher', 'Involvement', ')', ',', 'or', 'care-as-usual', '.']","(24, 29)","(135, 162)",-1,hl_p,24989854,Abstract,5,test,gold,2017.0
5863,"METHOD/DESIGN In a randomized controlled trial ( RCT ) with three conditions , 120 participants with ASD at the end of primary school ( 10-12 years of calendar age ) have been randomized to","SST , SST-PTI ( SST with Parent & Teacher Involvement )",", or care-as-usual .","['METHOD/DESIGN', 'In', 'a', 'randomized', 'controlled', 'trial', '(', 'RCT', ')', 'with', 'three', 'conditions', ',', '120', 'participants', 'with', 'ASD', 'at', 'the', 'end', 'of', 'primary', 'school', '(', '10-12', 'years', 'of', 'calendar', 'age', ')', 'have', 'been', 'randomized', 'to', 'SST', ',', 'SST-PTI', '(', 'SST', 'with', 'Parent', '&', 'Teacher', 'Involvement', ')', ',', 'or', 'care-as-usual', '.']","(34, 45)","(189, 244)",-1,hl_i,24989854,Abstract,5,test,gold,6240.0
5864,"METHOD/DESIGN In a randomized controlled trial ( RCT ) with three conditions , 120 participants with ASD at the end of primary school ( 10-12 years of calendar age ) have been randomized to SST , SST-PTI ( SST with Parent & Teacher Involvement ) , or",care-as-usual .,,"['METHOD/DESIGN', 'In', 'a', 'randomized', 'controlled', 'trial', '(', 'RCT', ')', 'with', 'three', 'conditions', ',', '120', 'participants', 'with', 'ASD', 'at', 'the', 'end', 'of', 'primary', 'school', '(', '10-12', 'years', 'of', 'calendar', 'age', ')', 'have', 'been', 'randomized', 'to', 'SST', ',', 'SST-PTI', '(', 'SST', 'with', 'Parent', '&', 'Teacher', 'Involvement', ')', ',', 'or', 'care-as-usual', '.']","(47, 49)","(250, 265)",-1,hl_i,24989854,Abstract,5,test,gold,
5865,The,SST,consists of 18 group sessions of 1.5 hours for the children .,"['The', 'SST', 'consists', 'of', '18', 'group', 'sessions', 'of', '1.5', 'hours', 'for', 'the', 'children', '.']","(1, 2)","(3, 6)",-1,ss_i,24989854,Abstract,6,test,gold,567.0
5866,The,SST,consists of 18 group sessions of 1.5 hours for the children .,"['The', 'SST', 'consists', 'of', '18', 'group', 'sessions', 'of', '1.5', 'hours', 'for', 'the', 'children', '.']","(1, 2)","(3, 6)",-1,hl_i,24989854,Abstract,6,test,gold,566.0
5867,In the,SST-PTI,"condition , parents additionally participate in 8 parent sessions and parents and teachers are actively involved in homework assignments .","['In', 'the', 'SST-PTI', 'condition', ',', 'parents', 'additionally', 'participate', 'in', '8', 'parent', 'sessions', 'and', 'parents', 'and', 'teachers', 'are', 'actively', 'involved', 'in', 'homework', 'assignments', '.']","(2, 3)","(6, 13)",-1,ss_i,24989854,Abstract,7,test,gold,
5868,In the,SST-PTI,"condition , parents additionally participate in 8 parent sessions and parents and teachers are actively involved in homework assignments .","['In', 'the', 'SST-PTI', 'condition', ',', 'parents', 'additionally', 'participate', 'in', '8', 'parent', 'sessions', 'and', 'parents', 'and', 'teachers', 'are', 'actively', 'involved', 'in', 'homework', 'assignments', '.']","(2, 3)","(6, 13)",-1,hl_i,24989854,Abstract,7,test,gold,
5869,Assessment takes place at three moments : before and immediately after the intervention period and at 6 months follow-up .,,,"['Assessment', 'takes', 'place', 'at', 'three', 'moments', ':', 'before', 'and', 'immediately', 'after', 'the', 'intervention', 'period', 'and', 'at', '6', 'months', 'follow-up', '.']",,,,,24989854,Abstract,8,test,gold,
5870,Primary outcome is,socialization,", as an aspect of adaptive functioning .","['Primary', 'outcome', 'is', 'socialization', ',', 'as', 'an', 'aspect', 'of', 'adaptive', 'functioning', '.']","(3, 4)","(18, 31)",-1,ss_o,24989854,Abstract,9,test,gold,1285.0
5871,"Primary outcome is socialization , as an aspect of",adaptive functioning .,,"['Primary', 'outcome', 'is', 'socialization', ',', 'as', 'an', 'aspect', 'of', 'adaptive', 'functioning', '.']","(9, 12)","(50, 72)",-1,ss_o,24989854,Abstract,9,test,gold,2940.0
5872,Primary outcome is,socialization,", as an aspect of adaptive functioning .","['Primary', 'outcome', 'is', 'socialization', ',', 'as', 'an', 'aspect', 'of', 'adaptive', 'functioning', '.']","(3, 4)","(18, 31)",-1,hl_o,24989854,Abstract,9,test,gold,1286.0
5873,Secondary outcomes focus on specific social skills children learn during,SST,and on more general social skills pertaining to home and community settings from a multi-informant perspective .,"['Secondary', 'outcomes', 'focus', 'on', 'specific', 'social', 'skills', 'children', 'learn', 'during', 'SST', 'and', 'on', 'more', 'general', 'social', 'skills', 'pertaining', 'to', 'home', 'and', 'community', 'settings', 'from', 'a', 'multi-informant', 'perspective', '.']","(10, 11)","(72, 75)",-1,ss_i,24989854,Abstract,10,test,gold,565.0
5874,Secondary outcomes focus on,specific social skills,children learn during SST and on more general social skills pertaining to home and community settings from a multi-informant perspective .,"['Secondary', 'outcomes', 'focus', 'on', 'specific', 'social', 'skills', 'children', 'learn', 'during', 'SST', 'and', 'on', 'more', 'general', 'social', 'skills', 'pertaining', 'to', 'home', 'and', 'community', 'settings', 'from', 'a', 'multi-informant', 'perspective', '.']","(4, 7)","(27, 49)",-1,ss_o,24989854,Abstract,10,test,gold,2871.0
5875,Secondary outcomes focus on specific social skills children learn during SST and on more,general social skills,pertaining to home and community settings from a multi-informant perspective .,"['Secondary', 'outcomes', 'focus', 'on', 'specific', 'social', 'skills', 'children', 'learn', 'during', 'SST', 'and', 'on', 'more', 'general', 'social', 'skills', 'pertaining', 'to', 'home', 'and', 'community', 'settings', 'from', 'a', 'multi-informant', 'perspective', '.']","(14, 17)","(88, 109)",-1,ss_o,24989854,Abstract,10,test,gold,2873.0
5876,Secondary outcomes focus on specific social skills children learn during,SST,and on more general social skills pertaining to home and community settings from a multi-informant perspective .,"['Secondary', 'outcomes', 'focus', 'on', 'specific', 'social', 'skills', 'children', 'learn', 'during', 'SST', 'and', 'on', 'more', 'general', 'social', 'skills', 'pertaining', 'to', 'home', 'and', 'community', 'settings', 'from', 'a', 'multi-informant', 'perspective', '.']","(10, 11)","(72, 75)",-1,hl_i,24989854,Abstract,10,test,gold,564.0
5877,Secondary outcomes focus on,specific social skills,children learn during SST and on more general social skills pertaining to home and community settings from a multi-informant perspective .,"['Secondary', 'outcomes', 'focus', 'on', 'specific', 'social', 'skills', 'children', 'learn', 'during', 'SST', 'and', 'on', 'more', 'general', 'social', 'skills', 'pertaining', 'to', 'home', 'and', 'community', 'settings', 'from', 'a', 'multi-informant', 'perspective', '.']","(4, 7)","(27, 49)",-1,hl_o,24989854,Abstract,10,test,gold,2872.0
5878,Secondary outcomes focus on specific social skills children learn during SST and on more,general social skills,pertaining to home and community settings from a multi-informant perspective .,"['Secondary', 'outcomes', 'focus', 'on', 'specific', 'social', 'skills', 'children', 'learn', 'during', 'SST', 'and', 'on', 'more', 'general', 'social', 'skills', 'pertaining', 'to', 'home', 'and', 'community', 'settings', 'from', 'a', 'multi-informant', 'perspective', '.']","(14, 17)","(88, 109)",-1,hl_o,24989854,Abstract,10,test,gold,2874.0
5879,"Additionally ,",possible predictors of treatment outcome,will be assessed .,"['Additionally', ',', 'possible', 'predictors', 'of', 'treatment', 'outcome', 'will', 'be', 'assessed', '.']","(2, 7)","(14, 54)",-1,ss_o,24989854,Abstract,11,test,gold,6396.0
5880,DISCUSSION The current study is an RCT study evaluating SST in a large sample of,Dutch children with ASD in a specific age range ( 10-12 years ) .,,"['DISCUSSION', 'The', 'current', 'study', 'is', 'an', 'RCT', 'study', 'evaluating', 'SST', 'in', 'a', 'large', 'sample', 'of', 'Dutch', 'children', 'with', 'ASD', 'in', 'a', 'specific', 'age', 'range', '(', '10-12', 'years', ')', '.']","(15, 29)","(80, 145)",-1,ss_p,24989854,Abstract,12,test,gold,6197.0
5881,DISCUSSION The current study is an RCT study evaluating,SST,in a large sample of Dutch children with ASD in a specific age range ( 10-12 years ) .,"['DISCUSSION', 'The', 'current', 'study', 'is', 'an', 'RCT', 'study', 'evaluating', 'SST', 'in', 'a', 'large', 'sample', 'of', 'Dutch', 'children', 'with', 'ASD', 'in', 'a', 'specific', 'age', 'range', '(', '10-12', 'years', ')', '.']","(9, 10)","(55, 58)",-1,ss_i,24989854,Abstract,12,test,gold,563.0
5882,DISCUSSION The current study is an RCT study evaluating SST in a large sample of,Dutch children with ASD in a specific age range ( 10-12 years ) .,,"['DISCUSSION', 'The', 'current', 'study', 'is', 'an', 'RCT', 'study', 'evaluating', 'SST', 'in', 'a', 'large', 'sample', 'of', 'Dutch', 'children', 'with', 'ASD', 'in', 'a', 'specific', 'age', 'range', '(', '10-12', 'years', ')', '.']","(15, 29)","(80, 145)",-1,hl_p,24989854,Abstract,12,test,gold,6198.0
5883,DISCUSSION The current study is an RCT study evaluating,SST,in a large sample of Dutch children with ASD in a specific age range ( 10-12 years ) .,"['DISCUSSION', 'The', 'current', 'study', 'is', 'an', 'RCT', 'study', 'evaluating', 'SST', 'in', 'a', 'large', 'sample', 'of', 'Dutch', 'children', 'with', 'ASD', 'in', 'a', 'specific', 'age', 'range', '(', '10-12', 'years', ')', '.']","(9, 10)","(55, 58)",-1,hl_i,24989854,Abstract,12,test,gold,562.0
5884,"Strengths of the study are the use of one manualized protocol , application of standardized and internationally used rating instruments , use of multiple raters , investigation of",generalization,"of learned skills to daily life , and the evaluation of efficacy in the longer term by follow-up measures at 6 months after the end of training .","['Strengths', 'of', 'the', 'study', 'are', 'the', 'use', 'of', 'one', 'manualized', 'protocol', ',', 'application', 'of', 'standardized', 'and', 'internationally', 'used', 'rating', 'instruments', ',', 'use', 'of', 'multiple', 'raters', ',', 'investigation', 'of', 'generalization', 'of', 'learned', 'skills', 'to', 'daily', 'life', ',', 'and', 'the', 'evaluation', 'of', 'efficacy', 'in', 'the', 'longer', 'term', 'by', 'follow-up', 'measures', 'at', '6', 'months', 'after', 'the', 'end', 'of', 'training', '.']","(28, 29)","(179, 193)",-1,ss_o,24989854,Abstract,13,test,gold,1199.0
5885,"Strengths of the study are the use of one manualized protocol , application of standardized and internationally used rating instruments , use of multiple raters , investigation of generalization of learned skills to daily life , and the evaluation of",efficacy,in the longer term by follow-up measures at 6 months after the end of training .,"['Strengths', 'of', 'the', 'study', 'are', 'the', 'use', 'of', 'one', 'manualized', 'protocol', ',', 'application', 'of', 'standardized', 'and', 'internationally', 'used', 'rating', 'instruments', ',', 'use', 'of', 'multiple', 'raters', ',', 'investigation', 'of', 'generalization', 'of', 'learned', 'skills', 'to', 'daily', 'life', ',', 'and', 'the', 'evaluation', 'of', 'efficacy', 'in', 'the', 'longer', 'term', 'by', 'follow-up', 'measures', 'at', '6', 'months', 'after', 'the', 'end', 'of', 'training', '.']","(40, 41)","(250, 258)",-1,ss_o,24989854,Abstract,13,test,gold,4792.0
5886,TRIAL REGISTRATION NTR2405 .,,,"['TRIAL', 'REGISTRATION', 'NTR2405', '.']",,,,,24989854,Abstract,14,test,gold,
5887,Safety and preliminary immunogenicity of,Cuban pneumococcal conjugate vaccine candidate in healthy children :,a randomized phase I clinical trial .,"['Safety', 'and', 'preliminary', 'immunogenicity', 'of', 'Cuban', 'pneumococcal', 'conjugate', 'vaccine', 'candidate', 'in', 'healthy', 'children', ':', 'a', 'randomized', 'phase', 'I', 'clinical', 'trial', '.']","(5, 14)","(40, 108)",-1,ss_p,25068497,Title,0,test,gold,6657.0
5888,Safety and preliminary immunogenicity of,Cuban pneumococcal conjugate vaccine,candidate in healthy children : a randomized phase I clinical trial .,"['Safety', 'and', 'preliminary', 'immunogenicity', 'of', 'Cuban', 'pneumococcal', 'conjugate', 'vaccine', 'candidate', 'in', 'healthy', 'children', ':', 'a', 'randomized', 'phase', 'I', 'clinical', 'trial', '.']","(5, 9)","(40, 76)",-1,ss_i,25068497,Title,0,test,gold,6658.0
5889,,Safety,and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in healthy children : a randomized phase I clinical trial .,"['Safety', 'and', 'preliminary', 'immunogenicity', 'of', 'Cuban', 'pneumococcal', 'conjugate', 'vaccine', 'candidate', 'in', 'healthy', 'children', ':', 'a', 'randomized', 'phase', 'I', 'clinical', 'trial', '.']","(0, 1)","(0, 6)",-1,ss_o,25068497,Title,0,test,gold,444.0
5890,Safety and,preliminary immunogenicity,of Cuban pneumococcal conjugate vaccine candidate in healthy children : a randomized phase I clinical trial .,"['Safety', 'and', 'preliminary', 'immunogenicity', 'of', 'Cuban', 'pneumococcal', 'conjugate', 'vaccine', 'candidate', 'in', 'healthy', 'children', ':', 'a', 'randomized', 'phase', 'I', 'clinical', 'trial', '.']","(2, 4)","(10, 36)",-1,ss_o,25068497,Title,0,test,gold,4879.0
5891,Safety and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in,healthy children,: a randomized phase I clinical trial .,"['Safety', 'and', 'preliminary', 'immunogenicity', 'of', 'Cuban', 'pneumococcal', 'conjugate', 'vaccine', 'candidate', 'in', 'healthy', 'children', ':', 'a', 'randomized', 'phase', 'I', 'clinical', 'trial', '.']","(11, 13)","(90, 106)",-1,hl_p,25068497,Title,0,test,gold,2267.0
5892,Safety and preliminary immunogenicity of,Cuban pneumococcal conjugate vaccine,candidate in healthy children : a randomized phase I clinical trial .,"['Safety', 'and', 'preliminary', 'immunogenicity', 'of', 'Cuban', 'pneumococcal', 'conjugate', 'vaccine', 'candidate', 'in', 'healthy', 'children', ':', 'a', 'randomized', 'phase', 'I', 'clinical', 'trial', '.']","(5, 9)","(40, 76)",-1,hl_i,25068497,Title,0,test,gold,6659.0
5893,,Safety,and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in healthy children : a randomized phase I clinical trial .,"['Safety', 'and', 'preliminary', 'immunogenicity', 'of', 'Cuban', 'pneumococcal', 'conjugate', 'vaccine', 'candidate', 'in', 'healthy', 'children', ':', 'a', 'randomized', 'phase', 'I', 'clinical', 'trial', '.']","(0, 1)","(0, 6)",-1,hl_o,25068497,Title,0,test,gold,443.0
5894,Safety and,preliminary immunogenicity,of Cuban pneumococcal conjugate vaccine candidate in healthy children : a randomized phase I clinical trial .,"['Safety', 'and', 'preliminary', 'immunogenicity', 'of', 'Cuban', 'pneumococcal', 'conjugate', 'vaccine', 'candidate', 'in', 'healthy', 'children', ':', 'a', 'randomized', 'phase', 'I', 'clinical', 'trial', '.']","(2, 4)","(10, 36)",-1,hl_o,25068497,Title,0,test,gold,4880.0
5895,A new,heptavalent conjugate vaccine ( PCV7-TT ),is under development in Cuba .,"['A', 'new', 'heptavalent', 'conjugate', 'vaccine', '(', 'PCV7-TT', ')', 'is', 'under', 'development', 'in', 'Cuba', '.']","(2, 8)","(5, 46)",-1,ss_i,25068497,Abstract,0,test,gold,5649.0
5896,A new,heptavalent conjugate vaccine ( PCV7-TT ),is under development in Cuba .,"['A', 'new', 'heptavalent', 'conjugate', 'vaccine', '(', 'PCV7-TT', ')', 'is', 'under', 'development', 'in', 'Cuba', '.']","(2, 8)","(5, 46)",-1,hl_i,25068497,Abstract,0,test,gold,5650.0
5897,,PCV7-TT,"contains 2 μg of serotypes 1 , 5 , 14 , 18C , 19F , 23F and 4 μg of 6B , each one conjugated to tetanus toxoid ( TT ) .","['PCV7-TT', 'contains', '2', 'μg', 'of', 'serotypes', '1', ',', '5', ',', '14', ',', '18C', ',', '19F', ',', '23F', 'and', '4', 'μg', 'of', '6B', ',', 'each', 'one', 'conjugated', 'to', 'tetanus', 'toxoid', '(', 'TT', ')', '.']","(0, 1)","(0, 7)",-1,ss_i,25068497,Abstract,1,test,gold,
5898,,PCV7-TT,"contains 2 μg of serotypes 1 , 5 , 14 , 18C , 19F , 23F and 4 μg of 6B , each one conjugated to tetanus toxoid ( TT ) .","['PCV7-TT', 'contains', '2', 'μg', 'of', 'serotypes', '1', ',', '5', ',', '14', ',', '18C', ',', '19F', ',', '23F', 'and', '4', 'μg', 'of', '6B', ',', 'each', 'one', 'conjugated', 'to', 'tetanus', 'toxoid', '(', 'TT', ')', '.']","(0, 1)","(0, 7)",-1,hl_i,25068497,Abstract,1,test,gold,
5899,This vaccine was designed with the serotypes that cause most invasive pneumococcal diseases ( IPD ) worldwide .,,,"['This', 'vaccine', 'was', 'designed', 'with', 'the', 'serotypes', 'that', 'cause', 'most', 'invasive', 'pneumococcal', 'diseases', '(', 'IPD', ')', 'worldwide', '.']",,,,,25068497,Abstract,2,test,gold,
5900,"In the present study , we investigated the safety and explored the immunogenicity of PCV7-TT during a controlled , randomized and double blind clinical trial phase I",in 4-5-year-old children,.,"['In', 'the', 'present', 'study', ',', 'we', 'investigated', 'the', 'safety', 'and', 'explored', 'the', 'immunogenicity', 'of', 'PCV7-TT', 'during', 'a', 'controlled', ',', 'randomized', 'and', 'double', 'blind', 'clinical', 'trial', 'phase', 'I', 'in', '4-5-year-old', 'children', '.']","(27, 30)","(165, 189)",-1,ss_p,25068497,Abstract,3,test,gold,2153.0
5901,"In the present study , we investigated the safety and explored the immunogenicity",of PCV7-TT,"during a controlled , randomized and double blind clinical trial phase I in 4-5-year-old children .","['In', 'the', 'present', 'study', ',', 'we', 'investigated', 'the', 'safety', 'and', 'explored', 'the', 'immunogenicity', 'of', 'PCV7-TT', 'during', 'a', 'controlled', ',', 'randomized', 'and', 'double', 'blind', 'clinical', 'trial', 'phase', 'I', 'in', '4-5-year-old', 'children', '.']","(13, 15)","(81, 91)",-1,ss_i,25068497,Abstract,3,test,gold,
5902,"In the present study , we investigated the safety and explored the immunogenicity of PCV7-TT during a controlled , randomized and double blind clinical trial phase I in 4-5-year-old",children .,,"['In', 'the', 'present', 'study', ',', 'we', 'investigated', 'the', 'safety', 'and', 'explored', 'the', 'immunogenicity', 'of', 'PCV7-TT', 'during', 'a', 'controlled', ',', 'randomized', 'and', 'double', 'blind', 'clinical', 'trial', 'phase', 'I', 'in', '4-5-year-old', 'children', '.']","(29, 31)","(181, 191)",-1,ss_i,25068497,Abstract,3,test,gold,2115.0
5903,"In the present study , we investigated",the safety,"and explored the immunogenicity of PCV7-TT during a controlled , randomized and double blind clinical trial phase I in 4-5-year-old children .","['In', 'the', 'present', 'study', ',', 'we', 'investigated', 'the', 'safety', 'and', 'explored', 'the', 'immunogenicity', 'of', 'PCV7-TT', 'during', 'a', 'controlled', ',', 'randomized', 'and', 'double', 'blind', 'clinical', 'trial', 'phase', 'I', 'in', '4-5-year-old', 'children', '.']","(7, 9)","(38, 48)",-1,ss_o,25068497,Abstract,3,test,gold,453.0
5904,"In the present study , we investigated the safety and explored",the immunogenicity,"of PCV7-TT during a controlled , randomized and double blind clinical trial phase I in 4-5-year-old children .","['In', 'the', 'present', 'study', ',', 'we', 'investigated', 'the', 'safety', 'and', 'explored', 'the', 'immunogenicity', 'of', 'PCV7-TT', 'during', 'a', 'controlled', ',', 'randomized', 'and', 'double', 'blind', 'clinical', 'trial', 'phase', 'I', 'in', '4-5-year-old', 'children', '.']","(11, 13)","(62, 80)",-1,ss_o,25068497,Abstract,3,test,gold,4881.0
5905,"In the present study , we investigated the safety and explored the immunogenicity of PCV7-TT during a controlled , randomized and double blind clinical trial phase I in",4-5-year-old children,.,"['In', 'the', 'present', 'study', ',', 'we', 'investigated', 'the', 'safety', 'and', 'explored', 'the', 'immunogenicity', 'of', 'PCV7-TT', 'during', 'a', 'controlled', ',', 'randomized', 'and', 'double', 'blind', 'clinical', 'trial', 'phase', 'I', 'in', '4-5-year-old', 'children', '.']","(28, 30)","(168, 189)",-1,hl_p,25068497,Abstract,3,test,gold,2114.0
5906,"In the present study , we investigated the safety and explored the immunogenicity of",PCV7-TT,"during a controlled , randomized and double blind clinical trial phase I in 4-5-year-old children .","['In', 'the', 'present', 'study', ',', 'we', 'investigated', 'the', 'safety', 'and', 'explored', 'the', 'immunogenicity', 'of', 'PCV7-TT', 'during', 'a', 'controlled', ',', 'randomized', 'and', 'double', 'blind', 'clinical', 'trial', 'phase', 'I', 'in', '4-5-year-old', 'children', '.']","(14, 15)","(84, 91)",-1,hl_i,25068497,Abstract,3,test,gold,
5907,"In the present study , we investigated the",safety,"and explored the immunogenicity of PCV7-TT during a controlled , randomized and double blind clinical trial phase I in 4-5-year-old children .","['In', 'the', 'present', 'study', ',', 'we', 'investigated', 'the', 'safety', 'and', 'explored', 'the', 'immunogenicity', 'of', 'PCV7-TT', 'during', 'a', 'controlled', ',', 'randomized', 'and', 'double', 'blind', 'clinical', 'trial', 'phase', 'I', 'in', '4-5-year-old', 'children', '.']","(8, 9)","(42, 48)",-1,hl_o,25068497,Abstract,3,test,gold,458.0
5908,"In the present study , we investigated the safety and explored the",immunogenicity,"of PCV7-TT during a controlled , randomized and double blind clinical trial phase I in 4-5-year-old children .","['In', 'the', 'present', 'study', ',', 'we', 'investigated', 'the', 'safety', 'and', 'explored', 'the', 'immunogenicity', 'of', 'PCV7-TT', 'during', 'a', 'controlled', ',', 'randomized', 'and', 'double', 'blind', 'clinical', 'trial', 'phase', 'I', 'in', '4-5-year-old', 'children', '.']","(12, 13)","(66, 80)",-1,hl_o,25068497,Abstract,3,test,gold,4882.0
5909,,PCV7-TT,was well tolerated and as safe as Synflorix used as control vaccine .,"['PCV7-TT', 'was', 'well', 'tolerated', 'and', 'as', 'safe', 'as', 'Synflorix', 'used', 'as', 'control', 'vaccine', '.']","(0, 1)","(0, 7)",-1,ss_i,25068497,Abstract,4,test,gold,
5910,PCV7-TT was well tolerated and as safe,as Synflorix,used as control vaccine .,"['PCV7-TT', 'was', 'well', 'tolerated', 'and', 'as', 'safe', 'as', 'Synflorix', 'used', 'as', 'control', 'vaccine', '.']","(7, 9)","(38, 50)",-1,ss_i,25068497,Abstract,4,test,gold,117.0
5911,PCV7-TT was,well tolerated,and as safe as Synflorix used as control vaccine .,"['PCV7-TT', 'was', 'well', 'tolerated', 'and', 'as', 'safe', 'as', 'Synflorix', 'used', 'as', 'control', 'vaccine', '.']","(2, 4)","(11, 25)",-1,ss_o,25068497,Abstract,4,test,gold,861.0
5912,PCV7-TT was well tolerated and,as safe,as Synflorix used as control vaccine .,"['PCV7-TT', 'was', 'well', 'tolerated', 'and', 'as', 'safe', 'as', 'Synflorix', 'used', 'as', 'control', 'vaccine', '.']","(5, 7)","(30, 37)",-1,ss_o,25068497,Abstract,4,test,gold,877.0
5913,,PCV7-TT,was well tolerated and as safe as Synflorix used as control vaccine .,"['PCV7-TT', 'was', 'well', 'tolerated', 'and', 'as', 'safe', 'as', 'Synflorix', 'used', 'as', 'control', 'vaccine', '.']","(0, 1)","(0, 7)",-1,hl_i,25068497,Abstract,4,test,gold,
5914,PCV7-TT was well tolerated and as safe as,Synflorix,used as control vaccine .,"['PCV7-TT', 'was', 'well', 'tolerated', 'and', 'as', 'safe', 'as', 'Synflorix', 'used', 'as', 'control', 'vaccine', '.']","(8, 9)","(41, 50)",-1,hl_i,25068497,Abstract,4,test,gold,118.0
5915,"Following a single-dose vaccination , all individual serotypes included",in PCV7-TT,induced statistically significant increase of IgG GMC and OPA GMT .,"['Following', 'a', 'single-dose', 'vaccination', ',', 'all', 'individual', 'serotypes', 'included', 'in', 'PCV7-TT', 'induced', 'statistically', 'significant', 'increase', 'of', 'IgG', 'GMC', 'and', 'OPA', 'GMT', '.']","(9, 11)","(71, 81)",-1,ss_i,25068497,Abstract,5,test,gold,1186.0
5916,"Following a single-dose vaccination , all individual serotypes included in PCV7-TT induced statistically significant increase",of IgG GMC and OPA GMT,.,"['Following', 'a', 'single-dose', 'vaccination', ',', 'all', 'individual', 'serotypes', 'included', 'in', 'PCV7-TT', 'induced', 'statistically', 'significant', 'increase', 'of', 'IgG', 'GMC', 'and', 'OPA', 'GMT', '.']","(15, 21)","(125, 147)",-1,ss_o,25068497,Abstract,5,test,gold,1659.0
5917,"Following a single-dose vaccination , all individual serotypes included in",PCV7-TT,induced statistically significant increase of IgG GMC and OPA GMT .,"['Following', 'a', 'single-dose', 'vaccination', ',', 'all', 'individual', 'serotypes', 'included', 'in', 'PCV7-TT', 'induced', 'statistically', 'significant', 'increase', 'of', 'IgG', 'GMC', 'and', 'OPA', 'GMT', '.']","(10, 11)","(74, 81)",-1,hl_i,25068497,Abstract,5,test,gold,
5918,"Following a single-dose vaccination , all individual serotypes included in PCV7-TT induced statistically significant increase of",IgG GMC,and OPA GMT .,"['Following', 'a', 'single-dose', 'vaccination', ',', 'all', 'individual', 'serotypes', 'included', 'in', 'PCV7-TT', 'induced', 'statistically', 'significant', 'increase', 'of', 'IgG', 'GMC', 'and', 'OPA', 'GMT', '.']","(16, 18)","(128, 135)",-1,hl_o,25068497,Abstract,5,test,gold,1660.0
5919,"Following a single-dose vaccination , all individual serotypes included in PCV7-TT induced statistically significant increase of IgG GMC and",OPA GMT,.,"['Following', 'a', 'single-dose', 'vaccination', ',', 'all', 'individual', 'serotypes', 'included', 'in', 'PCV7-TT', 'induced', 'statistically', 'significant', 'increase', 'of', 'IgG', 'GMC', 'and', 'OPA', 'GMT', '.']","(19, 21)","(140, 147)",-1,hl_o,25068497,Abstract,5,test,gold,1489.0
5920,These are the first clinical results,of PCV7-TT,in children and they pave the way toward next clinical trials in children and infants .,"['These', 'are', 'the', 'first', 'clinical', 'results', 'of', 'PCV7-TT', 'in', 'children', 'and', 'they', 'pave', 'the', 'way', 'toward', 'next', 'clinical', 'trials', 'in', 'children', 'and', 'infants', '.']","(6, 8)","(36, 46)",-1,ss_i,25068497,Abstract,6,test,gold,
5921,These are the first clinical results of,PCV7-TT,in children and they pave the way toward next clinical trials in children and infants .,"['These', 'are', 'the', 'first', 'clinical', 'results', 'of', 'PCV7-TT', 'in', 'children', 'and', 'they', 'pave', 'the', 'way', 'toward', 'next', 'clinical', 'trials', 'in', 'children', 'and', 'infants', '.']","(7, 8)","(39, 46)",-1,hl_i,25068497,Abstract,6,test,gold,
5922,This clinical trial was published in the Cuban Public Register of Clinical Trials with code RPCEC00000173 .,,,"['This', 'clinical', 'trial', 'was', 'published', 'in', 'the', 'Cuban', 'Public', 'Register', 'of', 'Clinical', 'Trials', 'with', 'code', 'RPCEC00000173', '.']",,,,,25068497,Abstract,7,test,gold,
5923,Atomoxetine in,autism spectrum disorder :,"no effects on social functioning ; some beneficial effects on stereotyped behaviors , inappropriate speech , and fear of change .","['Atomoxetine', 'in', 'autism', 'spectrum', 'disorder', ':', 'no', 'effects', 'on', 'social', 'functioning', ';', 'some', 'beneficial', 'effects', 'on', 'stereotyped', 'behaviors', ',', 'inappropriate', 'speech', ',', 'and', 'fear', 'of', 'change', '.']","(2, 6)","(14, 40)",-1,ss_p,25369243,Title,0,test,gold,6011.0
5924,,Atomoxetine,"in autism spectrum disorder : no effects on social functioning ; some beneficial effects on stereotyped behaviors , inappropriate speech , and fear of change .","['Atomoxetine', 'in', 'autism', 'spectrum', 'disorder', ':', 'no', 'effects', 'on', 'social', 'functioning', ';', 'some', 'beneficial', 'effects', 'on', 'stereotyped', 'behaviors', ',', 'inappropriate', 'speech', ',', 'and', 'fear', 'of', 'change', '.']","(0, 1)","(0, 11)",-1,ss_i,25369243,Title,0,test,gold,1038.0
5925,Atomoxetine in autism spectrum disorder : no effects on,social functioning ;,"some beneficial effects on stereotyped behaviors , inappropriate speech , and fear of change .","['Atomoxetine', 'in', 'autism', 'spectrum', 'disorder', ':', 'no', 'effects', 'on', 'social', 'functioning', ';', 'some', 'beneficial', 'effects', 'on', 'stereotyped', 'behaviors', ',', 'inappropriate', 'speech', ',', 'and', 'fear', 'of', 'change', '.']","(9, 12)","(55, 75)",-1,ss_o,25369243,Title,0,test,gold,2945.0
5926,Atomoxetine in autism spectrum disorder : no effects on social functioning ; some beneficial effects on,"stereotyped behaviors , inappropriate speech , and fear of change .",,"['Atomoxetine', 'in', 'autism', 'spectrum', 'disorder', ':', 'no', 'effects', 'on', 'social', 'functioning', ';', 'some', 'beneficial', 'effects', 'on', 'stereotyped', 'behaviors', ',', 'inappropriate', 'speech', ',', 'and', 'fear', 'of', 'change', '.']","(16, 27)","(103, 170)",-1,ss_o,25369243,Title,0,test,gold,6405.0
5927,Atomoxetine in,autism spectrum disorder :,"no effects on social functioning ; some beneficial effects on stereotyped behaviors , inappropriate speech , and fear of change .","['Atomoxetine', 'in', 'autism', 'spectrum', 'disorder', ':', 'no', 'effects', 'on', 'social', 'functioning', ';', 'some', 'beneficial', 'effects', 'on', 'stereotyped', 'behaviors', ',', 'inappropriate', 'speech', ',', 'and', 'fear', 'of', 'change', '.']","(2, 6)","(14, 40)",-1,hl_p,25369243,Title,0,test,gold,6010.0
5928,,Atomoxetine,"in autism spectrum disorder : no effects on social functioning ; some beneficial effects on stereotyped behaviors , inappropriate speech , and fear of change .","['Atomoxetine', 'in', 'autism', 'spectrum', 'disorder', ':', 'no', 'effects', 'on', 'social', 'functioning', ';', 'some', 'beneficial', 'effects', 'on', 'stereotyped', 'behaviors', ',', 'inappropriate', 'speech', ',', 'and', 'fear', 'of', 'change', '.']","(0, 1)","(0, 11)",-1,hl_i,25369243,Title,0,test,gold,1039.0
5929,Atomoxetine in autism spectrum disorder : no effects on,social functioning ;,"some beneficial effects on stereotyped behaviors , inappropriate speech , and fear of change .","['Atomoxetine', 'in', 'autism', 'spectrum', 'disorder', ':', 'no', 'effects', 'on', 'social', 'functioning', ';', 'some', 'beneficial', 'effects', 'on', 'stereotyped', 'behaviors', ',', 'inappropriate', 'speech', ',', 'and', 'fear', 'of', 'change', '.']","(9, 12)","(55, 75)",-1,hl_o,25369243,Title,0,test,gold,2944.0
5930,Atomoxetine in autism spectrum disorder : no effects on social functioning ; some beneficial effects on,stereotyped behaviors,", inappropriate speech , and fear of change .","['Atomoxetine', 'in', 'autism', 'spectrum', 'disorder', ':', 'no', 'effects', 'on', 'social', 'functioning', ';', 'some', 'beneficial', 'effects', 'on', 'stereotyped', 'behaviors', ',', 'inappropriate', 'speech', ',', 'and', 'fear', 'of', 'change', '.']","(16, 18)","(103, 124)",-1,hl_o,25369243,Title,0,test,gold,6409.0
5931,"Atomoxetine in autism spectrum disorder : no effects on social functioning ; some beneficial effects on stereotyped behaviors ,",inappropriate speech,", and fear of change .","['Atomoxetine', 'in', 'autism', 'spectrum', 'disorder', ':', 'no', 'effects', 'on', 'social', 'functioning', ';', 'some', 'beneficial', 'effects', 'on', 'stereotyped', 'behaviors', ',', 'inappropriate', 'speech', ',', 'and', 'fear', 'of', 'change', '.']","(19, 21)","(127, 147)",-1,hl_o,25369243,Title,0,test,gold,2609.0
5932,"Atomoxetine in autism spectrum disorder : no effects on social functioning ; some beneficial effects on stereotyped behaviors , inappropriate speech , and",fear of change,.,"['Atomoxetine', 'in', 'autism', 'spectrum', 'disorder', ':', 'no', 'effects', 'on', 'social', 'functioning', ';', 'some', 'beneficial', 'effects', 'on', 'stereotyped', 'behaviors', ',', 'inappropriate', 'speech', ',', 'and', 'fear', 'of', 'change', '.']","(23, 26)","(154, 168)",-1,hl_o,25369243,Title,0,test,gold,969.0
5933,UNLABELLED Abstract Objective : The objective of this study was to investigate the short-term treatment effects of atomoxetine on autism spectrum disorder ( ASD ) symptoms in,children and adolescents with both ASD and attention-deficit/hyperactivity disorder ( ADHD ) .,,"['UNLABELLED', 'Abstract', 'Objective', ':', 'The', 'objective', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'short-term', 'treatment', 'effects', 'of', 'atomoxetine', 'on', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'symptoms', 'in', 'children', 'and', 'adolescents', 'with', 'both', 'ASD', 'and', 'attention-deficit/hyperactivity', 'disorder', '(', 'ADHD', ')', '.']","(27, 40)","(174, 268)",-1,ss_p,25369243,Abstract,0,test,gold,6033.0
5934,UNLABELLED Abstract Objective : The objective of this study was to investigate the short-term treatment effects of,atomoxetine,on autism spectrum disorder ( ASD ) symptoms in children and adolescents with both ASD and attention-deficit/hyperactivity disorder ( ADHD ) .,"['UNLABELLED', 'Abstract', 'Objective', ':', 'The', 'objective', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'short-term', 'treatment', 'effects', 'of', 'atomoxetine', 'on', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'symptoms', 'in', 'children', 'and', 'adolescents', 'with', 'both', 'ASD', 'and', 'attention-deficit/hyperactivity', 'disorder', '(', 'ADHD', ')', '.']","(17, 18)","(114, 125)",-1,ss_i,25369243,Abstract,0,test,gold,5587.0
5935,UNLABELLED Abstract Objective : The objective of this study was to investigate the short-term treatment,effects,of atomoxetine on autism spectrum disorder ( ASD ) symptoms in children and adolescents with both ASD and attention-deficit/hyperactivity disorder ( ADHD ) .,"['UNLABELLED', 'Abstract', 'Objective', ':', 'The', 'objective', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'short-term', 'treatment', 'effects', 'of', 'atomoxetine', 'on', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'symptoms', 'in', 'children', 'and', 'adolescents', 'with', 'both', 'ASD', 'and', 'attention-deficit/hyperactivity', 'disorder', '(', 'ADHD', ')', '.']","(15, 16)","(103, 110)",-1,ss_o,25369243,Abstract,0,test,gold,2376.0
5936,UNLABELLED Abstract Objective : The objective of this study was to investigate the short-term treatment effects of atomoxetine on autism spectrum disorder ( ASD ) symptoms in,children and adolescents,with both ASD and attention-deficit/hyperactivity disorder ( ADHD ) .,"['UNLABELLED', 'Abstract', 'Objective', ':', 'The', 'objective', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'short-term', 'treatment', 'effects', 'of', 'atomoxetine', 'on', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'symptoms', 'in', 'children', 'and', 'adolescents', 'with', 'both', 'ASD', 'and', 'attention-deficit/hyperactivity', 'disorder', '(', 'ADHD', ')', '.']","(27, 30)","(174, 198)",-1,hl_p,25369243,Abstract,0,test,gold,2104.0
5937,UNLABELLED Abstract Objective : The objective of this study was to investigate the short-term treatment effects of atomoxetine on autism spectrum disorder ( ASD ) symptoms in children and adolescents with both,ASD and attention-deficit/hyperactivity disorder ( ADHD ),.,"['UNLABELLED', 'Abstract', 'Objective', ':', 'The', 'objective', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'short-term', 'treatment', 'effects', 'of', 'atomoxetine', 'on', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'symptoms', 'in', 'children', 'and', 'adolescents', 'with', 'both', 'ASD', 'and', 'attention-deficit/hyperactivity', 'disorder', '(', 'ADHD', ')', '.']","(32, 39)","(209, 266)",-1,hl_p,25369243,Abstract,0,test,gold,6173.0
5938,UNLABELLED Abstract Objective : The objective of this study was to investigate the short-term treatment effects of,atomoxetine,on autism spectrum disorder ( ASD ) symptoms in children and adolescents with both ASD and attention-deficit/hyperactivity disorder ( ADHD ) .,"['UNLABELLED', 'Abstract', 'Objective', ':', 'The', 'objective', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'short-term', 'treatment', 'effects', 'of', 'atomoxetine', 'on', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', 'symptoms', 'in', 'children', 'and', 'adolescents', 'with', 'both', 'ASD', 'and', 'attention-deficit/hyperactivity', 'disorder', '(', 'ADHD', ')', '.']","(17, 18)","(114, 125)",-1,hl_i,25369243,Abstract,0,test,gold,5588.0
5939,METHODS A total of,"97 patients 6-17 years of age , with ASD and ADHD",", were treated with 1.2 mg/kg/day of atomoxetine during an 8 week double-blind placebo-controlled period .","['METHODS', 'A', 'total', 'of', '97', 'patients', '6-17', 'years', 'of', 'age', ',', 'with', 'ASD', 'and', 'ADHD', ',', 'were', 'treated', 'with', '1.2', 'mg/kg/day', 'of', 'atomoxetine', 'during', 'an', '8', 'week', 'double-blind', 'placebo-controlled', 'period', '.']","(4, 15)","(18, 67)",-1,ss_p,25369243,Abstract,1,test,gold,6200.0
5940,"METHODS A total of 97 patients 6-17 years of age , with ASD and ADHD , were treated with 1.2 mg/kg/day",of atomoxetine,during an 8 week double-blind placebo-controlled period .,"['METHODS', 'A', 'total', 'of', '97', 'patients', '6-17', 'years', 'of', 'age', ',', 'with', 'ASD', 'and', 'ADHD', ',', 'were', 'treated', 'with', '1.2', 'mg/kg/day', 'of', 'atomoxetine', 'during', 'an', '8', 'week', 'double-blind', 'placebo-controlled', 'period', '.']","(21, 23)","(102, 116)",-1,ss_i,25369243,Abstract,1,test,gold,5586.0
5941,"METHODS A total of 97 patients 6-17 years of age , with ASD and ADHD , were treated with 1.2 mg/kg/day of atomoxetine during an 8 week",double-blind placebo-controlled,period .,"['METHODS', 'A', 'total', 'of', '97', 'patients', '6-17', 'years', 'of', 'age', ',', 'with', 'ASD', 'and', 'ADHD', ',', 'were', 'treated', 'with', '1.2', 'mg/kg/day', 'of', 'atomoxetine', 'during', 'an', '8', 'week', 'double-blind', 'placebo-controlled', 'period', '.']","(27, 29)","(134, 165)",-1,ss_i,25369243,Abstract,1,test,gold,
5942,METHODS A total of,97,"patients 6-17 years of age , with ASD and ADHD , were treated with 1.2 mg/kg/day of atomoxetine during an 8 week double-blind placebo-controlled period .","['METHODS', 'A', 'total', 'of', '97', 'patients', '6-17', 'years', 'of', 'age', ',', 'with', 'ASD', 'and', 'ADHD', ',', 'were', 'treated', 'with', '1.2', 'mg/kg/day', 'of', 'atomoxetine', 'during', 'an', '8', 'week', 'double-blind', 'placebo-controlled', 'period', '.']","(4, 5)","(18, 20)",-1,hl_p,25369243,Abstract,1,test,gold,
5943,METHODS A total of 97 patients,6-17 years of age,", with ASD and ADHD , were treated with 1.2 mg/kg/day of atomoxetine during an 8 week double-blind placebo-controlled period .","['METHODS', 'A', 'total', 'of', '97', 'patients', '6-17', 'years', 'of', 'age', ',', 'with', 'ASD', 'and', 'ADHD', ',', 'were', 'treated', 'with', '1.2', 'mg/kg/day', 'of', 'atomoxetine', 'during', 'an', '8', 'week', 'double-blind', 'placebo-controlled', 'period', '.']","(6, 10)","(30, 47)",-1,hl_p,25369243,Abstract,1,test,gold,2019.0
5944,"METHODS A total of 97 patients 6-17 years of age , with",ASD and ADHD,", were treated with 1.2 mg/kg/day of atomoxetine during an 8 week double-blind placebo-controlled period .","['METHODS', 'A', 'total', 'of', '97', 'patients', '6-17', 'years', 'of', 'age', ',', 'with', 'ASD', 'and', 'ADHD', ',', 'were', 'treated', 'with', '1.2', 'mg/kg/day', 'of', 'atomoxetine', 'during', 'an', '8', 'week', 'double-blind', 'placebo-controlled', 'period', '.']","(12, 15)","(55, 67)",-1,hl_p,25369243,Abstract,1,test,gold,6174.0
5945,"METHODS A total of 97 patients 6-17 years of age , with ASD and ADHD , were treated with 1.2 mg/kg/day of",atomoxetine,during an 8 week double-blind placebo-controlled period .,"['METHODS', 'A', 'total', 'of', '97', 'patients', '6-17', 'years', 'of', 'age', ',', 'with', 'ASD', 'and', 'ADHD', ',', 'were', 'treated', 'with', '1.2', 'mg/kg/day', 'of', 'atomoxetine', 'during', 'an', '8', 'week', 'double-blind', 'placebo-controlled', 'period', '.']","(22, 23)","(105, 116)",-1,hl_i,25369243,Abstract,1,test,gold,5585.0
5946,"METHODS A total of 97 patients 6-17 years of age , with ASD and ADHD , were treated with 1.2 mg/kg/day of atomoxetine during an 8 week double-blind",placebo-controlled,period .,"['METHODS', 'A', 'total', 'of', '97', 'patients', '6-17', 'years', 'of', 'age', ',', 'with', 'ASD', 'and', 'ADHD', ',', 'were', 'treated', 'with', '1.2', 'mg/kg/day', 'of', 'atomoxetine', 'during', 'an', '8', 'week', 'double-blind', 'placebo-controlled', 'period', '.']","(28, 29)","(147, 165)",-1,hl_i,25369243,Abstract,1,test,gold,
5947,"Here , we investigated effects on two parent-based secondary outcome","measures , the Aberrant Behavior Checklist ( ABC ) and the Children 's Social Behavior Questionnaire ( CSBQ )",.,"['Here', ',', 'we', 'investigated', 'effects', 'on', 'two', 'parent-based', 'secondary', 'outcome', 'measures', ',', 'the', 'Aberrant', 'Behavior', 'Checklist', '(', 'ABC', ')', 'and', 'the', 'Children', ""'s"", 'Social', 'Behavior', 'Questionnaire', '(', 'CSBQ', ')', '.']","(10, 29)","(68, 177)",-1,ss_o,25369243,Abstract,2,test,gold,6285.0
5948,RESULTS After 8 weeks of double-blind,"treatment , atomoxetine","administration was associated with significant treatment effects on the ABC subscales Hyperactivity , Inappropriate Speech , and Stereotypic Behavior , and on the CSBQ subscale Fear for Changes .","['RESULTS', 'After', '8', 'weeks', 'of', 'double-blind', 'treatment', ',', 'atomoxetine', 'administration', 'was', 'associated', 'with', 'significant', 'treatment', 'effects', 'on', 'the', 'ABC', 'subscales', 'Hyperactivity', ',', 'Inappropriate', 'Speech', ',', 'and', 'Stereotypic', 'Behavior', ',', 'and', 'on', 'the', 'CSBQ', 'subscale', 'Fear', 'for', 'Changes', '.']","(6, 9)","(37, 60)",-1,ss_i,25369243,Abstract,3,test,gold,5580.0
5949,"RESULTS After 8 weeks of double-blind treatment , atomoxetine administration was associated with significant treatment effects on","the ABC subscales Hyperactivity , Inappropriate Speech , and Stereotypic Behavior",", and on the CSBQ subscale Fear for Changes .","['RESULTS', 'After', '8', 'weeks', 'of', 'double-blind', 'treatment', ',', 'atomoxetine', 'administration', 'was', 'associated', 'with', 'significant', 'treatment', 'effects', 'on', 'the', 'ABC', 'subscales', 'Hyperactivity', ',', 'Inappropriate', 'Speech', ',', 'and', 'Stereotypic', 'Behavior', ',', 'and', 'on', 'the', 'CSBQ', 'subscale', 'Fear', 'for', 'Changes', '.']","(17, 28)","(129, 210)",-1,ss_o,25369243,Abstract,3,test,gold,6291.0
5950,"RESULTS After 8 weeks of double-blind treatment , atomoxetine administration was associated with significant treatment effects on the ABC subscales Hyperactivity , Inappropriate Speech , and Stereotypic Behavior , and on",the CSBQ subscale Fear for Changes,.,"['RESULTS', 'After', '8', 'weeks', 'of', 'double-blind', 'treatment', ',', 'atomoxetine', 'administration', 'was', 'associated', 'with', 'significant', 'treatment', 'effects', 'on', 'the', 'ABC', 'subscales', 'Hyperactivity', ',', 'Inappropriate', 'Speech', ',', 'and', 'Stereotypic', 'Behavior', ',', 'and', 'on', 'the', 'CSBQ', 'subscale', 'Fear', 'for', 'Changes', '.']","(31, 37)","(220, 254)",-1,ss_o,25369243,Abstract,3,test,gold,6237.0
5951,"RESULTS After 8 weeks of double-blind treatment ,",atomoxetine,"administration was associated with significant treatment effects on the ABC subscales Hyperactivity , Inappropriate Speech , and Stereotypic Behavior , and on the CSBQ subscale Fear for Changes .","['RESULTS', 'After', '8', 'weeks', 'of', 'double-blind', 'treatment', ',', 'atomoxetine', 'administration', 'was', 'associated', 'with', 'significant', 'treatment', 'effects', 'on', 'the', 'ABC', 'subscales', 'Hyperactivity', ',', 'Inappropriate', 'Speech', ',', 'and', 'Stereotypic', 'Behavior', ',', 'and', 'on', 'the', 'CSBQ', 'subscale', 'Fear', 'for', 'Changes', '.']","(8, 9)","(49, 60)",-1,hl_i,25369243,Abstract,3,test,gold,5584.0
5952,"RESULTS After 8 weeks of double-blind treatment , atomoxetine administration was associated with significant treatment effects on the",ABC subscales Hyperactivity,", Inappropriate Speech , and Stereotypic Behavior , and on the CSBQ subscale Fear for Changes .","['RESULTS', 'After', '8', 'weeks', 'of', 'double-blind', 'treatment', ',', 'atomoxetine', 'administration', 'was', 'associated', 'with', 'significant', 'treatment', 'effects', 'on', 'the', 'ABC', 'subscales', 'Hyperactivity', ',', 'Inappropriate', 'Speech', ',', 'and', 'Stereotypic', 'Behavior', ',', 'and', 'on', 'the', 'CSBQ', 'subscale', 'Fear', 'for', 'Changes', '.']","(18, 21)","(133, 160)",-1,hl_o,25369243,Abstract,3,test,gold,6380.0
5953,"RESULTS After 8 weeks of double-blind treatment , atomoxetine administration was associated with significant treatment effects on the ABC subscales Hyperactivity ,",Inappropriate Speech,", and Stereotypic Behavior , and on the CSBQ subscale Fear for Changes .","['RESULTS', 'After', '8', 'weeks', 'of', 'double-blind', 'treatment', ',', 'atomoxetine', 'administration', 'was', 'associated', 'with', 'significant', 'treatment', 'effects', 'on', 'the', 'ABC', 'subscales', 'Hyperactivity', ',', 'Inappropriate', 'Speech', ',', 'and', 'Stereotypic', 'Behavior', ',', 'and', 'on', 'the', 'CSBQ', 'subscale', 'Fear', 'for', 'Changes', '.']","(22, 24)","(163, 183)",-1,hl_o,25369243,Abstract,3,test,gold,2610.0
5954,"RESULTS After 8 weeks of double-blind treatment , atomoxetine administration was associated with significant treatment effects on the ABC subscales Hyperactivity , Inappropriate Speech , and",Stereotypic Behavior,", and on the CSBQ subscale Fear for Changes .","['RESULTS', 'After', '8', 'weeks', 'of', 'double-blind', 'treatment', ',', 'atomoxetine', 'administration', 'was', 'associated', 'with', 'significant', 'treatment', 'effects', 'on', 'the', 'ABC', 'subscales', 'Hyperactivity', ',', 'Inappropriate', 'Speech', ',', 'and', 'Stereotypic', 'Behavior', ',', 'and', 'on', 'the', 'CSBQ', 'subscale', 'Fear', 'for', 'Changes', '.']","(26, 28)","(190, 210)",-1,hl_o,25369243,Abstract,3,test,gold,2600.0
5955,"RESULTS After 8 weeks of double-blind treatment , atomoxetine administration was associated with significant treatment effects on the ABC subscales Hyperactivity , Inappropriate Speech , and Stereotypic Behavior , and on the",CSBQ subscale Fear for Changes,.,"['RESULTS', 'After', '8', 'weeks', 'of', 'double-blind', 'treatment', ',', 'atomoxetine', 'administration', 'was', 'associated', 'with', 'significant', 'treatment', 'effects', 'on', 'the', 'ABC', 'subscales', 'Hyperactivity', ',', 'Inappropriate', 'Speech', ',', 'and', 'Stereotypic', 'Behavior', ',', 'and', 'on', 'the', 'CSBQ', 'subscale', 'Fear', 'for', 'Changes', '.']","(32, 37)","(224, 254)",-1,hl_o,25369243,Abstract,3,test,gold,6238.0
5956,CONCLUSIONS Our study results indicate no beneficial effects,of atomoxetine,on social functioning .,"['CONCLUSIONS', 'Our', 'study', 'results', 'indicate', 'no', 'beneficial', 'effects', 'of', 'atomoxetine', 'on', 'social', 'functioning', '.']","(8, 10)","(60, 74)",-1,ss_i,25369243,Abstract,4,test,gold,5583.0
5957,,"However , atomoxetine",may ameliorate restricted and stereotyped behaviors and communication .,"['However', ',', 'atomoxetine', 'may', 'ameliorate', 'restricted', 'and', 'stereotyped', 'behaviors', 'and', 'communication', '.']","(0, 3)","(0, 21)",-1,ss_i,25369243,Abstract,5,test,gold,5581.0
5958,"However , atomoxetine may",ameliorate restricted and stereotyped behaviors and communication,.,"['However', ',', 'atomoxetine', 'may', 'ameliorate', 'restricted', 'and', 'stereotyped', 'behaviors', 'and', 'communication', '.']","(4, 11)","(25, 90)",-1,ss_o,25369243,Abstract,5,test,gold,6406.0
5959,"However ,",atomoxetine,may ameliorate restricted and stereotyped behaviors and communication .,"['However', ',', 'atomoxetine', 'may', 'ameliorate', 'restricted', 'and', 'stereotyped', 'behaviors', 'and', 'communication', '.']","(2, 3)","(9, 20)",-1,hl_i,25369243,Abstract,5,test,gold,5582.0
5960,"However , atomoxetine may ameliorate restricted and",stereotyped behaviors,and communication .,"['However', ',', 'atomoxetine', 'may', 'ameliorate', 'restricted', 'and', 'stereotyped', 'behaviors', 'and', 'communication', '.']","(7, 9)","(51, 72)",-1,hl_o,25369243,Abstract,5,test,gold,6410.0
5961,"However , atomoxetine may ameliorate restricted and stereotyped behaviors and",communication,.,"['However', ',', 'atomoxetine', 'may', 'ameliorate', 'restricted', 'and', 'stereotyped', 'behaviors', 'and', 'communication', '.']","(10, 11)","(77, 90)",-1,hl_o,25369243,Abstract,5,test,gold,1295.0
5962,This study has been registered in ClinicalTrials.gov ( www.clinicaltrials.gov ) under registration number NCT00380692 .,,,"['This', 'study', 'has', 'been', 'registered', 'in', 'ClinicalTrials.gov', '(', 'www.clinicaltrials.gov', ')', 'under', 'registration', 'number', 'NCT00380692', '.']",,,,,25369243,Abstract,6,test,gold,
5963,Randomised trial of text messaging on adherence to,cardiovascular preventive treatment,( INTERACT trial ) .,"['Randomised', 'trial', 'of', 'text', 'messaging', 'on', 'adherence', 'to', 'cardiovascular', 'preventive', 'treatment', '(', 'INTERACT', 'trial', ')', '.']","(8, 11)","(50, 85)",-1,ss_p,25479285,Title,0,test,gold,6944.0
5964,Randomised trial of,text messaging,on adherence to cardiovascular preventive treatment ( INTERACT trial ) .,"['Randomised', 'trial', 'of', 'text', 'messaging', 'on', 'adherence', 'to', 'cardiovascular', 'preventive', 'treatment', '(', 'INTERACT', 'trial', ')', '.']","(3, 5)","(19, 33)",-1,ss_i,25479285,Title,0,test,gold,2985.0
5965,Randomised trial of text messaging on,adherence to cardiovascular preventive treatment,( INTERACT trial ) .,"['Randomised', 'trial', 'of', 'text', 'messaging', 'on', 'adherence', 'to', 'cardiovascular', 'preventive', 'treatment', '(', 'INTERACT', 'trial', ')', '.']","(6, 11)","(37, 85)",-1,ss_o,25479285,Title,0,test,gold,6945.0
5966,Randomised trial of text messaging on,adherence,to cardiovascular preventive treatment ( INTERACT trial ) .,"['Randomised', 'trial', 'of', 'text', 'messaging', 'on', 'adherence', 'to', 'cardiovascular', 'preventive', 'treatment', '(', 'INTERACT', 'trial', ')', '.']","(6, 7)","(37, 46)",-1,hl_o,25479285,Title,0,test,gold,407.0
5967,BACKGROUND About one third of patients prescribed blood pressure or lipid-lowering drugs for the prevention of coronary heart disease and stroke do not take their medication as prescribed .,,,"['BACKGROUND', 'About', 'one', 'third', 'of', 'patients', 'prescribed', 'blood', 'pressure', 'or', 'lipid-lowering', 'drugs', 'for', 'the', 'prevention', 'of', 'coronary', 'heart', 'disease', 'and', 'stroke', 'do', 'not', 'take', 'their', 'medication', 'as', 'prescribed', '.']",,,,,25479285,Abstract,0,test,gold,
5968,We conducted a randomized trial to evaluate,text messaging,as a means of improving adherence to cardiovascular disease preventive treatment .,"['We', 'conducted', 'a', 'randomized', 'trial', 'to', 'evaluate', 'text', 'messaging', 'as', 'a', 'means', 'of', 'improving', 'adherence', 'to', 'cardiovascular', 'disease', 'preventive', 'treatment', '.']","(7, 9)","(43, 57)",-1,ss_i,25479285,Abstract,1,test,gold,2986.0
5969,We conducted a randomized trial to evaluate text messaging as a means of improving,adherence to cardiovascular disease preventive treatment .,,"['We', 'conducted', 'a', 'randomized', 'trial', 'to', 'evaluate', 'text', 'messaging', 'as', 'a', 'means', 'of', 'improving', 'adherence', 'to', 'cardiovascular', 'disease', 'preventive', 'treatment', '.']","(14, 21)","(82, 140)",-1,ss_o,25479285,Abstract,1,test,gold,6943.0
5970,We conducted a randomized trial to evaluate,text messaging,as a means of improving adherence to cardiovascular disease preventive treatment .,"['We', 'conducted', 'a', 'randomized', 'trial', 'to', 'evaluate', 'text', 'messaging', 'as', 'a', 'means', 'of', 'improving', 'adherence', 'to', 'cardiovascular', 'disease', 'preventive', 'treatment', '.']","(7, 9)","(43, 57)",-1,hl_i,25479285,Abstract,1,test,gold,2984.0
5971,We conducted a randomized trial to evaluate text messaging as a means of improving,adherence,to cardiovascular disease preventive treatment .,"['We', 'conducted', 'a', 'randomized', 'trial', 'to', 'evaluate', 'text', 'messaging', 'as', 'a', 'means', 'of', 'improving', 'adherence', 'to', 'cardiovascular', 'disease', 'preventive', 'treatment', '.']","(14, 15)","(82, 91)",-1,hl_o,25479285,Abstract,1,test,gold,405.0
5972,METHODS,303 patients taking blood pressure and/or lipid-lowering medications,"were randomly assigned to being sent text messages ( Text group , 151 ) or not being sent them ( No text group , 152 ) .","['METHODS', '303', 'patients', 'taking', 'blood', 'pressure', 'and/or', 'lipid-lowering', 'medications', 'were', 'randomly', 'assigned', 'to', 'being', 'sent', 'text', 'messages', '(', 'Text', 'group', ',', '151', ')', 'or', 'not', 'being', 'sent', 'them', '(', 'No', 'text', 'group', ',', '152', ')', '.']","(1, 9)","(7, 75)",-1,ss_p,25479285,Abstract,2,test,gold,6719.0
5973,METHODS 303 patients taking blood pressure and/or lipid-lowering medications were randomly assigned to being sent,text messages ( Text,"group , 151 ) or not being sent them ( No text group , 152 ) .","['METHODS', '303', 'patients', 'taking', 'blood', 'pressure', 'and/or', 'lipid-lowering', 'medications', 'were', 'randomly', 'assigned', 'to', 'being', 'sent', 'text', 'messages', '(', 'Text', 'group', ',', '151', ')', 'or', 'not', 'being', 'sent', 'them', '(', 'No', 'text', 'group', ',', '152', ')', '.']","(15, 19)","(113, 133)",-1,ss_i,25479285,Abstract,2,test,gold,2980.0
5974,"METHODS 303 patients taking blood pressure and/or lipid-lowering medications were randomly assigned to being sent text messages ( Text group , 151 ) or",not being sent them ( No text,"group , 152 ) .","['METHODS', '303', 'patients', 'taking', 'blood', 'pressure', 'and/or', 'lipid-lowering', 'medications', 'were', 'randomly', 'assigned', 'to', 'being', 'sent', 'text', 'messages', '(', 'Text', 'group', ',', '151', ')', 'or', 'not', 'being', 'sent', 'them', '(', 'No', 'text', 'group', ',', '152', ')', '.']","(24, 31)","(151, 180)",-1,ss_i,25479285,Abstract,2,test,gold,2991.0
5975,METHODS,303 patients taking blood pressure and/or lipid-lowering medications,"were randomly assigned to being sent text messages ( Text group , 151 ) or not being sent them ( No text group , 152 ) .","['METHODS', '303', 'patients', 'taking', 'blood', 'pressure', 'and/or', 'lipid-lowering', 'medications', 'were', 'randomly', 'assigned', 'to', 'being', 'sent', 'text', 'messages', '(', 'Text', 'group', ',', '151', ')', 'or', 'not', 'being', 'sent', 'them', '(', 'No', 'text', 'group', ',', '152', ')', '.']","(1, 9)","(7, 75)",-1,hl_p,25479285,Abstract,2,test,gold,6720.0
5976,METHODS 303 patients taking blood pressure and/or lipid-lowering medications were randomly assigned to being sent,text messages ( Text,"group , 151 ) or not being sent them ( No text group , 152 ) .","['METHODS', '303', 'patients', 'taking', 'blood', 'pressure', 'and/or', 'lipid-lowering', 'medications', 'were', 'randomly', 'assigned', 'to', 'being', 'sent', 'text', 'messages', '(', 'Text', 'group', ',', '151', ')', 'or', 'not', 'being', 'sent', 'them', '(', 'No', 'text', 'group', ',', '152', ')', '.']","(15, 19)","(113, 133)",-1,hl_i,25479285,Abstract,2,test,gold,2981.0
5977,"METHODS 303 patients taking blood pressure and/or lipid-lowering medications were randomly assigned to being sent text messages ( Text group , 151 ) or",not being sent them,"( No text group , 152 ) .","['METHODS', '303', 'patients', 'taking', 'blood', 'pressure', 'and/or', 'lipid-lowering', 'medications', 'were', 'randomly', 'assigned', 'to', 'being', 'sent', 'text', 'messages', '(', 'Text', 'group', ',', '151', ')', 'or', 'not', 'being', 'sent', 'them', '(', 'No', 'text', 'group', ',', '152', ')', '.']","(24, 28)","(151, 170)",-1,hl_i,25479285,Abstract,2,test,gold,2992.0
5978,"Texts were sent daily for 2 weeks , alternate days for 2 weeks and weekly thereafter for 22 weeks ( 6 months overall ) , using an automated computer programme .",,,"['Texts', 'were', 'sent', 'daily', 'for', '2', 'weeks', ',', 'alternate', 'days', 'for', '2', 'weeks', 'and', 'weekly', 'thereafter', 'for', '22', 'weeks', '(', '6', 'months', 'overall', ')', ',', 'using', 'an', 'automated', 'computer', 'programme', '.']",,,,,25479285,Abstract,3,test,gold,
5979,"Patients were asked to respond on whether they had taken their medication , whether the",text,"reminded them to do so if they had forgotten , and if they had not taken their medication to determine if there was a reason for not doing so .","['Patients', 'were', 'asked', 'to', 'respond', 'on', 'whether', 'they', 'had', 'taken', 'their', 'medication', ',', 'whether', 'the', 'text', 'reminded', 'them', 'to', 'do', 'so', 'if', 'they', 'had', 'forgotten', ',', 'and', 'if', 'they', 'had', 'not', 'taken', 'their', 'medication', 'to', 'determine', 'if', 'there', 'was', 'a', 'reason', 'for', 'not', 'doing', 'so', '.']","(15, 16)","(87, 91)",-1,ss_i,25479285,Abstract,4,test,gold,1253.0
5980,"At 6 months ,",use of medication,was assessed .,"['At', '6', 'months', ',', 'use', 'of', 'medication', 'was', 'assessed', '.']","(4, 7)","(13, 30)",-1,ss_o,25479285,Abstract,5,test,gold,5066.0
5981,"RESULTS Two patients were lost to follow-up , providing data on 301 for analysis .",,,"['RESULTS', 'Two', 'patients', 'were', 'lost', 'to', 'follow-up', ',', 'providing', 'data', 'on', '301', 'for', 'analysis', '.']",,,,,25479285,Abstract,6,test,gold,
5982,In the No text group 38/151 ( 25 % ) took less than 80 % of the,prescribed regimen,( ie .,"['In', 'the', 'No', 'text', 'group', '38/151', '(', '25', '%', ')', 'took', 'less', 'than', '80', '%', 'of', 'the', 'prescribed', 'regimen', '(', 'ie', '.']","(17, 19)","(63, 81)",-1,ss_o,25479285,Abstract,7,test,gold,5599.0
5983,stopped medication completely or took it on fewer than 22 of the last 28 days of follow-up ) compared to 14/150 patients ( 9 % ) in the,Text,"group - an improvement in adherence affecting 16 per 100 patients ( 95 % CI 7 to 24 ) , p < 0.001 .","['stopped', 'medication', 'completely', 'or', 'took', 'it', 'on', 'fewer', 'than', '22', 'of', 'the', 'last', '28', 'days', 'of', 'follow-up', ')', 'compared', 'to', '14/150', 'patients', '(', '9', '%', ')', 'in', 'the', 'Text', 'group', '-', 'an', 'improvement', 'in', 'adherence', 'affecting', '16', 'per', '100', 'patients', '(', '95', '%', 'CI', '7', 'to', '24', ')', ',', 'p', '<', '0.001', '.']","(28, 29)","(135, 139)",-1,ss_i,25479285,Abstract,8,test,gold,1251.0
5984,stopped medication completely or took it on fewer than 22 of the last 28 days of follow-up ) compared to 14/150 patients ( 9 % ) in the Text group - an improvement in,adherence,"affecting 16 per 100 patients ( 95 % CI 7 to 24 ) , p < 0.001 .","['stopped', 'medication', 'completely', 'or', 'took', 'it', 'on', 'fewer', 'than', '22', 'of', 'the', 'last', '28', 'days', 'of', 'follow-up', ')', 'compared', 'to', '14/150', 'patients', '(', '9', '%', ')', 'in', 'the', 'Text', 'group', '-', 'an', 'improvement', 'in', 'adherence', 'affecting', '16', 'per', '100', 'patients', '(', '95', '%', 'CI', '7', 'to', '24', ')', ',', 'p', '<', '0.001', '.']","(34, 35)","(166, 175)",-1,ss_o,25479285,Abstract,8,test,gold,404.0
5985,stopped medication completely or took it on fewer than 22 of the last 28 days of follow-up ) compared to 14/150 patients ( 9 % ) in the,Text,"group - an improvement in adherence affecting 16 per 100 patients ( 95 % CI 7 to 24 ) , p < 0.001 .","['stopped', 'medication', 'completely', 'or', 'took', 'it', 'on', 'fewer', 'than', '22', 'of', 'the', 'last', '28', 'days', 'of', 'follow-up', ')', 'compared', 'to', '14/150', 'patients', '(', '9', '%', ')', 'in', 'the', 'Text', 'group', '-', 'an', 'improvement', 'in', 'adherence', 'affecting', '16', 'per', '100', 'patients', '(', '95', '%', 'CI', '7', 'to', '24', ')', ',', 'p', '<', '0.001', '.']","(28, 29)","(135, 139)",-1,hl_i,25479285,Abstract,8,test,gold,1252.0
5986,stopped medication completely or took it on fewer than 22 of the last 28 days of follow-up ) compared to 14/150 patients ( 9 % ) in the Text group - an improvement in,adherence,"affecting 16 per 100 patients ( 95 % CI 7 to 24 ) , p < 0.001 .","['stopped', 'medication', 'completely', 'or', 'took', 'it', 'on', 'fewer', 'than', '22', 'of', 'the', 'last', '28', 'days', 'of', 'follow-up', ')', 'compared', 'to', '14/150', 'patients', '(', '9', '%', ')', 'in', 'the', 'Text', 'group', '-', 'an', 'improvement', 'in', 'adherence', 'affecting', '16', 'per', '100', 'patients', '(', '95', '%', 'CI', '7', 'to', '24', ')', ',', 'p', '<', '0.001', '.']","(34, 35)","(166, 175)",-1,hl_o,25479285,Abstract,8,test,gold,403.0
5987,The,texts,"reminded 98/151 patients ( 65 % ) to take medication on at least one occasion and lead to 20/151 ( 13 % ) who stopped taking medication because of concern over efficacy or side-effects , resuming treatment .","['The', 'texts', 'reminded', '98/151', 'patients', '(', '65', '%', ')', 'to', 'take', 'medication', 'on', 'at', 'least', 'one', 'occasion', 'and', 'lead', 'to', '20/151', '(', '13', '%', ')', 'who', 'stopped', 'taking', 'medication', 'because', 'of', 'concern', 'over', 'efficacy', 'or', 'side-effects', ',', 'resuming', 'treatment', '.']","(1, 2)","(3, 8)",-1,ss_i,25479285,Abstract,9,test,gold,1254.0
5988,The texts reminded 98/151 patients ( 65 % ) to take medication on at least one occasion and lead to 20/151 ( 13 % ) who,stopped taking medication,"because of concern over efficacy or side-effects , resuming treatment .","['The', 'texts', 'reminded', '98/151', 'patients', '(', '65', '%', ')', 'to', 'take', 'medication', 'on', 'at', 'least', 'one', 'occasion', 'and', 'lead', 'to', '20/151', '(', '13', '%', ')', 'who', 'stopped', 'taking', 'medication', 'because', 'of', 'concern', 'over', 'efficacy', 'or', 'side-effects', ',', 'resuming', 'treatment', '.']","(26, 29)","(119, 144)",-1,ss_o,25479285,Abstract,9,test,gold,5062.0
5989,"CONCLUSIONS In patients taking blood pressure or lipid-lowering treatment for the prevention of cardiovascular disease ,",text messaging,improved medication adherence compared with no text messaging .,"['CONCLUSIONS', 'In', 'patients', 'taking', 'blood', 'pressure', 'or', 'lipid-lowering', 'treatment', 'for', 'the', 'prevention', 'of', 'cardiovascular', 'disease', ',', 'text', 'messaging', 'improved', 'medication', 'adherence', 'compared', 'with', 'no', 'text', 'messaging', '.']","(16, 18)","(120, 134)",-1,ss_i,25479285,Abstract,10,test,gold,2983.0
5990,"CONCLUSIONS In patients taking blood pressure or lipid-lowering treatment for the prevention of cardiovascular disease , text messaging improved medication adherence compared with",no text messaging .,,"['CONCLUSIONS', 'In', 'patients', 'taking', 'blood', 'pressure', 'or', 'lipid-lowering', 'treatment', 'for', 'the', 'prevention', 'of', 'cardiovascular', 'disease', ',', 'text', 'messaging', 'improved', 'medication', 'adherence', 'compared', 'with', 'no', 'text', 'messaging', '.']","(23, 27)","(179, 198)",-1,ss_i,25479285,Abstract,10,test,gold,2987.0
5991,"CONCLUSIONS In patients taking blood pressure or lipid-lowering treatment for the prevention of cardiovascular disease , text messaging improved",medication adherence,compared with no text messaging .,"['CONCLUSIONS', 'In', 'patients', 'taking', 'blood', 'pressure', 'or', 'lipid-lowering', 'treatment', 'for', 'the', 'prevention', 'of', 'cardiovascular', 'disease', ',', 'text', 'messaging', 'improved', 'medication', 'adherence', 'compared', 'with', 'no', 'text', 'messaging', '.']","(19, 21)","(144, 164)",-1,ss_o,25479285,Abstract,10,test,gold,412.0
5992,CONCLUSIONS In patients,taking blood pressure or lipid-lowering treatment for the prevention of cardiovascular disease,", text messaging improved medication adherence compared with no text messaging .","['CONCLUSIONS', 'In', 'patients', 'taking', 'blood', 'pressure', 'or', 'lipid-lowering', 'treatment', 'for', 'the', 'prevention', 'of', 'cardiovascular', 'disease', ',', 'text', 'messaging', 'improved', 'medication', 'adherence', 'compared', 'with', 'no', 'text', 'messaging', '.']","(3, 15)","(23, 117)",-1,hl_p,25479285,Abstract,10,test,gold,5939.0
5993,"CONCLUSIONS In patients taking blood pressure or lipid-lowering treatment for the prevention of cardiovascular disease ,",text messaging,improved medication adherence compared with no text messaging .,"['CONCLUSIONS', 'In', 'patients', 'taking', 'blood', 'pressure', 'or', 'lipid-lowering', 'treatment', 'for', 'the', 'prevention', 'of', 'cardiovascular', 'disease', ',', 'text', 'messaging', 'improved', 'medication', 'adherence', 'compared', 'with', 'no', 'text', 'messaging', '.']","(16, 18)","(120, 134)",-1,hl_i,25479285,Abstract,10,test,gold,2982.0
5994,"CONCLUSIONS In patients taking blood pressure or lipid-lowering treatment for the prevention of cardiovascular disease , text messaging improved medication adherence compared with",no text messaging .,,"['CONCLUSIONS', 'In', 'patients', 'taking', 'blood', 'pressure', 'or', 'lipid-lowering', 'treatment', 'for', 'the', 'prevention', 'of', 'cardiovascular', 'disease', ',', 'text', 'messaging', 'improved', 'medication', 'adherence', 'compared', 'with', 'no', 'text', 'messaging', '.']","(23, 27)","(179, 198)",-1,hl_i,25479285,Abstract,10,test,gold,2988.0
5995,"CONCLUSIONS In patients taking blood pressure or lipid-lowering treatment for the prevention of cardiovascular disease , text messaging improved",medication adherence,compared with no text messaging .,"['CONCLUSIONS', 'In', 'patients', 'taking', 'blood', 'pressure', 'or', 'lipid-lowering', 'treatment', 'for', 'the', 'prevention', 'of', 'cardiovascular', 'disease', ',', 'text', 'messaging', 'improved', 'medication', 'adherence', 'compared', 'with', 'no', 'text', 'messaging', '.']","(19, 21)","(144, 164)",-1,hl_o,25479285,Abstract,10,test,gold,413.0
5996,TRIAL REGISTRATION Controlled-Trials.com ISRCTN74757601 .,,,"['TRIAL', 'REGISTRATION', 'Controlled-Trials.com', 'ISRCTN74757601', '.']",,,,,25479285,Abstract,11,test,gold,
5997,Regional ventricular performance and exercise training in,children and young adults after repair of tetralogy of Fallot :,randomized controlled pilot study .,"['Regional', 'ventricular', 'performance', 'and', 'exercise', 'training', 'in', 'children', 'and', 'young', 'adults', 'after', 'repair', 'of', 'tetralogy', 'of', 'Fallot', ':', 'randomized', 'controlled', 'pilot', 'study', '.']","(7, 18)","(57, 120)",-1,ss_p,25784723,Title,0,test,gold,7054.0
5998,Regional ventricular performance and,exercise training,in children and young adults after repair of tetralogy of Fallot : randomized controlled pilot study .,"['Regional', 'ventricular', 'performance', 'and', 'exercise', 'training', 'in', 'children', 'and', 'young', 'adults', 'after', 'repair', 'of', 'tetralogy', 'of', 'Fallot', ':', 'randomized', 'controlled', 'pilot', 'study', '.']","(4, 6)","(36, 53)",-1,ss_i,25784723,Title,0,test,gold,2745.0
5999,Regional ventricular performance and exercise training in,children and young adults after repair of tetralogy of Fallot,: randomized controlled pilot study .,"['Regional', 'ventricular', 'performance', 'and', 'exercise', 'training', 'in', 'children', 'and', 'young', 'adults', 'after', 'repair', 'of', 'tetralogy', 'of', 'Fallot', ':', 'randomized', 'controlled', 'pilot', 'study', '.']","(7, 17)","(57, 118)",-1,hl_p,25784723,Title,0,test,gold,7055.0
6000,Regional ventricular performance and,exercise training,in children and young adults after repair of tetralogy of Fallot : randomized controlled pilot study .,"['Regional', 'ventricular', 'performance', 'and', 'exercise', 'training', 'in', 'children', 'and', 'young', 'adults', 'after', 'repair', 'of', 'tetralogy', 'of', 'Fallot', ':', 'randomized', 'controlled', 'pilot', 'study', '.']","(4, 6)","(36, 53)",-1,hl_i,25784723,Title,0,test,gold,2746.0
6001,BACKGROUND Public-health guidelines recommend patients with congenital heart disease to exercise .,,,"['BACKGROUND', 'Public-health', 'guidelines', 'recommend', 'patients', 'with', 'congenital', 'heart', 'disease', 'to', 'exercise', '.']",,,,,25784723,Abstract,0,test,gold,
6002,Studies have shown that patients with congenital heart disease can improve physical exercise capacity .,,,"['Studies', 'have', 'shown', 'that', 'patients', 'with', 'congenital', 'heart', 'disease', 'can', 'improve', 'physical', 'exercise', 'capacity', '.']",,,,,25784723,Abstract,1,test,gold,
6003,The effect of,training,on regional ventricular performance has hardly been studied .,"['The', 'effect', 'of', 'training', 'on', 'regional', 'ventricular', 'performance', 'has', 'hardly', 'been', 'studied', '.']","(3, 4)","(13, 21)",-1,ss_i,25784723,Abstract,2,test,gold,1291.0
6004,The effect of training on,regional ventricular performance,has hardly been studied .,"['The', 'effect', 'of', 'training', 'on', 'regional', 'ventricular', 'performance', 'has', 'hardly', 'been', 'studied', '.']","(5, 8)","(25, 57)",-1,ss_o,25784723,Abstract,2,test,gold,6782.0
6005,The effect of,training,on regional ventricular performance has hardly been studied .,"['The', 'effect', 'of', 'training', 'on', 'regional', 'ventricular', 'performance', 'has', 'hardly', 'been', 'studied', '.']","(3, 4)","(13, 21)",-1,hl_i,25784723,Abstract,2,test,gold,1292.0
6006,We performed a pilot study to assess whether an exercise training program would result in adverse changes of regional ventricular performance in,patients with corrected tetralogy of Fallot .,,"['We', 'performed', 'a', 'pilot', 'study', 'to', 'assess', 'whether', 'an', 'exercise', 'training', 'program', 'would', 'result', 'in', 'adverse', 'changes', 'of', 'regional', 'ventricular', 'performance', 'in', 'patients', 'with', 'corrected', 'tetralogy', 'of', 'Fallot', '.']","(22, 29)","(144, 189)",-1,ss_p,25784723,Abstract,3,test,gold,7056.0
6007,We performed a pilot study to assess whether an,exercise training program,would result in adverse changes of regional ventricular performance in patients with corrected tetralogy of Fallot .,"['We', 'performed', 'a', 'pilot', 'study', 'to', 'assess', 'whether', 'an', 'exercise', 'training', 'program', 'would', 'result', 'in', 'adverse', 'changes', 'of', 'regional', 'ventricular', 'performance', 'in', 'patients', 'with', 'corrected', 'tetralogy', 'of', 'Fallot', '.']","(9, 12)","(47, 72)",-1,ss_i,25784723,Abstract,3,test,gold,2739.0
6008,We performed a pilot study to assess whether an exercise training program would result in,adverse changes of regional ventricular performance,in patients with corrected tetralogy of Fallot .,"['We', 'performed', 'a', 'pilot', 'study', 'to', 'assess', 'whether', 'an', 'exercise', 'training', 'program', 'would', 'result', 'in', 'adverse', 'changes', 'of', 'regional', 'ventricular', 'performance', 'in', 'patients', 'with', 'corrected', 'tetralogy', 'of', 'Fallot', '.']","(15, 21)","(89, 140)",-1,ss_o,25784723,Abstract,3,test,gold,6781.0
6009,We performed a pilot study to assess whether an exercise training program would result in adverse changes of regional ventricular performance in,patients with corrected tetralogy of Fallot .,,"['We', 'performed', 'a', 'pilot', 'study', 'to', 'assess', 'whether', 'an', 'exercise', 'training', 'program', 'would', 'result', 'in', 'adverse', 'changes', 'of', 'regional', 'ventricular', 'performance', 'in', 'patients', 'with', 'corrected', 'tetralogy', 'of', 'Fallot', '.']","(22, 29)","(144, 189)",-1,hl_p,25784723,Abstract,3,test,gold,7057.0
6010,We performed a pilot study to assess whether an,exercise training program,would result in adverse changes of regional ventricular performance in patients with corrected tetralogy of Fallot .,"['We', 'performed', 'a', 'pilot', 'study', 'to', 'assess', 'whether', 'an', 'exercise', 'training', 'program', 'would', 'result', 'in', 'adverse', 'changes', 'of', 'regional', 'ventricular', 'performance', 'in', 'patients', 'with', 'corrected', 'tetralogy', 'of', 'Fallot', '.']","(9, 12)","(47, 72)",-1,hl_i,25784723,Abstract,3,test,gold,2740.0
6011,METHODS AND RESULTS Multicenter prospective randomized controlled pilot study in,patients with tetralogy of Fallot aged 10 to 25 years .,,"['METHODS', 'AND', 'RESULTS', 'Multicenter', 'prospective', 'randomized', 'controlled', 'pilot', 'study', 'in', 'patients', 'with', 'tetralogy', 'of', 'Fallot', 'aged', '10', 'to', '25', 'years', '.']","(10, 21)","(80, 135)",-1,ss_p,25784723,Abstract,4,test,gold,7058.0
6012,METHODS AND RESULTS Multicenter prospective randomized controlled pilot study in,patients with tetralogy of Fallot aged 10 to 25 years,.,"['METHODS', 'AND', 'RESULTS', 'Multicenter', 'prospective', 'randomized', 'controlled', 'pilot', 'study', 'in', 'patients', 'with', 'tetralogy', 'of', 'Fallot', 'aged', '10', 'to', '25', 'years', '.']","(10, 20)","(80, 133)",-1,hl_p,25784723,Abstract,4,test,gold,7059.0
6013,A 12-week standardized aerobic dynamic,exercise training program,( 3 one-hour sessions per week ) was used .,"['A', '12-week', 'standardized', 'aerobic', 'dynamic', 'exercise', 'training', 'program', '(', '3', 'one-hour', 'sessions', 'per', 'week', ')', 'was', 'used', '.']","(5, 8)","(38, 63)",-1,ss_i,25784723,Abstract,5,test,gold,2738.0
6014,A 12-week standardized aerobic dynamic,exercise training program,( 3 one-hour sessions per week ) was used .,"['A', '12-week', 'standardized', 'aerobic', 'dynamic', 'exercise', 'training', 'program', '(', '3', 'one-hour', 'sessions', 'per', 'week', ')', 'was', 'used', '.']","(5, 8)","(38, 63)",-1,hl_i,25784723,Abstract,5,test,gold,2737.0
6015,Pre- and post-training,"cardiopulmonary exercise tests , MRI , and echocardiography , including tissue-Doppler imaging",", were performed .","['Pre-', 'and', 'post-training', 'cardiopulmonary', 'exercise', 'tests', ',', 'MRI', ',', 'and', 'echocardiography', ',', 'including', 'tissue-Doppler', 'imaging', ',', 'were', 'performed', '.']","(3, 15)","(22, 116)",-1,ss_o,25784723,Abstract,6,test,gold,5968.0
6016,Pre- and post-training,"cardiopulmonary exercise tests , MRI , and echocardiography , including tissue-Doppler imaging",", were performed .","['Pre-', 'and', 'post-training', 'cardiopulmonary', 'exercise', 'tests', ',', 'MRI', ',', 'and', 'echocardiography', ',', 'including', 'tissue-Doppler', 'imaging', ',', 'were', 'performed', '.']","(3, 15)","(22, 116)",-1,hl_o,25784723,Abstract,6,test,gold,5969.0
6017,Patients were randomized to the,exercise,group ( n=28 ) or control group ( n=20 ) .,"['Patients', 'were', 'randomized', 'to', 'the', 'exercise', 'group', '(', 'n=28', ')', 'or', 'control', 'group', '(', 'n=20', ')', '.']","(5, 6)","(31, 39)",-1,ss_i,25784723,Abstract,7,test,gold,2771.0
6018,Patients were randomized to the exercise group ( n=28 ) or,control,group ( n=20 ) .,"['Patients', 'were', 'randomized', 'to', 'the', 'exercise', 'group', '(', 'n=28', ')', 'or', 'control', 'group', '(', 'n=20', ')', '.']","(11, 12)","(58, 65)",-1,ss_i,25784723,Abstract,7,test,gold,897.0
6019,Patients were randomized to the,exercise,group ( n=28 ) or control group ( n=20 ) .,"['Patients', 'were', 'randomized', 'to', 'the', 'exercise', 'group', '(', 'n=28', ')', 'or', 'control', 'group', '(', 'n=20', ')', '.']","(5, 6)","(31, 39)",-1,hl_i,25784723,Abstract,7,test,gold,2770.0
6020,Patients were randomized to the exercise group ( n=28 ) or,control,group ( n=20 ) .,"['Patients', 'were', 'randomized', 'to', 'the', 'exercise', 'group', '(', 'n=28', ')', 'or', 'control', 'group', '(', 'n=20', ')', '.']","(11, 12)","(58, 65)",-1,hl_i,25784723,Abstract,7,test,gold,896.0
6021,One patient in the,exercise,group dropped out .,"['One', 'patient', 'in', 'the', 'exercise', 'group', 'dropped', 'out', '.']","(4, 5)","(18, 26)",-1,ss_i,25784723,Abstract,8,test,gold,2769.0
6022,One patient in the,exercise,group dropped out .,"['One', 'patient', 'in', 'the', 'exercise', 'group', 'dropped', 'out', '.']","(4, 5)","(18, 26)",-1,hl_i,25784723,Abstract,8,test,gold,2768.0
6023,Change in tissue-Doppler imaging parameters was similar in the,exercise,"group and control group ( change in right ventricle free wall peak velocity E ' exercise group , 0.8±2.6 cm/s ; control group , 0.9±4.1 ; peak velocity A ' exercise group , 0.4±2.4 m/s ; control group 4.6±18.1 cm/s ) .","['Change', 'in', 'tissue-Doppler', 'imaging', 'parameters', 'was', 'similar', 'in', 'the', 'exercise', 'group', 'and', 'control', 'group', '(', 'change', 'in', 'right', 'ventricle', 'free', 'wall', 'peak', 'velocity', 'E', ""'"", 'exercise', 'group', ',', '0.8±2.6', 'cm/s', ';', 'control', 'group', ',', '0.9±4.1', ';', 'peak', 'velocity', 'A', ""'"", 'exercise', 'group', ',', '0.4±2.4', 'm/s', ';', 'control', 'group', '4.6±18.1', 'cm/s', ')', '.']","(9, 10)","(62, 70)",-1,ss_i,25784723,Abstract,9,test,gold,2767.0
6024,Change in tissue-Doppler imaging parameters was similar in the exercise group and,control,"group ( change in right ventricle free wall peak velocity E ' exercise group , 0.8±2.6 cm/s ; control group , 0.9±4.1 ; peak velocity A ' exercise group , 0.4±2.4 m/s ; control group 4.6±18.1 cm/s ) .","['Change', 'in', 'tissue-Doppler', 'imaging', 'parameters', 'was', 'similar', 'in', 'the', 'exercise', 'group', 'and', 'control', 'group', '(', 'change', 'in', 'right', 'ventricle', 'free', 'wall', 'peak', 'velocity', 'E', ""'"", 'exercise', 'group', ',', '0.8±2.6', 'cm/s', ';', 'control', 'group', ',', '0.9±4.1', ';', 'peak', 'velocity', 'A', ""'"", 'exercise', 'group', ',', '0.4±2.4', 'm/s', ';', 'control', 'group', '4.6±18.1', 'cm/s', ')', '.']","(12, 13)","(81, 88)",-1,ss_i,25784723,Abstract,9,test,gold,895.0
6025,Change in tissue-Doppler imaging parameters was similar in the exercise group and control group ( change in right ventricle free wall peak velocity E ',exercise,"group , 0.8±2.6 cm/s ; control group , 0.9±4.1 ; peak velocity A ' exercise group , 0.4±2.4 m/s ; control group 4.6±18.1 cm/s ) .","['Change', 'in', 'tissue-Doppler', 'imaging', 'parameters', 'was', 'similar', 'in', 'the', 'exercise', 'group', 'and', 'control', 'group', '(', 'change', 'in', 'right', 'ventricle', 'free', 'wall', 'peak', 'velocity', 'E', ""'"", 'exercise', 'group', ',', '0.8±2.6', 'cm/s', ';', 'control', 'group', ',', '0.9±4.1', ';', 'peak', 'velocity', 'A', ""'"", 'exercise', 'group', ',', '0.4±2.4', 'm/s', ';', 'control', 'group', '4.6±18.1', 'cm/s', ')', '.']","(25, 26)","(151, 159)",-1,ss_i,25784723,Abstract,9,test,gold,2766.0
6026,"Change in tissue-Doppler imaging parameters was similar in the exercise group and control group ( change in right ventricle free wall peak velocity E ' exercise group , 0.8±2.6",cm/s ; control,"group , 0.9±4.1 ; peak velocity A ' exercise group , 0.4±2.4 m/s ; control group 4.6±18.1 cm/s ) .","['Change', 'in', 'tissue-Doppler', 'imaging', 'parameters', 'was', 'similar', 'in', 'the', 'exercise', 'group', 'and', 'control', 'group', '(', 'change', 'in', 'right', 'ventricle', 'free', 'wall', 'peak', 'velocity', 'E', ""'"", 'exercise', 'group', ',', '0.8±2.6', 'cm/s', ';', 'control', 'group', ',', '0.9±4.1', ';', 'peak', 'velocity', 'A', ""'"", 'exercise', 'group', ',', '0.4±2.4', 'm/s', ';', 'control', 'group', '4.6±18.1', 'cm/s', ')', '.']","(29, 32)","(176, 190)",-1,ss_i,25784723,Abstract,9,test,gold,894.0
6027,"Change in tissue-Doppler imaging parameters was similar in the exercise group and control group ( change in right ventricle free wall peak velocity E ' exercise group , 0.8±2.6 cm/s ; control group , 0.9±4.1 ; peak velocity",A ' exercise,"group , 0.4±2.4 m/s ; control group 4.6±18.1 cm/s ) .","['Change', 'in', 'tissue-Doppler', 'imaging', 'parameters', 'was', 'similar', 'in', 'the', 'exercise', 'group', 'and', 'control', 'group', '(', 'change', 'in', 'right', 'ventricle', 'free', 'wall', 'peak', 'velocity', 'E', ""'"", 'exercise', 'group', ',', '0.8±2.6', 'cm/s', ';', 'control', 'group', ',', '0.9±4.1', ';', 'peak', 'velocity', 'A', ""'"", 'exercise', 'group', ',', '0.4±2.4', 'm/s', ';', 'control', 'group', '4.6±18.1', 'cm/s', ')', '.']","(38, 41)","(223, 235)",-1,ss_i,25784723,Abstract,9,test,gold,2762.0
6028,"Change in tissue-Doppler imaging parameters was similar in the exercise group and control group ( change in right ventricle free wall peak velocity E ' exercise group , 0.8±2.6 cm/s ; control group , 0.9±4.1 ; peak velocity A ' exercise group , 0.4±2.4",m/s ; control,group 4.6±18.1 cm/s ) .,"['Change', 'in', 'tissue-Doppler', 'imaging', 'parameters', 'was', 'similar', 'in', 'the', 'exercise', 'group', 'and', 'control', 'group', '(', 'change', 'in', 'right', 'ventricle', 'free', 'wall', 'peak', 'velocity', 'E', ""'"", 'exercise', 'group', ',', '0.8±2.6', 'cm/s', ';', 'control', 'group', ',', '0.9±4.1', ';', 'peak', 'velocity', 'A', ""'"", 'exercise', 'group', ',', '0.4±2.4', 'm/s', ';', 'control', 'group', '4.6±18.1', 'cm/s', ')', '.']","(44, 47)","(252, 265)",-1,ss_i,25784723,Abstract,9,test,gold,893.0
6029,,Change in tissue-Doppler imaging parameters,"was similar in the exercise group and control group ( change in right ventricle free wall peak velocity E ' exercise group , 0.8±2.6 cm/s ; control group , 0.9±4.1 ; peak velocity A ' exercise group , 0.4±2.4 m/s ; control group 4.6±18.1 cm/s ) .","['Change', 'in', 'tissue-Doppler', 'imaging', 'parameters', 'was', 'similar', 'in', 'the', 'exercise', 'group', 'and', 'control', 'group', '(', 'change', 'in', 'right', 'ventricle', 'free', 'wall', 'peak', 'velocity', 'E', ""'"", 'exercise', 'group', ',', '0.8±2.6', 'cm/s', ';', 'control', 'group', ',', '0.9±4.1', ';', 'peak', 'velocity', 'A', ""'"", 'exercise', 'group', ',', '0.4±2.4', 'm/s', ';', 'control', 'group', '4.6±18.1', 'cm/s', ')', '.']","(0, 5)","(0, 43)",-1,ss_o,25784723,Abstract,9,test,gold,1822.0
6030,Change in tissue-Doppler imaging parameters was similar in the,exercise,"group and control group ( change in right ventricle free wall peak velocity E ' exercise group , 0.8±2.6 cm/s ; control group , 0.9±4.1 ; peak velocity A ' exercise group , 0.4±2.4 m/s ; control group 4.6±18.1 cm/s ) .","['Change', 'in', 'tissue-Doppler', 'imaging', 'parameters', 'was', 'similar', 'in', 'the', 'exercise', 'group', 'and', 'control', 'group', '(', 'change', 'in', 'right', 'ventricle', 'free', 'wall', 'peak', 'velocity', 'E', ""'"", 'exercise', 'group', ',', '0.8±2.6', 'cm/s', ';', 'control', 'group', ',', '0.9±4.1', ';', 'peak', 'velocity', 'A', ""'"", 'exercise', 'group', ',', '0.4±2.4', 'm/s', ';', 'control', 'group', '4.6±18.1', 'cm/s', ')', '.']","(9, 10)","(62, 70)",-1,hl_i,25784723,Abstract,9,test,gold,2765.0
6031,Change in tissue-Doppler imaging parameters was similar in the exercise group and,control,"group ( change in right ventricle free wall peak velocity E ' exercise group , 0.8±2.6 cm/s ; control group , 0.9±4.1 ; peak velocity A ' exercise group , 0.4±2.4 m/s ; control group 4.6±18.1 cm/s ) .","['Change', 'in', 'tissue-Doppler', 'imaging', 'parameters', 'was', 'similar', 'in', 'the', 'exercise', 'group', 'and', 'control', 'group', '(', 'change', 'in', 'right', 'ventricle', 'free', 'wall', 'peak', 'velocity', 'E', ""'"", 'exercise', 'group', ',', '0.8±2.6', 'cm/s', ';', 'control', 'group', ',', '0.9±4.1', ';', 'peak', 'velocity', 'A', ""'"", 'exercise', 'group', ',', '0.4±2.4', 'm/s', ';', 'control', 'group', '4.6±18.1', 'cm/s', ')', '.']","(12, 13)","(81, 88)",-1,hl_i,25784723,Abstract,9,test,gold,892.0
6032,,Change in tissue-Doppler imaging parameters,"was similar in the exercise group and control group ( change in right ventricle free wall peak velocity E ' exercise group , 0.8±2.6 cm/s ; control group , 0.9±4.1 ; peak velocity A ' exercise group , 0.4±2.4 m/s ; control group 4.6±18.1 cm/s ) .","['Change', 'in', 'tissue-Doppler', 'imaging', 'parameters', 'was', 'similar', 'in', 'the', 'exercise', 'group', 'and', 'control', 'group', '(', 'change', 'in', 'right', 'ventricle', 'free', 'wall', 'peak', 'velocity', 'E', ""'"", 'exercise', 'group', ',', '0.8±2.6', 'cm/s', ';', 'control', 'group', ',', '0.9±4.1', ';', 'peak', 'velocity', 'A', ""'"", 'exercise', 'group', ',', '0.4±2.4', 'm/s', ';', 'control', 'group', '4.6±18.1', 'cm/s', ')', '.']","(0, 5)","(0, 43)",-1,hl_o,25784723,Abstract,9,test,gold,1823.0
6033,CONCLUSIONS This randomized controlled pilot study provides preliminary data suggesting that regional ventricular performance is well maintained during 3-month aerobic dynamic exercise,training in children and young adults with repaired tetralogy of Fallot,.,"['CONCLUSIONS', 'This', 'randomized', 'controlled', 'pilot', 'study', 'provides', 'preliminary', 'data', 'suggesting', 'that', 'regional', 'ventricular', 'performance', 'is', 'well', 'maintained', 'during', '3-month', 'aerobic', 'dynamic', 'exercise', 'training', 'in', 'children', 'and', 'young', 'adults', 'with', 'repaired', 'tetralogy', 'of', 'Fallot', '.']","(22, 33)","(184, 255)",-1,ss_p,25784723,Abstract,10,test,gold,7053.0
6034,CONCLUSIONS This randomized controlled pilot study provides preliminary data suggesting that regional ventricular performance is well maintained during 3-month aerobic,dynamic exercise training,in children and young adults with repaired tetralogy of Fallot .,"['CONCLUSIONS', 'This', 'randomized', 'controlled', 'pilot', 'study', 'provides', 'preliminary', 'data', 'suggesting', 'that', 'regional', 'ventricular', 'performance', 'is', 'well', 'maintained', 'during', '3-month', 'aerobic', 'dynamic', 'exercise', 'training', 'in', 'children', 'and', 'young', 'adults', 'with', 'repaired', 'tetralogy', 'of', 'Fallot', '.']","(20, 23)","(167, 192)",-1,ss_i,25784723,Abstract,10,test,gold,2743.0
6035,CONCLUSIONS This randomized controlled pilot study provides preliminary data suggesting,that regional ventricular performance,is well maintained during 3-month aerobic dynamic exercise training in children and young adults with repaired tetralogy of Fallot .,"['CONCLUSIONS', 'This', 'randomized', 'controlled', 'pilot', 'study', 'provides', 'preliminary', 'data', 'suggesting', 'that', 'regional', 'ventricular', 'performance', 'is', 'well', 'maintained', 'during', '3-month', 'aerobic', 'dynamic', 'exercise', 'training', 'in', 'children', 'and', 'young', 'adults', 'with', 'repaired', 'tetralogy', 'of', 'Fallot', '.']","(10, 14)","(87, 124)",-1,ss_o,25784723,Abstract,10,test,gold,6783.0
6036,CONCLUSIONS This randomized controlled pilot study provides preliminary data suggesting that regional ventricular performance is well maintained during 3-month aerobic dynamic,exercise training,in children and young adults with repaired tetralogy of Fallot .,"['CONCLUSIONS', 'This', 'randomized', 'controlled', 'pilot', 'study', 'provides', 'preliminary', 'data', 'suggesting', 'that', 'regional', 'ventricular', 'performance', 'is', 'well', 'maintained', 'during', '3-month', 'aerobic', 'dynamic', 'exercise', 'training', 'in', 'children', 'and', 'young', 'adults', 'with', 'repaired', 'tetralogy', 'of', 'Fallot', '.']","(21, 23)","(175, 192)",-1,hl_i,25784723,Abstract,10,test,gold,2744.0
6037,This information might help patients adhere to current public-health guidelines .,,,"['This', 'information', 'might', 'help', 'patients', 'adhere', 'to', 'current', 'public-health', 'guidelines', '.']",,,,,25784723,Abstract,11,test,gold,
6038,CLINICAL TRIAL REGISTRATION URL : http// : www.trialregister.nl .,,,"['CLINICAL', 'TRIAL', 'REGISTRATION', 'URL', ':', 'http//', ':', 'www.trialregister.nl', '.']",,,,,25784723,Abstract,12,test,gold,
6039,Unique identifier : NTR2731 .,,,"['Unique', 'identifier', ':', 'NTR2731', '.']",,,,,25784723,Abstract,13,test,gold,
6040,Subjective and objective levels of physical activity and their association with cardiorespiratory fitness in,rheumatoid arthritis patients .,,"['Subjective', 'and', 'objective', 'levels', 'of', 'physical', 'activity', 'and', 'their', 'association', 'with', 'cardiorespiratory', 'fitness', 'in', 'rheumatoid', 'arthritis', 'patients', '.']","(14, 18)","(108, 139)",-1,ss_p,25885649,Title,0,test,gold,7028.0
6041,Subjective and objective levels of,physical activity,and their association with cardiorespiratory fitness in rheumatoid arthritis patients .,"['Subjective', 'and', 'objective', 'levels', 'of', 'physical', 'activity', 'and', 'their', 'association', 'with', 'cardiorespiratory', 'fitness', 'in', 'rheumatoid', 'arthritis', 'patients', '.']","(5, 7)","(34, 51)",-1,ss_i,25885649,Title,0,test,gold,2881.0
6042,Subjective and objective levels of,physical activity,and their association with cardiorespiratory fitness in rheumatoid arthritis patients .,"['Subjective', 'and', 'objective', 'levels', 'of', 'physical', 'activity', 'and', 'their', 'association', 'with', 'cardiorespiratory', 'fitness', 'in', 'rheumatoid', 'arthritis', 'patients', '.']","(5, 7)","(34, 51)",-1,ss_o,25885649,Title,0,test,gold,2880.0
6043,Subjective and objective levels of physical activity and their association with cardiorespiratory fitness in,rheumatoid arthritis patients .,,"['Subjective', 'and', 'objective', 'levels', 'of', 'physical', 'activity', 'and', 'their', 'association', 'with', 'cardiorespiratory', 'fitness', 'in', 'rheumatoid', 'arthritis', 'patients', '.']","(14, 18)","(108, 139)",-1,hl_p,25885649,Title,0,test,gold,7029.0
6044,INTRODUCTION The aims of the present study were : ( a ) to examine the agreement between subjective ( assessed via the International Physical Activity Questionnaire ; IPAQ ) and objective ( accelerometry ; GT3X ) physical activity ( PA ) levels in,patients with rheumatoid arthritis ( RA ),", and ( b ) to evaluate the associations of RA patients ' subjective and objective PA to their scores on the maximal oxygen uptake test ( VO2max ) .","['INTRODUCTION', 'The', 'aims', 'of', 'the', 'present', 'study', 'were', ':', '(', 'a', ')', 'to', 'examine', 'the', 'agreement', 'between', 'subjective', '(', 'assessed', 'via', 'the', 'International', 'Physical', 'Activity', 'Questionnaire', ';', 'IPAQ', ')', 'and', 'objective', '(', 'accelerometry', ';', 'GT3X', ')', 'physical', 'activity', '(', 'PA', ')', 'levels', 'in', 'patients', 'with', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'and', '(', 'b', ')', 'to', 'evaluate', 'the', 'associations', 'of', 'RA', 'patients', ""'"", 'subjective', 'and', 'objective', 'PA', 'to', 'their', 'scores', 'on', 'the', 'maximal', 'oxygen', 'uptake', 'test', '(', 'VO2max', ')', '.']","(43, 50)","(247, 288)",-1,ss_p,25885649,Abstract,0,test,gold,7030.0
6045,"INTRODUCTION The aims of the present study were : ( a ) to examine the agreement between subjective ( assessed via the International Physical Activity Questionnaire ; IPAQ ) and objective ( accelerometry ; GT3X ) physical activity ( PA ) levels in patients with rheumatoid arthritis ( RA ) , and ( b ) to evaluate the associations of",RA patients ',subjective and objective PA to their scores on the maximal oxygen uptake test ( VO2max ) .,"['INTRODUCTION', 'The', 'aims', 'of', 'the', 'present', 'study', 'were', ':', '(', 'a', ')', 'to', 'examine', 'the', 'agreement', 'between', 'subjective', '(', 'assessed', 'via', 'the', 'International', 'Physical', 'Activity', 'Questionnaire', ';', 'IPAQ', ')', 'and', 'objective', '(', 'accelerometry', ';', 'GT3X', ')', 'physical', 'activity', '(', 'PA', ')', 'levels', 'in', 'patients', 'with', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'and', '(', 'b', ')', 'to', 'evaluate', 'the', 'associations', 'of', 'RA', 'patients', ""'"", 'subjective', 'and', 'objective', 'PA', 'to', 'their', 'scores', 'on', 'the', 'maximal', 'oxygen', 'uptake', 'test', '(', 'VO2max', ')', '.']","(60, 63)","(333, 346)",-1,ss_p,25885649,Abstract,0,test,gold,2207.0
6046,INTRODUCTION The aims of the present study were : ( a ) to examine the agreement between subjective ( assessed via the International Physical Activity Questionnaire ; IPAQ ) and objective ( accelerometry ; GT3X ),physical activity ( PA ),"levels in patients with rheumatoid arthritis ( RA ) , and ( b ) to evaluate the associations of RA patients ' subjective and objective PA to their scores on the maximal oxygen uptake test ( VO2max ) .","['INTRODUCTION', 'The', 'aims', 'of', 'the', 'present', 'study', 'were', ':', '(', 'a', ')', 'to', 'examine', 'the', 'agreement', 'between', 'subjective', '(', 'assessed', 'via', 'the', 'International', 'Physical', 'Activity', 'Questionnaire', ';', 'IPAQ', ')', 'and', 'objective', '(', 'accelerometry', ';', 'GT3X', ')', 'physical', 'activity', '(', 'PA', ')', 'levels', 'in', 'patients', 'with', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'and', '(', 'b', ')', 'to', 'evaluate', 'the', 'associations', 'of', 'RA', 'patients', ""'"", 'subjective', 'and', 'objective', 'PA', 'to', 'their', 'scores', 'on', 'the', 'maximal', 'oxygen', 'uptake', 'test', '(', 'VO2max', ')', '.']","(36, 41)","(212, 236)",-1,ss_i,25885649,Abstract,0,test,gold,2878.0
6047,"INTRODUCTION The aims of the present study were : ( a ) to examine the agreement between subjective ( assessed via the International Physical Activity Questionnaire ; IPAQ ) and objective ( accelerometry ; GT3X ) physical activity ( PA ) levels in patients with rheumatoid arthritis ( RA ) , and ( b ) to evaluate the associations of RA patients ' subjective and objective",PA,to their scores on the maximal oxygen uptake test ( VO2max ) .,"['INTRODUCTION', 'The', 'aims', 'of', 'the', 'present', 'study', 'were', ':', '(', 'a', ')', 'to', 'examine', 'the', 'agreement', 'between', 'subjective', '(', 'assessed', 'via', 'the', 'International', 'Physical', 'Activity', 'Questionnaire', ';', 'IPAQ', ')', 'and', 'objective', '(', 'accelerometry', ';', 'GT3X', ')', 'physical', 'activity', '(', 'PA', ')', 'levels', 'in', 'patients', 'with', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'and', '(', 'b', ')', 'to', 'evaluate', 'the', 'associations', 'of', 'RA', 'patients', ""'"", 'subjective', 'and', 'objective', 'PA', 'to', 'their', 'scores', 'on', 'the', 'maximal', 'oxygen', 'uptake', 'test', '(', 'VO2max', ')', '.']","(66, 67)","(372, 374)",-1,ss_i,25885649,Abstract,0,test,gold,759.0
6048,INTRODUCTION The aims of the present study were : ( a ) to examine the,agreement,"between subjective ( assessed via the International Physical Activity Questionnaire ; IPAQ ) and objective ( accelerometry ; GT3X ) physical activity ( PA ) levels in patients with rheumatoid arthritis ( RA ) , and ( b ) to evaluate the associations of RA patients ' subjective and objective PA to their scores on the maximal oxygen uptake test ( VO2max ) .","['INTRODUCTION', 'The', 'aims', 'of', 'the', 'present', 'study', 'were', ':', '(', 'a', ')', 'to', 'examine', 'the', 'agreement', 'between', 'subjective', '(', 'assessed', 'via', 'the', 'International', 'Physical', 'Activity', 'Questionnaire', ';', 'IPAQ', ')', 'and', 'objective', '(', 'accelerometry', ';', 'GT3X', ')', 'physical', 'activity', '(', 'PA', ')', 'levels', 'in', 'patients', 'with', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'and', '(', 'b', ')', 'to', 'evaluate', 'the', 'associations', 'of', 'RA', 'patients', ""'"", 'subjective', 'and', 'objective', 'PA', 'to', 'their', 'scores', 'on', 'the', 'maximal', 'oxygen', 'uptake', 'test', '(', 'VO2max', ')', '.']","(15, 16)","(70, 79)",-1,ss_o,25885649,Abstract,0,test,gold,1230.0
6049,INTRODUCTION The aims of the present study were : ( a ) to examine the agreement between,subjective ( assessed via the International Physical Activity Questionnaire ; IPAQ ) and objective ( accelerometry ; GT3X ) physical activity ( PA ) levels,"in patients with rheumatoid arthritis ( RA ) , and ( b ) to evaluate the associations of RA patients ' subjective and objective PA to their scores on the maximal oxygen uptake test ( VO2max ) .","['INTRODUCTION', 'The', 'aims', 'of', 'the', 'present', 'study', 'were', ':', '(', 'a', ')', 'to', 'examine', 'the', 'agreement', 'between', 'subjective', '(', 'assessed', 'via', 'the', 'International', 'Physical', 'Activity', 'Questionnaire', ';', 'IPAQ', ')', 'and', 'objective', '(', 'accelerometry', ';', 'GT3X', ')', 'physical', 'activity', '(', 'PA', ')', 'levels', 'in', 'patients', 'with', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'and', '(', 'b', ')', 'to', 'evaluate', 'the', 'associations', 'of', 'RA', 'patients', ""'"", 'subjective', 'and', 'objective', 'PA', 'to', 'their', 'scores', 'on', 'the', 'maximal', 'oxygen', 'uptake', 'test', '(', 'VO2max', ')', '.']","(17, 42)","(88, 243)",-1,ss_o,25885649,Abstract,0,test,gold,5898.0
6050,"INTRODUCTION The aims of the present study were : ( a ) to examine the agreement between subjective ( assessed via the International Physical Activity Questionnaire ; IPAQ ) and objective ( accelerometry ; GT3X ) physical activity ( PA ) levels in patients with rheumatoid arthritis ( RA ) , and ( b ) to evaluate the",associations,of RA patients ' subjective and objective PA to their scores on the maximal oxygen uptake test ( VO2max ) .,"['INTRODUCTION', 'The', 'aims', 'of', 'the', 'present', 'study', 'were', ':', '(', 'a', ')', 'to', 'examine', 'the', 'agreement', 'between', 'subjective', '(', 'assessed', 'via', 'the', 'International', 'Physical', 'Activity', 'Questionnaire', ';', 'IPAQ', ')', 'and', 'objective', '(', 'accelerometry', ';', 'GT3X', ')', 'physical', 'activity', '(', 'PA', ')', 'levels', 'in', 'patients', 'with', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'and', '(', 'b', ')', 'to', 'evaluate', 'the', 'associations', 'of', 'RA', 'patients', ""'"", 'subjective', 'and', 'objective', 'PA', 'to', 'their', 'scores', 'on', 'the', 'maximal', 'oxygen', 'uptake', 'test', '(', 'VO2max', ')', '.']","(58, 59)","(317, 329)",-1,ss_o,25885649,Abstract,0,test,gold,1080.0
6051,"INTRODUCTION The aims of the present study were : ( a ) to examine the agreement between subjective ( assessed via the International Physical Activity Questionnaire ; IPAQ ) and objective ( accelerometry ; GT3X ) physical activity ( PA ) levels in patients with rheumatoid arthritis ( RA ) , and ( b ) to evaluate the associations of RA patients '",subjective and objective PA,to their scores on the maximal oxygen uptake test ( VO2max ) .,"['INTRODUCTION', 'The', 'aims', 'of', 'the', 'present', 'study', 'were', ':', '(', 'a', ')', 'to', 'examine', 'the', 'agreement', 'between', 'subjective', '(', 'assessed', 'via', 'the', 'International', 'Physical', 'Activity', 'Questionnaire', ';', 'IPAQ', ')', 'and', 'objective', '(', 'accelerometry', ';', 'GT3X', ')', 'physical', 'activity', '(', 'PA', ')', 'levels', 'in', 'patients', 'with', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'and', '(', 'b', ')', 'to', 'evaluate', 'the', 'associations', 'of', 'RA', 'patients', ""'"", 'subjective', 'and', 'objective', 'PA', 'to', 'their', 'scores', 'on', 'the', 'maximal', 'oxygen', 'uptake', 'test', '(', 'VO2max', ')', '.']","(63, 67)","(347, 374)",-1,ss_o,25885649,Abstract,0,test,gold,6447.0
6052,"INTRODUCTION The aims of the present study were : ( a ) to examine the agreement between subjective ( assessed via the International Physical Activity Questionnaire ; IPAQ ) and objective ( accelerometry ; GT3X ) physical activity ( PA ) levels in patients with rheumatoid arthritis ( RA ) , and ( b ) to evaluate the associations of RA patients ' subjective and objective PA to their",scores on the maximal oxygen uptake test ( VO2max ) .,,"['INTRODUCTION', 'The', 'aims', 'of', 'the', 'present', 'study', 'were', ':', '(', 'a', ')', 'to', 'examine', 'the', 'agreement', 'between', 'subjective', '(', 'assessed', 'via', 'the', 'International', 'Physical', 'Activity', 'Questionnaire', ';', 'IPAQ', ')', 'and', 'objective', '(', 'accelerometry', ';', 'GT3X', ')', 'physical', 'activity', '(', 'PA', ')', 'levels', 'in', 'patients', 'with', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'and', '(', 'b', ')', 'to', 'evaluate', 'the', 'associations', 'of', 'RA', 'patients', ""'"", 'subjective', 'and', 'objective', 'PA', 'to', 'their', 'scores', 'on', 'the', 'maximal', 'oxygen', 'uptake', 'test', '(', 'VO2max', ')', '.']","(69, 80)","(384, 437)",-1,ss_o,25885649,Abstract,0,test,gold,6496.0
6053,INTRODUCTION The aims of the present study were : ( a ) to examine the agreement between subjective ( assessed via the International Physical Activity Questionnaire ; IPAQ ) and objective ( accelerometry ; GT3X ) physical activity ( PA ) levels in,patients with rheumatoid arthritis ( RA ),", and ( b ) to evaluate the associations of RA patients ' subjective and objective PA to their scores on the maximal oxygen uptake test ( VO2max ) .","['INTRODUCTION', 'The', 'aims', 'of', 'the', 'present', 'study', 'were', ':', '(', 'a', ')', 'to', 'examine', 'the', 'agreement', 'between', 'subjective', '(', 'assessed', 'via', 'the', 'International', 'Physical', 'Activity', 'Questionnaire', ';', 'IPAQ', ')', 'and', 'objective', '(', 'accelerometry', ';', 'GT3X', ')', 'physical', 'activity', '(', 'PA', ')', 'levels', 'in', 'patients', 'with', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'and', '(', 'b', ')', 'to', 'evaluate', 'the', 'associations', 'of', 'RA', 'patients', ""'"", 'subjective', 'and', 'objective', 'PA', 'to', 'their', 'scores', 'on', 'the', 'maximal', 'oxygen', 'uptake', 'test', '(', 'VO2max', ')', '.']","(43, 50)","(247, 288)",-1,hl_p,25885649,Abstract,0,test,gold,7031.0
6054,INTRODUCTION The aims of the present study were : ( a ) to examine the agreement between subjective ( assessed via the,International Physical Activity Questionnaire ; IPAQ ),"and objective ( accelerometry ; GT3X ) physical activity ( PA ) levels in patients with rheumatoid arthritis ( RA ) , and ( b ) to evaluate the associations of RA patients ' subjective and objective PA to their scores on the maximal oxygen uptake test ( VO2max ) .","['INTRODUCTION', 'The', 'aims', 'of', 'the', 'present', 'study', 'were', ':', '(', 'a', ')', 'to', 'examine', 'the', 'agreement', 'between', 'subjective', '(', 'assessed', 'via', 'the', 'International', 'Physical', 'Activity', 'Questionnaire', ';', 'IPAQ', ')', 'and', 'objective', '(', 'accelerometry', ';', 'GT3X', ')', 'physical', 'activity', '(', 'PA', ')', 'levels', 'in', 'patients', 'with', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'and', '(', 'b', ')', 'to', 'evaluate', 'the', 'associations', 'of', 'RA', 'patients', ""'"", 'subjective', 'and', 'objective', 'PA', 'to', 'their', 'scores', 'on', 'the', 'maximal', 'oxygen', 'uptake', 'test', '(', 'VO2max', ')', '.']","(22, 29)","(118, 172)",-1,hl_o,25885649,Abstract,0,test,gold,6251.0
6055,INTRODUCTION The aims of the present study were : ( a ) to examine the agreement between subjective ( assessed via the International Physical Activity Questionnaire ; IPAQ ) and objective ( accelerometry ;,GT3X ) physical activity ( PA ),"levels in patients with rheumatoid arthritis ( RA ) , and ( b ) to evaluate the associations of RA patients ' subjective and objective PA to their scores on the maximal oxygen uptake test ( VO2max ) .","['INTRODUCTION', 'The', 'aims', 'of', 'the', 'present', 'study', 'were', ':', '(', 'a', ')', 'to', 'examine', 'the', 'agreement', 'between', 'subjective', '(', 'assessed', 'via', 'the', 'International', 'Physical', 'Activity', 'Questionnaire', ';', 'IPAQ', ')', 'and', 'objective', '(', 'accelerometry', ';', 'GT3X', ')', 'physical', 'activity', '(', 'PA', ')', 'levels', 'in', 'patients', 'with', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'and', '(', 'b', ')', 'to', 'evaluate', 'the', 'associations', 'of', 'RA', 'patients', ""'"", 'subjective', 'and', 'objective', 'PA', 'to', 'their', 'scores', 'on', 'the', 'maximal', 'oxygen', 'uptake', 'test', '(', 'VO2max', ')', '.']","(34, 41)","(205, 236)",-1,hl_o,25885649,Abstract,0,test,gold,2879.0
6056,"INTRODUCTION The aims of the present study were : ( a ) to examine the agreement between subjective ( assessed via the International Physical Activity Questionnaire ; IPAQ ) and objective ( accelerometry ; GT3X ) physical activity ( PA ) levels in patients with rheumatoid arthritis ( RA ) , and ( b ) to evaluate the associations of RA patients ' subjective and objective PA to their scores on the",maximal oxygen uptake test ( VO2max ),.,"['INTRODUCTION', 'The', 'aims', 'of', 'the', 'present', 'study', 'were', ':', '(', 'a', ')', 'to', 'examine', 'the', 'agreement', 'between', 'subjective', '(', 'assessed', 'via', 'the', 'International', 'Physical', 'Activity', 'Questionnaire', ';', 'IPAQ', ')', 'and', 'objective', '(', 'accelerometry', ';', 'GT3X', ')', 'physical', 'activity', '(', 'PA', ')', 'levels', 'in', 'patients', 'with', 'rheumatoid', 'arthritis', '(', 'RA', ')', ',', 'and', '(', 'b', ')', 'to', 'evaluate', 'the', 'associations', 'of', 'RA', 'patients', ""'"", 'subjective', 'and', 'objective', 'PA', 'to', 'their', 'scores', 'on', 'the', 'maximal', 'oxygen', 'uptake', 'test', '(', 'VO2max', ')', '.']","(72, 79)","(398, 435)",-1,hl_o,25885649,Abstract,0,test,gold,6497.0
6057,METHODS The participants wore the GT3X for seven days before completing the,IPAQ and VO2max test .,,"['METHODS', 'The', 'participants', 'wore', 'the', 'GT3X', 'for', 'seven', 'days', 'before', 'completing', 'the', 'IPAQ', 'and', 'VO2max', 'test', '.']","(12, 17)","(75, 97)",-1,ss_o,25885649,Abstract,1,test,gold,1671.0
6058,METHODS The participants wore the GT3X for seven days before completing the,IPAQ,and VO2max test .,"['METHODS', 'The', 'participants', 'wore', 'the', 'GT3X', 'for', 'seven', 'days', 'before', 'completing', 'the', 'IPAQ', 'and', 'VO2max', 'test', '.']","(12, 13)","(75, 79)",-1,hl_o,25885649,Abstract,1,test,gold,1176.0
6059,METHODS The participants wore the GT3X for seven days before completing the IPAQ and,VO2max,test .,"['METHODS', 'The', 'participants', 'wore', 'the', 'GT3X', 'for', 'seven', 'days', 'before', 'completing', 'the', 'IPAQ', 'and', 'VO2max', 'test', '.']","(14, 15)","(84, 90)",-1,hl_o,25885649,Abstract,1,test,gold,1676.0
6060,The Bland-Altman plot was used to illustrate the agreement between the objective and subjective,PA,"data , and the Wilcoxon test was employed to examine the differences .","['The', 'Bland-Altman', 'plot', 'was', 'used', 'to', 'illustrate', 'the', 'agreement', 'between', 'the', 'objective', 'and', 'subjective', 'PA', 'data', ',', 'and', 'the', 'Wilcoxon', 'test', 'was', 'employed', 'to', 'examine', 'the', 'differences', '.']","(14, 15)","(95, 97)",-1,ss_i,25885649,Abstract,2,test,gold,760.0
6061,The,Bland-Altman plot,"was used to illustrate the agreement between the objective and subjective PA data , and the Wilcoxon test was employed to examine the differences .","['The', 'Bland-Altman', 'plot', 'was', 'used', 'to', 'illustrate', 'the', 'agreement', 'between', 'the', 'objective', 'and', 'subjective', 'PA', 'data', ',', 'and', 'the', 'Wilcoxon', 'test', 'was', 'employed', 'to', 'examine', 'the', 'differences', '.']","(1, 3)","(3, 20)",-1,ss_o,25885649,Abstract,2,test,gold,1195.0
6062,The Bland-Altman plot was used to illustrate the,agreement,"between the objective and subjective PA data , and the Wilcoxon test was employed to examine the differences .","['The', 'Bland-Altman', 'plot', 'was', 'used', 'to', 'illustrate', 'the', 'agreement', 'between', 'the', 'objective', 'and', 'subjective', 'PA', 'data', ',', 'and', 'the', 'Wilcoxon', 'test', 'was', 'employed', 'to', 'examine', 'the', 'differences', '.']","(8, 9)","(48, 57)",-1,ss_o,25885649,Abstract,2,test,gold,1231.0
6063,"The Bland-Altman plot was used to illustrate the agreement between the objective and subjective PA data , and the",Wilcoxon test,was employed to examine the differences .,"['The', 'Bland-Altman', 'plot', 'was', 'used', 'to', 'illustrate', 'the', 'agreement', 'between', 'the', 'objective', 'and', 'subjective', 'PA', 'data', ',', 'and', 'the', 'Wilcoxon', 'test', 'was', 'employed', 'to', 'examine', 'the', 'differences', '.']","(19, 21)","(113, 126)",-1,ss_o,25885649,Abstract,2,test,gold,1853.0
6064,The association between the,PA,measurement and VO2max test was examined via the correlations and the magnitude was presented by the Steiger 's Z value .,"['The', 'association', 'between', 'the', 'PA', 'measurement', 'and', 'VO2max', 'test', 'was', 'examined', 'via', 'the', 'correlations', 'and', 'the', 'magnitude', 'was', 'presented', 'by', 'the', 'Steiger', ""'s"", 'Z', 'value', '.']","(4, 5)","(27, 29)",-1,ss_i,25885649,Abstract,3,test,gold,758.0
6065,The,association between the PA measurement and VO2max test was examined via the correlations and the magnitude was presented by the Steiger 's Z value .,,"['The', 'association', 'between', 'the', 'PA', 'measurement', 'and', 'VO2max', 'test', 'was', 'examined', 'via', 'the', 'correlations', 'and', 'the', 'magnitude', 'was', 'presented', 'by', 'the', 'Steiger', ""'s"", 'Z', 'value', '.']","(1, 26)","(3, 151)",-1,ss_o,25885649,Abstract,3,test,gold,5899.0
6066,The association between the,PA,measurement and VO2max test was examined via the correlations and the magnitude was presented by the Steiger 's Z value .,"['The', 'association', 'between', 'the', 'PA', 'measurement', 'and', 'VO2max', 'test', 'was', 'examined', 'via', 'the', 'correlations', 'and', 'the', 'magnitude', 'was', 'presented', 'by', 'the', 'Steiger', ""'s"", 'Z', 'value', '.']","(4, 5)","(27, 29)",-1,hl_i,25885649,Abstract,3,test,gold,757.0
6067,The association between the,PA measurement,and VO2max test was examined via the correlations and the magnitude was presented by the Steiger 's Z value .,"['The', 'association', 'between', 'the', 'PA', 'measurement', 'and', 'VO2max', 'test', 'was', 'examined', 'via', 'the', 'correlations', 'and', 'the', 'magnitude', 'was', 'presented', 'by', 'the', 'Steiger', ""'s"", 'Z', 'value', '.']","(4, 6)","(27, 41)",-1,hl_o,25885649,Abstract,3,test,gold,746.0
6068,The association between the PA measurement and,VO2max,test was examined via the correlations and the magnitude was presented by the Steiger 's Z value .,"['The', 'association', 'between', 'the', 'PA', 'measurement', 'and', 'VO2max', 'test', 'was', 'examined', 'via', 'the', 'correlations', 'and', 'the', 'magnitude', 'was', 'presented', 'by', 'the', 'Steiger', ""'s"", 'Z', 'value', '.']","(7, 8)","(46, 52)",-1,hl_o,25885649,Abstract,3,test,gold,1677.0
6069,RESULTS,"Sixty-eight RA patients ( age=55±13 years , body mass index : 27.8±5.4 kg/m2 , median of disease duration=5 ( 2-8 ) yrs )",were recruited .,"['RESULTS', 'Sixty-eight', 'RA', 'patients', '(', 'age=55±13', 'years', ',', 'body', 'mass', 'index', ':', '27.8±5.4', 'kg/m2', ',', 'median', 'of', 'disease', 'duration=5', '(', '2-8', ')', 'yrs', ')', 'were', 'recruited', '.']","(1, 24)","(7, 128)",-1,ss_p,25885649,Abstract,4,test,gold,6461.0
6070,RESULTS,Sixty-eight RA,"patients ( age=55±13 years , body mass index : 27.8±5.4 kg/m2 , median of disease duration=5 ( 2-8 ) yrs ) were recruited .","['RESULTS', 'Sixty-eight', 'RA', 'patients', '(', 'age=55±13', 'years', ',', 'body', 'mass', 'index', ':', '27.8±5.4', 'kg/m2', ',', 'median', 'of', 'disease', 'duration=5', '(', '2-8', ')', 'yrs', ')', 'were', 'recruited', '.']","(1, 3)","(7, 21)",-1,hl_p,25885649,Abstract,4,test,gold,2208.0
6071,RESULTS Sixty-eight RA patients (,age=55±13 years,", body mass index : 27.8±5.4 kg/m2 , median of disease duration=5 ( 2-8 ) yrs ) were recruited .","['RESULTS', 'Sixty-eight', 'RA', 'patients', '(', 'age=55±13', 'years', ',', 'body', 'mass', 'index', ':', '27.8±5.4', 'kg/m2', ',', 'median', 'of', 'disease', 'duration=5', '(', '2-8', ')', 'yrs', ')', 'were', 'recruited', '.']","(5, 7)","(33, 48)",-1,hl_p,25885649,Abstract,4,test,gold,2027.0
6072,Smaller differences between the subjective and objective measures were found,when PA,was assessed at the moderate level .,"['Smaller', 'differences', 'between', 'the', 'subjective', 'and', 'objective', 'measures', 'were', 'found', 'when', 'PA', 'was', 'assessed', 'at', 'the', 'moderate', 'level', '.']","(10, 12)","(76, 83)",-1,ss_i,25885649,Abstract,5,test,gold,753.0
6073,Smaller differences between,the subjective and objective measures,were found when PA was assessed at the moderate level .,"['Smaller', 'differences', 'between', 'the', 'subjective', 'and', 'objective', 'measures', 'were', 'found', 'when', 'PA', 'was', 'assessed', 'at', 'the', 'moderate', 'level', '.']","(3, 8)","(27, 64)",-1,ss_o,25885649,Abstract,5,test,gold,6448.0
6074,Smaller differences between the subjective and objective measures were found when PA was assessed at the moderate,level .,,"['Smaller', 'differences', 'between', 'the', 'subjective', 'and', 'objective', 'measures', 'were', 'found', 'when', 'PA', 'was', 'assessed', 'at', 'the', 'moderate', 'level', '.']","(17, 19)","(113, 120)",-1,ss_o,25885649,Abstract,5,test,gold,1224.0
6075,Smaller differences between the subjective and objective measures were found when,PA,was assessed at the moderate level .,"['Smaller', 'differences', 'between', 'the', 'subjective', 'and', 'objective', 'measures', 'were', 'found', 'when', 'PA', 'was', 'assessed', 'at', 'the', 'moderate', 'level', '.']","(11, 12)","(81, 83)",-1,hl_o,25885649,Abstract,5,test,gold,756.0
6076,,Wilcoxon tests,"revealed that patients reported less time spent engaged in sedentary behaviours ( Z=-6.80 , P < 0.01 ) and light PA ( Z=-6.89 , P < 0.01 ) and more moderate PA ( Z=-6.26 , P < 0.01 ) than was objectively indicated .","['Wilcoxon', 'tests', 'revealed', 'that', 'patients', 'reported', 'less', 'time', 'spent', 'engaged', 'in', 'sedentary', 'behaviours', '(', 'Z=-6.80', ',', 'P', '<', '0.01', ')', 'and', 'light', 'PA', '(', 'Z=-6.89', ',', 'P', '<', '0.01', ')', 'and', 'more', 'moderate', 'PA', '(', 'Z=-6.26', ',', 'P', '<', '0.01', ')', 'than', 'was', 'objectively', 'indicated', '.']","(0, 2)","(0, 14)",-1,ss_o,25885649,Abstract,6,test,gold,1854.0
6077,Wilcoxon tests revealed that patients reported less time spent engaged,in sedentary behaviours,"( Z=-6.80 , P < 0.01 ) and light PA ( Z=-6.89 , P < 0.01 ) and more moderate PA ( Z=-6.26 , P < 0.01 ) than was objectively indicated .","['Wilcoxon', 'tests', 'revealed', 'that', 'patients', 'reported', 'less', 'time', 'spent', 'engaged', 'in', 'sedentary', 'behaviours', '(', 'Z=-6.80', ',', 'P', '<', '0.01', ')', 'and', 'light', 'PA', '(', 'Z=-6.89', ',', 'P', '<', '0.01', ')', 'and', 'more', 'moderate', 'PA', '(', 'Z=-6.26', ',', 'P', '<', '0.01', ')', 'than', 'was', 'objectively', 'indicated', '.']","(10, 13)","(70, 93)",-1,ss_o,25885649,Abstract,6,test,gold,2255.0
6078,"Wilcoxon tests revealed that patients reported less time spent engaged in sedentary behaviours ( Z=-6.80 , P < 0.01 )",and light PA,"( Z=-6.89 , P < 0.01 ) and more moderate PA ( Z=-6.26 , P < 0.01 ) than was objectively indicated .","['Wilcoxon', 'tests', 'revealed', 'that', 'patients', 'reported', 'less', 'time', 'spent', 'engaged', 'in', 'sedentary', 'behaviours', '(', 'Z=-6.80', ',', 'P', '<', '0.01', ')', 'and', 'light', 'PA', '(', 'Z=-6.89', ',', 'P', '<', '0.01', ')', 'and', 'more', 'moderate', 'PA', '(', 'Z=-6.26', ',', 'P', '<', '0.01', ')', 'than', 'was', 'objectively', 'indicated', '.']","(20, 23)","(117, 129)",-1,ss_o,25885649,Abstract,6,test,gold,748.0
6079,"Wilcoxon tests revealed that patients reported less time spent engaged in sedentary behaviours ( Z=-6.80 , P < 0.01 ) and light PA ( Z=-6.89 , P < 0.01 ) and",more moderate PA,"( Z=-6.26 , P < 0.01 ) than was objectively indicated .","['Wilcoxon', 'tests', 'revealed', 'that', 'patients', 'reported', 'less', 'time', 'spent', 'engaged', 'in', 'sedentary', 'behaviours', '(', 'Z=-6.80', ',', 'P', '<', '0.01', ')', 'and', 'light', 'PA', '(', 'Z=-6.89', ',', 'P', '<', '0.01', ')', 'and', 'more', 'moderate', 'PA', '(', 'Z=-6.26', ',', 'P', '<', '0.01', ')', 'than', 'was', 'objectively', 'indicated', '.']","(31, 34)","(157, 173)",-1,ss_o,25885649,Abstract,6,test,gold,742.0
6080,Wilcoxon tests revealed that patients reported less time spent engaged in,sedentary behaviours,"( Z=-6.80 , P < 0.01 ) and light PA ( Z=-6.89 , P < 0.01 ) and more moderate PA ( Z=-6.26 , P < 0.01 ) than was objectively indicated .","['Wilcoxon', 'tests', 'revealed', 'that', 'patients', 'reported', 'less', 'time', 'spent', 'engaged', 'in', 'sedentary', 'behaviours', '(', 'Z=-6.80', ',', 'P', '<', '0.01', ')', 'and', 'light', 'PA', '(', 'Z=-6.89', ',', 'P', '<', '0.01', ')', 'and', 'more', 'moderate', 'PA', '(', 'Z=-6.26', ',', 'P', '<', '0.01', ')', 'than', 'was', 'objectively', 'indicated', '.']","(11, 13)","(73, 93)",-1,hl_o,25885649,Abstract,6,test,gold,2256.0
6081,"Wilcoxon tests revealed that patients reported less time spent engaged in sedentary behaviours ( Z=-6.80 , P < 0.01 ) and",light PA,"( Z=-6.89 , P < 0.01 ) and more moderate PA ( Z=-6.26 , P < 0.01 ) than was objectively indicated .","['Wilcoxon', 'tests', 'revealed', 'that', 'patients', 'reported', 'less', 'time', 'spent', 'engaged', 'in', 'sedentary', 'behaviours', '(', 'Z=-6.80', ',', 'P', '<', '0.01', ')', 'and', 'light', 'PA', '(', 'Z=-6.89', ',', 'P', '<', '0.01', ')', 'and', 'more', 'moderate', 'PA', '(', 'Z=-6.26', ',', 'P', '<', '0.01', ')', 'than', 'was', 'objectively', 'indicated', '.']","(21, 23)","(121, 129)",-1,hl_o,25885649,Abstract,6,test,gold,749.0
6082,Significant positive correlations were revealed between VO2max with,all PA,"levels derived from accelerometry ( light PA rho=.35 , P < .01 ; moderate PA rho=.34 , P=.01 ; moderate and vigorous PA , ( MVPA ) rho=.33 , P=.01 ) , and a negative association to sedentary time ( ST ) emerged ( rho=-.27 , P=.04 ) .","['Significant', 'positive', 'correlations', 'were', 'revealed', 'between', 'VO2max', 'with', 'all', 'PA', 'levels', 'derived', 'from', 'accelerometry', '(', 'light', 'PA', 'rho=.35', ',', 'P', '<', '.01', ';', 'moderate', 'PA', 'rho=.34', ',', 'P=.01', ';', 'moderate', 'and', 'vigorous', 'PA', ',', '(', 'MVPA', ')', 'rho=.33', ',', 'P=.01', ')', ',', 'and', 'a', 'negative', 'association', 'to', 'sedentary', 'time', '(', 'ST', ')', 'emerged', '(', 'rho=-.27', ',', 'P=.04', ')', '.']","(8, 10)","(67, 73)",-1,ss_i,25885649,Abstract,7,test,gold,751.0
6083,Significant positive correlations were revealed,between VO2max,"with all PA levels derived from accelerometry ( light PA rho=.35 , P < .01 ; moderate PA rho=.34 , P=.01 ; moderate and vigorous PA , ( MVPA ) rho=.33 , P=.01 ) , and a negative association to sedentary time ( ST ) emerged ( rho=-.27 , P=.04 ) .","['Significant', 'positive', 'correlations', 'were', 'revealed', 'between', 'VO2max', 'with', 'all', 'PA', 'levels', 'derived', 'from', 'accelerometry', '(', 'light', 'PA', 'rho=.35', ',', 'P', '<', '.01', ';', 'moderate', 'PA', 'rho=.34', ',', 'P=.01', ';', 'moderate', 'and', 'vigorous', 'PA', ',', '(', 'MVPA', ')', 'rho=.33', ',', 'P=.01', ')', ',', 'and', 'a', 'negative', 'association', 'to', 'sedentary', 'time', '(', 'ST', ')', 'emerged', '(', 'rho=-.27', ',', 'P=.04', ')', '.']","(5, 7)","(47, 61)",-1,ss_o,25885649,Abstract,7,test,gold,1672.0
6084,Significant positive correlations were revealed between VO2max with all PA levels derived,from accelerometry,"( light PA rho=.35 , P < .01 ; moderate PA rho=.34 , P=.01 ; moderate and vigorous PA , ( MVPA ) rho=.33 , P=.01 ) , and a negative association to sedentary time ( ST ) emerged ( rho=-.27 , P=.04 ) .","['Significant', 'positive', 'correlations', 'were', 'revealed', 'between', 'VO2max', 'with', 'all', 'PA', 'levels', 'derived', 'from', 'accelerometry', '(', 'light', 'PA', 'rho=.35', ',', 'P', '<', '.01', ';', 'moderate', 'PA', 'rho=.34', ',', 'P=.01', ';', 'moderate', 'and', 'vigorous', 'PA', ',', '(', 'MVPA', ')', 'rho=.33', ',', 'P=.01', ')', ',', 'and', 'a', 'negative', 'association', 'to', 'sedentary', 'time', '(', 'ST', ')', 'emerged', '(', 'rho=-.27', ',', 'P=.04', ')', '.']","(12, 14)","(89, 107)",-1,ss_o,25885649,Abstract,7,test,gold,1178.0
6085,"Significant positive correlations were revealed between VO2max with all PA levels derived from accelerometry ( light PA rho=.35 , P < .01 ; moderate PA rho=.34 , P=.01 ; moderate and vigorous PA , ( MVPA ) rho=.33 , P=.01 ) , and a negative association",to sedentary time ( ST ),"emerged ( rho=-.27 , P=.04 ) .","['Significant', 'positive', 'correlations', 'were', 'revealed', 'between', 'VO2max', 'with', 'all', 'PA', 'levels', 'derived', 'from', 'accelerometry', '(', 'light', 'PA', 'rho=.35', ',', 'P', '<', '.01', ';', 'moderate', 'PA', 'rho=.34', ',', 'P=.01', ';', 'moderate', 'and', 'vigorous', 'PA', ',', '(', 'MVPA', ')', 'rho=.33', ',', 'P=.01', ')', ',', 'and', 'a', 'negative', 'association', 'to', 'sedentary', 'time', '(', 'ST', ')', 'emerged', '(', 'rho=-.27', ',', 'P=.04', ')', '.']","(46, 52)","(252, 276)",-1,ss_o,25885649,Abstract,7,test,gold,2252.0
6086,"Significant positive correlations were revealed between VO2max with all PA levels derived from accelerometry ( light PA rho=.35 , P < .01 ; moderate PA rho=.34 , P=.01 ; moderate and vigorous PA , ( MVPA ) rho=.33 , P=.01 ) , and a negative association to sedentary time ( ST ) emerged ( rho=-.27 ,",P=.04 ) .,,"['Significant', 'positive', 'correlations', 'were', 'revealed', 'between', 'VO2max', 'with', 'all', 'PA', 'levels', 'derived', 'from', 'accelerometry', '(', 'light', 'PA', 'rho=.35', ',', 'P', '<', '.01', ';', 'moderate', 'PA', 'rho=.34', ',', 'P=.01', ';', 'moderate', 'and', 'vigorous', 'PA', ',', '(', 'MVPA', ')', 'rho=.33', ',', 'P=.01', ')', ',', 'and', 'a', 'negative', 'association', 'to', 'sedentary', 'time', '(', 'ST', ')', 'emerged', '(', 'rho=-.27', ',', 'P=.04', ')', '.']","(56, 59)","(298, 307)",-1,ss_o,25885649,Abstract,7,test,gold,
6087,Significant positive correlations were revealed between,VO2max,"with all PA levels derived from accelerometry ( light PA rho=.35 , P < .01 ; moderate PA rho=.34 , P=.01 ; moderate and vigorous PA , ( MVPA ) rho=.33 , P=.01 ) , and a negative association to sedentary time ( ST ) emerged ( rho=-.27 , P=.04 ) .","['Significant', 'positive', 'correlations', 'were', 'revealed', 'between', 'VO2max', 'with', 'all', 'PA', 'levels', 'derived', 'from', 'accelerometry', '(', 'light', 'PA', 'rho=.35', ',', 'P', '<', '.01', ';', 'moderate', 'PA', 'rho=.34', ',', 'P=.01', ';', 'moderate', 'and', 'vigorous', 'PA', ',', '(', 'MVPA', ')', 'rho=.33', ',', 'P=.01', ')', ',', 'and', 'a', 'negative', 'association', 'to', 'sedentary', 'time', '(', 'ST', ')', 'emerged', '(', 'rho=-.27', ',', 'P=.04', ')', '.']","(6, 7)","(55, 61)",-1,hl_o,25885649,Abstract,7,test,gold,1675.0
6088,Significant positive correlations were revealed between VO2max with all,PA levels,"derived from accelerometry ( light PA rho=.35 , P < .01 ; moderate PA rho=.34 , P=.01 ; moderate and vigorous PA , ( MVPA ) rho=.33 , P=.01 ) , and a negative association to sedentary time ( ST ) emerged ( rho=-.27 , P=.04 ) .","['Significant', 'positive', 'correlations', 'were', 'revealed', 'between', 'VO2max', 'with', 'all', 'PA', 'levels', 'derived', 'from', 'accelerometry', '(', 'light', 'PA', 'rho=.35', ',', 'P', '<', '.01', ';', 'moderate', 'PA', 'rho=.34', ',', 'P=.01', ';', 'moderate', 'and', 'vigorous', 'PA', ',', '(', 'MVPA', ')', 'rho=.33', ',', 'P=.01', ')', ',', 'and', 'a', 'negative', 'association', 'to', 'sedentary', 'time', '(', 'ST', ')', 'emerged', '(', 'rho=-.27', ',', 'P=.04', ')', '.']","(9, 11)","(71, 80)",-1,hl_o,25885649,Abstract,7,test,gold,750.0
6089,"Significant positive correlations were revealed between VO2max with all PA levels derived from accelerometry ( light PA rho=.35 , P < .01 ; moderate PA rho=.34 , P=.01 ; moderate and vigorous PA , ( MVPA ) rho=.33 , P=.01 ) , and a negative association to",sedentary time,"( ST ) emerged ( rho=-.27 , P=.04 ) .","['Significant', 'positive', 'correlations', 'were', 'revealed', 'between', 'VO2max', 'with', 'all', 'PA', 'levels', 'derived', 'from', 'accelerometry', '(', 'light', 'PA', 'rho=.35', ',', 'P', '<', '.01', ';', 'moderate', 'PA', 'rho=.34', ',', 'P=.01', ';', 'moderate', 'and', 'vigorous', 'PA', ',', '(', 'MVPA', ')', 'rho=.33', ',', 'P=.01', ')', ',', 'and', 'a', 'negative', 'association', 'to', 'sedentary', 'time', '(', 'ST', ')', 'emerged', '(', 'rho=-.27', ',', 'P=.04', ')', '.']","(47, 49)","(255, 269)",-1,hl_o,25885649,Abstract,7,test,gold,2254.0
6090,IPAQ-reported,moderate PA,"and MVPA positively correlated with maxV02 ( rho=.25 , P=.01 , rho=.27 , P=.01 , respectively ) .","['IPAQ-reported', 'moderate', 'PA', 'and', 'MVPA', 'positively', 'correlated', 'with', 'maxV02', '(', 'rho=.25', ',', 'P=.01', ',', 'rho=.27', ',', 'P=.01', ',', 'respectively', ')', '.']","(1, 3)","(13, 24)",-1,ss_i,25885649,Abstract,8,test,gold,743.0
6091,,IPAQ-reported moderate PA and MVPA,"positively correlated with maxV02 ( rho=.25 , P=.01 , rho=.27 , P=.01 , respectively ) .","['IPAQ-reported', 'moderate', 'PA', 'and', 'MVPA', 'positively', 'correlated', 'with', 'maxV02', '(', 'rho=.25', ',', 'P=.01', ',', 'rho=.27', ',', 'P=.01', ',', 'respectively', ')', '.']","(0, 5)","(0, 34)",-1,ss_o,25885649,Abstract,8,test,gold,741.0
6092,IPAQ-reported moderate PA and MVPA positively correlated,with maxV02,"( rho=.25 , P=.01 , rho=.27 , P=.01 , respectively ) .","['IPAQ-reported', 'moderate', 'PA', 'and', 'MVPA', 'positively', 'correlated', 'with', 'maxV02', '(', 'rho=.25', ',', 'P=.01', ',', 'rho=.27', ',', 'P=.01', ',', 'respectively', ')', '.']","(7, 9)","(56, 67)",-1,ss_o,25885649,Abstract,8,test,gold,1181.0
6093,,IPAQ-reported,"moderate PA and MVPA positively correlated with maxV02 ( rho=.25 , P=.01 , rho=.27 , P=.01 , respectively ) .","['IPAQ-reported', 'moderate', 'PA', 'and', 'MVPA', 'positively', 'correlated', 'with', 'maxV02', '(', 'rho=.25', ',', 'P=.01', ',', 'rho=.27', ',', 'P=.01', ',', 'respectively', ')', '.']","(0, 1)","(0, 13)",-1,hl_o,25885649,Abstract,8,test,gold,
6094,IPAQ-reported moderate,PA,"and MVPA positively correlated with maxV02 ( rho=.25 , P=.01 , rho=.27 , P=.01 , respectively ) .","['IPAQ-reported', 'moderate', 'PA', 'and', 'MVPA', 'positively', 'correlated', 'with', 'maxV02', '(', 'rho=.25', ',', 'P=.01', ',', 'rho=.27', ',', 'P=.01', ',', 'respectively', ')', '.']","(2, 3)","(22, 24)",-1,hl_o,25885649,Abstract,8,test,gold,755.0
6095,IPAQ-reported moderate PA and,MVPA,"positively correlated with maxV02 ( rho=.25 , P=.01 , rho=.27 , P=.01 , respectively ) .","['IPAQ-reported', 'moderate', 'PA', 'and', 'MVPA', 'positively', 'correlated', 'with', 'maxV02', '(', 'rho=.25', ',', 'P=.01', ',', 'rho=.27', ',', 'P=.01', ',', 'respectively', ')', '.']","(4, 5)","(29, 33)",-1,hl_o,25885649,Abstract,8,test,gold,88.0
6096,Differences between the magnitude of correlations between,the IPAQ-VO2 max and GT3X-VO2 max,"were only significant for ST ( Z=3.43 , P < .01 ) .","['Differences', 'between', 'the', 'magnitude', 'of', 'correlations', 'between', 'the', 'IPAQ-VO2', 'max', 'and', 'GT3X-VO2', 'max', 'were', 'only', 'significant', 'for', 'ST', '(', 'Z=3.43', ',', 'P', '<', '.01', ')', '.']","(7, 13)","(57, 90)",-1,ss_o,25885649,Abstract,9,test,gold,1343.0
6097,Differences between the magnitude of correlations between the,IPAQ-VO2 max,"and GT3X-VO2 max were only significant for ST ( Z=3.43 , P < .01 ) .","['Differences', 'between', 'the', 'magnitude', 'of', 'correlations', 'between', 'the', 'IPAQ-VO2', 'max', 'and', 'GT3X-VO2', 'max', 'were', 'only', 'significant', 'for', 'ST', '(', 'Z=3.43', ',', 'P', '<', '.01', ')', '.']","(8, 10)","(61, 73)",-1,hl_o,25885649,Abstract,9,test,gold,1344.0
6098,Differences between the magnitude of correlations between the IPAQ-VO2 max and,GT3X-VO2 max,"were only significant for ST ( Z=3.43 , P < .01 ) .","['Differences', 'between', 'the', 'magnitude', 'of', 'correlations', 'between', 'the', 'IPAQ-VO2', 'max', 'and', 'GT3X-VO2', 'max', 'were', 'only', 'significant', 'for', 'ST', '(', 'Z=3.43', ',', 'P', '<', '.01', ')', '.']","(11, 13)","(78, 90)",-1,hl_o,25885649,Abstract,9,test,gold,1345.0
6099,"CONCLUSIONS Via responses to the IPAQ , RA patients reported that they were less sedentary and engaged in more higher",intensity PA,than what was objectively assessed .,"['CONCLUSIONS', 'Via', 'responses', 'to', 'the', 'IPAQ', ',', 'RA', 'patients', 'reported', 'that', 'they', 'were', 'less', 'sedentary', 'and', 'engaged', 'in', 'more', 'higher', 'intensity', 'PA', 'than', 'what', 'was', 'objectively', 'assessed', '.']","(20, 22)","(117, 129)",-1,ss_i,25885649,Abstract,10,test,gold,744.0
6100,CONCLUSIONS Via responses to,the IPAQ,", RA patients reported that they were less sedentary and engaged in more higher intensity PA than what was objectively assessed .","['CONCLUSIONS', 'Via', 'responses', 'to', 'the', 'IPAQ', ',', 'RA', 'patients', 'reported', 'that', 'they', 'were', 'less', 'sedentary', 'and', 'engaged', 'in', 'more', 'higher', 'intensity', 'PA', 'than', 'what', 'was', 'objectively', 'assessed', '.']","(4, 6)","(28, 36)",-1,ss_o,25885649,Abstract,10,test,gold,1177.0
6101,"CONCLUSIONS Via responses to the IPAQ , RA patients reported that they were",less sedentary,and engaged in more higher intensity PA than what was objectively assessed .,"['CONCLUSIONS', 'Via', 'responses', 'to', 'the', 'IPAQ', ',', 'RA', 'patients', 'reported', 'that', 'they', 'were', 'less', 'sedentary', 'and', 'engaged', 'in', 'more', 'higher', 'intensity', 'PA', 'than', 'what', 'was', 'objectively', 'assessed', '.']","(13, 15)","(75, 89)",-1,ss_o,25885649,Abstract,10,test,gold,2253.0
6102,"CONCLUSIONS Via responses to the IPAQ , RA patients reported that they were less sedentary and engaged in more higher",intensity PA,than what was objectively assessed .,"['CONCLUSIONS', 'Via', 'responses', 'to', 'the', 'IPAQ', ',', 'RA', 'patients', 'reported', 'that', 'they', 'were', 'less', 'sedentary', 'and', 'engaged', 'in', 'more', 'higher', 'intensity', 'PA', 'than', 'what', 'was', 'objectively', 'assessed', '.']","(20, 22)","(117, 129)",-1,ss_o,25885649,Abstract,10,test,gold,745.0
6103,"CONCLUSIONS Via responses to the IPAQ , RA patients reported that they were less sedentary and engaged in more higher intensity PA than what was objectively",assessed .,,"['CONCLUSIONS', 'Via', 'responses', 'to', 'the', 'IPAQ', ',', 'RA', 'patients', 'reported', 'that', 'they', 'were', 'less', 'sedentary', 'and', 'engaged', 'in', 'more', 'higher', 'intensity', 'PA', 'than', 'what', 'was', 'objectively', 'assessed', '.']","(26, 28)","(156, 166)",-1,ss_o,25885649,Abstract,10,test,gold,1308.0
6104,Accelerometry data correlated with VO2max at,all PA,levels .,"['Accelerometry', 'data', 'correlated', 'with', 'VO2max', 'at', 'all', 'PA', 'levels', '.']","(6, 8)","(44, 50)",-1,ss_i,25885649,Abstract,11,test,gold,752.0
6105,,Accelerometry,data correlated with VO2max at all PA levels .,"['Accelerometry', 'data', 'correlated', 'with', 'VO2max', 'at', 'all', 'PA', 'levels', '.']","(0, 1)","(0, 13)",-1,ss_o,25885649,Abstract,11,test,gold,
6106,Accelerometry data correlated,with VO2max,at all PA levels .,"['Accelerometry', 'data', 'correlated', 'with', 'VO2max', 'at', 'all', 'PA', 'levels', '.']","(3, 5)","(29, 40)",-1,ss_o,25885649,Abstract,11,test,gold,1673.0
6107,Only subjective moderate,and MPVA,correlated with VO2max .,"['Only', 'subjective', 'moderate', 'and', 'MPVA', 'correlated', 'with', 'VO2max', '.']","(3, 5)","(24, 32)",-1,ss_o,25885649,Abstract,12,test,gold,1055.0
6108,Only subjective moderate and MPVA correlated,with VO2max,.,"['Only', 'subjective', 'moderate', 'and', 'MPVA', 'correlated', 'with', 'VO2max', '.']","(6, 8)","(44, 55)",-1,ss_o,25885649,Abstract,12,test,gold,1674.0
6109,Findings suggest that self-reported PA and ST should be interpreted with caution,in people with RA,and complemented with accelerometry when possible .,"['Findings', 'suggest', 'that', 'self-reported', 'PA', 'and', 'ST', 'should', 'be', 'interpreted', 'with', 'caution', 'in', 'people', 'with', 'RA', 'and', 'complemented', 'with', 'accelerometry', 'when', 'possible', '.']","(12, 16)","(80, 97)",-1,ss_p,25885649,Abstract,13,test,gold,2206.0
6110,Findings suggest that,self-reported PA,and ST should be interpreted with caution in people with RA and complemented with accelerometry when possible .,"['Findings', 'suggest', 'that', 'self-reported', 'PA', 'and', 'ST', 'should', 'be', 'interpreted', 'with', 'caution', 'in', 'people', 'with', 'RA', 'and', 'complemented', 'with', 'accelerometry', 'when', 'possible', '.']","(3, 5)","(21, 37)",-1,ss_i,25885649,Abstract,13,test,gold,754.0
6111,Findings suggest that,self-reported PA and ST,should be interpreted with caution in people with RA and complemented with accelerometry when possible .,"['Findings', 'suggest', 'that', 'self-reported', 'PA', 'and', 'ST', 'should', 'be', 'interpreted', 'with', 'caution', 'in', 'people', 'with', 'RA', 'and', 'complemented', 'with', 'accelerometry', 'when', 'possible', '.']","(3, 7)","(21, 44)",-1,ss_o,25885649,Abstract,13,test,gold,747.0
6112,Findings suggest that self-reported PA and ST should be interpreted with caution in people with RA and complemented,with accelerometry,when possible .,"['Findings', 'suggest', 'that', 'self-reported', 'PA', 'and', 'ST', 'should', 'be', 'interpreted', 'with', 'caution', 'in', 'people', 'with', 'RA', 'and', 'complemented', 'with', 'accelerometry', 'when', 'possible', '.']","(18, 20)","(115, 133)",-1,ss_o,25885649,Abstract,13,test,gold,1179.0
6113,TRIAL REGISTRATION Trial registration : ClinicalTrials.gov ISRCTN04121489 .,,,"['TRIAL', 'REGISTRATION', 'Trial', 'registration', ':', 'ClinicalTrials.gov', 'ISRCTN04121489', '.']",,,,,25885649,Abstract,14,test,gold,
6114,Registered 5 September 2012 .,,,"['Registered', '5', 'September', '2012', '.']",,,,,25885649,Abstract,15,test,gold,
6115,A randomised controlled trial of,personalised decision support,delivered via the internet for bowel cancer screening with a faecal occult blood test : the effects of tailoring of messages according to social cognitive variables on participation .,"['A', 'randomised', 'controlled', 'trial', 'of', 'personalised', 'decision', 'support', 'delivered', 'via', 'the', 'internet', 'for', 'bowel', 'cancer', 'screening', 'with', 'a', 'faecal', 'occult', 'blood', 'test', ':', 'the', 'effects', 'of', 'tailoring', 'of', 'messages', 'according', 'to', 'social', 'cognitive', 'variables', 'on', 'participation', '.']","(5, 8)","(32, 61)",-1,ss_i,25886492,Title,0,test,gold,929.0
6116,A randomised controlled trial of personalised decision support delivered via the internet for bowel cancer screening with a,faecal occult blood test :,the effects of tailoring of messages according to social cognitive variables on participation .,"['A', 'randomised', 'controlled', 'trial', 'of', 'personalised', 'decision', 'support', 'delivered', 'via', 'the', 'internet', 'for', 'bowel', 'cancer', 'screening', 'with', 'a', 'faecal', 'occult', 'blood', 'test', ':', 'the', 'effects', 'of', 'tailoring', 'of', 'messages', 'according', 'to', 'social', 'cognitive', 'variables', 'on', 'participation', '.']","(18, 23)","(123, 149)",-1,ss_o,25886492,Title,0,test,gold,4515.0
6117,A randomised controlled trial of,personalised decision support,delivered via the internet for bowel cancer screening with a faecal occult blood test : the effects of tailoring of messages according to social cognitive variables on participation .,"['A', 'randomised', 'controlled', 'trial', 'of', 'personalised', 'decision', 'support', 'delivered', 'via', 'the', 'internet', 'for', 'bowel', 'cancer', 'screening', 'with', 'a', 'faecal', 'occult', 'blood', 'test', ':', 'the', 'effects', 'of', 'tailoring', 'of', 'messages', 'according', 'to', 'social', 'cognitive', 'variables', 'on', 'participation', '.']","(5, 8)","(32, 61)",-1,hl_i,25886492,Title,0,test,gold,930.0
6118,"BACKGROUND In Australia , bowel cancer screening participation using",faecal occult blood testing ( FOBT ),is low .,"['BACKGROUND', 'In', 'Australia', ',', 'bowel', 'cancer', 'screening', 'participation', 'using', 'faecal', 'occult', 'blood', 'testing', '(', 'FOBT', ')', 'is', 'low', '.']","(9, 16)","(68, 104)",-1,ss_o,25886492,Abstract,0,test,gold,4516.0
6119,Decision support tailored to psychological predictors of participation may increase screening .,,,"['Decision', 'support', 'tailored', 'to', 'psychological', 'predictors', 'of', 'participation', 'may', 'increase', 'screening', '.']",,,,,25886492,Abstract,1,test,gold,
6120,The study compared,tailored computerised decision support,to non-tailored computer or paper information .,"['The', 'study', 'compared', 'tailored', 'computerised', 'decision', 'support', 'to', 'non-tailored', 'computer', 'or', 'paper', 'information', '.']","(3, 7)","(18, 56)",-1,ss_i,25886492,Abstract,2,test,gold,931.0
6121,The study compared tailored computerised decision support to,non-tailored computer or paper information .,,"['The', 'study', 'compared', 'tailored', 'computerised', 'decision', 'support', 'to', 'non-tailored', 'computer', 'or', 'paper', 'information', '.']","(8, 14)","(60, 104)",-1,ss_i,25886492,Abstract,2,test,gold,1255.0
6122,The study compared,tailored computerised decision support,to non-tailored computer or paper information .,"['The', 'study', 'compared', 'tailored', 'computerised', 'decision', 'support', 'to', 'non-tailored', 'computer', 'or', 'paper', 'information', '.']","(3, 7)","(18, 56)",-1,hl_i,25886492,Abstract,2,test,gold,932.0
6123,The primary outcome was,FOBT return,within 12 weeks .,"['The', 'primary', 'outcome', 'was', 'FOBT', 'return', 'within', '12', 'weeks', '.']","(4, 6)","(23, 34)",-1,ss_o,25886492,Abstract,3,test,gold,4141.0
6124,The primary outcome was,FOBT return,within 12 weeks .,"['The', 'primary', 'outcome', 'was', 'FOBT', 'return', 'within', '12', 'weeks', '.']","(4, 6)","(23, 34)",-1,hl_o,25886492,Abstract,3,test,gold,4142.0
6125,Additional analyses were conducted,on movement in decision to screen,and change on psychological variables .,"['Additional', 'analyses', 'were', 'conducted', 'on', 'movement', 'in', 'decision', 'to', 'screen', 'and', 'change', 'on', 'psychological', 'variables', '.']","(4, 10)","(34, 67)",-1,ss_o,25886492,Abstract,4,test,gold,948.0
6126,Additional analyses were conducted on movement in decision to screen and change,on psychological variables,.,"['Additional', 'analyses', 'were', 'conducted', 'on', 'movement', 'in', 'decision', 'to', 'screen', 'and', 'change', 'on', 'psychological', 'variables', '.']","(12, 15)","(79, 105)",-1,ss_o,25886492,Abstract,4,test,gold,1831.0
6127,"METHODS A parallel , randomised controlled ,","trial invited 25,511 people aged 50-74 years",to complete an eligibility questionnaire .,"['METHODS', 'A', 'parallel', ',', 'randomised', 'controlled', ',', 'trial', 'invited', '25,511', 'people', 'aged', '50-74', 'years', 'to', 'complete', 'an', 'eligibility', 'questionnaire', '.']","(7, 14)","(44, 88)",-1,ss_p,25886492,Abstract,5,test,gold,2038.0
6128,"METHODS A parallel , randomised controlled , trial invited","25,511",people aged 50-74 years to complete an eligibility questionnaire .,"['METHODS', 'A', 'parallel', ',', 'randomised', 'controlled', ',', 'trial', 'invited', '25,511', 'people', 'aged', '50-74', 'years', 'to', 'complete', 'an', 'eligibility', 'questionnaire', '.']","(9, 10)","(58, 64)",-1,hl_p,25886492,Abstract,5,test,gold,
6129,"METHODS A parallel , randomised controlled , trial invited 25,511 people",aged 50-74,years to complete an eligibility questionnaire .,"['METHODS', 'A', 'parallel', ',', 'randomised', 'controlled', ',', 'trial', 'invited', '25,511', 'people', 'aged', '50-74', 'years', 'to', 'complete', 'an', 'eligibility', 'questionnaire', '.']","(11, 13)","(72, 82)",-1,hl_p,25886492,Abstract,5,test,gold,2031.0
6130,"Eligible respondents ( n = 3,408 ) were","assigned to Tailored Personalised Decision Support ( TPDS ) , Non-Tailored PDS ( NTPDS ) , or Control","( CG ) ( intention-to-treat , ITT sample ) .","['Eligible', 'respondents', '(', 'n', '=', '3,408', ')', 'were', 'assigned', 'to', 'Tailored', 'Personalised', 'Decision', 'Support', '(', 'TPDS', ')', ',', 'Non-Tailored', 'PDS', '(', 'NTPDS', ')', ',', 'or', 'Control', '(', 'CG', ')', '(', 'intention-to-treat', ',', 'ITT', 'sample', ')', '.']","(8, 26)","(39, 140)",-1,ss_i,25886492,Abstract,6,test,gold,6263.0
6131,"Eligible respondents ( n = 3,408 ) were assigned to Tailored Personalised Decision Support ( TPDS ) , Non-Tailored PDS ( NTPDS ) , or Control ( CG ) ( intention-to-treat , ITT",sample ) .,,"['Eligible', 'respondents', '(', 'n', '=', '3,408', ')', 'were', 'assigned', 'to', 'Tailored', 'Personalised', 'Decision', 'Support', '(', 'TPDS', ')', ',', 'Non-Tailored', 'PDS', '(', 'NTPDS', ')', ',', 'or', 'Control', '(', 'CG', ')', '(', 'intention-to-treat', ',', 'ITT', 'sample', ')', '.']","(33, 36)","(175, 185)",-1,ss_i,25886492,Abstract,6,test,gold,1859.0
6132,"Eligible respondents ( n = 3,408 ) were assigned to",Tailored Personalised Decision Support ( TPDS ),", Non-Tailored PDS ( NTPDS ) , or Control ( CG ) ( intention-to-treat , ITT sample ) .","['Eligible', 'respondents', '(', 'n', '=', '3,408', ')', 'were', 'assigned', 'to', 'Tailored', 'Personalised', 'Decision', 'Support', '(', 'TPDS', ')', ',', 'Non-Tailored', 'PDS', '(', 'NTPDS', ')', ',', 'or', 'Control', '(', 'CG', ')', '(', 'intention-to-treat', ',', 'ITT', 'sample', ')', '.']","(10, 17)","(51, 98)",-1,hl_i,25886492,Abstract,6,test,gold,6264.0
6133,"Eligible respondents ( n = 3,408 ) were assigned to Tailored Personalised Decision Support ( TPDS ) ,",Non-Tailored PDS ( NTPDS ),", or Control ( CG ) ( intention-to-treat , ITT sample ) .","['Eligible', 'respondents', '(', 'n', '=', '3,408', ')', 'were', 'assigned', 'to', 'Tailored', 'Personalised', 'Decision', 'Support', '(', 'TPDS', ')', ',', 'Non-Tailored', 'PDS', '(', 'NTPDS', ')', ',', 'or', 'Control', '(', 'CG', ')', '(', 'intention-to-treat', ',', 'ITT', 'sample', ')', '.']","(18, 23)","(101, 127)",-1,hl_i,25886492,Abstract,6,test,gold,1016.0
6134,"Eligible respondents ( n = 3,408 ) were assigned to Tailored Personalised Decision Support ( TPDS ) , Non-Tailored PDS ( NTPDS ) , or",Control,"( CG ) ( intention-to-treat , ITT sample ) .","['Eligible', 'respondents', '(', 'n', '=', '3,408', ')', 'were', 'assigned', 'to', 'Tailored', 'Personalised', 'Decision', 'Support', '(', 'TPDS', ')', ',', 'Non-Tailored', 'PDS', '(', 'NTPDS', ')', ',', 'or', 'Control', '(', 'CG', ')', '(', 'intention-to-treat', ',', 'ITT', 'sample', ')', '.']","(25, 26)","(133, 140)",-1,hl_i,25886492,Abstract,6,test,gold,1297.0
6135,,TPDS and NTPDS,groups completed an on-line baseline survey ( BS ) and accessed generic information .,"['TPDS', 'and', 'NTPDS', 'groups', 'completed', 'an', 'on-line', 'baseline', 'survey', '(', 'BS', ')', 'and', 'accessed', 'generic', 'information', '.']","(0, 3)","(0, 14)",-1,ss_i,25886492,Abstract,7,test,gold,1017.0
6136,TPDS and NTPDS groups completed an on-line baseline survey ( BS ) and accessed generic information,.,,"['TPDS', 'and', 'NTPDS', 'groups', 'completed', 'an', 'on-line', 'baseline', 'survey', '(', 'BS', ')', 'and', 'accessed', 'generic', 'information', '.']","(16, 17)","(98, 99)",-1,ss_i,25886492,Abstract,7,test,gold,
6137,,TPDS,and NTPDS groups completed an on-line baseline survey ( BS ) and accessed generic information .,"['TPDS', 'and', 'NTPDS', 'groups', 'completed', 'an', 'on-line', 'baseline', 'survey', '(', 'BS', ')', 'and', 'accessed', 'generic', 'information', '.']","(0, 1)","(0, 4)",-1,hl_i,25886492,Abstract,7,test,gold,1018.0
6138,TPDS and,NTPDS,groups completed an on-line baseline survey ( BS ) and accessed generic information .,"['TPDS', 'and', 'NTPDS', 'groups', 'completed', 'an', 'on-line', 'baseline', 'survey', '(', 'BS', ')', 'and', 'accessed', 'generic', 'information', '.']","(2, 3)","(8, 13)",-1,hl_i,25886492,Abstract,7,test,gold,
6139,,The,TPDS group additionally received a tailored intervention .,"['The', 'TPDS', 'group', 'additionally', 'received', 'a', 'tailored', 'intervention', '.']","(0, 1)","(0, 3)",-1,ss_i,25886492,Abstract,8,test,gold,1175.0
6140,The TPDS group additionally received a tailored,intervention,.,"['The', 'TPDS', 'group', 'additionally', 'received', 'a', 'tailored', 'intervention', '.']","(7, 8)","(47, 59)",-1,ss_i,25886492,Abstract,8,test,gold,4023.0
6141,The TPDS group additionally received a,tailored intervention,.,"['The', 'TPDS', 'group', 'additionally', 'received', 'a', 'tailored', 'intervention', '.']","(6, 8)","(38, 59)",-1,hl_i,25886492,Abstract,8,test,gold,4024.0
6142,CG participants completed a paper BS only .,,,"['CG', 'participants', 'completed', 'a', 'paper', 'BS', 'only', '.']",,,,,25886492,Abstract,9,test,gold,
6143,"Those completing the BS ( n = 2270 ) were mailed an FOBT and requested to complete an endpoint survey ( ES ) that re-measured BS variables ( per-protocol , PP sample )",.,,"['Those', 'completing', 'the', 'BS', '(', 'n', '=', '2270', ')', 'were', 'mailed', 'an', 'FOBT', 'and', 'requested', 'to', 'complete', 'an', 'endpoint', 'survey', '(', 'ES', ')', 'that', 're-measured', 'BS', 'variables', '(', 'per-protocol', ',', 'PP', 'sample', ')', '.']","(33, 34)","(167, 168)",-1,ss_o,25886492,Abstract,10,test,gold,
6144,,RESULTS FOBT,"return : In the ITT sample , there was no significant difference between any group ( χ ( 2 ) ( 2 ) = 2.57 , p = .26 ; TPDS , 32.5 % ; NTPDS , 33 % ; and CG , 34.5 % ) .","['RESULTS', 'FOBT', 'return', ':', 'In', 'the', 'ITT', 'sample', ',', 'there', 'was', 'no', 'significant', 'difference', 'between', 'any', 'group', '(', 'χ', '(', '2', ')', '(', '2', ')', '=', '2.57', ',', 'p', '=', '.26', ';', 'TPDS', ',', '32.5', '%', ';', 'NTPDS', ',', '33', '%', ';', 'and', 'CG', ',', '34.5', '%', ')', '.']","(0, 2)","(0, 12)",-1,ss_o,25886492,Abstract,11,test,gold,361.0
6145,"In the PP sample , FOBT return in the internet groups was significantly higher than the paper group ( χ ( 2 ) ( 2 ) = 17.01 , p < .001 ; TPDS , 80 % ; NTPDS , 83 % ; and","CG , 74 % )",.,"['In', 'the', 'PP', 'sample', ',', 'FOBT', 'return', 'in', 'the', 'internet', 'groups', 'was', 'significantly', 'higher', 'than', 'the', 'paper', 'group', '(', 'χ', '(', '2', ')', '(', '2', ')', '=', '17.01', ',', 'p', '<', '.001', ';', 'TPDS', ',', '80', '%', ';', 'NTPDS', ',', '83', '%', ';', 'and', 'CG', ',', '74', '%', ')', '.']","(44, 49)","(169, 180)",-1,ss_i,25886492,Abstract,12,test,gold,1504.0
6146,,In the PP sample,", FOBT return in the internet groups was significantly higher than the paper group ( χ ( 2 ) ( 2 ) = 17.01 , p < .001 ; TPDS , 80 % ; NTPDS , 83 % ; and CG , 74 % ) .","['In', 'the', 'PP', 'sample', ',', 'FOBT', 'return', 'in', 'the', 'internet', 'groups', 'was', 'significantly', 'higher', 'than', 'the', 'paper', 'group', '(', 'χ', '(', '2', ')', '(', '2', ')', '=', '17.01', ',', 'p', '<', '.001', ';', 'TPDS', ',', '80', '%', ';', 'NTPDS', ',', '83', '%', ';', 'and', 'CG', ',', '74', '%', ')', '.']","(0, 4)","(0, 16)",-1,ss_o,25886492,Abstract,12,test,gold,1857.0
6147,"In the PP sample , FOBT return in the internet groups was significantly higher than the paper group ( χ ( 2 ) ( 2 ) = 17.01 , p < .001 ; TPDS ,",80 % ; NTPDS,", 83 % ; and CG , 74 % ) .","['In', 'the', 'PP', 'sample', ',', 'FOBT', 'return', 'in', 'the', 'internet', 'groups', 'was', 'significantly', 'higher', 'than', 'the', 'paper', 'group', '(', 'χ', '(', '2', ')', '(', '2', ')', '=', '17.01', ',', 'p', '<', '.001', ';', 'TPDS', ',', '80', '%', ';', 'NTPDS', ',', '83', '%', ';', 'and', 'CG', ',', '74', '%', ')', '.']","(35, 39)","(143, 155)",-1,ss_o,25886492,Abstract,12,test,gold,1505.0
6148,,FOBT completion,"by TPDS and NTPDS did not differ ( χ ( 2 ) ( 1 ) = 2.23 , p = .13 ) .","['FOBT', 'completion', 'by', 'TPDS', 'and', 'NTPDS', 'did', 'not', 'differ', '(', 'χ', '(', '2', ')', '(', '1', ')', '=', '2.23', ',', 'p', '=', '.13', ')', '.']","(0, 2)","(0, 15)",-1,ss_i,25886492,Abstract,13,test,gold,4140.0
6149,Age was positively associated with kit return .,,,"['Age', 'was', 'positively', 'associated', 'with', 'kit', 'return', '.']",,,,,25886492,Abstract,14,test,gold,
6150,Decision to screen : 2227/2270 of the PP sample provided complete BS data .,,,"['Decision', 'to', 'screen', ':', '2227/2270', 'of', 'the', 'PP', 'sample', 'provided', 'complete', 'BS', 'data', '.']",,,,,25886492,Abstract,15,test,gold,
6151,Participants not wanting to screen at,baseline ( 1083/2227 ),and allocated to TPDS and NTPDS were significantly more likely to decide to screen and return an FOBT than those assigned to the CG .,"['Participants', 'not', 'wanting', 'to', 'screen', 'at', 'baseline', '(', '1083/2227', ')', 'and', 'allocated', 'to', 'TPDS', 'and', 'NTPDS', 'were', 'significantly', 'more', 'likely', 'to', 'decide', 'to', 'screen', 'and', 'return', 'an', 'FOBT', 'than', 'those', 'assigned', 'to', 'the', 'CG', '.']","(6, 10)","(37, 59)",-1,ss_i,25886492,Abstract,16,test,gold,1311.0
6152,Participants not wanting to screen at baseline ( 1083/2227 ) and allocated to TPDS and NTPDS were significantly more likely to decide to screen and return an FOBT than,those assigned to the,CG .,"['Participants', 'not', 'wanting', 'to', 'screen', 'at', 'baseline', '(', '1083/2227', ')', 'and', 'allocated', 'to', 'TPDS', 'and', 'NTPDS', 'were', 'significantly', 'more', 'likely', 'to', 'decide', 'to', 'screen', 'and', 'return', 'an', 'FOBT', 'than', 'those', 'assigned', 'to', 'the', 'CG', '.']","(29, 33)","(167, 188)",-1,ss_i,25886492,Abstract,16,test,gold,1149.0
6153,Participants not wanting to screen at baseline ( 1083/2227 ) and allocated to TPDS and NTPDS were significantly,more likely to,decide to screen and return an FOBT than those assigned to the CG .,"['Participants', 'not', 'wanting', 'to', 'screen', 'at', 'baseline', '(', '1083/2227', ')', 'and', 'allocated', 'to', 'TPDS', 'and', 'NTPDS', 'were', 'significantly', 'more', 'likely', 'to', 'decide', 'to', 'screen', 'and', 'return', 'an', 'FOBT', 'than', 'those', 'assigned', 'to', 'the', 'CG', '.']","(18, 21)","(111, 125)",-1,ss_o,25886492,Abstract,16,test,gold,1154.0
6154,Participants not wanting to screen at baseline ( 1083/2227 ) and allocated to TPDS and NTPDS were significantly more likely to decide to screen and return an,FOBT than those,assigned to the CG .,"['Participants', 'not', 'wanting', 'to', 'screen', 'at', 'baseline', '(', '1083/2227', ')', 'and', 'allocated', 'to', 'TPDS', 'and', 'NTPDS', 'were', 'significantly', 'more', 'likely', 'to', 'decide', 'to', 'screen', 'and', 'return', 'an', 'FOBT', 'than', 'those', 'assigned', 'to', 'the', 'CG', '.']","(27, 30)","(157, 172)",-1,ss_o,25886492,Abstract,16,test,gold,4139.0
6155,FOBT return by TPDS and NTPDS did not differ from one,"another ( OR = 1.16 , p = .42 )",.,"['FOBT', 'return', 'by', 'TPDS', 'and', 'NTPDS', 'did', 'not', 'differ', 'from', 'one', 'another', '(', 'OR', '=', '1.16', ',', 'p', '=', '.42', ')', '.']","(11, 21)","(53, 84)",-1,ss_o,25886492,Abstract,17,test,gold,6459.0
6156,Change on psychosocial,predictors : Analysis of change indicated that salience and,coherence of screening and self-efficacy were improved and faecal aversion decreased by tailored messaging .,"['Change', 'on', 'psychosocial', 'predictors', ':', 'Analysis', 'of', 'change', 'indicated', 'that', 'salience', 'and', 'coherence', 'of', 'screening', 'and', 'self-efficacy', 'were', 'improved', 'and', 'faecal', 'aversion', 'decreased', 'by', 'tailored', 'messaging', '.']","(3, 12)","(22, 81)",-1,ss_o,25886492,Abstract,18,test,gold,6394.0
6157,"CONCLUSIONS Online information resources may have a role in encouraging internet-enabled people who are uncommitted to screening to change their attitudes , perceptions and behaviour .",,,"['CONCLUSIONS', 'Online', 'information', 'resources', 'may', 'have', 'a', 'role', 'in', 'encouraging', 'internet-enabled', 'people', 'who', 'are', 'uncommitted', 'to', 'screening', 'to', 'change', 'their', 'attitudes', ',', 'perceptions', 'and', 'behaviour', '.']",,,,,25886492,Abstract,19,test,gold,
6158,TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN12610000095066 .,,,"['TRIAL', 'REGISTRATION', 'Australian', 'New', 'Zealand', 'Clinical', 'Trials', 'Registry', 'ACTRN12610000095066', '.']",,,,,25886492,Abstract,20,test,gold,
6159,Sedation during endoscopic,retrograde cholangiopancreatography :,a randomized controlled study of patient-controlled propofol sedation and that given by a nurse anesthetist .,"['Sedation', 'during', 'endoscopic', 'retrograde', 'cholangiopancreatography', ':', 'a', 'randomized', 'controlled', 'study', 'of', 'patient-controlled', 'propofol', 'sedation', 'and', 'that', 'given', 'by', 'a', 'nurse', 'anesthetist', '.']","(3, 6)","(26, 63)",-1,ss_p,25898782,Title,0,test,gold,1317.0
6160,Sedation during endoscopic retrograde cholangiopancreatography : a randomized controlled study of patient-controlled,propofol,sedation and that given by a nurse anesthetist .,"['Sedation', 'during', 'endoscopic', 'retrograde', 'cholangiopancreatography', ':', 'a', 'randomized', 'controlled', 'study', 'of', 'patient-controlled', 'propofol', 'sedation', 'and', 'that', 'given', 'by', 'a', 'nurse', 'anesthetist', '.']","(12, 13)","(116, 124)",-1,ss_i,25898782,Title,0,test,gold,4694.0
6161,Sedation during endoscopic,retrograde cholangiopancreatography :,a randomized controlled study of patient-controlled propofol sedation and that given by a nurse anesthetist .,"['Sedation', 'during', 'endoscopic', 'retrograde', 'cholangiopancreatography', ':', 'a', 'randomized', 'controlled', 'study', 'of', 'patient-controlled', 'propofol', 'sedation', 'and', 'that', 'given', 'by', 'a', 'nurse', 'anesthetist', '.']","(3, 6)","(26, 63)",-1,hl_p,25898782,Title,0,test,gold,1318.0
6162,Sedation during endoscopic retrograde cholangiopancreatography : a randomized controlled study of patient-controlled,propofol,sedation and that given by a nurse anesthetist .,"['Sedation', 'during', 'endoscopic', 'retrograde', 'cholangiopancreatography', ':', 'a', 'randomized', 'controlled', 'study', 'of', 'patient-controlled', 'propofol', 'sedation', 'and', 'that', 'given', 'by', 'a', 'nurse', 'anesthetist', '.']","(12, 13)","(116, 124)",-1,hl_i,25898782,Title,0,test,gold,4693.0
6163,OBJECTIVE Different regimens are used for sedation during endoscopic retrograde cholangiopancreatography ( ERCP ) .,,,"['OBJECTIVE', 'Different', 'regimens', 'are', 'used', 'for', 'sedation', 'during', 'endoscopic', 'retrograde', 'cholangiopancreatography', '(', 'ERCP', ')', '.']",,,,,25898782,Abstract,0,test,gold,
6164,"Our objectives were to compare safety , ease of treatment , recovery , and patients ' experiences using",patient-controlled sedation,"( PCS ) with propofol , nurse anesthetist-controlled sedation ( ACS ) , or the department 's standard of care , midazolam given by the procedure team ( control group ) .","['Our', 'objectives', 'were', 'to', 'compare', 'safety', ',', 'ease', 'of', 'treatment', ',', 'recovery', ',', 'and', 'patients', ""'"", 'experiences', 'using', 'patient-controlled', 'sedation', '(', 'PCS', ')', 'with', 'propofol', ',', 'nurse', 'anesthetist-controlled', 'sedation', '(', 'ACS', ')', ',', 'or', 'the', 'department', ""'s"", 'standard', 'of', 'care', ',', 'midazolam', 'given', 'by', 'the', 'procedure', 'team', '(', 'control', 'group', ')', '.']","(18, 20)","(103, 130)",-1,ss_i,25898782,Abstract,1,test,gold,4123.0
6165,"Our objectives were to compare safety , ease of treatment , recovery , and patients ' experiences using patient-controlled sedation ( PCS ) with",propofol,", nurse anesthetist-controlled sedation ( ACS ) , or the department 's standard of care , midazolam given by the procedure team ( control group ) .","['Our', 'objectives', 'were', 'to', 'compare', 'safety', ',', 'ease', 'of', 'treatment', ',', 'recovery', ',', 'and', 'patients', ""'"", 'experiences', 'using', 'patient-controlled', 'sedation', '(', 'PCS', ')', 'with', 'propofol', ',', 'nurse', 'anesthetist-controlled', 'sedation', '(', 'ACS', ')', ',', 'or', 'the', 'department', ""'s"", 'standard', 'of', 'care', ',', 'midazolam', 'given', 'by', 'the', 'procedure', 'team', '(', 'control', 'group', ')', '.']","(24, 25)","(144, 152)",-1,ss_i,25898782,Abstract,1,test,gold,4692.0
6166,"Our objectives were to compare safety , ease of treatment , recovery , and patients ' experiences using patient-controlled sedation ( PCS ) with propofol , nurse",anesthetist-controlled sedation,"( ACS ) , or the department 's standard of care , midazolam given by the procedure team ( control group ) .","['Our', 'objectives', 'were', 'to', 'compare', 'safety', ',', 'ease', 'of', 'treatment', ',', 'recovery', ',', 'and', 'patients', ""'"", 'experiences', 'using', 'patient-controlled', 'sedation', '(', 'PCS', ')', 'with', 'propofol', ',', 'nurse', 'anesthetist-controlled', 'sedation', '(', 'ACS', ')', ',', 'or', 'the', 'department', ""'s"", 'standard', 'of', 'care', ',', 'midazolam', 'given', 'by', 'the', 'procedure', 'team', '(', 'control', 'group', ')', '.']","(27, 29)","(161, 192)",-1,ss_i,25898782,Abstract,1,test,gold,4121.0
6167,"Our objectives were to compare safety , ease of treatment , recovery , and patients ' experiences using patient-controlled sedation ( PCS ) with propofol , nurse anesthetist-controlled sedation ( ACS ) , or the department 's","standard of care , midazolam",given by the procedure team ( control group ) .,"['Our', 'objectives', 'were', 'to', 'compare', 'safety', ',', 'ease', 'of', 'treatment', ',', 'recovery', ',', 'and', 'patients', ""'"", 'experiences', 'using', 'patient-controlled', 'sedation', '(', 'PCS', ')', 'with', 'propofol', ',', 'nurse', 'anesthetist-controlled', 'sedation', '(', 'ACS', ')', ',', 'or', 'the', 'department', ""'s"", 'standard', 'of', 'care', ',', 'midazolam', 'given', 'by', 'the', 'procedure', 'team', '(', 'control', 'group', ')', '.']","(37, 42)","(224, 252)",-1,ss_i,25898782,Abstract,1,test,gold,4964.0
6168,Our objectives were to compare,"safety , ease of treatment , recovery , and patients ' experiences","using patient-controlled sedation ( PCS ) with propofol , nurse anesthetist-controlled sedation ( ACS ) , or the department 's standard of care , midazolam given by the procedure team ( control group ) .","['Our', 'objectives', 'were', 'to', 'compare', 'safety', ',', 'ease', 'of', 'treatment', ',', 'recovery', ',', 'and', 'patients', ""'"", 'experiences', 'using', 'patient-controlled', 'sedation', '(', 'PCS', ')', 'with', 'propofol', ',', 'nurse', 'anesthetist-controlled', 'sedation', '(', 'ACS', ')', ',', 'or', 'the', 'department', ""'s"", 'standard', 'of', 'care', ',', 'midazolam', 'given', 'by', 'the', 'procedure', 'team', '(', 'control', 'group', ')', '.']","(5, 17)","(30, 96)",-1,ss_o,25898782,Abstract,1,test,gold,3886.0
6169,"Our objectives were to compare safety , ease of treatment , recovery , and patients ' experiences using",patient-controlled sedation,"( PCS ) with propofol , nurse anesthetist-controlled sedation ( ACS ) , or the department 's standard of care , midazolam given by the procedure team ( control group ) .","['Our', 'objectives', 'were', 'to', 'compare', 'safety', ',', 'ease', 'of', 'treatment', ',', 'recovery', ',', 'and', 'patients', ""'"", 'experiences', 'using', 'patient-controlled', 'sedation', '(', 'PCS', ')', 'with', 'propofol', ',', 'nurse', 'anesthetist-controlled', 'sedation', '(', 'ACS', ')', ',', 'or', 'the', 'department', ""'s"", 'standard', 'of', 'care', ',', 'midazolam', 'given', 'by', 'the', 'procedure', 'team', '(', 'control', 'group', ')', '.']","(18, 20)","(103, 130)",-1,hl_i,25898782,Abstract,1,test,gold,4120.0
6170,"Our objectives were to compare safety , ease of treatment , recovery , and patients ' experiences using patient-controlled sedation ( PCS ) with",propofol,", nurse anesthetist-controlled sedation ( ACS ) , or the department 's standard of care , midazolam given by the procedure team ( control group ) .","['Our', 'objectives', 'were', 'to', 'compare', 'safety', ',', 'ease', 'of', 'treatment', ',', 'recovery', ',', 'and', 'patients', ""'"", 'experiences', 'using', 'patient-controlled', 'sedation', '(', 'PCS', ')', 'with', 'propofol', ',', 'nurse', 'anesthetist-controlled', 'sedation', '(', 'ACS', ')', ',', 'or', 'the', 'department', ""'s"", 'standard', 'of', 'care', ',', 'midazolam', 'given', 'by', 'the', 'procedure', 'team', '(', 'control', 'group', ')', '.']","(24, 25)","(144, 152)",-1,hl_i,25898782,Abstract,1,test,gold,4691.0
6171,"Our objectives were to compare safety , ease of treatment , recovery , and patients ' experiences using patient-controlled sedation ( PCS ) with propofol , nurse",anesthetist-controlled sedation,"( ACS ) , or the department 's standard of care , midazolam given by the procedure team ( control group ) .","['Our', 'objectives', 'were', 'to', 'compare', 'safety', ',', 'ease', 'of', 'treatment', ',', 'recovery', ',', 'and', 'patients', ""'"", 'experiences', 'using', 'patient-controlled', 'sedation', '(', 'PCS', ')', 'with', 'propofol', ',', 'nurse', 'anesthetist-controlled', 'sedation', '(', 'ACS', ')', ',', 'or', 'the', 'department', ""'s"", 'standard', 'of', 'care', ',', 'midazolam', 'given', 'by', 'the', 'procedure', 'team', '(', 'control', 'group', ')', '.']","(27, 29)","(161, 192)",-1,hl_i,25898782,Abstract,1,test,gold,4119.0
6172,"Our objectives were to compare safety , ease of treatment , recovery , and patients ' experiences using patient-controlled sedation ( PCS ) with propofol , nurse anesthetist-controlled sedation ( ACS ) , or the department 's","standard of care , midazolam",given by the procedure team ( control group ) .,"['Our', 'objectives', 'were', 'to', 'compare', 'safety', ',', 'ease', 'of', 'treatment', ',', 'recovery', ',', 'and', 'patients', ""'"", 'experiences', 'using', 'patient-controlled', 'sedation', '(', 'PCS', ')', 'with', 'propofol', ',', 'nurse', 'anesthetist-controlled', 'sedation', '(', 'ACS', ')', ',', 'or', 'the', 'department', ""'s"", 'standard', 'of', 'care', ',', 'midazolam', 'given', 'by', 'the', 'procedure', 'team', '(', 'control', 'group', ')', '.']","(37, 42)","(224, 252)",-1,hl_i,25898782,Abstract,1,test,gold,4965.0
6173,Our objectives were to compare,safety,", ease of treatment , recovery , and patients ' experiences using patient-controlled sedation ( PCS ) with propofol , nurse anesthetist-controlled sedation ( ACS ) , or the department 's standard of care , midazolam given by the procedure team ( control group ) .","['Our', 'objectives', 'were', 'to', 'compare', 'safety', ',', 'ease', 'of', 'treatment', ',', 'recovery', ',', 'and', 'patients', ""'"", 'experiences', 'using', 'patient-controlled', 'sedation', '(', 'PCS', ')', 'with', 'propofol', ',', 'nurse', 'anesthetist-controlled', 'sedation', '(', 'ACS', ')', ',', 'or', 'the', 'department', ""'s"", 'standard', 'of', 'care', ',', 'midazolam', 'given', 'by', 'the', 'procedure', 'team', '(', 'control', 'group', ')', '.']","(5, 6)","(30, 36)",-1,hl_o,25898782,Abstract,1,test,gold,457.0
6174,"Our objectives were to compare safety ,",ease of treatment,", recovery , and patients ' experiences using patient-controlled sedation ( PCS ) with propofol , nurse anesthetist-controlled sedation ( ACS ) , or the department 's standard of care , midazolam given by the procedure team ( control group ) .","['Our', 'objectives', 'were', 'to', 'compare', 'safety', ',', 'ease', 'of', 'treatment', ',', 'recovery', ',', 'and', 'patients', ""'"", 'experiences', 'using', 'patient-controlled', 'sedation', '(', 'PCS', ')', 'with', 'propofol', ',', 'nurse', 'anesthetist-controlled', 'sedation', '(', 'ACS', ')', ',', 'or', 'the', 'department', ""'s"", 'standard', 'of', 'care', ',', 'midazolam', 'given', 'by', 'the', 'procedure', 'team', '(', 'control', 'group', ')', '.']","(7, 10)","(39, 56)",-1,hl_o,25898782,Abstract,1,test,gold,3989.0
6175,"Our objectives were to compare safety , ease of treatment ,",recovery,", and patients ' experiences using patient-controlled sedation ( PCS ) with propofol , nurse anesthetist-controlled sedation ( ACS ) , or the department 's standard of care , midazolam given by the procedure team ( control group ) .","['Our', 'objectives', 'were', 'to', 'compare', 'safety', ',', 'ease', 'of', 'treatment', ',', 'recovery', ',', 'and', 'patients', ""'"", 'experiences', 'using', 'patient-controlled', 'sedation', '(', 'PCS', ')', 'with', 'propofol', ',', 'nurse', 'anesthetist-controlled', 'sedation', '(', 'ACS', ')', ',', 'or', 'the', 'department', ""'s"", 'standard', 'of', 'care', ',', 'midazolam', 'given', 'by', 'the', 'procedure', 'team', '(', 'control', 'group', ')', '.']","(11, 12)","(59, 67)",-1,hl_o,25898782,Abstract,1,test,gold,945.0
6176,"Our objectives were to compare safety , ease of treatment , recovery , and",patients ' experiences,"using patient-controlled sedation ( PCS ) with propofol , nurse anesthetist-controlled sedation ( ACS ) , or the department 's standard of care , midazolam given by the procedure team ( control group ) .","['Our', 'objectives', 'were', 'to', 'compare', 'safety', ',', 'ease', 'of', 'treatment', ',', 'recovery', ',', 'and', 'patients', ""'"", 'experiences', 'using', 'patient-controlled', 'sedation', '(', 'PCS', ')', 'with', 'propofol', ',', 'nurse', 'anesthetist-controlled', 'sedation', '(', 'ACS', ')', ',', 'or', 'the', 'department', ""'s"", 'standard', 'of', 'care', ',', 'midazolam', 'given', 'by', 'the', 'procedure', 'team', '(', 'control', 'group', ')', '.']","(14, 17)","(74, 96)",-1,hl_o,25898782,Abstract,1,test,gold,3733.0
6177,MATERIAL AND METHODS The,study included 281 adults in 301 procedures .,,"['MATERIAL', 'AND', 'METHODS', 'The', 'study', 'included', '281', 'adults', 'in', '301', 'procedures', '.']","(4, 12)","(24, 69)",-1,ss_p,25898782,Abstract,2,test,gold,2093.0
6178,MATERIAL AND METHODS The study included,281 adults,in 301 procedures .,"['MATERIAL', 'AND', 'METHODS', 'The', 'study', 'included', '281', 'adults', 'in', '301', 'procedures', '.']","(6, 8)","(39, 49)",-1,hl_p,25898782,Abstract,2,test,gold,2161.0
6179,The PCS group ( n = 101 ) delivered bolus doses of 5 mg of,propofol,according to their need for sedation .,"['The', 'PCS', 'group', '(', 'n', '=', '101', ')', 'delivered', 'bolus', 'doses', 'of', '5', 'mg', 'of', 'propofol', 'according', 'to', 'their', 'need', 'for', 'sedation', '.']","(15, 16)","(58, 66)",-1,ss_i,25898782,Abstract,3,test,gold,4690.0
6180,The PCS group ( n = 101 ) delivered bolus doses of 5 mg of,propofol,according to their need for sedation .,"['The', 'PCS', 'group', '(', 'n', '=', '101', ')', 'delivered', 'bolus', 'doses', 'of', '5', 'mg', 'of', 'propofol', 'according', 'to', 'their', 'need', 'for', 'sedation', '.']","(15, 16)","(58, 66)",-1,hl_i,25898782,Abstract,3,test,gold,4689.0
6181,The ACS group ( n = 100 ) had 2-8 mg/kg/h of,propofol,"infused , with the target for sedation being level 3 of the Observer 's Assessment of Alertness/Sedation ( OAA/S ) scale .","['The', 'ACS', 'group', '(', 'n', '=', '100', ')', 'had', '2-8', 'mg/kg/h', 'of', 'propofol', 'infused', ',', 'with', 'the', 'target', 'for', 'sedation', 'being', 'level', '3', 'of', 'the', 'Observer', ""'s"", 'Assessment', 'of', 'Alertness/Sedation', '(', 'OAA/S', ')', 'scale', '.']","(12, 13)","(44, 52)",-1,ss_i,25898782,Abstract,4,test,gold,4688.0
6182,"The ACS group ( n = 100 ) had 2-8 mg/kg/h of propofol infused , with the target for sedation being level 3 of the",Observer 's Assessment of Alertness/Sedation ( OAA/S ) scale .,,"['The', 'ACS', 'group', '(', 'n', '=', '100', ')', 'had', '2-8', 'mg/kg/h', 'of', 'propofol', 'infused', ',', 'with', 'the', 'target', 'for', 'sedation', 'being', 'level', '3', 'of', 'the', 'Observer', ""'s"", 'Assessment', 'of', 'Alertness/Sedation', '(', 'OAA/S', ')', 'scale', '.']","(25, 35)","(113, 175)",-1,ss_o,25898782,Abstract,4,test,gold,1368.0
6183,The ACS group ( n = 100 ) had 2-8 mg/kg/h of,propofol,"infused , with the target for sedation being level 3 of the Observer 's Assessment of Alertness/Sedation ( OAA/S ) scale .","['The', 'ACS', 'group', '(', 'n', '=', '100', ')', 'had', '2-8', 'mg/kg/h', 'of', 'propofol', 'infused', ',', 'with', 'the', 'target', 'for', 'sedation', 'being', 'level', '3', 'of', 'the', 'Observer', ""'s"", 'Assessment', 'of', 'Alertness/Sedation', '(', 'OAA/S', ')', 'scale', '.']","(12, 13)","(44, 52)",-1,hl_i,25898782,Abstract,4,test,gold,4687.0
6184,The control group was given 2-3 mg of,midazolam,for induction and additional 1 mg if required .,"['The', 'control', 'group', 'was', 'given', '2-3', 'mg', 'of', 'midazolam', 'for', 'induction', 'and', 'additional', '1', 'mg', 'if', 'required', '.']","(8, 9)","(37, 46)",-1,ss_i,25898782,Abstract,5,test,gold,4959.0
6185,The control group was given 2-3 mg of,midazolam,for induction and additional 1 mg if required .,"['The', 'control', 'group', 'was', 'given', '2-3', 'mg', 'of', 'midazolam', 'for', 'induction', 'and', 'additional', '1', 'mg', 'if', 'required', '.']","(8, 9)","(37, 46)",-1,hl_i,25898782,Abstract,5,test,gold,4958.0
6186,RESULTS PCS and ACS increased the ease of the procedure and reduced the number of sedation failures compared to,midazolam,sedation ( ACS n = 0 ; PCS n = 4 ; midazolam n = 20 ) .,"['RESULTS', 'PCS', 'and', 'ACS', 'increased', 'the', 'ease', 'of', 'the', 'procedure', 'and', 'reduced', 'the', 'number', 'of', 'sedation', 'failures', 'compared', 'to', 'midazolam', 'sedation', '(', 'ACS', 'n', '=', '0', ';', 'PCS', 'n', '=', '4', ';', 'midazolam', 'n', '=', '20', ')', '.']","(19, 20)","(111, 120)",-1,ss_i,25898782,Abstract,6,test,gold,4957.0
6187,RESULTS PCS and ACS increased the ease of the procedure and reduced the number of sedation failures compared to midazolam sedation ( ACS n = 0 ; PCS n = 4 ;,midazolam,n = 20 ) .,"['RESULTS', 'PCS', 'and', 'ACS', 'increased', 'the', 'ease', 'of', 'the', 'procedure', 'and', 'reduced', 'the', 'number', 'of', 'sedation', 'failures', 'compared', 'to', 'midazolam', 'sedation', '(', 'ACS', 'n', '=', '0', ';', 'PCS', 'n', '=', '4', ';', 'midazolam', 'n', '=', '20', ')', '.']","(32, 33)","(156, 165)",-1,ss_i,25898782,Abstract,6,test,gold,4956.0
6188,RESULTS PCS and ACS increased the,ease of the procedure,and reduced the number of sedation failures compared to midazolam sedation ( ACS n = 0 ; PCS n = 4 ; midazolam n = 20 ) .,"['RESULTS', 'PCS', 'and', 'ACS', 'increased', 'the', 'ease', 'of', 'the', 'procedure', 'and', 'reduced', 'the', 'number', 'of', 'sedation', 'failures', 'compared', 'to', 'midazolam', 'sedation', '(', 'ACS', 'n', '=', '0', ';', 'PCS', 'n', '=', '4', ';', 'midazolam', 'n', '=', '20', ')', '.']","(6, 10)","(33, 54)",-1,ss_o,25898782,Abstract,6,test,gold,4165.0
6189,RESULTS PCS and ACS increased the ease of the procedure and reduced the,number of sedation failures,compared to midazolam sedation ( ACS n = 0 ; PCS n = 4 ; midazolam n = 20 ) .,"['RESULTS', 'PCS', 'and', 'ACS', 'increased', 'the', 'ease', 'of', 'the', 'procedure', 'and', 'reduced', 'the', 'number', 'of', 'sedation', 'failures', 'compared', 'to', 'midazolam', 'sedation', '(', 'ACS', 'n', '=', '0', ';', 'PCS', 'n', '=', '4', ';', 'midazolam', 'n', '=', '20', ')', '.']","(13, 17)","(71, 98)",-1,ss_o,25898782,Abstract,6,test,gold,4124.0
6190,RESULTS PCS and ACS increased the ease of the procedure and reduced the number of sedation failures compared to,midazolam,sedation ( ACS n = 0 ; PCS n = 4 ; midazolam n = 20 ) .,"['RESULTS', 'PCS', 'and', 'ACS', 'increased', 'the', 'ease', 'of', 'the', 'procedure', 'and', 'reduced', 'the', 'number', 'of', 'sedation', 'failures', 'compared', 'to', 'midazolam', 'sedation', '(', 'ACS', 'n', '=', '0', ';', 'PCS', 'n', '=', '4', ';', 'midazolam', 'n', '=', '20', ')', '.']","(19, 20)","(111, 120)",-1,hl_i,25898782,Abstract,6,test,gold,4955.0
6191,RESULTS PCS and ACS increased the ease of the procedure and reduced the number of sedation failures compared to midazolam sedation ( ACS n = 0 ; PCS n = 4 ;,midazolam,n = 20 ) .,"['RESULTS', 'PCS', 'and', 'ACS', 'increased', 'the', 'ease', 'of', 'the', 'procedure', 'and', 'reduced', 'the', 'number', 'of', 'sedation', 'failures', 'compared', 'to', 'midazolam', 'sedation', '(', 'ACS', 'n', '=', '0', ';', 'PCS', 'n', '=', '4', ';', 'midazolam', 'n', '=', '20', ')', '.']","(32, 33)","(156, 165)",-1,hl_i,25898782,Abstract,6,test,gold,4954.0
6192,RESULTS PCS and ACS increased the,ease of the procedure,and reduced the number of sedation failures compared to midazolam sedation ( ACS n = 0 ; PCS n = 4 ; midazolam n = 20 ) .,"['RESULTS', 'PCS', 'and', 'ACS', 'increased', 'the', 'ease', 'of', 'the', 'procedure', 'and', 'reduced', 'the', 'number', 'of', 'sedation', 'failures', 'compared', 'to', 'midazolam', 'sedation', '(', 'ACS', 'n', '=', '0', ';', 'PCS', 'n', '=', '4', ';', 'midazolam', 'n', '=', '20', ')', '.']","(6, 10)","(33, 54)",-1,hl_o,25898782,Abstract,6,test,gold,4166.0
6193,RESULTS PCS and ACS increased the ease of the procedure and reduced the,number of sedation failures,compared to midazolam sedation ( ACS n = 0 ; PCS n = 4 ; midazolam n = 20 ) .,"['RESULTS', 'PCS', 'and', 'ACS', 'increased', 'the', 'ease', 'of', 'the', 'procedure', 'and', 'reduced', 'the', 'number', 'of', 'sedation', 'failures', 'compared', 'to', 'midazolam', 'sedation', '(', 'ACS', 'n', '=', '0', ';', 'PCS', 'n', '=', '4', ';', 'midazolam', 'n', '=', '20', ')', '.']","(13, 17)","(71, 98)",-1,hl_o,25898782,Abstract,6,test,gold,4125.0
6194,"The ACS group had more deeply sedated patients ( OAA/S level 2 ) , desaturation , and obstructed airways than the PCS and",midazolam,groups .,"['The', 'ACS', 'group', 'had', 'more', 'deeply', 'sedated', 'patients', '(', 'OAA/S', 'level', '2', ')', ',', 'desaturation', ',', 'and', 'obstructed', 'airways', 'than', 'the', 'PCS', 'and', 'midazolam', 'groups', '.']","(23, 24)","(121, 130)",-1,ss_i,25898782,Abstract,7,test,gold,4953.0
6195,"The ACS group had more deeply sedated patients ( OAA/S level 2 ) , desaturation , and obstructed airways than the PCS and",midazolam,groups .,"['The', 'ACS', 'group', 'had', 'more', 'deeply', 'sedated', 'patients', '(', 'OAA/S', 'level', '2', ')', ',', 'desaturation', ',', 'and', 'obstructed', 'airways', 'than', 'the', 'PCS', 'and', 'midazolam', 'groups', '.']","(23, 24)","(121, 130)",-1,hl_i,25898782,Abstract,7,test,gold,4952.0
6196,,Time to full recovery ( Aldrete score,≥9 ) was shortest following PCS .,"['Time', 'to', 'full', 'recovery', '(', 'Aldrete', 'score', '≥9', ')', 'was', 'shortest', 'following', 'PCS', '.']","(0, 7)","(0, 37)",-1,ss_o,25898782,Abstract,8,test,gold,1456.0
6197,,Time to full recovery ( Aldrete score,≥9 ) was shortest following PCS .,"['Time', 'to', 'full', 'recovery', '(', 'Aldrete', 'score', '≥9', ')', 'was', 'shortest', 'following', 'PCS', '.']","(0, 7)","(0, 37)",-1,hl_o,25898782,Abstract,8,test,gold,1457.0
6198,PCS resulted in the,least fatigue and pain,after the procedure .,"['PCS', 'resulted', 'in', 'the', 'least', 'fatigue', 'and', 'pain', 'after', 'the', 'procedure', '.']","(4, 8)","(19, 41)",-1,ss_o,25898782,Abstract,9,test,gold,2701.0
6199,PCS resulted in the least fatigue and pain after the,procedure .,,"['PCS', 'resulted', 'in', 'the', 'least', 'fatigue', 'and', 'pain', 'after', 'the', 'procedure', '.']","(10, 12)","(52, 63)",-1,ss_o,25898782,Abstract,9,test,gold,4164.0
6200,,Patients ' preference,for PCS and ACS was the same .,"['Patients', ""'"", 'preference', 'for', 'PCS', 'and', 'ACS', 'was', 'the', 'same', '.']","(0, 3)","(0, 21)",-1,ss_o,25898782,Abstract,10,test,gold,3857.0
6201,CONCLUSION PCS,with propofol,is superior to midazolam and comparable to ACS .,"['CONCLUSION', 'PCS', 'with', 'propofol', 'is', 'superior', 'to', 'midazolam', 'and', 'comparable', 'to', 'ACS', '.']","(2, 4)","(14, 27)",-1,ss_i,25898782,Abstract,11,test,gold,4685.0
6202,CONCLUSION PCS with propofol is superior,to midazolam,and comparable to ACS .,"['CONCLUSION', 'PCS', 'with', 'propofol', 'is', 'superior', 'to', 'midazolam', 'and', 'comparable', 'to', 'ACS', '.']","(6, 8)","(40, 52)",-1,ss_i,25898782,Abstract,11,test,gold,4951.0
6203,CONCLUSION PCS with,propofol,is superior to midazolam and comparable to ACS .,"['CONCLUSION', 'PCS', 'with', 'propofol', 'is', 'superior', 'to', 'midazolam', 'and', 'comparable', 'to', 'ACS', '.']","(3, 4)","(19, 27)",-1,hl_i,25898782,Abstract,11,test,gold,4686.0
6204,CONCLUSION PCS with propofol is superior to,midazolam,and comparable to ACS .,"['CONCLUSION', 'PCS', 'with', 'propofol', 'is', 'superior', 'to', 'midazolam', 'and', 'comparable', 'to', 'ACS', '.']","(7, 8)","(43, 52)",-1,hl_i,25898782,Abstract,11,test,gold,4950.0
6205,PCS resulted in,"a rapid recovery , fewer respiratory events",", and was almost as effective as ACS in ensuring a successful examination .","['PCS', 'resulted', 'in', 'a', 'rapid', 'recovery', ',', 'fewer', 'respiratory', 'events', ',', 'and', 'was', 'almost', 'as', 'effective', 'as', 'ACS', 'in', 'ensuring', 'a', 'successful', 'examination', '.']","(3, 10)","(15, 58)",-1,ss_o,25898782,Abstract,12,test,gold,941.0
6206,"PCS resulted in a rapid recovery , fewer respiratory events , and was almost",as effective,as ACS in ensuring a successful examination .,"['PCS', 'resulted', 'in', 'a', 'rapid', 'recovery', ',', 'fewer', 'respiratory', 'events', ',', 'and', 'was', 'almost', 'as', 'effective', 'as', 'ACS', 'in', 'ensuring', 'a', 'successful', 'examination', '.']","(14, 16)","(76, 88)",-1,ss_o,25898782,Abstract,12,test,gold,837.0
6207,Sensory Adapted Dental Environments to Enhance Oral Care for,Children with Autism Spectrum Disorders :,A Randomized Controlled Pilot Study .,"['Sensory', 'Adapted', 'Dental', 'Environments', 'to', 'Enhance', 'Oral', 'Care', 'for', 'Children', 'with', 'Autism', 'Spectrum', 'Disorders', ':', 'A', 'Randomized', 'Controlled', 'Pilot', 'Study', '.']","(9, 15)","(60, 101)",-1,ss_p,25931290,Title,0,test,gold,6256.0
6208,,Sensory Adapted Dental Environments,to Enhance Oral Care for Children with Autism Spectrum Disorders : A Randomized Controlled Pilot Study .,"['Sensory', 'Adapted', 'Dental', 'Environments', 'to', 'Enhance', 'Oral', 'Care', 'for', 'Children', 'with', 'Autism', 'Spectrum', 'Disorders', ':', 'A', 'Randomized', 'Controlled', 'Pilot', 'Study', '.']","(0, 4)","(0, 35)",-1,ss_i,25931290,Title,0,test,gold,6252.0
6209,Sensory Adapted Dental Environments to Enhance Oral Care for,Children,with Autism Spectrum Disorders : A Randomized Controlled Pilot Study .,"['Sensory', 'Adapted', 'Dental', 'Environments', 'to', 'Enhance', 'Oral', 'Care', 'for', 'Children', 'with', 'Autism', 'Spectrum', 'Disorders', ':', 'A', 'Randomized', 'Controlled', 'Pilot', 'Study', '.']","(9, 10)","(60, 68)",-1,hl_p,25931290,Title,0,test,gold,2174.0
6210,Sensory Adapted Dental Environments to Enhance Oral Care for Children with,Autism Spectrum Disorders,: A Randomized Controlled Pilot Study .,"['Sensory', 'Adapted', 'Dental', 'Environments', 'to', 'Enhance', 'Oral', 'Care', 'for', 'Children', 'with', 'Autism', 'Spectrum', 'Disorders', ':', 'A', 'Randomized', 'Controlled', 'Pilot', 'Study', '.']","(11, 14)","(74, 99)",-1,hl_p,25931290,Title,0,test,gold,6254.0
6211,,Sensory Adapted Dental Environments,to Enhance Oral Care for Children with Autism Spectrum Disorders : A Randomized Controlled Pilot Study .,"['Sensory', 'Adapted', 'Dental', 'Environments', 'to', 'Enhance', 'Oral', 'Care', 'for', 'Children', 'with', 'Autism', 'Spectrum', 'Disorders', ':', 'A', 'Randomized', 'Controlled', 'Pilot', 'Study', '.']","(0, 4)","(0, 35)",-1,hl_i,25931290,Title,0,test,gold,6253.0
6212,"This pilot and feasibility study examined the impact of a sensory adapted dental environment ( SADE ) to reduce distress , sensory discomfort , and perception of pain during oral prophylaxis for",children with autism spectrum disorder ( ASD ) .,,"['This', 'pilot', 'and', 'feasibility', 'study', 'examined', 'the', 'impact', 'of', 'a', 'sensory', 'adapted', 'dental', 'environment', '(', 'SADE', ')', 'to', 'reduce', 'distress', ',', 'sensory', 'discomfort', ',', 'and', 'perception', 'of', 'pain', 'during', 'oral', 'prophylaxis', 'for', 'children', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', '.']","(32, 41)","(194, 242)",-1,ss_p,25931290,Abstract,0,test,gold,6053.0
6213,This pilot and feasibility study examined the impact of a,sensory adapted dental environment ( SADE ),"to reduce distress , sensory discomfort , and perception of pain during oral prophylaxis for children with autism spectrum disorder ( ASD ) .","['This', 'pilot', 'and', 'feasibility', 'study', 'examined', 'the', 'impact', 'of', 'a', 'sensory', 'adapted', 'dental', 'environment', '(', 'SADE', ')', 'to', 'reduce', 'distress', ',', 'sensory', 'discomfort', ',', 'and', 'perception', 'of', 'pain', 'during', 'oral', 'prophylaxis', 'for', 'children', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', '.']","(10, 17)","(57, 100)",-1,ss_i,25931290,Abstract,0,test,gold,4090.0
6214,This pilot and feasibility study examined the impact of a sensory adapted dental environment ( SADE ) to reduce,"distress , sensory discomfort , and perception of pain",during oral prophylaxis for children with autism spectrum disorder ( ASD ) .,"['This', 'pilot', 'and', 'feasibility', 'study', 'examined', 'the', 'impact', 'of', 'a', 'sensory', 'adapted', 'dental', 'environment', '(', 'SADE', ')', 'to', 'reduce', 'distress', ',', 'sensory', 'discomfort', ',', 'and', 'perception', 'of', 'pain', 'during', 'oral', 'prophylaxis', 'for', 'children', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', '.']","(19, 28)","(111, 165)",-1,ss_o,25931290,Abstract,0,test,gold,2275.0
6215,"This pilot and feasibility study examined the impact of a sensory adapted dental environment ( SADE ) to reduce distress , sensory discomfort , and perception of pain during oral prophylaxis for",children,with autism spectrum disorder ( ASD ) .,"['This', 'pilot', 'and', 'feasibility', 'study', 'examined', 'the', 'impact', 'of', 'a', 'sensory', 'adapted', 'dental', 'environment', '(', 'SADE', ')', 'to', 'reduce', 'distress', ',', 'sensory', 'discomfort', ',', 'and', 'perception', 'of', 'pain', 'during', 'oral', 'prophylaxis', 'for', 'children', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', '.']","(32, 33)","(194, 202)",-1,hl_p,25931290,Abstract,0,test,gold,2113.0
6216,"This pilot and feasibility study examined the impact of a sensory adapted dental environment ( SADE ) to reduce distress , sensory discomfort , and perception of pain during oral prophylaxis for children with",autism spectrum disorder ( ASD ),.,"['This', 'pilot', 'and', 'feasibility', 'study', 'examined', 'the', 'impact', 'of', 'a', 'sensory', 'adapted', 'dental', 'environment', '(', 'SADE', ')', 'to', 'reduce', 'distress', ',', 'sensory', 'discomfort', ',', 'and', 'perception', 'of', 'pain', 'during', 'oral', 'prophylaxis', 'for', 'children', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', '.']","(34, 40)","(208, 240)",-1,hl_p,25931290,Abstract,0,test,gold,6042.0
6217,This pilot and feasibility study examined the impact of a,sensory adapted dental environment ( SADE ),"to reduce distress , sensory discomfort , and perception of pain during oral prophylaxis for children with autism spectrum disorder ( ASD ) .","['This', 'pilot', 'and', 'feasibility', 'study', 'examined', 'the', 'impact', 'of', 'a', 'sensory', 'adapted', 'dental', 'environment', '(', 'SADE', ')', 'to', 'reduce', 'distress', ',', 'sensory', 'discomfort', ',', 'and', 'perception', 'of', 'pain', 'during', 'oral', 'prophylaxis', 'for', 'children', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', '.']","(10, 17)","(57, 100)",-1,hl_i,25931290,Abstract,0,test,gold,4091.0
6218,This pilot and feasibility study examined the impact of a sensory adapted dental environment ( SADE ) to reduce,distress,", sensory discomfort , and perception of pain during oral prophylaxis for children with autism spectrum disorder ( ASD ) .","['This', 'pilot', 'and', 'feasibility', 'study', 'examined', 'the', 'impact', 'of', 'a', 'sensory', 'adapted', 'dental', 'environment', '(', 'SADE', ')', 'to', 'reduce', 'distress', ',', 'sensory', 'discomfort', ',', 'and', 'perception', 'of', 'pain', 'during', 'oral', 'prophylaxis', 'for', 'children', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', '.']","(19, 20)","(111, 119)",-1,hl_o,25931290,Abstract,0,test,gold,2596.0
6219,"This pilot and feasibility study examined the impact of a sensory adapted dental environment ( SADE ) to reduce distress ,",sensory discomfort,", and perception of pain during oral prophylaxis for children with autism spectrum disorder ( ASD ) .","['This', 'pilot', 'and', 'feasibility', 'study', 'examined', 'the', 'impact', 'of', 'a', 'sensory', 'adapted', 'dental', 'environment', '(', 'SADE', ')', 'to', 'reduce', 'distress', ',', 'sensory', 'discomfort', ',', 'and', 'perception', 'of', 'pain', 'during', 'oral', 'prophylaxis', 'for', 'children', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', '.']","(21, 23)","(122, 140)",-1,hl_o,25931290,Abstract,0,test,gold,2270.0
6220,"This pilot and feasibility study examined the impact of a sensory adapted dental environment ( SADE ) to reduce distress , sensory discomfort , and",perception of pain,during oral prophylaxis for children with autism spectrum disorder ( ASD ) .,"['This', 'pilot', 'and', 'feasibility', 'study', 'examined', 'the', 'impact', 'of', 'a', 'sensory', 'adapted', 'dental', 'environment', '(', 'SADE', ')', 'to', 'reduce', 'distress', ',', 'sensory', 'discomfort', ',', 'and', 'perception', 'of', 'pain', 'during', 'oral', 'prophylaxis', 'for', 'children', 'with', 'autism', 'spectrum', 'disorder', '(', 'ASD', ')', '.']","(25, 28)","(147, 165)",-1,hl_o,25931290,Abstract,0,test,gold,2282.0
6221,,"Participants were 44 children ages 6-12 ( n = 22 typical , n = 22 ASD ) .",,"['Participants', 'were', '44', 'children', 'ages', '6-12', '(', 'n', '=', '22', 'typical', ',', 'n', '=', '22', 'ASD', ')', '.']","(0, 18)","(0, 73)",-1,ss_p,25931290,Abstract,1,test,gold,6458.0
6222,Participants were,44 children ages 6-12,"( n = 22 typical , n = 22 ASD ) .","['Participants', 'were', '44', 'children', 'ages', '6-12', '(', 'n', '=', '22', 'typical', ',', 'n', '=', '22', 'ASD', ')', '.']","(2, 6)","(17, 38)",-1,hl_p,25931290,Abstract,1,test,gold,2156.0
6223,Participants were 44 children ages 6-12 (,"n = 22 typical , n = 22 ASD",) .,"['Participants', 'were', '44', 'children', 'ages', '6-12', '(', 'n', '=', '22', 'typical', ',', 'n', '=', '22', 'ASD', ')', '.']","(7, 16)","(41, 68)",-1,hl_p,25931290,Abstract,1,test,gold,6460.0
6224,"In an experimental crossover design , each participant underwent two professional dental cleanings , one in a",regular dental environment ( RDE ),"and one in a SADE , administered in a randomized and counterbalanced order 3-4 months apart .","['In', 'an', 'experimental', 'crossover', 'design', ',', 'each', 'participant', 'underwent', 'two', 'professional', 'dental', 'cleanings', ',', 'one', 'in', 'a', 'regular', 'dental', 'environment', '(', 'RDE', ')', 'and', 'one', 'in', 'a', 'SADE', ',', 'administered', 'in', 'a', 'randomized', 'and', 'counterbalanced', 'order', '3-4', 'months', 'apart', '.']","(17, 23)","(109, 143)",-1,ss_i,25931290,Abstract,2,test,gold,4088.0
6225,"In an experimental crossover design , each participant underwent two professional dental cleanings , one in a regular dental environment ( RDE ) and one in a",SADE,", administered in a randomized and counterbalanced order 3-4 months apart .","['In', 'an', 'experimental', 'crossover', 'design', ',', 'each', 'participant', 'underwent', 'two', 'professional', 'dental', 'cleanings', ',', 'one', 'in', 'a', 'regular', 'dental', 'environment', '(', 'RDE', ')', 'and', 'one', 'in', 'a', 'SADE', ',', 'administered', 'in', 'a', 'randomized', 'and', 'counterbalanced', 'order', '3-4', 'months', 'apart', '.']","(27, 28)","(157, 161)",-1,ss_i,25931290,Abstract,2,test,gold,1073.0
6226,"In an experimental crossover design , each participant underwent two professional dental cleanings , one in a",regular dental environment ( RDE ),"and one in a SADE , administered in a randomized and counterbalanced order 3-4 months apart .","['In', 'an', 'experimental', 'crossover', 'design', ',', 'each', 'participant', 'underwent', 'two', 'professional', 'dental', 'cleanings', ',', 'one', 'in', 'a', 'regular', 'dental', 'environment', '(', 'RDE', ')', 'and', 'one', 'in', 'a', 'SADE', ',', 'administered', 'in', 'a', 'randomized', 'and', 'counterbalanced', 'order', '3-4', 'months', 'apart', '.']","(17, 23)","(109, 143)",-1,hl_i,25931290,Abstract,2,test,gold,4089.0
6227,"In an experimental crossover design , each participant underwent two professional dental cleanings , one in a regular dental environment ( RDE ) and one in a",SADE,", administered in a randomized and counterbalanced order 3-4 months apart .","['In', 'an', 'experimental', 'crossover', 'design', ',', 'each', 'participant', 'underwent', 'two', 'professional', 'dental', 'cleanings', ',', 'one', 'in', 'a', 'regular', 'dental', 'environment', '(', 'RDE', ')', 'and', 'one', 'in', 'a', 'SADE', ',', 'administered', 'in', 'a', 'randomized', 'and', 'counterbalanced', 'order', '3-4', 'months', 'apart', '.']","(27, 28)","(157, 161)",-1,hl_i,25931290,Abstract,2,test,gold,1074.0
6228,Outcomes included measures of,"physiological anxiety , behavioral distress , pain intensity , and sensory discomfort .",,"['Outcomes', 'included', 'measures', 'of', 'physiological', 'anxiety', ',', 'behavioral', 'distress', ',', 'pain', 'intensity', ',', 'and', 'sensory', 'discomfort', '.']","(4, 17)","(29, 116)",-1,ss_o,25931290,Abstract,3,test,gold,7122.0
6229,Outcomes included measures of,physiological anxiety,", behavioral distress , pain intensity , and sensory discomfort .","['Outcomes', 'included', 'measures', 'of', 'physiological', 'anxiety', ',', 'behavioral', 'distress', ',', 'pain', 'intensity', ',', 'and', 'sensory', 'discomfort', '.']","(4, 6)","(29, 50)",-1,hl_o,25931290,Abstract,3,test,gold,2467.0
6230,"Outcomes included measures of physiological anxiety ,",behavioral distress,", pain intensity , and sensory discomfort .","['Outcomes', 'included', 'measures', 'of', 'physiological', 'anxiety', ',', 'behavioral', 'distress', ',', 'pain', 'intensity', ',', 'and', 'sensory', 'discomfort', '.']","(7, 9)","(53, 72)",-1,hl_o,25931290,Abstract,3,test,gold,2597.0
6231,"Outcomes included measures of physiological anxiety , behavioral distress ,",pain intensity,", and sensory discomfort .","['Outcomes', 'included', 'measures', 'of', 'physiological', 'anxiety', ',', 'behavioral', 'distress', ',', 'pain', 'intensity', ',', 'and', 'sensory', 'discomfort', '.']","(10, 12)","(75, 89)",-1,hl_o,25931290,Abstract,3,test,gold,2313.0
6232,"Outcomes included measures of physiological anxiety , behavioral distress , pain intensity , and",sensory discomfort,.,"['Outcomes', 'included', 'measures', 'of', 'physiological', 'anxiety', ',', 'behavioral', 'distress', ',', 'pain', 'intensity', ',', 'and', 'sensory', 'discomfort', '.']","(14, 16)","(96, 114)",-1,hl_o,25931290,Abstract,3,test,gold,2271.0
6233,Both groups exhibited decreased physiological anxiety and reported lower pain and sensory discomfort in the,SADE,"condition compared to RDE , indicating a beneficial effect of the SADE .","['Both', 'groups', 'exhibited', 'decreased', 'physiological', 'anxiety', 'and', 'reported', 'lower', 'pain', 'and', 'sensory', 'discomfort', 'in', 'the', 'SADE', 'condition', 'compared', 'to', 'RDE', ',', 'indicating', 'a', 'beneficial', 'effect', 'of', 'the', 'SADE', '.']","(15, 16)","(107, 111)",-1,ss_i,25931290,Abstract,4,test,gold,1072.0
6234,Both groups exhibited decreased physiological anxiety and reported lower pain and sensory discomfort in the SADE condition compared to,RDE,", indicating a beneficial effect of the SADE .","['Both', 'groups', 'exhibited', 'decreased', 'physiological', 'anxiety', 'and', 'reported', 'lower', 'pain', 'and', 'sensory', 'discomfort', 'in', 'the', 'SADE', 'condition', 'compared', 'to', 'RDE', ',', 'indicating', 'a', 'beneficial', 'effect', 'of', 'the', 'SADE', '.']","(19, 20)","(134, 137)",-1,ss_i,25931290,Abstract,4,test,gold,691.0
6235,"Both groups exhibited decreased physiological anxiety and reported lower pain and sensory discomfort in the SADE condition compared to RDE , indicating a beneficial effect of the",SADE .,,"['Both', 'groups', 'exhibited', 'decreased', 'physiological', 'anxiety', 'and', 'reported', 'lower', 'pain', 'and', 'sensory', 'discomfort', 'in', 'the', 'SADE', 'condition', 'compared', 'to', 'RDE', ',', 'indicating', 'a', 'beneficial', 'effect', 'of', 'the', 'SADE', '.']","(27, 29)","(178, 184)",-1,ss_i,25931290,Abstract,4,test,gold,1071.0
6236,Both groups exhibited decreased,physiological anxiety,"and reported lower pain and sensory discomfort in the SADE condition compared to RDE , indicating a beneficial effect of the SADE .","['Both', 'groups', 'exhibited', 'decreased', 'physiological', 'anxiety', 'and', 'reported', 'lower', 'pain', 'and', 'sensory', 'discomfort', 'in', 'the', 'SADE', 'condition', 'compared', 'to', 'RDE', ',', 'indicating', 'a', 'beneficial', 'effect', 'of', 'the', 'SADE', '.']","(4, 6)","(31, 52)",-1,ss_o,25931290,Abstract,4,test,gold,2468.0
6237,Both groups exhibited decreased physiological anxiety and reported lower,pain and sensory discomfort,"in the SADE condition compared to RDE , indicating a beneficial effect of the SADE .","['Both', 'groups', 'exhibited', 'decreased', 'physiological', 'anxiety', 'and', 'reported', 'lower', 'pain', 'and', 'sensory', 'discomfort', 'in', 'the', 'SADE', 'condition', 'compared', 'to', 'RDE', ',', 'indicating', 'a', 'beneficial', 'effect', 'of', 'the', 'SADE', '.']","(9, 13)","(72, 99)",-1,ss_o,25931290,Abstract,4,test,gold,2268.0
6238,Both groups exhibited decreased physiological anxiety and reported lower pain and sensory discomfort in the,SADE,"condition compared to RDE , indicating a beneficial effect of the SADE .","['Both', 'groups', 'exhibited', 'decreased', 'physiological', 'anxiety', 'and', 'reported', 'lower', 'pain', 'and', 'sensory', 'discomfort', 'in', 'the', 'SADE', 'condition', 'compared', 'to', 'RDE', ',', 'indicating', 'a', 'beneficial', 'effect', 'of', 'the', 'SADE', '.']","(15, 16)","(107, 111)",-1,hl_i,25931290,Abstract,4,test,gold,1070.0
6239,Both groups exhibited decreased physiological anxiety and reported lower pain and sensory discomfort in the SADE condition compared to,RDE,", indicating a beneficial effect of the SADE .","['Both', 'groups', 'exhibited', 'decreased', 'physiological', 'anxiety', 'and', 'reported', 'lower', 'pain', 'and', 'sensory', 'discomfort', 'in', 'the', 'SADE', 'condition', 'compared', 'to', 'RDE', ',', 'indicating', 'a', 'beneficial', 'effect', 'of', 'the', 'SADE', '.']","(19, 20)","(134, 137)",-1,hl_i,25931290,Abstract,4,test,gold,692.0
6240,"Both groups exhibited decreased physiological anxiety and reported lower pain and sensory discomfort in the SADE condition compared to RDE , indicating a beneficial effect of the",SADE .,,"['Both', 'groups', 'exhibited', 'decreased', 'physiological', 'anxiety', 'and', 'reported', 'lower', 'pain', 'and', 'sensory', 'discomfort', 'in', 'the', 'SADE', 'condition', 'compared', 'to', 'RDE', ',', 'indicating', 'a', 'beneficial', 'effect', 'of', 'the', 'SADE', '.']","(27, 29)","(178, 184)",-1,hl_i,25931290,Abstract,4,test,gold,1069.0
6241,Both groups exhibited decreased,physiological anxiety,"and reported lower pain and sensory discomfort in the SADE condition compared to RDE , indicating a beneficial effect of the SADE .","['Both', 'groups', 'exhibited', 'decreased', 'physiological', 'anxiety', 'and', 'reported', 'lower', 'pain', 'and', 'sensory', 'discomfort', 'in', 'the', 'SADE', 'condition', 'compared', 'to', 'RDE', ',', 'indicating', 'a', 'beneficial', 'effect', 'of', 'the', 'SADE', '.']","(4, 6)","(31, 52)",-1,hl_o,25931290,Abstract,4,test,gold,2466.0
6242,Both groups exhibited decreased physiological anxiety and reported lower,pain,"and sensory discomfort in the SADE condition compared to RDE , indicating a beneficial effect of the SADE .","['Both', 'groups', 'exhibited', 'decreased', 'physiological', 'anxiety', 'and', 'reported', 'lower', 'pain', 'and', 'sensory', 'discomfort', 'in', 'the', 'SADE', 'condition', 'compared', 'to', 'RDE', ',', 'indicating', 'a', 'beneficial', 'effect', 'of', 'the', 'SADE', '.']","(9, 10)","(72, 76)",-1,hl_o,25931290,Abstract,4,test,gold,2291.0
6243,Both groups exhibited decreased physiological anxiety and reported lower pain and,sensory discomfort,"in the SADE condition compared to RDE , indicating a beneficial effect of the SADE .","['Both', 'groups', 'exhibited', 'decreased', 'physiological', 'anxiety', 'and', 'reported', 'lower', 'pain', 'and', 'sensory', 'discomfort', 'in', 'the', 'SADE', 'condition', 'compared', 'to', 'RDE', ',', 'indicating', 'a', 'beneficial', 'effect', 'of', 'the', 'SADE', '.']","(11, 13)","(81, 99)",-1,hl_o,25931290,Abstract,4,test,gold,2269.0
6244,The effects of preoperative oral pregabalin and perioperative intravenous lidocaine infusion on postoperative morphine requirement in,patients undergoing laparatomy .,,"['The', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', 'in', 'patients', 'undergoing', 'laparatomy', '.']","(16, 20)","(133, 165)",-1,ss_p,25950425,Title,0,test,gold,3611.0
6245,The effects of preoperative oral,pregabalin,and perioperative intravenous lidocaine infusion on postoperative morphine requirement in patients undergoing laparatomy .,"['The', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', 'in', 'patients', 'undergoing', 'laparatomy', '.']","(5, 6)","(32, 42)",-1,ss_i,25950425,Title,0,test,gold,5596.0
6246,The effects of preoperative oral pregabalin and perioperative intravenous,lidocaine,infusion on postoperative morphine requirement in patients undergoing laparatomy .,"['The', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', 'in', 'patients', 'undergoing', 'laparatomy', '.']","(9, 10)","(73, 82)",-1,ss_i,25950425,Title,0,test,gold,4942.0
6247,The effects of preoperative oral pregabalin and perioperative intravenous lidocaine infusion on,postoperative morphine requirement,in patients undergoing laparatomy .,"['The', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', 'in', 'patients', 'undergoing', 'laparatomy', '.']","(12, 15)","(95, 129)",-1,ss_o,25950425,Title,0,test,gold,3535.0
6248,The effects of preoperative oral pregabalin and perioperative intravenous lidocaine infusion on postoperative morphine requirement in,patients undergoing laparatomy .,,"['The', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', 'in', 'patients', 'undergoing', 'laparatomy', '.']","(16, 20)","(133, 165)",-1,hl_p,25950425,Title,0,test,gold,3612.0
6249,The effects of preoperative oral,pregabalin,and perioperative intravenous lidocaine infusion on postoperative morphine requirement in patients undergoing laparatomy .,"['The', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', 'in', 'patients', 'undergoing', 'laparatomy', '.']","(5, 6)","(32, 42)",-1,hl_i,25950425,Title,0,test,gold,5597.0
6250,The effects of preoperative oral pregabalin and perioperative intravenous,lidocaine,infusion on postoperative morphine requirement in patients undergoing laparatomy .,"['The', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', 'in', 'patients', 'undergoing', 'laparatomy', '.']","(9, 10)","(73, 82)",-1,hl_i,25950425,Title,0,test,gold,4943.0
6251,The effects of preoperative oral pregabalin and perioperative intravenous lidocaine infusion on,postoperative morphine requirement,in patients undergoing laparatomy .,"['The', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', 'in', 'patients', 'undergoing', 'laparatomy', '.']","(12, 15)","(95, 129)",-1,hl_o,25950425,Title,0,test,gold,3536.0
6252,"OBJECTIVES To evaluate and compare the effects of preoperative oral pregabalin and perioperative intravenous lidocaine infusion on postoperative morphine requirement , adverse effects , patients ' satisfaction , mobilization , time to first defecation and time to discharge in",patients undergoing laparotomy .,,"['OBJECTIVES', 'To', 'evaluate', 'and', 'compare', 'the', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', ',', 'adverse', 'effects', ',', 'patients', ""'"", 'satisfaction', ',', 'mobilization', ',', 'time', 'to', 'first', 'defecation', 'and', 'time', 'to', 'discharge', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(39, 43)","(276, 308)",-1,ss_p,25950425,Abstract,0,test,gold,3610.0
6253,OBJECTIVES To evaluate and compare the effects of preoperative oral,pregabalin,"and perioperative intravenous lidocaine infusion on postoperative morphine requirement , adverse effects , patients ' satisfaction , mobilization , time to first defecation and time to discharge in patients undergoing laparotomy .","['OBJECTIVES', 'To', 'evaluate', 'and', 'compare', 'the', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', ',', 'adverse', 'effects', ',', 'patients', ""'"", 'satisfaction', ',', 'mobilization', ',', 'time', 'to', 'first', 'defecation', 'and', 'time', 'to', 'discharge', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(10, 11)","(67, 77)",-1,ss_i,25950425,Abstract,0,test,gold,5595.0
6254,OBJECTIVES To evaluate and compare the effects of preoperative oral pregabalin and perioperative intravenous,lidocaine,"infusion on postoperative morphine requirement , adverse effects , patients ' satisfaction , mobilization , time to first defecation and time to discharge in patients undergoing laparotomy .","['OBJECTIVES', 'To', 'evaluate', 'and', 'compare', 'the', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', ',', 'adverse', 'effects', ',', 'patients', ""'"", 'satisfaction', ',', 'mobilization', ',', 'time', 'to', 'first', 'defecation', 'and', 'time', 'to', 'discharge', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(14, 15)","(108, 117)",-1,ss_i,25950425,Abstract,0,test,gold,4941.0
6255,OBJECTIVES To evaluate and compare the effects of preoperative oral pregabalin and perioperative intravenous lidocaine infusion on,"postoperative morphine requirement , adverse effects , patients ' satisfaction , mobilization , time to first defecation and time to discharge",in patients undergoing laparotomy .,"['OBJECTIVES', 'To', 'evaluate', 'and', 'compare', 'the', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', ',', 'adverse', 'effects', ',', 'patients', ""'"", 'satisfaction', ',', 'mobilization', ',', 'time', 'to', 'first', 'defecation', 'and', 'time', 'to', 'discharge', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(17, 38)","(130, 272)",-1,ss_o,25950425,Abstract,0,test,gold,5945.0
6256,OBJECTIVES To evaluate and compare the effects of preoperative oral,pregabalin,"and perioperative intravenous lidocaine infusion on postoperative morphine requirement , adverse effects , patients ' satisfaction , mobilization , time to first defecation and time to discharge in patients undergoing laparotomy .","['OBJECTIVES', 'To', 'evaluate', 'and', 'compare', 'the', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', ',', 'adverse', 'effects', ',', 'patients', ""'"", 'satisfaction', ',', 'mobilization', ',', 'time', 'to', 'first', 'defecation', 'and', 'time', 'to', 'discharge', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(10, 11)","(67, 77)",-1,hl_i,25950425,Abstract,0,test,gold,5594.0
6257,OBJECTIVES To evaluate and compare the effects of preoperative oral pregabalin and perioperative intravenous,lidocaine,"infusion on postoperative morphine requirement , adverse effects , patients ' satisfaction , mobilization , time to first defecation and time to discharge in patients undergoing laparotomy .","['OBJECTIVES', 'To', 'evaluate', 'and', 'compare', 'the', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', ',', 'adverse', 'effects', ',', 'patients', ""'"", 'satisfaction', ',', 'mobilization', ',', 'time', 'to', 'first', 'defecation', 'and', 'time', 'to', 'discharge', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(14, 15)","(108, 117)",-1,hl_i,25950425,Abstract,0,test,gold,4940.0
6258,OBJECTIVES To evaluate and compare the effects of preoperative oral pregabalin and perioperative intravenous lidocaine infusion on,postoperative morphine requirement,", adverse effects , patients ' satisfaction , mobilization , time to first defecation and time to discharge in patients undergoing laparotomy .","['OBJECTIVES', 'To', 'evaluate', 'and', 'compare', 'the', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', ',', 'adverse', 'effects', ',', 'patients', ""'"", 'satisfaction', ',', 'mobilization', ',', 'time', 'to', 'first', 'defecation', 'and', 'time', 'to', 'discharge', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(17, 20)","(130, 164)",-1,hl_o,25950425,Abstract,0,test,gold,3534.0
6259,"OBJECTIVES To evaluate and compare the effects of preoperative oral pregabalin and perioperative intravenous lidocaine infusion on postoperative morphine requirement ,",adverse effects,", patients ' satisfaction , mobilization , time to first defecation and time to discharge in patients undergoing laparotomy .","['OBJECTIVES', 'To', 'evaluate', 'and', 'compare', 'the', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', ',', 'adverse', 'effects', ',', 'patients', ""'"", 'satisfaction', ',', 'mobilization', ',', 'time', 'to', 'first', 'defecation', 'and', 'time', 'to', 'discharge', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(21, 23)","(167, 182)",-1,hl_o,25950425,Abstract,0,test,gold,2387.0
6260,"OBJECTIVES To evaluate and compare the effects of preoperative oral pregabalin and perioperative intravenous lidocaine infusion on postoperative morphine requirement , adverse effects ,",patients ' satisfaction,", mobilization , time to first defecation and time to discharge in patients undergoing laparotomy .","['OBJECTIVES', 'To', 'evaluate', 'and', 'compare', 'the', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', ',', 'adverse', 'effects', ',', 'patients', ""'"", 'satisfaction', ',', 'mobilization', ',', 'time', 'to', 'first', 'defecation', 'and', 'time', 'to', 'discharge', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(24, 27)","(185, 208)",-1,hl_o,25950425,Abstract,0,test,gold,3846.0
6261,"OBJECTIVES To evaluate and compare the effects of preoperative oral pregabalin and perioperative intravenous lidocaine infusion on postoperative morphine requirement , adverse effects , patients ' satisfaction ,",mobilization,", time to first defecation and time to discharge in patients undergoing laparotomy .","['OBJECTIVES', 'To', 'evaluate', 'and', 'compare', 'the', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', ',', 'adverse', 'effects', ',', 'patients', ""'"", 'satisfaction', ',', 'mobilization', ',', 'time', 'to', 'first', 'defecation', 'and', 'time', 'to', 'discharge', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(28, 29)","(211, 223)",-1,hl_o,25950425,Abstract,0,test,gold,1283.0
6262,"OBJECTIVES To evaluate and compare the effects of preoperative oral pregabalin and perioperative intravenous lidocaine infusion on postoperative morphine requirement , adverse effects , patients ' satisfaction , mobilization ,",time to first defecation,and time to discharge in patients undergoing laparotomy .,"['OBJECTIVES', 'To', 'evaluate', 'and', 'compare', 'the', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', ',', 'adverse', 'effects', ',', 'patients', ""'"", 'satisfaction', ',', 'mobilization', ',', 'time', 'to', 'first', 'defecation', 'and', 'time', 'to', 'discharge', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(30, 34)","(226, 250)",-1,hl_o,25950425,Abstract,0,test,gold,3390.0
6263,"OBJECTIVES To evaluate and compare the effects of preoperative oral pregabalin and perioperative intravenous lidocaine infusion on postoperative morphine requirement , adverse effects , patients ' satisfaction , mobilization , time to first defecation and",time to discharge,in patients undergoing laparotomy .,"['OBJECTIVES', 'To', 'evaluate', 'and', 'compare', 'the', 'effects', 'of', 'preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'on', 'postoperative', 'morphine', 'requirement', ',', 'adverse', 'effects', ',', 'patients', ""'"", 'satisfaction', ',', 'mobilization', ',', 'time', 'to', 'first', 'defecation', 'and', 'time', 'to', 'discharge', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(35, 38)","(255, 272)",-1,hl_o,25950425,Abstract,0,test,gold,1150.0
6264,METHODS,Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy,"were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and normal saline infusion perioperatively ( control ) ; group L , placebo capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until skin closure .","['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(1, 14)","(7, 79)",-1,ss_p,25950425,Abstract,1,test,gold,3627.0
6265,"METHODS Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C ,",placebo,"capsules and normal saline infusion perioperatively ( control ) ; group L , placebo capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until skin closure .","['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(30, 31)","(154, 161)",-1,ss_i,25950425,Abstract,1,test,gold,4327.0
6266,"METHODS Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and",normal saline infusion,"perioperatively ( control ) ; group L , placebo capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until skin closure .","['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(33, 36)","(175, 197)",-1,ss_i,25950425,Abstract,1,test,gold,4927.0
6267,"METHODS Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and normal saline infusion perioperatively ( control ) ; group L ,",placebo,"capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until skin closure .","['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(44, 45)","(238, 245)",-1,ss_i,25950425,Abstract,1,test,gold,4326.0
6268,"METHODS Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and normal saline infusion perioperatively ( control ) ; group L , placebo capsules and",lidocaine,"1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until skin closure .","['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(47, 48)","(259, 268)",-1,ss_i,25950425,Abstract,1,test,gold,4939.0
6269,"METHODS Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and normal saline infusion perioperatively ( control ) ; group L , placebo capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150",mg oral pregabalin and normal saline infusion,"perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until skin closure .","['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(66, 73)","(366, 411)",-1,ss_i,25950425,Abstract,1,test,gold,4431.0
6270,"METHODS Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and normal saline infusion perioperatively ( control ) ; group L , placebo capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL ,",150 & nbsp ; mg oral pregabalin and lidocaine,2 mg⁄kg⁄h infusion until skin closure .,"['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(79, 88)","(445, 490)",-1,ss_i,25950425,Abstract,1,test,gold,4432.0
6271,"METHODS Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and normal saline infusion perioperatively ( control ) ; group L , placebo capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until",skin closure .,,"['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(92, 95)","(516, 530)",-1,ss_o,25950425,Abstract,1,test,gold,294.0
6272,METHODS,Eighty,"patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and normal saline infusion perioperatively ( control ) ; group L , placebo capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until skin closure .","['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(1, 2)","(7, 13)",-1,hl_p,25950425,Abstract,1,test,gold,2055.0
6273,METHODS Eighty patients (,18 to 65 years of age,") undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and normal saline infusion perioperatively ( control ) ; group L , placebo capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until skin closure .","['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(4, 10)","(25, 46)",-1,hl_p,25950425,Abstract,1,test,gold,2018.0
6274,METHODS Eighty patients ( 18 to 65 years of age ),undergoing elective laparotomy,"were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and normal saline infusion perioperatively ( control ) ; group L , placebo capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until skin closure .","['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(11, 14)","(49, 79)",-1,hl_p,25950425,Abstract,1,test,gold,3608.0
6275,"METHODS Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C ,",placebo,"capsules and normal saline infusion perioperatively ( control ) ; group L , placebo capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until skin closure .","['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(30, 31)","(154, 161)",-1,hl_i,25950425,Abstract,1,test,gold,4325.0
6276,"METHODS Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and",normal saline infusion,"perioperatively ( control ) ; group L , placebo capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until skin closure .","['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(33, 36)","(175, 197)",-1,hl_i,25950425,Abstract,1,test,gold,4928.0
6277,"METHODS Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and normal saline infusion perioperatively ( control ) ; group L ,",placebo,"capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until skin closure .","['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(44, 45)","(238, 245)",-1,hl_i,25950425,Abstract,1,test,gold,4324.0
6278,"METHODS Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and normal saline infusion perioperatively ( control ) ; group L , placebo capsules and",lidocaine,"1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until skin closure .","['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(47, 48)","(259, 268)",-1,hl_i,25950425,Abstract,1,test,gold,4938.0
6279,"METHODS Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and normal saline infusion perioperatively ( control ) ; group L , placebo capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral",pregabalin,"and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until skin closure .","['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(68, 69)","(374, 384)",-1,hl_i,25950425,Abstract,1,test,gold,5593.0
6280,"METHODS Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and normal saline infusion perioperatively ( control ) ; group L , placebo capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and",normal saline infusion,"perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and lidocaine 2 mg⁄kg⁄h infusion until skin closure .","['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(70, 73)","(389, 411)",-1,hl_i,25950425,Abstract,1,test,gold,4926.0
6281,"METHODS Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and normal saline infusion perioperatively ( control ) ; group L , placebo capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral",pregabalin,and lidocaine 2 mg⁄kg⁄h infusion until skin closure .,"['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(85, 86)","(466, 476)",-1,hl_i,25950425,Abstract,1,test,gold,5592.0
6282,"METHODS Eighty patients ( 18 to 65 years of age ) undergoing elective laparotomy were randomly divided into four groups ( n=20 in each group ) : group C , placebo capsules and normal saline infusion perioperatively ( control ) ; group L , placebo capsules and lidocaine 1 mg⁄kg intravenous bolus dose followed by 2 mg⁄kg⁄h infusion until skin closure ; group P , 150 mg oral pregabalin and normal saline infusion perioperatively ; and group PL , 150 & nbsp ; mg oral pregabalin and",lidocaine,2 mg⁄kg⁄h infusion until skin closure .,"['METHODS', 'Eighty', 'patients', '(', '18', 'to', '65', 'years', 'of', 'age', ')', 'undergoing', 'elective', 'laparotomy', 'were', 'randomly', 'divided', 'into', 'four', 'groups', '(', 'n=20', 'in', 'each', 'group', ')', ':', 'group', 'C', ',', 'placebo', 'capsules', 'and', 'normal', 'saline', 'infusion', 'perioperatively', '(', 'control', ')', ';', 'group', 'L', ',', 'placebo', 'capsules', 'and', 'lidocaine', '1', 'mg⁄kg', 'intravenous', 'bolus', 'dose', 'followed', 'by', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', ';', 'group', 'P', ',', '150', 'mg', 'oral', 'pregabalin', 'and', 'normal', 'saline', 'infusion', 'perioperatively', ';', 'and', 'group', 'PL', ',', '150', '&', 'nbsp', ';', 'mg', 'oral', 'pregabalin', 'and', 'lidocaine', '2', 'mg⁄kg⁄h', 'infusion', 'until', 'skin', 'closure', '.']","(87, 88)","(481, 490)",-1,hl_i,25950425,Abstract,1,test,gold,4937.0
6283,,"Hemodynamic parameters , visual analogue scale ( VAS ) scores , analgesic consumption , side effects , time to mobilization , time to first defecation , time to discharge and patients ' satisfaction",were recorded .,"['Hemodynamic', 'parameters', ',', 'visual', 'analogue', 'scale', '(', 'VAS', ')', 'scores', ',', 'analgesic', 'consumption', ',', 'side', 'effects', ',', 'time', 'to', 'mobilization', ',', 'time', 'to', 'first', 'defecation', ',', 'time', 'to', 'discharge', 'and', 'patients', ""'"", 'satisfaction', 'were', 'recorded', '.']","(0, 33)","(0, 198)",-1,ss_o,25950425,Abstract,2,test,gold,5946.0
6284,"Hemodynamic parameters , visual analogue scale ( VAS ) scores , analgesic consumption , side effects , time to mobilization , time to first defecation , time to discharge and patients ' satisfaction were",recorded .,,"['Hemodynamic', 'parameters', ',', 'visual', 'analogue', 'scale', '(', 'VAS', ')', 'scores', ',', 'analgesic', 'consumption', ',', 'side', 'effects', ',', 'time', 'to', 'mobilization', ',', 'time', 'to', 'first', 'defecation', ',', 'time', 'to', 'discharge', 'and', 'patients', ""'"", 'satisfaction', 'were', 'recorded', '.']","(34, 36)","(203, 213)",-1,ss_o,25950425,Abstract,2,test,gold,1209.0
6285,,RESULTS VAS,"scores of group L , group P and group PL were lower than group C ( P < 0.05 ) .","['RESULTS', 'VAS', 'scores', 'of', 'group', 'L', ',', 'group', 'P', 'and', 'group', 'PL', 'were', 'lower', 'than', 'group', 'C', '(', 'P', '<', '0.05', ')', '.']","(0, 2)","(0, 11)",-1,ss_o,25950425,Abstract,3,test,gold,362.0
6286,"RESULTS VAS scores of group L , group P and group PL were lower than group C",( P < 0.05 ) .,,"['RESULTS', 'VAS', 'scores', 'of', 'group', 'L', ',', 'group', 'P', 'and', 'group', 'PL', 'were', 'lower', 'than', 'group', 'C', '(', 'P', '<', '0.05', ')', '.']","(17, 23)","(76, 90)",-1,ss_o,25950425,Abstract,3,test,gold,834.0
6287,,Morphine consumption,of group P and group PL was lower than group C ( P < 0.05 ) .,"['Morphine', 'consumption', 'of', 'group', 'P', 'and', 'group', 'PL', 'was', 'lower', 'than', 'group', 'C', '(', 'P', '<', '0.05', ')', '.']","(0, 2)","(0, 20)",-1,ss_o,25950425,Abstract,4,test,gold,5527.0
6288,Morphine consumption of group P and group PL was lower than group C,( P < 0.05 ) .,,"['Morphine', 'consumption', 'of', 'group', 'P', 'and', 'group', 'PL', 'was', 'lower', 'than', 'group', 'C', '(', 'P', '<', '0.05', ')', '.']","(13, 19)","(67, 81)",-1,ss_o,25950425,Abstract,4,test,gold,835.0
6289,,Morphine consumption,of group P and group PL was lower than group C ( P < 0.05 ) .,"['Morphine', 'consumption', 'of', 'group', 'P', 'and', 'group', 'PL', 'was', 'lower', 'than', 'group', 'C', '(', 'P', '<', '0.05', ')', '.']","(0, 2)","(0, 20)",-1,hl_o,25950425,Abstract,4,test,gold,5528.0
6290,,Incidence,of nausea in group C was higher than group L and group PL .,"['Incidence', 'of', 'nausea', 'in', 'group', 'C', 'was', 'higher', 'than', 'group', 'L', 'and', 'group', 'PL', '.']","(0, 1)","(0, 9)",-1,ss_o,25950425,Abstract,5,test,gold,3348.0
6291,Incidence of nausea in group C was higher than group L and,group PL .,,"['Incidence', 'of', 'nausea', 'in', 'group', 'C', 'was', 'higher', 'than', 'group', 'L', 'and', 'group', 'PL', '.']","(12, 15)","(58, 68)",-1,ss_o,25950425,Abstract,5,test,gold,1085.0
6292,,Time to first defecation and mobilization,were shorter in group L and group PL compared with group C ( P < 0.05 ) .,"['Time', 'to', 'first', 'defecation', 'and', 'mobilization', 'were', 'shorter', 'in', 'group', 'L', 'and', 'group', 'PL', 'compared', 'with', 'group', 'C', '(', 'P', '<', '0.05', ')', '.']","(0, 6)","(0, 41)",-1,ss_o,25950425,Abstract,6,test,gold,3389.0
6293,,Time to first defecation,and mobilization were shorter in group L and group PL compared with group C ( P < 0.05 ) .,"['Time', 'to', 'first', 'defecation', 'and', 'mobilization', 'were', 'shorter', 'in', 'group', 'L', 'and', 'group', 'PL', 'compared', 'with', 'group', 'C', '(', 'P', '<', '0.05', ')', '.']","(0, 4)","(0, 24)",-1,hl_o,25950425,Abstract,6,test,gold,3391.0
6294,Time to first defecation and,mobilization,were shorter in group L and group PL compared with group C ( P < 0.05 ) .,"['Time', 'to', 'first', 'defecation', 'and', 'mobilization', 'were', 'shorter', 'in', 'group', 'L', 'and', 'group', 'PL', 'compared', 'with', 'group', 'C', '(', 'P', '<', '0.05', ')', '.']","(5, 6)","(28, 40)",-1,hl_o,25950425,Abstract,6,test,gold,1284.0
6295,CONCLUSION,Preoperative oral pregabalin,and perioperative intravenous lidocaine infusion decreased postoperative VAS scores .,"['CONCLUSION', 'Preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'decreased', 'postoperative', 'VAS', 'scores', '.']","(1, 4)","(10, 38)",-1,ss_i,25950425,Abstract,7,test,gold,3538.0
6296,CONCLUSION Preoperative oral pregabalin and perioperative,intravenous,lidocaine infusion decreased postoperative VAS scores .,"['CONCLUSION', 'Preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'decreased', 'postoperative', 'VAS', 'scores', '.']","(6, 7)","(57, 68)",-1,ss_i,25950425,Abstract,7,test,gold,195.0
6297,CONCLUSION Preoperative oral pregabalin and perioperative intravenous lidocaine infusion,decreased postoperative VAS,scores .,"['CONCLUSION', 'Preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'decreased', 'postoperative', 'VAS', 'scores', '.']","(9, 12)","(88, 115)",-1,ss_o,25950425,Abstract,7,test,gold,383.0
6298,CONCLUSION Preoperative oral,pregabalin,and perioperative intravenous lidocaine infusion decreased postoperative VAS scores .,"['CONCLUSION', 'Preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'decreased', 'postoperative', 'VAS', 'scores', '.']","(3, 4)","(28, 38)",-1,hl_i,25950425,Abstract,7,test,gold,5591.0
6299,CONCLUSION Preoperative oral pregabalin and perioperative intravenous,lidocaine,infusion decreased postoperative VAS scores .,"['CONCLUSION', 'Preoperative', 'oral', 'pregabalin', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'decreased', 'postoperative', 'VAS', 'scores', '.']","(7, 8)","(69, 78)",-1,hl_i,25950425,Abstract,7,test,gold,4936.0
6300,"Preoperative oral pregabalin decreased morphine requirement and perioperative intravenous lidocaine infusion hastened gastrointestinal motility and mobilization , and decreased the incidence of",nausea in patients undergoing laparotomy,.,"['Preoperative', 'oral', 'pregabalin', 'decreased', 'morphine', 'requirement', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'hastened', 'gastrointestinal', 'motility', 'and', 'mobilization', ',', 'and', 'decreased', 'the', 'incidence', 'of', 'nausea', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(22, 27)","(193, 233)",-1,ss_p,25950425,Abstract,8,test,gold,3613.0
6301,,Preoperative oral pregabalin,"decreased morphine requirement and perioperative intravenous lidocaine infusion hastened gastrointestinal motility and mobilization , and decreased the incidence of nausea in patients undergoing laparotomy .","['Preoperative', 'oral', 'pregabalin', 'decreased', 'morphine', 'requirement', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'hastened', 'gastrointestinal', 'motility', 'and', 'mobilization', ',', 'and', 'decreased', 'the', 'incidence', 'of', 'nausea', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(0, 3)","(0, 28)",-1,ss_i,25950425,Abstract,8,test,gold,3539.0
6302,Preoperative oral pregabalin decreased morphine requirement and perioperative,intravenous,"lidocaine infusion hastened gastrointestinal motility and mobilization , and decreased the incidence of nausea in patients undergoing laparotomy .","['Preoperative', 'oral', 'pregabalin', 'decreased', 'morphine', 'requirement', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'hastened', 'gastrointestinal', 'motility', 'and', 'mobilization', ',', 'and', 'decreased', 'the', 'incidence', 'of', 'nausea', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(8, 9)","(77, 88)",-1,ss_i,25950425,Abstract,8,test,gold,196.0
6303,Preoperative oral pregabalin,decreased morphine requirement,"and perioperative intravenous lidocaine infusion hastened gastrointestinal motility and mobilization , and decreased the incidence of nausea in patients undergoing laparotomy .","['Preoperative', 'oral', 'pregabalin', 'decreased', 'morphine', 'requirement', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'hastened', 'gastrointestinal', 'motility', 'and', 'mobilization', ',', 'and', 'decreased', 'the', 'incidence', 'of', 'nausea', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(3, 6)","(28, 58)",-1,ss_o,25950425,Abstract,8,test,gold,5114.0
6304,"Preoperative oral pregabalin decreased morphine requirement and perioperative intravenous lidocaine infusion hastened gastrointestinal motility and mobilization , and",decreased the incidence,of nausea in patients undergoing laparotomy .,"['Preoperative', 'oral', 'pregabalin', 'decreased', 'morphine', 'requirement', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'hastened', 'gastrointestinal', 'motility', 'and', 'mobilization', ',', 'and', 'decreased', 'the', 'incidence', 'of', 'nausea', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(18, 21)","(166, 189)",-1,ss_o,25950425,Abstract,8,test,gold,3347.0
6305,Preoperative oral,pregabalin,"decreased morphine requirement and perioperative intravenous lidocaine infusion hastened gastrointestinal motility and mobilization , and decreased the incidence of nausea in patients undergoing laparotomy .","['Preoperative', 'oral', 'pregabalin', 'decreased', 'morphine', 'requirement', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'hastened', 'gastrointestinal', 'motility', 'and', 'mobilization', ',', 'and', 'decreased', 'the', 'incidence', 'of', 'nausea', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(2, 3)","(17, 27)",-1,hl_i,25950425,Abstract,8,test,gold,5590.0
6306,Preoperative oral pregabalin decreased morphine requirement and perioperative intravenous,lidocaine,"infusion hastened gastrointestinal motility and mobilization , and decreased the incidence of nausea in patients undergoing laparotomy .","['Preoperative', 'oral', 'pregabalin', 'decreased', 'morphine', 'requirement', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'hastened', 'gastrointestinal', 'motility', 'and', 'mobilization', ',', 'and', 'decreased', 'the', 'incidence', 'of', 'nausea', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(9, 10)","(89, 98)",-1,hl_i,25950425,Abstract,8,test,gold,4935.0
6307,Preoperative oral pregabalin decreased,morphine requirement,"and perioperative intravenous lidocaine infusion hastened gastrointestinal motility and mobilization , and decreased the incidence of nausea in patients undergoing laparotomy .","['Preoperative', 'oral', 'pregabalin', 'decreased', 'morphine', 'requirement', 'and', 'perioperative', 'intravenous', 'lidocaine', 'infusion', 'hastened', 'gastrointestinal', 'motility', 'and', 'mobilization', ',', 'and', 'decreased', 'the', 'incidence', 'of', 'nausea', 'in', 'patients', 'undergoing', 'laparotomy', '.']","(4, 6)","(38, 58)",-1,hl_o,25950425,Abstract,8,test,gold,5115.0
6308,"Therefore , preoperative pregabalin with or without lidocaine provides superior pain",relief in patients undergoing laparatomy,.,"['Therefore', ',', 'preoperative', 'pregabalin', 'with', 'or', 'without', 'lidocaine', 'provides', 'superior', 'pain', 'relief', 'in', 'patients', 'undergoing', 'laparatomy', '.']","(11, 16)","(84, 124)",-1,ss_p,25950425,Abstract,9,test,gold,3609.0
6309,"Therefore ,",preoperative pregabalin,with or without lidocaine provides superior pain relief in patients undergoing laparatomy .,"['Therefore', ',', 'preoperative', 'pregabalin', 'with', 'or', 'without', 'lidocaine', 'provides', 'superior', 'pain', 'relief', 'in', 'patients', 'undergoing', 'laparatomy', '.']","(2, 4)","(11, 34)",-1,ss_i,25950425,Abstract,9,test,gold,3537.0
6310,"Therefore , preoperative pregabalin with",or without,lidocaine provides superior pain relief in patients undergoing laparatomy .,"['Therefore', ',', 'preoperative', 'pregabalin', 'with', 'or', 'without', 'lidocaine', 'provides', 'superior', 'pain', 'relief', 'in', 'patients', 'undergoing', 'laparatomy', '.']","(5, 7)","(40, 50)",-1,ss_i,25950425,Abstract,9,test,gold,1159.0
6311,"Therefore , preoperative pregabalin with or without lidocaine",provides superior pain,relief in patients undergoing laparatomy .,"['Therefore', ',', 'preoperative', 'pregabalin', 'with', 'or', 'without', 'lidocaine', 'provides', 'superior', 'pain', 'relief', 'in', 'patients', 'undergoing', 'laparatomy', '.']","(8, 11)","(61, 83)",-1,ss_o,25950425,Abstract,9,test,gold,2310.0
6312,"Therefore , preoperative",pregabalin,with or without lidocaine provides superior pain relief in patients undergoing laparatomy .,"['Therefore', ',', 'preoperative', 'pregabalin', 'with', 'or', 'without', 'lidocaine', 'provides', 'superior', 'pain', 'relief', 'in', 'patients', 'undergoing', 'laparatomy', '.']","(3, 4)","(24, 34)",-1,hl_i,25950425,Abstract,9,test,gold,5589.0
6313,A New Interactive Screening Test for,Autism Spectrum Disorders in Toddlers .,,"['A', 'New', 'Interactive', 'Screening', 'Test', 'for', 'Autism', 'Spectrum', 'Disorders', 'in', 'Toddlers', '.']","(6, 12)","(36, 75)",-1,ss_p,26210844,Title,0,test,gold,6257.0
6314,A New,Interactive Screening Test,for Autism Spectrum Disorders in Toddlers .,"['A', 'New', 'Interactive', 'Screening', 'Test', 'for', 'Autism', 'Spectrum', 'Disorders', 'in', 'Toddlers', '.']","(2, 5)","(5, 31)",-1,ss_i,26210844,Title,0,test,gold,6259.0
6315,A New Interactive Screening Test for,Autism Spectrum Disorders,in Toddlers .,"['A', 'New', 'Interactive', 'Screening', 'Test', 'for', 'Autism', 'Spectrum', 'Disorders', 'in', 'Toddlers', '.']","(6, 9)","(36, 61)",-1,hl_p,26210844,Title,0,test,gold,6255.0
6316,A New Interactive Screening Test for Autism Spectrum Disorders in,Toddlers,.,"['A', 'New', 'Interactive', 'Screening', 'Test', 'for', 'Autism', 'Spectrum', 'Disorders', 'in', 'Toddlers', '.']","(10, 11)","(65, 73)",-1,hl_p,26210844,Title,0,test,gold,2171.0
6317,A New,Interactive Screening Test,for Autism Spectrum Disorders in Toddlers .,"['A', 'New', 'Interactive', 'Screening', 'Test', 'for', 'Autism', 'Spectrum', 'Disorders', 'in', 'Toddlers', '.']","(2, 5)","(5, 31)",-1,hl_i,26210844,Title,0,test,gold,6260.0
6318,OBJECTIVE To develop a clinically valid interactive level 2 screening assessment for,autism spectrum disorders ( ASD ) in toddlers,"that is brief , easily administered , and scored by clinicians .","['OBJECTIVE', 'To', 'develop', 'a', 'clinically', 'valid', 'interactive', 'level', '2', 'screening', 'assessment', 'for', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', 'in', 'toddlers', 'that', 'is', 'brief', ',', 'easily', 'administered', ',', 'and', 'scored', 'by', 'clinicians', '.']","(12, 20)","(84, 129)",-1,ss_p,26210844,Abstract,0,test,gold,6036.0
6319,OBJECTIVE To develop a clinically valid interactive level 2 screening assessment for,autism spectrum disorders ( ASD ),"in toddlers that is brief , easily administered , and scored by clinicians .","['OBJECTIVE', 'To', 'develop', 'a', 'clinically', 'valid', 'interactive', 'level', '2', 'screening', 'assessment', 'for', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', 'in', 'toddlers', 'that', 'is', 'brief', ',', 'easily', 'administered', ',', 'and', 'scored', 'by', 'clinicians', '.']","(12, 18)","(84, 117)",-1,hl_p,26210844,Abstract,0,test,gold,6041.0
6320,OBJECTIVE To develop a clinically valid interactive level 2 screening assessment for autism spectrum disorders ( ASD ) in,toddlers,"that is brief , easily administered , and scored by clinicians .","['OBJECTIVE', 'To', 'develop', 'a', 'clinically', 'valid', 'interactive', 'level', '2', 'screening', 'assessment', 'for', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', 'in', 'toddlers', 'that', 'is', 'brief', ',', 'easily', 'administered', ',', 'and', 'scored', 'by', 'clinicians', '.']","(19, 20)","(121, 129)",-1,hl_p,26210844,Abstract,0,test,gold,2172.0
6321,"STUDY DESIGN We describe the development , training , standardization , and validation of the",Rapid Interactive Screening Test,for Autism in Toddlers ( RITA-T ) with ASD-specific diagnostic instruments .,"['STUDY', 'DESIGN', 'We', 'describe', 'the', 'development', ',', 'training', ',', 'standardization', ',', 'and', 'validation', 'of', 'the', 'Rapid', 'Interactive', 'Screening', 'Test', 'for', 'Autism', 'in', 'Toddlers', '(', 'RITA-T', ')', 'with', 'ASD-specific', 'diagnostic', 'instruments', '.']","(15, 19)","(93, 125)",-1,ss_i,26210844,Abstract,1,test,gold,6261.0
6322,"STUDY DESIGN We describe the development , training , standardization , and validation of the",Rapid Interactive Screening Test for Autism in Toddlers ( RITA-T ),with ASD-specific diagnostic instruments .,"['STUDY', 'DESIGN', 'We', 'describe', 'the', 'development', ',', 'training', ',', 'standardization', ',', 'and', 'validation', 'of', 'the', 'Rapid', 'Interactive', 'Screening', 'Test', 'for', 'Autism', 'in', 'Toddlers', '(', 'RITA-T', ')', 'with', 'ASD-specific', 'diagnostic', 'instruments', '.']","(15, 26)","(93, 159)",-1,ss_o,26210844,Abstract,1,test,gold,6258.0
6323,"STUDY DESIGN We describe the development , training , standardization , and validation of the",Rapid Interactive Screening Test,for Autism in Toddlers ( RITA-T ) with ASD-specific diagnostic instruments .,"['STUDY', 'DESIGN', 'We', 'describe', 'the', 'development', ',', 'training', ',', 'standardization', ',', 'and', 'validation', 'of', 'the', 'Rapid', 'Interactive', 'Screening', 'Test', 'for', 'Autism', 'in', 'Toddlers', '(', 'RITA-T', ')', 'with', 'ASD-specific', 'diagnostic', 'instruments', '.']","(15, 19)","(93, 125)",-1,hl_i,26210844,Abstract,1,test,gold,6262.0
6324,The,RITA-T,can be administered and scored in 10 minutes .,"['The', 'RITA-T', 'can', 'be', 'administered', 'and', 'scored', 'in', '10', 'minutes', '.']","(1, 2)","(3, 9)",-1,ss_i,26210844,Abstract,2,test,gold,
6325,The,RITA-T,can be administered and scored in 10 minutes .,"['The', 'RITA-T', 'can', 'be', 'administered', 'and', 'scored', 'in', '10', 'minutes', '.']","(1, 2)","(3, 9)",-1,ss_o,26210844,Abstract,2,test,gold,
6326,The,RITA-T,can be administered and scored in 10 minutes .,"['The', 'RITA-T', 'can', 'be', 'administered', 'and', 'scored', 'in', '10', 'minutes', '.']","(1, 2)","(3, 9)",-1,hl_i,26210844,Abstract,2,test,gold,
6327,We studied the validity of the RITA-T to distinguish between,toddlers with ASD from toddlers with developmental delay ( DD ) /non-ASD in an early childhood clinic .,,"['We', 'studied', 'the', 'validity', 'of', 'the', 'RITA-T', 'to', 'distinguish', 'between', 'toddlers', 'with', 'ASD', 'from', 'toddlers', 'with', 'developmental', 'delay', '(', 'DD', ')', '/non-ASD', 'in', 'an', 'early', 'childhood', 'clinic', '.']","(10, 28)","(60, 163)",-1,ss_p,26210844,Abstract,3,test,gold,6187.0
6328,We studied the validity of the,RITA-T,to distinguish between toddlers with ASD from toddlers with developmental delay ( DD ) /non-ASD in an early childhood clinic .,"['We', 'studied', 'the', 'validity', 'of', 'the', 'RITA-T', 'to', 'distinguish', 'between', 'toddlers', 'with', 'ASD', 'from', 'toddlers', 'with', 'developmental', 'delay', '(', 'DD', ')', '/non-ASD', 'in', 'an', 'early', 'childhood', 'clinic', '.']","(6, 7)","(30, 36)",-1,ss_i,26210844,Abstract,3,test,gold,
6329,We studied the validity of the,RITA-T,to distinguish between toddlers with ASD from toddlers with developmental delay ( DD ) /non-ASD in an early childhood clinic .,"['We', 'studied', 'the', 'validity', 'of', 'the', 'RITA-T', 'to', 'distinguish', 'between', 'toddlers', 'with', 'ASD', 'from', 'toddlers', 'with', 'developmental', 'delay', '(', 'DD', ')', '/non-ASD', 'in', 'an', 'early', 'childhood', 'clinic', '.']","(6, 7)","(30, 36)",-1,ss_o,26210844,Abstract,3,test,gold,
6330,We studied the validity of the RITA-T to distinguish between,toddlers with ASD from toddlers with developmental delay ( DD ) /non-ASD in an early childhood clinic .,,"['We', 'studied', 'the', 'validity', 'of', 'the', 'RITA-T', 'to', 'distinguish', 'between', 'toddlers', 'with', 'ASD', 'from', 'toddlers', 'with', 'developmental', 'delay', '(', 'DD', ')', '/non-ASD', 'in', 'an', 'early', 'childhood', 'clinic', '.']","(10, 28)","(60, 163)",-1,hl_p,26210844,Abstract,3,test,gold,6188.0
6331,We studied the validity of the,RITA-T,to distinguish between toddlers with ASD from toddlers with developmental delay ( DD ) /non-ASD in an early childhood clinic .,"['We', 'studied', 'the', 'validity', 'of', 'the', 'RITA-T', 'to', 'distinguish', 'between', 'toddlers', 'with', 'ASD', 'from', 'toddlers', 'with', 'developmental', 'delay', '(', 'DD', ')', '/non-ASD', 'in', 'an', 'early', 'childhood', 'clinic', '.']","(6, 7)","(30, 36)",-1,hl_i,26210844,Abstract,3,test,gold,
6332,We also evaluated the test 's performance in,toddlers with no developmental concerns .,,"['We', 'also', 'evaluated', 'the', 'test', ""'s"", 'performance', 'in', 'toddlers', 'with', 'no', 'developmental', 'concerns', '.']","(8, 14)","(44, 85)",-1,ss_p,26210844,Abstract,4,test,gold,2094.0
6333,We also evaluated the,test 's performance,in toddlers with no developmental concerns .,"['We', 'also', 'evaluated', 'the', 'test', ""'s"", 'performance', 'in', 'toddlers', 'with', 'no', 'developmental', 'concerns', '.']","(4, 7)","(21, 40)",-1,ss_o,26210844,Abstract,4,test,gold,1862.0
6334,We also evaluated the test 's performance in,toddlers with no developmental concerns .,,"['We', 'also', 'evaluated', 'the', 'test', ""'s"", 'performance', 'in', 'toddlers', 'with', 'no', 'developmental', 'concerns', '.']","(8, 14)","(44, 85)",-1,hl_p,26210844,Abstract,4,test,gold,2095.0
6335,"We identified a cutoff score based on sensitivity , specificity , and positive predictive value of the",RITA-T,that best differentiates between ASD and DD/non-ASD .,"['We', 'identified', 'a', 'cutoff', 'score', 'based', 'on', 'sensitivity', ',', 'specificity', ',', 'and', 'positive', 'predictive', 'value', 'of', 'the', 'RITA-T', 'that', 'best', 'differentiates', 'between', 'ASD', 'and', 'DD/non-ASD', '.']","(17, 18)","(102, 108)",-1,ss_i,26210844,Abstract,5,test,gold,
6336,We identified a,cutoff score,"based on sensitivity , specificity , and positive predictive value of the RITA-T that best differentiates between ASD and DD/non-ASD .","['We', 'identified', 'a', 'cutoff', 'score', 'based', 'on', 'sensitivity', ',', 'specificity', ',', 'and', 'positive', 'predictive', 'value', 'of', 'the', 'RITA-T', 'that', 'best', 'differentiates', 'between', 'ASD', 'and', 'DD/non-ASD', '.']","(3, 5)","(15, 27)",-1,ss_o,26210844,Abstract,5,test,gold,1439.0
6337,We identified a cutoff score based on,"sensitivity , specificity , and positive predictive value of the RITA-T",that best differentiates between ASD and DD/non-ASD .,"['We', 'identified', 'a', 'cutoff', 'score', 'based', 'on', 'sensitivity', ',', 'specificity', ',', 'and', 'positive', 'predictive', 'value', 'of', 'the', 'RITA-T', 'that', 'best', 'differentiates', 'between', 'ASD', 'and', 'DD/non-ASD', '.']","(7, 18)","(37, 108)",-1,ss_o,26210844,Abstract,5,test,gold,6386.0
6338,"We identified a cutoff score based on sensitivity , specificity , and positive predictive value of the",RITA-T,that best differentiates between ASD and DD/non-ASD .,"['We', 'identified', 'a', 'cutoff', 'score', 'based', 'on', 'sensitivity', ',', 'specificity', ',', 'and', 'positive', 'predictive', 'value', 'of', 'the', 'RITA-T', 'that', 'best', 'differentiates', 'between', 'ASD', 'and', 'DD/non-ASD', '.']","(17, 18)","(102, 108)",-1,hl_i,26210844,Abstract,5,test,gold,
6339,We identified a,cutoff score,"based on sensitivity , specificity , and positive predictive value of the RITA-T that best differentiates between ASD and DD/non-ASD .","['We', 'identified', 'a', 'cutoff', 'score', 'based', 'on', 'sensitivity', ',', 'specificity', ',', 'and', 'positive', 'predictive', 'value', 'of', 'the', 'RITA-T', 'that', 'best', 'differentiates', 'between', 'ASD', 'and', 'DD/non-ASD', '.']","(3, 5)","(15, 27)",-1,hl_o,26210844,Abstract,5,test,gold,1440.0
6340,We identified a cutoff score based on,"sensitivity , specificity , and positive predictive value",of the RITA-T that best differentiates between ASD and DD/non-ASD .,"['We', 'identified', 'a', 'cutoff', 'score', 'based', 'on', 'sensitivity', ',', 'specificity', ',', 'and', 'positive', 'predictive', 'value', 'of', 'the', 'RITA-T', 'that', 'best', 'differentiates', 'between', 'ASD', 'and', 'DD/non-ASD', '.']","(7, 15)","(37, 94)",-1,hl_o,26210844,Abstract,5,test,gold,6387.0
6341,"We identified a cutoff score based on sensitivity , specificity , and positive predictive value of the",RITA-T,that best differentiates between ASD and DD/non-ASD .,"['We', 'identified', 'a', 'cutoff', 'score', 'based', 'on', 'sensitivity', ',', 'specificity', ',', 'and', 'positive', 'predictive', 'value', 'of', 'the', 'RITA-T', 'that', 'best', 'differentiates', 'between', 'ASD', 'and', 'DD/non-ASD', '.']","(17, 18)","(102, 108)",-1,hl_o,26210844,Abstract,5,test,gold,
6342,RESULTS,A total of 61 toddlers were enrolled .,,"['RESULTS', 'A', 'total', 'of', '61', 'toddlers', 'were', 'enrolled', '.']","(1, 9)","(7, 45)",-1,ss_p,26210844,Abstract,6,test,gold,2098.0
6343,RESULTS,A total of 61 toddlers,were enrolled .,"['RESULTS', 'A', 'total', 'of', '61', 'toddlers', 'were', 'enrolled', '.']","(1, 6)","(7, 29)",-1,hl_p,26210844,Abstract,6,test,gold,2099.0
6344,,RITA-T scores,were correlated with ASD-specific diagnostic tools ( r = 0.79 ; P < .01 ) and ASD clinical diagnoses ( r = 0.77 ; P < .01 ) .,"['RITA-T', 'scores', 'were', 'correlated', 'with', 'ASD-specific', 'diagnostic', 'tools', '(', 'r', '=', '0.79', ';', 'P', '<', '.01', ')', 'and', 'ASD', 'clinical', 'diagnoses', '(', 'r', '=', '0.77', ';', 'P', '<', '.01', ')', '.']","(0, 2)","(0, 13)",-1,ss_o,26210844,Abstract,7,test,gold,1434.0
6345,,RITA-T scores,were correlated with ASD-specific diagnostic tools ( r = 0.79 ; P < .01 ) and ASD clinical diagnoses ( r = 0.77 ; P < .01 ) .,"['RITA-T', 'scores', 'were', 'correlated', 'with', 'ASD-specific', 'diagnostic', 'tools', '(', 'r', '=', '0.79', ';', 'P', '<', '.01', ')', 'and', 'ASD', 'clinical', 'diagnoses', '(', 'r', '=', '0.77', ';', 'P', '<', '.01', ')', '.']","(0, 2)","(0, 13)",-1,hl_o,26210844,Abstract,7,test,gold,1435.0
6346,Mean,scores,"were significantly different in subjects with ASD , those with DD/non-ASD , and those with no developmental concerns ( 20.8 vs 13 vs 10.6 , respectively ; P < .0001 ) .","['Mean', 'scores', 'were', 'significantly', 'different', 'in', 'subjects', 'with', 'ASD', ',', 'those', 'with', 'DD/non-ASD', ',', 'and', 'those', 'with', 'no', 'developmental', 'concerns', '(', '20.8', 'vs', '13', 'vs', '10.6', ',', 'respectively', ';', 'P', '<', '.0001', ')', '.']","(1, 2)","(4, 10)",-1,ss_o,26210844,Abstract,8,test,gold,1433.0
6347,Mean,scores,"were significantly different in subjects with ASD , those with DD/non-ASD , and those with no developmental concerns ( 20.8 vs 13 vs 10.6 , respectively ; P < .0001 ) .","['Mean', 'scores', 'were', 'significantly', 'different', 'in', 'subjects', 'with', 'ASD', ',', 'those', 'with', 'DD/non-ASD', ',', 'and', 'those', 'with', 'no', 'developmental', 'concerns', '(', '20.8', 'vs', '13', 'vs', '10.6', ',', 'respectively', ';', 'P', '<', '.0001', ')', '.']","(1, 2)","(4, 10)",-1,hl_o,26210844,Abstract,8,test,gold,1432.0
6348,"At a cutoff score of > 14 , the",RITA-T,"had a sensitivity of 1.00 , specificity of 0.84 , and positive predictive value of 0.88 for identifying ASD risk in a high-risk group .","['At', 'a', 'cutoff', 'score', 'of', '>', '14', ',', 'the', 'RITA-T', 'had', 'a', 'sensitivity', 'of', '1.00', ',', 'specificity', 'of', '0.84', ',', 'and', 'positive', 'predictive', 'value', 'of', '0.88', 'for', 'identifying', 'ASD', 'risk', 'in', 'a', 'high-risk', 'group', '.']","(9, 10)","(31, 37)",-1,ss_i,26210844,Abstract,9,test,gold,
6349,"At a cutoff score of > 14 , the",RITA-T,"had a sensitivity of 1.00 , specificity of 0.84 , and positive predictive value of 0.88 for identifying ASD risk in a high-risk group .","['At', 'a', 'cutoff', 'score', 'of', '>', '14', ',', 'the', 'RITA-T', 'had', 'a', 'sensitivity', 'of', '1.00', ',', 'specificity', 'of', '0.84', ',', 'and', 'positive', 'predictive', 'value', 'of', '0.88', 'for', 'identifying', 'ASD', 'risk', 'in', 'a', 'high-risk', 'group', '.']","(9, 10)","(31, 37)",-1,ss_o,26210844,Abstract,9,test,gold,
6350,"At a cutoff score of > 14 , the RITA-T had a",sensitivity,"of 1.00 , specificity of 0.84 , and positive predictive value of 0.88 for identifying ASD risk in a high-risk group .","['At', 'a', 'cutoff', 'score', 'of', '>', '14', ',', 'the', 'RITA-T', 'had', 'a', 'sensitivity', 'of', '1.00', ',', 'specificity', 'of', '0.84', ',', 'and', 'positive', 'predictive', 'value', 'of', '0.88', 'for', 'identifying', 'ASD', 'risk', 'in', 'a', 'high-risk', 'group', '.']","(12, 13)","(44, 55)",-1,ss_o,26210844,Abstract,9,test,gold,1395.0
6351,"At a cutoff score of > 14 , the RITA-T had a sensitivity of 1.00 ,",specificity,"of 0.84 , and positive predictive value of 0.88 for identifying ASD risk in a high-risk group .","['At', 'a', 'cutoff', 'score', 'of', '>', '14', ',', 'the', 'RITA-T', 'had', 'a', 'sensitivity', 'of', '1.00', ',', 'specificity', 'of', '0.84', ',', 'and', 'positive', 'predictive', 'value', 'of', '0.88', 'for', 'identifying', 'ASD', 'risk', 'in', 'a', 'high-risk', 'group', '.']","(16, 17)","(66, 77)",-1,ss_o,26210844,Abstract,9,test,gold,1399.0
6352,"At a cutoff score of > 14 , the RITA-T had a sensitivity of 1.00 , specificity of 0.84 , and",positive predictive value,of 0.88 for identifying ASD risk in a high-risk group .,"['At', 'a', 'cutoff', 'score', 'of', '>', '14', ',', 'the', 'RITA-T', 'had', 'a', 'sensitivity', 'of', '1.00', ',', 'specificity', 'of', '0.84', ',', 'and', 'positive', 'predictive', 'value', 'of', '0.88', 'for', 'identifying', 'ASD', 'risk', 'in', 'a', 'high-risk', 'group', '.']","(21, 24)","(92, 117)",-1,ss_o,26210844,Abstract,9,test,gold,6388.0
6353,"At a cutoff score of > 14 , the",RITA-T,"had a sensitivity of 1.00 , specificity of 0.84 , and positive predictive value of 0.88 for identifying ASD risk in a high-risk group .","['At', 'a', 'cutoff', 'score', 'of', '>', '14', ',', 'the', 'RITA-T', 'had', 'a', 'sensitivity', 'of', '1.00', ',', 'specificity', 'of', '0.84', ',', 'and', 'positive', 'predictive', 'value', 'of', '0.88', 'for', 'identifying', 'ASD', 'risk', 'in', 'a', 'high-risk', 'group', '.']","(9, 10)","(31, 37)",-1,hl_i,26210844,Abstract,9,test,gold,
6354,CONCLUSION The RITA-T is a promising new level 2 interactive screening tool for improving the early identification of,ASD in toddlers,in general pediatric and early intervention settings and allowing access to treatment .,"['CONCLUSION', 'The', 'RITA-T', 'is', 'a', 'promising', 'new', 'level', '2', 'interactive', 'screening', 'tool', 'for', 'improving', 'the', 'early', 'identification', 'of', 'ASD', 'in', 'toddlers', 'in', 'general', 'pediatric', 'and', 'early', 'intervention', 'settings', 'and', 'allowing', 'access', 'to', 'treatment', '.']","(18, 21)","(117, 132)",-1,ss_p,26210844,Abstract,10,test,gold,6084.0
6355,CONCLUSION The,RITA-T,is a promising new level 2 interactive screening tool for improving the early identification of ASD in toddlers in general pediatric and early intervention settings and allowing access to treatment .,"['CONCLUSION', 'The', 'RITA-T', 'is', 'a', 'promising', 'new', 'level', '2', 'interactive', 'screening', 'tool', 'for', 'improving', 'the', 'early', 'identification', 'of', 'ASD', 'in', 'toddlers', 'in', 'general', 'pediatric', 'and', 'early', 'intervention', 'settings', 'and', 'allowing', 'access', 'to', 'treatment', '.']","(2, 3)","(14, 20)",-1,ss_i,26210844,Abstract,10,test,gold,
6356,CONCLUSION The,RITA-T,is a promising new level 2 interactive screening tool for improving the early identification of ASD in toddlers in general pediatric and early intervention settings and allowing access to treatment .,"['CONCLUSION', 'The', 'RITA-T', 'is', 'a', 'promising', 'new', 'level', '2', 'interactive', 'screening', 'tool', 'for', 'improving', 'the', 'early', 'identification', 'of', 'ASD', 'in', 'toddlers', 'in', 'general', 'pediatric', 'and', 'early', 'intervention', 'settings', 'and', 'allowing', 'access', 'to', 'treatment', '.']","(2, 3)","(14, 20)",-1,ss_o,26210844,Abstract,10,test,gold,
6357,CONCLUSION The RITA-T is a promising new level 2 interactive screening tool for improving the early identification of,ASD in toddlers,in general pediatric and early intervention settings and allowing access to treatment .,"['CONCLUSION', 'The', 'RITA-T', 'is', 'a', 'promising', 'new', 'level', '2', 'interactive', 'screening', 'tool', 'for', 'improving', 'the', 'early', 'identification', 'of', 'ASD', 'in', 'toddlers', 'in', 'general', 'pediatric', 'and', 'early', 'intervention', 'settings', 'and', 'allowing', 'access', 'to', 'treatment', '.']","(18, 21)","(117, 132)",-1,hl_p,26210844,Abstract,10,test,gold,6085.0
6358,CONCLUSION The,RITA-T,is a promising new level 2 interactive screening tool for improving the early identification of ASD in toddlers in general pediatric and early intervention settings and allowing access to treatment .,"['CONCLUSION', 'The', 'RITA-T', 'is', 'a', 'promising', 'new', 'level', '2', 'interactive', 'screening', 'tool', 'for', 'improving', 'the', 'early', 'identification', 'of', 'ASD', 'in', 'toddlers', 'in', 'general', 'pediatric', 'and', 'early', 'intervention', 'settings', 'and', 'allowing', 'access', 'to', 'treatment', '.']","(2, 3)","(14, 20)",-1,hl_i,26210844,Abstract,10,test,gold,
6359,Inference-Based Approach versus Cognitive Behavioral Therapy in the Treatment of,Obsessive-Compulsive Disorder with Poor Insight :,A 24-Session Randomized Controlled Trial .,"['Inference-Based', 'Approach', 'versus', 'Cognitive', 'Behavioral', 'Therapy', 'in', 'the', 'Treatment', 'of', 'Obsessive-Compulsive', 'Disorder', 'with', 'Poor', 'Insight', ':', 'A', '24-Session', 'Randomized', 'Controlled', 'Trial', '.']","(10, 16)","(80, 129)",-1,ss_p,26278470,Title,0,test,gold,6235.0
6360,,Inference-Based Approach,versus Cognitive Behavioral Therapy in the Treatment of Obsessive-Compulsive Disorder with Poor Insight : A 24-Session Randomized Controlled Trial .,"['Inference-Based', 'Approach', 'versus', 'Cognitive', 'Behavioral', 'Therapy', 'in', 'the', 'Treatment', 'of', 'Obsessive-Compulsive', 'Disorder', 'with', 'Poor', 'Insight', ':', 'A', '24-Session', 'Randomized', 'Controlled', 'Trial', '.']","(0, 2)","(0, 24)",-1,ss_i,26278470,Title,0,test,gold,436.0
6361,Inference-Based Approach versus,Cognitive Behavioral Therapy,in the Treatment of Obsessive-Compulsive Disorder with Poor Insight : A 24-Session Randomized Controlled Trial .,"['Inference-Based', 'Approach', 'versus', 'Cognitive', 'Behavioral', 'Therapy', 'in', 'the', 'Treatment', 'of', 'Obsessive-Compulsive', 'Disorder', 'with', 'Poor', 'Insight', ':', 'A', '24-Session', 'Randomized', 'Controlled', 'Trial', '.']","(3, 6)","(31, 59)",-1,ss_i,26278470,Title,0,test,gold,6324.0
6362,Inference-Based Approach versus Cognitive Behavioral Therapy in the Treatment of,Obsessive-Compulsive Disorder with Poor Insight :,A 24-Session Randomized Controlled Trial .,"['Inference-Based', 'Approach', 'versus', 'Cognitive', 'Behavioral', 'Therapy', 'in', 'the', 'Treatment', 'of', 'Obsessive-Compulsive', 'Disorder', 'with', 'Poor', 'Insight', ':', 'A', '24-Session', 'Randomized', 'Controlled', 'Trial', '.']","(10, 16)","(80, 129)",-1,hl_p,26278470,Title,0,test,gold,6236.0
6363,,Inference-Based Approach,versus Cognitive Behavioral Therapy in the Treatment of Obsessive-Compulsive Disorder with Poor Insight : A 24-Session Randomized Controlled Trial .,"['Inference-Based', 'Approach', 'versus', 'Cognitive', 'Behavioral', 'Therapy', 'in', 'the', 'Treatment', 'of', 'Obsessive-Compulsive', 'Disorder', 'with', 'Poor', 'Insight', ':', 'A', '24-Session', 'Randomized', 'Controlled', 'Trial', '.']","(0, 2)","(0, 24)",-1,hl_i,26278470,Title,0,test,gold,437.0
6364,Inference-Based Approach versus,Cognitive Behavioral Therapy,in the Treatment of Obsessive-Compulsive Disorder with Poor Insight : A 24-Session Randomized Controlled Trial .,"['Inference-Based', 'Approach', 'versus', 'Cognitive', 'Behavioral', 'Therapy', 'in', 'the', 'Treatment', 'of', 'Obsessive-Compulsive', 'Disorder', 'with', 'Poor', 'Insight', ':', 'A', '24-Session', 'Randomized', 'Controlled', 'Trial', '.']","(3, 6)","(31, 59)",-1,hl_i,26278470,Title,0,test,gold,6325.0
6365,"OBJECTIVE Obsessive-compulsive disorder ( OCD ) with poor insight has severe consequences for patients ; nonetheless , no randomized controlled trial has ever been performed to evaluate the effectiveness of any treatment specifically for",poor-insight OCD .,,"['OBJECTIVE', 'Obsessive-compulsive', 'disorder', '(', 'OCD', ')', 'with', 'poor', 'insight', 'has', 'severe', 'consequences', 'for', 'patients', ';', 'nonetheless', ',', 'no', 'randomized', 'controlled', 'trial', 'has', 'ever', 'been', 'performed', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'any', 'treatment', 'specifically', 'for', 'poor-insight', 'OCD', '.']","(34, 37)","(237, 255)",-1,ss_p,26278470,Abstract,0,test,gold,2558.0
6366,"OBJECTIVE Obsessive-compulsive disorder ( OCD ) with poor insight has severe consequences for patients ; nonetheless , no randomized controlled trial has ever been performed to evaluate the",effectiveness,of any treatment specifically for poor-insight OCD .,"['OBJECTIVE', 'Obsessive-compulsive', 'disorder', '(', 'OCD', ')', 'with', 'poor', 'insight', 'has', 'severe', 'consequences', 'for', 'patients', ';', 'nonetheless', ',', 'no', 'randomized', 'controlled', 'trial', 'has', 'ever', 'been', 'performed', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'any', 'treatment', 'specifically', 'for', 'poor-insight', 'OCD', '.']","(28, 29)","(189, 202)",-1,ss_o,26278470,Abstract,0,test,gold,391.0
6367,"A new psychotherapy for OCD , the",inference-based approach ( IBA ),", targets insight in OCD by strengthening normal sensory-driven reality testing .","['A', 'new', 'psychotherapy', 'for', 'OCD', ',', 'the', 'inference-based', 'approach', '(', 'IBA', ')', ',', 'targets', 'insight', 'in', 'OCD', 'by', 'strengthening', 'normal', 'sensory-driven', 'reality', 'testing', '.']","(7, 12)","(33, 65)",-1,ss_i,26278470,Abstract,1,test,gold,552.0
6368,"A new psychotherapy for OCD , the",inference-based approach ( IBA ),", targets insight in OCD by strengthening normal sensory-driven reality testing .","['A', 'new', 'psychotherapy', 'for', 'OCD', ',', 'the', 'inference-based', 'approach', '(', 'IBA', ')', ',', 'targets', 'insight', 'in', 'OCD', 'by', 'strengthening', 'normal', 'sensory-driven', 'reality', 'testing', '.']","(7, 12)","(33, 65)",-1,hl_i,26278470,Abstract,1,test,gold,553.0
6369,The goal of the present study is to compare the effectiveness of this new treatment to the effectiveness of cognitive behavior therapy ( CBT ) for,patients with OCD with poor insight .,,"['The', 'goal', 'of', 'the', 'present', 'study', 'is', 'to', 'compare', 'the', 'effectiveness', 'of', 'this', 'new', 'treatment', 'to', 'the', 'effectiveness', 'of', 'cognitive', 'behavior', 'therapy', '(', 'CBT', ')', 'for', 'patients', 'with', 'OCD', 'with', 'poor', 'insight', '.']","(26, 33)","(146, 183)",-1,ss_p,26278470,Abstract,2,test,gold,6961.0
6370,The goal of the present study is to compare the effectiveness of this new treatment to the effectiveness of,cognitive behavior therapy ( CBT ),for patients with OCD with poor insight .,"['The', 'goal', 'of', 'the', 'present', 'study', 'is', 'to', 'compare', 'the', 'effectiveness', 'of', 'this', 'new', 'treatment', 'to', 'the', 'effectiveness', 'of', 'cognitive', 'behavior', 'therapy', '(', 'CBT', ')', 'for', 'patients', 'with', 'OCD', 'with', 'poor', 'insight', '.']","(19, 25)","(107, 141)",-1,ss_i,26278470,Abstract,2,test,gold,6322.0
6371,The goal of the present study is to compare the,effectiveness,of this new treatment to the effectiveness of cognitive behavior therapy ( CBT ) for patients with OCD with poor insight .,"['The', 'goal', 'of', 'the', 'present', 'study', 'is', 'to', 'compare', 'the', 'effectiveness', 'of', 'this', 'new', 'treatment', 'to', 'the', 'effectiveness', 'of', 'cognitive', 'behavior', 'therapy', '(', 'CBT', ')', 'for', 'patients', 'with', 'OCD', 'with', 'poor', 'insight', '.']","(10, 11)","(47, 60)",-1,ss_o,26278470,Abstract,2,test,gold,390.0
6372,The goal of the present study is to compare the effectiveness of this new treatment to the,effectiveness,of cognitive behavior therapy ( CBT ) for patients with OCD with poor insight .,"['The', 'goal', 'of', 'the', 'present', 'study', 'is', 'to', 'compare', 'the', 'effectiveness', 'of', 'this', 'new', 'treatment', 'to', 'the', 'effectiveness', 'of', 'cognitive', 'behavior', 'therapy', '(', 'CBT', ')', 'for', 'patients', 'with', 'OCD', 'with', 'poor', 'insight', '.']","(17, 18)","(90, 103)",-1,ss_o,26278470,Abstract,2,test,gold,389.0
6373,The goal of the present study is to compare the effectiveness of this new treatment to the effectiveness of cognitive behavior therapy ( CBT ) for,patients with OCD with poor insight .,,"['The', 'goal', 'of', 'the', 'present', 'study', 'is', 'to', 'compare', 'the', 'effectiveness', 'of', 'this', 'new', 'treatment', 'to', 'the', 'effectiveness', 'of', 'cognitive', 'behavior', 'therapy', '(', 'CBT', ')', 'for', 'patients', 'with', 'OCD', 'with', 'poor', 'insight', '.']","(26, 33)","(146, 183)",-1,hl_p,26278470,Abstract,2,test,gold,6962.0
6374,The goal of the present study is to compare the effectiveness of this new treatment to the effectiveness of,cognitive behavior therapy ( CBT ),for patients with OCD with poor insight .,"['The', 'goal', 'of', 'the', 'present', 'study', 'is', 'to', 'compare', 'the', 'effectiveness', 'of', 'this', 'new', 'treatment', 'to', 'the', 'effectiveness', 'of', 'cognitive', 'behavior', 'therapy', '(', 'CBT', ')', 'for', 'patients', 'with', 'OCD', 'with', 'poor', 'insight', '.']","(19, 25)","(107, 141)",-1,hl_i,26278470,Abstract,2,test,gold,6323.0
6375,"METHOD A randomized controlled trial was conducted , in which",90 patients with OCD with poor insight,received either 24 CBT sessions or 24 IBA sessions .,"['METHOD', 'A', 'randomized', 'controlled', 'trial', 'was', 'conducted', ',', 'in', 'which', '90', 'patients', 'with', 'OCD', 'with', 'poor', 'insight', 'received', 'either', '24', 'CBT', 'sessions', 'or', '24', 'IBA', 'sessions', '.']","(10, 17)","(61, 99)",-1,ss_p,26278470,Abstract,3,test,gold,6960.0
6376,"METHOD A randomized controlled trial was conducted , in which 90 patients with OCD with poor insight received either 24",CBT,sessions or 24 IBA sessions .,"['METHOD', 'A', 'randomized', 'controlled', 'trial', 'was', 'conducted', ',', 'in', 'which', '90', 'patients', 'with', 'OCD', 'with', 'poor', 'insight', 'received', 'either', '24', 'CBT', 'sessions', 'or', '24', 'IBA', 'sessions', '.']","(20, 21)","(119, 122)",-1,ss_i,26278470,Abstract,3,test,gold,327.0
6377,"METHOD A randomized controlled trial was conducted , in which 90 patients with OCD with poor insight received either 24 CBT sessions or 24",IBA,sessions .,"['METHOD', 'A', 'randomized', 'controlled', 'trial', 'was', 'conducted', ',', 'in', 'which', '90', 'patients', 'with', 'OCD', 'with', 'poor', 'insight', 'received', 'either', '24', 'CBT', 'sessions', 'or', '24', 'IBA', 'sessions', '.']","(24, 25)","(138, 141)",-1,ss_i,26278470,Abstract,3,test,gold,550.0
6378,"METHOD A randomized controlled trial was conducted , in which",90 patients with OCD with poor insight,received either 24 CBT sessions or 24 IBA sessions .,"['METHOD', 'A', 'randomized', 'controlled', 'trial', 'was', 'conducted', ',', 'in', 'which', '90', 'patients', 'with', 'OCD', 'with', 'poor', 'insight', 'received', 'either', '24', 'CBT', 'sessions', 'or', '24', 'IBA', 'sessions', '.']","(10, 17)","(61, 99)",-1,hl_p,26278470,Abstract,3,test,gold,6959.0
6379,"METHOD A randomized controlled trial was conducted , in which 90 patients with OCD with poor insight received either 24",CBT,sessions or 24 IBA sessions .,"['METHOD', 'A', 'randomized', 'controlled', 'trial', 'was', 'conducted', ',', 'in', 'which', '90', 'patients', 'with', 'OCD', 'with', 'poor', 'insight', 'received', 'either', '24', 'CBT', 'sessions', 'or', '24', 'IBA', 'sessions', '.']","(20, 21)","(119, 122)",-1,hl_i,26278470,Abstract,3,test,gold,326.0
6380,"METHOD A randomized controlled trial was conducted , in which 90 patients with OCD with poor insight received either 24 CBT sessions or 24",IBA,sessions .,"['METHOD', 'A', 'randomized', 'controlled', 'trial', 'was', 'conducted', ',', 'in', 'which', '90', 'patients', 'with', 'OCD', 'with', 'poor', 'insight', 'received', 'either', '24', 'CBT', 'sessions', 'or', '24', 'IBA', 'sessions', '.']","(24, 25)","(138, 141)",-1,hl_i,26278470,Abstract,3,test,gold,551.0
6381,The primary outcome measure was the,Yale-Brown Obsessive Compulsive Scale ( YBOCS ) .,,"['The', 'primary', 'outcome', 'measure', 'was', 'the', 'Yale-Brown', 'Obsessive', 'Compulsive', 'Scale', '(', 'YBOCS', ')', '.']","(6, 14)","(35, 84)",-1,ss_o,26278470,Abstract,4,test,gold,6221.0
6382,The primary outcome measure was the,Yale-Brown Obsessive Compulsive Scale ( YBOCS ) .,,"['The', 'primary', 'outcome', 'measure', 'was', 'the', 'Yale-Brown', 'Obsessive', 'Compulsive', 'Scale', '(', 'YBOCS', ')', '.']","(6, 14)","(35, 84)",-1,hl_o,26278470,Abstract,4,test,gold,6222.0
6383,Secondary outcome measures were,"level of insight , anxiety and depressive symptoms , and quality of life .",,"['Secondary', 'outcome', 'measures', 'were', 'level', 'of', 'insight', ',', 'anxiety', 'and', 'depressive', 'symptoms', ',', 'and', 'quality', 'of', 'life', '.']","(4, 18)","(31, 105)",-1,ss_o,26278470,Abstract,5,test,gold,7118.0
6384,Secondary outcome measures were,"level of insight , anxiety and depressive symptoms , and quality of life .",,"['Secondary', 'outcome', 'measures', 'were', 'level', 'of', 'insight', ',', 'anxiety', 'and', 'depressive', 'symptoms', ',', 'and', 'quality', 'of', 'life', '.']","(4, 18)","(31, 105)",-1,hl_o,26278470,Abstract,5,test,gold,7119.0
6385,,Mixed-effects models,were used to determine the treatment effect .,"['Mixed-effects', 'models', 'were', 'used', 'to', 'determine', 'the', 'treatment', 'effect', '.']","(0, 2)","(0, 20)",-1,ss_o,26278470,Abstract,6,test,gold,1313.0
6386,"RESULTS In both conditions , a significant",OCD symptom reduction,"was reached , but no condition effects were established .","['RESULTS', 'In', 'both', 'conditions', ',', 'a', 'significant', 'OCD', 'symptom', 'reduction', 'was', 'reached', ',', 'but', 'no', 'condition', 'effects', 'were', 'established', '.']","(7, 10)","(42, 63)",-1,ss_o,26278470,Abstract,7,test,gold,3367.0
6387,"RESULTS In both conditions , a significant OCD symptom reduction was reached , but no",condition effects,were established .,"['RESULTS', 'In', 'both', 'conditions', ',', 'a', 'significant', 'OCD', 'symptom', 'reduction', 'was', 'reached', ',', 'but', 'no', 'condition', 'effects', 'were', 'established', '.']","(15, 17)","(85, 102)",-1,ss_o,26278470,Abstract,7,test,gold,2388.0
6388,"RESULTS In both conditions , a significant",OCD symptom reduction,"was reached , but no condition effects were established .","['RESULTS', 'In', 'both', 'conditions', ',', 'a', 'significant', 'OCD', 'symptom', 'reduction', 'was', 'reached', ',', 'but', 'no', 'condition', 'effects', 'were', 'established', '.']","(7, 10)","(42, 63)",-1,hl_o,26278470,Abstract,7,test,gold,3368.0
6389,"Post hoc , in a small subgroup of patients with the worst insight ( n = 23 ) , it was found that the patients treated with the",IBA,"reached a significantly higher OCD symptom reduction than the patients treated with CBT [ estimated marginal mean = -7.77 , t ( 219.45 ) = -2.4 , p = 0.017 ] .","['Post', 'hoc', ',', 'in', 'a', 'small', 'subgroup', 'of', 'patients', 'with', 'the', 'worst', 'insight', '(', 'n', '=', '23', ')', ',', 'it', 'was', 'found', 'that', 'the', 'patients', 'treated', 'with', 'the', 'IBA', 'reached', 'a', 'significantly', 'higher', 'OCD', 'symptom', 'reduction', 'than', 'the', 'patients', 'treated', 'with', 'CBT', '[', 'estimated', 'marginal', 'mean', '=', '-7.77', ',', 't', '(', '219.45', ')', '=', '-2.4', ',', 'p', '=', '0.017', ']', '.']","(28, 29)","(126, 129)",-1,ss_i,26278470,Abstract,8,test,gold,549.0
6390,"Post hoc , in a small subgroup of patients with the worst insight ( n = 23 ) , it was found that the patients treated with the IBA reached a significantly higher OCD symptom reduction than the patients treated with",CBT,"[ estimated marginal mean = -7.77 , t ( 219.45 ) = -2.4 , p = 0.017 ] .","['Post', 'hoc', ',', 'in', 'a', 'small', 'subgroup', 'of', 'patients', 'with', 'the', 'worst', 'insight', '(', 'n', '=', '23', ')', ',', 'it', 'was', 'found', 'that', 'the', 'patients', 'treated', 'with', 'the', 'IBA', 'reached', 'a', 'significantly', 'higher', 'OCD', 'symptom', 'reduction', 'than', 'the', 'patients', 'treated', 'with', 'CBT', '[', 'estimated', 'marginal', 'mean', '=', '-7.77', ',', 't', '(', '219.45', ')', '=', '-2.4', ',', 'p', '=', '0.017', ']', '.']","(41, 42)","(214, 217)",-1,ss_i,26278470,Abstract,8,test,gold,325.0
6391,"Post hoc , in a small subgroup of patients with the worst insight ( n = 23 ) , it was found that the patients treated with the IBA reached a significantly higher",OCD symptom reduction,"than the patients treated with CBT [ estimated marginal mean = -7.77 , t ( 219.45 ) = -2.4 , p = 0.017 ] .","['Post', 'hoc', ',', 'in', 'a', 'small', 'subgroup', 'of', 'patients', 'with', 'the', 'worst', 'insight', '(', 'n', '=', '23', ')', ',', 'it', 'was', 'found', 'that', 'the', 'patients', 'treated', 'with', 'the', 'IBA', 'reached', 'a', 'significantly', 'higher', 'OCD', 'symptom', 'reduction', 'than', 'the', 'patients', 'treated', 'with', 'CBT', '[', 'estimated', 'marginal', 'mean', '=', '-7.77', ',', 't', '(', '219.45', ')', '=', '-2.4', ',', 'p', '=', '0.017', ']', '.']","(33, 36)","(161, 182)",-1,ss_o,26278470,Abstract,8,test,gold,3366.0
6392,"Post hoc , in a small subgroup of patients with the worst insight ( n = 23 ) , it was found that the patients treated with the",IBA,"reached a significantly higher OCD symptom reduction than the patients treated with CBT [ estimated marginal mean = -7.77 , t ( 219.45 ) = -2.4 , p = 0.017 ] .","['Post', 'hoc', ',', 'in', 'a', 'small', 'subgroup', 'of', 'patients', 'with', 'the', 'worst', 'insight', '(', 'n', '=', '23', ')', ',', 'it', 'was', 'found', 'that', 'the', 'patients', 'treated', 'with', 'the', 'IBA', 'reached', 'a', 'significantly', 'higher', 'OCD', 'symptom', 'reduction', 'than', 'the', 'patients', 'treated', 'with', 'CBT', '[', 'estimated', 'marginal', 'mean', '=', '-7.77', ',', 't', '(', '219.45', ')', '=', '-2.4', ',', 'p', '=', '0.017', ']', '.']","(28, 29)","(126, 129)",-1,hl_i,26278470,Abstract,8,test,gold,548.0
6393,"Post hoc , in a small subgroup of patients with the worst insight ( n = 23 ) , it was found that the patients treated with the IBA reached a significantly higher OCD symptom reduction than the patients treated with",CBT,"[ estimated marginal mean = -7.77 , t ( 219.45 ) = -2.4 , p = 0.017 ] .","['Post', 'hoc', ',', 'in', 'a', 'small', 'subgroup', 'of', 'patients', 'with', 'the', 'worst', 'insight', '(', 'n', '=', '23', ')', ',', 'it', 'was', 'found', 'that', 'the', 'patients', 'treated', 'with', 'the', 'IBA', 'reached', 'a', 'significantly', 'higher', 'OCD', 'symptom', 'reduction', 'than', 'the', 'patients', 'treated', 'with', 'CBT', '[', 'estimated', 'marginal', 'mean', '=', '-7.77', ',', 't', '(', '219.45', ')', '=', '-2.4', ',', 'p', '=', '0.017', ']', '.']","(41, 42)","(214, 217)",-1,hl_i,26278470,Abstract,8,test,gold,324.0
6394,"Post hoc , in a small subgroup of patients with the worst insight ( n = 23 ) , it was found that the patients treated with the IBA reached a significantly higher",OCD symptom reduction,"than the patients treated with CBT [ estimated marginal mean = -7.77 , t ( 219.45 ) = -2.4 , p = 0.017 ] .","['Post', 'hoc', ',', 'in', 'a', 'small', 'subgroup', 'of', 'patients', 'with', 'the', 'worst', 'insight', '(', 'n', '=', '23', ')', ',', 'it', 'was', 'found', 'that', 'the', 'patients', 'treated', 'with', 'the', 'IBA', 'reached', 'a', 'significantly', 'higher', 'OCD', 'symptom', 'reduction', 'than', 'the', 'patients', 'treated', 'with', 'CBT', '[', 'estimated', 'marginal', 'mean', '=', '-7.77', ',', 't', '(', '219.45', ')', '=', '-2.4', ',', 'p', '=', '0.017', ']', '.']","(33, 36)","(161, 182)",-1,hl_o,26278470,Abstract,8,test,gold,3365.0
6395,CONCLUSION,Patients with OCD with poor insight,improve significantly after psychological treatment .,"['CONCLUSION', 'Patients', 'with', 'OCD', 'with', 'poor', 'insight', 'improve', 'significantly', 'after', 'psychological', 'treatment', '.']","(1, 7)","(10, 45)",-1,ss_p,26278470,Abstract,9,test,gold,6963.0
6396,CONCLUSION,Patients with OCD with poor insight,improve significantly after psychological treatment .,"['CONCLUSION', 'Patients', 'with', 'OCD', 'with', 'poor', 'insight', 'improve', 'significantly', 'after', 'psychological', 'treatment', '.']","(1, 7)","(10, 45)",-1,hl_p,26278470,Abstract,9,test,gold,6964.0
6397,The results of this study suggest that both,CBT,and the IBA are effective treatments for OCD with poor insight .,"['The', 'results', 'of', 'this', 'study', 'suggest', 'that', 'both', 'CBT', 'and', 'the', 'IBA', 'are', 'effective', 'treatments', 'for', 'OCD', 'with', 'poor', 'insight', '.']","(8, 9)","(43, 46)",-1,ss_i,26278470,Abstract,10,test,gold,323.0
6398,The results of this study suggest that both CBT and the,IBA,are effective treatments for OCD with poor insight .,"['The', 'results', 'of', 'this', 'study', 'suggest', 'that', 'both', 'CBT', 'and', 'the', 'IBA', 'are', 'effective', 'treatments', 'for', 'OCD', 'with', 'poor', 'insight', '.']","(11, 12)","(55, 58)",-1,ss_i,26278470,Abstract,10,test,gold,547.0
6399,The results of this study suggest that both CBT and the IBA are,effective,treatments for OCD with poor insight .,"['The', 'results', 'of', 'this', 'study', 'suggest', 'that', 'both', 'CBT', 'and', 'the', 'IBA', 'are', 'effective', 'treatments', 'for', 'OCD', 'with', 'poor', 'insight', '.']","(13, 14)","(63, 72)",-1,ss_o,26278470,Abstract,10,test,gold,847.0
6400,The results of this study suggest that both,CBT,and the IBA are effective treatments for OCD with poor insight .,"['The', 'results', 'of', 'this', 'study', 'suggest', 'that', 'both', 'CBT', 'and', 'the', 'IBA', 'are', 'effective', 'treatments', 'for', 'OCD', 'with', 'poor', 'insight', '.']","(8, 9)","(43, 46)",-1,hl_i,26278470,Abstract,10,test,gold,322.0
6401,The results of this study suggest that both CBT and the,IBA,are effective treatments for OCD with poor insight .,"['The', 'results', 'of', 'this', 'study', 'suggest', 'that', 'both', 'CBT', 'and', 'the', 'IBA', 'are', 'effective', 'treatments', 'for', 'OCD', 'with', 'poor', 'insight', '.']","(11, 12)","(55, 58)",-1,hl_i,26278470,Abstract,10,test,gold,546.0
6402,The IBA might be more promising than CBT for,patients with more extreme poor insight .,,"['The', 'IBA', 'might', 'be', 'more', 'promising', 'than', 'CBT', 'for', 'patients', 'with', 'more', 'extreme', 'poor', 'insight', '.']","(9, 16)","(44, 85)",-1,ss_p,26278470,Abstract,11,test,gold,6958.0
6403,The,IBA,might be more promising than CBT for patients with more extreme poor insight .,"['The', 'IBA', 'might', 'be', 'more', 'promising', 'than', 'CBT', 'for', 'patients', 'with', 'more', 'extreme', 'poor', 'insight', '.']","(1, 2)","(3, 6)",-1,ss_i,26278470,Abstract,11,test,gold,545.0
6404,The IBA might be more promising than,CBT,for patients with more extreme poor insight .,"['The', 'IBA', 'might', 'be', 'more', 'promising', 'than', 'CBT', 'for', 'patients', 'with', 'more', 'extreme', 'poor', 'insight', '.']","(7, 8)","(36, 39)",-1,ss_i,26278470,Abstract,11,test,gold,321.0
6405,The,IBA,might be more promising than CBT for patients with more extreme poor insight .,"['The', 'IBA', 'might', 'be', 'more', 'promising', 'than', 'CBT', 'for', 'patients', 'with', 'more', 'extreme', 'poor', 'insight', '.']","(1, 2)","(3, 6)",-1,hl_i,26278470,Abstract,11,test,gold,544.0
6406,The IBA might be more promising than,CBT,for patients with more extreme poor insight .,"['The', 'IBA', 'might', 'be', 'more', 'promising', 'than', 'CBT', 'for', 'patients', 'with', 'more', 'extreme', 'poor', 'insight', '.']","(7, 8)","(36, 39)",-1,hl_i,26278470,Abstract,11,test,gold,320.0
6407,[ The effect of,ionic,and nonionic x-ray contrast media on myocardial perfusion and myocardial function ] .,"['[', 'The', 'effect', 'of', 'ionic', 'and', 'nonionic', 'x-ray', 'contrast', 'media', 'on', 'myocardial', 'perfusion', 'and', 'myocardial', 'function', ']', '.']","(4, 5)","(15, 20)",-1,ss_i,2678230,Title,0,test,gold,316.0
6408,[ The effect of ionic and,nonionic x-ray contrast,media on myocardial perfusion and myocardial function ] .,"['[', 'The', 'effect', 'of', 'ionic', 'and', 'nonionic', 'x-ray', 'contrast', 'media', 'on', 'myocardial', 'perfusion', 'and', 'myocardial', 'function', ']', '.']","(6, 9)","(25, 48)",-1,ss_i,2678230,Title,0,test,gold,1782.0
6409,[ The effect of ionic and nonionic x-ray contrast media on,myocardial perfusion and myocardial function ],.,"['[', 'The', 'effect', 'of', 'ionic', 'and', 'nonionic', 'x-ray', 'contrast', 'media', 'on', 'myocardial', 'perfusion', 'and', 'myocardial', 'function', ']', '.']","(11, 17)","(58, 104)",-1,ss_o,2678230,Title,0,test,gold,6791.0
6410,[ The effect of,ionic,and nonionic x-ray contrast media on myocardial perfusion and myocardial function ] .,"['[', 'The', 'effect', 'of', 'ionic', 'and', 'nonionic', 'x-ray', 'contrast', 'media', 'on', 'myocardial', 'perfusion', 'and', 'myocardial', 'function', ']', '.']","(4, 5)","(15, 20)",-1,hl_i,2678230,Title,0,test,gold,317.0
6411,[ The effect of ionic and,nonionic x-ray contrast,media on myocardial perfusion and myocardial function ] .,"['[', 'The', 'effect', 'of', 'ionic', 'and', 'nonionic', 'x-ray', 'contrast', 'media', 'on', 'myocardial', 'perfusion', 'and', 'myocardial', 'function', ']', '.']","(6, 9)","(25, 48)",-1,hl_i,2678230,Title,0,test,gold,1783.0
6412,[ The effect of ionic and nonionic x-ray contrast media on myocardial perfusion and,myocardial,function ] .,"['[', 'The', 'effect', 'of', 'ionic', 'and', 'nonionic', 'x-ray', 'contrast', 'media', 'on', 'myocardial', 'perfusion', 'and', 'myocardial', 'function', ']', '.']","(14, 15)","(83, 93)",-1,hl_o,2678230,Title,0,test,gold,3224.0
6413,"The influence of injections of Amidotrizoate and Iopromide into the left coronary artery on global myocardial perfusion and function ( pressures in the left ventricle , heart rate ) as well as excitation formation and transmission was studied in",16 patients with ischaemic heart disease .,,"['The', 'influence', 'of', 'injections', 'of', 'Amidotrizoate', 'and', 'Iopromide', 'into', 'the', 'left', 'coronary', 'artery', 'on', 'global', 'myocardial', 'perfusion', 'and', 'function', '(', 'pressures', 'in', 'the', 'left', 'ventricle', ',', 'heart', 'rate', ')', 'as', 'well', 'as', 'excitation', 'formation', 'and', 'transmission', 'was', 'studied', 'in', '16', 'patients', 'with', 'ischaemic', 'heart', 'disease', '.']","(39, 46)","(245, 287)",-1,ss_p,2678230,Abstract,0,test,gold,7047.0
6414,The influence of injections of,Amidotrizoate,"and Iopromide into the left coronary artery on global myocardial perfusion and function ( pressures in the left ventricle , heart rate ) as well as excitation formation and transmission was studied in 16 patients with ischaemic heart disease .","['The', 'influence', 'of', 'injections', 'of', 'Amidotrizoate', 'and', 'Iopromide', 'into', 'the', 'left', 'coronary', 'artery', 'on', 'global', 'myocardial', 'perfusion', 'and', 'function', '(', 'pressures', 'in', 'the', 'left', 'ventricle', ',', 'heart', 'rate', ')', 'as', 'well', 'as', 'excitation', 'formation', 'and', 'transmission', 'was', 'studied', 'in', '16', 'patients', 'with', 'ischaemic', 'heart', 'disease', '.']","(5, 6)","(30, 43)",-1,ss_i,2678230,Abstract,0,test,gold,
6415,The influence of injections of Amidotrizoate and,Iopromide,"into the left coronary artery on global myocardial perfusion and function ( pressures in the left ventricle , heart rate ) as well as excitation formation and transmission was studied in 16 patients with ischaemic heart disease .","['The', 'influence', 'of', 'injections', 'of', 'Amidotrizoate', 'and', 'Iopromide', 'into', 'the', 'left', 'coronary', 'artery', 'on', 'global', 'myocardial', 'perfusion', 'and', 'function', '(', 'pressures', 'in', 'the', 'left', 'ventricle', ',', 'heart', 'rate', ')', 'as', 'well', 'as', 'excitation', 'formation', 'and', 'transmission', 'was', 'studied', 'in', '16', 'patients', 'with', 'ischaemic', 'heart', 'disease', '.']","(7, 8)","(48, 57)",-1,ss_i,2678230,Abstract,0,test,gold,
6416,The influence of injections of Amidotrizoate and Iopromide into the left coronary artery on,"global myocardial perfusion and function ( pressures in the left ventricle , heart rate )",as well as excitation formation and transmission was studied in 16 patients with ischaemic heart disease .,"['The', 'influence', 'of', 'injections', 'of', 'Amidotrizoate', 'and', 'Iopromide', 'into', 'the', 'left', 'coronary', 'artery', 'on', 'global', 'myocardial', 'perfusion', 'and', 'function', '(', 'pressures', 'in', 'the', 'left', 'ventricle', ',', 'heart', 'rate', ')', 'as', 'well', 'as', 'excitation', 'formation', 'and', 'transmission', 'was', 'studied', 'in', '16', 'patients', 'with', 'ischaemic', 'heart', 'disease', '.']","(14, 29)","(91, 180)",-1,ss_o,2678230,Abstract,0,test,gold,5979.0
6417,"The influence of injections of Amidotrizoate and Iopromide into the left coronary artery on global myocardial perfusion and function ( pressures in the left ventricle , heart rate ) as well as",excitation formation and transmission,was studied in 16 patients with ischaemic heart disease .,"['The', 'influence', 'of', 'injections', 'of', 'Amidotrizoate', 'and', 'Iopromide', 'into', 'the', 'left', 'coronary', 'artery', 'on', 'global', 'myocardial', 'perfusion', 'and', 'function', '(', 'pressures', 'in', 'the', 'left', 'ventricle', ',', 'heart', 'rate', ')', 'as', 'well', 'as', 'excitation', 'formation', 'and', 'transmission', 'was', 'studied', 'in', '16', 'patients', 'with', 'ischaemic', 'heart', 'disease', '.']","(32, 36)","(192, 229)",-1,ss_o,2678230,Abstract,0,test,gold,3187.0
6418,"The influence of injections of Amidotrizoate and Iopromide into the left coronary artery on global myocardial perfusion and function ( pressures in the left ventricle , heart rate ) as well as excitation formation and transmission was studied in",16 patients with ischaemic heart disease,.,"['The', 'influence', 'of', 'injections', 'of', 'Amidotrizoate', 'and', 'Iopromide', 'into', 'the', 'left', 'coronary', 'artery', 'on', 'global', 'myocardial', 'perfusion', 'and', 'function', '(', 'pressures', 'in', 'the', 'left', 'ventricle', ',', 'heart', 'rate', ')', 'as', 'well', 'as', 'excitation', 'formation', 'and', 'transmission', 'was', 'studied', 'in', '16', 'patients', 'with', 'ischaemic', 'heart', 'disease', '.']","(39, 45)","(245, 285)",-1,hl_p,2678230,Abstract,0,test,gold,7048.0
6419,The influence of injections of,Amidotrizoate,"and Iopromide into the left coronary artery on global myocardial perfusion and function ( pressures in the left ventricle , heart rate ) as well as excitation formation and transmission was studied in 16 patients with ischaemic heart disease .","['The', 'influence', 'of', 'injections', 'of', 'Amidotrizoate', 'and', 'Iopromide', 'into', 'the', 'left', 'coronary', 'artery', 'on', 'global', 'myocardial', 'perfusion', 'and', 'function', '(', 'pressures', 'in', 'the', 'left', 'ventricle', ',', 'heart', 'rate', ')', 'as', 'well', 'as', 'excitation', 'formation', 'and', 'transmission', 'was', 'studied', 'in', '16', 'patients', 'with', 'ischaemic', 'heart', 'disease', '.']","(5, 6)","(30, 43)",-1,hl_i,2678230,Abstract,0,test,gold,
6420,The influence of injections of Amidotrizoate and,Iopromide,"into the left coronary artery on global myocardial perfusion and function ( pressures in the left ventricle , heart rate ) as well as excitation formation and transmission was studied in 16 patients with ischaemic heart disease .","['The', 'influence', 'of', 'injections', 'of', 'Amidotrizoate', 'and', 'Iopromide', 'into', 'the', 'left', 'coronary', 'artery', 'on', 'global', 'myocardial', 'perfusion', 'and', 'function', '(', 'pressures', 'in', 'the', 'left', 'ventricle', ',', 'heart', 'rate', ')', 'as', 'well', 'as', 'excitation', 'formation', 'and', 'transmission', 'was', 'studied', 'in', '16', 'patients', 'with', 'ischaemic', 'heart', 'disease', '.']","(7, 8)","(48, 57)",-1,hl_i,2678230,Abstract,0,test,gold,
6421,The influence of injections of Amidotrizoate and Iopromide into the left coronary artery on,global myocardial perfusion and function,"( pressures in the left ventricle , heart rate ) as well as excitation formation and transmission was studied in 16 patients with ischaemic heart disease .","['The', 'influence', 'of', 'injections', 'of', 'Amidotrizoate', 'and', 'Iopromide', 'into', 'the', 'left', 'coronary', 'artery', 'on', 'global', 'myocardial', 'perfusion', 'and', 'function', '(', 'pressures', 'in', 'the', 'left', 'ventricle', ',', 'heart', 'rate', ')', 'as', 'well', 'as', 'excitation', 'formation', 'and', 'transmission', 'was', 'studied', 'in', '16', 'patients', 'with', 'ischaemic', 'heart', 'disease', '.']","(14, 19)","(91, 131)",-1,hl_o,2678230,Abstract,0,test,gold,6792.0
6422,No statistically significant differences in myocardial perfusion measured were found with xenon-133 in this small group between rest and,dipyridamole,load for ionic and non-ionic contrast media .,"['No', 'statistically', 'significant', 'differences', 'in', 'myocardial', 'perfusion', 'measured', 'were', 'found', 'with', 'xenon-133', 'in', 'this', 'small', 'group', 'between', 'rest', 'and', 'dipyridamole', 'load', 'for', 'ionic', 'and', 'non-ionic', 'contrast', 'media', '.']","(19, 20)","(136, 148)",-1,ss_i,2678230,Abstract,1,test,gold,5737.0
6423,No statistically significant differences in,myocardial perfusion,measured were found with xenon-133 in this small group between rest and dipyridamole load for ionic and non-ionic contrast media .,"['No', 'statistically', 'significant', 'differences', 'in', 'myocardial', 'perfusion', 'measured', 'were', 'found', 'with', 'xenon-133', 'in', 'this', 'small', 'group', 'between', 'rest', 'and', 'dipyridamole', 'load', 'for', 'ionic', 'and', 'non-ionic', 'contrast', 'media', '.']","(5, 7)","(43, 63)",-1,ss_o,2678230,Abstract,1,test,gold,6794.0
6424,No statistically significant differences in,myocardial perfusion,measured were found with xenon-133 in this small group between rest and dipyridamole load for ionic and non-ionic contrast media .,"['No', 'statistically', 'significant', 'differences', 'in', 'myocardial', 'perfusion', 'measured', 'were', 'found', 'with', 'xenon-133', 'in', 'this', 'small', 'group', 'between', 'rest', 'and', 'dipyridamole', 'load', 'for', 'ionic', 'and', 'non-ionic', 'contrast', 'media', '.']","(5, 7)","(43, 63)",-1,hl_o,2678230,Abstract,1,test,gold,6795.0
6425,[ The sympatho-adrenergic stress reaction in,ear surgery,using various anesthesia technics ] .,"['[', 'The', 'sympatho-adrenergic', 'stress', 'reaction', 'in', 'ear', 'surgery', 'using', 'various', 'anesthesia', 'technics', ']', '.']","(6, 8)","(44, 55)",-1,ss_p,2803397,Title,0,test,gold,3657.0
6426,,[ The sympatho-adrenergic stress reaction,in ear surgery using various anesthesia technics ] .,"['[', 'The', 'sympatho-adrenergic', 'stress', 'reaction', 'in', 'ear', 'surgery', 'using', 'various', 'anesthesia', 'technics', ']', '.']","(0, 5)","(0, 41)",-1,ss_o,2803397,Title,0,test,gold,2446.0
6427,[ The sympatho-adrenergic stress reaction in,ear surgery,using various anesthesia technics ] .,"['[', 'The', 'sympatho-adrenergic', 'stress', 'reaction', 'in', 'ear', 'surgery', 'using', 'various', 'anesthesia', 'technics', ']', '.']","(6, 8)","(44, 55)",-1,hl_p,2803397,Title,0,test,gold,3658.0
6428,The aim of the present study was to investigate the effects of various anaesthetic procedures on the endocrine stress responses during,ear microsurgical operations .,,"['The', 'aim', 'of', 'the', 'present', 'study', 'was', 'to', 'investigate', 'the', 'effects', 'of', 'various', 'anaesthetic', 'procedures', 'on', 'the', 'endocrine', 'stress', 'responses', 'during', 'ear', 'microsurgical', 'operations', '.']","(21, 25)","(134, 164)",-1,ss_p,2803397,Abstract,0,test,gold,3125.0
6429,The aim of the present study was to investigate the effects of various anaesthetic procedures on the,endocrine stress responses,during ear microsurgical operations .,"['The', 'aim', 'of', 'the', 'present', 'study', 'was', 'to', 'investigate', 'the', 'effects', 'of', 'various', 'anaesthetic', 'procedures', 'on', 'the', 'endocrine', 'stress', 'responses', 'during', 'ear', 'microsurgical', 'operations', '.']","(17, 20)","(100, 126)",-1,ss_o,2803397,Abstract,0,test,gold,2469.0
6430,The aim of the present study was to investigate the effects of various anaesthetic procedures on the endocrine stress responses during,ear microsurgical operations .,,"['The', 'aim', 'of', 'the', 'present', 'study', 'was', 'to', 'investigate', 'the', 'effects', 'of', 'various', 'anaesthetic', 'procedures', 'on', 'the', 'endocrine', 'stress', 'responses', 'during', 'ear', 'microsurgical', 'operations', '.']","(21, 25)","(134, 164)",-1,hl_p,2803397,Abstract,0,test,gold,3126.0
6431,,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients","under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(0, 14)","(0, 101)",-1,ss_p,2803397,Abstract,1,test,gold,1789.0
6432,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1",halothane,"anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(23, 24)","(165, 174)",-1,ss_i,2803397,Abstract,1,test,gold,141.0
6433,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with",lidocaine,"and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(30, 31)","(236, 245)",-1,ss_i,2803397,Abstract,1,test,gold,4934.0
6434,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and",ornipressin,"( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(32, 33)","(250, 261)",-1,ss_i,2803397,Abstract,1,test,gold,
6435,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2",fentanyl,"anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(41, 42)","(283, 291)",-1,ss_i,2803397,Abstract,1,test,gold,5091.0
6436,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with",lidocaine,"and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(47, 48)","(340, 349)",-1,ss_i,2803397,Abstract,1,test,gold,4933.0
6437,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and",ornipressin,"( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(49, 50)","(354, 365)",-1,ss_i,2803397,Abstract,1,test,gold,
6438,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3",fentanyl,"anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(58, 59)","(387, 395)",-1,ss_i,2803397,Abstract,1,test,gold,5090.0
6439,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with",lidocaine,"and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(65, 66)","(457, 466)",-1,ss_i,2803397,Abstract,1,test,gold,4932.0
6440,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and",epinephrine,"( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(67, 68)","(471, 482)",-1,ss_i,2803397,Abstract,1,test,gold,5446.0
6441,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with",prilocaine,and epinephrine ( n = 14 ) .,"['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(81, 82)","(553, 563)",-1,ss_i,2803397,Abstract,1,test,gold,145.0
6442,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and",epinephrine,( n = 14 ) .,"['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(83, 84)","(568, 579)",-1,ss_i,2803397,Abstract,1,test,gold,5447.0
6443,,"Simple mastoidectomies , radical mastoidectomies and tympano plastics","were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(0, 8)","(0, 69)",-1,hl_p,2803397,Abstract,1,test,gold,1790.0
6444,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in",49,"patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(12, 13)","(89, 91)",-1,hl_p,2803397,Abstract,1,test,gold,
6445,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1",halothane,"anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(23, 24)","(165, 174)",-1,hl_i,2803397,Abstract,1,test,gold,142.0
6446,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with",lidocaine,"and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(30, 31)","(236, 245)",-1,hl_i,2803397,Abstract,1,test,gold,4931.0
6447,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and",ornipressin,"( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(32, 33)","(250, 261)",-1,hl_i,2803397,Abstract,1,test,gold,
6448,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2",fentanyl,"anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(41, 42)","(283, 291)",-1,hl_i,2803397,Abstract,1,test,gold,5089.0
6449,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with",lidocaine,"and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(47, 48)","(340, 349)",-1,hl_i,2803397,Abstract,1,test,gold,4930.0
6450,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and",ornipressin,"( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(49, 50)","(354, 365)",-1,hl_i,2803397,Abstract,1,test,gold,
6451,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3",fentanyl,"anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(58, 59)","(387, 395)",-1,hl_i,2803397,Abstract,1,test,gold,5088.0
6452,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with",lidocaine,"and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(65, 66)","(457, 466)",-1,hl_i,2803397,Abstract,1,test,gold,4929.0
6453,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and",epinephrine,"( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and epinephrine ( n = 14 ) .","['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(67, 68)","(471, 482)",-1,hl_i,2803397,Abstract,1,test,gold,5445.0
6454,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with",prilocaine,and epinephrine ( n = 14 ) .,"['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(81, 82)","(553, 563)",-1,hl_i,2803397,Abstract,1,test,gold,146.0
6455,"Simple mastoidectomies , radical mastoidectomies and tympano plastics were carried out in 49 patients under the following randomised anaesthetic procedures : Group 1 halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin ( n = 14 ) , Group 2 fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin ( n = 10 ) , Group 3 fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine ( n = 14 ) , and Group 4 retroauricular infiltration anaesthesia with prilocaine and",epinephrine,( n = 14 ) .,"['Simple', 'mastoidectomies', ',', 'radical', 'mastoidectomies', 'and', 'tympano', 'plastics', 'were', 'carried', 'out', 'in', '49', 'patients', 'under', 'the', 'following', 'randomised', 'anaesthetic', 'procedures', ':', 'Group', '1', 'halothane', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '14', ')', ',', 'Group', '2', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'anaesthesia', 'with', 'lidocaine', 'and', 'ornipressin', '(', 'n', '=', '10', ')', ',', 'Group', '3', 'fentanyl', 'anaesthesia', 'and', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'lidocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', ',', 'and', 'Group', '4', 'retroauricular', 'infiltration', 'anaesthesia', 'with', 'prilocaine', 'and', 'epinephrine', '(', 'n', '=', '14', ')', '.']","(83, 84)","(568, 579)",-1,hl_i,2803397,Abstract,1,test,gold,5444.0
6456,The,"plasma levels of epinephrine , norepinephrine , glucose , lactate and free glycerol","were measured in addition to mean arterial pressure ( MAP ) and heart rate ( HR ) immediately before anaesthesia , 10 minutes after skin incision , 10 minutes after having started bone drilling , at the end of the operation and 3 hours after operation .","['The', 'plasma', 'levels', 'of', 'epinephrine', ',', 'norepinephrine', ',', 'glucose', ',', 'lactate', 'and', 'free', 'glycerol', 'were', 'measured', 'in', 'addition', 'to', 'mean', 'arterial', 'pressure', '(', 'MAP', ')', 'and', 'heart', 'rate', '(', 'HR', ')', 'immediately', 'before', 'anaesthesia', ',', '10', 'minutes', 'after', 'skin', 'incision', ',', '10', 'minutes', 'after', 'having', 'started', 'bone', 'drilling', ',', 'at', 'the', 'end', 'of', 'the', 'operation', 'and', '3', 'hours', 'after', 'operation', '.']","(1, 14)","(3, 86)",-1,ss_o,2803397,Abstract,2,test,gold,6532.0
6457,"The plasma levels of epinephrine , norepinephrine , glucose , lactate and free glycerol were measured in addition to",mean arterial pressure ( MAP ) and heart rate ( HR ),"immediately before anaesthesia , 10 minutes after skin incision , 10 minutes after having started bone drilling , at the end of the operation and 3 hours after operation .","['The', 'plasma', 'levels', 'of', 'epinephrine', ',', 'norepinephrine', ',', 'glucose', ',', 'lactate', 'and', 'free', 'glycerol', 'were', 'measured', 'in', 'addition', 'to', 'mean', 'arterial', 'pressure', '(', 'MAP', ')', 'and', 'heart', 'rate', '(', 'HR', ')', 'immediately', 'before', 'anaesthesia', ',', '10', 'minutes', 'after', 'skin', 'incision', ',', '10', 'minutes', 'after', 'having', 'started', 'bone', 'drilling', ',', 'at', 'the', 'end', 'of', 'the', 'operation', 'and', '3', 'hours', 'after', 'operation', '.']","(19, 31)","(116, 168)",-1,ss_o,2803397,Abstract,2,test,gold,6725.0
6458,The,"plasma levels of epinephrine , norepinephrine , glucose , lactate","and free glycerol were measured in addition to mean arterial pressure ( MAP ) and heart rate ( HR ) immediately before anaesthesia , 10 minutes after skin incision , 10 minutes after having started bone drilling , at the end of the operation and 3 hours after operation .","['The', 'plasma', 'levels', 'of', 'epinephrine', ',', 'norepinephrine', ',', 'glucose', ',', 'lactate', 'and', 'free', 'glycerol', 'were', 'measured', 'in', 'addition', 'to', 'mean', 'arterial', 'pressure', '(', 'MAP', ')', 'and', 'heart', 'rate', '(', 'HR', ')', 'immediately', 'before', 'anaesthesia', ',', '10', 'minutes', 'after', 'skin', 'incision', ',', '10', 'minutes', 'after', 'having', 'started', 'bone', 'drilling', ',', 'at', 'the', 'end', 'of', 'the', 'operation', 'and', '3', 'hours', 'after', 'operation', '.']","(1, 11)","(3, 68)",-1,hl_o,2803397,Abstract,2,test,gold,6533.0
6459,All data were subjected to covariance analysis including the age factor .,,,"['All', 'data', 'were', 'subjected', 'to', 'covariance', 'analysis', 'including', 'the', 'age', 'factor', '.']",,,,,2803397,Abstract,3,test,gold,
6460,,Plasma catecholamine concentrations,remained within the normal range during the investigation in patients subjected to general anaesthesia ( Groups 1-3 ) .,"['Plasma', 'catecholamine', 'concentrations', 'remained', 'within', 'the', 'normal', 'range', 'during', 'the', 'investigation', 'in', 'patients', 'subjected', 'to', 'general', 'anaesthesia', '(', 'Groups', '1-3', ')', '.']","(0, 3)","(0, 35)",-1,ss_o,2803397,Abstract,4,test,gold,4509.0
6461,,Plasma catecholamine concentrations,remained within the normal range during the investigation in patients subjected to general anaesthesia ( Groups 1-3 ) .,"['Plasma', 'catecholamine', 'concentrations', 'remained', 'within', 'the', 'normal', 'range', 'during', 'the', 'investigation', 'in', 'patients', 'subjected', 'to', 'general', 'anaesthesia', '(', 'Groups', '1-3', ')', '.']","(0, 3)","(0, 35)",-1,hl_o,2803397,Abstract,4,test,gold,4510.0
6462,,Plasma catecholamines ( epinephrine and norepinephrine ),increased significantly in Group 4 ( retroauricular infiltration anaesthesia ) .,"['Plasma', 'catecholamines', '(', 'epinephrine', 'and', 'norepinephrine', ')', 'increased', 'significantly', 'in', 'Group', '4', '(', 'retroauricular', 'infiltration', 'anaesthesia', ')', '.']","(0, 7)","(0, 56)",-1,ss_o,2803397,Abstract,5,test,gold,6611.0
6463,,Plasma catecholamines ( epinephrine and norepinephrine ),increased significantly in Group 4 ( retroauricular infiltration anaesthesia ) .,"['Plasma', 'catecholamines', '(', 'epinephrine', 'and', 'norepinephrine', ')', 'increased', 'significantly', 'in', 'Group', '4', '(', 'retroauricular', 'infiltration', 'anaesthesia', ')', '.']","(0, 7)","(0, 56)",-1,hl_o,2803397,Abstract,5,test,gold,6612.0
6464,There were no group variabilities with regard to,MAP,and HR .,"['There', 'were', 'no', 'group', 'variabilities', 'with', 'regard', 'to', 'MAP', 'and', 'HR', '.']","(8, 9)","(48, 51)",-1,ss_o,2803397,Abstract,6,test,gold,1077.0
6465,There were no group variabilities with regard to MAP and,HR .,,"['There', 'were', 'no', 'group', 'variabilities', 'with', 'regard', 'to', 'MAP', 'and', 'HR', '.']","(10, 12)","(56, 60)",-1,ss_o,2803397,Abstract,6,test,gold,1088.0
6466,There were no group variabilities with regard to,MAP,and HR .,"['There', 'were', 'no', 'group', 'variabilities', 'with', 'regard', 'to', 'MAP', 'and', 'HR', '.']","(8, 9)","(48, 51)",-1,hl_o,2803397,Abstract,6,test,gold,1078.0
6467,There were no group variabilities with regard to MAP and,HR .,,"['There', 'were', 'no', 'group', 'variabilities', 'with', 'regard', 'to', 'MAP', 'and', 'HR', '.']","(10, 12)","(56, 60)",-1,hl_o,2803397,Abstract,6,test,gold,1089.0
6468,The,plasma levels of epinephrine and norepinephrine,"demonstrate a direct response to stress followed by a secondary change in glucose , lactate and free glycerol .","['The', 'plasma', 'levels', 'of', 'epinephrine', 'and', 'norepinephrine', 'demonstrate', 'a', 'direct', 'response', 'to', 'stress', 'followed', 'by', 'a', 'secondary', 'change', 'in', 'glucose', ',', 'lactate', 'and', 'free', 'glycerol', '.']","(1, 7)","(3, 50)",-1,ss_o,2803397,Abstract,7,test,gold,6609.0
6469,The plasma levels of epinephrine and norepinephrine demonstrate a direct response to stress followed by a secondary change in,"glucose , lactate and free glycerol .",,"['The', 'plasma', 'levels', 'of', 'epinephrine', 'and', 'norepinephrine', 'demonstrate', 'a', 'direct', 'response', 'to', 'stress', 'followed', 'by', 'a', 'secondary', 'change', 'in', 'glucose', ',', 'lactate', 'and', 'free', 'glycerol', '.']","(19, 26)","(125, 162)",-1,ss_o,2803397,Abstract,7,test,gold,6572.0
6470,The,plasma levels of epinephrine and norepinephrine,"demonstrate a direct response to stress followed by a secondary change in glucose , lactate and free glycerol .","['The', 'plasma', 'levels', 'of', 'epinephrine', 'and', 'norepinephrine', 'demonstrate', 'a', 'direct', 'response', 'to', 'stress', 'followed', 'by', 'a', 'secondary', 'change', 'in', 'glucose', ',', 'lactate', 'and', 'free', 'glycerol', '.']","(1, 7)","(3, 50)",-1,hl_o,2803397,Abstract,7,test,gold,6610.0
6471,The plasma levels of epinephrine and norepinephrine demonstrate a direct response to stress followed by a secondary change in,"glucose , lactate and free glycerol .",,"['The', 'plasma', 'levels', 'of', 'epinephrine', 'and', 'norepinephrine', 'demonstrate', 'a', 'direct', 'response', 'to', 'stress', 'followed', 'by', 'a', 'secondary', 'change', 'in', 'glucose', ',', 'lactate', 'and', 'free', 'glycerol', '.']","(19, 26)","(125, 162)",-1,hl_o,2803397,Abstract,7,test,gold,6573.0
6472,The beneficial effect of general anaesthesia is documented by normal plasma levels of epinephrine and norepinephrine throughout the operation .,,,"['The', 'beneficial', 'effect', 'of', 'general', 'anaesthesia', 'is', 'documented', 'by', 'normal', 'plasma', 'levels', 'of', 'epinephrine', 'and', 'norepinephrine', 'throughout', 'the', 'operation', '.']",,,,,2803397,Abstract,8,test,gold,
6473,( ABSTRACT TRUNCATED AT 250 WORDS ),,,"['(', 'ABSTRACT', 'TRUNCATED', 'AT', '250', 'WORDS', ')']",,,,,2803397,Abstract,9,test,gold,
6474,Low doses of ketazolam in,anxiety :,"a double-blind , placebo-controlled study .","['Low', 'doses', 'of', 'ketazolam', 'in', 'anxiety', ':', 'a', 'double-blind', ',', 'placebo-controlled', 'study', '.']","(5, 7)","(25, 34)",-1,ss_p,2908133,Title,0,test,gold,2436.0
6475,Low doses of,ketazolam,"in anxiety : a double-blind , placebo-controlled study .","['Low', 'doses', 'of', 'ketazolam', 'in', 'anxiety', ':', 'a', 'double-blind', ',', 'placebo-controlled', 'study', '.']","(3, 4)","(12, 21)",-1,ss_i,2908133,Title,0,test,gold,
6476,Low doses of ketazolam in,anxiety :,"a double-blind , placebo-controlled study .","['Low', 'doses', 'of', 'ketazolam', 'in', 'anxiety', ':', 'a', 'double-blind', ',', 'placebo-controlled', 'study', '.']","(5, 7)","(25, 34)",-1,hl_p,2908133,Title,0,test,gold,2435.0
6477,Low doses of,ketazolam,"in anxiety : a double-blind , placebo-controlled study .","['Low', 'doses', 'of', 'ketazolam', 'in', 'anxiety', ':', 'a', 'double-blind', ',', 'placebo-controlled', 'study', '.']","(3, 4)","(12, 21)",-1,hl_i,2908133,Title,0,test,gold,
6478,"A multicenter , double-blind , between-patient trial comparing two doses of ketazolam ( 15 and 30 mg ) with placebo , each given once daily , in the evening , to",92 outpatients affected by generalized anxiety disorders,"for at least 1 month , was carried out .","['A', 'multicenter', ',', 'double-blind', ',', 'between-patient', 'trial', 'comparing', 'two', 'doses', 'of', 'ketazolam', '(', '15', 'and', '30', 'mg', ')', 'with', 'placebo', ',', 'each', 'given', 'once', 'daily', ',', 'in', 'the', 'evening', ',', 'to', '92', 'outpatients', 'affected', 'by', 'generalized', 'anxiety', 'disorders', 'for', 'at', 'least', '1', 'month', ',', 'was', 'carried', 'out', '.']","(31, 38)","(161, 217)",-1,ss_p,2908133,Abstract,0,test,gold,6969.0
6479,"A multicenter , double-blind , between-patient trial comparing two doses of",ketazolam,"( 15 and 30 mg ) with placebo , each given once daily , in the evening , to 92 outpatients affected by generalized anxiety disorders for at least 1 month , was carried out .","['A', 'multicenter', ',', 'double-blind', ',', 'between-patient', 'trial', 'comparing', 'two', 'doses', 'of', 'ketazolam', '(', '15', 'and', '30', 'mg', ')', 'with', 'placebo', ',', 'each', 'given', 'once', 'daily', ',', 'in', 'the', 'evening', ',', 'to', '92', 'outpatients', 'affected', 'by', 'generalized', 'anxiety', 'disorders', 'for', 'at', 'least', '1', 'month', ',', 'was', 'carried', 'out', '.']","(11, 12)","(75, 84)",-1,ss_i,2908133,Abstract,0,test,gold,
6480,"A multicenter , double-blind , between-patient trial comparing two doses of ketazolam ( 15 and 30 mg ) with",placebo,", each given once daily , in the evening , to 92 outpatients affected by generalized anxiety disorders for at least 1 month , was carried out .","['A', 'multicenter', ',', 'double-blind', ',', 'between-patient', 'trial', 'comparing', 'two', 'doses', 'of', 'ketazolam', '(', '15', 'and', '30', 'mg', ')', 'with', 'placebo', ',', 'each', 'given', 'once', 'daily', ',', 'in', 'the', 'evening', ',', 'to', '92', 'outpatients', 'affected', 'by', 'generalized', 'anxiety', 'disorders', 'for', 'at', 'least', '1', 'month', ',', 'was', 'carried', 'out', '.']","(19, 20)","(107, 114)",-1,ss_i,2908133,Abstract,0,test,gold,4323.0
6481,"A multicenter , double-blind , between-patient trial comparing two doses of ketazolam ( 15 and 30 mg ) with placebo , each given once daily , in the evening , to",92 outpatients affected by generalized anxiety disorders,"for at least 1 month , was carried out .","['A', 'multicenter', ',', 'double-blind', ',', 'between-patient', 'trial', 'comparing', 'two', 'doses', 'of', 'ketazolam', '(', '15', 'and', '30', 'mg', ')', 'with', 'placebo', ',', 'each', 'given', 'once', 'daily', ',', 'in', 'the', 'evening', ',', 'to', '92', 'outpatients', 'affected', 'by', 'generalized', 'anxiety', 'disorders', 'for', 'at', 'least', '1', 'month', ',', 'was', 'carried', 'out', '.']","(31, 38)","(161, 217)",-1,hl_p,2908133,Abstract,0,test,gold,6970.0
6482,"A multicenter , double-blind , between-patient trial comparing two doses of",ketazolam,"( 15 and 30 mg ) with placebo , each given once daily , in the evening , to 92 outpatients affected by generalized anxiety disorders for at least 1 month , was carried out .","['A', 'multicenter', ',', 'double-blind', ',', 'between-patient', 'trial', 'comparing', 'two', 'doses', 'of', 'ketazolam', '(', '15', 'and', '30', 'mg', ')', 'with', 'placebo', ',', 'each', 'given', 'once', 'daily', ',', 'in', 'the', 'evening', ',', 'to', '92', 'outpatients', 'affected', 'by', 'generalized', 'anxiety', 'disorders', 'for', 'at', 'least', '1', 'month', ',', 'was', 'carried', 'out', '.']","(11, 12)","(75, 84)",-1,hl_i,2908133,Abstract,0,test,gold,
6483,"A multicenter , double-blind , between-patient trial comparing two doses of ketazolam ( 15 and 30 mg ) with",placebo,", each given once daily , in the evening , to 92 outpatients affected by generalized anxiety disorders for at least 1 month , was carried out .","['A', 'multicenter', ',', 'double-blind', ',', 'between-patient', 'trial', 'comparing', 'two', 'doses', 'of', 'ketazolam', '(', '15', 'and', '30', 'mg', ')', 'with', 'placebo', ',', 'each', 'given', 'once', 'daily', ',', 'in', 'the', 'evening', ',', 'to', '92', 'outpatients', 'affected', 'by', 'generalized', 'anxiety', 'disorders', 'for', 'at', 'least', '1', 'month', ',', 'was', 'carried', 'out', '.']","(19, 20)","(107, 114)",-1,hl_i,2908133,Abstract,0,test,gold,4322.0
6484,After 1-week washout period 47 patients were randomized to,ketazolam,"15 mg , and 45 to placebo for 15 days ( first period ) .","['After', '1-week', 'washout', 'period', '47', 'patients', 'were', 'randomized', 'to', 'ketazolam', '15', 'mg', ',', 'and', '45', 'to', 'placebo', 'for', '15', 'days', '(', 'first', 'period', ')', '.']","(9, 10)","(58, 67)",-1,ss_i,2908133,Abstract,1,test,gold,
6485,"After 1-week washout period 47 patients were randomized to ketazolam 15 mg , and 45 to",placebo,for 15 days ( first period ) .,"['After', '1-week', 'washout', 'period', '47', 'patients', 'were', 'randomized', 'to', 'ketazolam', '15', 'mg', ',', 'and', '45', 'to', 'placebo', 'for', '15', 'days', '(', 'first', 'period', ')', '.']","(16, 17)","(86, 93)",-1,ss_i,2908133,Abstract,1,test,gold,4321.0
6486,After 1-week washout period 47 patients were randomized to,ketazolam,"15 mg , and 45 to placebo for 15 days ( first period ) .","['After', '1-week', 'washout', 'period', '47', 'patients', 'were', 'randomized', 'to', 'ketazolam', '15', 'mg', ',', 'and', '45', 'to', 'placebo', 'for', '15', 'days', '(', 'first', 'period', ')', '.']","(9, 10)","(58, 67)",-1,hl_i,2908133,Abstract,1,test,gold,
6487,"After 1-week washout period 47 patients were randomized to ketazolam 15 mg , and 45 to",placebo,for 15 days ( first period ) .,"['After', '1-week', 'washout', 'period', '47', 'patients', 'were', 'randomized', 'to', 'ketazolam', '15', 'mg', ',', 'and', '45', 'to', 'placebo', 'for', '15', 'days', '(', 'first', 'period', ')', '.']","(16, 17)","(86, 93)",-1,hl_i,2908133,Abstract,1,test,gold,4320.0
6488,"At the end of this period , if the patient experienced a decrease on the total Hamilton Anxiety Rating Scale ( HAM-A ) of at least 25 % of basal value , the treatment was kept unchanged for a further 15 days , otherwise 15 mg of",ketazolam,were added to the previous treatment ( second period ) .,"['At', 'the', 'end', 'of', 'this', 'period', ',', 'if', 'the', 'patient', 'experienced', 'a', 'decrease', 'on', 'the', 'total', 'Hamilton', 'Anxiety', 'Rating', 'Scale', '(', 'HAM-A', ')', 'of', 'at', 'least', '25', '%', 'of', 'basal', 'value', ',', 'the', 'treatment', 'was', 'kept', 'unchanged', 'for', 'a', 'further', '15', 'days', ',', 'otherwise', '15', 'mg', 'of', 'ketazolam', 'were', 'added', 'to', 'the', 'previous', 'treatment', '(', 'second', 'period', ')', '.']","(47, 48)","(228, 237)",-1,ss_i,2908133,Abstract,2,test,gold,
6489,"At the end of this period , if the patient experienced a decrease on the",total Hamilton Anxiety Rating Scale ( HAM-A ),"of at least 25 % of basal value , the treatment was kept unchanged for a further 15 days , otherwise 15 mg of ketazolam were added to the previous treatment ( second period ) .","['At', 'the', 'end', 'of', 'this', 'period', ',', 'if', 'the', 'patient', 'experienced', 'a', 'decrease', 'on', 'the', 'total', 'Hamilton', 'Anxiety', 'Rating', 'Scale', '(', 'HAM-A', ')', 'of', 'at', 'least', '25', '%', 'of', 'basal', 'value', ',', 'the', 'treatment', 'was', 'kept', 'unchanged', 'for', 'a', 'further', '15', 'days', ',', 'otherwise', '15', 'mg', 'of', 'ketazolam', 'were', 'added', 'to', 'the', 'previous', 'treatment', '(', 'second', 'period', ')', '.']","(15, 23)","(72, 117)",-1,ss_o,2908133,Abstract,2,test,gold,6212.0
6490,"At the end of this period , if the patient experienced a decrease on the total Hamilton Anxiety Rating Scale ( HAM-A ) of at least 25 % of basal value , the treatment was kept unchanged for a further 15 days , otherwise 15 mg of",ketazolam,were added to the previous treatment ( second period ) .,"['At', 'the', 'end', 'of', 'this', 'period', ',', 'if', 'the', 'patient', 'experienced', 'a', 'decrease', 'on', 'the', 'total', 'Hamilton', 'Anxiety', 'Rating', 'Scale', '(', 'HAM-A', ')', 'of', 'at', 'least', '25', '%', 'of', 'basal', 'value', ',', 'the', 'treatment', 'was', 'kept', 'unchanged', 'for', 'a', 'further', '15', 'days', ',', 'otherwise', '15', 'mg', 'of', 'ketazolam', 'were', 'added', 'to', 'the', 'previous', 'treatment', '(', 'second', 'period', ')', '.']","(47, 48)","(228, 237)",-1,hl_i,2908133,Abstract,2,test,gold,
6491,"At the end of this period , if the patient experienced a decrease on the",total Hamilton Anxiety Rating Scale ( HAM-A ),"of at least 25 % of basal value , the treatment was kept unchanged for a further 15 days , otherwise 15 mg of ketazolam were added to the previous treatment ( second period ) .","['At', 'the', 'end', 'of', 'this', 'period', ',', 'if', 'the', 'patient', 'experienced', 'a', 'decrease', 'on', 'the', 'total', 'Hamilton', 'Anxiety', 'Rating', 'Scale', '(', 'HAM-A', ')', 'of', 'at', 'least', '25', '%', 'of', 'basal', 'value', ',', 'the', 'treatment', 'was', 'kept', 'unchanged', 'for', 'a', 'further', '15', 'days', ',', 'otherwise', '15', 'mg', 'of', 'ketazolam', 'were', 'added', 'to', 'the', 'previous', 'treatment', '(', 'second', 'period', ')', '.']","(15, 23)","(72, 117)",-1,hl_o,2908133,Abstract,2,test,gold,6213.0
6492,,Anxiety,was rated after 2 and 4 weeks with the Italian HAM-A scale and with a 4-point scale ( patient 's assessment ) .,"['Anxiety', 'was', 'rated', 'after', '2', 'and', '4', 'weeks', 'with', 'the', 'Italian', 'HAM-A', 'scale', 'and', 'with', 'a', '4-point', 'scale', '(', 'patient', ""'s"", 'assessment', ')', '.']","(0, 1)","(0, 7)",-1,ss_o,2908133,Abstract,3,test,gold,2450.0
6493,Anxiety was rated after 2 and 4 weeks with the,Italian HAM-A scale and with a 4-point scale ( patient 's assessment ) .,,"['Anxiety', 'was', 'rated', 'after', '2', 'and', '4', 'weeks', 'with', 'the', 'Italian', 'HAM-A', 'scale', 'and', 'with', 'a', '4-point', 'scale', '(', 'patient', ""'s"", 'assessment', ')', '.']","(10, 24)","(46, 118)",-1,ss_o,2908133,Abstract,3,test,gold,3884.0
6494,Anxiety was rated after 2 and 4 weeks with the,Italian HAM-A scale,and with a 4-point scale ( patient 's assessment ) .,"['Anxiety', 'was', 'rated', 'after', '2', 'and', '4', 'weeks', 'with', 'the', 'Italian', 'HAM-A', 'scale', 'and', 'with', 'a', '4-point', 'scale', '(', 'patient', ""'s"", 'assessment', ')', '.']","(10, 13)","(46, 65)",-1,hl_o,2908133,Abstract,3,test,gold,1372.0
6495,Anxiety was rated after 2 and 4 weeks with the Italian HAM-A scale and with a,4-point scale ( patient 's assessment ) .,,"['Anxiety', 'was', 'rated', 'after', '2', 'and', '4', 'weeks', 'with', 'the', 'Italian', 'HAM-A', 'scale', 'and', 'with', 'a', '4-point', 'scale', '(', 'patient', ""'s"", 'assessment', ')', '.']","(16, 24)","(77, 118)",-1,hl_o,2908133,Abstract,3,test,gold,3885.0
6496,,Seventy-eight patients completed the first period and 75 the whole study .,,"['Seventy-eight', 'patients', 'completed', 'the', 'first', 'period', 'and', '75', 'the', 'whole', 'study', '.']","(0, 12)","(0, 74)",-1,ss_p,2908133,Abstract,4,test,gold,5862.0
6497,,Seventy-eight,patients completed the first period and 75 the whole study .,"['Seventy-eight', 'patients', 'completed', 'the', 'first', 'period', 'and', '75', 'the', 'whole', 'study', '.']","(0, 1)","(0, 13)",-1,hl_p,2908133,Abstract,4,test,gold,
6498,Seventy-eight patients completed the first period and,75,the whole study .,"['Seventy-eight', 'patients', 'completed', 'the', 'first', 'period', 'and', '75', 'the', 'whole', 'study', '.']","(7, 8)","(53, 55)",-1,hl_p,2908133,Abstract,4,test,gold,
6499,"During the first period the percentage of responders was almost identical in both treatment groups , but during the second period a further slight improvement was observed in the early",placebo,"responders , while the HAM-A score of patients on ketazolam continued to improve significantly ( p less than 0.01 ) throughout the study .","['During', 'the', 'first', 'period', 'the', 'percentage', 'of', 'responders', 'was', 'almost', 'identical', 'in', 'both', 'treatment', 'groups', ',', 'but', 'during', 'the', 'second', 'period', 'a', 'further', 'slight', 'improvement', 'was', 'observed', 'in', 'the', 'early', 'placebo', 'responders', ',', 'while', 'the', 'HAM-A', 'score', 'of', 'patients', 'on', 'ketazolam', 'continued', 'to', 'improve', 'significantly', '(', 'p', 'less', 'than', '0.01', ')', 'throughout', 'the', 'study', '.']","(30, 31)","(184, 191)",-1,ss_i,2908133,Abstract,5,test,gold,4319.0
6500,"During the first period the percentage of responders was almost identical in both treatment groups , but during the second period a further slight improvement was observed in the early placebo responders , while the HAM-A score of patients on",ketazolam,continued to improve significantly ( p less than 0.01 ) throughout the study .,"['During', 'the', 'first', 'period', 'the', 'percentage', 'of', 'responders', 'was', 'almost', 'identical', 'in', 'both', 'treatment', 'groups', ',', 'but', 'during', 'the', 'second', 'period', 'a', 'further', 'slight', 'improvement', 'was', 'observed', 'in', 'the', 'early', 'placebo', 'responders', ',', 'while', 'the', 'HAM-A', 'score', 'of', 'patients', 'on', 'ketazolam', 'continued', 'to', 'improve', 'significantly', '(', 'p', 'less', 'than', '0.01', ')', 'throughout', 'the', 'study', '.']","(40, 41)","(242, 251)",-1,ss_i,2908133,Abstract,5,test,gold,
6501,"During the first period the percentage of responders was almost identical in both treatment groups , but during the second period a further slight improvement was observed in the early placebo responders , while the",HAM-A score,of patients on ketazolam continued to improve significantly ( p less than 0.01 ) throughout the study .,"['During', 'the', 'first', 'period', 'the', 'percentage', 'of', 'responders', 'was', 'almost', 'identical', 'in', 'both', 'treatment', 'groups', ',', 'but', 'during', 'the', 'second', 'period', 'a', 'further', 'slight', 'improvement', 'was', 'observed', 'in', 'the', 'early', 'placebo', 'responders', ',', 'while', 'the', 'HAM-A', 'score', 'of', 'patients', 'on', 'ketazolam', 'continued', 'to', 'improve', 'significantly', '(', 'p', 'less', 'than', '0.01', ')', 'throughout', 'the', 'study', '.']","(35, 37)","(215, 226)",-1,ss_o,2908133,Abstract,5,test,gold,1442.0
6502,"During the first period the percentage of responders was almost identical in both treatment groups , but during the second period a further slight improvement was observed in the early",placebo,"responders , while the HAM-A score of patients on ketazolam continued to improve significantly ( p less than 0.01 ) throughout the study .","['During', 'the', 'first', 'period', 'the', 'percentage', 'of', 'responders', 'was', 'almost', 'identical', 'in', 'both', 'treatment', 'groups', ',', 'but', 'during', 'the', 'second', 'period', 'a', 'further', 'slight', 'improvement', 'was', 'observed', 'in', 'the', 'early', 'placebo', 'responders', ',', 'while', 'the', 'HAM-A', 'score', 'of', 'patients', 'on', 'ketazolam', 'continued', 'to', 'improve', 'significantly', '(', 'p', 'less', 'than', '0.01', ')', 'throughout', 'the', 'study', '.']","(30, 31)","(184, 191)",-1,hl_i,2908133,Abstract,5,test,gold,4318.0
6503,"During the first period the percentage of responders was almost identical in both treatment groups , but during the second period a further slight improvement was observed in the early placebo responders , while the HAM-A score of patients on",ketazolam,continued to improve significantly ( p less than 0.01 ) throughout the study .,"['During', 'the', 'first', 'period', 'the', 'percentage', 'of', 'responders', 'was', 'almost', 'identical', 'in', 'both', 'treatment', 'groups', ',', 'but', 'during', 'the', 'second', 'period', 'a', 'further', 'slight', 'improvement', 'was', 'observed', 'in', 'the', 'early', 'placebo', 'responders', ',', 'while', 'the', 'HAM-A', 'score', 'of', 'patients', 'on', 'ketazolam', 'continued', 'to', 'improve', 'significantly', '(', 'p', 'less', 'than', '0.01', ')', 'throughout', 'the', 'study', '.']","(40, 41)","(242, 251)",-1,hl_i,2908133,Abstract,5,test,gold,
6504,"During the first period the percentage of responders was almost identical in both treatment groups , but during the second period a further slight improvement was observed in the early placebo responders , while the",HAM-A score,of patients on ketazolam continued to improve significantly ( p less than 0.01 ) throughout the study .,"['During', 'the', 'first', 'period', 'the', 'percentage', 'of', 'responders', 'was', 'almost', 'identical', 'in', 'both', 'treatment', 'groups', ',', 'but', 'during', 'the', 'second', 'period', 'a', 'further', 'slight', 'improvement', 'was', 'observed', 'in', 'the', 'early', 'placebo', 'responders', ',', 'while', 'the', 'HAM-A', 'score', 'of', 'patients', 'on', 'ketazolam', 'continued', 'to', 'improve', 'significantly', '(', 'p', 'less', 'than', '0.01', ')', 'throughout', 'the', 'study', '.']","(35, 37)","(215, 226)",-1,hl_o,2908133,Abstract,5,test,gold,1441.0
6505,"Likewise a significant ( p less than 0.001 ) difference between treatments was observed , on the",4-point scale,", in the population as a whole ( end of first period ) as well as in responder patients ( end second period ) .","['Likewise', 'a', 'significant', '(', 'p', 'less', 'than', '0.001', ')', 'difference', 'between', 'treatments', 'was', 'observed', ',', 'on', 'the', '4-point', 'scale', ',', 'in', 'the', 'population', 'as', 'a', 'whole', '(', 'end', 'of', 'first', 'period', ')', 'as', 'well', 'as', 'in', 'responder', 'patients', '(', 'end', 'second', 'period', ')', '.']","(17, 19)","(96, 109)",-1,ss_o,2908133,Abstract,6,test,gold,1373.0
6506,"Likewise a significant ( p less than 0.001 ) difference between treatments was observed , on the",4-point scale,", in the population as a whole ( end of first period ) as well as in responder patients ( end second period ) .","['Likewise', 'a', 'significant', '(', 'p', 'less', 'than', '0.001', ')', 'difference', 'between', 'treatments', 'was', 'observed', ',', 'on', 'the', '4-point', 'scale', ',', 'in', 'the', 'population', 'as', 'a', 'whole', '(', 'end', 'of', 'first', 'period', ')', 'as', 'well', 'as', 'in', 'responder', 'patients', '(', 'end', 'second', 'period', ')', '.']","(17, 19)","(96, 109)",-1,hl_o,2908133,Abstract,6,test,gold,1374.0
6507,"Tolerability was good , except in 1 patient on",placebo,", who was withdrawn from the study because of severe headache .","['Tolerability', 'was', 'good', ',', 'except', 'in', '1', 'patient', 'on', 'placebo', ',', 'who', 'was', 'withdrawn', 'from', 'the', 'study', 'because', 'of', 'severe', 'headache', '.']","(9, 10)","(46, 53)",-1,ss_i,2908133,Abstract,7,test,gold,4317.0
6508,"Tolerability was good , except in 1 patient on placebo , who was withdrawn from the study because of",severe headache .,,"['Tolerability', 'was', 'good', ',', 'except', 'in', '1', 'patient', 'on', 'placebo', ',', 'who', 'was', 'withdrawn', 'from', 'the', 'study', 'because', 'of', 'severe', 'headache', '.']","(19, 22)","(100, 117)",-1,ss_o,2908133,Abstract,7,test,gold,2699.0
6509,"Tolerability was good , except in 1 patient on",placebo,", who was withdrawn from the study because of severe headache .","['Tolerability', 'was', 'good', ',', 'except', 'in', '1', 'patient', 'on', 'placebo', ',', 'who', 'was', 'withdrawn', 'from', 'the', 'study', 'because', 'of', 'severe', 'headache', '.']","(9, 10)","(46, 53)",-1,hl_i,2908133,Abstract,7,test,gold,4316.0
6510,"Tolerability was good , except in 1 patient on placebo , who was withdrawn from the study because of",severe headache .,,"['Tolerability', 'was', 'good', ',', 'except', 'in', '1', 'patient', 'on', 'placebo', ',', 'who', 'was', 'withdrawn', 'from', 'the', 'study', 'because', 'of', 'severe', 'headache', '.']","(19, 22)","(100, 117)",-1,hl_o,2908133,Abstract,7,test,gold,2700.0
6511,,Levobunolol,compared with timolol : a four-year study .,"['Levobunolol', 'compared', 'with', 'timolol', ':', 'a', 'four-year', 'study', '.']","(0, 1)","(0, 11)",-1,ss_i,3067745,Title,0,test,gold,
6512,Levobunolol compared with,timolol :,a four-year study .,"['Levobunolol', 'compared', 'with', 'timolol', ':', 'a', 'four-year', 'study', '.']","(3, 5)","(25, 34)",-1,ss_i,3067745,Title,0,test,gold,5458.0
6513,,Levobunolol,compared with timolol : a four-year study .,"['Levobunolol', 'compared', 'with', 'timolol', ':', 'a', 'four-year', 'study', '.']","(0, 1)","(0, 11)",-1,hl_i,3067745,Title,0,test,gold,
6514,Levobunolol compared with,timolol :,a four-year study .,"['Levobunolol', 'compared', 'with', 'timolol', ':', 'a', 'four-year', 'study', '.']","(3, 5)","(25, 34)",-1,hl_i,3067745,Title,0,test,gold,5457.0
6515,,Fifty-one patients with raised intraocular pressure ( IOP ),"were treated for up to four years with one of three ophthalmic solutions : 0.5 % levobunolol , 1 % levobunolol , or 0.5 % timolol .","['Fifty-one', 'patients', 'with', 'raised', 'intraocular', 'pressure', '(', 'IOP', ')', 'were', 'treated', 'for', 'up', 'to', 'four', 'years', 'with', 'one', 'of', 'three', 'ophthalmic', 'solutions', ':', '0.5', '%', 'levobunolol', ',', '1', '%', 'levobunolol', ',', 'or', '0.5', '%', 'timolol', '.']","(0, 9)","(0, 59)",-1,ss_p,3067745,Abstract,0,test,gold,1686.0
6516,Fifty-one patients with raised intraocular pressure ( IOP ) were treated for up to four years with one of three ophthalmic solutions : 0.5 %,levobunolol,", 1 % levobunolol , or 0.5 % timolol .","['Fifty-one', 'patients', 'with', 'raised', 'intraocular', 'pressure', '(', 'IOP', ')', 'were', 'treated', 'for', 'up', 'to', 'four', 'years', 'with', 'one', 'of', 'three', 'ophthalmic', 'solutions', ':', '0.5', '%', 'levobunolol', ',', '1', '%', 'levobunolol', ',', 'or', '0.5', '%', 'timolol', '.']","(25, 26)","(140, 151)",-1,ss_i,3067745,Abstract,0,test,gold,
6517,"Fifty-one patients with raised intraocular pressure ( IOP ) were treated for up to four years with one of three ophthalmic solutions : 0.5 % levobunolol , 1 %",levobunolol,", or 0.5 % timolol .","['Fifty-one', 'patients', 'with', 'raised', 'intraocular', 'pressure', '(', 'IOP', ')', 'were', 'treated', 'for', 'up', 'to', 'four', 'years', 'with', 'one', 'of', 'three', 'ophthalmic', 'solutions', ':', '0.5', '%', 'levobunolol', ',', '1', '%', 'levobunolol', ',', 'or', '0.5', '%', 'timolol', '.']","(29, 30)","(158, 169)",-1,ss_i,3067745,Abstract,0,test,gold,
6518,"Fifty-one patients with raised intraocular pressure ( IOP ) were treated for up to four years with one of three ophthalmic solutions : 0.5 % levobunolol , 1 % levobunolol , or 0.5 %",timolol .,,"['Fifty-one', 'patients', 'with', 'raised', 'intraocular', 'pressure', '(', 'IOP', ')', 'were', 'treated', 'for', 'up', 'to', 'four', 'years', 'with', 'one', 'of', 'three', 'ophthalmic', 'solutions', ':', '0.5', '%', 'levobunolol', ',', '1', '%', 'levobunolol', ',', 'or', '0.5', '%', 'timolol', '.']","(34, 36)","(181, 190)",-1,ss_i,3067745,Abstract,0,test,gold,5456.0
6519,Fifty-one patients with raised,intraocular pressure ( IOP ),"were treated for up to four years with one of three ophthalmic solutions : 0.5 % levobunolol , 1 % levobunolol , or 0.5 % timolol .","['Fifty-one', 'patients', 'with', 'raised', 'intraocular', 'pressure', '(', 'IOP', ')', 'were', 'treated', 'for', 'up', 'to', 'four', 'years', 'with', 'one', 'of', 'three', 'ophthalmic', 'solutions', ':', '0.5', '%', 'levobunolol', ',', '1', '%', 'levobunolol', ',', 'or', '0.5', '%', 'timolol', '.']","(4, 9)","(30, 58)",-1,ss_o,3067745,Abstract,0,test,gold,1689.0
6520,,Fifty-one patients,"with raised intraocular pressure ( IOP ) were treated for up to four years with one of three ophthalmic solutions : 0.5 % levobunolol , 1 % levobunolol , or 0.5 % timolol .","['Fifty-one', 'patients', 'with', 'raised', 'intraocular', 'pressure', '(', 'IOP', ')', 'were', 'treated', 'for', 'up', 'to', 'four', 'years', 'with', 'one', 'of', 'three', 'ophthalmic', 'solutions', ':', '0.5', '%', 'levobunolol', ',', '1', '%', 'levobunolol', ',', 'or', '0.5', '%', 'timolol', '.']","(0, 2)","(0, 18)",-1,hl_p,3067745,Abstract,0,test,gold,3740.0
6521,Fifty-one patients with,raised intraocular pressure ( IOP ),"were treated for up to four years with one of three ophthalmic solutions : 0.5 % levobunolol , 1 % levobunolol , or 0.5 % timolol .","['Fifty-one', 'patients', 'with', 'raised', 'intraocular', 'pressure', '(', 'IOP', ')', 'were', 'treated', 'for', 'up', 'to', 'four', 'years', 'with', 'one', 'of', 'three', 'ophthalmic', 'solutions', ':', '0.5', '%', 'levobunolol', ',', '1', '%', 'levobunolol', ',', 'or', '0.5', '%', 'timolol', '.']","(3, 9)","(23, 58)",-1,hl_p,3067745,Abstract,0,test,gold,1688.0
6522,Fifty-one patients with raised intraocular pressure ( IOP ) were treated for up to four years with one of three ophthalmic solutions : 0.5 %,levobunolol,", 1 % levobunolol , or 0.5 % timolol .","['Fifty-one', 'patients', 'with', 'raised', 'intraocular', 'pressure', '(', 'IOP', ')', 'were', 'treated', 'for', 'up', 'to', 'four', 'years', 'with', 'one', 'of', 'three', 'ophthalmic', 'solutions', ':', '0.5', '%', 'levobunolol', ',', '1', '%', 'levobunolol', ',', 'or', '0.5', '%', 'timolol', '.']","(25, 26)","(140, 151)",-1,hl_i,3067745,Abstract,0,test,gold,
6523,"Fifty-one patients with raised intraocular pressure ( IOP ) were treated for up to four years with one of three ophthalmic solutions : 0.5 % levobunolol , 1 %",levobunolol,", or 0.5 % timolol .","['Fifty-one', 'patients', 'with', 'raised', 'intraocular', 'pressure', '(', 'IOP', ')', 'were', 'treated', 'for', 'up', 'to', 'four', 'years', 'with', 'one', 'of', 'three', 'ophthalmic', 'solutions', ':', '0.5', '%', 'levobunolol', ',', '1', '%', 'levobunolol', ',', 'or', '0.5', '%', 'timolol', '.']","(29, 30)","(158, 169)",-1,hl_i,3067745,Abstract,0,test,gold,
6524,"Fifty-one patients with raised intraocular pressure ( IOP ) were treated for up to four years with one of three ophthalmic solutions : 0.5 % levobunolol , 1 % levobunolol , or 0.5 %",timolol .,,"['Fifty-one', 'patients', 'with', 'raised', 'intraocular', 'pressure', '(', 'IOP', ')', 'were', 'treated', 'for', 'up', 'to', 'four', 'years', 'with', 'one', 'of', 'three', 'ophthalmic', 'solutions', ':', '0.5', '%', 'levobunolol', ',', '1', '%', 'levobunolol', ',', 'or', '0.5', '%', 'timolol', '.']","(34, 36)","(181, 190)",-1,hl_i,3067745,Abstract,0,test,gold,5455.0
6525,"The study was conducted as a double-masked , randomised trial in which medications were administered twice daily to both eyes .",,,"['The', 'study', 'was', 'conducted', 'as', 'a', 'double-masked', ',', 'randomised', 'trial', 'in', 'which', 'medications', 'were', 'administered', 'twice', 'daily', 'to', 'both', 'eyes', '.']",,,,,3067745,Abstract,1,test,gold,
6526,,Levobunolol,and timolol were equally effective in reducing overall mean IOP ; reductions were greater than 8.8 mmHg in all three treatment groups .,"['Levobunolol', 'and', 'timolol', 'were', 'equally', 'effective', 'in', 'reducing', 'overall', 'mean', 'IOP', ';', 'reductions', 'were', 'greater', 'than', '8.8', 'mmHg', 'in', 'all', 'three', 'treatment', 'groups', '.']","(0, 1)","(0, 11)",-1,ss_i,3067745,Abstract,2,test,gold,
6527,Levobunolol and,timolol,were equally effective in reducing overall mean IOP ; reductions were greater than 8.8 mmHg in all three treatment groups .,"['Levobunolol', 'and', 'timolol', 'were', 'equally', 'effective', 'in', 'reducing', 'overall', 'mean', 'IOP', ';', 'reductions', 'were', 'greater', 'than', '8.8', 'mmHg', 'in', 'all', 'three', 'treatment', 'groups', '.']","(2, 3)","(15, 22)",-1,ss_i,3067745,Abstract,2,test,gold,5454.0
6528,Levobunolol and timolol were equally,effective,in reducing overall mean IOP ; reductions were greater than 8.8 mmHg in all three treatment groups .,"['Levobunolol', 'and', 'timolol', 'were', 'equally', 'effective', 'in', 'reducing', 'overall', 'mean', 'IOP', ';', 'reductions', 'were', 'greater', 'than', '8.8', 'mmHg', 'in', 'all', 'three', 'treatment', 'groups', '.']","(5, 6)","(36, 45)",-1,ss_o,3067745,Abstract,2,test,gold,846.0
6529,Levobunolol and timolol were equally effective in reducing,overall mean IOP ;,reductions were greater than 8.8 mmHg in all three treatment groups .,"['Levobunolol', 'and', 'timolol', 'were', 'equally', 'effective', 'in', 'reducing', 'overall', 'mean', 'IOP', ';', 'reductions', 'were', 'greater', 'than', '8.8', 'mmHg', 'in', 'all', 'three', 'treatment', 'groups', '.']","(8, 12)","(58, 76)",-1,ss_o,3067745,Abstract,2,test,gold,1708.0
6530,,Levobunolol,and timolol were equally effective in reducing overall mean IOP ; reductions were greater than 8.8 mmHg in all three treatment groups .,"['Levobunolol', 'and', 'timolol', 'were', 'equally', 'effective', 'in', 'reducing', 'overall', 'mean', 'IOP', ';', 'reductions', 'were', 'greater', 'than', '8.8', 'mmHg', 'in', 'all', 'three', 'treatment', 'groups', '.']","(0, 1)","(0, 11)",-1,hl_i,3067745,Abstract,2,test,gold,
6531,Levobunolol and,timolol,were equally effective in reducing overall mean IOP ; reductions were greater than 8.8 mmHg in all three treatment groups .,"['Levobunolol', 'and', 'timolol', 'were', 'equally', 'effective', 'in', 'reducing', 'overall', 'mean', 'IOP', ';', 'reductions', 'were', 'greater', 'than', '8.8', 'mmHg', 'in', 'all', 'three', 'treatment', 'groups', '.']","(2, 3)","(15, 22)",-1,hl_i,3067745,Abstract,2,test,gold,5453.0
6532,Levobunolol and timolol were equally effective in reducing,overall mean IOP ;,reductions were greater than 8.8 mmHg in all three treatment groups .,"['Levobunolol', 'and', 'timolol', 'were', 'equally', 'effective', 'in', 'reducing', 'overall', 'mean', 'IOP', ';', 'reductions', 'were', 'greater', 'than', '8.8', 'mmHg', 'in', 'all', 'three', 'treatment', 'groups', '.']","(8, 12)","(58, 76)",-1,hl_o,3067745,Abstract,2,test,gold,1709.0
6533,The study showed,levobunolol,to be as safe and effective as timolol in the long-term control of raised IOP .,"['The', 'study', 'showed', 'levobunolol', 'to', 'be', 'as', 'safe', 'and', 'effective', 'as', 'timolol', 'in', 'the', 'long-term', 'control', 'of', 'raised', 'IOP', '.']","(3, 4)","(16, 27)",-1,ss_i,3067745,Abstract,3,test,gold,
6534,The study showed levobunolol to be as safe and effective as,timolol,in the long-term control of raised IOP .,"['The', 'study', 'showed', 'levobunolol', 'to', 'be', 'as', 'safe', 'and', 'effective', 'as', 'timolol', 'in', 'the', 'long-term', 'control', 'of', 'raised', 'IOP', '.']","(11, 12)","(59, 66)",-1,ss_i,3067745,Abstract,3,test,gold,5452.0
6535,The study showed levobunolol to be as safe and,effective,as timolol in the long-term control of raised IOP .,"['The', 'study', 'showed', 'levobunolol', 'to', 'be', 'as', 'safe', 'and', 'effective', 'as', 'timolol', 'in', 'the', 'long-term', 'control', 'of', 'raised', 'IOP', '.']","(9, 10)","(46, 55)",-1,ss_o,3067745,Abstract,3,test,gold,845.0
6536,The study showed,levobunolol,to be as safe and effective as timolol in the long-term control of raised IOP .,"['The', 'study', 'showed', 'levobunolol', 'to', 'be', 'as', 'safe', 'and', 'effective', 'as', 'timolol', 'in', 'the', 'long-term', 'control', 'of', 'raised', 'IOP', '.']","(3, 4)","(16, 27)",-1,hl_i,3067745,Abstract,3,test,gold,
6537,The study showed levobunolol to be as safe and effective as,timolol,in the long-term control of raised IOP .,"['The', 'study', 'showed', 'levobunolol', 'to', 'be', 'as', 'safe', 'and', 'effective', 'as', 'timolol', 'in', 'the', 'long-term', 'control', 'of', 'raised', 'IOP', '.']","(11, 12)","(59, 66)",-1,hl_i,3067745,Abstract,3,test,gold,5451.0
6538,Role of angiotensin-converting enzyme inhibitors in early antihypertensive treatment in,non-insulin dependent diabetes mellitus .,,"['Role', 'of', 'angiotensin-converting', 'enzyme', 'inhibitors', 'in', 'early', 'antihypertensive', 'treatment', 'in', 'non-insulin', 'dependent', 'diabetes', 'mellitus', '.']","(10, 15)","(87, 128)",-1,ss_p,3074300,Title,0,test,gold,6906.0
6539,Role of,angiotensin-converting enzyme inhibitors,in early antihypertensive treatment in non-insulin dependent diabetes mellitus .,"['Role', 'of', 'angiotensin-converting', 'enzyme', 'inhibitors', 'in', 'early', 'antihypertensive', 'treatment', 'in', 'non-insulin', 'dependent', 'diabetes', 'mellitus', '.']","(2, 5)","(7, 47)",-1,ss_i,3074300,Title,0,test,gold,4559.0
6540,Role of angiotensin-converting enzyme inhibitors in early antihypertensive treatment in,non-insulin dependent diabetes mellitus .,,"['Role', 'of', 'angiotensin-converting', 'enzyme', 'inhibitors', 'in', 'early', 'antihypertensive', 'treatment', 'in', 'non-insulin', 'dependent', 'diabetes', 'mellitus', '.']","(10, 15)","(87, 128)",-1,hl_p,3074300,Title,0,test,gold,6907.0
6541,Role of,angiotensin-converting enzyme inhibitors,in early antihypertensive treatment in non-insulin dependent diabetes mellitus .,"['Role', 'of', 'angiotensin-converting', 'enzyme', 'inhibitors', 'in', 'early', 'antihypertensive', 'treatment', 'in', 'non-insulin', 'dependent', 'diabetes', 'mellitus', '.']","(2, 5)","(7, 47)",-1,hl_i,3074300,Title,0,test,gold,4560.0
6542,The effect of captopril monotherapy on blood pressure and metabolism was investigated in a placebo-controlled study in,30 non-insulin dependent ( Type II ) diabetic subjects,during a 3-week observation period ( run-in/drug ; placebo/wash-out ) on a metabolic ward .,"['The', 'effect', 'of', 'captopril', 'monotherapy', 'on', 'blood', 'pressure', 'and', 'metabolism', 'was', 'investigated', 'in', 'a', 'placebo-controlled', 'study', 'in', '30', 'non-insulin', 'dependent', '(', 'Type', 'II', ')', 'diabetic', 'subjects', 'during', 'a', '3-week', 'observation', 'period', '(', 'run-in/drug', ';', 'placebo/wash-out', ')', 'on', 'a', 'metabolic', 'ward', '.']","(17, 26)","(118, 172)",-1,ss_p,3074300,Abstract,0,test,gold,6894.0
6543,The effect of,captopril,monotherapy on blood pressure and metabolism was investigated in a placebo-controlled study in 30 non-insulin dependent ( Type II ) diabetic subjects during a 3-week observation period ( run-in/drug ; placebo/wash-out ) on a metabolic ward .,"['The', 'effect', 'of', 'captopril', 'monotherapy', 'on', 'blood', 'pressure', 'and', 'metabolism', 'was', 'investigated', 'in', 'a', 'placebo-controlled', 'study', 'in', '30', 'non-insulin', 'dependent', '(', 'Type', 'II', ')', 'diabetic', 'subjects', 'during', 'a', '3-week', 'observation', 'period', '(', 'run-in/drug', ';', 'placebo/wash-out', ')', 'on', 'a', 'metabolic', 'ward', '.']","(3, 4)","(13, 22)",-1,ss_i,3074300,Abstract,0,test,gold,168.0
6544,The effect of captopril monotherapy on blood pressure and metabolism was investigated in a,placebo-controlled,study in 30 non-insulin dependent ( Type II ) diabetic subjects during a 3-week observation period ( run-in/drug ; placebo/wash-out ) on a metabolic ward .,"['The', 'effect', 'of', 'captopril', 'monotherapy', 'on', 'blood', 'pressure', 'and', 'metabolism', 'was', 'investigated', 'in', 'a', 'placebo-controlled', 'study', 'in', '30', 'non-insulin', 'dependent', '(', 'Type', 'II', ')', 'diabetic', 'subjects', 'during', 'a', '3-week', 'observation', 'period', '(', 'run-in/drug', ';', 'placebo/wash-out', ')', 'on', 'a', 'metabolic', 'ward', '.']","(14, 15)","(90, 108)",-1,ss_i,3074300,Abstract,0,test,gold,
6545,The effect of captopril monotherapy on blood pressure and metabolism was investigated in a placebo-controlled study in 30 non-insulin dependent ( Type II ) diabetic subjects during a 3-week observation period ( run-in/drug ;,placebo/wash-out ),on a metabolic ward .,"['The', 'effect', 'of', 'captopril', 'monotherapy', 'on', 'blood', 'pressure', 'and', 'metabolism', 'was', 'investigated', 'in', 'a', 'placebo-controlled', 'study', 'in', '30', 'non-insulin', 'dependent', '(', 'Type', 'II', ')', 'diabetic', 'subjects', 'during', 'a', '3-week', 'observation', 'period', '(', 'run-in/drug', ';', 'placebo/wash-out', ')', 'on', 'a', 'metabolic', 'ward', '.']","(34, 36)","(224, 242)",-1,ss_i,3074300,Abstract,0,test,gold,
6546,The effect of captopril monotherapy on,blood pressure and metabolism,was investigated in a placebo-controlled study in 30 non-insulin dependent ( Type II ) diabetic subjects during a 3-week observation period ( run-in/drug ; placebo/wash-out ) on a metabolic ward .,"['The', 'effect', 'of', 'captopril', 'monotherapy', 'on', 'blood', 'pressure', 'and', 'metabolism', 'was', 'investigated', 'in', 'a', 'placebo-controlled', 'study', 'in', '30', 'non-insulin', 'dependent', '(', 'Type', 'II', ')', 'diabetic', 'subjects', 'during', 'a', '3-week', 'observation', 'period', '(', 'run-in/drug', ';', 'placebo/wash-out', ')', 'on', 'a', 'metabolic', 'ward', '.']","(6, 10)","(38, 67)",-1,ss_o,3074300,Abstract,0,test,gold,6704.0
6547,The effect of captopril monotherapy on blood pressure and metabolism was investigated in a placebo-controlled study in,30 non-insulin dependent ( Type II ) diabetic subjects,during a 3-week observation period ( run-in/drug ; placebo/wash-out ) on a metabolic ward .,"['The', 'effect', 'of', 'captopril', 'monotherapy', 'on', 'blood', 'pressure', 'and', 'metabolism', 'was', 'investigated', 'in', 'a', 'placebo-controlled', 'study', 'in', '30', 'non-insulin', 'dependent', '(', 'Type', 'II', ')', 'diabetic', 'subjects', 'during', 'a', '3-week', 'observation', 'period', '(', 'run-in/drug', ';', 'placebo/wash-out', ')', 'on', 'a', 'metabolic', 'ward', '.']","(17, 26)","(118, 172)",-1,hl_p,3074300,Abstract,0,test,gold,6895.0
6548,The effect of,captopril,monotherapy on blood pressure and metabolism was investigated in a placebo-controlled study in 30 non-insulin dependent ( Type II ) diabetic subjects during a 3-week observation period ( run-in/drug ; placebo/wash-out ) on a metabolic ward .,"['The', 'effect', 'of', 'captopril', 'monotherapy', 'on', 'blood', 'pressure', 'and', 'metabolism', 'was', 'investigated', 'in', 'a', 'placebo-controlled', 'study', 'in', '30', 'non-insulin', 'dependent', '(', 'Type', 'II', ')', 'diabetic', 'subjects', 'during', 'a', '3-week', 'observation', 'period', '(', 'run-in/drug', ';', 'placebo/wash-out', ')', 'on', 'a', 'metabolic', 'ward', '.']","(3, 4)","(13, 22)",-1,hl_i,3074300,Abstract,0,test,gold,169.0
6549,The effect of captopril monotherapy on blood pressure and metabolism was investigated in a,placebo-controlled,study in 30 non-insulin dependent ( Type II ) diabetic subjects during a 3-week observation period ( run-in/drug ; placebo/wash-out ) on a metabolic ward .,"['The', 'effect', 'of', 'captopril', 'monotherapy', 'on', 'blood', 'pressure', 'and', 'metabolism', 'was', 'investigated', 'in', 'a', 'placebo-controlled', 'study', 'in', '30', 'non-insulin', 'dependent', '(', 'Type', 'II', ')', 'diabetic', 'subjects', 'during', 'a', '3-week', 'observation', 'period', '(', 'run-in/drug', ';', 'placebo/wash-out', ')', 'on', 'a', 'metabolic', 'ward', '.']","(14, 15)","(90, 108)",-1,hl_i,3074300,Abstract,0,test,gold,
6550,The effect of captopril monotherapy on,blood pressure,and metabolism was investigated in a placebo-controlled study in 30 non-insulin dependent ( Type II ) diabetic subjects during a 3-week observation period ( run-in/drug ; placebo/wash-out ) on a metabolic ward .,"['The', 'effect', 'of', 'captopril', 'monotherapy', 'on', 'blood', 'pressure', 'and', 'metabolism', 'was', 'investigated', 'in', 'a', 'placebo-controlled', 'study', 'in', '30', 'non-insulin', 'dependent', '(', 'Type', 'II', ')', 'diabetic', 'subjects', 'during', 'a', '3-week', 'observation', 'period', '(', 'run-in/drug', ';', 'placebo/wash-out', ')', 'on', 'a', 'metabolic', 'ward', '.']","(6, 8)","(38, 52)",-1,hl_o,3074300,Abstract,0,test,gold,6705.0
6551,The effect of captopril monotherapy on blood pressure and,metabolism,was investigated in a placebo-controlled study in 30 non-insulin dependent ( Type II ) diabetic subjects during a 3-week observation period ( run-in/drug ; placebo/wash-out ) on a metabolic ward .,"['The', 'effect', 'of', 'captopril', 'monotherapy', 'on', 'blood', 'pressure', 'and', 'metabolism', 'was', 'investigated', 'in', 'a', 'placebo-controlled', 'study', 'in', '30', 'non-insulin', 'dependent', '(', 'Type', 'II', ')', 'diabetic', 'subjects', 'during', 'a', '3-week', 'observation', 'period', '(', 'run-in/drug', ';', 'placebo/wash-out', ')', 'on', 'a', 'metabolic', 'ward', '.']","(9, 10)","(57, 67)",-1,hl_o,3074300,Abstract,0,test,gold,5509.0
6552,,Captopril,significantly reduced both systolic and diastolic blood pressure ( 154/90 +/- 5/2 vs. 144/86 +/- 4/3 mmHg ) without major side effects .,"['Captopril', 'significantly', 'reduced', 'both', 'systolic', 'and', 'diastolic', 'blood', 'pressure', '(', '154/90', '+/-', '5/2', 'vs.', '144/86', '+/-', '4/3', 'mmHg', ')', 'without', 'major', 'side', 'effects', '.']","(0, 1)","(0, 9)",-1,ss_i,3074300,Abstract,1,test,gold,1036.0
6553,Captopril significantly reduced both,systolic and diastolic blood pressure,( 154/90 +/- 5/2 vs. 144/86 +/- 4/3 mmHg ) without major side effects .,"['Captopril', 'significantly', 'reduced', 'both', 'systolic', 'and', 'diastolic', 'blood', 'pressure', '(', '154/90', '+/-', '5/2', 'vs.', '144/86', '+/-', '4/3', 'mmHg', ')', 'without', 'major', 'side', 'effects', '.']","(4, 9)","(36, 73)",-1,ss_o,3074300,Abstract,1,test,gold,6687.0
6554,,Captopril,significantly reduced both systolic and diastolic blood pressure ( 154/90 +/- 5/2 vs. 144/86 +/- 4/3 mmHg ) without major side effects .,"['Captopril', 'significantly', 'reduced', 'both', 'systolic', 'and', 'diastolic', 'blood', 'pressure', '(', '154/90', '+/-', '5/2', 'vs.', '144/86', '+/-', '4/3', 'mmHg', ')', 'without', 'major', 'side', 'effects', '.']","(0, 1)","(0, 9)",-1,hl_i,3074300,Abstract,1,test,gold,1037.0
6555,Captopril significantly reduced both,systolic and diastolic blood pressure,( 154/90 +/- 5/2 vs. 144/86 +/- 4/3 mmHg ) without major side effects .,"['Captopril', 'significantly', 'reduced', 'both', 'systolic', 'and', 'diastolic', 'blood', 'pressure', '(', '154/90', '+/-', '5/2', 'vs.', '144/86', '+/-', '4/3', 'mmHg', ')', 'without', 'major', 'side', 'effects', '.']","(4, 9)","(36, 73)",-1,hl_o,3074300,Abstract,1,test,gold,6688.0
6556,Mean run-in,postprandial blood glucose concentrations,"were also reduced upon ACE-inhibition ( 9 a.m. : 12.7 +/- 0.4 vs. 11.1 +/- 0.4 mmol/l ; 1 p.m. : 11.0 +/- 0.3 vs. 8.9 +/- 0.3 mmol/l ; P less than 0.05 ) , while blood kinin concentrations ( 40.0 +/- 2.5 pmol/l ) were approximately doubled ( 108.8 +/- 23.5 pmol/l ; P less than 0.05 ) .","['Mean', 'run-in', 'postprandial', 'blood', 'glucose', 'concentrations', 'were', 'also', 'reduced', 'upon', 'ACE-inhibition', '(', '9', 'a.m.', ':', '12.7', '+/-', '0.4', 'vs.', '11.1', '+/-', '0.4', 'mmol/l', ';', '1', 'p.m.', ':', '11.0', '+/-', '0.3', 'vs.', '8.9', '+/-', '0.3', 'mmol/l', ';', 'P', 'less', 'than', '0.05', ')', ',', 'while', 'blood', 'kinin', 'concentrations', '(', '40.0', '+/-', '2.5', 'pmol/l', ')', 'were', 'approximately', 'doubled', '(', '108.8', '+/-', '23.5', 'pmol/l', ';', 'P', 'less', 'than', '0.05', ')', '.']","(2, 6)","(11, 52)",-1,ss_o,3074300,Abstract,2,test,gold,6574.0
6557,"Mean run-in postprandial blood glucose concentrations were also reduced upon ACE-inhibition ( 9 a.m. : 12.7 +/- 0.4 vs. 11.1 +/- 0.4 mmol/l ; 1 p.m. : 11.0 +/- 0.3 vs. 8.9 +/- 0.3 mmol/l ; P less than 0.05 ) , while",blood kinin concentrations,( 40.0 +/- 2.5 pmol/l ) were approximately doubled ( 108.8 +/- 23.5 pmol/l ; P less than 0.05 ) .,"['Mean', 'run-in', 'postprandial', 'blood', 'glucose', 'concentrations', 'were', 'also', 'reduced', 'upon', 'ACE-inhibition', '(', '9', 'a.m.', ':', '12.7', '+/-', '0.4', 'vs.', '11.1', '+/-', '0.4', 'mmol/l', ';', '1', 'p.m.', ':', '11.0', '+/-', '0.3', 'vs.', '8.9', '+/-', '0.3', 'mmol/l', ';', 'P', 'less', 'than', '0.05', ')', ',', 'while', 'blood', 'kinin', 'concentrations', '(', '40.0', '+/-', '2.5', 'pmol/l', ')', 'were', 'approximately', 'doubled', '(', '108.8', '+/-', '23.5', 'pmol/l', ';', 'P', 'less', 'than', '0.05', ')', '.']","(43, 46)","(215, 241)",-1,ss_o,3074300,Abstract,2,test,gold,4511.0
6558,Mean run-in,postprandial blood glucose concentrations,"were also reduced upon ACE-inhibition ( 9 a.m. : 12.7 +/- 0.4 vs. 11.1 +/- 0.4 mmol/l ; 1 p.m. : 11.0 +/- 0.3 vs. 8.9 +/- 0.3 mmol/l ; P less than 0.05 ) , while blood kinin concentrations ( 40.0 +/- 2.5 pmol/l ) were approximately doubled ( 108.8 +/- 23.5 pmol/l ; P less than 0.05 ) .","['Mean', 'run-in', 'postprandial', 'blood', 'glucose', 'concentrations', 'were', 'also', 'reduced', 'upon', 'ACE-inhibition', '(', '9', 'a.m.', ':', '12.7', '+/-', '0.4', 'vs.', '11.1', '+/-', '0.4', 'mmol/l', ';', '1', 'p.m.', ':', '11.0', '+/-', '0.3', 'vs.', '8.9', '+/-', '0.3', 'mmol/l', ';', 'P', 'less', 'than', '0.05', ')', ',', 'while', 'blood', 'kinin', 'concentrations', '(', '40.0', '+/-', '2.5', 'pmol/l', ')', 'were', 'approximately', 'doubled', '(', '108.8', '+/-', '23.5', 'pmol/l', ';', 'P', 'less', 'than', '0.05', ')', '.']","(2, 6)","(11, 52)",-1,hl_o,3074300,Abstract,2,test,gold,6575.0
6559,"Mean run-in postprandial blood glucose concentrations were also reduced upon ACE-inhibition ( 9 a.m. : 12.7 +/- 0.4 vs. 11.1 +/- 0.4 mmol/l ; 1 p.m. : 11.0 +/- 0.3 vs. 8.9 +/- 0.3 mmol/l ; P less than 0.05 ) , while",blood kinin concentrations,( 40.0 +/- 2.5 pmol/l ) were approximately doubled ( 108.8 +/- 23.5 pmol/l ; P less than 0.05 ) .,"['Mean', 'run-in', 'postprandial', 'blood', 'glucose', 'concentrations', 'were', 'also', 'reduced', 'upon', 'ACE-inhibition', '(', '9', 'a.m.', ':', '12.7', '+/-', '0.4', 'vs.', '11.1', '+/-', '0.4', 'mmol/l', ';', '1', 'p.m.', ':', '11.0', '+/-', '0.3', 'vs.', '8.9', '+/-', '0.3', 'mmol/l', ';', 'P', 'less', 'than', '0.05', ')', ',', 'while', 'blood', 'kinin', 'concentrations', '(', '40.0', '+/-', '2.5', 'pmol/l', ')', 'were', 'approximately', 'doubled', '(', '108.8', '+/-', '23.5', 'pmol/l', ';', 'P', 'less', 'than', '0.05', ')', '.']","(43, 46)","(215, 241)",-1,hl_o,3074300,Abstract,2,test,gold,4512.0
6560,,"Body mass index , fasting plasma insulin , serum electrolyte pattern , uric acid , white blood count , lipid profile as well as hepatic and renal function",parameters remained unaltered throughout the observation period .,"['Body', 'mass', 'index', ',', 'fasting', 'plasma', 'insulin', ',', 'serum', 'electrolyte', 'pattern', ',', 'uric', 'acid', ',', 'white', 'blood', 'count', ',', 'lipid', 'profile', 'as', 'well', 'as', 'hepatic', 'and', 'renal', 'function', 'parameters', 'remained', 'unaltered', 'throughout', 'the', 'observation', 'period', '.']","(0, 28)","(0, 154)",-1,ss_o,3074300,Abstract,3,test,gold,5811.0
6561,,"Body mass index , fasting plasma insulin , serum electrolyte pattern , uric acid , white blood count , lipid profile",as well as hepatic and renal function parameters remained unaltered throughout the observation period .,"['Body', 'mass', 'index', ',', 'fasting', 'plasma', 'insulin', ',', 'serum', 'electrolyte', 'pattern', ',', 'uric', 'acid', ',', 'white', 'blood', 'count', ',', 'lipid', 'profile', 'as', 'well', 'as', 'hepatic', 'and', 'renal', 'function', 'parameters', 'remained', 'unaltered', 'throughout', 'the', 'observation', 'period', '.']","(0, 21)","(0, 116)",-1,hl_o,3074300,Abstract,3,test,gold,5812.0
6562,"Body mass index , fasting plasma insulin , serum electrolyte pattern , uric acid , white blood count , lipid profile as well as",hepatic and renal function,parameters remained unaltered throughout the observation period .,"['Body', 'mass', 'index', ',', 'fasting', 'plasma', 'insulin', ',', 'serum', 'electrolyte', 'pattern', ',', 'uric', 'acid', ',', 'white', 'blood', 'count', ',', 'lipid', 'profile', 'as', 'well', 'as', 'hepatic', 'and', 'renal', 'function', 'parameters', 'remained', 'unaltered', 'throughout', 'the', 'observation', 'period', '.']","(24, 28)","(127, 153)",-1,hl_o,3074300,Abstract,3,test,gold,3204.0
6563,The data are in line with recent experimental studies showing a beneficial metabolic effect of captopril in,Type II diabetes .,,"['The', 'data', 'are', 'in', 'line', 'with', 'recent', 'experimental', 'studies', 'showing', 'a', 'beneficial', 'metabolic', 'effect', 'of', 'captopril', 'in', 'Type', 'II', 'diabetes', '.']","(17, 21)","(107, 125)",-1,ss_p,3074300,Abstract,4,test,gold,6896.0
6564,The data are in line with recent experimental studies showing a beneficial metabolic effect of,captopril,in Type II diabetes .,"['The', 'data', 'are', 'in', 'line', 'with', 'recent', 'experimental', 'studies', 'showing', 'a', 'beneficial', 'metabolic', 'effect', 'of', 'captopril', 'in', 'Type', 'II', 'diabetes', '.']","(15, 16)","(94, 103)",-1,ss_i,3074300,Abstract,4,test,gold,167.0
6565,The data are in line with recent experimental studies showing a beneficial,metabolic effect,of captopril in Type II diabetes .,"['The', 'data', 'are', 'in', 'line', 'with', 'recent', 'experimental', 'studies', 'showing', 'a', 'beneficial', 'metabolic', 'effect', 'of', 'captopril', 'in', 'Type', 'II', 'diabetes', '.']","(12, 14)","(74, 90)",-1,ss_o,3074300,Abstract,4,test,gold,2347.0
6566,The data are in line with recent experimental studies showing a beneficial metabolic effect of,captopril,in Type II diabetes .,"['The', 'data', 'are', 'in', 'line', 'with', 'recent', 'experimental', 'studies', 'showing', 'a', 'beneficial', 'metabolic', 'effect', 'of', 'captopril', 'in', 'Type', 'II', 'diabetes', '.']","(15, 16)","(94, 103)",-1,hl_i,3074300,Abstract,4,test,gold,166.0
6567,ACE inhibitors might therefore become first-line drugs in early antihypertensive intervention in,Type II diabetic patients .,,"['ACE', 'inhibitors', 'might', 'therefore', 'become', 'first-line', 'drugs', 'in', 'early', 'antihypertensive', 'intervention', 'in', 'Type', 'II', 'diabetic', 'patients', '.']","(12, 17)","(96, 123)",-1,ss_p,3074300,Abstract,5,test,gold,6900.0
6568,,ACE inhibitors,might therefore become first-line drugs in early antihypertensive intervention in Type II diabetic patients .,"['ACE', 'inhibitors', 'might', 'therefore', 'become', 'first-line', 'drugs', 'in', 'early', 'antihypertensive', 'intervention', 'in', 'Type', 'II', 'diabetic', 'patients', '.']","(0, 2)","(0, 14)",-1,ss_i,3074300,Abstract,5,test,gold,4557.0
6569,ACE inhibitors might therefore become first-line drugs in early antihypertensive intervention in,Type II diabetic,patients .,"['ACE', 'inhibitors', 'might', 'therefore', 'become', 'first-line', 'drugs', 'in', 'early', 'antihypertensive', 'intervention', 'in', 'Type', 'II', 'diabetic', 'patients', '.']","(12, 15)","(96, 112)",-1,hl_p,3074300,Abstract,5,test,gold,6897.0
6570,,ACE inhibitors,might therefore become first-line drugs in early antihypertensive intervention in Type II diabetic patients .,"['ACE', 'inhibitors', 'might', 'therefore', 'become', 'first-line', 'drugs', 'in', 'early', 'antihypertensive', 'intervention', 'in', 'Type', 'II', 'diabetic', 'patients', '.']","(0, 2)","(0, 14)",-1,hl_i,3074300,Abstract,5,test,gold,4558.0
6571,Double-blind comparison of doxepin versus bupropion in,outpatients with a major depressive disorder .,,"['Double-blind', 'comparison', 'of', 'doxepin', 'versus', 'bupropion', 'in', 'outpatients', 'with', 'a', 'major', 'depressive', 'disorder', '.']","(7, 14)","(54, 100)",-1,ss_p,3081600,Title,0,test,gold,6967.0
6572,Double-blind comparison of,doxepin,versus bupropion in outpatients with a major depressive disorder .,"['Double-blind', 'comparison', 'of', 'doxepin', 'versus', 'bupropion', 'in', 'outpatients', 'with', 'a', 'major', 'depressive', 'disorder', '.']","(3, 4)","(26, 33)",-1,ss_i,3081600,Title,0,test,gold,5539.0
6573,Double-blind comparison of doxepin versus,bupropion,in outpatients with a major depressive disorder .,"['Double-blind', 'comparison', 'of', 'doxepin', 'versus', 'bupropion', 'in', 'outpatients', 'with', 'a', 'major', 'depressive', 'disorder', '.']","(5, 6)","(41, 50)",-1,ss_i,3081600,Title,0,test,gold,5244.0
6574,Double-blind comparison of doxepin versus bupropion in,outpatients with a major depressive disorder .,,"['Double-blind', 'comparison', 'of', 'doxepin', 'versus', 'bupropion', 'in', 'outpatients', 'with', 'a', 'major', 'depressive', 'disorder', '.']","(7, 14)","(54, 100)",-1,hl_p,3081600,Title,0,test,gold,6968.0
6575,Double-blind comparison of,doxepin,versus bupropion in outpatients with a major depressive disorder .,"['Double-blind', 'comparison', 'of', 'doxepin', 'versus', 'bupropion', 'in', 'outpatients', 'with', 'a', 'major', 'depressive', 'disorder', '.']","(3, 4)","(26, 33)",-1,hl_i,3081600,Title,0,test,gold,5540.0
6576,Double-blind comparison of doxepin versus,bupropion,in outpatients with a major depressive disorder .,"['Double-blind', 'comparison', 'of', 'doxepin', 'versus', 'bupropion', 'in', 'outpatients', 'with', 'a', 'major', 'depressive', 'disorder', '.']","(5, 6)","(41, 50)",-1,hl_i,3081600,Title,0,test,gold,5243.0
6577,A double-blind controlled study comparing the effects of bupropion to doxepin in,outpatients with primary depression,was conducted to evaluate efficacy and safety differences between the two drugs .,"['A', 'double-blind', 'controlled', 'study', 'comparing', 'the', 'effects', 'of', 'bupropion', 'to', 'doxepin', 'in', 'outpatients', 'with', 'primary', 'depression', 'was', 'conducted', 'to', 'evaluate', 'efficacy', 'and', 'safety', 'differences', 'between', 'the', 'two', 'drugs', '.']","(12, 16)","(80, 115)",-1,ss_p,3081600,Abstract,0,test,gold,6982.0
6578,A double-blind controlled study comparing the effects of,bupropion,to doxepin in outpatients with primary depression was conducted to evaluate efficacy and safety differences between the two drugs .,"['A', 'double-blind', 'controlled', 'study', 'comparing', 'the', 'effects', 'of', 'bupropion', 'to', 'doxepin', 'in', 'outpatients', 'with', 'primary', 'depression', 'was', 'conducted', 'to', 'evaluate', 'efficacy', 'and', 'safety', 'differences', 'between', 'the', 'two', 'drugs', '.']","(8, 9)","(56, 65)",-1,ss_i,3081600,Abstract,0,test,gold,5242.0
6579,A double-blind controlled study comparing the effects of bupropion to,doxepin,in outpatients with primary depression was conducted to evaluate efficacy and safety differences between the two drugs .,"['A', 'double-blind', 'controlled', 'study', 'comparing', 'the', 'effects', 'of', 'bupropion', 'to', 'doxepin', 'in', 'outpatients', 'with', 'primary', 'depression', 'was', 'conducted', 'to', 'evaluate', 'efficacy', 'and', 'safety', 'differences', 'between', 'the', 'two', 'drugs', '.']","(10, 11)","(69, 76)",-1,ss_i,3081600,Abstract,0,test,gold,5538.0
6580,A double-blind controlled study comparing the effects of bupropion to doxepin in outpatients with primary depression was conducted to evaluate,efficacy,and safety differences between the two drugs .,"['A', 'double-blind', 'controlled', 'study', 'comparing', 'the', 'effects', 'of', 'bupropion', 'to', 'doxepin', 'in', 'outpatients', 'with', 'primary', 'depression', 'was', 'conducted', 'to', 'evaluate', 'efficacy', 'and', 'safety', 'differences', 'between', 'the', 'two', 'drugs', '.']","(20, 21)","(142, 150)",-1,ss_o,3081600,Abstract,0,test,gold,4791.0
6581,A double-blind controlled study comparing the effects of bupropion to doxepin in outpatients with primary depression was conducted to evaluate efficacy and,safety differences,between the two drugs .,"['A', 'double-blind', 'controlled', 'study', 'comparing', 'the', 'effects', 'of', 'bupropion', 'to', 'doxepin', 'in', 'outpatients', 'with', 'primary', 'depression', 'was', 'conducted', 'to', 'evaluate', 'efficacy', 'and', 'safety', 'differences', 'between', 'the', 'two', 'drugs', '.']","(22, 24)","(155, 173)",-1,ss_o,3081600,Abstract,0,test,gold,449.0
6582,A double-blind controlled study comparing the effects of bupropion to doxepin in,outpatients with primary depression,was conducted to evaluate efficacy and safety differences between the two drugs .,"['A', 'double-blind', 'controlled', 'study', 'comparing', 'the', 'effects', 'of', 'bupropion', 'to', 'doxepin', 'in', 'outpatients', 'with', 'primary', 'depression', 'was', 'conducted', 'to', 'evaluate', 'efficacy', 'and', 'safety', 'differences', 'between', 'the', 'two', 'drugs', '.']","(12, 16)","(80, 115)",-1,hl_p,3081600,Abstract,0,test,gold,6983.0
6583,A double-blind controlled study comparing the effects of,bupropion,to doxepin in outpatients with primary depression was conducted to evaluate efficacy and safety differences between the two drugs .,"['A', 'double-blind', 'controlled', 'study', 'comparing', 'the', 'effects', 'of', 'bupropion', 'to', 'doxepin', 'in', 'outpatients', 'with', 'primary', 'depression', 'was', 'conducted', 'to', 'evaluate', 'efficacy', 'and', 'safety', 'differences', 'between', 'the', 'two', 'drugs', '.']","(8, 9)","(56, 65)",-1,hl_i,3081600,Abstract,0,test,gold,5241.0
6584,A double-blind controlled study comparing the effects of bupropion to,doxepin,in outpatients with primary depression was conducted to evaluate efficacy and safety differences between the two drugs .,"['A', 'double-blind', 'controlled', 'study', 'comparing', 'the', 'effects', 'of', 'bupropion', 'to', 'doxepin', 'in', 'outpatients', 'with', 'primary', 'depression', 'was', 'conducted', 'to', 'evaluate', 'efficacy', 'and', 'safety', 'differences', 'between', 'the', 'two', 'drugs', '.']","(10, 11)","(69, 76)",-1,hl_i,3081600,Abstract,0,test,gold,5537.0
6585,A double-blind controlled study comparing the effects of bupropion to doxepin in outpatients with primary depression was conducted to evaluate,efficacy,and safety differences between the two drugs .,"['A', 'double-blind', 'controlled', 'study', 'comparing', 'the', 'effects', 'of', 'bupropion', 'to', 'doxepin', 'in', 'outpatients', 'with', 'primary', 'depression', 'was', 'conducted', 'to', 'evaluate', 'efficacy', 'and', 'safety', 'differences', 'between', 'the', 'two', 'drugs', '.']","(20, 21)","(142, 150)",-1,hl_o,3081600,Abstract,0,test,gold,4790.0
6586,A double-blind controlled study comparing the effects of bupropion to doxepin in outpatients with primary depression was conducted to evaluate efficacy and,safety,differences between the two drugs .,"['A', 'double-blind', 'controlled', 'study', 'comparing', 'the', 'effects', 'of', 'bupropion', 'to', 'doxepin', 'in', 'outpatients', 'with', 'primary', 'depression', 'was', 'conducted', 'to', 'evaluate', 'efficacy', 'and', 'safety', 'differences', 'between', 'the', 'two', 'drugs', '.']","(22, 23)","(155, 161)",-1,hl_o,3081600,Abstract,0,test,gold,456.0
6587,Following a 7-day,placebo,"washout period , patients could be treated for up to 13 weeks on either treatment .","['Following', 'a', '7-day', 'placebo', 'washout', 'period', ',', 'patients', 'could', 'be', 'treated', 'for', 'up', 'to', '13', 'weeks', 'on', 'either', 'treatment', '.']","(3, 4)","(17, 24)",-1,ss_i,3081600,Abstract,1,test,gold,4315.0
6588,Following a 7-day,placebo,"washout period , patients could be treated for up to 13 weeks on either treatment .","['Following', 'a', '7-day', 'placebo', 'washout', 'period', ',', 'patients', 'could', 'be', 'treated', 'for', 'up', 'to', '13', 'weeks', 'on', 'either', 'treatment', '.']","(3, 4)","(17, 24)",-1,hl_i,3081600,Abstract,1,test,gold,4314.0
6589,,Antidepressant response,"was assessed by the Hamilton Depression and Anxiety Scales , Clinical Global Severity and Improvement Ratings , and the Zung Self-Rating Depression Scale .","['Antidepressant', 'response', 'was', 'assessed', 'by', 'the', 'Hamilton', 'Depression', 'and', 'Anxiety', 'Scales', ',', 'Clinical', 'Global', 'Severity', 'and', 'Improvement', 'Ratings', ',', 'and', 'the', 'Zung', 'Self-Rating', 'Depression', 'Scale', '.']","(0, 2)","(0, 23)",-1,ss_o,3081600,Abstract,2,test,gold,2513.0
6590,Antidepressant response was assessed by the,"Hamilton Depression and Anxiety Scales , Clinical Global Severity and Improvement Ratings , and the Zung Self-Rating Depression Scale .",,"['Antidepressant', 'response', 'was', 'assessed', 'by', 'the', 'Hamilton', 'Depression', 'and', 'Anxiety', 'Scales', ',', 'Clinical', 'Global', 'Severity', 'and', 'Improvement', 'Ratings', ',', 'and', 'the', 'Zung', 'Self-Rating', 'Depression', 'Scale', '.']","(6, 26)","(43, 178)",-1,ss_o,3081600,Abstract,2,test,gold,6279.0
6591,,Antidepressant response,"was assessed by the Hamilton Depression and Anxiety Scales , Clinical Global Severity and Improvement Ratings , and the Zung Self-Rating Depression Scale .","['Antidepressant', 'response', 'was', 'assessed', 'by', 'the', 'Hamilton', 'Depression', 'and', 'Anxiety', 'Scales', ',', 'Clinical', 'Global', 'Severity', 'and', 'Improvement', 'Ratings', ',', 'and', 'the', 'Zung', 'Self-Rating', 'Depression', 'Scale', '.']","(0, 2)","(0, 23)",-1,hl_o,3081600,Abstract,2,test,gold,2514.0
6592,Antidepressant response was assessed by the,Hamilton Depression and Anxiety Scales,", Clinical Global Severity and Improvement Ratings , and the Zung Self-Rating Depression Scale .","['Antidepressant', 'response', 'was', 'assessed', 'by', 'the', 'Hamilton', 'Depression', 'and', 'Anxiety', 'Scales', ',', 'Clinical', 'Global', 'Severity', 'and', 'Improvement', 'Ratings', ',', 'and', 'the', 'Zung', 'Self-Rating', 'Depression', 'Scale', '.']","(6, 11)","(43, 81)",-1,hl_o,3081600,Abstract,2,test,gold,6217.0
6593,"Antidepressant response was assessed by the Hamilton Depression and Anxiety Scales ,",Clinical Global Severity and Improvement Ratings,", and the Zung Self-Rating Depression Scale .","['Antidepressant', 'response', 'was', 'assessed', 'by', 'the', 'Hamilton', 'Depression', 'and', 'Anxiety', 'Scales', ',', 'Clinical', 'Global', 'Severity', 'and', 'Improvement', 'Ratings', ',', 'and', 'the', 'Zung', 'Self-Rating', 'Depression', 'Scale', '.']","(12, 18)","(84, 132)",-1,hl_o,3081600,Abstract,2,test,gold,6214.0
6594,"Antidepressant response was assessed by the Hamilton Depression and Anxiety Scales , Clinical Global Severity and Improvement Ratings , and the",Zung Self-Rating Depression Scale,.,"['Antidepressant', 'response', 'was', 'assessed', 'by', 'the', 'Hamilton', 'Depression', 'and', 'Anxiety', 'Scales', ',', 'Clinical', 'Global', 'Severity', 'and', 'Improvement', 'Ratings', ',', 'and', 'the', 'Zung', 'Self-Rating', 'Depression', 'Scale', '.']","(21, 25)","(143, 176)",-1,hl_o,3081600,Abstract,2,test,gold,6218.0
6595,Comparable,efficacy,between the compounds was found across the 13-week study .,"['Comparable', 'efficacy', 'between', 'the', 'compounds', 'was', 'found', 'across', 'the', '13-week', 'study', '.']","(1, 2)","(10, 18)",-1,ss_o,3081600,Abstract,3,test,gold,4789.0
6596,Comparable,efficacy,between the compounds was found across the 13-week study .,"['Comparable', 'efficacy', 'between', 'the', 'compounds', 'was', 'found', 'across', 'the', '13-week', 'study', '.']","(1, 2)","(10, 18)",-1,hl_o,3081600,Abstract,3,test,gold,4788.0
6597,,Doxepin,"differed from bupropion mainly on the sleep factor of the Hamilton Depression Scale , with doxepin improving sleep to a greater extent than bupropion .","['Doxepin', 'differed', 'from', 'bupropion', 'mainly', 'on', 'the', 'sleep', 'factor', 'of', 'the', 'Hamilton', 'Depression', 'Scale', ',', 'with', 'doxepin', 'improving', 'sleep', 'to', 'a', 'greater', 'extent', 'than', 'bupropion', '.']","(0, 1)","(0, 7)",-1,ss_i,3081600,Abstract,4,test,gold,130.0
6598,Doxepin differed from,bupropion,"mainly on the sleep factor of the Hamilton Depression Scale , with doxepin improving sleep to a greater extent than bupropion .","['Doxepin', 'differed', 'from', 'bupropion', 'mainly', 'on', 'the', 'sleep', 'factor', 'of', 'the', 'Hamilton', 'Depression', 'Scale', ',', 'with', 'doxepin', 'improving', 'sleep', 'to', 'a', 'greater', 'extent', 'than', 'bupropion', '.']","(3, 4)","(21, 30)",-1,ss_i,3081600,Abstract,4,test,gold,5240.0
6599,"Doxepin differed from bupropion mainly on the sleep factor of the Hamilton Depression Scale , with",doxepin,improving sleep to a greater extent than bupropion .,"['Doxepin', 'differed', 'from', 'bupropion', 'mainly', 'on', 'the', 'sleep', 'factor', 'of', 'the', 'Hamilton', 'Depression', 'Scale', ',', 'with', 'doxepin', 'improving', 'sleep', 'to', 'a', 'greater', 'extent', 'than', 'bupropion', '.']","(16, 17)","(98, 105)",-1,ss_i,3081600,Abstract,4,test,gold,5536.0
6600,"Doxepin differed from bupropion mainly on the sleep factor of the Hamilton Depression Scale , with doxepin improving sleep to a greater extent than",bupropion .,,"['Doxepin', 'differed', 'from', 'bupropion', 'mainly', 'on', 'the', 'sleep', 'factor', 'of', 'the', 'Hamilton', 'Depression', 'Scale', ',', 'with', 'doxepin', 'improving', 'sleep', 'to', 'a', 'greater', 'extent', 'than', 'bupropion', '.']","(24, 26)","(147, 158)",-1,ss_i,3081600,Abstract,4,test,gold,5239.0
6601,Doxepin differed from bupropion mainly on the,sleep,"factor of the Hamilton Depression Scale , with doxepin improving sleep to a greater extent than bupropion .","['Doxepin', 'differed', 'from', 'bupropion', 'mainly', 'on', 'the', 'sleep', 'factor', 'of', 'the', 'Hamilton', 'Depression', 'Scale', ',', 'with', 'doxepin', 'improving', 'sleep', 'to', 'a', 'greater', 'extent', 'than', 'bupropion', '.']","(7, 8)","(45, 50)",-1,ss_o,3081600,Abstract,4,test,gold,2578.0
6602,Doxepin differed from bupropion mainly on the sleep factor of the,Hamilton Depression Scale,", with doxepin improving sleep to a greater extent than bupropion .","['Doxepin', 'differed', 'from', 'bupropion', 'mainly', 'on', 'the', 'sleep', 'factor', 'of', 'the', 'Hamilton', 'Depression', 'Scale', ',', 'with', 'doxepin', 'improving', 'sleep', 'to', 'a', 'greater', 'extent', 'than', 'bupropion', '.']","(11, 14)","(65, 90)",-1,ss_o,3081600,Abstract,4,test,gold,6219.0
6603,"Doxepin differed from bupropion mainly on the sleep factor of the Hamilton Depression Scale , with doxepin improving",sleep,to a greater extent than bupropion .,"['Doxepin', 'differed', 'from', 'bupropion', 'mainly', 'on', 'the', 'sleep', 'factor', 'of', 'the', 'Hamilton', 'Depression', 'Scale', ',', 'with', 'doxepin', 'improving', 'sleep', 'to', 'a', 'greater', 'extent', 'than', 'bupropion', '.']","(18, 19)","(116, 121)",-1,ss_o,3081600,Abstract,4,test,gold,2579.0
6604,,Doxepin,"differed from bupropion mainly on the sleep factor of the Hamilton Depression Scale , with doxepin improving sleep to a greater extent than bupropion .","['Doxepin', 'differed', 'from', 'bupropion', 'mainly', 'on', 'the', 'sleep', 'factor', 'of', 'the', 'Hamilton', 'Depression', 'Scale', ',', 'with', 'doxepin', 'improving', 'sleep', 'to', 'a', 'greater', 'extent', 'than', 'bupropion', '.']","(0, 1)","(0, 7)",-1,hl_i,3081600,Abstract,4,test,gold,131.0
6605,Doxepin differed from,bupropion,"mainly on the sleep factor of the Hamilton Depression Scale , with doxepin improving sleep to a greater extent than bupropion .","['Doxepin', 'differed', 'from', 'bupropion', 'mainly', 'on', 'the', 'sleep', 'factor', 'of', 'the', 'Hamilton', 'Depression', 'Scale', ',', 'with', 'doxepin', 'improving', 'sleep', 'to', 'a', 'greater', 'extent', 'than', 'bupropion', '.']","(3, 4)","(21, 30)",-1,hl_i,3081600,Abstract,4,test,gold,5238.0
6606,"Doxepin differed from bupropion mainly on the sleep factor of the Hamilton Depression Scale , with",doxepin,improving sleep to a greater extent than bupropion .,"['Doxepin', 'differed', 'from', 'bupropion', 'mainly', 'on', 'the', 'sleep', 'factor', 'of', 'the', 'Hamilton', 'Depression', 'Scale', ',', 'with', 'doxepin', 'improving', 'sleep', 'to', 'a', 'greater', 'extent', 'than', 'bupropion', '.']","(16, 17)","(98, 105)",-1,hl_i,3081600,Abstract,4,test,gold,5535.0
6607,"Doxepin differed from bupropion mainly on the sleep factor of the Hamilton Depression Scale , with doxepin improving sleep to a greater extent than",bupropion .,,"['Doxepin', 'differed', 'from', 'bupropion', 'mainly', 'on', 'the', 'sleep', 'factor', 'of', 'the', 'Hamilton', 'Depression', 'Scale', ',', 'with', 'doxepin', 'improving', 'sleep', 'to', 'a', 'greater', 'extent', 'than', 'bupropion', '.']","(24, 26)","(147, 158)",-1,hl_i,3081600,Abstract,4,test,gold,5237.0
6608,Doxepin differed from bupropion mainly on the,sleep,"factor of the Hamilton Depression Scale , with doxepin improving sleep to a greater extent than bupropion .","['Doxepin', 'differed', 'from', 'bupropion', 'mainly', 'on', 'the', 'sleep', 'factor', 'of', 'the', 'Hamilton', 'Depression', 'Scale', ',', 'with', 'doxepin', 'improving', 'sleep', 'to', 'a', 'greater', 'extent', 'than', 'bupropion', '.']","(7, 8)","(45, 50)",-1,hl_o,3081600,Abstract,4,test,gold,2577.0
6609,Doxepin differed from bupropion mainly on the sleep factor of the,Hamilton Depression Scale,", with doxepin improving sleep to a greater extent than bupropion .","['Doxepin', 'differed', 'from', 'bupropion', 'mainly', 'on', 'the', 'sleep', 'factor', 'of', 'the', 'Hamilton', 'Depression', 'Scale', ',', 'with', 'doxepin', 'improving', 'sleep', 'to', 'a', 'greater', 'extent', 'than', 'bupropion', '.']","(11, 14)","(65, 90)",-1,hl_o,3081600,Abstract,4,test,gold,6220.0
6610,"Doxepin differed from bupropion mainly on the sleep factor of the Hamilton Depression Scale , with doxepin improving",sleep,to a greater extent than bupropion .,"['Doxepin', 'differed', 'from', 'bupropion', 'mainly', 'on', 'the', 'sleep', 'factor', 'of', 'the', 'Hamilton', 'Depression', 'Scale', ',', 'with', 'doxepin', 'improving', 'sleep', 'to', 'a', 'greater', 'extent', 'than', 'bupropion', '.']","(18, 19)","(116, 121)",-1,hl_o,3081600,Abstract,4,test,gold,2576.0
6611,,Doxepin,"produced a greater incidence of anticholinergic side effects , including dry mouth , constipation , sleepiness , and tiredness , in comparison to bupropion .","['Doxepin', 'produced', 'a', 'greater', 'incidence', 'of', 'anticholinergic', 'side', 'effects', ',', 'including', 'dry', 'mouth', ',', 'constipation', ',', 'sleepiness', ',', 'and', 'tiredness', ',', 'in', 'comparison', 'to', 'bupropion', '.']","(0, 1)","(0, 7)",-1,ss_i,3081600,Abstract,5,test,gold,129.0
6612,"Doxepin produced a greater incidence of anticholinergic side effects , including dry mouth , constipation , sleepiness , and tiredness , in comparison to",bupropion .,,"['Doxepin', 'produced', 'a', 'greater', 'incidence', 'of', 'anticholinergic', 'side', 'effects', ',', 'including', 'dry', 'mouth', ',', 'constipation', ',', 'sleepiness', ',', 'and', 'tiredness', ',', 'in', 'comparison', 'to', 'bupropion', '.']","(24, 26)","(153, 164)",-1,ss_i,3081600,Abstract,5,test,gold,5236.0
6613,Doxepin produced a greater incidence of,anticholinergic side effects,", including dry mouth , constipation , sleepiness , and tiredness , in comparison to bupropion .","['Doxepin', 'produced', 'a', 'greater', 'incidence', 'of', 'anticholinergic', 'side', 'effects', ',', 'including', 'dry', 'mouth', ',', 'constipation', ',', 'sleepiness', ',', 'and', 'tiredness', ',', 'in', 'comparison', 'to', 'bupropion', '.']","(6, 9)","(39, 67)",-1,ss_o,3081600,Abstract,5,test,gold,2364.0
6614,"Doxepin produced a greater incidence of anticholinergic side effects , including","dry mouth , constipation , sleepiness , and tiredness",", in comparison to bupropion .","['Doxepin', 'produced', 'a', 'greater', 'incidence', 'of', 'anticholinergic', 'side', 'effects', ',', 'including', 'dry', 'mouth', ',', 'constipation', ',', 'sleepiness', ',', 'and', 'tiredness', ',', 'in', 'comparison', 'to', 'bupropion', '.']","(11, 20)","(80, 133)",-1,ss_o,3081600,Abstract,5,test,gold,7128.0
6615,,Doxepin,"produced a greater incidence of anticholinergic side effects , including dry mouth , constipation , sleepiness , and tiredness , in comparison to bupropion .","['Doxepin', 'produced', 'a', 'greater', 'incidence', 'of', 'anticholinergic', 'side', 'effects', ',', 'including', 'dry', 'mouth', ',', 'constipation', ',', 'sleepiness', ',', 'and', 'tiredness', ',', 'in', 'comparison', 'to', 'bupropion', '.']","(0, 1)","(0, 7)",-1,hl_i,3081600,Abstract,5,test,gold,128.0
6616,"Doxepin produced a greater incidence of anticholinergic side effects , including dry mouth , constipation , sleepiness , and tiredness , in comparison to",bupropion .,,"['Doxepin', 'produced', 'a', 'greater', 'incidence', 'of', 'anticholinergic', 'side', 'effects', ',', 'including', 'dry', 'mouth', ',', 'constipation', ',', 'sleepiness', ',', 'and', 'tiredness', ',', 'in', 'comparison', 'to', 'bupropion', '.']","(24, 26)","(153, 164)",-1,hl_i,3081600,Abstract,5,test,gold,5235.0
6617,Doxepin produced a greater incidence of,anticholinergic side effects,", including dry mouth , constipation , sleepiness , and tiredness , in comparison to bupropion .","['Doxepin', 'produced', 'a', 'greater', 'incidence', 'of', 'anticholinergic', 'side', 'effects', ',', 'including', 'dry', 'mouth', ',', 'constipation', ',', 'sleepiness', ',', 'and', 'tiredness', ',', 'in', 'comparison', 'to', 'bupropion', '.']","(6, 9)","(39, 67)",-1,hl_o,3081600,Abstract,5,test,gold,2365.0
6618,"Doxepin produced a greater incidence of anticholinergic side effects , including","dry mouth , constipation , sleepiness , and tiredness",", in comparison to bupropion .","['Doxepin', 'produced', 'a', 'greater', 'incidence', 'of', 'anticholinergic', 'side', 'effects', ',', 'including', 'dry', 'mouth', ',', 'constipation', ',', 'sleepiness', ',', 'and', 'tiredness', ',', 'in', 'comparison', 'to', 'bupropion', '.']","(11, 20)","(80, 133)",-1,hl_o,3081600,Abstract,5,test,gold,7129.0
6619,"Also , increased appetite and weight gain were consistent side effects of",doxepin,relative to bupropion .,"['Also', ',', 'increased', 'appetite', 'and', 'weight', 'gain', 'were', 'consistent', 'side', 'effects', 'of', 'doxepin', 'relative', 'to', 'bupropion', '.']","(12, 13)","(73, 80)",-1,ss_i,3081600,Abstract,6,test,gold,5534.0
6620,"Also , increased appetite and weight gain were consistent side effects of doxepin relative to",bupropion .,,"['Also', ',', 'increased', 'appetite', 'and', 'weight', 'gain', 'were', 'consistent', 'side', 'effects', 'of', 'doxepin', 'relative', 'to', 'bupropion', '.']","(15, 17)","(93, 104)",-1,ss_i,3081600,Abstract,6,test,gold,5234.0
6621,"Also ,",increased appetite and weight gain,were consistent side effects of doxepin relative to bupropion .,"['Also', ',', 'increased', 'appetite', 'and', 'weight', 'gain', 'were', 'consistent', 'side', 'effects', 'of', 'doxepin', 'relative', 'to', 'bupropion', '.']","(2, 7)","(6, 40)",-1,ss_o,3081600,Abstract,6,test,gold,1913.0
6622,"Also , increased appetite and weight gain were consistent",side effects,of doxepin relative to bupropion .,"['Also', ',', 'increased', 'appetite', 'and', 'weight', 'gain', 'were', 'consistent', 'side', 'effects', 'of', 'doxepin', 'relative', 'to', 'bupropion', '.']","(9, 11)","(57, 69)",-1,ss_o,3081600,Abstract,6,test,gold,2370.0
6623,"Also , increased appetite and weight gain were consistent side effects of",doxepin,relative to bupropion .,"['Also', ',', 'increased', 'appetite', 'and', 'weight', 'gain', 'were', 'consistent', 'side', 'effects', 'of', 'doxepin', 'relative', 'to', 'bupropion', '.']","(12, 13)","(73, 80)",-1,hl_i,3081600,Abstract,6,test,gold,5533.0
6624,"Also , increased appetite and weight gain were consistent side effects of doxepin relative to",bupropion .,,"['Also', ',', 'increased', 'appetite', 'and', 'weight', 'gain', 'were', 'consistent', 'side', 'effects', 'of', 'doxepin', 'relative', 'to', 'bupropion', '.']","(15, 17)","(93, 104)",-1,hl_i,3081600,Abstract,6,test,gold,5233.0
6625,"Also , increased",appetite and weight gain,were consistent side effects of doxepin relative to bupropion .,"['Also', ',', 'increased', 'appetite', 'and', 'weight', 'gain', 'were', 'consistent', 'side', 'effects', 'of', 'doxepin', 'relative', 'to', 'bupropion', '.']","(3, 7)","(16, 40)",-1,hl_o,3081600,Abstract,6,test,gold,1914.0
6626,"Review of the Multicenter Trial Committee report : a prospective , randomized study on the",prophylaxis,of postoperative deep venous thrombosis .,"['Review', 'of', 'the', 'Multicenter', 'Trial', 'Committee', 'report', ':', 'a', 'prospective', ',', 'randomized', 'study', 'on', 'the', 'prophylaxis', 'of', 'postoperative', 'deep', 'venous', 'thrombosis', '.']","(15, 16)","(90, 101)",-1,ss_o,3534803,Title,0,test,gold,3419.0
6627,The etiology of postoperative deep venous thrombosis ( DVT ) is thought to be due to a combination of factors including,"stasis , a hypercoagulable state and venous endothelial damage .",,"['The', 'etiology', 'of', 'postoperative', 'deep', 'venous', 'thrombosis', '(', 'DVT', ')', 'is', 'thought', 'to', 'be', 'due', 'to', 'a', 'combination', 'of', 'factors', 'including', 'stasis', ',', 'a', 'hypercoagulable', 'state', 'and', 'venous', 'endothelial', 'damage', '.']","(21, 31)","(119, 183)",-1,ss_o,3534803,Abstract,0,test,gold,6809.0
6628,Methods of prophylaxis are directed toward correcting one or more of these pathologic events .,,,"['Methods', 'of', 'prophylaxis', 'are', 'directed', 'toward', 'correcting', 'one', 'or', 'more', 'of', 'these', 'pathologic', 'events', '.']",,,,,3534803,Abstract,1,test,gold,
6629,Methods counteracting more than one of these factors can be expected to be even more effective .,,,"['Methods', 'counteracting', 'more', 'than', 'one', 'of', 'these', 'factors', 'can', 'be', 'expected', 'to', 'be', 'even', 'more', 'effective', '.']",,,,,3534803,Abstract,2,test,gold,
6630,The combination of,dihydroergotamine ( DHE ),and heparin was anticipated to minimize stasis and the hypercoagulable state respectively .,"['The', 'combination', 'of', 'dihydroergotamine', '(', 'DHE', ')', 'and', 'heparin', 'was', 'anticipated', 'to', 'minimize', 'stasis', 'and', 'the', 'hypercoagulable', 'state', 'respectively', '.']","(3, 7)","(18, 43)",-1,ss_i,3534803,Abstract,3,test,gold,5496.0
6631,The combination of dihydroergotamine ( DHE ) and,heparin,was anticipated to minimize stasis and the hypercoagulable state respectively .,"['The', 'combination', 'of', 'dihydroergotamine', '(', 'DHE', ')', 'and', 'heparin', 'was', 'anticipated', 'to', 'minimize', 'stasis', 'and', 'the', 'hypercoagulable', 'state', 'respectively', '.']","(8, 9)","(48, 55)",-1,ss_i,3534803,Abstract,3,test,gold,5030.0
6632,The combination of dihydroergotamine ( DHE ) and heparin was anticipated to minimize,stasis and the hypercoagulable state,respectively .,"['The', 'combination', 'of', 'dihydroergotamine', '(', 'DHE', ')', 'and', 'heparin', 'was', 'anticipated', 'to', 'minimize', 'stasis', 'and', 'the', 'hypercoagulable', 'state', 'respectively', '.']","(13, 18)","(84, 120)",-1,ss_o,3534803,Abstract,3,test,gold,2661.0
6633,The combination of,dihydroergotamine ( DHE ),and heparin was anticipated to minimize stasis and the hypercoagulable state respectively .,"['The', 'combination', 'of', 'dihydroergotamine', '(', 'DHE', ')', 'and', 'heparin', 'was', 'anticipated', 'to', 'minimize', 'stasis', 'and', 'the', 'hypercoagulable', 'state', 'respectively', '.']","(3, 7)","(18, 43)",-1,hl_i,3534803,Abstract,3,test,gold,5497.0
6634,The combination of dihydroergotamine ( DHE ) and,heparin,was anticipated to minimize stasis and the hypercoagulable state respectively .,"['The', 'combination', 'of', 'dihydroergotamine', '(', 'DHE', ')', 'and', 'heparin', 'was', 'anticipated', 'to', 'minimize', 'stasis', 'and', 'the', 'hypercoagulable', 'state', 'respectively', '.']","(8, 9)","(48, 55)",-1,hl_i,3534803,Abstract,3,test,gold,5031.0
6635,"Based upon current experimental evidence and current theory , an additional benefit might include minimizing venous endothelial injury by controlling venomotor tone .",,,"['Based', 'upon', 'current', 'experimental', 'evidence', 'and', 'current', 'theory', ',', 'an', 'additional', 'benefit', 'might', 'include', 'minimizing', 'venous', 'endothelial', 'injury', 'by', 'controlling', 'venomotor', 'tone', '.']",,,,,3534803,Abstract,4,test,gold,
6636,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the",United States,"evaluating the prophylactic efficacy of DHE 0.5 mg plus heparin 5000 U , DHE 0.5 mg plus heparin 2500 U , heparin 5000 U , and DHE 0.5 mg versus placebo .","['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(15, 17)","(95, 108)",-1,ss_p,3534803,Abstract,5,test,gold,1270.0
6637,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the United States evaluating the prophylactic efficacy of",DHE,"0.5 mg plus heparin 5000 U , DHE 0.5 mg plus heparin 2500 U , heparin 5000 U , and DHE 0.5 mg versus placebo .","['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(22, 23)","(149, 152)",-1,ss_i,3534803,Abstract,5,test,gold,5494.0
6638,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the United States evaluating the prophylactic efficacy of DHE 0.5 mg plus",heparin,"5000 U , DHE 0.5 mg plus heparin 2500 U , heparin 5000 U , and DHE 0.5 mg versus placebo .","['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(26, 27)","(165, 172)",-1,ss_i,3534803,Abstract,5,test,gold,5029.0
6639,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the United States evaluating the prophylactic efficacy of DHE 0.5 mg plus heparin 5000 U ,",DHE,"0.5 mg plus heparin 2500 U , heparin 5000 U , and DHE 0.5 mg versus placebo .","['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(30, 31)","(182, 185)",-1,ss_i,3534803,Abstract,5,test,gold,5495.0
6640,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the United States evaluating the prophylactic efficacy of DHE 0.5 mg plus heparin 5000 U , DHE 0.5 mg plus",heparin,"2500 U , heparin 5000 U , and DHE 0.5 mg versus placebo .","['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(34, 35)","(198, 205)",-1,ss_i,3534803,Abstract,5,test,gold,5028.0
6641,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the United States evaluating the prophylactic efficacy of DHE 0.5 mg plus heparin 5000 U , DHE 0.5 mg plus heparin 2500 U ,",heparin,"5000 U , and DHE 0.5 mg versus placebo .","['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(38, 39)","(215, 222)",-1,ss_i,3534803,Abstract,5,test,gold,5027.0
6642,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the United States evaluating the prophylactic efficacy of DHE 0.5 mg plus heparin 5000 U , DHE 0.5 mg plus heparin 2500 U , heparin 5000 U , and",DHE,0.5 mg versus placebo .,"['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(43, 44)","(236, 239)",-1,ss_i,3534803,Abstract,5,test,gold,5493.0
6643,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the United States evaluating the prophylactic efficacy of DHE 0.5 mg plus heparin 5000 U , DHE 0.5 mg plus heparin 2500 U , heparin 5000 U , and DHE 0.5 mg versus",placebo .,,"['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(47, 49)","(254, 263)",-1,ss_i,3534803,Abstract,5,test,gold,4313.0
6644,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the United States evaluating the",prophylactic efficacy,"of DHE 0.5 mg plus heparin 5000 U , DHE 0.5 mg plus heparin 2500 U , heparin 5000 U , and DHE 0.5 mg versus placebo .","['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(19, 21)","(124, 145)",-1,ss_o,3534803,Abstract,5,test,gold,4858.0
6645,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the",United States,"evaluating the prophylactic efficacy of DHE 0.5 mg plus heparin 5000 U , DHE 0.5 mg plus heparin 2500 U , heparin 5000 U , and DHE 0.5 mg versus placebo .","['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(15, 17)","(95, 108)",-1,hl_p,3534803,Abstract,5,test,gold,1271.0
6646,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the United States evaluating the prophylactic efficacy of",DHE,"0.5 mg plus heparin 5000 U , DHE 0.5 mg plus heparin 2500 U , heparin 5000 U , and DHE 0.5 mg versus placebo .","['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(22, 23)","(149, 152)",-1,hl_i,3534803,Abstract,5,test,gold,5492.0
6647,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the United States evaluating the prophylactic efficacy of DHE 0.5 mg plus",heparin,"5000 U , DHE 0.5 mg plus heparin 2500 U , heparin 5000 U , and DHE 0.5 mg versus placebo .","['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(26, 27)","(165, 172)",-1,hl_i,3534803,Abstract,5,test,gold,5026.0
6648,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the United States evaluating the prophylactic efficacy of DHE 0.5 mg plus heparin 5000 U ,",DHE,"0.5 mg plus heparin 2500 U , heparin 5000 U , and DHE 0.5 mg versus placebo .","['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(30, 31)","(182, 185)",-1,hl_i,3534803,Abstract,5,test,gold,5491.0
6649,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the United States evaluating the prophylactic efficacy of DHE 0.5 mg plus heparin 5000 U , DHE 0.5 mg plus",heparin,"2500 U , heparin 5000 U , and DHE 0.5 mg versus placebo .","['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(34, 35)","(198, 205)",-1,hl_i,3534803,Abstract,5,test,gold,5025.0
6650,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the United States evaluating the prophylactic efficacy of DHE 0.5 mg plus heparin 5000 U , DHE 0.5 mg plus heparin 2500 U ,",heparin,"5000 U , and DHE 0.5 mg versus placebo .","['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(38, 39)","(215, 222)",-1,hl_i,3534803,Abstract,5,test,gold,5024.0
6651,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the United States evaluating the prophylactic efficacy of DHE 0.5 mg plus heparin 5000 U , DHE 0.5 mg plus heparin 2500 U , heparin 5000 U , and",DHE,0.5 mg versus placebo .,"['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(43, 44)","(236, 239)",-1,hl_i,3534803,Abstract,5,test,gold,5490.0
6652,"A prospective , randomized , double-blind , multicenter trial was designed and performed in the United States evaluating the prophylactic efficacy of DHE 0.5 mg plus heparin 5000 U , DHE 0.5 mg plus heparin 2500 U , heparin 5000 U , and DHE 0.5 mg versus",placebo .,,"['A', 'prospective', ',', 'randomized', ',', 'double-blind', ',', 'multicenter', 'trial', 'was', 'designed', 'and', 'performed', 'in', 'the', 'United', 'States', 'evaluating', 'the', 'prophylactic', 'efficacy', 'of', 'DHE', '0.5', 'mg', 'plus', 'heparin', '5000', 'U', ',', 'DHE', '0.5', 'mg', 'plus', 'heparin', '2500', 'U', ',', 'heparin', '5000', 'U', ',', 'and', 'DHE', '0.5', 'mg', 'versus', 'placebo', '.']","(47, 49)","(254, 263)",-1,hl_i,3534803,Abstract,5,test,gold,4312.0
6653,,General surgical patients including those undergoing noncardiac thoracic and pelvic operations who were identified at moderate to high risk for postop DVT were included .,,"['General', 'surgical', 'patients', 'including', 'those', 'undergoing', 'noncardiac', 'thoracic', 'and', 'pelvic', 'operations', 'who', 'were', 'identified', 'at', 'moderate', 'to', 'high', 'risk', 'for', 'postop', 'DVT', 'were', 'included', '.']","(0, 25)","(0, 170)",-1,ss_p,3534803,Abstract,6,test,gold,6007.0
6654,,General surgical patients including those undergoing noncardiac thoracic and pelvic operations who were identified at moderate to high risk for postop DVT were included .,,"['General', 'surgical', 'patients', 'including', 'those', 'undergoing', 'noncardiac', 'thoracic', 'and', 'pelvic', 'operations', 'who', 'were', 'identified', 'at', 'moderate', 'to', 'high', 'risk', 'for', 'postop', 'DVT', 'were', 'included', '.']","(0, 25)","(0, 170)",-1,hl_p,3534803,Abstract,6,test,gold,6008.0
6655,Study medications were injected subcutaneously two hours preoperatively and every 12 hours postoperatively for 5-7 days or until the 125I-fibrinogen-uptake test ( RFUT ) became positive .,,,"['Study', 'medications', 'were', 'injected', 'subcutaneously', 'two', 'hours', 'preoperatively', 'and', 'every', '12', 'hours', 'postoperatively', 'for', '5-7', 'days', 'or', 'until', 'the', '125I-fibrinogen-uptake', 'test', '(', 'RFUT', ')', 'became', 'positive', '.']",,,,,3534803,Abstract,7,test,gold,
6656,,Eight hundred and eighty eight patients were entered into this trial and 744 ( 85 % ) completed the study .,,"['Eight', 'hundred', 'and', 'eighty', 'eight', 'patients', 'were', 'entered', 'into', 'this', 'trial', 'and', '744', '(', '85', '%', ')', 'completed', 'the', 'study', '.']","(0, 21)","(0, 107)",-1,ss_p,3534803,Abstract,8,test,gold,5845.0
6657,,Eight hundred and eighty eight,patients were entered into this trial and 744 ( 85 % ) completed the study .,"['Eight', 'hundred', 'and', 'eighty', 'eight', 'patients', 'were', 'entered', 'into', 'this', 'trial', 'and', '744', '(', '85', '%', ')', 'completed', 'the', 'study', '.']","(0, 5)","(0, 30)",-1,hl_p,3534803,Abstract,8,test,gold,2060.0
6658,Eight hundred and eighty eight patients were entered into this trial and,744,( 85 % ) completed the study .,"['Eight', 'hundred', 'and', 'eighty', 'eight', 'patients', 'were', 'entered', 'into', 'this', 'trial', 'and', '744', '(', '85', '%', ')', 'completed', 'the', 'study', '.']","(12, 13)","(72, 75)",-1,hl_p,3534803,Abstract,8,test,gold,
6659,Results showed a statistically significant benefit from,DHE/Hep,5000 compared to placebo ( p less than 0.01 ) and compared to other active agents ( p less than 0.05 ) .,"['Results', 'showed', 'a', 'statistically', 'significant', 'benefit', 'from', 'DHE/Hep', '5000', 'compared', 'to', 'placebo', '(', 'p', 'less', 'than', '0.01', ')', 'and', 'compared', 'to', 'other', 'active', 'agents', '(', 'p', 'less', 'than', '0.05', ')', '.']","(7, 8)","(55, 62)",-1,ss_i,3534803,Abstract,9,test,gold,
6660,Results showed a statistically significant benefit from DHE/Hep 5000 compared to,placebo,( p less than 0.01 ) and compared to other active agents ( p less than 0.05 ) .,"['Results', 'showed', 'a', 'statistically', 'significant', 'benefit', 'from', 'DHE/Hep', '5000', 'compared', 'to', 'placebo', '(', 'p', 'less', 'than', '0.01', ')', 'and', 'compared', 'to', 'other', 'active', 'agents', '(', 'p', 'less', 'than', '0.05', ')', '.']","(11, 12)","(80, 87)",-1,ss_i,3534803,Abstract,9,test,gold,4311.0
6661,Results showed a statistically significant benefit from,DHE/Hep,5000 compared to placebo ( p less than 0.01 ) and compared to other active agents ( p less than 0.05 ) .,"['Results', 'showed', 'a', 'statistically', 'significant', 'benefit', 'from', 'DHE/Hep', '5000', 'compared', 'to', 'placebo', '(', 'p', 'less', 'than', '0.01', ')', 'and', 'compared', 'to', 'other', 'active', 'agents', '(', 'p', 'less', 'than', '0.05', ')', '.']","(7, 8)","(55, 62)",-1,hl_i,3534803,Abstract,9,test,gold,
6662,Results showed a statistically significant benefit from DHE/Hep 5000 compared to,placebo,( p less than 0.01 ) and compared to other active agents ( p less than 0.05 ) .,"['Results', 'showed', 'a', 'statistically', 'significant', 'benefit', 'from', 'DHE/Hep', '5000', 'compared', 'to', 'placebo', '(', 'p', 'less', 'than', '0.01', ')', 'and', 'compared', 'to', 'other', 'active', 'agents', '(', 'p', 'less', 'than', '0.05', ')', '.']","(11, 12)","(80, 87)",-1,hl_i,3534803,Abstract,9,test,gold,4310.0
6663,None of the other active agents showed a statistically significant prophylactic benefit .,,,"['None', 'of', 'the', 'other', 'active', 'agents', 'showed', 'a', 'statistically', 'significant', 'prophylactic', 'benefit', '.']",,,,,3534803,Abstract,10,test,gold,
6664,( ABSTRACT TRUNCATED AT 250 WORDS ),,,"['(', 'ABSTRACT', 'TRUNCATED', 'AT', '250', 'WORDS', ')']",,,,,3534803,Abstract,11,test,gold,
6665,[ The chemotherapy of,advanced breast cancer .,,"['[', 'The', 'chemotherapy', 'of', 'advanced', 'breast', 'cancer', '.']","(4, 8)","(21, 45)",-1,ss_p,361799,Title,0,test,gold,6878.0
6666,[ The,chemotherapy,of advanced breast cancer .,"['[', 'The', 'chemotherapy', 'of', 'advanced', 'breast', 'cancer', '.']","(2, 3)","(5, 17)",-1,ss_i,361799,Title,0,test,gold,4248.0
6667,[ The chemotherapy of,advanced breast cancer .,,"['[', 'The', 'chemotherapy', 'of', 'advanced', 'breast', 'cancer', '.']","(4, 8)","(21, 45)",-1,hl_p,361799,Title,0,test,gold,6879.0
6668,[ The,chemotherapy,of advanced breast cancer .,"['[', 'The', 'chemotherapy', 'of', 'advanced', 'breast', 'cancer', '.']","(2, 3)","(5, 17)",-1,hl_i,361799,Title,0,test,gold,4247.0
6669,A report on the first,600 cases,in a cooperative programme to carry out a systematic study ( 1974-1977 ) ( author 's transl ) ] .,"['A', 'report', 'on', 'the', 'first', '600', 'cases', 'in', 'a', 'cooperative', 'programme', 'to', 'carry', 'out', 'a', 'systematic', 'study', '(', '1974-1977', ')', '(', 'author', ""'s"", 'transl', ')', ']', '.']","(5, 7)","(21, 30)",-1,ss_p,361799,Abstract,0,test,gold,1146.0
6670,A report on the first,600 cases,in a cooperative programme to carry out a systematic study ( 1974-1977 ) ( author 's transl ) ] .,"['A', 'report', 'on', 'the', 'first', '600', 'cases', 'in', 'a', 'cooperative', 'programme', 'to', 'carry', 'out', 'a', 'systematic', 'study', '(', '1974-1977', ')', '(', 'author', ""'s"", 'transl', ')', ']', '.']","(5, 7)","(21, 30)",-1,hl_p,361799,Abstract,0,test,gold,1147.0
6671,The authors explain the objectives and the structure of a programme evolved for the methodic study of,advanced breast cancers,which they have worked out and carried out in cooperation with the departments of medicine in eight French anticancer centres .,"['The', 'authors', 'explain', 'the', 'objectives', 'and', 'the', 'structure', 'of', 'a', 'programme', 'evolved', 'for', 'the', 'methodic', 'study', 'of', 'advanced', 'breast', 'cancers', 'which', 'they', 'have', 'worked', 'out', 'and', 'carried', 'out', 'in', 'cooperation', 'with', 'the', 'departments', 'of', 'medicine', 'in', 'eight', 'French', 'anticancer', 'centres', '.']","(17, 20)","(101, 124)",-1,ss_p,361799,Abstract,1,test,gold,6876.0
6672,The authors explain the objectives and the structure of a programme evolved for the methodic study of advanced breast cancers which they have worked out and carried out in cooperation with the departments of medicine,in eight French anticancer centres .,,"['The', 'authors', 'explain', 'the', 'objectives', 'and', 'the', 'structure', 'of', 'a', 'programme', 'evolved', 'for', 'the', 'methodic', 'study', 'of', 'advanced', 'breast', 'cancers', 'which', 'they', 'have', 'worked', 'out', 'and', 'carried', 'out', 'in', 'cooperation', 'with', 'the', 'departments', 'of', 'medicine', 'in', 'eight', 'French', 'anticancer', 'centres', '.']","(35, 41)","(216, 252)",-1,ss_p,361799,Abstract,1,test,gold,5722.0
6673,The authors explain the objectives and the structure of a programme evolved for the methodic study of,advanced breast cancers,which they have worked out and carried out in cooperation with the departments of medicine in eight French anticancer centres .,"['The', 'authors', 'explain', 'the', 'objectives', 'and', 'the', 'structure', 'of', 'a', 'programme', 'evolved', 'for', 'the', 'methodic', 'study', 'of', 'advanced', 'breast', 'cancers', 'which', 'they', 'have', 'worked', 'out', 'and', 'carried', 'out', 'in', 'cooperation', 'with', 'the', 'departments', 'of', 'medicine', 'in', 'eight', 'French', 'anticancer', 'centres', '.']","(17, 20)","(101, 124)",-1,hl_p,361799,Abstract,1,test,gold,6877.0
6674,The authors explain the objectives and the structure of a programme evolved for the methodic study of advanced breast cancers which they have worked out and carried out in cooperation with the departments of medicine,in eight French anticancer centres,.,"['The', 'authors', 'explain', 'the', 'objectives', 'and', 'the', 'structure', 'of', 'a', 'programme', 'evolved', 'for', 'the', 'methodic', 'study', 'of', 'advanced', 'breast', 'cancers', 'which', 'they', 'have', 'worked', 'out', 'and', 'carried', 'out', 'in', 'cooperation', 'with', 'the', 'departments', 'of', 'medicine', 'in', 'eight', 'French', 'anticancer', 'centres', '.']","(35, 40)","(216, 250)",-1,hl_p,361799,Abstract,1,test,gold,5723.0
6675,"They analyse the initial phases , which correspond to the three first years of work .",,,"['They', 'analyse', 'the', 'initial', 'phases', ',', 'which', 'correspond', 'to', 'the', 'three', 'first', 'years', 'of', 'work', '.']",,,,,361799,Abstract,2,test,gold,
6676,They give the state of the results that have been obtained in,603 patients,using three protocols for treatment .,"['They', 'give', 'the', 'state', 'of', 'the', 'results', 'that', 'have', 'been', 'obtained', 'in', '603', 'patients', 'using', 'three', 'protocols', 'for', 'treatment', '.']","(12, 14)","(61, 73)",-1,ss_p,361799,Abstract,3,test,gold,3739.0
6677,They give the state of the results that have been obtained in,603 patients,using three protocols for treatment .,"['They', 'give', 'the', 'state', 'of', 'the', 'results', 'that', 'have', 'been', 'obtained', 'in', '603', 'patients', 'using', 'three', 'protocols', 'for', 'treatment', '.']","(12, 14)","(61, 73)",-1,hl_p,361799,Abstract,3,test,gold,3738.0
6678,These consisted of the administration in interrupted doses of,chemotherapy,which consisted of vincristine associated for the one part with cyclophosphamide and 5-fluoro-uracil and on the other hand with doxorubicine or/and with methotrexate .,"['These', 'consisted', 'of', 'the', 'administration', 'in', 'interrupted', 'doses', 'of', 'chemotherapy', 'which', 'consisted', 'of', 'vincristine', 'associated', 'for', 'the', 'one', 'part', 'with', 'cyclophosphamide', 'and', '5-fluoro-uracil', 'and', 'on', 'the', 'other', 'hand', 'with', 'doxorubicine', 'or/and', 'with', 'methotrexate', '.']","(9, 10)","(61, 73)",-1,ss_i,361799,Abstract,4,test,gold,4246.0
6679,These consisted of the administration in interrupted doses of chemotherapy which consisted of,vincristine,associated for the one part with cyclophosphamide and 5-fluoro-uracil and on the other hand with doxorubicine or/and with methotrexate .,"['These', 'consisted', 'of', 'the', 'administration', 'in', 'interrupted', 'doses', 'of', 'chemotherapy', 'which', 'consisted', 'of', 'vincristine', 'associated', 'for', 'the', 'one', 'part', 'with', 'cyclophosphamide', 'and', '5-fluoro-uracil', 'and', 'on', 'the', 'other', 'hand', 'with', 'doxorubicine', 'or/and', 'with', 'methotrexate', '.']","(13, 14)","(93, 104)",-1,ss_i,361799,Abstract,4,test,gold,5735.0
6680,These consisted of the administration in interrupted doses of chemotherapy which consisted of vincristine associated for the one part with,cyclophosphamide,and 5-fluoro-uracil and on the other hand with doxorubicine or/and with methotrexate .,"['These', 'consisted', 'of', 'the', 'administration', 'in', 'interrupted', 'doses', 'of', 'chemotherapy', 'which', 'consisted', 'of', 'vincristine', 'associated', 'for', 'the', 'one', 'part', 'with', 'cyclophosphamide', 'and', '5-fluoro-uracil', 'and', 'on', 'the', 'other', 'hand', 'with', 'doxorubicine', 'or/and', 'with', 'methotrexate', '.']","(20, 21)","(138, 154)",-1,ss_i,361799,Abstract,4,test,gold,5746.0
6681,These consisted of the administration in interrupted doses of chemotherapy which consisted of vincristine associated for the one part with cyclophosphamide and,5-fluoro-uracil,and on the other hand with doxorubicine or/and with methotrexate .,"['These', 'consisted', 'of', 'the', 'administration', 'in', 'interrupted', 'doses', 'of', 'chemotherapy', 'which', 'consisted', 'of', 'vincristine', 'associated', 'for', 'the', 'one', 'part', 'with', 'cyclophosphamide', 'and', '5-fluoro-uracil', 'and', 'on', 'the', 'other', 'hand', 'with', 'doxorubicine', 'or/and', 'with', 'methotrexate', '.']","(22, 23)","(159, 174)",-1,ss_i,361799,Abstract,4,test,gold,
6682,These consisted of the administration in interrupted doses of chemotherapy which consisted of vincristine associated for the one part with cyclophosphamide and 5-fluoro-uracil and on the other hand with,doxorubicine,or/and with methotrexate .,"['These', 'consisted', 'of', 'the', 'administration', 'in', 'interrupted', 'doses', 'of', 'chemotherapy', 'which', 'consisted', 'of', 'vincristine', 'associated', 'for', 'the', 'one', 'part', 'with', 'cyclophosphamide', 'and', '5-fluoro-uracil', 'and', 'on', 'the', 'other', 'hand', 'with', 'doxorubicine', 'or/and', 'with', 'methotrexate', '.']","(29, 30)","(202, 214)",-1,ss_i,361799,Abstract,4,test,gold,
6683,These consisted of the administration in interrupted doses of chemotherapy which consisted of vincristine associated for the one part with cyclophosphamide and 5-fluoro-uracil and on the other hand with doxorubicine or/and with,methotrexate .,,"['These', 'consisted', 'of', 'the', 'administration', 'in', 'interrupted', 'doses', 'of', 'chemotherapy', 'which', 'consisted', 'of', 'vincristine', 'associated', 'for', 'the', 'one', 'part', 'with', 'cyclophosphamide', 'and', '5-fluoro-uracil', 'and', 'on', 'the', 'other', 'hand', 'with', 'doxorubicine', 'or/and', 'with', 'methotrexate', '.']","(32, 34)","(227, 241)",-1,ss_i,361799,Abstract,4,test,gold,5140.0
6684,These consisted of the administration in interrupted doses of,chemotherapy,which consisted of vincristine associated for the one part with cyclophosphamide and 5-fluoro-uracil and on the other hand with doxorubicine or/and with methotrexate .,"['These', 'consisted', 'of', 'the', 'administration', 'in', 'interrupted', 'doses', 'of', 'chemotherapy', 'which', 'consisted', 'of', 'vincristine', 'associated', 'for', 'the', 'one', 'part', 'with', 'cyclophosphamide', 'and', '5-fluoro-uracil', 'and', 'on', 'the', 'other', 'hand', 'with', 'doxorubicine', 'or/and', 'with', 'methotrexate', '.']","(9, 10)","(61, 73)",-1,hl_i,361799,Abstract,4,test,gold,4245.0
6685,These consisted of the administration in interrupted doses of chemotherapy which consisted of,vincristine,associated for the one part with cyclophosphamide and 5-fluoro-uracil and on the other hand with doxorubicine or/and with methotrexate .,"['These', 'consisted', 'of', 'the', 'administration', 'in', 'interrupted', 'doses', 'of', 'chemotherapy', 'which', 'consisted', 'of', 'vincristine', 'associated', 'for', 'the', 'one', 'part', 'with', 'cyclophosphamide', 'and', '5-fluoro-uracil', 'and', 'on', 'the', 'other', 'hand', 'with', 'doxorubicine', 'or/and', 'with', 'methotrexate', '.']","(13, 14)","(93, 104)",-1,hl_i,361799,Abstract,4,test,gold,5736.0
6686,These consisted of the administration in interrupted doses of chemotherapy which consisted of vincristine associated for the one part with,cyclophosphamide,and 5-fluoro-uracil and on the other hand with doxorubicine or/and with methotrexate .,"['These', 'consisted', 'of', 'the', 'administration', 'in', 'interrupted', 'doses', 'of', 'chemotherapy', 'which', 'consisted', 'of', 'vincristine', 'associated', 'for', 'the', 'one', 'part', 'with', 'cyclophosphamide', 'and', '5-fluoro-uracil', 'and', 'on', 'the', 'other', 'hand', 'with', 'doxorubicine', 'or/and', 'with', 'methotrexate', '.']","(20, 21)","(138, 154)",-1,hl_i,361799,Abstract,4,test,gold,5747.0
6687,These consisted of the administration in interrupted doses of chemotherapy which consisted of vincristine associated for the one part with cyclophosphamide and,5-fluoro-uracil,and on the other hand with doxorubicine or/and with methotrexate .,"['These', 'consisted', 'of', 'the', 'administration', 'in', 'interrupted', 'doses', 'of', 'chemotherapy', 'which', 'consisted', 'of', 'vincristine', 'associated', 'for', 'the', 'one', 'part', 'with', 'cyclophosphamide', 'and', '5-fluoro-uracil', 'and', 'on', 'the', 'other', 'hand', 'with', 'doxorubicine', 'or/and', 'with', 'methotrexate', '.']","(22, 23)","(159, 174)",-1,hl_i,361799,Abstract,4,test,gold,
6688,These consisted of the administration in interrupted doses of chemotherapy which consisted of vincristine associated for the one part with cyclophosphamide and 5-fluoro-uracil and on the other hand with,doxorubicine,or/and with methotrexate .,"['These', 'consisted', 'of', 'the', 'administration', 'in', 'interrupted', 'doses', 'of', 'chemotherapy', 'which', 'consisted', 'of', 'vincristine', 'associated', 'for', 'the', 'one', 'part', 'with', 'cyclophosphamide', 'and', '5-fluoro-uracil', 'and', 'on', 'the', 'other', 'hand', 'with', 'doxorubicine', 'or/and', 'with', 'methotrexate', '.']","(29, 30)","(202, 214)",-1,hl_i,361799,Abstract,4,test,gold,
6689,These consisted of the administration in interrupted doses of chemotherapy which consisted of vincristine associated for the one part with cyclophosphamide and 5-fluoro-uracil and on the other hand with doxorubicine or/and with,methotrexate .,,"['These', 'consisted', 'of', 'the', 'administration', 'in', 'interrupted', 'doses', 'of', 'chemotherapy', 'which', 'consisted', 'of', 'vincristine', 'associated', 'for', 'the', 'one', 'part', 'with', 'cyclophosphamide', 'and', '5-fluoro-uracil', 'and', 'on', 'the', 'other', 'hand', 'with', 'doxorubicine', 'or/and', 'with', 'methotrexate', '.']","(32, 34)","(227, 241)",-1,hl_i,361799,Abstract,4,test,gold,5139.0
6690,From this study there emerged the value of combined therapy using,doxorubicine,"as much because of the frequency with which results better than 50 % were obtained ( in a randomised trial ) as by their quality , which was made clear in an important series of 240 cases .","['From', 'this', 'study', 'there', 'emerged', 'the', 'value', 'of', 'combined', 'therapy', 'using', 'doxorubicine', 'as', 'much', 'because', 'of', 'the', 'frequency', 'with', 'which', 'results', 'better', 'than', '50', '%', 'were', 'obtained', '(', 'in', 'a', 'randomised', 'trial', ')', 'as', 'by', 'their', 'quality', ',', 'which', 'was', 'made', 'clear', 'in', 'an', 'important', 'series', 'of', '240', 'cases', '.']","(11, 12)","(65, 77)",-1,ss_i,361799,Abstract,5,test,gold,
6691,From this study there emerged the value of combined therapy using doxorubicine as much because of the frequency with which,results,"better than 50 % were obtained ( in a randomised trial ) as by their quality , which was made clear in an important series of 240 cases .","['From', 'this', 'study', 'there', 'emerged', 'the', 'value', 'of', 'combined', 'therapy', 'using', 'doxorubicine', 'as', 'much', 'because', 'of', 'the', 'frequency', 'with', 'which', 'results', 'better', 'than', '50', '%', 'were', 'obtained', '(', 'in', 'a', 'randomised', 'trial', ')', 'as', 'by', 'their', 'quality', ',', 'which', 'was', 'made', 'clear', 'in', 'an', 'important', 'series', 'of', '240', 'cases', '.']","(20, 21)","(122, 129)",-1,ss_o,361799,Abstract,5,test,gold,1860.0
6692,From this study there emerged the value of combined therapy using doxorubicine as much because of the frequency with which results better than 50 % were obtained ( in a randomised trial ) as by their,quality,", which was made clear in an important series of 240 cases .","['From', 'this', 'study', 'there', 'emerged', 'the', 'value', 'of', 'combined', 'therapy', 'using', 'doxorubicine', 'as', 'much', 'because', 'of', 'the', 'frequency', 'with', 'which', 'results', 'better', 'than', '50', '%', 'were', 'obtained', '(', 'in', 'a', 'randomised', 'trial', ')', 'as', 'by', 'their', 'quality', ',', 'which', 'was', 'made', 'clear', 'in', 'an', 'important', 'series', 'of', '240', 'cases', '.']","(36, 37)","(199, 206)",-1,ss_o,361799,Abstract,5,test,gold,1384.0
6693,From this study there emerged the value of combined therapy using,doxorubicine,"as much because of the frequency with which results better than 50 % were obtained ( in a randomised trial ) as by their quality , which was made clear in an important series of 240 cases .","['From', 'this', 'study', 'there', 'emerged', 'the', 'value', 'of', 'combined', 'therapy', 'using', 'doxorubicine', 'as', 'much', 'because', 'of', 'the', 'frequency', 'with', 'which', 'results', 'better', 'than', '50', '%', 'were', 'obtained', '(', 'in', 'a', 'randomised', 'trial', ')', 'as', 'by', 'their', 'quality', ',', 'which', 'was', 'made', 'clear', 'in', 'an', 'important', 'series', 'of', '240', 'cases', '.']","(11, 12)","(65, 77)",-1,hl_i,361799,Abstract,5,test,gold,
6694,From this study there emerged the value of combined therapy using doxorubicine as much because of the frequency with which results better than 50 % were obtained ( in a randomised trial ) as by their,quality,", which was made clear in an important series of 240 cases .","['From', 'this', 'study', 'there', 'emerged', 'the', 'value', 'of', 'combined', 'therapy', 'using', 'doxorubicine', 'as', 'much', 'because', 'of', 'the', 'frequency', 'with', 'which', 'results', 'better', 'than', '50', '%', 'were', 'obtained', '(', 'in', 'a', 'randomised', 'trial', ')', 'as', 'by', 'their', 'quality', ',', 'which', 'was', 'made', 'clear', 'in', 'an', 'important', 'series', 'of', '240', 'cases', '.']","(36, 37)","(199, 206)",-1,hl_o,361799,Abstract,5,test,gold,1385.0
6695,"They point out the conditions required to initiate the place of such a scheme in all complex therapy which aims as much at palliation as at cure , and point out how important it is to be methodical in the application of",chemotherapy,in order to ensure its development as an anticancer therapy .,"['They', 'point', 'out', 'the', 'conditions', 'required', 'to', 'initiate', 'the', 'place', 'of', 'such', 'a', 'scheme', 'in', 'all', 'complex', 'therapy', 'which', 'aims', 'as', 'much', 'at', 'palliation', 'as', 'at', 'cure', ',', 'and', 'point', 'out', 'how', 'important', 'it', 'is', 'to', 'be', 'methodical', 'in', 'the', 'application', 'of', 'chemotherapy', 'in', 'order', 'to', 'ensure', 'its', 'development', 'as', 'an', 'anticancer', 'therapy', '.']","(42, 43)","(219, 231)",-1,ss_i,361799,Abstract,6,test,gold,4244.0
6696,"They point out the conditions required to initiate the place of such a scheme in all complex therapy which aims as much at palliation as at cure , and point out how important it is to be methodical in the application of",chemotherapy,in order to ensure its development as an anticancer therapy .,"['They', 'point', 'out', 'the', 'conditions', 'required', 'to', 'initiate', 'the', 'place', 'of', 'such', 'a', 'scheme', 'in', 'all', 'complex', 'therapy', 'which', 'aims', 'as', 'much', 'at', 'palliation', 'as', 'at', 'cure', ',', 'and', 'point', 'out', 'how', 'important', 'it', 'is', 'to', 'be', 'methodical', 'in', 'the', 'application', 'of', 'chemotherapy', 'in', 'order', 'to', 'ensure', 'its', 'development', 'as', 'an', 'anticancer', 'therapy', '.']","(42, 43)","(219, 231)",-1,hl_i,361799,Abstract,6,test,gold,4243.0
6697,Ascaris and,growth rates :,a randomized trial of treatment .,"['Ascaris', 'and', 'growth', 'rates', ':', 'a', 'randomized', 'trial', 'of', 'treatment', '.']","(2, 5)","(11, 25)",-1,ss_o,384815,Title,0,test,gold,1919.0
6698,,Three hundred forty-one Tanzanian preschool children,were randomly assigned to levamisole or placebo treatment given at three-month intervals .,"['Three', 'hundred', 'forty-one', 'Tanzanian', 'preschool', 'children', 'were', 'randomly', 'assigned', 'to', 'levamisole', 'or', 'placebo', 'treatment', 'given', 'at', 'three-month', 'intervals', '.']","(0, 6)","(0, 52)",-1,ss_p,384815,Abstract,0,test,gold,2058.0
6699,Three hundred forty-one Tanzanian preschool children were randomly assigned to,levamisole,or placebo treatment given at three-month intervals .,"['Three', 'hundred', 'forty-one', 'Tanzanian', 'preschool', 'children', 'were', 'randomly', 'assigned', 'to', 'levamisole', 'or', 'placebo', 'treatment', 'given', 'at', 'three-month', 'intervals', '.']","(10, 11)","(78, 88)",-1,ss_i,384815,Abstract,0,test,gold,5036.0
6700,Three hundred forty-one Tanzanian preschool children were randomly assigned to levamisole or,placebo,treatment given at three-month intervals .,"['Three', 'hundred', 'forty-one', 'Tanzanian', 'preschool', 'children', 'were', 'randomly', 'assigned', 'to', 'levamisole', 'or', 'placebo', 'treatment', 'given', 'at', 'three-month', 'intervals', '.']","(12, 13)","(92, 99)",-1,ss_i,384815,Abstract,0,test,gold,4309.0
6701,,Three hundred forty-one Tanzanian preschool children,were randomly assigned to levamisole or placebo treatment given at three-month intervals .,"['Three', 'hundred', 'forty-one', 'Tanzanian', 'preschool', 'children', 'were', 'randomly', 'assigned', 'to', 'levamisole', 'or', 'placebo', 'treatment', 'given', 'at', 'three-month', 'intervals', '.']","(0, 6)","(0, 52)",-1,hl_p,384815,Abstract,0,test,gold,2059.0
6702,Three hundred forty-one Tanzanian preschool children were randomly assigned to,levamisole,or placebo treatment given at three-month intervals .,"['Three', 'hundred', 'forty-one', 'Tanzanian', 'preschool', 'children', 'were', 'randomly', 'assigned', 'to', 'levamisole', 'or', 'placebo', 'treatment', 'given', 'at', 'three-month', 'intervals', '.']","(10, 11)","(78, 88)",-1,hl_i,384815,Abstract,0,test,gold,5037.0
6703,Three hundred forty-one Tanzanian preschool children were randomly assigned to levamisole or,placebo,treatment given at three-month intervals .,"['Three', 'hundred', 'forty-one', 'Tanzanian', 'preschool', 'children', 'were', 'randomly', 'assigned', 'to', 'levamisole', 'or', 'placebo', 'treatment', 'given', 'at', 'three-month', 'intervals', '.']","(12, 13)","(92, 99)",-1,hl_i,384815,Abstract,0,test,gold,4308.0
6704,,Weights and heights,were measured at the tri-monthly treatment visits for a period of one year .,"['Weights', 'and', 'heights', 'were', 'measured', 'at', 'the', 'tri-monthly', 'treatment', 'visits', 'for', 'a', 'period', 'of', 'one', 'year', '.']","(0, 3)","(0, 19)",-1,ss_o,384815,Abstract,1,test,gold,1404.0
6705,,Weights and heights,were measured at the tri-monthly treatment visits for a period of one year .,"['Weights', 'and', 'heights', 'were', 'measured', 'at', 'the', 'tri-monthly', 'treatment', 'visits', 'for', 'a', 'period', 'of', 'one', 'year', '.']","(0, 3)","(0, 19)",-1,hl_o,384815,Abstract,1,test,gold,1405.0
6706,"Among the 273 children who were seen and weighed at the one-year follow-up visit , the rate of weight gain was 8 per cent greater for those receiving",levamisole,than for placebo-treated controls ( p = .06 ) .,"['Among', 'the', '273', 'children', 'who', 'were', 'seen', 'and', 'weighed', 'at', 'the', 'one-year', 'follow-up', 'visit', ',', 'the', 'rate', 'of', 'weight', 'gain', 'was', '8', 'per', 'cent', 'greater', 'for', 'those', 'receiving', 'levamisole', 'than', 'for', 'placebo-treated', 'controls', '(', 'p', '=', '.06', ')', '.']","(28, 29)","(149, 159)",-1,ss_i,384815,Abstract,2,test,gold,5035.0
6707,"Among the 273 children who were seen and weighed at the one-year follow-up visit , the rate of weight gain was 8 per cent greater for those receiving levamisole than for",placebo-treated,controls ( p = .06 ) .,"['Among', 'the', '273', 'children', 'who', 'were', 'seen', 'and', 'weighed', 'at', 'the', 'one-year', 'follow-up', 'visit', ',', 'the', 'rate', 'of', 'weight', 'gain', 'was', '8', 'per', 'cent', 'greater', 'for', 'those', 'receiving', 'levamisole', 'than', 'for', 'placebo-treated', 'controls', '(', 'p', '=', '.06', ')', '.']","(31, 32)","(169, 184)",-1,ss_i,384815,Abstract,2,test,gold,
6708,"Among the 273 children who were seen and weighed at the one-year follow-up visit , the",rate of weight gain,was 8 per cent greater for those receiving levamisole than for placebo-treated controls ( p = .06 ) .,"['Among', 'the', '273', 'children', 'who', 'were', 'seen', 'and', 'weighed', 'at', 'the', 'one-year', 'follow-up', 'visit', ',', 'the', 'rate', 'of', 'weight', 'gain', 'was', '8', 'per', 'cent', 'greater', 'for', 'those', 'receiving', 'levamisole', 'than', 'for', 'placebo-treated', 'controls', '(', 'p', '=', '.06', ')', '.']","(16, 20)","(86, 105)",-1,ss_o,384815,Abstract,2,test,gold,1904.0
6709,"Among the 273 children who were seen and weighed at the one-year follow-up visit , the rate of weight gain was 8 per cent greater for those receiving",levamisole,than for placebo-treated controls ( p = .06 ) .,"['Among', 'the', '273', 'children', 'who', 'were', 'seen', 'and', 'weighed', 'at', 'the', 'one-year', 'follow-up', 'visit', ',', 'the', 'rate', 'of', 'weight', 'gain', 'was', '8', 'per', 'cent', 'greater', 'for', 'those', 'receiving', 'levamisole', 'than', 'for', 'placebo-treated', 'controls', '(', 'p', '=', '.06', ')', '.']","(28, 29)","(149, 159)",-1,hl_i,384815,Abstract,2,test,gold,5034.0
6710,"Among the 273 children who were seen and weighed at the one-year follow-up visit , the rate of weight gain was 8 per cent greater for those receiving levamisole than for",placebo-treated,controls ( p = .06 ) .,"['Among', 'the', '273', 'children', 'who', 'were', 'seen', 'and', 'weighed', 'at', 'the', 'one-year', 'follow-up', 'visit', ',', 'the', 'rate', 'of', 'weight', 'gain', 'was', '8', 'per', 'cent', 'greater', 'for', 'those', 'receiving', 'levamisole', 'than', 'for', 'placebo-treated', 'controls', '(', 'p', '=', '.06', ')', '.']","(31, 32)","(169, 184)",-1,hl_i,384815,Abstract,2,test,gold,
6711,"Among the 273 children who were seen and weighed at the one-year follow-up visit , the",rate of weight gain,was 8 per cent greater for those receiving levamisole than for placebo-treated controls ( p = .06 ) .,"['Among', 'the', '273', 'children', 'who', 'were', 'seen', 'and', 'weighed', 'at', 'the', 'one-year', 'follow-up', 'visit', ',', 'the', 'rate', 'of', 'weight', 'gain', 'was', '8', 'per', 'cent', 'greater', 'for', 'those', 'receiving', 'levamisole', 'than', 'for', 'placebo-treated', 'controls', '(', 'p', '=', '.06', ')', '.']","(16, 20)","(86, 105)",-1,hl_o,384815,Abstract,2,test,gold,1905.0
6712,"In 78 children known to be infected with Ascaris at baseline , the rate of weight gain was 21 per cent greater in children treated with",levamisole,than in those receiving placebo ( p = .03 ) .,"['In', '78', 'children', 'known', 'to', 'be', 'infected', 'with', 'Ascaris', 'at', 'baseline', ',', 'the', 'rate', 'of', 'weight', 'gain', 'was', '21', 'per', 'cent', 'greater', 'in', 'children', 'treated', 'with', 'levamisole', 'than', 'in', 'those', 'receiving', 'placebo', '(', 'p', '=', '.03', ')', '.']","(26, 27)","(135, 145)",-1,ss_i,384815,Abstract,3,test,gold,5033.0
6713,"In 78 children known to be infected with Ascaris at baseline , the rate of weight gain was 21 per cent greater in children treated with levamisole than in those receiving",placebo,( p = .03 ) .,"['In', '78', 'children', 'known', 'to', 'be', 'infected', 'with', 'Ascaris', 'at', 'baseline', ',', 'the', 'rate', 'of', 'weight', 'gain', 'was', '21', 'per', 'cent', 'greater', 'in', 'children', 'treated', 'with', 'levamisole', 'than', 'in', 'those', 'receiving', 'placebo', '(', 'p', '=', '.03', ')', '.']","(31, 32)","(170, 177)",-1,ss_i,384815,Abstract,3,test,gold,4307.0
6714,"In 78 children known to be infected with Ascaris at baseline , the",rate of weight gain,was 21 per cent greater in children treated with levamisole than in those receiving placebo ( p = .03 ) .,"['In', '78', 'children', 'known', 'to', 'be', 'infected', 'with', 'Ascaris', 'at', 'baseline', ',', 'the', 'rate', 'of', 'weight', 'gain', 'was', '21', 'per', 'cent', 'greater', 'in', 'children', 'treated', 'with', 'levamisole', 'than', 'in', 'those', 'receiving', 'placebo', '(', 'p', '=', '.03', ')', '.']","(13, 17)","(66, 85)",-1,ss_o,384815,Abstract,3,test,gold,1903.0
6715,In 78,children,"known to be infected with Ascaris at baseline , the rate of weight gain was 21 per cent greater in children treated with levamisole than in those receiving placebo ( p = .03 ) .","['In', '78', 'children', 'known', 'to', 'be', 'infected', 'with', 'Ascaris', 'at', 'baseline', ',', 'the', 'rate', 'of', 'weight', 'gain', 'was', '21', 'per', 'cent', 'greater', 'in', 'children', 'treated', 'with', 'levamisole', 'than', 'in', 'those', 'receiving', 'placebo', '(', 'p', '=', '.03', ')', '.']","(2, 3)","(5, 13)",-1,hl_p,384815,Abstract,3,test,gold,2112.0
6716,"In 78 children known to be infected with Ascaris at baseline , the rate of weight gain was 21 per cent greater in children treated with",levamisole,than in those receiving placebo ( p = .03 ) .,"['In', '78', 'children', 'known', 'to', 'be', 'infected', 'with', 'Ascaris', 'at', 'baseline', ',', 'the', 'rate', 'of', 'weight', 'gain', 'was', '21', 'per', 'cent', 'greater', 'in', 'children', 'treated', 'with', 'levamisole', 'than', 'in', 'those', 'receiving', 'placebo', '(', 'p', '=', '.03', ')', '.']","(26, 27)","(135, 145)",-1,hl_i,384815,Abstract,3,test,gold,5032.0
6717,"In 78 children known to be infected with Ascaris at baseline , the rate of weight gain was 21 per cent greater in children treated with levamisole than in those receiving",placebo,( p = .03 ) .,"['In', '78', 'children', 'known', 'to', 'be', 'infected', 'with', 'Ascaris', 'at', 'baseline', ',', 'the', 'rate', 'of', 'weight', 'gain', 'was', '21', 'per', 'cent', 'greater', 'in', 'children', 'treated', 'with', 'levamisole', 'than', 'in', 'those', 'receiving', 'placebo', '(', 'p', '=', '.03', ')', '.']","(31, 32)","(170, 177)",-1,hl_i,384815,Abstract,3,test,gold,4306.0
6718,"In 78 children known to be infected with Ascaris at baseline , the",rate of weight gain,was 21 per cent greater in children treated with levamisole than in those receiving placebo ( p = .03 ) .,"['In', '78', 'children', 'known', 'to', 'be', 'infected', 'with', 'Ascaris', 'at', 'baseline', ',', 'the', 'rate', 'of', 'weight', 'gain', 'was', '21', 'per', 'cent', 'greater', 'in', 'children', 'treated', 'with', 'levamisole', 'than', 'in', 'those', 'receiving', 'placebo', '(', 'p', '=', '.03', ')', '.']","(13, 17)","(66, 85)",-1,hl_o,384815,Abstract,3,test,gold,1902.0
6719,The rate of height gain was no different for treatment and,placebo,groups .,"['The', 'rate', 'of', 'height', 'gain', 'was', 'no', 'different', 'for', 'treatment', 'and', 'placebo', 'groups', '.']","(11, 12)","(58, 65)",-1,ss_i,384815,Abstract,4,test,gold,4305.0
6720,The,rate of height gain,was no different for treatment and placebo groups .,"['The', 'rate', 'of', 'height', 'gain', 'was', 'no', 'different', 'for', 'treatment', 'and', 'placebo', 'groups', '.']","(1, 5)","(3, 22)",-1,ss_o,384815,Abstract,4,test,gold,1900.0
6721,The rate of height gain was no different for treatment and,placebo,groups .,"['The', 'rate', 'of', 'height', 'gain', 'was', 'no', 'different', 'for', 'treatment', 'and', 'placebo', 'groups', '.']","(11, 12)","(58, 65)",-1,hl_i,384815,Abstract,4,test,gold,4304.0
6722,The,rate of height gain,was no different for treatment and placebo groups .,"['The', 'rate', 'of', 'height', 'gain', 'was', 'no', 'different', 'for', 'treatment', 'and', 'placebo', 'groups', '.']","(1, 5)","(3, 22)",-1,hl_o,384815,Abstract,4,test,gold,1901.0
6723,Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in,insulin dependent diabetes mellitus :,the Oslo study .,"['Rapid', 'tightening', 'of', 'blood', 'glucose', 'control', 'leads', 'to', 'transient', 'deterioration', 'of', 'retinopathy', 'in', 'insulin', 'dependent', 'diabetes', 'mellitus', ':', 'the', 'Oslo', 'study', '.']","(13, 18)","(92, 129)",-1,ss_p,3919804,Title,0,test,gold,6908.0
6724,Rapid tightening of,blood glucose,control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus : the Oslo study .,"['Rapid', 'tightening', 'of', 'blood', 'glucose', 'control', 'leads', 'to', 'transient', 'deterioration', 'of', 'retinopathy', 'in', 'insulin', 'dependent', 'diabetes', 'mellitus', ':', 'the', 'Oslo', 'study', '.']","(3, 5)","(19, 32)",-1,ss_o,3919804,Title,0,test,gold,6578.0
6725,Rapid tightening of blood glucose control leads to,transient deterioration of retinopathy,in insulin dependent diabetes mellitus : the Oslo study .,"['Rapid', 'tightening', 'of', 'blood', 'glucose', 'control', 'leads', 'to', 'transient', 'deterioration', 'of', 'retinopathy', 'in', 'insulin', 'dependent', 'diabetes', 'mellitus', ':', 'the', 'Oslo', 'study', '.']","(8, 12)","(50, 88)",-1,ss_o,3919804,Title,0,test,gold,3550.0
6726,Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in,insulin dependent diabetes mellitus :,the Oslo study .,"['Rapid', 'tightening', 'of', 'blood', 'glucose', 'control', 'leads', 'to', 'transient', 'deterioration', 'of', 'retinopathy', 'in', 'insulin', 'dependent', 'diabetes', 'mellitus', ':', 'the', 'Oslo', 'study', '.']","(13, 18)","(92, 129)",-1,hl_p,3919804,Title,0,test,gold,6909.0
6727,Rapid tightening of blood glucose control leads to transient deterioration of,retinopathy,in insulin dependent diabetes mellitus : the Oslo study .,"['Rapid', 'tightening', 'of', 'blood', 'glucose', 'control', 'leads', 'to', 'transient', 'deterioration', 'of', 'retinopathy', 'in', 'insulin', 'dependent', 'diabetes', 'mellitus', ':', 'the', 'Oslo', 'study', '.']","(11, 12)","(77, 88)",-1,hl_o,3919804,Title,0,test,gold,3555.0
6728,In a study of retinopathy during one year of tight blood glucose control,45 type I ( insulin dependent ) diabetics without proliferative retinopathy,"were randomised to receive either continuous subcutaneous insulin infusion , multiple insulin injections , or conventional insulin treatment ( controls ) .","['In', 'a', 'study', 'of', 'retinopathy', 'during', 'one', 'year', 'of', 'tight', 'blood', 'glucose', 'control', '45', 'type', 'I', '(', 'insulin', 'dependent', ')', 'diabetics', 'without', 'proliferative', 'retinopathy', 'were', 'randomised', 'to', 'receive', 'either', 'continuous', 'subcutaneous', 'insulin', 'infusion', ',', 'multiple', 'insulin', 'injections', ',', 'or', 'conventional', 'insulin', 'treatment', '(', 'controls', ')', '.']","(13, 24)","(72, 147)",-1,ss_p,3919804,Abstract,0,test,gold,5933.0
6729,In a study of retinopathy during one year of tight blood glucose control 45 type I ( insulin dependent ) diabetics without proliferative retinopathy were randomised to receive either continuous subcutaneous,insulin infusion,", multiple insulin injections , or conventional insulin treatment ( controls ) .","['In', 'a', 'study', 'of', 'retinopathy', 'during', 'one', 'year', 'of', 'tight', 'blood', 'glucose', 'control', '45', 'type', 'I', '(', 'insulin', 'dependent', ')', 'diabetics', 'without', 'proliferative', 'retinopathy', 'were', 'randomised', 'to', 'receive', 'either', 'continuous', 'subcutaneous', 'insulin', 'infusion', ',', 'multiple', 'insulin', 'injections', ',', 'or', 'conventional', 'insulin', 'treatment', '(', 'controls', ')', '.']","(31, 33)","(206, 222)",-1,ss_i,3919804,Abstract,0,test,gold,4900.0
6730,"In a study of retinopathy during one year of tight blood glucose control 45 type I ( insulin dependent ) diabetics without proliferative retinopathy were randomised to receive either continuous subcutaneous insulin infusion , multiple",insulin injections,", or conventional insulin treatment ( controls ) .","['In', 'a', 'study', 'of', 'retinopathy', 'during', 'one', 'year', 'of', 'tight', 'blood', 'glucose', 'control', '45', 'type', 'I', '(', 'insulin', 'dependent', ')', 'diabetics', 'without', 'proliferative', 'retinopathy', 'were', 'randomised', 'to', 'receive', 'either', 'continuous', 'subcutaneous', 'insulin', 'infusion', ',', 'multiple', 'insulin', 'injections', ',', 'or', 'conventional', 'insulin', 'treatment', '(', 'controls', ')', '.']","(35, 37)","(234, 252)",-1,ss_i,3919804,Abstract,0,test,gold,4902.0
6731,"In a study of retinopathy during one year of tight blood glucose control 45 type I ( insulin dependent ) diabetics without proliferative retinopathy were randomised to receive either continuous subcutaneous insulin infusion , multiple insulin injections , or conventional",insulin treatment,( controls ) .,"['In', 'a', 'study', 'of', 'retinopathy', 'during', 'one', 'year', 'of', 'tight', 'blood', 'glucose', 'control', '45', 'type', 'I', '(', 'insulin', 'dependent', ')', 'diabetics', 'without', 'proliferative', 'retinopathy', 'were', 'randomised', 'to', 'receive', 'either', 'continuous', 'subcutaneous', 'insulin', 'infusion', ',', 'multiple', 'insulin', 'injections', ',', 'or', 'conventional', 'insulin', 'treatment', '(', 'controls', ')', '.']","(40, 42)","(271, 288)",-1,ss_i,3919804,Abstract,0,test,gold,4895.0
6732,In a study of retinopathy during one year of tight,blood glucose,"control 45 type I ( insulin dependent ) diabetics without proliferative retinopathy were randomised to receive either continuous subcutaneous insulin infusion , multiple insulin injections , or conventional insulin treatment ( controls ) .","['In', 'a', 'study', 'of', 'retinopathy', 'during', 'one', 'year', 'of', 'tight', 'blood', 'glucose', 'control', '45', 'type', 'I', '(', 'insulin', 'dependent', ')', 'diabetics', 'without', 'proliferative', 'retinopathy', 'were', 'randomised', 'to', 'receive', 'either', 'continuous', 'subcutaneous', 'insulin', 'infusion', ',', 'multiple', 'insulin', 'injections', ',', 'or', 'conventional', 'insulin', 'treatment', '(', 'controls', ')', '.']","(10, 12)","(50, 63)",-1,ss_o,3919804,Abstract,0,test,gold,6579.0
6733,In a study of retinopathy during one year of tight blood glucose control,45 type I ( insulin dependent ) diabetics without proliferative retinopathy,"were randomised to receive either continuous subcutaneous insulin infusion , multiple insulin injections , or conventional insulin treatment ( controls ) .","['In', 'a', 'study', 'of', 'retinopathy', 'during', 'one', 'year', 'of', 'tight', 'blood', 'glucose', 'control', '45', 'type', 'I', '(', 'insulin', 'dependent', ')', 'diabetics', 'without', 'proliferative', 'retinopathy', 'were', 'randomised', 'to', 'receive', 'either', 'continuous', 'subcutaneous', 'insulin', 'infusion', ',', 'multiple', 'insulin', 'injections', ',', 'or', 'conventional', 'insulin', 'treatment', '(', 'controls', ')', '.']","(13, 24)","(72, 147)",-1,hl_p,3919804,Abstract,0,test,gold,5934.0
6734,In a study of retinopathy during one year of tight blood glucose control 45 type I ( insulin dependent ) diabetics without proliferative retinopathy were randomised to receive either continuous subcutaneous,insulin infusion,", multiple insulin injections , or conventional insulin treatment ( controls ) .","['In', 'a', 'study', 'of', 'retinopathy', 'during', 'one', 'year', 'of', 'tight', 'blood', 'glucose', 'control', '45', 'type', 'I', '(', 'insulin', 'dependent', ')', 'diabetics', 'without', 'proliferative', 'retinopathy', 'were', 'randomised', 'to', 'receive', 'either', 'continuous', 'subcutaneous', 'insulin', 'infusion', ',', 'multiple', 'insulin', 'injections', ',', 'or', 'conventional', 'insulin', 'treatment', '(', 'controls', ')', '.']","(31, 33)","(206, 222)",-1,hl_i,3919804,Abstract,0,test,gold,4901.0
6735,"In a study of retinopathy during one year of tight blood glucose control 45 type I ( insulin dependent ) diabetics without proliferative retinopathy were randomised to receive either continuous subcutaneous insulin infusion , multiple",insulin injections,", or conventional insulin treatment ( controls ) .","['In', 'a', 'study', 'of', 'retinopathy', 'during', 'one', 'year', 'of', 'tight', 'blood', 'glucose', 'control', '45', 'type', 'I', '(', 'insulin', 'dependent', ')', 'diabetics', 'without', 'proliferative', 'retinopathy', 'were', 'randomised', 'to', 'receive', 'either', 'continuous', 'subcutaneous', 'insulin', 'infusion', ',', 'multiple', 'insulin', 'injections', ',', 'or', 'conventional', 'insulin', 'treatment', '(', 'controls', ')', '.']","(35, 37)","(234, 252)",-1,hl_i,3919804,Abstract,0,test,gold,4903.0
6736,"In a study of retinopathy during one year of tight blood glucose control 45 type I ( insulin dependent ) diabetics without proliferative retinopathy were randomised to receive either continuous subcutaneous insulin infusion , multiple insulin injections , or conventional",insulin treatment,( controls ) .,"['In', 'a', 'study', 'of', 'retinopathy', 'during', 'one', 'year', 'of', 'tight', 'blood', 'glucose', 'control', '45', 'type', 'I', '(', 'insulin', 'dependent', ')', 'diabetics', 'without', 'proliferative', 'retinopathy', 'were', 'randomised', 'to', 'receive', 'either', 'continuous', 'subcutaneous', 'insulin', 'infusion', ',', 'multiple', 'insulin', 'injections', ',', 'or', 'conventional', 'insulin', 'treatment', '(', 'controls', ')', '.']","(40, 42)","(271, 288)",-1,hl_i,3919804,Abstract,0,test,gold,4896.0
6737,Near normoglycaemia was achieved with continuous infusion and multiple injections but not with conventional treatment .,,,"['Near', 'normoglycaemia', 'was', 'achieved', 'with', 'continuous', 'infusion', 'and', 'multiple', 'injections', 'but', 'not', 'with', 'conventional', 'treatment', '.']",,,,,3919804,Abstract,1,test,gold,
6738,Blind evaluation of,fluorescein angiograms,"performed three monthly showed progression of retinopathy in the control group , transient deterioration in the continuous infusion group , and no change in the multiple injection group .","['Blind', 'evaluation', 'of', 'fluorescein', 'angiograms', 'performed', 'three', 'monthly', 'showed', 'progression', 'of', 'retinopathy', 'in', 'the', 'control', 'group', ',', 'transient', 'deterioration', 'in', 'the', 'continuous', 'infusion', 'group', ',', 'and', 'no', 'change', 'in', 'the', 'multiple', 'injection', 'group', '.']","(3, 5)","(19, 41)",-1,ss_o,3919804,Abstract,2,test,gold,4143.0
6739,Blind evaluation of fluorescein angiograms performed three monthly showed,progression of retinopathy,"in the control group , transient deterioration in the continuous infusion group , and no change in the multiple injection group .","['Blind', 'evaluation', 'of', 'fluorescein', 'angiograms', 'performed', 'three', 'monthly', 'showed', 'progression', 'of', 'retinopathy', 'in', 'the', 'control', 'group', ',', 'transient', 'deterioration', 'in', 'the', 'continuous', 'infusion', 'group', ',', 'and', 'no', 'change', 'in', 'the', 'multiple', 'injection', 'group', '.']","(9, 12)","(73, 99)",-1,ss_o,3919804,Abstract,2,test,gold,3551.0
6740,Blind evaluation of,fluorescein angiograms,"performed three monthly showed progression of retinopathy in the control group , transient deterioration in the continuous infusion group , and no change in the multiple injection group .","['Blind', 'evaluation', 'of', 'fluorescein', 'angiograms', 'performed', 'three', 'monthly', 'showed', 'progression', 'of', 'retinopathy', 'in', 'the', 'control', 'group', ',', 'transient', 'deterioration', 'in', 'the', 'continuous', 'infusion', 'group', ',', 'and', 'no', 'change', 'in', 'the', 'multiple', 'injection', 'group', '.']","(3, 5)","(19, 41)",-1,hl_o,3919804,Abstract,2,test,gold,4144.0
6741,Blind evaluation of fluorescein angiograms performed three monthly showed,progression of retinopathy,"in the control group , transient deterioration in the continuous infusion group , and no change in the multiple injection group .","['Blind', 'evaluation', 'of', 'fluorescein', 'angiograms', 'performed', 'three', 'monthly', 'showed', 'progression', 'of', 'retinopathy', 'in', 'the', 'control', 'group', ',', 'transient', 'deterioration', 'in', 'the', 'continuous', 'infusion', 'group', ',', 'and', 'no', 'change', 'in', 'the', 'multiple', 'injection', 'group', '.']","(9, 12)","(73, 99)",-1,hl_o,3919804,Abstract,2,test,gold,3552.0
6742,Half the patients receiving continuous infusion and multiple injections developed retinal cotton wool spots after three to six months .,,,"['Half', 'the', 'patients', 'receiving', 'continuous', 'infusion', 'and', 'multiple', 'injections', 'developed', 'retinal', 'cotton', 'wool', 'spots', 'after', 'three', 'to', 'six', 'months', '.']",,,,,3919804,Abstract,3,test,gold,
6743,These changes regressed in all but four patients after 12 months .,,,"['These', 'changes', 'regressed', 'in', 'all', 'but', 'four', 'patients', 'after', '12', 'months', '.']",,,,,3919804,Abstract,4,test,gold,
6744,Control patients did not develop,cotton wool spots .,,"['Control', 'patients', 'did', 'not', 'develop', 'cotton', 'wool', 'spots', '.']","(5, 9)","(32, 51)",-1,ss_o,3919804,Abstract,5,test,gold,2719.0
6745,Control patients did not develop,cotton wool spots .,,"['Control', 'patients', 'did', 'not', 'develop', 'cotton', 'wool', 'spots', '.']","(5, 9)","(32, 51)",-1,hl_o,3919804,Abstract,5,test,gold,2720.0
6746,Patients who developed cotton wool spots are characterised by a larger decrement in,glycosylated haemoglobin and blood glucose values,", more frequent episodes of hypoglycaemia , a longer duration of diabetes , and more severe retinopathy at onset .","['Patients', 'who', 'developed', 'cotton', 'wool', 'spots', 'are', 'characterised', 'by', 'a', 'larger', 'decrement', 'in', 'glycosylated', 'haemoglobin', 'and', 'blood', 'glucose', 'values', ',', 'more', 'frequent', 'episodes', 'of', 'hypoglycaemia', ',', 'a', 'longer', 'duration', 'of', 'diabetes', ',', 'and', 'more', 'severe', 'retinopathy', 'at', 'onset', '.']","(13, 19)","(83, 132)",-1,ss_o,3919804,Abstract,6,test,gold,6576.0
6747,"Patients who developed cotton wool spots are characterised by a larger decrement in glycosylated haemoglobin and blood glucose values , more",frequent episodes of hypoglycaemia,", a longer duration of diabetes , and more severe retinopathy at onset .","['Patients', 'who', 'developed', 'cotton', 'wool', 'spots', 'are', 'characterised', 'by', 'a', 'larger', 'decrement', 'in', 'glycosylated', 'haemoglobin', 'and', 'blood', 'glucose', 'values', ',', 'more', 'frequent', 'episodes', 'of', 'hypoglycaemia', ',', 'a', 'longer', 'duration', 'of', 'diabetes', ',', 'and', 'more', 'severe', 'retinopathy', 'at', 'onset', '.']","(21, 25)","(140, 174)",-1,ss_o,3919804,Abstract,6,test,gold,3461.0
6748,"Patients who developed cotton wool spots are characterised by a larger decrement in glycosylated haemoglobin and blood glucose values , more frequent episodes of hypoglycaemia , a longer",duration of diabetes,", and more severe retinopathy at onset .","['Patients', 'who', 'developed', 'cotton', 'wool', 'spots', 'are', 'characterised', 'by', 'a', 'larger', 'decrement', 'in', 'glycosylated', 'haemoglobin', 'and', 'blood', 'glucose', 'values', ',', 'more', 'frequent', 'episodes', 'of', 'hypoglycaemia', ',', 'a', 'longer', 'duration', 'of', 'diabetes', ',', 'and', 'more', 'severe', 'retinopathy', 'at', 'onset', '.']","(28, 31)","(186, 206)",-1,ss_o,3919804,Abstract,6,test,gold,3806.0
6749,"Patients who developed cotton wool spots are characterised by a larger decrement in glycosylated haemoglobin and blood glucose values , more frequent episodes of hypoglycaemia , a longer duration of diabetes , and more severe",retinopathy at onset .,,"['Patients', 'who', 'developed', 'cotton', 'wool', 'spots', 'are', 'characterised', 'by', 'a', 'larger', 'decrement', 'in', 'glycosylated', 'haemoglobin', 'and', 'blood', 'glucose', 'values', ',', 'more', 'frequent', 'episodes', 'of', 'hypoglycaemia', ',', 'a', 'longer', 'duration', 'of', 'diabetes', ',', 'and', 'more', 'severe', 'retinopathy', 'at', 'onset', '.']","(35, 39)","(225, 247)",-1,ss_o,3919804,Abstract,6,test,gold,3553.0
6750,Patients who developed cotton wool spots are characterised by a larger decrement in,glycosylated haemoglobin,"and blood glucose values , more frequent episodes of hypoglycaemia , a longer duration of diabetes , and more severe retinopathy at onset .","['Patients', 'who', 'developed', 'cotton', 'wool', 'spots', 'are', 'characterised', 'by', 'a', 'larger', 'decrement', 'in', 'glycosylated', 'haemoglobin', 'and', 'blood', 'glucose', 'values', ',', 'more', 'frequent', 'episodes', 'of', 'hypoglycaemia', ',', 'a', 'longer', 'duration', 'of', 'diabetes', ',', 'and', 'more', 'severe', 'retinopathy', 'at', 'onset', '.']","(13, 15)","(83, 107)",-1,hl_o,3919804,Abstract,6,test,gold,133.0
6751,Patients who developed cotton wool spots are characterised by a larger decrement in glycosylated haemoglobin and,blood glucose values,", more frequent episodes of hypoglycaemia , a longer duration of diabetes , and more severe retinopathy at onset .","['Patients', 'who', 'developed', 'cotton', 'wool', 'spots', 'are', 'characterised', 'by', 'a', 'larger', 'decrement', 'in', 'glycosylated', 'haemoglobin', 'and', 'blood', 'glucose', 'values', ',', 'more', 'frequent', 'episodes', 'of', 'hypoglycaemia', ',', 'a', 'longer', 'duration', 'of', 'diabetes', ',', 'and', 'more', 'severe', 'retinopathy', 'at', 'onset', '.']","(16, 19)","(112, 132)",-1,hl_o,3919804,Abstract,6,test,gold,6577.0
6752,"Patients who developed cotton wool spots are characterised by a larger decrement in glycosylated haemoglobin and blood glucose values , more frequent",episodes of hypoglycaemia,", a longer duration of diabetes , and more severe retinopathy at onset .","['Patients', 'who', 'developed', 'cotton', 'wool', 'spots', 'are', 'characterised', 'by', 'a', 'larger', 'decrement', 'in', 'glycosylated', 'haemoglobin', 'and', 'blood', 'glucose', 'values', ',', 'more', 'frequent', 'episodes', 'of', 'hypoglycaemia', ',', 'a', 'longer', 'duration', 'of', 'diabetes', ',', 'and', 'more', 'severe', 'retinopathy', 'at', 'onset', '.']","(22, 25)","(149, 174)",-1,hl_o,3919804,Abstract,6,test,gold,3462.0
6753,"Patients who developed cotton wool spots are characterised by a larger decrement in glycosylated haemoglobin and blood glucose values , more frequent episodes of hypoglycaemia , a longer",duration of diabetes,", and more severe retinopathy at onset .","['Patients', 'who', 'developed', 'cotton', 'wool', 'spots', 'are', 'characterised', 'by', 'a', 'larger', 'decrement', 'in', 'glycosylated', 'haemoglobin', 'and', 'blood', 'glucose', 'values', ',', 'more', 'frequent', 'episodes', 'of', 'hypoglycaemia', ',', 'a', 'longer', 'duration', 'of', 'diabetes', ',', 'and', 'more', 'severe', 'retinopathy', 'at', 'onset', '.']","(28, 31)","(186, 206)",-1,hl_o,3919804,Abstract,6,test,gold,3807.0
6754,"Patients who developed cotton wool spots are characterised by a larger decrement in glycosylated haemoglobin and blood glucose values , more frequent episodes of hypoglycaemia , a longer duration of diabetes , and more severe",retinopathy,at onset .,"['Patients', 'who', 'developed', 'cotton', 'wool', 'spots', 'are', 'characterised', 'by', 'a', 'larger', 'decrement', 'in', 'glycosylated', 'haemoglobin', 'and', 'blood', 'glucose', 'values', ',', 'more', 'frequent', 'episodes', 'of', 'hypoglycaemia', ',', 'a', 'longer', 'duration', 'of', 'diabetes', ',', 'and', 'more', 'severe', 'retinopathy', 'at', 'onset', '.']","(35, 36)","(225, 236)",-1,hl_o,3919804,Abstract,6,test,gold,3556.0
6755,A large and rapid fall in,blood glucose concentration,may promote transient deterioration of diabetic retinopathy .,"['A', 'large', 'and', 'rapid', 'fall', 'in', 'blood', 'glucose', 'concentration', 'may', 'promote', 'transient', 'deterioration', 'of', 'diabetic', 'retinopathy', '.']","(6, 9)","(25, 52)",-1,ss_o,3919804,Abstract,7,test,gold,6580.0
6756,A large and rapid fall in blood glucose concentration may promote transient deterioration of diabetic,retinopathy .,,"['A', 'large', 'and', 'rapid', 'fall', 'in', 'blood', 'glucose', 'concentration', 'may', 'promote', 'transient', 'deterioration', 'of', 'diabetic', 'retinopathy', '.']","(15, 17)","(101, 114)",-1,ss_o,3919804,Abstract,7,test,gold,3554.0
6757,A large and rapid fall in,blood glucose concentration,may promote transient deterioration of diabetic retinopathy .,"['A', 'large', 'and', 'rapid', 'fall', 'in', 'blood', 'glucose', 'concentration', 'may', 'promote', 'transient', 'deterioration', 'of', 'diabetic', 'retinopathy', '.']","(6, 9)","(25, 52)",-1,hl_o,3919804,Abstract,7,test,gold,6581.0
6758,Protection of man from natural infection with influenza A2 Hong Kong virus by,amantadine :,a controlled field trial .,"['Protection', 'of', 'man', 'from', 'natural', 'infection', 'with', 'influenza', 'A2', 'Hong', 'Kong', 'virus', 'by', 'amantadine', ':', 'a', 'controlled', 'field', 'trial', '.']","(13, 15)","(77, 89)",-1,ss_i,4919024,Title,0,test,gold,5014.0
6759,Protection of man from natural infection with influenza A2 Hong Kong virus by,amantadine,: a controlled field trial .,"['Protection', 'of', 'man', 'from', 'natural', 'infection', 'with', 'influenza', 'A2', 'Hong', 'Kong', 'virus', 'by', 'amantadine', ':', 'a', 'controlled', 'field', 'trial', '.']","(13, 14)","(77, 87)",-1,hl_i,4919024,Title,0,test,gold,5015.0
6760,Prophylactic administration of amantadine in doses of 100 mg. twice a day offered statistically significant protection against influenza A2 infection in a double-blind field trial involving,391 medical student volunteers during the influenza A2 Hong Kong epidemic in Helsinki in the winter of 1969 .,,"['Prophylactic', 'administration', 'of', 'amantadine', 'in', 'doses', 'of', '100', 'mg.', 'twice', 'a', 'day', 'offered', 'statistically', 'significant', 'protection', 'against', 'influenza', 'A2', 'infection', 'in', 'a', 'double-blind', 'field', 'trial', 'involving', '391', 'medical', 'student', 'volunteers', 'during', 'the', 'influenza', 'A2', 'Hong', 'Kong', 'epidemic', 'in', 'Helsinki', 'in', 'the', 'winter', 'of', '1969', '.']","(26, 45)","(189, 298)",-1,ss_p,4919024,Abstract,0,test,gold,5877.0
6761,Prophylactic administration of,amantadine,in doses of 100 mg. twice a day offered statistically significant protection against influenza A2 infection in a double-blind field trial involving 391 medical student volunteers during the influenza A2 Hong Kong epidemic in Helsinki in the winter of 1969 .,"['Prophylactic', 'administration', 'of', 'amantadine', 'in', 'doses', 'of', '100', 'mg.', 'twice', 'a', 'day', 'offered', 'statistically', 'significant', 'protection', 'against', 'influenza', 'A2', 'infection', 'in', 'a', 'double-blind', 'field', 'trial', 'involving', '391', 'medical', 'student', 'volunteers', 'during', 'the', 'influenza', 'A2', 'Hong', 'Kong', 'epidemic', 'in', 'Helsinki', 'in', 'the', 'winter', 'of', '1969', '.']","(3, 4)","(30, 40)",-1,ss_i,4919024,Abstract,0,test,gold,5013.0
6762,Prophylactic administration of amantadine in doses of 100 mg. twice a day offered statistically significant protection against influenza A2 infection in a double-blind field trial involving,391 medical student volunteers during the influenza A2 Hong Kong epidemic in Helsinki in the winter of 1969,.,"['Prophylactic', 'administration', 'of', 'amantadine', 'in', 'doses', 'of', '100', 'mg.', 'twice', 'a', 'day', 'offered', 'statistically', 'significant', 'protection', 'against', 'influenza', 'A2', 'infection', 'in', 'a', 'double-blind', 'field', 'trial', 'involving', '391', 'medical', 'student', 'volunteers', 'during', 'the', 'influenza', 'A2', 'Hong', 'Kong', 'epidemic', 'in', 'Helsinki', 'in', 'the', 'winter', 'of', '1969', '.']","(26, 44)","(189, 296)",-1,hl_p,4919024,Abstract,0,test,gold,5878.0
6763,Prophylactic administration of,amantadine,in doses of 100 mg. twice a day offered statistically significant protection against influenza A2 infection in a double-blind field trial involving 391 medical student volunteers during the influenza A2 Hong Kong epidemic in Helsinki in the winter of 1969 .,"['Prophylactic', 'administration', 'of', 'amantadine', 'in', 'doses', 'of', '100', 'mg.', 'twice', 'a', 'day', 'offered', 'statistically', 'significant', 'protection', 'against', 'influenza', 'A2', 'infection', 'in', 'a', 'double-blind', 'field', 'trial', 'involving', '391', 'medical', 'student', 'volunteers', 'during', 'the', 'influenza', 'A2', 'Hong', 'Kong', 'epidemic', 'in', 'Helsinki', 'in', 'the', 'winter', 'of', '1969', '.']","(3, 4)","(30, 40)",-1,hl_i,4919024,Abstract,0,test,gold,5012.0
6764,"Serologically verified influenza , as measured by complement fixation and/or haemagglutination inhibition , occurred in 27 out of 192 students in the",amantadine,"group against 57 out of 199 in the placebo group , giving a protection rate of 52 % .","['Serologically', 'verified', 'influenza', ',', 'as', 'measured', 'by', 'complement', 'fixation', 'and/or', 'haemagglutination', 'inhibition', ',', 'occurred', 'in', '27', 'out', 'of', '192', 'students', 'in', 'the', 'amantadine', 'group', 'against', '57', 'out', 'of', '199', 'in', 'the', 'placebo', 'group', ',', 'giving', 'a', 'protection', 'rate', 'of', '52', '%', '.']","(22, 23)","(149, 159)",-1,ss_i,4919024,Abstract,1,test,gold,5011.0
6765,"Serologically verified influenza , as measured by complement fixation and/or haemagglutination inhibition , occurred in 27 out of 192 students in the amantadine group against 57 out of 199 in the",placebo,"group , giving a protection rate of 52 % .","['Serologically', 'verified', 'influenza', ',', 'as', 'measured', 'by', 'complement', 'fixation', 'and/or', 'haemagglutination', 'inhibition', ',', 'occurred', 'in', '27', 'out', 'of', '192', 'students', 'in', 'the', 'amantadine', 'group', 'against', '57', 'out', 'of', '199', 'in', 'the', 'placebo', 'group', ',', 'giving', 'a', 'protection', 'rate', 'of', '52', '%', '.']","(31, 32)","(195, 202)",-1,ss_i,4919024,Abstract,1,test,gold,4303.0
6766,,Serologically verified influenza,", as measured by complement fixation and/or haemagglutination inhibition , occurred in 27 out of 192 students in the amantadine group against 57 out of 199 in the placebo group , giving a protection rate of 52 % .","['Serologically', 'verified', 'influenza', ',', 'as', 'measured', 'by', 'complement', 'fixation', 'and/or', 'haemagglutination', 'inhibition', ',', 'occurred', 'in', '27', 'out', 'of', '192', 'students', 'in', 'the', 'amantadine', 'group', 'against', '57', 'out', 'of', '199', 'in', 'the', 'placebo', 'group', ',', 'giving', 'a', 'protection', 'rate', 'of', '52', '%', '.']","(0, 3)","(0, 32)",-1,ss_o,4919024,Abstract,1,test,gold,3399.0
6767,"Serologically verified influenza , as measured by",complement fixation and/or haemagglutination inhibition,", occurred in 27 out of 192 students in the amantadine group against 57 out of 199 in the placebo group , giving a protection rate of 52 % .","['Serologically', 'verified', 'influenza', ',', 'as', 'measured', 'by', 'complement', 'fixation', 'and/or', 'haemagglutination', 'inhibition', ',', 'occurred', 'in', '27', 'out', 'of', '192', 'students', 'in', 'the', 'amantadine', 'group', 'against', '57', 'out', 'of', '199', 'in', 'the', 'placebo', 'group', ',', 'giving', 'a', 'protection', 'rate', 'of', '52', '%', '.']","(7, 12)","(49, 104)",-1,ss_o,4919024,Abstract,1,test,gold,3183.0
6768,"Serologically verified influenza , as measured by complement fixation and/or haemagglutination inhibition , occurred in 27 out of 192 students in the",amantadine,"group against 57 out of 199 in the placebo group , giving a protection rate of 52 % .","['Serologically', 'verified', 'influenza', ',', 'as', 'measured', 'by', 'complement', 'fixation', 'and/or', 'haemagglutination', 'inhibition', ',', 'occurred', 'in', '27', 'out', 'of', '192', 'students', 'in', 'the', 'amantadine', 'group', 'against', '57', 'out', 'of', '199', 'in', 'the', 'placebo', 'group', ',', 'giving', 'a', 'protection', 'rate', 'of', '52', '%', '.']","(22, 23)","(149, 159)",-1,hl_i,4919024,Abstract,1,test,gold,5010.0
6769,"Serologically verified influenza , as measured by complement fixation and/or haemagglutination inhibition , occurred in 27 out of 192 students in the amantadine group against 57 out of 199 in the",placebo,"group , giving a protection rate of 52 % .","['Serologically', 'verified', 'influenza', ',', 'as', 'measured', 'by', 'complement', 'fixation', 'and/or', 'haemagglutination', 'inhibition', ',', 'occurred', 'in', '27', 'out', 'of', '192', 'students', 'in', 'the', 'amantadine', 'group', 'against', '57', 'out', 'of', '199', 'in', 'the', 'placebo', 'group', ',', 'giving', 'a', 'protection', 'rate', 'of', '52', '%', '.']","(31, 32)","(195, 202)",-1,hl_i,4919024,Abstract,1,test,gold,4302.0
6770,,Serologically verified influenza,", as measured by complement fixation and/or haemagglutination inhibition , occurred in 27 out of 192 students in the amantadine group against 57 out of 199 in the placebo group , giving a protection rate of 52 % .","['Serologically', 'verified', 'influenza', ',', 'as', 'measured', 'by', 'complement', 'fixation', 'and/or', 'haemagglutination', 'inhibition', ',', 'occurred', 'in', '27', 'out', 'of', '192', 'students', 'in', 'the', 'amantadine', 'group', 'against', '57', 'out', 'of', '199', 'in', 'the', 'placebo', 'group', ',', 'giving', 'a', 'protection', 'rate', 'of', '52', '%', '.']","(0, 3)","(0, 32)",-1,hl_o,4919024,Abstract,1,test,gold,3400.0
6771,"Serologically verified influenza , as measured by",complement fixation and/or haemagglutination inhibition,", occurred in 27 out of 192 students in the amantadine group against 57 out of 199 in the placebo group , giving a protection rate of 52 % .","['Serologically', 'verified', 'influenza', ',', 'as', 'measured', 'by', 'complement', 'fixation', 'and/or', 'haemagglutination', 'inhibition', ',', 'occurred', 'in', '27', 'out', 'of', '192', 'students', 'in', 'the', 'amantadine', 'group', 'against', '57', 'out', 'of', '199', 'in', 'the', 'placebo', 'group', ',', 'giving', 'a', 'protection', 'rate', 'of', '52', '%', '.']","(7, 12)","(49, 104)",-1,hl_o,4919024,Abstract,1,test,gold,3184.0
6772,The treatment of,asthma in adults,using sodium cromoglycate pressurized aerosol : a double-blind controlled trial .,"['The', 'treatment', 'of', 'asthma', 'in', 'adults', 'using', 'sodium', 'cromoglycate', 'pressurized', 'aerosol', ':', 'a', 'double-blind', 'controlled', 'trial', '.']","(3, 6)","(16, 32)",-1,ss_p,6418441,Title,0,test,gold,3812.0
6773,The treatment of asthma in adults using,sodium cromoglycate,pressurized aerosol : a double-blind controlled trial .,"['The', 'treatment', 'of', 'asthma', 'in', 'adults', 'using', 'sodium', 'cromoglycate', 'pressurized', 'aerosol', ':', 'a', 'double-blind', 'controlled', 'trial', '.']","(7, 9)","(39, 58)",-1,ss_i,6418441,Title,0,test,gold,1594.0
6774,The treatment of,asthma,in adults using sodium cromoglycate pressurized aerosol : a double-blind controlled trial .,"['The', 'treatment', 'of', 'asthma', 'in', 'adults', 'using', 'sodium', 'cromoglycate', 'pressurized', 'aerosol', ':', 'a', 'double-blind', 'controlled', 'trial', '.']","(3, 4)","(16, 22)",-1,hl_p,6418441,Title,0,test,gold,3458.0
6775,The treatment of asthma in,adults,using sodium cromoglycate pressurized aerosol : a double-blind controlled trial .,"['The', 'treatment', 'of', 'asthma', 'in', 'adults', 'using', 'sodium', 'cromoglycate', 'pressurized', 'aerosol', ':', 'a', 'double-blind', 'controlled', 'trial', '.']","(5, 6)","(26, 32)",-1,hl_p,6418441,Title,0,test,gold,2160.0
6776,The treatment of asthma in adults using,sodium cromoglycate,pressurized aerosol : a double-blind controlled trial .,"['The', 'treatment', 'of', 'asthma', 'in', 'adults', 'using', 'sodium', 'cromoglycate', 'pressurized', 'aerosol', ':', 'a', 'double-blind', 'controlled', 'trial', '.']","(7, 9)","(39, 58)",-1,hl_i,6418441,Title,0,test,gold,1595.0
6777,Sodium cromoglycate formulated as a pressurized aerosol ( 2 mg 4-times daily ) and placebo were compared in,31 adult asthmatic patients,in a double-blind crossover trial lasting 12 weeks .,"['Sodium', 'cromoglycate', 'formulated', 'as', 'a', 'pressurized', 'aerosol', '(', '2', 'mg', '4-times', 'daily', ')', 'and', 'placebo', 'were', 'compared', 'in', '31', 'adult', 'asthmatic', 'patients', 'in', 'a', 'double-blind', 'crossover', 'trial', 'lasting', '12', 'weeks', '.']","(18, 22)","(107, 134)",-1,ss_p,6418441,Abstract,0,test,gold,3815.0
6778,,Sodium cromoglycate,formulated as a pressurized aerosol ( 2 mg 4-times daily ) and placebo were compared in 31 adult asthmatic patients in a double-blind crossover trial lasting 12 weeks .,"['Sodium', 'cromoglycate', 'formulated', 'as', 'a', 'pressurized', 'aerosol', '(', '2', 'mg', '4-times', 'daily', ')', 'and', 'placebo', 'were', 'compared', 'in', '31', 'adult', 'asthmatic', 'patients', 'in', 'a', 'double-blind', 'crossover', 'trial', 'lasting', '12', 'weeks', '.']","(0, 2)","(0, 19)",-1,ss_i,6418441,Abstract,0,test,gold,1586.0
6779,Sodium cromoglycate formulated as a pressurized aerosol ( 2 mg 4-times daily ) and,placebo,were compared in 31 adult asthmatic patients in a double-blind crossover trial lasting 12 weeks .,"['Sodium', 'cromoglycate', 'formulated', 'as', 'a', 'pressurized', 'aerosol', '(', '2', 'mg', '4-times', 'daily', ')', 'and', 'placebo', 'were', 'compared', 'in', '31', 'adult', 'asthmatic', 'patients', 'in', 'a', 'double-blind', 'crossover', 'trial', 'lasting', '12', 'weeks', '.']","(14, 15)","(82, 89)",-1,ss_i,6418441,Abstract,0,test,gold,4301.0
6780,Sodium cromoglycate formulated as a pressurized aerosol ( 2 mg 4-times daily ) and placebo were compared in,31 adult asthmatic,patients in a double-blind crossover trial lasting 12 weeks .,"['Sodium', 'cromoglycate', 'formulated', 'as', 'a', 'pressurized', 'aerosol', '(', '2', 'mg', '4-times', 'daily', ')', 'and', 'placebo', 'were', 'compared', 'in', '31', 'adult', 'asthmatic', 'patients', 'in', 'a', 'double-blind', 'crossover', 'trial', 'lasting', '12', 'weeks', '.']","(18, 21)","(107, 125)",-1,hl_p,6418441,Abstract,0,test,gold,3816.0
6781,,Sodium cromoglycate,formulated as a pressurized aerosol ( 2 mg 4-times daily ) and placebo were compared in 31 adult asthmatic patients in a double-blind crossover trial lasting 12 weeks .,"['Sodium', 'cromoglycate', 'formulated', 'as', 'a', 'pressurized', 'aerosol', '(', '2', 'mg', '4-times', 'daily', ')', 'and', 'placebo', 'were', 'compared', 'in', '31', 'adult', 'asthmatic', 'patients', 'in', 'a', 'double-blind', 'crossover', 'trial', 'lasting', '12', 'weeks', '.']","(0, 2)","(0, 19)",-1,hl_i,6418441,Abstract,0,test,gold,1587.0
6782,Sodium cromoglycate formulated as a pressurized aerosol ( 2 mg 4-times daily ) and,placebo,were compared in 31 adult asthmatic patients in a double-blind crossover trial lasting 12 weeks .,"['Sodium', 'cromoglycate', 'formulated', 'as', 'a', 'pressurized', 'aerosol', '(', '2', 'mg', '4-times', 'daily', ')', 'and', 'placebo', 'were', 'compared', 'in', '31', 'adult', 'asthmatic', 'patients', 'in', 'a', 'double-blind', 'crossover', 'trial', 'lasting', '12', 'weeks', '.']","(14, 15)","(82, 89)",-1,hl_i,6418441,Abstract,0,test,gold,4300.0
6783,,Sodium cromoglycate,"was superior to placebo in improving breathlessness at rest ( p less than 0.001 ) , breathlessness on exertion ( p less than 0.05 ) and the quality of sleep ( p less than 0.001 ) , and also in improving the morning peak expiratory flow rate value ( p less than 0.05 ) .","['Sodium', 'cromoglycate', 'was', 'superior', 'to', 'placebo', 'in', 'improving', 'breathlessness', 'at', 'rest', '(', 'p', 'less', 'than', '0.001', ')', ',', 'breathlessness', 'on', 'exertion', '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'quality', 'of', 'sleep', '(', 'p', 'less', 'than', '0.001', ')', ',', 'and', 'also', 'in', 'improving', 'the', 'morning', 'peak', 'expiratory', 'flow', 'rate', 'value', '(', 'p', 'less', 'than', '0.05', ')', '.']","(0, 2)","(0, 19)",-1,ss_i,6418441,Abstract,1,test,gold,1585.0
6784,Sodium cromoglycate was superior to,placebo,"in improving breathlessness at rest ( p less than 0.001 ) , breathlessness on exertion ( p less than 0.05 ) and the quality of sleep ( p less than 0.001 ) , and also in improving the morning peak expiratory flow rate value ( p less than 0.05 ) .","['Sodium', 'cromoglycate', 'was', 'superior', 'to', 'placebo', 'in', 'improving', 'breathlessness', 'at', 'rest', '(', 'p', 'less', 'than', '0.001', ')', ',', 'breathlessness', 'on', 'exertion', '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'quality', 'of', 'sleep', '(', 'p', 'less', 'than', '0.001', ')', ',', 'and', 'also', 'in', 'improving', 'the', 'morning', 'peak', 'expiratory', 'flow', 'rate', 'value', '(', 'p', 'less', 'than', '0.05', ')', '.']","(5, 6)","(35, 42)",-1,ss_i,6418441,Abstract,1,test,gold,4299.0
6785,Sodium cromoglycate was superior to placebo in improving,breathlessness at rest,"( p less than 0.001 ) , breathlessness on exertion ( p less than 0.05 ) and the quality of sleep ( p less than 0.001 ) , and also in improving the morning peak expiratory flow rate value ( p less than 0.05 ) .","['Sodium', 'cromoglycate', 'was', 'superior', 'to', 'placebo', 'in', 'improving', 'breathlessness', 'at', 'rest', '(', 'p', 'less', 'than', '0.001', ')', ',', 'breathlessness', 'on', 'exertion', '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'quality', 'of', 'sleep', '(', 'p', 'less', 'than', '0.001', ')', ',', 'and', 'also', 'in', 'improving', 'the', 'morning', 'peak', 'expiratory', 'flow', 'rate', 'value', '(', 'p', 'less', 'than', '0.05', ')', '.']","(8, 11)","(56, 78)",-1,ss_o,6418441,Abstract,1,test,gold,2682.0
6786,"Sodium cromoglycate was superior to placebo in improving breathlessness at rest ( p less than 0.001 ) ,",breathlessness on exertion,"( p less than 0.05 ) and the quality of sleep ( p less than 0.001 ) , and also in improving the morning peak expiratory flow rate value ( p less than 0.05 ) .","['Sodium', 'cromoglycate', 'was', 'superior', 'to', 'placebo', 'in', 'improving', 'breathlessness', 'at', 'rest', '(', 'p', 'less', 'than', '0.001', ')', ',', 'breathlessness', 'on', 'exertion', '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'quality', 'of', 'sleep', '(', 'p', 'less', 'than', '0.001', ')', ',', 'and', 'also', 'in', 'improving', 'the', 'morning', 'peak', 'expiratory', 'flow', 'rate', 'value', '(', 'p', 'less', 'than', '0.05', ')', '.']","(18, 21)","(103, 129)",-1,ss_o,6418441,Abstract,1,test,gold,2684.0
6787,"Sodium cromoglycate was superior to placebo in improving breathlessness at rest ( p less than 0.001 ) , breathlessness on exertion ( p less than 0.05 ) and the",quality of sleep,"( p less than 0.001 ) , and also in improving the morning peak expiratory flow rate value ( p less than 0.05 ) .","['Sodium', 'cromoglycate', 'was', 'superior', 'to', 'placebo', 'in', 'improving', 'breathlessness', 'at', 'rest', '(', 'p', 'less', 'than', '0.001', ')', ',', 'breathlessness', 'on', 'exertion', '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'quality', 'of', 'sleep', '(', 'p', 'less', 'than', '0.001', ')', ',', 'and', 'also', 'in', 'improving', 'the', 'morning', 'peak', 'expiratory', 'flow', 'rate', 'value', '(', 'p', 'less', 'than', '0.05', ')', '.']","(29, 32)","(159, 175)",-1,ss_o,6418441,Abstract,1,test,gold,2580.0
6788,"Sodium cromoglycate was superior to placebo in improving breathlessness at rest ( p less than 0.001 ) , breathlessness on exertion ( p less than 0.05 ) and the quality of sleep ( p less than 0.001 ) , and also in improving the",morning peak expiratory flow rate value,( p less than 0.05 ) .,"['Sodium', 'cromoglycate', 'was', 'superior', 'to', 'placebo', 'in', 'improving', 'breathlessness', 'at', 'rest', '(', 'p', 'less', 'than', '0.001', ')', ',', 'breathlessness', 'on', 'exertion', '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'quality', 'of', 'sleep', '(', 'p', 'less', 'than', '0.001', ')', ',', 'and', 'also', 'in', 'improving', 'the', 'morning', 'peak', 'expiratory', 'flow', 'rate', 'value', '(', 'p', 'less', 'than', '0.05', ')', '.']","(44, 50)","(226, 265)",-1,ss_o,6418441,Abstract,1,test,gold,1734.0
6789,,Sodium cromoglycate,"was superior to placebo in improving breathlessness at rest ( p less than 0.001 ) , breathlessness on exertion ( p less than 0.05 ) and the quality of sleep ( p less than 0.001 ) , and also in improving the morning peak expiratory flow rate value ( p less than 0.05 ) .","['Sodium', 'cromoglycate', 'was', 'superior', 'to', 'placebo', 'in', 'improving', 'breathlessness', 'at', 'rest', '(', 'p', 'less', 'than', '0.001', ')', ',', 'breathlessness', 'on', 'exertion', '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'quality', 'of', 'sleep', '(', 'p', 'less', 'than', '0.001', ')', ',', 'and', 'also', 'in', 'improving', 'the', 'morning', 'peak', 'expiratory', 'flow', 'rate', 'value', '(', 'p', 'less', 'than', '0.05', ')', '.']","(0, 2)","(0, 19)",-1,hl_i,6418441,Abstract,1,test,gold,1584.0
6790,Sodium cromoglycate was superior to,placebo,"in improving breathlessness at rest ( p less than 0.001 ) , breathlessness on exertion ( p less than 0.05 ) and the quality of sleep ( p less than 0.001 ) , and also in improving the morning peak expiratory flow rate value ( p less than 0.05 ) .","['Sodium', 'cromoglycate', 'was', 'superior', 'to', 'placebo', 'in', 'improving', 'breathlessness', 'at', 'rest', '(', 'p', 'less', 'than', '0.001', ')', ',', 'breathlessness', 'on', 'exertion', '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'quality', 'of', 'sleep', '(', 'p', 'less', 'than', '0.001', ')', ',', 'and', 'also', 'in', 'improving', 'the', 'morning', 'peak', 'expiratory', 'flow', 'rate', 'value', '(', 'p', 'less', 'than', '0.05', ')', '.']","(5, 6)","(35, 42)",-1,hl_i,6418441,Abstract,1,test,gold,4298.0
6791,Sodium cromoglycate was superior to placebo in improving,breathlessness at rest,"( p less than 0.001 ) , breathlessness on exertion ( p less than 0.05 ) and the quality of sleep ( p less than 0.001 ) , and also in improving the morning peak expiratory flow rate value ( p less than 0.05 ) .","['Sodium', 'cromoglycate', 'was', 'superior', 'to', 'placebo', 'in', 'improving', 'breathlessness', 'at', 'rest', '(', 'p', 'less', 'than', '0.001', ')', ',', 'breathlessness', 'on', 'exertion', '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'quality', 'of', 'sleep', '(', 'p', 'less', 'than', '0.001', ')', ',', 'and', 'also', 'in', 'improving', 'the', 'morning', 'peak', 'expiratory', 'flow', 'rate', 'value', '(', 'p', 'less', 'than', '0.05', ')', '.']","(8, 11)","(56, 78)",-1,hl_o,6418441,Abstract,1,test,gold,2683.0
6792,"Sodium cromoglycate was superior to placebo in improving breathlessness at rest ( p less than 0.001 ) ,",breathlessness on exertion,"( p less than 0.05 ) and the quality of sleep ( p less than 0.001 ) , and also in improving the morning peak expiratory flow rate value ( p less than 0.05 ) .","['Sodium', 'cromoglycate', 'was', 'superior', 'to', 'placebo', 'in', 'improving', 'breathlessness', 'at', 'rest', '(', 'p', 'less', 'than', '0.001', ')', ',', 'breathlessness', 'on', 'exertion', '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'quality', 'of', 'sleep', '(', 'p', 'less', 'than', '0.001', ')', ',', 'and', 'also', 'in', 'improving', 'the', 'morning', 'peak', 'expiratory', 'flow', 'rate', 'value', '(', 'p', 'less', 'than', '0.05', ')', '.']","(18, 21)","(103, 129)",-1,hl_o,6418441,Abstract,1,test,gold,2685.0
6793,"Sodium cromoglycate was superior to placebo in improving breathlessness at rest ( p less than 0.001 ) , breathlessness on exertion ( p less than 0.05 ) and the",quality of sleep,"( p less than 0.001 ) , and also in improving the morning peak expiratory flow rate value ( p less than 0.05 ) .","['Sodium', 'cromoglycate', 'was', 'superior', 'to', 'placebo', 'in', 'improving', 'breathlessness', 'at', 'rest', '(', 'p', 'less', 'than', '0.001', ')', ',', 'breathlessness', 'on', 'exertion', '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'quality', 'of', 'sleep', '(', 'p', 'less', 'than', '0.001', ')', ',', 'and', 'also', 'in', 'improving', 'the', 'morning', 'peak', 'expiratory', 'flow', 'rate', 'value', '(', 'p', 'less', 'than', '0.05', ')', '.']","(29, 32)","(159, 175)",-1,hl_o,6418441,Abstract,1,test,gold,2581.0
6794,"Sodium cromoglycate was superior to placebo in improving breathlessness at rest ( p less than 0.001 ) , breathlessness on exertion ( p less than 0.05 ) and the quality of sleep ( p less than 0.001 ) , and also in improving the",morning peak expiratory flow rate value,( p less than 0.05 ) .,"['Sodium', 'cromoglycate', 'was', 'superior', 'to', 'placebo', 'in', 'improving', 'breathlessness', 'at', 'rest', '(', 'p', 'less', 'than', '0.001', ')', ',', 'breathlessness', 'on', 'exertion', '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'quality', 'of', 'sleep', '(', 'p', 'less', 'than', '0.001', ')', ',', 'and', 'also', 'in', 'improving', 'the', 'morning', 'peak', 'expiratory', 'flow', 'rate', 'value', '(', 'p', 'less', 'than', '0.05', ')', '.']","(44, 50)","(226, 265)",-1,hl_o,6418441,Abstract,1,test,gold,1735.0
6795,"Both the patients ' ( p less than 0.05 ) and the clinicians ' ( p less than 0.01 ) treatment opinions , and their treatment preferences ( p less than 0.05 ) , favoured",sodium cromoglycate .,,"['Both', 'the', 'patients', ""'"", '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'clinicians', ""'"", '(', 'p', 'less', 'than', '0.01', ')', 'treatment', 'opinions', ',', 'and', 'their', 'treatment', 'preferences', '(', 'p', 'less', 'than', '0.05', ')', ',', 'favoured', 'sodium', 'cromoglycate', '.']","(35, 38)","(167, 188)",-1,ss_i,6418441,Abstract,2,test,gold,1593.0
6796,Both the patients ' ( p less than 0.05 ) and the clinicians ' ( p less than 0.01 ),treatment opinions,", and their treatment preferences ( p less than 0.05 ) , favoured sodium cromoglycate .","['Both', 'the', 'patients', ""'"", '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'clinicians', ""'"", '(', 'p', 'less', 'than', '0.01', ')', 'treatment', 'opinions', ',', 'and', 'their', 'treatment', 'preferences', '(', 'p', 'less', 'than', '0.05', ')', ',', 'favoured', 'sodium', 'cromoglycate', '.']","(20, 22)","(82, 100)",-1,ss_o,6418441,Abstract,2,test,gold,3983.0
6797,"Both the patients ' ( p less than 0.05 ) and the clinicians ' ( p less than 0.01 ) treatment opinions , and their",treatment preferences,"( p less than 0.05 ) , favoured sodium cromoglycate .","['Both', 'the', 'patients', ""'"", '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'clinicians', ""'"", '(', 'p', 'less', 'than', '0.01', ')', 'treatment', 'opinions', ',', 'and', 'their', 'treatment', 'preferences', '(', 'p', 'less', 'than', '0.05', ')', ',', 'favoured', 'sodium', 'cromoglycate', '.']","(25, 27)","(113, 134)",-1,ss_o,6418441,Abstract,2,test,gold,3854.0
6798,"Both the patients ' ( p less than 0.05 ) and the clinicians ' ( p less than 0.01 ) treatment opinions , and their treatment preferences ( p less than 0.05 ) , favoured",sodium cromoglycate .,,"['Both', 'the', 'patients', ""'"", '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'clinicians', ""'"", '(', 'p', 'less', 'than', '0.01', ')', 'treatment', 'opinions', ',', 'and', 'their', 'treatment', 'preferences', '(', 'p', 'less', 'than', '0.05', ')', ',', 'favoured', 'sodium', 'cromoglycate', '.']","(35, 38)","(167, 188)",-1,hl_i,6418441,Abstract,2,test,gold,1592.0
6799,"Both the patients ' ( p less than 0.05 ) and the clinicians ' ( p less than 0.01 ) treatment opinions , and their",treatment preferences,"( p less than 0.05 ) , favoured sodium cromoglycate .","['Both', 'the', 'patients', ""'"", '(', 'p', 'less', 'than', '0.05', ')', 'and', 'the', 'clinicians', ""'"", '(', 'p', 'less', 'than', '0.01', ')', 'treatment', 'opinions', ',', 'and', 'their', 'treatment', 'preferences', '(', 'p', 'less', 'than', '0.05', ')', ',', 'favoured', 'sodium', 'cromoglycate', '.']","(25, 27)","(113, 134)",-1,hl_o,6418441,Abstract,2,test,gold,3855.0
6800,"Moreover , usage of bronchodilators ( theophylline and aerosol beta-stimulants combined ) declined significantly ( p less than 0.001 ) during",sodium cromoglycate,treatment compared to placebo .,"['Moreover', ',', 'usage', 'of', 'bronchodilators', '(', 'theophylline', 'and', 'aerosol', 'beta-stimulants', 'combined', ')', 'declined', 'significantly', '(', 'p', 'less', 'than', '0.001', ')', 'during', 'sodium', 'cromoglycate', 'treatment', 'compared', 'to', 'placebo', '.']","(21, 23)","(141, 160)",-1,ss_i,6418441,Abstract,3,test,gold,1591.0
6801,"Moreover , usage of bronchodilators ( theophylline and aerosol beta-stimulants combined ) declined significantly ( p less than 0.001 ) during sodium cromoglycate treatment compared to",placebo .,,"['Moreover', ',', 'usage', 'of', 'bronchodilators', '(', 'theophylline', 'and', 'aerosol', 'beta-stimulants', 'combined', ')', 'declined', 'significantly', '(', 'p', 'less', 'than', '0.001', ')', 'during', 'sodium', 'cromoglycate', 'treatment', 'compared', 'to', 'placebo', '.']","(26, 28)","(183, 192)",-1,ss_i,6418441,Abstract,3,test,gold,4297.0
6802,"Moreover , usage of bronchodilators ( theophylline and aerosol beta-stimulants combined ) declined significantly ( p less than 0.001 ) during",sodium cromoglycate,treatment compared to placebo .,"['Moreover', ',', 'usage', 'of', 'bronchodilators', '(', 'theophylline', 'and', 'aerosol', 'beta-stimulants', 'combined', ')', 'declined', 'significantly', '(', 'p', 'less', 'than', '0.001', ')', 'during', 'sodium', 'cromoglycate', 'treatment', 'compared', 'to', 'placebo', '.']","(21, 23)","(141, 160)",-1,hl_i,6418441,Abstract,3,test,gold,1590.0
6803,"Moreover , usage of bronchodilators ( theophylline and aerosol beta-stimulants combined ) declined significantly ( p less than 0.001 ) during sodium cromoglycate treatment compared to",placebo .,,"['Moreover', ',', 'usage', 'of', 'bronchodilators', '(', 'theophylline', 'and', 'aerosol', 'beta-stimulants', 'combined', ')', 'declined', 'significantly', '(', 'p', 'less', 'than', '0.001', ')', 'during', 'sodium', 'cromoglycate', 'treatment', 'compared', 'to', 'placebo', '.']","(26, 28)","(183, 192)",-1,hl_i,6418441,Abstract,3,test,gold,4296.0
6804,No,side-effects,were reported .,"['No', 'side-effects', 'were', 'reported', '.']","(1, 2)","(2, 14)",-1,ss_o,6418441,Abstract,4,test,gold,
6805,No,side-effects,were reported .,"['No', 'side-effects', 'were', 'reported', '.']","(1, 2)","(2, 14)",-1,hl_o,6418441,Abstract,4,test,gold,
6806,The results of this study show that,sodium cromoglycate,"delivered by pressurized aerosol was significantly superior to placebo , not only in improving asthmatic symptoms , but also in reducing the amount of concomitant bronchodilator therapy required .","['The', 'results', 'of', 'this', 'study', 'show', 'that', 'sodium', 'cromoglycate', 'delivered', 'by', 'pressurized', 'aerosol', 'was', 'significantly', 'superior', 'to', 'placebo', ',', 'not', 'only', 'in', 'improving', 'asthmatic', 'symptoms', ',', 'but', 'also', 'in', 'reducing', 'the', 'amount', 'of', 'concomitant', 'bronchodilator', 'therapy', 'required', '.']","(7, 9)","(35, 54)",-1,ss_i,6418441,Abstract,5,test,gold,1589.0
6807,The results of this study show that sodium cromoglycate delivered by pressurized aerosol was significantly superior to,placebo,", not only in improving asthmatic symptoms , but also in reducing the amount of concomitant bronchodilator therapy required .","['The', 'results', 'of', 'this', 'study', 'show', 'that', 'sodium', 'cromoglycate', 'delivered', 'by', 'pressurized', 'aerosol', 'was', 'significantly', 'superior', 'to', 'placebo', ',', 'not', 'only', 'in', 'improving', 'asthmatic', 'symptoms', ',', 'but', 'also', 'in', 'reducing', 'the', 'amount', 'of', 'concomitant', 'bronchodilator', 'therapy', 'required', '.']","(17, 18)","(118, 125)",-1,ss_i,6418441,Abstract,5,test,gold,4295.0
6808,The results of this study show that sodium cromoglycate delivered by pressurized aerosol was significantly,superior,"to placebo , not only in improving asthmatic symptoms , but also in reducing the amount of concomitant bronchodilator therapy required .","['The', 'results', 'of', 'this', 'study', 'show', 'that', 'sodium', 'cromoglycate', 'delivered', 'by', 'pressurized', 'aerosol', 'was', 'significantly', 'superior', 'to', 'placebo', ',', 'not', 'only', 'in', 'improving', 'asthmatic', 'symptoms', ',', 'but', 'also', 'in', 'reducing', 'the', 'amount', 'of', 'concomitant', 'bronchodilator', 'therapy', 'required', '.']","(15, 16)","(106, 114)",-1,ss_o,6418441,Abstract,5,test,gold,1222.0
6809,"The results of this study show that sodium cromoglycate delivered by pressurized aerosol was significantly superior to placebo , not only in improving",asthmatic symptoms,", but also in reducing the amount of concomitant bronchodilator therapy required .","['The', 'results', 'of', 'this', 'study', 'show', 'that', 'sodium', 'cromoglycate', 'delivered', 'by', 'pressurized', 'aerosol', 'was', 'significantly', 'superior', 'to', 'placebo', ',', 'not', 'only', 'in', 'improving', 'asthmatic', 'symptoms', ',', 'but', 'also', 'in', 'reducing', 'the', 'amount', 'of', 'concomitant', 'bronchodilator', 'therapy', 'required', '.']","(23, 25)","(150, 168)",-1,ss_o,6418441,Abstract,5,test,gold,3262.0
6810,"The results of this study show that sodium cromoglycate delivered by pressurized aerosol was significantly superior to placebo , not only in improving asthmatic symptoms , but also in reducing the amount of concomitant",bronchodilator therapy required .,,"['The', 'results', 'of', 'this', 'study', 'show', 'that', 'sodium', 'cromoglycate', 'delivered', 'by', 'pressurized', 'aerosol', 'was', 'significantly', 'superior', 'to', 'placebo', ',', 'not', 'only', 'in', 'improving', 'asthmatic', 'symptoms', ',', 'but', 'also', 'in', 'reducing', 'the', 'amount', 'of', 'concomitant', 'bronchodilator', 'therapy', 'required', '.']","(34, 38)","(218, 251)",-1,ss_o,6418441,Abstract,5,test,gold,4203.0
6811,The results of this study show that,sodium cromoglycate,"delivered by pressurized aerosol was significantly superior to placebo , not only in improving asthmatic symptoms , but also in reducing the amount of concomitant bronchodilator therapy required .","['The', 'results', 'of', 'this', 'study', 'show', 'that', 'sodium', 'cromoglycate', 'delivered', 'by', 'pressurized', 'aerosol', 'was', 'significantly', 'superior', 'to', 'placebo', ',', 'not', 'only', 'in', 'improving', 'asthmatic', 'symptoms', ',', 'but', 'also', 'in', 'reducing', 'the', 'amount', 'of', 'concomitant', 'bronchodilator', 'therapy', 'required', '.']","(7, 9)","(35, 54)",-1,hl_i,6418441,Abstract,5,test,gold,1588.0
6812,The results of this study show that sodium cromoglycate delivered by pressurized aerosol was significantly superior to,placebo,", not only in improving asthmatic symptoms , but also in reducing the amount of concomitant bronchodilator therapy required .","['The', 'results', 'of', 'this', 'study', 'show', 'that', 'sodium', 'cromoglycate', 'delivered', 'by', 'pressurized', 'aerosol', 'was', 'significantly', 'superior', 'to', 'placebo', ',', 'not', 'only', 'in', 'improving', 'asthmatic', 'symptoms', ',', 'but', 'also', 'in', 'reducing', 'the', 'amount', 'of', 'concomitant', 'bronchodilator', 'therapy', 'required', '.']","(17, 18)","(118, 125)",-1,hl_i,6418441,Abstract,5,test,gold,4294.0
6813,"The results of this study show that sodium cromoglycate delivered by pressurized aerosol was significantly superior to placebo , not only in improving",asthmatic symptoms,", but also in reducing the amount of concomitant bronchodilator therapy required .","['The', 'results', 'of', 'this', 'study', 'show', 'that', 'sodium', 'cromoglycate', 'delivered', 'by', 'pressurized', 'aerosol', 'was', 'significantly', 'superior', 'to', 'placebo', ',', 'not', 'only', 'in', 'improving', 'asthmatic', 'symptoms', ',', 'but', 'also', 'in', 'reducing', 'the', 'amount', 'of', 'concomitant', 'bronchodilator', 'therapy', 'required', '.']","(23, 25)","(150, 168)",-1,hl_o,6418441,Abstract,5,test,gold,3263.0
6814,Effects of mild physical exercise on serum lipoproteins and metabolites of arachidonic acid : a controlled randomised trial in,middle aged men .,,"['Effects', 'of', 'mild', 'physical', 'exercise', 'on', 'serum', 'lipoproteins', 'and', 'metabolites', 'of', 'arachidonic', 'acid', ':', 'a', 'controlled', 'randomised', 'trial', 'in', 'middle', 'aged', 'men', '.']","(19, 23)","(126, 143)",-1,ss_p,6421395,Title,0,test,gold,2032.0
6815,Effects of,mild physical exercise,on serum lipoproteins and metabolites of arachidonic acid : a controlled randomised trial in middle aged men .,"['Effects', 'of', 'mild', 'physical', 'exercise', 'on', 'serum', 'lipoproteins', 'and', 'metabolites', 'of', 'arachidonic', 'acid', ':', 'a', 'controlled', 'randomised', 'trial', 'in', 'middle', 'aged', 'men', '.']","(2, 5)","(10, 32)",-1,ss_i,6421395,Title,0,test,gold,2782.0
6816,Effects of mild physical exercise on,serum lipoproteins and metabolites of arachidonic acid :,a controlled randomised trial in middle aged men .,"['Effects', 'of', 'mild', 'physical', 'exercise', 'on', 'serum', 'lipoproteins', 'and', 'metabolites', 'of', 'arachidonic', 'acid', ':', 'a', 'controlled', 'randomised', 'trial', 'in', 'middle', 'aged', 'men', '.']","(6, 14)","(36, 92)",-1,ss_o,6421395,Title,0,test,gold,6561.0
6817,Effects of mild physical exercise on serum lipoproteins and metabolites of arachidonic acid : a controlled randomised trial in,middle aged men .,,"['Effects', 'of', 'mild', 'physical', 'exercise', 'on', 'serum', 'lipoproteins', 'and', 'metabolites', 'of', 'arachidonic', 'acid', ':', 'a', 'controlled', 'randomised', 'trial', 'in', 'middle', 'aged', 'men', '.']","(19, 23)","(126, 143)",-1,hl_p,6421395,Title,0,test,gold,2033.0
6818,Effects of,mild physical exercise,on serum lipoproteins and metabolites of arachidonic acid : a controlled randomised trial in middle aged men .,"['Effects', 'of', 'mild', 'physical', 'exercise', 'on', 'serum', 'lipoproteins', 'and', 'metabolites', 'of', 'arachidonic', 'acid', ':', 'a', 'controlled', 'randomised', 'trial', 'in', 'middle', 'aged', 'men', '.']","(2, 5)","(10, 32)",-1,hl_i,6421395,Title,0,test,gold,2783.0
6819,Effects of mild physical exercise on,serum lipoproteins,and metabolites of arachidonic acid : a controlled randomised trial in middle aged men .,"['Effects', 'of', 'mild', 'physical', 'exercise', 'on', 'serum', 'lipoproteins', 'and', 'metabolites', 'of', 'arachidonic', 'acid', ':', 'a', 'controlled', 'randomised', 'trial', 'in', 'middle', 'aged', 'men', '.']","(6, 8)","(36, 54)",-1,hl_o,6421395,Title,0,test,gold,4476.0
6820,Effects of mild physical exercise on serum lipoproteins and,metabolites of arachidonic acid :,a controlled randomised trial in middle aged men .,"['Effects', 'of', 'mild', 'physical', 'exercise', 'on', 'serum', 'lipoproteins', 'and', 'metabolites', 'of', 'arachidonic', 'acid', ':', 'a', 'controlled', 'randomised', 'trial', 'in', 'middle', 'aged', 'men', '.']","(9, 14)","(59, 92)",-1,hl_o,6421395,Title,0,test,gold,4669.0
6821,To study the effects of physical exercise on biochemical risk factors for ischaemic heart disease,31 healthy middle aged men,undertook regular physical exercise for two months and 29 served as controls in a randomised trial .,"['To', 'study', 'the', 'effects', 'of', 'physical', 'exercise', 'on', 'biochemical', 'risk', 'factors', 'for', 'ischaemic', 'heart', 'disease', '31', 'healthy', 'middle', 'aged', 'men', 'undertook', 'regular', 'physical', 'exercise', 'for', 'two', 'months', 'and', '29', 'served', 'as', 'controls', 'in', 'a', 'randomised', 'trial', '.']","(15, 20)","(97, 123)",-1,ss_p,6421395,Abstract,0,test,gold,2036.0
6822,To study the effects of,physical exercise,on biochemical risk factors for ischaemic heart disease 31 healthy middle aged men undertook regular physical exercise for two months and 29 served as controls in a randomised trial .,"['To', 'study', 'the', 'effects', 'of', 'physical', 'exercise', 'on', 'biochemical', 'risk', 'factors', 'for', 'ischaemic', 'heart', 'disease', '31', 'healthy', 'middle', 'aged', 'men', 'undertook', 'regular', 'physical', 'exercise', 'for', 'two', 'months', 'and', '29', 'served', 'as', 'controls', 'in', 'a', 'randomised', 'trial', '.']","(5, 7)","(23, 40)",-1,ss_i,6421395,Abstract,0,test,gold,2786.0
6823,To study the effects of physical exercise on biochemical risk factors for ischaemic heart disease 31 healthy middle aged men undertook,regular physical exercise,for two months and 29 served as controls in a randomised trial .,"['To', 'study', 'the', 'effects', 'of', 'physical', 'exercise', 'on', 'biochemical', 'risk', 'factors', 'for', 'ischaemic', 'heart', 'disease', '31', 'healthy', 'middle', 'aged', 'men', 'undertook', 'regular', 'physical', 'exercise', 'for', 'two', 'months', 'and', '29', 'served', 'as', 'controls', 'in', 'a', 'randomised', 'trial', '.']","(21, 24)","(134, 159)",-1,ss_i,6421395,Abstract,0,test,gold,2788.0
6824,To study the effects of physical exercise on,biochemical risk factors for ischaemic heart disease,31 healthy middle aged men undertook regular physical exercise for two months and 29 served as controls in a randomised trial .,"['To', 'study', 'the', 'effects', 'of', 'physical', 'exercise', 'on', 'biochemical', 'risk', 'factors', 'for', 'ischaemic', 'heart', 'disease', '31', 'healthy', 'middle', 'aged', 'men', 'undertook', 'regular', 'physical', 'exercise', 'for', 'two', 'months', 'and', '29', 'served', 'as', 'controls', 'in', 'a', 'randomised', 'trial', '.']","(8, 15)","(44, 96)",-1,ss_o,6421395,Abstract,0,test,gold,6938.0
6825,To study the effects of physical exercise on biochemical risk factors for ischaemic heart disease,31 healthy middle aged men,undertook regular physical exercise for two months and 29 served as controls in a randomised trial .,"['To', 'study', 'the', 'effects', 'of', 'physical', 'exercise', 'on', 'biochemical', 'risk', 'factors', 'for', 'ischaemic', 'heart', 'disease', '31', 'healthy', 'middle', 'aged', 'men', 'undertook', 'regular', 'physical', 'exercise', 'for', 'two', 'months', 'and', '29', 'served', 'as', 'controls', 'in', 'a', 'randomised', 'trial', '.']","(15, 20)","(97, 123)",-1,hl_p,6421395,Abstract,0,test,gold,2037.0
6826,To study the effects of,physical exercise,on biochemical risk factors for ischaemic heart disease 31 healthy middle aged men undertook regular physical exercise for two months and 29 served as controls in a randomised trial .,"['To', 'study', 'the', 'effects', 'of', 'physical', 'exercise', 'on', 'biochemical', 'risk', 'factors', 'for', 'ischaemic', 'heart', 'disease', '31', 'healthy', 'middle', 'aged', 'men', 'undertook', 'regular', 'physical', 'exercise', 'for', 'two', 'months', 'and', '29', 'served', 'as', 'controls', 'in', 'a', 'randomised', 'trial', '.']","(5, 7)","(23, 40)",-1,hl_i,6421395,Abstract,0,test,gold,2787.0
6827,To study the effects of physical exercise on biochemical risk factors for ischaemic heart disease 31 healthy middle aged men undertook,regular physical exercise,for two months and 29 served as controls in a randomised trial .,"['To', 'study', 'the', 'effects', 'of', 'physical', 'exercise', 'on', 'biochemical', 'risk', 'factors', 'for', 'ischaemic', 'heart', 'disease', '31', 'healthy', 'middle', 'aged', 'men', 'undertook', 'regular', 'physical', 'exercise', 'for', 'two', 'months', 'and', '29', 'served', 'as', 'controls', 'in', 'a', 'randomised', 'trial', '.']","(21, 24)","(134, 159)",-1,hl_i,6421395,Abstract,0,test,gold,2789.0
6828,To study the effects of physical exercise on,biochemical risk factors for ischaemic heart disease,31 healthy middle aged men undertook regular physical exercise for two months and 29 served as controls in a randomised trial .,"['To', 'study', 'the', 'effects', 'of', 'physical', 'exercise', 'on', 'biochemical', 'risk', 'factors', 'for', 'ischaemic', 'heart', 'disease', '31', 'healthy', 'middle', 'aged', 'men', 'undertook', 'regular', 'physical', 'exercise', 'for', 'two', 'months', 'and', '29', 'served', 'as', 'controls', 'in', 'a', 'randomised', 'trial', '.']","(8, 15)","(44, 96)",-1,hl_o,6421395,Abstract,0,test,gold,6939.0
6829,In the men taking,regular exercise,serum cholesterol concentrations increased 26 % more in the high density lipoprotein subfraction two ( HDL2 ) and decreased 31 % more in the subfraction three ( HDL3 ) and 9 % more in the low density lipoprotein fraction than in the control group .,"['In', 'the', 'men', 'taking', 'regular', 'exercise', 'serum', 'cholesterol', 'concentrations', 'increased', '26', '%', 'more', 'in', 'the', 'high', 'density', 'lipoprotein', 'subfraction', 'two', '(', 'HDL2', ')', 'and', 'decreased', '31', '%', 'more', 'in', 'the', 'subfraction', 'three', '(', 'HDL3', ')', 'and', '9', '%', 'more', 'in', 'the', 'low', 'density', 'lipoprotein', 'fraction', 'than', 'in', 'the', 'control', 'group', '.']","(4, 6)","(17, 33)",-1,ss_i,6421395,Abstract,1,test,gold,2792.0
6830,In the men taking regular exercise,serum cholesterol concentrations,increased 26 % more in the high density lipoprotein subfraction two ( HDL2 ) and decreased 31 % more in the subfraction three ( HDL3 ) and 9 % more in the low density lipoprotein fraction than in the control group .,"['In', 'the', 'men', 'taking', 'regular', 'exercise', 'serum', 'cholesterol', 'concentrations', 'increased', '26', '%', 'more', 'in', 'the', 'high', 'density', 'lipoprotein', 'subfraction', 'two', '(', 'HDL2', ')', 'and', 'decreased', '31', '%', 'more', 'in', 'the', 'subfraction', 'three', '(', 'HDL3', ')', 'and', '9', '%', 'more', 'in', 'the', 'low', 'density', 'lipoprotein', 'fraction', 'than', 'in', 'the', 'control', 'group', '.']","(6, 9)","(34, 66)",-1,ss_o,6421395,Abstract,1,test,gold,6564.0
6831,In the men taking regular exercise serum cholesterol concentrations increased 26 % more in the,high density lipoprotein subfraction two ( HDL2 ),and decreased 31 % more in the subfraction three ( HDL3 ) and 9 % more in the low density lipoprotein fraction than in the control group .,"['In', 'the', 'men', 'taking', 'regular', 'exercise', 'serum', 'cholesterol', 'concentrations', 'increased', '26', '%', 'more', 'in', 'the', 'high', 'density', 'lipoprotein', 'subfraction', 'two', '(', 'HDL2', ')', 'and', 'decreased', '31', '%', 'more', 'in', 'the', 'subfraction', 'three', '(', 'HDL3', ')', 'and', '9', '%', 'more', 'in', 'the', 'low', 'density', 'lipoprotein', 'fraction', 'than', 'in', 'the', 'control', 'group', '.']","(15, 23)","(94, 143)",-1,ss_o,6421395,Abstract,1,test,gold,6544.0
6832,In the men taking regular exercise serum cholesterol concentrations increased 26 % more in the high density lipoprotein subfraction two ( HDL2 ) and decreased 31 % more in the,subfraction three ( HDL3 ),and 9 % more in the low density lipoprotein fraction than in the control group .,"['In', 'the', 'men', 'taking', 'regular', 'exercise', 'serum', 'cholesterol', 'concentrations', 'increased', '26', '%', 'more', 'in', 'the', 'high', 'density', 'lipoprotein', 'subfraction', 'two', '(', 'HDL2', ')', 'and', 'decreased', '31', '%', 'more', 'in', 'the', 'subfraction', 'three', '(', 'HDL3', ')', 'and', '9', '%', 'more', 'in', 'the', 'low', 'density', 'lipoprotein', 'fraction', 'than', 'in', 'the', 'control', 'group', '.']","(30, 35)","(175, 201)",-1,ss_o,6421395,Abstract,1,test,gold,1183.0
6833,In the men taking regular exercise serum cholesterol concentrations increased 26 % more in the high density lipoprotein subfraction two ( HDL2 ) and decreased 31 % more in the subfraction three ( HDL3 ) and 9 % more in the,low density lipoprotein fraction,than in the control group .,"['In', 'the', 'men', 'taking', 'regular', 'exercise', 'serum', 'cholesterol', 'concentrations', 'increased', '26', '%', 'more', 'in', 'the', 'high', 'density', 'lipoprotein', 'subfraction', 'two', '(', 'HDL2', ')', 'and', 'decreased', '31', '%', 'more', 'in', 'the', 'subfraction', 'three', '(', 'HDL3', ')', 'and', '9', '%', 'more', 'in', 'the', 'low', 'density', 'lipoprotein', 'fraction', 'than', 'in', 'the', 'control', 'group', '.']","(41, 45)","(222, 254)",-1,ss_o,6421395,Abstract,1,test,gold,6542.0
6834,In the men taking regular exercise,serum cholesterol concentrations,increased 26 % more in the high density lipoprotein subfraction two ( HDL2 ) and decreased 31 % more in the subfraction three ( HDL3 ) and 9 % more in the low density lipoprotein fraction than in the control group .,"['In', 'the', 'men', 'taking', 'regular', 'exercise', 'serum', 'cholesterol', 'concentrations', 'increased', '26', '%', 'more', 'in', 'the', 'high', 'density', 'lipoprotein', 'subfraction', 'two', '(', 'HDL2', ')', 'and', 'decreased', '31', '%', 'more', 'in', 'the', 'subfraction', 'three', '(', 'HDL3', ')', 'and', '9', '%', 'more', 'in', 'the', 'low', 'density', 'lipoprotein', 'fraction', 'than', 'in', 'the', 'control', 'group', '.']","(6, 9)","(34, 66)",-1,hl_o,6421395,Abstract,1,test,gold,6565.0
6835,In the men taking regular exercise serum cholesterol concentrations increased 26 % more in the,high density lipoprotein subfraction two ( HDL2 ),and decreased 31 % more in the subfraction three ( HDL3 ) and 9 % more in the low density lipoprotein fraction than in the control group .,"['In', 'the', 'men', 'taking', 'regular', 'exercise', 'serum', 'cholesterol', 'concentrations', 'increased', '26', '%', 'more', 'in', 'the', 'high', 'density', 'lipoprotein', 'subfraction', 'two', '(', 'HDL2', ')', 'and', 'decreased', '31', '%', 'more', 'in', 'the', 'subfraction', 'three', '(', 'HDL3', ')', 'and', '9', '%', 'more', 'in', 'the', 'low', 'density', 'lipoprotein', 'fraction', 'than', 'in', 'the', 'control', 'group', '.']","(15, 23)","(94, 143)",-1,hl_o,6421395,Abstract,1,test,gold,6545.0
6836,In the men taking regular exercise serum cholesterol concentrations increased 26 % more in the high density lipoprotein subfraction two ( HDL2 ) and decreased 31 % more in the,subfraction three ( HDL3 ),and 9 % more in the low density lipoprotein fraction than in the control group .,"['In', 'the', 'men', 'taking', 'regular', 'exercise', 'serum', 'cholesterol', 'concentrations', 'increased', '26', '%', 'more', 'in', 'the', 'high', 'density', 'lipoprotein', 'subfraction', 'two', '(', 'HDL2', ')', 'and', 'decreased', '31', '%', 'more', 'in', 'the', 'subfraction', 'three', '(', 'HDL3', ')', 'and', '9', '%', 'more', 'in', 'the', 'low', 'density', 'lipoprotein', 'fraction', 'than', 'in', 'the', 'control', 'group', '.']","(30, 35)","(175, 201)",-1,hl_o,6421395,Abstract,1,test,gold,1184.0
6837,In the men taking regular exercise serum cholesterol concentrations increased 26 % more in the high density lipoprotein subfraction two ( HDL2 ) and decreased 31 % more in the subfraction three ( HDL3 ) and 9 % more in the,low density lipoprotein fraction,than in the control group .,"['In', 'the', 'men', 'taking', 'regular', 'exercise', 'serum', 'cholesterol', 'concentrations', 'increased', '26', '%', 'more', 'in', 'the', 'high', 'density', 'lipoprotein', 'subfraction', 'two', '(', 'HDL2', ')', 'and', 'decreased', '31', '%', 'more', 'in', 'the', 'subfraction', 'three', '(', 'HDL3', ')', 'and', '9', '%', 'more', 'in', 'the', 'low', 'density', 'lipoprotein', 'fraction', 'than', 'in', 'the', 'control', 'group', '.']","(41, 45)","(222, 254)",-1,hl_o,6421395,Abstract,1,test,gold,6543.0
6838,A tendency towards increased plasma 6-keto-prostaglandin F1 alpha concentration and decreased serum thromboxane B2 concentration was found during the period of,regular exercise,", but prostaglandin E2 concentrations remained unchanged .","['A', 'tendency', 'towards', 'increased', 'plasma', '6-keto-prostaglandin', 'F1', 'alpha', 'concentration', 'and', 'decreased', 'serum', 'thromboxane', 'B2', 'concentration', 'was', 'found', 'during', 'the', 'period', 'of', 'regular', 'exercise', ',', 'but', 'prostaglandin', 'E2', 'concentrations', 'remained', 'unchanged', '.']","(21, 23)","(159, 175)",-1,ss_i,6421395,Abstract,2,test,gold,2793.0
6839,A tendency towards increased,plasma 6-keto-prostaglandin F1 alpha concentration,"and decreased serum thromboxane B2 concentration was found during the period of regular exercise , but prostaglandin E2 concentrations remained unchanged .","['A', 'tendency', 'towards', 'increased', 'plasma', '6-keto-prostaglandin', 'F1', 'alpha', 'concentration', 'and', 'decreased', 'serum', 'thromboxane', 'B2', 'concentration', 'was', 'found', 'during', 'the', 'period', 'of', 'regular', 'exercise', ',', 'but', 'prostaglandin', 'E2', 'concentrations', 'remained', 'unchanged', '.']","(4, 9)","(28, 78)",-1,ss_o,6421395,Abstract,2,test,gold,4445.0
6840,A tendency towards increased plasma 6-keto-prostaglandin F1 alpha concentration and decreased,serum thromboxane B2 concentration,"was found during the period of regular exercise , but prostaglandin E2 concentrations remained unchanged .","['A', 'tendency', 'towards', 'increased', 'plasma', '6-keto-prostaglandin', 'F1', 'alpha', 'concentration', 'and', 'decreased', 'serum', 'thromboxane', 'B2', 'concentration', 'was', 'found', 'during', 'the', 'period', 'of', 'regular', 'exercise', ',', 'but', 'prostaglandin', 'E2', 'concentrations', 'remained', 'unchanged', '.']","(11, 15)","(93, 127)",-1,ss_o,6421395,Abstract,2,test,gold,4498.0
6841,"A tendency towards increased plasma 6-keto-prostaglandin F1 alpha concentration and decreased serum thromboxane B2 concentration was found during the period of regular exercise , but",prostaglandin E2 concentrations,remained unchanged .,"['A', 'tendency', 'towards', 'increased', 'plasma', '6-keto-prostaglandin', 'F1', 'alpha', 'concentration', 'and', 'decreased', 'serum', 'thromboxane', 'B2', 'concentration', 'was', 'found', 'during', 'the', 'period', 'of', 'regular', 'exercise', ',', 'but', 'prostaglandin', 'E2', 'concentrations', 'remained', 'unchanged', '.']","(25, 28)","(182, 213)",-1,ss_o,6421395,Abstract,2,test,gold,4496.0
6842,A tendency towards increased plasma 6-keto-prostaglandin F1 alpha concentration and decreased serum thromboxane B2 concentration was found during the period of regular,exercise,", but prostaglandin E2 concentrations remained unchanged .","['A', 'tendency', 'towards', 'increased', 'plasma', '6-keto-prostaglandin', 'F1', 'alpha', 'concentration', 'and', 'decreased', 'serum', 'thromboxane', 'B2', 'concentration', 'was', 'found', 'during', 'the', 'period', 'of', 'regular', 'exercise', ',', 'but', 'prostaglandin', 'E2', 'concentrations', 'remained', 'unchanged', '.']","(22, 23)","(167, 175)",-1,hl_i,6421395,Abstract,2,test,gold,2764.0
6843,A tendency towards increased,plasma 6-keto-prostaglandin F1 alpha concentration,"and decreased serum thromboxane B2 concentration was found during the period of regular exercise , but prostaglandin E2 concentrations remained unchanged .","['A', 'tendency', 'towards', 'increased', 'plasma', '6-keto-prostaglandin', 'F1', 'alpha', 'concentration', 'and', 'decreased', 'serum', 'thromboxane', 'B2', 'concentration', 'was', 'found', 'during', 'the', 'period', 'of', 'regular', 'exercise', ',', 'but', 'prostaglandin', 'E2', 'concentrations', 'remained', 'unchanged', '.']","(4, 9)","(28, 78)",-1,hl_o,6421395,Abstract,2,test,gold,4446.0
6844,A tendency towards increased plasma 6-keto-prostaglandin F1 alpha concentration and decreased,serum thromboxane B2 concentration,"was found during the period of regular exercise , but prostaglandin E2 concentrations remained unchanged .","['A', 'tendency', 'towards', 'increased', 'plasma', '6-keto-prostaglandin', 'F1', 'alpha', 'concentration', 'and', 'decreased', 'serum', 'thromboxane', 'B2', 'concentration', 'was', 'found', 'during', 'the', 'period', 'of', 'regular', 'exercise', ',', 'but', 'prostaglandin', 'E2', 'concentrations', 'remained', 'unchanged', '.']","(11, 15)","(93, 127)",-1,hl_o,6421395,Abstract,2,test,gold,4499.0
6845,"A tendency towards increased plasma 6-keto-prostaglandin F1 alpha concentration and decreased serum thromboxane B2 concentration was found during the period of regular exercise , but",prostaglandin E2 concentrations,remained unchanged .,"['A', 'tendency', 'towards', 'increased', 'plasma', '6-keto-prostaglandin', 'F1', 'alpha', 'concentration', 'and', 'decreased', 'serum', 'thromboxane', 'B2', 'concentration', 'was', 'found', 'during', 'the', 'period', 'of', 'regular', 'exercise', ',', 'but', 'prostaglandin', 'E2', 'concentrations', 'remained', 'unchanged', '.']","(25, 28)","(182, 213)",-1,hl_o,6421395,Abstract,2,test,gold,4497.0
6846,The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in serum HDL2 cholesterol concentration in the group taking,regular exercise .,,"['The', 'increase', 'in', 'plasma', '6-keto-prostaglandin', 'F1', 'alpha', 'concentration', 'was', 'associated', 'with', 'an', 'increase', 'in', 'serum', 'HDL2', 'cholesterol', 'concentration', 'in', 'the', 'group', 'taking', 'regular', 'exercise', '.']","(22, 25)","(158, 176)",-1,ss_i,6421395,Abstract,3,test,gold,2791.0
6847,The increase in,plasma 6-keto-prostaglandin F1 alpha concentration,was associated with an increase in serum HDL2 cholesterol concentration in the group taking regular exercise .,"['The', 'increase', 'in', 'plasma', '6-keto-prostaglandin', 'F1', 'alpha', 'concentration', 'was', 'associated', 'with', 'an', 'increase', 'in', 'serum', 'HDL2', 'cholesterol', 'concentration', 'in', 'the', 'group', 'taking', 'regular', 'exercise', '.']","(3, 8)","(15, 65)",-1,ss_o,6421395,Abstract,3,test,gold,4444.0
6848,The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in,serum HDL2 cholesterol concentration,in the group taking regular exercise .,"['The', 'increase', 'in', 'plasma', '6-keto-prostaglandin', 'F1', 'alpha', 'concentration', 'was', 'associated', 'with', 'an', 'increase', 'in', 'serum', 'HDL2', 'cholesterol', 'concentration', 'in', 'the', 'group', 'taking', 'regular', 'exercise', '.']","(14, 18)","(101, 137)",-1,ss_o,6421395,Abstract,3,test,gold,6566.0
6849,The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in serum HDL2 cholesterol concentration in the group taking regular,exercise .,,"['The', 'increase', 'in', 'plasma', '6-keto-prostaglandin', 'F1', 'alpha', 'concentration', 'was', 'associated', 'with', 'an', 'increase', 'in', 'serum', 'HDL2', 'cholesterol', 'concentration', 'in', 'the', 'group', 'taking', 'regular', 'exercise', '.']","(23, 25)","(166, 176)",-1,hl_i,6421395,Abstract,3,test,gold,2763.0
6850,The increase in,plasma 6-keto-prostaglandin F1 alpha concentration,was associated with an increase in serum HDL2 cholesterol concentration in the group taking regular exercise .,"['The', 'increase', 'in', 'plasma', '6-keto-prostaglandin', 'F1', 'alpha', 'concentration', 'was', 'associated', 'with', 'an', 'increase', 'in', 'serum', 'HDL2', 'cholesterol', 'concentration', 'in', 'the', 'group', 'taking', 'regular', 'exercise', '.']","(3, 8)","(15, 65)",-1,hl_o,6421395,Abstract,3,test,gold,4443.0
6851,The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in,serum HDL2 cholesterol concentration,in the group taking regular exercise .,"['The', 'increase', 'in', 'plasma', '6-keto-prostaglandin', 'F1', 'alpha', 'concentration', 'was', 'associated', 'with', 'an', 'increase', 'in', 'serum', 'HDL2', 'cholesterol', 'concentration', 'in', 'the', 'group', 'taking', 'regular', 'exercise', '.']","(14, 18)","(101, 137)",-1,hl_o,6421395,Abstract,3,test,gold,6567.0
6852,Our data suggest that mild regular physical exercise favourably influences cholesterol distribution in serum lipoproteins in,healthy middle aged men,and may have beneficial effects on circulating metabolites of arachidonic acid .,"['Our', 'data', 'suggest', 'that', 'mild', 'regular', 'physical', 'exercise', 'favourably', 'influences', 'cholesterol', 'distribution', 'in', 'serum', 'lipoproteins', 'in', 'healthy', 'middle', 'aged', 'men', 'and', 'may', 'have', 'beneficial', 'effects', 'on', 'circulating', 'metabolites', 'of', 'arachidonic', 'acid', '.']","(16, 20)","(124, 147)",-1,ss_p,6421395,Abstract,4,test,gold,2035.0
6853,Our data suggest that,mild regular physical exercise,favourably influences cholesterol distribution in serum lipoproteins in healthy middle aged men and may have beneficial effects on circulating metabolites of arachidonic acid .,"['Our', 'data', 'suggest', 'that', 'mild', 'regular', 'physical', 'exercise', 'favourably', 'influences', 'cholesterol', 'distribution', 'in', 'serum', 'lipoproteins', 'in', 'healthy', 'middle', 'aged', 'men', 'and', 'may', 'have', 'beneficial', 'effects', 'on', 'circulating', 'metabolites', 'of', 'arachidonic', 'acid', '.']","(4, 8)","(21, 51)",-1,ss_i,6421395,Abstract,4,test,gold,2784.0
6854,Our data suggest that mild regular physical exercise favourably influences cholesterol distribution in,serum lipoproteins,in healthy middle aged men and may have beneficial effects on circulating metabolites of arachidonic acid .,"['Our', 'data', 'suggest', 'that', 'mild', 'regular', 'physical', 'exercise', 'favourably', 'influences', 'cholesterol', 'distribution', 'in', 'serum', 'lipoproteins', 'in', 'healthy', 'middle', 'aged', 'men', 'and', 'may', 'have', 'beneficial', 'effects', 'on', 'circulating', 'metabolites', 'of', 'arachidonic', 'acid', '.']","(13, 15)","(102, 120)",-1,ss_o,6421395,Abstract,4,test,gold,4477.0
6855,Our data suggest that mild regular physical exercise favourably influences cholesterol distribution in serum lipoproteins in healthy middle aged men and may have beneficial effects on,circulating metabolites of arachidonic acid .,,"['Our', 'data', 'suggest', 'that', 'mild', 'regular', 'physical', 'exercise', 'favourably', 'influences', 'cholesterol', 'distribution', 'in', 'serum', 'lipoproteins', 'in', 'healthy', 'middle', 'aged', 'men', 'and', 'may', 'have', 'beneficial', 'effects', 'on', 'circulating', 'metabolites', 'of', 'arachidonic', 'acid', '.']","(26, 32)","(183, 228)",-1,ss_o,6421395,Abstract,4,test,gold,4670.0
6856,Our data suggest that mild regular physical exercise favourably influences cholesterol distribution in serum lipoproteins in,healthy middle aged men,and may have beneficial effects on circulating metabolites of arachidonic acid .,"['Our', 'data', 'suggest', 'that', 'mild', 'regular', 'physical', 'exercise', 'favourably', 'influences', 'cholesterol', 'distribution', 'in', 'serum', 'lipoproteins', 'in', 'healthy', 'middle', 'aged', 'men', 'and', 'may', 'have', 'beneficial', 'effects', 'on', 'circulating', 'metabolites', 'of', 'arachidonic', 'acid', '.']","(16, 20)","(124, 147)",-1,hl_p,6421395,Abstract,4,test,gold,2034.0
6857,Our data suggest that,mild regular physical exercise,favourably influences cholesterol distribution in serum lipoproteins in healthy middle aged men and may have beneficial effects on circulating metabolites of arachidonic acid .,"['Our', 'data', 'suggest', 'that', 'mild', 'regular', 'physical', 'exercise', 'favourably', 'influences', 'cholesterol', 'distribution', 'in', 'serum', 'lipoproteins', 'in', 'healthy', 'middle', 'aged', 'men', 'and', 'may', 'have', 'beneficial', 'effects', 'on', 'circulating', 'metabolites', 'of', 'arachidonic', 'acid', '.']","(4, 8)","(21, 51)",-1,hl_i,6421395,Abstract,4,test,gold,2785.0
6858,Our data suggest that mild regular physical exercise favourably influences cholesterol distribution in,serum lipoproteins,in healthy middle aged men and may have beneficial effects on circulating metabolites of arachidonic acid .,"['Our', 'data', 'suggest', 'that', 'mild', 'regular', 'physical', 'exercise', 'favourably', 'influences', 'cholesterol', 'distribution', 'in', 'serum', 'lipoproteins', 'in', 'healthy', 'middle', 'aged', 'men', 'and', 'may', 'have', 'beneficial', 'effects', 'on', 'circulating', 'metabolites', 'of', 'arachidonic', 'acid', '.']","(13, 15)","(102, 120)",-1,hl_o,6421395,Abstract,4,test,gold,4475.0
6859,Our data suggest that mild regular physical exercise favourably influences cholesterol distribution in serum lipoproteins in healthy middle aged men and may have beneficial effects on,circulating metabolites of arachidonic acid .,,"['Our', 'data', 'suggest', 'that', 'mild', 'regular', 'physical', 'exercise', 'favourably', 'influences', 'cholesterol', 'distribution', 'in', 'serum', 'lipoproteins', 'in', 'healthy', 'middle', 'aged', 'men', 'and', 'may', 'have', 'beneficial', 'effects', 'on', 'circulating', 'metabolites', 'of', 'arachidonic', 'acid', '.']","(26, 32)","(183, 228)",-1,hl_o,6421395,Abstract,4,test,gold,4671.0
6860,Experimental hyaline membrane disease in,the premature monkey :,effects of antenatal dexamethasone .,"['Experimental', 'hyaline', 'membrane', 'disease', 'in', 'the', 'premature', 'monkey', ':', 'effects', 'of', 'antenatal', 'dexamethasone', '.']","(5, 9)","(40, 62)",-1,ss_p,6920252,Title,0,test,gold,951.0
6861,Experimental hyaline membrane disease in the premature monkey : effects of antenatal,dexamethasone .,,"['Experimental', 'hyaline', 'membrane', 'disease', 'in', 'the', 'premature', 'monkey', ':', 'effects', 'of', 'antenatal', 'dexamethasone', '.']","(12, 14)","(84, 99)",-1,ss_i,6920252,Title,0,test,gold,5123.0
6862,Experimental hyaline membrane disease in,the premature monkey :,effects of antenatal dexamethasone .,"['Experimental', 'hyaline', 'membrane', 'disease', 'in', 'the', 'premature', 'monkey', ':', 'effects', 'of', 'antenatal', 'dexamethasone', '.']","(5, 9)","(40, 62)",-1,hl_p,6920252,Title,0,test,gold,952.0
6863,Experimental hyaline membrane disease in the premature monkey : effects of antenatal,dexamethasone .,,"['Experimental', 'hyaline', 'membrane', 'disease', 'in', 'the', 'premature', 'monkey', ':', 'effects', 'of', 'antenatal', 'dexamethasone', '.']","(12, 14)","(84, 99)",-1,hl_i,6920252,Title,0,test,gold,5122.0
6864,"A blind , randomized trial of antenatal glucocorticoid treatment was conducted using the",premature monkey ( Macaca nemestrina ) model of hyaline membrane disease ( HMD ) .,,"['A', 'blind', ',', 'randomized', 'trial', 'of', 'antenatal', 'glucocorticoid', 'treatment', 'was', 'conducted', 'using', 'the', 'premature', 'monkey', '(', 'Macaca', 'nemestrina', ')', 'model', 'of', 'hyaline', 'membrane', 'disease', '(', 'HMD', ')', '.']","(13, 28)","(88, 170)",-1,ss_p,6920252,Abstract,0,test,gold,6655.0
6865,"A blind , randomized trial of antenatal",glucocorticoid,treatment was conducted using the premature monkey ( Macaca nemestrina ) model of hyaline membrane disease ( HMD ) .,"['A', 'blind', ',', 'randomized', 'trial', 'of', 'antenatal', 'glucocorticoid', 'treatment', 'was', 'conducted', 'using', 'the', 'premature', 'monkey', '(', 'Macaca', 'nemestrina', ')', 'model', 'of', 'hyaline', 'membrane', 'disease', '(', 'HMD', ')', '.']","(7, 8)","(39, 53)",-1,ss_i,6920252,Abstract,0,test,gold,5505.0
6866,"A blind , randomized trial of antenatal glucocorticoid treatment was conducted using the",premature monkey ( Macaca nemestrina ) model of hyaline membrane disease ( HMD ) .,,"['A', 'blind', ',', 'randomized', 'trial', 'of', 'antenatal', 'glucocorticoid', 'treatment', 'was', 'conducted', 'using', 'the', 'premature', 'monkey', '(', 'Macaca', 'nemestrina', ')', 'model', 'of', 'hyaline', 'membrane', 'disease', '(', 'HMD', ')', '.']","(13, 28)","(88, 170)",-1,hl_p,6920252,Abstract,0,test,gold,6656.0
6867,"A blind , randomized trial of antenatal",glucocorticoid,treatment was conducted using the premature monkey ( Macaca nemestrina ) model of hyaline membrane disease ( HMD ) .,"['A', 'blind', ',', 'randomized', 'trial', 'of', 'antenatal', 'glucocorticoid', 'treatment', 'was', 'conducted', 'using', 'the', 'premature', 'monkey', '(', 'Macaca', 'nemestrina', ')', 'model', 'of', 'hyaline', 'membrane', 'disease', '(', 'HMD', ')', '.']","(7, 8)","(39, 53)",-1,hl_i,6920252,Abstract,0,test,gold,5506.0
6868,,Twelve dams,"received dexamethasone ( 2 mg/dose ) 72 , 48 , and 24 h before abdominal delivery at 135 +/- 1 days of gestation .","['Twelve', 'dams', 'received', 'dexamethasone', '(', '2', 'mg/dose', ')', '72', ',', '48', ',', 'and', '24', 'h', 'before', 'abdominal', 'delivery', 'at', '135', '+/-', '1', 'days', 'of', 'gestation', '.']","(0, 2)","(0, 11)",-1,ss_p,6920252,Abstract,1,test,gold,2053.0
6869,Twelve dams received,dexamethasone,"( 2 mg/dose ) 72 , 48 , and 24 h before abdominal delivery at 135 +/- 1 days of gestation .","['Twelve', 'dams', 'received', 'dexamethasone', '(', '2', 'mg/dose', ')', '72', ',', '48', ',', 'and', '24', 'h', 'before', 'abdominal', 'delivery', 'at', '135', '+/-', '1', 'days', 'of', 'gestation', '.']","(3, 4)","(20, 33)",-1,ss_i,6920252,Abstract,1,test,gold,5121.0
6870,,Twelve dams,"received dexamethasone ( 2 mg/dose ) 72 , 48 , and 24 h before abdominal delivery at 135 +/- 1 days of gestation .","['Twelve', 'dams', 'received', 'dexamethasone', '(', '2', 'mg/dose', ')', '72', ',', '48', ',', 'and', '24', 'h', 'before', 'abdominal', 'delivery', 'at', '135', '+/-', '1', 'days', 'of', 'gestation', '.']","(0, 2)","(0, 11)",-1,hl_p,6920252,Abstract,1,test,gold,2054.0
6871,Twelve dams received,dexamethasone,"( 2 mg/dose ) 72 , 48 , and 24 h before abdominal delivery at 135 +/- 1 days of gestation .","['Twelve', 'dams', 'received', 'dexamethasone', '(', '2', 'mg/dose', ')', '72', ',', '48', ',', 'and', '24', 'h', 'before', 'abdominal', 'delivery', 'at', '135', '+/-', '1', 'days', 'of', 'gestation', '.']","(3, 4)","(20, 33)",-1,hl_i,6920252,Abstract,1,test,gold,5120.0
6872,,Twelve control animals,received saline .,"['Twelve', 'control', 'animals', 'received', 'saline', '.']","(0, 3)","(0, 22)",-1,ss_p,6920252,Abstract,2,test,gold,2051.0
6873,Twelve control animals received,saline .,,"['Twelve', 'control', 'animals', 'received', 'saline', '.']","(4, 6)","(31, 39)",-1,ss_i,6920252,Abstract,2,test,gold,4915.0
6874,,Twelve control animals,received saline .,"['Twelve', 'control', 'animals', 'received', 'saline', '.']","(0, 3)","(0, 22)",-1,hl_p,6920252,Abstract,2,test,gold,2052.0
6875,Twelve control animals received,saline .,,"['Twelve', 'control', 'animals', 'received', 'saline', '.']","(4, 6)","(31, 39)",-1,hl_i,6920252,Abstract,2,test,gold,4914.0
6876,Infants of,dexamethasone-treated,"dams had significantly lower incidence and severity of HMD than did infants of control animals ( 50 versus 92 % , p less than 0.05 ) .","['Infants', 'of', 'dexamethasone-treated', 'dams', 'had', 'significantly', 'lower', 'incidence', 'and', 'severity', 'of', 'HMD', 'than', 'did', 'infants', 'of', 'control', 'animals', '(', '50', 'versus', '92', '%', ',', 'p', 'less', 'than', '0.05', ')', '.']","(2, 3)","(10, 31)",-1,ss_i,6920252,Abstract,3,test,gold,
6877,Infants of dexamethasone-treated dams had significantly lower,incidence and severity of HMD,"than did infants of control animals ( 50 versus 92 % , p less than 0.05 ) .","['Infants', 'of', 'dexamethasone-treated', 'dams', 'had', 'significantly', 'lower', 'incidence', 'and', 'severity', 'of', 'HMD', 'than', 'did', 'infants', 'of', 'control', 'animals', '(', '50', 'versus', '92', '%', ',', 'p', 'less', 'than', '0.05', ')', '.']","(7, 12)","(61, 90)",-1,ss_o,6920252,Abstract,3,test,gold,3343.0
6878,Infants of,dexamethasone-treated,"dams had significantly lower incidence and severity of HMD than did infants of control animals ( 50 versus 92 % , p less than 0.05 ) .","['Infants', 'of', 'dexamethasone-treated', 'dams', 'had', 'significantly', 'lower', 'incidence', 'and', 'severity', 'of', 'HMD', 'than', 'did', 'infants', 'of', 'control', 'animals', '(', '50', 'versus', '92', '%', ',', 'p', 'less', 'than', '0.05', ')', '.']","(2, 3)","(10, 31)",-1,hl_i,6920252,Abstract,3,test,gold,
6879,Infants of dexamethasone-treated dams had significantly lower,incidence and severity of HMD,"than did infants of control animals ( 50 versus 92 % , p less than 0.05 ) .","['Infants', 'of', 'dexamethasone-treated', 'dams', 'had', 'significantly', 'lower', 'incidence', 'and', 'severity', 'of', 'HMD', 'than', 'did', 'infants', 'of', 'control', 'animals', '(', '50', 'versus', '92', '%', ',', 'p', 'less', 'than', '0.05', ')', '.']","(7, 12)","(61, 90)",-1,hl_o,6920252,Abstract,3,test,gold,3344.0
6880,Improvement with treatment was markedly greater for males than for females .,,,"['Improvement', 'with', 'treatment', 'was', 'markedly', 'greater', 'for', 'males', 'than', 'for', 'females', '.']",,,,,6920252,Abstract,4,test,gold,
6881,Differences in volume-pressure behavior of the excised lungs included greater distensibility in the infants from,dexamethasone-treated,"dams ( 20.6 +/- 7.1 ml/g dry lung versus 14.7 +/- 6.1 , p less than 0.05 ) and enhanced deflation stability with treatment .","['Differences', 'in', 'volume-pressure', 'behavior', 'of', 'the', 'excised', 'lungs', 'included', 'greater', 'distensibility', 'in', 'the', 'infants', 'from', 'dexamethasone-treated', 'dams', '(', '20.6', '+/-', '7.1', 'ml/g', 'dry', 'lung', 'versus', '14.7', '+/-', '6.1', ',', 'p', 'less', 'than', '0.05', ')', 'and', 'enhanced', 'deflation', 'stability', 'with', 'treatment', '.']","(15, 16)","(112, 133)",-1,ss_i,6920252,Abstract,5,test,gold,
6882,Differences in,volume-pressure behavior,"of the excised lungs included greater distensibility in the infants from dexamethasone-treated dams ( 20.6 +/- 7.1 ml/g dry lung versus 14.7 +/- 6.1 , p less than 0.05 ) and enhanced deflation stability with treatment .","['Differences', 'in', 'volume-pressure', 'behavior', 'of', 'the', 'excised', 'lungs', 'included', 'greater', 'distensibility', 'in', 'the', 'infants', 'from', 'dexamethasone-treated', 'dams', '(', '20.6', '+/-', '7.1', 'ml/g', 'dry', 'lung', 'versus', '14.7', '+/-', '6.1', ',', 'p', 'less', 'than', '0.05', ')', 'and', 'enhanced', 'deflation', 'stability', 'with', 'treatment', '.']","(2, 4)","(14, 38)",-1,ss_o,6920252,Abstract,5,test,gold,2601.0
6883,Differences in volume-pressure behavior of the excised lungs included greater,distensibility,"in the infants from dexamethasone-treated dams ( 20.6 +/- 7.1 ml/g dry lung versus 14.7 +/- 6.1 , p less than 0.05 ) and enhanced deflation stability with treatment .","['Differences', 'in', 'volume-pressure', 'behavior', 'of', 'the', 'excised', 'lungs', 'included', 'greater', 'distensibility', 'in', 'the', 'infants', 'from', 'dexamethasone-treated', 'dams', '(', '20.6', '+/-', '7.1', 'ml/g', 'dry', 'lung', 'versus', '14.7', '+/-', '6.1', ',', 'p', 'less', 'than', '0.05', ')', 'and', 'enhanced', 'deflation', 'stability', 'with', 'treatment', '.']","(10, 11)","(77, 91)",-1,ss_o,6920252,Abstract,5,test,gold,70.0
6884,"Differences in volume-pressure behavior of the excised lungs included greater distensibility in the infants from dexamethasone-treated dams ( 20.6 +/- 7.1 ml/g dry lung versus 14.7 +/- 6.1 , p less than 0.05 ) and enhanced",deflation stability,with treatment .,"['Differences', 'in', 'volume-pressure', 'behavior', 'of', 'the', 'excised', 'lungs', 'included', 'greater', 'distensibility', 'in', 'the', 'infants', 'from', 'dexamethasone-treated', 'dams', '(', '20.6', '+/-', '7.1', 'ml/g', 'dry', 'lung', 'versus', '14.7', '+/-', '6.1', ',', 'p', 'less', 'than', '0.05', ')', 'and', 'enhanced', 'deflation', 'stability', 'with', 'treatment', '.']","(36, 38)","(222, 241)",-1,ss_o,6920252,Abstract,5,test,gold,2643.0
6885,Differences in volume-pressure behavior of the excised lungs included greater distensibility in the infants from,dexamethasone-treated,"dams ( 20.6 +/- 7.1 ml/g dry lung versus 14.7 +/- 6.1 , p less than 0.05 ) and enhanced deflation stability with treatment .","['Differences', 'in', 'volume-pressure', 'behavior', 'of', 'the', 'excised', 'lungs', 'included', 'greater', 'distensibility', 'in', 'the', 'infants', 'from', 'dexamethasone-treated', 'dams', '(', '20.6', '+/-', '7.1', 'ml/g', 'dry', 'lung', 'versus', '14.7', '+/-', '6.1', ',', 'p', 'less', 'than', '0.05', ')', 'and', 'enhanced', 'deflation', 'stability', 'with', 'treatment', '.']","(15, 16)","(112, 133)",-1,hl_i,6920252,Abstract,5,test,gold,
6886,Differences in,volume-pressure behavior,"of the excised lungs included greater distensibility in the infants from dexamethasone-treated dams ( 20.6 +/- 7.1 ml/g dry lung versus 14.7 +/- 6.1 , p less than 0.05 ) and enhanced deflation stability with treatment .","['Differences', 'in', 'volume-pressure', 'behavior', 'of', 'the', 'excised', 'lungs', 'included', 'greater', 'distensibility', 'in', 'the', 'infants', 'from', 'dexamethasone-treated', 'dams', '(', '20.6', '+/-', '7.1', 'ml/g', 'dry', 'lung', 'versus', '14.7', '+/-', '6.1', ',', 'p', 'less', 'than', '0.05', ')', 'and', 'enhanced', 'deflation', 'stability', 'with', 'treatment', '.']","(2, 4)","(14, 38)",-1,hl_o,6920252,Abstract,5,test,gold,2602.0
6887,Differences in volume-pressure behavior of the excised lungs included greater,distensibility,"in the infants from dexamethasone-treated dams ( 20.6 +/- 7.1 ml/g dry lung versus 14.7 +/- 6.1 , p less than 0.05 ) and enhanced deflation stability with treatment .","['Differences', 'in', 'volume-pressure', 'behavior', 'of', 'the', 'excised', 'lungs', 'included', 'greater', 'distensibility', 'in', 'the', 'infants', 'from', 'dexamethasone-treated', 'dams', '(', '20.6', '+/-', '7.1', 'ml/g', 'dry', 'lung', 'versus', '14.7', '+/-', '6.1', ',', 'p', 'less', 'than', '0.05', ')', 'and', 'enhanced', 'deflation', 'stability', 'with', 'treatment', '.']","(10, 11)","(77, 91)",-1,hl_o,6920252,Abstract,5,test,gold,71.0
6888,"Differences in volume-pressure behavior of the excised lungs included greater distensibility in the infants from dexamethasone-treated dams ( 20.6 +/- 7.1 ml/g dry lung versus 14.7 +/- 6.1 , p less than 0.05 ) and enhanced",deflation stability,with treatment .,"['Differences', 'in', 'volume-pressure', 'behavior', 'of', 'the', 'excised', 'lungs', 'included', 'greater', 'distensibility', 'in', 'the', 'infants', 'from', 'dexamethasone-treated', 'dams', '(', '20.6', '+/-', '7.1', 'ml/g', 'dry', 'lung', 'versus', '14.7', '+/-', '6.1', ',', 'p', 'less', 'than', '0.05', ')', 'and', 'enhanced', 'deflation', 'stability', 'with', 'treatment', '.']","(36, 38)","(222, 241)",-1,hl_o,6920252,Abstract,5,test,gold,2644.0
6889,Accelerated production of surface active material ( SAM ) phospholipids in infants from,dexamethasone-treated,"dams was indicated by increases in total lung phospholipid ( 84.5 +/- 8.1 mg/g dry lung versus 75.1 +/- 9.9 , p less than 0.025 ) , alveolar lavage fluid phospholipid ( 5.65 +/- 3.33 mg/g dry lung versus 3.01 +/- 1.84 , p less than 0.05 ) , and alveolar lavage fluid disaturated phosphatidylcholine ( DPC ) ( 2.47 +/- 1.84 mg/g dry lung versus 1.06 +/- 1.05 , p less than 0.05 ) .","['Accelerated', 'production', 'of', 'surface', 'active', 'material', '(', 'SAM', ')', 'phospholipids', 'in', 'infants', 'from', 'dexamethasone-treated', 'dams', 'was', 'indicated', 'by', 'increases', 'in', 'total', 'lung', 'phospholipid', '(', '84.5', '+/-', '8.1', 'mg/g', 'dry', 'lung', 'versus', '75.1', '+/-', '9.9', ',', 'p', 'less', 'than', '0.025', ')', ',', 'alveolar', 'lavage', 'fluid', 'phospholipid', '(', '5.65', '+/-', '3.33', 'mg/g', 'dry', 'lung', 'versus', '3.01', '+/-', '1.84', ',', 'p', 'less', 'than', '0.05', ')', ',', 'and', 'alveolar', 'lavage', 'fluid', 'disaturated', 'phosphatidylcholine', '(', 'DPC', ')', '(', '2.47', '+/-', '1.84', 'mg/g', 'dry', 'lung', 'versus', '1.06', '+/-', '1.05', ',', 'p', 'less', 'than', '0.05', ')', '.']","(13, 14)","(87, 108)",-1,ss_i,6920252,Abstract,6,test,gold,
6890,Accelerated,production of surface active material ( SAM ) phospholipids,"in infants from dexamethasone-treated dams was indicated by increases in total lung phospholipid ( 84.5 +/- 8.1 mg/g dry lung versus 75.1 +/- 9.9 , p less than 0.025 ) , alveolar lavage fluid phospholipid ( 5.65 +/- 3.33 mg/g dry lung versus 3.01 +/- 1.84 , p less than 0.05 ) , and alveolar lavage fluid disaturated phosphatidylcholine ( DPC ) ( 2.47 +/- 1.84 mg/g dry lung versus 1.06 +/- 1.05 , p less than 0.05 ) .","['Accelerated', 'production', 'of', 'surface', 'active', 'material', '(', 'SAM', ')', 'phospholipids', 'in', 'infants', 'from', 'dexamethasone-treated', 'dams', 'was', 'indicated', 'by', 'increases', 'in', 'total', 'lung', 'phospholipid', '(', '84.5', '+/-', '8.1', 'mg/g', 'dry', 'lung', 'versus', '75.1', '+/-', '9.9', ',', 'p', 'less', 'than', '0.025', ')', ',', 'alveolar', 'lavage', 'fluid', 'phospholipid', '(', '5.65', '+/-', '3.33', 'mg/g', 'dry', 'lung', 'versus', '3.01', '+/-', '1.84', ',', 'p', 'less', 'than', '0.05', ')', ',', 'and', 'alveolar', 'lavage', 'fluid', 'disaturated', 'phosphatidylcholine', '(', 'DPC', ')', '(', '2.47', '+/-', '1.84', 'mg/g', 'dry', 'lung', 'versus', '1.06', '+/-', '1.05', ',', 'p', 'less', 'than', '0.05', ')', '.']","(1, 10)","(11, 70)",-1,ss_o,6920252,Abstract,6,test,gold,4676.0
6891,Accelerated production of surface active material ( SAM ) phospholipids in infants from dexamethasone-treated dams was indicated by increases in,total lung phospholipid,"( 84.5 +/- 8.1 mg/g dry lung versus 75.1 +/- 9.9 , p less than 0.025 ) , alveolar lavage fluid phospholipid ( 5.65 +/- 3.33 mg/g dry lung versus 3.01 +/- 1.84 , p less than 0.05 ) , and alveolar lavage fluid disaturated phosphatidylcholine ( DPC ) ( 2.47 +/- 1.84 mg/g dry lung versus 1.06 +/- 1.05 , p less than 0.05 ) .","['Accelerated', 'production', 'of', 'surface', 'active', 'material', '(', 'SAM', ')', 'phospholipids', 'in', 'infants', 'from', 'dexamethasone-treated', 'dams', 'was', 'indicated', 'by', 'increases', 'in', 'total', 'lung', 'phospholipid', '(', '84.5', '+/-', '8.1', 'mg/g', 'dry', 'lung', 'versus', '75.1', '+/-', '9.9', ',', 'p', 'less', 'than', '0.025', ')', ',', 'alveolar', 'lavage', 'fluid', 'phospholipid', '(', '5.65', '+/-', '3.33', 'mg/g', 'dry', 'lung', 'versus', '3.01', '+/-', '1.84', ',', 'p', 'less', 'than', '0.05', ')', ',', 'and', 'alveolar', 'lavage', 'fluid', 'disaturated', 'phosphatidylcholine', '(', 'DPC', ')', '(', '2.47', '+/-', '1.84', 'mg/g', 'dry', 'lung', 'versus', '1.06', '+/-', '1.05', ',', 'p', 'less', 'than', '0.05', ')', '.']","(20, 23)","(144, 167)",-1,ss_o,6920252,Abstract,6,test,gold,3174.0
6892,"Accelerated production of surface active material ( SAM ) phospholipids in infants from dexamethasone-treated dams was indicated by increases in total lung phospholipid ( 84.5 +/- 8.1 mg/g dry lung versus 75.1 +/- 9.9 , p less than 0.025 ) ,",alveolar lavage fluid phospholipid,"( 5.65 +/- 3.33 mg/g dry lung versus 3.01 +/- 1.84 , p less than 0.05 ) , and alveolar lavage fluid disaturated phosphatidylcholine ( DPC ) ( 2.47 +/- 1.84 mg/g dry lung versus 1.06 +/- 1.05 , p less than 0.05 ) .","['Accelerated', 'production', 'of', 'surface', 'active', 'material', '(', 'SAM', ')', 'phospholipids', 'in', 'infants', 'from', 'dexamethasone-treated', 'dams', 'was', 'indicated', 'by', 'increases', 'in', 'total', 'lung', 'phospholipid', '(', '84.5', '+/-', '8.1', 'mg/g', 'dry', 'lung', 'versus', '75.1', '+/-', '9.9', ',', 'p', 'less', 'than', '0.025', ')', ',', 'alveolar', 'lavage', 'fluid', 'phospholipid', '(', '5.65', '+/-', '3.33', 'mg/g', 'dry', 'lung', 'versus', '3.01', '+/-', '1.84', ',', 'p', 'less', 'than', '0.05', ')', ',', 'and', 'alveolar', 'lavage', 'fluid', 'disaturated', 'phosphatidylcholine', '(', 'DPC', ')', '(', '2.47', '+/-', '1.84', 'mg/g', 'dry', 'lung', 'versus', '1.06', '+/-', '1.05', ',', 'p', 'less', 'than', '0.05', ')', '.']","(41, 45)","(241, 275)",-1,ss_o,6920252,Abstract,6,test,gold,6802.0
6893,"Accelerated production of surface active material ( SAM ) phospholipids in infants from dexamethasone-treated dams was indicated by increases in total lung phospholipid ( 84.5 +/- 8.1 mg/g dry lung versus 75.1 +/- 9.9 , p less than 0.025 ) , alveolar lavage fluid phospholipid ( 5.65 +/- 3.33 mg/g dry lung versus 3.01 +/- 1.84 , p less than 0.05 ) , and",alveolar lavage fluid disaturated phosphatidylcholine,"( DPC ) ( 2.47 +/- 1.84 mg/g dry lung versus 1.06 +/- 1.05 , p less than 0.05 ) .","['Accelerated', 'production', 'of', 'surface', 'active', 'material', '(', 'SAM', ')', 'phospholipids', 'in', 'infants', 'from', 'dexamethasone-treated', 'dams', 'was', 'indicated', 'by', 'increases', 'in', 'total', 'lung', 'phospholipid', '(', '84.5', '+/-', '8.1', 'mg/g', 'dry', 'lung', 'versus', '75.1', '+/-', '9.9', ',', 'p', 'less', 'than', '0.025', ')', ',', 'alveolar', 'lavage', 'fluid', 'phospholipid', '(', '5.65', '+/-', '3.33', 'mg/g', 'dry', 'lung', 'versus', '3.01', '+/-', '1.84', ',', 'p', 'less', 'than', '0.05', ')', ',', 'and', 'alveolar', 'lavage', 'fluid', 'disaturated', 'phosphatidylcholine', '(', 'DPC', ')', '(', '2.47', '+/-', '1.84', 'mg/g', 'dry', 'lung', 'versus', '1.06', '+/-', '1.05', ',', 'p', 'less', 'than', '0.05', ')', '.']","(64, 69)","(354, 407)",-1,ss_o,6920252,Abstract,6,test,gold,6800.0
6894,Accelerated production of surface active material ( SAM ) phospholipids in infants from,dexamethasone-treated,"dams was indicated by increases in total lung phospholipid ( 84.5 +/- 8.1 mg/g dry lung versus 75.1 +/- 9.9 , p less than 0.025 ) , alveolar lavage fluid phospholipid ( 5.65 +/- 3.33 mg/g dry lung versus 3.01 +/- 1.84 , p less than 0.05 ) , and alveolar lavage fluid disaturated phosphatidylcholine ( DPC ) ( 2.47 +/- 1.84 mg/g dry lung versus 1.06 +/- 1.05 , p less than 0.05 ) .","['Accelerated', 'production', 'of', 'surface', 'active', 'material', '(', 'SAM', ')', 'phospholipids', 'in', 'infants', 'from', 'dexamethasone-treated', 'dams', 'was', 'indicated', 'by', 'increases', 'in', 'total', 'lung', 'phospholipid', '(', '84.5', '+/-', '8.1', 'mg/g', 'dry', 'lung', 'versus', '75.1', '+/-', '9.9', ',', 'p', 'less', 'than', '0.025', ')', ',', 'alveolar', 'lavage', 'fluid', 'phospholipid', '(', '5.65', '+/-', '3.33', 'mg/g', 'dry', 'lung', 'versus', '3.01', '+/-', '1.84', ',', 'p', 'less', 'than', '0.05', ')', ',', 'and', 'alveolar', 'lavage', 'fluid', 'disaturated', 'phosphatidylcholine', '(', 'DPC', ')', '(', '2.47', '+/-', '1.84', 'mg/g', 'dry', 'lung', 'versus', '1.06', '+/-', '1.05', ',', 'p', 'less', 'than', '0.05', ')', '.']","(13, 14)","(87, 108)",-1,hl_i,6920252,Abstract,6,test,gold,
6895,Accelerated,production of surface active material ( SAM ) phospholipids,"in infants from dexamethasone-treated dams was indicated by increases in total lung phospholipid ( 84.5 +/- 8.1 mg/g dry lung versus 75.1 +/- 9.9 , p less than 0.025 ) , alveolar lavage fluid phospholipid ( 5.65 +/- 3.33 mg/g dry lung versus 3.01 +/- 1.84 , p less than 0.05 ) , and alveolar lavage fluid disaturated phosphatidylcholine ( DPC ) ( 2.47 +/- 1.84 mg/g dry lung versus 1.06 +/- 1.05 , p less than 0.05 ) .","['Accelerated', 'production', 'of', 'surface', 'active', 'material', '(', 'SAM', ')', 'phospholipids', 'in', 'infants', 'from', 'dexamethasone-treated', 'dams', 'was', 'indicated', 'by', 'increases', 'in', 'total', 'lung', 'phospholipid', '(', '84.5', '+/-', '8.1', 'mg/g', 'dry', 'lung', 'versus', '75.1', '+/-', '9.9', ',', 'p', 'less', 'than', '0.025', ')', ',', 'alveolar', 'lavage', 'fluid', 'phospholipid', '(', '5.65', '+/-', '3.33', 'mg/g', 'dry', 'lung', 'versus', '3.01', '+/-', '1.84', ',', 'p', 'less', 'than', '0.05', ')', ',', 'and', 'alveolar', 'lavage', 'fluid', 'disaturated', 'phosphatidylcholine', '(', 'DPC', ')', '(', '2.47', '+/-', '1.84', 'mg/g', 'dry', 'lung', 'versus', '1.06', '+/-', '1.05', ',', 'p', 'less', 'than', '0.05', ')', '.']","(1, 10)","(11, 70)",-1,hl_o,6920252,Abstract,6,test,gold,4677.0
6896,Accelerated production of surface active material ( SAM ) phospholipids in infants from dexamethasone-treated dams was indicated by increases in,total lung phospholipid,"( 84.5 +/- 8.1 mg/g dry lung versus 75.1 +/- 9.9 , p less than 0.025 ) , alveolar lavage fluid phospholipid ( 5.65 +/- 3.33 mg/g dry lung versus 3.01 +/- 1.84 , p less than 0.05 ) , and alveolar lavage fluid disaturated phosphatidylcholine ( DPC ) ( 2.47 +/- 1.84 mg/g dry lung versus 1.06 +/- 1.05 , p less than 0.05 ) .","['Accelerated', 'production', 'of', 'surface', 'active', 'material', '(', 'SAM', ')', 'phospholipids', 'in', 'infants', 'from', 'dexamethasone-treated', 'dams', 'was', 'indicated', 'by', 'increases', 'in', 'total', 'lung', 'phospholipid', '(', '84.5', '+/-', '8.1', 'mg/g', 'dry', 'lung', 'versus', '75.1', '+/-', '9.9', ',', 'p', 'less', 'than', '0.025', ')', ',', 'alveolar', 'lavage', 'fluid', 'phospholipid', '(', '5.65', '+/-', '3.33', 'mg/g', 'dry', 'lung', 'versus', '3.01', '+/-', '1.84', ',', 'p', 'less', 'than', '0.05', ')', ',', 'and', 'alveolar', 'lavage', 'fluid', 'disaturated', 'phosphatidylcholine', '(', 'DPC', ')', '(', '2.47', '+/-', '1.84', 'mg/g', 'dry', 'lung', 'versus', '1.06', '+/-', '1.05', ',', 'p', 'less', 'than', '0.05', ')', '.']","(20, 23)","(144, 167)",-1,hl_o,6920252,Abstract,6,test,gold,3175.0
6897,"Accelerated production of surface active material ( SAM ) phospholipids in infants from dexamethasone-treated dams was indicated by increases in total lung phospholipid ( 84.5 +/- 8.1 mg/g dry lung versus 75.1 +/- 9.9 , p less than 0.025 ) ,",alveolar lavage fluid phospholipid,"( 5.65 +/- 3.33 mg/g dry lung versus 3.01 +/- 1.84 , p less than 0.05 ) , and alveolar lavage fluid disaturated phosphatidylcholine ( DPC ) ( 2.47 +/- 1.84 mg/g dry lung versus 1.06 +/- 1.05 , p less than 0.05 ) .","['Accelerated', 'production', 'of', 'surface', 'active', 'material', '(', 'SAM', ')', 'phospholipids', 'in', 'infants', 'from', 'dexamethasone-treated', 'dams', 'was', 'indicated', 'by', 'increases', 'in', 'total', 'lung', 'phospholipid', '(', '84.5', '+/-', '8.1', 'mg/g', 'dry', 'lung', 'versus', '75.1', '+/-', '9.9', ',', 'p', 'less', 'than', '0.025', ')', ',', 'alveolar', 'lavage', 'fluid', 'phospholipid', '(', '5.65', '+/-', '3.33', 'mg/g', 'dry', 'lung', 'versus', '3.01', '+/-', '1.84', ',', 'p', 'less', 'than', '0.05', ')', ',', 'and', 'alveolar', 'lavage', 'fluid', 'disaturated', 'phosphatidylcholine', '(', 'DPC', ')', '(', '2.47', '+/-', '1.84', 'mg/g', 'dry', 'lung', 'versus', '1.06', '+/-', '1.05', ',', 'p', 'less', 'than', '0.05', ')', '.']","(41, 45)","(241, 275)",-1,hl_o,6920252,Abstract,6,test,gold,6803.0
6898,"Accelerated production of surface active material ( SAM ) phospholipids in infants from dexamethasone-treated dams was indicated by increases in total lung phospholipid ( 84.5 +/- 8.1 mg/g dry lung versus 75.1 +/- 9.9 , p less than 0.025 ) , alveolar lavage fluid phospholipid ( 5.65 +/- 3.33 mg/g dry lung versus 3.01 +/- 1.84 , p less than 0.05 ) , and",alveolar lavage fluid disaturated phosphatidylcholine,"( DPC ) ( 2.47 +/- 1.84 mg/g dry lung versus 1.06 +/- 1.05 , p less than 0.05 ) .","['Accelerated', 'production', 'of', 'surface', 'active', 'material', '(', 'SAM', ')', 'phospholipids', 'in', 'infants', 'from', 'dexamethasone-treated', 'dams', 'was', 'indicated', 'by', 'increases', 'in', 'total', 'lung', 'phospholipid', '(', '84.5', '+/-', '8.1', 'mg/g', 'dry', 'lung', 'versus', '75.1', '+/-', '9.9', ',', 'p', 'less', 'than', '0.025', ')', ',', 'alveolar', 'lavage', 'fluid', 'phospholipid', '(', '5.65', '+/-', '3.33', 'mg/g', 'dry', 'lung', 'versus', '3.01', '+/-', '1.84', ',', 'p', 'less', 'than', '0.05', ')', ',', 'and', 'alveolar', 'lavage', 'fluid', 'disaturated', 'phosphatidylcholine', '(', 'DPC', ')', '(', '2.47', '+/-', '1.84', 'mg/g', 'dry', 'lung', 'versus', '1.06', '+/-', '1.05', ',', 'p', 'less', 'than', '0.05', ')', '.']","(64, 69)","(354, 407)",-1,hl_o,6920252,Abstract,6,test,gold,6801.0
6899,Incorporation of 14C-palmitate into lung lipid was not influenced by,dexamethasone,", but a significantly greater portion of the label appeared in the DPC fraction with treatment .","['Incorporation', 'of', '14C-palmitate', 'into', 'lung', 'lipid', 'was', 'not', 'influenced', 'by', 'dexamethasone', ',', 'but', 'a', 'significantly', 'greater', 'portion', 'of', 'the', 'label', 'appeared', 'in', 'the', 'DPC', 'fraction', 'with', 'treatment', '.']","(10, 11)","(68, 81)",-1,ss_i,6920252,Abstract,7,test,gold,5119.0
6900,Incorporation of,14C-palmitate,"into lung lipid was not influenced by dexamethasone , but a significantly greater portion of the label appeared in the DPC fraction with treatment .","['Incorporation', 'of', '14C-palmitate', 'into', 'lung', 'lipid', 'was', 'not', 'influenced', 'by', 'dexamethasone', ',', 'but', 'a', 'significantly', 'greater', 'portion', 'of', 'the', 'label', 'appeared', 'in', 'the', 'DPC', 'fraction', 'with', 'treatment', '.']","(2, 3)","(16, 29)",-1,ss_o,6920252,Abstract,7,test,gold,
6901,Incorporation of 14C-palmitate into,lung lipid,"was not influenced by dexamethasone , but a significantly greater portion of the label appeared in the DPC fraction with treatment .","['Incorporation', 'of', '14C-palmitate', 'into', 'lung', 'lipid', 'was', 'not', 'influenced', 'by', 'dexamethasone', ',', 'but', 'a', 'significantly', 'greater', 'portion', 'of', 'the', 'label', 'appeared', 'in', 'the', 'DPC', 'fraction', 'with', 'treatment', '.']","(4, 6)","(35, 45)",-1,ss_o,6920252,Abstract,7,test,gold,3172.0
6902,"Incorporation of 14C-palmitate into lung lipid was not influenced by dexamethasone , but a significantly greater portion of the label appeared in the",DPC fraction,with treatment .,"['Incorporation', 'of', '14C-palmitate', 'into', 'lung', 'lipid', 'was', 'not', 'influenced', 'by', 'dexamethasone', ',', 'but', 'a', 'significantly', 'greater', 'portion', 'of', 'the', 'label', 'appeared', 'in', 'the', 'DPC', 'fraction', 'with', 'treatment', '.']","(23, 25)","(149, 161)",-1,ss_o,6920252,Abstract,7,test,gold,1148.0
6903,Incorporation of 14C-palmitate into lung lipid was not influenced by,dexamethasone,", but a significantly greater portion of the label appeared in the DPC fraction with treatment .","['Incorporation', 'of', '14C-palmitate', 'into', 'lung', 'lipid', 'was', 'not', 'influenced', 'by', 'dexamethasone', ',', 'but', 'a', 'significantly', 'greater', 'portion', 'of', 'the', 'label', 'appeared', 'in', 'the', 'DPC', 'fraction', 'with', 'treatment', '.']","(10, 11)","(68, 81)",-1,hl_i,6920252,Abstract,7,test,gold,5118.0
6904,Incorporation of,14C-palmitate,"into lung lipid was not influenced by dexamethasone , but a significantly greater portion of the label appeared in the DPC fraction with treatment .","['Incorporation', 'of', '14C-palmitate', 'into', 'lung', 'lipid', 'was', 'not', 'influenced', 'by', 'dexamethasone', ',', 'but', 'a', 'significantly', 'greater', 'portion', 'of', 'the', 'label', 'appeared', 'in', 'the', 'DPC', 'fraction', 'with', 'treatment', '.']","(2, 3)","(16, 29)",-1,hl_o,6920252,Abstract,7,test,gold,
6905,Incorporation of 14C-palmitate into,lung lipid,"was not influenced by dexamethasone , but a significantly greater portion of the label appeared in the DPC fraction with treatment .","['Incorporation', 'of', '14C-palmitate', 'into', 'lung', 'lipid', 'was', 'not', 'influenced', 'by', 'dexamethasone', ',', 'but', 'a', 'significantly', 'greater', 'portion', 'of', 'the', 'label', 'appeared', 'in', 'the', 'DPC', 'fraction', 'with', 'treatment', '.']","(4, 6)","(35, 45)",-1,hl_o,6920252,Abstract,7,test,gold,3173.0
6906,Antenatal dexamethasone treatment was successful in reducing the incidence and severity of experimental HMD,in this animal model ;,"the beneficial effects of treatment were associated with accelerated maturation of fetal pulmonary functions , including , but not limited to , synthetic metabolism of SAM phospholipid .","['Antenatal', 'dexamethasone', 'treatment', 'was', 'successful', 'in', 'reducing', 'the', 'incidence', 'and', 'severity', 'of', 'experimental', 'HMD', 'in', 'this', 'animal', 'model', ';', 'the', 'beneficial', 'effects', 'of', 'treatment', 'were', 'associated', 'with', 'accelerated', 'maturation', 'of', 'fetal', 'pulmonary', 'functions', ',', 'including', ',', 'but', 'not', 'limited', 'to', ',', 'synthetic', 'metabolism', 'of', 'SAM', 'phospholipid', '.']","(14, 19)","(107, 129)",-1,ss_p,6920252,Abstract,8,test,gold,954.0
6907,Antenatal,dexamethasone,"treatment was successful in reducing the incidence and severity of experimental HMD in this animal model ; the beneficial effects of treatment were associated with accelerated maturation of fetal pulmonary functions , including , but not limited to , synthetic metabolism of SAM phospholipid .","['Antenatal', 'dexamethasone', 'treatment', 'was', 'successful', 'in', 'reducing', 'the', 'incidence', 'and', 'severity', 'of', 'experimental', 'HMD', 'in', 'this', 'animal', 'model', ';', 'the', 'beneficial', 'effects', 'of', 'treatment', 'were', 'associated', 'with', 'accelerated', 'maturation', 'of', 'fetal', 'pulmonary', 'functions', ',', 'including', ',', 'but', 'not', 'limited', 'to', ',', 'synthetic', 'metabolism', 'of', 'SAM', 'phospholipid', '.']","(1, 2)","(9, 22)",-1,ss_i,6920252,Abstract,8,test,gold,5117.0
6908,Antenatal dexamethasone treatment was successful in reducing the,incidence and severity of experimental HMD,"in this animal model ; the beneficial effects of treatment were associated with accelerated maturation of fetal pulmonary functions , including , but not limited to , synthetic metabolism of SAM phospholipid .","['Antenatal', 'dexamethasone', 'treatment', 'was', 'successful', 'in', 'reducing', 'the', 'incidence', 'and', 'severity', 'of', 'experimental', 'HMD', 'in', 'this', 'animal', 'model', ';', 'the', 'beneficial', 'effects', 'of', 'treatment', 'were', 'associated', 'with', 'accelerated', 'maturation', 'of', 'fetal', 'pulmonary', 'functions', ',', 'including', ',', 'but', 'not', 'limited', 'to', ',', 'synthetic', 'metabolism', 'of', 'SAM', 'phospholipid', '.']","(8, 14)","(64, 106)",-1,ss_o,6920252,Abstract,8,test,gold,3341.0
6909,Antenatal dexamethasone treatment was successful in reducing the incidence and severity of experimental HMD in this animal model ; the beneficial,effects,"of treatment were associated with accelerated maturation of fetal pulmonary functions , including , but not limited to , synthetic metabolism of SAM phospholipid .","['Antenatal', 'dexamethasone', 'treatment', 'was', 'successful', 'in', 'reducing', 'the', 'incidence', 'and', 'severity', 'of', 'experimental', 'HMD', 'in', 'this', 'animal', 'model', ';', 'the', 'beneficial', 'effects', 'of', 'treatment', 'were', 'associated', 'with', 'accelerated', 'maturation', 'of', 'fetal', 'pulmonary', 'functions', ',', 'including', ',', 'but', 'not', 'limited', 'to', ',', 'synthetic', 'metabolism', 'of', 'SAM', 'phospholipid', '.']","(21, 22)","(145, 152)",-1,ss_o,6920252,Abstract,8,test,gold,2375.0
6910,Antenatal dexamethasone treatment was successful in reducing the incidence and severity of experimental HMD in this animal model ; the beneficial effects of treatment were associated with accelerated maturation of,fetal pulmonary functions,", including , but not limited to , synthetic metabolism of SAM phospholipid .","['Antenatal', 'dexamethasone', 'treatment', 'was', 'successful', 'in', 'reducing', 'the', 'incidence', 'and', 'severity', 'of', 'experimental', 'HMD', 'in', 'this', 'animal', 'model', ';', 'the', 'beneficial', 'effects', 'of', 'treatment', 'were', 'associated', 'with', 'accelerated', 'maturation', 'of', 'fetal', 'pulmonary', 'functions', ',', 'including', ',', 'but', 'not', 'limited', 'to', ',', 'synthetic', 'metabolism', 'of', 'SAM', 'phospholipid', '.']","(30, 33)","(213, 238)",-1,ss_o,6920252,Abstract,8,test,gold,3142.0
6911,Antenatal,dexamethasone,"treatment was successful in reducing the incidence and severity of experimental HMD in this animal model ; the beneficial effects of treatment were associated with accelerated maturation of fetal pulmonary functions , including , but not limited to , synthetic metabolism of SAM phospholipid .","['Antenatal', 'dexamethasone', 'treatment', 'was', 'successful', 'in', 'reducing', 'the', 'incidence', 'and', 'severity', 'of', 'experimental', 'HMD', 'in', 'this', 'animal', 'model', ';', 'the', 'beneficial', 'effects', 'of', 'treatment', 'were', 'associated', 'with', 'accelerated', 'maturation', 'of', 'fetal', 'pulmonary', 'functions', ',', 'including', ',', 'but', 'not', 'limited', 'to', ',', 'synthetic', 'metabolism', 'of', 'SAM', 'phospholipid', '.']","(1, 2)","(9, 22)",-1,hl_i,6920252,Abstract,8,test,gold,5116.0
6912,Antenatal dexamethasone treatment was successful in reducing the,incidence and severity of experimental HMD,"in this animal model ; the beneficial effects of treatment were associated with accelerated maturation of fetal pulmonary functions , including , but not limited to , synthetic metabolism of SAM phospholipid .","['Antenatal', 'dexamethasone', 'treatment', 'was', 'successful', 'in', 'reducing', 'the', 'incidence', 'and', 'severity', 'of', 'experimental', 'HMD', 'in', 'this', 'animal', 'model', ';', 'the', 'beneficial', 'effects', 'of', 'treatment', 'were', 'associated', 'with', 'accelerated', 'maturation', 'of', 'fetal', 'pulmonary', 'functions', ',', 'including', ',', 'but', 'not', 'limited', 'to', ',', 'synthetic', 'metabolism', 'of', 'SAM', 'phospholipid', '.']","(8, 14)","(64, 106)",-1,hl_o,6920252,Abstract,8,test,gold,3342.0
6913,Antenatal dexamethasone treatment was successful in reducing the incidence and severity of experimental HMD in this animal model ; the beneficial effects of treatment were associated with accelerated maturation of,fetal pulmonary functions,", including , but not limited to , synthetic metabolism of SAM phospholipid .","['Antenatal', 'dexamethasone', 'treatment', 'was', 'successful', 'in', 'reducing', 'the', 'incidence', 'and', 'severity', 'of', 'experimental', 'HMD', 'in', 'this', 'animal', 'model', ';', 'the', 'beneficial', 'effects', 'of', 'treatment', 'were', 'associated', 'with', 'accelerated', 'maturation', 'of', 'fetal', 'pulmonary', 'functions', ',', 'including', ',', 'but', 'not', 'limited', 'to', ',', 'synthetic', 'metabolism', 'of', 'SAM', 'phospholipid', '.']","(30, 33)","(213, 238)",-1,hl_o,6920252,Abstract,8,test,gold,3143.0
6914,EORTC protocols in,prostatic cancer .,,"['EORTC', 'protocols', 'in', 'prostatic', 'cancer', '.']","(3, 6)","(18, 36)",-1,ss_p,6938020,Title,0,test,gold,6886.0
6915,EORTC protocols in,prostatic cancer .,,"['EORTC', 'protocols', 'in', 'prostatic', 'cancer', '.']","(3, 6)","(18, 36)",-1,hl_p,6938020,Title,0,test,gold,6887.0
6916,An interim report .,,,"['An', 'interim', 'report', '.']",,,,,6938020,Abstract,0,test,gold,
6917,Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in,previously untreated patients with prostatic cancer,"in order to compare low dose Stilboestrol versus Cyproterone acetate versus Medroxyprogesterone acetate in the first trial , and Stilboestrol versus Estracyt in the second trial .","['Two', 'parallel', 'prospective', 'randomized', 'studies', 'have', 'been', 'undertaken', 'by', 'the', 'EORTC', 'Urological', 'Group', 'in', 'previously', 'untreated', 'patients', 'with', 'prostatic', 'cancer', 'in', 'order', 'to', 'compare', 'low', 'dose', 'Stilboestrol', 'versus', 'Cyproterone', 'acetate', 'versus', 'Medroxyprogesterone', 'acetate', 'in', 'the', 'first', 'trial', ',', 'and', 'Stilboestrol', 'versus', 'Estracyt', 'in', 'the', 'second', 'trial', '.']","(14, 20)","(97, 148)",-1,ss_p,6938020,Abstract,1,test,gold,6843.0
6918,Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in previously untreated patients with prostatic cancer in order to compare low dose,Stilboestrol,"versus Cyproterone acetate versus Medroxyprogesterone acetate in the first trial , and Stilboestrol versus Estracyt in the second trial .","['Two', 'parallel', 'prospective', 'randomized', 'studies', 'have', 'been', 'undertaken', 'by', 'the', 'EORTC', 'Urological', 'Group', 'in', 'previously', 'untreated', 'patients', 'with', 'prostatic', 'cancer', 'in', 'order', 'to', 'compare', 'low', 'dose', 'Stilboestrol', 'versus', 'Cyproterone', 'acetate', 'versus', 'Medroxyprogesterone', 'acetate', 'in', 'the', 'first', 'trial', ',', 'and', 'Stilboestrol', 'versus', 'Estracyt', 'in', 'the', 'second', 'trial', '.']","(26, 27)","(178, 190)",-1,ss_i,6938020,Abstract,1,test,gold,
6919,Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in previously untreated patients with prostatic cancer in order to compare low dose Stilboestrol versus,Cyproterone acetate,"versus Medroxyprogesterone acetate in the first trial , and Stilboestrol versus Estracyt in the second trial .","['Two', 'parallel', 'prospective', 'randomized', 'studies', 'have', 'been', 'undertaken', 'by', 'the', 'EORTC', 'Urological', 'Group', 'in', 'previously', 'untreated', 'patients', 'with', 'prostatic', 'cancer', 'in', 'order', 'to', 'compare', 'low', 'dose', 'Stilboestrol', 'versus', 'Cyproterone', 'acetate', 'versus', 'Medroxyprogesterone', 'acetate', 'in', 'the', 'first', 'trial', ',', 'and', 'Stilboestrol', 'versus', 'Estracyt', 'in', 'the', 'second', 'trial', '.']","(28, 30)","(198, 217)",-1,ss_i,6938020,Abstract,1,test,gold,298.0
6920,Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in previously untreated patients with prostatic cancer in order to compare low dose Stilboestrol versus Cyproterone acetate versus,Medroxyprogesterone acetate,"in the first trial , and Stilboestrol versus Estracyt in the second trial .","['Two', 'parallel', 'prospective', 'randomized', 'studies', 'have', 'been', 'undertaken', 'by', 'the', 'EORTC', 'Urological', 'Group', 'in', 'previously', 'untreated', 'patients', 'with', 'prostatic', 'cancer', 'in', 'order', 'to', 'compare', 'low', 'dose', 'Stilboestrol', 'versus', 'Cyproterone', 'acetate', 'versus', 'Medroxyprogesterone', 'acetate', 'in', 'the', 'first', 'trial', ',', 'and', 'Stilboestrol', 'versus', 'Estracyt', 'in', 'the', 'second', 'trial', '.']","(31, 33)","(225, 252)",-1,ss_i,6938020,Abstract,1,test,gold,297.0
6921,"Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in previously untreated patients with prostatic cancer in order to compare low dose Stilboestrol versus Cyproterone acetate versus Medroxyprogesterone acetate in the first trial , and",Stilboestrol,versus Estracyt in the second trial .,"['Two', 'parallel', 'prospective', 'randomized', 'studies', 'have', 'been', 'undertaken', 'by', 'the', 'EORTC', 'Urological', 'Group', 'in', 'previously', 'untreated', 'patients', 'with', 'prostatic', 'cancer', 'in', 'order', 'to', 'compare', 'low', 'dose', 'Stilboestrol', 'versus', 'Cyproterone', 'acetate', 'versus', 'Medroxyprogesterone', 'acetate', 'in', 'the', 'first', 'trial', ',', 'and', 'Stilboestrol', 'versus', 'Estracyt', 'in', 'the', 'second', 'trial', '.']","(39, 40)","(278, 290)",-1,ss_i,6938020,Abstract,1,test,gold,
6922,"Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in previously untreated patients with prostatic cancer in order to compare low dose Stilboestrol versus Cyproterone acetate versus Medroxyprogesterone acetate in the first trial , and Stilboestrol versus",Estracyt,in the second trial .,"['Two', 'parallel', 'prospective', 'randomized', 'studies', 'have', 'been', 'undertaken', 'by', 'the', 'EORTC', 'Urological', 'Group', 'in', 'previously', 'untreated', 'patients', 'with', 'prostatic', 'cancer', 'in', 'order', 'to', 'compare', 'low', 'dose', 'Stilboestrol', 'versus', 'Cyproterone', 'acetate', 'versus', 'Medroxyprogesterone', 'acetate', 'in', 'the', 'first', 'trial', ',', 'and', 'Stilboestrol', 'versus', 'Estracyt', 'in', 'the', 'second', 'trial', '.']","(41, 42)","(298, 306)",-1,ss_i,6938020,Abstract,1,test,gold,
6923,Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in,previously untreated patients with prostatic cancer,"in order to compare low dose Stilboestrol versus Cyproterone acetate versus Medroxyprogesterone acetate in the first trial , and Stilboestrol versus Estracyt in the second trial .","['Two', 'parallel', 'prospective', 'randomized', 'studies', 'have', 'been', 'undertaken', 'by', 'the', 'EORTC', 'Urological', 'Group', 'in', 'previously', 'untreated', 'patients', 'with', 'prostatic', 'cancer', 'in', 'order', 'to', 'compare', 'low', 'dose', 'Stilboestrol', 'versus', 'Cyproterone', 'acetate', 'versus', 'Medroxyprogesterone', 'acetate', 'in', 'the', 'first', 'trial', ',', 'and', 'Stilboestrol', 'versus', 'Estracyt', 'in', 'the', 'second', 'trial', '.']","(14, 20)","(97, 148)",-1,hl_p,6938020,Abstract,1,test,gold,6844.0
6924,Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in previously untreated patients with prostatic cancer in order to compare low dose,Stilboestrol,"versus Cyproterone acetate versus Medroxyprogesterone acetate in the first trial , and Stilboestrol versus Estracyt in the second trial .","['Two', 'parallel', 'prospective', 'randomized', 'studies', 'have', 'been', 'undertaken', 'by', 'the', 'EORTC', 'Urological', 'Group', 'in', 'previously', 'untreated', 'patients', 'with', 'prostatic', 'cancer', 'in', 'order', 'to', 'compare', 'low', 'dose', 'Stilboestrol', 'versus', 'Cyproterone', 'acetate', 'versus', 'Medroxyprogesterone', 'acetate', 'in', 'the', 'first', 'trial', ',', 'and', 'Stilboestrol', 'versus', 'Estracyt', 'in', 'the', 'second', 'trial', '.']","(26, 27)","(178, 190)",-1,hl_i,6938020,Abstract,1,test,gold,
6925,Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in previously untreated patients with prostatic cancer in order to compare low dose Stilboestrol versus,Cyproterone acetate,"versus Medroxyprogesterone acetate in the first trial , and Stilboestrol versus Estracyt in the second trial .","['Two', 'parallel', 'prospective', 'randomized', 'studies', 'have', 'been', 'undertaken', 'by', 'the', 'EORTC', 'Urological', 'Group', 'in', 'previously', 'untreated', 'patients', 'with', 'prostatic', 'cancer', 'in', 'order', 'to', 'compare', 'low', 'dose', 'Stilboestrol', 'versus', 'Cyproterone', 'acetate', 'versus', 'Medroxyprogesterone', 'acetate', 'in', 'the', 'first', 'trial', ',', 'and', 'Stilboestrol', 'versus', 'Estracyt', 'in', 'the', 'second', 'trial', '.']","(28, 30)","(198, 217)",-1,hl_i,6938020,Abstract,1,test,gold,296.0
6926,Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in previously untreated patients with prostatic cancer in order to compare low dose Stilboestrol versus Cyproterone acetate versus,Medroxyprogesterone acetate,"in the first trial , and Stilboestrol versus Estracyt in the second trial .","['Two', 'parallel', 'prospective', 'randomized', 'studies', 'have', 'been', 'undertaken', 'by', 'the', 'EORTC', 'Urological', 'Group', 'in', 'previously', 'untreated', 'patients', 'with', 'prostatic', 'cancer', 'in', 'order', 'to', 'compare', 'low', 'dose', 'Stilboestrol', 'versus', 'Cyproterone', 'acetate', 'versus', 'Medroxyprogesterone', 'acetate', 'in', 'the', 'first', 'trial', ',', 'and', 'Stilboestrol', 'versus', 'Estracyt', 'in', 'the', 'second', 'trial', '.']","(31, 33)","(225, 252)",-1,hl_i,6938020,Abstract,1,test,gold,295.0
6927,"Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in previously untreated patients with prostatic cancer in order to compare low dose Stilboestrol versus Cyproterone acetate versus Medroxyprogesterone acetate in the first trial , and",Stilboestrol,versus Estracyt in the second trial .,"['Two', 'parallel', 'prospective', 'randomized', 'studies', 'have', 'been', 'undertaken', 'by', 'the', 'EORTC', 'Urological', 'Group', 'in', 'previously', 'untreated', 'patients', 'with', 'prostatic', 'cancer', 'in', 'order', 'to', 'compare', 'low', 'dose', 'Stilboestrol', 'versus', 'Cyproterone', 'acetate', 'versus', 'Medroxyprogesterone', 'acetate', 'in', 'the', 'first', 'trial', ',', 'and', 'Stilboestrol', 'versus', 'Estracyt', 'in', 'the', 'second', 'trial', '.']","(39, 40)","(278, 290)",-1,hl_i,6938020,Abstract,1,test,gold,
6928,"Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in previously untreated patients with prostatic cancer in order to compare low dose Stilboestrol versus Cyproterone acetate versus Medroxyprogesterone acetate in the first trial , and Stilboestrol versus",Estracyt,in the second trial .,"['Two', 'parallel', 'prospective', 'randomized', 'studies', 'have', 'been', 'undertaken', 'by', 'the', 'EORTC', 'Urological', 'Group', 'in', 'previously', 'untreated', 'patients', 'with', 'prostatic', 'cancer', 'in', 'order', 'to', 'compare', 'low', 'dose', 'Stilboestrol', 'versus', 'Cyproterone', 'acetate', 'versus', 'Medroxyprogesterone', 'acetate', 'in', 'the', 'first', 'trial', ',', 'and', 'Stilboestrol', 'versus', 'Estracyt', 'in', 'the', 'second', 'trial', '.']","(41, 42)","(298, 306)",-1,hl_i,6938020,Abstract,1,test,gold,
6929,"Although the follow up is still short , no superiority of the other drugs over",Stilboestrol,had appeared so far with regard to either objective response or significant side effects apart from gynaecomastia .,"['Although', 'the', 'follow', 'up', 'is', 'still', 'short', ',', 'no', 'superiority', 'of', 'the', 'other', 'drugs', 'over', 'Stilboestrol', 'had', 'appeared', 'so', 'far', 'with', 'regard', 'to', 'either', 'objective', 'response', 'or', 'significant', 'side', 'effects', 'apart', 'from', 'gynaecomastia', '.']","(15, 16)","(78, 90)",-1,ss_i,6938020,Abstract,2,test,gold,
6930,"Although the follow up is still short , no superiority of the other drugs over Stilboestrol had appeared so far with regard to either objective response or significant",side effects,apart from gynaecomastia .,"['Although', 'the', 'follow', 'up', 'is', 'still', 'short', ',', 'no', 'superiority', 'of', 'the', 'other', 'drugs', 'over', 'Stilboestrol', 'had', 'appeared', 'so', 'far', 'with', 'regard', 'to', 'either', 'objective', 'response', 'or', 'significant', 'side', 'effects', 'apart', 'from', 'gynaecomastia', '.']","(28, 30)","(167, 179)",-1,ss_o,6938020,Abstract,2,test,gold,2369.0
6931,"Although the follow up is still short , no superiority of the other drugs over Stilboestrol had appeared so far with regard to either objective response or significant side effects apart from",gynaecomastia .,,"['Although', 'the', 'follow', 'up', 'is', 'still', 'short', ',', 'no', 'superiority', 'of', 'the', 'other', 'drugs', 'over', 'Stilboestrol', 'had', 'appeared', 'so', 'far', 'with', 'regard', 'to', 'either', 'objective', 'response', 'or', 'significant', 'side', 'effects', 'apart', 'from', 'gynaecomastia', '.']","(32, 34)","(191, 206)",-1,ss_o,6938020,Abstract,2,test,gold,58.0
6932,"Although the follow up is still short , no superiority of the other drugs over",Stilboestrol,had appeared so far with regard to either objective response or significant side effects apart from gynaecomastia .,"['Although', 'the', 'follow', 'up', 'is', 'still', 'short', ',', 'no', 'superiority', 'of', 'the', 'other', 'drugs', 'over', 'Stilboestrol', 'had', 'appeared', 'so', 'far', 'with', 'regard', 'to', 'either', 'objective', 'response', 'or', 'significant', 'side', 'effects', 'apart', 'from', 'gynaecomastia', '.']","(15, 16)","(78, 90)",-1,hl_i,6938020,Abstract,2,test,gold,
6933,"Although the follow up is still short , no superiority of the other drugs over Stilboestrol had appeared so far with regard to either objective response or significant",side effects,apart from gynaecomastia .,"['Although', 'the', 'follow', 'up', 'is', 'still', 'short', ',', 'no', 'superiority', 'of', 'the', 'other', 'drugs', 'over', 'Stilboestrol', 'had', 'appeared', 'so', 'far', 'with', 'regard', 'to', 'either', 'objective', 'response', 'or', 'significant', 'side', 'effects', 'apart', 'from', 'gynaecomastia', '.']","(28, 30)","(167, 179)",-1,hl_o,6938020,Abstract,2,test,gold,2368.0
6934,"Although the follow up is still short , no superiority of the other drugs over Stilboestrol had appeared so far with regard to either objective response or significant side effects apart from",gynaecomastia .,,"['Although', 'the', 'follow', 'up', 'is', 'still', 'short', ',', 'no', 'superiority', 'of', 'the', 'other', 'drugs', 'over', 'Stilboestrol', 'had', 'appeared', 'so', 'far', 'with', 'regard', 'to', 'either', 'objective', 'response', 'or', 'significant', 'side', 'effects', 'apart', 'from', 'gynaecomastia', '.']","(32, 34)","(191, 206)",-1,hl_o,6938020,Abstract,2,test,gold,59.0
6935,"In the third trial ,",patients with advanced disease no longer responsive to hormonal treatment,were randomized to either Adriamycin or Procarbazine .,"['In', 'the', 'third', 'trial', ',', 'patients', 'with', 'advanced', 'disease', 'no', 'longer', 'responsive', 'to', 'hormonal', 'treatment', 'were', 'randomized', 'to', 'either', 'Adriamycin', 'or', 'Procarbazine', '.']","(5, 15)","(20, 93)",-1,ss_p,6938020,Abstract,3,test,gold,5935.0
6936,"In the third trial , patients with advanced disease no longer responsive to hormonal treatment were randomized to either",Adriamycin,or Procarbazine .,"['In', 'the', 'third', 'trial', ',', 'patients', 'with', 'advanced', 'disease', 'no', 'longer', 'responsive', 'to', 'hormonal', 'treatment', 'were', 'randomized', 'to', 'either', 'Adriamycin', 'or', 'Procarbazine', '.']","(19, 20)","(120, 130)",-1,ss_i,6938020,Abstract,3,test,gold,5733.0
6937,"In the third trial , patients with advanced disease no longer responsive to hormonal treatment were randomized to either Adriamycin or",Procarbazine .,,"['In', 'the', 'third', 'trial', ',', 'patients', 'with', 'advanced', 'disease', 'no', 'longer', 'responsive', 'to', 'hormonal', 'treatment', 'were', 'randomized', 'to', 'either', 'Adriamycin', 'or', 'Procarbazine', '.']","(21, 23)","(134, 148)",-1,ss_i,6938020,Abstract,3,test,gold,
6938,"In the third trial ,",patients with advanced disease no longer responsive to hormonal treatment,were randomized to either Adriamycin or Procarbazine .,"['In', 'the', 'third', 'trial', ',', 'patients', 'with', 'advanced', 'disease', 'no', 'longer', 'responsive', 'to', 'hormonal', 'treatment', 'were', 'randomized', 'to', 'either', 'Adriamycin', 'or', 'Procarbazine', '.']","(5, 15)","(20, 93)",-1,hl_p,6938020,Abstract,3,test,gold,5936.0
6939,"In the third trial , patients with advanced disease no longer responsive to hormonal treatment were randomized to either",Adriamycin,or Procarbazine .,"['In', 'the', 'third', 'trial', ',', 'patients', 'with', 'advanced', 'disease', 'no', 'longer', 'responsive', 'to', 'hormonal', 'treatment', 'were', 'randomized', 'to', 'either', 'Adriamycin', 'or', 'Procarbazine', '.']","(19, 20)","(120, 130)",-1,hl_i,6938020,Abstract,3,test,gold,5734.0
6940,"In the third trial , patients with advanced disease no longer responsive to hormonal treatment were randomized to either Adriamycin or",Procarbazine .,,"['In', 'the', 'third', 'trial', ',', 'patients', 'with', 'advanced', 'disease', 'no', 'longer', 'responsive', 'to', 'hormonal', 'treatment', 'were', 'randomized', 'to', 'either', 'Adriamycin', 'or', 'Procarbazine', '.']","(21, 23)","(134, 148)",-1,hl_i,6938020,Abstract,3,test,gold,
6941,Toxicity and early death were particularly frequent in,Procarbazine,"treated patients , whereas most patients progressed in both treatment groups .","['Toxicity', 'and', 'early', 'death', 'were', 'particularly', 'frequent', 'in', 'Procarbazine', 'treated', 'patients', ',', 'whereas', 'most', 'patients', 'progressed', 'in', 'both', 'treatment', 'groups', '.']","(8, 9)","(54, 66)",-1,ss_i,6938020,Abstract,4,test,gold,
6942,,Toxicity and early death,"were particularly frequent in Procarbazine treated patients , whereas most patients progressed in both treatment groups .","['Toxicity', 'and', 'early', 'death', 'were', 'particularly', 'frequent', 'in', 'Procarbazine', 'treated', 'patients', ',', 'whereas', 'most', 'patients', 'progressed', 'in', 'both', 'treatment', 'groups', '.']","(0, 4)","(0, 24)",-1,ss_o,6938020,Abstract,4,test,gold,3489.0
6943,Toxicity and early death were particularly frequent in,Procarbazine,"treated patients , whereas most patients progressed in both treatment groups .","['Toxicity', 'and', 'early', 'death', 'were', 'particularly', 'frequent', 'in', 'Procarbazine', 'treated', 'patients', ',', 'whereas', 'most', 'patients', 'progressed', 'in', 'both', 'treatment', 'groups', '.']","(8, 9)","(54, 66)",-1,hl_i,6938020,Abstract,4,test,gold,
6944,,Toxicity and early death,"were particularly frequent in Procarbazine treated patients , whereas most patients progressed in both treatment groups .","['Toxicity', 'and', 'early', 'death', 'were', 'particularly', 'frequent', 'in', 'Procarbazine', 'treated', 'patients', ',', 'whereas', 'most', 'patients', 'progressed', 'in', 'both', 'treatment', 'groups', '.']","(0, 4)","(0, 24)",-1,hl_o,6938020,Abstract,4,test,gold,3490.0
6945,A controlled study of,psychiatric hospital,versus community treatment - the effect on relatives .,"['A', 'controlled', 'study', 'of', 'psychiatric', 'hospital', 'versus', 'community', 'treatment', '-', 'the', 'effect', 'on', 'relatives', '.']","(4, 6)","(21, 41)",-1,ss_i,6951573,Title,0,test,gold,3831.0
6946,A controlled study of psychiatric hospital versus,community treatment,- the effect on relatives .,"['A', 'controlled', 'study', 'of', 'psychiatric', 'hospital', 'versus', 'community', 'treatment', '-', 'the', 'effect', 'on', 'relatives', '.']","(7, 9)","(49, 68)",-1,ss_i,6951573,Title,0,test,gold,3986.0
6947,A controlled study of psychiatric hospital versus community treatment - the,effect on relatives .,,"['A', 'controlled', 'study', 'of', 'psychiatric', 'hospital', 'versus', 'community', 'treatment', '-', 'the', 'effect', 'on', 'relatives', '.']","(11, 15)","(75, 96)",-1,ss_o,6951573,Title,0,test,gold,2329.0
6948,A controlled study of,psychiatric hospital,versus community treatment - the effect on relatives .,"['A', 'controlled', 'study', 'of', 'psychiatric', 'hospital', 'versus', 'community', 'treatment', '-', 'the', 'effect', 'on', 'relatives', '.']","(4, 6)","(21, 41)",-1,hl_i,6951573,Title,0,test,gold,3832.0
6949,A controlled study of psychiatric hospital versus,community treatment,- the effect on relatives .,"['A', 'controlled', 'study', 'of', 'psychiatric', 'hospital', 'versus', 'community', 'treatment', '-', 'the', 'effect', 'on', 'relatives', '.']","(7, 9)","(49, 68)",-1,hl_i,6951573,Title,0,test,gold,3987.0
6950,A controlled study of psychiatric hospital versus community treatment - the,effect on relatives .,,"['A', 'controlled', 'study', 'of', 'psychiatric', 'hospital', 'versus', 'community', 'treatment', '-', 'the', 'effect', 'on', 'relatives', '.']","(11, 15)","(75, 96)",-1,hl_o,6951573,Title,0,test,gold,2330.0
6951,,One hundred and twenty patients presenting at Macquarie Hospital for admission,were randomly allocated into two groups .,"['One', 'hundred', 'and', 'twenty', 'patients', 'presenting', 'at', 'Macquarie', 'Hospital', 'for', 'admission', 'were', 'randomly', 'allocated', 'into', 'two', 'groups', '.']","(0, 11)","(0, 78)",-1,ss_p,6951573,Abstract,0,test,gold,5850.0
6952,,One hundred and twenty patients presenting at Macquarie Hospital for admission,were randomly allocated into two groups .,"['One', 'hundred', 'and', 'twenty', 'patients', 'presenting', 'at', 'Macquarie', 'Hospital', 'for', 'admission', 'were', 'randomly', 'allocated', 'into', 'two', 'groups', '.']","(0, 11)","(0, 78)",-1,hl_p,6951573,Abstract,0,test,gold,5851.0
6953,The control group patients received,standard hospital care and follow-up .,,"['The', 'control', 'group', 'patients', 'received', 'standard', 'hospital', 'care', 'and', 'follow-up', '.']","(5, 11)","(35, 73)",-1,ss_i,6951573,Abstract,1,test,gold,3955.0
6954,The control group patients received,standard hospital care and follow-up .,,"['The', 'control', 'group', 'patients', 'received', 'standard', 'hospital', 'care', 'and', 'follow-up', '.']","(5, 11)","(35, 73)",-1,hl_i,6951573,Abstract,1,test,gold,3956.0
6955,The project group patients were not admitted if this could be avoided ; instead they were,taken back to the community,"by the project team who provided them and their relatives with comprehensive , assertive and prolonged follow-up treatment backed by a 24-hour crisis service .","['The', 'project', 'group', 'patients', 'were', 'not', 'admitted', 'if', 'this', 'could', 'be', 'avoided', ';', 'instead', 'they', 'were', 'taken', 'back', 'to', 'the', 'community', 'by', 'the', 'project', 'team', 'who', 'provided', 'them', 'and', 'their', 'relatives', 'with', 'comprehensive', ',', 'assertive', 'and', 'prolonged', 'follow-up', 'treatment', 'backed', 'by', 'a', '24-hour', 'crisis', 'service', '.']","(16, 21)","(89, 116)",-1,ss_i,6951573,Abstract,2,test,gold,949.0
6956,"The project group patients were not admitted if this could be avoided ; instead they were taken back to the community by the project team who provided them and their relatives with comprehensive , assertive and prolonged",follow-up treatment,backed by a 24-hour crisis service .,"['The', 'project', 'group', 'patients', 'were', 'not', 'admitted', 'if', 'this', 'could', 'be', 'avoided', ';', 'instead', 'they', 'were', 'taken', 'back', 'to', 'the', 'community', 'by', 'the', 'project', 'team', 'who', 'provided', 'them', 'and', 'their', 'relatives', 'with', 'comprehensive', ',', 'assertive', 'and', 'prolonged', 'follow-up', 'treatment', 'backed', 'by', 'a', '24-hour', 'crisis', 'service', '.']","(37, 39)","(220, 239)",-1,ss_i,6951573,Abstract,2,test,gold,3993.0
6957,The project group patients were not admitted if this could be avoided ; instead they were taken,back to the community,"by the project team who provided them and their relatives with comprehensive , assertive and prolonged follow-up treatment backed by a 24-hour crisis service .","['The', 'project', 'group', 'patients', 'were', 'not', 'admitted', 'if', 'this', 'could', 'be', 'avoided', ';', 'instead', 'they', 'were', 'taken', 'back', 'to', 'the', 'community', 'by', 'the', 'project', 'team', 'who', 'provided', 'them', 'and', 'their', 'relatives', 'with', 'comprehensive', ',', 'assertive', 'and', 'prolonged', 'follow-up', 'treatment', 'backed', 'by', 'a', '24-hour', 'crisis', 'service', '.']","(17, 21)","(95, 116)",-1,hl_i,6951573,Abstract,2,test,gold,950.0
6958,"The project group patients were not admitted if this could be avoided ; instead they were taken back to the community by the project team who provided them and their relatives with comprehensive , assertive and prolonged",follow-up treatment,backed by a 24-hour crisis service .,"['The', 'project', 'group', 'patients', 'were', 'not', 'admitted', 'if', 'this', 'could', 'be', 'avoided', ';', 'instead', 'they', 'were', 'taken', 'back', 'to', 'the', 'community', 'by', 'the', 'project', 'team', 'who', 'provided', 'them', 'and', 'their', 'relatives', 'with', 'comprehensive', ',', 'assertive', 'and', 'prolonged', 'follow-up', 'treatment', 'backed', 'by', 'a', '24-hour', 'crisis', 'service', '.']","(37, 39)","(220, 239)",-1,hl_i,6951573,Abstract,2,test,gold,3992.0
6959,The majority ( 63 % ) of the project group had no,admission,during the 10 month study period .,"['The', 'majority', '(', '63', '%', ')', 'of', 'the', 'project', 'group', 'had', 'no', 'admission', 'during', 'the', '10', 'month', 'study', 'period', '.']","(12, 13)","(49, 58)",-1,ss_o,6951573,Abstract,3,test,gold,3823.0
6960,"Initially , the",burden on the relatives,"of the project group was higher , but by one month it was somewhat lower and by four months it was significantly lower than the burden on the control group relatives .","['Initially', ',', 'the', 'burden', 'on', 'the', 'relatives', 'of', 'the', 'project', 'group', 'was', 'higher', ',', 'but', 'by', 'one', 'month', 'it', 'was', 'somewhat', 'lower', 'and', 'by', 'four', 'months', 'it', 'was', 'significantly', 'lower', 'than', 'the', 'burden', 'on', 'the', 'control', 'group', 'relatives', '.']","(3, 7)","(15, 38)",-1,ss_o,6951573,Abstract,4,test,gold,2472.0
6961,"Initially , the burden on the relatives of the project group was higher , but by one month it was somewhat lower and by four months it was significantly lower than the",burden on the control group relatives .,,"['Initially', ',', 'the', 'burden', 'on', 'the', 'relatives', 'of', 'the', 'project', 'group', 'was', 'higher', ',', 'but', 'by', 'one', 'month', 'it', 'was', 'somewhat', 'lower', 'and', 'by', 'four', 'months', 'it', 'was', 'significantly', 'lower', 'than', 'the', 'burden', 'on', 'the', 'control', 'group', 'relatives', '.']","(32, 39)","(167, 206)",-1,ss_o,6951573,Abstract,4,test,gold,2471.0
6962,"Initially , the",burden on the relatives,"of the project group was higher , but by one month it was somewhat lower and by four months it was significantly lower than the burden on the control group relatives .","['Initially', ',', 'the', 'burden', 'on', 'the', 'relatives', 'of', 'the', 'project', 'group', 'was', 'higher', ',', 'but', 'by', 'one', 'month', 'it', 'was', 'somewhat', 'lower', 'and', 'by', 'four', 'months', 'it', 'was', 'significantly', 'lower', 'than', 'the', 'burden', 'on', 'the', 'control', 'group', 'relatives', '.']","(3, 7)","(15, 38)",-1,hl_o,6951573,Abstract,4,test,gold,2473.0
6963,Relatives of the project group patients were significantly more,satisfied,with the treatment than control group relatives .,"['Relatives', 'of', 'the', 'project', 'group', 'patients', 'were', 'significantly', 'more', 'satisfied', 'with', 'the', 'treatment', 'than', 'control', 'group', 'relatives', '.']","(9, 10)","(63, 72)",-1,ss_o,6951573,Abstract,5,test,gold,1237.0
6964,Relatives of the project group patients were significantly more,satisfied,with the treatment than control group relatives .,"['Relatives', 'of', 'the', 'project', 'group', 'patients', 'were', 'significantly', 'more', 'satisfied', 'with', 'the', 'treatment', 'than', 'control', 'group', 'relatives', '.']","(9, 10)","(63, 72)",-1,hl_o,6951573,Abstract,5,test,gold,1238.0
6965,It is clearly feasible to treat most,psychiatric patients,in the community without increasing the burden on their relatives .,"['It', 'is', 'clearly', 'feasible', 'to', 'treat', 'most', 'psychiatric', 'patients', 'in', 'the', 'community', 'without', 'increasing', 'the', 'burden', 'on', 'their', 'relatives', '.']","(7, 9)","(36, 56)",-1,ss_p,6951573,Abstract,6,test,gold,3828.0
6966,It is clearly feasible to treat most psychiatric patients in the community without increasing the,burden on their relatives .,,"['It', 'is', 'clearly', 'feasible', 'to', 'treat', 'most', 'psychiatric', 'patients', 'in', 'the', 'community', 'without', 'increasing', 'the', 'burden', 'on', 'their', 'relatives', '.']","(15, 20)","(97, 124)",-1,ss_o,6951573,Abstract,6,test,gold,2474.0
6967,It is clearly feasible to treat most,psychiatric patients,in the community without increasing the burden on their relatives .,"['It', 'is', 'clearly', 'feasible', 'to', 'treat', 'most', 'psychiatric', 'patients', 'in', 'the', 'community', 'without', 'increasing', 'the', 'burden', 'on', 'their', 'relatives', '.']","(7, 9)","(36, 56)",-1,hl_p,6951573,Abstract,6,test,gold,3829.0
6968,It is clearly feasible to treat most psychiatric patients in the community without increasing the,burden on their relatives .,,"['It', 'is', 'clearly', 'feasible', 'to', 'treat', 'most', 'psychiatric', 'patients', 'in', 'the', 'community', 'without', 'increasing', 'the', 'burden', 'on', 'their', 'relatives', '.']","(15, 20)","(97, 124)",-1,hl_o,6951573,Abstract,6,test,gold,2475.0
6969,Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with,"diet , clofibrate",and niceritrol .,"['Changes', 'in', 'the', 'fatty', 'acid', 'composition', 'of', 'the', 'plasma', 'lipid', 'esters', 'during', 'lipid-lowering', 'treatment', 'with', 'diet', ',', 'clofibrate', 'and', 'niceritrol', '.']","(15, 18)","(101, 118)",-1,ss_i,6989377,Title,0,test,gold,1538.0
6970,"Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet , clofibrate and",niceritrol .,,"['Changes', 'in', 'the', 'fatty', 'acid', 'composition', 'of', 'the', 'plasma', 'lipid', 'esters', 'during', 'lipid-lowering', 'treatment', 'with', 'diet', ',', 'clofibrate', 'and', 'niceritrol', '.']","(19, 21)","(123, 135)",-1,ss_i,6989377,Title,0,test,gold,
6971,,Changes in the fatty acid composition of the plasma lipid esters,"during lipid-lowering treatment with diet , clofibrate and niceritrol .","['Changes', 'in', 'the', 'fatty', 'acid', 'composition', 'of', 'the', 'plasma', 'lipid', 'esters', 'during', 'lipid-lowering', 'treatment', 'with', 'diet', ',', 'clofibrate', 'and', 'niceritrol', '.']","(0, 11)","(0, 64)",-1,ss_o,6989377,Title,0,test,gold,6498.0
6972,Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with,diet,", clofibrate and niceritrol .","['Changes', 'in', 'the', 'fatty', 'acid', 'composition', 'of', 'the', 'plasma', 'lipid', 'esters', 'during', 'lipid-lowering', 'treatment', 'with', 'diet', ',', 'clofibrate', 'and', 'niceritrol', '.']","(15, 16)","(101, 105)",-1,hl_i,6989377,Title,0,test,gold,1537.0
6973,"Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet ,",clofibrate,and niceritrol .,"['Changes', 'in', 'the', 'fatty', 'acid', 'composition', 'of', 'the', 'plasma', 'lipid', 'esters', 'during', 'lipid-lowering', 'treatment', 'with', 'diet', ',', 'clofibrate', 'and', 'niceritrol', '.']","(17, 18)","(108, 118)",-1,hl_i,6989377,Title,0,test,gold,
6974,"Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet , clofibrate and",niceritrol .,,"['Changes', 'in', 'the', 'fatty', 'acid', 'composition', 'of', 'the', 'plasma', 'lipid', 'esters', 'during', 'lipid-lowering', 'treatment', 'with', 'diet', ',', 'clofibrate', 'and', 'niceritrol', '.']","(19, 21)","(123, 135)",-1,hl_i,6989377,Title,0,test,gold,
6975,Changes in the,fatty acid composition of the plasma lipid esters,"during lipid-lowering treatment with diet , clofibrate and niceritrol .","['Changes', 'in', 'the', 'fatty', 'acid', 'composition', 'of', 'the', 'plasma', 'lipid', 'esters', 'during', 'lipid-lowering', 'treatment', 'with', 'diet', ',', 'clofibrate', 'and', 'niceritrol', '.']","(3, 11)","(14, 63)",-1,hl_o,6989377,Title,0,test,gold,6502.0
6976,Reduction of the proportion of linoleate by,clofibrate,but not by niceritrol .,"['Reduction', 'of', 'the', 'proportion', 'of', 'linoleate', 'by', 'clofibrate', 'but', 'not', 'by', 'niceritrol', '.']","(7, 8)","(43, 53)",-1,ss_i,6989377,Abstract,0,test,gold,
6977,Reduction of the proportion of linoleate by clofibrate but not by,niceritrol .,,"['Reduction', 'of', 'the', 'proportion', 'of', 'linoleate', 'by', 'clofibrate', 'but', 'not', 'by', 'niceritrol', '.']","(11, 13)","(65, 77)",-1,ss_i,6989377,Abstract,0,test,gold,
6978,Reduction of the,proportion of linoleate,by clofibrate but not by niceritrol .,"['Reduction', 'of', 'the', 'proportion', 'of', 'linoleate', 'by', 'clofibrate', 'but', 'not', 'by', 'niceritrol', '.']","(3, 6)","(16, 39)",-1,ss_o,6989377,Abstract,0,test,gold,1214.0
6979,Reduction of the proportion of,linoleate,by clofibrate but not by niceritrol .,"['Reduction', 'of', 'the', 'proportion', 'of', 'linoleate', 'by', 'clofibrate', 'but', 'not', 'by', 'niceritrol', '.']","(5, 6)","(30, 39)",-1,hl_o,6989377,Abstract,0,test,gold,
6980,The fatty acid composition of the plasma lipid esters has been studied during lipid-lowering treatment of,95 patients with atherosclerotic disease .,,"['The', 'fatty', 'acid', 'composition', 'of', 'the', 'plasma', 'lipid', 'esters', 'has', 'been', 'studied', 'during', 'lipid-lowering', 'treatment', 'of', '95', 'patients', 'with', 'atherosclerotic', 'disease', '.']","(16, 22)","(105, 147)",-1,ss_p,6989377,Abstract,1,test,gold,7044.0
6981,The,fatty acid composition of the plasma lipid esters,has been studied during lipid-lowering treatment of 95 patients with atherosclerotic disease .,"['The', 'fatty', 'acid', 'composition', 'of', 'the', 'plasma', 'lipid', 'esters', 'has', 'been', 'studied', 'during', 'lipid-lowering', 'treatment', 'of', '95', 'patients', 'with', 'atherosclerotic', 'disease', '.']","(1, 9)","(3, 52)",-1,ss_o,6989377,Abstract,1,test,gold,6503.0
6982,The fatty acid composition of the plasma lipid esters has been studied during lipid-lowering treatment of,95 patients with atherosclerotic disease,.,"['The', 'fatty', 'acid', 'composition', 'of', 'the', 'plasma', 'lipid', 'esters', 'has', 'been', 'studied', 'during', 'lipid-lowering', 'treatment', 'of', '95', 'patients', 'with', 'atherosclerotic', 'disease', '.']","(16, 21)","(105, 145)",-1,hl_p,6989377,Abstract,1,test,gold,7045.0
6983,The,fatty acid composition of the plasma lipid esters,has been studied during lipid-lowering treatment of 95 patients with atherosclerotic disease .,"['The', 'fatty', 'acid', 'composition', 'of', 'the', 'plasma', 'lipid', 'esters', 'has', 'been', 'studied', 'during', 'lipid-lowering', 'treatment', 'of', '95', 'patients', 'with', 'atherosclerotic', 'disease', '.']","(1, 9)","(3, 52)",-1,hl_o,6989377,Abstract,1,test,gold,6501.0
6984,During the first two months of the trial only a diet was prescribed .,,,"['During', 'the', 'first', 'two', 'months', 'of', 'the', 'trial', 'only', 'a', 'diet', 'was', 'prescribed', '.']",,,,,6989377,Abstract,2,test,gold,
6985,During the ensuing two months either,clofibrate,"or niceritrol , a nicotinic acid ester , was added in a randomized order .","['During', 'the', 'ensuing', 'two', 'months', 'either', 'clofibrate', 'or', 'niceritrol', ',', 'a', 'nicotinic', 'acid', 'ester', ',', 'was', 'added', 'in', 'a', 'randomized', 'order', '.']","(6, 7)","(36, 46)",-1,ss_i,6989377,Abstract,3,test,gold,
6986,During the ensuing two months either clofibrate or,niceritrol,", a nicotinic acid ester , was added in a randomized order .","['During', 'the', 'ensuing', 'two', 'months', 'either', 'clofibrate', 'or', 'niceritrol', ',', 'a', 'nicotinic', 'acid', 'ester', ',', 'was', 'added', 'in', 'a', 'randomized', 'order', '.']","(8, 9)","(50, 60)",-1,ss_i,6989377,Abstract,3,test,gold,
6987,During the ensuing two months either,clofibrate,"or niceritrol , a nicotinic acid ester , was added in a randomized order .","['During', 'the', 'ensuing', 'two', 'months', 'either', 'clofibrate', 'or', 'niceritrol', ',', 'a', 'nicotinic', 'acid', 'ester', ',', 'was', 'added', 'in', 'a', 'randomized', 'order', '.']","(6, 7)","(36, 46)",-1,hl_i,6989377,Abstract,3,test,gold,
6988,During the ensuing two months either clofibrate or,niceritrol,", a nicotinic acid ester , was added in a randomized order .","['During', 'the', 'ensuing', 'two', 'months', 'either', 'clofibrate', 'or', 'niceritrol', ',', 'a', 'nicotinic', 'acid', 'ester', ',', 'was', 'added', 'in', 'a', 'randomized', 'order', '.']","(8, 9)","(50, 60)",-1,hl_i,6989377,Abstract,3,test,gold,
6989,During the last two months the second drug was added .,,,"['During', 'the', 'last', 'two', 'months', 'the', 'second', 'drug', 'was', 'added', '.']",,,,,6989377,Abstract,4,test,gold,
6990,The combined treatment with,"diet , clofibrate",and niceritrol caused highly significant serum lipid reductions .,"['The', 'combined', 'treatment', 'with', 'diet', ',', 'clofibrate', 'and', 'niceritrol', 'caused', 'highly', 'significant', 'serum', 'lipid', 'reductions', '.']","(4, 7)","(27, 44)",-1,ss_i,6989377,Abstract,5,test,gold,1536.0
6991,"The combined treatment with diet , clofibrate and",niceritrol,caused highly significant serum lipid reductions .,"['The', 'combined', 'treatment', 'with', 'diet', ',', 'clofibrate', 'and', 'niceritrol', 'caused', 'highly', 'significant', 'serum', 'lipid', 'reductions', '.']","(8, 9)","(49, 59)",-1,ss_i,6989377,Abstract,5,test,gold,
6992,"The combined treatment with diet , clofibrate and niceritrol caused highly significant",serum lipid reductions .,,"['The', 'combined', 'treatment', 'with', 'diet', ',', 'clofibrate', 'and', 'niceritrol', 'caused', 'highly', 'significant', 'serum', 'lipid', 'reductions', '.']","(12, 16)","(86, 110)",-1,ss_o,6989377,Abstract,5,test,gold,4478.0
6993,The combined treatment with,diet,", clofibrate and niceritrol caused highly significant serum lipid reductions .","['The', 'combined', 'treatment', 'with', 'diet', ',', 'clofibrate', 'and', 'niceritrol', 'caused', 'highly', 'significant', 'serum', 'lipid', 'reductions', '.']","(4, 5)","(27, 31)",-1,hl_i,6989377,Abstract,5,test,gold,1535.0
6994,"The combined treatment with diet ,",clofibrate,and niceritrol caused highly significant serum lipid reductions .,"['The', 'combined', 'treatment', 'with', 'diet', ',', 'clofibrate', 'and', 'niceritrol', 'caused', 'highly', 'significant', 'serum', 'lipid', 'reductions', '.']","(6, 7)","(34, 44)",-1,hl_i,6989377,Abstract,5,test,gold,
6995,"The combined treatment with diet , clofibrate and",niceritrol,caused highly significant serum lipid reductions .,"['The', 'combined', 'treatment', 'with', 'diet', ',', 'clofibrate', 'and', 'niceritrol', 'caused', 'highly', 'significant', 'serum', 'lipid', 'reductions', '.']","(8, 9)","(49, 59)",-1,hl_i,6989377,Abstract,5,test,gold,
6996,"The combined treatment with diet , clofibrate and niceritrol caused highly significant",serum lipid,reductions .,"['The', 'combined', 'treatment', 'with', 'diet', ',', 'clofibrate', 'and', 'niceritrol', 'caused', 'highly', 'significant', 'serum', 'lipid', 'reductions', '.']","(12, 14)","(86, 97)",-1,hl_o,6989377,Abstract,5,test,gold,4479.0
6997,The,fatty acid composition in the plasma lipid esters,was determined in samples from each trial period to measure the degree of dietary adherence .,"['The', 'fatty', 'acid', 'composition', 'in', 'the', 'plasma', 'lipid', 'esters', 'was', 'determined', 'in', 'samples', 'from', 'each', 'trial', 'period', 'to', 'measure', 'the', 'degree', 'of', 'dietary', 'adherence', '.']","(1, 9)","(3, 52)",-1,ss_o,6989377,Abstract,6,test,gold,6499.0
6998,The fatty acid composition in the plasma lipid esters was determined in samples from each trial period to measure the,degree of dietary adherence .,,"['The', 'fatty', 'acid', 'composition', 'in', 'the', 'plasma', 'lipid', 'esters', 'was', 'determined', 'in', 'samples', 'from', 'each', 'trial', 'period', 'to', 'measure', 'the', 'degree', 'of', 'dietary', 'adherence', '.']","(20, 25)","(117, 146)",-1,ss_o,6989377,Abstract,6,test,gold,410.0
6999,The,fatty acid composition in the plasma lipid esters,was determined in samples from each trial period to measure the degree of dietary adherence .,"['The', 'fatty', 'acid', 'composition', 'in', 'the', 'plasma', 'lipid', 'esters', 'was', 'determined', 'in', 'samples', 'from', 'each', 'trial', 'period', 'to', 'measure', 'the', 'degree', 'of', 'dietary', 'adherence', '.']","(1, 9)","(3, 52)",-1,hl_o,6989377,Abstract,6,test,gold,6500.0
7000,During,dietary treatment,the relative content of saturated and monounsaturated fatty acids secreased and the polyunsaturated fatty acids increased with an increasing ratio between pulyunsaturated and saturated fatty acids ( P/S ratio ) in the cholesterol esters and triglycerides .,"['During', 'dietary', 'treatment', 'the', 'relative', 'content', 'of', 'saturated', 'and', 'monounsaturated', 'fatty', 'acids', 'secreased', 'and', 'the', 'polyunsaturated', 'fatty', 'acids', 'increased', 'with', 'an', 'increasing', 'ratio', 'between', 'pulyunsaturated', 'and', 'saturated', 'fatty', 'acids', '(', 'P/S', 'ratio', ')', 'in', 'the', 'cholesterol', 'esters', 'and', 'triglycerides', '.']","(1, 3)","(6, 23)",-1,ss_i,6989377,Abstract,7,test,gold,3962.0
7001,During dietary treatment the relative,content of saturated and monounsaturated fatty acids,secreased and the polyunsaturated fatty acids increased with an increasing ratio between pulyunsaturated and saturated fatty acids ( P/S ratio ) in the cholesterol esters and triglycerides .,"['During', 'dietary', 'treatment', 'the', 'relative', 'content', 'of', 'saturated', 'and', 'monounsaturated', 'fatty', 'acids', 'secreased', 'and', 'the', 'polyunsaturated', 'fatty', 'acids', 'increased', 'with', 'an', 'increasing', 'ratio', 'between', 'pulyunsaturated', 'and', 'saturated', 'fatty', 'acids', '(', 'P/S', 'ratio', ')', 'in', 'the', 'cholesterol', 'esters', 'and', 'triglycerides', '.']","(5, 12)","(37, 89)",-1,ss_o,6989377,Abstract,7,test,gold,4608.0
7002,During dietary treatment the relative content of saturated and monounsaturated fatty acids secreased and the,polyunsaturated fatty acids,increased with an increasing ratio between pulyunsaturated and saturated fatty acids ( P/S ratio ) in the cholesterol esters and triglycerides .,"['During', 'dietary', 'treatment', 'the', 'relative', 'content', 'of', 'saturated', 'and', 'monounsaturated', 'fatty', 'acids', 'secreased', 'and', 'the', 'polyunsaturated', 'fatty', 'acids', 'increased', 'with', 'an', 'increasing', 'ratio', 'between', 'pulyunsaturated', 'and', 'saturated', 'fatty', 'acids', '(', 'P/S', 'ratio', ')', 'in', 'the', 'cholesterol', 'esters', 'and', 'triglycerides', '.']","(15, 18)","(108, 135)",-1,ss_o,6989377,Abstract,7,test,gold,4617.0
7003,During dietary treatment the relative content of saturated and monounsaturated fatty acids secreased and the polyunsaturated fatty acids increased with an increasing,ratio between pulyunsaturated and saturated fatty acids ( P/S ratio ) in the cholesterol esters and triglycerides .,,"['During', 'dietary', 'treatment', 'the', 'relative', 'content', 'of', 'saturated', 'and', 'monounsaturated', 'fatty', 'acids', 'secreased', 'and', 'the', 'polyunsaturated', 'fatty', 'acids', 'increased', 'with', 'an', 'increasing', 'ratio', 'between', 'pulyunsaturated', 'and', 'saturated', 'fatty', 'acids', '(', 'P/S', 'ratio', ')', 'in', 'the', 'cholesterol', 'esters', 'and', 'triglycerides', '.']","(22, 40)","(165, 280)",-1,ss_o,6989377,Abstract,7,test,gold,6507.0
7004,During dietary treatment the relative,content of saturated and monounsaturated fatty acids,secreased and the polyunsaturated fatty acids increased with an increasing ratio between pulyunsaturated and saturated fatty acids ( P/S ratio ) in the cholesterol esters and triglycerides .,"['During', 'dietary', 'treatment', 'the', 'relative', 'content', 'of', 'saturated', 'and', 'monounsaturated', 'fatty', 'acids', 'secreased', 'and', 'the', 'polyunsaturated', 'fatty', 'acids', 'increased', 'with', 'an', 'increasing', 'ratio', 'between', 'pulyunsaturated', 'and', 'saturated', 'fatty', 'acids', '(', 'P/S', 'ratio', ')', 'in', 'the', 'cholesterol', 'esters', 'and', 'triglycerides', '.']","(5, 12)","(37, 89)",-1,hl_o,6989377,Abstract,7,test,gold,4609.0
7005,During dietary treatment the relative content of saturated and monounsaturated fatty acids secreased and the,polyunsaturated fatty acids,increased with an increasing ratio between pulyunsaturated and saturated fatty acids ( P/S ratio ) in the cholesterol esters and triglycerides .,"['During', 'dietary', 'treatment', 'the', 'relative', 'content', 'of', 'saturated', 'and', 'monounsaturated', 'fatty', 'acids', 'secreased', 'and', 'the', 'polyunsaturated', 'fatty', 'acids', 'increased', 'with', 'an', 'increasing', 'ratio', 'between', 'pulyunsaturated', 'and', 'saturated', 'fatty', 'acids', '(', 'P/S', 'ratio', ')', 'in', 'the', 'cholesterol', 'esters', 'and', 'triglycerides', '.']","(15, 18)","(108, 135)",-1,hl_o,6989377,Abstract,7,test,gold,4618.0
7006,During dietary treatment the relative content of saturated and monounsaturated fatty acids secreased and the polyunsaturated fatty acids increased with an increasing,ratio between pulyunsaturated and saturated fatty acids ( P/S ratio ),in the cholesterol esters and triglycerides .,"['During', 'dietary', 'treatment', 'the', 'relative', 'content', 'of', 'saturated', 'and', 'monounsaturated', 'fatty', 'acids', 'secreased', 'and', 'the', 'polyunsaturated', 'fatty', 'acids', 'increased', 'with', 'an', 'increasing', 'ratio', 'between', 'pulyunsaturated', 'and', 'saturated', 'fatty', 'acids', '(', 'P/S', 'ratio', ')', 'in', 'the', 'cholesterol', 'esters', 'and', 'triglycerides', '.']","(22, 33)","(165, 234)",-1,hl_o,6989377,Abstract,7,test,gold,4605.0
7007,Only minor changes were seen in the,phospholipids .,,"['Only', 'minor', 'changes', 'were', 'seen', 'in', 'the', 'phospholipids', '.']","(7, 9)","(35, 50)",-1,ss_o,6989377,Abstract,8,test,gold,1570.0
7008,Only minor changes were seen in the,phospholipids .,,"['Only', 'minor', 'changes', 'were', 'seen', 'in', 'the', 'phospholipids', '.']","(7, 9)","(35, 50)",-1,hl_o,6989377,Abstract,8,test,gold,1571.0
7009,The changes caused by the,diet,were partly reversed by clofibrate while niceritrol did not cause any major changes of the fatty acid composition .,"['The', 'changes', 'caused', 'by', 'the', 'diet', 'were', 'partly', 'reversed', 'by', 'clofibrate', 'while', 'niceritrol', 'did', 'not', 'cause', 'any', 'major', 'changes', 'of', 'the', 'fatty', 'acid', 'composition', '.']","(5, 6)","(25, 29)",-1,ss_i,6989377,Abstract,9,test,gold,1534.0
7010,The changes caused by the diet were partly reversed by,clofibrate,while niceritrol did not cause any major changes of the fatty acid composition .,"['The', 'changes', 'caused', 'by', 'the', 'diet', 'were', 'partly', 'reversed', 'by', 'clofibrate', 'while', 'niceritrol', 'did', 'not', 'cause', 'any', 'major', 'changes', 'of', 'the', 'fatty', 'acid', 'composition', '.']","(10, 11)","(54, 64)",-1,ss_i,6989377,Abstract,9,test,gold,
7011,The changes caused by the diet were partly reversed by clofibrate while,niceritrol,did not cause any major changes of the fatty acid composition .,"['The', 'changes', 'caused', 'by', 'the', 'diet', 'were', 'partly', 'reversed', 'by', 'clofibrate', 'while', 'niceritrol', 'did', 'not', 'cause', 'any', 'major', 'changes', 'of', 'the', 'fatty', 'acid', 'composition', '.']","(12, 13)","(71, 81)",-1,ss_i,6989377,Abstract,9,test,gold,
7012,The changes caused by the diet were partly reversed by clofibrate while niceritrol did not cause any major,changes of the fatty acid composition .,,"['The', 'changes', 'caused', 'by', 'the', 'diet', 'were', 'partly', 'reversed', 'by', 'clofibrate', 'while', 'niceritrol', 'did', 'not', 'cause', 'any', 'major', 'changes', 'of', 'the', 'fatty', 'acid', 'composition', '.']","(18, 25)","(106, 145)",-1,ss_o,6989377,Abstract,9,test,gold,4665.0
7013,The changes caused by the,diet,were partly reversed by clofibrate while niceritrol did not cause any major changes of the fatty acid composition .,"['The', 'changes', 'caused', 'by', 'the', 'diet', 'were', 'partly', 'reversed', 'by', 'clofibrate', 'while', 'niceritrol', 'did', 'not', 'cause', 'any', 'major', 'changes', 'of', 'the', 'fatty', 'acid', 'composition', '.']","(5, 6)","(25, 29)",-1,hl_i,6989377,Abstract,9,test,gold,1533.0
7014,The changes caused by the diet were partly reversed by,clofibrate,while niceritrol did not cause any major changes of the fatty acid composition .,"['The', 'changes', 'caused', 'by', 'the', 'diet', 'were', 'partly', 'reversed', 'by', 'clofibrate', 'while', 'niceritrol', 'did', 'not', 'cause', 'any', 'major', 'changes', 'of', 'the', 'fatty', 'acid', 'composition', '.']","(10, 11)","(54, 64)",-1,hl_i,6989377,Abstract,9,test,gold,
7015,The changes caused by the diet were partly reversed by clofibrate while,niceritrol,did not cause any major changes of the fatty acid composition .,"['The', 'changes', 'caused', 'by', 'the', 'diet', 'were', 'partly', 'reversed', 'by', 'clofibrate', 'while', 'niceritrol', 'did', 'not', 'cause', 'any', 'major', 'changes', 'of', 'the', 'fatty', 'acid', 'composition', '.']","(12, 13)","(71, 81)",-1,hl_i,6989377,Abstract,9,test,gold,
7016,The changes caused by the diet were partly reversed by clofibrate while niceritrol did not cause any major changes of the,fatty acid composition .,,"['The', 'changes', 'caused', 'by', 'the', 'diet', 'were', 'partly', 'reversed', 'by', 'clofibrate', 'while', 'niceritrol', 'did', 'not', 'cause', 'any', 'major', 'changes', 'of', 'the', 'fatty', 'acid', 'composition', '.']","(21, 25)","(121, 145)",-1,hl_o,6989377,Abstract,9,test,gold,4666.0
7017,,Clofibrate,"treatment coincided with increasing amounts of monounsaturated fatty acids , especially oleate ( 18 : 1 ) , in the cholesterol esters , triglycerides and phospholipids while there were significant reductions of the content of linoleic ( 18 : 2 ) acid in both the cholesterol esters and triglycerides .","['Clofibrate', 'treatment', 'coincided', 'with', 'increasing', 'amounts', 'of', 'monounsaturated', 'fatty', 'acids', ',', 'especially', 'oleate', '(', '18', ':', '1', ')', ',', 'in', 'the', 'cholesterol', 'esters', ',', 'triglycerides', 'and', 'phospholipids', 'while', 'there', 'were', 'significant', 'reductions', 'of', 'the', 'content', 'of', 'linoleic', '(', '18', ':', '2', ')', 'acid', 'in', 'both', 'the', 'cholesterol', 'esters', 'and', 'triglycerides', '.']","(0, 1)","(0, 10)",-1,ss_i,6989377,Abstract,10,test,gold,
7018,Clofibrate treatment coincided with increasing,"amounts of monounsaturated fatty acids , especially oleate ( 18 : 1 ) , in the cholesterol esters , triglycerides and phospholipids",while there were significant reductions of the content of linoleic ( 18 : 2 ) acid in both the cholesterol esters and triglycerides .,"['Clofibrate', 'treatment', 'coincided', 'with', 'increasing', 'amounts', 'of', 'monounsaturated', 'fatty', 'acids', ',', 'especially', 'oleate', '(', '18', ':', '1', ')', ',', 'in', 'the', 'cholesterol', 'esters', ',', 'triglycerides', 'and', 'phospholipids', 'while', 'there', 'were', 'significant', 'reductions', 'of', 'the', 'content', 'of', 'linoleic', '(', '18', ':', '2', ')', 'acid', 'in', 'both', 'the', 'cholesterol', 'esters', 'and', 'triglycerides', '.']","(5, 27)","(46, 177)",-1,ss_o,6989377,Abstract,10,test,gold,6504.0
7019,"Clofibrate treatment coincided with increasing amounts of monounsaturated fatty acids , especially oleate ( 18 : 1 ) , in the cholesterol esters , triglycerides and phospholipids while there were significant reductions of the",content of linoleic ( 18 : 2 ) acid in both the cholesterol esters and triglycerides .,,"['Clofibrate', 'treatment', 'coincided', 'with', 'increasing', 'amounts', 'of', 'monounsaturated', 'fatty', 'acids', ',', 'especially', 'oleate', '(', '18', ':', '1', ')', ',', 'in', 'the', 'cholesterol', 'esters', ',', 'triglycerides', 'and', 'phospholipids', 'while', 'there', 'were', 'significant', 'reductions', 'of', 'the', 'content', 'of', 'linoleic', '(', '18', ':', '2', ')', 'acid', 'in', 'both', 'the', 'cholesterol', 'esters', 'and', 'triglycerides', '.']","(34, 51)","(225, 311)",-1,ss_o,6989377,Abstract,10,test,gold,6508.0
7020,,Clofibrate,"treatment coincided with increasing amounts of monounsaturated fatty acids , especially oleate ( 18 : 1 ) , in the cholesterol esters , triglycerides and phospholipids while there were significant reductions of the content of linoleic ( 18 : 2 ) acid in both the cholesterol esters and triglycerides .","['Clofibrate', 'treatment', 'coincided', 'with', 'increasing', 'amounts', 'of', 'monounsaturated', 'fatty', 'acids', ',', 'especially', 'oleate', '(', '18', ':', '1', ')', ',', 'in', 'the', 'cholesterol', 'esters', ',', 'triglycerides', 'and', 'phospholipids', 'while', 'there', 'were', 'significant', 'reductions', 'of', 'the', 'content', 'of', 'linoleic', '(', '18', ':', '2', ')', 'acid', 'in', 'both', 'the', 'cholesterol', 'esters', 'and', 'triglycerides', '.']","(0, 1)","(0, 10)",-1,hl_i,6989377,Abstract,10,test,gold,
7021,Clofibrate treatment coincided with increasing amounts of,monounsaturated fatty acids,", especially oleate ( 18 : 1 ) , in the cholesterol esters , triglycerides and phospholipids while there were significant reductions of the content of linoleic ( 18 : 2 ) acid in both the cholesterol esters and triglycerides .","['Clofibrate', 'treatment', 'coincided', 'with', 'increasing', 'amounts', 'of', 'monounsaturated', 'fatty', 'acids', ',', 'especially', 'oleate', '(', '18', ':', '1', ')', ',', 'in', 'the', 'cholesterol', 'esters', ',', 'triglycerides', 'and', 'phospholipids', 'while', 'there', 'were', 'significant', 'reductions', 'of', 'the', 'content', 'of', 'linoleic', '(', '18', ':', '2', ')', 'acid', 'in', 'both', 'the', 'cholesterol', 'esters', 'and', 'triglycerides', '.']","(7, 10)","(57, 84)",-1,hl_o,6989377,Abstract,10,test,gold,4616.0
7022,"Clofibrate treatment coincided with increasing amounts of monounsaturated fatty acids , especially",oleate,"( 18 : 1 ) , in the cholesterol esters , triglycerides and phospholipids while there were significant reductions of the content of linoleic ( 18 : 2 ) acid in both the cholesterol esters and triglycerides .","['Clofibrate', 'treatment', 'coincided', 'with', 'increasing', 'amounts', 'of', 'monounsaturated', 'fatty', 'acids', ',', 'especially', 'oleate', '(', '18', ':', '1', ')', ',', 'in', 'the', 'cholesterol', 'esters', ',', 'triglycerides', 'and', 'phospholipids', 'while', 'there', 'were', 'significant', 'reductions', 'of', 'the', 'content', 'of', 'linoleic', '(', '18', ':', '2', ')', 'acid', 'in', 'both', 'the', 'cholesterol', 'esters', 'and', 'triglycerides', '.']","(12, 13)","(98, 104)",-1,hl_o,6989377,Abstract,10,test,gold,
7023,"Clofibrate treatment coincided with increasing amounts of monounsaturated fatty acids , especially oleate ( 18 : 1 ) , in the cholesterol esters ,",triglycerides and phospholipids,while there were significant reductions of the content of linoleic ( 18 : 2 ) acid in both the cholesterol esters and triglycerides .,"['Clofibrate', 'treatment', 'coincided', 'with', 'increasing', 'amounts', 'of', 'monounsaturated', 'fatty', 'acids', ',', 'especially', 'oleate', '(', '18', ':', '1', ')', ',', 'in', 'the', 'cholesterol', 'esters', ',', 'triglycerides', 'and', 'phospholipids', 'while', 'there', 'were', 'significant', 'reductions', 'of', 'the', 'content', 'of', 'linoleic', '(', '18', ':', '2', ')', 'acid', 'in', 'both', 'the', 'cholesterol', 'esters', 'and', 'triglycerides', '.']","(24, 27)","(146, 177)",-1,hl_o,6989377,Abstract,10,test,gold,1569.0
7024,"Clofibrate treatment coincided with increasing amounts of monounsaturated fatty acids , especially oleate ( 18 : 1 ) , in the cholesterol esters , triglycerides and phospholipids while there were significant reductions of the",content of linoleic ( 18 : 2 ) acid,in both the cholesterol esters and triglycerides .,"['Clofibrate', 'treatment', 'coincided', 'with', 'increasing', 'amounts', 'of', 'monounsaturated', 'fatty', 'acids', ',', 'especially', 'oleate', '(', '18', ':', '1', ')', ',', 'in', 'the', 'cholesterol', 'esters', ',', 'triglycerides', 'and', 'phospholipids', 'while', 'there', 'were', 'significant', 'reductions', 'of', 'the', 'content', 'of', 'linoleic', '(', '18', ':', '2', ')', 'acid', 'in', 'both', 'the', 'cholesterol', 'esters', 'and', 'triglycerides', '.']","(34, 43)","(225, 260)",-1,hl_o,6989377,Abstract,10,test,gold,1602.0
7025,The 18 : 2/18 : 1 ratio decreased significantly in all the lipid esters analyzed .,,,"['The', '18', ':', '2/18', ':', '1', 'ratio', 'decreased', 'significantly', 'in', 'all', 'the', 'lipid', 'esters', 'analyzed', '.']",,,,,6989377,Abstract,11,test,gold,
7026,"However , the P/S ratio was not significantly affected , partly because the relative content of saturated fatty acids also tended to decrease during",clofibrate,treatment .,"['However', ',', 'the', 'P/S', 'ratio', 'was', 'not', 'significantly', 'affected', ',', 'partly', 'because', 'the', 'relative', 'content', 'of', 'saturated', 'fatty', 'acids', 'also', 'tended', 'to', 'decrease', 'during', 'clofibrate', 'treatment', '.']","(24, 25)","(148, 158)",-1,ss_i,6989377,Abstract,12,test,gold,
7027,"However , the",P/S ratio,"was not significantly affected , partly because the relative content of saturated fatty acids also tended to decrease during clofibrate treatment .","['However', ',', 'the', 'P/S', 'ratio', 'was', 'not', 'significantly', 'affected', ',', 'partly', 'because', 'the', 'relative', 'content', 'of', 'saturated', 'fatty', 'acids', 'also', 'tended', 'to', 'decrease', 'during', 'clofibrate', 'treatment', '.']","(3, 5)","(13, 22)",-1,ss_o,6989377,Abstract,12,test,gold,1480.0
7028,"However , the P/S ratio was not significantly affected , partly because the",relative content of saturated fatty acids,also tended to decrease during clofibrate treatment .,"['However', ',', 'the', 'P/S', 'ratio', 'was', 'not', 'significantly', 'affected', ',', 'partly', 'because', 'the', 'relative', 'content', 'of', 'saturated', 'fatty', 'acids', 'also', 'tended', 'to', 'decrease', 'during', 'clofibrate', 'treatment', '.']","(13, 19)","(75, 116)",-1,ss_o,6989377,Abstract,12,test,gold,4613.0
7029,"However , the",P/S ratio,"was not significantly affected , partly because the relative content of saturated fatty acids also tended to decrease during clofibrate treatment .","['However', ',', 'the', 'P/S', 'ratio', 'was', 'not', 'significantly', 'affected', ',', 'partly', 'because', 'the', 'relative', 'content', 'of', 'saturated', 'fatty', 'acids', 'also', 'tended', 'to', 'decrease', 'during', 'clofibrate', 'treatment', '.']","(3, 5)","(13, 22)",-1,hl_o,6989377,Abstract,12,test,gold,1479.0
7030,"However , the P/S ratio was not significantly affected , partly because the relative content of",saturated fatty acids,also tended to decrease during clofibrate treatment .,"['However', ',', 'the', 'P/S', 'ratio', 'was', 'not', 'significantly', 'affected', ',', 'partly', 'because', 'the', 'relative', 'content', 'of', 'saturated', 'fatty', 'acids', 'also', 'tended', 'to', 'decrease', 'during', 'clofibrate', 'treatment', '.']","(16, 19)","(95, 116)",-1,hl_o,6989377,Abstract,12,test,gold,4614.0
7031,It is concluded that addition of,clofibrate,treatment to patients who are on a diet enriched with polyunsaturated fats is associated with a change from polyunsaturated to monounsaturated fatty acids in the plasma lipid esters but does not significantly effect the ratio between polyunsaturated and saturated fatty acids .,"['It', 'is', 'concluded', 'that', 'addition', 'of', 'clofibrate', 'treatment', 'to', 'patients', 'who', 'are', 'on', 'a', 'diet', 'enriched', 'with', 'polyunsaturated', 'fats', 'is', 'associated', 'with', 'a', 'change', 'from', 'polyunsaturated', 'to', 'monounsaturated', 'fatty', 'acids', 'in', 'the', 'plasma', 'lipid', 'esters', 'but', 'does', 'not', 'significantly', 'effect', 'the', 'ratio', 'between', 'polyunsaturated', 'and', 'saturated', 'fatty', 'acids', '.']","(6, 7)","(32, 42)",-1,ss_i,6989377,Abstract,13,test,gold,
7032,It is concluded that addition of clofibrate treatment to patients who are on a,diet,enriched with polyunsaturated fats is associated with a change from polyunsaturated to monounsaturated fatty acids in the plasma lipid esters but does not significantly effect the ratio between polyunsaturated and saturated fatty acids .,"['It', 'is', 'concluded', 'that', 'addition', 'of', 'clofibrate', 'treatment', 'to', 'patients', 'who', 'are', 'on', 'a', 'diet', 'enriched', 'with', 'polyunsaturated', 'fats', 'is', 'associated', 'with', 'a', 'change', 'from', 'polyunsaturated', 'to', 'monounsaturated', 'fatty', 'acids', 'in', 'the', 'plasma', 'lipid', 'esters', 'but', 'does', 'not', 'significantly', 'effect', 'the', 'ratio', 'between', 'polyunsaturated', 'and', 'saturated', 'fatty', 'acids', '.']","(14, 15)","(78, 82)",-1,ss_i,6989377,Abstract,13,test,gold,1532.0
7033,It is concluded that addition of clofibrate treatment to patients who are on a diet enriched with polyunsaturated fats is associated with a,change from polyunsaturated to monounsaturated fatty acids in the plasma lipid esters,but does not significantly effect the ratio between polyunsaturated and saturated fatty acids .,"['It', 'is', 'concluded', 'that', 'addition', 'of', 'clofibrate', 'treatment', 'to', 'patients', 'who', 'are', 'on', 'a', 'diet', 'enriched', 'with', 'polyunsaturated', 'fats', 'is', 'associated', 'with', 'a', 'change', 'from', 'polyunsaturated', 'to', 'monounsaturated', 'fatty', 'acids', 'in', 'the', 'plasma', 'lipid', 'esters', 'but', 'does', 'not', 'significantly', 'effect', 'the', 'ratio', 'between', 'polyunsaturated', 'and', 'saturated', 'fatty', 'acids', '.']","(23, 35)","(139, 224)",-1,ss_o,6989377,Abstract,13,test,gold,6505.0
7034,It is concluded that addition of clofibrate treatment to patients who are on a diet enriched with polyunsaturated fats is associated with a change from polyunsaturated to monounsaturated fatty acids in the plasma lipid esters but does not significantly effect the,ratio between polyunsaturated and saturated fatty acids .,,"['It', 'is', 'concluded', 'that', 'addition', 'of', 'clofibrate', 'treatment', 'to', 'patients', 'who', 'are', 'on', 'a', 'diet', 'enriched', 'with', 'polyunsaturated', 'fats', 'is', 'associated', 'with', 'a', 'change', 'from', 'polyunsaturated', 'to', 'monounsaturated', 'fatty', 'acids', 'in', 'the', 'plasma', 'lipid', 'esters', 'but', 'does', 'not', 'significantly', 'effect', 'the', 'ratio', 'between', 'polyunsaturated', 'and', 'saturated', 'fatty', 'acids', '.']","(41, 49)","(263, 320)",-1,ss_o,6989377,Abstract,13,test,gold,4606.0
7035,It is concluded that addition of clofibrate treatment to patients who are on a diet enriched with polyunsaturated fats is associated with a change from,polyunsaturated to monounsaturated fatty acids in the plasma lipid esters,but does not significantly effect the ratio between polyunsaturated and saturated fatty acids .,"['It', 'is', 'concluded', 'that', 'addition', 'of', 'clofibrate', 'treatment', 'to', 'patients', 'who', 'are', 'on', 'a', 'diet', 'enriched', 'with', 'polyunsaturated', 'fats', 'is', 'associated', 'with', 'a', 'change', 'from', 'polyunsaturated', 'to', 'monounsaturated', 'fatty', 'acids', 'in', 'the', 'plasma', 'lipid', 'esters', 'but', 'does', 'not', 'significantly', 'effect', 'the', 'ratio', 'between', 'polyunsaturated', 'and', 'saturated', 'fatty', 'acids', '.']","(25, 35)","(151, 224)",-1,hl_o,6989377,Abstract,13,test,gold,6506.0
7036,It is concluded that addition of clofibrate treatment to patients who are on a diet enriched with polyunsaturated fats is associated with a change from polyunsaturated to monounsaturated fatty acids in the plasma lipid esters but does not significantly effect the,ratio between polyunsaturated and saturated fatty acids .,,"['It', 'is', 'concluded', 'that', 'addition', 'of', 'clofibrate', 'treatment', 'to', 'patients', 'who', 'are', 'on', 'a', 'diet', 'enriched', 'with', 'polyunsaturated', 'fats', 'is', 'associated', 'with', 'a', 'change', 'from', 'polyunsaturated', 'to', 'monounsaturated', 'fatty', 'acids', 'in', 'the', 'plasma', 'lipid', 'esters', 'but', 'does', 'not', 'significantly', 'effect', 'the', 'ratio', 'between', 'polyunsaturated', 'and', 'saturated', 'fatty', 'acids', '.']","(41, 49)","(263, 320)",-1,hl_o,6989377,Abstract,13,test,gold,4607.0
7037,The fatty acid changes caused by,clofibrate,treatment and counteracted by an increased amount of polyunsaturated fat in the diet .,"['The', 'fatty', 'acid', 'changes', 'caused', 'by', 'clofibrate', 'treatment', 'and', 'counteracted', 'by', 'an', 'increased', 'amount', 'of', 'polyunsaturated', 'fat', 'in', 'the', 'diet', '.']","(6, 7)","(32, 42)",-1,ss_i,6989377,Abstract,14,test,gold,
7038,The fatty acid changes caused by clofibrate treatment and counteracted by an increased amount of polyunsaturated fat in the,diet .,,"['The', 'fatty', 'acid', 'changes', 'caused', 'by', 'clofibrate', 'treatment', 'and', 'counteracted', 'by', 'an', 'increased', 'amount', 'of', 'polyunsaturated', 'fat', 'in', 'the', 'diet', '.']","(19, 21)","(123, 129)",-1,ss_i,6989377,Abstract,14,test,gold,1531.0
7039,,The fatty acid changes,caused by clofibrate treatment and counteracted by an increased amount of polyunsaturated fat in the diet .,"['The', 'fatty', 'acid', 'changes', 'caused', 'by', 'clofibrate', 'treatment', 'and', 'counteracted', 'by', 'an', 'increased', 'amount', 'of', 'polyunsaturated', 'fat', 'in', 'the', 'diet', '.']","(0, 4)","(0, 22)",-1,ss_o,6989377,Abstract,14,test,gold,4664.0
7040,The fatty acid changes caused by,clofibrate,treatment and counteracted by an increased amount of polyunsaturated fat in the diet .,"['The', 'fatty', 'acid', 'changes', 'caused', 'by', 'clofibrate', 'treatment', 'and', 'counteracted', 'by', 'an', 'increased', 'amount', 'of', 'polyunsaturated', 'fat', 'in', 'the', 'diet', '.']","(6, 7)","(32, 42)",-1,hl_i,6989377,Abstract,14,test,gold,
7041,The fatty acid changes caused by clofibrate treatment and counteracted by an increased amount of polyunsaturated fat in the,diet .,,"['The', 'fatty', 'acid', 'changes', 'caused', 'by', 'clofibrate', 'treatment', 'and', 'counteracted', 'by', 'an', 'increased', 'amount', 'of', 'polyunsaturated', 'fat', 'in', 'the', 'diet', '.']","(19, 21)","(123, 129)",-1,hl_i,6989377,Abstract,14,test,gold,1530.0
7042,The fatty,acid changes,caused by clofibrate treatment and counteracted by an increased amount of polyunsaturated fat in the diet .,"['The', 'fatty', 'acid', 'changes', 'caused', 'by', 'clofibrate', 'treatment', 'and', 'counteracted', 'by', 'an', 'increased', 'amount', 'of', 'polyunsaturated', 'fat', 'in', 'the', 'diet', '.']","(2, 4)","(9, 21)",-1,hl_o,6989377,Abstract,14,test,gold,966.0
7043,"The efficacy of prophylactic ondansetron , droperidol , perphenazine , and metoclopramide in the prevention of nausea and vomiting after",major gynecologic surgery .,,"['The', 'efficacy', 'of', 'prophylactic', 'ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'in', 'the', 'prevention', 'of', 'nausea', 'and', 'vomiting', 'after', 'major', 'gynecologic', 'surgery', '.']","(20, 24)","(136, 163)",-1,ss_p,7598243,Title,0,test,gold,3663.0
7044,The efficacy of prophylactic,"ondansetron , droperidol , perphenazine",", and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery .","['The', 'efficacy', 'of', 'prophylactic', 'ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'in', 'the', 'prevention', 'of', 'nausea', 'and', 'vomiting', 'after', 'major', 'gynecologic', 'surgery', '.']","(4, 9)","(28, 67)",-1,ss_i,7598243,Title,0,test,gold,5629.0
7045,"The efficacy of prophylactic ondansetron , droperidol , perphenazine , and",metoclopramide,in the prevention of nausea and vomiting after major gynecologic surgery .,"['The', 'efficacy', 'of', 'prophylactic', 'ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'in', 'the', 'prevention', 'of', 'nausea', 'and', 'vomiting', 'after', 'major', 'gynecologic', 'surgery', '.']","(11, 12)","(74, 88)",-1,ss_i,7598243,Title,0,test,gold,5313.0
7046,The,efficacy,"of prophylactic ondansetron , droperidol , perphenazine , and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery .","['The', 'efficacy', 'of', 'prophylactic', 'ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'in', 'the', 'prevention', 'of', 'nausea', 'and', 'vomiting', 'after', 'major', 'gynecologic', 'surgery', '.']","(1, 2)","(3, 11)",-1,ss_o,7598243,Title,0,test,gold,4787.0
7047,The efficacy of prophylactic,ondansetron,", droperidol , perphenazine , and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery .","['The', 'efficacy', 'of', 'prophylactic', 'ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'in', 'the', 'prevention', 'of', 'nausea', 'and', 'vomiting', 'after', 'major', 'gynecologic', 'surgery', '.']","(4, 5)","(28, 39)",-1,hl_i,7598243,Title,0,test,gold,5636.0
7048,"The efficacy of prophylactic ondansetron ,",droperidol,", perphenazine , and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery .","['The', 'efficacy', 'of', 'prophylactic', 'ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'in', 'the', 'prevention', 'of', 'nausea', 'and', 'vomiting', 'after', 'major', 'gynecologic', 'surgery', '.']","(6, 7)","(42, 52)",-1,hl_i,7598243,Title,0,test,gold,34.0
7049,"The efficacy of prophylactic ondansetron , droperidol ,",perphenazine,", and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery .","['The', 'efficacy', 'of', 'prophylactic', 'ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'in', 'the', 'prevention', 'of', 'nausea', 'and', 'vomiting', 'after', 'major', 'gynecologic', 'surgery', '.']","(8, 9)","(55, 67)",-1,hl_i,7598243,Title,0,test,gold,5618.0
7050,"The efficacy of prophylactic ondansetron , droperidol , perphenazine , and",metoclopramide,in the prevention of nausea and vomiting after major gynecologic surgery .,"['The', 'efficacy', 'of', 'prophylactic', 'ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'in', 'the', 'prevention', 'of', 'nausea', 'and', 'vomiting', 'after', 'major', 'gynecologic', 'surgery', '.']","(11, 12)","(74, 88)",-1,hl_i,7598243,Title,0,test,gold,5312.0
7051,The prophylactic antiemetic,efficacy,of intravenous ( i.v . ),"['The', 'prophylactic', 'antiemetic', 'efficacy', 'of', 'intravenous', '(', 'i.v', '.', ')']","(3, 4)","(27, 35)",-1,ss_o,7598243,Abstract,0,test,gold,4786.0
7052,"ondansetron , droperidol , perphenazine , and metoclopramide was evaluated in a prospective , double-blind study of",360 ASA physical status I-III patients undergoing total abdominal hysterectomy ( TAH ) .,,"['ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'was', 'evaluated', 'in', 'a', 'prospective', ',', 'double-blind', 'study', 'of', '360', 'ASA', 'physical', 'status', 'I-III', 'patients', 'undergoing', 'total', 'abdominal', 'hysterectomy', '(', 'TAH', ')', '.']","(17, 31)","(115, 203)",-1,ss_p,7598243,Abstract,1,test,gold,3619.0
7053,,"ondansetron , droperidol , perphenazine",", and metoclopramide was evaluated in a prospective , double-blind study of 360 ASA physical status I-III patients undergoing total abdominal hysterectomy ( TAH ) .","['ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'was', 'evaluated', 'in', 'a', 'prospective', ',', 'double-blind', 'study', 'of', '360', 'ASA', 'physical', 'status', 'I-III', 'patients', 'undergoing', 'total', 'abdominal', 'hysterectomy', '(', 'TAH', ')', '.']","(0, 5)","(0, 39)",-1,ss_i,7598243,Abstract,1,test,gold,5630.0
7054,"ondansetron , droperidol , perphenazine , and",metoclopramide,"was evaluated in a prospective , double-blind study of 360 ASA physical status I-III patients undergoing total abdominal hysterectomy ( TAH ) .","['ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'was', 'evaluated', 'in', 'a', 'prospective', ',', 'double-blind', 'study', 'of', '360', 'ASA', 'physical', 'status', 'I-III', 'patients', 'undergoing', 'total', 'abdominal', 'hysterectomy', '(', 'TAH', ')', '.']","(7, 8)","(45, 59)",-1,ss_i,7598243,Abstract,1,test,gold,5311.0
7055,"ondansetron , droperidol , perphenazine , and metoclopramide was evaluated in a prospective , double-blind study of",360 ASA physical status I-III patients undergoing total abdominal hysterectomy ( TAH ),.,"['ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'was', 'evaluated', 'in', 'a', 'prospective', ',', 'double-blind', 'study', 'of', '360', 'ASA', 'physical', 'status', 'I-III', 'patients', 'undergoing', 'total', 'abdominal', 'hysterectomy', '(', 'TAH', ')', '.']","(17, 30)","(115, 201)",-1,hl_p,7598243,Abstract,1,test,gold,3620.0
7056,,ondansetron,", droperidol , perphenazine , and metoclopramide was evaluated in a prospective , double-blind study of 360 ASA physical status I-III patients undergoing total abdominal hysterectomy ( TAH ) .","['ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'was', 'evaluated', 'in', 'a', 'prospective', ',', 'double-blind', 'study', 'of', '360', 'ASA', 'physical', 'status', 'I-III', 'patients', 'undergoing', 'total', 'abdominal', 'hysterectomy', '(', 'TAH', ')', '.']","(0, 1)","(0, 11)",-1,hl_i,7598243,Abstract,1,test,gold,5637.0
7057,"ondansetron ,",droperidol,", perphenazine , and metoclopramide was evaluated in a prospective , double-blind study of 360 ASA physical status I-III patients undergoing total abdominal hysterectomy ( TAH ) .","['ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'was', 'evaluated', 'in', 'a', 'prospective', ',', 'double-blind', 'study', 'of', '360', 'ASA', 'physical', 'status', 'I-III', 'patients', 'undergoing', 'total', 'abdominal', 'hysterectomy', '(', 'TAH', ')', '.']","(2, 3)","(13, 23)",-1,hl_i,7598243,Abstract,1,test,gold,33.0
7058,"ondansetron , droperidol ,",perphenazine,", and metoclopramide was evaluated in a prospective , double-blind study of 360 ASA physical status I-III patients undergoing total abdominal hysterectomy ( TAH ) .","['ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'was', 'evaluated', 'in', 'a', 'prospective', ',', 'double-blind', 'study', 'of', '360', 'ASA', 'physical', 'status', 'I-III', 'patients', 'undergoing', 'total', 'abdominal', 'hysterectomy', '(', 'TAH', ')', '.']","(4, 5)","(26, 38)",-1,hl_i,7598243,Abstract,1,test,gold,5617.0
7059,"ondansetron , droperidol , perphenazine , and",metoclopramide,"was evaluated in a prospective , double-blind study of 360 ASA physical status I-III patients undergoing total abdominal hysterectomy ( TAH ) .","['ondansetron', ',', 'droperidol', ',', 'perphenazine', ',', 'and', 'metoclopramide', 'was', 'evaluated', 'in', 'a', 'prospective', ',', 'double-blind', 'study', 'of', '360', 'ASA', 'physical', 'status', 'I-III', 'patients', 'undergoing', 'total', 'abdominal', 'hysterectomy', '(', 'TAH', ')', '.']","(7, 8)","(45, 59)",-1,hl_i,7598243,Abstract,1,test,gold,5310.0
7060,"Subjects were randomized to receive i.v. , one of",ondansetron,"4 mg , droperidol 1.25 mg , perphenazine 5 mg , metoclopramide 10 mg , or placebo prior to induction of anesthesia .","['Subjects', 'were', 'randomized', 'to', 'receive', 'i.v.', ',', 'one', 'of', 'ondansetron', '4', 'mg', ',', 'droperidol', '1.25', 'mg', ',', 'perphenazine', '5', 'mg', ',', 'metoclopramide', '10', 'mg', ',', 'or', 'placebo', 'prior', 'to', 'induction', 'of', 'anesthesia', '.']","(9, 10)","(49, 60)",-1,ss_i,7598243,Abstract,2,test,gold,5635.0
7061,"Subjects were randomized to receive i.v. , one of ondansetron 4 mg ,",droperidol,"1.25 mg , perphenazine 5 mg , metoclopramide 10 mg , or placebo prior to induction of anesthesia .","['Subjects', 'were', 'randomized', 'to', 'receive', 'i.v.', ',', 'one', 'of', 'ondansetron', '4', 'mg', ',', 'droperidol', '1.25', 'mg', ',', 'perphenazine', '5', 'mg', ',', 'metoclopramide', '10', 'mg', ',', 'or', 'placebo', 'prior', 'to', 'induction', 'of', 'anesthesia', '.']","(13, 14)","(68, 78)",-1,ss_i,7598243,Abstract,2,test,gold,32.0
7062,"Subjects were randomized to receive i.v. , one of ondansetron 4 mg , droperidol 1.25 mg ,",perphenazine,"5 mg , metoclopramide 10 mg , or placebo prior to induction of anesthesia .","['Subjects', 'were', 'randomized', 'to', 'receive', 'i.v.', ',', 'one', 'of', 'ondansetron', '4', 'mg', ',', 'droperidol', '1.25', 'mg', ',', 'perphenazine', '5', 'mg', ',', 'metoclopramide', '10', 'mg', ',', 'or', 'placebo', 'prior', 'to', 'induction', 'of', 'anesthesia', '.']","(17, 18)","(89, 101)",-1,ss_i,7598243,Abstract,2,test,gold,5616.0
7063,"Subjects were randomized to receive i.v. , one of ondansetron 4 mg , droperidol 1.25 mg , perphenazine 5 mg ,",metoclopramide,"10 mg , or placebo prior to induction of anesthesia .","['Subjects', 'were', 'randomized', 'to', 'receive', 'i.v.', ',', 'one', 'of', 'ondansetron', '4', 'mg', ',', 'droperidol', '1.25', 'mg', ',', 'perphenazine', '5', 'mg', ',', 'metoclopramide', '10', 'mg', ',', 'or', 'placebo', 'prior', 'to', 'induction', 'of', 'anesthesia', '.']","(21, 22)","(109, 123)",-1,ss_i,7598243,Abstract,2,test,gold,5309.0
7064,"Subjects were randomized to receive i.v. , one of ondansetron 4 mg , droperidol 1.25 mg , perphenazine 5 mg , metoclopramide 10 mg , or",placebo,prior to induction of anesthesia .,"['Subjects', 'were', 'randomized', 'to', 'receive', 'i.v.', ',', 'one', 'of', 'ondansetron', '4', 'mg', ',', 'droperidol', '1.25', 'mg', ',', 'perphenazine', '5', 'mg', ',', 'metoclopramide', '10', 'mg', ',', 'or', 'placebo', 'prior', 'to', 'induction', 'of', 'anesthesia', '.']","(26, 27)","(135, 142)",-1,ss_i,7598243,Abstract,2,test,gold,4293.0
7065,"Subjects were randomized to receive i.v. , one of",ondansetron,"4 mg , droperidol 1.25 mg , perphenazine 5 mg , metoclopramide 10 mg , or placebo prior to induction of anesthesia .","['Subjects', 'were', 'randomized', 'to', 'receive', 'i.v.', ',', 'one', 'of', 'ondansetron', '4', 'mg', ',', 'droperidol', '1.25', 'mg', ',', 'perphenazine', '5', 'mg', ',', 'metoclopramide', '10', 'mg', ',', 'or', 'placebo', 'prior', 'to', 'induction', 'of', 'anesthesia', '.']","(9, 10)","(49, 60)",-1,hl_i,7598243,Abstract,2,test,gold,5634.0
7066,"Subjects were randomized to receive i.v. , one of ondansetron 4 mg ,",droperidol,"1.25 mg , perphenazine 5 mg , metoclopramide 10 mg , or placebo prior to induction of anesthesia .","['Subjects', 'were', 'randomized', 'to', 'receive', 'i.v.', ',', 'one', 'of', 'ondansetron', '4', 'mg', ',', 'droperidol', '1.25', 'mg', ',', 'perphenazine', '5', 'mg', ',', 'metoclopramide', '10', 'mg', ',', 'or', 'placebo', 'prior', 'to', 'induction', 'of', 'anesthesia', '.']","(13, 14)","(68, 78)",-1,hl_i,7598243,Abstract,2,test,gold,31.0
7067,"Subjects were randomized to receive i.v. , one of ondansetron 4 mg , droperidol 1.25 mg ,",perphenazine,"5 mg , metoclopramide 10 mg , or placebo prior to induction of anesthesia .","['Subjects', 'were', 'randomized', 'to', 'receive', 'i.v.', ',', 'one', 'of', 'ondansetron', '4', 'mg', ',', 'droperidol', '1.25', 'mg', ',', 'perphenazine', '5', 'mg', ',', 'metoclopramide', '10', 'mg', ',', 'or', 'placebo', 'prior', 'to', 'induction', 'of', 'anesthesia', '.']","(17, 18)","(89, 101)",-1,hl_i,7598243,Abstract,2,test,gold,5615.0
7068,"Subjects were randomized to receive i.v. , one of ondansetron 4 mg , droperidol 1.25 mg , perphenazine 5 mg ,",metoclopramide,"10 mg , or placebo prior to induction of anesthesia .","['Subjects', 'were', 'randomized', 'to', 'receive', 'i.v.', ',', 'one', 'of', 'ondansetron', '4', 'mg', ',', 'droperidol', '1.25', 'mg', ',', 'perphenazine', '5', 'mg', ',', 'metoclopramide', '10', 'mg', ',', 'or', 'placebo', 'prior', 'to', 'induction', 'of', 'anesthesia', '.']","(21, 22)","(109, 123)",-1,hl_i,7598243,Abstract,2,test,gold,5308.0
7069,"Subjects were randomized to receive i.v. , one of ondansetron 4 mg , droperidol 1.25 mg , perphenazine 5 mg , metoclopramide 10 mg , or",placebo,prior to induction of anesthesia .,"['Subjects', 'were', 'randomized', 'to', 'receive', 'i.v.', ',', 'one', 'of', 'ondansetron', '4', 'mg', ',', 'droperidol', '1.25', 'mg', ',', 'perphenazine', '5', 'mg', ',', 'metoclopramide', '10', 'mg', ',', 'or', 'placebo', 'prior', 'to', 'induction', 'of', 'anesthesia', '.']","(26, 27)","(135, 142)",-1,hl_i,7598243,Abstract,2,test,gold,4292.0
7070,Hypotension immediately after administration of,metoclopramide,was observed in two patients and four patients given ondansetron developed profound systolic hypotension at induction of anesthesia .,"['Hypotension', 'immediately', 'after', 'administration', 'of', 'metoclopramide', 'was', 'observed', 'in', 'two', 'patients', 'and', 'four', 'patients', 'given', 'ondansetron', 'developed', 'profound', 'systolic', 'hypotension', 'at', 'induction', 'of', 'anesthesia', '.']","(5, 6)","(47, 61)",-1,ss_i,7598243,Abstract,3,test,gold,5307.0
7071,Hypotension immediately after administration of metoclopramide was observed in two patients and four patients given,ondansetron,developed profound systolic hypotension at induction of anesthesia .,"['Hypotension', 'immediately', 'after', 'administration', 'of', 'metoclopramide', 'was', 'observed', 'in', 'two', 'patients', 'and', 'four', 'patients', 'given', 'ondansetron', 'developed', 'profound', 'systolic', 'hypotension', 'at', 'induction', 'of', 'anesthesia', '.']","(15, 16)","(115, 126)",-1,ss_i,7598243,Abstract,3,test,gold,5633.0
7072,,Hypotension,immediately after administration of metoclopramide was observed in two patients and four patients given ondansetron developed profound systolic hypotension at induction of anesthesia .,"['Hypotension', 'immediately', 'after', 'administration', 'of', 'metoclopramide', 'was', 'observed', 'in', 'two', 'patients', 'and', 'four', 'patients', 'given', 'ondansetron', 'developed', 'profound', 'systolic', 'hypotension', 'at', 'induction', 'of', 'anesthesia', '.']","(0, 1)","(0, 11)",-1,ss_o,7598243,Abstract,3,test,gold,68.0
7073,Hypotension immediately after administration of metoclopramide was observed in two patients and four patients given ondansetron developed profound,systolic hypotension,at induction of anesthesia .,"['Hypotension', 'immediately', 'after', 'administration', 'of', 'metoclopramide', 'was', 'observed', 'in', 'two', 'patients', 'and', 'four', 'patients', 'given', 'ondansetron', 'developed', 'profound', 'systolic', 'hypotension', 'at', 'induction', 'of', 'anesthesia', '.']","(18, 20)","(146, 166)",-1,ss_o,7598243,Abstract,3,test,gold,3530.0
7074,Hypotension immediately after administration of,metoclopramide,was observed in two patients and four patients given ondansetron developed profound systolic hypotension at induction of anesthesia .,"['Hypotension', 'immediately', 'after', 'administration', 'of', 'metoclopramide', 'was', 'observed', 'in', 'two', 'patients', 'and', 'four', 'patients', 'given', 'ondansetron', 'developed', 'profound', 'systolic', 'hypotension', 'at', 'induction', 'of', 'anesthesia', '.']","(5, 6)","(47, 61)",-1,hl_i,7598243,Abstract,3,test,gold,5306.0
7075,,Hypotension,immediately after administration of metoclopramide was observed in two patients and four patients given ondansetron developed profound systolic hypotension at induction of anesthesia .,"['Hypotension', 'immediately', 'after', 'administration', 'of', 'metoclopramide', 'was', 'observed', 'in', 'two', 'patients', 'and', 'four', 'patients', 'given', 'ondansetron', 'developed', 'profound', 'systolic', 'hypotension', 'at', 'induction', 'of', 'anesthesia', '.']","(0, 1)","(0, 11)",-1,hl_o,7598243,Abstract,3,test,gold,69.0
7076,Twenty-two percent of patients receiving,droperidol,became sedated .,"['Twenty-two', 'percent', 'of', 'patients', 'receiving', 'droperidol', 'became', 'sedated', '.']","(5, 6)","(40, 50)",-1,ss_i,7598243,Abstract,4,test,gold,30.0
7077,"Postoperatively , patients developing","severe nausea , retching , or vomiting , defined as severe emetic sequelae ( SES )",", were deemed to have failed antiemetic prophylaxis and received antiemetic rescue .","['Postoperatively', ',', 'patients', 'developing', 'severe', 'nausea', ',', 'retching', ',', 'or', 'vomiting', ',', 'defined', 'as', 'severe', 'emetic', 'sequelae', '(', 'SES', ')', ',', 'were', 'deemed', 'to', 'have', 'failed', 'antiemetic', 'prophylaxis', 'and', 'received', 'antiemetic', 'rescue', '.']","(4, 20)","(37, 119)",-1,ss_o,7598243,Abstract,5,test,gold,7125.0
7078,"Postoperatively , patients developing","severe nausea , retching , or vomiting",", defined as severe emetic sequelae ( SES ) , were deemed to have failed antiemetic prophylaxis and received antiemetic rescue .","['Postoperatively', ',', 'patients', 'developing', 'severe', 'nausea', ',', 'retching', ',', 'or', 'vomiting', ',', 'defined', 'as', 'severe', 'emetic', 'sequelae', '(', 'SES', ')', ',', 'were', 'deemed', 'to', 'have', 'failed', 'antiemetic', 'prophylaxis', 'and', 'received', 'antiemetic', 'rescue', '.']","(4, 11)","(37, 75)",-1,hl_o,7598243,Abstract,5,test,gold,7138.0
7079,"Postoperatively , patients developing severe nausea , retching , or vomiting , defined as",severe emetic sequelae ( SES ),", were deemed to have failed antiemetic prophylaxis and received antiemetic rescue .","['Postoperatively', ',', 'patients', 'developing', 'severe', 'nausea', ',', 'retching', ',', 'or', 'vomiting', ',', 'defined', 'as', 'severe', 'emetic', 'sequelae', '(', 'SES', ')', ',', 'were', 'deemed', 'to', 'have', 'failed', 'antiemetic', 'prophylaxis', 'and', 'received', 'antiemetic', 'rescue', '.']","(14, 20)","(89, 119)",-1,hl_o,7598243,Abstract,5,test,gold,3466.0
7080,A significantly larger number of patients who received i.v .,,,"['A', 'significantly', 'larger', 'number', 'of', 'patients', 'who', 'received', 'i.v', '.']",,,,,7598243,Abstract,6,test,gold,
7081,,ondansetron,"( 63 % ) , droperidol ( 76 % ) , and perphenazine ( 70 % ) were free of SES when compared to placebo ( 43 % ) ; P < 0.05 .","['ondansetron', '(', '63', '%', ')', ',', 'droperidol', '(', '76', '%', ')', ',', 'and', 'perphenazine', '(', '70', '%', ')', 'were', 'free', 'of', 'SES', 'when', 'compared', 'to', 'placebo', '(', '43', '%', ')', ';', 'P', '<', '0.05', '.']","(0, 1)","(0, 11)",-1,ss_i,7598243,Abstract,7,test,gold,5632.0
7082,"ondansetron ( 63 % ) ,",droperidol,"( 76 % ) , and perphenazine ( 70 % ) were free of SES when compared to placebo ( 43 % ) ; P < 0.05 .","['ondansetron', '(', '63', '%', ')', ',', 'droperidol', '(', '76', '%', ')', ',', 'and', 'perphenazine', '(', '70', '%', ')', 'were', 'free', 'of', 'SES', 'when', 'compared', 'to', 'placebo', '(', '43', '%', ')', ';', 'P', '<', '0.05', '.']","(6, 7)","(22, 32)",-1,ss_i,7598243,Abstract,7,test,gold,29.0
7083,"ondansetron ( 63 % ) , droperidol ( 76 % ) , and",perphenazine,( 70 % ) were free of SES when compared to placebo ( 43 % ) ; P < 0.05 .,"['ondansetron', '(', '63', '%', ')', ',', 'droperidol', '(', '76', '%', ')', ',', 'and', 'perphenazine', '(', '70', '%', ')', 'were', 'free', 'of', 'SES', 'when', 'compared', 'to', 'placebo', '(', '43', '%', ')', ';', 'P', '<', '0.05', '.']","(13, 14)","(48, 60)",-1,ss_i,7598243,Abstract,7,test,gold,5614.0
7084,"ondansetron ( 63 % ) , droperidol ( 76 % ) , and perphenazine ( 70 % ) were free of SES when compared to",placebo,( 43 % ) ; P < 0.05 .,"['ondansetron', '(', '63', '%', ')', ',', 'droperidol', '(', '76', '%', ')', ',', 'and', 'perphenazine', '(', '70', '%', ')', 'were', 'free', 'of', 'SES', 'when', 'compared', 'to', 'placebo', '(', '43', '%', ')', ';', 'P', '<', '0.05', '.']","(25, 26)","(104, 111)",-1,ss_i,7598243,Abstract,7,test,gold,4291.0
7085,"ondansetron ( 63 % ) , droperidol ( 76 % ) , and perphenazine ( 70 % ) were free of",SES,when compared to placebo ( 43 % ) ; P < 0.05 .,"['ondansetron', '(', '63', '%', ')', ',', 'droperidol', '(', '76', '%', ')', ',', 'and', 'perphenazine', '(', '70', '%', ')', 'were', 'free', 'of', 'SES', 'when', 'compared', 'to', 'placebo', '(', '43', '%', ')', ';', 'P', '<', '0.05', '.']","(21, 22)","(83, 86)",-1,ss_o,7598243,Abstract,7,test,gold,1116.0
7086,"ondansetron ( 63 % ) , droperidol ( 76 % ) , and perphenazine ( 70 % ) were free of",SES,when compared to placebo ( 43 % ) ; P < 0.05 .,"['ondansetron', '(', '63', '%', ')', ',', 'droperidol', '(', '76', '%', ')', ',', 'and', 'perphenazine', '(', '70', '%', ')', 'were', 'free', 'of', 'SES', 'when', 'compared', 'to', 'placebo', '(', '43', '%', ')', ';', 'P', '<', '0.05', '.']","(21, 22)","(83, 86)",-1,hl_o,7598243,Abstract,7,test,gold,1117.0
7087,,Metoclopramide,was ineffective .,"['Metoclopramide', 'was', 'ineffective', '.']","(0, 1)","(0, 14)",-1,ss_i,7598243,Abstract,8,test,gold,1035.0
7088,Although,"ondansetron , droperidol",", and perphenazine were effective in providing antiemetic prophylaxis , only i.v .","['Although', 'ondansetron', ',', 'droperidol', ',', 'and', 'perphenazine', 'were', 'effective', 'in', 'providing', 'antiemetic', 'prophylaxis', ',', 'only', 'i.v', '.']","(1, 4)","(8, 32)",-1,ss_i,7598243,Abstract,9,test,gold,5631.0
7089,"Although ondansetron , droperidol , and",perphenazine,"were effective in providing antiemetic prophylaxis , only i.v .","['Although', 'ondansetron', ',', 'droperidol', ',', 'and', 'perphenazine', 'were', 'effective', 'in', 'providing', 'antiemetic', 'prophylaxis', ',', 'only', 'i.v', '.']","(6, 7)","(39, 51)",-1,ss_i,7598243,Abstract,9,test,gold,5613.0
7090,"Although ondansetron , droperidol , and perphenazine were",effective,"in providing antiemetic prophylaxis , only i.v .","['Although', 'ondansetron', ',', 'droperidol', ',', 'and', 'perphenazine', 'were', 'effective', 'in', 'providing', 'antiemetic', 'prophylaxis', ',', 'only', 'i.v', '.']","(8, 9)","(57, 66)",-1,ss_o,7598243,Abstract,9,test,gold,844.0
7091,"Although ondansetron , droperidol , and perphenazine were",effective,"in providing antiemetic prophylaxis , only i.v .","['Although', 'ondansetron', ',', 'droperidol', ',', 'and', 'perphenazine', 'were', 'effective', 'in', 'providing', 'antiemetic', 'prophylaxis', ',', 'only', 'i.v', '.']","(8, 9)","(57, 66)",-1,hl_o,7598243,Abstract,9,test,gold,843.0
7092,,perphenazine,was free of side effects .,"['perphenazine', 'was', 'free', 'of', 'side', 'effects', '.']","(0, 1)","(0, 12)",-1,ss_i,7598243,Abstract,10,test,gold,5612.0
7093,perphenazine was free of,side effects .,,"['perphenazine', 'was', 'free', 'of', 'side', 'effects', '.']","(4, 7)","(24, 38)",-1,ss_o,7598243,Abstract,10,test,gold,2367.0
7094,perphenazine was free of,side effects .,,"['perphenazine', 'was', 'free', 'of', 'side', 'effects', '.']","(4, 7)","(24, 38)",-1,hl_o,7598243,Abstract,10,test,gold,2366.0
7095,"Hence , we conclude that",perphenazine,is the best choice for antiemetic prophylaxis after TAH .,"['Hence', ',', 'we', 'conclude', 'that', 'perphenazine', 'is', 'the', 'best', 'choice', 'for', 'antiemetic', 'prophylaxis', 'after', 'TAH', '.']","(5, 6)","(24, 36)",-1,ss_i,7598243,Abstract,11,test,gold,5611.0
7096,Effects of,individualized breast cancer risk counseling :,a randomized trial .,"['Effects', 'of', 'individualized', 'breast', 'cancer', 'risk', 'counseling', ':', 'a', 'randomized', 'trial', '.']","(2, 8)","(10, 56)",-1,ss_i,7707420,Title,0,test,gold,6872.0
7097,Effects of individualized breast cancer,risk counseling :,a randomized trial .,"['Effects', 'of', 'individualized', 'breast', 'cancer', 'risk', 'counseling', ':', 'a', 'randomized', 'trial', '.']","(5, 8)","(39, 56)",-1,ss_o,7707420,Title,0,test,gold,4032.0
7098,Effects of,individualized breast cancer risk counseling :,a randomized trial .,"['Effects', 'of', 'individualized', 'breast', 'cancer', 'risk', 'counseling', ':', 'a', 'randomized', 'trial', '.']","(2, 8)","(10, 56)",-1,hl_i,7707420,Title,0,test,gold,6873.0
7099,BACKGROUND Studies have shown that a majority of women with a family history of breast cancer have exaggerated perceptions of their own,risk,of this disease and experience excessive anxiety .,"['BACKGROUND', 'Studies', 'have', 'shown', 'that', 'a', 'majority', 'of', 'women', 'with', 'a', 'family', 'history', 'of', 'breast', 'cancer', 'have', 'exaggerated', 'perceptions', 'of', 'their', 'own', 'risk', 'of', 'this', 'disease', 'and', 'experience', 'excessive', 'anxiety', '.']","(22, 23)","(135, 139)",-1,ss_o,7707420,Abstract,0,test,gold,2496.0
7100,"In response to the need to communicate more accurate risk information to these women , specialized programs for breast cancer",risk,counseling have been initiated in medical centers across the United States .,"['In', 'response', 'to', 'the', 'need', 'to', 'communicate', 'more', 'accurate', 'risk', 'information', 'to', 'these', 'women', ',', 'specialized', 'programs', 'for', 'breast', 'cancer', 'risk', 'counseling', 'have', 'been', 'initiated', 'in', 'medical', 'centers', 'across', 'the', 'United', 'States', '.']","(20, 21)","(125, 129)",-1,ss_o,7707420,Abstract,1,test,gold,2495.0
7101,PURPOSE Our purpose was 1 ) to evaluate the impact of a standardized protocol for individualized breast cancer risk counseling on comprehension of personal risk among,first-degree relatives of index breast cancer patients,and 2 ) to identify women most and least likely to benefit from such counseling .,"['PURPOSE', 'Our', 'purpose', 'was', '1', ')', 'to', 'evaluate', 'the', 'impact', 'of', 'a', 'standardized', 'protocol', 'for', 'individualized', 'breast', 'cancer', 'risk', 'counseling', 'on', 'comprehension', 'of', 'personal', 'risk', 'among', 'first-degree', 'relatives', 'of', 'index', 'breast', 'cancer', 'patients', 'and', '2', ')', 'to', 'identify', 'women', 'most', 'and', 'least', 'likely', 'to', 'benefit', 'from', 'such', 'counseling', '.']","(26, 33)","(166, 220)",-1,ss_p,7707420,Abstract,2,test,gold,6826.0
7102,PURPOSE Our purpose was 1 ) to evaluate the impact of a standardized protocol for,individualized breast cancer risk counseling,on comprehension of personal risk among first-degree relatives of index breast cancer patients and 2 ) to identify women most and least likely to benefit from such counseling .,"['PURPOSE', 'Our', 'purpose', 'was', '1', ')', 'to', 'evaluate', 'the', 'impact', 'of', 'a', 'standardized', 'protocol', 'for', 'individualized', 'breast', 'cancer', 'risk', 'counseling', 'on', 'comprehension', 'of', 'personal', 'risk', 'among', 'first-degree', 'relatives', 'of', 'index', 'breast', 'cancer', 'patients', 'and', '2', ')', 'to', 'identify', 'women', 'most', 'and', 'least', 'likely', 'to', 'benefit', 'from', 'such', 'counseling', '.']","(15, 20)","(81, 125)",-1,ss_i,7707420,Abstract,2,test,gold,6871.0
7103,PURPOSE Our purpose was 1 ) to evaluate the impact of a standardized protocol for individualized breast cancer risk counseling on comprehension of personal risk among first-degree relatives of index breast cancer patients and 2 ) to identify women most and least likely to benefit from such,counseling .,,"['PURPOSE', 'Our', 'purpose', 'was', '1', ')', 'to', 'evaluate', 'the', 'impact', 'of', 'a', 'standardized', 'protocol', 'for', 'individualized', 'breast', 'cancer', 'risk', 'counseling', 'on', 'comprehension', 'of', 'personal', 'risk', 'among', 'first-degree', 'relatives', 'of', 'index', 'breast', 'cancer', 'patients', 'and', '2', ')', 'to', 'identify', 'women', 'most', 'and', 'least', 'likely', 'to', 'benefit', 'from', 'such', 'counseling', '.']","(47, 49)","(290, 302)",-1,ss_i,7707420,Abstract,2,test,gold,4027.0
7104,PURPOSE Our purpose was 1 ) to evaluate the impact of a standardized protocol for individualized breast cancer,risk,counseling on comprehension of personal risk among first-degree relatives of index breast cancer patients and 2 ) to identify women most and least likely to benefit from such counseling .,"['PURPOSE', 'Our', 'purpose', 'was', '1', ')', 'to', 'evaluate', 'the', 'impact', 'of', 'a', 'standardized', 'protocol', 'for', 'individualized', 'breast', 'cancer', 'risk', 'counseling', 'on', 'comprehension', 'of', 'personal', 'risk', 'among', 'first-degree', 'relatives', 'of', 'index', 'breast', 'cancer', 'patients', 'and', '2', ')', 'to', 'identify', 'women', 'most', 'and', 'least', 'likely', 'to', 'benefit', 'from', 'such', 'counseling', '.']","(18, 19)","(110, 114)",-1,ss_o,7707420,Abstract,2,test,gold,2494.0
7105,PURPOSE Our purpose was 1 ) to evaluate the impact of a standardized protocol for individualized breast cancer risk counseling on comprehension of personal risk among first-degree relatives of index breast cancer patients and 2 ) to identify women most and least likely to,benefit,from such counseling .,"['PURPOSE', 'Our', 'purpose', 'was', '1', ')', 'to', 'evaluate', 'the', 'impact', 'of', 'a', 'standardized', 'protocol', 'for', 'individualized', 'breast', 'cancer', 'risk', 'counseling', 'on', 'comprehension', 'of', 'personal', 'risk', 'among', 'first-degree', 'relatives', 'of', 'index', 'breast', 'cancer', 'patients', 'and', '2', ')', 'to', 'identify', 'women', 'most', 'and', 'least', 'likely', 'to', 'benefit', 'from', 'such', 'counseling', '.']","(44, 45)","(272, 279)",-1,ss_o,7707420,Abstract,2,test,gold,1219.0
7106,PURPOSE Our purpose was 1 ) to evaluate the impact of a standardized protocol for individualized breast cancer risk counseling on comprehension of personal risk among,first-degree relatives of index breast cancer patients,and 2 ) to identify women most and least likely to benefit from such counseling .,"['PURPOSE', 'Our', 'purpose', 'was', '1', ')', 'to', 'evaluate', 'the', 'impact', 'of', 'a', 'standardized', 'protocol', 'for', 'individualized', 'breast', 'cancer', 'risk', 'counseling', 'on', 'comprehension', 'of', 'personal', 'risk', 'among', 'first-degree', 'relatives', 'of', 'index', 'breast', 'cancer', 'patients', 'and', '2', ')', 'to', 'identify', 'women', 'most', 'and', 'least', 'likely', 'to', 'benefit', 'from', 'such', 'counseling', '.']","(26, 33)","(166, 220)",-1,hl_p,7707420,Abstract,2,test,gold,6827.0
7107,PURPOSE Our purpose was 1 ) to evaluate the impact of a standardized protocol for,individualized breast cancer risk counseling,on comprehension of personal risk among first-degree relatives of index breast cancer patients and 2 ) to identify women most and least likely to benefit from such counseling .,"['PURPOSE', 'Our', 'purpose', 'was', '1', ')', 'to', 'evaluate', 'the', 'impact', 'of', 'a', 'standardized', 'protocol', 'for', 'individualized', 'breast', 'cancer', 'risk', 'counseling', 'on', 'comprehension', 'of', 'personal', 'risk', 'among', 'first-degree', 'relatives', 'of', 'index', 'breast', 'cancer', 'patients', 'and', '2', ')', 'to', 'identify', 'women', 'most', 'and', 'least', 'likely', 'to', 'benefit', 'from', 'such', 'counseling', '.']","(15, 20)","(81, 125)",-1,hl_i,7707420,Abstract,2,test,gold,6870.0
7108,PURPOSE Our purpose was 1 ) to evaluate the impact of a standardized protocol for individualized breast cancer risk counseling on,comprehension of personal risk,among first-degree relatives of index breast cancer patients and 2 ) to identify women most and least likely to benefit from such counseling .,"['PURPOSE', 'Our', 'purpose', 'was', '1', ')', 'to', 'evaluate', 'the', 'impact', 'of', 'a', 'standardized', 'protocol', 'for', 'individualized', 'breast', 'cancer', 'risk', 'counseling', 'on', 'comprehension', 'of', 'personal', 'risk', 'among', 'first-degree', 'relatives', 'of', 'index', 'breast', 'cancer', 'patients', 'and', '2', ')', 'to', 'identify', 'women', 'most', 'and', 'least', 'likely', 'to', 'benefit', 'from', 'such', 'counseling', '.']","(21, 25)","(129, 159)",-1,hl_o,7707420,Abstract,2,test,gold,2484.0
7109,METHODS This study is a prospective randomized trial comparing,individualized breast cancer risk counseling,to general health counseling ( control ) .,"['METHODS', 'This', 'study', 'is', 'a', 'prospective', 'randomized', 'trial', 'comparing', 'individualized', 'breast', 'cancer', 'risk', 'counseling', 'to', 'general', 'health', 'counseling', '(', 'control', ')', '.']","(9, 14)","(62, 106)",-1,ss_i,7707420,Abstract,3,test,gold,6869.0
7110,METHODS This study is a prospective randomized trial comparing individualized breast cancer risk counseling to,general health counseling ( control ) .,,"['METHODS', 'This', 'study', 'is', 'a', 'prospective', 'randomized', 'trial', 'comparing', 'individualized', 'breast', 'cancer', 'risk', 'counseling', 'to', 'general', 'health', 'counseling', '(', 'control', ')', '.']","(15, 22)","(110, 149)",-1,ss_i,7707420,Abstract,3,test,gold,4025.0
7111,METHODS This study is a prospective randomized trial comparing individualized breast cancer,risk,counseling to general health counseling ( control ) .,"['METHODS', 'This', 'study', 'is', 'a', 'prospective', 'randomized', 'trial', 'comparing', 'individualized', 'breast', 'cancer', 'risk', 'counseling', 'to', 'general', 'health', 'counseling', '(', 'control', ')', '.']","(12, 13)","(91, 95)",-1,ss_o,7707420,Abstract,3,test,gold,2493.0
7112,METHODS This study is a prospective randomized trial comparing,individualized breast cancer risk counseling,to general health counseling ( control ) .,"['METHODS', 'This', 'study', 'is', 'a', 'prospective', 'randomized', 'trial', 'comparing', 'individualized', 'breast', 'cancer', 'risk', 'counseling', 'to', 'general', 'health', 'counseling', '(', 'control', ')', '.']","(9, 14)","(62, 106)",-1,hl_i,7707420,Abstract,3,test,gold,6868.0
7113,METHODS This study is a prospective randomized trial comparing individualized breast cancer risk counseling to,general health counseling ( control ) .,,"['METHODS', 'This', 'study', 'is', 'a', 'prospective', 'randomized', 'trial', 'comparing', 'individualized', 'breast', 'cancer', 'risk', 'counseling', 'to', 'general', 'health', 'counseling', '(', 'control', ')', '.']","(15, 22)","(110, 149)",-1,hl_i,7707420,Abstract,3,test,gold,4026.0
7114,We studied,200 women aged 35 years and older who had a family history of breast cancer in a first-degree relative .,,"['We', 'studied', '200', 'women', 'aged', '35', 'years', 'and', 'older', 'who', 'had', 'a', 'family', 'history', 'of', 'breast', 'cancer', 'in', 'a', 'first-degree', 'relative', '.']","(2, 22)","(10, 114)",-1,ss_p,7707420,Abstract,4,test,gold,5840.0
7115,We studied,200 women aged 35 years and older,who had a family history of breast cancer in a first-degree relative .,"['We', 'studied', '200', 'women', 'aged', '35', 'years', 'and', 'older', 'who', 'had', 'a', 'family', 'history', 'of', 'breast', 'cancer', 'in', 'a', 'first-degree', 'relative', '.']","(2, 9)","(10, 43)",-1,hl_p,7707420,Abstract,4,test,gold,2044.0
7116,We studied 200 women aged 35 years and older who had a,family history of breast cancer in a first-degree relative,.,"['We', 'studied', '200', 'women', 'aged', '35', 'years', 'and', 'older', 'who', 'had', 'a', 'family', 'history', 'of', 'breast', 'cancer', 'in', 'a', 'first-degree', 'relative', '.']","(12, 21)","(54, 112)",-1,hl_p,7707420,Abstract,4,test,gold,6892.0
7117,,Women with a personal history of cancer were excluded .,,"['Women', 'with', 'a', 'personal', 'history', 'of', 'cancer', 'were', 'excluded', '.']","(0, 10)","(0, 55)",-1,ss_p,7707420,Abstract,5,test,gold,6893.0
7118,,Women,with a personal history of cancer were excluded .,"['Women', 'with', 'a', 'personal', 'history', 'of', 'cancer', 'were', 'excluded', '.']","(0, 1)","(0, 5)",-1,hl_p,7707420,Abstract,5,test,gold,2238.0
7119,Women with a,personal history of cancer,were excluded .,"['Women', 'with', 'a', 'personal', 'history', 'of', 'cancer', 'were', 'excluded', '.']","(3, 7)","(12, 38)",-1,hl_p,7707420,Abstract,5,test,gold,6885.0
7120,,Risk comprehension,"was assessed as the concordance between perceived "" subjective "" lifetime breast cancer risk and estimated "" objective "" lifetime risk .","['Risk', 'comprehension', 'was', 'assessed', 'as', 'the', 'concordance', 'between', 'perceived', '""', 'subjective', '""', 'lifetime', 'breast', 'cancer', 'risk', 'and', 'estimated', '""', 'objective', '""', 'lifetime', 'risk', '.']","(0, 2)","(0, 18)",-1,ss_o,7707420,Abstract,6,test,gold,2482.0
7121,Risk comprehension was assessed as the,"concordance between perceived "" subjective "" lifetime breast cancer risk and estimated "" objective "" lifetime risk .",,"['Risk', 'comprehension', 'was', 'assessed', 'as', 'the', 'concordance', 'between', 'perceived', '""', 'subjective', '""', 'lifetime', 'breast', 'cancer', 'risk', 'and', 'estimated', '""', 'objective', '""', 'lifetime', 'risk', '.']","(6, 24)","(38, 154)",-1,ss_o,7707420,Abstract,6,test,gold,5912.0
7122,,Risk comprehension,"was assessed as the concordance between perceived "" subjective "" lifetime breast cancer risk and estimated "" objective "" lifetime risk .","['Risk', 'comprehension', 'was', 'assessed', 'as', 'the', 'concordance', 'between', 'perceived', '""', 'subjective', '""', 'lifetime', 'breast', 'cancer', 'risk', 'and', 'estimated', '""', 'objective', '""', 'lifetime', 'risk', '.']","(0, 2)","(0, 18)",-1,hl_o,7707420,Abstract,6,test,gold,2483.0
7123,RESULTS The results of logistic regression analysis showed that women who received,risk counseling,"were significantly more likely to improve their risk comprehension , compared with women in the control condition ( odds ratio [ OR ] = 3.5 ; 95 % confidence interval [ CI ] = 1.3-9.5 ; P = .01 ) .","['RESULTS', 'The', 'results', 'of', 'logistic', 'regression', 'analysis', 'showed', 'that', 'women', 'who', 'received', 'risk', 'counseling', 'were', 'significantly', 'more', 'likely', 'to', 'improve', 'their', 'risk', 'comprehension', ',', 'compared', 'with', 'women', 'in', 'the', 'control', 'condition', '(', 'odds', 'ratio', '[', 'OR', ']', '=', '3.5', ';', '95', '%', 'confidence', 'interval', '[', 'CI', ']', '=', '1.3-9.5', ';', 'P', '=', '.01', ')', '.']","(12, 14)","(82, 97)",-1,ss_i,7707420,Abstract,7,test,gold,4033.0
7124,RESULTS The results of logistic regression analysis showed that women who received,risk,"counseling were significantly more likely to improve their risk comprehension , compared with women in the control condition ( odds ratio [ OR ] = 3.5 ; 95 % confidence interval [ CI ] = 1.3-9.5 ; P = .01 ) .","['RESULTS', 'The', 'results', 'of', 'logistic', 'regression', 'analysis', 'showed', 'that', 'women', 'who', 'received', 'risk', 'counseling', 'were', 'significantly', 'more', 'likely', 'to', 'improve', 'their', 'risk', 'comprehension', ',', 'compared', 'with', 'women', 'in', 'the', 'control', 'condition', '(', 'odds', 'ratio', '[', 'OR', ']', '=', '3.5', ';', '95', '%', 'confidence', 'interval', '[', 'CI', ']', '=', '1.3-9.5', ';', 'P', '=', '.01', ')', '.']","(12, 13)","(82, 86)",-1,ss_o,7707420,Abstract,7,test,gold,2492.0
7125,RESULTS The results of logistic regression analysis showed that women who received risk counseling were significantly more likely to improve their,risk comprehension,", compared with women in the control condition ( odds ratio [ OR ] = 3.5 ; 95 % confidence interval [ CI ] = 1.3-9.5 ; P = .01 ) .","['RESULTS', 'The', 'results', 'of', 'logistic', 'regression', 'analysis', 'showed', 'that', 'women', 'who', 'received', 'risk', 'counseling', 'were', 'significantly', 'more', 'likely', 'to', 'improve', 'their', 'risk', 'comprehension', ',', 'compared', 'with', 'women', 'in', 'the', 'control', 'condition', '(', 'odds', 'ratio', '[', 'OR', ']', '=', '3.5', ';', '95', '%', 'confidence', 'interval', '[', 'CI', ']', '=', '1.3-9.5', ';', 'P', '=', '.01', ')', '.']","(21, 23)","(146, 164)",-1,ss_o,7707420,Abstract,7,test,gold,2485.0
7126,RESULTS The results of logistic regression analysis showed that women who received,risk counseling,"were significantly more likely to improve their risk comprehension , compared with women in the control condition ( odds ratio [ OR ] = 3.5 ; 95 % confidence interval [ CI ] = 1.3-9.5 ; P = .01 ) .","['RESULTS', 'The', 'results', 'of', 'logistic', 'regression', 'analysis', 'showed', 'that', 'women', 'who', 'received', 'risk', 'counseling', 'were', 'significantly', 'more', 'likely', 'to', 'improve', 'their', 'risk', 'comprehension', ',', 'compared', 'with', 'women', 'in', 'the', 'control', 'condition', '(', 'odds', 'ratio', '[', 'OR', ']', '=', '3.5', ';', '95', '%', 'confidence', 'interval', '[', 'CI', ']', '=', '1.3-9.5', ';', 'P', '=', '.01', ')', '.']","(12, 14)","(82, 97)",-1,hl_i,7707420,Abstract,7,test,gold,4031.0
7127,RESULTS The results of logistic regression analysis showed that women who received risk counseling were significantly more likely to improve their,risk comprehension,", compared with women in the control condition ( odds ratio [ OR ] = 3.5 ; 95 % confidence interval [ CI ] = 1.3-9.5 ; P = .01 ) .","['RESULTS', 'The', 'results', 'of', 'logistic', 'regression', 'analysis', 'showed', 'that', 'women', 'who', 'received', 'risk', 'counseling', 'were', 'significantly', 'more', 'likely', 'to', 'improve', 'their', 'risk', 'comprehension', ',', 'compared', 'with', 'women', 'in', 'the', 'control', 'condition', '(', 'odds', 'ratio', '[', 'OR', ']', '=', '3.5', ';', '95', '%', 'confidence', 'interval', '[', 'CI', ']', '=', '1.3-9.5', ';', 'P', '=', '.01', ')', '.']","(21, 23)","(146, 164)",-1,hl_o,7707420,Abstract,7,test,gold,2486.0
7128,"However , in both groups , about two thirds of women continued to overestimate their lifetime risks substantially following",counseling .,,"['However', ',', 'in', 'both', 'groups', ',', 'about', 'two', 'thirds', 'of', 'women', 'continued', 'to', 'overestimate', 'their', 'lifetime', 'risks', 'substantially', 'following', 'counseling', '.']","(19, 21)","(123, 135)",-1,ss_i,7707420,Abstract,8,test,gold,4028.0
7129,"However , in both groups , about two thirds of women continued to overestimate their",lifetime risks,substantially following counseling .,"['However', ',', 'in', 'both', 'groups', ',', 'about', 'two', 'thirds', 'of', 'women', 'continued', 'to', 'overestimate', 'their', 'lifetime', 'risks', 'substantially', 'following', 'counseling', '.']","(15, 17)","(84, 98)",-1,ss_o,7707420,Abstract,8,test,gold,2487.0
7130,"However , in both groups , about two thirds of women continued to overestimate their",lifetime risks,substantially following counseling .,"['However', ',', 'in', 'both', 'groups', ',', 'about', 'two', 'thirds', 'of', 'women', 'continued', 'to', 'overestimate', 'their', 'lifetime', 'risks', 'substantially', 'following', 'counseling', '.']","(15, 17)","(84, 98)",-1,hl_o,7707420,Abstract,8,test,gold,2488.0
7131,Examination of subjects by treatment interaction effects indicated that,risk counseling,did not produce improved comprehension among the large proportion of women who had high levels of anxious preoccupation with breast cancer at base line ( P = .02 ) .,"['Examination', 'of', 'subjects', 'by', 'treatment', 'interaction', 'effects', 'indicated', 'that', 'risk', 'counseling', 'did', 'not', 'produce', 'improved', 'comprehension', 'among', 'the', 'large', 'proportion', 'of', 'women', 'who', 'had', 'high', 'levels', 'of', 'anxious', 'preoccupation', 'with', 'breast', 'cancer', 'at', 'base', 'line', '(', 'P', '=', '.02', ')', '.']","(9, 11)","(71, 86)",-1,ss_i,7707420,Abstract,9,test,gold,4030.0
7132,Examination of subjects by treatment interaction effects indicated that,risk,counseling did not produce improved comprehension among the large proportion of women who had high levels of anxious preoccupation with breast cancer at base line ( P = .02 ) .,"['Examination', 'of', 'subjects', 'by', 'treatment', 'interaction', 'effects', 'indicated', 'that', 'risk', 'counseling', 'did', 'not', 'produce', 'improved', 'comprehension', 'among', 'the', 'large', 'proportion', 'of', 'women', 'who', 'had', 'high', 'levels', 'of', 'anxious', 'preoccupation', 'with', 'breast', 'cancer', 'at', 'base', 'line', '(', 'P', '=', '.02', ')', '.']","(9, 10)","(71, 75)",-1,ss_o,7707420,Abstract,9,test,gold,2491.0
7133,Examination of subjects by treatment interaction effects indicated that risk counseling did not produce improved,comprehension,among the large proportion of women who had high levels of anxious preoccupation with breast cancer at base line ( P = .02 ) .,"['Examination', 'of', 'subjects', 'by', 'treatment', 'interaction', 'effects', 'indicated', 'that', 'risk', 'counseling', 'did', 'not', 'produce', 'improved', 'comprehension', 'among', 'the', 'large', 'proportion', 'of', 'women', 'who', 'had', 'high', 'levels', 'of', 'anxious', 'preoccupation', 'with', 'breast', 'cancer', 'at', 'base', 'line', '(', 'P', '=', '.02', ')', '.']","(15, 16)","(112, 125)",-1,ss_o,7707420,Abstract,9,test,gold,2480.0
7134,Examination of subjects by treatment interaction effects indicated that,risk counseling,did not produce improved comprehension among the large proportion of women who had high levels of anxious preoccupation with breast cancer at base line ( P = .02 ) .,"['Examination', 'of', 'subjects', 'by', 'treatment', 'interaction', 'effects', 'indicated', 'that', 'risk', 'counseling', 'did', 'not', 'produce', 'improved', 'comprehension', 'among', 'the', 'large', 'proportion', 'of', 'women', 'who', 'had', 'high', 'levels', 'of', 'anxious', 'preoccupation', 'with', 'breast', 'cancer', 'at', 'base', 'line', '(', 'P', '=', '.02', ')', '.']","(9, 11)","(71, 86)",-1,hl_i,7707420,Abstract,9,test,gold,4029.0
7135,Examination of subjects by treatment interaction effects indicated that risk counseling did not produce improved,comprehension,among the large proportion of women who had high levels of anxious preoccupation with breast cancer at base line ( P = .02 ) .,"['Examination', 'of', 'subjects', 'by', 'treatment', 'interaction', 'effects', 'indicated', 'that', 'risk', 'counseling', 'did', 'not', 'produce', 'improved', 'comprehension', 'among', 'the', 'large', 'proportion', 'of', 'women', 'who', 'had', 'high', 'levels', 'of', 'anxious', 'preoccupation', 'with', 'breast', 'cancer', 'at', 'base', 'line', '(', 'P', '=', '.02', ')', '.']","(15, 16)","(112, 125)",-1,hl_o,7707420,Abstract,9,test,gold,2481.0
7136,"In addition , white women were less likely to benefit than African-American women ( OR = 0.34 ; 95 % CI = 0.11-0.99 ; P = .05 ) .",,,"['In', 'addition', ',', 'white', 'women', 'were', 'less', 'likely', 'to', 'benefit', 'than', 'African-American', 'women', '(', 'OR', '=', '0.34', ';', '95', '%', 'CI', '=', '0.11-0.99', ';', 'P', '=', '.05', ')', '.']",,,,,7707420,Abstract,10,test,gold,
7137,CONCLUSION Efforts to counsel women about their breast cancer,risks,are not likely to be effective unless their breast cancer anxieties are also addressed .,"['CONCLUSION', 'Efforts', 'to', 'counsel', 'women', 'about', 'their', 'breast', 'cancer', 'risks', 'are', 'not', 'likely', 'to', 'be', 'effective', 'unless', 'their', 'breast', 'cancer', 'anxieties', 'are', 'also', 'addressed', '.']","(9, 10)","(61, 66)",-1,ss_o,7707420,Abstract,11,test,gold,2489.0
7138,CONCLUSION Efforts to counsel women about their breast cancer risks are not likely to be,effective,unless their breast cancer anxieties are also addressed .,"['CONCLUSION', 'Efforts', 'to', 'counsel', 'women', 'about', 'their', 'breast', 'cancer', 'risks', 'are', 'not', 'likely', 'to', 'be', 'effective', 'unless', 'their', 'breast', 'cancer', 'anxieties', 'are', 'also', 'addressed', '.']","(15, 16)","(88, 97)",-1,ss_o,7707420,Abstract,11,test,gold,842.0
7139,IMPLICATIONS Attention to the psychological aspects of breast cancer risk will be critical in the development of,risk-counseling programs,"that incorporate testing for the recently cloned breast cancer susceptibility gene , BRCA1 ( and BRCA2 when that gene has also been cloned ) .","['IMPLICATIONS', 'Attention', 'to', 'the', 'psychological', 'aspects', 'of', 'breast', 'cancer', 'risk', 'will', 'be', 'critical', 'in', 'the', 'development', 'of', 'risk-counseling', 'programs', 'that', 'incorporate', 'testing', 'for', 'the', 'recently', 'cloned', 'breast', 'cancer', 'susceptibility', 'gene', ',', 'BRCA1', '(', 'and', 'BRCA2', 'when', 'that', 'gene', 'has', 'also', 'been', 'cloned', ')', '.']","(17, 19)","(112, 136)",-1,ss_i,7707420,Abstract,12,test,gold,1300.0
7140,IMPLICATIONS Attention to the psychological aspects of breast cancer,risk,"will be critical in the development of risk-counseling programs that incorporate testing for the recently cloned breast cancer susceptibility gene , BRCA1 ( and BRCA2 when that gene has also been cloned ) .","['IMPLICATIONS', 'Attention', 'to', 'the', 'psychological', 'aspects', 'of', 'breast', 'cancer', 'risk', 'will', 'be', 'critical', 'in', 'the', 'development', 'of', 'risk-counseling', 'programs', 'that', 'incorporate', 'testing', 'for', 'the', 'recently', 'cloned', 'breast', 'cancer', 'susceptibility', 'gene', ',', 'BRCA1', '(', 'and', 'BRCA2', 'when', 'that', 'gene', 'has', 'also', 'been', 'cloned', ')', '.']","(9, 10)","(68, 72)",-1,ss_o,7707420,Abstract,12,test,gold,2490.0
7141,IMPLICATIONS Attention to the psychological aspects of breast cancer risk will be critical in the development of,risk-counseling,"programs that incorporate testing for the recently cloned breast cancer susceptibility gene , BRCA1 ( and BRCA2 when that gene has also been cloned ) .","['IMPLICATIONS', 'Attention', 'to', 'the', 'psychological', 'aspects', 'of', 'breast', 'cancer', 'risk', 'will', 'be', 'critical', 'in', 'the', 'development', 'of', 'risk-counseling', 'programs', 'that', 'incorporate', 'testing', 'for', 'the', 'recently', 'cloned', 'breast', 'cancer', 'susceptibility', 'gene', ',', 'BRCA1', '(', 'and', 'BRCA2', 'when', 'that', 'gene', 'has', 'also', 'been', 'cloned', ')', '.']","(17, 18)","(112, 127)",-1,ss_o,7707420,Abstract,12,test,gold,
7142,IMPLICATIONS Attention to the psychological aspects of breast cancer risk will be critical in the development of,risk-counseling programs,"that incorporate testing for the recently cloned breast cancer susceptibility gene , BRCA1 ( and BRCA2 when that gene has also been cloned ) .","['IMPLICATIONS', 'Attention', 'to', 'the', 'psychological', 'aspects', 'of', 'breast', 'cancer', 'risk', 'will', 'be', 'critical', 'in', 'the', 'development', 'of', 'risk-counseling', 'programs', 'that', 'incorporate', 'testing', 'for', 'the', 'recently', 'cloned', 'breast', 'cancer', 'susceptibility', 'gene', ',', 'BRCA1', '(', 'and', 'BRCA2', 'when', 'that', 'gene', 'has', 'also', 'been', 'cloned', ')', '.']","(17, 19)","(112, 136)",-1,hl_i,7707420,Abstract,12,test,gold,1301.0
7143,[ Double-blind,placebo-controlled,study of the effectiveness and tolerability of 10 and 30 mg ketorolac tromethamine suppositories in post-cholecystectomy pain ] .,"['[', 'Double-blind', 'placebo-controlled', 'study', 'of', 'the', 'effectiveness', 'and', 'tolerability', 'of', '10', 'and', '30', 'mg', 'ketorolac', 'tromethamine', 'suppositories', 'in', 'post-cholecystectomy', 'pain', ']', '.']","(2, 3)","(14, 32)",-1,ss_i,7808649,Title,0,test,gold,
7144,[ Double-blind placebo-controlled study of the effectiveness and tolerability of 10 and 30 mg,ketorolac tromethamine,suppositories in post-cholecystectomy pain ] .,"['[', 'Double-blind', 'placebo-controlled', 'study', 'of', 'the', 'effectiveness', 'and', 'tolerability', 'of', '10', 'and', '30', 'mg', 'ketorolac', 'tromethamine', 'suppositories', 'in', 'post-cholecystectomy', 'pain', ']', '.']","(14, 16)","(93, 115)",-1,ss_i,7808649,Title,0,test,gold,193.0
7145,[ Double-blind placebo-controlled study of the,effectiveness,and tolerability of 10 and 30 mg ketorolac tromethamine suppositories in post-cholecystectomy pain ] .,"['[', 'Double-blind', 'placebo-controlled', 'study', 'of', 'the', 'effectiveness', 'and', 'tolerability', 'of', '10', 'and', '30', 'mg', 'ketorolac', 'tromethamine', 'suppositories', 'in', 'post-cholecystectomy', 'pain', ']', '.']","(6, 7)","(46, 59)",-1,ss_o,7808649,Title,0,test,gold,388.0
7146,[ Double-blind placebo-controlled study of the effectiveness and,tolerability,of 10 and 30 mg ketorolac tromethamine suppositories in post-cholecystectomy pain ] .,"['[', 'Double-blind', 'placebo-controlled', 'study', 'of', 'the', 'effectiveness', 'and', 'tolerability', 'of', '10', 'and', '30', 'mg', 'ketorolac', 'tromethamine', 'suppositories', 'in', 'post-cholecystectomy', 'pain', ']', '.']","(8, 9)","(64, 76)",-1,ss_o,7808649,Title,0,test,gold,4862.0
7147,[ Double-blind placebo-controlled study of the effectiveness and tolerability of 10 and 30 mg,ketorolac tromethamine,suppositories in post-cholecystectomy pain ] .,"['[', 'Double-blind', 'placebo-controlled', 'study', 'of', 'the', 'effectiveness', 'and', 'tolerability', 'of', '10', 'and', '30', 'mg', 'ketorolac', 'tromethamine', 'suppositories', 'in', 'post-cholecystectomy', 'pain', ']', '.']","(14, 16)","(93, 115)",-1,hl_i,7808649,Title,0,test,gold,194.0
7148,[ Double-blind placebo-controlled study of the,effectiveness,and tolerability of 10 and 30 mg ketorolac tromethamine suppositories in post-cholecystectomy pain ] .,"['[', 'Double-blind', 'placebo-controlled', 'study', 'of', 'the', 'effectiveness', 'and', 'tolerability', 'of', '10', 'and', '30', 'mg', 'ketorolac', 'tromethamine', 'suppositories', 'in', 'post-cholecystectomy', 'pain', ']', '.']","(6, 7)","(46, 59)",-1,hl_o,7808649,Title,0,test,gold,387.0
7149,[ Double-blind placebo-controlled study of the effectiveness and,tolerability,of 10 and 30 mg ketorolac tromethamine suppositories in post-cholecystectomy pain ] .,"['[', 'Double-blind', 'placebo-controlled', 'study', 'of', 'the', 'effectiveness', 'and', 'tolerability', 'of', '10', 'and', '30', 'mg', 'ketorolac', 'tromethamine', 'suppositories', 'in', 'post-cholecystectomy', 'pain', ']', '.']","(8, 9)","(64, 76)",-1,hl_o,7808649,Title,0,test,gold,4861.0
7150,"OBJECTIVE To evaluate the efficacy and tolerability of ketorolac tromethamine 10 mg and 30 mg suppositories in comparison to placebo , after single dose administration in",patients suffering from post-operative pain after cholecystectomy .,,"['OBJECTIVE', 'To', 'evaluate', 'the', 'efficacy', 'and', 'tolerability', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'in', 'comparison', 'to', 'placebo', ',', 'after', 'single', 'dose', 'administration', 'in', 'patients', 'suffering', 'from', 'post-operative', 'pain', 'after', 'cholecystectomy', '.']","(26, 34)","(170, 237)",-1,ss_p,7808649,Abstract,0,test,gold,7020.0
7151,OBJECTIVE To evaluate the efficacy and tolerability of,ketorolac tromethamine,"10 mg and 30 mg suppositories in comparison to placebo , after single dose administration in patients suffering from post-operative pain after cholecystectomy .","['OBJECTIVE', 'To', 'evaluate', 'the', 'efficacy', 'and', 'tolerability', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'in', 'comparison', 'to', 'placebo', ',', 'after', 'single', 'dose', 'administration', 'in', 'patients', 'suffering', 'from', 'post-operative', 'pain', 'after', 'cholecystectomy', '.']","(8, 10)","(54, 76)",-1,ss_i,7808649,Abstract,0,test,gold,192.0
7152,OBJECTIVE To evaluate the efficacy and tolerability of ketorolac tromethamine 10 mg and 30 mg suppositories in comparison to,placebo,", after single dose administration in patients suffering from post-operative pain after cholecystectomy .","['OBJECTIVE', 'To', 'evaluate', 'the', 'efficacy', 'and', 'tolerability', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'in', 'comparison', 'to', 'placebo', ',', 'after', 'single', 'dose', 'administration', 'in', 'patients', 'suffering', 'from', 'post-operative', 'pain', 'after', 'cholecystectomy', '.']","(19, 20)","(124, 131)",-1,ss_i,7808649,Abstract,0,test,gold,4290.0
7153,OBJECTIVE To evaluate the,efficacy,"and tolerability of ketorolac tromethamine 10 mg and 30 mg suppositories in comparison to placebo , after single dose administration in patients suffering from post-operative pain after cholecystectomy .","['OBJECTIVE', 'To', 'evaluate', 'the', 'efficacy', 'and', 'tolerability', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'in', 'comparison', 'to', 'placebo', ',', 'after', 'single', 'dose', 'administration', 'in', 'patients', 'suffering', 'from', 'post-operative', 'pain', 'after', 'cholecystectomy', '.']","(4, 5)","(25, 33)",-1,ss_o,7808649,Abstract,0,test,gold,4785.0
7154,OBJECTIVE To evaluate the efficacy and,tolerability,"of ketorolac tromethamine 10 mg and 30 mg suppositories in comparison to placebo , after single dose administration in patients suffering from post-operative pain after cholecystectomy .","['OBJECTIVE', 'To', 'evaluate', 'the', 'efficacy', 'and', 'tolerability', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'in', 'comparison', 'to', 'placebo', ',', 'after', 'single', 'dose', 'administration', 'in', 'patients', 'suffering', 'from', 'post-operative', 'pain', 'after', 'cholecystectomy', '.']","(6, 7)","(38, 50)",-1,ss_o,7808649,Abstract,0,test,gold,4860.0
7155,"OBJECTIVE To evaluate the efficacy and tolerability of ketorolac tromethamine 10 mg and 30 mg suppositories in comparison to placebo , after single dose administration in",patients suffering from post-operative pain after cholecystectomy .,,"['OBJECTIVE', 'To', 'evaluate', 'the', 'efficacy', 'and', 'tolerability', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'in', 'comparison', 'to', 'placebo', ',', 'after', 'single', 'dose', 'administration', 'in', 'patients', 'suffering', 'from', 'post-operative', 'pain', 'after', 'cholecystectomy', '.']","(26, 34)","(170, 237)",-1,hl_p,7808649,Abstract,0,test,gold,7021.0
7156,OBJECTIVE To evaluate the efficacy and tolerability of,ketorolac tromethamine,"10 mg and 30 mg suppositories in comparison to placebo , after single dose administration in patients suffering from post-operative pain after cholecystectomy .","['OBJECTIVE', 'To', 'evaluate', 'the', 'efficacy', 'and', 'tolerability', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'in', 'comparison', 'to', 'placebo', ',', 'after', 'single', 'dose', 'administration', 'in', 'patients', 'suffering', 'from', 'post-operative', 'pain', 'after', 'cholecystectomy', '.']","(8, 10)","(54, 76)",-1,hl_i,7808649,Abstract,0,test,gold,191.0
7157,OBJECTIVE To evaluate the efficacy and tolerability of ketorolac tromethamine 10 mg and 30 mg suppositories in comparison to,placebo,", after single dose administration in patients suffering from post-operative pain after cholecystectomy .","['OBJECTIVE', 'To', 'evaluate', 'the', 'efficacy', 'and', 'tolerability', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'in', 'comparison', 'to', 'placebo', ',', 'after', 'single', 'dose', 'administration', 'in', 'patients', 'suffering', 'from', 'post-operative', 'pain', 'after', 'cholecystectomy', '.']","(19, 20)","(124, 131)",-1,hl_i,7808649,Abstract,0,test,gold,4289.0
7158,OBJECTIVE To evaluate the,efficacy,"and tolerability of ketorolac tromethamine 10 mg and 30 mg suppositories in comparison to placebo , after single dose administration in patients suffering from post-operative pain after cholecystectomy .","['OBJECTIVE', 'To', 'evaluate', 'the', 'efficacy', 'and', 'tolerability', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'in', 'comparison', 'to', 'placebo', ',', 'after', 'single', 'dose', 'administration', 'in', 'patients', 'suffering', 'from', 'post-operative', 'pain', 'after', 'cholecystectomy', '.']","(4, 5)","(25, 33)",-1,hl_o,7808649,Abstract,0,test,gold,4784.0
7159,OBJECTIVE To evaluate the efficacy and,tolerability,"of ketorolac tromethamine 10 mg and 30 mg suppositories in comparison to placebo , after single dose administration in patients suffering from post-operative pain after cholecystectomy .","['OBJECTIVE', 'To', 'evaluate', 'the', 'efficacy', 'and', 'tolerability', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'in', 'comparison', 'to', 'placebo', ',', 'after', 'single', 'dose', 'administration', 'in', 'patients', 'suffering', 'from', 'post-operative', 'pain', 'after', 'cholecystectomy', '.']","(6, 7)","(38, 50)",-1,hl_o,7808649,Abstract,0,test,gold,4859.0
7160,"DESIGN Double-blind , randomized , controlled study .",,,"['DESIGN', 'Double-blind', ',', 'randomized', ',', 'controlled', 'study', '.']",,,,,7808649,Abstract,1,test,gold,
7161,SETTING Anaesthesia Service .,,,"['SETTING', 'Anaesthesia', 'Service', '.']",,,,,7808649,Abstract,2,test,gold,
7162,PATIENTS,99 patients with severe pain following surgery .,,"['PATIENTS', '99', 'patients', 'with', 'severe', 'pain', 'following', 'surgery', '.']","(1, 9)","(8, 56)",-1,ss_p,7808649,Abstract,3,test,gold,7022.0
7163,PATIENTS,99 patients with severe pain following surgery,.,"['PATIENTS', '99', 'patients', 'with', 'severe', 'pain', 'following', 'surgery', '.']","(1, 8)","(8, 54)",-1,hl_p,7808649,Abstract,3,test,gold,7023.0
7164,INTERVENTIONS Cholecystectomy .,,,"['INTERVENTIONS', 'Cholecystectomy', '.']",,,,,7808649,Abstract,4,test,gold,
7165,MEASUREMENTS AND MAIN RESULTS The analgesia activity of,ketorolac tromethamine,10 mg and 30 mg suppositories were evaluated after single dose administration by assessing pain intensity and pain relief using a 4 point scale ( VRS ) .,"['MEASUREMENTS', 'AND', 'MAIN', 'RESULTS', 'The', 'analgesia', 'activity', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'were', 'evaluated', 'after', 'single', 'dose', 'administration', 'by', 'assessing', 'pain', 'intensity', 'and', 'pain', 'relief', 'using', 'a', '4', 'point', 'scale', '(', 'VRS', ')', '.']","(8, 10)","(55, 77)",-1,ss_i,7808649,Abstract,5,test,gold,190.0
7166,MEASUREMENTS AND MAIN RESULTS The,analgesia activity,of ketorolac tromethamine 10 mg and 30 mg suppositories were evaluated after single dose administration by assessing pain intensity and pain relief using a 4 point scale ( VRS ) .,"['MEASUREMENTS', 'AND', 'MAIN', 'RESULTS', 'The', 'analgesia', 'activity', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'were', 'evaluated', 'after', 'single', 'dose', 'administration', 'by', 'assessing', 'pain', 'intensity', 'and', 'pain', 'relief', 'using', 'a', '4', 'point', 'scale', '(', 'VRS', ')', '.']","(5, 7)","(33, 51)",-1,ss_o,7808649,Abstract,5,test,gold,5448.0
7167,MEASUREMENTS AND MAIN RESULTS The analgesia activity of ketorolac tromethamine 10 mg and 30 mg suppositories were evaluated after single dose administration by,assessing pain intensity and pain relief,using a 4 point scale ( VRS ) .,"['MEASUREMENTS', 'AND', 'MAIN', 'RESULTS', 'The', 'analgesia', 'activity', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'were', 'evaluated', 'after', 'single', 'dose', 'administration', 'by', 'assessing', 'pain', 'intensity', 'and', 'pain', 'relief', 'using', 'a', '4', 'point', 'scale', '(', 'VRS', ')', '.']","(23, 29)","(159, 199)",-1,ss_o,7808649,Abstract,5,test,gold,2272.0
7168,MEASUREMENTS AND MAIN RESULTS The analgesia activity of ketorolac tromethamine 10 mg and 30 mg suppositories were evaluated after single dose administration by assessing pain intensity and pain relief using a,4 point scale ( VRS ),.,"['MEASUREMENTS', 'AND', 'MAIN', 'RESULTS', 'The', 'analgesia', 'activity', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'were', 'evaluated', 'after', 'single', 'dose', 'administration', 'by', 'assessing', 'pain', 'intensity', 'and', 'pain', 'relief', 'using', 'a', '4', 'point', 'scale', '(', 'VRS', ')', '.']","(31, 37)","(208, 229)",-1,ss_o,7808649,Abstract,5,test,gold,1494.0
7169,MEASUREMENTS AND MAIN RESULTS The analgesia activity of,ketorolac tromethamine,10 mg and 30 mg suppositories were evaluated after single dose administration by assessing pain intensity and pain relief using a 4 point scale ( VRS ) .,"['MEASUREMENTS', 'AND', 'MAIN', 'RESULTS', 'The', 'analgesia', 'activity', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'were', 'evaluated', 'after', 'single', 'dose', 'administration', 'by', 'assessing', 'pain', 'intensity', 'and', 'pain', 'relief', 'using', 'a', '4', 'point', 'scale', '(', 'VRS', ')', '.']","(8, 10)","(55, 77)",-1,hl_i,7808649,Abstract,5,test,gold,189.0
7170,MEASUREMENTS AND MAIN RESULTS The analgesia activity of ketorolac tromethamine 10 mg and 30 mg suppositories were evaluated after single dose administration by assessing,pain intensity and pain relief,using a 4 point scale ( VRS ) .,"['MEASUREMENTS', 'AND', 'MAIN', 'RESULTS', 'The', 'analgesia', 'activity', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'were', 'evaluated', 'after', 'single', 'dose', 'administration', 'by', 'assessing', 'pain', 'intensity', 'and', 'pain', 'relief', 'using', 'a', '4', 'point', 'scale', '(', 'VRS', ')', '.']","(24, 29)","(169, 199)",-1,hl_o,7808649,Abstract,5,test,gold,2273.0
7171,MEASUREMENTS AND MAIN RESULTS The analgesia activity of ketorolac tromethamine 10 mg and 30 mg suppositories were evaluated after single dose administration by assessing pain intensity and pain relief using a,4 point scale ( VRS ),.,"['MEASUREMENTS', 'AND', 'MAIN', 'RESULTS', 'The', 'analgesia', 'activity', 'of', 'ketorolac', 'tromethamine', '10', 'mg', 'and', '30', 'mg', 'suppositories', 'were', 'evaluated', 'after', 'single', 'dose', 'administration', 'by', 'assessing', 'pain', 'intensity', 'and', 'pain', 'relief', 'using', 'a', '4', 'point', 'scale', '(', 'VRS', ')', '.']","(31, 37)","(208, 229)",-1,hl_o,7808649,Abstract,5,test,gold,1495.0
7172,At the end of the treatment period overall assessment of,safety,and efficacy were recorded by physician and patient .,"['At', 'the', 'end', 'of', 'the', 'treatment', 'period', 'overall', 'assessment', 'of', 'safety', 'and', 'efficacy', 'were', 'recorded', 'by', 'physician', 'and', 'patient', '.']","(10, 11)","(56, 62)",-1,ss_o,7808649,Abstract,6,test,gold,455.0
7173,At the end of the treatment period overall assessment of safety and,efficacy,were recorded by physician and patient .,"['At', 'the', 'end', 'of', 'the', 'treatment', 'period', 'overall', 'assessment', 'of', 'safety', 'and', 'efficacy', 'were', 'recorded', 'by', 'physician', 'and', 'patient', '.']","(12, 13)","(67, 75)",-1,ss_o,7808649,Abstract,6,test,gold,4783.0
7174,At the end of the treatment period overall assessment of,safety,and efficacy were recorded by physician and patient .,"['At', 'the', 'end', 'of', 'the', 'treatment', 'period', 'overall', 'assessment', 'of', 'safety', 'and', 'efficacy', 'were', 'recorded', 'by', 'physician', 'and', 'patient', '.']","(10, 11)","(56, 62)",-1,hl_o,7808649,Abstract,6,test,gold,454.0
7175,At the end of the treatment period overall assessment of safety and,efficacy,were recorded by physician and patient .,"['At', 'the', 'end', 'of', 'the', 'treatment', 'period', 'overall', 'assessment', 'of', 'safety', 'and', 'efficacy', 'were', 'recorded', 'by', 'physician', 'and', 'patient', '.']","(12, 13)","(67, 75)",-1,hl_o,7808649,Abstract,6,test,gold,4782.0
7176,"The results show that in both active groups after 30 ' and until 4 hours ,",pain intensity,decreased significantly with respect to the baseline .,"['The', 'results', 'show', 'that', 'in', 'both', 'active', 'groups', 'after', '30', ""'"", 'and', 'until', '4', 'hours', ',', 'pain', 'intensity', 'decreased', 'significantly', 'with', 'respect', 'to', 'the', 'baseline', '.']","(16, 18)","(74, 88)",-1,ss_o,7808649,Abstract,7,test,gold,2312.0
7177,"The results show that in both active groups after 30 ' and until 4 hours ,",pain intensity,decreased significantly with respect to the baseline .,"['The', 'results', 'show', 'that', 'in', 'both', 'active', 'groups', 'after', '30', ""'"", 'and', 'until', '4', 'hours', ',', 'pain', 'intensity', 'decreased', 'significantly', 'with', 'respect', 'to', 'the', 'baseline', '.']","(16, 18)","(74, 88)",-1,hl_o,7808649,Abstract,7,test,gold,2311.0
7178,"However a statistically significant difference between groups of p < 0.02 , p < 0.01 and p < 0.05 was found in favour of the 30 mg dose respectively at 30 ' , 6 and 8 hours after administration .",,,"['However', 'a', 'statistically', 'significant', 'difference', 'between', 'groups', 'of', 'p', '<', '0.02', ',', 'p', '<', '0.01', 'and', 'p', '<', '0.05', 'was', 'found', 'in', 'favour', 'of', 'the', '30', 'mg', 'dose', 'respectively', 'at', '30', ""'"", ',', '6', 'and', '8', 'hours', 'after', 'administration', '.']",,,,,7808649,Abstract,8,test,gold,
7179,All the patients treated with,placebo,suppositories required another rescue analgesic drug and withdrew from the trial .,"['All', 'the', 'patients', 'treated', 'with', 'placebo', 'suppositories', 'required', 'another', 'rescue', 'analgesic', 'drug', 'and', 'withdrew', 'from', 'the', 'trial', '.']","(5, 6)","(29, 36)",-1,ss_i,7808649,Abstract,9,test,gold,4288.0
7180,All the patients treated with placebo suppositories required another,rescue analgesic drug,and withdrew from the trial .,"['All', 'the', 'patients', 'treated', 'with', 'placebo', 'suppositories', 'required', 'another', 'rescue', 'analgesic', 'drug', 'and', 'withdrew', 'from', 'the', 'trial', '.']","(9, 12)","(68, 89)",-1,ss_o,7808649,Abstract,9,test,gold,5057.0
7181,All the patients treated with,placebo,suppositories required another rescue analgesic drug and withdrew from the trial .,"['All', 'the', 'patients', 'treated', 'with', 'placebo', 'suppositories', 'required', 'another', 'rescue', 'analgesic', 'drug', 'and', 'withdrew', 'from', 'the', 'trial', '.']","(5, 6)","(29, 36)",-1,hl_i,7808649,Abstract,9,test,gold,4287.0
7182,All the patients treated with placebo suppositories required another,rescue analgesic drug,and withdrew from the trial .,"['All', 'the', 'patients', 'treated', 'with', 'placebo', 'suppositories', 'required', 'another', 'rescue', 'analgesic', 'drug', 'and', 'withdrew', 'from', 'the', 'trial', '.']","(9, 12)","(68, 89)",-1,hl_o,7808649,Abstract,9,test,gold,5058.0
7183,Three patients complained adverse events not related to treatment : two on,placebo,and one on ketorolac 10 mg .,"['Three', 'patients', 'complained', 'adverse', 'events', 'not', 'related', 'to', 'treatment', ':', 'two', 'on', 'placebo', 'and', 'one', 'on', 'ketorolac', '10', 'mg', '.']","(12, 13)","(74, 81)",-1,ss_i,7808649,Abstract,10,test,gold,4286.0
7184,Three patients complained adverse events not related to treatment : two on placebo and one on,ketorolac,10 mg .,"['Three', 'patients', 'complained', 'adverse', 'events', 'not', 'related', 'to', 'treatment', ':', 'two', 'on', 'placebo', 'and', 'one', 'on', 'ketorolac', '10', 'mg', '.']","(16, 17)","(93, 102)",-1,ss_i,7808649,Abstract,10,test,gold,188.0
7185,Three patients complained,adverse events,not related to treatment : two on placebo and one on ketorolac 10 mg .,"['Three', 'patients', 'complained', 'adverse', 'events', 'not', 'related', 'to', 'treatment', ':', 'two', 'on', 'placebo', 'and', 'one', 'on', 'ketorolac', '10', 'mg', '.']","(3, 5)","(25, 39)",-1,ss_o,7808649,Abstract,10,test,gold,3059.0
7186,Three patients complained,adverse events,not related to treatment : two on placebo and one on ketorolac 10 mg .,"['Three', 'patients', 'complained', 'adverse', 'events', 'not', 'related', 'to', 'treatment', ':', 'two', 'on', 'placebo', 'and', 'one', 'on', 'ketorolac', '10', 'mg', '.']","(3, 5)","(25, 39)",-1,hl_o,7808649,Abstract,10,test,gold,3058.0
7187,The,systemic and local tolerability,of the drug was good .,"['The', 'systemic', 'and', 'local', 'tolerability', 'of', 'the', 'drug', 'was', 'good', '.']","(1, 5)","(3, 34)",-1,ss_o,7808649,Abstract,11,test,gold,4876.0
7188,The,systemic and local tolerability,of the drug was good .,"['The', 'systemic', 'and', 'local', 'tolerability', 'of', 'the', 'drug', 'was', 'good', '.']","(1, 5)","(3, 34)",-1,hl_o,7808649,Abstract,11,test,gold,4877.0
7189,CONCLUSIONS This study shows that,ketorolac,"30 mg suppositories are effective in clinical conditions , such as after surgery , in which pain control must be achieved within the shortest time interval and maintained or improved by means of a single route of administration .","['CONCLUSIONS', 'This', 'study', 'shows', 'that', 'ketorolac', '30', 'mg', 'suppositories', 'are', 'effective', 'in', 'clinical', 'conditions', ',', 'such', 'as', 'after', 'surgery', ',', 'in', 'which', 'pain', 'control', 'must', 'be', 'achieved', 'within', 'the', 'shortest', 'time', 'interval', 'and', 'maintained', 'or', 'improved', 'by', 'means', 'of', 'a', 'single', 'route', 'of', 'administration', '.']","(5, 6)","(33, 42)",-1,ss_i,7808649,Abstract,12,test,gold,187.0
7190,CONCLUSIONS This study shows that ketorolac 30 mg suppositories are,effective,"in clinical conditions , such as after surgery , in which pain control must be achieved within the shortest time interval and maintained or improved by means of a single route of administration .","['CONCLUSIONS', 'This', 'study', 'shows', 'that', 'ketorolac', '30', 'mg', 'suppositories', 'are', 'effective', 'in', 'clinical', 'conditions', ',', 'such', 'as', 'after', 'surgery', ',', 'in', 'which', 'pain', 'control', 'must', 'be', 'achieved', 'within', 'the', 'shortest', 'time', 'interval', 'and', 'maintained', 'or', 'improved', 'by', 'means', 'of', 'a', 'single', 'route', 'of', 'administration', '.']","(10, 11)","(67, 76)",-1,ss_o,7808649,Abstract,12,test,gold,841.0
7191,CONCLUSIONS This study shows that,ketorolac,"30 mg suppositories are effective in clinical conditions , such as after surgery , in which pain control must be achieved within the shortest time interval and maintained or improved by means of a single route of administration .","['CONCLUSIONS', 'This', 'study', 'shows', 'that', 'ketorolac', '30', 'mg', 'suppositories', 'are', 'effective', 'in', 'clinical', 'conditions', ',', 'such', 'as', 'after', 'surgery', ',', 'in', 'which', 'pain', 'control', 'must', 'be', 'achieved', 'within', 'the', 'shortest', 'time', 'interval', 'and', 'maintained', 'or', 'improved', 'by', 'means', 'of', 'a', 'single', 'route', 'of', 'administration', '.']","(5, 6)","(33, 42)",-1,hl_i,7808649,Abstract,12,test,gold,186.0
7192,Efficacy of intramuscular oxytetracycline as a dry cow treatment for,Staphylococcus aureus mastitis .,,"['Efficacy', 'of', 'intramuscular', 'oxytetracycline', 'as', 'a', 'dry', 'cow', 'treatment', 'for', 'Staphylococcus', 'aureus', 'mastitis', '.']","(10, 14)","(68, 100)",-1,ss_p,7814711,Title,0,test,gold,6646.0
7193,Efficacy of intramuscular,oxytetracycline,as a dry cow treatment for Staphylococcus aureus mastitis .,"['Efficacy', 'of', 'intramuscular', 'oxytetracycline', 'as', 'a', 'dry', 'cow', 'treatment', 'for', 'Staphylococcus', 'aureus', 'mastitis', '.']","(3, 4)","(25, 40)",-1,ss_i,7814711,Title,0,test,gold,97.0
7194,,Efficacy,of intramuscular oxytetracycline as a dry cow treatment for Staphylococcus aureus mastitis .,"['Efficacy', 'of', 'intramuscular', 'oxytetracycline', 'as', 'a', 'dry', 'cow', 'treatment', 'for', 'Staphylococcus', 'aureus', 'mastitis', '.']","(0, 1)","(0, 8)",-1,ss_o,7814711,Title,0,test,gold,425.0
7195,Efficacy of intramuscular,oxytetracycline,as a dry cow treatment for Staphylococcus aureus mastitis .,"['Efficacy', 'of', 'intramuscular', 'oxytetracycline', 'as', 'a', 'dry', 'cow', 'treatment', 'for', 'Staphylococcus', 'aureus', 'mastitis', '.']","(3, 4)","(25, 40)",-1,hl_i,7814711,Title,0,test,gold,98.0
7196,To determine the efficacy of intramuscular oxytetracycline as a supplemental dry cow treatment for,"Staphylococcus aureus mastitis , 37 Holstein cows","were randomly assigned to two treatment groups : intracisternal infusion with a commercial preparation of cephapirin benzathine at drying off ( 20 cows ) and infusion with cephapirin benzathine at drying off and intramuscular oxytetracycline at 11 mg/kg once daily on d 7 , 8 , 9 , and 10 after drying off ( 17 cows ) .","['To', 'determine', 'the', 'efficacy', 'of', 'intramuscular', 'oxytetracycline', 'as', 'a', 'supplemental', 'dry', 'cow', 'treatment', 'for', 'Staphylococcus', 'aureus', 'mastitis', ',', '37', 'Holstein', 'cows', 'were', 'randomly', 'assigned', 'to', 'two', 'treatment', 'groups', ':', 'intracisternal', 'infusion', 'with', 'a', 'commercial', 'preparation', 'of', 'cephapirin', 'benzathine', 'at', 'drying', 'off', '(', '20', 'cows', ')', 'and', 'infusion', 'with', 'cephapirin', 'benzathine', 'at', 'drying', 'off', 'and', 'intramuscular', 'oxytetracycline', 'at', '11', 'mg/kg', 'once', 'daily', 'on', 'd', '7', ',', '8', ',', '9', ',', 'and', '10', 'after', 'drying', 'off', '(', '17', 'cows', ')', '.']","(14, 21)","(98, 147)",-1,ss_p,7814711,Abstract,0,test,gold,6647.0
7197,To determine the efficacy of intramuscular,oxytetracycline,"as a supplemental dry cow treatment for Staphylococcus aureus mastitis , 37 Holstein cows were randomly assigned to two treatment groups : intracisternal infusion with a commercial preparation of cephapirin benzathine at drying off ( 20 cows ) and infusion with cephapirin benzathine at drying off and intramuscular oxytetracycline at 11 mg/kg once daily on d 7 , 8 , 9 , and 10 after drying off ( 17 cows ) .","['To', 'determine', 'the', 'efficacy', 'of', 'intramuscular', 'oxytetracycline', 'as', 'a', 'supplemental', 'dry', 'cow', 'treatment', 'for', 'Staphylococcus', 'aureus', 'mastitis', ',', '37', 'Holstein', 'cows', 'were', 'randomly', 'assigned', 'to', 'two', 'treatment', 'groups', ':', 'intracisternal', 'infusion', 'with', 'a', 'commercial', 'preparation', 'of', 'cephapirin', 'benzathine', 'at', 'drying', 'off', '(', '20', 'cows', ')', 'and', 'infusion', 'with', 'cephapirin', 'benzathine', 'at', 'drying', 'off', 'and', 'intramuscular', 'oxytetracycline', 'at', '11', 'mg/kg', 'once', 'daily', 'on', 'd', '7', ',', '8', ',', '9', ',', 'and', '10', 'after', 'drying', 'off', '(', '17', 'cows', ')', '.']","(6, 7)","(42, 57)",-1,ss_i,7814711,Abstract,0,test,gold,96.0
7198,"To determine the efficacy of intramuscular oxytetracycline as a supplemental dry cow treatment for Staphylococcus aureus mastitis , 37 Holstein cows were randomly assigned to two treatment groups : intracisternal infusion with a commercial preparation of",cephapirin benzathine,"at drying off ( 20 cows ) and infusion with cephapirin benzathine at drying off and intramuscular oxytetracycline at 11 mg/kg once daily on d 7 , 8 , 9 , and 10 after drying off ( 17 cows ) .","['To', 'determine', 'the', 'efficacy', 'of', 'intramuscular', 'oxytetracycline', 'as', 'a', 'supplemental', 'dry', 'cow', 'treatment', 'for', 'Staphylococcus', 'aureus', 'mastitis', ',', '37', 'Holstein', 'cows', 'were', 'randomly', 'assigned', 'to', 'two', 'treatment', 'groups', ':', 'intracisternal', 'infusion', 'with', 'a', 'commercial', 'preparation', 'of', 'cephapirin', 'benzathine', 'at', 'drying', 'off', '(', '20', 'cows', ')', 'and', 'infusion', 'with', 'cephapirin', 'benzathine', 'at', 'drying', 'off', 'and', 'intramuscular', 'oxytetracycline', 'at', '11', 'mg/kg', 'once', 'daily', 'on', 'd', '7', ',', '8', ',', '9', ',', 'and', '10', 'after', 'drying', 'off', '(', '17', 'cows', ')', '.']","(36, 38)","(254, 275)",-1,ss_i,7814711,Abstract,0,test,gold,
7199,"To determine the efficacy of intramuscular oxytetracycline as a supplemental dry cow treatment for Staphylococcus aureus mastitis , 37 Holstein cows were randomly assigned to two treatment groups : intracisternal infusion with a commercial preparation of cephapirin benzathine at drying off ( 20 cows ) and infusion with",cephapirin benzathine,"at drying off and intramuscular oxytetracycline at 11 mg/kg once daily on d 7 , 8 , 9 , and 10 after drying off ( 17 cows ) .","['To', 'determine', 'the', 'efficacy', 'of', 'intramuscular', 'oxytetracycline', 'as', 'a', 'supplemental', 'dry', 'cow', 'treatment', 'for', 'Staphylococcus', 'aureus', 'mastitis', ',', '37', 'Holstein', 'cows', 'were', 'randomly', 'assigned', 'to', 'two', 'treatment', 'groups', ':', 'intracisternal', 'infusion', 'with', 'a', 'commercial', 'preparation', 'of', 'cephapirin', 'benzathine', 'at', 'drying', 'off', '(', '20', 'cows', ')', 'and', 'infusion', 'with', 'cephapirin', 'benzathine', 'at', 'drying', 'off', 'and', 'intramuscular', 'oxytetracycline', 'at', '11', 'mg/kg', 'once', 'daily', 'on', 'd', '7', ',', '8', ',', '9', ',', 'and', '10', 'after', 'drying', 'off', '(', '17', 'cows', ')', '.']","(48, 50)","(320, 341)",-1,ss_i,7814711,Abstract,0,test,gold,
7200,"To determine the efficacy of intramuscular oxytetracycline as a supplemental dry cow treatment for Staphylococcus aureus mastitis , 37 Holstein cows were randomly assigned to two treatment groups : intracisternal infusion with a commercial preparation of cephapirin benzathine at drying off ( 20 cows ) and infusion with cephapirin benzathine at drying off and intramuscular",oxytetracycline,"at 11 mg/kg once daily on d 7 , 8 , 9 , and 10 after drying off ( 17 cows ) .","['To', 'determine', 'the', 'efficacy', 'of', 'intramuscular', 'oxytetracycline', 'as', 'a', 'supplemental', 'dry', 'cow', 'treatment', 'for', 'Staphylococcus', 'aureus', 'mastitis', ',', '37', 'Holstein', 'cows', 'were', 'randomly', 'assigned', 'to', 'two', 'treatment', 'groups', ':', 'intracisternal', 'infusion', 'with', 'a', 'commercial', 'preparation', 'of', 'cephapirin', 'benzathine', 'at', 'drying', 'off', '(', '20', 'cows', ')', 'and', 'infusion', 'with', 'cephapirin', 'benzathine', 'at', 'drying', 'off', 'and', 'intramuscular', 'oxytetracycline', 'at', '11', 'mg/kg', 'once', 'daily', 'on', 'd', '7', ',', '8', ',', '9', ',', 'and', '10', 'after', 'drying', 'off', '(', '17', 'cows', ')', '.']","(55, 56)","(374, 389)",-1,ss_i,7814711,Abstract,0,test,gold,95.0
7201,To determine the,efficacy,"of intramuscular oxytetracycline as a supplemental dry cow treatment for Staphylococcus aureus mastitis , 37 Holstein cows were randomly assigned to two treatment groups : intracisternal infusion with a commercial preparation of cephapirin benzathine at drying off ( 20 cows ) and infusion with cephapirin benzathine at drying off and intramuscular oxytetracycline at 11 mg/kg once daily on d 7 , 8 , 9 , and 10 after drying off ( 17 cows ) .","['To', 'determine', 'the', 'efficacy', 'of', 'intramuscular', 'oxytetracycline', 'as', 'a', 'supplemental', 'dry', 'cow', 'treatment', 'for', 'Staphylococcus', 'aureus', 'mastitis', ',', '37', 'Holstein', 'cows', 'were', 'randomly', 'assigned', 'to', 'two', 'treatment', 'groups', ':', 'intracisternal', 'infusion', 'with', 'a', 'commercial', 'preparation', 'of', 'cephapirin', 'benzathine', 'at', 'drying', 'off', '(', '20', 'cows', ')', 'and', 'infusion', 'with', 'cephapirin', 'benzathine', 'at', 'drying', 'off', 'and', 'intramuscular', 'oxytetracycline', 'at', '11', 'mg/kg', 'once', 'daily', 'on', 'd', '7', ',', '8', ',', '9', ',', 'and', '10', 'after', 'drying', 'off', '(', '17', 'cows', ')', '.']","(3, 4)","(16, 24)",-1,ss_o,7814711,Abstract,0,test,gold,4781.0
7202,"To determine the efficacy of intramuscular oxytetracycline as a supplemental dry cow treatment for Staphylococcus aureus mastitis ,",37 Holstein cows,"were randomly assigned to two treatment groups : intracisternal infusion with a commercial preparation of cephapirin benzathine at drying off ( 20 cows ) and infusion with cephapirin benzathine at drying off and intramuscular oxytetracycline at 11 mg/kg once daily on d 7 , 8 , 9 , and 10 after drying off ( 17 cows ) .","['To', 'determine', 'the', 'efficacy', 'of', 'intramuscular', 'oxytetracycline', 'as', 'a', 'supplemental', 'dry', 'cow', 'treatment', 'for', 'Staphylococcus', 'aureus', 'mastitis', ',', '37', 'Holstein', 'cows', 'were', 'randomly', 'assigned', 'to', 'two', 'treatment', 'groups', ':', 'intracisternal', 'infusion', 'with', 'a', 'commercial', 'preparation', 'of', 'cephapirin', 'benzathine', 'at', 'drying', 'off', '(', '20', 'cows', ')', 'and', 'infusion', 'with', 'cephapirin', 'benzathine', 'at', 'drying', 'off', 'and', 'intramuscular', 'oxytetracycline', 'at', '11', 'mg/kg', 'once', 'daily', 'on', 'd', '7', ',', '8', ',', '9', ',', 'and', '10', 'after', 'drying', 'off', '(', '17', 'cows', ')', '.']","(18, 21)","(131, 147)",-1,hl_p,7814711,Abstract,0,test,gold,234.0
7203,To determine the efficacy of intramuscular,oxytetracycline,"as a supplemental dry cow treatment for Staphylococcus aureus mastitis , 37 Holstein cows were randomly assigned to two treatment groups : intracisternal infusion with a commercial preparation of cephapirin benzathine at drying off ( 20 cows ) and infusion with cephapirin benzathine at drying off and intramuscular oxytetracycline at 11 mg/kg once daily on d 7 , 8 , 9 , and 10 after drying off ( 17 cows ) .","['To', 'determine', 'the', 'efficacy', 'of', 'intramuscular', 'oxytetracycline', 'as', 'a', 'supplemental', 'dry', 'cow', 'treatment', 'for', 'Staphylococcus', 'aureus', 'mastitis', ',', '37', 'Holstein', 'cows', 'were', 'randomly', 'assigned', 'to', 'two', 'treatment', 'groups', ':', 'intracisternal', 'infusion', 'with', 'a', 'commercial', 'preparation', 'of', 'cephapirin', 'benzathine', 'at', 'drying', 'off', '(', '20', 'cows', ')', 'and', 'infusion', 'with', 'cephapirin', 'benzathine', 'at', 'drying', 'off', 'and', 'intramuscular', 'oxytetracycline', 'at', '11', 'mg/kg', 'once', 'daily', 'on', 'd', '7', ',', '8', ',', '9', ',', 'and', '10', 'after', 'drying', 'off', '(', '17', 'cows', ')', '.']","(6, 7)","(42, 57)",-1,hl_i,7814711,Abstract,0,test,gold,94.0
7204,"To determine the efficacy of intramuscular oxytetracycline as a supplemental dry cow treatment for Staphylococcus aureus mastitis , 37 Holstein cows were randomly assigned to two treatment groups : intracisternal infusion with a commercial preparation of",cephapirin benzathine,"at drying off ( 20 cows ) and infusion with cephapirin benzathine at drying off and intramuscular oxytetracycline at 11 mg/kg once daily on d 7 , 8 , 9 , and 10 after drying off ( 17 cows ) .","['To', 'determine', 'the', 'efficacy', 'of', 'intramuscular', 'oxytetracycline', 'as', 'a', 'supplemental', 'dry', 'cow', 'treatment', 'for', 'Staphylococcus', 'aureus', 'mastitis', ',', '37', 'Holstein', 'cows', 'were', 'randomly', 'assigned', 'to', 'two', 'treatment', 'groups', ':', 'intracisternal', 'infusion', 'with', 'a', 'commercial', 'preparation', 'of', 'cephapirin', 'benzathine', 'at', 'drying', 'off', '(', '20', 'cows', ')', 'and', 'infusion', 'with', 'cephapirin', 'benzathine', 'at', 'drying', 'off', 'and', 'intramuscular', 'oxytetracycline', 'at', '11', 'mg/kg', 'once', 'daily', 'on', 'd', '7', ',', '8', ',', '9', ',', 'and', '10', 'after', 'drying', 'off', '(', '17', 'cows', ')', '.']","(36, 38)","(254, 275)",-1,hl_i,7814711,Abstract,0,test,gold,
7205,"To determine the efficacy of intramuscular oxytetracycline as a supplemental dry cow treatment for Staphylococcus aureus mastitis , 37 Holstein cows were randomly assigned to two treatment groups : intracisternal infusion with a commercial preparation of cephapirin benzathine at drying off ( 20 cows ) and infusion with",cephapirin benzathine,"at drying off and intramuscular oxytetracycline at 11 mg/kg once daily on d 7 , 8 , 9 , and 10 after drying off ( 17 cows ) .","['To', 'determine', 'the', 'efficacy', 'of', 'intramuscular', 'oxytetracycline', 'as', 'a', 'supplemental', 'dry', 'cow', 'treatment', 'for', 'Staphylococcus', 'aureus', 'mastitis', ',', '37', 'Holstein', 'cows', 'were', 'randomly', 'assigned', 'to', 'two', 'treatment', 'groups', ':', 'intracisternal', 'infusion', 'with', 'a', 'commercial', 'preparation', 'of', 'cephapirin', 'benzathine', 'at', 'drying', 'off', '(', '20', 'cows', ')', 'and', 'infusion', 'with', 'cephapirin', 'benzathine', 'at', 'drying', 'off', 'and', 'intramuscular', 'oxytetracycline', 'at', '11', 'mg/kg', 'once', 'daily', 'on', 'd', '7', ',', '8', ',', '9', ',', 'and', '10', 'after', 'drying', 'off', '(', '17', 'cows', ')', '.']","(48, 50)","(320, 341)",-1,hl_i,7814711,Abstract,0,test,gold,
7206,"To determine the efficacy of intramuscular oxytetracycline as a supplemental dry cow treatment for Staphylococcus aureus mastitis , 37 Holstein cows were randomly assigned to two treatment groups : intracisternal infusion with a commercial preparation of cephapirin benzathine at drying off ( 20 cows ) and infusion with cephapirin benzathine at drying off and intramuscular",oxytetracycline,"at 11 mg/kg once daily on d 7 , 8 , 9 , and 10 after drying off ( 17 cows ) .","['To', 'determine', 'the', 'efficacy', 'of', 'intramuscular', 'oxytetracycline', 'as', 'a', 'supplemental', 'dry', 'cow', 'treatment', 'for', 'Staphylococcus', 'aureus', 'mastitis', ',', '37', 'Holstein', 'cows', 'were', 'randomly', 'assigned', 'to', 'two', 'treatment', 'groups', ':', 'intracisternal', 'infusion', 'with', 'a', 'commercial', 'preparation', 'of', 'cephapirin', 'benzathine', 'at', 'drying', 'off', '(', '20', 'cows', ')', 'and', 'infusion', 'with', 'cephapirin', 'benzathine', 'at', 'drying', 'off', 'and', 'intramuscular', 'oxytetracycline', 'at', '11', 'mg/kg', 'once', 'daily', 'on', 'd', '7', ',', '8', ',', '9', ',', 'and', '10', 'after', 'drying', 'off', '(', '17', 'cows', ')', '.']","(55, 56)","(374, 389)",-1,hl_i,7814711,Abstract,0,test,gold,93.0
7207,,Milk samples,"collected 7 , 14 , 30 , and 60 d after calving were plated for bacterial isolation within 24 h after collection and after 24 to 72 h of storage at -20 degrees C. Quarters were defined as infected if S. aureus was isolated from the fresh and frozen cultures from any one sample collected before drying off .","['Milk', 'samples', 'collected', '7', ',', '14', ',', '30', ',', 'and', '60', 'd', 'after', 'calving', 'were', 'plated', 'for', 'bacterial', 'isolation', 'within', '24', 'h', 'after', 'collection', 'and', 'after', '24', 'to', '72', 'h', 'of', 'storage', 'at', '-20', 'degrees', 'C.', 'Quarters', 'were', 'defined', 'as', 'infected', 'if', 'S.', 'aureus', 'was', 'isolated', 'from', 'the', 'fresh', 'and', 'frozen', 'cultures', 'from', 'any', 'one', 'sample', 'collected', 'before', 'drying', 'off', '.']","(0, 2)","(0, 12)",-1,ss_o,7814711,Abstract,1,test,gold,4521.0
7208,"Milk samples collected 7 , 14 , 30 , and 60 d after calving were plated for bacterial isolation within 24 h after collection and after 24 to 72 h of storage at -20 degrees C. Quarters were defined as",infected,if S. aureus was isolated from the fresh and frozen cultures from any one sample collected before drying off .,"['Milk', 'samples', 'collected', '7', ',', '14', ',', '30', ',', 'and', '60', 'd', 'after', 'calving', 'were', 'plated', 'for', 'bacterial', 'isolation', 'within', '24', 'h', 'after', 'collection', 'and', 'after', '24', 'to', '72', 'h', 'of', 'storage', 'at', '-20', 'degrees', 'C.', 'Quarters', 'were', 'defined', 'as', 'infected', 'if', 'S.', 'aureus', 'was', 'isolated', 'from', 'the', 'fresh', 'and', 'frozen', 'cultures', 'from', 'any', 'one', 'sample', 'collected', 'before', 'drying', 'off', '.']","(40, 41)","(199, 207)",-1,ss_o,7814711,Abstract,1,test,gold,1145.0
7209,An infected quarter was defined as cured if S. aureus was not isolated from the fresh or frozen culture from milk samples obtained following calving .,,,"['An', 'infected', 'quarter', 'was', 'defined', 'as', 'cured', 'if', 'S.', 'aureus', 'was', 'not', 'isolated', 'from', 'the', 'fresh', 'or', 'frozen', 'culture', 'from', 'milk', 'samples', 'obtained', 'following', 'calving', '.']",,,,,7814711,Abstract,2,test,gold,
7210,The rate of cure by 30 d after calving for systemic,oxytetracycline,"( in combination with cephapirin treatment ) was 29.4 % for infected quarters and 29.4 % for infected cows , compared with 27.5 and 25.0 % , respectively , for the cephapirin treatment only .","['The', 'rate', 'of', 'cure', 'by', '30', 'd', 'after', 'calving', 'for', 'systemic', 'oxytetracycline', '(', 'in', 'combination', 'with', 'cephapirin', 'treatment', ')', 'was', '29.4', '%', 'for', 'infected', 'quarters', 'and', '29.4', '%', 'for', 'infected', 'cows', ',', 'compared', 'with', '27.5', 'and', '25.0', '%', ',', 'respectively', ',', 'for', 'the', 'cephapirin', 'treatment', 'only', '.']","(11, 12)","(51, 66)",-1,ss_i,7814711,Abstract,3,test,gold,92.0
7211,The rate of cure by 30 d after calving for systemic oxytetracycline ( in combination with,cephapirin,"treatment ) was 29.4 % for infected quarters and 29.4 % for infected cows , compared with 27.5 and 25.0 % , respectively , for the cephapirin treatment only .","['The', 'rate', 'of', 'cure', 'by', '30', 'd', 'after', 'calving', 'for', 'systemic', 'oxytetracycline', '(', 'in', 'combination', 'with', 'cephapirin', 'treatment', ')', 'was', '29.4', '%', 'for', 'infected', 'quarters', 'and', '29.4', '%', 'for', 'infected', 'cows', ',', 'compared', 'with', '27.5', 'and', '25.0', '%', ',', 'respectively', ',', 'for', 'the', 'cephapirin', 'treatment', 'only', '.']","(16, 17)","(89, 99)",-1,ss_i,7814711,Abstract,3,test,gold,
7212,"The rate of cure by 30 d after calving for systemic oxytetracycline ( in combination with cephapirin treatment ) was 29.4 % for infected quarters and 29.4 % for infected cows , compared with 27.5 and 25.0 % , respectively , for the",cephapirin,treatment only .,"['The', 'rate', 'of', 'cure', 'by', '30', 'd', 'after', 'calving', 'for', 'systemic', 'oxytetracycline', '(', 'in', 'combination', 'with', 'cephapirin', 'treatment', ')', 'was', '29.4', '%', 'for', 'infected', 'quarters', 'and', '29.4', '%', 'for', 'infected', 'cows', ',', 'compared', 'with', '27.5', 'and', '25.0', '%', ',', 'respectively', ',', 'for', 'the', 'cephapirin', 'treatment', 'only', '.']","(43, 44)","(231, 241)",-1,ss_i,7814711,Abstract,3,test,gold,
7213,The,rate of cure,"by 30 d after calving for systemic oxytetracycline ( in combination with cephapirin treatment ) was 29.4 % for infected quarters and 29.4 % for infected cows , compared with 27.5 and 25.0 % , respectively , for the cephapirin treatment only .","['The', 'rate', 'of', 'cure', 'by', '30', 'd', 'after', 'calving', 'for', 'systemic', 'oxytetracycline', '(', 'in', 'combination', 'with', 'cephapirin', 'treatment', ')', 'was', '29.4', '%', 'for', 'infected', 'quarters', 'and', '29.4', '%', 'for', 'infected', 'cows', ',', 'compared', 'with', '27.5', 'and', '25.0', '%', ',', 'respectively', ',', 'for', 'the', 'cephapirin', 'treatment', 'only', '.']","(1, 4)","(3, 15)",-1,ss_o,7814711,Abstract,3,test,gold,1946.0
7214,The rate of cure by 30 d after calving for systemic,oxytetracycline,"( in combination with cephapirin treatment ) was 29.4 % for infected quarters and 29.4 % for infected cows , compared with 27.5 and 25.0 % , respectively , for the cephapirin treatment only .","['The', 'rate', 'of', 'cure', 'by', '30', 'd', 'after', 'calving', 'for', 'systemic', 'oxytetracycline', '(', 'in', 'combination', 'with', 'cephapirin', 'treatment', ')', 'was', '29.4', '%', 'for', 'infected', 'quarters', 'and', '29.4', '%', 'for', 'infected', 'cows', ',', 'compared', 'with', '27.5', 'and', '25.0', '%', ',', 'respectively', ',', 'for', 'the', 'cephapirin', 'treatment', 'only', '.']","(11, 12)","(51, 66)",-1,hl_i,7814711,Abstract,3,test,gold,91.0
7215,The rate of cure by 30 d after calving for systemic oxytetracycline ( in combination with,cephapirin,"treatment ) was 29.4 % for infected quarters and 29.4 % for infected cows , compared with 27.5 and 25.0 % , respectively , for the cephapirin treatment only .","['The', 'rate', 'of', 'cure', 'by', '30', 'd', 'after', 'calving', 'for', 'systemic', 'oxytetracycline', '(', 'in', 'combination', 'with', 'cephapirin', 'treatment', ')', 'was', '29.4', '%', 'for', 'infected', 'quarters', 'and', '29.4', '%', 'for', 'infected', 'cows', ',', 'compared', 'with', '27.5', 'and', '25.0', '%', ',', 'respectively', ',', 'for', 'the', 'cephapirin', 'treatment', 'only', '.']","(16, 17)","(89, 99)",-1,hl_i,7814711,Abstract,3,test,gold,
7216,"The rate of cure by 30 d after calving for systemic oxytetracycline ( in combination with cephapirin treatment ) was 29.4 % for infected quarters and 29.4 % for infected cows , compared with 27.5 and 25.0 % , respectively , for the",cephapirin,treatment only .,"['The', 'rate', 'of', 'cure', 'by', '30', 'd', 'after', 'calving', 'for', 'systemic', 'oxytetracycline', '(', 'in', 'combination', 'with', 'cephapirin', 'treatment', ')', 'was', '29.4', '%', 'for', 'infected', 'quarters', 'and', '29.4', '%', 'for', 'infected', 'cows', ',', 'compared', 'with', '27.5', 'and', '25.0', '%', ',', 'respectively', ',', 'for', 'the', 'cephapirin', 'treatment', 'only', '.']","(43, 44)","(231, 241)",-1,hl_i,7814711,Abstract,3,test,gold,
7217,The,rate of cure,"by 30 d after calving for systemic oxytetracycline ( in combination with cephapirin treatment ) was 29.4 % for infected quarters and 29.4 % for infected cows , compared with 27.5 and 25.0 % , respectively , for the cephapirin treatment only .","['The', 'rate', 'of', 'cure', 'by', '30', 'd', 'after', 'calving', 'for', 'systemic', 'oxytetracycline', '(', 'in', 'combination', 'with', 'cephapirin', 'treatment', ')', 'was', '29.4', '%', 'for', 'infected', 'quarters', 'and', '29.4', '%', 'for', 'infected', 'cows', ',', 'compared', 'with', '27.5', 'and', '25.0', '%', ',', 'respectively', ',', 'for', 'the', 'cephapirin', 'treatment', 'only', '.']","(1, 4)","(3, 15)",-1,hl_o,7814711,Abstract,3,test,gold,1947.0
7218,"Results including the culture at 60 d after calving were 21.2 and 22.5 % , respectively , for combination therapy and",cephapirin,therapy only .,"['Results', 'including', 'the', 'culture', 'at', '60', 'd', 'after', 'calving', 'were', '21.2', 'and', '22.5', '%', ',', 'respectively', ',', 'for', 'combination', 'therapy', 'and', 'cephapirin', 'therapy', 'only', '.']","(21, 22)","(117, 127)",-1,ss_i,7814711,Abstract,4,test,gold,
7219,Results including the,culture,"at 60 d after calving were 21.2 and 22.5 % , respectively , for combination therapy and cephapirin therapy only .","['Results', 'including', 'the', 'culture', 'at', '60', 'd', 'after', 'calving', 'were', '21.2', 'and', '22.5', '%', ',', 'respectively', ',', 'for', 'combination', 'therapy', 'and', 'cephapirin', 'therapy', 'only', '.']","(3, 4)","(21, 28)",-1,ss_o,7814711,Abstract,4,test,gold,1198.0
7220,"Results including the culture at 60 d after calving were 21.2 and 22.5 % , respectively , for combination therapy and",cephapirin,therapy only .,"['Results', 'including', 'the', 'culture', 'at', '60', 'd', 'after', 'calving', 'were', '21.2', 'and', '22.5', '%', ',', 'respectively', ',', 'for', 'combination', 'therapy', 'and', 'cephapirin', 'therapy', 'only', '.']","(21, 22)","(117, 127)",-1,hl_i,7814711,Abstract,4,test,gold,
7221,Systemic,oxytetracycline,", in combination with intramammary dry cow treatment , did not improve the rate of cure for S. aureus mastitis .","['Systemic', 'oxytetracycline', ',', 'in', 'combination', 'with', 'intramammary', 'dry', 'cow', 'treatment', ',', 'did', 'not', 'improve', 'the', 'rate', 'of', 'cure', 'for', 'S.', 'aureus', 'mastitis', '.']","(1, 2)","(8, 23)",-1,ss_i,7814711,Abstract,5,test,gold,90.0
7222,"Systemic oxytetracycline , in combination with intramammary dry cow treatment , did not improve the",rate of cure,for S. aureus mastitis .,"['Systemic', 'oxytetracycline', ',', 'in', 'combination', 'with', 'intramammary', 'dry', 'cow', 'treatment', ',', 'did', 'not', 'improve', 'the', 'rate', 'of', 'cure', 'for', 'S.', 'aureus', 'mastitis', '.']","(15, 18)","(99, 111)",-1,ss_o,7814711,Abstract,5,test,gold,1945.0
7223,Systemic,oxytetracycline,", in combination with intramammary dry cow treatment , did not improve the rate of cure for S. aureus mastitis .","['Systemic', 'oxytetracycline', ',', 'in', 'combination', 'with', 'intramammary', 'dry', 'cow', 'treatment', ',', 'did', 'not', 'improve', 'the', 'rate', 'of', 'cure', 'for', 'S.', 'aureus', 'mastitis', '.']","(1, 2)","(8, 23)",-1,hl_i,7814711,Abstract,5,test,gold,89.0
7224,"Systemic oxytetracycline , in combination with intramammary dry cow treatment , did not improve the",rate of cure,for S. aureus mastitis .,"['Systemic', 'oxytetracycline', ',', 'in', 'combination', 'with', 'intramammary', 'dry', 'cow', 'treatment', ',', 'did', 'not', 'improve', 'the', 'rate', 'of', 'cure', 'for', 'S.', 'aureus', 'mastitis', '.']","(15, 18)","(99, 111)",-1,hl_o,7814711,Abstract,5,test,gold,1944.0
7225,Epidemiology of stroke .,,,"['Epidemiology', 'of', 'stroke', '.']",,,,,7827398,Title,0,test,gold,
7226,Importance of preventive pharmacological strategies in,elderly patients,and associated costs .,"['Importance', 'of', 'preventive', 'pharmacological', 'strategies', 'in', 'elderly', 'patients', 'and', 'associated', 'costs', '.']","(6, 8)","(54, 70)",-1,ss_p,7827398,Abstract,0,test,gold,3760.0
7227,Importance of,preventive pharmacological strategies in elderly patients,and associated costs .,"['Importance', 'of', 'preventive', 'pharmacological', 'strategies', 'in', 'elderly', 'patients', 'and', 'associated', 'costs', '.']","(2, 8)","(13, 70)",-1,ss_i,7827398,Abstract,0,test,gold,6946.0
7228,Importance of,preventive pharmacological strategies,in elderly patients and associated costs .,"['Importance', 'of', 'preventive', 'pharmacological', 'strategies', 'in', 'elderly', 'patients', 'and', 'associated', 'costs', '.']","(2, 5)","(13, 50)",-1,ss_o,7827398,Abstract,0,test,gold,6947.0
7229,Importance of preventive pharmacological strategies in,elderly patients,and associated costs .,"['Importance', 'of', 'preventive', 'pharmacological', 'strategies', 'in', 'elderly', 'patients', 'and', 'associated', 'costs', '.']","(6, 8)","(54, 70)",-1,hl_p,7827398,Abstract,0,test,gold,3759.0
7230,Importance of,preventive pharmacological strategies,in elderly patients and associated costs .,"['Importance', 'of', 'preventive', 'pharmacological', 'strategies', 'in', 'elderly', 'patients', 'and', 'associated', 'costs', '.']","(2, 5)","(13, 50)",-1,hl_i,7827398,Abstract,0,test,gold,6948.0
7231,Stroke is a major cause of death and disability in developed countries .,,,"['Stroke', 'is', 'a', 'major', 'cause', 'of', 'death', 'and', 'disability', 'in', 'developed', 'countries', '.']",,,,,7827398,Abstract,1,test,gold,
7232,"The incidence of stroke increases exponentially with age , yet , traditionally , many medical practitioners have been reluctant to treat hypertension",in older patients .,,"['The', 'incidence', 'of', 'stroke', 'increases', 'exponentially', 'with', 'age', ',', 'yet', ',', 'traditionally', ',', 'many', 'medical', 'practitioners', 'have', 'been', 'reluctant', 'to', 'treat', 'hypertension', 'in', 'older', 'patients', '.']","(22, 26)","(149, 168)",-1,ss_p,7827398,Abstract,2,test,gold,3771.0
7233,The,incidence of stroke,"increases exponentially with age , yet , traditionally , many medical practitioners have been reluctant to treat hypertension in older patients .","['The', 'incidence', 'of', 'stroke', 'increases', 'exponentially', 'with', 'age', ',', 'yet', ',', 'traditionally', ',', 'many', 'medical', 'practitioners', 'have', 'been', 'reluctant', 'to', 'treat', 'hypertension', 'in', 'older', 'patients', '.']","(1, 4)","(3, 22)",-1,ss_o,7827398,Abstract,2,test,gold,3378.0
7234,"The incidence of stroke increases exponentially with age , yet , traditionally , many medical practitioners have been reluctant to treat hypertension in",older patients,.,"['The', 'incidence', 'of', 'stroke', 'increases', 'exponentially', 'with', 'age', ',', 'yet', ',', 'traditionally', ',', 'many', 'medical', 'practitioners', 'have', 'been', 'reluctant', 'to', 'treat', 'hypertension', 'in', 'older', 'patients', '.']","(23, 25)","(152, 166)",-1,hl_p,7827398,Abstract,2,test,gold,3772.0
7235,"Since 1991 , the results of 3 major trials -- the British Medical Research Council ( MRC ) trial of treatment in older adults , the Swedish Trial in",Old Patients with Hypertension,( STOP-Hypertension ) and the Systolic Hypertension in the Elderly Program ( SHEP ) -- have conclusively established the benefits of treating older patients ( > 60 years ) with both diastolic and isolated systolic hypertension .,"['Since', '1991', ',', 'the', 'results', 'of', '3', 'major', 'trials', '--', 'the', 'British', 'Medical', 'Research', 'Council', '(', 'MRC', ')', 'trial', 'of', 'treatment', 'in', 'older', 'adults', ',', 'the', 'Swedish', 'Trial', 'in', 'Old', 'Patients', 'with', 'Hypertension', '(', 'STOP-Hypertension', ')', 'and', 'the', 'Systolic', 'Hypertension', 'in', 'the', 'Elderly', 'Program', '(', 'SHEP', ')', '--', 'have', 'conclusively', 'established', 'the', 'benefits', 'of', 'treating', 'older', 'patients', '(', '>', '60', 'years', ')', 'with', 'both', 'diastolic', 'and', 'isolated', 'systolic', 'hypertension', '.']","(29, 33)","(148, 178)",-1,ss_p,7827398,Abstract,3,test,gold,3774.0
7236,"Since 1991 , the results of 3 major trials -- the British Medical Research Council ( MRC ) trial of treatment in older adults , the Swedish Trial in Old Patients with Hypertension ( STOP-Hypertension ) and the Systolic Hypertension in the Elderly Program ( SHEP ) -- have conclusively established the benefits of treating",older patients ( > 60 years ) with both diastolic and isolated systolic hypertension .,,"['Since', '1991', ',', 'the', 'results', 'of', '3', 'major', 'trials', '--', 'the', 'British', 'Medical', 'Research', 'Council', '(', 'MRC', ')', 'trial', 'of', 'treatment', 'in', 'older', 'adults', ',', 'the', 'Swedish', 'Trial', 'in', 'Old', 'Patients', 'with', 'Hypertension', '(', 'STOP-Hypertension', ')', 'and', 'the', 'Systolic', 'Hypertension', 'in', 'the', 'Elderly', 'Program', '(', 'SHEP', ')', '--', 'have', 'conclusively', 'established', 'the', 'benefits', 'of', 'treating', 'older', 'patients', '(', '>', '60', 'years', ')', 'with', 'both', 'diastolic', 'and', 'isolated', 'systolic', 'hypertension', '.']","(55, 70)","(321, 407)",-1,ss_p,7827398,Abstract,3,test,gold,6694.0
7237,"Since 1991 , the results of 3 major trials -- the British Medical Research Council ( MRC ) trial of treatment in older adults , the Swedish Trial in Old Patients with Hypertension ( STOP-Hypertension ) and the Systolic Hypertension in the Elderly Program ( SHEP ) -- have conclusively established the benefits of",treating older patients,( > 60 years ) with both diastolic and isolated systolic hypertension .,"['Since', '1991', ',', 'the', 'results', 'of', '3', 'major', 'trials', '--', 'the', 'British', 'Medical', 'Research', 'Council', '(', 'MRC', ')', 'trial', 'of', 'treatment', 'in', 'older', 'adults', ',', 'the', 'Swedish', 'Trial', 'in', 'Old', 'Patients', 'with', 'Hypertension', '(', 'STOP-Hypertension', ')', 'and', 'the', 'Systolic', 'Hypertension', 'in', 'the', 'Elderly', 'Program', '(', 'SHEP', ')', '--', 'have', 'conclusively', 'established', 'the', 'benefits', 'of', 'treating', 'older', 'patients', '(', '>', '60', 'years', ')', 'with', 'both', 'diastolic', 'and', 'isolated', 'systolic', 'hypertension', '.']","(54, 57)","(312, 335)",-1,ss_i,7827398,Abstract,3,test,gold,3766.0
7238,"Since 1991 , the results of 3 major trials -- the British Medical Research Council ( MRC ) trial of treatment in older adults , the Swedish Trial in",Old Patients with Hypertension,( STOP-Hypertension ) and the Systolic Hypertension in the Elderly Program ( SHEP ) -- have conclusively established the benefits of treating older patients ( > 60 years ) with both diastolic and isolated systolic hypertension .,"['Since', '1991', ',', 'the', 'results', 'of', '3', 'major', 'trials', '--', 'the', 'British', 'Medical', 'Research', 'Council', '(', 'MRC', ')', 'trial', 'of', 'treatment', 'in', 'older', 'adults', ',', 'the', 'Swedish', 'Trial', 'in', 'Old', 'Patients', 'with', 'Hypertension', '(', 'STOP-Hypertension', ')', 'and', 'the', 'Systolic', 'Hypertension', 'in', 'the', 'Elderly', 'Program', '(', 'SHEP', ')', '--', 'have', 'conclusively', 'established', 'the', 'benefits', 'of', 'treating', 'older', 'patients', '(', '>', '60', 'years', ')', 'with', 'both', 'diastolic', 'and', 'isolated', 'systolic', 'hypertension', '.']","(29, 33)","(148, 178)",-1,hl_p,7827398,Abstract,3,test,gold,3775.0
7239,"Since 1991 , the results of 3 major trials -- the British Medical Research Council ( MRC ) trial of treatment in older adults , the Swedish Trial in Old Patients with Hypertension ( STOP-Hypertension ) and the Systolic Hypertension in the Elderly Program ( SHEP ) -- have conclusively established the benefits of treating",older patients ( > 60 years ) with both diastolic and isolated systolic hypertension .,,"['Since', '1991', ',', 'the', 'results', 'of', '3', 'major', 'trials', '--', 'the', 'British', 'Medical', 'Research', 'Council', '(', 'MRC', ')', 'trial', 'of', 'treatment', 'in', 'older', 'adults', ',', 'the', 'Swedish', 'Trial', 'in', 'Old', 'Patients', 'with', 'Hypertension', '(', 'STOP-Hypertension', ')', 'and', 'the', 'Systolic', 'Hypertension', 'in', 'the', 'Elderly', 'Program', '(', 'SHEP', ')', '--', 'have', 'conclusively', 'established', 'the', 'benefits', 'of', 'treating', 'older', 'patients', '(', '>', '60', 'years', ')', 'with', 'both', 'diastolic', 'and', 'isolated', 'systolic', 'hypertension', '.']","(55, 70)","(321, 407)",-1,hl_p,7827398,Abstract,3,test,gold,6695.0
7240,"International guidelines for the management of hypertension -- including the Fifth Report of the Joint National Committee , the 1993 report of the World Health Organization and the International Society of Hypertension and the second report of the British Hypertension Society Working Party -- have all been modified to reflect the emerging evidence concerning the benefits of treating",older patients .,,"['International', 'guidelines', 'for', 'the', 'management', 'of', 'hypertension', '--', 'including', 'the', 'Fifth', 'Report', 'of', 'the', 'Joint', 'National', 'Committee', ',', 'the', '1993', 'report', 'of', 'the', 'World', 'Health', 'Organization', 'and', 'the', 'International', 'Society', 'of', 'Hypertension', 'and', 'the', 'second', 'report', 'of', 'the', 'British', 'Hypertension', 'Society', 'Working', 'Party', '--', 'have', 'all', 'been', 'modified', 'to', 'reflect', 'the', 'emerging', 'evidence', 'concerning', 'the', 'benefits', 'of', 'treating', 'older', 'patients', '.']","(58, 61)","(385, 401)",-1,ss_p,7827398,Abstract,4,test,gold,3773.0
7241,"International guidelines for the management of hypertension -- including the Fifth Report of the Joint National Committee , the 1993 report of the World Health Organization and the International Society of Hypertension and the second report of the British Hypertension Society Working Party -- have all been modified to reflect the emerging evidence concerning the benefits of",treating older patients .,,"['International', 'guidelines', 'for', 'the', 'management', 'of', 'hypertension', '--', 'including', 'the', 'Fifth', 'Report', 'of', 'the', 'Joint', 'National', 'Committee', ',', 'the', '1993', 'report', 'of', 'the', 'World', 'Health', 'Organization', 'and', 'the', 'International', 'Society', 'of', 'Hypertension', 'and', 'the', 'second', 'report', 'of', 'the', 'British', 'Hypertension', 'Society', 'Working', 'Party', '--', 'have', 'all', 'been', 'modified', 'to', 'reflect', 'the', 'emerging', 'evidence', 'concerning', 'the', 'benefits', 'of', 'treating', 'older', 'patients', '.']","(57, 61)","(376, 401)",-1,ss_i,7827398,Abstract,4,test,gold,3767.0
7242,Cost-effectiveness data are similarly in accord with giving high priority to the treatment of,older individuals with hypertension .,,"['Cost-effectiveness', 'data', 'are', 'similarly', 'in', 'accord', 'with', 'giving', 'high', 'priority', 'to', 'the', 'treatment', 'of', 'older', 'individuals', 'with', 'hypertension', '.']","(14, 19)","(93, 130)",-1,ss_p,7827398,Abstract,5,test,gold,3802.0
7243,Cost-effectiveness data are similarly in accord with giving high priority to the,treatment of older individuals,with hypertension .,"['Cost-effectiveness', 'data', 'are', 'similarly', 'in', 'accord', 'with', 'giving', 'high', 'priority', 'to', 'the', 'treatment', 'of', 'older', 'individuals', 'with', 'hypertension', '.']","(12, 16)","(80, 110)",-1,ss_i,7827398,Abstract,5,test,gold,3770.0
7244,,Cost-effectiveness data,are similarly in accord with giving high priority to the treatment of older individuals with hypertension .,"['Cost-effectiveness', 'data', 'are', 'similarly', 'in', 'accord', 'with', 'giving', 'high', 'priority', 'to', 'the', 'treatment', 'of', 'older', 'individuals', 'with', 'hypertension', '.']","(0, 2)","(0, 23)",-1,ss_o,7827398,Abstract,5,test,gold,1258.0
7245,Cost-effectiveness data are similarly in accord with giving high priority to the treatment of,older individuals with hypertension .,,"['Cost-effectiveness', 'data', 'are', 'similarly', 'in', 'accord', 'with', 'giving', 'high', 'priority', 'to', 'the', 'treatment', 'of', 'older', 'individuals', 'with', 'hypertension', '.']","(14, 19)","(93, 130)",-1,hl_p,7827398,Abstract,5,test,gold,3803.0
7246,,Cost-effectiveness data,are similarly in accord with giving high priority to the treatment of older individuals with hypertension .,"['Cost-effectiveness', 'data', 'are', 'similarly', 'in', 'accord', 'with', 'giving', 'high', 'priority', 'to', 'the', 'treatment', 'of', 'older', 'individuals', 'with', 'hypertension', '.']","(0, 2)","(0, 23)",-1,hl_o,7827398,Abstract,5,test,gold,1256.0
7247,Measurement of transfer factor during constant exhalation .,,,"['Measurement', 'of', 'transfer', 'factor', 'during', 'constant', 'exhalation', '.']",,,,,7831628,Title,0,test,gold,
7248,BACKGROUND,Transfer factor of the lung for carbon monoxide,( TLCO ) was measured by a new method based on analysis of the ratio of the concentrations of carbon monoxide to an inert gas ( methane ) relative to lung volume during a constant exhalation .,"['BACKGROUND', 'Transfer', 'factor', 'of', 'the', 'lung', 'for', 'carbon', 'monoxide', '(', 'TLCO', ')', 'was', 'measured', 'by', 'a', 'new', 'method', 'based', 'on', 'analysis', 'of', 'the', 'ratio', 'of', 'the', 'concentrations', 'of', 'carbon', 'monoxide', 'to', 'an', 'inert', 'gas', '(', 'methane', ')', 'relative', 'to', 'lung', 'volume', 'during', 'a', 'constant', 'exhalation', '.']","(1, 9)","(10, 57)",-1,ss_i,7831628,Abstract,0,test,gold,1711.0
7249,BACKGROUND,Transfer factor of the lung for carbon monoxide ( TLCO ),was measured by a new method based on analysis of the ratio of the concentrations of carbon monoxide to an inert gas ( methane ) relative to lung volume during a constant exhalation .,"['BACKGROUND', 'Transfer', 'factor', 'of', 'the', 'lung', 'for', 'carbon', 'monoxide', '(', 'TLCO', ')', 'was', 'measured', 'by', 'a', 'new', 'method', 'based', 'on', 'analysis', 'of', 'the', 'ratio', 'of', 'the', 'concentrations', 'of', 'carbon', 'monoxide', 'to', 'an', 'inert', 'gas', '(', 'methane', ')', 'relative', 'to', 'lung', 'volume', 'during', 'a', 'constant', 'exhalation', '.']","(1, 12)","(10, 66)",-1,ss_o,7831628,Abstract,0,test,gold,1712.0
7250,BACKGROUND Transfer factor of the lung for carbon monoxide ( TLCO ) was measured by a new method based on analysis of the,ratio of the concentrations of carbon monoxide,to an inert gas ( methane ) relative to lung volume during a constant exhalation .,"['BACKGROUND', 'Transfer', 'factor', 'of', 'the', 'lung', 'for', 'carbon', 'monoxide', '(', 'TLCO', ')', 'was', 'measured', 'by', 'a', 'new', 'method', 'based', 'on', 'analysis', 'of', 'the', 'ratio', 'of', 'the', 'concentrations', 'of', 'carbon', 'monoxide', 'to', 'an', 'inert', 'gas', '(', 'methane', ')', 'relative', 'to', 'lung', 'volume', 'during', 'a', 'constant', 'exhalation', '.']","(23, 30)","(121, 167)",-1,ss_o,7831628,Abstract,0,test,gold,1732.0
7251,BACKGROUND,Transfer factor of the lung for carbon monoxide ( TLCO ),was measured by a new method based on analysis of the ratio of the concentrations of carbon monoxide to an inert gas ( methane ) relative to lung volume during a constant exhalation .,"['BACKGROUND', 'Transfer', 'factor', 'of', 'the', 'lung', 'for', 'carbon', 'monoxide', '(', 'TLCO', ')', 'was', 'measured', 'by', 'a', 'new', 'method', 'based', 'on', 'analysis', 'of', 'the', 'ratio', 'of', 'the', 'concentrations', 'of', 'carbon', 'monoxide', 'to', 'an', 'inert', 'gas', '(', 'methane', ')', 'relative', 'to', 'lung', 'volume', 'during', 'a', 'constant', 'exhalation', '.']","(1, 12)","(10, 66)",-1,hl_o,7831628,Abstract,0,test,gold,1710.0
7252,"Since this new technique is based solely upon exhalation , anomalies associated with inspiration and breath holding do not affect results .",,,"['Since', 'this', 'new', 'technique', 'is', 'based', 'solely', 'upon', 'exhalation', ',', 'anomalies', 'associated', 'with', 'inspiration', 'and', 'breath', 'holding', 'do', 'not', 'affect', 'results', '.']",,,,,7831628,Abstract,1,test,gold,
7253,"Additionally , because prolonged breath holding is not required , measurements can readily be made in",dyspnoeic patients .,,"['Additionally', ',', 'because', 'prolonged', 'breath', 'holding', 'is', 'not', 'required', ',', 'measurements', 'can', 'readily', 'be', 'made', 'in', 'dyspnoeic', 'patients', '.']","(16, 19)","(101, 121)",-1,ss_p,7831628,Abstract,2,test,gold,3737.0
7254,"METHODS Exhalation TLCO ( TLCO , ex ) was compared with the standard ( Jones and Meade ) 10 second breath holding TLCO ( TLCO , bh ) in",100 consecutive patients .,,"['METHODS', 'Exhalation', 'TLCO', '(', 'TLCO', ',', 'ex', ')', 'was', 'compared', 'with', 'the', 'standard', '(', 'Jones', 'and', 'Meade', ')', '10', 'second', 'breath', 'holding', 'TLCO', '(', 'TLCO', ',', 'bh', ')', 'in', '100', 'consecutive', 'patients', '.']","(29, 33)","(135, 161)",-1,ss_p,7831628,Abstract,3,test,gold,3723.0
7255,METHODS Exhalation,TLCO ( TLCO,", ex ) was compared with the standard ( Jones and Meade ) 10 second breath holding TLCO ( TLCO , bh ) in 100 consecutive patients .","['METHODS', 'Exhalation', 'TLCO', '(', 'TLCO', ',', 'ex', ')', 'was', 'compared', 'with', 'the', 'standard', '(', 'Jones', 'and', 'Meade', ')', '10', 'second', 'breath', 'holding', 'TLCO', '(', 'TLCO', ',', 'bh', ')', 'in', '100', 'consecutive', 'patients', '.']","(2, 5)","(18, 29)",-1,ss_i,7831628,Abstract,3,test,gold,
7256,"METHODS Exhalation TLCO ( TLCO , ex ) was compared with the",standard ( Jones and Meade ),"10 second breath holding TLCO ( TLCO , bh ) in 100 consecutive patients .","['METHODS', 'Exhalation', 'TLCO', '(', 'TLCO', ',', 'ex', ')', 'was', 'compared', 'with', 'the', 'standard', '(', 'Jones', 'and', 'Meade', ')', '10', 'second', 'breath', 'holding', 'TLCO', '(', 'TLCO', ',', 'bh', ')', 'in', '100', 'consecutive', 'patients', '.']","(12, 18)","(59, 87)",-1,ss_i,7831628,Abstract,3,test,gold,1458.0
7257,"METHODS Exhalation TLCO ( TLCO , ex ) was compared with the standard ( Jones and Meade ) 10 second breath holding",TLCO ( TLCO,", bh ) in 100 consecutive patients .","['METHODS', 'Exhalation', 'TLCO', '(', 'TLCO', ',', 'ex', ')', 'was', 'compared', 'with', 'the', 'standard', '(', 'Jones', 'and', 'Meade', ')', '10', 'second', 'breath', 'holding', 'TLCO', '(', 'TLCO', ',', 'bh', ')', 'in', '100', 'consecutive', 'patients', '.']","(22, 25)","(113, 124)",-1,ss_i,7831628,Abstract,3,test,gold,
7258,METHODS,"Exhalation TLCO ( TLCO , ex )","was compared with the standard ( Jones and Meade ) 10 second breath holding TLCO ( TLCO , bh ) in 100 consecutive patients .","['METHODS', 'Exhalation', 'TLCO', '(', 'TLCO', ',', 'ex', ')', 'was', 'compared', 'with', 'the', 'standard', '(', 'Jones', 'and', 'Meade', ')', '10', 'second', 'breath', 'holding', 'TLCO', '(', 'TLCO', ',', 'bh', ')', 'in', '100', 'consecutive', 'patients', '.']","(1, 8)","(7, 36)",-1,ss_o,7831628,Abstract,3,test,gold,1075.0
7259,"METHODS Exhalation TLCO ( TLCO , ex ) was compared with the","standard ( Jones and Meade ) 10 second breath holding TLCO ( TLCO , bh )",in 100 consecutive patients .,"['METHODS', 'Exhalation', 'TLCO', '(', 'TLCO', ',', 'ex', ')', 'was', 'compared', 'with', 'the', 'standard', '(', 'Jones', 'and', 'Meade', ')', '10', 'second', 'breath', 'holding', 'TLCO', '(', 'TLCO', ',', 'bh', ')', 'in', '100', 'consecutive', 'patients', '.']","(12, 28)","(59, 131)",-1,ss_o,7831628,Abstract,3,test,gold,1460.0
7260,METHODS Exhalation,TLCO ( TLCO,", ex ) was compared with the standard ( Jones and Meade ) 10 second breath holding TLCO ( TLCO , bh ) in 100 consecutive patients .","['METHODS', 'Exhalation', 'TLCO', '(', 'TLCO', ',', 'ex', ')', 'was', 'compared', 'with', 'the', 'standard', '(', 'Jones', 'and', 'Meade', ')', '10', 'second', 'breath', 'holding', 'TLCO', '(', 'TLCO', ',', 'bh', ')', 'in', '100', 'consecutive', 'patients', '.']","(2, 5)","(18, 29)",-1,hl_i,7831628,Abstract,3,test,gold,
7261,"METHODS Exhalation TLCO ( TLCO , ex ) was compared with the",standard ( Jones and Meade ),"10 second breath holding TLCO ( TLCO , bh ) in 100 consecutive patients .","['METHODS', 'Exhalation', 'TLCO', '(', 'TLCO', ',', 'ex', ')', 'was', 'compared', 'with', 'the', 'standard', '(', 'Jones', 'and', 'Meade', ')', '10', 'second', 'breath', 'holding', 'TLCO', '(', 'TLCO', ',', 'bh', ')', 'in', '100', 'consecutive', 'patients', '.']","(12, 18)","(59, 87)",-1,hl_i,7831628,Abstract,3,test,gold,1459.0
7262,"METHODS Exhalation TLCO ( TLCO , ex ) was compared with the standard ( Jones and Meade ) 10 second breath holding",TLCO ( TLCO,", bh ) in 100 consecutive patients .","['METHODS', 'Exhalation', 'TLCO', '(', 'TLCO', ',', 'ex', ')', 'was', 'compared', 'with', 'the', 'standard', '(', 'Jones', 'and', 'Meade', ')', '10', 'second', 'breath', 'holding', 'TLCO', '(', 'TLCO', ',', 'bh', ')', 'in', '100', 'consecutive', 'patients', '.']","(22, 25)","(113, 124)",-1,hl_i,7831628,Abstract,3,test,gold,
7263,METHODS,"Exhalation TLCO ( TLCO , ex )","was compared with the standard ( Jones and Meade ) 10 second breath holding TLCO ( TLCO , bh ) in 100 consecutive patients .","['METHODS', 'Exhalation', 'TLCO', '(', 'TLCO', ',', 'ex', ')', 'was', 'compared', 'with', 'the', 'standard', '(', 'Jones', 'and', 'Meade', ')', '10', 'second', 'breath', 'holding', 'TLCO', '(', 'TLCO', ',', 'bh', ')', 'in', '100', 'consecutive', 'patients', '.']","(1, 8)","(7, 36)",-1,hl_o,7831628,Abstract,3,test,gold,1076.0
7264,"METHODS Exhalation TLCO ( TLCO , ex ) was compared with the","standard ( Jones and Meade ) 10 second breath holding TLCO ( TLCO , bh )",in 100 consecutive patients .,"['METHODS', 'Exhalation', 'TLCO', '(', 'TLCO', ',', 'ex', ')', 'was', 'compared', 'with', 'the', 'standard', '(', 'Jones', 'and', 'Meade', ')', '10', 'second', 'breath', 'holding', 'TLCO', '(', 'TLCO', ',', 'bh', ')', 'in', '100', 'consecutive', 'patients', '.']","(12, 28)","(59, 131)",-1,hl_o,7831628,Abstract,3,test,gold,1461.0
7265,Patients did not practise the exhalation manoeuvre prior to testing .,,,"['Patients', 'did', 'not', 'practise', 'the', 'exhalation', 'manoeuvre', 'prior', 'to', 'testing', '.']",,,,,7831628,Abstract,4,test,gold,
7266,RESULTS The comparative results were very close ; mean difference ( bias ) +/- standard deviation ( precision ) was 0.05 ( 0.84 ) mmol/min/kPa .,,,"['RESULTS', 'The', 'comparative', 'results', 'were', 'very', 'close', ';', 'mean', 'difference', '(', 'bias', ')', '+/-', 'standard', 'deviation', '(', 'precision', ')', 'was', '0.05', '(', '0.84', ')', 'mmol/min/kPa', '.']",,,,,7831628,Abstract,5,test,gold,
7267,The relation was equally strong in,patients with severe pulmonary disease ;,for patients with FEV1 < 1.51 the mean difference was 0.21 ( 0.80 ) mmol/min/kPa .,"['The', 'relation', 'was', 'equally', 'strong', 'in', 'patients', 'with', 'severe', 'pulmonary', 'disease', ';', 'for', 'patients', 'with', 'FEV1', '<', '1.51', 'the', 'mean', 'difference', 'was', '0.21', '(', '0.80', ')', 'mmol/min/kPa', '.']","(6, 12)","(34, 74)",-1,ss_p,7831628,Abstract,6,test,gold,7046.0
7268,The,relation,was equally strong in patients with severe pulmonary disease ; for patients with FEV1 < 1.51 the mean difference was 0.21 ( 0.80 ) mmol/min/kPa .,"['The', 'relation', 'was', 'equally', 'strong', 'in', 'patients', 'with', 'severe', 'pulmonary', 'disease', ';', 'for', 'patients', 'with', 'FEV1', '<', '1.51', 'the', 'mean', 'difference', 'was', '0.21', '(', '0.80', ')', 'mmol/min/kPa', '.']","(1, 2)","(3, 11)",-1,ss_o,7831628,Abstract,6,test,gold,1211.0
7269,The relation was equally strong in patients with severe pulmonary disease ; for patients with,FEV1,< 1.51 the mean difference was 0.21 ( 0.80 ) mmol/min/kPa .,"['The', 'relation', 'was', 'equally', 'strong', 'in', 'patients', 'with', 'severe', 'pulmonary', 'disease', ';', 'for', 'patients', 'with', 'FEV1', '<', '1.51', 'the', 'mean', 'difference', 'was', '0.21', '(', '0.80', ')', 'mmol/min/kPa', '.']","(15, 16)","(93, 97)",-1,ss_o,7831628,Abstract,6,test,gold,1669.0
7270,The,relation,was equally strong in patients with severe pulmonary disease ; for patients with FEV1 < 1.51 the mean difference was 0.21 ( 0.80 ) mmol/min/kPa .,"['The', 'relation', 'was', 'equally', 'strong', 'in', 'patients', 'with', 'severe', 'pulmonary', 'disease', ';', 'for', 'patients', 'with', 'FEV1', '<', '1.51', 'the', 'mean', 'difference', 'was', '0.21', '(', '0.80', ')', 'mmol/min/kPa', '.']","(1, 2)","(3, 11)",-1,hl_o,7831628,Abstract,6,test,gold,1212.0
7271,"CONCLUSIONS Since the results were essentially identical between the techniques , it seems that comparable pathophysiological factors affect",TLCO,during breath holding and constant exhalation .,"['CONCLUSIONS', 'Since', 'the', 'results', 'were', 'essentially', 'identical', 'between', 'the', 'techniques', ',', 'it', 'seems', 'that', 'comparable', 'pathophysiological', 'factors', 'affect', 'TLCO', 'during', 'breath', 'holding', 'and', 'constant', 'exhalation', '.']","(18, 19)","(140, 144)",-1,ss_i,7831628,Abstract,7,test,gold,
7272,Constant exhalation may therefore be a useful alternative to the breath holding technique for clinical measurement of,TLCO .,,"['Constant', 'exhalation', 'may', 'therefore', 'be', 'a', 'useful', 'alternative', 'to', 'the', 'breath', 'holding', 'technique', 'for', 'clinical', 'measurement', 'of', 'TLCO', '.']","(17, 19)","(117, 123)",-1,ss_i,7831628,Abstract,8,test,gold,
7273,Constant exhalation may therefore be a useful alternative to the breath holding technique for,clinical measurement of TLCO .,,"['Constant', 'exhalation', 'may', 'therefore', 'be', 'a', 'useful', 'alternative', 'to', 'the', 'breath', 'holding', 'technique', 'for', 'clinical', 'measurement', 'of', 'TLCO', '.']","(14, 19)","(93, 123)",-1,ss_o,7831628,Abstract,8,test,gold,4768.0
7274,The effect of two types of,teacher training,on implementation of Smart Choices : a tobacco prevention curriculum .,"['The', 'effect', 'of', 'two', 'types', 'of', 'teacher', 'training', 'on', 'implementation', 'of', 'Smart', 'Choices', ':', 'a', 'tobacco', 'prevention', 'curriculum', '.']","(6, 8)","(26, 42)",-1,ss_i,7844976,Title,0,test,gold,2824.0
7275,The effect of two types of teacher training on,implementation of Smart Choices :,a tobacco prevention curriculum .,"['The', 'effect', 'of', 'two', 'types', 'of', 'teacher', 'training', 'on', 'implementation', 'of', 'Smart', 'Choices', ':', 'a', 'tobacco', 'prevention', 'curriculum', '.']","(9, 14)","(46, 79)",-1,ss_o,7844976,Title,0,test,gold,357.0
7276,The effect of two types of,teacher training,on implementation of Smart Choices : a tobacco prevention curriculum .,"['The', 'effect', 'of', 'two', 'types', 'of', 'teacher', 'training', 'on', 'implementation', 'of', 'Smart', 'Choices', ':', 'a', 'tobacco', 'prevention', 'curriculum', '.']","(6, 8)","(26, 42)",-1,hl_i,7844976,Title,0,test,gold,2825.0
7277,This study examined the implementation phase of a four-year research project to test the,effectiveness,"of strategies to increase diffusion of Smart Choices , a school-based tobacco prevention program .","['This', 'study', 'examined', 'the', 'implementation', 'phase', 'of', 'a', 'four-year', 'research', 'project', 'to', 'test', 'the', 'effectiveness', 'of', 'strategies', 'to', 'increase', 'diffusion', 'of', 'Smart', 'Choices', ',', 'a', 'school-based', 'tobacco', 'prevention', 'program', '.']","(14, 15)","(88, 101)",-1,ss_o,7844976,Abstract,0,test,gold,386.0
7278,This study examined the implementation phase of a four-year research project to test the effectiveness of strategies to increase,diffusion of Smart Choices,", a school-based tobacco prevention program .","['This', 'study', 'examined', 'the', 'implementation', 'phase', 'of', 'a', 'four-year', 'research', 'project', 'to', 'test', 'the', 'effectiveness', 'of', 'strategies', 'to', 'increase', 'diffusion', 'of', 'Smart', 'Choices', ',', 'a', 'school-based', 'tobacco', 'prevention', 'program', '.']","(19, 23)","(128, 154)",-1,ss_o,7844976,Abstract,0,test,gold,355.0
7279,This study examined the implementation phase of a four-year research project to test the,effectiveness,"of strategies to increase diffusion of Smart Choices , a school-based tobacco prevention program .","['This', 'study', 'examined', 'the', 'implementation', 'phase', 'of', 'a', 'four-year', 'research', 'project', 'to', 'test', 'the', 'effectiveness', 'of', 'strategies', 'to', 'increase', 'diffusion', 'of', 'Smart', 'Choices', ',', 'a', 'school-based', 'tobacco', 'prevention', 'program', '.']","(14, 15)","(88, 101)",-1,hl_o,7844976,Abstract,0,test,gold,385.0
7280,This study examined the implementation phase of a four-year research project to test the effectiveness of strategies to increase,diffusion of Smart Choices,", a school-based tobacco prevention program .","['This', 'study', 'examined', 'the', 'implementation', 'phase', 'of', 'a', 'four-year', 'research', 'project', 'to', 'test', 'the', 'effectiveness', 'of', 'strategies', 'to', 'increase', 'diffusion', 'of', 'Smart', 'Choices', ',', 'a', 'school-based', 'tobacco', 'prevention', 'program', '.']","(19, 23)","(128, 154)",-1,hl_o,7844976,Abstract,0,test,gold,356.0
7281,The impact on curriculum implementation of two approaches to,teacher training,are compared .,"['The', 'impact', 'on', 'curriculum', 'implementation', 'of', 'two', 'approaches', 'to', 'teacher', 'training', 'are', 'compared', '.']","(9, 11)","(60, 76)",-1,ss_i,7844976,Abstract,1,test,gold,2823.0
7282,The,impact,on curriculum implementation of two approaches to teacher training are compared .,"['The', 'impact', 'on', 'curriculum', 'implementation', 'of', 'two', 'approaches', 'to', 'teacher', 'training', 'are', 'compared', '.']","(1, 2)","(3, 9)",-1,ss_o,7844976,Abstract,1,test,gold,956.0
7283,,School districts,were randomly assigned to a live workshop training or video training condition .,"['School', 'districts', 'were', 'randomly', 'assigned', 'to', 'a', 'live', 'workshop', 'training', 'or', 'video', 'training', 'condition', '.']","(0, 2)","(0, 16)",-1,ss_p,7844976,Abstract,2,test,gold,2183.0
7284,School districts were randomly assigned to a,live workshop training,or video training condition .,"['School', 'districts', 'were', 'randomly', 'assigned', 'to', 'a', 'live', 'workshop', 'training', 'or', 'video', 'training', 'condition', '.']","(7, 10)","(44, 66)",-1,ss_i,7844976,Abstract,2,test,gold,2826.0
7285,School districts were randomly assigned to a live workshop training or,video training condition .,,"['School', 'districts', 'were', 'randomly', 'assigned', 'to', 'a', 'live', 'workshop', 'training', 'or', 'video', 'training', 'condition', '.']","(11, 15)","(70, 96)",-1,ss_i,7844976,Abstract,2,test,gold,2830.0
7286,,School districts,were randomly assigned to a live workshop training or video training condition .,"['School', 'districts', 'were', 'randomly', 'assigned', 'to', 'a', 'live', 'workshop', 'training', 'or', 'video', 'training', 'condition', '.']","(0, 2)","(0, 16)",-1,hl_p,7844976,Abstract,2,test,gold,2184.0
7287,School districts were randomly assigned to a,live workshop training,or video training condition .,"['School', 'districts', 'were', 'randomly', 'assigned', 'to', 'a', 'live', 'workshop', 'training', 'or', 'video', 'training', 'condition', '.']","(7, 10)","(44, 66)",-1,hl_i,7844976,Abstract,2,test,gold,2827.0
7288,School districts were randomly assigned to a live workshop training or,video training condition .,,"['School', 'districts', 'were', 'randomly', 'assigned', 'to', 'a', 'live', 'workshop', 'training', 'or', 'video', 'training', 'condition', '.']","(11, 15)","(70, 96)",-1,hl_i,7844976,Abstract,2,test,gold,2831.0
7289,The outcome of the evaluation was,teachers ' implementation of Smart Choices .,,"['The', 'outcome', 'of', 'the', 'evaluation', 'was', 'teachers', ""'"", 'implementation', 'of', 'Smart', 'Choices', '.']","(6, 13)","(33, 77)",-1,ss_o,7844976,Abstract,3,test,gold,358.0
7290,The outcome of the evaluation was,teachers ' implementation of Smart Choices .,,"['The', 'outcome', 'of', 'the', 'evaluation', 'was', 'teachers', ""'"", 'implementation', 'of', 'Smart', 'Choices', '.']","(6, 13)","(33, 77)",-1,hl_o,7844976,Abstract,3,test,gold,359.0
7291,Results show a lower proportion of,video-trained teachers,"implemented the curriculum , but overall completeness and fidelity of implementation for those teachers who did teach the curriculum were comparable for the two groups .","['Results', 'show', 'a', 'lower', 'proportion', 'of', 'video-trained', 'teachers', 'implemented', 'the', 'curriculum', ',', 'but', 'overall', 'completeness', 'and', 'fidelity', 'of', 'implementation', 'for', 'those', 'teachers', 'who', 'did', 'teach', 'the', 'curriculum', 'were', 'comparable', 'for', 'the', 'two', 'groups', '.']","(6, 8)","(34, 56)",-1,ss_i,7844976,Abstract,4,test,gold,2192.0
7292,"Results show a lower proportion of video-trained teachers implemented the curriculum , but overall",completeness and fidelity of implementation,for those teachers who did teach the curriculum were comparable for the two groups .,"['Results', 'show', 'a', 'lower', 'proportion', 'of', 'video-trained', 'teachers', 'implemented', 'the', 'curriculum', ',', 'but', 'overall', 'completeness', 'and', 'fidelity', 'of', 'implementation', 'for', 'those', 'teachers', 'who', 'did', 'teach', 'the', 'curriculum', 'were', 'comparable', 'for', 'the', 'two', 'groups', '.']","(14, 19)","(98, 141)",-1,ss_o,7844976,Abstract,4,test,gold,1810.0
7293,Results show a lower proportion of,video-trained,"teachers implemented the curriculum , but overall completeness and fidelity of implementation for those teachers who did teach the curriculum were comparable for the two groups .","['Results', 'show', 'a', 'lower', 'proportion', 'of', 'video-trained', 'teachers', 'implemented', 'the', 'curriculum', ',', 'but', 'overall', 'completeness', 'and', 'fidelity', 'of', 'implementation', 'for', 'those', 'teachers', 'who', 'did', 'teach', 'the', 'curriculum', 'were', 'comparable', 'for', 'the', 'two', 'groups', '.']","(6, 7)","(34, 47)",-1,hl_i,7844976,Abstract,4,test,gold,
7294,"Results show a lower proportion of video-trained teachers implemented the curriculum , but overall",completeness and fidelity of implementation,for those teachers who did teach the curriculum were comparable for the two groups .,"['Results', 'show', 'a', 'lower', 'proportion', 'of', 'video-trained', 'teachers', 'implemented', 'the', 'curriculum', ',', 'but', 'overall', 'completeness', 'and', 'fidelity', 'of', 'implementation', 'for', 'those', 'teachers', 'who', 'did', 'teach', 'the', 'curriculum', 'were', 'comparable', 'for', 'the', 'two', 'groups', '.']","(14, 19)","(98, 141)",-1,hl_o,7844976,Abstract,4,test,gold,1811.0
7295,,Video-trained teachers,", however , were less likely to use brainstorming and student presentations/role plays , two of the methods prescribed by the curriculum .","['Video-trained', 'teachers', ',', 'however', ',', 'were', 'less', 'likely', 'to', 'use', 'brainstorming', 'and', 'student', 'presentations/role', 'plays', ',', 'two', 'of', 'the', 'methods', 'prescribed', 'by', 'the', 'curriculum', '.']","(0, 2)","(0, 22)",-1,ss_i,7844976,Abstract,5,test,gold,2193.0
7296,,Video-trained,"teachers , however , were less likely to use brainstorming and student presentations/role plays , two of the methods prescribed by the curriculum .","['Video-trained', 'teachers', ',', 'however', ',', 'were', 'less', 'likely', 'to', 'use', 'brainstorming', 'and', 'student', 'presentations/role', 'plays', ',', 'two', 'of', 'the', 'methods', 'prescribed', 'by', 'the', 'curriculum', '.']","(0, 1)","(0, 13)",-1,hl_i,7844976,Abstract,5,test,gold,
7297,Implications of the results for,teacher training,are discussed .,"['Implications', 'of', 'the', 'results', 'for', 'teacher', 'training', 'are', 'discussed', '.']","(5, 7)","(31, 47)",-1,ss_i,7844976,Abstract,6,test,gold,2822.0
7298,Necessary but not sufficient : the effect of screening and feedback on outcomes of,primary care patients with untreated anxiety .,,"['Necessary', 'but', 'not', 'sufficient', ':', 'the', 'effect', 'of', 'screening', 'and', 'feedback', 'on', 'outcomes', 'of', 'primary', 'care', 'patients', 'with', 'untreated', 'anxiety', '.']","(14, 21)","(82, 128)",-1,ss_p,7853069,Title,0,test,gold,6971.0
7299,Necessary but not sufficient : the effect of screening and feedback on,outcomes,of primary care patients with untreated anxiety .,"['Necessary', 'but', 'not', 'sufficient', ':', 'the', 'effect', 'of', 'screening', 'and', 'feedback', 'on', 'outcomes', 'of', 'primary', 'care', 'patients', 'with', 'untreated', 'anxiety', '.']","(12, 13)","(70, 78)",-1,ss_o,7853069,Title,0,test,gold,422.0
7300,Necessary but not sufficient : the effect of screening and feedback on outcomes of,primary care patients with untreated anxiety .,,"['Necessary', 'but', 'not', 'sufficient', ':', 'the', 'effect', 'of', 'screening', 'and', 'feedback', 'on', 'outcomes', 'of', 'primary', 'care', 'patients', 'with', 'untreated', 'anxiety', '.']","(14, 21)","(82, 128)",-1,hl_p,7853069,Title,0,test,gold,6972.0
7301,Necessary but not sufficient : the effect of,screening,and feedback on outcomes of primary care patients with untreated anxiety .,"['Necessary', 'but', 'not', 'sufficient', ':', 'the', 'effect', 'of', 'screening', 'and', 'feedback', 'on', 'outcomes', 'of', 'primary', 'care', 'patients', 'with', 'untreated', 'anxiety', '.']","(8, 9)","(44, 53)",-1,hl_i,7853069,Title,0,test,gold,1289.0
7302,Necessary but not sufficient : the effect of screening and,feedback,on outcomes of primary care patients with untreated anxiety .,"['Necessary', 'but', 'not', 'sufficient', ':', 'the', 'effect', 'of', 'screening', 'and', 'feedback', 'on', 'outcomes', 'of', 'primary', 'care', 'patients', 'with', 'untreated', 'anxiety', '.']","(10, 11)","(58, 66)",-1,hl_i,7853069,Title,0,test,gold,2528.0
7303,OBJECTIVE To consider the impact on primary care patient outcomes of using both a screener to determine elevated anxiety levels among,patients with previously undetected anxiety,and a physician intervention to inform physicians of their patients ' conditions .,"['OBJECTIVE', 'To', 'consider', 'the', 'impact', 'on', 'primary', 'care', 'patient', 'outcomes', 'of', 'using', 'both', 'a', 'screener', 'to', 'determine', 'elevated', 'anxiety', 'levels', 'among', 'patients', 'with', 'previously', 'undetected', 'anxiety', 'and', 'a', 'physician', 'intervention', 'to', 'inform', 'physicians', 'of', 'their', 'patients', ""'"", 'conditions', '.']","(21, 26)","(133, 176)",-1,ss_p,7853069,Abstract,0,test,gold,6974.0
7304,OBJECTIVE To consider the impact on primary care patient outcomes of using both a,screener,to determine elevated anxiety levels among patients with previously undetected anxiety and a physician intervention to inform physicians of their patients ' conditions .,"['OBJECTIVE', 'To', 'consider', 'the', 'impact', 'on', 'primary', 'care', 'patient', 'outcomes', 'of', 'using', 'both', 'a', 'screener', 'to', 'determine', 'elevated', 'anxiety', 'levels', 'among', 'patients', 'with', 'previously', 'undetected', 'anxiety', 'and', 'a', 'physician', 'intervention', 'to', 'inform', 'physicians', 'of', 'their', 'patients', ""'"", 'conditions', '.']","(14, 15)","(81, 89)",-1,ss_i,7853069,Abstract,0,test,gold,1290.0
7305,OBJECTIVE To consider the impact on primary care patient outcomes of using both a screener to determine elevated anxiety levels among patients with previously undetected anxiety and a,physician intervention,to inform physicians of their patients ' conditions .,"['OBJECTIVE', 'To', 'consider', 'the', 'impact', 'on', 'primary', 'care', 'patient', 'outcomes', 'of', 'using', 'both', 'a', 'screener', 'to', 'determine', 'elevated', 'anxiety', 'levels', 'among', 'patients', 'with', 'previously', 'undetected', 'anxiety', 'and', 'a', 'physician', 'intervention', 'to', 'inform', 'physicians', 'of', 'their', 'patients', ""'"", 'conditions', '.']","(28, 30)","(183, 205)",-1,ss_i,7853069,Abstract,0,test,gold,4015.0
7306,OBJECTIVE To consider the impact on primary care patient outcomes of using both a screener to determine,elevated anxiety levels,among patients with previously undetected anxiety and a physician intervention to inform physicians of their patients ' conditions .,"['OBJECTIVE', 'To', 'consider', 'the', 'impact', 'on', 'primary', 'care', 'patient', 'outcomes', 'of', 'using', 'both', 'a', 'screener', 'to', 'determine', 'elevated', 'anxiety', 'levels', 'among', 'patients', 'with', 'previously', 'undetected', 'anxiety', 'and', 'a', 'physician', 'intervention', 'to', 'inform', 'physicians', 'of', 'their', 'patients', ""'"", 'conditions', '.']","(17, 20)","(103, 126)",-1,ss_o,7853069,Abstract,0,test,gold,2453.0
7307,OBJECTIVE To consider the impact on primary care patient outcomes of using both a screener to determine elevated anxiety levels among,patients with previously undetected anxiety,and a physician intervention to inform physicians of their patients ' conditions .,"['OBJECTIVE', 'To', 'consider', 'the', 'impact', 'on', 'primary', 'care', 'patient', 'outcomes', 'of', 'using', 'both', 'a', 'screener', 'to', 'determine', 'elevated', 'anxiety', 'levels', 'among', 'patients', 'with', 'previously', 'undetected', 'anxiety', 'and', 'a', 'physician', 'intervention', 'to', 'inform', 'physicians', 'of', 'their', 'patients', ""'"", 'conditions', '.']","(21, 26)","(133, 176)",-1,hl_p,7853069,Abstract,0,test,gold,6975.0
7308,DESIGN Participating physicians were randomized to either the,demonstration,"or the control arm , and patients were assigned to a study arm based on the randomization of their physicians .","['DESIGN', 'Participating', 'physicians', 'were', 'randomized', 'to', 'either', 'the', 'demonstration', 'or', 'the', 'control', 'arm', ',', 'and', 'patients', 'were', 'assigned', 'to', 'a', 'study', 'arm', 'based', 'on', 'the', 'randomization', 'of', 'their', 'physicians', '.']","(8, 9)","(61, 74)",-1,ss_i,7853069,Abstract,1,test,gold,1281.0
7309,DESIGN Participating physicians were randomized to either the,demonstration,"or the control arm , and patients were assigned to a study arm based on the randomization of their physicians .","['DESIGN', 'Participating', 'physicians', 'were', 'randomized', 'to', 'either', 'the', 'demonstration', 'or', 'the', 'control', 'arm', ',', 'and', 'patients', 'were', 'assigned', 'to', 'a', 'study', 'arm', 'based', 'on', 'the', 'randomization', 'of', 'their', 'physicians', '.']","(8, 9)","(61, 74)",-1,hl_i,7853069,Abstract,1,test,gold,1282.0
7310,The patients were followed for change in outcome measures during the five-month study period .,,,"['The', 'patients', 'were', 'followed', 'for', 'change', 'in', 'outcome', 'measures', 'during', 'the', 'five-month', 'study', 'period', '.']",,,,,7853069,Abstract,2,test,gold,
7311,"SETTING A mixed-model health maintenance organization serving approximately 110,000 enrollees in central Colorado .",,,"['SETTING', 'A', 'mixed-model', 'health', 'maintenance', 'organization', 'serving', 'approximately', '110,000', 'enrollees', 'in', 'central', 'Colorado', '.']",,,,,7853069,Abstract,3,test,gold,
7312,PATIENTS/PARTICIPANTS,"573 patients who had unrecognized and untreated anxiety identified from the approximately 8,000 patients who completed the waiting room screening questionnaire .",,"['PATIENTS/PARTICIPANTS', '573', 'patients', 'who', 'had', 'unrecognized', 'and', 'untreated', 'anxiety', 'identified', 'from', 'the', 'approximately', '8,000', 'patients', 'who', 'completed', 'the', 'waiting', 'room', 'screening', 'questionnaire', '.']","(1, 23)","(21, 182)",-1,ss_p,7853069,Abstract,4,test,gold,5909.0
7313,PATIENTS/PARTICIPANTS,573 patients who had unrecognized and untreated anxiety,"identified from the approximately 8,000 patients who completed the waiting room screening questionnaire .","['PATIENTS/PARTICIPANTS', '573', 'patients', 'who', 'had', 'unrecognized', 'and', 'untreated', 'anxiety', 'identified', 'from', 'the', 'approximately', '8,000', 'patients', 'who', 'completed', 'the', 'waiting', 'room', 'screening', 'questionnaire', '.']","(1, 9)","(21, 76)",-1,hl_p,7853069,Abstract,4,test,gold,6973.0
7314,INTERVENTIONS A,physician intervention,served the dual function of 1 ) providing an educational demonstration of anxiety in the primary care setting and 2 ) providing a reporting system for summarizing the anxiety symptom levels and functioning status of the patients enrolled in the study .,"['INTERVENTIONS', 'A', 'physician', 'intervention', 'served', 'the', 'dual', 'function', 'of', '1', ')', 'providing', 'an', 'educational', 'demonstration', 'of', 'anxiety', 'in', 'the', 'primary', 'care', 'setting', 'and', '2', ')', 'providing', 'a', 'reporting', 'system', 'for', 'summarizing', 'the', 'anxiety', 'symptom', 'levels', 'and', 'functioning', 'status', 'of', 'the', 'patients', 'enrolled', 'in', 'the', 'study', '.']","(2, 4)","(15, 37)",-1,ss_i,7853069,Abstract,5,test,gold,4016.0
7315,INTERVENTIONS A physician intervention served the dual function of 1 ) providing an educational demonstration of anxiety in the primary care setting and 2 ) providing a reporting system for summarizing the,anxiety symptom levels,and functioning status of the patients enrolled in the study .,"['INTERVENTIONS', 'A', 'physician', 'intervention', 'served', 'the', 'dual', 'function', 'of', '1', ')', 'providing', 'an', 'educational', 'demonstration', 'of', 'anxiety', 'in', 'the', 'primary', 'care', 'setting', 'and', '2', ')', 'providing', 'a', 'reporting', 'system', 'for', 'summarizing', 'the', 'anxiety', 'symptom', 'levels', 'and', 'functioning', 'status', 'of', 'the', 'patients', 'enrolled', 'in', 'the', 'study', '.']","(32, 35)","(205, 227)",-1,ss_o,7853069,Abstract,5,test,gold,2454.0
7316,INTERVENTIONS A physician intervention served the dual function of 1 ) providing an educational demonstration of anxiety in the primary care setting and 2 ) providing a reporting system for summarizing the anxiety symptom levels and,functioning status,of the patients enrolled in the study .,"['INTERVENTIONS', 'A', 'physician', 'intervention', 'served', 'the', 'dual', 'function', 'of', '1', ')', 'providing', 'an', 'educational', 'demonstration', 'of', 'anxiety', 'in', 'the', 'primary', 'care', 'setting', 'and', '2', ')', 'providing', 'a', 'reporting', 'system', 'for', 'summarizing', 'the', 'anxiety', 'symptom', 'levels', 'and', 'functioning', 'status', 'of', 'the', 'patients', 'enrolled', 'in', 'the', 'study', '.']","(36, 38)","(232, 250)",-1,ss_o,7853069,Abstract,5,test,gold,2948.0
7317,INTERVENTIONS A,physician intervention,served the dual function of 1 ) providing an educational demonstration of anxiety in the primary care setting and 2 ) providing a reporting system for summarizing the anxiety symptom levels and functioning status of the patients enrolled in the study .,"['INTERVENTIONS', 'A', 'physician', 'intervention', 'served', 'the', 'dual', 'function', 'of', '1', ')', 'providing', 'an', 'educational', 'demonstration', 'of', 'anxiety', 'in', 'the', 'primary', 'care', 'setting', 'and', '2', ')', 'providing', 'a', 'reporting', 'system', 'for', 'summarizing', 'the', 'anxiety', 'symptom', 'levels', 'and', 'functioning', 'status', 'of', 'the', 'patients', 'enrolled', 'in', 'the', 'study', '.']","(2, 4)","(15, 37)",-1,hl_i,7853069,Abstract,5,test,gold,4014.0
7318,MEASUREMENTS AND MAIN RESULTS,Patient outcomes,"were measured as changes in global anxiety scores , functioning and well-being , and patients ' reports of global improvements .","['MEASUREMENTS', 'AND', 'MAIN', 'RESULTS', 'Patient', 'outcomes', 'were', 'measured', 'as', 'changes', 'in', 'global', 'anxiety', 'scores', ',', 'functioning', 'and', 'well-being', ',', 'and', 'patients', ""'"", 'reports', 'of', 'global', 'improvements', '.']","(4, 6)","(29, 45)",-1,ss_o,7853069,Abstract,6,test,gold,3850.0
7319,MEASUREMENTS AND MAIN RESULTS Patient outcomes were measured as changes in,"global anxiety scores , functioning and well-being",", and patients ' reports of global improvements .","['MEASUREMENTS', 'AND', 'MAIN', 'RESULTS', 'Patient', 'outcomes', 'were', 'measured', 'as', 'changes', 'in', 'global', 'anxiety', 'scores', ',', 'functioning', 'and', 'well-being', ',', 'and', 'patients', ""'"", 'reports', 'of', 'global', 'improvements', '.']","(11, 18)","(74, 124)",-1,ss_o,7853069,Abstract,6,test,gold,2457.0
7320,"MEASUREMENTS AND MAIN RESULTS Patient outcomes were measured as changes in global anxiety scores , functioning and well-being , and",patients ' reports of global improvements .,,"['MEASUREMENTS', 'AND', 'MAIN', 'RESULTS', 'Patient', 'outcomes', 'were', 'measured', 'as', 'changes', 'in', 'global', 'anxiety', 'scores', ',', 'functioning', 'and', 'well-being', ',', 'and', 'patients', ""'"", 'reports', 'of', 'global', 'improvements', '.']","(20, 27)","(131, 174)",-1,ss_o,7853069,Abstract,6,test,gold,3887.0
7321,MEASUREMENTS AND MAIN RESULTS Patient outcomes were measured as changes in,global anxiety scores,", functioning and well-being , and patients ' reports of global improvements .","['MEASUREMENTS', 'AND', 'MAIN', 'RESULTS', 'Patient', 'outcomes', 'were', 'measured', 'as', 'changes', 'in', 'global', 'anxiety', 'scores', ',', 'functioning', 'and', 'well-being', ',', 'and', 'patients', ""'"", 'reports', 'of', 'global', 'improvements', '.']","(11, 14)","(74, 95)",-1,hl_o,7853069,Abstract,6,test,gold,2458.0
7322,"MEASUREMENTS AND MAIN RESULTS Patient outcomes were measured as changes in global anxiety scores ,",functioning and well-being,", and patients ' reports of global improvements .","['MEASUREMENTS', 'AND', 'MAIN', 'RESULTS', 'Patient', 'outcomes', 'were', 'measured', 'as', 'changes', 'in', 'global', 'anxiety', 'scores', ',', 'functioning', 'and', 'well-being', ',', 'and', 'patients', ""'"", 'reports', 'of', 'global', 'improvements', '.']","(15, 18)","(98, 124)",-1,hl_o,7853069,Abstract,6,test,gold,2949.0
7323,"MEASUREMENTS AND MAIN RESULTS Patient outcomes were measured as changes in global anxiety scores , functioning and well-being , and",patients ' reports of global improvements .,,"['MEASUREMENTS', 'AND', 'MAIN', 'RESULTS', 'Patient', 'outcomes', 'were', 'measured', 'as', 'changes', 'in', 'global', 'anxiety', 'scores', ',', 'functioning', 'and', 'well-being', ',', 'and', 'patients', ""'"", 'reports', 'of', 'global', 'improvements', '.']","(20, 27)","(131, 174)",-1,hl_o,7853069,Abstract,6,test,gold,3888.0
7324,CONCLUSIONS The findings indicate that this method of reporting symptoms and functioning status to primary care physicians did not significantly change patient outcomes .,,,"['CONCLUSIONS', 'The', 'findings', 'indicate', 'that', 'this', 'method', 'of', 'reporting', 'symptoms', 'and', 'functioning', 'status', 'to', 'primary', 'care', 'physicians', 'did', 'not', 'significantly', 'change', 'patient', 'outcomes', '.']",,,,,7853069,Abstract,7,test,gold,
7325,Improvement in outcomes appeared to be more closely associated with the patient 's severity of psychological distress .,,,"['Improvement', 'in', 'outcomes', 'appeared', 'to', 'be', 'more', 'closely', 'associated', 'with', 'the', 'patient', ""'s"", 'severity', 'of', 'psychological', 'distress', '.']",,,,,7853069,Abstract,8,test,gold,
7326,Double-blind randomized evaluation of intercostal nerve blocks as an adjuvant to subarachnoid administered morphine for,post-thoracotomy,analgesia .,"['Double-blind', 'randomized', 'evaluation', 'of', 'intercostal', 'nerve', 'blocks', 'as', 'an', 'adjuvant', 'to', 'subarachnoid', 'administered', 'morphine', 'for', 'post-thoracotomy', 'analgesia', '.']","(15, 16)","(119, 135)",-1,ss_p,8519720,Title,0,test,gold,
7327,Double-blind randomized evaluation of,intercostal nerve blocks,as an adjuvant to subarachnoid administered morphine for post-thoracotomy analgesia .,"['Double-blind', 'randomized', 'evaluation', 'of', 'intercostal', 'nerve', 'blocks', 'as', 'an', 'adjuvant', 'to', 'subarachnoid', 'administered', 'morphine', 'for', 'post-thoracotomy', 'analgesia', '.']","(4, 7)","(37, 61)",-1,ss_i,8519720,Title,0,test,gold,3095.0
7328,Double-blind randomized evaluation of intercostal nerve blocks as an adjuvant to subarachnoid administered,morphine,for post-thoracotomy analgesia .,"['Double-blind', 'randomized', 'evaluation', 'of', 'intercostal', 'nerve', 'blocks', 'as', 'an', 'adjuvant', 'to', 'subarachnoid', 'administered', 'morphine', 'for', 'post-thoracotomy', 'analgesia', '.']","(13, 14)","(106, 114)",-1,ss_i,8519720,Title,0,test,gold,5097.0
7329,Double-blind randomized evaluation of,intercostal nerve blocks,as an adjuvant to subarachnoid administered morphine for post-thoracotomy analgesia .,"['Double-blind', 'randomized', 'evaluation', 'of', 'intercostal', 'nerve', 'blocks', 'as', 'an', 'adjuvant', 'to', 'subarachnoid', 'administered', 'morphine', 'for', 'post-thoracotomy', 'analgesia', '.']","(4, 7)","(37, 61)",-1,hl_i,8519720,Title,0,test,gold,3096.0
7330,Double-blind randomized evaluation of intercostal nerve blocks as an adjuvant to subarachnoid administered,morphine,for post-thoracotomy analgesia .,"['Double-blind', 'randomized', 'evaluation', 'of', 'intercostal', 'nerve', 'blocks', 'as', 'an', 'adjuvant', 'to', 'subarachnoid', 'administered', 'morphine', 'for', 'post-thoracotomy', 'analgesia', '.']","(13, 14)","(106, 114)",-1,hl_i,8519720,Title,0,test,gold,5096.0
7331,BACKGROUND AND OBJECTIVES Thoracotomy is associated with,pain,and compromised pulmonary function .,"['BACKGROUND', 'AND', 'OBJECTIVES', 'Thoracotomy', 'is', 'associated', 'with', 'pain', 'and', 'compromised', 'pulmonary', 'function', '.']","(7, 8)","(56, 60)",-1,ss_o,8519720,Abstract,0,test,gold,2290.0
7332,BACKGROUND AND OBJECTIVES Thoracotomy is associated with pain and compromised,pulmonary function .,,"['BACKGROUND', 'AND', 'OBJECTIVES', 'Thoracotomy', 'is', 'associated', 'with', 'pain', 'and', 'compromised', 'pulmonary', 'function', '.']","(10, 13)","(77, 97)",-1,ss_o,8519720,Abstract,0,test,gold,3148.0
7333,,Intercostal nerve blocks ( INB ),and subarachnoid morphine ( SM ) act on different portions of the pain pathway .,"['Intercostal', 'nerve', 'blocks', '(', 'INB', ')', 'and', 'subarachnoid', 'morphine', '(', 'SM', ')', 'act', 'on', 'different', 'portions', 'of', 'the', 'pain', 'pathway', '.']","(0, 6)","(0, 32)",-1,ss_i,8519720,Abstract,1,test,gold,3097.0
7334,Intercostal nerve blocks ( INB ) and,subarachnoid morphine ( SM ),act on different portions of the pain pathway .,"['Intercostal', 'nerve', 'blocks', '(', 'INB', ')', 'and', 'subarachnoid', 'morphine', '(', 'SM', ')', 'act', 'on', 'different', 'portions', 'of', 'the', 'pain', 'pathway', '.']","(7, 12)","(36, 64)",-1,ss_i,8519720,Abstract,1,test,gold,5112.0
7335,,Intercostal nerve blocks ( INB ),and subarachnoid morphine ( SM ) act on different portions of the pain pathway .,"['Intercostal', 'nerve', 'blocks', '(', 'INB', ')', 'and', 'subarachnoid', 'morphine', '(', 'SM', ')', 'act', 'on', 'different', 'portions', 'of', 'the', 'pain', 'pathway', '.']","(0, 6)","(0, 32)",-1,hl_i,8519720,Abstract,1,test,gold,3098.0
7336,Intercostal nerve blocks ( INB ) and,subarachnoid morphine ( SM ),act on different portions of the pain pathway .,"['Intercostal', 'nerve', 'blocks', '(', 'INB', ')', 'and', 'subarachnoid', 'morphine', '(', 'SM', ')', 'act', 'on', 'different', 'portions', 'of', 'the', 'pain', 'pathway', '.']","(7, 12)","(36, 64)",-1,hl_i,8519720,Abstract,1,test,gold,5113.0
7337,Each is effective for post-thoracotomy,pain,relief .,"['Each', 'is', 'effective', 'for', 'post-thoracotomy', 'pain', 'relief', '.']","(5, 6)","(38, 42)",-1,ss_o,8519720,Abstract,2,test,gold,2289.0
7338,Each is effective for post-thoracotomy,pain,relief .,"['Each', 'is', 'effective', 'for', 'post-thoracotomy', 'pain', 'relief', '.']","(5, 6)","(38, 42)",-1,hl_o,8519720,Abstract,2,test,gold,2288.0
7339,The combination of these two modalities in relieving,post-thoracotomy pain,and improving postoperative pulmonary function has not been investigated .,"['The', 'combination', 'of', 'these', 'two', 'modalities', 'in', 'relieving', 'post-thoracotomy', 'pain', 'and', 'improving', 'postoperative', 'pulmonary', 'function', 'has', 'not', 'been', 'investigated', '.']","(8, 10)","(52, 73)",-1,ss_o,8519720,Abstract,3,test,gold,2287.0
7340,The combination of these two modalities in relieving post-thoracotomy pain and improving,postoperative pulmonary function,has not been investigated .,"['The', 'combination', 'of', 'these', 'two', 'modalities', 'in', 'relieving', 'post-thoracotomy', 'pain', 'and', 'improving', 'postoperative', 'pulmonary', 'function', 'has', 'not', 'been', 'investigated', '.']","(12, 15)","(88, 120)",-1,ss_o,8519720,Abstract,3,test,gold,3144.0
7341,The combination of these two modalities in relieving,post-thoracotomy pain,and improving postoperative pulmonary function has not been investigated .,"['The', 'combination', 'of', 'these', 'two', 'modalities', 'in', 'relieving', 'post-thoracotomy', 'pain', 'and', 'improving', 'postoperative', 'pulmonary', 'function', 'has', 'not', 'been', 'investigated', '.']","(8, 10)","(52, 73)",-1,hl_o,8519720,Abstract,3,test,gold,2286.0
7342,The combination of these two modalities in relieving post-thoracotomy pain and improving,postoperative pulmonary function,has not been investigated .,"['The', 'combination', 'of', 'these', 'two', 'modalities', 'in', 'relieving', 'post-thoracotomy', 'pain', 'and', 'improving', 'postoperative', 'pulmonary', 'function', 'has', 'not', 'been', 'investigated', '.']","(12, 15)","(88, 120)",-1,hl_o,8519720,Abstract,3,test,gold,3145.0
7343,"METHODS In a double-blind study ,",20 patients undergoing lateral thoracotomy for lung resection,were randomized to receive 0.5 mg SM preoperatively and INB with bupivacaine ( INB+ ) prior to wound closure or 0.5 mg SM with INB using saline ( INB- ) .,"['METHODS', 'In', 'a', 'double-blind', 'study', ',', '20', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'for', 'lung', 'resection', 'were', 'randomized', 'to', 'receive', '0.5', 'mg', 'SM', 'preoperatively', 'and', 'INB', 'with', 'bupivacaine', '(', 'INB+', ')', 'prior', 'to', 'wound', 'closure', 'or', '0.5', 'mg', 'SM', 'with', 'INB', 'using', 'saline', '(', 'INB-', ')', '.']","(6, 14)","(33, 94)",-1,ss_p,8519720,Abstract,4,test,gold,5957.0
7344,"METHODS In a double-blind study , 20 patients undergoing lateral thoracotomy for lung resection were randomized to receive 0.5 mg",SM,preoperatively and INB with bupivacaine ( INB+ ) prior to wound closure or 0.5 mg SM with INB using saline ( INB- ) .,"['METHODS', 'In', 'a', 'double-blind', 'study', ',', '20', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'for', 'lung', 'resection', 'were', 'randomized', 'to', 'receive', '0.5', 'mg', 'SM', 'preoperatively', 'and', 'INB', 'with', 'bupivacaine', '(', 'INB+', ')', 'prior', 'to', 'wound', 'closure', 'or', '0.5', 'mg', 'SM', 'with', 'INB', 'using', 'saline', '(', 'INB-', ')', '.']","(20, 21)","(129, 131)",-1,ss_i,8519720,Abstract,4,test,gold,665.0
7345,"METHODS In a double-blind study , 20 patients undergoing lateral thoracotomy for lung resection were randomized to receive 0.5 mg SM preoperatively and",INB,with bupivacaine ( INB+ ) prior to wound closure or 0.5 mg SM with INB using saline ( INB- ) .,"['METHODS', 'In', 'a', 'double-blind', 'study', ',', '20', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'for', 'lung', 'resection', 'were', 'randomized', 'to', 'receive', '0.5', 'mg', 'SM', 'preoperatively', 'and', 'INB', 'with', 'bupivacaine', '(', 'INB+', ')', 'prior', 'to', 'wound', 'closure', 'or', '0.5', 'mg', 'SM', 'with', 'INB', 'using', 'saline', '(', 'INB-', ')', '.']","(23, 24)","(151, 154)",-1,ss_i,8519720,Abstract,4,test,gold,558.0
7346,"METHODS In a double-blind study , 20 patients undergoing lateral thoracotomy for lung resection were randomized to receive 0.5 mg SM preoperatively and INB with",bupivacaine,( INB+ ) prior to wound closure or 0.5 mg SM with INB using saline ( INB- ) .,"['METHODS', 'In', 'a', 'double-blind', 'study', ',', '20', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'for', 'lung', 'resection', 'were', 'randomized', 'to', 'receive', '0.5', 'mg', 'SM', 'preoperatively', 'and', 'INB', 'with', 'bupivacaine', '(', 'INB+', ')', 'prior', 'to', 'wound', 'closure', 'or', '0.5', 'mg', 'SM', 'with', 'INB', 'using', 'saline', '(', 'INB-', ')', '.']","(25, 26)","(160, 171)",-1,ss_i,8519720,Abstract,4,test,gold,5738.0
7347,"METHODS In a double-blind study , 20 patients undergoing lateral thoracotomy for lung resection were randomized to receive 0.5 mg SM preoperatively and INB with bupivacaine ( INB+ ) prior to wound closure or 0.5 mg",SM,with INB using saline ( INB- ) .,"['METHODS', 'In', 'a', 'double-blind', 'study', ',', '20', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'for', 'lung', 'resection', 'were', 'randomized', 'to', 'receive', '0.5', 'mg', 'SM', 'preoperatively', 'and', 'INB', 'with', 'bupivacaine', '(', 'INB+', ')', 'prior', 'to', 'wound', 'closure', 'or', '0.5', 'mg', 'SM', 'with', 'INB', 'using', 'saline', '(', 'INB-', ')', '.']","(36, 37)","(214, 216)",-1,ss_i,8519720,Abstract,4,test,gold,666.0
7348,"METHODS In a double-blind study , 20 patients undergoing lateral thoracotomy for lung resection were randomized to receive 0.5 mg SM preoperatively and INB with bupivacaine ( INB+ ) prior to wound closure or 0.5 mg SM with",INB,using saline ( INB- ) .,"['METHODS', 'In', 'a', 'double-blind', 'study', ',', '20', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'for', 'lung', 'resection', 'were', 'randomized', 'to', 'receive', '0.5', 'mg', 'SM', 'preoperatively', 'and', 'INB', 'with', 'bupivacaine', '(', 'INB+', ')', 'prior', 'to', 'wound', 'closure', 'or', '0.5', 'mg', 'SM', 'with', 'INB', 'using', 'saline', '(', 'INB-', ')', '.']","(38, 39)","(222, 225)",-1,ss_i,8519720,Abstract,4,test,gold,559.0
7349,"METHODS In a double-blind study , 20 patients undergoing lateral thoracotomy for lung resection were randomized to receive 0.5 mg SM preoperatively and INB with bupivacaine ( INB+ ) prior to wound closure or 0.5 mg SM with INB using",saline ( INB- ),.,"['METHODS', 'In', 'a', 'double-blind', 'study', ',', '20', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'for', 'lung', 'resection', 'were', 'randomized', 'to', 'receive', '0.5', 'mg', 'SM', 'preoperatively', 'and', 'INB', 'with', 'bupivacaine', '(', 'INB+', ')', 'prior', 'to', 'wound', 'closure', 'or', '0.5', 'mg', 'SM', 'with', 'INB', 'using', 'saline', '(', 'INB-', ')', '.']","(40, 44)","(232, 247)",-1,ss_i,8519720,Abstract,4,test,gold,4913.0
7350,"METHODS In a double-blind study , 20 patients undergoing lateral thoracotomy for lung resection were randomized to receive 0.5 mg",SM,preoperatively and INB with bupivacaine ( INB+ ) prior to wound closure or 0.5 mg SM with INB using saline ( INB- ) .,"['METHODS', 'In', 'a', 'double-blind', 'study', ',', '20', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'for', 'lung', 'resection', 'were', 'randomized', 'to', 'receive', '0.5', 'mg', 'SM', 'preoperatively', 'and', 'INB', 'with', 'bupivacaine', '(', 'INB+', ')', 'prior', 'to', 'wound', 'closure', 'or', '0.5', 'mg', 'SM', 'with', 'INB', 'using', 'saline', '(', 'INB-', ')', '.']","(20, 21)","(129, 131)",-1,hl_i,8519720,Abstract,4,test,gold,664.0
7351,"METHODS In a double-blind study , 20 patients undergoing lateral thoracotomy for lung resection were randomized to receive 0.5 mg SM preoperatively and",INB with bupivacaine ( INB+ ),prior to wound closure or 0.5 mg SM with INB using saline ( INB- ) .,"['METHODS', 'In', 'a', 'double-blind', 'study', ',', '20', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'for', 'lung', 'resection', 'were', 'randomized', 'to', 'receive', '0.5', 'mg', 'SM', 'preoperatively', 'and', 'INB', 'with', 'bupivacaine', '(', 'INB+', ')', 'prior', 'to', 'wound', 'closure', 'or', '0.5', 'mg', 'SM', 'with', 'INB', 'using', 'saline', '(', 'INB-', ')', '.']","(23, 29)","(151, 180)",-1,hl_i,8519720,Abstract,4,test,gold,560.0
7352,"METHODS In a double-blind study , 20 patients undergoing lateral thoracotomy for lung resection were randomized to receive 0.5 mg SM preoperatively and INB with bupivacaine ( INB+ ) prior to wound closure or 0.5 mg",SM,with INB using saline ( INB- ) .,"['METHODS', 'In', 'a', 'double-blind', 'study', ',', '20', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'for', 'lung', 'resection', 'were', 'randomized', 'to', 'receive', '0.5', 'mg', 'SM', 'preoperatively', 'and', 'INB', 'with', 'bupivacaine', '(', 'INB+', ')', 'prior', 'to', 'wound', 'closure', 'or', '0.5', 'mg', 'SM', 'with', 'INB', 'using', 'saline', '(', 'INB-', ')', '.']","(36, 37)","(214, 216)",-1,hl_i,8519720,Abstract,4,test,gold,663.0
7353,"METHODS In a double-blind study , 20 patients undergoing lateral thoracotomy for lung resection were randomized to receive 0.5 mg SM preoperatively and INB with bupivacaine ( INB+ ) prior to wound closure or 0.5 mg SM with",INB using saline ( INB- ),.,"['METHODS', 'In', 'a', 'double-blind', 'study', ',', '20', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'for', 'lung', 'resection', 'were', 'randomized', 'to', 'receive', '0.5', 'mg', 'SM', 'preoperatively', 'and', 'INB', 'with', 'bupivacaine', '(', 'INB+', ')', 'prior', 'to', 'wound', 'closure', 'or', '0.5', 'mg', 'SM', 'with', 'INB', 'using', 'saline', '(', 'INB-', ')', '.']","(38, 44)","(222, 247)",-1,hl_i,8519720,Abstract,4,test,gold,561.0
7354,,"Visual analog scale pain scores at rest , with cough , and with movement of the ipsilateral arm , forced expiratory volume in 1 second ( FEV1 ) , and forced vital capacity ( FVC )","were measured at 4 , 24 , 48 , and 72 hours after the operation .","['Visual', 'analog', 'scale', 'pain', 'scores', 'at', 'rest', ',', 'with', 'cough', ',', 'and', 'with', 'movement', 'of', 'the', 'ipsilateral', 'arm', ',', 'forced', 'expiratory', 'volume', 'in', '1', 'second', '(', 'FEV1', ')', ',', 'and', 'forced', 'vital', 'capacity', '(', 'FVC', ')', 'were', 'measured', 'at', '4', ',', '24', ',', '48', ',', 'and', '72', 'hours', 'after', 'the', 'operation', '.']","(0, 36)","(0, 179)",-1,ss_o,8519720,Abstract,5,test,gold,5994.0
7355,,Visual analog scale pain scores,"at rest , with cough , and with movement of the ipsilateral arm , forced expiratory volume in 1 second ( FEV1 ) , and forced vital capacity ( FVC ) were measured at 4 , 24 , 48 , and 72 hours after the operation .","['Visual', 'analog', 'scale', 'pain', 'scores', 'at', 'rest', ',', 'with', 'cough', ',', 'and', 'with', 'movement', 'of', 'the', 'ipsilateral', 'arm', ',', 'forced', 'expiratory', 'volume', 'in', '1', 'second', '(', 'FEV1', ')', ',', 'and', 'forced', 'vital', 'capacity', '(', 'FVC', ')', 'were', 'measured', 'at', '4', ',', '24', ',', '48', ',', 'and', '72', 'hours', 'after', 'the', 'operation', '.']","(0, 5)","(0, 31)",-1,hl_o,8519720,Abstract,5,test,gold,6437.0
7356,"Visual analog scale pain scores at rest ,","with cough , and with movement of the ipsilateral arm , forced expiratory volume in 1 second ( FEV1 )",", and forced vital capacity ( FVC ) were measured at 4 , 24 , 48 , and 72 hours after the operation .","['Visual', 'analog', 'scale', 'pain', 'scores', 'at', 'rest', ',', 'with', 'cough', ',', 'and', 'with', 'movement', 'of', 'the', 'ipsilateral', 'arm', ',', 'forced', 'expiratory', 'volume', 'in', '1', 'second', '(', 'FEV1', ')', ',', 'and', 'forced', 'vital', 'capacity', '(', 'FVC', ')', 'were', 'measured', 'at', '4', ',', '24', ',', '48', ',', 'and', '72', 'hours', 'after', 'the', 'operation', '.']","(8, 28)","(41, 142)",-1,hl_o,8519720,Abstract,5,test,gold,5995.0
7357,"Visual analog scale pain scores at rest , with cough , and with movement of the ipsilateral arm , forced expiratory volume in 1 second ( FEV1 ) , and",forced vital capacity ( FVC ),"were measured at 4 , 24 , 48 , and 72 hours after the operation .","['Visual', 'analog', 'scale', 'pain', 'scores', 'at', 'rest', ',', 'with', 'cough', ',', 'and', 'with', 'movement', 'of', 'the', 'ipsilateral', 'arm', ',', 'forced', 'expiratory', 'volume', 'in', '1', 'second', '(', 'FEV1', ')', ',', 'and', 'forced', 'vital', 'capacity', '(', 'FVC', ')', 'were', 'measured', 'at', '4', ',', '24', ',', '48', ',', 'and', '72', 'hours', 'after', 'the', 'operation', '.']","(30, 36)","(149, 178)",-1,hl_o,8519720,Abstract,5,test,gold,612.0
7358,,Opioid use,was measured during the initial 24 hours after the operation .,"['Opioid', 'use', 'was', 'measured', 'during', 'the', 'initial', '24', 'hours', 'after', 'the', 'operation', '.']","(0, 2)","(0, 10)",-1,ss_o,8519720,Abstract,6,test,gold,5529.0
7359,,Opioid use,was measured during the initial 24 hours after the operation .,"['Opioid', 'use', 'was', 'measured', 'during', 'the', 'initial', '24', 'hours', 'after', 'the', 'operation', '.']","(0, 2)","(0, 10)",-1,hl_o,8519720,Abstract,6,test,gold,5530.0
7360,"RESULTS At 4 hours , the",INB+,"group demonstrated better FEV1 ( 56.6 % vs. 40.4 % of baseline , P < .05 ) and FVC values ( 54.6 % vs. 39.6 % of baseline , P < .05 ) and less resting and cough pain ( P < .05 ) .","['RESULTS', 'At', '4', 'hours', ',', 'the', 'INB+', 'group', 'demonstrated', 'better', 'FEV1', '(', '56.6', '%', 'vs.', '40.4', '%', 'of', 'baseline', ',', 'P', '<', '.05', ')', 'and', 'FVC', 'values', '(', '54.6', '%', 'vs.', '39.6', '%', 'of', 'baseline', ',', 'P', '<', '.05', ')', 'and', 'less', 'resting', 'and', 'cough', 'pain', '(', 'P', '<', '.05', ')', '.']","(6, 7)","(24, 28)",-1,ss_i,8519720,Abstract,7,test,gold,
7361,"RESULTS At 4 hours , the INB+ group demonstrated better",FEV1,"( 56.6 % vs. 40.4 % of baseline , P < .05 ) and FVC values ( 54.6 % vs. 39.6 % of baseline , P < .05 ) and less resting and cough pain ( P < .05 ) .","['RESULTS', 'At', '4', 'hours', ',', 'the', 'INB+', 'group', 'demonstrated', 'better', 'FEV1', '(', '56.6', '%', 'vs.', '40.4', '%', 'of', 'baseline', ',', 'P', '<', '.05', ')', 'and', 'FVC', 'values', '(', '54.6', '%', 'vs.', '39.6', '%', 'of', 'baseline', ',', 'P', '<', '.05', ')', 'and', 'less', 'resting', 'and', 'cough', 'pain', '(', 'P', '<', '.05', ')', '.']","(10, 11)","(55, 59)",-1,ss_o,8519720,Abstract,7,test,gold,1670.0
7362,"RESULTS At 4 hours , the INB+ group demonstrated better FEV1 ( 56.6 % vs. 40.4 % of baseline , P < .05 ) and",FVC,"values ( 54.6 % vs. 39.6 % of baseline , P < .05 ) and less resting and cough pain ( P < .05 ) .","['RESULTS', 'At', '4', 'hours', ',', 'the', 'INB+', 'group', 'demonstrated', 'better', 'FEV1', '(', '56.6', '%', 'vs.', '40.4', '%', 'of', 'baseline', ',', 'P', '<', '.05', ')', 'and', 'FVC', 'values', '(', '54.6', '%', 'vs.', '39.6', '%', 'of', 'baseline', ',', 'P', '<', '.05', ')', 'and', 'less', 'resting', 'and', 'cough', 'pain', '(', 'P', '<', '.05', ')', '.']","(25, 26)","(108, 111)",-1,ss_o,8519720,Abstract,7,test,gold,613.0
7363,"RESULTS At 4 hours , the INB+ group demonstrated better FEV1 ( 56.6 % vs. 40.4 % of baseline , P < .05 ) and FVC values ( 54.6 % vs. 39.6 % of baseline , P < .05 ) and less",resting and cough pain,( P < .05 ) .,"['RESULTS', 'At', '4', 'hours', ',', 'the', 'INB+', 'group', 'demonstrated', 'better', 'FEV1', '(', '56.6', '%', 'vs.', '40.4', '%', 'of', 'baseline', ',', 'P', '<', '.05', ')', 'and', 'FVC', 'values', '(', '54.6', '%', 'vs.', '39.6', '%', 'of', 'baseline', ',', 'P', '<', '.05', ')', 'and', 'less', 'resting', 'and', 'cough', 'pain', '(', 'P', '<', '.05', ')', '.']","(42, 46)","(172, 194)",-1,ss_o,8519720,Abstract,7,test,gold,3113.0
7364,"RESULTS At 4 hours , the",INB+,"group demonstrated better FEV1 ( 56.6 % vs. 40.4 % of baseline , P < .05 ) and FVC values ( 54.6 % vs. 39.6 % of baseline , P < .05 ) and less resting and cough pain ( P < .05 ) .","['RESULTS', 'At', '4', 'hours', ',', 'the', 'INB+', 'group', 'demonstrated', 'better', 'FEV1', '(', '56.6', '%', 'vs.', '40.4', '%', 'of', 'baseline', ',', 'P', '<', '.05', ')', 'and', 'FVC', 'values', '(', '54.6', '%', 'vs.', '39.6', '%', 'of', 'baseline', ',', 'P', '<', '.05', ')', 'and', 'less', 'resting', 'and', 'cough', 'pain', '(', 'P', '<', '.05', ')', '.']","(6, 7)","(24, 28)",-1,hl_i,8519720,Abstract,7,test,gold,
7365,"RESULTS At 4 hours , the INB+ group demonstrated better",FEV1,"( 56.6 % vs. 40.4 % of baseline , P < .05 ) and FVC values ( 54.6 % vs. 39.6 % of baseline , P < .05 ) and less resting and cough pain ( P < .05 ) .","['RESULTS', 'At', '4', 'hours', ',', 'the', 'INB+', 'group', 'demonstrated', 'better', 'FEV1', '(', '56.6', '%', 'vs.', '40.4', '%', 'of', 'baseline', ',', 'P', '<', '.05', ')', 'and', 'FVC', 'values', '(', '54.6', '%', 'vs.', '39.6', '%', 'of', 'baseline', ',', 'P', '<', '.05', ')', 'and', 'less', 'resting', 'and', 'cough', 'pain', '(', 'P', '<', '.05', ')', '.']","(10, 11)","(55, 59)",-1,hl_o,8519720,Abstract,7,test,gold,1668.0
7366,"RESULTS At 4 hours , the INB+ group demonstrated better FEV1 ( 56.6 % vs. 40.4 % of baseline , P < .05 ) and",FVC,"values ( 54.6 % vs. 39.6 % of baseline , P < .05 ) and less resting and cough pain ( P < .05 ) .","['RESULTS', 'At', '4', 'hours', ',', 'the', 'INB+', 'group', 'demonstrated', 'better', 'FEV1', '(', '56.6', '%', 'vs.', '40.4', '%', 'of', 'baseline', ',', 'P', '<', '.05', ')', 'and', 'FVC', 'values', '(', '54.6', '%', 'vs.', '39.6', '%', 'of', 'baseline', ',', 'P', '<', '.05', ')', 'and', 'less', 'resting', 'and', 'cough', 'pain', '(', 'P', '<', '.05', ')', '.']","(25, 26)","(108, 111)",-1,hl_o,8519720,Abstract,7,test,gold,614.0
7367,"However , FEV1 continued to decline in the",INB+,group at 24 hours to lower than the INB- group although pain scores were similar beyond 4 hours .,"['However', ',', 'FEV1', 'continued', 'to', 'decline', 'in', 'the', 'INB+', 'group', 'at', '24', 'hours', 'to', 'lower', 'than', 'the', 'INB-', 'group', 'although', 'pain', 'scores', 'were', 'similar', 'beyond', '4', 'hours', '.']","(8, 9)","(42, 46)",-1,ss_i,8519720,Abstract,8,test,gold,
7368,"However , FEV1 continued to decline in the INB+ group at 24 hours to lower than the",INB-,group although pain scores were similar beyond 4 hours .,"['However', ',', 'FEV1', 'continued', 'to', 'decline', 'in', 'the', 'INB+', 'group', 'at', '24', 'hours', 'to', 'lower', 'than', 'the', 'INB-', 'group', 'although', 'pain', 'scores', 'were', 'similar', 'beyond', '4', 'hours', '.']","(17, 18)","(83, 87)",-1,ss_i,8519720,Abstract,8,test,gold,
7369,"However ,",FEV1,continued to decline in the INB+ group at 24 hours to lower than the INB- group although pain scores were similar beyond 4 hours .,"['However', ',', 'FEV1', 'continued', 'to', 'decline', 'in', 'the', 'INB+', 'group', 'at', '24', 'hours', 'to', 'lower', 'than', 'the', 'INB-', 'group', 'although', 'pain', 'scores', 'were', 'similar', 'beyond', '4', 'hours', '.']","(2, 3)","(9, 13)",-1,ss_o,8519720,Abstract,8,test,gold,1667.0
7370,"However , FEV1 continued to decline in the INB+ group at 24 hours to lower than the INB- group although",pain scores,were similar beyond 4 hours .,"['However', ',', 'FEV1', 'continued', 'to', 'decline', 'in', 'the', 'INB+', 'group', 'at', '24', 'hours', 'to', 'lower', 'than', 'the', 'INB-', 'group', 'although', 'pain', 'scores', 'were', 'similar', 'beyond', '4', 'hours', '.']","(20, 22)","(103, 114)",-1,ss_o,8519720,Abstract,8,test,gold,2321.0
7371,"However , FEV1 continued to decline in the",INB+,group at 24 hours to lower than the INB- group although pain scores were similar beyond 4 hours .,"['However', ',', 'FEV1', 'continued', 'to', 'decline', 'in', 'the', 'INB+', 'group', 'at', '24', 'hours', 'to', 'lower', 'than', 'the', 'INB-', 'group', 'although', 'pain', 'scores', 'were', 'similar', 'beyond', '4', 'hours', '.']","(8, 9)","(42, 46)",-1,hl_i,8519720,Abstract,8,test,gold,
7372,"However , FEV1 continued to decline in the INB+ group at 24 hours to lower than the",INB-,group although pain scores were similar beyond 4 hours .,"['However', ',', 'FEV1', 'continued', 'to', 'decline', 'in', 'the', 'INB+', 'group', 'at', '24', 'hours', 'to', 'lower', 'than', 'the', 'INB-', 'group', 'although', 'pain', 'scores', 'were', 'similar', 'beyond', '4', 'hours', '.']","(17, 18)","(83, 87)",-1,hl_i,8519720,Abstract,8,test,gold,
7373,"However ,",FEV1,continued to decline in the INB+ group at 24 hours to lower than the INB- group although pain scores were similar beyond 4 hours .,"['However', ',', 'FEV1', 'continued', 'to', 'decline', 'in', 'the', 'INB+', 'group', 'at', '24', 'hours', 'to', 'lower', 'than', 'the', 'INB-', 'group', 'although', 'pain', 'scores', 'were', 'similar', 'beyond', '4', 'hours', '.']","(2, 3)","(9, 13)",-1,hl_o,8519720,Abstract,8,test,gold,1666.0
7374,"However , FEV1 continued to decline in the INB+ group at 24 hours to lower than the INB- group although",pain scores,were similar beyond 4 hours .,"['However', ',', 'FEV1', 'continued', 'to', 'decline', 'in', 'the', 'INB+', 'group', 'at', '24', 'hours', 'to', 'lower', 'than', 'the', 'INB-', 'group', 'although', 'pain', 'scores', 'were', 'similar', 'beyond', '4', 'hours', '.']","(20, 22)","(103, 114)",-1,hl_o,8519720,Abstract,8,test,gold,2322.0
7375,Opioid usage during the first 24 hours was similar,( INB-,", 16.7 mg vs. INB+ , 13.2 mg , P = .7 ) .","['Opioid', 'usage', 'during', 'the', 'first', '24', 'hours', 'was', 'similar', '(', 'INB-', ',', '16.7', 'mg', 'vs.', 'INB+', ',', '13.2', 'mg', ',', 'P', '=', '.7', ')', '.']","(9, 11)","(50, 56)",-1,ss_i,8519720,Abstract,9,test,gold,
7376,"Opioid usage during the first 24 hours was similar ( INB- , 16.7 mg vs.",INB+,", 13.2 mg , P = .7 ) .","['Opioid', 'usage', 'during', 'the', 'first', '24', 'hours', 'was', 'similar', '(', 'INB-', ',', '16.7', 'mg', 'vs.', 'INB+', ',', '13.2', 'mg', ',', 'P', '=', '.7', ')', '.']","(15, 16)","(71, 75)",-1,ss_i,8519720,Abstract,9,test,gold,
7377,,Opioid usage,"during the first 24 hours was similar ( INB- , 16.7 mg vs. INB+ , 13.2 mg , P = .7 ) .","['Opioid', 'usage', 'during', 'the', 'first', '24', 'hours', 'was', 'similar', '(', 'INB-', ',', '16.7', 'mg', 'vs.', 'INB+', ',', '13.2', 'mg', ',', 'P', '=', '.7', ')', '.']","(0, 2)","(0, 12)",-1,ss_o,8519720,Abstract,9,test,gold,5531.0
7378,Opioid usage during the first 24 hours was similar (,INB-,", 16.7 mg vs. INB+ , 13.2 mg , P = .7 ) .","['Opioid', 'usage', 'during', 'the', 'first', '24', 'hours', 'was', 'similar', '(', 'INB-', ',', '16.7', 'mg', 'vs.', 'INB+', ',', '13.2', 'mg', ',', 'P', '=', '.7', ')', '.']","(10, 11)","(52, 56)",-1,hl_i,8519720,Abstract,9,test,gold,
7379,"Opioid usage during the first 24 hours was similar ( INB- , 16.7 mg vs.",INB+,", 13.2 mg , P = .7 ) .","['Opioid', 'usage', 'during', 'the', 'first', '24', 'hours', 'was', 'similar', '(', 'INB-', ',', '16.7', 'mg', 'vs.', 'INB+', ',', '13.2', 'mg', ',', 'P', '=', '.7', ')', '.']","(15, 16)","(71, 75)",-1,hl_i,8519720,Abstract,9,test,gold,
7380,,Opioid usage,"during the first 24 hours was similar ( INB- , 16.7 mg vs. INB+ , 13.2 mg , P = .7 ) .","['Opioid', 'usage', 'during', 'the', 'first', '24', 'hours', 'was', 'similar', '(', 'INB-', ',', '16.7', 'mg', 'vs.', 'INB+', ',', '13.2', 'mg', ',', 'P', '=', '.7', ')', '.']","(0, 2)","(0, 12)",-1,hl_o,8519720,Abstract,9,test,gold,5532.0
7381,CONCLUSIONS Although postoperative,INB,"provided modest improvements in pain and pulmonary function when used as an adjuvant to 0.5 mg SM for post-thoracotomy analgesia , the benefits were transient .","['CONCLUSIONS', 'Although', 'postoperative', 'INB', 'provided', 'modest', 'improvements', 'in', 'pain', 'and', 'pulmonary', 'function', 'when', 'used', 'as', 'an', 'adjuvant', 'to', '0.5', 'mg', 'SM', 'for', 'post-thoracotomy', 'analgesia', ',', 'the', 'benefits', 'were', 'transient', '.']","(3, 4)","(34, 37)",-1,ss_i,8519720,Abstract,10,test,gold,557.0
7382,CONCLUSIONS Although postoperative INB provided modest improvements in pain and pulmonary function when used as an adjuvant to 0.5 mg,SM,"for post-thoracotomy analgesia , the benefits were transient .","['CONCLUSIONS', 'Although', 'postoperative', 'INB', 'provided', 'modest', 'improvements', 'in', 'pain', 'and', 'pulmonary', 'function', 'when', 'used', 'as', 'an', 'adjuvant', 'to', '0.5', 'mg', 'SM', 'for', 'post-thoracotomy', 'analgesia', ',', 'the', 'benefits', 'were', 'transient', '.']","(20, 21)","(133, 135)",-1,ss_i,8519720,Abstract,10,test,gold,662.0
7383,CONCLUSIONS Although postoperative INB provided modest improvements in,pain and pulmonary function,"when used as an adjuvant to 0.5 mg SM for post-thoracotomy analgesia , the benefits were transient .","['CONCLUSIONS', 'Although', 'postoperative', 'INB', 'provided', 'modest', 'improvements', 'in', 'pain', 'and', 'pulmonary', 'function', 'when', 'used', 'as', 'an', 'adjuvant', 'to', '0.5', 'mg', 'SM', 'for', 'post-thoracotomy', 'analgesia', ',', 'the', 'benefits', 'were', 'transient', '.']","(8, 12)","(70, 97)",-1,ss_o,8519720,Abstract,10,test,gold,3146.0
7384,CONCLUSIONS Although postoperative,INB,"provided modest improvements in pain and pulmonary function when used as an adjuvant to 0.5 mg SM for post-thoracotomy analgesia , the benefits were transient .","['CONCLUSIONS', 'Although', 'postoperative', 'INB', 'provided', 'modest', 'improvements', 'in', 'pain', 'and', 'pulmonary', 'function', 'when', 'used', 'as', 'an', 'adjuvant', 'to', '0.5', 'mg', 'SM', 'for', 'post-thoracotomy', 'analgesia', ',', 'the', 'benefits', 'were', 'transient', '.']","(3, 4)","(34, 37)",-1,hl_i,8519720,Abstract,10,test,gold,556.0
7385,CONCLUSIONS Although postoperative INB provided modest improvements in pain and pulmonary function when used as an adjuvant to 0.5 mg,SM,"for post-thoracotomy analgesia , the benefits were transient .","['CONCLUSIONS', 'Although', 'postoperative', 'INB', 'provided', 'modest', 'improvements', 'in', 'pain', 'and', 'pulmonary', 'function', 'when', 'used', 'as', 'an', 'adjuvant', 'to', '0.5', 'mg', 'SM', 'for', 'post-thoracotomy', 'analgesia', ',', 'the', 'benefits', 'were', 'transient', '.']","(20, 21)","(133, 135)",-1,hl_i,8519720,Abstract,10,test,gold,661.0
7386,The authors do not recommend adding INB for,patients undergoing lateral thoracotomy,who receive 0.5 mg SM .,"['The', 'authors', 'do', 'not', 'recommend', 'adding', 'INB', 'for', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'who', 'receive', '0.5', 'mg', 'SM', '.']","(8, 12)","(43, 82)",-1,ss_p,8519720,Abstract,11,test,gold,3614.0
7387,The authors do not recommend adding,INB,for patients undergoing lateral thoracotomy who receive 0.5 mg SM .,"['The', 'authors', 'do', 'not', 'recommend', 'adding', 'INB', 'for', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'who', 'receive', '0.5', 'mg', 'SM', '.']","(6, 7)","(35, 38)",-1,ss_i,8519720,Abstract,11,test,gold,555.0
7388,The authors do not recommend adding INB for patients undergoing lateral thoracotomy who receive 0.5 mg,SM .,,"['The', 'authors', 'do', 'not', 'recommend', 'adding', 'INB', 'for', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'who', 'receive', '0.5', 'mg', 'SM', '.']","(16, 18)","(102, 106)",-1,ss_i,8519720,Abstract,11,test,gold,660.0
7389,The authors do not recommend adding,INB,for patients undergoing lateral thoracotomy who receive 0.5 mg SM .,"['The', 'authors', 'do', 'not', 'recommend', 'adding', 'INB', 'for', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'who', 'receive', '0.5', 'mg', 'SM', '.']","(6, 7)","(35, 38)",-1,hl_i,8519720,Abstract,11,test,gold,554.0
7390,The authors do not recommend adding INB for patients undergoing lateral thoracotomy who receive 0.5 mg,SM,.,"['The', 'authors', 'do', 'not', 'recommend', 'adding', 'INB', 'for', 'patients', 'undergoing', 'lateral', 'thoracotomy', 'who', 'receive', '0.5', 'mg', 'SM', '.']","(16, 17)","(102, 104)",-1,hl_i,8519720,Abstract,11,test,gold,659.0
7391,The effects of sevoflurane and isoflurane on recovery from,outpatient surgery .,,"['The', 'effects', 'of', 'sevoflurane', 'and', 'isoflurane', 'on', 'recovery', 'from', 'outpatient', 'surgery', '.']","(9, 12)","(58, 78)",-1,ss_p,8726604,Title,0,test,gold,3661.0
7392,The effects of,sevoflurane,and isoflurane on recovery from outpatient surgery .,"['The', 'effects', 'of', 'sevoflurane', 'and', 'isoflurane', 'on', 'recovery', 'from', 'outpatient', 'surgery', '.']","(3, 4)","(14, 25)",-1,ss_i,8726604,Title,0,test,gold,5422.0
7393,The effects of sevoflurane and,isoflurane,on recovery from outpatient surgery .,"['The', 'effects', 'of', 'sevoflurane', 'and', 'isoflurane', 'on', 'recovery', 'from', 'outpatient', 'surgery', '.']","(5, 6)","(30, 40)",-1,ss_i,8726604,Title,0,test,gold,5411.0
7394,The effects of sevoflurane and isoflurane on recovery from,outpatient surgery .,,"['The', 'effects', 'of', 'sevoflurane', 'and', 'isoflurane', 'on', 'recovery', 'from', 'outpatient', 'surgery', '.']","(9, 12)","(58, 78)",-1,hl_p,8726604,Title,0,test,gold,3662.0
7395,The effects of,sevoflurane,and isoflurane on recovery from outpatient surgery .,"['The', 'effects', 'of', 'sevoflurane', 'and', 'isoflurane', 'on', 'recovery', 'from', 'outpatient', 'surgery', '.']","(3, 4)","(14, 25)",-1,hl_i,8726604,Title,0,test,gold,5420.0
7396,The effects of sevoflurane and,isoflurane,on recovery from outpatient surgery .,"['The', 'effects', 'of', 'sevoflurane', 'and', 'isoflurane', 'on', 'recovery', 'from', 'outpatient', 'surgery', '.']","(5, 6)","(30, 40)",-1,hl_i,8726604,Title,0,test,gold,5412.0
7397,"This randomized , open-label study compared the investigational inhalational anesthetic sevoflurane with isoflurane in",47 healthy women undergoing elective ambulatory surgery .,,"['This', 'randomized', ',', 'open-label', 'study', 'compared', 'the', 'investigational', 'inhalational', 'anesthetic', 'sevoflurane', 'with', 'isoflurane', 'in', '47', 'healthy', 'women', 'undergoing', 'elective', 'ambulatory', 'surgery', '.']","(14, 22)","(118, 175)",-1,ss_p,8726604,Abstract,0,test,gold,3625.0
7398,"This randomized , open-label study compared the investigational inhalational anesthetic",sevoflurane,with isoflurane in 47 healthy women undergoing elective ambulatory surgery .,"['This', 'randomized', ',', 'open-label', 'study', 'compared', 'the', 'investigational', 'inhalational', 'anesthetic', 'sevoflurane', 'with', 'isoflurane', 'in', '47', 'healthy', 'women', 'undergoing', 'elective', 'ambulatory', 'surgery', '.']","(10, 11)","(87, 98)",-1,ss_i,8726604,Abstract,0,test,gold,5419.0
7399,"This randomized , open-label study compared the investigational inhalational anesthetic sevoflurane with",isoflurane,in 47 healthy women undergoing elective ambulatory surgery .,"['This', 'randomized', ',', 'open-label', 'study', 'compared', 'the', 'investigational', 'inhalational', 'anesthetic', 'sevoflurane', 'with', 'isoflurane', 'in', '47', 'healthy', 'women', 'undergoing', 'elective', 'ambulatory', 'surgery', '.']","(12, 13)","(104, 114)",-1,ss_i,8726604,Abstract,0,test,gold,5410.0
7400,"This randomized , open-label study compared the investigational inhalational anesthetic sevoflurane with isoflurane in",47 healthy women undergoing elective ambulatory surgery,.,"['This', 'randomized', ',', 'open-label', 'study', 'compared', 'the', 'investigational', 'inhalational', 'anesthetic', 'sevoflurane', 'with', 'isoflurane', 'in', '47', 'healthy', 'women', 'undergoing', 'elective', 'ambulatory', 'surgery', '.']","(14, 21)","(118, 173)",-1,hl_p,8726604,Abstract,0,test,gold,3626.0
7401,"This randomized , open-label study compared the investigational inhalational anesthetic",sevoflurane,with isoflurane in 47 healthy women undergoing elective ambulatory surgery .,"['This', 'randomized', ',', 'open-label', 'study', 'compared', 'the', 'investigational', 'inhalational', 'anesthetic', 'sevoflurane', 'with', 'isoflurane', 'in', '47', 'healthy', 'women', 'undergoing', 'elective', 'ambulatory', 'surgery', '.']","(10, 11)","(87, 98)",-1,hl_i,8726604,Abstract,0,test,gold,5418.0
7402,"This randomized , open-label study compared the investigational inhalational anesthetic sevoflurane with",isoflurane,in 47 healthy women undergoing elective ambulatory surgery .,"['This', 'randomized', ',', 'open-label', 'study', 'compared', 'the', 'investigational', 'inhalational', 'anesthetic', 'sevoflurane', 'with', 'isoflurane', 'in', '47', 'healthy', 'women', 'undergoing', 'elective', 'ambulatory', 'surgery', '.']","(12, 13)","(104, 114)",-1,hl_i,8726604,Abstract,0,test,gold,5409.0
7403,The,women,were randomized to receive either sevoflurane or isoflurane in 60 % nitrous oxide-oxygen .,"['The', 'women', 'were', 'randomized', 'to', 'receive', 'either', 'sevoflurane', 'or', 'isoflurane', 'in', '60', '%', 'nitrous', 'oxide-oxygen', '.']","(1, 2)","(3, 8)",-1,ss_p,8726604,Abstract,1,test,gold,2241.0
7404,The women were randomized to receive either,sevoflurane,or isoflurane in 60 % nitrous oxide-oxygen .,"['The', 'women', 'were', 'randomized', 'to', 'receive', 'either', 'sevoflurane', 'or', 'isoflurane', 'in', '60', '%', 'nitrous', 'oxide-oxygen', '.']","(7, 8)","(43, 54)",-1,ss_i,8726604,Abstract,1,test,gold,5417.0
7405,The women were randomized to receive either sevoflurane or,isoflurane,in 60 % nitrous oxide-oxygen .,"['The', 'women', 'were', 'randomized', 'to', 'receive', 'either', 'sevoflurane', 'or', 'isoflurane', 'in', '60', '%', 'nitrous', 'oxide-oxygen', '.']","(9, 10)","(58, 68)",-1,ss_i,8726604,Abstract,1,test,gold,5408.0
7406,The,women,were randomized to receive either sevoflurane or isoflurane in 60 % nitrous oxide-oxygen .,"['The', 'women', 'were', 'randomized', 'to', 'receive', 'either', 'sevoflurane', 'or', 'isoflurane', 'in', '60', '%', 'nitrous', 'oxide-oxygen', '.']","(1, 2)","(3, 8)",-1,hl_p,8726604,Abstract,1,test,gold,2240.0
7407,The women were randomized to receive either,sevoflurane,or isoflurane in 60 % nitrous oxide-oxygen .,"['The', 'women', 'were', 'randomized', 'to', 'receive', 'either', 'sevoflurane', 'or', 'isoflurane', 'in', '60', '%', 'nitrous', 'oxide-oxygen', '.']","(7, 8)","(43, 54)",-1,hl_i,8726604,Abstract,1,test,gold,5416.0
7408,The women were randomized to receive either sevoflurane or,isoflurane,in 60 % nitrous oxide-oxygen .,"['The', 'women', 'were', 'randomized', 'to', 'receive', 'either', 'sevoflurane', 'or', 'isoflurane', 'in', '60', '%', 'nitrous', 'oxide-oxygen', '.']","(9, 10)","(58, 68)",-1,hl_i,8726604,Abstract,1,test,gold,5407.0
7409,Induction with,thiopental,3-6 mg/kg was followed by vecuronium 0.1 mg/kg and fentanyl 0-200 micrograms .,"['Induction', 'with', 'thiopental', '3-6', 'mg/kg', 'was', 'followed', 'by', 'vecuronium', '0.1', 'mg/kg', 'and', 'fentanyl', '0-200', 'micrograms', '.']","(2, 3)","(14, 24)",-1,ss_i,8726604,Abstract,2,test,gold,5423.0
7410,Induction with thiopental 3-6 mg/kg was followed by,vecuronium,0.1 mg/kg and fentanyl 0-200 micrograms .,"['Induction', 'with', 'thiopental', '3-6', 'mg/kg', 'was', 'followed', 'by', 'vecuronium', '0.1', 'mg/kg', 'and', 'fentanyl', '0-200', 'micrograms', '.']","(8, 9)","(51, 61)",-1,ss_i,8726604,Abstract,2,test,gold,143.0
7411,Induction with thiopental 3-6 mg/kg was followed by vecuronium 0.1 mg/kg and,fentanyl,0-200 micrograms .,"['Induction', 'with', 'thiopental', '3-6', 'mg/kg', 'was', 'followed', 'by', 'vecuronium', '0.1', 'mg/kg', 'and', 'fentanyl', '0-200', 'micrograms', '.']","(12, 13)","(76, 84)",-1,ss_i,8726604,Abstract,2,test,gold,5087.0
7412,Induction with,thiopental,3-6 mg/kg was followed by vecuronium 0.1 mg/kg and fentanyl 0-200 micrograms .,"['Induction', 'with', 'thiopental', '3-6', 'mg/kg', 'was', 'followed', 'by', 'vecuronium', '0.1', 'mg/kg', 'and', 'fentanyl', '0-200', 'micrograms', '.']","(2, 3)","(14, 24)",-1,hl_i,8726604,Abstract,2,test,gold,5424.0
7413,Induction with thiopental 3-6 mg/kg was followed by,vecuronium,0.1 mg/kg and fentanyl 0-200 micrograms .,"['Induction', 'with', 'thiopental', '3-6', 'mg/kg', 'was', 'followed', 'by', 'vecuronium', '0.1', 'mg/kg', 'and', 'fentanyl', '0-200', 'micrograms', '.']","(8, 9)","(51, 61)",-1,hl_i,8726604,Abstract,2,test,gold,144.0
7414,Induction with thiopental 3-6 mg/kg was followed by vecuronium 0.1 mg/kg and,fentanyl,0-200 micrograms .,"['Induction', 'with', 'thiopental', '3-6', 'mg/kg', 'was', 'followed', 'by', 'vecuronium', '0.1', 'mg/kg', 'and', 'fentanyl', '0-200', 'micrograms', '.']","(12, 13)","(76, 84)",-1,hl_i,8726604,Abstract,2,test,gold,5086.0
7415,,"Duration of anesthesia , time to emergence , orientation , length of stay in the surgical unit , and hospital discharge",were recorded .,"['Duration', 'of', 'anesthesia', ',', 'time', 'to', 'emergence', ',', 'orientation', ',', 'length', 'of', 'stay', 'in', 'the', 'surgical', 'unit', ',', 'and', 'hospital', 'discharge', 'were', 'recorded', '.']","(0, 21)","(0, 119)",-1,ss_o,8726604,Abstract,3,test,gold,5888.0
7416,,Duration of anesthesia,", time to emergence , orientation , length of stay in the surgical unit , and hospital discharge were recorded .","['Duration', 'of', 'anesthesia', ',', 'time', 'to', 'emergence', ',', 'orientation', ',', 'length', 'of', 'stay', 'in', 'the', 'surgical', 'unit', ',', 'and', 'hospital', 'discharge', 'were', 'recorded', '.']","(0, 3)","(0, 22)",-1,hl_o,8726604,Abstract,3,test,gold,4111.0
7417,"Duration of anesthesia ,",time to emergence,", orientation , length of stay in the surgical unit , and hospital discharge were recorded .","['Duration', 'of', 'anesthesia', ',', 'time', 'to', 'emergence', ',', 'orientation', ',', 'length', 'of', 'stay', 'in', 'the', 'surgical', 'unit', ',', 'and', 'hospital', 'discharge', 'were', 'recorded', '.']","(4, 7)","(24, 41)",-1,hl_o,8726604,Abstract,3,test,gold,1204.0
7418,"Duration of anesthesia , time to emergence ,",orientation,", length of stay in the surgical unit , and hospital discharge were recorded .","['Duration', 'of', 'anesthesia', ',', 'time', 'to', 'emergence', ',', 'orientation', ',', 'length', 'of', 'stay', 'in', 'the', 'surgical', 'unit', ',', 'and', 'hospital', 'discharge', 'were', 'recorded', '.']","(8, 9)","(44, 55)",-1,hl_o,8726604,Abstract,3,test,gold,1296.0
7419,"Duration of anesthesia , time to emergence , orientation ,",length of stay in the surgical unit,", and hospital discharge were recorded .","['Duration', 'of', 'anesthesia', ',', 'time', 'to', 'emergence', ',', 'orientation', ',', 'length', 'of', 'stay', 'in', 'the', 'surgical', 'unit', ',', 'and', 'hospital', 'discharge', 'were', 'recorded', '.']","(10, 17)","(58, 93)",-1,hl_o,8726604,Abstract,3,test,gold,3700.0
7420,"The emergence , length of stay , and discharge times after discontinuation of",sevoflurane,"were 9.7 +/- 0.7 , 120.6 +/- 8.0 , and 244 +/- 15 minutes , respectively , and for isoflurane were 11.9 +/- 1.4 , 106.8 +/- 7.1 , and 282 +/- 24 minutes , respectively ( NS ) .","['The', 'emergence', ',', 'length', 'of', 'stay', ',', 'and', 'discharge', 'times', 'after', 'discontinuation', 'of', 'sevoflurane', 'were', '9.7', '+/-', '0.7', ',', '120.6', '+/-', '8.0', ',', 'and', '244', '+/-', '15', 'minutes', ',', 'respectively', ',', 'and', 'for', 'isoflurane', 'were', '11.9', '+/-', '1.4', ',', '106.8', '+/-', '7.1', ',', 'and', '282', '+/-', '24', 'minutes', ',', 'respectively', '(', 'NS', ')', '.']","(13, 14)","(77, 88)",-1,ss_i,8726604,Abstract,4,test,gold,5415.0
7421,"The emergence , length of stay , and discharge times after discontinuation of sevoflurane were 9.7 +/- 0.7 , 120.6 +/- 8.0 , and 244 +/- 15 minutes , respectively , and for",isoflurane,"were 11.9 +/- 1.4 , 106.8 +/- 7.1 , and 282 +/- 24 minutes , respectively ( NS ) .","['The', 'emergence', ',', 'length', 'of', 'stay', ',', 'and', 'discharge', 'times', 'after', 'discontinuation', 'of', 'sevoflurane', 'were', '9.7', '+/-', '0.7', ',', '120.6', '+/-', '8.0', ',', 'and', '244', '+/-', '15', 'minutes', ',', 'respectively', ',', 'and', 'for', 'isoflurane', 'were', '11.9', '+/-', '1.4', ',', '106.8', '+/-', '7.1', ',', 'and', '282', '+/-', '24', 'minutes', ',', 'respectively', '(', 'NS', ')', '.']","(33, 34)","(172, 182)",-1,ss_i,8726604,Abstract,4,test,gold,5406.0
7422,,"The emergence , length of stay , and discharge times after discontinuation","of sevoflurane were 9.7 +/- 0.7 , 120.6 +/- 8.0 , and 244 +/- 15 minutes , respectively , and for isoflurane were 11.9 +/- 1.4 , 106.8 +/- 7.1 , and 282 +/- 24 minutes , respectively ( NS ) .","['The', 'emergence', ',', 'length', 'of', 'stay', ',', 'and', 'discharge', 'times', 'after', 'discontinuation', 'of', 'sevoflurane', 'were', '9.7', '+/-', '0.7', ',', '120.6', '+/-', '8.0', ',', 'and', '244', '+/-', '15', 'minutes', ',', 'respectively', ',', 'and', 'for', 'isoflurane', 'were', '11.9', '+/-', '1.4', ',', '106.8', '+/-', '7.1', ',', 'and', '282', '+/-', '24', 'minutes', ',', 'respectively', '(', 'NS', ')', '.']","(0, 12)","(0, 74)",-1,ss_o,8726604,Abstract,4,test,gold,3693.0
7423,"The emergence , length of stay , and discharge times after discontinuation of",sevoflurane,"were 9.7 +/- 0.7 , 120.6 +/- 8.0 , and 244 +/- 15 minutes , respectively , and for isoflurane were 11.9 +/- 1.4 , 106.8 +/- 7.1 , and 282 +/- 24 minutes , respectively ( NS ) .","['The', 'emergence', ',', 'length', 'of', 'stay', ',', 'and', 'discharge', 'times', 'after', 'discontinuation', 'of', 'sevoflurane', 'were', '9.7', '+/-', '0.7', ',', '120.6', '+/-', '8.0', ',', 'and', '244', '+/-', '15', 'minutes', ',', 'respectively', ',', 'and', 'for', 'isoflurane', 'were', '11.9', '+/-', '1.4', ',', '106.8', '+/-', '7.1', ',', 'and', '282', '+/-', '24', 'minutes', ',', 'respectively', '(', 'NS', ')', '.']","(13, 14)","(77, 88)",-1,hl_i,8726604,Abstract,4,test,gold,5414.0
7424,"The emergence , length of stay , and discharge times after discontinuation of sevoflurane were 9.7 +/- 0.7 , 120.6 +/- 8.0 , and 244 +/- 15 minutes , respectively , and for",isoflurane,"were 11.9 +/- 1.4 , 106.8 +/- 7.1 , and 282 +/- 24 minutes , respectively ( NS ) .","['The', 'emergence', ',', 'length', 'of', 'stay', ',', 'and', 'discharge', 'times', 'after', 'discontinuation', 'of', 'sevoflurane', 'were', '9.7', '+/-', '0.7', ',', '120.6', '+/-', '8.0', ',', 'and', '244', '+/-', '15', 'minutes', ',', 'respectively', ',', 'and', 'for', 'isoflurane', 'were', '11.9', '+/-', '1.4', ',', '106.8', '+/-', '7.1', ',', 'and', '282', '+/-', '24', 'minutes', ',', 'respectively', '(', 'NS', ')', '.']","(33, 34)","(172, 182)",-1,hl_i,8726604,Abstract,4,test,gold,5405.0
7425,The,"emergence , length of stay , and discharge times","after discontinuation of sevoflurane were 9.7 +/- 0.7 , 120.6 +/- 8.0 , and 244 +/- 15 minutes , respectively , and for isoflurane were 11.9 +/- 1.4 , 106.8 +/- 7.1 , and 282 +/- 24 minutes , respectively ( NS ) .","['The', 'emergence', ',', 'length', 'of', 'stay', ',', 'and', 'discharge', 'times', 'after', 'discontinuation', 'of', 'sevoflurane', 'were', '9.7', '+/-', '0.7', ',', '120.6', '+/-', '8.0', ',', 'and', '244', '+/-', '15', 'minutes', ',', 'respectively', ',', 'and', 'for', 'isoflurane', 'were', '11.9', '+/-', '1.4', ',', '106.8', '+/-', '7.1', ',', 'and', '282', '+/-', '24', 'minutes', ',', 'respectively', '(', 'NS', ')', '.']","(1, 10)","(3, 51)",-1,hl_o,8726604,Abstract,4,test,gold,3694.0
7426,The,isoflurane,group had a higher frequency of postoperative cough .,"['The', 'isoflurane', 'group', 'had', 'a', 'higher', 'frequency', 'of', 'postoperative', 'cough', '.']","(1, 2)","(3, 13)",-1,ss_i,8726604,Abstract,5,test,gold,5404.0
7427,The isoflurane group had a higher frequency of,postoperative cough .,,"['The', 'isoflurane', 'group', 'had', 'a', 'higher', 'frequency', 'of', 'postoperative', 'cough', '.']","(8, 11)","(46, 67)",-1,ss_o,8726604,Abstract,5,test,gold,3114.0
7428,The isoflurane group had a higher frequency of,postoperative cough .,,"['The', 'isoflurane', 'group', 'had', 'a', 'higher', 'frequency', 'of', 'postoperative', 'cough', '.']","(8, 11)","(46, 67)",-1,hl_o,8726604,Abstract,5,test,gold,3115.0
7429,"At the end of surgery , the",sevoflurane,"group received a deeper level of anesthesia ( minimum alveolar concentration 1.5 vs 1.3 ) , however , these patients were oriented earlier ( 13.6 +/- 1.1 min vs 17.0 +/- 1.5 min isoflurane ; p = 0.02 ) after discontinuation of anesthesia , although this difference is of little clinical significance .","['At', 'the', 'end', 'of', 'surgery', ',', 'the', 'sevoflurane', 'group', 'received', 'a', 'deeper', 'level', 'of', 'anesthesia', '(', 'minimum', 'alveolar', 'concentration', '1.5', 'vs', '1.3', ')', ',', 'however', ',', 'these', 'patients', 'were', 'oriented', 'earlier', '(', '13.6', '+/-', '1.1', 'min', 'vs', '17.0', '+/-', '1.5', 'min', 'isoflurane', ';', 'p', '=', '0.02', ')', 'after', 'discontinuation', 'of', 'anesthesia', ',', 'although', 'this', 'difference', 'is', 'of', 'little', 'clinical', 'significance', '.']","(7, 8)","(27, 38)",-1,ss_i,8726604,Abstract,6,test,gold,5413.0
7430,"At the end of surgery , the sevoflurane group received a deeper level of anesthesia ( minimum alveolar concentration 1.5 vs 1.3 ) , however , these patients were oriented earlier ( 13.6 +/- 1.1 min vs 17.0 +/- 1.5 min",isoflurane ;,"p = 0.02 ) after discontinuation of anesthesia , although this difference is of little clinical significance .","['At', 'the', 'end', 'of', 'surgery', ',', 'the', 'sevoflurane', 'group', 'received', 'a', 'deeper', 'level', 'of', 'anesthesia', '(', 'minimum', 'alveolar', 'concentration', '1.5', 'vs', '1.3', ')', ',', 'however', ',', 'these', 'patients', 'were', 'oriented', 'earlier', '(', '13.6', '+/-', '1.1', 'min', 'vs', '17.0', '+/-', '1.5', 'min', 'isoflurane', ';', 'p', '=', '0.02', ')', 'after', 'discontinuation', 'of', 'anesthesia', ',', 'although', 'this', 'difference', 'is', 'of', 'little', 'clinical', 'significance', '.']","(41, 43)","(217, 229)",-1,ss_i,8726604,Abstract,6,test,gold,5403.0
7431,"At the end of surgery , the sevoflurane group received a deeper",level of anesthesia,"( minimum alveolar concentration 1.5 vs 1.3 ) , however , these patients were oriented earlier ( 13.6 +/- 1.1 min vs 17.0 +/- 1.5 min isoflurane ; p = 0.02 ) after discontinuation of anesthesia , although this difference is of little clinical significance .","['At', 'the', 'end', 'of', 'surgery', ',', 'the', 'sevoflurane', 'group', 'received', 'a', 'deeper', 'level', 'of', 'anesthesia', '(', 'minimum', 'alveolar', 'concentration', '1.5', 'vs', '1.3', ')', ',', 'however', ',', 'these', 'patients', 'were', 'oriented', 'earlier', '(', '13.6', '+/-', '1.1', 'min', 'vs', '17.0', '+/-', '1.5', 'min', 'isoflurane', ';', 'p', '=', '0.02', ')', 'after', 'discontinuation', 'of', 'anesthesia', ',', 'although', 'this', 'difference', 'is', 'of', 'little', 'clinical', 'significance', '.']","(12, 15)","(63, 82)",-1,ss_o,8726604,Abstract,6,test,gold,4112.0
7432,"At the end of surgery , the sevoflurane group received a deeper level of",anesthesia,"( minimum alveolar concentration 1.5 vs 1.3 ) , however , these patients were oriented earlier ( 13.6 +/- 1.1 min vs 17.0 +/- 1.5 min isoflurane ; p = 0.02 ) after discontinuation of anesthesia , although this difference is of little clinical significance .","['At', 'the', 'end', 'of', 'surgery', ',', 'the', 'sevoflurane', 'group', 'received', 'a', 'deeper', 'level', 'of', 'anesthesia', '(', 'minimum', 'alveolar', 'concentration', '1.5', 'vs', '1.3', ')', ',', 'however', ',', 'these', 'patients', 'were', 'oriented', 'earlier', '(', '13.6', '+/-', '1.1', 'min', 'vs', '17.0', '+/-', '1.5', 'min', 'isoflurane', ';', 'p', '=', '0.02', ')', 'after', 'discontinuation', 'of', 'anesthesia', ',', 'although', 'this', 'difference', 'is', 'of', 'little', 'clinical', 'significance', '.']","(14, 15)","(72, 82)",-1,hl_o,8726604,Abstract,6,test,gold,4113.0
7433,Fluoroscopic functional evaluation of,bileaflet prostheses :,effect of different intraoperative valve orientation .,"['Fluoroscopic', 'functional', 'evaluation', 'of', 'bileaflet', 'prostheses', ':', 'effect', 'of', 'different', 'intraoperative', 'valve', 'orientation', '.']","(4, 7)","(37, 59)",-1,ss_i,8771302,Title,0,test,gold,4082.0
7434,,Fluoroscopic functional evaluation,of bileaflet prostheses : effect of different intraoperative valve orientation .,"['Fluoroscopic', 'functional', 'evaluation', 'of', 'bileaflet', 'prostheses', ':', 'effect', 'of', 'different', 'intraoperative', 'valve', 'orientation', '.']","(0, 3)","(0, 34)",-1,ss_o,8771302,Title,0,test,gold,918.0
7435,Fluoroscopic functional evaluation of,bileaflet prostheses :,effect of different intraoperative valve orientation .,"['Fluoroscopic', 'functional', 'evaluation', 'of', 'bileaflet', 'prostheses', ':', 'effect', 'of', 'different', 'intraoperative', 'valve', 'orientation', '.']","(4, 7)","(37, 59)",-1,hl_i,8771302,Title,0,test,gold,4083.0
7436,"Fluoroscopy is a reliable , easy , and readily available technique to follow-up prosthesis functioning after heart valve surgery .",,,"['Fluoroscopy', 'is', 'a', 'reliable', ',', 'easy', ',', 'and', 'readily', 'available', 'technique', 'to', 'follow-up', 'prosthesis', 'functioning', 'after', 'heart', 'valve', 'surgery', '.']",,,,,8771302,Abstract,0,test,gold,
7437,The different orientation given to the,prosthesis,may represent a limitation of the technique accounting for unsatisfactory results in 10 % to 40 % of the cases .,"['The', 'different', 'orientation', 'given', 'to', 'the', 'prosthesis', 'may', 'represent', 'a', 'limitation', 'of', 'the', 'technique', 'accounting', 'for', 'unsatisfactory', 'results', 'in', '10', '%', 'to', '40', '%', 'of', 'the', 'cases', '.']","(6, 7)","(38, 48)",-1,ss_i,8771302,Abstract,1,test,gold,4076.0
7438,The aim of the study was to evaluate whether and to what extent different intraoperative valve orientation influence feasibility and accuracy of postoperative fluoroscopic evaluation of,bileaflet prostheses .,,"['The', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'whether', 'and', 'to', 'what', 'extent', 'different', 'intraoperative', 'valve', 'orientation', 'influence', 'feasibility', 'and', 'accuracy', 'of', 'postoperative', 'fluoroscopic', 'evaluation', 'of', 'bileaflet', 'prostheses', '.']","(26, 29)","(185, 207)",-1,ss_i,8771302,Abstract,2,test,gold,4081.0
7439,The aim of the study was to evaluate whether and to what extent different intraoperative valve orientation influence,feasibility,and accuracy of postoperative fluoroscopic evaluation of bileaflet prostheses .,"['The', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'whether', 'and', 'to', 'what', 'extent', 'different', 'intraoperative', 'valve', 'orientation', 'influence', 'feasibility', 'and', 'accuracy', 'of', 'postoperative', 'fluoroscopic', 'evaluation', 'of', 'bileaflet', 'prostheses', '.']","(18, 19)","(116, 127)",-1,ss_o,8771302,Abstract,2,test,gold,911.0
7440,The aim of the study was to evaluate whether and to what extent different intraoperative valve orientation influence feasibility and,accuracy,of postoperative fluoroscopic evaluation of bileaflet prostheses .,"['The', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'whether', 'and', 'to', 'what', 'extent', 'different', 'intraoperative', 'valve', 'orientation', 'influence', 'feasibility', 'and', 'accuracy', 'of', 'postoperative', 'fluoroscopic', 'evaluation', 'of', 'bileaflet', 'prostheses', '.']","(20, 21)","(132, 140)",-1,ss_o,8771302,Abstract,2,test,gold,1812.0
7441,The aim of the study was to evaluate whether and to what extent different intraoperative valve orientation influence feasibility and accuracy of,postoperative fluoroscopic evaluation,of bileaflet prostheses .,"['The', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'whether', 'and', 'to', 'what', 'extent', 'different', 'intraoperative', 'valve', 'orientation', 'influence', 'feasibility', 'and', 'accuracy', 'of', 'postoperative', 'fluoroscopic', 'evaluation', 'of', 'bileaflet', 'prostheses', '.']","(22, 25)","(144, 181)",-1,ss_o,8771302,Abstract,2,test,gold,4134.0
7442,The aim of the study was to evaluate whether and to what extent different intraoperative valve orientation influence feasibility and accuracy of postoperative fluoroscopic evaluation of,bileaflet prostheses .,,"['The', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'whether', 'and', 'to', 'what', 'extent', 'different', 'intraoperative', 'valve', 'orientation', 'influence', 'feasibility', 'and', 'accuracy', 'of', 'postoperative', 'fluoroscopic', 'evaluation', 'of', 'bileaflet', 'prostheses', '.']","(26, 29)","(185, 207)",-1,hl_i,8771302,Abstract,2,test,gold,4080.0
7443,The aim of the study was to evaluate whether and to what extent different intraoperative valve orientation influence,feasibility,and accuracy of postoperative fluoroscopic evaluation of bileaflet prostheses .,"['The', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'whether', 'and', 'to', 'what', 'extent', 'different', 'intraoperative', 'valve', 'orientation', 'influence', 'feasibility', 'and', 'accuracy', 'of', 'postoperative', 'fluoroscopic', 'evaluation', 'of', 'bileaflet', 'prostheses', '.']","(18, 19)","(116, 127)",-1,hl_o,8771302,Abstract,2,test,gold,910.0
7444,The aim of the study was to evaluate whether and to what extent different intraoperative valve orientation influence feasibility and,accuracy,of postoperative fluoroscopic evaluation of bileaflet prostheses .,"['The', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'whether', 'and', 'to', 'what', 'extent', 'different', 'intraoperative', 'valve', 'orientation', 'influence', 'feasibility', 'and', 'accuracy', 'of', 'postoperative', 'fluoroscopic', 'evaluation', 'of', 'bileaflet', 'prostheses', '.']","(20, 21)","(132, 140)",-1,hl_o,8771302,Abstract,2,test,gold,1813.0
7445,We prospectively evaluated,"90 patients who had aortic , mitral , and/or tricuspid valve replacement with Sorin Bicarbon or CarboMedics bileaflet prostheses .",,"['We', 'prospectively', 'evaluated', '90', 'patients', 'who', 'had', 'aortic', ',', 'mitral', ',', 'and/or', 'tricuspid', 'valve', 'replacement', 'with', 'Sorin', 'Bicarbon', 'or', 'CarboMedics', 'bileaflet', 'prostheses', '.']","(3, 23)","(26, 156)",-1,ss_p,8771302,Abstract,3,test,gold,5972.0
7446,"We prospectively evaluated 90 patients who had aortic , mitral , and/or tricuspid valve replacement with",Sorin Bicarbon or CarboMedics bileaflet prostheses .,,"['We', 'prospectively', 'evaluated', '90', 'patients', 'who', 'had', 'aortic', ',', 'mitral', ',', 'and/or', 'tricuspid', 'valve', 'replacement', 'with', 'Sorin', 'Bicarbon', 'or', 'CarboMedics', 'bileaflet', 'prostheses', '.']","(16, 23)","(104, 156)",-1,ss_i,8771302,Abstract,3,test,gold,4072.0
7447,We prospectively evaluated,"90 patients who had aortic , mitral , and/or tricuspid valve replacement with Sorin Bicarbon or CarboMedics bileaflet prostheses",.,"['We', 'prospectively', 'evaluated', '90', 'patients', 'who', 'had', 'aortic', ',', 'mitral', ',', 'and/or', 'tricuspid', 'valve', 'replacement', 'with', 'Sorin', 'Bicarbon', 'or', 'CarboMedics', 'bileaflet', 'prostheses', '.']","(3, 22)","(26, 154)",-1,hl_p,8771302,Abstract,3,test,gold,5973.0
7448,"We prospectively evaluated 90 patients who had aortic , mitral , and/or tricuspid valve replacement with",Sorin Bicarbon or CarboMedics bileaflet prostheses .,,"['We', 'prospectively', 'evaluated', '90', 'patients', 'who', 'had', 'aortic', ',', 'mitral', ',', 'and/or', 'tricuspid', 'valve', 'replacement', 'with', 'Sorin', 'Bicarbon', 'or', 'CarboMedics', 'bileaflet', 'prostheses', '.']","(16, 23)","(104, 156)",-1,hl_i,8771302,Abstract,3,test,gold,4073.0
7449,Fifty percent of the patients in each group were randomly assigned to receive,prostheses,oriented in a perpendicular or a parallel position with respect to the ventricular septum .,"['Fifty', 'percent', 'of', 'the', 'patients', 'in', 'each', 'group', 'were', 'randomly', 'assigned', 'to', 'receive', 'prostheses', 'oriented', 'in', 'a', 'perpendicular', 'or', 'a', 'parallel', 'position', 'with', 'respect', 'to', 'the', 'ventricular', 'septum', '.']","(13, 14)","(77, 87)",-1,ss_i,8771302,Abstract,4,test,gold,4079.0
7450,Fifty percent of the patients in each group were randomly assigned to receive,prostheses,oriented in a perpendicular or a parallel position with respect to the ventricular septum .,"['Fifty', 'percent', 'of', 'the', 'patients', 'in', 'each', 'group', 'were', 'randomly', 'assigned', 'to', 'receive', 'prostheses', 'oriented', 'in', 'a', 'perpendicular', 'or', 'a', 'parallel', 'position', 'with', 'respect', 'to', 'the', 'ventricular', 'septum', '.']","(13, 14)","(77, 87)",-1,hl_i,8771302,Abstract,4,test,gold,4078.0
7451,Fluoroscopic evaluation was considered appropriate when the,prosthesis ',""" tilting disk "" projection was obtained .","['Fluoroscopic', 'evaluation', 'was', 'considered', 'appropriate', 'when', 'the', 'prosthesis', ""'"", '""', 'tilting', 'disk', '""', 'projection', 'was', 'obtained', '.']","(7, 9)","(59, 71)",-1,ss_i,8771302,Abstract,5,test,gold,4077.0
7452,,Fluoroscopic evaluation,"was considered appropriate when the prosthesis ' "" tilting disk "" projection was obtained .","['Fluoroscopic', 'evaluation', 'was', 'considered', 'appropriate', 'when', 'the', 'prosthesis', ""'"", '""', 'tilting', 'disk', '""', 'projection', 'was', 'obtained', '.']","(0, 2)","(0, 23)",-1,ss_o,8771302,Abstract,5,test,gold,919.0
7453,The,valve 's hemodynamic performance was investigated through Doppler study .,,"['The', 'valve', ""'s"", 'hemodynamic', 'performance', 'was', 'investigated', 'through', 'Doppler', 'study', '.']","(1, 11)","(3, 76)",-1,ss_o,8771302,Abstract,6,test,gold,6813.0
7454,The valve 's,hemodynamic performance,was investigated through Doppler study .,"['The', 'valve', ""'s"", 'hemodynamic', 'performance', 'was', 'investigated', 'through', 'Doppler', 'study', '.']","(3, 5)","(12, 35)",-1,hl_o,8771302,Abstract,6,test,gold,3240.0
7455,A proper,fluoroscopic evaluation,"was rapidly ( 15 +/- 5 seconds ) achieved in all patients with the former orientation , whereas it was impossible to obtain it in 8 of 20 ( 40 % ) , 19 of 20 ( 95 % ) , and 4 of 5 ( 80 % ) of patients with the latter orientation .","['A', 'proper', 'fluoroscopic', 'evaluation', 'was', 'rapidly', '(', '15', '+/-', '5', 'seconds', ')', 'achieved', 'in', 'all', 'patients', 'with', 'the', 'former', 'orientation', ',', 'whereas', 'it', 'was', 'impossible', 'to', 'obtain', 'it', 'in', '8', 'of', '20', '(', '40', '%', ')', ',', '19', 'of', '20', '(', '95', '%', ')', ',', 'and', '4', 'of', '5', '(', '80', '%', ')', 'of', 'patients', 'with', 'the', 'latter', 'orientation', '.']","(2, 4)","(8, 31)",-1,ss_o,8771302,Abstract,7,test,gold,4137.0
7456,A proper,fluoroscopic evaluation,"was rapidly ( 15 +/- 5 seconds ) achieved in all patients with the former orientation , whereas it was impossible to obtain it in 8 of 20 ( 40 % ) , 19 of 20 ( 95 % ) , and 4 of 5 ( 80 % ) of patients with the latter orientation .","['A', 'proper', 'fluoroscopic', 'evaluation', 'was', 'rapidly', '(', '15', '+/-', '5', 'seconds', ')', 'achieved', 'in', 'all', 'patients', 'with', 'the', 'former', 'orientation', ',', 'whereas', 'it', 'was', 'impossible', 'to', 'obtain', 'it', 'in', '8', 'of', '20', '(', '40', '%', ')', ',', '19', 'of', '20', '(', '95', '%', ')', ',', 'and', '4', 'of', '5', '(', '80', '%', ')', 'of', 'patients', 'with', 'the', 'latter', 'orientation', '.']","(2, 4)","(8, 31)",-1,hl_o,8771302,Abstract,7,test,gold,4138.0
7457,"In the remaining patients extremely angulated , uneasy projection was often required to get a correct fluoroscopic image .",,,"['In', 'the', 'remaining', 'patients', 'extremely', 'angulated', ',', 'uneasy', 'projection', 'was', 'often', 'required', 'to', 'get', 'a', 'correct', 'fluoroscopic', 'image', '.']",,,,,8771302,Abstract,8,test,gold,
7458,The Doppler study showed a similarly favorable,hemodynamic performance,regardless of valve orientation .,"['The', 'Doppler', 'study', 'showed', 'a', 'similarly', 'favorable', 'hemodynamic', 'performance', 'regardless', 'of', 'valve', 'orientation', '.']","(7, 9)","(46, 69)",-1,ss_o,8771302,Abstract,9,test,gold,3241.0
7459,The Doppler study showed a similarly favorable,hemodynamic performance,regardless of valve orientation .,"['The', 'Doppler', 'study', 'showed', 'a', 'similarly', 'favorable', 'hemodynamic', 'performance', 'regardless', 'of', 'valve', 'orientation', '.']","(7, 9)","(46, 69)",-1,hl_o,8771302,Abstract,9,test,gold,3239.0
7460,,Prosthesis,orientation crucially affects the rate of success of the fluoroscopic evaluation .,"['Prosthesis', 'orientation', 'crucially', 'affects', 'the', 'rate', 'of', 'success', 'of', 'the', 'fluoroscopic', 'evaluation', '.']","(0, 1)","(0, 10)",-1,ss_i,8771302,Abstract,10,test,gold,1107.0
7461,Prosthesis orientation crucially affects the,rate of success of the fluoroscopic evaluation .,,"['Prosthesis', 'orientation', 'crucially', 'affects', 'the', 'rate', 'of', 'success', 'of', 'the', 'fluoroscopic', 'evaluation', '.']","(5, 13)","(44, 92)",-1,ss_o,8771302,Abstract,10,test,gold,4132.0
7462,,Prosthesis,orientation crucially affects the rate of success of the fluoroscopic evaluation .,"['Prosthesis', 'orientation', 'crucially', 'affects', 'the', 'rate', 'of', 'success', 'of', 'the', 'fluoroscopic', 'evaluation', '.']","(0, 1)","(0, 10)",-1,hl_i,8771302,Abstract,10,test,gold,1108.0
7463,Prosthesis orientation crucially affects the,rate of success of the fluoroscopic evaluation .,,"['Prosthesis', 'orientation', 'crucially', 'affects', 'the', 'rate', 'of', 'success', 'of', 'the', 'fluoroscopic', 'evaluation', '.']","(5, 13)","(44, 92)",-1,hl_o,8771302,Abstract,10,test,gold,4133.0
7464,The orientation perpendicular to the ventricular septum greatly facilitates the postoperative,feasibility and accuracy of fluoroscopy,", and it is not detrimental to the valve 's hemodynamic performance .","['The', 'orientation', 'perpendicular', 'to', 'the', 'ventricular', 'septum', 'greatly', 'facilitates', 'the', 'postoperative', 'feasibility', 'and', 'accuracy', 'of', 'fluoroscopy', ',', 'and', 'it', 'is', 'not', 'detrimental', 'to', 'the', 'valve', ""'s"", 'hemodynamic', 'performance', '.']","(11, 16)","(93, 132)",-1,ss_o,8771302,Abstract,11,test,gold,1816.0
7465,"The orientation perpendicular to the ventricular septum greatly facilitates the postoperative feasibility and accuracy of fluoroscopy , and it is not detrimental to the",valve 's hemodynamic performance .,,"['The', 'orientation', 'perpendicular', 'to', 'the', 'ventricular', 'septum', 'greatly', 'facilitates', 'the', 'postoperative', 'feasibility', 'and', 'accuracy', 'of', 'fluoroscopy', ',', 'and', 'it', 'is', 'not', 'detrimental', 'to', 'the', 'valve', ""'s"", 'hemodynamic', 'performance', '.']","(24, 29)","(168, 202)",-1,ss_o,8771302,Abstract,11,test,gold,3231.0
7466,The orientation perpendicular to the ventricular septum greatly facilitates the postoperative,feasibility,"and accuracy of fluoroscopy , and it is not detrimental to the valve 's hemodynamic performance .","['The', 'orientation', 'perpendicular', 'to', 'the', 'ventricular', 'septum', 'greatly', 'facilitates', 'the', 'postoperative', 'feasibility', 'and', 'accuracy', 'of', 'fluoroscopy', ',', 'and', 'it', 'is', 'not', 'detrimental', 'to', 'the', 'valve', ""'s"", 'hemodynamic', 'performance', '.']","(11, 12)","(93, 104)",-1,hl_o,8771302,Abstract,11,test,gold,909.0
7467,The orientation perpendicular to the ventricular septum greatly facilitates the postoperative feasibility and,accuracy of fluoroscopy,", and it is not detrimental to the valve 's hemodynamic performance .","['The', 'orientation', 'perpendicular', 'to', 'the', 'ventricular', 'septum', 'greatly', 'facilitates', 'the', 'postoperative', 'feasibility', 'and', 'accuracy', 'of', 'fluoroscopy', ',', 'and', 'it', 'is', 'not', 'detrimental', 'to', 'the', 'valve', ""'s"", 'hemodynamic', 'performance', '.']","(13, 16)","(109, 132)",-1,hl_o,8771302,Abstract,11,test,gold,1817.0
7468,"The orientation perpendicular to the ventricular septum greatly facilitates the postoperative feasibility and accuracy of fluoroscopy , and it is not detrimental to the",valve 's hemodynamic performance .,,"['The', 'orientation', 'perpendicular', 'to', 'the', 'ventricular', 'septum', 'greatly', 'facilitates', 'the', 'postoperative', 'feasibility', 'and', 'accuracy', 'of', 'fluoroscopy', ',', 'and', 'it', 'is', 'not', 'detrimental', 'to', 'the', 'valve', ""'s"", 'hemodynamic', 'performance', '.']","(24, 29)","(168, 202)",-1,hl_o,8771302,Abstract,11,test,gold,3232.0
7469,This valve orientation may provide a better,fluoroscopic,window whenever a valve dysfunction is suspected .,"['This', 'valve', 'orientation', 'may', 'provide', 'a', 'better', 'fluoroscopic', 'window', 'whenever', 'a', 'valve', 'dysfunction', 'is', 'suspected', '.']","(7, 8)","(43, 55)",-1,ss_o,8771302,Abstract,12,test,gold,4135.0
7470,This valve orientation may provide a better,fluoroscopic,window whenever a valve dysfunction is suspected .,"['This', 'valve', 'orientation', 'may', 'provide', 'a', 'better', 'fluoroscopic', 'window', 'whenever', 'a', 'valve', 'dysfunction', 'is', 'suspected', '.']","(7, 8)","(43, 55)",-1,hl_o,8771302,Abstract,12,test,gold,4136.0
7471,The effect of,tunnelling,on epidural catheter migration .,"['The', 'effect', 'of', 'tunnelling', 'on', 'epidural', 'catheter', 'migration', '.']","(3, 4)","(13, 23)",-1,ss_i,8779382,Title,0,test,gold,
7472,The,effect,of tunnelling on epidural catheter migration .,"['The', 'effect', 'of', 'tunnelling', 'on', 'epidural', 'catheter', 'migration', '.']","(1, 2)","(3, 9)",-1,ss_o,8779382,Title,0,test,gold,2334.0
7473,The effect of,tunnelling,on epidural catheter migration .,"['The', 'effect', 'of', 'tunnelling', 'on', 'epidural', 'catheter', 'migration', '.']","(3, 4)","(13, 23)",-1,hl_i,8779382,Title,0,test,gold,
7474,"A prospective , randomised study of",82 patients having postoperative epidural analgesia,was performed to determine whether the tunnelling of an epidural catheter influences its migration .,"['A', 'prospective', ',', 'randomised', 'study', 'of', '82', 'patients', 'having', 'postoperative', 'epidural', 'analgesia', 'was', 'performed', 'to', 'determine', 'whether', 'the', 'tunnelling', 'of', 'an', 'epidural', 'catheter', 'influences', 'its', 'migration', '.']","(6, 12)","(35, 86)",-1,ss_p,8779382,Abstract,0,test,gold,5962.0
7475,"A prospective , randomised study of 82 patients having postoperative epidural analgesia was performed to determine whether the",tunnelling,of an epidural catheter influences its migration .,"['A', 'prospective', ',', 'randomised', 'study', 'of', '82', 'patients', 'having', 'postoperative', 'epidural', 'analgesia', 'was', 'performed', 'to', 'determine', 'whether', 'the', 'tunnelling', 'of', 'an', 'epidural', 'catheter', 'influences', 'its', 'migration', '.']","(18, 19)","(126, 136)",-1,ss_i,8779382,Abstract,0,test,gold,
7476,"A prospective , randomised study of 82 patients having postoperative epidural analgesia was performed to determine whether the tunnelling of an epidural catheter influences its",migration .,,"['A', 'prospective', ',', 'randomised', 'study', 'of', '82', 'patients', 'having', 'postoperative', 'epidural', 'analgesia', 'was', 'performed', 'to', 'determine', 'whether', 'the', 'tunnelling', 'of', 'an', 'epidural', 'catheter', 'influences', 'its', 'migration', '.']","(25, 27)","(176, 187)",-1,ss_o,8779382,Abstract,0,test,gold,1321.0
7477,"A prospective , randomised study of",82 patients having postoperative epidural analgesia,was performed to determine whether the tunnelling of an epidural catheter influences its migration .,"['A', 'prospective', ',', 'randomised', 'study', 'of', '82', 'patients', 'having', 'postoperative', 'epidural', 'analgesia', 'was', 'performed', 'to', 'determine', 'whether', 'the', 'tunnelling', 'of', 'an', 'epidural', 'catheter', 'influences', 'its', 'migration', '.']","(6, 12)","(35, 86)",-1,hl_p,8779382,Abstract,0,test,gold,5963.0
7478,"A prospective , randomised study of 82 patients having postoperative epidural analgesia was performed to determine whether the",tunnelling,of an epidural catheter influences its migration .,"['A', 'prospective', ',', 'randomised', 'study', 'of', '82', 'patients', 'having', 'postoperative', 'epidural', 'analgesia', 'was', 'performed', 'to', 'determine', 'whether', 'the', 'tunnelling', 'of', 'an', 'epidural', 'catheter', 'influences', 'its', 'migration', '.']","(18, 19)","(126, 136)",-1,hl_i,8779382,Abstract,0,test,gold,
7479,"A prospective , randomised study of 82 patients having postoperative epidural analgesia was performed to determine whether the tunnelling of an epidural catheter influences its",migration .,,"['A', 'prospective', ',', 'randomised', 'study', 'of', '82', 'patients', 'having', 'postoperative', 'epidural', 'analgesia', 'was', 'performed', 'to', 'determine', 'whether', 'the', 'tunnelling', 'of', 'an', 'epidural', 'catheter', 'influences', 'its', 'migration', '.']","(25, 27)","(176, 187)",-1,hl_o,8779382,Abstract,0,test,gold,1322.0
7480,,Tunnelling,of the catheter subcutaneously for a distance of 5 cm reduced the incidence of inward migration of 1 cm or more ( p < 0.01 ) compared to a standard method of fixation with a transparent adhesive dressing .,"['Tunnelling', 'of', 'the', 'catheter', 'subcutaneously', 'for', 'a', 'distance', 'of', '5', 'cm', 'reduced', 'the', 'incidence', 'of', 'inward', 'migration', 'of', '1', 'cm', 'or', 'more', '(', 'p', '<', '0.01', ')', 'compared', 'to', 'a', 'standard', 'method', 'of', 'fixation', 'with', 'a', 'transparent', 'adhesive', 'dressing', '.']","(0, 1)","(0, 10)",-1,ss_i,8779382,Abstract,1,test,gold,1114.0
7481,Tunnelling of the catheter subcutaneously for a distance of 5 cm reduced the,incidence of inward migration,of 1 cm or more ( p < 0.01 ) compared to a standard method of fixation with a transparent adhesive dressing .,"['Tunnelling', 'of', 'the', 'catheter', 'subcutaneously', 'for', 'a', 'distance', 'of', '5', 'cm', 'reduced', 'the', 'incidence', 'of', 'inward', 'migration', 'of', '1', 'cm', 'or', 'more', '(', 'p', '<', '0.01', ')', 'compared', 'to', 'a', 'standard', 'method', 'of', 'fixation', 'with', 'a', 'transparent', 'adhesive', 'dressing', '.']","(13, 17)","(76, 105)",-1,ss_o,8779382,Abstract,1,test,gold,3345.0
7482,,Tunnelling,of the catheter subcutaneously for a distance of 5 cm reduced the incidence of inward migration of 1 cm or more ( p < 0.01 ) compared to a standard method of fixation with a transparent adhesive dressing .,"['Tunnelling', 'of', 'the', 'catheter', 'subcutaneously', 'for', 'a', 'distance', 'of', '5', 'cm', 'reduced', 'the', 'incidence', 'of', 'inward', 'migration', 'of', '1', 'cm', 'or', 'more', '(', 'p', '<', '0.01', ')', 'compared', 'to', 'a', 'standard', 'method', 'of', 'fixation', 'with', 'a', 'transparent', 'adhesive', 'dressing', '.']","(0, 1)","(0, 10)",-1,hl_i,8779382,Abstract,1,test,gold,1115.0
7483,Tunnelling of the catheter subcutaneously for a distance of 5 cm reduced the,incidence of inward migration,of 1 cm or more ( p < 0.01 ) compared to a standard method of fixation with a transparent adhesive dressing .,"['Tunnelling', 'of', 'the', 'catheter', 'subcutaneously', 'for', 'a', 'distance', 'of', '5', 'cm', 'reduced', 'the', 'incidence', 'of', 'inward', 'migration', 'of', '1', 'cm', 'or', 'more', '(', 'p', '<', '0.01', ')', 'compared', 'to', 'a', 'standard', 'method', 'of', 'fixation', 'with', 'a', 'transparent', 'adhesive', 'dressing', '.']","(13, 17)","(76, 105)",-1,hl_o,8779382,Abstract,1,test,gold,3346.0
7484,This effect was more marked if the epidural catheter was sited in the thoracic rather than the lumbar area .,,,"['This', 'effect', 'was', 'more', 'marked', 'if', 'the', 'epidural', 'catheter', 'was', 'sited', 'in', 'the', 'thoracic', 'rather', 'than', 'the', 'lumbar', 'area', '.']",,,,,8779382,Abstract,2,test,gold,
7485,Sixty two percent ( n = 26 ) of,tunnelled catheters,"remained within 0.5 cm of their original position compared to 38 % ( n = 16 ) of non-tunnelled catheters , although this difference was not statistically significant .","['Sixty', 'two', 'percent', '(', 'n', '=', '26', ')', 'of', 'tunnelled', 'catheters', 'remained', 'within', '0.5', 'cm', 'of', 'their', 'original', 'position', 'compared', 'to', '38', '%', '(', 'n', '=', '16', ')', 'of', 'non-tunnelled', 'catheters', ',', 'although', 'this', 'difference', 'was', 'not', 'statistically', 'significant', '.']","(9, 11)","(31, 50)",-1,ss_i,8779382,Abstract,3,test,gold,4050.0
7486,Sixty two percent ( n = 26 ) of tunnelled catheters remained within 0.5 cm of their original position compared to 38 % ( n = 16 ) of,non-tunnelled catheters,", although this difference was not statistically significant .","['Sixty', 'two', 'percent', '(', 'n', '=', '26', ')', 'of', 'tunnelled', 'catheters', 'remained', 'within', '0.5', 'cm', 'of', 'their', 'original', 'position', 'compared', 'to', '38', '%', '(', 'n', '=', '16', ')', 'of', 'non-tunnelled', 'catheters', ',', 'although', 'this', 'difference', 'was', 'not', 'statistically', 'significant', '.']","(29, 31)","(132, 155)",-1,ss_i,8779382,Abstract,3,test,gold,4049.0
7487,Sixty two percent ( n = 26 ) of tunnelled catheters remained within 0.5 cm of their original,position,"compared to 38 % ( n = 16 ) of non-tunnelled catheters , although this difference was not statistically significant .","['Sixty', 'two', 'percent', '(', 'n', '=', '26', ')', 'of', 'tunnelled', 'catheters', 'remained', 'within', '0.5', 'cm', 'of', 'their', 'original', 'position', 'compared', 'to', '38', '%', '(', 'n', '=', '16', ')', 'of', 'non-tunnelled', 'catheters', ',', 'although', 'this', 'difference', 'was', 'not', 'statistically', 'significant', '.']","(18, 19)","(92, 100)",-1,ss_o,8779382,Abstract,3,test,gold,1207.0
7488,Sixty two percent ( n = 26 ) of,tunnelled catheters,"remained within 0.5 cm of their original position compared to 38 % ( n = 16 ) of non-tunnelled catheters , although this difference was not statistically significant .","['Sixty', 'two', 'percent', '(', 'n', '=', '26', ')', 'of', 'tunnelled', 'catheters', 'remained', 'within', '0.5', 'cm', 'of', 'their', 'original', 'position', 'compared', 'to', '38', '%', '(', 'n', '=', '16', ')', 'of', 'non-tunnelled', 'catheters', ',', 'although', 'this', 'difference', 'was', 'not', 'statistically', 'significant', '.']","(9, 11)","(31, 50)",-1,hl_i,8779382,Abstract,3,test,gold,4051.0
7489,Sixty two percent ( n = 26 ) of tunnelled catheters remained within 0.5 cm of their original position compared to 38 % ( n = 16 ) of,non-tunnelled catheters,", although this difference was not statistically significant .","['Sixty', 'two', 'percent', '(', 'n', '=', '26', ')', 'of', 'tunnelled', 'catheters', 'remained', 'within', '0.5', 'cm', 'of', 'their', 'original', 'position', 'compared', 'to', '38', '%', '(', 'n', '=', '16', ')', 'of', 'non-tunnelled', 'catheters', ',', 'although', 'this', 'difference', 'was', 'not', 'statistically', 'significant', '.']","(29, 31)","(132, 155)",-1,hl_i,8779382,Abstract,3,test,gold,4047.0
7490,Outward catheter migration was not reduced by subcutaneous,tunnelling .,,"['Outward', 'catheter', 'migration', 'was', 'not', 'reduced', 'by', 'subcutaneous', 'tunnelling', '.']","(8, 10)","(58, 70)",-1,ss_i,8779382,Abstract,4,test,gold,
7491,Outward,catheter migration,was not reduced by subcutaneous tunnelling .,"['Outward', 'catheter', 'migration', 'was', 'not', 'reduced', 'by', 'subcutaneous', 'tunnelling', '.']","(1, 3)","(7, 25)",-1,ss_o,8779382,Abstract,4,test,gold,4052.0
7492,Outward catheter migration was not reduced by subcutaneous,tunnelling .,,"['Outward', 'catheter', 'migration', 'was', 'not', 'reduced', 'by', 'subcutaneous', 'tunnelling', '.']","(8, 10)","(58, 70)",-1,hl_i,8779382,Abstract,4,test,gold,
7493,Outward,catheter migration,was not reduced by subcutaneous tunnelling .,"['Outward', 'catheter', 'migration', 'was', 'not', 'reduced', 'by', 'subcutaneous', 'tunnelling', '.']","(1, 3)","(7, 25)",-1,hl_o,8779382,Abstract,4,test,gold,4053.0
7494,Effects of tryptophan depletion in,drug-free adults with autistic disorder .,,"['Effects', 'of', 'tryptophan', 'depletion', 'in', 'drug-free', 'adults', 'with', 'autistic', 'disorder', '.']","(5, 11)","(34, 75)",-1,ss_p,8911222,Title,0,test,gold,6108.0
7495,Effects of,tryptophan depletion,in drug-free adults with autistic disorder .,"['Effects', 'of', 'tryptophan', 'depletion', 'in', 'drug-free', 'adults', 'with', 'autistic', 'disorder', '.']","(2, 4)","(10, 30)",-1,ss_i,8911222,Title,0,test,gold,4466.0
7496,Effects of tryptophan depletion in,drug-free adults,with autistic disorder .,"['Effects', 'of', 'tryptophan', 'depletion', 'in', 'drug-free', 'adults', 'with', 'autistic', 'disorder', '.']","(5, 7)","(34, 50)",-1,hl_p,8911222,Title,0,test,gold,2159.0
7497,Effects of tryptophan depletion in drug-free adults with,autistic disorder,.,"['Effects', 'of', 'tryptophan', 'depletion', 'in', 'drug-free', 'adults', 'with', 'autistic', 'disorder', '.']","(8, 10)","(56, 73)",-1,hl_p,8911222,Title,0,test,gold,6165.0
7498,BACKGROUND The primary objective of this study was to investigate the behavioral and biochemical responses to acute tryptophan depletion in,drug-free adult patients with autistic disorder .,,"['BACKGROUND', 'The', 'primary', 'objective', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'behavioral', 'and', 'biochemical', 'responses', 'to', 'acute', 'tryptophan', 'depletion', 'in', 'drug-free', 'adult', 'patients', 'with', 'autistic', 'disorder', '.']","(20, 27)","(139, 188)",-1,ss_p,8911222,Abstract,0,test,gold,6110.0
7499,BACKGROUND The primary objective of this study was to investigate the behavioral and biochemical responses to acute,tryptophan depletion,in drug-free adult patients with autistic disorder .,"['BACKGROUND', 'The', 'primary', 'objective', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'behavioral', 'and', 'biochemical', 'responses', 'to', 'acute', 'tryptophan', 'depletion', 'in', 'drug-free', 'adult', 'patients', 'with', 'autistic', 'disorder', '.']","(17, 19)","(115, 135)",-1,ss_i,8911222,Abstract,0,test,gold,4467.0
7500,BACKGROUND The primary objective of this study was to investigate the,behavioral and biochemical responses,to acute tryptophan depletion in drug-free adult patients with autistic disorder .,"['BACKGROUND', 'The', 'primary', 'objective', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'behavioral', 'and', 'biochemical', 'responses', 'to', 'acute', 'tryptophan', 'depletion', 'in', 'drug-free', 'adult', 'patients', 'with', 'autistic', 'disorder', '.']","(11, 15)","(69, 105)",-1,ss_o,8911222,Abstract,0,test,gold,2470.0
7501,BACKGROUND The primary objective of this study was to investigate the behavioral and biochemical responses to acute tryptophan depletion in,drug-free adult patients with autistic disorder .,,"['BACKGROUND', 'The', 'primary', 'objective', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'behavioral', 'and', 'biochemical', 'responses', 'to', 'acute', 'tryptophan', 'depletion', 'in', 'drug-free', 'adult', 'patients', 'with', 'autistic', 'disorder', '.']","(20, 27)","(139, 188)",-1,hl_p,8911222,Abstract,0,test,gold,6111.0
7502,METHODS,"Twenty drug-free adults with autistic disorder ( 16 men and 4 women ) ( mean [ +/- SD ] age , 30.5 +/- 8.5 years )","underwent short-term tryptophan depletion in a double-blind , placebo-controlled , randomized crossover design .","['METHODS', 'Twenty', 'drug-free', 'adults', 'with', 'autistic', 'disorder', '(', '16', 'men', 'and', '4', 'women', ')', '(', 'mean', '[', '+/-', 'SD', ']', 'age', ',', '30.5', '+/-', '8.5', 'years', ')', 'underwent', 'short-term', 'tryptophan', 'depletion', 'in', 'a', 'double-blind', ',', 'placebo-controlled', ',', 'randomized', 'crossover', 'design', '.']","(1, 27)","(7, 121)",-1,ss_p,8911222,Abstract,1,test,gold,5833.0
7503,"METHODS Twenty drug-free adults with autistic disorder ( 16 men and 4 women ) ( mean [ +/- SD ] age , 30.5 +/- 8.5 years ) underwent short-term",tryptophan depletion,"in a double-blind , placebo-controlled , randomized crossover design .","['METHODS', 'Twenty', 'drug-free', 'adults', 'with', 'autistic', 'disorder', '(', '16', 'men', 'and', '4', 'women', ')', '(', 'mean', '[', '+/-', 'SD', ']', 'age', ',', '30.5', '+/-', '8.5', 'years', ')', 'underwent', 'short-term', 'tryptophan', 'depletion', 'in', 'a', 'double-blind', ',', 'placebo-controlled', ',', 'randomized', 'crossover', 'design', '.']","(29, 31)","(143, 163)",-1,ss_i,8911222,Abstract,1,test,gold,4465.0
7504,METHODS,Twenty drug-free adults with autistic disorder,"( 16 men and 4 women ) ( mean [ +/- SD ] age , 30.5 +/- 8.5 years ) underwent short-term tryptophan depletion in a double-blind , placebo-controlled , randomized crossover design .","['METHODS', 'Twenty', 'drug-free', 'adults', 'with', 'autistic', 'disorder', '(', '16', 'men', 'and', '4', 'women', ')', '(', 'mean', '[', '+/-', 'SD', ']', 'age', ',', '30.5', '+/-', '8.5', 'years', ')', 'underwent', 'short-term', 'tryptophan', 'depletion', 'in', 'a', 'double-blind', ',', 'placebo-controlled', ',', 'randomized', 'crossover', 'design', '.']","(1, 7)","(7, 53)",-1,hl_p,8911222,Abstract,1,test,gold,6103.0
7505,METHODS Twenty drug-free adults with autistic disorder (,16 men and 4 women,") ( mean [ +/- SD ] age , 30.5 +/- 8.5 years ) underwent short-term tryptophan depletion in a double-blind , placebo-controlled , randomized crossover design .","['METHODS', 'Twenty', 'drug-free', 'adults', 'with', 'autistic', 'disorder', '(', '16', 'men', 'and', '4', 'women', ')', '(', 'mean', '[', '+/-', 'SD', ']', 'age', ',', '30.5', '+/-', '8.5', 'years', ')', 'underwent', 'short-term', 'tryptophan', 'depletion', 'in', 'a', 'double-blind', ',', 'placebo-controlled', ',', 'randomized', 'crossover', 'design', '.']","(8, 13)","(56, 74)",-1,hl_p,8911222,Abstract,1,test,gold,2237.0
7506,METHODS Twenty drug-free adults with autistic disorder ( 16 men and 4 women ) (,"mean [ +/- SD ] age , 30.5 +/- 8.5 years",") underwent short-term tryptophan depletion in a double-blind , placebo-controlled , randomized crossover design .","['METHODS', 'Twenty', 'drug-free', 'adults', 'with', 'autistic', 'disorder', '(', '16', 'men', 'and', '4', 'women', ')', '(', 'mean', '[', '+/-', 'SD', ']', 'age', ',', '30.5', '+/-', '8.5', 'years', ')', 'underwent', 'short-term', 'tryptophan', 'depletion', 'in', 'a', 'double-blind', ',', 'placebo-controlled', ',', 'randomized', 'crossover', 'design', '.']","(15, 26)","(79, 119)",-1,hl_p,8911222,Abstract,1,test,gold,2005.0
7507,"METHODS Twenty drug-free adults with autistic disorder ( 16 men and 4 women ) ( mean [ +/- SD ] age , 30.5 +/- 8.5 years ) underwent short-term",tryptophan depletion,"in a double-blind , placebo-controlled , randomized crossover design .","['METHODS', 'Twenty', 'drug-free', 'adults', 'with', 'autistic', 'disorder', '(', '16', 'men', 'and', '4', 'women', ')', '(', 'mean', '[', '+/-', 'SD', ']', 'age', ',', '30.5', '+/-', '8.5', 'years', ')', 'underwent', 'short-term', 'tryptophan', 'depletion', 'in', 'a', 'double-blind', ',', 'placebo-controlled', ',', 'randomized', 'crossover', 'design', '.']","(29, 31)","(143, 163)",-1,hl_i,8911222,Abstract,1,test,gold,4464.0
7508,"Patients received a 24-hour ,",low-tryptophan diet,followed the next morning by an amino acid drink .,"['Patients', 'received', 'a', '24-hour', ',', 'low-tryptophan', 'diet', 'followed', 'the', 'next', 'morning', 'by', 'an', 'amino', 'acid', 'drink', '.']","(5, 7)","(29, 48)",-1,ss_i,8911222,Abstract,2,test,gold,1529.0
7509,"Patients received a 24-hour , low-tryptophan diet followed the next morning by an",amino acid drink .,,"['Patients', 'received', 'a', '24-hour', ',', 'low-tryptophan', 'diet', 'followed', 'the', 'next', 'morning', 'by', 'an', 'amino', 'acid', 'drink', '.']","(13, 17)","(81, 99)",-1,ss_i,8911222,Abstract,2,test,gold,4659.0
7510,"Patients received a 24-hour ,",low-tryptophan diet,followed the next morning by an amino acid drink .,"['Patients', 'received', 'a', '24-hour', ',', 'low-tryptophan', 'diet', 'followed', 'the', 'next', 'morning', 'by', 'an', 'amino', 'acid', 'drink', '.']","(5, 7)","(29, 48)",-1,hl_i,8911222,Abstract,2,test,gold,1528.0
7511,"Patients received a 24-hour , low-tryptophan diet followed the next morning by an",amino acid drink .,,"['Patients', 'received', 'a', '24-hour', ',', 'low-tryptophan', 'diet', 'followed', 'the', 'next', 'morning', 'by', 'an', 'amino', 'acid', 'drink', '.']","(13, 17)","(81, 99)",-1,hl_i,8911222,Abstract,2,test,gold,4660.0
7512,Behavioral ratings were obtained on the morning of the,amino acid drink,"( baseline ) and 180 , 300 , and 420 minutes after the drink .","['Behavioral', 'ratings', 'were', 'obtained', 'on', 'the', 'morning', 'of', 'the', 'amino', 'acid', 'drink', '(', 'baseline', ')', 'and', '180', ',', '300', ',', 'and', '420', 'minutes', 'after', 'the', 'drink', '.']","(9, 12)","(54, 70)",-1,ss_i,8911222,Abstract,3,test,gold,4658.0
7513,,Behavioral ratings,"were obtained on the morning of the amino acid drink ( baseline ) and 180 , 300 , and 420 minutes after the drink .","['Behavioral', 'ratings', 'were', 'obtained', 'on', 'the', 'morning', 'of', 'the', 'amino', 'acid', 'drink', '(', 'baseline', ')', 'and', '180', ',', '300', ',', 'and', '420', 'minutes', 'after', 'the', 'drink', '.']","(0, 2)","(0, 18)",-1,ss_o,8911222,Abstract,3,test,gold,6230.0
7514,Behavioral ratings were obtained on the morning of the,amino acid drink,"( baseline ) and 180 , 300 , and 420 minutes after the drink .","['Behavioral', 'ratings', 'were', 'obtained', 'on', 'the', 'morning', 'of', 'the', 'amino', 'acid', 'drink', '(', 'baseline', ')', 'and', '180', ',', '300', ',', 'and', '420', 'minutes', 'after', 'the', 'drink', '.']","(9, 12)","(54, 70)",-1,hl_i,8911222,Abstract,3,test,gold,4657.0
7515,,Plasma free and total tryptophan levels,were obtained at baseline and 5 hours after the drink .,"['Plasma', 'free', 'and', 'total', 'tryptophan', 'levels', 'were', 'obtained', 'at', 'baseline', 'and', '5', 'hours', 'after', 'the', 'drink', '.']","(0, 6)","(0, 39)",-1,ss_o,8911222,Abstract,4,test,gold,4472.0
7516,,Plasma free and total tryptophan levels,were obtained at baseline and 5 hours after the drink .,"['Plasma', 'free', 'and', 'total', 'tryptophan', 'levels', 'were', 'obtained', 'at', 'baseline', 'and', '5', 'hours', 'after', 'the', 'drink', '.']","(0, 6)","(0, 39)",-1,hl_o,8911222,Abstract,4,test,gold,4473.0
7517,The active and sham testing sessions were separated by 7 days .,,,"['The', 'active', 'and', 'sham', 'testing', 'sessions', 'were', 'separated', 'by', '7', 'days', '.']",,,,,8911222,Abstract,5,test,gold,
7518,RESULTS Eleven ( 65 % ) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term,tryptophan depletion,", but none of the 17 patients showed any significant change in clinical status from baseline after sham depletion ( P = .001 ) .","['RESULTS', 'Eleven', '(', '65', '%', ')', 'of', 'the', '17', 'patients', 'who', 'completed', 'both', 'test', 'days', 'showed', 'a', 'significant', 'global', 'worsening', 'of', 'behavioral', 'symptoms', 'with', 'short-term', 'tryptophan', 'depletion', ',', 'but', 'none', 'of', 'the', '17', 'patients', 'showed', 'any', 'significant', 'change', 'in', 'clinical', 'status', 'from', 'baseline', 'after', 'sham', 'depletion', '(', 'P', '=', '.001', ')', '.']","(25, 27)","(148, 168)",-1,ss_i,8911222,Abstract,6,test,gold,4463.0
7519,"RESULTS Eleven ( 65 % ) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion , but none of the 17 patients showed any significant change in clinical status from baseline after",sham depletion,( P = .001 ) .,"['RESULTS', 'Eleven', '(', '65', '%', ')', 'of', 'the', '17', 'patients', 'who', 'completed', 'both', 'test', 'days', 'showed', 'a', 'significant', 'global', 'worsening', 'of', 'behavioral', 'symptoms', 'with', 'short-term', 'tryptophan', 'depletion', ',', 'but', 'none', 'of', 'the', '17', 'patients', 'showed', 'any', 'significant', 'change', 'in', 'clinical', 'status', 'from', 'baseline', 'after', 'sham', 'depletion', '(', 'P', '=', '.001', ')', '.']","(44, 46)","(268, 282)",-1,ss_i,8911222,Abstract,6,test,gold,1316.0
7520,RESULTS Eleven ( 65 % ) of the 17 patients who completed both test days showed a significant global worsening of,behavioral symptoms,"with short-term tryptophan depletion , but none of the 17 patients showed any significant change in clinical status from baseline after sham depletion ( P = .001 ) .","['RESULTS', 'Eleven', '(', '65', '%', ')', 'of', 'the', '17', 'patients', 'who', 'completed', 'both', 'test', 'days', 'showed', 'a', 'significant', 'global', 'worsening', 'of', 'behavioral', 'symptoms', 'with', 'short-term', 'tryptophan', 'depletion', ',', 'but', 'none', 'of', 'the', '17', 'patients', 'showed', 'any', 'significant', 'change', 'in', 'clinical', 'status', 'from', 'baseline', 'after', 'sham', 'depletion', '(', 'P', '=', '.001', ')', '.']","(21, 23)","(112, 131)",-1,ss_o,8911222,Abstract,6,test,gold,3286.0
7521,,Tryptophan depletion,"led to a significant increase in behaviors such as whirling , flapping , pacing , banging and hitting self , rocking , and toe walking ( P < .05 ) .","['Tryptophan', 'depletion', 'led', 'to', 'a', 'significant', 'increase', 'in', 'behaviors', 'such', 'as', 'whirling', ',', 'flapping', ',', 'pacing', ',', 'banging', 'and', 'hitting', 'self', ',', 'rocking', ',', 'and', 'toe', 'walking', '(', 'P', '<', '.05', ')', '.']","(0, 2)","(0, 20)",-1,ss_i,8911222,Abstract,7,test,gold,4461.0
7522,Tryptophan depletion led to a significant increase in,"behaviors such as whirling , flapping , pacing , banging and hitting self , rocking , and toe walking",( P < .05 ) .,"['Tryptophan', 'depletion', 'led', 'to', 'a', 'significant', 'increase', 'in', 'behaviors', 'such', 'as', 'whirling', ',', 'flapping', ',', 'pacing', ',', 'banging', 'and', 'hitting', 'self', ',', 'rocking', ',', 'and', 'toe', 'walking', '(', 'P', '<', '.05', ')', '.']","(8, 27)","(53, 154)",-1,ss_o,8911222,Abstract,7,test,gold,6337.0
7523,Tryptophan depletion led to a significant increase in behaviors such as,"whirling , flapping , pacing , banging and hitting self , rocking , and toe walking",( P < .05 ) .,"['Tryptophan', 'depletion', 'led', 'to', 'a', 'significant', 'increase', 'in', 'behaviors', 'such', 'as', 'whirling', ',', 'flapping', ',', 'pacing', ',', 'banging', 'and', 'hitting', 'self', ',', 'rocking', ',', 'and', 'toe', 'walking', '(', 'P', '<', '.05', ')', '.']","(11, 27)","(71, 154)",-1,hl_o,8911222,Abstract,7,test,gold,6338.0
7524,"In addition , patients were significantly less",calm and happy,and more anxious .,"['In', 'addition', ',', 'patients', 'were', 'significantly', 'less', 'calm', 'and', 'happy', 'and', 'more', 'anxious', '.']","(7, 10)","(46, 60)",-1,ss_o,8911222,Abstract,8,test,gold,873.0
7525,"In addition , patients were significantly less calm and happy and more",anxious .,,"['In', 'addition', ',', 'patients', 'were', 'significantly', 'less', 'calm', 'and', 'happy', 'and', 'more', 'anxious', '.']","(12, 14)","(70, 79)",-1,ss_o,8911222,Abstract,8,test,gold,1240.0
7526,"In addition , patients were significantly less",calm and happy,and more anxious .,"['In', 'addition', ',', 'patients', 'were', 'significantly', 'less', 'calm', 'and', 'happy', 'and', 'more', 'anxious', '.']","(7, 10)","(46, 60)",-1,hl_o,8911222,Abstract,8,test,gold,874.0
7527,"In addition , patients were significantly less calm and happy and more",anxious .,,"['In', 'addition', ',', 'patients', 'were', 'significantly', 'less', 'calm', 'and', 'happy', 'and', 'more', 'anxious', '.']","(12, 14)","(70, 79)",-1,hl_o,8911222,Abstract,8,test,gold,1241.0
7528,No significant change was observed in,social relatedness or repetitive thoughts and behavior .,,"['No', 'significant', 'change', 'was', 'observed', 'in', 'social', 'relatedness', 'or', 'repetitive', 'thoughts', 'and', 'behavior', '.']","(6, 14)","(37, 93)",-1,ss_o,8911222,Abstract,9,test,gold,6403.0
7529,No significant change was observed in,social relatedness or repetitive thoughts and behavior .,,"['No', 'significant', 'change', 'was', 'observed', 'in', 'social', 'relatedness', 'or', 'repetitive', 'thoughts', 'and', 'behavior', '.']","(6, 14)","(37, 93)",-1,hl_o,8911222,Abstract,9,test,gold,6404.0
7530,"Plasma total and free tryptophan levels were reduced 86 % and 69 % , respectively , 5 hours after the",tryptophan-deficient amino acid drink .,,"['Plasma', 'total', 'and', 'free', 'tryptophan', 'levels', 'were', 'reduced', '86', '%', 'and', '69', '%', ',', 'respectively', ',', '5', 'hours', 'after', 'the', 'tryptophan-deficient', 'amino', 'acid', 'drink', '.']","(20, 25)","(101, 140)",-1,ss_i,8911222,Abstract,10,test,gold,4656.0
7531,,Plasma total and free tryptophan levels,"were reduced 86 % and 69 % , respectively , 5 hours after the tryptophan-deficient amino acid drink .","['Plasma', 'total', 'and', 'free', 'tryptophan', 'levels', 'were', 'reduced', '86', '%', 'and', '69', '%', ',', 'respectively', ',', '5', 'hours', 'after', 'the', 'tryptophan-deficient', 'amino', 'acid', 'drink', '.']","(0, 6)","(0, 39)",-1,ss_o,8911222,Abstract,10,test,gold,4471.0
7532,,Plasma total and free tryptophan levels,"were reduced 86 % and 69 % , respectively , 5 hours after the tryptophan-deficient amino acid drink .","['Plasma', 'total', 'and', 'free', 'tryptophan', 'levels', 'were', 'reduced', '86', '%', 'and', '69', '%', ',', 'respectively', ',', '5', 'hours', 'after', 'the', 'tryptophan-deficient', 'amino', 'acid', 'drink', '.']","(0, 6)","(0, 39)",-1,hl_o,8911222,Abstract,10,test,gold,4470.0
7533,Patients who had a significant global exacerbation of symptoms had significantly higher baseline plasma total tryptophan levels ( P < .001 ) and Autism Behavior Checklist scores ( P = .005 ) than did patients who showed no significant change in symptoms after,tryptophan depletion .,,"['Patients', 'who', 'had', 'a', 'significant', 'global', 'exacerbation', 'of', 'symptoms', 'had', 'significantly', 'higher', 'baseline', 'plasma', 'total', 'tryptophan', 'levels', '(', 'P', '<', '.001', ')', 'and', 'Autism', 'Behavior', 'Checklist', 'scores', '(', 'P', '=', '.005', ')', 'than', 'did', 'patients', 'who', 'showed', 'no', 'significant', 'change', 'in', 'symptoms', 'after', 'tryptophan', 'depletion', '.']","(43, 46)","(259, 281)",-1,ss_i,8911222,Abstract,11,test,gold,4462.0
7534,Patients who had a significant global exacerbation of,symptoms,had significantly higher baseline plasma total tryptophan levels ( P < .001 ) and Autism Behavior Checklist scores ( P = .005 ) than did patients who showed no significant change in symptoms after tryptophan depletion .,"['Patients', 'who', 'had', 'a', 'significant', 'global', 'exacerbation', 'of', 'symptoms', 'had', 'significantly', 'higher', 'baseline', 'plasma', 'total', 'tryptophan', 'levels', '(', 'P', '<', '.001', ')', 'and', 'Autism', 'Behavior', 'Checklist', 'scores', '(', 'P', '=', '.005', ')', 'than', 'did', 'patients', 'who', 'showed', 'no', 'significant', 'change', 'in', 'symptoms', 'after', 'tryptophan', 'depletion', '.']","(8, 9)","(53, 61)",-1,ss_o,8911222,Abstract,11,test,gold,3277.0
7535,Patients who had a significant global exacerbation of symptoms had significantly higher baseline,plasma total tryptophan levels,( P < .001 ) and Autism Behavior Checklist scores ( P = .005 ) than did patients who showed no significant change in symptoms after tryptophan depletion .,"['Patients', 'who', 'had', 'a', 'significant', 'global', 'exacerbation', 'of', 'symptoms', 'had', 'significantly', 'higher', 'baseline', 'plasma', 'total', 'tryptophan', 'levels', '(', 'P', '<', '.001', ')', 'and', 'Autism', 'Behavior', 'Checklist', 'scores', '(', 'P', '=', '.005', ')', 'than', 'did', 'patients', 'who', 'showed', 'no', 'significant', 'change', 'in', 'symptoms', 'after', 'tryptophan', 'depletion', '.']","(13, 17)","(96, 126)",-1,ss_o,8911222,Abstract,11,test,gold,4468.0
7536,Patients who had a significant global exacerbation of symptoms had significantly higher baseline plasma total tryptophan levels ( P < .001 ) and,Autism Behavior Checklist scores,( P = .005 ) than did patients who showed no significant change in symptoms after tryptophan depletion .,"['Patients', 'who', 'had', 'a', 'significant', 'global', 'exacerbation', 'of', 'symptoms', 'had', 'significantly', 'higher', 'baseline', 'plasma', 'total', 'tryptophan', 'levels', '(', 'P', '<', '.001', ')', 'and', 'Autism', 'Behavior', 'Checklist', 'scores', '(', 'P', '=', '.005', ')', 'than', 'did', 'patients', 'who', 'showed', 'no', 'significant', 'change', 'in', 'symptoms', 'after', 'tryptophan', 'depletion', '.']","(23, 27)","(144, 176)",-1,ss_o,8911222,Abstract,11,test,gold,6288.0
7537,Patients who had a significant global exacerbation of symptoms had significantly higher baseline plasma total tryptophan levels ( P < .001 ) and Autism Behavior Checklist scores ( P = .005 ) than did patients who showed no significant change in,symptoms,after tryptophan depletion .,"['Patients', 'who', 'had', 'a', 'significant', 'global', 'exacerbation', 'of', 'symptoms', 'had', 'significantly', 'higher', 'baseline', 'plasma', 'total', 'tryptophan', 'levels', '(', 'P', '<', '.001', ')', 'and', 'Autism', 'Behavior', 'Checklist', 'scores', '(', 'P', '=', '.005', ')', 'than', 'did', 'patients', 'who', 'showed', 'no', 'significant', 'change', 'in', 'symptoms', 'after', 'tryptophan', 'depletion', '.']","(41, 42)","(244, 252)",-1,ss_o,8911222,Abstract,11,test,gold,3276.0
7538,Patients who had a significant global exacerbation of symptoms had significantly higher baseline,plasma total tryptophan levels,( P < .001 ) and Autism Behavior Checklist scores ( P = .005 ) than did patients who showed no significant change in symptoms after tryptophan depletion .,"['Patients', 'who', 'had', 'a', 'significant', 'global', 'exacerbation', 'of', 'symptoms', 'had', 'significantly', 'higher', 'baseline', 'plasma', 'total', 'tryptophan', 'levels', '(', 'P', '<', '.001', ')', 'and', 'Autism', 'Behavior', 'Checklist', 'scores', '(', 'P', '=', '.005', ')', 'than', 'did', 'patients', 'who', 'showed', 'no', 'significant', 'change', 'in', 'symptoms', 'after', 'tryptophan', 'depletion', '.']","(13, 17)","(96, 126)",-1,hl_o,8911222,Abstract,11,test,gold,4469.0
7539,Patients who had a significant global exacerbation of symptoms had significantly higher baseline plasma total tryptophan levels ( P < .001 ) and,Autism Behavior Checklist scores,( P = .005 ) than did patients who showed no significant change in symptoms after tryptophan depletion .,"['Patients', 'who', 'had', 'a', 'significant', 'global', 'exacerbation', 'of', 'symptoms', 'had', 'significantly', 'higher', 'baseline', 'plasma', 'total', 'tryptophan', 'levels', '(', 'P', '<', '.001', ')', 'and', 'Autism', 'Behavior', 'Checklist', 'scores', '(', 'P', '=', '.005', ')', 'than', 'did', 'patients', 'who', 'showed', 'no', 'significant', 'change', 'in', 'symptoms', 'after', 'tryptophan', 'depletion', '.']","(23, 27)","(144, 176)",-1,hl_o,8911222,Abstract,11,test,gold,6289.0
7540,CONCLUSIONS The results of this study are consistent with previous research that has implicated a dysregulation in serotonin function in some,patients with autism .,,"['CONCLUSIONS', 'The', 'results', 'of', 'this', 'study', 'are', 'consistent', 'with', 'previous', 'research', 'that', 'has', 'implicated', 'a', 'dysregulation', 'in', 'serotonin', 'function', 'in', 'some', 'patients', 'with', 'autism', '.']","(21, 25)","(141, 163)",-1,ss_p,8911222,Abstract,12,test,gold,6132.0
7541,CONCLUSIONS The results of this study are consistent with previous research that has implicated a dysregulation in serotonin function in some,patients with autism .,,"['CONCLUSIONS', 'The', 'results', 'of', 'this', 'study', 'are', 'consistent', 'with', 'previous', 'research', 'that', 'has', 'implicated', 'a', 'dysregulation', 'in', 'serotonin', 'function', 'in', 'some', 'patients', 'with', 'autism', '.']","(21, 25)","(141, 163)",-1,hl_p,8911222,Abstract,12,test,gold,6133.0
7542,These data suggest that the short-term reduction of serotonin precursor availability may exacerbate some,symptoms,characteristic of autism in some patients .,"['These', 'data', 'suggest', 'that', 'the', 'short-term', 'reduction', 'of', 'serotonin', 'precursor', 'availability', 'may', 'exacerbate', 'some', 'symptoms', 'characteristic', 'of', 'autism', 'in', 'some', 'patients', '.']","(14, 15)","(104, 112)",-1,ss_o,8911222,Abstract,13,test,gold,3275.0
7543,These data suggest that the short-term reduction of serotonin precursor availability may exacerbate some,symptoms,characteristic of autism in some patients .,"['These', 'data', 'suggest', 'that', 'the', 'short-term', 'reduction', 'of', 'serotonin', 'precursor', 'availability', 'may', 'exacerbate', 'some', 'symptoms', 'characteristic', 'of', 'autism', 'in', 'some', 'patients', '.']","(14, 15)","(104, 112)",-1,hl_o,8911222,Abstract,13,test,gold,3274.0
7544,Continued investigation into the role of serotonin in the pathogenesis and treatment of autistic disorder is warranted .,,,"['Continued', 'investigation', 'into', 'the', 'role', 'of', 'serotonin', 'in', 'the', 'pathogenesis', 'and', 'treatment', 'of', 'autistic', 'disorder', 'is', 'warranted', '.']",,,,,8911222,Abstract,14,test,gold,
7545,"A double-blind , placebo-controlled study of fluvoxamine in",adults with autistic disorder .,,"['A', 'double-blind', ',', 'placebo-controlled', 'study', 'of', 'fluvoxamine', 'in', 'adults', 'with', 'autistic', 'disorder', '.']","(8, 13)","(59, 90)",-1,ss_p,8911223,Title,0,test,gold,6109.0
7546,"A double-blind , placebo-controlled study of",fluvoxamine,in adults with autistic disorder .,"['A', 'double-blind', ',', 'placebo-controlled', 'study', 'of', 'fluvoxamine', 'in', 'adults', 'with', 'autistic', 'disorder', '.']","(6, 7)","(44, 55)",-1,ss_i,8911223,Title,0,test,gold,5553.0
7547,"A double-blind , placebo-controlled study of fluvoxamine in",adults with autistic disorder .,,"['A', 'double-blind', ',', 'placebo-controlled', 'study', 'of', 'fluvoxamine', 'in', 'adults', 'with', 'autistic', 'disorder', '.']","(8, 13)","(59, 90)",-1,hl_p,8911223,Title,0,test,gold,6107.0
7548,"A double-blind ,",placebo-controlled,study of fluvoxamine in adults with autistic disorder .,"['A', 'double-blind', ',', 'placebo-controlled', 'study', 'of', 'fluvoxamine', 'in', 'adults', 'with', 'autistic', 'disorder', '.']","(3, 4)","(16, 34)",-1,hl_i,8911223,Title,0,test,gold,
7549,"A double-blind , placebo-controlled study of",fluvoxamine,in adults with autistic disorder .,"['A', 'double-blind', ',', 'placebo-controlled', 'study', 'of', 'fluvoxamine', 'in', 'adults', 'with', 'autistic', 'disorder', '.']","(6, 7)","(44, 55)",-1,hl_i,8911223,Title,0,test,gold,5554.0
7550,BACKGROUND Autistic disorder is characterized by a fundamental disturbance in,"social interaction , impairments in communication",", and a markedly restricted repertoire of activities and interests .","['BACKGROUND', 'Autistic', 'disorder', 'is', 'characterized', 'by', 'a', 'fundamental', 'disturbance', 'in', 'social', 'interaction', ',', 'impairments', 'in', 'communication', ',', 'and', 'a', 'markedly', 'restricted', 'repertoire', 'of', 'activities', 'and', 'interests', '.']","(10, 16)","(77, 126)",-1,ss_o,8911223,Abstract,0,test,gold,2959.0
7551,"BACKGROUND Autistic disorder is characterized by a fundamental disturbance in social interaction , impairments in communication , and a markedly",restricted repertoire of activities and interests .,,"['BACKGROUND', 'Autistic', 'disorder', 'is', 'characterized', 'by', 'a', 'fundamental', 'disturbance', 'in', 'social', 'interaction', ',', 'impairments', 'in', 'communication', ',', 'and', 'a', 'markedly', 'restricted', 'repertoire', 'of', 'activities', 'and', 'interests', '.']","(20, 27)","(144, 195)",-1,ss_o,8911223,Abstract,0,test,gold,2965.0
7552,Abnormalities in the serotonin neurotransmitter system have been identified in some persons with autism .,,,"['Abnormalities', 'in', 'the', 'serotonin', 'neurotransmitter', 'system', 'have', 'been', 'identified', 'in', 'some', 'persons', 'with', 'autism', '.']",,,,,8911223,Abstract,1,test,gold,
7553,No consistently effective and safe drugs have been developed for treating the,symptoms,of autism .,"['No', 'consistently', 'effective', 'and', 'safe', 'drugs', 'have', 'been', 'developed', 'for', 'treating', 'the', 'symptoms', 'of', 'autism', '.']","(12, 13)","(77, 85)",-1,ss_o,8911223,Abstract,2,test,gold,3273.0
7554,METHODS,Thirty adults with autistic disorder,"completed a 12-week double-blind , placebo-controlled trial of the potent and selective serotonin uptake inhibitor fluvoxamine maleate .","['METHODS', 'Thirty', 'adults', 'with', 'autistic', 'disorder', 'completed', 'a', '12-week', 'double-blind', ',', 'placebo-controlled', 'trial', 'of', 'the', 'potent', 'and', 'selective', 'serotonin', 'uptake', 'inhibitor', 'fluvoxamine', 'maleate', '.']","(1, 6)","(7, 43)",-1,ss_p,8911223,Abstract,3,test,gold,6104.0
7555,"METHODS Thirty adults with autistic disorder completed a 12-week double-blind ,",placebo-controlled,trial of the potent and selective serotonin uptake inhibitor fluvoxamine maleate .,"['METHODS', 'Thirty', 'adults', 'with', 'autistic', 'disorder', 'completed', 'a', '12-week', 'double-blind', ',', 'placebo-controlled', 'trial', 'of', 'the', 'potent', 'and', 'selective', 'serotonin', 'uptake', 'inhibitor', 'fluvoxamine', 'maleate', '.']","(11, 12)","(79, 97)",-1,ss_i,8911223,Abstract,3,test,gold,
7556,"METHODS Thirty adults with autistic disorder completed a 12-week double-blind , placebo-controlled trial of the potent and selective serotonin uptake inhibitor",fluvoxamine maleate .,,"['METHODS', 'Thirty', 'adults', 'with', 'autistic', 'disorder', 'completed', 'a', '12-week', 'double-blind', ',', 'placebo-controlled', 'trial', 'of', 'the', 'potent', 'and', 'selective', 'serotonin', 'uptake', 'inhibitor', 'fluvoxamine', 'maleate', '.']","(21, 24)","(159, 180)",-1,ss_i,8911223,Abstract,3,test,gold,5555.0
7557,METHODS,Thirty adults,"with autistic disorder completed a 12-week double-blind , placebo-controlled trial of the potent and selective serotonin uptake inhibitor fluvoxamine maleate .","['METHODS', 'Thirty', 'adults', 'with', 'autistic', 'disorder', 'completed', 'a', '12-week', 'double-blind', ',', 'placebo-controlled', 'trial', 'of', 'the', 'potent', 'and', 'selective', 'serotonin', 'uptake', 'inhibitor', 'fluvoxamine', 'maleate', '.']","(1, 3)","(7, 20)",-1,hl_p,8911223,Abstract,3,test,gold,2057.0
7558,METHODS Thirty adults with,autistic disorder,"completed a 12-week double-blind , placebo-controlled trial of the potent and selective serotonin uptake inhibitor fluvoxamine maleate .","['METHODS', 'Thirty', 'adults', 'with', 'autistic', 'disorder', 'completed', 'a', '12-week', 'double-blind', ',', 'placebo-controlled', 'trial', 'of', 'the', 'potent', 'and', 'selective', 'serotonin', 'uptake', 'inhibitor', 'fluvoxamine', 'maleate', '.']","(4, 6)","(26, 43)",-1,hl_p,8911223,Abstract,3,test,gold,6163.0
7559,"METHODS Thirty adults with autistic disorder completed a 12-week double-blind ,",placebo-controlled,trial of the potent and selective serotonin uptake inhibitor fluvoxamine maleate .,"['METHODS', 'Thirty', 'adults', 'with', 'autistic', 'disorder', 'completed', 'a', '12-week', 'double-blind', ',', 'placebo-controlled', 'trial', 'of', 'the', 'potent', 'and', 'selective', 'serotonin', 'uptake', 'inhibitor', 'fluvoxamine', 'maleate', '.']","(11, 12)","(79, 97)",-1,hl_i,8911223,Abstract,3,test,gold,
7560,"METHODS Thirty adults with autistic disorder completed a 12-week double-blind , placebo-controlled trial of the potent and selective serotonin uptake inhibitor",fluvoxamine maleate .,,"['METHODS', 'Thirty', 'adults', 'with', 'autistic', 'disorder', 'completed', 'a', '12-week', 'double-blind', ',', 'placebo-controlled', 'trial', 'of', 'the', 'potent', 'and', 'selective', 'serotonin', 'uptake', 'inhibitor', 'fluvoxamine', 'maleate', '.']","(21, 24)","(159, 180)",-1,hl_i,8911223,Abstract,3,test,gold,5556.0
7561,,Behavioral ratings,"were obtained at baseline and after 4 , 8 , and 12 weeks of treatment .","['Behavioral', 'ratings', 'were', 'obtained', 'at', 'baseline', 'and', 'after', '4', ',', '8', ',', 'and', '12', 'weeks', 'of', 'treatment', '.']","(0, 2)","(0, 18)",-1,ss_o,8911223,Abstract,4,test,gold,6231.0
7562,,Behavioral ratings,"were obtained at baseline and after 4 , 8 , and 12 weeks of treatment .","['Behavioral', 'ratings', 'were', 'obtained', 'at', 'baseline', 'and', 'after', '4', ',', '8', ',', 'and', '12', 'weeks', 'of', 'treatment', '.']","(0, 2)","(0, 18)",-1,hl_o,8911223,Abstract,4,test,gold,6229.0
7563,RESULTS Eight ( 53 % ) of 15 patients in the,fluvoxamine-treated,group were categorized as responders compared with none of 15 in the placebo group ( P = .001 ) .,"['RESULTS', 'Eight', '(', '53', '%', ')', 'of', '15', 'patients', 'in', 'the', 'fluvoxamine-treated', 'group', 'were', 'categorized', 'as', 'responders', 'compared', 'with', 'none', 'of', '15', 'in', 'the', 'placebo', 'group', '(', 'P', '=', '.001', ')', '.']","(11, 12)","(44, 63)",-1,ss_i,8911223,Abstract,5,test,gold,
7564,RESULTS Eight ( 53 % ) of 15 patients in the fluvoxamine-treated group were categorized as responders compared with none of 15 in the,placebo,group ( P = .001 ) .,"['RESULTS', 'Eight', '(', '53', '%', ')', 'of', '15', 'patients', 'in', 'the', 'fluvoxamine-treated', 'group', 'were', 'categorized', 'as', 'responders', 'compared', 'with', 'none', 'of', '15', 'in', 'the', 'placebo', 'group', '(', 'P', '=', '.001', ')', '.']","(24, 25)","(133, 140)",-1,ss_i,8911223,Abstract,5,test,gold,4285.0
7565,RESULTS Eight ( 53 % ) of 15 patients in the,fluvoxamine-treated,group were categorized as responders compared with none of 15 in the placebo group ( P = .001 ) .,"['RESULTS', 'Eight', '(', '53', '%', ')', 'of', '15', 'patients', 'in', 'the', 'fluvoxamine-treated', 'group', 'were', 'categorized', 'as', 'responders', 'compared', 'with', 'none', 'of', '15', 'in', 'the', 'placebo', 'group', '(', 'P', '=', '.001', ')', '.']","(11, 12)","(44, 63)",-1,hl_i,8911223,Abstract,5,test,gold,
7566,RESULTS Eight ( 53 % ) of 15 patients in the fluvoxamine-treated group were categorized as responders compared with none of 15 in the,placebo,group ( P = .001 ) .,"['RESULTS', 'Eight', '(', '53', '%', ')', 'of', '15', 'patients', 'in', 'the', 'fluvoxamine-treated', 'group', 'were', 'categorized', 'as', 'responders', 'compared', 'with', 'none', 'of', '15', 'in', 'the', 'placebo', 'group', '(', 'P', '=', '.001', ')', '.']","(24, 25)","(133, 140)",-1,hl_i,8911223,Abstract,5,test,gold,4284.0
7567,,Fluvoxamine,"was superior to placebo in reducing repetitive thoughts and behavior ( P < .001 ) , maladaptive behavior ( P < .001 ) , and aggression ( P < .03 ) , and in improving some aspects of social relatedness ( P < .04 ) , especially language usage ( P < .008 ) .","['Fluvoxamine', 'was', 'superior', 'to', 'placebo', 'in', 'reducing', 'repetitive', 'thoughts', 'and', 'behavior', '(', 'P', '<', '.001', ')', ',', 'maladaptive', 'behavior', '(', 'P', '<', '.001', ')', ',', 'and', 'aggression', '(', 'P', '<', '.03', ')', ',', 'and', 'in', 'improving', 'some', 'aspects', 'of', 'social', 'relatedness', '(', 'P', '<', '.04', ')', ',', 'especially', 'language', 'usage', '(', 'P', '<', '.008', ')', '.']","(0, 1)","(0, 11)",-1,ss_i,8911223,Abstract,6,test,gold,1042.0
7568,Fluvoxamine was superior to,placebo,"in reducing repetitive thoughts and behavior ( P < .001 ) , maladaptive behavior ( P < .001 ) , and aggression ( P < .03 ) , and in improving some aspects of social relatedness ( P < .04 ) , especially language usage ( P < .008 ) .","['Fluvoxamine', 'was', 'superior', 'to', 'placebo', 'in', 'reducing', 'repetitive', 'thoughts', 'and', 'behavior', '(', 'P', '<', '.001', ')', ',', 'maladaptive', 'behavior', '(', 'P', '<', '.001', ')', ',', 'and', 'aggression', '(', 'P', '<', '.03', ')', ',', 'and', 'in', 'improving', 'some', 'aspects', 'of', 'social', 'relatedness', '(', 'P', '<', '.04', ')', ',', 'especially', 'language', 'usage', '(', 'P', '<', '.008', ')', '.']","(4, 5)","(27, 34)",-1,ss_i,8911223,Abstract,6,test,gold,4283.0
7569,Fluvoxamine was superior to placebo in reducing,repetitive thoughts and behavior,"( P < .001 ) , maladaptive behavior ( P < .001 ) , and aggression ( P < .03 ) , and in improving some aspects of social relatedness ( P < .04 ) , especially language usage ( P < .008 ) .","['Fluvoxamine', 'was', 'superior', 'to', 'placebo', 'in', 'reducing', 'repetitive', 'thoughts', 'and', 'behavior', '(', 'P', '<', '.001', ')', ',', 'maladaptive', 'behavior', '(', 'P', '<', '.001', ')', ',', 'and', 'aggression', '(', 'P', '<', '.03', ')', ',', 'and', 'in', 'improving', 'some', 'aspects', 'of', 'social', 'relatedness', '(', 'P', '<', '.04', ')', ',', 'especially', 'language', 'usage', '(', 'P', '<', '.008', ')', '.']","(7, 11)","(47, 79)",-1,ss_o,8911223,Abstract,6,test,gold,6407.0
7570,"Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior ( P < .001 ) ,",maladaptive behavior,"( P < .001 ) , and aggression ( P < .03 ) , and in improving some aspects of social relatedness ( P < .04 ) , especially language usage ( P < .008 ) .","['Fluvoxamine', 'was', 'superior', 'to', 'placebo', 'in', 'reducing', 'repetitive', 'thoughts', 'and', 'behavior', '(', 'P', '<', '.001', ')', ',', 'maladaptive', 'behavior', '(', 'P', '<', '.001', ')', ',', 'and', 'aggression', '(', 'P', '<', '.03', ')', ',', 'and', 'in', 'improving', 'some', 'aspects', 'of', 'social', 'relatedness', '(', 'P', '<', '.04', ')', ',', 'especially', 'language', 'usage', '(', 'P', '<', '.008', ')', '.']","(17, 19)","(95, 115)",-1,ss_o,8911223,Abstract,6,test,gold,6413.0
7571,"Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior ( P < .001 ) , maladaptive behavior ( P < .001 ) , and",aggression,"( P < .03 ) , and in improving some aspects of social relatedness ( P < .04 ) , especially language usage ( P < .008 ) .","['Fluvoxamine', 'was', 'superior', 'to', 'placebo', 'in', 'reducing', 'repetitive', 'thoughts', 'and', 'behavior', '(', 'P', '<', '.001', ')', ',', 'maladaptive', 'behavior', '(', 'P', '<', '.001', ')', ',', 'and', 'aggression', '(', 'P', '<', '.03', ')', ',', 'and', 'in', 'improving', 'some', 'aspects', 'of', 'social', 'relatedness', '(', 'P', '<', '.04', ')', ',', 'especially', 'language', 'usage', '(', 'P', '<', '.008', ')', '.']","(26, 27)","(135, 145)",-1,ss_o,8911223,Abstract,6,test,gold,2592.0
7572,"Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior ( P < .001 ) , maladaptive behavior ( P < .001 ) , and aggression ( P < .03 ) , and in improving some aspects of",social relatedness,"( P < .04 ) , especially language usage ( P < .008 ) .","['Fluvoxamine', 'was', 'superior', 'to', 'placebo', 'in', 'reducing', 'repetitive', 'thoughts', 'and', 'behavior', '(', 'P', '<', '.001', ')', ',', 'maladaptive', 'behavior', '(', 'P', '<', '.001', ')', ',', 'and', 'aggression', '(', 'P', '<', '.03', ')', ',', 'and', 'in', 'improving', 'some', 'aspects', 'of', 'social', 'relatedness', '(', 'P', '<', '.04', ')', ',', 'especially', 'language', 'usage', '(', 'P', '<', '.008', ')', '.']","(39, 41)","(193, 211)",-1,ss_o,8911223,Abstract,6,test,gold,2960.0
7573,"Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior ( P < .001 ) , maladaptive behavior ( P < .001 ) , and aggression ( P < .03 ) , and in improving some aspects of social relatedness ( P < .04 ) , especially",language usage,( P < .008 ) .,"['Fluvoxamine', 'was', 'superior', 'to', 'placebo', 'in', 'reducing', 'repetitive', 'thoughts', 'and', 'behavior', '(', 'P', '<', '.001', ')', ',', 'maladaptive', 'behavior', '(', 'P', '<', '.001', ')', ',', 'and', 'aggression', '(', 'P', '<', '.03', ')', ',', 'and', 'in', 'improving', 'some', 'aspects', 'of', 'social', 'relatedness', '(', 'P', '<', '.04', ')', ',', 'especially', 'language', 'usage', '(', 'P', '<', '.008', ')', '.']","(48, 50)","(237, 251)",-1,ss_o,8911223,Abstract,6,test,gold,2616.0
7574,,Fluvoxamine,"was superior to placebo in reducing repetitive thoughts and behavior ( P < .001 ) , maladaptive behavior ( P < .001 ) , and aggression ( P < .03 ) , and in improving some aspects of social relatedness ( P < .04 ) , especially language usage ( P < .008 ) .","['Fluvoxamine', 'was', 'superior', 'to', 'placebo', 'in', 'reducing', 'repetitive', 'thoughts', 'and', 'behavior', '(', 'P', '<', '.001', ')', ',', 'maladaptive', 'behavior', '(', 'P', '<', '.001', ')', ',', 'and', 'aggression', '(', 'P', '<', '.03', ')', ',', 'and', 'in', 'improving', 'some', 'aspects', 'of', 'social', 'relatedness', '(', 'P', '<', '.04', ')', ',', 'especially', 'language', 'usage', '(', 'P', '<', '.008', ')', '.']","(0, 1)","(0, 11)",-1,hl_i,8911223,Abstract,6,test,gold,1043.0
7575,Fluvoxamine was superior to,placebo,"in reducing repetitive thoughts and behavior ( P < .001 ) , maladaptive behavior ( P < .001 ) , and aggression ( P < .03 ) , and in improving some aspects of social relatedness ( P < .04 ) , especially language usage ( P < .008 ) .","['Fluvoxamine', 'was', 'superior', 'to', 'placebo', 'in', 'reducing', 'repetitive', 'thoughts', 'and', 'behavior', '(', 'P', '<', '.001', ')', ',', 'maladaptive', 'behavior', '(', 'P', '<', '.001', ')', ',', 'and', 'aggression', '(', 'P', '<', '.03', ')', ',', 'and', 'in', 'improving', 'some', 'aspects', 'of', 'social', 'relatedness', '(', 'P', '<', '.04', ')', ',', 'especially', 'language', 'usage', '(', 'P', '<', '.008', ')', '.']","(4, 5)","(27, 34)",-1,hl_i,8911223,Abstract,6,test,gold,4282.0
7576,Fluvoxamine was superior to placebo in reducing,repetitive thoughts and behavior,"( P < .001 ) , maladaptive behavior ( P < .001 ) , and aggression ( P < .03 ) , and in improving some aspects of social relatedness ( P < .04 ) , especially language usage ( P < .008 ) .","['Fluvoxamine', 'was', 'superior', 'to', 'placebo', 'in', 'reducing', 'repetitive', 'thoughts', 'and', 'behavior', '(', 'P', '<', '.001', ')', ',', 'maladaptive', 'behavior', '(', 'P', '<', '.001', ')', ',', 'and', 'aggression', '(', 'P', '<', '.03', ')', ',', 'and', 'in', 'improving', 'some', 'aspects', 'of', 'social', 'relatedness', '(', 'P', '<', '.04', ')', ',', 'especially', 'language', 'usage', '(', 'P', '<', '.008', ')', '.']","(7, 11)","(47, 79)",-1,hl_o,8911223,Abstract,6,test,gold,6408.0
7577,"Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior ( P < .001 ) ,",maladaptive behavior,"( P < .001 ) , and aggression ( P < .03 ) , and in improving some aspects of social relatedness ( P < .04 ) , especially language usage ( P < .008 ) .","['Fluvoxamine', 'was', 'superior', 'to', 'placebo', 'in', 'reducing', 'repetitive', 'thoughts', 'and', 'behavior', '(', 'P', '<', '.001', ')', ',', 'maladaptive', 'behavior', '(', 'P', '<', '.001', ')', ',', 'and', 'aggression', '(', 'P', '<', '.03', ')', ',', 'and', 'in', 'improving', 'some', 'aspects', 'of', 'social', 'relatedness', '(', 'P', '<', '.04', ')', ',', 'especially', 'language', 'usage', '(', 'P', '<', '.008', ')', '.']","(17, 19)","(95, 115)",-1,hl_o,8911223,Abstract,6,test,gold,6414.0
7578,"Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior ( P < .001 ) , maladaptive behavior ( P < .001 ) , and",aggression,"( P < .03 ) , and in improving some aspects of social relatedness ( P < .04 ) , especially language usage ( P < .008 ) .","['Fluvoxamine', 'was', 'superior', 'to', 'placebo', 'in', 'reducing', 'repetitive', 'thoughts', 'and', 'behavior', '(', 'P', '<', '.001', ')', ',', 'maladaptive', 'behavior', '(', 'P', '<', '.001', ')', ',', 'and', 'aggression', '(', 'P', '<', '.03', ')', ',', 'and', 'in', 'improving', 'some', 'aspects', 'of', 'social', 'relatedness', '(', 'P', '<', '.04', ')', ',', 'especially', 'language', 'usage', '(', 'P', '<', '.008', ')', '.']","(26, 27)","(135, 145)",-1,hl_o,8911223,Abstract,6,test,gold,2590.0
7579,"Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior ( P < .001 ) , maladaptive behavior ( P < .001 ) , and aggression ( P < .03 ) , and in improving some aspects of",social relatedness,"( P < .04 ) , especially language usage ( P < .008 ) .","['Fluvoxamine', 'was', 'superior', 'to', 'placebo', 'in', 'reducing', 'repetitive', 'thoughts', 'and', 'behavior', '(', 'P', '<', '.001', ')', ',', 'maladaptive', 'behavior', '(', 'P', '<', '.001', ')', ',', 'and', 'aggression', '(', 'P', '<', '.03', ')', ',', 'and', 'in', 'improving', 'some', 'aspects', 'of', 'social', 'relatedness', '(', 'P', '<', '.04', ')', ',', 'especially', 'language', 'usage', '(', 'P', '<', '.008', ')', '.']","(39, 41)","(193, 211)",-1,hl_o,8911223,Abstract,6,test,gold,2961.0
7580,"Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior ( P < .001 ) , maladaptive behavior ( P < .001 ) , and aggression ( P < .03 ) , and in improving some aspects of social relatedness ( P < .04 ) , especially",language usage,( P < .008 ) .,"['Fluvoxamine', 'was', 'superior', 'to', 'placebo', 'in', 'reducing', 'repetitive', 'thoughts', 'and', 'behavior', '(', 'P', '<', '.001', ')', ',', 'maladaptive', 'behavior', '(', 'P', '<', '.001', ')', ',', 'and', 'aggression', '(', 'P', '<', '.03', ')', ',', 'and', 'in', 'improving', 'some', 'aspects', 'of', 'social', 'relatedness', '(', 'P', '<', '.04', ')', ',', 'especially', 'language', 'usage', '(', 'P', '<', '.008', ')', '.']","(48, 50)","(237, 251)",-1,hl_o,8911223,Abstract,6,test,gold,2617.0
7581,,Treatment response,"was not correlated with age level of autistic behavior , or full-scale IQ .","['Treatment', 'response', 'was', 'not', 'correlated', 'with', 'age', 'level', 'of', 'autistic', 'behavior', ',', 'or', 'full-scale', 'IQ', '.']","(0, 2)","(0, 18)",-1,ss_o,8911223,Abstract,7,test,gold,2534.0
7582,Treatment response was not correlated with,age level of autistic behavior,", or full-scale IQ .","['Treatment', 'response', 'was', 'not', 'correlated', 'with', 'age', 'level', 'of', 'autistic', 'behavior', ',', 'or', 'full-scale', 'IQ', '.']","(6, 11)","(42, 72)",-1,ss_o,8911223,Abstract,7,test,gold,6161.0
7583,"Treatment response was not correlated with age level of autistic behavior , or",full-scale IQ .,,"['Treatment', 'response', 'was', 'not', 'correlated', 'with', 'age', 'level', 'of', 'autistic', 'behavior', ',', 'or', 'full-scale', 'IQ', '.']","(13, 16)","(78, 93)",-1,ss_o,8911223,Abstract,7,test,gold,1418.0
7584,"Other than mild sedation and nausea in a few patients ,",fluvoxamine,was well tolerated .,"['Other', 'than', 'mild', 'sedation', 'and', 'nausea', 'in', 'a', 'few', 'patients', ',', 'fluvoxamine', 'was', 'well', 'tolerated', '.']","(11, 12)","(55, 66)",-1,ss_i,8911223,Abstract,8,test,gold,5552.0
7585,Other than,mild sedation and nausea,"in a few patients , fluvoxamine was well tolerated .","['Other', 'than', 'mild', 'sedation', 'and', 'nausea', 'in', 'a', 'few', 'patients', ',', 'fluvoxamine', 'was', 'well', 'tolerated', '.']","(2, 6)","(10, 34)",-1,ss_o,8911223,Abstract,8,test,gold,7135.0
7586,"Other than mild sedation and nausea in a few patients ,",fluvoxamine,was well tolerated .,"['Other', 'than', 'mild', 'sedation', 'and', 'nausea', 'in', 'a', 'few', 'patients', ',', 'fluvoxamine', 'was', 'well', 'tolerated', '.']","(11, 12)","(55, 66)",-1,hl_i,8911223,Abstract,8,test,gold,5551.0
7587,Other than,mild sedation and nausea,"in a few patients , fluvoxamine was well tolerated .","['Other', 'than', 'mild', 'sedation', 'and', 'nausea', 'in', 'a', 'few', 'patients', ',', 'fluvoxamine', 'was', 'well', 'tolerated', '.']","(2, 6)","(10, 34)",-1,hl_o,8911223,Abstract,8,test,gold,7136.0
7588,No,"dyskinesias , adverse cardiovascular events , or seizures",occurred .,"['No', 'dyskinesias', ',', 'adverse', 'cardiovascular', 'events', ',', 'or', 'seizures', 'occurred', '.']","(1, 9)","(2, 59)",-1,ss_o,8911223,Abstract,9,test,gold,7090.0
7589,No,"dyskinesias , adverse cardiovascular events , or seizures",occurred .,"['No', 'dyskinesias', ',', 'adverse', 'cardiovascular', 'events', ',', 'or', 'seizures', 'occurred', '.']","(1, 9)","(2, 59)",-1,hl_o,8911223,Abstract,9,test,gold,7091.0
7590,CONCLUSIONS Fluvoxamine is more effective than placebo in the short-term treatment of the symptoms of,autistic disorder in adults .,,"['CONCLUSIONS', 'Fluvoxamine', 'is', 'more', 'effective', 'than', 'placebo', 'in', 'the', 'short-term', 'treatment', 'of', 'the', 'symptoms', 'of', 'autistic', 'disorder', 'in', 'adults', '.']","(15, 20)","(101, 130)",-1,ss_p,8911223,Abstract,10,test,gold,6106.0
7591,CONCLUSIONS,Fluvoxamine,is more effective than placebo in the short-term treatment of the symptoms of autistic disorder in adults .,"['CONCLUSIONS', 'Fluvoxamine', 'is', 'more', 'effective', 'than', 'placebo', 'in', 'the', 'short-term', 'treatment', 'of', 'the', 'symptoms', 'of', 'autistic', 'disorder', 'in', 'adults', '.']","(1, 2)","(11, 22)",-1,ss_i,8911223,Abstract,10,test,gold,1041.0
7592,CONCLUSIONS Fluvoxamine is more effective than,placebo,in the short-term treatment of the symptoms of autistic disorder in adults .,"['CONCLUSIONS', 'Fluvoxamine', 'is', 'more', 'effective', 'than', 'placebo', 'in', 'the', 'short-term', 'treatment', 'of', 'the', 'symptoms', 'of', 'autistic', 'disorder', 'in', 'adults', '.']","(6, 7)","(46, 53)",-1,ss_i,8911223,Abstract,10,test,gold,4281.0
7593,CONCLUSIONS Fluvoxamine is more,effective,than placebo in the short-term treatment of the symptoms of autistic disorder in adults .,"['CONCLUSIONS', 'Fluvoxamine', 'is', 'more', 'effective', 'than', 'placebo', 'in', 'the', 'short-term', 'treatment', 'of', 'the', 'symptoms', 'of', 'autistic', 'disorder', 'in', 'adults', '.']","(4, 5)","(31, 40)",-1,ss_o,8911223,Abstract,10,test,gold,840.0
7594,CONCLUSIONS Fluvoxamine is more effective than placebo in the short-term treatment of the,symptoms,of autistic disorder in adults .,"['CONCLUSIONS', 'Fluvoxamine', 'is', 'more', 'effective', 'than', 'placebo', 'in', 'the', 'short-term', 'treatment', 'of', 'the', 'symptoms', 'of', 'autistic', 'disorder', 'in', 'adults', '.']","(13, 14)","(89, 97)",-1,ss_o,8911223,Abstract,10,test,gold,3272.0
7595,CONCLUSIONS,Fluvoxamine,is more effective than placebo in the short-term treatment of the symptoms of autistic disorder in adults .,"['CONCLUSIONS', 'Fluvoxamine', 'is', 'more', 'effective', 'than', 'placebo', 'in', 'the', 'short-term', 'treatment', 'of', 'the', 'symptoms', 'of', 'autistic', 'disorder', 'in', 'adults', '.']","(1, 2)","(11, 22)",-1,hl_i,8911223,Abstract,10,test,gold,1040.0
7596,CONCLUSIONS Fluvoxamine is more effective than,placebo,in the short-term treatment of the symptoms of autistic disorder in adults .,"['CONCLUSIONS', 'Fluvoxamine', 'is', 'more', 'effective', 'than', 'placebo', 'in', 'the', 'short-term', 'treatment', 'of', 'the', 'symptoms', 'of', 'autistic', 'disorder', 'in', 'adults', '.']","(6, 7)","(46, 53)",-1,hl_i,8911223,Abstract,10,test,gold,4280.0
7597,Controlled studies of,fluvoxamine,and other potent and selective serotonin uptake inhibitors seem warranted in children and adolescents with autism .,"['Controlled', 'studies', 'of', 'fluvoxamine', 'and', 'other', 'potent', 'and', 'selective', 'serotonin', 'uptake', 'inhibitors', 'seem', 'warranted', 'in', 'children', 'and', 'adolescents', 'with', 'autism', '.']","(3, 4)","(21, 32)",-1,ss_i,8911223,Abstract,11,test,gold,5550.0
7598,Controlled studies of,fluvoxamine,and other potent and selective serotonin uptake inhibitors seem warranted in children and adolescents with autism .,"['Controlled', 'studies', 'of', 'fluvoxamine', 'and', 'other', 'potent', 'and', 'selective', 'serotonin', 'uptake', 'inhibitors', 'seem', 'warranted', 'in', 'children', 'and', 'adolescents', 'with', 'autism', '.']","(3, 4)","(21, 32)",-1,hl_i,8911223,Abstract,11,test,gold,5549.0
7599,Methodology of serial ECG classification using an adaptation of the NOVACODE for Q wave myocardial infarction in the Bypass Angioplasty Revascularization Investigation ( BARI ) .,,,"['Methodology', 'of', 'serial', 'ECG', 'classification', 'using', 'an', 'adaptation', 'of', 'the', 'NOVACODE', 'for', 'Q', 'wave', 'myocardial', 'infarction', 'in', 'the', 'Bypass', 'Angioplasty', 'Revascularization', 'Investigation', '(', 'BARI', ')', '.']",,,,,8913901,Title,0,test,gold,
7600,Serial electrocardiographic ( ECG ) changes are a critical component of the diagnostic algorithm for classification of myocardial ischemic events in large-scale clinical trials .,,,"['Serial', 'electrocardiographic', '(', 'ECG', ')', 'changes', 'are', 'a', 'critical', 'component', 'of', 'the', 'diagnostic', 'algorithm', 'for', 'classification', 'of', 'myocardial', 'ischemic', 'events', 'in', 'large-scale', 'clinical', 'trials', '.']",,,,,8913901,Abstract,0,test,gold,
7601,"This study describes a computerized serial ECG classification program developed at the St. Louis University Core ECG Laboratory for use in the Bypass Angioplasty Revascularization Investigation ( BARI ) trial , in which",patients with multivessel coronary artery disease,were randomized to receive either coronary artery bypass grafting or percutaneous transluminal coronary angioplasty .,"['This', 'study', 'describes', 'a', 'computerized', 'serial', 'ECG', 'classification', 'program', 'developed', 'at', 'the', 'St.', 'Louis', 'University', 'Core', 'ECG', 'Laboratory', 'for', 'use', 'in', 'the', 'Bypass', 'Angioplasty', 'Revascularization', 'Investigation', '(', 'BARI', ')', 'trial', ',', 'in', 'which', 'patients', 'with', 'multivessel', 'coronary', 'artery', 'disease', 'were', 'randomized', 'to', 'receive', 'either', 'coronary', 'artery', 'bypass', 'grafting', 'or', 'percutaneous', 'transluminal', 'coronary', 'angioplasty', '.']","(33, 39)","(219, 268)",-1,ss_p,8913901,Abstract,1,test,gold,6735.0
7602,"This study describes a computerized serial ECG classification program developed at the St. Louis University Core ECG Laboratory for use in the Bypass Angioplasty Revascularization Investigation ( BARI ) trial , in which patients with multivessel coronary artery disease were randomized to receive either",coronary artery bypass grafting,or percutaneous transluminal coronary angioplasty .,"['This', 'study', 'describes', 'a', 'computerized', 'serial', 'ECG', 'classification', 'program', 'developed', 'at', 'the', 'St.', 'Louis', 'University', 'Core', 'ECG', 'Laboratory', 'for', 'use', 'in', 'the', 'Bypass', 'Angioplasty', 'Revascularization', 'Investigation', '(', 'BARI', ')', 'trial', ',', 'in', 'which', 'patients', 'with', 'multivessel', 'coronary', 'artery', 'disease', 'were', 'randomized', 'to', 'receive', 'either', 'coronary', 'artery', 'bypass', 'grafting', 'or', 'percutaneous', 'transluminal', 'coronary', 'angioplasty', '.']","(44, 48)","(303, 334)",-1,ss_i,8913901,Abstract,1,test,gold,6747.0
7603,"This study describes a computerized serial ECG classification program developed at the St. Louis University Core ECG Laboratory for use in the Bypass Angioplasty Revascularization Investigation ( BARI ) trial , in which patients with multivessel coronary artery disease were randomized to receive either coronary artery bypass grafting or",percutaneous transluminal coronary angioplasty .,,"['This', 'study', 'describes', 'a', 'computerized', 'serial', 'ECG', 'classification', 'program', 'developed', 'at', 'the', 'St.', 'Louis', 'University', 'Core', 'ECG', 'Laboratory', 'for', 'use', 'in', 'the', 'Bypass', 'Angioplasty', 'Revascularization', 'Investigation', '(', 'BARI', ')', 'trial', ',', 'in', 'which', 'patients', 'with', 'multivessel', 'coronary', 'artery', 'disease', 'were', 'randomized', 'to', 'receive', 'either', 'coronary', 'artery', 'bypass', 'grafting', 'or', 'percutaneous', 'transluminal', 'coronary', 'angioplasty', '.']","(49, 54)","(338, 386)",-1,ss_i,8913901,Abstract,1,test,gold,6749.0
7604,"This study describes a computerized serial ECG classification program developed at the St. Louis University Core ECG Laboratory for use in the Bypass Angioplasty Revascularization Investigation ( BARI ) trial , in which",patients with multivessel coronary artery disease,were randomized to receive either coronary artery bypass grafting or percutaneous transluminal coronary angioplasty .,"['This', 'study', 'describes', 'a', 'computerized', 'serial', 'ECG', 'classification', 'program', 'developed', 'at', 'the', 'St.', 'Louis', 'University', 'Core', 'ECG', 'Laboratory', 'for', 'use', 'in', 'the', 'Bypass', 'Angioplasty', 'Revascularization', 'Investigation', '(', 'BARI', ')', 'trial', ',', 'in', 'which', 'patients', 'with', 'multivessel', 'coronary', 'artery', 'disease', 'were', 'randomized', 'to', 'receive', 'either', 'coronary', 'artery', 'bypass', 'grafting', 'or', 'percutaneous', 'transluminal', 'coronary', 'angioplasty', '.']","(33, 39)","(219, 268)",-1,hl_p,8913901,Abstract,1,test,gold,6736.0
7605,"This study describes a computerized serial ECG classification program developed at the St. Louis University Core ECG Laboratory for use in the Bypass Angioplasty Revascularization Investigation ( BARI ) trial , in which patients with multivessel coronary artery disease were randomized to receive either",coronary artery bypass grafting,or percutaneous transluminal coronary angioplasty .,"['This', 'study', 'describes', 'a', 'computerized', 'serial', 'ECG', 'classification', 'program', 'developed', 'at', 'the', 'St.', 'Louis', 'University', 'Core', 'ECG', 'Laboratory', 'for', 'use', 'in', 'the', 'Bypass', 'Angioplasty', 'Revascularization', 'Investigation', '(', 'BARI', ')', 'trial', ',', 'in', 'which', 'patients', 'with', 'multivessel', 'coronary', 'artery', 'disease', 'were', 'randomized', 'to', 'receive', 'either', 'coronary', 'artery', 'bypass', 'grafting', 'or', 'percutaneous', 'transluminal', 'coronary', 'angioplasty', '.']","(44, 48)","(303, 334)",-1,hl_i,8913901,Abstract,1,test,gold,6748.0
7606,"This study describes a computerized serial ECG classification program developed at the St. Louis University Core ECG Laboratory for use in the Bypass Angioplasty Revascularization Investigation ( BARI ) trial , in which patients with multivessel coronary artery disease were randomized to receive either coronary artery bypass grafting or",percutaneous transluminal coronary angioplasty .,,"['This', 'study', 'describes', 'a', 'computerized', 'serial', 'ECG', 'classification', 'program', 'developed', 'at', 'the', 'St.', 'Louis', 'University', 'Core', 'ECG', 'Laboratory', 'for', 'use', 'in', 'the', 'Bypass', 'Angioplasty', 'Revascularization', 'Investigation', '(', 'BARI', ')', 'trial', ',', 'in', 'which', 'patients', 'with', 'multivessel', 'coronary', 'artery', 'disease', 'were', 'randomized', 'to', 'receive', 'either', 'coronary', 'artery', 'bypass', 'grafting', 'or', 'percutaneous', 'transluminal', 'coronary', 'angioplasty', '.']","(49, 54)","(338, 386)",-1,hl_i,8913901,Abstract,1,test,gold,6750.0
7607,The St. Louis University program detects and codes,"serial changes in Q , ST , and T wave items according to Minnesota code ( MC ) criteria",using a modified NOVACODE hierarchical classification system .,"['The', 'St.', 'Louis', 'University', 'program', 'detects', 'and', 'codes', 'serial', 'changes', 'in', 'Q', ',', 'ST', ',', 'and', 'T', 'wave', 'items', 'according', 'to', 'Minnesota', 'code', '(', 'MC', ')', 'criteria', 'using', 'a', 'modified', 'NOVACODE', 'hierarchical', 'classification', 'system', '.']","(8, 27)","(50, 137)",-1,ss_o,8913901,Abstract,2,test,gold,6452.0
7608,The St. Louis University program detects and codes,"serial changes in Q , ST , and T wave items",according to Minnesota code ( MC ) criteria using a modified NOVACODE hierarchical classification system .,"['The', 'St.', 'Louis', 'University', 'program', 'detects', 'and', 'codes', 'serial', 'changes', 'in', 'Q', ',', 'ST', ',', 'and', 'T', 'wave', 'items', 'according', 'to', 'Minnesota', 'code', '(', 'MC', ')', 'criteria', 'using', 'a', 'modified', 'NOVACODE', 'hierarchical', 'classification', 'system', '.']","(8, 19)","(50, 93)",-1,hl_o,8913901,Abstract,2,test,gold,6453.0
7609,Measurements using a seven-power calibrated coding loupe are used to generate the MC from a customized software program .,,,"['Measurements', 'using', 'a', 'seven-power', 'calibrated', 'coding', 'loupe', 'are', 'used', 'to', 'generate', 'the', 'MC', 'from', 'a', 'customized', 'software', 'program', '.']",,,,,8913901,Abstract,3,test,gold,
7610,Significant minor or major,changes,are detected by the serial comparison program and referred to a physician coder for verification .,"['Significant', 'minor', 'or', 'major', 'changes', 'are', 'detected', 'by', 'the', 'serial', 'comparison', 'program', 'and', 'referred', 'to', 'a', 'physician', 'coder', 'for', 'verification', '.']","(4, 5)","(26, 33)",-1,ss_o,8913901,Abstract,4,test,gold,967.0
7611,Serial comparison coding rules are used to adjust for weaknesses in the standard MC classification system resulting from instability at decision boundaries .,,,"['Serial', 'comparison', 'coding', 'rules', 'are', 'used', 'to', 'adjust', 'for', 'weaknesses', 'in', 'the', 'standard', 'MC', 'classification', 'system', 'resulting', 'from', 'instability', 'at', 'decision', 'boundaries', '.']",,,,,8913901,Abstract,5,test,gold,
7612,Of,"4,244 BARI randomized and registry study participants with follow-up ECGs received at the Core ECG Laboratory as of March 1995",", a grade 2 MC Q wave progression was noted in 568 participants ( 13.4 % ) using MC criteria alone , as compared with 367 ( 8.6 % ) after the St. Louis University coding rules were applied .","['Of', '4,244', 'BARI', 'randomized', 'and', 'registry', 'study', 'participants', 'with', 'follow-up', 'ECGs', 'received', 'at', 'the', 'Core', 'ECG', 'Laboratory', 'as', 'of', 'March', '1995', ',', 'a', 'grade', '2', 'MC', 'Q', 'wave', 'progression', 'was', 'noted', 'in', '568', 'participants', '(', '13.4', '%', ')', 'using', 'MC', 'criteria', 'alone', ',', 'as', 'compared', 'with', '367', '(', '8.6', '%', ')', 'after', 'the', 'St.', 'Louis', 'University', 'coding', 'rules', 'were', 'applied', '.']","(1, 21)","(2, 128)",-1,ss_p,8913901,Abstract,6,test,gold,5902.0
7613,"Of 4,244 BARI randomized and registry study participants with follow-up ECGs received at the Core ECG Laboratory as of March 1995 , a grade 2",MC Q wave progression,"was noted in 568 participants ( 13.4 % ) using MC criteria alone , as compared with 367 ( 8.6 % ) after the St. Louis University coding rules were applied .","['Of', '4,244', 'BARI', 'randomized', 'and', 'registry', 'study', 'participants', 'with', 'follow-up', 'ECGs', 'received', 'at', 'the', 'Core', 'ECG', 'Laboratory', 'as', 'of', 'March', '1995', ',', 'a', 'grade', '2', 'MC', 'Q', 'wave', 'progression', 'was', 'noted', 'in', '568', 'participants', '(', '13.4', '%', ')', 'using', 'MC', 'criteria', 'alone', ',', 'as', 'compared', 'with', '367', '(', '8.6', '%', ')', 'after', 'the', 'St.', 'Louis', 'University', 'coding', 'rules', 'were', 'applied', '.']","(25, 29)","(141, 162)",-1,ss_o,8913901,Abstract,6,test,gold,3311.0
7614,Of,"4,244","BARI randomized and registry study participants with follow-up ECGs received at the Core ECG Laboratory as of March 1995 , a grade 2 MC Q wave progression was noted in 568 participants ( 13.4 % ) using MC criteria alone , as compared with 367 ( 8.6 % ) after the St. Louis University coding rules were applied .","['Of', '4,244', 'BARI', 'randomized', 'and', 'registry', 'study', 'participants', 'with', 'follow-up', 'ECGs', 'received', 'at', 'the', 'Core', 'ECG', 'Laboratory', 'as', 'of', 'March', '1995', ',', 'a', 'grade', '2', 'MC', 'Q', 'wave', 'progression', 'was', 'noted', 'in', '568', 'participants', '(', '13.4', '%', ')', 'using', 'MC', 'criteria', 'alone', ',', 'as', 'compared', 'with', '367', '(', '8.6', '%', ')', 'after', 'the', 'St.', 'Louis', 'University', 'coding', 'rules', 'were', 'applied', '.']","(1, 2)","(2, 7)",-1,hl_p,8913901,Abstract,6,test,gold,
7615,"Of 4,244 BARI randomized and",registry study participants with follow-up ECGs received at the Core ECG Laboratory as of March 1995,", a grade 2 MC Q wave progression was noted in 568 participants ( 13.4 % ) using MC criteria alone , as compared with 367 ( 8.6 % ) after the St. Louis University coding rules were applied .","['Of', '4,244', 'BARI', 'randomized', 'and', 'registry', 'study', 'participants', 'with', 'follow-up', 'ECGs', 'received', 'at', 'the', 'Core', 'ECG', 'Laboratory', 'as', 'of', 'March', '1995', ',', 'a', 'grade', '2', 'MC', 'Q', 'wave', 'progression', 'was', 'noted', 'in', '568', 'participants', '(', '13.4', '%', ')', 'using', 'MC', 'criteria', 'alone', ',', 'as', 'compared', 'with', '367', '(', '8.6', '%', ')', 'after', 'the', 'St.', 'Louis', 'University', 'coding', 'rules', 'were', 'applied', '.']","(5, 21)","(28, 128)",-1,hl_p,8913901,Abstract,6,test,gold,5903.0
7616,The incidence of grade 1,MC Q wave progressions,"was 16.4 % ( 697/4,244 ) versus 6.1 % ( 259/4,244 ) when the St. Louis University program was applied .","['The', 'incidence', 'of', 'grade', '1', 'MC', 'Q', 'wave', 'progressions', 'was', '16.4', '%', '(', '697/4,244', ')', 'versus', '6.1', '%', '(', '259/4,244', ')', 'when', 'the', 'St.', 'Louis', 'University', 'program', 'was', 'applied', '.']","(5, 9)","(24, 46)",-1,ss_o,8913901,Abstract,7,test,gold,3312.0
7617,Intraobserver variability for grade 2,Q wave progression codes,determined from a sample of 812 serial .,"['Intraobserver', 'variability', 'for', 'grade', '2', 'Q', 'wave', 'progression', 'codes', 'determined', 'from', 'a', 'sample', 'of', '812', 'serial', '.']","(5, 9)","(37, 61)",-1,ss_o,8913901,Abstract,8,test,gold,3310.0
7618,Analysis of,prevention program,effectiveness with clustered data using generalized estimating equations .,"['Analysis', 'of', 'prevention', 'program', 'effectiveness', 'with', 'clustered', 'data', 'using', 'generalized', 'estimating', 'equations', '.']","(2, 4)","(11, 29)",-1,ss_i,8916620,Title,0,test,gold,4041.0
7619,Analysis of prevention program,effectiveness,with clustered data using generalized estimating equations .,"['Analysis', 'of', 'prevention', 'program', 'effectiveness', 'with', 'clustered', 'data', 'using', 'generalized', 'estimating', 'equations', '.']","(4, 5)","(30, 43)",-1,ss_o,8916620,Title,0,test,gold,384.0
7620,Analysis of,prevention program,effectiveness with clustered data using generalized estimating equations .,"['Analysis', 'of', 'prevention', 'program', 'effectiveness', 'with', 'clustered', 'data', 'using', 'generalized', 'estimating', 'equations', '.']","(2, 4)","(11, 29)",-1,hl_p,8916620,Title,0,test,gold,4042.0
7621,Experimental studies of,prevention programs,often randomize clusters of individuals rather than individuals to treatment conditions .,"['Experimental', 'studies', 'of', 'prevention', 'programs', 'often', 'randomize', 'clusters', 'of', 'individuals', 'rather', 'than', 'individuals', 'to', 'treatment', 'conditions', '.']","(3, 5)","(23, 42)",-1,ss_i,8916620,Abstract,0,test,gold,4040.0
7622,"When the correlation among individuals within clusters is not accounted for in statistical analysis , the standard errors are biased , potentially resulting in misleading conclusions about the significance of treatment effects .",,,"['When', 'the', 'correlation', 'among', 'individuals', 'within', 'clusters', 'is', 'not', 'accounted', 'for', 'in', 'statistical', 'analysis', ',', 'the', 'standard', 'errors', 'are', 'biased', ',', 'potentially', 'resulting', 'in', 'misleading', 'conclusions', 'about', 'the', 'significance', 'of', 'treatment', 'effects', '.']",,,,,8916620,Abstract,1,test,gold,
7623,This study demonstrates the,generalized estimating equations ( GEE ),"method , focusing specifically on the GEE-independent method , to control for within-cluster correlation in regression models with either continuous or binary outcomes .","['This', 'study', 'demonstrates', 'the', 'generalized', 'estimating', 'equations', '(', 'GEE', ')', 'method', ',', 'focusing', 'specifically', 'on', 'the', 'GEE-independent', 'method', ',', 'to', 'control', 'for', 'within-cluster', 'correlation', 'in', 'regression', 'models', 'with', 'either', 'continuous', 'or', 'binary', 'outcomes', '.']","(4, 10)","(27, 67)",-1,ss_i,8916620,Abstract,2,test,gold,1832.0
7624,"This study demonstrates the generalized estimating equations ( GEE ) method , focusing specifically on the",GEE-independent,"method , to control for within-cluster correlation in regression models with either continuous or binary outcomes .","['This', 'study', 'demonstrates', 'the', 'generalized', 'estimating', 'equations', '(', 'GEE', ')', 'method', ',', 'focusing', 'specifically', 'on', 'the', 'GEE-independent', 'method', ',', 'to', 'control', 'for', 'within-cluster', 'correlation', 'in', 'regression', 'models', 'with', 'either', 'continuous', 'or', 'binary', 'outcomes', '.']","(16, 17)","(106, 121)",-1,ss_i,8916620,Abstract,2,test,gold,
7625,This study demonstrates the,generalized estimating equations ( GEE ),"method , focusing specifically on the GEE-independent method , to control for within-cluster correlation in regression models with either continuous or binary outcomes .","['This', 'study', 'demonstrates', 'the', 'generalized', 'estimating', 'equations', '(', 'GEE', ')', 'method', ',', 'focusing', 'specifically', 'on', 'the', 'GEE-independent', 'method', ',', 'to', 'control', 'for', 'within-cluster', 'correlation', 'in', 'regression', 'models', 'with', 'either', 'continuous', 'or', 'binary', 'outcomes', '.']","(4, 10)","(27, 67)",-1,hl_i,8916620,Abstract,2,test,gold,1833.0
7626,"This study demonstrates the generalized estimating equations ( GEE ) method , focusing specifically on the",GEE-independent,"method , to control for within-cluster correlation in regression models with either continuous or binary outcomes .","['This', 'study', 'demonstrates', 'the', 'generalized', 'estimating', 'equations', '(', 'GEE', ')', 'method', ',', 'focusing', 'specifically', 'on', 'the', 'GEE-independent', 'method', ',', 'to', 'control', 'for', 'within-cluster', 'correlation', 'in', 'regression', 'models', 'with', 'either', 'continuous', 'or', 'binary', 'outcomes', '.']","(16, 17)","(106, 121)",-1,hl_i,8916620,Abstract,2,test,gold,
7627,The,GEE-independent,method yields consistent and robust variance estimates .,"['The', 'GEE-independent', 'method', 'yields', 'consistent', 'and', 'robust', 'variance', 'estimates', '.']","(1, 2)","(3, 18)",-1,ss_i,8916620,Abstract,3,test,gold,
7628,The,GEE-independent,method yields consistent and robust variance estimates .,"['The', 'GEE-independent', 'method', 'yields', 'consistent', 'and', 'robust', 'variance', 'estimates', '.']","(1, 2)","(3, 18)",-1,hl_i,8916620,Abstract,3,test,gold,
7629,"Data from project DARE , a",youth substance abuse prevention program,", are used for illustration .","['Data', 'from', 'project', 'DARE', ',', 'a', 'youth', 'substance', 'abuse', 'prevention', 'program', ',', 'are', 'used', 'for', 'illustration', '.']","(6, 11)","(26, 66)",-1,hl_p,8916620,Abstract,4,test,gold,4036.0
7630,Prevention of spinal anesthesia-induced hypotension,in the elderly :,"comparison between preanesthetic administration of crystalloids , colloids , and no prehydration .","['Prevention', 'of', 'spinal', 'anesthesia-induced', 'hypotension', 'in', 'the', 'elderly', ':', 'comparison', 'between', 'preanesthetic', 'administration', 'of', 'crystalloids', ',', 'colloids', ',', 'and', 'no', 'prehydration', '.']","(5, 9)","(51, 67)",-1,ss_p,8989009,Title,0,test,gold,2214.0
7631,Prevention of spinal anesthesia-induced hypotension in the elderly : comparison between preanesthetic administration of,"crystalloids , colloids",", and no prehydration .","['Prevention', 'of', 'spinal', 'anesthesia-induced', 'hypotension', 'in', 'the', 'elderly', ':', 'comparison', 'between', 'preanesthetic', 'administration', 'of', 'crystalloids', ',', 'colloids', ',', 'and', 'no', 'prehydration', '.']","(14, 17)","(119, 142)",-1,ss_i,8989009,Title,0,test,gold,314.0
7632,"Prevention of spinal anesthesia-induced hypotension in the elderly : comparison between preanesthetic administration of crystalloids , colloids , and",no prehydration .,,"['Prevention', 'of', 'spinal', 'anesthesia-induced', 'hypotension', 'in', 'the', 'elderly', ':', 'comparison', 'between', 'preanesthetic', 'administration', 'of', 'crystalloids', ',', 'colloids', ',', 'and', 'no', 'prehydration', '.']","(19, 22)","(149, 166)",-1,ss_i,8989009,Title,0,test,gold,1142.0
7633,Prevention of spinal anesthesia-induced hypotension in,the elderly,": comparison between preanesthetic administration of crystalloids , colloids , and no prehydration .","['Prevention', 'of', 'spinal', 'anesthesia-induced', 'hypotension', 'in', 'the', 'elderly', ':', 'comparison', 'between', 'preanesthetic', 'administration', 'of', 'crystalloids', ',', 'colloids', ',', 'and', 'no', 'prehydration', '.']","(6, 8)","(54, 65)",-1,hl_p,8989009,Title,0,test,gold,2215.0
7634,Prevention of spinal anesthesia-induced hypotension in the elderly : comparison between preanesthetic administration of,crystalloids,", colloids , and no prehydration .","['Prevention', 'of', 'spinal', 'anesthesia-induced', 'hypotension', 'in', 'the', 'elderly', ':', 'comparison', 'between', 'preanesthetic', 'administration', 'of', 'crystalloids', ',', 'colloids', ',', 'and', 'no', 'prehydration', '.']","(14, 15)","(119, 131)",-1,hl_i,8989009,Title,0,test,gold,
7635,"Prevention of spinal anesthesia-induced hypotension in the elderly : comparison between preanesthetic administration of crystalloids ,",colloids,", and no prehydration .","['Prevention', 'of', 'spinal', 'anesthesia-induced', 'hypotension', 'in', 'the', 'elderly', ':', 'comparison', 'between', 'preanesthetic', 'administration', 'of', 'crystalloids', ',', 'colloids', ',', 'and', 'no', 'prehydration', '.']","(16, 17)","(134, 142)",-1,hl_i,8989009,Title,0,test,gold,315.0
7636,"Prevention of spinal anesthesia-induced hypotension in the elderly : comparison between preanesthetic administration of crystalloids , colloids , and",no prehydration .,,"['Prevention', 'of', 'spinal', 'anesthesia-induced', 'hypotension', 'in', 'the', 'elderly', ':', 'comparison', 'between', 'preanesthetic', 'administration', 'of', 'crystalloids', ',', 'colloids', ',', 'and', 'no', 'prehydration', '.']","(19, 22)","(149, 166)",-1,hl_i,8989009,Title,0,test,gold,1143.0
7637,The practice of routinely prehydrating patients by infusing a,crystalloid,"or colloid solution ( up to 1.0 L/70 kg ) for prevention of spinal anesthesia-induced hypotension has been challenged recently , after several reports of failure to demonstrate its efficacy in young women .","['The', 'practice', 'of', 'routinely', 'prehydrating', 'patients', 'by', 'infusing', 'a', 'crystalloid', 'or', 'colloid', 'solution', '(', 'up', 'to', '1.0', 'L/70', 'kg', ')', 'for', 'prevention', 'of', 'spinal', 'anesthesia-induced', 'hypotension', 'has', 'been', 'challenged', 'recently', ',', 'after', 'several', 'reports', 'of', 'failure', 'to', 'demonstrate', 'its', 'efficacy', 'in', 'young', 'women', '.']","(9, 10)","(61, 72)",-1,ss_i,8989009,Abstract,0,test,gold,176.0
7638,The practice of routinely prehydrating patients by infusing a crystalloid or,colloid solution,"( up to 1.0 L/70 kg ) for prevention of spinal anesthesia-induced hypotension has been challenged recently , after several reports of failure to demonstrate its efficacy in young women .","['The', 'practice', 'of', 'routinely', 'prehydrating', 'patients', 'by', 'infusing', 'a', 'crystalloid', 'or', 'colloid', 'solution', '(', 'up', 'to', '1.0', 'L/70', 'kg', ')', 'for', 'prevention', 'of', 'spinal', 'anesthesia-induced', 'hypotension', 'has', 'been', 'challenged', 'recently', ',', 'after', 'several', 'reports', 'of', 'failure', 'to', 'demonstrate', 'its', 'efficacy', 'in', 'young', 'women', '.']","(11, 13)","(76, 92)",-1,ss_i,8989009,Abstract,0,test,gold,302.0
7639,"The practice of routinely prehydrating patients by infusing a crystalloid or colloid solution ( up to 1.0 L/70 kg ) for prevention of spinal anesthesia-induced hypotension has been challenged recently , after several reports of failure to demonstrate its",efficacy,in young women .,"['The', 'practice', 'of', 'routinely', 'prehydrating', 'patients', 'by', 'infusing', 'a', 'crystalloid', 'or', 'colloid', 'solution', '(', 'up', 'to', '1.0', 'L/70', 'kg', ')', 'for', 'prevention', 'of', 'spinal', 'anesthesia-induced', 'hypotension', 'has', 'been', 'challenged', 'recently', ',', 'after', 'several', 'reports', 'of', 'failure', 'to', 'demonstrate', 'its', 'efficacy', 'in', 'young', 'women', '.']","(39, 40)","(254, 262)",-1,ss_o,8989009,Abstract,0,test,gold,4780.0
7640,The practice of routinely prehydrating patients by infusing a,crystalloid,"or colloid solution ( up to 1.0 L/70 kg ) for prevention of spinal anesthesia-induced hypotension has been challenged recently , after several reports of failure to demonstrate its efficacy in young women .","['The', 'practice', 'of', 'routinely', 'prehydrating', 'patients', 'by', 'infusing', 'a', 'crystalloid', 'or', 'colloid', 'solution', '(', 'up', 'to', '1.0', 'L/70', 'kg', ')', 'for', 'prevention', 'of', 'spinal', 'anesthesia-induced', 'hypotension', 'has', 'been', 'challenged', 'recently', ',', 'after', 'several', 'reports', 'of', 'failure', 'to', 'demonstrate', 'its', 'efficacy', 'in', 'young', 'women', '.']","(9, 10)","(61, 72)",-1,hl_i,8989009,Abstract,0,test,gold,177.0
7641,The practice of routinely prehydrating patients by infusing a crystalloid or,colloid solution,"( up to 1.0 L/70 kg ) for prevention of spinal anesthesia-induced hypotension has been challenged recently , after several reports of failure to demonstrate its efficacy in young women .","['The', 'practice', 'of', 'routinely', 'prehydrating', 'patients', 'by', 'infusing', 'a', 'crystalloid', 'or', 'colloid', 'solution', '(', 'up', 'to', '1.0', 'L/70', 'kg', ')', 'for', 'prevention', 'of', 'spinal', 'anesthesia-induced', 'hypotension', 'has', 'been', 'challenged', 'recently', ',', 'after', 'several', 'reports', 'of', 'failure', 'to', 'demonstrate', 'its', 'efficacy', 'in', 'young', 'women', '.']","(11, 13)","(76, 92)",-1,hl_i,8989009,Abstract,0,test,gold,303.0
7642,We compared the incidence and frequency of hypotension and vasopressor therapy after spinal anesthesia and no prehydration with crystalloid and colloid prehydration,in elderly patients .,,"['We', 'compared', 'the', 'incidence', 'and', 'frequency', 'of', 'hypotension', 'and', 'vasopressor', 'therapy', 'after', 'spinal', 'anesthesia', 'and', 'no', 'prehydration', 'with', 'crystalloid', 'and', 'colloid', 'prehydration', 'in', 'elderly', 'patients', '.']","(22, 26)","(164, 185)",-1,ss_p,8989009,Abstract,1,test,gold,3757.0
7643,We compared the incidence and frequency of hypotension and vasopressor therapy after spinal anesthesia and,no prehydration,with crystalloid and colloid prehydration in elderly patients .,"['We', 'compared', 'the', 'incidence', 'and', 'frequency', 'of', 'hypotension', 'and', 'vasopressor', 'therapy', 'after', 'spinal', 'anesthesia', 'and', 'no', 'prehydration', 'with', 'crystalloid', 'and', 'colloid', 'prehydration', 'in', 'elderly', 'patients', '.']","(15, 17)","(106, 121)",-1,ss_i,8989009,Abstract,1,test,gold,1141.0
7644,We compared the incidence and frequency of hypotension and vasopressor therapy after spinal anesthesia and no prehydration with,crystalloid,and colloid prehydration in elderly patients .,"['We', 'compared', 'the', 'incidence', 'and', 'frequency', 'of', 'hypotension', 'and', 'vasopressor', 'therapy', 'after', 'spinal', 'anesthesia', 'and', 'no', 'prehydration', 'with', 'crystalloid', 'and', 'colloid', 'prehydration', 'in', 'elderly', 'patients', '.']","(18, 19)","(127, 138)",-1,ss_i,8989009,Abstract,1,test,gold,175.0
7645,We compared the incidence and frequency of hypotension and vasopressor therapy after spinal anesthesia and no prehydration with crystalloid and,colloid prehydration,in elderly patients .,"['We', 'compared', 'the', 'incidence', 'and', 'frequency', 'of', 'hypotension', 'and', 'vasopressor', 'therapy', 'after', 'spinal', 'anesthesia', 'and', 'no', 'prehydration', 'with', 'crystalloid', 'and', 'colloid', 'prehydration', 'in', 'elderly', 'patients', '.']","(20, 22)","(143, 163)",-1,ss_i,8989009,Abstract,1,test,gold,312.0
7646,We compared the,incidence and frequency of hypotension and vasopressor therapy,after spinal anesthesia and no prehydration with crystalloid and colloid prehydration in elderly patients .,"['We', 'compared', 'the', 'incidence', 'and', 'frequency', 'of', 'hypotension', 'and', 'vasopressor', 'therapy', 'after', 'spinal', 'anesthesia', 'and', 'no', 'prehydration', 'with', 'crystalloid', 'and', 'colloid', 'prehydration', 'in', 'elderly', 'patients', '.']","(3, 11)","(15, 77)",-1,ss_o,8989009,Abstract,1,test,gold,7105.0
7647,We compared the incidence and frequency of hypotension and vasopressor therapy after spinal anesthesia and no prehydration with crystalloid and colloid prehydration in,elderly patients,.,"['We', 'compared', 'the', 'incidence', 'and', 'frequency', 'of', 'hypotension', 'and', 'vasopressor', 'therapy', 'after', 'spinal', 'anesthesia', 'and', 'no', 'prehydration', 'with', 'crystalloid', 'and', 'colloid', 'prehydration', 'in', 'elderly', 'patients', '.']","(23, 25)","(167, 183)",-1,hl_p,8989009,Abstract,1,test,gold,3758.0
7648,We compared the incidence and frequency of hypotension and vasopressor therapy after spinal anesthesia and,no prehydration,with crystalloid and colloid prehydration in elderly patients .,"['We', 'compared', 'the', 'incidence', 'and', 'frequency', 'of', 'hypotension', 'and', 'vasopressor', 'therapy', 'after', 'spinal', 'anesthesia', 'and', 'no', 'prehydration', 'with', 'crystalloid', 'and', 'colloid', 'prehydration', 'in', 'elderly', 'patients', '.']","(15, 17)","(106, 121)",-1,hl_i,8989009,Abstract,1,test,gold,1140.0
7649,We compared the incidence and frequency of hypotension and vasopressor therapy after spinal anesthesia and no prehydration with,crystalloid,and colloid prehydration in elderly patients .,"['We', 'compared', 'the', 'incidence', 'and', 'frequency', 'of', 'hypotension', 'and', 'vasopressor', 'therapy', 'after', 'spinal', 'anesthesia', 'and', 'no', 'prehydration', 'with', 'crystalloid', 'and', 'colloid', 'prehydration', 'in', 'elderly', 'patients', '.']","(18, 19)","(127, 138)",-1,hl_i,8989009,Abstract,1,test,gold,174.0
7650,We compared the incidence and frequency of hypotension and vasopressor therapy after spinal anesthesia and no prehydration with crystalloid and,colloid prehydration,in elderly patients .,"['We', 'compared', 'the', 'incidence', 'and', 'frequency', 'of', 'hypotension', 'and', 'vasopressor', 'therapy', 'after', 'spinal', 'anesthesia', 'and', 'no', 'prehydration', 'with', 'crystalloid', 'and', 'colloid', 'prehydration', 'in', 'elderly', 'patients', '.']","(20, 22)","(143, 163)",-1,hl_i,8989009,Abstract,1,test,gold,313.0
7651,We compared the,incidence and frequency of hypotension and vasopressor therapy,after spinal anesthesia and no prehydration with crystalloid and colloid prehydration in elderly patients .,"['We', 'compared', 'the', 'incidence', 'and', 'frequency', 'of', 'hypotension', 'and', 'vasopressor', 'therapy', 'after', 'spinal', 'anesthesia', 'and', 'no', 'prehydration', 'with', 'crystalloid', 'and', 'colloid', 'prehydration', 'in', 'elderly', 'patients', '.']","(3, 11)","(15, 77)",-1,hl_o,8989009,Abstract,1,test,gold,7106.0
7652,,Eighty-five ASA grade I or II patients ( aged 60-89 yr ) for elective total hip replacement,"were randomized to receive 500 mL crystalloid solution ( Hartmanns , n = 29 ) , 500 mL colloid ( Haemaccel , n = 28 ) , or no prehydration ( n = 28 ) over 10 min prior to spinal anesthesia .","['Eighty-five', 'ASA', 'grade', 'I', 'or', 'II', 'patients', '(', 'aged', '60-89', 'yr', ')', 'for', 'elective', 'total', 'hip', 'replacement', 'were', 'randomized', 'to', 'receive', '500', 'mL', 'crystalloid', 'solution', '(', 'Hartmanns', ',', 'n', '=', '29', ')', ',', '500', 'mL', 'colloid', '(', 'Haemaccel', ',', 'n', '=', '28', ')', ',', 'or', 'no', 'prehydration', '(', 'n', '=', '28', ')', 'over', '10', 'min', 'prior', 'to', 'spinal', 'anesthesia', '.']","(0, 17)","(0, 91)",-1,ss_p,8989009,Abstract,2,test,gold,5865.0
7653,Eighty-five ASA grade I or II patients ( aged 60-89 yr ) for elective total hip replacement were randomized to receive 500 mL,crystalloid solution ( Hartmanns,", n = 29 ) , 500 mL colloid ( Haemaccel , n = 28 ) , or no prehydration ( n = 28 ) over 10 min prior to spinal anesthesia .","['Eighty-five', 'ASA', 'grade', 'I', 'or', 'II', 'patients', '(', 'aged', '60-89', 'yr', ')', 'for', 'elective', 'total', 'hip', 'replacement', 'were', 'randomized', 'to', 'receive', '500', 'mL', 'crystalloid', 'solution', '(', 'Hartmanns', ',', 'n', '=', '29', ')', ',', '500', 'mL', 'colloid', '(', 'Haemaccel', ',', 'n', '=', '28', ')', ',', 'or', 'no', 'prehydration', '(', 'n', '=', '28', ')', 'over', '10', 'min', 'prior', 'to', 'spinal', 'anesthesia', '.']","(23, 27)","(125, 157)",-1,ss_i,8989009,Abstract,2,test,gold,304.0
7654,"Eighty-five ASA grade I or II patients ( aged 60-89 yr ) for elective total hip replacement were randomized to receive 500 mL crystalloid solution ( Hartmanns , n = 29 ) , 500 mL",colloid ( Haemaccel,", n = 28 ) , or no prehydration ( n = 28 ) over 10 min prior to spinal anesthesia .","['Eighty-five', 'ASA', 'grade', 'I', 'or', 'II', 'patients', '(', 'aged', '60-89', 'yr', ')', 'for', 'elective', 'total', 'hip', 'replacement', 'were', 'randomized', 'to', 'receive', '500', 'mL', 'crystalloid', 'solution', '(', 'Hartmanns', ',', 'n', '=', '29', ')', ',', '500', 'mL', 'colloid', '(', 'Haemaccel', ',', 'n', '=', '28', ')', ',', 'or', 'no', 'prehydration', '(', 'n', '=', '28', ')', 'over', '10', 'min', 'prior', 'to', 'spinal', 'anesthesia', '.']","(35, 38)","(178, 197)",-1,ss_i,8989009,Abstract,2,test,gold,311.0
7655,"Eighty-five ASA grade I or II patients ( aged 60-89 yr ) for elective total hip replacement were randomized to receive 500 mL crystalloid solution ( Hartmanns , n = 29 ) , 500 mL colloid ( Haemaccel , n = 28 ) , or",no prehydration,( n = 28 ) over 10 min prior to spinal anesthesia .,"['Eighty-five', 'ASA', 'grade', 'I', 'or', 'II', 'patients', '(', 'aged', '60-89', 'yr', ')', 'for', 'elective', 'total', 'hip', 'replacement', 'were', 'randomized', 'to', 'receive', '500', 'mL', 'crystalloid', 'solution', '(', 'Hartmanns', ',', 'n', '=', '29', ')', ',', '500', 'mL', 'colloid', '(', 'Haemaccel', ',', 'n', '=', '28', ')', ',', 'or', 'no', 'prehydration', '(', 'n', '=', '28', ')', 'over', '10', 'min', 'prior', 'to', 'spinal', 'anesthesia', '.']","(45, 47)","(214, 229)",-1,ss_i,8989009,Abstract,2,test,gold,1139.0
7656,,Eighty-five ASA grade I or II patients ( aged 60-89 yr ) for elective total hip replacement,"were randomized to receive 500 mL crystalloid solution ( Hartmanns , n = 29 ) , 500 mL colloid ( Haemaccel , n = 28 ) , or no prehydration ( n = 28 ) over 10 min prior to spinal anesthesia .","['Eighty-five', 'ASA', 'grade', 'I', 'or', 'II', 'patients', '(', 'aged', '60-89', 'yr', ')', 'for', 'elective', 'total', 'hip', 'replacement', 'were', 'randomized', 'to', 'receive', '500', 'mL', 'crystalloid', 'solution', '(', 'Hartmanns', ',', 'n', '=', '29', ')', ',', '500', 'mL', 'colloid', '(', 'Haemaccel', ',', 'n', '=', '28', ')', ',', 'or', 'no', 'prehydration', '(', 'n', '=', '28', ')', 'over', '10', 'min', 'prior', 'to', 'spinal', 'anesthesia', '.']","(0, 17)","(0, 91)",-1,hl_p,8989009,Abstract,2,test,gold,5866.0
7657,Eighty-five ASA grade I or II patients ( aged 60-89 yr ) for elective total hip replacement were randomized to receive 500 mL,crystalloid solution,"( Hartmanns , n = 29 ) , 500 mL colloid ( Haemaccel , n = 28 ) , or no prehydration ( n = 28 ) over 10 min prior to spinal anesthesia .","['Eighty-five', 'ASA', 'grade', 'I', 'or', 'II', 'patients', '(', 'aged', '60-89', 'yr', ')', 'for', 'elective', 'total', 'hip', 'replacement', 'were', 'randomized', 'to', 'receive', '500', 'mL', 'crystalloid', 'solution', '(', 'Hartmanns', ',', 'n', '=', '29', ')', ',', '500', 'mL', 'colloid', '(', 'Haemaccel', ',', 'n', '=', '28', ')', ',', 'or', 'no', 'prehydration', '(', 'n', '=', '28', ')', 'over', '10', 'min', 'prior', 'to', 'spinal', 'anesthesia', '.']","(23, 25)","(125, 145)",-1,hl_i,8989009,Abstract,2,test,gold,305.0
7658,"Eighty-five ASA grade I or II patients ( aged 60-89 yr ) for elective total hip replacement were randomized to receive 500 mL crystalloid solution ( Hartmanns , n = 29 ) , 500 mL",colloid ( Haemaccel,", n = 28 ) , or no prehydration ( n = 28 ) over 10 min prior to spinal anesthesia .","['Eighty-five', 'ASA', 'grade', 'I', 'or', 'II', 'patients', '(', 'aged', '60-89', 'yr', ')', 'for', 'elective', 'total', 'hip', 'replacement', 'were', 'randomized', 'to', 'receive', '500', 'mL', 'crystalloid', 'solution', '(', 'Hartmanns', ',', 'n', '=', '29', ')', ',', '500', 'mL', 'colloid', '(', 'Haemaccel', ',', 'n', '=', '28', ')', ',', 'or', 'no', 'prehydration', '(', 'n', '=', '28', ')', 'over', '10', 'min', 'prior', 'to', 'spinal', 'anesthesia', '.']","(35, 38)","(178, 197)",-1,hl_i,8989009,Abstract,2,test,gold,310.0
7659,"Eighty-five ASA grade I or II patients ( aged 60-89 yr ) for elective total hip replacement were randomized to receive 500 mL crystalloid solution ( Hartmanns , n = 29 ) , 500 mL colloid ( Haemaccel , n = 28 ) , or",no prehydration,( n = 28 ) over 10 min prior to spinal anesthesia .,"['Eighty-five', 'ASA', 'grade', 'I', 'or', 'II', 'patients', '(', 'aged', '60-89', 'yr', ')', 'for', 'elective', 'total', 'hip', 'replacement', 'were', 'randomized', 'to', 'receive', '500', 'mL', 'crystalloid', 'solution', '(', 'Hartmanns', ',', 'n', '=', '29', ')', ',', '500', 'mL', 'colloid', '(', 'Haemaccel', ',', 'n', '=', '28', ')', ',', 'or', 'no', 'prehydration', '(', 'n', '=', '28', ')', 'over', '10', 'min', 'prior', 'to', 'spinal', 'anesthesia', '.']","(45, 47)","(214, 229)",-1,hl_i,8989009,Abstract,2,test,gold,1138.0
7660,,Hypotension,"was defined as a 30 % decrease from baseline systolic blood pressure ( BP ) or systolic < 90 mm Hg , and was treated with ephedrine 3-mg boluses .","['Hypotension', 'was', 'defined', 'as', 'a', '30', '%', 'decrease', 'from', 'baseline', 'systolic', 'blood', 'pressure', '(', 'BP', ')', 'or', 'systolic', '<', '90', 'mm', 'Hg', ',', 'and', 'was', 'treated', 'with', 'ephedrine', '3-mg', 'boluses', '.']","(0, 1)","(0, 11)",-1,ss_o,8989009,Abstract,3,test,gold,67.0
7661,Hypotension was defined as a,30 % decrease from baseline systolic blood pressure ( BP ),"or systolic < 90 mm Hg , and was treated with ephedrine 3-mg boluses .","['Hypotension', 'was', 'defined', 'as', 'a', '30', '%', 'decrease', 'from', 'baseline', 'systolic', 'blood', 'pressure', '(', 'BP', ')', 'or', 'systolic', '<', '90', 'mm', 'Hg', ',', 'and', 'was', 'treated', 'with', 'ephedrine', '3-mg', 'boluses', '.']","(5, 16)","(28, 86)",-1,ss_o,8989009,Abstract,3,test,gold,6730.0
7662,Hypotension was defined as a 30 % decrease from baseline systolic blood pressure ( BP ) or,systolic < 90 mm Hg,", and was treated with ephedrine 3-mg boluses .","['Hypotension', 'was', 'defined', 'as', 'a', '30', '%', 'decrease', 'from', 'baseline', 'systolic', 'blood', 'pressure', '(', 'BP', ')', 'or', 'systolic', '<', '90', 'mm', 'Hg', ',', 'and', 'was', 'treated', 'with', 'ephedrine', '3-mg', 'boluses', '.']","(17, 22)","(90, 109)",-1,ss_o,8989009,Abstract,3,test,gold,6691.0
7663,,Hypotension,"was defined as a 30 % decrease from baseline systolic blood pressure ( BP ) or systolic < 90 mm Hg , and was treated with ephedrine 3-mg boluses .","['Hypotension', 'was', 'defined', 'as', 'a', '30', '%', 'decrease', 'from', 'baseline', 'systolic', 'blood', 'pressure', '(', 'BP', ')', 'or', 'systolic', '<', '90', 'mm', 'Hg', ',', 'and', 'was', 'treated', 'with', 'ephedrine', '3-mg', 'boluses', '.']","(0, 1)","(0, 11)",-1,hl_o,8989009,Abstract,3,test,gold,66.0
7664,Hypotension was defined as a 30 % decrease from baseline,systolic blood pressure,"( BP ) or systolic < 90 mm Hg , and was treated with ephedrine 3-mg boluses .","['Hypotension', 'was', 'defined', 'as', 'a', '30', '%', 'decrease', 'from', 'baseline', 'systolic', 'blood', 'pressure', '(', 'BP', ')', 'or', 'systolic', '<', '90', 'mm', 'Hg', ',', 'and', 'was', 'treated', 'with', 'ephedrine', '3-mg', 'boluses', '.']","(10, 13)","(56, 79)",-1,hl_o,8989009,Abstract,3,test,gold,6712.0
7665,Although absolute systolic BP readings were significantly higher in the,colloid,"group between 6 and 30 min ( P < 0.05 ) , the incidence of hypotension was not significantly different between the groups .","['Although', 'absolute', 'systolic', 'BP', 'readings', 'were', 'significantly', 'higher', 'in', 'the', 'colloid', 'group', 'between', '6', 'and', '30', 'min', '(', 'P', '<', '0.05', ')', ',', 'the', 'incidence', 'of', 'hypotension', 'was', 'not', 'significantly', 'different', 'between', 'the', 'groups', '.']","(10, 11)","(71, 78)",-1,ss_i,8989009,Abstract,4,test,gold,309.0
7666,Although,absolute systolic BP readings,"were significantly higher in the colloid group between 6 and 30 min ( P < 0.05 ) , the incidence of hypotension was not significantly different between the groups .","['Although', 'absolute', 'systolic', 'BP', 'readings', 'were', 'significantly', 'higher', 'in', 'the', 'colloid', 'group', 'between', '6', 'and', '30', 'min', '(', 'P', '<', '0.05', ')', ',', 'the', 'incidence', 'of', 'hypotension', 'was', 'not', 'significantly', 'different', 'between', 'the', 'groups', '.']","(1, 5)","(8, 37)",-1,ss_o,8989009,Abstract,4,test,gold,6685.0
7667,"Although absolute systolic BP readings were significantly higher in the colloid group between 6 and 30 min ( P < 0.05 ) , the",incidence of hypotension,was not significantly different between the groups .,"['Although', 'absolute', 'systolic', 'BP', 'readings', 'were', 'significantly', 'higher', 'in', 'the', 'colloid', 'group', 'between', '6', 'and', '30', 'min', '(', 'P', '<', '0.05', ')', ',', 'the', 'incidence', 'of', 'hypotension', 'was', 'not', 'significantly', 'different', 'between', 'the', 'groups', '.']","(24, 27)","(125, 149)",-1,ss_o,8989009,Abstract,4,test,gold,3532.0
7668,Although absolute systolic BP readings were significantly higher in the,colloid,"group between 6 and 30 min ( P < 0.05 ) , the incidence of hypotension was not significantly different between the groups .","['Although', 'absolute', 'systolic', 'BP', 'readings', 'were', 'significantly', 'higher', 'in', 'the', 'colloid', 'group', 'between', '6', 'and', '30', 'min', '(', 'P', '<', '0.05', ')', ',', 'the', 'incidence', 'of', 'hypotension', 'was', 'not', 'significantly', 'different', 'between', 'the', 'groups', '.']","(10, 11)","(71, 78)",-1,hl_i,8989009,Abstract,4,test,gold,308.0
7669,Although,absolute systolic BP readings,"were significantly higher in the colloid group between 6 and 30 min ( P < 0.05 ) , the incidence of hypotension was not significantly different between the groups .","['Although', 'absolute', 'systolic', 'BP', 'readings', 'were', 'significantly', 'higher', 'in', 'the', 'colloid', 'group', 'between', '6', 'and', '30', 'min', '(', 'P', '<', '0.05', ')', ',', 'the', 'incidence', 'of', 'hypotension', 'was', 'not', 'significantly', 'different', 'between', 'the', 'groups', '.']","(1, 5)","(8, 37)",-1,hl_o,8989009,Abstract,4,test,gold,6686.0
7670,"Although absolute systolic BP readings were significantly higher in the colloid group between 6 and 30 min ( P < 0.05 ) , the",incidence of hypotension,was not significantly different between the groups .,"['Although', 'absolute', 'systolic', 'BP', 'readings', 'were', 'significantly', 'higher', 'in', 'the', 'colloid', 'group', 'between', '6', 'and', '30', 'min', '(', 'P', '<', '0.05', ')', ',', 'the', 'incidence', 'of', 'hypotension', 'was', 'not', 'significantly', 'different', 'between', 'the', 'groups', '.']","(24, 27)","(125, 149)",-1,hl_o,8989009,Abstract,4,test,gold,3533.0
7671,The incidence of,ephedrine,"use , incidence of nausea/vomiting , and median total dose of ephedrine were similar in all groups .","['The', 'incidence', 'of', 'ephedrine', 'use', ',', 'incidence', 'of', 'nausea/vomiting', ',', 'and', 'median', 'total', 'dose', 'of', 'ephedrine', 'were', 'similar', 'in', 'all', 'groups', '.']","(3, 4)","(16, 25)",-1,ss_i,8989009,Abstract,5,test,gold,5077.0
7672,"The incidence of ephedrine use , incidence of nausea/vomiting , and median total dose of",ephedrine,were similar in all groups .,"['The', 'incidence', 'of', 'ephedrine', 'use', ',', 'incidence', 'of', 'nausea/vomiting', ',', 'and', 'median', 'total', 'dose', 'of', 'ephedrine', 'were', 'similar', 'in', 'all', 'groups', '.']","(15, 16)","(88, 97)",-1,ss_i,8989009,Abstract,5,test,gold,5078.0
7673,The,"incidence of ephedrine use , incidence of nausea/vomiting , and median total dose of ephedrine",were similar in all groups .,"['The', 'incidence', 'of', 'ephedrine', 'use', ',', 'incidence', 'of', 'nausea/vomiting', ',', 'and', 'median', 'total', 'dose', 'of', 'ephedrine', 'were', 'similar', 'in', 'all', 'groups', '.']","(1, 16)","(3, 97)",-1,ss_o,8989009,Abstract,5,test,gold,6462.0
7674,The,incidence of ephedrine use,", incidence of nausea/vomiting , and median total dose of ephedrine were similar in all groups .","['The', 'incidence', 'of', 'ephedrine', 'use', ',', 'incidence', 'of', 'nausea/vomiting', ',', 'and', 'median', 'total', 'dose', 'of', 'ephedrine', 'were', 'similar', 'in', 'all', 'groups', '.']","(1, 5)","(3, 29)",-1,hl_o,8989009,Abstract,5,test,gold,5076.0
7675,"The incidence of ephedrine use ,",incidence of nausea/vomiting,", and median total dose of ephedrine were similar in all groups .","['The', 'incidence', 'of', 'ephedrine', 'use', ',', 'incidence', 'of', 'nausea/vomiting', ',', 'and', 'median', 'total', 'dose', 'of', 'ephedrine', 'were', 'similar', 'in', 'all', 'groups', '.']","(6, 9)","(32, 60)",-1,hl_o,8989009,Abstract,5,test,gold,3349.0
7676,"The incidence of ephedrine use , incidence of nausea/vomiting , and",median total dose of ephedrine,were similar in all groups .,"['The', 'incidence', 'of', 'ephedrine', 'use', ',', 'incidence', 'of', 'nausea/vomiting', ',', 'and', 'median', 'total', 'dose', 'of', 'ephedrine', 'were', 'similar', 'in', 'all', 'groups', '.']","(11, 16)","(67, 97)",-1,hl_o,8989009,Abstract,5,test,gold,5048.0
7677,"We conclude that , in",elderly patients undergoing elective procedures,", withholding prehydration is not associated with any greater degree of hypotension or need for vasopressor therapy compared with crystalloid or colloid prehydration .","['We', 'conclude', 'that', ',', 'in', 'elderly', 'patients', 'undergoing', 'elective', 'procedures', ',', 'withholding', 'prehydration', 'is', 'not', 'associated', 'with', 'any', 'greater', 'degree', 'of', 'hypotension', 'or', 'need', 'for', 'vasopressor', 'therapy', 'compared', 'with', 'crystalloid', 'or', 'colloid', 'prehydration', '.']","(5, 10)","(21, 68)",-1,ss_p,8989009,Abstract,6,test,gold,3628.0
7678,"We conclude that , in elderly patients undergoing elective procedures , withholding",prehydration,is not associated with any greater degree of hypotension or need for vasopressor therapy compared with crystalloid or colloid prehydration .,"['We', 'conclude', 'that', ',', 'in', 'elderly', 'patients', 'undergoing', 'elective', 'procedures', ',', 'withholding', 'prehydration', 'is', 'not', 'associated', 'with', 'any', 'greater', 'degree', 'of', 'hypotension', 'or', 'need', 'for', 'vasopressor', 'therapy', 'compared', 'with', 'crystalloid', 'or', 'colloid', 'prehydration', '.']","(12, 13)","(83, 95)",-1,ss_i,8989009,Abstract,6,test,gold,
7679,"We conclude that , in elderly patients undergoing elective procedures , withholding prehydration is not associated with any greater degree of hypotension or need for vasopressor therapy compared with",crystalloid,or colloid prehydration .,"['We', 'conclude', 'that', ',', 'in', 'elderly', 'patients', 'undergoing', 'elective', 'procedures', ',', 'withholding', 'prehydration', 'is', 'not', 'associated', 'with', 'any', 'greater', 'degree', 'of', 'hypotension', 'or', 'need', 'for', 'vasopressor', 'therapy', 'compared', 'with', 'crystalloid', 'or', 'colloid', 'prehydration', '.']","(29, 30)","(199, 210)",-1,ss_i,8989009,Abstract,6,test,gold,173.0
7680,"We conclude that , in elderly patients undergoing elective procedures , withholding prehydration is not associated with any greater degree of hypotension or need for vasopressor therapy compared with crystalloid or",colloid prehydration .,,"['We', 'conclude', 'that', ',', 'in', 'elderly', 'patients', 'undergoing', 'elective', 'procedures', ',', 'withholding', 'prehydration', 'is', 'not', 'associated', 'with', 'any', 'greater', 'degree', 'of', 'hypotension', 'or', 'need', 'for', 'vasopressor', 'therapy', 'compared', 'with', 'crystalloid', 'or', 'colloid', 'prehydration', '.']","(31, 34)","(214, 236)",-1,ss_i,8989009,Abstract,6,test,gold,307.0
7681,"We conclude that , in elderly patients undergoing elective procedures , withholding prehydration is not associated with any greater",degree of hypotension or need for vasopressor therapy,compared with crystalloid or colloid prehydration .,"['We', 'conclude', 'that', ',', 'in', 'elderly', 'patients', 'undergoing', 'elective', 'procedures', ',', 'withholding', 'prehydration', 'is', 'not', 'associated', 'with', 'any', 'greater', 'degree', 'of', 'hypotension', 'or', 'need', 'for', 'vasopressor', 'therapy', 'compared', 'with', 'crystalloid', 'or', 'colloid', 'prehydration', '.']","(19, 27)","(131, 184)",-1,ss_o,8989009,Abstract,6,test,gold,7104.0
7682,"We conclude that , in",elderly patients undergoing elective procedures,", withholding prehydration is not associated with any greater degree of hypotension or need for vasopressor therapy compared with crystalloid or colloid prehydration .","['We', 'conclude', 'that', ',', 'in', 'elderly', 'patients', 'undergoing', 'elective', 'procedures', ',', 'withholding', 'prehydration', 'is', 'not', 'associated', 'with', 'any', 'greater', 'degree', 'of', 'hypotension', 'or', 'need', 'for', 'vasopressor', 'therapy', 'compared', 'with', 'crystalloid', 'or', 'colloid', 'prehydration', '.']","(5, 10)","(21, 68)",-1,hl_p,8989009,Abstract,6,test,gold,3629.0
7683,"We conclude that , in elderly patients undergoing elective procedures , withholding prehydration is not associated with any greater degree of hypotension or need for vasopressor therapy compared with",crystalloid,or colloid prehydration .,"['We', 'conclude', 'that', ',', 'in', 'elderly', 'patients', 'undergoing', 'elective', 'procedures', ',', 'withholding', 'prehydration', 'is', 'not', 'associated', 'with', 'any', 'greater', 'degree', 'of', 'hypotension', 'or', 'need', 'for', 'vasopressor', 'therapy', 'compared', 'with', 'crystalloid', 'or', 'colloid', 'prehydration', '.']","(29, 30)","(199, 210)",-1,hl_i,8989009,Abstract,6,test,gold,172.0
7684,"We conclude that , in elderly patients undergoing elective procedures , withholding prehydration is not associated with any greater degree of hypotension or need for vasopressor therapy compared with crystalloid or",colloid prehydration .,,"['We', 'conclude', 'that', ',', 'in', 'elderly', 'patients', 'undergoing', 'elective', 'procedures', ',', 'withholding', 'prehydration', 'is', 'not', 'associated', 'with', 'any', 'greater', 'degree', 'of', 'hypotension', 'or', 'need', 'for', 'vasopressor', 'therapy', 'compared', 'with', 'crystalloid', 'or', 'colloid', 'prehydration', '.']","(31, 34)","(214, 236)",-1,hl_i,8989009,Abstract,6,test,gold,306.0
7685,"We conclude that , in elderly patients undergoing elective procedures , withholding prehydration is not associated with any greater degree of",hypotension,or need for vasopressor therapy compared with crystalloid or colloid prehydration .,"['We', 'conclude', 'that', ',', 'in', 'elderly', 'patients', 'undergoing', 'elective', 'procedures', ',', 'withholding', 'prehydration', 'is', 'not', 'associated', 'with', 'any', 'greater', 'degree', 'of', 'hypotension', 'or', 'need', 'for', 'vasopressor', 'therapy', 'compared', 'with', 'crystalloid', 'or', 'colloid', 'prehydration', '.']","(21, 22)","(141, 152)",-1,hl_o,8989009,Abstract,6,test,gold,3531.0
7686,"We conclude that , in elderly patients undergoing elective procedures , withholding prehydration is not associated with any greater degree of hypotension or",need for vasopressor therapy,compared with crystalloid or colloid prehydration .,"['We', 'conclude', 'that', ',', 'in', 'elderly', 'patients', 'undergoing', 'elective', 'procedures', ',', 'withholding', 'prehydration', 'is', 'not', 'associated', 'with', 'any', 'greater', 'degree', 'of', 'hypotension', 'or', 'need', 'for', 'vasopressor', 'therapy', 'compared', 'with', 'crystalloid', 'or', 'colloid', 'prehydration', '.']","(23, 27)","(156, 184)",-1,hl_o,8989009,Abstract,6,test,gold,4202.0
7687,[ Antazoline/tetryzoline eyedrops in comparison with levocabastine eyedrops in,acute allergic conjunctivitis ],.,"['[', 'Antazoline/tetryzoline', 'eyedrops', 'in', 'comparison', 'with', 'levocabastine', 'eyedrops', 'in', 'acute', 'allergic', 'conjunctivitis', ']', '.']","(9, 13)","(78, 109)",-1,ss_p,9229602,Title,0,test,gold,3582.0
7688,,[ Antazoline/tetryzoline,eyedrops in comparison with levocabastine eyedrops in acute allergic conjunctivitis ] .,"['[', 'Antazoline/tetryzoline', 'eyedrops', 'in', 'comparison', 'with', 'levocabastine', 'eyedrops', 'in', 'acute', 'allergic', 'conjunctivitis', ']', '.']","(0, 2)","(0, 24)",-1,ss_i,9229602,Title,0,test,gold,
7689,[ Antazoline/tetryzoline eyedrops in comparison with,levocabastine,eyedrops in acute allergic conjunctivitis ] .,"['[', 'Antazoline/tetryzoline', 'eyedrops', 'in', 'comparison', 'with', 'levocabastine', 'eyedrops', 'in', 'acute', 'allergic', 'conjunctivitis', ']', '.']","(6, 7)","(52, 65)",-1,ss_i,9229602,Title,0,test,gold,
7690,[ Antazoline/tetryzoline eyedrops in comparison with levocabastine eyedrops in,acute allergic conjunctivitis ],.,"['[', 'Antazoline/tetryzoline', 'eyedrops', 'in', 'comparison', 'with', 'levocabastine', 'eyedrops', 'in', 'acute', 'allergic', 'conjunctivitis', ']', '.']","(9, 13)","(78, 109)",-1,hl_p,9229602,Title,0,test,gold,3583.0
7691,[,Antazoline/tetryzoline,eyedrops in comparison with levocabastine eyedrops in acute allergic conjunctivitis ] .,"['[', 'Antazoline/tetryzoline', 'eyedrops', 'in', 'comparison', 'with', 'levocabastine', 'eyedrops', 'in', 'acute', 'allergic', 'conjunctivitis', ']', '.']","(1, 2)","(1, 23)",-1,hl_i,9229602,Title,0,test,gold,
7692,[ Antazoline/tetryzoline eyedrops in comparison with,levocabastine,eyedrops in acute allergic conjunctivitis ] .,"['[', 'Antazoline/tetryzoline', 'eyedrops', 'in', 'comparison', 'with', 'levocabastine', 'eyedrops', 'in', 'acute', 'allergic', 'conjunctivitis', ']', '.']","(6, 7)","(52, 65)",-1,hl_i,9229602,Title,0,test,gold,
7693,BACKGROUND Allergic conjunctivitis is one of the most frequent allergic diseases of the anterior eye segment .,,,"['BACKGROUND', 'Allergic', 'conjunctivitis', 'is', 'one', 'of', 'the', 'most', 'frequent', 'allergic', 'diseases', 'of', 'the', 'anterior', 'eye', 'segment', '.']",,,,,9229602,Abstract,0,test,gold,
7694,"METHODS This multicentre , clinical trial was an investigation to compare the antiallergic efficacy , local tolerance and safety of",Antazolin/Tetryzolin,eye drops and Levocabastine eye drops .,"['METHODS', 'This', 'multicentre', ',', 'clinical', 'trial', 'was', 'an', 'investigation', 'to', 'compare', 'the', 'antiallergic', 'efficacy', ',', 'local', 'tolerance', 'and', 'safety', 'of', 'Antazolin/Tetryzolin', 'eye', 'drops', 'and', 'Levocabastine', 'eye', 'drops', '.']","(20, 21)","(131, 151)",-1,ss_i,9229602,Abstract,1,test,gold,
7695,"METHODS This multicentre , clinical trial was an investigation to compare the antiallergic efficacy , local tolerance and safety of Antazolin/Tetryzolin eye drops and",Levocabastine,eye drops .,"['METHODS', 'This', 'multicentre', ',', 'clinical', 'trial', 'was', 'an', 'investigation', 'to', 'compare', 'the', 'antiallergic', 'efficacy', ',', 'local', 'tolerance', 'and', 'safety', 'of', 'Antazolin/Tetryzolin', 'eye', 'drops', 'and', 'Levocabastine', 'eye', 'drops', '.']","(24, 25)","(166, 179)",-1,ss_i,9229602,Abstract,1,test,gold,
7696,"METHODS This multicentre , clinical trial was an investigation to compare the antiallergic","efficacy , local tolerance and safety",of Antazolin/Tetryzolin eye drops and Levocabastine eye drops .,"['METHODS', 'This', 'multicentre', ',', 'clinical', 'trial', 'was', 'an', 'investigation', 'to', 'compare', 'the', 'antiallergic', 'efficacy', ',', 'local', 'tolerance', 'and', 'safety', 'of', 'Antazolin/Tetryzolin', 'eye', 'drops', 'and', 'Levocabastine', 'eye', 'drops', '.']","(13, 19)","(90, 127)",-1,ss_o,9229602,Abstract,1,test,gold,4776.0
7697,"METHODS This multicentre , clinical trial was an investigation to compare the antiallergic efficacy , local tolerance and safety of",Antazolin/Tetryzolin,eye drops and Levocabastine eye drops .,"['METHODS', 'This', 'multicentre', ',', 'clinical', 'trial', 'was', 'an', 'investigation', 'to', 'compare', 'the', 'antiallergic', 'efficacy', ',', 'local', 'tolerance', 'and', 'safety', 'of', 'Antazolin/Tetryzolin', 'eye', 'drops', 'and', 'Levocabastine', 'eye', 'drops', '.']","(20, 21)","(131, 151)",-1,hl_i,9229602,Abstract,1,test,gold,
7698,"METHODS This multicentre , clinical trial was an investigation to compare the antiallergic efficacy , local tolerance and safety of Antazolin/Tetryzolin eye drops and",Levocabastine,eye drops .,"['METHODS', 'This', 'multicentre', ',', 'clinical', 'trial', 'was', 'an', 'investigation', 'to', 'compare', 'the', 'antiallergic', 'efficacy', ',', 'local', 'tolerance', 'and', 'safety', 'of', 'Antazolin/Tetryzolin', 'eye', 'drops', 'and', 'Levocabastine', 'eye', 'drops', '.']","(24, 25)","(166, 179)",-1,hl_i,9229602,Abstract,1,test,gold,
7699,,69 patients,were treated over a 2 weeks course of therapy .,"['69', 'patients', 'were', 'treated', 'over', 'a', '2', 'weeks', 'course', 'of', 'therapy', '.']","(0, 2)","(0, 11)",-1,ss_p,9229602,Abstract,2,test,gold,3736.0
7700,,69 patients,were treated over a 2 weeks course of therapy .,"['69', 'patients', 'were', 'treated', 'over', 'a', '2', 'weeks', 'course', 'of', 'therapy', '.']","(0, 2)","(0, 11)",-1,hl_p,9229602,Abstract,2,test,gold,3735.0
7701,The,subjective and objective ocular symptoms,were documented over the treatment period .,"['The', 'subjective', 'and', 'objective', 'ocular', 'symptoms', 'were', 'documented', 'over', 'the', 'treatment', 'period', '.']","(1, 6)","(3, 43)",-1,ss_o,9229602,Abstract,3,test,gold,6442.0
7702,The,subjective and objective ocular symptoms,were documented over the treatment period .,"['The', 'subjective', 'and', 'objective', 'ocular', 'symptoms', 'were', 'documented', 'over', 'the', 'treatment', 'period', '.']","(1, 6)","(3, 43)",-1,hl_o,9229602,Abstract,3,test,gold,6443.0
7703,RESULTS Both eye drops reduced,subjective and objective ocular symptoms,effective .,"['RESULTS', 'Both', 'eye', 'drops', 'reduced', 'subjective', 'and', 'objective', 'ocular', 'symptoms', 'effective', '.']","(5, 10)","(30, 70)",-1,ss_o,9229602,Abstract,4,test,gold,6441.0
7704,RESULTS Both eye drops reduced,subjective and objective ocular symptoms,effective .,"['RESULTS', 'Both', 'eye', 'drops', 'reduced', 'subjective', 'and', 'objective', 'ocular', 'symptoms', 'effective', '.']","(5, 10)","(30, 70)",-1,hl_o,9229602,Abstract,4,test,gold,6440.0
7705,The difference between the treatments ( p = 0.0395 ) was the faster onset of action of,Antazolin/Tetryzolin,30 minutes after administration of the first drop of trial medication .,"['The', 'difference', 'between', 'the', 'treatments', '(', 'p', '=', '0.0395', ')', 'was', 'the', 'faster', 'onset', 'of', 'action', 'of', 'Antazolin/Tetryzolin', '30', 'minutes', 'after', 'administration', 'of', 'the', 'first', 'drop', 'of', 'trial', 'medication', '.']","(17, 18)","(86, 106)",-1,ss_i,9229602,Abstract,5,test,gold,
7706,The difference between the treatments ( p = 0.0395 ) was the faster,onset of action,of Antazolin/Tetryzolin 30 minutes after administration of the first drop of trial medication .,"['The', 'difference', 'between', 'the', 'treatments', '(', 'p', '=', '0.0395', ')', 'was', 'the', 'faster', 'onset', 'of', 'action', 'of', 'Antazolin/Tetryzolin', '30', 'minutes', 'after', 'administration', 'of', 'the', 'first', 'drop', 'of', 'trial', 'medication', '.']","(13, 16)","(67, 82)",-1,ss_o,9229602,Abstract,5,test,gold,3324.0
7707,The difference between the treatments ( p = 0.0395 ) was the faster onset of action of,Antazolin/Tetryzolin,30 minutes after administration of the first drop of trial medication .,"['The', 'difference', 'between', 'the', 'treatments', '(', 'p', '=', '0.0395', ')', 'was', 'the', 'faster', 'onset', 'of', 'action', 'of', 'Antazolin/Tetryzolin', '30', 'minutes', 'after', 'administration', 'of', 'the', 'first', 'drop', 'of', 'trial', 'medication', '.']","(17, 18)","(86, 106)",-1,hl_i,9229602,Abstract,5,test,gold,
7708,The difference between the treatments ( p = 0.0395 ) was the faster,onset of action,of Antazolin/Tetryzolin 30 minutes after administration of the first drop of trial medication .,"['The', 'difference', 'between', 'the', 'treatments', '(', 'p', '=', '0.0395', ')', 'was', 'the', 'faster', 'onset', 'of', 'action', 'of', 'Antazolin/Tetryzolin', '30', 'minutes', 'after', 'administration', 'of', 'the', 'first', 'drop', 'of', 'trial', 'medication', '.']","(13, 16)","(67, 82)",-1,hl_o,9229602,Abstract,5,test,gold,3325.0
7709,CONCLUSION A fast and,effective onset of action,is of high clinical relevance .,"['CONCLUSION', 'A', 'fast', 'and', 'effective', 'onset', 'of', 'action', 'is', 'of', 'high', 'clinical', 'relevance', '.']","(4, 8)","(21, 46)",-1,ss_o,9229602,Abstract,6,test,gold,3323.0
7710,Therefore the benefits of using,Antazolin/Tetryzolin,eye drops was clearly outweigh .,"['Therefore', 'the', 'benefits', 'of', 'using', 'Antazolin/Tetryzolin', 'eye', 'drops', 'was', 'clearly', 'outweigh', '.']","(5, 6)","(31, 51)",-1,ss_i,9229602,Abstract,7,test,gold,
7711,Therefore the benefits of using,Antazolin/Tetryzolin,eye drops was clearly outweigh .,"['Therefore', 'the', 'benefits', 'of', 'using', 'Antazolin/Tetryzolin', 'eye', 'drops', 'was', 'clearly', 'outweigh', '.']","(5, 6)","(31, 51)",-1,hl_i,9229602,Abstract,7,test,gold,
7712,Effect of treatment with paromomycin on endotoxemia in,patients with alcoholic liver disease -- a,"double-blind , placebo-controlled trial .","['Effect', 'of', 'treatment', 'with', 'paromomycin', 'on', 'endotoxemia', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '--', 'a', 'double-blind', ',', 'placebo-controlled', 'trial', '.']","(8, 15)","(54, 96)",-1,ss_p,9394106,Title,0,test,gold,7036.0
7713,Effect of treatment with,paromomycin,"on endotoxemia in patients with alcoholic liver disease -- a double-blind , placebo-controlled trial .","['Effect', 'of', 'treatment', 'with', 'paromomycin', 'on', 'endotoxemia', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '--', 'a', 'double-blind', ',', 'placebo-controlled', 'trial', '.']","(4, 5)","(24, 35)",-1,ss_i,9394106,Title,0,test,gold,247.0
7714,"Effect of treatment with paromomycin on endotoxemia in patients with alcoholic liver disease -- a double-blind ,",placebo-controlled,trial .,"['Effect', 'of', 'treatment', 'with', 'paromomycin', 'on', 'endotoxemia', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '--', 'a', 'double-blind', ',', 'placebo-controlled', 'trial', '.']","(17, 18)","(112, 130)",-1,ss_i,9394106,Title,0,test,gold,
7715,Effect of treatment with paromomycin on,endotoxemia,"in patients with alcoholic liver disease -- a double-blind , placebo-controlled trial .","['Effect', 'of', 'treatment', 'with', 'paromomycin', 'on', 'endotoxemia', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '--', 'a', 'double-blind', ',', 'placebo-controlled', 'trial', '.']","(6, 7)","(39, 50)",-1,ss_o,9394106,Title,0,test,gold,52.0
7716,Effect of treatment with paromomycin on endotoxemia in,patients with alcoholic liver disease,"-- a double-blind , placebo-controlled trial .","['Effect', 'of', 'treatment', 'with', 'paromomycin', 'on', 'endotoxemia', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '--', 'a', 'double-blind', ',', 'placebo-controlled', 'trial', '.']","(8, 13)","(54, 91)",-1,hl_p,9394106,Title,0,test,gold,7037.0
7717,Effect of treatment with,paromomycin,"on endotoxemia in patients with alcoholic liver disease -- a double-blind , placebo-controlled trial .","['Effect', 'of', 'treatment', 'with', 'paromomycin', 'on', 'endotoxemia', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '--', 'a', 'double-blind', ',', 'placebo-controlled', 'trial', '.']","(4, 5)","(24, 35)",-1,hl_i,9394106,Title,0,test,gold,248.0
7718,"Effect of treatment with paromomycin on endotoxemia in patients with alcoholic liver disease -- a double-blind ,",placebo-controlled,trial .,"['Effect', 'of', 'treatment', 'with', 'paromomycin', 'on', 'endotoxemia', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '--', 'a', 'double-blind', ',', 'placebo-controlled', 'trial', '.']","(17, 18)","(112, 130)",-1,hl_i,9394106,Title,0,test,gold,
7719,Effect of treatment with paromomycin on,endotoxemia,"in patients with alcoholic liver disease -- a double-blind , placebo-controlled trial .","['Effect', 'of', 'treatment', 'with', 'paromomycin', 'on', 'endotoxemia', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '--', 'a', 'double-blind', ',', 'placebo-controlled', 'trial', '.']","(6, 7)","(39, 50)",-1,hl_o,9394106,Title,0,test,gold,53.0
7720,The results of experimental and clinical studies support the hypothesis that gut-derived endotoxins might be of relevance for the development and course of alcoholic liver disease .,,,"['The', 'results', 'of', 'experimental', 'and', 'clinical', 'studies', 'support', 'the', 'hypothesis', 'that', 'gut-derived', 'endotoxins', 'might', 'be', 'of', 'relevance', 'for', 'the', 'development', 'and', 'course', 'of', 'alcoholic', 'liver', 'disease', '.']",,,,,9394106,Abstract,0,test,gold,
7721,"The aim of this study was to test the effect of a nonabsorbable , broad-spectrum antibiotic on endotoxemia in",patients with alcoholic liver disease .,,"['The', 'aim', 'of', 'this', 'study', 'was', 'to', 'test', 'the', 'effect', 'of', 'a', 'nonabsorbable', ',', 'broad-spectrum', 'antibiotic', 'on', 'endotoxemia', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '.']","(19, 25)","(109, 148)",-1,ss_p,9394106,Abstract,1,test,gold,7035.0
7722,"The aim of this study was to test the effect of a nonabsorbable , broad-spectrum",antibiotic,on endotoxemia in patients with alcoholic liver disease .,"['The', 'aim', 'of', 'this', 'study', 'was', 'to', 'test', 'the', 'effect', 'of', 'a', 'nonabsorbable', ',', 'broad-spectrum', 'antibiotic', 'on', 'endotoxemia', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '.']","(15, 16)","(80, 90)",-1,ss_i,9394106,Abstract,1,test,gold,5085.0
7723,"The aim of this study was to test the effect of a nonabsorbable , broad-spectrum antibiotic on",endotoxemia,in patients with alcoholic liver disease .,"['The', 'aim', 'of', 'this', 'study', 'was', 'to', 'test', 'the', 'effect', 'of', 'a', 'nonabsorbable', ',', 'broad-spectrum', 'antibiotic', 'on', 'endotoxemia', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '.']","(17, 18)","(94, 105)",-1,ss_o,9394106,Abstract,1,test,gold,51.0
7724,"The aim of this study was to test the effect of a nonabsorbable , broad-spectrum antibiotic on endotoxemia in",patients with alcoholic liver disease .,,"['The', 'aim', 'of', 'this', 'study', 'was', 'to', 'test', 'the', 'effect', 'of', 'a', 'nonabsorbable', ',', 'broad-spectrum', 'antibiotic', 'on', 'endotoxemia', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '.']","(19, 25)","(109, 148)",-1,hl_p,9394106,Abstract,1,test,gold,7034.0
7725,"The aim of this study was to test the effect of a nonabsorbable , broad-spectrum antibiotic on",endotoxemia,in patients with alcoholic liver disease .,"['The', 'aim', 'of', 'this', 'study', 'was', 'to', 'test', 'the', 'effect', 'of', 'a', 'nonabsorbable', ',', 'broad-spectrum', 'antibiotic', 'on', 'endotoxemia', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '.']","(17, 18)","(94, 105)",-1,hl_o,9394106,Abstract,1,test,gold,50.0
7726,,"Fifty patients with alcoholic liver disease ( 27 with cirrhosis , 23 without cirrhosis )","were randomly assigned to receive either paromomycin sulfate ( 3 x 1 g/day ) or placebo in a double-blind fashion for at least 3 weeks , and if possible 4 weeks .","['Fifty', 'patients', 'with', 'alcoholic', 'liver', 'disease', '(', '27', 'with', 'cirrhosis', ',', '23', 'without', 'cirrhosis', ')', 'were', 'randomly', 'assigned', 'to', 'receive', 'either', 'paromomycin', 'sulfate', '(', '3', 'x', '1', 'g/day', ')', 'or', 'placebo', 'in', 'a', 'double-blind', 'fashion', 'for', 'at', 'least', '3', 'weeks', ',', 'and', 'if', 'possible', '4', 'weeks', '.']","(0, 15)","(0, 88)",-1,ss_p,9394106,Abstract,2,test,gold,5931.0
7727,"Fifty patients with alcoholic liver disease ( 27 with cirrhosis , 23 without cirrhosis ) were randomly assigned to receive either",paromomycin sulfate,"( 3 x 1 g/day ) or placebo in a double-blind fashion for at least 3 weeks , and if possible 4 weeks .","['Fifty', 'patients', 'with', 'alcoholic', 'liver', 'disease', '(', '27', 'with', 'cirrhosis', ',', '23', 'without', 'cirrhosis', ')', 'were', 'randomly', 'assigned', 'to', 'receive', 'either', 'paromomycin', 'sulfate', '(', '3', 'x', '1', 'g/day', ')', 'or', 'placebo', 'in', 'a', 'double-blind', 'fashion', 'for', 'at', 'least', '3', 'weeks', ',', 'and', 'if', 'possible', '4', 'weeks', '.']","(21, 23)","(129, 148)",-1,ss_i,9394106,Abstract,2,test,gold,251.0
7728,"Fifty patients with alcoholic liver disease ( 27 with cirrhosis , 23 without cirrhosis ) were randomly assigned to receive either paromomycin sulfate ( 3 x 1 g/day ) or",placebo,"in a double-blind fashion for at least 3 weeks , and if possible 4 weeks .","['Fifty', 'patients', 'with', 'alcoholic', 'liver', 'disease', '(', '27', 'with', 'cirrhosis', ',', '23', 'without', 'cirrhosis', ')', 'were', 'randomly', 'assigned', 'to', 'receive', 'either', 'paromomycin', 'sulfate', '(', '3', 'x', '1', 'g/day', ')', 'or', 'placebo', 'in', 'a', 'double-blind', 'fashion', 'for', 'at', 'least', '3', 'weeks', ',', 'and', 'if', 'possible', '4', 'weeks', '.']","(30, 31)","(168, 175)",-1,ss_i,9394106,Abstract,2,test,gold,4279.0
7729,,"Fifty patients with alcoholic liver disease ( 27 with cirrhosis , 23 without cirrhosis )","were randomly assigned to receive either paromomycin sulfate ( 3 x 1 g/day ) or placebo in a double-blind fashion for at least 3 weeks , and if possible 4 weeks .","['Fifty', 'patients', 'with', 'alcoholic', 'liver', 'disease', '(', '27', 'with', 'cirrhosis', ',', '23', 'without', 'cirrhosis', ')', 'were', 'randomly', 'assigned', 'to', 'receive', 'either', 'paromomycin', 'sulfate', '(', '3', 'x', '1', 'g/day', ')', 'or', 'placebo', 'in', 'a', 'double-blind', 'fashion', 'for', 'at', 'least', '3', 'weeks', ',', 'and', 'if', 'possible', '4', 'weeks', '.']","(0, 15)","(0, 88)",-1,hl_p,9394106,Abstract,2,test,gold,5932.0
7730,"Fifty patients with alcoholic liver disease ( 27 with cirrhosis , 23 without cirrhosis ) were randomly assigned to receive either",paromomycin sulfate,"( 3 x 1 g/day ) or placebo in a double-blind fashion for at least 3 weeks , and if possible 4 weeks .","['Fifty', 'patients', 'with', 'alcoholic', 'liver', 'disease', '(', '27', 'with', 'cirrhosis', ',', '23', 'without', 'cirrhosis', ')', 'were', 'randomly', 'assigned', 'to', 'receive', 'either', 'paromomycin', 'sulfate', '(', '3', 'x', '1', 'g/day', ')', 'or', 'placebo', 'in', 'a', 'double-blind', 'fashion', 'for', 'at', 'least', '3', 'weeks', ',', 'and', 'if', 'possible', '4', 'weeks', '.']","(21, 23)","(129, 148)",-1,hl_i,9394106,Abstract,2,test,gold,252.0
7731,"Fifty patients with alcoholic liver disease ( 27 with cirrhosis , 23 without cirrhosis ) were randomly assigned to receive either paromomycin sulfate ( 3 x 1 g/day ) or",placebo,"in a double-blind fashion for at least 3 weeks , and if possible 4 weeks .","['Fifty', 'patients', 'with', 'alcoholic', 'liver', 'disease', '(', '27', 'with', 'cirrhosis', ',', '23', 'without', 'cirrhosis', ')', 'were', 'randomly', 'assigned', 'to', 'receive', 'either', 'paromomycin', 'sulfate', '(', '3', 'x', '1', 'g/day', ')', 'or', 'placebo', 'in', 'a', 'double-blind', 'fashion', 'for', 'at', 'least', '3', 'weeks', ',', 'and', 'if', 'possible', '4', 'weeks', '.']","(30, 31)","(168, 175)",-1,hl_i,9394106,Abstract,2,test,gold,4278.0
7732,,"Endotoxin concentration , liver function tests , and other laboratory parameters",were determined in weekly intervals .,"['Endotoxin', 'concentration', ',', 'liver', 'function', 'tests', ',', 'and', 'other', 'laboratory', 'parameters', 'were', 'determined', 'in', 'weekly', 'intervals', '.']","(0, 11)","(0, 80)",-1,ss_o,9394106,Abstract,3,test,gold,3149.0
7733,,Endotoxin concentration,", liver function tests , and other laboratory parameters were determined in weekly intervals .","['Endotoxin', 'concentration', ',', 'liver', 'function', 'tests', ',', 'and', 'other', 'laboratory', 'parameters', 'were', 'determined', 'in', 'weekly', 'intervals', '.']","(0, 2)","(0, 23)",-1,hl_o,9394106,Abstract,3,test,gold,4507.0
7734,"Endotoxin concentration ,",liver function tests,", and other laboratory parameters were determined in weekly intervals .","['Endotoxin', 'concentration', ',', 'liver', 'function', 'tests', ',', 'and', 'other', 'laboratory', 'parameters', 'were', 'determined', 'in', 'weekly', 'intervals', '.']","(3, 6)","(25, 45)",-1,hl_o,9394106,Abstract,3,test,gold,3155.0
7735,Endotoxin concentration was also determined in,15 healthy controls .,,"['Endotoxin', 'concentration', 'was', 'also', 'determined', 'in', '15', 'healthy', 'controls', '.']","(6, 10)","(46, 67)",-1,ss_p,9394106,Abstract,4,test,gold,907.0
7736,,Endotoxin concentration,was also determined in 15 healthy controls .,"['Endotoxin', 'concentration', 'was', 'also', 'determined', 'in', '15', 'healthy', 'controls', '.']","(0, 2)","(0, 23)",-1,ss_o,9394106,Abstract,4,test,gold,4508.0
7737,Endotoxin concentration was also determined in,15 healthy controls,.,"['Endotoxin', 'concentration', 'was', 'also', 'determined', 'in', '15', 'healthy', 'controls', '.']","(6, 9)","(46, 65)",-1,hl_p,9394106,Abstract,4,test,gold,905.0
7738,,Endotoxin concentration,was also determined in 15 healthy controls .,"['Endotoxin', 'concentration', 'was', 'also', 'determined', 'in', '15', 'healthy', 'controls', '.']","(0, 2)","(0, 23)",-1,hl_o,9394106,Abstract,4,test,gold,4506.0
7739,Groups receiving,paromomycin,or placebo were similar for clinical and biological items collected initially .,"['Groups', 'receiving', 'paromomycin', 'or', 'placebo', 'were', 'similar', 'for', 'clinical', 'and', 'biological', 'items', 'collected', 'initially', '.']","(2, 3)","(16, 27)",-1,ss_i,9394106,Abstract,5,test,gold,246.0
7740,Groups receiving paromomycin or,placebo,were similar for clinical and biological items collected initially .,"['Groups', 'receiving', 'paromomycin', 'or', 'placebo', 'were', 'similar', 'for', 'clinical', 'and', 'biological', 'items', 'collected', 'initially', '.']","(4, 5)","(31, 38)",-1,ss_i,9394106,Abstract,5,test,gold,4277.0
7741,Groups receiving,paromomycin,or placebo were similar for clinical and biological items collected initially .,"['Groups', 'receiving', 'paromomycin', 'or', 'placebo', 'were', 'similar', 'for', 'clinical', 'and', 'biological', 'items', 'collected', 'initially', '.']","(2, 3)","(16, 27)",-1,hl_i,9394106,Abstract,5,test,gold,245.0
7742,Groups receiving paromomycin or,placebo,were similar for clinical and biological items collected initially .,"['Groups', 'receiving', 'paromomycin', 'or', 'placebo', 'were', 'similar', 'for', 'clinical', 'and', 'biological', 'items', 'collected', 'initially', '.']","(4, 5)","(31, 38)",-1,hl_i,9394106,Abstract,5,test,gold,4276.0
7743,Mean initial endotoxin concentrations were significantly elevated in both groups ( mean +/- SEM ;,paromomycin,", 16.7 +/- 5.3 pg/ml ; placebo , 17.5 +/- 6.9 pg/ml ; healthy controls , 2.3 +/- 0.4 pg/ml ) .","['Mean', 'initial', 'endotoxin', 'concentrations', 'were', 'significantly', 'elevated', 'in', 'both', 'groups', '(', 'mean', '+/-', 'SEM', ';', 'paromomycin', ',', '16.7', '+/-', '5.3', 'pg/ml', ';', 'placebo', ',', '17.5', '+/-', '6.9', 'pg/ml', ';', 'healthy', 'controls', ',', '2.3', '+/-', '0.4', 'pg/ml', ')', '.']","(15, 16)","(97, 108)",-1,ss_i,9394106,Abstract,6,test,gold,244.0
7744,"Mean initial endotoxin concentrations were significantly elevated in both groups ( mean +/- SEM ; paromomycin , 16.7 +/- 5.3 pg/ml ;",placebo,", 17.5 +/- 6.9 pg/ml ; healthy controls , 2.3 +/- 0.4 pg/ml ) .","['Mean', 'initial', 'endotoxin', 'concentrations', 'were', 'significantly', 'elevated', 'in', 'both', 'groups', '(', 'mean', '+/-', 'SEM', ';', 'paromomycin', ',', '16.7', '+/-', '5.3', 'pg/ml', ';', 'placebo', ',', '17.5', '+/-', '6.9', 'pg/ml', ';', 'healthy', 'controls', ',', '2.3', '+/-', '0.4', 'pg/ml', ')', '.']","(22, 23)","(132, 139)",-1,ss_i,9394106,Abstract,6,test,gold,4275.0
7745,Mean initial,endotoxin concentrations,"were significantly elevated in both groups ( mean +/- SEM ; paromomycin , 16.7 +/- 5.3 pg/ml ; placebo , 17.5 +/- 6.9 pg/ml ; healthy controls , 2.3 +/- 0.4 pg/ml ) .","['Mean', 'initial', 'endotoxin', 'concentrations', 'were', 'significantly', 'elevated', 'in', 'both', 'groups', '(', 'mean', '+/-', 'SEM', ';', 'paromomycin', ',', '16.7', '+/-', '5.3', 'pg/ml', ';', 'placebo', ',', '17.5', '+/-', '6.9', 'pg/ml', ';', 'healthy', 'controls', ',', '2.3', '+/-', '0.4', 'pg/ml', ')', '.']","(2, 4)","(12, 36)",-1,ss_o,9394106,Abstract,6,test,gold,4503.0
7746,Mean initial endotoxin concentrations were significantly elevated in both groups ( mean +/- SEM ;,paromomycin,", 16.7 +/- 5.3 pg/ml ; placebo , 17.5 +/- 6.9 pg/ml ; healthy controls , 2.3 +/- 0.4 pg/ml ) .","['Mean', 'initial', 'endotoxin', 'concentrations', 'were', 'significantly', 'elevated', 'in', 'both', 'groups', '(', 'mean', '+/-', 'SEM', ';', 'paromomycin', ',', '16.7', '+/-', '5.3', 'pg/ml', ';', 'placebo', ',', '17.5', '+/-', '6.9', 'pg/ml', ';', 'healthy', 'controls', ',', '2.3', '+/-', '0.4', 'pg/ml', ')', '.']","(15, 16)","(97, 108)",-1,hl_i,9394106,Abstract,6,test,gold,243.0
7747,"Mean initial endotoxin concentrations were significantly elevated in both groups ( mean +/- SEM ; paromomycin , 16.7 +/- 5.3 pg/ml ;",placebo,", 17.5 +/- 6.9 pg/ml ; healthy controls , 2.3 +/- 0.4 pg/ml ) .","['Mean', 'initial', 'endotoxin', 'concentrations', 'were', 'significantly', 'elevated', 'in', 'both', 'groups', '(', 'mean', '+/-', 'SEM', ';', 'paromomycin', ',', '16.7', '+/-', '5.3', 'pg/ml', ';', 'placebo', ',', '17.5', '+/-', '6.9', 'pg/ml', ';', 'healthy', 'controls', ',', '2.3', '+/-', '0.4', 'pg/ml', ')', '.']","(22, 23)","(132, 139)",-1,hl_i,9394106,Abstract,6,test,gold,4274.0
7748,Mean initial,endotoxin concentrations,"were significantly elevated in both groups ( mean +/- SEM ; paromomycin , 16.7 +/- 5.3 pg/ml ; placebo , 17.5 +/- 6.9 pg/ml ; healthy controls , 2.3 +/- 0.4 pg/ml ) .","['Mean', 'initial', 'endotoxin', 'concentrations', 'were', 'significantly', 'elevated', 'in', 'both', 'groups', '(', 'mean', '+/-', 'SEM', ';', 'paromomycin', ',', '16.7', '+/-', '5.3', 'pg/ml', ';', 'placebo', ',', '17.5', '+/-', '6.9', 'pg/ml', ';', 'healthy', 'controls', ',', '2.3', '+/-', '0.4', 'pg/ml', ')', '.']","(2, 4)","(12, 36)",-1,hl_o,9394106,Abstract,6,test,gold,4504.0
7749,Although the mean endotoxin concentration was lower in the verum group after 1 week,( paromomycin,", 8.0 +/- 1.9 pg/ml ; placebo , 14.6 +/- 3.5 pg/ml ; p > 0.05 ) , paromomycin treatment had no significant effect on endotoxin concentration or liver function tests during the 4-week period .","['Although', 'the', 'mean', 'endotoxin', 'concentration', 'was', 'lower', 'in', 'the', 'verum', 'group', 'after', '1', 'week', '(', 'paromomycin', ',', '8.0', '+/-', '1.9', 'pg/ml', ';', 'placebo', ',', '14.6', '+/-', '3.5', 'pg/ml', ';', 'p', '>', '0.05', ')', ',', 'paromomycin', 'treatment', 'had', 'no', 'significant', 'effect', 'on', 'endotoxin', 'concentration', 'or', 'liver', 'function', 'tests', 'during', 'the', '4-week', 'period', '.']","(14, 16)","(83, 96)",-1,ss_i,9394106,Abstract,7,test,gold,242.0
7750,"Although the mean endotoxin concentration was lower in the verum group after 1 week ( paromomycin , 8.0 +/- 1.9 pg/ml ;",placebo,", 14.6 +/- 3.5 pg/ml ; p > 0.05 ) , paromomycin treatment had no significant effect on endotoxin concentration or liver function tests during the 4-week period .","['Although', 'the', 'mean', 'endotoxin', 'concentration', 'was', 'lower', 'in', 'the', 'verum', 'group', 'after', '1', 'week', '(', 'paromomycin', ',', '8.0', '+/-', '1.9', 'pg/ml', ';', 'placebo', ',', '14.6', '+/-', '3.5', 'pg/ml', ';', 'p', '>', '0.05', ')', ',', 'paromomycin', 'treatment', 'had', 'no', 'significant', 'effect', 'on', 'endotoxin', 'concentration', 'or', 'liver', 'function', 'tests', 'during', 'the', '4-week', 'period', '.']","(22, 23)","(119, 126)",-1,ss_i,9394106,Abstract,7,test,gold,4273.0
7751,"Although the mean endotoxin concentration was lower in the verum group after 1 week ( paromomycin , 8.0 +/- 1.9 pg/ml ; placebo , 14.6 +/- 3.5 pg/ml ; p > 0.05 ) ,",paromomycin,treatment had no significant effect on endotoxin concentration or liver function tests during the 4-week period .,"['Although', 'the', 'mean', 'endotoxin', 'concentration', 'was', 'lower', 'in', 'the', 'verum', 'group', 'after', '1', 'week', '(', 'paromomycin', ',', '8.0', '+/-', '1.9', 'pg/ml', ';', 'placebo', ',', '14.6', '+/-', '3.5', 'pg/ml', ';', 'p', '>', '0.05', ')', ',', 'paromomycin', 'treatment', 'had', 'no', 'significant', 'effect', 'on', 'endotoxin', 'concentration', 'or', 'liver', 'function', 'tests', 'during', 'the', '4-week', 'period', '.']","(34, 35)","(163, 174)",-1,ss_i,9394106,Abstract,7,test,gold,241.0
7752,Although the mean,endotoxin concentration,"was lower in the verum group after 1 week ( paromomycin , 8.0 +/- 1.9 pg/ml ; placebo , 14.6 +/- 3.5 pg/ml ; p > 0.05 ) , paromomycin treatment had no significant effect on endotoxin concentration or liver function tests during the 4-week period .","['Although', 'the', 'mean', 'endotoxin', 'concentration', 'was', 'lower', 'in', 'the', 'verum', 'group', 'after', '1', 'week', '(', 'paromomycin', ',', '8.0', '+/-', '1.9', 'pg/ml', ';', 'placebo', ',', '14.6', '+/-', '3.5', 'pg/ml', ';', 'p', '>', '0.05', ')', ',', 'paromomycin', 'treatment', 'had', 'no', 'significant', 'effect', 'on', 'endotoxin', 'concentration', 'or', 'liver', 'function', 'tests', 'during', 'the', '4-week', 'period', '.']","(3, 5)","(17, 40)",-1,ss_o,9394106,Abstract,7,test,gold,4501.0
7753,"Although the mean endotoxin concentration was lower in the verum group after 1 week ( paromomycin , 8.0 +/- 1.9 pg/ml ; placebo , 14.6 +/- 3.5 pg/ml ; p > 0.05 ) , paromomycin treatment had no significant effect on",endotoxin concentration or liver function tests,during the 4-week period .,"['Although', 'the', 'mean', 'endotoxin', 'concentration', 'was', 'lower', 'in', 'the', 'verum', 'group', 'after', '1', 'week', '(', 'paromomycin', ',', '8.0', '+/-', '1.9', 'pg/ml', ';', 'placebo', ',', '14.6', '+/-', '3.5', 'pg/ml', ';', 'p', '>', '0.05', ')', ',', 'paromomycin', 'treatment', 'had', 'no', 'significant', 'effect', 'on', 'endotoxin', 'concentration', 'or', 'liver', 'function', 'tests', 'during', 'the', '4-week', 'period', '.']","(41, 47)","(214, 261)",-1,ss_o,9394106,Abstract,7,test,gold,3150.0
7754,Although the mean endotoxin concentration was lower in the verum group after 1 week (,paromomycin,", 8.0 +/- 1.9 pg/ml ; placebo , 14.6 +/- 3.5 pg/ml ; p > 0.05 ) , paromomycin treatment had no significant effect on endotoxin concentration or liver function tests during the 4-week period .","['Although', 'the', 'mean', 'endotoxin', 'concentration', 'was', 'lower', 'in', 'the', 'verum', 'group', 'after', '1', 'week', '(', 'paromomycin', ',', '8.0', '+/-', '1.9', 'pg/ml', ';', 'placebo', ',', '14.6', '+/-', '3.5', 'pg/ml', ';', 'p', '>', '0.05', ')', ',', 'paromomycin', 'treatment', 'had', 'no', 'significant', 'effect', 'on', 'endotoxin', 'concentration', 'or', 'liver', 'function', 'tests', 'during', 'the', '4-week', 'period', '.']","(15, 16)","(85, 96)",-1,hl_i,9394106,Abstract,7,test,gold,240.0
7755,"Although the mean endotoxin concentration was lower in the verum group after 1 week ( paromomycin , 8.0 +/- 1.9 pg/ml ;",placebo,", 14.6 +/- 3.5 pg/ml ; p > 0.05 ) , paromomycin treatment had no significant effect on endotoxin concentration or liver function tests during the 4-week period .","['Although', 'the', 'mean', 'endotoxin', 'concentration', 'was', 'lower', 'in', 'the', 'verum', 'group', 'after', '1', 'week', '(', 'paromomycin', ',', '8.0', '+/-', '1.9', 'pg/ml', ';', 'placebo', ',', '14.6', '+/-', '3.5', 'pg/ml', ';', 'p', '>', '0.05', ')', ',', 'paromomycin', 'treatment', 'had', 'no', 'significant', 'effect', 'on', 'endotoxin', 'concentration', 'or', 'liver', 'function', 'tests', 'during', 'the', '4-week', 'period', '.']","(22, 23)","(119, 126)",-1,hl_i,9394106,Abstract,7,test,gold,4272.0
7756,"Although the mean endotoxin concentration was lower in the verum group after 1 week ( paromomycin , 8.0 +/- 1.9 pg/ml ; placebo , 14.6 +/- 3.5 pg/ml ; p > 0.05 ) ,",paromomycin,treatment had no significant effect on endotoxin concentration or liver function tests during the 4-week period .,"['Although', 'the', 'mean', 'endotoxin', 'concentration', 'was', 'lower', 'in', 'the', 'verum', 'group', 'after', '1', 'week', '(', 'paromomycin', ',', '8.0', '+/-', '1.9', 'pg/ml', ';', 'placebo', ',', '14.6', '+/-', '3.5', 'pg/ml', ';', 'p', '>', '0.05', ')', ',', 'paromomycin', 'treatment', 'had', 'no', 'significant', 'effect', 'on', 'endotoxin', 'concentration', 'or', 'liver', 'function', 'tests', 'during', 'the', '4-week', 'period', '.']","(34, 35)","(163, 174)",-1,hl_i,9394106,Abstract,7,test,gold,239.0
7757,Although the mean,endotoxin concentration,"was lower in the verum group after 1 week ( paromomycin , 8.0 +/- 1.9 pg/ml ; placebo , 14.6 +/- 3.5 pg/ml ; p > 0.05 ) , paromomycin treatment had no significant effect on endotoxin concentration or liver function tests during the 4-week period .","['Although', 'the', 'mean', 'endotoxin', 'concentration', 'was', 'lower', 'in', 'the', 'verum', 'group', 'after', '1', 'week', '(', 'paromomycin', ',', '8.0', '+/-', '1.9', 'pg/ml', ';', 'placebo', ',', '14.6', '+/-', '3.5', 'pg/ml', ';', 'p', '>', '0.05', ')', ',', 'paromomycin', 'treatment', 'had', 'no', 'significant', 'effect', 'on', 'endotoxin', 'concentration', 'or', 'liver', 'function', 'tests', 'during', 'the', '4-week', 'period', '.']","(3, 5)","(17, 40)",-1,hl_o,9394106,Abstract,7,test,gold,4502.0
7758,"Although the mean endotoxin concentration was lower in the verum group after 1 week ( paromomycin , 8.0 +/- 1.9 pg/ml ; placebo , 14.6 +/- 3.5 pg/ml ; p > 0.05 ) , paromomycin treatment had no significant effect on",endotoxin concentration,or liver function tests during the 4-week period .,"['Although', 'the', 'mean', 'endotoxin', 'concentration', 'was', 'lower', 'in', 'the', 'verum', 'group', 'after', '1', 'week', '(', 'paromomycin', ',', '8.0', '+/-', '1.9', 'pg/ml', ';', 'placebo', ',', '14.6', '+/-', '3.5', 'pg/ml', ';', 'p', '>', '0.05', ')', ',', 'paromomycin', 'treatment', 'had', 'no', 'significant', 'effect', 'on', 'endotoxin', 'concentration', 'or', 'liver', 'function', 'tests', 'during', 'the', '4-week', 'period', '.']","(41, 43)","(214, 237)",-1,hl_o,9394106,Abstract,7,test,gold,4500.0
7759,"Although the mean endotoxin concentration was lower in the verum group after 1 week ( paromomycin , 8.0 +/- 1.9 pg/ml ; placebo , 14.6 +/- 3.5 pg/ml ; p > 0.05 ) , paromomycin treatment had no significant effect on endotoxin concentration or",liver function tests,during the 4-week period .,"['Although', 'the', 'mean', 'endotoxin', 'concentration', 'was', 'lower', 'in', 'the', 'verum', 'group', 'after', '1', 'week', '(', 'paromomycin', ',', '8.0', '+/-', '1.9', 'pg/ml', ';', 'placebo', ',', '14.6', '+/-', '3.5', 'pg/ml', ';', 'p', '>', '0.05', ')', ',', 'paromomycin', 'treatment', 'had', 'no', 'significant', 'effect', 'on', 'endotoxin', 'concentration', 'or', 'liver', 'function', 'tests', 'during', 'the', '4-week', 'period', '.']","(44, 47)","(241, 261)",-1,hl_o,9394106,Abstract,7,test,gold,3156.0
7760,The beneficial effect of paromomycin treatment on endotoxemia in cirrhotics reported in earlier studies could not be reproduced under the conditions of this trial in,patients with alcoholic liver disease .,,"['The', 'beneficial', 'effect', 'of', 'paromomycin', 'treatment', 'on', 'endotoxemia', 'in', 'cirrhotics', 'reported', 'in', 'earlier', 'studies', 'could', 'not', 'be', 'reproduced', 'under', 'the', 'conditions', 'of', 'this', 'trial', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '.']","(25, 31)","(165, 204)",-1,ss_p,9394106,Abstract,8,test,gold,7033.0
7761,The beneficial effect of,paromomycin,treatment on endotoxemia in cirrhotics reported in earlier studies could not be reproduced under the conditions of this trial in patients with alcoholic liver disease .,"['The', 'beneficial', 'effect', 'of', 'paromomycin', 'treatment', 'on', 'endotoxemia', 'in', 'cirrhotics', 'reported', 'in', 'earlier', 'studies', 'could', 'not', 'be', 'reproduced', 'under', 'the', 'conditions', 'of', 'this', 'trial', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '.']","(4, 5)","(24, 35)",-1,ss_i,9394106,Abstract,8,test,gold,238.0
7762,The beneficial effect of paromomycin treatment on endotoxemia in cirrhotics reported in earlier studies could not be reproduced under the conditions of this trial in,patients with alcoholic liver disease .,,"['The', 'beneficial', 'effect', 'of', 'paromomycin', 'treatment', 'on', 'endotoxemia', 'in', 'cirrhotics', 'reported', 'in', 'earlier', 'studies', 'could', 'not', 'be', 'reproduced', 'under', 'the', 'conditions', 'of', 'this', 'trial', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '.']","(25, 31)","(165, 204)",-1,hl_p,9394106,Abstract,8,test,gold,7032.0
7763,The beneficial effect of,paromomycin,treatment on endotoxemia in cirrhotics reported in earlier studies could not be reproduced under the conditions of this trial in patients with alcoholic liver disease .,"['The', 'beneficial', 'effect', 'of', 'paromomycin', 'treatment', 'on', 'endotoxemia', 'in', 'cirrhotics', 'reported', 'in', 'earlier', 'studies', 'could', 'not', 'be', 'reproduced', 'under', 'the', 'conditions', 'of', 'this', 'trial', 'in', 'patients', 'with', 'alcoholic', 'liver', 'disease', '.']","(4, 5)","(24, 35)",-1,hl_i,9394106,Abstract,8,test,gold,237.0
7764,Effect of indomethacin phonophoresis on the relief of,temporomandibular joint pain .,,"['Effect', 'of', 'indomethacin', 'phonophoresis', 'on', 'the', 'relief', 'of', 'temporomandibular', 'joint', 'pain', '.']","(8, 12)","(53, 83)",-1,ss_p,9481998,Title,0,test,gold,3122.0
7765,Effect of,indomethacin phonophoresis,on the relief of temporomandibular joint pain .,"['Effect', 'of', 'indomethacin', 'phonophoresis', 'on', 'the', 'relief', 'of', 'temporomandibular', 'joint', 'pain', '.']","(2, 4)","(9, 35)",-1,ss_i,9481998,Title,0,test,gold,5525.0
7766,Effect of indomethacin phonophoresis on the relief of temporomandibular joint,pain .,,"['Effect', 'of', 'indomethacin', 'phonophoresis', 'on', 'the', 'relief', 'of', 'temporomandibular', 'joint', 'pain', '.']","(10, 12)","(77, 83)",-1,ss_o,9481998,Title,0,test,gold,2285.0
7767,Effect of indomethacin phonophoresis on the relief of,temporomandibular joint pain .,,"['Effect', 'of', 'indomethacin', 'phonophoresis', 'on', 'the', 'relief', 'of', 'temporomandibular', 'joint', 'pain', '.']","(8, 12)","(53, 83)",-1,hl_p,9481998,Title,0,test,gold,3123.0
7768,Effect of,indomethacin phonophoresis,on the relief of temporomandibular joint pain .,"['Effect', 'of', 'indomethacin', 'phonophoresis', 'on', 'the', 'relief', 'of', 'temporomandibular', 'joint', 'pain', '.']","(2, 4)","(9, 35)",-1,hl_i,9481998,Title,0,test,gold,5526.0
7769,The pain-relieving effect of indomethacin phonophoresis on,temporomandibular ( TMJ ) joint pain,"was evaluated in a double-blind , placebo-controlled clinical trial .","['The', 'pain-relieving', 'effect', 'of', 'indomethacin', 'phonophoresis', 'on', 'temporomandibular', '(', 'TMJ', ')', 'joint', 'pain', 'was', 'evaluated', 'in', 'a', 'double-blind', ',', 'placebo-controlled', 'clinical', 'trial', '.']","(7, 13)","(58, 94)",-1,ss_p,9481998,Abstract,0,test,gold,3121.0
7770,The pain-relieving effect of,indomethacin phonophoresis,"on temporomandibular ( TMJ ) joint pain was evaluated in a double-blind , placebo-controlled clinical trial .","['The', 'pain-relieving', 'effect', 'of', 'indomethacin', 'phonophoresis', 'on', 'temporomandibular', '(', 'TMJ', ')', 'joint', 'pain', 'was', 'evaluated', 'in', 'a', 'double-blind', ',', 'placebo-controlled', 'clinical', 'trial', '.']","(4, 6)","(28, 54)",-1,ss_i,9481998,Abstract,0,test,gold,5524.0
7771,"The pain-relieving effect of indomethacin phonophoresis on temporomandibular ( TMJ ) joint pain was evaluated in a double-blind ,",placebo-controlled,clinical trial .,"['The', 'pain-relieving', 'effect', 'of', 'indomethacin', 'phonophoresis', 'on', 'temporomandibular', '(', 'TMJ', ')', 'joint', 'pain', 'was', 'evaluated', 'in', 'a', 'double-blind', ',', 'placebo-controlled', 'clinical', 'trial', '.']","(19, 20)","(129, 147)",-1,ss_i,9481998,Abstract,0,test,gold,
7772,The,pain-relieving,"effect of indomethacin phonophoresis on temporomandibular ( TMJ ) joint pain was evaluated in a double-blind , placebo-controlled clinical trial .","['The', 'pain-relieving', 'effect', 'of', 'indomethacin', 'phonophoresis', 'on', 'temporomandibular', '(', 'TMJ', ')', 'joint', 'pain', 'was', 'evaluated', 'in', 'a', 'double-blind', ',', 'placebo-controlled', 'clinical', 'trial', '.']","(1, 2)","(3, 17)",-1,ss_o,9481998,Abstract,0,test,gold,
7773,The pain-relieving effect of,indomethacin phonophoresis,"on temporomandibular ( TMJ ) joint pain was evaluated in a double-blind , placebo-controlled clinical trial .","['The', 'pain-relieving', 'effect', 'of', 'indomethacin', 'phonophoresis', 'on', 'temporomandibular', '(', 'TMJ', ')', 'joint', 'pain', 'was', 'evaluated', 'in', 'a', 'double-blind', ',', 'placebo-controlled', 'clinical', 'trial', '.']","(4, 6)","(28, 54)",-1,hl_i,9481998,Abstract,0,test,gold,5523.0
7774,"The pain-relieving effect of indomethacin phonophoresis on temporomandibular ( TMJ ) joint pain was evaluated in a double-blind ,",placebo-controlled,clinical trial .,"['The', 'pain-relieving', 'effect', 'of', 'indomethacin', 'phonophoresis', 'on', 'temporomandibular', '(', 'TMJ', ')', 'joint', 'pain', 'was', 'evaluated', 'in', 'a', 'double-blind', ',', 'placebo-controlled', 'clinical', 'trial', '.']","(19, 20)","(129, 147)",-1,hl_i,9481998,Abstract,0,test,gold,
7775,The,pain-relieving,"effect of indomethacin phonophoresis on temporomandibular ( TMJ ) joint pain was evaluated in a double-blind , placebo-controlled clinical trial .","['The', 'pain-relieving', 'effect', 'of', 'indomethacin', 'phonophoresis', 'on', 'temporomandibular', '(', 'TMJ', ')', 'joint', 'pain', 'was', 'evaluated', 'in', 'a', 'double-blind', ',', 'placebo-controlled', 'clinical', 'trial', '.']","(1, 2)","(3, 17)",-1,hl_o,9481998,Abstract,0,test,gold,
7776,,"Twenty subjects , who have TMJ pain , were included for this study",and randomly assigned to either the experimental group ( n = 10 ) or the control group ( n = 10 ) .,"['Twenty', 'subjects', ',', 'who', 'have', 'TMJ', 'pain', ',', 'were', 'included', 'for', 'this', 'study', 'and', 'randomly', 'assigned', 'to', 'either', 'the', 'experimental', 'group', '(', 'n', '=', '10', ')', 'or', 'the', 'control', 'group', '(', 'n', '=', '10', ')', '.']","(0, 13)","(0, 66)",-1,ss_p,9481998,Abstract,1,test,gold,3707.0
7777,,"Twenty subjects , who have TMJ pain",", were included for this study and randomly assigned to either the experimental group ( n = 10 ) or the control group ( n = 10 ) .","['Twenty', 'subjects', ',', 'who', 'have', 'TMJ', 'pain', ',', 'were', 'included', 'for', 'this', 'study', 'and', 'randomly', 'assigned', 'to', 'either', 'the', 'experimental', 'group', '(', 'n', '=', '10', ')', 'or', 'the', 'control', 'group', '(', 'n', '=', '10', ')', '.']","(0, 7)","(0, 35)",-1,hl_p,9481998,Abstract,1,test,gold,3708.0
7778,"Each treatment consisted of the application of ultrasound massage ( 1.0 MHz , 0.8 to 1.5 W/cm2 continuous output ) for 15 minutes to the painful temporomandibular joint .",,,"['Each', 'treatment', 'consisted', 'of', 'the', 'application', 'of', 'ultrasound', 'massage', '(', '1.0', 'MHz', ',', '0.8', 'to', '1.5', 'W/cm2', 'continuous', 'output', ')', 'for', '15', 'minutes', 'to', 'the', 'painful', 'temporomandibular', 'joint', '.']",,,,,9481998,Abstract,2,test,gold,
7779,"As a conducting medium , 1 %",indomethacin,cream was used for the experimental group and placebo cream for the control group respectively .,"['As', 'a', 'conducting', 'medium', ',', '1', '%', 'indomethacin', 'cream', 'was', 'used', 'for', 'the', 'experimental', 'group', 'and', 'placebo', 'cream', 'for', 'the', 'control', 'group', 'respectively', '.']","(7, 8)","(28, 40)",-1,ss_i,9481998,Abstract,3,test,gold,5522.0
7780,"As a conducting medium , 1 % indomethacin cream was used for the experimental group and",placebo,cream for the control group respectively .,"['As', 'a', 'conducting', 'medium', ',', '1', '%', 'indomethacin', 'cream', 'was', 'used', 'for', 'the', 'experimental', 'group', 'and', 'placebo', 'cream', 'for', 'the', 'control', 'group', 'respectively', '.']","(16, 17)","(87, 94)",-1,ss_i,9481998,Abstract,3,test,gold,4271.0
7781,"As a conducting medium , 1 %",indomethacin,cream was used for the experimental group and placebo cream for the control group respectively .,"['As', 'a', 'conducting', 'medium', ',', '1', '%', 'indomethacin', 'cream', 'was', 'used', 'for', 'the', 'experimental', 'group', 'and', 'placebo', 'cream', 'for', 'the', 'control', 'group', 'respectively', '.']","(7, 8)","(28, 40)",-1,hl_i,9481998,Abstract,3,test,gold,5521.0
7782,"As a conducting medium , 1 % indomethacin cream was used for the experimental group and",placebo,cream for the control group respectively .,"['As', 'a', 'conducting', 'medium', ',', '1', '%', 'indomethacin', 'cream', 'was', 'used', 'for', 'the', 'experimental', 'group', 'and', 'placebo', 'cream', 'for', 'the', 'control', 'group', 'respectively', '.']","(16, 17)","(87, 94)",-1,hl_i,9481998,Abstract,3,test,gold,4270.0
7783,,Pre- and post-treatment pain levels and pain sensitivity,were assessed with visual analogue scales ( VAS ) and pressure pain threshold ( PPT ) .,"['Pre-', 'and', 'post-treatment', 'pain', 'levels', 'and', 'pain', 'sensitivity', 'were', 'assessed', 'with', 'visual', 'analogue', 'scales', '(', 'VAS', ')', 'and', 'pressure', 'pain', 'threshold', '(', 'PPT', ')', '.']","(0, 8)","(0, 56)",-1,ss_o,9481998,Abstract,4,test,gold,2277.0
7784,Pre- and post-treatment pain levels and pain sensitivity were assessed with,visual analogue scales ( VAS ) and pressure pain threshold ( PPT ) .,,"['Pre-', 'and', 'post-treatment', 'pain', 'levels', 'and', 'pain', 'sensitivity', 'were', 'assessed', 'with', 'visual', 'analogue', 'scales', '(', 'VAS', ')', 'and', 'pressure', 'pain', 'threshold', '(', 'PPT', ')', '.']","(11, 25)","(75, 143)",-1,ss_o,9481998,Abstract,4,test,gold,6438.0
7785,Pre- and post-treatment,pain levels,and pain sensitivity were assessed with visual analogue scales ( VAS ) and pressure pain threshold ( PPT ) .,"['Pre-', 'and', 'post-treatment', 'pain', 'levels', 'and', 'pain', 'sensitivity', 'were', 'assessed', 'with', 'visual', 'analogue', 'scales', '(', 'VAS', ')', 'and', 'pressure', 'pain', 'threshold', '(', 'PPT', ')', '.']","(3, 5)","(23, 34)",-1,hl_o,9481998,Abstract,4,test,gold,2308.0
7786,Pre- and post-treatment pain levels and,pain sensitivity,were assessed with visual analogue scales ( VAS ) and pressure pain threshold ( PPT ) .,"['Pre-', 'and', 'post-treatment', 'pain', 'levels', 'and', 'pain', 'sensitivity', 'were', 'assessed', 'with', 'visual', 'analogue', 'scales', '(', 'VAS', ')', 'and', 'pressure', 'pain', 'threshold', '(', 'PPT', ')', '.']","(6, 8)","(39, 55)",-1,hl_o,9481998,Abstract,4,test,gold,1396.0
7787,Pre- and post-treatment pain levels and pain sensitivity were assessed with,visual analogue scales ( VAS ),and pressure pain threshold ( PPT ) .,"['Pre-', 'and', 'post-treatment', 'pain', 'levels', 'and', 'pain', 'sensitivity', 'were', 'assessed', 'with', 'visual', 'analogue', 'scales', '(', 'VAS', ')', 'and', 'pressure', 'pain', 'threshold', '(', 'PPT', ')', '.']","(11, 17)","(75, 105)",-1,hl_o,9481998,Abstract,4,test,gold,6439.0
7788,Pre- and post-treatment pain levels and pain sensitivity were assessed with visual analogue scales ( VAS ) and,pressure pain threshold ( PPT ),.,"['Pre-', 'and', 'post-treatment', 'pain', 'levels', 'and', 'pain', 'sensitivity', 'were', 'assessed', 'with', 'visual', 'analogue', 'scales', '(', 'VAS', ')', 'and', 'pressure', 'pain', 'threshold', '(', 'PPT', ')', '.']","(18, 24)","(110, 141)",-1,hl_o,9481998,Abstract,4,test,gold,2276.0
7789,Mean data indicated that,post-treatment VAS,"was significantly decreased and post-treatment PPT was significantly increased in the experimental group , not in the control group .","['Mean', 'data', 'indicated', 'that', 'post-treatment', 'VAS', 'was', 'significantly', 'decreased', 'and', 'post-treatment', 'PPT', 'was', 'significantly', 'increased', 'in', 'the', 'experimental', 'group', ',', 'not', 'in', 'the', 'control', 'group', '.']","(4, 6)","(24, 42)",-1,ss_o,9481998,Abstract,5,test,gold,378.0
7790,Mean data indicated that post-treatment VAS was significantly decreased and,post-treatment PPT,"was significantly increased in the experimental group , not in the control group .","['Mean', 'data', 'indicated', 'that', 'post-treatment', 'VAS', 'was', 'significantly', 'decreased', 'and', 'post-treatment', 'PPT', 'was', 'significantly', 'increased', 'in', 'the', 'experimental', 'group', ',', 'not', 'in', 'the', 'control', 'group', '.']","(10, 12)","(75, 93)",-1,ss_o,9481998,Abstract,5,test,gold,1096.0
7791,Mean data indicated that,post-treatment VAS,"was significantly decreased and post-treatment PPT was significantly increased in the experimental group , not in the control group .","['Mean', 'data', 'indicated', 'that', 'post-treatment', 'VAS', 'was', 'significantly', 'decreased', 'and', 'post-treatment', 'PPT', 'was', 'significantly', 'increased', 'in', 'the', 'experimental', 'group', ',', 'not', 'in', 'the', 'control', 'group', '.']","(4, 6)","(24, 42)",-1,hl_o,9481998,Abstract,5,test,gold,379.0
7792,Mean data indicated that post-treatment VAS was significantly decreased and,post-treatment PPT,"was significantly increased in the experimental group , not in the control group .","['Mean', 'data', 'indicated', 'that', 'post-treatment', 'VAS', 'was', 'significantly', 'decreased', 'and', 'post-treatment', 'PPT', 'was', 'significantly', 'increased', 'in', 'the', 'experimental', 'group', ',', 'not', 'in', 'the', 'control', 'group', '.']","(10, 12)","(75, 93)",-1,hl_o,9481998,Abstract,5,test,gold,1097.0
7793,The results of this study suggest that,indomethacin phonophoresis,provides significant pain relieving effect over the TMJ pain .,"['The', 'results', 'of', 'this', 'study', 'suggest', 'that', 'indomethacin', 'phonophoresis', 'provides', 'significant', 'pain', 'relieving', 'effect', 'over', 'the', 'TMJ', 'pain', '.']","(7, 9)","(38, 64)",-1,ss_i,9481998,Abstract,6,test,gold,5520.0
7794,The results of this study suggest that indomethacin phonophoresis provides significant,pain,relieving effect over the TMJ pain .,"['The', 'results', 'of', 'this', 'study', 'suggest', 'that', 'indomethacin', 'phonophoresis', 'provides', 'significant', 'pain', 'relieving', 'effect', 'over', 'the', 'TMJ', 'pain', '.']","(11, 12)","(86, 90)",-1,ss_o,9481998,Abstract,6,test,gold,2284.0
7795,The results of this study suggest that,indomethacin phonophoresis,provides significant pain relieving effect over the TMJ pain .,"['The', 'results', 'of', 'this', 'study', 'suggest', 'that', 'indomethacin', 'phonophoresis', 'provides', 'significant', 'pain', 'relieving', 'effect', 'over', 'the', 'TMJ', 'pain', '.']","(7, 9)","(38, 64)",-1,hl_i,9481998,Abstract,6,test,gold,5519.0
7796,The results of this study suggest that indomethacin phonophoresis provides significant,pain,relieving effect over the TMJ pain .,"['The', 'results', 'of', 'this', 'study', 'suggest', 'that', 'indomethacin', 'phonophoresis', 'provides', 'significant', 'pain', 'relieving', 'effect', 'over', 'the', 'TMJ', 'pain', '.']","(11, 12)","(86, 90)",-1,hl_o,9481998,Abstract,6,test,gold,2283.0
7797,"Systemic hemodynamic , neurohormonal , and renal effects of a steady-state infusion of human brain natriuretic peptide in",patients with hemodynamically decompensated heart failure .,,"['Systemic', 'hemodynamic', ',', 'neurohormonal', ',', 'and', 'renal', 'effects', 'of', 'a', 'steady-state', 'infusion', 'of', 'human', 'brain', 'natriuretic', 'peptide', 'in', 'patients', 'with', 'hemodynamically', 'decompensated', 'heart', 'failure', '.']","(18, 25)","(121, 180)",-1,ss_p,9573502,Title,0,test,gold,7073.0
7798,"Systemic hemodynamic , neurohormonal , and renal effects of a steady-state infusion of",human brain natriuretic peptide,in patients with hemodynamically decompensated heart failure .,"['Systemic', 'hemodynamic', ',', 'neurohormonal', ',', 'and', 'renal', 'effects', 'of', 'a', 'steady-state', 'infusion', 'of', 'human', 'brain', 'natriuretic', 'peptide', 'in', 'patients', 'with', 'hemodynamically', 'decompensated', 'heart', 'failure', '.']","(13, 17)","(86, 117)",-1,ss_i,9573502,Title,0,test,gold,6638.0
7799,,"Systemic hemodynamic , neurohormonal , and renal effects",of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure .,"['Systemic', 'hemodynamic', ',', 'neurohormonal', ',', 'and', 'renal', 'effects', 'of', 'a', 'steady-state', 'infusion', 'of', 'human', 'brain', 'natriuretic', 'peptide', 'in', 'patients', 'with', 'hemodynamically', 'decompensated', 'heart', 'failure', '.']","(0, 8)","(0, 56)",-1,ss_o,9573502,Title,0,test,gold,6814.0
7800,"Systemic hemodynamic , neurohormonal , and renal effects of a steady-state infusion of human brain natriuretic peptide in",patients with hemodynamically decompensated heart failure .,,"['Systemic', 'hemodynamic', ',', 'neurohormonal', ',', 'and', 'renal', 'effects', 'of', 'a', 'steady-state', 'infusion', 'of', 'human', 'brain', 'natriuretic', 'peptide', 'in', 'patients', 'with', 'hemodynamically', 'decompensated', 'heart', 'failure', '.']","(18, 25)","(121, 180)",-1,hl_p,9573502,Title,0,test,gold,7074.0
7801,"Systemic hemodynamic , neurohormonal , and renal effects of a steady-state infusion of",human brain natriuretic peptide,in patients with hemodynamically decompensated heart failure .,"['Systemic', 'hemodynamic', ',', 'neurohormonal', ',', 'and', 'renal', 'effects', 'of', 'a', 'steady-state', 'infusion', 'of', 'human', 'brain', 'natriuretic', 'peptide', 'in', 'patients', 'with', 'hemodynamically', 'decompensated', 'heart', 'failure', '.']","(13, 17)","(86, 117)",-1,hl_i,9573502,Title,0,test,gold,6639.0
7802,,"Systemic hemodynamic , neurohormonal",", and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure .","['Systemic', 'hemodynamic', ',', 'neurohormonal', ',', 'and', 'renal', 'effects', 'of', 'a', 'steady-state', 'infusion', 'of', 'human', 'brain', 'natriuretic', 'peptide', 'in', 'patients', 'with', 'hemodynamically', 'decompensated', 'heart', 'failure', '.']","(0, 4)","(0, 36)",-1,hl_o,9573502,Title,0,test,gold,3233.0
7803,"Systemic hemodynamic , neurohormonal , and",renal effects,of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure .,"['Systemic', 'hemodynamic', ',', 'neurohormonal', ',', 'and', 'renal', 'effects', 'of', 'a', 'steady-state', 'infusion', 'of', 'human', 'brain', 'natriuretic', 'peptide', 'in', 'patients', 'with', 'hemodynamically', 'decompensated', 'heart', 'failure', '.']","(6, 8)","(42, 55)",-1,hl_o,9573502,Title,0,test,gold,2356.0
7804,BACKGROUND,Human brain natriuretic peptide ( hBNP ),is a promising agent for the treatment of decompensated cardiac failure .,"['BACKGROUND', 'Human', 'brain', 'natriuretic', 'peptide', '(', 'hBNP', ')', 'is', 'a', 'promising', 'agent', 'for', 'the', 'treatment', 'of', 'decompensated', 'cardiac', 'failure', '.']","(1, 8)","(10, 50)",-1,ss_i,9573502,Abstract,0,test,gold,6640.0
7805,BACKGROUND,Human brain natriuretic peptide ( hBNP ),is a promising agent for the treatment of decompensated cardiac failure .,"['BACKGROUND', 'Human', 'brain', 'natriuretic', 'peptide', '(', 'hBNP', ')', 'is', 'a', 'promising', 'agent', 'for', 'the', 'treatment', 'of', 'decompensated', 'cardiac', 'failure', '.']","(1, 8)","(10, 50)",-1,hl_i,9573502,Abstract,0,test,gold,6641.0
7806,"However , the systemic hemodynamic , neurohormonal , and renal effects of",hBNP,have been incompletely studied in human heart failure .,"['However', ',', 'the', 'systemic', 'hemodynamic', ',', 'neurohormonal', ',', 'and', 'renal', 'effects', 'of', 'hBNP', 'have', 'been', 'incompletely', 'studied', 'in', 'human', 'heart', 'failure', '.']","(12, 13)","(73, 77)",-1,ss_i,9573502,Abstract,1,test,gold,
7807,"However , the","systemic hemodynamic , neurohormonal , and renal effects",of hBNP have been incompletely studied in human heart failure .,"['However', ',', 'the', 'systemic', 'hemodynamic', ',', 'neurohormonal', ',', 'and', 'renal', 'effects', 'of', 'hBNP', 'have', 'been', 'incompletely', 'studied', 'in', 'human', 'heart', 'failure', '.']","(3, 11)","(13, 69)",-1,ss_o,9573502,Abstract,1,test,gold,6815.0
7808,"However , the systemic hemodynamic , neurohormonal , and renal effects of",hBNP,have been incompletely studied in human heart failure .,"['However', ',', 'the', 'systemic', 'hemodynamic', ',', 'neurohormonal', ',', 'and', 'renal', 'effects', 'of', 'hBNP', 'have', 'been', 'incompletely', 'studied', 'in', 'human', 'heart', 'failure', '.']","(12, 13)","(73, 77)",-1,hl_i,9573502,Abstract,1,test,gold,
7809,"However , the",systemic hemodynamic,", neurohormonal , and renal effects of hBNP have been incompletely studied in human heart failure .","['However', ',', 'the', 'systemic', 'hemodynamic', ',', 'neurohormonal', ',', 'and', 'renal', 'effects', 'of', 'hBNP', 'have', 'been', 'incompletely', 'studied', 'in', 'human', 'heart', 'failure', '.']","(3, 5)","(13, 33)",-1,hl_o,9573502,Abstract,1,test,gold,3234.0
7810,"However , the systemic hemodynamic ,",neurohormonal,", and renal effects of hBNP have been incompletely studied in human heart failure .","['However', ',', 'the', 'systemic', 'hemodynamic', ',', 'neurohormonal', ',', 'and', 'renal', 'effects', 'of', 'hBNP', 'have', 'been', 'incompletely', 'studied', 'in', 'human', 'heart', 'failure', '.']","(6, 7)","(36, 49)",-1,hl_o,9573502,Abstract,1,test,gold,73.0
7811,"However , the systemic hemodynamic , neurohormonal , and",renal effects,of hBNP have been incompletely studied in human heart failure .,"['However', ',', 'the', 'systemic', 'hemodynamic', ',', 'neurohormonal', ',', 'and', 'renal', 'effects', 'of', 'hBNP', 'have', 'been', 'incompletely', 'studied', 'in', 'human', 'heart', 'failure', '.']","(9, 11)","(56, 69)",-1,hl_o,9573502,Abstract,1,test,gold,2357.0
7812,METHODS AND RESULTS The effects of a continuous 4-hour infusion of hBNP were determined in,16 decompensated heart failure patients,"in an invasive , randomized , double-blind , placebo-controlled study .","['METHODS', 'AND', 'RESULTS', 'The', 'effects', 'of', 'a', 'continuous', '4-hour', 'infusion', 'of', 'hBNP', 'were', 'determined', 'in', '16', 'decompensated', 'heart', 'failure', 'patients', 'in', 'an', 'invasive', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', '.']","(15, 20)","(90, 129)",-1,ss_p,9573502,Abstract,2,test,gold,7071.0
7813,METHODS AND RESULTS The effects of a continuous 4-hour infusion of,hBNP,"were determined in 16 decompensated heart failure patients in an invasive , randomized , double-blind , placebo-controlled study .","['METHODS', 'AND', 'RESULTS', 'The', 'effects', 'of', 'a', 'continuous', '4-hour', 'infusion', 'of', 'hBNP', 'were', 'determined', 'in', '16', 'decompensated', 'heart', 'failure', 'patients', 'in', 'an', 'invasive', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', '.']","(11, 12)","(66, 70)",-1,ss_i,9573502,Abstract,2,test,gold,
7814,"METHODS AND RESULTS The effects of a continuous 4-hour infusion of hBNP were determined in 16 decompensated heart failure patients in an invasive , randomized , double-blind ,",placebo-controlled,study .,"['METHODS', 'AND', 'RESULTS', 'The', 'effects', 'of', 'a', 'continuous', '4-hour', 'infusion', 'of', 'hBNP', 'were', 'determined', 'in', '16', 'decompensated', 'heart', 'failure', 'patients', 'in', 'an', 'invasive', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', '.']","(28, 29)","(175, 193)",-1,ss_i,9573502,Abstract,2,test,gold,
7815,METHODS AND RESULTS The effects of a continuous 4-hour infusion of hBNP were determined in,16 decompensated heart failure patients,"in an invasive , randomized , double-blind , placebo-controlled study .","['METHODS', 'AND', 'RESULTS', 'The', 'effects', 'of', 'a', 'continuous', '4-hour', 'infusion', 'of', 'hBNP', 'were', 'determined', 'in', '16', 'decompensated', 'heart', 'failure', 'patients', 'in', 'an', 'invasive', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', '.']","(15, 20)","(90, 129)",-1,hl_p,9573502,Abstract,2,test,gold,7072.0
7816,METHODS AND RESULTS The effects of a continuous 4-hour infusion of,hBNP,"were determined in 16 decompensated heart failure patients in an invasive , randomized , double-blind , placebo-controlled study .","['METHODS', 'AND', 'RESULTS', 'The', 'effects', 'of', 'a', 'continuous', '4-hour', 'infusion', 'of', 'hBNP', 'were', 'determined', 'in', '16', 'decompensated', 'heart', 'failure', 'patients', 'in', 'an', 'invasive', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', '.']","(11, 12)","(66, 70)",-1,hl_i,9573502,Abstract,2,test,gold,
7817,"METHODS AND RESULTS The effects of a continuous 4-hour infusion of hBNP were determined in 16 decompensated heart failure patients in an invasive , randomized , double-blind ,",placebo-controlled,study .,"['METHODS', 'AND', 'RESULTS', 'The', 'effects', 'of', 'a', 'continuous', '4-hour', 'infusion', 'of', 'hBNP', 'were', 'determined', 'in', '16', 'decompensated', 'heart', 'failure', 'patients', 'in', 'an', 'invasive', ',', 'randomized', ',', 'double-blind', ',', 'placebo-controlled', 'study', '.']","(28, 29)","(175, 193)",-1,hl_i,9573502,Abstract,2,test,gold,
7818,"Patients were evaluated during three 4-hour study periods : baseline , treatment",( placebo,"[ n = 4 ] versus hBNP 0.025 or 0.05 microgram/kg/min [ n = 12 ] ) , and post-treatment .","['Patients', 'were', 'evaluated', 'during', 'three', '4-hour', 'study', 'periods', ':', 'baseline', ',', 'treatment', '(', 'placebo', '[', 'n', '=', '4', ']', 'versus', 'hBNP', '0.025', 'or', '0.05', 'microgram/kg/min', '[', 'n', '=', '12', ']', ')', ',', 'and', 'post-treatment', '.']","(12, 14)","(80, 89)",-1,ss_i,9573502,Abstract,3,test,gold,4269.0
7819,"Patients were evaluated during three 4-hour study periods : baseline , treatment ( placebo [ n = 4 ] versus",hBNP,"0.025 or 0.05 microgram/kg/min [ n = 12 ] ) , and post-treatment .","['Patients', 'were', 'evaluated', 'during', 'three', '4-hour', 'study', 'periods', ':', 'baseline', ',', 'treatment', '(', 'placebo', '[', 'n', '=', '4', ']', 'versus', 'hBNP', '0.025', 'or', '0.05', 'microgram/kg/min', '[', 'n', '=', '12', ']', ')', ',', 'and', 'post-treatment', '.']","(20, 21)","(107, 111)",-1,ss_i,9573502,Abstract,3,test,gold,
7820,"Patients were evaluated during three 4-hour study periods : baseline , treatment (",placebo,"[ n = 4 ] versus hBNP 0.025 or 0.05 microgram/kg/min [ n = 12 ] ) , and post-treatment .","['Patients', 'were', 'evaluated', 'during', 'three', '4-hour', 'study', 'periods', ':', 'baseline', ',', 'treatment', '(', 'placebo', '[', 'n', '=', '4', ']', 'versus', 'hBNP', '0.025', 'or', '0.05', 'microgram/kg/min', '[', 'n', '=', '12', ']', ')', ',', 'and', 'post-treatment', '.']","(13, 14)","(82, 89)",-1,hl_i,9573502,Abstract,3,test,gold,4268.0
7821,"Patients were evaluated during three 4-hour study periods : baseline , treatment ( placebo [ n = 4 ] versus",hBNP,"0.025 or 0.05 microgram/kg/min [ n = 12 ] ) , and post-treatment .","['Patients', 'were', 'evaluated', 'during', 'three', '4-hour', 'study', 'periods', ':', 'baseline', ',', 'treatment', '(', 'placebo', '[', 'n', '=', '4', ']', 'versus', 'hBNP', '0.025', 'or', '0.05', 'microgram/kg/min', '[', 'n', '=', '12', ']', ')', ',', 'and', 'post-treatment', '.']","(20, 21)","(107, 111)",-1,hl_i,9573502,Abstract,3,test,gold,
7822,Urinary volume losses were replaced hourly to separate the vasodilatory and diuretic effects of,hBNP .,,"['Urinary', 'volume', 'losses', 'were', 'replaced', 'hourly', 'to', 'separate', 'the', 'vasodilatory', 'and', 'diuretic', 'effects', 'of', 'hBNP', '.']","(14, 16)","(95, 101)",-1,ss_i,9573502,Abstract,4,test,gold,
7823,,Urinary volume losses,were replaced hourly to separate the vasodilatory and diuretic effects of hBNP .,"['Urinary', 'volume', 'losses', 'were', 'replaced', 'hourly', 'to', 'separate', 'the', 'vasodilatory', 'and', 'diuretic', 'effects', 'of', 'hBNP', '.']","(0, 3)","(0, 21)",-1,ss_o,9573502,Abstract,4,test,gold,1727.0
7824,Urinary volume losses were replaced hourly to separate the vasodilatory and diuretic effects of,hBNP .,,"['Urinary', 'volume', 'losses', 'were', 'replaced', 'hourly', 'to', 'separate', 'the', 'vasodilatory', 'and', 'diuretic', 'effects', 'of', 'hBNP', '.']","(14, 16)","(95, 101)",-1,hl_i,9573502,Abstract,4,test,gold,
7825,Two patients in the,hBNP,group were excluded from the analysis because of adverse events .,"['Two', 'patients', 'in', 'the', 'hBNP', 'group', 'were', 'excluded', 'from', 'the', 'analysis', 'because', 'of', 'adverse', 'events', '.']","(4, 5)","(19, 23)",-1,ss_i,9573502,Abstract,5,test,gold,
7826,Two patients in the hBNP group were excluded from the analysis because of,adverse events .,,"['Two', 'patients', 'in', 'the', 'hBNP', 'group', 'were', 'excluded', 'from', 'the', 'analysis', 'because', 'of', 'adverse', 'events', '.']","(13, 16)","(73, 89)",-1,ss_o,9573502,Abstract,5,test,gold,3057.0
7827,Two patients in the,hBNP,group were excluded from the analysis because of adverse events .,"['Two', 'patients', 'in', 'the', 'hBNP', 'group', 'were', 'excluded', 'from', 'the', 'analysis', 'because', 'of', 'adverse', 'events', '.']","(4, 5)","(19, 23)",-1,hl_i,9573502,Abstract,5,test,gold,
7828,Two patients in the hBNP group were excluded from the analysis because of,adverse events .,,"['Two', 'patients', 'in', 'the', 'hBNP', 'group', 'were', 'excluded', 'from', 'the', 'analysis', 'because', 'of', 'adverse', 'events', '.']","(13, 16)","(73, 89)",-1,hl_o,9573502,Abstract,5,test,gold,3056.0
7829,,hBNP,"significantly ( P < .001 ) reduced right atrial pressure and pulmonary capillary wedge pressure by approximately 30 % and 40 % , respectively .","['hBNP', 'significantly', '(', 'P', '<', '.001', ')', 'reduced', 'right', 'atrial', 'pressure', 'and', 'pulmonary', 'capillary', 'wedge', 'pressure', 'by', 'approximately', '30', '%', 'and', '40', '%', ',', 'respectively', '.']","(0, 1)","(0, 4)",-1,ss_i,9573502,Abstract,6,test,gold,
7830,hBNP significantly ( P < .001 ) reduced,right atrial pressure and pulmonary capillary wedge pressure,"by approximately 30 % and 40 % , respectively .","['hBNP', 'significantly', '(', 'P', '<', '.001', ')', 'reduced', 'right', 'atrial', 'pressure', 'and', 'pulmonary', 'capillary', 'wedge', 'pressure', 'by', 'approximately', '30', '%', 'and', '40', '%', ',', 'respectively', '.']","(8, 16)","(39, 99)",-1,ss_o,9573502,Abstract,6,test,gold,6723.0
7831,,hBNP,"significantly ( P < .001 ) reduced right atrial pressure and pulmonary capillary wedge pressure by approximately 30 % and 40 % , respectively .","['hBNP', 'significantly', '(', 'P', '<', '.001', ')', 'reduced', 'right', 'atrial', 'pressure', 'and', 'pulmonary', 'capillary', 'wedge', 'pressure', 'by', 'approximately', '30', '%', 'and', '40', '%', ',', 'respectively', '.']","(0, 1)","(0, 4)",-1,hl_i,9573502,Abstract,6,test,gold,
7832,hBNP significantly ( P < .001 ) reduced,right atrial pressure and pulmonary capillary wedge pressure,"by approximately 30 % and 40 % , respectively .","['hBNP', 'significantly', '(', 'P', '<', '.001', ')', 'reduced', 'right', 'atrial', 'pressure', 'and', 'pulmonary', 'capillary', 'wedge', 'pressure', 'by', 'approximately', '30', '%', 'and', '40', '%', ',', 'respectively', '.']","(8, 16)","(39, 99)",-1,hl_o,9573502,Abstract,6,test,gold,6724.0
7833,,hBNP,also significantly lowered systemic vascular resistance from 1722 +/- 139 to 1101 +/- 83 dynes.s.cm-5 ( P < .05 ) .,"['hBNP', 'also', 'significantly', 'lowered', 'systemic', 'vascular', 'resistance', 'from', '1722', '+/-', '139', 'to', '1101', '+/-', '83', 'dynes.s.cm-5', '(', 'P', '<', '.05', ')', '.']","(0, 1)","(0, 4)",-1,ss_i,9573502,Abstract,7,test,gold,
7834,hBNP also significantly lowered,systemic vascular resistance,from 1722 +/- 139 to 1101 +/- 83 dynes.s.cm-5 ( P < .05 ) .,"['hBNP', 'also', 'significantly', 'lowered', 'systemic', 'vascular', 'resistance', 'from', '1722', '+/-', '139', 'to', '1101', '+/-', '83', 'dynes.s.cm-5', '(', 'P', '<', '.05', ')', '.']","(4, 7)","(31, 59)",-1,ss_o,9573502,Abstract,7,test,gold,6804.0
7835,,hBNP,also significantly lowered systemic vascular resistance from 1722 +/- 139 to 1101 +/- 83 dynes.s.cm-5 ( P < .05 ) .,"['hBNP', 'also', 'significantly', 'lowered', 'systemic', 'vascular', 'resistance', 'from', '1722', '+/-', '139', 'to', '1101', '+/-', '83', 'dynes.s.cm-5', '(', 'P', '<', '.05', ')', '.']","(0, 1)","(0, 4)",-1,hl_i,9573502,Abstract,7,test,gold,
7836,hBNP also significantly lowered,systemic vascular resistance,from 1722 +/- 139 to 1101 +/- 83 dynes.s.cm-5 ( P < .05 ) .,"['hBNP', 'also', 'significantly', 'lowered', 'systemic', 'vascular', 'resistance', 'from', '1722', '+/-', '139', 'to', '1101', '+/-', '83', 'dynes.s.cm-5', '(', 'P', '<', '.05', ')', '.']","(4, 7)","(31, 59)",-1,hl_o,9573502,Abstract,7,test,gold,6805.0
7837,These unloading effects of,hBNP,produced a 28 % increase in cardiac index ( P < .05 ) with no change in heart rate .,"['These', 'unloading', 'effects', 'of', 'hBNP', 'produced', 'a', '28', '%', 'increase', 'in', 'cardiac', 'index', '(', 'P', '<', '.05', ')', 'with', 'no', 'change', 'in', 'heart', 'rate', '.']","(4, 5)","(26, 30)",-1,ss_i,9573502,Abstract,8,test,gold,
7838,These unloading effects of hBNP produced a 28 % increase in,cardiac index,( P < .05 ) with no change in heart rate .,"['These', 'unloading', 'effects', 'of', 'hBNP', 'produced', 'a', '28', '%', 'increase', 'in', 'cardiac', 'index', '(', 'P', '<', '.05', ')', 'with', 'no', 'change', 'in', 'heart', 'rate', '.']","(11, 13)","(59, 72)",-1,ss_o,9573502,Abstract,8,test,gold,1998.0
7839,These unloading effects of hBNP produced a 28 % increase in cardiac index ( P < .05 ) with no change in,heart rate .,,"['These', 'unloading', 'effects', 'of', 'hBNP', 'produced', 'a', '28', '%', 'increase', 'in', 'cardiac', 'index', '(', 'P', '<', '.05', ')', 'with', 'no', 'change', 'in', 'heart', 'rate', '.']","(22, 25)","(103, 115)",-1,ss_o,9573502,Abstract,8,test,gold,1940.0
7840,These unloading effects of,hBNP,produced a 28 % increase in cardiac index ( P < .05 ) with no change in heart rate .,"['These', 'unloading', 'effects', 'of', 'hBNP', 'produced', 'a', '28', '%', 'increase', 'in', 'cardiac', 'index', '(', 'P', '<', '.05', ')', 'with', 'no', 'change', 'in', 'heart', 'rate', '.']","(4, 5)","(26, 30)",-1,hl_i,9573502,Abstract,8,test,gold,
7841,These unloading effects of hBNP produced a 28 % increase in,cardiac index,( P < .05 ) with no change in heart rate .,"['These', 'unloading', 'effects', 'of', 'hBNP', 'produced', 'a', '28', '%', 'increase', 'in', 'cardiac', 'index', '(', 'P', '<', '.05', ')', 'with', 'no', 'change', 'in', 'heart', 'rate', '.']","(11, 13)","(59, 72)",-1,hl_o,9573502,Abstract,8,test,gold,1999.0
7842,These unloading effects of hBNP produced a 28 % increase in cardiac index ( P < .05 ) with no change in,heart rate .,,"['These', 'unloading', 'effects', 'of', 'hBNP', 'produced', 'a', '28', '%', 'increase', 'in', 'cardiac', 'index', '(', 'P', '<', '.05', ')', 'with', 'no', 'change', 'in', 'heart', 'rate', '.']","(22, 25)","(103, 115)",-1,hl_o,9573502,Abstract,8,test,gold,1941.0
7843,Compared to,"placebo , hBNP",decreased plasma norepinephrine and aldosterone .,"['Compared', 'to', 'placebo', ',', 'hBNP', 'decreased', 'plasma', 'norepinephrine', 'and', 'aldosterone', '.']","(2, 5)","(11, 25)",-1,ss_i,9573502,Abstract,9,test,gold,4267.0
7844,"Compared to placebo , hBNP decreased",plasma norepinephrine and aldosterone .,,"['Compared', 'to', 'placebo', ',', 'hBNP', 'decreased', 'plasma', 'norepinephrine', 'and', 'aldosterone', '.']","(6, 11)","(36, 75)",-1,ss_o,9573502,Abstract,9,test,gold,6607.0
7845,Compared to,placebo,", hBNP decreased plasma norepinephrine and aldosterone .","['Compared', 'to', 'placebo', ',', 'hBNP', 'decreased', 'plasma', 'norepinephrine', 'and', 'aldosterone', '.']","(2, 3)","(11, 18)",-1,hl_i,9573502,Abstract,9,test,gold,4266.0
7846,"Compared to placebo ,",hBNP,decreased plasma norepinephrine and aldosterone .,"['Compared', 'to', 'placebo', ',', 'hBNP', 'decreased', 'plasma', 'norepinephrine', 'and', 'aldosterone', '.']","(4, 5)","(21, 25)",-1,hl_i,9573502,Abstract,9,test,gold,
7847,"Compared to placebo , hBNP decreased",plasma norepinephrine and aldosterone .,,"['Compared', 'to', 'placebo', ',', 'hBNP', 'decreased', 'plasma', 'norepinephrine', 'and', 'aldosterone', '.']","(6, 11)","(36, 75)",-1,hl_o,9573502,Abstract,9,test,gold,6608.0
7848,Renal hemodynamics were unaffected by,hBNP ;,"however , most patients were resistant to its natriuretic effect .","['Renal', 'hemodynamics', 'were', 'unaffected', 'by', 'hBNP', ';', 'however', ',', 'most', 'patients', 'were', 'resistant', 'to', 'its', 'natriuretic', 'effect', '.']","(5, 7)","(37, 43)",-1,ss_i,9573502,Abstract,10,test,gold,
7849,,Renal hemodynamics,"were unaffected by hBNP ; however , most patients were resistant to its natriuretic effect .","['Renal', 'hemodynamics', 'were', 'unaffected', 'by', 'hBNP', ';', 'however', ',', 'most', 'patients', 'were', 'resistant', 'to', 'its', 'natriuretic', 'effect', '.']","(0, 2)","(0, 18)",-1,ss_o,9573502,Abstract,10,test,gold,3205.0
7850,"Renal hemodynamics were unaffected by hBNP ; however , most patients were resistant to its",natriuretic effect .,,"['Renal', 'hemodynamics', 'were', 'unaffected', 'by', 'hBNP', ';', 'however', ',', 'most', 'patients', 'were', 'resistant', 'to', 'its', 'natriuretic', 'effect', '.']","(15, 18)","(90, 110)",-1,ss_o,9573502,Abstract,10,test,gold,2344.0
7851,Renal hemodynamics were unaffected by,hBNP ;,"however , most patients were resistant to its natriuretic effect .","['Renal', 'hemodynamics', 'were', 'unaffected', 'by', 'hBNP', ';', 'however', ',', 'most', 'patients', 'were', 'resistant', 'to', 'its', 'natriuretic', 'effect', '.']","(5, 7)","(37, 43)",-1,hl_i,9573502,Abstract,10,test,gold,
7852,,Renal hemodynamics,"were unaffected by hBNP ; however , most patients were resistant to its natriuretic effect .","['Renal', 'hemodynamics', 'were', 'unaffected', 'by', 'hBNP', ';', 'however', ',', 'most', 'patients', 'were', 'resistant', 'to', 'its', 'natriuretic', 'effect', '.']","(0, 2)","(0, 18)",-1,hl_o,9573502,Abstract,10,test,gold,3206.0
7853,"Renal hemodynamics were unaffected by hBNP ; however , most patients were resistant to its",natriuretic effect .,,"['Renal', 'hemodynamics', 'were', 'unaffected', 'by', 'hBNP', ';', 'however', ',', 'most', 'patients', 'were', 'resistant', 'to', 'its', 'natriuretic', 'effect', '.']","(15, 18)","(90, 110)",-1,hl_o,9573502,Abstract,10,test,gold,2345.0
7854,CONCLUSIONS 1 ) The predominant hemodynamic effects of,hBNP,were a decrease in cardiac preload and systemic vascular resistance .,"['CONCLUSIONS', '1', ')', 'The', 'predominant', 'hemodynamic', 'effects', 'of', 'hBNP', 'were', 'a', 'decrease', 'in', 'cardiac', 'preload', 'and', 'systemic', 'vascular', 'resistance', '.']","(8, 9)","(54, 58)",-1,ss_i,9573502,Abstract,11,test,gold,
7855,CONCLUSIONS 1 ) The predominant,hemodynamic effects,of hBNP were a decrease in cardiac preload and systemic vascular resistance .,"['CONCLUSIONS', '1', ')', 'The', 'predominant', 'hemodynamic', 'effects', 'of', 'hBNP', 'were', 'a', 'decrease', 'in', 'cardiac', 'preload', 'and', 'systemic', 'vascular', 'resistance', '.']","(5, 7)","(31, 50)",-1,ss_o,9573502,Abstract,11,test,gold,3235.0
7856,CONCLUSIONS 1 ) The predominant hemodynamic effects of hBNP were a decrease in,cardiac preload and systemic vascular resistance .,,"['CONCLUSIONS', '1', ')', 'The', 'predominant', 'hemodynamic', 'effects', 'of', 'hBNP', 'were', 'a', 'decrease', 'in', 'cardiac', 'preload', 'and', 'systemic', 'vascular', 'resistance', '.']","(13, 20)","(78, 128)",-1,ss_o,9573502,Abstract,11,test,gold,6806.0
7857,CONCLUSIONS 1 ) The predominant hemodynamic effects of,hBNP,were a decrease in cardiac preload and systemic vascular resistance .,"['CONCLUSIONS', '1', ')', 'The', 'predominant', 'hemodynamic', 'effects', 'of', 'hBNP', 'were', 'a', 'decrease', 'in', 'cardiac', 'preload', 'and', 'systemic', 'vascular', 'resistance', '.']","(8, 9)","(54, 58)",-1,hl_i,9573502,Abstract,11,test,gold,
7858,CONCLUSIONS 1 ) The predominant,hemodynamic effects,of hBNP were a decrease in cardiac preload and systemic vascular resistance .,"['CONCLUSIONS', '1', ')', 'The', 'predominant', 'hemodynamic', 'effects', 'of', 'hBNP', 'were', 'a', 'decrease', 'in', 'cardiac', 'preload', 'and', 'systemic', 'vascular', 'resistance', '.']","(5, 7)","(31, 50)",-1,hl_o,9573502,Abstract,11,test,gold,3236.0
7859,CONCLUSIONS 1 ) The predominant hemodynamic effects of hBNP were a decrease in,cardiac preload and systemic vascular resistance .,,"['CONCLUSIONS', '1', ')', 'The', 'predominant', 'hemodynamic', 'effects', 'of', 'hBNP', 'were', 'a', 'decrease', 'in', 'cardiac', 'preload', 'and', 'systemic', 'vascular', 'resistance', '.']","(13, 20)","(78, 128)",-1,hl_o,9573502,Abstract,11,test,gold,6807.0
7860,2 ),hBNP,also improved cardiac output without increasing heart rate .,"['2', ')', 'hBNP', 'also', 'improved', 'cardiac', 'output', 'without', 'increasing', 'heart', 'rate', '.']","(2, 3)","(3, 7)",-1,ss_i,9573502,Abstract,12,test,gold,
7861,2 ) hBNP also improved,cardiac output,without increasing heart rate .,"['2', ')', 'hBNP', 'also', 'improved', 'cardiac', 'output', 'without', 'increasing', 'heart', 'rate', '.']","(5, 7)","(22, 36)",-1,ss_o,9573502,Abstract,12,test,gold,3221.0
7862,2 ) hBNP also improved cardiac output without increasing,heart rate .,,"['2', ')', 'hBNP', 'also', 'improved', 'cardiac', 'output', 'without', 'increasing', 'heart', 'rate', '.']","(9, 12)","(56, 68)",-1,ss_o,9573502,Abstract,12,test,gold,1939.0
7863,2 ),hBNP,also improved cardiac output without increasing heart rate .,"['2', ')', 'hBNP', 'also', 'improved', 'cardiac', 'output', 'without', 'increasing', 'heart', 'rate', '.']","(2, 3)","(3, 7)",-1,hl_i,9573502,Abstract,12,test,gold,
7864,2 ) hBNP also improved,cardiac output,without increasing heart rate .,"['2', ')', 'hBNP', 'also', 'improved', 'cardiac', 'output', 'without', 'increasing', 'heart', 'rate', '.']","(5, 7)","(22, 36)",-1,hl_o,9573502,Abstract,12,test,gold,3222.0
7865,2 ) hBNP also improved cardiac output without increasing,heart rate .,,"['2', ')', 'hBNP', 'also', 'improved', 'cardiac', 'output', 'without', 'increasing', 'heart', 'rate', '.']","(9, 12)","(56, 68)",-1,hl_o,9573502,Abstract,12,test,gold,1938.0
7866,3 ) Plasma norepinephrine and aldosterone levels decreased during,hBNP,infusion .,"['3', ')', 'Plasma', 'norepinephrine', 'and', 'aldosterone', 'levels', 'decreased', 'during', 'hBNP', 'infusion', '.']","(9, 10)","(65, 69)",-1,ss_i,9573502,Abstract,13,test,gold,
7867,3 ),Plasma norepinephrine and aldosterone levels,decreased during hBNP infusion .,"['3', ')', 'Plasma', 'norepinephrine', 'and', 'aldosterone', 'levels', 'decreased', 'during', 'hBNP', 'infusion', '.']","(2, 7)","(3, 47)",-1,ss_o,9573502,Abstract,13,test,gold,6605.0
7868,3 ) Plasma norepinephrine and aldosterone levels decreased during,hBNP,infusion .,"['3', ')', 'Plasma', 'norepinephrine', 'and', 'aldosterone', 'levels', 'decreased', 'during', 'hBNP', 'infusion', '.']","(9, 10)","(65, 69)",-1,hl_i,9573502,Abstract,13,test,gold,
7869,3 ),Plasma norepinephrine and aldosterone levels,decreased during hBNP infusion .,"['3', ')', 'Plasma', 'norepinephrine', 'and', 'aldosterone', 'levels', 'decreased', 'during', 'hBNP', 'infusion', '.']","(2, 7)","(3, 47)",-1,hl_o,9573502,Abstract,13,test,gold,6606.0
7870,4 ) hBNP is pharmacologically active and has potential in the therapy for,decompensated heart failure .,,"['4', ')', 'hBNP', 'is', 'pharmacologically', 'active', 'and', 'has', 'potential', 'in', 'the', 'therapy', 'for', 'decompensated', 'heart', 'failure', '.']","(13, 17)","(73, 102)",-1,ss_p,9573502,Abstract,14,test,gold,7066.0
7871,4 ),hBNP,is pharmacologically active and has potential in the therapy for decompensated heart failure .,"['4', ')', 'hBNP', 'is', 'pharmacologically', 'active', 'and', 'has', 'potential', 'in', 'the', 'therapy', 'for', 'decompensated', 'heart', 'failure', '.']","(2, 3)","(3, 7)",-1,ss_i,9573502,Abstract,14,test,gold,
7872,4 ),hBNP,is pharmacologically active and has potential in the therapy for decompensated heart failure .,"['4', ')', 'hBNP', 'is', 'pharmacologically', 'active', 'and', 'has', 'potential', 'in', 'the', 'therapy', 'for', 'decompensated', 'heart', 'failure', '.']","(2, 3)","(3, 7)",-1,hl_i,9573502,Abstract,14,test,gold,
7873,Salbutamol or mist in,acute bronchiolitis .,,"['Salbutamol', 'or', 'mist', 'in', 'acute', 'bronchiolitis', '.']","(4, 7)","(21, 42)",-1,ss_p,9695300,Title,0,test,gold,3468.0
7874,,Salbutamol,or mist in acute bronchiolitis .,"['Salbutamol', 'or', 'mist', 'in', 'acute', 'bronchiolitis', '.']","(0, 1)","(0, 10)",-1,ss_i,9695300,Title,0,test,gold,5040.0
7875,Salbutamol or,mist,in acute bronchiolitis .,"['Salbutamol', 'or', 'mist', 'in', 'acute', 'bronchiolitis', '.']","(2, 3)","(13, 17)",-1,ss_i,9695300,Title,0,test,gold,276.0
7876,Salbutamol or mist in,acute bronchiolitis .,,"['Salbutamol', 'or', 'mist', 'in', 'acute', 'bronchiolitis', '.']","(4, 7)","(21, 42)",-1,hl_p,9695300,Title,0,test,gold,3469.0
7877,,Salbutamol,or mist in acute bronchiolitis .,"['Salbutamol', 'or', 'mist', 'in', 'acute', 'bronchiolitis', '.']","(0, 1)","(0, 10)",-1,hl_i,9695300,Title,0,test,gold,5041.0
7878,Salbutamol or,mist,in acute bronchiolitis .,"['Salbutamol', 'or', 'mist', 'in', 'acute', 'bronchiolitis', '.']","(2, 3)","(13, 17)",-1,hl_i,9695300,Title,0,test,gold,277.0
7879,BACKGROUND The role of bronchodilators in the treatment of bronchiolitis remains controversial .,,,"['BACKGROUND', 'The', 'role', 'of', 'bronchodilators', 'in', 'the', 'treatment', 'of', 'bronchiolitis', 'remains', 'controversial', '.']",,,,,9695300,Abstract,0,test,gold,
7880,"METHODS A double-blind ,",placebo,controlled trial was performed to evaluate the clinical response to nebulized salbutamol .,"['METHODS', 'A', 'double-blind', ',', 'placebo', 'controlled', 'trial', 'was', 'performed', 'to', 'evaluate', 'the', 'clinical', 'response', 'to', 'nebulized', 'salbutamol', '.']","(4, 5)","(24, 31)",-1,ss_i,9695300,Abstract,1,test,gold,4265.0
7881,"METHODS A double-blind , placebo controlled trial was performed to evaluate the clinical response to nebulized",salbutamol .,,"['METHODS', 'A', 'double-blind', ',', 'placebo', 'controlled', 'trial', 'was', 'performed', 'to', 'evaluate', 'the', 'clinical', 'response', 'to', 'nebulized', 'salbutamol', '.']","(16, 18)","(110, 122)",-1,ss_i,9695300,Abstract,1,test,gold,5044.0
7882,"METHODS A double-blind , placebo controlled trial was performed to evaluate the",clinical response,to nebulized salbutamol .,"['METHODS', 'A', 'double-blind', ',', 'placebo', 'controlled', 'trial', 'was', 'performed', 'to', 'evaluate', 'the', 'clinical', 'response', 'to', 'nebulized', 'salbutamol', '.']","(12, 14)","(79, 96)",-1,ss_o,9695300,Abstract,1,test,gold,4770.0
7883,"METHODS A double-blind , placebo controlled trial was performed to evaluate the clinical response to nebulized",salbutamol,.,"['METHODS', 'A', 'double-blind', ',', 'placebo', 'controlled', 'trial', 'was', 'performed', 'to', 'evaluate', 'the', 'clinical', 'response', 'to', 'nebulized', 'salbutamol', '.']","(16, 17)","(110, 120)",-1,hl_i,9695300,Abstract,1,test,gold,5045.0
7884,,One hundred and fifty-six infants aged between 7 weeks and 24 months who had had an episode of wheezing and other signs and symptoms of bronchiolitis,were randomized to three groups as follows : ( i ) nebulized salbutamol was administered to 52 patients in group I at a dose of 0.15 mg/kg in 2 mL saline ; ( ii ) saline was nebulized to 52 patients in group II and ( iii ) in group III 52 patients received mist in a tent .,"['One', 'hundred', 'and', 'fifty-six', 'infants', 'aged', 'between', '7', 'weeks', 'and', '24', 'months', 'who', 'had', 'had', 'an', 'episode', 'of', 'wheezing', 'and', 'other', 'signs', 'and', 'symptoms', 'of', 'bronchiolitis', 'were', 'randomized', 'to', 'three', 'groups', 'as', 'follows', ':', '(', 'i', ')', 'nebulized', 'salbutamol', 'was', 'administered', 'to', '52', 'patients', 'in', 'group', 'I', 'at', 'a', 'dose', 'of', '0.15', 'mg/kg', 'in', '2', 'mL', 'saline', ';', '(', 'ii', ')', 'saline', 'was', 'nebulized', 'to', '52', 'patients', 'in', 'group', 'II', 'and', '(', 'iii', ')', 'in', 'group', 'III', '52', 'patients', 'received', 'mist', 'in', 'a', 'tent', '.']","(0, 26)","(0, 149)",-1,ss_p,9695300,Abstract,2,test,gold,5824.0
7885,One hundred and fifty-six infants aged between 7 weeks and 24 months who had had an episode of wheezing and other signs and symptoms of bronchiolitis were randomized to three groups as follows : ( i ) nebulized,salbutamol,was administered to 52 patients in group I at a dose of 0.15 mg/kg in 2 mL saline ; ( ii ) saline was nebulized to 52 patients in group II and ( iii ) in group III 52 patients received mist in a tent .,"['One', 'hundred', 'and', 'fifty-six', 'infants', 'aged', 'between', '7', 'weeks', 'and', '24', 'months', 'who', 'had', 'had', 'an', 'episode', 'of', 'wheezing', 'and', 'other', 'signs', 'and', 'symptoms', 'of', 'bronchiolitis', 'were', 'randomized', 'to', 'three', 'groups', 'as', 'follows', ':', '(', 'i', ')', 'nebulized', 'salbutamol', 'was', 'administered', 'to', '52', 'patients', 'in', 'group', 'I', 'at', 'a', 'dose', 'of', '0.15', 'mg/kg', 'in', '2', 'mL', 'saline', ';', '(', 'ii', ')', 'saline', 'was', 'nebulized', 'to', '52', 'patients', 'in', 'group', 'II', 'and', '(', 'iii', ')', 'in', 'group', 'III', '52', 'patients', 'received', 'mist', 'in', 'a', 'tent', '.']","(38, 39)","(210, 220)",-1,ss_i,9695300,Abstract,2,test,gold,5043.0
7886,One hundred and fifty-six infants aged between 7 weeks and 24 months who had had an episode of wheezing and other signs and symptoms of bronchiolitis were randomized to three groups as follows : ( i ) nebulized salbutamol was administered to 52 patients in group I at a dose of 0.15 mg/kg in 2 mL,saline ;,( ii ) saline was nebulized to 52 patients in group II and ( iii ) in group III 52 patients received mist in a tent .,"['One', 'hundred', 'and', 'fifty-six', 'infants', 'aged', 'between', '7', 'weeks', 'and', '24', 'months', 'who', 'had', 'had', 'an', 'episode', 'of', 'wheezing', 'and', 'other', 'signs', 'and', 'symptoms', 'of', 'bronchiolitis', 'were', 'randomized', 'to', 'three', 'groups', 'as', 'follows', ':', '(', 'i', ')', 'nebulized', 'salbutamol', 'was', 'administered', 'to', '52', 'patients', 'in', 'group', 'I', 'at', 'a', 'dose', 'of', '0.15', 'mg/kg', 'in', '2', 'mL', 'saline', ';', '(', 'ii', ')', 'saline', 'was', 'nebulized', 'to', '52', 'patients', 'in', 'group', 'II', 'and', '(', 'iii', ')', 'in', 'group', 'III', '52', 'patients', 'received', 'mist', 'in', 'a', 'tent', '.']","(56, 58)","(296, 304)",-1,ss_i,9695300,Abstract,2,test,gold,4912.0
7887,One hundred and fifty-six infants aged between 7 weeks and 24 months who had had an episode of wheezing and other signs and symptoms of bronchiolitis were randomized to three groups as follows : ( i ) nebulized salbutamol was administered to 52 patients in group I at a dose of 0.15 mg/kg in 2 mL saline ; ( ii ),saline,was nebulized to 52 patients in group II and ( iii ) in group III 52 patients received mist in a tent .,"['One', 'hundred', 'and', 'fifty-six', 'infants', 'aged', 'between', '7', 'weeks', 'and', '24', 'months', 'who', 'had', 'had', 'an', 'episode', 'of', 'wheezing', 'and', 'other', 'signs', 'and', 'symptoms', 'of', 'bronchiolitis', 'were', 'randomized', 'to', 'three', 'groups', 'as', 'follows', ':', '(', 'i', ')', 'nebulized', 'salbutamol', 'was', 'administered', 'to', '52', 'patients', 'in', 'group', 'I', 'at', 'a', 'dose', 'of', '0.15', 'mg/kg', 'in', '2', 'mL', 'saline', ';', '(', 'ii', ')', 'saline', 'was', 'nebulized', 'to', '52', 'patients', 'in', 'group', 'II', 'and', '(', 'iii', ')', 'in', 'group', 'III', '52', 'patients', 'received', 'mist', 'in', 'a', 'tent', '.']","(61, 62)","(312, 318)",-1,ss_i,9695300,Abstract,2,test,gold,4911.0
7888,One hundred and fifty-six infants aged between 7 weeks and 24 months who had had an episode of wheezing and other signs and symptoms of bronchiolitis were randomized to three groups as follows : ( i ) nebulized salbutamol was administered to 52 patients in group I at a dose of 0.15 mg/kg in 2 mL saline ; ( ii ) saline was nebulized to 52 patients in group II and ( iii ) in group III 52 patients received,mist,in a tent .,"['One', 'hundred', 'and', 'fifty-six', 'infants', 'aged', 'between', '7', 'weeks', 'and', '24', 'months', 'who', 'had', 'had', 'an', 'episode', 'of', 'wheezing', 'and', 'other', 'signs', 'and', 'symptoms', 'of', 'bronchiolitis', 'were', 'randomized', 'to', 'three', 'groups', 'as', 'follows', ':', '(', 'i', ')', 'nebulized', 'salbutamol', 'was', 'administered', 'to', '52', 'patients', 'in', 'group', 'I', 'at', 'a', 'dose', 'of', '0.15', 'mg/kg', 'in', '2', 'mL', 'saline', ';', '(', 'ii', ')', 'saline', 'was', 'nebulized', 'to', '52', 'patients', 'in', 'group', 'II', 'and', '(', 'iii', ')', 'in', 'group', 'III', '52', 'patients', 'received', 'mist', 'in', 'a', 'tent', '.']","(80, 81)","(406, 410)",-1,ss_i,9695300,Abstract,2,test,gold,275.0
7889,,One hundred and fifty-six infants aged between 7 weeks and 24 months,who had had an episode of wheezing and other signs and symptoms of bronchiolitis were randomized to three groups as follows : ( i ) nebulized salbutamol was administered to 52 patients in group I at a dose of 0.15 mg/kg in 2 mL saline ; ( ii ) saline was nebulized to 52 patients in group II and ( iii ) in group III 52 patients received mist in a tent .,"['One', 'hundred', 'and', 'fifty-six', 'infants', 'aged', 'between', '7', 'weeks', 'and', '24', 'months', 'who', 'had', 'had', 'an', 'episode', 'of', 'wheezing', 'and', 'other', 'signs', 'and', 'symptoms', 'of', 'bronchiolitis', 'were', 'randomized', 'to', 'three', 'groups', 'as', 'follows', ':', '(', 'i', ')', 'nebulized', 'salbutamol', 'was', 'administered', 'to', '52', 'patients', 'in', 'group', 'I', 'at', 'a', 'dose', 'of', '0.15', 'mg/kg', 'in', '2', 'mL', 'saline', ';', '(', 'ii', ')', 'saline', 'was', 'nebulized', 'to', '52', 'patients', 'in', 'group', 'II', 'and', '(', 'iii', ')', 'in', 'group', 'III', '52', 'patients', 'received', 'mist', 'in', 'a', 'tent', '.']","(0, 12)","(0, 68)",-1,hl_p,9695300,Abstract,2,test,gold,5838.0
7890,One hundred and fifty-six infants aged between 7 weeks and 24 months who had,had an episode of wheezing and other signs and symptoms of bronchiolitis,were randomized to three groups as follows : ( i ) nebulized salbutamol was administered to 52 patients in group I at a dose of 0.15 mg/kg in 2 mL saline ; ( ii ) saline was nebulized to 52 patients in group II and ( iii ) in group III 52 patients received mist in a tent .,"['One', 'hundred', 'and', 'fifty-six', 'infants', 'aged', 'between', '7', 'weeks', 'and', '24', 'months', 'who', 'had', 'had', 'an', 'episode', 'of', 'wheezing', 'and', 'other', 'signs', 'and', 'symptoms', 'of', 'bronchiolitis', 'were', 'randomized', 'to', 'three', 'groups', 'as', 'follows', ':', '(', 'i', ')', 'nebulized', 'salbutamol', 'was', 'administered', 'to', '52', 'patients', 'in', 'group', 'I', 'at', 'a', 'dose', 'of', '0.15', 'mg/kg', 'in', '2', 'mL', 'saline', ';', '(', 'ii', ')', 'saline', 'was', 'nebulized', 'to', '52', 'patients', 'in', 'group', 'II', 'and', '(', 'iii', ')', 'in', 'group', 'III', '52', 'patients', 'received', 'mist', 'in', 'a', 'tent', '.']","(14, 26)","(76, 148)",-1,hl_p,9695300,Abstract,2,test,gold,7110.0
7891,One hundred and fifty-six infants aged between 7 weeks and 24 months who had had an episode of wheezing and other signs and symptoms of bronchiolitis were randomized to three groups as follows : ( i ) nebulized,salbutamol,was administered to 52 patients in group I at a dose of 0.15 mg/kg in 2 mL saline ; ( ii ) saline was nebulized to 52 patients in group II and ( iii ) in group III 52 patients received mist in a tent .,"['One', 'hundred', 'and', 'fifty-six', 'infants', 'aged', 'between', '7', 'weeks', 'and', '24', 'months', 'who', 'had', 'had', 'an', 'episode', 'of', 'wheezing', 'and', 'other', 'signs', 'and', 'symptoms', 'of', 'bronchiolitis', 'were', 'randomized', 'to', 'three', 'groups', 'as', 'follows', ':', '(', 'i', ')', 'nebulized', 'salbutamol', 'was', 'administered', 'to', '52', 'patients', 'in', 'group', 'I', 'at', 'a', 'dose', 'of', '0.15', 'mg/kg', 'in', '2', 'mL', 'saline', ';', '(', 'ii', ')', 'saline', 'was', 'nebulized', 'to', '52', 'patients', 'in', 'group', 'II', 'and', '(', 'iii', ')', 'in', 'group', 'III', '52', 'patients', 'received', 'mist', 'in', 'a', 'tent', '.']","(38, 39)","(210, 220)",-1,hl_i,9695300,Abstract,2,test,gold,5042.0
7892,One hundred and fifty-six infants aged between 7 weeks and 24 months who had had an episode of wheezing and other signs and symptoms of bronchiolitis were randomized to three groups as follows : ( i ) nebulized salbutamol was administered to 52 patients in group I at a dose of 0.15 mg/kg in 2 mL,saline,; ( ii ) saline was nebulized to 52 patients in group II and ( iii ) in group III 52 patients received mist in a tent .,"['One', 'hundred', 'and', 'fifty-six', 'infants', 'aged', 'between', '7', 'weeks', 'and', '24', 'months', 'who', 'had', 'had', 'an', 'episode', 'of', 'wheezing', 'and', 'other', 'signs', 'and', 'symptoms', 'of', 'bronchiolitis', 'were', 'randomized', 'to', 'three', 'groups', 'as', 'follows', ':', '(', 'i', ')', 'nebulized', 'salbutamol', 'was', 'administered', 'to', '52', 'patients', 'in', 'group', 'I', 'at', 'a', 'dose', 'of', '0.15', 'mg/kg', 'in', '2', 'mL', 'saline', ';', '(', 'ii', ')', 'saline', 'was', 'nebulized', 'to', '52', 'patients', 'in', 'group', 'II', 'and', '(', 'iii', ')', 'in', 'group', 'III', '52', 'patients', 'received', 'mist', 'in', 'a', 'tent', '.']","(56, 57)","(296, 302)",-1,hl_i,9695300,Abstract,2,test,gold,4910.0
7893,One hundred and fifty-six infants aged between 7 weeks and 24 months who had had an episode of wheezing and other signs and symptoms of bronchiolitis were randomized to three groups as follows : ( i ) nebulized salbutamol was administered to 52 patients in group I at a dose of 0.15 mg/kg in 2 mL saline ; ( ii ),saline,was nebulized to 52 patients in group II and ( iii ) in group III 52 patients received mist in a tent .,"['One', 'hundred', 'and', 'fifty-six', 'infants', 'aged', 'between', '7', 'weeks', 'and', '24', 'months', 'who', 'had', 'had', 'an', 'episode', 'of', 'wheezing', 'and', 'other', 'signs', 'and', 'symptoms', 'of', 'bronchiolitis', 'were', 'randomized', 'to', 'three', 'groups', 'as', 'follows', ':', '(', 'i', ')', 'nebulized', 'salbutamol', 'was', 'administered', 'to', '52', 'patients', 'in', 'group', 'I', 'at', 'a', 'dose', 'of', '0.15', 'mg/kg', 'in', '2', 'mL', 'saline', ';', '(', 'ii', ')', 'saline', 'was', 'nebulized', 'to', '52', 'patients', 'in', 'group', 'II', 'and', '(', 'iii', ')', 'in', 'group', 'III', '52', 'patients', 'received', 'mist', 'in', 'a', 'tent', '.']","(61, 62)","(312, 318)",-1,hl_i,9695300,Abstract,2,test,gold,4909.0
7894,One hundred and fifty-six infants aged between 7 weeks and 24 months who had had an episode of wheezing and other signs and symptoms of bronchiolitis were randomized to three groups as follows : ( i ) nebulized salbutamol was administered to 52 patients in group I at a dose of 0.15 mg/kg in 2 mL saline ; ( ii ) saline was nebulized to 52 patients in group II and ( iii ) in group III 52 patients received,mist,in a tent .,"['One', 'hundred', 'and', 'fifty-six', 'infants', 'aged', 'between', '7', 'weeks', 'and', '24', 'months', 'who', 'had', 'had', 'an', 'episode', 'of', 'wheezing', 'and', 'other', 'signs', 'and', 'symptoms', 'of', 'bronchiolitis', 'were', 'randomized', 'to', 'three', 'groups', 'as', 'follows', ':', '(', 'i', ')', 'nebulized', 'salbutamol', 'was', 'administered', 'to', '52', 'patients', 'in', 'group', 'I', 'at', 'a', 'dose', 'of', '0.15', 'mg/kg', 'in', '2', 'mL', 'saline', ';', '(', 'ii', ')', 'saline', 'was', 'nebulized', 'to', '52', 'patients', 'in', 'group', 'II', 'and', '(', 'iii', ')', 'in', 'group', 'III', '52', 'patients', 'received', 'mist', 'in', 'a', 'tent', '.']","(80, 81)","(406, 410)",-1,hl_i,9695300,Abstract,2,test,gold,274.0
7895,All three groups were administered,oxygen,during the procedures .,"['All', 'three', 'groups', 'were', 'administered', 'oxygen', 'during', 'the', 'procedures', '.']","(5, 6)","(34, 40)",-1,ss_i,9695300,Abstract,3,test,gold,259.0
7896,All three groups were administered,oxygen,during the procedures .,"['All', 'three', 'groups', 'were', 'administered', 'oxygen', 'during', 'the', 'procedures', '.']","(5, 6)","(34, 40)",-1,hl_i,9695300,Abstract,3,test,gold,257.0
7897,Treatment was repeated with the same agent after 30 min if the,respiratory score,was 5 or more .,"['Treatment', 'was', 'repeated', 'with', 'the', 'same', 'agent', 'after', '30', 'min', 'if', 'the', 'respiratory', 'score', 'was', '5', 'or', 'more', '.']","(12, 14)","(62, 79)",-1,ss_o,9695300,Abstract,4,test,gold,3450.0
7898,,"Respiratory rate , heart rate , oxygen saturation and presence of cyanosis , wheezing , retractions",were recorded before and after each treatment .,"['Respiratory', 'rate', ',', 'heart', 'rate', ',', 'oxygen', 'saturation', 'and', 'presence', 'of', 'cyanosis', ',', 'wheezing', ',', 'retractions', 'were', 'recorded', 'before', 'and', 'after', 'each', 'treatment', '.']","(0, 16)","(0, 99)",-1,ss_o,9695300,Abstract,5,test,gold,6721.0
7899,,"Respiratory rate , heart rate , oxygen saturation and presence of cyanosis , wheezing , retractions",were recorded before and after each treatment .,"['Respiratory', 'rate', ',', 'heart', 'rate', ',', 'oxygen', 'saturation', 'and', 'presence', 'of', 'cyanosis', ',', 'wheezing', ',', 'retractions', 'were', 'recorded', 'before', 'and', 'after', 'each', 'treatment', '.']","(0, 16)","(0, 99)",-1,hl_o,9695300,Abstract,5,test,gold,6722.0
7900,RESULTS The decrease in the,respiratory score,"was 5.2 +/- 1.8 , 0.82 +/- 2.4 and 1.7 +/- 1.3 in group I , II and III , respectively .","['RESULTS', 'The', 'decrease', 'in', 'the', 'respiratory', 'score', 'was', '5.2', '+/-', '1.8', ',', '0.82', '+/-', '2.4', 'and', '1.7', '+/-', '1.3', 'in', 'group', 'I', ',', 'II', 'and', 'III', ',', 'respectively', '.']","(5, 7)","(27, 44)",-1,ss_o,9695300,Abstract,6,test,gold,3451.0
7901,RESULTS The decrease in the,respiratory score,"was 5.2 +/- 1.8 , 0.82 +/- 2.4 and 1.7 +/- 1.3 in group I , II and III , respectively .","['RESULTS', 'The', 'decrease', 'in', 'the', 'respiratory', 'score', 'was', '5.2', '+/-', '1.8', ',', '0.82', '+/-', '2.4', 'and', '1.7', '+/-', '1.3', 'in', 'group', 'I', ',', 'II', 'and', 'III', ',', 'respectively', '.']","(5, 7)","(27, 44)",-1,hl_o,9695300,Abstract,6,test,gold,3449.0
7902,The decrease in group I was significantly higher than in the other groups .,,,"['The', 'decrease', 'in', 'group', 'I', 'was', 'significantly', 'higher', 'than', 'in', 'the', 'other', 'groups', '.']",,,,,9695300,Abstract,7,test,gold,
7903,,Heart rate,was similar between groups .,"['Heart', 'rate', 'was', 'similar', 'between', 'groups', '.']","(0, 2)","(0, 10)",-1,ss_o,9695300,Abstract,8,test,gold,1942.0
7904,,Heart rate,was similar between groups .,"['Heart', 'rate', 'was', 'similar', 'between', 'groups', '.']","(0, 2)","(0, 10)",-1,hl_o,9695300,Abstract,8,test,gold,1943.0
7905,,Oxygen saturation,decreased in group I without reaching statistical significance .,"['Oxygen', 'saturation', 'decreased', 'in', 'group', 'I', 'without', 'reaching', 'statistical', 'significance', '.']","(0, 2)","(0, 17)",-1,ss_o,9695300,Abstract,9,test,gold,260.0
7906,,Oxygen saturation,decreased in group I without reaching statistical significance .,"['Oxygen', 'saturation', 'decreased', 'in', 'group', 'I', 'without', 'reaching', 'statistical', 'significance', '.']","(0, 2)","(0, 17)",-1,hl_o,9695300,Abstract,9,test,gold,261.0
7907,CONCLUSIONS Salbutamol was shown to be effective and safe in the treatment of,acute bronchiolitis .,,"['CONCLUSIONS', 'Salbutamol', 'was', 'shown', 'to', 'be', 'effective', 'and', 'safe', 'in', 'the', 'treatment', 'of', 'acute', 'bronchiolitis', '.']","(13, 16)","(77, 98)",-1,ss_p,9695300,Abstract,10,test,gold,3467.0
7908,CONCLUSIONS,Salbutamol,was shown to be effective and safe in the treatment of acute bronchiolitis .,"['CONCLUSIONS', 'Salbutamol', 'was', 'shown', 'to', 'be', 'effective', 'and', 'safe', 'in', 'the', 'treatment', 'of', 'acute', 'bronchiolitis', '.']","(1, 2)","(11, 21)",-1,ss_i,9695300,Abstract,10,test,gold,5039.0
7909,CONCLUSIONS Salbutamol was shown to be,effective,and safe in the treatment of acute bronchiolitis .,"['CONCLUSIONS', 'Salbutamol', 'was', 'shown', 'to', 'be', 'effective', 'and', 'safe', 'in', 'the', 'treatment', 'of', 'acute', 'bronchiolitis', '.']","(6, 7)","(38, 47)",-1,ss_o,9695300,Abstract,10,test,gold,839.0
7910,CONCLUSIONS Salbutamol was shown to be effective and,safe,in the treatment of acute bronchiolitis .,"['CONCLUSIONS', 'Salbutamol', 'was', 'shown', 'to', 'be', 'effective', 'and', 'safe', 'in', 'the', 'treatment', 'of', 'acute', 'bronchiolitis', '.']","(8, 9)","(52, 56)",-1,ss_o,9695300,Abstract,10,test,gold,879.0
7911,CONCLUSIONS,Salbutamol,was shown to be effective and safe in the treatment of acute bronchiolitis .,"['CONCLUSIONS', 'Salbutamol', 'was', 'shown', 'to', 'be', 'effective', 'and', 'safe', 'in', 'the', 'treatment', 'of', 'acute', 'bronchiolitis', '.']","(1, 2)","(11, 21)",-1,hl_i,9695300,Abstract,10,test,gold,5038.0
7912,CONCLUSIONS Salbutamol was shown to be,effective,and safe in the treatment of acute bronchiolitis .,"['CONCLUSIONS', 'Salbutamol', 'was', 'shown', 'to', 'be', 'effective', 'and', 'safe', 'in', 'the', 'treatment', 'of', 'acute', 'bronchiolitis', '.']","(6, 7)","(38, 47)",-1,hl_o,9695300,Abstract,10,test,gold,838.0
7913,CONCLUSIONS Salbutamol was shown to be effective and,safe,in the treatment of acute bronchiolitis .,"['CONCLUSIONS', 'Salbutamol', 'was', 'shown', 'to', 'be', 'effective', 'and', 'safe', 'in', 'the', 'treatment', 'of', 'acute', 'bronchiolitis', '.']","(8, 9)","(52, 56)",-1,hl_o,9695300,Abstract,10,test,gold,878.0
7914,Inhaled fluticasone reduces sputum inflammatory indices in,severe bronchiectasis .,,"['Inhaled', 'fluticasone', 'reduces', 'sputum', 'inflammatory', 'indices', 'in', 'severe', 'bronchiectasis', '.']","(7, 10)","(58, 81)",-1,ss_p,9730996,Title,0,test,gold,3441.0
7915,Inhaled,fluticasone,reduces sputum inflammatory indices in severe bronchiectasis .,"['Inhaled', 'fluticasone', 'reduces', 'sputum', 'inflammatory', 'indices', 'in', 'severe', 'bronchiectasis', '.']","(1, 2)","(7, 18)",-1,ss_i,9730996,Title,0,test,gold,5215.0
7916,Inhaled fluticasone reduces,sputum inflammatory indices,in severe bronchiectasis .,"['Inhaled', 'fluticasone', 'reduces', 'sputum', 'inflammatory', 'indices', 'in', 'severe', 'bronchiectasis', '.']","(3, 6)","(27, 54)",-1,ss_o,9730996,Title,0,test,gold,4532.0
7917,Inhaled fluticasone reduces sputum inflammatory indices in,severe bronchiectasis .,,"['Inhaled', 'fluticasone', 'reduces', 'sputum', 'inflammatory', 'indices', 'in', 'severe', 'bronchiectasis', '.']","(7, 10)","(58, 81)",-1,hl_p,9730996,Title,0,test,gold,3442.0
7918,Inhaled,fluticasone,reduces sputum inflammatory indices in severe bronchiectasis .,"['Inhaled', 'fluticasone', 'reduces', 'sputum', 'inflammatory', 'indices', 'in', 'severe', 'bronchiectasis', '.']","(1, 2)","(7, 18)",-1,hl_i,9730996,Title,0,test,gold,5216.0
7919,Inhaled fluticasone reduces,sputum inflammatory indices,in severe bronchiectasis .,"['Inhaled', 'fluticasone', 'reduces', 'sputum', 'inflammatory', 'indices', 'in', 'severe', 'bronchiectasis', '.']","(3, 6)","(27, 54)",-1,hl_o,9730996,Title,0,test,gold,4533.0
7920,"Although corticosteroid therapy might be clinically beneficial for bronchiectasis , very little is known of its effects on the",inflammatory and infective markers,in bronchiectasis .,"['Although', 'corticosteroid', 'therapy', 'might', 'be', 'clinically', 'beneficial', 'for', 'bronchiectasis', ',', 'very', 'little', 'is', 'known', 'of', 'its', 'effects', 'on', 'the', 'inflammatory', 'and', 'infective', 'markers', 'in', 'bronchiectasis', '.']","(19, 23)","(126, 160)",-1,ss_o,9730996,Abstract,0,test,gold,3157.0
7921,"Although corticosteroid therapy might be clinically beneficial for bronchiectasis , very little is known of its effects on the",inflammatory and infective markers,in bronchiectasis .,"['Although', 'corticosteroid', 'therapy', 'might', 'be', 'clinically', 'beneficial', 'for', 'bronchiectasis', ',', 'very', 'little', 'is', 'known', 'of', 'its', 'effects', 'on', 'the', 'inflammatory', 'and', 'infective', 'markers', 'in', 'bronchiectasis', '.']","(19, 23)","(126, 160)",-1,hl_o,9730996,Abstract,0,test,gold,3158.0
7922,"We have therefore performed a double-blind , placebo-controlled study to evaluate the effects of a 4-wk administration of inhaled fluticasone in",bronchiectasis .,,"['We', 'have', 'therefore', 'performed', 'a', 'double-blind', ',', 'placebo-controlled', 'study', 'to', 'evaluate', 'the', 'effects', 'of', 'a', '4-wk', 'administration', 'of', 'inhaled', 'fluticasone', 'in', 'bronchiectasis', '.']","(21, 23)","(144, 160)",-1,ss_p,9730996,Abstract,1,test,gold,3445.0
7923,"We have therefore performed a double-blind ,",placebo-controlled,study to evaluate the effects of a 4-wk administration of inhaled fluticasone in bronchiectasis .,"['We', 'have', 'therefore', 'performed', 'a', 'double-blind', ',', 'placebo-controlled', 'study', 'to', 'evaluate', 'the', 'effects', 'of', 'a', '4-wk', 'administration', 'of', 'inhaled', 'fluticasone', 'in', 'bronchiectasis', '.']","(7, 8)","(44, 62)",-1,ss_i,9730996,Abstract,1,test,gold,
7924,"We have therefore performed a double-blind , placebo-controlled study to evaluate the effects of a 4-wk administration of inhaled",fluticasone,in bronchiectasis .,"['We', 'have', 'therefore', 'performed', 'a', 'double-blind', ',', 'placebo-controlled', 'study', 'to', 'evaluate', 'the', 'effects', 'of', 'a', '4-wk', 'administration', 'of', 'inhaled', 'fluticasone', 'in', 'bronchiectasis', '.']","(19, 20)","(129, 140)",-1,ss_i,9730996,Abstract,1,test,gold,5214.0
7925,"We have therefore performed a double-blind ,",placebo-controlled,study to evaluate the effects of a 4-wk administration of inhaled fluticasone in bronchiectasis .,"['We', 'have', 'therefore', 'performed', 'a', 'double-blind', ',', 'placebo-controlled', 'study', 'to', 'evaluate', 'the', 'effects', 'of', 'a', '4-wk', 'administration', 'of', 'inhaled', 'fluticasone', 'in', 'bronchiectasis', '.']","(7, 8)","(44, 62)",-1,hl_i,9730996,Abstract,1,test,gold,
7926,"We have therefore performed a double-blind , placebo-controlled study to evaluate the effects of a 4-wk administration of inhaled",fluticasone,in bronchiectasis .,"['We', 'have', 'therefore', 'performed', 'a', 'double-blind', ',', 'placebo-controlled', 'study', 'to', 'evaluate', 'the', 'effects', 'of', 'a', '4-wk', 'administration', 'of', 'inhaled', 'fluticasone', 'in', 'bronchiectasis', '.']","(19, 20)","(129, 140)",-1,hl_i,9730996,Abstract,1,test,gold,5213.0
7927,,Twenty-four patients ( 12 female ; mean age 51 yr ),were randomized into receiving either inhaled fluticasone ( 500 microgram twice daily ) via the Accuhaler device ( n = 12 ) or placebo .,"['Twenty-four', 'patients', '(', '12', 'female', ';', 'mean', 'age', '51', 'yr', ')', 'were', 'randomized', 'into', 'receiving', 'either', 'inhaled', 'fluticasone', '(', '500', 'microgram', 'twice', 'daily', ')', 'via', 'the', 'Accuhaler', 'device', '(', 'n', '=', '12', ')', 'or', 'placebo', '.']","(0, 11)","(0, 51)",-1,ss_p,9730996,Abstract,2,test,gold,2006.0
7928,Twenty-four patients ( 12 female ; mean age 51 yr ) were randomized into receiving either inhaled,fluticasone,( 500 microgram twice daily ) via the Accuhaler device ( n = 12 ) or placebo .,"['Twenty-four', 'patients', '(', '12', 'female', ';', 'mean', 'age', '51', 'yr', ')', 'were', 'randomized', 'into', 'receiving', 'either', 'inhaled', 'fluticasone', '(', '500', 'microgram', 'twice', 'daily', ')', 'via', 'the', 'Accuhaler', 'device', '(', 'n', '=', '12', ')', 'or', 'placebo', '.']","(17, 18)","(97, 108)",-1,ss_i,9730996,Abstract,2,test,gold,5212.0
7929,Twenty-four patients ( 12 female ; mean age 51 yr ) were randomized into receiving either inhaled fluticasone ( 500 microgram twice daily ) via the Accuhaler device ( n = 12 ) or,placebo .,,"['Twenty-four', 'patients', '(', '12', 'female', ';', 'mean', 'age', '51', 'yr', ')', 'were', 'randomized', 'into', 'receiving', 'either', 'inhaled', 'fluticasone', '(', '500', 'microgram', 'twice', 'daily', ')', 'via', 'the', 'Accuhaler', 'device', '(', 'n', '=', '12', ')', 'or', 'placebo', '.']","(34, 36)","(178, 187)",-1,ss_i,9730996,Abstract,2,test,gold,4264.0
7930,,Twenty-four,patients ( 12 female ; mean age 51 yr ) were randomized into receiving either inhaled fluticasone ( 500 microgram twice daily ) via the Accuhaler device ( n = 12 ) or placebo .,"['Twenty-four', 'patients', '(', '12', 'female', ';', 'mean', 'age', '51', 'yr', ')', 'were', 'randomized', 'into', 'receiving', 'either', 'inhaled', 'fluticasone', '(', '500', 'microgram', 'twice', 'daily', ')', 'via', 'the', 'Accuhaler', 'device', '(', 'n', '=', '12', ')', 'or', 'placebo', '.']","(0, 1)","(0, 11)",-1,hl_p,9730996,Abstract,2,test,gold,
7931,Twenty-four patients (,12,female ; mean age 51 yr ) were randomized into receiving either inhaled fluticasone ( 500 microgram twice daily ) via the Accuhaler device ( n = 12 ) or placebo .,"['Twenty-four', 'patients', '(', '12', 'female', ';', 'mean', 'age', '51', 'yr', ')', 'were', 'randomized', 'into', 'receiving', 'either', 'inhaled', 'fluticasone', '(', '500', 'microgram', 'twice', 'daily', ')', 'via', 'the', 'Accuhaler', 'device', '(', 'n', '=', '12', ')', 'or', 'placebo', '.']","(3, 4)","(22, 24)",-1,hl_p,9730996,Abstract,2,test,gold,
7932,Twenty-four patients ( 12 female ;,mean age 51 yr,) were randomized into receiving either inhaled fluticasone ( 500 microgram twice daily ) via the Accuhaler device ( n = 12 ) or placebo .,"['Twenty-four', 'patients', '(', '12', 'female', ';', 'mean', 'age', '51', 'yr', ')', 'were', 'randomized', 'into', 'receiving', 'either', 'inhaled', 'fluticasone', '(', '500', 'microgram', 'twice', 'daily', ')', 'via', 'the', 'Accuhaler', 'device', '(', 'n', '=', '12', ')', 'or', 'placebo', '.']","(6, 10)","(34, 48)",-1,hl_p,9730996,Abstract,2,test,gold,2007.0
7933,Twenty-four patients ( 12 female ; mean age 51 yr ) were randomized into receiving either inhaled,fluticasone,( 500 microgram twice daily ) via the Accuhaler device ( n = 12 ) or placebo .,"['Twenty-four', 'patients', '(', '12', 'female', ';', 'mean', 'age', '51', 'yr', ')', 'were', 'randomized', 'into', 'receiving', 'either', 'inhaled', 'fluticasone', '(', '500', 'microgram', 'twice', 'daily', ')', 'via', 'the', 'Accuhaler', 'device', '(', 'n', '=', '12', ')', 'or', 'placebo', '.']","(17, 18)","(97, 108)",-1,hl_i,9730996,Abstract,2,test,gold,5211.0
7934,Twenty-four patients ( 12 female ; mean age 51 yr ) were randomized into receiving either inhaled fluticasone ( 500 microgram twice daily ) via the Accuhaler device ( n = 12 ) or,placebo .,,"['Twenty-four', 'patients', '(', '12', 'female', ';', 'mean', 'age', '51', 'yr', ')', 'were', 'randomized', 'into', 'receiving', 'either', 'inhaled', 'fluticasone', '(', '500', 'microgram', 'twice', 'daily', ')', 'via', 'the', 'Accuhaler', 'device', '(', 'n', '=', '12', ')', 'or', 'placebo', '.']","(34, 36)","(178, 187)",-1,hl_i,9730996,Abstract,2,test,gold,4263.0
7935,"At each visit ,","spirometry , 24-h sputum volume , sputum leukocyte density , bacterial densities , and concentrations of interleukin ( IL ) -1beta , IL-8 , tumor necrosis factor-alpha ( TNF-alpha ) , and leukotriene B4 ( LTB4 )",were determined .,"['At', 'each', 'visit', ',', 'spirometry', ',', '24-h', 'sputum', 'volume', ',', 'sputum', 'leukocyte', 'density', ',', 'bacterial', 'densities', ',', 'and', 'concentrations', 'of', 'interleukin', '(', 'IL', ')', '-1beta', ',', 'IL-8', ',', 'tumor', 'necrosis', 'factor-alpha', '(', 'TNF-alpha', ')', ',', 'and', 'leukotriene', 'B4', '(', 'LTB4', ')', 'were', 'determined', '.']","(4, 41)","(15, 226)",-1,ss_o,9730996,Abstract,3,test,gold,5803.0
7936,"At each visit ,","spirometry , 24-h sputum volume , sputum leukocyte density , bacterial densities",", and concentrations of interleukin ( IL ) -1beta , IL-8 , tumor necrosis factor-alpha ( TNF-alpha ) , and leukotriene B4 ( LTB4 ) were determined .","['At', 'each', 'visit', ',', 'spirometry', ',', '24-h', 'sputum', 'volume', ',', 'sputum', 'leukocyte', 'density', ',', 'bacterial', 'densities', ',', 'and', 'concentrations', 'of', 'interleukin', '(', 'IL', ')', '-1beta', ',', 'IL-8', ',', 'tumor', 'necrosis', 'factor-alpha', '(', 'TNF-alpha', ')', ',', 'and', 'leukotriene', 'B4', '(', 'LTB4', ')', 'were', 'determined', '.']","(4, 16)","(15, 95)",-1,hl_o,9730996,Abstract,3,test,gold,5804.0
7937,"At each visit , spirometry , 24-h sputum volume , sputum leukocyte density , bacterial densities , and","concentrations of interleukin ( IL ) -1beta , IL-8 , tumor necrosis factor-alpha ( TNF-alpha )",", and leukotriene B4 ( LTB4 ) were determined .","['At', 'each', 'visit', ',', 'spirometry', ',', '24-h', 'sputum', 'volume', ',', 'sputum', 'leukocyte', 'density', ',', 'bacterial', 'densities', ',', 'and', 'concentrations', 'of', 'interleukin', '(', 'IL', ')', '-1beta', ',', 'IL-8', ',', 'tumor', 'necrosis', 'factor-alpha', '(', 'TNF-alpha', ')', ',', 'and', 'leukotriene', 'B4', '(', 'LTB4', ')', 'were', 'determined', '.']","(18, 34)","(102, 196)",-1,hl_o,9730996,Abstract,3,test,gold,6864.0
7938,"At each visit , spirometry , 24-h sputum volume , sputum leukocyte density , bacterial densities , and concentrations of interleukin ( IL ) -1beta , IL-8 , tumor necrosis factor-alpha ( TNF-alpha ) , and",leukotriene B4 ( LTB4 ),were determined .,"['At', 'each', 'visit', ',', 'spirometry', ',', '24-h', 'sputum', 'volume', ',', 'sputum', 'leukocyte', 'density', ',', 'bacterial', 'densities', ',', 'and', 'concentrations', 'of', 'interleukin', '(', 'IL', ')', '-1beta', ',', 'IL-8', ',', 'tumor', 'necrosis', 'factor-alpha', '(', 'TNF-alpha', ')', ',', 'and', 'leukotriene', 'B4', '(', 'LTB4', ')', 'were', 'determined', '.']","(36, 41)","(203, 226)",-1,hl_o,9730996,Abstract,3,test,gold,3182.0
7939,"There was a significant ( p < 0.05 ) decrease in sputum leukocyte density and IL-1beta , IL-8 , and LTB4 after",fluticasone,treatment .,"['There', 'was', 'a', 'significant', '(', 'p', '<', '0.05', ')', 'decrease', 'in', 'sputum', 'leukocyte', 'density', 'and', 'IL-1beta', ',', 'IL-8', ',', 'and', 'LTB4', 'after', 'fluticasone', 'treatment', '.']","(22, 23)","(110, 121)",-1,ss_i,9730996,Abstract,4,test,gold,5210.0
7940,There was a significant ( p < 0.05 ) decrease in,"sputum leukocyte density and IL-1beta , IL-8 , and LTB4",after fluticasone treatment .,"['There', 'was', 'a', 'significant', '(', 'p', '<', '0.05', ')', 'decrease', 'in', 'sputum', 'leukocyte', 'density', 'and', 'IL-1beta', ',', 'IL-8', ',', 'and', 'LTB4', 'after', 'fluticasone', 'treatment', '.']","(11, 21)","(48, 103)",-1,ss_o,9730996,Abstract,4,test,gold,4534.0
7941,"There was a significant ( p < 0.05 ) decrease in sputum leukocyte density and IL-1beta , IL-8 , and LTB4 after",fluticasone,treatment .,"['There', 'was', 'a', 'significant', '(', 'p', '<', '0.05', ')', 'decrease', 'in', 'sputum', 'leukocyte', 'density', 'and', 'IL-1beta', ',', 'IL-8', ',', 'and', 'LTB4', 'after', 'fluticasone', 'treatment', '.']","(22, 23)","(110, 121)",-1,hl_i,9730996,Abstract,4,test,gold,5209.0
7942,There was a significant ( p < 0.05 ) decrease in,sputum leukocyte density,"and IL-1beta , IL-8 , and LTB4 after fluticasone treatment .","['There', 'was', 'a', 'significant', '(', 'p', '<', '0.05', ')', 'decrease', 'in', 'sputum', 'leukocyte', 'density', 'and', 'IL-1beta', ',', 'IL-8', ',', 'and', 'LTB4', 'after', 'fluticasone', 'treatment', '.']","(11, 14)","(48, 72)",-1,hl_o,9730996,Abstract,4,test,gold,4535.0
7943,There was a significant ( p < 0.05 ) decrease in sputum leukocyte density and,"IL-1beta , IL-8",", and LTB4 after fluticasone treatment .","['There', 'was', 'a', 'significant', '(', 'p', '<', '0.05', ')', 'decrease', 'in', 'sputum', 'leukocyte', 'density', 'and', 'IL-1beta', ',', 'IL-8', ',', 'and', 'LTB4', 'after', 'fluticasone', 'treatment', '.']","(15, 18)","(77, 92)",-1,hl_o,9730996,Abstract,4,test,gold,
7944,"There was a significant ( p < 0.05 ) decrease in sputum leukocyte density and IL-1beta , IL-8 , and",LTB4,after fluticasone treatment .,"['There', 'was', 'a', 'significant', '(', 'p', '<', '0.05', ')', 'decrease', 'in', 'sputum', 'leukocyte', 'density', 'and', 'IL-1beta', ',', 'IL-8', ',', 'and', 'LTB4', 'after', 'fluticasone', 'treatment', '.']","(20, 21)","(99, 103)",-1,hl_o,9730996,Abstract,4,test,gold,136.0
7945,The,fluticasone,group had one and the placebo group three episodes of exacerbation .,"['The', 'fluticasone', 'group', 'had', 'one', 'and', 'the', 'placebo', 'group', 'three', 'episodes', 'of', 'exacerbation', '.']","(1, 2)","(3, 14)",-1,ss_i,9730996,Abstract,5,test,gold,5208.0
7946,The fluticasone group had one and the,placebo,group three episodes of exacerbation .,"['The', 'fluticasone', 'group', 'had', 'one', 'and', 'the', 'placebo', 'group', 'three', 'episodes', 'of', 'exacerbation', '.']","(7, 8)","(37, 44)",-1,ss_i,9730996,Abstract,5,test,gold,4262.0
7947,The,fluticasone,group had one and the placebo group three episodes of exacerbation .,"['The', 'fluticasone', 'group', 'had', 'one', 'and', 'the', 'placebo', 'group', 'three', 'episodes', 'of', 'exacerbation', '.']","(1, 2)","(3, 14)",-1,hl_i,9730996,Abstract,5,test,gold,5207.0
7948,The fluticasone group had one and the,placebo,group three episodes of exacerbation .,"['The', 'fluticasone', 'group', 'had', 'one', 'and', 'the', 'placebo', 'group', 'three', 'episodes', 'of', 'exacerbation', '.']","(7, 8)","(37, 44)",-1,hl_i,9730996,Abstract,5,test,gold,4261.0
7949,There were no significant changes in,spirometry,( p > 0.05 ) or any reported adverse reactions in either group .,"['There', 'were', 'no', 'significant', 'changes', 'in', 'spirometry', '(', 'p', '>', '0.05', ')', 'or', 'any', 'reported', 'adverse', 'reactions', 'in', 'either', 'group', '.']","(6, 7)","(36, 46)",-1,ss_o,9730996,Abstract,6,test,gold,3452.0
7950,There were no significant changes in spirometry ( p > 0.05 ) or any,reported adverse reactions,in either group .,"['There', 'were', 'no', 'significant', 'changes', 'in', 'spirometry', '(', 'p', '>', '0.05', ')', 'or', 'any', 'reported', 'adverse', 'reactions', 'in', 'either', 'group', '.']","(14, 17)","(67, 93)",-1,ss_o,9730996,Abstract,6,test,gold,3038.0
7951,There were no significant changes in,spirometry,( p > 0.05 ) or any reported adverse reactions in either group .,"['There', 'were', 'no', 'significant', 'changes', 'in', 'spirometry', '(', 'p', '>', '0.05', ')', 'or', 'any', 'reported', 'adverse', 'reactions', 'in', 'either', 'group', '.']","(6, 7)","(36, 46)",-1,hl_o,9730996,Abstract,6,test,gold,3453.0
7952,There were no significant changes in spirometry ( p > 0.05 ) or any reported,adverse reactions,in either group .,"['There', 'were', 'no', 'significant', 'changes', 'in', 'spirometry', '(', 'p', '>', '0.05', ')', 'or', 'any', 'reported', 'adverse', 'reactions', 'in', 'either', 'group', '.']","(15, 17)","(76, 93)",-1,hl_o,9730996,Abstract,6,test,gold,3039.0
7953,The results of this study show that high-dose fluticasone is effective in reducing the sputum inflammatory indices in,bronchiectasis .,,"['The', 'results', 'of', 'this', 'study', 'show', 'that', 'high-dose', 'fluticasone', 'is', 'effective', 'in', 'reducing', 'the', 'sputum', 'inflammatory', 'indices', 'in', 'bronchiectasis', '.']","(18, 20)","(117, 133)",-1,ss_p,9730996,Abstract,7,test,gold,3446.0
7954,The results of this study show that high-dose,fluticasone,is effective in reducing the sputum inflammatory indices in bronchiectasis .,"['The', 'results', 'of', 'this', 'study', 'show', 'that', 'high-dose', 'fluticasone', 'is', 'effective', 'in', 'reducing', 'the', 'sputum', 'inflammatory', 'indices', 'in', 'bronchiectasis', '.']","(8, 9)","(45, 56)",-1,ss_i,9730996,Abstract,7,test,gold,5206.0
7955,The results of this study show that high-dose fluticasone is effective in reducing the,sputum inflammatory indices,in bronchiectasis .,"['The', 'results', 'of', 'this', 'study', 'show', 'that', 'high-dose', 'fluticasone', 'is', 'effective', 'in', 'reducing', 'the', 'sputum', 'inflammatory', 'indices', 'in', 'bronchiectasis', '.']","(14, 17)","(86, 113)",-1,ss_o,9730996,Abstract,7,test,gold,4531.0
7956,The results of this study show that high-dose fluticasone is effective in reducing the,sputum inflammatory indices,in bronchiectasis .,"['The', 'results', 'of', 'this', 'study', 'show', 'that', 'high-dose', 'fluticasone', 'is', 'effective', 'in', 'reducing', 'the', 'sputum', 'inflammatory', 'indices', 'in', 'bronchiectasis', '.']","(14, 17)","(86, 113)",-1,hl_o,9730996,Abstract,7,test,gold,4530.0
7957,Large-scale and long-term studies are indicated to evaluate the effects of inhaled steroid therapy on the inflammatory components in,bronchiectasis .,,"['Large-scale', 'and', 'long-term', 'studies', 'are', 'indicated', 'to', 'evaluate', 'the', 'effects', 'of', 'inhaled', 'steroid', 'therapy', 'on', 'the', 'inflammatory', 'components', 'in', 'bronchiectasis', '.']","(19, 21)","(132, 148)",-1,ss_p,9730996,Abstract,8,test,gold,3444.0
7958,Large-scale and long-term studies are indicated to evaluate the effects of inhaled,steroid,therapy on the inflammatory components in bronchiectasis .,"['Large-scale', 'and', 'long-term', 'studies', 'are', 'indicated', 'to', 'evaluate', 'the', 'effects', 'of', 'inhaled', 'steroid', 'therapy', 'on', 'the', 'inflammatory', 'components', 'in', 'bronchiectasis', '.']","(12, 13)","(82, 89)",-1,ss_i,9730996,Abstract,8,test,gold,5079.0
7959,Large-scale and long-term studies are indicated to evaluate the effects of inhaled steroid therapy on the,inflammatory components,in bronchiectasis .,"['Large-scale', 'and', 'long-term', 'studies', 'are', 'indicated', 'to', 'evaluate', 'the', 'effects', 'of', 'inhaled', 'steroid', 'therapy', 'on', 'the', 'inflammatory', 'components', 'in', 'bronchiectasis', '.']","(16, 18)","(105, 128)",-1,ss_o,9730996,Abstract,8,test,gold,215.0
7960,Large-scale and long-term studies are indicated to evaluate the effects of inhaled steroid therapy on the inflammatory components in,bronchiectasis .,,"['Large-scale', 'and', 'long-term', 'studies', 'are', 'indicated', 'to', 'evaluate', 'the', 'effects', 'of', 'inhaled', 'steroid', 'therapy', 'on', 'the', 'inflammatory', 'components', 'in', 'bronchiectasis', '.']","(19, 21)","(132, 148)",-1,hl_p,9730996,Abstract,8,test,gold,3443.0
7961,Amonafide : An active agent in the treatment of,previously untreated advanced breast cancer -- a,cancer and leukemia group B study ( CALGB 8642 ) .,"['Amonafide', ':', 'An', 'active', 'agent', 'in', 'the', 'treatment', 'of', 'previously', 'untreated', 'advanced', 'breast', 'cancer', '--', 'a', 'cancer', 'and', 'leukemia', 'group', 'B', 'study', '(', 'CALGB', '8642', ')', '.']","(9, 16)","(47, 95)",-1,ss_p,9816035,Title,0,test,gold,6846.0
7962,,Amonafide :,An active agent in the treatment of previously untreated advanced breast cancer -- a cancer and leukemia group B study ( CALGB 8642 ) .,"['Amonafide', ':', 'An', 'active', 'agent', 'in', 'the', 'treatment', 'of', 'previously', 'untreated', 'advanced', 'breast', 'cancer', '--', 'a', 'cancer', 'and', 'leukemia', 'group', 'B', 'study', '(', 'CALGB', '8642', ')', '.']","(0, 2)","(0, 11)",-1,ss_i,9816035,Title,0,test,gold,
7963,Amonafide : An active agent in the treatment of,previously untreated advanced breast cancer -- a,cancer and leukemia group B study ( CALGB 8642 ) .,"['Amonafide', ':', 'An', 'active', 'agent', 'in', 'the', 'treatment', 'of', 'previously', 'untreated', 'advanced', 'breast', 'cancer', '--', 'a', 'cancer', 'and', 'leukemia', 'group', 'B', 'study', '(', 'CALGB', '8642', ')', '.']","(9, 16)","(47, 95)",-1,hl_p,9816035,Title,0,test,gold,6847.0
7964,,Amonafide :,An active agent in the treatment of previously untreated advanced breast cancer -- a cancer and leukemia group B study ( CALGB 8642 ) .,"['Amonafide', ':', 'An', 'active', 'agent', 'in', 'the', 'treatment', 'of', 'previously', 'untreated', 'advanced', 'breast', 'cancer', '--', 'a', 'cancer', 'and', 'leukemia', 'group', 'B', 'study', '(', 'CALGB', '8642', ')', '.']","(0, 2)","(0, 11)",-1,hl_i,9816035,Title,0,test,gold,
7965,,Amonafide,is a new imide derivative of naphthalic acid .,"['Amonafide', 'is', 'a', 'new', 'imide', 'derivative', 'of', 'naphthalic', 'acid', '.']","(0, 1)","(0, 9)",-1,ss_i,9816035,Abstract,0,test,gold,
7966,,Amonafide,is a new imide derivative of naphthalic acid .,"['Amonafide', 'is', 'a', 'new', 'imide', 'derivative', 'of', 'naphthalic', 'acid', '.']","(0, 1)","(0, 9)",-1,hl_i,9816035,Abstract,0,test,gold,
7967,The drug had demonstrated significant activity in preclinical studies and some activity in Phase I trials .,,,"['The', 'drug', 'had', 'demonstrated', 'significant', 'activity', 'in', 'preclinical', 'studies', 'and', 'some', 'activity', 'in', 'Phase', 'I', 'trials', '.']",,,,,9816035,Abstract,1,test,gold,
7968,The drug is extensively metabolized and detected in plasma and urine .,,,"['The', 'drug', 'is', 'extensively', 'metabolized', 'and', 'detected', 'in', 'plasma', 'and', 'urine', '.']",,,,,9816035,Abstract,2,test,gold,
7969,"Its toxicity has previously been correlated to the formation of an active metabolite , N-acetyl-amonafide .",,,"['Its', 'toxicity', 'has', 'previously', 'been', 'correlated', 'to', 'the', 'formation', 'of', 'an', 'active', 'metabolite', ',', 'N-acetyl-amonafide', '.']",,,,,9816035,Abstract,3,test,gold,
7970,,Amonafide,was chosen for inclusion in the Cancer and Leukemia Group B ( CALGB ) master metastatic breast cancer protocol .,"['Amonafide', 'was', 'chosen', 'for', 'inclusion', 'in', 'the', 'Cancer', 'and', 'Leukemia', 'Group', 'B', '(', 'CALGB', ')', 'master', 'metastatic', 'breast', 'cancer', 'protocol', '.']","(0, 1)","(0, 9)",-1,ss_i,9816035,Abstract,4,test,gold,
7971,,Amonafide,was chosen for inclusion in the Cancer and Leukemia Group B ( CALGB ) master metastatic breast cancer protocol .,"['Amonafide', 'was', 'chosen', 'for', 'inclusion', 'in', 'the', 'Cancer', 'and', 'Leukemia', 'Group', 'B', '(', 'CALGB', ')', 'master', 'metastatic', 'breast', 'cancer', 'protocol', '.']","(0, 1)","(0, 9)",-1,hl_i,9816035,Abstract,4,test,gold,
7972,CALGB 8642 randomizes,previously untreated metastatic breast cancer patients,"either to one of several Phase II agents given for up to four cycles and then followed by standard cyclophosphamide-doxorubicin-5-fluorouracil , or to immediate treatment with standard cyclophosphamide-doxorubicin-5-fluorouracil .","['CALGB', '8642', 'randomizes', 'previously', 'untreated', 'metastatic', 'breast', 'cancer', 'patients', 'either', 'to', 'one', 'of', 'several', 'Phase', 'II', 'agents', 'given', 'for', 'up', 'to', 'four', 'cycles', 'and', 'then', 'followed', 'by', 'standard', 'cyclophosphamide-doxorubicin-5-fluorouracil', ',', 'or', 'to', 'immediate', 'treatment', 'with', 'standard', 'cyclophosphamide-doxorubicin-5-fluorouracil', '.']","(3, 9)","(21, 75)",-1,ss_p,9816035,Abstract,5,test,gold,6835.0
7973,CALGB 8642 randomizes previously untreated metastatic breast cancer patients either to one of several Phase II agents given for up to four cycles and then followed by standard,cyclophosphamide-doxorubicin-5-fluorouracil,", or to immediate treatment with standard cyclophosphamide-doxorubicin-5-fluorouracil .","['CALGB', '8642', 'randomizes', 'previously', 'untreated', 'metastatic', 'breast', 'cancer', 'patients', 'either', 'to', 'one', 'of', 'several', 'Phase', 'II', 'agents', 'given', 'for', 'up', 'to', 'four', 'cycles', 'and', 'then', 'followed', 'by', 'standard', 'cyclophosphamide-doxorubicin-5-fluorouracil', ',', 'or', 'to', 'immediate', 'treatment', 'with', 'standard', 'cyclophosphamide-doxorubicin-5-fluorouracil', '.']","(28, 29)","(175, 218)",-1,ss_i,9816035,Abstract,5,test,gold,
7974,"CALGB 8642 randomizes previously untreated metastatic breast cancer patients either to one of several Phase II agents given for up to four cycles and then followed by standard cyclophosphamide-doxorubicin-5-fluorouracil , or to immediate treatment with standard",cyclophosphamide-doxorubicin-5-fluorouracil .,,"['CALGB', '8642', 'randomizes', 'previously', 'untreated', 'metastatic', 'breast', 'cancer', 'patients', 'either', 'to', 'one', 'of', 'several', 'Phase', 'II', 'agents', 'given', 'for', 'up', 'to', 'four', 'cycles', 'and', 'then', 'followed', 'by', 'standard', 'cyclophosphamide-doxorubicin-5-fluorouracil', ',', 'or', 'to', 'immediate', 'treatment', 'with', 'standard', 'cyclophosphamide-doxorubicin-5-fluorouracil', '.']","(36, 38)","(261, 306)",-1,ss_i,9816035,Abstract,5,test,gold,
7975,CALGB 8642 randomizes,previously untreated metastatic breast cancer patients,"either to one of several Phase II agents given for up to four cycles and then followed by standard cyclophosphamide-doxorubicin-5-fluorouracil , or to immediate treatment with standard cyclophosphamide-doxorubicin-5-fluorouracil .","['CALGB', '8642', 'randomizes', 'previously', 'untreated', 'metastatic', 'breast', 'cancer', 'patients', 'either', 'to', 'one', 'of', 'several', 'Phase', 'II', 'agents', 'given', 'for', 'up', 'to', 'four', 'cycles', 'and', 'then', 'followed', 'by', 'standard', 'cyclophosphamide-doxorubicin-5-fluorouracil', ',', 'or', 'to', 'immediate', 'treatment', 'with', 'standard', 'cyclophosphamide-doxorubicin-5-fluorouracil', '.']","(3, 9)","(21, 75)",-1,hl_p,9816035,Abstract,5,test,gold,6836.0
7976,The end point of CALGB 8642 is to,"assess the difference in survival , toxicity , and overall response",when limited exposure to Phase II agents precedes standard chemotherapy .,"['The', 'end', 'point', 'of', 'CALGB', '8642', 'is', 'to', 'assess', 'the', 'difference', 'in', 'survival', ',', 'toxicity', ',', 'and', 'overall', 'response', 'when', 'limited', 'exposure', 'to', 'Phase', 'II', 'agents', 'precedes', 'standard', 'chemotherapy', '.']","(8, 19)","(33, 100)",-1,ss_o,9816035,Abstract,6,test,gold,6473.0
7977,The end point of CALGB 8642 is to assess the difference in,survival,", toxicity , and overall response when limited exposure to Phase II agents precedes standard chemotherapy .","['The', 'end', 'point', 'of', 'CALGB', '8642', 'is', 'to', 'assess', 'the', 'difference', 'in', 'survival', ',', 'toxicity', ',', 'and', 'overall', 'response', 'when', 'limited', 'exposure', 'to', 'Phase', 'II', 'agents', 'precedes', 'standard', 'chemotherapy', '.']","(12, 13)","(58, 66)",-1,hl_o,9816035,Abstract,6,test,gold,1959.0
7978,"The end point of CALGB 8642 is to assess the difference in survival ,",toxicity,", and overall response when limited exposure to Phase II agents precedes standard chemotherapy .","['The', 'end', 'point', 'of', 'CALGB', '8642', 'is', 'to', 'assess', 'the', 'difference', 'in', 'survival', ',', 'toxicity', ',', 'and', 'overall', 'response', 'when', 'limited', 'exposure', 'to', 'Phase', 'II', 'agents', 'precedes', 'standard', 'chemotherapy', '.']","(14, 15)","(69, 77)",-1,hl_o,9816035,Abstract,6,test,gold,3495.0
7979,"The end point of CALGB 8642 is to assess the difference in survival , toxicity , and",overall response,when limited exposure to Phase II agents precedes standard chemotherapy .,"['The', 'end', 'point', 'of', 'CALGB', '8642', 'is', 'to', 'assess', 'the', 'difference', 'in', 'survival', ',', 'toxicity', ',', 'and', 'overall', 'response', 'when', 'limited', 'exposure', 'to', 'Phase', 'II', 'agents', 'precedes', 'standard', 'chemotherapy', '.']","(17, 19)","(84, 100)",-1,hl_o,9816035,Abstract,6,test,gold,2519.0
7980,This report deals only with,amonafide,as a Phase II agent .,"['This', 'report', 'deals', 'only', 'with', 'amonafide', 'as', 'a', 'Phase', 'II', 'agent', '.']","(5, 6)","(27, 36)",-1,ss_i,9816035,Abstract,7,test,gold,1059.0
7981,This report deals only with,amonafide,as a Phase II agent .,"['This', 'report', 'deals', 'only', 'with', 'amonafide', 'as', 'a', 'Phase', 'II', 'agent', '.']","(5, 6)","(27, 36)",-1,hl_i,9816035,Abstract,7,test,gold,1060.0
7982,Comparisons with the,cyclophosphamide-doxorubicin-5-fluorouracil,arm will not be addressed .,"['Comparisons', 'with', 'the', 'cyclophosphamide-doxorubicin-5-fluorouracil', 'arm', 'will', 'not', 'be', 'addressed', '.']","(3, 4)","(20, 63)",-1,ss_i,9816035,Abstract,8,test,gold,
7983,,Patients had to have histologically documented measurable breast cancer and a performance status of 0-1 .,,"['Patients', 'had', 'to', 'have', 'histologically', 'documented', 'measurable', 'breast', 'cancer', 'and', 'a', 'performance', 'status', 'of', '0-1', '.']","(0, 16)","(0, 105)",-1,ss_p,9816035,Abstract,9,test,gold,5955.0
7984,,Patients had to have histologically documented measurable breast cancer and a performance status of 0-1 .,,"['Patients', 'had', 'to', 'have', 'histologically', 'documented', 'measurable', 'breast', 'cancer', 'and', 'a', 'performance', 'status', 'of', '0-1', '.']","(0, 16)","(0, 105)",-1,hl_p,9816035,Abstract,9,test,gold,5956.0
7985,,Patients could not have had prior chemotherapy for metastatic disease .,,"['Patients', 'could', 'not', 'have', 'had', 'prior', 'chemotherapy', 'for', 'metastatic', 'disease', '.']","(0, 11)","(0, 71)",-1,ss_p,9816035,Abstract,10,test,gold,5925.0
7986,,Patients could not have had prior chemotherapy for metastatic disease .,,"['Patients', 'could', 'not', 'have', 'had', 'prior', 'chemotherapy', 'for', 'metastatic', 'disease', '.']","(0, 11)","(0, 71)",-1,hl_p,9816035,Abstract,10,test,gold,5926.0
7987,,Prior adjuvant chemotherapy was permitted .,,"['Prior', 'adjuvant', 'chemotherapy', 'was', 'permitted', '.']","(0, 6)","(0, 43)",-1,ss_p,9816035,Abstract,11,test,gold,5176.0
7988,,Prior adjuvant chemotherapy was permitted .,,"['Prior', 'adjuvant', 'chemotherapy', 'was', 'permitted', '.']","(0, 6)","(0, 43)",-1,hl_p,9816035,Abstract,11,test,gold,5177.0
7989,,Patients could not have visceral crisis .,,"['Patients', 'could', 'not', 'have', 'visceral', 'crisis', '.']","(0, 7)","(0, 41)",-1,ss_p,9816035,Abstract,12,test,gold,3710.0
7990,,Patients could not have visceral crisis .,,"['Patients', 'could', 'not', 'have', 'visceral', 'crisis', '.']","(0, 7)","(0, 41)",-1,hl_p,9816035,Abstract,12,test,gold,3711.0
7991,,Amonafide,was given at 300 mg/m2/day i.v .,"['Amonafide', 'was', 'given', 'at', '300', 'mg/m2/day', 'i.v', '.']","(0, 1)","(0, 9)",-1,ss_i,9816035,Abstract,13,test,gold,
7992,,Amonafide,was given at 300 mg/m2/day i.v .,"['Amonafide', 'was', 'given', 'at', '300', 'mg/m2/day', 'i.v', '.']","(0, 1)","(0, 9)",-1,hl_i,9816035,Abstract,13,test,gold,
7993,"for 5 days , and repeated at 21-day intervals for a maximum of four cycles .",,,"['for', '5', 'days', ',', 'and', 'repeated', 'at', '21-day', 'intervals', 'for', 'a', 'maximum', 'of', 'four', 'cycles', '.']",,,,,9816035,Abstract,14,test,gold,
7994,Escalation and reduction in dose was mandated dependent on hematotoxicity or lack thereof .,,,"['Escalation', 'and', 'reduction', 'in', 'dose', 'was', 'mandated', 'dependent', 'on', 'hematotoxicity', 'or', 'lack', 'thereof', '.']",,,,,9816035,Abstract,15,test,gold,
7995,,Toxicity,was primarily hematological and bimodal : 32 % had grade 3 or 4 leukopenia and 24 % had grade 3 or 4 thrombocytopenia ; 22 % had no leukopenia and 44 % had no thrombocytopenia .,"['Toxicity', 'was', 'primarily', 'hematological', 'and', 'bimodal', ':', '32', '%', 'had', 'grade', '3', 'or', '4', 'leukopenia', 'and', '24', '%', 'had', 'grade', '3', 'or', '4', 'thrombocytopenia', ';', '22', '%', 'had', 'no', 'leukopenia', 'and', '44', '%', 'had', 'no', 'thrombocytopenia', '.']","(0, 1)","(0, 8)",-1,ss_o,9816035,Abstract,16,test,gold,3487.0
7996,Toxicity was primarily,hematological,and bimodal : 32 % had grade 3 or 4 leukopenia and 24 % had grade 3 or 4 thrombocytopenia ; 22 % had no leukopenia and 44 % had no thrombocytopenia .,"['Toxicity', 'was', 'primarily', 'hematological', 'and', 'bimodal', ':', '32', '%', 'had', 'grade', '3', 'or', '4', 'leukopenia', 'and', '24', '%', 'had', 'grade', '3', 'or', '4', 'thrombocytopenia', ';', '22', '%', 'had', 'no', 'leukopenia', 'and', '44', '%', 'had', 'no', 'thrombocytopenia', '.']","(3, 4)","(22, 35)",-1,ss_o,9816035,Abstract,16,test,gold,3484.0
7997,Toxicity was primarily hematological and bimodal : 32 % had grade 3 or 4,leukopenia,and 24 % had grade 3 or 4 thrombocytopenia ; 22 % had no leukopenia and 44 % had no thrombocytopenia .,"['Toxicity', 'was', 'primarily', 'hematological', 'and', 'bimodal', ':', '32', '%', 'had', 'grade', '3', 'or', '4', 'leukopenia', 'and', '24', '%', 'had', 'grade', '3', 'or', '4', 'thrombocytopenia', ';', '22', '%', 'had', 'no', 'leukopenia', 'and', '44', '%', 'had', 'no', 'thrombocytopenia', '.']","(14, 15)","(72, 82)",-1,ss_o,9816035,Abstract,16,test,gold,3507.0
7998,Toxicity was primarily hematological and bimodal : 32 % had grade 3 or 4 leukopenia and 24 % had grade 3 or 4,thrombocytopenia ;,22 % had no leukopenia and 44 % had no thrombocytopenia .,"['Toxicity', 'was', 'primarily', 'hematological', 'and', 'bimodal', ':', '32', '%', 'had', 'grade', '3', 'or', '4', 'leukopenia', 'and', '24', '%', 'had', 'grade', '3', 'or', '4', 'thrombocytopenia', ';', '22', '%', 'had', 'no', 'leukopenia', 'and', '44', '%', 'had', 'no', 'thrombocytopenia', '.']","(23, 25)","(109, 127)",-1,ss_o,9816035,Abstract,16,test,gold,3520.0
7999,Toxicity was primarily hematological and bimodal : 32 % had grade 3 or 4 leukopenia and 24 % had grade 3 or 4 thrombocytopenia ; 22 % had no,leukopenia,and 44 % had no thrombocytopenia .,"['Toxicity', 'was', 'primarily', 'hematological', 'and', 'bimodal', ':', '32', '%', 'had', 'grade', '3', 'or', '4', 'leukopenia', 'and', '24', '%', 'had', 'grade', '3', 'or', '4', 'thrombocytopenia', ';', '22', '%', 'had', 'no', 'leukopenia', 'and', '44', '%', 'had', 'no', 'thrombocytopenia', '.']","(29, 30)","(140, 150)",-1,ss_o,9816035,Abstract,16,test,gold,3505.0
8000,Toxicity was primarily hematological and bimodal : 32 % had grade 3 or 4 leukopenia and 24 % had grade 3 or 4 thrombocytopenia ; 22 % had no leukopenia and 44 % had no,thrombocytopenia .,,"['Toxicity', 'was', 'primarily', 'hematological', 'and', 'bimodal', ':', '32', '%', 'had', 'grade', '3', 'or', '4', 'leukopenia', 'and', '24', '%', 'had', 'grade', '3', 'or', '4', 'thrombocytopenia', ';', '22', '%', 'had', 'no', 'leukopenia', 'and', '44', '%', 'had', 'no', 'thrombocytopenia', '.']","(35, 37)","(167, 185)",-1,ss_o,9816035,Abstract,16,test,gold,3521.0
8001,,Toxicity,was primarily hematological and bimodal : 32 % had grade 3 or 4 leukopenia and 24 % had grade 3 or 4 thrombocytopenia ; 22 % had no leukopenia and 44 % had no thrombocytopenia .,"['Toxicity', 'was', 'primarily', 'hematological', 'and', 'bimodal', ':', '32', '%', 'had', 'grade', '3', 'or', '4', 'leukopenia', 'and', '24', '%', 'had', 'grade', '3', 'or', '4', 'thrombocytopenia', ';', '22', '%', 'had', 'no', 'leukopenia', 'and', '44', '%', 'had', 'no', 'thrombocytopenia', '.']","(0, 1)","(0, 8)",-1,hl_o,9816035,Abstract,16,test,gold,3488.0
8002,Toxicity was primarily hematological and bimodal : 32 % had grade 3 or 4,leukopenia,and 24 % had grade 3 or 4 thrombocytopenia ; 22 % had no leukopenia and 44 % had no thrombocytopenia .,"['Toxicity', 'was', 'primarily', 'hematological', 'and', 'bimodal', ':', '32', '%', 'had', 'grade', '3', 'or', '4', 'leukopenia', 'and', '24', '%', 'had', 'grade', '3', 'or', '4', 'thrombocytopenia', ';', '22', '%', 'had', 'no', 'leukopenia', 'and', '44', '%', 'had', 'no', 'thrombocytopenia', '.']","(14, 15)","(72, 82)",-1,hl_o,9816035,Abstract,16,test,gold,3504.0
8003,Toxicity was primarily hematological and bimodal : 32 % had grade 3 or 4 leukopenia and 24 % had grade 3 or 4,thrombocytopenia,; 22 % had no leukopenia and 44 % had no thrombocytopenia .,"['Toxicity', 'was', 'primarily', 'hematological', 'and', 'bimodal', ':', '32', '%', 'had', 'grade', '3', 'or', '4', 'leukopenia', 'and', '24', '%', 'had', 'grade', '3', 'or', '4', 'thrombocytopenia', ';', '22', '%', 'had', 'no', 'leukopenia', 'and', '44', '%', 'had', 'no', 'thrombocytopenia', '.']","(23, 24)","(109, 125)",-1,hl_o,9816035,Abstract,16,test,gold,3519.0
8004,Toxicity was primarily hematological and bimodal : 32 % had grade 3 or 4 leukopenia and 24 % had grade 3 or 4 thrombocytopenia ; 22 % had no,leukopenia,and 44 % had no thrombocytopenia .,"['Toxicity', 'was', 'primarily', 'hematological', 'and', 'bimodal', ':', '32', '%', 'had', 'grade', '3', 'or', '4', 'leukopenia', 'and', '24', '%', 'had', 'grade', '3', 'or', '4', 'thrombocytopenia', ';', '22', '%', 'had', 'no', 'leukopenia', 'and', '44', '%', 'had', 'no', 'thrombocytopenia', '.']","(29, 30)","(140, 150)",-1,hl_o,9816035,Abstract,16,test,gold,3503.0
8005,Toxicity was primarily hematological and bimodal : 32 % had grade 3 or 4 leukopenia and 24 % had grade 3 or 4 thrombocytopenia ; 22 % had no leukopenia and 44 % had no,thrombocytopenia,.,"['Toxicity', 'was', 'primarily', 'hematological', 'and', 'bimodal', ':', '32', '%', 'had', 'grade', '3', 'or', '4', 'leukopenia', 'and', '24', '%', 'had', 'grade', '3', 'or', '4', 'thrombocytopenia', ';', '22', '%', 'had', 'no', 'leukopenia', 'and', '44', '%', 'had', 'no', 'thrombocytopenia', '.']","(35, 36)","(167, 183)",-1,hl_o,9816035,Abstract,16,test,gold,3518.0
8006,The,response rate,"was 18 % , including one complete response .","['The', 'response', 'rate', 'was', '18', '%', ',', 'including', 'one', 'complete', 'response', '.']","(1, 3)","(3, 16)",-1,ss_o,9816035,Abstract,17,test,gold,1926.0
8007,The,response rate,"was 18 % , including one complete response .","['The', 'response', 'rate', 'was', '18', '%', ',', 'including', 'one', 'complete', 'response', '.']","(1, 3)","(3, 16)",-1,hl_o,9816035,Abstract,17,test,gold,1925.0
8008,When response was analyzed by,hematological toxicity,", there was a 35.7 % response if patients had leukopenia grade 3/4 ( versus 8.3 % , P = 0.08 ) .","['When', 'response', 'was', 'analyzed', 'by', 'hematological', 'toxicity', ',', 'there', 'was', 'a', '35.7', '%', 'response', 'if', 'patients', 'had', 'leukopenia', 'grade', '3/4', '(', 'versus', '8.3', '%', ',', 'P', '=', '0.08', ')', '.']","(5, 7)","(29, 51)",-1,ss_o,9816035,Abstract,18,test,gold,3485.0
8009,"When response was analyzed by hematological toxicity , there was a 35.7 % response if patients had",leukopenia,"grade 3/4 ( versus 8.3 % , P = 0.08 ) .","['When', 'response', 'was', 'analyzed', 'by', 'hematological', 'toxicity', ',', 'there', 'was', 'a', '35.7', '%', 'response', 'if', 'patients', 'had', 'leukopenia', 'grade', '3/4', '(', 'versus', '8.3', '%', ',', 'P', '=', '0.08', ')', '.']","(17, 18)","(98, 108)",-1,ss_o,9816035,Abstract,18,test,gold,3502.0
8010,When response was analyzed by,hematological toxicity,", there was a 35.7 % response if patients had leukopenia grade 3/4 ( versus 8.3 % , P = 0.08 ) .","['When', 'response', 'was', 'analyzed', 'by', 'hematological', 'toxicity', ',', 'there', 'was', 'a', '35.7', '%', 'response', 'if', 'patients', 'had', 'leukopenia', 'grade', '3/4', '(', 'versus', '8.3', '%', ',', 'P', '=', '0.08', ')', '.']","(5, 7)","(29, 51)",-1,hl_o,9816035,Abstract,18,test,gold,3486.0
8011,"When response was analyzed by hematological toxicity , there was a 35.7 % response if patients had",leukopenia,"grade 3/4 ( versus 8.3 % , P = 0.08 ) .","['When', 'response', 'was', 'analyzed', 'by', 'hematological', 'toxicity', ',', 'there', 'was', 'a', '35.7', '%', 'response', 'if', 'patients', 'had', 'leukopenia', 'grade', '3/4', '(', 'versus', '8.3', '%', ',', 'P', '=', '0.08', ')', '.']","(17, 18)","(98, 108)",-1,hl_o,9816035,Abstract,18,test,gold,3501.0
8012,There was a 50 % response if patients had,thrombocytopenia,"grade 3/4 ( versus 7.1 % , P = < 0.01 ) .","['There', 'was', 'a', '50', '%', 'response', 'if', 'patients', 'had', 'thrombocytopenia', 'grade', '3/4', '(', 'versus', '7.1', '%', ',', 'P', '=', '<', '0.01', ')', '.']","(9, 10)","(41, 57)",-1,ss_o,9816035,Abstract,19,test,gold,3517.0
8013,There was a 50 % response if patients had,thrombocytopenia,"grade 3/4 ( versus 7.1 % , P = < 0.01 ) .","['There', 'was', 'a', '50', '%', 'response', 'if', 'patients', 'had', 'thrombocytopenia', 'grade', '3/4', '(', 'versus', '7.1', '%', ',', 'P', '=', '<', '0.01', ')', '.']","(9, 10)","(41, 57)",-1,hl_o,9816035,Abstract,19,test,gold,3516.0
8014,We conclude that,amonafide,is somewhat active in previously untreated breast cancer patients .,"['We', 'conclude', 'that', 'amonafide', 'is', 'somewhat', 'active', 'in', 'previously', 'untreated', 'breast', 'cancer', 'patients', '.']","(3, 4)","(16, 25)",-1,ss_i,9816035,Abstract,20,test,gold,1058.0
8015,We conclude that amonafide is somewhat active in,previously untreated breast cancer patients,.,"['We', 'conclude', 'that', 'amonafide', 'is', 'somewhat', 'active', 'in', 'previously', 'untreated', 'breast', 'cancer', 'patients', '.']","(8, 13)","(48, 91)",-1,hl_p,9816035,Abstract,20,test,gold,6845.0
8016,We conclude that,amonafide,is somewhat active in previously untreated breast cancer patients .,"['We', 'conclude', 'that', 'amonafide', 'is', 'somewhat', 'active', 'in', 'previously', 'untreated', 'breast', 'cancer', 'patients', '.']","(3, 4)","(16, 25)",-1,hl_i,9816035,Abstract,20,test,gold,1057.0
8017,"There may be a steep dose-response curve , based on the significant correlation between myelosuppression and response .",,,"['There', 'may', 'be', 'a', 'steep', 'dose-response', 'curve', ',', 'based', 'on', 'the', 'significant', 'correlation', 'between', 'myelosuppression', 'and', 'response', '.']",,,,,9816035,Abstract,21,test,gold,
8018,"Rates of responses in patients adequately dosed ( i.e. , with significant hematotoxicity ) with",amonafide,ranged from 35 to 50 % .,"['Rates', 'of', 'responses', 'in', 'patients', 'adequately', 'dosed', '(', 'i.e.', ',', 'with', 'significant', 'hematotoxicity', ')', 'with', 'amonafide', 'ranged', 'from', '35', 'to', '50', '%', '.']","(15, 16)","(95, 104)",-1,ss_i,9816035,Abstract,22,test,gold,1056.0
8019,,Rates of responses,"in patients adequately dosed ( i.e. , with significant hematotoxicity ) with amonafide ranged from 35 to 50 % .","['Rates', 'of', 'responses', 'in', 'patients', 'adequately', 'dosed', '(', 'i.e.', ',', 'with', 'significant', 'hematotoxicity', ')', 'with', 'amonafide', 'ranged', 'from', '35', 'to', '50', '%', '.']","(0, 3)","(0, 18)",-1,ss_o,9816035,Abstract,22,test,gold,1915.0
8020,"Rates of responses in patients adequately dosed ( i.e. , with significant",hematotoxicity ),with amonafide ranged from 35 to 50 % .,"['Rates', 'of', 'responses', 'in', 'patients', 'adequately', 'dosed', '(', 'i.e.', ',', 'with', 'significant', 'hematotoxicity', ')', 'with', 'amonafide', 'ranged', 'from', '35', 'to', '50', '%', '.']","(12, 14)","(73, 89)",-1,ss_o,9816035,Abstract,22,test,gold,
8021,,Rates of responses,"in patients adequately dosed ( i.e. , with significant hematotoxicity ) with amonafide ranged from 35 to 50 % .","['Rates', 'of', 'responses', 'in', 'patients', 'adequately', 'dosed', '(', 'i.e.', ',', 'with', 'significant', 'hematotoxicity', ')', 'with', 'amonafide', 'ranged', 'from', '35', 'to', '50', '%', '.']","(0, 3)","(0, 18)",-1,hl_o,9816035,Abstract,22,test,gold,1916.0
8022,Further studies will incorporate individualized dosing based on pretreatment acetylator phenotyping .,,,"['Further', 'studies', 'will', 'incorporate', 'individualized', 'dosing', 'based', 'on', 'pretreatment', 'acetylator', 'phenotyping', '.']",,,,,9816035,Abstract,23,test,gold,
